7910951
D003473_D010243 NONE agents_7\NNS|nondepolarizing (r_appos) neuromuscular_5\JJ|to (r_pobj) due_2\IN|Prolonged|. (r_prep) paralysis_1\NN|NONE
D000305_D010243 NONE corticosteroids_9\NNS|blocking|and (r_conj) agents_7\NNS|nondepolarizing (r_appos) neuromuscular_5\JJ|to (r_pobj) due_2\IN|Prolonged|. (r_prep) paralysis_1\NN|NONE
D003473_D012131 NONE NMBAs_25\NNP|NONE (r_pobj) of_22\IN|the (r_prep) discontinuation_21\NN|NONE (r_pobj) following_19\VBG|prolonged (r_prep) weakness_18\NN|who (r_dobj) developed_16\VBD|acute|respiratory (r_relcl) insufficiency_14\NN|NONE
D000305_D009468 NONE corticosteroids_30\NNS|to (r_pobj) due_28\IN|)|(|most (r_prep) likely_27\JJ|most|due|( (r_parataxis) likely_16\JJ|at (r_parataxis) pathology_8\NN|to (l_prep) at_9\IN|likely (l_pobj) junction_13\NN|NONE
D003473_D009468 CID NMBA_21\NNP|to (r_pobj) due_17\IN|most|likely|( (r_prep) likely_16\JJ|at (r_parataxis) pathology_8\NN|to (l_prep) at_9\IN|likely (l_pobj) junction_13\NN|NONE
D000305_D018908 NONE corticosteroids_30\NNS|to (r_pobj) due_28\IN|)|(|most (r_prep) likely_27\JJ|most|due|( (r_parataxis) likely_16\JJ|at (r_parataxis) pathology_8\NN|to (r_pobj) due_6\JJ|.|weakness (r_acomp) is_5\VBZ|NONE (l_nsubj) weakness_1\NN|.|due
D003473_D018908 CID agents_9\NNS|NONE (r_pobj) of_5\IN|term|The (r_prep) use_4\NN|has|,|recently|been|as|.|been (r_nsubjpass) implicated_18\VBN|NONE (l_prep) as_19\IN|use|has|,|recently|been|.|been (l_pobj) cause_21\NN|NONE (l_prep) of_22\IN|a (l_pobj) weakness_25\NN|NONE
D003473_D018908 CID NMBA_13\NNP|blocking|(|)|neuromuscular (r_appos) agents_9\NNS|NONE (r_pobj) of_5\IN|term|The (r_prep) use_4\NN|has|,|recently|been|as|.|been (r_nsubjpass) implicated_18\VBN|NONE (l_prep) as_19\IN|use|has|,|recently|been|.|been (l_pobj) cause_21\NN|NONE (l_prep) of_22\IN|a (l_pobj) weakness_25\NN|NONE
D003473_D018908 CID NMBAs_25\NNP|NONE (r_pobj) of_22\IN|the (r_prep) discontinuation_21\NN|NONE (r_pobj) following_19\VBG|prolonged (r_prep) weakness_18\NN|who
D003473_D018908 CID NMBA_21\NNP|to (r_pobj) due_17\IN|most|likely|( (r_prep) likely_16\JJ|at (r_parataxis) pathology_8\NN|to (r_pobj) due_6\JJ|.|weakness (r_acomp) is_5\VBZ|NONE (l_nsubj) weakness_1\NN|.|due
19692487
D008094_D011141 NONE lithium_6\NN| (r_npadvmod) induced_8\VBN|NONE (r_amod) polyuria_9\NN|NONE
D008094_D011141 NONE lithium_8\NN| (r_npadvmod) induced_10\VBN|NONE (r_amod) polyuria_11\NN|NONE
D008094_D011141 NONE lithium_7\NN| (r_npadvmod) induced_9\VBN|in (r_amod) polyuria_10\NN|to
D008094_D011141 NONE lithium_10\NN| (r_npadvmod) induced_12\VBN|urine|and (r_amod) polyuria_13\NN|NONE
D008094_D011141 NONE lithium_7\NN| (r_npadvmod) induced_9\VBN|likely (r_amod) polyuria_10\NN|via|PGE(|that
D011458_D011141 NONE E_17\NN|NONE (r_appos) microsomal_15\JJ|NONE (r_pobj) in_14\IN|mice (r_prep) deficient_13\JJ|NONE (r_pobj) in_11\IN|induced (r_prep) polyuria_10\NN|to
D015232_D011141 NONE )_29\-RRB-|NONE (r_punct) PGE(2_28\NNP|high|output|and (r_appos) urine_27\NN|NONE (r_pobj) of_25\IN|complete (r_prep) blockade_24\NN|NONE (r_pobj) by_21\IN|NONE (r_agent) accompanied_20\VBN|resistant|,|mice|mPGES|,|In|. (r_advcl) were_6\VBD|NONE (l_acomp) resistant_8\JJ|,|mice|mPGES|accompanied|,|In|. (l_prep) to_9\IN|largely (l_pobj) polyuria_13\NN|NONE
D015232_D011141 NONE )_5\-RRB-|mPGESderived (r_punct) PGE(2_4\NNP|via|that|polyuria (r_nsubj) mediates_6\VBZ|We|. (l_dobj) polyuria_10\NN|via|PGE(|that
9522143
D002045_D034381 CID bupivacaine_19\NN|NONE (r_pobj) than_16\IN| (r_prep) loss_9\NN|NONE
D002045_D034381 CID bupivacaine_17\NN|NONE (r_pobj) after_16\IN| (r_prep) dB_15\NN|and (r_conj) prilocaine_12\NN|NONE (r_pobj) after_11\IN|loss|.|dB (r_prep) was_7\VBD|NONE (l_nsubj) loss_3\NN|.|dB|after
D011318_D034381 CID prilocaine_2\NN|NONE (r_dobj) given_1\VBN|P (r_acl) Patients_0\NNS|likely|. (r_nsubj) were_3\VBD|NONE (l_acomp) likely_5\JJ|.|Patients (l_xcomp) develop_7\VB|more (l_xcomp) hearing_8\VBG|to (l_dobj) loss_9\NN|NONE
D011318_D034381 CID prilocaine_12\NN|NONE (r_pobj) after_11\IN|loss|.|dB (r_prep) was_7\VBD|NONE (l_nsubj) loss_3\NN|.|dB|after
9199746
D000583_D013290 NONE amikacin_6\JJ|following (r_prep) presumed_5\VBN|NONE (l_prep) following_9\VBG|amikacin (l_pobj) treatment_10\NN|NONE (l_prep) with_11\IN|NONE (l_pobj) amikacin_12\JJ|NONE (l_conj) vancomycin_14\NNP|and (l_prep) for_15\IN|NONE (l_pobj) endophthalmitis_20\NN|NONE
D000583_D013290 NONE amikacin_12\JJ|NONE (l_conj) vancomycin_14\NNP|and (l_prep) for_15\IN|NONE (l_pobj) endophthalmitis_20\NN|NONE
D019793_D013684 NONE fluorescein_1\NN|NONE (r_amod) angiography_2\NN|.|closure|Fundus (r_nsubj) confirmed_3\VBD|NONE (l_dobj) closure_6\NN|angiography|.|Fundus (l_conj) telangiectasis_8\NN|and|capillary|macular
D014640_D013290 NONE vancomycin_14\NNP|and (l_prep) for_15\IN|NONE (l_pobj) endophthalmitis_20\NN|NONE
D000583_D064420 NONE amikacin_4\RB|NONE (l_nsubj) toxicity_1\NN|.
D000583_D012164 CID amikacin_6\JJ|following (l_pobj) toxicity_8\NN|NONE
D000583_D012164 CID amikacin_12\JJ|NONE (r_pobj) with_11\IN|NONE (r_prep) treatment_10\NN|NONE (r_pobj) following_9\VBG|amikacin (r_prep) presumed_5\VBN|NONE (l_prep) amikacin_6\JJ|following (l_pobj) toxicity_8\NN|NONE
D014640_D012164 NONE vancomycin_14\NNP|and (r_conj) amikacin_12\JJ|NONE (r_pobj) with_11\IN|NONE (r_prep) treatment_10\NN|NONE (r_pobj) following_9\VBG|amikacin (r_prep) presumed_5\VBN|NONE (l_prep) amikacin_6\JJ|following (l_pobj) toxicity_8\NN|NONE
D000617_D009877 NONE aminoglycosides_2\NNS|have|Although|prognosis|substantially (r_nsubj) improved_5\VBN|may|.|,|recovery|infarction (l_dobj) prognosis_7\NN|have|aminoglycosides|Although|substantially (l_prep) in_8\IN|visual (l_pobj) endophthalmitis_9\NN|NONE
D000617_D007238 NONE aminoglycosides_2\NNS|have|Although|prognosis|substantially (r_nsubj) improved_5\VBN|may|.|,|recovery|infarction (r_advcl) impair_14\VB|NONE (l_nsubj) infarction_12\NN|may|.|,|recovery|improved
19940105
D006220_D002375 CID haloperidol_22\NN| (r_npadvmod) induced_24\VBN|in (r_amod) catalepsy_25\NN|intrastriatal|that
D006220_D002375 CID haloperidol_8\NN| (r_npadvmod) induced_10\VBN|NONE (r_amod) catalepsy_11\NN|NONE
C507346_D002375 NONE AMN082_20\NNP|NONE (r_pobj) of_19\IN|.|(|)|nmol (r_prep) administration_12\NN|NONE (r_dobj) intrastriatal_11\JJ|catalepsy|that (r_csubj) reverses_21\VBZ|we|Here|.|, (l_dobj) catalepsy_25\NN|intrastriatal|that
C507346_D002375 NONE AMN082_3\NNP|In|.|duration|, (r_nsubj) reduces_4\VBZ|NONE (l_dobj) duration_6\NN|In|.|AMN|, (l_prep) of_7\IN|in|the (l_pobj) catalepsy_11\NN|NONE
D016627_D018476 NONE 6-OHDA_31\CD| (r_advmod) lesioned_33\VBN|bilateral (r_amod) rats_34\NNS|NONE (r_pobj) of_29\IN|a (r_prep) cue_28\NN|NONE (r_pobj) to_26\IN|to (r_prep) respond_25\VB|,|In|AMN|.|time (r_xcomp) reverses_19\VBZ|NONE (l_prep) In_0\IN|,|AMN|.|respond|time (l_pobj) task_4\NN|NONE (l_acl) used_6\VBN|complex|a (l_xcomp) evaluate_8\VB|commonly (l_dobj) symptoms_11\NNS|to (l_amod) akinetic_10\JJ|major|of
C507346_D018476 NONE AMN082_18\NNP|,|In|.|respond|time (r_nsubj) reverses_19\VBZ|NONE (l_prep) In_0\IN|,|AMN|.|respond|time (l_pobj) task_4\NN|NONE (l_acl) used_6\VBN|complex|a (l_xcomp) evaluate_8\VB|commonly (l_dobj) symptoms_11\NNS|to (l_amod) akinetic_10\JJ|major|of
D018698_D010300 NONE glutamate_1\NN|receptor| (r_nmod) subtype_4\NN|.|symptoms|in (r_nsubj) modulates_5\VBZ|NONE (l_prep) in_8\IN|.|symptoms|subtype (l_pobj) models_10\NNS|NONE (l_prep) of_11\IN|rodent (l_pobj) disease_14\NN|NONE
D018698_D010300 NONE glutamate_1\NN|mGlu (r_nmod) receptors_5\NNS|represent|.|and|transmission (r_nsubj) modulate_6\VBP|NONE (l_conj) represent_15\VBP|receptors|.|and|transmission (l_dobj) targets_18\NNS|NONE (l_prep) for_19\IN|promising|therapeutic (l_pobj) treatment_21\NN|NONE (l_prep) of_22\IN|symptomatic (l_pobj) disease_25\NN|NONE
D018698_D010300 NONE glutamate_1\NN|mGlu (r_nmod) receptors_5\NNS|represent|.|and|transmission (r_nsubj) modulate_6\VBP|NONE (l_conj) represent_15\VBP|receptors|.|and|transmission (l_dobj) targets_18\NNS|NONE (l_prep) for_19\IN|promising|therapeutic (l_pobj) treatment_21\NN|NONE (l_prep) of_22\IN|symptomatic (l_pobj) disease_25\NN|NONE (l_appos) PD_27\NNP|(|)|Parkinson
C507346_D010300 NONE AMN082_1\NNP|.|in|thus|were (r_nsubjpass) tested_15\VBN|NONE (l_prep) in_16\IN|.|thus|AMN|were (l_pobj) models_19\NNS|NONE (l_prep) of_20\IN|different|rodent (l_pobj) PD_21\NNP|NONE
C507346_D010300 NONE AMN082_18\NNP|,|In|.|respond|time (r_nsubj) reverses_19\VBZ|NONE (l_prep) In_0\IN|,|AMN|.|respond|time (l_pobj) task_4\NN|NONE (l_acl) used_6\VBN|complex|a (l_xcomp) evaluate_8\VB|commonly (l_dobj) symptoms_11\NNS|to (l_prep) of_12\IN|akinetic|major (l_pobj) patients_14\NNS|NONE (l_compound) PD_13\NNP|NONE
C507346_D010300 NONE AMN082_3\NNP|NONE (r_pobj) of_2\IN|Higher (r_prep) doses_1\NNS|effect|. (r_nsubj) have_11\VBP|NONE (l_dobj) effect_13\NN|doses|. (l_prep) on_14\IN|no (l_pobj) models_17\NNS|NONE (l_prep) of_18\IN|the|same (l_pobj) PD_19\NNP|NONE
D016627_D010300 NONE 6-OHDA_31\CD| (r_advmod) lesioned_33\VBN|bilateral (r_amod) rats_34\NNS|NONE (r_pobj) of_29\IN|a (r_prep) cue_28\NN|NONE (r_pobj) to_26\IN|to (r_prep) respond_25\VB|,|In|AMN|.|time (r_xcomp) reverses_19\VBZ|NONE (l_prep) In_0\IN|,|AMN|.|respond|time (l_pobj) task_4\NN|NONE (l_acl) used_6\VBN|complex|a (l_xcomp) evaluate_8\VB|commonly (l_dobj) symptoms_11\NNS|to (l_prep) of_12\IN|akinetic|major (l_pobj) patients_14\NNS|NONE (l_compound) PD_13\NNP|NONE
2312209
D007548_D009203 CID dinitrate_7\NN|NONE (r_pobj) of_5\IN|sublingual (r_prep) administration_4\NN|NONE (r_dobj) following_2\VBG|.|Myocardial (r_prep) infarction_1\NN|NONE
D007548_D009203 CID dinitrate_22\NN|NONE (r_pobj) of_20\IN|the (r_prep) administration_19\NN|NONE (r_pobj) following_17\VBG|sublingually|infarction|necrosis|. (r_prep) suffered_8\VBD|NONE (l_dobj) infarction_12\NN|sublingually|necrosis|.|following
D007548_D009336 NONE dinitrate_22\NN|NONE (r_pobj) of_20\IN|the (r_prep) administration_19\NN|NONE (r_pobj) following_17\VBG|sublingually|infarction|necrosis|. (r_prep) suffered_8\VBD|NONE (l_nsubj) necrosis_7\NN|sublingually|infarction|.|following
11431197
D011899_D009395 CID Ranitidine_0\NNP| (r_npadvmod) induced_2\VBN|in|.|acute|interstitial (r_amod) nephritis_5\NN|NONE
D011899_D009395 CID ranitidine_5\NN| (r_npadvmod) induced_7\VBN|acute|interstitial (r_amod) nephritis_10\NN|NONE
20973483
D006220_D002375 CID haloperidol_53\NN| (r_npadvmod) induced_55\VBN|model|,|model|, (r_amod) catalepsy_56\NN|NONE
D016627_D010300 NONE 6-hydroxydopamine_67\NN|(|) (r_nmod) 6-OHDA_69\CD|,|lesion|of|rat (r_nummod) model_72\NN|,|model|,|induced (r_appos) catalepsy_56\NN|NONE (r_pobj) of_52\IN|mouse (r_prep) models_51\NNS|NONE (r_pobj) including_47\VBG|Parkinson (r_prep) disease_46\NN|NONE
D016627_D010300 NONE 6-OHDA_69\CD|,|lesion|of|rat (r_nummod) model_72\NN|,|model|,|induced (r_appos) catalepsy_56\NN|NONE (r_pobj) of_52\IN|mouse (r_prep) models_51\NNS|NONE (r_pobj) including_47\VBG|Parkinson (r_prep) disease_46\NN|NONE
D016627_D002375 NONE 6-hydroxydopamine_67\NN|(|) (r_nmod) 6-OHDA_69\CD|,|lesion|of|rat (r_nummod) model_72\NN|,|model|,|induced (r_appos) catalepsy_56\NN|NONE
D016627_D002375 NONE 6-OHDA_69\CD|,|lesion|of|rat (r_nummod) model_72\NN|,|model|,|induced (r_appos) catalepsy_56\NN|NONE
D015632_D010300 NONE MPTP_80\NNP| (r_npadvmod) treated_82\VBN|primate|human (r_amod) model_87\NN|number|and (r_conj) across_37\IN|Compound|after|,|antagonist|.|, (l_pobj) number_39\NN|model|and (l_prep) of_40\IN|a (l_pobj) models_42\NNS|NONE (l_prep) of_43\IN|animal (l_pobj) disease_46\NN|NONE
D012110_D010300 NONE reserpine_61\NN| (r_npadvmod) induced_63\VBN|NONE (r_compound) akinesia_64\NN|NONE (r_pobj) of_60\IN|mouse (r_prep) model_59\NN|model|,|,|induced (r_appos) catalepsy_56\NN|NONE (r_pobj) of_52\IN|mouse (r_prep) models_51\NNS|NONE (r_pobj) including_47\VBG|Parkinson (r_prep) disease_46\NN|NONE
D016627_D004409 NONE 6-hydroxydopamine_67\NN|(|) (r_nmod) 6-OHDA_69\CD|,|lesion|of|rat (r_nummod) model_72\NN|,|model|,|induced (r_appos) catalepsy_56\NN|NONE (l_appos) model_59\NN|model|,|,|induced (l_prep) of_60\IN|mouse (l_pobj) akinesia_64\NN|NONE
D016627_D004409 NONE 6-OHDA_69\CD|,|lesion|of|rat (r_nummod) model_72\NN|,|model|,|induced (r_appos) catalepsy_56\NN|NONE (l_appos) model_59\NN|model|,|,|induced (l_prep) of_60\IN|mouse (l_pobj) akinesia_64\NN|NONE
D012110_D002375 NONE reserpine_61\NN| (r_npadvmod) induced_63\VBN|NONE (r_compound) akinesia_64\NN|NONE (r_pobj) of_60\IN|mouse (r_prep) model_59\NN|model|,|,|induced (r_appos) catalepsy_56\NN|NONE
D012110_D004409 CID reserpine_61\NN| (r_npadvmod) induced_63\VBN|NONE (r_compound) akinesia_64\NN|NONE
D015632_D004409 NONE MPTP_80\NNP| (r_npadvmod) treated_82\VBN|primate|human (r_amod) model_87\NN|number|and (r_conj) across_37\IN|Compound|after|,|antagonist|.|, (l_pobj) number_39\NN|model|and (l_prep) of_40\IN|a (l_pobj) models_42\NNS|NONE (l_prep) of_43\IN|animal (l_pobj) disease_46\NN|NONE (l_prep) including_47\VBG|Parkinson (l_pobj) models_51\NNS|NONE (l_prep) of_52\IN|mouse (l_pobj) catalepsy_56\NN|NONE (l_appos) model_59\NN|model|,|,|induced (l_prep) of_60\IN|mouse (l_pobj) akinesia_64\NN|NONE
D006220_D004409 NONE haloperidol_53\NN| (r_npadvmod) induced_55\VBN|model|,|model|, (r_amod) catalepsy_56\NN|NONE (l_appos) model_59\NN|model|,|,|induced (l_prep) of_60\IN|mouse (l_pobj) akinesia_64\NN|NONE
D058915_D010300 NONE antagonist_11\NN|NONE (l_prep) in_12\IN|a|AA|receptor|adenosine|A (l_pobj) models_14\NNS|NONE (l_prep) of_15\IN|animal (l_pobj) disease_18\NN|NONE
D058915_D010300 NONE antagonist_11\NN|NONE (l_prep) in_12\IN|receptor|adenosine|)|a|A(A)/A( (l_pobj) models_15\NNS|NONE (l_prep) of_16\IN|animal|several (l_pobj) disease_19\NN|NONE
D006220_D010300 NONE haloperidol_53\NN| (r_npadvmod) induced_55\VBN|model|,|model|, (r_amod) catalepsy_56\NN|NONE (r_pobj) of_52\IN|mouse (r_prep) models_51\NNS|NONE (r_pobj) including_47\VBG|Parkinson (r_prep) disease_46\NN|NONE
D015632_D002375 NONE MPTP_80\NNP| (r_npadvmod) treated_82\VBN|primate|human (r_amod) model_87\NN|number|and (r_conj) across_37\IN|Compound|after|,|antagonist|.|, (l_pobj) number_39\NN|model|and (l_prep) of_40\IN|a (l_pobj) models_42\NNS|NONE (l_prep) of_43\IN|animal (l_pobj) disease_46\NN|NONE (l_prep) including_47\VBG|Parkinson (l_pobj) models_51\NNS|NONE (l_prep) of_52\IN|mouse (l_pobj) catalepsy_56\NN|NONE
11079278
D008790_D017202 NONE metoprolol_3\NN|NONE (l_conj) metoprolol_6\NN|intravenous|or (l_conj) glucagon_8\NN|intravenous|plus (l_prep) on_9\IN|NONE (l_pobj) ischemia_14\NN|NONE
D008790_D017202 NONE metoprolol_6\NN|intravenous|or (l_conj) glucagon_8\NN|intravenous|plus (l_prep) on_9\IN|NONE (l_pobj) ischemia_14\NN|NONE
D008790_D017202 NONE metoprolol_5\FW|During|eliminates|or|.|, (r_nsubj) attenuates_6\VBZ|NONE (l_conj) eliminates_8\VBZ|metoprolol|During|or|.|, (l_dobj) evidence_9\NN|NONE (l_prep) of_10\IN|NONE (l_pobj) ischemia_12\NN|NONE
D004280_D017202 CID dobutamine_10\NN| (r_npadvmod) induced_12\VBN|myocardial (r_amod) ischemia_14\NN|NONE
D004280_D017202 CID dobutamine_1\NN|NONE (r_pcomp) During_0\IN|metoprolol|eliminates|or|.|, (r_prep) attenuates_6\VBZ|NONE (l_conj) eliminates_8\VBZ|metoprolol|During|or|.|, (l_dobj) evidence_9\NN|NONE (l_prep) of_10\IN|NONE (l_pobj) ischemia_12\NN|NONE
8595686
D008012_D010146 NONE lidocaine_3\NN|incidence|reduces|that (r_nsubj) reduces_4\VBZ|We|. (l_dobj) incidence_6\NN|reduces|lidocaine|that (l_prep) of_9\IN|the|severity|and (l_pobj) pain_12\NN|NONE
D013874_D010146 NONE Thiopentone_0\NN|for|. (r_compound) pretreatment_1\NN|NONE (l_prep) for_2\IN|.|Thiopentone (l_pobj) pain_5\NN|NONE
D013874_D010146 NONE thiopentone_17\NN|only|severity|whereas (r_nsubj) reduces_19\VBZ|incidence|lidocaine|that (r_advcl) reduces_4\VBZ|We|. (l_dobj) incidence_6\NN|reduces|lidocaine|that (l_prep) of_9\IN|the|severity|and (l_pobj) pain_12\NN|NONE
D015742_D010146 CID propofol_3\JJ|injection|in (r_amod) pain_5\NN|NONE
D015742_D010146 CID propofol_3\JJ|injection|in (r_amod) pain_5\NN|study|.
D015742_D010146 CID propofol_10\JJ|injection|in (r_amod) pain_12\NN|NONE
8424298
D007741_D007022 CID labetalol_6\NN|NONE (r_pobj) by_5\IN|NONE (r_agent) induced_4\VBN|deliberate (r_acl) hypotension_3\NN|NONE
D007741_D007022 CID labetalol_16\NN|NONE (r_pobj) by_15\IN|NONE (r_agent) induced_14\VBN|deliberate (r_acl) hypotension_13\NN|NONE
D007741_D007022 CID labetalol_16\NN|NONE (l_prep) with_17\IN|NONE (l_pobj) group_21\NN|NONE (l_amod) hypotensive_20\JJ|isoflurane|(
D007741_D007022 CID labetalol_7\NN|NONE (r_pobj) by_6\IN|hypotension|that (r_prep) induced_5\VBN|results|.|has (l_nsubj) hypotension_4\NN|by|that
D007530_D007022 CID isoflurane_8\NN|NONE (r_pobj) with_7\IN|NONE (r_prep) labetalol_6\NN|NONE (r_pobj) by_5\IN|NONE (r_agent) induced_4\VBN|deliberate (r_acl) hypotension_3\NN|NONE
D007530_D007022 CID isoflurane_18\JJ|hypotensive|( (r_amod) group_21\NN|NONE (r_pobj) with_17\IN|NONE (r_prep) labetalol_16\NN|NONE (r_pobj) by_15\IN|NONE (r_agent) induced_14\VBN|deliberate (r_acl) hypotension_13\NN|NONE
D007530_D007022 CID isoflurane_18\JJ|hypotensive|( (r_amod) group_21\NN|NONE (l_amod) hypotensive_20\JJ|isoflurane|(
D007530_D007022 CID isoflurane_9\NN|NONE (r_pobj) with_8\IN|NONE (r_prep) labetalol_7\NN|NONE (r_pobj) by_6\IN|hypotension|that (r_prep) induced_5\VBN|results|.|has (l_nsubj) hypotension_4\NN|by|that
18086064
D020927_D009203 NONE Dexmedetomidine_0\NNP|with|was (r_nsubjpass) associated_2\VBN|infarction|cause|%|;|(|CI|, (r_ccomp) mortality_14\NN|NONE (l_appos) infarction_35\NN|cause|%|;|(|CI|,|associated
11679859
D011346_D017109 CID prochlorperazine_3\NN|NONE (r_pobj) of_2\IN|Intravenous (r_prep) administration_1\NN|does|incidence|.|not (r_nsubj) affect_12\VB|NONE (l_dobj) incidence_14\NN|does|administration|.|not (l_prep) of_15\IN|the (l_pobj) akathisia_16\NN|NONE
D011346_D017109 CID prochlorperazine_12\NN|NONE (r_pobj) of_10\IN|NONE (r_prep) administration_9\NN|NONE (r_pobj) after_8\IN|NONE (r_prep) akathisia_7\NN|NONE
D011346_D017109 CID prochlorperazine_10\NN|when|was|by (r_nsubjpass) administered_12\VBN|%|A|in (r_advcl) reduction_3\NN|was|not|. (l_prep) in_4\IN|%|administered|A (l_pobj) incidence_6\NN|NONE (l_prep) of_7\IN|the (l_pobj) akathisia_8\NN|NONE
D011346_D014839 NONE prochlorperazine_8\NN|NONE (l_prep) for_9\IN|NONE (l_pobj) headache_10\NN|NONE (l_conj) nausea_12\NN|, (l_conj) vomiting_15\NN|,|or
D011346_D006261 NONE prochlorperazine_8\NN|NONE (l_prep) for_9\IN|NONE (l_pobj) headache_10\NN|NONE
D011346_D006261 NONE prochlorperazine_3\NN|NONE (r_pobj) of_2\IN|The|in (r_prep) efficacy_1\NN|not|made|affected|,|likewise|did|. (l_prep) in_4\IN|of|The (l_pobj) treatment_6\NN|NONE (l_prep) of_7\IN|the (l_pobj) headache_8\NN|NONE
D011346_D009325 NONE prochlorperazine_8\NN|NONE (l_prep) for_9\IN|NONE (l_pobj) headache_10\NN|NONE (l_conj) nausea_12\NN|,
D011346_D009325 NONE prochlorperazine_3\NN|NONE (r_pobj) of_2\IN|The|in (r_prep) efficacy_1\NN|not|made|affected|,|likewise|did|. (l_prep) in_4\IN|of|The (l_pobj) treatment_6\NN|NONE (l_prep) of_7\IN|the (l_pobj) headache_8\NN|NONE (l_conj) nausea_10\NN|and
921394
D007649_D003866 NONE ketamine_2\NN|NONE (r_pobj) of_1\IN|mg|in|. (r_prep) Injections_0\NNS|NONE (l_dep) mg_10\NN|of|in|. (l_prep) into_11\IN|NONE (l_pobj) artery_13\NN|NONE (l_acl) produced_14\VBD|the (l_dobj) depression_16\NN|by
D007649_D013610 CID ketamine_18\NN| (r_npadvmod) induced_20\VBN|the (r_amod) tachycardia_21\NN|NONE
2578334
D008770_D011230 CID nitrosourea_65\NN|,|,|benzo[a]pyrene|the|three (r_appos) carcinogens_51\NNS|NONE (r_pobj) by_48\IN|NONE (r_agent) induced_47\VBN|the|of (r_acl) phase_43\NN|NONE (r_pobj) during_41\IN|.|was|AzC|to (r_prep) given_38\VBN|NONE (l_nsubjpass) 5-AzC_24\CD|.|during|was|to (l_advcl) test_1\VB|azacytidine|)|,|inhibitor|(|,|,|mg/kg (l_dobj) validity_3\NN|To (l_prep) of_4\IN|the (l_pobj) hypothesis_6\NN|NONE (l_acl) plays_11\VBZ|the (l_prep) in_15\IN|role|that|hypomethylation (l_pobj) initiation_17\NN|NONE (l_prep) of_18\IN|the (l_pobj) process_20\NN|NONE
D001564_D011230 CID benzo[a]-pyrene_53\NN|,|,|nitrosourea|the|three (r_appos) carcinogens_51\NNS|NONE (r_pobj) by_48\IN|NONE (r_agent) induced_47\VBN|the|of (r_acl) phase_43\NN|NONE (r_pobj) during_41\IN|.|was|AzC|to (r_prep) given_38\VBN|NONE (l_nsubjpass) 5-AzC_24\CD|.|during|was|to (l_advcl) test_1\VB|azacytidine|)|,|inhibitor|(|,|,|mg/kg (l_dobj) validity_3\NN|To (l_prep) of_4\IN|the (l_pobj) hypothesis_6\NN|NONE (l_acl) plays_11\VBZ|the (l_prep) in_15\IN|role|that|hypomethylation (l_pobj) initiation_17\NN|NONE (l_prep) of_18\IN|the (l_pobj) process_20\NN|NONE
D019813_D011230 CID 1,2-dimethylhydrazine_71\CD|(|mg/kg|and|) (r_conj) 60_67\CD|,DMH|||mg/kg|methyl|N (r_appos) nitrosourea_65\NN|,|,|benzo[a]pyrene|the|three (r_appos) carcinogens_51\NNS|NONE (r_pobj) by_48\IN|NONE (r_agent) induced_47\VBN|the|of (r_acl) phase_43\NN|NONE (r_pobj) during_41\IN|.|was|AzC|to (r_prep) given_38\VBN|NONE (l_nsubjpass) 5-AzC_24\CD|.|during|was|to (l_advcl) test_1\VB|azacytidine|)|,|inhibitor|(|,|,|mg/kg (l_dobj) validity_3\NN|To (l_prep) of_4\IN|the (l_pobj) hypothesis_6\NN|NONE (l_acl) plays_11\VBZ|the (l_prep) in_15\IN|role|that|hypomethylation (l_pobj) initiation_17\NN|NONE (l_prep) of_18\IN|the (l_pobj) process_20\NN|NONE
D019813_D011230 CID 1,2-DMH_73\NNP||||mg/kg|methyl|N (r_appos) nitrosourea_65\NN|,|,|benzo[a]pyrene|the|three (r_appos) carcinogens_51\NNS|NONE (r_pobj) by_48\IN|NONE (r_agent) induced_47\VBN|the|of (r_acl) phase_43\NN|NONE (r_pobj) during_41\IN|.|was|AzC|to (r_prep) given_38\VBN|NONE (l_nsubjpass) 5-AzC_24\CD|.|during|was|to (l_advcl) test_1\VB|azacytidine|)|,|inhibitor|(|,|,|mg/kg (l_dobj) validity_3\NN|To (l_prep) of_4\IN|the (l_pobj) hypothesis_6\NN|NONE (l_acl) plays_11\VBZ|the (l_prep) in_15\IN|role|that|hypomethylation (l_pobj) initiation_17\NN|NONE (l_prep) of_18\IN|the (l_pobj) process_20\NN|NONE
D001374_D011230 CID 5-azacytidine_0\RB|initiation|. (r_nsubj) potentiates_1\VBZ|NONE (l_dobj) initiation_2\NN|azacytidine|. (l_acl) induced_3\VBN|NONE (l_agent) by_4\IN|NONE (l_pobj) carcinogens_5\NNS|NONE
D001374_D011230 CID 5-azacytidine_22\JJ|)|,|inhibitor|(|,|test|,|mg/kg (r_punct) 5-AzC_24\CD|.|during|was|to (l_advcl) test_1\VB|azacytidine|)|,|inhibitor|(|,|,|mg/kg (l_dobj) validity_3\NN|To (l_prep) of_4\IN|the (l_pobj) hypothesis_6\NN|NONE (l_acl) plays_11\VBZ|the (l_prep) in_15\IN|role|that|hypomethylation (l_pobj) initiation_17\NN|NONE (l_prep) of_18\IN|the (l_pobj) process_20\NN|NONE
D001374_D011230 CID 5-AzC_24\CD|.|during|was|to (l_advcl) test_1\VB|azacytidine|)|,|inhibitor|(|,|,|mg/kg (l_dobj) validity_3\NN|To (l_prep) of_4\IN|the (l_pobj) hypothesis_6\NN|NONE (l_acl) plays_11\VBZ|the (l_prep) in_15\IN|role|that|hypomethylation (l_pobj) initiation_17\NN|NONE (l_prep) of_18\IN|the (l_pobj) process_20\NN|NONE
18483878
D003520_D003556 CID cyclophosphamide_15\NN|NONE (r_pobj) with_14\IN|NONE (r_prep) mice_13\NNS|VIP/|cystitis|)|(|polypeptide (r_appos) knockout_9\NN|NONE (l_appos) cystitis_18\NN|VIP/|)|(|mice|polypeptide
D003520_D003556 CID CYP)-induced_17\VBN|NONE (r_compound) cystitis_18\NN|VIP/|)|(|mice|polypeptide
D003520_D003556 CID cyclophosphamide_14\NN|NONE (r_pobj) after_13\IN|cystitis|VIP(/|function|. (r_prep) altered_4\JJ|NONE (l_dobj) cystitis_17\NN|after|VIP(/|function|.
D003520_D003556 CID CYP)-induced_16\VBN|( (r_amod) cystitis_17\NN|after|VIP(/|function|.
D003520_D003556 CID CYP_32\NNP| (r_npadvmod) induced_34\VBN|h|;|;|mg/kg|(|i.p.|) (r_amod) cystitis_35\NN|NONE
D003520_D001745 NONE CYP_22\NNP|NONE (r_pobj) with_21\IN|NONE (r_prep) WT_20\NNP|NONE (r_pobj) in_19\IN|that (r_prep) observed_18\VBD|are|above|,|mediators|mice (r_advcl) increased_15\VBN|data|. (l_advcl) mice_7\NNS|are|above|observed|,|mediators (l_prep) with_8\IN|in|that (l_pobj) inflammation_10\NN|NONE
8514073
D008874_D010146 NONE midazolam_32\JJ|the (r_amod) group_33\NN|NONE (r_pobj) in_30\IN|(|.|patients|)| (r_prep) %_23\NN|NONE (r_pobj) with_21\IN|NONE (r_prep) compared_20\VBN|.|Pain|in (r_prep) occurred_5\VBD|NONE (l_nsubj) Pain_0\NN|compared|.|in
D008874_D014652 CID midazolam_3\FW|NONE (r_pobj) of_2\IN|.|Venous (r_prep) complications_1\NNS|NONE
D008874_D014652 CID midazolam_11\DT|NONE (r_pobj) with_10\IN|are|complications (r_prep) associated_9\VBN|studies|have|Although (l_nsubjpass) complications_7\NNS|with|are
D008874_D014652 CID midazolam_14\NN|or (r_conj) diazepam_12\NN|NONE (r_pobj) of_11\IN|intravenous|in (r_prep) injection_10\NN|NONE (r_pobj) after_8\IN|incidence|prospectively|We|. (r_prep) evaluated_2\VBD|NONE (l_dobj) incidence_4\NN|prospectively|We|after|. (l_prep) of_5\IN|the (l_pobj) complications_7\NNS|NONE
D008874_D014652 CID midazolam_17\NNP|NONE (r_pobj) with_16\IN|. (r_prep) than_15\IN|(|)|of (r_prep) 22_10\CD|complications|Overall|.|frequent|, (r_npadvmod) were_4\VBD|NONE (l_nsubj) complications_3\NNS|Overall|.||frequent|,
D000431_D014652 NONE alcohol_19\NN|,|and|pain (r_compound) use_20\NN|of|dwell|, (r_conj) time_14\NN|,|intravenous|catheter (r_conj) site_11\NN|nonsteroidal|inflammatory|drug|, (r_conj) use_7\NN|, (r_appos) Smoking_0\NN|effect|. (r_nsubj) had_27\VBD|NONE (l_dobj) effect_29\NN|.|Smoking (l_prep) on_30\IN|no (l_pobj) incidence_32\NN|NONE (l_prep) of_33\IN|the (l_pobj) complications_35\NNS|NONE
D003975_D014652 CID diazepam_5\NN|NONE (r_pobj) versus_4\FW|NONE (r_prep) midazolam_3\FW|NONE (r_pobj) of_2\IN|.|Venous (r_prep) complications_1\NNS|NONE
D003975_D014652 CID diazepam_14\NN|NONE (r_pobj) with_13\IN|NONE (r_prep) than_12\IN|NONE (r_prep) midazolam_11\DT|NONE (r_pobj) with_10\IN|are|complications (r_prep) associated_9\VBN|studies|have|Although (l_nsubjpass) complications_7\NNS|with|are
D003975_D014652 CID diazepam_12\NN|NONE (r_pobj) of_11\IN|intravenous|in (r_prep) injection_10\NN|NONE (r_pobj) after_8\IN|incidence|prospectively|We|. (r_prep) evaluated_2\VBD|NONE (l_dobj) incidence_4\NN|prospectively|We|after|. (l_prep) of_5\IN|the (l_pobj) complications_7\NNS|NONE
D003975_D014652 CID diazepam_8\NN|NONE (r_pobj) with_7\IN|more (r_prep) frequent_6\JJ|complications|Overall|.||, (r_acomp) were_4\VBD|NONE (l_nsubj) complications_3\NNS|Overall|.||frequent|,
D000431_D010146 NONE alcohol_19\NN|,|and|pain (r_compound) use_20\NN|of|dwell|, (l_conj) pain_23\NN|,|alcohol|and
D003975_D010146 NONE diazepam_18\NN|the (r_compound) group_19\NN|NONE (r_pobj) in_16\IN|NONE (r_prep) patients_15\NNS|NONE (r_pobj) of_14\IN||(||) (r_prep) %_8\NN|NONE (r_pobj) in_6\IN|compared|.|Pain (r_prep) occurred_5\VBD|NONE (l_nsubj) Pain_0\NN|compared|.|in
12574103
D003907_D006973 CID dexamethasone_1\NN|Prenatal (r_compound) programs_2\NNS|injury|in|and|. (r_compound) hypertension_3\NN|NONE
D003907_D006973 CID dexamethasone_11\NN|if|increase (r_nsubj) programmed_12\VBD|to (l_dobj) increase_15\NN|if|dexamethasone (l_prep) in_16\IN|progressive|a (l_pobj) pressure_18\NN|NONE
D003907_D006973 CID dexamethasone_5\NN|that|on (r_dobj) received_3\VBD|Male (r_relcl) rats_1\NNS|had|pressures|at (r_nsubj) elevated_23\VBN|reduction|;|did|not|.|group (l_dobj) pressures_25\NNS|had|rats|at
D003907_D006973 CID dexamethasone_5\NN|in|that (r_nsubj) results_8\VBZ|.|study (l_prep) in_9\IN|dexamethasone|that (l_pobj) reduction_11\NN|NONE (l_prep) in_12\IN|a (l_pobj) number_14\NN|NONE (l_conj) glomerulosclerosis_16\NN|glomerular|administered|, (l_conj) hypertension_19\NN|and|,
D003907_D005921 NONE dexamethasone_3\NN|had|rats|.|on (r_dobj) given_2\VBN|NONE (l_advcl) had_11\VBD|dexamethasone|rats|.|on (l_dobj) glomeruli_13\NNS|NONE (l_prep) with_14\IN|than|more (l_pobj) glomerulosclerosis_15\NN|NONE
D003907_D005921 NONE dexamethasone_5\NN|in|that (r_nsubj) results_8\VBZ|.|study (l_prep) in_9\IN|dexamethasone|that (l_pobj) reduction_11\NN|NONE (l_prep) in_12\IN|a (l_pobj) number_14\NN|NONE (l_conj) glomerulosclerosis_16\NN|glomerular|administered|,
D003907_D007674 CID dexamethasone_1\NN|Prenatal (r_compound) programs_2\NNS|injury|in|and|. (r_compound) hypertension_3\NN|NONE (l_conj) injury_6\NN|in|and|.|programs
D003907_D007674 CID dexamethasone_11\NN|if|increase (r_nsubj) programmed_12\VBD|to (l_dobj) increase_15\NN|if|dexamethasone (l_prep) in_16\IN|progressive|a (l_pobj) pressure_18\NN|NONE (l_conj) injury_21\NN|blood|and
D003907_D007674 CID dexamethasone_4\NN|Offspring|on (r_dobj) administered_3\VBN|compared|.|reduction (r_csubj) had_11\VBD|NONE (l_dobj) reduction_15\NN|compared|administered|. (l_prep) in_16\IN|%|a (l_pobj) number_18\NN|NONE
D003907_D007674 CID dexamethasone_5\NN|that|on (r_dobj) received_3\VBD|Male (r_relcl) rats_1\NNS|had|pressures|at (r_nsubj) elevated_23\VBN|reduction|;|did|not|.|group (r_ccomp) have_37\VB|NONE (l_dobj) reduction_39\NN|;|did|not|.|group|elevated (l_prep) in_40\IN|a (l_pobj) number_42\NN|NONE
D003907_D007674 CID dexamethasone_5\NN|in|that (r_nsubj) results_8\VBZ|.|study (l_prep) in_9\IN|dexamethasone|that (l_pobj) reduction_11\NN|NONE (l_prep) in_12\IN|a (l_pobj) number_14\NN|NONE
7988234
D008790_D000799 CID metoprolol_6\NN|NONE (r_pobj) of_5\IN|intravenous|the (r_prep) administration_4\NN|NONE (r_dobj) following_1\VBG|. (r_prep) Angioedema_0\NNP|NONE
D008790_D000799 CID metoprolol_12\NN|.|was|resulting|During|,|, (r_nsubjpass) given_14\VBN|NONE (l_advcl) resulting_16\VBG|.|was|metoprolol|During|,|, (l_prep) in_17\IN|NONE (l_pobj) angioedema_19\NN|NONE
D004155_D000799 NONE diphenhydramine_9\NN|intravenous|and (r_conj) steroids_7\NNS|NONE (r_pobj) with_5\IN|.|after|angioedema (r_prep) resolved_2\VBD|NONE (l_nsubj) angioedema_1\NN|.|with|after
D013256_D000799 NONE steroids_7\NNS|NONE (r_pobj) with_5\IN|.|after|angioedema (r_prep) resolved_2\VBD|NONE (l_nsubj) angioedema_1\NN|.|with|after
D017706_D000799 CID lisinopril_6\NN|NONE (r_compound) therapy_7\NN|NONE (r_pobj) to_5\IN|of|A (r_prep) history_1\NN|.|was (l_prep) of_2\IN|to|A (l_pobj) angioedema_3\NN|NONE
983936
D004176_D009202 NONE dipyridamole_5\NN|,|acetylsalicylic (l_conj) hydrocortisone_8\NN|and|, (l_prep) on_9\IN|NONE (l_pobj) injury_14\NN|NONE
D006854_D009202 NONE hydrocortisone_8\NN|and|, (l_prep) on_9\IN|NONE (l_pobj) injury_14\NN|NONE
D004837_D009202 CID epinephrine_10\NN| (r_npadvmod) induced_12\VBN|in|myocardial (r_amod) injury_14\NN|NONE
D004837_D009202 CID epinephrine_9\NN|( (r_amod) infusion_10\NN|myocardial|diffuse (r_appos) injury_7\NN|NONE
D004837_D009203 NONE epinephrine_9\NN|( (r_amod) infusion_10\NN|myocardial|diffuse (r_appos) injury_7\NN|NONE (r_dobj) producing_4\VBG|NONE (r_pcomp) for_3\IN|reproducible|)|A (r_prep) model_2\NN|.|study|has|been (r_nsubjpass) developed_14\VBN|NONE (l_advcl) study_16\VB|.|has|model|been (l_dobj) effects_19\NNS|to (l_prep) of_20\IN|cardioprotective|the (l_pobj) agents_21\NNS|NONE (l_relcl) alter_26\VB|or|maneuvers (l_dobj) evolution_28\NN|might|which (l_prep) of_29\IN|the (l_pobj) infarction_32\NN|NONE
D001241_D009202 NONE acid_3\NN|NONE (l_conj) dipyridamole_5\NN|,|acetylsalicylic (l_conj) hydrocortisone_8\NN|and|, (l_prep) on_9\IN|NONE (l_pobj) injury_14\NN|NONE
2980315
D007472_D014693 NONE iohexol_20\NN|%|and (r_conj) iopentol_14\NN|NONE (r_pobj) after_13\IN|less|)|p|(|than (r_prep) 0.05_11\CD|than|Frequencies|lower|. (r_parataxis) were_4\VBD|NONE (l_nsubj) Frequencies_0\NNS|than|lower|.|. (l_prep) of_1\IN|NONE (l_pobj) fibrillation_3\NN|NONE
D008794_D014693 CID metrizoate_27\NN|NONE (r_pobj) after_26\IN|NONE (r_prep) than_25\IN|Frequencies|lower|.|. (r_prep) were_4\VBD|NONE (l_nsubj) Frequencies_0\NNS|than|lower|.|. (l_prep) of_1\IN|NONE (l_pobj) fibrillation_3\NN|NONE
C053571_D014693 NONE iopentol_14\NN|NONE (r_pobj) after_13\IN|less|)|p|(|than (r_prep) 0.05_11\CD|than|Frequencies|lower|. (r_parataxis) were_4\VBD|NONE (l_nsubj) Frequencies_0\NNS|than|lower|.|. (l_prep) of_1\IN|NONE (l_pobj) fibrillation_3\NN|NONE
9041081
D000305_D009798 CID corticosteroid_25\NN|NONE (r_compound) therapy_26\NN|was|after (r_nsubjpass) discontinued_28\VBN|that (r_advcl) resolved_23\VBD|) (r_relcl) IOP_20\NNP|elevated|intraocular|induced|( (r_appos) pressure_18\NN|During|.|patients|,
D013256_D009798 NONE steroid_13\NN| (r_npadvmod) induced_15\VBN|IOP|elevated|intraocular|( (r_amod) pressure_18\NN|During|.|patients|,
D013256_D009798 NONE steroid_2\NN| (r_npadvmod) induced_4\VBN|IOP (r_amod) rise_6\NN|.|did|cause|not
19923525
D005996_D008569 CID nitroglycerin_6\NN| (r_npadvmod) induced_8\VBN|in (r_amod) hypotension_9\NN|NONE (r_pobj) by_5\IN|NONE (r_agent) caused_4\VBN|memory (r_acl) impairment_3\NN|Nimodipine|.
D009553_D007022 NONE Nimodipine_0\NNP|impairment|. (r_nsubj) prevents_1\VBZ|NONE (l_dobj) impairment_3\NN|Nimodipine|. (l_acl) caused_4\VBN|memory (l_agent) by_5\IN|NONE (l_pobj) hypotension_9\NN|NONE
D009553_D007022 NONE nimodipine_5\NN|at (r_nsubj) administered_9\VBN|the (r_acl) hypothesis_3\NN|We (r_dobj) tested_1\VBD|(|.|would|memory|hypotension (r_ccomp) preserve_19\VB|NONE (l_nsubj) hypotension_17\NN|tested|(|.|would|memory
D009553_D007022 NONE NIMO_7\NNP|)|that|( (r_appos) nimodipine_5\NN|at (r_nsubj) administered_9\VBN|the (r_acl) hypothesis_3\NN|We (r_dobj) tested_1\VBD|(|.|would|memory|hypotension (r_ccomp) preserve_19\VB|NONE (l_nsubj) hypotension_17\NN|tested|(|.|would|memory
D009553_D007022 NONE NIMO_27\NN|+ (r_conj) NTG_25\NNP|, (r_appos) saline_23\NN|NONE (r_pobj) with_22\IN|NONE (r_prep) injected_21\VBN|NONE (r_acl) those_20\DT|NONE (r_pobj) with_19\IN|NONE (r_prep) compared_18\VBN|or|delayed|decrease|, (r_prep) showed_5\VBD|Mice|to|. (r_conj) subjected_1\VBN|NONE (l_prep) to_2\IN|Mice|.|showed (l_pobj) episodes_4\NNS|NONE (l_amod) hypotensive_3\JJ|NONE
D009553_D007022 NONE NIMO_0\NN|but|improve|.|disruption (r_advmod) attenuated_1\VBD|NONE (l_conj) improve_17\VB|but|.|disruption|NIMO (l_prep) in_19\IN|did|latency|not (l_pobj) absence_21\NN|NONE (l_prep) of_22\IN|the (l_pobj) hypotension_23\NN|NONE
D009553_D007022 NONE NIMO_4\NNP|NONE (r_pobj) of_3\IN|observed|The (r_prep) effect_2\NN|attributable|.|have|,|were|may (r_nsubj) been_7\VBN|NONE (l_acomp) attributable_8\JJ|effect|.|have|,|were|may (l_prep) to_9\IN|NONE (l_pobj) preservation_11\NN|NONE (l_prep) during_15\IN|of|the (l_pobj) hypotension_16\NN|NONE
D002118_D007022 NONE calcium_13\NN|NONE (r_compound) homeostasis_14\NN|NONE (r_pobj) of_12\IN|the|during (r_prep) preservation_11\NN|NONE (l_prep) during_15\IN|of|the (l_pobj) hypotension_16\NN|NONE
D009553_D008569 NONE Nimodipine_0\NNP|impairment|. (r_nsubj) prevents_1\VBZ|NONE (l_dobj) impairment_3\NN|Nimodipine|.
D005996_D007022 CID nitroglycerin_6\NN| (r_npadvmod) induced_8\VBN|in (r_amod) hypotension_9\NN|NONE
D005996_D007022 CID nitroglycerin_14\NN|NONE (r_pobj) of_13\IN|the (r_prep) onset_12\NN|NONE (r_pobj) at_10\IN|nimodipine (r_prep) administered_9\VBN|the (r_acl) hypothesis_3\NN|We (r_dobj) tested_1\VBD|(|.|would|memory|hypotension (r_ccomp) preserve_19\VB|NONE (l_nsubj) hypotension_17\NN|tested|(|.|would|memory
D005996_D007022 CID NTG)-induced_16\JJ|NONE (r_amod) hypotension_17\NN|tested|(|.|would|memory
D005996_D007022 CID NTG_25\NNP|, (r_appos) saline_23\NN|NONE (r_pobj) with_22\IN|NONE (r_prep) injected_21\VBN|NONE (r_acl) those_20\DT|NONE (r_pobj) with_19\IN|NONE (r_prep) compared_18\VBN|or|delayed|decrease|, (r_prep) showed_5\VBD|Mice|to|. (r_conj) subjected_1\VBN|NONE (l_prep) to_2\IN|Mice|.|showed (l_pobj) episodes_4\NNS|NONE (l_amod) hypotensive_3\JJ|NONE
D005996_D007022 CID NTG_31\NNP|)|respectively (r_dobj) delayed_30\VBN|or|compared|decrease|, (r_conj) showed_5\VBD|Mice|to|. (r_conj) subjected_1\VBN|NONE (l_prep) to_2\IN|Mice|.|showed (l_pobj) episodes_4\NNS|NONE (l_amod) hypotensive_3\JJ|NONE
D005996_D007022 CID NTG_9\NNP|NONE (r_pobj) of_8\IN|the (r_prep) injection_7\NN|impairment|In|,|.|after|,|had (r_nsubj) produced_13\VBD|NONE (l_conj) had_30\VBD|impairment|In|,|injection|.|after|, (l_advcl) delayed_27\VBN|effect (l_dobj) hypotension_29\NN|whereas
D005996_D007022 CID NTG_13\NNP|NONE (r_pobj) by_12\IN|NONE (r_agent) caused_11\VBN|term (r_acl) memory_10\NN|NONE (r_pobj) of_6\IN|NONE (r_prep) consolidation_5\NN|NONE (r_pobj) in_4\IN|the (r_prep) disruption_3\NN|but|improve|.|NIMO (r_dobj) attenuated_1\VBD|NONE (l_conj) improve_17\VB|but|.|disruption|NIMO (l_prep) in_19\IN|did|latency|not (l_pobj) absence_21\NN|NONE (l_prep) of_22\IN|the (l_pobj) hypotension_23\NN|NONE
8669433
D000082_D007676 NONE acetaminophen_3\NN|NONE (r_pobj) of_2\IN|.|as|Habitual|comparison|: (r_prep) use_1\NN|NONE (l_prep) as_4\IN|.|of|Habitual|comparison|: (l_pobj) factor_7\NN|NONE (l_prep) for_8\IN|a|risk (l_pobj) failure_11\NN|NONE
D000082_D007676 NONE acetaminophen_27\NN|NONE (r_pobj) of_26\IN|habitual (r_prep) use_25\NN|with|also|,|that|with|is (r_nsubjpass) associated_30\VBN|However|.|,|studies (l_prep) with_31\IN|with|also|use|,|that|is (l_pobj) failure_34\NN|NONE
D000082_D007676 NONE acetaminophen_27\NN|NONE (r_pobj) of_26\IN|habitual (r_prep) use_25\NN|with|also|,|that|with|is (r_nsubjpass) associated_30\VBN|However|.|,|studies (l_prep) with_31\IN|with|also|use|,|that|is (l_pobj) failure_34\NN|NONE (l_conj) ESRD_36\NNP|chronic|and|renal
D000082_D007676 NONE acetaminophen_7\RB|both|and (r_conj) phenacetin_5\NN|,|with|that|may|to (r_nsubj) contribute_9\VB|studies|. (l_prep) to_10\IN|,|phenacetin|with|that|may (l_pobj) burden_12\NN|NONE (l_prep) of_13\IN|the (l_pobj) ESRD_14\NNP|NONE
D000082_D007676 NONE acetaminophen_6\NN|NONE (r_pobj) of_5\IN|habitual|alone (r_prep) use_4\NN|that|risk (r_nsubj) increases_8\VBZ|The (l_dobj) risk_10\NN|that|use (l_prep) of_11\IN|the (l_pobj) ESRD_12\NNP|NONE
D010615_D007676 CID phenacetin_16\NN|NONE (r_pobj) with_15\IN|a (r_prep) comparison_14\NN|.|of|as|Habitual|: (r_appos) use_1\NN|NONE (l_prep) as_4\IN|.|of|Habitual|comparison|: (l_pobj) factor_7\NN|NONE (l_prep) for_8\IN|a|risk (l_pobj) failure_11\NN|NONE
D010615_D007676 CID phenacetin_14\NN|NONE (r_pobj) of_13\IN|habitual (r_prep) use_12\NN|is|,|with|that|with (r_nsubjpass) associated_16\VBN|.|studies (l_prep) with_17\IN|is|,|with|that|use (l_pobj) development_19\NN|NONE (l_prep) of_20\IN|the (l_pobj) failure_23\NN|NONE
D010615_D007676 CID phenacetin_14\NN|NONE (r_pobj) of_13\IN|habitual (r_prep) use_12\NN|is|,|with|that|with (r_nsubjpass) associated_16\VBN|.|studies (l_prep) with_17\IN|is|,|with|that|use (l_pobj) development_19\NN|NONE (l_prep) of_20\IN|the (l_pobj) failure_23\NN|NONE (l_conj) disease_29\NN|chronic|and|renal
D010615_D007676 CID phenacetin_14\NN|NONE (r_pobj) of_13\IN|habitual (r_prep) use_12\NN|is|,|with|that|with (r_nsubjpass) associated_16\VBN|.|studies (l_prep) with_17\IN|is|,|with|that|use (l_pobj) development_19\NN|NONE (l_prep) of_20\IN|the (l_pobj) failure_23\NN|NONE (l_conj) disease_29\NN|chronic|and|renal (l_appos) ESRD_31\NNP|stage|)|renal|(
D010615_D007676 CID phenacetin_5\NN|,|with|that|may|to (r_nsubj) contribute_9\VB|studies|. (l_prep) to_10\IN|,|phenacetin|with|that|may (l_pobj) burden_12\NN|NONE (l_prep) of_13\IN|the (l_pobj) ESRD_14\NNP|NONE
12549952
D002231_D056486 CID carbimazole_36\NN|NONE (r_pobj) with_35\IN|concomitant (r_prep) treatment_34\NN|while (r_pobj) on_32\IN|could|that|have|from (r_prep) resulted_21\VBN|the|first|of (r_relcl) case_15\NN|.|,|increasing|this (r_attr) is_12\VBZ|NONE (l_advcl) increasing_3\VBG|.|,|this|case (l_dobj) evidence_4\NN|is (l_prep) of_5\IN|induced (l_pobj) hepatotoxicity_6\NN|NONE
D016642_D056486 CID bupropion_3\NN|hepatotoxicity|that|in (r_nsubj) induced_4\VBD|The (l_dobj) hepatotoxicity_5\NN|bupropion|that|in
D016642_D056486 CID bupropion_9\NN|NONE (r_pobj) by_8\IN|NONE (r_agent) induced_7\VBN|of (r_acl) evidence_4\NN|is (l_prep) of_5\IN|induced (l_pobj) hepatotoxicity_6\NN|NONE
D016642_D056486 CID bupropion_30\NN|NONE (r_dobj) receiving_29\VBG|a (r_acl) patient_28\JJ|NONE (r_pobj) in_26\IN|acute|liver (r_prep) failure_25\NN|NONE (r_pobj) from_22\IN|could|on|that|have (r_prep) resulted_21\VBN|the|first|of (r_relcl) case_15\NN|.|,|increasing|this (r_attr) is_12\VBZ|NONE (l_advcl) increasing_3\VBG|.|,|this|case (l_dobj) evidence_4\NN|is (l_prep) of_5\IN|induced (l_pobj) hepatotoxicity_6\NN|NONE
D016642_D056486 CID bupropion_13\NN|NONE (l_acl) given_14\VBN|NONE (l_prep) with_16\IN|concurrently (l_pobj) drugs_19\NNS|NONE (l_amod) hepatotoxic_18\JJ|other
D002231_D006980 NONE carbimazole_15\NN|NONE (r_pobj) with_14\IN|man|propranolol|.|had|been|and (r_prep) treated_13\VBN|NONE (l_nsubjpass) man_5\NN|with|propranolol|.|had|been|and (l_prep) with_6\IN|Chinese|old|A (l_pobj) history_8\NN|NONE (l_prep) of_9\IN|a (l_pobj) hyperthyroidism_10\NN|NONE
D016642_D017093 NONE bupropion_14\NN|NONE (r_pobj) of_13\IN|concurrent (r_prep) use_12\NN|NONE (r_pobj) with_10\IN|possibly (r_prep) associated_9\VBN|liver|fatal (r_acl) failure_7\NN|NONE
D016642_D017114 CID bupropion_5\NN|NONE (r_pobj) with_3\IN|Acute|liver|. (r_prep) failure_2\NN|NONE
D016642_D017114 CID bupropion_9\NN|NONE (r_pobj) by_8\IN|NONE (r_agent) induced_7\VBN|of (r_acl) evidence_4\NN|is (r_dobj) increasing_3\VBG|.|,|this|case (r_advcl) is_12\VBZ|NONE (l_attr) case_15\NN|.|,|increasing|this (l_relcl) resulted_21\VBN|the|first|of (l_prep) from_22\IN|could|on|that|have (l_pobj) failure_25\NN|NONE
D016642_D017114 CID bupropion_30\NN|NONE (r_dobj) receiving_29\VBG|a (r_acl) patient_28\JJ|NONE (r_pobj) in_26\IN|acute|liver (r_prep) failure_25\NN|NONE
D016642_D017114 CID bupropion_13\NN|NONE (r_pobj) by_12\IN|NONE (r_agent) induced_11\VBN|acute|liver (r_acl) insult_10\NN|NONE
D002231_D017114 CID carbimazole_7\NN|NONE (r_compound) therapy_8\NN|concurrent|and (r_conj) bupropion_5\NN|NONE (r_pobj) with_3\IN|Acute|liver|. (r_prep) failure_2\NN|NONE
D002231_D017114 CID carbimazole_36\NN|NONE (r_pobj) with_35\IN|concomitant (r_prep) treatment_34\NN|while (r_pobj) on_32\IN|could|that|have|from (r_prep) resulted_21\VBN|the|first|of (l_prep) from_22\IN|could|on|that|have (l_pobj) failure_25\NN|NONE
D002231_D017093 NONE carbimazole_16\NN|and (r_conj) bupropion_14\NN|NONE (r_pobj) of_13\IN|concurrent (r_prep) use_12\NN|NONE (r_pobj) with_10\IN|possibly (r_prep) associated_9\VBN|liver|fatal (r_acl) failure_7\NN|NONE
D011433_D006980 NONE propranolol_17\NN|man|with|.|had|been|and (r_conj) treated_13\VBN|NONE (l_nsubjpass) man_5\NN|with|propranolol|.|had|been|and (l_prep) with_6\IN|Chinese|old|A (l_pobj) history_8\NN|NONE (l_prep) of_9\IN|a (l_pobj) hyperthyroidism_10\NN|NONE
2564649
D011224_D009127 NONE prazosin_32\NN|NONE (r_pobj) with_25\IN|prior|of|electrolytic (r_prep) lesions_18\NNS|NONE (r_pobj) by_15\IN|even (r_agent) reduced_14\VBN|significantly|.|rigidity|or|was (r_conj) antagonized_11\VBN|NONE (l_nsubjpass) rigidity_4\NN|significantly|.|reduced|or|was
D005283_D009127 CID fentanyl_8\NN| (r_npadvmod) induced_10\VBN|in|muscular (r_amod) rigidity_12\NN|NONE
D005283_D009127 CID fentanyl_17\NN|dose (r_compound) anesthesia_18\NN|NONE (r_pobj) with_13\IN|that|is (r_prep) associated_12\VBN|side|a|known (r_relcl) effect_9\NN|rigidity|Whereas (r_attr) is_3\VBZ|with|)|paucity|.|, (l_nsubj) rigidity_2\NN|effect|Whereas
D005283_D009127 CID fentanyl_10\NN|NONE (r_pobj) by_9\IN|muscular (r_prep) rigidity_8\NN|NONE
591536
D006493_D001791 NONE heparin_8\VBN| (r_npadvmod) induced_10\VBN|platelet (r_amod) aggregation_12\NN|.|factor
D006493_D013921 CID heparin_6\JJ|systemic (r_compound) therapy_7\NN|NONE (r_dobj) receiving_4\VBG|NONE (r_acl) patients_3\NNS|NONE (r_pobj) in_2\IN|:|.|complication|Arterial (r_prep) thromboembolism_1\NN|NONE (l_appos) complication_10\NN|:|in|.|Arterial (l_acl) associated_11\VBN|a (l_prep) with_12\IN|NONE (l_pobj) thrombocytopenia_16\NN|NONE
D006493_D013921 CID heparin_13\NN| (r_npadvmod) induced_15\VBN|NONE (r_amod) thrombocytopenia_16\NN|NONE
D006493_D013921 CID heparin_24\JJ|NONE (r_compound) therapy_25\NN|NONE (r_pobj) of_23\IN|the (r_prep) initiation_22\NN|days (r_pobj) after_20\IN|NONE (r_prep) occurring_15\VBG|thrombi (r_pcomp) by_7\IN|preceded|,|arterial (r_prep) occlusion_6\NN|Characteristic|. (l_acl) preceded_27\VBN|,|by|arterial (l_agent) by_28\IN|NONE (l_pobj) thrombocytopenia_30\NN|NONE
D006493_D013921 CID heparin_8\VBN| (r_npadvmod) induced_10\VBN|platelet (r_amod) aggregation_12\NN|.|factor (r_attr) is_7\VBZ|NONE (l_nsubj) factor_2\NN|.|aggregation (l_acl) relating_3\VBG|The|common (l_dobj) thromboembolism_4\NN|NONE (l_conj) thrombocytopenia_6\NN|and
D006493_D013923 NONE heparin_6\JJ|systemic (r_compound) therapy_7\NN|NONE (r_dobj) receiving_4\VBG|NONE (r_acl) patients_3\NNS|NONE (r_pobj) in_2\IN|:|.|complication|Arterial (r_prep) thromboembolism_1\NN|NONE
D006493_D013923 NONE heparin_13\NN| (r_npadvmod) induced_15\VBN|NONE (r_amod) thrombocytopenia_16\NN|NONE (r_pobj) with_12\IN|NONE (r_prep) associated_11\VBN|a (r_acl) complication_10\NN|:|in|.|Arterial (r_appos) thromboembolism_1\NN|NONE
D006493_D013923 NONE heparin_8\JJ|systemic (r_compound) therapy_9\NN|NONE (r_pobj) of_6\IN|a|recognized (r_prep) complication_5\NN|thromboembolism|. (r_attr) is_2\VBZ|NONE (l_nsubj) thromboembolism_1\NN|complication|.
D006493_D013923 NONE heparin_8\VBN| (r_npadvmod) induced_10\VBN|platelet (r_amod) aggregation_12\NN|.|factor (r_attr) is_7\VBZ|NONE (l_nsubj) factor_2\NN|.|aggregation (l_acl) relating_3\VBG|The|common (l_dobj) thromboembolism_4\NN|NONE
D006493_D013927 NONE heparin_24\JJ|NONE (r_compound) therapy_25\NN|NONE (r_pobj) of_23\IN|the (r_prep) initiation_22\NN|days (r_pobj) after_20\IN|NONE (r_prep) occurring_15\VBG|thrombi (r_pcomp) by_7\IN|preceded|,|arterial (l_pobj) thrombi_11\NN|occurring
D006493_D007511 NONE heparin_24\JJ|NONE (r_compound) therapy_25\NN|NONE (r_pobj) of_23\IN|the (r_prep) initiation_22\NN|days (r_pobj) after_20\IN|NONE (r_prep) occurring_15\VBG|thrombi (r_pcomp) by_7\IN|preceded|,|arterial (l_pobj) thrombi_11\NN|occurring (l_prep) with_12\IN|fibrin (l_pobj) ischemia_14\NN|NONE
D006493_D001157 CID heparin_24\JJ|NONE (r_compound) therapy_25\NN|NONE (r_pobj) of_23\IN|the (r_prep) initiation_22\NN|days (r_pobj) after_20\IN|NONE (r_prep) occurring_15\VBG|thrombi (r_pcomp) by_7\IN|preceded|,|arterial (r_prep) occlusion_6\NN|Characteristic|.
6794356
D008094_D014262 NONE lithium_18\NN|high|a (r_compound) level_19\NN|and|,|heart (r_conj) failure_12\NN|,|atrial (r_conj) flutter_8\JJ|,|massive|tricuspid (r_conj) regurgitation_5\NN|NONE
D008094_D014262 NONE lithium_26\NN|NONE (r_compound) compounds_27\NNS|NONE (r_pobj) to_25\IN|in (r_prep) exposed_24\VBN|NONE (r_acl) infants_23\NNS|NONE (r_pobj) among_22\IN|cardiac (r_prep) disease_21\NN|NONE (r_pobj) with_19\IN|NONE (r_prep) patient_18\NN|th|. (r_dobj) described_17\VBN|patient|This|,|and (r_conj) is_1\VBZ|NONE (l_attr) patient_4\NN|This|,|described|and (l_relcl) manifest_7\VB|the|first (l_dobj) regurgitation_9\NN|initially|to
D008094_D006333 NONE lithium_18\NN|high|a (r_compound) level_19\NN|and|,|heart (r_conj) failure_12\NN|,|atrial
D016651_D006331 NONE carbonate_1\NN|in|.|taken|factor|may (r_nsubj) be_3\VB|NONE (l_prep) in_6\IN|.|taken|factor|carbonate|may (l_pobj) incidence_9\NN|NONE (l_prep) of_10\IN|increasing|the (l_pobj) disease_13\NN|NONE
D008094_D001282 NONE lithium_18\NN|high|a (r_compound) level_19\NN|and|,|heart (r_conj) failure_12\NN|,|atrial (r_conj) flutter_8\JJ|,|massive|tricuspid
D008094_D001282 NONE lithium_26\NN|NONE (r_compound) compounds_27\NNS|NONE (r_pobj) to_25\IN|in (r_prep) exposed_24\VBN|NONE (r_acl) infants_23\NNS|NONE (r_pobj) among_22\IN|cardiac (r_prep) disease_21\NN|NONE (r_pobj) with_19\IN|NONE (r_prep) patient_18\NN|th|. (r_dobj) described_17\VBN|patient|This|,|and (r_conj) is_1\VBZ|NONE (l_attr) patient_4\NN|This|,|described|and (l_relcl) manifest_7\VB|the|first (l_dobj) regurgitation_9\NN|initially|to (l_conj) flutter_12\NN|and|tricuspid
D016651_D064420 NONE carbonate_5\NN|NONE (r_compound) toxicity_6\NN|in|and|Tricuspid|.|valve
D008094_D006331 NONE lithium_26\NN|NONE (r_compound) compounds_27\NNS|NONE (r_pobj) to_25\IN|in (r_prep) exposed_24\VBN|NONE (r_acl) infants_23\NNS|NONE (r_pobj) among_22\IN|cardiac (r_prep) disease_21\NN|NONE
D016651_D014262 NONE carbonate_5\NN|NONE (r_compound) toxicity_6\NN|in|and|Tricuspid|.|valve (r_conj) regurgitation_2\NN|NONE
9351491
D006220_D010302 CID haloperidol_16\NN|and|%|(|) (r_conj) risperidone_10\NN|NONE (r_pobj) with_9\IN|NONE (r_prep) treated_8\VBN|NONE (r_acl) subjects_7\NNS|NONE (r_pobj) in_6\IN|.|was|parkinsonism|observed|and (r_prep) observed_5\VBN|NONE (l_nsubjpass) parkinsonism_3\NN|.|in|was|observed|and
D018967_D010302 CID risperidone_10\NN|NONE (r_pobj) with_9\IN|NONE (r_prep) treated_8\VBN|NONE (r_acl) subjects_7\NNS|NONE (r_pobj) in_6\IN|.|was|parkinsonism|observed|and (r_prep) observed_5\VBN|NONE (l_nsubjpass) parkinsonism_3\NN|.|in|was|observed|and
D018967_D011618 NONE risperidone_6\NN|pharmacologic (r_poss) profile_9\NN|decreased|efficacy|that|may|and (r_nsubj) produce_11\VB|have|studies (l_dobj) efficacy_13\NN|decreased|that|may|and|profile (l_prep) for_14\IN|improved (l_pobj) symptoms_17\NNS|NONE
2951327
D005996_D013610 NONE nitroglycerin_103\NN|or (r_conj) hydralazine_101\NN|NONE (r_pobj) by_100\IN|NONE (r_agent) induced_99\VBN|comparable (r_acl) hypotension_98\NN|NONE (r_pobj) to_96\IN|NONE (r_prep) contrast_95\NN|NONE (r_pobj) in_94\IN|which (r_prep) is_93\VBZ|,|were (r_advcl) observed_90\VBN|,|+/|pressure|.|+/ (r_conj) was_29\VBD|NONE (l_appos) +/-_45\NN|,|pressure|.|+/|observed (l_conj) tachycardia_70\NN|but|or|p||%|,|
D005996_D007022 CID nitroglycerin_103\NN|or (r_conj) hydralazine_101\NN|NONE (r_pobj) by_100\IN|NONE (r_agent) induced_99\VBN|comparable (r_acl) hypotension_98\NN|NONE
D006830_D013610 NONE hydralazine_101\NN|NONE (r_pobj) by_100\IN|NONE (r_agent) induced_99\VBN|comparable (r_acl) hypotension_98\NN|NONE (r_pobj) to_96\IN|NONE (r_prep) contrast_95\NN|NONE (r_pobj) in_94\IN|which (r_prep) is_93\VBZ|,|were (r_advcl) observed_90\VBN|,|+/|pressure|.|+/ (r_conj) was_29\VBD|NONE (l_appos) +/-_45\NN|,|pressure|.|+/|observed (l_conj) tachycardia_70\NN|but|or|p||%|,|
D009638_D013610 NONE norepinephrine_76\NN|release|the|( (r_amod) rate_78\NN|NONE (r_pobj) of_74\IN|no (r_prep) augmentation_73\NN|min|)|no|and (r_conj) tachycardia_70\NN|but|or|p||%|,|
D006830_D007022 CID hydralazine_101\NN|NONE (r_pobj) by_100\IN|NONE (r_agent) induced_99\VBN|comparable (r_acl) hypotension_98\NN|NONE
D009638_D007022 NONE norepinephrine_76\NN|release|the|( (r_amod) rate_78\NN|NONE (r_pobj) of_74\IN|no (r_prep) augmentation_73\NN|min|)|no|and (r_conj) tachycardia_70\NN|but|or|p||%|,| (r_conj) +/-_45\NN|,|pressure|.|+/|observed (r_appos) was_29\VBD|NONE (l_conj) observed_90\VBN|,|+/|pressure|.|+/ (l_advcl) is_93\VBZ|,|were (l_prep) in_94\IN|which (l_pobj) contrast_95\NN|NONE (l_prep) to_96\IN|NONE (l_pobj) hypotension_98\NN|NONE
6888657
D004054_D010911 CID diethylstilbestrol_12\NN|NONE (r_pobj) with_11\IN|chronic (r_prep) treatment_10\NN|NONE (r_pobj) by_8\IN|implanted|tumors|were|in|. (r_agent) induced_3\VBN|NONE (l_nsubjpass) tumors_1\NNS|implanted|by|were|in|.
D004054_D010911 CID DES_14\NNP|,|subcutaneously|(|in (r_npadvmod) implanted_21\VBN|by|tumors|were|in|. (r_parataxis) induced_3\VBN|NONE (l_nsubjpass) tumors_1\NNS|implanted|by|were|in|.
D004967_D010911 NONE estrogen_2\NN| (r_npadvmod) induced_4\VBN|in|adenohypophyseal (r_amod) tumors_6\NNS|NONE
D004054_D009369 NONE DES_12\NNP| (r_npadvmod) induced_14\VBN|the (r_amod) tumor_15\NN|further|as
17702969
D005473_D006976 CID fluoxetine_3\NN|hypertension|to (r_advmod) induces_4\VBZ|Prenatal|. (l_dobj) hypertension_7\NN|fluoxetine|to
D005473_D006976 CID fluoxetine_4\NN|NONE (r_amod) exposure_5\NN|prevalence|that|prenatally (r_nsubj) increases_7\VBZ|data|. (l_dobj) prevalence_9\NN|that|prenatally|exposure (l_prep) of_10\IN|the (l_pobj) syndrome_14\NN|NONE
D005473_D006976 CID fluoxetine_20\NN|in|protective (r_amod) effect_21\NN|current|of|the (r_appos) evidence_14\NN|NONE (l_prep) of_15\IN|current|effect|the (l_pobj) hypertension_18\NN|NONE
D005473_D006976 CID fluoxetine_5\NN|NONE (r_amod) exposure_6\NN|in|by|.|and|evidenced|compared|, (r_nsubj) resulted_7\VBD|NONE (l_prep) in_8\IN|by|.|and|evidenced|exposure|compared|, (l_pobj) hypertension_11\NN|NONE
D005473_D006976 CID fluoxetine_6\NN|in (r_amod) exposure_7\NN|In|as|hypertension|.|, (r_nsubj) induces_10\VBZ|NONE (l_dobj) hypertension_12\NN|In|as|exposure|.|,
D005473_D005315 CID fluoxetine_3\NN|hypertension|to (r_advmod) induces_4\VBZ|Prenatal|. (l_dobj) hypertension_7\NN|fluoxetine|to
D005473_D005315 CID fluoxetine_5\NN|NONE (r_amod) exposure_6\NN|in|by|.|and|evidenced|compared|, (r_nsubj) resulted_7\VBD|NONE (l_prep) in_8\IN|by|.|and|evidenced|exposure|compared|, (l_pobj) hypertension_11\NN|NONE
9390208
C085788_D001943 NONE MFL_21\NNP|dose|(|)|leucovorin|benefit|and|: (r_appos) 5-FU_17\CD|NONE (r_pobj) of_13\IN|hour|continuous (r_prep) infusion_12\NN|of|. (r_conj) Treatment_0\NN|NONE (l_prep) of_1\IN|infusion|. (l_pobj) cancer_6\NN|NONE
D008942_D001943 NONE mitoxantrone_8\NN|NONE (r_pobj) by_7\IN|metastatic|treated|breast (r_prep) cancer_6\NN|NONE
D008942_D001943 NONE mitoxantrone_20\NN|NONE (r_pobj) by_19\IN|,|for|m|we|with|,|,|m|patients|.|on|,|From (r_prep) treated_8\VBD|NONE (l_dobj) patients_10\NNS|by|,|for|m|we|with|,|,|m|.|on|,|From (l_prep) with_11\IN| (l_pobj) cancer_18\NN|NONE
D002955_D001943 NONE leucovorin_19\NN|dose|(|)|MFL|benefit|and|: (r_conj) 5-FU_17\CD|NONE (r_pobj) of_13\IN|hour|continuous (r_prep) infusion_12\NN|of|. (r_conj) Treatment_0\NN|NONE (l_prep) of_1\IN|infusion|. (l_pobj) cancer_6\NN|NONE
D002955_D001943 NONE leucovorin_43\NN|together (r_pobj) with_42\IN|by|,|for|m|we|,|,|m|patients|.|on|,|From (r_prep) treated_8\VBD|NONE (l_dobj) patients_10\NNS|by|,|for|m|we|with|,|,|m|.|on|,|From (l_prep) with_11\IN| (l_pobj) cancer_18\NN|NONE
D008942_D064420 NONE mitoxantrone_8\NN|NONE (r_pobj) by_7\IN|metastatic|treated|breast (r_prep) cancer_6\NN|NONE (r_pobj) of_1\IN|infusion|. (r_prep) Treatment_0\NN|NONE (l_conj) infusion_12\NN|of|. (l_prep) of_13\IN|hour|continuous (l_pobj) 5-FU_17\CD|NONE (l_conj) benefit_26\NN|dose|(|)|leucovorin|MFL|and|: (l_conj) toxicity_32\NN|low|palliative|and
C085788_D064420 NONE MFL_21\NNP|dose|(|)|leucovorin|benefit|and|: (r_appos) 5-FU_17\CD|NONE (l_conj) benefit_26\NN|dose|(|)|leucovorin|MFL|and|: (l_conj) toxicity_32\NN|low|palliative|and
C085788_D064420 NONE regimen_2\NN|induces|and|.|benefit (r_nsubj) achieves_3\VBZ|NONE (l_conj) induces_8\VBZ|and|regimen|.|benefit (l_dobj) toxicity_10\NN|at
D005472_D001943 NONE 5-FU_17\CD|NONE (r_pobj) of_13\IN|hour|continuous (r_prep) infusion_12\NN|of|. (r_conj) Treatment_0\NN|NONE (l_prep) of_1\IN|infusion|. (l_pobj) cancer_6\NN|NONE
D005472_D001943 NONE 5-FU_34\CD|NONE (r_pobj) of_33\IN|continuous (r_prep) infusion_32\NN|and| (r_conj) day_28\NN|NONE (r_pobj) on_27\IN|by|,|for|m|we|with|,|,|m|patients|.|,|From (r_prep) treated_8\VBD|NONE (l_dobj) patients_10\NNS|by|,|for|m|we|with|,|,|m|.|on|,|From (l_prep) with_11\IN| (l_pobj) cancer_18\NN|NONE
D005472_D064420 NONE 5-FU_17\CD|NONE (l_conj) benefit_26\NN|dose|(|)|leucovorin|MFL|and|: (l_conj) toxicity_32\NN|low|palliative|and
D002955_D064420 NONE leucovorin_19\NN|dose|(|)|MFL|benefit|and|: (r_conj) 5-FU_17\CD|NONE (l_conj) benefit_26\NN|dose|(|)|leucovorin|MFL|and|: (l_conj) toxicity_32\NN|low|palliative|and
3856631
D001663_D052016 NONE bilirubin_10\NN|NONE (r_amod) elevations_11\NNS|,|serum|transient|neutropenia|and (r_conj) transaminase_8\NN|toxicities|. (l_appos) neutropenia_13\NN|,|serum|transient|and|elevations (l_conj) mucositis_16\NN|and|,
D001663_D009503 NONE bilirubin_10\NN|NONE (r_amod) elevations_11\NNS|,|serum|transient|neutropenia|and (r_conj) transaminase_8\NN|toxicities|. (l_appos) neutropenia_13\NN|,|serum|transient|and|elevations
D001663_D064420 NONE bilirubin_10\NN|NONE (r_amod) elevations_11\NNS|,|serum|transient|neutropenia|and (r_conj) transaminase_8\NN|toxicities|. (r_attr) were_5\VBD|NONE (l_nsubj) toxicities_3\NNS|.|transaminase
D008727_D008577 NONE methotrexate_10\NNP|NONE (r_pobj) with_5\IN|meningeal (r_prep) leukemia_4\NN|NONE
D008727_D054198 NONE methotrexate_18\NNP|designed|dose|intravenous|a (r_compound) regimen_19\NN|NONE (r_pobj) with_12\IN|children|were|. (r_prep) treated_11\VBN|NONE (l_nsubjpass) children_1\NNS|were|.|with (l_prep) with_2\IN|developed|Twenty (l_pobj) leukemia_5\NN|NONE
D008727_D054198 NONE methotrexate_28\NNP|of|CSF (r_compound) concentrations_29\NNS|without (r_dobj) maintain_26\VB|to|and (r_conj) achieve_24\VB|was|that (r_xcomp) designed_22\VBN|dose|intravenous|methotrexate|a (r_relcl) regimen_19\NN|NONE (r_pobj) with_12\IN|children|were|. (r_prep) treated_11\VBN|NONE (l_nsubjpass) children_1\NNS|were|.|with (l_prep) with_2\IN|developed|Twenty (l_pobj) leukemia_5\NN|NONE
D008727_D054198 NONE methotrexate_4\NN|.|treatment (r_nsubj) is_5\VBZ|NONE (l_attr) treatment_8\NN|.|methotrexate (l_prep) for_9\IN|effective|an (l_pobj) induction_11\NN|NONE (l_prep) after_14\IN|the|of (l_pobj) relapse_16\NN|NONE (l_prep) in_17\IN|meningeal (l_pobj) leukemia_20\NN|NONE
D008727_D002493 NONE methotrexate_18\NNP|designed|dose|intravenous|a (r_compound) regimen_19\NN|NONE (r_pobj) with_12\IN|children|were|. (r_prep) treated_11\VBN|NONE (l_nsubjpass) children_1\NNS|were|.|with (l_relcl) developed_7\VBD|with|Twenty (l_dobj) disease_9\NN|who
D008727_D002493 NONE methotrexate_28\NNP|of|CSF (r_compound) concentrations_29\NNS|without (r_dobj) maintain_26\VB|to|and (r_conj) achieve_24\VB|was|that (r_xcomp) designed_22\VBN|dose|intravenous|methotrexate|a (r_relcl) regimen_19\NN|NONE (r_pobj) with_12\IN|children|were|. (r_prep) treated_11\VBN|NONE (l_nsubjpass) children_1\NNS|were|.|with (l_relcl) developed_7\VBD|with|Twenty (l_dobj) disease_9\NN|who
18589141
D006493_D013927 NONE sodium_2\NN|at|prevent|.|in|is (r_nsubjpass) used_16\VBN|NONE (l_xcomp) prevent_24\VB|at|.|in|sodium|is (l_dobj) thrombosis_25\NN|to|after
D006493_D013927 NONE UFH_4\NNP|heparin|)|heparin|(|Unfractionated|or (r_appos) sodium_2\NN|at|prevent|.|in|is (r_nsubjpass) used_16\VBN|NONE (l_xcomp) prevent_24\VB|at|.|in|sodium|is (l_dobj) thrombosis_25\NN|to|after
D006493_D001791 NONE heparin_1\NN| (r_npadvmod) induced_3\VBN|The|aggregation (r_amod) test_6\NN|negative|in|. (l_compound) aggregation_5\NN|The|induced
D006493_D013921 CID Heparin_0\NNP| (r_npadvmod) induced_2\VBN|after|. (r_amod) thrombocytopenia_3\NN|NONE
D006493_D013921 CID Heparin_0\NNP| (r_npadvmod) induced_2\VBN|HIT (r_amod) thrombocytopenia_3\NN|resulting|,|reaction|decreases|.
D006493_D013921 CID Heparin_0\NNP| (r_npadvmod) induced_2\VBN|HIT (r_amod) thrombocytopenia_3\NN|resulting|,|reaction|decreases|. (l_appos) HIT_5\NNP|induced
D006493_D013921 CID heparin_15\NN|NONE (r_pobj) to_14\IN|adverse|an|mediated (r_prep) reaction_13\NN|resulting|thrombocytopenia|,|decreases|. (r_attr) is_7\VBZ|NONE (l_nsubj) thrombocytopenia_3\NN|resulting|,|reaction|decreases|.
D006493_D013921 CID heparin_15\NN|NONE (r_pobj) to_14\IN|adverse|an|mediated (r_prep) reaction_13\NN|resulting|thrombocytopenia|,|decreases|. (r_attr) is_7\VBZ|NONE (l_nsubj) thrombocytopenia_3\NN|resulting|,|reaction|decreases|. (l_appos) HIT_5\NNP|induced
D006493_D013921 CID 4/heparin_10\NN| (r_nummod) reactive_12\JJ|NONE (r_amod) antibody_13\NN|(|in|)|antibody (r_nmod) positivity_18\NN|of|after|The (r_conj) frequencies_1\NNS|.|,|however|,|unknown (l_prep) of_2\IN|after|The|positivity (l_pobj) HIT_3\NN|NONE
D006493_D013921 CID 4/heparin_10\NN| (r_nummod) reactive_12\JJ|NONE (r_amod) antibody_13\NN|(|in|)|antibody (r_nmod) positivity_18\NN|of|after|The (l_nmod) antibody_16\NN|(|in|)|antibody (l_nmod) HIT_15\NNP|NONE
D006493_D013921 CID UFH_7\NN| (r_npadvmod) related_9\VBN|NONE (r_amod) HIT_10\NN|None|.
D006495_D013927 NONE heparin_11\NN|UFH|heparin|)|(|Unfractionated|or (r_conj) sodium_2\NN|at|prevent|.|in|is (r_nsubjpass) used_16\VBN|NONE (l_xcomp) prevent_24\VB|at|.|in|sodium|is (l_dobj) thrombosis_25\NN|to|after
1564236
D004176_D006940 CID dipyridamole_1\NN| (r_npadvmod) induced_3\VBN|NONE (r_amod) hyperemia_4\NN|NONE
D004176_D006940 CID dipyridamole_24\NN| (r_npadvmod) induced_26\VBN|NONE (r_amod) hyperemia_27\NN|NONE
D004176_D006940 CID dipyridamole_11\NN| (r_npadvmod) induced_13\VBN|NONE (r_amod) hyperemia_14\NN|NONE
D013793_D023921 NONE thallium-201_18\JJ|emission (r_amod) tomography_23\NN|NONE (r_pobj) with_17\IN|NONE (r_prep) correlation_16\NN|.|Relation|with|: (r_appos) observed_4\VBN|NONE (l_prep) with_5\IN|correlation|.|Relation|: (l_pobj) contrast_7\NN|NONE (l_prep) to_9\IN|myocardial|echocardiography (l_pobj) severity_11\NN|NONE (l_prep) of_12\IN|the (l_pobj) stenosis_14\NN|NONE
D004176_D023921 NONE dipyridamole_1\NN| (r_npadvmod) induced_3\VBN|NONE (r_amod) hyperemia_4\NN|NONE (r_pobj) During_0\IN|area|.||by|, (r_prep) had_16\VBD|NONE (l_nsubj) 12_6\CD|area|.|During|by|, (l_prep) of_7\IN|NONE (l_pobj) dogs_10\NNS|NONE (l_prep) with_11\IN||the (l_pobj) stenosis_15\NN|NONE
1835291
D013806_D002318 CID theophylline_9\JJ|NONE (r_amod) use_10\NN|NONE (r_pobj) after_8\IN|NONE (r_prep) experienced_7\VBN|NONE (r_acl) those_6\DT|systems|were|,|.|did (r_nsubj) involve_12\VB|NONE (l_dobj) systems_17\NNS|were|,|.|did|those
D013806_D029424 NONE theophylline_7\NN|ipratropium|and (r_conj) bromide_5\NN|NONE (r_pobj) of_3\IN|Acute|bronchodilating|in|. (r_prep) effects_2\NNS|NONE (l_prep) in_8\IN|Acute|bronchodilating|.|of (l_pobj) disease_12\NN|NONE
D013806_D029424 NONE theophylline_19\NN|acting (r_amod) tablets_20\NNS|micrograms|ipratropium|bromide|and|(|) (r_conj) aerosol_10\NN|NONE (r_pobj) of_7\IN|a|titrated|single (r_prep) dose_6\NN|NONE (r_pobj) of_3\IN|The|bronchodilator (r_prep) effects_2\NNS|in|were|. (r_nsubjpass) compared_37\VBN|NONE (l_prep) in_38\IN|effects|were|. (l_pobj) study_48\NN|NONE (l_prep) in_49\IN|blind|controlled|,|a|crossover (l_pobj) patients_51\NNS|NONE (l_prep) with_52\IN| (l_pobj) disease_58\NN|NONE
D013806_D029424 NONE theophylline_12\NN|NONE (r_pobj) than_10\IN|potent|a (r_prep) bronchodilator_9\NN|that|ipratropium|in (r_attr) is_5\VBZ|.|results (l_prep) in_13\IN|bronchodilator|that|ipratropium (l_pobj) patients_14\NNS|NONE (l_prep) with_15\IN|NONE (l_pobj) obstruction_18\NN|NONE
D013806_D005767 CID theophylline_9\JJ|NONE (r_amod) use_10\NN|NONE (r_pobj) after_8\IN|NONE (r_prep) experienced_7\VBN|NONE (r_acl) those_6\DT|systems|were|,|.|did (r_nsubj) involve_12\VB|NONE (l_dobj) systems_17\NNS|were|,|.|did|those
D009241_D029424 NONE bromide_5\NN|NONE (r_pobj) of_3\IN|Acute|bronchodilating|in|. (r_prep) effects_2\NNS|NONE (l_prep) in_8\IN|Acute|bronchodilating|.|of (l_pobj) disease_12\NN|NONE
D009241_D029424 NONE bromide_9\NN|micrograms|ipratropium|and|(|)|tablets (r_compound) aerosol_10\NN|NONE (r_pobj) of_7\IN|a|titrated|single (r_prep) dose_6\NN|NONE (r_pobj) of_3\IN|The|bronchodilator (r_prep) effects_2\NNS|in|were|. (r_nsubjpass) compared_37\VBN|NONE (l_prep) in_38\IN|effects|were|. (l_pobj) study_48\NN|NONE (l_prep) in_49\IN|blind|controlled|,|a|crossover (l_pobj) patients_51\NNS|NONE (l_prep) with_52\IN| (l_pobj) disease_58\NN|NONE
D009241_D029424 NONE ipratropium_4\NN|bronchodilator|that|in (r_nsubj) is_5\VBZ|.|results (l_prep) in_13\IN|bronchodilator|that|ipratropium (l_pobj) patients_14\NNS|NONE (l_prep) with_15\IN|NONE (l_pobj) obstruction_18\NN|NONE
9630698
D006220_D009127 CID haloperidol_5\NN|NONE (r_pobj) by_4\IN|rigidity|.|was|) (r_agent) induced_3\VBN|NONE (l_nsubjpass) rigidity_1\NN|by|.|was|)
D006220_D009127 CID haloperidol_34\NN| (r_advmod) induced_36\VBN|muscle|activity|(|)|and|MMG|the|both (r_amod) rigidity_38\NN|NONE
D005998_D009127 NONE glycine_8\NN|NONE (r_compound) site_9\NN|a|selective (r_compound) antagonist_10\NN|,DCKA|,dichlorokynurenic|,|,|) (r_appos) acid_1\NN|.|into|decreased|in|,|, (r_nsubj) injected_12\VBN|NONE (l_conj) decreased_31\VBD|.|into|in|,|,|acid (l_dobj) rigidity_38\NN|NONE
C066192_D009127 NONE acid_1\NN|.|into|decreased|in|,|, (r_nsubj) injected_12\VBN|NONE (l_conj) decreased_31\VBD|.|into|in|,|,|acid (l_dobj) rigidity_38\NN|NONE
C066192_D009127 NONE 5,7-DCKA_3\CD|,dichlorokynurenic|antagonist|,|,|) (r_appos) acid_1\NN|.|into|decreased|in|,|, (r_nsubj) injected_12\VBN|NONE (l_conj) decreased_31\VBD|.|into|in|,|,|acid (l_dobj) rigidity_38\NN|NONE
19289093
D002809_D007022 CID sulfate_19\NN|elicit|an|oversulfated (r_nmod) derivative_23\NN|NONE (l_relcl) elicit_26\VB|sulfate|an|oversulfated (l_dobj) response_29\NN|could|that|following (l_amod) hypotensive_28\JJ|a|in
D006493_D007022 NONE heparin_8\JJ|NONE (r_compound) products_9\NNS|NONE (r_pobj) of_7\IN|commercial (r_prep) lots_6\NNS|NONE (r_pobj) of_4\IN|a (r_prep) number_3\NN|,|.|Recently|were|contaminated (r_nsubjpass) found_11\VBN|NONE (l_xcomp) contaminated_14\VBN|,|.|Recently|were|number (l_prep) with_15\IN|to|be (l_pobj) derivative_23\NN|NONE (l_relcl) elicit_26\VB|sulfate|an|oversulfated (l_dobj) response_29\NN|could|that|following (l_amod) hypotensive_28\JJ|a|in
D006493_D007022 NONE heparin_3\JJ|both|and|derivative|contaminated (r_compound) products_4\NNS|NONE (r_dobj) Using_0\VBG|,|produces|we|. (r_advcl) showed_12\VBD|NONE (l_ccomp) produces_16\VBZ|,|Using|we|. (l_dobj) hypotension_20\NN|OSCS|that
18809400
D017239_D010523 CID paclitaxel_32\NN|NONE (r_pobj) to_31\IN|sensory|DRG|(|) (r_prep) neurons_30\NNS|dorsal|root (r_appos) ganglion_25\NN|NONE (r_pobj) of_22\IN|primary (r_prep) cultures_21\NNS|NONE (r_dobj) exposing_19\VBG|NONE (r_pcomp) by_18\IN|drugs|closely|that|in (r_prep) mimic_13\VBP|of|vitro|in|an (r_relcl) model_5\NN|induced|We|. (r_dobj) used_1\VBD|NONE (l_xcomp) induced_8\VBD|model|We|. (l_dobj) neuropathy_10\NN|NONE
D017239_D028361 NONE paclitaxel_7\NN|and|both (r_conj) cisplatin_5\NN|that|impairment (r_nsubj) cause_8\VBP|results|. (l_dobj) impairment_11\NN|cisplatin|that
D017239_D028361 NONE paclitaxel_11\NN|cisplatin|both|and (r_pobj) in_10\IN|an|common|early (r_prep) event_8\NN|.|In|induced|toxicity (r_attr) is_4\VBZ|NONE (l_nsubj) toxicity_3\NN|event|.|In|induced
D008063_D010523 NONE acid_7\NN|and|risk|encourage|might|that (r_nsubj) reduce_9\VB|.|findings (l_dobj) risk_11\NN|and|encourage|might|acid|that (l_prep) of_12\IN|the (l_pcomp) developing_13\VBG|NONE (l_dobj) toxicity_16\NN|NONE
D008063_D020258 NONE acid_3\NN|damage|. (r_nsubj) prevents_4\VBZ|NONE (l_dobj) damage_6\NN|acid|. (l_conj) neurotoxicity_8\NN|mitochondrial|and|in
D008063_D020258 NONE acid_7\NN|plays|if|,|induced|neuroprotective (r_nsubj) is_8\VBZ|.|study (l_advcl) induced_12\VBN|plays|if|,|acid|neuroprotective (l_dobj) neurotoxicity_13\NN|NONE
D008063_D020258 NONE acid_35\NN|NONE (r_pobj) of_31\IN|neuroprotective (r_prep) effects_30\NNS|if|on (r_nsubj) depend_36\VBP|and|if|role|,|damage (r_conj) plays_18\VBZ|if|,|acid|induced|neuroprotective (r_advcl) is_8\VBZ|.|study (l_advcl) induced_12\VBN|plays|if|,|acid|neuroprotective (l_dobj) neurotoxicity_13\NN|NONE
D008063_D020258 NONE acid_3\NN|induced|effects (r_nsubj) exerts_4\VBZ|toxicity|and|:|.|it|induces (l_conj) induced_9\VBN|acid|effects (l_dobj) neurotoxicity_10\NN|NONE
D008063_D001480 NONE acid_10\NN|NONE (r_pobj) of_6\IN|the|in (r_prep) efficacy_5\NN|apoptosis|and (l_prep) in_11\IN|the|of (l_pcomp) preventing_12\VBG|NONE (l_dobj) damage_14\NN|NONE
D008063_D001480 NONE acid_34\NN|toxic|and (r_conj) agents_29\NNS|NONE (r_pobj) to_27\IN|NONE (r_prep) exposure_26\NN|NONE (r_pobj) after_25\IN|the|of|and|morphology (r_prep) function_19\NN|and (r_conj) apoptosis_16\NN|efficacy|and (r_conj) investigating_3\VBG|approach|. (l_dobj) efficacy_5\NN|apoptosis|and (l_prep) in_11\IN|the|of (l_pcomp) preventing_12\VBG|NONE (l_dobj) damage_14\NN|NONE
D002945_D020258 NONE cisplatin_13\NN|both|paclitaxel|and (r_conj) in_10\IN|an|common|early (r_prep) event_8\NN|.|In|induced|toxicity (r_attr) is_4\VBZ|NONE (l_advcl) induced_14\VBN|event|.|In|toxicity (l_dobj) neurotoxicity_15\NN|NONE
D002945_D010523 CID cisplatin_34\NN|and (r_conj) paclitaxel_32\NN|NONE (r_pobj) to_31\IN|sensory|DRG|(|) (r_prep) neurons_30\NNS|dorsal|root (r_appos) ganglion_25\NN|NONE (r_pobj) of_22\IN|primary (r_prep) cultures_21\NNS|NONE (r_dobj) exposing_19\VBG|NONE (r_pcomp) by_18\IN|drugs|closely|that|in (r_prep) mimic_13\VBP|of|vitro|in|an (r_relcl) model_5\NN|induced|We|. (r_dobj) used_1\VBD|NONE (l_xcomp) induced_8\VBD|model|We|. (l_dobj) neuropathy_10\NN|NONE
D008063_D009422 NONE acid_3\NN|damage|. (r_nsubj) prevents_4\VBZ|NONE (l_dobj) damage_6\NN|acid|. (l_prep) in_9\IN|mitochondrial|and|neurotoxicity (l_pobj) neuropathy_12\NN|NONE
D008063_D028361 NONE acid_3\NN|damage|. (r_nsubj) prevents_4\VBZ|NONE (l_dobj) damage_6\NN|acid|.
D008063_D028361 NONE acid_7\NN|plays|if|,|induced|neuroprotective (r_nsubj) is_8\VBZ|.|study (l_advcl) plays_18\VBZ|if|,|acid|induced|neuroprotective (l_nsubj) damage_17\NN|and|if|depend|role|,
D008063_D028361 NONE acid_35\NN|NONE (r_pobj) of_31\IN|neuroprotective (r_prep) effects_30\NNS|if|on (r_nsubj) depend_36\VBP|and|if|role|,|damage (r_conj) plays_18\VBZ|if|,|acid|induced|neuroprotective (l_nsubj) damage_17\NN|and|if|depend|role|,
D008063_D028361 NONE acid_3\NN|induced|effects (r_nsubj) exerts_4\VBZ|toxicity|and|:|.|it|induces (r_ccomp) rescues_16\VBZ|NONE (l_dobj) toxicity_19\NN|and|:|exerts|.|it|induces
D002945_D028361 NONE cisplatin_5\NN|that|impairment (r_nsubj) cause_8\VBP|results|. (l_dobj) impairment_11\NN|cisplatin|that
D002945_D028361 NONE cisplatin_13\NN|both|paclitaxel|and (r_conj) in_10\IN|an|common|early (r_prep) event_8\NN|.|In|induced|toxicity (r_attr) is_4\VBZ|NONE (l_nsubj) toxicity_3\NN|event|.|In|induced
D017239_D020258 NONE paclitaxel_11\NN|cisplatin|both|and (r_pobj) in_10\IN|an|common|early (r_prep) event_8\NN|.|In|induced|toxicity (r_attr) is_4\VBZ|NONE (l_advcl) induced_14\VBN|event|.|In|toxicity (l_dobj) neurotoxicity_15\NN|NONE
D008063_D009410 NONE acid_7\NN|plays|if|,|induced|neuroprotective (r_nsubj) is_8\VBZ|.|study (l_advcl) plays_18\VBZ|if|,|acid|induced|neuroprotective (l_dobj) role_21\NN|and|if|depend|,|damage (l_prep) in_22\IN|a|critical (l_pobj) cascade_25\NN|NONE
D008063_D009410 NONE acid_35\NN|NONE (r_pobj) of_31\IN|neuroprotective (r_prep) effects_30\NNS|if|on (r_nsubj) depend_36\VBP|and|if|role|,|damage (r_conj) plays_18\VBZ|if|,|acid|induced|neuroprotective (l_dobj) role_21\NN|and|if|depend|,|damage (l_prep) in_22\IN|a|critical (l_pobj) cascade_25\NN|NONE
17919553
C106791_D064420 NONE telithromycin_15\NNS|Based|,|,|and|suggested|cause (r_nsubj) was_16\VBD|NONE (l_prep) Based_0\VBN|telithromycin|,|,|and|suggested|cause (l_prep) on_1\IN|NONE (l_pobj) score_3\NN|NONE (l_prep) on_6\IN|a|of (l_pobj) scale_13\NN|NONE (l_compound) probability_12\NN|the (l_compound) reaction_11\NN|NONE
C106791_D056486 CID telithromycin_6\NNS|NONE (r_relcl) exposure_4\NN|NONE (r_pobj) after_3\IN|Acute|hepatitis|. (r_prep) attack_2\NN|NONE (l_compound) hepatitis_1\NNP|Acute|.|after
C106791_D056486 CID telithromycin_19\NNS|NONE (r_compound) usage_20\NN|NONE (r_pobj) after_18\IN|suffered|.|that|"|, (r_prep) occurred_17\VBD|NONE (l_ccomp) suffered_3\VBN|.|that|after|"|, (l_dobj) episode_6\NN|had|patient (l_prep) of_7\IN|a|previous (l_pobj) hepatitis_10\NN|NONE
C106791_D056486 CID telithromycin_15\NNS|Based|,|,|and|suggested|cause (r_nsubj) was_16\VBD|NONE (l_attr) cause_19\NN|Based|telithromycin|,|,|and|suggested (l_prep) of_20\IN|probable|the (l_pobj) hepatitis_22\NN|NONE
C106791_D056486 CID telithromycin_15\NNS|Based|,|,|and|suggested|cause (r_nsubj) was_16\VBD|NONE (l_conj) suggested_30\VBD|Based|telithromycin|,|,|and|cause (l_dobj) hepatitis_35\NN|.|findings
C106791_D056486 CID telithromycin_21\NNS|who|time (r_dobj) prescribed_20\VBD|attending|the (r_relcl) physician_18\NN|NONE (r_pobj) to_15\IN|had|incident|been|if (r_prep) communicated_14\VBN|have|been|Recurrence|might|. (r_advcl) avoided_7\VBN|NONE (l_nsubjpass) Recurrence_0\NN|have|been|communicated|might|. (l_prep) of_1\IN|NONE (l_pobj) attack_3\NN|NONE (l_compound) hepatitis_2\NN|NONE
C106791_D056486 CID telithromycin_14\NNS|NONE (r_pobj) of_13\IN|the (r_prep) administration_12\NN|NONE (r_pobj) with_10\IN|probably (r_prep) associated_9\VBN|of|a (r_acl) case_4\NN|.|Here|we (l_prep) of_5\IN|associated|a (l_pobj) hepatitis_7\NN|NONE
14742097
D020280_D020018 CID sertraline_8\NN|either|, (r_conj) fluoxetine_6\NN|NONE (r_dobj) receiving_4\VBG|Nineteen|dysfunctional (r_acl) women_3\NNS|in|. (l_amod) dysfunctional_2\JJ|Nineteen|receiving
D004809_D020018 NONE ephedrine_10\NN|NONE (r_pobj) of_9\IN|crossover|,|randomized|for|.|controlled|,|A (r_prep) study_8\NN|NONE (l_prep) for_11\IN|crossover|,|of|randomized|.|controlled|,|A (l_pobj) dysfunction_17\NN|NONE
D004809_D020018 NONE ephedrine_9\NN|,|whether|effects (r_nsubj) has_28\VBZ|to (l_dobj) effects_30\NNS|ephedrine|,|whether (l_prep) in_31\IN|beneficial (l_pcomp) reversing_32\VBG|NONE (l_dobj) dysfunction_37\NN|NONE
D004809_D020018 NONE ephedrine_35\NN|NONE (r_pobj) of_34\IN|mg|on|the (r_prep) effects_33\NNS|NONE (r_pobj) of_31\IN|blind|cross|,|controlled|,|,|week|an (r_prep) study_30\NN|NONE (r_pobj) in_13\IN|women|. (r_prep) participated_12\VBD|NONE (l_nsubj) women_3\NNS|in|. (l_amod) dysfunctional_2\JJ|Nineteen|receiving
D017374_D020018 CID paroxetine_11\NN|,|or (r_conj) sertraline_8\NN|either|, (r_conj) fluoxetine_6\NN|NONE (r_dobj) receiving_4\VBG|Nineteen|dysfunctional (r_acl) women_3\NNS|in|. (l_amod) dysfunctional_2\JJ|Nineteen|receiving
D005473_D020018 CID fluoxetine_6\NN|NONE (r_dobj) receiving_4\VBG|Nineteen|dysfunctional (r_acl) women_3\NNS|in|. (l_amod) dysfunctional_2\JJ|Nineteen|receiving
6861444
D009638_D006973 CID noradrenaline_3\NN|NONE (r_pobj) of_2\IN|Intrarenal (r_prep) infusion_1\NN|at|.|hypertension (r_nsubj) caused_4\VBD|NONE (l_dobj) hypertension_5\NN|at|.|infusion
D009638_D006973 CID noradrenaline_8\NN|chronic|intrarenal (r_amod) infusion_9\NN|NONE (r_pobj) after_5\IN|NONE (r_prep) hypertension_4\NN|by|that|is
D009638_D006973 CID noradrenaline_18\NN|NONE (r_dobj) circulating_17\VBG|NONE (r_pcomp) of_16\IN|higher (r_prep) levels_15\NNS|and|by (r_pobj) by_12\IN|that|is|hypertension (r_agent) produced_11\VBN|.|results (l_nsubjpass) hypertension_4\NN|by|that|is
8953972
D004837_D006973 NONE Epinephrine_0\NN|role (r_nsubj) has_1\VBZ|;|by|however|, (r_ccomp) use_14\NN|be|should|.|with (l_prep) by_15\IN|;|has|however|, (l_pobj) paramedics_16\NNS|NONE (l_prep) in_17\IN|NONE (l_pobj) patients_18\NNS|NONE (l_prep) with_19\IN|NONE (l_pobj) reaction_22\NN|NONE (l_conj) hypertension_25\NN|and|suspected|allergic
D004837_D012128 NONE epinephrine_26\NN|to (r_dobj) administer_24\VB|.|paramedics|onset (r_xcomp) led_16\VBD|NONE (l_nsubj) onset_2\NN|.|paramedics|administer (l_prep) of_3\IN|The|sudden (l_pobj) distress_5\NN|NONE
D004837_D005076 NONE epinephrine_26\NN|to (r_dobj) administer_24\VB|.|paramedics|onset (r_xcomp) led_16\VBD|NONE (l_nsubj) onset_2\NN|.|paramedics|administer (l_prep) of_3\IN|The|sudden (l_pobj) distress_5\NN|NONE (l_conj) rash_7\JJ|,|respiratory
D004837_D013345 CID epinephrine_8\NN|NONE (r_pobj) of_7\IN|prehospital (r_prep) use_6\NN|NONE (r_pobj) with_4\IN|NONE (r_prep) associated_3\VBN|intracranial|Fatal|. (r_acl) bleeding_2\NN|NONE
D004837_D004342 NONE Epinephrine_0\NN|role (r_nsubj) has_1\VBZ|;|by|however|, (r_ccomp) use_14\NN|be|should|.|with (l_prep) by_15\IN|;|has|however|, (l_pobj) paramedics_16\NNS|NONE (l_prep) in_17\IN|NONE (l_pobj) patients_18\NNS|NONE (l_prep) with_19\IN|NONE (l_pobj) reaction_22\NN|NONE
D004837_D006323 CID Epinephrine_0\NN|role (r_nsubj) has_1\VBZ|;|by|however|, (l_dobj) role_4\NN|Epinephrine (l_prep) in_5\IN|proven|a (l_pobj) arrest_7\NN|NONE
11099450
D007980_D004409 CID levodopa_33\RB| (r_npadvmod) induced_35\VBN|)|LID|( (r_amod) dyskinesias_36\NNS|off|and|parkinsonian
D007980_D004409 CID levodopa_33\RB| (r_npadvmod) induced_35\VBN|)|LID|( (r_amod) dyskinesias_36\NNS|off|and|parkinsonian (l_appos) LID_38\NNP|induced|)|(
D007980_D004409 CID levodopa_8\JJ|responsiveness|of|and|the|preoperative (r_compound) responsiveness_9\NN|NONE (r_pobj) between_5\IN|Program|significant|positive (r_prep) correlations_4\NNS|was|.|We|in|, (r_dobj) found_1\VBD|NONE (l_advcl) was_45\VBD|correlations|.|We|in|, (l_attr) correlation_47\NN|there|whereas (l_prep) with_48\IN|no (l_pobj) improvement_50\NN|NONE (l_prep) in_51\IN|the (l_pobj) LID_52\NNP|NONE
D007980_D004409 CID levodopa_15\JJ|the|of (r_compound) responsiveness_16\NN|of|levodopa|and|the|preoperative (r_conj) responsiveness_9\NN|NONE (r_pobj) between_5\IN|Program|significant|positive (r_prep) correlations_4\NNS|was|.|We|in|, (r_dobj) found_1\VBD|NONE (l_advcl) was_45\VBD|correlations|.|We|in|, (l_attr) correlation_47\NN|there|whereas (l_prep) with_48\IN|no (l_pobj) improvement_50\NN|NONE (l_prep) in_51\IN|the (l_pobj) LID_52\NNP|NONE
D007980_D004409 CID levodopa_5\JJ|for (r_compound) responsiveness_6\NN|NONE (l_prep) for_7\IN|levodopa (l_pobj) outcome_9\NN|NONE (l_prep) of_10\IN|the (l_pobj) signs_15\NNS|NONE (l_conj) LID_17\NNP|off|and|parkinsonian
D007980_D004409 CID levodopa_5\JJ|for (r_compound) responsiveness_6\NN|NONE (l_prep) for_7\IN|levodopa (l_pobj) outcome_9\NN|NONE (l_prep) of_10\IN|the (l_pobj) signs_15\NNS|NONE (l_conj) LID_17\NNP|off|and|parkinsonian (l_conj) correlations_21\NNS|and (l_prep) of_22\IN|different|the (l_pobj) volume_25\NN|NONE (l_prep) with_26\IN|lesion|ventral (l_pobj) dyskinesias_27\NNS|NONE
D007980_D004409 CID levodopa_5\JJ|for (r_compound) responsiveness_6\NN|NONE (r_pobj) of_4\IN|The|predictive|differential (r_prep) value_3\NN|be|. (r_nsubj) indicate_34\VBP|NONE (l_ccomp) be_42\VB|value|. (l_acomp) responsible_43\JJ|may|substrates|that (l_prep) for_44\IN|NONE (l_pobj) signs_52\NNS|generation (l_conj) dyskinesias_54\NNS|and|off
D007980_D010300 NONE levodopa_33\RB| (r_npadvmod) induced_35\VBN|)|LID|( (r_amod) dyskinesias_36\NNS|off|and|parkinsonian (r_conj) signs_31\NNS|NONE (l_poss) parkinsonian_27\NN|off|and|dyskinesias
D007980_D010300 NONE levodopa_5\JJ|for (r_compound) responsiveness_6\NN|NONE (l_prep) for_7\IN|levodopa (l_pobj) outcome_9\NN|NONE (l_prep) of_10\IN|the (l_pobj) signs_15\NNS|NONE (l_poss) parkinsonian_11\NN|off|LID|and
D007980_D010300 NONE levodopa_5\JJ|for (r_compound) responsiveness_6\NN|NONE (l_prep) for_7\IN|levodopa (l_pobj) outcome_9\NN|NONE (l_prep) of_10\IN|the (l_pobj) signs_15\NNS|NONE (l_conj) LID_17\NNP|off|and|parkinsonian (l_conj) correlations_21\NNS|and (l_prep) of_22\IN|different|the (l_pobj) volume_25\NN|NONE (l_prep) with_26\IN|lesion|ventral (l_pobj) dyskinesias_27\NNS|NONE (l_conj) parkinsonian_29\NN|and|signs
D007980_D010300 NONE levodopa_5\JJ|for (r_compound) responsiveness_6\NN|NONE (r_pobj) of_4\IN|The|predictive|differential (r_prep) value_3\NN|be|. (r_nsubj) indicate_34\VBP|NONE (l_ccomp) be_42\VB|value|. (l_acomp) responsible_43\JJ|may|substrates|that (l_prep) for_44\IN|NONE (l_pobj) generation_46\NN|signs (l_prep) of_47\IN|the (l_pobj) parkinsonian_48\NN|NONE
19642243
C096918_D000163 NONE tenofovir_8\NNS|NONE (r_pobj) on_7\IN|with (r_prep) patients_4\NNS|NONE (l_prep) with_5\IN|on (l_pobj) AIDS_6\NNP|NONE
C418563_D051437 NONE fumarate_18\NN|were|as|who (r_dobj) receiving_15\VBG| (r_relcl) patients_12\NNS|NONE (r_pobj) in_10\IN|prolonged|a|of (r_prep) course_6\NN|NONE (r_pobj) after_3\IN|failure|. (r_prep) developed_2\VBD|NONE (l_nsubj) failure_1\NN|after|.
D014640_D010019 NONE vancomycin_12\NNP|prolonged (r_amod) course_13\NN|for|while (r_dobj) receiving_10\VBG|Acute|.|renal|in (l_prep) for_14\IN|while|course (l_pobj) osteomyelitis_15\NN|NONE
D014640_D051437 NONE vancomycin_8\NNP|NONE (r_amod) therapy_9\NN|NONE (r_pobj) of_7\IN|in|prolonged|a (r_prep) course_6\NN|NONE (r_pobj) after_3\IN|failure|. (r_prep) developed_2\VBD|NONE (l_nsubj) failure_1\NN|after|.
D014640_D051437 NONE vancomycin_17\NNP|NONE (r_pobj) of_16\IN|prolonged (r_prep) administration_15\NN|NONE (r_pobj) during_13\IN|may|that|risk|tenofovir (r_prep) raise_7\VB|NONE (l_dobj) risk_9\NN|may|that|during|tenofovir (l_prep) of_10\IN|the (l_pobj) failure_12\NN|NONE
C096918_D058186 NONE tenofovir_8\NNS|NONE (r_pobj) on_7\IN|with (r_prep) patients_4\NNS|NONE (r_pobj) in_3\IN|Acute|.|renal|receiving (r_prep) failure_2\NN|NONE
C096918_D005198 NONE Tenofovir_0\NNP|been|has|because|.|in (r_nsubjpass) implicated_3\VBN|NONE (l_prep) in_4\IN|been|has|because|.|Tenofovir (l_pobj) development_6\NN|NONE (l_prep) of_7\IN|the (l_pobj) syndrome_9\NN|NONE
D014640_D058186 CID vancomycin_12\NNP|prolonged (r_amod) course_13\NN|for|while (r_dobj) receiving_10\VBG|Acute|.|renal|in (r_advcl) failure_2\NN|NONE
C096918_D010019 NONE tenofovir_8\NNS|NONE (r_pobj) on_7\IN|with (r_prep) patients_4\NNS|NONE (r_pobj) in_3\IN|Acute|.|renal|receiving (r_prep) failure_2\NN|NONE (l_advcl) receiving_10\VBG|Acute|.|renal|in (l_prep) for_14\IN|while|course (l_pobj) osteomyelitis_15\NN|NONE
D014640_D007674 NONE Vancomycin_0\NNP|NONE (r_compound) nephrotoxicity_1\NN|infrequent|but|.|result
D014640_D007674 NONE Vancomycin_0\NNP|NONE (r_compound) nephrotoxicity_1\NN|infrequent|but|.|result (r_nsubj) is_2\VBZ|NONE (l_conj) result_6\VB|infrequent|but|nephrotoxicity|. (l_prep) from_7\IN|may (l_pobj) coadministration_8\NN|NONE (l_prep) with_9\IN|NONE (l_pobj) agent_12\NN|NONE (l_amod) nephrotoxic_11\JJ|a
D014640_D000163 NONE vancomycin_12\NNP|prolonged (r_amod) course_13\NN|for|while (r_dobj) receiving_10\VBG|Acute|.|renal|in (r_advcl) failure_2\NN|NONE (l_prep) in_3\IN|Acute|.|renal|receiving (l_pobj) patients_4\NNS|NONE (l_prep) with_5\IN|on (l_pobj) AIDS_6\NNP|NONE
C096918_D051437 NONE Tenofovir_0\NNP|been|has|because|.|in (r_nsubjpass) implicated_3\VBN|NONE (l_prep) in_4\IN|been|has|because|.|Tenofovir (l_pobj) development_6\NN|NONE (l_prep) of_7\IN|the (l_pobj) syndrome_9\NN|NONE (l_conj) insufficiency_12\NN|and|Fanconi
C096918_D051437 NONE tenofovir_5\NNS|may|that|during|risk (r_nsubj) raise_7\VB|NONE (l_dobj) risk_9\NN|may|that|during|tenofovir (l_prep) of_10\IN|the (l_pobj) failure_12\NN|NONE
7453952
D018021_D059606 NONE LiCl_37\NNP|NONE (r_pobj) with_36\IN|chronically (r_prep) treated_35\VBN|effect|,|in|was|. (r_conj) investigated_30\VBN|NONE (l_nsubjpass) effect_1\NN|treated|,|in|was|. (l_prep) on_4\IN|of|The (l_pobj) polydipsia_8\NN|and|on
D011188_D003919 NONE potassium_48\NN|the (r_compound) level_49\NN|NONE (r_pobj) in_45\IN|an (r_prep) elevation_44\NN|lithium|in|and|the (r_conj) concentration_31\NN|NONE (r_pobj) between_28\IN|the (r_prep) ratio_27\NN|NONE (r_pobj) of_25\IN|a (r_prep) reduction_24\NN|NONE (r_pobj) by_22\IN|was|In|.|,|attenuation (r_agent) accompanied_21\VBN|NONE (l_nsubjpass) attenuation_6\NN|was|In|.|,|by (l_prep) of_7\IN|the (l_pobj) syndrome_17\NN|NONE
D008094_D003919 CID lithium_3\NN| (r_npadvmod) induced_5\VBN|by|the|in|like (r_amod) syndrome_11\NN|NONE
D008094_D003919 CID lithium_9\NN| (r_npadvmod) induced_11\VBN|like|the|by (r_amod) syndrome_17\NN|NONE
D008094_D003919 CID lithium_30\NN|in|and|the|elevation (r_compound) concentration_31\NN|NONE (r_pobj) between_28\IN|the (r_prep) ratio_27\NN|NONE (r_pobj) of_25\IN|a (r_prep) reduction_24\NN|NONE (r_pobj) by_22\IN|was|In|.|,|attenuation (r_agent) accompanied_21\VBN|NONE (l_nsubjpass) attenuation_6\NN|was|In|.|,|by (l_prep) of_7\IN|the (l_pobj) syndrome_17\NN|NONE
D000584_D011141 NONE amiloride_3\NN|NONE (r_pobj) of_2\IN|The|on (r_prep) effect_1\NN|treated|,|in|was|. (l_prep) on_4\IN|of|The (l_pobj) polydipsia_8\NN|and|on (l_conj) polyuria_10\NN|induced|and
D000584_D011141 NONE amiloride_5\NN|acute|to (r_compound) administration_6\NN|might|patients|but|that|result (l_prep) to_7\IN|acute|amiloride (l_pobj) patients_11\NNS|NONE (l_acl) suffering_12\VBG|treated (l_prep) from_13\IN|NONE (l_pobj) polydipsia_14\NN|NONE (l_conj) polyuria_16\NN|and
D000584_D011141 NONE amiloride_23\JJ|prolonged (r_compound) supplementation_24\NN|would|in|be|and (r_nsubj) result_26\VB|might|patients|but|that|administration (r_conj) relieve_18\VB|It|is|. (l_nsubj) administration_6\NN|might|patients|but|that|result (l_prep) to_7\IN|acute|amiloride (l_pobj) patients_11\NNS|NONE (l_acl) suffering_12\VBG|treated (l_prep) from_13\IN|NONE (l_pobj) polydipsia_14\NN|NONE (l_conj) polyuria_16\NN|and
D008094_D059606 NONE lithium_5\NN| (r_npadvmod) induced_7\VBN|and|polyuria (r_amod) polydipsia_8\NN|and|on
D008094_D059606 NONE lithium_14\NN|the|in (r_compound) concentration_15\NN|NONE (r_pobj) on_12\IN|and|polydipsia (r_conj) on_4\IN|of|The (l_pobj) polydipsia_8\NN|and|on
D008094_D059606 NONE lithium_8\NN| (r_npadvmod) treated_10\VBN|suffering (r_amod) patients_11\NNS|NONE (l_acl) suffering_12\VBG|treated (l_prep) from_13\IN|NONE (l_pobj) polydipsia_14\NN|NONE
D008094_D059606 NONE lithium_29\NN|elevated (r_compound) levels_30\NNS|NONE (r_pobj) in_27\IN|supplementation|would|be|and (r_prep) result_26\VB|might|patients|but|that|administration (r_conj) relieve_18\VB|It|is|. (l_nsubj) administration_6\NN|might|patients|but|that|result (l_prep) to_7\IN|acute|amiloride (l_pobj) patients_11\NNS|NONE (l_acl) suffering_12\VBG|treated (l_prep) from_13\IN|NONE (l_pobj) polydipsia_14\NN|NONE
D018021_D011141 NONE LiCl_37\NNP|NONE (r_pobj) with_36\IN|chronically (r_prep) treated_35\VBN|effect|,|in|was|. (r_conj) investigated_30\VBN|NONE (l_nsubjpass) effect_1\NN|treated|,|in|was|. (l_prep) on_4\IN|of|The (l_pobj) polydipsia_8\NN|and|on (l_conj) polyuria_10\NN|induced|and
D008094_D011141 NONE lithium_5\NN| (r_npadvmod) induced_7\VBN|and|polyuria (r_amod) polydipsia_8\NN|and|on (l_conj) polyuria_10\NN|induced|and
D008094_D011141 NONE lithium_14\NN|the|in (r_compound) concentration_15\NN|NONE (r_pobj) on_12\IN|and|polydipsia (r_conj) on_4\IN|of|The (l_pobj) polydipsia_8\NN|and|on (l_conj) polyuria_10\NN|induced|and
D008094_D011141 NONE lithium_8\NN| (r_npadvmod) treated_10\VBN|suffering (r_amod) patients_11\NNS|NONE (l_acl) suffering_12\VBG|treated (l_prep) from_13\IN|NONE (l_pobj) polydipsia_14\NN|NONE (l_conj) polyuria_16\NN|and
D008094_D011141 NONE lithium_29\NN|elevated (r_compound) levels_30\NNS|NONE (r_pobj) in_27\IN|supplementation|would|be|and (r_prep) result_26\VB|might|patients|but|that|administration (r_conj) relieve_18\VB|It|is|. (l_nsubj) administration_6\NN|might|patients|but|that|result (l_prep) to_7\IN|acute|amiloride (l_pobj) patients_11\NNS|NONE (l_acl) suffering_12\VBG|treated (l_prep) from_13\IN|NONE (l_pobj) polydipsia_14\NN|NONE (l_conj) polyuria_16\NN|and
D000584_D003919 NONE amiloride_13\NN|NONE (r_pobj) by_12\IN|induced|the|in|like (r_prep) syndrome_11\NN|NONE
D000584_D003919 NONE amiloride_19\NN|NONE (r_pobj) by_18\IN|like|the|induced (r_prep) syndrome_17\NN|NONE
D000584_D059606 NONE amiloride_3\NN|NONE (r_pobj) of_2\IN|The|on (r_prep) effect_1\NN|treated|,|in|was|. (l_prep) on_4\IN|of|The (l_pobj) polydipsia_8\NN|and|on
D000584_D059606 NONE amiloride_5\NN|acute|to (r_compound) administration_6\NN|might|patients|but|that|result (l_prep) to_7\IN|acute|amiloride (l_pobj) patients_11\NNS|NONE (l_acl) suffering_12\VBG|treated (l_prep) from_13\IN|NONE (l_pobj) polydipsia_14\NN|NONE
D000584_D059606 NONE amiloride_23\JJ|prolonged (r_compound) supplementation_24\NN|would|in|be|and (r_nsubj) result_26\VB|might|patients|but|that|administration (r_conj) relieve_18\VB|It|is|. (l_nsubj) administration_6\NN|might|patients|but|that|result (l_prep) to_7\IN|acute|amiloride (l_pobj) patients_11\NNS|NONE (l_acl) suffering_12\VBG|treated (l_prep) from_13\IN|NONE (l_pobj) polydipsia_14\NN|NONE
20331935
D018967_D006966 CID risperidone_12\NN| (r_npadvmod) induced_14\VBN|on (r_amod) hyperprolactinemia_15\NN|NONE
D018967_D006966 CID risperidone_17\NN|NONE (r_pobj) with_16\IN|NONE (r_prep) treated_15\VBN|of| (r_acl) %_6\NN|NONE (r_pobj) in_4\IN|NONE (r_prep) present_3\JJ|:|.|Hyperprolactinemia (r_acomp) was_2\VBD|NONE (l_nsubj) Hyperprolactinemia_1\NNP|:|.|present
D018967_D006966 CID risperidone_8\NN|were|after (r_nsubjpass) started_12\VBN|fractures||occurred|,|and (r_advcl) occurred_6\VBD|NONE (l_conj) occurred_16\VBD|fractures||,|and|started (l_prep) in_17\IN|none|. (l_pobj) patients_18\NNS|NONE (l_prep) with_19\IN|NONE (l_pobj) hyperprolactinemia_20\NN|NONE
D018967_D006966 CID risperidone_7\NN| (r_npadvmod) induced_9\VBN|and|treatment (r_amod) hyperprolactinemia_10\NN|to|lower
D013739_D006966 NONE testosterone_1\NN|Serum (r_compound) concentration_2\NN|but|.|with|affected (r_nsubj) increased_3\VBD|NONE (l_conj) affected_10\VBN|but|concentration|.|with (l_agent) by_11\IN|was|not (l_pobj) hyperprolactinemia_12\NN|NONE
D018967_D050723 NONE risperidone_8\NN|were|after (r_nsubjpass) started_12\VBN|fractures||occurred|,|and (r_advcl) occurred_6\VBD|NONE (l_nsubj) fractures_3\NNS||occurred|,|and|started
18083142
D004221_D001008 NONE disulfiram_14\NN|NONE (r_pobj) of_13\IN|,|inhibitor (r_prep) administration_12\NN|NONE (r_pobj) following_11\VBG|in|was|.|anxiety|also (r_prep) attenuated_6\VBN|NONE (l_nsubjpass) anxiety_3\NN|in|was|.|also|following
D003042_D001008 CID cocaine_12\NN| (r_npadvmod) induced_14\VBN|NONE (r_amod) anxiety_15\NN|NONE
D003042_D001008 CID cocaine_4\NN|underlying|rewarding (r_poss) effects_7\NNS|While|extensively|mechanisms|been|have (r_nsubjpass) studied_10\VBN|been|has|,|attention|.|to (r_advcl) paid_17\VBN|NONE (l_dative) to_18\IN|been|has|studied|,|attention|. (l_pobj) states_22\NNS|NONE (l_acl) induced_23\VBN|the|behavioral|unpleasant (l_agent) by_24\IN|NONE (l_pobj) cocaine_25\NN|NONE (l_prep) as_28\IN|, (l_pobj) anxiety_29\NN|such
D003042_D001008 CID cocaine_25\NN|NONE (l_prep) as_28\IN|, (l_pobj) anxiety_29\NN|such
D003042_D001008 CID cocaine_43\NN| (r_npadvmod) induced_45\VBN|NONE (r_amod) anxiety_46\NN|NONE
D003042_D001008 CID cocaine_4\NN|behavior|dependently|measured|,|that (r_nsubj) increased_8\VBN|:|We|. (l_dobj) behavior_12\NN|cocaine|dependently|measured|,|that (l_amod) like_11\JJ|in (l_npadvmod) anxiety_9\NN|NONE
D003042_D001008 CID Cocaine_0\NN| (r_npadvmod) induced_2\VBN|NONE (r_amod) anxiety_3\NN|in|was|.|also|following
D003042_D001008 CID cocaine_20\NN| (r_npadvmod) induced_22\VBN|blocked|like (r_amod) behavior_26\NN|in (l_amod) like_25\JJ|blocked|induced (l_npadvmod) anxiety_23\NN|
D003042_D001008 CID cocaine_14\NN| (r_npadvmod) induced_16\VBN|in (r_amod) anxiety_17\NN|NONE
D009638_D001008 NONE Norepinephrine_0\NN|through (r_compound) signaling_1\VBG|.|critical (r_nsubj) is_7\VBZ|NONE (l_acomp) critical_8\JJ|.|signaling (l_prep) for_9\IN|NONE (l_pobj) expression_10\NN|NONE (l_prep) of_11\IN|NONE (l_pobj) anxiety_15\NN|NONE
D009638_D001008 NONE norepinephrine_22\NN|which (r_dobj) lack_21\VBP|Dbh|,|)|(|,|/ (r_relcl) mice_18\NNS|hydroxylase|dopamine (r_appos) knockout_13\NN|NONE (r_pobj) of_8\IN|the (r_prep) performance_7\NN|.|examine|,|in|we|In (r_dobj) evaluated_5\VBD|NONE (l_advcl) examine_36\VB|.|,|performance|in|we|In (l_dobj) contribution_38\NN|to (l_prep) of_39\IN|the (l_pobj) signaling_41\NN|NONE (l_prep) to_42\IN|noradrenergic (l_pobj) anxiety_46\NN|NONE
D009638_D001008 NONE NE_24\NNP|NONE (r_appos) norepinephrine_22\NN|which (r_dobj) lack_21\VBP|Dbh|,|)|(|,|/ (r_relcl) mice_18\NNS|hydroxylase|dopamine (r_appos) knockout_13\NN|NONE (r_pobj) of_8\IN|the (r_prep) performance_7\NN|.|examine|,|in|we|In (r_dobj) evaluated_5\VBD|NONE (l_advcl) examine_36\VB|.|,|performance|in|we|In (l_dobj) contribution_38\NN|to (l_prep) of_39\IN|the (l_pobj) signaling_41\NN|NONE (l_prep) to_42\IN|noradrenergic (l_pobj) anxiety_46\NN|NONE
D015016_D001008 NONE yohimbine_48\NN|the|)|alpha( (r_appos) antagonist_47\NN|antagonist|the|and (r_conj) prazosin_42\NN|while|effect (r_nsubj) had_49\VBD|,|that|with (r_advcl) pretreatment_10\NN|we|.|In|, (l_prep) with_11\IN|,|that|had (l_pobj) antagonist_17\NN|NONE (l_acl) propranolol_18\NN|the|adrenergic|receptor (l_dobj) behavior_26\NN|in (l_amod) like_25\JJ|blocked|induced (l_npadvmod) anxiety_23\NN|
D011224_D001008 NONE prazosin_42\NN|while|effect (r_nsubj) had_49\VBD|,|that|with (r_advcl) pretreatment_10\NN|we|.|In|, (l_prep) with_11\IN|,|that|had (l_pobj) antagonist_17\NN|NONE (l_acl) propranolol_18\NN|the|adrenergic|receptor (l_dobj) behavior_26\NN|in (l_amod) like_25\JJ|blocked|induced (l_npadvmod) anxiety_23\NN|
D011433_D001008 NONE propranolol_18\NN|the|adrenergic|receptor (l_dobj) behavior_26\NN|in (l_amod) like_25\JJ|blocked|induced (l_npadvmod) anxiety_23\NN|
D004298_D001008 NONE dopamine_9\NN|hydroxylase|mice (r_compound) knockout_13\NN|NONE (r_pobj) of_8\IN|the (r_prep) performance_7\NN|.|examine|,|in|we|In (r_dobj) evaluated_5\VBD|NONE (l_advcl) examine_36\VB|.|,|performance|in|we|In (l_dobj) contribution_38\NN|to (l_prep) of_39\IN|the (l_pobj) signaling_41\NN|NONE (l_prep) to_42\IN|noradrenergic (l_pobj) anxiety_46\NN|NONE
D004298_D001008 NONE dopamine_17\NN|beta|a| (r_nmod) hydroxylase_20\NN|)|DBH|( (r_nmod) inhibitor_24\NN|,|of (r_appos) administration_12\NN|NONE (r_pobj) following_11\VBG|in|was|.|anxiety|also (r_prep) attenuated_6\VBN|NONE (l_nsubjpass) anxiety_3\NN|in|was|.|also|following
9549528
D007980_D004409 CID dopa_9\NN| (r_npadvmod) induced_11\VBN|dose (r_amod) dyskinesia_15\NN|NONE
D007980_D004409 CID dopa_42\NN|, (r_compound) medication_43\NN|NONE (r_pobj) on_39\IN|parkinsonian (r_prep) patients_38\NNS|NONE (r_pobj) of_36\IN|two (r_prep) groups_35\NNS|NONE (r_pobj) of_33\IN|supplementary|motor|the (r_prep) cortex_32\NN|NONE (r_pobj) in_26\IN|of|the (r_prep) execution_15\NN|NONE (r_pobj) by_13\IN|NONE (r_agent) induced_12\VBN|) (r_acl) changes_11\NNS|rCBF|regional|blood|cerebral|(|the (r_conj) flow_7\NN|induced|have|We|. (r_dobj) studied_2\VBN|NONE (l_conj) induced_52\VBD|have|flow|We|. (l_dobj) dyskinesia_53\NN|of|one|and|,
D007980_D004409 CID dopa_42\NN|, (r_compound) medication_43\NN|NONE (r_pobj) on_39\IN|parkinsonian (r_prep) patients_38\NNS|NONE (r_pobj) of_36\IN|two (r_prep) groups_35\NNS|NONE (r_pobj) of_33\IN|supplementary|motor|the (r_prep) cortex_32\NN|NONE (r_pobj) in_26\IN|of|the (r_prep) execution_15\NN|NONE (r_pobj) by_13\IN|NONE (r_agent) induced_12\VBN|) (r_acl) changes_11\NNS|rCBF|regional|blood|cerebral|(|the (r_conj) flow_7\NN|induced|have|We|. (r_dobj) studied_2\VBN|NONE (l_conj) induced_52\VBD|have|flow|We|. (l_dobj) dyskinesia_53\NN|of|one|and|, (l_conj) other_61\JJ|)||(|and|n (l_prep) with_62\IN|the (l_pobj) dyskinesia_67\NN|NONE
D007980_D004409 CID dopa_51\NN|NONE (r_pobj) without_48\IN|the|first (r_prep) one_47\NN|of|and|,|dyskinesia (r_nsubj) induced_52\VBD|have|flow|We|. (l_dobj) dyskinesia_53\NN|of|one|and|,
D007980_D004409 CID dopa_51\NN|NONE (r_pobj) without_48\IN|the|first (r_prep) one_47\NN|of|and|,|dyskinesia (r_nsubj) induced_52\VBD|have|flow|We|. (l_dobj) dyskinesia_53\NN|of|one|and|, (l_conj) other_61\JJ|)||(|and|n (l_prep) with_62\IN|the (l_pobj) dyskinesia_67\NN|NONE
D007980_D004409 CID dopa_17\NN| (r_npadvmod) induced_19\VBN|dose (r_amod) dyskinesia_22\NN|NONE (r_pobj) like_14\IN|abnormal|,|involuntary|hyperkinetic|an (r_prep) movement_12\NN|,|due|that
D007980_D004409 CID dopa_17\NN| (r_npadvmod) induced_19\VBN|dose (r_amod) dyskinesia_22\NN|NONE
D007980_D006948 NONE dopa_17\NN| (r_npadvmod) induced_19\VBN|dose (r_amod) dyskinesia_22\NN|NONE (r_pobj) like_14\IN|abnormal|,|involuntary|hyperkinetic|an (r_prep) movement_12\NN|,|due|that (l_amod) hyperkinetic_9\JJ|abnormal|,|involuntary|an|like
D007980_D020734 NONE dopa_9\NN| (r_npadvmod) induced_11\VBN|dose (r_amod) dyskinesia_15\NN|NONE (r_pobj) with_6\IN|parkinsonian (r_prep) patients_5\NNS|NONE (l_amod) parkinsonian_4\JJ|with
D007980_D020734 NONE dopa_42\NN|, (r_compound) medication_43\NN|NONE (r_pobj) on_39\IN|parkinsonian (r_prep) patients_38\NNS|NONE (l_amod) parkinsonian_37\JJ|on
D007980_D020734 NONE dopa_51\NN|NONE (r_pobj) without_48\IN|the|first (r_prep) one_47\NN|of|and|,|dyskinesia (r_nsubj) induced_52\VBD|have|flow|We|. (r_conj) studied_2\VBN|NONE (l_dobj) flow_7\NN|induced|have|We|. (l_conj) changes_11\NNS|rCBF|regional|blood|cerebral|(|the (l_acl) induced_12\VBN|) (l_agent) by_13\IN|NONE (l_pobj) execution_15\NN|NONE (l_prep) in_26\IN|of|the (l_pobj) cortex_32\NN|NONE (l_prep) of_33\IN|supplementary|motor|the (l_pobj) groups_35\NNS|NONE (l_prep) of_36\IN|two (l_pobj) patients_38\NNS|NONE (l_amod) parkinsonian_37\JJ|on
12481039
D010862_D012640 CID pilocarpine_17\NN| (r_npadvmod) induced_19\VBN|NONE (r_amod) seizures_20\NNS|NONE (r_pobj) for_16\IN|NONE (r_prep) threshold_15\NN|reduced|and (r_conj) latency_13\NN|NONE (r_pobj) by_11\IN|as (r_agent) indicated_10\VBN|,|.|seemed|susceptibility|but|mice|, (r_advcl) displayed_3\VBD|NONE (l_dobj) susceptibility_5\NN|,|.|seemed|but|mice|indicated|, (l_prep) to_6\IN|increased (l_pobj) seizures_7\NNS|NONE
D010862_D012640 CID pilocarpine_17\NN| (r_npadvmod) induced_19\VBN|NONE (r_amod) seizures_20\NNS|NONE
D012964_D012640 NONE sodium_1\NN|NONE (r_compound) channel_2\NN|.|Reduced|,|dependence (r_compound) density_3\NN|NONE (l_appos) dependence_7\NN|.|Reduced|,|channel (l_conj) susceptibility_13\NN|,|and|of|altered|voltage (l_prep) to_14\IN|increased (l_pobj) seizures_15\NNS|NONE
D012964_D012640 NONE sodium_19\NN|NONE (r_compound) channel_20\NN|beta (r_compound) 2-subunits_22\NNS|mice (r_dobj) lacking_18\VBG|NONE (r_pcomp) in_16\IN|NONE (r_prep) seizures_15\NNS|NONE
15893386
D013390_D014313 CID Succinylcholine_0\NN| (r_npadvmod) induced_2\VBN|during|masseter|.|muscle (r_amod) rigidity_5\NN|NONE
D013390_D014313 CID succinylcholine_17\NN|Sch|)|(|during (r_nmod) administration_21\NN|NONE (r_pobj) after_16\IN|we|Here|,|case|. (r_prep) describe_3\VBP|NONE (l_dobj) case_5\NN|we|Here|after|,|. (l_prep) of_6\IN|a (l_pobj) rigidity_10\NN|NONE
D013390_D014313 CID succinylcholine_17\NN|Sch|)|(|during (r_nmod) administration_21\NN|NONE (r_pobj) after_16\IN|we|Here|,|case|. (r_prep) describe_3\VBP|NONE (l_dobj) case_5\NN|we|Here|after|,|. (l_prep) of_6\IN|a (l_pobj) rigidity_10\NN|NONE (l_appos) jaw_12\NN|muscle|(|masseter|)|severe (l_prep) of_13\IN|NONE (l_pobj) steel_14\NN|NONE
D013390_D014313 CID Sch_19\NNP|)|succinylcholine|(|during (r_nmod) administration_21\NN|NONE (r_pobj) after_16\IN|we|Here|,|case|. (r_prep) describe_3\VBP|NONE (l_dobj) case_5\NN|we|Here|after|,|. (l_prep) of_6\IN|a (l_pobj) rigidity_10\NN|NONE
D013390_D014313 CID Sch_19\NNP|)|succinylcholine|(|during (r_nmod) administration_21\NN|NONE (r_pobj) after_16\IN|we|Here|,|case|. (r_prep) describe_3\VBP|NONE (l_dobj) case_5\NN|we|Here|after|,|. (l_prep) of_6\IN|a (l_pobj) rigidity_10\NN|NONE (l_appos) jaw_12\NN|muscle|(|masseter|)|severe (l_prep) of_13\IN|NONE (l_pobj) steel_14\NN|NONE
D015742_D008305 NONE propofol_5\JJ|NONE (r_amod) infusion_6\NN|NONE (r_pobj) with_4\IN|.|were|was|Anesthesia|uneventfully (r_prep) continued_2\VBN|NONE (l_advcl) were_10\VBD|.|was|Anesthesia|uneventfully|with (l_acomp) available_11\JJ|while|facilities (l_xcomp) detect_13\VB|NONE (l_conj) treat_15\VB|to|and (l_dobj) hyperthermia_17\NN|NONE
1468485
D003520_D006470 CID cyclophosphamide_7\NN| (r_npadvmod) induced_9\VBN|intractable|hemorrhagic (r_amod) cystitis_11\NN|NONE
D003520_D006470 CID cyclophosphamide_10\NN|for (r_compound) therapy_11\NN|to (r_pobj) due_8\IN|We|case|. (r_prep) report_1\VBP|NONE (l_dobj) case_3\NN|We|due|. (l_prep) of_4\IN|a (l_pobj) cystitis_7\NN|NONE
D003520_D006470 CID cyclophosphamide_16\NN|NONE (r_pobj) of_15\IN|the (r_prep) treatment_14\NN|NONE (r_pobj) in_12\IN|safe|a (r_prep) alternative_11\NN|.|cystitis|,|In|can|form (r_dobj) offer_8\VB|NONE (l_dobj) cystitis_20\NN|.|,|In|can|form|alternative
D010100_D003556 NONE oxygen_1\NN|Hyperbaric|.|for (r_compound) therapy_2\NN|NONE (l_prep) for_3\IN|oxygen|Hyperbaric|. (l_pobj) control_4\NN|NONE (l_prep) of_5\IN|NONE (l_pobj) cystitis_11\NN|NONE
D003520_D014890 NONE cyclophosphamide_10\NN|for (r_compound) therapy_11\NN|to (l_prep) for_12\IN|cyclophosphamide (l_pobj) granulomatosis_15\NN|NONE
D010100_D006470 NONE oxygen_1\NN|Hyperbaric|.|for (r_compound) therapy_2\NN|NONE (l_prep) for_3\IN|oxygen|Hyperbaric|. (l_pobj) control_4\NN|NONE (l_prep) of_5\IN|NONE (l_pobj) cystitis_11\NN|NONE
D003520_D003556 CID cyclophosphamide_7\NN| (r_npadvmod) induced_9\VBN|intractable|hemorrhagic (r_amod) cystitis_11\NN|NONE
D003520_D003556 CID cyclophosphamide_10\NN|for (r_compound) therapy_11\NN|to (r_pobj) due_8\IN|We|case|. (r_prep) report_1\VBP|NONE (l_dobj) case_3\NN|We|due|. (l_prep) of_4\IN|a (l_pobj) cystitis_7\NN|NONE
D003520_D003556 CID cyclophosphamide_16\NN|NONE (r_pobj) of_15\IN|the (r_prep) treatment_14\NN|NONE (r_pobj) in_12\IN|safe|a (r_prep) alternative_11\NN|.|cystitis|,|In|can|form (r_dobj) offer_8\VB|NONE (l_dobj) cystitis_20\NN|.|,|In|can|form|alternative
D015237_D006470 NONE alpha_14\NN|NONE (r_pobj) of_11\IN|instillation|and|physiological (r_prep) saline_8\NN|NONE (r_pobj) with_6\IN|bladder (r_prep) irrigation_5\NN|NONE (r_pobj) including_3\VBG|,|Conservative|, (r_prep) treatment_1\NN|control|. (r_nsubj) failed_16\VBD|NONE (l_xcomp) control_19\VB|treatment|. (l_dobj) hemorrhage_20\NN|to|totally
8649546
D011433_D010300 NONE propranolol_7\NN|NONE (l_prep) in_8\IN|NONE (l_pobj) disease_11\NN|NONE
D011433_D010300 NONE propranolol_18\NN|.|patients (r_dobj) received_14\VBN|NONE (l_nsubj) patients_1\NNS|propranolol|. (l_acl) suffering_2\VBG|Seven (l_prep) from_3\IN|with (l_pobj) disease_6\NN|NONE
D011433_D010300 NONE propranolol_18\NN|.|patients (r_dobj) received_14\VBN|NONE (l_nsubj) patients_1\NNS|propranolol|. (l_acl) suffering_2\VBG|Seven (l_prep) from_3\IN|with (l_pobj) disease_6\NN|NONE (l_appos) PD_8\NNP|Parkinson|(|)
D007980_D004409 CID levodopa_2\NN| (r_npadvmod) induced_4\VBN|NONE (r_amod) dyskinesia_5\NN|NONE
D007980_D004409 CID levodopa_14\RB| (r_npadvmod) induced_16\VBN|in|ballistic (r_amod) dyskinesia_20\NN|administration|that|may
D007980_D010300 NONE levodopa_2\NN| (r_npadvmod) induced_4\VBN|NONE (r_amod) dyskinesia_5\NN|NONE (r_pobj) of_1\IN|by|. (r_prep) Improvement_0\NN|NONE (l_prep) by_6\IN|.|of (l_pcomp) propranolol_7\NN|NONE (l_prep) in_8\IN|NONE (l_pobj) disease_11\NN|NONE
D007980_D010300 NONE levodopa_14\RB| (r_npadvmod) induced_16\VBN|in|ballistic (r_amod) dyskinesia_20\NN|administration|that|may (l_prep) in_21\IN|induced|ballistic (l_pobj) PD_22\NNP|NONE
D011433_D004409 NONE propranolol_7\NN|NONE (r_pcomp) by_6\IN|.|of (r_prep) Improvement_0\NN|NONE (l_prep) of_1\IN|by|. (l_pobj) dyskinesia_5\NN|NONE
D011433_D004409 NONE propranolol_18\NN|.|patients (r_dobj) received_14\VBN|NONE (l_nsubj) patients_1\NNS|propranolol|. (l_acl) suffering_2\VBG|Seven (l_prep) with_10\IN|from (l_pobj) dyskinesia_13\NN|NONE
3535719
D000617_D006311 NONE aminoglycoside_3\NN| (r_npadvmod) associated_5\VBN|NONE (r_amod) ototoxicity_6\NN|that|severe
D009428_D007674 CID netilmicin_10\NNS|NONE (r_pobj) with_9\IN|NONE (r_prep) treated_8\VBN|NONE (r_acl) patients_7\NNS|NONE (r_pobj) in_6\IN|a|)|similar|(|% (r_prep) proportion_5\NN|NONE (r_pobj) in_2\IN|.|Nephrotoxicity (r_prep) occurred_1\VBD|NONE (l_nsubj) Nephrotoxicity_0\NN|in|.
D014031_D064420 NONE tobramycin_7\JJ|NONE (l_nsubj) efficacy_1\NN|.|in (l_conj) toxicity_3\NN|and|Relative
D010878_D007239 NONE sodium_17\NN|NONE (r_pobj) with_15\IN|in (r_prep) conjunction_14\NN|NONE (l_prep) in_18\IN|with (l_pobj) patients_21\NNS|NONE (l_prep) with_22\IN|immunocompromised| (l_pobj) infections_25\NNS|NONE
D014031_D007239 NONE sulfate_12\NN|netilmicin|or (r_conj) sulfate_9\NN|NONE (r_pobj) of_7\IN|safety|the|and (r_prep) efficacy_4\NN|prospectively|We|in|. (r_dobj) compared_2\VBD|NONE (l_prep) in_13\IN|efficacy|prospectively|We|. (l_pobj) conjunction_14\NN|NONE (l_prep) in_18\IN|with (l_pobj) patients_21\NNS|NONE (l_prep) with_22\IN|immunocompromised| (l_pobj) infections_25\NNS|NONE
D009428_D007239 NONE sulfate_9\NN|NONE (r_pobj) of_7\IN|safety|the|and (r_prep) efficacy_4\NN|prospectively|We|in|. (r_dobj) compared_2\VBD|NONE (l_prep) in_13\IN|efficacy|prospectively|We|. (l_pobj) conjunction_14\NN|NONE (l_prep) in_18\IN|with (l_pobj) patients_21\NNS|NONE (l_prep) with_22\IN|immunocompromised| (l_pobj) infections_25\NNS|NONE
D014031_D007674 CID tobramycin_12\JJ|and (r_conj) netilmicin_10\NNS|NONE (r_pobj) with_9\IN|NONE (r_prep) treated_8\VBN|NONE (r_acl) patients_7\NNS|NONE (r_pobj) in_6\IN|a|)|similar|(|% (r_prep) proportion_5\NN|NONE (r_pobj) in_2\IN|.|Nephrotoxicity (r_prep) occurred_1\VBD|NONE (l_nsubj) Nephrotoxicity_0\NN|in|.
D010878_D006311 CID piperacillin_12\VB|and| (r_conj) netilmicin_10\NNS|NONE (r_pobj) of_8\IN|.|)|four|( (r_prep) %_6\NN|and|in (r_pobj) in_2\IN|.|Ototoxicity (r_prep) occurred_1\VBD|NONE (l_nsubj) Ototoxicity_0\NN|.|in
D010878_D006311 CID piperacillin_24\NN| (r_npadvmod) treated_26\VBN|NONE (r_amod) patients_27\NNS|and| (r_conj) tobramycin_22\NNS|NONE (r_pobj) of_20\IN|||)|( (r_prep) %_18\NN|NONE (r_pobj) in_14\IN|and|% (r_conj) in_2\IN|.|Ototoxicity (r_prep) occurred_1\VBD|NONE (l_nsubj) Ototoxicity_0\NN|.|in
D009428_D064420 NONE netilmicin_5\NNS|NONE (r_pobj) of_4\IN|and (r_prep) toxicity_3\NN|and|Relative
D009428_D006311 CID netilmicin_10\NNS|NONE (r_pobj) of_8\IN|.|)|four|( (r_prep) %_6\NN|and|in (r_pobj) in_2\IN|.|Ototoxicity (r_prep) occurred_1\VBD|NONE (l_nsubj) Ototoxicity_0\NN|.|in
D009428_D006311 CID netilmicin_15\NNS|NONE (r_pobj) with_14\IN|often|than (r_prep) reversible_13\JJ|and|less (r_conj) severe_9\JJ|ototoxicity|that (r_acomp) was_7\VBD|We|. (l_nsubj) ototoxicity_6\NN|that|severe
D014031_D006311 CID tobramycin_22\NNS|NONE (r_pobj) of_20\IN|||)|( (r_prep) %_18\NN|NONE (r_pobj) in_14\IN|and|% (r_conj) in_2\IN|.|Ototoxicity (r_prep) occurred_1\VBD|NONE (l_nsubj) Ototoxicity_0\NN|.|in
D014031_D006311 CID tobramycin_18\NNS|NONE (r_pobj) with_17\IN|NONE (r_prep) than_16\IN|often|with (r_prep) reversible_13\JJ|and|less (r_conj) severe_9\JJ|ototoxicity|that (r_acomp) was_7\VBD|We|. (l_nsubj) ototoxicity_6\NN|that|severe
17042910
D003907_D006973 CID dexamethasone_7\NN| (r_npadvmod) induced_9\VBN|in (r_amod) hypertension_10\NN|NONE
D003907_D006973 CID Dexamethasone_0\NNP|NONE (l_parataxis) characterized_5\VBN|production (l_nsubjpass) hypertension_3\NN|and|(|increased|is|by
D003907_D006973 CID Dex)-induced_2\JJ|NONE (r_amod) hypertension_3\NN|and|(|increased|is|by
D013481_D006973 NONE superoxide_19\NN|NONE (r_advmod) increased_18\VBN|hypertension|and|(|is|by (r_conj) characterized_5\VBN|production (l_nsubjpass) hypertension_3\NN|and|(|increased|is|by
D013481_D006973 NONE O2-_21\NNPS|)|.|( (r_nmod) production_23\NN|characterized (r_appos) Dexamethasone_0\NNP|NONE (l_parataxis) characterized_5\VBN|production (l_nsubjpass) hypertension_3\NN|and|(|increased|is|by
D013481_D006973 NONE O2-_22\JJ|NO|reduced|in (r_compound) production_23\NN|NONE (l_prep) in_24\IN|O|NO|reduced (l_pobj) forms_26\NNS|NONE (l_prep) of_27\IN|various (l_pobj) hypertension_28\NN|NONE
C065179_D006973 NONE atorvastatin_5\NN|NONE (r_pobj) of_4\IN|in|.|oxidant (r_prep) effects_3\NNS|NONE (l_prep) in_6\IN|.|of|oxidant (l_pobj) hypertension_10\NN|NONE
C065179_D006973 NONE Atorvastatin_0\NNP|.|properties (r_nsubj) possesses_4\VBZ|NONE (l_dobj) properties_6\NNS|Atorvastatin|. (l_relcl) reported_10\VBN|pleiotropic (l_xcomp) improve_12\VB|that|been|have (l_prep) through_15\IN|function|to (l_pobj) availability_17\NN|NONE (l_prep) of_18\IN|increased (l_pobj) production_23\NN|NONE (l_prep) in_24\IN|O|NO|reduced (l_pobj) forms_26\NNS|NONE (l_prep) of_27\IN|various (l_pobj) hypertension_28\NN|NONE
C065179_D006973 NONE Ato_2\NNP|) (r_appos) Atorvastatin_0\NNP|.|properties (r_nsubj) possesses_4\VBZ|NONE (l_dobj) properties_6\NNS|Atorvastatin|. (l_relcl) reported_10\VBN|pleiotropic (l_xcomp) improve_12\VB|that|been|have (l_prep) through_15\IN|function|to (l_pobj) availability_17\NN|NONE (l_prep) of_18\IN|increased (l_pobj) production_23\NN|NONE (l_prep) in_24\IN|O|NO|reduced (l_pobj) forms_26\NNS|NONE (l_prep) of_27\IN|various (l_pobj) hypertension_28\NN|NONE
D009569_D006973 NONE oxide_12\NN|(|)|NO (r_nmod) deficiency_16\NN|NONE (r_pobj) with_10\IN|NONE (r_prep) associated_9\VBN|endothelial (r_acl) dysfunction_8\NN|NONE (r_pobj) by_6\IN|hypertension|and|(|increased|is (r_agent) characterized_5\VBN|production (l_nsubjpass) hypertension_3\NN|and|(|increased|is|by
D009569_D006973 NONE NO_14\NNP|(|)|oxide (r_intj) deficiency_16\NN|NONE (r_pobj) with_10\IN|NONE (r_prep) associated_9\VBN|endothelial (r_acl) dysfunction_8\NN|NONE (r_pobj) by_6\IN|hypertension|and|(|increased|is (r_agent) characterized_5\VBN|production (l_nsubjpass) hypertension_3\NN|and|(|increased|is|by
D009569_D006973 NONE NO_19\DT|O|reduced|in (r_amod) production_23\NN|NONE (l_prep) in_24\IN|O|NO|reduced (l_pobj) forms_26\NNS|NONE (l_prep) of_27\IN|various (l_pobj) hypertension_28\NN|NONE
12443032
D003042_D002637 CID Cocaine_0\NN|pain (r_nsubj) related_1\VBN|are|tip|we|?|: (l_dobj) pain_3\NN|Cocaine
D003042_D002637 CID cocaine_6\NN|NONE (r_pobj) of_5\IN|produce|the (r_prep) tendency_4\NN|In|,|.|be (l_acl) produce_8\VB|the|of (l_dobj) pain_10\NN|to
D003042_D002637 CID cocaine_6\NN|NONE (r_pobj) of_5\IN|produce|the (r_prep) tendency_4\NN|In|,|.|be (r_nsubj) ought_11\MD|NONE (l_xcomp) be_13\VB|In|,|.|tendency (l_advcl) faced_22\VBN|in|to (l_prep) with_23\IN|when (l_pobj) victim_26\NN|NONE (l_prep) of_27\IN|is|young|a (l_pobj) pain_29\NN|NONE
D003042_D002637 CID cocaine_7\NN|NONE (r_compound) use_8\NN|NONE (r_pobj) to_6\IN|NONE (r_prep) related_5\VBN|The|of (r_acl) mechanism_1\NN|and|discussed|is (l_prep) of_2\IN|The|related (l_pobj) pain_4\NN|NONE
20196116
D001663_D001927 NONE bilirubin_11\NN|: (l_appos) time_21\NN|serum|(|dL|)|, (l_conj) encephalopathy_37\NN|,|and|prolongation|prothrombin
D000995_D017114 CID Antituberculosis_0\NNP|failure||profile|therapy|. (r_nsubj) induced_3\VBN|NONE (l_dobj) failure_6\NN||profile|therapy|Antituberculosis|.
D000995_D017114 CID Antituberculosis_0\NN|(|failure (r_compound) therapy_1\NN|ALF|. (l_appos) failure_6\NN|(|Antituberculosis
D000995_D017114 CID Antituberculosis_0\NN|(|failure (r_compound) therapy_1\NN|ALF|. (l_appos) failure_6\NN|(|Antituberculosis (l_appos) ALF_10\NNP|liver|)|acute|(|ATT)associated
D000995_D017114 CID Antituberculosis_0\NN|(|failure (r_compound) therapy_1\NN|ALF|. (r_nsubj) is_12\VBZ|NONE (l_attr) ALF_18\NNP|.|therapy
2826064
D010096_D007008 NONE oxprenolol_8\NN|NONE (r_pobj) by_7\IN|its (r_prep) abolishment_6\NN|mediated|.|and (r_conj) hypokalemia_3\NN|NONE
D010096_D007008 NONE oxprenolol_6\NN|NONE (r_pobj) of_5\IN|the (r_prep) efficacy_4\NN|.|Subsequently|with|we|in|, (r_dobj) investigated_2\VBD|NONE (l_prep) in_7\IN|.|Subsequently|efficacy|with|we|, (l_pcomp) antagonizing_8\VBG|NONE (l_dobj) hypokalemia_10\NN|NONE
D010096_D007008 NONE oxprenolol_7\NN|NONE (r_amod) pretreatment_8\NN|NONE (r_pobj) after_6\IN|terbutaline|higher (r_prep) concentrations_5\NNS|NONE (r_pobj) of_2\IN|NONE (r_prep) spite_1\NN|NONE (r_pobj) In_0\IN|hypokalemia|by|.|,|completely|was (r_prep) antagonized_15\VBN|NONE (l_nsubjpass) hypokalemia_11\NN|In|by|.|,|completely|was
D013726_D007008 CID terbutaline_9\NN| (r_npadvmod) induced_11\VBN|NONE (r_amod) hypokalemia_12\NN|NONE
D013726_D007008 CID terbutaline_4\JJ|after|higher (r_compound) concentrations_5\NNS|NONE (r_pobj) of_2\IN|NONE (r_prep) spite_1\NN|NONE (r_pobj) In_0\IN|hypokalemia|by|.|,|completely|was (r_prep) antagonized_15\VBN|NONE (l_nsubjpass) hypokalemia_11\NN|In|by|.|,|completely|was
18619688
D004317_D006333 CID Adriamycin_0\NNP| (r_advmod) induced_2\VBN|cardiomyocyte (r_amod) death_5\NN|role|.|in (r_nsubj) plays_6\VBZ|NONE (l_prep) in_10\IN|role|.|death (l_pobj) model_13\NN|NONE (l_prep) of_14\IN|a|rat (l_pobj) failure_16\NN|NONE
D004317_D006333 CID adriamycin_7\NNS|NONE (r_pobj) by_6\IN|NONE (r_agent) induced_5\VBN|underlying|heart|mechanisms (r_acl) failure_4\NN|complicated|.
D004317_D006333 CID adriamycin_20\NNS|NONE (r_pobj) by_19\IN|NONE (r_agent) induced_18\VBN|of|the (r_acl) progression_14\NN|NONE (l_prep) of_15\IN|induced|the (l_pobj) failure_17\NN|NONE
D004317_D006333 CID adriamycin_20\NNS|NONE (r_pobj) by_19\IN|NONE (r_agent) induced_18\VBN|of|the (r_acl) progression_14\NN|NONE (r_pobj) in_12\IN|autophagy|whether|was (r_prep) involved_11\VBN|develop|,|to (r_ccomp) investigate_7\VB|.|aim (l_advcl) develop_26\VB|,|to|involved (l_dobj) strategy_30\NN|that|so|can|we (l_prep) for_31\IN|a|novel|treatment (l_pobj) failure_33\NN|NONE
D004317_D006333 CID adriamycin_23\NNS|NONE (r_pobj) by_22\IN|NONE (r_agent) induced_21\VBN|heart|failure|of|a (r_acl) model_18\NN|NONE (l_compound) failure_17\NN|heart|induced|of|a
D004317_D006333 CID adriamycin_17\NNS|NONE (r_pobj) by_16\IN|NONE (r_agent) induced_15\VBN|.|role|death|in (r_advcl) plays_3\VBZ|NONE (l_prep) in_7\IN|.|induced|role|death (l_pobj) pathogenesis_9\NN|NONE (l_prep) of_10\IN|the (l_pobj) failure_12\NN|NONE
D004317_D006333 CID adriamycin_13\NNS|NONE (r_pobj) by_12\IN|via (r_agent) caused_11\VBN|heart (r_acl) failure_10\NN|NONE
D004317_D003643 NONE Adriamycin_0\NNP| (r_advmod) induced_2\VBN|cardiomyocyte (r_amod) death_5\NN|role|.|in
D004317_D003643 NONE adriamycin_17\NNS|NONE (r_pobj) by_16\IN|NONE (r_agent) induced_15\VBN|.|role|death|in (r_advcl) plays_3\VBZ|NONE (l_nsubj) death_2\NN|.|induced|role|in
C025946_D006333 NONE 3-methyladenine_2\LS|:|, (r_appos) METHODS_0\NNS|inhibitor|in|.|was (r_nsubjpass) used_13\VBN|NONE (l_prep) in_14\IN|inhibitor|.|was|METHODS (l_pobj) model_18\NN|NONE (l_compound) failure_17\NN|heart|induced|of|a
C025946_D006333 NONE 3MA_4\VBN|NONE (r_appos) 3-methyladenine_2\LS|:|, (r_appos) METHODS_0\NNS|inhibitor|in|.|was (r_nsubjpass) used_13\VBN|NONE (l_prep) in_14\IN|inhibitor|.|was|METHODS (l_pobj) model_18\NN|NONE (l_compound) failure_17\NN|heart|induced|of|a
9165568
D018967_D001480 NONE risperidone_14\NN|NONE (r_pobj) with_13\IN|of|the|low (r_prep) frequency_9\NN|to (l_prep) of_10\IN|with|the|low (l_pobj) symptoms_12\NNS|NONE
D018967_D009459 CID risperidone_4\NN|NONE (r_pobj) with_3\IN|malignant|Neuroleptic|. (r_prep) syndrome_2\NN|NONE
D018967_D009459 CID risperidone_12\NN|NONE (r_pobj) with_11\IN|NONE (r_prep) monotherapy_10\NN|NONE (r_pobj) after_9\IN|syndrome|woman|. (r_prep) developed_5\VBD|NONE (l_dobj) syndrome_8\NN|woman|after|.
D018967_D009459 CID risperidone_11\NN|NONE (r_pobj) with_10\IN|that|protection (r_prep) observed_9\VBN|It|ensure|. (r_ccomp) appears_1\VBZ|NONE (l_conj) ensure_14\VB|It|.|observed (l_dobj) protection_15\NN|not|does (l_prep) from_16\IN|NONE (l_pobj) syndrome_19\NN|NONE
D004298_D009459 NONE dopamine_10\NN|in|D|receptor (r_compound) blockade_13\NN|NONE (r_pobj) of_9\IN|a (r_prep) result_8\NN|to (r_attr) be_6\VB|.|syndrome|is (r_xcomp) thought_4\VBN|NONE (l_nsubjpass) syndrome_2\NN|.|is|be
8386779
D010208_D007172 NONE papaverine_25\NN||: (r_appos) drugs_21\NNS|NONE (r_pobj) of_19\IN|a (r_prep) combination_18\NN|NONE (r_pobj) of_16\IN|. (r_prep) ml._15\NN|.|total (r_dobj) received_13\VBD|NONE (l_nsubj) total_1\NN|.|ml. (l_prep) of_2\IN|A (l_pobj) patients_5\NNS|NONE (l_relcl) presented_7\VBD||consecutive (l_prep) with_11\IN|to|who (l_pobj) impotence_12\NN|NONE
D017693_D007172 NONE bicarbonate_1\NN|.|induced|pain (r_nsubj) alleviates_2\VBZ|NONE (l_advcl) induced_5\VBN|.|bicarbonate|pain (l_agent) by_6\IN|NONE (l_pobj) injections_8\NNS|NONE (l_prep) for_9\IN|intracavernous (l_pobj) dysfunction_11\NN|NONE
D017693_D004414 NONE bicarbonate_1\NN|.|induced|pain (r_nsubj) alleviates_2\VBZ|NONE (l_dobj) pain_4\NN|.|bicarbonate|induced
D017693_D004414 NONE bicarbonate_43\NN|NONE (r_pobj) of_41\IN|the (r_prep) addition_40\NN|NONE (r_pobj) without_38\IN|or (r_conj) with_36\IN|intracorporeal (r_prep) injections_35\NNS|NONE (r_pobj) following_33\VBG|incidence (r_prep) comparing_27\VBG|a|randomized (r_acl) study_26\NN|we|,|In|medications. (r_dobj) performed_23\VBD|NONE (l_prep) In_0\IN|study|we|,|medications. (l_pobj) attempt_2\NN|NONE (l_acl) determine_4\VB|an (l_ccomp) be_13\VB|to (l_nsubj) pain_7\NN|due|whether|could
D017693_D004414 NONE bicarbonate_43\NN|NONE (r_pobj) of_41\IN|the (r_prep) addition_40\NN|NONE (r_pobj) without_38\IN|or (r_conj) with_36\IN|intracorporeal (r_prep) injections_35\NNS|NONE (r_pobj) following_33\VBG|incidence (r_prep) comparing_27\VBG|a|randomized (l_dobj) incidence_29\NN|following (l_prep) of_30\IN|the (l_pobj) pain_32\NN|NONE
D017693_D004414 NONE bicarbonate_6\NN|NONE (r_pobj) without_4\IN|added||the (r_prep) patients_3\NNS|NONE (r_pobj) Of_0\IN|.|complained|due|,|of (r_prep) complained_16\VBD|NONE (l_prep) of_17\IN|Of|.|complained|due|, (l_pobj) pain_19\NN|NONE
D017693_D004414 NONE bicarbonate_6\NN|NONE (r_pobj) without_4\IN|added||the (r_prep) patients_3\NNS|NONE (r_pobj) Of_0\IN|.|complained|due|,|of (r_prep) complained_16\VBD|NONE (l_advcl) complained_40\VBD|Of|.|due|,|of (l_prep) of_41\IN|while| (l_pobj) pain_43\NN|NONE
D017693_D004414 NONE bicarbonate_39\NN|who (r_dobj) received_37\VBD|)|%||(|the (r_relcl) men_31\NNS|NONE (r_pobj) of_28\IN|only (r_prep) 1_27\CD|while|of (r_nsubj) complained_40\VBD|Of|.|due|,|of (r_advcl) complained_16\VBD|NONE (l_prep) of_17\IN|Of|.|complained|due|, (l_pobj) pain_19\NN|NONE
D017693_D004414 NONE bicarbonate_39\NN|who (r_dobj) received_37\VBD|)|%||(|the (r_relcl) men_31\NNS|NONE (r_pobj) of_28\IN|only (r_prep) 1_27\CD|while|of (r_nsubj) complained_40\VBD|Of|.|due|,|of (l_prep) of_41\IN|while| (l_pobj) pain_43\NN|NONE
3220106
D009538_D006948 CID nicotine_3\NN| (r_npadvmod) induced_5\VBN|in|locomotor (r_amod) hyperactivity_7\NN|NONE
D009538_D006948 CID nicotine_10\NN| (r_npadvmod) treated_12\VBN|chronic (r_amod) rats_13\NNS|NONE (r_pobj) in_8\IN|induced|locomotor (r_prep) hyperactivity_7\NN|NONE
D009538_D006948 CID nicotine_5\NN| (r_npadvmod) treated_7\VBN|chronic (r_amod) rats_8\NNS|hyperactivity|that|in|initially|due|, (r_nsubj) develop_9\VBP|followed|.|results (l_dobj) hyperactivity_11\NN|that|rats|in|initially|due|,
D009538_D006948 CID nicotine_15\NN|NONE (r_pobj) to_14\IN|NONE (r_prep) response_13\NN|NONE (r_pobj) in_12\IN|hyperactivity|that|rats|initially|due|, (r_prep) develop_9\VBP|followed|.|results (l_dobj) hyperactivity_11\NN|that|rats|in|initially|due|,
D004298_D006948 NONE DA_28\NNP|NONE (r_compound) concentration_29\NN|and|nicotinic (r_conj) receptors_26\NNS|NONE (r_pobj) of_24\IN|the|both (r_prep) density_23\NN|NONE (r_pobj) of_20\IN|NONE (r_prep) increases_19\NNS|to (r_pobj) due_17\JJ|hyperactivity|that|rats|in|initially|, (r_prep) develop_9\VBP|followed|.|results (l_dobj) hyperactivity_11\NN|that|rats|in|initially|due|,
D004298_D006948 NONE DA_34\NNP|in|receptor (r_compound) supersensitivity_36\NN|NONE (r_dobj) inducing_33\VBG|NONE (r_pcomp) by_32\IN|NONE (r_agent) followed_31\VBN|.|develop|results (r_advcl) suggest_2\VBP|NONE (l_ccomp) develop_9\VBP|followed|.|results (l_dobj) hyperactivity_11\NN|that|rats|in|initially|due|,
85485
D001556_D017093 NONE hexachloride_17\NN|NONE (r_pobj) by_11\IN|examined|Peroxisomes|.|in (r_prep) induced_8\VBN|NONE (l_nsubj) Peroxisomes_0\NNS|examined|.|by|in (l_prep) in_1\IN|NONE (l_pobj) lesions_7\NNS|hepatomas
D001556_D006528 CID hexachloride_15\NN|NONE (r_pobj) by_11\IN|NONE (r_agent) induced_10\VBN|in|. (r_acl) Changes_0\NNS|NONE (l_prep) in_1\IN|induced|. (l_pobj) peroxisomes_2\NNS|NONE (l_prep) in_3\IN|NONE (l_pobj) liver_5\NN|NONE (l_conj) hepatoma_7\NN|preneoplastic|and
D001556_D006528 CID hexachloride_17\NN|NONE (r_pobj) by_11\IN|examined|Peroxisomes|.|in (r_prep) induced_8\VBN|NONE (l_nsubj) Peroxisomes_0\NNS|examined|.|by|in (l_prep) in_1\IN|NONE (l_pobj) hepatomas_2\NNS|lesions
C012282_D006528 NONE chlorophenoxyisobutyrate_31\NN| (r_appos) alpha_27\NN|NONE (r_appos) ethyl_25\NN|NONE (r_pobj) to_24\IN|,|not|with|cells|did|.|were (r_prep) respond_23\VB|NONE (l_advcl) were_5\VBD|,|to|not|with|cells|did|. (l_nsubj) most_1\JJS|contained|and|tumors|Although (l_prep) of_2\IN|NONE (l_pobj) hepatomas_4\NNS|NONE
C012282_D009369 NONE chlorophenoxyisobutyrate_31\NN| (r_appos) alpha_27\NN|NONE (r_appos) ethyl_25\NN|NONE (r_pobj) to_24\IN|,|not|with|cells|did|.|were (r_prep) respond_23\VB|NONE (l_advcl) were_5\VBD|,|to|not|with|cells|did|. (l_attr) tumors_9\NNS|most|contained|and|Although
C012282_D009369 NONE chlorophenoxyisobutyrate_31\NN| (r_appos) alpha_27\NN|NONE (r_appos) ethyl_25\NN|NONE (r_pobj) to_24\IN|,|not|with|cells|did|.|were (r_prep) respond_23\VB|NONE (l_nsubj) cells_20\NNS|,|to|not|with|did|.|were (l_compound) tumor_19\NN|the
8305357
D003630_D012514 NONE daunorubicin_1\NN|NONE (l_dobj) sarcoma_6\NN|in|.|Liposomal
D003630_D012514 NONE daunorubicin_18\NN|NONE (r_pobj) of_16\IN|NONE (r_prep) safety_15\NN|the|in|and (r_conj) efficacy_13\NN|to (r_dobj) assess_11\VB|a|II|clinical|randomized (r_relcl) trial_9\NN|related|We|. (r_dobj) report_1\VBP|NONE (l_ccomp) related_27\VBD|We|trial|. (l_dobj) sarcoma_30\NN|NONE
D003630_D012514 NONE daunorubicin_7\NN|,|agent|In|. (r_nsubj) was_8\VBD|NONE (l_attr) agent_14\NN|,|In|.|daunorubicin (l_prep) in_15\IN|an|effective (l_pobj) treatment_17\NN|NONE (l_prep) of_18\IN|the (l_pobj) sarcoma_21\NN|NONE
D003630_D000163 NONE daunorubicin_18\NN|NONE (r_pobj) of_16\IN|NONE (r_prep) safety_15\NN|the|in|and (r_conj) efficacy_13\NN|to (l_prep) in_22\IN|the|safety|and (l_pobj) treatment_24\NN|NONE (l_prep) of_25\IN|the (l_pobj) AIDS_26\NNP|NONE
18441470
D008094_D012804 CID lithium_14\NN|NONE (r_pobj) of_13\IN|the|adverse|cardiovascular (r_prep) effects_12\NNS|NONE (r_pobj) among_8\IN|been|frequently|has|dysfunction|. (r_prep) reported_5\VBN|NONE (l_nsubjpass) dysfunction_2\NN|been|frequently|has|among|.
D008094_D013575 NONE lithium_17\NN|NONE (r_compound) therapy_18\NN|NONE (r_pobj) to_16\IN|,|necessitating|In|block|,|.|secondary (r_prep) developed_14\VBD|NONE (l_nsubj) block_10\NN|,|necessitating|In|,|.|to|secondary (l_prep) with_11\IN|)|(|complete|AV|atrioventricular (l_pobj) attacks_13\NNS|NONE
D008094_D013575 NONE lithium_1\NN|NONE (r_compound) levels_2\NNS|under|.|during (r_nsubj) remained_3\VBD|NONE (l_prep) during_10\IN|under|.|levels (l_pobj) attacks_13\NNS|NONE
D008094_D054537 CID lithium_5\NN|NONE (r_compound) therapy_6\NN|NONE (r_pobj) to_4\IN|NONE (r_prep) secondary_3\JJ|Complete|atrioventricular|. (r_amod) block_2\NN|NONE
D008094_D054537 CID lithium_17\NN|NONE (r_compound) therapy_18\NN|NONE (r_pobj) to_16\IN|,|necessitating|In|block|,|.|secondary (r_prep) developed_14\VBD|NONE (l_nsubj) block_10\NN|,|necessitating|In|,|.|to|secondary
7059267
D002747_D003924 NONE chlorpropamide_12\NN|NONE (r_pobj) with_11\IN|woman (r_prep) treated_10\VBN|neuropathy|. (l_nsubj) woman_4\NN|with (l_prep) with_5\IN|old|A (l_pobj) diabetes_9\NNS|NONE
D002747_D003924 NONE Diabenese_14\NNP|(|) (r_appos) chlorpropamide_12\NN|NONE (r_pobj) with_11\IN|woman (r_prep) treated_10\VBN|neuropathy|. (l_nsubj) woman_4\NN|with (l_prep) with_5\IN|old|A (l_pobj) diabetes_9\NNS|NONE
D002747_D003924 NONE chlorpropamide_26\NN|NONE (r_amod) therapy_27\NN|NONE (r_pobj) of_25\IN|NONE (r_prep) discontinuation_24\NN|NONE (r_pobj) with_23\IN|that (r_prep) resolved_22\VBD|a|optic|toxic (r_relcl) neuropathy_20\NN|.|treated (r_dobj) had_16\VBD|NONE (l_csubj) treated_10\VBN|neuropathy|. (l_nsubj) woman_4\NN|with (l_prep) with_5\IN|old|A (l_pobj) diabetes_9\NNS|NONE
D002747_D009901 CID Chlorpropamide_0\NN| (r_npadvmod) induced_2\VBN|.|optic (r_amod) neuropathy_4\NN|NONE
D002747_D009901 CID chlorpropamide_12\NN|NONE (r_pobj) with_11\IN|woman (r_prep) treated_10\VBN|neuropathy|. (r_csubj) had_16\VBD|NONE (l_dobj) neuropathy_20\NN|.|treated
D002747_D009901 CID Diabenese_14\NNP|(|) (r_appos) chlorpropamide_12\NN|NONE (r_pobj) with_11\IN|woman (r_prep) treated_10\VBN|neuropathy|. (r_csubj) had_16\VBD|NONE (l_dobj) neuropathy_20\NN|.|treated
D002747_D009901 CID chlorpropamide_26\NN|NONE (r_amod) therapy_27\NN|NONE (r_pobj) of_25\IN|NONE (r_prep) discontinuation_24\NN|NONE (r_pobj) with_23\IN|that (r_prep) resolved_22\VBD|a|optic|toxic (r_relcl) neuropathy_20\NN|.|treated
10193204
D004837_D013927 CID epinephrine_21\NN|plus (r_conj) collagen_19\NN|NONE (r_pobj) by_18\IN|in (r_agent) induced_17\VBN|the|experimental (r_acl) thrombosis_16\NN|NONE
D004837_D013927 CID EP_23\NN|NONE (r_appos) epinephrine_21\NN|plus (r_conj) collagen_19\NN|NONE (r_pobj) by_18\IN|in (r_agent) induced_17\VBN|the|experimental (r_acl) thrombosis_16\NN|NONE
C060802_D001778 NONE FAN_12\NNP|and (r_conj) TET_10\NNP|NONE (r_pobj) of_9\IN|the|on (r_prep) effects_8\NNS|to (r_dobj) investigate_6\VB|study|,|and|in|was (r_advcl) undertaken_4\VBN|NONE (l_conj) in_34\IN|study|investigate|,|and|was (l_nsubj) aggregation_30\NN|vitro|. (l_conj) coagulation_33\NN|and|platelet
D004837_D001778 NONE epinephrine_21\NN|plus (r_conj) collagen_19\NN|NONE (r_pobj) by_18\IN|in (r_agent) induced_17\VBN|the|experimental (r_acl) thrombosis_16\NN|NONE (r_pobj) on_13\IN|of|the (r_prep) effects_8\NNS|to (r_dobj) investigate_6\VB|study|,|and|in|was (r_advcl) undertaken_4\VBN|NONE (l_conj) in_34\IN|study|investigate|,|and|was (l_nsubj) aggregation_30\NN|vitro|. (l_conj) coagulation_33\NN|and|platelet
D004837_D001778 NONE EP_23\NN|NONE (r_appos) epinephrine_21\NN|plus (r_conj) collagen_19\NN|NONE (r_pobj) by_18\IN|in (r_agent) induced_17\VBN|the|experimental (r_acl) thrombosis_16\NN|NONE (r_pobj) on_13\IN|of|the (r_prep) effects_8\NNS|to (r_dobj) investigate_6\VB|study|,|and|in|was (r_advcl) undertaken_4\VBN|NONE (l_conj) in_34\IN|study|investigate|,|and|was (l_nsubj) aggregation_30\NN|vitro|. (l_conj) coagulation_33\NN|and|platelet
C009438_D013927 NONE tetrandrine_2\NN|NONE (r_pobj) of_1\IN|on|. (r_prep) Effects_0\NNS|NONE (l_prep) on_5\IN|of|. (l_pobj) thrombosis_7\NN|NONE
C009438_D013927 NONE TET_10\NNP|NONE (r_pobj) of_9\IN|the|on (r_prep) effects_8\NNS|to (l_prep) on_13\IN|of|the (l_pobj) thrombosis_16\NN|NONE
C009438_D013927 NONE TET_15\NNP|NONE (r_pobj) of_14\IN|i.p.|the|)|(|mg/kg (r_prep) administration_7\NN|.|inhibition|,|acetylsalicylic|,|In (r_nsubj) showed_20\VBD|NONE (l_dobj) inhibition_22\NN|.|,|acetylsalicylic|administration|,|In (l_prep) of_23\IN|the|by|respectively|, (l_pobj) thrombosis_24\NN|NONE
C009438_D001778 NONE TET_10\NNP|NONE (r_pobj) of_9\IN|the|on (r_prep) effects_8\NNS|to (r_dobj) investigate_6\VB|study|,|and|in|was (r_advcl) undertaken_4\VBN|NONE (l_conj) in_34\IN|study|investigate|,|and|was (l_nsubj) aggregation_30\NN|vitro|. (l_conj) coagulation_33\NN|and|platelet
C060802_D001791 NONE fangchinoline_4\NN|and (r_conj) tetrandrine_2\NN|NONE (r_pobj) of_1\IN|on|. (r_prep) Effects_0\NNS|NONE (l_prep) on_5\IN|of|. (l_pobj) thrombosis_7\NN|NONE (l_prep) in_8\IN|experimental (l_pobj) mice_9\NNS|NONE (l_conj) aggregation_13\NN|and
C060802_D001791 NONE FAN_12\NNP|and (r_conj) TET_10\NNP|NONE (r_pobj) of_9\IN|the|on (r_prep) effects_8\NNS|to (r_dobj) investigate_6\VB|study|,|and|in|was (r_advcl) undertaken_4\VBN|NONE (l_conj) in_34\IN|study|investigate|,|and|was (l_nsubj) aggregation_30\NN|vitro|.
C060802_D001791 NONE FAN_16\NNP|and (r_conj) TET_14\NNP|dependently|In|dose|,|. (r_nsubj) showed_17\VBD|NONE (l_prep) In_0\IN|TET|dependently|dose|,|. (l_pobj) aggregations_5\NNS|NONE
D004837_D001791 NONE epinephrine_21\NN|plus (r_conj) collagen_19\NN|NONE (r_pobj) by_18\IN|in (r_agent) induced_17\VBN|the|experimental (r_acl) thrombosis_16\NN|NONE (r_pobj) on_13\IN|of|the (r_prep) effects_8\NNS|to (r_dobj) investigate_6\VB|study|,|and|in|was (r_advcl) undertaken_4\VBN|NONE (l_conj) in_34\IN|study|investigate|,|and|was (l_nsubj) aggregation_30\NN|vitro|.
D004837_D001791 NONE EP_23\NN|NONE (r_appos) epinephrine_21\NN|plus (r_conj) collagen_19\NN|NONE (r_pobj) by_18\IN|in (r_agent) induced_17\VBN|the|experimental (r_acl) thrombosis_16\NN|NONE (r_pobj) on_13\IN|of|the (r_prep) effects_8\NNS|to (r_dobj) investigate_6\VB|study|,|and|in|was (r_advcl) undertaken_4\VBN|NONE (l_conj) in_34\IN|study|investigate|,|and|was (l_nsubj) aggregation_30\NN|vitro|.
D001241_D013927 NONE acid_36\NN|,|showed|while|,|mg/kg|control (r_dobj) acetylsalicylic_35\JJ|.|inhibition|,|administration|,|In (r_advcl) showed_20\VBD|NONE (l_dobj) inhibition_22\NN|.|,|acetylsalicylic|administration|,|In (l_prep) of_23\IN|the|by|respectively|, (l_pobj) thrombosis_24\NN|NONE
D001241_D013927 NONE ASA_38\NNP|NONE (r_appos) acid_36\NN|,|showed|while|,|mg/kg|control (r_dobj) acetylsalicylic_35\JJ|.|inhibition|,|administration|,|In (r_advcl) showed_20\VBD|NONE (l_dobj) inhibition_22\NN|.|,|acetylsalicylic|administration|,|In (l_prep) of_23\IN|the|by|respectively|, (l_pobj) thrombosis_24\NN|NONE
C060802_D013927 NONE fangchinoline_4\NN|and (r_conj) tetrandrine_2\NN|NONE (r_pobj) of_1\IN|on|. (r_prep) Effects_0\NNS|NONE (l_prep) on_5\IN|of|. (l_pobj) thrombosis_7\NN|NONE
C060802_D013927 NONE FAN_12\NNP|and (r_conj) TET_10\NNP|NONE (r_pobj) of_9\IN|the|on (r_prep) effects_8\NNS|to (l_prep) on_13\IN|of|the (l_pobj) thrombosis_16\NN|NONE
C060802_D013927 NONE FAN_17\NNP|and (r_conj) TET_15\NNP|NONE (r_pobj) of_14\IN|i.p.|the|)|(|mg/kg (r_prep) administration_7\NN|.|inhibition|,|acetylsalicylic|,|In (r_nsubj) showed_20\VBD|NONE (l_dobj) inhibition_22\NN|.|,|acetylsalicylic|administration|,|In (l_prep) of_23\IN|the|by|respectively|, (l_pobj) thrombosis_24\NN|NONE
C009438_D001791 NONE tetrandrine_2\NN|NONE (r_pobj) of_1\IN|on|. (r_prep) Effects_0\NNS|NONE (l_prep) on_5\IN|of|. (l_pobj) thrombosis_7\NN|NONE (l_prep) in_8\IN|experimental (l_pobj) mice_9\NNS|NONE (l_conj) aggregation_13\NN|and
C009438_D001791 NONE TET_10\NNP|NONE (r_pobj) of_9\IN|the|on (r_prep) effects_8\NNS|to (r_dobj) investigate_6\VB|study|,|and|in|was (r_advcl) undertaken_4\VBN|NONE (l_conj) in_34\IN|study|investigate|,|and|was (l_nsubj) aggregation_30\NN|vitro|.
C009438_D001791 NONE TET_14\NNP|dependently|In|dose|,|. (r_nsubj) showed_17\VBD|NONE (l_prep) In_0\IN|TET|dependently|dose|,|. (l_pobj) aggregations_5\NNS|NONE
15638391
D006220_D006966 CID haloperidol_16\NN|NONE (r_pobj) by_15\IN|process|. (r_agent) induced_14\VBN|NONE (l_nsubj) process_1\NN|.|by (l_prep) of_2\IN|Aging (l_pobj) cells_4\NNS|NONE (l_prep) of_5\IN|epithelial (l_pobj) lobe_10\NN|NONE (l_prep) in_11\IN|prostate|rat|lateral|the (l_pobj) hyperprolactinemia_13\NN|NONE
D006220_D006966 CID haloperidol_15\NN|NONE (r_pobj) by_14\IN|NONE (r_agent) induced_13\VBN|.|examine|aim (r_advcl) was_5\VBD|NONE (l_xcomp) examine_7\VB|.|induced|aim (l_dobj) influence_9\NN|to|, (l_prep) of_10\IN|the (l_pobj) hyperprolactinemia_11\NN|NONE
D006220_D006966 CID HAL_17\NNP|on (r_appos) haloperidol_15\NN|NONE (r_pobj) by_14\IN|NONE (r_agent) induced_13\VBN|.|examine|aim (r_advcl) was_5\VBD|NONE (l_xcomp) examine_7\VB|.|induced|aim (l_dobj) influence_9\NN|to|, (l_prep) of_10\IN|the (l_pobj) hyperprolactinemia_11\NN|NONE
7834920
D007538_D014397 NONE isoniazid_9\NN|discovered|regimen|patient|and|.|and (l_prep) for_10\IN|NONE (l_pobj) tuberculosis_12\NN|NONE
D007538_D051437 NONE isoniazid_9\NN|discovered|regimen|patient|and|.|and (r_conj) underwent_2\VBD|NONE (l_conj) discovered_15\VBN|regimen|patient|and|.|and|isoniazid (l_xcomp) developed_18\VBN|was (l_dobj) signs_19\NNS|after|to|have (l_prep) of_20\IN|NONE (l_pobj) failure_23\NN|NONE
D012293_D051437 CID rifampin_7\NN|NONE (r_pobj) of_6\IN|a|month (r_prep) regimen_5\NN|discovered|patient|and|.|and|isoniazid (r_dobj) underwent_2\VBD|NONE (l_conj) discovered_15\VBN|regimen|patient|and|.|and|isoniazid (l_xcomp) developed_18\VBN|was (l_dobj) signs_19\NNS|after|to|have (l_prep) of_20\IN|NONE (l_pobj) failure_23\NN|NONE
D012293_D014397 NONE rifampin_6\NN|intermittent|for (r_amod) therapy_7\NN|NONE (l_prep) for_8\IN|intermittent|rifampin (l_pobj) tuberculosis_10\NN|NONE
D012293_D014397 NONE rifampin_7\NN|NONE (r_pobj) of_6\IN|a|month (r_prep) regimen_5\NN|discovered|patient|and|.|and|isoniazid (r_dobj) underwent_2\VBD|NONE (l_conj) isoniazid_9\NN|discovered|regimen|patient|and|.|and (l_prep) for_10\IN|NONE (l_pobj) tuberculosis_12\NN|NONE
D012293_D005921 CID rifampin_6\NN|intermittent|for (r_amod) therapy_7\NN|NONE (r_pobj) with_4\IN|NONE (r_prep) associated_3\VBN|NONE (r_acl) glomerulonephritis_2\NN|Crescentic|.
D012293_D005921 CID rifampin_17\NN|NONE (r_pobj) with_16\IN|NONE (r_prep) treated_15\VBN|a (r_acl) patient_14\NN|NONE (r_pobj) in_12\IN|of|had|an|unusual (r_prep) finding_6\NN|study|. (l_prep) of_7\IN|in|had|an|unusual (l_pobj) glomerulonephritis_11\NN|NONE
D012293_D005921 CID rifampin_20\NN|NONE (r_pobj) with_19\IN|NONE (r_prep) treated_18\VBN|a (r_acl) patient_17\NN|NONE (r_pobj) in_15\IN|of|unusual|the (r_prep) occurrence_5\NN|report|. (l_prep) of_6\IN|unusual|in|the (l_pobj) glomerulonephritis_9\NN|NONE
D012293_D005921 CID rifampin_20\NN|NONE (r_pobj) with_19\IN|NONE (r_prep) treated_18\VBN|a (r_acl) patient_17\NN|NONE (r_pobj) in_15\IN|of|unusual|the (r_prep) occurrence_5\NN|report|. (l_prep) of_6\IN|unusual|in|the (l_pobj) glomerulonephritis_9\NN|NONE (l_prep) with_10\IN|progressive (l_pobj) crescents_11\NNS|NONE (l_conj) glomerulonephritis_14\NN|and
1969772
D012964_D007022 NONE sodium_25\NN|induced|)|(|P (r_amod) hypotension_29\NN|NONE (r_pobj) during_24\IN|+/| (r_prep) decreased_18\VBD|during|and|flow|. (r_conj) increased_6\VBD|NONE (l_prep) during_7\IN|decreased|and|flow|. (l_pobj) hypotension_11\NN|NONE
D012964_D007022 NONE sodium_25\NN|induced|)|(|P (r_amod) hypotension_29\NN|NONE
D004298_D007022 NONE dopamine-1_4\NNS|a|selective|receptor|causes (r_punct) agonist_9\NN|.|Fenoldopam (l_relcl) causes_11\VBZ|dopamine|a|selective|receptor (l_conj) preserves_23\VBZ|to|and|that|vasodilatation (l_prep) during_29\IN|flow (l_pobj) hypotension_31\NN|NONE
D018818_D007022 CID fenoldopam_9\NN|NONE (r_pobj) with_8\IN|.|in|Preservation (r_prep) induced_7\VBN|NONE (l_nsubj) Preservation_0\NN|.|in|with (l_prep) during_5\IN|of (l_pobj) hypotension_6\NN|NONE
D018818_D007022 CID fenoldopam_3\NN|The (r_relcl) hypothesis_1\NN|.|be|tested|could|induce (r_nsubjpass) used_6\VBN|NONE (l_xcomp) induce_8\VB|hypothesis|.|be|tested|could (l_dobj) hypotension_9\NN|and|preserve|to
D018818_D007022 CID fenoldopam_8\NN| (r_npadvmod) induced_10\VBN||+/| (r_amod) hypotension_11\NN|NONE
D018818_D007022 CID fenoldopam_8\NN| (r_npadvmod) induced_10\VBN||+/| (r_amod) hypotension_11\NN|NONE (r_pobj) during_7\IN|decreased|and|flow|. (r_prep) increased_6\VBD|NONE (l_conj) decreased_18\VBD|during|and|flow|. (l_prep) during_24\IN|+/| (l_pobj) hypotension_29\NN|NONE
D009599_D007022 CID nitroprusside_26\RB| (r_advmod) induced_28\VBN|)|(|sodium|P (r_amod) hypotension_29\NN|NONE (r_pobj) during_24\IN|+/| (r_prep) decreased_18\VBD|during|and|flow|. (r_conj) increased_6\VBD|NONE (l_prep) during_7\IN|decreased|and|flow|. (l_pobj) hypotension_11\NN|NONE
D009599_D007022 CID nitroprusside_26\RB| (r_advmod) induced_28\VBN|)|(|sodium|P (r_amod) hypotension_29\NN|NONE
D009599_D007022 CID nitroprusside_1\NN|vasodilator|. (r_nsubj) is_2\VBZ|NONE (l_attr) vasodilator_10\NN|.|nitroprusside (l_relcl) produce_13\VB|venous|arteriolar (l_prep) during_22\IN|redistribution|that|can (l_pobj) hypotension_24\NN|NONE
11009181
D001058_D001523 NONE apomorphine_6\NN|subcutaneous (r_compound) treatment_7\NN|NONE (r_pobj) of_4\IN|main|side|The (r_prep) effects_3\NNS|are|,|.|play|to (r_nsubjpass) related_9\VBN|NONE (l_advcl) play_20\VBP|effects|are|,|.|to (l_nsubj) sedation_16\NN|whereas|role (l_conj) complications_19\NNS|and (l_amod) psychiatric_18\JJ|NONE
D001058_D004409 NONE apomorphine_13\NN|continuous (r_compound) infusions_14\NNS|NONE (r_pobj) with_10\IN|NONE (r_prep) monotherapy_9\NN|is|with|that (r_nsubjpass) associated_16\VBN|clinical (l_prep) with_17\IN|monotherapy|is|that (l_pobj) reductions_19\NNS|NONE (l_prep) of_20\IN|marked (l_pobj) dyskinesias_25\NNS|NONE
D007980_D004409 CID levodopa_22\NN| (r_npadvmod) induced_24\VBN|preexisting (r_amod) dyskinesias_25\NNS|NONE
D001058_D010300 NONE Apomorphine_0\NNP|NONE (l_appos) therapy_4\NN|.|: (l_prep) for_5\IN|an|underutilized (l_pobj) disease_8\NN|NONE
D001058_D010300 NONE Apomorphine_0\NNP|.|drug (r_nsubj) was_1\VBD|NONE (l_attr) drug_5\NN|Apomorphine|. (l_acl) used_7\VBN|dopaminergic|the|first (l_xcomp) treat_9\VB|ever (l_dobj) symptoms_10\NNS|to (l_prep) of_11\IN|NONE (l_pobj) disease_14\NN|NONE
D001058_D010300 NONE apomorphine_24\NN|NONE (r_pobj) of_23\IN|subcutaneous (r_prep) administration_22\NN|NONE (r_pobj) by_20\IN|disease (r_prep) treating_15\VBG|NONE (l_dobj) disease_19\NN|by
D001058_D010300 NONE apomorphine_8\NN|subcutaneous|in (r_compound) treatment_9\NN|NONE (l_prep) in_10\IN|apomorphine|subcutaneous (l_pobj) disease_14\NN|NONE
19387625
D002211_D010146 NONE capsaicin_7\NN| (r_npadvmod) induced_9\VBN|secondary (r_amod) hyperalgesia_11\NN|NONE (r_pobj) in_6\IN|pain|perceived (r_prep) intensity_5\NN|NONE (l_compound) pain_4\NN|perceived|in
D002211_D010146 NONE capsaicin_16\NN| (r_npadvmod) induced_18\VBN|secondary (r_amod) hyperalgesia_20\NN|NONE (r_pobj) in_15\IN|NONE (r_prep) attention_14\NN|NONE (r_pobj) by_13\IN|ratings|how|are|that (r_agent) affected_12\VBN|.|However|is|,|it|not (l_nsubjpass) ratings_10\NNS|how|are|by|that (l_compound) intensity_9\NN|NONE (l_compound) pain_8\NN|NONE
D002211_D010146 NONE capsaicin_7\NN|and|modulation (r_compound) treatment_8\NN|NONE (r_pobj) between_6\IN|no (r_prep) interaction_5\NN|NONE (r_dobj) showing_3\VBG|affect|,|findings|. (r_csubj) suggest_12\VBP|NONE (l_ccomp) affect_22\VB|,|findings|.|showing (l_dobj) pain_24\NN|might|through|hyperalgesia|that
D002211_D010146 NONE capsaicin_14\NN| (r_npadvmod) induced_16\VBN|and|attention|secondary (r_amod) hyperalgesia_18\NN|might|through|pain|that (r_nsubj) affect_22\VB|,|findings|.|showing (l_dobj) pain_24\NN|might|through|hyperalgesia|that
D002211_D006930 CID capsaicin_7\NN| (r_npadvmod) induced_9\VBN|secondary (r_amod) hyperalgesia_11\NN|NONE
D002211_D006930 CID capsaicin_16\NN| (r_npadvmod) induced_18\VBN|secondary (r_amod) hyperalgesia_20\NN|NONE
D002211_D006930 CID capsaicin_20\NN| (r_npadvmod) untreated_22\VBN|control|, (r_amod) condition_25\NN|NONE (r_pobj) of_19\IN|NONE (r_prep) that_18\DT|NONE (r_pobj) to_17\IN|very (r_prep) similar_16\JJ|magnitude|that (r_acomp) is_14\VBZ|.|was|Furthermore|it|, (l_nsubj) magnitude_7\NN|that|similar (l_prep) of_8\IN|the (l_pobj) modulation_10\NN|NONE (l_prep) in_11\IN|attentional (l_pobj) hyperalgesia_13\NN|NONE
D002211_D006930 CID capsaicin_7\NN|and|modulation (r_compound) treatment_8\NN|NONE (r_pobj) between_6\IN|no (r_prep) interaction_5\NN|NONE (r_dobj) showing_3\VBG|affect|,|findings|. (r_csubj) suggest_12\VBP|NONE (l_ccomp) affect_22\VB|,|findings|.|showing (l_nsubj) hyperalgesia_18\NN|might|through|pain|that
D002211_D006930 CID capsaicin_14\NN| (r_npadvmod) induced_16\VBN|and|attention|secondary (r_amod) hyperalgesia_18\NN|might|through|pain|that
2435991
C032151_D001145 NONE cibenzoline_4\NN|NONE (r_pobj) of_3\IN|on|.|Antiarrhythmic|plasma (r_prep) concentrations_2\NNS|NONE (l_prep) on_5\IN|.|of|Antiarrhythmic|plasma (l_pobj) arrhythmias_8\NNS|NONE
C032151_D001145 NONE cibenzoline_20\NN|NONE (r_pobj) of_19\IN|antiarrhythmic (r_prep) effects_18\NNS|determined|Using|,|and|were (r_nsubjpass) examined_22\VBN|NONE (l_advcl) Using_0\VBG|determined|,|and|were|effects (l_dobj) arrhythmias_15\NNS|NONE
C032151_D001145 NONE cibenzoline_20\NN|NONE (r_pobj) of_19\IN|antiarrhythmic (r_prep) effects_18\NNS|determined|Using|,|and|were (r_nsubjpass) examined_22\VBN|NONE (l_conj) determined_34\VBN|Using|,|and|were|effects (l_nsubjpass) concentration_28\NN|was|. (l_prep) for_29\IN|the|minimum|plasma|effective (l_pobj) model_32\NN|NONE (l_compound) arrhythmia_31\NN|each
C032151_D001145 NONE Cibenzoline_0\NNP|,|and|.|were|arrhythmias|induced (r_nsubj) suppressed_1\VBD|NONE (l_dobj) arrhythmias_4\NNS|,|and|Cibenzoline|.|were|induced
C032151_D001145 NONE Cibenzoline_0\NNP|,|and|.|were|arrhythmias|induced (r_nsubj) suppressed_1\VBD|NONE (l_conj) induced_14\VBN|,|and|Cibenzoline|.|were|arrhythmias (l_nsubj) concentrations_11\NNS|by (l_prep) for_12\IN|the|minimum|plasma|effective (l_pobj) arrhythmias_13\NNS|NONE
C032151_D001145 NONE cibenzoline_1\NN|and|given|Because|found|effects (r_nsubj) had_2\VBD|usefulness|is|,|. (l_advcl) given_19\VBN|and|Because|found|cibenzoline|effects (l_prep) to_20\IN|when (l_pobj) dogs_24\NNS|NONE (l_compound) arrhythmia_23\NN|coronary
D004071_D001145 CID digitalis-_7\NN|stage|,|coronary (r_conj) ligation-_5\JJ|ventricular|canine (r_nmod) arrhythmias_15\NNS|NONE
D004071_D001145 CID digitalis-_7\NN|stage|,|coronary (r_conj) ligation-_5\JJ|ventricular|canine (r_nmod) arrhythmias_15\NNS|NONE (r_dobj) Using_0\VBG|determined|,|and|were|effects (r_advcl) examined_22\VBN|NONE (l_conj) determined_34\VBN|Using|,|and|were|effects (l_nsubjpass) concentration_28\NN|was|. (l_prep) for_29\IN|the|minimum|plasma|effective (l_pobj) model_32\NN|NONE (l_compound) arrhythmia_31\NN|each
D004071_D001145 CID digitalis_24\NN|h|,|coronary (r_conj) ligation_22\NN|,|coronary|h (r_appos) ligation_18\NN|NONE (r_pobj) by_15\IN|concentrations (r_agent) induced_14\VBN|,|and|Cibenzoline|.|were|arrhythmias (r_conj) suppressed_1\VBD|NONE (l_dobj) arrhythmias_4\NNS|,|and|Cibenzoline|.|were|induced
D004071_D001145 CID digitalis_24\NN|h|,|coronary (r_conj) ligation_22\NN|,|coronary|h (r_appos) ligation_18\NN|NONE (r_pobj) by_15\IN|concentrations (r_agent) induced_14\VBN|,|and|Cibenzoline|.|were|arrhythmias (l_nsubj) concentrations_11\NNS|by (l_prep) for_12\IN|the|minimum|plasma|effective (l_pobj) arrhythmias_13\NNS|NONE
C032151_D003866 NONE cibenzoline_1\NN|and|given|Because|found|effects (r_nsubj) had_2\VBD|usefulness|is|,|. (l_dobj) effects_10\NNS|and|given|Because|found|cibenzoline (l_amod) depressive_9\JJ|node
C032151_D007022 NONE cibenzoline_1\NN|and|given|Because|found|effects (r_nsubj) had_2\VBD|usefulness|is|,|. (l_dobj) effects_10\NNS|and|given|Because|found|cibenzoline (l_nmod) node_8\NN|depressive (l_amod) hypotensive_5\JJ|weak|only
D004837_D001145 CID adrenaline_10\RB| (r_npadvmod) induced_12\VBN|and|, (r_conj) digitalis-_7\NN|stage|,|coronary (r_conj) ligation-_5\JJ|ventricular|canine (r_nmod) arrhythmias_15\NNS|NONE
D004837_D001145 CID adrenaline_10\RB| (r_npadvmod) induced_12\VBN|and|, (r_conj) digitalis-_7\NN|stage|,|coronary (r_conj) ligation-_5\JJ|ventricular|canine (r_nmod) arrhythmias_15\NNS|NONE (r_dobj) Using_0\VBG|determined|,|and|were|effects (r_advcl) examined_22\VBN|NONE (l_conj) determined_34\VBN|Using|,|and|were|effects (l_nsubjpass) concentration_28\NN|was|. (l_prep) for_29\IN|the|minimum|plasma|effective (l_pobj) model_32\NN|NONE (l_compound) arrhythmia_31\NN|each
D004837_D001145 CID adrenaline_27\NN|and|, (r_conj) digitalis_24\NN|h|,|coronary (r_conj) ligation_22\NN|,|coronary|h (r_appos) ligation_18\NN|NONE (r_pobj) by_15\IN|concentrations (r_agent) induced_14\VBN|,|and|Cibenzoline|.|were|arrhythmias (r_conj) suppressed_1\VBD|NONE (l_dobj) arrhythmias_4\NNS|,|and|Cibenzoline|.|were|induced
D004837_D001145 CID adrenaline_27\NN|and|, (r_conj) digitalis_24\NN|h|,|coronary (r_conj) ligation_22\NN|,|coronary|h (r_appos) ligation_18\NN|NONE (r_pobj) by_15\IN|concentrations (r_agent) induced_14\VBN|,|and|Cibenzoline|.|were|arrhythmias (l_nsubj) concentrations_11\NNS|by (l_prep) for_12\IN|the|minimum|plasma|effective (l_pobj) arrhythmias_13\NNS|NONE
D004837_D001145 CID adrenaline_3\NN| (r_npadvmod) induced_5\VBN|NONE (r_amod) arrhythmia_6\NN|NONE
D004837_D001145 CID adrenaline_3\NN| (r_npadvmod) induced_5\VBN|NONE (r_amod) arrhythmia_6\NN|NONE (r_pobj) for_2\IN|The (r_prep) concentration_1\NN|.|higher (r_nsubj) was_7\VBD|NONE (l_acomp) higher_9\JJR|.|concentration (l_prep) than_10\IN|significantly (l_pobj) those_11\DT|NONE (l_prep) for_12\IN|NONE (l_pobj) types_15\NNS|NONE (l_prep) of_16\IN|other|the (l_pobj) arrhythmias_17\NNS|NONE
1749407
D010100_D009203 NONE oxygen_22\NN|myocardial|associated (r_compound) demand_23\NN|NONE (r_pobj) in_20\IN|an (r_prep) increase_19\NN|NONE (r_pobj) from_17\IN|may|In|infarction|,|. (r_prep) result_16\VB|NONE (l_nsubj) infarction_14\NN|may|In|,|from|.
D003042_D009203 CID Cocaine_0\NN| (r_npadvmod) induced_2\VBN|.|observations|:|myocardial (r_amod) infarction_4\NN|NONE
D003042_D009203 CID cocaine_13\NN|may|by|in (r_nsubj) result_15\VB|several|possible (l_prep) in_16\IN|may|by|cocaine (l_pobj) infarction_19\NN|NONE
D003042_D009203 CID cocaine_26\NN| (r_npadvmod) induced_28\VBN|in (r_amod) increase_29\NN|NONE (r_pobj) with_25\IN|NONE (r_prep) associated_24\VBN|myocardial|oxygen (r_acl) demand_23\NN|NONE (r_pobj) in_20\IN|an (r_prep) increase_19\NN|NONE (r_pobj) from_17\IN|may|In|infarction|,|. (r_prep) result_16\VB|NONE (l_nsubj) infarction_14\NN|may|In|,|from|.
D003042_D013035 NONE cocaine_16\NN| (r_npadvmod) induced_18\VBN|NONE (r_amod) vasoconstriction_19\NN|NONE (r_pobj) of_15\IN|the (r_prep) locus_14\NN|.|speculative (r_nsubj) remains_20\VBZ|findings|,|,|circumstantial|and|With (r_conj) are_8\VBP|NONE (l_prep) With_0\IN|findings|,|,|remains|circumstantial|and (l_pobj) regard_1\NN|NONE (l_prep) to_2\IN|NONE (l_pobj) spasm_3\NN|NONE
D003042_D013927 NONE cocaine_11\NN|NONE (r_pobj) of_10\IN|thrombotic|,|a|primary (r_prep) effect_9\NN|NONE (l_amod) thrombotic_8\JJ|of|,|a|primary
7862923
D002746_D019965 NONE chlorpromazine_24\NN|, (r_conj) haloperidol_22\NN|concomitantly (r_dobj) using_20\VBG|difficult|six|psychotic|schizophrenic (r_acl) patients_19\NNS|NONE (l_amod) psychotic_18\JJ|difficult|six|using|schizophrenic
D003024_D012559 NONE clozapine_26\NN|or (r_conj) chlorpromazine_24\NN|, (r_conj) haloperidol_22\NN|concomitantly (r_dobj) using_20\VBG|difficult|six|psychotic|schizophrenic (r_acl) patients_19\NNS|NONE (l_amod) schizophrenic_15\JJ|difficult|six|psychotic|using
D002220_D012559 NONE Carbamazepine_0\NNP|to|.|among|was (r_nsubjpass) switched_2\VBN|NONE (l_prep) among_8\IN|to|Carbamazepine|.|was (l_pobj) patients_19\NNS|NONE (l_amod) schizophrenic_15\JJ|difficult|six|psychotic|using
C036006_D019965 NONE oxcarbazepine_7\NN|NONE (r_pobj) to_3\IN|Carbamazepine|.|among|was (r_prep) switched_2\VBN|NONE (l_prep) among_8\IN|to|Carbamazepine|.|was (l_pobj) patients_19\NNS|NONE (l_amod) psychotic_18\JJ|difficult|six|using|schizophrenic
D003024_D019965 NONE clozapine_26\NN|or (r_conj) chlorpromazine_24\NN|, (r_conj) haloperidol_22\NN|concomitantly (r_dobj) using_20\VBG|difficult|six|psychotic|schizophrenic (r_acl) patients_19\NNS|NONE (l_amod) psychotic_18\JJ|difficult|six|using|schizophrenic
D002746_D012559 NONE chlorpromazine_24\NN|, (r_conj) haloperidol_22\NN|concomitantly (r_dobj) using_20\VBG|difficult|six|psychotic|schizophrenic (r_acl) patients_19\NNS|NONE (l_amod) schizophrenic_15\JJ|difficult|six|psychotic|using
D006220_D019965 NONE haloperidol_22\NN|concomitantly (r_dobj) using_20\VBG|difficult|six|psychotic|schizophrenic (r_acl) patients_19\NNS|NONE (l_amod) psychotic_18\JJ|difficult|six|using|schizophrenic
C036006_D012559 NONE oxcarbazepine_7\NN|NONE (r_pobj) to_3\IN|Carbamazepine|.|among|was (r_prep) switched_2\VBN|NONE (l_prep) among_8\IN|to|Carbamazepine|.|was (l_pobj) patients_19\NNS|NONE (l_amod) schizophrenic_15\JJ|difficult|six|psychotic|using
D002220_D019965 NONE Carbamazepine_0\NNP|to|.|among|was (r_nsubjpass) switched_2\VBN|NONE (l_prep) among_8\IN|to|Carbamazepine|.|was (l_pobj) patients_19\NNS|NONE (l_amod) psychotic_18\JJ|difficult|six|using|schizophrenic
D006220_D012559 NONE haloperidol_22\NN|concomitantly (r_dobj) using_20\VBG|difficult|six|psychotic|schizophrenic (r_acl) patients_19\NNS|NONE (l_amod) schizophrenic_15\JJ|difficult|six|psychotic|using
7072798
D002701_D001855 NONE chloramphenicol_13\NN|NONE (r_pobj) with_12\IN|topical|for (r_prep) treatment_11\NN|NONE (r_pobj) after_9\IN|the|second|of (r_prep) report_4\NN|,|This|reported|. (r_attr) was_1\VBD|NONE (l_advcl) reported_29\VBN|,|This|report|. (l_nsubjpass) cases_20\NNS|been|although|have|also (l_prep) of_21\IN|two (l_pobj) hypoplasia_25\NN|NONE
D002701_D000741 CID chloramphenicol_8\NN|NONE (r_pobj) of_6\IN|topical (r_prep) administration_5\NN|NONE (r_pobj) following_3\VBG|Fatal|.|aplastic (r_prep) anemia_2\NN|NONE
D002701_D000741 CID chloramphenicol_22\NN|NONE (r_pobj) with_21\IN|topical (r_prep) therapy_20\NN|NONE (r_dobj) beginning_18\VBG|extraction|and (r_conj) undergoing_14\VBG|months (r_pcomp) after_13\IN|of|.|woman (r_prep) died_5\VBD|NONE (l_prep) of_6\IN|.|woman|after (l_pobj) anemia_8\NN|NONE
D002701_D000741 CID chloramphenicol_13\NN|an|idiosyncratic (r_acl) response_11\NN|NONE (r_pobj) with_8\IN|was|.|pattern (r_prep) associated_7\VBN|NONE (l_nsubjpass) pattern_1\NN|was|with|. (l_prep) of_2\IN|The (l_pobj) anemia_5\NN|NONE
D002701_D000741 CID chloramphenicol_13\NN|NONE (r_pobj) with_12\IN|topical|for (r_prep) treatment_11\NN|NONE (r_pobj) after_9\IN|the|second|of (r_prep) report_4\NN|,|This|reported|. (l_prep) of_5\IN|the|second|after (l_pobj) anemia_8\NN|NONE
D002701_D005128 NONE chloramphenicol_11\NN|NONE (r_pobj) with_8\IN|NONE (r_prep) associated_7\VBN|ocular (r_acl) toxicity_6\NN|NONE
D002701_D002386 NONE chloramphenicol_22\NN|NONE (r_pobj) with_21\IN|topical (r_prep) therapy_20\NN|NONE (r_dobj) beginning_18\VBG|extraction|and (r_conj) undergoing_14\VBG|months (l_dobj) extraction_16\NN|and|beginning (l_compound) cataract_15\NN|NONE
3708922
D016572_D064420 NONE CSA_4\NNP|NONE (r_pobj) of_3\IN|drugs|The|combined|with (r_prep) administration_2\NN|.|CSA|induced|did|not (r_nsubj) aggravate_38\VB|NONE (l_ccomp) induced_41\VBN|.|CSA|did|not|administration (l_dobj) toxicity_42\NN|NONE
D016572_D064420 NONE CSA_40\NNP|.|induced|did|not|administration (r_dobj) aggravate_38\VB|NONE (l_ccomp) induced_41\VBN|.|CSA|did|not|administration (l_dobj) toxicity_42\NN|NONE
D007654_D064420 NONE ketoconazole_26\NN|amphothericin|and (r_conj) B_24\NN|at|used|)|,|,|,|( (r_conj) gentamicin_16\NN|such (r_pobj) as_15\IN|a|nephrotoxic|, (r_prep) potential_12\NN|NONE (r_pobj) with_9\IN|drugs|The|combined|of (r_prep) administration_2\NN|.|CSA|induced|did|not (r_nsubj) aggravate_38\VB|NONE (l_ccomp) induced_41\VBN|.|CSA|did|not|administration (l_dobj) toxicity_42\NN|NONE
D005839_D007674 NONE gentamicin_16\NN|such (r_pobj) as_15\IN|a|nephrotoxic|, (r_prep) potential_12\NN|NONE (l_amod) nephrotoxic_11\JJ|a|as|,
D005839_D007674 NONE Gentamicin_0\NNP|nephrotoxicity|,|however|,|. (r_nsubj) increased_7\VBD|NONE (l_dobj) nephrotoxicity_9\NN|Gentamicin|,|however|,|.
D007654_D007674 NONE ketoconazole_26\NN|amphothericin|and (r_conj) B_24\NN|at|used|)|,|,|,|( (r_conj) gentamicin_16\NN|such (r_pobj) as_15\IN|a|nephrotoxic|, (r_prep) potential_12\NN|NONE (l_amod) nephrotoxic_11\JJ|a|as|,
D000666_D007674 NONE B_24\NN|at|used|)|,|,|,|( (r_conj) gentamicin_16\NN|such (r_pobj) as_15\IN|a|nephrotoxic|, (r_prep) potential_12\NN|NONE (l_amod) nephrotoxic_11\JJ|a|as|,
D016572_D007674 CID cyclosporine_1\NN|:|Experimental|risk|. (r_compound) nephrotoxicity_2\NN|NONE
D016572_D007674 CID cyclosporine_3\NN|or|in (r_pobj) of_2\IN|The (l_conj) in_9\IN|cyclosporine|or (l_pobj) combination_10\NN|NONE (l_prep) with_11\IN|NONE (l_pobj) chemotherapeutics_13\NNS|NONE (l_prep) in_14\IN|various (l_pobj) development_16\NN|NONE (l_prep) of_17\IN|the (l_pobj) toxicity_19\NN|NONE
D016572_D007674 CID CSA_5\NNP|NONE (r_appos) cyclosporine_3\NN|or|in (r_pobj) of_2\IN|The (l_conj) in_9\IN|cyclosporine|or (l_pobj) combination_10\NN|NONE (l_prep) with_11\IN|NONE (l_pobj) chemotherapeutics_13\NNS|NONE (l_prep) in_14\IN|various (l_pobj) development_16\NN|NONE (l_prep) of_17\IN|the (l_pobj) toxicity_19\NN|NONE
D016572_D007674 CID CSA_4\NNP|NONE (r_pobj) of_3\IN|drugs|The|combined|with (r_prep) administration_2\NN|.|CSA|induced|did|not (l_prep) with_9\IN|drugs|The|combined|of (l_pobj) potential_12\NN|NONE (l_amod) nephrotoxic_11\JJ|a|as|,
D016572_D007674 CID CSA_40\NNP|.|induced|did|not|administration (r_dobj) aggravate_38\VB|NONE (l_nsubj) administration_2\NN|.|CSA|induced|did|not (l_prep) with_9\IN|drugs|The|combined|of (l_pobj) potential_12\NN|NONE (l_amod) nephrotoxic_11\JJ|a|as|,
D016572_D007674 CID CSA_8\NNP|NONE (r_compound) nephrotoxicity_9\NN|Gentamicin|,|however|,|.
D016572_D007674 CID CSA_6\NNP|NONE (r_pobj) by_5\IN|NONE (r_agent) induced_4\VBN|the (r_acl) nephrotoxicity_3\NN|mechanism|Thus|.|,
D005839_D064420 NONE gentamicin_16\NN|such (r_pobj) as_15\IN|a|nephrotoxic|, (r_prep) potential_12\NN|NONE (r_pobj) with_9\IN|drugs|The|combined|of (r_prep) administration_2\NN|.|CSA|induced|did|not (r_nsubj) aggravate_38\VB|NONE (l_ccomp) induced_41\VBN|.|CSA|did|not|administration (l_dobj) toxicity_42\NN|NONE
D000666_D064420 NONE B_24\NN|at|used|)|,|,|,|( (r_conj) gentamicin_16\NN|such (r_pobj) as_15\IN|a|nephrotoxic|, (r_prep) potential_12\NN|NONE (r_pobj) with_9\IN|drugs|The|combined|of (r_prep) administration_2\NN|.|CSA|induced|did|not (r_nsubj) aggravate_38\VB|NONE (l_ccomp) induced_41\VBN|.|CSA|did|not|administration (l_dobj) toxicity_42\NN|NONE
9105126
D013256_D018658 CID steroid_9\NN|term (r_compound) therapy_10\NN|NONE (r_pobj) with_5\IN|NONE (r_prep) associated_4\VBN|septal|.|Postinfarction|ventricular (r_acl) defect_3\NN|NONE
D013256_D018658 CID steroid_13\NN|term (r_compound) therapy_14\NN|NONE (r_pobj) on_9\IN|NONE (r_prep) patients_8\NNS|NONE (r_pobj) in_7\IN|postinfarction|septal|ventricular (r_prep) rupture_6\NN|NONE
D013256_D018658 CID steroid_4\NN|rupture|and (r_compound) therapy_5\NN|NONE (l_conj) rupture_10\NN|and|steroid
3827439
D000666_D058186 CID amphotericin_6\JJ|NONE (r_pobj) from_5\IN|.|reversible|Recurrent|renal|acute (r_prep) failure_4\NN|NONE
D000666_D058186 CID B_18\NNP|NONE (r_pobj) of_16\IN|the (r_prep) administration_15\NN|immediately|on (r_dobj) following_13\VBG|acute|renal (r_acl) failure_11\NN|.|patient
D000666_D058186 CID amphotericin_3\JJ|.|We|that|activate (r_advmod) propose_1\VBP|NONE (l_conj) activate_15\VB|.|We|that|amphotericin (l_advcl) contributing_20\VBG|,|feedback|may|,|,|in (l_prep) to_21\IN|thereby (l_pobj) failure_24\NN|NONE
D000666_D013174 NONE B_18\NNP|NONE (r_pobj) of_16\IN|the (r_prep) administration_15\NN|immediately|on (r_dobj) following_13\VBG|acute|renal (r_acl) failure_11\NN|.|patient (r_dobj) developed_8\VBD|NONE (l_nsubj) patient_1\NN|failure|. (l_conj) disseminated_6\VBN|with|and|A (l_dobj) sporotrichosis_7\NN|NONE
D000666_D005355 NONE B_18\NNP|NONE (r_pobj) of_16\IN|the (r_prep) administration_15\NN|immediately|on (r_dobj) following_13\VBG|acute|renal (r_acl) failure_11\NN|.|patient (r_dobj) developed_8\VBD|NONE (l_nsubj) patient_1\NN|failure|. (l_prep) with_2\IN|and|disseminated|A (l_pobj) cirrhosis_4\NN|NONE
11897407
D005937_D007238 NONE acid_9\NN|NONE (r_pobj) on_7\IN|NONE (r_prep) based_6\VBN|A|avid|new (r_acl) radiopharmaceutical_5\NN|was|.|in (l_amod) avid_4\JJ|A|based|new (l_npadvmod) infarct_2\NN|
D007545_D007238 NONE isoproterenol_18\NN|NONE (r_pobj) with_17\IN|be|easily|can (r_prep) obtained_16\VBN|ligation|.|model (r_conj) implies_7\VBZ|NONE (l_nsubj) model_2\NN|ligation|obtained|. (l_acl) used_3\VBN|The|animal (l_xcomp) produce_5\VB|NONE (l_dobj) infarction_6\NN|to
D007545_D007238 NONE isoproterenol_12\JJ|NONE (r_compound) administration_13\NN|NONE (r_pobj) after_11\IN| (r_prep) h_10\NN|rats|that|infarct (r_npadvmod) developed_6\VBD|.|studies (l_dobj) infarct_8\NN|h|rats|that
D007545_D009203 CID isoproterenol_6\NN| (r_npadvmod) induced_8\VBN|myocardial|in (r_amod) infarction_10\NN|NONE
D007545_D009203 CID isoproterenol_22\NN| (r_npadvmod) induced_24\VBN|myocardial|acute (r_amod) infarction_27\NN|NONE
C067171_D009203 NONE glucarate_2\NN|NONE (l_prep) for_3\IN|mTc||. (l_pobj) detection_4\NN|NONE (l_prep) of_5\IN|NONE (l_pobj) infarction_10\NN|NONE
C067171_D009203 NONE glucarate_2\NN|,|easy|stable|used|and|. (r_nsubj) was_3\VBD|NONE (l_conj) used_14\VBN|,|easy|stable|and|glucarate|. (l_xcomp) study_16\VB|was (l_dobj) biodistribution_18\NN|to (l_prep) in_19\IN|its (l_pobj) rats_20\NNS|NONE (l_prep) with_21\IN|NONE (l_pobj) infarction_27\NN|NONE
8617710
D006220_D003072 CID haloperidol_14\NN|NONE (r_pobj) with_13\IN|cognitive (r_prep) impairment_12\NN|NONE
D006220_D003072 CID haloperidol_13\NN|NONE (r_pobj) of_12\IN|NONE (r_prep) administration_11\NN|hours (r_pobj) after_10\IN|.|was|but|Impairment|was|on (r_prep) observed_5\VBN|NONE (l_nsubjpass) Impairment_0\NN|.|was|but|after|was|on (l_prep) of_1\IN|NONE (l_pobj) function_3\NN|NONE
D006220_D003072 CID Haloperidol_0\NNP|.|profile (r_nsubj) produced_1\VBD|NONE (l_dobj) profile_4\NN|.|Haloperidol (l_prep) of_5\IN|worsened|a|clear (l_pobj) impairment_7\NN|NONE
D020280_D003072 NONE sertraline_4\NN|NONE (r_pobj) of_3\IN|on (r_prep) effect_2\NN|NONE (l_prep) on_5\IN|of (l_pobj) sensitization_9\NN|NONE (l_prep) of_10\IN|based (l_pobj) impairment_12\NN|NONE
D020280_D003072 NONE sertraline_14\NN|concomitant (r_compound) administration_15\NN|NONE (r_pobj) by_12\IN|not|that|was (r_agent) worsened_11\VBN|of|a|clear (r_relcl) profile_4\NN|.|Haloperidol (l_prep) of_5\IN|worsened|a|clear (l_pobj) impairment_7\NN|NONE
12084448
D007069_D010954 NONE ifosfamide_27\NN|NONE (r_pobj) of_26\IN|for|the (r_prep) infusion_25\NN|NONE (l_prep) for_28\IN|the|of (l_pobj) plasmacytoma_29\NN|NONE
D007069_D009207 CID ifosfamide_27\NN|NONE (r_pobj) of_26\IN|for|the (r_prep) infusion_25\NN|NONE (r_pobj) after_23\IN|myoclonus (r_prep) disabling_14\VBG|a|of (l_dobj) myoclonus_16\NN|after
D007069_D009207 CID ifosfamide_12\JJ|NONE (r_pobj) of_11\IN|NONE (r_prep) infusion_10\NN|NONE (r_pobj) during_9\IN|findings|following|the|of|, (r_prep) presence_6\NN|.|In|associated|, (r_nsubj) suggest_31\VBP|NONE (l_ccomp) associated_36\VBN|.|In|presence|, (l_nsubjpass) myoclonus_34\NN|with|is|that
D007069_D009207 CID IFX_41\NNP|NONE (r_pobj) of_40\IN|the (r_prep) use_39\NN|NONE (r_pobj) with_37\IN|is|myoclonus|that (r_prep) associated_36\VBN|.|In|presence|, (l_nsubjpass) myoclonus_34\NN|with|is|that
D007069_D001927 CID Ifosfamide_0\NNP|presenting|. (r_compound) encephalopathy_1\NN|NONE
D007069_D020820 NONE Ifosfamide_0\NNP|presenting|. (r_compound) encephalopathy_1\NN|NONE (l_acl) presenting_2\VBG|.|Ifosfamide (l_prep) with_3\IN|NONE (l_pobj) asterixis_4\NNS|NONE
D007069_D020820 NONE ifosfamide_3\NN|NONE (r_pobj) of_2\IN|The (r_prep) administration_1\NN|and|was|resolved (r_nsubjpass) discontinued_5\VBN|NONE (l_conj) resolved_12\VBD|and|was|administration (l_nsubj) asterixis_11\NNS|.|within|completely
D007069_D020820 NONE ifosfamide_12\JJ|NONE (r_pobj) of_11\IN|NONE (r_prep) infusion_10\NN|NONE (r_pobj) during_9\IN|findings|following|the|of|, (r_prep) presence_6\NN|.|In|associated|, (l_prep) of_7\IN|findings|following|the|during|, (l_pobj) asterixis_8\NNS|NONE
D007069_D020820 NONE IFX_41\NNP|NONE (r_pobj) of_40\IN|the (r_prep) use_39\NN|NONE (r_pobj) with_37\IN|is|myoclonus|that (r_prep) associated_36\VBN|.|In|presence|, (r_ccomp) suggest_31\VBP|NONE (l_nsubj) presence_6\NN|.|In|associated|, (l_prep) of_7\IN|findings|following|the|during|, (l_pobj) asterixis_8\NNS|NONE
11875660
D001374_D009436 NONE 5-azacytidine_6\NN|NONE (r_pobj) by_5\IN|at (r_agent) induced_4\VBN|the (r_acl) exencephaly_3\NNS|,|let|We|.
18439803
D018698_D012640 NONE glutamate_38\NN|NONE (r_pobj) of_37\IN|a|pronounced (r_prep) reduction_36\NN|NONE (r_pobj) by_33\IN|NONE (r_agent) offset_32\VBN|reduction|that|and|minor (r_conj) was_28\VBD|Based|is|.|it (r_ccomp) suggested_19\VBN|NONE (l_prep) Based_0\VBN|is|.|it|was (l_prep) on_1\IN|NONE (l_pobj) finding_3\NN|NONE (l_acl) protect_9\VB|the (l_dobj) animals_11\NNS|that|could|VPU (l_prep) against_12\IN|the (l_pobj) seizure_16\NN|NONE
D018698_D012640 NONE glutamate_17\NN|NONE (r_pobj) in_16\IN|induced (r_prep) increases_15\NNS|VPU|drastically|that|could (r_dobj) reduce_11\VB|the (r_relcl) finding_6\NN|, (r_appos) VPA_3\NNP|NONE (r_pobj) like_2\IN|for|should|.|Therefore|,|, (r_prep) account_21\VB|NONE (l_prep) for_27\IN|should|.|Therefore|,|like|, (l_pobj) activity_30\NN|partly|, (l_acl) observed_31\VBN|anticonvulsant|its (l_prep) in_32\IN|NONE (l_pobj) seizure_36\NN|NONE
C108761_D012640 NONE N-(2-propylpentanoyl)urea_3\NNP|NONE (r_pobj) of_2\IN|.|Acute|on|in (r_prep) effects_1\NNS|NONE (l_prep) in_9\IN|.|Acute|on|of (l_pobj) seizure_13\NN|NONE
C108761_D012640 NONE VPU_0\NNS|,|exhibiting|.|potent (r_nsubj) was_1\VBD|NONE (l_advcl) exhibiting_7\VBG|,|VPU|.|potent (l_dobj) dose_11\NN|was (l_prep) of_16\IN|ED(|median|the|)|effective (l_pobj) mg/kg_18\NNS|NONE (l_prep) in_19\IN| (l_pcomp) protecting_20\VBG|NONE (l_prep) against_22\IN|rats (l_pobj) seizure_26\NN|NONE
C108761_D012640 NONE VPU_5\NNPS|animals|that|could (r_nsubj) protect_9\VB|the (l_dobj) animals_11\NNS|that|could|VPU (l_prep) against_12\IN|the (l_pobj) seizure_16\NN|NONE
C108761_D012640 NONE VPU_8\NNP|increases|drastically|that|could (r_nsubj) reduce_11\VB|the (r_relcl) finding_6\NN|, (r_appos) VPA_3\NNP|NONE (r_pobj) like_2\IN|for|should|.|Therefore|,|, (r_prep) account_21\VB|NONE (l_prep) for_27\IN|should|.|Therefore|,|like|, (l_pobj) activity_30\NN|partly|, (l_acl) observed_31\VBN|anticonvulsant|its (l_prep) in_32\IN|NONE (l_pobj) seizure_36\NN|NONE
D000596_D012640 NONE acid_7\NN|hippocampal (r_compound) neurotransmitters_8\NNS|NONE (r_pobj) on_4\IN|.|Acute|of|in (r_prep) effects_1\NNS|NONE (l_prep) in_9\IN|.|Acute|on|of (l_pobj) seizure_13\NN|NONE
D000596_D012640 NONE acid_26\NN|inhibitory (r_compound) neurotransmitters_27\NNS|NONE (r_pobj) of_23\IN|the (r_prep) reduction_22\NN|that|offset|and|minor (r_nsubj) was_28\VBD|Based|is|.|it (r_ccomp) suggested_19\VBN|NONE (l_prep) Based_0\VBN|is|.|it|was (l_prep) on_1\IN|NONE (l_pobj) finding_3\NN|NONE (l_acl) protect_9\VB|the (l_dobj) animals_11\NNS|that|could|VPU (l_prep) against_12\IN|the (l_pobj) seizure_16\NN|NONE
D014635_D012640 NONE VPA_5\NNP|NONE (r_pobj) than_4\IN|more (r_prep) potent_3\JJ|,|exhibiting|VPU|. (r_acomp) was_1\VBD|NONE (l_advcl) exhibiting_7\VBG|,|VPU|.|potent (l_dobj) dose_11\NN|was (l_prep) of_16\IN|ED(|median|the|)|effective (l_pobj) mg/kg_18\NNS|NONE (l_prep) in_19\IN| (l_pcomp) protecting_20\VBG|NONE (l_prep) against_22\IN|rats (l_pobj) seizure_26\NN|NONE
D014635_D012640 NONE VPA_32\NNP|NONE (r_pobj) for_31\IN|corresponding|the (r_prep) value_30\NN|mg/kg|whereas (r_nsubj) was_33\VBD|dose (r_advcl) exhibiting_7\VBG|,|VPU|.|potent (l_dobj) dose_11\NN|was (l_prep) of_16\IN|ED(|median|the|)|effective (l_pobj) mg/kg_18\NNS|NONE (l_prep) in_19\IN| (l_pcomp) protecting_20\VBG|NONE (l_prep) against_22\IN|rats (l_pobj) seizure_26\NN|NONE
D014635_D012640 NONE VPA_7\NNP|and (r_conj) VPU_5\NNPS|animals|that|could (r_nsubj) protect_9\VB|the (l_dobj) animals_11\NNS|that|could|VPU (l_prep) against_12\IN|the (l_pobj) seizure_16\NN|NONE
D014635_D012640 NONE VPA_3\NNP|NONE (r_pobj) like_2\IN|for|should|.|Therefore|,|, (r_prep) account_21\VB|NONE (l_prep) for_27\IN|should|.|Therefore|,|like|, (l_pobj) activity_30\NN|partly|, (l_acl) observed_31\VBN|anticonvulsant|its (l_prep) in_32\IN|NONE (l_pobj) seizure_36\NN|NONE
D001224_D012640 NONE aspartate_40\NN|and (r_conj) glutamate_38\NN|NONE (r_pobj) of_37\IN|a|pronounced (r_prep) reduction_36\NN|NONE (r_pobj) by_33\IN|NONE (r_agent) offset_32\VBN|reduction|that|and|minor (r_conj) was_28\VBD|Based|is|.|it (r_ccomp) suggested_19\VBN|NONE (l_prep) Based_0\VBN|is|.|it|was (l_prep) on_1\IN|NONE (l_pobj) finding_3\NN|NONE (l_acl) protect_9\VB|the (l_dobj) animals_11\NNS|that|could|VPU (l_prep) against_12\IN|the (l_pobj) seizure_16\NN|NONE
D001224_D012640 NONE aspartate_19\NN|and (r_conj) glutamate_17\NN|NONE (r_pobj) in_16\IN|induced (r_prep) increases_15\NNS|VPU|drastically|that|could (r_dobj) reduce_11\VB|the (r_relcl) finding_6\NN|, (r_appos) VPA_3\NNP|NONE (r_pobj) like_2\IN|for|should|.|Therefore|,|, (r_prep) account_21\VB|NONE (l_prep) for_27\IN|should|.|Therefore|,|like|, (l_pobj) activity_30\NN|partly|, (l_acl) observed_31\VBN|anticonvulsant|its (l_prep) in_32\IN|NONE (l_pobj) seizure_36\NN|NONE
D010862_D012640 CID pilocarpine_10\NN| (r_npadvmod) induced_12\VBN|in (r_amod) seizure_13\NN|NONE
D010862_D012640 CID pilocarpine_23\NN| (r_npadvmod) induced_25\VBN|NONE (r_amod) seizure_26\NN|NONE
D010862_D012640 CID pilocarpine_13\NN| (r_npadvmod) induced_15\VBN|NONE (r_amod) seizure_16\NN|NONE
D010862_D012640 CID pilocarpine_12\NN| (r_npadvmod) induced_14\VBN|in (r_amod) increases_15\NNS|VPU|drastically|that|could (r_dobj) reduce_11\VB|the (r_relcl) finding_6\NN|, (r_appos) VPA_3\NNP|NONE (r_pobj) like_2\IN|for|should|.|Therefore|,|, (r_prep) account_21\VB|NONE (l_prep) for_27\IN|should|.|Therefore|,|like|, (l_pobj) activity_30\NN|partly|, (l_acl) observed_31\VBN|anticonvulsant|its (l_prep) in_32\IN|NONE (l_pobj) seizure_36\NN|NONE
D010862_D012640 CID pilocarpine_33\NN| (r_npadvmod) induced_35\VBN|in (r_amod) seizure_36\NN|NONE
19803309
D013390_D009224 NONE suxamethonium_29\NN|NONE (r_pobj) of_27\IN|for|standard|a (r_prep) dose_26\NN|NONE (r_pobj) following_23\VBG|spasm|life (r_prep) threatening_20\VBG|who (r_ccomp) developed_18\VBD|healthy|a|,|old (r_relcl) primigravida_15\NN|NONE (r_pobj) in_8\IN|of|an|undiagnosed (r_prep) case_4\NN|.|We (l_prep) of_5\IN|an|in|undiagnosed (l_pobj) congenita_7\NN|NONE
D013390_D014313 CID suxamethonium_29\NN|NONE (r_pobj) of_27\IN|for|standard|a (r_prep) dose_26\NN|NONE (r_pobj) following_23\VBG|spasm|life (r_prep) threatening_20\VBG|who (l_dobj) spasm_22\NN|following|life
10807237
D003042_D017542 CID Cocaine_0\NN|NONE (r_compound) use_1\NN|.|rupture|at (r_nsubj) predisposed_2\VBN|NONE (l_dobj) rupture_4\NN|.|use|at
D003042_D000783 NONE cocaine_12\NN| (r_npadvmod) related_14\VBN|NONE (r_amod) aneurysms_15\NNS|NONE
D003042_D000783 NONE cocaine_25\NN| (r_npadvmod) related_27\VBN|NONE (r_amod) aneurysms_28\NNS|NONE
D003042_D000783 NONE Cocaine_0\NN|NONE (r_compound) use_1\NN|.|rupture|at (r_nsubj) predisposed_2\VBN|NONE (l_prep) at_5\IN|.|use|rupture (l_conj) in_11\IN|and|age (l_pobj) aneurysms_14\NNS|NONE
9495837
D000109_D000647 NONE acetylcholine_73\NN|extracellular (r_amod) levels_75\NNS|NONE (r_pobj) in_72\IN|an (r_prep) increase_71\NN|NONE (r_pobj) through_69\IN|NONE (r_prep) /-)-PG-9_68\NFP|.|ratio|+|,|profiles|have (r_punct) shown_44\VBN|NONE (l_dobj) ratio_48\NN|.|+|,|profiles|/)PG|have (l_relcl) be_53\VB|an|M/M|selectivity|of (l_acomp) responsible_54\JJ|that|might (l_prep) for_55\IN|NONE (l_pobj) antinociception_57\NN|NONE (l_conj) effect_63\NN|induced|the|and (l_amod) amnesic_62\JJ|the
D004025_D000647 CID dicyclomine_26\NN|i.p.|and|)|mg (r_conj) kg-1_22\NNP|(|in (r_appos) scopolamine_18\NN|NONE (r_pobj) by_17\IN|NONE (r_agent) induced_16\VBN|NONE (r_acl) amnesia_15\NN|to
D012601_D000647 CID scopolamine_18\NN|NONE (r_pobj) by_17\IN|NONE (r_agent) induced_16\VBN|NONE (r_acl) amnesia_15\NN|to
C087567_D000647 NONE /-)-PG-9_2\.|able|+|(|. (r_nsubj) was_11\VBD|NONE (l_acomp) able_12\JJ|+|(|/)PG|. (l_xcomp) prevent_14\VB|NONE (l_dobj) amnesia_15\NN|to
C087567_D000647 NONE /-)-PG-9_5\NFP|+|( (r_conj) of_2\IN|deferens|determined|Affinity (r_prep) profiles_1\NNS|.|ratio|+|,|/)PG|have (r_nsubj) shown_44\VBN|NONE (l_dobj) ratio_48\NN|.|+|,|profiles|/)PG|have (l_relcl) be_53\VB|an|M/M|selectivity|of (l_acomp) responsible_54\JJ|that|might (l_prep) for_55\IN|NONE (l_pobj) antinociception_57\NN|NONE (l_conj) effect_63\NN|induced|the|and (l_amod) amnesic_62\JJ|the
C087567_D000647 NONE /-)-PG-9_68\NFP|.|ratio|+|,|profiles|have (r_punct) shown_44\VBN|NONE (l_dobj) ratio_48\NN|.|+|,|profiles|/)PG|have (l_relcl) be_53\VB|an|M/M|selectivity|of (l_acomp) responsible_54\JJ|that|might (l_prep) for_55\IN|NONE (l_pobj) antinociception_57\NN|NONE (l_conj) effect_63\NN|induced|the|and (l_amod) amnesic_62\JJ|the
17786501
D004221_D000437 NONE disulfiram_15\NN|NONE (r_pobj) of_14\IN|for|chronic (r_prep) use_13\NN|NONE (l_prep) for_16\IN|of|chronic (l_pobj) management_19\NN|NONE (l_compound) dependence_18\NN|alcohol
D004221_D000437 NONE disulfiram_4\NN|.|He|had|for|been (r_dobj) taking_3\VBG|NONE (l_prep) for_5\IN|disulfiram|.|He|had|been (l_pobj) dependence_7\NN|NONE
D004221_D009901 NONE Disulfiram_0\NNP| (r_npadvmod) induced_2\VBN|and|neuropathy|transient (r_amod) optic_4\JJ|a|.|:|case (l_conj) neuropathy_7\NN|and|transient|induced
D004221_D009901 NONE disulfiram_15\NN|NONE (r_pobj) of_14\IN|for|chronic (r_prep) use_13\NN|NONE (r_pobj) after_11\IN|case|To (r_prep) report_3\VB|.|: (l_dobj) case_5\NN|after|To (l_prep) of_6\IN|a (l_pobj) optic_7\JJ|NONE (l_conj) neuropathy_10\NN|and
D004221_D010523 NONE Disulfiram_0\NNP| (r_npadvmod) induced_2\VBN|and|neuropathy|transient (r_amod) optic_4\JJ|a|.|:|case (l_conj) neuropathy_7\NN|and|transient|induced
D004221_D010523 NONE disulfiram_15\NN|NONE (r_pobj) of_14\IN|for|chronic (r_prep) use_13\NN|NONE (r_pobj) after_11\IN|case|To (r_prep) report_3\VB|.|: (l_dobj) case_5\NN|after|To (l_prep) of_6\IN|a (l_pobj) optic_7\JJ|NONE (l_conj) neuropathy_10\NN|and
2696505
D009599_D006973 NONE nitroprusside_31\NN|NONE (r_pobj) of_30\IN|NONE (r_prep) discontinuation_29\NN|NONE (r_pobj) after_28\IN|associated|;|.|was|in|hypertension (r_prep) observed_24\VBN|NONE (l_nsubjpass) hypertension_22\NN|associated|;|.|was|in|after
D007741_D007022 CID labetalol_4\NN|NONE (l_conj) nitroprusside_6\RB|and (l_prep) for_7\IN|NONE (l_pobj) hypotension_9\NN|NONE
D007741_D007022 CID labetalol_5\RB| (r_npadvmod) induced_7\VBN|and|hypotension (r_amod) hypotension_8\NN|In|.|were|,|in
D007741_D007022 CID labetalol_5\RB| (r_npadvmod) induced_7\VBN|and|hypotension (r_amod) hypotension_8\NN|In|.|were|,|in (l_conj) hypotension_13\NN|induced|and
D009599_D016534 CID nitroprusside_31\NN|NONE (r_pobj) of_30\IN|NONE (r_prep) discontinuation_29\NN|NONE (r_pobj) after_28\IN|associated|;|.|was|in|hypertension (r_prep) observed_24\VBN|NONE (l_ccomp) associated_3\VBN|;|.|was|in|hypertension|after (l_advcl) increase_13\NN|infusion|with|was (l_prep) in_14\IN|NONE (l_pobj) rate_16\NN|NONE (l_conj) output_19\NN|heart|and
D009599_D007022 CID nitroprusside_6\RB|and (l_prep) for_7\IN|NONE (l_pobj) hypotension_9\NN|NONE
D009599_D007022 CID nitroprusside_10\RB| (r_advmod) induced_12\VBN|NONE (r_amod) hypotension_13\NN|induced|and (r_conj) hypotension_8\NN|In|.|were|,|in
D009599_D007022 CID nitroprusside_10\RB| (r_advmod) induced_12\VBN|NONE (r_amod) hypotension_13\NN|induced|and
8919272
D014635_D022124 NONE valproate_15\NNP|NONE (r_amod) encephalopathy_16\NNP|NONE (r_pobj) of_14\IN|the (r_prep) development_13\NN|NONE (r_pobj) upon_11\IN|influence|mainly|, (r_prep) hyperammonemia_9\NN|is|.
D014635_D009422 NONE valproate_10\NN|NONE (l_dobj) disorders_43\NNS|.|Polfa|at|application|to
D014635_D009422 NONE valproate_49\NNP|(|"|"|) (r_amod) encephalopathy_50\JJ|cerebellum (r_appos) damage_46\NN|NONE (r_dobj) indicating_44\VBG|revealed|neurological (r_acl) disorders_43\NNS|.|Polfa|at|application|to
D014635_D002526 NONE valproate_10\NN|NONE (l_dobj) disorders_43\NNS|.|Polfa|at|application|to (l_acl) indicating_44\VBG|revealed|neurological (l_dobj) damage_46\NN|NONE
D014635_D002526 NONE valproate_49\NNP|(|"|"|) (r_amod) encephalopathy_50\JJ|cerebellum (r_appos) damage_46\NN|NONE
D014635_D001927 CID valproate_11\NN|NONE (l_nsubj) features_1\NNS|to|. (l_prep) of_2\IN|after|Morphological (l_pobj) encephalopathy_3\NN|NONE
D014635_D001927 CID valproate_10\NN|NONE (l_dobj) disorders_43\NNS|.|Polfa|at|application|to (l_acl) indicating_44\VBG|revealed|neurological (l_dobj) damage_46\NN|NONE (l_appos) encephalopathy_50\JJ|cerebellum
D014635_D001927 CID valproate_49\NNP|(|"|"|) (r_amod) encephalopathy_50\JJ|cerebellum
D014635_D001927 CID valproate_15\NNP|NONE (r_amod) encephalopathy_16\NNP|NONE
D014635_D056486 NONE valproate_15\NNP|NONE (r_amod) encephalopathy_16\NNP|NONE (r_pobj) of_14\IN|the (r_prep) development_13\NN|NONE (r_pobj) upon_11\IN|influence|mainly|, (r_prep) hyperammonemia_9\NN|is|. (l_nsubj) influence_2\NN|mainly|upon|, (l_prep) of_3\IN|,|The|possible (l_pobj) damage_6\NN|NONE
3714122
D010755_D020258 NONE organophosphate_33\NN|,|)|N'diisopropylphosphorodiamidofluoridate (r_appos) Mipafox_24\NNP|NONE (r_pobj) to_23\IN|acutely (r_prep) exposed_22\VBN|NONE (r_acl) rats_20\NNS|NONE (r_pobj) in_19\IN|correlation|was|. (r_prep) examined_18\VBN|NONE (l_nsubjpass) correlation_1\NN|was|in|. (l_prep) between_2\IN|The (l_pobj) damage_4\NN|NONE (l_prep) of_7\IN|inhibition|neuropathic|and (l_pobj) esterase_9\NN|NONE (l_amod) neurotoxic_8\JJ|enzyme|or
D010755_D020258 NONE organophosphate_33\NN|,|)|N'diisopropylphosphorodiamidofluoridate (l_amod) neurotoxic_32\JJ|a
C005238_D009422 NONE mipafox_7\NN| (r_npadvmod) induced_9\VBN|neuropathic|in (r_amod) damage_11\NN|esterase|and|neurotoxic
C005238_D009422 NONE Mipafox_24\NNP|NONE (r_pobj) to_23\IN|acutely (r_prep) exposed_22\VBN|NONE (r_acl) rats_20\NNS|NONE (r_pobj) in_19\IN|correlation|was|. (r_prep) examined_18\VBN|NONE (l_nsubjpass) correlation_1\NN|was|in|. (l_prep) between_2\IN|The (l_pobj) damage_4\NN|NONE
C005238_D009422 NONE Mipafox_24\NNP|NONE (r_pobj) to_23\IN|acutely (r_prep) exposed_22\VBN|NONE (r_acl) rats_20\NNS|NONE (r_pobj) in_19\IN|correlation|was|. (r_prep) examined_18\VBN|NONE (l_nsubjpass) correlation_1\NN|was|in|. (l_prep) between_2\IN|The (l_pobj) damage_4\NN|NONE (l_prep) of_7\IN|inhibition|neuropathic|and (l_pobj) esterase_9\NN|NONE (l_conj) enzyme_13\NN|neurotoxic|or (l_compound) target_12\NN|NTE|(|) (l_compound) neuropathy_11\NN|NONE
C005238_D009422 NONE N'-diisopropylphosphorodiamidofluoridate_28\NNP|,|)|organophosphate (r_appos) Mipafox_24\NNP|NONE (r_pobj) to_23\IN|acutely (r_prep) exposed_22\VBN|NONE (r_acl) rats_20\NNS|NONE (r_pobj) in_19\IN|correlation|was|. (r_prep) examined_18\VBN|NONE (l_nsubjpass) correlation_1\NN|was|in|. (l_prep) between_2\IN|The (l_pobj) damage_4\NN|NONE
C005238_D009422 NONE N'-diisopropylphosphorodiamidofluoridate_28\NNP|,|)|organophosphate (r_appos) Mipafox_24\NNP|NONE (r_pobj) to_23\IN|acutely (r_prep) exposed_22\VBN|NONE (r_acl) rats_20\NNS|NONE (r_pobj) in_19\IN|correlation|was|. (r_prep) examined_18\VBN|NONE (l_nsubjpass) correlation_1\NN|was|in|. (l_prep) between_2\IN|The (l_pobj) damage_4\NN|NONE (l_prep) of_7\IN|inhibition|neuropathic|and (l_pobj) esterase_9\NN|NONE (l_conj) enzyme_13\NN|neurotoxic|or (l_compound) target_12\NN|NTE|(|) (l_compound) neuropathy_11\NN|NONE
C005238_D009422 NONE Mipafox_18\NNP|NONE (r_compound) exposure_19\NN|shortly|damage|later|after|can (r_nsubj) predict_21\VB|NONE (l_dobj) damage_23\NN|shortly|exposure|later|after|can
D010755_D009422 NONE organophosphate_33\NN|,|)|N'diisopropylphosphorodiamidofluoridate (r_appos) Mipafox_24\NNP|NONE (r_pobj) to_23\IN|acutely (r_prep) exposed_22\VBN|NONE (r_acl) rats_20\NNS|NONE (r_pobj) in_19\IN|correlation|was|. (r_prep) examined_18\VBN|NONE (l_nsubjpass) correlation_1\NN|was|in|. (l_prep) between_2\IN|The (l_pobj) damage_4\NN|NONE
D010755_D009422 NONE organophosphate_33\NN|,|)|N'diisopropylphosphorodiamidofluoridate (r_appos) Mipafox_24\NNP|NONE (r_pobj) to_23\IN|acutely (r_prep) exposed_22\VBN|NONE (r_acl) rats_20\NNS|NONE (r_pobj) in_19\IN|correlation|was|. (r_prep) examined_18\VBN|NONE (l_nsubjpass) correlation_1\NN|was|in|. (l_prep) between_2\IN|The (l_pobj) damage_4\NN|NONE (l_prep) of_7\IN|inhibition|neuropathic|and (l_pobj) esterase_9\NN|NONE (l_conj) enzyme_13\NN|neurotoxic|or (l_compound) target_12\NN|NTE|(|) (l_compound) neuropathy_11\NN|NONE
C005238_D020258 NONE mipafox_7\NN| (r_npadvmod) induced_9\VBN|neuropathic|in (r_amod) damage_11\NN|esterase|and|neurotoxic (r_conj) inhibition_5\NN|NONE (l_amod) neurotoxic_3\JJ|esterase|and|damage
C005238_D020258 NONE Mipafox_24\NNP|NONE (r_pobj) to_23\IN|acutely (r_prep) exposed_22\VBN|NONE (r_acl) rats_20\NNS|NONE (r_pobj) in_19\IN|correlation|was|. (r_prep) examined_18\VBN|NONE (l_nsubjpass) correlation_1\NN|was|in|. (l_prep) between_2\IN|The (l_pobj) damage_4\NN|NONE (l_prep) of_7\IN|inhibition|neuropathic|and (l_pobj) esterase_9\NN|NONE (l_amod) neurotoxic_8\JJ|enzyme|or
C005238_D020258 NONE Mipafox_24\NNP|NONE (l_appos) organophosphate_33\NN|,|)|N'diisopropylphosphorodiamidofluoridate (l_amod) neurotoxic_32\JJ|a
C005238_D020258 NONE N'-diisopropylphosphorodiamidofluoridate_28\NNP|,|)|organophosphate (r_appos) Mipafox_24\NNP|NONE (r_pobj) to_23\IN|acutely (r_prep) exposed_22\VBN|NONE (r_acl) rats_20\NNS|NONE (r_pobj) in_19\IN|correlation|was|. (r_prep) examined_18\VBN|NONE (l_nsubjpass) correlation_1\NN|was|in|. (l_prep) between_2\IN|The (l_pobj) damage_4\NN|NONE (l_prep) of_7\IN|inhibition|neuropathic|and (l_pobj) esterase_9\NN|NONE (l_amod) neurotoxic_8\JJ|enzyme|or
C005238_D020258 NONE N'-diisopropylphosphorodiamidofluoridate_28\NNP|,|)|organophosphate (r_appos) Mipafox_24\NNP|NONE (l_appos) organophosphate_33\NN|,|)|N'diisopropylphosphorodiamidofluoridate (l_amod) neurotoxic_32\JJ|a
C005238_D013118 CID Mipafox_5\NNP|NONE (r_pobj) of_4\IN|less|inhibited (r_prep) dosages_3\NNS|,|in|In|degree|. (r_nsubj) produced_39\VBN|NONE (l_dobj) degree_41\NN|,|in|In|dosages|. (l_prep) of_42\IN|this (l_pobj) damage_44\NN|NONE
7542793
D016572_D064420 NONE CsA_4\NNP|NONE (l_conj) toxicity_7\NN|and
D016559_D006984 NONE Fujimycine_9\NNP||)|and (r_conj) mg/kg_6\NN|Cyclosporin|CsA|,|; (r_appos) A_1\NNP|.|reduction|given (r_nsubj) caused_29\VBD|NONE (l_dobj) reduction_31\NN|.|A|given (l_prep) of_32\IN|a (l_pobj) rate_35\NN|NONE (l_appos) changes_38\NNS|filtration|glomerular|, (l_conj) hypertrophy_45\NN|of|degenerative|and|,
D016559_D006984 NONE FK506_11\NNP|but|rapamycin|,|mg/kg|;|( (r_appos) Fujimycine_9\NNP||)|and (r_conj) mg/kg_6\NN|Cyclosporin|CsA|,|; (r_appos) A_1\NNP|.|reduction|given (r_nsubj) caused_29\VBD|NONE (l_dobj) reduction_31\NN|.|A|given (l_prep) of_32\IN|a (l_pobj) rate_35\NN|NONE (l_appos) changes_38\NNS|filtration|glomerular|, (l_conj) hypertrophy_45\NN|of|degenerative|and|,
D016559_D007674 CID FK506_5\NNP|and|.|of|inhibition|: (r_conj) Nephrotoxicity_0\NN|NONE
D016559_D007674 CID FK506_10\NNP|that|through|effects|likely|is (r_nsubjpass) mediated_13\VBN|.|results (l_nsubjpass) effects_6\NNS|that|through|likely|is|FK (l_amod) nephrotoxic_5\JJ|of|and|the
D016559_D064420 NONE FK506_6\NNP|NONE (r_compound) toxicity_7\NN|and
D020123_D006984 NONE rapamycin_23\NNS|but|FK|,|mg/kg|;|( (r_conj) Fujimycine_9\NNP||)|and (r_conj) mg/kg_6\NN|Cyclosporin|CsA|,|; (r_appos) A_1\NNP|.|reduction|given (r_nsubj) caused_29\VBD|NONE (l_dobj) reduction_31\NN|.|A|given (l_prep) of_32\IN|a (l_pobj) rate_35\NN|NONE (l_appos) changes_38\NNS|filtration|glomerular|, (l_conj) hypertrophy_45\NN|of|degenerative|and|,
D016572_D006984 NONE A_1\NNP|.|reduction|given (r_nsubj) caused_29\VBD|NONE (l_dobj) reduction_31\NN|.|A|given (l_prep) of_32\IN|a (l_pobj) rate_35\NN|NONE (l_appos) changes_38\NNS|filtration|glomerular|, (l_conj) hypertrophy_45\NN|of|degenerative|and|,
D016572_D006984 NONE CsA_3\NNP|Cyclosporin|mg/kg|,|; (r_appos) A_1\NNP|.|reduction|given (r_nsubj) caused_29\VBD|NONE (l_dobj) reduction_31\NN|.|A|given (l_prep) of_32\IN|a (l_pobj) rate_35\NN|NONE (l_appos) changes_38\NNS|filtration|glomerular|, (l_conj) hypertrophy_45\NN|of|degenerative|and|,
D016572_D007674 CID A_3\NNP|NONE (r_pobj) of_1\IN|and|.|inhibition|:|FK (r_prep) Nephrotoxicity_0\NN|NONE
D016572_D007674 CID CsA_8\NNP|NONE (r_pobj) of_7\IN|nephrotoxic|and|the (r_prep) effects_6\NNS|that|through|likely|is|FK (l_amod) nephrotoxic_5\JJ|of|and|the
D018942_D006984 NONE macrolide_21\NN|not|mg/kg|(|related|the|immunosuppressant|) (r_amod) rapamycin_23\NNS|but|FK|,|mg/kg|;|( (r_conj) Fujimycine_9\NNP||)|and (r_conj) mg/kg_6\NN|Cyclosporin|CsA|,|; (r_appos) A_1\NNP|.|reduction|given (r_nsubj) caused_29\VBD|NONE (l_dobj) reduction_31\NN|.|A|given (l_prep) of_32\IN|a (l_pobj) rate_35\NN|NONE (l_appos) changes_38\NNS|filtration|glomerular|, (l_conj) hypertrophy_45\NN|of|degenerative|and|,
16596970
D010862_D001308 CID Pilocarpine_0\NNP|NONE (r_amod) seizures_1\NNS|.|impairment (r_nsubj) cause_2\IN|NONE (l_dobj) impairment_6\NN|.|seizures (l_prep) in_7\IN|dependent (l_pobj) discrimination_10\NN|NONE
D010862_D012640 NONE Pilocarpine_0\NNP|NONE (r_amod) seizures_1\NNS|.|impairment
D010862_D012640 NONE Pilocarpine_0\NN|status|epilepticus (r_nsubj) induced_4\VBN|epilepticus|;|,|in|had|. (r_ccomp) resulted_12\VBD|NONE (l_prep) in_13\IN|epilepticus|;|,|induced|had|. (l_pobj) loss_16\NN|NONE (l_conj) seizures_19\NNS|and|CA|cell
D010862_D012640 NONE Pilocarpine_0\NN|status|epilepticus (r_nsubj) induced_4\VBN|epilepticus|;|,|in|had|. (r_ccomp) resulted_12\VBD|NONE (l_advcl) had_24\VBD|epilepticus|;|,|in|induced|. (l_dobj) loss_27\NN|rats|whereas (l_conj) seizures_30\NNS|no|or|cell
D010862_D013226 CID Pilocarpine_0\NN|status|epilepticus (r_nsubj) induced_4\VBN|epilepticus|;|,|in|had|. (l_advmod) epilepticus_6\NN|Pilocarpine|status
D010862_D013226 CID Pilocarpine_0\NN|status|epilepticus (r_nsubj) induced_4\VBN|epilepticus|;|,|in|had|. (r_ccomp) resulted_12\VBD|NONE (l_nsubj) epilepticus_9\NN|;|,|in|induced|had|.
3123611
D003276_D002819 CID contraception_4\NN|NONE (r_pobj) with_2\IN|NONE (r_prep) associated_1\VBN|. (r_acl) Chorea_0\NNP|NONE
D003276_D002819 CID contraceptives_7\NNS|while (r_dobj) receiving_5\VBG|patients|.|chorea (r_advcl) developed_2\VBD|NONE (l_dobj) chorea_3\NN|patients|receiving|.
D003276_D002819 CID contraception_12\NN|NONE (r_pobj) after_9\IN|patient|chorea|. (r_prep) had_3\VBD|NONE (l_dobj) chorea_8\NN|patient|after|.
D000661_D002819 CID amphetamine_5\NN| (r_npadvmod) induced_7\VBN|acute (r_amod) chorea_8\NN|patient|after|.
1423339
D011433_D064420 NONE propranolol_4\JJ|NONE (r_amod) toxicity_5\NN|NONE
D011433_D064420 NONE propranolol_14\JJ|NONE (r_amod) toxicity_15\NN|NONE
D011433_D003704 NONE propranolol_14\JJ|NONE (r_amod) toxicity_15\NN|NONE (r_pobj) of_13\IN|a (r_prep) result_12\NN|NONE (r_pobj) as_10\IN|.|woman|dementia (r_prep) developed_3\VBD|NONE (l_dobj) dementia_9\NN|.|as|woman
D011433_D000544 NONE propranolol_14\JJ|NONE (r_amod) toxicity_15\NN|NONE (r_pobj) of_13\IN|a (r_prep) result_12\NN|NONE (r_pobj) as_10\IN|.|woman|dementia (r_prep) developed_3\VBD|NONE (l_dobj) dementia_9\NN|.|as|woman (l_amod) like_7\JJ|subacute|an (l_npadvmod) Alzheimer_5\NNP|
D011433_D000647 CID propranolol_4\JJ|NONE (r_amod) toxicity_5\NN|NONE (r_pobj) with_3\IN|NONE (r_prep) associated_2\VBN|Amnestic|report|:|. (r_acl) syndrome_1\NN|NONE
7420681
D014031_D051437 CID sulfate_28\NN|for|or|gentamicin (r_conj) sulfate_25\NN|NONE (r_pobj) of_23\IN|NONE (r_prep) day_22\NN|/|/||mg (r_appos) kg_20\NNS|NONE (r_pobj) with_14\IN|NONE (r_prep) treated_13\VBN||and|with (r_conj) patients_5\NNS|prospectively|up|In|were|for|.|, (r_nsubjpass) followed_36\VBN|NONE (l_prep) for_39\IN|patients|prospectively|up|In|were|.|, (l_pobj) development_41\NN|NONE (l_prep) of_42\IN|the (l_pobj) failure_47\NN|NONE
D014031_D051437 CID tobramycin_9\RB| (r_npadvmod) treated_11\VBN|the (r_amod) patients_12\NNS|NONE (r_pobj) of_7\IN|(||and||) (r_prep) %_5\NN|NONE (r_pobj) of_1\IN|NONE (r_prep) Five_0\CD|.|failure| (r_nsubj) had_27\VBD|NONE (l_dobj) failure_29\NN|.||Five
D014031_D051437 CID tobramycin_16\JJ|often|as (r_acomp) was_15\VBD|gentamicin|Thus|was|,|with|. (r_advcl) associated_4\VBN|NONE (l_prep) with_5\IN|gentamicin|was|Thus|was|,|. (l_pobj) failure_7\NN|NONE
D005839_D051437 CID sulfate_25\NN|NONE (r_pobj) of_23\IN|NONE (r_prep) day_22\NN|/|/||mg (r_appos) kg_20\NNS|NONE (r_pobj) with_14\IN|NONE (r_prep) treated_13\VBN||and|with (r_conj) patients_5\NNS|prospectively|up|In|were|for|.|, (r_nsubjpass) followed_36\VBN|NONE (l_prep) for_39\IN|patients|prospectively|up|In|were|.|, (l_pobj) development_41\NN|NONE (l_prep) of_42\IN|the (l_pobj) failure_47\NN|NONE
D005839_D051437 CID gentamicin_23\NN| (r_npadvmod) treated_25\VBN|the (r_amod) patients_26\NNS|NONE (r_pobj) of_21\IN|%|of|) (r_prep) 16_14\CD|.|failure|Five (r_nsubj) had_27\VBD|NONE (l_dobj) failure_29\NN|.||Five
D005839_D051437 CID gentamicin_2\NN|was|Thus|was|,|with|. (r_nsubjpass) associated_4\VBN|NONE (l_prep) with_5\IN|gentamicin|was|Thus|was|,|. (l_pobj) failure_7\NN|NONE
D014031_D006311 NONE sulfate_4\NN|and|Gentamicin (r_conj) sulfate_1\NN|demonstrate|. (r_nsubj) continue_5\VBP|NONE (l_xcomp) demonstrate_7\VB|.|sulfate (l_dobj) ototoxicity_8\NN|to
D014031_D007674 NONE tobramycin_3\JJ|NONE (r_pobj) of_2\IN|Clinical|gentamicin|and|. (r_prep) nephrotoxicity_1\NN|NONE
D014031_D007674 NONE sulfate_4\NN|and|Gentamicin (r_conj) sulfate_1\NN|demonstrate|. (r_nsubj) continue_5\VBP|NONE (l_xcomp) demonstrate_7\VB|.|sulfate (l_dobj) ototoxicity_8\NN|to (l_conj) nephrotoxicity_10\NN|and|in
D005839_D007674 NONE gentamicin_5\NN|Clinical|and|.|of (r_conj) nephrotoxicity_1\NN|NONE
D005839_D007674 NONE sulfate_1\NN|demonstrate|. (r_nsubj) continue_5\VBP|NONE (l_xcomp) demonstrate_7\VB|.|sulfate (l_dobj) ototoxicity_8\NN|to (l_conj) nephrotoxicity_10\NN|and|in
D005839_D006311 NONE sulfate_1\NN|demonstrate|. (r_nsubj) continue_5\VBP|NONE (l_xcomp) demonstrate_7\VB|.|sulfate (l_dobj) ototoxicity_8\NN|to
D000617_D051437 NONE aminoglycoside_43\NN| (r_npadvmod) related_45\VBN|,|renal|defined (r_amod) failure_47\NN|NONE
3496378
D014217_D007565 CID troleandomycin_5\NN|NONE (r_pobj) of_4\IN|NONE (r_prep) administration_3\NN|NONE (r_pobj) after_2\IN|associated|Jaundice|for|.|and (r_prep) occurred_1\VBD|NONE (l_nsubj) Jaundice_0\NN|associated|after|for|.|and
D014217_D056486 CID troleandomycin_3\NN| (r_npadvmod) induced_5\VBN|acute (r_amod) hepatitis_7\NN|NONE
D014217_D056486 CID troleandomycin_9\NN|in| (r_npadvmod) induced_11\VBN|a (r_relcl) patient_6\NN|NONE (r_pobj) of_4\IN|the (r_prep) case_3\NN|We|.|followed (r_dobj) report_1\VBP|NONE (l_ccomp) followed_14\VBN|We|.|case (l_nsubjpass) hepatitis_12\NN|was|by
D014217_D056486 CID troleandomycin_8\NN| (r_npadvmod) induced_10\VBN|acute (r_amod) hepatitis_12\NN|can|cholestasis|that
D014217_D002779 CID troleandomycin_3\NN| (r_npadvmod) induced_5\VBN|acute (r_amod) hepatitis_7\NN|NONE (r_pobj) after_2\IN|Prolonged|. (r_prep) cholestasis_1\NN|NONE
D014217_D002779 CID troleandomycin_9\NN|in| (r_npadvmod) induced_11\VBN|a (r_relcl) patient_6\NN|NONE (r_pobj) of_4\IN|the (r_prep) case_3\NN|We|.|followed (r_dobj) report_1\VBP|NONE (l_ccomp) followed_14\VBN|We|.|case (l_agent) by_15\IN|hepatitis|was (l_pobj) cholestasis_18\NN|NONE
D014217_D002779 CID troleandomycin_8\NN| (r_npadvmod) induced_10\VBN|acute (r_amod) hepatitis_12\NN|can|cholestasis|that (r_dobj) follow_7\VB|.|observation (l_nsubj) cholestasis_5\NN|can|hepatitis|that
D014217_D004802 CID troleandomycin_5\NN|NONE (r_pobj) of_4\IN|NONE (r_prep) administration_3\NN|NONE (r_pobj) after_2\IN|associated|Jaundice|for|.|and (r_prep) occurred_1\VBD|NONE (l_conj) associated_11\VBN|after|Jaundice|for|.|and (l_prep) with_12\IN|was (l_pobj) hypereosinophilia_13\NNS|NONE
10526274
C030852_D002289 NONE vinorelbine_2\NN|plus (l_prep) in_3\IN|NONE (l_pobj) patients_8\NNS|NONE (l_compound) carcinoma_7\NN|nonsmall
C030852_D002289 NONE VNB_14\NNP|and (r_conj) GEM_12\NNP|NONE (r_pobj) of_11\IN|the|in (r_prep) combination_10\NN|NONE (l_prep) in_15\IN|of|the (l_pobj) patients_17\NNS|NONE (l_prep) with_18\IN|elderly (l_pobj) NSCLC_20\NNP|NONE
C056507_D002289 NONE Gemcitabine_0\NNP|.|years (l_conj) vinorelbine_2\NN|plus (l_prep) in_3\IN|NONE (l_pobj) patients_8\NNS|NONE (l_compound) carcinoma_7\NN|nonsmall
C056507_D002289 NONE GEM_12\NNP|NONE (r_pobj) of_11\IN|the|in (r_prep) combination_10\NN|NONE (l_prep) in_15\IN|of|the (l_pobj) patients_17\NNS|NONE (l_prep) with_18\IN|elderly (l_pobj) NSCLC_20\NNP|NONE
D002945_D002289 NONE cisplatin_20\NN|can|not|who (r_dobj) receive_19\VB|or|patients|older|or| (r_relcl) years_11\NNS|.|Gemcitabine (r_npadvmod) age_9\NN|NONE (l_nsubj) Gemcitabine_0\NNP|.|years (l_conj) vinorelbine_2\NN|plus (l_prep) in_3\IN|NONE (l_pobj) patients_8\NNS|NONE (l_compound) carcinoma_7\NN|nonsmall
D002945_D002289 NONE cisplatin_28\NN|NONE (r_dobj) receiving_27\VBG|NONE (r_pcomp) to_26\IN|some (r_prep) contraindication_25\NN|NONE (r_pobj) with_23\IN|NONE (r_prep) those_22\DT|advanced|or (r_conj) NSCLC_20\NNP|NONE
D002945_D002289 NONE cisplatin_33\NN|NONE (r_dobj) receiving_32\VBG|NONE (r_pcomp) to_31\IN|some (r_prep) contraindication_30\NN|who (r_dobj) had_28\VBD||but|age (r_conj) were_21\VBD|years|and (r_conj) /=_16\NFP|,|were|were|.|patients (r_punct) included_8\VBN|NONE (l_nsubjpass) patients_3\NNS|,|were|were|/=|. (l_prep) with_4\IN|nine (l_pobj) NSCLC_6\NNP|NONE
C056507_D064420 NONE GEM_1\NNP|with|may|.|(|)|,|rate (r_nsubj) obtain_4\VB|NONE (l_prep) with_17\IN|GEM|may|.|(|)|,|rate (l_pobj) toxicity_19\NN|NONE
C056507_D064420 NONE GEM_12\NNP|NONE (r_pobj) of_11\IN|the|in (r_prep) combination_10\NN|NONE (r_pobj) of_8\IN|and|the|toxicity (r_prep) efficacy_5\NN|In|.|were (l_conj) toxicity_7\NN|and|of|the
C030852_D064420 NONE VNB_14\NNP|and (r_conj) GEM_12\NNP|NONE (r_pobj) of_11\IN|the|in (r_prep) combination_10\NN|NONE (r_pobj) of_8\IN|and|the|toxicity (r_prep) efficacy_5\NN|In|.|were (l_conj) toxicity_7\NN|and|of|the
D002945_D064420 NONE cisplatin_28\NN|NONE (r_dobj) receiving_27\VBG|NONE (r_pcomp) to_26\IN|some (r_prep) contraindication_25\NN|NONE (r_pobj) with_23\IN|NONE (r_prep) those_22\DT|advanced|or (r_conj) NSCLC_20\NNP|NONE (r_pobj) with_18\IN|elderly (r_prep) patients_17\NNS|NONE (r_pobj) in_15\IN|of|the (r_prep) combination_10\NN|NONE (r_pobj) of_8\IN|and|the|toxicity (r_prep) efficacy_5\NN|In|.|were (l_conj) toxicity_7\NN|and|of|the
12842176
D010634_D012640 NONE phenobarbital_35\JJ|NONE (r_pobj) with_34\IN|NONE (r_prep) pretreatment_33\NN|, (r_conj) convulsions_31\NNS|produce|that
D010634_D012640 NONE phenobarbital_35\JJ|NONE (r_pobj) with_34\IN|NONE (r_prep) pretreatment_33\NN|, (r_conj) convulsions_31\NNS|produce|that (r_dobj) induced_30\VBN|further|have|studies (r_ccomp) shown_4\VBN|significantly|induced|incidence|,|. (r_ccomp) increased_57\VBD|NONE (l_advcl) induced_62\VBN|significantly|incidence|,|shown|. (l_dobj) convulsions_63\NNS|NONE
D000431_D012640 NONE ethanol_46\NN|of|an|or|B/B|inducer|, (r_conj) inducer_41\NN|)|PB|(|, (r_appos) phenobarbital_35\JJ|NONE (r_pobj) with_34\IN|NONE (r_prep) pretreatment_33\NN|, (r_conj) convulsions_31\NNS|produce|that
D000431_D012640 NONE ethanol_46\NN|of|an|or|B/B|inducer|, (r_conj) inducer_41\NN|)|PB|(|, (r_appos) phenobarbital_35\JJ|NONE (r_pobj) with_34\IN|NONE (r_prep) pretreatment_33\NN|, (r_conj) convulsions_31\NNS|produce|that (r_dobj) induced_30\VBN|further|have|studies (r_ccomp) shown_4\VBN|significantly|induced|incidence|,|. (r_ccomp) increased_57\VBD|NONE (l_advcl) induced_62\VBN|significantly|incidence|,|shown|. (l_dobj) convulsions_63\NNS|NONE
D000431_D012640 NONE ethanol_35\NN|or (r_conj) PB_33\NNP|inducible|P (r_nmod) isoenzymes_38\NNS|NONE (r_pobj) by_32\IN|NONE (r_agent) formed_31\VBN|its (r_acl) metabolites_30\NNS|per|or (r_conj) lindane_25\NN|are|in|that (r_nsubjpass) involved_40\VBN|NONE (r_ccomp) indicating_23\VBG|Similarly|in|was|blocked|.|, (r_advcl) increased_17\VBN|NONE (l_advcl) blocked_9\VBN|Similarly|indicating|in|was|.|, (l_agent) by_10\IN|was|when|metabolism (l_pobj) incidence_13\NN|NONE (l_prep) of_14\IN|chloride (l_pobj) convulsions_15\NNS|NONE
D000431_D064420 NONE ethanol_35\NN|or (r_conj) PB_33\NNP|inducible|P (r_nmod) isoenzymes_38\NNS|NONE (r_pobj) by_32\IN|NONE (r_agent) formed_31\VBN|its (r_acl) metabolites_30\NNS|per|or (r_conj) lindane_25\NN|are|in|that (r_nsubjpass) involved_40\VBN|NONE (l_prep) in_41\IN|lindane|are|that (l_pobj) toxicity_44\NN|NONE
D001556_D020258 NONE lindane_2\NN|NONE (r_pobj) of_1\IN|NONE (r_prep) Effect_0\NN|neurotoxicity|influence|. (r_nsubj) induced_16\VBN|NONE (l_dobj) neurotoxicity_17\NN|Effect|influence|.
D001556_D020258 NONE lindane_15\NN|NONE (r_pobj) in_14\IN|P (r_prep) modulation_13\NN|NONE (r_pobj) of_11\IN|NONE (r_prep) influence_10\NN|neurotoxicity|Effect|. (r_nsubj) induced_16\VBN|NONE (l_dobj) neurotoxicity_17\NN|Effect|influence|.
C018021_D064420 NONE chloride_12\NN|of (r_compound) incidence_13\NN|NONE (r_pobj) by_10\IN|was|when|metabolism (r_agent) blocked_9\VBN|Similarly|indicating|in|was|.|, (r_advcl) increased_17\VBN|NONE (l_advcl) indicating_23\VBG|Similarly|in|was|blocked|.|, (l_ccomp) involved_40\VBN|NONE (l_prep) in_41\IN|lindane|are|that (l_pobj) toxicity_44\NN|NONE
D008748_D012640 NONE 3-methylcholanthrene_9\NN|MC (r_pobj) of_8\IN|,|inducer (r_prep) pretreatment_7\NN|effect|did|not|while|, (r_nsubj) produce_21\VB|that|convulsions (r_advcl) induced_30\VBN|further|have|studies (l_dobj) convulsions_31\NNS|produce|that
D008748_D012640 NONE 3-methylcholanthrene_9\NN|MC (r_pobj) of_8\IN|,|inducer (r_prep) pretreatment_7\NN|effect|did|not|while|, (r_nsubj) produce_21\VB|that|convulsions (r_advcl) induced_30\VBN|further|have|studies (r_ccomp) shown_4\VBN|significantly|induced|incidence|,|. (r_ccomp) increased_57\VBD|NONE (l_advcl) induced_62\VBN|significantly|incidence|,|shown|. (l_dobj) convulsions_63\NNS|NONE
D008748_D012640 NONE MC_11\NNP|methylcholanthrene (r_pobj) of_8\IN|,|inducer (r_prep) pretreatment_7\NN|effect|did|not|while|, (r_nsubj) produce_21\VB|that|convulsions (r_advcl) induced_30\VBN|further|have|studies (l_dobj) convulsions_31\NNS|produce|that
D008748_D012640 NONE MC_11\NNP|methylcholanthrene (r_pobj) of_8\IN|,|inducer (r_prep) pretreatment_7\NN|effect|did|not|while|, (r_nsubj) produce_21\VB|that|convulsions (r_advcl) induced_30\VBN|further|have|studies (r_ccomp) shown_4\VBN|significantly|induced|incidence|,|. (r_ccomp) increased_57\VBD|NONE (l_advcl) induced_62\VBN|significantly|incidence|,|shown|. (l_dobj) convulsions_63\NNS|NONE
C018021_D012640 NONE chloride_12\NN|of (r_compound) incidence_13\NN|NONE (l_prep) of_14\IN|chloride (l_pobj) convulsions_15\NNS|NONE
D001556_D064420 NONE lindane_7\NN|NONE (r_pobj) of_6\IN|the|Pmediated (r_prep) metabolism_5\NN|was|by|when (r_nsubjpass) blocked_9\VBN|Similarly|indicating|in|was|.|, (r_advcl) increased_17\VBN|NONE (l_advcl) indicating_23\VBG|Similarly|in|was|blocked|.|, (l_ccomp) involved_40\VBN|NONE (l_prep) in_41\IN|lindane|are|that (l_pobj) toxicity_44\NN|NONE
D001556_D064420 NONE lindane_22\NN|NONE (r_pobj) with_21\IN|NONE (r_prep) treated_20\VBN|NONE (r_acl) animals_19\NNS|NONE (r_pobj) in_18\IN|Similarly|indicating|was|blocked|.|, (r_prep) increased_17\VBN|NONE (l_advcl) indicating_23\VBG|Similarly|in|was|blocked|.|, (l_ccomp) involved_40\VBN|NONE (l_prep) in_41\IN|lindane|are|that (l_pobj) toxicity_44\NN|NONE
D001556_D064420 NONE lindane_25\NN|are|in|that (r_nsubjpass) involved_40\VBN|NONE (l_prep) in_41\IN|lindane|are|that (l_pobj) toxicity_44\NN|NONE
D001556_D012640 CID lindane_29\NN|NONE (r_pobj) of_28\IN|the (r_prep) incidence_27\NN|NONE (r_pobj) in_25\IN|significant|any (r_prep) effect_24\NN|did|not|while|pretreatment|, (r_dobj) produce_21\VB|that|convulsions (r_advcl) induced_30\VBN|further|have|studies (l_dobj) convulsions_31\NNS|produce|that
D001556_D012640 CID lindane_29\NN|NONE (r_pobj) of_28\IN|the (r_prep) incidence_27\NN|NONE (r_pobj) in_25\IN|significant|any (r_prep) effect_24\NN|did|not|while|pretreatment|, (r_dobj) produce_21\VB|that|convulsions (r_advcl) induced_30\VBN|further|have|studies (r_ccomp) shown_4\VBN|significantly|induced|incidence|,|. (r_ccomp) increased_57\VBD|NONE (l_advcl) induced_62\VBN|significantly|incidence|,|shown|. (l_dobj) convulsions_63\NNS|NONE
D001556_D012640 CID lindane_61\NN|NONE (r_pobj) of_60\IN|the (r_prep) incidence_59\NN|significantly|induced|,|shown|. (r_dobj) increased_57\VBD|NONE (l_ccomp) shown_4\VBN|significantly|induced|incidence|,|. (l_ccomp) induced_30\VBN|further|have|studies (l_dobj) convulsions_31\NNS|produce|that
D001556_D012640 CID lindane_61\NN|NONE (r_pobj) of_60\IN|the (r_prep) incidence_59\NN|significantly|induced|,|shown|. (r_dobj) increased_57\VBD|NONE (l_advcl) induced_62\VBN|significantly|incidence|,|shown|. (l_dobj) convulsions_63\NNS|NONE
D001556_D012640 CID lindane_7\NN|NONE (r_pobj) of_6\IN|the|Pmediated (r_prep) metabolism_5\NN|was|by|when (r_nsubjpass) blocked_9\VBN|Similarly|indicating|in|was|.|, (l_agent) by_10\IN|was|when|metabolism (l_pobj) incidence_13\NN|NONE (l_prep) of_14\IN|chloride (l_pobj) convulsions_15\NNS|NONE
D001556_D012640 CID lindane_22\NN|NONE (r_pobj) with_21\IN|NONE (r_prep) treated_20\VBN|NONE (r_acl) animals_19\NNS|NONE (r_pobj) in_18\IN|Similarly|indicating|was|blocked|.|, (r_prep) increased_17\VBN|NONE (l_advcl) blocked_9\VBN|Similarly|indicating|in|was|.|, (l_agent) by_10\IN|was|when|metabolism (l_pobj) incidence_13\NN|NONE (l_prep) of_14\IN|chloride (l_pobj) convulsions_15\NNS|NONE
D001556_D012640 CID lindane_25\NN|are|in|that (r_nsubjpass) involved_40\VBN|NONE (r_ccomp) indicating_23\VBG|Similarly|in|was|blocked|.|, (r_advcl) increased_17\VBN|NONE (l_advcl) blocked_9\VBN|Similarly|indicating|in|was|.|, (l_agent) by_10\IN|was|when|metabolism (l_pobj) incidence_13\NN|NONE (l_prep) of_14\IN|chloride (l_pobj) convulsions_15\NNS|NONE
12695819
D016559_D020258 NONE tacrolimus_7\NN| (r_npadvmod) induced_9\VBN|in (r_amod) neurotoxicity_10\NN|NONE
D016559_D020258 NONE tacrolimus_15\NN| (r_npadvmod) induced_17\VBN|NONE (r_amod) neurotoxicity_18\NN|NONE
D016559_D009422 NONE tacrolimus_17\NNS|NONE (l_relcl) developed_19\VBD|NONE (l_dobj) complications_21\NNS|who
3425586
D003622_D007918 NONE dapsone_23\NN|NONE (r_pobj) of_22\IN|associated|a (r_prep) dose_21\NN|while (r_dobj) taking_19\VBG|woman|anemia|. (r_advcl) developed_12\VBD|NONE (l_nsubj) woman_2\NN|anemia|taking|. (l_conj) leprosy_11\NN|Cambodian|with|A
D003622_D000743 CID Dapsone_0\NN| (r_npadvmod) associated_2\VBN|Heinz|in|body|hemolytic|. (r_amod) anemia_6\NN|NONE
D003622_D000743 CID dapsone_23\NN|NONE (r_pobj) of_22\IN|associated|a (r_prep) dose_21\NN|while (r_dobj) taking_19\VBG|woman|anemia|. (r_advcl) developed_12\VBD|NONE (l_dobj) anemia_17\NN|woman|taking|.
D003622_D000743 CID dapsone_21\NN|at|does|anemia|not|since (r_nsubj) cause_24\VB|,|to|sensitivity|in (l_dobj) anemia_26\NN|at|does|not|since|dapsone
D003622_D006461 NONE dapsone_23\NN|NONE (r_pobj) of_22\IN|associated|a (r_prep) dose_21\NN|while (l_acl) associated_32\VBN|of|a (l_prep) with_33\IN|usually|not (l_pobj) hemolysis_35\NN|NONE
2917114
D006024_D001919 NONE glycopyrronium_2\NN|NONE (r_pobj) of_1\IN|.|micrograms|given (r_prep) Use_0\NN|NONE (l_acl) given_12\VBN|of|.|micrograms (l_conj) was_19\VBD|,|min|, (l_acomp) sufficient_20\JJ|NONE (l_xcomp) minimize_22\VB|NONE (l_dobj) bradycardias_28\NNS|to
D004491_D001919 CID edrophonium_17\NN|NONE (r_pobj) before_15\IN| (r_prep) min_14\NN|,|,|was (r_dobj) given_12\VBN|of|.|micrograms (l_conj) was_19\VBD|,|min|, (l_acomp) sufficient_20\JJ|NONE (l_xcomp) minimize_22\VB|NONE (l_dobj) bradycardias_28\NNS|to
D004491_D001919 CID edrophonium_25\NN| (r_npadvmod) induced_27\VBN|early|, (r_amod) bradycardias_28\NNS|to
8012887
D006493_D001791 NONE heparin_14\JJ|NONE (r_pobj) with_13\IN|NONE (r_prep) patients_12\NNS|NONE (r_pobj) in_11\IN|has|defined|Ancrod|for|but|successfully|induced|,|been (r_prep) used_3\VBN|NONE (l_advcl) induced_15\VBN|has|defined|Ancrod|for|but|successfully|in|,|been (l_dobj) aggregation_17\NN|NONE
D006493_D001791 NONE heparin_23\NN|NONE (r_pobj) to_22\IN|brief (r_prep) reexposure_21\NN|who (r_dobj) require_19\VBP|platelet (r_relcl) aggregation_17\NN|NONE
D006493_D013927 CID heparin_7\NN| (r_npadvmod) induced_9\VBN|arterial (r_amod) thrombosis_11\NN|NONE
D006493_D013927 CID heparin_6\NN| (r_npadvmod) induced_8\VBN|NONE (r_amod) thrombosis_9\NN|NONE
D006493_D013927 CID heparin_14\JJ|NONE (r_pobj) with_13\IN|NONE (r_prep) patients_12\NNS|NONE (r_pobj) in_11\IN|has|defined|Ancrod|for|but|successfully|induced|,|been (r_prep) used_3\VBN|NONE (l_prep) for_5\IN|has|defined|Ancrod|but|successfully|in|induced|,|been (l_pobj) prophylaxis_6\NN|NONE (l_prep) against_7\IN|NONE (l_pobj) development_8\NN|NONE (l_prep) of_9\IN|NONE (l_pobj) thrombosis_10\NN|NONE
D006493_D013927 CID heparin_14\JJ|NONE (r_pobj) with_13\IN|NONE (r_prep) patients_12\NNS|NONE (r_pobj) in_11\IN|has|defined|Ancrod|for|but|successfully|induced|,|been (r_prep) used_3\VBN|NONE (l_conj) defined_39\VBN|has|Ancrod|for|but|successfully|in|induced|,|been (l_auxpass) is_36\VBZ|not|well|. (l_nsubj) success_27\NN|NONE (l_prep) in_28\IN|its (l_pobj) patients_29\NNS|NONE (l_relcl) developed_32\VBN|NONE (l_dobj) syndrome_35\NN|have|who (l_compound) thrombosis_34\NN|the
D006493_D013927 CID heparin_23\NN|NONE (r_pobj) to_22\IN|brief (r_prep) reexposure_21\NN|who (r_dobj) require_19\VBP|platelet (r_relcl) aggregation_17\NN|NONE (r_dobj) induced_15\VBN|has|defined|Ancrod|for|but|successfully|in|,|been (r_advcl) used_3\VBN|NONE (l_prep) for_5\IN|has|defined|Ancrod|but|successfully|in|induced|,|been (l_pobj) prophylaxis_6\NN|NONE (l_prep) against_7\IN|NONE (l_pobj) development_8\NN|NONE (l_prep) of_9\IN|NONE (l_pobj) thrombosis_10\NN|NONE
D006493_D013927 CID heparin_23\NN|NONE (r_pobj) to_22\IN|brief (r_prep) reexposure_21\NN|who (r_dobj) require_19\VBP|platelet (r_relcl) aggregation_17\NN|NONE (r_dobj) induced_15\VBN|has|defined|Ancrod|for|but|successfully|in|,|been (r_advcl) used_3\VBN|NONE (l_conj) defined_39\VBN|has|Ancrod|for|but|successfully|in|induced|,|been (l_auxpass) is_36\VBZ|not|well|. (l_nsubj) success_27\NN|NONE (l_prep) in_28\IN|its (l_pobj) patients_29\NNS|NONE (l_relcl) developed_32\VBN|NONE (l_dobj) syndrome_35\NN|have|who (l_compound) thrombosis_34\NN|the
D006493_D013927 CID heparin_14\NN| (r_npadvmod) induced_16\VBN|NONE (r_amod) thrombosis_17\NN|NONE
16471092
C099041_D053201 NONE tolterodine_14\JJ|NONE (r_amod) treatment_15\NN|NONE (r_pobj) after_13\IN|Urinary|.|and|quality (r_prep) symptoms_1\NNS|NONE (l_conj) quality_3\NN|after|Urinary|.|and (l_prep) of_4\IN|NONE (l_pobj) changes_6\NNS|NONE (l_prep) with_10\IN|life|in (l_pobj) bladder_12\NN|NONE
C099041_D053201 NONE tolterodine_22\JJ|NONE (r_amod) treatment_23\NN|NONE (r_pobj) after_21\IN|To|symptoms (r_prep) study_3\VB|.|: (l_dobj) symptoms_6\NNS|after|To (l_conj) quality_8\NN|urinary|and|the (l_prep) of_9\IN|NONE (l_pobj) changes_11\NNS|NONE (l_prep) with_15\IN|life|in (l_pobj) bladder_17\NN|NONE
C099041_D053201 NONE tolterodine_22\JJ|NONE (r_amod) treatment_23\NN|NONE (r_pobj) after_21\IN|To|symptoms (r_prep) study_3\VB|.|: (l_dobj) symptoms_6\NNS|after|To (l_conj) quality_8\NN|urinary|and|the (l_prep) of_9\IN|NONE (l_pobj) changes_11\NNS|NONE (l_prep) with_15\IN|life|in (l_pobj) bladder_17\NN|NONE (l_appos) OAB_19\NNP|)|overactive|(
C099041_D053201 NONE Tolterodine_0\NNP|improved|and|well|was (r_nsubjpass) tolerated_3\VBN|NONE (l_conj) improved_7\VBD|and|Tolterodine|well|was (l_dobj) quality_9\NN|.|effects (l_prep) with_15\IN|of|the|in (l_pobj) OAB_16\NNP|NONE
12707296
D006854_D006973 NONE cortisol_7\NN| (r_npadvmod) induced_9\VBN|NONE (r_amod) hypertension_10\NN|NONE
D006854_D006973 NONE cortisol_12\NN| (r_npadvmod) induced_14\VBN|NONE (r_amod) hypertension_15\NN|NONE
D006854_D006973 NONE cortisol_3\NN| (r_npadvmod) induced_5\VBN|in (r_amod) increases_6\NNS|are|not|with|that (l_prep) in_7\IN|induced (l_pobj) pressure_9\NN|NONE
D001120_D006973 NONE arginine_2\NN|with|.|in (r_compound) transport_3\NN|NONE (l_prep) with_6\IN|arginine|.|in (l_pobj) hypertension_10\NN|NONE
D001120_D006973 NONE arginine_4\NN||L| (r_compound) nitric_6\NN|oxide|deficient|A (r_compound) system_8\NN|is|.|in (r_nsubjpass) implicated_10\VBN|NONE (l_prep) in_11\IN|is|.|system (l_pobj) hypertension_15\NN|NONE
D001120_D006973 NONE arginine_19\NN|transport|the (r_compound) system_21\NN|NONE (r_pobj) in_15\IN|NONE (r_prep) abnormalities_14\NNS|NONE (r_pobj) with_13\IN|are|not|increases|that (r_prep) associated_12\VBN|We|. (l_nsubjpass) increases_6\NNS|are|not|with|that (l_prep) in_7\IN|induced (l_pobj) pressure_9\NN|NONE
D009569_D006973 NONE oxide_7\NN|deficient|nitric|A (r_compound) system_8\NN|is|.|in (r_nsubjpass) implicated_10\VBN|NONE (l_prep) in_11\IN|is|.|system (l_pobj) hypertension_15\NN|NONE
783197
D010042_D003324 NONE ouabain_2\NN|NONE (l_prep) on_3\IN|NONE (l_pobj) supply_6\NN|NONE (l_conj) demand_8\NN|myocardial|and|oxygen (l_prep) in_9\IN|NONE (l_pobj) patients_10\NNS|NONE (l_prep) with_11\IN|NONE (l_pobj) disease_15\NN|NONE
D010042_D003324 NONE ouabain_5\NN|NONE (r_pobj) of_4\IN|weight|the|on|) (r_prep) effects_3\NNS|We|. (l_prep) on_12\IN|of|weight|the|) (l_pobj) parameters_19\NNS|NONE (l_prep) in_20\IN|volumetric|without|metabolic (l_pobj) patients_22\NNS|NONE (l_prep) with_23\IN| (l_pobj) disease_28\NN|NONE
D010042_D003324 NONE ouabain_26\JJ|NONE (r_compound) administration_27\NN|NONE (r_pobj) after_25\IN|is (r_prep) falls_24\VBZ|.|We|left (r_conj) conclude_1\VBP|NONE (l_ccomp) left_18\VBD|.|We|falls (l_nsubj) patients_4\NNS|volume|in|that (l_prep) with_5\IN|NONE (l_pobj) disease_9\NN|NONE
D010042_D006333 NONE ouabain_5\NN|NONE (r_pobj) of_4\IN|weight|the|on|) (r_prep) effects_3\NNS|We|. (l_prep) on_12\IN|of|weight|the|) (l_pobj) parameters_19\NNS|NONE (l_prep) without_29\IN|volumetric|in|metabolic (l_pobj) failure_33\NN|NONE
D010042_D006333 NONE ouabain_26\JJ|NONE (r_compound) administration_27\NN|NONE (r_pobj) after_25\IN|is (r_prep) falls_24\VBZ|.|We|left (r_conj) conclude_1\VBP|NONE (l_ccomp) left_18\VBD|.|We|falls (l_nsubj) patients_4\NNS|volume|in|that (l_prep) with_5\IN|NONE (l_pobj) disease_9\NN|NONE (l_relcl) are_11\VBP|artery|chronic|coronary (l_prep) in_13\IN|not|who (l_pobj) failure_17\NN|NONE
D010100_D003324 NONE oxygen_5\NN|myocardial|and|demand (r_compound) supply_6\NN|NONE (l_conj) demand_8\NN|myocardial|and|oxygen (l_prep) in_9\IN|NONE (l_pobj) patients_10\NNS|NONE (l_prep) with_11\IN|NONE (l_pobj) disease_15\NN|NONE
D010100_D003324 NONE oxygen_7\NN|and|myocardial|demand (r_compound) supply_8\NN|NONE (r_pobj) on_5\IN|digitalis (r_prep) glycosides_4\NNS|NONE (r_pobj) of_2\IN|The (r_prep) effects_1\NNS|.|of|,|but|measured (r_nsubj) are_11\VBP|NONE (l_prep) of_12\IN|.|,|effects|but|measured (l_pobj) interest_14\NN|NONE (l_prep) in_15\IN|particular (l_pobj) presence_17\NN|NONE (l_prep) of_18\IN|the (l_pobj) disease_22\NN|NONE
D010042_D002303 CID ouabain_26\JJ|NONE (r_compound) administration_27\NN|NONE (r_pobj) after_25\IN|is (r_prep) falls_24\VBZ|.|We|left
D004071_D003324 NONE glycosides_4\NNS|NONE (r_pobj) of_2\IN|The (r_prep) effects_1\NNS|.|of|,|but|measured (r_nsubj) are_11\VBP|NONE (l_prep) of_12\IN|.|,|effects|but|measured (l_pobj) interest_14\NN|NONE (l_prep) in_15\IN|particular (l_pobj) presence_17\NN|NONE (l_prep) of_18\IN|the (l_pobj) disease_22\NN|NONE
7880714
2004
D000639_D002037 CID Elavil_5\NNP|nortriptyline (r_conj) Aventyl_0\NNP|left|in|branch|produced|.|each (r_nsubj) block_14\NN|NONE
D000639_D002037 CID amitriptyline_7\FW|NONE (r_appos) Elavil_5\NNP|nortriptyline (r_conj) Aventyl_0\NNP|left|in|branch|produced|.|each (r_nsubj) block_14\NN|NONE
D009661_D002037 CID Aventyl_0\NNP|left|in|branch|produced|.|each (r_nsubj) block_14\NN|NONE
D009661_D002037 CID nortriptyline_2\NN|Elavil (r_appos) Aventyl_0\NNP|left|in|branch|produced|.|each (r_nsubj) block_14\NN|NONE
D008012_D001145 NONE lidocaine_8\NN|NONE (r_pobj) of_7\IN|intravenous (r_prep) administration_6\NN|and (r_pobj) to_4\IN|arrhythmias|direct (r_prep) responded_3\VBD|in|pacing|;|.|was (l_nsubj) arrhythmias_2\NNS|to|direct
D002746_D013617 NONE Thorazine_7\NN|NONE (r_dobj) receiving_6\VBG|one (r_acl) patient_5\NN|NONE (r_pobj) in_3\IN|.|tachycardia (r_prep) developed_2\VBN|NONE (l_nsubj) tachycardia_1\NN|.|in
D002746_D013617 NONE chlorpromazine_9\NN|NONE (r_appos) Thorazine_7\NN|NONE (r_dobj) receiving_6\VBG|one (r_acl) patient_5\NN|NONE (r_pobj) in_3\IN|.|tachycardia (r_prep) developed_2\VBN|NONE (l_nsubj) tachycardia_1\NN|.|in
D010640_D005117 NONE phenothiazines_16\NNS|NONE (r_dobj) receiving_15\VBG|NONE (r_acl) patients_14\NNS|NONE (r_pobj) to_13\IN|cardiac (r_prep) complications_12\NNS|NONE
D011433_D001145 NONE propranolol_27\NN|NONE (r_pobj) of_26\IN|and|administration|some|combined (r_prep) instances_22\NNS|NONE (r_pobj) in_20\IN|pacing|;|.|responded|was (r_prep) required_19\VBN|NONE (l_ccomp) responded_3\VBD|in|pacing|;|.|was (l_nsubj) arrhythmias_2\NNS|to|direct
D013881_D017180 CID Mellaril_8\NNP|be|was|,|receiving|. (r_nsubj) appeared_12\VBD|NONE (l_xcomp) be_14\VB|was|,|Mellaril|receiving|. (l_acomp) responsible_15\JJ|to (l_prep) for_16\IN|NONE (l_pobj) cases_18\NNS|NONE (l_prep) of_19\IN|,|five (l_pobj) tachycardia_21\NN|NONE
D013881_D017180 CID thioridazine_10\NNP|) (r_appos) Mellaril_8\NNP|be|was|,|receiving|. (r_nsubj) appeared_12\VBD|NONE (l_xcomp) be_14\VB|was|,|Mellaril|receiving|. (l_acomp) responsible_15\JJ|to (l_prep) for_16\IN|NONE (l_pobj) cases_18\NNS|NONE (l_prep) of_19\IN|,|five (l_pobj) tachycardia_21\NN|NONE
15130900
D003520_D001749 CID cyclophosphamide_12\NN|NONE (r_pobj) to_11\IN|and|relation (r_prep) risks_8\NNS|Wegener|: (r_appos) granulomatosis_6\NN|NONE (r_pobj) in_3\IN|.|bladder|Urinary (r_prep) cancer_2\NN|NONE
D003520_D001749 CID cyclophosphamide_16\NN|NONE (r_pobj) to_15\IN|,|its|in (r_prep) relation_14\NN|and|To|and|,|characterise (r_conj) assess_3\VB|.|: (l_conj) characterise_5\VB|and|To|and|relation|, (l_dobj) risk_7\NN|NONE (l_prep) of_8\IN|the (l_pobj) cancer_10\NN|NONE
D003520_D001749 CID cyclophosphamide_18\NN|NONE (l_conj) cancer_21\NN|and
D003520_D001749 CID cyclophosphamide_12\NN|NONE (r_pobj) in_11\IN|g||every|(|OR (r_prep) increment_10\NN|NONE (r_pobj) for_6\IN|risk|. (r_prep) doubled_5\VBD|NONE (l_nsubj) risk_1\NN|for|. (l_prep) of_2\IN|The (l_pobj) cancer_4\NN|NONE
D003520_D001749 CID cyclophosphamide_9\NN|NONE (r_pobj) between_8\IN|response|a|risk|and (r_prep) relationship_7\NN|results|. (l_conj) risk_12\NN|response|a|and|between (l_prep) of_13\IN|,|risks|the (l_pobj) cancer_15\NN|NONE
D003520_D014890 NONE cyclophosphamide_12\NN|NONE (r_pobj) to_11\IN|and|relation (r_prep) risks_8\NNS|Wegener|: (r_appos) granulomatosis_6\NN|NONE
D003520_D014890 NONE cyclophosphamide_16\NN|NONE (r_pobj) to_15\IN|,|its|in (r_prep) relation_14\NN|and|To|and|,|characterise (l_prep) in_18\IN|,|its|to (l_pobj) patients_19\NNS|NONE (l_prep) with_20\IN|NONE (l_pobj) granulomatosis_23\NN|NONE
D003520_D014890 NONE cyclophosphamide_9\NN|NONE (r_pobj) between_8\IN|response|a|risk|and (r_prep) relationship_7\NN|results|. (l_conj) risk_12\NN|response|a|and|between (l_conj) risks_19\NNS|of|,|the (l_conj) possibility_28\NN|in|cumulative|,|high|and (l_prep) of_29\IN|the (l_pobj) factors_31\NNS|NONE (l_acl) operating_32\VBG|risk (l_prep) before_34\IN|NONE (l_pobj) granulomatosis_37\NN|even
18162529
D012313_D006966 NONE acid_5\NN|prolactin|messenger|signaling|Hypothalamic|, (r_compound) levels_6\NNS|dependent|. (l_conj) signaling_9\NN|acid|prolactin|messenger|Hypothalamic|, (l_conj) inhibition_13\NN|,|and|prolactin (l_amod) hyperprolactinemic_12\JJ|of
D004298_D006966 NONE dopamine_5\NN|NONE (r_compound) antagonist_6\NN|the (r_compound) sulpiride_7\NN|NONE (r_pobj) by_3\IN|NONE (r_agent) induced_2\VBN|Chronic (r_acl) hyperprolactinemia_1\NN|.|but|in|,|frequency
D013469_D006966 CID sulpiride_7\NN|NONE (r_pobj) by_3\IN|NONE (r_agent) induced_2\VBN|Chronic (r_acl) hyperprolactinemia_1\NN|.|but|in|,|frequency
D004967_D006966 NONE estrogen_20\NN| (r_npadvmod) induced_22\VBN|LH|the (r_amod) surge_24\NN|LH|and|pulsatile (r_conj) secretion_17\NN|neuroendocrine|necessary|two|: (r_appos) parameters_9\NNS|hyperprolactinemia|whether (r_dobj) inhibited_6\VBD|first|.|We (l_nsubj) hyperprolactinemia_5\NN|whether|parameters
D013256_D006966 NONE steroid_14\NN| (r_npadvmod) dependent_16\JJ|a (r_amod) manner_17\NN|NONE (r_pobj) in_12\IN|is|by|frequency|that (r_prep) inhibited_8\VBN|.|data (l_agent) by_9\IN|is|frequency|that|in (l_pobj) hyperprolactinemia_11\NN|NONE
D004958_D006966 NONE estradiol_22\NN|NONE (r_pobj) on_21\IN|NONE (r_prep) dependent_20\JJ|levels|. (r_acomp) are_19\VBP|NONE (l_nsubj) levels_6\NNS|dependent|. (l_conj) signaling_9\NN|acid|prolactin|messenger|Hypothalamic|, (l_conj) inhibition_13\NN|,|and|prolactin (l_amod) hyperprolactinemic_12\JJ|of
D004958_D006966 NONE estradiol_30\NN|NONE (r_pobj) of_29\IN|low|chronic (r_prep) levels_28\NNS|NONE (r_pobj) of_25\IN|the (r_prep) presence_24\NN|only (r_pobj) in_22\IN|hyperprolactinemia|.|but|,|frequency (r_conj) caused_8\VBD|NONE (l_nsubj) hyperprolactinemia_1\NN|.|but|in|,|frequency
11426838
C050232_D064420 NONE tolylguanidine_22\NN|agonist|and|)|BD|the (r_nmod) DTG_24\NNP|,|putative|the (r_appos) antagonists_9\NNS|NONE (r_pobj) by_6\IN|NONE (r_agent) provided_5\VBN|the (r_acl) protection_4\NN|NONE (r_pobj) to_2\IN|NONE (r_prep) contrast_1\NN|NONE (r_pobj) In_0\IN|.|each|toxicity (r_prep) worsened_37\VBD|NONE (l_dobj) toxicity_40\NN|In|.|each
C050232_D064420 NONE DTG_24\NNP|,|putative|the (r_appos) antagonists_9\NNS|NONE (r_pobj) by_6\IN|NONE (r_agent) provided_5\VBN|the (r_acl) protection_4\NN|NONE (r_pobj) to_2\IN|NONE (r_prep) contrast_1\NN|NONE (r_pobj) In_0\IN|.|each|toxicity (r_prep) worsened_37\VBD|NONE (l_dobj) toxicity_40\NN|In|.|each
-1_D012640 NONE BD1018_10\NN|NONE (r_pobj) with_9\IN|treatment|significantly (r_punct) attenuated_17\VBD|and|induced|lethality (r_amod) convulsions_21\NNS|studies|.
-1_D012640 NONE LR132_15\NNS|or|, (r_conj) BD1063_12\NNP|, (r_conj) BD1018_10\NN|NONE (r_pobj) with_9\IN|treatment|significantly (r_punct) attenuated_17\VBD|and|induced|lethality (r_amod) convulsions_21\NNS|studies|.
D009838_D012640 NONE oligodeoxynucleotide_23\NN|,|sigma (r_appos) receptors_19\NNS|NONE (r_pobj) of_17\IN|NONE (r_prep) antagonism_16\NN|NONE (r_dobj) involved_15\VBD|novel|the (r_acl) ligands_14\NNS|NONE (r_pobj) of_11\IN|cocaine|the (r_prep) effects_10\NNS|that|was|also|attenuate (r_nsubjpass) shown_29\VBN|the (l_xcomp) attenuate_32\VB|that|effects|was|also (l_dobj) effects_38\NNS|significantly|to (l_amod) convulsive_34\JJ|stimulatory|the|of
D003042_D064420 NONE cocaine_42\NN|NONE (r_pobj) of_41\IN|behavioral|the (r_prep) toxicity_40\NN|In|.|each
D003042_D012640 CID cocaine_18\NN| (r_npadvmod) induced_20\VBN|and|attenuated|lethality (r_amod) convulsions_21\NNS|studies|.
D003042_D012640 CID cocaine_9\NN|of|the (r_compound) effects_10\NNS|that|was|also|attenuate (r_nsubjpass) shown_29\VBN|the (l_xcomp) attenuate_32\VB|that|effects|was|also (l_dobj) effects_38\NNS|significantly|to (l_amod) convulsive_34\JJ|stimulatory|the|of
D003042_D012640 CID cocaine_40\NN|NONE (r_pobj) of_39\IN|stimulatory|the|convulsive (r_prep) effects_38\NNS|significantly|to (l_amod) convulsive_34\JJ|stimulatory|the|of
C093337_D012640 NONE BD1063_12\NNP|, (r_conj) BD1018_10\NN|NONE (r_pobj) with_9\IN|treatment|significantly (r_punct) attenuated_17\VBD|and|induced|lethality (r_amod) convulsions_21\NNS|studies|.
-1_D064420 NONE BD1031_32\NN|agonist|tolylguanidine|and|)|the (r_conj) DTG_24\NNP|,|putative|the (r_appos) antagonists_9\NNS|NONE (r_pobj) by_6\IN|NONE (r_agent) provided_5\VBN|the (r_acl) protection_4\NN|NONE (r_pobj) to_2\IN|NONE (r_prep) contrast_1\NN|NONE (r_pobj) In_0\IN|.|each|toxicity (r_prep) worsened_37\VBD|NONE (l_dobj) toxicity_40\NN|In|.|each
-1_D064420 NONE 3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane_34\NN|novel|the|agonist (r_appos) BD1031_32\NN|agonist|tolylguanidine|and|)|the (r_conj) DTG_24\NNP|,|putative|the (r_appos) antagonists_9\NNS|NONE (r_pobj) by_6\IN|NONE (r_agent) provided_5\VBN|the (r_acl) protection_4\NN|NONE (r_pobj) to_2\IN|NONE (r_prep) contrast_1\NN|NONE (r_pobj) In_0\IN|.|each|toxicity (r_prep) worsened_37\VBD|NONE (l_dobj) toxicity_40\NN|In|.|each
9214597
D004967_D010911 NONE estrogen_14\NN| (r_npadvmod) induced_16\VBN|NONE (r_amod) rat_17\NN|pituitary (r_nmod) tumors_19\NNS|NONE
D004967_D010911 NONE estrogen_22\NN| (r_npadvmod) initiated_24\VBN|tumor (r_amod) angiogenesis_26\NN|Over|may|. (r_dobj) mediate_21\VB|NONE (l_prep) Over_0\IN|angiogenesis|may|. (l_pobj) expression_1\NN|NONE (l_prep) of_2\IN|NONE (l_pobj) factor_6\NN|NONE (l_conj) receptor_9\NN|vascular|and|growth|endothelial (l_prep) during_10\IN|its (l_pobj) development_12\NN|NONE (l_prep) of_13\IN|the (l_pobj) tumors_19\NNS|NONE
D004967_D009369 NONE estrogen_14\NN| (r_npadvmod) induced_16\VBN|NONE (r_amod) rat_17\NN|pituitary (r_nmod) tumors_19\NNS|NONE (r_pobj) of_13\IN|the (r_prep) development_12\NN|NONE (r_pobj) during_10\IN|its (r_prep) receptor_9\NN|vascular|and|growth|endothelial (r_conj) factor_6\NN|NONE (r_pobj) of_2\IN|NONE (r_prep) expression_1\NN|NONE (r_pobj) Over_0\IN|angiogenesis|may|. (r_prep) mediate_21\VB|NONE (l_dobj) angiogenesis_26\NN|Over|may|. (l_compound) tumor_25\NN|initiated
D004967_D009369 NONE estrogen_22\NN| (r_npadvmod) initiated_24\VBN|tumor (r_amod) angiogenesis_26\NN|Over|may|. (l_compound) tumor_25\NN|initiated
D004967_D009369 NONE Estrogens_0\NNP|.|can|in|angiogenesis (l_relcl) associated_5\VBN|,|, (l_prep) with_6\IN|which|have|been (l_pobj) types_8\NNS|NONE (l_prep) of_9\IN|several (l_pobj) cancers_13\NNS|NONE
D004967_D009369 NONE Estrogens_0\NNP|.|can|in|angiogenesis (r_nsubj) induce_16\VB|NONE (l_dobj) angiogenesis_18\NN|.|can|in|Estrogens (l_compound) tumor_17\NN|NONE
D004967_D009369 NONE estrogen_9\NN|NONE (r_compound) carcinogenesis_10\NN|NONE (r_pobj) during_8\IN|still|,|.|details|,|unknown (r_prep) are_12\VBP|NONE (l_nsubj) details_2\NNS|still|,|.|,|unknown|during (l_prep) of_3\IN|mechanistic|The|induction (l_pobj) angiogenesis_5\NN|NONE (l_compound) tumor_4\NN|NONE
D004967_D009369 NONE estrogen_5\NN|NONE (r_pobj) of_4\IN|the (r_prep) role_3\NN|in|To (r_dobj) elucidate_1\VB|using|density|,|was (l_prep) in_6\IN|role|To (l_pobj) regulation_8\NN|NONE (l_prep) of_9\IN|in|the (l_pobj) angiogenesis_11\NN|NONE (l_compound) tumor_10\NN|NONE
D004967_D009369 NONE estrogen_27\NN|NONE (r_pobj) of_26\IN|the (r_prep) regulation_25\NN|NONE (r_pobj) of_23\IN|the|initial (r_prep) step_22\NN|NONE (r_pobj) in_19\IN|may|over|role|that (r_prep) play_15\VB|.|induced|findings (r_ccomp) suggest_2\VBP|NONE (l_ccomp) induced_28\VBN|.|findings|play (l_dobj) angiogenesis_30\NN|in (l_compound) tumor_29\NN|NONE
D004967_D063646 NONE estrogen_9\NN|NONE (r_compound) carcinogenesis_10\NN|NONE
11027904
D004091_D010146 NONE hydromorphone_38\NN|common (r_parataxis) opioid_36\NN|NONE (r_pobj) of_34\IN|therapeutic (r_prep) doses_33\NNS|NONE (r_pobj) of_31\IN|oral (r_prep) administration_30\NN|NONE (r_pobj) after_28\IN|both|and (r_conj) before_26\IN|By|.|agents|was|, (r_advmod) examined_23\VBN|NONE (l_prep) By_0\IN|.|agents|was|before|, (l_pcomp) using_1\VBG|NONE (l_dobj) tolerance_13\NN|,|design (l_prep) to_14\IN|NONE (l_pobj) pain_21\NN|NONE
D008691_D010146 NONE methadone_3\NN| (r_npadvmod) maintained_5\VBN|opioid (r_amod) abusers_7\NNS|NONE (r_pobj) in_2\IN|Pain|. (r_prep) responses_1\NNS|NONE (l_compound) Pain_0\NN|in|.
D008691_D010146 NONE methadone_19\NN| (r_compound) maintenance_21\NN|n|(|(|MM|)|)| (r_nmod) treatment_25\NN|NONE (r_pobj) in_18\IN|in (r_prep) stabilized_17\VBD|a|of (r_acl) sample_13\NN|NONE (r_pobj) in_11\IN|response|pain|and (r_prep) tolerance_7\NN|to (l_compound) pain_6\NN|response|in|and
D008691_D009293 NONE methadone_19\NN| (r_compound) maintenance_21\NN|n|(|(|MM|)|)| (r_nmod) treatment_25\NN|NONE (r_pobj) in_18\IN|in (r_prep) stabilized_17\VBD|a|of (r_acl) sample_13\NN|NONE (l_prep) of_14\IN|stabilized|a (l_pobj) addicts_16\NNS|NONE
D020910_D010146 NONE ketorolac_48\RB|analgesic (r_nmod) agents_53\NNS|By|.|was|before|, (r_conj) examined_23\VBN|NONE (l_prep) By_0\IN|.|agents|was|before|, (l_pcomp) using_1\VBG|NONE (l_dobj) tolerance_13\NN|,|design (l_prep) to_14\IN|NONE (l_pobj) pain_21\NN|NONE
11263551
D016572_-1 NONE cyclosporine_18\NN|NONE (r_pobj) of_17\IN|side|a|rare (r_prep) effect_16\NN|and|diagnosed|Syndrome|. (r_attr) is_10\VBZ|NONE (l_nsubj) Syndrome_6\NNP|and|diagnosed|.|effect (l_appos) CIPS_8\NNP|inhibitor|)|The|Pain|(
D016559_-1 NONE tacrolimus_20\NN|or (r_conj) cyclosporine_18\NN|NONE (r_pobj) of_17\IN|side|a|rare (r_prep) effect_16\NN|and|diagnosed|Syndrome|. (r_attr) is_10\VBZ|NONE (l_nsubj) Syndrome_6\NNP|and|diagnosed|.|effect (l_appos) CIPS_8\NNP|inhibitor|)|The|Pain|(
D016572_D010146 CID cyclosporine-_3\NN|trough (r_nmod) levels_7\NNS|NONE (r_pobj) of_2\IN|administration|The|and (r_prep) reduction_1\NN|.|to (r_nsubj) led_15\VBD|NONE (l_prep) to_16\IN|.|reduction (l_pobj) relief_17\NN|NONE (l_prep) of_18\IN|NONE (l_pobj) pain_19\NN|NONE
D016572_D010146 CID cyclosporine_18\NN|NONE (r_pobj) of_17\IN|side|a|rare (r_prep) effect_16\NN|and|diagnosed|Syndrome|. (r_attr) is_10\VBZ|NONE (l_nsubj) Syndrome_6\NNP|and|diagnosed|.|effect (l_compound) Pain_5\NNP|inhibitor|CIPS|)|The|(
D016559_D010146 CID tacrolimus_5\VB|NONE (r_compound) trough_6\NN|cyclosporine (r_compound) levels_7\NNS|NONE (r_pobj) of_2\IN|administration|The|and (r_prep) reduction_1\NN|.|to (r_nsubj) led_15\VBD|NONE (l_prep) to_16\IN|.|reduction (l_pobj) relief_17\NN|NONE (l_prep) of_18\IN|NONE (l_pobj) pain_19\NN|NONE
D016559_D010146 CID tacrolimus_20\NN|or (r_conj) cyclosporine_18\NN|NONE (r_pobj) of_17\IN|side|a|rare (r_prep) effect_16\NN|and|diagnosed|Syndrome|. (r_attr) is_10\VBZ|NONE (l_nsubj) Syndrome_6\NNP|and|diagnosed|.|effect (l_compound) Pain_5\NNP|inhibitor|CIPS|)|The|(
D002118_D010146 NONE calcium_12\NN|NONE (r_compound) channel_13\NN|NONE (r_compound) blockers_14\NNS|NONE (r_pobj) of_11\IN|the (r_prep) administration_10\NN|The|of|and (r_conj) reduction_1\NN|.|to (r_nsubj) led_15\VBD|NONE (l_prep) to_16\IN|.|reduction (l_pobj) relief_17\NN|NONE (l_prep) of_18\IN|NONE (l_pobj) pain_19\NN|NONE
6286738
D002762_D054559 CID D3_5\NNP|NONE (r_pobj) of_3\IN|parenteral|Large|D|(|) (r_prep) doses_2\NNS|were|with|. (r_nsubjpass) associated_18\VBN|NONE (l_prep) with_19\IN|were|doses|. (l_pobj) hypercalcemia_21\NN|NONE (l_conj) hyperphosphatemia_23\NN|prolonged|,
D002762_D054559 CID D3_15\NNP|parenteral|of|Large|(|) (r_appos) doses_2\NNS|were|with|. (r_nsubjpass) associated_18\VBN|NONE (l_prep) with_19\IN|were|doses|. (l_pobj) hypercalcemia_21\NN|NONE (l_conj) hyperphosphatemia_23\NN|prolonged|,
D002762_D054559 CID D3_30\NNP|NONE (r_pobj) of_28\IN|large (r_prep) increases_27\NNS|,|and (r_conj) hyperphosphatemia_23\NN|prolonged|,
D002762_D064420 NONE D3_1\NN|.|in (r_compound) toxicity_2\NN|NONE
D002762_D064420 NONE D3_3\NNP|NONE (r_compound) toxicity_4\NN|NONE
D002762_D064420 NONE D3_3\NNP|NONE (r_compound) toxicity_4\NN|NONE (r_pobj) of_1\IN|NONE (r_prep) Signs_0\NNS|not|were|in (r_nsubjpass) observed_7\VBN|cows|,|.|commonly|died|however|signs|; (r_ccomp) developed_18\VBN|NONE (l_dobj) signs_20\NNS|observed|cows|,|.|commonly|died|however|; (l_prep) of_21\IN|severe (l_pobj) toxicity_24\NN|NONE
D002762_D064420 NONE D3_23\NNP|and|cows (r_compound) toxicity_24\NN|NONE (r_pobj) of_21\IN|severe (r_prep) signs_20\NNS|observed|cows|,|.|commonly|died|however|; (r_dobj) developed_18\VBN|NONE (l_ccomp) observed_7\VBN|cows|,|.|commonly|died|however|signs|; (l_nsubjpass) Signs_0\NNS|not|were|in (l_prep) of_1\IN|NONE (l_pobj) toxicity_4\NN|NONE
D002762_D064420 NONE D3_23\NNP|and|cows (r_compound) toxicity_24\NN|NONE
D002762_D064420 NONE D3_7\NN|NONE (r_pobj) of_5\IN|in|the|margin|and|extreme (r_prep) toxicity_4\NN|of
D002762_D064420 NONE D3_22\NNP|NONE (r_pobj) of_20\IN|NONE (r_prep) doses_19\NNS|NONE (r_pobj) between_18\IN|NONE (r_prep) safety_17\NN|NONE (r_pobj) of_16\IN|low|the (r_prep) margin_15\NN|in|the|and|extreme|of (r_conj) toxicity_4\NN|of
D002762_D064420 NONE D3_38\NNP|not|prevent|that|injected|can|be (r_nsubjpass) used_42\VBN|Because|we|.|, (r_ccomp) concluded_35\VBD|NONE (l_prep) Because_0\IN|we|.|used|, (l_pobj) toxicity_4\NN|of
D002762_D010319 NONE D3_7\NNP|NONE (r_pobj) with_5\IN|NONE (r_prep) treated_4\VBN|the (r_acl) cows_3\NNS|NONE (r_pobj) of_1\IN|NONE (r_prep) None_0\NN|during|signs (r_nsubj) showed_8\VBD|%|;|during|,|.|signs|however (l_dobj) signs_9\NNS|None|during (l_prep) of_10\IN|NONE (l_pobj) fever_12\NN|NONE
D002762_D010319 NONE D3_7\NNP|NONE (r_pobj) with_5\IN|NONE (r_prep) treated_4\VBN|the (r_acl) cows_3\NNS|NONE (r_pobj) of_1\IN|NONE (r_prep) None_0\NN|during|signs (r_nsubj) showed_8\VBD|%|;|during|,|.|signs|however (r_ccomp) developed_26\VBD|NONE (l_dobj) signs_28\NNS|%|;|during|showed|,|.|however (l_prep) of_29\IN|clinical (l_pobj) fever_31\NN|NONE
D002762_D010319 NONE D3_7\NN|NONE (r_pobj) of_5\IN|in|the|margin|and|extreme (r_prep) toxicity_4\NN|of (l_conj) margin_15\NN|in|the|and|extreme|of (l_prep) of_16\IN|low|the (l_pobj) safety_17\NN|NONE (l_prep) between_18\IN|NONE (l_pobj) doses_19\NNS|NONE (l_prep) of_20\IN|NONE (l_pobj) D3_22\NNP|NONE (l_relcl) prevent_24\VBP|vitamin (l_dobj) fever_26\NN|that
D002762_D010319 NONE D3_7\NN|NONE (r_pobj) of_5\IN|in|the|margin|and|extreme (r_prep) toxicity_4\NN|of (l_conj) margin_15\NN|in|the|and|extreme|of (l_prep) of_16\IN|low|the (l_pobj) safety_17\NN|NONE (l_prep) between_18\IN|NONE (l_pobj) doses_19\NNS|NONE (l_prep) of_20\IN|NONE (l_pobj) D3_22\NNP|NONE (l_relcl) prevent_24\VBP|vitamin (l_dobj) fever_26\NN|that (l_relcl) induce_30\VBP|and|milk|doses (l_dobj) fever_32\NN|that
D002762_D010319 NONE D3_7\NN|NONE (r_pobj) of_5\IN|in|the|margin|and|extreme (r_prep) toxicity_4\NN|of (r_pobj) Because_0\IN|we|.|used|, (r_prep) concluded_35\VBD|NONE (l_ccomp) used_42\VBN|Because|we|.|, (l_xcomp) prevent_45\VB|not|D|that|injected|can|be (l_dobj) fever_47\NN|to|practically
D002762_D010319 NONE D3_22\NNP|NONE (l_relcl) prevent_24\VBP|vitamin (l_dobj) fever_26\NN|that
D002762_D010319 NONE D3_22\NNP|NONE (l_relcl) prevent_24\VBP|vitamin (l_dobj) fever_26\NN|that (l_relcl) induce_30\VBP|and|milk|doses (l_dobj) fever_32\NN|that
D002762_D010319 NONE D3_22\NNP|NONE (r_pobj) of_20\IN|NONE (r_prep) doses_19\NNS|NONE (r_pobj) between_18\IN|NONE (r_prep) safety_17\NN|NONE (r_pobj) of_16\IN|low|the (r_prep) margin_15\NN|in|the|and|extreme|of (r_conj) toxicity_4\NN|of (r_pobj) Because_0\IN|we|.|used|, (r_prep) concluded_35\VBD|NONE (l_ccomp) used_42\VBN|Because|we|.|, (l_xcomp) prevent_45\VB|not|D|that|injected|can|be (l_dobj) fever_47\NN|to|practically
D002762_D010319 NONE D3_38\NNP|not|prevent|that|injected|can|be (r_nsubjpass) used_42\VBN|Because|we|.|, (r_ccomp) concluded_35\VBD|NONE (l_prep) Because_0\IN|we|.|used|, (l_pobj) toxicity_4\NN|of (l_conj) margin_15\NN|in|the|and|extreme|of (l_prep) of_16\IN|low|the (l_pobj) safety_17\NN|NONE (l_prep) between_18\IN|NONE (l_pobj) doses_19\NNS|NONE (l_prep) of_20\IN|NONE (l_pobj) D3_22\NNP|NONE (l_relcl) prevent_24\VBP|vitamin (l_dobj) fever_26\NN|that
D002762_D010319 NONE D3_38\NNP|not|prevent|that|injected|can|be (r_nsubjpass) used_42\VBN|Because|we|.|, (r_ccomp) concluded_35\VBD|NONE (l_prep) Because_0\IN|we|.|used|, (l_pobj) toxicity_4\NN|of (l_conj) margin_15\NN|in|the|and|extreme|of (l_prep) of_16\IN|low|the (l_pobj) safety_17\NN|NONE (l_prep) between_18\IN|NONE (l_pobj) doses_19\NNS|NONE (l_prep) of_20\IN|NONE (l_pobj) D3_22\NNP|NONE (l_relcl) prevent_24\VBP|vitamin (l_dobj) fever_26\NN|that (l_relcl) induce_30\VBP|and|milk|doses (l_dobj) fever_32\NN|that
D002762_D010319 NONE D3_38\NNP|not|prevent|that|injected|can|be (r_nsubjpass) used_42\VBN|Because|we|.|, (l_xcomp) prevent_45\VB|not|D|that|injected|can|be (l_dobj) fever_47\NN|to|practically
D002762_D006934 CID D3_5\NNP|NONE (r_pobj) of_3\IN|parenteral|Large|D|(|) (r_prep) doses_2\NNS|were|with|. (r_nsubjpass) associated_18\VBN|NONE (l_prep) with_19\IN|were|doses|. (l_pobj) hypercalcemia_21\NN|NONE
D002762_D006934 CID D3_15\NNP|parenteral|of|Large|(|) (r_appos) doses_2\NNS|were|with|. (r_nsubjpass) associated_18\VBN|NONE (l_prep) with_19\IN|were|doses|. (l_pobj) hypercalcemia_21\NN|NONE
D002762_D006934 CID D3_30\NNP|NONE (r_pobj) of_28\IN|large (r_prep) increases_27\NNS|,|and (r_conj) hyperphosphatemia_23\NN|prolonged|, (r_conj) hypercalcemia_21\NN|NONE
150790
D007538_D001523 NONE isoniazid_22\NN|NONE (r_pobj) of_21\IN|the|therapeutic (r_prep) administration_20\NN|NONE (r_pobj) after_17\IN|difficulties (r_prep) sleeping_15\VBG|,|and (r_conj) irritability_12\NN|,
D007538_D002653 CID isoniazid_8\NN|NONE (r_pobj) by_7\IN|NONE (r_agent) unmasked_6\VBD|.|behavioral|dependent|A (r_acl) disorder_5\NN|NONE
D007538_D002653 CID isoniazid_22\NN|NONE (r_pobj) of_21\IN|the|therapeutic (r_prep) administration_20\NN|NONE (r_pobj) after_17\IN|difficulties (r_prep) sleeping_15\VBG|,|and (r_conj) irritability_12\NN|, (r_conj) hyperkinesis_10\NN|NONE (r_pobj) with_9\IN|,|.|deterioration|girl (r_prep) had_5\VBD|NONE (l_dobj) deterioration_7\NN|with|,|.|girl
D007538_D012893 NONE isoniazid_22\NN|NONE (r_pobj) of_21\IN|the|therapeutic (r_prep) administration_20\NN|NONE (r_pobj) after_17\IN|difficulties (r_prep) sleeping_15\VBG|,|and (l_dobj) difficulties_16\NNS|after
D011736_D006948 NONE pyridoxine_3\NN|NONE (r_pobj) of_2\IN|Periodic (r_prep) withdrawal_1\NN|was|with|. (r_nsubjpass) associated_5\VBN|NONE (l_prep) with_6\IN|was|.|withdrawal (l_pobj) return_7\NN|NONE (l_prep) of_8\IN|NONE (l_pobj) hyperkinesis_10\NN|NONE
D007538_D006948 CID isoniazid_22\NN|NONE (r_pobj) of_21\IN|the|therapeutic (r_prep) administration_20\NN|NONE (r_pobj) after_17\IN|difficulties (r_prep) sleeping_15\VBG|,|and (r_conj) irritability_12\NN|, (r_conj) hyperkinesis_10\NN|NONE
D011736_D002653 NONE pyridoxine_1\JJ| (r_advmod) dependent_3\JJ|.|unmasked|behavioral|A (r_amod) disorder_5\NN|NONE
1700207
D012964_D001145 NONE Na_7\NNP|channel (r_compound) blockers_9\NNS|NONE (r_pobj) by_6\IN|which|is (r_agent) suppressed_5\VBN|Digitalis|,|, (r_relcl) arrhythmia_1\NN|was|by|.
D006221_D001145 NONE halothane_17\NN| (r_npadvmod) anesthetized_19\VBN|NONE (r_amod) dogs_20\NNS|NONE (r_pobj) in_16\IN|adrenaline (r_prep) infusion_15\NN|NONE (r_pobj) by_13\IN|.|was|arrhythmia (r_agent) induced_12\VBN|NONE (l_nsubjpass) arrhythmia_1\NN|.|was|by
D010424_D001145 NONE pentobarbital_23\NN| (r_npadvmod) anesthetized_25\VBN|NONE (r_amod) dogs_26\NNS|NONE (r_pobj) in_22\IN|(|)|of|i.v. (r_prep) injection_19\NN|intermittent (r_appos) intravenous_15\JJ|NONE (r_pobj) by_13\IN|was|arrhythmia|. (r_agent) induced_12\VBN|NONE (l_nsubjpass) arrhythmia_1\NN|was|by|.
C032151_D001145 NONE cibenzoline_6\NN|NONE (l_prep) on_7\IN|NONE (l_pobj) arrhythmias_10\NNS|NONE
C032151_D001145 NONE -cibenzoline_6\:|(|+ (r_conj) of_2\IN|and|examined|Antiarrhythmic (r_prep) effects_1\NNS|NONE (l_conj) examined_11\VBN|of|and|Antiarrhythmic (l_advcl) using_12\VBG|(|.|)cibenzoline|were (l_dobj) models_17\NNS|NONE (l_compound) arrhythmia_16\NN|two|canine
C032151_D001145 NONE -)-cibenzoline_9\:|(|.|using|were (r_nsubjpass) examined_11\VBN|of|and|Antiarrhythmic (l_advcl) using_12\VBG|(|.|)cibenzoline|were (l_dobj) models_17\NNS|NONE (l_compound) arrhythmia_16\NN|two|canine
C032151_D001145 NONE -cibenzoline_8\,|) (r_punct) suppressed_9\VBN|.|respectively|i.v.|digitalis|, (r_amod) arrhythmias_15\NNS|NONE
C032151_D001145 NONE -cibenzoline_9\:|arrhythmias (r_punct) for_10\IN|effective|of|plasma|The|minimum (l_pobj) arrhythmias_16\NNS|cibenzoline
C032151_D001145 NONE -)-cibenzoline_9\NNP|(|arrhythmia|, (r_nsubj) suppressed_10\VBD|NONE (l_dobj) arrhythmia_15\NN|(|)cibenzoline|,
C032151_D001145 NONE -)-cibenzoline_9\NNP|(|arrhythmia|, (r_nsubj) suppressed_10\VBD|NONE (r_pcomp) of_7\IN|NONE (r_prep) i.v._6\NN|lower|of|A (r_appos) dose_2\NN|whereas|.|was|mg/kg|suppress (r_nsubjpass) needed_22\VBN|NONE (l_advcl) suppress_24\VB|whereas|.|was|dose|mg/kg (l_dobj) arrhythmias_28\NNS|to
C032151_D001145 NONE -)-cibenzoline_7\:|minimum|The|effective|of|plasma (l_prep) for_8\IN|( (l_pobj) arrhythmia_14\NN|NONE
D004070_D001145 NONE Digitalis_0\NNP|,|suppressed|, (r_compound) arrhythmia_1\NN|was|by|.
D004070_D001145 NONE digitalis-_10\NN|.|suppressed|respectively|i.v.|, (r_amod) arrhythmias_15\NNS|NONE
D004070_D001145 NONE digitalis-_11\NN|NONE (r_amod) arrhythmias_16\NNS|cibenzoline
D004070_D001145 NONE digitalis_12\NN| (r_npadvmod) induced_14\VBN|the (r_amod) arrhythmia_15\NN|(|)cibenzoline|,
D004070_D001145 NONE digitalis_12\NN| (r_npadvmod) induced_14\VBN|the (r_amod) arrhythmia_15\NN|(|)cibenzoline|, (r_dobj) suppressed_10\VBD|NONE (r_pcomp) of_7\IN|NONE (r_prep) i.v._6\NN|lower|of|A (r_appos) dose_2\NN|whereas|.|was|mg/kg|suppress (r_nsubjpass) needed_22\VBN|NONE (l_advcl) suppress_24\VB|whereas|.|was|dose|mg/kg (l_dobj) arrhythmias_28\NNS|to
D004070_D001145 NONE digitalis-_9\NN|NONE (r_amod) arrhythmia_14\NN|NONE
D004837_D001145 CID adrenaline_14\NN|in (r_amod) infusion_15\NN|NONE (r_pobj) by_13\IN|.|was|arrhythmia (r_agent) induced_12\VBN|NONE (l_nsubjpass) arrhythmia_1\NN|.|was|by
D004837_D001145 CID adrenaline_12\NN| (r_npadvmod) induced_14\VBN|and (r_conj) digitalis-_10\NN|.|suppressed|respectively|i.v.|, (r_amod) arrhythmias_15\NNS|NONE
D004837_D001145 CID adrenaline_13\NN| (r_npadvmod) induced_15\VBN|and (r_conj) digitalis-_11\NN|NONE (r_amod) arrhythmias_16\NNS|cibenzoline
D004837_D001145 CID adrenaline_25\NN| (r_npadvmod) induced_27\VBN|NONE (r_amod) arrhythmias_28\NNS|to (r_dobj) suppress_24\VB|whereas|.|was|dose|mg/kg (r_advcl) needed_22\VBN|NONE (l_nsubjpass) dose_2\NN|whereas|.|was|mg/kg|suppress (l_appos) i.v._6\NN|lower|of|A (l_prep) of_7\IN|NONE (l_pcomp) suppressed_10\VBD|NONE (l_dobj) arrhythmia_15\NN|(|)cibenzoline|,
D004837_D001145 CID adrenaline_25\NN| (r_npadvmod) induced_27\VBN|NONE (r_amod) arrhythmias_28\NNS|to
D004837_D001145 CID adrenaline_11\NN| (r_npadvmod) induced_13\VBN|and (r_conj) digitalis-_9\NN|NONE (r_amod) arrhythmia_14\NN|NONE
D010042_D001145 CID ouabain_21\NN|NONE (r_pobj) of_20\IN|(|)|in|i.v. (r_prep) injection_19\NN|intermittent (r_appos) intravenous_15\JJ|NONE (r_pobj) by_13\IN|was|arrhythmia|. (r_agent) induced_12\VBN|NONE (l_nsubjpass) arrhythmia_1\NN|was|by|.
D002118_D001145 NONE Ca_7\NNP|NONE (r_aux) channel_8\NN|NONE (r_compound) blockers_9\NNS|NONE (r_pobj) by_6\IN|which|is (r_agent) suppressed_5\VBN|,|Adrenaline|, (r_relcl) arrhythmia_1\NN|.|was|by
8741744
D009538_D009069 NONE nicotine_29\NN|NONE (r_pobj) by_28\IN|NONE (r_agent) caused_27\VBN|locomotor|)|kg(|(|i.m.|early|the|field|(|,|)|min|) (r_acl) hypoactivity_26\NN|,|lesions|enhanced|.|Compared|,
D009538_D009069 NONE nicotine_48\NN| (r_npadvmod) induced_50\VBN|(|later|the|min (r_amod) hyperactivity_51\NN|and|,|raised (r_dobj) enhanced_39\VBD|,|hypoactivity|lesions|.|Compared|, (r_advcl) blunted_14\VBD|NONE (l_dobj) hypoactivity_26\NN|,|lesions|enhanced|.|Compared|,
D009538_D006948 CID nicotine_29\NN|NONE (r_pobj) by_28\IN|NONE (r_agent) caused_27\VBN|locomotor|)|kg(|(|i.m.|early|the|field|(|,|)|min|) (r_acl) hypoactivity_26\NN|,|lesions|enhanced|.|Compared|, (r_dobj) blunted_14\VBD|NONE (l_advcl) enhanced_39\VBD|,|hypoactivity|lesions|.|Compared|, (l_dobj) hyperactivity_51\NN|and|,|raised
D009538_D006948 CID nicotine_48\NN| (r_npadvmod) induced_50\VBN|(|later|the|min (r_amod) hyperactivity_51\NN|and|,|raised
10027919
D002117_D001851 CID Calcitriol_0\NNP|NONE (r_compound) therapy_1\NN|levels|has|in|.|but (r_nsubj) suppresses_2\VBZ|NONE (l_conj) has_17\VBZ|levels|therapy|in|.|but (l_dobj) drawbacks_19\NNS|NONE (l_prep) including_21\VBG|,|several (l_pobj) hypercalcemia_22\NN|NONE (l_conj) suppression_25\NN|and/or (l_prep) of_26\IN|marked (l_pobj) turnover_28\NN|NONE
D002117_D001851 CID Calcitriol_0\NNP|NONE (r_compound) therapy_1\NN|levels|has|in|.|but (r_nsubj) suppresses_2\VBZ|NONE (l_conj) has_17\VBZ|levels|therapy|in|.|but (l_dobj) drawbacks_19\NNS|NONE (l_prep) including_21\VBG|,|several (l_pobj) hypercalcemia_22\NN|NONE (l_conj) suppression_25\NN|and/or (l_prep) of_26\IN|marked (l_pobj) turnover_28\NN|NONE (l_relcl) lead_32\VB|,|bone (l_prep) to_33\IN|may|which (l_pobj) disease_36\NN|NONE
C051883_D051437 NONE 22-oxacalcitriol_0\JJ|.|hyperparathyroidism|without (r_nsubj) suppresses_1\VBZ|NONE (l_prep) without_4\IN|.|oxacalcitriol|hyperparathyroidism (l_pcomp) inducing_5\VBG|NONE (l_dobj) turnover_8\NN|NONE (l_prep) in_9\IN|bone|low (l_pobj) dogs_10\NNS|NONE (l_prep) with_11\IN|NONE (l_pobj) failure_13\NN|NONE
C051883_D051437 NONE OCT_4\NNP|,|levels|In|after|significantly|. (r_nsubj) decreased_6\VBD|NONE (l_prep) after_11\IN|OCT|,|levels|In|significantly|. (l_pobj) induction_13\NN|soon (l_prep) of_14\IN|the (l_pobj) insufficiency_16\NN|NONE
C051883_D051437 NONE OCT_6\NNP|though|does|even|not|completely|occurrence (r_nsubj) prevent_10\VB|it|that|induce|,|may|of|in (l_dobj) occurrence_12\NN|though|does|even|OCT|not|completely (l_prep) in_15\IN|of|the (l_pobj) dogs_17\NNS|NONE (l_prep) with_18\IN|experimental (l_pobj) insufficiency_20\NN|NONE
C051883_D007674 NONE OCT_9\NNP|NONE (r_pobj) of_8\IN|the|on (r_prep) effects_7\NNS|to (l_prep) on_10\IN|of|the (l_pobj) levels_13\NNS|NONE (l_conj) turnover_16\NN|serum|PTH|and (l_prep) in_17\IN|bone (l_pobj) states_18\NNS|NONE (l_prep) of_19\IN|NONE (l_pobj) function_24\NN|NONE
D002117_D006934 CID Calcitriol_0\NNP|NONE (r_compound) therapy_1\NN|levels|has|in|.|but (r_nsubj) suppresses_2\VBZ|NONE (l_conj) has_17\VBZ|levels|therapy|in|.|but (l_dobj) drawbacks_19\NNS|NONE (l_prep) including_21\VBG|,|several (l_pobj) hypercalcemia_22\NN|NONE
C051883_D006962 NONE 22-oxacalcitriol_0\JJ|.|hyperparathyroidism|without (r_nsubj) suppresses_1\VBZ|NONE (l_dobj) hyperparathyroidism_3\NN|.|oxacalcitriol|without
C051883_D006962 NONE OCT_7\NNP|In|,|during|.|levels (r_nsubj) stabilized_14\VBD|NONE (l_prep) In_0\IN|,|during|.|levels|OCT (l_pobj) hyperparathyroidism_5\NN|NONE
C051883_D006962 NONE OCT_6\NNP|though|does|even|not|completely|occurrence (r_nsubj) prevent_10\VB|it|that|induce|,|may|of|in (r_advcl) be_24\VB|results|. (l_prep) in_27\IN|it|that|induce|,|may|of|prevent (l_pobj) management_29\NN|NONE (l_prep) of_30\IN|the (l_pobj) hyperparathyroidism_32\NN|NONE
C051883_D001851 NONE 22-oxacalcitriol_0\JJ|.|hyperparathyroidism|without (r_nsubj) suppresses_1\VBZ|NONE (l_prep) without_4\IN|.|oxacalcitriol|hyperparathyroidism (l_pcomp) inducing_5\VBG|NONE (l_dobj) turnover_8\NN|NONE
C051883_D001851 NONE OCT_6\NNP|though|does|even|not|completely|occurrence (r_nsubj) prevent_10\VB|it|that|induce|,|may|of|in (r_advcl) be_24\VB|results|. (l_advcl) induce_37\VB|it|that|,|may|of|prevent|in (l_dobj) turnover_40\NN|,|it|does|because|increase|and|not
C051883_D001851 NONE OCT_6\NNP|though|does|even|not|completely|occurrence (r_nsubj) prevent_10\VB|it|that|induce|,|may|of|in (r_advcl) be_24\VB|results|. (l_advcl) induce_37\VB|it|that|,|may|of|prevent|in (l_conj) increase_47\VB|,|turnover|it|does|because|and|not (l_dobj) risk_49\NN|not|therefore|does|, (l_prep) of_50\IN|the (l_pobj) disease_53\NN|NONE
C051883_D005355 NONE OCT_4\NNP|but|,|In|alter|,|.|formation (r_nsubj) reversed_5\VBD|NONE (l_dobj) formation_8\NN|but|,|In|alter|,|OCT|. (l_prep) as_11\IN|bone|,|abnormal (l_pobj) osteoid_13\NN|such (l_conj) fibrosis_15\NN|and|woven
C051883_D006934 CID OCT_6\NNP|though|does|even|not|completely|occurrence (r_nsubj) prevent_10\VB|it|that|induce|,|may|of|in (l_dobj) occurrence_12\NN|though|does|even|OCT|not|completely (l_prep) of_13\IN|in|the (l_pobj) hypercalcemia_14\NN|NONE
D002117_D051437 NONE Calcitriol_0\NNP|NONE (r_compound) therapy_1\NN|levels|has|in|.|but (r_nsubj) suppresses_2\VBZ|NONE (l_prep) in_11\IN|levels|has|therapy|.|but (l_pobj) patients_12\NNS|NONE (l_prep) with_13\IN|NONE (l_pobj) failure_15\NN|NONE
C051883_-1 NONE OCT_4\NNP|but|,|In|alter|,|.|formation (r_nsubj) reversed_5\VBD|NONE (l_dobj) formation_8\NN|but|,|In|alter|,|OCT|. (l_prep) as_11\IN|bone|,|abnormal (l_pobj) osteoid_13\NN|such
17343925
D012906_D034381 CID smoking_3\NN|NONE (r_pobj) of_2\IN|The (r_prep) influence_1\NN|has|,|associated|not|.|been (r_nsubjpass) estimated_13\VBN|NONE (l_advcl) associated_20\VBN|has|,|influence|not|.|been (l_prep) with_21\IN|has|been|smoking|although|positively (l_pcomp) hearing_22\VBG|NONE (l_dobj) loss_23\NN|NONE
D012906_D034381 CID smoking_16\NN|has|been|with|although|positively (r_nsubjpass) associated_20\VBN|has|,|influence|not|.|been (l_prep) with_21\IN|has|been|smoking|although|positively (l_pcomp) hearing_22\VBG|NONE (l_dobj) loss_23\NN|NONE
20558148
D006220_D002375 CID haloperidol_12\NN| (r_npadvmod) induced_14\VBN|NONE (r_amod) catalepsy_15\NN|can|.|neurotransmission
D006220_D002375 CID haloperidol_25\NN|receptor|the (r_appos) blocker_24\NN|NONE (r_pobj) by_20\IN|NONE (r_agent) induced_19\VBN|the (r_acl) catalepsy_18\NN|NONE
D006220_D002375 CID Haloperidol_0\NN| (r_npadvmod) induced_2\VBN|NONE (r_amod) catalepsy_3\NN|microl|.|microl|with|was|)
D006220_D002375 CID haloperidol_15\NN|NONE (r_pobj) of_14\IN|systemic (r_prep) injections_13\NNS|NONE (r_pobj) to_11\IN|NONE (r_prep) previous_10\JJ|NONE (r_amod) AP7_9\RB|of|and|intracollicular|that (r_conj) microinjection_5\NN|results|attenuated|. (r_dobj) showed_2\VBD|NONE (l_ccomp) attenuated_17\VBD|microinjection|results|. (l_dobj) catalepsy_19\NN|indicated|significantly|,
D006220_D002375 CID haloperidol_17\NN| (r_npadvmod) induced_19\VBN|influence (r_amod) catalepsy_20\NN|NONE
D016291_D002375 NONE MK-801_16\NNP|of|(|)|and|mmol/.|AP|or| (r_punct) microl_22\NN|.|microl|catalepsy|with|was|) (r_dobj) challenged_5\VBN|NONE (l_nsubjpass) catalepsy_3\NN|microl|.|microl|with|was|)
D016291_D002375 NONE MK-801_7\NNP|NONE (r_punct) and_8\CC|of|AP|intracollicular|that (r_cc) microinjection_5\NN|results|attenuated|. (r_dobj) showed_2\VBD|NONE (l_ccomp) attenuated_17\VBD|microinjection|results|. (l_dobj) catalepsy_19\NN|indicated|significantly|,
D016202_D002375 NONE NMDA_4\NNP|NONE (r_compound) receptors_5\NNS|NONE (r_pobj) by_3\IN|in (r_agent) mediated_2\VBN|Glutamatergic (r_acl) neurotransmission_1\NN|can|catalepsy|. (r_nsubj) modulate_11\VB|NONE (l_dobj) catalepsy_15\NN|can|.|neurotransmission
D016202_D002375 NONE NMDA_12\NNP|NONE (r_compound) receptor_13\NN|glutamate|, (r_compound) antagonists_14\NNS|NONE (r_pobj) of_10\IN|prior|intracollicular (r_prep) microinjections_9\NNS|NONE (r_pobj) with_6\IN|microl|.|microl|catalepsy|was|) (r_prep) challenged_5\VBN|NONE (l_nsubjpass) catalepsy_3\NN|microl|.|microl|with|was|)
D016202_D002375 NONE NMDA_37\NNP|NMDA|the (r_compound) receptor_38\NN|NONE (r_pobj) of_35\IN|MK|(|)|and|mmol/.|AP|or| (r_prep) microl_22\NN|.|microl|catalepsy|with|was|) (r_dobj) challenged_5\VBN|NONE (l_nsubjpass) catalepsy_3\NN|microl|.|microl|with|was|)
D016202_D002375 NONE aspartate_46\NNP|agonist|(|, (r_nmod) NMDA_48\NNP|the|NMDA (r_appos) receptor_38\NN|NONE (r_pobj) of_35\IN|MK|(|)|and|mmol/.|AP|or| (r_prep) microl_22\NN|.|microl|catalepsy|with|was|) (r_dobj) challenged_5\VBN|NONE (l_nsubjpass) catalepsy_3\NN|microl|.|microl|with|was|)
D016202_D002375 NONE NMDA_48\NNP|the|NMDA (r_appos) receptor_38\NN|NONE (r_pobj) of_35\IN|MK|(|)|and|mmol/.|AP|or| (r_prep) microl_22\NN|.|microl|catalepsy|with|was|) (r_dobj) challenged_5\VBN|NONE (l_nsubjpass) catalepsy_3\NN|microl|.|microl|with|was|)
C031231_D002375 NONE AP7_25\RB|of|MK|(|)|and|mmol/.|or| (r_conj) microl_22\NN|.|microl|catalepsy|with|was|) (r_dobj) challenged_5\VBN|NONE (l_nsubjpass) catalepsy_3\NN|microl|.|microl|with|was|)
C031231_D002375 NONE AP7_9\RB|of|and|intracollicular|that (r_conj) microinjection_5\NN|results|attenuated|. (r_dobj) showed_2\VBD|NONE (l_ccomp) attenuated_17\VBD|microinjection|results|. (l_dobj) catalepsy_19\NN|indicated|significantly|,
D000596_D002375 NONE acid_9\NN| (r_npadvmod) mediated_11\VBN|amino|excitatory (r_amod) mechanisms_12\NNS|NONE (r_pobj) of_6\IN|on|the|in (r_prep) influence_5\NN|study (l_prep) on_16\IN|of|the|in (l_pobj) catalepsy_18\NN|NONE
D004298_D002375 NONE dopamine_22\NN|NONE (r_compound) receptor_23\NN|haloperidol|the (r_compound) blocker_24\NN|NONE (r_pobj) by_20\IN|NONE (r_agent) induced_19\VBN|the (r_acl) catalepsy_18\NN|NONE
D018698_D002375 NONE glutamate_11\NN|receptor|, (r_compound) antagonists_14\NNS|NONE (r_pobj) of_10\IN|prior|intracollicular (r_prep) microinjections_9\NNS|NONE (r_pobj) with_6\IN|microl|.|microl|catalepsy|was|) (r_prep) challenged_5\VBN|NONE (l_nsubjpass) catalepsy_3\NN|microl|.|microl|with|was|)
D018698_D002375 NONE glutamate_4\NN| (r_npadvmod) mediated_6\VBN|and|participate|in|that (r_amod) mechanisms_7\NNS|findings|. (l_prep) in_8\IN|and|mediated|participate|that (l_pobj) circuits_11\NNS|NONE (l_prep) at_12\IN|the|neural (l_pobj) catalepsy_20\NN|NONE
12596116
D015282_D005402 NONE octreotide_10\NN|enhance|,|after|.|hypertension (r_advmod) developed_2\VBD|NONE (l_advcl) enhance_13\VB|octreotide|,|after|.|hypertension (l_dobj) resolution_14\NN|to (l_prep) of_15\IN|NONE (l_pobj) fistula_17\NN|NONE
D015282_D000860 NONE Octreotide_0\NNP|hypoxemia||. (r_npadvmod) induced_2\VBN|NONE (l_dobj) hypoxemia_3\NN||.|Octreotide
D015282_D006976 CID Octreotide_0\NNP|hypoxemia||. (r_npadvmod) induced_2\VBN|NONE (l_dobj) hypoxemia_3\NN||.|Octreotide (l_conj) hypertension_6\NN|in|and
D015282_D006976 CID octreotide_10\NN|enhance|,|after|.|hypertension (r_advmod) developed_2\VBD|NONE (l_nsubj) hypertension_1\NN|enhance|octreotide|,|after|.
10074612
D008775_D003645 NONE methylprednisolone_16\NN|NONE (r_pobj) of_14\IN|a|high (r_prep) dose_13\NN|NONE (r_pobj) after_10\IN|.|mechanisms|study (r_prep) reviews_2\VBZ|NONE (l_dobj) mechanisms_6\NNS|.|after|study (l_prep) of_7\IN|current|the|proposed (l_pobj) death_9\NN|NONE
D008775_D003645 NONE IVMP_18\NN|intravenous (r_appos) methylprednisolone_16\NN|NONE (r_pobj) of_14\IN|a|high (r_prep) dose_13\NN|NONE (r_pobj) after_10\IN|.|mechanisms|study (r_prep) reviews_2\VBZ|NONE (l_dobj) mechanisms_6\NNS|.|after|study (l_prep) of_7\IN|current|the|proposed (l_pobj) death_9\NN|NONE
D008775_D006323 CID methylprednisolone_11\NN|NONE (r_pobj) after_6\IN|NONE (r_prep) asystole_5\NN|,|and
D008775_D006323 CID methylprednisolone_18\NN|NONE (r_pobj) of_14\IN|in|intravenous (r_prep) administration_13\NN|NONE (r_pobj) after_11\IN|NONE (r_prep) asystole_10\NN|and|,
D008775_D001919 CID methylprednisolone_11\NN|NONE (r_pobj) after_6\IN|NONE (r_prep) asystole_5\NN|,|and (r_conj) bradycardia_2\NNP|,|.
D008775_D001919 CID methylprednisolone_18\NN|NONE (r_pobj) of_14\IN|in|intravenous (r_prep) administration_13\NN|NONE (r_pobj) after_11\IN|NONE (r_prep) asystole_10\NN|and|, (r_conj) bradycardia_7\NNP|,
D008775_D007022 CID methylprednisolone_11\NN|NONE (r_pobj) after_6\IN|NONE (r_prep) asystole_5\NN|,|and (r_conj) bradycardia_2\NNP|,|. (r_conj) Hypotension_0\NN|NONE
D008775_D007022 CID methylprednisolone_18\NN|NONE (r_pobj) of_14\IN|in|intravenous (r_prep) administration_13\NN|NONE (r_pobj) after_11\IN|NONE (r_prep) asystole_10\NN|and|, (r_conj) bradycardia_7\NNP|, (r_conj) hypotension_5\NN|NONE
11706060
D002118_D009202 NONE calcium_30\NN|sarcoplasmic|)|[|]|SERCA (r_compound) ATPase_31\NNP|factor|mRNA|and|(|ventricular (r_conj) encoding_21\VBG|of (r_parataxis) quantitation_10\NN|, (l_prep) of_11\IN|encoding (l_pobj) abundance_12\NN|NONE (l_prep) of_13\IN|NONE (l_pobj) markers_15\NNS|NONE (l_prep) of_16\IN|molecular (l_pobj) CM_17\NNP|NONE
D019344_D009202 NONE lactate_8\NN|in (r_dobj) elevates_6\VBZ|and|cardiomyopathy|.|therapy|Combined (r_conj) causes_3\VBZ|NONE (l_advmod) cardiomyopathy_4\NN|and|.|therapy|elevates|Combined
D019344_D009202 NONE lactate_18\NN|NONE (r_pobj) in_15\IN|CM|and (r_conj) in_9\IN|through|is|therapy|. (l_pobj) CM_12\NNP|in|and (l_amod) cardiomyopathy_10\NN|(|)
D019344_D009202 NONE lactate_18\NN|NONE (r_pobj) in_15\IN|CM|and (r_conj) in_9\IN|through|is|therapy|. (l_pobj) CM_12\NNP|in|and
D019344_D009202 NONE LA_20\NNP|elevated|)|plasma|in|( (r_appos) lactate_18\NN|NONE (r_pobj) in_15\IN|CM|and (r_conj) in_9\IN|through|is|therapy|. (l_pobj) CM_12\NNP|in|and (l_amod) cardiomyopathy_10\NN|(|)
D019344_D009202 NONE LA_20\NNP|elevated|)|plasma|in|( (r_appos) lactate_18\NN|NONE (r_pobj) in_15\IN|CM|and (r_conj) in_9\IN|through|is|therapy|. (l_pobj) CM_12\NNP|in|and
D019344_D009202 NONE LA_41\NNP|NONE (r_pobj) of_39\IN|NONE (r_prep) determination_38\NN|mice|,|.|At|,|echocardiography|and (r_conj) underwent_7\VBD|NONE (l_dobj) echocardiography_8\RB|determination|mice|,|.|At|,|and (l_appos) quantitation_10\NN|, (l_prep) of_11\IN|encoding (l_pobj) abundance_12\NN|NONE (l_prep) of_13\IN|NONE (l_pobj) markers_15\NNS|NONE (l_prep) of_16\IN|molecular (l_pobj) CM_17\NNP|NONE
D019344_D009202 NONE LA_10\NNP|NONE (r_pobj) with_8\IN|mitochondrial (r_prep) CM_7\NNP|HAART|that
D019259_D000163 NONE lamivudine_43\NN|NONE (r_pobj) of_40\IN|HAART|the (r_prep) combination_39\NN|NONE (r_pobj) with_36\IN|mice|.|were|determine|, (r_prep) treated_35\VBN|NONE (l_nsubjpass) mice_15\NNS|with|.|were|determine|, (l_compound) AIDS_14\NNP|hemizygous|old|transgenic|pol
D019469_D000163 NONE indinavir_46\NNS|and|zidovudine|,|, (r_conj) lamivudine_43\NN|NONE (r_pobj) of_40\IN|HAART|the (r_prep) combination_39\NN|NONE (r_pobj) with_36\IN|mice|.|were|determine|, (r_prep) treated_35\VBN|NONE (l_nsubjpass) mice_15\NNS|with|.|were|determine|, (l_compound) AIDS_14\NNP|hemizygous|old|transgenic|pol
D019344_D028361 NONE lactate_18\NN|NONE (r_pobj) in_15\IN|CM|and (r_conj) in_9\IN|through|is|therapy|. (r_prep) implicated_8\VBN|NONE (l_prep) through_24\IN|in|is|therapy|. (l_pobj) mechanisms_25\NNS|NONE (l_prep) of_26\IN|NONE (l_pobj) dysfunction_28\NN|NONE
D019344_D028361 NONE LA_20\NNP|elevated|)|plasma|in|( (r_appos) lactate_18\NN|NONE (r_pobj) in_15\IN|CM|and (r_conj) in_9\IN|through|is|therapy|. (r_prep) implicated_8\VBN|NONE (l_prep) through_24\IN|in|is|therapy|. (l_pobj) mechanisms_25\NNS|NONE (l_prep) of_26\IN|NONE (l_pobj) dysfunction_28\NN|NONE
D019344_D000163 NONE lactate_8\NN|in (r_dobj) elevates_6\VBZ|and|cardiomyopathy|.|therapy|Combined (l_prep) in_9\IN|lactate (l_pobj) mice_12\NNS|NONE (l_compound) AIDS_11\NNP|transgenic
D019344_D000163 NONE lactate_18\NN|NONE (l_prep) in_22\IN|elevated|)|LA|plasma|( (l_pobj) AIDS_23\NNP|NONE
D019344_D000163 NONE LA_20\NNP|elevated|)|plasma|in|( (r_appos) lactate_18\NN|NONE (l_prep) in_22\IN|elevated|)|LA|plasma|( (l_pobj) AIDS_23\NNP|NONE
D019344_D000163 NONE LA_10\NNP|NONE (l_prep) in_11\IN|elevated (l_pobj) mice_14\NNS|NONE (l_compound) transgenic_13\JJ|NONE (l_compound) AIDS_12\NNP|NONE
D015215_D000163 NONE zidovudine_41\NN|and|,|indinavir|, (r_nmod) lamivudine_43\NN|NONE (r_pobj) of_40\IN|HAART|the (r_prep) combination_39\NN|NONE (r_pobj) with_36\IN|mice|.|were|determine|, (r_prep) treated_35\VBN|NONE (l_nsubjpass) mice_15\NNS|with|.|were|determine|, (l_compound) AIDS_14\NNP|hemizygous|old|transgenic|pol
15009014
D001285_D006940 NONE atropine_16\NN|NONE (r_pobj) by_10\IN|also|increases|were|. (r_agent) abolished_9\VBN|NONE (l_nsubjpass) increases_2\NNS|also|were|.|by (l_prep) in_3\IN|The|evoked (l_pobj) flow_6\NN|NONE
D002211_D006940 CID Capsaicin_0\NNS|induced|.|to (r_nsubj) applied_7\VBN|NONE (l_conj) induced_13\VBN|.|Capsaicin|to (l_dobj) increases_14\NNS|provoked (l_prep) in_15\IN|and (l_pobj) flow_20\NN|NONE
20722491
C110904_D003967 CID capecitabine_7\NN|NONE (r_pobj) of_6\IN|reported|The|toxic (r_prep) effects_5\NNS|.|diarrhea (r_nsubj) are_8\VBP|NONE (l_attr) diarrhea_9\NN|effects|.
C110904_D014839 CID capecitabine_7\NN|NONE (r_pobj) of_6\IN|reported|The|toxic (r_prep) effects_5\NNS|.|diarrhea (r_nsubj) are_8\VBP|NONE (l_attr) diarrhea_9\NN|effects|. (l_appos) nausea_11\NN|, (l_conj) vomiting_13\NN|,
C110904_D013280 CID capecitabine_7\NN|NONE (r_pobj) of_6\IN|reported|The|toxic (r_prep) effects_5\NNS|.|diarrhea (r_nsubj) are_8\VBP|NONE (l_attr) diarrhea_9\NN|effects|. (l_appos) nausea_11\NN|, (l_conj) vomiting_13\NN|, (l_conj) stomatitis_15\JJ|,
C110904_D008107 NONE Capecitabine_0\NNP|.|given|and|profile (r_nsubj) has_1\VBZ|NONE (l_conj) given_11\VBN|Capecitabine|.|and|profile (l_prep) to_13\IN|be|safely|can (l_pobj) patients_14\NNS|NONE (l_prep) with_15\IN|NONE (l_pobj) dysfunctions_22\NNS|NONE
D005472_D015179 NONE 5-FU_1\CD|have|,|.|mainstay (r_nsubj) been_5\VBN|NONE (l_attr) mainstay_7\NN|have|FU|,|. (l_prep) of_8\IN|for|the (l_pobj) treatment_9\NN|NONE (l_prep) for_10\IN|NONE (l_pobj) tumors_13\NNS|NONE (l_prep) including_15\VBG|,|,|solid|several (l_pobj) colorectal_16\NN|NONE (l_conj) breast_18\NN|, (l_conj) cancers_23\NNS|and
D005472_D001943 NONE 5-FU_1\CD|have|,|.|mainstay (r_nsubj) been_5\VBN|NONE (l_attr) mainstay_7\NN|have|FU|,|. (l_prep) of_8\IN|for|the (l_pobj) treatment_9\NN|NONE (l_prep) for_10\IN|NONE (l_pobj) tumors_13\NNS|NONE (l_prep) including_15\VBG|,|,|solid|several (l_pobj) colorectal_16\NN|NONE (l_conj) breast_18\NN|, (l_conj) cancers_23\NNS|and
C110904_D007674 NONE capecitabine_10\NN|NONE (r_pobj) of_9\IN|the|in (r_prep) safety_8\NN|NONE (l_prep) in_11\IN|of|the (l_pobj) populations_13\NNS|NONE (l_prep) as_15\IN|special (l_pobj) patients_16\NNS|such (l_prep) with_17\IN|NONE (l_pobj) disease_24\NN|NONE
C110904_D007674 NONE Capecitabine_0\NNP|.|given|and|profile (r_nsubj) has_1\VBZ|NONE (l_conj) given_11\VBN|Capecitabine|.|and|profile (l_prep) to_13\IN|be|safely|can (l_pobj) patients_14\NNS|NONE (l_prep) with_15\IN|NONE (l_pobj) dysfunctions_22\NNS|NONE
C110904_D009325 CID capecitabine_7\NN|NONE (r_pobj) of_6\IN|reported|The|toxic (r_prep) effects_5\NNS|.|diarrhea (r_nsubj) are_8\VBP|NONE (l_attr) diarrhea_9\NN|effects|. (l_appos) nausea_11\NN|,
C110904_D060831 CID capecitabine_7\NN|NONE (r_pobj) of_6\IN|reported|The|toxic (r_prep) effects_5\NNS|.|diarrhea (r_nsubj) are_8\VBP|NONE (l_attr) diarrhea_9\NN|effects|. (l_appos) nausea_11\NN|, (l_conj) vomiting_13\NN|, (l_conj) stomatitis_15\JJ|, (l_conj) syndrome_20\NN|and
D005472_D009369 NONE 5-FU_1\CD|have|,|.|mainstay (r_nsubj) been_5\VBN|NONE (l_attr) mainstay_7\NN|have|FU|,|. (l_prep) of_8\IN|for|the (l_pobj) treatment_9\NN|NONE (l_prep) for_10\IN|NONE (l_pobj) tumors_13\NNS|NONE
D005472_D006258 NONE 5-FU_1\CD|have|,|.|mainstay (r_nsubj) been_5\VBN|NONE (l_attr) mainstay_7\NN|have|FU|,|. (l_prep) of_8\IN|for|the (l_pobj) treatment_9\NN|NONE (l_prep) for_10\IN|NONE (l_pobj) tumors_13\NNS|NONE (l_prep) including_15\VBG|,|,|solid|several (l_pobj) colorectal_16\NN|NONE (l_conj) breast_18\NN|, (l_conj) cancers_23\NNS|and
15515654
D003676_D006319 CID DFO_6\NNP|or|withdrawal (r_compound) reduction_7\NN|NONE (r_pobj) to_5\IN|Subjects|.|were (r_prep) submitted_4\VBN|NONE (l_nsubjpass) Subjects_0\NNS|to|.|were (l_prep) with_1\IN|NONE (l_pobj) SNHL_2\NNP|NONE
D003676_D006311 NONE DFO_6\NNP|NONE (r_pobj) than_5\IN|NONE (r_prep) other_4\JJ|ototoxic|,|,|No (r_amod) factor_2\NN|.|present (l_compound) ototoxic_1\JJ|other|,|,|No
D003676_D034381 NONE DFO_5\NNP|in|contributing (r_poss) role_8\NN|NONE (l_prep) in_9\IN|DFO|contributing (l_pobj) development_11\NN|NONE (l_prep) of_12\IN|the (l_pobj) impairment_14\NN|NONE
8319760
D011692_D009404 CID aminonucleoside_26\NN|appearance|in|,|by (r_advmod) induced_19\VBN|markedly|.|by|)|was|,|antagonist (l_nsubj) appearance_1\NN|in|,|by|aminonucleoside (l_prep) of_2\IN|The (l_pobj) syndromes_4\NNS|NONE
D001806_D009404 NONE urea_17\NN|NONE (r_pobj) in_14\IN|NONE (r_prep) increase_13\NN|and (r_conj) hypercholesterolemia_11\NN|, (r_conj) hypoalbuminemia_9\NN|, (r_conj) proteinuria_7\NN|such (r_pobj) as_6\IN|nephrotic (r_prep) syndromes_4\NNS|NONE
D001806_D034141 NONE urea_17\NN|NONE (r_pobj) in_14\IN|NONE (r_prep) increase_13\NN|and (r_conj) hypercholesterolemia_11\NN|, (r_conj) hypoalbuminemia_9\NN|,
D019808_D034141 NONE 753_35\CD|NONE (r_nummod) Dup_34\NN|( (r_nmod) losartan_37\NN|NONE (r_pobj) of_33\IN|oral (r_prep) administration_32\NN|NONE (r_pobj) by_30\IN|markedly|.|)|was|,|antagonist|induced (r_agent) inhibited_29\VBN|NONE (l_ccomp) induced_19\VBN|markedly|.|by|)|was|,|antagonist (l_nsubj) appearance_1\NN|in|,|by|aminonucleoside (l_prep) of_2\IN|The (l_pobj) syndromes_4\NNS|NONE (l_prep) as_6\IN|nephrotic (l_pobj) proteinuria_7\NN|such (l_conj) hypoalbuminemia_9\NN|,
D019808_D034141 NONE losartan_37\NN|NONE (r_pobj) of_33\IN|oral (r_prep) administration_32\NN|NONE (r_pobj) by_30\IN|markedly|.|)|was|,|antagonist|induced (r_agent) inhibited_29\VBN|NONE (l_ccomp) induced_19\VBN|markedly|.|by|)|was|,|antagonist (l_nsubj) appearance_1\NN|in|,|by|aminonucleoside (l_prep) of_2\IN|The (l_pobj) syndromes_4\NNS|NONE (l_prep) as_6\IN|nephrotic (l_pobj) proteinuria_7\NN|such (l_conj) hypoalbuminemia_9\NN|,
D000804_D009404 NONE II_43\NNP|,|receptor|at|angiotensin|a (r_compound) antagonist_45\NN|markedly|.|by|)|was|,|induced (r_appos) inhibited_29\VBN|NONE (l_ccomp) induced_19\VBN|markedly|.|by|)|was|,|antagonist (l_nsubj) appearance_1\NN|in|,|by|aminonucleoside (l_prep) of_2\IN|The (l_pobj) syndromes_4\NNS|NONE
D000804_D011507 NONE II_43\NNP|,|receptor|at|angiotensin|a (r_compound) antagonist_45\NN|markedly|.|by|)|was|,|induced (r_appos) inhibited_29\VBN|NONE (l_ccomp) induced_19\VBN|markedly|.|by|)|was|,|antagonist (l_nsubj) appearance_1\NN|in|,|by|aminonucleoside (l_prep) of_2\IN|The (l_pobj) syndromes_4\NNS|NONE (l_prep) as_6\IN|nephrotic (l_pobj) proteinuria_7\NN|such
D011692_D034141 CID aminonucleoside_26\NN|appearance|in|,|by (r_advmod) induced_19\VBN|markedly|.|by|)|was|,|antagonist (l_nsubj) appearance_1\NN|in|,|by|aminonucleoside (l_prep) of_2\IN|The (l_pobj) syndromes_4\NNS|NONE (l_prep) as_6\IN|nephrotic (l_pobj) proteinuria_7\NN|such (l_conj) hypoalbuminemia_9\NN|,
D001806_D006937 NONE urea_17\NN|NONE (r_pobj) in_14\IN|NONE (r_prep) increase_13\NN|and (r_conj) hypercholesterolemia_11\NN|,
D011692_D011507 CID aminonucleoside_26\NN|appearance|in|,|by (r_advmod) induced_19\VBN|markedly|.|by|)|was|,|antagonist (l_nsubj) appearance_1\NN|in|,|by|aminonucleoside (l_prep) of_2\IN|The (l_pobj) syndromes_4\NNS|NONE (l_prep) as_6\IN|nephrotic (l_pobj) proteinuria_7\NN|such
D000804_D006937 NONE II_43\NNP|,|receptor|at|angiotensin|a (r_compound) antagonist_45\NN|markedly|.|by|)|was|,|induced (r_appos) inhibited_29\VBN|NONE (l_ccomp) induced_19\VBN|markedly|.|by|)|was|,|antagonist (l_nsubj) appearance_1\NN|in|,|by|aminonucleoside (l_prep) of_2\IN|The (l_pobj) syndromes_4\NNS|NONE (l_prep) as_6\IN|nephrotic (l_pobj) proteinuria_7\NN|such (l_conj) hypoalbuminemia_9\NN|, (l_conj) hypercholesterolemia_11\NN|,
D011692_D006937 CID aminonucleoside_26\NN|appearance|in|,|by (r_advmod) induced_19\VBN|markedly|.|by|)|was|,|antagonist (l_nsubj) appearance_1\NN|in|,|by|aminonucleoside (l_prep) of_2\IN|The (l_pobj) syndromes_4\NNS|NONE (l_prep) as_6\IN|nephrotic (l_pobj) proteinuria_7\NN|such (l_conj) hypoalbuminemia_9\NN|, (l_conj) hypercholesterolemia_11\NN|,
D019808_D009401 NONE 753_1\CD|NONE (r_nummod) Dup_0\NN|.|development (r_nsubj) prevents_2\VBZ|NONE (l_dobj) development_4\NN|Dup|. (l_prep) of_5\IN|the (l_pobj) nephrosis_10\NN|puromycin
D000804_D034141 NONE II_43\NNP|,|receptor|at|angiotensin|a (r_compound) antagonist_45\NN|markedly|.|by|)|was|,|induced (r_appos) inhibited_29\VBN|NONE (l_ccomp) induced_19\VBN|markedly|.|by|)|was|,|antagonist (l_nsubj) appearance_1\NN|in|,|by|aminonucleoside (l_prep) of_2\IN|The (l_pobj) syndromes_4\NNS|NONE (l_prep) as_6\IN|nephrotic (l_pobj) proteinuria_7\NN|such (l_conj) hypoalbuminemia_9\NN|,
D001806_D011507 NONE urea_17\NN|NONE (r_pobj) in_14\IN|NONE (r_prep) increase_13\NN|and (r_conj) hypercholesterolemia_11\NN|, (r_conj) hypoalbuminemia_9\NN|, (r_conj) proteinuria_7\NN|such
D019808_D009404 NONE 753_35\CD|NONE (r_nummod) Dup_34\NN|( (r_nmod) losartan_37\NN|NONE (r_pobj) of_33\IN|oral (r_prep) administration_32\NN|NONE (r_pobj) by_30\IN|markedly|.|)|was|,|antagonist|induced (r_agent) inhibited_29\VBN|NONE (l_ccomp) induced_19\VBN|markedly|.|by|)|was|,|antagonist (l_nsubj) appearance_1\NN|in|,|by|aminonucleoside (l_prep) of_2\IN|The (l_pobj) syndromes_4\NNS|NONE
D019808_D009404 NONE losartan_37\NN|NONE (r_pobj) of_33\IN|oral (r_prep) administration_32\NN|NONE (r_pobj) by_30\IN|markedly|.|)|was|,|antagonist|induced (r_agent) inhibited_29\VBN|NONE (l_ccomp) induced_19\VBN|markedly|.|by|)|was|,|antagonist (l_nsubj) appearance_1\NN|in|,|by|aminonucleoside (l_prep) of_2\IN|The (l_pobj) syndromes_4\NNS|NONE
D019808_D011507 NONE 753_35\CD|NONE (r_nummod) Dup_34\NN|( (r_nmod) losartan_37\NN|NONE (r_pobj) of_33\IN|oral (r_prep) administration_32\NN|NONE (r_pobj) by_30\IN|markedly|.|)|was|,|antagonist|induced (r_agent) inhibited_29\VBN|NONE (l_ccomp) induced_19\VBN|markedly|.|by|)|was|,|antagonist (l_nsubj) appearance_1\NN|in|,|by|aminonucleoside (l_prep) of_2\IN|The (l_pobj) syndromes_4\NNS|NONE (l_prep) as_6\IN|nephrotic (l_pobj) proteinuria_7\NN|such
D019808_D011507 NONE losartan_37\NN|NONE (r_pobj) of_33\IN|oral (r_prep) administration_32\NN|NONE (r_pobj) by_30\IN|markedly|.|)|was|,|antagonist|induced (r_agent) inhibited_29\VBN|NONE (l_ccomp) induced_19\VBN|markedly|.|by|)|was|,|antagonist (l_nsubj) appearance_1\NN|in|,|by|aminonucleoside (l_prep) of_2\IN|The (l_pobj) syndromes_4\NNS|NONE (l_prep) as_6\IN|nephrotic (l_pobj) proteinuria_7\NN|such
D000809_D009401 NONE angiotensin_10\NN|in|the (r_compound) system_11\NN|NONE (l_prep) in_12\IN|angiotensin|the (l_pobj) development_14\NN|NONE (l_prep) of_15\IN|the (l_pobj) nephrosis_20\NN|puromycin
D011692_D009401 NONE aminonucleoside_7\NN| (r_advmod) induced_9\VBN|NONE (r_amod) nephrosis_10\NN|puromycin
D011692_D009401 NONE aminonucleoside_17\NN| (r_advmod) induced_19\VBN|NONE (r_amod) nephrosis_20\NN|puromycin
D019808_D006937 NONE 753_35\CD|NONE (r_nummod) Dup_34\NN|( (r_nmod) losartan_37\NN|NONE (r_pobj) of_33\IN|oral (r_prep) administration_32\NN|NONE (r_pobj) by_30\IN|markedly|.|)|was|,|antagonist|induced (r_agent) inhibited_29\VBN|NONE (l_ccomp) induced_19\VBN|markedly|.|by|)|was|,|antagonist (l_nsubj) appearance_1\NN|in|,|by|aminonucleoside (l_prep) of_2\IN|The (l_pobj) syndromes_4\NNS|NONE (l_prep) as_6\IN|nephrotic (l_pobj) proteinuria_7\NN|such (l_conj) hypoalbuminemia_9\NN|, (l_conj) hypercholesterolemia_11\NN|,
D019808_D006937 NONE losartan_37\NN|NONE (r_pobj) of_33\IN|oral (r_prep) administration_32\NN|NONE (r_pobj) by_30\IN|markedly|.|)|was|,|antagonist|induced (r_agent) inhibited_29\VBN|NONE (l_ccomp) induced_19\VBN|markedly|.|by|)|was|,|antagonist (l_nsubj) appearance_1\NN|in|,|by|aminonucleoside (l_prep) of_2\IN|The (l_pobj) syndromes_4\NNS|NONE (l_prep) as_6\IN|nephrotic (l_pobj) proteinuria_7\NN|such (l_conj) hypoalbuminemia_9\NN|, (l_conj) hypercholesterolemia_11\NN|,
11198499
D000809_D009128 NONE angiotensin_14\NN|, (r_appos) lisinopril_11\NN|NONE (r_pobj) with_10\IN|chronically (r_prep) treated_9\VBN|a|,|old (r_acl) boy_7\NN|.|authors|control (r_dobj) present_2\VBP|NONE (l_advcl) control_20\VB|.|authors|boy (l_dobj) hypertension_21\NN|to (l_relcl) developed_23\VBD|NONE (l_prep) following_25\VBG|who|hypotension (l_pobj) addition_27\NN|NONE (l_prep) for_35\IN|of|the (l_pobj) treatment_37\NN|NONE (l_prep) of_38\IN|the (l_pobj) spasticity_39\NN|NONE
D017706_D006973 NONE lisinopril_11\NN|NONE (r_pobj) with_10\IN|chronically (r_prep) treated_9\VBN|a|,|old (r_acl) boy_7\NN|.|authors|control (r_dobj) present_2\VBP|NONE (l_advcl) control_20\VB|.|authors|boy (l_dobj) hypertension_21\NN|to
D017706_D007022 CID lisinopril_11\NN|NONE (r_pobj) with_10\IN|chronically (r_prep) treated_9\VBN|a|,|old (r_acl) boy_7\NN|.|authors|control (r_dobj) present_2\VBP|NONE (l_advcl) control_20\VB|.|authors|boy (l_dobj) hypertension_21\NN|to (l_relcl) developed_23\VBD|NONE (l_dobj) hypotension_24\NN|who|following
C023754_D007022 CID tizanidine_5\NN|NONE (r_pobj) of_4\IN|in|the (r_prep) initiation_3\NN|NONE (r_dobj) following_1\VBG|. (r_acl) Hypotension_0\NN|NONE
C023754_D007022 CID tizanidine_29\NN|NONE (r_pobj) of_28\IN|the|for (r_prep) addition_27\NN|NONE (r_pobj) following_25\VBG|who|hypotension (r_prep) developed_23\VBD|NONE (l_dobj) hypotension_24\NN|who|following
D000809_D006973 NONE angiotensin_12\NN|NONE (l_acl) converting_13\VBG|an (l_prep) for_16\IN|inhibitor (l_pobj) hypertension_18\NN|NONE
D000809_D006973 NONE angiotensin_14\NN|, (r_appos) lisinopril_11\NN|NONE (r_pobj) with_10\IN|chronically (r_prep) treated_9\VBN|a|,|old (r_acl) boy_7\NN|.|authors|control (r_dobj) present_2\VBP|NONE (l_advcl) control_20\VB|.|authors|boy (l_dobj) hypertension_21\NN|to
D017706_D009128 NONE lisinopril_11\NN|NONE (r_pobj) with_10\IN|chronically (r_prep) treated_9\VBN|a|,|old (r_acl) boy_7\NN|.|authors|control (r_dobj) present_2\VBP|NONE (l_advcl) control_20\VB|.|authors|boy (l_dobj) hypertension_21\NN|to (l_relcl) developed_23\VBD|NONE (l_prep) following_25\VBG|who|hypotension (l_pobj) addition_27\NN|NONE (l_prep) for_35\IN|of|the (l_pobj) treatment_37\NN|NONE (l_prep) of_38\IN|the (l_pobj) spasticity_39\NN|NONE
D000809_D007022 NONE angiotensin_12\NN|NONE (r_pobj) with_10\IN|NONE (r_prep) treated_9\VBN|a (r_acl) patient_8\NN|NONE (r_pobj) in_6\IN|of|the (r_prep) initiation_3\NN|NONE (r_dobj) following_1\VBG|. (r_acl) Hypotension_0\NN|NONE
D000809_D007022 NONE angiotensin_4\NN|NONE (r_pobj) with_3\IN|chronically|Adults (r_prep) treated_2\VBN|may|ability|. (r_csubj) have_9\VB|NONE (l_dobj) ability_12\NN|may|.|treated (l_acl) respond_14\VB|a|limited (l_prep) to_15\IN|blocked|to (l_pobj) hypotension_16\NN|NONE
D000809_D007022 NONE angiotensin_14\NN|, (r_appos) lisinopril_11\NN|NONE (r_pobj) with_10\IN|chronically (r_prep) treated_9\VBN|a|,|old (r_acl) boy_7\NN|.|authors|control (r_dobj) present_2\VBP|NONE (l_advcl) control_20\VB|.|authors|boy (l_dobj) hypertension_21\NN|to (l_relcl) developed_23\VBD|NONE (l_dobj) hypotension_24\NN|who|following
C023754_D009128 NONE tizanidine_29\NN|NONE (r_pobj) of_28\IN|the|for (r_prep) addition_27\NN|NONE (l_prep) for_35\IN|of|the (l_pobj) treatment_37\NN|NONE (l_prep) of_38\IN|the (l_pobj) spasticity_39\NN|NONE
C023754_D009128 NONE tizanidine_4\NN|NONE (r_pobj) of_3\IN|The|possible (r_prep) interaction_2\NN|in|prescribing|.|should|be (r_nsubjpass) kept_11\VBN|NONE (l_advcl) prescribing_15\VBG|in|.|should|interaction|be (l_xcomp) treat_18\VB|therapy|when (l_dobj) hypertension_20\NN|to (l_conj) spasticity_22\NN|or|in|either
C023754_D006973 NONE tizanidine_5\NN|NONE (r_pobj) of_4\IN|in|the (r_prep) initiation_3\NN|NONE (l_prep) in_6\IN|of|the (l_pobj) patient_8\NN|NONE (l_acl) treated_9\VBN|a (l_prep) with_10\IN|NONE (l_pobj) angiotensin_12\NN|NONE (l_acl) converting_13\VBG|an (l_prep) for_16\IN|inhibitor (l_pobj) hypertension_18\NN|NONE
C023754_D006973 NONE tizanidine_29\NN|NONE (r_pobj) of_28\IN|the|for (r_prep) addition_27\NN|NONE (r_pobj) following_25\VBG|who|hypotension (r_prep) developed_23\VBD|NONE (r_relcl) hypertension_21\NN|to
C023754_D006973 NONE tizanidine_4\NN|NONE (r_pobj) of_3\IN|The|possible (r_prep) interaction_2\NN|in|prescribing|.|should|be (r_nsubjpass) kept_11\VBN|NONE (l_advcl) prescribing_15\VBG|in|.|should|interaction|be (l_xcomp) treat_18\VB|therapy|when (l_dobj) hypertension_20\NN|to
12063090
D009020_D059350 NONE morphine_7\NN|NONE (r_pobj) between_6\IN|a|significant (r_prep) interaction_5\NN|suggesting|.|findings|, (r_dobj) show_2\VBP|NONE (l_advcl) suggesting_15\VBG|.|findings|interaction|, (l_ccomp) be_20\VB|NONE (l_acomp) useful_21\JJ|combination|could|that (l_prep) for_22\IN|NONE (l_pobj) treatment_24\NN|NONE (l_prep) of_25\IN|the (l_pobj) pain_27\NN|NONE
D002606_D010146 NONE charcoal_25\NN|NONE (r_compound) meal_26\NN|the (r_compound) test_27\NN|.|was|evaluate (r_nsubjpass) used_29\VBN|model|,|were|effects|,|using|On (r_conj) assessed_8\VBN|NONE (l_conj) model_21\NN|,|were|effects|,|used|using|On (l_amod) induced_18\VBN|impairment|and|, (l_npadvmod) pain_16\NN|
D004177_D003248 NONE Metamizol_0\NNP|antinociception|. (r_nsubj) potentiates_1\VBZ|NONE (l_dobj) antinociception_3\NN|Metamizol|. (l_conj) constipation_6\NN|but|morphine
D004177_D003248 NONE metamizol_20\NN|NONE (r_pobj) with_16\IN|antinociceptive|of|in|the (r_prep) effects_7\NNS|(|)|work|day|.|rats (l_amod) antinociceptive_4\NN|of|in|with|the (l_conj) constipating_6\JJ|and
D004177_D003248 NONE metamizol_20\NN|did|not|constipation (r_nsubj) potentiate_23\VB|NONE (l_dobj) constipation_27\NN|metamizol|did|not
D004177_D059350 NONE metamizol_9\NN|and|in (r_conj) morphine_7\NN|NONE (r_pobj) between_6\IN|a|significant (r_prep) interaction_5\NN|suggesting|.|findings|, (r_dobj) show_2\VBP|NONE (l_advcl) suggesting_15\VBG|.|findings|interaction|, (l_ccomp) be_20\VB|NONE (l_acomp) useful_21\JJ|combination|could|that (l_prep) for_22\IN|NONE (l_pobj) treatment_24\NN|NONE (l_prep) of_25\IN|the (l_pobj) pain_27\NN|NONE
D009020_D003248 CID morphine_2\NN|constipation|but (r_compound) antinociception_3\NN|Metamizol|. (l_conj) constipation_6\NN|but|morphine
D009020_D003248 CID morphine_15\NN|NONE (r_pobj) of_11\IN|the (r_prep) combination_10\NN|NONE (r_pobj) of_8\IN|antinociceptive|in|with|the (r_prep) effects_7\NNS|(|)|work|day|.|rats (l_amod) antinociceptive_4\NN|of|in|with|the (l_conj) constipating_6\JJ|and
D009020_D003248 CID morphine_4\NN|In|after|respectively|suggesting|,|,|transit|.|, (r_nsubj) inhibited_5\VBD|NONE (l_advcl) suggesting_23\VBG|morphine|In|after|respectively|,|,|transit|.|, (l_ccomp) develop_28\VB|NONE (l_prep) to_29\IN|that|not|did|tolerance (l_pobj) effects_32\NNS|NONE (l_amod) constipating_31\JJ|the
D009020_D003248 CID morphine_10\NN|NONE (r_pobj) by_9\IN|regardless (r_agent) produced_8\VBN|NONE (r_acl) that_7\DT|NONE (r_pobj) to_6\IN|NONE (r_prep) similar_5\JJ|intestinal (r_amod) transit_4\NN|suggesting|combination|,|. (r_dobj) inhibited_2\VBD|NONE (l_advcl) suggesting_18\VBG|transit|combination|,|. (l_ccomp) potentiate_23\VB|NONE (l_dobj) constipation_27\NN|metamizol|did|not
D009020_D003248 CID morphine_24\NN| (r_npadvmod) induced_26\VBN|NONE (r_amod) constipation_27\NN|metamizol|did|not
3311455
D016572_D007674 CID cyclosporine_17\NN|NONE (r_pobj) with_16\IN|term (r_prep) therapy_15\NN|NONE (r_pobj) to_11\IN|NONE (r_prep) secondary_10\JJ|chronic (r_amod) nephrotoxicity_9\NN|NONE
D016572_D007674 CID cyclosporine_8\NN|NONE (r_pobj) of_7\IN|even|lower|these (r_prep) dosages_6\NNS|nephrotoxicity|that|can|required (r_nsubj) cause_10\VB|We|. (l_dobj) nephrotoxicity_12\NN|that|can|dosages|required
8267029
D010396_D005921 CID Penicillamine_0\NN|glomerulonephritis|.|in| (r_nsubj) induced_2\VBN|NONE (l_dobj) glomerulonephritis_5\NN|.|in|Penicillamine|
D010396_D005921 CID penicillamine_21\NN|day|(|) (r_nmod) treatment_28\NN|NONE (r_pobj) of_18\IN| (r_prep) months_17\NNS|NONE (r_pobj) after_15\IN|woman|.|glomerulonephritis (r_prep) presented_8\VBD|NONE (l_dobj) glomerulonephritis_11\NN|after|woman|.
D010396_D005921 CID penicillamine_21\NN|day|(|) (r_nmod) treatment_28\NN|NONE (r_pobj) of_18\IN| (r_prep) months_17\NNS|NONE (r_pobj) after_15\IN|woman|.|glomerulonephritis (r_prep) presented_8\VBD|NONE (l_dobj) glomerulonephritis_11\NN|after|woman|. (l_appos) RPGN_13\NNP|progressive
D010396_D005921 CID penicillamine_11\NN|NONE (r_compound) treatment_12\NN|NONE (r_pobj) of_8\IN|the (r_prep) course_7\NN|NONE (r_pobj) in_5\IN|of|This|new (r_prep) case_2\NN|need|. (l_prep) of_3\IN|This|new|in (l_pobj) RPGN_4\NNP|NONE
D010396_D011507 NONE penicillamine_11\NN|NONE (r_compound) treatment_12\NN|NONE (r_pobj) of_8\IN|the (r_prep) course_7\NN|NONE (r_pobj) in_5\IN|of|This|new (r_prep) case_2\NN|need|. (r_nsubj) emphasizes_13\VBZ|NONE (l_dobj) need_15\NN|case|. (l_prep) for_16\IN|the (l_pobj) monitoring_18\NN|NONE (l_prep) of_19\IN|frequent (l_pobj) function_21\NN|NONE (l_conj) evaluation_23\NN|renal|and (l_prep) of_24\IN|NONE (l_pobj) sediment_26\NN|NONE (l_conj) proteinuria_28\NN|and|urinary|in
D010396_D001172 NONE Penicillamine_0\NN|glomerulonephritis|.|in| (r_nsubj) induced_2\VBN|NONE (l_prep) in_6\IN|glomerulonephritis|.|Penicillamine| (l_pobj) patient_8\NN|NONE (l_prep) with_9\IN|a (l_pobj) arthritis_11\NN|NONE
D010396_D001172 NONE penicillamine_21\NN|day|(|) (r_nmod) treatment_28\NN|NONE (r_pobj) of_18\IN| (r_prep) months_17\NNS|NONE (r_pobj) after_15\IN|woman|.|glomerulonephritis (r_prep) presented_8\VBD|NONE (l_nsubj) woman_4\NN|after|.|glomerulonephritis (l_prep) with_5\IN|old|A (l_pobj) arthritis_7\NN|NONE
11208990
D004317_D009404 CID adriamycin_25\NNS|NONE (r_pobj) of_24\IN|a|single (r_prep) injection_23\NN|NONE (r_pobj) by_20\IN|NONE (r_agent) induced_19\VBN|of|an|experimental (r_acl) model_15\NN|NONE (l_prep) of_16\IN|an|experimental|induced (l_pobj) syndrome_18\NN|NONE
D004317_D009404 CID ADR_27\NNP|(|) (r_appos) adriamycin_25\NNS|NONE (r_pobj) of_24\IN|a|single (r_prep) injection_23\NN|NONE (r_pobj) by_20\IN|NONE (r_agent) induced_19\VBN|of|an|experimental (r_acl) model_15\NN|NONE (l_prep) of_16\IN|an|experimental|induced (l_pobj) syndrome_18\NN|NONE
D009569_D007674 NONE oxide_3\NN|NONE (r_compound) production_4\NN|NONE (r_pobj) of_1\IN|.|apoptosis|and (r_prep) Association_0\NN|NONE (l_conj) apoptosis_6\NN|.|of|and (l_prep) in_7\IN|NONE (l_pobj) model_9\NN|NONE (l_prep) of_10\IN|a (l_pobj) nephropathy_12\NN|NONE
D009569_D009401 NONE NO_5\UH|NONE (r_intj) between_4\IN|NONE (r_prep) interactions_3\NNS|important|that|in (r_nsubj) are_8\VBP|We|. (l_prep) in_10\IN|interactions|important|that (l_pobj) pathogenesis_12\NN|NONE (l_prep) of_13\IN|the (l_pobj) nephrosis_18\NN|NONE
D004317_D009395 NONE ADR_9\NNP|NONE (r_pobj) with_8\IN|NONE (r_prep) treated_7\VBN|NONE (r_acl) rats_6\NNS|NONE (r_pobj) of_5\IN|the (r_prep) kidneys_4\NNS|NONE (r_pobj) of_2\IN|Histopathological (r_prep) examination_1\NN|areas|. (r_nsubj) revealed_10\VBD|NONE (l_dobj) areas_12\NNS|examination|. (l_prep) of_13\IN|focal (l_pobj) proliferation_15\NN|NONE (l_conj) inflammation_19\NN|and|mesangial
D004317_D007674 NONE ADR_7\NNP| (r_npadvmod) induced_9\VBN|NONE (r_amod) nephropathy_10\NN|NONE
D004317_D007674 NONE ADR_8\NNP| (r_compound) nephropathy_10\NN|P|(|the|)
D004317_D007674 NONE ADR_13\NNP| (r_compound) nephropathy_15\NN|the
D004317_D007674 NONE ADR_4\NNP| (r_compound) nephropathy_6\NN|the
D004317_D009401 NONE ADR_15\NNP| (r_npadvmod) induced_17\VBN|the (r_amod) nephrosis_18\NN|NONE
D009573_D007674 NONE nitrite_1\NN|Urine (r_compound) levels_2\NNS|in|were|significantly|. (r_nsubjpass) increased_5\VBN|NONE (l_prep) in_6\IN|were|significantly|levels|. (l_pobj) group_11\NN|NONE (l_compound) nephropathy_10\NN|P|(|the|)
D009569_D009404 NONE NO_6\DT|association (r_intj) of_5\IN|the (l_pobj) association_9\NN|NO (l_prep) with_10\IN|its (l_pobj) apoptosis_11\NN|NONE (l_prep) in_12\IN|NONE (l_pobj) model_15\NN|NONE (l_prep) of_16\IN|an|experimental|induced (l_pobj) syndrome_18\NN|NONE
D010656_D007674 NONE phenylephrine_3\NN|the (r_nmod) responses_7\NNS|NONE (r_pobj) In_0\IN|.|impaired (r_prep) were_8\VBD|NONE (l_acomp) impaired_10\VBN|In|. (l_prep) in_11\IN|significantly (l_pobj) group_16\NN|NONE (l_compound) nephropathy_15\NN|the
D004317_C537346 NONE ADR_9\NNP|NONE (r_pobj) with_8\IN|NONE (r_prep) treated_7\VBN|NONE (r_acl) rats_6\NNS|NONE (r_pobj) of_5\IN|the (r_prep) kidneys_4\NNS|NONE (r_pobj) of_2\IN|Histopathological (r_prep) examination_1\NN|areas|. (r_nsubj) revealed_10\VBD|NONE (l_dobj) areas_12\NNS|examination|. (l_prep) of_13\IN|focal (l_pobj) proliferation_15\NN|NONE
D000109_D007674 NONE acetylcholine_5\NN|NONE (r_npadvmod) related_6\VBN|IPRK|and (r_conj) phenylephrine_3\NN|the (r_nmod) responses_7\NNS|NONE (r_pobj) In_0\IN|.|impaired (r_prep) were_8\VBD|NONE (l_acomp) impaired_10\VBN|In|. (l_prep) in_11\IN|significantly (l_pobj) group_16\NN|NONE (l_compound) nephropathy_15\NN|the
4008111
D000638_D012848 CID Amiodarone_0\NN| (r_npadvmod) induced_2\VBN|sinoatrial|. (r_amod) block_4\NN|NONE
D000638_D012848 CID amiodarone_7\NN|chronic|in (r_compound) administration_8\NN|to (r_pobj) due_4\JJ|.|block|We|,|syndrome (r_prep) observed_1\VBD|NONE (l_dobj) block_3\NN|.|We|,|due|syndrome
D000638_D012848 CID amiodarone_5\NN|NONE (r_pobj) of_4\IN|the (r_prep) dosage_3\NN|NONE (r_pobj) in_1\IN|NONE (r_prep) Reduction_0\NN|.|in (r_nsubj) resulted_6\VBD|NONE (l_prep) in_7\IN|.|Reduction (l_pobj) disappearance_9\NN|NONE (l_prep) of_10\IN|and|the|persistence (l_pobj) block_13\NN|NONE
D000638_D013617 NONE amiodarone_7\NN|chronic|in (r_compound) administration_8\NN|to (r_pobj) due_4\JJ|.|block|We|,|syndrome (r_prep) observed_1\VBD|NONE (l_dobj) syndrome_24\NN|.|block|We|,|due (l_conj) tachycardia_27\NN|White|and
D000638_D009202 NONE amiodarone_7\NN|chronic|in (r_compound) administration_8\NN|to (l_prep) in_9\IN|chronic|amiodarone (l_pobj) boy_14\NN|NONE (l_prep) with_15\IN|a|old (l_pobj) cardiomyopathy_17\NN|NONE
D000638_D012804 NONE amiodarone_5\NN|NONE (r_pobj) of_4\IN|the (r_prep) dosage_3\NN|NONE (r_pobj) in_1\IN|NONE (r_prep) Reduction_0\NN|.|in (r_nsubj) resulted_6\VBD|NONE (l_prep) in_7\IN|.|Reduction (l_pobj) disappearance_9\NN|NONE (l_conj) persistence_16\NN|and|of|the (l_prep) of_17\IN|the (l_pobj) bradycardia_20\NNP|NONE
D000638_D014927 NONE amiodarone_7\NN|chronic|in (r_compound) administration_8\NN|to (r_pobj) due_4\JJ|.|block|We|,|syndrome (r_prep) observed_1\VBD|NONE (l_dobj) syndrome_24\NN|.|block|We|,|due
20727411
D007649_D018754 NONE ketamine_5\NN|supporting|.|In|,|symptoms|, (r_nsubj) exacerbates_6\VBZ|NONE (l_advcl) supporting_13\VBG|.|In|,|ketamine|symptoms|, (l_dobj) hypothesis_15\NN|NONE (l_prep) of_16\IN|the (l_pobj) dysfunction_19\NN|NONE
D007649_D011605 CID Ketamine_0\NN|psychosis|. (r_nsubj) elicited_1\VBD|NONE (l_dobj) psychosis_2\NN|Ketamine|.
-1_D011605 NONE ketamine_5\NN|NONE (r_pobj) of_2\IN|Neural (r_prep) correlates_1\NNS|psychosis|during|. (r_nsubj) induced_6\VBD|NONE (l_dobj) psychosis_7\NN|correlates|during|.
D016202_D012559 NONE aspartate_8\NNP|The|glutamatergic|(|)|NMDA (r_nmod) receptor_12\NN|been|in|has|. (r_nsubjpass) implicated_15\VBN|NONE (l_prep) in_16\IN|been|has|.|receptor (l_pobj) pathophysiology_18\NN|NONE (l_prep) of_19\IN|the (l_pobj) schizophrenia_20\NN|NONE
D016202_D012559 NONE NMDA_10\NNP|The|glutamatergic|(|)|aspartate (r_nmod) receptor_12\NN|been|in|has|. (r_nsubjpass) implicated_15\VBN|NONE (l_prep) in_16\IN|been|has|.|receptor (l_pobj) pathophysiology_18\NN|NONE (l_prep) of_19\IN|the (l_pobj) schizophrenia_20\NN|NONE
D016202_D012559 NONE NMDA_13\NNP|competitive|receptor (r_compound) antagonist_15\NN|the (r_compound) ketamine_16\NN|NONE (r_pobj) of_8\IN|subanesthetic|a (r_prep) dose_7\NN|Administered|,|.|to (r_nsubj) leads_17\VBZ|NONE (l_prep) to_18\IN|Administered|,|dose|. (l_pobj) symptoms_20\NNS|NONE (l_amod) similar_21\JJ|psychopathological (l_prep) to_22\IN|NONE (l_pobj) those_23\DT|NONE (l_acl) observed_24\VBN|NONE (l_prep) in_25\IN|NONE (l_pobj) schizophrenia_26\NN|NONE
D016202_D012559 NONE NMDA_10\NNP|an|receptor|in (r_compound) dysfunction_12\NN|NONE (l_prep) in_13\IN|NMDA|an|receptor (l_pobj) pathophysiology_15\NN|NONE (l_prep) of_16\IN|the (l_pobj) schizophrenia_17\NN|NONE
D007649_D012559 NONE ketamine_16\NN|NONE (r_pobj) of_8\IN|subanesthetic|a (r_prep) dose_7\NN|Administered|,|.|to (r_nsubj) leads_17\VBZ|NONE (l_prep) to_18\IN|Administered|,|dose|. (l_pobj) symptoms_20\NNS|NONE (l_amod) similar_21\JJ|psychopathological (l_prep) to_22\IN|NONE (l_pobj) those_23\DT|NONE (l_acl) observed_24\VBN|NONE (l_prep) in_25\IN|NONE (l_pobj) schizophrenia_26\NN|NONE
D007649_D012559 NONE ketamine_5\NN|supporting|.|In|,|symptoms|, (r_nsubj) exacerbates_6\VBZ|NONE (l_prep) In_0\IN|supporting|.|,|ketamine|symptoms|, (l_pobj) patients_1\NNS|NONE (l_prep) with_2\IN|NONE (l_pobj) schizophrenia_3\NN|NONE
D007649_D012559 NONE Ketamine_0\NN|,|changes|in|. (r_nsubj) induces_1\VBZ|NONE (l_dobj) changes_3\NNS|,|Ketamine|in|. (l_prep) in_4\IN|activation (l_pobj) subjects_6\NNS|NONE (l_amod) similar_7\JJ|healthy (l_prep) to_8\IN|NONE (l_pobj) those_9\DT|NONE (l_acl) observed_10\VBN|NONE (l_prep) in_11\IN|NONE (l_pobj) patients_12\NNS|NONE (l_prep) with_13\IN|NONE (l_pobj) schizophrenia_14\NN|NONE
11587867
D014750_D003711 CID vincristine_28\NN|NONE (r_pobj) to_27\IN|NONE (r_prep) exposed_26\VBN|NONE (r_acl) areas_25\NNS|NONE (r_pobj) in_24\IN|accompanied|,|pseudocystic (r_prep) transformation_23\NN|of|as (r_conj) degeneration_14\NN|investigations|. (l_prep) of_15\IN|transformation|as (l_pobj) myelin_16\NN|NONE (l_conj) axons_18\NNS|and
D014750_D009410 CID vincristine_28\NN|NONE (r_pobj) to_27\IN|NONE (r_prep) exposed_26\VBN|NONE (r_acl) areas_25\NNS|NONE (r_pobj) in_24\IN|accompanied|,|pseudocystic (r_prep) transformation_23\NN|of|as (r_conj) degeneration_14\NN|investigations|. (l_prep) of_15\IN|transformation|as (l_pobj) myelin_16\NN|NONE (l_conj) axons_18\NNS|and
D014750_D001927 NONE vincristin_6\NN|:|report|accidental|intrathecal (r_compound) administration_7\NN|to (r_pobj) due_2\IN|Fatal|. (r_prep) myeloencephalopathy_1\NN|NONE
D014750_D054198 NONE vincristine_9\NN|in|intrathecal|accidental (r_compound) instillation_10\NN|NONE (l_prep) in_11\IN|vincristine|intrathecal|accidental (l_pobj) girl_15\NN|NONE (l_prep) with_16\IN|a|old|year (l_pobj) leucemia_20\NN|NONE
D014750_D054198 NONE vincristine_9\NN|in|intrathecal|accidental (r_compound) instillation_10\NN|NONE (l_prep) in_11\IN|vincristine|intrathecal|accidental (l_pobj) girl_15\NN|NONE (l_prep) with_16\IN|a|old|year (l_pobj) leucemia_20\NN|NONE (l_conj) man_25\NN|and|lymphoblastic|recurrent|acute (l_prep) with_26\IN|old|year|a (l_pobj) lymphoma_28\NN|NONE
D014750_-1 NONE vincristine_28\NN|NONE (r_pobj) to_27\IN|NONE (r_prep) exposed_26\VBN|NONE (r_acl) areas_25\NNS|NONE (r_pobj) in_24\IN|accompanied|,|pseudocystic (r_prep) transformation_23\NN|of|as
7802851
D000525_D001259 CID alprazolam_5\NN|NONE (r_compound) patients_6\NNS|,|.|reactions|Compared (r_nsubj) developed_7\VBD|NONE (l_dobj) reactions_10\NNS|,|.|patients|Compared (l_conj) effects_31\NNS|adverse|and|of|;|(|)|% (l_appos) sedation_34\NN|more||side|, (l_conj) irritability_36\NN|particularly|, (l_conj) memory_39\NN|, (l_conj) loss_42\NN|impaired|, (l_conj) ataxia_44\NN|weight|and
D000525_D001523 NONE alprazolam_5\NN|NONE (r_compound) patients_6\NNS|,|.|reactions|Compared (r_nsubj) developed_7\VBD|NONE (l_dobj) reactions_10\NNS|,|.|patients|Compared (l_prep) of_18\IN|adverse|and|;|(|)|%|effects (l_pobj) depression_19\NN|NONE (l_conj) enuresis_21\NN|, (l_conj) disinhibition_23\NN|, (l_conj) aggression_25\NN|and
D000525_D001523 NONE alprazolam_5\NN|NONE (r_compound) patients_6\NNS|,|.|reactions|Compared (r_nsubj) developed_7\VBD|NONE (l_dobj) reactions_10\NNS|,|.|patients|Compared (l_conj) effects_31\NNS|adverse|and|of|;|(|)|% (l_appos) sedation_34\NN|more||side|, (l_conj) irritability_36\NN|particularly|,
D000525_D000379 NONE alprazolam_3\NN|NONE (r_pobj) of_2\IN|,|effect|and|in|The (r_prep) efficacy_1\NN|were|. (l_prep) in_6\IN|of|,|effect|and|The (l_pobj) disorder_8\NN|NONE (l_prep) with_9\IN|panic (l_pobj) agoraphobia_10\NNP|NONE
D000525_D000379 NONE alprazolam_20\NN|In|were|. (r_xcomp) randomised_18\VBN|NONE (l_prep) In_0\IN|alprazolam|were|. (l_pobj) London_1\NNP|NONE (l_conj) patients_5\NNS|and (l_relcl) met_7\VBD||Toronto (l_dobj) criteria_11\NNS|who (l_prep) for_12\IN|III (l_pobj) disorder_14\NN|NONE (l_prep) with_15\IN|panic (l_pobj) agoraphobia_16\NNP|NONE
D000525_D004775 CID alprazolam_5\NN|NONE (r_compound) patients_6\NNS|,|.|reactions|Compared (r_nsubj) developed_7\VBD|NONE (l_dobj) reactions_10\NNS|,|.|patients|Compared (l_prep) of_18\IN|adverse|and|;|(|)|%|effects (l_pobj) depression_19\NN|NONE (l_conj) enuresis_21\NN|,
D000525_D015431 CID alprazolam_5\NN|NONE (r_compound) patients_6\NNS|,|.|reactions|Compared (r_nsubj) developed_7\VBD|NONE (l_dobj) reactions_10\NNS|,|.|patients|Compared (l_conj) effects_31\NNS|adverse|and|of|;|(|)|% (l_appos) sedation_34\NN|more||side|, (l_conj) irritability_36\NN|particularly|, (l_conj) memory_39\NN|, (l_conj) loss_42\NN|impaired|,
D000525_D016584 NONE alprazolam_3\NN|NONE (r_pobj) of_2\IN|,|effect|and|in|The (r_prep) efficacy_1\NN|were|. (l_prep) in_6\IN|of|,|effect|and|The (l_pobj) disorder_8\NN|NONE
D000525_D016584 NONE alprazolam_20\NN|In|were|. (r_xcomp) randomised_18\VBN|NONE (l_prep) In_0\IN|alprazolam|were|. (l_pobj) London_1\NNP|NONE (l_conj) patients_5\NNS|and (l_relcl) met_7\VBD||Toronto (l_dobj) criteria_11\NNS|who (l_prep) for_12\IN|III (l_pobj) disorder_14\NN|NONE
D000525_D003866 CID alprazolam_5\NN|NONE (r_compound) patients_6\NNS|,|.|reactions|Compared (r_nsubj) developed_7\VBD|NONE (l_dobj) reactions_10\NNS|,|.|patients|Compared (l_prep) of_18\IN|adverse|and|;|(|)|%|effects (l_pobj) depression_19\NN|NONE
D000525_D008569 CID alprazolam_5\NN|NONE (r_compound) patients_6\NNS|,|.|reactions|Compared (r_nsubj) developed_7\VBD|NONE (l_dobj) reactions_10\NNS|,|.|patients|Compared (l_conj) effects_31\NNS|adverse|and|of|;|(|)|% (l_appos) sedation_34\NN|more||side|, (l_conj) irritability_36\NN|particularly|, (l_conj) memory_39\NN|,
9228650
C049860_D000544 NONE NIK-247_4\NNP|drug|may|that (r_nsubj) be_6\VB|.|findings (l_attr) drug_9\NN|NIK|may|that (l_prep) for_10\IN|useful|a (l_pobj) treatment_12\NN|NONE (l_prep) of_13\IN|the (l_pobj) disease_16\NN|NONE
C049860_D000647 CID NIK-247_2\NNP|NONE (l_prep) on_3\IN|NONE (l_pobj) cholinesterase_4\NN|NONE (l_conj) amnesia_9\NN|and
C049860_D000647 CID NIK-247_3\NNP|NONE (r_pobj) of_2\IN|The (r_prep) effects_1\NNS|,|compared|were|and|.|amnesia (r_nsubjpass) examined_15\VBN|NONE (l_nsubjpass) amnesia_10\NN|,|compared|effects|were|and|.
C049860_D000647 CID NIK-247_4\NNP|affect|amnesia|but|that (r_nsubj) improves_16\VBZ|.|findings (l_dobj) amnesia_20\NN|NIK|affect|but|that
D013619_D000647 CID tacrine_27\NN|cholinesterase|the|known (r_appos) inhibitors_26\NNS|NONE (r_pobj) of_20\IN|NONE (r_prep) those_19\DT|NONE (r_pobj) with_18\IN|NONE (r_prep) compared_17\VBN|,|effects|were|and|.|amnesia (r_conj) examined_15\VBN|NONE (l_nsubjpass) amnesia_10\NN|,|compared|effects|were|and|.
D012601_D000647 CID scopolamine_6\NN| (r_npadvmod) induced_8\VBN|NONE (r_amod) amnesia_9\NN|and
D012601_D000647 CID scopolamine_7\NN| (r_npadvmod) induced_9\VBN|movement|and (r_amod) amnesia_10\NN|,|compared|effects|were|and|.
D012601_D000647 CID scopolamine_14\NN|NONE (r_pobj) by_13\IN|in (r_agent) induced_12\VBN|the (r_acl) amnesia_11\NN|.|significantly|compounds|p.o.
D012601_D000647 CID scopolamine_17\NN| (r_npadvmod) induced_19\VBN|NONE (r_amod) amnesia_20\NN|NIK|affect|but|that
C076946_D000647 CID E-2020_29\NNS|and (r_conj) tacrine_27\NN|cholinesterase|the|known (r_appos) inhibitors_26\NNS|NONE (r_pobj) of_20\IN|NONE (r_prep) those_19\DT|NONE (r_pobj) with_18\IN|NONE (r_prep) compared_17\VBN|,|effects|were|and|.|amnesia (r_conj) examined_15\VBN|NONE (l_nsubjpass) amnesia_10\NN|,|compared|effects|were|and|.
9636837
D002945_D020258 NONE cisplatin_11\NN|( (r_nmod) CDDP_13\NNP|NONE (r_pobj) over_10\IN|of|most|The (r_prep) striking_2\JJ|.|)|rate (r_nsubj) is_15\VBZ|NONE (l_attr) rate_19\NN|.|)|striking (l_prep) of_20\IN|reduced|its (l_pobj) effects_22\NNS|NONE (l_amod) neurotoxic_21\JJ|NONE
D002945_D020258 NONE CDDP_13\NNP|NONE (r_pobj) over_10\IN|of|most|The (r_prep) striking_2\JJ|.|)|rate (r_nsubj) is_15\VBZ|NONE (l_attr) rate_19\NN|.|)|striking (l_prep) of_20\IN|reduced|its (l_pobj) effects_22\NNS|NONE (l_amod) neurotoxic_21\JJ|NONE
D002945_D020258 NONE CDDP_23\NNP|NONE (r_pobj) by_22\IN|NONE (r_agent) caused_21\VBN|NONE (r_acl) those_20\DT|NONE (r_pobj) to_19\IN|closely (r_prep) similar_18\JJ|is|.|type (r_acomp) are_15\VBP|and|in|neurotoxic|,|CBDCA (r_conj) is_1\VBZ|NONE (l_acomp) neurotoxic_2\JJ|and|are|in|,|CBDCA
D002945_D020258 NONE CDDP_23\NNP|NONE (r_pobj) by_22\IN|NONE (r_agent) caused_21\VBN|NONE (r_acl) those_20\DT|NONE (r_pobj) to_19\IN|closely (r_prep) similar_18\JJ|is|.|type (r_acomp) are_15\VBP|and|in|neurotoxic|,|CBDCA (l_ccomp) is_26\VBZ|similar|.|type (l_ccomp) induced_31\VBN|it|that|probable (l_nsubjpass) neurotoxicity_29\NN|in|that|by|is
D016190_D010523 CID CBDCA_5\NNP|association|intensity|and (r_nmod) schedules_9\NNS|NONE (r_pobj) of_4\IN|the (r_prep) use_3\NN|concern|However|.|may|, (r_nsubj) cause_20\VB|NONE (l_dobj) concern_22\NN|However|.|use|may|, (l_prep) about_23\IN|some (l_pobj) safety_25\NN|NONE (l_prep) with_26\IN|its (l_pobj) respect_27\NN|NONE (l_prep) to_28\IN|NONE (l_pobj) damage_32\NN|NONE
D016190_D010523 CID CBDCA_0\JJ|NONE (r_compound) administration_1\NN|neurotoxicity|. (r_nsubj) induced_2\VBD|NONE (l_dobj) neurotoxicity_7\NN|administration|.
D016190_D020258 NONE carboplatin_4\NN|CBDCA|(|) (r_poss) advantages_6\NNS|NONE (r_pobj) of_3\IN|over|most|The (r_prep) striking_2\JJ|.|)|rate (r_nsubj) is_15\VBZ|NONE (l_attr) rate_19\NN|.|)|striking (l_prep) of_20\IN|reduced|its (l_pobj) effects_22\NNS|NONE (l_amod) neurotoxic_21\JJ|NONE
D016190_D020258 NONE CBDCA_8\NNP|(|carboplatin|) (r_appos) advantages_6\NNS|NONE (r_pobj) of_3\IN|over|most|The (r_prep) striking_2\JJ|.|)|rate (r_nsubj) is_15\VBZ|NONE (l_attr) rate_19\NN|.|)|striking (l_prep) of_20\IN|reduced|its (l_pobj) effects_22\NNS|NONE (l_amod) neurotoxic_21\JJ|NONE
D016190_D020258 NONE CBDCA_5\NNP|association|intensity|and (r_nmod) schedules_9\NNS|NONE (l_conj) association_12\NN|CBDCA|intensity|and (l_prep) with_13\IN|the|in (l_pobj) drugs_16\NNS|NONE (l_amod) neurotoxic_15\JJ|other
D016190_D020258 NONE CBDCA_0\NNP|and|are|in|neurotoxic|, (r_nsubj) is_1\VBZ|NONE (l_acomp) neurotoxic_2\JJ|and|are|in|,|CBDCA
D016190_D020258 NONE CBDCA_0\NNP|and|are|in|neurotoxic|, (r_nsubj) is_1\VBZ|NONE (l_conj) are_15\VBP|and|in|neurotoxic|,|CBDCA (l_ccomp) is_26\VBZ|similar|.|type (l_ccomp) induced_31\VBN|it|that|probable (l_nsubjpass) neurotoxicity_29\NN|in|that|by|is
18261172
D000806_D011507 NONE inhibitor_1\NN|.|development (r_nsubj) reduced_11\VBN|NONE (l_dobj) development_13\NN|.|inhibitor (l_compound) proteinuria_12\NN|NONE
D000806_D011507 NONE ACEi_5\NNP|monitored|ARB|patients|/|and (r_nmod) therapy_8\NN|NONE (l_acl) monitored_11\VBD|ACEi|ARB|patients|/|and (l_prep) for_12\IN|NONE (l_pobj) proteinuria_13\NN|NONE
D057911_D007674 NONE ARB_7\NNP|ACEi|monitored|patients|/|and (r_compound) therapy_8\NN|NONE (r_pobj) with_4\IN|Srl|and|be|should|increased|. (r_prep) used_3\VBN|NONE (l_conj) increased_15\VBD|Srl|and|be|should|with|. (l_dobj) dysfunction_17\NN|NONE
D020123_D011507 CID sirolimus_6\NN| (r_npadvmod) based_8\VBN|in (r_amod) immunosuppression_9\NN|NONE (r_pobj) to_5\IN|NONE (r_prep) switch_4\NN|NONE (r_pobj) after_3\IN|of|. (r_prep) Development_0\NN|NONE (l_prep) of_1\IN|.|after (l_pobj) proteinuria_2\NN|NONE
D020123_D011507 CID sirolmus_7\NN|effects|(|immunosuppressive|IS (r_nsubj) lacks_11\VBZ|following|.|proteinuria|however|been|,|;|has (r_ccomp) reported_23\VBN|NONE (l_nsubjpass) proteinuria_17\NN|lacks|following|.|however|been|,|;|has
D020123_D011507 CID Srl_9\NNP|drug|)|(|) (r_appos) sirolmus_7\NN|effects|(|immunosuppressive|IS (r_nsubj) lacks_11\VBZ|following|.|proteinuria|however|been|,|;|has (r_ccomp) reported_23\VBN|NONE (l_nsubjpass) proteinuria_17\NN|lacks|following|.|however|been|,|;|has
D020123_D011507 CID Srl_20\NNP|NONE (r_pobj) with_19\IN|NONE (r_prep) associated_18\VBN|NONE (r_acl) proteinuria_17\NN|lacks|following|.|however|been|,|;|has
D020123_D011507 CID Srl_10\NNP|NONE (r_pobj) with_9\IN|NONE (r_prep) associated_8\VBN|of|the (r_acl) incidence_5\NN|.|In|,|unknown (l_prep) of_6\IN|associated|the (l_pobj) proteinuria_7\NN|NONE
D020123_D011507 CID Srl_12\NNP|NONE (r_pobj) to_11\IN|NONE (r_prep) switch_10\NN|NONE (r_pobj) after_9\IN|Thus|.|may|in|,|proteinuria (r_prep) develop_4\VB|NONE (l_nsubj) proteinuria_2\NN|Thus|.|may|after|in|,
D020123_D011507 CID Srl_0\NNP|and|be|should|increased|with|. (r_nsubjpass) used_3\VBN|NONE (l_prep) with_4\IN|Srl|and|be|should|increased|. (l_pobj) therapy_8\NN|NONE (l_acl) monitored_11\VBD|ACEi|ARB|patients|/|and (l_prep) for_12\IN|NONE (l_pobj) proteinuria_13\NN|NONE
D020123_D007674 NONE sirolmus_7\NN|effects|(|immunosuppressive|IS (r_nsubj) lacks_11\VBZ|following|.|proteinuria|however|been|,|;|has (l_dobj) effects_13\NNS|sirolmus|(|immunosuppressive|IS (l_amod) nephrotoxic_12\JJ|NONE
D020123_D007674 NONE Srl_9\NNP|drug|)|(|) (r_appos) sirolmus_7\NN|effects|(|immunosuppressive|IS (r_nsubj) lacks_11\VBZ|following|.|proteinuria|however|been|,|;|has (l_dobj) effects_13\NNS|sirolmus|(|immunosuppressive|IS (l_amod) nephrotoxic_12\JJ|NONE
D020123_D007674 NONE Srl_20\NNP|NONE (r_pobj) with_19\IN|NONE (r_prep) associated_18\VBN|NONE (r_acl) proteinuria_17\NN|lacks|following|.|however|been|,|;|has (r_nsubjpass) reported_23\VBN|NONE (l_ccomp) lacks_11\VBZ|following|.|proteinuria|however|been|,|;|has (l_dobj) effects_13\NNS|sirolmus|(|immunosuppressive|IS (l_amod) nephrotoxic_12\JJ|NONE
D020123_D007674 NONE Srl_0\NNP|and|be|should|increased|with|. (r_nsubjpass) used_3\VBN|NONE (l_conj) increased_15\VBD|Srl|and|be|should|with|. (l_dobj) dysfunction_17\NN|NONE
D057911_D011507 NONE blocker_6\NN|ARB|)|( (r_nmod) therapy_10\NN|ACE|and (r_conj) inhibitor_1\NN|.|development (r_nsubj) reduced_11\VBN|NONE (l_dobj) development_13\NN|.|inhibitor (l_compound) proteinuria_12\NN|NONE
D057911_D011507 NONE ARB_8\NNP|blocker|)|( (r_nmod) therapy_10\NN|ACE|and (r_conj) inhibitor_1\NN|.|development (r_nsubj) reduced_11\VBN|NONE (l_dobj) development_13\NN|.|inhibitor (l_compound) proteinuria_12\NN|NONE
D057911_D011507 NONE ARB_7\NNP|ACEi|monitored|patients|/|and (r_compound) therapy_8\NN|NONE (l_acl) monitored_11\VBD|ACEi|ARB|patients|/|and (l_prep) for_12\IN|NONE (l_pobj) proteinuria_13\NN|NONE
D000806_D007674 NONE ACEi_5\NNP|monitored|ARB|patients|/|and (r_nmod) therapy_8\NN|NONE (r_pobj) with_4\IN|Srl|and|be|should|increased|. (r_prep) used_3\VBN|NONE (l_conj) increased_15\VBD|Srl|and|be|should|with|. (l_dobj) dysfunction_17\NN|NONE
12921865
C105051_D012640 NONE ganaxolone_18\NN|pregnanone|and (r_conj) pregnanolone_9\NN|alpha|,|(|) (r_appos) Allopregnanolone_0\NN|were|.|for (r_nsubjpass) tested_34\VBN|NONE (l_prep) for_35\IN|Allopregnanolone|were|. (l_pobj) ability_37\NN|NONE (l_acl) suppress_39\VB|their (l_dobj) expression_41\NN|to (l_appos) effect_44\NN|the|( (l_conj) development_47\NN|and|anticonvulsant|) (l_prep) of_52\IN|effect|(|) (l_pobj) seizures_56\NNS|NONE
C105051_D012640 NONE pregnan-20-one_31\NNP|NONE (r_appos) 3alpha_25\CD|NONE (r_appos) allopregnanolone_24\NN|NONE (r_pobj) of_23\IN|a|synthetic (r_prep) derivative_22\NN|(|) (r_appos) ganaxolone_18\NN|pregnanone|and (r_conj) pregnanolone_9\NN|alpha|,|(|) (r_appos) Allopregnanolone_0\NN|were|.|for (r_nsubjpass) tested_34\VBN|NONE (l_prep) for_35\IN|Allopregnanolone|were|. (l_pobj) ability_37\NN|NONE (l_acl) suppress_39\VB|their (l_dobj) expression_41\NN|to (l_appos) effect_44\NN|the|( (l_conj) development_47\NN|and|anticonvulsant|) (l_prep) of_52\IN|effect|(|) (l_pobj) seizures_56\NNS|NONE
C105051_D012640 NONE ganaxolone_18\NN|and|only (r_conj) allopregnanolone_16\NN|development|whereas (r_nsubj) inhibited_19\VBD|All|,|.|expression (r_advcl) suppressed_7\VBD|NONE (l_dobj) expression_9\NN|All|inhibited|,|. (l_prep) of_10\IN|the (l_pobj) seizures_12\NNS|NONE
D013256_D012640 NONE steroids_4\NNS|NONE (l_prep) against_5\IN|neuroactive (l_pobj) seizures_9\NNS|NONE
D013256_D012640 NONE steroid_13\NN|to (l_relcl) modulate_16\VBP|endogenous|synthetic|two|one|neuroactive (l_dobj) acid_21\NN|positively|that (l_appos) receptor_26\NN|GABA(A|the|)|(|)|aminobutyric (l_prep) against_27\IN|NONE (l_pobj) increase_29\NN|NONE (l_prep) in_30\IN|the (l_pobj) sensitivity_31\NN|NONE (l_prep) to_32\IN|NONE (l_pobj) effects_35\NNS|NONE (l_prep) of_36\IN|the|convulsant (l_pobj) cocaine_37\NN|NONE (l_acl) engendered_38\VBN|NONE (l_agent) by_39\IN|NONE (l_pobj) administration_42\NN|NONE (l_appos) kindling_45\NN|repeated|)|(|cocaine (l_compound) seizure_44\NN|NONE
D013256_D009422 NONE steroids_1\NNS|actions|. (r_nsubj) demonstrate_2\VBP|NONE (l_dobj) actions_4\NNS|steroids|. (l_relcl) have_6\VBP|pharmacological (l_dobj) relevance_7\NN|that (l_prep) for_8\IN|NONE (l_pobj) host_10\NN|NONE (l_prep) of_11\IN|a (l_pobj) disorders_15\NNS|NONE
D013256_D001523 NONE steroids_1\NNS|actions|. (r_nsubj) demonstrate_2\VBP|NONE (l_dobj) actions_4\NNS|steroids|. (l_relcl) have_6\VBP|pharmacological (l_dobj) relevance_7\NN|that (l_prep) for_8\IN|NONE (l_pobj) host_10\NN|NONE (l_prep) of_11\IN|a (l_pobj) disorders_15\NNS|NONE
D011280_D012640 NONE Allopregnanolone_0\NN|were|.|for (r_nsubjpass) tested_34\VBN|NONE (l_prep) for_35\IN|Allopregnanolone|were|. (l_pobj) ability_37\NN|NONE (l_acl) suppress_39\VB|their (l_dobj) expression_41\NN|to (l_appos) effect_44\NN|the|( (l_conj) development_47\NN|and|anticonvulsant|) (l_prep) of_52\IN|effect|(|) (l_pobj) seizures_56\NNS|NONE
D011280_D012640 NONE pregnan-20-one_6\NNP|NONE (r_advmod) 3alpha_2\CD|pregnanolone|,|(|) (r_appos) Allopregnanolone_0\NN|were|.|for (r_nsubjpass) tested_34\VBN|NONE (l_prep) for_35\IN|Allopregnanolone|were|. (l_pobj) ability_37\NN|NONE (l_acl) suppress_39\VB|their (l_dobj) expression_41\NN|to (l_appos) effect_44\NN|the|( (l_conj) development_47\NN|and|anticonvulsant|) (l_prep) of_52\IN|effect|(|) (l_pobj) seizures_56\NNS|NONE
D011280_D012640 NONE pregnanolone_9\NN|alpha|,|(|) (r_appos) Allopregnanolone_0\NN|were|.|for (r_nsubjpass) tested_34\VBN|NONE (l_prep) for_35\IN|Allopregnanolone|were|. (l_pobj) ability_37\NN|NONE (l_acl) suppress_39\VB|their (l_dobj) expression_41\NN|to (l_appos) effect_44\NN|the|( (l_conj) development_47\NN|and|anticonvulsant|) (l_prep) of_52\IN|effect|(|) (l_pobj) seizures_56\NNS|NONE
D011280_D012640 NONE pregnan-20-one_15\NNP|ganaxolone|and (r_parataxis) pregnanolone_9\NN|alpha|,|(|) (r_appos) Allopregnanolone_0\NN|were|.|for (r_nsubjpass) tested_34\VBN|NONE (l_prep) for_35\IN|Allopregnanolone|were|. (l_pobj) ability_37\NN|NONE (l_acl) suppress_39\VB|their (l_dobj) expression_41\NN|to (l_appos) effect_44\NN|the|( (l_conj) development_47\NN|and|anticonvulsant|) (l_prep) of_52\IN|effect|(|) (l_pobj) seizures_56\NNS|NONE
D011280_D012640 NONE allopregnanolone_24\NN|NONE (r_pobj) of_23\IN|a|synthetic (r_prep) derivative_22\NN|(|) (r_appos) ganaxolone_18\NN|pregnanone|and (r_conj) pregnanolone_9\NN|alpha|,|(|) (r_appos) Allopregnanolone_0\NN|were|.|for (r_nsubjpass) tested_34\VBN|NONE (l_prep) for_35\IN|Allopregnanolone|were|. (l_pobj) ability_37\NN|NONE (l_acl) suppress_39\VB|their (l_dobj) expression_41\NN|to (l_appos) effect_44\NN|the|( (l_conj) development_47\NN|and|anticonvulsant|) (l_prep) of_52\IN|effect|(|) (l_pobj) seizures_56\NNS|NONE
D011280_D012640 NONE allopregnanolone_16\NN|development|whereas (r_nsubj) inhibited_19\VBD|All|,|.|expression (r_advcl) suppressed_7\VBD|NONE (l_dobj) expression_9\NN|All|inhibited|,|. (l_prep) of_10\IN|the (l_pobj) seizures_12\NNS|NONE
D005680_D012640 NONE acid_21\NN|positively|that (l_appos) receptor_26\NN|GABA(A|the|)|(|)|aminobutyric (l_prep) against_27\IN|NONE (l_pobj) increase_29\NN|NONE (l_prep) in_30\IN|the (l_pobj) sensitivity_31\NN|NONE (l_prep) to_32\IN|NONE (l_pobj) effects_35\NNS|NONE (l_prep) of_36\IN|the|convulsant (l_pobj) cocaine_37\NN|NONE (l_acl) engendered_38\VBN|NONE (l_agent) by_39\IN|NONE (l_pobj) administration_42\NN|NONE (l_appos) kindling_45\NN|repeated|)|(|cocaine (l_compound) seizure_44\NN|NONE
D005680_D012640 NONE GABA(A_23\NNP|the|)|(|)|aminobutyric|receptor (r_appos) acid_21\NN|positively|that (l_appos) receptor_26\NN|GABA(A|the|)|(|)|aminobutyric (l_prep) against_27\IN|NONE (l_pobj) increase_29\NN|NONE (l_prep) in_30\IN|the (l_pobj) sensitivity_31\NN|NONE (l_prep) to_32\IN|NONE (l_pobj) effects_35\NNS|NONE (l_prep) of_36\IN|the|convulsant (l_pobj) cocaine_37\NN|NONE (l_acl) engendered_38\VBN|NONE (l_agent) by_39\IN|NONE (l_pobj) administration_42\NN|NONE (l_appos) kindling_45\NN|repeated|)|(|cocaine (l_compound) seizure_44\NN|NONE
D005680_D012640 NONE GABA(A_4\NN|these|positive|) (r_nmod) modulators_6\NNS|NONE (r_pobj) of_1\IN|NONE (r_prep) All_0\DT|inhibited|,|.|expression (r_nsubj) suppressed_7\VBD|NONE (l_dobj) expression_9\NN|All|inhibited|,|. (l_prep) of_10\IN|the (l_pobj) seizures_12\NNS|NONE
D003042_D012640 CID cocaine_6\NN||kindled (r_compound) seizures_9\NNS|NONE
D003042_D012640 CID cocaine_37\NN|NONE (l_acl) engendered_38\VBN|NONE (l_agent) by_39\IN|NONE (l_pobj) administration_42\NN|NONE (l_appos) kindling_45\NN|repeated|)|(|cocaine (l_compound) seizure_44\NN|NONE
D003042_D012640 CID cocaine_41\NN|repeated|)|kindling|( (r_compound) administration_42\NN|NONE (l_appos) kindling_45\NN|repeated|)|(|cocaine (l_compound) seizure_44\NN|NONE
D003042_D012640 CID cocaine_53\NN| (r_npadvmod) kindled_55\VBN|in (r_amod) seizures_56\NNS|NONE
D003042_D012640 CID cocaine_10\NN|NONE (r_pobj) of_7\IN|daily (r_prep) administration_6\NN|NONE (r_pobj) by_4\IN|for|.|Kindled|were (r_agent) induced_3\VBN|NONE (l_csubjpass) Kindled_0\VBN|for|.|by|were (l_dobj) seizures_1\NNS|NONE
11007689
D016572_D057049 CID Cyclosporine_0\NN|NONE (l_conj) microangiopathy_6\NN|and|.
D016572_D057049 CID cyclosporine_13\NN|NONE (r_pobj) of_12\IN|the (r_prep) use_11\NN|NONE (r_pobj) with_9\IN|NONE (r_prep) associated_8\VBN|TMA|thrombotic (r_acl) microangiopathy_4\NN|NONE
D016572_D057049 CID cyclosporine_13\NN|NONE (r_pobj) of_12\IN|the (r_prep) use_11\NN|NONE (r_pobj) with_9\IN|NONE (r_prep) associated_8\VBN|TMA|thrombotic (r_acl) microangiopathy_4\NN|NONE (l_appos) TMA_6\NNP|thrombotic|associated
D016572_D057049 CID cyclosporine_20\NN| (r_npadvmod) induced_22\VBN|NONE (r_amod) TMA_23\NNP|NONE
D016572_D057049 CID cyclosporine_16\NN|NONE (r_pobj) to_15\IN|sequentially (r_prep) exposed_13\VBN|NONE (r_acl) patients_12\NNS|NONE (r_pobj) in_11\IN|of|the (r_prep) recurrence_8\NN|NONE (l_prep) of_9\IN|the|in (l_pobj) TMA_10\NNP|NONE
D016572_D057049 CID cyclosporine_13\NN| (r_npadvmod) induced_15\VBN|responded (r_amod) TMA_16\NNP|who
D016572_D057049 CID cyclosporine_23\NN|NONE (r_pobj) of_22\IN|the|in (r_prep) withdrawal_21\NN|NONE (r_pobj) to_19\IN|that (r_prep) responded_18\VBD|induced (r_relcl) TMA_16\NNP|who
D016572_D057049 CID cyclosporine_5\NN|NONE (r_pobj) from_4\IN|who|are|to (r_prep) switched_3\VBN|NONE (r_relcl) Patients_0\NNS|closely|should|be|.|for (r_nsubjpass) monitored_14\VBN|NONE (l_prep) for_15\IN|closely|Patients|should|be|. (l_pobj) signs_17\NNS|NONE (l_prep) of_20\IN|symptoms|the|and (l_pobj) TMA_22\NNP|NONE
D016559_D057049 CID tacrolimus_2\NN| (r_npadvmod) associated_4\VBN|thrombotic (r_amod) microangiopathy_6\NN|and|.
D016559_D057049 CID tacrolimus_6\NN|NONE (r_pobj) to_5\IN|NONE (r_prep) switching_4\VBG|has|.|be|As|been|, (r_nsubjpass) reported_9\VBN|NONE (l_xcomp) be_11\VB|switching|has|.|As|been|, (l_attr) option_15\NN|to (l_prep) in_16\IN|a|viable|therapeutic (l_pobj) setting_18\NN|NONE (l_prep) of_19\IN|the (l_pobj) TMA_23\NNP|NONE
D016559_D057049 CID tacrolimus_6\NN|NONE (r_pobj) of_5\IN|the|widespread (r_prep) application_4\NN|NONE (r_pobj) With_0\IN|,|also|been|.|has|TMA (r_prep) recognized_18\VBN|NONE (l_nsubjpass) TMA_14\NNP|,|also|With|been|.|has
D016559_D057049 CID tacrolimus_11\NN| (r_npadvmod) associated_13\VBN|NONE (r_amod) TMA_14\NNP|,|also|With|been|.|has
D016559_D057049 CID tacrolimus_18\NN|and (r_conj) cyclosporine_16\NN|NONE (r_pobj) to_15\IN|sequentially (r_prep) exposed_13\VBN|NONE (r_acl) patients_12\NNS|NONE (r_pobj) in_11\IN|of|the (r_prep) recurrence_8\NN|NONE (l_prep) of_9\IN|the|in (l_pobj) TMA_10\NNP|NONE
D016559_D057049 CID tacrolimus_2\NN|NONE (r_pobj) of_1\IN|NONE (r_prep) Introduction_0\NN|.|in (r_nsubj) resulted_8\VBD|NONE (l_prep) in_9\IN|Introduction|. (l_pobj) recurrence_11\NN|NONE (l_prep) of_12\IN|the|and|loss (l_pobj) TMA_13\NNP|NONE
D016559_D057049 CID tacrolimus_7\NN|NONE (r_pobj) to_6\IN|who|from|are (r_prep) switched_3\VBN|NONE (r_relcl) Patients_0\NNS|closely|should|be|.|for (r_nsubjpass) monitored_14\VBN|NONE (l_prep) for_15\IN|closely|Patients|should|be|. (l_pobj) signs_17\NNS|NONE (l_prep) of_20\IN|symptoms|the|and (l_pobj) TMA_22\NNP|NONE
7199841
C004616_D010243 CID CE_11\NN|seven| (r_nmod) %_15\NN|NONE (r_pobj) of_8\IN|subarachnoid (r_prep) injection_7\NN|that (r_dobj) received_5\VBD||)|the (r_relcl) animals_3\NNS|NONE (r_pobj) Of_0\IN|limb|developed|. (r_prep) paralysis_21\NN|NONE
C004616_D013118 CID CE_12\NNP|that (r_dobj) received_9\VBD|the (r_relcl) animals_7\NNS|NONE (r_pobj) of_5\IN|spinal||the (r_prep) cords_4\NNS|NONE (r_pobj) Of_0\IN|NONE (r_prep) 13_14\CD|,|necrosis (r_nsubj) showed_15\VBD|.|;|normal|roots (l_dobj) necrosis_17\NN|,|
D002045_D010243 NONE bupivacaine_6\NN|that (r_dobj) received_5\VBD|the (r_relcl) animals_3\NNS|NONE (r_pobj) of_1\IN|saline|, (r_prep) None_0\NN|to|. (r_nsubj) titrated_14\VBN|NONE (l_prep) to_15\IN|None|. (l_pobj) paralysis_23\NN|NONE
6728084
D000617_D007674 NONE aminoglycoside_3\NN|on (r_compound) treatment_4\NN|NONE (r_pobj) of_2\IN|.|Nephrotoxic (r_prep) effects_1\NNS|NONE (l_amod) Nephrotoxic_0\JJ|of|.
D000617_D007674 NONE aminoglycosides_2\NNS|.|Thus|may|as|, (r_nsubj) act_4\VB|NONE (l_prep) as_5\IN|.|Thus|may|,|aminoglycosides (l_pobj) nephrotoxicants_6\NNS|NONE (l_prep) at_7\IN|NONE (l_pobj) impairment_13\NN|NONE (l_prep) of_14\IN|inducing|glomerular (l_pobj) reabsorption_16\NN|NONE
2569282
D020927_D009127 NONE Dexmedetomidine_0\NNP|,|.|acting|,|rigidity (r_nsubj) prevents_8\VBZ|NONE (l_dobj) rigidity_13\NN|,|.|acting|Dexmedetomidine|,
D020927_D009127 NONE MED_13\NNP|NONE (r_pobj) with_10\IN|NONE (r_prep) treatment_9\NN|rigidity|if (r_nsubj) prevents_14\VBZ|In|.|authors|, (l_dobj) rigidity_17\NN|if|treatment
D020927_D009127 NONE MED_5\NNP|rigidity|,|In|. (r_nsubj) prevented_6\VBD|NONE (l_dobj) rigidity_11\NN|,|In|MED|.
D015760_D009127 CID alfentanil_23\NN|dose|in (r_compound) anesthesia_24\NN|NONE (r_pobj) by_19\IN|NONE (r_agent) caused_18\VBN|the|muscle (r_acl) rigidity_17\NN|if|treatment
D015760_D009127 CID alfentanil_7\NN| (r_npadvmod) induced_9\VBN|muscle|in (r_amod) rigidity_11\NN|,|In|MED|.
D020927_D012021 NONE MED_6\NNP|The|dose (r_compound) animals_7\NNS|,|lacked|flaccid|.|and (r_nsubj) were_8\VBD|NONE (l_conj) lacked_14\VBD|,|animals|flaccid|.|and (l_dobj) response_17\NN|NONE (l_compound) startle_16\JJ|a|during
D020927_D009123 NONE dexmedetomidine_7\NN|capable|. (r_nsubj) is_13\VBZ|NONE (l_acomp) capable_14\JJ|.|dexmedetomidine (l_prep) of_15\IN|NONE (l_pcomp) inducing_16\VBG|NONE (l_dobj) flaccidity_18\NN|NONE
D020927_D009123 NONE MED_11\NNP|agonist|alpha|The|selective (r_appos) dexmedetomidine_7\NN|capable|. (r_nsubj) is_13\VBZ|NONE (l_acomp) capable_14\JJ|.|dexmedetomidine (l_prep) of_15\IN|NONE (l_pcomp) inducing_16\VBG|NONE (l_dobj) flaccidity_18\NN|NONE
D020927_D018476 NONE MED_6\NNP|The|dose (r_compound) animals_7\NNS|,|lacked|flaccid|.|and (r_nsubj) were_8\VBD|NONE (l_acomp) flaccid_9\JJ|,|lacked|animals|.|and (l_conj) akinetic_11\JJ|,
19893084
D005839_D058186 CID gentamicin_12\NN|NONE (r_pcomp) by_11\IN|NONE (r_agent) induced_10\VBN|acute|renal (r_acl) failure_9\NN|NONE
18363626
D020927_D001919 CID dexmedetomidine_1\NN|NONE (r_amod) sedation_2\NN|with|was|Although (r_nsubjpass) associated_4\VBN|,|within|were|.|pressures (l_prep) with_5\IN|sedation|was|Although (l_pobj) incidence_9\NN|NONE (l_prep) of_10\IN|%|a (l_pobj) bradycardia_11\NN|NONE
D010100_D001919 NONE oxygen_30\NN|NONE (r_compound) saturations_31\NNS|normal|and|adjusted (r_conj) range_28\NN|NONE (r_pobj) of_23\IN| (r_prep) %_22\NN|NONE (r_pobj) within_20\IN|,|associated|were|.|pressures (r_prep) were_19\VBD|NONE (l_advcl) associated_4\VBN|,|within|were|.|pressures (l_prep) with_5\IN|sedation|was|Although (l_pobj) incidence_9\NN|NONE (l_prep) of_10\IN|%|a (l_pobj) bradycardia_11\NN|NONE
3560095
D005480_D001171 NONE Flurbiprofen_0\NNP|NONE (l_prep) in_1\IN|. (l_pobj) treatment_3\NN|NONE (l_prep) of_4\IN|the (l_pobj) arthritis_7\NN|NONE
D005480_D001171 NONE flurbiprofen_13\JJ|NONE (r_pobj) with_12\IN|who|were|day|at (r_prep) treated_11\VBN|rheumatoid|juvenile|, (r_relcl) arthritis_7\NN|NONE
D005480_D001168 NONE flurbiprofen_13\JJ|NONE (r_pobj) with_12\IN|who|were|day|at (r_prep) treated_11\VBN|rheumatoid|juvenile|, (r_relcl) arthritis_7\NN|NONE (r_pobj) with_4\IN|,|four (r_prep) patients_3\NNS|decreases|. (r_nsubj) had_26\VBD|NONE (l_dobj) decreases_29\NNS|patients|. (l_prep) in_32\IN|after|from|significant (l_pobj) indices_35\NNS|NONE (l_compound) arthritis_34\NN|
6699841
D005279_D007681 NONE calcium_18\NN|, (r_conj) sulindac_15\NN|NONE (r_pobj) with_14\IN|previously|had|been|who (r_prep) treated_13\VBN|,|,|A|with|old (r_relcl) man_4\NN|.|necrosis|after (r_nsubj) developed_27\VBD|NONE (l_dobj) necrosis_30\NN|.|after|man
D005279_D007681 NONE calcium_18\NN|, (r_conj) sulindac_15\NN|NONE (r_pobj) with_14\IN|previously|had|been|who (r_prep) treated_13\VBN|,|,|A|with|old (r_relcl) man_4\NN|.|necrosis|after (r_nsubj) developed_27\VBD|NONE (l_dobj) necrosis_30\NN|.|after|man (l_appos) RPN_32\NNP|(|papillary|renal|)
D009288_D001172 NONE naproxen_39\NN|NONE (r_compound) therapy_40\NN|NONE (r_pobj) of_38\IN|NONE (r_prep) institution_37\NN|months (r_pobj) after_36\IN|.|necrosis|man (r_prep) developed_27\VBD|NONE (l_nsubj) man_4\NN|.|necrosis|after (l_prep) with_5\IN|,|,|A|old|treated (l_pobj) arthritis_7\NN|NONE
D006046_D001172 NONE gold_24\NN|NONE (r_compound) salts_25\NNS|and|dose|high (r_conj) salicylates_22\NNS|,|fenoprofen (r_conj) calcium_18\NN|, (r_conj) sulindac_15\NN|NONE (r_pobj) with_14\IN|previously|had|been|who (r_prep) treated_13\VBN|,|,|A|with|old (r_relcl) man_4\NN|.|necrosis|after (l_prep) with_5\IN|,|,|A|old|treated (l_pobj) arthritis_7\NN|NONE
D012459_D001172 NONE salicylates_22\NNS|,|fenoprofen (r_conj) calcium_18\NN|, (r_conj) sulindac_15\NN|NONE (r_pobj) with_14\IN|previously|had|been|who (r_prep) treated_13\VBN|,|,|A|with|old (r_relcl) man_4\NN|.|necrosis|after (l_prep) with_5\IN|,|,|A|old|treated (l_pobj) arthritis_7\NN|NONE
D013467_D007681 NONE sulindac_15\NN|NONE (r_pobj) with_14\IN|previously|had|been|who (r_prep) treated_13\VBN|,|,|A|with|old (r_relcl) man_4\NN|.|necrosis|after (r_nsubj) developed_27\VBD|NONE (l_dobj) necrosis_30\NN|.|after|man
D013467_D007681 NONE sulindac_15\NN|NONE (r_pobj) with_14\IN|previously|had|been|who (r_prep) treated_13\VBN|,|,|A|with|old (r_relcl) man_4\NN|.|necrosis|after (r_nsubj) developed_27\VBD|NONE (l_dobj) necrosis_30\NN|.|after|man (l_appos) RPN_32\NNP|(|papillary|renal|)
D013467_D007681 NONE sulindac_15\NN|NONE (r_pobj) of_14\IN|possible (r_prep) advantages_13\NNS|NONE (r_dobj) discuss_11\VB|to|RPN|and (r_conj) linking_4\VBG|previous (l_dobj) RPN_5\NNP|to|and|discuss
D013467_D007674 NONE sulindac_15\NN|NONE (l_prep) in_16\IN|NONE (l_pobj) patients_17\NNS|NONE (l_relcl) experienced_20\VBN|NONE (l_dobj) toxicity_22\NN|have|who
D013467_D001172 NONE sulindac_15\NN|NONE (r_pobj) with_14\IN|previously|had|been|who (r_prep) treated_13\VBN|,|,|A|with|old (r_relcl) man_4\NN|.|necrosis|after (l_prep) with_5\IN|,|,|A|old|treated (l_pobj) arthritis_7\NN|NONE
D009288_D007681 CID naproxen_5\NN|to (r_pobj) due_3\IN|Renal|papillary|. (r_prep) necrosis_2\NN|NONE
D009288_D007681 CID naproxen_39\NN|NONE (r_compound) therapy_40\NN|NONE (r_pobj) of_38\IN|NONE (r_prep) institution_37\NN|months (r_pobj) after_36\IN|.|necrosis|man (r_prep) developed_27\VBD|NONE (l_dobj) necrosis_30\NN|.|after|man
D009288_D007681 CID naproxen_39\NN|NONE (r_compound) therapy_40\NN|NONE (r_pobj) of_38\IN|NONE (r_prep) institution_37\NN|months (r_pobj) after_36\IN|.|necrosis|man (r_prep) developed_27\VBD|NONE (l_dobj) necrosis_30\NN|.|after|man (l_appos) RPN_32\NNP|(|papillary|renal|)
D012459_D007681 NONE salicylates_22\NNS|,|fenoprofen (r_conj) calcium_18\NN|, (r_conj) sulindac_15\NN|NONE (r_pobj) with_14\IN|previously|had|been|who (r_prep) treated_13\VBN|,|,|A|with|old (r_relcl) man_4\NN|.|necrosis|after (r_nsubj) developed_27\VBD|NONE (l_dobj) necrosis_30\NN|.|after|man
D012459_D007681 NONE salicylates_22\NNS|,|fenoprofen (r_conj) calcium_18\NN|, (r_conj) sulindac_15\NN|NONE (r_pobj) with_14\IN|previously|had|been|who (r_prep) treated_13\VBN|,|,|A|with|old (r_relcl) man_4\NN|.|necrosis|after (r_nsubj) developed_27\VBD|NONE (l_dobj) necrosis_30\NN|.|after|man (l_appos) RPN_32\NNP|(|papillary|renal|)
D005279_D001172 NONE calcium_18\NN|, (r_conj) sulindac_15\NN|NONE (r_pobj) with_14\IN|previously|had|been|who (r_prep) treated_13\VBN|,|,|A|with|old (r_relcl) man_4\NN|.|necrosis|after (l_prep) with_5\IN|,|,|A|old|treated (l_pobj) arthritis_7\NN|NONE
D006046_D007681 NONE gold_24\NN|NONE (r_compound) salts_25\NNS|and|dose|high (r_conj) salicylates_22\NNS|,|fenoprofen (r_conj) calcium_18\NN|, (r_conj) sulindac_15\NN|NONE (r_pobj) with_14\IN|previously|had|been|who (r_prep) treated_13\VBN|,|,|A|with|old (r_relcl) man_4\NN|.|necrosis|after (r_nsubj) developed_27\VBD|NONE (l_dobj) necrosis_30\NN|.|after|man
D006046_D007681 NONE gold_24\NN|NONE (r_compound) salts_25\NNS|and|dose|high (r_conj) salicylates_22\NNS|,|fenoprofen (r_conj) calcium_18\NN|, (r_conj) sulindac_15\NN|NONE (r_pobj) with_14\IN|previously|had|been|who (r_prep) treated_13\VBN|,|,|A|with|old (r_relcl) man_4\NN|.|necrosis|after (r_nsubj) developed_27\VBD|NONE (l_dobj) necrosis_30\NN|.|after|man (l_appos) RPN_32\NNP|(|papillary|renal|)
16720068
D017374_D009459 CID paroxetine_9\NN|NONE (r_pobj) with_8\IN|concomitant (r_prep) treatment_7\NN|NONE (r_pobj) to_5\IN|NONE (r_prep) related_4\VBN|.|malignant|Possible|neuroleptic (r_acl) syndrome_3\NN|NONE
D017374_D009459 CID paroxetine_24\NN|NONE (r_pobj) after_22\IN|symptoms|can|that (r_prep) occur_21\VB|thus (r_ccomp) demonstrating_14\VBG|patient|.|,|with (r_advcl) presented_2\VBN|NONE (l_prep) with_3\IN|patient|.|,|demonstrating (l_pobj) symptoms_4\NNS|NONE (l_prep) of_5\IN|NONE (l_pobj) syndrome_8\NN|NONE
D017374_D009459 CID paroxetine_24\NN|NONE (r_pobj) after_22\IN|symptoms|can|that (r_prep) occur_21\VB|thus (r_ccomp) demonstrating_14\VBG|patient|.|,|with (r_advcl) presented_2\VBN|NONE (l_prep) with_3\IN|patient|.|,|demonstrating (l_pobj) symptoms_4\NNS|NONE (l_prep) of_5\IN|NONE (l_pobj) syndrome_8\NN|NONE (l_appos) NMS_10\NNP|malignant|neuroleptic
D017374_D009459 CID paroxetine_24\NN|NONE (r_pobj) after_22\IN|symptoms|can|that (r_prep) occur_21\VB|thus (l_nsubj) symptoms_19\NNS|after|can|that (l_amod) like_18\JJ|NONE (l_npadvmod) NMS_16\NNP|
D000525_D011596 NONE alprazolam_7\NN|NONE (r_compound) treatment_8\NN|and (r_conj) paroxetine_5\NN|NONE (r_pobj) of_4\IN|th|the (r_prep) day_3\NN|NONE (r_pobj) On_0\IN|,|.|retardation|patient (r_prep) exhibited_12\VBD|NONE (l_dobj) retardation_15\NN|,|On|.|patient
D000525_D014202 NONE alprazolam_7\NN|NONE (r_compound) treatment_8\NN|and (r_conj) paroxetine_5\NN|NONE (r_pobj) of_4\IN|th|the (r_prep) day_3\NN|NONE (r_pobj) On_0\IN|,|.|retardation|patient (r_prep) exhibited_12\VBD|NONE (l_dobj) retardation_15\NN|,|On|.|patient (l_conj) disorientation_17\NN|marked|,|psychomotor (l_conj) rigidity_22\NN|,|and (l_prep) with_23\IN|muscle|severe (l_pobj) tremors_24\NNS|NONE
D000525_D009127 NONE alprazolam_7\NN|NONE (r_compound) treatment_8\NN|and (r_conj) paroxetine_5\NN|NONE (r_pobj) of_4\IN|th|the (r_prep) day_3\NN|NONE (r_pobj) On_0\IN|,|.|retardation|patient (r_prep) exhibited_12\VBD|NONE (l_dobj) retardation_15\NN|,|On|.|patient (l_conj) disorientation_17\NN|marked|,|psychomotor (l_conj) rigidity_22\NN|,|and
D000525_D009459 CID alprazolam_11\NN|and (r_conj) paroxetine_9\NN|NONE (r_pobj) with_8\IN|concomitant (r_prep) treatment_7\NN|NONE (r_pobj) to_5\IN|NONE (r_prep) related_4\VBN|.|malignant|Possible|neuroleptic (r_acl) syndrome_3\NN|NONE
D000525_D009459 CID alprazolam_26\NN|NONE (r_compound) treatment_27\NN|and|combined (r_conj) paroxetine_24\NN|NONE (r_pobj) after_22\IN|symptoms|can|that (r_prep) occur_21\VB|thus (r_ccomp) demonstrating_14\VBG|patient|.|,|with (r_advcl) presented_2\VBN|NONE (l_prep) with_3\IN|patient|.|,|demonstrating (l_pobj) symptoms_4\NNS|NONE (l_prep) of_5\IN|NONE (l_pobj) syndrome_8\NN|NONE
D000525_D009459 CID alprazolam_26\NN|NONE (r_compound) treatment_27\NN|and|combined (r_conj) paroxetine_24\NN|NONE (r_pobj) after_22\IN|symptoms|can|that (r_prep) occur_21\VB|thus (r_ccomp) demonstrating_14\VBG|patient|.|,|with (r_advcl) presented_2\VBN|NONE (l_prep) with_3\IN|patient|.|,|demonstrating (l_pobj) symptoms_4\NNS|NONE (l_prep) of_5\IN|NONE (l_pobj) syndrome_8\NN|NONE (l_appos) NMS_10\NNP|malignant|neuroleptic
D000525_D009459 CID alprazolam_26\NN|NONE (r_compound) treatment_27\NN|and|combined (r_conj) paroxetine_24\NN|NONE (r_pobj) after_22\IN|symptoms|can|that (r_prep) occur_21\VB|thus (l_nsubj) symptoms_19\NNS|after|can|that (l_amod) like_18\JJ|NONE (l_npadvmod) NMS_16\NNP|
D017374_D009127 NONE paroxetine_5\NN|NONE (r_pobj) of_4\IN|th|the (r_prep) day_3\NN|NONE (r_pobj) On_0\IN|,|.|retardation|patient (r_prep) exhibited_12\VBD|NONE (l_dobj) retardation_15\NN|,|On|.|patient (l_conj) disorientation_17\NN|marked|,|psychomotor (l_conj) rigidity_22\NN|,|and
D017374_D014202 NONE paroxetine_5\NN|NONE (r_pobj) of_4\IN|th|the (r_prep) day_3\NN|NONE (r_pobj) On_0\IN|,|.|retardation|patient (r_prep) exhibited_12\VBD|NONE (l_dobj) retardation_15\NN|,|On|.|patient (l_conj) disorientation_17\NN|marked|,|psychomotor (l_conj) rigidity_22\NN|,|and (l_prep) with_23\IN|muscle|severe (l_pobj) tremors_24\NNS|NONE
D017374_D011596 NONE paroxetine_5\NN|NONE (r_pobj) of_4\IN|th|the (r_prep) day_3\NN|NONE (r_pobj) On_0\IN|,|.|retardation|patient (r_prep) exhibited_12\VBD|NONE (l_dobj) retardation_15\NN|,|On|.|patient
20103708
D013311_D058186 NONE streptozotocin_13\RB| (r_npadvmod) induced_15\VBN|renal (r_amod) damage_17\NN|NONE
D010100_D051437 NONE oxygen_20\NN|(|reactive|ROS|) (r_compound) species_21\NNS|NONE (r_pobj) of_18\IN|the (r_prep) production_17\NN|NONE (r_pobj) by_15\IN|which|is (r_agent) accompanied_14\VBN|major|of|the|, (r_relcl) causes_7\NNS|NONE (l_prep) of_8\IN|major|accompanied|the|, (l_pobj) failure_10\NN|NONE
D010100_D003928 NONE oxygen_20\NN|(|reactive|ROS|) (r_compound) species_21\NNS|NONE (r_pobj) of_18\IN|the (r_prep) production_17\NN|NONE (r_pobj) by_15\IN|which|is (r_agent) accompanied_14\VBN|major|of|the|, (r_relcl) causes_7\NNS|NONE (r_pobj) of_4\IN|NONE (r_prep) one_3\CD|.|nephropathy (r_attr) is_2\VBZ|NONE (l_nsubj) nephropathy_1\NN|.|one
D013311_D003928 CID streptozotocin_6\JJ| (r_npadvmod) induced_8\VBN|diabetic (r_amod) nephropathy_10\NN|NONE
D013311_D003928 CID streptozotocin_22\RB| (r_npadvmod) induced_24\VBN|.|explore|:|,|in|a|nephropathy (r_amod) model_27\NN|NONE (l_ccomp) explore_2\VBP|.|:|,|induced|in|a|nephropathy (l_dobj) role_5\NN|We (l_prep) against_8\IN|the|of|protective (l_pobj) nephropathy_10\NN|NONE
D013311_D003928 CID streptozotocin_22\RB| (r_npadvmod) induced_24\VBN|.|explore|:|,|in|a|nephropathy (r_amod) model_27\NN|NONE (l_ccomp) explore_2\VBP|.|:|,|induced|in|a|nephropathy (l_dobj) role_5\NN|We (l_prep) against_8\IN|the|of|protective (l_pobj) nephropathy_10\NN|NONE (l_acl) using_11\VBG|diabetic (l_prep) from_16\IN|tissues (l_pobj) patients_19\NNS|NONE (l_compound) nephropathy_18\NN|diabetic
D013311_D003928 CID streptozotocin_22\RB| (r_npadvmod) induced_24\VBN|.|explore|:|,|in|a|nephropathy (r_amod) model_27\NN|NONE (l_compound) nephropathy_26\NN|.|explore|:|,|induced|in|a
18808529
D007545_D007511 CID isoproterenol_29\NN|NONE (r_pobj) by_28\IN|NONE (r_agent) induced_27\VBN|in|the|severe (r_acl) alterations_11\NNS|.|changes (r_dobj) explain_8\VBP|NONE (l_nsubj) changes_1\NNS|alterations|. (l_acl) related_3\VBN|,|,|These (l_prep) to_4\IN|NONE (l_pobj) injury_6\NN|NONE
D010100_D007022 NONE oxygen_15\NN|NONE (r_compound) supply_16\NN|NONE (r_pobj) of_14\IN|a|vs. (r_prep) mismatch_13\NN|explanation|. (l_prep) vs._17\IN|a|of (l_pobj) demand_18\NN|NONE (l_prep) following_19\VBG|NONE (l_pobj) hyperactivity_24\NN|NONE (l_nmod) hypotension_21\NN|myocardial
D007545_D009202 CID Isoproterenol_0\NN|.|correlation|:|loss (r_nsubj) induces_1\VBZ|NONE (l_dobj) correlation_10\NN|.|:|Isoproterenol|loss (l_prep) with_11\IN|NONE (l_pobj) injury_13\NN|NONE
D007545_D009202 CID isoproterenol_3\NN| (r_npadvmod) induced_5\VBN|myocardial (r_amod) damage_7\NN|NONE
D007545_D009202 CID isoproterenol_3\NN| (r_npadvmod) induced_5\VBN|myocardial (r_amod) damage_7\NN|NONE (r_pobj) of_2\IN|The (r_prep) mechanism_1\NN|is|,|unknown|but (r_nsubj) is_8\VBZ|NONE (l_conj) is_25\VBZ|,|unknown|mechanism|but (l_nsubj) mismatch_13\NN|explanation|. (l_prep) vs._17\IN|a|of (l_pobj) demand_18\NN|NONE (l_prep) following_19\VBG|NONE (l_pobj) hyperactivity_24\NN|NONE
D010100_D009202 NONE oxygen_15\NN|NONE (r_compound) supply_16\NN|NONE (r_pobj) of_14\IN|a|vs. (r_prep) mismatch_13\NN|explanation|. (r_nsubj) is_25\VBZ|,|unknown|mechanism|but (r_conj) is_8\VBZ|NONE (l_nsubj) mechanism_1\NN|is|,|unknown|but (l_prep) of_2\IN|The (l_pobj) damage_7\NN|NONE
D010100_D009202 NONE oxygen_15\NN|NONE (r_compound) supply_16\NN|NONE (r_pobj) of_14\IN|a|vs. (r_prep) mismatch_13\NN|explanation|. (l_prep) vs._17\IN|a|of (l_pobj) demand_18\NN|NONE (l_prep) following_19\VBG|NONE (l_pobj) hyperactivity_24\NN|NONE
D007545_D007022 NONE isoproterenol_3\NN| (r_npadvmod) induced_5\VBN|myocardial (r_amod) damage_7\NN|NONE (r_pobj) of_2\IN|The (r_prep) mechanism_1\NN|is|,|unknown|but (r_nsubj) is_8\VBZ|NONE (l_conj) is_25\VBZ|,|unknown|mechanism|but (l_nsubj) mismatch_13\NN|explanation|. (l_prep) vs._17\IN|a|of (l_pobj) demand_18\NN|NONE (l_prep) following_19\VBG|NONE (l_pobj) hyperactivity_24\NN|NONE (l_nmod) hypotension_21\NN|myocardial
7468724
D013726_D002318 CID terbutaline_4\JJ|for (r_compound) treatment_5\NN|NONE (r_pobj) with_3\IN|NONE (r_prep) associated_2\VBN|Cardiovascular|. (r_acl) complications_1\NNS|NONE
D013726_D002318 CID terbutaline_11\NN|NONE (r_pobj) with_10\IN|NONE (r_prep) treated_9\VBN| (r_acl) patients_8\NNS|NONE (r_pobj) in_4\IN|.|complications (r_prep) occurred_3\VBD|NONE (l_nsubj) complications_2\NNS|.|in
D013726_D007752 NONE terbutaline_4\JJ|for (r_compound) treatment_5\NN|NONE (l_prep) for_6\IN|terbutaline (l_pobj) labor_8\NN|NONE
D013726_D007752 NONE terbutaline_11\NN|NONE (l_prep) for_12\IN|NONE (l_pobj) labor_14\NN|NONE
7647582
D007530_D004342 NONE isoflurane_12\RB|and (l_prep) with_13\IN|NONE (l_pobj) hypersensitivity_15\NN|NONE
D007530_D004342 NONE isoflurane_13\NN|by|and/or (r_conj) enflurane_11\NN|alone|could|supports|condition|.|halothane (r_nsubj) produce_15\VB|NONE (l_dobj) condition_18\NN|alone|could|supports|.|halothane|enflurane (l_compound) hypersensitivity_17\NN|similar|a
D014269_D056486 NONE trifluoroacetyl_11\JJ|NONE (r_compound) adduct_12\NN|(|bound|)|biotransformation|a (r_appos) product_9\NN|NONE (r_pobj) to_3\IN|antibody|An (r_prep) response_2\NN|been|.|on|has (r_nsubjpass) detected_16\VBN|NONE (l_prep) on_17\IN|been|.|response|has (l_pobj) patients_20\NNS|NONE (l_compound) hepatitis_19\NN|halothane
D006221_D056486 CID halothane_25\NN|previous (r_relcl) exposure_23\NN|NONE (r_pobj) following_21\VBG|anesthetics|alone|with|.|have|been (r_agent) associated_10\VBN|NONE (l_prep) with_11\IN|anesthetics|alone|following|.|have|been (l_pobj) injury_17\NN|NONE
D006221_D056486 CID Halothane_0\NNP|NONE (r_compound) hepatitis_1\NN|involve|.
D006221_D056486 CID halothane_18\NN|hepatitis (r_amod) patients_20\NNS|NONE (l_compound) hepatitis_19\NN|halothane
D006221_D056486 CID halothane_23\NN|NONE (r_compound) hepatitis_24\NN|NONE
D006221_D056486 CID halothane_30\NN|alone|could|supports|condition|.|enflurane (r_advcl) produce_15\VB|NONE (l_dobj) condition_18\NN|alone|could|supports|.|halothane|enflurane (l_amod) similar_19\JJ|hypersensitivity|a (l_prep) to_20\IN|NONE (l_pobj) that_21\DT|NONE (l_prep) of_22\IN|NONE (l_pobj) hepatitis_24\NN|NONE
D006221_D004342 NONE halothane_18\NN|NONE (r_pobj) by_17\IN|NONE (r_agent) induced_16\VBN|the (r_acl) hypersensitivity_15\NN|NONE
D006221_D004342 NONE halothane_23\NN|NONE (r_compound) hepatitis_24\NN|NONE (r_pobj) of_22\IN|NONE (r_prep) that_21\DT|NONE (r_pobj) to_20\IN|NONE (r_prep) similar_19\JJ|hypersensitivity|a (r_amod) condition_18\NN|alone|could|supports|.|halothane|enflurane (l_compound) hypersensitivity_17\NN|similar|a
D006221_D004342 NONE halothane_30\NN|alone|could|supports|condition|.|enflurane (r_advcl) produce_15\VB|NONE (l_dobj) condition_18\NN|alone|could|supports|.|halothane|enflurane (l_compound) hypersensitivity_17\NN|similar|a
D004737_D056486 CID enflurane_4\NN|Two|halogenated|,|, (r_conj) anesthetics_2\NNS|alone|with|following|.|have|been (r_nsubjpass) associated_10\VBN|NONE (l_prep) with_11\IN|anesthetics|alone|following|.|have|been (l_pobj) injury_17\NN|NONE
D004737_D056486 CID enflurane_11\NN|alone|could|supports|condition|.|halothane (r_nsubj) produce_15\VB|NONE (l_dobj) condition_18\NN|alone|could|supports|.|halothane|enflurane (l_amod) similar_19\JJ|hypersensitivity|a (l_prep) to_20\IN|NONE (l_pobj) that_21\DT|NONE (l_prep) of_22\IN|NONE (l_pobj) hepatitis_24\NN|NONE
D004737_D004342 NONE enflurane_10\NN|NONE (l_conj) isoflurane_12\RB|and (l_prep) with_13\IN|NONE (l_pobj) hypersensitivity_15\NN|NONE
D004737_D004342 NONE enflurane_11\NN|alone|could|supports|condition|.|halothane (r_nsubj) produce_15\VB|NONE (l_dobj) condition_18\NN|alone|could|supports|.|halothane|enflurane (l_compound) hypersensitivity_17\NN|similar|a
D007530_D056486 CID isoflurane_6\RB|and (r_conj) enflurane_4\NN|Two|halogenated|,|, (r_conj) anesthetics_2\NNS|alone|with|following|.|have|been (r_nsubjpass) associated_10\VBN|NONE (l_prep) with_11\IN|anesthetics|alone|following|.|have|been (l_pobj) injury_17\NN|NONE
D007530_D056486 CID isoflurane_13\NN|by|and/or (r_conj) enflurane_11\NN|alone|could|supports|condition|.|halothane (r_nsubj) produce_15\VB|NONE (l_dobj) condition_18\NN|alone|could|supports|.|halothane|enflurane (l_amod) similar_19\JJ|hypersensitivity|a (l_prep) to_20\IN|NONE (l_pobj) that_21\DT|NONE (l_prep) of_22\IN|NONE (l_pobj) hepatitis_24\NN|NONE
347884
D006220_D019967 NONE haloperidol_6\NN|NONE (r_pobj) with_5\IN|blind|double|the (r_prep) study_4\NN|NONE (r_pobj) In_0\IN|substances|be|,|.|were (r_prep) found_11\VBN|NONE (l_xcomp) be_13\VB|substances|In|,|.|were (l_acomp) effective_15\JJ|to (l_prep) in_16\IN|highly (l_pobj) treatment_18\NN|NONE (l_prep) of_19\IN|the (l_pobj) syndromes_21\NNS|NONE (l_acl) belonging_22\VBG|psychotic (l_prep) to_24\IN|predominantly (l_pobj) group_27\NN|NONE
1919871
D001241_D007681 CID aspirin_20\NN|NONE (r_pobj) with_19\IN|continuous|term (r_prep) treatment_18\NN|NONE (r_pobj) during_13\IN|NONE (r_prep) developed_12\VBN|decreased|a|urinary|concentrating (r_acl) ability_11\NN|(|)|and|Renal|papillary|RPN|. (r_conj) necrosis_2\NN|NONE
D001241_D007681 CID aspirin_20\NN|NONE (r_pobj) with_19\IN|continuous|term (r_prep) treatment_18\NN|NONE (r_pobj) during_13\IN|NONE (r_prep) developed_12\VBN|decreased|a|urinary|concentrating (r_acl) ability_11\NN|(|)|and|Renal|papillary|RPN|. (r_conj) necrosis_2\NN|NONE (l_appos) RPN_4\NNP|(|)|and|ability|Renal|papillary|.
D000082_D007681 CID paracetamol_22\JJ|in|and (r_conj) aspirin_20\NN|NONE (r_pobj) with_19\IN|continuous|term (r_prep) treatment_18\NN|NONE (r_pobj) during_13\IN|NONE (r_prep) developed_12\VBN|decreased|a|urinary|concentrating (r_acl) ability_11\NN|(|)|and|Renal|papillary|RPN|. (r_conj) necrosis_2\NN|NONE
D000082_D007681 CID paracetamol_22\JJ|in|and (r_conj) aspirin_20\NN|NONE (r_pobj) with_19\IN|continuous|term (r_prep) treatment_18\NN|NONE (r_pobj) during_13\IN|NONE (r_prep) developed_12\VBN|decreased|a|urinary|concentrating (r_acl) ability_11\NN|(|)|and|Renal|papillary|RPN|. (r_conj) necrosis_2\NN|NONE (l_appos) RPN_4\NNP|(|)|and|ability|Renal|papillary|.
3403780
D000082_D000138 CID Paracetamol_0\NN| (r_npadvmod) associated_2\VBN|.|acidosis|, (r_amod) coma_3\NN|NONE (l_appos) acidosis_6\NN|.|associated|,
D000082_D000138 CID paracetamol_13\JJ|NONE (r_compound) ingestion_14\NN|NONE (r_pobj) following_12\VBG|acute|failure|and|renal (r_prep) failure_8\NN|case|.|is|, (r_nsubjpass) presented_16\VBN|NONE (l_nsubjpass) case_1\NN|.|is|failure|, (l_prep) of_2\IN|A (l_pobj) acidosis_4\NN|NONE
D000082_D017114 CID paracetamol_13\JJ|NONE (r_compound) ingestion_14\NN|NONE (r_pobj) following_12\VBG|acute|failure|and|renal (r_prep) failure_8\NN|case|.|is|, (l_conj) failure_11\NN|following|acute|and|renal
D000082_D058186 CID paracetamol_13\JJ|NONE (r_compound) ingestion_14\NN|NONE (r_pobj) following_12\VBG|acute|failure|and|renal (r_prep) failure_8\NN|case|.|is|, (l_conj) failure_11\NN|following|acute|and|renal
D000082_D058186 NONE Paracetamol_0\NN| (r_npadvmod) associated_2\VBN|.|acidosis|, (r_amod) coma_3\NN|NONE (l_appos) acidosis_6\NN|.|associated|, (l_conj) failure_11\NN|,|metabolic
D000082_D003128 NONE Paracetamol_0\NN| (r_npadvmod) associated_2\VBN|.|acidosis|, (r_amod) coma_3\NN|NONE
D000082_D017093 NONE Paracetamol_0\NN| (r_npadvmod) associated_2\VBN|.|acidosis|, (r_amod) coma_3\NN|NONE (l_appos) acidosis_6\NN|.|associated|, (l_conj) failure_11\NN|,|metabolic
1141447
D008094_D003919 CID lithium_7\NN| (r_npadvmod) induced_9\VBN|diabetes (r_amod) insipidus_11\NN|NONE
D008094_D003919 CID lithium_3\NN| (r_npadvmod) induced_5\VBN|diabetes (r_amod) insipidus_7\NN|NONE
8278214
D009020_D006930 CID morphine_11\NN|NONE (r_pobj) with_8\IN|NONE (r_prep) treated_7\VBN|cancer|terminal (r_acl) patients_6\NNS|NONE (r_pobj) in_3\IN|NONE (r_prep) myoclonus_2\NN|.|and (r_conj) Hyperalgesia_0\NNP|NONE
D009020_D006930 CID morphine_16\NN|NONE (r_pobj) of_14\IN|high (r_prep) doses_13\NNS|NONE (r_pobj) with_11\IN|.|developed|patients (r_prep) treated_10\VBN|NONE (l_advcl) developed_17\VBN|with|.|patients (l_dobj) hyperalgesia_18\NN|NONE
D009020_D006930 CID morphine_16\NN|NONE (r_pobj) of_15\IN|high (r_prep) doses_14\NNS|/|hyperalgesia|and (r_conj) myoclonus_11\NN|NONE (l_nmod) hyperalgesia_9\NN|doses|/|and
D009020_D006930 CID morphine_27\NN|that|,|role|for (r_nsubj) plays_33\VBZ|,|support|are|. (r_ccomp) indicates_25\VBZ|NONE (l_advcl) are_17\VBP|,|support|plays|. (l_nsubj) descriptions_4\NNS|available|Although (l_prep) of_5\IN|clinical|few (l_pobj) relationship_7\NN|NONE (l_prep) between_8\IN|the (l_pobj) myoclonus_11\NN|NONE (l_nmod) hyperalgesia_9\NN|doses|/|and
D009020_D009207 CID morphine_11\NN|NONE (r_pobj) with_8\IN|NONE (r_prep) treated_7\VBN|cancer|terminal (r_acl) patients_6\NNS|NONE (r_pobj) in_3\IN|NONE (r_prep) myoclonus_2\NN|.|and
D009020_D009207 CID morphine_16\NN|NONE (r_pobj) of_15\IN|high (r_prep) doses_14\NNS|/|hyperalgesia|and (r_conj) myoclonus_11\NN|NONE
D009020_D009207 CID morphine_27\NN|that|,|role|for (r_nsubj) plays_33\VBZ|,|support|are|. (r_ccomp) indicates_25\VBZ|NONE (l_advcl) are_17\VBP|,|support|plays|. (l_nsubj) descriptions_4\NNS|available|Although (l_prep) of_5\IN|clinical|few (l_pobj) relationship_7\NN|NONE (l_prep) between_8\IN|the (l_pobj) myoclonus_11\NN|NONE
D009020_D009369 NONE morphine_11\NN|NONE (r_pobj) with_8\IN|NONE (r_prep) treated_7\VBN|cancer|terminal (r_acl) patients_6\NNS|NONE (l_compound) cancer_5\NN|treated|terminal
D009020_D009369 NONE morphine_16\NN|NONE (r_pobj) of_14\IN|high (r_prep) doses_13\NNS|NONE (r_pobj) with_11\IN|.|developed|patients (r_prep) treated_10\VBN|NONE (l_nsubj) patients_2\NNS|with|.|developed (l_compound) cancer_1\NN|in|Eight
18752389
C492458_D017114 CID mg_33\NN|/ (r_nummod) day_35\NN|||mg (r_npadvmod) ezetimibe_31\NN|to (r_dobj) simvastatin_27\NN|after|transplantation (r_advcl) necessitating_13\VBG|fulminant|hepatic (r_acl) failure_12\NN|who
C532833_D056486 NONE acid_25\NN|NONE (r_pobj) of_22\IN|the (r_prep) glucuronidation_21\NN|have|resulting|,|may (r_dobj) inhibited_19\VBN|.|glucuronidation|and|Ezetimibe (l_advcl) resulting_27\VBG|have|,|may|glucuronidation (l_prep) in_28\IN|NONE (l_pobj) exposure_31\NN|NONE (l_conj) hepatotoxicity_34\NN|simvastatin|increased|and
D019821_D017114 NONE simvastatin_21\NN|/|mg| (r_nmod) day_25\NN|NONE (r_pobj) from_20\IN|NONE (r_prep) conversion_19\NN|weeks (r_pobj) after_18\IN|transplantation|simvastatin (r_prep) necessitating_13\VBG|fulminant|hepatic (r_acl) failure_12\NN|who
C108606_D056486 NONE ezetimibe_10\NN|NONE (r_pobj) with_9\IN|not|events|.|widely|However|,|been|have (r_prep) published_8\VBN|NONE (l_nsubjpass) events_3\NNS|not|.|widely|However|,|been|have|with (l_amod) hepatotoxic_2\JJ|NONE
C108606_D056486 NONE Ezetimibe_0\NNP|.|inhibited|glucuronidation|and (r_nsubj) undergoes_1\VBZ|NONE (l_conj) inhibited_19\VBN|.|glucuronidation|and|Ezetimibe (l_advcl) resulting_27\VBG|have|,|may|glucuronidation (l_prep) in_28\IN|NONE (l_pobj) exposure_31\NN|NONE (l_conj) hepatotoxicity_34\NN|simvastatin|increased|and
C108606_D056486 NONE ezetimibe_17\NN|of (r_compound) inhibition_18\NN|NONE (r_pobj) by_16\IN|the|simvastatin|increased (r_prep) exposure_15\NN|that|mechanism (r_attr) is_11\VBZ|We|. (l_nsubj) mechanism_4\NN|that|exposure (l_prep) of_5\IN|the (l_pobj) hepatotoxicity_10\NN|NONE
C492458_D017093 NONE ezetimibe_2\NN| (r_npadvmod) induced_4\VBN|hepatic|necessitating|. (r_amod) failure_6\NN|NONE
C492458_D017093 NONE ezetimibe_13\NN| (r_npadvmod) induced_15\VBN|resulted|liver (r_amod) failure_17\NN|NONE
D019821_D056486 NONE simvastatin_9\NN|NONE (r_pobj) with_8\IN|been|for|had|.|panel (r_prep) maintained_7\VBN|NONE (l_prep) for_10\IN|been|had|with|.|panel (l_pobj) months_12\NNS|NONE (l_prep) before_13\IN| (l_pobj) conversion_15\NN|NONE (l_prep) without_16\IN|the (l_pobj) evidence_17\NN|NONE (l_prep) of_18\IN|NONE (l_pobj) hepatotoxicity_19\NN|NONE
D019821_D056486 NONE simvastatin_30\NN|hepatotoxicity|increased|and (r_amod) exposure_31\NN|NONE (l_conj) hepatotoxicity_34\NN|simvastatin|increased|and
D019821_D056486 NONE simvastatin_14\NN|the|by|increased (r_amod) exposure_15\NN|that|mechanism (r_attr) is_11\VBZ|We|. (l_nsubj) mechanism_4\NN|that|exposure (l_prep) of_5\IN|the (l_pobj) hepatotoxicity_10\NN|NONE
D015283_D003866 NONE escitalopram_2\NNP|and|)|taking|( (r_conj) Simvastatinezetimibe_0\NNP|excluded|were|and|, (l_relcl) taking_7\VBG|and|)|escitalopram|( (l_prep) for_8\IN|she|was|which (l_pobj) depression_9\NN|NONE
C492458_D056486 CID ezetimibe_17\NN|combination|the (r_appos) agent_14\NN|or (r_conj) ezetimibe_10\NN|NONE (r_pobj) with_9\IN|not|events|.|widely|However|,|been|have (r_prep) published_8\VBN|NONE (l_nsubjpass) events_3\NNS|not|.|widely|However|,|been|have|with (l_amod) hepatotoxic_2\JJ|NONE
C492458_D056486 CID Simvastatinezetimibe_0\NNP|excluded|were|and|, (r_nsubjpass) discontinued_12\VBN|NONE (l_conj) excluded_21\VBN|Simvastatinezetimibe|were|and|, (l_nsubjpass) causes_17\NNS|.|were (l_prep) of_18\IN|potential|other (l_pobj) hepatotoxicity_19\NN|NONE
C492458_D056486 CID simvastatinezetimibe_7\NN| (r_npadvmod) induced_9\VBN|the (r_amod) hepatotoxicity_10\NN|NONE
C492458_D056486 CID ezetimibe_10\NN|NONE (r_pobj) with_7\IN|potential (r_prep) hepatotoxicity_6\NN|NONE
D014530_D056486 NONE diphosphate_6\NN|in|UGT (r_compound) glucoronosyltransferases_7\NNS|NONE (r_pobj) by_4\IN|extensive (r_prep) glucuronidation_3\NN|.|inhibited|and|Ezetimibe (r_dobj) undergoes_1\VBZ|NONE (l_conj) inhibited_19\VBN|.|glucuronidation|and|Ezetimibe (l_advcl) resulting_27\VBG|have|,|may|glucuronidation (l_prep) in_28\IN|NONE (l_pobj) exposure_31\NN|NONE (l_conj) hepatotoxicity_34\NN|simvastatin|increased|and
D015283_D056486 NONE escitalopram_2\NNP|and|)|taking|( (r_conj) Simvastatinezetimibe_0\NNP|excluded|were|and|, (r_nsubjpass) discontinued_12\VBN|NONE (l_conj) excluded_21\VBN|Simvastatinezetimibe|were|and|, (l_nsubjpass) causes_17\NNS|.|were (l_prep) of_18\IN|potential|other (l_pobj) hepatotoxicity_19\NN|NONE
C492458_D003866 NONE Simvastatinezetimibe_0\NNP|excluded|were|and|, (l_relcl) taking_7\VBG|and|)|escitalopram|( (l_prep) for_8\IN|she|was|which (l_pobj) depression_9\NN|NONE
17612891
D003024_D011618 NONE clozapine_2\NN|NONE (r_pobj) Considering_0\VBG|standard (r_csubj) remains_3\VBZ|need|,|there|. (l_attr) standard_6\NN|Considering (l_prep) in_7\IN|the|gold (l_pobj) treatment_8\NN|NONE (l_prep) of_9\IN|NONE (l_pobj) psychosis_11\NN|NONE
D003024_D012559 NONE clozapine_16\NN|NONE (r_pobj) of_15\IN|NONE (r_prep) commencement_14\NN|NONE (r_pobj) after_13\IN|onset|male|. (r_prep) developed_7\VBD|NONE (l_nsubj) male_4\NN|after|onset|. (l_prep) with_5\IN|old|A (l_pobj) schizophrenia_6\NN|NONE
D003024_D009205 CID clozapine_4\NN|NONE (r_pobj) with_3\IN|NONE (r_prep) associated_2\VBN|Acute|. (r_acl) myocarditis_1\NN|NONE
D003024_D009205 CID clozapine_10\NN|NONE (r_pobj) of_9\IN|the (r_prep) commencement_8\NN|NONE (r_pobj) with_6\IN|NONE (r_prep) associated_5\VBN|of|A (r_acl) case_1\NN|highlighting|,|is|. (l_prep) of_2\IN|associated|A (l_pobj) myocarditis_4\NN|NONE
D003024_D009205 CID clozapine_16\NN|NONE (r_pobj) of_15\IN|NONE (r_prep) commencement_14\NN|NONE (r_pobj) after_13\IN|onset|male|. (r_prep) developed_7\VBD|NONE (l_dobj) onset_10\NN|after|male|. (l_prep) of_11\IN|a|sudden (l_pobj) myocarditis_12\NN|NONE
D003024_D009205 CID clozapine_11\NN|NONE (r_pobj) of_10\IN|the (r_prep) use_9\NN|NONE (r_pobj) with_7\IN|NONE (r_prep) associated_6\VBN|recognized|an (r_acl) complication_5\NN|Myocarditis|. (r_attr) is_1\VBZ|NONE (l_nsubj) Myocarditis_0\NNP|complication|.
3782049
D008972_D012559 NONE molindone_18\NN|NONE (r_compound) administration_19\NN|NONE (r_pobj) following_17\VBG|failure|massive|and (r_prep) rhabdomyolysis_11\NN|to (r_dobj) illustrate_9\VB|case|.|is (r_xcomp) reported_7\VBN|NONE (l_nsubjpass) case_1\NN|illustrate|.|is (l_prep) of_2\IN|The (l_pobj) patient_5\NN|NONE (l_amod) schizophrenic_4\JJ|a
D008972_D058186 CID molindone_18\NN|NONE (r_compound) administration_19\NN|NONE (r_pobj) following_17\VBG|failure|massive|and (r_prep) rhabdomyolysis_11\NN|to (l_conj) failure_16\NN|following|massive|and
D008972_D012206 CID molindone_6\NN|NONE (r_compound) administration_7\NN|NONE (r_pobj) following_5\VBG|massive (r_prep) rhabdomyolysis_4\NN|NONE
D008972_D012206 CID molindone_18\NN|NONE (r_compound) administration_19\NN|NONE (r_pobj) following_17\VBG|failure|massive|and (r_prep) rhabdomyolysis_11\NN|to
8268147
D010396_D064420 NONE penicillamine_3\NN|for|has|been|Although (r_nsubjpass) used_6\VBN|usefulness|.|toxicity|, (r_advcl) limits_13\VBZ|NONE (l_nsubj) toxicity_12\NN|used|usefulness|.|,
D010396_D003882 NONE penicillamine_14\NN|NONE (r_compound) treatment_15\NN|NONE (r_pobj) of_11\IN|autoimmune|the (r_prep) complications_10\NNS|NONE (r_pobj) of_7\IN|NONE (r_prep) one_6\CD|NONE (r_pobj) as_5\IN|can|dermatomyositis|remains|,|but (r_prep) develop_4\VB|NONE (l_nsubj) dermatomyositis_2\NN|can|remains|,|but|as
D010396_D003882 NONE penicillamine_4\NN|NONE (r_compound) therapy_5\NN|NONE (r_dobj) receiving_1\VBG|NONE (r_acl) Patients_0\NNS|should|carefully|be|.|for (r_nsubjpass) followed_8\VBN|NONE (l_prep) for_10\IN|should|carefully|be|Patients|. (l_pobj) development_12\NN|NONE (l_prep) of_13\IN|the (l_pobj) complications_15\NNS|NONE (l_prep) like_16\IN|autoimmune (l_pobj) dermatomyositis_19\NN|NONE
D010396_D017285 CID penicillamine_15\NN|NONE (r_pobj) with_12\IN|NONE (r_prep) treated_11\VBN|biliary|primary (r_acl) cirrhosis_10\NN|NONE (r_pobj) with_7\IN|a (r_prep) patient_6\NN|NONE (r_pobj) in_4\IN|of|.|A (r_prep) case_1\NN|NONE (l_prep) of_2\IN|in|.|A (l_pobj) polymyositis_3\NN|NONE
D010396_D017285 CID penicillamine_14\NN|NONE (r_compound) treatment_15\NN|NONE (r_pobj) of_11\IN|autoimmune|the (r_prep) complications_10\NNS|NONE (r_pobj) of_7\IN|NONE (r_prep) one_6\CD|NONE (r_pobj) as_5\IN|can|dermatomyositis|remains|,|but (r_prep) develop_4\VB|NONE (l_nsubj) dermatomyositis_2\NN|can|remains|,|but|as (l_nmod) Polymyositis_0\NNP|/
D010396_D017285 CID penicillamine_16\NN|NONE (r_compound) therapy_17\NN|while (r_dobj) receiving_13\VBG|polymyositis|who (r_advcl) developed_10\VBD|primary|biliary|, (l_dobj) polymyositis_11\NN|who|receiving
D010396_D017285 CID penicillamine_4\NN|NONE (r_compound) therapy_5\NN|NONE (r_dobj) receiving_1\VBG|NONE (r_acl) Patients_0\NNS|should|carefully|be|.|for (r_nsubjpass) followed_8\VBN|NONE (l_prep) for_10\IN|should|carefully|be|Patients|. (l_pobj) development_12\NN|NONE (l_prep) of_13\IN|the (l_pobj) complications_15\NNS|NONE (l_prep) like_16\IN|autoimmune (l_pobj) dermatomyositis_19\NN|NONE (l_nmod) polymyositis_17\NN|/
D010396_D008105 NONE penicillamine_15\NN|NONE (r_pobj) with_12\IN|NONE (r_prep) treated_11\VBN|biliary|primary (r_acl) cirrhosis_10\NN|NONE
D010396_D008105 NONE penicillamine_16\NN|NONE (r_compound) therapy_17\NN|while (r_dobj) receiving_13\VBG|polymyositis|who (r_advcl) developed_10\VBD|primary|biliary|, (r_relcl) cirrhosis_7\NN|NONE
D010396_D012216 NONE penicillamine_3\NN|for|has|been|Although (r_nsubjpass) used_6\VBN|usefulness|.|toxicity|, (l_prep) for_7\IN|penicillamine|has|been|Although (l_pobj) diseases_10\NNS|NONE
11166519
D003042_D012640 CID cocaine_1\NN| (r_npadvmod) induced_3\VBN|Acute|sensitivity|.|: (r_amod) seizures_4\NNS|NONE
D003042_D012640 CID cocaine_22\NN|NONE (r_pobj) of_21\IN|a|single (r_prep) injection_20\NN|NONE (r_pobj) by_17\IN|NONE (r_agent) induced_16\VBN|behavioral (r_acl) seizures_15\NNS|NONE
D003042_D012640 CID cocaine_14\NN| (r_npadvmod) induced_16\VBN|NONE (r_amod) seizures_17\NNS|NONE
11752354
C033273_D009203 NONE gestodene_21\NN|levonorgestrel|i.e.|,|and|(|or|) (r_conj) desogestrel_19\NN|third| (r_appos) generation_15\NN|oral (r_nmod) contraceptives_33\NNS|NONE (r_pobj) in_12\IN|NONE (r_prep) included_11\VBN|the|of (r_acl) type_8\NN|NONE (r_pobj) to_6\IN|NONE (r_prep) according_5\VBG|We|identified|,|association (r_prep) investigated_1\VBD|NONE (l_conj) identified_64\VBD|We|according|,|association (l_conj) enrolled_66\VBD|In|dose|:|and|.|,|we|, (l_dobj) women_68\NNS|year|,|through| (l_relcl) had_77\VBN| (l_dobj) infarction_81\NN|had|who
C033273_D009203 NONE gestodene_21\NN|levonorgestrel|i.e.|,|and|(|or|) (r_conj) desogestrel_19\NN|third| (r_appos) generation_15\NN|oral (r_nmod) contraceptives_33\NNS|NONE (r_pobj) in_12\IN|NONE (r_prep) included_11\VBN|the|of (r_acl) type_8\NN|NONE (r_pobj) to_6\IN|NONE (r_prep) according_5\VBG|We|identified|,|association (r_prep) investigated_1\VBD|NONE (l_conj) identified_64\VBD|We|according|,|association (l_conj) enrolled_66\VBD|In|dose|:|and|.|,|we|, (l_dobj) women_68\NNS|year|,|through| (l_relcl) had_77\VBN| (l_dobj) infarction_81\NN|had|who (l_prep) between_82\IN|myocardial|first|a (l_pobj) 1990_83\CD|NONE (l_conj) women_89\NNS|and||and (l_relcl) had_93\VBN|control| (l_dobj) infarction_96\NN|and|not|who|matched|had
D011372_D009203 NONE progestagen_10\NN|NONE (r_pobj) of_9\IN|included|the (r_prep) type_8\NN|NONE (r_pobj) to_6\IN|NONE (r_prep) according_5\VBG|We|identified|,|association (r_prep) investigated_1\VBD|NONE (l_conj) identified_64\VBD|We|according|,|association (l_conj) enrolled_66\VBD|In|dose|:|and|.|,|we|, (l_dobj) women_68\NNS|year|,|through| (l_relcl) had_77\VBN| (l_dobj) infarction_81\NN|had|who
D011372_D009203 NONE progestagen_10\NN|NONE (r_pobj) of_9\IN|included|the (r_prep) type_8\NN|NONE (r_pobj) to_6\IN|NONE (r_prep) according_5\VBG|We|identified|,|association (r_prep) investigated_1\VBD|NONE (l_conj) identified_64\VBD|We|according|,|association (l_conj) enrolled_66\VBD|In|dose|:|and|.|,|we|, (l_dobj) women_68\NNS|year|,|through| (l_relcl) had_77\VBN| (l_dobj) infarction_81\NN|had|who (l_prep) between_82\IN|myocardial|first|a (l_pobj) 1990_83\CD|NONE (l_conj) women_89\NNS|and||and (l_relcl) had_93\VBN|control| (l_dobj) infarction_96\NN|and|not|who|matched|had
D016912_D009203 NONE levonorgestrel_30\JJ|i.e.|,|and|gestodene|(|or|) (r_conj) desogestrel_19\NN|third| (r_appos) generation_15\NN|oral (r_nmod) contraceptives_33\NNS|NONE (r_pobj) in_12\IN|NONE (r_prep) included_11\VBN|the|of (r_acl) type_8\NN|NONE (r_pobj) to_6\IN|NONE (r_prep) according_5\VBG|We|identified|,|association (r_prep) investigated_1\VBD|NONE (l_conj) identified_64\VBD|We|according|,|association (l_conj) enrolled_66\VBD|In|dose|:|and|.|,|we|, (l_dobj) women_68\NNS|year|,|through| (l_relcl) had_77\VBN| (l_dobj) infarction_81\NN|had|who
D016912_D009203 NONE levonorgestrel_30\JJ|i.e.|,|and|gestodene|(|or|) (r_conj) desogestrel_19\NN|third| (r_appos) generation_15\NN|oral (r_nmod) contraceptives_33\NNS|NONE (r_pobj) in_12\IN|NONE (r_prep) included_11\VBN|the|of (r_acl) type_8\NN|NONE (r_pobj) to_6\IN|NONE (r_prep) according_5\VBG|We|identified|,|association (r_prep) investigated_1\VBD|NONE (l_conj) identified_64\VBD|We|according|,|association (l_conj) enrolled_66\VBD|In|dose|:|and|.|,|we|, (l_dobj) women_68\NNS|year|,|through| (l_relcl) had_77\VBN| (l_dobj) infarction_81\NN|had|who (l_prep) between_82\IN|myocardial|first|a (l_pobj) 1990_83\CD|NONE (l_conj) women_89\NNS|and||and (l_relcl) had_93\VBN|control| (l_dobj) infarction_96\NN|and|not|who|matched|had
D003276_D009203 CID contraceptives_1\NNS|NONE (l_conj) risk_4\NN|and|Oral|. (l_prep) of_5\IN|the (l_pobj) infarction_7\NN|NONE
D003276_D009203 CID contraceptives_7\NNS|NONE (r_pobj) of_5\IN|the|and|risk (r_prep) use_4\NN|NONE (l_conj) risk_10\NN|the|of|and (l_prep) of_11\IN|the (l_pobj) infarction_13\NN|NONE
D003276_D009203 CID contraceptives_33\NNS|NONE (r_pobj) in_12\IN|NONE (r_prep) included_11\VBN|the|of (r_acl) type_8\NN|NONE (r_pobj) to_6\IN|NONE (r_prep) according_5\VBG|We|identified|,|association (r_prep) investigated_1\VBD|NONE (l_conj) identified_64\VBD|We|according|,|association (l_conj) enrolled_66\VBD|In|dose|:|and|.|,|we|, (l_dobj) women_68\NNS|year|,|through| (l_relcl) had_77\VBN| (l_dobj) infarction_81\NN|had|who
D003276_D009203 CID contraceptives_33\NNS|NONE (r_pobj) in_12\IN|NONE (r_prep) included_11\VBN|the|of (r_acl) type_8\NN|NONE (r_pobj) to_6\IN|NONE (r_prep) according_5\VBG|We|identified|,|association (r_prep) investigated_1\VBD|NONE (l_conj) identified_64\VBD|We|according|,|association (l_conj) enrolled_66\VBD|In|dose|:|and|.|,|we|, (l_dobj) women_68\NNS|year|,|through| (l_relcl) had_77\VBN| (l_dobj) infarction_81\NN|had|who (l_prep) between_82\IN|myocardial|first|a (l_pobj) 1990_83\CD|NONE (l_conj) women_89\NNS|and||and (l_relcl) had_93\VBN|control| (l_dobj) infarction_96\NN|and|not|who|matched|had
D003276_D009203 CID contraceptive_39\NN|NONE (r_pobj) of_36\IN|any (r_prep) type_35\NN|compared|who|, (r_dobj) used_33\VBD|NONE (r_relcl) women_31\NNS|NONE (r_pobj) among_30\IN|myocardial (r_prep) infarction_29\NN|NONE
D003276_D009203 CID contraceptives_5\NNS|who (r_dobj) used_3\VBD|NONE (r_relcl) women_1\NNS|NONE (r_pobj) Among_0\IN|interval|for|:|,|ratio (r_prep) was_10\VBD|was|among|.|risk (r_ccomp) increased_53\VBN|NONE (l_nsubjpass) risk_48\NN|was|was|among|. (l_prep) of_49\IN|The (l_pobj) infarction_51\NN|NONE
D003276_D009203 CID contraceptives_62\NNS|who (r_dobj) used_57\VBD|NONE (r_relcl) women_55\NNS|NONE (r_pobj) among_54\IN|was|was|.|risk (r_prep) increased_53\VBN|NONE (l_nsubjpass) risk_48\NN|was|was|among|. (l_prep) of_49\IN|The (l_pobj) infarction_51\NN|NONE
D003276_D009203 CID contraceptives_12\NNS|who|had (r_dobj) used_10\VBD|NONE (r_relcl) women_8\NNS|NONE (r_pobj) among_7\IN|NONE (r_prep) similar_6\JJ|.|risk (r_acomp) was_5\VBD|NONE (l_nsubj) risk_1\NN|similar|. (l_prep) of_2\IN|The (l_pobj) infarction_4\NN|NONE
D017135_D009203 NONE desogestrel_19\NN|third| (r_appos) generation_15\NN|oral (r_nmod) contraceptives_33\NNS|NONE (r_pobj) in_12\IN|NONE (r_prep) included_11\VBN|the|of (r_acl) type_8\NN|NONE (r_pobj) to_6\IN|NONE (r_prep) according_5\VBG|We|identified|,|association (r_prep) investigated_1\VBD|NONE (l_conj) identified_64\VBD|We|according|,|association (l_conj) enrolled_66\VBD|In|dose|:|and|.|,|we|, (l_dobj) women_68\NNS|year|,|through| (l_relcl) had_77\VBN| (l_dobj) infarction_81\NN|had|who
D017135_D009203 NONE desogestrel_19\NN|third| (r_appos) generation_15\NN|oral (r_nmod) contraceptives_33\NNS|NONE (r_pobj) in_12\IN|NONE (r_prep) included_11\VBN|the|of (r_acl) type_8\NN|NONE (r_pobj) to_6\IN|NONE (r_prep) according_5\VBG|We|identified|,|association (r_prep) investigated_1\VBD|NONE (l_conj) identified_64\VBD|We|according|,|association (l_conj) enrolled_66\VBD|In|dose|:|and|.|,|we|, (l_dobj) women_68\NNS|year|,|through| (l_relcl) had_77\VBN| (l_dobj) infarction_81\NN|had|who (l_prep) between_82\IN|myocardial|first|a (l_pobj) 1990_83\CD|NONE (l_conj) women_89\NNS|and||and (l_relcl) had_93\VBN|control| (l_dobj) infarction_96\NN|and|not|who|matched|had
D004967_D009203 NONE estrogen_38\NN|NONE (r_pobj) of_37\IN|,|presence|and|the (r_prep) dose_36\NN|In|:|and|.|enrolled|,|we|, (r_dep) identified_64\VBD|We|according|,|association (l_conj) enrolled_66\VBD|In|dose|:|and|.|,|we|, (l_dobj) women_68\NNS|year|,|through| (l_relcl) had_77\VBN| (l_dobj) infarction_81\NN|had|who
D004967_D009203 NONE estrogen_38\NN|NONE (r_pobj) of_37\IN|,|presence|and|the (r_prep) dose_36\NN|In|:|and|.|enrolled|,|we|, (r_dep) identified_64\VBD|We|according|,|association (l_conj) enrolled_66\VBD|In|dose|:|and|.|,|we|, (l_dobj) women_68\NNS|year|,|through| (l_relcl) had_77\VBN| (l_dobj) infarction_81\NN|had|who (l_prep) between_82\IN|myocardial|first|a (l_pobj) 1990_83\CD|NONE (l_conj) women_89\NNS|and||and (l_relcl) had_93\VBN|control| (l_dobj) infarction_96\NN|and|not|who|matched|had
11860495
D005680_D000647 NONE GABA(A)R_15\NNP|NONE (r_compound) ligands_16\NNS|and (r_conj) NMDAR_13\NNP|NONE (r_pobj) of_12\IN|like|the (r_prep) effects_11\NNS|to (l_amod) like_10\JJ|of|the (l_amod) amnesic_8\JJ|
D013256_D000647 NONE Steroid_0\NN|properties|and (r_compound) structure_1\NN|.|effects (r_nsubj) determine_5\VBP|NONE (l_dobj) effects_10\NNS|.|structure (l_amod) amnesic_9\JJ|in|the|of
D012601_D000647 CID scopolamine_21\NN| (r_npadvmod) induced_23\VBN|NONE (r_amod) amnesia_24\NN|NONE
D012601_D000647 CID scopolamine_25\NN| (r_npadvmod) induced_27\VBN|NONE (r_amod) amnesia_28\NN|NONE
C018370_D000647 NONE sulphate_13\NN|NONE (r_pobj) of_11\IN|in|the|amnesic (r_prep) effects_10\NNS|.|structure (l_amod) amnesic_9\JJ|in|the|of
C018370_D000647 NONE PREGS_2\NNP|,|.|Moreover|able (r_nsubj) is_3\VBZ|NONE (l_acomp) able_4\JJ|,|.|PREGS|Moreover (l_xcomp) reverse_6\VB|NONE (l_dobj) effects_11\NNS|to (l_amod) like_10\JJ|of|the (l_amod) amnesic_8\JJ|
C018370_D000647 NONE PREGS_6\NNP|NONE (r_pobj) of_5\IN|enhancing|The (r_prep) effects_4\NNS|in|were|. (r_nsubjpass) tested_11\VBN|NONE (l_prep) in_12\IN|effects|were|. (l_pobj) task_16\NN|NONE (l_acl) using_17\VBG|avoidance|passive|the (l_dobj) model_19\NN|NONE (l_prep) of_20\IN|the (l_pobj) amnesia_24\NN|NONE
C018370_D000647 NONE PREGS_10\NNP|NONE (r_pobj) of_8\IN|be|the (r_prep) ability_7\NN|NONE (l_acl) be_12\VB|of|the (l_attr) order_14\NN|to (l_amod) effective_18\JJ|an|of (l_prep) than_19\IN|more (l_pobj) enantiomer_22\NN|NONE (l_prep) in_23\IN|synthetic|its (l_pcomp) reversing_24\VBG|NONE (l_dobj) amnesia_28\NN|NONE
3371379
D002118_D020258 NONE calcium_19\NN|NONE (r_compound) entry_20\NN|the (r_compound) blocker_21\NN|NONE (r_pobj) of_17\IN|NONE (r_prep) discontinuation_16\NN|NONE (r_pobj) after_15\IN|complete (r_prep) recovery_14\NN|patients|. (r_dobj) showed_12\VBD|NONE (l_nsubj) patients_1\NNS|recovery|. (l_prep) with_2\IN|Two (l_pobj) signs_3\NNS|NONE (l_prep) of_4\IN|after (l_pobj) neurotoxicity_6\NN|NONE
D014700_D020258 CID Verapamil_0\NNP|.||neurotoxicity (r_npadvmod) induced_2\VBN|NONE (l_dobj) neurotoxicity_4\NN|.|Verapamil|
D014700_D020258 CID verapamil_11\NN|NONE (r_pobj) with_10\IN|combined (r_prep) treatment_9\NN|NONE (r_pobj) after_7\IN|of (r_prep) signs_3\NNS|NONE (l_prep) of_4\IN|after (l_pobj) neurotoxicity_6\NN|NONE
D002220_D020258 CID carbamazepine_3\NN|NONE (r_compound) neurotoxicity_4\NN|.|Verapamil|
D002220_D020258 CID carbamazepine_5\JJ|NONE (r_compound) neurotoxicity_6\NN|NONE
11147747
D020280_D014549 CID sertraline_22\NN|the|serotonin|inhibitors|selective|third|as|and|, (r_conj) paroxetine_20\NN|NONE (r_pobj) to_14\IN|who|secondary (r_prep) developed_11\VBD|female| (l_dobj) secondary_13\JJ|who|to (l_compound) incontinence_12\NN|NONE
D016651_D014549 CID carbonate_12\NN|were|patients|also (r_dobj) taking_10\VBG|the| (r_relcl) cases_5\NNS|NONE (r_pobj) of_2\IN|NONE (r_prep) 2_1\CD|NONE (r_pobj) In_0\IN|both|,|have|.|could|to (r_prep) contributed_23\VBN|NONE (l_prep) to_24\IN|both|,|have|.|could|In (l_pobj) incontinence_26\NN|NONE
D018490_D014549 CID antidepressants_1\NNS|NONE (l_conj) incontinence_4\NN|.|Serotonergic|and
D018490_D014549 CID antidepressants_8\NNS|NONE (r_pobj) to_6\IN|NONE (r_prep) secondary_5\JJ|NONE (r_amod) incontinence_4\NN|be|by|could|that
D017374_D014549 CID paroxetine_20\NN|NONE (r_pobj) to_14\IN|who|secondary (r_prep) developed_11\VBD|female| (l_dobj) secondary_13\JJ|who|to (l_compound) incontinence_12\NN|NONE
C047426_D014549 CID venlafaxine_10\NN|while (r_dobj) taking_9\VBG|incontinence|who (r_advcl) experienced_6\VBD|male| (l_dobj) incontinence_7\NN|taking|who
C047426_D014549 CID venlafaxine_35\NNP|NONE (r_pobj) on_34\IN|effect|who (r_prep) developed_30\VBD|a (r_relcl) third_28\NN|the|sertraline|serotonin|inhibitors|selective|as|and|, (r_conj) paroxetine_20\NN|NONE (r_pobj) to_14\IN|who|secondary (r_prep) developed_11\VBD|female| (l_dobj) secondary_13\JJ|who|to (l_compound) incontinence_12\NN|NONE
D012701_D014549 NONE serotonin_17\NN|the|sertraline|inhibitors|selective|third|as|and|, (r_compound) paroxetine_20\NN|NONE (r_pobj) to_14\IN|who|secondary (r_prep) developed_11\VBD|female| (l_dobj) secondary_13\JJ|who|to (l_compound) incontinence_12\NN|NONE
11861791
D004317_D006333 CID doxorubicin_11\NN| (r_npadvmod) induced_13\VBN|heart (r_amod) failure_15\NN|NONE
C434926_D006331 NONE PJ34_19\NNP|NONE (r_pobj) with_14\IN|pharmacological (r_prep) inhibition_13\NN|genetic|or (r_conj) deletion_10\NN|NONE (r_pobj) by_8\IN|approach|, (r_prep) Using_0\VBG|.|we|role|,|now (r_advcl) demonstrate_23\VBP|NONE (l_dobj) role_25\NN|Using|.|we|,|now (l_prep) in_28\IN|of|the (l_pobj) development_30\NN|NONE (l_prep) of_31\IN|the (l_pobj) dysfunction_33\NN|NONE
C434926_D006331 NONE PJ34_3\NNP|NONE (r_pobj) with_1\IN|NONE (r_prep) Treatment_0\NN|dysfunction|increased|significantly|.|and (r_nsubj) improved_5\VBD|NONE (l_dobj) dysfunction_7\NN|increased|significantly|.|Treatment|and
D004317_D066126 NONE doxorubicin_12\NN|NONE (r_pobj) of_11\IN|the (r_prep) cardiotoxicity_10\NN|NONE
D004317_D066126 NONE DOX_14\NNP|antibiotic|, (r_appos) doxorubicin_12\NN|NONE (r_pobj) of_11\IN|the (r_prep) cardiotoxicity_10\NN|NONE
D004317_D066126 NONE DOX_13\NNP| (r_npadvmod) induced_15\VBN|the (r_amod) cardiotoxicity_16\NN|NONE
D004317_D066126 NONE DOX_9\NNP|NONE (r_pobj) of_8\IN|the (r_prep) cardiotoxicity_7\NN|NONE
D004317_D006331 NONE DOX_36\NNP|NONE (r_pobj) by_35\IN|NONE (r_agent) induced_34\VBN|cardiac (r_acl) dysfunction_33\NN|NONE
D018943_D066126 NONE anthracycline_21\NN|antitumor|used|a (r_amod) antibiotic_22\NN|DOX|, (r_appos) doxorubicin_12\NN|NONE (r_pobj) of_11\IN|the (r_prep) cardiotoxicity_10\NN|NONE
D011064_D006333 NONE )_5\-RRB-|ribose (r_punct) polymerase_6\NN|NONE (r_pobj) of_1\IN|NONE (r_prep) Activation_0\NN|.|to (r_nsubj) contributes_7\VBZ|NONE (l_prep) to_8\IN|.|Activation (l_pobj) development_9\NN|NONE (l_prep) of_10\IN|NONE (l_pobj) failure_15\NN|NONE
D004317_D005117 NONE DOX_16\NNP|the (r_compound) treatment_17\NN|NONE (r_pobj) with_14\IN|NONE (r_prep) associated_13\VBN|cardiac|severe (r_acl) complications_12\NNS|NONE
2096243
C017367_D056784 CID carmofur_19\NN| (r_npadvmod) induced_21\VBN|NONE (r_amod) leukoencephalopathy_22\NN|NONE
C017367_D056784 CID carmofur_2\NN| (r_npadvmod) induced_4\VBN|NONE (r_amod) leukoencephalopathy_5\JJ|.|Consequently|,|in|uncommonly|may
C017367_D010554 NONE carmofur_2\NN| (r_npadvmod) induced_4\VBN|NONE (r_amod) leukoencephalopathy_5\JJ|.|Consequently|,|in|uncommonly|may (r_nsubj) result_8\VB|NONE (l_prep) in_9\IN|.|Consequently|,|leukoencephalopathy|uncommonly|may (l_pobj) syndrome_12\NN|NONE
C017367_D019965 CID Carmofur_0\NN| (r_npadvmod) induced_2\VBN|mental|organic|. (r_amod) disorders_5\NNS|NONE
C017367_D019965 CID carmofur_19\NN| (r_npadvmod) induced_21\VBN|NONE (r_amod) leukoencephalopathy_22\NN|NONE (r_pobj) of_18\IN|the (r_prep) onset_17\NN|NONE (r_pobj) after_15\IN|prognostic|the (r_prep) period_14\NN|NONE (r_pobj) in_11\IN|old|a (r_prep) female_10\NN|NONE (r_pobj) in_5\IN|was|disorder|. (r_prep) observed_4\VBN|NONE (l_nsubjpass) disorder_2\NN|was|.|in
11022397
D012601_D008569 CID scopolamine_12\NN| (r_npadvmod) induced_14\VBN|in|size|;|. (r_amod) impairment_15\NN|NONE (l_prep) in_16\IN|induced|size|;|. (l_pobj) recall_18\NN|NONE
D012601_D008569 CID scopolamine_11\NN| (r_npadvmod) induced_13\VBN|in|greater (r_amod) impairment_14\NN|,|.|recall|Compared|group|)|after (r_dobj) had_9\VBD|NONE (l_dobj) recall_17\NN|,|.|Compared|impairment|group|)|after
D014331_D008569 NONE tropicamide_8\NN|NONE (r_pobj) of_7\IN|NONE (r_prep) administration_6\NN|NONE (r_pobj) after_5\IN|Pupil|at (r_prep) size_1\NN|induced|in|;|. (r_ccomp) impairment_15\NN|NONE (l_prep) in_16\IN|induced|size|;|. (l_pobj) recall_18\NN|NONE
D010862_D008569 NONE pilocarpine_10\NN|and (r_conj) tropicamide_8\NN|NONE (r_pobj) of_7\IN|NONE (r_prep) administration_6\NN|NONE (r_pobj) after_5\IN|Pupil|at (r_prep) size_1\NN|induced|in|;|. (r_ccomp) impairment_15\NN|NONE (l_prep) in_16\IN|induced|size|;|. (l_pobj) recall_18\NN|NONE
11467664
D008687_D041781 CID metformin_7\NN|NONE (r_pobj) of_6\IN|the (r_prep) use_5\NN|NONE (r_pobj) with_3\IN|NONE (r_prep) associated_2\VBN|.|Cholestatic (r_acl) jaundice_1\NN|NONE
D008687_D041781 CID hydrochloride_15\NN|NONE (r_pobj) with_13\IN|NONE (r_prep) treatment_12\NN|NONE (r_pobj) of_11\IN|NONE (r_prep) initiation_10\NN|shortly (r_pobj) after_9\IN|who|jaundice (r_prep) developed_5\VBD|a (l_dobj) jaundice_7\NN|after|who
D008687_D056486 NONE metformin_12\NN|NONE (r_pobj) of_11\IN|the (r_prep) initiation_10\NN|wk (r_pobj) after_8\IN|of|the (r_prep) onset_2\NN|NONE (r_pobj) Given_0\VBN|represents|,|we (r_prep) believe_15\VBP|case|,|. (l_ccomp) represents_19\VBZ|Given|,|we (l_dobj) example_21\NN|case|that (l_prep) of_22\IN|an (l_pobj) hepatotoxicity_26\NN|NONE
D008687_D056486 NONE metformin_23\NN| (r_npadvmod) associated_25\VBN|NONE (r_amod) hepatotoxicity_26\NN|NONE
D008687_D007565 NONE hydrochloride_1\NN|,|resolved|and|was (r_nsubjpass) discontinued_3\VBN|NONE (l_conj) resolved_10\VBN|,|and|hydrochloride|was (l_nsubj) jaundice_9\NN|slowly|.|over
D008687_D007565 NONE metformin_12\NN|NONE (r_pobj) of_11\IN|the (r_prep) initiation_10\NN|wk (r_pobj) after_8\IN|of|the (r_prep) onset_2\NN|NONE (l_prep) of_3\IN|the|after (l_pobj) jaundice_5\NN|NONE
D008687_D007565 NONE metformin_23\NN| (r_npadvmod) associated_25\VBN|NONE (r_amod) hepatotoxicity_26\NN|NONE (r_pobj) of_22\IN|an (r_prep) example_21\NN|case|that (r_dobj) represents_19\VBZ|Given|,|we (r_ccomp) believe_15\VBP|case|,|. (l_prep) Given_0\VBN|represents|,|we (l_pobj) onset_2\NN|NONE (l_prep) of_3\IN|the|after (l_pobj) jaundice_5\NN|NONE
17111419
D002118_D006996 NONE calcium_9\NN|NONE (r_compound) chelation_10\NN|NONE (r_pobj) to_8\IN|by|a|resulting|severe (r_prep) reaction_7\NN|NONE (l_acl) resulting_15\VBG|to|by|a|severe (l_prep) in_16\IN|NONE (l_pobj) hypocalcemia_19\NN|NONE
D002034_D006996 NONE bumetanide_9\NN|loop|that (r_nsubj) is_10\VBZ|,|.|was|it|Upon (l_attr) loop_12\NN|bumetanide|that (l_relcl) cause_16\VB|a|diuretic (l_dobj) hypocalcemia_18\NN|may|that
C102006_D006996 CID citrate_13\NN|NONE (r_compound) anticoagulant_14\NN|NONE (r_pobj) by_11\IN|to|a|resulting|severe (r_prep) reaction_7\NN|NONE (l_acl) resulting_15\VBG|to|by|a|severe (l_prep) in_16\IN|NONE (l_pobj) hypocalcemia_19\NN|NONE
C102006_D006996 CID citrate_22\JJ|NONE (r_compound) toxicity_23\NN|NONE (r_pobj) to_21\IN|NONE (r_pcomp) due_20\IN|severe (r_amod) reactions_19\NNS|NONE (r_dobj) prevent_17\VB|to (r_xcomp) help_16\VB|that|is|screening (r_xcomp) recommended_14\VBN|.|We (l_nsubjpass) screening_4\NN|that|is|help (l_prep) for_5\IN|careful (l_pobj) medications_6\NNS|NONE (l_conj) conditions_9\NNS|and (l_acl) predisposing_10\VBG|underlying (l_prep) to_11\IN|NONE (l_pobj) hypocalcemia_12\NN|NONE
D002125_C536214 NONE gluconate_5\NN|NONE (r_pobj) with_2\IN|Empirical (r_prep) treatment_1\NN|,|was|subsided|and (r_nsubjpass) initiated_7\VBN|NONE (l_conj) subsided_13\VBD|,|was|treatment|and (l_nsubj) contractions_11\NNS|over|.|slowly
C102006_D064420 NONE citrate_1\JJ|Severe (r_compound) toxicity_2\NN|donation|.
C102006_D064420 NONE citrate_6\JJ|severe (r_compound) toxicity_7\NN|NONE
C102006_D064420 NONE citrate_22\JJ|NONE (r_compound) toxicity_23\NN|NONE
D049994_D006996 NONE diuretic_13\NN|cause|a (r_amod) loop_12\NN|bumetanide|that (l_relcl) cause_16\VB|a|diuretic (l_dobj) hypocalcemia_18\NN|may|that
20510337
D012643_D009369 NONE selenium_46\NN|in (r_nmod) ions_49\NNS|NONE (r_pobj) of_45\IN|the (r_prep) reductions_44\NNS|resulted (r_dobj) attenuated_42\VBD|elevations|,|and (r_conj) decreased_24\VBD|.|significantly|level|(|deficits|)|Q|suppressed|,|, (l_dobj) elevations_26\NNS|,|attenuated|and (l_prep) of_27\IN|the (l_pobj) factor_30\NN|NONE (l_compound) tumor_28\NN|necrosis|alpha
D002945_D007674 NONE cisplatin_5\NN|in|acute (r_amod) nephrotoxicity_6\NN|treatment|.
D002945_D007674 NONE cisplatin_8\NN|NONE (r_pobj) by_7\IN|NONE (r_agent) mediated_6\VBN|renal|tissue|histopathological (r_acl) damage_5\NN|.|Also|by|was|,
D002945_D007674 NONE cisplatin_15\NN|acute|encountered (r_amod) nephrotoxicity_16\NN|NONE
D009569_D009336 NONE oxide_35\NN|,| (r_conj) alpha_32\NN|necrosis|tumor (r_appos) factor_30\NN|NONE (l_compound) necrosis_29\NN|alpha|tumor
C024989_D007674 NONE Q10_1\NNP|Coenzyme (r_compound) treatment_2\NN|nephrotoxicity|. (r_nsubj) ameliorates_3\VBZ|NONE (l_dobj) nephrotoxicity_6\NN|treatment|.
C024989_D007674 NONE Q10_13\NNP|coenzyme (r_compound) treatment_14\NN|NONE (r_pobj) by_11\IN|.|Also|damage|was|, (r_agent) ameliorated_10\VBN|NONE (l_nsubjpass) damage_5\NN|.|Also|by|was|,
C024989_D007674 NONE Q10_5\NNP|option|that (r_nsubj) represents_6\VBZ|was|.|It (l_dobj) option_10\NN|Q|that (l_acl) protect_12\VB|potential|therapeutic|a (l_prep) against_13\IN|to (l_pobj) nephrotoxicity_16\NN|NONE
D010984_D009369 NONE platinum_37\NN|NONE (r_compound) ion_38\NN|NONE (r_compound) concentration_39\NN|nitric|and (r_conj) oxide_35\NN|,| (r_conj) alpha_32\NN|necrosis|tumor (r_appos) factor_30\NN|NONE (l_compound) tumor_28\NN|necrosis|alpha
D015032_D009369 NONE zinc_48\NN|and (r_conj) selenium_46\NN|in (r_nmod) ions_49\NNS|NONE (r_pobj) of_45\IN|the (r_prep) reductions_44\NNS|resulted (r_dobj) attenuated_42\VBD|elevations|,|and (r_conj) decreased_24\VBD|.|significantly|level|(|deficits|)|Q|suppressed|,|, (l_dobj) elevations_26\NNS|,|attenuated|and (l_prep) of_27\IN|the (l_pobj) factor_30\NN|NONE (l_compound) tumor_28\NN|necrosis|alpha
D005978_D009369 NONE glutathione_12\NN|activity|reduced|and (r_compound) level_13\NN|.|significantly|(|deficits|)|Q|decreased|suppressed|,|, (r_dobj) compensated_3\VBD|NONE (l_conj) decreased_24\VBD|.|significantly|level|(|deficits|)|Q|suppressed|,|, (l_dobj) elevations_26\NNS|,|attenuated|and (l_prep) of_27\IN|the (l_pobj) factor_30\NN|NONE (l_compound) tumor_28\NN|necrosis|alpha
D012643_D009336 NONE selenium_46\NN|in (r_nmod) ions_49\NNS|NONE (r_pobj) of_45\IN|the (r_prep) reductions_44\NNS|resulted (r_dobj) attenuated_42\VBD|elevations|,|and (r_conj) decreased_24\VBD|.|significantly|level|(|deficits|)|Q|suppressed|,|, (l_dobj) elevations_26\NNS|,|attenuated|and (l_prep) of_27\IN|the (l_pobj) factor_30\NN|NONE (l_compound) necrosis_29\NN|alpha|tumor
D002945_D009369 NONE cisplatin_55\JJ|NONE (r_amod) administration_56\NN|NONE (r_pobj) from_54\IN|NONE (r_prep) resulted_53\VBD|reductions (r_advcl) attenuated_42\VBD|elevations|,|and (r_conj) decreased_24\VBD|.|significantly|level|(|deficits|)|Q|suppressed|,|, (l_dobj) elevations_26\NNS|,|attenuated|and (l_prep) of_27\IN|the (l_pobj) factor_30\NN|NONE (l_compound) tumor_28\NN|necrosis|alpha
C024989_D009369 NONE Q10_1\NNP|.|significantly|level|(|deficits|)|decreased|suppressed|,|, (r_nsubj) compensated_3\VBD|NONE (l_conj) decreased_24\VBD|.|significantly|level|(|deficits|)|Q|suppressed|,|, (l_dobj) elevations_26\NNS|,|attenuated|and (l_prep) of_27\IN|the (l_pobj) factor_30\NN|NONE (l_compound) tumor_28\NN|necrosis|alpha
D002945_D009336 NONE cisplatin_55\JJ|NONE (r_amod) administration_56\NN|NONE (r_pobj) from_54\IN|NONE (r_prep) resulted_53\VBD|reductions (r_advcl) attenuated_42\VBD|elevations|,|and (r_conj) decreased_24\VBD|.|significantly|level|(|deficits|)|Q|suppressed|,|, (l_dobj) elevations_26\NNS|,|attenuated|and (l_prep) of_27\IN|the (l_pobj) factor_30\NN|NONE (l_compound) necrosis_29\NN|alpha|tumor
D009569_D009369 NONE oxide_35\NN|,| (r_conj) alpha_32\NN|necrosis|tumor (r_appos) factor_30\NN|NONE (l_compound) tumor_28\NN|necrosis|alpha
D005978_D009336 NONE glutathione_12\NN|activity|reduced|and (r_compound) level_13\NN|.|significantly|(|deficits|)|Q|decreased|suppressed|,|, (r_dobj) compensated_3\VBD|NONE (l_conj) decreased_24\VBD|.|significantly|level|(|deficits|)|Q|suppressed|,|, (l_dobj) elevations_26\NNS|,|attenuated|and (l_prep) of_27\IN|the (l_pobj) factor_30\NN|NONE (l_compound) necrosis_29\NN|alpha|tumor
D013481_D009336 NONE superoxide_15\NN|dismutase (r_amod) activity_17\NN|glutathione|reduced|and (r_conj) level_13\NN|.|significantly|(|deficits|)|Q|decreased|suppressed|,|, (r_dobj) compensated_3\VBD|NONE (l_conj) decreased_24\VBD|.|significantly|level|(|deficits|)|Q|suppressed|,|, (l_dobj) elevations_26\NNS|,|attenuated|and (l_prep) of_27\IN|the (l_pobj) factor_30\NN|NONE (l_compound) necrosis_29\NN|alpha|tumor
D013481_D009369 NONE superoxide_15\NN|dismutase (r_amod) activity_17\NN|glutathione|reduced|and (r_conj) level_13\NN|.|significantly|(|deficits|)|Q|decreased|suppressed|,|, (r_dobj) compensated_3\VBD|NONE (l_conj) decreased_24\VBD|.|significantly|level|(|deficits|)|Q|suppressed|,|, (l_dobj) elevations_26\NNS|,|attenuated|and (l_prep) of_27\IN|the (l_pobj) factor_30\NN|NONE (l_compound) tumor_28\NN|necrosis|alpha
C024989_D009336 NONE Q10_1\NNP|.|significantly|level|(|deficits|)|decreased|suppressed|,|, (r_nsubj) compensated_3\VBD|NONE (l_conj) decreased_24\VBD|.|significantly|level|(|deficits|)|Q|suppressed|,|, (l_dobj) elevations_26\NNS|,|attenuated|and (l_prep) of_27\IN|the (l_pobj) factor_30\NN|NONE (l_compound) necrosis_29\NN|alpha|tumor
D002945_D058186 CID cisplatin_21\NN|NONE (r_pobj) of_20\IN|)|i.p.|(|mg/kg|single|a (r_prep) injection_19\NN|NONE (r_pobj) by_15\IN|NONE (r_agent) induced_14\VBN|in|effect|was|. (r_advcl) investigated_7\VBN|NONE (l_prep) in_8\IN|effect|was|.|induced (l_pobj) mice_9\NNS|NONE (l_prep) with_10\IN|NONE (l_pobj) injury_13\NN|NONE
D010984_D009336 NONE platinum_37\NN|NONE (r_compound) ion_38\NN|NONE (r_compound) concentration_39\NN|nitric|and (r_conj) oxide_35\NN|,| (r_conj) alpha_32\NN|necrosis|tumor (r_appos) factor_30\NN|NONE (l_compound) necrosis_29\NN|alpha|tumor
C024989_D058186 NONE Q10_5\NNP|NONE (r_pobj) of_3\IN|nephroprotective|The (r_prep) effect_2\NN|in|was|.|induced (r_nsubjpass) investigated_7\VBN|NONE (l_prep) in_8\IN|effect|was|.|induced (l_pobj) mice_9\NNS|NONE (l_prep) with_10\IN|NONE (l_pobj) injury_13\NN|NONE
D015032_D009336 NONE zinc_48\NN|and (r_conj) selenium_46\NN|in (r_nmod) ions_49\NNS|NONE (r_pobj) of_45\IN|the (r_prep) reductions_44\NNS|resulted (r_dobj) attenuated_42\VBD|elevations|,|and (r_conj) decreased_24\VBD|.|significantly|level|(|deficits|)|Q|suppressed|,|, (l_dobj) elevations_26\NNS|,|attenuated|and (l_prep) of_27\IN|the (l_pobj) factor_30\NN|NONE (l_compound) necrosis_29\NN|alpha|tumor
6103707
D005445_D010146 CID flunitrazepam_7\NN|NONE (r_pobj) of_6\IN|i.m. (r_prep) injection_5\NN|NONE (r_pobj) on_3\IN|NONE (r_prep) pain_2\NN|There|often|.
3800626
D010423_D009135 CID pentazocine_8\NN| (r_advmod) induced_10\VBN|fibrous (r_amod) myopathy_12\NNS|to
D010423_D009135 CID pentazocine_13\NN|repeated (r_compound) injection_14\NN|NONE (r_pobj) of_11\IN|,|known|common|side|a (r_prep) effect_10\NN|.|myopathy (r_attr) is_2\VBZ|NONE (l_nsubj) myopathy_1\NN|effect|.
D010423_D009135 CID pentazocine_10\NN| (r_npadvmod) induced_12\VBN|NONE (r_compound) myopathy_13\NN|NONE
D010423_D009135 CID pentazocine_8\NN| (r_advmod) induced_10\VBN|of|fibrous|documented (r_amod) myopathy_12\NNS|NONE
D010423_D009135 CID pentazocine_8\NN| (r_advmod) induced_10\VBN|of|fibrous|documented (r_amod) myopathy_12\NNS|NONE (r_pobj) with_6\IN|a|old|history|bilaterally|and (r_prep) woman_5\NN|NONE (r_pobj) In_0\IN|,|examination|lesion|,|.|in (r_prep) showed_32\VBD|NONE (l_prep) in_51\IN|,|examination|lesion|,|In|. (l_pobj) addition_52\NN|NONE (l_prep) to_53\IN|NONE (l_pobj) myopathy_56\NN|NONE
D010423_D020425 CID pentazocine_8\NN| (r_advmod) induced_10\VBN|fibrous (r_amod) myopathy_12\NNS|to (r_pobj) due_6\IN|Compression|of|. (r_prep) neuropathy_1\NN|NONE (l_prep) of_2\IN|due|Compression|. (l_pobj) nerve_5\NN|NONE
D010423_D009408 CID pentazocine_8\NN| (r_advmod) induced_10\VBN|fibrous (r_amod) myopathy_12\NNS|to (r_pobj) due_6\IN|Compression|of|. (r_prep) neuropathy_1\NN|NONE (l_prep) of_2\IN|due|Compression|. (l_pobj) nerve_5\NN|NONE
D010423_D009408 CID pentazocine_10\NN| (r_npadvmod) induced_12\VBN|NONE (r_compound) myopathy_13\NN|NONE (r_pobj) by_9\IN|NONE (r_agent) affected_8\VBN|fibrotic (r_acl) muscle_7\NN|to (r_pobj) due_4\IN|compression (r_amod) neuropathy_3\NN|been|has|not|However|previously|,|.
D010423_D005355 CID pentazocine_8\NN| (r_advmod) induced_10\VBN|fibrous (r_amod) myopathy_12\NNS|to
D010423_D005355 CID pentazocine_13\NN|repeated (r_compound) injection_14\NN|NONE (r_pobj) of_11\IN|,|known|common|side|a (r_prep) effect_10\NN|.|myopathy (r_attr) is_2\VBZ|NONE (l_nsubj) myopathy_1\NN|effect|.
D010423_D005355 CID pentazocine_8\NN| (r_advmod) induced_10\VBN|of|fibrous|documented (r_amod) myopathy_12\NNS|NONE
D010423_D005355 CID pentazocine_8\NN| (r_advmod) induced_10\VBN|of|fibrous|documented (r_amod) myopathy_12\NNS|NONE (r_pobj) with_6\IN|a|old|history|bilaterally|and (r_prep) woman_5\NN|NONE (r_pobj) In_0\IN|,|examination|lesion|,|.|in (r_prep) showed_32\VBD|NONE (l_prep) in_51\IN|,|examination|lesion|,|In|. (l_pobj) addition_52\NN|NONE (l_prep) to_53\IN|NONE (l_pobj) myopathy_56\NN|NONE
8423889
D005473_D010300 NONE fluoxetine_21\NN|NONE (r_pobj) to_18\IN|NONE (r_prep) exposure_17\NN|NONE (r_pobj) after_16\IN|increased|in|of|the (r_prep) amount_4\NN|We|. (l_prep) in_8\IN|increased|of|the|after (l_pobj) patients_10\NNS|NONE (l_prep) with_11\IN|four (l_pobj) disease_15\NN|NONE
D005473_D010300 NONE fluoxetine_11\NN|NONE (r_pobj) of_10\IN|a|relevant|in|antagonistic (r_prep) capacity_9\NN|NONE (l_prep) in_12\IN|a|relevant|of|antagonistic (l_pobj) patients_16\NNS|NONE (l_compound) disease_15\NN|Parkinson
D004298_D010300 NONE dopamine_6\NN| (r_npadvmod) antagonistic_8\JJ|a|relevant|of|in (r_amod) capacity_9\NN|NONE (l_prep) in_12\IN|a|relevant|of|antagonistic (l_pobj) patients_16\NNS|NONE (l_compound) disease_15\NN|Parkinson
D000928_D010300 NONE antidepressant_20\JJ|the (r_amod) fluoxetine_21\NN|NONE (r_pobj) to_18\IN|NONE (r_prep) exposure_17\NN|NONE (r_pobj) after_16\IN|increased|in|of|the (r_prep) amount_4\NN|We|. (l_prep) in_8\IN|increased|of|the|after (l_pobj) patients_10\NNS|NONE (l_prep) with_11\IN|four (l_pobj) disease_15\NN|NONE
D005473_D009069 CID fluoxetine_5\NN|NONE (r_amod) medication_6\NN|NONE (r_pobj) after_4\IN|of|. (r_prep) Increase_0\NNP|NONE (l_prep) of_1\IN|after|. (l_pobj) disability_3\NN|NONE
D005473_D009069 CID fluoxetine_21\NN|NONE (r_pobj) to_18\IN|NONE (r_prep) exposure_17\NN|NONE (r_pobj) after_16\IN|increased|in|of|the (r_prep) amount_4\NN|We|. (l_prep) of_5\IN|increased|in|the|after (l_pobj) disability_7\NN|NONE
D000928_D009069 NONE antidepressant_20\JJ|the (r_amod) fluoxetine_21\NN|NONE (r_pobj) to_18\IN|NONE (r_prep) exposure_17\NN|NONE (r_pobj) after_16\IN|increased|in|of|the (r_prep) amount_4\NN|We|. (l_prep) of_5\IN|increased|in|the|after (l_pobj) disability_7\NN|NONE
16858720
D014859_D006470 NONE warfarin_1\JJ| (r_compound) drug_3\NN|A (r_compound) interaction_4\NN|could|in|considered|to|.|have (r_nsubj) contributed_7\VBN|NONE (l_prep) to_8\IN|could|interaction|in|considered|.|have (l_pobj) haemorrhage_10\NN|NONE
D014859_D006470 NONE warfarin_1\JJ| (r_compound) drug_3\NN|A (r_compound) interaction_4\NN|could|in|considered|to|.|have (r_nsubj) contributed_7\VBN|NONE (l_conj) considered_34\VBN|could|interaction|in|to|.|have (l_nsubjpass) complication_32\NN|was|being (l_amod) bleeding_31\VBG|the
D014859_D006470 NONE warfarin_19\JJ|the (r_compound) patients_20\NNS|NONE (r_pobj) of_17\IN||(|)| (r_prep) %_15\NN|in|and (r_pobj) in_11\IN|could|interaction|considered|to|.|have (r_prep) contributed_7\VBN|NONE (l_prep) to_8\IN|could|interaction|in|considered|.|have (l_pobj) haemorrhage_10\NN|NONE
D014859_D006470 NONE warfarin_19\JJ|the (r_compound) patients_20\NNS|NONE (r_pobj) of_17\IN||(|)| (r_prep) %_15\NN|in|and (r_pobj) in_11\IN|could|interaction|considered|to|.|have (r_prep) contributed_7\VBN|NONE (l_conj) considered_34\VBN|could|interaction|in|to|.|have (l_nsubjpass) complication_32\NN|was|being (l_amod) bleeding_31\VBG|the
D014859_D002543 CID warfarin_4\NN|NONE (r_pobj) by_3\IN|influence (r_agent) induced_2\VBN|.|Cerebral (r_acl) haemorrhage_1\NN|NONE
D014859_D002543 CID warfarin_9\RB| (r_npadvmod) induced_11\VBN|cerebral (r_amod) haemorrhages_13\NNS|NONE
D014859_D002543 CID warfarin_16\JJ|to (r_pobj) due_14\IN|frequency|To|. (r_prep) evaluate_1\VB|NONE (l_dobj) frequency_3\NN|due|To|. (l_prep) of_8\IN|,|the|severity (l_pobj) haemorrhages_13\NNS|NONE
D014859_D002543 CID warfarin_18\JJ| (r_compound) drug_20\NN|in (r_compound) interactions_21\NNS|and (r_conj) warfarin_16\JJ|to (r_pobj) due_14\IN|frequency|To|. (r_prep) evaluate_1\VB|NONE (l_dobj) frequency_3\NN|due|To|. (l_prep) of_8\IN|,|the|severity (l_pobj) haemorrhages_13\NNS|NONE
D014859_D002543 CID warfarin_8\JJ|NONE (r_nmod) interactions_13\NNS|whether|could|haemorrhage|have (r_nsubj) caused_16\VBN|to (l_dobj) haemorrhage_19\NN|whether|could|interactions|have
D014859_D002543 CID warfarin_10\JJ| (r_compound) drug_12\NN|and (r_conj) warfarin_8\JJ|NONE (r_nmod) interactions_13\NNS|whether|could|haemorrhage|have (r_nsubj) caused_16\VBN|to (l_dobj) haemorrhage_19\NN|whether|could|interactions|have
D014859_D002543 CID warfarin_17\JJ|NONE (r_compound) treatment_18\NN|NONE (r_pobj) to_16\IN|NONE (r_prep) related_15\VBN|NONE (r_amod) as_14\IN|were|Among|. (r_prep) assessed_13\VBN|NONE (l_prep) Among_0\IN|were|as|. (l_pobj) patients_2\NNS|NONE (l_prep) with_3\IN| (l_pobj) haemorrhage_5\NN|NONE
D014859_D002543 CID Warfarin_0\NNP| (r_npadvmod) induced_2\VBN|cerebral (r_amod) haemorrhages_4\NNS|problem|.
D014859_D002543 CID warfarin_4\RB| (r_npadvmod) related_6\VBN|cerebral (r_amod) haemorrhages_8\NNS|NONE
D014859_D002543 CID warfarin_26\NN|NONE (r_pobj) with_25\IN|to (r_prep) interact_24\VB|NONE (r_xcomp) known_22\VBN|NONE (r_acl) drugs_21\NNS|when (r_dobj) prescribing_20\VBG|if|caution|had|been (r_advcl) taken_18\VBN|have|been|proportion|.|might (r_advcl) prevented_12\VBN|NONE (l_nsubjpass) proportion_2\NN|have|been|taken|.|might (l_prep) of_3\IN|significant|A (l_pobj) haemorrhages_8\NNS|NONE
11243580
D009569_D012640 NONE oxide_20\NN|)|(|NAME|methyl (r_appos) ester_12\NN|NONE (r_pobj) of_2\IN|The (r_prep) effects_1\NNS|.|were|on|, (r_nsubjpass) investigated_36\VBN|NONE (l_prep) on_37\IN|.|effects|were|, (l_pobj) convulsions_41\NNS|NONE
D009569_D012640 NONE NO_22\NNP|synthase|)|and|arginine (r_intj) inhibitor_25\NN|(|a|,|nitric|precursor (r_appos) oxide_20\NN|)|(|NAME|methyl (r_appos) ester_12\NN|NONE (r_pobj) of_2\IN|The (r_prep) effects_1\NNS|.|were|on|, (r_nsubjpass) investigated_36\VBN|NONE (l_prep) on_37\IN|.|effects|were|, (l_pobj) convulsions_41\NNS|NONE
D009569_D012640 NONE NO_32\JJ|a (r_det) precursor_33\NN|(|a|,|inhibitor|nitric (r_appos) oxide_20\NN|)|(|NAME|methyl (r_appos) ester_12\NN|NONE (r_pobj) of_2\IN|The (r_prep) effects_1\NNS|.|were|on|, (r_nsubjpass) investigated_36\VBN|NONE (l_prep) on_37\IN|.|effects|were|, (l_pobj) convulsions_41\NNS|NONE
D009569_D012640 NONE NO_5\DT|that|mediator (r_nsubj) is_6\VBZ|may|.|results (l_attr) mediator_9\NN|that|NO (l_prep) in_10\IN|a|proconvulsant (l_pobj) convulsions_14\NNS|NONE
D019331_D012640 NONE ester_12\NN|NONE (r_pobj) of_2\IN|The (r_prep) effects_1\NNS|.|were|on|, (r_nsubjpass) investigated_36\VBN|NONE (l_prep) on_37\IN|.|effects|were|, (l_pobj) convulsions_41\NNS|NONE
D019331_D012640 NONE NAME_16\NN|)|(|oxide|methyl (r_appos) ester_12\NN|NONE (r_pobj) of_2\IN|The (r_prep) effects_1\NNS|.|were|on|, (r_nsubjpass) investigated_36\VBN|NONE (l_prep) on_37\IN|.|effects|were|, (l_pobj) convulsions_41\NNS|NONE
D019331_D012640 NONE NAME_2\NNP|significantly|.|incidence (r_nsubj) decreased_16\VBD|NONE (l_dobj) incidence_18\NN|NAME|significantly|. (l_appos) convulsions_26\NNS|the|of
D008012_D012640 CID lidocaine_6\NN| (r_npadvmod) induced_8\VBN|in (r_amod) convulsion_9\NN|NONE
D008012_D012640 CID lidocaine_38\NN| (r_npadvmod) induced_40\VBN|NONE (r_amod) convulsions_41\NNS|NONE
D008012_D012640 CID lidocaine_20\NN|NONE (r_pobj) of_19\IN|the|convulsions (r_prep) incidence_18\NN|NAME|significantly|. (l_appos) convulsions_26\NNS|the|of
D008012_D012640 CID lidocaine_12\NN|NONE (r_pobj) of_11\IN|,|(|mg/kg|the|convulsions (r_prep) incidence_10\NN|.|In|treatment|, (l_appos) convulsions_18\NNS|,|(|mg/kg|of|the
D008012_D012640 CID lidocaine_11\NN| (r_npadvmod) induced_13\VBN|NONE (r_amod) convulsions_14\NNS|NONE
D001120_D012640 NONE arginine_29\NN|NO|synthase|)|and (r_conj) inhibitor_25\NN|(|a|,|nitric|precursor (r_appos) oxide_20\NN|)|(|NAME|methyl (r_appos) ester_12\NN|NONE (r_pobj) of_2\IN|The (r_prep) effects_1\NNS|.|were|on|, (r_nsubjpass) investigated_36\VBN|NONE (l_prep) on_37\IN|.|effects|were|, (l_pobj) convulsions_41\NNS|NONE
D001120_D012640 NONE arginine_6\NN|the (r_compound) treatment_7\NN|.|In|incidence|, (r_nsubj) increased_8\VBD|NONE (l_dobj) incidence_10\NN|.|In|treatment|, (l_appos) convulsions_18\NNS|,|(|mg/kg|of|the
D003975_D012640 NONE diazepam_10\NN|L|mg/kg|)|and|i.p.| (r_conj) NAME_2\NNP|significantly|.|incidence (r_nsubj) decreased_16\VBD|NONE (l_dobj) incidence_18\NN|NAME|significantly|. (l_appos) convulsions_26\NNS|the|of
2385256
D008274_D009468 NONE magnesium_17\NN|for|parenteral (r_compound) administration_18\NN|NONE (r_pobj) after_15\IN|who|quadriplegic (r_prep) became_12\VBD|neuromuscular (r_relcl) disease_10\NN|NONE
D008274_D009157 CID magnesium_6\NN|NONE (r_compound) administration_7\NN|NONE (r_pobj) after_5\IN|NONE (r_prep) weakness_4\NN|NONE (r_pobj) as_3\IN|NONE (r_prep) presenting_2\VBG|Myasthenia|. (r_acl) gravis_1\NN|NONE
D008274_D009157 CID magnesium_3\NN|NONE (r_compound) administration_4\NN|NONE (r_pobj) after_2\IN|NONE (r_prep) paralysis_1\NN|been|Although|in|has (r_nsubjpass) described_7\VBN|,|previously|not|has|it|be|.|been (l_prep) in_8\IN|paralysis|been|Although|has (l_pobj) patients_9\NNS|NONE (l_prep) with_10\IN|NONE (l_pobj) gravis_13\NN|NONE
D008274_D011782 NONE magnesium_17\NN|for|parenteral (r_compound) administration_18\NN|NONE (r_pobj) after_15\IN|who|quadriplegic (r_prep) became_12\VBD|neuromuscular (l_acomp) quadriplegic_14\JJ|who|after
D008274_D010243 NONE magnesium_3\NN|NONE (r_compound) administration_4\NN|NONE (r_pobj) after_2\IN|NONE (r_prep) paralysis_1\NN|been|Although|in|has
D008274_D020511 NONE magnesium_10\NN|NONE (r_pobj) of_9\IN|the|neuromuscular (r_prep) effects_8\NNS|NONE (r_pobj) to_5\IN|unusually (r_prep) sensitive_4\JJ|who (r_acomp) are_2\VBP|NONE (r_relcl) Patients_0\NNS|be|.|should|of (r_nsubjpass) suspected_13\VBN|NONE (l_prep) of_14\IN|be|Patients|.|should (l_pcomp) having_15\VBG|NONE (l_dobj) disorder_18\NN|NONE (l_prep) of_19\IN|an|underlying (l_pobj) transmission_21\NN|NONE
D008274_D011225 NONE magnesium_17\NN|for|parenteral (r_compound) administration_18\NN|NONE (l_prep) for_19\IN|parenteral|magnesium (l_pobj) preeclampsia_20\NN|NONE
20528871
D003520_D015458 NONE cyclophosphamide_8\NN|and|, (r_conj) etoposide_5\RB|,|in (r_conj) nelarabine_3\NN|NONE (l_prep) in_9\IN|,|etoposide (l_pobj) leukaemia_18\NN|NONE (l_conj) lymphoma_20\NN|relapsed|refractory|/|and|lymphoblastic
D003520_D015458 NONE cyclophosphamide_19\NN|chemotherapy|and|CPM|)|and|( (r_conj) VP_16\NNP|of| (r_appos) d_12\SYM|NONE (r_pobj) with_10\IN|)|( (r_prep) AraG_8\NNP|NONE (r_appos) nelarabine_6\JJ|NONE (r_pobj) of_5\IN| (r_prep) d_4\SYM|NONE (r_pobj) of_2\IN|A (r_prep) combination_1\NN|in|.|as|was (r_nsubjpass) used_28\VBN|NONE (l_prep) in_32\IN|.|as|combination|was (l_pobj) children_34\NNS|NONE (l_prep) with_35\IN|seven (l_pobj) leukaemia_42\NN|NONE (l_conj) lymphoma_44\NN|refractory|cell|or
D003520_D015458 NONE CPM_21\NNP|chemotherapy|and|cyclophosphamide|)|and|( (r_appos) VP_16\NNP|of| (r_appos) d_12\SYM|NONE (r_pobj) with_10\IN|)|( (r_prep) AraG_8\NNP|NONE (r_appos) nelarabine_6\JJ|NONE (r_pobj) of_5\IN| (r_prep) d_4\SYM|NONE (r_pobj) of_2\IN|A (r_prep) combination_1\NN|in|.|as|was (r_nsubjpass) used_28\VBN|NONE (l_prep) in_32\IN|.|as|combination|was (l_pobj) children_34\NNS|NONE (l_prep) with_35\IN|seven (l_pobj) leukaemia_42\NN|NONE (l_conj) lymphoma_44\NN|refractory|cell|or
C104457_D006402 CID AraG_8\NNP|NONE (r_pobj) than_7\IN|the (r_prep) combination_6\NN|NONE (r_pobj) for_4\IN|NONE (r_prep) greater_3\JJR|,|was|toxicity|. (r_acomp) was_2\VBD|NONE (l_nsubj) toxicity_1\NN|greater|,|was|.
D005047_D016399 NONE etoposide_5\RB|,|in (r_conj) nelarabine_3\NN|NONE (l_prep) in_9\IN|,|etoposide (l_pobj) leukaemia_18\NN|NONE (l_conj) lymphoma_20\NN|relapsed|refractory|/|and|lymphoblastic
D005047_D016399 NONE etoposide_14\NN|NONE (r_pobj) of_13\IN|VP| (r_prep) d_12\SYM|NONE (r_pobj) with_10\IN|)|( (r_prep) AraG_8\NNP|NONE (r_appos) nelarabine_6\JJ|NONE (r_pobj) of_5\IN| (r_prep) d_4\SYM|NONE (r_pobj) of_2\IN|A (r_prep) combination_1\NN|in|.|as|was (r_nsubjpass) used_28\VBN|NONE (l_prep) in_32\IN|.|as|combination|was (l_pobj) children_34\NNS|NONE (l_prep) with_35\IN|seven (l_pobj) leukaemia_42\NN|NONE (l_conj) lymphoma_44\NN|refractory|cell|or
D005047_D016399 NONE VP_16\NNP|of| (r_appos) d_12\SYM|NONE (r_pobj) with_10\IN|)|( (r_prep) AraG_8\NNP|NONE (r_appos) nelarabine_6\JJ|NONE (r_pobj) of_5\IN| (r_prep) d_4\SYM|NONE (r_pobj) of_2\IN|A (r_prep) combination_1\NN|in|.|as|was (r_nsubjpass) used_28\VBN|NONE (l_prep) in_32\IN|.|as|combination|was (l_pobj) children_34\NNS|NONE (l_prep) with_35\IN|seven (l_pobj) leukaemia_42\NN|NONE (l_conj) lymphoma_44\NN|refractory|cell|or
C104457_D016399 NONE nelarabine_3\NN|NONE (l_prep) in_9\IN|,|etoposide (l_pobj) leukaemia_18\NN|NONE (l_conj) lymphoma_20\NN|relapsed|refractory|/|and|lymphoblastic
C104457_D016399 NONE nelarabine_6\JJ|NONE (r_pobj) of_5\IN| (r_prep) d_4\SYM|NONE (r_pobj) of_2\IN|A (r_prep) combination_1\NN|in|.|as|was (r_nsubjpass) used_28\VBN|NONE (l_prep) in_32\IN|.|as|combination|was (l_pobj) children_34\NNS|NONE (l_prep) with_35\IN|seven (l_pobj) leukaemia_42\NN|NONE (l_conj) lymphoma_44\NN|refractory|cell|or
C104457_D016399 NONE AraG_8\NNP|NONE (r_appos) nelarabine_6\JJ|NONE (r_pobj) of_5\IN| (r_prep) d_4\SYM|NONE (r_pobj) of_2\IN|A (r_prep) combination_1\NN|in|.|as|was (r_nsubjpass) used_28\VBN|NONE (l_prep) in_32\IN|.|as|combination|was (l_pobj) children_34\NNS|NONE (l_prep) with_35\IN|seven (l_pobj) leukaemia_42\NN|NONE (l_conj) lymphoma_44\NN|refractory|cell|or
C104457_D015458 NONE nelarabine_3\NN|NONE (l_prep) in_9\IN|,|etoposide (l_pobj) leukaemia_18\NN|NONE (l_conj) lymphoma_20\NN|relapsed|refractory|/|and|lymphoblastic
C104457_D015458 NONE nelarabine_6\JJ|NONE (r_pobj) of_5\IN| (r_prep) d_4\SYM|NONE (r_pobj) of_2\IN|A (r_prep) combination_1\NN|in|.|as|was (r_nsubjpass) used_28\VBN|NONE (l_prep) in_32\IN|.|as|combination|was (l_pobj) children_34\NNS|NONE (l_prep) with_35\IN|seven (l_pobj) leukaemia_42\NN|NONE (l_conj) lymphoma_44\NN|refractory|cell|or
C104457_D015458 NONE AraG_8\NNP|NONE (r_appos) nelarabine_6\JJ|NONE (r_pobj) of_5\IN| (r_prep) d_4\SYM|NONE (r_pobj) of_2\IN|A (r_prep) combination_1\NN|in|.|as|was (r_nsubjpass) used_28\VBN|NONE (l_prep) in_32\IN|.|as|combination|was (l_pobj) children_34\NNS|NONE (l_prep) with_35\IN|seven (l_pobj) leukaemia_42\NN|NONE (l_conj) lymphoma_44\NN|refractory|cell|or
D005047_D015458 NONE etoposide_5\RB|,|in (r_conj) nelarabine_3\NN|NONE (l_prep) in_9\IN|,|etoposide (l_pobj) leukaemia_18\NN|NONE (l_conj) lymphoma_20\NN|relapsed|refractory|/|and|lymphoblastic
D005047_D015458 NONE etoposide_14\NN|NONE (r_pobj) of_13\IN|VP| (r_prep) d_12\SYM|NONE (r_pobj) with_10\IN|)|( (r_prep) AraG_8\NNP|NONE (r_appos) nelarabine_6\JJ|NONE (r_pobj) of_5\IN| (r_prep) d_4\SYM|NONE (r_pobj) of_2\IN|A (r_prep) combination_1\NN|in|.|as|was (r_nsubjpass) used_28\VBN|NONE (l_prep) in_32\IN|.|as|combination|was (l_pobj) children_34\NNS|NONE (l_prep) with_35\IN|seven (l_pobj) leukaemia_42\NN|NONE (l_conj) lymphoma_44\NN|refractory|cell|or
D005047_D015458 NONE VP_16\NNP|of| (r_appos) d_12\SYM|NONE (r_pobj) with_10\IN|)|( (r_prep) AraG_8\NNP|NONE (r_appos) nelarabine_6\JJ|NONE (r_pobj) of_5\IN| (r_prep) d_4\SYM|NONE (r_pobj) of_2\IN|A (r_prep) combination_1\NN|in|.|as|was (r_nsubjpass) used_28\VBN|NONE (l_prep) in_32\IN|.|as|combination|was (l_pobj) children_34\NNS|NONE (l_prep) with_35\IN|seven (l_pobj) leukaemia_42\NN|NONE (l_conj) lymphoma_44\NN|refractory|cell|or
C104457_D059352 CID AraG_8\NNP|NONE (r_pobj) to_6\IN|NONE (r_prep) attributable_5\JJ|side|common|The (r_amod) effects_4\NNS|.|neuropathy (r_nsubj) included_9\VBD|NONE (l_dobj) neuropathy_17\NN|effects|. (l_conj) pain_20\NN|Grade|and|sensory
C104457_D009422 CID AraG_8\NNP|NONE (r_pobj) to_6\IN|NONE (r_prep) attributable_5\JJ|side|common|The (r_amod) effects_4\NNS|.|neuropathy (r_nsubj) included_9\VBD|NONE (l_dobj) neuropathy_17\NN|effects|.
C104457_D009422 CID AraG_7\NN|as (r_dobj) giving_6\VBG|NONE (r_pcomp) of_5\IN|the (r_prep) safety_4\NN|experience|.|,|monitored (r_dobj) supports_2\VBZ|NONE (l_advcl) monitored_24\VBN|experience|.|safety|, (l_nsubjpass) toxicity_20\NN|closely|although|must|be
D005047_D009422 NONE etoposide_14\NN|NONE (r_pobj) with_13\IN|NONE (r_prep) synchrony_12\NN|NONE (r_pobj) in_11\IN|salvage (r_prep) therapy_10\NN|NONE (r_pobj) as_8\IN|AraG (r_prep) giving_6\VBG|NONE (r_pcomp) of_5\IN|the (r_prep) safety_4\NN|experience|.|,|monitored (r_dobj) supports_2\VBZ|NONE (l_advcl) monitored_24\VBN|experience|.|safety|, (l_nsubjpass) toxicity_20\NN|closely|although|must|be
D003520_D016399 NONE cyclophosphamide_8\NN|and|, (r_conj) etoposide_5\RB|,|in (r_conj) nelarabine_3\NN|NONE (l_prep) in_9\IN|,|etoposide (l_pobj) leukaemia_18\NN|NONE (l_conj) lymphoma_20\NN|relapsed|refractory|/|and|lymphoblastic
D003520_D016399 NONE cyclophosphamide_19\NN|chemotherapy|and|CPM|)|and|( (r_conj) VP_16\NNP|of| (r_appos) d_12\SYM|NONE (r_pobj) with_10\IN|)|( (r_prep) AraG_8\NNP|NONE (r_appos) nelarabine_6\JJ|NONE (r_pobj) of_5\IN| (r_prep) d_4\SYM|NONE (r_pobj) of_2\IN|A (r_prep) combination_1\NN|in|.|as|was (r_nsubjpass) used_28\VBN|NONE (l_prep) in_32\IN|.|as|combination|was (l_pobj) children_34\NNS|NONE (l_prep) with_35\IN|seven (l_pobj) leukaemia_42\NN|NONE (l_conj) lymphoma_44\NN|refractory|cell|or
D003520_D016399 NONE CPM_21\NNP|chemotherapy|and|cyclophosphamide|)|and|( (r_appos) VP_16\NNP|of| (r_appos) d_12\SYM|NONE (r_pobj) with_10\IN|)|( (r_prep) AraG_8\NNP|NONE (r_appos) nelarabine_6\JJ|NONE (r_pobj) of_5\IN| (r_prep) d_4\SYM|NONE (r_pobj) of_2\IN|A (r_prep) combination_1\NN|in|.|as|was (r_nsubjpass) used_28\VBN|NONE (l_prep) in_32\IN|.|as|combination|was (l_pobj) children_34\NNS|NONE (l_prep) with_35\IN|seven (l_pobj) leukaemia_42\NN|NONE (l_conj) lymphoma_44\NN|refractory|cell|or
D003520_D009422 NONE cyclophosphamide_16\NN|and (r_conj) etoposide_14\NN|NONE (r_pobj) with_13\IN|NONE (r_prep) synchrony_12\NN|NONE (r_pobj) in_11\IN|salvage (r_prep) therapy_10\NN|NONE (r_pobj) as_8\IN|AraG (r_prep) giving_6\VBG|NONE (r_pcomp) of_5\IN|the (r_prep) safety_4\NN|experience|.|,|monitored (r_dobj) supports_2\VBZ|NONE (l_advcl) monitored_24\VBN|experience|.|safety|, (l_nsubjpass) toxicity_20\NN|closely|although|must|be
15572383
D004317_D009404 NONE adriamycin_3\NNS|NONE (l_pobj) proteinuria_7\NN|.|anticipated|, (l_amod) nephrotic_5\JJ|damage|elicited|range|,
D004317_D005923 NONE adriamycin_3\NNS|NONE (l_pobj) proteinuria_7\NN|.|anticipated|, (l_conj) damage_11\NN|nephrotic|elicited|range|, (l_conj) glomerulosclerosis_15\NN|interstitial|renal|and
D004317_D011507 CID adriamycin_10\NNS|NONE (r_pobj) by_9\IN|.|After|was|proteinuria|, (r_agent) induced_8\VBN|NONE (l_nsubjpass) proteinuria_6\NN|.|After|was|by|,
D004317_D011507 CID adriamycin_3\NNS|NONE (l_pobj) proteinuria_7\NN|.|anticipated|,
D004317_D011507 CID adriamycin_12\NNS|with|ACE|positively (r_advcl) correlated_4\VBD|NONE (l_prep) with_5\IN|ACE|positively|adriamycin (l_pobj) rise_8\NN|NONE (l_prep) in_9\IN|the|relative (l_pobj) proteinuria_10\NN|NONE
D004317_D007674 NONE adriamycin_12\NNS| (r_advmod) induced_14\VBN|renal (r_amod) damage_16\NN|NONE
D004317_D007674 NONE adriamycin_23\NNS|NONE (r_pobj) of_22\IN|in|a|single (r_prep) injection_21\NN|NONE (r_pobj) by_18\IN|NONE (r_agent) induced_17\VBN|of|the (r_acl) severity_13\NN|NONE (l_prep) of_14\IN|the|induced (l_pobj) damage_16\NN|NONE
D004317_D007674 NONE adriamycin_3\NNS|NONE (l_pobj) proteinuria_7\NN|.|anticipated|, (l_conj) damage_11\NN|nephrotic|elicited|range|,
D004317_D007674 NONE adriamycin_10\NNS| (r_advmod) induced_12\VBN|in|renal (r_amod) damage_14\NN|NONE
18442015
D006632_D014456 NONE histamine_19\NN|mast|peroxide|, (r_compound) release_20\NN|by|, (l_conj) peroxide_23\NN|mast|histamine|, (l_appos) permeability_31\NN|lipid (l_prep) in_32\IN|microvascular|generation (l_pcomp) modulating_33\VBG|NONE (l_dobj) hemorrhage_35\NN|NONE (l_conj) ulcer_37\NN|gastric|and|in
D006632_D014456 NONE histamine_10\NN|permeability|, (r_compound) concentration_11\NN|LPO|mucosal|, (l_conj) permeability_14\NN|,|histamine (l_conj) content_18\NN|microvascular|, (l_conj) areas_21\NNS|hemoglobin|and|luminal (l_compound) ulcer_20\NN|NONE
D006632_D014456 NONE histamine_16\NN|,|generation (r_compound) release_17\NN|back|,||gastric|acid (r_conj) diffusion_14\NN|NONE (r_pobj) including_9\VBG|,|ulcerogenic|increased (r_prep) factors_7\NNS|NONE (r_pobj) with_4\IN|ulcers (r_prep) accompanied_3\VBN|also|.|in|were (l_nsubj) ulcers_2\NNS|with
D006632_D014456 NONE histamine_6\NN|NONE (r_pobj) of_5\IN|to|positive|a (r_prep) correlation_4\NN|,|was|.|in|Moreover (l_prep) to_7\IN|positive|a|of (l_conj) to_11\IN|hemorrhage|and (l_pobj) ulcer_12\NN|NONE
D006632_D014456 NONE histamine_18\NN|and|permeability (r_compound) release_19\NN|LPO|,|,|produce|.|ameliorated (r_conj) generation_16\NN|NONE (l_ccomp) produce_2\VB|LPO|,|,|.|ameliorated|release (l_dobj) ulcer_5\NN|Atherosclerosis|via|could
D014700_D006471 NONE verapamil_3\NN|NONE (r_pobj) of_2\IN|.|on|Protective (r_prep) effect_1\NN|NONE (l_prep) on_4\IN|.|Protective|of (l_pobj) ulcers_7\NNS|NONE (l_amod) hemorrhagic_6\JJ|in|gastric
D014700_D006471 NONE verapamil_15\NN|NONE (r_pobj) by_12\IN|dependently (r_agent) ameliorated_11\VBN|.|ulcer (r_acomp) were_7\VBD|NONE (l_nsubj) ulcer_2\NN|.|ameliorated (l_amod) hemorrhagic_1\JJ|parameters|This|and
D014700_D006471 NONE verapamil_28\NN|NONE (r_pobj) by_27\IN|be|could|that|in (r_agent) ameliorated_26\VBN|LPO|,|,|produce|.|release (r_relcl) generation_16\NN|NONE (l_ccomp) produce_2\VB|LPO|,|,|.|ameliorated|release (l_dobj) ulcer_5\NN|Atherosclerosis|via|could (l_amod) hemorrhagic_4\JJ|gastric
D014700_D014456 NONE verapamil_3\NN|NONE (r_pobj) of_2\IN|.|on|Protective (r_prep) effect_1\NN|NONE (l_prep) on_4\IN|.|Protective|of (l_pobj) ulcers_7\NNS|NONE
D014700_D014456 NONE verapamil_6\NN|NONE (r_pobj) of_5\IN|protective|the|on (r_prep) effect_4\NN|was|,|.|Additionally (l_prep) on_7\IN|protective|of|the (l_pobj) model_10\NN|NONE (l_compound) ulcer_9\NN|this
D014700_D014456 NONE verapamil_15\NN|NONE (r_pobj) by_12\IN|dependently (r_agent) ameliorated_11\VBN|.|ulcer (r_acomp) were_7\VBD|NONE (l_nsubj) ulcer_2\NN|.|ameliorated
D014700_D014456 NONE verapamil_28\NN|NONE (r_pobj) by_27\IN|be|could|that|in (r_agent) ameliorated_26\VBN|LPO|,|,|produce|.|release (r_relcl) generation_16\NN|NONE (l_ccomp) produce_2\VB|LPO|,|,|.|ameliorated|release (l_dobj) ulcer_5\NN|Atherosclerosis|via|could
D002784_D050197 CID cholesterol_49\NN|and|vitamin (r_conj) D2_47\NN|NONE (r_pobj) of_45\IN|NONE (r_prep) coadministration_44\NN|NONE (r_pobj) by_43\IN|release|, (r_prep) induced_42\VBN|.|aim|examine (l_nsubj) release_20\NN|by|, (l_conj) peroxide_23\NN|mast|histamine|, (l_appos) permeability_31\NN|lipid (l_prep) in_32\IN|microvascular|generation (l_pcomp) modulating_33\VBG|NONE (l_dobj) hemorrhage_35\NN|NONE (l_prep) in_38\IN|gastric|ulcer|and (l_pobj) rats_39\NNS|NONE (l_prep) with_40\IN|NONE (l_pobj) atherosclerosis_41\NN|NONE
D002784_D050197 CID cholesterol_23\NN|vitamin|and (r_conj) D2_21\NN|induce|kg (r_dobj) containing_19\VBG|NONE (l_advcl) induce_25\VB|D|kg (l_dobj) atherosclerosis_26\NN|to
D002784_D050197 CID cholesterol_10\NN|,|serum (r_conj) calcium_7\NN|such (r_pobj) as_5\IN|,|atherosclerotic|Elevated (r_prep) parameters_2\NNS|in|were|. (l_amod) atherosclerotic_1\JJ|,|as|Elevated
D002784_D050197 CID cholesterol_10\NN|,|serum (r_conj) calcium_7\NN|such (r_pobj) as_5\IN|,|atherosclerotic|Elevated (r_prep) parameters_2\NNS|in|were|. (r_nsubjpass) obtained_18\VBN|NONE (l_prep) in_19\IN|parameters|were|. (l_pobj) rats_21\NNS|NONE (l_amod) atherosclerotic_20\JJ|NONE
D006632_D006471 NONE histamine_19\NN|mast|peroxide|, (r_compound) release_20\NN|by|, (l_conj) peroxide_23\NN|mast|histamine|, (l_appos) permeability_31\NN|lipid (l_prep) in_32\IN|microvascular|generation (l_pcomp) modulating_33\VBG|NONE (l_dobj) hemorrhage_35\NN|NONE
D006632_D006471 NONE histamine_6\NN|NONE (r_pobj) of_5\IN|to|positive|a (r_prep) correlation_4\NN|,|was|.|in|Moreover (l_prep) to_7\IN|positive|a|of (l_pobj) hemorrhage_9\NN|to|and
D006632_D006471 NONE histamine_18\NN|and|permeability (r_compound) release_19\NN|LPO|,|,|produce|.|ameliorated (r_conj) generation_16\NN|NONE (l_ccomp) produce_2\VB|LPO|,|,|.|ameliorated|release (l_dobj) ulcer_5\NN|Atherosclerosis|via|could (l_amod) hemorrhagic_4\JJ|gastric
D006632_D050197 NONE histamine_19\NN|mast|peroxide|, (r_compound) release_20\NN|by|, (l_conj) peroxide_23\NN|mast|histamine|, (l_appos) permeability_31\NN|lipid (l_prep) in_32\IN|microvascular|generation (l_pcomp) modulating_33\VBG|NONE (l_dobj) hemorrhage_35\NN|NONE (l_prep) in_38\IN|gastric|ulcer|and (l_pobj) rats_39\NNS|NONE (l_prep) with_40\IN|NONE (l_pobj) atherosclerosis_41\NN|NONE
D006632_D050197 NONE histamine_6\NN|NONE (r_pobj) of_5\IN|to|positive|a (r_prep) correlation_4\NN|,|was|.|in|Moreover (r_nsubjpass) found_14\VBN|NONE (l_prep) in_15\IN|,|was|.|correlation|Moreover (l_pobj) rats_18\NNS|NONE (l_amod) atherosclerotic_17\JJ|those
D006632_D050197 NONE histamine_18\NN|and|permeability (r_compound) release_19\NN|LPO|,|,|produce|.|ameliorated (r_conj) generation_16\NN|NONE (l_ccomp) produce_2\VB|LPO|,|,|.|ameliorated|release (l_nsubj) Atherosclerosis_0\NN|via|could|ulcer
D002784_D006471 CID cholesterol_49\NN|and|vitamin (r_conj) D2_47\NN|NONE (r_pobj) of_45\IN|NONE (r_prep) coadministration_44\NN|NONE (r_pobj) by_43\IN|release|, (r_prep) induced_42\VBN|.|aim|examine (l_nsubj) release_20\NN|by|, (l_conj) peroxide_23\NN|mast|histamine|, (l_appos) permeability_31\NN|lipid (l_prep) in_32\IN|microvascular|generation (l_pcomp) modulating_33\VBG|NONE (l_dobj) hemorrhage_35\NN|NONE
D010634_D014456 NONE luminal_16\JJ|areas|hemoglobin|and (r_amod) content_18\NN|microvascular|, (l_conj) areas_21\NNS|hemoglobin|and|luminal (l_compound) ulcer_20\NN|NONE
D010634_D014456 NONE luminal_22\JJ|hemoglobin (r_amod) content_24\NN|LPO|and (r_conj) generation_20\NN|histamine|, (r_conj) release_17\NN|back|,||gastric|acid (r_conj) diffusion_14\NN|NONE (r_pobj) including_9\VBG|,|ulcerogenic|increased (r_prep) factors_7\NNS|NONE (r_pobj) with_4\IN|ulcers (r_prep) accompanied_3\VBN|also|.|in|were (l_nsubj) ulcers_2\NNS|with
D004872_D014456 CID D2_47\NN|NONE (r_pobj) of_45\IN|NONE (r_prep) coadministration_44\NN|NONE (r_pobj) by_43\IN|release|, (r_prep) induced_42\VBN|.|aim|examine (l_nsubj) release_20\NN|by|, (l_conj) peroxide_23\NN|mast|histamine|, (l_appos) permeability_31\NN|lipid (l_prep) in_32\IN|microvascular|generation (l_pcomp) modulating_33\VBG|NONE (l_dobj) hemorrhage_35\NN|NONE (l_conj) ulcer_37\NN|gastric|and|in
D004872_D006471 CID D2_47\NN|NONE (r_pobj) of_45\IN|NONE (r_prep) coadministration_44\NN|NONE (r_pobj) by_43\IN|release|, (r_prep) induced_42\VBN|.|aim|examine (l_nsubj) release_20\NN|by|, (l_conj) peroxide_23\NN|mast|histamine|, (l_appos) permeability_31\NN|lipid (l_prep) in_32\IN|microvascular|generation (l_pcomp) modulating_33\VBG|NONE (l_dobj) hemorrhage_35\NN|NONE
D014700_D050197 NONE verapamil_3\NN|NONE (r_pobj) of_2\IN|.|on|Protective (r_prep) effect_1\NN|NONE (l_prep) on_4\IN|.|Protective|of (l_pobj) ulcers_7\NNS|NONE (l_prep) in_8\IN|gastric|hemorrhagic (l_pobj) rats_11\NNS|NONE (l_amod) atherosclerotic_10\JJ|severe
D014700_D050197 NONE verapamil_28\NN|NONE (r_pobj) by_27\IN|be|could|that|in (r_agent) ameliorated_26\VBN|LPO|,|,|produce|.|release (r_relcl) generation_16\NN|NONE (l_ccomp) produce_2\VB|LPO|,|,|.|ameliorated|release (l_nsubj) Atherosclerosis_0\NN|via|could|ulcer
D002118_D050197 NONE calcium_7\NN|such (r_pobj) as_5\IN|,|atherosclerotic|Elevated (r_prep) parameters_2\NNS|in|were|. (l_amod) atherosclerotic_1\JJ|,|as|Elevated
D002118_D050197 NONE calcium_7\NN|such (r_pobj) as_5\IN|,|atherosclerotic|Elevated (r_prep) parameters_2\NNS|in|were|. (r_nsubjpass) obtained_18\VBN|NONE (l_prep) in_19\IN|parameters|were|. (l_pobj) rats_21\NNS|NONE (l_amod) atherosclerotic_20\JJ|NONE
D004872_D050197 CID D2_47\NN|NONE (r_pobj) of_45\IN|NONE (r_prep) coadministration_44\NN|NONE (r_pobj) by_43\IN|release|, (r_prep) induced_42\VBN|.|aim|examine (l_nsubj) release_20\NN|by|, (l_conj) peroxide_23\NN|mast|histamine|, (l_appos) permeability_31\NN|lipid (l_prep) in_32\IN|microvascular|generation (l_pcomp) modulating_33\VBG|NONE (l_dobj) hemorrhage_35\NN|NONE (l_prep) in_38\IN|gastric|ulcer|and (l_pobj) rats_39\NNS|NONE (l_prep) with_40\IN|NONE (l_pobj) atherosclerosis_41\NN|NONE
D004872_D050197 CID D2_21\NN|induce|kg (r_dobj) containing_19\VBG|NONE (l_advcl) induce_25\VB|D|kg (l_dobj) atherosclerosis_26\NN|to
D002784_D014456 CID cholesterol_49\NN|and|vitamin (r_conj) D2_47\NN|NONE (r_pobj) of_45\IN|NONE (r_prep) coadministration_44\NN|NONE (r_pobj) by_43\IN|release|, (r_prep) induced_42\VBN|.|aim|examine (l_nsubj) release_20\NN|by|, (l_conj) peroxide_23\NN|mast|histamine|, (l_appos) permeability_31\NN|lipid (l_prep) in_32\IN|microvascular|generation (l_pcomp) modulating_33\VBG|NONE (l_dobj) hemorrhage_35\NN|NONE (l_conj) ulcer_37\NN|gastric|and|in
9952311
D004317_D028361 CID adriamycin_7\NNS| (r_npadvmod) induced_9\VBN|NONE (r_amod) cardiomyopathy_10\NN|NONE (r_pobj) in_6\IN|of|suppression|Structural|in|.|: (r_prep) impairment_3\NN|NONE (l_prep) of_4\IN|in|suppression|Structural|in|.|: (l_pobj) mitochondria_5\NN|NONE
D004317_D028361 CID ADR_21\NNP|NONE (r_pobj) of_20\IN|deteriorating|the|on (r_prep) effects_19\NNS|impairment|that (r_nsubj) involve_25\VBP|,|.|Knowing|we (l_dobj) impairment_30\NN|that|effects
D004317_D001145 NONE ADR_10\NNP|NONE (r_pobj) with_9\IN|NONE (r_prep) mice_8\NNS|NONE (r_pobj) of_7\IN| (r_prep) treatment_6\NN|arrhythmias|swelling|that (r_nsubj) caused_11\VBD|results|. (l_dobj) arrhythmias_13\NNS|treatment|swelling|that
D004317_D009202 NONE adriamycin_7\NNS| (r_npadvmod) induced_9\VBN|NONE (r_amod) cardiomyopathy_10\NN|NONE
D004317_D002318 NONE adriamycin_3\NNS|NONE (r_pobj) of_2\IN|The|in (r_prep) use_1\NN|due|been|.|has (r_nsubjpass) limited_12\VBN|NONE (l_prep) due_13\IN|been|.|use|has (l_pcomp) to_14\IN|NONE (l_pobj) toxicity_18\NN|NONE
D004317_D002318 NONE ADR_5\NNP|(|) (r_appos) adriamycin_3\NNS|NONE (r_pobj) of_2\IN|The|in (r_prep) use_1\NN|due|been|.|has (r_nsubjpass) limited_12\VBN|NONE (l_prep) due_13\IN|been|.|use|has (l_pcomp) to_14\IN|NONE (l_pobj) toxicity_18\NN|NONE
D004317_D001919 CID ADR_10\NNP|NONE (r_pobj) with_9\IN|NONE (r_prep) mice_8\NNS|NONE (r_pobj) of_7\IN| (r_prep) treatment_6\NN|arrhythmias|swelling|that (r_nsubj) caused_11\VBD|results|. (l_dobj) arrhythmias_13\NNS|treatment|swelling|that (l_acl) characterized_14\VBN|cardiovascular (l_agent) by_15\IN|NONE (l_pobj) bradycardia_16\NNP|NONE
D004317_D004487 NONE ADR_10\NNP|NONE (r_pobj) with_9\IN|NONE (r_prep) mice_8\NNS|NONE (r_pobj) of_7\IN| (r_prep) treatment_6\NN|arrhythmias|swelling|that (r_nsubj) caused_11\VBD|results|. (l_ccomp) swelling_51\NN|treatment|arrhythmias|that
D004317_D009369 NONE adriamycin_3\NNS|NONE (r_pobj) of_2\IN|The|in (r_prep) use_1\NN|due|been|.|has (l_prep) in_7\IN|of|The (l_pobj) chemotherapy_9\NN|NONE (l_compound) cancer_8\NN|NONE
D004317_D009369 NONE ADR_5\NNP|(|) (r_appos) adriamycin_3\NNS|NONE (r_pobj) of_2\IN|The|in (r_prep) use_1\NN|due|been|.|has (l_prep) in_7\IN|of|The (l_pobj) chemotherapy_9\NN|NONE (l_compound) cancer_8\NN|NONE
11282081
D002118_D001281 NONE Ca(2_23\NNP|NONE (r_dobj) decreases_19\VBZ|occurrence|tachycardia|and (r_conj) promotes_7\VBZ|:|. (l_dobj) occurrence_9\NN|decreases|tachycardia|and (l_prep) of_12\IN|and|maintenance|the (l_pobj) fibrillation_14\NN|NONE
D002118_D001281 NONE Ca(2_23\NNP|NONE (r_dobj) decreases_19\VBZ|occurrence|tachycardia|and (r_conj) promotes_7\VBZ|:|. (l_dobj) occurrence_9\NN|decreases|tachycardia|and (l_prep) of_12\IN|and|maintenance|the (l_pobj) fibrillation_14\NN|NONE (l_appos) AF_16\NNP|)|(|atrial
D002118_D001281 NONE Ca(2_11\NN|) (r_nmod) channel_13\NN|acute|type (r_compound) blockade_14\NN|can|AF|,|that|consistent (r_nsubj) promote_16\VB|a|clinical (l_dobj) AF_17\NNP|can|,|that|consistent|blockade
D002118_D001281 NONE Ca(2_11\NN|) (r_nmod) channel_13\NN|acute|type (r_compound) blockade_14\NN|can|AF|,|that|consistent (r_nsubj) promote_16\VB|a|clinical (l_advcl) consistent_19\JJ|can|AF|,|that|blockade (l_prep) with_20\IN|NONE (l_pobj) effect_24\NN|NONE (l_compound) AF_22\NNP|an|of|promoting
D002118_D001281 NONE Ca(2_26\NNP|channel (r_nmod) inhibition_30\NN|NONE (r_pobj) of_25\IN|AF|an|promoting (r_prep) effect_24\NN|NONE (r_pobj) with_20\IN|NONE (r_prep) consistent_19\JJ|can|AF|,|that|blockade (r_advcl) promote_16\VB|a|clinical (l_dobj) AF_17\NNP|can|,|that|consistent|blockade
D002118_D001281 NONE Ca(2_26\NNP|channel (r_nmod) inhibition_30\NN|NONE (r_pobj) of_25\IN|AF|an|promoting (r_prep) effect_24\NN|NONE (l_compound) AF_22\NNP|an|of|promoting
D002118_D001281 NONE Ca(2_9\NNP|channel (r_nmod) blockers_13\NNS|NONE (r_pobj) by_8\IN|AF (r_prep) promotion_7\NN|NONE (l_compound) AF_6\NNP|by
D002698_D001281 NONE chloralose_21\NN|anesthetized (r_amod) dogs_23\NNS|NONE (r_pobj) to_18\IN|.|verapamil|we|,|evaluate (r_prep) administered_16\VBD|NONE (l_advcl) evaluate_1\VB|.|verapamil|to|we|, (l_dobj) mechanisms_4\NNS|To (l_prep) of_5\IN|potential|the (l_pobj) promotion_7\NN|NONE (l_compound) AF_6\NNP|by
D014700_D001281 CID verapamil_2\NN|NONE (r_pobj) of_1\IN|and|on|determinants|. (r_prep) Effects_0\NNS|NONE (l_prep) on_3\IN|of|and|determinants|. (l_pobj) fibrillation_5\NN|NONE
D014700_D001281 CID verapamil_17\NN|.|to|we|,|evaluate (r_dobj) administered_16\VBD|NONE (l_advcl) evaluate_1\VB|.|verapamil|to|we|, (l_dobj) mechanisms_4\NNS|To (l_prep) of_5\IN|potential|the (l_pobj) promotion_7\NN|NONE (l_compound) AF_6\NNP|by
D014700_D001281 CID Verapamil_1\NNP|increasing|:|in|,|promotion (r_nsubj) caused_2\VBD|NONE (l_dobj) promotion_4\NN|increasing|:|in|,|Verapamil (l_compound) AF_3\NNP|NONE
D014700_D001281 CID Verapamil_1\NNP|increasing|:|in|,|promotion (r_nsubj) caused_2\VBD|NONE (l_advcl) increasing_9\VBG|:|in|,|Verapamil|promotion (l_dobj) duration_11\NN|NONE (l_prep) of_12\IN|mean|induced (l_pobj) AF_13\NNP|NONE
D014700_D001281 CID verapamil_4\NN|,|from|,|decreased|In|,|accelerated|mean|.|period (r_nsubj) shortened_5\VBN|NONE (l_conj) accelerated_43\VBN|,|from|,|decreased|In|,|mean|.|verapamil|period (l_conj) decreased_47\VBD|conduction|heterogeneously|and (l_dobj) length_50\NN|to (l_prep) of_51\IN|the|cycle (l_pobj) 94+/-4_54\CD|NONE (l_nmod) AF_52\NNP|(
D014700_D001281 CID verapamil_22\NNP|( (r_nmod) n=5_24\NNS|NONE (r_pobj) by_21\IN|NONE (r_agent) caused_20\VBN|NONE (r_acl) that_19\DT|NONE (r_pobj) to_18\IN|NONE (r_prep) similar_17\JJ|conduction (r_amod) acceleration_16\NN|) (r_dobj) produced_14\VBD|,|did|.|Diltiazem|not|but|ERP (r_conj) affect_3\VB|NONE (l_dobj) ERP_4\NNP|,|did|.|Diltiazem|not|produced|but (l_conj) length_8\NN|, (l_compound) AF_6\NNP|duration|or|cycle
D014700_D001281 CID verapamil_22\NNP|( (r_nmod) n=5_24\NNS|NONE (r_pobj) by_21\IN|NONE (r_agent) caused_20\VBN|NONE (r_acl) that_19\DT|NONE (r_pobj) to_18\IN|NONE (r_prep) similar_17\JJ|conduction (r_amod) acceleration_16\NN|) (r_dobj) produced_14\VBD|,|did|.|Diltiazem|not|but|ERP (r_conj) affect_3\VB|NONE (l_dobj) ERP_4\NNP|,|did|.|Diltiazem|not|produced|but (l_conj) length_8\NN|, (l_conj) duration_11\NN|AF|or|cycle (l_compound) AF_10\NNP|NONE
D014700_D001281 CID verapamil_7\NN|.|In|promote|refractoriness|, (r_nsubj) failed_8\VBD|NONE (l_xcomp) promote_10\VB|.|In|refractoriness|,|verapamil (l_dobj) AF_11\NNP|to|increased|and
D014700_D001281 CID verapamil_4\NN|AF|that|by (r_nsubj) promoted_5\VBD|mapping|. (l_dobj) AF_6\NNP|that|verapamil|by
D014700_D001281 CID Verapamil_0\NNP|by|effect|AF|in|.|, (r_nsubj) promotes_1\VBZ|NONE (l_dobj) AF_2\NNP|by|effect|in|.|,|Verapamil
D009020_D001281 NONE morphine_19\NN| (r_npadvmod) chloralose_21\NN|anesthetized (r_amod) dogs_23\NNS|NONE (r_pobj) to_18\IN|.|verapamil|we|,|evaluate (r_prep) administered_16\VBD|NONE (l_advcl) evaluate_1\VB|.|verapamil|to|we|, (l_dobj) mechanisms_4\NNS|To (l_prep) of_5\IN|potential|the (l_pobj) promotion_7\NN|NONE (l_compound) AF_6\NNP|by
D004110_D001281 NONE Diltiazem_0\NNP|,|did|.|not|produced|but|ERP (r_nsubj) affect_3\VB|NONE (l_dobj) ERP_4\NNP|,|did|.|Diltiazem|not|produced|but (l_conj) length_8\NN|, (l_compound) AF_6\NNP|duration|or|cycle
D004110_D001281 NONE Diltiazem_0\NNP|,|did|.|not|produced|but|ERP (r_nsubj) affect_3\VB|NONE (l_dobj) ERP_4\NNP|,|did|.|Diltiazem|not|produced|but (l_conj) length_8\NN|, (l_conj) duration_11\NN|AF|or|cycle (l_compound) AF_10\NNP|NONE
D004110_D001281 NONE diltiazem_23\NN|NONE (r_pobj) by_22\IN|not (r_agent) shared_21\VBN|and|dependent|an (r_conj) effect_13\NN|by|AF|in|.|,|Verapamil (r_dobj) promotes_1\VBZ|NONE (l_dobj) AF_2\NNP|by|effect|in|.|,|Verapamil
D002118_D013617 NONE Ca(2_23\NNP|NONE (r_dobj) decreases_19\VBZ|occurrence|tachycardia|and (r_conj) promotes_7\VBZ|:|. (l_nsubj) tachycardia_3\NN|occurrence|decreases|and
8106150
D016291_D020734 NONE MK-801_15\NNP|NONE (r_punct) ,_16\,|movements|.|at|but|markedly|drugs (r_punct) reduced_18\VBD|NONE (l_conj) at_23\IN|movements|.|,|but|markedly|drugs (l_pobj) cost_25\NN|NONE (l_prep) of_26\IN|the (l_pobj) return_28\NN|NONE (l_prep) of_29\IN|a (l_pobj) symptomatology_31\NN|NONE (l_amod) parkinsonian_30\JJ|NONE
D001418_D004409 NONE Baclofen_0\NNP|.|also|useful (r_nsubj) was_1\VBD|NONE (l_acomp) useful_3\JJ|.|also|Baclofen (l_prep) against_7\IN|in (l_pobj) form_11\NN|NONE (l_prep) of_12\IN|dystonic|a (l_pobj) dyskinesia_13\NN|NONE
D010830_D004409 NONE physostigmine_6\NN|, (r_conj) clonidine_4\NN|NONE (r_pobj) including_3\VBG|Several|, (r_prep) drugs_1\NNS|movements|.|at|,|but|markedly (r_nsubj) reduced_18\VBD|NONE (l_dobj) movements_21\NNS|.|at|,|but|markedly|drugs (l_amod) dyskinetic_20\JJ|the
D007980_D004409 NONE dopa_7\NN| (r_npadvmod) induced_9\VBN|in (r_amod) dyskinesias_10\NNS|NONE
D007980_D004409 NONE DOPA_19\NNP|NONE (r_pobj) with_16\IN|NONE (r_prep) combination_15\NN|NONE (r_pobj) in_14\IN|then|were|see|series|. (r_prep) tested_13\VBN|NONE (l_advcl) see_21\VB|then|were|series|.|in (l_ccomp) modified_28\VBN|to (l_nsubjpass) movements_25\NNS|be|if|would (l_amod) dyskinetic_24\JJ|the
D003000_D004409 NONE clonidine_4\NN|NONE (r_pobj) including_3\VBG|Several|, (r_prep) drugs_1\NNS|movements|.|at|,|but|markedly (r_nsubj) reduced_18\VBD|NONE (l_dobj) movements_21\NNS|.|at|,|but|markedly|drugs (l_amod) dyskinetic_20\JJ|the
D011433_D020734 NONE propranolol_12\NN|MDOT|, (r_conj) methysergide_8\NN|, (r_conj) physostigmine_6\NN|, (r_conj) clonidine_4\NN|NONE (r_pobj) including_3\VBG|Several|, (r_prep) drugs_1\NNS|movements|.|at|,|but|markedly (r_nsubj) reduced_18\VBD|NONE (l_conj) at_23\IN|movements|.|,|but|markedly|drugs (l_pobj) cost_25\NN|NONE (l_prep) of_26\IN|the (l_pobj) return_28\NN|NONE (l_prep) of_29\IN|a (l_pobj) symptomatology_31\NN|NONE (l_amod) parkinsonian_30\JJ|NONE
D003000_D020734 NONE clonidine_4\NN|NONE (r_pobj) including_3\VBG|Several|, (r_prep) drugs_1\NNS|movements|.|at|,|but|markedly (r_nsubj) reduced_18\VBD|NONE (l_conj) at_23\IN|movements|.|,|but|markedly|drugs (l_pobj) cost_25\NN|NONE (l_prep) of_26\IN|the (l_pobj) return_28\NN|NONE (l_prep) of_29\IN|a (l_pobj) symptomatology_31\NN|NONE (l_amod) parkinsonian_30\JJ|NONE
D001285_D020821 NONE Atropine_0\NNP|into|movements|. (r_nsubj) converted_1\VBD|NONE (l_dobj) movements_4\NNS|into|Atropine|. (l_amod) dystonic_3\JJ|the
-1_D020734 NONE 5-MDOT_10\CD|propranolol|, (r_conj) methysergide_8\NN|, (r_conj) physostigmine_6\NN|, (r_conj) clonidine_4\NN|NONE (r_pobj) including_3\VBG|Several|, (r_prep) drugs_1\NNS|movements|.|at|,|but|markedly (r_nsubj) reduced_18\VBD|NONE (l_conj) at_23\IN|movements|.|,|but|markedly|drugs (l_pobj) cost_25\NN|NONE (l_prep) of_26\IN|the (l_pobj) return_28\NN|NONE (l_prep) of_29\IN|a (l_pobj) symptomatology_31\NN|NONE (l_amod) parkinsonian_30\JJ|NONE
D015632_D020734 CID MPTP_11\NNP|NONE (r_pobj) with_8\IN|NONE (r_prep) parkinsonian_7\NN|group|was|.
D010830_D020734 NONE physostigmine_6\NN|, (r_conj) clonidine_4\NN|NONE (r_pobj) including_3\VBG|Several|, (r_prep) drugs_1\NNS|movements|.|at|,|but|markedly (r_nsubj) reduced_18\VBD|NONE (l_conj) at_23\IN|movements|.|,|but|markedly|drugs (l_pobj) cost_25\NN|NONE (l_prep) of_26\IN|the (l_pobj) return_28\NN|NONE (l_prep) of_29\IN|a (l_pobj) symptomatology_31\NN|NONE (l_amod) parkinsonian_30\JJ|NONE
D008784_D020734 NONE methysergide_8\NN|, (r_conj) physostigmine_6\NN|, (r_conj) clonidine_4\NN|NONE (r_pobj) including_3\VBG|Several|, (r_prep) drugs_1\NNS|movements|.|at|,|but|markedly (r_nsubj) reduced_18\VBD|NONE (l_conj) at_23\IN|movements|.|,|but|markedly|drugs (l_pobj) cost_25\NN|NONE (l_prep) of_26\IN|the (l_pobj) return_28\NN|NONE (l_prep) of_29\IN|a (l_pobj) symptomatology_31\NN|NONE (l_amod) parkinsonian_30\JJ|NONE
D008614_D004409 NONE meperidine_4\RB|and (r_conj) yohimbine_2\NN|However|.|movements|predominantly|, (r_nsubj) reduced_5\VBN|NONE (l_dobj) movements_9\NNS|However|.|predominantly|yohimbine|, (l_amod) dyskinetic_8\JJ|the
D015632_D004409 NONE MPTP_12\NNP| (r_npadvmod) treated_14\VBN|NONE (r_amod) monkeys_15\NNS|NONE (r_pobj) in_11\IN|induced (r_prep) dyskinesias_10\NNS|NONE
D016291_D004409 NONE MK-801_15\NNP|NONE (r_punct) ,_16\,|movements|.|at|but|markedly|drugs (r_punct) reduced_18\VBD|NONE (l_dobj) movements_21\NNS|.|at|,|but|markedly|drugs (l_amod) dyskinetic_20\JJ|the
D015016_D004409 NONE yohimbine_2\NN|However|.|movements|predominantly|, (r_nsubj) reduced_5\VBN|NONE (l_dobj) movements_9\NNS|However|.|predominantly|yohimbine|, (l_amod) dyskinetic_8\JJ|the
D001418_D020821 NONE Baclofen_0\NNP|.|also|useful (r_nsubj) was_1\VBD|NONE (l_acomp) useful_3\JJ|.|also|Baclofen (l_prep) against_7\IN|in (l_pobj) form_11\NN|NONE (l_amod) dystonic_10\JJ|a|of
D011433_D004409 NONE propranolol_12\NN|MDOT|, (r_conj) methysergide_8\NN|, (r_conj) physostigmine_6\NN|, (r_conj) clonidine_4\NN|NONE (r_pobj) including_3\VBG|Several|, (r_prep) drugs_1\NNS|movements|.|at|,|but|markedly (r_nsubj) reduced_18\VBD|NONE (l_dobj) movements_21\NNS|.|at|,|but|markedly|drugs (l_amod) dyskinetic_20\JJ|the
D001285_D002819 NONE Atropine_0\NNP|into|movements|. (r_nsubj) converted_1\VBD|NONE (l_prep) into_5\IN|Atropine|movements|. (l_pobj) chorea_6\NN|NONE
D008784_D004409 NONE methysergide_8\NN|, (r_conj) physostigmine_6\NN|, (r_conj) clonidine_4\NN|NONE (r_pobj) including_3\VBG|Several|, (r_prep) drugs_1\NNS|movements|.|at|,|but|markedly (r_nsubj) reduced_18\VBD|NONE (l_dobj) movements_21\NNS|.|at|,|but|markedly|drugs (l_amod) dyskinetic_20\JJ|the
-1_D004409 NONE 5-MDOT_10\CD|propranolol|, (r_conj) methysergide_8\NN|, (r_conj) physostigmine_6\NN|, (r_conj) clonidine_4\NN|NONE (r_pobj) including_3\VBG|Several|, (r_prep) drugs_1\NNS|movements|.|at|,|but|markedly (r_nsubj) reduced_18\VBD|NONE (l_dobj) movements_21\NNS|.|at|,|but|markedly|drugs (l_amod) dyskinetic_20\JJ|the
D004298_D004409 NONE dopamine_10\NN|NONE (r_pobj) than_9\IN|NONE (r_prep) other_8\JJ|NONE (r_amod) neurotransmitters_7\NNS|NONE (r_pobj) on_6\IN|primarily (r_prep) acting_4\VBG|NONE (r_acl) agents_3\NNS|NONE (r_pobj) of_2\IN|A (r_prep) series_1\NN|then|were|see|.|in (r_nsubjpass) tested_13\VBN|NONE (l_advcl) see_21\VB|then|were|series|.|in (l_ccomp) modified_28\VBN|to (l_nsubjpass) movements_25\NNS|be|if|would (l_amod) dyskinetic_24\JJ|the
10579464
C121249_D002375 CID NRA0160_0\NNP|.|significantly|catalepsy|exceed|in|, (r_nsubj) induced_4\VBN|NONE (l_dobj) catalepsy_5\NN|.|significantly|exceed|in|,|NRA
D003024_D002375 CID clozapine_2\NN|and (r_conj) NRA0160_0\NNP|.|significantly|catalepsy|exceed|in|, (r_nsubj) induced_4\VBN|NONE (l_dobj) catalepsy_5\NN|.|significantly|exceed|in|,|NRA
D003024_D006948 NONE clozapine_2\NN|and (r_conj) NRA0160_0\NNP|.|hyperactivity (r_nsubj) antagonized_3\VBN|NONE (l_dobj) hyperactivity_5\NN|.|NRA
C121249_D006948 NONE NRA0160_0\NNP|.|hyperactivity (r_nsubj) antagonized_3\VBN|NONE (l_dobj) hyperactivity_5\NN|.|NRA
D008694_D006948 CID methamphetamine_8\NN|NONE (r_pobj) by_7\IN|in (r_agent) induced_6\VBN|locomotor (r_acl) hyperactivity_5\NN|.|NRA
D008694_D006948 CID MAP_10\NNP|(|) (r_appos) methamphetamine_8\NN|NONE (r_pobj) by_7\IN|in (r_agent) induced_6\VBN|locomotor (r_acl) hyperactivity_5\NN|.|NRA
10414674
D007660_D006470 NONE ketoprofen_1\NN|on|is|If|before (r_nsubjpass) used_3\VBN|,|.|may|factor|it (r_advcl) pose_13\VB|NONE (l_dobj) factor_17\NN|,|.|may|used|it (l_prep) for_18\IN|risk|an|additional (l_pobj) hemorrhage_19\NN|NONE
D007660_D002532 NONE ketoprofen_1\NN|on|is|If|before (r_nsubjpass) used_3\VBN|,|.|may|factor|it (l_prep) on_6\IN|ketoprofen|is|If|before (l_pobj) aneurysms_9\NNS|NONE
D000082_D013345 NONE acetaminophen_35\RB|a|weak|,|, (r_advmod) NSAID_33\NNP|)|,|or|n|ketoprofen|g|(|,||times (r_conj) group_24\NN|starting|times|to|ketoprofen (r_dobj) receive_11\VB|Patients|)|(|were|. (r_xcomp) randomized_9\VBN|NONE (l_nsubjpass) Patients_0\NNS|)|receive|(|were|. (l_prep) with_1\IN|NONE (l_pobj) hemorrhage_4\NN|NONE
D000082_D013345 NONE acetaminophen_35\RB|a|weak|,|, (r_advmod) NSAID_33\NNP|)|,|or|n|ketoprofen|g|(|,||times (r_conj) group_24\NN|starting|times|to|ketoprofen (r_dobj) receive_11\VB|Patients|)|(|were|. (r_xcomp) randomized_9\VBN|NONE (l_punct) (_5\-LRB-|Patients|)|receive|were|. (l_preconj) SAH_6\NNP|NONE
D000082_D013345 NONE acetaminophen_35\RB|a|weak|,|, (r_advmod) NSAID_33\NNP|)|,|or|n|ketoprofen|g|(|,||times (r_conj) group_24\NN|starting|times|to|ketoprofen (r_dobj) receive_11\VB|Patients|)|(|were|. (l_parataxis) starting_52\VBG|times|to|ketoprofen|group (l_prep) after_54\IN|group|(|immediately (l_pobj) diagnosis_56\NN|NONE (l_prep) of_57\IN|the (l_pobj) SAH_59\NNP|NONE
D000082_D013345 NONE acetaminophen_45\NN|n||, (r_compound) group_46\NN|(|after|immediately (r_nsubj) starting_52\VBG|times|to|ketoprofen|group (r_parataxis) receive_11\VB|Patients|)|(|were|. (r_xcomp) randomized_9\VBN|NONE (l_nsubjpass) Patients_0\NNS|)|receive|(|were|. (l_prep) with_1\IN|NONE (l_pobj) hemorrhage_4\NN|NONE
D000082_D013345 NONE acetaminophen_45\NN|n||, (r_compound) group_46\NN|(|after|immediately (r_nsubj) starting_52\VBG|times|to|ketoprofen|group (r_parataxis) receive_11\VB|Patients|)|(|were|. (r_xcomp) randomized_9\VBN|NONE (l_punct) (_5\-LRB-|Patients|)|receive|were|. (l_preconj) SAH_6\NNP|NONE
D000082_D013345 NONE acetaminophen_45\NN|n||, (r_compound) group_46\NN|(|after|immediately (r_nsubj) starting_52\VBG|times|to|ketoprofen|group (l_prep) after_54\IN|group|(|immediately (l_pobj) diagnosis_56\NN|NONE (l_prep) of_57\IN|the (l_pobj) SAH_59\NNP|NONE
D000082_D013345 NONE acetaminophen_3\RB|but (l_dobj) function_6\NN|.|not (l_prep) in_7\IN|impaired|platelet (l_pobj) patients_8\NNS|NONE (l_prep) with_9\IN|NONE (l_pobj) SAH_10\NNP|NONE
D000244_D001791 NONE diphosphate_9\NN|NONE (r_pobj) of_7\IN| (r_prep) microM_6\NNS|NONE (r_pobj) by_4\IN|decreased|aggregation|. (r_prep) induced_3\VBN|NONE (l_nsubj) aggregation_2\NN|decreased|.|by
D007660_D017542 NONE ketoprofen_13\JJ|starting|times|to|group (r_dobj) receive_11\VB|Patients|)|(|were|. (l_parataxis) starting_52\VBG|times|to|ketoprofen|group (l_prep) after_54\IN|group|(|immediately (l_pobj) diagnosis_56\NN|NONE (l_prep) of_57\IN|the (l_pobj) SAH_59\NNP|NONE (l_amod) aneurysmal_58\JJ|NONE
D007660_D017542 NONE ketoprofen_23\JJ|)|,|or|NSAID|n|g|(|,||times (r_compound) group_24\NN|starting|times|to|ketoprofen (r_dobj) receive_11\VB|Patients|)|(|were|. (l_parataxis) starting_52\VBG|times|to|ketoprofen|group (l_prep) after_54\IN|group|(|immediately (l_pobj) diagnosis_56\NN|NONE (l_prep) of_57\IN|the (l_pobj) SAH_59\NNP|NONE (l_amod) aneurysmal_58\JJ|NONE
D000082_D001791 NONE acetaminophen_9\NN|the (r_compound) group_10\NN|NONE (r_pobj) in_7\IN|In|.|aggregation|compared|on|, (r_prep) increased_6\VBD|NONE (l_nsubj) aggregation_5\NN|In|.|in|compared|on|,
D000082_D001791 NONE acetaminophen_9\NN|the (r_compound) group_10\NN|NONE (r_pobj) in_7\IN|In|.|aggregation|compared|on|, (r_prep) increased_6\VBD|NONE (l_advcl) compared_17\VBN|In|.|aggregation|in|on|, (l_prep) with_18\IN|as (l_pobj) results_23\NNS|NONE (l_compound) aggregation_22\NN|P|)|(|the
D007660_D006406 CID ketoprofen_4\JJ|the (r_compound) group_5\NN|NONE (r_pobj) in_2\IN|One (r_prep) patient_1\NN|hematoma|. (r_nsubj) developed_6\VBD|NONE (l_dobj) hematoma_10\NN|.|patient
D007660_D013345 NONE ketoprofen_13\JJ|starting|times|to|group (r_dobj) receive_11\VB|Patients|)|(|were|. (r_xcomp) randomized_9\VBN|NONE (l_nsubjpass) Patients_0\NNS|)|receive|(|were|. (l_prep) with_1\IN|NONE (l_pobj) hemorrhage_4\NN|NONE
D007660_D013345 NONE ketoprofen_13\JJ|starting|times|to|group (r_dobj) receive_11\VB|Patients|)|(|were|. (r_xcomp) randomized_9\VBN|NONE (l_punct) (_5\-LRB-|Patients|)|receive|were|. (l_preconj) SAH_6\NNP|NONE
D007660_D013345 NONE ketoprofen_13\JJ|starting|times|to|group (r_dobj) receive_11\VB|Patients|)|(|were|. (l_parataxis) starting_52\VBG|times|to|ketoprofen|group (l_prep) after_54\IN|group|(|immediately (l_pobj) diagnosis_56\NN|NONE (l_prep) of_57\IN|the (l_pobj) SAH_59\NNP|NONE
D007660_D013345 NONE ketoprofen_23\JJ|)|,|or|NSAID|n|g|(|,||times (r_compound) group_24\NN|starting|times|to|ketoprofen (r_dobj) receive_11\VB|Patients|)|(|were|. (r_xcomp) randomized_9\VBN|NONE (l_nsubjpass) Patients_0\NNS|)|receive|(|were|. (l_prep) with_1\IN|NONE (l_pobj) hemorrhage_4\NN|NONE
D007660_D013345 NONE ketoprofen_23\JJ|)|,|or|NSAID|n|g|(|,||times (r_compound) group_24\NN|starting|times|to|ketoprofen (r_dobj) receive_11\VB|Patients|)|(|were|. (r_xcomp) randomized_9\VBN|NONE (l_punct) (_5\-LRB-|Patients|)|receive|were|. (l_preconj) SAH_6\NNP|NONE
D007660_D013345 NONE ketoprofen_23\JJ|)|,|or|NSAID|n|g|(|,||times (r_compound) group_24\NN|starting|times|to|ketoprofen (r_dobj) receive_11\VB|Patients|)|(|were|. (l_parataxis) starting_52\VBG|times|to|ketoprofen|group (l_prep) after_54\IN|group|(|immediately (l_pobj) diagnosis_56\NN|NONE (l_prep) of_57\IN|the (l_pobj) SAH_59\NNP|NONE
D007660_D013345 NONE Ketoprofen_0\NNP|NONE (l_conj) acetaminophen_3\RB|but (l_dobj) function_6\NN|.|not (l_prep) in_7\IN|impaired|platelet (l_pobj) patients_8\NNS|NONE (l_prep) with_9\IN|NONE (l_pobj) SAH_10\NNP|NONE
D000082_D017542 NONE acetaminophen_35\RB|a|weak|,|, (r_advmod) NSAID_33\NNP|)|,|or|n|ketoprofen|g|(|,||times (r_conj) group_24\NN|starting|times|to|ketoprofen (r_dobj) receive_11\VB|Patients|)|(|were|. (l_parataxis) starting_52\VBG|times|to|ketoprofen|group (l_prep) after_54\IN|group|(|immediately (l_pobj) diagnosis_56\NN|NONE (l_prep) of_57\IN|the (l_pobj) SAH_59\NNP|NONE (l_amod) aneurysmal_58\JJ|NONE
D000082_D017542 NONE acetaminophen_45\NN|n||, (r_compound) group_46\NN|(|after|immediately (r_nsubj) starting_52\VBG|times|to|ketoprofen|group (l_prep) after_54\IN|group|(|immediately (l_pobj) diagnosis_56\NN|NONE (l_prep) of_57\IN|the (l_pobj) SAH_59\NNP|NONE (l_amod) aneurysmal_58\JJ|NONE
D007660_D001791 CID ketoprofen_14\NN|NONE (r_pobj) of_13\IN|NONE (r_prep) administration_12\NN|NONE (r_pobj) after_11\IN|NONE (r_prep) decreased_10\VBD|aggregation|.|by (r_conj) induced_3\VBN|NONE (l_nsubj) aggregation_2\NN|decreased|.|by
18726058
D010208_D003389 NONE papaverine_13\NN|NONE (r_pobj) with_11\IN|a|few (r_prep) cases_10\NNS|NONE (r_pobj) in_7\IN|dysfunction|been|has|. (r_prep) described_6\VBN|NONE (l_nsubjpass) dysfunction_3\NN|been|has|in|.
D010208_D003389 NONE papaverine_8\NN|NONE (r_pobj) from_7\IN|potential|nerve (r_prep) deficits_6\NNS|to
D010208_D020301 NONE hydrochloride_1\NN|.|vasodilator (r_nsubj) is_2\VBZ|NONE (l_attr) vasodilator_7\NN|.|hydrochloride (l_acl) used_8\VBD|a|acting (l_xcomp) manage_10\VB|NONE (l_dobj) vasospasm_11\NN|during|to
D010208_D020301 NONE papaverine_18\NN|who|for (r_dobj) received_16\VBD|those (l_prep) for_19\IN|who|papaverine (l_pobj) vasospasm_20\NN|NONE
D010208_D020301 NONE papaverine_1\NN|as|was|. (r_nsubjpass) used_3\VBN|NONE (l_prep) as_4\IN|papaverine|was|. (l_pobj) action_8\NN|NONE (l_acl) manage_10\VB|direct|a|therapeutic (l_dobj) vasospasm_11\NN|in|to
D010208_D020301 NONE papaverine_1\NN|was|.|with (l_prep) for_2\IN|Topical (l_pobj) treatment_4\NN|NONE (l_prep) of_5\IN|the (l_pobj) vasospasm_6\NN|NONE
11858397
D004917_D016171 CID erythromycin_10\NNP|and (r_conj) cisapride_8\RB|when|were|simultaneously (r_nsubjpass) given_12\VBN|pointes|patient|also|. (r_advcl) developed_3\VBD|NONE (l_dobj) pointes_6\FW|given|patient|also|.
D020117_D016171 CID cisapride_8\RB|when|were|simultaneously (r_nsubjpass) given_12\VBN|pointes|patient|also|. (r_advcl) developed_3\VBD|NONE (l_dobj) pointes_6\FW|given|patient|also|.
D008787_D016171 CID metoclopramide_5\NN|NONE (r_pobj) by_4\IN|with|in (r_agent) induced_3\VBN|Torsade|.|de (r_acl) pointes_2\NNS|NONE
D008787_D016171 CID metoclopramide_26\NN|NONE (r_pobj) of_25\IN|intravenous (r_prep) administration_24\NN|NONE (r_pobj) after_20\IN|who|pointes (r_prep) developed_16\VBD|a|old|with (l_dobj) pointes_19\NNS|after|who
D008787_D016171 CID metoclopramide_6\NN|that|clinically|pointes (r_nsubj) provokes_7\VBZ|the|first (l_dobj) pointes_10\FW|that|clinically|metoclopramide
D008787_D016171 CID Metoclopramide_0\NNP|in|be|cautiously|should|. (r_nsubjpass) used_3\VBN|NONE (l_prep) in_5\IN|Metoclopramide|be|cautiously|should|. (l_pobj) patients_6\NNS|NONE (l_prep) with_7\IN|NONE (l_pobj) risk_9\NN|NONE (l_prep) of_10\IN|a (l_pobj) pointes_13\FW|NONE
D008787_D002037 NONE metoclopramide_5\NN|NONE (r_pobj) by_4\IN|with|in (r_agent) induced_3\VBN|Torsade|.|de (l_prep) with_10\IN|by|in (l_pobj) block_16\NN|NONE
D008787_D002037 NONE metoclopramide_26\NN|NONE (r_pobj) of_25\IN|intravenous (r_prep) administration_24\NN|NONE (r_pobj) after_20\IN|who|pointes (r_prep) developed_16\VBD|a|old|with (r_relcl) woman_7\NN|NONE (l_prep) with_8\IN|developed|a|old (l_pobj) block_14\NN|NONE
2320800
D007069_D001943 NONE ifosfamide_5\JJ|dose (r_compound) chemotherapy_6\NN|in|.|anuria (r_dobj) complicating_2\VBG|NONE (l_prep) in_7\IN|.|anuria|chemotherapy (l_pobj) patient_11\NN|NONE (l_compound) cancer_10\NN|with|a
D007069_D001943 NONE ifosfamide_34\NN| (r_pobj) after_28\IN|the (r_prep) day_27\NN|,|failure|.|woman (r_npadvmod) developed_17\VBD|NONE (l_nsubj) woman_6\NN|,|failure|.|day (l_prep) with_7\IN|treated|,|,|old|A (l_pobj) cancer_10\NN|NONE
D007069_D007674 CID ifosfamide_5\JJ|dose (r_compound) chemotherapy_6\NN|in|.|anuria (r_dobj) complicating_2\VBG|NONE (l_prep) in_7\IN|.|anuria|chemotherapy (l_pobj) patient_11\NN|NONE (l_prep) with_12\IN|cancer|a (l_pobj) function_16\NN|NONE
D007069_D007674 CID Ifosfamide_0\NNP|.|drug (r_nsubj) is_1\VBZ|NONE (l_attr) drug_5\NN|.|Ifosfamide (l_amod) nephrotoxic_4\JJ|a|with|known
D007069_D007674 CID Ifosfamide_0\NNP|.|drug (r_nsubj) is_1\VBZ|NONE (l_attr) drug_5\NN|.|Ifosfamide (l_prep) with_6\IN|nephrotoxic|a|known (l_pobj) tubulopathies_8\NNS|NONE
D007069_D007674 CID ifosfamide_5\NN|NONE (r_pobj) of_4\IN|in|careful (r_prep) use_3\NN|We|. (l_prep) in_6\IN|careful|of (l_pobj) patients_7\NNS|NONE (l_acl) pretreated_8\VBN|NONE (l_prep) with_9\IN|NONE (l_pobj) chemotherapy_11\NN|NONE (l_amod) nephrotoxic_10\JJ|and|perfusion
D007069_D051437 NONE ifosfamide_34\NN| (r_pobj) after_28\IN|the (r_prep) day_27\NN|,|failure|.|woman (r_npadvmod) developed_17\VBD|NONE (l_dobj) failure_22\NN|,|.|woman|day
D002945_D051437 NONE cisplatin_15\NN|NONE (r_pobj) with_14\IN|previously (r_prep) treated_13\VBN|,|,|old|with|A (r_acl) woman_6\NN|,|failure|.|day (r_nsubj) developed_17\VBD|NONE (l_dobj) failure_22\NN|,|.|woman|day
D007069_D001002 CID ifosfamide_5\JJ|dose (r_compound) chemotherapy_6\NN|in|.|anuria (r_dobj) complicating_2\VBG|NONE (l_nsubj) anuria_1\NN|in|.|chemotherapy
D007069_D001002 CID ifosfamide_34\NN| (r_pobj) after_28\IN|the (r_prep) day_27\NN|,|failure|.|woman (r_npadvmod) developed_17\VBD|NONE (l_dobj) failure_22\NN|,|.|woman|day (l_prep) with_23\IN|an|irreversible|lethal|renal (l_pobj) anuria_24\NN|NONE
D007069_D001002 CID ifosfamide_11\NN|NONE (r_xcomp) due_9\JJ|anuria|that|mainly|,|occurring (r_acomp) was_7\VBD|strongly|We|. (l_nsubj) anuria_6\NN|due|that|mainly|,|occurring
D002945_D007022 NONE cisplatin_20\NN|previous (r_amod) chemotherapy_21\NN|and|with|having (r_dobj) received_18\VBN|in (l_prep) with_23\IN|and|chemotherapy|having (l_pobj) perfusion_26\NN|NONE (l_prep) due_27\IN|poor|kidney (l_pcomp) to_28\IN|NONE (l_pobj) hypotension_30\NN|NONE
D002945_D001002 NONE cisplatin_15\NN|NONE (r_pobj) with_14\IN|previously (r_prep) treated_13\VBN|,|,|old|with|A (r_acl) woman_6\NN|,|failure|.|day (r_nsubj) developed_17\VBD|NONE (l_dobj) failure_22\NN|,|.|woman|day (l_prep) with_23\IN|an|irreversible|lethal|renal (l_pobj) anuria_24\NN|NONE
D002945_D001002 NONE cisplatin_20\NN|previous (r_amod) chemotherapy_21\NN|and|with|having (r_dobj) received_18\VBN|in (r_advcl) occurring_13\VBG|anuria|due|that|mainly|, (r_advcl) was_7\VBD|strongly|We|. (l_nsubj) anuria_6\NN|due|that|mainly|,|occurring
D007069_D007022 NONE ifosfamide_11\NN|NONE (r_xcomp) due_9\JJ|anuria|that|mainly|,|occurring (r_acomp) was_7\VBD|strongly|We|. (l_advcl) occurring_13\VBG|anuria|due|that|mainly|, (l_advcl) received_18\VBN|in (l_prep) with_23\IN|and|chemotherapy|having (l_pobj) perfusion_26\NN|NONE (l_prep) due_27\IN|poor|kidney (l_pcomp) to_28\IN|NONE (l_pobj) hypotension_30\NN|NONE
D002945_D001943 NONE cisplatin_15\NN|NONE (r_pobj) with_14\IN|previously (r_prep) treated_13\VBN|,|,|old|with|A (r_acl) woman_6\NN|,|failure|.|day (l_prep) with_7\IN|treated|,|,|old|A (l_pobj) cancer_10\NN|NONE
12013711
D018967_D010468 CID Risperidone_0\NNP| (r_npadvmod) associated_2\VBN|in|visual|.|benign|transient|,|with (r_amod) disturbances_7\NNS|NONE
D018967_D010468 CID risperidone_17\NN|NONE (r_pobj) with_16\IN|NONE (r_prep) treatment_15\NN|NONE (r_dobj) starting_14\VBG|NONE (r_pcomp) after_13\IN|immediately|which (r_prep) appeared_11\VBD|visual|transient|, (r_relcl) disturbances_8\NNS|NONE
D018967_D010468 CID Risperidone_0\NNP|NONE (r_compound) administration_1\NN|wore|was|and (r_nsubjpass) continued_3\VBN|NONE (l_conj) wore_9\VBD|administration|was|and (l_nsubj) disturbances_7\NNS|.|gradually|off
D018967_D001480 NONE risperidone_26\NN|NONE (r_pobj) with_25\IN|patients|were|.|successfully (r_prep) treated_24\VBN|NONE (l_nsubjpass) patients_2\NNS|with|were|.|successfully (l_relcl) had_5\VBD|Two|,|schizophrenic|, (l_conj) developed_16\VBN|who|and|history (l_dobj) EPS_17\NNP|who|previously|with|had
D008238_D010468 NONE LSD_16\NNP|NONE (r_compound) abuse_17\NN|NONE (r_pobj) of_15\IN|past|a (r_prep) history_14\NN|NONE (r_pobj) with_11\IN|in|visual|.|benign|associated|transient|, (r_prep) disturbances_7\NNS|NONE
D008238_D010468 NONE LSD_14\NNP|prior (r_compound) consumption_15\NN|NONE (r_pobj) to_12\IN|NONE (r_prep) related_11\VBN|"|" (r_acl) flashbacks_9\NNS|NONE (r_pobj) as_7\IN|previously (r_prep) experienced_6\VBN|visual (r_acl) disturbances_4\NNS|.|imagery
D018967_D012559 NONE Risperidone_0\NNP| (r_npadvmod) associated_2\VBN|in|visual|.|benign|transient|,|with (r_amod) disturbances_7\NNS|NONE (l_prep) in_8\IN|visual|.|benign|associated|transient|,|with (l_pobj) patients_10\NNS|NONE (l_amod) schizophrenic_9\JJ|NONE
D018967_D012559 NONE risperidone_26\NN|NONE (r_pobj) with_25\IN|patients|were|.|successfully (r_prep) treated_24\VBN|NONE (l_nsubjpass) patients_2\NNS|with|were|.|successfully (l_amod) schizophrenic_1\JJ|Two|had|,|,
D008238_D012559 NONE LSD_16\NNP|NONE (r_compound) abuse_17\NN|NONE (r_pobj) of_15\IN|past|a (r_prep) history_14\NN|NONE (r_pobj) with_11\IN|in|visual|.|benign|associated|transient|, (r_prep) disturbances_7\NNS|NONE (l_prep) in_8\IN|visual|.|benign|associated|transient|,|with (l_pobj) patients_10\NNS|NONE (l_amod) schizophrenic_9\JJ|NONE
D008238_D012559 NONE LSD_10\NNP|NONE (r_compound) abuse_11\NN|NONE (r_pobj) of_9\IN|prior|a (r_prep) history_8\NN|developed|who|and (r_dobj) had_5\VBD|Two|,|schizophrenic|, (r_relcl) patients_2\NNS|with|were|.|successfully (l_amod) schizophrenic_1\JJ|Two|had|,|,
D008238_D001480 NONE LSD_10\NNP|NONE (r_compound) abuse_11\NN|NONE (r_pobj) of_9\IN|prior|a (r_prep) history_8\NN|developed|who|and (r_dobj) had_5\VBD|Two|,|schizophrenic|, (l_conj) developed_16\VBN|who|and|history (l_dobj) EPS_17\NNP|who|previously|with|had
17400887
D013726_D001321 CID terbutaline_6\JJ|in|neonatal (r_compound) treatment_7\NN|NONE (r_pobj) after_4\IN|implications|.|:|Neuroinflammation (r_prep) abnormalities_3\NNS|NONE (l_appos) implications_11\NNS|.|after|:|Neuroinflammation (l_prep) for_12\IN|NONE (l_pobj) autism_13\NN|NONE
D013726_D001321 CID Terbutaline_0\NNP|has|with|.|been (r_nsubjpass) associated_13\VBN|NONE (l_prep) with_14\IN|has|.|Terbutaline|been (l_pobj) concordance_16\NN|NONE (l_prep) for_17\IN|increased (l_pobj) autism_18\NN|NONE
D013726_D007752 NONE Terbutaline_0\NNP|has|with|.|been (l_appos) agonist_4\NN|,|, (l_acl) used_5\VBN|a|betaadrenoceptor (l_xcomp) arrest_7\VB|NONE (l_dobj) labor_9\NN|to
D013726_D001523 NONE terbutaline_6\JJ|in|neonatal (r_compound) treatment_7\NN|NONE (r_pobj) after_4\IN|implications|.|:|Neuroinflammation (r_prep) abnormalities_3\NNS|NONE
D013726_D020078 NONE terbutaline_6\JJ|in|neonatal (r_compound) treatment_7\NN|NONE (r_pobj) after_4\IN|implications|.|:|Neuroinflammation (r_prep) abnormalities_3\NNS|NONE (l_nmod) Neuroinflammation_0\NN|implications|.|after|:
19234905
D014635_D006423 NONE Valproate_33\NNP|NONE (r_pobj) with_32\IN|which|within|partly (r_prep) improved_28\VBD|one|after|movements (r_advcl) developed_18\VBN|after|and|one|.|observed|hemianopsia|: (r_conj) had_8\VBD|NONE (l_dobj) hemianopsia_12\NN|after|and|one|.|observed|developed|:
D007980_D004409 CID levodopa_55\RB| (r_npadvmod) induced_57\VBN|NONE (r_amod) dyskinesias_58\NNS|were|.
9698967
D008619_D004387 NONE mepivacaine_43\NN| (r_amod) mg_45\NN|containing (r_pobj) with_42\IN|axillary (r_prep) block_41\NN|NONE (r_pobj) of_39\IN|NONE (r_prep) performance_38\NN|NONE (r_pobj) after_37\IN| (r_prep) min_36\NN|,|for|male|,|II|classification|ASA (r_appos) group_28\NN|in|was|,|increase|. (l_prep) for_51\IN|,|male|min|,|II|classification|ASA (l_pobj) correction_52\NN|NONE (l_prep) of_53\IN|NONE (l_pobj) contracture_56\NN|NONE
D008619_D011595 NONE mepivacaine_43\NN| (r_amod) mg_45\NN|containing (r_pobj) with_42\IN|axillary (r_prep) block_41\NN|NONE (r_pobj) of_39\IN|NONE (r_prep) performance_38\NN|NONE (r_pobj) after_37\IN| (r_prep) min_36\NN|,|for|male|,|II|classification|ASA (r_appos) group_28\NN|in|was|,|increase|. (r_appos) observed_21\VBN|NONE (l_nsubjpass) increase_1\NN|group|in|was|,|. (l_acl) accompanied_6\VBN|,|in|,|An (l_agent) by_7\IN|NONE (l_pobj) fibrillation_9\NN|NONE (l_conj) agitation_11\NN|,|atrial
D004837_D011595 NONE adrenaline_47\NN|NONE (r_dobj) containing_46\VBG|mg (r_pcomp) with_42\IN|axillary (r_prep) block_41\NN|NONE (r_pobj) of_39\IN|NONE (r_prep) performance_38\NN|NONE (r_pobj) after_37\IN| (r_prep) min_36\NN|,|for|male|,|II|classification|ASA (r_appos) group_28\NN|in|was|,|increase|. (r_appos) observed_21\VBN|NONE (l_nsubjpass) increase_1\NN|group|in|was|,|. (l_acl) accompanied_6\VBN|,|in|,|An (l_agent) by_7\IN|NONE (l_pobj) fibrillation_9\NN|NONE (l_conj) agitation_11\NN|,|atrial
D004837_D006973 CID adrenaline_47\NN|NONE (r_dobj) containing_46\VBG|mg (r_pcomp) with_42\IN|axillary (r_prep) block_41\NN|NONE (r_pobj) of_39\IN|NONE (r_prep) performance_38\NN|NONE (r_pobj) after_37\IN| (r_prep) min_36\NN|,|for|male|,|II|classification|ASA (r_appos) group_28\NN|in|was|,|increase|. (r_appos) observed_21\VBN|NONE (l_nsubjpass) increase_1\NN|group|in|was|,|. (l_prep) in_2\IN|,|accompanied|,|An (l_pobj) pressure_4\NN|NONE
D008619_D001281 CID mepivacaine_43\NN| (r_amod) mg_45\NN|containing (r_pobj) with_42\IN|axillary (r_prep) block_41\NN|NONE (r_pobj) of_39\IN|NONE (r_prep) performance_38\NN|NONE (r_pobj) after_37\IN| (r_prep) min_36\NN|,|for|male|,|II|classification|ASA (r_appos) group_28\NN|in|was|,|increase|. (r_appos) observed_21\VBN|NONE (l_nsubjpass) increase_1\NN|group|in|was|,|. (l_acl) accompanied_6\VBN|,|in|,|An (l_agent) by_7\IN|NONE (l_pobj) fibrillation_9\NN|NONE
D008619_D014474 NONE mepivacaine_43\NN| (r_amod) mg_45\NN|containing (r_pobj) with_42\IN|axillary (r_prep) block_41\NN|NONE (r_pobj) of_39\IN|NONE (r_prep) performance_38\NN|NONE (r_pobj) after_37\IN| (r_prep) min_36\NN|,|for|male|,|II|classification|ASA (r_appos) group_28\NN|in|was|,|increase|. (r_appos) observed_21\VBN|NONE (l_nsubjpass) increase_1\NN|group|in|was|,|. (l_acl) accompanied_6\VBN|,|in|,|An (l_agent) by_7\IN|NONE (l_pobj) fibrillation_9\NN|NONE (l_conj) agitation_11\NN|,|atrial (l_conj) shouts_14\NNS|, (l_prep) of_17\IN|incomprehensible|and|loss (l_pobj) consciousness_18\NN|NONE
D004837_D004387 NONE adrenaline_47\NN|NONE (r_dobj) containing_46\VBG|mg (r_pcomp) with_42\IN|axillary (r_prep) block_41\NN|NONE (r_pobj) of_39\IN|NONE (r_prep) performance_38\NN|NONE (r_pobj) after_37\IN| (r_prep) min_36\NN|,|for|male|,|II|classification|ASA (r_appos) group_28\NN|in|was|,|increase|. (l_prep) for_51\IN|,|male|min|,|II|classification|ASA (l_pobj) correction_52\NN|NONE (l_prep) of_53\IN|NONE (l_pobj) contracture_56\NN|NONE
D004837_D001281 CID adrenaline_47\NN|NONE (r_dobj) containing_46\VBG|mg (r_pcomp) with_42\IN|axillary (r_prep) block_41\NN|NONE (r_pobj) of_39\IN|NONE (r_prep) performance_38\NN|NONE (r_pobj) after_37\IN| (r_prep) min_36\NN|,|for|male|,|II|classification|ASA (r_appos) group_28\NN|in|was|,|increase|. (r_appos) observed_21\VBN|NONE (l_nsubjpass) increase_1\NN|group|in|was|,|. (l_acl) accompanied_6\VBN|,|in|,|An (l_agent) by_7\IN|NONE (l_pobj) fibrillation_9\NN|NONE
D004837_D019954 NONE adrenaline_47\NN|NONE (r_dobj) containing_46\VBG|mg (r_pcomp) with_42\IN|axillary (r_prep) block_41\NN|NONE (r_pobj) of_39\IN|NONE (r_prep) performance_38\NN|NONE (r_pobj) after_37\IN| (r_prep) min_36\NN|,|for|male|,|II|classification|ASA (r_appos) group_28\NN|in|was|,|increase|. (r_appos) observed_21\VBN|NONE (l_nsubjpass) increase_1\NN|group|in|was|,|. (l_acl) accompanied_6\VBN|,|in|,|An (l_agent) by_7\IN|NONE (l_pobj) fibrillation_9\NN|NONE (l_conj) agitation_11\NN|,|atrial (l_conj) shouts_14\NNS|,
D008619_D019954 NONE mepivacaine_43\NN| (r_amod) mg_45\NN|containing (r_pobj) with_42\IN|axillary (r_prep) block_41\NN|NONE (r_pobj) of_39\IN|NONE (r_prep) performance_38\NN|NONE (r_pobj) after_37\IN| (r_prep) min_36\NN|,|for|male|,|II|classification|ASA (r_appos) group_28\NN|in|was|,|increase|. (r_appos) observed_21\VBN|NONE (l_nsubjpass) increase_1\NN|group|in|was|,|. (l_acl) accompanied_6\VBN|,|in|,|An (l_agent) by_7\IN|NONE (l_pobj) fibrillation_9\NN|NONE (l_conj) agitation_11\NN|,|atrial (l_conj) shouts_14\NNS|,
D008619_D006973 CID mepivacaine_43\NN| (r_amod) mg_45\NN|containing (r_pobj) with_42\IN|axillary (r_prep) block_41\NN|NONE (r_pobj) of_39\IN|NONE (r_prep) performance_38\NN|NONE (r_pobj) after_37\IN| (r_prep) min_36\NN|,|for|male|,|II|classification|ASA (r_appos) group_28\NN|in|was|,|increase|. (r_appos) observed_21\VBN|NONE (l_nsubjpass) increase_1\NN|group|in|was|,|. (l_prep) in_2\IN|,|accompanied|,|An (l_pobj) pressure_4\NN|NONE
D004837_D014474 NONE adrenaline_47\NN|NONE (r_dobj) containing_46\VBG|mg (r_pcomp) with_42\IN|axillary (r_prep) block_41\NN|NONE (r_pobj) of_39\IN|NONE (r_prep) performance_38\NN|NONE (r_pobj) after_37\IN| (r_prep) min_36\NN|,|for|male|,|II|classification|ASA (r_appos) group_28\NN|in|was|,|increase|. (r_appos) observed_21\VBN|NONE (l_nsubjpass) increase_1\NN|group|in|was|,|. (l_acl) accompanied_6\VBN|,|in|,|An (l_agent) by_7\IN|NONE (l_pobj) fibrillation_9\NN|NONE (l_conj) agitation_11\NN|,|atrial (l_conj) shouts_14\NNS|, (l_prep) of_17\IN|incomprehensible|and|loss (l_pobj) consciousness_18\NN|NONE
839274
D003276_D020518 CID contraceptives_14\NNS|NONE (r_pobj) on_12\IN|of|nodular|focal (r_prep) hyperplasia_5\NN|and|Hepatic
D003276_D020518 CID contraceptives_18\NNS|NONE (r_pobj) of_16\IN|the (r_prep) use_15\NN|NONE (r_pobj) with_13\IN|presumably (r_prep) associated_12\VBD|of (r_acl) one_6\CD|Two|of|and (l_prep) of_7\IN|associated (l_pobj) hyperplasia_10\NN|NONE
D003276_D000236 CID contraceptives_14\NNS|NONE (r_pobj) on_12\IN|of|nodular|focal (r_prep) hyperplasia_5\NN|and|Hepatic (r_conj) adenomas_1\NNS|case|.|:
D003276_D000236 CID contraceptives_18\NNS|NONE (r_pobj) of_16\IN|the (r_prep) use_15\NN|NONE (r_pobj) with_13\IN|presumably (r_prep) associated_12\VBD|of (r_acl) one_6\CD|Two|of|and (r_conj) cases_1\NNS|,|.|are (l_prep) of_2\IN|Two|and|one (l_pobj) adenoma_4\NN|NONE
3115150
D015760_D009127 CID alfentanil_3\NN| (r_npadvmod) induced_5\VBN|muscle (r_amod) rigidity_7\NN|pretreatment|.
D015760_D009127 CID alfentanil_29\NN|significantly|pretreatment|rigidity|. (r_advcl) attenuated_14\VBD|NONE (l_dobj) rigidity_17\NN|significantly|pretreatment|alfentanil|.
D015760_D009127 CID alfentanil_15\NNS|NONE (r_pobj) by_14\IN|NONE (r_agent) produced_13\VBN|the (r_acl) rigidity_12\NN|significantly|to
D015760_D009127 CID alfentanil_19\NNS|NONE (r_pobj) by_18\IN|,|animals|Despite (r_agent) followed_17\VBN|.|motionless (l_prep) Despite_0\IN|,|animals|by (l_pobj) absence_2\NN|NONE (l_prep) of_3\IN|the (l_pobj) rigidity_4\NN|NONE
D015760_D009127 CID alfentanil_35\NN|alone (r_advmod) receiving_34\VBG|NONE (r_acl) animals_33\NNS|than (r_nsubj) were_32\VBD|less|to (r_advcl) responsive_27\JJ|,|and|, (r_conj) flaccid_23\JJ|NONE (r_conj) motionless_21\JJ|.|followed (r_acomp) were_20\VBD|NONE (l_csubj) followed_17\VBN|.|motionless (l_prep) Despite_0\IN|,|animals|by (l_pobj) absence_2\NN|NONE (l_prep) of_3\IN|the (l_pobj) rigidity_4\NN|NONE
D012701_D012131 NONE serotonin_3\NN|NONE (r_compound) antagonists_4\NNS|NONE (r_pobj) with_1\IN|NONE (r_prep) Pretreatment_0\NN|be|may|,|useful|. (r_nsubj) be_6\VB|NONE (l_advcl) be_20\VB|may|,|Pretreatment|useful|. (l_xcomp) assess_23\VB|will|although|studies|necessary (l_dobj) interaction_25\NN|to (l_prep) of_26\IN|the (l_pobj) CNS_29\NNP|NONE (l_conj) cardiovascular_31\JJ|enhanced|, (l_conj) depression_35\NN|,|and
D012701_D009127 NONE serotonin_9\NN|a|receptor|specific (r_compound) antagonist_11\NN|,|Systemic|with|, (r_appos) pretreatment_1\NN|significantly|rigidity|alfentanil|. (r_nsubj) attenuated_14\VBD|NONE (l_dobj) rigidity_17\NN|significantly|pretreatment|alfentanil|.
D012701_D009127 NONE serotonin_3\NN|NONE (r_compound) antagonists_4\NNS|NONE (r_pobj) with_1\IN|NONE (r_prep) Pretreatment_0\NN|be|may|,|useful|. (r_nsubj) be_6\VB|NONE (l_acomp) useful_8\JJ|be|may|,|Pretreatment|. (l_prep) in_9\IN|clinically (l_pcomp) attenuating_10\VBG|NONE (l_dobj) rigidity_14\NN|NONE
D002707_D009127 NONE Chlordiazepoxide_0\VB|influence|. (r_nsubj) failed_7\VBD|NONE (l_xcomp) influence_10\VB|Chlordiazepoxide|. (l_dobj) rigidity_12\NN|significantly|to
D007650_D009127 NONE Ketanserin_0\JJ|NONE (r_compound) pretreatment_1\NN|rigidity|. (r_nsubj) reverses_2\VBZ|NONE (l_dobj) rigidity_7\NN|pretreatment|.
D007650_D009127 NONE ketanserin_3\NN|NONE (r_pobj) with_2\IN|,|antagonist|Systemic|, (r_prep) pretreatment_1\NN|significantly|rigidity|alfentanil|. (r_nsubj) attenuated_14\VBD|NONE (l_dobj) rigidity_17\NN|significantly|pretreatment|alfentanil|.
D007650_D009127 NONE ketanserin_9\JJ|that (r_dobj) received_8\VBD|mg/kg (r_relcl) animals_6\NNS|,|Despite|by (r_nsubj) followed_17\VBN|.|motionless (l_prep) Despite_0\IN|,|animals|by (l_pobj) absence_2\NN|NONE (l_prep) of_3\IN|the (l_pobj) rigidity_4\NN|NONE
D012701_D002318 NONE serotonin_3\NN|NONE (r_compound) antagonists_4\NNS|NONE (r_pobj) with_1\IN|NONE (r_prep) Pretreatment_0\NN|be|may|,|useful|. (r_nsubj) be_6\VB|NONE (l_advcl) be_20\VB|may|,|Pretreatment|useful|. (l_xcomp) assess_23\VB|will|although|studies|necessary (l_dobj) interaction_25\NN|to (l_prep) of_26\IN|the (l_pobj) CNS_29\NNP|NONE (l_conj) cardiovascular_31\JJ|enhanced|, (l_conj) depression_35\NN|,|and
2598570
D000431_D006255 NONE alcohol_83\NN|to (r_dobj) use_82\VB|and|;|to|.|in|were|; (r_conj) participate_47\VB|NONE (l_ccomp) were_2\VBD|and|;|to|.|in|use|; (l_conj) suffer_24\VB|patients|likely (l_prep) from_25\IN|NONE (l_pobj) fever_27\NN|NONE
D007052_D006073 NONE ibuprofen_15\NNP|analgesic|)|(|other (r_appos) agents_12\NNS|NONE (r_pobj) of_9\IN|concurrent (r_prep) use_8\NN|young|,|disease|, (r_appos) age_5\NN|.|factors (l_conj) disease_20\NN|young|use|,|, (l_conj) history_29\NN|,|,|increase|history|preexisting|,|,|renal|increase (l_prep) of_30\IN|a (l_pobj) gout_31\NN|NONE
D007052_D007669 NONE ibuprofen_15\NNP|analgesic|)|(|other (r_appos) agents_12\NNS|NONE (r_pobj) of_9\IN|concurrent (r_prep) use_8\NN|young|,|disease|, (r_appos) age_5\NN|.|factors (l_conj) disease_20\NN|young|use|,|, (l_conj) history_23\NN|,|,|history|increase|preexisting|,|,|renal|increase (l_prep) of_24\IN|a (l_pobj) stones_26\NNS|NONE
D007052_D007674 NONE ibuprofen_15\NNP|analgesic|)|(|other (r_appos) agents_12\NNS|NONE (r_pobj) of_9\IN|concurrent (r_prep) use_8\NN|young|,|disease|, (r_appos) age_5\NN|.|factors (l_conj) disease_20\NN|young|use|,|,
D000431_D001249 NONE alcohol_83\NN|to (r_dobj) use_82\VB|and|;|to|.|in|were|; (r_conj) participate_47\VB|NONE (l_ccomp) were_2\VBD|and|;|to|.|in|use|; (l_conj) suffer_24\VB|patients|likely (l_prep) from_25\IN|NONE (l_pobj) fever_27\NN|NONE (l_conj) asthma_29\NN|ratio|(|hay|and
D013496_D021501 CID suprofen_9\NN|NONE (r_pobj) from_8\IN|.|of|The (r_prep) epidemiology_1\NN|NONE (l_prep) of_2\IN|.|from|The (l_pobj) syndrome_7\NN|NONE (l_compound) pain_6\NN|flank
7977601
17608141
D004298_D020258 NONE dopamine_27\NN|the|induced|nigrostriatal (r_compound) neurotoxicity_28\NN|NONE
D004298_D020258 NONE dopamine_19\NN|nigrostriatal|induced (r_compound) neurotoxicity_20\NN|NONE
D008694_D005334 CID methamphetamine_10\NN| (r_npadvmod) elicited_12\VBN|NONE (r_amod) hyperthermia_13\NN|basal|or|body|the
D008070_D020258 NONE lipopolysaccharide_11\NN|NONE (r_compound) pretreatment_12\NN|NONE (r_pobj) by_10\IN|dopaminergic|nigrostriatal|in (r_prep) neurotoxicity_7\NN|Attenuation|.||methamphetamine
D008070_D020258 NONE lipopolysaccharide_9\NN|NONE (r_pobj) of_8\IN|factor|,|the (r_prep) roles_7\NNS|,|.|we|In (l_appos) factor_17\NN|of|,|the (l_conj) treatment_19\NN|,|a|inflammatory (l_prep) in_20\IN|NONE (l_pcomp) modulating_21\VBG|NONE (l_dobj) neurotoxicity_28\NN|NONE
D008070_D020258 NONE lipopolysaccharide_8\NN|in|systemic (r_compound) pretreatment_9\NN|NONE (l_prep) in_10\IN|lipopolysaccharide|systemic (l_pcomp) exerting_11\VBG|NONE (l_dobj) protection_13\NN|NONE (l_prep) against_14\IN|effective (l_pobj) neurotoxicity_20\NN|NONE
D008694_D009422 NONE methamphetamine_10\NN| (r_npadvmod) induced_12\VBN|dopaminergic|terminal (r_amod) damage_15\NN|NONE
D008694_D020258 NONE methamphetamine_2\NN|Attenuation|.||neurotoxicity (r_npadvmod) induced_4\VBN|NONE (l_dobj) neurotoxicity_7\NN|Attenuation|.||methamphetamine
D008694_D020258 NONE methamphetamine_23\NN| (r_npadvmod) induced_25\VBN|the|dopamine|nigrostriatal (r_amod) neurotoxicity_28\NN|NONE
D008694_D020258 NONE methamphetamine_15\NN| (r_npadvmod) induced_17\VBN|nigrostriatal|dopamine (r_amod) neurotoxicity_20\NN|NONE
D008070_D005334 NONE Lipopolysaccharide_0\JJ|NONE (r_compound) pretreatment_1\NN|.|temperature|later|did|not (r_nsubj) affect_4\VB|NONE (l_dobj) temperature_8\NN|pretreatment|.|later|did|not (l_conj) hyperthermia_13\NN|basal|or|body|the
7088431
D004054_D018262 CID DES_6\NNP| (r_npadvmod) exposed_8\VBN|under (r_amod) offspring_9\NN|NONE (r_pobj) in_5\IN|of|. (r_prep) Development_0\NN|NONE (l_prep) of_1\IN|in|. (l_pobj) adenocarcinoma_4\NN|NONE
D004054_D018262 CID diethylstilbestrol_21\NN|NONE (r_pobj) to_20\IN|in (r_prep) exposed_17\VBN|young (r_acl) women_16\NNS|NONE (r_pobj) in_14\IN|follow| (r_prep) up_13\NN|NONE (r_pobj) at_10\IN|cases (r_prep) detected_9\VBD|are|. (l_nsubj) cases_1\NNS|at (l_prep) of_2\IN|Two (l_pobj) adenocarcinoma_5\NN|NONE (l_prep) of_6\IN|clear|cell (l_pobj) vagina_8\NN|NONE
D004054_D014625 CID diethylstilbestrol_21\NN|NONE (r_pobj) to_20\IN|in (r_prep) exposed_17\VBN|young (r_acl) women_16\NNS|NONE (r_pobj) in_14\IN|follow| (r_prep) up_13\NN|NONE (r_pobj) at_10\IN|cases (r_prep) detected_9\VBD|are|. (l_nsubj) cases_1\NNS|at (l_prep) of_2\IN|Two (l_pobj) adenocarcinoma_5\NN|NONE (l_prep) of_6\IN|clear|cell (l_pobj) vagina_8\NN|NONE
3413271
D004837_D000787 NONE epinephrine_1\NN|.|evidenced|ischemia (r_nsubj) produced_4\VBD|NONE (l_advcl) evidenced_8\VBN|epinephrine|.|ischemia (l_agent) by_9\IN|as (l_pobj) depression_12\NN|NONE (l_conj) angina_14\NN|and|segment|ST
D004837_D007511 NONE epinephrine_6\NN|NONE (l_appos) comparison_8\NN|: (l_prep) with_9\IN|NONE (l_pobj) ischemia_13\NN|NONE
D004837_D007511 NONE epinephrine_13\NN|exercise|and (r_amod) infusion_14\NN|NONE (r_pobj) during_12\IN|were|.|consumption|signs (r_prep) compared_11\VBN|NONE (l_nsubjpass) signs_1\NNS|during|were|.|consumption (l_prep) of_2\IN|Objective (l_pobj) ischemia_3\NN|NONE
D004837_D007511 NONE epinephrine_28\NN| (r_npadvmod) induced_30\VBN|NONE (r_amod) ischemia_31\NN|while|by|was
D004837_D007511 NONE epinephrine_7\NN|NONE (r_pobj) by_6\IN|NONE (r_agent) produced_5\VBN|that|, (r_acl) ischemia_4\NN|as|may|during
D004837_D017202 CID epinephrine_6\NN|NONE (r_pobj) by_5\IN|Mechanisms|. (r_prep) induced_4\VBN|NONE (l_nsubj) Mechanisms_0\NNS|.|by (l_prep) of_1\IN|NONE (l_pobj) ischemia_3\NN|NONE
D004837_D017202 CID epinephrine_3\NN|NONE (r_pobj) of_2\IN|The|in (r_prep) role_1\NN|was|in|. (l_prep) in_4\IN|of|The (l_pcomp) eliciting_5\VBG|NONE (l_dobj) ischemia_7\NN|NONE
D004837_D017202 CID epinephrine_1\NN|.|evidenced|ischemia (r_nsubj) produced_4\VBD|NONE (l_dobj) ischemia_6\NN|epinephrine|.|evidenced
D004837_D017202 CID epinephrine_9\NN|NONE (r_pobj) by_8\IN|NONE (r_agent) induced_7\VBN|the|of (r_acl) mechanisms_3\NNS|.|However|different|, (l_prep) of_4\IN|the|induced (l_pobj) ischemia_6\NN|NONE
D004837_D017202 CID epinephrine_28\NN| (r_npadvmod) induced_30\VBN|NONE (r_amod) ischemia_31\NN|while|by|was (r_nsubjpass) characterized_33\VBN|.|ischemia|,|with|was|predominantly|by (r_advcl) marked_6\VBN|NONE (l_nsubjpass) ischemia_4\NN|.|,|with|was|characterized|predominantly|by
D004837_D003324 NONE epinephrine_3\NN|NONE (r_pobj) of_2\IN|The|in (r_prep) role_1\NN|was|in|. (r_nsubjpass) examined_9\VBN|NONE (l_prep) in_10\IN|was|role|. (l_pobj) patients_11\NNS|NONE (l_prep) with_12\IN|NONE (l_pobj) disease_15\NN|NONE
D004837_D003866 NONE epinephrine_1\NN|.|evidenced|ischemia (r_nsubj) produced_4\VBD|NONE (l_advcl) evidenced_8\VBN|epinephrine|.|ischemia (l_agent) by_9\IN|as (l_pobj) depression_12\NN|NONE
D010100_D007511 NONE oxygen_8\NN|myocardial|increasing (r_compound) consumption_9\NN|during|were|.|signs (r_nsubjpass) compared_11\VBN|NONE (l_nsubjpass) signs_1\NNS|during|were|.|consumption (l_prep) of_2\IN|Objective (l_pobj) ischemia_3\NN|NONE
16574713
D018817_D020258 NONE 3,4-methylenedioxymethamphetamine_1\CD|has|been|damage|Although|MDMA (r_nsubjpass) shown_9\VBN|is|about|.|little|, (r_advcl) known_26\VBN|NONE (l_prep) about_27\IN|shown|is|.|little|, (l_pobj) consequences_32\NNS|NONE (l_prep) of_33\IN|the|term (l_pobj) lesions_39\NNS|NONE
D018817_D020258 NONE MDMA_3\NNP|has|,methylenedioxymethamphetamine|been|damage|Although (r_nsubjpass) shown_9\VBN|is|about|.|little|, (r_advcl) known_26\VBN|NONE (l_prep) about_27\IN|shown|is|.|little|, (l_pobj) consequences_32\NNS|NONE (l_prep) of_33\IN|the|term (l_pobj) lesions_39\NNS|NONE
D018817_D020258 NONE ecstasy_5\NN|(|)|or (r_conj) MDMA_3\NNP|has|,methylenedioxymethamphetamine|been|damage|Although (r_nsubjpass) shown_9\VBN|is|about|.|little|, (r_advcl) known_26\VBN|NONE (l_prep) about_27\IN|shown|is|.|little|, (l_pobj) consequences_32\NNS|NONE (l_prep) of_33\IN|the|term (l_pobj) lesions_39\NNS|NONE
D018817_D020258 NONE MDMA_34\NNP| (r_npadvmod) induced_36\VBN|neurotoxic|HT|on (r_amod) lesions_39\NNS|NONE
D012701_D020258 NONE serotonin_13\NN|to (r_dobj) damage_11\VB|has|,methylenedioxymethamphetamine|been|Although|MDMA (r_xcomp) shown_9\VBN|is|about|.|little|, (r_advcl) known_26\VBN|NONE (l_prep) about_27\IN|shown|is|.|little|, (l_pobj) consequences_32\NNS|NONE (l_prep) of_33\IN|the|term (l_pobj) lesions_39\NNS|NONE
D012701_D020258 NONE 5-HT_15\CD|humans|and|(|in|) (r_nmod) neurons_17\NNS|brain (r_appos) serotonin_13\NN|to (r_dobj) damage_11\VB|has|,methylenedioxymethamphetamine|been|Although|MDMA (r_xcomp) shown_9\VBN|is|about|.|little|, (r_advcl) known_26\VBN|NONE (l_prep) about_27\IN|shown|is|.|little|, (l_pobj) consequences_32\NNS|NONE (l_prep) of_33\IN|the|term (l_pobj) lesions_39\NNS|NONE
D012701_D020258 NONE 5-HT_37\CD|neurotoxic|on|induced (r_nummod) lesions_39\NNS|NONE
D012701_D020258 NONE 5-HT_44\CD|in|is (r_nsubjpass) involved_46\VBN|,|as (r_relcl) functions_41\NNS|NONE (r_pobj) on_40\IN|neurotoxic|HT|induced (r_prep) lesions_39\NNS|NONE
D018817_D008569 CID MDMA_12\NNP|moderate (r_compound) users_13\NNS|NONE (r_pobj) in_10\IN|In|.|was|evidence|, (r_prep) observed_9\VBN|NONE (l_nsubjpass) evidence_4\NN|in|In|.|was|, (l_prep) of_5\IN|no (l_pobj) impairment_7\NN|NONE
D018817_D008569 CID MDMA_4\NNP|NONE (r_pobj) of_3\IN|the|in (r_prep) use_2\NN|to|.|may|While|use (l_prep) in_5\IN|of|the (l_pobj) quantities_6\NNS|NONE (l_relcl) considered_10\VBN|NONE (l_oprd) associated_16\VBN|that|may|be (l_prep) with_17\IN|"|not|is|" (l_pobj) functioning_20\VBG|NONE
D018817_D008569 CID MDMA_4\NNP|NONE (r_pobj) of_3\IN|the|in (r_prep) use_2\NN|to|.|may|While|use (r_nsubj) lead_28\VB|NONE (l_prep) to_29\IN|.|may|While|use|use (l_pobj) impairments_33\NNS|NONE
D018817_D008569 CID MDMA_25\NNP|NONE (r_compound) use_26\NN|NONE (r_pobj) of_24\IN|heavy (r_prep) use_23\NN|to|.|may|While|use (r_nsubj) lead_28\VB|NONE (l_nsubj) use_2\NN|to|.|may|While|use (l_prep) in_5\IN|of|the (l_pobj) quantities_6\NNS|NONE (l_relcl) considered_10\VBN|NONE (l_oprd) associated_16\VBN|that|may|be (l_prep) with_17\IN|"|not|is|" (l_pobj) functioning_20\VBG|NONE
D018817_D008569 CID MDMA_25\NNP|NONE (r_compound) use_26\NN|NONE (r_pobj) of_24\IN|heavy (r_prep) use_23\NN|to|.|may|While|use (r_nsubj) lead_28\VB|NONE (l_prep) to_29\IN|.|may|While|use|use (l_pobj) impairments_33\NNS|NONE
809711
D005996_D007022 CID Nitroglycerin_0\NNP|been|reduce|has (r_nsubjpass) shown_3\VBN|effect|,|by|in|. (r_ccomp) potentiated_17\VBN|NONE (l_agent) by_21\IN|effect|,|in|shown|. (l_pobj) agents_22\NNS|NONE (l_relcl) reverse_24\VBP|NONE (l_dobj) hypotension_28\NN|that
D005996_D007022 CID nitroglycerin_25\NN| (r_npadvmod) induced_27\VBN|NONE (r_amod) hypotension_28\NN|that
D005996_D009203 NONE nitroglycerin_9\NN|NONE (r_pobj) of_7\IN|beneficial|the|in (r_prep) effects_6\NNS|NONE (l_prep) in_10\IN|of|beneficial|the (l_pobj) patients_11\NNS|NONE (l_prep) with_12\IN|NONE (l_pobj) infarction_15\NN|NONE
D005996_D009203 NONE Nitroglycerin_0\NNP|been|reduce|has (r_nsubjpass) shown_3\VBN|effect|,|by|in|. (l_xcomp) reduce_5\VB|been|has|Nitroglycerin (l_prep) during_10\IN|elevation|to (l_pobj) infarction_13\NN|NONE
D005996_D009203 NONE nitroglycerin_25\NN| (r_npadvmod) induced_27\VBN|NONE (r_amod) hypotension_28\NN|that (r_dobj) reverse_24\VBP|NONE (r_relcl) agents_22\NNS|NONE (r_pobj) by_21\IN|effect|,|in|shown|. (r_agent) potentiated_17\VBN|NONE (l_ccomp) shown_3\VBN|effect|,|by|in|. (l_xcomp) reduce_5\VB|been|has|Nitroglycerin (l_prep) during_10\IN|elevation|to (l_pobj) infarction_13\NN|NONE
D005996_D009203 NONE nitroglycerin_9\NN|+/|patients (r_dobj) received_7\VBD|NONE (l_nsubj) patients_1\NNS|+/|nitroglycerin (l_prep) with_2\IN|Ten (l_pobj) infarctions_6\NNS|NONE
D005996_D009203 NONE nitroglycerin_8\NN|NONE (r_pobj) to_7\IN|NONE (r_prep) phenylephrine_6\NN|NONE (r_pobj) of_5\IN|NONE (r_prep) addition_4\NN|beneficial|that|not (r_nsubj) is_9\VBZ|results|. (l_acomp) beneficial_11\JJ|addition|that|not (l_prep) in_12\IN|NONE (l_pobj) treatment_14\NN|NONE (l_prep) of_15\IN|the (l_pobj) patients_16\NNS|NONE (l_prep) with_17\IN|NONE (l_pobj) infarction_20\NN|NONE
D010656_D009203 NONE phenylephrine_2\NN|NONE (l_prep) of_3\IN|NONE (l_pobj) effects_6\NNS|NONE (l_prep) in_10\IN|of|beneficial|the (l_pobj) patients_11\NNS|NONE (l_prep) with_12\IN|NONE (l_pobj) infarction_15\NN|NONE
D010656_D009203 NONE phenylephrine_6\NN|NONE (r_pobj) of_5\IN|NONE (r_prep) addition_4\NN|beneficial|that|not (r_nsubj) is_9\VBZ|results|. (l_acomp) beneficial_11\JJ|addition|that|not (l_prep) in_12\IN|NONE (l_pobj) treatment_14\NN|NONE (l_prep) of_15\IN|the (l_pobj) patients_16\NNS|NONE (l_prep) with_17\IN|NONE (l_pobj) infarction_20\NN|NONE
137340
D009388_D006948 NONE neostigmine_6\NN|penetrate|and|both|, (r_conj) methscopolamine_4\NN|.|,|effect|,|In (r_nsubj) had_18\VBD|NONE (l_dobj) effect_20\NN|.|,|methscopolamine|,|In (l_prep) on_21\IN|no (l_pobj) hyperactivity_23\NN|NONE
D010134_D006948 NONE chlorophenylalamine_9\NN|NONE (r_pobj) with_6\IN|NONE (r_prep) pretreatment_5\NN|,|On|change|depletor|,|,|. (r_nsubj) caused_25\VBD|NONE (l_dobj) change_28\NN|pretreatment|,|On|depletor|,|,|. (l_prep) in_29\IN|no|significant (l_pobj) hyperactivity_31\NN|NONE
D012701_D006948 NONE serotonin_22\NN|a (r_compound) depletor_23\NN|pretreatment|,|On|change|,|,|. (r_nsubj) caused_25\VBD|NONE (l_dobj) change_28\NN|pretreatment|,|On|depletor|,|,|. (l_prep) in_29\IN|no|significant (l_pobj) hyperactivity_31\NN|NONE
D009020_D006948 CID morphine_5\NN| (r_npadvmod) induced_7\VBN|in (r_amod) increase_8\NN|NONE (l_prep) in_9\IN|induced (l_pobj) activity_11\NN|NONE
D009020_D006948 CID morphine_7\NN| (r_npadvmod) induced_9\VBN|the|in (r_amod) increase_10\NN|NONE (l_prep) in_11\IN|the|induced (l_pobj) activity_13\NN|NONE
D009020_D006948 CID morphine_7\NN| (r_compound) HC1_9\NNP|NONE (r_pobj) of_6\IN| (r_prep) mg/kg_5\NN|NONE (r_pobj) of_3\IN|subcutaneous|The (r_prep) administration_2\NN|.|increase (r_nsubj) produced_10\VBD|NONE (l_dobj) increase_13\NN|administration|. (l_prep) in_14\IN|marked|a (l_pobj) activity_16\NN|NONE
D009020_D006948 CID morphine_1\NN| (r_npadvmod) induced_3\VBN|The (r_amod) hyperactivity_4\NN|.|by|attenuated|and|was
D009020_D006948 CID morphine_26\NN|NONE (r_pobj) by_25\IN|NONE (r_agent) produced_24\VBN|the (r_acl) hyperactivity_23\NN|NONE
D012601_D006948 CID scopolamine_8\NN|NONE (r_pobj) by_7\IN|.|attenuated|and|hyperactivity|was (r_agent) potentiated_6\VBN|NONE (l_nsubjpass) hyperactivity_4\NN|.|by|attenuated|and|was
D010830_D006948 NONE physostigmine_12\NN|NONE (r_pobj) by_11\IN|NONE (r_agent) attenuated_10\VBN|.|by|and|hyperactivity|was (r_conj) potentiated_6\VBN|NONE (l_nsubjpass) hyperactivity_4\NN|.|by|attenuated|and|was
D019832_D006948 NONE methscopolamine_4\NN|.|,|effect|,|In (r_nsubj) had_18\VBD|NONE (l_dobj) effect_20\NN|.|,|methscopolamine|,|In (l_prep) on_21\IN|no (l_pobj) hyperactivity_23\NN|NONE
10706004
D019331_D006973 NONE ester_49\NN|/|/|day||mg (r_appos) kg_40\NNS|NONE (r_pobj) with_36\IN|synthase (r_prep) inhibition_35\NN|NONE (r_pobj) by_31\IN|NONE (r_prep) rats_30\NNS|NONE (r_pobj) in_29\IN|for (r_prep) induced_28\VBN|response|we|assess|,|. (r_advcl) studied_14\VBD|NONE (l_dobj) response_16\NN|we|assess|,|induced|. (l_prep) of_17\IN|the (l_pobj) K)-ATPase_22\NNP|NONE (l_prep) to_23\IN|(|,|cardiac|Na (l_pobj) hypertension_27\NN|NONE
D019331_D006973 NONE NAME_53\NNP|)|methyl|arginine (r_appos) ester_49\NN|/|/|day||mg (r_appos) kg_40\NNS|NONE (r_pobj) with_36\IN|synthase (r_prep) inhibition_35\NN|NONE (r_pobj) by_31\IN|NONE (r_prep) rats_30\NNS|NONE (r_pobj) in_29\IN|for (r_prep) induced_28\VBN|response|we|assess|,|. (r_advcl) studied_14\VBD|NONE (l_dobj) response_16\NN|we|assess|,|induced|. (l_prep) of_17\IN|the (l_pobj) K)-ATPase_22\NNP|NONE (l_prep) to_23\IN|(|,|cardiac|Na (l_pobj) hypertension_27\NN|NONE
D012964_D006973 NONE sodium_2\NN|of (r_nmod) affinities_5\NNS|NONE (r_pobj) of_1\IN|.|during (r_prep) Changes_0\NNS|NONE (l_prep) during_13\IN|of|. (l_conj) after_15\IN|and (l_pobj) hypertension_19\NN|NONE
D012964_D006973 NONE Na_10\UH|cardiac|(|,|the (r_nmod) K)-ATPase_12\NNP|NONE (r_pobj) of_6\IN|sodium (r_prep) affinities_5\NNS|NONE (r_pobj) of_1\IN|.|during (r_prep) Changes_0\NNS|NONE (l_prep) during_13\IN|of|. (l_conj) after_15\IN|and (l_pobj) hypertension_19\NN|NONE
D012964_D006973 NONE sodium_9\NN|intracellular (r_compound) level_10\NN|NONE (r_pobj) of_7\IN|NONE (r_prep) elevation_6\NN|,|In|in|.|was (r_nsubjpass) documented_12\VBN|NONE (l_prep) In_0\IN|,|elevation|in|.|was (l_pobj) models_2\NNS|NONE (l_prep) of_3\IN|several (l_pobj) hypertension_4\NN|NONE
D012964_D006973 NONE Na+_11\NNP|NONE (r_pobj) of_10\IN|transmembraneous (r_prep) transport_9\NN|NONE (r_pobj) in_7\IN|NONE (r_prep) disturbances_6\NNS|NONE (r_pobj) of_5\IN|the|molecular (r_prep) basis_4\NN|To (r_dobj) assess_1\VB|response|we|,|induced|. (r_advcl) studied_14\VBD|NONE (l_dobj) response_16\NN|we|assess|,|induced|. (l_prep) of_17\IN|the (l_pobj) K)-ATPase_22\NNP|NONE (l_prep) to_23\IN|(|,|cardiac|Na (l_pobj) hypertension_27\NN|NONE
D012964_D006973 NONE Na_20\UH|(|,|cardiac|to (r_nmod) K)-ATPase_22\NNP|NONE (l_prep) to_23\IN|(|,|cardiac|Na (l_pobj) hypertension_27\NN|NONE
D012964_D006973 NONE Na_9\NNP|,|,|(|K)ATPase|due|, (r_npadvmod) increased_12\VBD|After|of|.|revealed|,|the (r_parataxis) activity_6\NN|NONE (l_prep) After_0\IN|increased|of|.|revealed|,|the (l_pobj) recovery_1\NN|NONE (l_prep) from_2\IN|NONE (l_pobj) hypertension_3\NN|NONE
D012964_D006973 NONE Na+-extrusion_12\NN|NONE (r_pobj) by_10\IN|from|as (r_agent) accompanied_9\VBN|a|reversible (r_acl) hypertension_8\NN|Inhibition|.
D012964_D006973 NONE Na+-binding_21\NN|deteriorated|of (r_compound) properties_22\NNS|NONE (r_pobj) of_19\IN|a (r_prep) consequence_18\NN|NONE (r_pobj) as_16\IN|from|by (r_prep) accompanied_9\VBN|a|reversible (r_acl) hypertension_8\NN|Inhibition|.
D012964_D006973 NONE Na_26\UH|the|(|, (r_nmod) K)-ATPase_28\NNP|NONE (r_pobj) of_23\IN|Na+binding|deteriorated (r_prep) properties_22\NNS|NONE (r_pobj) of_19\IN|a (r_prep) consequence_18\NN|NONE (r_pobj) as_16\IN|from|by (r_prep) accompanied_9\VBN|a|reversible (r_acl) hypertension_8\NN|Inhibition|.
D012964_D003866 NONE Na+-extrusion_12\NN|NONE (l_amod) depressed_11\JJ|NONE
D012964_D003866 NONE Na+-binding_21\NN|deteriorated|of (r_compound) properties_22\NNS|NONE (r_pobj) of_19\IN|a (r_prep) consequence_18\NN|NONE (r_pobj) as_16\IN|from|by (r_prep) accompanied_9\VBN|a|reversible (l_agent) by_10\IN|from|as (l_pobj) Na+-extrusion_12\NN|NONE (l_amod) depressed_11\JJ|NONE
D012964_D003866 NONE Na_26\UH|the|(|, (r_nmod) K)-ATPase_28\NNP|NONE (r_pobj) of_23\IN|Na+binding|deteriorated (r_prep) properties_22\NNS|NONE (r_pobj) of_19\IN|a (r_prep) consequence_18\NN|NONE (r_pobj) as_16\IN|from|by (r_prep) accompanied_9\VBN|a|reversible (l_agent) by_10\IN|from|as (l_pobj) Na+-extrusion_12\NN|NONE (l_amod) depressed_11\JJ|NONE
D009569_D006973 CID oxide_17\NN|NONE (r_npadvmod) deficient_18\JJ|nitric (r_amod) hypertension_19\NN|NONE
D009569_D006973 CID NO_2\DT|NONE (r_det) synthesis_3\NN|NONE (r_pobj) of_1\IN|NONE (r_prep) Inhibition_0\NN|hypertension|. (r_nsubj) induces_4\VBZ|NONE (l_dobj) hypertension_6\NN|Inhibition|.
D009569_D006973 CID NO_24\JJ| (r_npadvmod) deficient_26\JJ|NONE (r_amod) hypertension_27\NN|NONE
D009569_D006973 CID NO_32\JJ| (r_compound) synthase_34\NN|with (r_compound) inhibition_35\NN|NONE (r_pobj) by_31\IN|NONE (r_prep) rats_30\NNS|NONE (r_pobj) in_29\IN|for (r_prep) induced_28\VBN|response|we|assess|,|. (r_advcl) studied_14\VBD|NONE (l_dobj) response_16\NN|we|assess|,|induced|. (l_prep) of_17\IN|the (l_pobj) K)-ATPase_22\NNP|NONE (l_prep) to_23\IN|(|,|cardiac|Na (l_pobj) hypertension_27\NN|NONE
D009569_D006973 CID NO_2\JJ| (r_compound) synthase_4\NN|NONE (r_pobj) of_1\IN|NONE (r_prep) Inhibition_0\NN|hypertension|. (r_nsubj) induced_5\VBD|NONE (l_dobj) hypertension_8\NN|Inhibition|.
D011188_D003866 NONE K)-ATPase_28\NNP|NONE (r_pobj) of_23\IN|Na+binding|deteriorated (r_prep) properties_22\NNS|NONE (r_pobj) of_19\IN|a (r_prep) consequence_18\NN|NONE (r_pobj) as_16\IN|from|by (r_prep) accompanied_9\VBN|a|reversible (l_agent) by_10\IN|from|as (l_pobj) Na+-extrusion_12\NN|NONE (l_amod) depressed_11\JJ|NONE
D000255_D006973 NONE ATP_4\NNP|and (r_conj) sodium_2\NN|of (r_nmod) affinities_5\NNS|NONE (r_pobj) of_1\IN|.|during (r_prep) Changes_0\NNS|NONE (l_prep) during_13\IN|of|. (l_conj) after_15\IN|and (l_pobj) hypertension_19\NN|NONE
D000255_D006973 NONE ATP_20\NNP| (r_npadvmod) binding_22\VBG|the (r_amod) site_23\NN|NONE (r_pobj) of_18\IN|higher (r_prep) affinity_17\NN|to (r_pobj) due_14\IN|,|,|(|K)ATPase|,|Na (r_prep) increased_12\VBD|After|of|.|revealed|,|the (r_parataxis) activity_6\NN|NONE (l_prep) After_0\IN|increased|of|.|revealed|,|the (l_pobj) recovery_1\NN|NONE (l_prep) from_2\IN|NONE (l_pobj) hypertension_3\NN|NONE
D000255_D006973 NONE ATP_33\NNP|NONE (r_pobj) for_32\IN|the|Km|lowered (r_prep) value_31\NN|NONE (r_pobj) from_27\IN|as (r_prep) revealed_26\VBN|After|increased|of|.|,|the (r_advcl) activity_6\NN|NONE (l_prep) After_0\IN|increased|of|.|revealed|,|the (l_pobj) recovery_1\NN|NONE (l_prep) from_2\IN|NONE (l_pobj) hypertension_3\NN|NONE
D009569_D003866 NONE NO_2\JJ| (r_compound) synthase_4\NN|NONE (r_pobj) of_1\IN|NONE (r_prep) Inhibition_0\NN|hypertension|. (r_nsubj) induced_5\VBD|NONE (l_dobj) hypertension_8\NN|Inhibition|. (l_acl) accompanied_9\VBN|a|reversible (l_agent) by_10\IN|from|as (l_pobj) Na+-extrusion_12\NN|NONE (l_amod) depressed_11\JJ|NONE
D011188_D006973 NONE K)-ATPase_12\NNP|NONE (r_pobj) of_6\IN|sodium (r_prep) affinities_5\NNS|NONE (r_pobj) of_1\IN|.|during (r_prep) Changes_0\NNS|NONE (l_prep) during_13\IN|of|. (l_conj) after_15\IN|and (l_pobj) hypertension_19\NN|NONE
D011188_D006973 NONE K)-ATPase_22\NNP|NONE (l_prep) to_23\IN|(|,|cardiac|Na (l_pobj) hypertension_27\NN|NONE
D011188_D006973 NONE K)-ATPase_11\NNP|,|,|(|due|,|Na (r_nsubj) increased_12\VBD|After|of|.|revealed|,|the (r_parataxis) activity_6\NN|NONE (l_prep) After_0\IN|increased|of|.|revealed|,|the (l_pobj) recovery_1\NN|NONE (l_prep) from_2\IN|NONE (l_pobj) hypertension_3\NN|NONE
D011188_D006973 NONE K)-ATPase_28\NNP|NONE (r_pobj) of_23\IN|Na+binding|deteriorated (r_prep) properties_22\NNS|NONE (r_pobj) of_19\IN|a (r_prep) consequence_18\NN|NONE (r_pobj) as_16\IN|from|by (r_prep) accompanied_9\VBN|a|reversible (r_acl) hypertension_8\NN|Inhibition|.
18791946
D002939_D007565 CID ciprofloxacin_16\NNS|NONE (r_pobj) of_14\IN|day|for (r_prep) administration_13\NN|NONE (r_pobj) after_11\IN|with|.|man (r_prep) reported_5\VBN|NONE (l_prep) with_6\IN|.|man|after (l_pobj) pain_8\NN|NONE (l_conj) jaundice_10\NN|and|abdominal
D002939_D014552 NONE ciprofloxacin_16\NNS|NONE (r_pobj) of_14\IN|day|for (r_prep) administration_13\NN|NONE (l_prep) for_17\IN|day|of (l_pobj) suspect_19\NN|NONE (l_prep) of_20\IN|a (l_pobj) infection_23\NN|NONE
D002939_D015746 CID ciprofloxacin_16\NNS|NONE (r_pobj) of_14\IN|day|for (r_prep) administration_13\NN|NONE (r_pobj) after_11\IN|with|.|man (r_prep) reported_5\VBN|NONE (l_prep) with_6\IN|.|man|after (l_pobj) pain_8\NN|NONE
D002939_D000743 CID ciprofloxacin_7\NNS|NONE (r_pobj) with_6\IN|NONE (r_prep) associated_5\VBN|Severe|anaemia|and (r_acl) thrombocytopenia_1\JJ|.|with|a|case|: (l_conj) anaemia_4\NN|Severe|associated|and
D002939_D000743 CID ciprofloxacin_5\NNS|,|may|in|thrombocytopenia|that (r_nsubj) precipitate_7\VB|.|report (l_dobj) thrombocytopenia_11\JJ|,|may|in|ciprofloxacin|that (l_conj) anaemia_14\NN|and|threatening
D002939_D013921 CID ciprofloxacin_7\NNS|NONE (r_pobj) with_6\IN|NONE (r_prep) associated_5\VBN|Severe|anaemia|and (r_acl) thrombocytopenia_1\JJ|.|with|a|case|:
D002939_D013921 CID ciprofloxacin_5\NNS|,|may|in|thrombocytopenia|that (r_nsubj) precipitate_7\VB|.|report (l_dobj) thrombocytopenia_11\JJ|,|may|in|ciprofloxacin|that
1420741
D016572_D003424 NONE cyclosporin_16\NN|NONE (r_pobj) to_15\IN|NONE (r_prep) similar_14\JJ|immunosuppressive (r_amod) properties_13\NNS|NONE (r_pobj) with_11\IN|an (r_prep) antibiotic_10\NN|:|of|. (r_appos) Treatment_0\NN|NONE (l_prep) of_1\IN|:|antibiotic|. (l_pobj) disease_4\NN|NONE
D005672_D015212 NONE acid_13\NN|NONE (r_pobj) of_11\IN|the|at (r_prep) use_10\NN|NONE (l_prep) at_14\IN|the|of (l_pobj) level_17\NN|NONE (l_prep) in_18\IN|the|cytokine (l_pobj) disease_21\NN|NONE
D005672_D003424 NONE acid_7\NN|NONE (r_pobj) with_5\IN|Crohn (r_prep) disease_4\NN|NONE
D005672_D003424 NONE acid_28\NN|fusidic|in (r_compound) treatment_29\NN|NONE (r_pobj) of_26\IN|NONE (r_prep) tolerability_25\NN|the|and (r_conj) pharmacodynamics_23\NNS|to (r_dobj) estimate_21\VB|,|.|study|Because|was (r_advcl) undertaken_19\VBN|NONE (l_prep) Because_0\IN|,|.|estimate|study|was (l_pobj) need_3\NN|of (l_prep) for_4\IN|the (l_pobj) development_6\NN|NONE (l_prep) of_7\IN|the (l_pobj) treatments_9\NNS|NONE (l_prep) for_10\IN|new (l_pobj) disease_13\NN|NONE
D005672_D003424 NONE acid_9\NN|that|of|may|fusidic|in (r_nsubj) be_11\VB|results|. (l_prep) in_14\IN|that|acid|of|may|fusidic (l_pobj) patients_21\NNS|NONE (l_compound) disease_20\NN|Crohn|selected|chronic|active|is
3780846
D006220_D009127 CID haloperidol_7\NN|In|was|,|in|. (r_nsubjpass) used_14\VBN|NONE (l_prep) in_15\IN|In|was|haloperidol|,|. (l_pobj) order_16\NN|NONE (l_acl) block_18\VB|NONE (l_conj) estimate_24\VB|and|activation|to (l_dobj) degree_27\NN|to (l_prep) of_28\IN|real|the (l_pobj) tolerance_30\NN|NONE (l_prep) to_31\IN|the (l_pobj) rigidity_33\NN|NONE
D006220_D009127 CID Haloperidol_0\NNP|rigidity|. (r_nsubj) enhanced_1\VBD|NONE (l_dobj) rigidity_3\NN|Haloperidol|.
D009020_D018476 CID morphine_6\NN|NONE (r_pobj) with_5\IN|for|Rats|showed|.|h|showed|and|withdrawn (r_prep) treated_1\VBD|NONE (l_conj) showed_27\VBD|for|Rats|.|h|showed|and|withdrawn|with (l_prep) after_30\IN|half|rigidity (l_pobj) dose_33\NN|NONE (l_relcl) was_37\VBD|of|the|test|group (l_conj) were_46\VBD|not|that|less|and (l_acomp) akinetic_47\JJ|NONE
D009020_D018476 CID morphine_35\NN|NONE (r_pobj) of_34\IN|the|test|was|group (r_prep) dose_33\NN|NONE (l_relcl) was_37\VBD|of|the|test|group (l_conj) were_46\VBD|not|that|less|and (l_acomp) akinetic_47\JJ|NONE
D009020_D009127 CID morphine_14\NN|NONE (r_pobj) by_13\IN|in (r_agent) produced_12\VBN|muscular|the (r_acl) rigidity_11\NN|NONE
D009020_D009127 CID morphine_10\NN|NONE (r_pobj) by_9\IN|NONE (r_agent) produced_8\VBN|muscular|the (r_acl) rigidity_7\NN|NONE
D009020_D009127 CID morphine_9\NN|NONE (r_pobj) of_8\IN|a|test|)|mg/kg|( (r_prep) dose_7\NN|controls (r_dobj) given_4\VBN|.|rigidity (r_csubj) showed_15\VBD|NONE (l_dobj) rigidity_18\NN|.|given
D009020_D009127 CID morphine_6\NN|NONE (r_pobj) with_5\IN|for|Rats|showed|.|h|showed|and|withdrawn (r_prep) treated_1\VBD|NONE (l_conj) showed_27\VBD|for|Rats|.|h|showed|and|withdrawn|with (l_dobj) rigidity_29\NN|half|after
D009020_D009127 CID morphine_35\NN|NONE (r_pobj) of_34\IN|the|test|was|group (r_prep) dose_33\NN|NONE (r_pobj) after_30\IN|half|rigidity (r_prep) showed_27\VBD|for|Rats|.|h|showed|and|withdrawn|with (l_dobj) rigidity_29\NN|half|after
D009020_D009127 CID morphine_16\NN|NONE (r_pobj) of_15\IN|in|an (r_prep) action_14\NN|NONE (r_pobj) to_12\IN|NONE (r_prep) due_11\JJ|to (r_acomp) be_10\VB|which|is (r_xcomp) assumed_8\VBN|,|, (r_relcl) rigidity_4\NN|that|be|can|by
354896
D008012_D003866 NONE lidocaine_8\NN|NONE (r_pobj) of_7\IN|a|mg|in|single (r_prep) bolus_6\NN|NONE (r_pobj) of_2\IN|Intravenous (r_prep) administration_1\NN|in|. (r_nsubj) resulted_15\VBD|NONE (l_prep) in_16\IN|administration|. (l_pobj) depression_18\NN|NONE
D008012_D006323 CID Lidocaine_0\NN| (r_npadvmod) induced_2\VBN|.|cardiac (r_amod) asystole_4\NN|NONE
D008012_D001919 NONE lidocaine_29\NN|NONE (r_pobj) to_28\IN|a|true (r_prep) idiosyncrasy_27\NN|,|,|this|probably|.|thus (r_dobj) represented_24\VBD|;|conditions|patient|and (r_conj) had_2\VBD|NONE (l_dobj) conditions_6\NNS|;|patient|represented|and (l_relcl) predisposed_10\VBN|associated|no|apparent (l_prep) to_12\IN|him|which|might|have (l_pobj) development_14\NN|NONE (l_prep) of_15\IN|the (l_pobj) bradyarrhythmias_16\NNS|NONE
15957009
D014236_D008569 NONE metrifonate_15\NN|(|,||p.o.|intraperitoneally|mg/kg|and (r_conj) Ro4368554_2\NNP|deficits|Both|)|,|. (r_nsubj) reversed_24\VBD|NONE (l_dobj) deficits_26\NNS|Both|)|,|Ro|.
D014364_D008569 NONE TRP_31\NNP|NONE (r_compound) depletion_32\NN|(|mg/kg|,|i.p.|mg/kg|and|and|, (r_conj) scopolamine_29\NN|NONE (r_pobj) by_28\IN|NONE (r_agent) induced_27\VBN|memory (r_acl) deficits_26\NNS|Both|)|,|Ro|.
D012601_D008569 CID scopolamine_29\NN|NONE (r_pobj) by_28\IN|NONE (r_agent) induced_27\VBN|memory (r_acl) deficits_26\NNS|Both|)|,|Ro|.
D012701_D008569 NONE 5-HT(6_45\CD|,|possibly|,|other|receptor (r_compound) antagonists_48\NNS|be|in|that|may|mechanisms|and (r_conj) involved_31\VBN|NONE (r_ccomp) suggesting_25\VBG|,|,|.|,|In|improve|it|cholinergic (r_advcl) reversed_16\VBD|NONE (l_dobj) cholinergic_18\JJ|,|,|.|,|In|suggesting|improve|it (l_conj) deficit_23\NN|and|a
C507242_D008569 NONE Ro4368554_5\NN|performance|.|antagonist|in (r_nsubj) restores_6\VBZ|NONE (l_prep) in_9\IN|performance|.|Ro|antagonist (l_pobj) models_13\NNS|NONE (l_prep) of_14\IN|in|cholinergic (l_pobj) deficiency_16\NN|NONE
C507242_D008569 NONE Ro4368554_2\NNP|deficits|Both|)|,|. (r_nsubj) reversed_24\VBD|NONE (l_dobj) deficits_26\NNS|Both|)|,|Ro|.
C507242_D008569 NONE Ro4368554_4\NN|not|although|did|deficit (r_nsubj) improve_7\VB|,|,|.|,|In|suggesting|it|cholinergic (r_advcl) reversed_16\VBD|NONE (l_dobj) cholinergic_18\JJ|,|,|.|,|In|suggesting|improve|it (l_conj) deficit_23\NN|and|a
C507242_D008569 NONE Ro4368554_39\NN|NONE (r_pobj) by_38\IN|of|the (r_prep) facilitation_34\NN|NONE (r_pobj) in_32\IN|be|that|may|antagonists|mechanisms|and (r_prep) involved_31\VBN|NONE (r_ccomp) suggesting_25\VBG|,|,|.|,|In|improve|it|cholinergic (r_advcl) reversed_16\VBD|NONE (l_dobj) cholinergic_18\JJ|,|,|.|,|In|suggesting|improve|it (l_conj) deficit_23\NN|and|a
6111982
D010869_D001145 NONE pindolol_8\NN|and (l_xcomp) inhibiting_9\VBG|NONE (l_dobj) arrhythmia_12\NN|in
D010042_D001145 CID ouabain_11\JJ|the (r_compound) arrhythmia_12\NN|in
D011433_D001145 NONE propranolol_6\NN|NONE (l_conj) pindolol_8\NN|and (l_xcomp) inhibiting_9\VBG|NONE (l_dobj) arrhythmia_12\NN|in
11391224
D003042_D057049 NONE cocaine_23\NN| (r_npadvmod) related_25\VBN|renal|acute (r_amod) failure_28\NN|crescentic|,|and (r_conj) glomerulonephritis_20\NN|Schonlein|, (r_conj) nephritis_17\NN|, (r_conj) nephritis_12\NN|microangiopathy (r_dobj) lupus_11\NN|.|,||cases (l_nsubj) microangiopathy_9\NN|nephritis
D003042_D006974 NONE cocaine_23\NN| (r_npadvmod) related_25\VBN|renal|acute (r_amod) failure_28\NN|crescentic|,|and (r_conj) glomerulonephritis_20\NN|Schonlein|, (r_conj) nephritis_17\NN|, (r_conj) nephritis_12\NN|microangiopathy (r_dobj) lupus_11\NN|.|,||cases (r_conj) included_2\VBD|NONE (l_dobj) cases_3\NNS|.|lupus|,| (l_prep) of_4\IN|NONE (l_pobj) hypertension_6\NN|NONE
D003042_D008181 NONE cocaine_23\NN| (r_npadvmod) related_25\VBN|renal|acute (r_amod) failure_28\NN|crescentic|,|and (r_conj) glomerulonephritis_20\NN|Schonlein|, (r_conj) nephritis_17\NN|, (r_conj) nephritis_12\NN|microangiopathy
D003042_D011695 NONE cocaine_23\NN| (r_npadvmod) related_25\VBN|renal|acute (r_amod) failure_28\NN|crescentic|,|and (r_conj) glomerulonephritis_20\NN|Schonlein|, (r_conj) nephritis_17\NN|,
D003042_D005921 NONE cocaine_23\NN| (r_npadvmod) related_25\VBN|renal|acute (r_amod) failure_28\NN|crescentic|,|and (r_conj) glomerulonephritis_20\NN|Schonlein|,
D003042_D058186 CID cocaine_23\NN| (r_npadvmod) related_25\VBN|renal|acute (r_amod) failure_28\NN|crescentic|,|and
10835440
D009553_D007022 CID Nimodipine_2\NNP|Stroke|INWEST|)|Intravenous|West|European|The|( (r_compound) Trial_6\NN|correlation|. (r_nsubj) found_10\VBD|NONE (l_dobj) correlation_12\NN|Trial|. (l_prep) between_13\IN|a (l_pobj) reduction_17\NN|NONE (l_prep) in_18\IN|outcome|and|induced (l_pobj) pressure_20\NN|NONE
D009553_D007022 CID nimodipine_14\NN| (r_npadvmod) induced_16\VBN|in|outcome|and (r_amod) reduction_17\NN|NONE (l_prep) in_18\IN|outcome|and|induced (l_pobj) pressure_20\NN|NONE
D009553_D007022 CID Nimodipine_0\NNP|NONE (r_compound) treatment_1\NN|.|in (r_nsubj) resulted_2\VBD|NONE (l_prep) in_3\IN|treatment|. (l_pobj) reduction_7\NN|NONE (l_prep) in_8\IN|significant|a (l_pobj) BP_10\NNP|NONE
D009553_D020521 NONE nimodipine_3\NN|NONE (r_pobj) of_1\IN|after|. (r_prep) Effect_0\NN|NONE (l_prep) after_9\IN|of|. (l_pobj) stroke_11\NN|NONE
D009553_D020521 NONE Nimodipine_2\NNP|Stroke|INWEST|)|Intravenous|West|European|The|( (r_compound) Trial_6\NN|correlation|. (l_compound) Stroke_5\NNP|Nimodipine|INWEST|)|Intravenous|West|European|The|(
D009553_D020521 NONE Nimodipine_2\NNP|Stroke|INWEST|)|Intravenous|West|European|The|( (r_compound) Trial_6\NN|correlation|. (r_nsubj) found_10\VBD|NONE (l_dobj) correlation_12\NN|Trial|. (l_prep) between_13\IN|a (l_pobj) reduction_17\NN|NONE (l_conj) outcome_27\NN|in|and|induced (l_prep) in_28\IN|an|unfavorable (l_pobj) stroke_30\NN|NONE
D009553_D020521 NONE nimodipine_14\NN| (r_npadvmod) induced_16\VBN|in|outcome|and (r_amod) reduction_17\NN|NONE (r_pobj) between_13\IN|a (r_prep) correlation_12\NN|Trial|. (r_dobj) found_10\VBD|NONE (l_nsubj) Trial_6\NN|correlation|. (l_compound) Stroke_5\NNP|Nimodipine|INWEST|)|Intravenous|West|European|The|(
D009553_D020521 NONE nimodipine_14\NN| (r_npadvmod) induced_16\VBN|in|outcome|and (r_amod) reduction_17\NN|NONE (l_conj) outcome_27\NN|in|and|induced (l_prep) in_28\IN|an|unfavorable (l_pobj) stroke_30\NN|NONE
D009553_D020521 NONE nimodipine_15\NN|NONE (r_pobj) of_11\IN|the|intravenous (r_prep) administration_10\NN|NONE (r_pobj) after_7\IN|after|neurological (r_prep) worsening_6\VBG|NONE (l_prep) after_16\IN|after|neurological (l_pobj) stroke_18\NN|NONE
D009553_D002544 NONE nimodipine_34\NN|/|mg| (r_parataxis) h_28\NN|placebo|,|to (r_appos) receive_19\VB|METHODS|consecutively|.|were (r_advcl) allocated_17\VBN|NONE (l_nsubjpass) METHODS_0\NNS|receive|consecutively|.|were (l_appos) Patients_2\NNS|: (l_prep) with_3\IN|within|)|( (l_pobj) diagnosis_6\NN|NONE (l_prep) of_7\IN|a|clinical (l_pobj) stroke_9\NN|NONE
D009553_D002544 NONE nimodipine_49\NN|dose|n=|(|)|or (r_conj) nimodipine_34\NN|/|mg| (r_parataxis) h_28\NN|placebo|,|to (r_appos) receive_19\VB|METHODS|consecutively|.|were (r_advcl) allocated_17\VBN|NONE (l_nsubjpass) METHODS_0\NNS|receive|consecutively|.|were (l_appos) Patients_2\NNS|: (l_prep) with_3\IN|within|)|( (l_pobj) diagnosis_6\NN|NONE (l_prep) of_7\IN|a|clinical (l_pobj) stroke_9\NN|NONE
3125768
D015760_D009127 CID alfentanil_4\NN| (r_npadvmod) induced_6\VBN|NONE (r_amod) rigidity_7\NN|NONE
D015760_D009127 CID alfentanil_8\NN| (r_npadvmod) induced_10\VBN|in (r_amod) rigidity_11\NN|NONE
D015760_D009127 CID alfentanil_9\NN|rigidity|used|and|be|,|that|should|, (r_advcl) prevented_7\VBN|.|observations (l_nsubjpass) rigidity_4\NN|used|and|be|,|that|alfentanil|should|,
C032943_D009127 NONE metocurine_10\NN|NONE (r_pobj) with_9\IN|was|rigidity|when (r_prep) abolished_8\VBN|.|variables|to (l_nsubjpass) rigidity_6\NN|was|with|when
227508
D008750_D007022 CID methyldopa_8\NN|NONE (r_pobj) of_3\IN|The|hypotensive (r_prep) effect_2\NN|partially|.|was|also|by (l_amod) hypotensive_1\JJ|The|of
D009270_D007022 NONE naloxone_14\NN|NONE (r_pobj) by_13\IN|partially|.|effect|was|also (r_agent) reversed_12\VBN|NONE (l_nsubjpass) effect_2\NN|partially|.|was|also|by (l_amod) hypotensive_1\JJ|The|of
D003000_D006973 NONE clonidine_17\NN|NONE (r_pobj) by_15\IN|NONE (r_agent) produced_14\VBN|and|blood|rate (r_acl) pressure_10\NN|NONE (r_pobj) in_8\IN|the (r_prep) decrease_7\NN|In|inhibited|,|,|hypertensive|. (r_dobj) rats_5\NNS|NONE (l_amod) hypertensive_4\JJ|In|inhibited|,|,|.|decrease
D003000_D006973 NONE clonidine_7\NN|membranes (r_preconj) In_0\IN|not|did|influence|,|,|and|binding (l_pobj) membranes_2\NNS|clonidine (l_prep) from_3\IN|brain (l_pobj) rats_6\NNS|NONE (l_amod) hypertensive_5\JJ|NONE
D003000_D006973 NONE clonidine_42\NN| (r_npadvmod) suppressible_44\NN|of (r_amod) binding_45\NN|naloxone|)|.|did|not (r_dobj) influence_41\VB|not|did|,|In|,|and|binding (r_conj) influence_18\VB|NONE (l_prep) In_0\IN|not|did|influence|,|,|and|binding (l_pobj) membranes_2\NNS|clonidine (l_prep) from_3\IN|brain (l_pobj) rats_6\NNS|NONE (l_amod) hypertensive_5\JJ|NONE
D009270_D006973 NONE naloxone_30\NN|)|.|did|not|binding (r_nsubj) influence_41\VB|not|did|,|In|,|and|binding (r_conj) influence_18\VB|NONE (l_prep) In_0\IN|not|did|influence|,|,|and|binding (l_pobj) membranes_2\NNS|clonidine (l_prep) from_3\IN|brain (l_pobj) rats_6\NNS|NONE (l_amod) hypertensive_5\JJ|NONE
-1_D006973 NONE nalozone_31\NN|NONE (r_pobj) by_30\IN|NONE (r_agent) reversed_29\VBN|was|micrograms|mg/kg|or|,|, (r_conj) inhibited_27\VBN|In|,|,|hypertensive|.|decrease (r_conj) rats_5\NNS|NONE (l_amod) hypertensive_4\JJ|In|inhibited|,|,|.|decrease
-1_D006973 NONE 3H]-naloxone_23\CD|NONE (r_pobj) of_21\IN|stereoselective (r_prep) binding_20\NN|not|did|influence|,|In|,|and (r_dobj) influence_18\VB|NONE (l_prep) In_0\IN|not|did|influence|,|,|and|binding (l_pobj) membranes_2\NNS|clonidine (l_prep) from_3\IN|brain (l_pobj) rats_6\NNS|NONE (l_amod) hypertensive_5\JJ|NONE
-1_D006973 NONE 3H]-dihydroergocryptine_48\CD|(| (r_nummod) nM_51\NNP|NONE (r_pobj) of_46\IN|suppressible (r_prep) binding_45\NN|naloxone|)|.|did|not (r_dobj) influence_41\VB|not|did|,|In|,|and|binding (r_conj) influence_18\VB|NONE (l_prep) In_0\IN|not|did|influence|,|,|and|binding (l_pobj) membranes_2\NNS|clonidine (l_prep) from_3\IN|brain (l_pobj) rats_6\NNS|NONE (l_amod) hypertensive_5\JJ|NONE
7628595
D015215_D001855 CID zidovudine_20\NNP|(|marrow|ZDV)induced (r_nmod) suppression_25\NN|NONE
D015215_D001855 CID ZDV)-induced_22\VBN|(|marrow|zidovudine (r_amod) suppression_25\NN|NONE
D015215_D001855 CID ZDV_7\NNP|NONE (r_compound) therapy_8\NN|NONE (r_pobj) of_6\IN|acid|folinic (r_prep) supplementation_5\NN|Vitamin|and (r_conj) B12_1\NN|does|,|.|useful|excluded|not (r_nsubj) seem_11\VB|NONE (l_oprd) useful_12\JJ|does|,|B|.|excluded|not (l_prep) in_13\IN|NONE (l_pcomp) preventing_14\VBG|NONE (l_conj) reducing_16\VBG|or (l_dobj) myelotoxicity_20\NN|in
D015215_D001855 CID ZDV_17\NNP| (r_npadvmod) induced_19\VBN|NONE (r_amod) myelotoxicity_20\NN|in
D014805_D064420 NONE B12_6\NN|NONE (l_conj) supplementation_10\NN|and|vitamin (l_prep) in_11\IN|folinic|acid (l_pcomp) preventing_12\VBG|NONE (l_dobj) toxicity_14\NN|NONE
D015215_D064420 NONE zidovudine_16\NN|NONE (r_pobj) of_15\IN|hematologic (r_prep) toxicity_14\NN|NONE
D005492_D001855 NONE folate_8\JJ|development|and (r_compound) levels_9\NNS|vitamin|or (l_conj) development_11\NN|and|folate (l_prep) of_12\IN|NONE (l_pobj) myelosuppression_13\NN|NONE
D002955_D001855 NONE acid_16\NN|folinic|in (r_compound) supplementation_17\NN|and|vitamin (l_prep) in_18\IN|folinic|acid (l_pcomp) preventing_19\VBG|NONE (l_dobj) suppression_25\NN|NONE
D002955_D001855 NONE acid_4\NN|of|folinic (r_compound) supplementation_5\NN|Vitamin|and (r_conj) B12_1\NN|does|,|.|useful|excluded|not (r_nsubj) seem_11\VB|NONE (l_oprd) useful_12\JJ|does|,|B|.|excluded|not (l_prep) in_13\IN|NONE (l_pcomp) preventing_14\VBG|NONE (l_conj) reducing_16\VBG|or (l_dobj) myelotoxicity_20\NN|in
D015215_D015658 NONE ZDV_21\NNP|alone|to (r_dobj) receive_19\VB|were|virus (r_xcomp) randomized_17\VBN|NONE (l_nsubjpass) virus_5\NN|were|receive (l_appos) patients_8\NNS|immunodeficiency|five|human (l_amod) HIV)-infected_7\VBN|with|(
D014805_D001855 NONE B12_13\NN|NONE (l_conj) supplementation_17\NN|and|vitamin (l_prep) in_18\IN|folinic|acid (l_pcomp) preventing_19\VBG|NONE (l_dobj) suppression_25\NN|NONE
D014805_D001855 NONE B12_6\NN|NONE (l_conj) levels_9\NNS|vitamin|or (l_conj) development_11\NN|and|folate (l_prep) of_12\IN|NONE (l_pobj) myelosuppression_13\NN|NONE
D014805_D001855 NONE B12_1\NN|does|,|.|useful|excluded|not (r_nsubj) seem_11\VB|NONE (l_oprd) useful_12\JJ|does|,|B|.|excluded|not (l_prep) in_13\IN|NONE (l_pcomp) preventing_14\VBG|NONE (l_conj) reducing_16\VBG|or (l_dobj) myelotoxicity_20\NN|in
D002955_D064420 NONE acid_9\NN|folinic|in (r_compound) supplementation_10\NN|and|vitamin (l_prep) in_11\IN|folinic|acid (l_pcomp) preventing_12\VBG|NONE (l_dobj) toxicity_14\NN|NONE
15036754
D010755_D012640 NONE Organophosphate_0\NNP| (r_npadvmod) induced_2\VBN|prevention|and|of|. (r_amod) convulsions_3\NNS|NONE
C048599_D011041 NONE CPA_1\NN|,|diazepam|immediately|after|was|When (r_nsubjpass) given_7\VBN|.|delayed|,|,|treatments (r_advcl) prevented_16\VBD|NONE (l_conj) delayed_18\VBN|.|,|given|,|treatments (l_conj) shortened_20\VBN|or (l_dobj) occurrence_22\NN|NONE (l_prep) of_23\IN|the (l_pobj) signs_25\NNS|NONE (l_prep) of_26\IN|serious (l_pobj) poisoning_27\NN|NONE
C048599_D011041 NONE CPA_3\NN|In|reduced|occurrence|.|,|and (r_nsubj) prevented_12\VBD|NONE (l_dobj) occurrence_14\NN|In|reduced|.|,|CPA|and (l_prep) of_15\IN|the (l_pobj) signs_17\NNS|NONE (l_prep) of_18\IN|serious (l_pobj) poisoning_19\NN|NONE
D010755_D004194 NONE Organophosphate_0\NNP| (r_npadvmod) induced_2\VBN|prevention|and|of|. (r_amod) convulsions_3\NNS|NONE (l_prep) of_6\IN|prevention|and|.|induced (l_pobj) damages_8\NNS|NONE
D010755_D064420 NONE OPs_4\NNS|NONE (r_pobj) of_3\IN|acute|The (r_prep) toxicity_2\NN|result|.
D010755_D064420 NONE OP_10\NN| (r_npadvmod) induced_12\VBN|typical|toxicity|severe (r_amod) signs_14\NNS|NONE (l_compound) toxicity_13\NN|typical|severe|induced
D007531_D064420 NONE DFP_4\NNP| (r_compound) atropine_6\NN|NONE (r_pobj) with_3\IN|showed|rats|. (r_prep) treated_2\VBD|NONE (l_conj) showed_7\VBD|rats|.|with (l_dobj) signs_14\NNS|NONE (l_compound) toxicity_13\NN|typical|severe|induced
D007531_D064420 NONE DFP_10\NNP|NONE (r_compound) toxicity_11\NN|NONE
D007531_D064420 NONE DFP_26\NNP|NONE (r_pobj) of_25\IN|in|the (r_prep) toxicity_24\NN|thus
D007531_D011041 NONE DFP_10\NNP| (r_compound) atropine_12\NN|NONE (r_pobj) after_9\IN|,|CPA|diazepam|immediately|was|When (r_prep) given_7\VBN|.|delayed|,|,|treatments (r_advcl) prevented_16\VBD|NONE (l_conj) delayed_18\VBN|.|,|given|,|treatments (l_conj) shortened_20\VBN|or (l_dobj) occurrence_22\NN|NONE (l_prep) of_23\IN|the (l_pobj) signs_25\NNS|NONE (l_prep) of_26\IN|serious (l_pobj) poisoning_27\NN|NONE
D007531_D011041 NONE DFP_26\NNP|NONE (r_pobj) of_25\IN|in|the (r_prep) toxicity_24\NN|thus (r_dobj) reduced_22\VBD|In|occurrence|.|,|CPA|and (r_conj) prevented_12\VBD|NONE (l_dobj) occurrence_14\NN|In|reduced|.|,|CPA|and (l_prep) of_15\IN|the (l_pobj) signs_17\NNS|NONE (l_prep) of_18\IN|serious (l_pobj) poisoning_19\NN|NONE
D003975_D011041 NONE diazepam_3\NN|,|CPA|immediately|after|was|When (r_nsubjpass) given_7\VBN|.|delayed|,|,|treatments (r_advcl) prevented_16\VBD|NONE (l_conj) delayed_18\VBN|.|,|given|,|treatments (l_conj) shortened_20\VBN|or (l_dobj) occurrence_22\NN|NONE (l_prep) of_23\IN|the (l_pobj) signs_25\NNS|NONE (l_prep) of_26\IN|serious (l_pobj) poisoning_27\NN|NONE
D003975_D011041 NONE diazepam_5\NN|, (r_conj) CPA_3\NN|In|reduced|occurrence|.|,|and (r_nsubj) prevented_12\VBD|NONE (l_dobj) occurrence_14\NN|In|reduced|.|,|CPA|and (l_prep) of_15\IN|the (l_pobj) signs_17\NNS|NONE (l_prep) of_18\IN|serious (l_pobj) poisoning_19\NN|NONE
D001285_D064420 NONE atropine_6\NN|NONE (r_pobj) with_3\IN|showed|rats|. (r_prep) treated_2\VBD|NONE (l_conj) showed_7\VBD|rats|.|with (l_dobj) signs_14\NNS|NONE (l_compound) toxicity_13\NN|typical|severe|induced
D001285_D064420 NONE Atropine_0\NNP| (r_compound) MK801_2\NNP|.|protection|did|not (r_nsubj) offer_5\VB|NONE (l_dobj) protection_8\NN|.|MK|did|not (l_prep) against_9\IN|additional|any (l_pobj) toxicity_11\NN|NONE
D001285_D064420 NONE atropine_11\NN|NONE (r_pobj) with_10\IN|NONE (r_prep) combination_9\NN|NONE (r_pobj) in_8\IN|and|PAM (r_prep) diazepam_5\NN|, (r_conj) CPA_3\NN|In|reduced|occurrence|.|,|and (r_nsubj) prevented_12\VBD|NONE (l_conj) reduced_22\VBD|In|occurrence|.|,|CPA|and (l_dobj) toxicity_24\NN|thus
D003975_D064420 NONE diazepam_5\NN|, (r_conj) CPA_3\NN|In|reduced|occurrence|.|,|and (r_nsubj) prevented_12\VBD|NONE (l_conj) reduced_22\VBD|In|occurrence|.|,|CPA|and (l_dobj) toxicity_24\NN|thus
D011220_D011041 NONE 2PAM_5\CD|or (r_conj) diazepam_3\NN|,|CPA|immediately|after|was|When (r_nsubjpass) given_7\VBN|.|delayed|,|,|treatments (r_advcl) prevented_16\VBD|NONE (l_conj) delayed_18\VBN|.|,|given|,|treatments (l_conj) shortened_20\VBN|or (l_dobj) occurrence_22\NN|NONE (l_prep) of_23\IN|the (l_pobj) signs_25\NNS|NONE (l_prep) of_26\IN|serious (l_pobj) poisoning_27\NN|NONE
D011220_D011041 NONE 2PAM_7\CD|and|in (r_conj) diazepam_5\NN|, (r_conj) CPA_3\NN|In|reduced|occurrence|.|,|and (r_nsubj) prevented_12\VBD|NONE (l_dobj) occurrence_14\NN|In|reduced|.|,|CPA|and (l_prep) of_15\IN|the (l_pobj) signs_17\NNS|NONE (l_prep) of_18\IN|serious (l_pobj) poisoning_19\NN|NONE
D000109_D064420 NONE acetylcholine_25\NN|)|ACh|( (r_nmod) levels_29\NNS|which (r_dobj) elevates_24\VBZ|(|central|)|,|CNS|nervous|the (r_relcl) system_18\NN|NONE (r_pobj) in_14\IN|NONE (r_prep) AChEs_13\NNP|NONE (r_pobj) with_12\IN|irreversible|their (r_prep) binding_11\NN|NONE (r_pobj) of_8\IN|the (r_prep) result_7\NN|.|toxicity (r_attr) is_5\VBZ|NONE (l_nsubj) toxicity_2\NN|result|.
D000109_D064420 NONE ACh_27\NNS|)|acetylcholine|( (r_nmod) levels_29\NNS|which (r_dobj) elevates_24\VBZ|(|central|)|,|CNS|nervous|the (r_relcl) system_18\NN|NONE (r_pobj) in_14\IN|NONE (r_prep) AChEs_13\NNP|NONE (r_pobj) with_12\IN|irreversible|their (r_prep) binding_11\NN|NONE (r_pobj) of_8\IN|the (r_prep) result_7\NN|.|toxicity (r_attr) is_5\VBZ|NONE (l_nsubj) toxicity_2\NN|result|.
D011220_D064420 NONE 2PAM_7\CD|and|in (r_conj) diazepam_5\NN|, (r_conj) CPA_3\NN|In|reduced|occurrence|.|,|and (r_nsubj) prevented_12\VBD|NONE (l_conj) reduced_22\VBD|In|occurrence|.|,|CPA|and (l_dobj) toxicity_24\NN|thus
D016291_D064420 NONE MK801_2\NNP|.|protection|did|not (r_nsubj) offer_5\VB|NONE (l_dobj) protection_8\NN|.|MK|did|not (l_prep) against_9\IN|additional|any (l_pobj) toxicity_11\NN|NONE
D001285_D011041 NONE atropine_12\NN|NONE (r_pobj) after_9\IN|,|CPA|diazepam|immediately|was|When (r_prep) given_7\VBN|.|delayed|,|,|treatments (r_advcl) prevented_16\VBD|NONE (l_conj) delayed_18\VBN|.|,|given|,|treatments (l_conj) shortened_20\VBN|or (l_dobj) occurrence_22\NN|NONE (l_prep) of_23\IN|the (l_pobj) signs_25\NNS|NONE (l_prep) of_26\IN|serious (l_pobj) poisoning_27\NN|NONE
D001285_D011041 NONE atropine_11\NN|NONE (r_pobj) with_10\IN|NONE (r_prep) combination_9\NN|NONE (r_pobj) in_8\IN|and|PAM (r_prep) diazepam_5\NN|, (r_conj) CPA_3\NN|In|reduced|occurrence|.|,|and (r_nsubj) prevented_12\VBD|NONE (l_dobj) occurrence_14\NN|In|reduced|.|,|CPA|and (l_prep) of_15\IN|the (l_pobj) signs_17\NNS|NONE (l_prep) of_18\IN|serious (l_pobj) poisoning_19\NN|NONE
C048599_D064420 NONE CPA_3\NN|In|reduced|occurrence|.|,|and (r_nsubj) prevented_12\VBD|NONE (l_conj) reduced_22\VBD|In|occurrence|.|,|CPA|and (l_dobj) toxicity_24\NN|thus
8864707
D010672_D004827 NONE phenytoin_10\NNP|NONE (r_compound) overdosages_11\NNS|NONE (r_pobj) after_9\IN|resonance|in|.|of (r_prep) volumetry_2\NN|NONE (l_prep) in_6\IN|resonance|after|.|of (l_pobj) patients_8\NNS|NONE (l_amod) epileptic_7\JJ|NONE
D010672_D002526 NONE phenytoin_11\JJ|and|atrophy (r_compound) medication_12\NN|NONE (l_conj) atrophy_15\NN|and|phenytoin
D010672_D002526 NONE phenytoin_3\JJ|NONE (r_compound) overdosage_4\NN|and|in|does|necessarily|not|that|is (r_nsubj) result_8\VB|We|. (l_prep) in_9\IN|and|overdosage|does|necessarily|not|that|is (l_pobj) atrophy_11\NN|NONE
D010672_D002526 NONE phenytoin_3\JJ|NONE (r_compound) overdosage_4\NN|and|in|does|necessarily|not|that|is (r_nsubj) result_8\VB|We|. (l_conj) is_14\VBZ|and|in|overdosage|does|necessarily|not|that (l_ccomp) was_19\VBD|unlikely|it (l_attr) cause_22\NN|that|medication (l_prep) of_23\IN|only|the (l_pobj) atrophy_25\NN|NONE
D010672_D002526 NONE phenytoin_17\JJ|NONE (r_compound) medication_18\NN|that|cause (r_nsubj) was_19\VBD|unlikely|it (r_ccomp) is_14\VBZ|and|in|overdosage|does|necessarily|not|that (r_conj) result_8\VB|We|. (l_prep) in_9\IN|and|overdosage|does|necessarily|not|that|is (l_pobj) atrophy_11\NN|NONE
D010672_D002526 NONE phenytoin_17\JJ|NONE (r_compound) medication_18\NN|that|cause (r_nsubj) was_19\VBD|unlikely|it (l_attr) cause_22\NN|that|medication (l_prep) of_23\IN|only|the (l_pobj) atrophy_25\NN|NONE
D010672_D062787 CID phenytoin_10\NNP|NONE (r_compound) overdosages_11\NNS|NONE
D010672_D062787 CID phenytoin_3\JJ|NONE (r_compound) overdosage_4\NN|and|in|does|necessarily|not|that|is
D010672_D062787 CID phenytoin_17\JJ|NONE (r_compound) medication_18\NN|that|cause (r_nsubj) was_19\VBD|unlikely|it (r_ccomp) is_14\VBZ|and|in|overdosage|does|necessarily|not|that (r_conj) result_8\VB|We|. (l_nsubj) overdosage_4\NN|and|in|does|necessarily|not|that|is
D010672_D012640 NONE phenytoin_15\JJ|volume|and|serum (r_compound) levels_17\NNS|NONE (r_pobj) of_14\IN|NONE (r_prep) elevation_13\NN|seizure|, (r_conj) duration_11\NN|NONE (l_compound) seizure_10\NN|,|elevation
11581460
D005283_D001745 CID fentanyl_22\NN|NONE (r_pobj) of_21\IN|continuous (r_prep) infusion_20\NN|NONE (r_pobj) of_18\IN|a (r_prep) result_17\NN|NONE (r_pobj) as_15\IN|hydronephrosis (r_prep) mimicking_13\VBG|pelvocalyceal|renal (r_acl) dilatation_12\NN|NONE (r_pobj) to_9\IN|NONE (r_prep) leading_8\VBG|of| (r_acl) cases_3\NNS|Here|.|are|, (l_prep) of_4\IN||leading (l_pobj) retention_7\NN|NONE
D005283_D009127 NONE fentanyl_5\NN|NONE (r_compound) administration_6\NN|NONE (r_pobj) of_4\IN|Various|reported|side (r_prep) effects_3\NNS|rigidity|. (r_nsubj) include_7\VBP|NONE (l_dobj) rigidity_10\NN|effects|.
D005283_D001919 CID fentanyl_5\NN|NONE (r_compound) administration_6\NN|NONE (r_pobj) of_4\IN|Various|reported|side (r_prep) effects_3\NNS|rigidity|. (r_nsubj) include_7\VBP|NONE (l_dobj) rigidity_10\NN|effects|. (l_conj) hypotension_12\NN|wall|chest|, (l_conj) depression_15\NN|, (l_conj) bradycardia_18\NN|respiratory|,|and
D005283_D007022 CID fentanyl_5\NN|NONE (r_compound) administration_6\NN|NONE (r_pobj) of_4\IN|Various|reported|side (r_prep) effects_3\NNS|rigidity|. (r_nsubj) include_7\VBP|NONE (l_dobj) rigidity_10\NN|effects|. (l_conj) hypotension_12\NN|wall|chest|,
D005283_D016055 CID fentanyl_12\NN|NONE (r_pobj) of_11\IN|continuous|intravenous (r_prep) infusion_10\NN|NONE (r_pobj) of_7\IN|a (r_prep) result_6\NN|NONE (r_pobj) as_4\IN|of|Bladder (r_prep) retention_1\NN|.|:|case (l_prep) of_2\IN|Bladder|as (l_pobj) urine_3\NN|NONE
D005283_D006869 NONE fentanyl_22\NN|NONE (r_pobj) of_21\IN|continuous (r_prep) infusion_20\NN|NONE (r_pobj) of_18\IN|a (r_prep) result_17\NN|NONE (r_pobj) as_15\IN|hydronephrosis (r_prep) mimicking_13\VBG|pelvocalyceal|renal (l_dobj) hydronephrosis_14\NN|as
D005283_D012131 CID fentanyl_5\NN|NONE (r_compound) administration_6\NN|NONE (r_pobj) of_4\IN|Various|reported|side (r_prep) effects_3\NNS|rigidity|. (r_nsubj) include_7\VBP|NONE (l_dobj) rigidity_10\NN|effects|. (l_conj) hypotension_12\NN|wall|chest|, (l_conj) depression_15\NN|,
10704919
D024502_D006461 NONE tocopherol_13\NN|NONE (r_pobj) of_10\IN|acetate|and|low (r_prep) concentrations_9\NNS|NONE (r_pobj) by_7\IN|indicating|inactivated|.|effect|is (r_agent) prevented_6\VBN|NONE (l_nsubjpass) effect_2\NN|indicating|inactivated|.|is|by (l_amod) hemolytic_1\JJ|The|of
D024502_D006461 NONE tocopherol_13\NN|NONE (r_pobj) of_10\IN|acetate|and|low (r_prep) concentrations_9\NNS|NONE (r_pobj) by_7\IN|indicating|inactivated|.|effect|is (r_agent) prevented_6\VBN|NONE (l_advcl) indicating_34\VBG|inactivated|.|effect|is|by (l_ccomp) related_42\VBN|NONE (l_nsubjpass) hemolysis_39\NN|to|not|is|that
D024502_D006461 NONE T_17\NNP||(|alpha|) (r_appos) tocopherol_13\NN|NONE (r_pobj) of_10\IN|acetate|and|low (r_prep) concentrations_9\NNS|NONE (r_pobj) by_7\IN|indicating|inactivated|.|effect|is (r_agent) prevented_6\VBN|NONE (l_nsubjpass) effect_2\NN|indicating|inactivated|.|is|by (l_amod) hemolytic_1\JJ|The|of
D024502_D006461 NONE T_17\NNP||(|alpha|) (r_appos) tocopherol_13\NN|NONE (r_pobj) of_10\IN|acetate|and|low (r_prep) concentrations_9\NNS|NONE (r_pobj) by_7\IN|indicating|inactivated|.|effect|is (r_agent) prevented_6\VBN|NONE (l_advcl) indicating_34\VBG|inactivated|.|effect|is|by (l_ccomp) related_42\VBN|NONE (l_nsubjpass) hemolysis_39\NN|to|not|is|that
D024502_D006461 NONE acetate_23\NN|and|of|low (r_conj) concentrations_9\NNS|NONE (r_pobj) by_7\IN|indicating|inactivated|.|effect|is (r_agent) prevented_6\VBN|NONE (l_nsubjpass) effect_2\NN|indicating|inactivated|.|is|by (l_amod) hemolytic_1\JJ|The|of
D024502_D006461 NONE acetate_23\NN|and|of|low (r_conj) concentrations_9\NNS|NONE (r_pobj) by_7\IN|indicating|inactivated|.|effect|is (r_agent) prevented_6\VBN|NONE (l_advcl) indicating_34\VBG|inactivated|.|effect|is|by (l_ccomp) related_42\VBN|NONE (l_nsubjpass) hemolysis_39\NN|to|not|is|that
D024502_D006461 NONE TAc_27\NNS|(|)|tocopherol (r_appos) acetate_23\NN|and|of|low (r_conj) concentrations_9\NNS|NONE (r_pobj) by_7\IN|indicating|inactivated|.|effect|is (r_agent) prevented_6\VBN|NONE (l_nsubjpass) effect_2\NN|indicating|inactivated|.|is|by (l_amod) hemolytic_1\JJ|The|of
D024502_D006461 NONE TAc_27\NNS|(|)|tocopherol (r_appos) acetate_23\NN|and|of|low (r_conj) concentrations_9\NNS|NONE (r_pobj) by_7\IN|indicating|inactivated|.|effect|is (r_agent) prevented_6\VBN|NONE (l_advcl) indicating_34\VBG|inactivated|.|effect|is|by (l_ccomp) related_42\VBN|NONE (l_nsubjpass) hemolysis_39\NN|to|not|is|that
D017665_D006461 NONE hydroxyl_32\NN|)|( (r_dobj) inactivated_30\VBN|indicating|.|effect|is|by (r_parataxis) prevented_6\VBN|NONE (l_nsubjpass) effect_2\NN|indicating|inactivated|.|is|by (l_amod) hemolytic_1\JJ|The|of
D017665_D006461 NONE hydroxyl_32\NN|)|( (r_dobj) inactivated_30\VBN|indicating|.|effect|is|by (r_parataxis) prevented_6\VBN|NONE (l_advcl) indicating_34\VBG|inactivated|.|effect|is|by (l_ccomp) related_42\VBN|NONE (l_nsubjpass) hemolysis_39\NN|to|not|is|that
D013629_D001943 NONE Tamoxifen_0\NNP|.|,|changes|drug (r_nsubj) induces_18\VBZ|NONE (l_nsubj) drug_7\NN|Tamoxifen|.|,|changes (l_acl) prescribed_10\VBN|the|antiestrogenic (l_prep) in_11\IN|widely (l_pobj) chemotherapy_13\NN|NONE (l_prep) of_14\IN|the (l_pobj) cancer_16\NN|NONE
D013629_D001943 NONE TAM_2\NNP|, (r_appos) Tamoxifen_0\NNP|.|,|changes|drug (r_nsubj) induces_18\VBZ|NONE (l_nsubj) drug_7\NN|Tamoxifen|.|,|changes (l_acl) prescribed_10\VBN|the|antiestrogenic (l_prep) in_11\IN|widely (l_pobj) chemotherapy_13\NN|NONE (l_prep) of_14\IN|the (l_pobj) cancer_16\NN|NONE
D013629_D000743 CID Tamoxifen_0\NNP|.|,|changes|drug (r_nsubj) induces_18\VBZ|NONE (l_dobj) changes_19\NNS|Tamoxifen|.|,|drug (l_prep) in_20\IN|NONE (l_pobj) shape_23\NN|NONE (l_prep) of_24\IN|normal|discoid (l_pobj) erythrocytes_25\NNS|NONE (l_conj) anemia_28\NN|and
D013629_D000743 CID TAM_2\NNP|, (r_appos) Tamoxifen_0\NNP|.|,|changes|drug (r_nsubj) induces_18\VBZ|NONE (l_dobj) changes_19\NNS|Tamoxifen|.|,|drug (l_prep) in_20\IN|NONE (l_pobj) shape_23\NN|NONE (l_prep) of_24\IN|normal|discoid (l_pobj) erythrocytes_25\NNS|NONE (l_conj) anemia_28\NN|and
D013629_D000743 CID TAM_6\NNP|NONE (r_pobj) of_5\IN|the|on (r_prep) effects_4\NNS|attempting|work|,|. (r_dobj) evaluates_2\VBZ|NONE (l_advcl) attempting_12\VBG|effects|work|,|. (l_xcomp) identify_14\VB|NONE (l_dobj) mechanisms_17\NNS|to (l_prep) on_18\IN|and|underlying|involvement|the (l_pobj) anemia_23\NN|NONE
D013629_D000743 CID TAM_19\NNP| (r_npadvmod) induced_21\VBN|hemolytic (r_amod) anemia_23\NN|NONE
D013629_D000743 CID TAM_13\NNP|NONE (r_pobj) by_12\IN|NONE (r_agent) promoted_11\VBN|mechanical (r_acl) stability_10\NN|resulting|, (r_dobj) decreased_8\VBD|and|defects|shape|. (l_conj) resulting_15\VBG|stability|, (l_prep) in_16\IN|NONE (l_pobj) anemia_18\NN|NONE
D024505_D006461 NONE tocopherols_9\NNS|NONE (r_pobj) by_8\IN|the|from (r_prep) protection_5\NN|that|is|to (l_prep) from_6\IN|the|by (l_pobj) hemolysis_7\NN|NONE
D013629_D006461 CID tamoxifen_6\NN|NONE (r_pobj) by_5\IN|related|.|Hemolysis (r_agent) induced_4\VBN|NONE (l_nsubj) Hemolysis_0\NNP|related|.|by
D013629_D006461 CID TAM_0\NNP|.|hemolysis (r_nsubj) induces_1\VBZ|NONE (l_dobj) hemolysis_2\NN|.|TAM
D013629_D006461 CID TAM_13\NNP|.|hemolysis (r_nsubj) induces_14\VBZ|extension|but|variable|, (r_conj) is_4\VBZ|NONE (l_nsubj) extension_1\NN|but|induces|variable|, (l_prep) of_2\IN|The (l_pobj) hemolysis_3\NN|NONE
D013629_D006461 CID TAM_13\NNP|.|hemolysis (r_nsubj) induces_14\VBZ|extension|but|variable|, (l_dobj) hemolysis_16\NN|TAM|.
D013629_D006461 CID TAM_4\NNP|NONE (r_pobj) of_3\IN|The|hemolytic (r_prep) effect_2\NN|indicating|inactivated|.|is|by (l_amod) hemolytic_1\JJ|The|of
D013629_D006461 CID TAM_4\NNP|NONE (r_pobj) of_3\IN|The|hemolytic (r_prep) effect_2\NN|indicating|inactivated|.|is|by (r_nsubjpass) prevented_6\VBN|NONE (l_advcl) indicating_34\VBG|inactivated|.|effect|is|by (l_ccomp) related_42\VBN|NONE (l_nsubjpass) hemolysis_39\NN|to|not|is|that
D013629_D006461 CID TAM_36\NNP| (r_npadvmod) induced_38\VBN|NONE (r_amod) hemolysis_39\NN|to|not|is|that (r_nsubjpass) related_42\VBN|NONE (r_ccomp) indicating_34\VBG|inactivated|.|effect|is|by (r_advcl) prevented_6\VBN|NONE (l_nsubjpass) effect_2\NN|indicating|inactivated|.|is|by (l_amod) hemolytic_1\JJ|The|of
D013629_D006461 CID TAM_36\NNP| (r_npadvmod) induced_38\VBN|NONE (r_amod) hemolysis_39\NN|to|not|is|that
D013629_D006461 CID TAM_17\NNP| (r_npadvmod) induced_19\VBN|NONE (r_amod) hemolysis_20\NN|NONE
D013629_D006461 CID TAM_3\NNP|NONE (r_pobj) by_2\IN|NONE (r_agent) caused_1\VBN|NONE (r_acl) Hemolysis_0\NNP|,|was|by|according|excluding|,|not|.
D013629_D006461 CID TAM_3\NNP|NONE (r_pobj) by_2\IN|NONE (r_agent) caused_1\VBN|NONE (r_acl) Hemolysis_0\NNP|,|was|by|according|excluding|,|not|. (r_nsubjpass) preceded_6\VBN|NONE (l_prep) excluding_18\VBG|,|was|by|according|,|not|.|Hemolysis (l_pobj) mechanism_24\NN|also (l_prep) of_25\IN|type|a|osmotic (l_pobj) hemolysis_26\NN|NONE
D013629_D006461 CID TAM_15\NNP|and|a|decreased|in (r_compound) incorporation_16\NN|NONE (r_pobj) to_12\IN|that|protection|is (r_prep) related_11\VBN|effects|avoided (l_nsubjpass) protection_5\NN|that|is|to (l_prep) from_6\IN|the|by (l_pobj) hemolysis_7\NN|NONE
D013629_D006461 CID TAM_2\NNP| (r_npadvmod) induced_4\VBN|,|leading|from|Therefore|hemolysis|,|. (r_amod) results_6\NNS|NONE (l_compound) hemolysis_5\NN|,|leading|from|Therefore|,|induced|.
D010100_D006461 NONE oxygen_7\NN|and|oxidation (r_compound) consumption_8\NN|NONE (r_pobj) of_6\IN|NONE (r_prep) absence_5\NN|NONE (r_pobj) by_4\IN|.|was|further|determined|This (r_agent) evidenced_3\VBN|NONE (l_conj) determined_13\VBN|by|.|was|further|This (l_prep) in_14\IN|NONE (l_pobj) parallel_15\NN|NONE (l_prep) with_16\IN|NONE (l_pobj) hemolysis_20\NN|NONE
D011188_D006461 NONE K(+_11\NNP|NONE (r_pobj) of_10\IN|)|the|from (r_prep) leakage_9\NN|NONE (r_pobj) by_7\IN|,|was|according|excluding|,|not|.|Hemolysis (r_agent) preceded_6\VBN|NONE (l_nsubjpass) Hemolysis_0\NNP|,|was|by|according|excluding|,|not|.
D011188_D006461 NONE K(+_11\NNP|NONE (r_pobj) of_10\IN|)|the|from (r_prep) leakage_9\NN|NONE (r_pobj) by_7\IN|,|was|according|excluding|,|not|.|Hemolysis (r_agent) preceded_6\VBN|NONE (l_prep) excluding_18\VBG|,|was|by|according|,|not|.|Hemolysis (l_pobj) mechanism_24\NN|also (l_prep) of_25\IN|type|a|osmotic (l_pobj) hemolysis_26\NN|NONE
10721819
D004298_D001919 NONE dopamine_27\NN|NONE (r_compound) D2_28\NN|peripheral (r_compound) receptors_29\NNS|NONE (r_pobj) at_25\IN|of|the (r_prep) bradycardia_21\NN|to
D007545_D013610 NONE isoproterenol_7\NN|NONE (l_prep) on_8\IN|NONE (l_pobj) tachycardia_12\NN|NONE
D007545_D013610 NONE isoproterenol_10\NN|NONE (r_pobj) with_9\IN|prolonged (r_prep) pretreatment_8\NN|in|tachycardia|could|whether (r_nsubj) abolish_12\VB|to (l_dobj) tachycardia_16\NN|in|pretreatment|could|whether
D007545_D013610 NONE isoproterenol_7\JJ|NONE (r_compound) pretreatment_8\NN|NONE (r_pobj) by_6\IN|NONE (r_prep) unaffected_5\JJ|hypotension|,|reversed|. (r_acomp) was_4\VBD|NONE (l_advcl) reversed_13\VBN|hypotension|,|.|unaffected (l_nsubjpass) tachycardia_11\NN|,|to|while|effect|was
D007545_D013610 NONE isoproterenol_5\JJ|day (r_compound) pretreatment_6\NN|but|reversed|not|that (r_nsubj) abolished_9\VBD|.|results (l_conj) reversed_11\VBD|but|pretreatment|not|that (l_dobj) tachycardia_15\NN|effect|,|to
D007545_D001919 CID isoproterenol_7\JJ|NONE (r_compound) pretreatment_8\NN|NONE (r_pobj) by_6\IN|NONE (r_prep) unaffected_5\JJ|hypotension|,|reversed|. (r_acomp) was_4\VBD|NONE (l_advcl) reversed_13\VBN|hypotension|,|.|unaffected (l_prep) to_14\IN|,|tachycardia|while|effect|was (l_pobj) bradycardia_16\NNS|NONE
D007545_D001919 CID isoproterenol_5\JJ|day (r_compound) pretreatment_6\NN|but|reversed|not|that (r_nsubj) abolished_9\VBD|.|results (l_conj) reversed_11\VBD|but|pretreatment|not|that (l_prep) to_16\IN|tachycardia|effect|, (l_pobj) bradycardia_17\NNP|NONE
D004294_D013610 NONE domperidone_26\NN|NONE (r_pobj) by_24\IN|partly|was|that (r_agent) reduced_23\VBN|)|mg/kg|an (r_relcl) effect_19\NN|,|tachycardia|to|while|was (r_npadvmod) reversed_13\VBN|hypotension|,|.|unaffected (l_nsubjpass) tachycardia_11\NN|,|to|while|effect|was
D001971_D013610 CID bromocriptine_9\NN| (r_npadvmod) induced_11\VBN|NONE (r_amod) tachycardia_12\NN|NONE
D001971_D013610 CID bromocriptine_5\NN| (r_npadvmod) induced_7\VBN|,|,|persisted (r_amod) tachycardia_8\NN|that
D001971_D013610 CID bromocriptine_13\NN| (r_npadvmod) induced_15\VBN|NONE (r_amod) tachycardia_16\NN|in|pretreatment|could|whether
D001971_D013610 CID bromocriptine_5\NN|In|hypotension|.|, (r_nsubj) induced_12\VBD|NONE (l_dobj) hypotension_14\NN|In|.|,|bromocriptine (l_conj) tachycardia_16\NN|and|significant
D001971_D013610 CID Bromocriptine_0\NNP| (r_npadvmod) induced_2\VBN|NONE (r_amod) hypotension_3\NN|,|reversed|.|unaffected (r_nsubj) was_4\VBD|NONE (l_advcl) reversed_13\VBN|hypotension|,|.|unaffected (l_nsubjpass) tachycardia_11\NN|,|to|while|effect|was
D001971_D013610 CID bromocriptine_12\NN| (r_npadvmod) induced_14\VBN|NONE (r_amod) tachycardia_15\NN|effect|,|to
D001971_D013610 CID bromocriptine_13\NN|NONE (r_pobj) of_12\IN|central|the (r_prep) tachycardia_11\NN|predominate|,|in|that|,
D004298_D013610 NONE dopamine_27\NN|NONE (r_compound) D2_28\NN|peripheral (r_compound) receptors_29\NNS|NONE (r_pobj) at_25\IN|of|the (r_prep) bradycardia_21\NN|to (r_dobj) mask_19\VB|to|and (r_conj) predominate_16\VB|,|tachycardia|in|that|, (r_xcomp) appears_14\VBZ|They|. (l_nsubj) tachycardia_11\NN|predominate|,|in|that|,
D001971_D001919 NONE Bromocriptine_0\NNP| (r_npadvmod) induced_2\VBN|NONE (r_amod) hypotension_3\NN|,|reversed|.|unaffected (r_nsubj) was_4\VBD|NONE (l_advcl) reversed_13\VBN|hypotension|,|.|unaffected (l_prep) to_14\IN|,|tachycardia|while|effect|was (l_pobj) bradycardia_16\NNS|NONE
D001971_D001919 NONE bromocriptine_12\NN| (r_npadvmod) induced_14\VBN|NONE (r_amod) tachycardia_15\NN|effect|,|to (r_dobj) reversed_11\VBD|but|pretreatment|not|that (l_prep) to_16\IN|tachycardia|effect|, (l_pobj) bradycardia_17\NNP|NONE
D001971_D001919 NONE bromocriptine_13\NN|NONE (r_pobj) of_12\IN|central|the (r_prep) tachycardia_11\NN|predominate|,|in|that|, (r_nsubj) appears_14\VBZ|They|. (l_xcomp) predominate_16\VB|,|tachycardia|in|that|, (l_conj) mask_19\VB|to|and (l_dobj) bradycardia_21\NN|to
D007545_D006332 CID Isoproterenol_0\JJ|for (r_compound) pretreatment_1\NN|without|.|hypertrophy (r_nsubj) caused_5\VBD|NONE (l_dobj) hypertrophy_7\NN|without|.|pretreatment
D007545_D007022 NONE isoproterenol_7\JJ|NONE (r_compound) pretreatment_8\NN|NONE (r_pobj) by_6\IN|NONE (r_prep) unaffected_5\JJ|hypotension|,|reversed|. (r_acomp) was_4\VBD|NONE (l_nsubj) hypotension_3\NN|,|reversed|.|unaffected
D004294_D001919 CID domperidone_26\NN|NONE (r_pobj) by_24\IN|partly|was|that (r_agent) reduced_23\VBN|)|mg/kg|an (r_relcl) effect_19\NN|,|tachycardia|to|while|was (r_npadvmod) reversed_13\VBN|hypotension|,|.|unaffected (l_prep) to_14\IN|,|tachycardia|while|effect|was (l_pobj) bradycardia_16\NNS|NONE
D001971_D007022 CID bromocriptine_5\NN|In|hypotension|.|, (r_nsubj) induced_12\VBD|NONE (l_dobj) hypotension_14\NN|In|.|,|bromocriptine
D001971_D007022 CID Bromocriptine_0\NNP| (r_npadvmod) induced_2\VBN|NONE (r_amod) hypotension_3\NN|,|reversed|.|unaffected
D004294_D007022 NONE domperidone_26\NN|NONE (r_pobj) by_24\IN|partly|was|that (r_agent) reduced_23\VBN|)|mg/kg|an (r_relcl) effect_19\NN|,|tachycardia|to|while|was (r_npadvmod) reversed_13\VBN|hypotension|,|.|unaffected (r_advcl) was_4\VBD|NONE (l_nsubj) hypotension_3\NN|,|reversed|.|unaffected
20304337
D003042_-1 NONE cocaine_8\NN|NONE (r_pobj) to_7\IN|.|prenatally|dysgenesis (r_prep) exposed_6\VBN|NONE (l_nsubj) dysgenesis_1\NN|.|prenatally|to
9406968
D008094_D003919 NONE lithium_15\NN| (r_npadvmod) induced_17\VBN|NONE (r_amod) diabetes_18\NN|the|insipidus (r_compound) rat_20\NN|NONE (l_compound) insipidus_19\NN|diabetes|the
D008094_D003919 NONE Li_35\NNP| (r_npadvmod) induced_37\VBN|NONE (r_amod) diabetes_38\NN|the|insipidus (r_compound) rat_40\NN|NONE (l_compound) insipidus_39\NN|the|diabetes
D008094_D003681 NONE Li_35\NNP| (r_npadvmod) induced_37\VBN|NONE (r_amod) diabetes_38\NN|the|insipidus (r_compound) rat_40\NN|NONE (r_pobj) of_33\IN|the (r_prep) SON_32\NN|the|and (r_conj) PVN_29\NN|NONE (r_pobj) in_27\IN|AVP|gene (r_prep) expression_26\NN|NONE (r_pobj) of_23\IN|the (r_prep) upregulation_22\NN|the|of (r_conj) elevation_16\NN|NONE (r_pobj) to_14\IN|may|that|dehydration (r_prep) contribute_13\VB|.|results (l_nsubj) dehydration_4\NN|may|that|to
D014667_D003919 NONE vasopressin_5\NN|in (r_compound) gene_6\NN|NONE (l_prep) in_7\IN|vasopressin (l_pobj) nuclei_12\NNS|NONE (l_prep) of_13\IN|the|paraventricular (l_pobj) rat_20\NN|NONE (l_compound) insipidus_19\NN|diabetes|the
D018021_D011141 CID LiCl_9\NNP|for|that (r_dobj) contained_8\VBD|a (r_relcl) diet_6\NN|NONE (r_dobj) consuming_4\VBG|The|Wistar|male (r_acl) rats_3\NNS|.|polyuria (r_nsubj) developed_19\VBN|NONE (l_dobj) polyuria_21\NN|.|rats
D008094_D011141 NONE lithium_26\NN|NONE (r_pobj) with_25\IN|NONE (r_prep) rats_24\NNS|NONE (r_pobj) in_23\IN|was|gene|.|using|polyuria|expression (r_prep) investigated_22\VBN|NONE (l_parataxis) polyuria_29\NN|in|was|gene|.|using|expression
D008094_D011141 NONE Li)-induced_28\JJ|(|, (r_amod) polyuria_29\NN|in|was|gene|.|using|expression
D001127_D003681 NONE AVP_19\NNP|NONE (r_pobj) of_17\IN|upregulation|the (r_prep) elevation_16\NN|NONE (r_pobj) to_14\IN|may|that|dehydration (r_prep) contribute_13\VB|.|results (l_nsubj) dehydration_4\NN|may|that|to
D001127_D003681 NONE AVP_24\NNP|in|gene (r_compound) expression_26\NN|NONE (r_pobj) of_23\IN|the (r_prep) upregulation_22\NN|the|of (r_conj) elevation_16\NN|NONE (r_pobj) to_14\IN|may|that|dehydration (r_prep) contribute_13\VB|.|results (l_nsubj) dehydration_4\NN|may|that|to
D001127_D003919 NONE AVP_19\NNP|NONE (r_pobj) of_17\IN|upregulation|the (r_prep) elevation_16\NN|NONE (l_conj) upregulation_22\NN|the|of (l_prep) of_23\IN|the (l_pobj) expression_26\NN|NONE (l_prep) in_27\IN|AVP|gene (l_pobj) PVN_29\NN|NONE (l_conj) SON_32\NN|the|and (l_prep) of_33\IN|the (l_pobj) rat_40\NN|NONE (l_compound) insipidus_39\NN|the|diabetes
D001127_D003919 NONE AVP_24\NNP|in|gene (r_compound) expression_26\NN|NONE (l_prep) in_27\IN|AVP|gene (l_pobj) PVN_29\NN|NONE (l_conj) SON_32\NN|the|and (l_prep) of_33\IN|the (l_pobj) rat_40\NN|NONE (l_compound) insipidus_39\NN|the|diabetes
D001127_D011141 NONE vasopressin_4\NN|NONE (r_pobj) of_2\IN|The (r_prep) expression_1\NN|in|was|gene|.|using|polyuria (r_nsubjpass) investigated_22\VBN|NONE (l_parataxis) polyuria_29\NN|in|was|gene|.|using|expression
D001127_D011141 NONE AVP_6\NNP|in|(|) (r_nmod) gene_8\NN|in|was|.|using|polyuria|expression (r_nsubjpass) investigated_22\VBN|NONE (l_parataxis) polyuria_29\NN|in|was|gene|.|using|expression
7263204
D000493_D000741 NONE allopurinol_14\NN|NONE (r_pobj) than_13\IN|NONE (r_prep) other_12\JJ|no (r_amod) drugs_11\NNS|in|were (r_nsubjpass) given_18\VBN|case|.|is (r_relcl) described_7\VBN|NONE (l_nsubjpass) case_1\NN|given|.|is (l_prep) of_2\IN|A (l_pobj) anemia_5\NN|NONE
D007213_D000741 CID indomethacin_5\NN|to (r_pobj) due_3\IN|Fatal||lymphocyte|.|aplastic (r_amod) anemia_2\NN|NONE
D007213_D000741 CID indomethacin_1\NN|been|as|has|Although (r_nsubjpass) implicated_4\VBN|,|been|has|not|.|definitely|role (l_prep) as_5\IN|been|has|indomethacin|Although (l_pobj) cause_8\NN|NONE (l_prep) of_9\IN|a|possible (l_pobj) anemia_11\NN|NONE
D007213_D000741 CID indomethacin_16\NN|and (r_conj) allopurinol_14\NN|NONE (r_pobj) than_13\IN|NONE (r_prep) other_12\JJ|no (r_amod) drugs_11\NNS|in|were (r_nsubjpass) given_18\VBN|case|.|is (r_relcl) described_7\VBN|NONE (l_nsubjpass) case_1\NN|given|.|is (l_prep) of_2\IN|A (l_pobj) anemia_5\NN|NONE
D007213_D000741 CID indomethacin_6\NN|NONE (r_pobj) with_5\IN|positive|transformation|A (r_prep) test_4\NN|role|.|further (r_nsubj) substantiates_10\VBZ|NONE (l_dobj) role_13\NN|test|.|further (l_prep) in_17\IN|the|of|potential (l_pcomp) causing_18\VBG|NONE (l_dobj) anemia_20\NN|in
1732369
D004317_D009202 CID Doxorubicin_0\NNP|.|agent (r_nsubj) is_1\VBZ|NONE (l_attr) agent_6\NN|.|Doxorubicin (l_acl) known_7\VBN|anticancer|an|chemotherapeutic|effective (l_xcomp) cause_9\VB|NONE (l_dobj) cardiomyopathy_13\NN|to
D004317_D006331 NONE doxorubicin_13\NN|to (r_pobj) due_11\IN|cardiac (r_amod) damage_10\NN|NONE
D004317_D006331 NONE doxorubicin_35\NN|NONE (r_pobj) with_34\IN|from (r_prep) treated_33\VBN|asymptomatic|term|of (r_acl) survivors_29\NNS|to (r_dobj) differentiate_24\VB|infusion (r_xcomp) using_20\VBG|develop|study|was|,|. (r_xcomp) performed_19\VBN|NONE (l_advcl) develop_1\VB|using|study|was|,|. (l_dobj) test_7\NN|To (l_prep) for_8\IN|a|sensitive|echocardiographic|screening (l_pobj) damage_10\NN|NONE
D004280_D009369 NONE Dobutamine_0\NNP|:|indicator|echocardiography|. (r_nsubj) stress_1\VBP|NONE (l_appos) indicator_6\NN|:|Dobutamine|echocardiography|. (l_prep) of_7\IN|sensitive|a (l_pobj) function_10\NN|NONE (l_prep) in_11\IN|diminished|myocardial (l_pobj) survivors_19\NNS|NONE (l_prep) of_20\IN|term|treated|asymptomatic (l_pobj) cancer_22\NN|NONE
D004280_D009369 NONE dobutamine_21\NN|NONE (r_compound) infusion_22\NN|differentiate (r_dobj) using_20\VBG|develop|study|was|,|. (l_xcomp) differentiate_24\VB|infusion (l_dobj) survivors_29\NNS|to (l_prep) of_30\IN|asymptomatic|term|treated (l_pobj) cancer_32\NN|NONE
D004280_D006331 NONE dobutamine_21\NN|NONE (r_compound) infusion_22\NN|differentiate (r_dobj) using_20\VBG|develop|study|was|,|. (r_xcomp) performed_19\VBN|NONE (l_advcl) develop_1\VB|using|study|was|,|. (l_dobj) test_7\NN|To (l_prep) for_8\IN|a|sensitive|echocardiographic|screening (l_pobj) damage_10\NN|NONE
D004317_D009369 NONE doxorubicin_13\NN| (r_npadvmod) treated_15\VBN|term|asymptomatic|of (r_amod) survivors_19\NNS|NONE (l_prep) of_20\IN|term|treated|asymptomatic (l_pobj) cancer_22\NN|NONE
D004317_D009369 NONE doxorubicin_13\NN|to (r_pobj) due_11\IN|cardiac (r_amod) damage_10\NN|NONE (r_pobj) for_8\IN|a|sensitive|echocardiographic|screening (r_prep) test_7\NN|To (r_dobj) develop_1\VB|using|study|was|,|. (r_advcl) performed_19\VBN|NONE (l_xcomp) using_20\VBG|develop|study|was|,|. (l_xcomp) differentiate_24\VB|infusion (l_dobj) survivors_29\NNS|to (l_prep) of_30\IN|asymptomatic|term|treated (l_pobj) cancer_32\NN|NONE
D004317_D009369 NONE doxorubicin_35\NN|NONE (r_pobj) with_34\IN|from (r_prep) treated_33\VBN|asymptomatic|term|of (r_acl) survivors_29\NNS|to (l_prep) of_30\IN|asymptomatic|term|treated (l_pobj) cancer_32\NN|NONE
11773892
D003404_D006530 NONE creatinine_13\NN|higher|,|percentage|,|preoperative|requirement (r_compound) levels_14\NNS|patients|,|Compared|. (l_appos) percentage_18\NN|higher|,|,|preoperative|requirement|creatinine (l_prep) of_19\IN|a|greater (l_pobj) patients_20\NNS|NONE (l_prep) with_21\IN|NONE (l_pobj) syndrome_23\NN|NONE
D003404_D006530 NONE creatinine_42\NN|for|percentage|and|in|,|higher (r_conj) requirement_27\NN|higher|,|percentage|,|preoperative|creatinine (r_appos) levels_14\NNS|patients|,|Compared|. (l_appos) percentage_18\NN|higher|,|,|preoperative|requirement|creatinine (l_prep) of_19\IN|a|greater (l_pobj) patients_20\NNS|NONE (l_prep) with_21\IN|NONE (l_pobj) syndrome_23\NN|NONE
D003404_D006530 NONE creatinine_11\NN|are|Patients|and|. (r_dobj) have_4\VBP|NONE (l_conj) are_13\VBP|Patients|and|.|creatinine (l_acomp) likely_15\JJ|NONE (l_xcomp) have_17\VB|more (l_dobj) syndrome_19\NN|to
D003404_D007676 NONE creatinine_20\NN|, (r_conj) CRF_16\NNP|CRF|,|; (r_conj) Controls_7\NNS|n=|three|>|and|;|: (l_conj) CRF_10\NNP|,|;|CRF
D003404_D007676 NONE creatinine_20\NN|, (r_conj) CRF_16\NNP|CRF|,|; (r_conj) Controls_7\NNS|n=|three|>|and|;|: (l_conj) CRF_10\NNP|,|;|CRF (l_conj) ESRD_12\NNP|no|or
D003404_D007676 NONE creatinine_20\NN|, (r_conj) CRF_16\NNP|CRF|,|;
D003404_D007676 NONE creatinine_20\NN|, (r_conj) CRF_16\NNP|CRF|,|; (r_conj) Controls_7\NNS|n=|three|>|and|;|: (r_appos) groups_5\NNS|NONE (l_conj) n=45_32\JJ|Controls|three|>|and|;|: (l_nmod) ESRD_30\NNS|.
D003404_D007676 NONE creatinine_13\NN|higher|,|percentage|,|preoperative|requirement (r_compound) levels_14\NNS|patients|,|Compared|. (r_dobj) had_9\VBD|NONE (l_nsubj) patients_8\NNS|levels|,|Compared|. (l_nmod) CRF_5\NNP|ESRD
D003404_D007676 NONE creatinine_13\NN|higher|,|percentage|,|preoperative|requirement (r_compound) levels_14\NNS|patients|,|Compared|. (r_dobj) had_9\VBD|NONE (l_nsubj) patients_8\NNS|levels|,|Compared|. (l_compound) ESRD_7\NNP|CRF
D003404_D007676 NONE creatinine_42\NN|for|percentage|and|in|,|higher (r_conj) requirement_27\NN|higher|,|percentage|,|preoperative|creatinine (r_appos) levels_14\NNS|patients|,|Compared|. (r_dobj) had_9\VBD|NONE (l_nsubj) patients_8\NNS|levels|,|Compared|. (l_nmod) CRF_5\NNP|ESRD
D003404_D007676 NONE creatinine_42\NN|for|percentage|and|in|,|higher (r_conj) requirement_27\NN|higher|,|percentage|,|preoperative|creatinine (r_appos) levels_14\NNS|patients|,|Compared|. (r_dobj) had_9\VBD|NONE (l_nsubj) patients_8\NNS|levels|,|Compared|. (l_compound) ESRD_7\NNP|CRF
D003404_D007676 NONE creatinine_16\NN|NONE (r_pobj) of_14\IN|and|an|compared|, (r_prep) increase_13\NN|that|factors|respectively|postoperatively (r_nsubj) were_31\VBD|.|analysis (l_attr) factors_34\NNS|that|respectively|increase|postoperatively (l_prep) for_35\IN|independent|risk|with (l_pobj) development_37\NN|NONE (l_prep) of_38\IN|the (l_pobj) CRF_39\NNP|NONE
D003404_D007676 NONE creatinine_16\NN|NONE (r_pobj) of_14\IN|and|an|compared|, (r_prep) increase_13\NN|that|factors|respectively|postoperatively (r_nsubj) were_31\VBD|.|analysis (l_attr) factors_34\NNS|that|respectively|increase|postoperatively (l_prep) for_35\IN|independent|risk|with (l_pobj) development_37\NN|NONE (l_prep) of_38\IN|the (l_pobj) CRF_39\NNP|NONE (l_conj) ESRD_41\NNP|or
D003404_D007676 NONE creatinine_11\NN|are|Patients|and|. (r_dobj) have_4\VBP|NONE (l_nsubj) Patients_0\NNS|are|and|.|creatinine (l_relcl) develop_2\VBP|NONE (l_dobj) ESRD_3\NNS|who
D003404_D007676 NONE creatinine_6\NN|NONE (r_pobj) of_4\IN|postoperatively|at|an (r_prep) increase_3\NN|.|However|predictive|, (r_nsubj) is_11\VBZ|NONE (l_acomp) predictive_13\JJ|.|increase|However|, (l_prep) of_14\IN|more (l_pobj) development_16\NN|NONE (l_prep) of_17\IN|the (l_pobj) CRF_18\NNP|NONE
D003404_D007676 NONE creatinine_6\NN|NONE (r_pobj) of_4\IN|postoperatively|at|an (r_prep) increase_3\NN|.|However|predictive|, (r_nsubj) is_11\VBZ|NONE (l_acomp) predictive_13\JJ|.|increase|However|, (l_prep) of_14\IN|more (l_pobj) development_16\NN|NONE (l_prep) of_17\IN|the (l_pobj) CRF_18\NNP|NONE (l_conj) ESRD_20\NNP|or
D016572_D007674 CID cyclosporine_3\VBP|The|calcineurin (r_appos) inhibitors_2\NNS|both|are|.|be (r_nsubjpass) known_8\VBN|NONE (l_xcomp) be_10\VB|both|are|inhibitors|. (l_acomp) nephrotoxic_11\JJ|to
D016559_D007674 CID tacrolimus_5\NN|and (r_conj) cyclosporine_3\VBP|The|calcineurin (r_appos) inhibitors_2\NNS|both|are|.|be (r_nsubjpass) known_8\VBN|NONE (l_xcomp) be_10\VB|both|are|inhibitors|. (l_acomp) nephrotoxic_11\JJ|to
3358181
D012312_D014693 CID ritodrine_6\JJ|NONE (r_compound) therapy_7\NN|NONE (r_pobj) after_5\IN|cesarean (r_prep) section_4\NN|NONE (r_pobj) during_2\IN|.|:|interaction|Ventricular (r_prep) tachyarrhythmias_1\NNS|NONE
D010656_D013610 NONE phenylephrine_22\NN|such (l_relcl) treat_24\VB|NONE (l_prep) with_27\IN|patients|to (l_pobj) tachycardia_28\NNS|NONE
D012312_D007752 NONE ritodrine_6\RB|NONE (l_prep) for_7\IN|NONE (l_pobj) labor_9\NN|NONE
D012312_D007752 NONE ritodrine_19\NN|NONE (r_pobj) of_18\IN|residual|and|effects|the|betamimetic (r_prep) effects_17\NNS|NONE (r_pobj) between_13\IN|NONE (r_prep) interactions_12\NNS|may|that|patients (r_dobj) risk_11\VB|.|case (l_nsubj) patients_4\NNS|may|interactions|that (l_acl) receiving_5\VBG|NONE (l_dobj) ritodrine_6\RB|NONE (l_prep) for_7\IN|NONE (l_pobj) labor_9\NN|NONE
D010656_D007022 NONE phenylephrine_22\NN|such (l_relcl) treat_24\VB|NONE (l_dobj) patients_26\NNS|with|to (l_amod) hypotensive_25\JJ|NONE
D012312_D002318 NONE ritodrine_15\NN|NONE (r_pobj) of_14\IN|an (r_prep) infusion_13\NN|NONE (r_pobj) of_11\IN|NONE (r_prep) cessation_10\NN|even (r_pobj) after_9\IN|serious|cardiovascular (r_prep) complications_7\NNS|NONE
8473723
D016666_D012640 CID fluvoxamine_6\NN|combined (r_compound) treatment_7\NN|NONE (r_pobj) by_2\IN|.|Seizures (r_agent) induced_1\VBN|NONE (l_nsubj) Seizures_0\NNS|.|by
D016666_D012640 CID fluvoxamine_8\NN|induced|combined (r_nmod) seizures_12\NNS|NONE
D008728_D012640 CID levomepromazine_4\JJ| (r_amod) fluvoxamine_6\NN|combined (r_compound) treatment_7\NN|NONE (r_pobj) by_2\IN|.|Seizures (r_agent) induced_1\VBN|NONE (l_nsubj) Seizures_0\NNS|.|by
D008728_D012640 CID levomepromazine_6\JJ| (r_amod) fluvoxamine_8\NN|induced|combined (r_nmod) seizures_12\NNS|NONE
8372922
18544179
D003907_D009325 NONE dexamethasone_41\NN|NONE (r_pobj) with_36\IN| (r_prep) %_35\NN|and| (r_conj) %_32\NN|NONE (r_pobj) from_30\IN|,|respectively (r_prep) discharge_29\NN|NONE (r_pobj) to_28\IN|NONE (r_prep) prior_27\RB|moderate|did|and/or|incidence|,|to (r_advmod) reduce_17\VB|,|Omission|incidence|not|but|.|did (l_conj) moderate_23\JJ|did|and/or|prior|incidence|,|to (l_prep) to_24\TO|NONE (l_pobj) nausea_26\NN|NONE
D003907_D020250 NONE dexamethasone_41\NN|NONE (r_pobj) with_36\IN| (r_prep) %_35\NN|and| (r_conj) %_32\NN|NONE (r_pobj) from_30\IN|,|respectively (r_prep) discharge_29\NN|NONE (r_pobj) to_28\IN|NONE (r_prep) prior_27\RB|moderate|did|and/or|incidence|,|to (r_advmod) reduce_17\VB|,|Omission|incidence|not|but|.|did (r_conj) reduce_5\VB|NONE (l_dobj) incidence_8\NN|,|Omission|not|but|.|did|reduce (l_prep) of_9\IN|overall|the (l_pobj) nausea_11\NN|NONE (l_conj) vomiting_13\NN|and|postoperative
D003907_D020250 NONE Dexamethasone_0\NNP|effect|. (r_nsubj) had_1\VBD|NONE (l_dobj) effect_4\NN|Dexamethasone|. (l_prep) on_5\IN|significant|no (l_pobj) incidence_7\NN|NONE (l_prep) of_10\IN|the|or|severity (l_pobj) nausea_12\NN|NONE (l_conj) vomiting_14\NN|and|postoperative
C009250_D012131 NONE sevoflurane_9\NN| (r_npadvmod) sparing_11\VBG|no (r_amod) effect_12\NN|depression|and (r_dobj) had_7\VBD|Fentanyl|.|but|movement|did (l_conj) depression_16\NN|effect|and
D005283_D020250 CID fentanyl_2\NN|NONE (r_pobj) of_1\IN|NONE (r_prep) Omission_0\NN|,|incidence|not|but|.|did|reduce (r_nsubj) reduce_5\VB|NONE (l_dobj) incidence_8\NN|,|Omission|not|but|.|did|reduce (l_prep) of_9\IN|overall|the (l_pobj) nausea_11\NN|NONE (l_conj) vomiting_13\NN|and|postoperative
D005283_D020250 CID fentanyl_37\NN||fentanyl (r_nmod) dexamethasone_41\NN|NONE (r_pobj) with_36\IN| (r_prep) %_35\NN|and| (r_conj) %_32\NN|NONE (r_pobj) from_30\IN|,|respectively (r_prep) discharge_29\NN|NONE (r_pobj) to_28\IN|NONE (r_prep) prior_27\RB|moderate|did|and/or|incidence|,|to (r_advmod) reduce_17\VB|,|Omission|incidence|not|but|.|did (r_conj) reduce_5\VB|NONE (l_dobj) incidence_8\NN|,|Omission|not|but|.|did|reduce (l_prep) of_9\IN|overall|the (l_pobj) nausea_11\NN|NONE (l_conj) vomiting_13\NN|and|postoperative
D005283_D020250 CID fentanyl_39\NN||fentanyl (r_compound) dexamethasone_41\NN|NONE (r_pobj) with_36\IN| (r_prep) %_35\NN|and| (r_conj) %_32\NN|NONE (r_pobj) from_30\IN|,|respectively (r_prep) discharge_29\NN|NONE (r_pobj) to_28\IN|NONE (r_prep) prior_27\RB|moderate|did|and/or|incidence|,|to (r_advmod) reduce_17\VB|,|Omission|incidence|not|but|.|did (r_conj) reduce_5\VB|NONE (l_dobj) incidence_8\NN|,|Omission|not|but|.|did|reduce (l_prep) of_9\IN|overall|the (l_pobj) nausea_11\NN|NONE (l_conj) vomiting_13\NN|and|postoperative
D005283_D020250 CID fentanyl_3\NN|the (r_compound) groups_4\NNS|NONE (r_dobj) Combining_0\VBG|(|reducing|P|decreased|.|,|benefits (r_csubj) revealed_5\VBD|NONE (l_advcl) reducing_15\VBG|(|P|decreased|Combining|.|,|benefits (l_dobj) nausea_17\NN|prior (l_conj) vomiting_19\NN|postoperative|and
D005283_D020250 CID fentanyl_1\NN|and|As|had|nausea (r_nsubj) exacerbated_2\VBD|it|,|.|be (l_dobj) nausea_4\NN|fentanyl|and|As|had (l_conj) vomiting_6\VBG|postoperative|and
C009250_D020250 NONE sevoflurane_9\NN|NONE (r_pobj) with_8\IN|of (r_prep) advantages_1\NNS|NONE (r_pobj) Despite_0\IN|.|frequently|nausea (r_prep) occurs_15\VBZ|NONE (l_nsubj) nausea_12\NN|.|frequently|Despite (l_conj) vomiting_14\NN|and|postoperative
C009250_D020250 NONE sevoflurane_23\NN|in (r_compound) anaesthesia_24\NN|NONE (r_pobj) after_22\IN|the||first (r_prep) h_21\NN|NONE (r_pobj) in_17\IN|.|incidence|study (r_prep) examined_5\VBD|NONE (l_dobj) incidence_7\NN|in|.|study (l_prep) of_10\IN|the|and|severity (l_pobj) nausea_12\NN|NONE (l_conj) vomiting_14\NN|and|postoperative
C009250_D020250 NONE sevoflurane_31\NN|unnecessary|an (r_relcl) supplement_29\NN|to (r_attr) be_23\VB|it|,|.|exacerbated (r_xcomp) appears_21\VBZ|NONE (l_advcl) exacerbated_2\VBD|it|,|.|be (l_dobj) nausea_4\NN|fentanyl|and|As|had (l_conj) vomiting_6\VBG|postoperative|and
D005283_D007022 CID Fentanyl_0\NNP|.|but|movement|did|had (r_nsubj) reduce_2\VB|NONE (l_conj) had_7\VBD|Fentanyl|.|but|movement|did (l_conj) depression_16\NN|effect|and (l_conj) hypotension_18\NN|increased|,|respiratory
C009250_D010146 NONE sevoflurane_12\NN|NONE (r_pobj) after_11\IN|nausea|Omitting|,|.|,|without (r_prep) reduces_2\VBZ|NONE (l_prep) without_7\IN|nausea|Omitting|,|.|,|after (l_pcomp) increasing_8\VBG|NONE (l_dobj) pain_9\NN|NONE
C009250_D010146 NONE sevoflurane_23\NN|in (r_compound) anaesthesia_24\NN|NONE (r_pobj) after_22\IN|the||first (r_prep) h_21\NN|NONE (r_pobj) in_17\IN|.|incidence|study (r_prep) examined_5\VBD|NONE (l_dobj) incidence_7\NN|in|.|study (l_prep) of_10\IN|the|and|severity (l_pobj) nausea_12\NN|NONE (l_conj) vomiting_14\NN|and|postoperative (l_conj) pain_16\NN|and
C009250_D001919 NONE sevoflurane_9\NN| (r_npadvmod) sparing_11\VBG|no (r_amod) effect_12\NN|depression|and (r_dobj) had_7\VBD|Fentanyl|.|but|movement|did (l_conj) depression_16\NN|effect|and (l_conj) hypotension_18\NN|increased|,|respiratory (l_conj) bradycardia_20\NN|and
D005283_D010149 NONE fentanyl_1\NN|and|As|had|nausea (r_nsubj) exacerbated_2\VBD|it|,|.|be (l_dobj) nausea_4\NN|fentanyl|and|As|had (l_conj) vomiting_6\VBG|postoperative|and (l_prep) without_7\IN|NONE (l_pobj) improvement_9\NN|NONE (l_prep) in_10\IN|an (l_pobj) pain_12\NN|NONE
D005283_D010146 NONE fentanyl_1\NN|NONE (r_dobj) Omitting_0\VBG|nausea|,|.|,|without|after (r_csubj) reduces_2\VBZ|NONE (l_prep) without_7\IN|nausea|Omitting|,|.|,|after (l_pcomp) increasing_8\VBG|NONE (l_dobj) pain_9\NN|NONE
D005283_D010146 NONE fentanyl_11\NN|NONE (r_pobj) of_10\IN|the (r_prep) omission_9\NN|NONE (r_pobj) by_7\IN|NONE (r_prep) unaffected_6\JJ|severity|. (r_acomp) were_5\VBD|NONE (l_nsubj) severity_1\NN|.|unaffected (l_compound) Pain_0\NN|requirements|and
D005283_D009325 NONE fentanyl_1\NN|NONE (r_dobj) Omitting_0\VBG|nausea|,|.|,|without|after (r_csubj) reduces_2\VBZ|NONE (l_dobj) nausea_3\NN|Omitting|,|.|,|without|after
D005283_D009325 NONE fentanyl_2\NN|NONE (r_pobj) of_1\IN|NONE (r_prep) Omission_0\NN|,|incidence|not|but|.|did|reduce (r_nsubj) reduce_5\VB|NONE (l_conj) reduce_17\VB|,|Omission|incidence|not|but|.|did (l_conj) moderate_23\JJ|did|and/or|prior|incidence|,|to (l_prep) to_24\TO|NONE (l_pobj) nausea_26\NN|NONE
D005283_D009325 NONE fentanyl_37\NN||fentanyl (r_nmod) dexamethasone_41\NN|NONE (r_pobj) with_36\IN| (r_prep) %_35\NN|and| (r_conj) %_32\NN|NONE (r_pobj) from_30\IN|,|respectively (r_prep) discharge_29\NN|NONE (r_pobj) to_28\IN|NONE (r_prep) prior_27\RB|moderate|did|and/or|incidence|,|to (r_advmod) reduce_17\VB|,|Omission|incidence|not|but|.|did (l_conj) moderate_23\JJ|did|and/or|prior|incidence|,|to (l_prep) to_24\TO|NONE (l_pobj) nausea_26\NN|NONE
D005283_D009325 NONE fentanyl_39\NN||fentanyl (r_compound) dexamethasone_41\NN|NONE (r_pobj) with_36\IN| (r_prep) %_35\NN|and| (r_conj) %_32\NN|NONE (r_pobj) from_30\IN|,|respectively (r_prep) discharge_29\NN|NONE (r_pobj) to_28\IN|NONE (r_prep) prior_27\RB|moderate|did|and/or|incidence|,|to (r_advmod) reduce_17\VB|,|Omission|incidence|not|but|.|did (l_conj) moderate_23\JJ|did|and/or|prior|incidence|,|to (l_prep) to_24\TO|NONE (l_pobj) nausea_26\NN|NONE
D005283_D009325 NONE fentanyl_3\NN|the (r_compound) groups_4\NNS|NONE (r_dobj) Combining_0\VBG|(|reducing|P|decreased|.|,|benefits (r_csubj) revealed_5\VBD|NONE (l_advcl) reducing_15\VBG|(|P|decreased|Combining|.|,|benefits (l_dobj) nausea_17\NN|prior (l_conj) vomiting_19\NN|postoperative|and (l_conj) nausea_21\NN|and
D005283_D009325 NONE fentanyl_3\NN|the (r_compound) groups_4\NNS|NONE (r_dobj) Combining_0\VBG|(|reducing|P|decreased|.|,|benefits (r_csubj) revealed_5\VBD|NONE (l_advcl) decreased_57\VBN|(|reducing|P|Combining|.|,|benefits (l_nsubjpass) nausea_50\NN|P|was|from|)|while|(
D005283_D014839 NONE fentanyl_1\NN|NONE (r_dobj) Omitting_0\VBG|nausea|,|.|,|without|after (r_csubj) reduces_2\VBZ|NONE (l_dobj) nausea_3\NN|Omitting|,|.|,|without|after (l_conj) vomiting_5\NN|and
D005283_D014839 NONE fentanyl_2\NN|NONE (r_pobj) of_1\IN|NONE (r_prep) Omission_0\NN|,|incidence|not|but|.|did|reduce (r_nsubj) reduce_5\VB|NONE (l_conj) reduce_17\VB|,|Omission|incidence|not|but|.|did (l_dobj) incidence_19\NN|moderate|did|and/or|prior|,|to (l_prep) of_20\IN|the (l_pobj) vomiting_21\NN|NONE
D005283_D014839 NONE fentanyl_37\NN||fentanyl (r_nmod) dexamethasone_41\NN|NONE (r_pobj) with_36\IN| (r_prep) %_35\NN|and| (r_conj) %_32\NN|NONE (r_pobj) from_30\IN|,|respectively (r_prep) discharge_29\NN|NONE (r_pobj) to_28\IN|NONE (r_prep) prior_27\RB|moderate|did|and/or|incidence|,|to (r_advmod) reduce_17\VB|,|Omission|incidence|not|but|.|did (l_dobj) incidence_19\NN|moderate|did|and/or|prior|,|to (l_prep) of_20\IN|the (l_pobj) vomiting_21\NN|NONE
D005283_D014839 NONE fentanyl_39\NN||fentanyl (r_compound) dexamethasone_41\NN|NONE (r_pobj) with_36\IN| (r_prep) %_35\NN|and| (r_conj) %_32\NN|NONE (r_pobj) from_30\IN|,|respectively (r_prep) discharge_29\NN|NONE (r_pobj) to_28\IN|NONE (r_prep) prior_27\RB|moderate|did|and/or|incidence|,|to (r_advmod) reduce_17\VB|,|Omission|incidence|not|but|.|did (l_dobj) incidence_19\NN|moderate|did|and/or|prior|,|to (l_prep) of_20\IN|the (l_pobj) vomiting_21\NN|NONE
C009250_D014839 NONE sevoflurane_12\NN|NONE (r_pobj) after_11\IN|nausea|Omitting|,|.|,|without (r_prep) reduces_2\VBZ|NONE (l_dobj) nausea_3\NN|Omitting|,|.|,|without|after (l_conj) vomiting_5\NN|and
C009250_D009325 NONE sevoflurane_12\NN|NONE (r_pobj) after_11\IN|nausea|Omitting|,|.|,|without (r_prep) reduces_2\VBZ|NONE (l_dobj) nausea_3\NN|Omitting|,|.|,|without|after
D005283_D001919 CID Fentanyl_0\NNP|.|but|movement|did|had (r_nsubj) reduce_2\VB|NONE (l_conj) had_7\VBD|Fentanyl|.|but|movement|did (l_conj) depression_16\NN|effect|and (l_conj) hypotension_18\NN|increased|,|respiratory (l_conj) bradycardia_20\NN|and
D003907_D014839 NONE dexamethasone_41\NN|NONE (r_pobj) with_36\IN| (r_prep) %_35\NN|and| (r_conj) %_32\NN|NONE (r_pobj) from_30\IN|,|respectively (r_prep) discharge_29\NN|NONE (r_pobj) to_28\IN|NONE (r_prep) prior_27\RB|moderate|did|and/or|incidence|,|to (r_advmod) reduce_17\VB|,|Omission|incidence|not|but|.|did (l_dobj) incidence_19\NN|moderate|did|and/or|prior|,|to (l_prep) of_20\IN|the (l_pobj) vomiting_21\NN|NONE
C009250_D010149 NONE sevoflurane_31\NN|unnecessary|an (r_relcl) supplement_29\NN|to (r_attr) be_23\VB|it|,|.|exacerbated (r_xcomp) appears_21\VBZ|NONE (l_advcl) exacerbated_2\VBD|it|,|.|be (l_dobj) nausea_4\NN|fentanyl|and|As|had (l_conj) vomiting_6\VBG|postoperative|and (l_prep) without_7\IN|NONE (l_pobj) improvement_9\NN|NONE (l_prep) in_10\IN|an (l_pobj) pain_12\NN|NONE
C009250_D007022 NONE sevoflurane_9\NN| (r_npadvmod) sparing_11\VBG|no (r_amod) effect_12\NN|depression|and (r_dobj) had_7\VBD|Fentanyl|.|but|movement|did (l_conj) depression_16\NN|effect|and (l_conj) hypotension_18\NN|increased|,|respiratory
D005283_D012131 CID Fentanyl_0\NNP|.|but|movement|did|had (r_nsubj) reduce_2\VB|NONE (l_conj) had_7\VBD|Fentanyl|.|but|movement|did (l_conj) depression_16\NN|effect|and
1436384
D016202_D020258 NONE NMDA_19\NNP|NONE (r_compound) receptors_20\NNS|that|and|is|effect (r_dobj) involves_18\VBZ|the (l_nsubj) effect_8\NN|receptors|that|and|is (l_amod) neurotoxic_7\JJ|the|of
D016202_D020258 NONE NMDA_26\NNP|with|an|receptor (r_compound) antagonist_28\NN|that|LY (r_attr) is_24\VBZ|receptors|that|and|effect (r_conj) involves_18\VBZ|the (l_nsubj) effect_8\NN|receptors|that|and|is (l_amod) neurotoxic_7\JJ|the|of
D004298_D020258 NONE dopamine_8\NN|striatal|in (r_compound) neurons_9\NNS|NONE (r_pobj) toward_6\IN|induced (r_prep) neurotoxicity_5\NN|NONE
D004298_D020258 NONE dopamine_16\NN|nigrostriatal (r_compound) neurons_17\NNS|NONE (r_pobj) toward_14\IN|amphetamine|related (r_prep) compounds_13\NNS|NONE (r_pobj) of_9\IN|the|neurotoxic (r_prep) effect_8\NN|receptors|that|and|is (l_amod) neurotoxic_7\JJ|the|of
D000661_D020258 CID amphetamine_2\NN| (r_npadvmod) induced_4\VBN|toward (r_amod) neurotoxicity_5\NN|NONE
D000661_D020258 CID amphetamine_10\NN|related|toward (r_nmod) compounds_13\NNS|NONE (r_pobj) of_9\IN|the|neurotoxic (r_prep) effect_8\NN|receptors|that|and|is (l_amod) neurotoxic_7\JJ|the|of
C070935_D020258 NONE LY274614_13\NNP|NONE (r_pobj) by_12\IN|NONE (r_prep) rodents_11\NNS|NONE (r_pobj) in_10\IN|striatal|dopamine (r_prep) neurons_9\NNS|NONE (r_pobj) toward_6\IN|induced (r_prep) neurotoxicity_5\NN|NONE
C070935_D020258 NONE LY274614_23\NNP|antagonist|that (r_nsubj) is_24\VBZ|receptors|that|and|effect (r_conj) involves_18\VBZ|the (l_nsubj) effect_8\NN|receptors|that|and|is (l_amod) neurotoxic_7\JJ|the|of
D000596_D020258 NONE acid_18\NN|an|excitatory (r_compound) antagonist_19\NN|, (r_appos) LY274614_13\NNP|NONE (r_pobj) by_12\IN|NONE (r_prep) rodents_11\NNS|NONE (r_pobj) in_10\IN|striatal|dopamine (r_prep) neurons_9\NNS|NONE (r_pobj) toward_6\IN|induced (r_prep) neurotoxicity_5\NN|NONE
12139551
D008787_D006323 CID metoclopramide_4\NN|a|intravenous|of|causing (r_compound) case_7\NN|NONE (r_pobj) after_2\IN|Cardiac|. (r_prep) arrest_1\NN|NONE
D008787_D006323 CID metoclopramide_4\NN|a|intravenous|of|causing (r_compound) case_7\NN|NONE (l_acl) causing_14\VBG|a|intravenous|of|metoclopramide (l_dobj) episodes_16\NNS|NONE (l_prep) of_17\IN|five (l_pobj) arrest_19\NN|NONE
D008787_D006323 CID metoclopramide_13\NN|NONE (r_pobj) of_12\IN|five|repeated (r_prep) injections_11\NNS|NONE (r_pobj) of_8\IN|a|intravenous|metoclopramide|causing (r_prep) case_7\NN|NONE (r_pobj) after_2\IN|Cardiac|. (r_prep) arrest_1\NN|NONE
D008787_D006323 CID metoclopramide_13\NN|NONE (r_pobj) of_12\IN|five|repeated (r_prep) injections_11\NNS|NONE (r_pobj) of_8\IN|a|intravenous|metoclopramide|causing (r_prep) case_7\NN|NONE (l_acl) causing_14\VBG|a|intravenous|of|metoclopramide (l_dobj) episodes_16\NNS|NONE (l_prep) of_17\IN|five (l_pobj) arrest_19\NN|NONE
D008787_D006323 CID metoclopramide_8\NN|NONE (r_pobj) of_7\IN|intravenous (r_prep) injection_6\NN|immediately|was|by|where|repeatedly (r_nsubjpass) followed_11\VBN|a (l_agent) by_12\IN|immediately|was|injection|where|repeatedly (l_pobj) asystole_13\NN|NONE
D008787_D006323 CID metoclopramide_3\JJ|during|mg|After|patient (r_dobj) received_2\VBD|.|,|clear|it|was|followed (r_ccomp) is_24\VBZ|NONE (l_advcl) followed_37\VBN|.|,|clear|received|it|was (l_agent) by_38\IN|NONE (l_pobj) asystole_39\NN|NONE
D008787_D006323 CID metoclopramide_30\NN|NONE (r_pobj) of_29\IN|every (r_prep) administration_28\NN|)|(|immediately|that|within (r_nsubj) was_31\VBD|.|,|clear|received|it|followed (r_ccomp) is_24\VBZ|NONE (l_advcl) followed_37\VBN|.|,|clear|received|it|was (l_agent) by_38\IN|NONE (l_pobj) asystole_39\NN|NONE
D008787_D006323 CID metoclopramide_10\NN|NONE (r_pobj) by_9\IN|NONE (r_agent) caused_8\VBN|of (r_acl) episodes_4\NNS|NONE (l_prep) of_5\IN|caused (l_pobj) arrest_7\NN|NONE
9625142
D001663_D000744 NONE bilirubin_21\NN|NONE (r_pobj) in_19\IN|a|and|gradual|decrease (r_prep) increase_18\NN|there|,|.|returned (l_conj) decrease_24\NN|a|and|gradual|in (l_prep) in_25\IN|a (l_pobj) concentration_27\NN|NONE (l_acl) caused_28\VBN|hemoglobin (l_agent) by_29\IN|NONE (l_pobj) anemia_33\NN|NONE
D002443_D056486 CID ceftriaxone_11\NN|NONE (r_pobj) by_10\IN|.|hepatitis (r_prep) induced_9\VBN|NONE (l_nsubj) hepatitis_1\NNP|.|by
D002443_D056486 CID ceftriaxone_12\NN|NONE (r_dobj) ingesting_10\VBG|shortly (r_pcomp) after_9\IN|.|hepatitis|man (r_prep) developed_5\VBD|NONE (l_dobj) hepatitis_7\NN|after|.|man
D047090_D000744 NONE lactam_11\NN|the (r_compound) antibiotic_12\NN|NONE (r_dobj) withholding_8\VBG|NONE (r_pcomp) after_7\IN|to|gradually|transaminases|Although (r_prep) returned_4\VBD|increase|there|,|. (r_advcl) was_15\VBD|NONE (l_attr) increase_18\NN|there|,|.|returned (l_conj) decrease_24\NN|a|and|gradual|in (l_prep) in_25\IN|a (l_pobj) concentration_27\NN|NONE (l_acl) caused_28\VBN|hemoglobin (l_agent) by_29\IN|NONE (l_pobj) anemia_33\NN|NONE
D047090_-1 NONE lactam_11\NN|the (r_compound) antibiotic_12\NN|NONE (r_dobj) withholding_8\VBG|NONE (r_pcomp) after_7\IN|to|gradually|transaminases|Although (r_prep) returned_4\VBD|increase|there|,|. (r_advcl) was_15\VBD|NONE (l_attr) increase_18\NN|there|,|.|returned (l_conj) decrease_24\NN|a|and|gradual|in (l_prep) in_25\IN|a (l_pobj) concentration_27\NN|NONE (l_acl) caused_28\VBN|hemoglobin (l_agent) by_29\IN|NONE (l_pobj) anemia_33\NN|NONE (l_conj) erythroblastocytopenia_35\NN|an|autoimmune|hemolytic|and
D002443_D000744 CID ceftriaxone_11\NN|NONE (r_pobj) by_10\IN|.|hepatitis (r_prep) induced_9\VBN|NONE (l_nsubj) hepatitis_1\NNP|.|by (l_appos) anemia_5\NN|Acute|,
D001663_-1 NONE bilirubin_21\NN|NONE (r_pobj) in_19\IN|a|and|gradual|decrease (r_prep) increase_18\NN|there|,|.|returned (l_conj) decrease_24\NN|a|and|gradual|in (l_prep) in_25\IN|a (l_pobj) concentration_27\NN|NONE (l_acl) caused_28\VBN|hemoglobin (l_agent) by_29\IN|NONE (l_pobj) anemia_33\NN|NONE (l_conj) erythroblastocytopenia_35\NN|an|autoimmune|hemolytic|and
D002443_-1 NONE ceftriaxone_11\NN|NONE (r_pobj) by_10\IN|.|hepatitis (r_prep) induced_9\VBN|NONE (l_nsubj) hepatitis_1\NNP|.|by (l_appos) anemia_5\NN|Acute|, (l_conj) erythroblastocytopenia_8\NN|,|autoimmune|and|hemolytic
7248170
D010634_D013163 NONE phenobarbitone_60\NN| (r_npadvmod) primed_62\VBN|the (r_amod) rat_63\NN|NONE (r_pobj) in_58\IN|ascites|tetrachloride|increased|.|intragastrically (r_prep) given_56\VBN|NONE (l_nsubj) ascites_20\VBZ|in|tetrachloride|increased|.|intragastrically (l_conj) albumin_27\NN|greater|yield|, (l_conj) splenomegaly_35\JJ|less|plasma|,
D010634_D013163 NONE phenobarbitone_88\NN| (r_npadvmod) induced_90\VBN|of|the (r_amod) enlargement_91\NN|NONE (r_pobj) of_86\IN|the (r_prep) peak_85\NN|NONE (r_pobj) at_83\IN|calibrating (r_prep) giving_73\VBG|NONE (r_pcomp) by_72\IN|from|was (r_prep) increased_65\VBN|ascites|in|tetrachloride|.|intragastrically (r_conj) given_56\VBN|NONE (l_nsubj) ascites_20\VBZ|in|tetrachloride|increased|.|intragastrically (l_conj) albumin_27\NN|greater|yield|, (l_conj) splenomegaly_35\JJ|less|plasma|,
D010634_D006529 CID Phenobarbitone_0\NNP| (r_npadvmod) induced_2\VBN|relationship|.|of|: (r_amod) enlargement_3\NN|NONE (l_prep) of_4\IN|induced|relationship|.|: (l_pobj) liver_6\NN|NONE
D010634_D006529 CID phenobarbitone_60\NN| (r_npadvmod) primed_62\VBN|the (r_amod) rat_63\NN|NONE (r_pobj) in_58\IN|ascites|tetrachloride|increased|.|intragastrically (r_prep) given_56\VBN|NONE (l_conj) increased_65\VBN|ascites|in|tetrachloride|.|intragastrically (l_prep) by_72\IN|from|was (l_pcomp) giving_73\VBG|NONE (l_prep) at_83\IN|calibrating (l_pobj) peak_85\NN|NONE (l_prep) of_86\IN|the (l_pobj) enlargement_91\NN|NONE (l_prep) of_92\IN|induced|the (l_pobj) liver_94\NN|NONE
D010634_D006529 CID phenobarbitone_88\NN| (r_npadvmod) induced_90\VBN|of|the (r_amod) enlargement_91\NN|NONE (l_prep) of_92\IN|induced|the (l_pobj) liver_94\NN|NONE
D002251_D006529 NONE tetrachloride_15\NN| (r_advmod) induced_17\VBN|carbon (r_amod) cirrhosis_18\NN|NONE (r_pobj) to_13\TO|its (r_prep) relationship_12\NN|induced|.|of|: (r_appos) enlargement_3\NN|NONE (l_prep) of_4\IN|induced|relationship|.|: (l_pobj) liver_6\NN|NONE
D002251_D006529 NONE tetrachloride_55\NN|ascites|in|increased|.|intragastrically (r_advmod) given_56\VBN|NONE (l_conj) increased_65\VBN|ascites|in|tetrachloride|.|intragastrically (l_prep) by_72\IN|from|was (l_pcomp) giving_73\VBG|NONE (l_prep) at_83\IN|calibrating (l_pobj) peak_85\NN|NONE (l_prep) of_86\IN|the (l_pobj) enlargement_91\NN|NONE (l_prep) of_92\IN|induced|the (l_pobj) liver_94\NN|NONE
D002251_D006529 NONE tetrachloride_82\NN|the|"|dose|initial|" (r_advmod) calibrating_77\VBG|at (r_dative) giving_73\VBG|NONE (l_prep) at_83\IN|calibrating (l_pobj) peak_85\NN|NONE (l_prep) of_86\IN|the (l_pobj) enlargement_91\NN|NONE (l_prep) of_92\IN|induced|the (l_pobj) liver_94\NN|NONE
D002251_D005355 NONE tetrachloride_15\NN| (r_advmod) induced_17\VBN|carbon (r_amod) cirrhosis_18\NN|NONE
D002251_D001201 NONE tetrachloride_55\NN|ascites|in|increased|.|intragastrically (r_advmod) given_56\VBN|NONE (l_nsubj) ascites_20\VBZ|in|tetrachloride|increased|.|intragastrically
D002251_D001201 NONE tetrachloride_82\NN|the|"|dose|initial|" (r_advmod) calibrating_77\VBG|at (r_dative) giving_73\VBG|NONE (r_pcomp) by_72\IN|from|was (r_prep) increased_65\VBN|ascites|in|tetrachloride|.|intragastrically (r_conj) given_56\VBN|NONE (l_nsubj) ascites_20\VBZ|in|tetrachloride|increased|.|intragastrically
D010634_D001201 NONE phenobarbitone_60\NN| (r_npadvmod) primed_62\VBN|the (r_amod) rat_63\NN|NONE (r_pobj) in_58\IN|ascites|tetrachloride|increased|.|intragastrically (r_prep) given_56\VBN|NONE (l_nsubj) ascites_20\VBZ|in|tetrachloride|increased|.|intragastrically
D010634_D001201 NONE phenobarbitone_88\NN| (r_npadvmod) induced_90\VBN|of|the (r_amod) enlargement_91\NN|NONE (r_pobj) of_86\IN|the (r_prep) peak_85\NN|NONE (r_pobj) at_83\IN|calibrating (r_prep) giving_73\VBG|NONE (r_pcomp) by_72\IN|from|was (r_prep) increased_65\VBN|ascites|in|tetrachloride|.|intragastrically (r_conj) given_56\VBN|NONE (l_nsubj) ascites_20\VBZ|in|tetrachloride|increased|.|intragastrically
D002251_D013163 NONE tetrachloride_55\NN|ascites|in|increased|.|intragastrically (r_advmod) given_56\VBN|NONE (l_nsubj) ascites_20\VBZ|in|tetrachloride|increased|.|intragastrically (l_conj) albumin_27\NN|greater|yield|, (l_conj) splenomegaly_35\JJ|less|plasma|,
D002251_D013163 NONE tetrachloride_82\NN|the|"|dose|initial|" (r_advmod) calibrating_77\VBG|at (r_dative) giving_73\VBG|NONE (r_pcomp) by_72\IN|from|was (r_prep) increased_65\VBN|ascites|in|tetrachloride|.|intragastrically (r_conj) given_56\VBN|NONE (l_nsubj) ascites_20\VBZ|in|tetrachloride|increased|.|intragastrically (l_conj) albumin_27\NN|greater|yield|, (l_conj) splenomegaly_35\JJ|less|plasma|,
D002251_D008103 CID tetrachloride_55\NN|ascites|in|increased|.|intragastrically (r_advmod) given_56\VBN|NONE (l_nsubj) ascites_20\VBZ|in|tetrachloride|increased|.|intragastrically (l_nsubj) yield_1\NN|greater|,|albumin (l_prep) of_2\IN|The (l_pobj) cirrhosis_4\NN|NONE (l_prep) of_5\IN|severe (l_pobj) liver_7\NN|NONE
D002251_D008103 CID tetrachloride_82\NN|the|"|dose|initial|" (r_advmod) calibrating_77\VBG|at (r_dative) giving_73\VBG|NONE (r_pcomp) by_72\IN|from|was (r_prep) increased_65\VBN|ascites|in|tetrachloride|.|intragastrically (r_conj) given_56\VBN|NONE (l_nsubj) ascites_20\VBZ|in|tetrachloride|increased|.|intragastrically (l_nsubj) yield_1\NN|greater|,|albumin (l_prep) of_2\IN|The (l_pobj) cirrhosis_4\NN|NONE (l_prep) of_5\IN|severe (l_pobj) liver_7\NN|NONE
D010634_D008103 CID phenobarbitone_60\NN| (r_npadvmod) primed_62\VBN|the (r_amod) rat_63\NN|NONE (r_pobj) in_58\IN|ascites|tetrachloride|increased|.|intragastrically (r_prep) given_56\VBN|NONE (l_nsubj) ascites_20\VBZ|in|tetrachloride|increased|.|intragastrically (l_nsubj) yield_1\NN|greater|,|albumin (l_prep) of_2\IN|The (l_pobj) cirrhosis_4\NN|NONE (l_prep) of_5\IN|severe (l_pobj) liver_7\NN|NONE
D010634_D008103 CID phenobarbitone_88\NN| (r_npadvmod) induced_90\VBN|of|the (r_amod) enlargement_91\NN|NONE (r_pobj) of_86\IN|the (r_prep) peak_85\NN|NONE (r_pobj) at_83\IN|calibrating (r_prep) giving_73\VBG|NONE (r_pcomp) by_72\IN|from|was (r_prep) increased_65\VBN|ascites|in|tetrachloride|.|intragastrically (r_conj) given_56\VBN|NONE (l_nsubj) ascites_20\VBZ|in|tetrachloride|increased|.|intragastrically (l_nsubj) yield_1\NN|greater|,|albumin (l_prep) of_2\IN|The (l_pobj) cirrhosis_4\NN|NONE (l_prep) of_5\IN|severe (l_pobj) liver_7\NN|NONE
D002251_D001284 NONE tetrachloride_55\NN|ascites|in|increased|.|intragastrically (r_advmod) given_56\VBN|NONE (l_nsubj) ascites_20\VBZ|in|tetrachloride|increased|.|intragastrically (l_conj) albumin_27\NN|greater|yield|, (l_conj) splenomegaly_35\JJ|less|plasma|, (l_conj) atrophy_44\NN|and|,|after|
D002251_D001284 NONE tetrachloride_82\NN|the|"|dose|initial|" (r_advmod) calibrating_77\VBG|at (r_dative) giving_73\VBG|NONE (r_pcomp) by_72\IN|from|was (r_prep) increased_65\VBN|ascites|in|tetrachloride|.|intragastrically (r_conj) given_56\VBN|NONE (l_nsubj) ascites_20\VBZ|in|tetrachloride|increased|.|intragastrically (l_conj) albumin_27\NN|greater|yield|, (l_conj) splenomegaly_35\JJ|less|plasma|, (l_conj) atrophy_44\NN|and|,|after|
D010634_D001284 NONE phenobarbitone_60\NN| (r_npadvmod) primed_62\VBN|the (r_amod) rat_63\NN|NONE (r_pobj) in_58\IN|ascites|tetrachloride|increased|.|intragastrically (r_prep) given_56\VBN|NONE (l_nsubj) ascites_20\VBZ|in|tetrachloride|increased|.|intragastrically (l_conj) albumin_27\NN|greater|yield|, (l_conj) splenomegaly_35\JJ|less|plasma|, (l_conj) atrophy_44\NN|and|,|after|
D010634_D001284 NONE phenobarbitone_88\NN| (r_npadvmod) induced_90\VBN|of|the (r_amod) enlargement_91\NN|NONE (r_pobj) of_86\IN|the (r_prep) peak_85\NN|NONE (r_pobj) at_83\IN|calibrating (r_prep) giving_73\VBG|NONE (r_pcomp) by_72\IN|from|was (r_prep) increased_65\VBN|ascites|in|tetrachloride|.|intragastrically (r_conj) given_56\VBN|NONE (l_nsubj) ascites_20\VBZ|in|tetrachloride|increased|.|intragastrically (l_conj) albumin_27\NN|greater|yield|, (l_conj) splenomegaly_35\JJ|less|plasma|, (l_conj) atrophy_44\NN|and|,|after|
D010634_D005355 NONE Phenobarbitone_0\NNP| (r_npadvmod) induced_2\VBN|relationship|.|of|: (r_amod) enlargement_3\NN|NONE (l_appos) relationship_12\NN|induced|.|of|: (l_prep) to_13\TO|its (l_pobj) cirrhosis_18\NN|NONE
12653683
D011692_D009404 CID aminonucleoside_15\RB| (r_advmod) induced_17\VBN|puromycin|nephrotic (r_amod) syndrome_19\NN|NONE
D011692_D009404 CID aminonucleoside_12\NN|We|.|abundance|in (l_pobj) syndrome_16\NN|NONE
D011692_D009404 CID PAN)-induced_14\VBN|nephrotic (r_amod) syndrome_16\NN|NONE
D011692_D009404 CID PAN_22\NNP| (r_npadvmod) induced_24\VBN|in|nephrotic (r_amod) syndrome_26\NN|NONE
D012964_D011507 NONE sodium_5\NN|concentration|, (r_compound) excretion_6\NN|NONE (l_conj) concentration_10\NN|sodium|, (l_conj) proteinuria_12\NN|aldosterone|and
D012964_D011507 NONE sodium_4\NN|NONE (r_compound) excretion_5\NN|NONE (r_pobj) of_2\IN|The|appearance|and (r_prep) kinetics_1\NNS|.|comparable (l_conj) appearance_8\NN|The|of|and (l_prep) of_9\IN|the (l_pobj) proteinuria_10\NN|NONE
D000450_D009404 NONE aldosterone_38\NN|NONE (r_pobj) by_37\IN|the (r_prep) regulation_36\NN|NONE (r_pobj) from_34\IN|to|after (r_prep) escape_33\VB|NONE (r_xcomp) appears_31\VBZ|but|In|,|,|.|in|expression|is (r_conj) increased_11\VBN|NONE (l_prep) in_12\IN|but|In|,|,|appears|.|expression|is (l_pobj) phase_16\NN|NONE (l_prep) of_17\IN|early|the (l_pobj) model_20\NN|NONE (l_prep) of_21\IN|experimental|the (l_pobj) syndrome_26\NN|NONE
D012964_D009404 NONE sodium_1\NN|subunit|Epithelial|.|(|)|ENaC (r_compound) channel_2\NN|NONE (l_appos) subunit_6\NN|Epithelial|sodium|.|(|)|ENaC (l_appos) mRNA_7\NN|NONE (l_conj) expression_10\NN|and (l_prep) in_11\IN|protein (l_pobj) rats_12\NNS|NONE (l_prep) with_13\IN|NONE (l_pobj) syndrome_19\NN|NONE
D012964_D009404 NONE sodium_6\NN|NONE (r_compound) excretion_7\NN|during|In|.|is|, (r_nsubjpass) decreased_9\VBN|NONE (l_prep) In_0\IN|during|.|is|,|excretion (l_pobj) syndrome_3\NN|NONE
D000450_D011507 NONE aldosterone_9\NN|proteinuria|and (r_compound) concentration_10\NN|sodium|, (l_conj) proteinuria_12\NN|aldosterone|and
D011692_D011507 CID PAN_28\NNP|NONE (r_pobj) of_26\IN|single|a (r_prep) dose_25\NN|NONE (r_pobj) with_22\IN|NONE (r_prep) treated_21\VBN|Dawley|male (r_acl) rats_20\NNS|NONE (r_pobj) in_15\IN|courses|.|were (r_prep) studied_14\VBN|NONE (l_nsubjpass) courses_2\NNS|.|were|in (l_prep) of_3\IN|time|The (l_pobj) excretion_6\NN|NONE (l_conj) concentration_10\NN|sodium|, (l_conj) proteinuria_12\NN|aldosterone|and
19370593
D004967_D005705 CID oestrogen_3\NN|term (r_nmod) HT_6\NNP|,|increase|risk|.|but|significantly|after (r_nsubj) increased_8\VBD|NONE (l_dobj) risk_10\NN|,|increase|.|but|significantly|HT|after (l_prep) of_11\IN|the (l_pobj) embolism_15\NN|NONE (l_appos) disease_20\NN|thrombo|(||,|venous
D004967_D020521 CID oestrogen_3\NN|term (r_nmod) HT_6\NNP|,|increase|risk|.|but|significantly|after (r_nsubj) increased_8\VBD|NONE (l_dobj) risk_10\NN|,|increase|.|but|significantly|HT|after (l_prep) of_11\IN|the (l_pobj) embolism_15\NN|NONE (l_appos) disease_20\NN|thrombo|(||,|venous (l_nmod) stroke_17\NN|gallbladder
D004967_D054556 CID oestrogen_3\NN|term (r_nmod) HT_6\NNP|,|increase|risk|.|but|significantly|after (r_nsubj) increased_8\VBD|NONE (l_dobj) risk_10\NN|,|increase|.|but|significantly|HT|after (l_prep) of_11\IN|the (l_pobj) embolism_15\NN|NONE
D004967_D001943 NONE oestrogen_3\NN|term (r_nmod) HT_6\NNP|,|increase|risk|.|but|significantly|after (r_nsubj) increased_8\VBD|NONE (l_conj) increase_42\VB|,|risk|.|but|significantly|HT|after (l_dobj) risk_44\NN|not|significantly|did (l_prep) of_45\IN|the (l_pobj) cancer_47\NN|NONE
3653576
C004504_D058186 CID 2-bromoethylamine_36\NN|NONE (r_punct) ._42\.|produced|PAN|,|and (r_punct) puromycin_29\NNS|NONE (l_ccomp) produced_20\VBN|PAN|,|.|and (l_nsubjpass) models_2\NNS|by|were|, (l_prep) of_3\IN|experimental|Acute (l_pobj) damage_5\NN|NONE
C004504_D058186 CID BEA_38\NNP|,|respectively (r_nmod) 2-bromoethylamine_36\NN|NONE (r_punct) ._42\.|produced|PAN|,|and (r_punct) puromycin_29\NNS|NONE (l_ccomp) produced_20\VBN|PAN|,|.|and (l_nsubjpass) models_2\NNS|by|were|, (l_prep) of_3\IN|experimental|Acute (l_pobj) damage_5\NN|NONE
C004504_D007674 NONE BEA_6\NNP|or (r_conj) HCBD_4\NNP|NONE (r_pobj) by_3\IN|NONE (r_agent) produced_2\VBN|Tubular (r_acl) damage_1\NN|from|quantitatively|was|. (r_nsubjpass) discriminated_8\VBN|NONE (l_prep) from_13\IN|damage|quantitatively|was|. (l_pobj) damage_15\NN|NONE
C001335_D058186 CID hexachloro-1:3-butadiene_24\,|NONE (r_pobj) of_23\IN|NONE (r_prep) administration_22\NN|NONE (r_pobj) by_21\IN|were|,|models (r_agent) produced_20\VBN|PAN|,|.|and (l_nsubjpass) models_2\NNS|by|were|, (l_prep) of_3\IN|experimental|Acute (l_pobj) damage_5\NN|NONE
C001335_D058186 CID HCBD_26\NNP|)|( (r_appos) hexachloro-1:3-butadiene_24\,|NONE (r_pobj) of_23\IN|NONE (r_prep) administration_22\NN|NONE (r_pobj) by_21\IN|were|,|models (r_agent) produced_20\VBN|PAN|,|.|and (l_nsubjpass) models_2\NNS|by|were|, (l_prep) of_3\IN|experimental|Acute (l_pobj) damage_5\NN|NONE
D011692_D007674 NONE PAN_18\NNP|NONE (r_pobj) by_17\IN|NONE (r_agent) produced_16\VBN|glomerular (r_acl) damage_15\NN|NONE
C001335_D007674 NONE HCBD_4\NNP|NONE (r_pobj) by_3\IN|NONE (r_agent) produced_2\VBN|Tubular (r_acl) damage_1\NN|from|quantitatively|was|. (r_nsubjpass) discriminated_8\VBN|NONE (l_prep) from_13\IN|damage|quantitatively|was|. (l_pobj) damage_15\NN|NONE
D011692_D058186 CID aminonucleoside_30\NN|(|) (r_nmod) PAN_32\NNP|produced|,|.|and (r_npadvmod) puromycin_29\NNS|NONE (l_ccomp) produced_20\VBN|PAN|,|.|and (l_nsubjpass) models_2\NNS|by|were|, (l_prep) of_3\IN|experimental|Acute (l_pobj) damage_5\NN|NONE
D011692_D058186 CID PAN_32\NNP|produced|,|.|and (r_npadvmod) puromycin_29\NNS|NONE (l_ccomp) produced_20\VBN|PAN|,|.|and (l_nsubjpass) models_2\NNS|by|were|, (l_prep) of_3\IN|experimental|Acute (l_pobj) damage_5\NN|NONE
12684739
D020888_D019966 NONE GVG_35\NNP|NONE (r_pobj) of_29\IN|the (r_prep) effects_28\NNS|Given|we|,|.|accumbens (r_dobj) explored_26\VBD|NONE (l_prep) Given_0\VBN|we|,|.|accumbens|effects (l_pobj) success_3\NN|NONE (l_prep) for_4\IN|preclinical|its (l_pcomp) treating_5\VBG|NONE (l_dobj) abuse_7\NN|NONE
D020888_D005128 CID GVG_35\NNP|NONE (r_pobj) of_29\IN|the (r_prep) effects_28\NNS|Given|we|,|.|accumbens (r_dobj) explored_26\VBD|NONE (l_prep) Given_0\VBN|we|,|.|accumbens|effects (l_pobj) success_3\NN|NONE (l_prep) for_4\IN|preclinical|its (l_pcomp) treating_5\VBG|NONE (l_dobj) abuse_7\NN|NONE (l_conj) risk_11\NN|substance|and (l_prep) of_12\IN|the|increased (l_pobj) defects_15\NNS|NONE
D020888_D005128 CID GVG_35\NNP|NONE (r_pobj) of_29\IN|the (r_prep) effects_28\NNS|Given|we|,|.|accumbens (r_dobj) explored_26\VBD|NONE (l_prep) Given_0\VBN|we|,|.|accumbens|effects (l_pobj) success_3\NN|NONE (l_prep) for_4\IN|preclinical|its (l_pcomp) treating_5\VBG|NONE (l_dobj) abuse_7\NN|NONE (l_conj) risk_11\NN|substance|and (l_prep) of_12\IN|the|increased (l_pobj) defects_15\NNS|NONE (l_appos) VFD_17\NNP|visual|associated|field
D004298_D019966 NONE dopamine_47\NN|( (r_appos) accumbens_43\NNS|Given|we|,|.|effects (r_oprd) explored_26\VBD|NONE (l_prep) Given_0\VBN|we|,|.|accumbens|effects (l_pobj) success_3\NN|NONE (l_prep) for_4\IN|preclinical|its (l_pcomp) treating_5\VBG|NONE (l_dobj) abuse_7\NN|NONE
D004298_D019966 NONE DA_49\NNP|(|)|)|NAcc (r_appos) dopamine_47\NN|( (r_appos) accumbens_43\NNS|Given|we|,|.|effects (r_oprd) explored_26\VBD|NONE (l_prep) Given_0\VBN|we|,|.|accumbens|effects (l_pobj) success_3\NN|NONE (l_prep) for_4\IN|preclinical|its (l_pcomp) treating_5\VBG|NONE (l_dobj) abuse_7\NN|NONE
D003042_D019966 NONE cocaine_37\NN| (r_npadvmod) induced_39\VBN|in (r_amod) increases_40\NNS|NONE (r_pobj) on_36\IN|chronic|dose (r_prep) GVG_35\NNP|NONE (r_pobj) of_29\IN|the (r_prep) effects_28\NNS|Given|we|,|.|accumbens (r_dobj) explored_26\VBD|NONE (l_prep) Given_0\VBN|we|,|.|accumbens|effects (l_pobj) success_3\NN|NONE (l_prep) for_4\IN|preclinical|its (l_pcomp) treating_5\VBG|NONE (l_dobj) abuse_7\NN|NONE
D004298_D005128 NONE dopamine_47\NN|( (r_appos) accumbens_43\NNS|Given|we|,|.|effects (r_oprd) explored_26\VBD|NONE (l_prep) Given_0\VBN|we|,|.|accumbens|effects (l_pobj) success_3\NN|NONE (l_prep) for_4\IN|preclinical|its (l_pcomp) treating_5\VBG|NONE (l_dobj) abuse_7\NN|NONE (l_conj) risk_11\NN|substance|and (l_prep) of_12\IN|the|increased (l_pobj) defects_15\NNS|NONE
D004298_D005128 NONE dopamine_47\NN|( (r_appos) accumbens_43\NNS|Given|we|,|.|effects (r_oprd) explored_26\VBD|NONE (l_prep) Given_0\VBN|we|,|.|accumbens|effects (l_pobj) success_3\NN|NONE (l_prep) for_4\IN|preclinical|its (l_pcomp) treating_5\VBG|NONE (l_dobj) abuse_7\NN|NONE (l_conj) risk_11\NN|substance|and (l_prep) of_12\IN|the|increased (l_pobj) defects_15\NNS|NONE (l_appos) VFD_17\NNP|visual|associated|field
D004298_D005128 NONE DA_49\NNP|(|)|)|NAcc (r_appos) dopamine_47\NN|( (r_appos) accumbens_43\NNS|Given|we|,|.|effects (r_oprd) explored_26\VBD|NONE (l_prep) Given_0\VBN|we|,|.|accumbens|effects (l_pobj) success_3\NN|NONE (l_prep) for_4\IN|preclinical|its (l_pcomp) treating_5\VBG|NONE (l_dobj) abuse_7\NN|NONE (l_conj) risk_11\NN|substance|and (l_prep) of_12\IN|the|increased (l_pobj) defects_15\NNS|NONE
D004298_D005128 NONE DA_49\NNP|(|)|)|NAcc (r_appos) dopamine_47\NN|( (r_appos) accumbens_43\NNS|Given|we|,|.|effects (r_oprd) explored_26\VBD|NONE (l_prep) Given_0\VBN|we|,|.|accumbens|effects (l_pobj) success_3\NN|NONE (l_prep) for_4\IN|preclinical|its (l_pcomp) treating_5\VBG|NONE (l_dobj) abuse_7\NN|NONE (l_conj) risk_11\NN|substance|and (l_prep) of_12\IN|the|increased (l_pobj) defects_15\NNS|NONE (l_appos) VFD_17\NNP|visual|associated|field
D003042_D005128 NONE cocaine_37\NN| (r_npadvmod) induced_39\VBN|in (r_amod) increases_40\NNS|NONE (r_pobj) on_36\IN|chronic|dose (r_prep) GVG_35\NNP|NONE (r_pobj) of_29\IN|the (r_prep) effects_28\NNS|Given|we|,|.|accumbens (r_dobj) explored_26\VBD|NONE (l_prep) Given_0\VBN|we|,|.|accumbens|effects (l_pobj) success_3\NN|NONE (l_prep) for_4\IN|preclinical|its (l_pcomp) treating_5\VBG|NONE (l_dobj) abuse_7\NN|NONE (l_conj) risk_11\NN|substance|and (l_prep) of_12\IN|the|increased (l_pobj) defects_15\NNS|NONE
D003042_D005128 NONE cocaine_37\NN| (r_npadvmod) induced_39\VBN|in (r_amod) increases_40\NNS|NONE (r_pobj) on_36\IN|chronic|dose (r_prep) GVG_35\NNP|NONE (r_pobj) of_29\IN|the (r_prep) effects_28\NNS|Given|we|,|.|accumbens (r_dobj) explored_26\VBD|NONE (l_prep) Given_0\VBN|we|,|.|accumbens|effects (l_pobj) success_3\NN|NONE (l_prep) for_4\IN|preclinical|its (l_pcomp) treating_5\VBG|NONE (l_dobj) abuse_7\NN|NONE (l_conj) risk_11\NN|substance|and (l_prep) of_12\IN|the|increased (l_pobj) defects_15\NNS|NONE (l_appos) VFD_17\NNP|visual|associated|field
11195262
D014635_D004830 NONE VPA_4\NNP|been|He|had|.|was|for (r_dobj) taking_3\VBG|NONE (l_prep) for_5\IN|been|VPA|He|had|.|was (l_pobj) treatment_6\NN|NONE (l_prep) of_7\IN|NONE (l_pobj) convulsions_13\NNS|NONE
D014635_D002493 NONE VPA_30\NNP|NONE (r_pobj) of_29\IN|the|term (r_prep) administration_28\NN|a|of|and (r_conj) weakness_17\NN|NONE (l_prep) of_18\IN|a|and|administration (l_pobj) system_22\NN|NONE
D014635_D007177 CID valproate_3\NN|NONE (l_prep) to_4\IN|.|Contribution (l_pobj) syndrome_6\NN|NONE (l_prep) of_7\IN|the (l_pobj) secretion_9\NN|NONE (l_prep) of_10\IN|inappropriate (l_pobj) hormone_12\NN|NONE
D014635_D007177 CID valproate_14\NN|the|of (l_conj) developed_21\VBD|)|VPA|and|( (l_dobj) syndrome_23\NN|subsequently|who (l_prep) of_24\IN|the (l_pobj) secretion_26\NN|NONE (l_prep) of_27\IN|inappropriate (l_pobj) hormone_29\NN|NONE
D014635_D007177 CID valproate_14\NN|the|of (l_conj) developed_21\VBD|)|VPA|and|( (l_dobj) syndrome_23\NN|subsequently|who (l_prep) of_24\IN|the (l_pobj) secretion_26\NN|NONE (l_prep) of_27\IN|inappropriate (l_pobj) hormone_29\NN|NONE (l_appos) SIADH_31\NNP|(|)|antidiuretic
D014635_D007177 CID VPA_16\NNP|)|developed|and|( (r_npadvmod) valproate_14\NN|the|of (l_conj) developed_21\VBD|)|VPA|and|( (l_dobj) syndrome_23\NN|subsequently|who (l_prep) of_24\IN|the (l_pobj) secretion_26\NN|NONE (l_prep) of_27\IN|inappropriate (l_pobj) hormone_29\NN|NONE
D014635_D007177 CID VPA_16\NNP|)|developed|and|( (r_npadvmod) valproate_14\NN|the|of (l_conj) developed_21\VBD|)|VPA|and|( (l_dobj) syndrome_23\NN|subsequently|who (l_prep) of_24\IN|the (l_pobj) secretion_26\NN|NONE (l_prep) of_27\IN|inappropriate (l_pobj) hormone_29\NN|NONE (l_appos) SIADH_31\NNP|(|)|antidiuretic
D014635_D007177 CID VPA_30\NNP|NONE (r_pobj) of_29\IN|the|term (r_prep) administration_28\NN|a|of|and (r_conj) weakness_17\NN|NONE (r_pobj) including_15\VBG|NONE (r_prep) factors_14\NNS|NONE (r_pobj) of_13\IN|a (r_prep) combination_12\NN|NONE (r_pobj) of_10\IN|the (r_prep) result_9\NN|episode|to (r_attr) be_7\VB|We|. (l_nsubj) episode_3\NN|to|result (l_prep) of_4\IN|this (l_pobj) SIADH_5\NNP|NONE
9931093
D016559_D006973 CID 506-induced_3\JJ|in|. (r_nummod) hypertension_4\NN|NONE
D016559_D006973 CID 506_5\CD|NONE (r_nummod) FK_4\NNP|NONE (r_pobj) of_3\IN|The|clinical (r_prep) utility_2\NN|.|by|is (r_nsubjpass) complicated_7\VBN|NONE (l_agent) by_8\IN|.|is|utility (l_pobj) hypertension_10\NN|NONE
D016559_D006973 CID 506-induced_6\JJ|FK (r_compound) hypertension_7\NN|NONE
D016559_D006973 CID 506_16\CD|NONE (r_nummod) FK_15\NNP|NONE (r_pobj) of_14\IN|chronic|on|the (r_prep) effects_13\NNS|,|we|clarify|expression (r_dobj) studied_10\VBD|NONE (l_advcl) clarify_1\VB|,|effects|we|expression (l_dobj) mechanisms_3\NNS|To (l_prep) of_4\IN|the (l_pobj) hypertension_7\NN|NONE
D016559_D006973 CID 506-induced_17\JJ|NONE (r_nummod) FK_16\NNP|in (r_poss) hypertension_18\NN|NONE
D016559_D006973 CID 506-induced_4\JJ|in|FK (r_nummod) hypertension_5\NN|d|.
C079574_D006973 NONE 139317_14\CD|on (r_nummod) FR_13\NNP|receptor|A (l_prep) on_15\IN| (l_pobj) hypertension_18\NN|NONE
D009569_D006973 NONE oxide_44\NN|,|the|.|(|endothelial|nitric|activity (r_compound) synthase_45\NN|of|ET|,|and|the|converting (r_conj) expression_27\NN|,|effects|we|clarify (r_dobj) studied_10\VBD|NONE (l_advcl) clarify_1\VB|,|effects|we|expression (l_dobj) mechanisms_3\NNS|To (l_prep) of_4\IN|the (l_pobj) hypertension_7\NN|NONE
D016559_D007674 NONE 506_5\CD|NONE (r_nummod) FK_4\NNP|NONE (r_pobj) of_3\IN|The|clinical (r_prep) utility_2\NN|.|by|is (r_nsubjpass) complicated_7\VBN|NONE (l_agent) by_8\IN|.|is|utility (l_pobj) hypertension_10\NN|NONE (l_conj) nephrotoxicity_12\NN|substantial|and
12907309
C121465_D064420 NONE MPEP_12\NNP|NONE (r_pobj) by_11\IN|the|of (r_prep) blockade_8\NN|that|neurones|may (r_nsubj) protect_14\VB|results|. (l_dobj) neurones_16\NNS|blockade|that|may (l_prep) against_17\IN|dopaminergic (l_pobj) toxicity_21\NN|NONE
D004298_D020258 NONE dopamine_22\NN|and|in|inhibition (r_compound) outflow_23\NN|NONE (r_pobj) in_21\IN|a (r_prep) decrease_20\NN|NONE (r_pobj) with_18\IN|.|action|is (r_prep) associated_17\VBN|NONE (l_nsubjpass) action_1\NN|.|with|is (l_prep) in_10\IN|,|Neuroprotective|of|antagonist|, (l_pobj) neurotoxicity_15\NN|NONE
D008694_D005334 CID methamphetamine_11\NN| (r_npadvmod) induced_13\VBN|dopaminergic (r_amod) neurotoxicity_15\NN|NONE (r_pobj) in_10\IN|,|Neuroprotective|of|antagonist|, (r_prep) action_1\NN|.|with|is (r_nsubjpass) associated_17\VBN|NONE (l_prep) with_18\IN|.|action|is (l_pobj) decrease_20\NN|NONE (l_prep) in_21\IN|a (l_pobj) outflow_23\NN|NONE (l_conj) inhibition_25\NN|and|dopamine|in (l_prep) of_26\IN|NONE (l_pobj) hyperthermia_27\NN|NONE
D008694_D005334 CID methamphetamine_12\NN| (r_npadvmod) induced_14\VBN|the|in|dopamine (r_amod) efflux_16\NN|NONE (r_pobj) of_10\IN|the|due (r_prep) reduction_9\NN|NONE (r_pobj) with_7\IN|,|with|be|and|Neuroprotection|.|may (r_prep) associated_6\VBN|NONE (l_conj) with_29\IN|with|,|be|and|Neuroprotection|.|may (l_pobj) decrease_31\NN|NONE (l_prep) in_32\IN|a (l_pobj) hyperthermia_33\NN|NONE
C121465_D020258 NONE MPEP_3\NNP|NONE (r_pobj) of_2\IN|in|,|Neuroprotective|antagonist|, (r_prep) action_1\NN|.|with|is (l_prep) in_10\IN|,|Neuroprotective|of|antagonist|, (l_pobj) neurotoxicity_15\NN|NONE
D004298_D005334 NONE dopamine_22\NN|and|in|inhibition (r_compound) outflow_23\NN|NONE (l_conj) inhibition_25\NN|and|dopamine|in (l_prep) of_26\IN|NONE (l_pobj) hyperthermia_27\NN|NONE
D004298_D005334 NONE dopamine_15\NN|the|in|induced (r_compound) efflux_16\NN|NONE (r_pobj) of_10\IN|the|due (r_prep) reduction_9\NN|NONE (r_pobj) with_7\IN|,|with|be|and|Neuroprotection|.|may (r_prep) associated_6\VBN|NONE (l_conj) with_29\IN|with|,|be|and|Neuroprotection|.|may (l_pobj) decrease_31\NN|NONE (l_prep) in_32\IN|a (l_pobj) hyperthermia_33\NN|NONE
D008694_D020258 NONE methamphetamine_11\NN| (r_npadvmod) induced_13\VBN|dopaminergic (r_amod) neurotoxicity_15\NN|NONE
C121465_D005334 NONE MPEP_3\NNP|NONE (r_pobj) of_2\IN|in|,|Neuroprotective|antagonist|, (r_prep) action_1\NN|.|with|is (r_nsubjpass) associated_17\VBN|NONE (l_prep) with_18\IN|.|action|is (l_pobj) decrease_20\NN|NONE (l_prep) in_21\IN|a (l_pobj) outflow_23\NN|NONE (l_conj) inhibition_25\NN|and|dopamine|in (l_prep) of_26\IN|NONE (l_pobj) hyperthermia_27\NN|NONE
C121465_D005334 NONE MPEP_3\NNP|NONE (r_pobj) by_2\IN|NONE (r_agent) rendered_1\VBN|NONE (r_acl) Neuroprotection_0\NNP|with|,|with|be|and|.|may (r_nsubjpass) associated_6\VBN|NONE (l_conj) with_29\IN|with|,|be|and|Neuroprotection|.|may (l_pobj) decrease_31\NN|NONE (l_prep) in_32\IN|a (l_pobj) hyperthermia_33\NN|NONE
D008694_D064420 NONE methamphetamine_18\NN| (r_npadvmod) induced_20\VBN|NONE (r_amod) toxicity_21\NN|NONE
435349
D013390_D013746 NONE Sch_20\NNP|when|mg|was (r_nsubjpass) exceeded_24\VBN|there|when|response|either (r_advcl) was_7\VBD|was|.|infusion (l_attr) response_10\NN|there|exceeded|when|either (l_prep) to_11\IN|no|muscular (l_pobj) stimulation_13\NN|NONE (l_compound) tetanic_12\JJ|of|or
D013390_D005207 CID Suxamethonium_0\JJ|infusion|observed|.|and (r_compound) rate_2\NN|NONE (l_conj) observed_4\JJ|infusion|Suxamethonium|.|and (l_dobj) fasciculations_5\NNS|NONE
9869257
D012601_D000647 CID scopolamine_36\NN|NONE (r_pobj) by_29\IN|NONE (r_agent) induced_28\VBN|NONE (r_acl) amnesia_27\NN|NONE
C098725_D000647 CID S-(-)-ET-126_41\NNP|the|Mselective (r_appos) antagonist_40\NN|antimuscarinic|both|and|non|the|selective|drug (r_conj) scopolamine_36\NN|NONE (r_pobj) by_29\IN|NONE (r_agent) induced_28\VBN|NONE (r_acl) amnesia_27\NN|NONE
C087567_D000647 NONE PG-9_8\NNP|,|In|,|.|before|prevented (r_nsubj) administered_18\VBN|NONE (l_conj) prevented_26\VBN|,|In|,|.|before|PG (l_dobj) amnesia_27\NN|NONE
C087567_D000647 NONE PG-9_6\NNP|,|per|)|i.c.v. (r_nmod) microg_11\NN|,|In|.|demonstrating|also|able|, (r_nsubj) was_17\VBD|NONE (l_acomp) able_19\JJ|,|In|.|demonstrating|microg|also|, (l_xcomp) prevent_21\VB|NONE (l_dobj) amnesia_25\NN|to
19729346
D010098_D059350 NONE oxycodone_30\NN|NONE (r_pobj) of_26\IN|a|mg (r_prep) dose_25\NN|NONE (r_pobj) to_22\IN|NONE (r_prep) response_21\NN|NONE (r_pobj) in_20\IN|NONE (r_prep) changes_19\NNS|who|from|are|not (r_dobj) suffering_11\VBG|older|healthy (l_prep) from_12\IN|who|are|not|changes (l_pobj) pain_14\NN|NONE
D010098_D010146 NONE oxycodone_18\NN|NONE (r_pobj) of_14\IN|in|a|mg|single (r_prep) dose_13\NN|NONE (r_pobj) of_9\IN|neurocognitive|objective|the (r_prep) effects_8\NNS|years|study|,|)|.|adults|and (r_dobj) measured_2\VBD|NONE (l_dobj) adults_39\NNS|years|study|,|)|.|effects|and (l_relcl) suffering_43\VBG|NONE (l_prep) from_44\IN|who|were|not (l_pobj) pain_49\NN|NONE
17490864
D000661_D006948 CID Amphetamine_0\NN| (r_npadvmod) induced_2\VBN|locomotor (r_amod) hyperactivity_4\NN|.|similar
7890216
D014580_D042882 NONE acid_13\NN|NONE (r_pobj) to_10\IN|NONE (r_prep) response_9\NN|:|of|. (r_appos) Composition_0\NN|NONE (l_prep) of_1\IN|response|:|. (l_pobj) stones_4\NNS|NONE
D002784_D042882 NONE cholesterol_21\NN|and| (r_conj) %_17\NN|they|that (r_dobj) contained_15\VBD|analysis|.|, (r_ccomp) showed_12\VBD|NONE (l_nsubj) analysis_1\NN|contained|.|, (l_prep) of_2\IN|Chemical (l_pobj) stones_4\NNS|NONE
D002784_D042882 NONE cholesterol_36\NN|NONE (r_nsubj) rich_37\JJ|that|stones (r_acomp) were_35\VBD|NONE (r_ccomp) suggesting_31\VBG|dissolution|After|,|.|five|, (r_advcl) showed_12\VBD|NONE (l_dobj) dissolution_29\NN|After|,|suggesting|.|five|, (l_compound) stone_28\NN|partial|either|gall
D002784_D042882 NONE cholesterol_14\NN|and|,|rich (r_conj) multiple_11\JJ|, (r_conj) small_9\JJ|generally|,|although|in|, (r_acomp) are_7\VBP|In|octreotide|,|have|stones (r_ccomp) induced_4\VBN|NONE (l_dobj) stones_6\NNS|In|octreotide|,|have|are
D002784_D042882 NONE cholesterol_14\NN|and|,|rich (r_conj) multiple_11\JJ|, (r_conj) small_9\JJ|generally|,|although|in|, (r_acomp) are_7\VBP|In|octreotide|,|have|stones (l_prep) in_18\IN|generally|small|,|although|, (l_pobj) common_19\JJ|NONE (l_prep) with_20\IN|NONE (l_pobj) disease_24\NN|NONE
D002784_D042882 NONE cholesterol_14\NN|and|,|rich (r_conj) multiple_11\JJ|, (r_conj) small_9\JJ|generally|,|although|in|, (r_acomp) are_7\VBP|In|octreotide|,|have|stones (r_ccomp) induced_4\VBN|NONE (l_conj) have_31\VB|In|octreotide|,|are|stones (l_dobj) duct_35\NN|at|.|patients|will (l_conj) stones_39\NNS|a|and|blocked|cystic
D015282_D042882 CID octreotide_7\NN|NONE (r_pobj) with_6\IN|NONE (r_prep) associated_5\VBN|gall|bladder (r_acl) stones_4\NNS|NONE
D015282_D042882 CID Octreotide_0\NNP|,|stones|in|. (r_nsubj) induces_8\VBZ|NONE (l_dobj) stones_11\NNS|,|Octreotide|in|.
D015282_D042882 CID octreotide_28\NN|NONE (r_pobj) in_26\IN|direct (r_prep) methods_25\NNS|NONE (r_pobj) by_21\IN|was|.|,|treated|is|this (r_agent) investigated_20\VBN|NONE (l_conj) treated_29\VBD|was|.|,|is|by|this (l_prep) with_32\IN|patients (l_pobj) stones_34\NNS|NONE
D015282_D042882 CID octreotide_3\NN|In|,|have|are|stones (r_advmod) induced_4\VBN|NONE (l_dobj) stones_6\NNS|In|octreotide|,|have|are
D015282_D042882 CID octreotide_3\NN|In|,|have|are|stones (r_advmod) induced_4\VBN|NONE (l_ccomp) are_7\VBP|In|octreotide|,|have|stones (l_prep) in_18\IN|generally|small|,|although|, (l_pobj) common_19\JJ|NONE (l_prep) with_20\IN|NONE (l_pobj) disease_24\NN|NONE
D015282_D042882 CID octreotide_3\NN|In|,|have|are|stones (r_advmod) induced_4\VBN|NONE (l_conj) have_31\VB|In|octreotide|,|are|stones (l_dobj) duct_35\NN|at|.|patients|will (l_conj) stones_39\NNS|a|and|blocked|cystic
D015282_D000172 NONE Octreotide_0\NNP|,|stones|in|. (l_appos) treatment_4\NN|, (l_prep) for_5\IN|an|effective (l_pobj) acromegaly_6\NNS|NONE
D015282_D000172 NONE octreotide_28\NN|NONE (r_pobj) in_26\IN|direct (r_prep) methods_25\NNS|NONE (r_pobj) by_21\IN|was|.|,|treated|is|this (r_agent) investigated_20\VBN|NONE (l_conj) treated_29\VBD|was|.|,|is|by|this (l_dobj) patients_31\NNS|with (l_compound) acromegalic_30\JJ|NONE
D002118_D042882 NONE calcium_41\NN|NONE (r_dobj) containing_40\VBG|gall|some (r_acl) stones_39\NNS|a|and|blocked|cystic (r_conj) duct_35\NN|at|.|patients|will (r_dobj) have_31\VB|In|octreotide|,|are|stones (r_conj) induced_4\VBN|NONE (l_dobj) stones_6\NNS|In|octreotide|,|have|are
D002118_D042882 NONE calcium_41\NN|NONE (r_dobj) containing_40\VBG|gall|some (r_acl) stones_39\NNS|a|and|blocked|cystic (r_conj) duct_35\NN|at|.|patients|will (r_dobj) have_31\VB|In|octreotide|,|are|stones (r_conj) induced_4\VBN|NONE (l_ccomp) are_7\VBP|In|octreotide|,|have|stones (l_prep) in_18\IN|generally|small|,|although|, (l_pobj) common_19\JJ|NONE (l_prep) with_20\IN|NONE (l_pobj) disease_24\NN|NONE
D002118_D042882 NONE calcium_41\NN|NONE (r_dobj) containing_40\VBG|gall|some (r_acl) stones_39\NNS|a|and|blocked|cystic
19674115
D011718_D000857 CID pyrazinamide_4\NN|NONE (r_pobj) by_3\IN|.|dysosmia (r_agent) induced_2\VBN|NONE (l_nsubj) dysosmia_1\NN|.|by
D011718_D000857 CID pyrazinamide_10\VB|NONE (r_xcomp) related_8\VBN|olfactory|reversible (r_acl) disorder_7\NN|NONE
D011718_D000857 CID pyrazinamide_4\JJ|NONE (r_compound) withdrawal_5\NN|completely (r_pobj) after_3\IN|recurred|and|.|Dysosmia (r_prep) disappeared_1\VBD|NONE (l_nsubj) Dysosmia_0\NNP|recurred|and|.|after
D011718_D056486 NONE Pyrazinamide_0\NNP|can|effects|. (r_nsubj) have_2\VB|NONE (l_dobj) effects_4\NNS|can|Pyrazinamide|. (l_prep) as_6\IN|adverse (l_pobj) toxicity_8\NN|such
D011718_D033461 NONE Pyrazinamide_0\NNP|can|effects|. (r_nsubj) have_2\VB|NONE (l_dobj) effects_4\NNS|can|Pyrazinamide|. (l_prep) as_6\IN|adverse (l_pobj) toxicity_8\NN|such (l_conj) disorders_13\NNS|hepatic|, (l_nmod) hyperuricemia_10\NN|NONE
19269743
D002211_D010146 CID capsaicin_9\NN| (r_npadvmod) induced_11\VBN|NONE (r_amod) pain_12\NN|NONE
D002211_D010146 CID capsaicin_21\NN|NONE (r_pobj) of_20\IN|microg|three (r_prep) doses_19\NNS|NONE (r_pobj) of_17\IN|separated|intradermal (r_prep) injections_16\NNS|)|volunteers|.|In|,|,|given (r_dobj) received_14\VBD|NONE (l_prep) In_0\IN|)|volunteers|.|injections|,|,|given (l_pobj) order_1\NN|NONE (l_acl) address_3\VB|NONE (l_dobj) memory_8\NN|to (l_compound) pain_7\NN|term
D002211_D010146 CID capsaicin_11\NN|p<.|)|( (r_compound) doses_12\NNS|NONE (r_pobj) across_10\IN|reliably|,|magnitude|to|regardless (r_prep) discriminate_5\VB|NONE (l_dobj) magnitude_7\NN|reliably|,|across|to|regardless (l_compound) pain_6\NN|duration|and
16428221
D008774_D014657 NONE methylphenidate_3\NN|be|should|that|in (l_dobj) vasculitis_5\NN|NONE
D008774_D014657 NONE methylphenidate_18\NN|NONE (r_compound) therapy_19\NN|NONE (r_pobj) of_17\IN|a (r_prep) history_16\NN|neurological|and (r_conj) symptoms_13\NNS|NONE (r_pobj) with_11\IN|NONE (r_prep) patients_10\NNS|NONE (r_pobj) in_9\IN|be|should|that|methylphenidate (r_prep) considered_8\VBN|We|. (l_nsubjpass) methylphenidate_3\NN|be|should|that|in (l_dobj) vasculitis_5\NN|NONE
D008774_D019969 NONE methylphenidate_20\NN|in (r_compound) intake_21\NN|NONE (r_pobj) after_19\IN|been|has|stroke|in|. (r_prep) reported_18\VBN|is|well|,|and|vasculitis (r_conj) documented_8\VBN|NONE (l_nsubjpass) vasculitis_1\NN|is|well|,|reported|and (l_acl) associated_2\VBN|Cerebral (l_prep) with_3\IN|NONE (l_pobj) abuse_5\NN|NONE
D008774_D020293 CID methylphenidate_4\NN|oral|in (r_compound) intake_5\NN|NONE (r_dobj) following_2\VBG|.|report|Cerebral|: (r_prep) vasculitis_1\NNS|NONE
D008774_D020293 CID methylphenidate_20\NN|in (r_compound) intake_21\NN|NONE (r_pobj) after_19\IN|been|has|stroke|in|. (r_prep) reported_18\VBN|is|well|,|and|vasculitis (r_conj) documented_8\VBN|NONE (l_nsubjpass) vasculitis_1\NN|is|well|,|reported|and
D008774_D002544 NONE methylphenidate_20\NN|in (r_compound) intake_21\NN|NONE (r_pobj) after_19\IN|been|has|stroke|in|. (r_prep) reported_18\VBN|is|well|,|and|vasculitis (l_nsubjpass) stroke_15\NN|been|has|after|in|.
D008774_D002544 NONE methylphenidate_14\NN|NONE (r_pobj) with_13\IN|and|who|suffered|was|due (r_prep) treated_12\VBN|a|old (l_conj) suffered_19\VBD|and|who|was|due|with (l_prep) from_20\IN|NONE (l_pobj) strokes_23\NNS|NONE
D008774_D006948 NONE methylphenidate_14\NN|NONE (r_pobj) with_13\IN|and|who|suffered|was|due (r_prep) treated_12\VBN|a|old (l_prep) due_15\IN|and|who|suffered|was|with (l_pobj) hyperactivity_17\NN|to
2559236
D004317_D000419 CID adriamycin_7\NNS|NONE (r_pobj) of_6\IN|and|single|a (r_prep) dose_5\NN|Rats|.|divided|were (r_dobj) given_2\VBN|NONE (l_advcl) divided_12\VBD|Rats|.|were|dose (l_prep) into_13\IN|later (l_pobj) groups_15\NNS|NONE (l_acl) matched_16\VBN|four (l_prep) for_17\IN|NONE (l_pobj) albuminuria_18\NN|NONE
D004656_D009401 NONE enalapril_10\NN|enzyme (r_appos) inhibitor_6\NN|NONE (r_pobj) of_2\IN|The (r_prep) effect_1\NN|was|in|with|. (r_nsubjpass) assessed_12\VBN|NONE (l_prep) with_18\IN|was|in|effect|. (l_pobj) nephrosis_21\NN|NONE
D004656_D009401 NONE enalapril_17\NN|NONE (r_pobj) of_16\IN|on|the (r_prep) effect_15\NN|to (l_prep) on_18\IN|of|the (l_pobj) progression_19\NN|NONE (l_prep) of_20\IN|NONE (l_pobj) injury_22\NN|NONE (l_prep) in_23\IN|renal (l_pobj) nephrosis_25\NN|NONE
D004656_D000419 NONE enalapril_7\DT|that|vs.||pressure (r_nsubj) reduced_8\JJ|studies|. (l_prep) vs._16\IN|enalapril|that||pressure (l_pobj) Hg_21\NNP|NONE (l_conj) pressure_36\NN|and|,|)|,|group|mm|P (l_appos) +/-_39\SYM|(|or|(|glomerular|+/|capillary|)|GFR (l_prep) without_53\IN|||vs. (l_pcomp) reducing_54\VBG|NONE (l_dobj) albuminuria_55\NN|NONE
D004656_D000419 NONE enalapril_1\NN|NONE (r_compound) treatment_2\NN|NONE (r_nsubj) reduced_3\VBN|.|blood|without (r_amod) pressure_5\NN|NONE (l_prep) without_6\IN|.|blood|reduced (l_pcomp) reducing_7\VBG|NONE (l_dobj) albuminuria_8\NN|in
D004317_D007674 NONE adriamycin_9\NNS| (r_npadvmod) induced_11\VBN|NONE (r_amod) nephropathy_12\NN|NONE
D004317_D007674 NONE adriamycin_24\JJ|NONE (r_amod) nephrosis_25\NN|NONE (r_pobj) in_23\IN|renal (r_prep) injury_22\NN|NONE
D004317_D009401 CID adriamycin_20\NNS|established (r_amod) nephrosis_21\NN|NONE
D004317_D009401 CID adriamycin_24\JJ|NONE (r_amod) nephrosis_25\NN|NONE
D004656_D007674 NONE enalapril_17\NN|NONE (r_pobj) of_16\IN|on|the (r_prep) effect_15\NN|to (l_prep) on_18\IN|of|the (l_pobj) progression_19\NN|NONE (l_prep) of_20\IN|NONE (l_pobj) injury_22\NN|NONE
17437408
D010862_D012640 CID pilocarpine_11\NN| (r_npadvmod) induced_13\VBN|in (r_amod) seizures_14\NNS|NONE
3703509
D011241_D059606 NONE prednisone_5\NN|NONE (r_pobj) to_3\IN|short (r_prep) exposure_2\NN|NONE (r_pobj) Following_0\VBG|lethargy|.|,|,|increasing|boys (r_prep) developed_9\VBD|NONE (l_advcl) increasing_12\VBG|lethargy|.|,|,|boys|Following (l_dobj) somnolence_13\NN|NONE (l_conj) polydipsia_15\NN|,
D019344_D007662 NONE lactate_13\NN|a|known (r_compound) level_14\NN|NONE (r_pobj) without_9\IN|in (r_prep) present_4\JJ|.|acidosis|was (l_prep) in_5\IN|without (l_pobj) one_6\CD|NONE (l_conj) ketosis_8\NN|and
D019344_D000140 NONE lactate_13\NN|a|known (r_compound) level_14\NN|NONE (r_pobj) without_9\IN|in (r_prep) present_4\JJ|.|acidosis|was (r_acomp) was_3\VBD|NONE (l_nsubj) acidosis_2\NN|present|.|was
D011241_D006963 NONE prednisone_5\NN|NONE (r_pobj) to_3\IN|short (r_prep) exposure_2\NN|NONE (r_pobj) Following_0\VBG|lethargy|.|,|,|increasing|boys (r_prep) developed_9\VBD|NONE (l_advcl) increasing_12\VBG|lethargy|.|,|,|boys|Following (l_dobj) somnolence_13\NN|NONE (l_conj) polydipsia_15\NN|, (l_conj) polyphagia_17\NN|,
D011241_D053609 NONE prednisone_5\NN|NONE (r_pobj) to_3\IN|short (r_prep) exposure_2\NN|NONE (r_pobj) Following_0\VBG|lethargy|.|,|,|increasing|boys (r_prep) developed_9\VBD|NONE (l_dobj) lethargy_10\NN|.|,|,|increasing|boys|Following
D011241_D006970 NONE prednisone_5\NN|NONE (r_pobj) to_3\IN|short (r_prep) exposure_2\NN|NONE (r_pobj) Following_0\VBG|lethargy|.|,|,|increasing|boys (r_prep) developed_9\VBD|NONE (l_advcl) increasing_12\VBG|lethargy|.|,|,|boys|Following (l_dobj) somnolence_13\NN|NONE
D011241_D011141 NONE prednisone_5\NN|NONE (r_pobj) to_3\IN|short (r_prep) exposure_2\NN|NONE (r_pobj) Following_0\VBG|lethargy|.|,|,|increasing|boys (r_prep) developed_9\VBD|NONE (l_advcl) increasing_12\VBG|lethargy|.|,|,|boys|Following (l_dobj) somnolence_13\NN|NONE (l_conj) polydipsia_15\NN|, (l_conj) polyphagia_17\NN|, (l_conj) polyuria_20\NN|and|,
7707116
D015474_D009447 NONE acid_7\NN|NONE (r_pobj) of_3\IN|following|in (r_prep) trial_2\NN|.|Phase (l_prep) in_8\IN|of|following (l_pobj) children_9\NNS|NONE (l_prep) with_10\IN|NONE (l_pobj) neuroblastoma_11\NN|NONE
D015474_D009447 NONE acid_11\NN|NONE (r_pobj) with_7\IN|cell|neuroblastoma (r_prep) lines_6\NNS|NONE (l_compound) neuroblastoma_4\NN|cell|with
D015474_D009447 NONE RA_15\NNP|retinoic (r_appos) acid_11\NN|NONE (r_pobj) with_7\IN|cell|neuroblastoma (r_prep) lines_6\NNS|NONE (l_compound) neuroblastoma_4\NN|cell|with
D015474_D009447 NONE RA_3\NNP|responses|Since|has (r_nsubj) demonstrated_5\VBN|may|it|,|.|effective (l_dobj) responses_7\NNS|RA|Since|has (l_prep) in_8\IN|clinical (l_pobj) patients_10\NNS|NONE (l_compound) neuroblastoma_9\NN|NONE
D015474_D009447 NONE RA_24\NNP|NONE (r_pobj) of_21\IN|and|pharmacokinetics|administered|, (r_prep) toxicities_17\NNS|(|)|MTD|tolerated|the|,|following (l_acl) administered_25\VBD|and|pharmacokinetics|of|, (l_prep) on_26\IN|NONE (l_pobj) schedule_29\NN|NONE (l_prep) in_30\IN|an|intermittent (l_pobj) children_31\NNS|NONE (l_prep) with_32\IN|NONE (l_pobj) neuroblastoma_33\NN|NONE
D015474_D006934 CID RA_13\NNP|serum (r_compound) levels_14\NNS|NONE (r_pobj) by_9\IN|be|may (r_agent) predicted_8\VBN|DLT|.|hypercalcemia|and|, (r_conj) included_2\VBD|NONE (l_dobj) hypercalcemia_3\NN|DLT|.|and|predicted|,
D015474_D064420 NONE RA_24\NNP|NONE (r_pobj) of_21\IN|and|pharmacokinetics|administered|, (r_prep) toxicities_17\NNS|(|)|MTD|tolerated|the|,|following
D015474_D064420 NONE RA_6\NNP|was|after (r_nsubjpass) discontinued_8\VBN|toxicities|. (r_advcl) resolved_2\VBD|NONE (l_nsubj) toxicities_1\NNS|discontinued|.
10193809
D011692_D011507 CID aminonucleoside_1\NN|NONE (r_amod) Puromycin_0\NNP|was|induce|to|. (r_nsubjpass) administered_6\VBN|NONE (l_advcl) induce_12\VB|was|to|Puromycin|. (l_dobj) proteinuria_13\NN|to
D011692_D011507 CID PAN_3\NNP|NONE (r_appos) aminonucleoside_1\NN|NONE (r_amod) Puromycin_0\NNP|was|induce|to|. (r_nsubjpass) administered_6\VBN|NONE (l_advcl) induce_12\VB|was|to|Puromycin|. (l_dobj) proteinuria_13\NN|to
19319147
D014859_D020521 NONE Warfarin_0\NNP| (r_npadvmod) associated_2\VBN|)|ICH|intracerebral (r_amod) hemorrhage_4\NN|.|type (r_nsubj) is_10\VBZ|NONE (l_attr) type_13\NN|.|hemorrhage (l_prep) of_14\IN|a|severe (l_pobj) stroke_15\NN|NONE
D014859_D006470 NONE warfarin_12\RB| (r_npadvmod) associated_14\VBN|intracerebral (r_amod) hemorrhage_16\NN|NONE (r_pobj) of_11\IN|mouse|a (r_prep) model_10\NN|NONE (r_pobj) in_7\IN|.|volume|reversal (r_prep) reduces_4\VBZ|NONE (l_dobj) volume_6\NN|.|reversal|in (l_compound) hemorrhage_5\NN|NONE
C025667_D002543 NONE PCC_5\NNP|to|in|treatment (r_nsubj) be_7\VB|NONE (l_attr) treatment_11\NN|to|in|PCC (l_prep) for_12\IN|acute|an|effective (l_pobj) ICH_15\NNP|NONE
D014859_D002543 CID warfarin_12\RB| (r_npadvmod) associated_14\VBN|intracerebral (r_amod) hemorrhage_16\NN|NONE
D014859_D002543 CID Warfarin_0\NNP| (r_npadvmod) associated_2\VBN|)|ICH|intracerebral (r_amod) hemorrhage_4\NN|.|type
D014859_D002543 CID Warfarin_0\NNP| (r_npadvmod) associated_2\VBN|)|ICH|intracerebral (r_amod) hemorrhage_4\NN|.|type (l_appos) ICH_8\NNP|)|associated|intracerebral
3769769
D014282_D001919 CID hydrochloride_4\NN|to (r_pobj) due_1\JJ|. (r_amod) Bradycardia_0\NNS|NONE
D014282_D012559 NONE hydrochloride_12\NN|NONE (r_dobj) trihexyphenidyl_11\JJ|.|with|was|patient (r_conj) treated_5\VBN|NONE (l_nsubjpass) patient_3\NN|.|trihexyphenidyl|with|was (l_amod) schizophrenic_2\JJ|A|chronic
17344566
D013974_D003161 NONE thyroxine_7\NN|.|with (r_nsubj) presented_10\VBD|NONE (l_prep) with_11\IN|.|thyroxine (l_pobj) syndrome_15\NN|NONE
D019821_D007037 NONE Simvastatin_0\NNP| (r_npadvmod) induced_2\VBN|and|myonecrosis|.|compartment|associated (r_amod) syndrome_6\NN|NONE (l_acl) associated_9\VBN|and|myonecrosis|induced|.|compartment (l_prep) with_10\IN|NONE (l_pobj) hypothyroidism_11\NN|NONE
D019821_D007037 NONE simvastatin_9\NN|taking|and|old|A (r_conj) thyroxine_7\NN|.|with (l_compound) taking_6\VBG|and|old|A|simvastatin (l_nsubj) male_5\NN|NONE (l_amod) hypothyroid_4\JJ|NONE
D013974_D009135 NONE thyroxine_7\NN|.|with (r_nsubj) presented_10\VBD|NONE (l_prep) with_11\IN|.|thyroxine (l_pobj) syndrome_15\NN|NONE (l_conj) myonecrosis_17\NN|compartment|and
D019821_D009135 NONE Simvastatin_0\NNP| (r_npadvmod) induced_2\VBN|and|myonecrosis|.|compartment|associated (r_amod) syndrome_6\NN|NONE (l_conj) myonecrosis_8\NN|and|induced|.|compartment|associated
D019821_D009135 NONE simvastatin_9\NN|taking|and|old|A (r_conj) thyroxine_7\NN|.|with (r_nsubj) presented_10\VBD|NONE (l_prep) with_11\IN|.|thyroxine (l_pobj) syndrome_15\NN|NONE (l_conj) myonecrosis_17\NN|compartment|and
D013974_D007037 NONE thyroxine_7\NN|.|with (l_compound) taking_6\VBG|and|old|A|simvastatin (l_nsubj) male_5\NN|NONE (l_amod) hypothyroid_4\JJ|NONE
D019821_D003161 CID Simvastatin_0\NNP| (r_npadvmod) induced_2\VBN|and|myonecrosis|.|compartment|associated (r_amod) syndrome_6\NN|NONE
D019821_D003161 CID simvastatin_9\NN|taking|and|old|A (r_conj) thyroxine_7\NN|.|with (r_nsubj) presented_10\VBD|NONE (l_prep) with_11\IN|.|thyroxine (l_pobj) syndrome_15\NN|NONE
15531665
D005492_D003920 NONE folate_21\NN|vitamin|,|,|carotene|and (r_nmod) E_24\NN|NONE (r_pobj) of_20\IN|NONE (r_prep) intakes_19\NNS|of|and|, (r_conj) duration_14\NN|of|used (r_conj) type_8\NN|,|risk (l_prep) of_9\IN|used|duration (l_pobj) medication_11\NN|NONE (l_compound) diabetes_10\NN|NONE
D005492_D003920 NONE folate_21\NN|vitamin|,|,|carotene|and (r_nmod) E_24\NN|NONE (r_pobj) of_20\IN|NONE (r_prep) intakes_19\NNS|of|and|, (r_conj) duration_14\NN|of|used (l_prep) of_15\IN|and|,|intakes (l_pobj) diabetes_16\NNS|NONE
D001205_D003324 NONE C_6\NN|mortality|and|from (r_compound) intake_7\NN|NONE (r_pobj) between_4\IN|the (r_prep) relation_3\NN|,|We|disease|)|. (r_dobj) studied_1\VBD|NONE (l_dep) disease_22\NN|,|We|)|relation|.
D019207_D002318 NONE carotene_29\NN|vitamin|,|folate|,|and (r_conj) E_24\NN|NONE (r_pobj) of_20\IN|NONE (r_prep) intakes_19\NNS|of|and|, (r_conj) duration_14\NN|of|used (r_conj) type_8\NN|,|risk (r_appos) factors_6\NNS|NONE (l_compound) risk_5\NN|,|type (l_compound) disease_4\NN|NONE
D019207_D002318 NONE carotene_29\NN|vitamin|,|folate|,|and (l_appos) risks_34\NNS||beta|, (l_prep) of_35\IN|the|relative|adjusted (l_pobj) mortality_39\NN|NONE (l_compound) disease_38\NN|total|cardiovascular
D001205_D050197 NONE C_12\NN|NONE (r_pobj) of_10\IN|high|in|a (r_prep) intake_9\NN|atherosclerosis|might|that (r_nsubj) promote_17\VB|to (l_dobj) atherosclerosis_18\NN|might|that|intake
D001205_D002318 CID C_3\NN|risk|Does|? (r_nsubj) increase_4\VB|NONE (l_dobj) risk_7\NN|Does|?|C (l_compound) disease_6\NN|in
D001205_D002318 CID C_10\NN|and|from|mortality (r_compound) intake_11\NN|NONE (l_prep) from_14\IN|C|and|mortality (l_pobj) disease_16\NN|NONE
D001205_D002318 CID C_6\NN|mortality|and|from (r_compound) intake_7\NN|NONE (l_prep) from_10\IN|C|mortality|and (l_pobj) disease_13\NN|NONE
D001205_D002318 CID C_63\NN|from|total (r_compound) intake_64\NN|NONE (r_pobj) of_60\IN|NONE (r_prep) quintiles_59\NNS|NONE (r_pobj) across_58\IN|(|.|.|P|,|, (r_prep) 1.0_41\CD|After|.|adjustment (r_attr) were_40\VBD|NONE (l_nsubj) adjustment_1\NN|After|.|. (l_prep) for_2\IN|NONE (l_pobj) factors_6\NNS|NONE (l_compound) risk_5\NN|,|type (l_compound) disease_4\NN|NONE
D001205_D002318 CID C_63\NN|from|total (r_compound) intake_64\NN|NONE (r_pobj) of_60\IN|NONE (r_prep) quintiles_59\NNS|NONE (r_pobj) across_58\IN|(|.|.|P|,|, (r_prep) 1.0_41\CD|After|.|adjustment (r_attr) were_40\VBD|NONE (l_nsubj) adjustment_1\NN|After|.|. (l_prep) for_2\IN|NONE (l_pobj) factors_6\NNS|NONE (l_appos) type_8\NN|,|risk (l_conj) duration_14\NN|of|used (l_conj) intakes_19\NNS|of|and|, (l_prep) of_20\IN|NONE (l_pobj) E_24\NN|NONE (l_conj) carotene_29\NN|vitamin|,|folate|,|and (l_appos) risks_34\NNS||beta|, (l_prep) of_35\IN|the|relative|adjusted (l_pobj) mortality_39\NN|NONE (l_compound) disease_38\NN|total|cardiovascular
D001205_D002318 CID C_1\NN|NONE (r_compound) intake_2\NN|unrelated|. (r_nsubj) was_3\VBD|NONE (l_acomp) unrelated_4\JJ|.|intake (l_prep) to_5\IN|NONE (l_pobj) mortality_6\NN|NONE (l_prep) from_7\IN|in (l_pobj) disease_9\NN|NONE
D001205_D002318 CID C_3\NN|from|high|A (r_compound) intake_4\NN|is|with|. (r_nsubjpass) associated_8\VBN|NONE (l_prep) with_9\IN|is|.|intake (l_pobj) risk_12\NN|NONE (l_prep) of_13\IN|an|increased (l_pobj) mortality_16\NN|NONE (l_compound) disease_15\NN|in|cardiovascular
D014810_D002318 NONE E_24\NN|NONE (r_pobj) of_20\IN|NONE (r_prep) intakes_19\NNS|of|and|, (r_conj) duration_14\NN|of|used (r_conj) type_8\NN|,|risk (r_appos) factors_6\NNS|NONE (l_compound) risk_5\NN|,|type (l_compound) disease_4\NN|NONE
D014810_D002318 NONE E_24\NN|NONE (l_conj) carotene_29\NN|vitamin|,|folate|,|and (l_appos) risks_34\NNS||beta|, (l_prep) of_35\IN|the|relative|adjusted (l_pobj) mortality_39\NN|NONE (l_compound) disease_38\NN|total|cardiovascular
D005492_D002318 NONE folate_21\NN|vitamin|,|,|carotene|and (r_nmod) E_24\NN|NONE (r_pobj) of_20\IN|NONE (r_prep) intakes_19\NNS|of|and|, (r_conj) duration_14\NN|of|used (r_conj) type_8\NN|,|risk (r_appos) factors_6\NNS|NONE (l_compound) risk_5\NN|,|type (l_compound) disease_4\NN|NONE
D005492_D002318 NONE folate_21\NN|vitamin|,|,|carotene|and (r_nmod) E_24\NN|NONE (l_conj) carotene_29\NN|vitamin|,|folate|,|and (l_appos) risks_34\NNS||beta|, (l_prep) of_35\IN|the|relative|adjusted (l_pobj) mortality_39\NN|NONE (l_compound) disease_38\NN|total|cardiovascular
D001205_D020521 NONE C_6\NN|mortality|and|from (r_compound) intake_7\NN|NONE (r_pobj) between_4\IN|the (r_prep) relation_3\NN|,|We|disease|)|. (r_dobj) studied_1\VBD|NONE (l_dep) disease_22\NN|,|We|)|relation|. (l_conj) stroke_30\NN|,|coronary|and||n|artery
D001205_D003920 NONE C_3\NN|risk|Does|? (r_nsubj) increase_4\VB|NONE (l_dobj) risk_7\NN|Does|?|C (l_prep) in_8\IN|disease (l_pobj) women_9\NNS|NONE (l_prep) with_10\IN|NONE (l_pobj) diabetes_11\NNS|NONE
D001205_D003920 NONE C_12\NN|NONE (r_pobj) of_10\IN|high|in|a (r_prep) intake_9\NN|atherosclerosis|might|that (l_prep) in_13\IN|high|of|a (l_pobj) persons_15\NNS|NONE (l_amod) diabetic_14\JJ|NONE
D001205_D003920 NONE C_6\NN|mortality|and|from (r_compound) intake_7\NN|NONE (r_pobj) between_4\IN|the (r_prep) relation_3\NN|,|We|disease|)|. (r_dobj) studied_1\VBD|NONE (l_dep) disease_22\NN|,|We|)|relation|. (l_conj) stroke_30\NN|,|coronary|and||n|artery (l_prep) in_36\IN|(|n|)| (l_pobj) women_39\NNS|NONE (l_relcl) reported_41\VBD||postmenopausal (l_xcomp) being_42\VBG|who (l_acomp) diabetic_43\JJ|NONE
D001205_D003920 NONE C_63\NN|from|total (r_compound) intake_64\NN|NONE (r_pobj) of_60\IN|NONE (r_prep) quintiles_59\NNS|NONE (r_pobj) across_58\IN|(|.|.|P|,|, (r_prep) 1.0_41\CD|After|.|adjustment (r_attr) were_40\VBD|NONE (l_nsubj) adjustment_1\NN|After|.|. (l_prep) for_2\IN|NONE (l_pobj) factors_6\NNS|NONE (l_appos) type_8\NN|,|risk (l_prep) of_9\IN|used|duration (l_pobj) medication_11\NN|NONE (l_compound) diabetes_10\NN|NONE
D001205_D003920 NONE C_63\NN|from|total (r_compound) intake_64\NN|NONE (r_pobj) of_60\IN|NONE (r_prep) quintiles_59\NNS|NONE (r_pobj) across_58\IN|(|.|.|P|,|, (r_prep) 1.0_41\CD|After|.|adjustment (r_attr) were_40\VBD|NONE (l_nsubj) adjustment_1\NN|After|.|. (l_prep) for_2\IN|NONE (l_pobj) factors_6\NNS|NONE (l_appos) type_8\NN|,|risk (l_conj) duration_14\NN|of|used (l_prep) of_15\IN|and|,|intakes (l_pobj) diabetes_16\NNS|NONE
D001205_D003920 NONE C_3\NN|from|high|A (r_compound) intake_4\NN|is|with|. (r_nsubjpass) associated_8\VBN|NONE (l_prep) with_9\IN|is|.|intake (l_pobj) risk_12\NN|NONE (l_prep) of_13\IN|an|increased (l_pobj) mortality_16\NN|NONE (l_prep) in_17\IN|cardiovascular|disease (l_pobj) women_19\NNS|NONE (l_prep) with_20\IN|postmenopausal (l_pobj) diabetes_21\NNS|NONE
D019207_D003920 NONE carotene_29\NN|vitamin|,|folate|,|and (r_conj) E_24\NN|NONE (r_pobj) of_20\IN|NONE (r_prep) intakes_19\NNS|of|and|, (r_conj) duration_14\NN|of|used (r_conj) type_8\NN|,|risk (l_prep) of_9\IN|used|duration (l_pobj) medication_11\NN|NONE (l_compound) diabetes_10\NN|NONE
D019207_D003920 NONE carotene_29\NN|vitamin|,|folate|,|and (r_conj) E_24\NN|NONE (r_pobj) of_20\IN|NONE (r_prep) intakes_19\NNS|of|and|, (r_conj) duration_14\NN|of|used (l_prep) of_15\IN|and|,|intakes (l_pobj) diabetes_16\NNS|NONE
D014810_D003920 NONE E_24\NN|NONE (r_pobj) of_20\IN|NONE (r_prep) intakes_19\NNS|of|and|, (r_conj) duration_14\NN|of|used (r_conj) type_8\NN|,|risk (l_prep) of_9\IN|used|duration (l_pobj) medication_11\NN|NONE (l_compound) diabetes_10\NN|NONE
D014810_D003920 NONE E_24\NN|NONE (r_pobj) of_20\IN|NONE (r_prep) intakes_19\NNS|of|and|, (r_conj) duration_14\NN|of|used (l_prep) of_15\IN|and|,|intakes (l_pobj) diabetes_16\NNS|NONE
10225068
D008012_D020258 NONE lignocaine_6\NN|NONE (r_pobj) of_2\IN|The (r_prep) dose_1\NN|from (r_nsubj) ranged_8\VBD|by|likely|were|. (r_ccomp) caused_21\VBN|NONE (l_agent) by_22\IN|likely|ranged|were|. (l_pobj) neurotoxicity_24\NN|NONE
D008012_D020258 NONE lignocaine_29\NN|NONE (r_pobj) of_25\IN|direct (r_prep) neurotoxicity_24\NN|NONE
D008012_D011128 CID lignocaine_10\NN|NONE (r_pobj) with_6\IN|spinal (r_prep) anaesthesia_5\NN|NONE (r_pobj) after_3\IN|.|equina|review|: (r_prep) syndrome_2\NN|NONE
D008012_D011128 CID lignocaine_10\NN|NONE (r_pobj) with_6\IN|spinal (r_prep) anaesthesia_5\NN|NONE (r_pobj) after_3\IN|.|equina|review|: (r_prep) syndrome_2\NN|NONE (l_appos) review_13\NN|.|equina|after|: (l_prep) of_14\IN|reported|a (l_pobj) cases_16\NNS|NONE (l_prep) of_17\IN|six (l_pobj) syndrome_20\NN|NONE
18182964
D003000_D001919 CID clonidine_10\NN|NONE (r_pobj) with_9\IN|compared (r_prep) treated_8\VBN|NONE (r_acl) subjects_7\NNS|NONE (r_pobj) in_6\IN|more|of (r_prep) incidents_3\NNS|.|There (l_prep) of_4\IN|more|in (l_pobj) bradycardia_5\NN|NONE
D003000_D001919 CID clonidine_17\NN|NONE (r_pobj) with_16\IN|not (r_prep) treated_15\VBN|differences|but|% (r_acl) those_13\DT|NONE (r_pobj) with_12\IN|NONE (r_prep) compared_11\VBN|with (r_prep) treated_8\VBN|NONE (r_acl) subjects_7\NNS|NONE (r_pobj) in_6\IN|more|of (r_prep) incidents_3\NNS|.|There (l_prep) of_4\IN|more|in (l_pobj) bradycardia_5\NN|NONE
D003000_D001919 CID clonidine_2\NN|NONE (r_dobj) prescribing_1\VBG|NONE (r_acl) Physicians_0\NNS|for|and|should|.|advise (r_nsubj) monitor_4\VB|NONE (l_prep) for_5\IN|and|should|.|Physicians|advise (l_pobj) bradycardia_6\NN|NONE
D008774_D001289 NONE methylphenidate_12\NN|NONE (l_prep) with_15\IN|in (l_pobj) disorder_21\NN|NONE
D008774_D001289 NONE methylphenidate_12\NN|NONE (l_prep) with_15\IN|in (l_pobj) disorder_21\NN|NONE (l_appos) ADHD_23\NNP|(|hyperactivity|)
D008774_D001289 NONE methylphenidate_25\NN|n|,|to (r_conj) clonidine_18\NN|.|were|In|,|randomly|children (r_xcomp) assigned_16\VBN|NONE (l_nsubjpass) children_11\NNS|.|were|In|clonidine|,|randomly (l_prep) with_12\IN| (l_pobj) ADHD_13\NNP|NONE
D008774_D001289 NONE methylphenidate_34\NN|and (r_conj) clonidine_32\NN|(||(|n|or|placebo|)|,|,|n| (r_conj) methylphenidate_25\NN|n|,|to (r_conj) clonidine_18\NN|.|were|In|,|randomly|children (r_xcomp) assigned_16\VBN|NONE (l_nsubjpass) children_11\NNS|.|were|In|clonidine|,|randomly (l_prep) with_12\IN| (l_pobj) ADHD_13\NNP|NONE
D008774_D001289 NONE methylphenidate_6\NN|NONE (r_pobj) with_5\IN|alone|or (r_conj) used_2\VBN|,|, (r_acl) Clonidine_0\NNP|.|and|tolerated|safe (r_nsubj) appears_8\VBZ|NONE (l_conj) tolerated_12\VBN|.|and|safe|Clonidine (l_prep) in_13\IN|well (l_pobj) ADHD_15\NNP|NONE
D003000_D001289 NONE Clonidine_0\NNP|NONE (l_prep) for_1\IN|II (l_pobj) disorder_7\NN|NONE
D003000_D001289 NONE clonidine_7\NN|NONE (r_pobj) of_6\IN|and|tolerability|the (r_prep) safety_3\NN|To (r_dobj) examine_1\VB|with|alone|or (r_csubj) used_8\VBN|NONE (l_conj) with_11\IN|alone|examine|or (l_pobj) methylphenidate_12\NN|NONE (l_prep) with_15\IN|in (l_pobj) disorder_21\NN|NONE
D003000_D001289 NONE clonidine_7\NN|NONE (r_pobj) of_6\IN|and|tolerability|the (r_prep) safety_3\NN|To (r_dobj) examine_1\VB|with|alone|or (r_csubj) used_8\VBN|NONE (l_conj) with_11\IN|alone|examine|or (l_pobj) methylphenidate_12\NN|NONE (l_prep) with_15\IN|in (l_pobj) disorder_21\NN|NONE (l_appos) ADHD_23\NNP|(|hyperactivity|)
D003000_D001289 NONE clonidine_18\NN|.|were|In|,|randomly|children (r_xcomp) assigned_16\VBN|NONE (l_nsubjpass) children_11\NNS|.|were|In|clonidine|,|randomly (l_prep) with_12\IN| (l_pobj) ADHD_13\NNP|NONE
D003000_D001289 NONE clonidine_32\NN|(||(|n|or|placebo|)|,|,|n| (r_conj) methylphenidate_25\NN|n|,|to (r_conj) clonidine_18\NN|.|were|In|,|randomly|children (r_xcomp) assigned_16\VBN|NONE (l_nsubjpass) children_11\NNS|.|were|In|clonidine|,|randomly (l_prep) with_12\IN| (l_pobj) ADHD_13\NNP|NONE
D003000_D001289 NONE Clonidine_0\NNP|.|and|tolerated|safe (r_nsubj) appears_8\VBZ|NONE (l_conj) tolerated_12\VBN|.|and|safe|Clonidine (l_prep) in_13\IN|well (l_pobj) ADHD_15\NNP|NONE
D003000_D006970 NONE clonidine_4\NN|NONE (r_pobj) on_3\IN|.|but|resolved|Drowsiness|,|common (r_prep) was_1\VBD|NONE (l_nsubj) Drowsiness_0\NN|.|on|but|resolved|,|common
D003000_D006970 NONE clonidine_2\NN|NONE (r_dobj) prescribing_1\VBG|NONE (r_acl) Physicians_0\NNS|for|and|should|.|advise (r_nsubj) monitor_4\VB|NONE (l_conj) advise_8\VB|for|and|should|.|Physicians (l_dobj) patients_9\NNS|NONE (l_prep) about_10\IN|NONE (l_pobj) likelihood_13\NN|NONE (l_prep) of_14\IN|high|the (l_pobj) drowsiness_16\NN|NONE
7596955
C045645_D009325 CID CLZ_25\NNP|NONE (r_pobj) of_24\IN|NONE (r_prep) ingestion_23\NN|especially (r_pobj) after_22\IN|in|flush|, (r_prep) accompanying_11\VBG|a|short (l_dobj) flush_13\NN|after|in|, (l_prep) in_14\IN|facial (l_pobj) one_15\CD|NONE (l_conj) nausea_17\NN|and
C045645_D006261 CID CLZ_25\NNP|NONE (r_pobj) of_24\IN|NONE (r_prep) ingestion_23\NN|especially (r_pobj) after_22\IN|in|flush|, (r_prep) accompanying_11\VBG|a|short (r_acl) duration_10\NN|NONE (r_pobj) of_7\IN|NONE (r_prep) headache_6\NN|subjects|.
D000242_D001791 NONE cAMP_19\NNS|NONE (r_pobj) of_17\IN|NONE (r_prep) determination_16\NN|platelet|and|ex (r_conj) aggregation_14\NN|NONE
C045645_D005483 CID CLZ_25\NNP|NONE (r_pobj) of_24\IN|NONE (r_prep) ingestion_23\NN|especially (r_pobj) after_22\IN|in|flush|, (r_prep) accompanying_11\VBG|a|short (l_dobj) flush_13\NN|after|in|,
16960342
D019259_D006509 NONE lamivudine_17\NN|NONE (r_amod) monotherapy_18\NN|NONE (r_pobj) with_16\IN|NONE (r_prep) treatment_15\NN|NONE (r_pobj) after_14\IN|of|Sustained|.|clinical (r_prep) improvement_2\NN|NONE (l_prep) of_3\IN|Sustained|.|after|clinical (l_pobj) patient_5\NN|NONE (l_prep) with_6\IN|a (l_pobj) cirrhosis_13\NN|NONE (l_amod) related_12\VBN|decompensated (l_npadvmod) virus_10\NN| (l_compound) B_9\NNP|NONE
D019259_D005355 NONE lamivudine_17\NN|NONE (r_amod) monotherapy_18\NN|NONE (r_pobj) with_16\IN|NONE (r_prep) treatment_15\NN|NONE (r_pobj) after_14\IN|of|Sustained|.|clinical (r_prep) improvement_2\NN|NONE (l_prep) of_3\IN|Sustained|.|after|clinical (l_pobj) patient_5\NN|NONE (l_prep) with_6\IN|a (l_pobj) cirrhosis_13\NN|NONE
D019259_D005355 NONE lamivudine_3\NN|NONE (r_pobj) of_2\IN|The|to (r_prep) administration_1\NN|like|,|as|,|in|.|,|should|be (l_prep) to_4\IN|of|The (l_pobj) patients_5\NNS|NONE (l_prep) with_6\IN|NONE (l_pobj) cirrhosis_10\NN|NONE
16634859
D000431_D006130 CID alcohol_9\NN| (r_npadvmod) related_11\VBN|growth (r_amod) impairment_14\NN|NONE
D000431_D006130 CID alcohol_1\NN|NONE (r_compound) consumption_2\NN|postpregnancy|among|Any (r_compound) recognition_4\NN|.|in (r_nsubj) resulted_9\VBD|NONE (l_prep) in_10\IN|.|recognition (l_pobj) growth_13\NN|NONE
D000431_D006130 CID alcohol_1\NN|NONE (r_compound) consumption_2\NN|postpregnancy|among|Any (r_compound) recognition_4\NN|.|in (r_nsubj) resulted_9\VBD|NONE (l_prep) in_10\IN|.|recognition (l_pobj) growth_13\NN|NONE (l_conj) cranial_18\JJ|reduced|as|cerebellar (l_acl) body_20\NN|decreased (l_dobj) growth_21\NN|to|in
18541230
D011692_D009404 NONE aminonucleoside_18\RB| (r_advmod) induced_20\VBN|puromycin|is|, (r_amod) nephrosis_21\NN|NONE (l_relcl) is_24\VBZ|induced|puromycin|, (l_attr) model_27\NN|which (l_prep) of_28\IN|an|experimental (l_pobj) syndrome_31\NN|NONE
D011692_D009404 NONE aminonucleoside_14\RB| (r_advmod) induced_16\VBN|puromycin|nephrotic (r_amod) syndrome_18\NN|NONE
D011692_D006402 NONE aminonucleoside_6\NN| (r_advmod) induced_8\VBN|hematological (r_amod) abnormalities_10\NNS|puromycin|.|Treatment
D011692_D006949 NONE aminonucleoside_1\RB| (r_advmod) induced_3\VBN|and|renal|hyperlipidemia|Puromycin (r_amod) dysfunction_5\NN|.|also|were (l_conj) hyperlipidemia_7\NN|induced|and|renal|Puromycin
D011692_D009401 CID aminonucleoside_6\JJ|in (r_amod) nephrosis_7\NN|puromycin
D011692_D009401 CID aminonucleoside_18\RB| (r_advmod) induced_20\VBN|puromycin|is|, (r_amod) nephrosis_21\NN|NONE
D011692_D007674 NONE aminonucleoside_1\RB| (r_advmod) induced_3\VBN|and|renal|hyperlipidemia|Puromycin (r_amod) dysfunction_5\NN|.|also|were
17615423
D000638_D058186 CID amiodarone_13\NN|, (r_conj) simvastatin_11\NN|NONE (r_pobj) of_10\IN|concomitant (r_prep) use_9\NN|NONE (r_pobj) to_7\IN|NONE (r_prep) secondary_6\JJ|renal|acute (r_amod) failure_5\NN|and|Severe|.
D000638_D058186 CID amiodarone_11\NN|, (l_conj) atazanavir_14\NNS|,|and (l_acl) resulting_15\VBG|NONE (l_prep) in_16\IN|NONE (l_pobj) rhabdomyolysis_17\NN|NONE (l_conj) failure_21\NN|and
C413408_D058186 CID atazanavir_16\NNS|,|and (r_conj) amiodarone_13\NN|, (r_conj) simvastatin_11\NN|NONE (r_pobj) of_10\IN|concomitant (r_prep) use_9\NN|NONE (r_pobj) to_7\IN|NONE (r_prep) secondary_6\JJ|renal|acute (r_amod) failure_5\NN|and|Severe|.
C413408_D058186 CID atazanavir_14\NNS|,|and (l_acl) resulting_15\VBG|NONE (l_prep) in_16\IN|NONE (l_pobj) rhabdomyolysis_17\NN|NONE (l_conj) failure_21\NN|and
C413408_D012206 CID atazanavir_16\NNS|,|and (r_conj) amiodarone_13\NN|, (r_conj) simvastatin_11\NN|NONE (r_pobj) of_10\IN|concomitant (r_prep) use_9\NN|NONE (r_pobj) to_7\IN|NONE (r_prep) secondary_6\JJ|renal|acute (r_amod) failure_5\NN|and|Severe|. (r_conj) rhabdomyolysis_1\NN|NONE
C413408_D012206 CID atazanavir_14\NNS|,|and (l_acl) resulting_15\VBG|NONE (l_prep) in_16\IN|NONE (l_pobj) rhabdomyolysis_17\NN|NONE
D019821_D012206 CID simvastatin_11\NN|NONE (r_pobj) of_10\IN|concomitant (r_prep) use_9\NN|NONE (r_pobj) to_7\IN|NONE (r_prep) secondary_6\JJ|renal|acute (r_amod) failure_5\NN|and|Severe|. (r_conj) rhabdomyolysis_1\NN|NONE
D019821_D012206 CID simvastatin_9\NN|NONE (l_conj) amiodarone_11\NN|, (l_conj) atazanavir_14\NNS|,|and (l_acl) resulting_15\VBG|NONE (l_prep) in_16\IN|NONE (l_pobj) rhabdomyolysis_17\NN|NONE
D019821_D012206 CID simvastatin_14\NN|NONE (r_amod) metabolism_15\NN|that (r_dobj) inhibit_13\VBP|concomitant (r_relcl) drugs_11\NNS|NONE (r_pobj) of_9\IN|the (r_prep) presence_8\NN|NONE (r_pobj) in_6\IN|.|is|risk (r_prep) increased_5\VBN|NONE (l_nsubjpass) risk_1\NN|.|is|in (l_prep) of_2\IN|The (l_pobj) rhabdomyolysis_3\NN|NONE
D019821_D015658 NONE Simvastatin_0\NNP|human|patient|virus (r_nmod) medications_11\NNS|and|given|were|temporarily|all (l_compound) virus_10\NN|Simvastatin|human|patient
D000638_D012206 CID amiodarone_13\NN|, (r_conj) simvastatin_11\NN|NONE (r_pobj) of_10\IN|concomitant (r_prep) use_9\NN|NONE (r_pobj) to_7\IN|NONE (r_prep) secondary_6\JJ|renal|acute (r_amod) failure_5\NN|and|Severe|. (r_conj) rhabdomyolysis_1\NN|NONE
D000638_D012206 CID amiodarone_11\NN|, (l_conj) atazanavir_14\NNS|,|and (l_acl) resulting_15\VBG|NONE (l_prep) in_16\IN|NONE (l_pobj) rhabdomyolysis_17\NN|NONE
D000638_D015658 NONE amiodarone_2\NN|, (r_conj) Simvastatin_0\NNP|human|patient|virus (r_nmod) medications_11\NNS|and|given|were|temporarily|all (l_compound) virus_10\NN|Simvastatin|human|patient
D019821_D058186 CID simvastatin_11\NN|NONE (r_pobj) of_10\IN|concomitant (r_prep) use_9\NN|NONE (r_pobj) to_7\IN|NONE (r_prep) secondary_6\JJ|renal|acute (r_amod) failure_5\NN|and|Severe|.
D019821_D058186 CID simvastatin_9\NN|NONE (l_conj) amiodarone_11\NN|, (l_conj) atazanavir_14\NNS|,|and (l_acl) resulting_15\VBG|NONE (l_prep) in_16\IN|NONE (l_pobj) rhabdomyolysis_17\NN|NONE (l_conj) failure_21\NN|and
8800187
D015761_D064420 NONE 4-aminopyridine_5\CD|on (r_compound) therapy_6\NN|calcium|and (l_prep) on_7\IN|aminopyridine (l_pobj) toxicity_9\NN|NONE
D002122_D002318 NONE CaCl2_0\NNP|NONE (r_compound) therapy_1\NN|may|possibly|.|toxicity (r_nsubj) worsen_4\VB|NONE (l_dobj) toxicity_11\NN|therapy|may|possibly|.
D002118_D062787 NONE calcium_14\NN|NONE (r_compound) channel_15\NN|blocker (r_compound) overdose_17\NN|NONE
D002122_D001145 CID CaCl2_19\NNP|the (r_compound) group_20\NN|NONE (r_pobj) in_17\IN|(|.|) (r_prep) seizures_11\NNS|and|ventricular|. (r_conj) arrhythmias_4\NNS|NONE
D002122_D064420 NONE chloride_3\NN|NONE (l_conj) therapy_6\NN|calcium|and (l_prep) on_7\IN|aminopyridine (l_pobj) toxicity_9\NN|NONE
D002122_D002493 NONE CaCl2_0\NNP|NONE (r_compound) therapy_1\NN|may|possibly|.|toxicity (r_nsubj) worsen_4\VB|NONE (l_dobj) toxicity_11\NN|therapy|may|possibly|.
D002122_D007022 NONE CaCl2_3\NNP|or (r_pobj) of_2\IN|The (r_prep) administration_1\NN|.|did|hypotension|not (r_nsubj) reverse_8\VB|NONE (l_dobj) hypotension_13\NN|.|did|administration|not
D003891_D064420 NONE desipramine_8\JJ|in (r_amod) toxicity_9\NN|NONE
D002118_D007022 NONE calcium_7\NN|NONE (r_compound) channel_8\NN|in (r_compound) blockade_9\NN|NONE (l_prep) in_10\IN|channel (l_pobj) hypotension_15\NN|NONE
D002118_D007022 NONE calcium_8\NN|NONE (r_compound) channel_9\NN|in (r_compound) inhibition_10\NN|NONE (l_prep) in_11\IN|channel (l_pobj) pathogenesis_13\NN|NONE (l_prep) of_14\IN|the (l_pobj) hypotension_19\NN|NONE
D003891_D001919 CID desipramine_6\NN|the|antidepressant (r_compound) IP_7\NNP|rats|produce|. (r_dobj) received_2\VBD|NONE (l_advcl) produce_9\VB|IP|rats|. (l_dobj) prolongation_13\NN|hypotension|,|to (l_conj) bradycardia_16\NN|,|QRS|and
D015761_D007022 NONE 4-aminopyridine_5\NN|NONE (r_punct) did_6\VBD|.|hypotension|administration|not (r_aux) reverse_8\VB|NONE (l_dobj) hypotension_13\NN|.|did|administration|not
D017693_D007022 NONE NaHCO3_0\NNP|.|hypotension (r_nsubj) reversed_6\VBD|NONE (l_dobj) hypotension_7\NN|.|NaHCO
D003891_D007022 CID desipramine_6\NN|the|antidepressant (r_compound) IP_7\NNP|rats|produce|. (r_dobj) received_2\VBD|NONE (l_advcl) produce_9\VB|IP|rats|. (l_dobj) hypotension_10\NN|,|prolongation|to
D002122_D012640 NONE CaCl2_19\NNP|the (r_compound) group_20\NN|NONE (r_pobj) in_17\IN|(|.|) (r_prep) seizures_11\NNS|and|ventricular|.
6209318
D008801_D012817 CID mexiletine_16\NN|the (r_amod) group_17\NN|NONE (r_pobj) in_14\IN|than|more (r_prep) frequent_13\JJ|effects|. (r_acomp) were_11\VBD|NONE (l_nsubj) effects_3\NNS|frequent|. (l_appos) tremor_6\JJ|,|,|side|recognized (l_conj) problems_9\NNS|and|particularly
D008801_D003643 NONE mexiletine_6\NN|%|(|the|) (r_amod) group_7\NN|NONE (r_pobj) in_4\IN|more|than (r_prep) deaths_3\NNS|There
D008801_D009203 NONE mexiletine_9\NN|Perlongets (r_pobj) of_8\IN|the|release|sustained (r_prep) form_7\NN|NONE (r_pobj) of_3\IN|The|antiarrhythmic (r_prep) effects_2\NNS|in|were|. (r_nsubjpass) evaluated_16\VBN|NONE (l_prep) in_17\IN|effects|were|. (l_pobj) trial_23\NN|NONE (l_prep) in_24\IN|a|blind|placebo (l_pobj) patients_26\NNS|NONE (l_prep) with_27\IN| (l_pobj) infarction_31\NN|NONE
D008801_D009203 NONE Perlongets_13\NNP|mexiletine (r_pobj) of_8\IN|the|release|sustained (r_prep) form_7\NN|NONE (r_pobj) of_3\IN|The|antiarrhythmic (r_prep) effects_2\NNS|in|were|. (r_nsubjpass) evaluated_16\VBN|NONE (l_prep) in_17\IN|effects|were|. (l_pobj) trial_23\NN|NONE (l_prep) in_24\IN|a|blind|placebo (l_pobj) patients_26\NNS|NONE (l_prep) with_27\IN| (l_pobj) infarction_31\NN|NONE
D008801_D001145 NONE mexiletine_1\NN|:|antiarrhythmic|coronary|International|Report|. (r_nmod) trial_6\NN|NONE (l_appos) Report_9\NNP|:|antiarrhythmic|coronary|mexiletine|International|. (l_prep) on_10\IN|I. (l_pobj) arrhythmia_11\NN|NONE
D008801_D014202 CID mexiletine_16\NN|the (r_amod) group_17\NN|NONE (r_pobj) in_14\IN|than|more (r_prep) frequent_13\JJ|effects|. (r_acomp) were_11\VBD|NONE (l_nsubj) effects_3\NNS|frequent|. (l_appos) tremor_6\JJ|,|,|side|recognized
10411803
D002511_D000743 NONE cephalosporins_5\NNS|and (r_conj) Second-_0\NNP|with|increasingly|are|. (r_nsubjpass) associated_12\VBN|NONE (l_prep) with_13\IN|Second|increasingly|are|. (l_pobj) anemia_20\NN|NONE
D015313_D000743 CID cefotetan_9\NN|NONE (r_pobj) of_8\IN|prophylactic|in (r_prep) use_7\NN|NONE (r_pobj) with_5\IN|NONE (r_prep) associated_4\VBN|.|Severe|immune|hemolytic (r_acl) anemia_3\NN|NONE
D015313_D000743 CID cefotetan_8\JJ|,|generation|, (r_appos) cephalosporins_5\NNS|and (r_conj) Second-_0\NNP|with|increasingly|are|. (r_nsubjpass) associated_12\VBN|NONE (l_prep) with_13\IN|Second|increasingly|are|. (l_pobj) anemia_20\NN|NONE
D015313_D000743 CID cefotetan_9\NN| (r_npadvmod) induced_11\VBN|hemolytic (r_amod) anemias_13\NNS|NONE
D015313_D000743 CID cefotetan_20\JJ|prophylactically|had|for|who (r_dobj) received_19\VBN|NONE (r_relcl) patients_16\NNS|NONE (r_pobj) in_15\IN||that (r_prep) were_14\VBD|.|We (l_nsubj) 10_3\CD|in|that (l_prep) of_4\IN|NONE (l_pobj) cases_7\NNS|NONE (l_prep) of_8\IN|our| (l_pobj) anemias_13\NNS|NONE
17175308
D020123_D011507 CID sirolimus_4\VB|NONE (r_pobj) to_3\TO|in (r_prep) conversion_2\NN|NONE (r_pobj) after_1\IN|. (r_prep) Proteinuria_0\NNP|NONE
D020123_D011507 CID sirolimus_11\NN|NONE (r_compound) therapy_12\NN|NONE (r_pobj) of_10\IN|a (r_prep) consequence_9\NN|NONE (r_pobj) as_7\IN|remained|,|proteinuria|.|recently|been|,|has (r_prep) reported_6\VBN|NONE (l_nsubjpass) proteinuria_3\NN|remained|,|.|recently|been|,|as|has
D020123_D011507 CID SRL_18\NN|NONE (r_compound) conversion_19\NN|NONE (r_pobj) after_17\IN|proteinuria (r_prep) displayed_14\VBD|who|or (l_dobj) proteinuria_16\NN|after
D020123_D011507 CID SRL_8\NN|NONE (r_pobj) of_7\IN|as|the (r_prep) use_6\NN|NONE (r_pobj) after_4\IN|common|proteinuria|. (r_prep) was_2\VBD|NONE (l_nsubj) proteinuria_1\NN|common|after|.
D020123_D007674 NONE SRL_13\NNP|NONE (r_pobj) with_12\IN|was|due|cohort|,|as|) (r_prep) treated_11\VBN|NONE (l_prep) due_18\IN|was|cohort|,|with|as|) (l_pobj) nephropathy_22\NN|to (l_advmod) CAN_24\VB|(|chronic|n|(|allograft
D020123_D051436 NONE SRL_13\NNP|NONE (r_pobj) with_12\IN|was|due|cohort|,|as|) (r_prep) treated_11\VBN|NONE (l_prep) due_18\IN|was|cohort|,|with|as|) (l_pobj) nephropathy_22\NN|to
19719056
D002351_D004487 CID carrageenan_17\NN| (r_npadvmod) induced_19\VBN|edema|,|rat|paw (r_amod) model_23\NN|)|and (l_compound) edema_22\NN|,|rat|paw|induced
D019342_D004487 NONE acid_9\NN|NONE (r_dobj) using_7\VBG|activities|were|.|induced (r_advcl) ascertained_6\VBN|NONE (l_conj) induced_10\VBD|activities|were|using|. (l_xcomp) writhing_11\VBG|NONE (l_attr) model_12\NN|respectively (l_appos) mice_14\NNS|( (l_conj) model_23\NN|)|and (l_compound) edema_22\NN|,|rat|paw|induced
D002351_D010146 CID carrageenan_17\NN| (r_npadvmod) induced_19\VBN|edema|,|rat|paw (r_amod) model_23\NN|)|and (r_conj) mice_14\NNS|( (r_appos) model_12\NN|respectively (r_attr) writhing_11\VBG|NONE
D019342_D010146 NONE acid_9\NN|NONE (r_dobj) using_7\VBG|activities|were|.|induced (r_advcl) ascertained_6\VBN|NONE (l_conj) induced_10\VBD|activities|were|using|. (l_xcomp) writhing_11\VBG|NONE
3970039
D003520_D009369 NONE cyclophosphamide_17\NN|and (r_conj) azathioprine_15\NN|NONE (r_pobj) with_14\IN|NONE (r_prep) treated_13\VBN|term|of|several|and (r_acl) studies_7\NNS|There|have|.|increased (r_attr) been_2\VBN|NONE (l_conj) increased_29\VBN|studies|There|have|. (l_nsubjpass) incidence_20\NN|is|not (l_prep) of_21\IN|the (l_pobj) most_22\JJS|NONE (l_prep) of_23\IN|NONE (l_pobj) cancers_26\NNS|NONE
D003520_D002277 CID Cyclophosphamide_0\NNP|NONE (r_compound) therapy_1\NN|.|risk (r_nsubj) increases_2\VBZ|NONE (l_dobj) risk_4\NN|therapy|. (l_prep) of_5\IN|the (l_pobj) carcinoma_6\NN|NONE (l_prep) of_7\IN|NONE (l_pobj) bladder_9\NN|NONE
D001379_D001172 NONE azathioprine_15\NN|NONE (r_pobj) with_14\IN|NONE (r_prep) treated_13\VBN|term|of|several|and (r_acl) studies_7\NNS|There|have|.|increased (l_prep) of_8\IN|term|several|and|treated (l_pobj) patients_9\NNS|NONE (l_prep) with_10\IN|NONE (l_pobj) arthritis_12\NN|NONE
D001379_D008228 CID azathioprine_21\NN|both|alkylating|and (r_conj) agents_19\NNS|are|with|. (r_nsubjpass) associated_23\VBN|treated|,|and|risk (l_prep) with_24\IN|agents|are|. (l_pobj) development_26\NN|NONE (l_prep) of_27\IN|the (l_pobj) lymphoma_32\NN|NONE
D001379_D015470 NONE azathioprine_21\NN|both|alkylating|and (r_conj) agents_19\NNS|are|with|. (r_nsubjpass) associated_23\VBN|treated|,|and|risk (r_conj) have_5\VBP|NONE (l_dobj) risk_8\NN|treated|,|and|associated (l_prep) of_9\IN|increased|an (l_pobj) development_10\NN|NONE (l_prep) of_11\IN|NONE (l_pobj) leukemia_14\NN|NONE
D003520_D001172 NONE cyclophosphamide_17\NN|and (r_conj) azathioprine_15\NN|NONE (r_pobj) with_14\IN|NONE (r_prep) treated_13\VBN|term|of|several|and (r_acl) studies_7\NNS|There|have|.|increased (l_prep) of_8\IN|term|several|and|treated (l_pobj) patients_9\NNS|NONE (l_prep) with_10\IN|NONE (l_pobj) arthritis_12\NN|NONE
D000477_D009369 NONE agents_31\NNS|immunosuppressive|,|, (r_appos) drugs_27\NNS|NONE (r_pobj) of_25\IN|the|in (r_prep) use_24\NN|for|,|be|should|.|is (r_nsubjpass) reserved_41\VBN|still|and|,|are|being|Data (r_conj) collected_14\VBN|NONE (l_nsubjpass) Data_0\NNS|still|and|,|are|being|reserved (l_prep) on_1\IN|NONE (l_pobj) risk_5\NN|NONE (l_prep) of_6\IN|increased|possible|the (l_pobj) malignancy_7\NN|NONE
D000477_D001172 NONE agents_31\NNS|immunosuppressive|,|, (r_appos) drugs_27\NNS|NONE (r_pobj) of_25\IN|the|in (r_prep) use_24\NN|for|,|be|should|.|is (r_nsubjpass) reserved_41\VBN|still|and|,|are|being|Data (r_conj) collected_14\VBN|NONE (l_nsubjpass) Data_0\NNS|still|and|,|are|being|reserved (l_prep) on_1\IN|NONE (l_pobj) risk_5\NN|NONE (l_prep) of_6\IN|increased|possible|the (l_pobj) malignancy_7\NN|NONE (l_prep) in_8\IN|NONE (l_pobj) arthritis_10\NN|NONE
D000477_D001172 NONE agents_31\NNS|immunosuppressive|,|, (r_appos) drugs_27\NNS|NONE (r_pobj) of_25\IN|the|in (r_prep) use_24\NN|for|,|be|should|.|is (l_prep) in_33\IN|of|the (l_pobj) treatment_35\NN|NONE (l_prep) of_36\IN|the (l_pobj) arthritis_38\NN|NONE
D001379_D009369 NONE azathioprine_15\NN|NONE (r_pobj) with_14\IN|NONE (r_prep) treated_13\VBN|term|of|several|and (r_acl) studies_7\NNS|There|have|.|increased (r_attr) been_2\VBN|NONE (l_conj) increased_29\VBN|studies|There|have|. (l_nsubjpass) incidence_20\NN|is|not (l_prep) of_21\IN|the (l_pobj) most_22\JJS|NONE (l_prep) of_23\IN|NONE (l_pobj) cancers_26\NNS|NONE
D000477_D015470 CID agents_4\NNS|NONE (r_pobj) with_2\IN|Patients (r_prep) treated_1\VBN|,|and|risk|associated (r_csubj) have_5\VBP|NONE (l_dobj) risk_8\NN|treated|,|and|associated (l_prep) of_9\IN|increased|an (l_pobj) development_10\NN|NONE (l_prep) of_11\IN|NONE (l_pobj) leukemia_14\NN|NONE
D000477_D015470 CID agents_19\NNS|are|with|. (r_nsubjpass) associated_23\VBN|treated|,|and|risk (r_conj) have_5\VBP|NONE (l_dobj) risk_8\NN|treated|,|and|associated (l_prep) of_9\IN|increased|an (l_pobj) development_10\NN|NONE (l_prep) of_11\IN|NONE (l_pobj) leukemia_14\NN|NONE
D003520_D001749 CID Cyclophosphamide_0\NNP|NONE (r_compound) therapy_1\NN|.|risk (r_nsubj) increases_2\VBZ|NONE (l_dobj) risk_4\NN|therapy|. (l_prep) of_5\IN|the (l_pobj) carcinoma_6\NN|NONE (l_prep) of_7\IN|NONE (l_pobj) bladder_9\NN|NONE
D000477_D008228 CID agents_4\NNS|NONE (r_pobj) with_2\IN|Patients (r_prep) treated_1\VBN|,|and|risk|associated (r_csubj) have_5\VBP|NONE (l_conj) associated_23\VBN|treated|,|and|risk (l_prep) with_24\IN|agents|are|. (l_pobj) development_26\NN|NONE (l_prep) of_27\IN|the (l_pobj) lymphoma_32\NN|NONE
D000477_D008228 CID agents_19\NNS|are|with|. (r_nsubjpass) associated_23\VBN|treated|,|and|risk (l_prep) with_24\IN|agents|are|. (l_pobj) development_26\NN|NONE (l_prep) of_27\IN|the (l_pobj) lymphoma_32\NN|NONE
18410508
D004298_D020258 NONE DA_14\NNP|the|neuronal|in (r_compound) system_16\NN|NONE (l_prep) in_17\IN|the|DA|neuronal (l_pobj) models_19\NNS|NONE (l_prep) of_20\IN|mouse (l_pobj) neurotoxicity_21\NN|NONE
D004298_D020258 NONE DA_14\NNP|the|neuronal|in (r_compound) system_16\NN|NONE (r_pobj) for_12\IN|Because|damage|selective (r_prep) is_9\VBZ|we|,|.|plays (r_advcl) hypothesized_24\VBD|NONE (l_ccomp) plays_28\VBZ|we|,|.|is (l_dobj) role_30\NN|CXCR|that (l_prep) in_31\IN|a (l_pobj) neurotoxicity_35\NN|NONE
D008694_D009422 CID METH_6\NNP|NONE (r_pobj) by_5\IN|NONE (r_agent) caused_4\VBN|the|CNS (r_acl) damage_3\NN|for|Because|selective
D008694_D009422 CID METH_32\NNP| (r_npadvmod) induced_34\VBN|activation|and (r_amod) neurotoxicity_35\NN|NONE (r_pobj) in_31\IN|a (r_prep) role_30\NN|CXCR|that (r_dobj) plays_28\VBZ|we|,|.|is (r_ccomp) hypothesized_24\VBD|NONE (l_advcl) is_9\VBZ|we|,|.|plays (l_nsubj) damage_3\NN|for|Because|selective
D015632_D020258 NONE MPTP_8\NNP|and (r_conj) METH_6\NNP|NONE (r_pobj) by_5\IN|NONE (r_agent) caused_4\VBN|the|CNS (r_acl) damage_3\NN|for|Because|selective (r_nsubj) is_9\VBZ|we|,|.|plays (l_prep) for_12\IN|Because|damage|selective (l_pobj) system_16\NN|NONE (l_prep) in_17\IN|the|DA|neuronal (l_pobj) models_19\NNS|NONE (l_prep) of_20\IN|mouse (l_pobj) neurotoxicity_21\NN|NONE
D015632_D020258 NONE MPTP_8\NNP|and (r_conj) METH_6\NNP|NONE (r_pobj) by_5\IN|NONE (r_agent) caused_4\VBN|the|CNS (r_acl) damage_3\NN|for|Because|selective (r_nsubj) is_9\VBZ|we|,|.|plays (r_advcl) hypothesized_24\VBD|NONE (l_ccomp) plays_28\VBZ|we|,|.|is (l_dobj) role_30\NN|CXCR|that (l_prep) in_31\IN|a (l_pobj) neurotoxicity_35\NN|NONE
D008694_D020258 NONE Methamphetamine_0\NN| (r_npadvmod) induced_2\VBN|neurotoxicity (r_amod) activation_6\NN|.|not|are|by (l_nmod) neurotoxicity_3\NN|induced
D008694_D020258 NONE METH_6\NNP|NONE (r_pobj) by_5\IN|NONE (r_agent) caused_4\VBN|the|CNS (r_acl) damage_3\NN|for|Because|selective (r_nsubj) is_9\VBZ|we|,|.|plays (l_prep) for_12\IN|Because|damage|selective (l_pobj) system_16\NN|NONE (l_prep) in_17\IN|the|DA|neuronal (l_pobj) models_19\NNS|NONE (l_prep) of_20\IN|mouse (l_pobj) neurotoxicity_21\NN|NONE
D008694_D020258 NONE METH_6\NNP|NONE (r_pobj) by_5\IN|NONE (r_agent) caused_4\VBN|the|CNS (r_acl) damage_3\NN|for|Because|selective (r_nsubj) is_9\VBZ|we|,|.|plays (r_advcl) hypothesized_24\VBD|NONE (l_ccomp) plays_28\VBZ|we|,|.|is (l_dobj) role_30\NN|CXCR|that (l_prep) in_31\IN|a (l_pobj) neurotoxicity_35\NN|NONE
D008694_D020258 NONE METH_32\NNP| (r_npadvmod) induced_34\VBN|activation|and (r_amod) neurotoxicity_35\NN|NONE (r_pobj) in_31\IN|a (r_prep) role_30\NN|CXCR|that (r_dobj) plays_28\VBZ|we|,|.|is (r_ccomp) hypothesized_24\VBD|NONE (l_advcl) is_9\VBZ|we|,|.|plays (l_prep) for_12\IN|Because|damage|selective (l_pobj) system_16\NN|NONE (l_prep) in_17\IN|the|DA|neuronal (l_pobj) models_19\NNS|NONE (l_prep) of_20\IN|mouse (l_pobj) neurotoxicity_21\NN|NONE
D008694_D020258 NONE METH_32\NNP| (r_npadvmod) induced_34\VBN|activation|and (r_amod) neurotoxicity_35\NN|NONE
D008694_D020258 NONE METH_25\NNP|NONE (r_pobj) with_24\IN|.|and|examined|Mice|were (r_prep) treated_23\VBN|NONE (l_conj) examined_27\VBN|.|and|with|Mice|were (l_prep) for_28\IN|NONE (l_pobj) neurotoxicity_30\NN|NONE
D008694_D020258 NONE METH_11\NNP|or|activation (r_compound) neurotoxicity_12\NN|that|does|not|signaling
D015632_D009422 CID MPTP_17\NNP| (r_npadvmod) induced_19\VBN|of (r_amod) neurodegeneration_20\NN|NONE
D015632_D009422 CID MPTP_8\NNP|and (r_conj) METH_6\NNP|NONE (r_pobj) by_5\IN|NONE (r_agent) caused_4\VBN|the|CNS (r_acl) damage_3\NN|for|Because|selective
D004298_D009422 NONE DA_22\NNP|NONE (r_compound) neurons_23\NNS|NONE (r_pobj) of_21\IN|induced (r_prep) neurodegeneration_20\NN|NONE
D004298_D009422 NONE DA_14\NNP|the|neuronal|in (r_compound) system_16\NN|NONE (r_pobj) for_12\IN|Because|damage|selective (r_prep) is_9\VBZ|we|,|.|plays (l_nsubj) damage_3\NN|for|Because|selective
9195768
D018170_D010292 CID sumatriptan_7\NN|NONE (r_pobj) of_5\IN|the (r_prep) use_4\NN|NONE (r_dobj) following_2\VBG|Atypical (r_prep) sensations_1\NNS|of|,|.|common|but
11827497
D006493_D001157 CID Heparin_0\NNP| (r_npadvmod) induced_2\VBN|NONE (r_amod) thrombocytopenia_3\NN|.|after (r_nsubj) presents_4\VBZ|NONE (l_prep) after_9\IN|.|thrombocytopenia (l_pobj) exposure_11\NN|days (l_prep) with_13\IN|,|heparin (l_conj) without_15\IN|or (l_pobj) thromboemboli_19\NN|NONE
D006493_D001157 CID heparin_10\JJ|,|with (r_compound) exposure_11\NN|days (l_prep) with_13\IN|,|heparin (l_conj) without_15\IN|or (l_pobj) thromboemboli_19\NN|NONE
D006493_D054556 CID Heparin_0\NNP| (r_npadvmod) induced_2\VBN|NONE (r_amod) thrombocytopenia_3\NN|.|after (r_nsubj) presents_4\VBZ|NONE (l_prep) after_9\IN|.|thrombocytopenia (l_pobj) exposure_11\NN|days (l_prep) with_13\IN|,|heparin (l_conj) without_15\IN|or (l_pobj) thromboemboli_19\NN|NONE
D006493_D054556 CID heparin_10\JJ|,|with (r_compound) exposure_11\NN|days (l_prep) with_13\IN|,|heparin (l_conj) without_15\IN|or (l_pobj) thromboemboli_19\NN|NONE
D006493_D013921 CID heparin_3\NN| (r_npadvmod) induced_5\VBN|.|onset (r_amod) thrombocytopenia_6\NN|NONE
D006493_D013921 CID Heparin_0\NNP| (r_npadvmod) induced_2\VBN|NONE (r_amod) thrombocytopenia_3\NN|.|after
D006493_D013921 CID heparin_10\JJ|,|with (r_compound) exposure_11\NN|days (r_pobj) after_9\IN|.|thrombocytopenia (r_prep) presents_4\VBZ|NONE (l_nsubj) thrombocytopenia_3\NN|.|after
D006493_D013921 CID heparin_5\NN| (r_npadvmod) induced_7\VBN|NONE (r_amod) thrombocytopenia_8\NN|NONE
D006493_D013921 CID heparin_16\NN| (r_npadvmod) induced_18\VBN|NONE (r_amod) thrombocytopenia_19\NN|NONE
D006493_D013921 CID heparin_9\NN| (r_npadvmod) induced_11\VBN|NONE (r_amod) thrombocytopenia_12\NN|apparent|on|in
D006493_D013921 CID heparin_9\JJ|NONE (r_compound) exposure_10\NN|had|that (r_dobj) included_8\VBN|NONE (r_relcl) hospitalizations_5\NNS|NONE (r_pobj) after_4\IN|:|in|home|with|||Patients|,|return|. (r_prep) went_2\VBD|NONE (l_prep) with_16\IN|:|in|after|home|||Patients|,|return|. (l_pobj) thrombocytopenia_18\NN|NONE
D006493_D013921 CID heparin_3\NN| (r_npadvmod) induced_5\VBN|onset (r_amod) thrombocytopenia_6\NN|being|is|.|increasingly
D006493_D013921 CID heparin_8\NN| (r_npadvmod) induced_10\VBN|NONE (r_amod) thrombocytopenia_11\NN|,|physicians|avoid|must|returns
D006493_D013921 CID heparin_27\VBN|,|not|alternative (r_appos) anticoagulants_24\NNS|NONE (r_pobj) with_22\IN|NONE (r_prep) therapy_21\NN|be|;|.|should|,|consider (r_nsubjpass) initiated_31\VBN|NONE (l_ccomp) consider_7\VB|be|;|.|should|therapy|, (l_dobj) thrombocytopenia_11\NN|,|physicians|avoid|must|returns
D006493_D013923 NONE heparin_9\NN| (r_npadvmod) induced_11\VBN|NONE (r_amod) thrombocytopenia_12\NN|apparent|on|in (r_nsubj) became_13\VBD|year|a (l_prep) on_15\IN|apparent|in|thrombocytopenia (l_pobj) presentation_17\NN|NONE (l_prep) with_18\IN|delayed (l_pobj) complications_20\NNS|NONE (l_compound) thromboembolic_19\JJ|NONE
D006493_D013923 NONE heparin_13\NN| (r_npadvmod) induced_15\VBN|tests|platelet (r_nmod) factor_17\NN|NONE (r_pobj) of_12\IN|NONE (r_prep) results_11\NNS|,|,|onset|Platelet (r_appos) counts_3\VBZ|:|. (l_appos) onset_5\NN|,|,|results|Platelet (l_prep) of_6\IN|NONE (l_pobj) thromboembolism_9\NN|NONE
D006493_D013923 NONE heparin_9\JJ|NONE (r_compound) exposure_10\NN|had|that (r_dobj) included_8\VBN|NONE (r_relcl) hospitalizations_5\NNS|NONE (r_pobj) after_4\IN|:|in|home|with|||Patients|,|return|. (r_prep) went_2\VBD|NONE (l_advcl) return_23\VB|:|in|after|home|with|||Patients|,|. (l_prep) with_33\IN|to|to|only (l_pobj) complications_35\NNS|NONE (l_compound) thromboembolic_34\JJ|NONE
D006493_D013923 NONE heparin_8\NN| (r_npadvmod) induced_10\VBN|NONE (r_amod) thrombocytopenia_11\NN|,|physicians|avoid|must|returns (r_dobj) consider_7\VB|be|;|.|should|therapy|, (l_advcl) returns_17\NNS|,|physicians|avoid|must|thrombocytopenia (l_prep) with_18\IN|whenever|hospitalized|patient|a (l_pobj) thromboembolism_19\NN|NONE
D006493_D013923 NONE heparin_27\VBN|,|not|alternative (r_appos) anticoagulants_24\NNS|NONE (r_pobj) with_22\IN|NONE (r_prep) therapy_21\NN|be|;|.|should|,|consider (r_nsubjpass) initiated_31\VBN|NONE (l_ccomp) consider_7\VB|be|;|.|should|therapy|, (l_advcl) returns_17\NNS|,|physicians|avoid|must|thrombocytopenia (l_prep) with_18\IN|whenever|hospitalized|patient|a (l_pobj) thromboembolism_19\NN|NONE
21418164
D008130_D007674 NONE 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea_19\JJ|( (r_nmod) CCNU_21\NNP|NONE (r_dobj) receiving_18\VBG|bearing (r_acl) dogs_17\NNS|NONE (r_pobj) in_13\IN|haematological (r_prep) toxicities_12\NNS|NONE
D008130_D007674 NONE CCNU_21\NNP|NONE (r_dobj) receiving_18\VBG|bearing (r_acl) dogs_17\NNS|NONE (r_pobj) in_13\IN|haematological (r_prep) toxicities_12\NNS|NONE
D008130_D015620 NONE CCNU_0\NNP|was|commonly|in|. (r_nsubjpass) used_2\VBN|NONE (l_prep) in_5\IN|was|CCNU|commonly|. (l_pobj) treatment_7\NN|NONE (l_prep) of_8\IN|the (l_pobj) lymphoma_9\NN|NONE (l_conj) tumour_13\NN|, (l_conj) tumour_16\NN|cell|,|mast (l_conj) tumours_19\NNS|,|brain
D008130_D005767 NONE 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea_19\JJ|( (r_nmod) CCNU_21\NNP|NONE (r_dobj) receiving_18\VBG|bearing (r_acl) dogs_17\NNS|NONE (r_pobj) in_13\IN|haematological (r_prep) toxicities_12\NNS|NONE
D008130_D005767 NONE CCNU_21\NNP|NONE (r_dobj) receiving_18\VBG|bearing (r_acl) dogs_17\NNS|NONE (r_pobj) in_13\IN|haematological (r_prep) toxicities_12\NNS|NONE
D008130_D008223 NONE CCNU_0\NNP|was|commonly|in|. (r_nsubjpass) used_2\VBN|NONE (l_prep) in_5\IN|was|CCNU|commonly|. (l_pobj) treatment_7\NN|NONE (l_prep) of_8\IN|the (l_pobj) lymphoma_9\NN|NONE
D008130_D008223 NONE CCNU_0\NNP|was|commonly|in|. (r_nsubjpass) used_2\VBN|NONE (l_prep) in_5\IN|was|CCNU|commonly|. (l_pobj) treatment_7\NN|NONE (l_prep) of_8\IN|the (l_pobj) lymphoma_9\NN|NONE (l_conj) tumour_13\NN|, (l_conj) tumour_16\NN|cell|,|mast (l_conj) tumours_19\NNS|,|brain (l_conj) lymphoma_22\NN|and|histiocytic
D008130_D034801 NONE CCNU_0\NNP|was|commonly|in|. (r_nsubjpass) used_2\VBN|NONE (l_prep) in_5\IN|was|CCNU|commonly|. (l_pobj) treatment_7\NN|NONE (l_prep) of_8\IN|the (l_pobj) lymphoma_9\NN|NONE (l_conj) tumour_13\NN|,
D008130_D001932 NONE CCNU_0\NNP|was|commonly|in|. (r_nsubjpass) used_2\VBN|NONE (l_prep) in_5\IN|was|CCNU|commonly|. (l_pobj) treatment_7\NN|NONE (l_prep) of_8\IN|the (l_pobj) lymphoma_9\NN|NONE (l_conj) tumour_13\NN|, (l_conj) tumour_16\NN|cell|,|mast
D008130_D056486 NONE 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea_19\JJ|( (r_nmod) CCNU_21\NNP|NONE (r_dobj) receiving_18\VBG|bearing (r_acl) dogs_17\NNS|NONE (r_pobj) in_13\IN|haematological (r_prep) toxicities_12\NNS|NONE
D008130_D056486 NONE CCNU_21\NNP|NONE (r_dobj) receiving_18\VBG|bearing (r_acl) dogs_17\NNS|NONE (r_pobj) in_13\IN|haematological (r_prep) toxicities_12\NNS|NONE
D000409_D064420 NONE alanine_5\NN|elevated (r_compound) transaminase_6\NN|(|ALT (r_nmod) concentration_10\NN|renal|and|Potential (r_conj) toxicity_2\NN|.|in|were
D008130_D064420 NONE CCNU_0\NNP|toxicity|)|(|. (r_npadvmod) lomustine_2\NN|NONE (l_dobj) toxicity_4\NN|)|CCNU|(|.
D008130_D064420 NONE lomustine_2\NN|NONE (l_dobj) toxicity_4\NN|)|CCNU|(|.
D008130_D064420 NONE CCNU_6\NNP|NONE (r_pobj) with_5\IN|NONE (r_prep) treated_4\VBN||the (r_acl) dogs_3\NNS|NONE (r_pobj) Of_0\IN|,|criteria||. (r_prep) met_9\VBD|NONE (l_dobj) criteria_12\NNS|Of|,||. (l_prep) for_13\IN|inclusion|the (l_pobj) class_17\NN|NONE (l_prep) of_18\IN|one (l_pobj) toxicity_19\NN|NONE
D008130_D064420 NONE CCNU_0\NN| (r_npadvmod) associated_2\VBN|in (r_amod) toxicity_3\NN|but|common|.|is|,
D008130_D006402 NONE 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea_19\JJ|( (r_nmod) CCNU_21\NNP|NONE (r_dobj) receiving_18\VBG|bearing (r_acl) dogs_17\NNS|NONE (r_pobj) in_13\IN|haematological (r_prep) toxicities_12\NNS|NONE
D008130_D006402 NONE CCNU_21\NNP|NONE (r_dobj) receiving_18\VBG|bearing (r_acl) dogs_17\NNS|NONE (r_pobj) in_13\IN|haematological (r_prep) toxicities_12\NNS|NONE
1732442
D004317_D009202 CID adriamycin_8\NNS| (r_npadvmod) induced_10\VBN|with (r_amod) cardiomyopathy_11\NN|NONE
D004317_D009202 CID adriamycin_5\NNS| (r_amod) induced_7\VBN|NONE (r_amod) cardiomyopathy_8\NN|NONE
D004317_D009202 CID adriamycin_5\NNS| (r_amod) induced_7\VBN|NONE (r_amod) cardiomyopathy_8\NN|NONE (r_pobj) of_4\IN|a|rat (r_prep) model_3\NN|NONE (r_dobj) Using_0\VBG|we|,|hypothesis|. (r_advcl) tested_11\VBD|NONE (l_dobj) hypothesis_13\NN|we|Using|,|. (l_acl) appear_21\VB|the (l_conj) exacerbated_24\VBN|may|and|activity|that (l_advmod) dependently_27\RB|be (l_prep) in_28\IN|dose| (l_pobj) cardiomyopathy_30\NN|NONE
D004317_D009202 CID adriamycin_29\FW|NONE (r_amod) cardiomyopathy_30\NN|NONE (r_pobj) in_28\IN|dose| (r_prep) dependently_27\RB|be (r_advmod) exacerbated_24\VBN|may|and|activity|that (r_conj) appear_21\VB|the (r_acl) hypothesis_13\NN|we|Using|,|. (r_dobj) tested_11\VBD|NONE (l_advcl) Using_0\VBG|we|,|hypothesis|. (l_dobj) model_3\NN|NONE (l_prep) of_4\IN|a|rat (l_pobj) cardiomyopathy_8\NN|NONE
D004317_D009202 CID adriamycin_29\FW|NONE (r_amod) cardiomyopathy_30\NN|NONE
D004317_D009202 CID adriamycin_34\NNS| (r_amod) induced_36\VBN|NONE (r_amod) cardiomyopathy_37\NN|NONE (r_pobj) of_33\IN|NONE (r_prep) detection_32\NN|NONE (r_pobj) for_31\IN|useful|a (r_prep) method_30\NN|that|may|scintigraphy (r_attr) be_27\VB|appearance|. (r_ccomp) indicates_22\VBZ|NONE (l_nsubj) appearance_1\NN|be|. (l_prep) of_2\IN|The (l_pobj) activity_7\NN|NONE (l_prep) in_8\IN|cardiac|neuron|impaired (l_pobj) presence_10\NN|NONE (l_prep) of_11\IN|the (l_pobj) impairment_14\NN|NONE
D004317_D009202 CID adriamycin_34\NNS| (r_amod) induced_36\VBN|NONE (r_amod) cardiomyopathy_37\NN|NONE
D004317_C536522 NONE adriamycin_16\JJ|NONE (r_amod) treatment_17\NN|NONE (r_pobj) of_15\IN|the (r_prep) duration_14\NN|NONE (r_pobj) to_12\IN|NONE (r_prep) relation_11\NN|NONE (r_pobj) in_10\IN|mg/kg|degree|.|was (r_prep) analyzed_9\VBN|NONE (l_nsubjpass) degree_1\NN|mg/kg|.|in|was (l_prep) of_2\IN|The (l_pobj) degeneration_4\NN|NONE (l_prep) of_5\IN|vacuolar (l_pobj) cells_7\NNS|NONE
D004317_C536522 NONE adriamycin_34\NNS| (r_amod) induced_36\VBN|NONE (r_amod) cardiomyopathy_37\NN|NONE (r_pobj) of_33\IN|NONE (r_prep) detection_32\NN|NONE (r_pobj) for_31\IN|useful|a (r_prep) method_30\NN|that|may|scintigraphy (r_attr) be_27\VB|appearance|. (r_ccomp) indicates_22\VBZ|NONE (l_nsubj) appearance_1\NN|be|. (l_prep) of_2\IN|The (l_pobj) activity_7\NN|NONE (l_prep) in_8\IN|cardiac|neuron|impaired (l_pobj) presence_10\NN|NONE (l_prep) of_11\IN|the (l_pobj) impairment_14\NN|NONE (l_appos) degeneration_20\NN|)|(|myocardial|slight
D019797_C536522 NONE MIBG_24\NNP|NONE (r_compound) scintigraphy_25\NN|method|that|may (r_nsubj) be_27\VB|appearance|. (r_ccomp) indicates_22\VBZ|NONE (l_nsubj) appearance_1\NN|be|. (l_prep) of_2\IN|The (l_pobj) activity_7\NN|NONE (l_prep) in_8\IN|cardiac|neuron|impaired (l_pobj) presence_10\NN|NONE (l_prep) of_11\IN|the (l_pobj) impairment_14\NN|NONE (l_appos) degeneration_20\NN|)|(|myocardial|slight
D019797_D009202 NONE iodine-125-metaiodobenzylguanidine_13\NNP|NONE (r_pcomp) with_12\IN|induced (r_prep) cardiomyopathy_11\NN|NONE
D019797_D009202 NONE MIBG_24\NNP|NONE (r_compound) scintigraphy_25\NN|method|that|may (r_nsubj) be_27\VB|appearance|. (r_ccomp) indicates_22\VBZ|NONE (l_nsubj) appearance_1\NN|be|. (l_prep) of_2\IN|The (l_pobj) activity_7\NN|NONE (l_prep) in_8\IN|cardiac|neuron|impaired (l_pobj) presence_10\NN|NONE (l_prep) of_11\IN|the (l_pobj) impairment_14\NN|NONE
D019797_D009202 NONE MIBG_24\NNP|NONE (r_compound) scintigraphy_25\NN|method|that|may (r_nsubj) be_27\VB|appearance|. (l_attr) method_30\NN|that|may|scintigraphy (l_prep) for_31\IN|useful|a (l_pobj) detection_32\NN|NONE (l_prep) of_33\IN|NONE (l_pobj) cardiomyopathy_37\NN|NONE
8092427
-1_D007645 NONE BPO_8\NNP|NONE (r_pobj) to_7\IN|NONE (r_prep) negative_6\JJ|skin (r_amod) test_5\NN|patients (r_attr) were_3\VBD||negative|,|.|;|also||and (r_ccomp) were_17\VBD|NONE (l_acomp) negative_19\JJ||,|were|.|;|also||and (l_prep) to_20\IN|NONE (l_pobj) MDM_21\NNP|NONE
D000658_D004342 CID amoxicillin_4\NNP|NONE (r_pobj) to_3\IN|allergic|.|Immediate (r_prep) reactions_2\NNS|NONE
D000658_D004342 CID amoxicillin_39\NNP|NONE (r_pobj) to_38\IN|allergic|immediate|selective (r_prep) responses_37\NNS|were|or (r_dobj) had_33\VBD|history|,|with|establish|.|was|,|RAST (r_conj) used_22\VBN|NONE (l_xcomp) establish_24\VB|history|,|with|had|.|was|,|RAST (l_ccomp) allergic_27\JJ|to
D000658_D004342 CID amoxicillin_39\NNP|NONE (r_pobj) to_38\IN|allergic|immediate|selective (r_prep) responses_37\NNS|were|or (l_amod) allergic_36\JJ|immediate|to|selective
D000658_D004342 CID AX_41\NN|NONE (r_appos) amoxicillin_39\NNP|NONE (r_pobj) to_38\IN|allergic|immediate|selective (r_prep) responses_37\NNS|were|or (r_dobj) had_33\VBD|history|,|with|establish|.|was|,|RAST (r_conj) used_22\VBN|NONE (l_xcomp) establish_24\VB|history|,|with|had|.|was|,|RAST (l_ccomp) allergic_27\JJ|to
D000658_D004342 CID AX_41\NN|NONE (r_appos) amoxicillin_39\NNP|NONE (r_pobj) to_38\IN|allergic|immediate|selective (r_prep) responses_37\NNS|were|or (l_amod) allergic_36\JJ|immediate|to|selective
D000658_D004342 CID AX_11\NNP|with|immediate (r_compound) allergy_12\NN|NONE
D000658_D004342 CID AX_3\NN|NONE (r_pobj) with_2\IN|Challenge (r_prep) tests_1\NNS|and|were|establish|were|in (r_nsubjpass) performed_5\VBN|NONE (l_advcl) establish_14\VB|tests|and|were|were|in (l_dobj) diagnosis_16\NN|,|to (l_prep) of_17\IN|the (l_pobj) reaction_20\NN|NONE
D000658_D004342 CID AX_22\NN|NONE (r_pobj) to_21\IN|allergic|immediate (r_prep) reaction_20\NN|NONE
D000658_D004342 CID AX_38\NN|NONE (r_pobj) for_37\IN|NONE (r_prep) RAST_36\NNP|skin|and|both (r_conj) test_34\NN||) (r_appos) %_30\NN|in|negative|(|. (r_nsubj) were_39\VBD|tests|and|establish|were|in (r_conj) performed_5\VBN|NONE (l_advcl) establish_14\VB|tests|and|were|were|in (l_dobj) diagnosis_16\NN|,|to (l_prep) of_17\IN|the (l_pobj) reaction_20\NN|NONE
D000658_D004342 CID AX_6\NN| (r_npadvmod) allergic_8\JJ|tolerated
D010400_D004342 NONE PG_17\NNP|NONE (r_pobj) of_16\IN|good (r_prep) tolerance_15\NN|NONE (r_pobj) with_13\IN|immediate|AX (r_prep) allergy_12\NN|NONE
D010400_D004342 NONE PG_13\NNP|who|have (r_dobj) tolerated_12\VBN|allergic (r_relcl) patients_9\NNS|NONE (l_amod) allergic_8\JJ|tolerated
D010406_D004342 NONE penicillin_50\NN|other (r_compound) derivatives_51\NNS|NONE (r_pobj) with_48\IN|cross| (r_prep) reacting_47\VBG|NONE (r_acomp) were_44\VBD|responses|or (r_conj) had_33\VBD|history|,|with|establish|.|was|,|RAST (r_conj) used_22\VBN|NONE (l_xcomp) establish_24\VB|history|,|with|had|.|was|,|RAST (l_ccomp) allergic_27\JJ|to
D010406_D004342 NONE penicillin_50\NN|other (r_compound) derivatives_51\NNS|NONE (r_pobj) with_48\IN|cross| (r_prep) reacting_47\VBG|NONE (r_acomp) were_44\VBD|responses|or (r_conj) had_33\VBD|history|,|with|establish|.|was|,|RAST (l_dobj) responses_37\NNS|were|or (l_amod) allergic_36\JJ|immediate|to|selective
D010400_D007645 NONE PG_32\NNP|NONE (r_pobj) to_31\IN|of|)|% (r_prep) 44_24\CD||negative|,|were|.|;|also|and (r_conj) were_17\VBD|NONE (l_acomp) negative_19\JJ||,|were|.|;|also||and (l_prep) to_20\IN|NONE (l_pobj) MDM_21\NNP|NONE
D047090_D004342 NONE lactam_12\NN|NONE (r_amod) antibiotics_13\NNS|NONE (r_pobj) to_9\IN|suspected|allergic (r_prep) reactions_8\NNS|NONE
D047090_D004342 NONE lactam_31\NN|NONE (r_amod) antibiotics_32\NNS|NONE (r_pobj) to_28\IN|whether|patients (r_prep) allergic_27\JJ|to
D047090_D004342 NONE lactam_31\NN|NONE (r_amod) antibiotics_32\NNS|NONE (r_pobj) to_28\IN|whether|patients (r_prep) allergic_27\JJ|to (r_ccomp) establish_24\VB|history|,|with|had|.|was|,|RAST (r_xcomp) used_22\VBN|NONE (l_conj) had_33\VBD|history|,|with|establish|.|was|,|RAST (l_dobj) responses_37\NNS|were|or (l_amod) allergic_36\JJ|immediate|to|selective
D047090_D004342 NONE lactam_12\NN|NONE (r_amod) antibiotics_13\NNS|NONE (r_pobj) to_9\IN|NONE (r_prep) allergic_8\JJ|NONE
1592014
D003042_D003643 NONE cocaine_1\NN| (r_npadvmod) induced_3\VBN|NONE (r_amod) seizures_4\NNS|resulted|as|and|were|best|Whereas (r_nsubjpass) characterized_7\VBN|,|.|multiple|resulted|and|,|those (l_conj) resulted_16\VBD|as|and|were|seizures|best|Whereas (l_prep) in_17\IN|NONE (l_pobj) death_18\NN|NONE
D003042_D003643 NONE cocaine_1\NN| (r_npadvmod) induced_3\VBN|NONE (r_amod) seizures_4\NNS|resulted|as|and|were|best|Whereas (r_nsubjpass) characterized_7\VBN|,|.|multiple|resulted|and|,|those (r_advcl) were_24\VBD|NONE (l_conj) resulted_36\VBD|,|.|multiple|and|characterized|,|those (l_prep) in_37\IN|rarely (l_pobj) death_38\NN|NONE
D003042_D020521 NONE cocaine_8\NN|NONE (r_pobj) of_7\IN|(|) (r_prep) t1/2_5\NN|half| (r_appos) life_3\NN|but|short|,|The|occur (r_nsubj) is_9\VBZ|NONE (l_conj) occur_29\VB|but|short|,|The|life (l_nsubj) some_14\DT|.|hours|can (l_prep) of_15\IN|NONE (l_pobj) consequences_17\NNS|NONE (l_prep) of_18\IN|the (l_pobj) use_20\NN|NONE (l_prep) as_23\IN|,|its|, (l_pobj) seizures_24\NNS|such (l_conj) strokes_26\NNS|and
C005618_D012640 CID benzoylecgonine_6\NN|NONE (r_pobj) by_2\IN|.|Seizures (r_agent) induced_1\VBN|NONE (l_nsubj) Seizures_0\NNS|.|by
C005618_D012640 CID benzoylecgonine_11\NN|of|BE|the|major (r_appos) metabolite_7\NN|NONE (r_pobj) of_4\IN|the (r_prep) potential_3\NN|.|We|cause|, (r_dobj) evaluated_1\VBD|NONE (l_advcl) cause_17\VB|.|We|potential|, (l_dobj) seizures_18\NNS|to
C005618_D012640 CID BE_13\VB|of|the|benzoylecgonine|major (r_appos) metabolite_7\NN|NONE (r_pobj) of_4\IN|the (r_prep) potential_3\NN|.|We|cause|, (r_dobj) evaluated_1\VBD|NONE (l_advcl) cause_17\VB|.|We|potential|, (l_dobj) seizures_18\NNS|to
C005618_D012640 CID BE_0\VB| (r_advmod) Induced_2\VBN|NONE (r_amod) seizures_3\NNS|and|frequently|.|had
C005618_D012640 CID BE_23\NNP|NONE (r_pobj) by_22\IN|NONE (r_agent) induced_21\VBN|NONE (r_acl) those_20\DT|,|.|multiple|resulted|and|characterized|, (r_nsubj) were_24\VBD|NONE (l_advcl) characterized_7\VBN|,|.|multiple|resulted|and|,|those (l_nsubjpass) seizures_4\NNS|resulted|as|and|were|best|Whereas
C005618_D012640 CID BE_0\VB| (r_advmod) Injected_2\VBN|have (r_amod) rats_3\NNS|.|activity|without (l_relcl) have_7\VB|Injected (l_dobj) seizures_8\NNS|did|that|not
C005618_D012640 CID BE_0\VB| (r_advmod) Injected_2\VBN|have (r_amod) rats_3\NNS|.|activity|without (r_nsubj) had_9\VBD|NONE (l_prep) without_19\IN|.|activity|rats (l_pobj) seizures_20\NNS|NONE
C005618_D012640 CID BE_5\VB| (r_advmod) induced_7\VBN|and (r_conj) cocaine-_3\NN|NONE (r_nmod) seizures_8\NNS|in
C005618_D012640 CID BE_5\VB| (r_advmod) induced_7\VBN|and (r_conj) cocaine-_3\NN|NONE (r_nmod) seizures_8\NNS|in (r_nsubj) differ_9\VBP|The (r_relcl) finding_1\NN|mechanism|and|.|emphasizes (r_nsubj) suggests_13\VBZ|NONE (l_dobj) mechanism_17\NN|finding|and|.|emphasizes (l_prep) for_18\IN|one (l_pobj) seizures_22\NNS|NONE
C005618_D012640 CID BE_32\VB|importance|, (r_conj) emphasizes_24\VBZ|mechanism|finding|and|. (r_conj) suggests_13\VBZ|NONE (l_nsubj) finding_1\NN|mechanism|and|.|emphasizes (l_relcl) differ_9\VBP|The (l_nsubj) seizures_8\NNS|in
C005618_D012640 CID BE_32\VB|importance|, (r_conj) emphasizes_24\VBZ|mechanism|finding|and|. (r_conj) suggests_13\VBZ|NONE (l_dobj) mechanism_17\NN|finding|and|.|emphasizes (l_prep) for_18\IN|one (l_pobj) seizures_22\NNS|NONE
C005618_D003643 NONE BE_23\NNP|NONE (r_pobj) by_22\IN|NONE (r_agent) induced_21\VBN|NONE (r_acl) those_20\DT|,|.|multiple|resulted|and|characterized|, (r_nsubj) were_24\VBD|NONE (l_advcl) characterized_7\VBN|,|.|multiple|resulted|and|,|those (l_conj) resulted_16\VBD|as|and|were|seizures|best|Whereas (l_prep) in_17\IN|NONE (l_pobj) death_18\NN|NONE
C005618_D003643 NONE BE_23\NNP|NONE (r_pobj) by_22\IN|NONE (r_agent) induced_21\VBN|NONE (r_acl) those_20\DT|,|.|multiple|resulted|and|characterized|, (r_nsubj) were_24\VBD|NONE (l_conj) resulted_36\VBD|,|.|multiple|and|characterized|,|those (l_prep) in_37\IN|rarely (l_pobj) death_38\NN|NONE
D003042_D012640 CID cocaine_4\NN|NONE (r_compound) metabolite_5\NN|in|the (r_amod) benzoylecgonine_6\NN|NONE (r_pobj) by_2\IN|.|Seizures (r_agent) induced_1\VBN|NONE (l_nsubj) Seizures_0\NNS|.|by
D003042_D012640 CID cocaine_8\NN|NONE (r_pobj) of_7\IN|(|) (r_prep) t1/2_5\NN|half| (r_appos) life_3\NN|but|short|,|The|occur (r_nsubj) is_9\VBZ|NONE (l_conj) occur_29\VB|but|short|,|The|life (l_nsubj) some_14\DT|.|hours|can (l_prep) of_15\IN|NONE (l_pobj) consequences_17\NNS|NONE (l_prep) of_18\IN|the (l_pobj) use_20\NN|NONE (l_prep) as_23\IN|,|its|, (l_pobj) seizures_24\NNS|such
D003042_D012640 CID cocaine_9\NN|NONE (r_pobj) of_8\IN|BE|the|benzoylecgonine|major (r_prep) metabolite_7\NN|NONE (r_pobj) of_4\IN|the (r_prep) potential_3\NN|.|We|cause|, (r_dobj) evaluated_1\VBD|NONE (l_advcl) cause_17\VB|.|We|potential|, (l_dobj) seizures_18\NNS|to
D003042_D012640 CID cocaine_19\NN|NONE (r_pobj) of_18\IN|equimolar (r_prep) amounts_17\NNS|NONE (r_pobj) by_15\IN|NONE (r_agent) induced_14\VBN|NONE (r_acl) those_13\DT|NONE (r_pobj) than_12\IN|longer (r_prep) latencies_11\NNS|NONE (r_dobj) had_8\VBD|and|seizures|frequently|. (r_conj) occurred_4\VBD|NONE (l_nsubj) seizures_3\NNS|and|frequently|.|had
D003042_D012640 CID cocaine_1\NN| (r_npadvmod) induced_3\VBN|NONE (r_amod) seizures_4\NNS|resulted|as|and|were|best|Whereas
D003042_D012640 CID cocaine_15\NN| (r_npadvmod) injected_17\VBN|NONE (r_amod) animals_18\NNS|NONE (r_pobj) than_14\IN|more|locomotor (r_prep) activity_13\NN|.|rats|without (r_dobj) had_9\VBD|NONE (l_nsubj) rats_3\NNS|.|activity|without (l_relcl) have_7\VB|Injected (l_dobj) seizures_8\NNS|did|that|not
D003042_D012640 CID cocaine_15\NN| (r_npadvmod) injected_17\VBN|NONE (r_amod) animals_18\NNS|NONE (r_pobj) than_14\IN|more|locomotor (r_prep) activity_13\NN|.|rats|without (r_dobj) had_9\VBD|NONE (l_prep) without_19\IN|.|activity|rats (l_pobj) seizures_20\NNS|NONE
D003042_D012640 CID cocaine-_3\NN|NONE (r_nmod) seizures_8\NNS|in
D003042_D012640 CID cocaine-_3\NN|NONE (r_nmod) seizures_8\NNS|in (r_nsubj) differ_9\VBP|The (r_relcl) finding_1\NN|mechanism|and|.|emphasizes (r_nsubj) suggests_13\VBZ|NONE (l_dobj) mechanism_17\NN|finding|and|.|emphasizes (l_prep) for_18\IN|one (l_pobj) seizures_22\NNS|NONE
D003042_D012640 CID cocaine_19\NN| (r_npadvmod) induced_21\VBN|NONE (r_amod) seizures_22\NNS|NONE (r_pobj) for_18\IN|one (r_prep) mechanism_17\NN|finding|and|.|emphasizes (r_dobj) suggests_13\VBZ|NONE (l_nsubj) finding_1\NN|mechanism|and|.|emphasizes (l_relcl) differ_9\VBP|The (l_nsubj) seizures_8\NNS|in
D003042_D012640 CID cocaine_19\NN| (r_npadvmod) induced_21\VBN|NONE (r_amod) seizures_22\NNS|NONE
D003042_D012640 CID cocaine_29\NN|a (r_compound) metabolite_30\NN|NONE (r_pobj) of_27\IN|the (r_prep) importance_26\NN|BE|, (r_dobj) emphasizes_24\VBZ|mechanism|finding|and|. (r_conj) suggests_13\VBZ|NONE (l_nsubj) finding_1\NN|mechanism|and|.|emphasizes (l_relcl) differ_9\VBP|The (l_nsubj) seizures_8\NNS|in
D003042_D012640 CID cocaine_29\NN|a (r_compound) metabolite_30\NN|NONE (r_pobj) of_27\IN|the (r_prep) importance_26\NN|BE|, (r_dobj) emphasizes_24\VBZ|mechanism|finding|and|. (r_conj) suggests_13\VBZ|NONE (l_dobj) mechanism_17\NN|finding|and|.|emphasizes (l_prep) for_18\IN|one (l_pobj) seizures_22\NNS|NONE
1728915
D002220_D001523 NONE carbamazepine_1\NN|in|Because|is|widely (r_nsubjpass) used_4\VBN|,|recognition|.|implications (l_prep) in_5\IN|Because|is|widely|carbamazepine (l_pobj) treatment_7\NN|NONE (l_prep) of_8\IN|the (l_pobj) conditions_13\NNS|NONE (l_amod) neurologic_10\JJ|many (l_conj) psychiatric_12\JJ|and
D002220_D001919 CID carbamazepine_11\NN|NONE (r_pobj) by_10\IN|NONE (r_agent) induced_9\VBN|with|,|,|A (r_acl) patient_1\NN|review|. (l_prep) with_2\IN|induced|,|,|A (l_pobj) bradycardia_4\NNP|NONE
D002220_D001919 CID carbamazepine_28\NN|serum|therapeutic (r_compound) levels_30\NNS|NONE (r_pobj) with_22\IN|NONE (r_prep) associated_21\VBN|.|exclusively|group (r_advcl) consisted_3\VBD|NONE (l_advmod) exclusively_5\RB|.|associated|group (l_prep) of_6\IN|almost (l_pobj) women_8\NNS|NONE (l_relcl) developed_10\VBD|elderly|, (l_dobj) bradyarrhythmias_15\NNS|who
D002220_D054537 CID carbamazepine_11\NN|NONE (r_pobj) by_10\IN|NONE (r_agent) induced_9\VBN|with|,|,|A (r_acl) patient_1\NN|review|. (l_prep) with_2\IN|induced|,|,|A (l_pobj) bradycardia_4\NNP|NONE (l_conj) block_7\NN|sinus|and
D002220_D054537 CID carbamazepine_28\NN|serum|therapeutic (r_compound) levels_30\NNS|NONE (r_pobj) with_22\IN|NONE (r_prep) associated_21\VBN|.|exclusively|group (r_advcl) consisted_3\VBD|NONE (l_advmod) exclusively_5\RB|.|associated|group (l_prep) of_6\IN|almost (l_pobj) women_8\NNS|NONE (l_relcl) developed_10\VBD|elderly|, (l_dobj) bradyarrhythmias_15\NNS|who (l_conj) delay_19\NN|or|threatening
D002220_D062787 NONE carbamazepine_12\NN|a|massive (r_compound) overdose_13\NN|NONE
D002220_D013616 CID carbamazepine_12\NN|a|massive (r_compound) overdose_13\NN|NONE (r_pobj) of_9\IN|the (r_prep) setting_8\NN|NONE (r_pobj) in_6\IN|.|tachycardias|group (r_prep) developed_3\VBD|NONE (l_dobj) tachycardias_5\NNS|.|group|in
D002220_D006331 NONE Carbamazepine_0\NNP| (r_npadvmod) induced_2\VBN|.|cardiac (r_amod) dysfunction_4\NN|NONE
D002220_D006331 NONE carbamazepine_11\NN| (r_npadvmod) associated_13\VBN|cardiac (r_amod) dysfunction_15\NN|NONE
2265898
C009265_D007676 NONE levodopa_38\JJ|carbidopa|a (r_compound) preparation_39\NN|and|had|had|;|had|.|;|been|both (r_dobj) receiving_34\VBG|NONE (l_ccomp) had_11\VBD|and|had|had|;|preparation|.|;|been|both (l_dobj) failure_14\NN|but|patients|:|on|begun|presented|,
C009265_D001523 NONE levodopa_38\JJ|carbidopa|a (r_compound) preparation_39\NN|and|had|had|;|had|.|;|been|both (r_dobj) receiving_34\VBG|NONE (l_conj) had_43\VBD|and|had|;|preparation|had|.|;|been|both (l_dobj) onset_45\NN|both (l_prep) of_46\IN|the (l_pobj) seizures_50\NNS|NONE (l_nmod) hallucinosis_47\NN|,|were
C009265_D004827 CID carbidopa_6\NN|NONE (l_nsubj) epilepsy_1\NN|administration|/|.|in
C009265_D012640 NONE levodopa_38\JJ|carbidopa|a (r_compound) preparation_39\NN|and|had|had|;|had|.|;|been|both (r_dobj) receiving_34\VBG|NONE (l_conj) had_43\VBD|and|had|;|preparation|had|.|;|been|both (l_dobj) onset_45\NN|both (l_prep) of_46\IN|the (l_pobj) seizures_50\NNS|NONE
9564988
D064704_D012852 NONE levofloxacin_5\NN|NONE (r_pobj) of_4\IN|for|.|label (r_prep) assessment_3\NN|NONE (l_prep) for_6\IN|of|.|label (l_pobj) treatment_8\NN|NONE (l_prep) of_9\IN|the|in (l_pobj) sinusitis_12\NN|NONE
D064704_D012852 NONE levofloxacin_7\NN|NONE (r_pobj) of_6\IN|and|the|safety (r_prep) efficacy_3\NN|daily|in|To|. (r_dobj) evaluate_1\VB|NONE (l_prep) in_20\IN|daily|To|efficacy|. (l_pcomp) treating_21\VBG|NONE (l_prep) with_24\IN|outpatients (l_pobj) sinusitis_27\NN|NONE
D064704_D012852 NONE levofloxacin_7\VBZ|.|results|is (r_ccomp) indicate_5\VBP|NONE (l_ccomp) is_12\VBZ|.|results|levofloxacin (l_attr) treatment_17\NN|NONE (l_prep) for_18\IN|an|effective (l_pobj) sinusitis_21\NN|NONE
2224762
C027260_D009369 NONE 4'-0-tetrahydropyranyladriamycin_10\NNP|NONE (r_dobj) bolus_9\NN|study|A|) (r_appos) Phase_1\NN|in|.|was (r_nsubjpass) done_15\VBN|NONE (l_prep) in_16\IN|.|Phase|was (l_pobj) patients_18\NNS|NONE (l_prep) in_19\IN| (l_pobj) status_22\NN|NONE (l_prep) with_23\IN|good|performance (l_pobj) tumors_25\NNS|NONE
C027260_D009369 NONE Pirarubicin_12\NNP|NONE (r_appos) 4'-0-tetrahydropyranyladriamycin_10\NNP|NONE (r_dobj) bolus_9\NN|study|A|) (r_appos) Phase_1\NN|in|.|was (r_nsubjpass) done_15\VBN|NONE (l_prep) in_16\IN|.|Phase|was (l_pobj) patients_18\NNS|NONE (l_prep) in_19\IN| (l_pobj) status_22\NN|NONE (l_prep) with_23\IN|good|performance (l_pobj) tumors_25\NNS|NONE
8437969
D002927_D006331 NONE cimetidine_27\NN|while|hour (r_dobj) receiving_23\VBG|developed|episodes|, (r_advcl) recurrent_14\JJ|history|and|.|with|old|A (r_appos) man_4\NN|NONE (l_conj) history_9\NN|recurrent|and|.|with|old|A (l_prep) of_10\IN|no (l_pobj) disease_12\NN|NONE
D002927_D001919 CID cimetidine_7\NN|NONE (r_pobj) of_6\IN|intermittent|intravenous (r_prep) infusions_5\NNS|NONE (r_pobj) of_2\IN|The (r_prep) administration_1\NN|infrequently|is|with|. (r_nsubjpass) associated_10\VBN|NONE (l_prep) with_11\IN|infrequently|is|.|administration (l_pobj) development_13\NN|NONE (l_prep) of_14\IN|the (l_pobj) bradyarrhythmias_15\NNS|NONE
D002927_D001145 NONE cimetidine_6\NN|NONE (r_compound) administration_7\NN|NONE (r_pobj) to_5\IN|were|temporally|arrhythmias (r_prep) related_4\VBN|after|,|,|recur|.|and (l_nsubjpass) arrhythmias_1\NNS|were|to|temporally
D002927_D054138 CID cimetidine_7\NN|NONE (r_pobj) with_3\IN|NONE (r_prep) associated_2\VBN|.|Sinus (r_acl) arrest_1\NN|NONE
D002927_D054138 CID cimetidine_27\NN|while|hour (r_dobj) receiving_23\VBG|developed|episodes|, (r_advcl) recurrent_14\JJ|history|and|.|with|old|A (l_appos) episodes_17\NNS|developed|,|receiving (l_prep) of_18\IN|brief (l_pobj) arrest_21\NN|NONE
D002927_D054138 CID cimetidine_14\NN|NONE (r_pobj) with_10\IN|NONE (r_prep) associated_9\VBN|the|of|first|reported (r_acl) case_5\NN|This|. (l_prep) of_6\IN|the|associated|first|reported (l_pobj) arrest_8\NN|NONE
D011899_D001145 NONE ranitidine_18\NN|NONE (r_compound) treatment_19\NN|NONE (r_pobj) during_17\IN|not|did (r_prep) recur_16\VB|after|,|,|.|and|related (r_conj) disappeared_9\VBD|NONE (l_ccomp) related_4\VBN|after|,|,|recur|.|and (l_nsubjpass) arrhythmias_1\NNS|were|to|temporally
D002927_D007938 NONE cimetidine_27\NN|while|hour (r_dobj) receiving_23\VBG|developed|episodes|, (r_advcl) recurrent_14\JJ|history|and|.|with|old|A (r_appos) man_4\NN|NONE (l_prep) with_5\IN|recurrent|history|and|.|old|A (l_pobj) leukemia_6\NN|NONE
17019386
D008353_D005910 NONE mannitol_2\NN|NONE (r_pobj) of_1\IN|into (r_prep) Passage_0\NN|cause|.|: (r_nsubj) gliomas_7\NNS|NONE
D008353_D005910 NONE Mannitol_2\NN|: (r_appos) METHODS_0\NNS|had|as|was|. (r_nsubjpass) administered_14\VBN|NONE (l_parataxis) had_22\VBD|METHODS|as|was|. (l_dobj) glioma_24\NN|(|before|ten
D008353_D005910 NONE mannitol_5\NN|in (r_amod) concentrations_6\NNS|In|,|higher|.|mean (r_nsubj) were_10\VBD|NONE (l_prep) In_0\IN|,|higher|.|concentrations|mean (l_pobj) patients_3\NNS|NONE (l_compound) glioma_2\NN|most
D008353_D005910 NONE mannitol_13\NN|reversing|,|that|,|through|may|after|near (r_nsubj) leak_15\VB|of|The|. (l_prep) near_20\IN|reversing|,|that|,|through|may|mannitol|after (l_pobj) gliomas_21\NNS|NONE
D008353_D008579 NONE Mannitol_2\NN|: (r_appos) METHODS_0\NNS|had|as|was|. (r_nsubjpass) administered_14\VBN|NONE (l_parataxis) had_22\VBD|METHODS|as|was|. (l_dobj) glioma_24\NN|(|before|ten (l_conj) metastases_28\NNS|)|,|malignant (l_conj) meningioma_31\NN|seven|and|brain
D008353_D008579 NONE mannitol_8\NN|NONE (r_pobj) of_7\IN|plasma|patients (r_prep) concentrations_6\NNS|In|except|.|higher (l_compound) patients_4\NNS|of|plasma (l_nmod) meningioma_1\NN|NONE
D008353_D001932 NONE mannitol_5\NN|NONE (r_pobj) of_4\IN|Widespread|reduce (r_prep) use_3\NN|.|:|continues (l_acl) reduce_7\VB|of|Widespread (l_dobj) edema_9\NN|to (l_conj) ICP_13\NNP|and|brain (l_prep) in_14\IN|elevated|lower (l_pobj) patients_17\NNS|NONE (l_compound) tumor_16\NN|NONE
D008353_D001932 NONE mannitol_14\NN|NONE (r_pobj) of_13\IN|the|possible|into (r_prep) passage_12\NN|to|to|after (r_dobj) research_9\VB|.|we|As (l_prep) to_20\IN|to|passage|after (l_pobj) patients_24\NNS|NONE (l_compound) tumor_23\NN|
D008353_D004487 NONE mannitol_13\NN|reversing|,|that|,|through|may|after|near (r_nsubj) leak_15\VB|of|The|. (l_advcl) reversing_23\VBG|,|that|,|through|may|mannitol|after|near (l_conj) aggravating_34\VBG|gradient|, (l_dobj) edema_36\NN|promoting|and
D008353_D001929 NONE mannitol_5\NN|NONE (r_pobj) of_4\IN|Widespread|reduce (r_prep) use_3\NN|.|:|continues (l_acl) reduce_7\VB|of|Widespread (l_dobj) edema_9\NN|to
D008353_D019586 CID mannitol_5\NN|NONE (r_pobj) of_4\IN|Widespread|reduce (r_prep) use_3\NN|.|:|continues (l_acl) reduce_7\VB|of|Widespread (l_dobj) edema_9\NN|to (l_conj) ICP_13\NNP|and|brain
D008353_D009362 NONE Mannitol_2\NN|: (r_appos) METHODS_0\NNS|had|as|was|. (r_nsubjpass) administered_14\VBN|NONE (l_parataxis) had_22\VBD|METHODS|as|was|. (l_dobj) glioma_24\NN|(|before|ten (l_conj) metastases_28\NNS|)|,|malignant
D008353_D009362 NONE mannitol_8\NN|NONE (r_pobj) of_7\IN|plasma|patients (r_prep) concentrations_6\NNS|In|except|.|higher (l_compound) patients_4\NNS|of|plasma (l_nmod) meningioma_1\NN|NONE (l_conj) metastases_3\NNS|and
20735774
D000082_D017114 CID paracetamol_10\NN| (r_npadvmod) induced_12\VBN|acute|liver (r_amod) failure_15\NN|NONE
D000082_D017114 CID paracetamol_8\NN| (r_npadvmod) induced_10\VBN|acute|liver (r_amod) failure_13\NN|NONE
D000082_D017114 CID paracetamol_5\NN||whether (r_advmod) induced_7\VBN|failure|mortality (r_nmod) increases_11\VBZ|To (l_nsubj) failure_10\NN|mortality|induced
D000082_D017114 CID paracetamol_16\RB| (r_npadvmod) induced_18\VBN|whose|liver (r_amod) injury_20\NN|had|failure (r_nsubj) caused_22\VBN|the| (l_dobj) failure_26\NN|injury|had
D000082_D017114 CID paracetamol_16\RB| (r_npadvmod) induced_18\VBN|whose|liver (r_amod) injury_20\NN|had|failure (r_nsubj) caused_22\VBN|the| (r_relcl) patients_14\NNS|NONE (r_pobj) for_11\IN|slightly (r_prep) higher_10\JJR|On|,|was|rates|,|but (r_acomp) were_8\VBD|NONE (l_conj) was_46\VBD|higher|On|,|rates|,|but (l_conj) died_58\VBD|dependent|and|,|association (l_nsubj) survivors_53\NNS|,|.|of|were (l_prep) of_54\IN|no (l_pobj) failure_57\NN|NONE
D000082_D017114 CID Paracetamol_0\NNP| (r_npadvmod) induced_2\VBN|liver|acute (r_amod) failure_5\NN|did|.|not|mortality
D000082_D008107 NONE paracetamol_16\RB| (r_npadvmod) induced_18\VBN|whose|liver (r_amod) injury_20\NN|had|failure (r_nsubj) caused_22\VBN|the| (r_relcl) patients_14\NNS|NONE (r_pobj) for_11\IN|slightly (r_prep) higher_10\JJR|On|,|was|rates|,|but (r_acomp) were_8\VBD|NONE (l_conj) was_46\VBD|higher|On|,|rates|,|but (l_conj) died_58\VBD|dependent|and|,|association (l_prep) of_59\IN|survivors|,|.|were (l_pobj) disease_61\NN|NONE
D000082_D056486 NONE paracetamol_9\NN| (r_npadvmod) induced_11\VBN|acute|liver (r_amod) injury_14\NN|NONE
D000082_D056486 NONE paracetamol_16\RB| (r_npadvmod) induced_18\VBN|whose|liver (r_amod) injury_20\NN|had|failure
12448656
D013792_D002292 NONE thalidomide_5\NN|NONE (r_pobj) of_4\IN|.|phase|in|II|A (r_prep) study_3\NN|NONE (l_prep) in_6\IN|of|.|phase|II|A (l_pobj) carcinoma_11\NN|NONE
D013792_D002292 NONE thalidomide_9\NN|NONE (r_pobj) of_8\IN|activity|the|and (r_prep) toxicity_5\NN|To|in (r_dobj) evaluate_3\VB|:|. (l_prep) in_10\IN|To|toxicity (l_pobj) patients_11\NNS|and|measure (l_prep) with_12\IN|NONE (l_pobj) cancer_17\NN|NONE
D013792_D002292 NONE thalidomide_11\NN|NONE (r_pobj) of_10\IN|NONE (r_prep) activity_9\NN|NONE (r_pobj) of_8\IN|low|a|in (r_prep) level_7\NN|NONE (l_prep) in_12\IN|of|low|a (l_pobj) carcinoma_15\NN|NONE
D013792_D002292 NONE thalidomide_10\NN|NONE (l_prep) for_11\IN|NONE (l_pobj) carcinoma_14\NN|NONE
D013792_D064420 NONE thalidomide_9\NN|NONE (r_pobj) of_8\IN|activity|the|and (r_prep) toxicity_5\NN|To|in
3985451
D014859_D006470 NONE Warfarin_0\NNP| (r_npadvmod) induced_2\VBN|with|iliopsoas|. (r_amod) hemorrhage_4\NN|NONE
D014859_D015417 NONE warfarin_12\RB| (r_npadvmod) induced_14\VBN|peripheral (r_amod) neuropathy_16\NN|NONE (r_pobj) of_11\IN|the|common (r_prep) form_10\NN|palsy (r_dobj) represents_6\VBZ|it|.|is|by|; (r_ccomp) characterized_20\VBN|NONE (l_agent) by_21\IN|it|.|is|represents|; (l_pobj) pain_23\NN|NONE (l_conj) degrees_30\NNS|,|severe|in (l_prep) of_31\IN|contracture|and|varying|, (l_pobj) impairment_35\NN|NONE
D014859_D010146 NONE warfarin_12\NN|chronic (r_compound) therapy_13\NN|NONE (r_pobj) on_10\IN|old|a|sustained (r_prep) man_9\NN|NONE (l_relcl) sustained_15\VBD|old|on|a (l_conj) developed_21\VBD|tear|who|and (l_dobj) pain_23\NN|NONE
D014859_D010146 NONE warfarin_12\RB| (r_npadvmod) induced_14\VBN|peripheral (r_amod) neuropathy_16\NN|NONE (r_pobj) of_11\IN|the|common (r_prep) form_10\NN|palsy (r_dobj) represents_6\VBZ|it|.|is|by|; (r_ccomp) characterized_20\VBN|NONE (l_agent) by_21\IN|it|.|is|represents|; (l_pobj) pain_23\NN|NONE
D014859_D010523 NONE warfarin_12\RB| (r_npadvmod) induced_14\VBN|peripheral (r_amod) neuropathy_16\NN|NONE
D014859_D020428 CID Warfarin_0\NNP| (r_npadvmod) induced_2\VBN|with|iliopsoas|. (r_amod) hemorrhage_4\NN|NONE (l_prep) with_5\IN|induced|iliopsoas|. (l_pobj) palsy_9\JJ|NONE
D014859_D020428 CID warfarin_12\RB| (r_npadvmod) induced_14\VBN|peripheral (r_amod) neuropathy_16\NN|NONE (r_pobj) of_11\IN|the|common (r_prep) form_10\NN|palsy (r_dobj) represents_6\VBZ|it|.|is|by|; (l_nsubj) palsy_5\JJ|form
D014859_D009135 CID warfarin_12\NN|chronic (r_compound) therapy_13\NN|NONE (r_pobj) on_10\IN|old|a|sustained (r_prep) man_9\NN|NONE (l_relcl) sustained_15\VBD|old|on|a (l_dobj) tear_19\NN|who|and|developed
D014859_D003286 NONE warfarin_12\NN|chronic (r_compound) therapy_13\NN|NONE (r_pobj) on_10\IN|old|a|sustained (r_prep) man_9\NN|NONE (l_relcl) sustained_15\VBD|old|on|a (l_conj) developed_21\VBD|tear|who|and (l_dobj) pain_23\NN|NONE (l_conj) contracture_27\NN|increasing|and
D014859_D003286 NONE warfarin_12\RB| (r_npadvmod) induced_14\VBN|peripheral (r_amod) neuropathy_16\NN|NONE (r_pobj) of_11\IN|the|common (r_prep) form_10\NN|palsy (r_dobj) represents_6\VBZ|it|.|is|by|; (r_ccomp) characterized_20\VBN|NONE (l_agent) by_21\IN|it|.|is|represents|; (l_pobj) pain_23\NN|NONE (l_conj) degrees_30\NNS|,|severe|in (l_conj) contracture_39\NN|of|and|varying|,
12600698
C005435_D002544 NONE Edaravone_0\NNP|.|used|action|and (r_nsubj) has_7\VBZ|NONE (l_conj) used_15\VBN|.|action|Edaravone|and (l_xcomp) treat_20\VB|is|in (l_dobj) infarction_22\NN|to
D013307_D015837 CID streptomycin_5\NN| (r_npadvmod) induced_7\VBN|in (r_amod) vestibulotoxicity_8\NN|NONE
D013307_D015837 CID streptomycin_5\NNS| (r_npadvmod) induced_7\VBN|NONE (r_amod) vestibulotoxicity_8\NN|NONE
D013307_D015837 CID streptomycin_6\NN| (r_npadvmod) induced_8\VBN|NONE (r_amod) vestibulotoxicity_9\NN|edaravone|that
C005435_D015837 NONE edaravone_3\NN|NONE (r_pobj) of_2\IN|against|.|Protective (r_prep) effect_1\NN|NONE (l_prep) against_4\IN|of|.|Protective (l_pobj) vestibulotoxicity_8\NN|NONE
C005435_D015837 NONE edaravone_10\NN|NONE (r_pobj) by_9\IN|of|in (r_prep) alleviation_3\NN|study|. (l_prep) of_4\IN|by|in (l_pobj) vestibulotoxicity_8\NN|NONE
C005435_D015837 NONE edaravone_4\NN|that|vestibulotoxicity (r_nsubj) suppresses_5\VBZ|.|results (l_dobj) vestibulotoxicity_9\NN|edaravone|that
19105845
D016642_D012640 CID hydrochloride_8\NN| (r_npadvmod) induced_10\VBN|in (r_amod) seizures_11\NNS|NONE
D016642_D012640 CID bupropion_15\NN| (r_npadvmod) induced_17\VBN|NONE (r_amod) seizures_18\NNS|NONE
D016642_D012640 CID HCl_12\NNP|NONE (r_pobj) of_10\IN|intraperitoneal|the|infusion (r_prep) rates_9\NNS|mg/kg (r_dobj) varying_5\VBG|NONE (r_pcomp) of_4\IN|CD|,|the (r_prep) effect_3\NN|,|on|We|. (l_appos) CD50_22\NNP|,|the|of (l_amod) convulsive_18\JJ|)|dose|a|(
D016642_D012640 CID HCl_12\NNP|NONE (r_pobj) of_10\IN|intraperitoneal|the|infusion (r_prep) rates_9\NNS|mg/kg (r_dobj) varying_5\VBG|NONE (r_pcomp) of_4\IN|CD|,|the (r_prep) effect_3\NN|,|on|We|. (r_dobj) investigated_1\VBD|NONE (l_prep) on_25\IN|,|We|.|effect (l_pobj) incidence_27\NN|NONE (l_prep) of_30\IN|severity|and|the (l_pobj) convulsions_34\NNS|NONE
D016642_D012640 CID bupropion_31\NN| (r_npadvmod) induced_33\VBN|in (r_amod) convulsions_34\NNS|NONE (r_pobj) of_30\IN|severity|and|the (r_prep) incidence_27\NN|NONE (r_pobj) on_25\IN|,|We|.|effect (r_prep) investigated_1\VBD|NONE (l_dobj) effect_3\NN|,|on|We|. (l_appos) CD50_22\NNP|,|the|of (l_amod) convulsive_18\JJ|)|dose|a|(
D016642_D012640 CID bupropion_31\NN| (r_npadvmod) induced_33\VBN|in (r_amod) convulsions_34\NNS|NONE
D016642_D012640 CID HCl_9\NNP|:|mg/kg|%|by|.|induced|results (r_ccomp) showed_3\VBD|NONE (l_advcl) induced_15\VBD|:|mg/kg|%|HCl|by|.|results (l_dobj) convulsions_16\NNS|NONE
D016642_D012640 CID HCl_27\NNP|NONE (r_pobj) of_25\IN|the|infusion (r_prep) time_24\NN|mg/kg (r_dobj) increasing_20\VBG|=|odds|.|)|and|; (r_conj) ratio_15\NN|was|with|compared (r_nsubjpass) associated_31\VBN|was|analysis|. (l_prep) with_32\IN|was|ratio|compared (l_pobj) odds_37\NNS|NONE (l_prep) of_38\IN|reduced|%|a (l_pobj) convulsions_39\NNS|NONE
D016642_D012640 CID bupropion_19\NN|NONE (r_pobj) of_18\IN|risk|a|and|fixed (r_prep) dose_17\NN|NONE (l_amod) fixed_14\JJ|risk|of|a|and (l_conj) convulsive_16\JJ|and
D016642_D012640 CID bupropion_19\NN|NONE (r_pobj) of_18\IN|risk|a|and|fixed (r_prep) dose_17\NN|NONE (l_conj) risk_22\NN|of|a|and|fixed (l_prep) of_23\IN|the (l_pobj) convulsions_24\NNS|NONE
3762968
D014042_D014899 CID tolazamide_3\NN| (r_npadvmod) induced_5\VBN|Wernicke (r_amod) encephalopathy_8\NN|NONE
D014042_D014899 CID tolazamide_24\NN|NONE (r_pobj) with_23\IN|when (r_prep) treated_22\VBN|encephalopathy|who (r_advcl) developed_17\VBD|diabetic|a (l_dobj) encephalopathy_20\NN|treated|who
D014042_D014899 CID tolazamide_15\NN| (r_npadvmod) induced_17\VBN|Wernicke|from (r_amod) encephalopathy_20\NN|NONE
D014042_D020915 NONE tolazamide_24\NN|NONE (r_pobj) with_23\IN|when (r_prep) treated_22\VBN|encephalopathy|who (r_advcl) developed_17\VBD|diabetic|a (r_relcl) patient_15\NN|NONE (r_pobj) of_12\IN|NONE (r_prep) fibroblasts_11\NNS|NONE (r_pobj) from_10\IN|,|We|enzyme|in|. (r_prep) studied_1\VBD|NONE (l_prep) in_26\IN|,|We|from|enzyme|. (l_pobj) order_27\NN|NONE (l_acl) delineate_29\VB|NONE (l_ccomp) had_34\VBD|to (l_advcl) reported_50\VBN|abnormality|if|also|patient|, (l_prep) in_51\IN|as|previously (l_pobj) syndrome_56\NN|NONE
D014042_D020915 NONE tolazamide_15\NN| (r_npadvmod) induced_17\VBN|Wernicke|from (r_amod) encephalopathy_20\NN|NONE (r_pobj) with_14\IN|the (r_prep) patient_13\NN|and|Korsakoff|postalcoholic (r_conj) syndrome_10\NN|NONE
D013831_D014899 NONE thiamine_3\NN| (r_npadvmod) dependent_5\JJ|transketolase|,|a|, (r_amod) enzyme_6\NN|,|We|from|in|. (r_dobj) studied_1\VBD|NONE (l_prep) from_10\IN|,|We|enzyme|in|. (l_pobj) fibroblasts_11\NNS|NONE (l_prep) of_12\IN|NONE (l_pobj) patient_15\NN|NONE (l_relcl) developed_17\VBD|diabetic|a (l_dobj) encephalopathy_20\NN|treated|who
D014042_D003920 NONE tolazamide_24\NN|NONE (r_pobj) with_23\IN|when (r_prep) treated_22\VBN|encephalopathy|who (r_advcl) developed_17\VBD|diabetic|a (r_relcl) patient_15\NN|NONE (l_amod) diabetic_14\JJ|developed|a
D013835_D020915 NONE pyrophosphate_42\NN|NONE (r_pobj) for_40\IN|[|]|high (r_prep) Km_39\NNP|transketolase (r_appos) abnormality_36\NN|if|also|patient|,|reported (r_dobj) had_34\VBD|to (l_advcl) reported_50\VBN|abnormality|if|also|patient|, (l_prep) in_51\IN|as|previously (l_pobj) syndrome_56\NN|NONE
D013835_D020915 NONE TPP_44\NNP|)|thiamine|( (r_appos) pyrophosphate_42\NN|NONE (r_pobj) for_40\IN|[|]|high (r_prep) Km_39\NNP|transketolase (r_appos) abnormality_36\NN|if|also|patient|,|reported (r_dobj) had_34\VBD|to (l_advcl) reported_50\VBN|abnormality|if|also|patient|, (l_prep) in_51\IN|as|previously (l_pobj) syndrome_56\NN|NONE
D013831_D020915 NONE thiamine_3\NN| (r_npadvmod) dependent_5\JJ|transketolase|,|a|, (r_amod) enzyme_6\NN|,|We|from|in|. (r_dobj) studied_1\VBD|NONE (l_prep) in_26\IN|,|We|from|enzyme|. (l_pobj) order_27\NN|NONE (l_acl) delineate_29\VB|NONE (l_ccomp) had_34\VBD|to (l_advcl) reported_50\VBN|abnormality|if|also|patient|, (l_prep) in_51\IN|as|previously (l_pobj) syndrome_56\NN|NONE
D013835_D003920 NONE pyrophosphate_42\NN|NONE (r_pobj) for_40\IN|[|]|high (r_prep) Km_39\NNP|transketolase (r_appos) abnormality_36\NN|if|also|patient|,|reported (r_dobj) had_34\VBD|to (r_ccomp) delineate_29\VB|NONE (r_acl) order_27\NN|NONE (r_pobj) in_26\IN|,|We|from|enzyme|. (r_prep) studied_1\VBD|NONE (l_prep) from_10\IN|,|We|enzyme|in|. (l_pobj) fibroblasts_11\NNS|NONE (l_prep) of_12\IN|NONE (l_pobj) patient_15\NN|NONE (l_amod) diabetic_14\JJ|developed|a
D013835_D003920 NONE TPP_44\NNP|)|thiamine|( (r_appos) pyrophosphate_42\NN|NONE (r_pobj) for_40\IN|[|]|high (r_prep) Km_39\NNP|transketolase (r_appos) abnormality_36\NN|if|also|patient|,|reported (r_dobj) had_34\VBD|to (r_ccomp) delineate_29\VB|NONE (r_acl) order_27\NN|NONE (r_pobj) in_26\IN|,|We|from|enzyme|. (r_prep) studied_1\VBD|NONE (l_prep) from_10\IN|,|We|enzyme|in|. (l_pobj) fibroblasts_11\NNS|NONE (l_prep) of_12\IN|NONE (l_pobj) patient_15\NN|NONE (l_amod) diabetic_14\JJ|developed|a
D013835_D003920 NONE TPP_30\NNP|NONE (r_pobj) for_29\IN|its (r_prep) Km_28\NNP|NONE (r_pobj) by_26\IN|as (r_agent) determined_25\VBN|patient|that|transketolase (r_advcl) had_21\VBD|We|. (l_nsubj) patient_7\NN|that|transketolase|determined (l_conj) one_9\CD|the|mentioned|and|with (l_prep) of_10\IN|NONE (l_pobj) kindreds_13\NNS|NONE (l_amod) diabetic_12\JJ|the
D013835_D014899 NONE pyrophosphate_42\NN|NONE (r_pobj) for_40\IN|[|]|high (r_prep) Km_39\NNP|transketolase (r_appos) abnormality_36\NN|if|also|patient|,|reported (r_dobj) had_34\VBD|to (r_ccomp) delineate_29\VB|NONE (r_acl) order_27\NN|NONE (r_pobj) in_26\IN|,|We|from|enzyme|. (r_prep) studied_1\VBD|NONE (l_prep) from_10\IN|,|We|enzyme|in|. (l_pobj) fibroblasts_11\NNS|NONE (l_prep) of_12\IN|NONE (l_pobj) patient_15\NN|NONE (l_relcl) developed_17\VBD|diabetic|a (l_dobj) encephalopathy_20\NN|treated|who
D013835_D014899 NONE TPP_44\NNP|)|thiamine|( (r_appos) pyrophosphate_42\NN|NONE (r_pobj) for_40\IN|[|]|high (r_prep) Km_39\NNP|transketolase (r_appos) abnormality_36\NN|if|also|patient|,|reported (r_dobj) had_34\VBD|to (r_ccomp) delineate_29\VB|NONE (r_acl) order_27\NN|NONE (r_pobj) in_26\IN|,|We|from|enzyme|. (r_prep) studied_1\VBD|NONE (l_prep) from_10\IN|,|We|enzyme|in|. (l_pobj) fibroblasts_11\NNS|NONE (l_prep) of_12\IN|NONE (l_pobj) patient_15\NN|NONE (l_relcl) developed_17\VBD|diabetic|a (l_dobj) encephalopathy_20\NN|treated|who
D013835_D014899 NONE TPP_30\NNP|NONE (r_pobj) for_29\IN|its (r_prep) Km_28\NNP|NONE (r_pobj) by_26\IN|as (r_agent) determined_25\VBN|patient|that|transketolase (r_advcl) had_21\VBD|We|. (l_nsubj) patient_7\NN|that|transketolase|determined (l_prep) with_14\IN|the|mentioned|one|and (l_pobj) history_16\NN|NONE (l_prep) of_17\IN|no (l_pobj) encephalopathy_20\NN|NONE
D013831_D003920 NONE thiamine_3\NN| (r_npadvmod) dependent_5\JJ|transketolase|,|a|, (r_amod) enzyme_6\NN|,|We|from|in|. (r_dobj) studied_1\VBD|NONE (l_prep) from_10\IN|,|We|enzyme|in|. (l_pobj) fibroblasts_11\NNS|NONE (l_prep) of_12\IN|NONE (l_pobj) patient_15\NN|NONE (l_amod) diabetic_14\JJ|developed|a
6203452
D002945_D007674 CID cisplatin_30\VB|anemia|thrombocytopenia|and|and (r_amod) nephrotoxicity_31\NN|NONE
D001761_D051437 NONE bleomycin_26\NNS|with|, (r_conj) treatment_22\NN|NONE (r_pobj) after_21\IN|microangiopathy|.|patients (r_prep) developed_4\VBD|NONE (l_dobj) microangiopathy_6\NN|.|after|patients (l_acl) characterized_8\VBN|thrombotic (l_agent) by_9\IN|(|,|)|anemia (l_pobj) insufficiency_11\NN|NONE
D002945_D051437 NONE cisplatin_24\NN|NONE (r_pobj) with_23\IN|,|bleomycin (r_prep) treatment_22\NN|NONE (r_pobj) after_21\IN|microangiopathy|.|patients (r_prep) developed_4\VBD|NONE (l_dobj) microangiopathy_6\NN|.|after|patients (l_acl) characterized_8\VBN|thrombotic (l_agent) by_9\IN|(|,|)|anemia (l_pobj) insufficiency_11\NN|NONE
D002945_D051437 NONE cisplatin_30\VB|anemia|thrombocytopenia|and|and (r_amod) nephrotoxicity_31\NN|NONE (r_pobj) to_29\IN|may|be|because|failure (r_prep) ascribed_28\VBN|be|may|Diagnosis|,|.|or|missed (l_nsubjpass) failure_25\NN|may|be|because|to
D014748_D000743 NONE alkaloid_31\NN|a (r_amod) vinca_30\JJ|,|and (r_conj) bleomycin_26\NNS|with|, (r_conj) treatment_22\NN|NONE (r_pobj) after_21\IN|microangiopathy|.|patients (r_prep) developed_4\VBD|NONE (l_dobj) microangiopathy_6\NN|.|after|patients (l_acl) characterized_8\VBN|thrombotic (l_conj) anemia_15\NN|(|,|by|)
D002945_D057049 NONE cisplatin_24\NN|NONE (r_pobj) with_23\IN|,|bleomycin (r_prep) treatment_22\NN|NONE (r_pobj) after_21\IN|microangiopathy|.|patients (r_prep) developed_4\VBD|NONE (l_dobj) microangiopathy_6\NN|.|after|patients
D014748_D013921 NONE alkaloid_31\NN|a (r_amod) vinca_30\JJ|,|and (r_conj) bleomycin_26\NNS|with|, (r_conj) treatment_22\NN|NONE (r_pobj) after_21\IN|microangiopathy|.|patients (r_prep) developed_4\VBD|NONE (l_dobj) microangiopathy_6\NN|.|after|patients (l_acl) characterized_8\VBN|thrombotic (l_conj) anemia_15\NN|(|,|by|) (l_conj) thrombocytopenia_19\JJ|,|hemolytic|microangiopathic|and
D001761_D002277 NONE bleomycin_26\NNS|with|, (r_conj) treatment_22\NN|NONE (r_pobj) after_21\IN|microangiopathy|.|patients (r_prep) developed_4\VBD|NONE (l_nsubj) patients_1\NNS|microangiopathy|.|after (l_prep) with_2\IN|Five (l_pobj) carcinoma_3\NN|NONE
D014748_D057049 NONE alkaloid_31\NN|a (r_amod) vinca_30\JJ|,|and (r_conj) bleomycin_26\NNS|with|, (r_conj) treatment_22\NN|NONE (r_pobj) after_21\IN|microangiopathy|.|patients (r_prep) developed_4\VBD|NONE (l_dobj) microangiopathy_6\NN|.|after|patients
D014748_D051437 NONE alkaloid_31\NN|a (r_amod) vinca_30\JJ|,|and (r_conj) bleomycin_26\NNS|with|, (r_conj) treatment_22\NN|NONE (r_pobj) after_21\IN|microangiopathy|.|patients (r_prep) developed_4\VBD|NONE (l_dobj) microangiopathy_6\NN|.|after|patients (l_acl) characterized_8\VBN|thrombotic (l_agent) by_9\IN|(|,|)|anemia (l_pobj) insufficiency_11\NN|NONE
D001761_D000743 NONE bleomycin_26\NNS|with|, (r_conj) treatment_22\NN|NONE (r_pobj) after_21\IN|microangiopathy|.|patients (r_prep) developed_4\VBD|NONE (l_dobj) microangiopathy_6\NN|.|after|patients (l_acl) characterized_8\VBN|thrombotic (l_conj) anemia_15\NN|(|,|by|)
D001761_D057049 NONE bleomycin_26\NNS|with|, (r_conj) treatment_22\NN|NONE (r_pobj) after_21\IN|microangiopathy|.|patients (r_prep) developed_4\VBD|NONE (l_dobj) microangiopathy_6\NN|.|after|patients
D002945_D001855 NONE cisplatin_30\VB|anemia|thrombocytopenia|and|and (r_amod) nephrotoxicity_31\NN|NONE (l_conj) thrombocytopenia_36\NN|anemia|and|cisplatin|and (l_prep) to_37\IN|NONE (l_pobj) suppression_43\NN|NONE
D002945_D002277 NONE cisplatin_24\NN|NONE (r_pobj) with_23\IN|,|bleomycin (r_prep) treatment_22\NN|NONE (r_pobj) after_21\IN|microangiopathy|.|patients (r_prep) developed_4\VBD|NONE (l_nsubj) patients_1\NNS|microangiopathy|.|after (l_prep) with_2\IN|Five (l_pobj) carcinoma_3\NN|NONE
D014748_D002277 NONE alkaloid_31\NN|a (r_amod) vinca_30\JJ|,|and (r_conj) bleomycin_26\NNS|with|, (r_conj) treatment_22\NN|NONE (r_pobj) after_21\IN|microangiopathy|.|patients (r_prep) developed_4\VBD|NONE (l_nsubj) patients_1\NNS|microangiopathy|.|after (l_prep) with_2\IN|Five (l_pobj) carcinoma_3\NN|NONE
D002945_D013921 NONE cisplatin_24\NN|NONE (r_pobj) with_23\IN|,|bleomycin (r_prep) treatment_22\NN|NONE (r_pobj) after_21\IN|microangiopathy|.|patients (r_prep) developed_4\VBD|NONE (l_dobj) microangiopathy_6\NN|.|after|patients (l_acl) characterized_8\VBN|thrombotic (l_conj) anemia_15\NN|(|,|by|) (l_conj) thrombocytopenia_19\JJ|,|hemolytic|microangiopathic|and
D002945_D013921 NONE cisplatin_30\VB|anemia|thrombocytopenia|and|and (r_amod) nephrotoxicity_31\NN|NONE (l_conj) thrombocytopenia_36\NN|anemia|and|cisplatin|and
D001761_D013921 NONE bleomycin_26\NNS|with|, (r_conj) treatment_22\NN|NONE (r_pobj) after_21\IN|microangiopathy|.|patients (r_prep) developed_4\VBD|NONE (l_dobj) microangiopathy_6\NN|.|after|patients (l_acl) characterized_8\VBN|thrombotic (l_conj) anemia_15\NN|(|,|by|) (l_conj) thrombocytopenia_19\JJ|,|hemolytic|microangiopathic|and
D002945_D000740 NONE cisplatin_30\VB|anemia|thrombocytopenia|and|and (r_amod) nephrotoxicity_31\NN|NONE (l_conj) anemia_34\NN|thrombocytopenia|and|cisplatin|and
D002945_D000743 NONE cisplatin_24\NN|NONE (r_pobj) with_23\IN|,|bleomycin (r_prep) treatment_22\NN|NONE (r_pobj) after_21\IN|microangiopathy|.|patients (r_prep) developed_4\VBD|NONE (l_dobj) microangiopathy_6\NN|.|after|patients (l_acl) characterized_8\VBN|thrombotic (l_conj) anemia_15\NN|(|,|by|)
14745746
1711760
D010656_D006973 CID phenylephrine_4\NN| (r_npadvmod) induced_6\VBN|NONE (r_amod) hypertension_7\NN|that|,|h|aggravate
D007530_D006973 NONE isoflurane_1\JJ|NONE (r_amod) anesthesia_2\NN|NONE (r_pobj) Under_0\IN|MCA|.|was|, (r_prep) occluded_12\VBN|NONE (l_nsubjpass) MCA_5\NNP|.|was|Under|, (l_prep) of_6\IN|the (l_pobj) rats_10\NNS| (l_amod) hypertensive_9\JJ|NONE
D010656_D009410 NONE phenylephrine_4\NN| (r_npadvmod) induced_6\VBN|NONE (r_amod) hypertension_7\NN|that|,|h|aggravate (r_nsubj) instituted_8\VBD|data|. (l_advcl) aggravate_15\VB|that|hypertension|,|h (l_dobj) edema_16\NN|MCAO|does|after|not (l_acl) improves_24\VBZ|in (l_conj) reduces_37\VBZ|edema|it|and|,|that (l_dobj) area_39\NN|that|it (l_prep) of_40\IN|the (l_pobj) dysfunction_43\NN|NONE
D010656_D004487 NONE phenylephrine_4\NN| (r_npadvmod) induced_6\VBN|NONE (r_amod) hypertension_7\NN|that|,|h|aggravate (r_nsubj) instituted_8\VBD|data|. (l_advcl) aggravate_15\VB|that|hypertension|,|h (l_dobj) edema_16\NN|MCAO|does|after|not
D010656_D004487 NONE phenylephrine_4\NN| (r_npadvmod) induced_6\VBN|NONE (r_amod) hypertension_7\NN|that|,|h|aggravate (r_nsubj) instituted_8\VBD|data|. (l_advcl) aggravate_15\VB|that|hypertension|,|h (l_dobj) edema_16\NN|MCAO|does|after|not (l_acl) improves_24\VBZ|in (l_dobj) edema_25\NN|reduces|it|and|,|that
D010656_D020244 NONE phenylephrine_4\NN| (r_npadvmod) induced_6\VBN|NONE (r_amod) hypertension_7\NN|that|,|h|aggravate (r_nsubj) instituted_8\VBD|data|. (l_advcl) aggravate_15\VB|that|hypertension|,|h (l_nsubj) MCAO_12\NNP|does|after|not|edema
D010656_D007511 NONE phenylephrine_4\NN| (r_npadvmod) induced_6\VBN|NONE (r_amod) hypertension_7\NN|that|,|h|aggravate (r_nsubj) instituted_8\VBD|data|. (l_advcl) aggravate_15\VB|that|hypertension|,|h (l_dobj) edema_16\NN|MCAO|does|after|not (l_prep) in_17\IN|improves (l_pobj) core_20\NN|NONE (l_amod) ischemic_19\JJ|the
D010656_D007511 NONE phenylephrine_4\NN| (r_npadvmod) induced_6\VBN|NONE (r_amod) hypertension_7\NN|that|,|h|aggravate (r_nsubj) instituted_8\VBD|data|. (l_advcl) aggravate_15\VB|that|hypertension|,|h (l_dobj) edema_16\NN|MCAO|does|after|not (l_acl) improves_24\VBZ|in (l_dobj) edema_25\NN|reduces|it|and|,|that (l_prep) in_26\IN|NONE (l_pobj) periphery_28\NN|NONE (l_prep) of_29\IN|the (l_pobj) territory_32\NN|NONE (l_amod) ischemic_31\JJ|the
C009591_D009410 NONE 2,3,5-triphenyltetrazolium_8\CD|NONE (r_nummod) staining_9\VBG|NONE (r_pobj) by_7\IN|extent|.|was (r_agent) determined_6\VBN|NONE (l_nsubjpass) extent_1\NN|by|.|was (l_prep) of_2\IN|The (l_pobj) injury_4\NN|NONE
8387218
D016049_D064420 NONE didanosine_5\NN|NONE (r_pobj) of_4\IN|toxicity|The|and|) (r_prep) use_1\NN|NONE (l_conj) toxicity_3\NN|The|and|of|)
D016049_D064420 NONE ddI_7\NN|in (r_appos) didanosine_5\NN|NONE (r_pobj) of_4\IN|toxicity|The|and|) (r_prep) use_1\NN|NONE (l_conj) toxicity_3\NN|The|and|of|)
D016049_D015658 NONE didanosine_5\NN|NONE (l_prep) in_9\IN|ddI (l_pobj) individuals_14\NNS|NONE (l_amod) positive_13\JJ|AZT|intolerant|HIV
D016049_D015658 NONE ddI_7\NN|in (r_appos) didanosine_5\NN|NONE (l_prep) in_9\IN|ddI (l_pobj) individuals_14\NNS|NONE (l_amod) positive_13\JJ|AZT|intolerant|HIV
D015215_D064420 NONE zidovudine_17\NNP|NONE (r_pobj) to_16\IN|NONE (r_prep) intolerant_15\JJ|AZT|HIV|positive (r_amod) individuals_14\NNS|NONE (r_pobj) in_9\IN|ddI (r_prep) didanosine_5\NN|NONE (r_pobj) of_4\IN|toxicity|The|and|) (r_prep) use_1\NN|NONE (l_conj) toxicity_3\NN|The|and|of|)
D015215_D064420 NONE AZT_19\NNP|intolerant|HIV|positive (r_appos) individuals_14\NNS|NONE (r_pobj) in_9\IN|ddI (r_prep) didanosine_5\NN|NONE (r_pobj) of_4\IN|toxicity|The|and|) (r_prep) use_1\NN|NONE (l_conj) toxicity_3\NN|The|and|of|)
D015215_D015658 NONE zidovudine_17\NNP|NONE (r_pobj) to_16\IN|NONE (r_prep) intolerant_15\JJ|AZT|HIV|positive (r_amod) individuals_14\NNS|NONE (l_amod) positive_13\JJ|AZT|intolerant|HIV
D015215_D015658 NONE AZT_19\NNP|intolerant|HIV|positive (r_appos) individuals_14\NNS|NONE (l_amod) positive_13\JJ|AZT|intolerant|HIV
D016049_D018149 CID didanosine_24\NN|NONE (r_dobj) ceasing_23\VBG|NONE (r_pcomp) on_22\IN|to (r_prep) returned_19\VBN|and|not|.|did|,|treatment (r_conj) require_16\VB|but|curves|patients|were (r_conj) developed_2\VBD|NONE (l_dobj) curves_5\VBZ|but|require|patients|were
D016049_D003920 NONE didanosine_24\NN|NONE (r_dobj) ceasing_23\VBG|NONE (r_pcomp) on_22\IN|to (r_prep) returned_19\VBN|and|not|.|did|,|treatment (r_conj) require_16\VB|but|curves|patients|were (r_conj) developed_2\VBD|NONE (l_dobj) curves_5\VBZ|but|require|patients|were (l_amod) characteristic_6\JJ|tolerance (l_prep) of_7\IN|NONE (l_pobj) diabetes_8\NNS|NONE
7423039
D004317_D066126 CID adriamycin_3\JJ|NONE (r_amod) cardiotoxicity_4\NN|NONE
D004317_D066126 CID adriamycin_4\NNS|NONE (r_pobj) of_3\IN|cardiotoxic|The (r_prep) effects_2\NNS|were|in|. (l_amod) cardiotoxic_1\JJ|The|of
7197363
D001058_D012892 NONE apomorphine_10\NN| (r_npadvmod) induced_12\VBN|and|twitches (r_amod) aggressiveness_13\NN|NONE (r_pobj) on_9\IN|The|of (r_prep) effects_1\NNS|were|. (l_prep) of_2\IN|The|on (l_pobj) deprivation_5\NN|NONE
D001058_D012892 NONE apomorphine_10\NN| (r_npadvmod) induced_12\VBN|and|twitches (r_amod) aggressiveness_13\NN|NONE (r_pobj) on_9\IN|The|of (r_prep) effects_1\NNS|were|. (l_prep) of_2\IN|The|on (l_pobj) deprivation_5\NN|NONE (l_appos) REMD_7\NNP|(|sleep|REM|)
D001058_D012892 NONE apomorphine_7\NN| (r_npadvmod) induced_9\VBN|NONE (r_amod) aggressiveness_10\NN|reduced|,|.|and|hr|twitches (r_dobj) increased_6\VBD|NONE (l_nsubj) hr_3\NN|reduced|,|.|and|twitches|aggressiveness (l_prep) of_4\IN|eight (l_pobj) REMD_5\NNP|NONE
D001058_D012892 NONE apomorphine_7\NN| (r_npadvmod) induced_9\VBN|NONE (r_amod) aggressiveness_10\NN|reduced|,|.|and|hr|twitches (r_dobj) increased_6\VBD|NONE (l_conj) reduced_13\VBN|,|.|and|hr|twitches|aggressiveness (l_prep) after_16\IN|(|increased|or|) (l_pcomp) completing_17\VBG|immediately (l_prep) of_18\IN|NONE (l_pobj) REMD_19\NNP|NONE
D001058_D012892 NONE apomorphine_7\NN| (r_npadvmod) induced_9\VBN|NONE (r_amod) aggressiveness_10\NN|reduced|,|.|and|hr|twitches (r_dobj) increased_6\VBD|NONE (l_conj) reduced_13\VBN|,|.|and|hr|twitches|aggressiveness (l_conj) increased_22\VBN|(|or|)|after (l_prep) after_26\IN|hr (l_pcomp) completing_27\VBG|NONE (l_prep) of_28\IN|NONE (l_pobj) quipazine_31\NN|NONE (l_nmod) REMD_29\NNP|)|
D011814_D009069 CID quipazine_15\NN| (r_npadvmod) induced_17\VBN|NONE (r_amod) head_18\NN|in (r_compound) twitches_19\NNS|and|induced
D011814_D009069 CID quipazine_31\NN|NONE (r_pobj) of_28\IN|NONE (r_prep) completing_27\VBG|NONE (r_pcomp) after_26\IN|hr (r_prep) increased_22\VBN|(|or|)|after (r_conj) reduced_13\VBN|,|.|and|hr|twitches|aggressiveness (r_conj) increased_6\VBD|NONE (l_conj) twitches_35\NNS|reduced|,|.|and|hr|aggressiveness
D011814_D012892 NONE quipazine_15\NN| (r_npadvmod) induced_17\VBN|NONE (r_amod) head_18\NN|in (r_compound) twitches_19\NNS|and|induced (r_conj) aggressiveness_13\NN|NONE (r_pobj) on_9\IN|The|of (r_prep) effects_1\NNS|were|. (l_prep) of_2\IN|The|on (l_pobj) deprivation_5\NN|NONE
D011814_D012892 NONE quipazine_15\NN| (r_npadvmod) induced_17\VBN|NONE (r_amod) head_18\NN|in (r_compound) twitches_19\NNS|and|induced (r_conj) aggressiveness_13\NN|NONE (r_pobj) on_9\IN|The|of (r_prep) effects_1\NNS|were|. (l_prep) of_2\IN|The|on (l_pobj) deprivation_5\NN|NONE (l_appos) REMD_7\NNP|(|sleep|REM|)
D011814_D012892 NONE quipazine_31\NN|NONE (r_pobj) of_28\IN|NONE (r_prep) completing_27\VBG|NONE (r_pcomp) after_26\IN|hr (r_prep) increased_22\VBN|(|or|)|after (r_conj) reduced_13\VBN|,|.|and|hr|twitches|aggressiveness (r_conj) increased_6\VBD|NONE (l_nsubj) hr_3\NN|reduced|,|.|and|twitches|aggressiveness (l_prep) of_4\IN|eight (l_pobj) REMD_5\NNP|NONE
D011814_D012892 NONE quipazine_31\NN|NONE (r_pobj) of_28\IN|NONE (r_prep) completing_27\VBG|NONE (r_pcomp) after_26\IN|hr (r_prep) increased_22\VBN|(|or|)|after (r_conj) reduced_13\VBN|,|.|and|hr|twitches|aggressiveness (l_prep) after_16\IN|(|increased|or|) (l_pcomp) completing_17\VBG|immediately (l_prep) of_18\IN|NONE (l_pobj) REMD_19\NNP|NONE
D011814_D012892 NONE quipazine_31\NN|NONE (l_nmod) REMD_29\NNP|)|
D001058_D001523 CID apomorphine_10\NN| (r_npadvmod) induced_12\VBN|and|twitches (r_amod) aggressiveness_13\NN|NONE
D001058_D001523 CID apomorphine_7\NN| (r_npadvmod) induced_9\VBN|NONE (r_amod) aggressiveness_10\NN|reduced|,|.|and|hr|twitches
D001058_D009069 NONE apomorphine_10\NN| (r_npadvmod) induced_12\VBN|and|twitches (r_amod) aggressiveness_13\NN|NONE (l_conj) twitches_19\NNS|and|induced
D001058_D009069 NONE apomorphine_7\NN| (r_npadvmod) induced_9\VBN|NONE (r_amod) aggressiveness_10\NN|reduced|,|.|and|hr|twitches (r_dobj) increased_6\VBD|NONE (l_conj) twitches_35\NNS|reduced|,|.|and|hr|aggressiveness
D011814_D001523 NONE quipazine_15\NN| (r_npadvmod) induced_17\VBN|NONE (r_amod) head_18\NN|in (r_compound) twitches_19\NNS|and|induced (r_conj) aggressiveness_13\NN|NONE
D011814_D001523 NONE quipazine_31\NN|NONE (r_pobj) of_28\IN|NONE (r_prep) completing_27\VBG|NONE (r_pcomp) after_26\IN|hr (r_prep) increased_22\VBN|(|or|)|after (r_conj) reduced_13\VBN|,|.|and|hr|twitches|aggressiveness (r_conj) increased_6\VBD|NONE (l_dobj) aggressiveness_10\NN|reduced|,|.|and|hr|twitches
11256525
D000809_D006333 NONE angiotensin_24\NN|RAS|)|the|( (r_compound) system_25\NN|NONE (r_pobj) of_20\IN|a|strong (r_prep) activation_19\NN|NONE (r_pobj) in_16\IN|In|,|certainly|.|stenosis (r_prep) resulted_15\VBD|NONE (l_nsubj) stenosis_6\NN|in|In|,|certainly|. (l_acl) combined_7\VBN|artery|renal (l_prep) with_8\IN|NONE (l_pobj) failure_10\NN|NONE
D000588_D001002 NONE amine_26\NN|and (r_conj) furosemide_24\NN|dose (r_nmod) infusion_27\NN|NONE (r_pobj) despite_20\IN|which|hours (r_prep) lasted_17\VBD|,|sudden|a (r_relcl) anuria_14\NN|NONE
D019808_D001002 CID losartan_4\NN|NONE (r_amod) administration_5\NN|in (r_dobj) following_3\VBG|Repeated|transient|. (r_prep) anuria_2\NN|NONE
D019808_D001002 CID losartan_27\NN|NONE (r_amod) administration_28\NN|NONE (r_pobj) after_26\IN|who|episodes (r_prep) developed_20\VBD|and|solitary|insufficiency|a (l_dobj) episodes_22\NNS|after|who (l_prep) of_23\IN|two (l_pobj) anuria_25\NN|NONE
D019808_D001002 CID losartan_9\NN|NONE (r_pobj) of_8\IN| (r_prep) mg_7\NN|NONE (r_pobj) of_5\IN|first|the (r_prep) dose_4\NN|in|,|.|Surprisingly (r_nsubj) resulted_10\VBD|NONE (l_prep) in_11\IN|,|.|Surprisingly|dose (l_pobj) anuria_14\NN|NONE
D019808_D001002 CID losartan_7\NN|and|,|later|was|again|by|,|developed (r_nsubjpass) prescribed_9\VBN|NONE (l_conj) developed_22\VBD|and|,|losartan|later|was|again|by|, (l_dobj) episode_25\NN|,|after|patient|. (l_prep) of_26\IN|lasting|a|second (l_pobj) anuria_28\NN|NONE
D000809_D012078 NONE angiotensin_24\NN|RAS|)|the|( (r_compound) system_25\NN|NONE (r_pobj) of_20\IN|a|strong (r_prep) activation_19\NN|NONE (r_pobj) in_16\IN|In|,|certainly|.|stenosis (r_prep) resulted_15\VBD|NONE (l_nsubj) stenosis_6\NN|in|In|,|certainly|.
D005665_D001002 NONE furosemide_24\NN|dose (r_nmod) infusion_27\NN|NONE (r_pobj) despite_20\IN|which|hours (r_prep) lasted_17\VBD|,|sudden|a (r_relcl) anuria_14\NN|NONE
D019808_D051436 NONE losartan_27\NN|NONE (r_amod) administration_28\NN|NONE (r_pobj) after_26\IN|who|episodes (r_prep) developed_20\VBD|and|solitary|insufficiency|a (r_relcl) kidney_14\NN|NONE (l_conj) insufficiency_18\NN|and|solitary|a|developed
D019808_D014652 NONE losartan_12\NN|complications|used|that|and|can (r_nsubj) cause_14\VB|the (l_dobj) complications_17\NNS|used|that|and|can|losartan (l_prep) in_18\IN|serious|unexpected (l_pobj) patients_19\NNS|NONE (l_prep) with_20\IN|NONE (l_pobj) disease_22\NN|NONE
D000804_D014652 NONE II_9\NNP|receptor (r_compound) antagonist_11\NN|angiotensin|the (r_compound) losartan_12\NN|complications|used|that|and|can (r_nsubj) cause_14\VB|the (l_dobj) complications_17\NNS|used|that|and|can|losartan (l_prep) in_18\IN|serious|unexpected (l_pobj) patients_19\NNS|NONE (l_prep) with_20\IN|NONE (l_pobj) disease_22\NN|NONE
D019808_D006331 NONE losartan_5\NN|.|was|Due (l_compound) dysfunction_4\NN|NONE
D019808_D006973 NONE losartan_27\NN|NONE (r_amod) administration_28\NN|NONE (r_pobj) after_26\IN|who|episodes (r_prep) developed_20\VBD|and|solitary|insufficiency|a (r_relcl) kidney_14\NN|NONE (r_pobj) with_11\IN|hypertensive|old|a (r_prep) man_10\NN|NONE (l_amod) hypertensive_9\JJ|old|a|with
8441146
D006046_D000741 CID gold_12\NN|NONE (r_pobj) by_11\IN|which|was|in (r_agent) caused_10\VBN|severe|aplastic (r_relcl) anemia_7\NN|to
D010396_D000741 CID penicillamine_19\NN|in|and|one (r_conj) case_15\NN|NONE (r_pobj) in_13\IN|which|was|by (r_prep) caused_10\VBN|severe|aplastic (r_relcl) anemia_7\NN|to
16116131
D007980_D004409 CID levodopa_7\RB| (r_npadvmod) induced_9\VBN|NONE (r_amod) dyskinesia_10\NN|NONE
D001058_D010300 NONE apomorphine_46\NN|continuous (r_compound) infusion_47\NN|NONE (r_pobj) by_44\IN|NONE (r_agent) induced_43\VBN|dyskinetic|a (r_acl) state_42\NN|NONE (r_pobj) of_39\IN|a (r_prep) modification_38\NN|NONE (r_pobj) in_36\IN|modulation|whether|may (r_prep) result_35\VB|authors|,|Using|. (r_ccomp) investigated_28\VBN|NONE (l_advcl) Using_0\VBG|authors|,|result|. (l_parataxis) rTMS_6\NN|stimulation (l_prep) over_8\IN|)|( (l_pobj) area_12\NN|NONE (l_prep) in_16\IN|the|supplementary|SMA|motor (l_pobj) group_18\NN|NONE (l_prep) of_19\IN|a (l_pobj) patients_20\NNS|NONE (l_prep) with_21\IN|NONE (l_pobj) disease_24\NN|NONE
D001058_D004409 NONE apomorphine_46\NN|continuous (r_compound) infusion_47\NN|NONE (r_pobj) by_44\IN|NONE (r_agent) induced_43\VBN|dyskinetic|a (r_acl) state_42\NN|NONE (l_amod) dyskinetic_41\JJ|induced|a
15278670
D008012_D003866 NONE lidocaine_10\JJ|NONE (r_compound) toxicity_11\NN|NONE (r_pobj) of_9\IN|the|convulsive (r_prep) effect_8\NN|sevoflurane|but|carries|that (r_dobj) reduces_5\VBZ|It|is|. (l_conj) carries_13\VBZ|sevoflurane|but|that|effect (l_prep) due_16\IN|risk (l_pcomp) to_17\IN|NONE (l_pobj) depression_19\NN|NONE
D001030_D012640 NONE Apamin_0\NNP|but|tendency|was|) (r_nsubj) had_5\VBD|NONE (l_dobj) tendency_7\NN|but|was|)|Apamin (l_acl) decrease_9\VB|a (l_dobj) threshold_12\NN|to (l_amod) convulsive_11\JJ|)|(|the|+/
C009250_D012640 NONE sevoflurane_3\NN|NONE (r_pobj) of_2\IN|.|The|on (r_prep) effects_1\NNS|NONE (l_prep) on_4\IN|of|.|The (l_pobj) convulsions_8\NNS|NONE
C009250_D012640 NONE sevoflurane_3\NN|NONE (l_prep) on_4\IN|NONE (l_pobj) convulsions_8\NNS|NONE
C009250_D012640 NONE sevoflurane_40\NN|NONE (r_pobj) of_39\IN|the|tidal (r_prep) concentration_38\NN|%|when (r_nsubj) was_41\VBD|mg.|) (r_relcl) l(-1_31\NN|NONE (r_pobj) to_26\IN|significantly (r_prep) increasing_24\VBG|with|+/|)|)|,|threshold|. (r_advcl) was_8\VBD|NONE (l_nsubj) threshold_2\NN|with|+/|)|increasing|)|,|. (l_amod) convulsive_1\JJ|The|(|)|mean
C009250_D012640 NONE sevoflurane_10\NN|NONE (r_pobj) between_9\IN|convulsive|the (r_prep) threshold_8\NN|NONE (l_amod) convulsive_7\JJ|the|between
C009250_D012640 NONE sevoflurane_12\NN|NONE (r_pobj) of_11\IN|higher (r_prep) concentrations_10\NNS|when|decreased|and|were (r_nsubjpass) administered_16\VBN|rise|.|marked (l_conj) decreased_23\VBD|when|concentrations|and|were (l_nsubj) pressure_20\NN|in|and|in|significantly|, (l_prep) at_21\IN|the|blood (l_pobj) convulsions_22\NNS|NONE
C009250_D012640 NONE sevoflurane_28\NN|NONE (r_pobj) in_25\IN|pressure|and|in|significantly|, (r_prep) decreased_23\VBD|when|concentrations|and|were (l_nsubj) pressure_20\NN|in|and|in|significantly|, (l_prep) at_21\IN|the|blood (l_pobj) convulsions_22\NNS|NONE
C009250_D012640 NONE sevoflurane_4\NN|but|carries|that|effect (r_nsubj) reduces_5\VBZ|It|is|. (l_dobj) effect_8\NN|sevoflurane|but|carries|that (l_amod) convulsive_7\JJ|the|of
C009250_D064420 NONE sevoflurane_4\NN|but|carries|that|effect (r_nsubj) reduces_5\VBZ|It|is|. (l_dobj) effect_8\NN|sevoflurane|but|carries|that (l_prep) of_9\IN|the|convulsive (l_pobj) toxicity_11\NN|NONE
D008012_D064420 NONE lidocaine_10\JJ|NONE (r_compound) toxicity_11\NN|NONE
D008012_D012640 CID lidocaine_5\NN| (r_npadvmod) induced_7\VBN|NONE (r_amod) convulsions_8\NNS|NONE
D008012_D012640 CID lidocaine_5\NN| (r_npadvmod) induced_7\VBN|NONE (r_amod) convulsions_8\NNS|NONE
D008012_D012640 CID lidocaine_16\NN|)|mg.kg().min(|( (r_compound) infusion_17\NN|NONE (r_pobj) with_15\IN|+/|)|increasing|)|,|threshold|. (r_prep) was_8\VBD|NONE (l_nsubj) threshold_2\NN|with|+/|)|increasing|)|,|. (l_amod) convulsive_1\JJ|The|(|)|mean
D008012_D012640 CID lidocaine_10\JJ|NONE (r_compound) toxicity_11\NN|NONE (r_pobj) of_9\IN|the|convulsive (r_prep) effect_8\NN|sevoflurane|but|carries|that (l_amod) convulsive_7\JJ|the|of
C009250_D003866 NONE sevoflurane_4\NN|but|carries|that|effect (r_nsubj) reduces_5\VBZ|It|is|. (l_conj) carries_13\VBZ|sevoflurane|but|that|effect (l_prep) due_16\IN|risk (l_pcomp) to_17\IN|NONE (l_pobj) depression_19\NN|NONE
D004737_D012640 NONE enflurane_12\NN|and (r_conj) sevoflurane_10\NN|NONE (r_pobj) between_9\IN|convulsive|the (r_prep) threshold_8\NN|NONE (l_amod) convulsive_7\JJ|the|between
D004737_D012640 NONE enflurane_14\NN|or (r_conj) sevoflurane_12\NN|NONE (r_pobj) of_11\IN|higher (r_prep) concentrations_10\NNS|when|decreased|and|were (r_nsubjpass) administered_16\VBN|rise|.|marked (l_conj) decreased_23\VBD|when|concentrations|and|were (l_nsubj) pressure_20\NN|in|and|in|significantly|, (l_prep) at_21\IN|the|blood (l_pobj) convulsions_22\NNS|NONE
D004737_D012640 NONE enflurane_37\NN|and|. (r_conj) %_33\NN|NONE (r_pobj) in_31\IN|in|pressure|and|significantly|, (r_conj) decreased_23\VBD|when|concentrations|and|were (l_nsubj) pressure_20\NN|in|and|in|significantly|, (l_prep) at_21\IN|the|blood (l_pobj) convulsions_22\NNS|NONE
19889778
18996674
D004837_D011317 NONE epinephrine_1\NN|NONE (l_appos) treatment_6\NN|Intracavernous|:|. (l_prep) for_7\IN|a|invasive (l_pobj) priapism_8\NN|NONE
D003042_D011317 CID cocaine_9\NN|admitted|an|frequent (r_compound) user_10\NN|,|old|,|A (r_appos) man_4\NN|on|to|. (r_nsubj) presented_12\VBN|NONE (l_prep) on_20\IN|man|to|. (l_pobj) occasions_23\NNS|NONE (l_prep) with_24\IN|two|separate (l_pobj) history_26\NN|NONE (l_prep) of_27\IN|after|a (l_pobj) priapism_28\NN|NONE
D003042_D011317 CID cocaine_30\NN|NONE (r_compound) use_31\NN|NONE (r_pobj) after_29\IN|of|a (r_prep) history_26\NN|NONE (l_prep) of_27\IN|after|a (l_pobj) priapism_28\NN|NONE
12101159
D007547_D062787 NONE isosorbide_21\JJ|alcohol|,|and (r_compound) nitrate_22\NN|, (r_conj) aspirin_19\NN|, (r_conj) paracetamol_17\JJ|, (r_conj) diltiazem_15\NN|NONE (r_pobj) of_14\IN|. (r_prep) g_13\NN|NONE (r_pobj) including_9\VBG|a|mixed (r_prep) overdose_8\NN|.|man
D001241_D062787 NONE aspirin_19\NN|, (r_conj) paracetamol_17\JJ|, (r_conj) diltiazem_15\NN|NONE (r_pobj) of_14\IN|. (r_prep) g_13\NN|NONE (r_pobj) including_9\VBG|a|mixed (r_prep) overdose_8\NN|.|man
D002118_D006323 NONE calcium_13\NN|NONE (r_pobj) with_9\IN|NONE (r_prep) resuscitation_8\NN|;|arrest|. (r_dep) Delayed_0\VBN|NONE (l_dobj) arrest_3\NN|;|resuscitation|. (l_amod) asystolic_1\JJ|cardiac|after
D002118_D006323 NONE calcium_13\NN|NONE (r_pobj) with_9\IN|NONE (r_prep) resuscitation_8\NN|;|arrest|. (r_dep) Delayed_0\VBN|NONE (l_dobj) arrest_3\NN|;|resuscitation|.
D002118_D006323 NONE calcium_12\NN|in|intravenous|dose|aggressive (r_compound) therapy_13\NN|NONE (r_pobj) for_7\IN|a|,|with (r_prep) role_6\NN|there (l_prep) with_20\IN|a|for|, (l_pobj) onset_22\NN|particularly (l_prep) of_23\IN|the (l_pobj) asystole_24\NN|NONE
D002118_D062787 NONE calcium_13\NN|NONE (r_pobj) with_9\IN|NONE (r_prep) resuscitation_8\NN|;|arrest|. (r_dep) Delayed_0\VBN|NONE (l_dobj) arrest_3\NN|;|resuscitation|. (l_prep) after_4\IN|cardiac|asystolic (l_pobj) overdose_6\NN|NONE
D002118_D062787 NONE calcium_12\NN|in|intravenous|dose|aggressive (r_compound) therapy_13\NN|NONE (l_prep) in_14\IN|calcium|intravenous|dose|aggressive (l_pobj) overdose_17\NN|NONE
D004110_D062787 CID diltiazem_5\NN|NONE (r_compound) overdose_6\NN|NONE
D004110_D062787 CID diltiazem_15\NN|NONE (r_pobj) of_14\IN|. (r_prep) g_13\NN|NONE (r_pobj) including_9\VBG|a|mixed (r_prep) overdose_8\NN|.|man
D004110_D062787 CID diltiazem_16\NN|severe (r_compound) overdose_17\NN|NONE
D004110_D062787 CID diltiazem_11\NN|NONE (r_compound) overdose_12\NN|NONE
D009566_D062787 NONE nitrate_22\NN|, (r_conj) aspirin_19\NN|, (r_conj) paracetamol_17\JJ|, (r_conj) diltiazem_15\NN|NONE (r_pobj) of_14\IN|. (r_prep) g_13\NN|NONE (r_pobj) including_9\VBG|a|mixed (r_prep) overdose_8\NN|.|man
D004110_D006323 CID diltiazem_5\NN|NONE (r_compound) overdose_6\NN|NONE (r_pobj) after_4\IN|cardiac|asystolic (r_prep) arrest_3\NN|;|resuscitation|. (l_amod) asystolic_1\JJ|cardiac|after
D004110_D006323 CID diltiazem_5\NN|NONE (r_compound) overdose_6\NN|NONE (r_pobj) after_4\IN|cardiac|asystolic (r_prep) arrest_3\NN|;|resuscitation|.
D004110_D006323 CID diltiazem_16\NN|severe (r_compound) overdose_17\NN|NONE (r_pobj) in_14\IN|calcium|intravenous|dose|aggressive (r_prep) therapy_13\NN|NONE (r_pobj) for_7\IN|a|,|with (r_prep) role_6\NN|there (l_prep) with_20\IN|a|for|, (l_pobj) onset_22\NN|particularly (l_prep) of_23\IN|the (l_pobj) asystole_24\NN|NONE
D004110_D006323 CID diltiazem_11\NN|NONE (r_compound) overdose_12\NN|NONE (r_pobj) after_10\IN|of (r_prep) cases_6\NNS|NONE (l_prep) of_7\IN|after (l_pobj) arrest_9\NN|NONE
D000431_D062787 NONE alcohol_25\NN|,|and|isosorbide (r_conj) nitrate_22\NN|, (r_conj) aspirin_19\NN|, (r_conj) paracetamol_17\JJ|, (r_conj) diltiazem_15\NN|NONE (r_pobj) of_14\IN|. (r_prep) g_13\NN|NONE (r_pobj) including_9\VBG|a|mixed (r_prep) overdose_8\NN|.|man
D000082_D062787 NONE paracetamol_17\JJ|, (r_conj) diltiazem_15\NN|NONE (r_pobj) of_14\IN|. (r_prep) g_13\NN|NONE (r_pobj) including_9\VBG|a|mixed (r_prep) overdose_8\NN|.|man
7102237
D012601_D001049 NONE scopolamine_4\NN|NONE (r_pobj) with_3\IN|NONE (r_prep) premedicated_2\VBN|NONE (r_acl) patients_1\NNS|NONE (r_pobj) In_0\IN|slower|but|.|effect|,|found|,|occurred|mg/kg|)|, (r_prep) was_28\VBD|NONE (l_advcl) occurred_57\VBD|slower|but|.|effect|,|In|found|,|mg/kg|)|, (l_nsubj) apnoea_56\NN|although|in|often
D009020_D001049 NONE morphine_6\NN|mg|(|+|+ (r_conj) scopolamine_4\NN|NONE (r_pobj) with_3\IN|NONE (r_prep) premedicated_2\VBN|NONE (r_acl) patients_1\NNS|NONE (r_pobj) In_0\IN|slower|but|.|effect|,|found|,|occurred|mg/kg|)|, (r_prep) was_28\VBD|NONE (l_advcl) occurred_57\VBD|slower|but|.|effect|,|In|found|,|mg/kg|)|, (l_nsubj) apnoea_56\NN|although|in|often
D009567_D001049 NONE nitrazepam_11\NN|evening| (r_amod) mg_10\IN|(|+|morphine|+ (r_conj) scopolamine_4\NN|NONE (r_pobj) with_3\IN|NONE (r_prep) premedicated_2\VBN|NONE (r_acl) patients_1\NNS|NONE (r_pobj) In_0\IN|slower|but|.|effect|,|found|,|occurred|mg/kg|)|, (r_prep) was_28\VBD|NONE (l_advcl) occurred_57\VBD|slower|but|.|effect|,|In|found|,|mg/kg|)|, (l_nsubj) apnoea_56\NN|although|in|often
D008874_D001049 CID midazolam_24\JJ|NONE (r_pobj) of_23\IN|inducing|the (r_prep) effect_22\NN|slower|but|.|,|In|found|,|occurred|mg/kg|)|, (r_nsubj) was_28\VBD|NONE (l_advcl) occurred_57\VBD|slower|but|.|effect|,|In|found|,|mg/kg|)|, (l_nsubj) apnoea_56\NN|although|in|often
D008874_D001049 CID midazolam_50\JJ|the (r_amod) group_51\NN|NONE (r_pobj) in_48\IN|were|sequelae (r_prep) found_47\VBN|slower|but|.|effect|,|In|,|occurred|mg/kg|)|, (r_conj) was_28\VBD|NONE (l_advcl) occurred_57\VBD|slower|but|.|effect|,|In|found|,|mg/kg|)|, (l_nsubj) apnoea_56\NN|although|in|often
D008874_D001049 CID midazolam_62\JJ|the|lasted (r_amod) group_63\NN|NONE (r_pobj) in_60\IN|apnoea|although|often (r_prep) occurred_57\VBD|slower|but|.|effect|,|In|found|,|mg/kg|)|, (l_nsubj) apnoea_56\NN|although|in|often
D013874_D001049 CID thiopentone_36\NN|NONE (r_pobj) of_35\IN|NONE (r_prep) that_34\DT|NONE (r_pobj) than_33\IN|NONE (r_prep) onset_32\NN|NONE (r_pobj) in_31\IN|clearly (r_prep) slower_30\JJR|but|.|effect|,|In|found|,|occurred|mg/kg|)|, (r_acomp) was_28\VBD|NONE (l_advcl) occurred_57\VBD|slower|but|.|effect|,|In|found|,|mg/kg|)|, (l_nsubj) apnoea_56\NN|although|in|often
9672936
D008614_D010149 NONE Pethidine_0\NNP| (r_npadvmod) associated_2\VBN|.|in (r_amod) seizure_3\NN|NONE (l_prep) in_4\IN|.|associated (l_pobj) adolescent_7\JJ|NONE (l_acl) receiving_8\VBG|a|healthy (l_prep) for_10\IN|pethidine (l_pobj) control_13\NN|NONE (l_compound) pain_12\NN|postoperative
D008614_D010149 NONE pethidine_9\NN|for (r_dobj) receiving_8\VBG|a|healthy (l_prep) for_10\IN|pethidine (l_pobj) control_13\NN|NONE (l_compound) pain_12\NN|postoperative
D008614_D010149 NONE pethidine_11\NN|NONE (r_pobj) of_10\IN|old|intermittent|via|received|healthy|standard|A (r_prep) doses_9\NNS|for|. (r_nsubj) pump_21\NN|NONE (l_prep) for_22\IN|doses|. (l_pobj) management_23\NN|NONE (l_prep) of_24\IN|NONE (l_pobj) control_27\NN|NONE (l_compound) pain_26\NN|postoperative
D008614_D012640 CID Pethidine_0\NNP| (r_npadvmod) associated_2\VBN|.|in (r_amod) seizure_3\NN|NONE
D008614_D012640 CID pethidine_9\NN|for (r_dobj) receiving_8\VBG|a|healthy (r_acl) adolescent_7\JJ|NONE (r_pobj) in_4\IN|.|associated (r_prep) seizure_3\NN|NONE
20164825
D005839_D058186 CID gentamicin_4\NN| (r_npadvmod) mediated_6\VBN|acute|renal (r_amod) failure_9\NN|treatment|.|fully
D005839_D007674 NONE gentamicin_3\NN| (r_npadvmod) induced_5\VBN|experimental (r_amod) nephropathy_6\NN|.|by|Metformin
D005839_D007674 NONE gentamicin_12\NN|NONE (r_amod) nephrotoxicity_13\NN|can|improve|and|that|effects
D008687_D014652 NONE metformin_3\NN|prevent|apoptosis|can|induced|and|. (r_nsubj) diminish_5\VB|NONE (l_conj) prevent_15\VB|apoptosis|can|induced|and|.|metformin (l_dobj) dysfunction_17\NN|in
D008687_D058186 NONE Metformin_0\NNP|NONE (r_compound) treatment_1\NN|failure|.|fully (r_nsubj) blocked_3\VBD|NONE (l_dobj) failure_9\NN|treatment|.|fully
D005839_D064420 NONE gentamicin_14\NN|NONE (r_amod) toxicity_15\NN|NONE
D008687_D007674 NONE Metformin_0\NNP|.|by|nephropathy (r_nsubj) prevents_1\VBZ|NONE (l_dobj) nephropathy_6\NN|.|by|Metformin
D008687_D007674 NONE metformin_11\NN|NONE (r_pobj) by_10\IN|their (r_prep) correction_9\NN|vivo|and|of (r_conj) markers_3\NNS|NONE (l_prep) of_4\IN|vivo|and|correction (l_pobj) dysfunction_6\NN|NONE
D008687_D007674 NONE metformin_9\NN|NONE (r_pobj) of_8\IN|pleiotropic (r_prep) effects_7\NNS|can|improve|and|that|nephrotoxicity (r_nsubj) lessen_11\VB|study|Thus|.|, (l_dobj) nephrotoxicity_13\NN|can|improve|and|that|effects
3934126
D000617_D007674 NONE aminoglycoside_18\NN|NONE (r_dobj) receiving_16\VBG|NONE (r_acl) patients_15\NNS|NONE (r_pobj) to_14\IN|;|occurred|were|.|nephrotoxicity (r_prep) confined_13\VBN|NONE (l_nsubjpass) nephrotoxicity_9\NN|to|;|occurred|were|.
D014640_D013924 CID vancomycin_20\NNP|plus|an (r_appos) aminoglycoside_18\NN|NONE (r_dobj) receiving_16\VBG|NONE (r_acl) patients_15\NNS|NONE (r_pobj) to_14\IN|;|occurred|were|.|nephrotoxicity (r_prep) confined_13\VBN|NONE (l_ccomp) occurred_1\VBD|to|;|were|.|nephrotoxicity (l_nsubj) Thrombophlebitis_0\NNP|with
D000617_D006311 NONE aminoglycoside_18\NN|NONE (r_dobj) receiving_16\VBG|NONE (r_acl) patients_15\NNS|NONE (r_pobj) to_14\IN|;|occurred|were|.|nephrotoxicity (r_prep) confined_13\VBN|NONE (l_nsubjpass) nephrotoxicity_9\NN|to|;|occurred|were|. (l_conj) ototoxicity_11\NN|and
D014640_D007674 NONE vancomycin_20\NNP|plus|an (r_appos) aminoglycoside_18\NN|NONE (r_dobj) receiving_16\VBG|NONE (r_acl) patients_15\NNS|NONE (r_pobj) to_14\IN|;|occurred|were|.|nephrotoxicity (r_prep) confined_13\VBN|NONE (l_nsubjpass) nephrotoxicity_9\NN|to|;|occurred|were|.
D014640_D007239 NONE Vancomycin_0\NNP|curative|. (r_nsubj) was_1\VBD|NONE (l_acomp) curative_2\JJ|.|Vancomycin (l_prep) in_3\IN|NONE (l_pobj) %_5\NN|NONE (l_prep) of_6\IN| (l_pobj) patients_8\NNS|NONE (l_prep) with_9\IN| (l_pobj) infection_11\NN|NONE
D014640_D007239 NONE vancomycin_3\NNP|therapy|administered|,|that|, (r_nsubj) constitutes_8\VBZ|We|. (l_dobj) therapy_12\NN|administered|,|vancomycin|that|, (l_prep) for_13\IN|effective|safe|, (l_pobj) infections_14\NNS|NONE
D014640_D006311 CID vancomycin_20\NNP|plus|an (r_appos) aminoglycoside_18\NN|NONE (r_dobj) receiving_16\VBG|NONE (r_acl) patients_15\NNS|NONE (r_pobj) to_14\IN|;|occurred|were|.|nephrotoxicity (r_prep) confined_13\VBN|NONE (l_nsubjpass) nephrotoxicity_9\NN|to|;|occurred|were|. (l_conj) ototoxicity_11\NN|and
D000617_D013924 NONE aminoglycoside_18\NN|NONE (r_dobj) receiving_16\VBG|NONE (r_acl) patients_15\NNS|NONE (r_pobj) to_14\IN|;|occurred|were|.|nephrotoxicity (r_prep) confined_13\VBN|NONE (l_ccomp) occurred_1\VBD|to|;|were|.|nephrotoxicity (l_nsubj) Thrombophlebitis_0\NNP|with
20098969
D008694_D006212 NONE Methamphetamine_0\NN|stimulant|. (r_nsubj) is_1\VBZ|NONE (l_attr) stimulant_7\NN|Methamphetamine|. (l_relcl) increases_9\VBZ|,|a|powerful|addictive (l_conj) produce_16\VB|that|and|wakefulness (l_dobj) effects_18\NNS|can (l_prep) as_20\IN|other (l_pobj) dysrhythmias_22\NNS|such (l_conj) hypertension_24\NN|,|cardiac (l_conj) hallucinations_26\NNS|,
D008694_D003731 CID methamphetamine_3\NN|NONE (r_dobj) abusing_2\VBG|Dental (r_acl) patients_1\NNS|can|.|with (r_nsubj) present_5\VB|NONE (l_prep) with_6\IN|can|.|patients (l_pobj) hygiene_9\NN|NONE (l_conj) xerostomia_11\NN|oral|poor|, (l_conj) caries_14\NNS|,
D008694_D003731 CID methamphetamine_5\NN|NONE (r_pobj) of_4\IN|for|her (r_prep) use_3\NN|.|experienced|She|and (r_dobj) reported_1\VBD|NONE (l_conj) experienced_12\VBN|.|She|and|use (l_dobj) episodes_16\NNS|had|started|not
D008694_D057085 NONE methamphetamine_3\NN|NONE (r_dobj) abusing_2\VBG|Dental (r_acl) patients_1\NNS|can|.|with (r_nsubj) present_5\VB|NONE (l_prep) with_6\IN|can|.|patients (l_pobj) hygiene_9\NN|NONE (l_conj) xerostomia_11\NN|oral|poor|, (l_conj) caries_14\NNS|, (l_conj) wear_25\NN|rampant|mouth|,|(|and
D008694_D006973 NONE Methamphetamine_0\NN|stimulant|. (r_nsubj) is_1\VBZ|NONE (l_attr) stimulant_7\NN|Methamphetamine|. (l_relcl) increases_9\VBZ|,|a|powerful|addictive (l_conj) produce_16\VB|that|and|wakefulness (l_dobj) effects_18\NNS|can (l_prep) as_20\IN|other (l_pobj) dysrhythmias_22\NNS|such (l_conj) hypertension_24\NN|,|cardiac
D008694_D001145 NONE Methamphetamine_0\NN|stimulant|. (r_nsubj) is_1\VBZ|NONE (l_attr) stimulant_7\NN|Methamphetamine|. (l_relcl) increases_9\VBZ|,|a|powerful|addictive (l_conj) produce_16\VB|that|and|wakefulness (l_dobj) effects_18\NNS|can (l_prep) as_20\IN|other (l_pobj) dysrhythmias_22\NNS|such
D008694_-1 NONE methamphetamine_3\NN|NONE (r_dobj) abusing_2\VBG|Dental (r_acl) patients_1\NNS|can|.|with (r_nsubj) present_5\VB|NONE (l_prep) with_6\IN|can|.|patients (l_pobj) hygiene_9\NN|NONE (l_conj) xerostomia_11\NN|oral|poor|, (l_conj) caries_14\NNS|, (l_appos) mouth_18\NN|rampant|wear|,|(|and
D008694_-1 NONE methamphetamines_23\NNS|may|be|who (r_dobj) abusing_22\VBG|NONE (r_relcl) patients_18\NNS|NONE (r_dobj) manage_17\VBP|practitioners|and (r_conj) recognize_15\VBP|to (r_ccomp) help_12\VB|was|.|case (r_advcl) presented_10\VBN|NONE (l_nsubjpass) case_2\NN|help|was|. (l_acl) showing_3\VBG|clinical|This (l_dobj) manifestations_5\NNS|NONE (l_prep) of_6\IN|oral (l_pobj) mouth_8\NN|NONE
D008694_D001523 NONE Methamphetamine_0\NN|stimulant|. (r_nsubj) is_1\VBZ|NONE (l_attr) stimulant_7\NN|Methamphetamine|. (l_relcl) increases_9\VBZ|,|a|powerful|addictive (l_conj) produce_16\VB|that|and|wakefulness (l_dobj) effects_18\NNS|can (l_prep) as_20\IN|other (l_pobj) dysrhythmias_22\NNS|such (l_conj) hypertension_24\NN|,|cardiac (l_conj) hallucinations_26\NNS|, (l_conj) behavior_30\NN|,|and
D008694_D014987 NONE methamphetamine_3\NN|NONE (r_dobj) abusing_2\VBG|Dental (r_acl) patients_1\NNS|can|.|with (r_nsubj) present_5\VB|NONE (l_prep) with_6\IN|can|.|patients (l_pobj) hygiene_9\NN|NONE (l_conj) xerostomia_11\NN|oral|poor|,
15899738
D003401_D001281 CID creatine_5\NN|monohydrate (r_compound) supplementation_7\NN|NONE (r_pobj) with_4\IN|NONE (r_prep) associated_3\VBN|.|atrial|Lone (r_acl) fibrillation_2\NN|NONE
D003401_D001145 NONE creatine_5\NN|.|reports|have (l_prep) to_6\IN|NONE (l_pobj) development_8\NN|NONE (l_prep) of_9\IN|the (l_pobj) arrhythmia_10\NN|NONE
11379838
D017367_D001714 CID inhibitors_60\NNS|used|manic|previous|,|type|assessed (r_appos) episodes_39\NNS|NONE (r_pobj) of_36\IN|NONE (r_prep) number_35\NN|,|did (r_appos) those_11\DT|NONE (r_pobj) with_10\IN|Patients|were|. (r_prep) compared_9\VBN|NONE (l_nsubjpass) Patients_0\NNS|with|were|. (l_relcl) experienced_2\VBD|NONE (l_dobj) switch_7\NN|who (l_amod) manic_4\JJ|a
D017367_D001714 CID inhibitors_60\NNS|used|manic|previous|,|type|assessed (r_appos) episodes_39\NNS|NONE (r_pobj) of_36\IN|NONE (r_prep) number_35\NN|,|did (r_appos) those_11\DT|NONE (r_pobj) with_10\IN|Patients|were|. (r_prep) compared_9\VBN|NONE (l_nsubjpass) Patients_0\NNS|with|were|. (l_relcl) experienced_2\VBD|NONE (l_dobj) switch_7\NN|who (l_amod) manic_4\JJ|a (l_conj) hypomanic_6\JJ|or
D017367_D001714 CID inhibitors_60\NNS|used|manic|previous|,|type|assessed (r_appos) episodes_39\NNS|NONE (r_pobj) of_36\IN|NONE (r_prep) number_35\NN|,|did (r_appos) those_11\DT|NONE (l_relcl) did_13\VBD|number|, (l_prep) on_15\IN|not|who (l_pobj) variables_17\NNS|NONE (l_prep) including_18\VBG|several (l_pobj) age_19\NN|NONE (l_conj) sex_21\NN|, (l_conj) diagnosis_23\NN|, (l_appos) IV_27\NNP|NONE (l_appos) I_29\PRP|)|bipolar||DSM|(
D017367_D001714 CID inhibitors_60\NNS|used|manic|previous|,|type|assessed (r_appos) episodes_39\NNS|NONE (r_pobj) of_36\IN|NONE (r_prep) number_35\NN|,|did (r_appos) those_11\DT|NONE (l_relcl) did_13\VBD|number|, (l_prep) on_15\IN|not|who (l_pobj) variables_17\NNS|NONE (l_prep) including_18\VBG|several (l_pobj) age_19\NN|NONE (l_conj) sex_21\NN|, (l_conj) diagnosis_23\NN|, (l_appos) IV_27\NNP|NONE (l_appos) I_29\PRP|)|bipolar||DSM|( (l_prep) vs._30\IN|NONE (l_pobj) II_32\NNP|NONE
D017367_D001714 CID inhibitors_60\NNS|used|manic|previous|,|type|assessed (r_appos) episodes_39\NNS|NONE (l_amod) manic_38\JJ|used|inhibitors|previous|,|type|assessed
D017367_D001714 CID SSRIs_62\NNPS|,|use|serotonin|,|selective|reuptake|particularly|, (r_appos) inhibitors_60\NNS|used|manic|previous|,|type|assessed (r_appos) episodes_39\NNS|NONE (r_pobj) of_36\IN|NONE (r_prep) number_35\NN|,|did (r_appos) those_11\DT|NONE (r_pobj) with_10\IN|Patients|were|. (r_prep) compared_9\VBN|NONE (l_nsubjpass) Patients_0\NNS|with|were|. (l_relcl) experienced_2\VBD|NONE (l_dobj) switch_7\NN|who (l_amod) manic_4\JJ|a
D017367_D001714 CID SSRIs_62\NNPS|,|use|serotonin|,|selective|reuptake|particularly|, (r_appos) inhibitors_60\NNS|used|manic|previous|,|type|assessed (r_appos) episodes_39\NNS|NONE (r_pobj) of_36\IN|NONE (r_prep) number_35\NN|,|did (r_appos) those_11\DT|NONE (r_pobj) with_10\IN|Patients|were|. (r_prep) compared_9\VBN|NONE (l_nsubjpass) Patients_0\NNS|with|were|. (l_relcl) experienced_2\VBD|NONE (l_dobj) switch_7\NN|who (l_amod) manic_4\JJ|a (l_conj) hypomanic_6\JJ|or
D017367_D001714 CID SSRIs_62\NNPS|,|use|serotonin|,|selective|reuptake|particularly|, (r_appos) inhibitors_60\NNS|used|manic|previous|,|type|assessed (r_appos) episodes_39\NNS|NONE (r_pobj) of_36\IN|NONE (r_prep) number_35\NN|,|did (r_appos) those_11\DT|NONE (l_relcl) did_13\VBD|number|, (l_prep) on_15\IN|not|who (l_pobj) variables_17\NNS|NONE (l_prep) including_18\VBG|several (l_pobj) age_19\NN|NONE (l_conj) sex_21\NN|, (l_conj) diagnosis_23\NN|, (l_appos) IV_27\NNP|NONE (l_appos) I_29\PRP|)|bipolar||DSM|(
D017367_D001714 CID SSRIs_62\NNPS|,|use|serotonin|,|selective|reuptake|particularly|, (r_appos) inhibitors_60\NNS|used|manic|previous|,|type|assessed (r_appos) episodes_39\NNS|NONE (r_pobj) of_36\IN|NONE (r_prep) number_35\NN|,|did (r_appos) those_11\DT|NONE (l_relcl) did_13\VBD|number|, (l_prep) on_15\IN|not|who (l_pobj) variables_17\NNS|NONE (l_prep) including_18\VBG|several (l_pobj) age_19\NN|NONE (l_conj) sex_21\NN|, (l_conj) diagnosis_23\NN|, (l_appos) IV_27\NNP|NONE (l_appos) I_29\PRP|)|bipolar||DSM|( (l_prep) vs._30\IN|NONE (l_pobj) II_32\NNP|NONE
D017367_D001714 CID SSRIs_62\NNPS|,|use|serotonin|,|selective|reuptake|particularly|, (r_appos) inhibitors_60\NNS|used|manic|previous|,|type|assessed (r_appos) episodes_39\NNS|NONE (l_amod) manic_38\JJ|used|inhibitors|previous|,|type|assessed
D017367_D001714 CID SSRIs_29\NNS|NONE (r_pobj) with_28\IN|NONE (r_prep) treated_27\VBN|NONE (r_acl) patients_26\NNS|NONE (r_pobj) of_25\IN|the (r_prep) subgroup_24\NN|NONE (r_pobj) of_22\IN| (r_prep) %_21\NN|) (r_pobj) in_19\IN|;|episodes|(|(|%|,|and (r_prep) experienced_42\JJ|all (r_parataxis) patients_11\NNS|NONE (r_pobj) of_9\IN||and|% (r_prep) %_8\NN|NONE (r_pobj) in_6\IN|Switches|.|episodes (r_prep) occurred_5\VBD|NONE (l_nsubj) Switches_0\NNS|.|episodes|in (l_prep) to_1\IN|NONE (l_pobj) hypomania_2\NN|NONE
D017367_D001714 CID SSRIs_29\NNS|NONE (r_pobj) with_28\IN|NONE (r_prep) treated_27\VBN|NONE (r_acl) patients_26\NNS|NONE (r_pobj) of_25\IN|the (r_prep) subgroup_24\NN|NONE (r_pobj) of_22\IN| (r_prep) %_21\NN|) (r_pobj) in_19\IN|;|episodes|(|(|%|,|and (r_prep) experienced_42\JJ|all (r_parataxis) patients_11\NNS|NONE (r_pobj) of_9\IN||and|% (r_prep) %_8\NN|NONE (r_pobj) in_6\IN|Switches|.|episodes (r_prep) occurred_5\VBD|NONE (l_nsubj) Switches_0\NNS|.|episodes|in (l_prep) to_1\IN|NONE (l_pobj) hypomania_2\NN|NONE (l_conj) mania_4\NN|or
D017367_D001714 CID SSRIs_29\NNS|NONE (r_pobj) with_28\IN|NONE (r_prep) treated_27\VBN|NONE (r_acl) patients_26\NNS|NONE (r_pobj) of_25\IN|the (r_prep) subgroup_24\NN|NONE (r_pobj) of_22\IN| (r_prep) %_21\NN|) (r_pobj) in_19\IN|;|episodes|(|(|%|,|and (r_prep) experienced_42\JJ|all (l_dobj) episodes_44\NNS|;|(|(|in|%|,|and (l_amod) manic_43\JJ|NONE
D017367_D001714 CID SSRIs_29\NNS|NONE (r_pobj) with_28\IN|NONE (r_prep) treated_27\VBN|NONE (r_acl) patients_26\NNS|NONE (r_pobj) of_25\IN|the (r_prep) subgroup_24\NN|NONE (r_pobj) of_22\IN| (r_prep) %_21\NN|) (r_pobj) in_19\IN|;|episodes|(|(|%|,|and (r_prep) experienced_42\JJ|all (r_parataxis) patients_11\NNS|NONE (r_pobj) of_9\IN||and|% (r_prep) %_8\NN|NONE (r_pobj) in_6\IN|Switches|.|episodes (r_prep) occurred_5\VBD|NONE (l_npadvmod) episodes_56\NNS|Switches|.|in (l_amod) hypomanic_55\JJ|experienced
D000928_D001714 CID Antidepressant_0\NNP| (r_npadvmod) induced_2\VBN|identification|.|in|: (r_amod) mania_3\NN|NONE
D000928_D001714 CID Antidepressant_0\NNP| (r_npadvmod) induced_2\VBN|identification|.|in|: (r_amod) mania_3\NN|NONE (l_prep) in_4\IN|identification|induced|.|: (l_pobj) patients_6\NNS|NONE (l_amod) bipolar_5\JJ|NONE
D000928_D001714 CID antidepressants_10\NNS|NONE (r_pobj) with_9\IN|NONE (r_prep) associated_8\VBN|NONE (r_acl) mania_7\NN|NONE
D000928_D001714 CID antidepressants_10\NNS|NONE (r_pobj) with_9\IN|NONE (r_prep) associated_8\VBN|NONE (r_acl) mania_7\NN|NONE (r_pobj) to_6\IN|NONE (r_prep) switching_5\VBG|NONE (r_pcomp) of_4\IN|possible (r_prep) risks_3\NNS|NONE (r_pobj) about_1\IN|NONE (r_prep) Concerns_0\NNS|.|interfere (r_nsubj) continue_11\VBP|NONE (l_xcomp) interfere_13\VB|.|Concerns (l_prep) with_14\IN|to (l_pobj) establishment_16\NN|NONE (l_prep) of_17\IN|the (l_pobj) paradigm_21\NN|NONE (l_prep) for_22\IN|optimal|treatment|an (l_pobj) depression_24\NN|NONE
D000928_D001714 CID antidepressant_43\NN|NONE (r_amod) therapy_44\NN|NONE (r_pobj) of_42\IN|NONE (r_prep) type_41\NN|used|inhibitors|manic|previous|,|assessed (r_appos) episodes_39\NNS|NONE (r_pobj) of_36\IN|NONE (r_prep) number_35\NN|,|did (r_appos) those_11\DT|NONE (r_pobj) with_10\IN|Patients|were|. (r_prep) compared_9\VBN|NONE (l_nsubjpass) Patients_0\NNS|with|were|. (l_relcl) experienced_2\VBD|NONE (l_dobj) switch_7\NN|who (l_amod) manic_4\JJ|a
D000928_D001714 CID antidepressant_43\NN|NONE (r_amod) therapy_44\NN|NONE (r_pobj) of_42\IN|NONE (r_prep) type_41\NN|used|inhibitors|manic|previous|,|assessed (r_appos) episodes_39\NNS|NONE (r_pobj) of_36\IN|NONE (r_prep) number_35\NN|,|did (r_appos) those_11\DT|NONE (r_pobj) with_10\IN|Patients|were|. (r_prep) compared_9\VBN|NONE (l_nsubjpass) Patients_0\NNS|with|were|. (l_relcl) experienced_2\VBD|NONE (l_dobj) switch_7\NN|who (l_amod) manic_4\JJ|a (l_conj) hypomanic_6\JJ|or
D000928_D001714 CID antidepressant_43\NN|NONE (r_amod) therapy_44\NN|NONE (r_pobj) of_42\IN|NONE (r_prep) type_41\NN|used|inhibitors|manic|previous|,|assessed (r_appos) episodes_39\NNS|NONE (r_pobj) of_36\IN|NONE (r_prep) number_35\NN|,|did (r_appos) those_11\DT|NONE (l_relcl) did_13\VBD|number|, (l_prep) on_15\IN|not|who (l_pobj) variables_17\NNS|NONE (l_prep) including_18\VBG|several (l_pobj) age_19\NN|NONE (l_conj) sex_21\NN|, (l_conj) diagnosis_23\NN|, (l_appos) IV_27\NNP|NONE (l_appos) I_29\PRP|)|bipolar||DSM|(
D000928_D001714 CID antidepressant_43\NN|NONE (r_amod) therapy_44\NN|NONE (r_pobj) of_42\IN|NONE (r_prep) type_41\NN|used|inhibitors|manic|previous|,|assessed (r_appos) episodes_39\NNS|NONE (r_pobj) of_36\IN|NONE (r_prep) number_35\NN|,|did (r_appos) those_11\DT|NONE (l_relcl) did_13\VBD|number|, (l_prep) on_15\IN|not|who (l_pobj) variables_17\NNS|NONE (l_prep) including_18\VBG|several (l_pobj) age_19\NN|NONE (l_conj) sex_21\NN|, (l_conj) diagnosis_23\NN|, (l_appos) IV_27\NNP|NONE (l_appos) I_29\PRP|)|bipolar||DSM|( (l_prep) vs._30\IN|NONE (l_pobj) II_32\NNP|NONE
D000928_D001714 CID antidepressant_43\NN|NONE (r_amod) therapy_44\NN|NONE (r_pobj) of_42\IN|NONE (r_prep) type_41\NN|used|inhibitors|manic|previous|,|assessed (r_appos) episodes_39\NNS|NONE (l_amod) manic_38\JJ|used|inhibitors|previous|,|type|assessed
D000928_D001714 CID antidepressant_50\NN|NONE (r_amod) drugs_51\NNS|NONE (r_pobj) vs._49\IN|and|electroconvulsive (r_prep) therapy_48\NN|, (r_dobj) used_45\VBN|inhibitors|manic|previous|,|type|assessed (r_acl) episodes_39\NNS|NONE (r_pobj) of_36\IN|NONE (r_prep) number_35\NN|,|did (r_appos) those_11\DT|NONE (r_pobj) with_10\IN|Patients|were|. (r_prep) compared_9\VBN|NONE (l_nsubjpass) Patients_0\NNS|with|were|. (l_relcl) experienced_2\VBD|NONE (l_dobj) switch_7\NN|who (l_amod) manic_4\JJ|a
D000928_D001714 CID antidepressant_50\NN|NONE (r_amod) drugs_51\NNS|NONE (r_pobj) vs._49\IN|and|electroconvulsive (r_prep) therapy_48\NN|, (r_dobj) used_45\VBN|inhibitors|manic|previous|,|type|assessed (r_acl) episodes_39\NNS|NONE (r_pobj) of_36\IN|NONE (r_prep) number_35\NN|,|did (r_appos) those_11\DT|NONE (r_pobj) with_10\IN|Patients|were|. (r_prep) compared_9\VBN|NONE (l_nsubjpass) Patients_0\NNS|with|were|. (l_relcl) experienced_2\VBD|NONE (l_dobj) switch_7\NN|who (l_amod) manic_4\JJ|a (l_conj) hypomanic_6\JJ|or
D000928_D001714 CID antidepressant_50\NN|NONE (r_amod) drugs_51\NNS|NONE (r_pobj) vs._49\IN|and|electroconvulsive (r_prep) therapy_48\NN|, (r_dobj) used_45\VBN|inhibitors|manic|previous|,|type|assessed (r_acl) episodes_39\NNS|NONE (r_pobj) of_36\IN|NONE (r_prep) number_35\NN|,|did (r_appos) those_11\DT|NONE (l_relcl) did_13\VBD|number|, (l_prep) on_15\IN|not|who (l_pobj) variables_17\NNS|NONE (l_prep) including_18\VBG|several (l_pobj) age_19\NN|NONE (l_conj) sex_21\NN|, (l_conj) diagnosis_23\NN|, (l_appos) IV_27\NNP|NONE (l_appos) I_29\PRP|)|bipolar||DSM|(
D000928_D001714 CID antidepressant_50\NN|NONE (r_amod) drugs_51\NNS|NONE (r_pobj) vs._49\IN|and|electroconvulsive (r_prep) therapy_48\NN|, (r_dobj) used_45\VBN|inhibitors|manic|previous|,|type|assessed (r_acl) episodes_39\NNS|NONE (r_pobj) of_36\IN|NONE (r_prep) number_35\NN|,|did (r_appos) those_11\DT|NONE (l_relcl) did_13\VBD|number|, (l_prep) on_15\IN|not|who (l_pobj) variables_17\NNS|NONE (l_prep) including_18\VBG|several (l_pobj) age_19\NN|NONE (l_conj) sex_21\NN|, (l_conj) diagnosis_23\NN|, (l_appos) IV_27\NNP|NONE (l_appos) I_29\PRP|)|bipolar||DSM|( (l_prep) vs._30\IN|NONE (l_pobj) II_32\NNP|NONE
D000928_D001714 CID antidepressant_50\NN|NONE (r_amod) drugs_51\NNS|NONE (r_pobj) vs._49\IN|and|electroconvulsive (r_prep) therapy_48\NN|, (r_dobj) used_45\VBN|inhibitors|manic|previous|,|type|assessed (r_acl) episodes_39\NNS|NONE (l_amod) manic_38\JJ|used|inhibitors|previous|,|type|assessed
D008094_D001714 NONE lithium_73\NN|mood|)|( (r_appos) stabilizers_71\NNS|NONE (r_pobj) of_69\IN|NONE (r_prep) type_68\NN|temperament|,|and|and (r_conj) use_66\NN|,|serotonin|,|selective|reuptake|particularly|,|SSRIs (r_conj) inhibitors_60\NNS|used|manic|previous|,|type|assessed (r_appos) episodes_39\NNS|NONE (r_pobj) of_36\IN|NONE (r_prep) number_35\NN|,|did (r_appos) those_11\DT|NONE (r_pobj) with_10\IN|Patients|were|. (r_prep) compared_9\VBN|NONE (l_nsubjpass) Patients_0\NNS|with|were|. (l_relcl) experienced_2\VBD|NONE (l_dobj) switch_7\NN|who (l_amod) manic_4\JJ|a
D008094_D001714 NONE lithium_73\NN|mood|)|( (r_appos) stabilizers_71\NNS|NONE (r_pobj) of_69\IN|NONE (r_prep) type_68\NN|temperament|,|and|and (r_conj) use_66\NN|,|serotonin|,|selective|reuptake|particularly|,|SSRIs (r_conj) inhibitors_60\NNS|used|manic|previous|,|type|assessed (r_appos) episodes_39\NNS|NONE (r_pobj) of_36\IN|NONE (r_prep) number_35\NN|,|did (r_appos) those_11\DT|NONE (r_pobj) with_10\IN|Patients|were|. (r_prep) compared_9\VBN|NONE (l_nsubjpass) Patients_0\NNS|with|were|. (l_relcl) experienced_2\VBD|NONE (l_dobj) switch_7\NN|who (l_amod) manic_4\JJ|a (l_conj) hypomanic_6\JJ|or
D008094_D001714 NONE lithium_73\NN|mood|)|( (r_appos) stabilizers_71\NNS|NONE (r_pobj) of_69\IN|NONE (r_prep) type_68\NN|temperament|,|and|and (r_conj) use_66\NN|,|serotonin|,|selective|reuptake|particularly|,|SSRIs (r_conj) inhibitors_60\NNS|used|manic|previous|,|type|assessed (r_appos) episodes_39\NNS|NONE (r_pobj) of_36\IN|NONE (r_prep) number_35\NN|,|did (r_appos) those_11\DT|NONE (l_relcl) did_13\VBD|number|, (l_prep) on_15\IN|not|who (l_pobj) variables_17\NNS|NONE (l_prep) including_18\VBG|several (l_pobj) age_19\NN|NONE (l_conj) sex_21\NN|, (l_conj) diagnosis_23\NN|, (l_appos) IV_27\NNP|NONE (l_appos) I_29\PRP|)|bipolar||DSM|(
D008094_D001714 NONE lithium_73\NN|mood|)|( (r_appos) stabilizers_71\NNS|NONE (r_pobj) of_69\IN|NONE (r_prep) type_68\NN|temperament|,|and|and (r_conj) use_66\NN|,|serotonin|,|selective|reuptake|particularly|,|SSRIs (r_conj) inhibitors_60\NNS|used|manic|previous|,|type|assessed (r_appos) episodes_39\NNS|NONE (r_pobj) of_36\IN|NONE (r_prep) number_35\NN|,|did (r_appos) those_11\DT|NONE (l_relcl) did_13\VBD|number|, (l_prep) on_15\IN|not|who (l_pobj) variables_17\NNS|NONE (l_prep) including_18\VBG|several (l_pobj) age_19\NN|NONE (l_conj) sex_21\NN|, (l_conj) diagnosis_23\NN|, (l_appos) IV_27\NNP|NONE (l_appos) I_29\PRP|)|bipolar||DSM|( (l_prep) vs._30\IN|NONE (l_pobj) II_32\NNP|NONE
D008094_D001714 NONE lithium_73\NN|mood|)|( (r_appos) stabilizers_71\NNS|NONE (r_pobj) of_69\IN|NONE (r_prep) type_68\NN|temperament|,|and|and (r_conj) use_66\NN|,|serotonin|,|selective|reuptake|particularly|,|SSRIs (r_conj) inhibitors_60\NNS|used|manic|previous|,|type|assessed (r_appos) episodes_39\NNS|NONE (l_amod) manic_38\JJ|used|inhibitors|previous|,|type|assessed
15120741
D008274_D013226 NONE Mg(2+)-free_1\JJ|bicuculline (r_pobj) In_0\IN|stimulation|in|conditions|,|.|, (r_prep) resulted_21\VBD|NONE (l_prep) in_22\IN|stimulation|conditions|In|,|.|, (l_pobj) spike_26\NN|NONE (l_relcl) experience_41\VB|single|a|in|population (l_dobj) SE_42\NNP|did|not|that
D001640_D013226 NONE bicuculline_5\NN|Mg(+)free (r_pobj) In_0\IN|stimulation|in|conditions|,|.|, (r_prep) resulted_21\VBD|NONE (l_prep) in_22\IN|stimulation|conditions|In|,|.|, (l_pobj) spike_26\NN|NONE (l_relcl) experience_41\VB|single|a|in|population (l_dobj) SE_42\NNP|did|not|that
D018698_D013226 NONE glutamate_37\NN|NONE (r_compound) receptor_38\NN|ionotropic (r_compound) antagonists_39\NNS|NONE (r_pobj) by_35\IN|were|which (r_agent) blocked_34\VBN|s|, (r_relcl) duration_30\NN|NONE (r_pobj) of_25\IN|repetitive (r_prep) afterdischarges_24\NNS|DC|and|negative (r_conj) shifts_21\NNS|NONE (r_pobj) by_18\IN|,|,|at (r_prep) followed_11\VBD|In|in|.|stimulation|, (r_advcl) resulted_6\VBD|NONE (l_prep) In_0\IN|in|.|stimulation|,|followed (l_pobj) survivors_2\NNS|NONE (l_compound) SE_1\NNP|NONE
D018698_D013226 NONE glutamate_1\NN|Focal|of|at (r_compound) photostimulation_2\NN|in|. (r_nsubj) resulted_15\VBD|NONE (l_prep) in_16\IN|photostimulation|. (l_pobj) responses_18\NNS|NONE (l_prep) of_19\IN|population (l_pobj) duration_24\NN|NONE (l_prep) in_25\IN|groups|s|but (l_pobj) slices_26\NNS|NONE (l_prep) from_27\IN|NONE (l_pobj) survivors_29\NNS|NONE (l_compound) SE_28\NNP|NONE
D010862_D012640 CID pilocarpine_5\NN|systemic (r_compound) injection_6\NN|Similar|but|,|,|identified|SE (r_nsubj) causes_7\VBZ|NONE (l_dobj) SE_11\NNP|Similar|but|injection|,|,|identified (l_conj) development_16\NN|(|and|)|status|epilepticus (l_prep) of_17\IN|eventual|the (l_pobj) seizures_19\NNS|NONE
D010862_D013226 CID pilocarpine_5\NN|systemic (r_compound) injection_6\NN|Similar|but|,|,|identified|SE (r_nsubj) causes_7\VBZ|NONE (l_dobj) SE_11\NNP|Similar|but|injection|,|,|identified (l_nmod) epilepticus_9\NN|(|and|)|development|status
D010862_D013226 CID pilocarpine_5\NN|systemic (r_compound) injection_6\NN|Similar|but|,|,|identified|SE (r_nsubj) causes_7\VBZ|NONE (l_dobj) SE_11\NNP|Similar|but|injection|,|,|identified
D010862_D013226 CID pilocarpine_34\NN| (r_npadvmod) treated_36\VBN|NONE (r_amod) mice_37\NNS|control|and (r_conj) mice_32\NNS|NONE (r_pobj) from_30\IN|granule (r_prep) cells_29\NNS|NONE (r_pobj) in_27\IN|single|a|experience|population (r_prep) spike_26\NN|NONE (l_relcl) experience_41\VB|single|a|in|population (l_dobj) SE_42\NNP|did|not|that
6287825
D012256_D010523 CID riboflavin_9\NN|and (r_conj) thiamine_7\NN|NONE (r_pobj) of_6\IN|nutritional (r_prep) deficiency_5\NN|to (r_pobj) due_2\IN|Peripheral (r_prep) neuropathy_1\NNS|common|%|.|presented|and
D012256_D010523 CID riboflavin_9\NN|and (r_conj) thiamine_7\NN|NONE (r_pobj) of_6\IN|nutritional (r_prep) deficiency_5\NN|to (r_pobj) due_2\IN|Peripheral (r_prep) neuropathy_1\NNS|common|%|.|presented|and (r_nsubj) was_10\VBD|NONE (l_conj) presented_17\VBN|neuropathy|common|%|.|and (l_prep) as_19\IN|NONE (l_pobj) neuropathy_25\NN|mainly
D012256_D044342 NONE riboflavin_9\NN|and (r_conj) thiamine_7\NN|NONE (r_pobj) of_6\IN|nutritional (r_prep) deficiency_5\NN|to
D007538_D009422 NONE Isoniazid_0\NNP|.|agent (r_nsubj) was_1\VBD|NONE (l_attr) agent_5\NN|Isoniazid|. (l_prep) in_6\IN|frequent|the (l_pobj) neuropathy_10\NN|NONE
D013831_D044342 NONE thiamine_7\NN|NONE (r_pobj) of_6\IN|nutritional (r_prep) deficiency_5\NN|to
D013831_D010523 CID thiamine_7\NN|NONE (r_pobj) of_6\IN|nutritional (r_prep) deficiency_5\NN|to (r_pobj) due_2\IN|Peripheral (r_prep) neuropathy_1\NNS|common|%|.|presented|and
D013831_D010523 CID thiamine_7\NN|NONE (r_pobj) of_6\IN|nutritional (r_prep) deficiency_5\NN|to (r_pobj) due_2\IN|Peripheral (r_prep) neuropathy_1\NNS|common|%|.|presented|and (r_nsubj) was_10\VBD|NONE (l_conj) presented_17\VBN|neuropathy|common|%|.|and (l_prep) as_19\IN|NONE (l_pobj) neuropathy_25\NN|mainly
9587734
D013390_D006323 CID Suxamethonium_0\NN| (r_npadvmod) induced_2\VBN|cardiac|.|death|and|following (r_amod) arrest_4\NN|NONE
D013390_D006323 CID suxamethonium_21\NN|NONE (r_pobj) of_20\IN|the (r_prep) use_19\NN|NONE (r_pobj) following_17\VBG|a|of (r_prep) case_5\NN|report|. (l_prep) of_6\IN|following|a (l_pobj) arrest_8\NN|NONE
D013390_D006323 CID suxamethonium_5\NN|NONE (l_appos) arrest_10\NN|,
D013390_D003643 NONE Suxamethonium_0\NN| (r_npadvmod) induced_2\VBN|cardiac|.|death|and|following (r_amod) arrest_4\NN|NONE (l_conj) death_6\NN|induced|cardiac|.|and|following
D013390_D003643 NONE suxamethonium_21\NN|NONE (r_pobj) of_20\IN|the (r_prep) use_19\NN|NONE (r_pobj) following_17\VBG|a|of (r_prep) case_5\NN|report|. (l_prep) of_6\IN|following|a (l_pobj) arrest_8\NN|NONE (l_conj) death_11\NN|cardiac|and
D013390_D003643 NONE suxamethonium_11\NN|NONE (r_pobj) to_10\IN|NONE (r_prep) hypersensitivity_9\NN|NONE (r_pobj) by_8\IN|,|was|that|associated|death (r_agent) caused_7\VBN|.|It|is (l_nsubjpass) death_5\NN|by|,|was|that|associated
D013390_D004342 CID suxamethonium_11\NN|NONE (r_pobj) to_10\IN|NONE (r_prep) hypersensitivity_9\NN|NONE
D013390_D001919 CID suxamethonium_5\NN|NONE (l_appos) arrest_10\NN|, (l_amod) bradycardia_7\NN|cardiac
D013390_D006947 CID suxamethonium_21\NN|NONE (r_pobj) of_20\IN|the (r_prep) use_19\NN|NONE (r_pobj) following_17\VBG|a|of (r_prep) case_5\NN|report|. (l_prep) of_6\IN|following|a (l_pobj) arrest_8\NN|NONE (l_conj) death_11\NN|cardiac|and (l_prep) as_12\IN|subsequent (l_pobj) result_14\NN|NONE (l_prep) of_15\IN|a (l_pobj) hyperkalaemia_16\NN|NONE
D013390_D006947 CID suxamethonium_35\NN|NONE (r_pobj) of_34\IN|the (r_prep) administration_33\NN|NONE (r_pobj) following_31\VBG|no|of (r_prep) signs_15\NNS|.|Apart|,|there (l_prep) of_16\IN|no|following (l_conj) of_21\IN|or|damage (l_pobj) any_22\DT|NONE (l_prep) of_23\IN|NONE (l_pobj) conditions_28\NNS|NONE (l_prep) for_29\IN|known|the|predisposing|other (l_pobj) hyperkalaemia_30\NN|NONE
17020434
C055162_D001281 NONE Clopidogrel_7\NNP|study|)|with|Atrial|The|W|( (l_compound) Fibrillation_6\NNP|NONE
C055162_D001281 NONE clopidogrel_28\JJ|)|to|in|therapy (r_dobj) platelet_25\NN|NONE (r_xcomp) superior_23\JJ|warfarin|that (r_acomp) is_22\VBZ|Trial|.|has (r_ccomp) demonstrated_19\VBN|NONE (l_nsubj) Trial_8\NN|.|has|is (l_compound) Clopidogrel_7\NNP|study|)|with|Atrial|The|W|( (l_compound) Fibrillation_6\NNP|NONE
D001241_D020521 NONE aspirin_24\NN|that|by|risk (r_nsubj) reduces_26\VBZ|that|risk|warfarin|by|and|, (r_conj) reduces_13\VBZ|data|have|. (l_dobj) risk_15\NN|reduces|that|warfarin|by|and|, (l_prep) of_16\IN|the (l_pobj) stroke_17\NN|NONE
D001241_D020521 NONE aspirin_12\NN|NONE (l_prep) in_13\IN|NONE (l_pcomp) preventing_14\VBG|NONE (l_dobj) strokes_15\NNS|NONE
D014859_D020521 NONE warfarin_12\NN|reduces|that|risk|by|and|, (r_nsubj) reduces_13\VBZ|data|have|. (l_dobj) risk_15\NN|reduces|that|warfarin|by|and|, (l_prep) of_16\IN|the (l_pobj) stroke_17\NN|NONE
D014859_D020521 NONE warfarin_8\VB|,|,|Overall|,|.|with|superior|in (r_nsubj) is_9\VBZ|NONE (l_acomp) superior_10\JJ|,|,|Overall|,|.|with|warfarin|in (l_prep) to_11\IN|NONE (l_pobj) aspirin_12\NN|NONE (l_prep) in_13\IN|NONE (l_pcomp) preventing_14\VBG|NONE (l_dobj) strokes_15\NNS|NONE
D014812_D004617 NONE K_16\NNP|antagonist (r_compound) drugs_18\NNS|NONE (r_pobj) as_14\IN|as|in (r_prep) efficient_13\JJ|to (l_prep) in_19\IN|as|as (l_pobj) prevention_21\NN|NONE (l_prep) of_22\IN|the (l_pobj) events_24\NNS|NONE
D014859_D004617 NONE warfarin_21\NN|superior|that (r_nsubj) is_22\VBZ|Trial|.|has (l_acomp) superior_23\JJ|warfarin|that (l_xcomp) platelet_25\NN|NONE (l_prep) in_32\IN|)|to|clopidogrel|therapy (l_pobj) events_37\NNS|prevention
C081309_D004617 NONE Irbesartan_10\NNP|NONE (r_pobj) with_9\IN|study|)|Atrial|The|W|Clopidogrel|( (r_prep) Trial_8\NN|.|has|is (r_nsubj) demonstrated_19\VBN|NONE (l_ccomp) is_22\VBZ|Trial|.|has (l_acomp) superior_23\JJ|warfarin|that (l_xcomp) platelet_25\NN|NONE (l_prep) in_32\IN|)|to|clopidogrel|therapy (l_pobj) events_37\NNS|prevention
C081309_D001281 NONE Irbesartan_10\NNP|NONE (r_pobj) with_9\IN|study|)|Atrial|The|W|Clopidogrel|( (r_prep) Trial_8\NN|.|has|is (l_compound) Clopidogrel_7\NNP|study|)|with|Atrial|The|W|( (l_compound) Fibrillation_6\NNP|NONE
C426686_D004617 NONE Ximelagatran_0\NN|but|,|was|be|.|withdrawn (r_nsubjpass) found_9\VBN|NONE (l_xcomp) be_11\VB|but|,|was|.|Ximelagatran|withdrawn (l_acomp) efficient_13\JJ|to (l_prep) in_19\IN|as|as (l_pobj) prevention_21\NN|NONE (l_prep) of_22\IN|the (l_pobj) events_24\NNS|NONE
D014812_D056486 NONE K_16\NNP|antagonist (r_compound) drugs_18\NNS|NONE (r_pobj) as_14\IN|as|in (r_prep) efficient_13\JJ|to (r_acomp) be_11\VB|but|,|was|.|Ximelagatran|withdrawn (r_xcomp) found_9\VBN|NONE (l_conj) withdrawn_30\VBN|but|,|was|be|.|Ximelagatran (l_prep) because_31\IN|recently|been|has (l_pobj) tests_36\NNS|of (l_compound) function_35\NN|abnormal
D014859_D001281 NONE warfarin_21\NN|superior|that (r_nsubj) is_22\VBZ|Trial|.|has (r_ccomp) demonstrated_19\VBN|NONE (l_nsubj) Trial_8\NN|.|has|is (l_compound) Clopidogrel_7\NNP|study|)|with|Atrial|The|W|( (l_compound) Fibrillation_6\NNP|NONE
D000804_D001281 NONE II_7\CD|angiotensin|blocking (r_nummod) drugs_11\NNS|converting|enzyme|and (r_conj) inhibitors_4\NNS|.|promise (r_nsubj) hold_12\VBP|NONE (l_dobj) promise_13\NN|.|inhibitors (l_prep) in_14\IN|NONE (l_pobj) fibrillation_16\NN|NONE
D000809_D001281 NONE Angiotensin_0\NN| (r_npadvmod) converting_2\VBG|drugs|enzyme|and (r_amod) inhibitors_4\NNS|.|promise (r_nsubj) hold_12\VBP|NONE (l_dobj) promise_13\NN|.|inhibitors (l_prep) in_14\IN|NONE (l_pobj) fibrillation_16\NN|NONE
D000804_D020257 NONE II_7\CD|angiotensin|blocking (r_nummod) drugs_11\NNS|converting|enzyme|and (r_conj) inhibitors_4\NNS|.|promise (r_nsubj) hold_12\VBP|NONE (l_dobj) promise_13\NN|.|inhibitors (l_prep) in_14\IN|NONE (l_pobj) fibrillation_16\NN|NONE (l_prep) through_17\IN|atrial (l_pobj) remodelling_19\NN|NONE
C055162_D004617 NONE Clopidogrel_7\NNP|study|)|with|Atrial|The|W|( (r_compound) Trial_8\NN|.|has|is (r_nsubj) demonstrated_19\VBN|NONE (l_ccomp) is_22\VBZ|Trial|.|has (l_acomp) superior_23\JJ|warfarin|that (l_xcomp) platelet_25\NN|NONE (l_prep) in_32\IN|)|to|clopidogrel|therapy (l_pobj) events_37\NNS|prevention
C055162_D004617 NONE clopidogrel_28\JJ|)|to|in|therapy (r_dobj) platelet_25\NN|NONE (l_prep) in_32\IN|)|to|clopidogrel|therapy (l_pobj) events_37\NNS|prevention
D001241_D001281 NONE aspirin_30\NN|plus (r_conj) clopidogrel_28\JJ|)|to|in|therapy (r_dobj) platelet_25\NN|NONE (r_xcomp) superior_23\JJ|warfarin|that (r_acomp) is_22\VBZ|Trial|.|has (r_ccomp) demonstrated_19\VBN|NONE (l_nsubj) Trial_8\NN|.|has|is (l_compound) Clopidogrel_7\NNP|study|)|with|Atrial|The|W|( (l_compound) Fibrillation_6\NNP|NONE
D000809_D020257 NONE Angiotensin_0\NN| (r_npadvmod) converting_2\VBG|drugs|enzyme|and (r_amod) inhibitors_4\NNS|.|promise (r_nsubj) hold_12\VBP|NONE (l_dobj) promise_13\NN|.|inhibitors (l_prep) in_14\IN|NONE (l_pobj) fibrillation_16\NN|NONE (l_prep) through_17\IN|atrial (l_pobj) remodelling_19\NN|NONE
D001241_D004617 NONE aspirin_30\NN|plus (r_conj) clopidogrel_28\JJ|)|to|in|therapy (r_dobj) platelet_25\NN|NONE (l_prep) in_32\IN|)|to|clopidogrel|therapy (l_pobj) events_37\NNS|prevention
C426686_D056486 CID Ximelagatran_0\NN|but|,|was|be|.|withdrawn (r_nsubjpass) found_9\VBN|NONE (l_conj) withdrawn_30\VBN|but|,|was|be|.|Ximelagatran (l_prep) because_31\IN|recently|been|has (l_pobj) tests_36\NNS|of (l_compound) function_35\NN|abnormal
C479958_D001281 NONE Idraparinux_0\NNP|in|.|being|is (r_nsubjpass) evaluated_9\VBN|NONE (l_prep) in_10\IN|Idraparinux|.|being|is (l_pobj) patients_11\NNS|NONE (l_prep) with_12\IN|NONE (l_pobj) fibrillation_14\NN|NONE
1639466
D004656_D005921 NONE enalapril_14\JJ|NONE (r_compound) treatment_15\NN|NONE (r_pobj) after_13\IN|.|did|not|excretion (r_prep) change_12\VB|flow|but|, (l_nsubj) excretion_7\NN|.|did|not|after (l_conj) glomerulosclerosis_9\NN|and|albumin
D002118_D000419 NONE calcium_8\NN|the|nitrendipine (r_compound) channel_9\NN|NONE (l_appos) nitrendipine_11\NN|the|calcium (l_conj) angiotensin_14\NN|blocker|or (l_acl) converting_15\VBG|the (l_prep) on_19\IN|enalapril (l_pobj) pressure_21\NN|NONE (l_conj) albuminuria_23\NN|blood|,
D004656_D000419 NONE enalapril_18\NN|on (r_dobj) converting_15\VBG|the (l_prep) on_19\IN|enalapril (l_pobj) pressure_21\NN|NONE (l_conj) albuminuria_23\NN|blood|,
D009568_D005921 NONE nitrendipine_9\NN| (r_npadvmod) treated_11\VBN|the (r_amod) group_12\NN|NONE (r_pobj) in_7\IN|was|index|significantly|Furthermore|compared|.|, (r_prep) increased_6\VBN|NONE (l_nsubjpass) index_3\NN|was|significantly|Furthermore|compared|in|.|, (l_compound) glomerulosclerosis_2\NN|NONE
D002118_D006978 NONE calcium_4\NN|the (r_compound) channel_5\NN|NONE (r_pobj) of_2\IN|.|Adverse|nitrendipine (r_prep) effect_1\NN|NONE (l_appos) nitrendipine_7\NN|.|Adverse|of (l_prep) on_8\IN|blocker (l_pobj) nephrosclerosis_9\NN|NONE (l_prep) in_10\IN|NONE (l_pobj) rats_11\NNS|NONE (l_prep) with_12\IN|NONE (l_pobj) hypertension_14\NN|NONE
D002118_D006978 NONE calcium_8\NN|the|nitrendipine (r_compound) channel_9\NN|NONE (r_pobj) with_6\IN|week|a (r_prep) treatment_5\NN|NONE (r_pobj) of_2\IN|The (r_prep) effect_1\NN|.|in|was (r_nsubjpass) studied_35\VBN|NONE (l_prep) in_36\IN|.|effect|was (l_pobj) rats_37\NNS|NONE (l_prep) with_38\IN|NONE (l_pobj) kidney_41\NN|NONE (l_appos) hypertension_46\NN|,|two|
D000809_D006978 NONE angiotensin_14\NN|blocker|or (r_conj) nitrendipine_11\NN|the|calcium (r_appos) channel_9\NN|NONE (r_pobj) with_6\IN|week|a (r_prep) treatment_5\NN|NONE (r_pobj) of_2\IN|The (r_prep) effect_1\NN|.|in|was (r_nsubjpass) studied_35\VBN|NONE (l_prep) in_36\IN|.|effect|was (l_pobj) rats_37\NNS|NONE (l_prep) with_38\IN|NONE (l_pobj) kidney_41\NN|NONE (l_appos) hypertension_46\NN|,|two|
D002118_D009400 NONE calcium_4\NN|the (r_compound) channel_5\NN|NONE (r_pobj) of_2\IN|.|Adverse|nitrendipine (r_prep) effect_1\NN|NONE (l_appos) nitrendipine_7\NN|.|Adverse|of (l_prep) on_8\IN|blocker (l_pobj) nephrosclerosis_9\NN|NONE
D009568_D000419 CID nitrendipine_11\NN|the|calcium (l_conj) angiotensin_14\NN|blocker|or (l_acl) converting_15\VBG|the (l_prep) on_19\IN|enalapril (l_pobj) pressure_21\NN|NONE (l_conj) albuminuria_23\NN|blood|,
D009568_D000419 CID nitrendipine_5\NN| (r_npadvmod) treated_7\VBN|group|the (r_amod) albuminuria_9\NN|NONE
D009568_D009400 CID nitrendipine_7\NN|.|Adverse|of (l_prep) on_8\IN|blocker (l_pobj) nephrosclerosis_9\NN|NONE
D004656_D006973 NONE enalapril_33\NN| (r_npadvmod) treated_35\VBN|or|,|=|n|(|treated (r_amod) 8)_39\CD|)|(|hypertensive|untreated (r_appos) controls_27\NNS|three|: (r_appos) groups_23\NNS|NONE (r_pobj) to_21\IN|randomly|were|after|. (r_prep) assigned_20\VBN|NONE (l_prep) after_2\IN|randomly|were|to|. (l_pobj) clipping_3\VBG|weeks (l_prep) of_4\IN|NONE (l_pobj) artery_7\NN|NONE (l_appos) rats_10\NNS|Hg|one|renal|,|(|) (l_amod) hypertensive_9\JJ|NONE
D004656_D006973 NONE enalapril_33\NN| (r_npadvmod) treated_35\VBN|or|,|=|n|(|treated (r_amod) 8)_39\CD|)|(|hypertensive|untreated (r_appos) controls_27\NNS|three|: (l_amod) hypertensive_26\JJ|)|(|)|untreated
D004656_D006973 NONE enalapril_25\NN| (r_npadvmod) treated_27\VBN|the (r_amod) group_28\NN|NONE (r_pobj) in_23\IN|(|+/|compared (r_prep) lower_22\JJR|but|,|.|In|higher|in|size (l_prep) compared_37\VBN|(|+/|in (l_prep) with_38\IN|NONE (l_pobj) controls_41\NNS|NONE (l_amod) hypertensive_40\JJ|(|)|+/|the
D009568_D006973 NONE nitrendipine_42\NN||n (r_advmod) treated_44\VBN|or|,|=|n|treated|( (r_conj) 8)_39\CD|)|(|hypertensive|untreated (r_appos) controls_27\NNS|three|: (r_appos) groups_23\NNS|NONE (r_pobj) to_21\IN|randomly|were|after|. (r_prep) assigned_20\VBN|NONE (l_prep) after_2\IN|randomly|were|to|. (l_pobj) clipping_3\VBG|weeks (l_prep) of_4\IN|NONE (l_pobj) artery_7\NN|NONE (l_appos) rats_10\NNS|Hg|one|renal|,|(|) (l_amod) hypertensive_9\JJ|NONE
D009568_D006973 NONE nitrendipine_42\NN||n (r_advmod) treated_44\VBN|or|,|=|n|treated|( (r_conj) 8)_39\CD|)|(|hypertensive|untreated (r_appos) controls_27\NNS|three|: (l_amod) hypertensive_26\JJ|)|(|)|untreated
D009568_D006973 NONE nitrendipine_5\NN| (r_npadvmod) treated_7\VBN|group|the (r_amod) albuminuria_9\NN|NONE (r_pobj) in_3\IN|In|compared|.|,|progressively|from|to (r_prep) increased_10\VBD|NONE (l_prep) compared_20\VBN|In|in|.|,|progressively|from|to (l_prep) with_21\IN|NONE (l_pobj) hr_26\NN|NONE (l_prep) in_27\IN|mg/ (l_pobj) controls_30\NNS|NONE (l_amod) hypertensive_29\JJ|the
D009568_D006973 NONE nitrendipine_9\NN| (r_npadvmod) treated_11\VBN|the (r_amod) group_12\NN|NONE (r_pobj) in_7\IN|was|index|significantly|Furthermore|compared|.|, (r_prep) increased_6\VBN|NONE (l_prep) compared_13\VBN|was|index|significantly|Furthermore|in|.|, (l_prep) with_14\IN|NONE (l_pobj) controls_17\NNS|NONE (l_amod) hypertensive_16\JJ|(|.|)|the
D009568_D006973 NONE nitrendipine_9\NN| (r_npadvmod) treated_11\VBN|(|the|)|+/ (r_amod) group_12\NN|NONE (r_pobj) in_7\IN|but|,|.|In|higher|size|lower (r_prep) was_5\VBD|NONE (l_conj) lower_22\JJR|but|,|.|In|higher|in|size (l_prep) compared_37\VBN|(|+/|in (l_prep) with_38\IN|NONE (l_pobj) controls_41\NNS|NONE (l_amod) hypertensive_40\JJ|(|)|+/|the
D009568_D006978 NONE nitrendipine_7\NN|.|Adverse|of (l_prep) on_8\IN|blocker (l_pobj) nephrosclerosis_9\NN|NONE (l_prep) in_10\IN|NONE (l_pobj) rats_11\NNS|NONE (l_prep) with_12\IN|NONE (l_pobj) hypertension_14\NN|NONE
D009568_D006978 NONE nitrendipine_11\NN|the|calcium (r_appos) channel_9\NN|NONE (r_pobj) with_6\IN|week|a (r_prep) treatment_5\NN|NONE (r_pobj) of_2\IN|The (r_prep) effect_1\NN|.|in|was (r_nsubjpass) studied_35\VBN|NONE (l_prep) in_36\IN|.|effect|was (l_pobj) rats_37\NNS|NONE (l_prep) with_38\IN|NONE (l_pobj) kidney_41\NN|NONE (l_appos) hypertension_46\NN|,|two|
D000809_D000419 NONE angiotensin_14\NN|blocker|or (l_acl) converting_15\VBG|the (l_prep) on_19\IN|enalapril (l_pobj) pressure_21\NN|NONE (l_conj) albuminuria_23\NN|blood|,
D004656_D006978 NONE enalapril_18\NN|on (r_dobj) converting_15\VBG|the (r_acl) angiotensin_14\NN|blocker|or (r_conj) nitrendipine_11\NN|the|calcium (r_appos) channel_9\NN|NONE (r_pobj) with_6\IN|week|a (r_prep) treatment_5\NN|NONE (r_pobj) of_2\IN|The (r_prep) effect_1\NN|.|in|was (r_nsubjpass) studied_35\VBN|NONE (l_prep) in_36\IN|.|effect|was (l_pobj) rats_37\NNS|NONE (l_prep) with_38\IN|NONE (l_pobj) kidney_41\NN|NONE (l_appos) hypertension_46\NN|,|two|
12091028
D007649_D006212 CID ketamine_14\NN|complementary|necessary|the|only (l_advcl) buffers_17\VBZ|to (l_conj) decreases_22\VBZ|as|it|response|and (l_dobj) duration_24\NN|NONE (l_prep) of_27\IN|intensity|the|and (l_pobj) hallucinations_31\NNS|NONE
D003975_D006212 NONE Diazepam_0\NNP|,|drug|.|contraindicated|, (r_nsubj) remains_7\VBZ|NONE (l_attr) drug_12\NN|,|.|contraindicated|,|Diazepam (l_relcl) ketamine_14\NN|complementary|necessary|the|only (l_advcl) buffers_17\VBZ|to (l_conj) decreases_22\VBZ|as|it|response|and (l_dobj) duration_24\NN|NONE (l_prep) of_27\IN|intensity|the|and (l_pobj) hallucinations_31\NNS|NONE
4071154
D007213_D006947 CID indomethacin_24\NN|case|We|.|have (r_advcl) reported_2\VBN|NONE (l_dobj) case_4\NN|indomethacin|We|.|have (l_prep) of_5\IN|a|in (l_pobj) failure_9\NN|NONE (l_prep) with_10\IN|renal|oliguric|acute (l_pobj) hyperkalemia_11\NN|NONE
D007213_D009846 CID indomethacin_18\NN|NONE (r_pobj) of_17\IN|single|a (r_prep) dose_16\NN|exposure (r_pobj) to_13\IN|recurrence (r_punct) caused_19\VBD|restoration|.|withdrawal|, (l_dobj) recurrence_20\NN|to (l_prep) of_21\IN|NONE (l_pobj) oliguria_24\NN|NONE
D007213_D005355 CID indomethacin_24\NN|case|We|.|have (r_advcl) reported_2\VBN|NONE (l_dobj) case_4\NN|indomethacin|We|.|have (l_prep) in_12\IN|of|a (l_pobj) patient_14\NN|NONE (l_prep) with_15\IN|a (l_pobj) cirrhosis_16\NN|NONE
D007213_D001201 CID indomethacin_24\NN|case|We|.|have (r_advcl) reported_2\VBN|NONE (l_dobj) case_4\NN|indomethacin|We|.|have (l_prep) in_12\IN|of|a (l_pobj) patient_14\NN|NONE (l_prep) with_15\IN|a (l_pobj) cirrhosis_16\NN|NONE (l_conj) ascites_18\NNS|,
D007213_D051437 NONE Indomethacin_0\NNP| (r_npadvmod) induced_2\VBN|renal|:|.|recurrence (r_amod) insufficiency_4\NN|NONE
D007213_D051437 NONE indomethacin_24\NN|case|We|.|have (r_advcl) reported_2\VBN|NONE (l_dobj) case_4\NN|indomethacin|We|.|have (l_prep) of_5\IN|a|in (l_pobj) failure_9\NN|NONE
D007213_D011660 CID indomethacin_24\NN|case|We|.|have (r_advcl) reported_2\VBN|NONE (l_dobj) case_4\NN|indomethacin|We|.|have (l_prep) in_12\IN|of|a (l_pobj) patient_14\NN|NONE (l_prep) with_15\IN|a (l_pobj) cirrhosis_16\NN|NONE (l_conj) ascites_18\NNS|, (l_conj) pulmonale_22\NN|,|and
2051906
D001379_D008107 NONE azathioprine_30\NN|NONE (r_amod) therapy_31\NN|NONE (r_pobj) of_29\IN|NONE (r_prep) initiation_28\NN|months (r_pobj) after_27\IN|patient|features|. (r_prep) developed_17\VBD|NONE (l_nsubj) patient_4\NN|features|.|after (l_prep) with_6\IN|,|old|A (l_conj) without_10\IN|polymyositis|and (l_pobj) evidence_12\NN|NONE (l_prep) of_13\IN|previous (l_pobj) disease_15\NN|NONE
D001379_D002779 CID azathioprine_7\JJ|NONE (r_amod) therapy_8\NN|NONE (r_pobj) following_6\VBG|.|with|Reversible (r_prep) cholestasis_1\NN|NONE
D001379_D002779 CID azathioprine_7\JJ|NONE (r_amod) therapy_8\NN|NONE (r_pobj) following_6\VBG|.|with|Reversible (r_prep) cholestasis_1\NN|NONE (l_prep) with_2\IN|.|following|Reversible (l_pobj) injury_5\NN|NONE
D001379_D002779 CID azathioprine_30\NN|NONE (r_amod) therapy_31\NN|NONE (r_pobj) of_29\IN|NONE (r_prep) initiation_28\NN|months (r_pobj) after_27\IN|patient|features|. (r_prep) developed_17\VBD|NONE (l_dobj) features_21\NNS|patient|.|after (l_prep) of_22\IN|clinical (l_pobj) cholestasis_24\NN|NONE
D001379_D002779 CID azathioprine_12\RB| (r_advmod) induced_14\VBN|associated|reversible (r_amod) cholestasis_15\NN|NONE
D001379_D002779 CID azathioprine_12\RB| (r_advmod) induced_14\VBN|associated|reversible (r_amod) cholestasis_15\NN|NONE (l_acl) associated_16\VBN|induced|reversible (l_prep) with_17\IN|NONE (l_pobj) evidence_19\NN|NONE (l_prep) of_20\IN|histological (l_pobj) injury_23\NN|NONE
D001379_D017285 NONE azathioprine_30\NN|NONE (r_amod) therapy_31\NN|NONE (r_pobj) of_29\IN|NONE (r_prep) initiation_28\NN|months (r_pobj) after_27\IN|patient|features|. (r_prep) developed_17\VBD|NONE (l_nsubj) patient_4\NN|features|.|after (l_prep) with_6\IN|,|old|A (l_pobj) polymyositis_8\NN|without|and
803783
D010121_D006261 NONE Oxytocin_0\NN|during (r_compound) administration_1\NN|is|carried|. (r_nsubjpass) advocated_8\VBN|NONE (l_advcl) carried_14\VBN|is|administration|. (l_conj) instructed_33\VBD|,|if|out|be|can|only|and|under|it|aware (l_xcomp) watch_35\VB|NONE (l_conj) report_39\VB|to|and|diuresis (l_dobj) signs_42\NNS|NONE (l_prep) as_46\IN|of|such|early (l_pobj) asthenia_47\NNP|NONE (l_conj) irritability_50\NN|, (l_conj) headaches_53\NNS|or|muscular|,
D010121_D001247 NONE Oxytocin_0\NN|during (r_compound) administration_1\NN|is|carried|. (r_nsubjpass) advocated_8\VBN|NONE (l_advcl) carried_14\VBN|is|administration|. (l_conj) instructed_33\VBD|,|if|out|be|can|only|and|under|it|aware (l_xcomp) watch_35\VB|NONE (l_conj) report_39\VB|to|and|diuresis (l_dobj) signs_42\NNS|NONE (l_prep) as_46\IN|of|such|early (l_pobj) asthenia_47\NNP|NONE
D010121_D014869 CID oxytocin_4\NN|NONE (r_compound) administration_5\NN|NONE (r_pobj) with_3\IN|during (r_prep) associated_2\VBN|Water|. (r_acl) intoxication_1\NN|NONE
D010121_D014869 CID oxytocin_8\NN|NONE (r_compound) administration_9\NN|NONE (r_pobj) with_7\IN|during (r_prep) connection_6\NN|NONE (r_pobj) in_5\IN|water (r_prep) intoxication_4\NN|NONE
D010121_D014869 CID Oxytocin_0\NN|during (r_compound) administration_1\NN|is|carried|. (r_nsubjpass) advocated_8\VBN|NONE (l_advcl) carried_14\VBN|is|administration|. (l_advcl) aware_25\JJ|,|instructed|if|out|be|can|only|and|under|it (l_prep) of_26\IN|NONE (l_pobj) symptoms_28\NNS|NONE (l_prep) of_29\IN|the (l_pobj) intoxication_31\NN|NONE
D010121_D001523 NONE Oxytocin_0\NN|during (r_compound) administration_1\NN|is|carried|. (r_nsubjpass) advocated_8\VBN|NONE (l_advcl) carried_14\VBN|is|administration|. (l_conj) instructed_33\VBD|,|if|out|be|can|only|and|under|it|aware (l_xcomp) watch_35\VB|NONE (l_conj) report_39\VB|to|and|diuresis (l_dobj) signs_42\NNS|NONE (l_prep) as_46\IN|of|such|early (l_pobj) asthenia_47\NNP|NONE (l_conj) irritability_50\NN|,
D010121_D000031 NONE oxytocin_4\NN|NONE (r_compound) administration_5\NN|NONE (r_pobj) with_3\IN|during (r_prep) associated_2\VBN|Water|. (l_prep) during_6\IN|with (l_pobj) abortion_10\NN|NONE
D010121_D000031 NONE oxytocin_8\NN|NONE (r_compound) administration_9\NN|NONE (r_pobj) with_7\IN|during (r_prep) connection_6\NN|NONE (l_prep) during_10\IN|with (l_pobj) abortions_14\NNS|NONE
D010121_D000031 NONE Oxytocin_0\NN|during (r_compound) administration_1\NN|is|carried|. (l_prep) during_2\IN|Oxytocin (l_pobj) abortions_6\NNS|NONE
11078231
D004280_D000788 CID dobutamine_4\NN|spasm|can|in (r_nsubj) provoke_6\VB|findings|. (l_prep) in_9\IN|spasm|dobutamine|can (l_pobj) patients_11\NNS|NONE (l_prep) with_12\IN|some (l_pobj) angina_15\NN|NONE
D004280_D003329 CID dobutamine_8\NN|NONE (r_compound) stress_9\NN|NONE (r_compound) echocardiography_10\RB|NONE (r_pobj) during_7\IN|coronary|artery (r_prep) spasm_6\NN|to
D004280_D003329 CID dobutamine_19\NN|NONE (r_pobj) by_18\IN|whether|is|ischemia (r_agent) induced_17\VBN|to (l_nsubjpass) ischemia_11\NN|whether|is|by (l_amod) due_12\IN|myocardial (l_pcomp) to_13\IN|NONE (l_pobj) spasm_15\NN|NONE
D004280_D003329 CID dobutamine_4\NN|spasm|can|in (r_nsubj) provoke_6\VB|findings|. (l_dobj) spasm_8\NN|dobutamine|can|in
D004280_D017202 NONE dobutamine_8\NN|NONE (r_compound) stress_9\NN|NONE (r_compound) echocardiography_10\RB|NONE (r_pobj) during_7\IN|coronary|artery (r_prep) spasm_6\NN|to (r_pobj) due_2\IN|.|Myocardial (r_amod) ischemia_1\NN|NONE
D004280_D017202 NONE Dobutamine_0\NNP|echocardiography (r_nsubj) stress_1\NN|.|test (r_nsubj) is_6\VBZ|NONE (l_attr) test_12\NN|stress|. (l_prep) for_13\IN|useful|a|provocation (l_pobj) ischemia_15\NN|NONE
D004280_D017202 NONE dobutamine_19\NN|NONE (r_pobj) by_18\IN|whether|is|ischemia (r_agent) induced_17\VBN|to (l_nsubjpass) ischemia_11\NN|whether|is|by
D000109_D023921 NONE acetylcholine_8\NN|NONE (r_pobj) of_7\IN|intracoronary (r_prep) injection_6\NN|NONE (r_pobj) by_4\IN|was|,|and|documented|spasm (r_agent) induced_3\VBN|NONE (l_conj) documented_17\VBN|by|was|,|and|spasm (l_nsubjpass) stenosis_15\NN|.|was|on
16047871
D014859_D012871 NONE warfarin_11\NN|for (r_dobj) receiving_10\VBG|NONE (r_pcomp) after_9\IN|that (r_prep) developed_8\VBD|skin (r_relcl) eruptions_6\NNS|NONE
D014859_D012871 NONE warfarin_21\NN|was|after (r_nsubjpass) discontinued_23\VBN|in (r_advcl) resolved_16\VBD|LV|Cutaneous (r_acl) lesions_15\NNS|NONE (r_dobj) confirming_12\VBG|.|available|results|, (r_advcl) were_6\VBD|NONE (l_nsubj) results_1\NNS|.|available|confirming|, (l_prep) of_2\IN|The (l_pobj) biopsies_5\NNS|NONE (l_compound) lesion_4\NN|NONE
D014859_D018366 CID warfarin_21\NN|was|after (r_nsubjpass) discontinued_23\VBN|in (r_advcl) resolved_16\VBD|LV|Cutaneous (r_acl) lesions_15\NNS|NONE
D014859_C535509 NONE Warfarin_0\NNP| (r_npadvmod) induced_2\VBN|leukocytoclastic|. (r_amod) vasculitis_4\NN|NONE
D014859_C535509 NONE warfarin_12\NN|probably|to (r_pobj) due_10\JJ||with (r_amod) patients_3\NNS|We|. (l_prep) with_4\IN||due (l_pobj) LV_8\NNP|NONE
D014859_C535509 NONE warfarin_11\JJ|NONE (r_compound) therapy_12\NN|NONE (r_pobj) with_10\IN|NONE (r_prep) associated_9\VBN|a|adverse|onset (r_acl) reaction_8\NN|may|.|LV (r_attr) be_2\VB|NONE (l_nsubj) LV_0\NNP|may|.|reaction
10354657
D008094_D013959 NONE lithium_9\NN|,|age (r_compound) therapy_10\NN|NONE (r_pobj) of_8\IN|the (r_prep) duration_7\NN|NONE (r_pobj) to_5\IN|NONE (r_prep) respect_4\NN|NONE (r_pobj) with_3\IN|had|These|.|were (r_prep) evaluated_2\VBN|NONE (l_parataxis) had_25\VBD|These|.|were|with (l_dobj) relative_30\NN|)|(|or|whether|patient|not (l_prep) with_31\IN|a|degree (l_pobj) disease_33\NN|NONE
D008094_D013959 NONE lithium_22\NN|NONE (r_compound) therapy_23\NN|NONE (r_pobj) of_21\IN|NONE (r_prep) onset_20\NN|years (r_pobj) after_19\IN|after|had|(|patients|)|)|.|compared|onset (r_prep) accelerated_12\VBN|NONE (l_nsubj) patients_1\NNS|after|after|had|(|)|)|.|compared|onset (l_acl) having_2\VBG|All (l_dobj) relatives_6\NNS|NONE (l_acl) affected_7\VBN|degree (l_agent) by_8\IN|NONE (l_pobj) illness_10\NN|NONE
D008094_D013959 NONE lithium_38\NN|NONE (r_compound) therapy_39\NN|NONE (r_pobj) of_37\IN|NONE (r_prep) onset_36\NN|years (r_pobj) after_35\IN|after|had|(|patients|)|)|.|compared|onset (r_prep) accelerated_12\VBN|NONE (l_nsubj) patients_1\NNS|after|after|had|(|)|)|.|compared|onset (l_acl) having_2\VBG|All (l_dobj) relatives_6\NNS|NONE (l_acl) affected_7\VBN|degree (l_agent) by_8\IN|NONE (l_pobj) illness_10\NN|NONE
D008094_D013959 NONE lithium_12\NN|NONE (r_compound) therapy_13\NN|NONE (r_pobj) during_11\IN|a|for|risk (r_prep) factor_6\NN|illness|. (r_attr) is_3\VBZ|NONE (l_nsubj) illness_2\NN|factor|.
D008094_D007037 CID lithium_22\NN|NONE (r_compound) therapy_23\NN|NONE (r_pobj) of_21\IN|NONE (r_prep) onset_20\NN|years (r_pobj) after_19\IN|after|had|(|patients|)|)|.|compared|onset (r_prep) accelerated_12\VBN|NONE (l_dobj) onset_13\NN|after|after|had|(|patients|)|)|.|compared (l_prep) of_14\IN|( (l_pobj) hypothyroidism_15\NN|NONE
D008094_D007037 CID lithium_38\NN|NONE (r_compound) therapy_39\NN|NONE (r_pobj) of_37\IN|NONE (r_prep) onset_36\NN|years (r_pobj) after_35\IN|after|had|(|patients|)|)|.|compared|onset (r_prep) accelerated_12\VBN|NONE (l_dobj) onset_13\NN|after|after|had|(|patients|)|)|.|compared (l_prep) of_14\IN|( (l_pobj) hypothyroidism_15\NN|NONE
D008094_D007037 CID lithium_12\NN|NONE (r_compound) therapy_13\NN|NONE (r_pobj) during_11\IN|a|for|risk (r_prep) factor_6\NN|illness|. (l_prep) for_7\IN|a|risk|during (l_pobj) hypothyroidism_8\NN|NONE
D008094_D001714 NONE lithium_16\NN|maintenance|ranging (r_compound) therapy_18\NN|disorder (r_dobj) receiving_15\VBG|NONE (l_nsubj) disorder_14\NN|therapy
D008094_D006934 NONE lithium_12\NN|NONE (r_compound) therapy_13\NN|NONE (r_pobj) during_11\IN|a|for|risk (r_prep) factor_6\NN|illness|. (l_prep) for_7\IN|a|risk|during (l_pobj) hypothyroidism_8\NN|NONE (l_conj) hypercalcemia_10\NN|and
11419773
D002110_D001145 NONE Caffeine_0\NN| (r_nsubj) induced_2\VBN|:|danger|.|cardiac (r_amod) arrhythmia_4\NN|NONE
D002110_D014693 CID caffeine_34\NN|NONE (r_pobj) of_33\IN|high|a (r_prep) concentration_32\NN|NONE (r_dobj) containing_29\VBG|guarana|a|health|"|energy|" (r_acl) drink_28\NN|NONE (r_dobj) consuming_20\VBG|NONE (r_pcomp) after_19\IN|who|fibrillation (r_prep) developed_15\VBD|with|old|a (l_dobj) fibrillation_18\NN|who|after
D002110_D008945 NONE caffeine_34\NN|NONE (r_pobj) of_33\IN|high|a (r_prep) concentration_32\NN|NONE (r_dobj) containing_29\VBG|guarana|a|health|"|energy|" (r_acl) drink_28\NN|NONE (r_dobj) consuming_20\VBG|NONE (r_pcomp) after_19\IN|who|fibrillation (r_prep) developed_15\VBD|with|old|a (r_relcl) woman_6\NN|.|We (l_prep) with_7\IN|developed|old|a (l_pobj) prolapse_13\NN|NONE
9100294
D002118_D018376 NONE calcium_7\NN|NONE (r_compound) channel_8\NN|NONE (r_compound) blockers_9\NNS|NONE (r_pobj) to_6\IN|NONE (r_prep) exposed_5\VBN|Cardiovascular|in|. (r_acl) alterations_1\NNS|NONE
D002118_D018376 NONE calcium_7\NN|new (r_compound) channel_8\NN|,|Ro|a (r_compound) blocker_9\NN|alterations|,|that (r_nsubj) induced_16\VBD|.|investigation (l_dobj) alterations_18\NNS|,|that|blocker
D002118_D018376 NONE calcium_10\NN|NONE (r_compound) channel_11\NN|in (r_compound) blockers_12\NNS|that|malformations (r_nsubj) induce_15\VBP|the (l_dobj) malformations_17\NNS|that|blockers
D002118_D018376 NONE calcium_7\NN|NONE (r_compound) channel_8\NN|these (r_compound) blockers_9\NNS|NONE (r_pobj) of_5\IN|NONE (r_prep) one_4\CD|during|were|rats|. (r_dobj) administered_3\VBN|NONE (l_prep) during_10\IN|one|were|rats|. (l_pobj) period_12\NN|NONE (l_prep) of_13\IN|the (l_pobj) morphogenesis_15\NN|NONE (l_conj) offspring_18\NN|cardiac|and (l_acl) examined_19\VBD|the (l_prep) on_20\IN|NONE (l_pobj) day_21\NN|NONE (l_prep) of_23\IN| (l_pobj) gestation_24\NN|NONE (l_prep) for_25\IN|NONE (l_pobj) malformations_27\NNS|NONE
D002118_D018376 NONE calcium_15\NN|NONE (r_compound) channel_16\NN|four|the (r_compound) blockers_17\NNS|NONE (r_pobj) of_12\IN|NONE (r_prep) each_11\DT|NONE (r_pobj) to_10\IN|NONE (r_prep) exposure_9\NN|NONE (r_pobj) after_8\IN|was|was|,|incidence|but (r_prep) observed_7\VBN|NONE (l_nsubjpass) incidence_2\NN|was|was|,|after|but (l_prep) of_3\IN|low|A (l_pobj) malformations_5\NNS|NONE
D020748_D018376 CID 5967_14\CD|NONE (r_prep) 40_12\CD|NONE (r_nummod) Ro_11\NNP|,|a|channel (r_appos) blocker_9\NN|alterations|,|that (r_nsubj) induced_16\VBD|.|investigation (l_dobj) alterations_18\NNS|,|that|blocker
D009543_D018376 CID nifedipine_29\NN|and (r_conj) verapamil_27\NN|only (r_pobj) for_26\IN|statistically (r_prep) significant_24\JJ|incidence|. (r_acomp) was_22\VBD|was|,|incidence|after|but (r_conj) observed_7\VBN|NONE (l_nsubjpass) incidence_2\NN|was|was|,|after|but (l_prep) of_3\IN|low|A (l_pobj) malformations_5\NNS|NONE
D014700_D018376 CID verapamil_27\NN|only (r_pobj) for_26\IN|statistically (r_prep) significant_24\JJ|incidence|. (r_acomp) was_22\VBD|was|,|incidence|after|but (r_conj) observed_7\VBN|NONE (l_nsubjpass) incidence_2\NN|was|was|,|after|but (l_prep) of_3\IN|low|A (l_pobj) malformations_5\NNS|NONE
6292680
D018943_D009202 NONE anthracycline_11\NN|severe (r_amod) cardiomyopathy_12\NN|after|children|.
D004317_D009202 CID Doxorubicin_0\JJ|.|in (r_nsubj) cardiomyopathy_1\NN|NONE
D004317_D009202 CID doxorubicin_23\NN|NONE (r_pobj) of_22\IN|conventional (r_prep) dosage_21\NN|and|tumor|the (r_conj) bed_18\NN|NONE (r_pobj) to_15\IN|NONE (r_prep) irradiation_14\NN|NONE (r_pobj) after_13\IN|children|cardiomyopathy|. (r_prep) experienced_9\VBD|NONE (l_dobj) cardiomyopathy_12\NN|after|children|.
D004317_D009202 CID doxorubicin_30\NN|NONE (r_pobj) of_29\IN|the|on (r_prep) interaction_28\NN|NONE (r_pobj) to_26\IN|fields|that|portion (r_prep) include_16\VBP|the (r_acl) fact_8\NN|NONE (r_pobj) to_6\IN||)|cardiomyopathy|is|. (r_prep) attributed_3\VBN|NONE (l_nsubjpass) cardiomyopathy_1\NN||)|to|is|.
D004317_D009369 NONE doxorubicin_23\NN|NONE (r_pobj) of_22\IN|conventional (r_prep) dosage_21\NN|and|tumor|the (r_conj) bed_18\NN|NONE (l_compound) tumor_17\NN|and|the|dosage
D018943_D009396 NONE anthracycline_11\NN|severe (r_amod) cardiomyopathy_12\NN|after|children|. (r_dobj) experienced_9\VBD|NONE (l_nsubj) children_1\NNS|after|cardiomyopathy|. (l_prep) with_2\IN|Two (l_pobj) tumor_4\NN|NONE
D004317_D009396 NONE Doxorubicin_0\JJ|.|in (r_nsubj) cardiomyopathy_1\NN|NONE (l_prep) in_2\IN|.|Doxorubicin (l_pobj) children_3\NNS|NONE (l_prep) with_4\IN|NONE (l_pobj) tumor_9\NN|NONE
D004317_D009396 NONE doxorubicin_23\NN|NONE (r_pobj) of_22\IN|conventional (r_prep) dosage_21\NN|and|tumor|the (r_conj) bed_18\NN|NONE (r_pobj) to_15\IN|NONE (r_prep) irradiation_14\NN|NONE (r_pobj) after_13\IN|children|cardiomyopathy|. (r_prep) experienced_9\VBD|NONE (l_nsubj) children_1\NNS|after|cardiomyopathy|. (l_prep) with_2\IN|Two (l_pobj) tumor_4\NN|NONE
D004317_D009396 NONE doxorubicin_30\NN|NONE (r_pobj) of_29\IN|the|on (r_prep) interaction_28\NN|NONE (r_pobj) to_26\IN|fields|that|portion (r_prep) include_16\VBP|the (l_nsubj) fields_11\VBZ|to|that|portion (l_prep) for_12\IN|radiation (l_pobj) tumor_15\NN|NONE
D004317_D009396 NONE doxorubicin_4\NN|NONE (r_compound) dosage_5\NN|be|that|sharply|in (r_nsubjpass) restricted_8\VBN|is|.|It (l_prep) in_9\IN|dosage|be|that|sharply (l_pobj) children_10\NNS|NONE (l_prep) with_11\IN|NONE (l_pobj) tumor_13\NN|NONE
D018943_D009369 NONE anthracycline_11\NN|severe (r_amod) cardiomyopathy_12\NN|after|children|. (r_dobj) experienced_9\VBD|NONE (l_prep) after_13\IN|children|cardiomyopathy|. (l_pobj) irradiation_14\NN|NONE (l_prep) to_15\IN|NONE (l_pobj) bed_18\NN|NONE (l_compound) tumor_17\NN|and|the|dosage
19996135
D014148_D012640 CID Acid_4\NNP|.|is|with (r_nsubjpass) associated_6\VBN|NONE (l_prep) with_7\IN|.|is|Acid (l_pobj) seizures_10\NNS|NONE
D014148_D012640 CID TXA_19\NNP|seizures|and (r_compound) usage_20\NN|NONE (l_conj) seizures_22\NNS|TXA|and
D014148_D012640 CID TXA_9\NNP|NONE (r_compound) intraoperatively_10\NN|NONE (r_pobj) of_8\IN|ranging|high (r_prep) doses_7\NNS|had|,|patients|. (r_dobj) received_5\VBD|NONE (l_nsubj) patients_2\NNS|doses|had|,|. (l_prep) with_3\IN|All| (l_pobj) seizures_4\NNS|NONE
D014148_D012640 CID TXA_9\NN|NONE (r_pobj) of_5\IN|in|in (r_prep) use_4\NN|that|is|with (r_nsubjpass) associated_25\VBN|results|. (l_prep) with_26\IN|that|use|is (l_pobj) seizures_28\NNS|NONE
9326871
D004917_D005759 CID erythromycin_7\NNP|NONE (r_pobj) of_6\IN|the|effect (r_prep) profile_5\NN|is|Although (r_nsubjpass) established_9\VBN|is|experience|still|.|being (r_advcl) recorded_35\VBN|NONE (l_nsubjpass) experience_27\NN|is|established|still|.|being (l_prep) including_11\VBG|with|,|, (l_pobj) gastroenteritis_12\JJ|NONE
D004917_D066126 NONE erythromycin_11\NNP|NONE (r_pobj) of_10\IN|intravenous (r_prep) administration_9\NN|NONE (r_pobj) after_4\IN|reported|but|has|.|been|Cardiotoxicity (r_prep) demonstrated_3\VBN|NONE (l_nsubjpass) Cardiotoxicity_0\NN|reported|after|but|has|.|been
D017291_D017180 CID Clarithromycin_0\NN| (r_npadvmod) induced_2\VBN|.|ventricular (r_amod) tachycardia_4\NN|NONE
D018942_D005759 NONE macrolides_31\NNS|NONE (r_pobj) with_28\IN|including|,|, (r_prep) experience_27\NN|is|established|still|.|being (l_prep) including_11\VBG|with|,|, (l_pobj) gastroenteritis_12\JJ|NONE
D018942_D066126 NONE macrolides_20\NNS|NONE (r_pobj) with_17\IN|has|never|been (r_prep) reported_16\VBN|after|but|has|.|been|Cardiotoxicity (r_conj) demonstrated_3\VBN|NONE (l_nsubjpass) Cardiotoxicity_0\NN|reported|after|but|has|.|been
D017291_D001145 NONE clarithromycin_14\NN|NONE (r_pobj) of_13\IN|six|therapeutic (r_prep) doses_12\NNS|NONE (r_pobj) after_9\IN|that (r_prep) occurred_8\VBD|ventricular (r_relcl) dysrhythmias_6\NNS|NONE
9088814
D003911_D020141 NONE dextran_23\NN|NONE (r_amod) solution_24\NN|NONE (r_pobj) of_22\IN|the|same (r_prep) amount_21\NN|NONE (r_pobj) with_18\IN|it (r_prep) replacing_16\VBG|mL|and (r_conj) withdrawing_9\VBG|NONE (r_pcomp) by_8\IN|Haemodilution|and|were|,|was (r_prep) produced_7\VBN|NONE (l_nsubjpass) Haemodilution_0\NN|and|were|by|,|was
D001663_D007022 NONE bilirubin_68\NN|and (r_conj) LDH_65\NNP|, (r_conj) SGPT_63\NNP|, (r_appos) SGOT_61\NNP|.|increases (r_nsubj) showed_69\VBD|at|and|and|AKBR|,|decrease|,|after|showed (r_conj) showed_23\VBD|NONE (l_prep) after_42\IN|at|and|and|AKBR|,|decrease|,|showed|showed (l_pobj) start_44\NN|at|and|after (l_prep) of_45\IN|the (l_pobj) hypotension_46\NN|NONE
D000527_D007022 CID E1-induced_5\JJ|prolonged|and|on|haemodilution|prostaglandin (r_amod) hypotension_6\NN|NONE
D000527_D007022 CID E1_5\NN|NONE (l_appos) hypotension_8\NN|prostaglandin|prolonged
D000527_D007022 CID PGE1)-induced_7\JJ|haemodilution|(|and (r_amod) hypotension_8\NN|prostaglandin|prolonged
D000527_D007022 CID PGE1_10\NNP|NONE (r_pobj) with_9\IN|.|was|maintain|hypotension (r_prep) induced_8\VBN|NONE (l_nsubjpass) hypotension_1\NN|.|was|maintain|with
D000527_D007022 CID PGE1-induced_13\JJ|haemodilution|and (r_amod) hypotension_14\NN|NONE
D000527_D020141 NONE E1-induced_5\JJ|prolonged|and|on|haemodilution|prostaglandin (r_amod) hypotension_6\NN|NONE (l_conj) haemodilution_8\NN|prolonged|and|Einduced|on|prostaglandin
D000527_D020141 NONE E1_5\NN|NONE (l_appos) hypotension_8\NN|prostaglandin|prolonged (l_conj) haemodilution_10\NN|PGE)induced|(|and
D000527_D020141 NONE PGE1)-induced_7\JJ|haemodilution|(|and (r_amod) hypotension_8\NN|prostaglandin|prolonged (l_conj) haemodilution_10\NN|PGE)induced|(|and
D000527_D020141 NONE PGE1-induced_13\JJ|haemodilution|and (r_amod) hypotension_14\NN|NONE (l_conj) haemodilution_17\NN|PGEinduced|and
D000527_D008107 CID PGE1-induced_13\JJ|haemodilution|and (r_amod) hypotension_14\NN|NONE (r_pobj) of_12\IN| (r_prep) min_11\NN|NONE (r_pobj) of_7\IN|a|prolonged (r_prep) combination_6\NN|that|impairment|would (r_nsubj) cause_19\VB|results|. (l_dobj) impairment_20\NN|that|would|combination (l_prep) of_21\IN|NONE (l_pobj) function_23\NN|NONE
1987816
D008094_D011141 CID Lithium_0\NN| (r_npadvmod) induced_2\VBN|NONE (r_amod) polyuria_3\NN|related|.
2716967
D009020_D009127 NONE morphine_21\NN|or (r_conj) ketamine_19\NN|NONE (r_pobj) of_18\IN|the|relative|in (r_prep) predominance_17\NN|.|,|Latency (r_dobj) reflected_14\VBD|NONE (l_nsubj) Latency_0\NN|predominance|.|, (l_prep) to_1\IN|NONE (l_pobj) loss_3\NN|NONE (l_prep) of_4\IN|the (l_pobj) reflex_6\NN|NONE (l_conj) rigidity_8\NN|,|righting
D007649_D002375 CID ketamine_5\NN|NONE (r_pobj) of_4\IN|:|potentiation (r_prep) combinations_3\NNS|NONE (r_pobj) by_2\IN|.|Catalepsy (r_agent) induced_1\VBN|NONE (l_nsubj) Catalepsy_0\NNP|.|by
D007649_D002375 CID ketamine_5\NN|analgesia|that (r_nsubj) induced_8\VBN|induce|,|studies|tolerance (l_dobj) analgesia_9\NN|ketamine|that (l_conj) catalepsy_11\NN|and|in
D007649_D002375 CID ketamine_5\NN|analgesia|that (r_nsubj) induced_8\VBN|induce|,|studies|tolerance (r_ccomp) demonstrated_2\VBD|to|;|augmentation|was|. (l_advcl) induce_34\VB|induced|,|studies|tolerance (l_conj) augmented_42\VBD|whereas|pretreatment|tolerance|not|did|but (l_dobj) response_45\NN|rather (l_amod) cataleptic_44\JJ|the
D007649_D002375 CID ketamine_20\NN|NONE (r_pobj) with_19\IN| (r_prep) treatment_18\NN|NONE (r_nsubj) produced_21\VBD|to|cross| (r_amod) tolerance_24\NN|induced|induce|,|studies (r_dobj) demonstrated_2\VBD|to|;|augmentation|was|. (l_ccomp) induced_8\VBN|induce|,|studies|tolerance (l_dobj) analgesia_9\NN|ketamine|that (l_conj) catalepsy_11\NN|and|in
D007649_D002375 CID ketamine_20\NN|NONE (r_pobj) with_19\IN| (r_prep) treatment_18\NN|NONE (r_nsubj) produced_21\VBD|to|cross| (r_amod) tolerance_24\NN|induced|induce|,|studies (r_dobj) demonstrated_2\VBD|to|;|augmentation|was|. (l_advcl) induce_34\VB|induced|,|studies|tolerance (l_conj) augmented_42\VBD|whereas|pretreatment|tolerance|not|did|but (l_dobj) response_45\NN|rather (l_amod) cataleptic_44\JJ|the
D007649_D002375 CID ketamine_39\NN|NONE (r_pobj) to_38\IN||cross (r_prep) tolerance_37\NN|whereas|pretreatment|not|did|but|augmented (r_dobj) induce_34\VB|induced|,|studies|tolerance (r_advcl) demonstrated_2\VBD|to|;|augmentation|was|. (l_ccomp) induced_8\VBN|induce|,|studies|tolerance (l_dobj) analgesia_9\NN|ketamine|that (l_conj) catalepsy_11\NN|and|in
D007649_D002375 CID ketamine_39\NN|NONE (r_pobj) to_38\IN||cross (r_prep) tolerance_37\NN|whereas|pretreatment|not|did|but|augmented (r_dobj) induce_34\VB|induced|,|studies|tolerance (l_conj) augmented_42\VBD|whereas|pretreatment|tolerance|not|did|but (l_dobj) response_45\NN|rather (l_amod) cataleptic_44\JJ|the
D009020_D002375 CID morphine_7\NN|and (r_conj) ketamine_5\NN|NONE (r_pobj) of_4\IN|:|potentiation (r_prep) combinations_3\NNS|NONE (r_pobj) by_2\IN|.|Catalepsy (r_agent) induced_1\VBN|NONE (l_nsubj) Catalepsy_0\NNP|.|by
D009020_D002375 CID morphine_7\NN|both|and (r_conj) ketamine_5\NN|analgesia|that (r_nsubj) induced_8\VBN|induce|,|studies|tolerance (l_dobj) analgesia_9\NN|ketamine|that (l_conj) catalepsy_11\NN|and|in
D009020_D002375 CID morphine_7\NN|both|and (r_conj) ketamine_5\NN|analgesia|that (r_nsubj) induced_8\VBN|induce|,|studies|tolerance (r_ccomp) demonstrated_2\VBD|to|;|augmentation|was|. (l_advcl) induce_34\VB|induced|,|studies|tolerance (l_conj) augmented_42\VBD|whereas|pretreatment|tolerance|not|did|but (l_dobj) response_45\NN|rather (l_amod) cataleptic_44\JJ|the
D009020_D002375 CID morphine_26\NN|NONE (r_pobj) to_25\IN|produced|cross| (r_prep) tolerance_24\NN|induced|induce|,|studies (r_dobj) demonstrated_2\VBD|to|;|augmentation|was|. (l_ccomp) induced_8\VBN|induce|,|studies|tolerance (l_dobj) analgesia_9\NN|ketamine|that (l_conj) catalepsy_11\NN|and|in
D009020_D002375 CID morphine_26\NN|NONE (r_pobj) to_25\IN|produced|cross| (r_prep) tolerance_24\NN|induced|induce|,|studies (r_dobj) demonstrated_2\VBD|to|;|augmentation|was|. (l_advcl) induce_34\VB|induced|,|studies|tolerance (l_conj) augmented_42\VBD|whereas|pretreatment|tolerance|not|did|but (l_dobj) response_45\NN|rather (l_amod) cataleptic_44\JJ|the
D009020_D002375 CID morphine_31\NN|NONE (r_pobj) with_30\IN|NONE (r_prep) pretreatment_29\NN|whereas|tolerance|not|did|but|augmented (r_nsubj) induce_34\VB|induced|,|studies|tolerance (r_advcl) demonstrated_2\VBD|to|;|augmentation|was|. (l_ccomp) induced_8\VBN|induce|,|studies|tolerance (l_dobj) analgesia_9\NN|ketamine|that (l_conj) catalepsy_11\NN|and|in
D009020_D002375 CID morphine_31\NN|NONE (r_pobj) with_30\IN|NONE (r_prep) pretreatment_29\NN|whereas|tolerance|not|did|but|augmented (r_nsubj) induce_34\VB|induced|,|studies|tolerance (l_conj) augmented_42\VBD|whereas|pretreatment|tolerance|not|did|but (l_dobj) response_45\NN|rather (l_amod) cataleptic_44\JJ|the
D009020_D002375 CID morphine_53\NN|NONE (r_pobj) to_51\IN|;|demonstrated|augmentation|was|. (r_prep) attributed_50\VBN|NONE (l_ccomp) demonstrated_2\VBD|to|;|augmentation|was|. (l_ccomp) induced_8\VBN|induce|,|studies|tolerance (l_dobj) analgesia_9\NN|ketamine|that (l_conj) catalepsy_11\NN|and|in
D009020_D002375 CID morphine_53\NN|NONE (r_pobj) to_51\IN|;|demonstrated|augmentation|was|. (r_prep) attributed_50\VBN|NONE (l_ccomp) demonstrated_2\VBD|to|;|augmentation|was|. (l_advcl) induce_34\VB|induced|,|studies|tolerance (l_conj) augmented_42\VBD|whereas|pretreatment|tolerance|not|did|but (l_dobj) response_45\NN|rather (l_amod) cataleptic_44\JJ|the
D009020_D000699 NONE morphine_7\NN|both|and (r_conj) ketamine_5\NN|analgesia|that (r_nsubj) induced_8\VBN|induce|,|studies|tolerance (l_dobj) analgesia_9\NN|ketamine|that
D009020_D000699 NONE morphine_26\NN|NONE (r_pobj) to_25\IN|produced|cross| (r_prep) tolerance_24\NN|induced|induce|,|studies (r_dobj) demonstrated_2\VBD|to|;|augmentation|was|. (l_ccomp) induced_8\VBN|induce|,|studies|tolerance (l_dobj) analgesia_9\NN|ketamine|that
D009020_D000699 NONE morphine_31\NN|NONE (r_pobj) with_30\IN|NONE (r_prep) pretreatment_29\NN|whereas|tolerance|not|did|but|augmented (r_nsubj) induce_34\VB|induced|,|studies|tolerance (r_advcl) demonstrated_2\VBD|to|;|augmentation|was|. (l_ccomp) induced_8\VBN|induce|,|studies|tolerance (l_dobj) analgesia_9\NN|ketamine|that
D009020_D000699 NONE morphine_53\NN|NONE (r_pobj) to_51\IN|;|demonstrated|augmentation|was|. (r_prep) attributed_50\VBN|NONE (l_ccomp) demonstrated_2\VBD|to|;|augmentation|was|. (l_ccomp) induced_8\VBN|induce|,|studies|tolerance (l_dobj) analgesia_9\NN|ketamine|that
D009270_D002375 NONE Naloxone_0\NN|.|effects (r_nsubj) inhibited_1\VBD|NONE (l_dobj) effects_5\NNS|.|Naloxone (l_amod) cataleptic_4\JJ|the|induced
D009270_D002375 NONE naloxone_36\NN|NONE (r_pobj) for_35\IN|different|a (r_prep) ID50_34\NNP|of|and (r_conj) asymmetry_24\NN|in|, (r_conj) differences_16\NNS|the|,|induced (r_conj) catalepsy_14\NN|NONE
D007649_D000699 NONE ketamine_5\NN|analgesia|that (r_nsubj) induced_8\VBN|induce|,|studies|tolerance (l_dobj) analgesia_9\NN|ketamine|that
D007649_D000699 NONE ketamine_20\NN|NONE (r_pobj) with_19\IN| (r_prep) treatment_18\NN|NONE (r_nsubj) produced_21\VBD|to|cross| (r_amod) tolerance_24\NN|induced|induce|,|studies (r_dobj) demonstrated_2\VBD|to|;|augmentation|was|. (l_ccomp) induced_8\VBN|induce|,|studies|tolerance (l_dobj) analgesia_9\NN|ketamine|that
D007649_D000699 NONE ketamine_39\NN|NONE (r_pobj) to_38\IN||cross (r_prep) tolerance_37\NN|whereas|pretreatment|not|did|but|augmented (r_dobj) induce_34\VB|induced|,|studies|tolerance (r_advcl) demonstrated_2\VBD|to|;|augmentation|was|. (l_ccomp) induced_8\VBN|induce|,|studies|tolerance (l_dobj) analgesia_9\NN|ketamine|that
D009270_D009127 NONE naloxone_36\NN|NONE (r_pobj) for_35\IN|different|a (r_prep) ID50_34\NNP|of|and (r_conj) asymmetry_24\NN|in|, (r_conj) differences_16\NNS|the|,|induced (l_prep) in_17\IN|asymmetry|, (l_pobj) latency_18\NN|NONE (l_conj) rigidity_20\NN|,
D007649_D009127 NONE ketamine_19\NN|NONE (r_pobj) of_18\IN|the|relative|in (r_prep) predominance_17\NN|.|,|Latency (r_dobj) reflected_14\VBD|NONE (l_nsubj) Latency_0\NN|predominance|.|, (l_prep) to_1\IN|NONE (l_pobj) loss_3\NN|NONE (l_prep) of_4\IN|the (l_pobj) reflex_6\NN|NONE (l_conj) rigidity_8\NN|,|righting
7444978
D013307_D004409 CID streptomycin_48\NNS|NONE (r_pobj) to_47\IN|more (r_prep) sensitive_46\JJ|that|cochlea (r_acomp) is_44\VBZ|NONE (r_ccomp) indicating_40\VBG|;|sensitivities|occurred|,|within|.|from (r_advcl) occurred_23\VBD|NONE (l_ccomp) occurred_4\VBD|;|sensitivities|,|indicating|within|.|from (l_nsubj) movements_1\NNS|in
D013307_D004409 CID streptomycin_48\NNS|NONE (l_prep) than_49\IN|NONE (l_pobj) site_51\NN|NONE (l_amod) responsible_57\JJ|vestibular|(|the|) (l_prep) for_58\IN|NONE (l_pobj) dyskinesias_60\NNS|NONE
D013307_D020258 NONE streptomycin_11\NNS|NONE (r_pobj) of_10\IN|neurotoxic (r_prep) effects_9\NNS|NONE (l_amod) neurotoxic_8\JJ|of
D013307_D003638 CID streptomycin_48\NNS|NONE (r_pobj) to_47\IN|more (r_prep) sensitive_46\JJ|that|cochlea (r_acomp) is_44\VBZ|NONE (r_ccomp) indicating_40\VBG|;|sensitivities|occurred|,|within|.|from (r_advcl) occurred_23\VBD|NONE (l_ccomp) occurred_4\VBD|;|sensitivities|,|indicating|within|.|from (l_nsubj) movements_1\NNS|in (l_conj) deafness_3\NN|Abnormal|and
9669632
D020117_D043183 NONE cisapride_2\NN|NONE (r_pobj) of_1\IN|.|and|function|on (r_prep) Effects_0\NNS|NONE (l_conj) function_11\NN|of|.|and|on (l_prep) in_12\IN|bowel|motor|postcibal (l_pobj) patients_13\NNS|NONE (l_prep) with_14\IN|NONE (l_pobj) syndrome_17\NN|NONE
D020117_D043183 NONE cisapride_17\NN|to|effects (l_prep) on_19\IN|, (l_pobj) motility_22\NN|NONE (l_prep) in_25\IN|symptoms|postprandial|jejunal|and (l_pobj) syndrome_29\NN|NONE
D020117_D043183 NONE cisapride_17\NN|to|effects (l_prep) on_19\IN|, (l_pobj) motility_22\NN|NONE (l_prep) in_25\IN|symptoms|postprandial|jejunal|and (l_pobj) syndrome_29\NN|NONE (l_appos) IBS_31\NNP|)|(|irritable|bowel|the
D020117_D043183 NONE cisapride_36\NN|and (r_conj) before_28\IN|.|,|manometry|,|)|patients|daily|; (r_advmod) underwent_23\VBD|NONE (l_nsubj) patients_3\NNS|.|,|manometry|,|)|before|daily|; (l_prep) with_4\IN|eight (l_pobj) IBS_5\NNP|NONE
D020117_D043183 NONE cisapride_11\NN| (r_npadvmod) treated_13\VBN|predominant|IBS|score (r_amod) patients_18\NNS|NONE (l_compound) IBS_17\NNP|predominant|treated|score
D020117_D043183 NONE cisapride_11\NN|NONE (r_compound) therapy_12\NN|[|,|,|cisapride|after|)|+/|P|( (r_nmod) score_14\NN|patients|score|pretreatment|;|. (r_advcl) had_5\VBD|NONE (l_nsubj) patients_4\NNS|score|pretreatment|;|.|score (l_compound) IBS_3\NNP|predominant
D020117_D043183 NONE cisapride_25\NN|therapy|[|,|,|after|)|+/|P|( (r_conj) score_14\NN|patients|score|pretreatment|;|. (r_advcl) had_5\VBD|NONE (l_nsubj) patients_4\NNS|score|pretreatment|;|.|score (l_compound) IBS_3\NNP|predominant
D020117_D043183 NONE Cisapride_0\NNP|.|characteristics (r_nsubj) affects_1\VBZ|NONE (l_dobj) characteristics_4\NNS|.|Cisapride (l_conj) symptoms_7\NNS|and|contraction|jejunal (l_prep) in_8\IN|some (l_pobj) IBS_9\NNP|NONE
D020117_D003248 NONE cisapride_36\NN|and (r_conj) before_28\IN|.|,|manometry|,|)|patients|daily|; (r_advmod) underwent_23\VBD|NONE (l_nsubj) patients_3\NNS|.|,|manometry|,|)|before|daily|; (l_prep) with_4\IN|eight (l_pobj) IBS_5\NNP|NONE (l_appos) predominant_9\JJ|( (l_compound) constipation_7\NN|,|
D020117_D003248 NONE cisapride_11\NN| (r_npadvmod) treated_13\VBN|predominant|IBS|score (r_amod) patients_18\NNS|NONE (r_pobj) in_10\IN|lower|scores (r_prep) were_8\VBD|NONE (l_nsubj) scores_1\NNS|in|lower (l_acl) relating_2\VBG|Symptom (l_prep) to_3\IN|NONE (l_pobj) severity_5\NN|NONE (l_prep) of_6\IN|the (l_pobj) constipation_7\NN|NONE
D020117_D003248 NONE cisapride_11\NN| (r_npadvmod) treated_13\VBN|predominant|IBS|score (r_amod) patients_18\NNS|NONE (l_amod) predominant_16\JJ|IBS|treated|score (l_compound) constipation_14\NN|
D020117_D003967 NONE cisapride_36\NN|and (r_conj) before_28\IN|.|,|manometry|,|)|patients|daily|; (r_advmod) underwent_23\VBD|NONE (l_punct) ;_14\:|.|,|manometry|,|)|patients|before|daily (l_preconj) predominant_17\JJ|NONE (l_compound) diarrhoea_15\NN|
D020117_D003967 NONE cisapride_14\NN|the (r_nmod) groups_17\NNS|NONE (r_pobj) between_12\IN|.|were|In|differences (r_prep) observed_11\VBN|NONE (l_prep) In_0\IN|.|were|between|differences (l_pobj) patients_4\NNS|NONE (l_amod) predominant_3\JJ|NONE (l_npadvmod) diarrhoea_1\NN|
D020117_D003967 NONE cisapride_1\NN| (r_npadvmod) treated_3\VBN|predominant (r_amod) patients_7\NNS|NONE (l_amod) predominant_6\JJ|treated (l_npadvmod) diarrhoea_4\NN|
D020117_D003967 NONE cisapride_11\NN|NONE (r_compound) therapy_12\NN|[|,|,|cisapride|after|)|+/|P|( (r_nmod) score_14\NN|patients|score|pretreatment|;|. (r_advcl) had_5\VBD|NONE (l_nsubj) patients_4\NNS|score|pretreatment|;|.|score (l_amod) predominant_2\JJ|IBS (l_npadvmod) Diarrhoea_0\NN|
D020117_D003967 NONE cisapride_25\NN|therapy|[|,|,|after|)|+/|P|( (r_conj) score_14\NN|patients|score|pretreatment|;|. (r_advcl) had_5\VBD|NONE (l_nsubj) patients_4\NNS|score|pretreatment|;|.|score (l_amod) predominant_2\JJ|IBS (l_npadvmod) Diarrhoea_0\NN|
D020117_D010146 NONE cisapride_11\NN|NONE (r_compound) therapy_12\NN|[|,|,|cisapride|after|)|+/|P|( (r_nmod) score_14\NN|patients|score|pretreatment|;|. (r_advcl) had_5\VBD|NONE (l_dobj) score_9\NN|patients|pretreatment|;|.|score (l_compound) pain_8\NN|a|higher
D020117_D010146 NONE cisapride_25\NN|therapy|[|,|,|after|)|+/|P|( (r_conj) score_14\NN|patients|score|pretreatment|;|. (r_advcl) had_5\VBD|NONE (l_dobj) score_9\NN|patients|pretreatment|;|.|score (l_compound) pain_8\NN|a|higher
11928786
D016642_D002318 NONE Zyban_0\NNP|.|toxicity (r_nsubj) caused_1\VBD|NONE (l_dobj) toxicity_6\NN|.|Zyban
D003975_D013610 NONE diazepam_5\NN|NONE (l_conj) tachycardia_9\NN|and
D016642_D062787 NONE Zyban_0\NNP|.|toxicity (r_nsubj) caused_1\VBD|NONE (l_dobj) toxicity_6\NN|.|Zyban (l_prep) in_7\IN|significant|neurological (l_pobj) overdose_8\NN|NONE
D000241_D012640 NONE adenosine_14\NN|NONE (r_pobj) with_13\IN|was|successfully (r_prep) treated_12\VBN|were|.|seizures|with (r_conj) treated_3\VBN|NONE (l_nsubjpass) seizures_1\NNS|were|.|with|treated
D000241_D013610 NONE adenosine_14\NN|NONE (r_pobj) with_13\IN|was|successfully (r_prep) treated_12\VBN|were|.|seizures|with (r_conj) treated_3\VBN|NONE (l_prep) with_4\IN|were|.|seizures|treated (l_pobj) diazepam_5\NN|NONE (l_conj) tachycardia_9\NN|and
D003975_D012640 NONE diazepam_5\NN|NONE (r_pobj) with_4\IN|were|.|seizures|treated (r_prep) treated_3\VBN|NONE (l_nsubjpass) seizures_1\NNS|were|.|with|treated
D016642_D020258 NONE Zyban_0\NNP|.|toxicity (r_nsubj) caused_1\VBD|NONE (l_dobj) toxicity_6\NN|.|Zyban
D016642_D064420 NONE Bupropion_0\NNP|(|)|.|Zyban (r_nmod) toxicity_4\NN|NONE
D016642_D064420 NONE Zyban_2\NNP|(|)|Bupropion|. (r_nmod) toxicity_4\NN|NONE
33969
D001590_D010302 NONE benztropine_2\NN|and|. (l_prep) in_3\IN|NONE (l_pobj) parkinsonism_7\NN|NONE
D001590_D010302 NONE benztropine_9\VB|.|In|was (l_prep) in_10\IN|to|induced (l_pobj) treatment_12\NN|NONE (l_prep) of_13\IN|the (l_pobj) parkinsonism_14\NN|NONE
D001590_D010302 NONE benztropine_2\NN|and (r_conj) Ethopropazine_0\NN|be|were|and|were|. (r_nsubjpass) found_4\VBN|NONE (l_xcomp) be_6\VB|were|and|Ethopropazine|were|. (l_acomp) effective_8\JJ|to (l_prep) in_9\IN|equally (l_pcomp) controlling_10\VBG|NONE (l_dobj) symptoms_12\NNS|NONE
D001590_D010302 NONE benztropine_3\NN|not|,|because|that|drug (r_nsubj) is_4\VBZ|This|. (l_attr) drug_8\NN|not|,|benztropine|because|that (l_prep) in_11\IN|the|anticholinergic|of (l_pobj) treatment_13\NN|NONE (l_prep) of_14\IN|the (l_pobj) symptoms_19\NNS|NONE
C017610_D012559 NONE enanthate_18\NN|NONE (l_prep) in_19\IN|NONE (l_pobj) outpatients_22\NNS|NONE (l_amod) schizophrenic_21\JJ|
D001590_D001008 CID benztropine_2\NN|treated|compared|,|However|and|,|increase (r_nsubj) had_5\VBD|NONE (l_conj) treated_28\VBN|compared|,|However|benztropine|and|,|increase (l_nsubj) anxiety_23\NN|.|patients|than
D011352_D004409 NONE procyclindine_17\JJ|NONE (r_compound) treatment_18\NN|NONE (r_pobj) during_16\IN|their (r_prep) condition_15\NN|NONE (r_pobj) to_13\IN|NONE (r_prep) compared_12\VBN|treated|,|However|benztropine|and|,|increase (r_prep) had_5\VBD|NONE (l_dobj) increase_8\NN|treated|compared|,|However|benztropine|and|, (l_prep) in_9\IN|a|significant (l_pobj) dyskinesia_11\JJ|NONE
D011352_D003866 NONE procyclindine_17\JJ|NONE (r_compound) treatment_18\NN|NONE (r_pobj) during_16\IN|their (r_prep) condition_15\NN|NONE (r_pobj) to_13\IN|NONE (r_prep) compared_12\VBN|treated|,|However|benztropine|and|,|increase (r_prep) had_5\VBD|NONE (l_conj) treated_28\VBN|compared|,|However|benztropine|and|,|increase (l_nsubj) anxiety_23\NN|.|patients|than (l_conj) depression_25\NN|more|and
D001590_D003866 CID benztropine_2\NN|treated|compared|,|However|and|,|increase (r_nsubj) had_5\VBD|NONE (l_conj) treated_28\VBN|compared|,|However|benztropine|and|,|increase (l_nsubj) anxiety_23\NN|.|patients|than (l_conj) depression_25\NN|more|and
C017610_D010302 CID enanthate_18\NN|NONE (r_amod) fluphenazine_17\JJ|NONE (r_pobj) by_16\IN|NONE (r_agent) induced_15\VBN|to|in (r_advcl) benztropine_9\VB|.|In|was (l_prep) in_10\IN|to|induced (l_pobj) treatment_12\NN|NONE (l_prep) of_13\IN|the (l_pobj) parkinsonism_14\NN|NONE
C084820_D010302 NONE Ethopropazine_0\NN|NONE (l_conj) benztropine_2\NN|and|. (l_prep) in_3\IN|NONE (l_pobj) parkinsonism_7\NN|NONE
C084820_D010302 NONE ethopropazine_5\NN|NONE (r_pobj) In_0\IN|.|was|benztropine (r_prep) compared_7\VBN|NONE (l_xcomp) benztropine_9\VB|.|In|was (l_prep) in_10\IN|to|induced (l_pobj) treatment_12\NN|NONE (l_prep) of_13\IN|the (l_pobj) parkinsonism_14\NN|NONE
C084820_D010302 NONE Ethopropazine_0\NN|be|were|and|were|. (r_nsubjpass) found_4\VBN|NONE (l_xcomp) be_6\VB|were|and|Ethopropazine|were|. (l_acomp) effective_8\JJ|to (l_prep) in_9\IN|equally (l_pcomp) controlling_10\VBG|NONE (l_dobj) symptoms_12\NNS|NONE
C084820_D012559 NONE ethopropazine_5\NN|NONE (r_pobj) In_0\IN|.|was|benztropine (r_prep) compared_7\VBN|NONE (l_xcomp) benztropine_9\VB|.|In|was (l_advcl) induced_15\VBN|to|in (l_agent) by_16\IN|NONE (l_pobj) fluphenazine_17\JJ|NONE (l_amod) enanthate_18\NN|NONE (l_prep) in_19\IN|NONE (l_pobj) outpatients_22\NNS|NONE (l_amod) schizophrenic_21\JJ|
D011352_D001008 NONE procyclindine_17\JJ|NONE (r_compound) treatment_18\NN|NONE (r_pobj) during_16\IN|their (r_prep) condition_15\NN|NONE (r_pobj) to_13\IN|NONE (r_prep) compared_12\VBN|treated|,|However|benztropine|and|,|increase (r_prep) had_5\VBD|NONE (l_conj) treated_28\VBN|compared|,|However|benztropine|and|,|increase (l_nsubj) anxiety_23\NN|.|patients|than
D001590_D012559 NONE benztropine_9\VB|.|In|was (l_advcl) induced_15\VBN|to|in (l_agent) by_16\IN|NONE (l_pobj) fluphenazine_17\JJ|NONE (l_amod) enanthate_18\NN|NONE (l_prep) in_19\IN|NONE (l_pobj) outpatients_22\NNS|NONE (l_amod) schizophrenic_21\JJ|
D011352_D010302 NONE procyclidine_18\NN|NONE (r_pobj) as_17\IN|as (r_prep) efficacious_16\JJ|drug|, (r_acomp) were_14\VBD|be|and|Ethopropazine|were|. (r_conj) found_4\VBN|NONE (l_xcomp) be_6\VB|were|and|Ethopropazine|were|. (l_acomp) effective_8\JJ|to (l_prep) in_9\IN|equally (l_pcomp) controlling_10\VBG|NONE (l_dobj) symptoms_12\NNS|NONE
C084820_D004409 NONE ethopropazine_27\NN|NONE (r_pobj) than_26\IN|.|patients|anxiety (r_mark) treated_28\VBN|compared|,|However|benztropine|and|,|increase (r_conj) had_5\VBD|NONE (l_dobj) increase_8\NN|treated|compared|,|However|benztropine|and|, (l_prep) in_9\IN|a|significant (l_pobj) dyskinesia_11\JJ|NONE
C084820_D001008 NONE ethopropazine_27\NN|NONE (r_pobj) than_26\IN|.|patients|anxiety (r_mark) treated_28\VBN|compared|,|However|benztropine|and|,|increase (l_nsubj) anxiety_23\NN|.|patients|than
C084820_D003866 NONE ethopropazine_27\NN|NONE (r_pobj) than_26\IN|.|patients|anxiety (r_mark) treated_28\VBN|compared|,|However|benztropine|and|,|increase (l_nsubj) anxiety_23\NN|.|patients|than (l_conj) depression_25\NN|more|and
D001590_D004409 CID benztropine_2\NN|treated|compared|,|However|and|,|increase (r_nsubj) had_5\VBD|NONE (l_dobj) increase_8\NN|treated|compared|,|However|benztropine|and|, (l_prep) in_9\IN|a|significant (l_pobj) dyskinesia_11\JJ|NONE
6133211
D012460_D015212 NONE sulphasalazine_15\NN|NONE (r_pobj) with_14\IN|NONE (r_prep) treatment_13\NN|who (r_dobj) received_12\VBD|inflammatory|bowel (r_relcl) disease_10\NN|NONE
D012460_D000013 NONE sulphasalazine_15\NN|NONE (r_pobj) with_14\IN|NONE (r_prep) treatment_13\NN|who (r_dobj) received_12\VBD|inflammatory|bowel (r_relcl) disease_10\NN|NONE (r_pobj) with_7\IN|two (r_prep) mothers_6\NNS|NONE (r_pobj) of_4\IN|NONE (r_prep) born_3\VBN|,|,|Three (r_acl) infants_1\NNS|.|have|were (r_nsubjpass) found_20\VBN|NONE (l_xcomp) have_22\VB|.|were|infants (l_dobj) anomalies_25\NNS|to
12851669
D004997_D054556 NONE ethinylestradiol_14\NN|cyproterone|combined|and (r_conj) acetate_12\NN|NONE (r_pobj) on_9\IN|NONE (r_prep) women_8\NNS|NONE (r_pobj) in_7\IN|venous (r_prep) thromboembolism_6\NN|NONE
D004997_D054556 NONE ethinylestradiol_17\NN|plus|cyproterone (r_conj) acetate_15\NN|NONE (r_pobj) on_13\IN|NONE (r_prep) women_12\NNS|NONE (r_pobj) among_11\IN|)|VTE|(|venous (r_prep) thromboembolism_7\NN|NONE
D004997_D054556 NONE ethinylestradiol_17\NN|plus|cyproterone (r_conj) acetate_15\NN|NONE (r_pobj) on_13\IN|NONE (r_prep) women_12\NNS|NONE (r_pobj) among_11\IN|)|VTE|(|venous (r_prep) thromboembolism_7\NN|NONE (l_appos) VTE_9\NNP|)|among|(|venous
D004997_D054556 NONE EE_21\NNP|NONE (r_appos) ethinylestradiol_17\NN|plus|cyproterone (r_conj) acetate_15\NN|NONE (r_pobj) on_13\IN|NONE (r_prep) women_12\NNS|NONE (r_pobj) among_11\IN|)|VTE|(|venous (r_prep) thromboembolism_7\NN|NONE
D004997_D054556 NONE EE_21\NNP|NONE (r_appos) ethinylestradiol_17\NN|plus|cyproterone (r_conj) acetate_15\NN|NONE (r_pobj) on_13\IN|NONE (r_prep) women_12\NNS|NONE (r_pobj) among_11\IN|)|VTE|(|venous (r_prep) thromboembolism_7\NN|NONE (l_appos) VTE_9\NNP|)|among|(|venous
D004997_D054556 NONE EE_67\NNP|NONE (r_pobj) on_64\IN|the (r_prep) women_63\NNS|NONE (r_pobj) among_61\IN|women (r_prep) years_60\NNS|NONE (r_pobj) per_56\IN|.|.|(|)|, (r_prep) range_50\NN|.|per|,|(|range|,|and (r_conj) range_9\NN|risk|. (r_attr) was_6\VBD|NONE (l_nsubj) risk_3\NN|range|. (l_prep) of_4\IN|corresponding|The|absolute (l_pobj) VTE_5\NNP|NONE
D004997_D054556 NONE EE_22\NNP|NONE (r_dobj) taking_19\VBG|NONE (r_acl) women_18\NNS|NONE (r_pobj) among_17\IN|NONE (r_prep) that_16\DT|NONE (r_pobj) to_15\IN|NONE (r_prep) similar_14\JJ|NONE (r_acomp) is_13\VBZ|risk|results|. (r_ccomp) suggest_2\VBP|NONE (l_dobj) risk_5\NN|results|.|is (l_prep) of_6\IN|absolute|among|the (l_pobj) VTE_7\NNP|NONE
D016912_D054556 NONE levonorgestrel_42\NN| (r_npadvmod) containing_44\VBG|NONE (r_amod) COCs_45\NNS|NONE (r_pobj) on_41\IN|NONE (r_prep) women_40\NNS|NONE (r_pobj) among_39\IN|women (r_prep) years_38\NNS|NONE (r_pobj) per_34\IN|.|,|(|range|,|range|and (r_prep) range_9\NN|risk|. (r_attr) was_6\VBD|NONE (l_nsubj) risk_3\NN|range|. (l_prep) of_4\IN|corresponding|The|absolute (l_pobj) VTE_5\NNP|NONE
D003277_D054556 CID contraceptives_30\NNS|NONE (r_pobj) on_27\IN|NONE (r_prep) women_26\NNS|NONE (r_pobj) among_25\IN|estimates|,|and|.|To (r_conj) achieve_1\VB|NONE (l_dobj) estimates_4\NNS|,|among|and|.|To (l_prep) of_5\IN|risk|absolute (l_pobj) thromboembolism_7\NN|NONE
D003277_D054556 CID contraceptives_30\NNS|NONE (r_pobj) on_27\IN|NONE (r_prep) women_26\NNS|NONE (r_pobj) among_25\IN|estimates|,|and|.|To (r_conj) achieve_1\VB|NONE (l_dobj) estimates_4\NNS|,|among|and|.|To (l_prep) of_5\IN|risk|absolute (l_pobj) thromboembolism_7\NN|NONE (l_appos) VTE_9\NNP|)|among|(|venous
D003277_D054556 CID COCs_32\NNPS|combined|oral|(|) (r_appos) contraceptives_30\NNS|NONE (r_pobj) on_27\IN|NONE (r_prep) women_26\NNS|NONE (r_pobj) among_25\IN|estimates|,|and|.|To (r_conj) achieve_1\VB|NONE (l_dobj) estimates_4\NNS|,|among|and|.|To (l_prep) of_5\IN|risk|absolute (l_pobj) thromboembolism_7\NN|NONE
D003277_D054556 CID COCs_32\NNPS|combined|oral|(|) (r_appos) contraceptives_30\NNS|NONE (r_pobj) on_27\IN|NONE (r_prep) women_26\NNS|NONE (r_pobj) among_25\IN|estimates|,|and|.|To (r_conj) achieve_1\VB|NONE (l_dobj) estimates_4\NNS|,|among|and|.|To (l_prep) of_5\IN|risk|absolute (l_pobj) thromboembolism_7\NN|NONE (l_appos) VTE_9\NNP|)|among|(|venous
D003277_D054556 CID COCs_19\NNS|while (r_pobj) on_18\IN|to|have|VTE (r_advcl) had_15\VBN|:|During|were|,|women|. (l_dobj) VTE_16\NNP|on|to|have
D003277_D054556 CID COCs_24\NNS|NONE (r_pobj) on_23\IN|the (r_prep) women_22\NNS|NONE (r_pobj) among_20\IN|women (r_prep) years_19\NNS|NONE (r_pobj) per_15\IN|.|) (r_prep) 3.1_11\CD|,|,|.|)|(|. (r_npadvmod) range_28\NN|.|per|,|(|,|range|and (r_appos) range_9\NN|risk|. (r_attr) was_6\VBD|NONE (l_nsubj) risk_3\NN|range|. (l_prep) of_4\IN|corresponding|The|absolute (l_pobj) VTE_5\NNP|NONE
D003277_D054556 CID COCs_45\NNS|NONE (r_pobj) on_41\IN|NONE (r_prep) women_40\NNS|NONE (r_pobj) among_39\IN|women (r_prep) years_38\NNS|NONE (r_pobj) per_34\IN|.|,|(|range|,|range|and (r_prep) range_9\NN|risk|. (r_attr) was_6\VBD|NONE (l_nsubj) risk_3\NN|range|. (l_prep) of_4\IN|corresponding|The|absolute (l_pobj) VTE_5\NNP|NONE
D003277_D054556 CID COCs_12\NNS|NONE (r_pobj) on_11\IN|Danish (r_prep) women_10\NNS|NONE (r_pobj) among_8\IN|absolute|of|the (r_prep) risk_5\NN|results|.|is (l_prep) of_6\IN|absolute|among|the (l_pobj) VTE_7\NNP|NONE
D017373_D054556 NONE acetate_12\NN|NONE (r_pobj) on_9\IN|NONE (r_prep) women_8\NNS|NONE (r_pobj) in_7\IN|venous (r_prep) thromboembolism_6\NN|NONE
D017373_D054556 NONE acetate_15\NN|NONE (r_pobj) on_13\IN|NONE (r_prep) women_12\NNS|NONE (r_pobj) among_11\IN|)|VTE|(|venous (r_prep) thromboembolism_7\NN|NONE
D017373_D054556 NONE acetate_15\NN|NONE (r_pobj) on_13\IN|NONE (r_prep) women_12\NNS|NONE (r_pobj) among_11\IN|)|VTE|(|venous (r_prep) thromboembolism_7\NN|NONE (l_appos) VTE_9\NNP|)|among|(|venous
D017373_D054556 NONE CPA_19\NNP|/|)|( (r_nmod) EE_21\NNP|NONE (r_appos) ethinylestradiol_17\NN|plus|cyproterone (r_conj) acetate_15\NN|NONE (r_pobj) on_13\IN|NONE (r_prep) women_12\NNS|NONE (r_pobj) among_11\IN|)|VTE|(|venous (r_prep) thromboembolism_7\NN|NONE
D017373_D054556 NONE CPA_19\NNP|/|)|( (r_nmod) EE_21\NNP|NONE (r_appos) ethinylestradiol_17\NN|plus|cyproterone (r_conj) acetate_15\NN|NONE (r_pobj) on_13\IN|NONE (r_prep) women_12\NNS|NONE (r_pobj) among_11\IN|)|VTE|(|venous (r_prep) thromboembolism_7\NN|NONE (l_appos) VTE_9\NNP|)|among|(|venous
D017373_D054556 NONE CPA_65\NNP|/ (r_nmod) EE_67\NNP|NONE (r_pobj) on_64\IN|the (r_prep) women_63\NNS|NONE (r_pobj) among_61\IN|women (r_prep) years_60\NNS|NONE (r_pobj) per_56\IN|.|.|(|)|, (r_prep) range_50\NN|.|per|,|(|range|,|and (r_conj) range_9\NN|risk|. (r_attr) was_6\VBD|NONE (l_nsubj) risk_3\NN|range|. (l_prep) of_4\IN|corresponding|The|absolute (l_pobj) VTE_5\NNP|NONE
D017373_D054556 NONE CPA_20\NNP|/ (r_nmod) EE_22\NNP|NONE (r_dobj) taking_19\VBG|NONE (r_acl) women_18\NNS|NONE (r_pobj) among_17\IN|NONE (r_prep) that_16\DT|NONE (r_pobj) to_15\IN|NONE (r_prep) similar_14\JJ|NONE (r_acomp) is_13\VBZ|risk|results|. (r_ccomp) suggest_2\VBP|NONE (l_dobj) risk_5\NN|results|.|is (l_prep) of_6\IN|absolute|among|the (l_pobj) VTE_7\NNP|NONE
14736955
C102006_D007674 NONE citrate_32\NN|NONE (r_compound) synthase_33\NN|increased (r_compound) activity_34\NN|of|depressed|and (r_conj) activities_15\NNS|,|significant|glomerular (r_appos) lesions_12\NNS|group|.
D004317_D009401 CID doxorubicin_10\NN|NONE (r_compound) nephrosis_11\NN|NONE
D013481_D007674 NONE superoxide_41\JJ|and|activities (r_amod) production_42\NN|NONE (r_pobj) with_40\IN|positively|.|was|Injury (r_prep) correlated_39\VBN|activities|inversely|Among|were|with (r_conj) correlated_10\VBN|NONE (l_prep) Among_0\IN|activities|correlated|inversely|were|with (l_pobj) injury_7\NN|animals
D013481_D007674 NONE superoxide_25\NN|NONE (l_prep) in_26\IN|NONE (l_pobj) lesions_31\NNS|NONE
D004317_D007674 NONE Doxorubicin_0\NNP|nephropathy|. (r_nsubj) induces_1\VBZ|NONE (l_dobj) nephropathy_6\NN|.|Doxorubicin
D004317_D007674 NONE Doxorubicin_0\NNP|nephropathy|. (r_nsubj) induces_1\VBZ|NONE (l_dobj) nephropathy_6\NN|.|Doxorubicin (l_acl) characterized_7\VBN|a|perpetuating (l_agent) by_8\IN|NONE (l_pobj) lesions_16\NNS|NONE
D004317_D007674 NONE doxorubicin_27\RB| (r_npadvmod) induced_29\VBN|renal (r_amod) lesions_31\NNS|NONE
18821488
C068820_D006456 CID WR242511_11\NNP|NONE (r_pobj) of_10\IN|minutes (r_prep) postinjection_9\NN|was|Furthermore|hemoglobinuria|occurred|,|and|, (r_dobj) noted_5\VBN|NONE (l_nsubjpass) hemoglobinuria_3\NN|postinjection|was|Furthermore|occurred|,|and|,
C068820_D008708 NONE WR242511_4\NNP|NONE (l_relcl) produced_7\VBD|,|, (l_dobj) methemoglobinemia_9\NN|in|which
C080436_D064420 NONE 8-aminoquinoline_8\JJ|NONE (r_compound) 8-[(4-amino_9\CD| (r_compound) l_11\NN| (r_compound) methylbutyl)amino]-_13\NN|the|(|hexyloxy)methoxymethylquinoline (r_punct) WR242511_18\NNP|NONE (r_pobj) of_6\IN|NONE (r_prep) administration_5\NN|NONE (r_pobj) following_4\VBG|)|.|in (r_prep) Toxicity_0\NN|NONE
C068820_D064420 NONE hexyloxy)-6-methoxy-4-methylquinoline_16\NNP|methylbutyl)amino]|the|( (r_nmod) WR242511_18\NNP|NONE (r_pobj) of_6\IN|NONE (r_prep) administration_5\NN|NONE (r_pobj) following_4\VBG|)|.|in (r_prep) Toxicity_0\NN|NONE
C068820_D064420 NONE WR242511_18\NNP|NONE (r_pobj) of_6\IN|NONE (r_prep) administration_5\NN|NONE (r_pobj) following_4\VBG|)|.|in (r_prep) Toxicity_0\NN|NONE
C068820_D064420 NONE WR242511_4\NNP|dissociated|should|be|that|not|as (r_nsubjpass) pursued_8\VBN|It|.|is (l_advcl) dissociated_27\VBN|should|be|WR|that|not|as (l_prep) from_28\IN|be|unless|successfully|characteristics|can (l_pobj) those_29\DT|NONE (l_acl) producing_30\VBG|NONE (l_dobj) toxicity_32\NN|NONE
C068820_D011041 NONE WR242511_4\NNP|dissociated|should|be|that|not|as (r_nsubjpass) pursued_8\VBN|It|.|is (l_prep) as_9\IN|dissociated|should|be|WR|that|not (l_pobj) pretreatment_11\NN|NONE (l_prep) for_12\IN|a (l_pobj) poisoning_14\NN|NONE
15580403
D012254_D006461 NONE ribavirin_3\JJ|in (r_compound) reduction_4\NN|NONE (l_prep) in_5\IN|ribavirin (l_pobj) patients_6\NNS|NONE (l_prep) with_7\IN|NONE (l_pobj) hemolysis_8\NN|NONE
D012254_D006461 NONE ribavirin_15\RB|and (r_conj) interferon_13\NN|NONE (r_pobj) of_12\IN|for|combination (r_prep) therapy_11\NN|NONE (r_pobj) during_9\IN|NONE (r_prep) hemolysis_8\NN|NONE
D012254_D006461 NONE ribavirin_13\JJ|in (r_compound) reduction_14\NN|NONE (l_prep) in_15\IN|ribavirin (l_pobj) patients_16\NNS|NONE (l_prep) with_17\IN|NONE (l_pobj) hemolysis_18\NN|NONE
D012254_D000740 NONE ribavirin_9\NN|NONE (r_pobj) of_8\IN|NONE (r_prep) reduction_7\NN|NONE (r_pobj) with_6\IN| (r_prep) patients_5\NNS|therapy|.|However|,|not|could|decreased (r_nsubj) continue_12\VB|NONE (l_advcl) decreased_24\VBD|patients|therapy|.|However|,|not|could (l_conj) occurred_33\VBD|or|because|values|to (l_nsubj) effects_32\NNS|B|) (l_amod) related_29\VBN|severe|side (l_npadvmod) anemia_27\NN|
D007372_D019698 NONE interferon_13\NN|NONE (r_pobj) of_12\IN|for|combination (r_prep) therapy_11\NN|NONE (l_prep) for_16\IN|of|combination (l_pobj) C._19\NNP|NONE
D007372_D006461 NONE interferon_13\NN|NONE (r_pobj) of_12\IN|for|combination (r_prep) therapy_11\NN|NONE (r_pobj) during_9\IN|NONE (r_prep) hemolysis_8\NN|NONE
D007372_D000743 CID interferon_14\NN|NONE (r_pobj) of_13\IN|combination|the (r_prep) therapy_12\NN|NONE (r_pobj) of_9\IN|adverse|major|the (r_prep) events_8\NNS|NONE (r_pobj) of_4\IN|NONE (r_prep) one_3\CD|anemia|. (r_attr) is_2\VBZ|NONE (l_nsubj) anemia_1\NN|one|.
D012254_D019698 NONE ribavirin_3\JJ|in (r_compound) reduction_4\NN|NONE (l_prep) in_5\IN|ribavirin (l_pobj) patients_6\NNS|NONE (l_prep) with_7\IN|NONE (l_pobj) hemolysis_8\NN|NONE (l_prep) during_9\IN|NONE (l_pobj) therapy_11\NN|NONE (l_prep) for_16\IN|of|combination (l_pobj) C._19\NNP|NONE
D012254_D019698 NONE ribavirin_15\RB|and (r_conj) interferon_13\NN|NONE (r_pobj) of_12\IN|for|combination (r_prep) therapy_11\NN|NONE (l_prep) for_16\IN|of|combination (l_pobj) C._19\NNP|NONE
D012254_D000743 CID ribavirin_16\NN|and (r_conj) interferon_14\NN|NONE (r_pobj) of_13\IN|combination|the (r_prep) therapy_12\NN|NONE (r_pobj) of_9\IN|adverse|major|the (r_prep) events_8\NNS|NONE (r_pobj) of_4\IN|NONE (r_prep) one_3\CD|anemia|. (r_attr) is_2\VBZ|NONE (l_nsubj) anemia_1\NN|one|.
D012254_D000743 CID ribavirin_2\RB| (r_npadvmod) related_4\VBN|hemolytic (r_amod) anemia_6\NN|of
9022662
C064210_D001289 NONE oxazolidine_3\JJ|an|is (r_compound) derivative_4\NN|Pemoline|. (l_relcl) is_6\VBZ|an|oxazolidine (l_conj) used_12\VBN|that|different|and (l_prep) in_13\IN|NONE (l_pobj) treatment_15\NN|NONE (l_prep) of_16\IN|the (l_pobj) disorder_19\NN|NONE
D010389_D062787 CID pemoline_12\NN|NONE (r_compound) overdose_13\NN|NONE
D010389_D002819 CID Pemoline_0\NNP|choreoathetosis (r_nsubj) induced_1\VBD|:|.|review|and|case|of (l_dobj) choreoathetosis_3\NN|Pemoline
D010389_D002819 CID pemoline_9\NN|NONE (l_relcl) experienced_11\VBD|NONE (l_dobj) choreoathetosis_13\NN|who
D010389_D002819 CID pemoline_12\NN|NONE (r_compound) overdose_13\NN|NONE (r_pobj) after_11\IN|NONE (r_prep) presenting_10\VBG|NONE (r_acl) patients_9\NNS|NONE (r_pobj) in_8\IN|possibility|be|should|. (r_prep) considered_7\VBN|NONE (l_nsubjpass) possibility_1\NN|be|should|in|. (l_prep) of_2\IN|The (l_pobj) movements_4\NNS|NONE (l_compound) choreoathetoid_3\JJ|NONE
D010389_D001264 CID Pemoline_0\NNP|choreoathetosis (r_nsubj) induced_1\VBD|:|.|review|and|case|of (l_dobj) choreoathetosis_3\NN|Pemoline
D010389_D001264 CID pemoline_9\NN|NONE (l_relcl) experienced_11\VBD|NONE (l_dobj) choreoathetosis_13\NN|who
D010389_D001264 CID pemoline_12\NN|NONE (r_compound) overdose_13\NN|NONE (r_pobj) after_11\IN|NONE (r_prep) presenting_10\VBG|NONE (r_acl) patients_9\NNS|NONE (r_pobj) in_8\IN|possibility|be|should|. (r_prep) considered_7\VBN|NONE (l_nsubjpass) possibility_1\NN|be|should|in|. (l_prep) of_2\IN|The (l_pobj) movements_4\NNS|NONE (l_compound) choreoathetoid_3\JJ|NONE
D010389_D009069 NONE Pemoline_0\NNP|in|not|as|has|.|commonly|been (r_nsubjpass) associated_5\VBN|NONE (l_prep) as_9\IN|in|not|Pemoline|has|.|commonly|been (l_pobj) cause_11\NN|NONE (l_prep) of_12\IN|a (l_pobj) disorders_15\NNS|NONE
D010389_D009069 NONE Pemoline_0\NN|associated|movement (r_nmod) disorder_3\NN|rarely|.|in|been|has
D001569_D001264 NONE benzodiazepines_10\NNS|NONE (r_pobj) of_8\IN|high (r_prep) doses_7\NNS|gastrointestinal|and (r_conj) decontamination_4\NN|.|in|children (r_dobj) received_2\VBD|NONE (l_prep) in_11\IN|.|decontamination|children (l_pobj) attempt_13\NN|NONE (l_acl) control_15\VB|an (l_dobj) movements_18\NNS|to (l_compound) choreoathetoid_17\JJ|the
D001569_D002819 NONE benzodiazepines_10\NNS|NONE (r_pobj) of_8\IN|high (r_prep) doses_7\NNS|gastrointestinal|and (r_conj) decontamination_4\NN|.|in|children (r_dobj) received_2\VBD|NONE (l_prep) in_11\IN|.|decontamination|children (l_pobj) attempt_13\NN|NONE (l_acl) control_15\VB|an (l_dobj) movements_18\NNS|to (l_compound) choreoathetoid_17\JJ|the
D008774_D001289 NONE methylphenidate_14\NN|NONE (r_pobj) with_13\IN|without|previously (r_prep) treated_12\VBN|deficit (r_acl) disorder_10\NN|NONE
D000662_D001289 NONE amphetamines_10\NNS|NONE (r_pobj) from_9\IN|structurally (r_prep) different_8\JJ|that|and|used (r_acomp) is_6\VBZ|an|oxazolidine (l_conj) used_12\VBN|that|different|and (l_prep) in_13\IN|NONE (l_pobj) treatment_15\NN|NONE (l_prep) of_16\IN|the (l_pobj) disorder_19\NN|NONE
D010389_D001289 NONE Pemoline_0\NNP|derivative|. (r_nsubj) is_1\VBZ|NONE (l_attr) derivative_4\NN|Pemoline|. (l_relcl) is_6\VBZ|an|oxazolidine (l_conj) used_12\VBN|that|different|and (l_prep) in_13\IN|NONE (l_pobj) treatment_15\NN|NONE (l_prep) of_16\IN|the (l_pobj) disorder_19\NN|NONE
8829025
D016559_D006973 CID tacrolimus_5\NNS|NONE (r_dobj) receiving_4\VBG|NONE (r_acl) patients_3\NNS|NONE (r_pobj) of_2\IN|Two (r_prep) groups_1\NNS|over|group|.|were|, (r_nsubjpass) compared_7\VBN|NONE (l_appos) group_16\NN|over|.|were|groups|, (l_acl) comprising_17\VBG|and|other|,|one (l_dobj) patients_19\NNS|NONE (l_amod) hypertensive_18\JJ|receiving
D016559_D006973 CID tacrolimus_12\NN|NONE (r_pobj) with_11\IN|NONE (r_prep) associated_10\VBN|the (r_acl) nephrotoxicity_9\NN|NONE (r_dobj) reducing_7\VBG|NONE (r_pcomp) on_6\IN|observed|positive|The|of (r_prep) impact_3\NN|.|should|factor (r_nsubj) be_18\VB|NONE (l_attr) factor_21\NN|.|should|impact (l_prep) in_22\IN|an|important (l_pcomp) selecting_23\VBG|NONE (l_xcomp) treat_27\VB|agent (l_dobj) hypertension_28\NN|to
D016559_D007674 NONE tacrolimus_12\NN|NONE (r_pobj) with_11\IN|NONE (r_prep) associated_10\VBN|the (r_acl) nephrotoxicity_9\NN|NONE
D009543_D007674 NONE nifedipine_5\NN|NONE (r_pobj) of_4\IN|observed|positive|on|The (r_prep) impact_3\NN|.|should|factor (l_prep) on_6\IN|observed|positive|The|of (l_pcomp) reducing_7\VBG|NONE (l_dobj) nephrotoxicity_9\NN|NONE
D009543_D006973 NONE nifedipine_23\NN|were|who (r_dobj) receiving_22\VBG|hypertensive (r_relcl) patients_19\NNS|NONE (l_amod) hypertensive_18\JJ|receiving
D009543_D006973 NONE nifedipine_33\NN|not (r_dobj) receiving_32\VBG|nonhypertensive (r_acl) patients_30\NNS|NONE (r_dobj) comprising_28\VBG|the (r_acl) other_27\JJ|and|,|comprising|one (r_conj) group_16\NN|over|.|were|groups|, (l_acl) comprising_17\VBG|and|other|,|one (l_dobj) patients_19\NNS|NONE (l_amod) hypertensive_18\JJ|receiving
D009543_D006973 NONE nifedipine_5\NN|NONE (r_pobj) of_4\IN|observed|positive|on|The (r_prep) impact_3\NN|.|should|factor (r_nsubj) be_18\VB|NONE (l_attr) factor_21\NN|.|should|impact (l_prep) in_22\IN|an|important (l_pcomp) selecting_23\VBG|NONE (l_xcomp) treat_27\VB|agent (l_dobj) hypertension_28\NN|to
20195852
C038192_D007674 CID iopromide_17\JJ|contrast|(|two|CM|, (r_appos) media_12\NNS|NONE (r_pobj) for_8\IN|of|the (r_prep) incidence_5\NN|study|among|.|, (l_prep) of_6\IN|for|the (l_pobj) CIN_7\NNP|NONE
D007472_D003490 NONE iohexol_19\NN|and (r_conj) iopromide_17\JJ|contrast|(|two|CM|, (r_appos) media_12\NNS|NONE (r_pobj) for_8\IN|of|the (r_prep) incidence_5\NN|study|among|.|, (r_dobj) determined_3\VBD|NONE (l_prep) among_21\IN|incidence|study|.|, (l_conj) compared_29\VBD|patients|and (l_dobj) rates_31\NNS|NONE (l_prep) for_32\IN|the (l_pobj) complication_34\NN|NONE (l_prep) in_35\IN|this (l_pobj) relation_36\NN|NONE (l_prep) to_37\IN|NONE (l_pobj) type_39\NN|NONE (l_conj) presence_46\NN|of|the|and|and|dosage (l_prep) of_47\IN|the (l_pobj) cyanosis_48\NN|NONE
C038192_D003490 NONE iopromide_17\JJ|contrast|(|two|CM|, (r_appos) media_12\NNS|NONE (r_pobj) for_8\IN|of|the (r_prep) incidence_5\NN|study|among|.|, (r_dobj) determined_3\VBD|NONE (l_prep) among_21\IN|incidence|study|.|, (l_conj) compared_29\VBD|patients|and (l_dobj) rates_31\NNS|NONE (l_prep) for_32\IN|the (l_pobj) complication_34\NN|NONE (l_prep) in_35\IN|this (l_pobj) relation_36\NN|NONE (l_prep) to_37\IN|NONE (l_pobj) type_39\NN|NONE (l_conj) presence_46\NN|of|the|and|and|dosage (l_prep) of_47\IN|the (l_pobj) cyanosis_48\NN|NONE
D003287_D003490 NONE media_12\NNS|NONE (r_pobj) for_8\IN|of|the (r_prep) incidence_5\NN|study|among|.|, (r_dobj) determined_3\VBD|NONE (l_prep) among_21\IN|incidence|study|.|, (l_conj) compared_29\VBD|patients|and (l_dobj) rates_31\NNS|NONE (l_prep) for_32\IN|the (l_pobj) complication_34\NN|NONE (l_prep) in_35\IN|this (l_pobj) relation_36\NN|NONE (l_prep) to_37\IN|NONE (l_pobj) type_39\NN|NONE (l_conj) presence_46\NN|of|the|and|and|dosage (l_prep) of_47\IN|the (l_pobj) cyanosis_48\NN|NONE
D003287_D003490 NONE CM_14\NNP|contrast|iopromide|(|two|, (r_appos) media_12\NNS|NONE (r_pobj) for_8\IN|of|the (r_prep) incidence_5\NN|study|among|.|, (r_dobj) determined_3\VBD|NONE (l_prep) among_21\IN|incidence|study|.|, (l_conj) compared_29\VBD|patients|and (l_dobj) rates_31\NNS|NONE (l_prep) for_32\IN|the (l_pobj) complication_34\NN|NONE (l_prep) in_35\IN|this (l_pobj) relation_36\NN|NONE (l_prep) to_37\IN|NONE (l_pobj) type_39\NN|NONE (l_conj) presence_46\NN|of|the|and|and|dosage (l_prep) of_47\IN|the (l_pobj) cyanosis_48\NN|NONE
D003287_D003490 NONE CM_43\NNP|NONE (r_pobj) of_42\IN|presence|the|and|and|dosage (r_prep) type_39\NN|NONE (l_conj) presence_46\NN|of|the|and|and|dosage (l_prep) of_47\IN|the (l_pobj) cyanosis_48\NN|NONE
D003287_D003490 NONE CM_13\NNP|NONE (r_pobj) of_10\IN|the (r_prep) type_9\NN|nor|on|,|not (r_pobj) on_7\IN|dosage|but (l_conj) on_16\IN|nor|type|,|not (l_pobj) presence_18\NN|NONE (l_prep) of_19\IN|the (l_pobj) cyanosis_20\NN|NONE
D007472_D007674 CID iohexol_19\NN|and (r_conj) iopromide_17\JJ|contrast|(|two|CM|, (r_appos) media_12\NNS|NONE (r_pobj) for_8\IN|of|the (r_prep) incidence_5\NN|study|among|.|, (l_prep) of_6\IN|for|the (l_pobj) CIN_7\NNP|NONE
D003287_D007674 CID media_8\NNS|.|by|Risk (r_dobj) contrast_7\NN|NONE (l_nsubj) Risk_0\NN|media|.|by (l_prep) of_1\IN|after (l_pobj) nephropathy_2\NN|NONE
D003287_D007674 CID media_6\NNS| (r_npadvmod) induced_8\VBN|(|in|CIN (r_amod) nephropathy_9\NN|nonionic
D003287_D007674 CID media_6\NNS| (r_npadvmod) induced_8\VBN|(|in|CIN (r_amod) nephropathy_9\NN|nonionic (l_appos) CIN_11\NNP|(|in|induced
D003287_D007674 CID media_12\NNS|NONE (r_pobj) for_8\IN|of|the (r_prep) incidence_5\NN|study|among|.|, (l_prep) of_6\IN|for|the (l_pobj) CIN_7\NNP|NONE
D003287_D007674 CID CM_14\NNP|contrast|iopromide|(|two|, (r_appos) media_12\NNS|NONE (r_pobj) for_8\IN|of|the (r_prep) incidence_5\NN|study|among|.|, (l_prep) of_6\IN|for|the (l_pobj) CIN_7\NNP|NONE
D003287_D007674 CID CM_43\NNP|NONE (r_pobj) of_42\IN|presence|the|and|and|dosage (r_prep) type_39\NN|NONE (r_pobj) to_37\IN|NONE (r_prep) relation_36\NN|NONE (r_pobj) in_35\IN|this (r_prep) complication_34\NN|NONE (r_pobj) for_32\IN|the (r_prep) rates_31\NNS|NONE (r_dobj) compared_29\VBD|patients|and (r_conj) among_21\IN|incidence|study|.|, (r_prep) determined_3\VBD|NONE (l_dobj) incidence_5\NN|study|among|.|, (l_prep) of_6\IN|for|the (l_pobj) CIN_7\NNP|NONE
D003287_D007674 CID CM_17\NNP|NONE (r_pobj) of_16\IN|proper|the (r_prep) dosage_15\NN|who (r_dobj) received_12\VBD|NONE (r_relcl) those_10\DT|NONE (r_pobj) among_9\IN|%|Whereas (r_prep) were_8\VBD|percentage|to|with|)|,|,|among|. (l_nsubj) %_2\NN|among|Whereas (l_prep) of_3\IN|. (l_pobj) patients_5\NNS|NONE (l_prep) with_6\IN|the (l_pobj) CIN_7\NNP|NONE
D003287_D007674 CID CM_17\NNP|NONE (r_pobj) of_16\IN|proper|the (r_prep) dosage_15\NN|who (r_dobj) received_12\VBD|NONE (r_relcl) those_10\DT|NONE (r_pobj) among_9\IN|%|Whereas (r_prep) were_8\VBD|percentage|to|with|)|,|,|among|. (r_advcl) increased_21\VBD|NONE (l_prep) with_32\IN|percentage|to|)|,|,|were|among|. (l_pobj) difference_35\NN|NONE (l_prep) in_36\IN|significant|a (l_pobj) incidence_38\NN|NONE (l_prep) of_39\IN|related|the (l_pobj) CIN_40\NNP|NONE
D003287_D007674 CID CM_47\NNP|NONE (r_pobj) of_46\IN|the|different (r_prep) dosages_45\NNS|NONE (r_pobj) to_42\IN|NONE (r_prep) related_41\VBN|of|the (r_acl) incidence_38\NN|NONE (r_pobj) in_36\IN|significant|a (r_prep) difference_35\NN|NONE (r_pobj) with_32\IN|percentage|to|)|,|,|were|among|. (r_prep) increased_21\VBD|NONE (l_advcl) were_8\VBD|percentage|to|with|)|,|,|among|. (l_nsubj) %_2\NN|among|Whereas (l_prep) of_3\IN|. (l_pobj) patients_5\NNS|NONE (l_prep) with_6\IN|the (l_pobj) CIN_7\NNP|NONE
D003287_D007674 CID CM_47\NNP|NONE (r_pobj) of_46\IN|the|different (r_prep) dosages_45\NNS|NONE (r_pobj) to_42\IN|NONE (r_prep) related_41\VBN|of|the (r_acl) incidence_38\NN|NONE (l_prep) of_39\IN|related|the (l_pobj) CIN_40\NNP|NONE
D003287_D007674 CID CM_13\NNP|NONE (r_pobj) of_10\IN|the (r_prep) type_9\NN|nor|on|,|not (r_pobj) on_7\IN|dosage|but (r_conj) on_3\IN|incidence|needed|and|, (r_prep) depends_2\VBZ|NONE (l_conj) needed_32\VBN|incidence|and|on|, (l_advcl) is_26\VBZ|concern|.|is|,|for (l_nsubj) CIN_24\NNP|usually|reversible|although
16725121
D003891_D012640 NONE desipramine_12\NN|NONE (r_pobj) of_11\IN|chronic (r_prep) administration_10\NN|NONE (r_pobj) by_8\IN|linking (r_agent) induced_7\VBN|of||Down|. (l_xcomp) linking_13\VBG|by (l_prep) to_14\IN|NONE (l_pobj) alteration_16\NN|NONE (l_prep) of_17\IN|and|the|counteraction (l_pobj) sensitivity_18\NN|NONE (l_prep) of_19\IN|NONE (l_pobj) convulsions_25\NNS|NONE
D003891_D012640 NONE desipramine_3\NN|NONE (r_pobj) of_2\IN|Daily (r_prep) administration_1\NN|decreased|.|and|incidence (r_nsubj) increased_4\VBD|NONE (l_dobj) incidence_6\NN|decreased|.|and|administration (l_prep) of_7\IN|the (l_pobj) appearance_8\NN|NONE (l_prep) of_9\IN|NONE (l_pobj) convulsions_13\NNS|NONE
D003891_D012640 NONE desipramine_3\NN|NONE (r_pobj) of_2\IN|Daily (r_prep) administration_1\NN|decreased|.|and|incidence (r_nsubj) increased_4\VBD|NONE (l_conj) decreased_15\VBD|.|and|administration|incidence (l_dobj) that_16\DT|NONE (l_prep) of_17\IN|NONE (l_pobj) convulsions_21\NNS|NONE
D003891_D012640 NONE desipramine_6\NN|NONE (r_pobj) with_5\IN|NONE (r_prep) lidocaine_4\NN|NONE (r_pobj) of_3\IN|Co| (r_prep) administration_2\NN|.|changes (r_nsubj) reversed_7\VBD|NONE (l_dobj) changes_9\NNS|administration|. (l_prep) of_10\IN|the|induced (l_pobj) activity_12\NN|NONE (l_amod) convulsive_11\JJ|of
D003891_D012640 NONE desipramine_22\NN|NONE (r_pobj) of_21\IN|repeated (r_prep) administration_20\NN|NONE (r_pobj) by_18\IN|NONE (r_agent) induced_17\VBN|the|of (r_acl) changes_9\NNS|administration|. (l_prep) of_10\IN|the|induced (l_pobj) activity_12\NN|NONE (l_amod) convulsive_11\JJ|of
D003891_D012640 NONE desipramine_15\NN|NONE (r_pobj) of_14\IN|chronic (r_prep) administration_13\NN|NONE (r_pobj) by_11\IN|NONE (r_agent) induced_10\VBN|of||down (r_acl) regulation_6\NN|that|may|relevant (r_nsubj) be_17\VB|.|results (l_acomp) relevant_18\JJ|regulation|that|may (l_prep) to_19\IN|NONE (l_pobj) sensitization_23\NN|NONE (l_prep) of_24\IN|induced (l_pobj) convulsions_26\NNS|NONE
D003891_D012640 NONE desipramine_20\NN| (r_advmod) induced_22\VBN|of (r_amod) sensitization_23\NN|NONE (l_prep) of_24\IN|induced (l_pobj) convulsions_26\NNS|NONE
D003891_D012640 NONE Desipramine_0\NN| (r_nsubj) induced_2\VBN|of (r_amod) sensitization_3\NN|.|may|mechanism (l_prep) of_4\IN|induced (l_pobj) seizures_6\NNS|NONE
D008012_D012640 CID lidocaine_10\NN| (r_npadvmod) induced_12\VBN|NONE (r_amod) convulsions_13\NNS|NONE
D008012_D012640 CID lidocaine_10\NN| (r_npadvmod) induced_12\VBN|NONE (r_amod) convulsions_13\NNS|NONE (r_pobj) of_9\IN|NONE (r_prep) appearance_8\NN|NONE (r_pobj) of_7\IN|the (r_prep) incidence_6\NN|decreased|.|and|administration (r_dobj) increased_4\VBD|NONE (l_conj) decreased_15\VBD|.|and|administration|incidence (l_dobj) that_16\DT|NONE (l_prep) of_17\IN|NONE (l_pobj) convulsions_21\NNS|NONE
D008012_D012640 CID lidocaine_4\NN|NONE (r_pobj) of_3\IN|Co| (r_prep) administration_2\NN|.|changes (r_nsubj) reversed_7\VBD|NONE (l_dobj) changes_9\NNS|administration|. (l_prep) of_10\IN|the|induced (l_pobj) activity_12\NN|NONE (l_amod) convulsive_11\JJ|of
D008012_D012640 CID lidocaine_14\NN|NONE (r_pobj) of_13\IN|convulsive (r_prep) activity_12\NN|NONE (l_amod) convulsive_11\JJ|of
D008012_D012640 CID lidocaine_25\NN|NONE (r_compound) convulsions_26\NNS|NONE
D008012_D012640 CID lidocaine_5\NN|NONE (r_compound) seizures_6\NNS|NONE
D009638_D012640 NONE norepinephrine_4\NN|transporter (r_amod) function_6\NN|NONE (r_pobj) of_3\IN||Down|induced|. (r_prep) regulation_2\NN|NONE (l_acl) induced_7\VBN|of||Down|. (l_xcomp) linking_13\VBG|by (l_prep) to_14\IN|NONE (l_pobj) alteration_16\NN|NONE (l_prep) of_17\IN|and|the|counteraction (l_pobj) sensitivity_18\NN|NONE (l_prep) of_19\IN|NONE (l_pobj) convulsions_25\NNS|NONE
D009638_D012640 NONE norepinephrine_2\NN|)|NET (r_compound) transporter_3\NN|by (r_nmod) function_7\NN|NONE (l_prep) by_8\IN|transporter (l_pobj) inhibition_10\NN|NONE (l_prep) in_13\IN|of|chronic (l_pobj) relation_14\NN|NONE (l_prep) to_15\IN|NONE (l_pobj) sensitization_16\NN|NONE (l_prep) to_17\IN|NONE (l_pobj) seizures_18\NNS|NONE
D003042_D012640 CID cocaine_21\NN|NONE (r_pobj) by_20\IN|NONE (r_agent) induce_19\VB|NONE (r_acl) seizures_18\NNS|NONE
D003042_D012640 CID cocaine_18\NN| (r_npadvmod) induced_20\VBN|NONE (r_amod) convulsions_21\NNS|NONE (r_pobj) of_17\IN|NONE (r_prep) that_16\DT|NONE (r_dobj) decreased_15\VBD|.|and|administration|incidence (r_conj) increased_4\VBD|NONE (l_dobj) incidence_6\NN|decreased|.|and|administration (l_prep) of_7\IN|the (l_pobj) appearance_8\NN|NONE (l_prep) of_9\IN|NONE (l_pobj) convulsions_13\NNS|NONE
D003042_D012640 CID cocaine_18\NN| (r_npadvmod) induced_20\VBN|NONE (r_amod) convulsions_21\NNS|NONE
D003042_D012640 CID cocaine_16\NN|and (r_conj) lidocaine_14\NN|NONE (r_pobj) of_13\IN|convulsive (r_prep) activity_12\NN|NONE (l_amod) convulsive_11\JJ|of
D003042_D012640 CID cocaine_19\NN|NONE (r_pobj) of_18\IN|repeated (r_prep) administration_17\NN|NONE (r_pobj) from_15\IN|NONE (r_prep) resulting_14\VBG|NONE (r_acl) kindling_13\VBG|NONE (r_pobj) from_12\IN|NONE (r_prep) distinct_11\JJ|a (r_amod) mechanism_10\NN|.|may|sensitization (r_dobj) have_8\VB|NONE (l_nsubj) sensitization_3\NN|.|may|mechanism (l_prep) of_4\IN|induced (l_pobj) seizures_6\NNS|NONE
19843802
D004837_D006973 CID epinephrine_5\NN|NONE (r_pobj) of_4\IN|injected|a (r_prep) bolus_3\NN|However|.|crisis|, (r_nsubj) provoked_11\VBD|NONE (l_dobj) crisis_14\NN|However|bolus|.|, (l_amod) hypertensive_13\JJ|a
6637851
D000638_D006323 NONE Amiodarone_0\NNP|was|to|. (r_nsubjpass) administered_2\VBN|NONE (l_prep) to_3\IN|Amiodarone|was|. (l_pobj) patients_5\NNS|NONE (l_conj) arrest_24\NN|or||sustained|
D000638_D064420 NONE amiodarone_10\NN|dose (r_compound) therapy_11\NN|NONE (r_pobj) of_6\IN|NONE (r_prep) toxicity_5\NN|and|for|.|term
D000638_D064420 NONE amiodarone_4\NN|in|effective|Although (r_nsubj) is_5\VBZ|it|toxicity|,|. (r_advcl) causes_25\VBZ|NONE (l_dobj) toxicity_27\NN|it|,|.|is
D000638_D014693 NONE amiodarone_10\NN|dose (r_compound) therapy_11\NN|NONE (r_pobj) of_6\IN|NONE (r_prep) toxicity_5\NN|and|for|.|term (r_conj) efficacy_3\NN|NONE (l_prep) for_12\IN|and|.|toxicity|term (l_pobj) tachycardia_14\NN|NONE (l_conj) fibrillation_17\NN|or|ventricular
D000638_D014693 NONE amiodarone_9\NN|NONE (r_pobj) with_8\IN|NONE (r_prep) treatment_7\NN|and|had|percent|. (r_dobj) continued_6\VBD|NONE (l_conj) had_11\VBD|and|treatment|percent|. (l_dobj) recurrence_13\NN|NONE (l_prep) of_14\IN|no|over (l_pobj) VT_16\NNP|NONE (l_conj) fibrillation_19\NN|(|)|symptomatic|or|VF
D000638_D014693 NONE amiodarone_9\NN|NONE (r_pobj) with_8\IN|NONE (r_prep) treatment_7\NN|and|had|percent|. (r_dobj) continued_6\VBD|NONE (l_conj) had_11\VBD|and|treatment|percent|. (l_dobj) recurrence_13\NN|NONE (l_prep) of_14\IN|no|over (l_pobj) VT_16\NNP|NONE (l_appos) VF_21\NNP|(|)|symptomatic|fibrillation|or
D000638_D014693 NONE amiodarone_4\NN|in|effective|Although (r_nsubj) is_5\VBZ|it|toxicity|,|. (l_prep) in_8\IN|effective|Although|amiodarone (l_pobj) treatment_13\NN|NONE (l_prep) of_14\IN|the|term (l_pobj) VT_15\NNP|NONE (l_conj) refractory_18\NN|or (l_compound) VF_17\NNP|to
D000638_D014693 NONE amiodarone_31\NN|NONE (r_pobj) with_30\IN|successfully|,|However|,|.|can|%|adjusted|be (r_prep) managed_29\VBN|NONE (l_nsubjpass) %_19\NN|successfully|,|However|,|.|can|adjusted|with|be (l_prep) of_20\IN| (l_pobj) patients_21\NNS|NONE (l_prep) with_22\IN|NONE (l_pobj) VT_23\NNP|NONE (l_conj) VF_25\NNP|or
D000638_D017180 NONE amiodarone_10\NN|dose (r_compound) therapy_11\NN|NONE (r_pobj) of_6\IN|NONE (r_prep) toxicity_5\NN|and|for|.|term (r_conj) efficacy_3\NN|NONE (l_prep) for_12\IN|and|.|toxicity|term (l_pobj) tachycardia_14\NN|NONE
D000638_D017180 NONE Amiodarone_0\NNP|was|to|. (r_nsubjpass) administered_2\VBN|NONE (l_prep) to_3\IN|Amiodarone|was|. (l_pobj) patients_5\NNS|NONE (l_relcl) sustained_8\VBN|or|||arrest (l_dobj) tachycardia_12\NN|had|who|,
D000638_D017180 NONE Amiodarone_0\NNP|was|to|. (r_nsubjpass) administered_2\VBN|NONE (l_prep) to_3\IN|Amiodarone|was|. (l_pobj) patients_5\NNS|NONE (l_relcl) sustained_8\VBN|or|||arrest (l_dobj) tachycardia_12\NN|had|who|, (l_appos) VT_14\NNP|(|symptomatic|)|ventricular
D000638_D017180 NONE amiodarone_9\NN|NONE (r_pobj) with_8\IN|NONE (r_prep) treatment_7\NN|and|had|percent|. (r_dobj) continued_6\VBD|NONE (l_conj) had_11\VBD|and|treatment|percent|. (l_dobj) recurrence_13\NN|NONE (l_prep) of_14\IN|no|over (l_pobj) VT_16\NNP|NONE
D000638_D017180 NONE amiodarone_17\NN|NONE (r_pobj) by_15\IN|successfully|were (r_agent) managed_14\VBN|recurrence|and|percent|. (r_conj) had_5\VBD|NONE (l_dobj) recurrence_8\NN|and|percent|.|managed (l_prep) of_9\IN|a|nonfatal (l_pobj) VT_10\NNP|NONE
D000638_D017180 NONE amiodarone_4\NN|in|effective|Although (r_nsubj) is_5\VBZ|it|toxicity|,|. (l_prep) in_8\IN|effective|Although|amiodarone (l_pobj) treatment_13\NN|NONE (l_prep) of_14\IN|the|term (l_pobj) VT_15\NNP|NONE
D000638_D017180 NONE amiodarone_31\NN|NONE (r_pobj) with_30\IN|successfully|,|However|,|.|can|%|adjusted|be (r_prep) managed_29\VBN|NONE (l_nsubjpass) %_19\NN|successfully|,|However|,|.|can|adjusted|with|be (l_prep) of_20\IN| (l_pobj) patients_21\NNS|NONE (l_prep) with_22\IN|NONE (l_pobj) VT_23\NNP|NONE
16428827
D002794_D000647 NONE choline_2\NN|NONE (r_compound) acetyltransferase_3\NN|improves|Daidzein|.|and|from (r_dobj) activates_1\VBZ|NONE (l_conj) improves_10\VBZ|acetyltransferase|Daidzein|.|and|from (l_dobj) amnesia_14\NN|NONE
D012601_D008569 NONE scopolamine_12\NN| (r_npadvmod) induced_14\VBN|of (r_amod) impairments_15\NNS|NONE (l_prep) of_16\IN|induced (l_pobj) learning_17\NN|NONE (l_conj) memory_19\NN|and
D002794_D000544 NONE choline_1\NN|activator|The|, (r_compound) acetyltransferase_2\NN|factor|. (r_nsubj) is_25\VBZ|NONE (l_attr) factor_28\NN|.|acetyltransferase (l_prep) in_29\IN|important|an (l_pobj) treatment_31\NN|NONE (l_prep) of_32\IN|the (l_pobj) disease_35\NN|NONE
D002794_D000544 NONE choline_1\NN|activator|The|, (r_compound) acetyltransferase_2\NN|factor|. (r_nsubj) is_25\VBZ|NONE (l_attr) factor_28\NN|.|acetyltransferase (l_prep) in_29\IN|important|an (l_pobj) treatment_31\NN|NONE (l_prep) of_32\IN|the (l_pobj) disease_35\NN|NONE (l_appos) AD_37\NN|)|Alzheimer
C004742_D000647 NONE Daidzein_0\NNP|acetyltransferase|improves|.|and|from (r_nsubj) activates_1\VBZ|NONE (l_conj) improves_10\VBZ|acetyltransferase|Daidzein|.|and|from (l_dobj) amnesia_14\NN|NONE
C004742_D000647 NONE daidzein_2\NN|NONE (r_pobj) of_1\IN|to|weight (r_prep) Administration_0\NN|was|.|according|,|significantly|reverse (r_nsubjpass) shown_12\VBN|NONE (l_xcomp) reverse_15\VB|Administration|was|.|according|,|significantly (l_dobj) amnesia_19\NN|to
C004742_D000647 NONE daidzein_4\NN|role|and|as|might|ameliorates|,|that (r_nsubj) play_6\VB|.|results (l_conj) ameliorates_21\VBZ|role|and|as|might|daidzein|,|that (l_dobj) amnesia_25\NN|also|it|that
D000109_D000544 NONE acetylcholine_20\NN|( (r_nmod) ACh_22\NNS|NONE (r_pobj) of_19\IN|enzymatic|the (r_prep) production_18\NN|NONE (r_pobj) of_15\IN|an (r_prep) augmentation_14\NN|NONE (r_pobj) via_12\IN|transmission|which (r_prep) enhances_9\VBZ|,|)|(|)|ChAT (r_relcl) activator_6\NN|choline|The|, (r_appos) acetyltransferase_2\NN|factor|. (r_nsubj) is_25\VBZ|NONE (l_attr) factor_28\NN|.|acetyltransferase (l_prep) in_29\IN|important|an (l_pobj) treatment_31\NN|NONE (l_prep) of_32\IN|the (l_pobj) disease_35\NN|NONE
D000109_D000544 NONE acetylcholine_20\NN|( (r_nmod) ACh_22\NNS|NONE (r_pobj) of_19\IN|enzymatic|the (r_prep) production_18\NN|NONE (r_pobj) of_15\IN|an (r_prep) augmentation_14\NN|NONE (r_pobj) via_12\IN|transmission|which (r_prep) enhances_9\VBZ|,|)|(|)|ChAT (r_relcl) activator_6\NN|choline|The|, (r_appos) acetyltransferase_2\NN|factor|. (r_nsubj) is_25\VBZ|NONE (l_attr) factor_28\NN|.|acetyltransferase (l_prep) in_29\IN|important|an (l_pobj) treatment_31\NN|NONE (l_prep) of_32\IN|the (l_pobj) disease_35\NN|NONE (l_appos) AD_37\NN|)|Alzheimer
D000109_D000544 NONE ACh_22\NNS|NONE (r_pobj) of_19\IN|enzymatic|the (r_prep) production_18\NN|NONE (r_pobj) of_15\IN|an (r_prep) augmentation_14\NN|NONE (r_pobj) via_12\IN|transmission|which (r_prep) enhances_9\VBZ|,|)|(|)|ChAT (r_relcl) activator_6\NN|choline|The|, (r_appos) acetyltransferase_2\NN|factor|. (r_nsubj) is_25\VBZ|NONE (l_attr) factor_28\NN|.|acetyltransferase (l_prep) in_29\IN|important|an (l_pobj) treatment_31\NN|NONE (l_prep) of_32\IN|the (l_pobj) disease_35\NN|NONE
D000109_D000544 NONE ACh_22\NNS|NONE (r_pobj) of_19\IN|enzymatic|the (r_prep) production_18\NN|NONE (r_pobj) of_15\IN|an (r_prep) augmentation_14\NN|NONE (r_pobj) via_12\IN|transmission|which (r_prep) enhances_9\VBZ|,|)|(|)|ChAT (r_relcl) activator_6\NN|choline|The|, (r_appos) acetyltransferase_2\NN|factor|. (r_nsubj) is_25\VBZ|NONE (l_attr) factor_28\NN|.|acetyltransferase (l_prep) in_29\IN|important|an (l_pobj) treatment_31\NN|NONE (l_prep) of_32\IN|the (l_pobj) disease_35\NN|NONE (l_appos) AD_37\NN|)|Alzheimer
C004742_D008569 NONE daidzein_7\NN|NONE (r_pobj) of_6\IN|from|the (r_prep) effects_5\NNS|to (l_prep) from_8\IN|of|the (l_pobj) thunbergiana_10\NNS|NONE (l_prep) on_11\IN|Pueraria (l_pobj) impairments_15\NNS|NONE (l_prep) of_16\IN|induced (l_pobj) learning_17\NN|NONE (l_conj) memory_19\NN|and
D000109_D000647 NONE acetylcholine_10\NN|NONE (r_compound) biosynthesis_11\NN|NONE (r_pobj) in_9\IN|a (r_prep) role_8\NN|and|as|might|ameliorates|daidzein|,|that (r_dobj) play_6\VB|.|results (l_conj) ameliorates_21\VBZ|role|and|as|might|daidzein|,|that (l_dobj) amnesia_25\NN|also|it|that
D012601_D000647 CID scopolamine_16\NN| (r_npadvmod) induced_18\VBN|NONE (r_amod) amnesia_19\NN|to
D012601_D000647 CID scopolamine_22\NN| (r_npadvmod) induced_24\VBN|NONE (r_amod) amnesia_25\NN|also|it|that
D012601_D007859 NONE scopolamine_12\NN| (r_npadvmod) induced_14\VBN|of (r_amod) impairments_15\NNS|NONE (l_prep) of_16\IN|induced (l_pobj) learning_17\NN|NONE (l_conj) memory_19\NN|and
C004742_D007859 NONE daidzein_7\NN|NONE (r_pobj) of_6\IN|from|the (r_prep) effects_5\NNS|to (l_prep) from_8\IN|of|the (l_pobj) thunbergiana_10\NNS|NONE (l_prep) on_11\IN|Pueraria (l_pobj) impairments_15\NNS|NONE (l_prep) of_16\IN|induced (l_pobj) learning_17\NN|NONE (l_conj) memory_19\NN|and
3300918
D002118_D004881 NONE calcium_4\NN|NONE (r_compound) channel_5\NN|and|antagonists (r_compound) blockers_6\NNS|NONE (r_pobj) of_3\IN|the (r_prep) advent_2\NN|NONE (r_pobj) Despite_0\IN|play|,|persists|preparations|,|. (r_prep) continue_15\VBP|NONE (l_advcl) persists_34\VBZ|play|,|preparations|,|Despite|. (l_nsubj) danger_28\NN|that|so (l_prep) of_29\IN|the (l_pobj) fire_33\NN|NONE
D008784_D014652 CID methysergide_20\NN|NONE (r_pobj) of_19\IN|by|the (r_prep) ingestion_18\NN|NONE (r_pobj) to_16\IN|,|is|secondary|case|. (r_prep) described_14\VBN|NONE (l_nsubjpass) case_2\NN|,|is|secondary|.|to (l_prep) of_3\IN|,|with|rare|A (l_pobj) vasospasm_5\NN|NONE
D002118_D008881 NONE calcium_4\NN|NONE (r_compound) channel_5\NN|and|antagonists (r_compound) blockers_6\NNS|NONE (r_pobj) of_3\IN|the (r_prep) advent_2\NN|NONE (r_pobj) Despite_0\IN|play|,|persists|preparations|,|. (r_prep) continue_15\VBP|NONE (l_xcomp) play_17\VB|,|persists|preparations|,|Despite|. (l_dobj) role_20\NN|to (l_prep) in_21\IN|a|major (l_pobj) therapy_23\NN|NONE (l_compound) migraine_22\NN|NONE
D004876_D008881 CID ergot_6\NN|NONE (r_pobj) of_5\IN|the (r_prep) history_4\NN|NONE (r_pobj) of_2\IN|A (r_prep) discussion_1\NN|.|discovery (r_nsubj) includes_7\VBZ|NONE (l_dobj) discovery_10\NN|.|discussion (l_appos) epidemics_13\NNS|original|,|its (l_relcl) caused_19\VBN|the|of (l_prep) through_20\IN|that|has|it (l_pobj) ages_22\NNS|NONE (l_conj) role_28\NN|the|and (l_prep) in_29\IN|past|its (l_pobj) management_31\NN|NONE (l_prep) of_32\IN|the (l_pobj) headache_34\NN|NONE
D004876_D008881 CID ergot_13\NN|NONE (r_compound) preparations_14\NNS|play|,|persists|,|Despite|. (r_nsubj) continue_15\VBP|NONE (l_xcomp) play_17\VB|,|persists|preparations|,|Despite|. (l_dobj) role_20\NN|to (l_prep) in_21\IN|a|major (l_pobj) therapy_23\NN|NONE (l_compound) migraine_22\NN|NONE
D004876_D004881 NONE ergot_13\NN|NONE (r_compound) preparations_14\NNS|play|,|persists|,|Despite|. (r_nsubj) continue_15\VBP|NONE (l_advcl) persists_34\VBZ|play|,|preparations|,|Despite|. (l_nsubj) danger_28\NN|that|so (l_prep) of_29\IN|the (l_pobj) fire_33\NN|NONE
D004876_D005734 NONE ergot_6\NN|NONE (r_pobj) of_5\IN|the (r_prep) history_4\NN|NONE (r_pobj) of_2\IN|A (r_prep) discussion_1\NN|.|discovery (r_nsubj) includes_7\VBZ|NONE (l_dobj) discovery_10\NN|.|discussion (l_appos) epidemics_13\NNS|original|,|its (l_prep) of_14\IN|caused|the (l_pobj) gangrene_15\NN|NONE
2670794
D002216_D051437 NONE Captopril_9\NNP|)|( (r_appos) enzyme_7\NN|on (r_dobj) converting_6\VBG|NONE (l_prep) on_11\IN|enzyme (l_pobj) insufficiency_15\NN|NONE
D002216_D051437 NONE Captopril_2\NNP|NONE (r_pobj) of_1\IN|,|)|mg/kg|(|inhibitor|, (r_prep) Injection_0\NN|insufficiency|. (r_nsubj) reduced_18\VBD|NONE (l_dobj) insufficiency_23\NN|Injection|.
D014148_D011665 NONE acid_14\NN|and (r_conj) thrombin_11\NN|NONE (r_pobj) of_10\IN|in (r_prep) injection_9\NN|NONE (r_pobj) by_8\IN|of (r_prep) Induction_0\NN|resembling|rise|. (r_nsubj) gives_21\VBZ|NONE (l_dobj) rise_22\NN|resembling|.|Induction (l_prep) to_23\IN|NONE (l_pobj) insufficiency_27\NN|NONE
D014148_D011665 NONE AMCA_16\NNP|tranexamic (r_appos) acid_14\NN|and (r_conj) thrombin_11\NN|NONE (r_pobj) of_10\IN|in (r_prep) injection_9\NN|NONE (r_pobj) by_8\IN|of (r_prep) Induction_0\NN|resembling|rise|. (r_nsubj) gives_21\VBZ|NONE (l_dobj) rise_22\NN|resembling|.|Induction (l_prep) to_23\IN|NONE (l_pobj) insufficiency_27\NN|NONE
D000809_D011665 NONE angiotensin_5\NN|NONE (l_acl) converting_6\VBG|NONE (l_prep) on_11\IN|enzyme (l_pobj) insufficiency_15\NN|NONE
D000809_D011665 NONE angiotensin_11\NN|NONE (r_pobj) of_10\IN|an (r_prep) inhibitor_9\NN|of|,|)|mg/kg|(|, (r_appos) Injection_0\NN|insufficiency|. (r_nsubj) reduced_18\VBD|NONE (l_dobj) insufficiency_23\NN|Injection|.
D002216_D007674 NONE Captopril_17\NNP|NONE (r_pobj) by_16\IN|.|damage|was (r_agent) prevented_15\VBN|NONE (l_nsubjpass) damage_1\NN|.|by|was
D002216_D007674 NONE Captopril_0\NNP|.|,|increase|,|diminishing|by|,|may (r_nsubj) reduce_8\VB|NONE (l_advcl) diminishing_26\VBG|.|,|increase|,|by|,|may|Captopril (l_prep) with_36\IN|aggregation|,|thereby (l_pobj) result_38\NN|NONE (l_acl) deposited_44\VBN|the (l_conj) produced_52\VBN|will|and|that|be|fibrin (l_nsubjpass) damage_49\NN|will|be
D002216_D004211 NONE Captopril_9\NNP|)|( (r_appos) enzyme_7\NN|on (r_dobj) converting_6\VBG|NONE (r_acl) angiotensin_5\NN|NONE (r_pobj) of_4\IN|an (r_prep) inhibitor_3\NN|NONE (r_pobj) of_1\IN|.|due (r_prep) Effects_0\NNS|NONE (l_amod) due_16\IN|of|. (l_pobj) coagulation_19\NN|to
D014148_D014947 NONE acid_14\NN|and (r_conj) thrombin_11\NN|NONE (r_pobj) of_10\IN|in (r_prep) injection_9\NN|NONE (r_pobj) by_8\IN|of (r_prep) Induction_0\NN|resembling|rise|. (r_nsubj) gives_21\VBZ|NONE (l_advcl) resembling_28\VBG|rise|.|Induction (l_ccomp) occurring_30\VBG|NONE (l_prep) after_31\IN|that (l_pobj) trauma_32\NN|NONE
D014148_D014947 NONE AMCA_16\NNP|tranexamic (r_appos) acid_14\NN|and (r_conj) thrombin_11\NN|NONE (r_pobj) of_10\IN|in (r_prep) injection_9\NN|NONE (r_pobj) by_8\IN|of (r_prep) Induction_0\NN|resembling|rise|. (r_nsubj) gives_21\VBZ|NONE (l_advcl) resembling_28\VBG|rise|.|Induction (l_ccomp) occurring_30\VBG|NONE (l_prep) after_31\IN|that (l_pobj) trauma_32\NN|NONE
D014148_D004211 CID acid_14\NN|and (r_conj) thrombin_11\NN|NONE (r_pobj) of_10\IN|in (r_prep) injection_9\NN|NONE (r_pobj) by_8\IN|of (r_prep) Induction_0\NN|resembling|rise|. (l_prep) of_1\IN|by (l_pobj) coagulation_3\NN|NONE
D014148_D004211 CID AMCA_16\NNP|tranexamic (r_appos) acid_14\NN|and (r_conj) thrombin_11\NN|NONE (r_pobj) of_10\IN|in (r_prep) injection_9\NN|NONE (r_pobj) by_8\IN|of (r_prep) Induction_0\NN|resembling|rise|. (l_prep) of_1\IN|by (l_pobj) coagulation_3\NN|NONE
D000809_D004211 NONE angiotensin_5\NN|NONE (r_pobj) of_4\IN|an (r_prep) inhibitor_3\NN|NONE (r_pobj) of_1\IN|.|due (r_prep) Effects_0\NNS|NONE (l_amod) due_16\IN|of|. (l_pobj) coagulation_19\NN|to
D002216_D011665 NONE Captopril_9\NNP|)|( (r_appos) enzyme_7\NN|on (r_dobj) converting_6\VBG|NONE (l_prep) on_11\IN|enzyme (l_pobj) insufficiency_15\NN|NONE
D002216_D011665 NONE Captopril_2\NNP|NONE (r_pobj) of_1\IN|,|)|mg/kg|(|inhibitor|, (r_prep) Injection_0\NN|insufficiency|. (r_nsubj) reduced_18\VBD|NONE (l_dobj) insufficiency_23\NN|Injection|.
D014508_D007674 NONE urea_9\NN|in|and (r_pobj) in_7\IN|an (r_prep) increase_6\NN|NONE (r_pobj) by_4\IN|as (r_agent) reflected_3\VBN|Renal (r_advcl) damage_1\NN|.|by|was
D014148_D018805 NONE acid_14\NN|and (r_conj) thrombin_11\NN|NONE (r_pobj) of_10\IN|in (r_prep) injection_9\NN|NONE (r_pobj) by_8\IN|of (r_prep) Induction_0\NN|resembling|rise|. (r_nsubj) gives_21\VBZ|NONE (l_advcl) resembling_28\VBG|rise|.|Induction (l_ccomp) occurring_30\VBG|NONE (l_prep) after_31\IN|that (l_pobj) trauma_32\NN|NONE (l_conj) sepsis_34\NN|or|in
D014148_D018805 NONE AMCA_16\NNP|tranexamic (r_appos) acid_14\NN|and (r_conj) thrombin_11\NN|NONE (r_pobj) of_10\IN|in (r_prep) injection_9\NN|NONE (r_pobj) by_8\IN|of (r_prep) Induction_0\NN|resembling|rise|. (r_nsubj) gives_21\VBZ|NONE (l_advcl) resembling_28\VBG|rise|.|Induction (l_ccomp) occurring_30\VBG|NONE (l_prep) after_31\IN|that (l_pobj) trauma_32\NN|NONE (l_conj) sepsis_34\NN|or|in
D014148_D051437 NONE acid_14\NN|and (r_conj) thrombin_11\NN|NONE (r_pobj) of_10\IN|in (r_prep) injection_9\NN|NONE (r_pobj) by_8\IN|of (r_prep) Induction_0\NN|resembling|rise|. (r_nsubj) gives_21\VBZ|NONE (l_dobj) rise_22\NN|resembling|.|Induction (l_prep) to_23\IN|NONE (l_pobj) insufficiency_27\NN|NONE
D014148_D051437 NONE AMCA_16\NNP|tranexamic (r_appos) acid_14\NN|and (r_conj) thrombin_11\NN|NONE (r_pobj) of_10\IN|in (r_prep) injection_9\NN|NONE (r_pobj) by_8\IN|of (r_prep) Induction_0\NN|resembling|rise|. (r_nsubj) gives_21\VBZ|NONE (l_dobj) rise_22\NN|resembling|.|Induction (l_prep) to_23\IN|NONE (l_pobj) insufficiency_27\NN|NONE
D000809_D051437 NONE angiotensin_5\NN|NONE (l_acl) converting_6\VBG|NONE (l_prep) on_11\IN|enzyme (l_pobj) insufficiency_15\NN|NONE
D000809_D051437 NONE angiotensin_11\NN|NONE (r_pobj) of_10\IN|an (r_prep) inhibitor_9\NN|of|,|)|mg/kg|(|, (r_appos) Injection_0\NN|insufficiency|. (r_nsubj) reduced_18\VBD|NONE (l_dobj) insufficiency_23\NN|Injection|.
2515254
D005996_D008881 CID nitroglycerin_11\NN|NONE (r_pobj) of_10\IN|one|sided|frontotemporal|a (r_prep) application_9\NN|patients|. (r_dobj) received_4\VBD|NONE (l_nsubj) patients_3\NNS|application|. (l_compound) migraine_2\NN|Twenty|common
D005996_D008881 CID nitroglycerin_7\NN|NONE (r_pobj) by_6\IN|in|attacks|.|were (r_agent) induced_5\VBN|NONE (l_nsubjpass) attacks_3\NNS|in|.|were|by (l_compound) migraine_2\NN|onset|Early
D005996_D008881 CID nitroglycerin_13\NN|NONE (r_pobj) with_11\IN|early|an|onset (r_prep) attack_10\NN|who (r_dobj) developed_6\VBD|migraine||,|, (r_relcl) patients_3\NNS|drug|in|Subsequently|. (l_compound) migraine_2\NN||developed|,|,
D005996_D008881 CID nitroglycerin_7\NN|NONE (r_pobj) of_6\IN|inducing|the (r_prep) effect_5\NN|Thus|suggesting|.|depend|, (l_amod) inducing_4\VBG|of|the (l_npadvmod) migraine_2\NN|
D005996_D008881 CID nitroglycerin_7\NN|NONE (r_pobj) of_6\IN|inducing|the (r_prep) effect_5\NN|Thus|suggesting|.|depend|, (r_nsubj) seems_8\VBZ|NONE (l_advcl) suggesting_21\VBG|Thus|effect|.|depend|, (l_ccomp) is_26\VBZ|NONE (l_prep) of_27\IN|region|that (l_pobj) importance_29\NN|NONE (l_prep) in_30\IN|crucial (l_pobj) development_32\NN|NONE (l_prep) of_33\IN|the (l_pobj) crisis_36\NN|NONE (l_compound) migraine_35\JJ|a
D005996_D010146 NONE nitroglycerin_7\NN|NONE (r_pobj) of_6\IN|inducing|the (r_prep) effect_5\NN|Thus|suggesting|.|depend|, (r_nsubj) seems_8\VBZ|NONE (l_xcomp) depend_10\VB|Thus|suggesting|effect|.|, (l_prep) on_11\IN|to (l_pobj) stimulation_13\NN|NONE (l_prep) of_14\IN|direct (l_pobj) site_17\NN|NONE (l_prep) of_18\IN|the|habitual (l_pobj) pain_19\NN|NONE
6640832
D004317_D002277 NONE adriamycin_2\NNS|Early|. (l_prep) in_3\IN|NONE (l_pobj) carcinoma_6\NN|NONE
D004317_D001749 NONE adriamycin_2\NNS|Early|. (l_prep) in_3\IN|NONE (l_pobj) carcinoma_6\NN|NONE
D004317_D001749 NONE Adriamycin_0\NNP|.|was|within|after|intravesically (r_nsubjpass) administered_7\VBN|NONE (l_prep) after_12\IN|.|was|within|Adriamycin|intravesically (l_pobj) resection_14\NN|NONE (l_prep) of_15\IN|transurethral (l_pobj) tumors_25\NNS|NONE
9754849
D003042_D020820 NONE cocaine_12\NN|NONE (r_pobj) with_11\IN|NONE (r_prep) intoxications_10\NNS|NONE (r_pobj) during_9\IN|to|abnormalities (r_prep) be_5\VB|.|hyperkinesias|are (l_attr) abnormalities_8\NNS|during|to
D003042_D006948 CID cocaine_12\NN|NONE (r_pobj) with_11\IN|NONE (r_prep) intoxications_10\NNS|NONE (r_pobj) during_9\IN|to|abnormalities (r_prep) be_5\VB|.|hyperkinesias|are (r_xcomp) known_3\VBN|NONE (l_nsubjpass) hyperkinesias_1\NNS|.|be|are
D003042_D002819 CID cocaine_12\NN|NONE (r_pobj) with_11\IN|NONE (r_prep) intoxications_10\NNS|NONE (r_pobj) during_9\IN|to|abnormalities (r_prep) be_5\VB|.|hyperkinesias|are (r_xcomp) known_3\VBN|NONE (l_nsubjpass) hyperkinesias_1\NNS|.|be|are
D003042_D002819 CID cocaine_32\NN|and (r_conj) heroine_30\NN|previously (r_dobj) abusing_29\VBG|an (r_acl) inpatient_27\NN|NONE (r_pobj) in_25\IN|to|rapid (r_prep) adjustment_15\NN|NONE (r_pobj) by_13\IN|both|transiently (r_agent) induced_12\VBN|movements (r_xcomp) choreoathetoid_8\JJ|and|report|.|This (l_dobj) movements_9\NNS|induced
D003932_D002819 NONE heroine_30\NN|previously (r_dobj) abusing_29\VBG|an (r_acl) inpatient_27\NN|NONE (r_pobj) in_25\IN|to|rapid (r_prep) adjustment_15\NN|NONE (r_pobj) by_13\IN|both|transiently (r_agent) induced_12\VBN|movements (r_xcomp) choreoathetoid_8\JJ|and|report|.|This (l_dobj) movements_9\NNS|induced
D008691_D002819 CID methadone_7\NN|NONE (r_pobj) to_6\IN|rapid (r_prep) adjustment_5\NN|NONE (r_pobj) with_3\IN|NONE (r_prep) associated_2\VBN|Choreoathetoid|. (r_acl) movements_1\NNS|NONE
D008691_D002819 CID methadone_24\NN|NONE (r_pobj) to_16\IN|rapid|in (r_prep) adjustment_15\NN|NONE (r_pobj) by_13\IN|both|transiently (r_agent) induced_12\VBN|movements (r_xcomp) choreoathetoid_8\JJ|and|report|.|This (l_dobj) movements_9\NNS|induced
18657397
D010400_D004827 CID potassium_20\NN|into|recorded (r_dobj) injecting_14\VBG|NONE (r_pcomp) by_13\IN|After|focus|,|.|was (r_prep) induced_12\VBN|NONE (l_nsubjpass) focus_10\NN|After|by|,|.|was (l_amod) epileptic_9\JJ|NONE
D010406_D004827 NONE penicillin_5\NN| (r_npadvmod) induced_7\VBN|epileptiform|in (r_amod) activity_9\NN|NONE
D010406_D004827 NONE Penicillin_0\NNP|NONE (r_compound) model_1\NN|model|. (r_nsubj) is_2\VBZ|NONE (l_attr) model_7\NN|model|. (l_prep) for_8\IN|used|experimental|a (l_pobj) research_10\NN|NONE (l_compound) epilepsy_9\NN|NONE
D010406_D004827 NONE penicillin_13\NN| (r_npadvmod) induced_15\VBN|epileptiform (r_amod) activity_17\NN|NONE
D010406_D004827 NONE penicillin_7\NN| (r_npadvmod) induced_9\VBN|activity|the (r_amod) periods_12\NNS|and|latent (l_compound) activity_11\NN|induced|the
7337133
D000082_D017093 CID acetaminophen_9\NN|NONE (r_compound) overdose_10\NN|NONE (r_pobj) in_8\IN|fulminant|hepatic (r_prep) failure_7\NN|NONE
D000082_D017093 CID acetaminophen_6\RB| (r_advmod) induced_8\VBN|fatal|fulminant|hepatic (r_amod) failure_11\NN|NONE
D000082_D001929 CID acetaminophen_9\NN|NONE (r_compound) overdose_10\NN|NONE (r_pobj) in_8\IN|fulminant|hepatic (r_prep) failure_7\NN|NONE (r_pobj) with_4\IN|NONE (r_prep) associated_3\VBN|:|.|Massive|role|cerebral (r_acl) edema_2\NN|NONE
D000082_D001929 CID acetaminophen_6\RB| (r_advmod) induced_8\VBN|fatal|fulminant|hepatic (r_amod) failure_11\NN|NONE (r_pobj) with_4\IN|a (r_prep) patient_3\NN|We|with|.|, (r_dobj) present_1\VBP|NONE (l_prep) with_13\IN|We|.|,|patient (l_pobj) signs_14\NNS|NONE (l_prep) of_17\IN|symptoms|and (l_pobj) edema_19\NN|NONE
D000082_D062787 NONE acetaminophen_9\NN|NONE (r_compound) overdose_10\NN|NONE
8475949
D010419_D017180 NONE pentamidine_3\NN|NONE (l_conj) tachycardia_7\NN|and
D010419_D017180 NONE isethionate_1\NN|with|has|been|. (r_nsubjpass) associated_4\VBN|NONE (l_prep) with_5\IN|has|been|.|isethionate (l_pobj) tachyarrhythmias_7\NNS|NONE
D008274_D016171 NONE magnesium_11\NN|serum|and|hypomagnesemia (r_compound) levels_12\NNS|NONE (r_pobj) to_9\IN|be|may|induce|.|pointes (r_prep) related_8\VBN|NONE (l_nsubjpass) pointes_5\FW|be|may|induce|to|.
D010419_D016171 CID isethionate_1\NN|with|has|been|. (r_nsubjpass) associated_4\VBN|NONE (l_prep) with_5\IN|has|been|.|isethionate (l_pobj) tachyarrhythmias_7\NNS|NONE (l_prep) including_9\VBG|ventricular|, (l_pobj) pointes_12\FW|NONE
D010419_D016171 CID Pentamidine_0\NNP| (r_npadvmod) induced_2\VBN|NONE (r_amod) torsade_3\NN|de (r_nmod) pointes_5\FW|be|may|induce|to|.
D010419_D016171 CID pentamidine_13\NN|NONE (r_pobj) with_12\IN|NONE (r_prep) treatment_11\NN|NONE (r_pobj) of_10\IN| (r_prep) days_9\NNS|NONE (r_pobj) of_7\IN|an (r_prep) average_6\NN|NONE (r_pobj) after_4\IN|pointes|. (r_prep) occurred_3\VBD|NONE (l_nsubj) pointes_2\NNS|after|.
D010419_D016171 CID pentamidine_14\NN|NONE (r_pobj) of_13\IN|NONE (r_prep) discontinuation_12\NN|possibly (r_pobj) without_11\IN|when|,|early (r_prep) recognized_7\VBN|pointes|be|.|can (r_advcl) treated_5\VBN|NONE (l_nsubjpass) pointes_2\FW|recognized|be|.|can
D010419_C537153 NONE Pentamidine_0\NNP| (r_npadvmod) induced_2\VBN|NONE (r_amod) torsade_3\NN|de (r_nmod) pointes_5\FW|be|may|induce|to|. (r_nsubjpass) related_8\VBN|NONE (l_prep) to_9\IN|be|may|induce|.|pointes (l_pobj) levels_12\NNS|NONE (l_conj) hypomagnesemia_14\NN|magnesium|serum|and
D008274_C537153 NONE magnesium_11\NN|serum|and|hypomagnesemia (r_compound) levels_12\NNS|NONE (l_conj) hypomagnesemia_14\NN|magnesium|serum|and
D008274_D008133 NONE magnesium_8\NN|early (r_compound) supplementation_9\NN|observed|is|,|. (r_nsubjpass) advocated_11\VBN|NONE (l_advcl) observed_5\VBN|supplementation|is|,|. (l_nsubjpass) prolongation_3\NN|When|is
12907924
D008774_D000544 NONE methylphenidate_18\NN|NONE (r_pobj) on_17\IN|man|was|. (r_prep) started_16\VBN|NONE (l_nsubjpass) man_4\NN|on|was|. (l_prep) with_5\IN|An|old (l_pobj) depression_9\NN|NONE (l_conj) disease_14\NN|and|resistant
D008774_D009771 CID Methylphenidate_0\NNP| (r_npadvmod) induced_2\VBN|in|compulsive|. (r_amod) symptoms_6\NNS|NONE
D008774_D009771 CID methylphenidate_12\NN|by|when|was (r_nsubjpass) replaced_14\VBN|over (r_advcl) diminished_7\VBN|but|.|behavior (r_conj) ensued_5\VBD|NONE (l_nsubj) behavior_4\NN|diminished|but|.
D016666_D009771 NONE fluvoxamine_16\NN|NONE (r_pobj) by_15\IN|methylphenidate|when|was (r_agent) replaced_14\VBN|over (r_advcl) diminished_7\VBN|but|.|behavior (r_conj) ensued_5\VBD|NONE (l_nsubj) behavior_4\NN|diminished|but|.
D008774_D061218 NONE methylphenidate_18\NN|NONE (r_pobj) on_17\IN|man|was|. (r_prep) started_16\VBN|NONE (l_nsubjpass) man_4\NN|on|was|. (l_prep) with_5\IN|An|old (l_pobj) depression_9\NN|NONE
18560792
D004298_D006349 NONE dopamine_33\NN|ergot (r_compound) agonists_34\NNS|NONE (r_pobj) to_29\IN|when|treatment|is (r_prep) converted_28\VBN|usual|that|improvement (r_advcl) is_22\VBZ|NONE (r_ccomp) reveals_17\VBZ|and|with (r_conj) treated_13\VBN|high|of|the (r_acl) frequency_5\NN|.|study (l_prep) of_6\IN|treated|high|the (l_pobj) regurgitation_9\NN|NONE
D010479_D010300 NONE pergolide_11\NN|NONE (r_pobj) with_10\IN|.|disease (r_prep) treated_9\VBN|NONE (l_nsubj) disease_2\NN|with|. (l_prep) in_3\IN|Valvular|heart (l_pobj) patients_4\NNS|NONE (l_prep) with_5\IN|NONE (l_pobj) disease_8\NN|NONE
D010479_D010300 NONE pergolide_17\NN|NONE (r_pobj) with_16\IN|NONE (r_prep) treated_15\VBN|with (r_acl) patients_7\NNS|NONE (l_prep) with_8\IN|treated (l_pobj) disease_11\NN|NONE
D010479_D010300 NONE pergolide_17\NN|NONE (r_pobj) with_16\IN|NONE (r_prep) treated_15\VBN|with (r_acl) patients_7\NNS|NONE (l_prep) with_8\IN|treated (l_pobj) disease_11\NN|NONE (l_appos) PD_13\NNP|Parkinson|)|(
D010479_D010300 NONE pergolide_9\NN|NONE (r_pobj) with_8\IN|patients (r_prep) treated_7\VBN|were|attend|. (l_nsubj) patients_2\NNS|with (l_compound) PD_1\NNP|All|in
D010479_D010300 NONE pergolide_15\NN|NONE (r_pobj) with_14\IN|and|reveals (r_prep) treated_13\VBN|high|of|the (r_acl) frequency_5\NN|.|study (l_prep) of_6\IN|treated|high|the (l_pobj) regurgitation_9\NN|NONE (l_prep) in_10\IN|restrictive|valve (l_pobj) patients_12\NNS|NONE (l_compound) PD_11\NNP|NONE
D004298_D010300 NONE dopamine_33\NN|ergot (r_compound) agonists_34\NNS|NONE (r_pobj) to_29\IN|when|treatment|is (r_prep) converted_28\VBN|usual|that|improvement (r_advcl) is_22\VBZ|NONE (r_ccomp) reveals_17\VBZ|and|with (r_conj) treated_13\VBN|high|of|the (r_acl) frequency_5\NN|.|study (l_prep) of_6\IN|treated|high|the (l_pobj) regurgitation_9\NN|NONE (l_prep) in_10\IN|restrictive|valve (l_pobj) patients_12\NNS|NONE (l_compound) PD_11\NNP|NONE
D010479_D006349 NONE pergolide_11\NN|NONE (r_pobj) with_10\IN|.|disease (r_prep) treated_9\VBN|NONE (l_nsubj) disease_2\NN|with|.
D010479_D006349 NONE pergolide_17\NN|NONE (r_pobj) with_16\IN|NONE (r_prep) treated_15\VBN|with (r_acl) patients_7\NNS|NONE (r_pobj) in_6\IN|.|abnormalities|have|been (r_prep) reported_5\VBN|NONE (l_nsubjpass) abnormalities_2\NNS|.|in|have|been
D010479_D006349 NONE pergolide_12\NN|NONE (r_pobj) of_11\IN|the (r_prep) role_10\NN|NONE (r_pobj) of_8\IN|NONE (r_prep) suggestive_7\JJ|of|,|restrictive|A (r_amod) pattern_2\NN|,|patients|in|.|was (l_prep) of_3\IN|suggestive|,|restrictive|A (l_pobj) regurgitation_5\NN|NONE
D010479_D006349 NONE Pergolide_0\NNP|,|was|.|resulting|in|returned (r_nsubjpass) discontinued_2\VBN|NONE (l_prep) in_3\IN|,|was|.|resulting|Pergolide|returned (l_pobj) patients_5\NNS|NONE (l_prep) with_6\IN| (l_pobj) disease_9\NN|NONE
D010479_D006349 NONE pergolide_15\NN|NONE (r_pobj) with_14\IN|and|reveals (r_prep) treated_13\VBN|high|of|the (r_acl) frequency_5\NN|.|study (l_prep) of_6\IN|treated|high|the (l_pobj) regurgitation_9\NN|NONE
D010479_D006333 NONE pergolide_12\NN|NONE (r_pobj) of_11\IN|the (r_prep) role_10\NN|NONE (r_pobj) of_8\IN|NONE (r_prep) suggestive_7\JJ|of|,|restrictive|A (r_amod) pattern_2\NN|,|patients|in|.|was (r_nsubjpass) observed_15\VBN|NONE (l_dobj) patients_22\NNS|,|in|pattern|.|was (l_prep) including_23\VBG|NONE (l_pobj) two_24\CD|NONE (l_prep) with_25\IN|NONE (l_pobj) failure_27\NN|NONE
D010479_D006333 NONE Pergolide_0\NNP|,|was|.|resulting|in|returned (r_nsubjpass) discontinued_2\VBN|NONE (l_advcl) resulting_11\VBG|,|was|.|in|Pergolide|returned (l_prep) in_12\IN|NONE (l_pobj) grade_16\NN|NONE (l_prep) at_20\IN|regurgitation|p=.|a|lower (l_pobj) transthoracic_23\NN|NONE (l_conj) patients_28\NNS|and|second|the|echocardiography (l_prep) with_29\IN|two|the (l_pobj) failure_31\NN|NONE
16867021
D001058_D002375 NONE apomorphine_19\NN| (r_npadvmod) induced_21\VBN|activities|climbing|and (r_amod) behavior_23\NN|effect|to (r_dobj) study_6\VB|study|.|was (l_dobj) effect_8\NN|behavior|to (l_prep) of_9\IN|the (l_pobj) ligands_12\NNS|NONE (l_prep) on_13\IN|histamine|H()receptor (l_pobj) catalepsy_17\NN|NONE
D001058_D002375 NONE apomorphine_12\NN|were|for|while (r_nsubjpass) used_26\VBN|was|,|by|.|Catalepsy (r_advcl) induced_2\VBN|NONE (l_nsubjpass) Catalepsy_0\NNP|was|,|by|used|.
D001058_D002375 NONE apomorphine_21\NN|NONE (r_dobj) reducing_20\VBG|and|hyperactivity (r_conj) reducing_14\VBG|,|catalepsy (r_conj) potentiating_8\VBG|NONE (l_dobj) catalepsy_12\NN|reducing|,
D006220_D002375 CID haloperidol_4\NN|NONE (r_pobj) by_3\IN|was|,|used|.|Catalepsy (r_agent) induced_2\VBN|NONE (l_nsubjpass) Catalepsy_0\NNP|was|,|by|used|.
D006220_D002375 CID haloperidol_4\NN|NONE (r_pobj) to_3\IN|NONE (r_prep) prior_2\RB|in|h||. (r_advmod) resulted_5\VBD|NONE (l_prep) in_6\IN|h||prior|. (l_pobj) increase_11\NN|NONE (l_prep) in_12\IN|a|(|P|)|dependent (l_pobj) catalepsy_14\NN|NONE
D006220_D002375 CID haloperidol_9\NN| (r_npadvmod) induced_11\VBN|NONE (r_amod) catalepsy_12\NN|reducing|,
C069357_D002375 NONE methylhistamine_3\NN|catalepsy|(|,|.|did|not|se (r_nsubj) cause_27\VB|NONE (l_dobj) catalepsy_28\NN|(|methylhistamine|,|.|did|not|se
C069357_D002375 NONE RAMH_5\NNP|R)alpha||microg (r_appos) methylhistamine_3\NN|catalepsy|(|,|.|did|not|se (r_nsubj) cause_27\VB|NONE (l_dobj) catalepsy_28\NN|(|methylhistamine|,|.|did|not|se
C052075_D002375 CID thioperamide_13\JJ|(|(|mg/kg||i.c.v.|)|and|) (r_conj) microg_9\NN|R)alpha|RAMH| (r_parataxis) methylhistamine_3\NN|catalepsy|(|,|.|did|not|se (r_nsubj) cause_27\VB|NONE (l_dobj) catalepsy_28\NN|(|methylhistamine|,|.|did|not|se
C052075_D002375 CID THP_15\NNP|(|) (r_appos) thioperamide_13\JJ|(|(|mg/kg||i.c.v.|)|and|) (r_conj) microg_9\NN|R)alpha|RAMH| (r_parataxis) methylhistamine_3\NN|catalepsy|(|,|.|did|not|se (r_nsubj) cause_27\VB|NONE (l_dobj) catalepsy_28\NN|(|methylhistamine|,|.|did|not|se
C052075_D002375 CID THP_0\NNP|.|profile|climbing (r_nsubj) exhibited_1\VBD|NONE (l_dobj) profile_6\NN|THP|.|climbing (l_prep) by_7\IN|an|like (l_pcomp) potentiating_8\VBG|NONE (l_dobj) catalepsy_12\NN|reducing|,
D000661_D006948 CID amphetamine_1\NN| (r_npadvmod) induced_3\VBN|NONE (r_amod) hyperactivity_4\NN|NONE
D000661_D006948 CID amphetamine_15\NN| (r_npadvmod) induced_17\VBN|NONE (r_amod) hyperactivity_18\NN|and|reducing
C052075_D006948 NONE THP_6\NNP|i.p.|)|reduced|locomotor|mg/kg (r_nmod) time_16\NN|,|and|On|,|distance|.|speed (r_npadvmod) traveled_19\VBD|NONE (l_prep) On_0\IN|,|and|,|distance|time|.|speed (l_pobj) hyperactivity_4\NN|NONE
C052075_D006948 NONE THP_0\NNP|.|profile|climbing (r_nsubj) exhibited_1\VBD|NONE (l_dobj) profile_6\NN|THP|.|climbing (l_prep) by_7\IN|an|like (l_pcomp) potentiating_8\VBG|NONE (l_conj) reducing_14\VBG|,|catalepsy (l_dobj) hyperactivity_18\NN|and|reducing
D001058_D006948 NONE apomorphine_21\NN|NONE (r_dobj) reducing_20\VBG|and|hyperactivity (r_conj) reducing_14\VBG|,|catalepsy (l_dobj) hyperactivity_18\NN|and|reducing
D000661_D002375 NONE amphetamine_25\NN| (r_npadvmod) induced_27\VBN|locomotor|in (r_amod) activities_29\NNS|induced|climbing|and (r_conj) behavior_23\NN|effect|to (r_dobj) study_6\VB|study|.|was (l_dobj) effect_8\NN|behavior|to (l_prep) of_9\IN|the (l_pobj) ligands_12\NNS|NONE (l_prep) on_13\IN|histamine|H()receptor (l_pobj) catalepsy_17\NN|NONE
D000661_D002375 NONE amphetamine_19\NN|(|and|mg/kg|) (r_conj) apomorphine_12\NN|were|for|while (r_nsubjpass) used_26\VBN|was|,|by|.|Catalepsy (r_advcl) induced_2\VBN|NONE (l_nsubjpass) Catalepsy_0\NNP|was|,|by|used|.
D000661_D002375 NONE amphetamine_15\NN| (r_npadvmod) induced_17\VBN|NONE (r_amod) hyperactivity_18\NN|and|reducing (r_dobj) reducing_14\VBG|,|catalepsy (r_conj) potentiating_8\VBG|NONE (l_dobj) catalepsy_12\NN|reducing|,
D006220_D006948 NONE haloperidol_9\NN| (r_npadvmod) induced_11\VBN|NONE (r_amod) catalepsy_12\NN|reducing|, (r_dobj) potentiating_8\VBG|NONE (l_conj) reducing_14\VBG|,|catalepsy (l_dobj) hyperactivity_18\NN|and|reducing
D006632_D002375 NONE histamine_10\NN|H()receptor|on (r_nmod) ligands_12\NNS|NONE (l_prep) on_13\IN|histamine|H()receptor (l_pobj) catalepsy_17\NN|NONE
2594614
D002045_D018376 NONE bupivacaine_16\NN| (r_npadvmod) induced_18\VBN|cardiovascular (r_amod) alterations_20\NNS|NONE
D002045_D001919 CID bupivacaine_5\NN|NONE (r_pobj) of_1\IN|(|)|to|mg/kg (r_prep) Administration_0\NN|.|decrease (r_nsubj) elicited_16\VBD|NONE (l_dobj) decrease_19\NN|.|Administration (l_prep) of_20\IN|(|marked|in|a|) (l_pobj) pressure_24\NN|NONE (l_appos) MBP_26\NNP|arterial|mean|(|leading|blood (l_conj) rate_30\NN|)|and (l_punct) )_33\-RRB-|HR|heart|(
D002045_D001919 CID bupivacaine_23\NN|NONE (r_compound) administration_24\NN|NONE (r_pobj) before_22\IN|)|i.v.| (r_prep) min_21\NN|of|antagonist|Intravenous|, (r_appos) injection_1\NN|decrease|. (r_nsubj) suppressed_30\VBD|NONE (l_dobj) decrease_33\NN|injection|. (l_prep) of_34\IN|the|both (l_pobj) MBP_35\NNP|NONE (l_conj) HR_37\NN|and
D002045_D001919 CID bupivacaine_12\NN|NONE (r_pobj) after_11\IN|mg/kg|BN|When|immediately|was (r_prep) injected_9\VBN|,|was|,|.|was|reversion (r_advcl) observed_29\VBN|NONE (l_nsubjpass) reversion_20\NN|injected|,|was|,|.|was (l_prep) of_21\IN|a|partial (l_pobj) decrease_23\NN|NONE (l_prep) of_24\IN|the (l_pobj) MBP_25\NNP|NONE (l_conj) HR_27\NN|and
D002045_D002318 NONE bupivacaine_15\NN| (r_npadvmod) induced_17\VBN|in|cardiovascular (r_amod) impairments_19\NNS|NONE
D002045_D002318 NONE bupivacaine_44\NN| (r_npadvmod) induced_46\VBN|cardiovascular (r_amod) toxicity_48\NN|NONE
C045856_D007022 NONE 52021_14\CD|mg/kg|)|)|(|PAF (r_appos) antagonist_12\NN|of|min|Intravenous|, (r_appos) injection_1\NN|decrease|. (r_nsubj) suppressed_30\VBD|NONE (l_dobj) decrease_33\NN|injection|. (l_prep) of_34\IN|the|both (l_pobj) MBP_35\NNP|NONE (l_conj) HR_37\NN|and
C045856_D007022 NONE 52021_2\CD|i.v.|mg/kg|) (r_nummod) BN_1\NNP|mg/kg|after|When|immediately|was (r_nsubjpass) injected_9\VBN|,|was|,|.|was|reversion (r_advcl) observed_29\VBN|NONE (l_nsubjpass) reversion_20\NN|injected|,|was|,|.|was (l_prep) of_21\IN|a|partial (l_pobj) decrease_23\NN|NONE (l_prep) of_24\IN|the (l_pobj) MBP_25\NNP|NONE (l_conj) HR_27\NN|and
C045856_D002318 NONE 52021_12\CD|NONE (r_nummod) BN_11\NNP|on|a|,|factor|activating|,|specific (r_appos) antagonist_9\NN|NONE (l_prep) on_14\IN|a|,|factor|activating|,|BN|specific (l_pobj) impairments_19\NNS|NONE
C045856_D002318 NONE 52021_5\CD|NONE (r_nummod) BN_4\NNP|NONE (r_pobj) of_3\IN|the (r_prep) administration_2\NN|did|,|not|,|MBP|at|at|Since (r_nsubj) alter_14\VB|bulk|action|.|clearly|, (r_advcl) demonstrate_29\VBP|NONE (l_dobj) action_32\NN|bulk|alter|.|clearly|, (l_prep) against_43\IN|a|,|,|of|antagonist|protective (l_pobj) toxicity_48\NN|NONE
C045856_D002318 NONE 52021_35\CD|NONE (r_nummod) BN_34\NNP|NONE (r_pobj) of_33\IN|a|,|,|antagonist|protective|against (r_prep) action_32\NN|bulk|alter|.|clearly|, (l_prep) against_43\IN|a|,|,|of|antagonist|protective (l_pobj) toxicity_48\NN|NONE
C045856_D001919 NONE 52021_14\CD|mg/kg|)|)|(|PAF (r_appos) antagonist_12\NN|of|min|Intravenous|, (r_appos) injection_1\NN|decrease|. (r_nsubj) suppressed_30\VBD|NONE (l_dobj) decrease_33\NN|injection|. (l_prep) of_34\IN|the|both (l_pobj) MBP_35\NNP|NONE (l_conj) HR_37\NN|and
C045856_D001919 NONE 52021_2\CD|i.v.|mg/kg|) (r_nummod) BN_1\NNP|mg/kg|after|When|immediately|was (r_nsubjpass) injected_9\VBN|,|was|,|.|was|reversion (r_advcl) observed_29\VBN|NONE (l_nsubjpass) reversion_20\NN|injected|,|was|,|.|was (l_prep) of_21\IN|a|partial (l_pobj) decrease_23\NN|NONE (l_prep) of_24\IN|the (l_pobj) MBP_25\NNP|NONE (l_conj) HR_27\NN|and
D002045_D007022 CID bupivacaine_5\NN|NONE (r_pobj) of_1\IN|(|)|to|mg/kg (r_prep) Administration_0\NN|.|decrease (r_nsubj) elicited_16\VBD|NONE (l_dobj) decrease_19\NN|.|Administration (l_prep) of_20\IN|(|marked|in|a|) (l_pobj) pressure_24\NN|NONE (l_appos) MBP_26\NNP|arterial|mean|(|leading|blood (l_conj) rate_30\NN|)|and (l_punct) )_33\-RRB-|HR|heart|(
D002045_D007022 CID bupivacaine_23\NN|NONE (r_compound) administration_24\NN|NONE (r_pobj) before_22\IN|)|i.v.| (r_prep) min_21\NN|of|antagonist|Intravenous|, (r_appos) injection_1\NN|decrease|. (r_nsubj) suppressed_30\VBD|NONE (l_dobj) decrease_33\NN|injection|. (l_prep) of_34\IN|the|both (l_pobj) MBP_35\NNP|NONE (l_conj) HR_37\NN|and
D002045_D007022 CID bupivacaine_12\NN|NONE (r_pobj) after_11\IN|mg/kg|BN|When|immediately|was (r_prep) injected_9\VBN|,|was|,|.|was|reversion (r_advcl) observed_29\VBN|NONE (l_nsubjpass) reversion_20\NN|injected|,|was|,|.|was (l_prep) of_21\IN|a|partial (l_pobj) decrease_23\NN|NONE (l_prep) of_24\IN|the (l_pobj) MBP_25\NNP|NONE (l_conj) HR_27\NN|and
2348231
D010431_D007383 CID pentoxifylline_6\NN|are|.|Trental|)|,|derivative|(|Many (r_dobj) taking_5\VBG|NONE (l_conj) derivative_13\NN|are|.|Trental|)|,|(|Many|pentoxifylline (l_relcl) improve_16\VB|methylxanthine|a (l_dobj) claudication_18\NN|may|which
D010431_D007383 CID Trental_8\NNP|are|.|)|,|derivative|(|Many|pentoxifylline (r_npadvmod) taking_5\VBG|NONE (l_conj) derivative_13\NN|are|.|Trental|)|,|(|Many|pentoxifylline (l_relcl) improve_16\VB|methylxanthine|a (l_dobj) claudication_18\NN|may|which
D004176_D006940 CID dipyridamole_7\NN| (r_npadvmod) induced_9\VBN|:|implications|coronary (r_amod) hyperemia_11\NN|Pentoxifylline|not|.|does
D004176_D006940 CID dipyridamole_15\JJ| (r_npadvmod) thallium-201_17\NN|myocardial (r_nmod) imaging_19\NN|NONE (r_pobj) for_14\IN|NONE (r_prep) implications_13\NNS|:|induced|coronary (r_appos) hyperemia_11\NN|Pentoxifylline|not|.|does
D004176_D006940 CID dipyridamole_3\NN| (r_dep) induced_5\VBN|coronary|like (r_amod) hyperemia_7\NN|stopped|pentoxifylline|and
D004176_D006940 CID dipyridamole_20\NN| (r_compound) thallium-201_22\NN|NONE (r_compound) imaging_23\NN|NONE (r_pobj) to_19\IN|NONE (r_prep) prior_18\RB|should|be (r_advmod) stopped_17\VBN|pentoxifylline|and|hyperemia (r_conj) inhibits_2\VBZ|unknown|. (l_dobj) hyperemia_7\NN|stopped|pentoxifylline|and
D004176_D006940 CID dipyridamole_7\NN| (r_npadvmod) induced_9\VBN|the (r_amod) hyperemia_10\NN|significantly|)|less|,|.|peak|dose
D004176_D006940 CID dipyridamole_7\NN| (r_npadvmod) induced_9\VBN|coronary (r_amod) hyperemia_11\NN|at|pentoxyifylline|not|that|does
C008514_D007383 NONE methylxanthine_12\NN|improve|a (r_compound) derivative_13\NN|are|.|Trental|)|,|(|Many|pentoxifylline (l_relcl) improve_16\VB|methylxanthine|a (l_dobj) claudication_18\NN|may|which
C008514_D006940 NONE methylxanthines_10\NNS|NONE (r_pobj) like_8\IN|induced|coronary (r_prep) hyperemia_7\NN|stopped|pentoxifylline|and
D010431_D006940 NONE Pentoxifylline_0\NNP|not|.|hyperemia|does (r_nsubj) inhibit_6\VB|NONE (l_dobj) hyperemia_11\NN|Pentoxifylline|not|.|does
D010431_D006940 NONE Trental_2\NNP|(|) (r_appos) Pentoxifylline_0\NNP|not|.|hyperemia|does (r_nsubj) inhibit_6\VB|NONE (l_dobj) hyperemia_11\NN|Pentoxifylline|not|.|does
D010431_D006940 NONE pentoxifylline_1\NN|stopped|and|hyperemia (r_nsubj) inhibits_2\VBZ|unknown|. (l_dobj) hyperemia_7\NN|stopped|pentoxifylline|and
D010431_D006940 NONE pentoxifylline_3\NN|NONE (r_pobj) of_2\IN|Neither (r_prep) dose_1\NN|significantly|)|less|,|hyperemia|.|peak (r_nsubj) decreased_5\VBD|NONE (l_dobj) hyperemia_10\NN|significantly|)|less|,|.|peak|dose
D010431_D006940 NONE pentoxyifylline_3\NN|at|not|that|does|hyperemia (r_nsubj) inhibit_6\VB|We|. (l_dobj) hyperemia_11\NN|at|pentoxyifylline|not|that|does
D013806_D006940 NONE theophylline_13\NN|such (r_pobj) as_12\IN|other (r_prep) methylxanthines_10\NNS|NONE (r_pobj) like_8\IN|induced|coronary (r_prep) hyperemia_7\NN|stopped|pentoxifylline|and
D013806_D006940 NONE theophylline_21\NN|NONE (r_pobj) after_20\IN|flow|lower (r_prep) was_17\VBD|while (r_ccomp) peak_13\JJ|significantly|)|less|,|hyperemia|.|dose (r_advcl) decreased_5\VBD|NONE (l_dobj) hyperemia_10\NN|significantly|)|less|,|.|peak|dose
D013793_D006940 NONE thallium-201_17\NN|myocardial (r_nmod) imaging_19\NN|NONE (r_pobj) for_14\IN|NONE (r_prep) implications_13\NNS|:|induced|coronary (r_appos) hyperemia_11\NN|Pentoxifylline|not|.|does
D013793_D006940 NONE thallium-201_22\NN|NONE (r_compound) imaging_23\NN|NONE (r_pobj) to_19\IN|NONE (r_prep) prior_18\RB|should|be (r_advmod) stopped_17\VBN|pentoxifylline|and|hyperemia (r_conj) inhibits_2\VBZ|unknown|. (l_dobj) hyperemia_7\NN|stopped|pentoxifylline|and
18464113
D006514_D006509 CID antigen_14\NN|undergoing|cancer|(|)|HBSAG|seropositive (r_nmod) patients_20\NNS|NONE (r_pobj) in_9\IN|virus (r_prep) reactivation_8\NN|NONE (l_compound) virus_7\NN|in (l_compound) B_6\NNP|NONE
D006514_D006509 CID HBSAG_16\NNP|undergoing|cancer|(|)|antigen|seropositive (r_nmod) patients_20\NNS|NONE (r_pobj) in_9\IN|virus (r_prep) reactivation_8\NN|NONE (l_compound) virus_7\NN|in (l_compound) B_6\NNP|NONE
D019259_D009369 NONE Lamivudine_0\NNP|NONE (l_prep) for_1\IN|. (l_pobj) prevention_3\NN|NONE (l_prep) of_4\IN|the (l_pobj) reactivation_8\NN|NONE (l_prep) in_9\IN|virus (l_pobj) patients_20\NNS|NONE (l_compound) cancer_19\NN|undergoing|(|)|antigen|HBSAG|seropositive
D019259_D009369 NONE lamivudine_20\NN|patients|In|,|compared|prior|. (r_dobj) received_16\VBD|NONE (l_nsubj) patients_5\NNS|In|,|lamivudine|compared|prior|. (l_compound) cancer_4\NN|have
D019259_D009369 NONE lamivudine_34\NN|did|not|who (r_dobj) receive_33\VB|historical|control (r_relcl) group_29\NN|NONE (r_pobj) with_26\IN|NONE (r_prep) compared_25\VBN|patients|In|,|lamivudine|prior|. (r_prep) received_16\VBD|NONE (l_nsubj) patients_5\NNS|In|,|lamivudine|compared|prior|. (l_compound) cancer_4\NN|have
D019259_D009369 NONE lamivudine_5\NN|during|significantly|incidence|that (r_nsubj) decreases_7\VBZ|study|. (l_dobj) incidence_9\NN|during|significantly|lamivudine|that (l_prep) of_10\IN|the (l_pobj) reactivation_12\NN|NONE (l_conj) morbidity_15\NN|and|HBV (l_prep) in_16\IN|overall (l_pobj) patients_18\NNS|NONE (l_compound) cancer_17\NN|NONE
D006514_D009369 NONE antigen_14\NN|undergoing|cancer|(|)|HBSAG|seropositive (r_nmod) patients_20\NNS|NONE (l_compound) cancer_19\NN|undergoing|(|)|antigen|HBSAG|seropositive
D006514_D009369 NONE HBSAG_16\NNP|undergoing|cancer|(|)|antigen|seropositive (r_nmod) patients_20\NNS|NONE (l_compound) cancer_19\NN|undergoing|(|)|antigen|HBSAG|seropositive
D019259_D056486 NONE lamivudine_3\NN|prophylactic|the (r_compound) group_4\NN|NONE (r_pobj) In_0\IN|patient|hepatitis|.|were (r_prep) observed_8\VBN|NONE (l_nsubjpass) hepatitis_6\NN|In|patient|.|were
D019259_D019337 NONE lamivudine_20\NN|patients|In|,|compared|prior|. (r_dobj) received_16\VBD|NONE (l_nsubj) patients_5\NNS|In|,|lamivudine|compared|prior|. (l_relcl) have_7\VBP|cancer (l_dobj) malignancies_11\NNS|who
D019259_D019337 NONE lamivudine_34\NN|did|not|who (r_dobj) receive_33\VB|historical|control (r_relcl) group_29\NN|NONE (r_pobj) with_26\IN|NONE (r_prep) compared_25\VBN|patients|In|,|lamivudine|prior|. (r_prep) received_16\VBD|NONE (l_nsubj) patients_5\NNS|In|,|lamivudine|compared|prior|. (l_relcl) have_7\VBP|cancer (l_dobj) malignancies_11\NNS|who
D019259_D006509 NONE Lamivudine_0\NNP|NONE (l_prep) for_1\IN|. (l_pobj) prevention_3\NN|NONE (l_prep) of_4\IN|the (l_pobj) reactivation_8\NN|NONE (l_compound) virus_7\NN|in (l_compound) B_6\NNP|NONE
D019259_D006509 NONE lamivudine_20\NN|patients|In|,|compared|prior|. (r_dobj) received_16\VBD|NONE (l_nsubj) patients_5\NNS|In|,|lamivudine|compared|prior|. (l_relcl) have_7\VBP|cancer (l_dobj) malignancies_11\NNS|who (l_prep) with_12\IN|solid (l_pobj) infection_15\NN|NONE
D019259_D006509 NONE lamivudine_34\NN|did|not|who (r_dobj) receive_33\VB|historical|control (r_relcl) group_29\NN|NONE (r_pobj) with_26\IN|NONE (r_prep) compared_25\VBN|patients|In|,|lamivudine|prior|. (r_prep) received_16\VBD|NONE (l_nsubj) patients_5\NNS|In|,|lamivudine|compared|prior|. (l_relcl) have_7\VBP|cancer (l_dobj) malignancies_11\NNS|who (l_prep) with_12\IN|solid (l_pobj) infection_15\NN|NONE
9401499
D013988_D000741 CID Ticlopidine_0\NNP| (r_npadvmod) induced_2\VBN|report|.|aplastic|: (r_amod) anemia_4\NN|NONE
D013988_D000741 CID ticlopidine_8\NN| (r_npadvmod) induced_10\VBN|aplastic (r_amod) anemia_12\NN|NONE
D013988_D000741 CID ticlopidine_2\NN| (r_npadvmod) induced_4\VBN|aplastic|with (r_amod) anemia_6\NN|NONE
D013988_D000380 CID ticlopidine_9\NN|NONE (r_pobj) of_8\IN|NONE (r_prep) initiation_7\NN|weeks (r_pobj) after_6\IN|,|Agranulocytosis (r_prep) occurred_1\VBD|examination|.|is (l_nsubj) Agranulocytosis_0\NN|,|after
18020536
D001569_D004244 CID BZDs_4\NNP|/ (r_nmod) RDs_6\NNS|NONE (r_pobj) of_3\IN|NONE (r_prep) use_2\NN|inability|was|However|,|with|.|, (r_nsubjpass) associated_8\VBN|NONE (l_prep) with_9\IN|inability|was|However|,|.|use|, (l_pobj) dizziness_10\NN|NONE
D001569_D007319 CID BZDs_4\NNP|/ (r_nmod) RDs_6\NNS|NONE (r_pobj) of_3\IN|NONE (r_prep) use_2\NN|inability|was|However|,|with|.|, (r_nsubjpass) associated_8\VBN|NONE (l_npadvmod) inability_12\NN|was|However|,|with|.|use|, (l_acl) sleep_14\VB|NONE
D001569_D003866 CID BZDs_4\NNP|/ (r_nmod) RDs_6\NNS|NONE (r_pobj) of_3\IN|NONE (r_prep) use_2\NN|inability|was|However|,|with|.|, (r_nsubjpass) associated_8\VBN|NONE (l_npadvmod) inability_12\NN|was|However|,|with|.|use|, (l_acl) sleep_14\VB|NONE (l_prep) after_15\IN|to (l_conj) with_31\IN|awaking|and (l_pobj) symptoms_34\NNS|NONE
D001569_D005221 CID BZDs_4\NNP|/ (r_nmod) RDs_6\NNS|NONE (r_pobj) of_3\IN|NONE (r_prep) use_2\NN|inability|was|However|,|with|.|, (r_nsubjpass) associated_8\VBN|NONE (l_npadvmod) inability_12\NN|was|However|,|with|.|use|, (l_acl) sleep_14\VB|NONE (l_prep) after_15\IN|to (l_pcomp) awaking_16\VBG|with|and (l_prep) at_17\IN|during|in (l_pobj) night_18\NN|NONE (l_conj) tiredness_20\NN|and
20470218
D008727_D004833 NONE methotrexate_32\NN|)|dose|(|syndrome||n|, (r_compound) toxicity_33\NN|,|(|reversible|)|stroke|posterior|leukoencephalopathy|n|, (r_conj) syndrome_6\NN|complications|. (l_conj) stroke_13\NN|,|(|reversible|)|posterior|leukoencephalopathy|n|toxicity|, (l_conj) epilepsy_22\NN|)|n||,|(
D008727_D007177 NONE methotrexate_32\NN|)|dose|(|syndrome||n|, (r_compound) toxicity_33\NN|,|(|reversible|)|stroke|posterior|leukoencephalopathy|n|, (l_conj) syndrome_40\NN|)|dose|(||n|methotrexate|, (l_prep) of_41\IN|and|events|, (l_pobj) secretion_45\NN|NONE
D008727_D020521 NONE methotrexate_32\NN|)|dose|(|syndrome||n|, (r_compound) toxicity_33\NN|,|(|reversible|)|stroke|posterior|leukoencephalopathy|n|, (r_conj) syndrome_6\NN|complications|. (l_conj) stroke_13\NN|,|(|reversible|)|posterior|leukoencephalopathy|n|toxicity|,
D008727_D064420 NONE methotrexate_32\NN|)|dose|(|syndrome||n|, (r_compound) toxicity_33\NN|,|(|reversible|)|stroke|posterior|leukoencephalopathy|n|,
D008727_D056784 NONE methotrexate_32\NN|)|dose|(|syndrome||n|, (r_compound) toxicity_33\NN|,|(|reversible|)|stroke|posterior|leukoencephalopathy|n|, (r_conj) syndrome_6\NN|complications|. (l_compound) leukoencephalopathy_5\JJ|,|(|reversible|)|stroke|posterior|n|toxicity|,
1848636
D013726_D007008 CID terbutaline_10\NN| (r_npadvmod) induced_12\VBN|NONE (r_amod) hypokalemia_13\NN|NONE
D008790_D007008 NONE metoprolol_8\NN|NONE (l_prep) of_9\IN|NONE (l_pobj) hypokalemia_13\NN|NONE
6504332
D010634_D012640 NONE phenobarbital_15\JJ|for (r_amod) therapy_16\NN|NONE (l_prep) for_17\IN|phenobarbital (l_pobj) seizures_18\NNS|NONE
D010634_D009422 NONE Phenobarbital_0\NN| (r_npadvmod) induced_2\VBN|.|in (r_amod) dyskinesia_3\NN|NONE (l_prep) in_4\IN|.|induced (l_pobj) child_9\NN|NONE (l_amod) impaired_8\VBN|a
D010634_D009422 NONE phenobarbital_15\JJ|for (r_amod) therapy_16\NN|NONE (r_dobj) starting_14\VBG|soon (r_pcomp) after_13\IN|dyskinesia|child|. (r_prep) developed_9\VBD|NONE (l_nsubj) child_4\NN|after|dyskinesia|. (l_prep) with_5\IN|old|A (l_pobj) impairment_8\NN|NONE
D010634_D004409 CID Phenobarbital_0\NN| (r_npadvmod) induced_2\VBN|.|in (r_amod) dyskinesia_3\NN|NONE
D010634_D004409 CID phenobarbital_15\JJ|for (r_amod) therapy_16\NN|NONE (r_dobj) starting_14\VBG|soon (r_pcomp) after_13\IN|dyskinesia|child|. (r_prep) developed_9\VBD|NONE (l_dobj) dyskinesia_11\JJ|after|child|.
D010634_D004409 CID phenobarbital_4\JJ|NONE (r_pobj) with_3\IN|repeat (r_prep) challenge_2\NN|NONE (r_pobj) On_0\IN|.|,|dyskinesia (r_prep) recurred_8\VBD|NONE (l_nsubj) dyskinesia_7\NN|.|,|On
D010634_D009069 NONE Phenobarbital_0\NN|.|be|should|to (r_nsubjpass) added_3\VBN|NONE (l_prep) to_4\IN|.|be|should|Phenobarbital (l_pobj) list_6\NN|NONE (l_prep) of_7\IN|the (l_pobj) drugs_9\NNS|NONE (l_relcl) cause_12\VB|anticonvulsant (l_dobj) disorders_14\NNS|that|can
19767176
C020972_D013226 NONE dithiocarbamate_1\NN|cortex|. (r_nsubj) protects_2\VBZ|NONE (l_dobj) cortex_5\NN|dithiocarbamate|. (l_prep) in_6\IN|piriform|the (l_pobj) model_11\NN|NONE (l_amod) epilepticus_10\NN|pilocarpine|status|the
C020972_D013226 NONE PDTC_3\NNP|NONE (r_pobj) of_2\IN|on|The (r_prep) effect_1\NN|.|in|was (l_prep) on_4\IN|of|The (l_pobj) loss_10\NN|NONE (l_amod) associated_8\VBN|cell|in|status (l_npadvmod) epilepticus_6\NN|
C020972_D013226 NONE PDTC_4\NNP|NONE (r_pobj) with_1\IN|before (r_prep) Treatment_0\NN|rate|to|.|epilepticus|significantly (r_nsubj) increased_11\VBD|NONE (l_advmod) epilepticus_9\NN|rate|to|.|Treatment|significantly
C020972_D013226 NONE PDTC_4\NNP|mg/kg||(|low (r_nmod) dose_8\NN|NONE (r_pobj) of_1\IN|) (r_prep) Administration_0\NN|.|effects|not|did (r_nsubj) exert_12\VB|NONE (l_dobj) effects_14\NNS|.|Administration|not|did (l_prep) on_15\IN|major (l_pobj) development_17\NN|NONE (l_prep) of_18\IN|the (l_pobj) epilepticus_21\NN|NONE
C020972_D013226 NONE PDTC_16\NNP| (r_npadvmod) treated_18\VBN|NONE (r_amod) rats_19\NNS|and (r_conj) vehicle-_14\NN|NONE (r_pobj) in_13\IN|was|.|decrease|following (r_prep) identified_12\VBN|NONE (l_prep) following_20\VBG|was|.|decrease|in (l_pobj) epilepticus_22\NN|NONE
D010100_D012640 NONE oxygen_9\NN|of|activation|reactive|and (r_compound) species_10\NNS|NONE (r_pobj) of_7\IN|the (r_prep) generation_6\NN|that|role|compared (r_nsubj) plays_17\VBZ|might|data|. (l_dobj) role_21\NN|that|generation|compared (l_prep) in_22\IN|central|a (l_pobj) damage_27\NN|NONE (l_amod) associated_25\VBN|neuronal|in (l_npadvmod) seizure_23\NN|
C020972_D009410 NONE PDTC_10\NNP|the|kappaB|and (r_conj) inhibitor_7\NN|cortex|In|,|.|,|affect (r_nsubj) protected_11\VBD|NONE (l_advcl) affect_20\VB|cortex|In|,|.|inhibitor|, (l_dobj) loss_23\NN|did|it|whereas|not
D010100_D009410 NONE oxygen_5\NN|reactive (r_compound) species_6\NNS|NONE (r_pobj) of_3\IN|activation|as (r_prep) production_2\NN|Both|in|.|have|been|, (r_nsubjpass) implicated_17\VBN|NONE (l_prep) in_18\IN|Both|.|have|been|production|, (l_pobj) damage_21\NN|NONE
D010100_D009410 NONE oxygen_9\NN|of|activation|reactive|and (r_compound) species_10\NNS|NONE (r_pobj) of_7\IN|the (r_prep) generation_6\NN|that|role|compared (r_nsubj) plays_17\VBZ|might|data|. (l_dobj) role_21\NN|that|generation|compared (l_prep) in_22\IN|central|a (l_pobj) damage_27\NN|NONE
D010862_D013226 CID pilocarpine_8\NN|epilepticus|status|the (r_amod) model_11\NN|NONE (l_amod) epilepticus_10\NN|pilocarpine|status|the
D010862_D013226 CID pilocarpine_23\NN|the|fractionated|rat (r_compound) model_24\NN|NONE (r_pobj) in_19\IN|effect|.|was (r_prep) evaluated_18\VBN|NONE (l_nsubjpass) effect_1\NN|.|in|was (l_prep) on_4\IN|of|The (l_pobj) loss_10\NN|NONE (l_amod) associated_8\VBN|cell|in|status (l_npadvmod) epilepticus_6\NN|
15632880
D011188_D003920 NONE potassium_17\NN|baseline|higher|and|doses (r_compound) levels_18\NNS|were|and|, (r_dobj) had_13\VBD|.|Patients|older|, (r_conj) were_4\VBD|NONE (l_acomp) older_5\JJR|.|Patients|had|, (l_conj) likely_8\JJ|and (l_xcomp) have_10\VB|more (l_dobj) diabetes_11\NNS|to
D011188_D003920 NONE potassium_22\NN|NONE (r_compound) supplement_23\NN|lower|baseline (r_compound) doses_24\NNS|baseline|higher|and|potassium (r_conj) levels_18\NNS|were|and|, (r_dobj) had_13\VBD|.|Patients|older|, (r_conj) were_4\VBD|NONE (l_acomp) older_5\JJR|.|Patients|had|, (l_conj) likely_8\JJ|and (l_xcomp) have_10\VB|more (l_dobj) diabetes_11\NNS|to
D011188_D006947 NONE K(+_7\NNP|NONE (r_appos) hyperkalemia_5\NN|who
D011188_D006947 NONE potassium_17\NN|baseline|higher|and|doses (r_compound) levels_18\NNS|were|and|, (r_dobj) had_13\VBD|.|Patients|older|, (r_conj) were_4\VBD|NONE (l_nsubj) Patients_0\NNS|.|had|older|, (l_relcl) developed_2\VBD|NONE (l_dobj) hyperkalemia_3\NN|who
D011188_D006947 NONE potassium_22\NN|NONE (r_compound) supplement_23\NN|lower|baseline (r_compound) doses_24\NNS|baseline|higher|and|potassium (r_conj) levels_18\NNS|were|and|, (r_dobj) had_13\VBD|.|Patients|older|, (r_conj) were_4\VBD|NONE (l_nsubj) Patients_0\NNS|.|had|older|, (l_relcl) developed_2\VBD|NONE (l_dobj) hyperkalemia_3\NN|who
D013148_D006947 CID Spironolactone_0\NNP|.||insufficiency (r_npadvmod) induced_2\VBN|NONE (l_dobj) insufficiency_4\NN|.||Spironolactone (l_conj) hyperkalemia_6\NN|renal|and|in
D013148_D006947 CID spironolactone_9\NN|NONE (r_pobj) of_8\IN|the (r_prep) use_7\NN|NONE (r_dobj) evaluating_5\VBG|controlled|previous|randomized|A (r_acl) trial_4\NN|risk|. (r_nsubj) reported_14\VBD|NONE (l_dobj) risk_17\NN|.|trial (l_prep) of_18\IN|low|a (l_pobj) hyperkalemia_19\NN|NONE
D013148_D006947 CID spironolactone_21\NN|NONE (r_pobj) with_20\IN|NONE (r_prep) treated_19\VBN|failure (r_acl) patients_18\NNS|NONE (r_pobj) in_15\IN|renal (r_prep) insufficiency_14\NN|and (r_conj) hyperkalemia_11\NN|NONE
D013148_D006947 CID spironolactone_13\NN|NONE (r_pobj) of_12\IN|NONE (r_prep) discontinuation_11\NN|.|seven|due (r_dobj) required_10\VBD|NONE (l_prep) due_14\IN|.|seven|discontinuation (l_pobj) hyperkalemia_16\NN|to
D013148_D006947 CID Spironolactone_0\NNP| (r_npadvmod) induced_2\VBN|and (r_amod) hyperkalemia_3\NN|renal
D013148_D051437 CID Spironolactone_0\NNP|.||insufficiency (r_npadvmod) induced_2\VBN|NONE (l_dobj) insufficiency_4\NN|.||Spironolactone
D013148_D051437 CID spironolactone_9\NN|NONE (r_pobj) of_8\IN|the (r_prep) use_7\NN|NONE (r_dobj) evaluating_5\VBG|controlled|previous|randomized|A (r_acl) trial_4\NN|risk|. (r_nsubj) reported_14\VBD|NONE (l_dobj) risk_17\NN|.|trial (l_prep) of_18\IN|low|a (l_pobj) hyperkalemia_19\NN|NONE (l_conj) insufficiency_26\NN|%|and|)|(
D013148_D051437 CID spironolactone_21\NN|NONE (r_pobj) with_20\IN|NONE (r_prep) treated_19\VBN|failure (r_acl) patients_18\NNS|NONE (r_pobj) in_15\IN|renal (r_prep) insufficiency_14\NN|and
D013148_D051437 CID spironolactone_13\NN|NONE (r_pobj) of_12\IN|NONE (r_prep) discontinuation_11\NN|.|seven|due (r_dobj) required_10\VBD|NONE (l_prep) due_14\IN|.|seven|discontinuation (l_pobj) hyperkalemia_16\NN|to (l_conj) failure_24\NN|)|or|n|(
D013148_D051437 CID Spironolactone_0\NNP| (r_npadvmod) induced_2\VBN|and (r_amod) hyperkalemia_3\NN|renal (r_nmod) insufficiency_6\NN|.|reported|common|in
D049971_D051437 NONE thiazide_31\NN|than (r_amod) diuretics_32\NNS|NONE (r_pobj) with_30\IN|be|to (r_prep) treated_29\VBN|more (r_xcomp) likely_26\JJ|NONE (r_acomp) were_24\VBD|and|doses|, (r_conj) required_16\VBD|weight|Patients|,|. (r_conj) had_5\VBD|NONE (l_nsubj) Patients_0\NNS|weight|,|required|. (l_relcl) developed_2\VBD|NONE (l_dobj) insufficiency_4\NN|who
D011188_D051437 NONE K(+_7\NNP|NONE (r_appos) hyperkalemia_5\NN|who (r_dobj) developed_4\VBD|NONE (r_relcl) patients_2\NNS|(|Cases (r_attr) were_1\VBD|NONE (l_nsubj) Cases_0\NNS|patients|( (l_appos) L_13\NN|NONE (l_conj) insufficiency_17\NN|mEq|)|>|or|/
D013148_D006333 NONE Spironolactone_0\NNP|.||insufficiency (r_npadvmod) induced_2\VBN|NONE (l_dobj) insufficiency_4\NN|.||Spironolactone (l_prep) in_7\IN|renal|and|hyperkalemia (l_pobj) patients_8\NNS|NONE (l_prep) with_9\IN|NONE (l_pobj) failure_11\NN|NONE
D013148_D006333 NONE spironolactone_9\NN|NONE (l_prep) in_10\IN|NONE (l_pobj) patients_13\NNS|NONE (l_compound) failure_12\NN|NONE
D013148_D006333 NONE spironolactone_11\NN|NONE (r_pobj) of_10\IN|the (r_prep) benefits_9\NNS|since|were (r_nsubjpass) reported_13\VBN|have|Because|treatments (r_advcl) changed_6\VBN|in|prevalence|.|may|, (l_nsubj) treatments_1\NNS|have|Because|reported (l_prep) for_2\IN|NONE (l_pobj) failure_4\NN|NONE
D013148_D006333 NONE spironolactone_21\NN|NONE (r_pobj) with_20\IN|NONE (r_prep) treated_19\VBN|failure (r_acl) patients_18\NNS|NONE (l_compound) failure_17\NN|treated
D013148_D006333 NONE spironolactone_12\NN|NONE (r_pobj) with_11\IN|NONE (r_prep) treated_10\VBN|failure (r_acl) patients_9\NNS|NONE (l_compound) failure_8\NN|treated
D003404_D051437 NONE creatinine_14\NN|lower|baseline|and|body (r_conj) weight_9\NN|Patients|,|required|. (r_dobj) had_5\VBD|NONE (l_nsubj) Patients_0\NNS|weight|,|required|. (l_relcl) developed_2\VBD|NONE (l_dobj) insufficiency_4\NN|who
88336
D009567_D062787 CID nitrazepam_19\NN|NONE (r_pobj) of_18\IN|suicidal|a (r_prep) overdose_17\NN|one|.
D009567_D062787 CID nitrazepam_3\JJ|two|and (r_amod) overdose_4\NN|NONE
D009567_D013375 NONE nitrazepam_19\NN|NONE (r_pobj) of_18\IN|suicidal|a (r_prep) overdose_17\NN|one|. (r_dobj) took_14\VBD|patients|for|and|,|doses (r_conj) received_2\VBD|NONE (l_prep) for_7\IN|patients|and|took|,|doses (l_pobj) symptoms_10\NNS|NONE
D002719_D003128 CID chlormethiazole_10\NN|NONE (r_compound) intoxication_11\NN|NONE (r_pobj) with_9\IN|NONE (r_prep) those_8\DT|NONE (r_pobj) of_7\IN|NONE (r_prep) two_6\CD|and|nitrazepam (r_conj) overdose_4\NN|NONE (r_pobj) with_2\IN|The (r_prep) patient_1\NN|showing|,|to|. (r_nsubj) conformed_12\VBD|NONE (l_prep) to_13\IN|showing|,|patient|. (l_pobj) criteria_15\NNS|NONE (l_prep) of_16\IN|the (l_pobj) coma_19\NN|'|'
D000431_D013375 NONE alcohol_8\NN|NONE (r_compound) withdrawal_9\NN|NONE (r_compound) symptoms_10\NNS|NONE
D000431_D062787 NONE alcohol_8\NN|NONE (r_compound) withdrawal_9\NN|NONE (r_compound) symptoms_10\NNS|NONE (r_pobj) for_7\IN|patients|and|took|,|doses (r_prep) received_2\VBD|NONE (l_conj) took_14\VBD|patients|for|and|,|doses (l_dobj) overdose_17\NN|one|.
D002719_D013375 NONE chlormethiazole_6\NN|NONE (r_pobj) of_5\IN|high (r_prep) doses_4\NNS|patients|for|and|took|, (r_dobj) received_2\VBD|NONE (l_prep) for_7\IN|patients|and|took|,|doses (l_pobj) symptoms_10\NNS|NONE
D002719_D062787 NONE chlormethiazole_6\NN|NONE (r_pobj) of_5\IN|high (r_prep) doses_4\NNS|patients|for|and|took|, (r_dobj) received_2\VBD|NONE (l_conj) took_14\VBD|patients|for|and|,|doses (l_dobj) overdose_17\NN|one|.
D002719_D062787 NONE chlormethiazole_10\NN|NONE (r_compound) intoxication_11\NN|NONE (r_pobj) with_9\IN|NONE (r_prep) those_8\DT|NONE (r_pobj) of_7\IN|NONE (r_prep) two_6\CD|and|nitrazepam (r_conj) overdose_4\NN|NONE
D009567_D003128 CID nitrazepam_3\JJ|two|and (r_amod) overdose_4\NN|NONE (r_pobj) with_2\IN|The (r_prep) patient_1\NN|showing|,|to|. (r_nsubj) conformed_12\VBD|NONE (l_prep) to_13\IN|showing|,|patient|. (l_pobj) criteria_15\NNS|NONE (l_prep) of_16\IN|the (l_pobj) coma_19\NN|'|'
19058474
D014859_D006470 NONE warfarin_26\NN|NONE (r_pobj) of_25\IN|his|usual (r_prep) dosage_24\NN|while (r_dobj) maintaining_21\VBG|for|who|juice (r_advcl) consumed_13\VBD|an|elderly (r_relcl) man_11\NN|NONE (r_pobj) in_8\IN|a|of (r_prep) case_3\NN|We|. (l_prep) of_4\IN|a|in (l_pobj) haemorrhage_7\NN|NONE
D014859_D010490 NONE warfarin_13\NN|NONE (r_pobj) with_12\IN|possible|of (r_prep) interaction_8\NN|to (r_pobj) due_5\IN|.|haemopericardium (r_prep) haemorrhage_4\NN|NONE (l_nmod) haemopericardium_1\NN|.|due
D014859_D006471 CID warfarin_13\NN|NONE (r_pobj) with_12\IN|possible|of (r_prep) interaction_8\NN|to (r_pobj) due_5\IN|.|haemopericardium (r_prep) haemorrhage_4\NN|NONE
6433367
D011453_D012640 NONE prostaglandin_2\JJ|synthetase (r_amod) inhibitors_4\NNS|NONE (r_pobj) of_1\IN|on|. (r_prep) Effect_0\NN|NONE (l_prep) on_5\IN|of|. (l_pobj) convulsions_8\NNS|NONE
D011453_D012640 NONE prostaglandins_5\NNS|NONE (r_pobj) of_4\IN|the (r_prep) relationship_3\NN|to|To (r_dobj) investigate_1\VB|effects|.|were|, (l_prep) to_9\TO|relationship|To (l_pobj) induction_11\NN|NONE (l_compound) seizure_10\NN|NONE
D011453_D012640 NONE prostaglandins_5\NNS|NONE (r_pobj) of_4\IN|the (r_prep) relationship_3\NN|to|To (r_dobj) investigate_1\VB|effects|.|were|, (r_advcl) evaluated_37\VBN|NONE (l_nsubjpass) effects_14\NNS|.|were|investigate|, (l_prep) on_20\IN|the|of (l_pobj) convulsions_21\NNS|NONE
D011453_D012640 NONE PGs_7\NNS|)|( (r_appos) prostaglandins_5\NNS|NONE (r_pobj) of_4\IN|the (r_prep) relationship_3\NN|to|To (r_dobj) investigate_1\VB|effects|.|were|, (l_prep) to_9\TO|relationship|To (l_pobj) induction_11\NN|NONE (l_compound) seizure_10\NN|NONE
D011453_D012640 NONE PGs_7\NNS|)|( (r_appos) prostaglandins_5\NNS|NONE (r_pobj) of_4\IN|the (r_prep) relationship_3\NN|to|To (r_dobj) investigate_1\VB|effects|.|were|, (r_advcl) evaluated_37\VBN|NONE (l_nsubjpass) effects_14\NNS|.|were|investigate|, (l_prep) on_20\IN|the|of (l_pobj) convulsions_21\NNS|NONE
D011453_D012640 NONE PGs_4\NNS|,|that|in|picrotoxin|are|but (r_nsubjpass) involved_6\VBN|.|results (l_prep) in_7\IN|,|that|PGs|picrotoxin|are|but (l_pobj) fluorthyl-_12\NNS|NONE (l_conj) convulsions_17\NNS|underlying|)|the|and
D011453_D012640 NONE PGs_4\NNS|,|that|in|picrotoxin|are|but (r_nsubjpass) involved_6\VBN|.|results (l_conj) picrotoxin-_21\XX|,|that|in|PGs|are|but (l_pobj) convulsions_29\NNS|,|electroshock|not
D010433_D012640 CID pentetrazol_28\NNP|electroshock|(|,|) (r_nmod) PTZ_30\NNP|, (r_conj) picrotoxin_26\JJ|, (r_conj) flurothyl_24\JJ|NONE (r_pobj) by_23\IN|NONE (r_agent) induced_22\VBN|NONE (r_acl) convulsions_21\NNS|NONE (r_pobj) on_20\IN|the|of (r_prep) effects_14\NNS|.|were|investigate|, (r_nsubjpass) evaluated_37\VBN|NONE (l_advcl) investigate_1\VB|effects|.|were|, (l_prep) to_9\TO|relationship|To (l_pobj) induction_11\NN|NONE (l_compound) seizure_10\NN|NONE
D010433_D012640 CID pentetrazol_28\NNP|electroshock|(|,|) (r_nmod) PTZ_30\NNP|, (r_conj) picrotoxin_26\JJ|, (r_conj) flurothyl_24\JJ|NONE (r_pobj) by_23\IN|NONE (r_agent) induced_22\VBN|NONE (r_acl) convulsions_21\NNS|NONE
D010433_D012640 CID PTZ_30\NNP|, (r_conj) picrotoxin_26\JJ|, (r_conj) flurothyl_24\JJ|NONE (r_pobj) by_23\IN|NONE (r_agent) induced_22\VBN|NONE (r_acl) convulsions_21\NNS|NONE (r_pobj) on_20\IN|the|of (r_prep) effects_14\NNS|.|were|investigate|, (r_nsubjpass) evaluated_37\VBN|NONE (l_advcl) investigate_1\VB|effects|.|were|, (l_prep) to_9\TO|relationship|To (l_pobj) induction_11\NN|NONE (l_compound) seizure_10\NN|NONE
D010433_D012640 CID PTZ_30\NNP|, (r_conj) picrotoxin_26\JJ|, (r_conj) flurothyl_24\JJ|NONE (r_pobj) by_23\IN|NONE (r_agent) induced_22\VBN|NONE (r_acl) convulsions_21\NNS|NONE
D010433_D012640 CID PTZ_14\NNP| (r_npadvmod) induced_16\VBN|NONE (r_amod) convulsions_17\NNS|underlying|)|the|and
D010433_D012640 CID PTZ_14\NNP| (r_npadvmod) induced_16\VBN|NONE (r_amod) convulsions_17\NNS|underlying|)|the|and (r_conj) fluorthyl-_12\NNS|NONE (r_pobj) in_7\IN|,|that|PGs|picrotoxin|are|but (r_prep) involved_6\VBN|.|results (l_conj) picrotoxin-_21\XX|,|that|in|PGs|are|but (l_pobj) convulsions_29\NNS|,|electroshock|not
D001640_D012640 CID bicuculline_35\NN|or (r_conj) electroshock_33\NN|pentetrazol|(|,|) (r_conj) PTZ_30\NNP|, (r_conj) picrotoxin_26\JJ|, (r_conj) flurothyl_24\JJ|NONE (r_pobj) by_23\IN|NONE (r_agent) induced_22\VBN|NONE (r_acl) convulsions_21\NNS|NONE (r_pobj) on_20\IN|the|of (r_prep) effects_14\NNS|.|were|investigate|, (r_nsubjpass) evaluated_37\VBN|NONE (l_advcl) investigate_1\VB|effects|.|were|, (l_prep) to_9\TO|relationship|To (l_pobj) induction_11\NN|NONE (l_compound) seizure_10\NN|NONE
D001640_D012640 CID bicuculline_35\NN|or (r_conj) electroshock_33\NN|pentetrazol|(|,|) (r_conj) PTZ_30\NNP|, (r_conj) picrotoxin_26\JJ|, (r_conj) flurothyl_24\JJ|NONE (r_pobj) by_23\IN|NONE (r_agent) induced_22\VBN|NONE (r_acl) convulsions_21\NNS|NONE
D001640_D012640 CID bicuculline_26\NN| (r_advmod) induced_28\VBN|or|, (r_conj) electroshock-_23\XX|,|convulsions|not (r_conj) picrotoxin-_21\XX|,|that|in|PGs|are|but (r_conj) involved_6\VBN|.|results (l_prep) in_7\IN|,|that|PGs|picrotoxin|are|but (l_pobj) fluorthyl-_12\NNS|NONE (l_conj) convulsions_17\NNS|underlying|)|the|and
D001640_D012640 CID bicuculline_26\NN| (r_advmod) induced_28\VBN|or|, (r_conj) electroshock-_23\XX|,|convulsions|not (r_conj) picrotoxin-_21\XX|,|that|in|PGs|are|but (l_pobj) convulsions_29\NNS|,|electroshock|not
D005481_D012640 CID flurothyl_24\JJ|NONE (r_pobj) by_23\IN|NONE (r_agent) induced_22\VBN|NONE (r_acl) convulsions_21\NNS|NONE (r_pobj) on_20\IN|the|of (r_prep) effects_14\NNS|.|were|investigate|, (r_nsubjpass) evaluated_37\VBN|NONE (l_advcl) investigate_1\VB|effects|.|were|, (l_prep) to_9\TO|relationship|To (l_pobj) induction_11\NN|NONE (l_compound) seizure_10\NN|NONE
D005481_D012640 CID flurothyl_24\JJ|NONE (r_pobj) by_23\IN|NONE (r_agent) induced_22\VBN|NONE (r_acl) convulsions_21\NNS|NONE
D005481_D012640 CID fluorthyl-_12\NNS|NONE (l_conj) convulsions_17\NNS|underlying|)|the|and
D005481_D012640 CID fluorthyl-_12\NNS|NONE (r_pobj) in_7\IN|,|that|PGs|picrotoxin|are|but (r_prep) involved_6\VBN|.|results (l_conj) picrotoxin-_21\XX|,|that|in|PGs|are|but (l_pobj) convulsions_29\NNS|,|electroshock|not
D010852_D012640 CID picrotoxin_26\JJ|, (r_conj) flurothyl_24\JJ|NONE (r_pobj) by_23\IN|NONE (r_agent) induced_22\VBN|NONE (r_acl) convulsions_21\NNS|NONE (r_pobj) on_20\IN|the|of (r_prep) effects_14\NNS|.|were|investigate|, (r_nsubjpass) evaluated_37\VBN|NONE (l_advcl) investigate_1\VB|effects|.|were|, (l_prep) to_9\TO|relationship|To (l_pobj) induction_11\NN|NONE (l_compound) seizure_10\NN|NONE
D010852_D012640 CID picrotoxin_26\JJ|, (r_conj) flurothyl_24\JJ|NONE (r_pobj) by_23\IN|NONE (r_agent) induced_22\VBN|NONE (r_acl) convulsions_21\NNS|NONE
D010852_D012640 CID picrotoxin-_21\XX|,|that|in|PGs|are|but (r_conj) involved_6\VBN|.|results (l_prep) in_7\IN|,|that|PGs|picrotoxin|are|but (l_pobj) fluorthyl-_12\NNS|NONE (l_conj) convulsions_17\NNS|underlying|)|the|and
D010852_D012640 CID picrotoxin-_21\XX|,|that|in|PGs|are|but (l_pobj) convulsions_29\NNS|,|electroshock|not
6732043
D000728_D012891 NONE androgens_7\NNS|NONE (r_pobj) of_6\IN|a (r_prep) role_5\NN|have|in|.|reports (r_dobj) favored_3\VBN|NONE (l_prep) in_8\IN|have|role|.|reports (l_pobj) pathogenesis_10\NN|NONE (l_prep) of_11\IN|the (l_pobj) apnea_13\NN|NONE
D000728_D020181 CID androgen_12\JJ|exogenous (r_compound) administration_13\NN|NONE (r_pobj) by_10\IN|a (r_prep) woman_9\NN|NONE (r_pobj) in_7\IN|the|apnea (r_prep) syndrome_6\NN|NONE
D000728_D020181 CID androgens_36\NNS|being|while (r_dobj) administered_34\VBN|who|changes|had (r_advcl) developed_22\VBN|a|old (l_dobj) changes_24\NNS|who|administered|had (l_conj) syndrome_27\NN|physical|and (l_prep) of_28\IN|the (l_pobj) apnea_31\NN|NONE
D000728_D020181 CID androgen_3\NN|of|abated|produced (r_nmod) symptoms_5\NNS|NONE (l_prep) of_6\IN|abated|androgen|produced (l_pobj) apnea_9\NN|NONE
D000728_D020181 CID androgen_15\NN|NONE (r_compound) therapy_16\NN|NONE (r_pobj) of_14\IN|possible|side|a (r_prep) effect_13\NN|must|Development|be|. (r_oprd) considered_9\VBN|NONE (l_nsubjpass) Development_0\NN|effect|must|be|. (l_prep) of_1\IN|NONE (l_pobj) syndrome_6\NN|NONE
2234245
D003676_D064420 NONE desferrioxamine_10\NN|NONE (r_pobj) of_9\IN|higher|the (r_prep) doses_8\NNS|NONE (r_dobj) receiving_5\VBG|NONE (r_acl) patients_4\NNS|NONE (r_pobj) in_3\IN|.|coincided|toxicity|or (r_prep) appeared_2\VBD|NONE (l_nsubj) toxicity_1\NN|.|in|coincided|or
D003676_D014786 NONE desferrioxamine_8\NN|NONE (r_dobj) receiving_7\VBG|hemodialyzed (r_acl) patients_6\NNS|NONE (r_pobj) in_4\IN|Ocular|. (r_prep) toxicity_3\NN|NONE
D003676_D014786 NONE desferrioxamine_10\NN|NONE (r_dobj) receiving_9\VBG|hemodialyzed||weekly (r_acl) patients_8\NNS|period (r_pobj) During_0\IN|for|were|for|. (r_prep) monitored_25\VBN|NONE (l_prep) for_26\IN|for|During|were|. (l_pobj) detection_27\NN|NONE (l_prep) of_28\IN|NONE (l_pobj) toxicity_30\NN|NONE
D003676_D014786 NONE desferrioxamine_15\NN|NONE (r_dobj) receiving_14\VBG|hemodialyzed (r_acl) patients_13\NNS|NONE (r_pobj) in_11\IN|infrequent|an (r_prep) complication_10\NN|toxicity|that|not (r_attr) is_6\VBZ|data|. (l_nsubj) toxicity_5\NN|complication|that|not
D003676_D006311 NONE desferrioxamine_8\NN|NONE (r_dobj) receiving_7\VBG|hemodialyzed (r_acl) patients_6\NNS|NONE (r_pobj) in_4\IN|Ocular|. (r_prep) toxicity_3\NN|NONE
D003676_D006311 NONE desferrioxamine_10\NN|NONE (r_dobj) receiving_9\VBG|hemodialyzed||weekly (r_acl) patients_8\NNS|period (r_pobj) During_0\IN|for|were|for|. (r_prep) monitored_25\VBN|NONE (l_prep) for_26\IN|for|During|were|. (l_pobj) detection_27\NN|NONE (l_prep) of_28\IN|NONE (l_pobj) toxicity_30\NN|NONE
D003676_D006311 NONE desferrioxamine_15\NN|NONE (r_dobj) receiving_14\VBG|hemodialyzed (r_acl) patients_13\NNS|NONE (r_pobj) in_11\IN|infrequent|an (r_prep) complication_10\NN|toxicity|that|not (r_attr) is_6\VBZ|data|. (l_nsubj) toxicity_5\NN|complication|that|not
D003676_D034381 NONE Desferrioxamine_0\NNP|NONE (r_compound) withdrawal_1\NN|.|,|in|and|reversal (r_nsubj) resulted_2\VBD|NONE (l_conj) reversal_22\NN|.|,|withdrawal|in|and (l_prep) of_23\IN|a|complete (l_pcomp) hearing_24\NN|NONE (l_dobj) loss_25\NN|in|in
-1_D064420 NONE aluminium_19\NN|or (r_conj) ferritin_17\NN|serum (r_nmod) levels_21\NNS|NONE (r_pobj) of_16\IN|the (r_prep) normalization_15\NN|NONE (r_pobj) with_13\IN|NONE (r_prep) coincided_12\VBD|.|in|toxicity|or (r_conj) appeared_2\VBD|NONE (l_nsubj) toxicity_1\NN|.|in|coincided|or
7724492
D003487_D007674 NONE cyanoacrylate_7\JJ|(|doxorubicin|adriamycin)loaded (r_compound) nanoparticles_8\NNS|NONE (r_pobj) of_3\IN|Acute|.|renal (r_prep) toxicity_2\NN|NONE
D004317_D005921 NONE doxorubicin_1\NN| (r_npadvmod) loaded_3\VBN|NONE (r_amod) nanoparticle_4\NN|Acute|DXNP|renal (r_nmod) toxicity_9\NN|was|in|. (r_nsubjpass) explored_11\VBN|NONE (l_prep) in_12\IN|was|toxicity|. (l_pobj) rats_15\NNS|NONE (l_conj) rats_17\NNS|both|normal|and (l_prep) with_18\IN|NONE (l_pobj) glomerulonephritis_20\NN|NONE
D004317_D005921 NONE DX_10\NNP|NONE (r_pobj) given_9\VBN|/ (r_prep) rats_8\NNS|In|,|,|.|in|within (r_nsubj) died_11\VBD|NONE (l_prep) In_0\IN|rats|,|,|.|in|within (l_pobj) rats_1\NNS|NONE (l_prep) with_2\IN|NONE (l_pobj) glomerulonephritis_5\NN|NONE
D004317_D011507 CID DX_16\NNP|NONE (r_pobj) with_15\IN|NONE (r_prep) treated_14\VBN|NONE (r_acl) those_13\DT|NONE (r_pobj) in_12\IN|NONE (r_prep) than_11\IN|with (r_prep) treated_8\VBN|NONE (r_acl) animals_7\NNS|NONE (r_pobj) in_6\IN|proteinuria|. (r_prep) appeared_5\VBD|NONE (l_nsubj) proteinuria_4\NN|.|in
D004317_D011507 CID doxorubicin_22\NN|day (r_compound) treatment_23\NN|NONE (r_pobj) after_21\IN|NONE (r_prep) prolonged_20\VBN|and||.|more (r_conj) intense_13\JJ|,|without (r_acomp) was_7\VBD|.|but|,|Proteinuria|in (r_conj) appeared_1\VBD|NONE (l_nsubj) Proteinuria_0\NNP|was|.|but|,|in
D004317_D011507 CID DX_39\NNP|and (r_conj) DXNP_37\NNP|NONE (r_pobj) between_36\IN|significant (r_prep) difference_35\NN|NONE (r_pobj) without_33\IN|intense|, (r_prep) was_7\VBD|.|but|,|Proteinuria|in (r_conj) appeared_1\VBD|NONE (l_nsubj) Proteinuria_0\NNP|was|.|but|,|in
D004317_D007674 NONE doxorubicin_4\NN|(|adriamycin)loaded|cyanoacrylate (r_nmod) nanoparticles_8\NNS|NONE (r_pobj) of_3\IN|Acute|.|renal (r_prep) toxicity_2\NN|NONE
D004317_D007674 NONE adriamycin)-loaded_6\VBN|(|doxorubicin|cyanoacrylate (r_amod) nanoparticles_8\NNS|NONE (r_pobj) of_3\IN|Acute|.|renal (r_prep) toxicity_2\NN|NONE
D004317_D007674 NONE doxorubicin_1\NN| (r_npadvmod) loaded_3\VBN|NONE (r_amod) nanoparticle_4\NN|Acute|DXNP|renal (r_nmod) toxicity_9\NN|was|in|.
D004317_D007674 NONE DX_16\NNP|NONE (r_pobj) than_14\IN|less (r_prep) animals_13\NNS|that|despite|,|in|,|DXNP|, (r_dobj) killed_11\VBD|.|results (l_prep) despite_18\IN|that|,|animals|in|,|DXNP|, (l_prep) of_19\IN|NONE (l_pobj) toxicity_23\NN|NONE
8766220
D014147_D010146 NONE Tramadol_0\NNP|.|opioid (r_nsubj) is_1\VBZ|NONE (l_attr) opioid_4\NN|.|Tramadol (l_prep) with_5\IN|weak|a (l_pobj) effects_6\NNS|NONE (l_relcl) used_14\VBN|on (l_xcomp) treat_16\VB|is|that (l_dobj) pain_18\NN|to
D014147_D010146 NONE Tramadol_0\NNP|.|opioid (r_nsubj) is_1\VBZ|NONE (l_attr) opioid_4\NN|.|Tramadol (l_prep) with_5\IN|weak|a (l_pobj) effects_6\NNS|NONE (l_relcl) used_14\VBN|on (l_xcomp) treat_16\VB|is|that (l_dobj) pain_18\NN|to (l_conj) pain_23\NN|cancer|and
D014147_D006212 CID tramadol_9\NN|NONE (r_pobj) of_8\IN|term (r_prep) intake_7\NN|NONE (r_pobj) after_3\IN|hallucinations|and|.|combined (r_prep) Nightmares_0\NNS|NONE (l_conj) hallucinations_2\NNS|after|and|.|combined
D014147_D006212 CID tramadol_25\NN|and|active (r_conj) drugs_23\NNS|NONE (r_pobj) of_19\IN|the (r_prep) withdrawal_18\NN|NONE (r_pobj) after_16\IN|only|that (r_prep) stopped_15\VBD|NONE (r_relcl) hallucinations_12\NNS|.|patient|after
D017374_-1 NONE paroxetine_7\NN|NONE (r_pobj) with_6\IN|NONE (r_prep) association_5\NN|NONE (r_pobj) in_4\IN|was|drug|dosulepine|.|and (r_prep) initiated_3\VBN|NONE (l_conj) dosulepine_9\JJ|was|drug|.|in|and (l_prep) in_11\IN|hydrochloride (l_pobj) patient_14\NN|NONE (l_amod) tetraparetic_13\JJ|with|a
D017374_D059350 NONE paroxetine_7\NN|NONE (r_pobj) with_6\IN|NONE (r_prep) association_5\NN|NONE (r_pobj) in_4\IN|was|drug|dosulepine|.|and (r_prep) initiated_3\VBN|NONE (l_conj) dosulepine_9\JJ|was|drug|.|in|and (l_prep) in_11\IN|hydrochloride (l_pobj) patient_14\NN|NONE (l_prep) with_15\IN|tetraparetic|a (l_pobj) pain_17\NN|NONE
D004308_-1 NONE hydrochloride_10\NN|in (r_dobj) dosulepine_9\JJ|was|drug|.|in|and (l_prep) in_11\IN|hydrochloride (l_pobj) patient_14\NN|NONE (l_amod) tetraparetic_13\JJ|with|a
D014147_D009369 NONE Tramadol_0\NNP|.|opioid (r_nsubj) is_1\VBZ|NONE (l_attr) opioid_4\NN|.|Tramadol (l_prep) with_5\IN|weak|a (l_pobj) effects_6\NNS|NONE (l_relcl) used_14\VBN|on (l_xcomp) treat_16\VB|is|that (l_dobj) pain_18\NN|to (l_compound) cancer_17\NN|pain|and
D004308_D059350 NONE hydrochloride_10\NN|in (r_dobj) dosulepine_9\JJ|was|drug|.|in|and (l_prep) in_11\IN|hydrochloride (l_pobj) patient_14\NN|NONE (l_prep) with_15\IN|tetraparetic|a (l_pobj) pain_17\NN|NONE
9766615
D003024_D001480 NONE clozapine_40\NN|(|)|seizure (r_appos) threshold_37\NN|effects|agranulocytosis|and|, (r_dobj) lowered_35\VBD|in|,|are (r_conj) associated_13\VBN|agents|,|risk|.|but (r_conj) have_4\VBP|NONE (l_dobj) risk_7\NN|agents|,|.|but|associated (l_prep) of_8\IN|lower|a (l_pobj) EPS_9\NNP|NONE
D003024_D001480 NONE clozapine_46\NN|NONE (r_appos) agranulocytosis_44\NN|effects|and|,|threshold (r_conj) lowered_35\VBD|in|,|are (r_conj) associated_13\VBN|agents|,|risk|.|but (r_conj) have_4\VBP|NONE (l_dobj) risk_7\NN|agents|,|.|but|associated (l_prep) of_8\IN|lower|a (l_pobj) EPS_9\NNP|NONE
D003024_D000380 CID clozapine_40\NN|(|)|seizure (r_appos) threshold_37\NN|effects|agranulocytosis|and|, (r_dobj) lowered_35\VBD|in|,|are (l_conj) agranulocytosis_44\NN|effects|and|,|threshold
D003024_D000380 CID clozapine_46\NN|NONE (r_appos) agranulocytosis_44\NN|effects|and|,|threshold
D003024_D012640 NONE clozapine_40\NN|(|)|seizure (r_appos) threshold_37\NN|effects|agranulocytosis|and|, (l_compound) seizure_36\NN|(|)|clozapine
D003024_D012640 NONE clozapine_46\NN|NONE (r_appos) agranulocytosis_44\NN|effects|and|,|threshold (r_conj) lowered_35\VBD|in|,|are (l_dobj) threshold_37\NN|effects|agranulocytosis|and|, (l_compound) seizure_36\NN|(|)|clozapine
D003024_D012735 NONE clozapine_40\NN|(|)|seizure (r_appos) threshold_37\NN|effects|agranulocytosis|and|, (r_dobj) lowered_35\VBD|in|,|are (l_nsubj) effects_21\NNS|agranulocytosis|and|,|threshold (l_conj) effects_24\NNS|,|cardiovascular|, (l_conj) gain_27\NN|,|anticholinergic (l_conj) dysfunction_30\NN|,|weight
D003024_D012735 NONE clozapine_46\NN|NONE (r_appos) agranulocytosis_44\NN|effects|and|,|threshold (r_conj) lowered_35\VBD|in|,|are (l_nsubj) effects_21\NNS|agranulocytosis|and|,|threshold (l_conj) effects_24\NNS|,|cardiovascular|, (l_conj) gain_27\NN|,|anticholinergic (l_conj) dysfunction_30\NN|,|weight
D003024_D015430 NONE clozapine_40\NN|(|)|seizure (r_appos) threshold_37\NN|effects|agranulocytosis|and|, (r_dobj) lowered_35\VBD|in|,|are (l_nsubj) effects_21\NNS|agranulocytosis|and|,|threshold (l_conj) effects_24\NNS|,|cardiovascular|, (l_conj) gain_27\NN|,|anticholinergic
D003024_D015430 NONE clozapine_46\NN|NONE (r_appos) agranulocytosis_44\NN|effects|and|,|threshold (r_conj) lowered_35\VBD|in|,|are (l_nsubj) effects_21\NNS|agranulocytosis|and|,|threshold (l_conj) effects_24\NNS|,|cardiovascular|, (l_conj) gain_27\NN|,|anticholinergic
1355091
C014282_D001919 CID cirazoline_9\NN|NONE (r_pobj) to_5\IN|NONE (r_prep) bradycardia_4\NNS|and|)|micrograms|pressor|and|The|i.v.|kg|Abbott|,|kg|,|noradrenaline
C014282_D001919 CID cirazoline_7\NN|NONE (r_pobj) of_6\IN|bradycardia (r_prep) effects_5\NNS|Both|and|the (l_amod) bradycardia_4\NN|of
D009638_D001919 CID noradrenaline_33\NN|and|bradycardia|)|micrograms|pressor|and|The|i.v.|kg|Abbott|,|kg|, (r_conj) responses_2\NNS|in|were|with|. (l_conj) bradycardia_4\NNS|and|)|micrograms|pressor|and|The|i.v.|kg|Abbott|,|kg|,|noradrenaline
D009638_D001919 CID noradrenaline_7\NN| (r_npadvmod) induced_9\VBN|in|pressor|the (r_amod) effect_11\NN|that (r_dobj) accompanied_5\VBD|the (r_relcl) bradycardia_3\NN|similar|despite|Furthermore|,
D011224_D007024 CID prazosin_9\NN| (r_npadvmod) pretreated_11\VBN|NONE (r_amod) conscious_12\JJ|hypertensive (r_amod) rats_15\NNS|NONE (r_pobj) in_7\IN|alpha|adrenoceptor (r_prep) blockade_6\NN|NONE (r_pobj) following_3\VBG|.|hypotension (r_prep) occurs_2\VBZ|NONE (l_nsubj) hypotension_1\NN|.|following
D011224_D007024 CID prazosin_15\NN|NONE (r_pobj) with_14\IN|NONE (r_prep) treated_13\VBN|orthostatic|in (r_acl) hypotension_9\NN|However|,|in|tilt|.|,|but
D011224_D007024 CID prazosin_22\NN|NONE (r_pobj) of_21\IN|acute (r_prep) dosing_20\NN|NONE (r_pobj) after_18\IN|or (r_conj) to_16\IN|either (r_prep) prior_15\RB|when (r_advmod) performed_13\VBN|not|hypotension|tilts|.|did (r_advcl) produce_9\VB|NONE (l_dobj) hypotension_11\NN|not|performed|tilts|.|did
C056299_D001919 CID Abbott-53693_22\NNP|and|bradycardia|)|micrograms|pressor|and|The|i.v.|kg|,|kg|,|noradrenaline (r_appos) responses_2\NNS|in|were|with|. (l_conj) bradycardia_4\NNS|and|)|micrograms|pressor|and|The|i.v.|kg|Abbott|,|kg|,|noradrenaline
C056299_D001919 CID Abbott-53693_9\NNP|NONE (r_pobj) of_8\IN|pressor|the (r_prep) effects_7\NNS|similar|On|,|was|,|but (r_nsubj) were_10\VBD|NONE (l_conj) was_22\VBD|similar|effects|On|,|,|but (l_nsubj) bradycardia_21\NN|greater|.
D011224_D006973 NONE prazosin_9\NN| (r_npadvmod) pretreated_11\VBN|NONE (r_amod) conscious_12\JJ|hypertensive (r_amod) rats_15\NNS|NONE (l_amod) hypertensive_14\JJ|conscious
D011224_D006973 NONE prazosin_7\NN|chronic (r_compound) treatment_8\NN|for|function|whether (r_nsubj) alters_9\VBZ|to (l_prep) for_14\IN|treatment|function|whether (l_pobj) control_16\NN|NONE (l_prep) in_21\IN|of|orthostatic (l_pobj) rats_25\NNS|NONE (l_amod) hypertensive_24\JJ|(|)|SHR|conscious
D011224_D001919 NONE prazosin_51\NN|chronic (r_compound) pretreatment_52\NN|NONE (r_pobj) without_49\IN|and (r_conj) with_47\IN|in|were|.|responses (r_prep) determined_43\VBN|NONE (l_nsubjpass) responses_2\NNS|in|were|with|. (l_conj) bradycardia_4\NNS|and|)|micrograms|pressor|and|The|i.v.|kg|Abbott|,|kg|,|noradrenaline
D011224_D001919 NONE prazosin_12\NN|NONE (r_pobj) in_10\IN|were|compared|.|pressor|treated (r_prep) abolished_9\VBN|NONE (l_nsubjpass) pressor_2\NN|were|compared|.|in|treated (l_conj) effects_5\NNS|Both|and|the (l_amod) bradycardia_4\NN|of
D011224_D001919 NONE prazosin_28\NN|chronic (r_compound) treatment_29\NN|NONE (r_pobj) with_26\IN|NONE (r_prep) SHR_25\NNP|NONE (r_pobj) in_24\IN|than (r_prep) greater_23\JJR|.|bradycardia (r_acomp) was_22\VBD|similar|effects|On|,|,|but (l_nsubj) bradycardia_21\NN|greater|.
D011224_D001919 NONE prazosin_20\NN|chronic (r_compound) treatment_21\NN|NONE (r_pobj) without_18\IN|and (r_conj) with_16\IN|NONE (r_prep) similar_15\JJ|bradycardia|despite|Furthermore|, (r_acomp) was_14\VBD|NONE (l_nsubj) bradycardia_3\NN|similar|despite|Furthermore|,
D015016_D007024 NONE rauwolscine_33\JJ|NONE (r_pobj) with_32\IN|NONE (r_prep) treated_31\VBN|the (r_acl) SHR_30\NN|not (r_pobj) in_28\IN|However|,|tilt|.|hypotension|,|but (r_conj) induced_7\VBN|NONE (l_dobj) hypotension_9\NN|However|,|in|tilt|.|,|but
11185967
D000431_D012640 NONE alcohol_8\NN| (r_npadvmod) related_10\VBN|seizure (r_amod) disorder_12\NN|underlying|or (l_compound) seizure_11\NN|related
D000431_D012640 NONE alcohol_8\NN| (r_npadvmod) related_10\VBN|seizure (r_amod) disorder_12\NN|underlying|or (r_conj) drug_6\NN|NONE (r_pobj) of_4\IN|NONE (r_prep) history_3\NN|,|,|Patient (r_appos) demographics_1\NNS|results|time|,|from|recorded|. (r_nsubj) estimated_14\VBN|NONE (l_prep) from_16\IN|results|time|,|demographics|recorded|. (l_pobj) seizure_17\NN|to
D000431_D019969 NONE alcohol_8\NN| (r_npadvmod) related_10\VBN|seizure (r_amod) disorder_12\NN|underlying|or (r_conj) drug_6\NN|NONE (r_pobj) of_4\IN|NONE (r_prep) history_3\NN|,|,|Patient (r_appos) demographics_1\NNS|results|time|,|from|recorded|. (r_nsubj) estimated_14\VBN|NONE (l_prep) from_16\IN|results|time|,|demographics|recorded|. (l_prep) to_18\IN|seizure (l_pobj) collection_20\NN|NONE (l_conj) history_22\NN|,|sample (l_conj) suspicion_24\NN|or (l_prep) of_25\IN|NONE (l_pobj) cocaine_26\NN|NONE (l_conj) abuse_29\NN|or
D000431_D019970 NONE alcohol_8\NN| (r_npadvmod) related_10\VBN|seizure (r_amod) disorder_12\NN|underlying|or (r_conj) drug_6\NN|NONE (r_pobj) of_4\IN|NONE (r_prep) history_3\NN|,|,|Patient (r_appos) demographics_1\NNS|results|time|,|from|recorded|. (r_nsubj) estimated_14\VBN|NONE (l_prep) from_16\IN|results|time|,|demographics|recorded|. (l_prep) to_18\IN|seizure (l_pobj) collection_20\NN|NONE (l_conj) history_22\NN|,|sample (l_conj) suspicion_24\NN|or (l_prep) of_25\IN|NONE (l_pobj) cocaine_26\NN|NONE (l_conj) abuse_29\NN|or
D000661_D012640 NONE amphetamine_18\NN|in|or (r_conj) cocaine_16\NN|NONE (l_prep) in_19\IN|amphetamine|or (l_pobj) patients_24\NNS|NONE (l_compound) seizure_23\NN|emergency
D000662_D012640 NONE amphetamines_11\NNS|in|and (r_conj) cocaine_9\NN|NONE (l_prep) in_12\IN|amphetamines|and (l_pobj) patients_15\NNS|NONE (l_compound) seizure_14\NN|NONE
D003042_D012640 NONE cocaine_16\NN|NONE (l_prep) in_19\IN|amphetamine|or (l_pobj) patients_24\NNS|NONE (l_compound) seizure_23\NN|emergency
D003042_D012640 NONE cocaine_9\NN|NONE (l_prep) in_12\IN|amphetamines|and (l_pobj) patients_15\NNS|NONE (l_compound) seizure_14\NN|NONE
2722224
D006854_D006973 CID Hydrocortisone_0\NNP|responsiveness|:||.|hypertension (r_npadvmod) induced_2\VBN|NONE (l_dobj) hypertension_3\NN|responsiveness|:||.|Hydrocortisone
D006854_D006973 CID hydrocortisone_7\NN|NONE (r_pobj) with_6\IN|blood (r_prep) pressure_5\NN|NONE
D006854_D016534 NONE hydrocortisone_7\NN|NONE (r_pobj) with_6\IN|blood (r_prep) pressure_5\NN|NONE (r_dobj) resting_3\VBG|NONE (r_pcomp) in_2\IN|The (r_prep) rise_1\NN|with|is|. (r_nsubjpass) associated_9\VBN|NONE (l_prep) with_10\IN|rise|is|. (l_pobj) output_14\NN|NONE
15897593
D064730_D001855 NONE Dexrazoxane_0\NNP|etoposide|against|. (r_nsubj) protects_1\VBZ|NONE (l_prep) against_2\IN|etoposide|.|Dexrazoxane (l_pobj) myelosuppression_3\NN|NONE
D064730_D001855 NONE dexrazoxane_3\NN|NONE (r_npadvmod) reduced_4\VBN|loss|and (r_amod) myelosuppression_5\NN|NONE
D064730_D001855 NONE dexrazoxane_3\NN|NONE (r_npadvmod) reduced_4\VBN|loss|and (r_amod) myelosuppression_5\NN|NONE (r_pobj) of_2\IN|Nontoxic|in|antagonized|from|and (r_prep) doses_1\NNS|myelosuppression|;|however|.|, (r_nsubj) dexrazoxane_27\NN|NONE (l_dobj) myelosuppression_30\NN|;|doses|however|.|,
D064730_D001855 NONE dexrazoxane_27\NN|NONE (l_nsubj) doses_1\NNS|myelosuppression|;|however|.|, (l_prep) of_2\IN|Nontoxic|in|antagonized|from|and (l_pobj) myelosuppression_5\NN|NONE
D064730_D001855 NONE dexrazoxane_27\NN|NONE (l_dobj) myelosuppression_30\NN|;|doses|however|.|,
D064730_D006402 NONE dexrazoxane_12\NN|NONE (r_pobj) of_11\IN|and (r_prep) coadministration_10\NN|NONE (r_pobj) following_9\VBG|the|hematologic (r_prep) toxicity_8\NN|Because|,|enhancers|was|:
D064730_D006402 NONE dexrazoxane_40\NN|NONE (r_dobj) doxorubicin_38\NN|,|and (r_conj) daunorubicin_35\NNS|, (r_conj) etoposide_33\VB|NONE (r_pobj) to_32\TO|of (r_prep) Sensitivity_24\NN|.|was|investigated|in (r_nsubjpass) determined_42\VBN|NONE (l_advcl) investigated_22\VBN|Sensitivity|.|was|in (l_nsubjpass) toxicity_8\NN|Because|,|enhancers|was|:
D064730_D006402 NONE dexrazoxane_8\NN|of (r_nmod) doses_11\NNS|NONE (r_dobj) combining_7\VBG|brain (r_acl) metastases_6\NNS|NONE (r_pobj) with_4\IN|NONE (r_prep) patients_3\NNS|NONE (r_pobj) in_2\IN|Clinical (r_prep) trials_1\NNS|ongoing|. (r_nsubj) is_14\VBZ|NONE (l_acomp) ongoing_15\JJ|trials|. (l_prep) with_16\IN|NONE (l_pobj) aim_18\NN|NONE (l_prep) of_19\IN|the (l_pcomp) improving_20\VBG|NONE (l_prep) without_22\IN|efficacy (l_pcomp) aggravating_23\VBG|NONE (l_dobj) toxicity_25\NN|NONE
D003630_D066126 NONE daunorubicin_2\NN|,|;|however|myelosuppression|.|use (r_ccomp) limit_30\VBP|NONE (l_nsubj) myelosuppression_26\NN|,|;|however|.|use|daunorubicin (l_conj) toxicity_29\NN|and
D004317_D006402 CID doxorubicin_38\NN|,|and (r_conj) daunorubicin_35\NNS|, (r_conj) etoposide_33\VB|NONE (r_pobj) to_32\TO|of (r_prep) Sensitivity_24\NN|.|was|investigated|in (r_nsubjpass) determined_42\VBN|NONE (l_advcl) investigated_22\VBN|Sensitivity|.|was|in (l_nsubjpass) toxicity_8\NN|Because|,|enhancers|was|:
D064730_D009362 NONE dexrazoxane_8\NN|of (r_nmod) doses_11\NNS|NONE (r_dobj) combining_7\VBG|brain (r_acl) metastases_6\NNS|NONE
D005047_D009362 NONE etoposide_13\NN|NONE (r_pobj) of_12\IN|dexrazoxane (r_prep) doses_11\NNS|NONE (r_dobj) combining_7\VBG|brain (r_acl) metastases_6\NNS|NONE
D004317_D015431 CID doxorubicin_41\NN|NONE (r_pobj) from_40\IN|vitro|the (r_prep) cytotoxicity_39\NN|weight|,|nor (r_conj) loss_33\NN|neither|,|reduced (r_conj) myelosuppression_30\NN|;|doses|however|.|, (r_dobj) dexrazoxane_27\NN|NONE (l_nsubj) doses_1\NNS|myelosuppression|;|however|.|, (l_prep) of_2\IN|Nontoxic|in|antagonized|from|and (l_pobj) myelosuppression_5\NN|NONE (l_conj) loss_8\NN|reduced|and
D004317_D015431 CID doxorubicin_41\NN|NONE (r_pobj) from_40\IN|vitro|the (r_prep) cytotoxicity_39\NN|weight|,|nor (r_conj) loss_33\NN|neither|,|reduced
D004317_D064420 NONE doxorubicin_41\NN|NONE (r_pobj) from_40\IN|vitro|the (r_prep) cytotoxicity_39\NN|weight|,|nor
D004317_D001855 NONE doxorubicin_16\RB|but|daunorubicin|and (r_conj) etoposide_11\NN|against|.|Dexrazoxane (r_advmod) protects_1\VBZ|NONE (l_prep) against_2\IN|etoposide|.|Dexrazoxane (l_pobj) myelosuppression_3\NN|NONE
D004317_D001855 NONE doxorubicin_4\NN|anthracyclines|are|and (r_conj) daunorubicin_2\NN|,|;|however|myelosuppression|.|use (r_ccomp) limit_30\VBP|NONE (l_nsubj) myelosuppression_26\NN|,|;|however|.|use|daunorubicin
D004317_D001855 NONE doxorubicin_41\NN|NONE (r_pobj) from_40\IN|vitro|the (r_prep) cytotoxicity_39\NN|weight|,|nor (r_conj) loss_33\NN|neither|,|reduced (r_conj) myelosuppression_30\NN|;|doses|however|.|, (r_dobj) dexrazoxane_27\NN|NONE (l_nsubj) doses_1\NNS|myelosuppression|;|however|.|, (l_prep) of_2\IN|Nontoxic|in|antagonized|from|and (l_pobj) myelosuppression_5\NN|NONE
D004317_D001855 NONE doxorubicin_41\NN|NONE (r_pobj) from_40\IN|vitro|the (r_prep) cytotoxicity_39\NN|weight|,|nor (r_conj) loss_33\NN|neither|,|reduced (r_conj) myelosuppression_30\NN|;|doses|however|.|,
D005047_D064420 NONE etoposide_12\RB|and (r_conj) daunorubicin_10\NN|NONE (r_pobj) from_9\IN|of|Nontoxic|in|antagonized|and (r_prep) doses_1\NNS|myelosuppression|;|however|.|, (r_nsubj) dexrazoxane_27\NN|NONE (l_dobj) myelosuppression_30\NN|;|doses|however|.|, (l_conj) loss_33\NN|neither|,|reduced (l_conj) cytotoxicity_39\NN|weight|,|nor
D005047_D015431 CID etoposide_12\RB|and (r_conj) daunorubicin_10\NN|NONE (r_pobj) from_9\IN|of|Nontoxic|in|antagonized|and (r_prep) doses_1\NNS|myelosuppression|;|however|.|, (l_prep) of_2\IN|Nontoxic|in|antagonized|from|and (l_pobj) myelosuppression_5\NN|NONE (l_conj) loss_8\NN|reduced|and
D005047_D015431 CID etoposide_12\RB|and (r_conj) daunorubicin_10\NN|NONE (r_pobj) from_9\IN|of|Nontoxic|in|antagonized|and (r_prep) doses_1\NNS|myelosuppression|;|however|.|, (r_nsubj) dexrazoxane_27\NN|NONE (l_dobj) myelosuppression_30\NN|;|doses|however|.|, (l_conj) loss_33\NN|neither|,|reduced
D011034_D001855 NONE epipodophyllotoxin_7\NN|and (r_conj) doxorubicin_4\NN|anthracyclines|are|and (r_conj) daunorubicin_2\NN|,|;|however|myelosuppression|.|use (r_ccomp) limit_30\VBP|NONE (l_nsubj) myelosuppression_26\NN|,|;|however|.|use|daunorubicin
D005047_D066126 NONE etoposide_8\NN|the (r_appos) epipodophyllotoxin_7\NN|and (r_conj) doxorubicin_4\NN|anthracyclines|are|and (r_conj) daunorubicin_2\NN|,|;|however|myelosuppression|.|use (r_ccomp) limit_30\VBP|NONE (l_nsubj) myelosuppression_26\NN|,|;|however|.|use|daunorubicin (l_conj) toxicity_29\NN|and
D018943_D001855 NONE anthracyclines_1\NNS|are|and|doxorubicin (r_nsubj) daunorubicin_2\NN|,|;|however|myelosuppression|.|use (r_ccomp) limit_30\VBP|NONE (l_nsubj) myelosuppression_26\NN|,|;|however|.|use|daunorubicin
D011034_D066126 NONE epipodophyllotoxin_7\NN|and (r_conj) doxorubicin_4\NN|anthracyclines|are|and (r_conj) daunorubicin_2\NN|,|;|however|myelosuppression|.|use (r_ccomp) limit_30\VBP|NONE (l_nsubj) myelosuppression_26\NN|,|;|however|.|use|daunorubicin (l_conj) toxicity_29\NN|and
D003630_D006402 CID daunorubicin_35\NNS|, (r_conj) etoposide_33\VB|NONE (r_pobj) to_32\TO|of (r_prep) Sensitivity_24\NN|.|was|investigated|in (r_nsubjpass) determined_42\VBN|NONE (l_advcl) investigated_22\VBN|Sensitivity|.|was|in (l_nsubjpass) toxicity_8\NN|Because|,|enhancers|was|:
D003630_D015431 CID daunorubicin_10\NN|NONE (r_pobj) from_9\IN|of|Nontoxic|in|antagonized|and (r_prep) doses_1\NNS|myelosuppression|;|however|.|, (l_prep) of_2\IN|Nontoxic|in|antagonized|from|and (l_pobj) myelosuppression_5\NN|NONE (l_conj) loss_8\NN|reduced|and
D003630_D015431 CID daunorubicin_10\NN|NONE (r_pobj) from_9\IN|of|Nontoxic|in|antagonized|and (r_prep) doses_1\NNS|myelosuppression|;|however|.|, (r_nsubj) dexrazoxane_27\NN|NONE (l_dobj) myelosuppression_30\NN|;|doses|however|.|, (l_conj) loss_33\NN|neither|,|reduced
D003630_D001855 NONE daunorubicin_13\NNS|but|and|doxorubicin (r_conj) etoposide_11\NN|against|.|Dexrazoxane (r_advmod) protects_1\VBZ|NONE (l_prep) against_2\IN|etoposide|.|Dexrazoxane (l_pobj) myelosuppression_3\NN|NONE
D003630_D001855 NONE daunorubicin_2\NN|,|;|however|myelosuppression|.|use (r_ccomp) limit_30\VBP|NONE (l_nsubj) myelosuppression_26\NN|,|;|however|.|use|daunorubicin
D003630_D001855 NONE daunorubicin_10\NN|NONE (r_pobj) from_9\IN|of|Nontoxic|in|antagonized|and (r_prep) doses_1\NNS|myelosuppression|;|however|.|, (l_prep) of_2\IN|Nontoxic|in|antagonized|from|and (l_pobj) myelosuppression_5\NN|NONE
D003630_D001855 NONE daunorubicin_10\NN|NONE (r_pobj) from_9\IN|of|Nontoxic|in|antagonized|and (r_prep) doses_1\NNS|myelosuppression|;|however|.|, (r_nsubj) dexrazoxane_27\NN|NONE (l_dobj) myelosuppression_30\NN|;|doses|however|.|,
D018943_D066126 NONE anthracyclines_1\NNS|are|and|doxorubicin (r_nsubj) daunorubicin_2\NN|,|;|however|myelosuppression|.|use (r_ccomp) limit_30\VBP|NONE (l_nsubj) myelosuppression_26\NN|,|;|however|.|use|daunorubicin (l_conj) toxicity_29\NN|and
D018943_D066126 NONE anthracycline_9\NN| (r_advmod) induced_11\VBN|NONE (r_amod) cardiotoxicity_12\NN|NONE
D064730_D066126 NONE Dexrazoxane_0\NNP|.|for|is (r_nsubjpass) recommended_5\VBN|NONE (l_prep) for_6\IN|.|Dexrazoxane|is (l_pobj) protection_7\NN|NONE (l_prep) against_8\IN|NONE (l_pobj) cardiotoxicity_12\NN|NONE
D064730_D066126 NONE ICRF-187_2\NN|NONE (r_appos) Dexrazoxane_0\NNP|.|for|is (r_nsubjpass) recommended_5\VBN|NONE (l_prep) for_6\IN|.|Dexrazoxane|is (l_pobj) protection_7\NN|NONE (l_prep) against_8\IN|NONE (l_pobj) cardiotoxicity_12\NN|NONE
D005047_D006402 CID etoposide_33\VB|NONE (r_pobj) to_32\TO|of (r_prep) Sensitivity_24\NN|.|was|investigated|in (r_nsubjpass) determined_42\VBN|NONE (l_advcl) investigated_22\VBN|Sensitivity|.|was|in (l_nsubjpass) toxicity_8\NN|Because|,|enhancers|was|:
D005047_D006402 CID etoposide_13\NN|NONE (r_pobj) of_12\IN|dexrazoxane (r_prep) doses_11\NNS|NONE (r_dobj) combining_7\VBG|brain (r_acl) metastases_6\NNS|NONE (r_pobj) with_4\IN|NONE (r_prep) patients_3\NNS|NONE (r_pobj) in_2\IN|Clinical (r_prep) trials_1\NNS|ongoing|. (r_nsubj) is_14\VBZ|NONE (l_acomp) ongoing_15\JJ|trials|. (l_prep) with_16\IN|NONE (l_pobj) aim_18\NN|NONE (l_prep) of_19\IN|the (l_pcomp) improving_20\VBG|NONE (l_prep) without_22\IN|efficacy (l_pcomp) aggravating_23\VBG|NONE (l_dobj) toxicity_25\NN|NONE
D064730_D064420 NONE dexrazoxane_3\NN|NONE (r_npadvmod) reduced_4\VBN|loss|and (r_amod) myelosuppression_5\NN|NONE (r_pobj) of_2\IN|Nontoxic|in|antagonized|from|and (r_prep) doses_1\NNS|myelosuppression|;|however|.|, (r_nsubj) dexrazoxane_27\NN|NONE (l_dobj) myelosuppression_30\NN|;|doses|however|.|, (l_conj) loss_33\NN|neither|,|reduced (l_conj) cytotoxicity_39\NN|weight|,|nor
D064730_D064420 NONE dexrazoxane_27\NN|NONE (l_dobj) myelosuppression_30\NN|;|doses|however|.|, (l_conj) loss_33\NN|neither|,|reduced (l_conj) cytotoxicity_39\NN|weight|,|nor
D004317_D066126 NONE doxorubicin_4\NN|anthracyclines|are|and (r_conj) daunorubicin_2\NN|,|;|however|myelosuppression|.|use (r_ccomp) limit_30\VBP|NONE (l_nsubj) myelosuppression_26\NN|,|;|however|.|use|daunorubicin (l_conj) toxicity_29\NN|and
D003630_D064420 NONE daunorubicin_10\NN|NONE (r_pobj) from_9\IN|of|Nontoxic|in|antagonized|and (r_prep) doses_1\NNS|myelosuppression|;|however|.|, (r_nsubj) dexrazoxane_27\NN|NONE (l_dobj) myelosuppression_30\NN|;|doses|however|.|, (l_conj) loss_33\NN|neither|,|reduced (l_conj) cytotoxicity_39\NN|weight|,|nor
D005047_D001855 NONE etoposide_11\NN|against|.|Dexrazoxane (r_advmod) protects_1\VBZ|NONE (l_prep) against_2\IN|etoposide|.|Dexrazoxane (l_pobj) myelosuppression_3\NN|NONE
D005047_D001855 NONE etoposide_8\NN|the (r_appos) epipodophyllotoxin_7\NN|and (r_conj) doxorubicin_4\NN|anthracyclines|are|and (r_conj) daunorubicin_2\NN|,|;|however|myelosuppression|.|use (r_ccomp) limit_30\VBP|NONE (l_nsubj) myelosuppression_26\NN|,|;|however|.|use|daunorubicin
D005047_D001855 NONE etoposide_12\RB|and (r_conj) daunorubicin_10\NN|NONE (r_pobj) from_9\IN|of|Nontoxic|in|antagonized|and (r_prep) doses_1\NNS|myelosuppression|;|however|.|, (l_prep) of_2\IN|Nontoxic|in|antagonized|from|and (l_pobj) myelosuppression_5\NN|NONE
D005047_D001855 NONE etoposide_12\RB|and (r_conj) daunorubicin_10\NN|NONE (r_pobj) from_9\IN|of|Nontoxic|in|antagonized|and (r_prep) doses_1\NNS|myelosuppression|;|however|.|, (r_nsubj) dexrazoxane_27\NN|NONE (l_dobj) myelosuppression_30\NN|;|doses|however|.|,
D064730_D015431 NONE dexrazoxane_3\NN|NONE (r_npadvmod) reduced_4\VBN|loss|and (r_amod) myelosuppression_5\NN|NONE (l_conj) loss_8\NN|reduced|and
D064730_D015431 NONE dexrazoxane_3\NN|NONE (r_npadvmod) reduced_4\VBN|loss|and (r_amod) myelosuppression_5\NN|NONE (r_pobj) of_2\IN|Nontoxic|in|antagonized|from|and (r_prep) doses_1\NNS|myelosuppression|;|however|.|, (r_nsubj) dexrazoxane_27\NN|NONE (l_dobj) myelosuppression_30\NN|;|doses|however|.|, (l_conj) loss_33\NN|neither|,|reduced
D064730_D015431 NONE dexrazoxane_27\NN|NONE (l_nsubj) doses_1\NNS|myelosuppression|;|however|.|, (l_prep) of_2\IN|Nontoxic|in|antagonized|from|and (l_pobj) myelosuppression_5\NN|NONE (l_conj) loss_8\NN|reduced|and
D064730_D015431 NONE dexrazoxane_27\NN|NONE (l_dobj) myelosuppression_30\NN|;|doses|however|.|, (l_conj) loss_33\NN|neither|,|reduced
11271907
D003520_D006470 CID cyclophosphamide_5\NN|NONE (r_compound) therapy_6\NN|NONE (r_pobj) to_4\IN|haemorrhagic|myocarditis (r_prep) secondary_3\JJ|. (l_amod) myocarditis_2\NN|to|haemorrhagic
D003520_D006470 CID cyclophosphamide_9\NN|NONE (r_compound) therapy_10\NN|NONE (r_pobj) of_8\IN|a|rare (r_prep) complication_7\NN|.|myocarditis (r_attr) is_2\VBZ|NONE (l_nsubj) myocarditis_1\NN|.|complication
D003520_D009205 CID cyclophosphamide_5\NN|NONE (r_compound) therapy_6\NN|NONE (r_pobj) to_4\IN|haemorrhagic|myocarditis (r_prep) secondary_3\JJ|. (l_amod) myocarditis_2\NN|to|haemorrhagic
D003520_D009205 CID cyclophosphamide_9\NN|NONE (r_compound) therapy_10\NN|NONE (r_pobj) of_8\IN|a|rare (r_prep) complication_7\NN|.|myocarditis (r_attr) is_2\VBZ|NONE (l_nsubj) myocarditis_1\NN|.|complication
9746003
D002220_D004832 CID carbamazepine_3\NN|NONE (l_conj) vigabatrin_5\VBP|and (l_prep) in_6\IN|NONE (l_pobj) seizures_9\NNS|NONE
D002220_D004832 CID Carbamazepine_0\NNP|in|.|are (r_nsubjpass) contraindicated_4\VBN|NONE (l_prep) in_5\IN|.|Carbamazepine|are (l_pobj) seizures_8\NNS|NONE
D002220_D009207 CID carbamazepine_9\NN|NONE (l_conj) two_11\CD|and (l_prep) of_12\IN|NONE (l_pobj) jerks_16\NNS|NONE
D002220_D009207 CID carbamazepine_23\NN|NONE (r_pobj) of_22\IN|NONE (r_prep) withdrawal_21\NN|NONE (r_pobj) on_20\IN|which (r_prep) resolved_19\VBD|these|developed|,|myoclonic (r_relcl) jerks_16\NNS|NONE
D020888_D004832 CID vigabatrin_5\VBP|and (l_prep) in_6\IN|NONE (l_pobj) seizures_9\NNS|NONE
D020888_D004832 CID vigabatrin_2\NN|and (r_conj) Carbamazepine_0\NNP|in|.|are (r_nsubjpass) contraindicated_4\VBN|NONE (l_prep) in_5\IN|.|Carbamazepine|are (l_pobj) seizures_8\NNS|NONE
14765563
D011803_D020922 NONE quinine_23\NN|available|.|,|banned (r_nsubj) is_24\VBZ|NONE (l_advcl) banned_8\VBD|available|quinine|.|, (l_dobj) use_10\NN|Although|due|Administration (l_prep) for_11\IN|its (l_pobj) cramps_14\NNS|NONE
D011803_D003221 CID quinine_7\NN|NONE (r_dobj) containing_6\VBG|NONE (r_acl) products_5\NNS|complications|may|that|status|in (r_nsubj) produce_9\VB|reports|. (l_dobj) complications_11\NNS|may|products|that|status|in (l_prep) including_13\VBG|,|neurological|, (l_pobj) confusion_14\NN|NONE
D011803_D003128 CID quinine_7\NN|NONE (r_dobj) containing_6\VBG|NONE (r_acl) products_5\NNS|complications|may|that|status|in (r_nsubj) produce_9\VB|reports|. (l_dobj) status_18\NN|complications|may|products|that|in (l_conj) seizures_20\NNS|,|mental|,|altered (l_conj) coma_23\NN|and|,
D011803_D012640 CID quinine_7\NN|NONE (r_dobj) containing_6\VBG|NONE (r_acl) products_5\NNS|complications|may|that|status|in (r_nsubj) produce_9\VB|reports|. (l_dobj) status_18\NN|complications|may|products|that|in (l_conj) seizures_20\NNS|,|mental|,|altered
D011803_D002493 NONE quinine_7\NN|NONE (r_dobj) containing_6\VBG|NONE (r_acl) products_5\NNS|complications|may|that|status|in (r_nsubj) produce_9\VB|reports|. (l_dobj) complications_11\NNS|may|products|that|status|in
20394767
D015016_D012021 CID yohimbine_2\NN|,|startle|suppressed|,|mCPP|Furthermore (r_nsubj) increased_3\VBN|NONE (l_dobj) startle_5\NN|yohimbine|,|suppressed|,|mCPP|Furthermore
D015016_D012021 CID yohimbine_2\NN|,|startle|suppressed|,|mCPP|Furthermore (r_nsubj) increased_3\VBN|NONE (l_conj) suppressed_13\VBD|yohimbine|,|startle|,|mCPP|Furthermore (l_dobj) startle_15\NN|suppressed|and
D015016_D012021 CID yohimbine_2\NN|,|startle|suppressed|,|mCPP|Furthermore (r_nsubj) increased_3\VBN|NONE (l_conj) suppressed_13\VBD|yohimbine|,|startle|,|mCPP|Furthermore (l_conj) suppressed_24\VBD|startle|and (l_dobj) startle_26\NN|PTZ|.
D010433_D012021 CID PTZ_23\NNP|startle|. (r_nsubj) suppressed_24\VBD|startle|and (r_conj) suppressed_13\VBD|yohimbine|,|startle|,|mCPP|Furthermore (r_conj) increased_3\VBN|NONE (l_dobj) startle_5\NN|yohimbine|,|suppressed|,|mCPP|Furthermore
D010433_D012021 CID PTZ_23\NNP|startle|. (r_nsubj) suppressed_24\VBD|startle|and (r_conj) suppressed_13\VBD|yohimbine|,|startle|,|mCPP|Furthermore (l_dobj) startle_15\NN|suppressed|and
D010433_D012021 CID PTZ_23\NNP|startle|. (r_nsubj) suppressed_24\VBD|startle|and (l_dobj) startle_26\NN|PTZ|.
C015068_D012021 CID mCPP_12\NNS|yohimbine|,|startle|suppressed|,|Furthermore (r_advcl) increased_3\VBN|NONE (l_dobj) startle_5\NN|yohimbine|,|suppressed|,|mCPP|Furthermore
C015068_D012021 CID mCPP_12\NNS|yohimbine|,|startle|suppressed|,|Furthermore (r_advcl) increased_3\VBN|NONE (l_conj) suppressed_13\VBD|yohimbine|,|startle|,|mCPP|Furthermore (l_dobj) startle_15\NN|suppressed|and
C015068_D012021 CID mCPP_12\NNS|yohimbine|,|startle|suppressed|,|Furthermore (r_advcl) increased_3\VBN|NONE (l_conj) suppressed_13\VBD|yohimbine|,|startle|,|mCPP|Furthermore (l_conj) suppressed_24\VBD|startle|and (l_dobj) startle_26\NN|PTZ|.
16005948
D003042_D003643 NONE cocaine_3\NN|NONE (r_compound) toxicity_4\NN|NONE (r_pobj) of_2\IN|Significant (r_prep) blockade_1\NN|with|was|. (r_nsubjpass) observed_6\VBN|NONE (l_prep) with_7\IN|was|.|blockade (l_pobj) dose_10\NN|NONE (l_appos) seizures_28\NNS|,|mg/kg|the|of|higher|reduced|)|, (l_prt) up_29\IN|by (l_prep) to_30\TO|NONE (l_pobj) %_32\NN|NONE (l_conj) death_34\NN||and
D003042_D003643 NONE cocaine_8\NN|even (r_compound) injection_9\NN|death|Importantly|.|GNCH|, (r_dobj) prevented_3\VBD|NONE (l_dobj) death_4\NN|Importantly|.|injection|GNCH|,
-1_D012640 NONE GNC92H2_12\NNP|NONE (r_pobj) of_11\IN|,|mg/kg|the|higher|reduced|seizures|)|, (r_prep) dose_10\NN|NONE (l_appos) seizures_28\NNS|,|mg/kg|the|of|higher|reduced|)|,
D003042_D064420 NONE cocaine_3\NN|NONE (r_compound) toxicity_4\NN|NONE
D003042_D062787 NONE cocaine_4\NN|NONE (r_pobj) of_3\IN|illicit|The (r_prep) use_2\NN|in (r_nsubj) continues_5\VBZ|elusive|. (l_prep) in_6\IN|use (l_pobj) proportions_8\NNS|NONE (l_conj) treatment_10\NN|and|epidemic (l_prep) for_11\IN|NONE (l_pobj) overdose_13\NN|NONE
-1_D062787 NONE GNC92H2_6\NNP|NONE (r_pobj) of_1\IN|.|as (r_prep) Evaluation_0\NN|NONE (l_prep) as_7\IN|.|of (l_pobj) immunotherapy_9\NN|NONE (l_prep) for_10\IN|an (l_pobj) overdose_12\NN|NONE
-1_D062787 NONE GNC92H2_7\NNP|NONE (r_pobj) of_3\IN|The|therapeutic (r_prep) potential_2\NN|was|using|. (r_nsubjpass) examined_9\VBN|NONE (l_advcl) using_10\VBG|potential|was|. (l_dobj) model_12\NN|NONE (l_prep) of_13\IN|a (l_pobj) overdose_15\NN|NONE
-1_D062787 NONE GNC92H2_7\NNP|NONE (r_pobj) of_6\IN|as|important|the (r_prep) potential_5\NN|.|results (l_prep) as_8\IN|of|important|the (l_pobj) tool_11\NN|NONE (l_prep) against_12\IN|a|therapeutic (l_pobj) overdose_14\NN|NONE
-1_D064420 NONE GNC92H2_12\NNP|NONE (r_pobj) of_11\IN|,|mg/kg|the|higher|reduced|seizures|)|, (r_prep) dose_10\NN|NONE (r_pobj) with_7\IN|was|.|blockade (r_prep) observed_6\VBN|NONE (l_nsubjpass) blockade_1\NN|with|was|. (l_prep) of_2\IN|Significant (l_pobj) toxicity_4\NN|NONE
-1_D003643 NONE GNC92H2_12\NNP|NONE (r_pobj) of_11\IN|,|mg/kg|the|higher|reduced|seizures|)|, (r_prep) dose_10\NN|NONE (l_appos) seizures_28\NNS|,|mg/kg|the|of|higher|reduced|)|, (l_prt) up_29\IN|by (l_prep) to_30\TO|NONE (l_pobj) %_32\NN|NONE (l_conj) death_34\NN||and
-1_D003643 NONE GNC92H2_2\NNP|death|Importantly|.|injection|, (r_nsubj) prevented_3\VBD|NONE (l_dobj) death_4\NN|Importantly|.|injection|GNCH|,
D003042_D012640 CID cocaine_3\NN|NONE (r_compound) toxicity_4\NN|NONE (r_pobj) of_2\IN|Significant (r_prep) blockade_1\NN|with|was|. (r_nsubjpass) observed_6\VBN|NONE (l_prep) with_7\IN|was|.|blockade (l_pobj) dose_10\NN|NONE (l_appos) seizures_28\NNS|,|mg/kg|the|of|higher|reduced|)|,
16225977
C012052_D012559 NONE Amisulpride_0\NNP|related|.|like|in (r_amod) symptoms_5\NNS|NONE (l_prep) in_6\IN|related|.|like|Amisulpride (l_pobj) schizophrenic_9\NN|NONE
C012052_D012559 NONE amisulpride_20\JJ|NONE (r_amod) treatment_21\NN|NONE (r_pobj) of_19\IN| (r_prep) months_18\NNS|NONE (r_pobj) after_16\IN|movements|who (r_prep) developed_9\VBD|a|mg|old|girl (r_relcl) schizophrenic_7\NN|We|.
C012052_D013981 CID Amisulpride_0\NNP|related|.|like|in (r_amod) symptoms_5\NNS|NONE
C012052_D013981 CID amisulpride_13\NN|NONE (r_pobj) of_12\IN|mg|the (r_prep) dose_11\NN|we|completely|after (r_dobj) reduced_9\VBD|.|symptoms (r_advcl) resolved_5\VBN|NONE (l_nsubj) symptoms_4\NNS|reduced|.
C012052_D013981 CID amisulpride_32\NN|,|or (r_conj) clozapine_29\NN|, (r_conj) quetiapine_27\NN|such (r_pobj) as_26\IN|atypical (r_prep) antipsychotics_24\NNS|NONE (r_pobj) with_22\IN|NONE (r_prep) treatment_21\NN|NONE (r_pobj) during_20\IN|in|that|symptoms|might (r_prep) occur_15\VB|patient|with|.|, (l_nsubj) symptoms_13\NNS|in|during|that|might
C069541_D013981 NONE quetiapine_24\NN|NONE (r_pobj) with_23\IN|NONE (r_prep) treatment_22\NN|NONE (r_pobj) during_21\IN|NONE (r_prep) occurring_20\VBG|that|symptoms (r_xcomp) show_8\VBP|case (l_dobj) symptoms_12\NNS|that|occurring
C069541_D013981 NONE quetiapine_27\NN|such (r_pobj) as_26\IN|atypical (r_prep) antipsychotics_24\NNS|NONE (r_pobj) with_22\IN|NONE (r_prep) treatment_21\NN|NONE (r_pobj) during_20\IN|in|that|symptoms|might (r_prep) occur_15\VB|patient|with|.|, (l_nsubj) symptoms_13\NNS|in|during|that|might
C076029_D013981 NONE olanzapine_13\NN|, (r_conj) risperidone_11\NN|such (r_pobj) as_10\IN|atypical (r_prep) antipsychotics_8\NNS|NONE (r_pobj) by_6\IN|can|.|disorders|be|effectively (r_agent) treated_5\VBN|NONE (l_nsubjpass) disorders_1\NNS|by|can|.|be|effectively
C012052_D020820 NONE amisulpride_20\JJ|NONE (r_amod) treatment_21\NN|NONE (r_pobj) of_19\IN| (r_prep) months_18\NNS|NONE (r_pobj) after_16\IN|movements|who (r_prep) developed_9\VBD|a|mg|old|girl (l_dobj) movements_15\NNS|who|after
D018967_D013981 NONE risperidone_11\NN|such (r_pobj) as_10\IN|atypical (r_prep) antipsychotics_8\NNS|NONE (r_pobj) by_6\IN|can|.|disorders|be|effectively (r_agent) treated_5\VBN|NONE (l_nsubjpass) disorders_1\NNS|by|can|.|be|effectively
C092292_D013981 NONE ziprasidone_15\NN|and (r_conj) olanzapine_13\NN|, (r_conj) risperidone_11\NN|such (r_pobj) as_10\IN|atypical (r_prep) antipsychotics_8\NNS|NONE (r_pobj) by_6\IN|can|.|disorders|be|effectively (r_agent) treated_5\VBN|NONE (l_nsubjpass) disorders_1\NNS|by|can|.|be|effectively
D003024_D013981 NONE clozapine_26\NN|or (r_conj) quetiapine_24\NN|NONE (r_pobj) with_23\IN|NONE (r_prep) treatment_22\NN|NONE (r_pobj) during_21\IN|NONE (r_prep) occurring_20\VBG|that|symptoms (r_xcomp) show_8\VBP|case (l_dobj) symptoms_12\NNS|that|occurring
D003024_D013981 NONE clozapine_29\NN|, (r_conj) quetiapine_27\NN|such (r_pobj) as_26\IN|atypical (r_prep) antipsychotics_24\NNS|NONE (r_pobj) with_22\IN|NONE (r_prep) treatment_21\NN|NONE (r_pobj) during_20\IN|in|that|symptoms|might (r_prep) occur_15\VB|patient|with|.|, (l_nsubj) symptoms_13\NNS|in|during|that|might
8643971
D017239_D006258 NONE paclitaxel_7\NN|NONE (r_pobj) of_6\IN|II (r_prep) study_5\NN|.|plus|cisplatin|A (r_dobj) phase_1\NN|NONE (l_conj) cisplatin_9\NN|.|plus|study|A (l_prep) as_10\IN|NONE (l_pobj) therapy_14\NN|NONE (l_prep) for_15\IN|results|:|line (l_pobj) cancers_19\NNS|NONE
D017239_D006258 NONE paclitaxel_13\NN|NONE (r_pobj) of_9\IN|Group|an (r_prep) study_8\NN|NONE (r_pobj) of_2\IN|Preliminary (r_prep) results_1\NNS|rate|used|. (r_nsubj) reported_27\VBD|NONE (l_dobj) rate_32\NN|results|used|. (l_prep) in_33\IN|a|,|and|%|response (l_pobj) patients_34\NNS|NONE (l_prep) with_35\IN|NONE (l_pobj) cancer_39\NN|NONE
D017239_D006258 NONE Taxol_15\NNP|agent (r_appos) paclitaxel_13\NN|NONE (r_pobj) of_9\IN|Group|an (r_prep) study_8\NN|NONE (r_pobj) of_2\IN|Preliminary (r_prep) results_1\NNS|rate|used|. (r_nsubj) reported_27\VBD|NONE (l_dobj) rate_32\NN|results|used|. (l_prep) in_33\IN|a|,|and|%|response (l_pobj) patients_34\NNS|NONE (l_prep) with_35\IN|NONE (l_pobj) cancer_39\NN|NONE
D017239_D006258 NONE paclitaxel_43\NN|cisplatin|the (r_nmod) combination_46\NN|and|improved|has|been|successfully (r_nsubjpass) used_49\VBN|rate|results|. (r_conj) reported_27\VBD|NONE (l_dobj) rate_32\NN|results|used|. (l_prep) in_33\IN|a|,|and|%|response (l_pobj) patients_34\NNS|NONE (l_prep) with_35\IN|NONE (l_pobj) cancer_39\NN|NONE
D017239_D006258 NONE paclitaxel_16\NN|escalating|combined (r_compound) doses_17\NNS|NONE (l_acl) combined_18\VBN|escalating|paclitaxel (l_prep) with_24\IN|with (l_pobj) support_30\NN|NONE (l_prep) in_31\IN|factor|granulocyte (l_pobj) patients_32\NNS|NONE (l_prep) with_33\IN|NONE (l_pobj) head_38\NN|NONE (l_conj) carcinoma_41\NN|inoperable|and|advanced|untreated
D017239_D006258 NONE Paclitaxel_0\NNP|regimen|cisplatin|warranted (r_nsubj) is_3\VBZ|NONE (l_attr) regimen_9\NN|Paclitaxel|cisplatin|warranted (l_prep) for_10\IN|and|effective|an|line (l_pobj) head_13\NN|NONE (l_conj) cancer_16\NN|advanced|and
D002945_D064420 NONE cisplatin_23\NN|NONE (r_pobj) with_19\IN|with (r_prep) combined_18\VBN|escalating|paclitaxel (r_acl) doses_17\NNS|NONE (r_pobj) of_14\IN|and|toxicity|the (r_prep) response_11\NN|to (l_conj) toxicity_13\NN|and|the|of
D017239_D064420 NONE paclitaxel_16\NN|escalating|combined (r_compound) doses_17\NNS|NONE (r_pobj) of_14\IN|and|toxicity|the (r_prep) response_11\NN|to (l_conj) toxicity_13\NN|and|the|of
D017239_D064420 NONE paclitaxel_5\NN|escalating (r_compound) doses_6\NNS|levels|,|permitted|and (r_dobj) incorporate_3\VBP|NONE (l_conj) permitted_17\VBN|levels|,|doses|and (l_advcl) permits_20\VBZ|escalations|are|. (l_nsubj) toxicity_19\NN|if
D002945_D006258 NONE cisplatin_9\NN|.|plus|study|A (l_prep) as_10\IN|NONE (l_pobj) therapy_14\NN|NONE (l_prep) for_15\IN|results|:|line (l_pobj) cancers_19\NNS|NONE
D002945_D006258 NONE cisplatin_45\NN|the|paclitaxel (r_compound) combination_46\NN|and|improved|has|been|successfully (r_nsubjpass) used_49\VBN|rate|results|. (r_conj) reported_27\VBD|NONE (l_dobj) rate_32\NN|results|used|. (l_prep) in_33\IN|a|,|and|%|response (l_pobj) patients_34\NNS|NONE (l_prep) with_35\IN|NONE (l_pobj) cancer_39\NN|NONE
D002945_D006258 NONE cisplatin_23\NN|NONE (r_pobj) with_19\IN|with (r_prep) combined_18\VBN|escalating|paclitaxel (l_prep) with_24\IN|with (l_pobj) support_30\NN|NONE (l_prep) in_31\IN|factor|granulocyte (l_pobj) patients_32\NNS|NONE (l_prep) with_33\IN|NONE (l_pobj) head_38\NN|NONE (l_conj) carcinoma_41\NN|inoperable|and|advanced|untreated
D002945_D006258 NONE cisplatin_2\NN|regimen|Paclitaxel|warranted (r_advmod) is_3\VBZ|NONE (l_attr) regimen_9\NN|Paclitaxel|cisplatin|warranted (l_prep) for_10\IN|and|effective|an|line (l_pobj) head_13\NN|NONE (l_conj) cancer_16\NN|advanced|and
D017239_D010051 NONE paclitaxel_13\NN|NONE (r_pobj) of_9\IN|Group|an (r_prep) study_8\NN|NONE (r_pobj) of_2\IN|Preliminary (r_prep) results_1\NNS|rate|used|. (r_nsubj) reported_27\VBD|NONE (l_conj) used_49\VBN|rate|results|. (l_conj) improved_54\VBN|and|combination|has|been|successfully (l_dobj) duration_57\NN|significantly|has (l_prep) in_58\IN|median|response (l_pobj) patients_61\NNS|NONE (l_compound) cancer_60\NN|ovarian
D017239_D010051 NONE Taxol_15\NNP|agent (r_appos) paclitaxel_13\NN|NONE (r_pobj) of_9\IN|Group|an (r_prep) study_8\NN|NONE (r_pobj) of_2\IN|Preliminary (r_prep) results_1\NNS|rate|used|. (r_nsubj) reported_27\VBD|NONE (l_conj) used_49\VBN|rate|results|. (l_conj) improved_54\VBN|and|combination|has|been|successfully (l_dobj) duration_57\NN|significantly|has (l_prep) in_58\IN|median|response (l_pobj) patients_61\NNS|NONE (l_compound) cancer_60\NN|ovarian
D017239_D010051 NONE paclitaxel_43\NN|cisplatin|the (r_nmod) combination_46\NN|and|improved|has|been|successfully (r_nsubjpass) used_49\VBN|rate|results|. (l_conj) improved_54\VBN|and|combination|has|been|successfully (l_dobj) duration_57\NN|significantly|has (l_prep) in_58\IN|median|response (l_pobj) patients_61\NNS|NONE (l_compound) cancer_60\NN|ovarian
D002945_D010051 NONE cisplatin_45\NN|the|paclitaxel (r_compound) combination_46\NN|and|improved|has|been|successfully (r_nsubjpass) used_49\VBN|rate|results|. (l_conj) improved_54\VBN|and|combination|has|been|successfully (l_dobj) duration_57\NN|significantly|has (l_prep) in_58\IN|median|response (l_pobj) patients_61\NNS|NONE (l_compound) cancer_60\NN|ovarian
9579567
D013629_D001943 NONE tamoxifen_1\NN|proposed|in|and|is|widely|Since (r_nsubjpass) used_4\VBN|,|must|.|be|carefully|effects (l_prep) in_5\IN|proposed|and|is|widely|Since|tamoxifen (l_pobj) treatment_8\NN|NONE (l_compound) cancer_7\NN|NONE
D013629_D001943 NONE tamoxifen_1\NN|proposed|in|and|is|widely|Since (r_nsubjpass) used_4\VBN|,|must|.|be|carefully|effects (l_conj) proposed_12\VBN|in|and|is|widely|Since|tamoxifen (l_prep) for_13\IN|has|been (l_pobj) prevention_15\NN|NONE (l_prep) of_16\IN|the (l_pobj) cancer_18\NN|NONE
D013629_D001943 NONE tamoxifen_9\NN|or|treatments (r_compound) use_10\NN|and|endometrial (r_conj) cancer_7\NN|NONE (r_pobj) between_5\IN|treated|the (r_prep) association_4\NN|.|have|We (l_acl) treated_16\VBN|between|the (l_prep) for_17\IN|in (l_pobj) cancer_19\NN|NONE
D013629_D001943 NONE tamoxifen_7\NN|NONE (r_pobj) of_6\IN|causal|a|in (r_prep) role_5\NN|,|results|.|used (r_dobj) suggest_2\VBP|NONE (l_advcl) used_14\VBN|,|results|.|role (l_xcomp) proposed_17\VBN|particularly|when (l_prep) for_18\IN|currently|as (l_pobj) prevention_21\NN|NONE (l_compound) cancer_20\NN|NONE
D013629_D001943 NONE tamoxifen_3\NN|for|who (r_dobj) receive_2\VBP|NONE (l_prep) for_4\IN|tamoxifen|who (l_pobj) cancer_6\NN|NONE
D013629_D001943 NONE tamoxifen_12\NN|NONE (r_pobj) of_11\IN|the|benefit (r_prep) ratio_10\NN|NONE (r_pobj) of_5\IN|term|as|A (r_prep) evaluation_4\NN|.|clearly|is (l_prep) as_13\IN|term|of|A (l_pobj) treatment_16\NN|NONE (l_prep) for_17\IN|preventive|a (l_pobj) cancer_19\NN|NONE
D013629_D016889 CID tamoxifen_9\NN|or|treatments (r_compound) use_10\NN|and|endometrial (r_conj) cancer_7\NN|NONE
D013629_D016889 CID tamoxifen_4\NN|had|who (r_dobj) received_3\VBN|NONE (r_relcl) Women_0\NNS|.|likely (r_nsubj) were_5\VBD|NONE (l_acomp) likely_8\JJ|.|Women (l_xcomp) have_10\VB|more (l_dobj) cancer_12\NN|to
D013629_D016889 CID tamoxifen_8\NN|had (r_advmod) received_7\VBN|who|and|cancer (r_conj) had_2\VBD|NONE (l_dobj) cancer_4\NN|received|who|and
D013629_D016889 CID tamoxifen_8\NN|had (r_advmod) received_7\VBN|who|and|cancer (r_conj) had_2\VBD|NONE (r_relcl) Women_0\NNS|.|disease (r_nsubj) had_9\VBD|NONE (l_dobj) disease_12\NN|.|Women (l_conj) prognosis_15\NN|and|advanced (l_prep) than_16\IN|poorer (l_pobj) those_17\DT|NONE (l_prep) with_18\IN|received (l_pobj) cancer_20\NN|NONE
D013629_D016889 CID tamoxifen_7\NN|NONE (r_pobj) of_6\IN|causal|a|in (r_prep) role_5\NN|,|results|.|used (l_prep) in_8\IN|causal|a|of (l_pobj) cancer_10\NN|NONE
D013629_D016889 CID tamoxifen_7\NN|NONE (r_pobj) with_6\IN|NONE (r_prep) treated_5\VBN|NONE (r_acl) women_4\NNS|NONE (r_pobj) in_3\IN|NONE (r_prep) diagnosed_2\VBD|Endometrial (r_acl) cancers_1\NNS|prognosis|.
D013629_D020178 NONE tamoxifen_8\NN|had (r_advmod) received_7\VBN|who|and|cancer (r_conj) had_2\VBD|NONE (r_relcl) Women_0\NNS|.|disease (r_nsubj) had_9\VBD|NONE (l_dobj) disease_12\NN|.|Women
3564823
D013874_D002545 NONE pentothal_12\NNS|was|intravenously|minimize|Following|.|, (r_nsubjpass) infused_15\VBN|NONE (l_advcl) minimize_17\VB|was|intravenously|pentothal|Following|.|, (l_dobj) ischaemia_19\NN|to
D008012_D020301 NONE lidocaine_11\NN|precluded|,|,|.|,|with|counteract|was (r_nsubjpass) given_13\VBN|NONE (l_advcl) counteract_24\VB|precluded|,|,|lidocaine|.|,|with|was (l_dobj) vasospasm_26\NN|to
D008012_D013035 NONE lidocaine_7\NN|NONE (r_pobj) by_6\IN|.|spasm (r_prep) relieved_5\VBN|NONE (l_nsubj) spasm_4\NN|.|by
19308880
D014635_D003221 CID acid_10\NN|NONE (r_pobj) with_8\IN|adverse|drug|a|serious (r_prep) reaction_7\NN|review|.|:|, (r_appos) Confusion_0\NN|NONE
D014635_D003221 CID acid_10\NN|NONE (r_pobj) with_8\IN|frequently (r_prep) observed_7\VBD|an|adverse|drug (r_acl) reaction_5\NN|Confusion|. (r_attr) is_1\VBZ|NONE (l_nsubj) Confusion_0\NN|.|reaction
D014635_D003221 CID acid_17\NN|NONE (r_pobj) with_15\IN|since (r_prep) reported_12\VBN|NONE (r_acl) confusion_11\NN|NONE
D014635_D003221 CID acid_9\NN|NONE (r_pobj) with_7\IN|:|cases|.|were (r_prep) reported_6\VBN|NONE (l_nsubjpass) cases_2\NNS|:|.|with|were (l_prep) of_3\IN| (l_pobj) confusion_4\NN|NONE
D014635_D003221 CID acid_10\NN|%|)|( (r_compound) exposure_11\NN|NONE (r_pobj) following_8\VBG|the|first|two (r_prep) weeks_7\NNS|NONE (r_pobj) during_3\IN|Confusion|.|mostly (r_prep) occurred_2\VBD|NONE (l_nsubj) Confusion_0\NN|during|.|mostly
D014635_D003221 CID acid_7\NN|NONE (r_pobj) with_5\IN|NONE (r_prep) confusion_4\NN|that|reaction
9293063
D003613_D006222 CID danazol_12\NN|NONE (r_pobj) with_11\IN|term (r_prep) treatment_10\NN|NONE (r_pobj) with_6\IN|NONE (r_prep) association_5\NN|NONE (r_pobj) in_4\IN|NONE (r_prep) occurring_3\VBG|duct|. (r_acl) hamartoma_2\NN|NONE
D003613_D006222 CID danazol_20\NN|term (r_compound) treatment_21\NN|NONE (r_pobj) on_16\IN|had|who (r_prep) been_15\VBN|a (r_relcl) patient_12\NN|NONE (r_pobj) in_10\IN|which (r_prep) developed_9\VBD|duct (r_relcl) hamartoma_7\NN|NONE
D003613_D001650 CID danazol_12\NN|NONE (r_pobj) with_11\IN|term (r_prep) treatment_10\NN|NONE (r_pobj) with_6\IN|NONE (r_prep) association_5\NN|NONE (r_pobj) in_4\IN|NONE (r_prep) occurring_3\VBG|duct|. (r_acl) hamartoma_2\NN|NONE
D003613_D001650 CID danazol_20\NN|term (r_compound) treatment_21\NN|NONE (r_pobj) on_16\IN|had|who (r_prep) been_15\VBN|a (r_relcl) patient_12\NN|NONE (r_pobj) in_10\IN|which (r_prep) developed_9\VBD|duct (r_relcl) hamartoma_7\NN|NONE
1415380
D011803_D006463 CID quinine_8\NN|NONE (r_pobj) of_7\IN|NONE (r_prep) ingestion_6\NN|NONE (r_pobj) with_5\IN|NONE (r_prep) associated_4\VBN|uremic|. (r_acl) syndrome_3\NN|NONE
D011803_D006463 CID quinine_5\NN|NONE (r_compound) ingestion_6\NN|NONE (r_pobj) following_4\VBG|uremic (r_prep) syndrome_3\NN|,|with|phenomenon|.
D011803_D006463 CID Quinine_0\NN| (r_npadvmod) associated_2\VBN|uremic (r_amod) syndrome_6\NN|.|probably|often
19657887
D004221_D005483 NONE disulfiram_7\NN| (r_npadvmod) like_9\JJ|with (r_amod) syndrome_10\NN|,|after|he|. (l_prep) with_11\IN|like (l_pcomp) flushing_12\NN|NONE
D000431_D005483 CID alcohol_9\NN|NONE (r_pobj) of_8\IN|the (r_prep) ingestion_7\NN|NONE (r_pobj) after_5\IN| (r_prep) hour_4\NN|NONE (r_pobj) In_0\IN|malaise|,|.|he (r_prep) developed_12\VBD|NONE (l_dobj) malaise_13\NN|In|,|.|he (l_prep) with_14\IN|NONE (l_pobj) flushing_15\NN|NONE (l_prep) of_16\IN|NONE (l_pobj) face_18\NN|NONE
D004221_D013610 NONE disulfiram_7\NN| (r_npadvmod) like_9\JJ|with (r_amod) syndrome_10\NN|,|after|he|. (l_prep) with_11\IN|like (l_pcomp) flushing_12\NN|NONE (l_conj) tachycardia_14\NN|,|after
D004221_D007022 NONE disulfiram_7\NN| (r_npadvmod) like_9\JJ|with (r_amod) syndrome_10\NN|,|after|he|. (l_prep) with_11\IN|like (l_pcomp) flushing_12\NN|NONE (l_conj) tachycardia_14\NN|,|after (l_conj) hypotension_18\NN|and|,
D000431_D013610 CID alcohol_9\NN|NONE (r_pobj) of_8\IN|the (r_prep) ingestion_7\NN|NONE (r_pobj) after_5\IN| (r_prep) hour_4\NN|NONE (r_pobj) In_0\IN|malaise|,|.|he (r_prep) developed_12\VBD|NONE (l_dobj) malaise_13\NN|In|,|.|he (l_prep) with_14\IN|NONE (l_pobj) flushing_15\NN|NONE (l_prep) of_16\IN|NONE (l_pobj) face_18\NN|NONE (l_conj) tachycardia_20\NN|,|the
D000431_D004417 CID alcohol_9\NN|NONE (r_pobj) of_8\IN|the (r_prep) ingestion_7\NN|NONE (r_pobj) after_5\IN| (r_prep) hour_4\NN|NONE (r_pobj) In_0\IN|malaise|,|.|he (r_prep) developed_12\VBD|NONE (l_dobj) malaise_13\NN|In|,|.|he (l_prep) with_14\IN|NONE (l_pobj) flushing_15\NN|NONE (l_prep) of_16\IN|NONE (l_pobj) face_18\NN|NONE (l_conj) tachycardia_20\NN|,|the (l_conj) dyspnea_23\NN|,|and
3070035
D002216_D051437 NONE captopril_2\NN| (r_npadvmod) induced_4\VBN|renal (r_amod) insufficiency_6\NN|NONE
D002216_D051437 NONE captopril_4\NN| (r_npadvmod) induced_6\VBN|renal (r_amod) failure_8\NN|NONE
D002216_D058186 CID captopril_27\NN|NONE (r_pobj) with_26\IN|NONE (r_prep) treatment_25\NN|NONE (r_pobj) following_24\VBG|sudden|of (r_prep) deterioration_20\NN|who (l_prep) of_21\IN|sudden|following (l_pobj) function_23\NN|NONE
D002216_D006978 NONE captopril_2\NN| (r_npadvmod) induced_4\VBN|renal (r_amod) insufficiency_6\NN|NONE (r_pobj) of_1\IN|.|after (r_prep) Reversibility_0\NN|NONE (l_prep) after_7\IN|.|of (l_pobj) use_9\NN|NONE (l_prep) in_10\IN|prolonged (l_pobj) case_13\NN|NONE (l_prep) of_14\IN|unusual|an (l_pobj) hypertension_16\NN|NONE
D002216_D006973 NONE captopril_27\NN|NONE (r_pobj) with_26\IN|NONE (r_prep) treatment_25\NN|NONE (r_pobj) following_24\VBG|sudden|of (r_prep) deterioration_20\NN|who (r_dobj) developed_18\VBD|solitary|,|a (r_relcl) kidney_15\NN|NONE (r_pobj) to_12\IN|renal|occluded|an (r_prep) artery_11\NN|NONE (r_pobj) with_7\IN|severe (r_prep) hypertension_6\NN|NONE
15867025
D006514_D006509 CID antigen_42\NN| (r_npadvmod) positive_44\JJ|immunity|surface|B|, (r_amod) mothers_45\NNS|NONE (r_pobj) to_38\IN|to|were|who (r_prep) born_37\VBN|NONE (r_relcl) infants_34\NNS|NONE (r_pobj) to_33\IN|of (r_prep) administration_27\NN|to|,|administration (r_conj) dose_22\NN|,|for|prenatal (r_conj) screening_8\NN|.|Assessment|on|:|was (l_prep) for_9\IN|dose|,|prenatal (l_pobj) B_11\NNP|NONE
D006514_D006509 CID antigen_42\NN| (r_npadvmod) positive_44\JJ|immunity|surface|B|, (r_amod) mothers_45\NNS|NONE (r_pobj) to_38\IN|to|were|who (r_prep) born_37\VBN|NONE (r_relcl) infants_34\NNS|NONE (r_pobj) to_33\IN|of (r_prep) administration_27\NN|to|,|administration (r_conj) dose_22\NN|,|for|prenatal (l_nsubj) administration_15\NN|to|,|administration (l_prep) of_16\IN|NONE (l_pobj) birth_21\NN|NONE (l_compound) vaccine_20\NN|the (l_compound) B_19\NNP|NONE
D006514_D006509 CID antigen_42\NN| (r_npadvmod) positive_44\JJ|immunity|surface|B|, (r_amod) mothers_45\NNS|NONE (r_pobj) to_38\IN|to|were|who (r_prep) born_37\VBN|NONE (r_relcl) infants_34\NNS|NONE (r_pobj) to_33\IN|of (r_prep) administration_27\NN|to|,|administration (l_prep) of_28\IN|to (l_pobj) globulin_32\NN|NONE (l_compound) B_30\NNP|immune
D006514_D006509 CID antigen_9\NN| (r_npadvmod) positive_11\JJ|surface|B (r_amod) mothers_12\NNS|NONE (r_pobj) to_5\IN|were|who (r_prep) born_4\VBN|All (r_relcl) infants_1\NNS|globulin|.|also (r_nsubj) received_14\VBD|NONE (l_dobj) globulin_18\NN|.|also|infants (l_compound) B_16\NN|immune
D006514_D012409 NONE antigen_42\NN| (r_npadvmod) positive_44\JJ|immunity|surface|B|, (r_amod) mothers_45\NNS|NONE (r_pobj) to_38\IN|to|were|who (r_prep) born_37\VBN|NONE (r_relcl) infants_34\NNS|NONE (r_pobj) to_33\IN|of (r_prep) administration_27\NN|to|,|administration (r_conj) dose_22\NN|,|for|prenatal (r_conj) screening_8\NN|.|Assessment|on|:|was (l_prep) for_9\IN|dose|,|prenatal (l_pobj) B_11\NNP|NONE (l_conj) rubella_13\NN|hepatitis|and
D006514_D012409 NONE antigen_42\NN| (r_npadvmod) positive_44\JJ|immunity|surface|B|, (r_amod) mothers_45\NNS|NONE (l_conj) immunity_48\NN|positive|surface|B|, (l_compound) rubella_47\NN|and|,|administration
D006514_D012409 NONE antigen_42\NN| (r_npadvmod) positive_44\JJ|immunity|surface|B|, (r_amod) mothers_45\NNS|NONE (l_conj) immunity_48\NN|positive|surface|B|, (l_conj) administration_51\NN|and|rubella|, (l_prep) of_52\IN|NONE (l_pobj) vaccine_58\NN|NONE (l_compound) rubella_57\NN|in
D006514_D012409 NONE antigen_42\NN| (r_npadvmod) positive_44\JJ|immunity|surface|B|, (r_amod) mothers_45\NNS|NONE (r_pobj) to_38\IN|to|were|who (r_prep) born_37\VBN|NONE (l_prep) to_59\TO|were|who|to (l_pobj) women_62\NNS|NONE (l_compound) rubella_60\VB|nonimmune
17511042
D012254_D063726 CID ribavirin_18\JJ|NONE (r_compound) treatment_19\NN|pegylated|and|interferon (r_conj) alpha-2b_16\NN|NONE (r_pobj) during_13\IN|in|delusional (r_prep) parasitosis_6\NN|NONE
D012254_D063726 CID ribavirin_20\RB|and (r_conj) weekly_18\RB|NONE (r_amod) alpha-2b_17\CD|We|.|woman (r_prep) present_1\VBP|NONE (l_dobj) woman_6\NN|We|alphab|. (l_relcl) developed_8\VBD|a|old (l_dobj) parasitosis_11\NN|who
D012254_D019698 NONE ribavirin_18\JJ|NONE (r_compound) treatment_19\NN|pegylated|and|interferon (r_conj) alpha-2b_16\NN|NONE (r_pobj) during_13\IN|in|delusional (r_prep) parasitosis_6\NN|NONE (l_prep) in_7\IN|during|delusional (l_pobj) patient_12\NN|NONE (l_compound) C_11\NN|chronic|a
D012254_D019698 NONE ribavirin_10\RB|and (r_conj) interferon_8\NN|NONE (r_pobj) with_7\IN|C|chronic (r_prep) patients_6\NNS|NONE (l_compound) C_5\NNP|with|chronic
C417083_D063726 CID alpha-2b_16\NN|NONE (r_pobj) during_13\IN|in|delusional (r_prep) parasitosis_6\NN|NONE
C417083_D063726 CID alpha-2b_17\CD|We|.|woman (r_prep) present_1\VBP|NONE (l_dobj) woman_6\NN|We|alphab|. (l_relcl) developed_8\VBD|a|old (l_dobj) parasitosis_11\NN|who
C417083_D019698 NONE alpha-2b_16\NN|NONE (r_pobj) during_13\IN|in|delusional (r_prep) parasitosis_6\NN|NONE (l_prep) in_7\IN|during|delusional (l_pobj) patient_12\NN|NONE (l_compound) C_11\NN|chronic|a
19356053
D020123_D009404 NONE sirolimus_16\NN|NONE (r_pobj) of_15\IN|the|development|and (r_prep) initiation_14\NN|NONE (l_conj) development_19\NN|of|the|and (l_prep) of_20\IN|the (l_pobj) proteinuria_24\NN|NONE (l_compound) range_23\NN|NONE (l_amod) nephrotic_21\JJ|
D003404_D011507 NONE creatinine_22\NN|estimate|, (r_compound) ratios_23\NNS|turbidometric|protein|or (r_conj) measurement_16\NN|NONE (r_pobj) by_14\IN|In|.|was|,|on|magnitude (r_agent) assessed_9\VBN|NONE (l_nsubjpass) magnitude_5\NN|In|.|was|by|,|on (l_prep) of_6\IN|the (l_pobj) proteinuria_7\NN|NONE
D003404_D011507 NONE creatinine_22\NN|estimate|, (r_compound) ratios_23\NNS|turbidometric|protein|or (l_appos) estimate_26\NN|,|creatinine (l_prep) of_27\IN|an|day (l_pobj) grams_28\NNS|NONE (l_prep) of_29\IN|NONE (l_pobj) proteinuria_30\NN|NONE
D020123_D011507 CID sirolimus_7\NN|NONE (r_pobj) of_6\IN|the (r_prep) administration_5\NN|to (r_pobj) following_3\VBG|.|significant (r_prep) proteinuria_2\NN|NONE
D020123_D011507 CID sirolimus_16\NN|NONE (r_pobj) of_15\IN|the (r_prep) use_14\NN|NONE (r_pobj) with_12\IN|NONE (r_prep) linked_11\VBN|significant (r_acl) proteinuria_10\NN|NONE
D020123_D011507 CID sirolimus_11\NN|NONE (r_compound) use_12\NN|NONE (r_pobj) with_10\IN|NONE (r_prep) associated_9\VBN|substantial (r_acl) proteinuria_8\NN|who
D020123_D011507 CID sirolimus_12\NN|and|proteinuria (r_compound) therapy_13\NN|NONE (l_conj) proteinuria_15\NN|sirolimus|and
D020123_D011507 CID sirolimus_12\NN|and|proteinuria (r_compound) therapy_13\NN|NONE (r_pobj) of_11\IN|the (r_prep) commencement_10\NN|NONE (r_pobj) between_8\IN|close|temporal|the (r_prep) association_7\NN|.|sirolimus|In|as|, (r_nsubj) implicated_16\VBN|NONE (l_prep) as_18\IN|.|sirolimus|In|association|, (l_pobj) etiology_22\NN|NONE (l_prep) of_23\IN|likely|the (l_pobj) proteinuria_25\NN|NONE
D020123_D011507 CID sirolimus_17\NN|.|In|association|as|, (r_dobj) implicated_16\VBN|NONE (l_nsubj) association_7\NN|.|sirolimus|In|as|, (l_prep) between_8\IN|close|temporal|the (l_pobj) commencement_10\NN|NONE (l_prep) of_11\IN|the (l_pobj) therapy_13\NN|NONE (l_conj) proteinuria_15\NN|sirolimus|and
D020123_D011507 CID sirolimus_17\NN|.|In|association|as|, (r_dobj) implicated_16\VBN|NONE (l_prep) as_18\IN|.|sirolimus|In|association|, (l_pobj) etiology_22\NN|NONE (l_prep) of_23\IN|likely|the (l_pobj) proteinuria_25\NN|NONE
D020123_D011507 CID sirolimus_16\NN|NONE (r_pobj) of_15\IN|the|development|and (r_prep) initiation_14\NN|NONE (l_conj) development_19\NN|of|the|and (l_prep) of_20\IN|the (l_pobj) proteinuria_24\NN|NONE
D020123_D011507 CID sirolimus_5\NN|NONE (r_compound) therapy_6\NN|NONE (r_pobj) with_4\IN|strongly|.|compared|Proteinuria (r_prep) correlated_1\VBD|NONE (l_nsubj) Proteinuria_0\NNP|strongly|with|.|compared
D020123_D011507 CID sirolimus_6\NN|NONE (r_pobj) of_5\IN|NONE (r_prep) discontinuation_4\NN|In|,|resolution|.|in|but|, (r_nsubj) resulted_7\VBD|NONE (l_conj) resolution_14\NN|In|,|.|discontinuation|in|but|, (l_prep) of_16\IN|not|, (l_pobj) proteinuria_17\NN|NONE
D020123_D011507 CID Sirolimus_0\NNP|aggravates|.|or (r_nsubj) induces_1\VBZ|NONE (l_conj) aggravates_3\VBZ|.|Sirolimus|or (l_dobj) proteinuria_7\NN|in
D020123_D011507 CID sirolimus_10\NN|when|is (r_nsubjpass) withdrawn_12\VBN|not|does|, (r_advcl) resolve_7\VB|but|,|.|Proteinuria|may (r_conj) improve_2\VB|NONE (l_nsubj) Proteinuria_0\NNP|but|resolve|,|.|may
D020123_D007674 NONE Sirolimus_0\NNP|have|,|.|agent|and (r_nsubj) is_1\VBZ|NONE (l_conj) have_13\VB|,|.|agent|Sirolimus|and (l_dobj) nephrotoxicity_15\NN|may
7416947
D004077_D020018 CID digoxin_13\NN|NONE (r_pobj) of_12\IN|term (r_prep) administration_11\NN|NONE (r_pobj) on_7\IN|NONE (r_prep) patients_6\NNS|NONE (r_pobj) of_5\IN|sexual (r_prep) dysfunction_4\NN|NONE
D004077_D012214 NONE digoxin_10\NN|NONE (r_pobj) without_9\IN|the|(|)|study (r_prep) group_7\NN|NONE (r_pobj) of_2\IN|The (r_prep) patients_1\NNS|selected|of|and|. (r_nsubj) were_12\VBD|NONE (l_conj) selected_29\VBN|patients|of|and|. (l_prep) from_30\IN|randomly|were (l_pobj) patients_35\NNS|NONE (l_compound) disease_34\NN|rheumatic|the
3670965
D001241_D012202 CID aspirin_16\JJ|NONE (r_compound) ingestion_17\NN|or (r_conj) salicylates_14\NNS|NONE (r_pobj) with_13\IN|NONE (r_prep) association_12\NN|NONE (r_pobj) of_11\IN|a|total (r_prep) lack_10\NN|NONE (r_pobj) despite_7\IN|.|,|be|syndrome|may|were|from (r_prep) disappearing_4\VBG|NONE (l_nsubj) syndrome_1\NN|.|,|be|may|despite|were|from
D012459_D012202 NONE salicylates_14\NNS|NONE (r_pobj) with_13\IN|NONE (r_prep) association_12\NN|NONE (r_pobj) of_11\IN|a|total (r_prep) lack_10\NN|NONE (r_pobj) despite_7\IN|.|,|be|syndrome|may|were|from (r_prep) disappearing_4\VBG|NONE (l_nsubj) syndrome_1\NN|.|,|be|may|despite|were|from
7066357
D011692_D009404 CID aminonucleoside_18\RB|by|.|in|Plasma (r_advmod) induced_12\VBN|NONE (l_nsubj) Plasma_0\NN|aminonucleoside|by|.|in (l_prep) during_6\IN|lipids|and (l_pobj) development_8\NN|NONE (l_prep) of_9\IN|the (l_pobj) syndrome_11\NN|NONE
D011692_D009404 CID aminonucleoside_19\NN|NONE (r_pobj) by_17\IN|NONE (r_agent) induced_16\VBN|the|of (r_acl) alterations_8\NNS|whether|to|,|due|or|, (l_prep) of_9\IN|induced|the (l_pobj) lipoproteins_11\NNS|NONE (l_acl) found_12\VBN|plasma (l_prep) in_13\IN|NONE (l_pobj) syndrome_15\NN|NONE
D011692_D009404 CID aminonucleoside_19\NN|NONE (r_pobj) by_17\IN|NONE (r_agent) induced_16\VBN|the|of (r_acl) alterations_8\NNS|whether|to|,|due|or|, (r_nsubj) were_20\VBD|to (l_acomp) due_21\JJ|alterations|whether|to|,|or|, (l_prep) to_22\IN|NONE (l_pobj) syndrome_24\NN|NONE
D011692_D009404 CID aminonucleoside_37\NN|NONE (r_pobj) to_35\IN|alterations|whether|,|due|or|, (r_prep) were_20\VBD|to (l_nsubj) alterations_8\NNS|whether|to|,|due|or|, (l_prep) of_9\IN|induced|the (l_pobj) lipoproteins_11\NNS|NONE (l_acl) found_12\VBN|plasma (l_prep) in_13\IN|NONE (l_pobj) syndrome_15\NN|NONE
D011692_D009404 CID aminonucleoside_37\NN|NONE (r_pobj) to_35\IN|alterations|whether|,|due|or|, (r_prep) were_20\VBD|to (l_acomp) due_21\JJ|alterations|whether|to|,|or|, (l_prep) to_22\IN|NONE (l_pobj) syndrome_24\NN|NONE
D011692_D009404 CID aminonucleoside_21\NN|purpose|.|investigate (l_conj) development_32\NN|and|mg/kg (l_prep) of_33\IN|the|subsequent (l_pobj) syndrome_35\NN|NONE
D002788_D009404 NONE esters_22\NNS|while|that|constant (r_nsubj) remained_25\VBD|.|level|In (r_advcl) decreased_15\VBD|NONE (l_prep) In_0\IN|.|level|remained (l_pobj) stage_4\NN|NONE (l_amod) nephrotic_3\JJ|NONE
D014280_D009404 NONE triacylglycerol_12\NN|fatty|, (r_conj) acids_10\NNS|NONE (r_pobj) of_8\IN|the|plasma (r_prep) level_7\NN|.|In|remained (r_nsubj) decreased_15\VBD|NONE (l_prep) In_0\IN|.|level|remained (l_pobj) stage_4\NN|NONE (l_amod) nephrotic_3\JJ|NONE
D005227_D009404 NONE acids_10\NNS|NONE (r_pobj) of_8\IN|the|plasma (r_prep) level_7\NN|.|In|remained (r_nsubj) decreased_15\VBD|NONE (l_prep) In_0\IN|.|level|remained (l_pobj) stage_4\NN|NONE (l_amod) nephrotic_3\JJ|NONE
873132
D004997_D002779 CID estradiol_12\NN| (r_npadvmod) induced_14\VBN|in (r_amod) cholestasis_15\NN|.|hydroxylation|sulfation
D003840_D002779 NONE acid_9\NN|NONE (r_pobj) of_7\IN||in|alpha (r_prep) hydroxylation_6\NN|.|cholestasis|sulfation (r_dobj) decreased_3\VBD|NONE (l_dobj) cholestasis_15\NN|.|hydroxylation|sulfation
8686832
D008012_D001416 CID lignocaine_11\NN|NONE (r_dobj) involving_7\VBG|spinal (r_acl) anaesthesia_6\NN|NONE (r_pobj) after_4\IN|back (r_prep) pain_3\NN|.|and
D008012_D001416 CID lignocaine_14\NN|NONE (r_pobj) of_10\IN|intrathecal|the (r_prep) use_9\NN|NONE (r_pobj) with_6\IN|Leg|is|. (r_prep) associated_5\VBN|NONE (l_nsubjpass) Leg_0\NNP|is|.|with (l_conj) pain_3\NN|back|and/or
D000431_D010146 NONE alcohol_27\NN|be|high|,|a (r_compound) intake_28\NN|NONE (r_pobj) to_24\IN|NONE (r_prep) admitted_23\VBD|NONE (r_acl) pain_22\NN|NONE (r_pobj) without_21\IN|and|seven (r_prep) pain_10\NN|NONE
D000431_D010146 NONE alcohol_27\NN|be|high|,|a (r_compound) intake_28\NN|NONE (r_pobj) to_24\IN|NONE (r_prep) admitted_23\VBD|NONE (r_acl) pain_22\NN|NONE
322550
D009599_D002303 NONE nitroprusside_1\JJ|NONE (r_amod) infusion_2\NN|.|increased|before|decrease|and (r_nsubj) produced_3\VBD|NONE (l_conj) increased_13\VBN|.|before|decrease|infusion|and (l_conj) decreased_17\VBD|and|rate|significantly (l_dobj) output_19\NN|NONE
D009599_D002303 NONE nitroprusside_1\JJ|low|of|infusion (r_amod) levels_4\NNS|NONE (r_pobj) During_0\IN|,|but|levels|produce|markedly|.|dynamics|do|not (r_prep) alter_10\VB|NONE (l_conj) produce_31\VBP|,|but|levels|During|markedly|.|dynamics|do|not (l_dobj) decreases_33\NNS|,|decreasing|, (l_prep) in_34\IN|marked (l_pobj) pressure_37\NN|NONE (l_conj) output_40\NN|blood|and|arterial
D014867_D002303 NONE H2O_22\NNP|high|of|) (r_punct) levels_16\NNS|,|but|During|produce|markedly|.|dynamics|do|not (r_conj) alter_10\VB|NONE (l_conj) produce_31\VBP|,|but|levels|During|markedly|.|dynamics|do|not (l_dobj) decreases_33\NNS|,|decreasing|, (l_prep) in_34\IN|marked (l_pobj) pressure_37\NN|NONE (l_conj) output_40\NN|blood|and|arterial
D014867_D007022 NONE H2O_22\NNP|high|of|) (r_punct) levels_16\NNS|,|but|During|produce|markedly|.|dynamics|do|not (r_conj) alter_10\VB|NONE (l_conj) produce_31\VBP|,|but|levels|During|markedly|.|dynamics|do|not (l_dobj) decreases_33\NNS|,|decreasing|, (l_prep) in_34\IN|marked (l_pobj) pressure_37\NN|NONE (l_conj) output_40\NN|blood|and|arterial
D009599_D007022 CID nitroprusside_8\RB| (r_advmod) induced_10\VBN|NONE (r_amod) hypotension_11\NN|NONE
D009599_D007022 CID nitroprusside_1\JJ|NONE (r_amod) infusion_2\NN|.|increased|before|decrease|and (r_nsubj) produced_3\VBD|NONE (l_dobj) decrease_6\NN|.|increased|before|infusion|and (l_prep) in_7\IN|a|further (l_pobj) pressure_10\NN|NONE
D009599_D007022 CID Nitroprusside_0\NNP|change|,|.|but|decreases (r_nsubj) caused_1\VBD|NONE (l_dobj) decreases_3\NNS|change|Nitroprusside|,|.|but (l_prep) in_4\IN|significant (l_pobj) pressure_7\NN|NONE
D009599_D007022 NONE nitroprusside_1\JJ|low|of|infusion (r_amod) levels_4\NNS|NONE (r_pobj) During_0\IN|,|but|levels|produce|markedly|.|dynamics|do|not (r_prep) alter_10\VB|NONE (l_conj) produce_31\VBP|,|but|levels|During|markedly|.|dynamics|do|not (l_dobj) decreases_33\NNS|,|decreasing|, (l_prep) in_34\IN|marked (l_pobj) pressure_37\NN|NONE (l_conj) output_40\NN|blood|and|arterial
2070391
D008012_D010146 CID lidocaine_6\NN|as (r_dobj) using_4\VBG|.|in (r_acl) Reduction_0\NN|NONE (l_prep) in_1\IN|using|. (l_pobj) pain_3\NN|NONE
D008012_D010146 CID lidocaine_11\NN|NONE (r_pobj) of_10\IN|the (r_prep) injection_9\NN|NONE (r_pobj) with_7\IN|NONE (r_prep) associated_6\VBN|NONE (r_acl) pain_5\NN|to|that|is
D008012_D010146 CID lidocaine_14\NN|NONE (r_pobj) of_13\IN|the (r_prep) pH_12\NN|to|into (r_dobj) adjust_10\VB|buffering|a (r_relcl) solution_8\NN|NONE (r_pobj) of_5\IN|the (r_prep) addition_4\NN|during|pain|if|would (r_nsubj) reduce_20\VB|To (l_dobj) pain_21\NN|during|if|would|addition
D008012_D010146 CID lidocaine_13\NN|and|in|lidocaine (r_dobj) receiving_11\VBG|NONE (r_pcomp) after_10\IN|to|severity (r_prep) quantify_5\VB|.|were|patients (l_dobj) severity_7\NN|to|after (l_prep) of_8\IN|the (l_pobj) pain_9\NN|NONE
D008012_D010146 CID lidocaine_20\NN|and|in|lidocaine (r_conj) receiving_11\VBG|NONE (r_pcomp) after_10\IN|to|severity (r_prep) quantify_5\VB|.|were|patients (l_dobj) severity_7\NN|to|after (l_prep) of_8\IN|the (l_pobj) pain_9\NN|NONE
D008012_D010146 CID lidocaine_6\NN|NONE (r_pobj) for_4\IN|mean|The|pain (r_prep) score_3\NN|.|lower (l_compound) pain_2\NN|for|mean|The
D008012_D010146 CID lidocaine_16\NN|NONE (r_pobj) for_14\IN|the|P|(|)|+/|mean|, (r_prep) score_13\NN|NONE (r_pobj) than_10\IN|significantly (r_prep) lower_9\JJR|score|. (r_acomp) was_7\VBD|NONE (l_nsubj) score_3\NN|.|lower (l_compound) pain_2\NN|for|mean|The
D008012_D010146 CID lidocaine_5\NN|NONE (r_pobj) of_3\IN|pH|The (r_prep) adjustment_2\NN|be|in|can|.|easily (r_nsubjpass) accomplished_8\VBN|NONE (l_prep) in_10\IN|be|adjustment|can|.|easily (l_pobj) laboratory_13\NN|NONE (l_prep) before_14\IN|catheterization|the (l_pobj) injection_15\NN|NONE (l_prep) in_18\IN|results|and (l_pobj) reduction_20\NN|NONE (l_prep) of_21\IN|a (l_pobj) pain_23\NN|NONE
19211690
D017673_D006973 NONE salt_11\NN| (r_npadvmod) sensitive_13\JJ|Dahl (r_amod) rats_14\NNS|NONE (r_pobj) in_9\IN|of (r_prep) upregulation_5\NN|and|dependent|. (r_conj) hypertension_3\NN|NONE
D013739_D006973 NONE Testosterone_0\NN| (r_npadvmod) dependent_2\JJ|and|upregulation|. (r_amod) hypertension_3\NN|NONE
D013739_D006973 NONE Testosterone_0\NN|to|.|through (r_nsubj) contributes_1\VBZ|NONE (l_prep) to_2\IN|Testosterone|.|through (l_pobj) development_4\NN|NONE (l_prep) of_5\IN|the (l_pobj) hypertension_6\NN|NONE
D013739_D007674 NONE testosterone_24\NN|NONE (r_pobj) by_23\IN|NONE (r_agent) mediated_22\VBN|intrarenal (r_acl) angiotensinogen_21\NN|NONE (r_pobj) of_19\IN|induced (r_prep) upregulation_18\NN|NONE (r_pobj) in_14\IN|sexual|causes|a (r_prep) dimorphism_13\NN|there|that (l_relcl) causes_27\VBZ|sexual|in|a (l_dobj) increases_28\NNS|also|that (l_prep) in_29\IN|NONE (l_pobj) BP_30\NNP|NONE (l_conj) injury_33\NN|and
D013739_D007674 NONE Testosterone_0\NN|in (r_compound) replacement_1\NN|BP|. (r_nsubj) increased_6\VBD|NONE (l_npadvmod) BP_7\NNP|.|replacement (l_appos) injury_10\NN|,
D013739_D007674 NONE Testosterone_0\NN|to|.|through (r_nsubj) contributes_1\VBZ|NONE (l_prep) to_2\IN|Testosterone|.|through (l_pobj) development_4\NN|NONE (l_prep) of_5\IN|the (l_pobj) hypertension_6\NN|NONE (l_conj) injury_9\NN|and|in
D000809_D007674 NONE angiotensin_25\NN|intrarenal|the (r_compound) system_26\NN|NONE (r_pobj) of_20\IN|NONE (r_prep) upregulation_19\NN|possibly (r_pobj) through_18\IN|to|Testosterone|. (r_prep) contributes_1\VBZ|NONE (l_prep) to_2\IN|Testosterone|.|through (l_pobj) development_4\NN|NONE (l_prep) of_5\IN|the (l_pobj) hypertension_6\NN|NONE (l_conj) injury_9\NN|and|in
D000809_D006973 NONE angiotensin_25\NN|intrarenal|the (r_compound) system_26\NN|NONE (r_pobj) of_20\IN|NONE (r_prep) upregulation_19\NN|possibly (r_pobj) through_18\IN|to|Testosterone|. (r_prep) contributes_1\VBZ|NONE (l_prep) to_2\IN|Testosterone|.|through (l_pobj) development_4\NN|NONE (l_prep) of_5\IN|the (l_pobj) hypertension_6\NN|NONE
9799166
D003042_D007511 NONE cocaine_3\NN|NONE (r_pobj) of_2\IN|with|The (r_prep) association_1\NN|on|.|is (l_prep) with_7\IN|of|The (l_pobj) stroke_11\NN|NONE (l_amod) hemorrhagic_8\JJ|NONE (l_conj) ischemic_10\JJ|and
D003042_D020521 CID cocaine_2\NN|and (r_conj) Stroke_0\NN|.
D003042_D020521 CID cocaine_3\NN|NONE (r_pobj) of_2\IN|with|The (r_prep) association_1\NN|on|.|is (l_prep) with_7\IN|of|The (l_pobj) stroke_11\NN|NONE
D003042_D020521 CID cocaine_11\NN|NONE (r_pobj) of_10\IN|NONE (r_prep) use_9\NN|and (r_conj) stroke_7\NN|NONE
D003042_D020521 CID cocaine_13\NN|NONE (r_dobj) using_12\VBG|NONE (r_pcomp) to_11\IN|who (r_prep) admitted_10\VBD|in (r_relcl) stroke_6\NN|NONE
D003042_D020521 CID cocaine_3\NN|NONE (r_pobj) of_2\IN|The (r_prep) use_1\NN|factor|. (r_nsubj) is_6\VBZ|NONE (l_attr) factor_10\NN|use|. (l_prep) for_11\IN|a|risk|strong (l_pobj) stroke_12\NN|NONE
D000661_D007511 NONE amphetamine_5\NN|NONE (r_compound) use_6\NN|and (r_conj) cocaine_3\NN|NONE (r_pobj) of_2\IN|with|The (r_prep) association_1\NN|on|.|is (l_prep) with_7\IN|of|The (l_pobj) stroke_11\NN|NONE (l_amod) hemorrhagic_8\JJ|NONE (l_conj) ischemic_10\JJ|and
D000661_D020521 CID amphetamine_4\NN|or (r_conj) cocaine_2\NN|and (r_conj) Stroke_0\NN|.
D000661_D020521 CID amphetamine_5\NN|NONE (r_compound) use_6\NN|and (r_conj) cocaine_3\NN|NONE (r_pobj) of_2\IN|with|The (r_prep) association_1\NN|on|.|is (l_prep) with_7\IN|of|The (l_pobj) stroke_11\NN|NONE
D000661_D020521 CID amphetamine_13\NN|and/or (r_conj) cocaine_11\NN|NONE (r_pobj) of_10\IN|NONE (r_prep) use_9\NN|and (r_conj) stroke_7\NN|NONE
D000661_D020521 CID amphetamine_15\NN|and/or (r_conj) cocaine_13\NN|NONE (r_dobj) using_12\VBG|NONE (r_pcomp) to_11\IN|who (r_prep) admitted_10\VBD|in (r_relcl) stroke_6\NN|NONE
D000661_D020521 CID amphetamine_5\NN|and/or (r_conj) cocaine_3\NN|NONE (r_pobj) of_2\IN|The (r_prep) use_1\NN|factor|. (r_nsubj) is_6\VBZ|NONE (l_attr) factor_10\NN|use|. (l_prep) for_11\IN|a|risk|strong (l_pobj) stroke_12\NN|NONE
10728962
D020105_D006333 NONE milrinone_5\NN| (r_npadvmod) induced_7\VBN|in (r_amod) hypotension_8\NN|NONE (l_prep) in_9\IN|induced (l_pobj) failure_12\NN|NONE
D020105_D006333 NONE milrinone_7\NN|such (l_prep) in_8\IN|NONE (l_pobj) treatment_10\NN|NONE (l_prep) of_11\IN|the (l_pobj) failure_14\NN|NONE
D020105_D006333 NONE milrinone_11\NN|NONE (r_pobj) with_10\IN|NONE (r_prep) treatment_9\NN|NONE (r_pobj) after_8\IN|NONE (r_prep) hypotension_7\NN|NONE (r_pobj) with_6\IN|heart|decompensated (r_prep) failure_5\NN|NONE
D020105_D006333 NONE milrinone_26\NN|NONE (r_pobj) of_25\IN|the|inotropic (r_prep) effect_24\NN|NONE (r_dobj) inhibiting_21\VBG|NONE (r_pcomp) without_20\IN|In|doses|.|pressure (r_prep) restored_17\VBD|NONE (l_prep) In_0\IN|doses|without|.|pressure (l_pobj) patients_1\NNS|NONE (l_prep) with_2\IN|NONE (l_pobj) failure_5\NN|NONE
D014667_D006333 NONE Vasopressin_0\NN|NONE (l_prep) in_1\IN|. (l_pobj) treatment_3\NN|NONE (l_prep) of_4\IN|the (l_pobj) hypotension_8\NN|NONE (l_prep) in_9\IN|induced (l_pobj) failure_12\NN|NONE
D014667_D006333 NONE vasopressin_16\NN|NONE (r_pobj) of_15\IN|low (r_prep) doses_14\NNS|In|without|.|pressure (r_nsubj) restored_17\VBD|NONE (l_prep) In_0\IN|doses|without|.|pressure (l_pobj) patients_1\NNS|NONE (l_prep) with_2\IN|NONE (l_pobj) failure_5\NN|NONE
D020105_D007022 CID milrinone_5\NN| (r_npadvmod) induced_7\VBN|in (r_amod) hypotension_8\NN|NONE
D020105_D007022 CID milrinone_7\NN|such (r_pobj) as_6\IN|phosphodiesterase (r_prep) inhibitors_4\NNS|NONE (r_pobj) of_2\IN|The (r_prep) use_1\NN|is|.|cause|frequently (r_nsubjpass) restricted_17\VBN|NONE (l_advcl) cause_20\VBP|is|use|.|frequently (l_dobj) vasodilation_21\NN|they|because (l_conj) hypotension_23\NN|and
D020105_D007022 CID milrinone_11\NN|NONE (r_pobj) with_10\IN|NONE (r_prep) treatment_9\NN|NONE (r_pobj) after_8\IN|NONE (r_prep) hypotension_7\NN|NONE
D020105_D007022 CID milrinone_26\NN|NONE (r_pobj) of_25\IN|the|inotropic (r_prep) effect_24\NN|NONE (r_dobj) inhibiting_21\VBG|NONE (r_pcomp) without_20\IN|In|doses|.|pressure (r_prep) restored_17\VBD|NONE (l_prep) In_0\IN|doses|without|.|pressure (l_pobj) patients_1\NNS|NONE (l_prep) with_2\IN|NONE (l_pobj) failure_5\NN|NONE (l_prep) with_6\IN|heart|decompensated (l_pobj) hypotension_7\NN|NONE
D014667_D007022 CID Vasopressin_0\NN|NONE (l_prep) in_1\IN|. (l_pobj) treatment_3\NN|NONE (l_prep) of_4\IN|the (l_pobj) hypotension_8\NN|NONE
D014667_D007022 CID vasopressin_16\NN|NONE (r_pobj) of_15\IN|low (r_prep) doses_14\NNS|In|without|.|pressure (r_nsubj) restored_17\VBD|NONE (l_prep) In_0\IN|doses|without|.|pressure (l_pobj) patients_1\NNS|NONE (l_prep) with_2\IN|NONE (l_pobj) failure_5\NN|NONE (l_prep) with_6\IN|heart|decompensated (l_pobj) hypotension_7\NN|NONE
3973521
7604176
D008148_D009135 NONE lovastatin_1\NN|with|While|have|been (r_nsubjpass) associated_6\VBN|.|,|myopathy|could|entity (l_prep) with_7\IN|While|lovastatin|have|been (l_pobj) myopathy_9\NNS|NONE
D008148_D009135 NONE lovastatin_1\NN|with|While|have|been (r_nsubjpass) associated_6\VBN|.|,|myopathy|could|entity (r_advcl) represent_16\VB|NONE (l_nsubj) myopathy_14\NNS|.|,|could|associated|entity
D019821_D009135 NONE simvastatin_3\NN|and (r_conj) lovastatin_1\NN|with|While|have|been (r_nsubjpass) associated_6\VBN|.|,|myopathy|could|entity (l_prep) with_7\IN|While|lovastatin|have|been (l_pobj) myopathy_9\NNS|NONE
D019821_D009135 NONE simvastatin_3\NN|and (r_conj) lovastatin_1\NN|with|While|have|been (r_nsubjpass) associated_6\VBN|.|,|myopathy|could|entity (r_advcl) represent_16\VB|NONE (l_nsubj) myopathy_14\NNS|.|,|could|associated|entity
D017035_D009220 CID pravastatin_11\NN|NONE (r_pobj) of_10\IN|the (r_prep) use_9\NN|NONE (r_pobj) with_7\IN|NONE (r_prep) associated_6\VBN|inhibitor|of|,|A (r_acl) case_1\NN|is|.|, (l_prep) of_2\IN|inhibitor|associated|,|A (l_pobj) myopathy_5\NNS|NONE
D017035_D006937 NONE pravastatin_2\RB|because|day|He|. (r_dobj) assumed_1\VBD|NONE (l_prep) because_9\IN|pravastatin|day|He|. (l_pobj) hypercholesterolemia_11\NN|of
D017035_D009135 NONE Pravastatin_0\NNP| (r_npadvmod) associated_2\VBN|. (r_amod) myopathy_3\NN|NONE
D017035_D009135 NONE pravastatin_17\JJ|NONE (r_amod) discontinuation_18\NN|NONE (r_pobj) after_16\IN|which|in (r_prep) resolved_11\VBD|lower|the (r_relcl) limbs_9\NNS|NONE (r_pobj) of_6\IN|acute (r_prep) myopathy_5\NN|NONE
D017035_D009135 NONE pravastatin_11\RB| (r_npadvmod) associated_13\VBN|NONE (r_amod) myopathy_14\NNS|.|,|could|associated|entity (r_nsubj) represent_16\VB|NONE (l_advcl) associated_6\VBN|.|,|myopathy|could|entity (l_prep) with_7\IN|While|lovastatin|have|been (l_pobj) myopathy_9\NNS|NONE
D017035_D009135 NONE pravastatin_11\RB| (r_npadvmod) associated_13\VBN|NONE (r_amod) myopathy_14\NNS|.|,|could|associated|entity
1595783
D000638_D004342 NONE amiodarone_4\NN|NONE (r_pobj) of_3\IN|The|pulmonary (r_prep) toxicity_2\NN|is|.|result (r_nsubjpass) thought_6\VBN|NONE (l_xcomp) result_8\VB|toxicity|is|. (l_prep) from_9\IN|to (l_pobj) injury_11\NN|NONE (l_acl) related_12\VBN|direct (l_prep) to_13\IN|NONE (l_pobj) accumulation_16\NN|NONE (l_prep) of_17\IN|the|intracellular (l_pobj) pneumonitis_25\NN|NONE
D000638_D000542 NONE amiodarone_4\NN|NONE (r_pobj) of_3\IN|The|pulmonary (r_prep) toxicity_2\NN|is|.|result (r_nsubjpass) thought_6\VBN|NONE (l_xcomp) result_8\VB|toxicity|is|. (l_prep) from_9\IN|to (l_pobj) injury_11\NN|NONE (l_acl) related_12\VBN|direct (l_prep) to_13\IN|NONE (l_pobj) accumulation_16\NN|NONE (l_prep) of_17\IN|the|intracellular (l_pobj) pneumonitis_25\NN|NONE
D000638_D011014 CID Amiodarone_0\NN|agent|. (r_nsubj) is_1\VBZ|NONE (l_attr) agent_5\NN|Amiodarone|. (l_appos) being_19\VBG|limited|effective|,|antiarrhythmic|an (l_attr) pneumonitis_20\NN|problematic|the
D000638_D008171 NONE Amiodarone_0\NN|pulmonary|. (r_amod) toxicity_2\NN|NONE
D000638_D008171 NONE amiodarone_4\NN|NONE (r_pobj) of_3\IN|The|pulmonary (r_prep) toxicity_2\NN|is|.|result
D000638_D008171 NONE amiodarone_6\NN| (r_npadvmod) induced_8\VBN|pulmonary (r_amod) toxicity_10\NN|NONE
9727773
D001067_D006976 CID suppressants_9\NNS|NONE (r_pobj) with_7\IN|NONE (r_prep) associated_6\VBN|.|High|of (r_acl) incidence_1\NN|NONE (l_prep) of_2\IN|.|associated|High (l_pobj) hypertension_5\NN|NONE
D001067_D006976 CID suppressant_21\NN|NONE (r_compound) drugs_22\NNS|NONE (r_pobj) of_19\IN|the (r_prep) intake_18\NN|NONE (r_pobj) with_16\IN|has|which|been (r_prep) associated_15\VBN|,|rare|a (r_relcl) disease_10\NN|hypertension|. (r_attr) is_3\VBZ|NONE (l_nsubj) hypertension_2\NN|disease|.
D001067_D006976 CID suppressants_18\NNS||was|,|had|. (r_dobj) taken_16\VBN|NONE (l_ccomp) was_9\VBD||suppressants|,|had|. (l_nsubj) diagnosis_4\NN|uncertain|In (l_prep) of_5\IN|the (l_pobj) hypertension_8\NN|NONE
D001067_D006976 CID suppressants_7\NNS|NONE (r_pobj) of_5\IN|unrestricted (r_prep) prescription_4\NN|NONE (r_pobj) of_2\IN|A (r_prep) policy_1\NN|may|to|. (r_nsubj) lead_9\VB|NONE (l_prep) to_10\IN|may|.|policy (l_pobj) incidence_13\NN|NONE (l_prep) of_14\IN|high|a (l_pobj) hypertension_18\NN|NONE
7352670
D012504_D006973 NONE saralasin_7\NN|NONE (r_pobj) by_6\IN|NONE (r_agent) prevented_5\VBN|.|Rebound|nitroprusside (r_acl) hypertensive_1\JJ|NONE
D012504_D006973 NONE saralasin_20\NN| (r_npadvmod) treated_22\VBN|the (r_amod) animals_23\NNS|whereas|change (r_nsubj) showed_24\VBD|During|increase|,|animals|. (r_advcl) demonstrated_7\VBD|NONE (l_dobj) increase_10\NN|During|,|showed|animals|. (l_prep) in_11\IN|to|a|progressive (l_pobj) pressure_13\NN|NONE
D000809_D007022 NONE angiotensin_6\NN|in (r_compound) system_7\NN|the| (l_prep) in_8\IN|angiotensin (l_pobj) maintenance_10\NN|NONE (l_prep) during_14\IN|the|of (l_pobj) anesthesia_16\NN|NONE (l_conj) nitroprusside_19\NN|sodium|halothane|and (l_parataxis) evaluated_24\VBN|NONE (l_nsubjpass) hypotension_22\NN|(|was
D000809_D007022 NONE angiotensin_8\NN|in (r_compound) system_9\NN||the (l_prep) in_10\IN|angiotensin (l_pcomp) antagonizing_11\VBG|NONE (l_dobj) effects_15\NNS|NONE (l_amod) hypotensive_14\JJ|combined|the|of
D009599_D007022 CID nitroprusside_19\NN|sodium|halothane|and (l_parataxis) evaluated_24\VBN|NONE (l_nsubjpass) hypotension_22\NN|(|was
D009599_D007022 CID SNP)-induced_21\VBN|NONE (r_amod) hypotension_22\NN|(|was
D009599_D007022 CID SNP_19\NNP|and (r_conj) halothane_17\NN|NONE (r_pobj) of_16\IN|combined|hypotensive|the (r_prep) effects_15\NNS|NONE (l_amod) hypotensive_14\JJ|combined|the|of
D009599_D006973 NONE nitroprusside_4\NN|.|Rebound|prevented (r_advmod) hypertensive_1\JJ|NONE
D009599_D006973 NONE SNP_2\NNP|the (r_compound) infusion_3\NN|NONE (r_pobj) During_0\IN|increase|,|showed|animals|. (r_prep) demonstrated_7\VBD|NONE (l_dobj) increase_10\NN|During|,|showed|animals|. (l_prep) in_11\IN|to|a|progressive (l_pobj) pressure_13\NN|NONE
D006221_D007022 CID halothane_15\NN|sodium|and|nitroprusside (r_compound) anesthesia_16\NN|NONE (l_conj) nitroprusside_19\NN|sodium|halothane|and (l_parataxis) evaluated_24\VBN|NONE (l_nsubjpass) hypotension_22\NN|(|was
D006221_D007022 CID halothane_17\NN|NONE (r_pobj) of_16\IN|combined|hypotensive|the (r_prep) effects_15\NNS|NONE (l_amod) hypotensive_14\JJ|combined|the|of
7269015
D002066_D006470 CID Busulfan_0\NNS| (r_npadvmod) induced_2\VBN|hemorrhagic|. (r_amod) cystitis_4\NN|NONE
D002066_D006470 CID busulfan_4\NNS| (r_npadvmod) induced_6\VBN|hemorrhage|a (r_amod) cystitis_8\NN|NONE
D002066_D003556 CID Busulfan_0\NNS| (r_npadvmod) induced_2\VBN|hemorrhagic|. (r_amod) cystitis_4\NN|NONE
D002066_D003556 CID busulfan_4\NNS| (r_npadvmod) induced_6\VBN|hemorrhage|a (r_amod) cystitis_8\NN|NONE
D002066_D003556 CID busulfan_7\NNS|and|cystitis (r_amod) cystitis_8\NN|NONE
D002066_D003556 CID busulfan_7\NNS|and|cystitis (r_amod) cystitis_8\NN|NONE (l_conj) cystitis_16\NN|busulfan|and
D002066_D002277 NONE busulfan_7\NNS|NONE (r_pobj) of_6\IN|known|the (r_prep) tendency_5\NN|NONE (r_pobj) of_2\IN|NONE (r_prep) view_1\NN|induce (r_pobj) In_0\IN|in|is|,|.|cytology (l_advcl) induce_9\VB|view (l_dobj) atypia_11\NN|to (l_conj) carcinoma_13\NN|in|and|cellular
D003520_D003556 NONE cyclophosphamide_13\NN| (r_npadvmod) induced_15\VBN|and|both (r_conj) radiation_11\NN|NONE (r_nmod) cystitis_16\NN|busulfan|and (r_conj) cystitis_8\NN|NONE
D003520_D003556 NONE cyclophosphamide_13\NN| (r_npadvmod) induced_15\VBN|and|both (r_conj) radiation_11\NN|NONE (r_nmod) cystitis_16\NN|busulfan|and
7189975
C004616_D012640 CID chloroprocaine_31\NN|the (r_compound) group_32\NN|NONE (r_pobj) of_29\IN| (r_prep) %_28\NN|and|in|, (r_pobj) in_26\IN|dose|fatal|in|,|. (r_prep) was_15\VBD|NONE (l_nsubj) dose_2\NN|fatal|in|,|in|. (l_appos) convulsions_8\NNS|CD|of|)|A
C004616_D012640 CID chloroprocaine_31\NN|the (r_compound) group_32\NN|NONE (r_pobj) of_29\IN| (r_prep) %_28\NN|and|in|, (r_pobj) in_26\IN|dose|fatal|in|,|. (r_prep) was_15\VBD|NONE (l_prep) in_17\IN|dose|fatal|,|in|. (l_pobj) %_19\NN|NONE (l_prep) of_20\IN| (l_pobj) seizures_24\NNS|NONE
D008012_D012640 CID lidocaine_40\NN|the (r_compound) group_41\NN|NONE (r_pobj) of_38\IN| (r_prep) %_37\NN|NONE (r_pobj) in_35\IN|and|%|, (r_conj) in_26\IN|dose|fatal|in|,|. (r_prep) was_15\VBD|NONE (l_nsubj) dose_2\NN|fatal|in|,|in|. (l_appos) convulsions_8\NNS|CD|of|)|A
D008012_D012640 CID lidocaine_40\NN|the (r_compound) group_41\NN|NONE (r_pobj) of_38\IN| (r_prep) %_37\NN|NONE (r_pobj) in_35\IN|and|%|, (r_conj) in_26\IN|dose|fatal|in|,|. (r_prep) was_15\VBD|NONE (l_prep) in_17\IN|dose|fatal|,|in|. (l_pobj) %_19\NN|NONE (l_prep) of_20\IN| (l_pobj) seizures_24\NNS|NONE
D002045_D012640 CID bupivacaine_21\NN| (r_npadvmod) induced_23\VBN|NONE (r_amod) seizures_24\NNS|NONE (r_pobj) of_20\IN| (r_prep) %_19\NN|NONE (r_pobj) in_17\IN|dose|fatal|,|in|. (r_prep) was_15\VBD|NONE (l_nsubj) dose_2\NN|fatal|in|,|in|. (l_appos) convulsions_8\NNS|CD|of|)|A
D002045_D012640 CID bupivacaine_21\NN| (r_npadvmod) induced_23\VBN|NONE (r_amod) seizures_24\NNS|NONE
10091616
D007980_D004409 CID levodopa_2\NN| (r_npadvmod) induced_4\VBN|by (r_amod) dyskinesias_5\NNS|NONE
D001058_D010300 NONE apomorphine_69\NN|NONE (r_pobj) of_68\IN|an|effective|single (r_prep) dose_67\NN|NONE (r_pobj) of_63\IN|NONE (r_prep) administration_62\NN|NONE (r_pobj) following_61\VBG|the|of (r_prep) worsening_55\VBG|NONE (r_pobj) on_53\IN|) (r_prep) tasks_52\NNS|aloud (r_dobj) speaking_49\VBG|role|,|to (r_dep) evaluate_16\VB|.|were|patients|in (r_advcl) included_11\VBN|NONE (l_nsubjpass) patients_1\NNS|.|were|evaluate|in (l_relcl) had_3\VBD|Ten (l_dobj) disease_6\NN|with|who
D001058_D004409 CID apomorphine_69\NN|NONE (r_pobj) of_68\IN|an|effective|single (r_prep) dose_67\NN|NONE (r_pobj) of_63\IN|NONE (r_prep) administration_62\NN|NONE (r_pobj) following_61\VBG|the|of (r_prep) worsening_55\VBG|NONE (r_pobj) on_53\IN|) (r_prep) tasks_52\NNS|aloud (r_dobj) speaking_49\VBG|role|,|to (r_dep) evaluate_16\VB|.|were|patients|in (r_advcl) included_11\VBN|NONE (l_nsubjpass) patients_1\NNS|.|were|evaluate|in (l_relcl) had_3\VBD|Ten (l_prep) with_7\IN|who|disease (l_pcomp) disabling_8\VBG|NONE (l_dobj) dyskinesia_9\NN|NONE
D001058_D004409 CID apomorphine_69\NN|NONE (r_pobj) of_68\IN|an|effective|single (r_prep) dose_67\NN|NONE (r_pobj) of_63\IN|NONE (r_prep) administration_62\NN|NONE (r_pobj) following_61\VBG|the|of (r_prep) worsening_55\VBG|NONE (l_prep) of_56\IN|the|following (l_pobj) dyskinesia_60\JJ|NONE
3560096
D007213_D006947 CID indomethacin_17\NN|such (r_pobj) as_16\IN|)|( (r_prep) NSAID_13\NNP|nonsteroidal|antiinflammatory (r_appos) agents_11\NNS|NONE (r_pobj) of_8\IN|a (r_prep) complication_7\NN|NONE (r_pobj) as_5\IN|recently|Hyperkalemia|.|been|has (r_prep) recognized_4\VBN|NONE (l_nsubjpass) Hyperkalemia_0\NNP|recently|.|as|been|has
D011188_D006947 NONE potassium_8\NN|to (r_dobj) effect_6\NN|NONE (r_xcomp) known_4\VBN|other|no (r_acl) medications_3\NNS|concomitantly|had|been|As (r_nsubjpass) given_11\VBN|,|course|.|suggestive (r_advcl) is_18\VBZ|NONE (l_acomp) suggestive_19\JJ|,|course|.|given (l_prep) of_20\IN|NONE (l_pobj) relationship_27\NN|NONE (l_prep) between_28\IN|cause|a (l_pobj) sulindac_29\NN|NONE (l_conj) hyperkalemia_31\NN|and
D013467_D006947 CID sulindac_3\NN|NONE (r_compound) therapy_4\NN|NONE (r_pobj) with_2\IN|NONE (r_prep) associated_1\VBN|. (r_acl) Hyperkalemia_0\NNP|NONE
D013467_D006947 CID sulindac_22\NN|NONE (r_compound) administration_23\NN|NONE (r_pobj) of_21\IN| (r_prep) days_20\NNS|NONE (r_pobj) within_16\IN|hyperkalemia (r_prep) developed_15\VBD|patients|.|We (l_nsubj) hyperkalemia_6\VBD|within
D013467_D006947 CID sulindac_29\NN|NONE (l_conj) hyperkalemia_31\NN|and
10901305
D007649_D004204 NONE ketamine_7\NN|NONE (l_prep) to_8\IN|NONE (l_pobj) manipulation_9\NN|NONE (l_prep) of_10\IN|NONE (l_pobj) fracture_12\NN|NONE (l_conj) dislocation_14\NN|the|or
D007649_D050723 NONE Ketamine_0\NN|NONE (l_dobj) sedation_1\NN|. (l_prep) for_2\IN|NONE (l_pobj) reduction_4\NN|NONE (l_prep) of_5\IN|the (l_pobj) fractures_8\NNS|NONE
D007649_D050723 NONE ketamine_14\NN|NONE (l_prep) for_15\IN|NONE (l_pobj) sedation_16\NN|NONE (l_prep) in_17\IN|NONE (l_pobj) treatment_19\NN|NONE (l_prep) of_20\IN|the (l_pobj) fractures_23\NNS|NONE
D007649_D050723 NONE ketamine_7\NN|NONE (l_prep) to_8\IN|NONE (l_pobj) manipulation_9\NN|NONE (l_prep) of_10\IN|NONE (l_pobj) fracture_12\NN|NONE
D007649_D050723 NONE Ketamine_0\NNP|quickly|sedation|reliably|. (r_nsubj) provided_7\VBD|NONE (l_dobj) sedation_9\NN|Ketamine|quickly|reliably|. (l_acl) facilitate_12\VB|adequate (l_dobj) reduction_14\NN|to|effectively (l_prep) of_15\IN|the (l_pobj) fractures_18\NNS|NONE
17074608
D014635_D007805 NONE valproate_32\NN|NONE (r_amod) therapy_33\NN|NONE (r_pobj) of_31\IN|NONE (r_prep) initiation_30\NN|shortly (r_pobj) after_29\IN|with|her (r_prep) presentation_22\NN|NONE (r_pobj) following_20\VBG|have|was|who (r_prep) found_15\VBN|,|and|language|mild|retardation (r_relcl) delay_8\NN|NONE
D005998_D020158 NONE glycine_15\NN|the|cleavage (r_compound) system_17\NN|NONE (r_pobj) in_13\IN|a (r_prep) defect_12\NN|in|to (r_nsubj) leads_18\VBZ|acid (r_relcl) metabolism_8\NN|NONE (r_pobj) of_5\IN|a (r_prep) disorder_4\NN|hyperglycinemia|. (r_attr) is_2\VBZ|NONE (l_nsubj) hyperglycinemia_1\NN|disorder|.
D005998_D020158 NONE glycine_23\NN|NONE (r_pobj) of_22\IN|an|in (r_prep) accumulation_21\NN|NONE (r_pobj) to_19\IN|in|defect (r_prep) leads_18\VBZ|acid (r_relcl) metabolism_8\NN|NONE (r_pobj) of_5\IN|a (r_prep) disorder_4\NN|hyperglycinemia|. (r_attr) is_2\VBZ|NONE (l_nsubj) hyperglycinemia_1\NN|disorder|.
D014635_D008607 NONE valproate_32\NN|NONE (r_amod) therapy_33\NN|NONE (r_pobj) of_31\IN|NONE (r_prep) initiation_30\NN|shortly (r_pobj) after_29\IN|with|her (r_prep) presentation_22\NN|NONE (r_pobj) following_20\VBG|have|was|who (r_prep) found_15\VBN|,|and|language|mild|retardation (r_relcl) delay_8\NN|NONE (l_conj) retardation_11\NN|,|and|language|found|mild
D005998_D000592 NONE glycine_15\NN|the|cleavage (r_compound) system_17\NN|NONE (r_pobj) in_13\IN|a (r_prep) defect_12\NN|in|to (r_nsubj) leads_18\VBZ|acid (r_relcl) metabolism_8\NN|NONE
D005998_D000592 NONE glycine_23\NN|NONE (r_pobj) of_22\IN|an|in (r_prep) accumulation_21\NN|NONE (r_pobj) to_19\IN|in|defect (r_prep) leads_18\VBZ|acid (r_relcl) metabolism_8\NN|NONE
D014635_D002819 CID Valproate_0\NNP| (r_npadvmod) induced_2\VBN|and|.|encephalopathy (r_amod) chorea_3\NN|NONE
D014635_D002819 CID valproate_32\NN|NONE (r_amod) therapy_33\NN|NONE (r_pobj) of_31\IN|NONE (r_prep) initiation_30\NN|shortly (r_pobj) after_29\IN|with|her (r_prep) presentation_22\NN|NONE (l_prep) with_23\IN|after|her (l_pobj) encephalopathy_25\NN|NONE (l_conj) chorea_27\NN|acute|and
D014635_D020158 NONE Valproate_0\NNP| (r_npadvmod) induced_2\VBN|and|.|encephalopathy (r_amod) chorea_3\NN|NONE (l_conj) encephalopathy_5\JJ|and|.|induced (l_prep) in_6\IN|NONE (l_pobj) hyperglycinemia_9\NN|NONE
D014635_D020158 NONE valproate_32\NN|NONE (r_amod) therapy_33\NN|NONE (r_pobj) of_31\IN|NONE (r_prep) initiation_30\NN|shortly (r_pobj) after_29\IN|with|her (r_prep) presentation_22\NN|NONE (r_pobj) following_20\VBG|have|was|who (r_prep) found_15\VBN|,|and|language|mild|retardation (l_xcomp) have_17\VB|was|following|who (l_dobj) hyperglycinemia_19\NN|to
D014635_D001927 CID Valproate_0\NNP| (r_npadvmod) induced_2\VBN|and|.|encephalopathy (r_amod) chorea_3\NN|NONE (l_conj) encephalopathy_5\JJ|and|.|induced
D014635_D001927 CID valproate_32\NN|NONE (r_amod) therapy_33\NN|NONE (r_pobj) of_31\IN|NONE (r_prep) initiation_30\NN|shortly (r_pobj) after_29\IN|with|her (r_prep) presentation_22\NN|NONE (l_prep) with_23\IN|after|her (l_pobj) encephalopathy_25\NN|NONE
2533791
D017325_D006509 NONE vaccine_25\NN|.|injections (r_dobj) derived_22\VBN|are|with|and|infants (r_conj) treated_3\VBN|NONE (l_prep) with_4\IN|are|derived|and|infants (l_pobj) injections_6\NNS|NONE (l_prep) of_7\IN|two (l_pobj) globulin_11\NN|NONE (l_compound) B_9\NNP|immune|HBIG
16132524
D017239_D005909 NONE paclitaxel_3\NN|/ (r_nmod) carboplatin_5\VB|)|liquid|cubic|for|crystalline (r_amod) phases_9\NNS|Intracavitary|(|. (l_prep) for_11\IN|carboplatin|)|liquid|cubic|crystalline (l_pobj) glioblastoma_13\NN|NONE
D017239_D005909 NONE paclitaxel_21\NN|NONE (r_pobj) of_20\IN|surgical|intracavitary|a (r_prep) application_19\NN|NONE (r_pobj) of_15\IN|encapsulated|term|and (r_prep) effects_14\NNS|and|, (r_conj) safety_8\NN|,|the (r_conj) feasibility_6\NN|For|in|,|.|are (r_nsubjpass) examined_31\VBN|NONE (l_prep) For_0\IN|in|,|.|feasibility|are (l_pobj) recurrences_3\NNS|NONE (l_compound) glioblastoma_2\NN|human
D017239_D005909 NONE paclitaxel_22\NN|NONE (r_pobj) of_21\IN|intracavitary|an (r_prep) application_20\NN|and|phases (r_dobj) received_17\VBD|and (r_conj) underwent_12\VBN|a|glioblastoma (r_acl) multiforme_11\NN|NONE (l_compound) glioblastoma_10\NN|a|underwent
D017239_D001929 CID paclitaxel_9\NN|suffered|Six|.|and (r_dobj) received_4\VBD|NONE (l_conj) suffered_11\VBD|paclitaxel|Six|.|and (l_prep) from_12\IN|received|, (l_prep) to_14\TO|moderate (l_pobj) edema_17\NN|NONE
D017239_D001929 CID paclitaxel_30\NN|NONE (r_pobj) of_27\IN|only|a (r_prep) total_26\NN|patients|while (r_dobj) received_23\VBD|from|, (r_advcl) suffered_11\VBD|paclitaxel|Six|.|and (l_prep) from_12\IN|received|, (l_prep) to_14\TO|moderate (l_pobj) edema_17\NN|NONE
D016190_D005909 NONE carboplatin_5\VB|)|liquid|cubic|for|crystalline (r_amod) phases_9\NNS|Intracavitary|(|. (l_prep) for_11\IN|carboplatin|)|liquid|cubic|crystalline (l_pobj) glioblastoma_13\NN|NONE
D016190_D005909 NONE carboplatin_23\NN|by (r_advmod) encapsulated_24\VBN|term|and|of (r_conj) effects_14\NNS|and|, (r_conj) safety_8\NN|,|the (r_conj) feasibility_6\NN|For|in|,|.|are (r_nsubjpass) examined_31\VBN|NONE (l_prep) For_0\IN|in|,|.|feasibility|are (l_pobj) recurrences_3\NNS|NONE (l_compound) glioblastoma_2\NN|human
D016190_D005909 NONE carboplatin_24\VB|cubic|in (r_amod) phases_26\NNS|application|and (r_conj) received_17\VBD|and (r_conj) underwent_12\VBN|a|glioblastoma (r_acl) multiforme_11\NN|NONE (l_compound) glioblastoma_10\NN|a|underwent
133615
D003276_D013923 NONE contraceptive_6\NN|oral (r_amod) therapy_7\NN|NONE (r_pobj) of_4\IN|Thromboembolic|:|.|in|report (r_prep) complications_3\NNS|NONE (l_amod) Thromboembolic_0\JJ|:|of|.|in|report
D003276_D001778 CID contraceptive_6\NN|oral (r_amod) therapy_7\NN|NONE (r_pobj) of_4\IN|Thromboembolic|:|.|in|report (r_prep) complications_3\NNS|NONE (l_prep) in_8\IN|Thromboembolic|:|of|.|report (l_pobj) relationship_9\NN|NONE (l_prep) to_10\IN|NONE (l_pobj) levels_12\NNS|NONE (l_prep) of_13\IN|pretreatment (l_pobj) factors_16\NNS|NONE (l_compound) coagulation_15\NN|NONE
3865016
D016572_D017254 NONE A_7\NNP|NONE (r_pobj) of_3\IN|concomitant|The (r_prep) administration_2\NN|.|in (r_nsubj) resulted_8\VBD|NONE (l_prep) in_9\IN|administration|. (l_pobj) eradication_10\NN|NONE (l_prep) of_11\IN|NONE (l_pobj) infiltration_15\NN|NONE
D005047_D017254 NONE etoposide_4\NN|NONE (r_nmod) A_7\NNP|NONE (r_pobj) of_3\IN|concomitant|The (r_prep) administration_2\NN|.|in (r_nsubj) resulted_8\VBD|NONE (l_prep) in_9\IN|administration|. (l_pobj) eradication_10\NN|NONE (l_prep) of_11\IN|NONE (l_pobj) infiltration_15\NN|NONE
D016572_D054218 NONE A_7\NNP|NONE (r_pobj) of_3\IN|synergistic|A (r_prep) effect_2\NN|was|.|in|in (r_nsubjpass) observed_9\VBN|NONE (l_prep) in_10\IN|was|.|in|effect (l_pobj) patient_12\NN|NONE (l_prep) with_13\IN|a (l_pobj) leukemia_18\NN|NONE
D005047_D054218 NONE etoposide_4\NN|NONE (r_nmod) A_7\NNP|NONE (r_pobj) of_3\IN|synergistic|A (r_prep) effect_2\NN|was|.|in|in (r_nsubjpass) observed_9\VBN|NONE (l_prep) in_10\IN|was|.|in|effect (l_pobj) patient_12\NN|NONE (l_prep) with_13\IN|a (l_pobj) leukemia_18\NN|NONE
20619828
D002997_D060845 CID Clomipramine_0\NNP|in (r_compound) exposure_1\NN|.|inflexibility|changes (r_nsubj) produced_5\VBD|NONE (l_npadvmod) inflexibility_25\NN|exposure|.|changes (l_appos) impairment_41\NN|behavioral|perseveration|(|,|, (l_conj) hoarding_51\NN|(|paradigm|working|memory|,
D002997_-1 NONE Clomipramine_0\NNP|in (r_compound) exposure_1\NN|.|inflexibility|changes (r_nsubj) produced_5\VBD|NONE (l_npadvmod) inflexibility_25\NN|exposure|.|changes
D002997_-1 NONE Clomipramine_0\NNP|in (r_compound) exposure_1\NN|.|inflexibility|changes (r_nsubj) produced_5\VBD|NONE (l_npadvmod) inflexibility_25\NN|exposure|.|changes (l_appos) impairment_41\NN|behavioral|perseveration|(|,|, (l_conj) hoarding_51\NN|(|paradigm|working|memory|, (l_conj) dysfunction_55\NN|and|,
D002997_D008569 CID Clomipramine_0\NNP|in (r_compound) exposure_1\NN|.|inflexibility|changes (r_nsubj) produced_5\VBD|NONE (l_npadvmod) inflexibility_25\NN|exposure|.|changes (l_appos) impairment_41\NN|behavioral|perseveration|(|,|,
D002997_D001008 CID Clomipramine_0\NNP|in (r_compound) exposure_1\NN|.|inflexibility|changes (r_nsubj) produced_5\VBD|NONE (l_dobj) changes_10\NNS|exposure|.|inflexibility (l_relcl) include_12\VBP|significant|behavioral (l_dobj) anxiety_14\NN|that
6115999
D001539_D011928 NONE bendrofluazide_23\NN|NONE (r_amod) treatment_24\NN|NONE (r_pobj) with_22\IN|NONE (r_prep) associated_21\VBN|in|,|and|,|glucose|impaired|phenomenon (r_acl) tolerance_11\NN|NONE (l_conj) phenomenon_29\NN|in|,|and|,|glucose|impaired|associated
D001539_D004417 NONE bendrofluazide_23\NN|NONE (r_amod) treatment_24\NN|NONE (r_pobj) with_22\IN|NONE (r_prep) associated_21\VBN|in|,|and|,|glucose|impaired|phenomenon (r_acl) tolerance_11\NN|NONE (l_conj) phenomenon_29\NN|in|,|and|,|glucose|impaired|associated (l_conj) dyspnoea_31\NN|Raynaud|and|in
D011433_D007172 CID propranolol_20\RB|than (r_dobj) taking_19\VBG|NONE (r_acl) patients_18\NNS|NONE (r_pobj) in_17\IN|frequently|also|.|impotence (r_prep) occurred_14\VBD|and|,|results|association (r_conj) show_2\VBP|NONE (l_dobj) association_4\NN|and|,|results|occurred (l_prep) between_5\IN|an (l_pobj) treatment_7\NN|NONE (l_conj) impotence_9\NN|bendrofluazide|and
D011433_D007172 CID propranolol_20\RB|than (r_dobj) taking_19\VBG|NONE (r_acl) patients_18\NNS|NONE (r_pobj) in_17\IN|frequently|also|.|impotence (r_prep) occurred_14\VBD|and|,|results|association (l_nsubj) impotence_12\NN|in|frequently|also|.
D011433_D003316 NONE propranolol_10\NN|the (r_amod) group_11\NN|NONE (r_pobj) in_8\IN|have|to (r_prep) occurred_7\VBN|is|disease|. (r_xcomp) known_4\VBN|NONE (l_nsubjpass) disease_2\NN|is|occurred|.
D001539_D006973 NONE bendrofluazide_3\VB|.|Adverse (l_conj) propranolol_5\NN|and|to (l_prep) for_6\IN|NONE (l_pobj) treatment_8\NN|NONE (l_prep) of_9\IN|the (l_pobj) hypertension_11\NN|NONE
D001539_D006973 NONE bendrofluazide_21\NN|four|:|treatment (r_amod) groups_19\NNS|NONE (r_pobj) of_16\IN|NONE (r_prep) one_15\CD|NONE (r_pobj) to_14\IN|Participants|randomly|are|. (r_prep) allocated_13\VBN|NONE (l_nsubjpass) Participants_0\NNS|randomly|are|to|. (l_prep) in_1\IN|NONE (l_pobj) trial_7\NN|NONE (l_prep) for_8\IN|the|Council|treatment (l_pobj) hypertension_10\NN|NONE
D011433_D011928 CID propranolol_37\NN|NONE (r_dobj) taking_36\VBG|and|women (r_acl) men_33\NNS|NONE (r_pobj) in_32\IN|Raynaud|and|dyspnoea (r_prep) phenomenon_29\NN|in|,|and|,|glucose|impaired|associated
D001539_D007172 CID bendrofluazide_6\JJ|and|impotence (r_amod) treatment_7\NN|NONE (l_conj) impotence_9\NN|bendrofluazide|and
D001539_D007172 CID bendrofluazide_6\JJ|and|impotence (r_amod) treatment_7\NN|NONE (r_pobj) between_5\IN|an (r_prep) association_4\NN|and|,|results|occurred (r_dobj) show_2\VBP|NONE (l_conj) occurred_14\VBD|and|,|results|association (l_nsubj) impotence_12\NN|in|frequently|also|.
D001539_D018149 CID bendrofluazide_23\NN|NONE (r_amod) treatment_24\NN|NONE (r_pobj) with_22\IN|NONE (r_prep) associated_21\VBN|in|,|and|,|glucose|impaired|phenomenon (r_acl) tolerance_11\NN|NONE
D001539_D006073 CID bendrofluazide_23\NN|NONE (r_amod) treatment_24\NN|NONE (r_pobj) with_22\IN|NONE (r_prep) associated_21\VBN|in|,|and|,|glucose|impaired|phenomenon (r_acl) tolerance_11\NN|NONE (l_prep) in_12\IN|,|and|,|glucose|impaired|phenomenon|associated (l_pobj) men_13\NNS|NONE (l_conj) women_15\NNS|and|in (l_conj) gout_17\NN|and
D011433_D018149 NONE propranolol_37\NN|NONE (r_dobj) taking_36\VBG|and|women (r_acl) men_33\NNS|NONE (r_pobj) in_32\IN|Raynaud|and|dyspnoea (r_prep) phenomenon_29\NN|in|,|and|,|glucose|impaired|associated (r_conj) tolerance_11\NN|NONE
D011433_D004417 CID propranolol_37\NN|NONE (r_dobj) taking_36\VBG|and|women (r_acl) men_33\NNS|NONE (r_pobj) in_32\IN|Raynaud|and|dyspnoea (r_prep) phenomenon_29\NN|in|,|and|,|glucose|impaired|associated (l_conj) dyspnoea_31\NN|Raynaud|and|in
D011433_D006973 NONE propranolol_5\NN|and|to (l_prep) for_6\IN|NONE (l_pobj) treatment_8\NN|NONE (l_prep) of_9\IN|the (l_pobj) hypertension_11\NN|NONE
D011433_D006973 NONE propranolol_23\NN|, (r_conj) bendrofluazide_21\NN|four|:|treatment (r_amod) groups_19\NNS|NONE (r_pobj) of_16\IN|NONE (r_prep) one_15\CD|NONE (r_pobj) to_14\IN|Participants|randomly|are|. (r_prep) allocated_13\VBN|NONE (l_nsubjpass) Participants_0\NNS|randomly|are|to|. (l_prep) in_1\IN|NONE (l_pobj) trial_7\NN|NONE (l_prep) for_8\IN|the|Council|treatment (l_pobj) hypertension_10\NN|NONE
D011433_D006073 NONE propranolol_37\NN|NONE (r_dobj) taking_36\VBG|and|women (r_acl) men_33\NNS|NONE (r_pobj) in_32\IN|Raynaud|and|dyspnoea (r_prep) phenomenon_29\NN|in|,|and|,|glucose|impaired|associated (r_conj) tolerance_11\NN|NONE (l_prep) in_12\IN|,|and|,|glucose|impaired|phenomenon|associated (l_pobj) men_13\NNS|NONE (l_conj) women_15\NNS|and|in (l_conj) gout_17\NN|and
19721134
D010862_D017180 NONE pilocarpine_5\NN|delayed|that|of (r_amod) onset_8\NN|data (r_dobj) showed_3\VBD|.|score|,|course|, (r_ccomp) decreased_12\VBD|NONE (l_dobj) course_15\NN|.|showed|score|,|, (l_prep) of_16\IN|the|time (l_pobj) tachycardia_18\NN|NONE (l_conj) fibrillation_20\NN|ventricular|and
D000157_D001145 CID aconitine_19\NN| (r_npadvmod) induced_21\VBN|both|and|models (r_amod) rat_22\NN|NONE (l_conj) models_30\NNS|both|and|induced (l_compound) arrhythmia_29\NN|induced
D000157_D001145 CID aconitine_17\NN|NONE (r_pobj) by_16\IN|NONE (r_agent) induced_15\VBN|pig|rat (r_acl) models_14\NNS|NONE (l_nmod) rat_10\NN|pig|induced (l_amod) arrhythmic_9\JJ|and
D002118_D001145 NONE Ca(2_34\NNP|NONE (r_pobj) of_33\IN|the (r_prep) improvement_32\NN|NONE (r_pobj) to_30\IN|mechanism|be|may (r_prep) related_29\VBN|the (r_relcl) cardiac_23\JJ|NONE (r_dobj) stimulating_21\VBG|NONE (r_pcomp) via_20\IN|NONE (r_prep) ouabain_19\RB|or (r_conj) aconitine_17\NN|NONE (r_pobj) by_16\IN|NONE (r_agent) induced_15\VBN|pig|rat (r_acl) models_14\NNS|NONE (l_nmod) rat_10\NN|pig|induced (l_amod) arrhythmic_9\JJ|and
D010042_D001145 CID ouabain_24\NN| (r_npadvmod) induced_26\VBN|arrhythmia (r_amod) models_30\NNS|both|and|induced (l_compound) arrhythmia_29\NN|induced
D010042_D001145 CID ouabain_19\RB|or (r_conj) aconitine_17\NN|NONE (r_pobj) by_16\IN|NONE (r_agent) induced_15\VBN|pig|rat (r_acl) models_14\NNS|NONE (l_nmod) rat_10\NN|pig|induced (l_amod) arrhythmic_9\JJ|and
D010862_D014693 NONE pilocarpine_5\NN|delayed|that|of (r_amod) onset_8\NN|data (r_dobj) showed_3\VBD|.|score|,|course|, (r_ccomp) decreased_12\VBD|NONE (l_dobj) course_15\NN|.|showed|score|,|, (l_prep) of_16\IN|the|time (l_pobj) tachycardia_18\NN|NONE (l_conj) fibrillation_20\NN|ventricular|and
D010862_D001145 NONE pilocarpine_9\NN|NONE (r_pobj) of_8\IN|the (r_prep) effects_7\NNS|to|and|explore (r_dobj) evaluate_5\VB|was|study|. (l_conj) explore_11\VB|to|and|effects (l_conj) using_17\VBG|,|mechanism (l_dobj) rat_22\NN|NONE (l_conj) models_30\NNS|both|and|induced (l_compound) arrhythmia_29\NN|induced
D010862_D001145 NONE pilocarpine_5\NN|delayed|that|of (r_amod) onset_8\NN|data (l_prep) of_9\IN|delayed|that|pilocarpine (l_pobj) arrhythmias_10\NNS|NONE
D010862_D001145 NONE pilocarpine_5\NN|delayed|that|of (r_amod) onset_8\NN|data (r_dobj) showed_3\VBD|.|score|,|course|, (r_ccomp) decreased_12\VBD|NONE (l_npadvmod) score_24\NN|.|showed|,|course|, (l_compound) arrhythmia_23\NN|and|,|reduced|increased
D010862_D001145 NONE pilocarpine_5\NN|delayed|that|of (r_amod) onset_8\NN|data (r_dobj) showed_3\VBD|.|score|,|course|, (r_ccomp) decreased_12\VBD|NONE (l_npadvmod) score_24\NN|.|showed|,|course|, (l_conj) increased_27\VBD|and|,|reduced|arrhythmia (l_dobj) time_30\NN|NONE (l_prep) of_31\IN|survival|the (l_pobj) rats_33\NNS|NONE (l_amod) arrhythmic_32\JJ|and|pigs
D010862_D001145 NONE pilocarpine_4\NN|actions|that (r_nsubj) produced_5\VBD|data|. (l_dobj) actions_7\NNS|pilocarpine|that (l_prep) on_8\IN|antiarrhythmic (l_pobj) models_14\NNS|NONE (l_nmod) rat_10\NN|pig|induced (l_amod) arrhythmic_9\JJ|and
16006300
D002118_D006996 NONE calcium_7\NN|received|higher|the (r_compound) concentrations_8\NNS|NONE (r_pobj) with_3\IN||The (r_prep) patients_2\NNS|caused|mg|intravenously|,|. (r_nsubj) pamidronate_10\JJ|NONE (l_relcl) caused_22\VBD|mg|intravenously|,|patients|. (l_dobj) hypocalcemia_24\NN|which
C019248_D006934 NONE Pamidronate_0\JJ|NONE (r_compound) treatment_1\NN|.|in|with|,|is (r_nsubjpass) associated_3\VBN|NONE (l_prep) in_11\IN|.|treatment|with|,|is (l_pobj) cases_12\NNS|even (l_prep) of_13\IN|NONE (l_pobj) hypercalcemia_16\NN|NONE
D002119_D064420 NONE carbonate_1\NN|syndrome|.|: (r_compound) toxicity_2\NN|NONE
C019248_D006996 CID pamidronate_10\JJ|NONE (l_relcl) caused_22\VBD|mg|intravenously|,|patients|. (l_dobj) hypocalcemia_24\NN|which
C019248_D006996 CID Pamidronate_0\JJ|NONE (r_compound) treatment_1\NN|.|in|with|,|is (r_nsubjpass) associated_3\VBN|NONE (l_prep) with_4\IN|.|in|treatment|,|is (l_pobj) risk_6\NN|NONE (l_prep) for_7\IN|considerable (l_pobj) hypocalcemia_8\NN|NONE
C097949_D000471 NONE D_27\JJ|NONE (r_compound) concentrations_28\NNS|and|related|, (r_conj) peptide_23\NN|PTH|low|,|parathyroid|)|( (r_conj) hormone_15\NN|and|relative|metabolic|, (r_conj) alkalosis_10\NN|acute|renal|,
C097949_D058186 NONE D_27\JJ|NONE (r_compound) concentrations_28\NNS|and|related|, (r_conj) peptide_23\NN|PTH|low|,|parathyroid|)|( (r_conj) hormone_15\NN|and|relative|metabolic|, (r_conj) alkalosis_10\NN|acute|renal|, (r_conj) insufficiency_6\NN|.|patients
D002119_D006934 CID carbonate_1\NN|syndrome|.|: (r_compound) toxicity_2\NN|NONE (l_appos) syndrome_9\NN|.|:|carbonate
D002119_D006934 CID carbonate_6\NN| (r_npadvmod) induced_8\VBN|NONE (r_amod) hypercalcemia_9\NN|NONE
D002119_D006934 CID carbonate_6\NN| (r_npadvmod) induced_8\VBN|NONE (r_amod) hypercalcemia_9\NN|NONE (r_pobj) with_4\IN| (r_prep) patients_3\NNS|and|gain|.|To (r_dobj) describe_1\VB|NONE (l_conj) gain_11\VB|and|patients|.|To (l_dobj) insights_12\NNS|NONE (l_prep) into_13\IN|NONE (l_pobj) cause_15\NN|NONE (l_prep) of_18\IN|and|the|management (l_pobj) syndrome_23\NN|NONE
D002119_D006934 CID carbonate_23\NN|NONE (r_pobj) of_19\IN|small|in (r_prep) amounts_18\NNS|NONE (r_pobj) by_16\IN|be|can (r_agent) precipitated_15\VBN|cause|may|and|syndrome|. (r_conj) be_5\VB|NONE (l_nsubj) syndrome_3\NN|cause|may|and|precipitated|.
D002119_D006934 CID carbonate_23\NN|NONE (r_pobj) of_19\IN|small|in (r_prep) amounts_18\NNS|NONE (r_pobj) by_16\IN|be|can (r_agent) precipitated_15\VBN|cause|may|and|syndrome|. (r_conj) be_5\VB|NONE (l_attr) cause_8\NN|may|and|syndrome|precipitated|. (l_prep) of_9\IN|a|common (l_pobj) hypercalcemia_11\NN|NONE
D002118_D006934 NONE calcium_18\NN|and|review|(|> (r_dobj) corrected_16\VBN|data|We|. (r_parataxis) report_1\VBP|NONE (l_dobj) data_6\NNS|corrected|We|. (l_prep) in_7\IN|clinical|the (l_pobj) patients_9\NNS|NONE (l_relcl) presented_11\VBD| (l_prep) with_12\IN|who (l_pobj) hypercalcemia_14\NN|NONE
D002118_D006934 NONE calcium_18\NN|and|review|(|> (r_dobj) corrected_16\VBN|data|We|. (l_conj) review_28\VB|calcium|and|(|> (l_dobj) literature_31\NN|NONE (l_prep) on_32\IN|the|pertinent (l_pobj) syndrome_36\NN|NONE
12905102
D003024_D003693 CID clozapine_2\NN|NONE (r_amod) treatment_3\NN|NONE (r_pobj) during_1\IN|:|factors|. (r_prep) Delirium_0\NN|NONE
D003024_D003693 CID clozapine_7\NN|NONE (r_compound) treatment_8\NN|NONE (r_pobj) during_6\IN|Incidence|for (r_prep) factors_3\NNS|clarification|. (l_prep) for_4\IN|Incidence|during (l_pobj) delirium_5\NN|NONE
D003024_D003693 CID clozapine_13\NN|NONE (r_pobj) with_12\IN|NONE (r_prep) treated_11\VBN|psychiatric|adult|all (r_acl) inpatients_10\NNS|to (r_dobj) identify_6\VB|,|records|reviewed|We|. (r_xcomp) used_1\VBD|NONE (l_conj) reviewed_20\VBD|identify|,|records|We|. (l_advcl) score_25\VB|records|,|and|tested (l_dobj) incidence_26\NN|to (l_prep) of_29\IN|severity|and (l_pobj) delirium_30\NN|NONE
D003024_D003693 CID clozapine_7\NN| (r_npadvmod) treated_9\VBN|NONE (r_amod) inpatients_10\NNS|NONE (r_pobj) of_6\IN| (r_prep) %_5\NN|NONE (r_pobj) in_3\IN|.|,|Delirium|in|was (r_prep) found_2\VBN|NONE (l_nsubjpass) Delirium_0\NNP|.|,|in|was|in
D003024_D001523 NONE clozapine_13\NN|NONE (r_pobj) with_12\IN|NONE (r_prep) treated_11\VBN|psychiatric|adult|all (r_acl) inpatients_10\NNS|to (l_amod) psychiatric_9\JJ|adult|treated|all
17943461
D015215_D009202 CID AZT_7\NNP| (r_npadvmod) induced_9\VBN|NONE (r_amod) cardiomyopathy_10\NN|NONE
D015215_D002311 CID zidovudine_12\NNP|;|AZT|HAART|the (r_appos) component_11\NN|whether|and|pathway|cause (r_nsubj) triggers_18\VBZ|to (l_conj) cause_28\VB|whether|component|and|pathway (l_dobj) disruption_30\NN|NONE (l_prep) in_31\IN|cytoskeletal (l_pobj) model_34\NN|NONE (l_prep) of_35\IN|a|murine (l_pobj) DCM_36\NNP|NONE
D015215_D002311 CID 3'-azido-2',3'-deoxythymidine_14\CD|NONE (r_appos) zidovudine_12\NNP|;|AZT|HAART|the (r_appos) component_11\NN|whether|and|pathway|cause (r_nsubj) triggers_18\VBZ|to (l_conj) cause_28\VB|whether|component|and|pathway (l_dobj) disruption_30\NN|NONE (l_prep) in_31\IN|cytoskeletal (l_pobj) model_34\NN|NONE (l_prep) of_35\IN|a|murine (l_pobj) DCM_36\NNP|NONE
D015215_D002311 CID AZT_16\NNP|zidovudine|;|HAART|the (r_appos) component_11\NN|whether|and|pathway|cause (r_nsubj) triggers_18\VBZ|to (l_conj) cause_28\VB|whether|component|and|pathway (l_dobj) disruption_30\NN|NONE (l_prep) in_31\IN|cytoskeletal (l_pobj) model_34\NN|NONE (l_prep) of_35\IN|a|murine (l_pobj) DCM_36\NNP|NONE
D015215_D002311 CID AZT_69\NNP|NONE (r_pobj) of_68\IN|different (r_prep) concentrations_67\NNS|NONE (r_dobj) containing_65\VBG|ad (r_acl) libitum_64\NN|:|METHODS|mice|.|In (r_dobj) received_61\VBD|NONE (l_prep) In_4\IN|:|METHODS|mice|.|libitum (l_pobj) order_5\NN|NONE (l_acl) investigate_7\VB|NONE (l_ccomp) triggers_18\VBZ|to (l_conj) cause_28\VB|whether|component|and|pathway (l_dobj) disruption_30\NN|NONE (l_prep) in_31\IN|cytoskeletal (l_pobj) model_34\NN|NONE (l_prep) of_35\IN|a|murine (l_pobj) DCM_36\NNP|NONE
D015215_D002311 CID AZT_3\NNP| (r_npadvmod) treated_5\VBN|NONE (r_amod) FasL_6\NNPS|Tg (r_compound) mice_8\NNS|In|with|,|dilation|,|.|in (r_nsubj) developed_9\VBD|NONE (l_dobj) dilation_11\NN|In|mice|with|,|,|.|in
26094
D008750_D001523 NONE dopa_13\NN|NONE (r_pobj) in_11\IN|NONE (r_prep) occurring_10\VBG|NONE (r_acl) depressions_9\NNS|NONE (r_pobj) of_8\IN|significant|treated|a (r_prep) number_7\NN|NONE (l_acl) treated_14\VBD|of|significant|a (l_dobj) patients_15\NNS|NONE (l_prep) with_16\IN|NONE (l_pobj) histories_18\NNS|NONE (l_amod) psychiatric_17\JJ|NONE
D008750_D003866 CID dopa_13\NN|NONE (r_pobj) in_11\IN|NONE (r_prep) occurring_10\VBG|NONE (r_acl) depressions_9\NNS|NONE
18006530
C071741_D010146 NONE remifentanil_11\NN|and|controlled (r_conj) propofol_9\NN|NONE (r_pobj) with_5\IN|NONE (r_prep) induction_4\NN|NONE (r_pobj) during_3\IN|of|. (r_prep) Reduction_0\NN|NONE (l_prep) of_1\IN|during|. (l_pobj) pain_2\NN|NONE
C071741_D010146 NONE remifentanil_11\NN|before (r_dobj) infusing_10\VBG|NONE (r_pcomp) by_9\IN|be|that|might|pain (r_prep) prevented_8\VBN|.|We (l_nsubjpass) pain_5\NN|be|that|might|by
C071741_D010146 NONE remifentanil_26\NN|NONE (r_pobj) of_25\IN|(|) (r_prep) Ce_23\NNP|prevent|the|site (r_appos) concentration_21\NN|to (l_relcl) prevent_28\VB|Ce|the|site (l_dobj) pain_30\NN|to|without
C071741_D010146 NONE Remifentanil_0\NN| (r_npadvmod) related_2\VBN|NONE (r_amod) complications_3\NNS|and|were|evaluated|during|, (r_nsubjpass) assessed_5\VBN|NONE (l_conj) evaluated_17\VBN|and|were|complications|during|, (l_nsubjpass) pain_12\NN|was|.|using
C071741_D010146 NONE remifentanil_8\NN|the (r_compound) infusion_9\NN|NONE (r_pobj) during_6\IN|and|were|complications|evaluated|, (r_prep) assessed_5\VBN|NONE (l_conj) evaluated_17\VBN|and|were|complications|during|, (l_nsubjpass) pain_12\NN|was|.|using
C071741_D010146 NONE remifentanil_9\NN|and (r_conj) propofol_7\NN|NONE (r_pobj) of_6\IN|with (r_prep) anaesthesia_3\NN|NONE (r_pobj) of_2\IN|NONE (r_prep) induction_1\NN|NONE (r_pobj) During_0\IN|.|)|was|,|without|reduction (r_prep) achieved_19\VBN|NONE (l_nsubjpass) reduction_13\NN|.|)|During|was|,|without (l_prep) in_14\IN|significant|a (l_pobj) pain_17\NN|NONE
C071741_D010146 NONE remifentanil_27\NN|NONE (r_pobj) of_26\IN|prior (r_prep) administration_25\NN|NONE (r_pobj) by_23\IN|significant|at (r_prep) complications_22\NNS|NONE (r_pobj) without_20\IN|.|)|During|was|,|reduction (r_prep) achieved_19\VBN|NONE (l_nsubjpass) reduction_13\NN|.|)|During|was|,|without (l_prep) in_14\IN|significant|a (l_pobj) pain_17\NN|NONE
D015742_D010146 CID propofol_9\NN|NONE (r_pobj) with_5\IN|NONE (r_prep) induction_4\NN|NONE (r_pobj) during_3\IN|of|. (r_prep) Reduction_0\NN|NONE (l_prep) of_1\IN|during|. (l_pobj) pain_2\NN|NONE
D015742_D010146 CID propofol_4\NN|NONE (r_pobj) of_3\IN|NONE (r_prep) injection_2\NN|NONE (r_pobj) on_1\IN|NONE (r_prep) Pain_0\NN|unpleasant|.
D015742_D010146 CID propofol_3\JJ|infusion (r_amod) pain_5\NN|be|that|might|by
D015742_D010146 CID propofol_15\JJ|in|the (r_amod) infusion_16\NN|NONE (r_dobj) starting_13\VBG|NONE (r_pcomp) before_12\IN|remifentanil (r_prep) infusing_10\VBG|NONE (r_pcomp) by_9\IN|be|that|might|pain (r_prep) prevented_8\VBN|.|We (l_nsubjpass) pain_5\NN|be|that|might|by
D015742_D010146 CID propofol_15\NN|NONE (r_pobj) by_14\IN|NONE (r_agent) caused_13\VBN|NONE (r_acl) pain_12\NN|was|.|using
D015742_D010146 CID propofol_26\JJ|the (r_amod) infusion_27\NN|NONE (r_pobj) during_24\IN|scale (r_prep) using_18\VBG|was|.|pain (r_advcl) evaluated_17\VBN|and|were|complications|during|, (l_nsubjpass) pain_12\NN|was|.|using
D015742_D010146 CID propofol_7\NN|NONE (r_pobj) of_6\IN|with (r_prep) anaesthesia_3\NN|NONE (r_pobj) of_2\IN|NONE (r_prep) induction_1\NN|NONE (r_pobj) During_0\IN|.|)|was|,|without|reduction (r_prep) achieved_19\VBN|NONE (l_nsubjpass) reduction_13\NN|.|)|During|was|,|without (l_prep) in_14\IN|significant|a (l_pobj) pain_17\NN|NONE
D015742_D010146 CID propofol_15\JJ|infusion (r_amod) pain_17\NN|NONE
18674790
D004041_D066126 NONE fat_1\JJ|obese|fed|High (r_amod) rats_6\NNS|sensitive|. (r_nsubj) are_7\VBP|NONE (l_acomp) sensitive_9\JJ|.|rats (l_prep) to_10\IN|highly (l_pobj) cardiotoxicity_14\NN|NONE
D004041_D066126 NONE fat_16\JJ|induces|,|high|)|(|HFD|% (r_amod) diet_17\NN|NONE (r_dobj) feeding_12\VBG|NONE (r_pcomp) by_11\IN|physiological|a (r_prep) intervention_10\NN|to|whether|, (r_nsubj) sensitizes_38\VBZ|we|,|In|. (l_prep) to_39\IN|intervention|whether|, (l_pobj) cardiotoxicity_43\NN|NONE
D004317_D009765 NONE doxorubicin_11\RB| (r_npadvmod) induced_13\VBN|NONE (r_compound) cardiotoxicity_14\NN|NONE (r_pobj) to_10\IN|highly (r_prep) sensitive_9\JJ|.|rats (r_acomp) are_7\VBP|NONE (l_nsubj) rats_6\NNS|sensitive|. (l_amod) obese_5\JJ|fed|High|fat
D004317_D009765 NONE doxorubicin_40\RB| (r_npadvmod) induced_42\VBN|NONE (r_compound) cardiotoxicity_43\NN|NONE (r_pobj) to_39\IN|intervention|whether|, (r_prep) sensitizes_38\VBZ|we|,|In|. (l_nsubj) intervention_10\NN|to|whether|, (l_prep) by_11\IN|physiological|a (l_pcomp) feeding_12\VBG|NONE (l_dobj) diet_17\NN|NONE (l_relcl) induces_23\VBZ|,|high|)|(|HFD|fat|% (l_dobj) obesity_24\NN|which|g
D004317_D009765 NONE doxorubicin_7\NN|(|,|mg|/|ip|) (r_nmod) kg_9\NNS|LD(|administered|.|A (r_appos) dose_3\NN|NONE (l_acl) administered_13\VBN|LD(|.|A|kg (l_prep) on_14\IN|NONE (l_pobj) day_15\NN|NONE (l_nummod) 43_16\CD|NONE (l_prep) of_17\IN|NONE (l_pobj) regimen_21\NN|NONE (l_acl) led_22\VBD|the|feeding|HFD (l_prep) to_23\IN|NONE (l_pobj) cardiotoxicity_25\NN|NONE (l_conj) dysfunction_28\NN|higher|, (l_conj) peroxidation_31\NN|,|cardiac (l_conj) mortality_36\NN|,|and|lipid (l_prep) in_37\IN|%|in (l_pobj) rats_43\NNS|NONE (l_amod) obese_39\JJ|the|OB|)|(
D004317_D009765 NONE doxorubicin_7\NN|(|,|mg|/|ip|) (r_nmod) kg_9\NNS|LD(|administered|.|A (r_appos) dose_3\NN|NONE (l_acl) administered_13\VBN|LD(|.|A|kg (l_prep) on_14\IN|NONE (l_pobj) day_15\NN|NONE (l_nummod) 43_16\CD|NONE (l_prep) of_17\IN|NONE (l_pobj) regimen_21\NN|NONE (l_acl) led_22\VBD|the|feeding|HFD (l_prep) to_23\IN|NONE (l_pobj) cardiotoxicity_25\NN|NONE (l_conj) dysfunction_28\NN|higher|, (l_conj) peroxidation_31\NN|,|cardiac (l_conj) mortality_36\NN|,|and|lipid (l_prep) in_37\IN|%|in (l_pobj) rats_43\NNS|NONE (l_nmod) OB_41\NNP|obese|the|)|(
D004317_D009765 NONE Doxorubicin_0\NNP|NONE (r_compound) toxicokinetics_1\NNS|NONE (r_compound) studies_2\NNS|.|change (r_nsubj) revealed_3\VBD|NONE (l_dobj) change_5\NN|.|studies (l_conj) hearts_27\NNS|and|no|in|)|in (l_compound) OB_26\NNP|NONE
D004317_D009765 NONE doxorubicin_9\NN|NONE (r_pobj) of_8\IN|NONE (r_prep) accumulation_7\NN|NONE (r_pobj) in_6\IN|and|no|hearts|)|in (r_prep) change_5\NN|.|studies (l_conj) hearts_27\NNS|and|no|in|)|in (l_compound) OB_26\NNP|NONE
D004317_D009765 NONE doxorubicin_109\NN|NONE (r_compound) administration_110\NN|NONE (r_pobj) after_108\IN|ADP|decreased (r_prep) ratio_107\NN|NONE (r_pobj) by_102\IN|NONE (r_agent) accompanied_101\VBN|in|%||(|) (r_acl) drop_96\NN|,|stress|kinase|and (r_conj) decreased_82\VBD|.|sensitized|studies (r_ccomp) revealed_2\VBD|NONE (l_ccomp) sensitized_7\VBN|decreased|.|studies (l_nsubjpass) rats_5\NNS|are|that|due (l_compound) OB_4\NNP|NONE
D004317_D009765 NONE doxorubicin_109\NN|NONE (r_compound) administration_110\NN|NONE (r_pobj) after_108\IN|ADP|decreased (r_prep) ratio_107\NN|NONE (r_pobj) by_102\IN|NONE (r_agent) accompanied_101\VBN|in|%||(|) (r_acl) drop_96\NN|,|stress|kinase|and (r_conj) decreased_82\VBD|.|sensitized|studies (l_nsubj) stress_16\NN|,|kinase|drop|and (l_acl) activated_35\VBN||oxyradical|leading|higher|)|( (l_dobj) oxidation_56\NN|alpha|downregulation (l_appos) heart_64\NN|decreased|)|(|,|cardiac|acid| (l_prep) versus_67\IN|in|)|g|min (l_pobj) heart_74\NN|NONE (l_prep) in_75\IN|.+/.|g (l_pobj) OB_76\NNP|NONE
D004317_D009765 NONE doxorubicin_12\RB| (r_npadvmod) induced_14\VBN|NONE (r_amod) cardiotoxicity_15\NN|NONE (r_pobj) to_11\IN|by|highly (r_prep) sensitized_10\JJ|In|rats|,|. (r_acomp) are_8\VBP|NONE (l_nsubj) rats_7\NNS|In|,|sensitized|. (l_amod) obese_6\JJ|induced
D004317_D006331 CID doxorubicin_7\NN|(|,|mg|/|ip|) (r_nmod) kg_9\NNS|LD(|administered|.|A (r_appos) dose_3\NN|NONE (l_acl) administered_13\VBN|LD(|.|A|kg (l_prep) on_14\IN|NONE (l_pobj) day_15\NN|NONE (l_nummod) 43_16\CD|NONE (l_prep) of_17\IN|NONE (l_pobj) regimen_21\NN|NONE (l_acl) led_22\VBD|the|feeding|HFD (l_prep) to_23\IN|NONE (l_pobj) cardiotoxicity_25\NN|NONE (l_conj) dysfunction_28\NN|higher|,
D000255_D066126 NONE ATP_21\NNP|cardiac|mitochondrial (r_compound) generation_22\NN|,|increasing|substantially (r_dobj) downregulating_18\VBG|NONE (r_pcomp) by_16\IN|to|highly (r_prep) sensitized_10\JJ|In|rats|,|. (l_prep) to_11\IN|by|highly (l_pobj) cardiotoxicity_15\NN|NONE
C010013_D009765 NONE doxorubicinol_11\NN|and (r_conj) doxorubicin_9\NN|NONE (r_pobj) of_8\IN|NONE (r_prep) accumulation_7\NN|NONE (r_pobj) in_6\IN|and|no|hearts|)|in (r_prep) change_5\NN|.|studies (l_conj) hearts_27\NNS|and|no|in|)|in (l_compound) OB_26\NNP|NONE
D004041_D009765 CID fat_1\JJ|obese|fed|High (r_amod) rats_6\NNS|sensitive|. (l_amod) obese_5\JJ|fed|High|fat
D004041_D009765 CID fat_16\JJ|induces|,|high|)|(|HFD|% (r_amod) diet_17\NN|NONE (l_relcl) induces_23\VBZ|,|high|)|(|HFD|fat|% (l_dobj) obesity_24\NN|which|g
D004317_D056486 NONE doxorubicin_7\NN|(|,|mg|/|ip|) (r_nmod) kg_9\NNS|LD(|administered|.|A (r_appos) dose_3\NN|NONE (l_acl) administered_13\VBN|LD(|.|A|kg (l_prep) on_14\IN|NONE (l_pobj) day_15\NN|NONE (l_nummod) 43_16\CD|NONE (l_prep) of_17\IN|NONE (l_pobj) regimen_21\NN|NONE (l_acl) led_22\VBD|the|feeding|HFD (l_prep) to_23\IN|NONE (l_pobj) cardiotoxicity_25\NN|NONE (l_conj) dysfunction_28\NN|higher|, (l_conj) peroxidation_31\NN|,|cardiac (l_conj) mortality_36\NN|,|and|lipid (l_prep) in_44\IN|%|in (l_pobj) absence_46\NN|NONE (l_prep) of_47\IN|the (l_pobj) toxicity_53\NN|NONE
D000249_D009765 NONE AMP_84\NN| (r_compound) alpha2_86\NN|protein|mitochondrial (r_compound) kinase_88\NN|,|stress|drop|and (r_dobj) decreased_82\VBD|.|sensitized|studies (r_ccomp) revealed_2\VBD|NONE (l_ccomp) sensitized_7\VBN|decreased|.|studies (l_nsubjpass) rats_5\NNS|are|that|due (l_compound) OB_4\NNP|NONE
D000249_D009765 NONE AMP_84\NN| (r_compound) alpha2_86\NN|protein|mitochondrial (r_compound) kinase_88\NN|,|stress|drop|and (r_dobj) decreased_82\VBD|.|sensitized|studies (l_nsubj) stress_16\NN|,|kinase|drop|and (l_acl) activated_35\VBN||oxyradical|leading|higher|)|( (l_dobj) oxidation_56\NN|alpha|downregulation (l_appos) heart_64\NN|decreased|)|(|,|cardiac|acid| (l_prep) versus_67\IN|in|)|g|min (l_pobj) heart_74\NN|NONE (l_prep) in_75\IN|.+/.|g (l_pobj) OB_76\NNP|NONE
D004317_D066126 NONE doxorubicin_11\RB| (r_npadvmod) induced_13\VBN|NONE (r_compound) cardiotoxicity_14\NN|NONE
D004317_D066126 NONE doxorubicin_4\NN|NONE (r_pobj) by_3\IN|NONE (r_prep) chemotherapy_2\NN|due|.|Often|is|, (r_nsubjpass) limited_9\VBN|NONE (l_prep) due_10\IN|chemotherapy|.|Often|is|, (l_pobj) life_12\NN|to (l_acl) threatening_13\VBG|NONE (l_dobj) cardiotoxicity_14\NN|during
D004317_D066126 NONE Adriamycin_6\NNP|NONE (r_punct) )_7\-RRB-|NONE (r_punct) is_8\VBZ|chemotherapy|due|.|Often|, (r_auxpass) limited_9\VBN|NONE (l_prep) due_10\IN|chemotherapy|.|Often|is|, (l_pobj) life_12\NN|to (l_acl) threatening_13\VBG|NONE (l_dobj) cardiotoxicity_14\NN|during
D004317_D066126 NONE doxorubicin_12\RB| (r_npadvmod) induced_14\VBN|NONE (r_amod) cardiotoxicity_15\NN|NONE
D004317_D066126 NONE doxorubicin_40\RB| (r_npadvmod) induced_42\VBN|NONE (r_compound) cardiotoxicity_43\NN|NONE
D004317_D066126 NONE doxorubicin_7\NN|(|,|mg|/|ip|) (r_nmod) kg_9\NNS|LD(|administered|.|A (r_appos) dose_3\NN|NONE (l_acl) administered_13\VBN|LD(|.|A|kg (l_prep) on_14\IN|NONE (l_pobj) day_15\NN|NONE (l_nummod) 43_16\CD|NONE (l_prep) of_17\IN|NONE (l_pobj) regimen_21\NN|NONE (l_acl) led_22\VBD|the|feeding|HFD (l_prep) to_23\IN|NONE (l_pobj) cardiotoxicity_25\NN|NONE
D004317_D066126 NONE doxorubicin_12\RB| (r_npadvmod) induced_14\VBN|NONE (r_amod) cardiotoxicity_15\NN|NONE
D004317_D007674 NONE doxorubicin_7\NN|(|,|mg|/|ip|) (r_nmod) kg_9\NNS|LD(|administered|.|A (r_appos) dose_3\NN|NONE (l_acl) administered_13\VBN|LD(|.|A|kg (l_prep) on_14\IN|NONE (l_pobj) day_15\NN|NONE (l_nummod) 43_16\CD|NONE (l_prep) of_17\IN|NONE (l_pobj) regimen_21\NN|NONE (l_acl) led_22\VBD|the|feeding|HFD (l_prep) to_23\IN|NONE (l_pobj) cardiotoxicity_25\NN|NONE (l_conj) dysfunction_28\NN|higher|, (l_conj) peroxidation_31\NN|,|cardiac (l_conj) mortality_36\NN|,|and|lipid (l_prep) in_44\IN|%|in (l_pobj) absence_46\NN|NONE (l_prep) of_47\IN|the (l_pobj) toxicity_53\NN|NONE
D000244_D009765 NONE ADP_106\NNP|decreased|after (r_compound) ratio_107\NN|NONE (r_pobj) by_102\IN|NONE (r_agent) accompanied_101\VBN|in|%||(|) (r_acl) drop_96\NN|,|stress|kinase|and (r_conj) decreased_82\VBD|.|sensitized|studies (r_ccomp) revealed_2\VBD|NONE (l_ccomp) sensitized_7\VBN|decreased|.|studies (l_nsubjpass) rats_5\NNS|are|that|due (l_compound) OB_4\NNP|NONE
D000244_D009765 NONE ADP_106\NNP|decreased|after (r_compound) ratio_107\NN|NONE (r_pobj) by_102\IN|NONE (r_agent) accompanied_101\VBN|in|%||(|) (r_acl) drop_96\NN|,|stress|kinase|and (r_conj) decreased_82\VBD|.|sensitized|studies (l_nsubj) stress_16\NN|,|kinase|drop|and (l_acl) activated_35\VBN||oxyradical|leading|higher|)|( (l_dobj) oxidation_56\NN|alpha|downregulation (l_appos) heart_64\NN|decreased|)|(|,|cardiac|acid| (l_prep) versus_67\IN|in|)|g|min (l_pobj) heart_74\NN|NONE (l_prep) in_75\IN|.+/.|g (l_pobj) OB_76\NNP|NONE
D000255_D009765 NONE ATP_99\NNP|cardiac (r_compound) levels_100\NNS|NONE (r_pobj) in_97\IN|accompanied|%||(|) (r_prep) drop_96\NN|,|stress|kinase|and (r_conj) decreased_82\VBD|.|sensitized|studies (r_ccomp) revealed_2\VBD|NONE (l_ccomp) sensitized_7\VBN|decreased|.|studies (l_nsubjpass) rats_5\NNS|are|that|due (l_compound) OB_4\NNP|NONE
D000255_D009765 NONE ATP_99\NNP|cardiac (r_compound) levels_100\NNS|NONE (r_pobj) in_97\IN|accompanied|%||(|) (r_prep) drop_96\NN|,|stress|kinase|and (r_conj) decreased_82\VBD|.|sensitized|studies (l_nsubj) stress_16\NN|,|kinase|drop|and (l_acl) activated_35\VBN||oxyradical|leading|higher|)|( (l_dobj) oxidation_56\NN|alpha|downregulation (l_appos) heart_64\NN|decreased|)|(|,|cardiac|acid| (l_prep) versus_67\IN|in|)|g|min (l_pobj) heart_74\NN|NONE (l_prep) in_75\IN|.+/.|g (l_pobj) OB_76\NNP|NONE
D000255_D009765 NONE ATP_104\NNP|/ (r_nmod) ADP_106\NNP|decreased|after (r_compound) ratio_107\NN|NONE (r_pobj) by_102\IN|NONE (r_agent) accompanied_101\VBN|in|%||(|) (r_acl) drop_96\NN|,|stress|kinase|and (r_conj) decreased_82\VBD|.|sensitized|studies (r_ccomp) revealed_2\VBD|NONE (l_ccomp) sensitized_7\VBN|decreased|.|studies (l_nsubjpass) rats_5\NNS|are|that|due (l_compound) OB_4\NNP|NONE
D000255_D009765 NONE ATP_104\NNP|/ (r_nmod) ADP_106\NNP|decreased|after (r_compound) ratio_107\NN|NONE (r_pobj) by_102\IN|NONE (r_agent) accompanied_101\VBN|in|%||(|) (r_acl) drop_96\NN|,|stress|kinase|and (r_conj) decreased_82\VBD|.|sensitized|studies (l_nsubj) stress_16\NN|,|kinase|drop|and (l_acl) activated_35\VBN||oxyradical|leading|higher|)|( (l_dobj) oxidation_56\NN|alpha|downregulation (l_appos) heart_64\NN|decreased|)|(|,|cardiac|acid| (l_prep) versus_67\IN|in|)|g|min (l_pobj) heart_74\NN|NONE (l_prep) in_75\IN|.+/.|g (l_pobj) OB_76\NNP|NONE
D000255_D009765 NONE ATP_21\NNP|cardiac|mitochondrial (r_compound) generation_22\NN|,|increasing|substantially (r_dobj) downregulating_18\VBG|NONE (r_pcomp) by_16\IN|to|highly (r_prep) sensitized_10\JJ|In|rats|,|. (r_acomp) are_8\VBP|NONE (l_nsubj) rats_7\NNS|In|,|sensitized|. (l_amod) obese_6\JJ|induced
3461217
D043343_D011471 CID propionate_45\NN||and|)|:|( (r_conj) CAS_35\NN|N|||nitroso (r_appos) methylurea_33\NN|NONE (r_pobj) with_26\IN|NONE (r_prep) treatments_25\NNS|NONE (r_pobj) following_24\VBG|rats|PAs (r_prep) developed_15\VBD|% (l_dobj) PAs_22\FW|rats|following (l_nmod) adenocarcinomas_20\NNS|(|,|)|palpable|large|prostate
D043343_D011471 CID propionate_45\NN||and|)|:|( (r_conj) CAS_35\NN|N|||nitroso (r_appos) methylurea_33\NN|NONE (r_pobj) with_26\IN|NONE (r_prep) treatments_25\NNS|NONE (r_pobj) following_24\VBG|rats|PAs (r_prep) developed_15\VBD|% (l_dobj) PAs_22\FW|rats|following
D043343_D011471 CID TP_19\NNP|only (r_pobj) with_18\IN|when (r_prep) treated_16\VBN|PA|.|rat|Within|, (r_advcl) developed_10\VBD|NONE (l_dobj) PA_14\NNP|treated|.|rat|Within|,
D043343_D011471 CID TP_6\NNP|In|as|.|with|,|, (r_nsubj) acted_7\VBD|NONE (l_prep) with_14\IN|In|as|.|,|TP|, (l_pobj) emphasis_16\NN|NONE (l_prep) on_17\IN|primary (l_pobj) development_19\NN|NONE (l_prep) of_20\IN|the (l_pobj) cancer_22\NN|NONE
D013739_D011471 NONE testosterone_21\NN|nitroso|||and|N (r_conj) methylurea_19\NN|NONE (r_pobj) with_12\IN|NONE (r_prep) treatments_11\NNS|NONE (r_pobj) by_10\IN|of|. (r_prep) Production_0\NN|NONE (l_prep) of_1\IN|by|. (l_pobj) cancer_4\NN|NONE
D043343_D009369 NONE TP_6\NNP|In|as|.|with|,|, (r_nsubj) acted_7\VBD|NONE (l_prep) as_8\IN|In|.|with|,|TP|, (l_pobj) agent_12\NN|NONE (l_compound) enhancement_11\NN|a (l_compound) tumor_10\NN|NONE
D008770_D011471 CID methylurea_19\NN|NONE (r_pobj) with_12\IN|NONE (r_prep) treatments_11\NNS|NONE (r_pobj) by_10\IN|of|. (r_prep) Production_0\NN|NONE (l_prep) of_1\IN|by|. (l_pobj) cancer_4\NN|NONE
D008770_D011471 CID methylurea_33\NN|NONE (r_pobj) with_26\IN|NONE (r_prep) treatments_25\NNS|NONE (r_pobj) following_24\VBG|rats|PAs (r_prep) developed_15\VBD|% (l_dobj) PAs_22\FW|rats|following (l_nmod) adenocarcinomas_20\NNS|(|,|)|palpable|large|prostate
D008770_D011471 CID methylurea_33\NN|NONE (r_pobj) with_26\IN|NONE (r_prep) treatments_25\NNS|NONE (r_pobj) following_24\VBG|rats|PAs (r_prep) developed_15\VBD|% (l_dobj) PAs_22\FW|rats|following
11900788
D001285_D002375 NONE atropine_3\NN|NONE (r_pobj) of_2\IN|,|.|naloxone|Intraperitoneal|catalepsy (r_prep) administration_1\NN|NONE (l_appos) catalepsy_14\NN|,|.|naloxone|Intraperitoneal|of
D001285_D002375 NONE atropine_3\NN|NONE (r_pobj) of_2\IN|Intracerebroventricular (r_prep) injection_1\NN|also|catalepsy|. (r_nsubj) decreased_10\VBD|NONE (l_dobj) catalepsy_11\NN|also|injection|.
D009270_D002375 NONE naloxone_5\NN|,|.|Intraperitoneal|of|catalepsy (r_appos) administration_1\NN|NONE (l_appos) catalepsy_14\NN|,|.|naloxone|Intraperitoneal|of
D009270_D002375 NONE naloxone_8\NN|and|, (r_conj) hexamethonium_5\NN|, (r_conj) atropine_3\NN|NONE (r_pobj) of_2\IN|Intracerebroventricular (r_prep) injection_1\NN|also|catalepsy|. (r_nsubj) decreased_10\VBD|NONE (l_dobj) catalepsy_11\NN|also|injection|.
D009020_D002375 CID morphine_3\NN| (r_npadvmod) induced_5\VBN|NONE (r_amod) catalepsy_6\NN|NONE
D009020_D002375 CID morphine_12\NN|NONE (r_pobj) by_11\IN|in (r_agent) induced_10\VBN|of|on (r_acl) effects_5\NNS|.|have|been|,|In (l_prep) on_8\IN|of|induced (l_pobj) catalepsy_9\NN|NONE
D009020_D002375 CID Morphine_0\NNP|.|catalepsy (r_nsubj) induced_4\VBD|NONE (l_dobj) catalepsy_9\NN|.|Morphine
D009020_D002375 CID morphine_20\NN|NONE (r_pobj) of_19\IN|with|a (r_prep) combination_18\NN|NONE (r_pobj) by_16\IN|NONE (r_agent) induced_15\VBN|reduced (r_acl) catalepsy_14\NN|,|.|naloxone|Intraperitoneal|of
D009020_D002375 CID morphine_14\NN|NONE (r_pobj) by_13\IN|NONE (r_agent) induced_12\VBN|NONE (r_acl) catalepsy_11\NN|also|injection|.
D009020_D002375 CID morphine_4\NN|NONE (r_compound) catalepsy_5\NN|can|,|by|that|be|and|mediated
D009020_D002375 CID morphine_19\NN|NONE (r_pobj) of_18\IN|induced|the (r_prep) potentiation_17\NN|be|also|through|may (r_nsubjpass) mediated_26\VBN|can|,|by|catalepsy|that|be|and (r_conj) elicited_8\VBN|It|was|. (l_nsubjpass) catalepsy_5\NN|can|,|by|that|be|and|mediated
D008464_D002375 NONE mecamylamine_7\NN|, (r_conj) naloxone_5\NN|,|.|Intraperitoneal|of|catalepsy (r_appos) administration_1\NN|NONE (l_appos) catalepsy_14\NN|,|.|naloxone|Intraperitoneal|of
D018738_D002375 NONE hexamethonium_10\NN|,|and (r_conj) mecamylamine_7\NN|, (r_conj) naloxone_5\NN|,|.|Intraperitoneal|of|catalepsy (r_appos) administration_1\NN|NONE (l_appos) catalepsy_14\NN|,|.|naloxone|Intraperitoneal|of
D018738_D002375 NONE hexamethonium_5\NN|, (r_conj) atropine_3\NN|NONE (r_pobj) of_2\IN|Intracerebroventricular (r_prep) injection_1\NN|also|catalepsy|. (r_nsubj) decreased_10\VBD|NONE (l_dobj) catalepsy_11\NN|also|injection|.
D009538_D002375 CID Nicotine_0\NN|.|of|in (r_compound) potentiation_1\NN|NONE (l_prep) of_2\IN|.|in|Nicotine (l_pobj) catalepsy_6\NN|NONE
D009538_D002375 CID nicotine_7\NN|NONE (r_pobj) of_6\IN|on|induced (r_prep) effects_5\NNS|.|have|been|,|In (l_prep) on_8\IN|of|induced (l_pobj) catalepsy_9\NN|NONE
D009538_D002375 CID nicotine_3\NN|but (r_conj) Morphine_0\NNP|.|catalepsy (r_nsubj) induced_4\VBD|NONE (l_dobj) catalepsy_9\NN|.|Morphine
D009538_D002375 CID nicotine_22\NN|NONE (r_pobj) with_21\IN|a|of (r_prep) combination_18\NN|NONE (r_pobj) by_16\IN|NONE (r_agent) induced_15\VBN|reduced (r_acl) catalepsy_14\NN|,|.|naloxone|Intraperitoneal|of
D009538_D002375 CID nicotine_16\NN|plus (r_conj) morphine_14\NN|NONE (r_pobj) by_13\IN|NONE (r_agent) induced_12\VBN|NONE (r_acl) catalepsy_11\NN|also|injection|.
D009538_D002375 CID nicotine_22\NN|NONE (r_pobj) by_21\IN|NONE (r_agent) induced_20\VBN|of|the (r_acl) potentiation_17\NN|be|also|through|may (r_nsubjpass) mediated_26\VBN|can|,|by|catalepsy|that|be|and (r_conj) elicited_8\VBN|It|was|. (l_nsubjpass) catalepsy_5\NN|can|,|by|that|be|and|mediated
16574712
D018817_D008569 NONE MDMA_12\NNP|NONE (r_pobj) of_11\IN|NONE (r_prep) users_10\NNS|NONE (r_pobj) in_9\IN|deficits|.|In|have|been (r_prep) reported_8\VBN|NONE (l_nsubjpass) deficits_5\NNS|in|.|In|have|been
D018817_D008569 NONE 3,4-methylenedioxymethamphetamine_14\CD|ecstasy|( (r_intj) MDMA_12\NNP|NONE (r_pobj) of_11\IN|NONE (r_prep) users_10\NNS|NONE (r_pobj) in_9\IN|deficits|.|In|have|been (r_prep) reported_8\VBN|NONE (l_nsubjpass) deficits_5\NNS|in|.|In|have|been
D018817_D008569 NONE ecstasy_16\NN|,methylenedioxymethamphetamine|( (r_appos) MDMA_12\NNP|NONE (r_pobj) of_11\IN|NONE (r_prep) users_10\NNS|NONE (r_pobj) in_9\IN|deficits|.|In|have|been (r_prep) reported_8\VBN|NONE (l_nsubjpass) deficits_5\NNS|in|.|In|have|been
D018817_D003072 CID MDMA_0\NN|polydrug (r_compound) users_2\NNS|.|impairments (r_nsubj) show_3\VBP|NONE (l_dobj) impairments_9\NNS|users|. (l_acl) coupled_10\VBN|executive|central|specific (l_prep) with_11\IN|NONE (l_pobj) processes_17\NNS|NONE
9848575
C055866_D009202 NONE SM-5887_9\NNP|novel|)|a|(|synthetic|anthracycline (r_appos) derivative_7\JJ|NONE (r_pobj) of_2\IN|Chronic|.|on (r_prep) effects_1\NNS|NONE (l_prep) on_11\IN|of|Chronic|. (l_pobj) heart_13\NN|NONE (l_conj) cardiomyopathy_18\NN|normal|and
C055866_D009202 NONE SM-5887_35\NNP|the (r_compound) administration_36\NN|changes|did|not|while|animals (r_nsubj) show_39\VB|Animals|decrease|electrocardiogram|,|. (r_advcl) demonstrated_8\VBD|NONE (l_dobj) decrease_16\NN|Animals|electrocardiogram|,|show|. (l_prep) of_17\IN|NONE (l_pobj) pressure_19\NN|NONE (l_conj) cardiomyopathy_25\NN|and|blood
C055866_D009202 NONE SM-5887_8\NNP|,|grade (r_nmod) cardiomyopathy_13\NN|NONE
C055866_D009202 NONE SM-5887_5\NNP|the (r_compound) treatment_6\NN|.|,|did|On|not|grade (r_nsubj) progress_9\VB|NONE (l_dobj) grade_11\NN|.|,|did|treatment|On|not (l_prep) of_12\IN|the (l_pobj) cardiomyopathy_13\NN|NONE
D004317_D009202 CID doxorubicin_15\RB| (r_npadvmod) induced_17\VBN|in (r_amod) cardiomyopathy_18\NN|normal|and
D004317_D009202 CID doxorubicin_7\NN|NONE (r_pobj) of_6\IN|six (r_prep) courses_5\NNS|which (r_dobj) received_2\VBD|NONE (r_relcl) Animals_0\NNS|decrease|electrocardiogram|,|show|. (r_nsubj) demonstrated_8\VBD|NONE (l_dobj) decrease_16\NN|Animals|electrocardiogram|,|show|. (l_prep) of_17\IN|NONE (l_pobj) pressure_19\NN|NONE (l_conj) cardiomyopathy_25\NN|and|blood
D004317_D009202 CID doxorubicin_22\NN|NONE (r_pobj) of_21\IN|(|mg/kg|four|) (r_prep) courses_20\NNS|NONE (r_pobj) by_18\IN|examine|.|in|was (r_agent) induced_15\VBN|NONE (l_csubjpass) examine_1\VB|by|.|in|was (l_dobj) effect_6\NN|To (l_prep) of_7\IN|a|cardiotoxic|deteriorating (l_pobj) cardiomyopathy_13\NN|NONE
D004317_D066126 NONE doxorubicin_28\NN|effect|the|cardiotoxic|chronic|and|of (r_appos) potential_9\NN|to (l_amod) cardiotoxic_8\JJ|effect|doxorubicin|the|chronic|and|of
D004317_D066126 NONE doxorubicin_28\NN|effect|the|cardiotoxic|chronic|and|of (r_appos) potential_9\NN|to (l_conj) effect_16\NN|doxorubicin|the|cardiotoxic|chronic|and|of (l_prep) on_19\IN|deteriorating|possible|of|a (l_pobj) cardiotoxicity_23\NN|NONE
D004317_D066126 NONE doxorubicin_22\NN|NONE (r_pobj) of_21\IN|(|mg/kg|four|) (r_prep) courses_20\NNS|NONE (r_pobj) by_18\IN|examine|.|in|was (r_agent) induced_15\VBN|NONE (l_csubjpass) examine_1\VB|by|.|in|was (l_dobj) effect_6\NN|To (l_amod) cardiotoxic_5\JJ|a|of|deteriorating
D004317_D066126 NONE doxorubicin_11\NN|the|additional (r_compound) treatment_12\NN|NONE (r_pobj) by_8\IN|were|.|changes (r_agent) enhanced_7\VBN|NONE (l_nsubjpass) changes_5\NNS|by|were|. (l_amod) cardiotoxic_4\JJ|grade|The
D004317_D066126 NONE doxorubicin_16\RB| (r_npadvmod) induced_18\VBN|in (r_amod) cardiotoxicity_19\NN|NONE (r_pobj) on_15\IN|deteriorating (r_prep) effect_14\NN|and|chronic (r_conj) cardiotoxicity_11\NN|NONE
D004317_D066126 NONE doxorubicin_16\RB| (r_npadvmod) induced_18\VBN|in (r_amod) cardiotoxicity_19\NN|NONE
D018943_D009202 NONE anthracycline_6\NN|novel|SM|)|a|(|synthetic (r_amod) derivative_7\JJ|NONE (r_pobj) of_2\IN|Chronic|.|on (r_prep) effects_1\NNS|NONE (l_prep) on_11\IN|of|Chronic|. (l_pobj) heart_13\NN|NONE (l_conj) cardiomyopathy_18\NN|normal|and
C055866_D066126 NONE SM-5887_11\NNP|NONE (r_pobj) of_10\IN|effect|doxorubicin|the|cardiotoxic|chronic|and (r_prep) potential_9\NN|to (l_amod) cardiotoxic_8\JJ|effect|doxorubicin|the|chronic|and|of
C055866_D066126 NONE SM-5887_11\NNP|NONE (r_pobj) of_10\IN|effect|doxorubicin|the|cardiotoxic|chronic|and (r_prep) potential_9\NN|to (l_conj) effect_16\NN|doxorubicin|the|cardiotoxic|chronic|and|of (l_prep) on_19\IN|deteriorating|possible|of|a (l_pobj) cardiotoxicity_23\NN|NONE
C055866_D066126 NONE SM-5887_18\NNP|NONE (r_pobj) of_17\IN|deteriorating|possible|a|on (r_prep) effect_16\NN|doxorubicin|the|cardiotoxic|chronic|and|of (r_conj) potential_9\NN|to (l_amod) cardiotoxic_8\JJ|effect|doxorubicin|the|chronic|and|of
C055866_D066126 NONE SM-5887_18\NNP|NONE (r_pobj) of_17\IN|deteriorating|possible|a|on (r_prep) effect_16\NN|doxorubicin|the|cardiotoxic|chronic|and|of (l_prep) on_19\IN|deteriorating|possible|of|a (l_pobj) cardiotoxicity_23\NN|NONE
C055866_D066126 NONE SM-5887_8\NNP|,|grade (r_nmod) cardiomyopathy_13\NN|NONE (r_pobj) of_7\IN|a|cardiotoxic|deteriorating (r_prep) effect_6\NN|To (l_amod) cardiotoxic_5\JJ|a|of|deteriorating
C055866_D066126 NONE SM-5887_3\NNP|.|In|,|does|not|potential (r_nsubj) have_6\VB|NONE (l_dobj) potential_8\NN|.|In|SM|,|does|not (l_prep) of_9\IN|any (l_pobj) cardiotoxicity_11\NN|NONE
C055866_D066126 NONE SM-5887_3\NNP|.|In|,|does|not|potential (r_nsubj) have_6\VB|NONE (l_dobj) potential_8\NN|.|In|SM|,|does|not (l_prep) of_9\IN|any (l_pobj) cardiotoxicity_11\NN|NONE (l_conj) effect_14\NN|and|chronic (l_prep) on_15\IN|deteriorating (l_pobj) cardiotoxicity_19\NN|NONE
2440413
D001640_D012640 CID bicuculline_26\NN|,|mercaptopropionic|MPA|BCC|,|(|STR|)|carbolinecarboxylate (r_conj) acid_21\NN|NONE (r_pobj) to_19\IN|NONE (r_pcomp) due_18\IN|seizure (r_prep) activity_17\NN|;|.|not|different|however|,|decreased (r_nsubj) was_46\VBD|NONE (l_ccomp) decreased_12\VBN|;|.|not|activity|different|however|, (l_nsubjpass) activity_1\NN|significantly|was (l_compound) Seizure_0\NN|due
D001640_D012640 CID bicuculline_26\NN|,|mercaptopropionic|MPA|BCC|,|(|STR|)|carbolinecarboxylate (r_conj) acid_21\NN|NONE (r_pobj) to_19\IN|NONE (r_pcomp) due_18\IN|seizure (r_prep) activity_17\NN|;|.|not|different|however|,|decreased (l_compound) seizure_16\NN|due
D001640_D012640 CID BCC_28\NNP|bicuculline|,|mercaptopropionic|MPA|,|(|STR|)|carbolinecarboxylate (r_appos) acid_21\NN|NONE (r_pobj) to_19\IN|NONE (r_pcomp) due_18\IN|seizure (r_prep) activity_17\NN|;|.|not|different|however|,|decreased (r_nsubj) was_46\VBD|NONE (l_ccomp) decreased_12\VBN|;|.|not|activity|different|however|, (l_nsubjpass) activity_1\NN|significantly|was (l_compound) Seizure_0\NN|due
D001640_D012640 CID BCC_28\NNP|bicuculline|,|mercaptopropionic|MPA|,|(|STR|)|carbolinecarboxylate (r_appos) acid_21\NN|NONE (r_pobj) to_19\IN|NONE (r_pcomp) due_18\IN|seizure (r_prep) activity_17\NN|;|.|not|different|however|,|decreased (l_compound) seizure_16\NN|due
D001556_D012640 NONE hexachlorocyclohexane_5\NN|NONE (r_pobj) of_2\IN|Differential|on|. (r_prep) effects_1\NNS|NONE (l_prep) on_9\IN|Differential|of|. (l_pobj) seizures_13\NNS|NONE
D001556_D012640 NONE lindane_7\NN|gamma| (r_appos) hexachlorocyclohexane_5\NN|NONE (r_pobj) of_2\IN|Differential|on|. (r_prep) effects_1\NNS|NONE (l_prep) on_9\IN|Differential|of|. (l_pobj) seizures_13\NNS|NONE
D001556_D012640 NONE hexachlorocyclohexane_2\NN|decrease|)|has|been (r_nsubjpass) shown_19\VBN|NONE (l_xcomp) decrease_21\VB|)|has|hexachlorocyclohexane|been (l_dobj) threshold_23\NN|to|to (l_compound) seizure_22\NN|NONE
D001556_D012640 NONE HCH_6\NNP|Gamma|(|,|ingredient|)||, (r_appos) hexachlorocyclohexane_2\NN|decrease|)|has|been (r_nsubjpass) shown_19\VBN|NONE (l_xcomp) decrease_21\VB|)|has|hexachlorocyclohexane|been (l_dobj) threshold_23\NN|to|to (l_compound) seizure_22\NN|NONE
D001556_D012640 NONE lindane_15\NN|NONE (r_pobj) of_12\IN|the|active (r_prep) ingredient_11\NN|Gamma|(|HCH|,|)||, (r_appos) hexachlorocyclohexane_2\NN|decrease|)|has|been (r_nsubjpass) shown_19\VBN|NONE (l_xcomp) decrease_21\VB|)|has|hexachlorocyclohexane|been (l_dobj) threshold_23\NN|to|to (l_compound) seizure_22\NN|NONE
D001556_D012640 NONE HCH_7\NNP|NONE (r_pobj) to_4\IN|NONE (r_prep) exposure_3\NN|NONE (r_pobj) after_2\IN||increase|and (r_prep) h_1\NN|)|after|.| (l_conj) increase_10\VB||and|after (l_prep) to_12\IN|conversely|threshold (l_pobj) seizures_16\NNS|NONE
D001556_D012640 NONE HCH_24\NNP|NONE (r_pobj) to_21\IN|NONE (r_prep) exposure_20\NN|NONE (r_pobj) after_19\IN|h|)|.| (r_prep) h_18\NN|NONE (l_dep) h_1\NN|)|after|.| (l_conj) increase_10\VB||and|after (l_prep) to_12\IN|conversely|threshold (l_pobj) seizures_16\NNS|NONE
D001556_D012640 NONE HCH_30\NNP|NONE (r_pobj) of_25\IN|intraperitoneal (r_prep) administration_24\NN|NONE (r_pobj) after_22\IN|In|was|,|.|in|severity|h (r_prep) tested_15\VBN|NONE (l_nsubjpass) severity_5\NN|In|was|,|.|in|after|h (l_prep) of_6\IN|the (l_pobj) response_7\NN|NONE (l_prep) to_8\IN|NONE (l_pobj) agents_13\NNS|NONE (l_amod) inducing_12\VBG|other (l_npadvmod) seizure_10\NN|
D001556_D012640 NONE HCH_8\NNP|NONE (r_pobj) of_5\IN|the (r_prep) administration_4\NN|NONE (r_pobj) after_2\IN|,|hour|activity|was (r_prep) increased_18\VBN|regardless|h|response|.|was|,|,|while (l_nsubjpass) activity_11\NN|after|,|hour|was (l_prep) of_12\IN|the (l_pobj) agents_16\NNS|NONE (l_amod) inducing_15\VBG|NONE (l_npadvmod) seizure_13\NN|
D001556_D012640 NONE HCH_31\NNP||after (r_appos) h_27\NN|regardless|response|increased|.|was|,|,|while (r_dep) observed_36\VBN|NONE (l_advcl) increased_18\VBN|regardless|h|response|.|was|,|,|while (l_nsubjpass) activity_11\NN|after|,|hour|was (l_prep) of_12\IN|the (l_pobj) agents_16\NNS|NONE (l_amod) inducing_15\VBG|NONE (l_npadvmod) seizure_13\NN|
D001556_D012640 NONE HCH_22\NNP|NONE (r_pobj) after_19\IN| (r_prep) h_18\NN|that|decreased|tolerance|may|,|to (r_npadvmod) occur_8\VB|data|. (l_prep) to_9\IN|that|decreased|tolerance|h|may|, (l_pobj) activity_11\NN|NONE (l_compound) seizure_10\NN|induced
D001556_D012640 NONE HCH_22\NNP|NONE (r_pobj) after_19\IN| (r_prep) h_18\NN|that|decreased|tolerance|may|,|to (r_npadvmod) occur_8\VB|data|. (l_advcl) decreased_36\VBN|that|tolerance|h|may|,|to (l_nsubjpass) response_26\NN|since|is (l_prep) to_27\IN|the (l_pobj) agents_34\NNS|NONE (l_amod) inducing_33\VBG|only|these|two (l_npadvmod) seizure_31\NN|
D001556_D012640 NONE HCH_20\NNP|may|that|channel|site (r_nsubj) be_22\VB|.|data (l_nsubj) site_7\NN|may|that|HCH|channel (l_amod) responsible_8\JJ|h|the (l_prep) for_9\IN|NONE (l_pobj) decrease_11\NN|NONE (l_prep) in_12\IN|the (l_pobj) activity_14\NN|NONE (l_compound) seizure_13\NN|NONE
C034818_D012640 CID carboline-3-carboxylate_36\NNP|bicuculline|,|mercaptopropionic|MPA|BCC|,|(|STR|) (r_conj) acid_21\NN|NONE (r_pobj) to_19\IN|NONE (r_pcomp) due_18\IN|seizure (r_prep) activity_17\NN|;|.|not|different|however|,|decreased (r_nsubj) was_46\VBD|NONE (l_ccomp) decreased_12\VBN|;|.|not|activity|different|however|, (l_nsubjpass) activity_1\NN|significantly|was (l_compound) Seizure_0\NN|due
C034818_D012640 CID carboline-3-carboxylate_36\NNP|bicuculline|,|mercaptopropionic|MPA|BCC|,|(|STR|) (r_conj) acid_21\NN|NONE (r_pobj) to_19\IN|NONE (r_pcomp) due_18\IN|seizure (r_prep) activity_17\NN|;|.|not|different|however|,|decreased (l_compound) seizure_16\NN|due
C034818_D012640 CID DMCM_38\NNP|B|)|methyl|||or|,dimethoxyethyl|(|strychnine|, (r_appos) carboline-3-carboxylate_36\NNP|bicuculline|,|mercaptopropionic|MPA|BCC|,|(|STR|) (r_conj) acid_21\NN|NONE (r_pobj) to_19\IN|NONE (r_pcomp) due_18\IN|seizure (r_prep) activity_17\NN|;|.|not|different|however|,|decreased (r_nsubj) was_46\VBD|NONE (l_ccomp) decreased_12\VBN|;|.|not|activity|different|however|, (l_nsubjpass) activity_1\NN|significantly|was (l_compound) Seizure_0\NN|due
C034818_D012640 CID DMCM_38\NNP|B|)|methyl|||or|,dimethoxyethyl|(|strychnine|, (r_appos) carboline-3-carboxylate_36\NNP|bicuculline|,|mercaptopropionic|MPA|BCC|,|(|STR|) (r_conj) acid_21\NN|NONE (r_pobj) to_19\IN|NONE (r_pcomp) due_18\IN|seizure (r_prep) activity_17\NN|;|.|not|different|however|,|decreased (l_compound) seizure_16\NN|due
D013331_D012640 CID strychnine_42\NN|DMCM|B|)|methyl|||or|,dimethoxyethyl|(|, (r_conj) carboline-3-carboxylate_36\NNP|bicuculline|,|mercaptopropionic|MPA|BCC|,|(|STR|) (r_conj) acid_21\NN|NONE (r_pobj) to_19\IN|NONE (r_pcomp) due_18\IN|seizure (r_prep) activity_17\NN|;|.|not|different|however|,|decreased (r_nsubj) was_46\VBD|NONE (l_ccomp) decreased_12\VBN|;|.|not|activity|different|however|, (l_nsubjpass) activity_1\NN|significantly|was (l_compound) Seizure_0\NN|due
D013331_D012640 CID strychnine_42\NN|DMCM|B|)|methyl|||or|,dimethoxyethyl|(|, (r_conj) carboline-3-carboxylate_36\NNP|bicuculline|,|mercaptopropionic|MPA|BCC|,|(|STR|) (r_conj) acid_21\NN|NONE (r_pobj) to_19\IN|NONE (r_pcomp) due_18\IN|seizure (r_prep) activity_17\NN|;|.|not|different|however|,|decreased (l_compound) seizure_16\NN|due
D013331_D012640 CID STR_44\NNP|bicuculline|,|mercaptopropionic|MPA|BCC|,|(|)|carbolinecarboxylate (r_appos) acid_21\NN|NONE (r_pobj) to_19\IN|NONE (r_pcomp) due_18\IN|seizure (r_prep) activity_17\NN|;|.|not|different|however|,|decreased (r_nsubj) was_46\VBD|NONE (l_ccomp) decreased_12\VBN|;|.|not|activity|different|however|, (l_nsubjpass) activity_1\NN|significantly|was (l_compound) Seizure_0\NN|due
D013331_D012640 CID STR_44\NNP|bicuculline|,|mercaptopropionic|MPA|BCC|,|(|)|carbolinecarboxylate (r_appos) acid_21\NN|NONE (r_pobj) to_19\IN|NONE (r_pcomp) due_18\IN|seizure (r_prep) activity_17\NN|;|.|not|different|however|,|decreased (l_compound) seizure_16\NN|due
D005680_D012640 NONE GABA_24\NNP| (r_compound) A_26\NNP|chloride|linked|the (r_nmod) channel_31\NN|may|that|HCH|site (r_attr) be_22\VB|.|data (l_nsubj) site_7\NN|may|that|HCH|channel (l_amod) responsible_8\JJ|h|the (l_prep) for_9\IN|NONE (l_pobj) decrease_11\NN|NONE (l_prep) in_12\IN|the (l_pobj) activity_14\NN|NONE (l_compound) seizure_13\NN|NONE
D010433_D012640 CID PTZ_27\NNP|NONE (r_pobj) to_24\TO|threshold|to (r_prep) decrease_21\VB|)|has|hexachlorocyclohexane|been (l_dobj) threshold_23\NN|to|to (l_compound) seizure_22\NN|NONE
D010433_D012640 CID PTZ_13\NNP| (r_npadvmod) induced_15\VBN|NONE (r_amod) seizures_16\NNS|NONE
D010433_D012640 CID PTZ_4\NNP|to (r_pobj) due_2\IN|Seizure (r_amod) activity_1\NN|significantly|was (l_compound) Seizure_0\NN|due
D010433_D012640 CID PTZ_4\NNP|to (r_pobj) due_2\IN|Seizure (r_amod) activity_1\NN|significantly|was (r_nsubjpass) decreased_12\VBN|;|.|not|activity|different|however|, (r_ccomp) was_46\VBD|NONE (l_nsubj) activity_17\NN|;|.|not|different|however|,|decreased (l_compound) seizure_16\NN|due
D010433_D012640 CID PTZ_14\NNP|NONE (r_pobj) by_13\IN|NONE (r_agent) induced_12\VBN|seizure (r_acl) activity_11\NN|NONE (l_compound) seizure_10\NN|induced
D010433_D012640 CID PTZ_14\NNP|NONE (r_pobj) by_13\IN|NONE (r_agent) induced_12\VBN|seizure (r_acl) activity_11\NN|NONE (r_pobj) to_9\IN|that|decreased|tolerance|h|may|, (r_prep) occur_8\VB|data|. (l_advcl) decreased_36\VBN|that|tolerance|h|may|,|to (l_nsubjpass) response_26\NN|since|is (l_prep) to_27\IN|the (l_pobj) agents_34\NNS|NONE (l_amod) inducing_33\VBG|only|these|two (l_npadvmod) seizure_31\NN|
D015097_D012640 CID acid_21\NN|NONE (r_pobj) to_19\IN|NONE (r_pcomp) due_18\IN|seizure (r_prep) activity_17\NN|;|.|not|different|however|,|decreased (r_nsubj) was_46\VBD|NONE (l_ccomp) decreased_12\VBN|;|.|not|activity|different|however|, (l_nsubjpass) activity_1\NN|significantly|was (l_compound) Seizure_0\NN|due
D015097_D012640 CID acid_21\NN|NONE (r_pobj) to_19\IN|NONE (r_pcomp) due_18\IN|seizure (r_prep) activity_17\NN|;|.|not|different|however|,|decreased (l_compound) seizure_16\NN|due
D015097_D012640 CID MPA_23\NNP|bicuculline|,|mercaptopropionic|BCC|,|(|STR|)|carbolinecarboxylate (r_appos) acid_21\NN|NONE (r_pobj) to_19\IN|NONE (r_pcomp) due_18\IN|seizure (r_prep) activity_17\NN|;|.|not|different|however|,|decreased (r_nsubj) was_46\VBD|NONE (l_ccomp) decreased_12\VBN|;|.|not|activity|different|however|, (l_nsubjpass) activity_1\NN|significantly|was (l_compound) Seizure_0\NN|due
D015097_D012640 CID MPA_23\NNP|bicuculline|,|mercaptopropionic|BCC|,|(|STR|)|carbolinecarboxylate (r_appos) acid_21\NN|NONE (r_pobj) to_19\IN|NONE (r_pcomp) due_18\IN|seizure (r_prep) activity_17\NN|;|.|not|different|however|,|decreased (l_compound) seizure_16\NN|due
D010852_D012640 CID picrotoxin_6\NN|and|PTX (r_conj) PTZ_4\NNP|to (r_pobj) due_2\IN|Seizure (r_amod) activity_1\NN|significantly|was (l_compound) Seizure_0\NN|due
D010852_D012640 CID picrotoxin_6\NN|and|PTX (r_conj) PTZ_4\NNP|to (r_pobj) due_2\IN|Seizure (r_amod) activity_1\NN|significantly|was (r_nsubjpass) decreased_12\VBN|;|.|not|activity|different|however|, (r_ccomp) was_46\VBD|NONE (l_nsubj) activity_17\NN|;|.|not|different|however|,|decreased (l_compound) seizure_16\NN|due
D010852_D012640 CID PTX_8\NNP|and|picrotoxin (r_appos) PTZ_4\NNP|to (r_pobj) due_2\IN|Seizure (r_amod) activity_1\NN|significantly|was (l_compound) Seizure_0\NN|due
D010852_D012640 CID PTX_8\NNP|and|picrotoxin (r_appos) PTZ_4\NNP|to (r_pobj) due_2\IN|Seizure (r_amod) activity_1\NN|significantly|was (r_nsubjpass) decreased_12\VBN|;|.|not|activity|different|however|, (r_ccomp) was_46\VBD|NONE (l_nsubj) activity_17\NN|;|.|not|different|however|,|decreased (l_compound) seizure_16\NN|due
D010852_D012640 CID PTX_16\NNP|and (r_conj) PTZ_14\NNP|NONE (r_pobj) by_13\IN|NONE (r_agent) induced_12\VBN|seizure (r_acl) activity_11\NN|NONE (l_compound) seizure_10\NN|induced
D010852_D012640 CID PTX_16\NNP|and (r_conj) PTZ_14\NNP|NONE (r_pobj) by_13\IN|NONE (r_agent) induced_12\VBN|seizure (r_acl) activity_11\NN|NONE (r_pobj) to_9\IN|that|decreased|tolerance|h|may|, (r_prep) occur_8\VB|data|. (l_advcl) decreased_36\VBN|that|tolerance|h|may|,|to (l_nsubjpass) response_26\NN|since|is (l_prep) to_27\IN|the (l_pobj) agents_34\NNS|NONE (l_amod) inducing_33\VBG|only|these|two (l_npadvmod) seizure_31\NN|
8480959
D003401_D009135 NONE creatine_7\NN|NONE (r_compound) kinase_8\NN|greater (r_compound) elevations_9\NNS|NONE (r_pobj) with_6\IN|muscle (r_prep) symptoms_5\NNS|NONE (r_pobj) as_3\IN|, (r_prep) defined_2\VBN|NONE (r_acl) Myopathy_0\NNP|associated|,|and|rare|.
D008148_D009135 CID lovastatin_31\NN|NONE (r_pobj) of_30\IN|the|daily|mg|recommended (r_prep) dose_29\NN|NONE (r_pobj) with_24\IN|NONE (r_prep) associated_23\VBN|,|and|Myopathy|rare|. (r_conj) was_20\VBD|NONE (l_nsubj) Myopathy_0\NNP|associated|,|and|rare|.
D008148_D006937 NONE lovastatin_4\NN|NONE (r_pobj) of_3\IN|tolerability|in|.|and (r_prep) Efficacy_0\NN|NONE (l_prep) in_5\IN|of|tolerability|.|and (l_pobj) women_7\NNS|NONE (l_prep) with_8\IN| (l_pobj) hypercholesterolemia_10\NN|NONE
D008148_D006937 NONE lovastatin_7\NN|NONE (r_pobj) of_6\IN|in|and|safety|the (r_prep) efficacy_3\NN|To|with|. (r_dobj) evaluate_1\VB|NONE (l_prep) with_10\IN|To|efficacy|. (l_pobj) hypercholesterolemia_12\NN|NONE
D008148_D006937 NONE Lovastatin_0\NNP|.|tolerated|effective|and (r_nsubj) is_1\VBZ|NONE (l_conj) tolerated_7\VBN|.|Lovastatin|effective|and (l_prep) as_8\IN|well|generally (l_pobj) therapy_9\NN|NONE (l_prep) for_10\IN|NONE (l_pobj) hypercholesterolemia_12\NN|NONE
19473225
D017239_D010523 CID paclitaxel_12\NN|NONE (r_pobj) of_11\IN|peripheral (r_prep) neurotoxicity_10\NN|NONE
D017239_D010523 CID paclitaxel_12\NN|NONE (r_pobj) with_11\IN|PAC (r_prep) chemotherapy_10\NN|NONE (r_pobj) for_9\IN|significant|a|limiting (r_prep) factor_8\NN|neuropathy|claimed|,|.|still (r_attr) is_3\VBZ|NONE (l_nsubj) neuropathy_2\NN|claimed|factor|,|.|still
D017239_D010523 CID PAC_14\NNP|with (r_appos) chemotherapy_10\NN|NONE (r_pobj) for_9\IN|significant|a|limiting (r_prep) factor_8\NN|neuropathy|claimed|,|.|still (r_attr) is_3\VBZ|NONE (l_nsubj) neuropathy_2\NN|claimed|factor|,|.|still
D017239_D010523 CID PAC_30\NNP|NONE (r_compound) neurotoxicity_31\NN|to (r_dobj) ameliorate_29\VB|glutamate|although|were (r_xcomp) claimed_27\VBN|neuropathy|factor|,|.|still (r_advcl) is_3\VBZ|NONE (l_nsubj) neuropathy_2\NN|claimed|factor|,|.|still
D017239_D010523 CID PAC_13\NNP| (r_npadvmod) induced_15\VBN|peripheral (r_amod) neuropathy_17\NN|in
D017239_D010523 CID PAC_21\NNP|NONE (r_pobj) of_20\IN|peripheral (r_prep) neurotoxicity_19\NN|NONE
D017239_D010051 NONE PAC_16\NNP| (r_npadvmod) containing_18\VBG|the|same (r_amod) regimen_19\NN|NONE (r_pobj) of_13\IN|six (r_prep) cycles_12\NNS|NONE (r_pobj) following_10\VBG|NONE (r_prep) analysis_9\NN|NONE (r_pobj) for_8\IN|NONE (r_prep) available_7\JJ|patients (r_acomp) were_6\VBD||received|by|at|.|and|,|,|been|had|: (l_nsubj) patients_5\NNS|available (l_compound) cancer_4\NN|ovarian|three
D018698_D010051 NONE glutamate_26\NN|NONE (r_pobj) by_25\IN|were||received|at|.|and|,|,|been|had|: (r_agent) supplemented_24\VBN|NONE (l_ccomp) were_6\VBD||received|by|at|.|and|,|,|been|had|: (l_nsubj) patients_5\NNS|available (l_compound) cancer_4\NN|ovarian|three
D000596_D010523 NONE acid_24\NN|related|its (r_compound) glutamine_25\NN|and (r_conj) glutamate_18\NN|ameliorate|although|were (r_nsubjpass) claimed_27\VBN|neuropathy|factor|,|.|still (r_advcl) is_3\VBZ|NONE (l_nsubj) neuropathy_2\NN|claimed|factor|,|.|still
D018698_D020258 NONE glutamate_18\NN|ameliorate|although|were (r_nsubjpass) claimed_27\VBN|neuropathy|factor|,|.|still (l_xcomp) ameliorate_29\VB|glutamate|although|were (l_dobj) neurotoxicity_31\NN|to
D018698_D020258 NONE glutamine_25\NN|and (r_conj) glutamate_18\NN|ameliorate|although|were (r_nsubjpass) claimed_27\VBN|neuropathy|factor|,|.|still (l_xcomp) ameliorate_29\VB|glutamate|although|were (l_dobj) neurotoxicity_31\NN|to
D018698_D010523 NONE glutamate_3\NN|term (r_compound) supplementation_4\NN|protect|. (r_nsubj) failed_5\VBD|NONE (l_xcomp) protect_7\VB|supplementation|. (l_prep) against_8\IN|to (l_pobj) neurotoxicity_10\NN|NONE
D018698_D010523 NONE glutamate_18\NN|ameliorate|although|were (r_nsubjpass) claimed_27\VBN|neuropathy|factor|,|.|still (r_advcl) is_3\VBZ|NONE (l_nsubj) neuropathy_2\NN|claimed|factor|,|.|still
D018698_D010523 NONE glutamine_25\NN|and (r_conj) glutamate_18\NN|ameliorate|although|were (r_nsubjpass) claimed_27\VBN|neuropathy|factor|,|.|still (r_advcl) is_3\VBZ|NONE (l_nsubj) neuropathy_2\NN|claimed|factor|,|.|still
D018698_D010523 NONE glutamate_9\NN|for (r_compound) supplementation_10\NN|NONE (l_prep) for_11\IN|glutamate (l_pcomp) preventing_12\VBG|NONE (l_dobj) neuropathy_17\NN|in
D018698_D010523 NONE glutamate_8\NN|at (r_compound) supplementation_9\NN|that|protect (r_nsubj) fails_14\VBZ|the (l_xcomp) protect_16\VB|that|supplementation (l_prep) against_17\IN|to (l_pobj) neurotoxicity_19\NN|NONE
D000596_D020258 NONE acid_24\NN|related|its (r_compound) glutamine_25\NN|and (r_conj) glutamate_18\NN|ameliorate|although|were (r_nsubjpass) claimed_27\VBN|neuropathy|factor|,|.|still (l_xcomp) ameliorate_29\VB|glutamate|although|were (l_dobj) neurotoxicity_31\NN|to
D017239_D020258 NONE paclitaxel_12\NN|NONE (r_pobj) with_11\IN|PAC (r_prep) chemotherapy_10\NN|NONE (r_pobj) for_9\IN|significant|a|limiting (r_prep) factor_8\NN|neuropathy|claimed|,|.|still (r_attr) is_3\VBZ|NONE (l_advcl) claimed_27\VBN|neuropathy|factor|,|.|still (l_xcomp) ameliorate_29\VB|glutamate|although|were (l_dobj) neurotoxicity_31\NN|to
D017239_D020258 NONE PAC_14\NNP|with (r_appos) chemotherapy_10\NN|NONE (r_pobj) for_9\IN|significant|a|limiting (r_prep) factor_8\NN|neuropathy|claimed|,|.|still (r_attr) is_3\VBZ|NONE (l_advcl) claimed_27\VBN|neuropathy|factor|,|.|still (l_xcomp) ameliorate_29\VB|glutamate|although|were (l_dobj) neurotoxicity_31\NN|to
D017239_D020258 NONE PAC_30\NNP|NONE (r_compound) neurotoxicity_31\NN|to
11279304
D003630_D006333 CID DNR_16\NNP|NONE (r_pobj) given_15\VBN|heart (r_acl) failure_14\NN|NONE
D018943_D006331 NONE anthracycline_4\NN|conventional (r_amod) therapy_5\NN|NONE (r_pobj) of_2\IN|The (r_prep) cardiotoxicity_1\NN|.|need (r_nsubj) highlights_6\VBZ|NONE (l_dobj) need_8\NN|cardiotoxicity|. (l_acl) search_10\VB|a (l_prep) for_11\IN|to (l_pobj) methods_12\NNS|NONE (l_relcl) are_14\VBP|NONE (l_acomp) sensitive_16\JJ|that (l_conj) capable_18\JJ|highly|and (l_prep) of_19\IN|NONE (l_pcomp) predicting_20\VBG|NONE (l_dobj) dysfunction_22\NN|NONE
D003630_D066126 NONE daunorubicin_36\NN|NONE (r_pobj) with_34\IN|NONE (r_prep) treated_33\VBN|acute (r_acl) leukemia_32\NN|NONE (r_pobj) with_30\IN|NONE (r_prep) patients_29\NNS|NONE (r_pobj) in_28\IN|induced (r_prep) cardiotoxicity_27\NN|NONE
D003630_D066126 NONE DNR)-containing_38\NN|NONE (r_compound) regimen_39\NNS|(|a (r_appos) daunorubicin_36\NN|NONE (r_pobj) with_34\IN|NONE (r_prep) treated_33\VBN|acute (r_acl) leukemia_32\NN|NONE (r_pobj) with_30\IN|NONE (r_prep) patients_29\NNS|NONE (r_pobj) in_28\IN|induced (r_prep) cardiotoxicity_27\NN|NONE
D018943_D066126 NONE anthracycline_7\NN| (r_advmod) induced_9\VBN|NONE (r_amod) cardiotoxicity_10\NN|NONE
D018943_D066126 NONE Anthracyclines_0\NNS|,|but|drugs|cause (r_nsubj) are_1\VBP|NONE (l_conj) cause_9\VBP|,|but|Anthracyclines|drugs (l_dobj) cardiotoxicity_13\NN|frequently|they|.
D018943_D066126 NONE anthracycline_4\NN|conventional (r_amod) therapy_5\NN|NONE (r_pobj) of_2\IN|The (r_prep) cardiotoxicity_1\NN|.|need
D018943_D066126 NONE anthracycline_24\NN| (r_advmod) induced_26\VBN|in (r_amod) cardiotoxicity_27\NN|NONE
D018943_D066126 NONE anthracycline_16\NN| (r_advmod) induced_18\VBN|NONE (r_compound) cardiotoxicity_19\NN|NONE
D018943_D015470 NONE anthracycline_24\NN| (r_advmod) induced_26\VBN|in (r_amod) cardiotoxicity_27\NN|NONE (l_prep) in_28\IN|induced (l_pobj) patients_29\NNS|NONE (l_prep) with_30\IN|NONE (l_pobj) leukemia_32\NN|NONE
D003630_D015470 NONE daunorubicin_36\NN|NONE (r_pobj) with_34\IN|NONE (r_prep) treated_33\VBN|acute (r_acl) leukemia_32\NN|NONE
D003630_D015470 NONE DNR)-containing_38\NN|NONE (r_compound) regimen_39\NNS|(|a (r_appos) daunorubicin_36\NN|NONE (r_pobj) with_34\IN|NONE (r_prep) treated_33\VBN|acute (r_acl) leukemia_32\NN|NONE
D003630_D015470 NONE DNR_9\NNP| (r_npadvmod) containing_11\VBG|a (r_amod) regimen_12\NN|NONE (r_pobj) with_7\IN|were|.|patients (r_prep) treated_6\VBN|NONE (l_nsubjpass) patients_1\NNS|were|.|with (l_prep) with_2\IN|Thirteen (l_pobj) leukemia_4\NN|NONE
9672273
D013629_D001943 NONE tamoxifen_5\NN|NONE (r_pobj) with_4\IN|.|findings|of|: (r_prep) Prevention_0\NN|NONE (l_prep) of_1\IN|.|findings|with|: (l_pobj) cancer_3\NN|NONE
D013629_D001943 NONE Tamoxifen_0\NNP|agent|associated|.|, (r_nsubj) is_1\VBZ|NONE (l_attr) agent_5\NN|associated|.|Tamoxifen|, (l_prep) in_6\IN|a|candidate|chemopreventive (l_pobj) cancer_8\NN|NONE
D013629_D001943 NONE tamoxifen_18\NN|NONE (r_pobj) of_17\IN|have|blind|a|controlled|(|randomised|in|in|)|, (r_prep) trial_16\NN|In|,|.|we (l_relcl) have_29\VB|blind|a|controlled|(|randomised|in|in|)|of|, (l_dobj) cancer_31\NN|not|did|who|had|and
D013629_D001943 NONE tamoxifen_17\NN|)|(| (r_nmod) arms_21\NNS|(|)|the|cases|and (r_conj) placebo_11\NN|NONE (r_pobj) between_9\IN|cancer (r_prep) frequency_8\NN|NONE (l_compound) cancer_7\NN|between
D013629_D001943 NONE tamoxifen_12\NN|NONE (r_dobj) receiving_11\VBG|used (r_acl) women_10\NNS|NONE (r_pobj) among_9\IN|a|:|significant|among|of (r_prep) reduction_5\NN|There (l_prep) of_6\IN|a|:|among|significant|among (l_pobj) cancer_8\NN|NONE
D013629_D001943 NONE tamoxifen_12\NN|NONE (r_dobj) receiving_11\VBG|used (r_acl) women_10\NNS|NONE (r_pobj) among_9\IN|a|:|significant|among|of (r_prep) reduction_5\NN|There (r_attr) is_1\VBZ|.|,|we|compared|cases (r_ccomp) found_36\VBD|NONE (l_dobj) cases_38\NNS|.|is|,|we|compared (l_prep) of_39\IN|eight (l_pobj) cancer_41\NN|NONE
D013629_D001943 NONE tamoxifen_51\NN|NONE (r_pobj) to_50\IN|NONE (r_prep) allocated_49\VBN| (r_acl) women_48\NNS|NONE (r_pobj) among_46\IN|one (r_prep) case_45\NN|NONE (r_pobj) with_43\IN|NONE (r_prep) compared_42\VBN|.|is|,|we|cases (r_prep) found_36\VBD|NONE (l_ccomp) is_1\VBZ|.|,|we|compared|cases (l_attr) reduction_5\NN|There (l_prep) of_6\IN|a|:|among|significant|among (l_pobj) cancer_8\NN|NONE
D013629_D001943 NONE tamoxifen_51\NN|NONE (r_pobj) to_50\IN|NONE (r_prep) allocated_49\VBN| (r_acl) women_48\NNS|NONE (r_pobj) among_46\IN|one (r_prep) case_45\NN|NONE (r_pobj) with_43\IN|NONE (r_prep) compared_42\VBN|.|is|,|we|cases (r_prep) found_36\VBD|NONE (l_dobj) cases_38\NNS|.|is|,|we|compared (l_prep) of_39\IN|eight (l_pobj) cancer_41\NN|NONE
D013629_D001943 NONE tamoxifen_29\NN|NONE (r_pobj) of_28\IN|postulated|protective|the (r_prep) effects_27\NNS|in|.|,|,|has|not|apparent (r_nsubj) are_30\VBP|NONE (l_prep) in_8\IN|effects|.|,|,|has|not|apparent (l_prep) at_13\IN|cohort (l_pobj) risk_19\NN|NONE (l_prep) of_20\IN|low (l_pobj) cancer_22\NN|NONE
D013629_D014652 CID tamoxifen_20\NN|NONE (r_pobj) on_19\IN|NONE (r_prep) women_18\NNS|NONE (r_pobj) among_17\IN|hypertriglyceridaemia|vascular|and (r_prep) events_14\NNS|NONE
D013629_D016889 NONE Tamoxifen_0\NNP|agent|associated|.|, (r_nsubj) is_1\VBZ|NONE (l_advcl) associated_15\VBN|agent|.|Tamoxifen|, (l_prep) with_16\IN|be|may|drug|although (l_pobj) development_18\NN|NONE (l_prep) of_19\IN|the (l_pobj) cancer_21\NN|NONE
D013629_D015228 CID tamoxifen_20\NN|NONE (r_pobj) on_19\IN|NONE (r_prep) women_18\NNS|NONE (r_pobj) among_17\IN|hypertriglyceridaemia|vascular|and (r_prep) events_14\NNS|NONE (l_conj) hypertriglyceridaemia_16\NN|vascular|and|among
17439425
D003907_D006973 CID dexamethasone_5\NN| (r_npadvmod) induced_7\VBN|in (r_amod) hypertension_8\NN|NONE
D003907_D006973 CID dexamethasone_23\NN| (r_npadvmod) induced_25\VBN|HT (r_amod) hypertension_26\NN|NONE
D003907_D006973 CID dexamethasone_23\NN| (r_npadvmod) induced_25\VBN|HT (r_amod) hypertension_26\NN|NONE (l_appos) HT_30\NNP|induced
D003907_D006973 CID dex_28\NN|)||( (r_compound) HT_30\NNP|induced (r_appos) hypertension_26\NN|NONE
D003907_D006973 CID dex_28\NN|)||( (r_compound) HT_30\NNP|induced
D003907_D006973 CID Dex_0\NNP|.|P|;|mmHg|+/|SBP (r_nsubj) increased_1\VBD|NONE (l_dobj) SBP_2\NNP|.|P|;|mmHg|+/|Dex
D003907_D006973 CID dex_4\NN| (r_compound) HT_6\NNP|.|not|Allopurinol|did
D000493_D006973 NONE Allopurinol_0\NNP|.|not|HT|did (r_nsubj) prevent_3\VB|NONE (l_dobj) HT_6\NNP|.|not|Allopurinol|did
D000493_D006973 NONE allopurinol_8\NN|that|prevent (r_nsubj) failed_9\VBD|previous|our (r_acl) findings_6\NNS|together (r_pobj) with_3\IN|hypertension|This|, (r_prep) induced_14\VBN|,|.|is (l_dobj) hypertension_15\NN|with|This|,
D000493_D006973 NONE allopurinol_8\NN|that|prevent (r_nsubj) failed_9\VBD|previous|our (r_acl) findings_6\NNS|together (r_pobj) with_3\IN|hypertension|This|, (r_prep) induced_14\VBN|,|.|is (r_ccomp) suggests_17\VBZ|NONE (l_ccomp) is_21\VBZ|,|.|induced (l_attr) determinant_25\NN|activity|not|that (l_prep) of_26\IN|major|a|in (l_pobj) HT_29\NNP|NONE
D003907_D015431 CID Dex_0\NNP|.|P|;|mmHg|+/|SBP (r_nsubj) increased_1\VBD|NONE (l_dep) P_13\NN|.|;|mmHg|+/|Dex|SBP (l_conj) decreased_18\VBN|)|and|. (l_dobj) thymus_19\NN|NONE (l_conj) bodyweights_26\NNS|P|and|(|)
D009569_D006973 NONE oxide_16\NN| (r_compound) redox_18\NN|nitric (r_compound) imbalance_19\NN|NONE (r_pobj) with_14\IN|.|is|hypertension (r_prep) associated_13\VBN|NONE (l_nsubjpass) hypertension_3\NN|.|with|is
D009569_D006973 NONE oxide_16\NN| (r_compound) redox_18\NN|nitric (r_compound) imbalance_19\NN|NONE (r_pobj) with_14\IN|.|is|hypertension (r_prep) associated_13\VBN|NONE (l_nsubjpass) hypertension_3\NN|.|with|is (l_appos) HT_7\NNP|induced|in
D019820_D006973 NONE xanthine_2\NN|NONE (r_compound) oxidase_3\NN|NONE (r_pobj) of_1\IN|.|in (r_prep) Role_0\NN|NONE (l_prep) in_4\IN|.|of (l_pobj) hypertension_8\NN|NONE
D019820_D006973 NONE xanthine_5\NN|implicated|,|XO|, (r_compound) oxidase_6\NN|NONE (r_pobj) of_4\IN|in|the (r_prep) role_3\NN|.|We (l_prep) in_22\IN|of|the (l_pobj) hypertension_26\NN|NONE
D019820_D006973 NONE xanthine_5\NN|implicated|,|XO|, (r_compound) oxidase_6\NN|NONE (r_pobj) of_4\IN|in|the (r_prep) role_3\NN|.|We (l_prep) in_22\IN|of|the (l_pobj) hypertension_26\NN|NONE (l_appos) HT_30\NNP|induced
2355241
D009638_D003643 NONE noradrenaline_31\NN|in|reduced (r_amod) levels_32\NNS|to (r_pobj) due_28\IN|a|hypotensive (r_amod) mechanism_27\NN|and|of|hypotensive|the (r_conj) effect_21\NN|may|.|incidence (r_dobj) reflect_18\VB|NONE (l_nsubj) incidence_2\NN|may|.|effect (l_prep) as_6\IN|low|of|The (l_pobj) cause_8\NN|NONE (l_prep) of_9\IN|in|a (l_pobj) death_10\NN|NONE
D007980_D007022 CID levodopa_23\NN|NONE (r_pobj) of_22\IN|and|hypotensive|mechanism|the (r_prep) effect_21\NN|may|.|incidence (l_amod) hypotensive_20\JJ|and|of|mechanism|the
D007980_D007022 CID levodopa_23\NN|NONE (r_pobj) of_22\IN|and|hypotensive|mechanism|the (r_prep) effect_21\NN|may|.|incidence (l_conj) mechanism_27\NN|and|of|hypotensive|the (l_amod) hypotensive_26\JJ|a|due
D007980_D010300 NONE levodopa_23\NN|NONE (r_pobj) of_22\IN|and|hypotensive|mechanism|the (r_prep) effect_21\NN|may|.|incidence (r_dobj) reflect_18\VB|NONE (l_nsubj) incidence_2\NN|may|.|effect (l_prep) as_6\IN|low|of|The (l_pobj) cause_8\NN|NONE (l_prep) in_11\IN|of|a (l_pobj) patients_12\NNS|NONE (l_prep) with_13\IN|NONE (l_pobj) disease_16\NN|NONE
D007980_D010300 NONE levodopa_23\NN|NONE (r_pobj) of_22\IN|and|hypotensive|mechanism|the (r_prep) effect_21\NN|may|.|incidence (l_conj) mechanism_27\NN|and|of|hypotensive|the (l_amod) due_28\IN|a|hypotensive (l_pobj) levels_32\NNS|to (l_prep) in_33\IN|reduced|noradrenaline (l_pobj) brain_36\NN|NONE (l_amod) parkinsonian_35\JJ|the
D007980_D003643 NONE levodopa_23\NN|NONE (r_pobj) of_22\IN|and|hypotensive|mechanism|the (r_prep) effect_21\NN|may|.|incidence (r_dobj) reflect_18\VB|NONE (l_nsubj) incidence_2\NN|may|.|effect (l_prep) as_6\IN|low|of|The (l_pobj) cause_8\NN|NONE (l_prep) of_9\IN|in|a (l_pobj) death_10\NN|NONE
D009638_D002543 NONE noradrenaline_31\NN|in|reduced (r_amod) levels_32\NNS|to (r_pobj) due_28\IN|a|hypotensive (r_amod) mechanism_27\NN|and|of|hypotensive|the (r_conj) effect_21\NN|may|.|incidence (r_dobj) reflect_18\VB|NONE (l_nsubj) incidence_2\NN|may|.|effect (l_prep) of_3\IN|as|low|The (l_pobj) haemorrhage_5\NN|NONE
D007980_D002543 NONE levodopa_23\NN|NONE (r_pobj) of_22\IN|and|hypotensive|mechanism|the (r_prep) effect_21\NN|may|.|incidence (r_dobj) reflect_18\VB|NONE (l_nsubj) incidence_2\NN|may|.|effect (l_prep) of_3\IN|as|low|The (l_pobj) haemorrhage_5\NN|NONE
D009638_D007022 NONE noradrenaline_31\NN|in|reduced (r_amod) levels_32\NNS|to (r_pobj) due_28\IN|a|hypotensive (r_amod) mechanism_27\NN|and|of|hypotensive|the (r_conj) effect_21\NN|may|.|incidence (l_amod) hypotensive_20\JJ|and|of|mechanism|the
D009638_D007022 NONE noradrenaline_31\NN|in|reduced (r_amod) levels_32\NNS|to (r_pobj) due_28\IN|a|hypotensive (r_amod) mechanism_27\NN|and|of|hypotensive|the (l_amod) hypotensive_26\JJ|a|due
D009638_D010300 NONE noradrenaline_31\NN|in|reduced (r_amod) levels_32\NNS|to (r_pobj) due_28\IN|a|hypotensive (r_amod) mechanism_27\NN|and|of|hypotensive|the (r_conj) effect_21\NN|may|.|incidence (r_dobj) reflect_18\VB|NONE (l_nsubj) incidence_2\NN|may|.|effect (l_prep) as_6\IN|low|of|The (l_pobj) cause_8\NN|NONE (l_prep) in_11\IN|of|a (l_pobj) patients_12\NNS|NONE (l_prep) with_13\IN|NONE (l_pobj) disease_16\NN|NONE
D009638_D010300 NONE noradrenaline_31\NN|in|reduced (r_amod) levels_32\NNS|to (l_prep) in_33\IN|reduced|noradrenaline (l_pobj) brain_36\NN|NONE (l_amod) parkinsonian_35\JJ|the
19300402
D001920_D003929 NONE Bradykinin_0\NN|streptozotocin|and|receptors|and|inhibitors|in (r_compound) antagonists_2\NNS|hyperalgesia|. (r_nsubj) induced_12\VBD|NONE (l_dobj) hyperalgesia_13\NN|.|antagonists (l_prep) in_14\IN|NONE (l_pobj) chemotherapy_15\NN|NONE (l_conj) model_20\NN|and (l_compound) rat_19\NN|diabetic (l_compound) neuropathy_18\NN|NONE
D014750_D003929 NONE vincristine_9\NN|NONE (r_pobj) in_8\IN|streptozotocin|and|receptors|Bradykinin|and|inhibitors (r_prep) antagonists_2\NNS|hyperalgesia|. (r_nsubj) induced_12\VBD|NONE (l_dobj) hyperalgesia_13\NN|.|antagonists (l_prep) in_14\IN|NONE (l_pobj) chemotherapy_15\NN|NONE (l_conj) model_20\NN|and (l_compound) rat_19\NN|diabetic (l_compound) neuropathy_18\NN|NONE
D009569_D006930 NONE oxide_5\NN|nitric (r_compound) synthase_6\NN|NONE (r_compound) inhibitors_7\NNS|streptozotocin|and|receptors|Bradykinin|and|in (r_conj) antagonists_2\NNS|hyperalgesia|. (r_nsubj) induced_12\VBD|NONE (l_dobj) hyperalgesia_13\NN|.|antagonists
D009569_D006930 NONE NO_13\DT|inducible (r_det) synthase_14\NN|of|and|but (r_conj) inhibition_7\NN|activity|that|hyperalgesia (r_nsubj) reduces_21\VBZ|results|. (l_dobj) hyperalgesia_23\NN|activity|that|inhibition
D009569_D006930 NONE NO_18\DT|not|synthase|neuronal (r_det) activity_20\NN|that|hyperalgesia|inhibition (r_nsubj) reduces_21\VBZ|results|. (l_dobj) hyperalgesia_23\NN|activity|that|inhibition
D009569_D006930 NONE NO_9\DT|activation|and|inducible (r_compound) synthase_10\NN|NONE (r_pobj) of_7\IN|both (r_prep) products_6\NNS|in|are|that (r_nsubjpass) involved_21\VBN|was|It|.|also (l_prep) in_22\IN|are|that|products (l_pobj) hyperalgesia_23\NN|NONE
D009569_D006930 NONE NO_13\DT|synthase|bradykinin|as|neuronal (r_det) activation_15\NN|and|NO|inducible (r_conj) synthase_10\NN|NONE (r_pobj) of_7\IN|both (r_prep) products_6\NNS|in|are|that (r_nsubjpass) involved_21\VBN|was|It|.|also (l_prep) in_22\IN|are|that|products (l_pobj) hyperalgesia_23\NN|NONE
D009569_D006930 NONE NO_7\DT|inducible (r_compound) synthase_8\NN|In|in|seemed|induced|,|, (r_nsubj) participates_9\VBZ|NONE (l_prep) In_0\IN|synthase|in|seemed|induced|,|, (l_pobj) hyperalgesia_4\NN|NONE
D009569_D006930 NONE NO_7\DT|inducible (r_compound) synthase_8\NN|In|in|seemed|induced|,|, (r_nsubj) participates_9\VBZ|NONE (l_advcl) induced_20\VBN|synthase|In|in|seemed|,|, (l_dobj) hyperalgesia_21\NN|in|whereas|
D009569_D006930 NONE NO_27\DT|neuronal|synthase (r_det) pathway_29\NN|to (r_dobj) activate_25\VB|bradykinin|. (r_xcomp) seemed_23\VBD|synthase|In|in|induced|,|, (r_conj) participates_9\VBZ|NONE (l_prep) In_0\IN|synthase|in|seemed|induced|,|, (l_pobj) hyperalgesia_4\NN|NONE
D009569_D006930 NONE NO_27\DT|neuronal|synthase (r_det) pathway_29\NN|to (r_dobj) activate_25\VB|bradykinin|. (r_xcomp) seemed_23\VBD|synthase|In|in|induced|,|, (r_conj) participates_9\VBZ|NONE (l_advcl) induced_20\VBN|synthase|In|in|seemed|,|, (l_dobj) hyperalgesia_21\NN|in|whereas|
D013311_D003929 CID streptozotocin_11\NNS|and|receptors|Bradykinin|and|inhibitors|in (r_conj) antagonists_2\NNS|hyperalgesia|. (r_nsubj) induced_12\VBD|NONE (l_dobj) hyperalgesia_13\NN|.|antagonists (l_prep) in_14\IN|NONE (l_pobj) chemotherapy_15\NN|NONE (l_conj) model_20\NN|and (l_compound) rat_19\NN|diabetic (l_compound) neuropathy_18\NN|NONE
D009569_D009437 NONE NO_12\DT|synthase (r_det) inhibitors_14\NNS|and|receptor (r_conj) antagonists_10\NNS|NONE (r_dobj) bradykinin_8\NN|NONE (r_pobj) of_7\IN|small (r_prep) doses_6\NNS|NONE (r_pobj) of_4\IN|concomitant (r_prep) administration_3\NN|effective|in|,|Therefore|,|.|can (r_nsubj) be_16\VB|NONE (l_acomp) effective_17\JJ|in|,|Therefore|,|.|administration|can (l_prep) in_18\IN|NONE (l_pobj) alleviation_19\NN|NONE (l_prep) of_20\IN|NONE (l_pobj) pain_22\NN|NONE
D013311_D006930 CID streptozotocin_11\NNS|and|receptors|Bradykinin|and|inhibitors|in (r_conj) antagonists_2\NNS|hyperalgesia|. (r_nsubj) induced_12\VBD|NONE (l_dobj) hyperalgesia_13\NN|.|antagonists
D013311_D006930 CID streptozotocin_1\JJ| (r_npadvmod) induced_3\VBN|NONE (r_amod) hyperalgesia_4\NN|NONE
D013311_D006930 CID streptozotocin_1\JJ| (r_npadvmod) induced_3\VBN|NONE (r_amod) hyperalgesia_4\NN|NONE (r_pobj) In_0\IN|synthase|in|seemed|induced|,|, (r_prep) participates_9\VBZ|NONE (l_advcl) induced_20\VBN|synthase|In|in|seemed|,|, (l_dobj) hyperalgesia_21\NN|in|whereas|
D014750_D006930 CID vincristine_9\NN|NONE (r_pobj) in_8\IN|streptozotocin|and|receptors|Bradykinin|and|inhibitors (r_prep) antagonists_2\NNS|hyperalgesia|. (r_nsubj) induced_12\VBD|NONE (l_dobj) hyperalgesia_13\NN|.|antagonists
D014750_D006930 CID vincristine_26\NN|NONE (r_pobj) by_25\IN|NONE (r_agent) produced_24\VBN|NONE (r_acl) hyperalgesia_23\NN|NONE
D014750_D006930 CID vincristine_18\NN|NONE (r_pobj) in_17\IN|hyperalgesia|whereas| (r_prep) induced_20\VBN|synthase|In|in|seemed|,|, (r_advcl) participates_9\VBZ|NONE (l_prep) In_0\IN|synthase|in|seemed|induced|,|, (l_pobj) hyperalgesia_4\NN|NONE
D014750_D006930 CID vincristine_18\NN|NONE (r_pobj) in_17\IN|hyperalgesia|whereas| (r_prep) induced_20\VBN|synthase|In|in|seemed|,|, (l_dobj) hyperalgesia_21\NN|in|whereas|
D009569_D003929 NONE oxide_5\NN|nitric (r_compound) synthase_6\NN|NONE (r_compound) inhibitors_7\NNS|streptozotocin|and|receptors|Bradykinin|and|in (r_conj) antagonists_2\NNS|hyperalgesia|. (r_nsubj) induced_12\VBD|NONE (l_dobj) hyperalgesia_13\NN|.|antagonists (l_prep) in_14\IN|NONE (l_pobj) chemotherapy_15\NN|NONE (l_conj) model_20\NN|and (l_compound) rat_19\NN|diabetic (l_compound) neuropathy_18\NN|NONE
D001920_D006930 NONE Bradykinin_0\NN|streptozotocin|and|receptors|and|inhibitors|in (r_compound) antagonists_2\NNS|hyperalgesia|. (r_nsubj) induced_12\VBD|NONE (l_dobj) hyperalgesia_13\NN|.|antagonists
D001920_D006930 NONE bradykinin_9\NN|NONE (r_compound) receptors_10\NNS|NONE (r_pobj) of_8\IN|and|but|synthase (r_prep) inhibition_7\NN|activity|that|hyperalgesia (r_nsubj) reduces_21\VBZ|results|. (l_dobj) hyperalgesia_23\NN|activity|that|inhibition
D001920_D006930 NONE bradykinin_19\NN|synthase|as|neuronal|NO (r_conj) activation_15\NN|and|NO|inducible (r_conj) synthase_10\NN|NONE (r_pobj) of_7\IN|both (r_prep) products_6\NNS|in|are|that (r_nsubjpass) involved_21\VBN|was|It|.|also (l_prep) in_22\IN|are|that|products (l_pobj) hyperalgesia_23\NN|NONE
D001920_D006930 NONE bradykinin_14\NN|NONE (r_pobj) of_13\IN|pronociceptive (r_prep) activity_12\NN|NONE (r_pobj) in_10\IN|synthase|In|seemed|induced|,|, (r_prep) participates_9\VBZ|NONE (l_prep) In_0\IN|synthase|in|seemed|induced|,|, (l_pobj) hyperalgesia_4\NN|NONE
D001920_D006930 NONE bradykinin_14\NN|NONE (r_pobj) of_13\IN|pronociceptive (r_prep) activity_12\NN|NONE (r_pobj) in_10\IN|synthase|In|seemed|induced|,|, (r_prep) participates_9\VBZ|NONE (l_advcl) induced_20\VBN|synthase|In|in|seemed|,|, (l_dobj) hyperalgesia_21\NN|in|whereas|
D001920_D006930 NONE bradykinin_22\NN|.|activate (r_nsubj) seemed_23\VBD|synthase|In|in|induced|,|, (r_conj) participates_9\VBZ|NONE (l_prep) In_0\IN|synthase|in|seemed|induced|,|, (l_pobj) hyperalgesia_4\NN|NONE
D001920_D006930 NONE bradykinin_22\NN|.|activate (r_nsubj) seemed_23\VBD|synthase|In|in|induced|,|, (r_conj) participates_9\VBZ|NONE (l_advcl) induced_20\VBN|synthase|In|in|seemed|,|, (l_dobj) hyperalgesia_21\NN|in|whereas|
D001920_D009437 NONE bradykinin_8\NN|NONE (r_pobj) of_7\IN|small (r_prep) doses_6\NNS|NONE (r_pobj) of_4\IN|concomitant (r_prep) administration_3\NN|effective|in|,|Therefore|,|.|can (r_nsubj) be_16\VB|NONE (l_acomp) effective_17\JJ|in|,|Therefore|,|.|administration|can (l_prep) in_18\IN|NONE (l_pobj) alleviation_19\NN|NONE (l_prep) of_20\IN|NONE (l_pobj) pain_22\NN|NONE
8410052
D019344_D001480 NONE lactate_10\NN|NONE (r_pobj) of_9\IN|at (r_prep) infusion_8\NN|by|or (r_pobj) by_7\IN|injury|was|. (r_agent) produced_6\VBN|NONE (l_nsubjpass) injury_1\NN|was|.|by (l_prep) in_2\IN|Focal (l_pobj) cortex_4\NN|NONE
D010862_D013226 CID pilocarpine_10\NN| (r_npadvmod) induced_12\VBN|prolonged (r_amod) status_13\NN|NONE (r_pobj) by_8\IN|.|were|Infarcts|epilepticus (r_agent) evoked_7\VBN|NONE (l_advmod) epilepticus_14\NN|.|by|were|Infarcts
D010862_D002544 CID pilocarpine_10\NN| (r_npadvmod) induced_12\VBN|prolonged (r_amod) status_13\NN|NONE (r_pobj) by_8\IN|.|were|Infarcts|epilepticus (r_agent) evoked_7\VBN|NONE (l_nsubjpass) Infarcts_0\NNS|.|by|were|epilepticus (l_prep) in_1\IN|NONE (l_pobj) reticulata_5\NNS|NONE
3962737
D000638_D056486 CID amiodarone_2\NN|NONE (r_pobj) of_1\IN|. (r_prep) Hepatotoxicity_0\NN|NONE
D000638_D056486 CID amiodarone_7\NN|NONE (r_compound) treatment_8\NN|due|with|A (r_appos) patient_1\NN|and|is|given|below (l_prep) with_2\IN|due|treatment|A (l_pobj) hepatitis_4\NN|NONE
D000638_D056486 CID amiodarone_7\NN|NONE (r_compound) treatment_8\NN|due|with|A (r_appos) patient_1\NN|and|is|given|below (r_nsubjpass) presented_10\VBN|NONE (l_conj) given_21\VBN|and|is|below|patient (l_nsubjpass) review_14\NN|is|. (l_prep) of_15\IN|a (l_pobj) hepatotoxicity_17\NN|NONE
D000638_D056486 CID amiodarone_19\NN|NONE (r_pobj) of_18\IN|the (r_prep) hepatotoxicity_17\NN|NONE (r_pobj) of_15\IN|a (r_prep) review_14\NN|is|. (r_nsubjpass) given_21\VBN|and|is|below|patient (r_conj) presented_10\VBN|NONE (l_nsubjpass) patient_1\NN|and|is|given|below (l_prep) with_2\IN|due|treatment|A (l_pobj) hepatitis_4\NN|NONE
D000638_D056486 CID amiodarone_19\NN|NONE (r_pobj) of_18\IN|the (r_prep) hepatotoxicity_17\NN|NONE
D000638_D056486 CID amiodarone_12\NN|including|,|, (r_compound) treatment_13\NN|NONE (r_pobj) to_11\IN|alterations (r_pcomp) due_10\IN|that|evidence|of (r_prep) exists_6\VBZ|is|.|It (l_prep) of_7\IN|that|due|evidence (l_pobj) injury_9\NN|NONE
D000638_D056486 CID amiodarone_12\NN|including|,|, (r_compound) treatment_13\NN|NONE (r_pobj) to_11\IN|alterations (r_pcomp) due_10\IN|that|evidence|of (l_pobj) alterations_18\NNS|to (l_acl) resembling_19\VBG|NONE (l_dobj) hepatitis_21\NN|NONE (l_appos) cirrhosis_27\NN|alcoholic|, (l_nmod) hepatitis_24\NN|cholestatic|of
D000638_D013610 NONE Amiodarone_0\NNP|has|in|.|effective (r_nsubj) proved_2\VBN|NONE (l_prep) in_5\IN|has|Amiodarone|.|effective (l_pobj) treatment_7\NN|NONE (l_prep) of_8\IN|the (l_pobj) tachyarrhythmias_12\NNS|NONE
D000638_D002779 CID amiodarone_7\NN|NONE (r_compound) treatment_8\NN|due|with|A (r_appos) patient_1\NN|and|is|given|below (l_prep) with_2\IN|due|treatment|A (l_pobj) hepatitis_4\NN|NONE
D000638_D002779 CID amiodarone_19\NN|NONE (r_pobj) of_18\IN|the (r_prep) hepatotoxicity_17\NN|NONE (r_pobj) of_15\IN|a (r_prep) review_14\NN|is|. (r_nsubjpass) given_21\VBN|and|is|below|patient (r_conj) presented_10\VBN|NONE (l_nsubjpass) patient_1\NN|and|is|given|below (l_prep) with_2\IN|due|treatment|A (l_pobj) hepatitis_4\NN|NONE
D000638_D002779 CID amiodarone_12\NN|including|,|, (r_compound) treatment_13\NN|NONE (r_pobj) to_11\IN|alterations (r_pcomp) due_10\IN|that|evidence|of (l_pobj) alterations_18\NNS|to (l_acl) resembling_19\VBG|NONE (l_dobj) hepatitis_21\NN|NONE (l_appos) cirrhosis_27\NN|alcoholic|, (l_nmod) hepatitis_24\NN|cholestatic|of
D000638_D005234 CID amiodarone_12\NN|including|,|, (r_compound) treatment_13\NN|NONE (l_prep) including_15\VBG|,|,|amiodarone (l_pobj) steatosis_16\NN|NONE
D000638_D006519 NONE amiodarone_12\NN|including|,|, (r_compound) treatment_13\NN|NONE (r_pobj) to_11\IN|alterations (r_pcomp) due_10\IN|that|evidence|of (l_pobj) alterations_18\NNS|to (l_acl) resembling_19\VBG|NONE (l_dobj) hepatitis_21\NN|NONE
D000638_D008103 CID amiodarone_12\NN|including|,|, (r_compound) treatment_13\NN|NONE (r_pobj) to_11\IN|alterations (r_pcomp) due_10\IN|that|evidence|of (l_pobj) alterations_18\NNS|to (l_acl) resembling_19\VBG|NONE (l_dobj) hepatitis_21\NN|NONE (l_appos) cirrhosis_27\NN|alcoholic|, (l_prep) of_28\IN|cholestatic|hepatitis (l_pobj) liver_30\NN|NONE
2054792
D004317_D005334 NONE adriamycin_2\NNS|NONE (r_pobj) of_1\IN|combined|. (r_prep) Effect_0\NN|NONE (l_acl) combined_3\VBN|of|. (l_prep) with_4\IN|on (l_pobj) hyperthermia_7\NN|NONE
D004317_D005334 NONE Adriamycin_3\NNP| (r_npadvmod) mediated_5\VBN|toxicities|antitumor|and (r_amod) activity_7\NN|NONE (l_conj) toxicities_11\NNS|mediated|antitumor|and (l_prep) by_12\IN|normal|tissue (l_pobj) hyperthermia_15\NN|NONE
D004317_D005334 NONE Adriamycin_13\NNP| (r_npadvmod) mediated_15\VBN|antitumor|and|both|effects (r_amod) activity_17\NN|.|hyperthermia (r_dobj) enhanced_11\VBD|NONE (l_nsubj) hyperthermia_2\NN|.|activity
D004317_D005334 NONE Adriamycin_7\NNP| (r_npadvmod) mediated_9\VBN|antitumor (r_amod) effect_11\NN|while|hyperthermia (r_dobj) enhances_6\VBZ|Thus|toxicity|and|eroded|,|is|also|,|, (l_nsubj) hyperthermia_5\NN|while|effect
D004317_D064420 NONE Adriamycin_3\NNP| (r_npadvmod) mediated_5\VBN|toxicities|antitumor|and (r_amod) activity_7\NN|NONE (l_conj) toxicities_11\NNS|mediated|antitumor|and
D004317_D064420 NONE Adriamycin_7\NNP| (r_npadvmod) mediated_9\VBN|antitumor (r_amod) effect_11\NN|while|hyperthermia (r_dobj) enhances_6\VBZ|Thus|toxicity|and|eroded|,|is|also|,|, (r_advcl) increased_18\VBN|NONE (l_nsubjpass) toxicity_15\NN|enhances|Thus|and|eroded|,|is|also|,|,
D004317_D009369 NONE adriamycin_2\NNS|NONE (r_pobj) of_1\IN|combined|. (r_prep) Effect_0\NN|NONE (l_acl) combined_3\VBN|of|. (l_prep) on_8\IN|with (l_pobj) tumor_9\NN|NONE
8996652
D005665_D006311 NONE furosemide_19\NN|particularly|and (r_conj) aminoglycosides_17\NNS|and|prolonged|a|,|dose (r_appos) administration_7\NN|NONE (r_pobj) to_4\IN|closely (r_prep) related_3\JJ|Ototoxicity|. (r_oprd) appeared_1\VBD|NONE (l_nsubj) Ototoxicity_0\NN|related|.
D005665_D006311 NONE furosemide_19\NN|particularly|and (r_conj) aminoglycosides_17\NNS|and|prolonged|a|,|dose (r_appos) administration_7\NN|NONE (l_conj) dose_11\NN|and|prolonged|a|,|aminoglycosides (l_prep) of_12\IN|total|higher (l_pobj) drugs_14\NNS|NONE (l_compound) ototoxic_13\JJ|NONE
D000617_D006311 NONE aminoglycosides_17\NNS|and|prolonged|a|,|dose (r_appos) administration_7\NN|NONE (r_pobj) to_4\IN|closely (r_prep) related_3\JJ|Ototoxicity|. (r_oprd) appeared_1\VBD|NONE (l_nsubj) Ototoxicity_0\NN|related|.
D000617_D006311 NONE aminoglycosides_17\NNS|and|prolonged|a|,|dose (r_appos) administration_7\NN|NONE (l_conj) dose_11\NN|and|prolonged|a|,|aminoglycosides (l_prep) of_12\IN|total|higher (l_pobj) drugs_14\NNS|NONE (l_compound) ototoxic_13\JJ|NONE
2422478
D015116_D020521 NONE 5,7-dihydroxytryptamine_53\CD|the|serotonin (r_appos) neurotoxin_52\NN|NONE (r_pobj) by_49\IN|was|injected (r_agent) abolished_48\VBN|h|and|.|In|hypotension (r_conj) caused_26\VBD|NONE (l_prep) In_0\IN|h|abolished|and|.|hypotension (l_pobj) rats_7\NNS|NONE (l_amod) prone_6\JJ|microinjection|,|hypertensive|, (l_npadvmod) stroke_4\NN|
D015116_D020521 NONE 5,7-DHT_55\NNP|NONE (r_appos) 5,7-dihydroxytryptamine_53\CD|the|serotonin (r_appos) neurotoxin_52\NN|NONE (r_pobj) by_49\IN|was|injected (r_agent) abolished_48\VBN|h|and|.|In|hypotension (r_conj) caused_26\VBD|NONE (l_prep) In_0\IN|h|abolished|and|.|hypotension (l_pobj) rats_7\NNS|NONE (l_amod) prone_6\JJ|microinjection|,|hypertensive|, (l_npadvmod) stroke_4\NN|
D015116_D007022 NONE 5,7-dihydroxytryptamine_53\CD|the|serotonin (r_appos) neurotoxin_52\NN|NONE (r_pobj) by_49\IN|was|injected (r_agent) abolished_48\VBN|h|and|.|In|hypotension (r_conj) caused_26\VBD|NONE (l_dobj) hypotension_29\NN|h|abolished|and|.|In
D015116_D007022 NONE 5,7-DHT_55\NNP|NONE (r_appos) 5,7-dihydroxytryptamine_53\CD|the|serotonin (r_appos) neurotoxin_52\NN|NONE (r_pobj) by_49\IN|was|injected (r_agent) abolished_48\VBN|h|and|.|In|hypotension (r_conj) caused_26\VBD|NONE (l_dobj) hypotension_29\NN|h|abolished|and|.|In
D015116_D007022 NONE 5,7-DHT_5\CD|NONE (r_pobj) of_4\IN|produce|intraspinal (r_prep) injection_3\NN|However|did|.|hypotension|,|not (r_nsubj) affect_23\VB|NONE (l_dobj) hypotension_25\NN|However|did|injection|.|,|not
D008750_D020521 NONE methyldopa_11\NN|NONE (r_pobj) of_10\IN|into (r_prep) microinjection_9\NN|prone|,|hypertensive|, (r_conj) rats_7\NNS|NONE (l_amod) prone_6\JJ|microinjection|,|hypertensive|, (l_npadvmod) stroke_4\NN|
D015116_D006973 NONE 5,7-dihydroxytryptamine_53\CD|the|serotonin (r_appos) neurotoxin_52\NN|NONE (r_pobj) by_49\IN|was|injected (r_agent) abolished_48\VBN|h|and|.|In|hypotension (r_conj) caused_26\VBD|NONE (l_prep) In_0\IN|h|abolished|and|.|hypotension (l_pobj) rats_7\NNS|NONE (l_amod) hypertensive_2\JJ|prone|microinjection|,|,
D015116_D006973 NONE 5,7-DHT_55\NNP|NONE (r_appos) 5,7-dihydroxytryptamine_53\CD|the|serotonin (r_appos) neurotoxin_52\NN|NONE (r_pobj) by_49\IN|was|injected (r_agent) abolished_48\VBN|h|and|.|In|hypotension (r_conj) caused_26\VBD|NONE (l_prep) In_0\IN|h|abolished|and|.|hypotension (l_pobj) rats_7\NNS|NONE (l_amod) hypertensive_2\JJ|prone|microinjection|,|,
D008750_D007022 CID methyldopa_13\NN|NONE (r_pobj) of_12\IN|hypotensive (r_prep) effect_11\NN|NONE (l_amod) hypotensive_10\JJ|of
D008750_D007022 CID methyldopa_10\NN|NONE (r_pobj) of_9\IN|onto (r_prep) microinjection_8\NN|response|that (r_nsubj) elicits_23\VBZ|have|experiments|. (l_dobj) response_26\NN|microinjection|that (l_amod) hypotensive_25\JJ|a|mediated
D008750_D007022 CID methyldopa_11\NN|NONE (r_pobj) of_10\IN|into (r_prep) microinjection_9\NN|prone|,|hypertensive|, (r_conj) rats_7\NNS|NONE (r_pobj) In_0\IN|h|abolished|and|.|hypotension (r_prep) caused_26\VBD|NONE (l_dobj) hypotension_29\NN|h|abolished|and|.|In
D008750_D007022 CID methyldopa_14\NN| (r_npadvmod) induced_16\VBN|a (r_amod) hypotension_17\NN|which|via
D008750_D007022 CID methyldopa_14\NN| (r_npadvmod) induced_16\VBN|a (r_amod) hypotension_17\NN|which|via (r_dobj) mediate_12\VBP|B|ventrolateral|the (r_relcl) cells_10\NNS|NONE (r_pobj) unlike_6\IN|cells|that|,|to|by|,|, (r_prep) contribute_30\VB|therefore|is|It|. (l_prep) to_31\IN|cells|that|unlike|,|by|,|, (l_pobj) action_34\NN|NONE (l_amod) hypotensive_33\JJ|of|the
D008750_D007022 CID methyldopa_36\NN|NONE (r_pobj) of_35\IN|the|hypotensive (r_prep) action_34\NN|NONE (r_pobj) to_31\IN|cells|that|unlike|,|by|,|, (r_prep) contribute_30\VB|therefore|is|It|. (l_prep) unlike_6\IN|cells|that|,|to|by|,|, (l_pobj) cells_10\NNS|NONE (l_relcl) mediate_12\VBP|B|ventrolateral|the (l_dobj) hypotension_17\NN|which|via
D008750_D007022 CID methyldopa_36\NN|NONE (r_pobj) of_35\IN|the|hypotensive (r_prep) action_34\NN|NONE (l_amod) hypotensive_33\JJ|of|the
D012701_D020521 NONE serotonin_19\NN|midline|cell|the|in (r_compound) group_21\NN|NONE (r_pobj) of_15\IN|the (r_prep) area_14\NN|NONE (r_pobj) into_12\IN|of (r_prep) microinjection_9\NN|prone|,|hypertensive|, (r_conj) rats_7\NNS|NONE (l_amod) prone_6\JJ|microinjection|,|hypertensive|, (l_npadvmod) stroke_4\NN|
D012701_D020521 NONE serotonin_51\NN|the|,dihydroxytryptamine (r_compound) neurotoxin_52\NN|NONE (r_pobj) by_49\IN|was|injected (r_agent) abolished_48\VBN|h|and|.|In|hypotension (r_conj) caused_26\VBD|NONE (l_prep) In_0\IN|h|abolished|and|.|hypotension (l_pobj) rats_7\NNS|NONE (l_amod) prone_6\JJ|microinjection|,|hypertensive|, (l_npadvmod) stroke_4\NN|
D008750_D006973 NONE methyldopa_11\NN|NONE (r_pobj) of_10\IN|into (r_prep) microinjection_9\NN|prone|,|hypertensive|, (r_conj) rats_7\NNS|NONE (l_amod) hypertensive_2\JJ|prone|microinjection|,|,
D012701_D007022 NONE serotonin_2\NN|in (r_compound) nerves_3\NNS|are|in|. (r_nsubjpass) involved_8\VBN|NONE (l_prep) in_9\IN|are|nerves|. (l_pobj) effect_11\NN|NONE (l_amod) hypotensive_10\JJ|of
D012701_D007022 NONE serotonin_18\NN|the (r_compound) neurons_19\NNS|NONE (r_pobj) of_15\IN|in|ventrolateral|the (r_prep) cells_14\NNS|NONE (r_pobj) onto_11\IN|of (r_prep) microinjection_8\NN|response|that (r_nsubj) elicits_23\VBZ|have|experiments|. (l_dobj) response_26\NN|microinjection|that (l_amod) hypotensive_25\JJ|a|mediated
D012701_D007022 NONE serotonin_19\NN|midline|cell|the|in (r_compound) group_21\NN|NONE (r_pobj) of_15\IN|the (r_prep) area_14\NN|NONE (r_pobj) into_12\IN|of (r_prep) microinjection_9\NN|prone|,|hypertensive|, (r_conj) rats_7\NNS|NONE (r_pobj) In_0\IN|h|abolished|and|.|hypotension (r_prep) caused_26\VBD|NONE (l_dobj) hypotension_29\NN|h|abolished|and|.|In
D012701_D007022 NONE serotonin_51\NN|the|,dihydroxytryptamine (r_compound) neurotoxin_52\NN|NONE (r_pobj) by_49\IN|was|injected (r_agent) abolished_48\VBN|h|and|.|In|hypotension (r_conj) caused_26\VBD|NONE (l_dobj) hypotension_29\NN|h|abolished|and|.|In
D012701_D007022 NONE serotonin_15\NN|in (r_compound) projections_16\NNS|only (r_dobj) descending_14\VBG|NONE (r_pcomp) of_12\IN|a|selective (r_prep) lesion_11\NN|to (r_dobj) produce_7\VB|of|intraspinal (r_relcl) injection_3\NN|However|did|.|hypotension|,|not (r_nsubj) affect_23\VB|NONE (l_dobj) hypotension_25\NN|However|did|injection|.|,|not
D012701_D007022 NONE serotonin_24\NN|the|in|B|midline (r_compound) cells_26\NNS|that|unlike|,|to|by|,|, (r_nsubj) contribute_30\VB|therefore|is|It|. (l_prep) unlike_6\IN|cells|that|,|to|by|,|, (l_pobj) cells_10\NNS|NONE (l_relcl) mediate_12\VBP|B|ventrolateral|the (l_dobj) hypotension_17\NN|which|via
D012701_D007022 NONE serotonin_24\NN|the|in|B|midline (r_compound) cells_26\NNS|that|unlike|,|to|by|,|, (r_nsubj) contribute_30\VB|therefore|is|It|. (l_prep) to_31\IN|cells|that|unlike|,|by|,|, (l_pobj) action_34\NN|NONE (l_amod) hypotensive_33\JJ|of|the
D012701_D006973 NONE serotonin_19\NN|midline|cell|the|in (r_compound) group_21\NN|NONE (r_pobj) of_15\IN|the (r_prep) area_14\NN|NONE (r_pobj) into_12\IN|of (r_prep) microinjection_9\NN|prone|,|hypertensive|, (r_conj) rats_7\NNS|NONE (l_amod) hypertensive_2\JJ|prone|microinjection|,|,
D012701_D006973 NONE serotonin_51\NN|the|,dihydroxytryptamine (r_compound) neurotoxin_52\NN|NONE (r_pobj) by_49\IN|was|injected (r_agent) abolished_48\VBN|h|and|.|In|hypotension (r_conj) caused_26\VBD|NONE (l_prep) In_0\IN|h|abolished|and|.|hypotension (l_pobj) rats_7\NNS|NONE (l_amod) hypertensive_2\JJ|prone|microinjection|,|,
8558192
C030852_D064420 NONE VNB_0\NNP|well|occurred|was|and (r_nsubjpass) tolerated_3\VBN|NONE (l_conj) occurred_13\VBD|well|VNB|was|and (l_nsubj) toxicity_12\NN|.|instances
C030852_D064420 NONE VNB_12\NNP|NONE (r_pobj) of_11\IN|in|further (r_prep) evaluation_10\NN|.|,|is|Given (r_nsubjpass) warranted_17\VBN|NONE (l_prep) Given_0\VBN|evaluation|.|,|is (l_pobj) profile_4\NN|NONE (l_conj) toxicity_7\NN|its|tolerance|and
D002945_D064420 NONE cisplatin_9\NN| (r_npadvmod) based_11\VBN|NONE (r_amod) chemotherapy_12\NN|NONE (r_pobj) with_8\IN|patients (r_prep) pretreated_7\VBN|assessable|. (r_csubj) were_13\VBD|NONE (l_acomp) assessable_14\JJ|pretreated|. (l_prep) for_15\IN|NONE (l_pobj) toxicity_16\NN|NONE
C030852_C562729 NONE vinorelbine_4\NN|NONE (r_pobj) of_3\IN|II|.|in (r_prep) trial_2\NN|NONE (l_prep) in_5\IN|II|.|of (l_pobj) carcinoma_10\NN|NONE
C030852_C562729 NONE vinorelbine_9\NN|NONE (r_pobj) of_8\IN|toxic (r_prep) effects_7\NNS|response|administered|and|the (r_conj) rate_4\NN|.|To (l_acl) administered_13\VBN|response|and|the|effects (l_prep) as_14\IN|NONE (l_pobj) agent_17\NN|NONE (l_prep) in_18\IN|a|single (l_pobj) carcinoma_23\NN|NONE
C030852_C562729 NONE VNB_11\NNP|)|( (r_appos) vinorelbine_9\NN|NONE (r_pobj) of_8\IN|toxic (r_prep) effects_7\NNS|response|administered|and|the (r_conj) rate_4\NN|.|To (l_acl) administered_13\VBN|response|and|the|effects (l_prep) as_14\IN|NONE (l_pobj) agent_17\NN|NONE (l_prep) in_18\IN|a|single (l_pobj) carcinoma_23\NN|NONE
C030852_C562729 NONE VNB_4\NNP|that|agent (r_nsubj) is_5\VBZ|data|. (l_attr) agent_8\NN|VNB|that (l_prep) in_9\IN|active|an (l_pobj) carcinoma_14\NN|NONE
19135948
C107135_D015470 NONE everolimus_6\NN|NONE (r_pobj) of_5\IN|in|with|a (r_prep) combination_4\NN|NONE (l_prep) with_19\IN|in|of|a (l_pobj) syndrome_22\NN|NONE (l_appos) leukemia_33\NN|myelodysplastic|undergoing|either
C107135_D015470 NONE everolimus_6\NN|NONE (r_pobj) of_5\IN|in|with|a (r_prep) combination_4\NN|NONE (l_prep) with_19\IN|in|of|a (l_pobj) syndrome_22\NN|NONE (l_appos) leukemia_33\NN|myelodysplastic|undergoing|either (l_appos) AML_35\NNP|MDS|(|(|myeloid|)
D016559_D009190 NONE tacrolimus_8\NN|and (r_conj) everolimus_6\NN|NONE (r_pobj) of_5\IN|in|with|a (r_prep) combination_4\NN|NONE (l_prep) with_19\IN|in|of|a (l_pobj) syndrome_22\NN|NONE
D016559_D009190 NONE tacrolimus_8\NN|and (r_conj) everolimus_6\NN|NONE (r_pobj) of_5\IN|in|with|a (r_prep) combination_4\NN|NONE (l_prep) with_19\IN|in|of|a (l_pobj) syndrome_22\NN|NONE (l_appos) leukemia_33\NN|myelodysplastic|undergoing|either (l_nmod) MDS_24\NNP|(|(|myeloid|)|AML
C107135_D006086 NONE everolimus_8\NN|NONE (r_pobj) with_7\IN|Graft|disease (r_prep) prophylaxis_6\VBN|microangiopathy|with|is|.|and (l_compound) disease_5\NN|with|Graft
C107135_D006504 CID everolimus_8\NN|NONE (r_pobj) with_7\IN|Graft|disease (r_prep) prophylaxis_6\VBN|microangiopathy|with|is|.|and (r_nsubjpass) associated_12\VBN|NONE (l_prep) with_13\IN|microangiopathy|is|prophylaxis|.|and (l_pobj) incidence_16\NN|NONE (l_prep) of_17\IN|high|a (l_pobj) syndrome_20\NN|NONE
D016559_D006086 NONE tacrolimus_10\NN|and (r_conj) everolimus_8\NN|NONE (r_pobj) with_7\IN|Graft|disease (r_prep) prophylaxis_6\VBN|microangiopathy|with|is|.|and (l_compound) disease_5\NN|with|Graft
C107135_D014652 CID everolimus_8\NN|NONE (r_pobj) with_7\IN|Graft|disease (r_prep) prophylaxis_6\VBN|microangiopathy|with|is|.|and (r_nsubjpass) associated_12\VBN|NONE (l_conj) microangiopathy_22\NN|with|is|prophylaxis|.|and
D016559_D014652 CID tacrolimus_10\NN|and (r_conj) everolimus_8\NN|NONE (r_pobj) with_7\IN|Graft|disease (r_prep) prophylaxis_6\VBN|microangiopathy|with|is|.|and (r_nsubjpass) associated_12\VBN|NONE (l_conj) microangiopathy_22\NN|with|is|prophylaxis|.|and
D016559_D015470 NONE tacrolimus_8\NN|and (r_conj) everolimus_6\NN|NONE (r_pobj) of_5\IN|in|with|a (r_prep) combination_4\NN|NONE (l_prep) with_19\IN|in|of|a (l_pobj) syndrome_22\NN|NONE (l_appos) leukemia_33\NN|myelodysplastic|undergoing|either
D016559_D015470 NONE tacrolimus_8\NN|and (r_conj) everolimus_6\NN|NONE (r_pobj) of_5\IN|in|with|a (r_prep) combination_4\NN|NONE (l_prep) with_19\IN|in|of|a (l_pobj) syndrome_22\NN|NONE (l_appos) leukemia_33\NN|myelodysplastic|undergoing|either (l_appos) AML_35\NNP|MDS|(|(|myeloid|)
D016559_D006504 CID tacrolimus_10\NN|and (r_conj) everolimus_8\NN|NONE (r_pobj) with_7\IN|Graft|disease (r_prep) prophylaxis_6\VBN|microangiopathy|with|is|.|and (r_nsubjpass) associated_12\VBN|NONE (l_prep) with_13\IN|microangiopathy|is|prophylaxis|.|and (l_pobj) incidence_16\NN|NONE (l_prep) of_17\IN|high|a (l_pobj) syndrome_20\NN|NONE
C107135_D009190 NONE everolimus_6\NN|NONE (r_pobj) of_5\IN|in|with|a (r_prep) combination_4\NN|NONE (l_prep) with_19\IN|in|of|a (l_pobj) syndrome_22\NN|NONE
C107135_D009190 NONE everolimus_6\NN|NONE (r_pobj) of_5\IN|in|with|a (r_prep) combination_4\NN|NONE (l_prep) with_19\IN|in|of|a (l_pobj) syndrome_22\NN|NONE (l_appos) leukemia_33\NN|myelodysplastic|undergoing|either (l_nmod) MDS_24\NNP|(|(|myeloid|)|AML
D008727_D006086 NONE methotrexate_5\NNP|NONE (r_pobj) with_4\IN|NONE (r_prep) combined_3\VBN|calcineurin|A (r_acl) inhibitor_2\NN|prophylaxis|. (r_nsubj) is_6\VBZ|NONE (l_attr) prophylaxis_9\NN|.|inhibitor (l_prep) for_10\IN|after|the|standard (l_pobj) disease_16\NN|NONE
D008727_D006086 NONE methotrexate_5\NNP|NONE (r_pobj) with_4\IN|NONE (r_prep) combined_3\VBN|calcineurin|A (r_acl) inhibitor_2\NN|prophylaxis|. (r_nsubj) is_6\VBZ|NONE (l_attr) prophylaxis_9\NN|.|inhibitor (l_prep) for_10\IN|after|the|standard (l_pobj) disease_16\NN|NONE (l_appos) GVHD_18\NNP|)|(|graft
9660111
D003000_D010554 NONE clonidine_28\NN|NONE (r_pobj) by_27\IN|in (r_agent) evoked_26\VBN|the (r_acl) aggressiveness_25\NN|in|as
D010656_D010554 NONE phenylephrine_7\NN|NONE (l_acl) evaluated_15\VBN|given (l_conj) aggressiveness_25\NN|in|as
D012110_D007035 CID reserpine_13\NN|the (r_compound) hypothermia_14\VBN|in|In|and|does|TRI|not|potentiate|.
D003913_D006948 CID amphetamine_13\NN|NONE (r_pobj) by_10\IN|NONE (r_agent) induced_9\VBN|the|locomotor (r_acl) hyperactivity_8\NN|.|TRI
D019257_D006948 CID quinpirole_15\NN||,|d (r_conj) amphetamine_13\NN|NONE (r_pobj) by_10\IN|NONE (r_agent) induced_9\VBN|the|locomotor (r_acl) hyperactivity_8\NN|.|TRI
D014299_D006948 CID TRI_0\NNP|hyperactivity|. (r_nsubj) increases_5\VBZ|NONE (l_dobj) hyperactivity_8\NN|.|TRI
D006916_D007035 NONE 5-hydroxytryptophan_22\JJ|the (r_poss) head_23\NN|in (r_compound) twitches_24\NNS|not|does (r_dobj) potentiate_20\VB|in|In|and|does|TRI|not|hypothermia|. (r_conj) antagonize_11\VB|NONE (l_dobj) hypothermia_14\VBN|in|In|and|does|TRI|not|potentiate|.
D014299_D007035 NONE TRI_4\NNP|in|In|and|does|not|potentiate|hypothermia|. (r_nsubj) antagonize_11\VB|NONE (l_dobj) hypothermia_14\VBN|in|In|and|does|TRI|not|potentiate|.
D004298_D006948 NONE dopamine_24\NN|effects|and (r_compound) D2_25\NN|)|)|(|hydroxy| (r_appos) dipropyloaminotetralin_22\NN|+|(|and (r_conj) quinpirole_15\NN||,|d (r_conj) amphetamine_13\NN|NONE (r_pobj) by_10\IN|NONE (r_agent) induced_9\VBN|the|locomotor (r_acl) hyperactivity_8\NN|.|TRI
8421099
D015282_D042882 CID octreotide_12\NN|(|)|somatostatin (r_appos) analog_10\NN|NONE (r_pobj) of_8\IN|the|term|on (r_prep) effects_7\NNS|NONE (l_prep) on_14\IN|the|of|term (l_pobj) function_16\NN|NONE (l_conj) formation_19\NN|and|in|gallbladder (l_compound) gallstone_18\NN|NONE
D015282_D042882 CID octreotide_3\NN|NONE (r_pobj) with_2\IN|NONE (r_prep) treatment_1\NN|NONE (r_pobj) During_0\IN|sludge|patients|.|had|, (r_prep) developed_7\VBD|NONE (l_conj) had_11\VBD|sludge|patients|During|.|, (l_dobj) gallstones_12\NNS|,||and|developed
D015282_D042882 CID octreotide_3\NN|NONE (r_pobj) of_2\IN|in (r_prep) withdrawal_1\NN|NONE (l_prep) in_4\IN|of (l_pobj) patients_6\NNS|NONE (l_prep) without_7\IN| (l_pobj) gallstones_8\NNS|NONE
D015282_D042882 CID octreotide_25\NN|in (r_compound) therapy_26\NN|NONE (r_pobj) during_24\IN|the|of|successive (r_prep) formation_15\NN|NONE (l_prep) of_16\IN|the|during|successive (l_pobj) sludge_18\NN|NONE (l_conj) gallstones_20\NNS|bile|,
D015282_D000172 NONE octreotide_12\NN|(|)|somatostatin (r_appos) analog_10\NN|NONE (r_pobj) of_8\IN|the|term|on (r_prep) effects_7\NNS|NONE (l_prep) on_14\IN|the|of|term (l_pobj) function_16\NN|NONE (l_prep) in_20\IN|formation|and|gallbladder (l_pobj) patients_23\NNS|NONE (l_compound) acromegalic_22\JJ|Chinese
D015282_D000172 NONE octreotide_26\NN|somatostatin|the (r_appos) analog_25\NN|NONE (r_pobj) of_22\IN|sc (r_prep) injection_21\NN|NONE (r_pobj) with_19\IN|for|day|in (r_prep) treated_18\VBN|with||Chinese (r_acl) patients_14\NNS|NONE (l_prep) with_15\IN||Chinese|treated (l_pobj) acromegaly_17\NNS|NONE
D015282_D000172 NONE octreotide_25\NN|in (r_compound) therapy_26\NN|NONE (l_prep) in_27\IN|octreotide (l_pobj) patients_30\NNS|NONE (l_compound) acromegalic_29\JJ|Chinese
D015282_D000172 NONE octreotide_16\NN|of|term (r_compound) therapy_17\NN|NONE (l_prep) of_18\IN|octreotide|term (l_pobj) patients_20\NNS|NONE (l_compound) acromegalic_19\JJ|NONE
D015282_D041881 CID octreotide_3\NN|NONE (r_pobj) with_2\IN|NONE (r_prep) treatment_1\NN|NONE (r_pobj) During_0\IN|sludge|patients|.|had|, (r_prep) developed_7\VBD|NONE (l_conj) had_11\VBD|sludge|patients|During|.|, (l_conj) developed_16\VBD|,||and|gallstones (l_dobj) cholecystitis_18\NN|requiring|
D015282_D002764 NONE octreotide_25\NN|in (r_compound) therapy_26\NN|NONE (r_pobj) during_24\IN|the|of|successive (r_prep) formation_15\NN|NONE (l_prep) of_16\IN|the|during|successive (l_pobj) sludge_18\NN|NONE (l_conj) gallstones_20\NNS|bile|, (l_conj) cholecystitis_23\NN|,|and
10457883
12639165
D013988_D007565 CID ticlopidine_7\NN|NONE (r_pobj) with_6\IN|NONE (r_prep) treatment_5\NN|NONE (r_pobj) following_4\VBG|jaundice|showed|patients|and|. (r_prep) developed_2\VBD|NONE (l_dobj) jaundice_3\NN|following|showed|patients|and|.
D013988_D056486 CID Ticlopidine_0\NNP| (r_npadvmod) induced_2\VBN|.|cholestatic (r_amod) hepatitis_4\NN|NONE
D013988_D056486 CID ticlopidine_5\NN| (r_npadvmod) induced_7\VBN|cholestatic (r_amod) hepatitis_9\NN|NONE
D013988_D056486 CID ticlopidine_8\NN|following (r_advmod) receiving_7\VBG|NONE (r_pcomp) after_6\IN|patients|hepatitis|,|with|. (r_prep) developed_2\VBD|NONE (l_dobj) hepatitis_5\NN|patients|,|with|after|.
D013988_D056486 CID ticlopidine_10\NN|a|of|rare (r_advmod) complication_5\NN|hepatitis (r_attr) is_2\VBZ|been|.|but|cases|;|have|few (l_nsubj) hepatitis_1\NN|complication
D013988_D056486 CID ticlopidine_7\NN|NONE (r_pobj) with_6\IN|NONE (r_prep) treatment_5\NN|NONE (r_pobj) following_4\VBG|jaundice|showed|patients|and|. (r_prep) developed_2\VBD|NONE (l_conj) showed_9\VBD|following|jaundice|patients|and|. (l_dobj) characteristics_14\NNS|NONE (l_prep) of_15\IN|the|,|clinical|resolved (l_pobj) hepatitis_17\NN|NONE
D013988_D056486 CID ticlopidine_8\NN|NONE (r_pobj) of_7\IN|adverse|be|a|rare (r_prep) effect_6\NN|hepatitis|. (r_attr) is_2\VBZ|NONE (l_nsubj) hepatitis_1\NN|.|effect
D013988_D002779 CID Ticlopidine_0\NNP| (r_npadvmod) induced_2\VBN|.|cholestatic (r_amod) hepatitis_4\NN|NONE
D013988_D002779 CID ticlopidine_5\NN| (r_npadvmod) induced_7\VBN|cholestatic (r_amod) hepatitis_9\NN|NONE
D013988_D002779 CID ticlopidine_8\NN|following (r_advmod) receiving_7\VBG|NONE (r_pcomp) after_6\IN|patients|hepatitis|,|with|. (r_prep) developed_2\VBD|NONE (l_dobj) hepatitis_5\NN|patients|,|with|after|.
D013988_D002779 CID ticlopidine_10\NN|a|of|rare (r_advmod) complication_5\NN|hepatitis (r_attr) is_2\VBZ|been|.|but|cases|;|have|few (l_nsubj) hepatitis_1\NN|complication
D013988_D002779 CID ticlopidine_7\NN|NONE (r_pobj) with_6\IN|NONE (r_prep) treatment_5\NN|NONE (r_pobj) following_4\VBG|jaundice|showed|patients|and|. (r_prep) developed_2\VBD|NONE (l_conj) showed_9\VBD|following|jaundice|patients|and|. (l_dobj) characteristics_14\NNS|NONE (l_prep) of_15\IN|the|,|clinical|resolved (l_pobj) hepatitis_17\NN|NONE
D013988_D002779 CID ticlopidine_4\NN| (r_npadvmod) induced_6\VBN|this (r_amod) cholestasis_7\NN|NONE
D013988_D002779 CID ticlopidine_8\NN|NONE (r_pobj) of_7\IN|adverse|be|a|rare (r_prep) effect_6\NN|hepatitis|. (r_attr) is_2\VBZ|NONE (l_nsubj) hepatitis_1\NN|.|effect
7007443
D000082_D017114 CID paracetamol_26\JJ|NONE (r_compound) overdose_27\NN|NONE (r_pobj) after_25\IN|who|failure (r_prep) survived_21\VBD|NONE (l_dobj) failure_24\NN|after|who
D000082_D017114 CID paracetamol_26\JJ|NONE (r_compound) overdose_27\NN|NONE (r_pobj) after_25\IN|who|failure (r_prep) survived_21\VBD|NONE (r_relcl) those_19\DT|NONE (r_pobj) in_18\IN|nearly (r_prep) fourfold_17\RB|who|and (r_conj) died_14\VBD|NONE (r_relcl) patients_12\NNS|NONE (r_pobj) in_11\IN|,|tenfold|.|increased|was|activity (r_prep) increased_8\VBN|NONE (l_advcl) increased_32\VBN|,|tenfold|.|in|was|activity (l_prep) in_34\IN|whereas|survived|activities|were|equally (l_pobj) patients_35\NNS|NONE (l_prep) with_36\IN|NONE (l_pobj) failure_39\NN|NONE
D000082_D006525 NONE paracetamol_26\JJ|NONE (r_compound) overdose_27\NN|NONE (r_pobj) after_25\IN|who|failure (r_prep) survived_21\VBD|NONE (r_relcl) those_19\DT|NONE (r_pobj) in_18\IN|nearly (r_prep) fourfold_17\RB|who|and (r_conj) died_14\VBD|NONE (r_relcl) patients_12\NNS|NONE (r_pobj) in_11\IN|,|tenfold|.|increased|was|activity (r_prep) increased_8\VBN|NONE (l_advcl) increased_32\VBN|,|tenfold|.|in|was|activity (l_prep) in_34\IN|whereas|survived|activities|were|equally (l_pobj) patients_35\NNS|NONE (l_prep) with_36\IN|NONE (l_pobj) failure_39\NN|NONE (l_amod) due_40\IN|hepatic|fulminant (l_pcomp) to_41\IN|NONE (l_pobj) hepatitis_43\NN|NONE
D000082_D062787 NONE paracetamol_26\JJ|NONE (r_compound) overdose_27\NN|NONE
18703024
D006220_D002375 CID haloperidol_3\NN| (r_npadvmod) induced_5\VBN|or|locomotion (r_amod) catalepsy_6\NN|NONE
D016291_D002375 NONE MK-801-induced_8\JJ|NONE (r_compound) locomotion_9\NN|or|induced (r_conj) catalepsy_6\NN|NONE
6634932
C002616_D017180 NONE UM-272_0\NNP|N|N|)|agent|(|,||, (r_punct) dimethylpropranolol_6\NNP|was|,|.|sublingually|to (r_nsubjpass) administered_15\VBN|NONE (l_prep) to_17\IN|was|dimethylpropranolol|,|.|sublingually (l_pobj) dogs_18\NNS|NONE (l_prep) with_19\IN|NONE (l_pobj) tachycardias_24\NNS|NONE
C002616_D017180 NONE dimethylpropranolol_6\NNP|was|,|.|sublingually|to (r_nsubjpass) administered_15\VBN|NONE (l_prep) to_17\IN|was|dimethylpropranolol|,|.|sublingually (l_pobj) dogs_18\NNS|NONE (l_prep) with_19\IN|NONE (l_pobj) tachycardias_24\NNS|NONE
C002616_D017180 NONE UM-272_1\NNP|Sublingual|tachycardia|.|sinus (r_punct) converted_2\VBD|NONE (l_dobj) tachycardia_4\NN|Sublingual|.|sinus|UM
D010042_D017180 CID ouabain_20\RB| (r_npadvmod) induced_22\VBN|ventricular (r_amod) tachycardias_24\NNS|NONE
11890511
1255900
D006493_D013924 NONE heparin_8\JJ|NONE (r_compound) therapy_9\NN|NONE (r_pobj) of_7\IN|for|the (r_prep) initiation_6\NN|NONE (l_prep) for_10\IN|of|the (l_pobj) thrombophlebitis_13\NN|NONE
16192988
D008694_D001523 CID Methamphetamine_0\NN|alterations|. (r_nsubj) causes_1\VBZ|NONE (l_dobj) alterations_2\NNS|Methamphetamine|. (l_relcl) display_16\VBP|in (l_dobj) aggressiveness_18\NN|that
D008694_D001523 CID methamphetamine_18\NN|NONE (r_pobj) in_17\IN|NONE (r_prep) common_16\JJ|NONE (r_acomp) are_15\VBP|,|and|have|behaviors|.|in|been (r_conj) reported_4\VBN|NONE (l_nsubjpass) behaviors_1\NNS|are|,|and|have|.|in|been
D008694_D001523 CID methamphetamine_18\NN|NONE (r_pobj) in_17\IN|NONE (r_prep) common_16\JJ|NONE (r_acomp) are_15\VBP|,|and|have|behaviors|.|in|been (r_conj) reported_4\VBN|NONE (l_prep) in_5\IN|are|,|and|have|behaviors|.|been (l_pobj) patients_6\NNS|NONE (l_relcl) suffer_8\VBP|NONE (l_prep) from_9\IN|who (l_pobj) disorders_12\NNS|NONE
D008694_D001523 CID METH_20\NN|NONE (r_nmod) abusers_22\NNS|( (r_appos) methamphetamine_18\NN|NONE (r_pobj) in_17\IN|NONE (r_prep) common_16\JJ|NONE (r_acomp) are_15\VBP|,|and|have|behaviors|.|in|been (r_conj) reported_4\VBN|NONE (l_nsubjpass) behaviors_1\NNS|are|,|and|have|.|in|been
D008694_D001523 CID METH_20\NN|NONE (r_nmod) abusers_22\NNS|( (r_appos) methamphetamine_18\NN|NONE (r_pobj) in_17\IN|NONE (r_prep) common_16\JJ|NONE (r_acomp) are_15\VBP|,|and|have|behaviors|.|in|been (r_conj) reported_4\VBN|NONE (l_prep) in_5\IN|are|,|and|have|behaviors|.|been (l_pobj) patients_6\NNS|NONE (l_relcl) suffer_8\VBP|NONE (l_prep) from_9\IN|who (l_pobj) disorders_12\NNS|NONE
D008694_D001523 CID METH_13\NNP|NONE (r_pobj) of_12\IN|multiple|)|single|( (r_prep) injections_11\NNS|significantly|aggressiveness|that (r_nsubj) increased_15\VBD|.|,|Herein|we (l_dobj) aggressiveness_16\NN|injections|significantly|that
D008694_D001523 CID METH_8\NNP| (r_npadvmod) induced_10\VBN|NONE (r_amod) hyperactivity_11\NN|NONE (r_pobj) to_7\IN|NONE (r_prep) secondary_6\JJ|.|increase|not (r_acomp) was_4\VBD|NONE (l_nsubj) increase_1\NN|.|secondary|not (l_prep) in_2\IN|This (l_pobj) aggressiveness_3\NN|NONE
D008694_D006948 NONE METH_8\NNP| (r_npadvmod) induced_10\VBN|NONE (r_amod) hyperactivity_11\NN|NONE
2528969
16181582
D014635_D004827 NONE Valproate_0\NNP| (r_npadvmod) induced_2\VBN|NONE (r_amod) encephalopathy_3\NN|syndrome|. (r_nsubj) is_4\VBZ|NONE (l_attr) syndrome_7\NN|encephalopathy|. (l_relcl) manifest_10\VB|rare|a (l_prep) in_11\RP|may|that (l_pobj) individuals_15\NNS|NONE (l_amod) epileptic_14\JJ|normal
D014635_D001927 CID Valproate_0\NNP| (r_npadvmod) induced_2\VBN|. (r_amod) encephalopathy_3\NN|NONE
D014635_D001927 CID Valproate_0\NNP| (r_npadvmod) induced_2\VBN|NONE (r_amod) encephalopathy_3\NN|syndrome|.
D014635_D001927 CID valproate_3\NN| (r_npadvmod) induced_5\VBN|NONE (r_amod) encephalopathy_6\NN|NONE
15673851
D009020_D020760 NONE morphine_23\NN|NONE (r_pobj) by_21\IN|after (r_agent) induced_20\VBN|of (l_prep) after_24\IN|by (l_pobj) interval_27\NN|NONE (l_prep) of_28\IN|noninjurious|a (l_pobj) ischemia_31\NN|NONE
D016202_D020760 NONE aspartate_10\NN|spinal (r_compound) receptors_11\NNS|NONE (r_pobj) of_2\IN|The (r_prep) activation_1\NN|may|.|to (r_nsubj) contribute_13\VB|NONE (l_prep) to_14\IN|may|activation|. (l_pobj) degeneration_15\NN|NONE (l_acl) induced_20\VBN|of (l_prep) after_24\IN|by (l_pobj) interval_27\NN|NONE (l_prep) of_28\IN|noninjurious|a (l_pobj) ischemia_31\NN|NONE
D016202_D020760 NONE NMDA_15\NNP|receptor (r_compound) activation_17\NN|NONE (r_pobj) via_14\IN|cord (r_prep) ischemia_13\NN|NONE
D016291_D020336 NONE MK-801_8\NNP|NONE (r_punct) (_9\-LRB-|)|on| (r_punct) mug_11\NN|,|effect|we|.|Second (l_prep) on_13\IN|)|(| (l_pobj) changes_16\NNS|NONE (l_prep) after_21\IN|in|the|histopathologic (l_pobj) paraparesis_26\NN|NONE
D016291_D020336 NONE MK-801_1\NNP|.|significantly|IT|after|number|compared (r_punct) reduced_3\VBD|NONE (l_prep) after_13\IN|.|significantly|IT|MK|number|compared (l_pobj) paraparesis_18\NN|NONE
D016202_D020336 NONE NMDA_21\NNP|receptor (r_compound) activation_23\NN|NONE (r_pobj) in_20\IN|is|which (r_prep) involved_19\VBN|,|CSF (r_relcl) glutamate_15\NN|NONE (r_pobj) in_13\IN|a|concomitant (r_prep) increase_12\NN|NONE (r_pobj) with_9\IN|morphine|that|paraparesis (r_prep) induces_6\VBZ|data|. (l_dobj) paraparesis_8\NN|morphine|that|with
D016202_D001157 NONE aspartate_20\NNP|(|NMDA|) (r_nmod) receptors_24\NNS|NONE (r_pobj) of_13\IN|NONE (r_prep) activation_12\NN|and|motor|spinal (r_conj) neurons_10\NNS|NONE (r_pobj) of_7\IN|the|after|following (r_prep) degeneration_6\NN|NONE (l_prep) following_28\VBG|the|after|of (l_pobj) interval_31\NN|NONE (l_prep) of_32\IN|a|noninjurious (l_pobj) occlusion_34\NN|NONE
D016202_D001157 NONE NMDA_22\NNP|(|aspartate|) (r_nmod) receptors_24\NNS|NONE (r_pobj) of_13\IN|NONE (r_prep) activation_12\NN|and|motor|spinal (r_conj) neurons_10\NNS|NONE (r_pobj) of_7\IN|the|after|following (r_prep) degeneration_6\NN|NONE (l_prep) following_28\VBG|the|after|of (l_pobj) interval_31\NN|NONE (l_prep) of_32\IN|a|noninjurious (l_pobj) occlusion_34\NN|NONE
D018698_D020336 NONE glutamate_15\NN|NONE (r_pobj) in_13\IN|a|concomitant (r_prep) increase_12\NN|NONE (r_pobj) with_9\IN|morphine|that|paraparesis (r_prep) induces_6\VBZ|data|. (l_dobj) paraparesis_8\NN|morphine|that|with
D009020_D001157 NONE morphine_27\NN|NONE (r_pobj) after_25\IN|the|of|following (r_prep) degeneration_6\NN|NONE (l_prep) following_28\VBG|the|after|of (l_pobj) interval_31\NN|NONE (l_prep) of_32\IN|a|noninjurious (l_pobj) occlusion_34\NN|NONE
D016202_D020258 NONE NMDA_15\NNP|receptor (r_compound) activation_17\NN|NONE (r_pobj) via_14\IN|cord (r_prep) ischemia_13\NN|NONE (r_pobj) of_10\IN|the (r_prep) setting_9\NN|NONE (r_pobj) in_7\IN|that|neurotoxic|opioids|may (r_prep) be_5\VB|We|. (l_acomp) neurotoxic_6\JJ|in|that|opioids|may
D009020_D020336 CID morphine_22\NN| (r_npadvmod) induced_24\VBN|spastic (r_amod) paraparesis_26\NN|NONE
D009020_D020336 CID morphine_14\NN| (r_npadvmod) induced_16\VBN|spastic (r_amod) paraparesis_18\NN|NONE
D009020_D020336 CID morphine_5\NN|that|with|paraparesis (r_nsubj) induces_6\VBZ|data|. (l_dobj) paraparesis_8\NN|morphine|that|with
20067456
D017367_D012735 NONE inhibitor_16\NN|NONE (r_pobj) by_11\IN|NONE (r_agent) induced_10\VBN|male|sexual (r_acl) dysfunction_9\NN|NONE
D017367_D012735 NONE inhibitor_28\NN|NONE (r_pobj) by_23\IN|.|is|,|determine (r_agent) induced_22\VBN|NONE (l_csubj) determine_1\VB|.|is|,|by (l_dobj) safety_3\NN|To (l_prep) of_6\IN|efficacy|and|the (l_pobj) bupropion_8\NN|NONE (l_prep) on_15\IN|SR|adjunctive (l_pobj) dysfunction_18\NN|NONE
D017367_D012735 NONE inhibitor_28\NN|NONE (r_pobj) by_23\IN|.|is|,|determine (r_agent) induced_22\VBN|NONE (l_csubj) determine_1\VB|.|is|,|by (l_dobj) safety_3\NN|To (l_prep) of_6\IN|efficacy|and|the (l_pobj) bupropion_8\NN|NONE (l_prep) on_15\IN|SR|adjunctive (l_pobj) dysfunction_18\NN|NONE (l_appos) SD_20\NN|male|(|sexual|)
D017367_D012735 NONE inhibitor_28\NN|NONE (r_pobj) by_23\IN|.|is|,|determine (r_agent) induced_22\VBN|NONE (l_advcl) is_35\VBZ|.|,|by|determine (l_nsubj) SD_34\NN|as|have|effect
D017367_D012735 NONE SSRI_30\NNP|)|a|(|selective|serotonin|reuptake (r_appos) inhibitor_28\NN|NONE (r_pobj) by_23\IN|.|is|,|determine (r_agent) induced_22\VBN|NONE (l_csubj) determine_1\VB|.|is|,|by (l_dobj) safety_3\NN|To (l_prep) of_6\IN|efficacy|and|the (l_pobj) bupropion_8\NN|NONE (l_prep) on_15\IN|SR|adjunctive (l_pobj) dysfunction_18\NN|NONE
D017367_D012735 NONE SSRI_30\NNP|)|a|(|selective|serotonin|reuptake (r_appos) inhibitor_28\NN|NONE (r_pobj) by_23\IN|.|is|,|determine (r_agent) induced_22\VBN|NONE (l_csubj) determine_1\VB|.|is|,|by (l_dobj) safety_3\NN|To (l_prep) of_6\IN|efficacy|and|the (l_pobj) bupropion_8\NN|NONE (l_prep) on_15\IN|SR|adjunctive (l_pobj) dysfunction_18\NN|NONE (l_appos) SD_20\NN|male|(|sexual|)
D017367_D012735 NONE SSRI_30\NNP|)|a|(|selective|serotonin|reuptake (r_appos) inhibitor_28\NN|NONE (r_pobj) by_23\IN|.|is|,|determine (r_agent) induced_22\VBN|NONE (l_advcl) is_35\VBZ|.|,|by|determine (l_nsubj) SD_34\NN|as|have|effect
D017367_D012735 NONE SSRIs_42\NNS|NONE (r_pobj) of_41\IN||common|side|a (r_prep) effect_40\NN|SD|as|have (r_attr) is_35\VBZ|.|,|by|determine (r_advcl) induced_22\VBN|NONE (l_csubj) determine_1\VB|.|is|,|by (l_dobj) safety_3\NN|To (l_prep) of_6\IN|efficacy|and|the (l_pobj) bupropion_8\NN|NONE (l_prep) on_15\IN|SR|adjunctive (l_pobj) dysfunction_18\NN|NONE
D017367_D012735 NONE SSRIs_42\NNS|NONE (r_pobj) of_41\IN||common|side|a (r_prep) effect_40\NN|SD|as|have (r_attr) is_35\VBZ|.|,|by|determine (r_advcl) induced_22\VBN|NONE (l_csubj) determine_1\VB|.|is|,|by (l_dobj) safety_3\NN|To (l_prep) of_6\IN|efficacy|and|the (l_pobj) bupropion_8\NN|NONE (l_prep) on_15\IN|SR|adjunctive (l_pobj) dysfunction_18\NN|NONE (l_appos) SD_20\NN|male|(|sexual|)
D017367_D012735 NONE SSRIs_42\NNS|NONE (r_pobj) of_41\IN||common|side|a (r_prep) effect_40\NN|SD|as|have (r_attr) is_35\VBZ|.|,|by|determine (l_nsubj) SD_34\NN|as|have|effect
D017367_D012735 NONE SSRI_21\NNP|NONE (r_pobj) of_20\IN|NONE (r_prep) type_19\NN|, (r_appos) SD_17\NN|NONE
D017367_D012735 NONE SSRIs_10\NNS|NONE (r_pobj) by_9\IN|NONE (r_agent) induced_8\VBN|for|an|effective (r_acl) treatment_4\NN|Bupropion|. (l_prep) for_5\IN|an|induced|effective (l_pobj) SD_7\NN|NONE
D016642_D012735 NONE bupropion_5\NN|NONE (l_prep) on_6\IN|adjunctive|the (l_pobj) dysfunction_9\NN|NONE
D016642_D012735 NONE bupropion_8\NN|NONE (l_prep) on_15\IN|SR|adjunctive (l_pobj) dysfunction_18\NN|NONE
D016642_D012735 NONE bupropion_8\NN|NONE (l_prep) on_15\IN|SR|adjunctive (l_pobj) dysfunction_18\NN|NONE (l_appos) SD_20\NN|male|(|sexual|)
D016642_D012735 NONE bupropion_8\NN|NONE (r_pobj) of_6\IN|efficacy|and|the (r_prep) safety_3\NN|To (r_dobj) determine_1\VB|.|is|,|by (r_csubj) induced_22\VBN|NONE (l_advcl) is_35\VBZ|.|,|by|determine (l_nsubj) SD_34\NN|as|have|effect
D016642_D012735 NONE Bupropion_0\NN|.|treatment (r_nsubj) is_1\VBZ|NONE (l_attr) treatment_4\NN|Bupropion|. (l_prep) for_5\IN|an|induced|effective (l_pobj) SD_7\NN|NONE
7752389
D015232_D053201 CID E2-induced_1\JJ|Prostaglandin|in|bladder|? (r_amod) hyperactivity_3\NN|NONE
D011453_D053201 NONE Prostanoids_0\NNS|to|,|via|,|may|. (r_nsubj) contribute_8\VBP|NONE (l_prep) to_9\IN|Prostanoids|,|via|,|may|. (l_pobj) urge_11\VB|NONE (l_conj) hyperactivity_14\NN|both|and|seen
D015320_D053201 NONE tachykinins_12\NNS|NONE (r_pobj) of_11\IN|NONE (r_prep) involvement_10\NN|,|normal|conscious|: (r_appos) rats_8\NNS|NONE (r_pobj) in_4\IN|Einduced|Prostaglandin|bladder|? (r_prep) hyperactivity_3\NN|NONE
D015320_D053201 NONE tachykinins_6\NNS|NONE (r_pobj) of_5\IN|NONE (r_prep) release_4\NN|NONE (r_pobj) via_3\IN|to|Prostanoids|,|,|may|. (r_prep) contribute_8\VBP|NONE (l_prep) to_9\IN|Prostanoids|,|via|,|may|. (l_pobj) urge_11\VB|NONE (l_conj) hyperactivity_14\NN|both|and|seen
15863244
D010894_D009139 CID piroxicam_24\NN|NONE (r_pobj) of_23\IN|the|highest (r_prep) dose_22\NN|NONE (r_pobj) with_19\IN|NONE (r_prep) treated_18\VBN|NONE (r_acl) rats_17\NNS|NONE (r_pobj) in_16\IN|were|toxicity|. (r_prep) found_15\VBN|NONE (l_nsubjpass) toxicity_1\NN|in|were|. (l_appos) retardation_5\NN|Maternal|, (l_conj) increase_8\NN|intrauterine|,|growth|and (l_prep) of_9\IN|NONE (l_pobj) variations_13\NNS|NONE
D010894_D009436 NONE piroxicam_23\NN|selective|COX|based (r_nmod) inhibitor_31\NN|NONE (r_pobj) to_22\IN|NONE (r_prep) exposed_21\VBN|rat (r_acl) fetuses_20\NNS|NONE (r_pobj) for_18\IN|was|analysis|. (r_prep) performed_17\VBN|NONE (l_nsubjpass) analysis_3\NN|was|for|. (l_prep) for_4\IN|statistical|The|pooled (l_pobj) defects_15\NNS|NONE
C106876_D064420 NONE DFU_17\NNP|selective|cyclooxygenase||in (r_appos) inhibitors_11\NNS|NONE (r_pobj) of_4\IN|developmental (r_prep) toxicity_3\NN|NONE
C106876_D064420 NONE DFU_22\NNP|of|the|developmental (r_conj) toxicity_10\NN|to
C106876_D064420 NONE phenyl-2(5H)-furanon_26\XX|NONE (l_ccomp) was_5\VBD|,dimethyl(fluorophenyl)(methylsulphonyl|)|)|; (l_xcomp) evaluate_7\VB|aim (l_dobj) toxicity_10\NN|to
C106876_D064420 NONE DFU_10\NNP|developmental|observed|the (r_nmod) toxicity_12\NN|NONE
D010894_D005317 CID piroxicam_24\NN|NONE (r_pobj) of_23\IN|the|highest (r_prep) dose_22\NN|NONE (r_pobj) with_19\IN|NONE (r_prep) treated_18\VBN|NONE (r_acl) rats_17\NNS|NONE (r_pobj) in_16\IN|were|toxicity|. (r_prep) found_15\VBN|NONE (l_nsubjpass) toxicity_1\NN|in|were|. (l_appos) retardation_5\NN|Maternal|,
D010894_D064420 NONE piroxicam_19\NN|NONE (r_compound) study_20\NN|and (r_conj) DFU_17\NNP|selective|cyclooxygenase||in (r_appos) inhibitors_11\NNS|NONE (r_pobj) of_4\IN|developmental (r_prep) toxicity_3\NN|NONE
D010894_D064420 NONE piroxicam_17\NN|NONE (r_pobj) of_11\IN|DFU|the|developmental (r_prep) toxicity_10\NN|to
D010894_D064420 NONE piroxicam_24\NN|NONE (r_pobj) of_23\IN|the|highest (r_prep) dose_22\NN|NONE (r_pobj) with_19\IN|NONE (r_prep) treated_18\VBN|NONE (r_acl) rats_17\NNS|NONE (r_pobj) in_16\IN|were|toxicity|. (r_prep) found_15\VBN|NONE (l_nsubjpass) toxicity_1\NN|in|were|.
D010894_D006345 NONE piroxicam_23\NN|selective|COX|based (r_nmod) inhibitor_31\NN|NONE (r_pobj) to_22\IN|NONE (r_prep) exposed_21\VBN|rat (r_acl) fetuses_20\NNS|NONE (r_pobj) for_18\IN|was|analysis|. (r_prep) performed_17\VBN|NONE (l_nsubjpass) analysis_3\NN|was|for|. (l_prep) for_4\IN|statistical|The|pooled (l_pobj) defects_15\NNS|NONE
20080419
D010862_D004827 CID pilocarpine_24\NN|NONE (r_pobj) by_23\IN|in (r_agent) induced_22\VBN|of|a (r_acl) model_19\NN|NONE (l_prep) of_20\IN|induced|a (l_pobj) epilepsy_21\NN|NONE
1147734
D011441_D006521 CID propylthiouracil_29\NN|NONE (r_pobj) of_28\IN|the (r_prep) administration_27\NN|NONE (r_pobj) by_25\IN|NONE (r_agent) caused_24\VBN|aggressive|chronic|active|)|( (r_acl) hepatitis_23\NN|NONE
D011441_D008107 NONE propylthiouracil_4\NN|NONE (r_pobj) by_3\IN|NONE (r_agent) caused_2\VBN|Liver|. (r_acl) disease_1\NN|NONE
18754075
D019386_D058186 CID alendronate_10\JJ|bisphosphonate|in (r_nmod) administration_12\NN|NONE (r_pobj) after_6\IN|failure|Massive|.|and (r_prep) proteinuria_1\NN|NONE (l_conj) failure_5\NN|after|Massive|.|and
D019386_D058186 CID sodium_9\NN|, (r_nmod) administration_11\NN|rapidly|up|.|amount|Within|with (r_nsubj) increased_19\VBD|NONE (l_prep) with_25\IN|rapidly|up|.|amount|administration|Within (l_pobj) failure_28\NN|NONE
D013256_D005923 NONE steroid_19\NN|NONE (r_compound) therapy_20\NN|NONE (r_pobj) to_18\IN|well|was|initially|man|. (r_prep) responding_16\VBG|NONE (l_nsubj) man_5\NN|well|was|initially|to|. (l_amod) due_9\IN|with|old|Japanese|A (l_pobj) glomerulosclerosis_13\NN|to
D019386_D011507 CID alendronate_10\JJ|bisphosphonate|in (r_nmod) administration_12\NN|NONE (r_pobj) after_6\IN|failure|Massive|.|and (r_prep) proteinuria_1\NN|NONE
D004164_D005923 NONE bisphosphonate_8\NN|alendronate|in (r_nmod) administration_12\NN|NONE (l_prep) in_13\IN|bisphosphonate|alendronate (l_pobj) patient_15\NN|NONE (l_prep) with_16\IN|a (l_pobj) glomerulosclerosis_19\NN|NONE
D004164_D058186 NONE bisphosphonate_8\NN|alendronate|in (r_nmod) administration_12\NN|NONE (r_pobj) after_6\IN|failure|Massive|.|and (r_prep) proteinuria_1\NN|NONE (l_conj) failure_5\NN|after|Massive|.|and
D004164_D058186 NONE bisphosphonate_6\NN|NONE (r_pobj) of_3\IN| (r_prep) days_2\NNS|NONE (r_pobj) Within_0\IN|rapidly|up|.|amount|administration|with (r_prep) increased_19\VBD|NONE (l_prep) with_25\IN|rapidly|up|.|amount|administration|Within (l_pobj) failure_28\NN|NONE
D004164_D058186 NONE bisphosphonates_11\NNS|can|intravenous|proteinuria|that (r_nsubj) aggravate_13\VB|.|report (l_dobj) proteinuria_14\NN|bisphosphonates|can|intravenous|that (l_conj) failure_18\NN|and
D004164_D011507 NONE bisphosphonate_8\NN|alendronate|in (r_nmod) administration_12\NN|NONE (r_pobj) after_6\IN|failure|Massive|.|and (r_prep) proteinuria_1\NN|NONE
D004164_D011507 NONE bisphosphonates_11\NNS|can|intravenous|proteinuria|that (r_nsubj) aggravate_13\VB|.|report (l_dobj) proteinuria_14\NN|bisphosphonates|can|intravenous|that
D019386_D005923 NONE alendronate_10\JJ|bisphosphonate|in (r_nmod) administration_12\NN|NONE (l_prep) in_13\IN|bisphosphonate|alendronate (l_pobj) patient_15\NN|NONE (l_prep) with_16\IN|a (l_pobj) glomerulosclerosis_19\NN|NONE
D013256_D009404 NONE steroid_19\NN|NONE (r_compound) therapy_20\NN|NONE (r_pobj) to_18\IN|well|was|initially|man|. (r_prep) responding_16\VBG|NONE (l_nsubj) man_5\NN|well|was|initially|to|. (l_prep) with_6\IN|due|old|Japanese|A (l_pobj) syndrome_8\NN|NONE
8643966
D017239_D064420 NONE paclitaxel_9\NN|hour|a|in (r_compound) infusion_10\NN|NONE (r_pobj) of_6\IN|and|the|toxicity (r_prep) efficacy_3\NN|We|. (l_conj) toxicity_5\NN|of|and|the
D017239_D064420 NONE Paclitaxel_0\NNP|agent|with|,|thus|. (r_nsubj) is_1\VBZ|NONE (l_prep) with_12\IN|agent|Paclitaxel|,|thus|. (l_pobj) infusion_15\NN|NONE (l_acl) proving_16\VBG|a|hour (l_oprd) effective_18\JJ|NONE (l_prep) to_19\IN|comparably (l_pobj) infusion_22\NN|NONE (l_conj) superior_24\JJ|and|hour|a (l_prep) in_25\IN|NONE (l_pobj) terms_26\NNS|NONE (l_prep) of_27\IN|NONE (l_pobj) incidence_29\NN|NONE (l_prep) of_30\IN|the (l_pobj) toxicity_34\NN|NONE
D017239_D001943 NONE Paclitaxel_0\NNP|activity|has|. (r_nsubj) demonstrated_15\VBN|NONE (l_dobj) activity_18\NN|Paclitaxel|has|. (l_prep) against_19\IN|antineoplastic|significant (l_pobj) types_22\NNS|NONE (l_appos) carcinoma_28\NN|,|tumor|different
D017239_D001943 NONE Taxol_2\NNP|Company (r_appos) Paclitaxel_0\NNP|activity|has|. (r_nsubj) demonstrated_15\VBN|NONE (l_dobj) activity_18\NN|Paclitaxel|has|. (l_prep) against_19\IN|antineoplastic|significant (l_pobj) types_22\NNS|NONE (l_appos) carcinoma_28\NN|,|tumor|different
D017239_D010051 NONE Paclitaxel_0\NNP|activity|has|. (r_nsubj) demonstrated_15\VBN|NONE (l_dobj) activity_18\NN|Paclitaxel|has|. (l_prep) against_19\IN|antineoplastic|significant (l_pobj) types_22\NNS|NONE (l_appos) carcinoma_28\NN|,|tumor|different
D017239_D010051 NONE Taxol_2\NNP|Company (r_appos) Paclitaxel_0\NNP|activity|has|. (r_nsubj) demonstrated_15\VBN|NONE (l_dobj) activity_18\NN|Paclitaxel|has|. (l_prep) against_19\IN|antineoplastic|significant (l_pobj) types_22\NNS|NONE (l_appos) carcinoma_28\NN|,|tumor|different
D017239_D002289 NONE paclitaxel_11\NN|NONE (r_pobj) with_10\IN|inoperable|small|lung|advanced (r_prep) cancer_9\NN|NONE
D017239_D002289 NONE paclitaxel_6\NN|in|hour (r_compound) infusions_7\NNS|NONE (l_prep) in_8\IN|hour|paclitaxel (l_pobj) patients_12\NNS|NONE (l_prep) with_13\IN|naive (l_pobj) IIIB_15\NNS|NONE (l_conj) cancer_23\NN|stage|or
D017239_D002289 NONE paclitaxel_6\NN|in|hour (r_compound) infusions_7\NNS|NONE (l_prep) in_8\IN|hour|paclitaxel (l_pobj) patients_12\NNS|NONE (l_prep) with_13\IN|naive (l_pobj) IIIB_15\NNS|NONE (l_conj) cancer_23\NN|stage|or (l_appos) NSCLC_25\NNP|small|IV|(|)|lung
D017239_D002289 NONE paclitaxel_9\NN|hour|a|in (r_compound) infusion_10\NN|NONE (l_prep) in_11\IN|hour|a|paclitaxel (l_pobj) trial_15\NN|NONE (l_prep) in_16\IN|II|phase (l_pobj) patients_17\NNS|NONE (l_prep) with_18\IN|NONE (l_pobj) IIIB_21\NNS|NONE (l_conj) NSCLC_24\NNP|or|stage
D017239_D002289 NONE paclitaxel_5\NN|NONE (r_pobj) with_4\IN|II|combined (r_prep) studies_3\NNS|Further (l_acl) combined_6\VBN|II|with (l_prep) with_7\IN|NONE (l_pobj) drugs_9\NNS|NONE (l_amod) active_10\JJ|other (l_prep) against_11\IN|NONE (l_pobj) NSCLC_12\NNP|NONE
D017239_D002289 NONE paclitaxel_21\NN|with (r_dobj) comparing_20\VBG|III (r_acl) studies_19\NNS|remain (r_dobj) phase_17\NN|are|and|phase|,|. (r_conj) indicated_14\VBN|NONE (l_nsubjpass) phase_1\NN|phase|are|and|,|. (l_dobj) studies_3\NNS|Further (l_acl) combined_6\VBN|II|with (l_prep) with_7\IN|NONE (l_pobj) drugs_9\NNS|NONE (l_amod) active_10\JJ|other (l_prep) against_11\IN|NONE (l_pobj) NSCLC_12\NNP|NONE
D017239_D009369 NONE Paclitaxel_0\NNP|activity|has|. (r_nsubj) demonstrated_15\VBN|NONE (l_dobj) activity_18\NN|Paclitaxel|has|. (l_prep) against_19\IN|antineoplastic|significant (l_pobj) types_22\NNS|NONE (l_compound) tumor_21\NN|,|carcinoma|different
D017239_D009369 NONE Taxol_2\NNP|Company (r_appos) Paclitaxel_0\NNP|activity|has|. (r_nsubj) demonstrated_15\VBN|NONE (l_dobj) activity_18\NN|Paclitaxel|has|. (l_prep) against_19\IN|antineoplastic|significant (l_pobj) types_22\NNS|NONE (l_compound) tumor_21\NN|,|carcinoma|different
6695415
D002110_D006973 CID caffeine_7\NN|if|to|can|in (r_nsubj) lead_9\VB|to (l_prep) in_12\IN|if|to|caffeine|can (l_pobj) rats_16\NNS|NONE (l_amod) normotensive_13\NN|NONE (l_conj) hypertensive_15\JJ|and/or
D002110_D006973 CID caffeine_4\NN|dose|)|single|(|A (r_compound) administration_5\NN|.|to (r_nsubj) lead_10\NN|NONE (l_prep) to_11\IN|.|administration (l_pobj) hypertension_13\NN|NONE
D002110_D006973 CID caffeine_4\NN|dose|)|single|(|A (r_compound) administration_5\NN|.|to (r_nsubj) lead_10\NN|NONE (l_prep) to_11\IN|.|administration (l_pobj) hypertension_13\NN|NONE (l_prep) in_14\IN|acute (l_pobj) animals_20\NNS|NONE (l_amod) normotensive_17\NN|the|both (l_conj) hypertensive_19\JJ|and
D002110_D006973 CID caffeine_6\NN|to|administered|that|can (r_nsubj) lead_8\VB|.|results (l_prep) to_9\IN|administered|that|caffeine|can (l_pobj) hemorrhage_11\NN|NONE (l_prep) in_12\IN|cerebral (l_pobj) animals_15\NNS|NONE (l_amod) hypertensive_14\JJ|NONE
D010665_D020521 CID Phenylpropanolamine_0\NNP|.|drug (r_nsubj) is_4\VBZ|NONE (l_attr) drug_6\NN|.|Phenylpropanolamine (l_relcl) associated_10\VBN|a (l_prep) with_11\IN|that|been|has (l_pobj) effects_14\NNS|NONE (l_prep) including_15\VBG|serious|side (l_pobj) stroke_16\NN|NONE
D010665_D020521 CID PPA_2\NNP|(|) (r_appos) Phenylpropanolamine_0\NNP|.|drug (r_nsubj) is_4\VBZ|NONE (l_attr) drug_6\NN|.|Phenylpropanolamine (l_relcl) associated_10\VBN|a (l_prep) with_11\IN|that|been|has (l_pobj) effects_14\NNS|NONE (l_prep) including_15\VBG|serious|side (l_pobj) stroke_16\NN|NONE
D010665_D020521 CID PPA_5\NNP|/ (r_nmod) caffeine_7\NN|if|to|can|in (r_nsubj) lead_9\VB|to (l_prep) to_10\IN|if|caffeine|can|in (l_pobj) stroke_11\NN|NONE
D002110_D020521 NONE caffeine_7\NN|if|to|can|in (r_nsubj) lead_9\VB|to (l_prep) to_10\IN|if|caffeine|can|in (l_pobj) stroke_11\NN|NONE
D010665_D002543 CID phenylpropanolamine_4\NN|NONE (r_pobj) with_3\IN|in (r_prep) associated_2\VBN|.|Cerebral (r_acl) hemorrhage_1\NN|NONE
D010665_D002543 CID PPA_4\NNP|/ (r_nmod) caffeine_6\NN|to|administered|that|can (r_nsubj) lead_8\VB|.|results (l_prep) to_9\IN|administered|that|caffeine|can (l_pobj) hemorrhage_11\NN|NONE
D010665_D006973 CID PPA_5\NNP|/ (r_nmod) caffeine_7\NN|if|to|can|in (r_nsubj) lead_9\VB|to (l_prep) in_12\IN|if|to|caffeine|can (l_pobj) rats_16\NNS|NONE (l_amod) normotensive_13\NN|NONE (l_conj) hypertensive_15\JJ|and/or
D010665_D006973 CID PPA_2\NNP|/ (r_nmod) caffeine_4\NN|dose|)|single|(|A (r_compound) administration_5\NN|.|to (r_nsubj) lead_10\NN|NONE (l_prep) to_11\IN|.|administration (l_pobj) hypertension_13\NN|NONE
D010665_D006973 CID PPA_2\NNP|/ (r_nmod) caffeine_4\NN|dose|)|single|(|A (r_compound) administration_5\NN|.|to (r_nsubj) lead_10\NN|NONE (l_prep) to_11\IN|.|administration (l_pobj) hypertension_13\NN|NONE (l_prep) in_14\IN|acute (l_pobj) animals_20\NNS|NONE (l_amod) normotensive_17\NN|the|both (l_conj) hypertensive_19\JJ|and
D010665_D006973 CID PPA_4\NNP|/ (r_nmod) caffeine_6\NN|to|administered|that|can (r_nsubj) lead_8\VB|.|results (l_prep) to_9\IN|administered|that|caffeine|can (l_pobj) hemorrhage_11\NN|NONE (l_prep) in_12\IN|cerebral (l_pobj) animals_15\NNS|NONE (l_amod) hypertensive_14\JJ|NONE
D002110_D002543 CID caffeine_8\NN|NONE (r_pobj) with_7\IN|NONE (r_prep) combination_6\NN|NONE (r_pobj) in_5\IN|with (r_prep) associated_2\VBN|.|Cerebral (r_acl) hemorrhage_1\NN|NONE
D002110_D002543 CID caffeine_6\NN|to|administered|that|can (r_nsubj) lead_8\VB|.|results (l_prep) to_9\IN|administered|that|caffeine|can (l_pobj) hemorrhage_11\NN|NONE
2505783
C004656_D006470 CID chloroacetaldehyde_7\NN|metabolite|that (r_nsubj) is_11\VBZ|NONE (l_attr) metabolite_14\NN|that|chloroacetaldehyde (l_relcl) carried_23\VBN|an|important|,|of (l_prep) in_25\IN|out|study|was (l_pobj) order_26\NN|NONE (l_acl) elucidate_28\VB|NONE (l_prep) in_33\IN|role|to (l_pobj) development_35\NN|NONE (l_prep) of_36\IN|the (l_pobj) cystitis_38\NN|NONE
C004656_D006470 CID CAA_9\NNP|NONE (r_appos) chloroacetaldehyde_7\NN|metabolite|that (r_nsubj) is_11\VBZ|NONE (l_attr) metabolite_14\NN|that|chloroacetaldehyde (l_relcl) carried_23\VBN|an|important|,|of (l_prep) in_25\IN|out|study|was (l_pobj) order_26\NN|NONE (l_acl) elucidate_28\VB|NONE (l_prep) in_33\IN|role|to (l_pobj) development_35\NN|NONE (l_prep) of_36\IN|the (l_pobj) cystitis_38\NN|NONE
C004656_D006470 CID CAA_32\NNP|NONE (r_pobj) of_31\IN|the (r_prep) role_30\NN|in|to (r_dobj) elucidate_28\VB|NONE (l_prep) in_33\IN|role|to (l_pobj) development_35\NN|NONE (l_prep) of_36\IN|the (l_pobj) cystitis_38\NN|NONE
C004656_D003556 CID chloroacetaldehyde_7\NN|metabolite|that (r_nsubj) is_11\VBZ|NONE (l_attr) metabolite_14\NN|that|chloroacetaldehyde (l_relcl) carried_23\VBN|an|important|,|of (l_prep) in_25\IN|out|study|was (l_pobj) order_26\NN|NONE (l_acl) elucidate_28\VB|NONE (l_prep) in_33\IN|role|to (l_pobj) development_35\NN|NONE (l_prep) of_36\IN|the (l_pobj) cystitis_38\NN|NONE
C004656_D003556 CID CAA_9\NNP|NONE (r_appos) chloroacetaldehyde_7\NN|metabolite|that (r_nsubj) is_11\VBZ|NONE (l_attr) metabolite_14\NN|that|chloroacetaldehyde (l_relcl) carried_23\VBN|an|important|,|of (l_prep) in_25\IN|out|study|was (l_pobj) order_26\NN|NONE (l_acl) elucidate_28\VB|NONE (l_prep) in_33\IN|role|to (l_pobj) development_35\NN|NONE (l_prep) of_36\IN|the (l_pobj) cystitis_38\NN|NONE
C004656_D003556 CID CAA_32\NNP|NONE (r_pobj) of_31\IN|the (r_prep) role_30\NN|in|to (r_dobj) elucidate_28\VB|NONE (l_prep) in_33\IN|role|to (l_pobj) development_35\NN|NONE (l_prep) of_36\IN|the (l_pobj) cystitis_38\NN|NONE
C004656_D001745 NONE CAA_4\NNP|does|after|administration|that|to|not (r_nsubj) contribute_10\VB|data|. (l_prep) to_11\IN|does|after|administration|that|CAA|not (l_pobj) damage_13\NN|NONE
20477932
C052342_D007859 NONE topiramate_22\NN|NONE (r_pobj) by_21\IN|NONE (r_prep) prevention_20\NN|,|and|of (r_conj) involvement_9\NN|and|:|learning (r_appos) memory_2\NN|.|Cocaine (l_conj) learning_4\VBG|and|:|involvement (l_dobj) impairments_5\NNS|NONE
C052342_D019970 NONE topiramate_26\NN|NONE (r_pobj) of_25\IN|the (r_prep) effect_24\NN|and|as|memory|spatial (r_conj) learning_17\NN|nNOS|)|, (r_conj) activity_14\NN|oxide|,|nitric|neuronal|therapy|( (r_conj) synthase_10\NN|oxidative|, (l_conj) therapy_31\NN|activity|oxide|,|nitric|neuronal|( (l_prep) for_32\IN|proposed|a (l_pobj) addiction_34\NN|NONE
D003042_D008569 CID Cocaine_0\NN|memory|. (r_nsubj) causes_1\VBZ|NONE (l_dobj) memory_2\NN|.|Cocaine (l_conj) learning_4\VBG|and|:|involvement (l_dobj) impairments_5\NNS|NONE
D003042_D064420 NONE cocaine_6\NN|including (r_compound) toxicity_7\NN|NONE
D003042_D064420 NONE cocaine_24\NN|and|the (r_conj) brain_22\NN|induced| (r_nmod) behaviour_27\NN|NONE (r_pobj) in_20\IN|oxidative (r_prep) status_19\NN|NONE (r_pobj) between_17\IN|the (r_prep) association_16\NN|an|but|in (r_conj) increase_10\NN|NONE (r_pobj) including_8\VBG|cocaine (r_prep) toxicity_7\NN|NONE
D003042_D007859 CID Cocaine_0\NN|memory|. (r_nsubj) causes_1\VBZ|NONE (l_dobj) memory_2\NN|.|Cocaine (l_conj) learning_4\VBG|and|:|involvement (l_dobj) impairments_5\NNS|NONE
C052342_D008569 NONE topiramate_22\NN|NONE (r_pobj) by_21\IN|NONE (r_prep) prevention_20\NN|,|and|of (r_conj) involvement_9\NN|and|:|learning (r_appos) memory_2\NN|.|Cocaine (l_conj) learning_4\VBG|and|:|involvement (l_dobj) impairments_5\NNS|NONE
D009569_D019970 NONE oxide_9\NN|activity|,|nitric|neuronal|therapy|( (r_compound) synthase_10\NN|oxidative|, (l_conj) therapy_31\NN|activity|oxide|,|nitric|neuronal|( (l_prep) for_32\IN|proposed|a (l_pobj) addiction_34\NN|NONE
D003042_D019970 NONE cocaine_43\NN|NONE (r_compound) administration_44\NN|NONE (r_pobj) of_42\IN|an|experimental|in (r_prep) model_41\NN|NONE (r_pobj) in_38\IN|.|Therefore|were|activity (r_prep) evaluated_37\VBN|NONE (l_nsubjpass) activity_2\NN|.|Therefore|were|in (l_appos) stress_5\NN|NFkappaB|,|, (l_conj) synthase_10\NN|oxidative|, (l_conj) therapy_31\NN|activity|oxide|,|nitric|neuronal|( (l_prep) for_32\IN|proposed|a (l_pobj) addiction_34\NN|NONE
4038130
D008619_D009135 CID mepivacaine_19\NN|NONE (r_pobj) to_18\IN|NONE (r_prep) exposure_17\NN|especially (r_pobj) after_16\IN|,|also|In|was|.|damage|,|in (r_prep) seen_10\VBN|NONE (l_prep) In_0\IN|,|also|after|was|.|damage|,|in (l_pobj) addition_1\NN|NONE (l_prep) to_2\IN|NONE (l_pobj) damage_4\NN|NONE
D004837_D009135 NONE epinephrine_23\NN|and|plus|lidocaine (r_conj) mepivacaine_19\NN|NONE (r_pobj) to_18\IN|NONE (r_prep) exposure_17\NN|especially (r_pobj) after_16\IN|,|also|In|was|.|damage|,|in (r_prep) seen_10\VBN|NONE (l_prep) In_0\IN|,|also|after|was|.|damage|,|in (l_pobj) addition_1\NN|NONE (l_prep) to_2\IN|NONE (l_pobj) damage_4\NN|NONE
D008012_D009135 CID lidocaine_21\NN|and|plus|epinephrine (r_conj) mepivacaine_19\NN|NONE (r_pobj) to_18\IN|NONE (r_prep) exposure_17\NN|especially (r_pobj) after_16\IN|,|also|In|was|.|damage|,|in (r_prep) seen_10\VBN|NONE (l_prep) In_0\IN|,|also|after|was|.|damage|,|in (l_pobj) addition_1\NN|NONE (l_prep) to_2\IN|NONE (l_pobj) damage_4\NN|NONE
9721172
D011241_D005355 NONE prednisone_6\NN|ursodeoxycholic|, (r_conj) acid_4\NN|NONE (r_pobj) with_2\IN|NONE (r_prep) therapy_1\NN|NONE (r_pobj) Despite_0\IN|with|unrelenting|,|. (r_prep) was_15\VBD|NONE (l_prep) with_18\IN|unrelenting|,|.|Despite (l_pobj) cirrhosis_19\NN|NONE
D007052_D001649 NONE ibuprofen_30\JJ|NONE (r_compound) use_31\NN|NONE (r_pobj) with_29\IN|;|was|child|temporally|.|this (r_prep) associated_28\VBN|NONE (l_nsubjpass) child_3\NN|;|was|temporally|with|.|this (l_relcl) developed_5\VBD|healthy|described|A (l_dobj) syndrome_15\NN|who
D016559_D005355 NONE tacrolimus_10\VB|,|and (r_conj) prednisone_6\NN|ursodeoxycholic|, (r_conj) acid_4\NN|NONE (r_pobj) with_2\IN|NONE (r_prep) therapy_1\NN|NONE (r_pobj) Despite_0\IN|with|unrelenting|,|. (r_prep) was_15\VBD|NONE (l_prep) with_18\IN|unrelenting|,|.|Despite (l_pobj) cirrhosis_19\NN|NONE
D007052_D013262 CID ibuprofen_30\JJ|NONE (r_compound) use_31\NN|NONE (r_pobj) with_29\IN|;|was|child|temporally|.|this (r_prep) associated_28\VBN|NONE (l_nsubjpass) child_3\NN|;|was|temporally|with|.|this (l_relcl) described_23\VBN|healthy|developed|A (l_nsubjpass) syndrome_21\NN|after|is
D014580_D002779 NONE acid_4\NN|NONE (l_conj) prednisone_6\NN|ursodeoxycholic|, (l_conj) tacrolimus_10\VB|,|and (l_conj) disease_14\NN|then|,
D011241_D002779 NONE prednisone_6\NN|ursodeoxycholic|, (l_conj) tacrolimus_10\VB|,|and (l_conj) disease_14\NN|then|,
D016559_D002779 NONE tacrolimus_10\VB|,|and (l_conj) disease_14\NN|then|,
D014580_D005355 NONE acid_4\NN|NONE (r_pobj) with_2\IN|NONE (r_prep) therapy_1\NN|NONE (r_pobj) Despite_0\IN|with|unrelenting|,|. (r_prep) was_15\VBD|NONE (l_prep) with_18\IN|unrelenting|,|.|Despite (l_pobj) cirrhosis_19\NN|NONE
16330293
9154656
D011692_D009404 CID nucleoside_11\NN|(|puromycin (r_nmod) PAN_13\NNP|NONE (r_pobj) of_7\IN|single|a (r_prep) injection_6\NN|NONE (r_pobj) by_3\IN|)|was|.|NS (r_agent) induced_2\VBN|NONE (l_nsubjpass) NS_0\NNP|)|was|.|by
D011692_D009404 CID PAN_13\NNP|NONE (r_pobj) of_7\IN|single|a (r_prep) injection_6\NN|NONE (r_pobj) by_3\IN|)|was|.|NS (r_agent) induced_2\VBN|NONE (l_nsubjpass) NS_0\NNP|)|was|.|by
D011692_D009404 CID PAN_19\NNP|NONE (r_compound) injection_20\NN|NONE (r_pobj) after_18\IN|excretion|on|were|Although (r_prep) observed_14\VBN|,|established|,|.|did|not|levels (r_advcl) change_34\VB|NONE (l_advcl) established_26\VBN|,|,|observed|.|did|not|levels (l_nsubjpass) NS_23\NNP|clearly|was|when
D011692_D009404 CID PAN_22\NNP|NONE (r_pobj) by_21\IN|NONE (r_agent) induced_20\VBN|the|of (r_acl) development_15\NN|NONE (l_prep) of_16\IN|the|induced (l_pobj) NS_19\NNP|NONE
D000809_D009404 NONE angiotensin_9\NN|the|system (r_compound) proteins_11\NNS|NONE (r_pobj) of_5\IN|excretion|and|Plasma (r_prep) concentration_1\NN|are|.|in (r_nsubjpass) altered_13\VBN|NONE (l_prep) in_14\IN|concentration|are|. (l_pobj) rats_15\NNS|NONE (l_prep) with_16\IN|NONE (l_pobj) syndrome_18\NN|NONE
D000809_D009404 NONE angiotensin_9\NN|the|system (r_compound) proteins_11\NNS|NONE (r_pobj) of_5\IN|excretion|and|Plasma (r_prep) concentration_1\NN|are|.|in (r_nsubjpass) altered_13\VBN|NONE (l_prep) in_14\IN|concentration|are|. (l_pobj) rats_15\NNS|NONE (l_prep) with_16\IN|NONE (l_pobj) syndrome_18\NN|NONE (l_appos) NS_20\NNP|nephrotic
11569530
C063968_D016171 NONE E4031_19\NNP|and (r_conj) cisapride_17\NN|, (r_conj) terodiline_15\NN|, (r_conj) terfenadine_13\NN|:|were|TDP (r_appos) investigated_11\VBN|NONE (l_nsubjpass) TDP_9\NNP|:|terfenadine|were
C010637_D016171 CID terodiline_21\NN|and|e.g. (r_conj) terfenadine_19\NN|(|the|) (r_appos) market_16\NN|NONE (r_pobj) from_14\IN|of (r_prep) withdrawal_10\NN|NONE (r_pobj) to_9\IN|has|that (r_prep) led_8\VBN|a||side (r_relcl) effect_5\NN|.|TDP (r_attr) is_1\VBZ|NONE (l_nsubj) TDP_0\NNP|effect|.
C010637_D016171 CID terodiline_15\NN|, (r_conj) terfenadine_13\NN|:|were|TDP (r_appos) investigated_11\VBN|NONE (l_nsubjpass) TDP_9\NNP|:|terfenadine|were
C010637_D016171 CID terodiline_12\NN|, (r_conj) terfenadine_10\NN|)|the|( (r_appos) clinic_8\NN|NONE (r_pobj) in_6\IN|have|TDP|that (r_prep) shown_4\VBN|NONE (l_dobj) TDP_5\NNP|have|in|that
D020117_D016171 CID cisapride_17\NN|, (r_conj) terodiline_15\NN|, (r_conj) terfenadine_13\NN|:|were|TDP (r_appos) investigated_11\VBN|NONE (l_nsubjpass) TDP_9\NNP|:|terfenadine|were
D020117_D016171 CID cisapride_14\JJ|, (r_conj) terodiline_12\NN|, (r_conj) terfenadine_10\NN|)|the|( (r_appos) clinic_8\NN|NONE (r_pobj) in_6\IN|have|TDP|that (r_prep) shown_4\VBN|NONE (l_dobj) TDP_5\NNP|have|in|that
D016593_D016171 CID terfenadine_19\NN|(|the|) (r_appos) market_16\NN|NONE (r_pobj) from_14\IN|of (r_prep) withdrawal_10\NN|NONE (r_pobj) to_9\IN|has|that (r_prep) led_8\VBN|a||side (r_relcl) effect_5\NN|.|TDP (r_attr) is_1\VBZ|NONE (l_nsubj) TDP_0\NNP|effect|.
D016593_D016171 CID terfenadine_13\NN|:|were|TDP (r_appos) investigated_11\VBN|NONE (l_nsubjpass) TDP_9\NNP|:|terfenadine|were
D016593_D016171 CID terfenadine_10\NN|)|the|( (r_appos) clinic_8\NN|NONE (r_pobj) in_6\IN|have|TDP|that (r_prep) shown_4\VBN|NONE (l_dobj) TDP_5\NNP|have|in|that
2549018
D005473_D001008 NONE fluoxetine_2\NN| (r_npadvmod) induced_4\VBN|of|typical|The (r_amod) symptoms_5\NNS|indistinguishable|. (l_prep) of_6\IN|typical|induced|The (l_pobj) restlessness_7\NN|NONE (l_conj) pacing_10\NN|, (l_conj) movements_13\NNS|,|constant (l_conj) anxiety_22\NN|and|of|,|purposeless
D005473_D017109 CID Fluoxetine_0\NNP| (r_npadvmod) induced_2\VBN|implications|:|. (r_amod) akathisia_3\NN|NONE
D005473_D017109 CID fluoxetine_3\NN|for (r_dobj) receiving_2\VBG|Five (r_acl) patients_1\NNS|.|akathisia (r_nsubj) developed_14\VBD|NONE (l_dobj) akathisia_15\NN|.|patients
D005473_D017109 CID fluoxetine_2\NN| (r_npadvmod) induced_4\VBN|of|typical|The (r_amod) symptoms_5\NNS|indistinguishable|. (r_nsubj) were_23\VBD|NONE (l_acomp) indistinguishable_24\JJ|.|symptoms (l_prep) from_25\IN|NONE (l_pobj) those_26\DT|NONE (l_prep) of_27\IN|NONE (l_pobj) akathisia_31\NN|NONE
D005473_D017109 CID fluoxetine_17\NN| (r_advmod) induced_19\VBN|NONE (r_amod) akathisia_20\NN|NONE (r_pobj) of_16\IN|the (r_prep) symptoms_15\NNS|milder|identical|,|that (r_nsubj) were_21\VBD|.|patients (r_ccomp) reported_12\VBD|NONE (l_nsubj) patients_1\NNS|.|were (l_relcl) experienced_4\VBN|Three (l_dobj) akathisia_8\NN|who|had
D005473_D017109 CID fluoxetine_17\NN| (r_advmod) induced_19\VBN|NONE (r_amod) akathisia_20\NN|NONE
D005473_D017109 CID fluoxetine_9\NN|NONE (r_pobj) of_8\IN|common|a|side (r_prep) effect_7\NN|to (r_attr) be_3\VB|.|and|responded|Akathisia (r_xcomp) appeared_1\VBD|NONE (l_nsubj) Akathisia_0\NNP|.|be|and|responded
D005473_D017109 CID fluoxetine_4\NN| (r_advmod) induced_6\VBN|NONE (r_amod) akathisia_7\NN|that|by|may|be|be
D005473_D017109 CID fluoxetine_4\NN| (r_advmod) induced_6\VBN|NONE (r_amod) akathisia_7\NN|that|by|may|be|be (r_nsubjpass) caused_10\VBN|authors|. (l_conj) be_36\VB|that|by|akathisia|may|be (l_nsubj) pathophysiology_21\NN|that|may|identical|" (l_prep) of_22\IN|the (l_pobj) akathisia_26\NN|NONE
D005473_D017109 CID fluoxetine_23\NN| (r_advmod) induced_25\VBN|and|jitteriness (r_amod) akathisia_26\NN|NONE (r_pobj) of_22\IN|the (r_prep) pathophysiology_21\NN|that|may|identical|" (r_nsubj) be_36\VB|that|by|akathisia|may|be (r_conj) caused_10\VBN|authors|. (l_nsubjpass) akathisia_7\NN|that|by|may|be|be
D005473_D017109 CID fluoxetine_23\NN| (r_advmod) induced_25\VBN|and|jitteriness (r_amod) akathisia_26\NN|NONE
D005473_D003865 NONE fluoxetine_3\NN|for (r_dobj) receiving_2\VBG|Five (l_prep) for_4\IN|fluoxetine (l_pobj) treatment_6\NN|NONE (l_prep) of_7\IN|the (l_pobj) disorder_10\NN|NONE (l_conj) depression_13\NN|obsessive|or|compulsive
D005473_D009771 NONE fluoxetine_3\NN|for (r_dobj) receiving_2\VBG|Five (l_prep) for_4\IN|fluoxetine (l_pobj) treatment_6\NN|NONE (l_prep) of_7\IN|the (l_pobj) disorder_10\NN|NONE
D011433_D017109 NONE propranolol_22\NN|,|adrenergic|the|reduction (r_acl) antagonist_21\NN|NONE (r_pobj) with_16\IN|NONE (r_prep) treatment_15\NN|NONE (r_pobj) to_14\IN|generally|well (r_prep) responded_12\VBD|.|be|and|Akathisia (r_conj) appeared_1\VBD|NONE (l_nsubj) Akathisia_0\NNP|.|be|and|responded
D000928_D017109 NONE antidepressant_29\NN| (r_npadvmod) induced_31\VBN|tricyclic|" (r_amod) jitteriness_33\NN|induced|and (r_conj) akathisia_26\NN|NONE (r_pobj) of_22\IN|the (r_prep) pathophysiology_21\NN|that|may|identical|" (r_nsubj) be_36\VB|that|by|akathisia|may|be (r_conj) caused_10\VBN|authors|. (l_nsubjpass) akathisia_7\NN|that|by|may|be|be
D000928_D017109 NONE antidepressant_29\NN| (r_npadvmod) induced_31\VBN|tricyclic|" (r_amod) jitteriness_33\NN|induced|and (r_conj) akathisia_26\NN|NONE
11230490
D003520_D064420 NONE cyclophosphamide_46\NN|NONE (r_pobj) of_45\IN|)|with (r_prep) combination_38\NN|NONE (r_pobj) in_37\IN|weeks|,|to|m(|doxorubicin|, (r_prep) receive_18\VB|were|.|patients (l_npadvmod) weeks_53\NNS|,|to|m(|doxorubicin|in|, (l_prep) until_54\IN||every (l_pobj) progression_56\NN|NONE (l_conj) toxicity_59\NN|disease|or
D003520_D001943 NONE cyclophosphamide_12\NN|encapsulated|and (r_conj) doxorubicin_10\NN|NONE (r_pobj) of_6\IN|preserved|antitumor (r_prep) efficacy_5\NN|compared|Reduced|and|. (r_conj) cardiotoxicity_1\NN|NONE (l_prep) compared_13\VBN|Reduced|and|efficacy|. (l_prep) in_19\IN|with (l_pobj) trial_24\NN|NONE (l_prep) of_25\IN|multicenter|randomized|a|, (l_pobj) cancer_28\NN|NONE
D003520_D001943 NONE cyclophosphamide_18\NN|and|conventional (r_conj) doxorubicin_16\NN|NONE (r_pobj) with_14\IN|in (r_prep) compared_13\VBN|Reduced|and|efficacy|. (l_prep) in_19\IN|with (l_pobj) trial_24\NN|NONE (l_prep) of_25\IN|multicenter|randomized|a|, (l_pobj) cancer_28\NN|NONE
D003520_D001943 NONE cyclophosphamide_24\NN|NONE (r_pobj) with_23\IN|NONE (r_prep) combination_22\NN|NONE (r_pobj) in_21\IN|The|,|Liposome|Corporation|) (r_prep) Company_12\NNP|cardiotoxicity|;|significantly|.|providing|determine (r_nsubj) reduces_26\VBZ|NONE (l_advcl) providing_30\VBG|cardiotoxicity|;|Company|significantly|.|determine (l_prep) in_34\IN|efficacy|while (l_pobj) treatment_38\NN|NONE (l_prep) of_39\IN|line (l_pobj) cancer_42\NN|NONE
D003520_D001943 NONE cyclophosphamide_24\NN|NONE (r_pobj) with_23\IN|NONE (r_prep) combination_22\NN|NONE (r_pobj) in_21\IN|The|,|Liposome|Corporation|) (r_prep) Company_12\NNP|cardiotoxicity|;|significantly|.|providing|determine (r_nsubj) reduces_26\VBZ|NONE (l_advcl) providing_30\VBG|cardiotoxicity|;|Company|significantly|.|determine (l_prep) in_34\IN|efficacy|while (l_pobj) treatment_38\NN|NONE (l_prep) of_39\IN|line (l_pobj) cancer_42\NN|NONE (l_appos) MBC_44\NNP|breast|metastatic
D003520_D001943 NONE cyclophosphamide_46\NN|NONE (r_pobj) of_45\IN|)|with (r_prep) combination_38\NN|NONE (r_pobj) in_37\IN|weeks|,|to|m(|doxorubicin|, (r_prep) receive_18\VB|were|.|patients (r_xcomp) randomized_16\VBN|NONE (l_nsubjpass) patients_5\NNS|were|receive|. (l_prep) with_6\IN|chemotherapy|and|seven (l_pobj) MBC_7\NNP|NONE
D003520_D001943 NONE cyclophosphamide_26\NN|NONE (r_pobj) with_25\IN|NONE (r_prep) combination_24\NN|NONE (r_pobj) in_23\IN|as|when (r_prep) used_22\VBN|efficacy|, (l_prep) as_27\IN|when|in (l_pobj) therapy_31\NN|NONE (l_prep) for_32\IN|line (l_pobj) MBC_33\NNP|NONE
D004317_D066126 NONE doxorubicin_10\NN|NONE (r_pobj) of_6\IN|preserved|antitumor (r_prep) efficacy_5\NN|compared|Reduced|and|. (r_conj) cardiotoxicity_1\NN|NONE
D004317_D066126 NONE doxorubicin_16\NN|NONE (r_pobj) with_14\IN|in (r_prep) compared_13\VBN|Reduced|and|efficacy|. (r_prep) cardiotoxicity_1\NN|NONE
D004317_D066126 NONE Myocet_3\NNP|whether|encapsulated (r_nmod) doxorubicin_8\NN|To (r_dobj) determine_1\VB|cardiotoxicity|;|Company|significantly|.|providing (r_advcl) reduces_26\VBZ|NONE (l_dobj) cardiotoxicity_28\NN|;|Company|significantly|.|providing|determine
D004317_D066126 NONE doxorubicin_8\NN|To (r_dobj) determine_1\VB|cardiotoxicity|;|Company|significantly|.|providing (r_advcl) reduces_26\VBZ|NONE (l_dobj) cardiotoxicity_28\NN|;|Company|significantly|.|providing|determine
D004317_D066126 NONE doxorubicin_27\NN|NONE (r_compound) cardiotoxicity_28\NN|;|Company|significantly|.|providing|determine
D004317_D066126 NONE Myocet_0\NNP|and|index|by|neutropenia|provides|. (r_nsubj) improves_1\VBZ|NONE (l_prep) by_7\IN|and|index|Myocet|neutropenia|provides|. (l_pcomp) reducing_9\VBG|NONE (l_dobj) cardiotoxicity_10\NN|significantly
D004317_D066126 NONE doxorubicin_6\NN|NONE (r_pobj) of_5\IN|the|therapeutic (r_prep) index_4\NN|and|Myocet|by|neutropenia|provides|. (r_dobj) improves_1\VBZ|NONE (l_prep) by_7\IN|and|index|Myocet|neutropenia|provides|. (l_pcomp) reducing_9\VBG|NONE (l_dobj) cardiotoxicity_10\NN|significantly
D003520_D009503 CID cyclophosphamide_26\NN|NONE (r_pobj) with_25\IN|NONE (r_prep) combination_24\NN|NONE (r_pobj) in_23\IN|as|when (r_prep) used_22\VBN|efficacy|, (r_advcl) provides_16\VBZ|and|index|Myocet|by|neutropenia|. (r_conj) improves_1\VBZ|NONE (l_dobj) neutropenia_14\NN|and|index|Myocet|by|provides|.
D003520_D066126 NONE cyclophosphamide_12\NN|encapsulated|and (r_conj) doxorubicin_10\NN|NONE (r_pobj) of_6\IN|preserved|antitumor (r_prep) efficacy_5\NN|compared|Reduced|and|. (r_conj) cardiotoxicity_1\NN|NONE
D003520_D066126 NONE cyclophosphamide_18\NN|and|conventional (r_conj) doxorubicin_16\NN|NONE (r_pobj) with_14\IN|in (r_prep) compared_13\VBN|Reduced|and|efficacy|. (r_prep) cardiotoxicity_1\NN|NONE
D003520_D066126 NONE cyclophosphamide_24\NN|NONE (r_pobj) with_23\IN|NONE (r_prep) combination_22\NN|NONE (r_pobj) in_21\IN|The|,|Liposome|Corporation|) (r_prep) Company_12\NNP|cardiotoxicity|;|significantly|.|providing|determine (r_nsubj) reduces_26\VBZ|NONE (l_dobj) cardiotoxicity_28\NN|;|Company|significantly|.|providing|determine
D003520_D066126 NONE cyclophosphamide_26\NN|NONE (r_pobj) with_25\IN|NONE (r_prep) combination_24\NN|NONE (r_pobj) in_23\IN|as|when (r_prep) used_22\VBN|efficacy|, (r_advcl) provides_16\VBZ|and|index|Myocet|by|neutropenia|. (r_conj) improves_1\VBZ|NONE (l_prep) by_7\IN|and|index|Myocet|neutropenia|provides|. (l_pcomp) reducing_9\VBG|NONE (l_dobj) cardiotoxicity_10\NN|significantly
D004317_D009503 CID Myocet_0\NNP|and|index|by|neutropenia|provides|. (r_nsubj) improves_1\VBZ|NONE (l_dobj) neutropenia_14\NN|and|index|Myocet|by|provides|.
D004317_D009503 CID doxorubicin_6\NN|NONE (r_pobj) of_5\IN|the|therapeutic (r_prep) index_4\NN|and|Myocet|by|neutropenia|provides|. (r_dobj) improves_1\VBZ|NONE (l_dobj) neutropenia_14\NN|and|index|Myocet|by|provides|.
D004317_D001943 NONE doxorubicin_10\NN|NONE (r_pobj) of_6\IN|preserved|antitumor (r_prep) efficacy_5\NN|compared|Reduced|and|. (r_conj) cardiotoxicity_1\NN|NONE (l_prep) compared_13\VBN|Reduced|and|efficacy|. (l_prep) in_19\IN|with (l_pobj) trial_24\NN|NONE (l_prep) of_25\IN|multicenter|randomized|a|, (l_pobj) cancer_28\NN|NONE
D004317_D001943 NONE doxorubicin_16\NN|NONE (r_pobj) with_14\IN|in (r_prep) compared_13\VBN|Reduced|and|efficacy|. (l_prep) in_19\IN|with (l_pobj) trial_24\NN|NONE (l_prep) of_25\IN|multicenter|randomized|a|, (l_pobj) cancer_28\NN|NONE
D004317_D001943 NONE Myocet_3\NNP|whether|encapsulated (r_nmod) doxorubicin_8\NN|To (r_dobj) determine_1\VB|cardiotoxicity|;|Company|significantly|.|providing (r_advcl) reduces_26\VBZ|NONE (l_advcl) providing_30\VBG|cardiotoxicity|;|Company|significantly|.|determine (l_prep) in_34\IN|efficacy|while (l_pobj) treatment_38\NN|NONE (l_prep) of_39\IN|line (l_pobj) cancer_42\NN|NONE
D004317_D001943 NONE Myocet_3\NNP|whether|encapsulated (r_nmod) doxorubicin_8\NN|To (r_dobj) determine_1\VB|cardiotoxicity|;|Company|significantly|.|providing (r_advcl) reduces_26\VBZ|NONE (l_advcl) providing_30\VBG|cardiotoxicity|;|Company|significantly|.|determine (l_prep) in_34\IN|efficacy|while (l_pobj) treatment_38\NN|NONE (l_prep) of_39\IN|line (l_pobj) cancer_42\NN|NONE (l_appos) MBC_44\NNP|breast|metastatic
D004317_D001943 NONE doxorubicin_8\NN|To (r_dobj) determine_1\VB|cardiotoxicity|;|Company|significantly|.|providing (r_advcl) reduces_26\VBZ|NONE (l_advcl) providing_30\VBG|cardiotoxicity|;|Company|significantly|.|determine (l_prep) in_34\IN|efficacy|while (l_pobj) treatment_38\NN|NONE (l_prep) of_39\IN|line (l_pobj) cancer_42\NN|NONE
D004317_D001943 NONE doxorubicin_8\NN|To (r_dobj) determine_1\VB|cardiotoxicity|;|Company|significantly|.|providing (r_advcl) reduces_26\VBZ|NONE (l_advcl) providing_30\VBG|cardiotoxicity|;|Company|significantly|.|determine (l_prep) in_34\IN|efficacy|while (l_pobj) treatment_38\NN|NONE (l_prep) of_39\IN|line (l_pobj) cancer_42\NN|NONE (l_appos) MBC_44\NNP|breast|metastatic
D004317_D001943 NONE doxorubicin_27\NN|NONE (r_compound) cardiotoxicity_28\NN|;|Company|significantly|.|providing|determine (r_dobj) reduces_26\VBZ|NONE (l_advcl) providing_30\VBG|cardiotoxicity|;|Company|significantly|.|determine (l_prep) in_34\IN|efficacy|while (l_pobj) treatment_38\NN|NONE (l_prep) of_39\IN|line (l_pobj) cancer_42\NN|NONE
D004317_D001943 NONE doxorubicin_27\NN|NONE (r_compound) cardiotoxicity_28\NN|;|Company|significantly|.|providing|determine (r_dobj) reduces_26\VBZ|NONE (l_advcl) providing_30\VBG|cardiotoxicity|;|Company|significantly|.|determine (l_prep) in_34\IN|efficacy|while (l_pobj) treatment_38\NN|NONE (l_prep) of_39\IN|line (l_pobj) cancer_42\NN|NONE (l_appos) MBC_44\NNP|breast|metastatic
D004317_D001943 NONE Myocet_26\NNP|)|( (r_nmod) M_28\NNP|NONE (r_pobj) of_25\IN||/|)|mg|either|or (r_prep) m(2_23\NN|weeks|,|to|doxorubicin|in|, (r_dobj) receive_18\VB|were|.|patients (r_xcomp) randomized_16\VBN|NONE (l_nsubjpass) patients_5\NNS|were|receive|. (l_prep) with_6\IN|chemotherapy|and|seven (l_pobj) MBC_7\NNP|NONE
D004317_D001943 NONE doxorubicin_32\NN|weeks|,|to|m(|in|, (r_dobj) receive_18\VB|were|.|patients (r_xcomp) randomized_16\VBN|NONE (l_nsubjpass) patients_5\NNS|were|receive|. (l_prep) with_6\IN|chemotherapy|and|seven (l_pobj) MBC_7\NNP|NONE
D004317_D001943 NONE Myocet_0\NNP|and|index|by|neutropenia|provides|. (r_nsubj) improves_1\VBZ|NONE (l_conj) provides_16\VBZ|and|index|Myocet|by|neutropenia|. (l_advcl) used_22\VBN|efficacy|, (l_prep) as_27\IN|when|in (l_pobj) therapy_31\NN|NONE (l_prep) for_32\IN|line (l_pobj) MBC_33\NNP|NONE
D004317_D001943 NONE doxorubicin_6\NN|NONE (r_pobj) of_5\IN|the|therapeutic (r_prep) index_4\NN|and|Myocet|by|neutropenia|provides|. (r_dobj) improves_1\VBZ|NONE (l_conj) provides_16\VBZ|and|index|Myocet|by|neutropenia|. (l_advcl) used_22\VBN|efficacy|, (l_prep) as_27\IN|when|in (l_pobj) therapy_31\NN|NONE (l_prep) for_32\IN|line (l_pobj) MBC_33\NNP|NONE
D004317_D064420 NONE Myocet_26\NNP|)|( (r_nmod) M_28\NNP|NONE (r_pobj) of_25\IN||/|)|mg|either|or (r_prep) m(2_23\NN|weeks|,|to|doxorubicin|in|, (r_dobj) receive_18\VB|were|.|patients (l_npadvmod) weeks_53\NNS|,|to|m(|doxorubicin|in|, (l_prep) until_54\IN||every (l_pobj) progression_56\NN|NONE (l_conj) toxicity_59\NN|disease|or
D004317_D064420 NONE doxorubicin_32\NN|weeks|,|to|m(|in|, (r_dobj) receive_18\VB|were|.|patients (l_npadvmod) weeks_53\NNS|,|to|m(|doxorubicin|in|, (l_prep) until_54\IN||every (l_pobj) progression_56\NN|NONE (l_conj) toxicity_59\NN|disease|or
17600377
D012601_D003072 CID scopolamine_17\NN| (r_npadvmod) injected_19\VBN|NONE (r_amod) rats_20\NNS|in|and (r_pobj) in_16\IN|cognitive (r_prep) decline_15\NN|coumarate|whether|could
C524754_D000544 NONE coumarate_17\NN|that|maltolyl|candidate (r_nsubj) is_18\VBZ|,|study|results|. (l_attr) candidate_22\NN|that|coumarate|maltolyl (l_prep) against_23\IN|effective|characterized|a (l_pobj) disease_26\NN|NONE
C524754_D003072 NONE coumarate_7\NN|,|,|novel|A (r_appos) compound_2\NN|and|shows|.|deficits (r_nsubj) attenuates_9\VBZ|NONE (l_dobj) deficits_11\NNS|and|shows|.|compound
C524754_D003072 NONE coumarate_11\NN|decline|whether|could (r_nsubj) improve_13\VB|,|we|In (l_dobj) decline_15\NN|coumarate|whether|could
C524754_D003072 NONE coumarate_3\NN|beta|attenuate|.|was (r_nsubjpass) found_5\VBN|NONE (l_xcomp) attenuate_7\VB|beta|.|coumarate|was (l_dobj) deficits_9\NNS|to
C524754_D003072 NONE coumarate_17\NN|that|maltolyl|candidate (r_nsubj) is_18\VBZ|,|study|results|. (l_attr) candidate_22\NN|that|coumarate|maltolyl (l_relcl) characterized_29\VBN|effective|against|a (l_agent) by_30\IN|that|is (l_pobj) death_34\NN|NONE (l_conj) decline_37\NN|spread|neuronal|and (l_prep) of_38\IN|progressive (l_pobj) function_40\NN|NONE
C544092_D003072 NONE beta_24\NN|NONE (r_pobj) in_22\IN|and|rats (r_conj) in_16\IN|cognitive (r_prep) decline_15\NN|coumarate|whether|could
C544092_D003072 NONE 42)-infused_34\VBN|NONE (r_amod) rats_35\NNS|amyloid (r_dobj) beta_31\NN|attenuate|.|coumarate|was (r_advcl) found_5\VBN|NONE (l_xcomp) attenuate_7\VB|beta|.|coumarate|was (l_dobj) deficits_9\NNS|to
C524754_D009410 NONE coumarate_17\NN|that|maltolyl|candidate (r_nsubj) is_18\VBZ|,|study|results|. (l_attr) candidate_22\NN|that|coumarate|maltolyl (l_relcl) characterized_29\VBN|effective|against|a (l_agent) by_30\IN|that|is (l_pobj) death_34\NN|NONE
C524754_D003704 NONE coumarate_7\NN|,|,|novel|A (r_appos) compound_2\NN|and|shows|.|deficits (r_nsubj) attenuates_9\VBZ|NONE (l_conj) shows_13\VBZ|and|.|compound|deficits (l_dobj) effects_15\NNS|NONE (l_prep) in_16\IN|neuroprotective (l_amod) vitro_17\FW|NONE (l_conj) in_19\IN|and (l_pobj) models_22\NNS|NONE (l_compound) dementia_21\NN|NONE
11912119
D007980_D004409 CID levodopa_3\RB| (r_npadvmod) induced_5\VBN|in (r_amod) dyskinesias_6\NNS|.|Force|and
D007980_D004409 CID levodopa_18\NN|NONE (r_compound) therapy_19\NN|NONE (r_pobj) of_17\IN|motor (r_prep) complications_16\NNS|NONE (r_pobj) to_14\IN|its (r_prep) relationship_13\NN|Parkinson|and (r_conj) disease_10\NN|NONE (r_pobj) in_7\IN|coordination|,|to|.|We (r_prep) assessed_1\VBD|NONE (l_prep) to_22\IN|coordination|,|.|We|in (l_pobj) dyskinesias_26\NNS|particularly
D007980_D004409 CID levodopa_18\NN|NONE (r_compound) therapy_19\NN|NONE (r_pobj) of_17\IN|motor (r_prep) complications_16\NNS|NONE (r_pobj) to_14\IN|its (r_prep) relationship_13\NN|Parkinson|and (r_conj) disease_10\NN|NONE (r_pobj) in_7\IN|coordination|,|to|.|We (r_prep) assessed_1\VBD|NONE (l_prep) to_22\IN|coordination|,|.|We|in (l_pobj) dyskinesias_26\NNS|particularly (l_appos) LID_28\NNP|(|induced|)
D007980_D004409 CID levodopa_23\VB| (r_npadvmod) induced_25\VBN|(|)|LID (r_amod) dyskinesias_26\NNS|particularly
D007980_D004409 CID levodopa_23\VB| (r_npadvmod) induced_25\VBN|(|)|LID (r_amod) dyskinesias_26\NNS|particularly (l_appos) LID_28\NNP|(|induced|)
D007980_D004409 CID levodopa_23\NN| (r_npadvmod) induced_25\VBN|LID|( (r_amod) dyskinesias_26\NNS|NONE (r_pobj) without_22\IN|and|disease|) (r_conj) with_9\IN|groups|.|We (l_pobj) disease_13\NN|and|without|) (l_conj) LID_15\NNP|n||(|,|Parkinson|+
D007980_D004409 CID levodopa_23\NN| (r_npadvmod) induced_25\VBN|LID|( (r_amod) dyskinesias_26\NNS|NONE
D007980_D004409 CID levodopa_23\NN| (r_npadvmod) induced_25\VBN|LID|( (r_amod) dyskinesias_26\NNS|NONE (l_appos) LID_32\NNP|(|induced
D007980_D004409 CID levodopa_28\RB|score|were|. (r_dobj) assessed_24\VBN|NONE (l_nsubjpass) score_2\NN|were|.|levodopa (l_prep) of_3\IN|The|motor (l_pobj) Scale_10\NNP|NONE (l_appos) score_14\NN|Parkinson|Rating|, (l_compound) dyskinesia_13\JJ|force|and|a|in
D007980_D004409 CID levodopa_21\NN|NONE (r_pobj) by_20\IN|)|In|.|force|significantly|,|was (r_agent) increased_19\VBN|NONE (l_prep) In_0\IN|)|.|by|force|significantly|,|was (l_pobj) disease_3\NN|NONE (l_conj) LID_5\NNP|+|Parkinson
D007980_D010300 NONE levodopa_3\RB| (r_npadvmod) induced_5\VBN|in (r_amod) dyskinesias_6\NNS|.|Force|and (l_prep) in_7\IN|induced (l_pobj) disease_10\NN|NONE
D007980_D010300 NONE levodopa_18\NN|NONE (r_compound) therapy_19\NN|NONE (r_pobj) of_17\IN|motor (r_prep) complications_16\NNS|NONE (r_pobj) to_14\IN|its (r_prep) relationship_13\NN|Parkinson|and (r_conj) disease_10\NN|NONE
D007980_D010300 NONE levodopa_23\VB| (r_npadvmod) induced_25\VBN|(|)|LID (r_amod) dyskinesias_26\NNS|particularly (r_pobj) to_22\IN|coordination|,|.|We|in (r_prep) assessed_1\VBD|NONE (l_prep) in_7\IN|coordination|,|to|.|We (l_pobj) disease_10\NN|NONE
D007980_D010300 NONE levodopa_23\NN| (r_npadvmod) induced_25\VBN|LID|( (r_amod) dyskinesias_26\NNS|NONE (r_pobj) without_22\IN|and|disease|) (r_conj) with_9\IN|groups|.|We (r_prep) studied_1\VBD|NONE (l_dobj) groups_3\NNS|.|with|We (l_prep) of_4\IN|two (l_pobj) patients_8\NNS|NONE (l_compound) disease_7\NN|Parkinson
D007980_D010300 NONE levodopa_23\NN| (r_npadvmod) induced_25\VBN|LID|( (r_amod) dyskinesias_26\NNS|NONE (r_pobj) without_22\IN|and|disease|) (r_conj) with_9\IN|groups|.|We (l_pobj) disease_13\NN|and|without|)
D007980_D010300 NONE levodopa_23\NN| (r_npadvmod) induced_25\VBN|LID|( (r_amod) dyskinesias_26\NNS|NONE (l_appos) LID_32\NNP|(|induced (l_compound) disease_30\NN||Parkinson|)|and||n|,|controls|,
D007980_D010300 NONE levodopa_28\RB|score|were|. (r_dobj) assessed_24\VBN|NONE (l_nsubjpass) score_2\NN|were|.|levodopa (l_prep) of_3\IN|The|motor (l_pobj) Scale_10\NNP|NONE (l_compound) Rating_9\NNP|score|Parkinson|, (l_compound) Disease_8\NNP|NONE
D007980_D010300 NONE levodopa_21\NN|NONE (r_pobj) by_20\IN|)|In|.|force|significantly|,|was (r_agent) increased_19\VBN|NONE (l_prep) In_0\IN|)|.|by|force|significantly|,|was (l_pobj) disease_3\NN|NONE
17244258
D003520_D003556 CID cyclophosphamide_9\NN| (r_npadvmod) induced_11\VBN|in (r_amod) cystitis_12\NN|NONE
D003520_D003556 CID cyclophosphamide_1\NN| (r_npadvmod) induced_3\VBN|in (r_amod) cystitis_4\NN|NONE
8665051
D000305_D009135 NONE corticosteroids_17\NNS|NONE (r_pobj) of_16\IN|massive (r_prep) doses_15\NNS|NONE (r_pobj) with_13\IN|NONE (r_prep) treated_12\VBN|NONE (r_acl) patients_11\NNS|NONE (r_pobj) in_10\IN|myopathy|that|may (r_prep) occur_9\VB|.|have|reports (l_nsubj) myopathy_7\NN|that|may|in
D008775_D000855 CID methylprednisolone_18\NN|saline|)|,|( (r_appos) C_15\NNP|NONE (r_pobj) of_12\IN|daily (r_prep) injection_11\NN|to (r_dobj) receive_9\VB|measured|.|rats|Therefore|,|showed|d|were|,|randomly|, (r_xcomp) assigned_7\VBN|NONE (l_conj) showed_46\VBD|measured|.|rats|Therefore|,|receive|d|were|,|randomly|, (l_dobj) reduction_49\NN|respectively|) (l_prep) of_50\IN|significant|a|in (l_pobj) intake_52\NN|NONE
D008775_D000855 CID M_20\NNP|triamcinolone|or|, (r_appos) methylprednisolone_18\NN|saline|)|,|( (r_appos) C_15\NNP|NONE (r_pobj) of_12\IN|daily (r_prep) injection_11\NN|to (r_dobj) receive_9\VB|measured|.|rats|Therefore|,|showed|d|were|,|randomly|, (r_xcomp) assigned_7\VBN|NONE (l_conj) showed_46\VBD|measured|.|rats|Therefore|,|receive|d|were|,|randomly|, (l_dobj) reduction_49\NN|respectively|) (l_prep) of_50\IN|significant|a|in (l_pobj) intake_52\NN|NONE
D008775_D000855 CID M_65\NNP|NONE (r_pobj) in_64\IN|NONE (r_prep) %_63\NN|the||(|treated (r_appos) groups_58\NNS|NONE (r_pobj) in_53\IN|significant|a|of (r_prep) reduction_49\NN|respectively|) (l_prep) of_50\IN|significant|a|in (l_pobj) intake_52\NN|NONE
D014221_D000855 CID triamcinolone_24\NN|M|or|, (r_conj) methylprednisolone_18\NN|saline|)|,|( (r_appos) C_15\NNP|NONE (r_pobj) of_12\IN|daily (r_prep) injection_11\NN|to (r_dobj) receive_9\VB|measured|.|rats|Therefore|,|showed|d|were|,|randomly|, (r_xcomp) assigned_7\VBN|NONE (l_conj) showed_46\VBD|measured|.|rats|Therefore|,|receive|d|were|,|randomly|, (l_dobj) reduction_49\NN|respectively|) (l_prep) of_50\IN|significant|a|in (l_pobj) intake_52\NN|NONE
D014221_D000855 CID T_26\NNP|NONE (r_appos) triamcinolone_24\NN|M|or|, (r_conj) methylprednisolone_18\NN|saline|)|,|( (r_appos) C_15\NNP|NONE (r_pobj) of_12\IN|daily (r_prep) injection_11\NN|to (r_dobj) receive_9\VB|measured|.|rats|Therefore|,|showed|d|were|,|randomly|, (r_xcomp) assigned_7\VBN|NONE (l_conj) showed_46\VBD|measured|.|rats|Therefore|,|receive|d|were|,|randomly|, (l_dobj) reduction_49\NN|respectively|) (l_prep) of_50\IN|significant|a|in (l_pobj) intake_52\NN|NONE
D014221_D000855 CID T_67\NNP|,|and (r_conj) M_65\NNP|NONE (r_pobj) in_64\IN|NONE (r_prep) %_63\NN|the||(|treated (r_appos) groups_58\NNS|NONE (r_pobj) in_53\IN|significant|a|of (r_prep) reduction_49\NN|respectively|) (l_prep) of_50\IN|significant|a|in (l_pobj) intake_52\NN|NONE
D013256_D009336 NONE steroid_18\NN|the (r_compound) groups_19\NNS|NONE (r_pobj) in_16\IN|IIb|and|fiber|atrophy (r_prep) atrophy_15\NN|revealed|.|ATPase|, (r_dobj) showed_11\VBD|NONE (l_advcl) revealed_32\VBD|atrophy|.|ATPase|, (l_dobj) pattern_36\NN|examinations|whereas (l_prep) with_37\IN|a|normal|muscular (l_pobj) absence_38\NN|NONE (l_prep) of_39\IN|NONE (l_pobj) necrosis_40\NN|NONE
D013256_D009336 NONE steroids_14\NNS|NONE (r_pobj) of_13\IN|massive (r_prep) doses_12\NNS|NONE (r_pobj) with_10\IN||)|(|term (r_prep) treatment_9\NN|that|wasting (r_nsubj) induced_15\VBD|We (r_ccomp) conclude_1\VBP|atrophy||;|,|types|resulting (r_ccomp) induced_30\VBD|steroid||necrosis|; (r_ccomp) caused_51\VBD|alone|was|by|not|.|atrophy|;|( (l_dobj) necrosis_53\NN|induced|steroid||;
D013256_D009336 NONE steroids_29\NNS|NONE (r_pobj) of_28\IN|both (r_prep) types_27\NNS|atrophy||conclude|;|,|resulting (r_nsubj) induced_30\VBD|steroid||necrosis|; (r_ccomp) caused_51\VBD|alone|was|by|not|.|atrophy|;|( (l_dobj) necrosis_53\NN|induced|steroid||;
D013256_D009336 NONE steroid_50\NN|induced||necrosis|; (r_nsubj) caused_51\VBD|alone|was|by|not|.|atrophy|;|( (l_dobj) necrosis_53\NN|induced|steroid||;
D014221_D009133 CID T_27\NNP|NONE (r_pobj) with_26\IN|IIa|also (r_prep) atrophy_25\NN|IIb|and|fiber|in (r_conj) atrophy_15\NN|revealed|.|ATPase|,
D014221_D009133 CID T_27\NNP|NONE (r_pobj) with_26\IN|IIa|also (r_prep) atrophy_25\NN|IIb|and|fiber|in
D014221_D009133 CID T_18\NNP|, (r_conj) C_16\NNP|(|)| (r_appos) rats_14\NNS|NONE (r_pobj) in_12\IN|NONE (r_prep) performed_11\VBN|(|a|fed|,|)|,|PF (r_acl) study_9\NN|Finally|,|was|. (r_nsubj) showed_24\VBD|NONE (l_ccomp) was_28\VBD|study|Finally|,|. (l_nsubj) atrophy_27\NN|pronounced|that
D014221_D009133 CID T_37\NNP| (r_npadvmod) treated_39\VBN|NONE (r_amod) animals_40\NNS|NONE (r_pobj) in_36\IN|NONE (r_prep) than_35\IN|in|less (r_prep) pronounced_31\VBN|that|atrophy (r_acomp) was_28\VBD|study|Finally|,|. (l_nsubj) atrophy_27\NN|pronounced|that
D008775_D013746 NONE M_19\NNP|NONE (r_pobj) with_18\IN|tension|longer|,|were|. (r_prep) was_16\VBD|in|time|and|was|, (l_advcl) were_24\VBD|tension|longer|with|,|. (l_nsubj) tensions_23\NNS|whereas|similar (l_compound) tetanic_22\JJ|NONE
D013256_D013746 NONE steroid_8\NN|both (r_compound) groups_9\NNS|NONE (r_pobj) in_6\IN|was|time|and|was|, (r_prep) prolonged_5\VBN|NONE (l_conj) was_16\VBD|in|time|and|was|, (l_advcl) were_24\VBD|tension|longer|with|,|. (l_nsubj) tensions_23\NNS|whereas|similar (l_compound) tetanic_22\JJ|NONE
D013256_D000855 NONE steroid_55\NN| (r_npadvmod) treated_57\VBN|the||(|% (r_amod) groups_58\NNS|NONE (r_pobj) in_53\IN|significant|a|of (r_prep) reduction_49\NN|respectively|) (l_prep) of_50\IN|significant|a|in (l_pobj) intake_52\NN|NONE
D013256_D001284 NONE steroids_14\NNS|NONE (r_pobj) of_13\IN|massive (r_prep) doses_12\NNS|NONE (r_pobj) with_10\IN||)|(|term (r_prep) treatment_9\NN|that|wasting (r_nsubj) induced_15\VBD|We (r_ccomp) conclude_1\VBP|atrophy||;|,|types|resulting (r_ccomp) induced_30\VBD|steroid||necrosis|; (l_dobj) atrophy_34\NN||conclude|;|,|types|resulting
D013256_D001284 NONE steroids_29\NNS|NONE (r_pobj) of_28\IN|both (r_prep) types_27\NNS|atrophy||conclude|;|,|resulting (r_nsubj) induced_30\VBD|steroid||necrosis|; (l_dobj) atrophy_34\NN||conclude|;|,|types|resulting
D013256_D001284 NONE steroid_50\NN|induced||necrosis|; (r_nsubj) caused_51\VBD|alone|was|by|not|.|atrophy|;|( (l_ccomp) induced_30\VBD|steroid||necrosis|; (l_dobj) atrophy_34\NN||conclude|;|,|types|resulting
D013256_D009133 NONE steroid_18\NN|the (r_compound) groups_19\NNS|NONE (r_pobj) in_16\IN|IIb|and|fiber|atrophy (r_prep) atrophy_15\NN|revealed|.|ATPase|,
D013256_D009133 NONE steroid_18\NN|the (r_compound) groups_19\NNS|NONE (r_pobj) in_16\IN|IIb|and|fiber|atrophy (r_prep) atrophy_15\NN|revealed|.|ATPase|, (l_conj) atrophy_25\NN|IIb|and|fiber|in
D013256_D009133 NONE steroids_14\NNS|NONE (r_pobj) of_13\IN|massive (r_prep) doses_12\NNS|NONE (r_pobj) with_10\IN||)|(|term (r_prep) treatment_9\NN|that|wasting (r_nsubj) induced_15\VBD|We (r_ccomp) conclude_1\VBP|atrophy||;|,|types|resulting (r_ccomp) induced_30\VBD|steroid||necrosis|; (r_ccomp) caused_51\VBD|alone|was|by|not|.|atrophy|;|( (r_ccomp) caused_63\VBN|NONE (l_nsubjpass) atrophy_60\NN|alone|was|by|not|.|caused|;|(
D013256_D009133 NONE steroids_29\NNS|NONE (r_pobj) of_28\IN|both (r_prep) types_27\NNS|atrophy||conclude|;|,|resulting (r_nsubj) induced_30\VBD|steroid||necrosis|; (r_ccomp) caused_51\VBD|alone|was|by|not|.|atrophy|;|( (r_ccomp) caused_63\VBN|NONE (l_nsubjpass) atrophy_60\NN|alone|was|by|not|.|caused|;|(
D013256_D009133 NONE steroid_50\NN|induced||necrosis|; (r_nsubj) caused_51\VBD|alone|was|by|not|.|atrophy|;|( (r_ccomp) caused_63\VBN|NONE (l_nsubjpass) atrophy_60\NN|alone|was|by|not|.|caused|;|(
D014221_D009336 NONE T_27\NNP|NONE (r_pobj) with_26\IN|IIa|also (r_prep) atrophy_25\NN|IIb|and|fiber|in (r_conj) atrophy_15\NN|revealed|.|ATPase|, (r_dobj) showed_11\VBD|NONE (l_advcl) revealed_32\VBD|atrophy|.|ATPase|, (l_dobj) pattern_36\NN|examinations|whereas (l_prep) with_37\IN|a|normal|muscular (l_pobj) absence_38\NN|NONE (l_prep) of_39\IN|NONE (l_pobj) necrosis_40\NN|NONE
9121607
D007608_D012640 CID acid_7\NN| (r_npadvmod) induced_9\VBN|and|limbic|status|pilocarpine (r_amod) seizures_11\NNS|NONE
D007608_D012640 CID acid_28\NN|NONE (r_pobj) by_26\IN|NONE (r_agent) induced_25\VBN|a|in|dependent (r_acl) delay_18\NN|Steroids|configurations|.|,|protect|but|also (l_prep) in_19\IN|a|induced|dependent (l_pobj) onset_21\NN|NONE (l_prep) of_22\IN|the (l_pobj) seizures_24\NNS|NONE
D007608_D012640 CID acid_28\NN|NONE (r_pobj) by_26\IN|NONE (r_agent) induced_25\VBN|a|in|dependent (r_acl) delay_18\NN|Steroids|configurations|.|,|protect|but|also (r_dobj) produced_13\VBD|NONE (l_conj) protect_40\VB|Steroids|configurations|.|delay|,|but|also (l_prep) against_41\IN|completely|did|not (l_pobj) seizures_43\NNS|NONE
D007608_D012640 CID acid_23\NN| (r_npadvmod) induced_25\VBN|epilepticus|limbic|kainic|and (r_amod) seizures_27\NNS|NONE
D007608_D012640 CID acid_14\NN| (r_npadvmod) induced_16\VBN|pilocarpine|and|status (r_amod) seizures_17\NNS|NONE
D007608_D013226 CID acid_7\NN| (r_npadvmod) induced_9\VBN|and|limbic|status|pilocarpine (r_amod) seizures_11\NNS|NONE (r_pobj) against_3\IN|epilepticus|.|steroids (r_prep) protect_2\VBP|NONE (l_advcl) epilepticus_14\NN|.|steroids|against
D007608_D013226 CID acid_23\NN| (r_npadvmod) induced_25\VBN|epilepticus|limbic|kainic|and (r_amod) seizures_27\NNS|NONE (l_conj) epilepticus_30\NN|limbic|kainic|induced|and
D007608_D013226 CID acid_14\NN| (r_npadvmod) induced_16\VBN|pilocarpine|and|status (r_amod) seizures_17\NNS|NONE (r_pobj) against_10\IN|NONE (r_prep) protecting_9\VBG|NONE (r_pcomp) in_8\IN|highly (r_prep) effective_7\JJ|,|steroids|epilepticus|and|that|be (r_acomp) are_5\VBP|.|We (l_advcl) epilepticus_20\NN|,|steroids|and|effective|that|be
D007608_D013226 CID acid_14\NN| (r_npadvmod) induced_16\VBN|pilocarpine|and|status (r_amod) seizures_17\NNS|NONE (r_pobj) against_10\IN|NONE (r_prep) protecting_9\VBG|NONE (r_pcomp) in_8\IN|highly (r_prep) effective_7\JJ|,|steroids|epilepticus|and|that|be (r_acomp) are_5\VBP|.|We (l_conj) be_26\VB|,|steroids|epilepticus|and|effective|that (l_advmod) epilepticus_37\NN|may|of|in
D001569_D064420 NONE benzodiazepine_10\JJ|than|in|the (r_amod) clonazepam_11\NN|less (r_advcl) potent_7\JJ|steroids|Although (r_acomp) were_4\VBD|values|clonazepam|.|,|indicating|steroids|, (r_advcl) had_26\VBD|NONE (l_advcl) indicating_48\VBG|values|clonazepam|.|,|steroids|,|were (l_ccomp) have_54\VB|NONE (l_dobj) toxicity_57\NN|that|steroids|may
D010862_D012640 CID pilocarpine-_4\NN|induced|and|limbic|status (r_nmod) seizures_11\NNS|NONE
D010862_D012640 CID pilocarpine_25\NN|NONE (r_pobj) against_24\IN|NONE (r_prep) protecting_23\VBG|NONE (r_pcomp) in_22\IN|highly (r_prep) effective_21\JJ|Steroids|mg/kg|values|. (r_acomp) were_19\VBD|NONE (l_parataxis) mg/kg_28\NNS|Steroids|values|.|effective (l_conj) s.c.)-induced_30\VBN|,||( (l_dobj) seizures_33\NNS|NONE
D010862_D012640 CID pilocarpine_15\NN|NONE (r_amod) seizures_16\NNS|NONE
D010862_D012640 CID pilocarpine_15\NN|NONE (r_amod) seizures_16\NNS|NONE (r_pobj) against_14\IN|NONE (r_prep) protecting_13\VBG|NONE (r_pcomp) in_12\IN|benzodiazepine|than|the (r_prep) clonazepam_11\NN|less (r_advcl) potent_7\JJ|steroids|Although (r_acomp) were_4\VBD|values|clonazepam|.|,|indicating|steroids|, (r_advcl) had_26\VBD|NONE (l_dobj) values_32\NNS|clonazepam|.|,|indicating|steroids|,|were (l_appos) TD50_34\NNP|protective|(|index|comparable|) (l_acl) divided_38\VBN|for (l_prep) for_41\IN|by (l_pobj) protection_43\NN|NONE (l_compound) seizure_42\NN|NONE
D010862_D012640 CID pilocarpine-_11\NN|induced|and|status (r_nmod) seizures_17\NNS|NONE
D013256_D064420 NONE steroids_3\NNS|potent|Although (r_nsubj) were_4\VBD|values|clonazepam|.|,|indicating|steroids|, (r_advcl) had_26\VBD|NONE (l_advcl) indicating_48\VBG|values|clonazepam|.|,|steroids|,|were (l_ccomp) have_54\VB|NONE (l_dobj) toxicity_57\NN|that|steroids|may
D013256_D064420 NONE steroids_18\NNS|values|clonazepam|.|,|indicating|,|were (r_nsubj) had_26\VBD|NONE (l_advcl) indicating_48\VBG|values|clonazepam|.|,|steroids|,|were (l_ccomp) have_54\VB|NONE (l_dobj) toxicity_57\NN|that|steroids|may
D013256_D064420 NONE steroids_52\NNS|that|toxicity|may (r_nsubj) have_54\VB|NONE (l_dobj) toxicity_57\NN|that|steroids|may
D013256_D013226 NONE steroids_1\NNS|epilepticus|.|against (r_nsubj) protect_2\VBP|NONE (l_advcl) epilepticus_14\NN|.|steroids|against
D013256_D013226 NONE Steroids_0\NNS|mg/kg|values|.|effective (r_nsubj) were_19\VBD|NONE (l_npadvmod) values_39\NNS|Steroids|mg/kg|.|effective (l_amod) epilepticus_36\NN|)|ED|mg/kg|(|,
D013256_D013226 NONE steroid_8\NN|NONE (r_pobj) of_6\IN|a|second (r_prep) dose_5\NN|when|was (r_nsubjpass) administered_10\VBN||However|after|, (r_advcl) hr_12\NN|,|complete|from (r_nmod) protection_19\NN|.|was (l_prep) from_20\IN|hr|,|complete (l_pobj) seizures_27\NNS|NONE (l_conj) epilepticus_30\NN|limbic|kainic|induced|and
D013256_D013226 NONE steroids_4\NNS|,|epilepticus|and|effective|that|be (r_nsubj) are_5\VBP|.|We (l_advcl) epilepticus_20\NN|,|steroids|and|effective|that|be
D013256_D013226 NONE steroids_4\NNS|,|epilepticus|and|effective|that|be (r_nsubj) are_5\VBP|.|We (l_conj) be_26\VB|,|steroids|epilepticus|and|effective|that (l_advmod) epilepticus_37\NN|may|of|in
D002998_D064420 NONE clonazepam_11\NN|less (r_advcl) potent_7\JJ|steroids|Although (r_acomp) were_4\VBD|values|clonazepam|.|,|indicating|steroids|, (r_advcl) had_26\VBD|NONE (l_advcl) indicating_48\VBG|values|clonazepam|.|,|steroids|,|were (l_ccomp) have_54\VB|NONE (l_dobj) toxicity_57\NN|that|steroids|may
D002998_D064420 NONE clonazepam_46\NN|values|.|,|indicating|steroids|,|were (r_advcl) had_26\VBD|NONE (l_advcl) indicating_48\VBG|values|clonazepam|.|,|steroids|,|were (l_ccomp) have_54\VB|NONE (l_dobj) toxicity_57\NN|that|steroids|may
D016202_D012640 NONE aspartate_6\NNP|NONE (l_appos) seizures_9\NNS|methyl||D|.
D016202_D012640 NONE NMDA)-induced_8\JJ|(|in (r_amod) seizures_9\NNS|methyl||D|.
D016202_D012640 NONE NMDA_10\NNP|NONE (r_pobj) in_9\IN|a|dependent|mg/kg|( (r_prep) delay_8\NN|steroids|protect|but|also|.|, (r_dobj) caused_3\VBD|NONE (l_conj) protect_22\VB|steroids|but|also|.|delay|, (l_prep) against_23\IN|completely|did|not (l_pobj) seizures_25\NNS|NONE
D016202_D012640 NONE NMDA_24\NNP|lethality|or (r_compound) seizures_25\NNS|NONE
D002998_D012640 NONE clonazepam_11\NN|less (l_prep) in_12\IN|benzodiazepine|than|the (l_pcomp) protecting_13\VBG|NONE (l_prep) against_14\IN|NONE (l_pobj) seizures_16\NNS|NONE
D002998_D012640 NONE clonazepam_11\NN|less (r_advcl) potent_7\JJ|steroids|Although (r_acomp) were_4\VBD|values|clonazepam|.|,|indicating|steroids|, (r_advcl) had_26\VBD|NONE (l_dobj) values_32\NNS|clonazepam|.|,|indicating|steroids|,|were (l_appos) TD50_34\NNP|protective|(|index|comparable|) (l_acl) divided_38\VBN|for (l_prep) for_41\IN|by (l_pobj) protection_43\NN|NONE (l_compound) seizure_42\NN|NONE
D002998_D012640 NONE clonazepam_46\NN|values|.|,|indicating|steroids|,|were (r_advcl) had_26\VBD|NONE (l_advcl) were_4\VBD|values|clonazepam|.|,|indicating|steroids|, (l_acomp) potent_7\JJ|steroids|Although (l_advcl) clonazepam_11\NN|less (l_prep) in_12\IN|benzodiazepine|than|the (l_pcomp) protecting_13\VBG|NONE (l_prep) against_14\IN|NONE (l_pobj) seizures_16\NNS|NONE
D002998_D012640 NONE clonazepam_46\NN|values|.|,|indicating|steroids|,|were (r_advcl) had_26\VBD|NONE (l_dobj) values_32\NNS|clonazepam|.|,|indicating|steroids|,|were (l_appos) TD50_34\NNP|protective|(|index|comparable|) (l_acl) divided_38\VBN|for (l_prep) for_41\IN|by (l_pobj) protection_43\NN|NONE (l_compound) seizure_42\NN|NONE
D013256_D012640 NONE steroids_1\NNS|epilepticus|.|against (r_nsubj) protect_2\VBP|NONE (l_prep) against_3\IN|epilepticus|.|steroids (l_pobj) seizures_11\NNS|NONE
D013256_D012640 NONE Steroids_0\NNS|mg/kg|values|.|effective (r_nsubj) were_19\VBD|NONE (l_parataxis) mg/kg_28\NNS|Steroids|values|.|effective (l_conj) s.c.)-induced_30\VBN|,||( (l_dobj) seizures_33\NNS|NONE
D013256_D012640 NONE steroids_3\NNS|potent|Although (r_nsubj) were_4\VBD|values|clonazepam|.|,|indicating|steroids|, (l_acomp) potent_7\JJ|steroids|Although (l_advcl) clonazepam_11\NN|less (l_prep) in_12\IN|benzodiazepine|than|the (l_pcomp) protecting_13\VBG|NONE (l_prep) against_14\IN|NONE (l_pobj) seizures_16\NNS|NONE
D013256_D012640 NONE steroids_3\NNS|potent|Although (r_nsubj) were_4\VBD|values|clonazepam|.|,|indicating|steroids|, (r_advcl) had_26\VBD|NONE (l_dobj) values_32\NNS|clonazepam|.|,|indicating|steroids|,|were (l_appos) TD50_34\NNP|protective|(|index|comparable|) (l_acl) divided_38\VBN|for (l_prep) for_41\IN|by (l_pobj) protection_43\NN|NONE (l_compound) seizure_42\NN|NONE
D013256_D012640 NONE steroids_18\NNS|values|clonazepam|.|,|indicating|,|were (r_nsubj) had_26\VBD|NONE (l_advcl) were_4\VBD|values|clonazepam|.|,|indicating|steroids|, (l_acomp) potent_7\JJ|steroids|Although (l_advcl) clonazepam_11\NN|less (l_prep) in_12\IN|benzodiazepine|than|the (l_pcomp) protecting_13\VBG|NONE (l_prep) against_14\IN|NONE (l_pobj) seizures_16\NNS|NONE
D013256_D012640 NONE steroids_18\NNS|values|clonazepam|.|,|indicating|,|were (r_nsubj) had_26\VBD|NONE (l_dobj) values_32\NNS|clonazepam|.|,|indicating|steroids|,|were (l_appos) TD50_34\NNP|protective|(|index|comparable|) (l_acl) divided_38\VBN|for (l_prep) for_41\IN|by (l_pobj) protection_43\NN|NONE (l_compound) seizure_42\NN|NONE
D013256_D012640 NONE steroids_52\NNS|that|toxicity|may (r_nsubj) have_54\VB|NONE (r_ccomp) indicating_48\VBG|values|clonazepam|.|,|steroids|,|were (r_advcl) had_26\VBD|NONE (l_advcl) were_4\VBD|values|clonazepam|.|,|indicating|steroids|, (l_acomp) potent_7\JJ|steroids|Although (l_advcl) clonazepam_11\NN|less (l_prep) in_12\IN|benzodiazepine|than|the (l_pcomp) protecting_13\VBG|NONE (l_prep) against_14\IN|NONE (l_pobj) seizures_16\NNS|NONE
D013256_D012640 NONE steroids_52\NNS|that|toxicity|may (r_nsubj) have_54\VB|NONE (r_ccomp) indicating_48\VBG|values|clonazepam|.|,|steroids|,|were (r_advcl) had_26\VBD|NONE (l_dobj) values_32\NNS|clonazepam|.|,|indicating|steroids|,|were (l_appos) TD50_34\NNP|protective|(|index|comparable|) (l_acl) divided_38\VBN|for (l_prep) for_41\IN|by (l_pobj) protection_43\NN|NONE (l_compound) seizure_42\NN|NONE
D013256_D012640 NONE Steroids_0\NNS|configurations|.|delay|,|protect|but|also (r_nsubj) produced_13\VBD|NONE (l_dobj) delay_18\NN|Steroids|configurations|.|,|protect|but|also (l_prep) in_19\IN|a|induced|dependent (l_pobj) onset_21\NN|NONE (l_prep) of_22\IN|the (l_pobj) seizures_24\NNS|NONE
D013256_D012640 NONE Steroids_0\NNS|configurations|.|delay|,|protect|but|also (r_nsubj) produced_13\VBD|NONE (l_conj) protect_40\VB|Steroids|configurations|.|delay|,|but|also (l_prep) against_41\IN|completely|did|not (l_pobj) seizures_43\NNS|NONE
D013256_D012640 NONE steroid_8\NN|NONE (r_pobj) of_6\IN|a|second (r_prep) dose_5\NN|when|was (r_nsubjpass) administered_10\VBN||However|after|, (r_advcl) hr_12\NN|,|complete|from (r_nmod) protection_19\NN|.|was (l_prep) from_20\IN|hr|,|complete (l_pobj) seizures_27\NNS|NONE
D013256_D012640 NONE steroids_1\NNS|protect|but|also|.|delay|, (r_nsubj) caused_3\VBD|NONE (l_conj) protect_22\VB|steroids|but|also|.|delay|, (l_prep) against_23\IN|completely|did|not (l_pobj) seizures_25\NNS|NONE
D013256_D012640 NONE steroids_4\NNS|,|epilepticus|and|effective|that|be (r_nsubj) are_5\VBP|.|We (l_acomp) effective_7\JJ|,|steroids|epilepticus|and|that|be (l_prep) in_8\IN|highly (l_pcomp) protecting_9\VBG|NONE (l_prep) against_10\IN|NONE (l_pobj) seizures_17\NNS|NONE
D010862_D064420 NONE pilocarpine_15\NN|NONE (r_amod) seizures_16\NNS|NONE (r_pobj) against_14\IN|NONE (r_prep) protecting_13\VBG|NONE (r_pcomp) in_12\IN|benzodiazepine|than|the (r_prep) clonazepam_11\NN|less (r_advcl) potent_7\JJ|steroids|Although (r_acomp) were_4\VBD|values|clonazepam|.|,|indicating|steroids|, (r_advcl) had_26\VBD|NONE (l_advcl) indicating_48\VBG|values|clonazepam|.|,|steroids|,|were (l_ccomp) have_54\VB|NONE (l_dobj) toxicity_57\NN|that|steroids|may
D010862_D013226 CID pilocarpine-_4\NN|induced|and|limbic|status (r_nmod) seizures_11\NNS|NONE (r_pobj) against_3\IN|epilepticus|.|steroids (r_prep) protect_2\VBP|NONE (l_advcl) epilepticus_14\NN|.|steroids|against
D010862_D013226 CID pilocarpine_25\NN|NONE (r_pobj) against_24\IN|NONE (r_prep) protecting_23\VBG|NONE (r_pcomp) in_22\IN|highly (r_prep) effective_21\JJ|Steroids|mg/kg|values|. (r_acomp) were_19\VBD|NONE (l_npadvmod) values_39\NNS|Steroids|mg/kg|.|effective (l_amod) epilepticus_36\NN|)|ED|mg/kg|(|,
D010862_D013226 CID pilocarpine-_11\NN|induced|and|status (r_nmod) seizures_17\NNS|NONE (r_pobj) against_10\IN|NONE (r_prep) protecting_9\VBG|NONE (r_pcomp) in_8\IN|highly (r_prep) effective_7\JJ|,|steroids|epilepticus|and|that|be (r_acomp) are_5\VBP|.|We (l_advcl) epilepticus_20\NN|,|steroids|and|effective|that|be
D010862_D013226 CID pilocarpine-_11\NN|induced|and|status (r_nmod) seizures_17\NNS|NONE (r_pobj) against_10\IN|NONE (r_prep) protecting_9\VBG|NONE (r_pcomp) in_8\IN|highly (r_prep) effective_7\JJ|,|steroids|epilepticus|and|that|be (r_acomp) are_5\VBP|.|We (l_conj) be_26\VB|,|steroids|epilepticus|and|effective|that (l_advmod) epilepticus_37\NN|may|of|in
D001569_D012640 NONE benzodiazepine_10\JJ|than|in|the (r_amod) clonazepam_11\NN|less (l_prep) in_12\IN|benzodiazepine|than|the (l_pcomp) protecting_13\VBG|NONE (l_prep) against_14\IN|NONE (l_pobj) seizures_16\NNS|NONE
D001569_D012640 NONE benzodiazepine_10\JJ|than|in|the (r_amod) clonazepam_11\NN|less (r_advcl) potent_7\JJ|steroids|Although (r_acomp) were_4\VBD|values|clonazepam|.|,|indicating|steroids|, (r_advcl) had_26\VBD|NONE (l_dobj) values_32\NNS|clonazepam|.|,|indicating|steroids|,|were (l_appos) TD50_34\NNP|protective|(|index|comparable|) (l_acl) divided_38\VBN|for (l_prep) for_41\IN|by (l_pobj) protection_43\NN|NONE (l_compound) seizure_42\NN|NONE
16167916
D020849_D054556 CID raloxifene_11\NN|NONE (r_compound) treatment_12\NN|NONE (r_pobj) to_10\IN|NONE (r_pcomp) due_9\IN|venous (r_amod) thromboembolism_8\NN|NONE
2466960
D005472_D007511 CID 5-FU_11\CD|for (r_compound) infusion_12\NN|NONE (r_dobj) undergoing_10\VBG| (r_acl) patients_9\NNS|NONE (r_pobj) on_7\IN|ECG|continuous (r_prep) monitoring_6\NN|prospectively|We|in|. (r_dobj) performed_2\VBD|NONE (l_prep) in_18\IN|prospectively|We|monitoring|. (l_pobj) order_19\NN|NONE (l_acl) assess_21\VB|NONE (l_dobj) incidence_23\NN|to (l_prep) of_24\IN|the (l_pobj) changes_27\NNS|NONE (l_compound) ST_26\NNP|NONE (l_amod) ischemic_25\JJ|NONE
D005472_D007511 CID 5-FU_15\CD|v|during (r_nummod) infusion_16\NN|NONE (r_pobj) to_14\IN|. (r_prep) prior_13\RB|incidence (r_advmod) was_9\VBD|+/|.|before|;|duration|during|v (l_nsubj) incidence_1\NN|prior (l_prep) of_2\IN|The (l_pobj) episodes_4\NNS|NONE (l_amod) ischemic_3\JJ|per|per
D005472_D007511 CID 5-FU_22\CD|)|P|( (r_nummod) infusion_23\NN|NONE (r_pobj) during_21\IN|FU|v (r_prep) infusion_16\NN|NONE (r_pobj) to_14\IN|. (r_prep) prior_13\RB|incidence (r_advmod) was_9\VBD|+/|.|before|;|duration|during|v (l_nsubj) incidence_1\NN|prior (l_prep) of_2\IN|The (l_pobj) episodes_4\NNS|NONE (l_amod) ischemic_3\JJ|per|per
D005472_D007511 CID 5-FU_46\CD|NONE (r_pobj) before_45\IN|+/|.|was|;|duration|during|v (r_prep) was_36\VBD|NONE (l_ccomp) was_9\VBD|+/|.|before|;|duration|during|v (l_nsubj) incidence_1\NN|prior (l_prep) of_2\IN|The (l_pobj) episodes_4\NNS|NONE (l_amod) ischemic_3\JJ|per|per
D005472_D007511 CID 5-FU_57\CD|NONE (r_pobj) during_56\IN|+/|.|was|before|;|duration|v (r_prep) was_36\VBD|NONE (l_ccomp) was_9\VBD|+/|.|before|;|duration|during|v (l_nsubj) incidence_1\NN|prior (l_prep) of_2\IN|The (l_pobj) episodes_4\NNS|NONE (l_amod) ischemic_3\JJ|per|per
D005472_D007511 CID 5-FU_3\CD|NONE (r_compound) infusion_4\NN|with|is|that (r_nsubjpass) associated_6\VBN|We|. (l_prep) with_7\IN|infusion|is|that (l_pobj) increase_10\NN|NONE (l_prep) in_11\IN|,|a|among|significant (l_pobj) deviation_15\NN|NONE (l_amod) suggestive_16\JJ|segment|silent (l_prep) of_17\IN|NONE (l_pobj) ischemia_18\NN|NONE
D005472_D000787 CID 5-FU_12\CD|NONE (r_nummod) infusion_13\NN|NONE (r_pobj) during_11\IN|patient|angina|.|)|:|were|( (r_prep) had_8\VBD|NONE (l_ccomp) were_2\VBD|patient|angina|.|)|:|during|( (l_nsubj) episodes_1\NNS|rare (l_compound) Anginal_0\JJ|NONE
D005472_D000787 CID 5-FU_12\CD|NONE (r_nummod) infusion_13\NN|NONE (r_pobj) during_11\IN|patient|angina|.|)|:|were|( (r_prep) had_8\VBD|NONE (l_dobj) angina_9\NN|patient|.|)|:|during|were|(
D005472_D003324 NONE 5-FU_3\CD|NONE (r_compound) infusion_4\NN|with|is|that (r_nsubjpass) associated_6\VBN|We|. (l_prep) with_7\IN|infusion|is|that (l_pobj) increase_10\NN|NONE (l_prep) among_21\IN|in|,|a|significant (l_pobj) patients_22\NNS|particularly (l_prep) with_23\IN|NONE (l_pobj) disease_26\NN|NONE
D005472_D066126 NONE fluorouracil_11\NN|FU|(|) (r_nmod) therapy_15\NN|NONE (r_pobj) with_10\IN|NONE (r_prep) associated_9\VBN|cardiac (r_acl) toxicity_8\NN|NONE
D005472_D066126 NONE 5-FU_13\CD|(|fluorouracil|) (r_nmod) therapy_15\NN|NONE (r_pobj) with_10\IN|NONE (r_prep) associated_9\VBN|cardiac (r_acl) toxicity_8\NN|NONE
D005472_D009369 NONE 5-FU_11\CD|for (r_compound) infusion_12\NN|NONE (l_prep) for_13\IN|FU (l_pobj) treatment_14\NN|NONE (l_prep) of_15\IN|NONE (l_pobj) tumors_17\NNS|NONE
3137399
D004317_D006333 CID doxorubicin_17\NN|m|mg||and (r_conj) MMC_11\NNP|NONE (r_pobj) after_7\IN|One|.|failure (r_prep) developed_4\VBD|NONE (l_dobj) failure_6\NN|One|.|after
D016685_D006333 CID MMC_11\NNP|NONE (r_pobj) after_7\IN|One|.|failure (r_prep) developed_4\VBD|NONE (l_dobj) failure_6\NN|One|.|after
D004317_D066126 NONE doxorubicin_21\NN|NONE (r_dobj) following_20\VBG|NONE (r_pcomp) given_19\VBN|especially|with|or|when (r_conj) combined_16\VBN|be|has|been|,|.|Since|C (r_advcl) suggested_9\VBN|NONE (l_xcomp) be_11\VB|has|been|,|.|combined|Since|C (l_acomp) cardiotoxic_12\JJ|to
D004317_D066126 NONE doxorubicin_47\NN|NONE (r_pobj) with_46\IN|also|)|(|previously (r_prep) treated_45\VBN|NONE (r_acl) patients_38\NNS|mainly (r_pobj) in_37\IN|cardiotoxicity|dependent|occurring|,|,|that (r_prep) is_20\VBZ|Based|,|we|. (l_nsubj) cardiotoxicity_19\NN|dependent|occurring|,|in|,|that
D016685_D066126 NONE C._12\NNP|NONE (r_pobj) by_10\IN|NONE (r_agent) induced_9\VBN|on|prospective|A (r_acl) study_2\NN|NONE (l_prep) on_3\IN|prospective|induced|A (l_pobj) dependency_6\NN|NONE (l_prep) of_7\IN|the|dose (l_pobj) cardiotoxicity_8\NN|NONE
D016685_D066126 NONE C_3\NNP|be|has|been|,|.|combined|Since (r_nsubjpass) suggested_9\VBN|NONE (l_xcomp) be_11\VB|has|been|,|.|combined|Since|C (l_acomp) cardiotoxic_12\JJ|to
D016685_D066126 NONE MMC_5\NN|mitomycin (r_appos) C_3\NNP|be|has|been|,|.|combined|Since (r_nsubjpass) suggested_9\VBN|NONE (l_xcomp) be_11\VB|has|been|,|.|combined|Since|C (l_acomp) cardiotoxic_12\JJ|to
D016685_D066126 NONE MMC_16\NN| (r_npadvmod) related_18\VBN|NONE (r_amod) cardiotoxicity_19\NN|dependent|occurring|,|in|,|that
17466854
D005839_D002386 NONE gentamicin_15\NN|and|incidence|.|To (l_prep) at_24\IN|into (l_pobj) end_26\NN|NONE (l_prep) of_27\IN|the (l_pobj) surgery_30\NN|NONE (l_compound) cataract_29\NN|routine
D008775_D006261 CID methylprednisolone_3\NN|NONE (r_pobj) of_2\IN|gentamicin|and|The (r_prep) administration_1\NN|was|to|. (r_nsubjpass) related_15\VBN|NONE (l_prep) to_16\IN|was|administration|. (l_pobj) incidence_19\NN|NONE (l_prep) of_20\IN|high|a (l_pobj) effects_22\NNS|NONE (l_prep) including_23\VBG|side (l_pobj) nausea_24\NN|NONE (l_conj) vomiting_26\NN|, (l_conj) headache_29\NN|and|,
D008775_D020250 CID methylprednisolone_3\NN|NONE (r_pobj) of_2\IN|gentamicin|and|The (r_prep) administration_1\NN|was|to|. (r_nsubjpass) related_15\VBN|NONE (l_prep) to_16\IN|was|administration|. (l_pobj) incidence_19\NN|NONE (l_prep) of_20\IN|high|a (l_pobj) effects_22\NNS|NONE (l_prep) including_23\VBG|side (l_pobj) nausea_24\NN|NONE (l_conj) vomiting_26\NN|,
D008775_D002386 NONE methylprednisolone_13\NN|NONE (r_pobj) of_12\IN|the (r_prep) administration_11\NN|NONE (r_pobj) after_9\IN|of|the (r_prep) incidence_3\NN|and|.|To|gentamicin (r_dobj) assess_1\VB|NONE (l_conj) gentamicin_15\NN|and|incidence|.|To (l_prep) at_24\IN|into (l_pobj) end_26\NN|NONE (l_prep) of_27\IN|the (l_pobj) surgery_30\NN|NONE (l_compound) cataract_29\NN|routine
D005839_D006261 CID gentamicin_5\NN|and|of|The (r_conj) administration_1\NN|was|to|. (r_nsubjpass) related_15\VBN|NONE (l_prep) to_16\IN|was|administration|. (l_pobj) incidence_19\NN|NONE (l_prep) of_20\IN|high|a (l_pobj) effects_22\NNS|NONE (l_prep) including_23\VBG|side (l_pobj) nausea_24\NN|NONE (l_conj) vomiting_26\NN|, (l_conj) headache_29\NN|and|,
D005839_D020250 CID gentamicin_5\NN|and|of|The (r_conj) administration_1\NN|was|to|. (r_nsubjpass) related_15\VBN|NONE (l_prep) to_16\IN|was|administration|. (l_pobj) incidence_19\NN|NONE (l_prep) of_20\IN|high|a (l_pobj) effects_22\NNS|NONE (l_prep) including_23\VBG|side (l_pobj) nausea_24\NN|NONE (l_conj) vomiting_26\NN|,
2572625
C013295_D056486 NONE thienodiazepine_27\NN|a (r_amod) derivative_28\NN|,|developed|a (r_appos) patient_6\NN|NONE (l_relcl) developed_8\VBD|,|derivative|a (l_dobj) hepatitis_10\NN|who|with|after
C084599_D056486 CID Clotiazepam_0\NNP| (r_npadvmod) induced_2\VBN|.|acute (r_amod) hepatitis_4\NN|NONE
C084599_D056486 CID clotiazepam_24\NN|NONE (r_pobj) of_23\IN|NONE (r_prep) administration_22\NN|NONE (r_pobj) of_21\IN|the (r_prep) onset_20\NN|months (r_pobj) after_18\IN|hepatitis|who|with (r_prep) developed_8\VBD|,|derivative|a (l_dobj) hepatitis_10\NN|who|with|after
C084599_D056486 CID clotiazepam_9\NN|chemically (r_xcomp) related_7\VBN|of|The|, (r_acl) administration_1\NN|not|,|did|with|and|.|induce (r_nsubj) interfere_13\VB|NONE (l_conj) induce_19\VB|not|,|did|administration|with|and|. (l_dobj) relapse_21\NN|did|not (l_prep) of_22\IN|any (l_pobj) hepatitis_23\NN|NONE
C084599_D056486 CID clotiazepam_4\NN|and|hepatitis|can|suggests|that (r_nsubj) induce_6\VB|observation|. (l_dobj) hepatitis_8\NN|and|clotiazepam|can|suggests|that
C084599_D056486 CID clotiazepam_4\NN|and|hepatitis|can|suggests|that (r_nsubj) induce_6\VB|observation|. (l_conj) suggests_10\VBZ|and|clotiazepam|hepatitis|can|that (l_ccomp) is_13\VBZ|NONE (l_attr) hepatotoxicity_16\NN|that|there
C084599_D056486 CID clotiazepam_18\NN|NONE (r_pobj) between_17\IN|cross (r_prep) hepatotoxicity_16\NN|that|there (r_attr) is_13\VBZ|NONE (r_ccomp) suggests_10\VBZ|and|clotiazepam|hepatitis|can|that (r_conj) induce_6\VB|observation|. (l_dobj) hepatitis_8\NN|and|clotiazepam|can|suggests|that
C084599_D056486 CID clotiazepam_18\NN|NONE (r_pobj) between_17\IN|cross (r_prep) hepatotoxicity_16\NN|that|there
D001569_D056486 NONE benzodiazepines_4\NNS|NONE (r_pobj) of_2\IN|related|The|, (r_prep) administration_1\NN|not|,|did|with|and|.|induce (r_nsubj) interfere_13\VB|NONE (l_conj) induce_19\VB|not|,|did|administration|with|and|. (l_dobj) relapse_21\NN|did|not (l_prep) of_22\IN|any (l_pobj) hepatitis_23\NN|NONE
D001569_D056486 NONE benzodiazepines_21\NNS|and (r_conj) clotiazepam_18\NN|NONE (r_pobj) between_17\IN|cross (r_prep) hepatotoxicity_16\NN|that|there (r_attr) is_13\VBZ|NONE (r_ccomp) suggests_10\VBZ|and|clotiazepam|hepatitis|can|that (r_conj) induce_6\VB|observation|. (l_dobj) hepatitis_8\NN|and|clotiazepam|can|suggests|that
D001569_D056486 NONE benzodiazepines_21\NNS|and (r_conj) clotiazepam_18\NN|NONE (r_pobj) between_17\IN|cross (r_prep) hepatotoxicity_16\NN|that|there
C013295_D047508 NONE thienodiazepine_27\NN|a (r_amod) derivative_28\NN|,|developed|a (r_appos) patient_6\NN|NONE (l_relcl) developed_8\VBD|,|derivative|a (l_prep) with_11\IN|hepatitis|who|after (l_pobj) necrosis_14\NN|NONE
C084599_D047508 NONE clotiazepam_24\NN|NONE (r_pobj) of_23\IN|NONE (r_prep) administration_22\NN|NONE (r_pobj) of_21\IN|the (r_prep) onset_20\NN|months (r_pobj) after_18\IN|hepatitis|who|with (r_prep) developed_8\VBD|,|derivative|a (l_prep) with_11\IN|hepatitis|who|after (l_pobj) necrosis_14\NN|NONE
7619765
D005047_D003327 NONE etoposide_11\RB|NONE (r_dobj) containing_10\VBG|NONE (r_acl) chemotherapy_9\NN|NONE (r_pobj) after_8\IN|occurrence|is|in|.|, (r_prep) reported_7\VBN|NONE (l_prep) in_13\IN|after|occurrence|is|.|, (l_pobj) man_15\NN|NONE (l_prep) with_16\IN|a (l_pobj) factors_19\NNS|NONE (l_prep) for_20\IN|no|risk (l_pobj) disease_23\NN|NONE
D005047_D009203 CID Etoposide_0\RB| (r_npadvmod) related_2\VBN|.|myocardial (r_amod) infarction_4\NN|NONE
D005047_D009203 CID etoposide_11\RB|NONE (r_dobj) containing_10\VBG|NONE (r_acl) chemotherapy_9\NN|NONE (r_pobj) after_8\IN|occurrence|is|in|.|, (r_prep) reported_7\VBN|NONE (l_nsubjpass) occurrence_1\NN|after|is|in|.|, (l_prep) of_2\IN|The (l_pobj) infarction_5\NN|NONE
17562951
D007479_D051436 NONE iopamidol_14\NN|NONE (r_pobj) of_13\IN|,|randomized|,|blind|in|a|multicenter (r_prep) comparison_12\NN|study|rate|. (l_prep) in_17\IN|of|,|randomized|,|blind|a|multicenter (l_pobj) patients_18\NNS|NONE (l_prep) with_19\IN|NONE (l_pobj) disease_22\NN|NONE
D007479_D003920 NONE iopamidol_24\NN|with (r_pobj) with_23\IN|%|dL|,|increases (r_prep) were_14\VBD|SCr|.|,|>|In (r_conj) increases_6\VBZ|NONE (l_prep) In_0\IN|SCr|.|were|,|> (l_pobj) patients_1\NNS|NONE (l_prep) with_2\IN|NONE (l_pobj) diabetes_3\NNS|NONE
D007479_D003920 NONE iopamidol_23\NN|NONE (r_pobj) of_22\IN|,|intraarterial|to|the (r_prep) administration_21\NN|NONE (r_pobj) after_18\IN|different|.|rate|not|with (r_prep) is_14\VBZ|NONE (l_prep) with_32\IN|different|.|after|rate|not (l_conj) without_34\IN|or (l_pobj) mellitus_36\NN|NONE
D007479_D007674 CID iopamidol_23\NN|NONE (r_pobj) of_22\IN|,|intraarterial|to|the (r_prep) administration_21\NN|NONE (r_pobj) after_18\IN|different|.|rate|not|with (r_prep) is_14\VBZ|NONE (l_nsubj) rate_1\NN|different|.|after|not|with (l_prep) of_2\IN|,|,|The|defined (l_pobj) nephropathy_6\NN|NONE
D000111_D003920 NONE acetylcysteine_16\NN|NONE (r_pobj) of_13\IN|NONE (r_prep) use_12\NN|presence|contrast|,|, (r_appos) volume_5\NN|In|,|.|,|and|,|estimated|SCr (l_appos) presence_7\NN|use|contrast|,|, (l_prep) of_8\IN|NONE (l_pobj) mellitus_10\NN|NONE
C044834_D007674 CID iodixanol_25\NN|or (r_conj) iopamidol_23\NN|NONE (r_pobj) of_22\IN|,|intraarterial|to|the (r_prep) administration_21\NN|NONE (r_pobj) after_18\IN|different|.|rate|not|with (r_prep) is_14\VBZ|NONE (l_nsubj) rate_1\NN|different|.|after|not|with (l_prep) of_2\IN|,|,|The|defined (l_pobj) nephropathy_6\NN|NONE
C044834_D051436 NONE iodixanol_16\NN|and (r_conj) iopamidol_14\NN|NONE (r_pobj) of_13\IN|,|randomized|,|blind|in|a|multicenter (r_prep) comparison_12\NN|study|rate|. (l_prep) in_17\IN|of|,|randomized|,|blind|a|multicenter (l_pobj) patients_18\NNS|NONE (l_prep) with_19\IN|NONE (l_pobj) disease_22\NN|NONE
C044834_D003920 NONE iodixanol_35\NN|NONE (r_pobj) with_34\IN|iopamidol (r_prep) with_23\IN|%|dL|,|increases (r_prep) were_14\VBD|SCr|.|,|>|In (r_conj) increases_6\VBZ|NONE (l_prep) In_0\IN|SCr|.|were|,|> (l_pobj) patients_1\NNS|NONE (l_prep) with_2\IN|NONE (l_pobj) diabetes_3\NNS|NONE
C044834_D003920 NONE iodixanol_25\NN|or (r_conj) iopamidol_23\NN|NONE (r_pobj) of_22\IN|,|intraarterial|to|the (r_prep) administration_21\NN|NONE (r_pobj) after_18\IN|different|.|rate|not|with (r_prep) is_14\VBZ|NONE (l_prep) with_32\IN|different|.|after|rate|not (l_conj) without_34\IN|or (l_pobj) mellitus_36\NN|NONE
3192036
16584858
D007545_D006331 NONE ISPH_14\NNP| (r_npadvmod) induced_16\VBN|NONE (r_amod) MI_17\NNP|NONE (r_pobj) against_13\IN|a|beneficial (r_prep) effect_12\NN|mangiferin|that|due (r_dobj) exerts_9\VBZ|.|is|it|From (l_prep) due_18\IN|mangiferin|that|effect (l_pcomp) to_19\IN|NONE (l_pobj) potential_22\NN|NONE (l_relcl) regulated_25\VBD|antioxidant|its|, (l_prep) against_30\IN|which|system (l_pobj) damage_32\NN|NONE
D001205_D009203 NONE C_31\NN|, (r_conj) cerruloplasmin_28\NN|such (r_pobj) as_27\IN|enzymic|levels (r_prep) antioxidants_25\NNS|,|catalase|superoxide|, (r_appos) dismutase_8\NN|such (r_pobj) as_6\IN|antioxidant (r_prep) enzymes_4\NNS|heart (r_dobj) tissue_2\NN|in|.|were (r_nsubjpass) altered_39\VBN|NONE (l_prep) in_40\IN|.|were|tissue (l_pobj) rats_42\NNS|NONE (l_compound) MI_41\NNP|NONE
D003401_D009202 NONE creatine_42\NN|damage|injection (r_conj) caused_20\VBD|level|,|. (l_dobj) damage_22\NN|injection|creatine
D014810_D009203 NONE E_34\NN|Vitamin|, (r_conj) C_31\NN|, (r_conj) cerruloplasmin_28\NN|such (r_pobj) as_27\IN|enzymic|levels (r_prep) antioxidants_25\NNS|,|catalase|superoxide|, (r_appos) dismutase_8\NN|such (r_pobj) as_6\IN|antioxidant (r_prep) enzymes_4\NNS|heart (r_dobj) tissue_2\NN|in|.|were (r_nsubjpass) altered_39\VBN|NONE (l_prep) in_40\IN|.|were|tissue (l_pobj) rats_42\NNS|NONE (l_compound) MI_41\NNP|NONE
D007545_D009202 NONE ISPH_3\NNP|NONE (r_pobj) of_2\IN|Subcutaneous|to (r_prep) injection_1\NN|damage|creatine (r_nsubj) caused_20\VBD|level|,|. (l_dobj) damage_22\NN|injection|creatine
D005978_D009203 NONE glutathione_12\NN|,|transferase (r_compound) peroxidase_13\NN|, (r_conj) catalase_10\NNP|,|superoxide|antioxidants|, (r_conj) dismutase_8\NN|such (r_pobj) as_6\IN|antioxidant (r_prep) enzymes_4\NNS|heart (r_dobj) tissue_2\NN|in|.|were (r_nsubjpass) altered_39\VBN|NONE (l_prep) in_40\IN|.|were|tissue (l_pobj) rats_42\NNS|NONE (l_compound) MI_41\NNP|NONE
D005978_D009203 NONE glutathione_15\NN|and|activities (r_compound) transferase_16\NN|glutathione|, (r_conj) peroxidase_13\NN|, (r_conj) catalase_10\NNP|,|superoxide|antioxidants|, (r_conj) dismutase_8\NN|such (r_pobj) as_6\IN|antioxidant (r_prep) enzymes_4\NNS|heart (r_dobj) tissue_2\NN|in|.|were (r_nsubjpass) altered_39\VBN|NONE (l_prep) in_40\IN|.|were|tissue (l_pobj) rats_42\NNS|NONE (l_compound) MI_41\NNP|NONE
D005978_D009203 NONE glutathione_18\NN|NONE (r_compound) reductase_19\NN|NONE (r_compound) activities_20\NNS|glutathione|and (r_conj) transferase_16\NN|glutathione|, (r_conj) peroxidase_13\NN|, (r_conj) catalase_10\NNP|,|superoxide|antioxidants|, (r_conj) dismutase_8\NN|such (r_pobj) as_6\IN|antioxidant (r_prep) enzymes_4\NNS|heart (r_dobj) tissue_2\NN|in|.|were (r_nsubjpass) altered_39\VBN|NONE (l_prep) in_40\IN|.|were|tissue (l_pobj) rats_42\NNS|NONE (l_compound) MI_41\NNP|NONE
D005978_D009203 NONE glutathione_36\NN|and|Vitamin (r_conj) E_34\NN|Vitamin|, (r_conj) C_31\NN|, (r_conj) cerruloplasmin_28\NN|such (r_pobj) as_27\IN|enzymic|levels (r_prep) antioxidants_25\NNS|,|catalase|superoxide|, (r_appos) dismutase_8\NN|such (r_pobj) as_6\IN|antioxidant (r_prep) enzymes_4\NNS|heart (r_dobj) tissue_2\NN|in|.|were (r_nsubjpass) altered_39\VBN|NONE (l_prep) in_40\IN|.|were|tissue (l_pobj) rats_42\NNS|NONE (l_compound) MI_41\NNP|NONE
D013481_D009203 NONE superoxide_7\JJ|,|catalase|antioxidants|, (r_amod) dismutase_8\NN|such (r_pobj) as_6\IN|antioxidant (r_prep) enzymes_4\NNS|heart (r_dobj) tissue_2\NN|in|.|were (r_nsubjpass) altered_39\VBN|NONE (l_prep) in_40\IN|.|were|tissue (l_pobj) rats_42\NNS|NONE (l_compound) MI_41\NNP|NONE
D014527_D009202 NONE acid_53\NN|and|uric|capacity (r_compound) level_54\NN|caused|,|. (r_dobj) increased_51\VBN|NONE (l_ccomp) caused_20\VBD|level|,|. (l_dobj) damage_22\NN|injection|creatine
D019344_D009202 NONE lactate_36\NN|)|LDH|( (r_compound) dehydrogenase_37\NN|NONE (r_pobj) of_34\IN|increased|the (r_prep) activity_33\NN|NONE (r_pobj) by_30\IN|was|which|and (r_agent) determined_29\VBN|rat|, (r_relcl) heart_25\NN|NONE (r_pobj) in_23\IN|myocardial (r_prep) damage_22\NN|injection|creatine
D007545_D009203 CID isoproterenol_10\NN| (r_npadvmod) induced_12\VBN|myocardial|in (r_amod) infarction_14\NN|NONE
D007545_D009203 CID isoproterenol_5\NN|NONE (r_pobj) on_4\IN|myocardial|)|(|MI|ISPH)induced|through|(|in (r_prep) infarction_9\NN|.|)|,|(
D007545_D009203 CID isoproterenol_5\NN|NONE (r_pobj) on_4\IN|myocardial|)|(|MI|ISPH)induced|through|(|in (r_prep) infarction_9\NN|.|)|,|( (l_appos) MI_11\NNP|myocardial|)|(|on|ISPH)induced|through|(|in
D007545_D009203 CID ISPH)-induced_7\JJ|myocardial|)|(|MI|on|through|(|in (r_amod) infarction_9\NN|.|)|,|(
D007545_D009203 CID ISPH)-induced_7\JJ|myocardial|)|(|MI|on|through|(|in (r_amod) infarction_9\NN|.|)|,|( (l_appos) MI_11\NNP|myocardial|)|(|on|ISPH)induced|through|(|in
D007545_D009203 CID ISPH_21\NNP| (r_npadvmod) induced_23\VBN|MI (r_amod) rats_25\NNS|NONE (l_compound) MI_24\NNP|induced
D007545_D009203 CID ISPH_14\NNP| (r_npadvmod) induced_16\VBN|NONE (r_amod) MI_17\NNP|NONE
C013592_D009203 NONE mangiferin_2\NN|NONE (l_prep) on_3\IN|NONE (l_pobj) alterations_5\NNS|NONE (l_prep) in_9\IN|status|and|biochemical (l_pobj) infarction_14\NN|NONE
C013592_D009203 NONE mangiferin_3\NN|NONE (r_pobj) with_2\IN|NONE (r_prep) pretreatment_1\NN|NONE (r_pobj) Upon_0\IN|weight|given|(|.|protected|in (r_prep) suspended_9\VBN|NONE (l_prep) given_17\VBN|weight|Upon|(|.|protected|in (l_prep) to_22\IN|for|intraperitoneally (l_pobj) rats_24\NNS|NONE (l_compound) MI_23\NNP|NONE
C013592_D009203 NONE mangiferin_16\JJ|NONE (r_compound) administration_17\NN|NONE (r_pobj) upon_15\IN|significantly|compared|.|tissue (r_prep) rose_13\VBD|NONE (l_prep) compared_19\VBN|upon|significantly|.|tissue (l_prep) to_20\IN|as (l_pobj) rats_25\NNS|NONE (l_compound) MI_24\NNP|induced
C013592_D009203 NONE mangiferin_8\NN|that|due|effect (r_nsubj) exerts_9\VBZ|.|is|it|From (l_dobj) effect_12\NN|mangiferin|that|due (l_prep) against_13\IN|a|beneficial (l_pobj) MI_17\NNP|NONE
C013592_D017202 NONE mangiferin_4\NN|NONE (r_pobj) of_3\IN|protective|The (r_prep) role_2\NN|.|by|was (r_nsubjpass) analyzed_6\VBN|NONE (l_agent) by_7\IN|.|was|role (l_pobj) test_14\NN|NONE (l_acl) used_15\VBN|TTC|chloride (l_prep) for_16\IN|NONE (l_pobj) assay_20\NN|NONE (l_prep) of_21\IN|macroscopic|mapping (l_pobj) myocardium_24\NN|NONE
C013592_D006331 NONE mangiferin_8\NN|that|due|effect (r_nsubj) exerts_9\VBZ|.|is|it|From (l_prep) due_18\IN|mangiferin|that|effect (l_pcomp) to_19\IN|NONE (l_pobj) potential_22\NN|NONE (l_relcl) regulated_25\VBD|antioxidant|its|, (l_prep) against_30\IN|which|system (l_pobj) damage_32\NN|NONE
D007501_D009202 NONE iron_58\NN|reduced|binding (r_nmod) capacity_60\NN|and|acid|uric (r_conj) level_54\NN|caused|,|. (r_dobj) increased_51\VBN|NONE (l_ccomp) caused_20\VBD|level|,|. (l_dobj) damage_22\NN|injection|creatine
D004121_D009203 NONE sulphoxide_15\RB|NONE (r_pobj) of_13\IN||) (r_prep) ml_12\NNS|NONE (r_pobj) in_10\IN|weight|given|Upon|(|.|protected (r_prep) suspended_9\VBN|NONE (l_prep) given_17\VBN|weight|Upon|(|.|protected|in (l_prep) to_22\IN|for|intraperitoneally (l_pobj) rats_24\NNS|NONE (l_compound) MI_23\NNP|NONE
C009591_D017202 NONE chloride_10\NN|TTC|used (r_nmod) test_14\NN|NONE (l_acl) used_15\VBN|TTC|chloride (l_prep) for_16\IN|NONE (l_pobj) assay_20\NN|NONE (l_prep) of_21\IN|macroscopic|mapping (l_pobj) myocardium_24\NN|NONE
C009591_D017202 NONE TTC_12\NNP|chloride|used (r_nmod) test_14\NN|NONE (l_acl) used_15\VBN|TTC|chloride (l_prep) for_16\IN|NONE (l_pobj) assay_20\NN|NONE (l_prep) of_21\IN|macroscopic|mapping (l_pobj) myocardium_24\NN|NONE
3961813
D003345_D009422 NONE corticosterone_9\NN|NONE (l_prep) on_10\IN|dietary (l_pobj) neuropathy_15\NN|NONE
D003345_D009422 NONE corticosterone_13\NN|NONE (r_pobj) of_12\IN|low|)|less|( (r_prep) concentrations_2\NNS|signs|effects|.|Although (r_nsubj) had_14\VBD|NONE (l_dobj) effects_16\NNS|signs|.|Although|concentrations (l_prep) on_17\IN|beneficial (l_pobj) neuropathy_21\NN|NONE
D007531_D009422 CID DFP_39\NNP|or|either (r_conj) TOTP_37\NNP|NONE (r_pobj) given_35\VBN|clinical|in|exacerbated (r_acl) signs_32\NNS|effects|.|Although|concentrations (r_dobj) had_14\VBD|NONE (l_dobj) effects_16\NNS|signs|.|Although|concentrations (l_prep) on_17\IN|beneficial (l_pobj) neuropathy_21\NN|NONE
D007531_D009410 CID DFP_18\NNP|or (r_conj) TOTP_16\NNP|NONE (r_pobj) given_15\VBN|.|evident|also|fibers (r_prep) were_3\VBD|NONE (l_nsubj) fibers_2\NNS|.|evident|also|given
D007531_D020258 NONE DFP_8\NNP|or (r_conj) TOTP_6\NNP|hr (r_pobj) after_5\IN|esterase (r_prep) activities_2\NNS|%|.|given (l_compound) esterase_1\NN|after (l_amod) Neurotoxic_0\JJ|NONE
C025541_D020258 NONE TOTP_6\NNP|hr (r_pobj) after_5\IN|esterase (r_prep) activities_2\NNS|%|.|given (l_compound) esterase_1\NN|after (l_amod) Neurotoxic_0\JJ|NONE
D010755_D020258 NONE organophosphorous_21\JJ|NONE (r_amod) compounds_22\NNS|not (r_dobj) given_20\VBN|%|.|activities (r_prep) were_9\VBD|NONE (l_nsubj) activities_2\NNS|%|.|given (l_compound) esterase_1\NN|after (l_amod) Neurotoxic_0\JJ|NONE
C025541_D009422 CID TOTP_18\NNP| (r_npadvmod) induced_20\VBN|greater|, (r_amod) neuropathy_21\NN|NONE
C025541_D009422 CID TOTP_37\NNP|NONE (r_pobj) given_35\VBN|clinical|in|exacerbated (r_acl) signs_32\NNS|effects|.|Although|concentrations (r_dobj) had_14\VBD|NONE (l_dobj) effects_16\NNS|signs|.|Although|concentrations (l_prep) on_17\IN|beneficial (l_pobj) neuropathy_21\NN|NONE
D010755_D009422 NONE organophosphorus_11\NN| (r_npadvmod) induced_13\VBN|delayed|in (r_amod) neuropathy_15\NN|NONE
C025541_D009410 CID TOTP_16\NNP|NONE (r_pobj) given_15\VBN|.|evident|also|fibers (r_prep) were_3\VBD|NONE (l_nsubj) fibers_2\NNS|.|evident|also|given
20466178
D016559_D012393 NONE tacrolimus_19\NN|% (r_compound) ointment_20\NN|for|while (r_dobj) using_13\VBG|who|eruptions (r_advcl) developed_6\VBD| (l_dobj) eruptions_11\NNS|using|who (l_amod) like_9\JJ|dermatitis (l_npadvmod) rosacea_7\NN|
C117268_D003872 CID pimecrolimus_9\NN|or (r_conj) tacrolimus_7\NN|such (r_pobj) as_6\IN|NONE (r_prep) immunomodulators_4\NNS|NONE (r_pobj) of_3\IN|Continuous|topical (r_prep) use_2\NN|should|as|.|be|,|reported (r_nsubjpass) regarded_12\VBN|NONE (l_prep) as_13\IN|should|.|be|,|use|reported (l_pobj) cause_16\NN|NONE (l_prep) of_17\IN|potential|a (l_pobj) dermatitis_19\NN|NONE
D016559_D003872 NONE tacrolimus_5\NN|topical (r_compound) treatment_6\NN|NONE (r_pobj) with_3\IN|NONE (r_prep) associated_2\VBN|Rosaceiform|. (r_acl) dermatitis_1\NN|NONE
D016559_D003872 NONE tacrolimus_19\NN|% (r_compound) ointment_20\NN|for|while (r_dobj) using_13\VBG|who|eruptions (r_advcl) developed_6\VBD| (l_dobj) eruptions_11\NNS|using|who (l_compound) dermatitis_10\NN|like
D016559_D003872 NONE tacrolimus_7\NN|such (r_pobj) as_6\IN|NONE (r_prep) immunomodulators_4\NNS|NONE (r_pobj) of_3\IN|Continuous|topical (r_prep) use_2\NN|should|as|.|be|,|reported (r_nsubjpass) regarded_12\VBN|NONE (l_prep) as_13\IN|should|.|be|,|use|reported (l_pobj) cause_16\NN|NONE (l_prep) of_17\IN|potential|a (l_pobj) dermatitis_19\NN|NONE
D016559_D005148 NONE tacrolimus_19\NN|% (r_compound) ointment_20\NN|for|while (r_dobj) using_13\VBG|who|eruptions (l_prep) for_21\IN|ointment|while (l_pobj) dermatitis_23\NN|NONE
D016559_D003875 NONE tacrolimus_19\NN|% (r_compound) ointment_20\NN|for|while (r_dobj) using_13\VBG|who|eruptions (r_advcl) developed_6\VBD| (l_dobj) eruptions_11\NNS|using|who
10539815
D003404_D006973 NONE creatinine_25\NN|,|ejection (r_conj) fraction_22\NN|,|history|, (r_conj) age_18\NN|NONE (l_appos) history_38\NN|fraction|,|, (l_prep) of_39\IN|NONE (l_pobj) hypertension_40\NN|NONE
D004232_D006973 NONE diuretic_49\JJ|, (r_conj) antiplatelet_47\JJ|NONE (r_pobj) of_46\IN|NONE (r_prep) use_45\NN|and|, (r_conj) diabetes_42\NNS|, (r_conj) hypertension_40\NN|NONE
D004656_D006333 NONE enalapril_26\NN|NONE (r_pobj) of_25\IN|,|a|randomized|,|controlled|for|blind (r_prep) trial_24\NN|(|,|SOLVD|Left|Ventricular|) (l_prep) for_27\IN|,|a|randomized|,|of|controlled|blind (l_pobj) treatment_29\NN|NONE (l_prep) of_30\IN|the (l_pobj) CHF_31\NNP|NONE
D004656_D006333 NONE Enalapril_0\NNP|NONE (r_compound) use_1\NN|increase|. (r_nsubj) caused_2\VBD|NONE (l_dobj) increase_6\NN|.|use (l_prep) in_7\IN|%|a (l_pobj) risk_9\NN|NONE (l_prep) of_10\IN|the (l_pobj) function_13\NN|NONE (l_prep) in_14\IN|decreased|renal (l_pobj) patients_15\NNS|NONE (l_prep) with_16\IN|NONE (l_pobj) CHF_17\NNP|NONE
D004656_D006333 NONE enalapril_23\JJ|the (r_compound) group_24\NN|NONE (r_pobj) in_21\IN|risk|was|compared|. (r_prep) reduced_20\VBN|but|was|Diabetes|with|, (r_conj) associated_2\VBN|NONE (l_prep) with_3\IN|but|was|Diabetes|reduced|, (l_pobj) risk_6\NN|NONE (l_prep) of_7\IN|an|increased (l_pobj) impairment_9\NN|NONE (l_prep) in_10\IN|renal (l_pobj) patients_12\NNS|NONE (l_prep) with_13\IN|all (l_pobj) CHF_14\NNP|NONE
D004656_D051437 CID enalapril_4\NN|NONE (r_pobj) to_3\IN|randomly (r_prep) assigned_2\VBN|NONE (r_acl) Patients_0\NNS|.|likelihood (r_nsubj) had_5\VBD|NONE (l_dobj) likelihood_10\NN|.|Patients (l_prep) of_11\IN|greater|a (l_pobj) function_14\NN|NONE
D004656_D051437 CID enalapril_9\NN|NONE (r_compound) groups_10\NNS|both|and|age|the (r_conj) placebo_7\NN|NONE (r_pobj) in_4\IN|were|,|.|,|were|By|with (r_prep) associated_20\VBN|NONE (l_prep) with_21\IN|in|were|,|.|,|were|By (l_pobj) function_24\NN|NONE
D004656_D051437 CID enalapril_23\JJ|the|ratio (r_compound) group_24\NN|NONE (r_pobj) in_21\IN|interval|significantly|,|so (r_prep) more_19\RBR|was|age|,|but|with (r_conj) associated_3\VBN|NONE (l_prep) with_4\IN|was|age|,|but|more (l_pobj) risk_7\NN|NONE (l_prep) of_8\IN|a|greater (l_pcomp) developing_9\VBG|NONE (l_dobj) function_12\NN|NONE
D004656_D051437 CID enalapril_26\NN|:|(|]|years|risk|[|RR (r_dep) ratio_29\NN|the|enalapril (r_appos) group_24\NN|NONE (r_pobj) in_21\IN|interval|significantly|,|so (r_prep) more_19\RBR|was|age|,|but|with (r_conj) associated_3\VBN|NONE (l_prep) with_4\IN|was|age|,|but|more (l_pobj) risk_7\NN|NONE (l_prep) of_8\IN|a|greater (l_pcomp) developing_9\VBG|NONE (l_dobj) function_12\NN|NONE
D004656_D051437 CID enalapril_15\JJ|(|%|the|) (r_compound) group_16\NN|NONE (r_pobj) in_13\IN|decreased|renal (r_prep) function_12\NN|NONE
D004656_D051437 CID Enalapril_0\NNP|NONE (r_compound) use_1\NN|increase|. (r_nsubj) caused_2\VBD|NONE (l_dobj) increase_6\NN|.|use (l_prep) in_7\IN|%|a (l_pobj) risk_9\NN|NONE (l_prep) of_10\IN|the (l_pobj) function_13\NN|NONE
D004656_D051437 CID enalapril_23\JJ|the (r_compound) group_24\NN|NONE (r_pobj) in_21\IN|risk|was|compared|. (r_prep) reduced_20\VBN|but|was|Diabetes|with|, (r_conj) associated_2\VBN|NONE (l_prep) with_3\IN|but|was|Diabetes|reduced|, (l_pobj) risk_6\NN|NONE (l_prep) of_7\IN|an|increased (l_pobj) impairment_9\NN|NONE
D004656_D018487 NONE enalapril_26\NN|NONE (r_pobj) of_25\IN|,|a|randomized|,|controlled|for|blind (r_prep) trial_24\NN|(|,|SOLVD|Left|Ventricular|) (r_appos) Dysfunction_9\NNP|NONE
D000809_D018487 NONE angiotensin_11\NN| (r_npadvmod) converting_13\VBG|NONE (r_amod) enzyme_14\NN|inhibitor (r_compound) therapy_16\NN|NONE (r_pobj) during_10\IN|with (r_prep) patients_6\NNS|NONE (r_pobj) in_5\IN|renal|decreased (r_prep) function_4\NN|NONE (r_pobj) of_1\IN|NONE (r_prep) Predictors_0\NNS|:|from (r_dep) results_18\NNS|NONE (l_prep) from_19\IN|:|Predictors (l_pobj) studies_21\NNS|NONE (l_prep) of_22\IN|the (l_pobj) dysfunction_25\NN|NONE
D000809_D006333 NONE angiotensin_11\NN| (r_npadvmod) converting_13\VBG|NONE (r_amod) enzyme_14\NN|inhibitor (r_compound) therapy_16\NN|NONE (r_pobj) during_10\IN|with (r_prep) patients_6\NNS|NONE (l_prep) with_7\IN|during (l_pobj) failure_9\NN|NONE
D000809_D006333 NONE angiotensin_1\NN| (r_npadvmod) converting_3\VBG|NONE (r_amod) enzyme_4\NN|inhibitor (r_compound) therapy_6\NN|in|Although|rates (r_nsubj) reduces_7\VBZ|may|also|function|,|it|. (l_prep) in_10\IN|Although|rates|therapy (l_pobj) patients_11\NNS|NONE (l_prep) with_12\IN|NONE (l_pobj) failure_15\NN|NONE
D000809_D006333 NONE angiotensin_1\NN| (r_npadvmod) converting_3\VBG|NONE (r_amod) enzyme_4\NN|inhibitor (r_compound) therapy_6\NN|in|Although|rates (r_nsubj) reduces_7\VBZ|may|also|function|,|it|. (l_prep) in_10\IN|Although|rates|therapy (l_pobj) patients_11\NNS|NONE (l_prep) with_12\IN|NONE (l_pobj) failure_15\NN|NONE (l_appos) CHF_17\NNP|congestive|heart
D000809_D006333 NONE angiotensin_17\NN| (r_npadvmod) converting_19\VBG|NONE (r_amod) enzyme_20\NN|inhibitor (r_compound) therapy_22\NN|who|are (r_dobj) prescribed_16\VBN|NONE (r_relcl) CHF_13\NNP|NONE
D004232_D003920 NONE diuretic_49\JJ|, (r_conj) antiplatelet_47\JJ|NONE (r_pobj) of_46\IN|NONE (r_prep) use_45\NN|and|, (r_conj) diabetes_42\NNS|,
D004232_D003920 NONE diuretic_14\JJ|,|and|diabetes (r_amod) therapy_15\NN|,|older (l_conj) diabetes_18\NNS|diuretic|,|and
D004232_D051437 CID diuretic_14\JJ|,|and|diabetes (r_amod) therapy_15\NN|,|older (r_conj) age_12\NN|both|and|groups|the (r_conj) placebo_7\NN|NONE (r_pobj) in_4\IN|were|,|.|,|were|By|with (r_prep) associated_20\VBN|NONE (l_prep) with_21\IN|in|were|,|.|,|were|By (l_pobj) function_24\NN|NONE
D004232_D051437 CID Diuretic_0\JJ|NONE (r_compound) therapy_1\NN|with|was|likewise|. (r_nsubjpass) associated_4\VBN|NONE (l_prep) with_5\IN|therapy|was|likewise|. (l_pobj) risk_8\NN|NONE (l_prep) of_9\IN|a|greater|than (l_pobj) function_12\NN|NONE
D004656_D003920 NONE enalapril_9\NN|NONE (r_compound) groups_10\NNS|both|and|age|the (r_conj) placebo_7\NN|NONE (l_conj) age_12\NN|both|and|groups|the (l_conj) therapy_15\NN|,|older (l_conj) diabetes_18\NNS|diuretic|,|and
D004656_D003920 NONE enalapril_2\NN|Conversely|RR|.|,|effect (r_nsubj) had_3\VBD|NONE (l_npadvmod) RR_9\NN|Conversely|.|,|enalapril|effect (l_nummod) 1.33_10\CD|( (l_prep) compared_19\VBN|NONE (l_prep) with_20\IN|, (l_pobj) placebo_21\NN|NONE (l_appos) CI_28\NNP|( (l_prep) in_33\IN|)|,|%|RR|. (l_pobj) patients_34\NNS|NONE (l_prep) with_35\IN|NONE (l_pobj) diabetes_36\NNS|NONE
D004656_D003920 NONE enalapril_23\JJ|the (r_compound) group_24\NN|NONE (r_pobj) in_21\IN|risk|was|compared|. (r_prep) reduced_20\VBN|but|was|Diabetes|with|, (r_conj) associated_2\VBN|NONE (l_nsubjpass) Diabetes_0\NN|but|was|with|reduced|,
D003404_D003920 NONE creatinine_25\NN|,|ejection (r_conj) fraction_22\NN|,|history|, (r_conj) age_18\NN|NONE (l_appos) history_38\NN|fraction|,|, (l_prep) of_39\IN|NONE (l_pobj) hypertension_40\NN|NONE (l_conj) diabetes_42\NNS|,
D000809_D051437 NONE angiotensin_11\NN| (r_npadvmod) converting_13\VBG|NONE (r_amod) enzyme_14\NN|inhibitor (r_compound) therapy_16\NN|NONE (r_pobj) during_10\IN|with (r_prep) patients_6\NNS|NONE (r_pobj) in_5\IN|renal|decreased (r_prep) function_4\NN|NONE
D000809_D051437 NONE angiotensin_1\NN| (r_npadvmod) converting_3\VBG|NONE (r_amod) enzyme_4\NN|inhibitor (r_compound) therapy_6\NN|in|Although|rates (r_nsubj) reduces_7\VBZ|may|also|function|,|it|. (r_advcl) cause_23\VB|NONE (l_dobj) function_26\NN|may|also|,|it|reduces|.
D000809_D051437 NONE angiotensin_17\NN| (r_npadvmod) converting_19\VBG|NONE (r_amod) enzyme_20\NN|inhibitor (r_compound) therapy_22\NN|who|are (r_dobj) prescribed_16\VBN|NONE (r_relcl) CHF_13\NNP|NONE (r_pobj) with_12\IN|NONE (r_prep) patients_11\NNS|NONE (r_pobj) in_10\IN|in (r_prep) reduction_6\NN|NONE (l_prep) in_7\IN|in (l_pobj) function_9\NN|NONE
D003404_D051437 NONE creatinine_10\NN|NONE (r_pobj) in_8\IN|a (r_prep) rise_7\NN|NONE (r_pobj) as_5\IN|/=.|was|function|> (r_prep) defined_4\VBN|NONE (l_nsubjpass) function_2\NN|/=.|was|as|>
15602202
D017963_D009395 CID azithromycin_6\PRP|NONE (r_pobj) by_5\IN|nephritis|. (r_prep) induced_4\VBN|NONE (l_nsubj) nephritis_3\NN|by|.
D017963_D009395 CID azithromycin_10\RB| (r_advmod) induced_12\VBN|interstitial|acute|, (r_amod) nephritis_16\NN|with|is|.|girl|,
12627929
D013792_D054556 CID thalidomide_11\NN|and (r_conj) docetaxel_9\NNS|NONE (r_pobj) of_8\IN|the|in (r_prep) combination_7\NN|NONE (r_pobj) with_5\IN|venous (r_prep) thromboembolism_4\NN|NONE
D013792_D054556 CID thalidomide_32\NN|NONE (r_pobj) with_31\IN|NONE (r_prep) combination_30\NN|NONE (r_pobj) in_29\IN|or (r_conj) alone_27\RB|were|who|with (r_advmod) treated_24\VBN|advanced|independent|prostate (r_relcl) cancer_21\NN|NONE (r_pobj) with_15\IN|NONE (r_prep) patients_14\NNS|NONE (r_pobj) in_13\IN|of|the (r_prep) frequency_6\NN|To (l_prep) of_7\IN|in|the (l_pobj) thromboembolism_9\NN|NONE
D013792_D054556 CID thalidomide_32\NN|NONE (r_pobj) with_31\IN|NONE (r_prep) combination_30\NN|NONE (r_pobj) in_29\IN|or (r_conj) alone_27\RB|were|who|with (r_advmod) treated_24\VBN|advanced|independent|prostate (r_relcl) cancer_21\NN|NONE (r_pobj) with_15\IN|NONE (r_prep) patients_14\NNS|NONE (r_pobj) in_13\IN|of|the (r_prep) frequency_6\NN|To (l_prep) of_7\IN|in|the (l_pobj) thromboembolism_9\NN|NONE (l_appos) VTE_11\NNP|(|)|venous
D013792_D054556 CID thalidomide_24\NN|plus|of (r_conj) 9_12\CD|VTE|whereas (r_nsubj) developed_25\VBD|None|VTE|.|, (r_advcl) developed_8\VBN|NONE (l_dobj) VTE_9\NNP|None|developed|.|,
D013792_D054556 CID thalidomide_24\NN|plus|of (r_conj) 9_12\CD|VTE|whereas (r_nsubj) developed_25\VBD|None|VTE|.|, (l_dobj) VTE_26\NNP||whereas
D013792_D054556 CID thalidomide_3\NN|NONE (r_pobj) of_2\IN|The|docetaxel (r_prep) addition_1\NN|.|significantly|frequency (r_nsubj) increases_13\VBZ|NONE (l_dobj) frequency_15\NN|.|significantly|addition (l_prep) of_16\IN|the (l_pobj) VTE_17\NNP|NONE
D013792_D011471 NONE thalidomide_11\NN|and (r_conj) docetaxel_9\NNS|NONE (r_pobj) of_8\IN|the|in (r_prep) combination_7\NN|NONE (l_prep) in_12\IN|of|the (l_pobj) patients_13\NNS|NONE (l_prep) with_14\IN|NONE (l_pobj) cancer_20\NN|NONE
D013792_D011471 NONE thalidomide_32\NN|NONE (r_pobj) with_31\IN|NONE (r_prep) combination_30\NN|NONE (r_pobj) in_29\IN|or (r_conj) alone_27\RB|were|who|with (r_advmod) treated_24\VBN|advanced|independent|prostate (r_relcl) cancer_21\NN|NONE
D013792_D011471 NONE thalidomide_3\NN|NONE (r_pobj) of_2\IN|The|docetaxel (r_prep) addition_1\NN|.|significantly|frequency (l_relcl) docetaxel_5\NNS|The|of (l_prep) in_6\IN|to (l_pobj) treatment_8\NN|NONE (l_prep) of_9\IN|the (l_pobj) cancer_11\NN|NONE
C067311_D054556 CID docetaxel_9\NNS|NONE (r_pobj) of_8\IN|the|in (r_prep) combination_7\NN|NONE (r_pobj) with_5\IN|venous (r_prep) thromboembolism_4\NN|NONE
C067311_D054556 CID docetaxel_26\NNS|NONE (r_pobj) with_25\IN|were|who|alone (r_prep) treated_24\VBN|advanced|independent|prostate (r_relcl) cancer_21\NN|NONE (r_pobj) with_15\IN|NONE (r_prep) patients_14\NNS|NONE (r_pobj) in_13\IN|of|the (r_prep) frequency_6\NN|To (l_prep) of_7\IN|in|the (l_pobj) thromboembolism_9\NN|NONE
C067311_D054556 CID docetaxel_26\NNS|NONE (r_pobj) with_25\IN|were|who|alone (r_prep) treated_24\VBN|advanced|independent|prostate (r_relcl) cancer_21\NN|NONE (r_pobj) with_15\IN|NONE (r_prep) patients_14\NNS|NONE (r_pobj) in_13\IN|of|the (r_prep) frequency_6\NN|To (l_prep) of_7\IN|in|the (l_pobj) thromboembolism_9\NN|NONE (l_appos) VTE_11\NNP|(|)|venous
C067311_D054556 CID docetaxel_6\NNS|alone|who (r_dobj) received_5\VBD| (r_relcl) patients_3\NNS|NONE (r_pobj) of_1\IN|NONE (r_prep) None_0\NN|VTE|developed|.|, (r_nsubj) developed_8\VBN|NONE (l_dobj) VTE_9\NNP|None|developed|.|,
C067311_D054556 CID docetaxel_6\NNS|alone|who (r_dobj) received_5\VBD| (r_relcl) patients_3\NNS|NONE (r_pobj) of_1\IN|NONE (r_prep) None_0\NN|VTE|developed|.|, (r_nsubj) developed_8\VBN|NONE (l_advcl) developed_25\VBD|None|VTE|.|, (l_dobj) VTE_26\NNP||whereas
C067311_D054556 CID docetaxel_22\NNS|who (r_dobj) received_21\VBD||(|)|% (r_relcl) patients_15\NNS|NONE (r_pobj) of_13\IN|plus|thalidomide (r_prep) 9_12\CD|VTE|whereas (r_nsubj) developed_25\VBD|None|VTE|.|, (r_advcl) developed_8\VBN|NONE (l_dobj) VTE_9\NNP|None|developed|.|,
C067311_D054556 CID docetaxel_22\NNS|who (r_dobj) received_21\VBD||(|)|% (r_relcl) patients_15\NNS|NONE (r_pobj) of_13\IN|plus|thalidomide (r_prep) 9_12\CD|VTE|whereas (r_nsubj) developed_25\VBD|None|VTE|.|, (l_dobj) VTE_26\NNP||whereas
C067311_D054556 CID docetaxel_5\NNS|The|of (r_relcl) addition_1\NN|.|significantly|frequency (r_nsubj) increases_13\VBZ|NONE (l_dobj) frequency_15\NN|.|significantly|addition (l_prep) of_16\IN|the (l_pobj) VTE_17\NNP|NONE
C067311_D011471 NONE docetaxel_9\NNS|NONE (r_pobj) of_8\IN|the|in (r_prep) combination_7\NN|NONE (l_prep) in_12\IN|of|the (l_pobj) patients_13\NNS|NONE (l_prep) with_14\IN|NONE (l_pobj) cancer_20\NN|NONE
C067311_D011471 NONE docetaxel_26\NNS|NONE (r_pobj) with_25\IN|were|who|alone (r_prep) treated_24\VBN|advanced|independent|prostate (r_relcl) cancer_21\NN|NONE
C067311_D011471 NONE docetaxel_5\NNS|The|of (l_prep) in_6\IN|to (l_pobj) treatment_8\NN|NONE (l_prep) of_9\IN|the (l_pobj) cancer_11\NN|NONE
8600333
D004317_D066126 NONE doxorubicin_3\NN| (r_npadvmod) induced_5\VBN|NONE (r_compound) cardiotoxicity_6\NN|NONE
C053519_D001859 NONE protocol_23\NN|NONE (r_pobj) to_17\IN|NONE (r_prep) according_16\VBG|who|were (r_prep) treated_15\VBN|term|of (r_relcl) survivors_8\NNS|NONE (l_prep) of_9\IN|treated|term (l_pobj) tumors_12\NNS|NONE
D004317_D001859 NONE doxorubicin_27\NN|NONE (r_pobj) including_26\VBG|NONE (r_prep) both_25\DT|,|T|Rosen (r_appos) protocol_23\NN|NONE (r_pobj) to_17\IN|NONE (r_prep) according_16\VBG|who|were (r_prep) treated_15\VBN|term|of (r_relcl) survivors_8\NNS|NONE (l_prep) of_9\IN|treated|term (l_pobj) tumors_12\NNS|NONE
11838826
D004298_D006966 NONE dopamine_8\NN|a|in (r_compound) agonist_9\NN|NONE (r_pobj) with_6\IN|induced (r_prep) hyperprolactinemia_5\NN|NONE
C047047_D011605 NONE cabergoline_55\NN|NONE (r_pobj) with_54\IN|males|)|dose|.|were (r_prep) treated_53\VBN|NONE (l_nsubjpass) males_1\NNS|)|with|dose|.|were (l_prep) with_9\IN|mL|(|,|)|(|)|with|Four|,|age (l_pobj) disorder_22\NN|NONE (l_conj) psychoses_24\NNS|edition|or|Diagnostic|bipolar
D018967_D001714 NONE risperidone_27\NN| (r_npadvmod) induced_29\VBN|in (r_amod) elevations_30\NNS|NONE (r_pobj) with_26\IN|mL|(|,|with|)|(|)|Four|,|age (r_prep) males_1\NNS|)|with|dose|.|were (l_prep) with_9\IN|mL|(|,|)|(|)|with|Four|,|age (l_pobj) disorder_22\NN|NONE
C047047_D006966 NONE cabergoline_11\NN|NONE (r_pobj) with_10\IN|induced (r_prep) hyperprolactinemia_9\NN|NONE
C047047_D006966 NONE cabergoline_16\NN|NONE (r_pobj) with_15\IN|NONE (r_prep) treated_14\VBN|induced (r_acl) hyperprolactinemia_13\NN|NONE
C047047_D006966 NONE Cabergoline_0\NNP|may|for|useful (r_nsubj) be_2\VB|.|,|;|research|however|is (l_prep) for_4\IN|Cabergoline|may|useful (l_pobj) treatment_6\NN|NONE (l_prep) of_7\IN|the|in (l_pobj) hyperprolactinemia_11\NN|NONE
C047047_D001523 NONE cabergoline_55\NN|NONE (r_pobj) with_54\IN|males|)|dose|.|were (r_prep) treated_53\VBN|NONE (l_nsubjpass) males_1\NNS|)|with|dose|.|were (l_prep) with_9\IN|mL|(|,|)|(|)|with|Four|,|age (l_pobj) disorder_22\NN|NONE (l_amod) Diagnostic_10\NNP|edition|psychoses|or|bipolar (l_conj) Manual_13\NNP|and (l_prep) of_14\IN|Statistical (l_pobj) Disorders_16\NNPS|NONE
D018967_D006966 CID risperidone_2\NN| (r_npadvmod) induced_4\VBN|with (r_amod) hyperprolactinemia_5\NN|NONE
D018967_D006966 CID Risperidone_0\NNP|is|.|with (r_nsubjpass) associated_16\VBN|NONE (l_prep) with_17\IN|Risperidone|is|. (l_pobj) hyperprolactinemia_18\NN|NONE
D018967_D006966 CID risperidone_6\NN| (r_npadvmod) induced_8\VBN|with (r_amod) hyperprolactinemia_9\NN|NONE
D018967_D006966 CID risperidone_10\NN| (r_npadvmod) induced_12\VBN|treated (r_amod) hyperprolactinemia_13\NN|NONE
D018967_D006966 CID risperidone_8\NN| (r_npadvmod) induced_10\VBN|NONE (r_amod) hyperprolactinemia_11\NN|NONE
D018967_D011605 NONE risperidone_27\NN| (r_npadvmod) induced_29\VBN|in (r_amod) elevations_30\NNS|NONE (r_pobj) with_26\IN|mL|(|,|with|)|(|)|Four|,|age (r_prep) males_1\NNS|)|with|dose|.|were (l_prep) with_9\IN|mL|(|,|)|(|)|with|Four|,|age (l_pobj) disorder_22\NN|NONE (l_conj) psychoses_24\NNS|edition|or|Diagnostic|bipolar
C047047_D001714 NONE cabergoline_55\NN|NONE (r_pobj) with_54\IN|males|)|dose|.|were (r_prep) treated_53\VBN|NONE (l_nsubjpass) males_1\NNS|)|with|dose|.|were (l_prep) with_9\IN|mL|(|,|)|(|)|with|Four|,|age (l_pobj) disorder_22\NN|NONE
D018967_D001523 NONE risperidone_27\NN| (r_npadvmod) induced_29\VBN|in (r_amod) elevations_30\NNS|NONE (r_pobj) with_26\IN|mL|(|,|with|)|(|)|Four|,|age (r_prep) males_1\NNS|)|with|dose|.|were (l_prep) with_9\IN|mL|(|,|)|(|)|with|Four|,|age (l_pobj) disorder_22\NN|NONE (l_amod) Diagnostic_10\NNP|edition|psychoses|or|bipolar (l_conj) Manual_13\NNP|and (l_prep) of_14\IN|Statistical (l_pobj) Disorders_16\NNPS|NONE
458486
C037689_D004409 NONE benzamide_4\RB|a|,|related|substituted (r_amod) derivative_5\JJ|involuntary|in|dose|peak (r_amod) movements_18\NNS|,|.
C037689_D010300 NONE benzamide_4\RB|a|,|related|substituted (r_amod) derivative_5\JJ|involuntary|in|dose|peak (r_amod) movements_18\NNS|,|. (l_prep) in_19\IN|involuntary|dose|derivative|peak (l_pobj) patients_21\NNS|NONE (l_prep) with_22\IN| (l_pobj) disease_26\NN|NONE
D008787_D004409 NONE metoclopramide_9\NN|NONE (r_pobj) to_8\IN|closely (r_prep) related_7\JJ|a|,|benzamide|substituted (r_acl) derivative_5\JJ|involuntary|in|dose|peak (r_amod) movements_18\NNS|,|.
D008787_D010300 NONE metoclopramide_9\NN|NONE (r_pobj) to_8\IN|closely (r_prep) related_7\JJ|a|,|benzamide|substituted (r_acl) derivative_5\JJ|involuntary|in|dose|peak (r_amod) movements_18\NNS|,|. (l_prep) in_19\IN|involuntary|dose|derivative|peak (l_pobj) patients_21\NNS|NONE (l_prep) with_22\IN| (l_pobj) disease_26\NN|NONE
D063325_D004409 NONE Tiapride_0\NNP|NONE (l_prep) in_1\IN|. (l_pobj) movements_6\NNS|NONE
D063325_D004409 NONE Tiapride_0\NNP|NONE (l_appos) movements_18\NNS|,|.
D063325_D004421 NONE Tiapride_0\NNP|induced|effect|. (r_nsubj) had_1\VBD|NONE (l_advcl) induced_7\VBN|Tiapride|effect|. (l_prep) of_10\IN||levodopa|morning (l_pobj) dystonia_17\NN|NONE
D007980_D004421 NONE levodopa_5\NN|of||morning (r_npadvmod) induced_7\VBN|Tiapride|effect|. (l_prep) of_10\IN||levodopa|morning (l_pobj) dystonia_17\NN|NONE
D063325_D010300 NONE Tiapride_0\NNP|NONE (l_appos) movements_18\NNS|,|. (l_prep) in_19\IN|involuntary|dose|derivative|peak (l_pobj) patients_21\NNS|NONE (l_prep) with_22\IN| (l_pobj) disease_26\NN|NONE
D007980_D010300 NONE levodopa_12\NN| (r_npadvmod) induced_14\VBN|reduced (r_amod) peak_15\NN|involuntary|in|dose|derivative (r_nmod) movements_18\NNS|,|. (l_prep) in_19\IN|involuntary|dose|derivative|peak (l_pobj) patients_21\NNS|NONE (l_prep) with_22\IN| (l_pobj) disease_26\NN|NONE
D007980_D004409 CID levodopa_2\NN| (r_npadvmod) induced_4\VBN|involuntary (r_amod) movements_6\NNS|NONE
D007980_D004409 CID levodopa_12\NN| (r_npadvmod) induced_14\VBN|reduced (r_amod) peak_15\NN|involuntary|in|dose|derivative (r_nmod) movements_18\NNS|,|.
D007980_D004409 CID levodopa_8\RB| (r_npadvmod) induced_10\VBN|NONE (r_amod) dyskinesias_11\NNS|by|that|are
D004298_D004409 NONE dopamine_21\NN|NONE (r_compound) receptors_22\NNS|NONE (r_pobj) of_20\IN|a|separate (r_prep) group_19\NN|NONE (r_pobj) of_16\IN|NONE (r_prep) overstimulation_15\NN|NONE (r_pobj) by_14\IN|that|dyskinesias|are (r_agent) caused_13\VBN|the (l_nsubjpass) dyskinesias_11\NNS|by|that|are
1535072
D015016_D019964 NONE yohimbine_28\NN|patients|.|were|basis|on (r_dobj) given_27\VBN|NONE (l_nsubjpass) patients_1\NNS|yohimbine|.|were|basis|on (l_prep) with_2\IN|Six (l_pobj) disorder_6\NN|NONE (l_conj) trichotillomania_8\NN|,|either|obsessive|compulsive (l_conj) anxiety_10\NN|, (l_conj) disorders_14\NNS|or|,
D015016_D014256 NONE yohimbine_28\NN|patients|.|were|basis|on (r_dobj) given_27\VBN|NONE (l_nsubjpass) patients_1\NNS|yohimbine|.|were|basis|on (l_prep) with_2\IN|Six (l_pobj) disorder_6\NN|NONE (l_conj) trichotillomania_8\NN|,|either|obsessive|compulsive
D015016_D009771 NONE yohimbine_28\NN|patients|.|were|basis|on (r_dobj) given_27\VBN|NONE (l_nsubjpass) patients_1\NNS|yohimbine|.|were|basis|on (l_prep) with_2\IN|Six (l_pobj) disorder_6\NN|NONE
D015016_D001008 NONE yohimbine_28\NN|patients|.|were|basis|on (r_dobj) given_27\VBN|NONE (l_nsubjpass) patients_1\NNS|yohimbine|.|were|basis|on (l_prep) with_2\IN|Six (l_pobj) disorder_6\NN|NONE (l_conj) trichotillomania_8\NN|,|either|obsessive|compulsive (l_conj) anxiety_10\NN|,
D015016_D001008 NONE yohimbine_3\NN|NONE (r_pobj) of_2\IN|Side (r_prep) effects_1\NNS|sweating|. (r_nsubj) included_4\VBD|NONE (l_dobj) sweating_6\NN|effects|. (l_conj) anxiety_9\NN|excessive|,
D015016_D020018 NONE Yohimbine_0\NNP|of|induced|. (r_compound) treatment_1\NN|NONE (l_prep) of_2\IN|Yohimbine|induced|. (l_pobj) effects_5\NNS|NONE
D015016_D020018 NONE yohimbine_6\NN|may|be|treat|that (r_nsubjpass) used_9\VBN|report|. (l_xcomp) treat_11\VB|may|be|yohimbine|that (l_dobj) effects_15\NNS|to
D015016_D020018 NONE yohimbine_3\NN|as|study|. (r_dobj) evaluated_2\VBD|NONE (l_prep) as_4\IN|study|.|yohimbine (l_pobj) treatment_6\NN|NONE (l_prep) for_7\IN|a (l_pobj) effects_11\NNS|NONE
D015016_D020018 NONE yohimbine_28\NN|patients|.|were|basis|on (r_dobj) given_27\VBN|NONE (l_nsubjpass) patients_1\NNS|yohimbine|.|were|basis|on (l_prep) with_2\IN|Six (l_pobj) disorder_6\NN|NONE (l_conj) trichotillomania_8\NN|,|either|obsessive|compulsive (l_conj) anxiety_10\NN|, (l_conj) disorders_14\NNS|or|, (l_relcl) suffered_16\VBD|affective (l_dobj) effects_19\NNS|who|after
D015016_D020018 NONE yohimbine_7\NN|treatment|may|that (r_nsubj) be_9\VB|.|results (l_attr) treatment_12\NN|may|yohimbine|that (l_prep) for_13\IN|an|effective (l_pobj) effects_17\NNS|NONE
D015016_D007172 NONE yohimbine_6\NN|that|and|behavior|be (r_nsubj) facilitates_7\VBZ|studies|. (l_conj) be_12\VB|that|and|behavior|yohimbine (l_acomp) helpful_13\JJ|may (l_prep) in_14\IN|NONE (l_pobj) treatment_16\NN|NONE (l_prep) of_17\IN|the (l_pobj) impotence_19\NN|NONE
D012701_D019964 NONE serotonin_23\NN|reuptake (r_compound) blockers_25\NNS|NONE (r_pobj) with_22\IN|NONE (r_prep) treatment_21\NN|NONE (r_pobj) after_20\IN|effects|who (r_prep) suffered_16\VBD|affective (r_relcl) disorders_14\NNS|or|,
D012701_D001008 NONE serotonin_23\NN|reuptake (r_compound) blockers_25\NNS|NONE (r_pobj) with_22\IN|NONE (r_prep) treatment_21\NN|NONE (r_pobj) after_20\IN|effects|who (r_prep) suffered_16\VBD|affective (r_relcl) disorders_14\NNS|or|, (r_conj) anxiety_10\NN|,
D012701_D020018 NONE serotonin_8\NN|reuptake (r_compound) blockers_10\NNS|NONE (r_pobj) by_7\IN|NONE (r_agent) induced_6\VBN|Yohimbine|of|. (r_acl) treatment_1\NN|NONE (l_prep) of_2\IN|Yohimbine|induced|. (l_pobj) effects_5\NNS|NONE
D012701_D020018 NONE serotonin_14\NN|reuptake (r_compound) blockers_16\NNS|NONE (r_pobj) by_13\IN|NONE (r_agent) caused_12\VBN|the|side|sexual (r_acl) effects_11\NNS|NONE
D012701_D020018 NONE serotonin_23\NN|reuptake (r_compound) blockers_25\NNS|NONE (r_pobj) with_22\IN|NONE (r_prep) treatment_21\NN|NONE (r_pobj) after_20\IN|effects|who (r_prep) suffered_16\VBD|affective (l_dobj) effects_19\NNS|who|after
D012701_D020018 NONE serotonin_20\NN|reuptake (r_compound) blockers_22\NNS|NONE (r_pobj) by_19\IN|NONE (r_agent) caused_18\VBN|side|sexual|the (r_acl) effects_17\NNS|NONE
D012701_D009771 NONE serotonin_23\NN|reuptake (r_compound) blockers_25\NNS|NONE (r_pobj) with_22\IN|NONE (r_prep) treatment_21\NN|NONE (r_pobj) after_20\IN|effects|who (r_prep) suffered_16\VBD|affective (r_relcl) disorders_14\NNS|or|, (r_conj) anxiety_10\NN|, (r_conj) trichotillomania_8\NN|,|either|obsessive|compulsive (r_conj) disorder_6\NN|NONE
D002997_D020018 CID clomipramine_17\NN|NONE (r_pobj) of_16\IN|side|the (r_prep) effects_15\NNS|to
D012701_D014256 NONE serotonin_23\NN|reuptake (r_compound) blockers_25\NNS|NONE (r_pobj) with_22\IN|NONE (r_prep) treatment_21\NN|NONE (r_pobj) after_20\IN|effects|who (r_prep) suffered_16\VBD|affective (r_relcl) disorders_14\NNS|or|, (r_conj) anxiety_10\NN|, (r_conj) trichotillomania_8\NN|,|either|obsessive|compulsive
2021202
D007530_D007022 CID isoflurane_6\RB| (r_npadvmod) induced_8\VBN|in|prolonged (r_amod) hypotension_9\NN|NONE
D007530_D007022 CID isoflurane_3\RB| (r_npadvmod) induced_5\VBN|on (r_amod) hypotension_6\NN|NONE
D007530_D007022 CID isoflurane_11\NN|inspired|the (r_amod) concentration_13\NN|maintain (r_dobj) increasing_9\VBG|NONE (r_pcomp) by_8\IN|mmHg|for|.|was|Hypotension (r_prep) induced_2\VBN|NONE (l_nsubjpass) Hypotension_0\NNP|mmHg|for|.|was|by
D007530_D007022 CID isoflurane_9\RB| (r_npadvmod) induced_11\VBN|and (r_amod) hypotension_12\NN|NONE
3173180
D008795_D006463 CID metronidazole_7\NN|NONE (r_pobj) with_6\IN|NONE (r_prep) treatment_5\NN|NONE (r_pobj) after_4\IN|uraemic|. (r_prep) syndrome_3\NN|NONE
D008795_D006463 CID metronidazole_19\NN|NONE (r_pobj) with_18\IN|NONE (r_prep) treatment_17\NN|NONE (r_pobj) after_16\IN|syndrome|who (r_prep) developed_10\VBD|six (l_dobj) syndrome_15\NN|who|after
D008795_D006463 CID metronidazole_4\NN|NONE (r_pobj) of_3\IN|the|in (r_prep) involvement_2\NN|firmly|is|not|While (l_prep) in_5\IN|the|of (l_pobj) aetiology_7\NN|NONE (l_prep) of_8\IN|the (l_pobj) syndrome_13\NN|NONE
D008795_D006463 CID metronidazole_4\NN|NONE (r_pobj) of_3\IN|the|in (r_prep) involvement_2\NN|firmly|is|not|While (r_nsubjpass) established_16\VBN|.|link|,|action (r_advcl) suggest_43\VBP|NONE (l_nsubj) action_20\NN|.|link|,|established (l_conj) evidence_33\NN|in|the|of (l_prep) of_34\IN|reported|the (l_pobj) changes_36\NNS|NONE (l_prep) in_37\IN|oxidation (l_pobj) syndrome_42\NN|NONE
D008795_D006463 CID metronidazole_4\NN|NONE (r_pobj) of_3\IN|the|in (r_prep) involvement_2\NN|firmly|is|not|While (r_nsubjpass) established_16\VBN|.|link|,|action (r_advcl) suggest_43\VBP|NONE (l_dobj) link_46\NN|.|,|action|established (l_prep) between_47\IN|a|possible (l_pobj) treatment_49\NN|NONE (l_conj) cases_52\NNS|metronidazole|and (l_prep) of_53\IN|some (l_pobj) syndrome_58\NN|NONE
D008795_D006463 CID metronidazole_48\NN|and|cases (r_amod) treatment_49\NN|NONE (r_pobj) between_47\IN|a|possible (r_prep) link_46\NN|.|,|action|established (r_dobj) suggest_43\VBP|NONE (l_advcl) established_16\VBN|.|link|,|action (l_nsubjpass) involvement_2\NN|firmly|is|not|While (l_prep) in_5\IN|the|of (l_pobj) aetiology_7\NN|NONE (l_prep) of_8\IN|the (l_pobj) syndrome_13\NN|NONE
D008795_D006463 CID metronidazole_48\NN|and|cases (r_amod) treatment_49\NN|NONE (r_pobj) between_47\IN|a|possible (r_prep) link_46\NN|.|,|action|established (r_dobj) suggest_43\VBP|NONE (l_nsubj) action_20\NN|.|link|,|established (l_conj) evidence_33\NN|in|the|of (l_prep) of_34\IN|reported|the (l_pobj) changes_36\NNS|NONE (l_prep) in_37\IN|oxidation (l_pobj) syndrome_42\NN|NONE
D008795_D006463 CID metronidazole_48\NN|and|cases (r_amod) treatment_49\NN|NONE (l_conj) cases_52\NNS|metronidazole|and (l_prep) of_53\IN|some (l_pobj) syndrome_58\NN|NONE
17975693
D002939_D001008 CID ciprofloxacin-_5\JJ|NONE (r_nmod) rats_10\NNS|behaviour|in|that (r_nsubj) showed_11\VBD|:|.|studied|results (l_dobj) behaviour_13\NN|in|that|rats
D009643_D001008 CID norfloxacin_7\NNS| (r_npadvmod) treated_9\VBN|and (r_conj) ciprofloxacin-_5\JJ|NONE (r_nmod) rats_10\NNS|behaviour|in|that (r_nsubj) showed_11\VBD|:|.|studied|results (l_dobj) behaviour_13\NN|in|that|rats
9545159
D004917_D016171 CID erythromycin_20\NNP|NONE (r_pobj) with_19\IN|concomitant (r_prep) administration_18\NN|NONE (r_pobj) after_16\IN|been|but|.|with|torsades|have|, (r_prep) reported_15\VBN|NONE (l_nsubjpass) torsades_5\NNS|been|after|but|.|with|have|, (l_dobj) pointes_7\FW|Prolongation
D004110_D008133 CID diltiazem_9\NN|NONE (r_compound) interaction_10\NN|NONE (r_pobj) to_6\IN|NONE (r_prep) related_5\VBN|the|QT (r_acl) interval_4\NN|NONE
D020117_D008133 CID cisapride_7\NN| (r_compound) diltiazem_9\NN|NONE (r_compound) interaction_10\NN|NONE (r_pobj) to_6\IN|NONE (r_prep) related_5\VBN|the|QT (r_acl) interval_4\NN|NONE
D020117_D015835 NONE Cisapride_0\NNP|for|.|is|widely (r_nsubjpass) prescribed_13\VBN|NONE (l_prep) for_14\IN|.|is|Cisapride|widely (l_pobj) treatment_16\NN|NONE (l_prep) of_17\IN|the (l_pobj) disorders_20\NNS|NONE
D004917_D008133 CID erythromycin_20\NNP|NONE (r_pobj) with_19\IN|concomitant (r_prep) administration_18\NN|NONE (r_pobj) after_16\IN|been|but|.|with|torsades|have|, (r_prep) reported_15\VBN|NONE (l_nsubjpass) torsades_5\NNS|been|after|but|.|with|have|, (l_nsubj) Prolongation_0\NN|pointes (l_prep) of_1\IN|, (l_pobj) interval_3\NN|NONE
D001393_D016171 CID azole_22\JJ|antifungal (r_amod) agents_24\NNS|or (r_conj) erythromycin_20\NNP|NONE (r_pobj) with_19\IN|concomitant (r_prep) administration_18\NN|NONE (r_pobj) after_16\IN|been|but|.|with|torsades|have|, (r_prep) reported_15\VBN|NONE (l_nsubjpass) torsades_5\NNS|been|after|but|.|with|have|, (l_dobj) pointes_7\FW|Prolongation
D001393_D008133 CID azole_22\JJ|antifungal (r_amod) agents_24\NNS|or (r_conj) erythromycin_20\NNP|NONE (r_pobj) with_19\IN|concomitant (r_prep) administration_18\NN|NONE (r_pobj) after_16\IN|been|but|.|with|torsades|have|, (r_prep) reported_15\VBN|NONE (l_nsubjpass) torsades_5\NNS|been|after|but|.|with|have|, (l_nsubj) Prolongation_0\NN|pointes (l_prep) of_1\IN|, (l_pobj) interval_3\NN|NONE
D020117_D006973 NONE cisapride_14\NN|was|for|who|for|, (r_dobj) taking_13\VBG|a|old (l_prep) for_31\IN|was|for|who|cisapride|, (l_pobj) hypertension_32\NN|NONE
D020117_D005764 NONE cisapride_14\NN|was|for|who|for|, (r_dobj) taking_13\VBG|a|old (l_prep) for_15\IN|was|who|cisapride|for|, (l_pobj) disorder_18\NN|NONE
D004110_D005764 NONE diltiazem_20\NN|agent|and|,|gastroesophageal|reflux (r_conj) disorder_18\NN|NONE
D004917_D016757 CID erythromycin_20\NNP|NONE (r_pobj) with_19\IN|concomitant (r_prep) administration_18\NN|NONE (r_pobj) after_16\IN|been|but|.|with|torsades|have|, (r_prep) reported_15\VBN|NONE (l_nsubjpass) torsades_5\NNS|been|after|but|.|with|have|, (l_dobj) pointes_7\FW|Prolongation (l_conj) death_12\NN|and|de|,
D004110_D006973 NONE diltiazem_20\NN|agent|and|,|gastroesophageal|reflux (r_conj) disorder_18\NN|NONE (r_pobj) for_15\IN|was|who|cisapride|for|, (r_prep) taking_13\VBG|a|old (l_prep) for_31\IN|was|for|who|cisapride|, (l_pobj) hypertension_32\NN|NONE
D001393_D016757 CID azole_22\JJ|antifungal (r_amod) agents_24\NNS|or (r_conj) erythromycin_20\NNP|NONE (r_pobj) with_19\IN|concomitant (r_prep) administration_18\NN|NONE (r_pobj) after_16\IN|been|but|.|with|torsades|have|, (r_prep) reported_15\VBN|NONE (l_nsubjpass) torsades_5\NNS|been|after|but|.|with|have|, (l_dobj) pointes_7\FW|Prolongation (l_conj) death_12\NN|and|de|,
15276120
D014859_D006470 CID warfarin_3\RB| (r_npadvmod) associated_5\VBN|NONE (r_amod) hemorrhage_6\NN|NONE
D014859_D006470 CID warfarin_4\RB| (r_npadvmod) related_6\VBN|at (r_amod) bleeding_7\NN|NONE
2220369
C015173_D005901 NONE epinephrine_28\NN|NONE (l_prep) for_29\IN|dipivalyl (l_pobj) glaucoma_31\NN|NONE
C015173_D020246 CID epinephrine_6\NN|Central|vein|.|and (r_conj) thrombosis_2\NN|NONE
C015173_D020246 CID epinephrine_28\NN|NONE (r_pobj) with_26\IN|medication|having (r_prep) started_23\VBN|NONE (r_pcomp) after_21\IN|who|in|thrombosis|day (r_prep) acquired_11\VBD|old|an (l_dobj) thrombosis_14\NN|who|in|after|day
14633084
D007069_D006470 CID ifosfamide_9\RB| (r_advmod) induced_11\VBN|hemorrhagic (r_amod) cystitis_13\NN|NONE
D007069_D006470 CID ifosfamide_16\NN|NONE (r_pobj) with_15\IN|side|limiting|a||of (r_prep) effect_12\NN|.|AIM (r_attr) is_7\VBZ|NONE (l_nsubj) AIM_0\VB|effect|. (l_appos) cystitis_3\NN|:
D007069_D006470 CID ifosfamide_16\NN|NONE (r_pobj) with_15\IN|side|limiting|a||of (r_prep) effect_12\NN|.|AIM (r_attr) is_7\VBZ|NONE (l_nsubj) AIM_0\VB|effect|. (l_appos) cystitis_3\NN|: (l_appos) HC_5\NNP|)|(|Hemorrhagic
D007069_D006470 CID IFS_18\NNP|(|) (r_appos) ifosfamide_16\NN|NONE (r_pobj) with_15\IN|side|limiting|a||of (r_prep) effect_12\NN|.|AIM (r_attr) is_7\VBZ|NONE (l_nsubj) AIM_0\VB|effect|. (l_appos) cystitis_3\NN|:
D007069_D006470 CID IFS_18\NNP|(|) (r_appos) ifosfamide_16\NN|NONE (r_pobj) with_15\IN|side|limiting|a||of (r_prep) effect_12\NN|.|AIM (r_attr) is_7\VBZ|NONE (l_nsubj) AIM_0\VB|effect|. (l_appos) cystitis_3\NN|: (l_appos) HC_5\NNP|)|(|Hemorrhagic
D007069_D006470 CID IFS_20\NNP| (r_npadvmod) induced_22\VBN|NONE (r_amod) HC_23\NN|NONE
D007069_D006470 CID IFS_9\NNP| (r_npadvmod) induced_11\VBN|NONE (r_amod) HC_12\NN|NONE
D015080_D006470 NONE mesna_4\NN|NONE (r_pobj) with_3\IN|for|of|. (r_prep) Use_0\NN|NONE (l_prep) for_5\IN|of|with|. (l_pobj) prevention_7\NN|NONE (l_prep) of_8\IN|the (l_pobj) cystitis_13\NN|NONE
D015080_D006470 NONE mesna_15\NN|NONE (r_pobj) with_14\IN|NONE (r_prep) combination_13\NN|NONE (r_pobj) in_12\IN|the|for|of (r_prep) use_9\NN|.|In|we|, (l_prep) for_16\IN|the|of|in (l_pobj) prevention_18\NN|NONE (l_prep) of_19\IN|the (l_pobj) HC_23\NN|NONE
D015080_D006470 NONE mesna_4\NN|NONE (r_pobj) with_3\IN|NONE (r_prep) combination_2\NN|NONE (r_pobj) in_1\IN|NONE (r_prep) Dexamethasone_0\NN|.|efficient (r_nsubj) was_5\VBD|NONE (l_acomp) efficient_6\JJ|.|Dexamethasone (l_prep) in_7\IN|NONE (l_pcomp) blocking_8\VBG|NONE (l_dobj) HC_12\NN|NONE
D015080_D006470 NONE mesna_9\NN|NONE (r_pobj) of_8\IN|with|last|two (r_prep) doses_7\NNS|NONE (r_pobj) of_4\IN|the (r_prep) replacement_3\NN|not|However|did|.|HC|, (r_nsubj) prevent_22\VB|NONE (l_dobj) HC_23\NN|not|However|did|.|replacement|,
D015080_D006470 NONE mesna_16\JJ|the|with (r_amod) doses_17\NNS|NONE (r_pobj) of_14\IN|NONE (r_prep) all_13\DT|or (r_conj) saline_11\NN|NONE (r_pobj) with_10\IN|of|last|two (r_prep) doses_7\NNS|NONE (r_pobj) of_4\IN|the (r_prep) replacement_3\NN|not|However|did|.|HC|, (r_nsubj) prevent_22\VB|NONE (l_dobj) HC_23\NN|not|However|did|.|replacement|,
D003907_D006470 NONE dexamethasone_2\NN|NONE (r_pobj) of_1\IN|for|with|. (r_prep) Use_0\NN|NONE (l_prep) for_5\IN|of|with|. (l_pobj) prevention_7\NN|NONE (l_prep) of_8\IN|the (l_pobj) cystitis_13\NN|NONE
D003907_D006470 NONE dexamethasone_11\NN|NONE (r_pobj) of_10\IN|the|for|in (r_prep) use_9\NN|.|In|we|, (l_prep) for_16\IN|the|of|in (l_pobj) prevention_18\NN|NONE (l_prep) of_19\IN|the (l_pobj) HC_23\NN|NONE
D003907_D006470 NONE Dexamethasone_0\NN|.|efficient (r_nsubj) was_5\VBD|NONE (l_acomp) efficient_6\JJ|.|Dexamethasone (l_prep) in_7\IN|NONE (l_pcomp) blocking_8\VBG|NONE (l_dobj) HC_12\NN|NONE
D003907_D006470 NONE dexamethasone_19\NN|NONE (r_pobj) with_18\IN|the|mesna (r_prep) doses_17\NNS|NONE (r_pobj) of_14\IN|NONE (r_prep) all_13\DT|or (r_conj) saline_11\NN|NONE (r_pobj) with_10\IN|of|last|two (r_prep) doses_7\NNS|NONE (r_pobj) of_4\IN|the (r_prep) replacement_3\NN|not|However|did|.|HC|, (r_nsubj) prevent_22\VB|NONE (l_dobj) HC_23\NN|not|However|did|.|replacement|,
D007069_D003556 CID ifosfamide_9\RB| (r_advmod) induced_11\VBN|hemorrhagic (r_amod) cystitis_13\NN|NONE
D007069_D003556 CID ifosfamide_16\NN|NONE (r_pobj) with_15\IN|side|limiting|a||of (r_prep) effect_12\NN|.|AIM (r_attr) is_7\VBZ|NONE (l_nsubj) AIM_0\VB|effect|. (l_appos) cystitis_3\NN|:
D007069_D003556 CID ifosfamide_16\NN|NONE (r_pobj) with_15\IN|side|limiting|a||of (r_prep) effect_12\NN|.|AIM (r_attr) is_7\VBZ|NONE (l_nsubj) AIM_0\VB|effect|. (l_appos) cystitis_3\NN|: (l_appos) HC_5\NNP|)|(|Hemorrhagic
D007069_D003556 CID IFS_18\NNP|(|) (r_appos) ifosfamide_16\NN|NONE (r_pobj) with_15\IN|side|limiting|a||of (r_prep) effect_12\NN|.|AIM (r_attr) is_7\VBZ|NONE (l_nsubj) AIM_0\VB|effect|. (l_appos) cystitis_3\NN|:
D007069_D003556 CID IFS_18\NNP|(|) (r_appos) ifosfamide_16\NN|NONE (r_pobj) with_15\IN|side|limiting|a||of (r_prep) effect_12\NN|.|AIM (r_attr) is_7\VBZ|NONE (l_nsubj) AIM_0\VB|effect|. (l_appos) cystitis_3\NN|: (l_appos) HC_5\NNP|)|(|Hemorrhagic
D007069_D003556 CID IFS_20\NNP| (r_npadvmod) induced_22\VBN|NONE (r_amod) HC_23\NN|NONE
D007069_D003556 CID IFS_9\NNP| (r_npadvmod) induced_11\VBN|NONE (r_amod) HC_12\NN|NONE
D003907_D003556 NONE dexamethasone_2\NN|NONE (r_pobj) of_1\IN|for|with|. (r_prep) Use_0\NN|NONE (l_prep) for_5\IN|of|with|. (l_pobj) prevention_7\NN|NONE (l_prep) of_8\IN|the (l_pobj) cystitis_13\NN|NONE
D003907_D003556 NONE dexamethasone_11\NN|NONE (r_pobj) of_10\IN|the|for|in (r_prep) use_9\NN|.|In|we|, (l_prep) for_16\IN|the|of|in (l_pobj) prevention_18\NN|NONE (l_prep) of_19\IN|the (l_pobj) HC_23\NN|NONE
D003907_D003556 NONE Dexamethasone_0\NN|.|efficient (r_nsubj) was_5\VBD|NONE (l_acomp) efficient_6\JJ|.|Dexamethasone (l_prep) in_7\IN|NONE (l_pcomp) blocking_8\VBG|NONE (l_dobj) HC_12\NN|NONE
D003907_D003556 NONE dexamethasone_19\NN|NONE (r_pobj) with_18\IN|the|mesna (r_prep) doses_17\NNS|NONE (r_pobj) of_14\IN|NONE (r_prep) all_13\DT|or (r_conj) saline_11\NN|NONE (r_pobj) with_10\IN|of|last|two (r_prep) doses_7\NNS|NONE (r_pobj) of_4\IN|the (r_prep) replacement_3\NN|not|However|did|.|HC|, (r_nsubj) prevent_22\VB|NONE (l_dobj) HC_23\NN|not|However|did|.|replacement|,
D015080_D003556 NONE mesna_4\NN|NONE (r_pobj) with_3\IN|for|of|. (r_prep) Use_0\NN|NONE (l_prep) for_5\IN|of|with|. (l_pobj) prevention_7\NN|NONE (l_prep) of_8\IN|the (l_pobj) cystitis_13\NN|NONE
D015080_D003556 NONE mesna_15\NN|NONE (r_pobj) with_14\IN|NONE (r_prep) combination_13\NN|NONE (r_pobj) in_12\IN|the|for|of (r_prep) use_9\NN|.|In|we|, (l_prep) for_16\IN|the|of|in (l_pobj) prevention_18\NN|NONE (l_prep) of_19\IN|the (l_pobj) HC_23\NN|NONE
D015080_D003556 NONE mesna_4\NN|NONE (r_pobj) with_3\IN|NONE (r_prep) combination_2\NN|NONE (r_pobj) in_1\IN|NONE (r_prep) Dexamethasone_0\NN|.|efficient (r_nsubj) was_5\VBD|NONE (l_acomp) efficient_6\JJ|.|Dexamethasone (l_prep) in_7\IN|NONE (l_pcomp) blocking_8\VBG|NONE (l_dobj) HC_12\NN|NONE
D015080_D003556 NONE mesna_9\NN|NONE (r_pobj) of_8\IN|with|last|two (r_prep) doses_7\NNS|NONE (r_pobj) of_4\IN|the (r_prep) replacement_3\NN|not|However|did|.|HC|, (r_nsubj) prevent_22\VB|NONE (l_dobj) HC_23\NN|not|However|did|.|replacement|,
D015080_D003556 NONE mesna_16\JJ|the|with (r_amod) doses_17\NNS|NONE (r_pobj) of_14\IN|NONE (r_prep) all_13\DT|or (r_conj) saline_11\NN|NONE (r_pobj) with_10\IN|of|last|two (r_prep) doses_7\NNS|NONE (r_pobj) of_4\IN|the (r_prep) replacement_3\NN|not|However|did|.|HC|, (r_nsubj) prevent_22\VB|NONE (l_dobj) HC_23\NN|not|However|did|.|replacement|,
8590259
C016986_D015814 CID apraclonidine_8\NN| (r_npadvmod) treated_10\VBN|NONE (r_amod) eyes_11\NNS|NONE (r_pobj) for_7\IN|significant|statistically|throughout|and (r_prep) significant_6\JJ|.|effects (r_acomp) were_4\VBD|NONE (l_nsubj) effects_3\NNS|significant|. (l_amod) hypotensive_2\JJ|ocular|The
C016986_D015814 CID apraclonidine_31\NN|NONE (r_pobj) of_28\IN|topical (r_prep) administration_27\NN|NONE (r_pobj) after_25\IN|three (r_prep) hours_24\NNS|NONE (r_pobj) from_22\IN|also|statistically|for (r_prep) significant_18\JJ|for|statistically|throughout|and (r_conj) significant_6\JJ|.|effects (r_acomp) were_4\VBD|NONE (l_nsubj) effects_3\NNS|significant|. (l_amod) hypotensive_2\JJ|ocular|The
16787750
D014635_D001855 CID VPA_17\NNP| (r_npadvmod) induced_19\VBN|and|encephalopathy|, (r_amod) hepatotoxicity_20\NN|in|may|.|complications (r_npadvmod) occur_4\VB|NONE (l_prep) in_5\IN|may|.|complications|hepatotoxicity (l_pobj) patients_7\NNS|NONE (l_prep) including_9\VBG|,|some (l_pobj) pancreatitis_11\NN|NONE (l_conj) suppression_15\NN|,|haemorrhagic
D014635_D001855 CID VPA_22\NNP| (r_npadvmod) induced_24\VBN|NONE (r_compound) encephalopathy_25\NN|and|,|induced (r_conj) hepatotoxicity_20\NN|in|may|.|complications (r_npadvmod) occur_4\VB|NONE (l_prep) in_5\IN|may|.|complications|hepatotoxicity (l_pobj) patients_7\NNS|NONE (l_prep) including_9\VBG|,|some (l_pobj) pancreatitis_11\NN|NONE (l_conj) suppression_15\NN|,|haemorrhagic
D014635_D022124 NONE VPA_4\NNP| (r_npadvmod) induced_6\VBN|NONE (r_amod) encephalopathy_7\NN|NONE (r_pobj) of_3\IN|typical|The (r_prep) signs_2\NNS|marked|consciousness|.|, (r_nsubj) are_8\VBP|NONE (l_advcl) marked_13\VBD|signs|consciousness|.|, (l_ccomp) slowing_16\VBG|sometimes (l_dobj) frequency_20\NN|background|, (l_prep) with_22\IN|seizure|,|increased (l_conj) without_24\IN|or (l_pobj) hyperammonemia_25\NN|NONE
D014635_D056486 CID VPA_17\NNP| (r_npadvmod) induced_19\VBN|and|encephalopathy|, (r_amod) hepatotoxicity_20\NN|in|may|.|complications
D014635_D056486 CID VPA_22\NNP| (r_npadvmod) induced_24\VBN|NONE (r_compound) encephalopathy_25\NN|and|,|induced (r_conj) hepatotoxicity_20\NN|in|may|.|complications
D014635_D010195 CID VPA_17\NNP| (r_npadvmod) induced_19\VBN|and|encephalopathy|, (r_amod) hepatotoxicity_20\NN|in|may|.|complications (r_npadvmod) occur_4\VB|NONE (l_prep) in_5\IN|may|.|complications|hepatotoxicity (l_pobj) patients_7\NNS|NONE (l_prep) including_9\VBG|,|some (l_pobj) pancreatitis_11\NN|NONE
D014635_D010195 CID VPA_22\NNP| (r_npadvmod) induced_24\VBN|NONE (r_compound) encephalopathy_25\NN|and|,|induced (r_conj) hepatotoxicity_20\NN|in|may|.|complications (r_npadvmod) occur_4\VB|NONE (l_prep) in_5\IN|may|.|complications|hepatotoxicity (l_pobj) patients_7\NNS|NONE (l_prep) including_9\VBG|,|some (l_pobj) pancreatitis_11\NN|NONE
D014635_D003244 CID VPA_4\NNP| (r_npadvmod) induced_6\VBN|NONE (r_amod) encephalopathy_7\NN|NONE (r_pobj) of_3\IN|typical|The (r_prep) signs_2\NNS|marked|consciousness|.|, (r_nsubj) are_8\VBP|NONE (l_attr) consciousness_10\NN|signs|marked|.|,
D014635_D012640 NONE VPA_4\NNP| (r_npadvmod) induced_6\VBN|NONE (r_amod) encephalopathy_7\NN|NONE (r_pobj) of_3\IN|typical|The (r_prep) signs_2\NNS|marked|consciousness|.|, (r_nsubj) are_8\VBP|NONE (l_advcl) marked_13\VBD|signs|consciousness|.|, (l_ccomp) slowing_16\VBG|sometimes (l_dobj) frequency_20\NN|background|, (l_compound) seizure_19\NN|with|,|increased
D014635_D001927 CID acid_1\NN|encephalopathy|cases|from|.|to (r_nsubj) induced_2\VBD|NONE (l_advmod) encephalopathy--19_3\NNP|cases|from|.|to|acid
D014635_D001927 CID VPA_18\NNP| (r_compound) therapy_20\NN|NONE (r_pobj) to_17\IN|in (r_prep) associated_16\VBN||a|side (r_acl) effect_15\NN|NONE (r_pobj) to_10\IN|encephalopathy|cases|from|.|acid (r_prep) induced_2\VBD|NONE (l_advmod) encephalopathy--19_3\NNP|cases|from|.|to|acid
D014635_D001927 CID VPA_17\NNP| (r_npadvmod) induced_19\VBN|and|encephalopathy|, (r_amod) hepatotoxicity_20\NN|in|may|.|complications (l_conj) encephalopathy_25\NN|and|,|induced
D014635_D001927 CID VPA_22\NNP| (r_npadvmod) induced_24\VBN|NONE (r_compound) encephalopathy_25\NN|and|,|induced
D014635_D001927 CID VPA_4\NNP| (r_npadvmod) induced_6\VBN|NONE (r_amod) encephalopathy_7\NN|NONE
D014635_D001927 CID VPA_9\NNP|NONE (r_pobj) of_8\IN|in|causative (r_prep) effect_7\NN|NONE (l_prep) in_10\IN|of|causative (l_pobj) patients_11\NNS|NONE (l_prep) with_12\IN|NONE (l_pobj) encephalopathy_13\JJ|NONE
D014635_D001927 CID VPA_5\NNP| (r_npadvmod) associated_7\VBN|in (r_amod) encephalopathy_8\NN|NONE
11961407
D014443_D009401 NONE tyrosine_2\NN|.|receptor|GLEPP|Ptpro|in (r_compound) phosphatase_3\NN|NONE (l_prep) in_7\IN|.|receptor|tyrosine|GLEPP|Ptpro (l_pobj) nephrosis_10\NN|NONE
D011692_D005921 NONE PAN_21\NNP|NONE (r_compound) injection_22\NN|NONE (r_pobj) after_20\IN|| (r_prep) days_19\NNS|were|.|Tissues|include|at (r_npadvmod) analyzed_2\VBN|NONE (l_advcl) include_26\VB|were|.|Tissues|days|at (l_dobj) phase_30\NN|so|to|as (l_appos) days_39\NNS|both|of|the|acute|(|associated (l_conj) phase_47\NN|)||and (l_acl) associated_50\VBN|chronic|of|the (l_prep) with_51\IN|NONE (l_pobj) glomerulosclerosis_52\NN|NONE
D011692_D009401 CID PAN_9\NNP|rat (r_compound) nephrosis_10\NN|NONE
D011692_D009401 CID aminonucleoside_1\JJ|Puromycin (r_amod) nephrosis_2\NN|by|aminonucleoside|was|.
D011692_D009401 CID aminonucleoside_11\NN|by|was|.|nephrosis (r_advmod) induced_4\VBN|NONE (l_nsubjpass) nephrosis_2\NN|by|aminonucleoside|was|.
D011692_D009401 CID PAN_13\NNP|NONE (r_appos) aminonucleoside_11\NN|by|was|.|nephrosis (r_advmod) induced_4\VBN|NONE (l_nsubjpass) nephrosis_2\NN|by|aminonucleoside|was|.
D011692_D011507 CID PAN_21\NNP|NONE (r_compound) injection_22\NN|NONE (r_pobj) after_20\IN|| (r_prep) days_19\NNS|were|.|Tissues|include|at (r_npadvmod) analyzed_2\VBN|NONE (l_advcl) include_26\VB|were|.|Tissues|days|at (l_dobj) phase_30\NN|so|to|as (l_prep) of_31\IN|both|days|the|acute|(|associated (l_pobj) proteinuria_32\NN|NONE
D011692_D011507 CID PAN_21\NNP|NONE (r_compound) injection_22\NN|NONE (r_pobj) after_20\IN|| (r_prep) days_19\NNS|were|.|Tissues|include|at (r_npadvmod) analyzed_2\VBN|NONE (l_advcl) include_26\VB|were|.|Tissues|days|at (l_dobj) phase_30\NN|so|to|as (l_appos) days_39\NNS|both|of|the|acute|(|associated (l_conj) phase_47\NN|)||and (l_prep) of_48\IN|chronic|associated|the (l_pobj) proteinuria_49\NN|NONE
2924746
D019946_D012640 NONE glycol_13\NN|,|common|a (r_appos) vehicle_10\NN|In|,|exhibit|by|,|,|.|was (r_nsubjpass) found_22\VBN|NONE (l_xcomp) exhibit_24\VB|In|,|by|,|,|.|was|vehicle (l_dobj) properties_26\NNS|to (l_prep) against_27\IN|protective (l_pobj) seizures_29\NNS|NONE
D005481_D015430 NONE HFDE_21\NNP| (r_npadvmod) induced_23\VBN|NONE (r_amod) seizures_24\NNS|NONE (r_pobj) against_20\IN|continuously (r_prep) protective_19\JJ|was|.|and|administration (r_acomp) was_17\VBD|NONE (l_conj) was_26\VBD|.|and|protective|administration (l_advcl) measured_30\VBN|toxic (l_agent) by_31\IN|as|over (l_pobj) gain_33\NN|NONE
D005481_D012640 CID ether_4\NN|NONE (r_pobj) by_2\IN|Seizures|.|found (r_prep) induced_1\VBN|NONE (l_nsubj) Seizures_0\NNS|.|by|found
D005481_D012640 CID ether_4\NN|NONE (r_pobj) by_2\IN|Seizures|.|found (r_prep) induced_1\VBN|NONE (l_conj) found_10\VBN|Seizures|.|by (l_xcomp) be_12\VB|were|also (l_prep) than_21\IN|to|measure (l_pobj) seizures_22\NNS|NONE
D005481_D012640 CID HFDE_6\NNP|hexafluorodiethyl (r_appos) ether_4\NN|NONE (r_pobj) by_2\IN|Seizures|.|found (r_prep) induced_1\VBN|NONE (l_nsubj) Seizures_0\NNS|.|by|found
D005481_D012640 CID HFDE_6\NNP|hexafluorodiethyl (r_appos) ether_4\NN|NONE (r_pobj) by_2\IN|Seizures|.|found (r_prep) induced_1\VBN|NONE (l_conj) found_10\VBN|Seizures|.|by (l_xcomp) be_12\VB|were|also (l_prep) than_21\IN|to|measure (l_pobj) seizures_22\NNS|NONE
D005481_D012640 CID HFDE_21\NNP| (r_npadvmod) induced_23\VBN|NONE (r_amod) seizures_24\NNS|NONE
D002220_D015430 NONE CBZ_3\NNP|NONE (r_pobj) of_2\IN|h|Oral|as (r_prep) administration_1\NN|was|.|and|protective (r_nsubj) was_17\VBD|NONE (l_conj) was_26\VBD|.|and|protective|administration (l_advcl) measured_30\VBN|toxic (l_agent) by_31\IN|as|over (l_pobj) gain_33\NN|NONE
D005492_D064420 NONE folate_17\JJ|tissue (r_compound) concentrations_18\NNS|and (r_conj) plasma_14\NN|NONE (r_pobj) on_13\IN|NONE (r_prep) effect_12\NN|and|, (r_conj) toxicity_9\NN|,
D002220_D064420 NONE carbamazepine_1\NN|in|.|:|efficacy (r_compound) treatment_2\NN|NONE (l_appos) efficacy_7\NN|in|carbamazepine|.|: (l_conj) toxicity_9\NN|,
D002220_D012640 NONE CBZ_20\NN|NONE (r_pobj) by_19\IN|NONE (r_prep) protection_18\NN|NONE (r_pobj) of_17\IN|sensitive|a (r_prep) measure_16\NN|to|than (r_attr) be_12\VB|were|also (r_xcomp) found_10\VBN|Seizures|.|by (r_conj) induced_1\VBN|NONE (l_nsubj) Seizures_0\NNS|.|by|found
D002220_D012640 NONE CBZ_20\NN|NONE (r_pobj) by_19\IN|NONE (r_prep) protection_18\NN|NONE (r_pobj) of_17\IN|sensitive|a (r_prep) measure_16\NN|to|than (r_attr) be_12\VB|were|also (l_prep) than_21\IN|to|measure (l_pobj) seizures_22\NNS|NONE
D002220_D012640 NONE CBZ_3\NNP|NONE (r_pobj) of_2\IN|h|Oral|as (r_prep) administration_1\NN|was|.|and|protective (r_nsubj) was_17\VBD|NONE (l_acomp) protective_19\JJ|was|.|and|administration (l_prep) against_20\IN|continuously (l_pobj) seizures_24\NNS|NONE
D019946_D015430 NONE glycol_13\NN|,|common|a (r_appos) vehicle_10\NN|In|,|exhibit|by|,|,|.|was (r_nsubjpass) found_22\VBN|NONE (l_xcomp) exhibit_24\VB|In|,|by|,|,|.|was|vehicle (l_dobj) properties_26\NNS|to (l_prep) against_27\IN|protective (l_pobj) seizures_29\NNS|NONE (l_conj) gain_33\NN|and|induced
2445283
D012254_D014766 NONE ribavirin_2\RB|NONE (r_pobj) of_1\IN|NONE (r_prep) Administration_0\NN|in|. (r_nsubj) resulted_3\VBD|NONE (l_prep) in_4\IN|Administration|. (l_pobj) neutralization_6\NN|NONE (l_prep) of_7\IN|a|and|drop (l_pobj) viremia_8\NN|NONE
D012254_D006478 NONE ribavirin_5\NN|NONE (r_pobj) of_4\IN|antiviral (r_prep) effect_3\NN|and|in|. (r_conj) Tolerance_0\NN|NONE (l_prep) in_6\IN|effect|and|. (l_pobj) patients_7\NNS|NONE (l_prep) with_8\IN|NONE (l_pobj) fever_11\NN|NONE
D012254_D006478 NONE ribavirin_5\NN|NONE (r_pobj) of_4\IN|antiviral (r_prep) effect_3\NN|and (r_conj) Tolerance_0\NN|was|in|. (r_nsubjpass) studied_7\VBN|NONE (l_prep) in_8\IN|was|Tolerance|. (l_pobj) patients_10\NNS|NONE (l_prep) with_11\IN| (l_pobj) fever_14\NN|NONE
D012254_D006478 NONE ribavirin_5\NN|NONE (r_pobj) of_4\IN|antiviral (r_prep) effect_3\NN|and (r_conj) Tolerance_0\NN|was|in|. (r_nsubjpass) studied_7\VBN|NONE (l_prep) in_8\IN|was|Tolerance|. (l_pobj) patients_10\NNS|NONE (l_prep) with_11\IN| (l_pobj) fever_14\NN|NONE (l_appos) AHF_16\NNP|Argentine|of|hemorrhagic|(|)
D012254_D006478 NONE ribavirin_7\NN|effect|that|managed|,|and (r_nsubj) has_8\VBZ|,|we|From (l_dobj) effect_11\NN|ribavirin|that|managed|,|and (l_prep) in_12\IN|antiviral|an (l_pobj) cases_14\NNS|NONE (l_prep) of_15\IN|advanced (l_pobj) AHF_16\NNP|NONE
D012254_D006478 NONE ribavirin_5\RB|NONE (r_pobj) of_4\IN|The|during|possible|beneficial (r_prep) effect_3\NN|.|is (l_prep) during_6\IN|of|The|possible|beneficial (l_pobj) days_9\NNS|NONE (l_prep) of_10\IN|initial|the (l_pobj) AHF_11\NNP|NONE
D012254_D000740 CID ribavirin_7\NN|effect|that|managed|,|and (r_nsubj) has_8\VBZ|,|we|From (l_conj) managed_31\VBN|effect|ribavirin|that|,|and (l_nsubjpass) anemia_20\NN|easily|can|.|be
8911359
D003520_D001749 CID Cyclophosphamide_0\NN|disease|associated|bladder||. (r_nmod) cancer_3\NN|NONE
D003520_D001749 CID cyclophosphamide_17\NN|cancer (r_pobj) with_16\IN|age|of|medical|The (l_pobj) cancer_20\NN|cyclophosphamide
D003520_D001749 CID Cyclophosphamide_0\NN|associated|bladder (r_nmod) tumor_3\NN|disease|.
D003520_D014523 NONE cyclophosphamide_13\NN|NONE (r_pobj) of_12\IN|,|treatment|the (r_prep) etiology_7\NN|NONE (r_pobj) of_5\IN|NONE (r_prep) knowledge_4\NN|.|We|cancer (r_dobj) gained_3\VBD|: (l_dobj) cancer_16\NN|knowledge|.|We
7504976
D002231_D002779 CID carbimazole_8\NN|NONE (r_pobj) by_7\IN|hepatitis (r_agent) induced_6\VBN|patients|. (l_nsubj) hepatitis_5\NN|by
D002231_D002779 CID omercazole_11\NN|)|( (r_appos) carbimazole_8\NN|NONE (r_pobj) by_7\IN|hepatitis (r_agent) induced_6\VBN|patients|. (l_nsubj) hepatitis_5\NN|by
D002231_D002779 CID carbimazole_12\NN|others|. (l_amod) mixed_4\JJ|a|following|) (l_conj) cholestatic_6\JJ|(
D002231_D056486 CID carbimazole_16\NN|NONE (r_pobj) between_15\IN|cross| (r_prep) reactivity_14\NN|NONE (r_pobj) with_11\IN|NONE (r_prep) one_10\CD|NONE (r_pobj) including_9\VBG|four (r_prep) cases_8\NNS|by|:|hepatitis|. (r_appos) induced_2\VBN|NONE (l_nsubj) hepatitis_1\NN|by|cases|:|.
D002231_D056486 CID carbimazole_8\NN|NONE (r_pobj) by_7\IN|hepatitis (r_agent) induced_6\VBN|patients|. (l_nsubj) hepatitis_5\NN|by
D002231_D056486 CID omercazole_11\NN|)|( (r_appos) carbimazole_8\NN|NONE (r_pobj) by_7\IN|hepatitis (r_agent) induced_6\VBN|patients|. (l_nsubj) hepatitis_5\NN|by
D002231_D056486 CID carbimazole_12\NN|others|. (l_amod) following_11\VBG|a|mixed|) (l_compound) hepatitis_10\NN|NONE
D002231_D056486 CID carbimazole_21\NN|had|.|experienced (r_dobj) replaced_20\VBN|NONE (l_nsubj) experienced_7\VBD|had|.|carbimazole (l_dobj) hepatitis_10\NN|One|further|)
C019269_D056486 NONE benzylthiouracil_18\NN|and (r_conj) carbimazole_16\NN|NONE (r_pobj) between_15\IN|cross| (r_prep) reactivity_14\NN|NONE (r_pobj) with_11\IN|NONE (r_prep) one_10\CD|NONE (r_pobj) including_9\VBG|four (r_prep) cases_8\NNS|by|:|hepatitis|. (r_appos) induced_2\VBN|NONE (l_nsubj) hepatitis_1\NN|by|cases|:|.
C019269_D056486 NONE Benzylthiouracil_14\NNP|NONE (r_pobj) after_13\IN|which (r_prep) appeared_12\VBD|cytolytic|a (r_relcl) hepatitis_10\NN|One|further|)
C019269_D056486 NONE ne_17\NNP|NONE (r_appos) Benzylthiouracil_14\NNP|NONE (r_pobj) after_13\IN|which (r_prep) appeared_12\VBD|cytolytic|a (r_relcl) hepatitis_10\NN|One|further|)
17682013
D008727_D002544 NONE methotrexate_21\NN|NONE (r_pobj) of_19\IN|NONE (r_prep) recipients_18\NNS|commonly (r_pobj) in_17\IN|has|leukoencephalopathy|,|as|.|been (r_prep) described_8\VBN|NONE (l_nsubjpass) leukoencephalopathy_2\JJ|has|,|as|.|been|in (l_acl) mimicking_3\VBG|transient|A (l_dobj) accident_5\NN|NONE
C110904_D056784 CID capecitabine_26\NN|,|its|and|derivative (r_conj) carmofur_23\NN|:|We|reports|and|fluorouracil|. (r_conj) identified_2\VBD|NONE (l_dobj) reports_4\NNS|:|carmofur|We|and|fluorouracil|. (l_prep) of_5\IN| (l_pobj) leukoencephalopathy_7\JJ|NONE
D008727_D056784 CID methotrexate_21\NN|NONE (r_pobj) of_19\IN|NONE (r_prep) recipients_18\NNS|commonly (r_pobj) in_17\IN|has|leukoencephalopathy|,|as|.|been (r_prep) described_8\VBN|NONE (l_nsubjpass) leukoencephalopathy_2\JJ|has|,|as|.|been|in
D008727_D056784 CID methotrexate_12\NNP|NONE (r_pobj) with_11\IN|NONE (r_prep) treated_10\VBN|NONE (r_acl) patients_9\NNS|NONE (r_pobj) in_8\IN|toxic (r_prep) leukoencephalopathy_7\JJ|NONE
D005472_D056784 CID 5-fluorouracil_19\CD|:|carmofur|We|reports|and|. (r_punct) identified_2\VBD|NONE (l_dobj) reports_4\NNS|:|carmofur|We|and|fluorouracil|. (l_prep) of_5\IN| (l_pobj) leukoencephalopathy_7\JJ|NONE
D008727_D007938 NONE methotrexate_21\NN|NONE (l_prep) for_22\IN|intrathecal (l_pobj) leukaemia_24\NN|NONE
C017367_D056784 CID carmofur_23\NN|:|We|reports|and|fluorouracil|. (r_conj) identified_2\VBD|NONE (l_dobj) reports_4\NNS|:|carmofur|We|and|fluorouracil|. (l_prep) of_5\IN| (l_pobj) leukoencephalopathy_7\JJ|NONE
6386793
D004308_D014786 NONE dothiepin_24\JJ|NONE (r_pobj) with_23\IN|than|significantly (r_prep) less_22\JJR|incidence|. (r_acomp) were_20\VBD|NONE (l_nsubj) incidence_2\NN|.|less (l_prep) of_3\IN|The|overall (l_pobj) effects_5\NNS|NONE (l_conj) frequency_8\NN|and|side (l_prep) of_11\IN|the|and|severity (l_pobj) vision_13\NN|NONE
D000639_D014987 CID amitriptyline_27\NN|NONE (r_pobj) with_26\IN|NONE (r_prep) than_25\IN|with|significantly (r_prep) less_22\JJR|incidence|. (r_acomp) were_20\VBD|NONE (l_nsubj) incidence_2\NN|.|less (l_prep) of_3\IN|The|overall (l_pobj) effects_5\NNS|NONE (l_conj) frequency_8\NN|and|side (l_prep) of_11\IN|the|and|severity (l_pobj) vision_13\NN|NONE (l_conj) mouth_16\NN|blurred|,
D000928_D003866 NONE antidepressant_8\NN|an|effective|associated (r_amod) drug_9\NN|to (l_acl) associated_10\VBN|antidepressant|an|effective (l_prep) with_11\IN|NONE (l_pobj) effects_14\NNS|NONE (l_prep) than_15\IN|side|fewer (l_pobj) amitriptyline_16\NN|NONE (l_prep) in_17\IN|NONE (l_pobj) treatment_19\NN|NONE (l_prep) of_20\IN|the (l_pobj) outpatients_22\NNS|NONE (l_amod) depressed_21\JJ|NONE
D000639_D003866 NONE amitriptyline_12\NN|and (r_conj) dothiepin_10\JJ|In|,|were|.|to (r_nsubjpass) compared_14\VBN|NONE (l_prep) to_15\IN|In|dothiepin|,|were|. (l_pobj) placebo_16\NN|NONE (l_prep) in_17\IN|NONE (l_pobj) treatment_19\NN|NONE (l_prep) of_20\IN|the (l_pobj) outpatients_23\NNS|NONE (l_amod) depressed_22\JJ|
D000639_D003866 NONE amitriptyline_2\NN|and (r_conj) Dothiepin_0\JJ|effective|and|,|were (r_nsubj) were_3\VBD|NONE (l_acomp) effective_5\JJ|and|,|Dothiepin|were (l_prep) in_6\IN|equally (l_pcomp) alleviating_7\VBG|NONE (l_dobj) symptoms_9\NNS|NONE (l_prep) of_10\IN|the (l_pobj) illness_12\NN|NONE
D000639_D003866 NONE amitriptyline_16\NN|NONE (l_prep) in_17\IN|NONE (l_pobj) treatment_19\NN|NONE (l_prep) of_20\IN|the (l_pobj) outpatients_22\NNS|NONE (l_amod) depressed_21\JJ|NONE
D004308_D003866 NONE hydrochloride_12\NN|NONE (r_pobj) of_10\IN|the|safety|and (r_prep) efficacy_7\NN|NONE (r_pobj) of_5\IN|blind|.|in|A (r_prep) study_4\NN|NONE (l_prep) in_13\IN|blind|.|of|A (l_pobj) treatment_15\NN|NONE (l_prep) of_16\IN|the (l_pobj) disorder_19\NN|NONE
D004308_D003866 NONE dothiepin_10\JJ|In|,|were|.|to (r_nsubjpass) compared_14\VBN|NONE (l_prep) to_15\IN|In|dothiepin|,|were|. (l_pobj) placebo_16\NN|NONE (l_prep) in_17\IN|NONE (l_pobj) treatment_19\NN|NONE (l_prep) of_20\IN|the (l_pobj) outpatients_23\NNS|NONE (l_amod) depressed_22\JJ|
D004308_D003866 NONE Dothiepin_0\JJ|effective|and|,|were (r_nsubj) were_3\VBD|NONE (l_acomp) effective_5\JJ|and|,|Dothiepin|were (l_prep) in_6\IN|equally (l_pcomp) alleviating_7\VBG|NONE (l_dobj) symptoms_9\NNS|NONE (l_prep) of_10\IN|the (l_pobj) illness_12\NN|NONE
D004308_D003866 NONE Dothiepin_0\NNP|was|be|.|thus (r_nsubjpass) found_3\VBN|NONE (l_xcomp) be_5\VB|was|Dothiepin|.|thus (l_attr) drug_9\NN|to (l_acl) associated_10\VBN|antidepressant|an|effective (l_prep) with_11\IN|NONE (l_pobj) effects_14\NNS|NONE (l_prep) than_15\IN|side|fewer (l_pobj) amitriptyline_16\NN|NONE (l_prep) in_17\IN|NONE (l_pobj) treatment_19\NN|NONE (l_prep) of_20\IN|the (l_pobj) outpatients_22\NNS|NONE (l_amod) depressed_21\JJ|NONE
D000639_D014786 CID amitriptyline_27\NN|NONE (r_pobj) with_26\IN|NONE (r_prep) than_25\IN|with|significantly (r_prep) less_22\JJR|incidence|. (r_acomp) were_20\VBD|NONE (l_nsubj) incidence_2\NN|.|less (l_prep) of_3\IN|The|overall (l_pobj) effects_5\NNS|NONE (l_conj) frequency_8\NN|and|side (l_prep) of_11\IN|the|and|severity (l_pobj) vision_13\NN|NONE
D004308_D014987 NONE dothiepin_24\JJ|NONE (r_pobj) with_23\IN|than|significantly (r_prep) less_22\JJR|incidence|. (r_acomp) were_20\VBD|NONE (l_nsubj) incidence_2\NN|.|less (l_prep) of_3\IN|The|overall (l_pobj) effects_5\NNS|NONE (l_conj) frequency_8\NN|and|side (l_prep) of_11\IN|the|and|severity (l_pobj) vision_13\NN|NONE (l_conj) mouth_16\NN|blurred|,
6436733
D014635_D004827 NONE acid_1\NN|.|was|to (r_nsubjpass) given_6\VBN|NONE (l_dative) to_7\IN|.|was|acid (l_pobj) patients_10\NNS|NONE (l_amod) epileptic_9\JJ|treated|
D014635_D004827 NONE VPA_3\NNP|Valproic|(|) (r_appos) acid_1\NN|.|was|to (r_nsubjpass) given_6\VBN|NONE (l_dative) to_7\IN|.|was|acid (l_pobj) patients_10\NNS|NONE (l_amod) epileptic_9\JJ|treated|
D000641_D006970 CID Ammonia_0\NN|were|higher|,|in|.|) (r_nsubj) was_4\VBD|NONE (l_prep) in_6\IN|were|Ammonia|higher|,|.|) (l_pobj) patients_7\NNS|NONE (l_relcl) complained_14\VBD|NONE (l_prep) of_15\IN|,|,|who|than|during (l_pobj) drowsiness_16\NN|NONE
D000641_D006970 CID NH3_2\NNP|NONE (r_appos) Ammonia_0\NN|were|higher|,|in|.|) (r_nsubj) was_4\VBD|NONE (l_prep) in_6\IN|were|Ammonia|higher|,|.|) (l_pobj) patients_7\NNS|NONE (l_relcl) complained_14\VBD|NONE (l_prep) of_15\IN|,|,|who|than|during (l_pobj) drowsiness_16\NN|NONE
D014635_D006970 CID VPA_35\NNP|plasma (r_compound) levels_37\NNS|although|similar (r_nsubj) were_38\VBD|Ammonia|higher|,|in|.|) (r_advcl) was_4\VBD|NONE (l_prep) in_6\IN|were|Ammonia|higher|,|.|) (l_pobj) patients_7\NNS|NONE (l_relcl) complained_14\VBD|NONE (l_prep) of_15\IN|,|,|who|than|during (l_pobj) drowsiness_16\NN|NONE
1833784
D005476_D006948 NONE fluphenazine_23\NN|antagonist|and|.|blocked|, (r_conj) raclopride_18\NN|NONE (l_ccomp) blocked_5\VBN|antagonist|and|.|fluphenazine|, (l_nsubjpass) hyperactivity_3\NN|by|was
D009538_D006948 CID nicotine_12\NN| (r_npadvmod) induced_14\VBN|in (r_amod) hyperactivity_15\NN|NONE
D009538_D006948 CID Nicotine_0\NNP|.|increase|but|,|had (r_nsubj) caused_5\VBD|NONE (l_dobj) increase_8\NN|.|Nicotine|but|,|had (l_prep) in_9\IN|a|significant|habituated (l_pobj) activity_11\NN|NONE
D009538_D006948 CID Nicotine_0\NN| (r_npadvmod) induced_2\VBN|NONE (r_amod) hyperactivity_3\NN|by|was
D009538_D006948 CID nicotine_7\NN| (r_npadvmod) induced_9\VBN|enhanced (r_amod) hyperactivity_10\NN|D|the
D009538_D006948 CID nicotine_5\NN|acute (r_compound) injection_6\NN|hyperactivity|that (r_nsubj) induces_7\VBZ|results|. (l_dobj) hyperactivity_10\NN|injection|that
D004298_D006948 NONE dopamine_8\NN|and (r_conj) D1_5\NN|NONE (r_nmod) receptors_9\NNS|NONE (r_pobj) of_4\IN|an|in (r_prep) involvement_3\NN|NONE (l_prep) in_10\IN|an|of (l_pcomp) mediating_11\VBG|NONE (l_dobj) hyperactivity_15\NN|NONE
D020891_D006948 NONE raclopride_18\NN|NONE (l_ccomp) blocked_5\VBN|antagonist|and|.|fluphenazine|, (l_nsubjpass) hyperactivity_3\NN|by|was
-1_D006948 NONE PHNO_5\NNP|NONE (r_npadvmod) enhanced_6\VBN|induced (r_amod) hyperactivity_10\NN|D|the
D015647_D006948 NONE 38393_17\CD|NONE (r_nummod) SKF_16\NNP|D|the (r_appos) agonist_15\NN|whereas|effect (r_nsubj) had_18\VBD|.|,|with (r_advcl) Pretreatment_0\NN|NONE (l_prep) with_1\IN|.|had|, (l_pobj) agonist_4\NN|NONE (l_appos) hyperactivity_10\NN|D|the
C534628_D006948 NONE 23390_12\CD|NONE (r_nummod) SCH_11\NNP|the|selective|D (r_appos) antagonist_10\NN|NONE (r_pobj) by_6\IN|hyperactivity|was (r_agent) blocked_5\VBN|antagonist|and|.|fluphenazine|, (l_nsubjpass) hyperactivity_3\NN|by|was
6203632
D007545_D006332 CID isoproterenol_2\NN| (r_npadvmod) induced_4\VBN|cardiac (r_amod) hypertrophy_6\NN|NONE
D007545_D006332 CID isoproterenol_17\NN|NONE (r_pobj) of_16\IN|)|ISO|(|daily|subcutaneous|weight (r_prep) injections_15\NNS|NONE (r_pobj) following_12\VBG|development|was|.|in (r_prep) studied_6\VBN|NONE (l_nsubjpass) development_1\NN|was|following|.|in (l_prep) of_2\IN|The (l_pobj) hypertrophy_4\NN|NONE
D007545_D006332 CID ISO_19\NN|)|of|(|daily|subcutaneous|weight (r_appos) injections_15\NNS|NONE (r_pobj) following_12\VBG|development|was|.|in (r_prep) studied_6\VBN|NONE (l_nsubjpass) development_1\NN|was|following|.|in (l_prep) of_2\IN|The (l_pobj) hypertrophy_4\NN|NONE
D007545_D006984 NONE ISO_8\NN|NONE (r_pobj) to_7\IN|the|adaptive (r_prep) response_6\NN|that|phase (r_nsubj) shows_9\VBZ|data|. (l_dobj) phase_13\NN|that|response (l_amod) hypertrophic_12\JJ|characterized|(|an|days|)|early
2673163
D003042_D002544 CID cocaine_14\NN|NONE (r_compound) use_15\NN|NONE (r_pobj) to_13\IN|NONE (r_prep) related_12\VBN|NONE (r_acl) stroke_11\NN|NONE (r_pobj) of_10\IN|the|apparent (r_prep) incidence_9\NN|is|that (r_nsubj) increasing_17\VBG|data (r_ccomp) indicate_2\VBP|;|(|in|primarily|stroke (r_ccomp) occurs_26\VBZ|route|;|may|stroke (r_ccomp) follow_37\VB|frequency|;|that|. (r_ccomp) exceeds_76\VBZ|NONE (l_dobj) that_77\DT|frequency|;|.|follow (l_prep) of_78\IN|NONE (l_pobj) infarction_80\NN|NONE
D003042_D002544 CID cocaine_22\NN| (r_npadvmod) associated_24\VBN||) (r_amod) stroke_25\NN|;|indicate|(|in|primarily (r_nsubj) occurs_26\VBZ|route|;|may|stroke (r_ccomp) follow_37\VB|frequency|;|that|. (r_ccomp) exceeds_76\VBZ|NONE (l_dobj) that_77\DT|frequency|;|.|follow (l_prep) of_78\IN|NONE (l_pobj) infarction_80\NN|NONE
D003042_D002544 CID cocaine_41\NN|NONE (r_compound) administration_42\NN|NONE (r_pobj) of_40\IN|any (r_prep) route_39\NN|;|may|stroke|occurs (r_dobj) follow_37\VB|frequency|;|that|. (r_ccomp) exceeds_76\VBZ|NONE (l_dobj) that_77\DT|frequency|;|.|follow (l_prep) of_78\IN|NONE (l_pobj) infarction_80\NN|NONE
D003042_D002544 CID cocaine_49\NN|NONE (r_compound) use_50\NN|frequently|after|with|is (r_nsubjpass) associated_53\VBN||;||and (r_advcl) stroke_47\NN|the|of (r_nmod) frequency_72\NN|;|that|.|follow (r_nsubj) exceeds_76\VBZ|NONE (l_dobj) that_77\DT|frequency|;|.|follow (l_prep) of_78\IN|NONE (l_pobj) infarction_80\NN|NONE
D003042_D002544 CID cocaine_66\NN| (r_npadvmod) associated_68\VBN|NONE (r_amod) stroke_69\NN|NONE (r_pobj) in_65\IN|)|(|, (r_prep) 5_63\CD|;||associated|and (r_conj) stroke_47\NN|the|of (r_nmod) frequency_72\NN|;|that|.|follow (r_nsubj) exceeds_76\VBZ|NONE (l_dobj) that_77\DT|frequency|;|.|follow (l_prep) of_78\IN|NONE (l_pobj) infarction_80\NN|NONE
D003042_D020300 NONE cocaine_14\NN|NONE (r_compound) use_15\NN|NONE (r_pobj) to_13\IN|NONE (r_prep) related_12\VBN|NONE (r_acl) stroke_11\NN|NONE (r_pobj) of_10\IN|the|apparent (r_prep) incidence_9\NN|is|that (r_nsubj) increasing_17\VBG|data (r_ccomp) indicate_2\VBP|;|(|in|primarily|stroke (r_ccomp) occurs_26\VBZ|route|;|may|stroke (r_ccomp) follow_37\VB|frequency|;|that|. (r_ccomp) exceeds_76\VBZ|NONE (l_nsubj) frequency_72\NN|;|that|.|follow (l_prep) of_73\IN|the|stroke (l_pobj) hemorrhage_75\NN|NONE
D003042_D020300 NONE cocaine_22\NN| (r_npadvmod) associated_24\VBN||) (r_amod) stroke_25\NN|;|indicate|(|in|primarily (r_nsubj) occurs_26\VBZ|route|;|may|stroke (r_ccomp) follow_37\VB|frequency|;|that|. (r_ccomp) exceeds_76\VBZ|NONE (l_nsubj) frequency_72\NN|;|that|.|follow (l_prep) of_73\IN|the|stroke (l_pobj) hemorrhage_75\NN|NONE
D003042_D020300 NONE cocaine_41\NN|NONE (r_compound) administration_42\NN|NONE (r_pobj) of_40\IN|any (r_prep) route_39\NN|;|may|stroke|occurs (r_dobj) follow_37\VB|frequency|;|that|. (r_ccomp) exceeds_76\VBZ|NONE (l_nsubj) frequency_72\NN|;|that|.|follow (l_prep) of_73\IN|the|stroke (l_pobj) hemorrhage_75\NN|NONE
D003042_D020300 NONE cocaine_49\NN|NONE (r_compound) use_50\NN|frequently|after|with|is (r_nsubjpass) associated_53\VBN||;||and (r_advcl) stroke_47\NN|the|of (r_nmod) frequency_72\NN|;|that|.|follow (l_prep) of_73\IN|the|stroke (l_pobj) hemorrhage_75\NN|NONE
D003042_D020300 NONE cocaine_66\NN| (r_npadvmod) associated_68\VBN|NONE (r_amod) stroke_69\NN|NONE (r_pobj) in_65\IN|)|(|, (r_prep) 5_63\CD|;||associated|and (r_conj) stroke_47\NN|the|of (r_nmod) frequency_72\NN|;|that|.|follow (l_prep) of_73\IN|the|stroke (l_pobj) hemorrhage_75\NN|NONE
D003042_D002532 NONE cocaine_14\NN|NONE (r_compound) use_15\NN|NONE (r_pobj) to_13\IN|NONE (r_prep) related_12\VBN|NONE (r_acl) stroke_11\NN|NONE (r_pobj) of_10\IN|the|apparent (r_prep) incidence_9\NN|is|that (r_nsubj) increasing_17\VBG|data (r_ccomp) indicate_2\VBP|;|(|in|primarily|stroke (r_ccomp) occurs_26\VBZ|route|;|may|stroke (r_ccomp) follow_37\VB|frequency|;|that|. (r_ccomp) exceeds_76\VBZ|NONE (l_nsubj) frequency_72\NN|;|that|.|follow (l_nmod) stroke_47\NN|the|of (l_advcl) associated_53\VBN||;||and (l_prep) with_54\IN|use|frequently|after|is (l_pobj) aneurysms_56\NNS|NONE
D003042_D002532 NONE cocaine_22\NN| (r_npadvmod) associated_24\VBN||) (r_amod) stroke_25\NN|;|indicate|(|in|primarily (r_nsubj) occurs_26\VBZ|route|;|may|stroke (r_ccomp) follow_37\VB|frequency|;|that|. (r_ccomp) exceeds_76\VBZ|NONE (l_nsubj) frequency_72\NN|;|that|.|follow (l_nmod) stroke_47\NN|the|of (l_advcl) associated_53\VBN||;||and (l_prep) with_54\IN|use|frequently|after|is (l_pobj) aneurysms_56\NNS|NONE
D003042_D002532 NONE cocaine_41\NN|NONE (r_compound) administration_42\NN|NONE (r_pobj) of_40\IN|any (r_prep) route_39\NN|;|may|stroke|occurs (r_dobj) follow_37\VB|frequency|;|that|. (r_ccomp) exceeds_76\VBZ|NONE (l_nsubj) frequency_72\NN|;|that|.|follow (l_nmod) stroke_47\NN|the|of (l_advcl) associated_53\VBN||;||and (l_prep) with_54\IN|use|frequently|after|is (l_pobj) aneurysms_56\NNS|NONE
D003042_D002532 NONE cocaine_49\NN|NONE (r_compound) use_50\NN|frequently|after|with|is (r_nsubjpass) associated_53\VBN||;||and (l_prep) with_54\IN|use|frequently|after|is (l_pobj) aneurysms_56\NNS|NONE
D003042_D002532 NONE cocaine_66\NN| (r_npadvmod) associated_68\VBN|NONE (r_amod) stroke_69\NN|NONE (r_pobj) in_65\IN|)|(|, (r_prep) 5_63\CD|;||associated|and (r_conj) stroke_47\NN|the|of (l_advcl) associated_53\VBN||;||and (l_prep) with_54\IN|use|frequently|after|is (l_pobj) aneurysms_56\NNS|NONE
D003042_D020521 NONE cocaine_3\NN|NONE (r_compound) use_4\NN|NONE (r_pobj) with_2\IN|NONE (r_prep) associated_1\VBN|. (r_acl) Stroke_0\NN|NONE
D003042_D020521 NONE cocaine_6\NN|NONE (r_compound) use_7\NN|in|was|to|review|and (r_nsubjpass) related_9\VBN|eight (l_prep) to_10\IN|use|in|was|review|and (l_pobj) stroke_11\NN|NONE
D003042_D020521 NONE cocaine_2\NN|by (r_compound) use_3\NN|.|Stroke (r_dobj) followed_1\VBD|NONE (l_nsubj) Stroke_0\NN|.|use
D003042_D020521 NONE cocaine_14\NN|NONE (r_compound) use_15\NN|NONE (r_pobj) to_13\IN|NONE (r_prep) related_12\VBN|NONE (r_acl) stroke_11\NN|NONE
D003042_D020521 NONE cocaine_14\NN|NONE (r_compound) use_15\NN|NONE (r_pobj) to_13\IN|NONE (r_prep) related_12\VBN|NONE (r_acl) stroke_11\NN|NONE (r_pobj) of_10\IN|the|apparent (r_prep) incidence_9\NN|is|that (r_nsubj) increasing_17\VBG|data (r_ccomp) indicate_2\VBP|;|(|in|primarily|stroke (r_ccomp) occurs_26\VBZ|route|;|may|stroke (l_nsubj) stroke_25\NN|;|indicate|(|in|primarily
D003042_D020521 NONE cocaine_14\NN|NONE (r_compound) use_15\NN|NONE (r_pobj) to_13\IN|NONE (r_prep) related_12\VBN|NONE (r_acl) stroke_11\NN|NONE (r_pobj) of_10\IN|the|apparent (r_prep) incidence_9\NN|is|that (r_nsubj) increasing_17\VBG|data (r_ccomp) indicate_2\VBP|;|(|in|primarily|stroke (r_ccomp) occurs_26\VBZ|route|;|may|stroke (r_ccomp) follow_37\VB|frequency|;|that|. (l_nsubj) stroke_35\NN|route|;|may|occurs
D003042_D020521 NONE cocaine_14\NN|NONE (r_compound) use_15\NN|NONE (r_pobj) to_13\IN|NONE (r_prep) related_12\VBN|NONE (r_acl) stroke_11\NN|NONE (r_pobj) of_10\IN|the|apparent (r_prep) incidence_9\NN|is|that (r_nsubj) increasing_17\VBG|data (r_ccomp) indicate_2\VBP|;|(|in|primarily|stroke (r_ccomp) occurs_26\VBZ|route|;|may|stroke (r_ccomp) follow_37\VB|frequency|;|that|. (r_ccomp) exceeds_76\VBZ|NONE (l_nsubj) frequency_72\NN|;|that|.|follow (l_nmod) stroke_47\NN|the|of
D003042_D020521 NONE cocaine_14\NN|NONE (r_compound) use_15\NN|NONE (r_pobj) to_13\IN|NONE (r_prep) related_12\VBN|NONE (r_acl) stroke_11\NN|NONE (r_pobj) of_10\IN|the|apparent (r_prep) incidence_9\NN|is|that (r_nsubj) increasing_17\VBG|data (r_ccomp) indicate_2\VBP|;|(|in|primarily|stroke (r_ccomp) occurs_26\VBZ|route|;|may|stroke (r_ccomp) follow_37\VB|frequency|;|that|. (r_ccomp) exceeds_76\VBZ|NONE (l_nsubj) frequency_72\NN|;|that|.|follow (l_nmod) stroke_47\NN|the|of (l_conj) 5_63\CD|;||associated|and (l_prep) in_65\IN|)|(|, (l_pobj) stroke_69\NN|NONE
D003042_D020521 NONE cocaine_22\NN| (r_npadvmod) associated_24\VBN||) (r_amod) stroke_25\NN|;|indicate|(|in|primarily (r_nsubj) occurs_26\VBZ|route|;|may|stroke (l_ccomp) indicate_2\VBP|;|(|in|primarily|stroke (l_ccomp) increasing_17\VBG|data (l_nsubj) incidence_9\NN|is|that (l_prep) of_10\IN|the|apparent (l_pobj) stroke_11\NN|NONE
D003042_D020521 NONE cocaine_22\NN| (r_npadvmod) associated_24\VBN||) (r_amod) stroke_25\NN|;|indicate|(|in|primarily
D003042_D020521 NONE cocaine_22\NN| (r_npadvmod) associated_24\VBN||) (r_amod) stroke_25\NN|;|indicate|(|in|primarily (r_nsubj) occurs_26\VBZ|route|;|may|stroke (r_ccomp) follow_37\VB|frequency|;|that|. (l_nsubj) stroke_35\NN|route|;|may|occurs
D003042_D020521 NONE cocaine_22\NN| (r_npadvmod) associated_24\VBN||) (r_amod) stroke_25\NN|;|indicate|(|in|primarily (r_nsubj) occurs_26\VBZ|route|;|may|stroke (r_ccomp) follow_37\VB|frequency|;|that|. (r_ccomp) exceeds_76\VBZ|NONE (l_nsubj) frequency_72\NN|;|that|.|follow (l_nmod) stroke_47\NN|the|of
D003042_D020521 NONE cocaine_22\NN| (r_npadvmod) associated_24\VBN||) (r_amod) stroke_25\NN|;|indicate|(|in|primarily (r_nsubj) occurs_26\VBZ|route|;|may|stroke (r_ccomp) follow_37\VB|frequency|;|that|. (r_ccomp) exceeds_76\VBZ|NONE (l_nsubj) frequency_72\NN|;|that|.|follow (l_nmod) stroke_47\NN|the|of (l_conj) 5_63\CD|;||associated|and (l_prep) in_65\IN|)|(|, (l_pobj) stroke_69\NN|NONE
D003042_D020521 NONE cocaine_41\NN|NONE (r_compound) administration_42\NN|NONE (r_pobj) of_40\IN|any (r_prep) route_39\NN|;|may|stroke|occurs (r_dobj) follow_37\VB|frequency|;|that|. (l_ccomp) occurs_26\VBZ|route|;|may|stroke (l_ccomp) indicate_2\VBP|;|(|in|primarily|stroke (l_ccomp) increasing_17\VBG|data (l_nsubj) incidence_9\NN|is|that (l_prep) of_10\IN|the|apparent (l_pobj) stroke_11\NN|NONE
D003042_D020521 NONE cocaine_41\NN|NONE (r_compound) administration_42\NN|NONE (r_pobj) of_40\IN|any (r_prep) route_39\NN|;|may|stroke|occurs (r_dobj) follow_37\VB|frequency|;|that|. (l_ccomp) occurs_26\VBZ|route|;|may|stroke (l_nsubj) stroke_25\NN|;|indicate|(|in|primarily
D003042_D020521 NONE cocaine_41\NN|NONE (r_compound) administration_42\NN|NONE (r_pobj) of_40\IN|any (r_prep) route_39\NN|;|may|stroke|occurs (r_dobj) follow_37\VB|frequency|;|that|. (l_nsubj) stroke_35\NN|route|;|may|occurs
D003042_D020521 NONE cocaine_41\NN|NONE (r_compound) administration_42\NN|NONE (r_pobj) of_40\IN|any (r_prep) route_39\NN|;|may|stroke|occurs (r_dobj) follow_37\VB|frequency|;|that|. (r_ccomp) exceeds_76\VBZ|NONE (l_nsubj) frequency_72\NN|;|that|.|follow (l_nmod) stroke_47\NN|the|of
D003042_D020521 NONE cocaine_41\NN|NONE (r_compound) administration_42\NN|NONE (r_pobj) of_40\IN|any (r_prep) route_39\NN|;|may|stroke|occurs (r_dobj) follow_37\VB|frequency|;|that|. (r_ccomp) exceeds_76\VBZ|NONE (l_nsubj) frequency_72\NN|;|that|.|follow (l_nmod) stroke_47\NN|the|of (l_conj) 5_63\CD|;||associated|and (l_prep) in_65\IN|)|(|, (l_pobj) stroke_69\NN|NONE
D003042_D020521 NONE cocaine_49\NN|NONE (r_compound) use_50\NN|frequently|after|with|is (r_nsubjpass) associated_53\VBN||;||and (r_advcl) stroke_47\NN|the|of (r_nmod) frequency_72\NN|;|that|.|follow (r_nsubj) exceeds_76\VBZ|NONE (l_ccomp) follow_37\VB|frequency|;|that|. (l_ccomp) occurs_26\VBZ|route|;|may|stroke (l_ccomp) indicate_2\VBP|;|(|in|primarily|stroke (l_ccomp) increasing_17\VBG|data (l_nsubj) incidence_9\NN|is|that (l_prep) of_10\IN|the|apparent (l_pobj) stroke_11\NN|NONE
D003042_D020521 NONE cocaine_49\NN|NONE (r_compound) use_50\NN|frequently|after|with|is (r_nsubjpass) associated_53\VBN||;||and (r_advcl) stroke_47\NN|the|of (r_nmod) frequency_72\NN|;|that|.|follow (r_nsubj) exceeds_76\VBZ|NONE (l_ccomp) follow_37\VB|frequency|;|that|. (l_ccomp) occurs_26\VBZ|route|;|may|stroke (l_nsubj) stroke_25\NN|;|indicate|(|in|primarily
D003042_D020521 NONE cocaine_49\NN|NONE (r_compound) use_50\NN|frequently|after|with|is (r_nsubjpass) associated_53\VBN||;||and (r_advcl) stroke_47\NN|the|of (r_nmod) frequency_72\NN|;|that|.|follow (r_nsubj) exceeds_76\VBZ|NONE (l_ccomp) follow_37\VB|frequency|;|that|. (l_nsubj) stroke_35\NN|route|;|may|occurs
D003042_D020521 NONE cocaine_49\NN|NONE (r_compound) use_50\NN|frequently|after|with|is (r_nsubjpass) associated_53\VBN||;||and (r_advcl) stroke_47\NN|the|of
D003042_D020521 NONE cocaine_49\NN|NONE (r_compound) use_50\NN|frequently|after|with|is (r_nsubjpass) associated_53\VBN||;||and (r_advcl) stroke_47\NN|the|of (l_conj) 5_63\CD|;||associated|and (l_prep) in_65\IN|)|(|, (l_pobj) stroke_69\NN|NONE
D003042_D020521 NONE cocaine_66\NN| (r_npadvmod) associated_68\VBN|NONE (r_amod) stroke_69\NN|NONE (r_pobj) in_65\IN|)|(|, (r_prep) 5_63\CD|;||associated|and (r_conj) stroke_47\NN|the|of (r_nmod) frequency_72\NN|;|that|.|follow (r_nsubj) exceeds_76\VBZ|NONE (l_ccomp) follow_37\VB|frequency|;|that|. (l_ccomp) occurs_26\VBZ|route|;|may|stroke (l_ccomp) indicate_2\VBP|;|(|in|primarily|stroke (l_ccomp) increasing_17\VBG|data (l_nsubj) incidence_9\NN|is|that (l_prep) of_10\IN|the|apparent (l_pobj) stroke_11\NN|NONE
D003042_D020521 NONE cocaine_66\NN| (r_npadvmod) associated_68\VBN|NONE (r_amod) stroke_69\NN|NONE (r_pobj) in_65\IN|)|(|, (r_prep) 5_63\CD|;||associated|and (r_conj) stroke_47\NN|the|of (r_nmod) frequency_72\NN|;|that|.|follow (r_nsubj) exceeds_76\VBZ|NONE (l_ccomp) follow_37\VB|frequency|;|that|. (l_ccomp) occurs_26\VBZ|route|;|may|stroke (l_nsubj) stroke_25\NN|;|indicate|(|in|primarily
D003042_D020521 NONE cocaine_66\NN| (r_npadvmod) associated_68\VBN|NONE (r_amod) stroke_69\NN|NONE (r_pobj) in_65\IN|)|(|, (r_prep) 5_63\CD|;||associated|and (r_conj) stroke_47\NN|the|of (r_nmod) frequency_72\NN|;|that|.|follow (r_nsubj) exceeds_76\VBZ|NONE (l_ccomp) follow_37\VB|frequency|;|that|. (l_nsubj) stroke_35\NN|route|;|may|occurs
D003042_D020521 NONE cocaine_66\NN| (r_npadvmod) associated_68\VBN|NONE (r_amod) stroke_69\NN|NONE (r_pobj) in_65\IN|)|(|, (r_prep) 5_63\CD|;||associated|and (r_conj) stroke_47\NN|the|of
D003042_D020521 NONE cocaine_66\NN| (r_npadvmod) associated_68\VBN|NONE (r_amod) stroke_69\NN|NONE
D003042_D001165 NONE cocaine_14\NN|NONE (r_compound) use_15\NN|NONE (r_pobj) to_13\IN|NONE (r_prep) related_12\VBN|NONE (r_acl) stroke_11\NN|NONE (r_pobj) of_10\IN|the|apparent (r_prep) incidence_9\NN|is|that (r_nsubj) increasing_17\VBG|data (r_ccomp) indicate_2\VBP|;|(|in|primarily|stroke (r_ccomp) occurs_26\VBZ|route|;|may|stroke (r_ccomp) follow_37\VB|frequency|;|that|. (r_ccomp) exceeds_76\VBZ|NONE (l_nsubj) frequency_72\NN|;|that|.|follow (l_nmod) stroke_47\NN|the|of (l_advcl) associated_53\VBN||;||and (l_prep) with_54\IN|use|frequently|after|is (l_pobj) aneurysms_56\NNS|NONE (l_conj) malformations_59\NNS|and|intracranial
D003042_D001165 NONE cocaine_22\NN| (r_npadvmod) associated_24\VBN||) (r_amod) stroke_25\NN|;|indicate|(|in|primarily (r_nsubj) occurs_26\VBZ|route|;|may|stroke (r_ccomp) follow_37\VB|frequency|;|that|. (r_ccomp) exceeds_76\VBZ|NONE (l_nsubj) frequency_72\NN|;|that|.|follow (l_nmod) stroke_47\NN|the|of (l_advcl) associated_53\VBN||;||and (l_prep) with_54\IN|use|frequently|after|is (l_pobj) aneurysms_56\NNS|NONE (l_conj) malformations_59\NNS|and|intracranial
D003042_D001165 NONE cocaine_41\NN|NONE (r_compound) administration_42\NN|NONE (r_pobj) of_40\IN|any (r_prep) route_39\NN|;|may|stroke|occurs (r_dobj) follow_37\VB|frequency|;|that|. (r_ccomp) exceeds_76\VBZ|NONE (l_nsubj) frequency_72\NN|;|that|.|follow (l_nmod) stroke_47\NN|the|of (l_advcl) associated_53\VBN||;||and (l_prep) with_54\IN|use|frequently|after|is (l_pobj) aneurysms_56\NNS|NONE (l_conj) malformations_59\NNS|and|intracranial
D003042_D001165 NONE cocaine_49\NN|NONE (r_compound) use_50\NN|frequently|after|with|is (r_nsubjpass) associated_53\VBN||;||and (l_prep) with_54\IN|use|frequently|after|is (l_pobj) aneurysms_56\NNS|NONE (l_conj) malformations_59\NNS|and|intracranial
D003042_D001165 NONE cocaine_66\NN| (r_npadvmod) associated_68\VBN|NONE (r_amod) stroke_69\NN|NONE (r_pobj) in_65\IN|)|(|, (r_prep) 5_63\CD|;||associated|and (r_conj) stroke_47\NN|the|of (l_advcl) associated_53\VBN||;||and (l_prep) with_54\IN|use|frequently|after|is (l_pobj) aneurysms_56\NNS|NONE (l_conj) malformations_59\NNS|and|intracranial
4812392
D001379_D011565 NONE azathioprine_4\NN|NONE (r_pobj) with_3\IN|NONE (r_prep) psoriasis_2\NN|NONE
D001379_D011565 NONE Azathioprine_0\JJ|NONE (r_det) treatment_1\NN|.|%|out (r_nsubj) benefited_2\VBD|NONE (l_prep) out_8\IN|.|treatment|% (l_prep) of_9\IN|NONE (l_pobj) patients_11\NNS|NONE (l_acl) suffering_12\VBG| (l_prep) from_13\IN|NONE (l_pobj) psoriasis_15\NN|NONE
D001379_D056486 NONE azathioprine_9\JJ|NONE (r_amod) therapy_10\NN|if|is|detected (r_nsubjpass) continued_12\VBN|biopsies|.|be|at|should (l_advcl) detected_20\VBN|therapy|if|is (l_nsubjpass) damage_17\NN|at|so|may|be|that
871943
D013390_D001049 CID succinylcholine_6\NN|NONE (r_compound) apnoea_7\NN|NONE
D013390_D001049 CID succinylcholine_10\NN|after|by|been|hours|have (r_nsubjpass) treated_13\VBN|apnoea|patients|. (r_advcl) demonstrating_2\VBG|NONE (l_dobj) apnoea_5\NN|patients|.|treated
D013390_D001049 CID succinylcholine_6\NN|NONE (r_compound) apnoea_7\NN|NONE
21294084
D010406_D004827 NONE penicillin_12\NN| (r_npadvmod) induced_14\VBN|epilepsy|in (r_amod) model_16\NN|NONE (r_pobj) in_11\IN|cortical|epileptic (r_prep) discharges_10\NNS|NONE (l_amod) epileptic_9\JJ|cortical|in
D010406_D004827 NONE penicillin_12\NN| (r_npadvmod) induced_14\VBN|epilepsy|in (r_amod) model_16\NN|NONE (l_compound) epilepsy_15\NN|induced|in
D010406_D004827 NONE penicillin_17\NN| (r_npadvmod) induced_19\VBN|epilepsy (r_amod) model_21\NN|NONE (r_pobj) in_16\IN|epileptic|cortical (r_prep) activity_15\NN|NONE (l_amod) epileptic_14\JJ|in|cortical
D010406_D004827 NONE penicillin_17\NN| (r_npadvmod) induced_19\VBN|epilepsy (r_amod) model_21\NN|NONE (l_compound) epilepsy_20\NN|induced
D010406_D004827 NONE penicillin_7\NN| (r_npadvmod) induced_9\VBN|cortical|the|epileptic|acute|independent (r_amod) activity_12\NN|.|DBS (l_amod) epileptic_11\JJ|cortical|the|induced|acute|independent
2840807
D000324_D004421 CID ACTH_10\NNP|of|)|neuropeptide (r_nmod) stimulation_12\NN|NONE (r_pobj) after_5\IN|like|.|A (r_prep) syndrome_4\NN|NONE (l_amod) like_3\JJ|.|after|A (l_npadvmod) dystonia_1\NN|
D009074_D004421 CID MSH_8\NNP|(|/ (r_nmod) ACTH_10\NNP|of|)|neuropeptide (r_nmod) stimulation_12\NN|NONE (r_pobj) after_5\IN|like|.|A (r_prep) syndrome_4\NN|NONE (l_amod) like_3\JJ|.|after|A (l_npadvmod) dystonia_1\NN|
D000324_D009069 NONE ACTH_20\NNP||N (r_compound) terminal_23\NN|the|at|resulted (r_compound) fragments_24\NNS|NONE (r_pobj) by_18\IN|)|a|receptors|(|;|were (r_agent) stimulated_17\VBN|.|However|released|certain|not|,|,|it|cause (r_ccomp) is_3\VBZ|NONE (l_conj) cause_57\VB|.|However|released|certain|not|,|,|it|stimulated (l_ccomp) resulted_94\VBD|indeed|did (l_nsubj) depression_62\NN|c|,|whether|inhibition|in (l_relcl) resulted_74\VBD|the|term|;|described|(|)|targets|at (l_prep) in_75\IN|that (l_pobj) duration_78\NN|NONE (l_prep) of_79\IN|long|the (l_pobj) disorder_82\NN|NONE
D000324_D003866 NONE ACTH_20\NNP||N (r_compound) terminal_23\NN|the|at|resulted (r_compound) fragments_24\NNS|NONE (r_pobj) by_18\IN|)|a|receptors|(|;|were (r_agent) stimulated_17\VBN|.|However|released|certain|not|,|,|it|cause (r_ccomp) is_3\VBZ|NONE (l_conj) cause_57\VB|.|However|released|certain|not|,|,|it|stimulated (l_ccomp) resulted_94\VBD|indeed|did (l_nsubj) depression_62\NN|c|,|whether|inhibition|in
6150641
D002927_D006402 NONE cimetidine_5\NN|NONE (r_pobj) of_4\IN|high (r_prep) doses_3\NNS|NONE (r_pobj) with_1\IN|NONE (r_prep) Treatment_0\NN|with|,|was|not|but|associated (r_nsubjpass) associated_32\VBN|NONE (l_prep) with_33\IN|,|was|not|but|associated|Treatment (l_pobj) toxicity_37\NN|NONE
D002927_D006402 NONE cimetidine_60\NN|NONE (r_compound) therapy_61\NN|NONE (r_pobj) with_59\IN|than (r_prep) seen_58\VBN|creatinine|lower|a (r_advcl) level_56\NN|NONE (r_pobj) with_50\IN|therapy|.|was (r_prep) associated_49\VBN|with|,|was|not|but|Treatment (r_conj) associated_32\VBN|NONE (l_prep) with_33\IN|,|was|not|but|associated|Treatment (l_pobj) toxicity_37\NN|NONE
D003404_D006402 NONE creatinine_55\NN|seen|lower|a (r_compound) level_56\NN|NONE (r_pobj) with_50\IN|therapy|.|was (r_prep) associated_49\VBN|with|,|was|not|but|Treatment (r_conj) associated_32\VBN|NONE (l_prep) with_33\IN|,|was|not|but|associated|Treatment (l_pobj) toxicity_37\NN|NONE
D002927_D056486 NONE cimetidine_5\NN|NONE (r_pobj) of_4\IN|high (r_prep) doses_3\NNS|NONE (r_pobj) with_1\IN|NONE (r_prep) Treatment_0\NN|with|,|was|not|but|associated (r_nsubjpass) associated_32\VBN|NONE (l_prep) with_33\IN|,|was|not|but|associated|Treatment (l_pobj) toxicity_37\NN|NONE
D002927_D056486 NONE cimetidine_60\NN|NONE (r_compound) therapy_61\NN|NONE (r_pobj) with_59\IN|than (r_prep) seen_58\VBN|creatinine|lower|a (r_advcl) level_56\NN|NONE (r_pobj) with_50\IN|therapy|.|was (r_prep) associated_49\VBN|with|,|was|not|but|Treatment (r_conj) associated_32\VBN|NONE (l_prep) with_33\IN|,|was|not|but|associated|Treatment (l_pobj) toxicity_37\NN|NONE
D011899_D006402 NONE ranitidine_18\NN|)|,|or|months (r_conj) median_12\NN|(|months|; (r_conj) cimetidine_5\NN|NONE (r_pobj) of_4\IN|high (r_prep) doses_3\NNS|NONE (r_pobj) with_1\IN|NONE (r_prep) Treatment_0\NN|with|,|was|not|but|associated (r_nsubjpass) associated_32\VBN|NONE (l_prep) with_33\IN|,|was|not|but|associated|Treatment (l_pobj) toxicity_37\NN|NONE
D011899_D006402 NONE ranitidine_46\NN|NONE (r_compound) therapy_47\NN|.|was|with (r_nsubjpass) associated_49\VBN|with|,|was|not|but|Treatment (r_conj) associated_32\VBN|NONE (l_prep) with_33\IN|,|was|not|but|associated|Treatment (l_pobj) toxicity_37\NN|NONE
D002927_D007172 CID cimetidine_12\NN|and|disappeared|while (r_dobj) taking_11\VBG|percent|changes|. (r_advcl) developed_5\VBD|NONE (l_dobj) changes_7\NNS|percent|taking|. (l_conj) impotence_9\NN|or|breast
D002927_D007172 CID cimetidine_21\NN|was|when|by (r_nsubjpass) replaced_23\VBN|changes|in (r_advcl) disappeared_19\VBD|cimetidine|and|while (r_conj) taking_11\VBG|percent|changes|. (r_advcl) developed_5\VBD|NONE (l_dobj) changes_7\NNS|percent|taking|. (l_conj) impotence_9\NN|or|breast
D011899_D007172 NONE ranitidine_25\NN|NONE (r_pobj) by_24\IN|was|when|cimetidine (r_agent) replaced_23\VBN|changes|in (r_advcl) disappeared_19\VBD|cimetidine|and|while (r_conj) taking_11\VBG|percent|changes|. (r_advcl) developed_5\VBD|NONE (l_dobj) changes_7\NNS|percent|taking|. (l_conj) impotence_9\NN|or|breast
D011899_D056486 NONE ranitidine_18\NN|)|,|or|months (r_conj) median_12\NN|(|months|; (r_conj) cimetidine_5\NN|NONE (r_pobj) of_4\IN|high (r_prep) doses_3\NNS|NONE (r_pobj) with_1\IN|NONE (r_prep) Treatment_0\NN|with|,|was|not|but|associated (r_nsubjpass) associated_32\VBN|NONE (l_prep) with_33\IN|,|was|not|but|associated|Treatment (l_pobj) toxicity_37\NN|NONE
D011899_D056486 NONE ranitidine_46\NN|NONE (r_compound) therapy_47\NN|.|was|with (r_nsubjpass) associated_49\VBN|with|,|was|not|but|Treatment (r_conj) associated_32\VBN|NONE (l_prep) with_33\IN|,|was|not|but|associated|Treatment (l_pobj) toxicity_37\NN|NONE
D003404_D056486 NONE creatinine_55\NN|seen|lower|a (r_compound) level_56\NN|NONE (r_pobj) with_50\IN|therapy|.|was (r_prep) associated_49\VBN|with|,|was|not|but|Treatment (r_conj) associated_32\VBN|NONE (l_prep) with_33\IN|,|was|not|but|associated|Treatment (l_pobj) toxicity_37\NN|NONE
14659530
D005996_D006261 NONE nitroglycerin_43\NN|NONE (r_pobj) by_42\IN|NONE (r_agent) provoked_41\VBN|migraine|the|delayed|genuine (r_acl) attack_40\NN|changes|to|and (r_conj) investigate_8\VB|aim|. (l_dobj) changes_9\NNS|to|attack|and (l_prep) during_31\IN|in (l_pobj) headache_34\NN|NONE
D012701_D006261 NONE serotonin_24\NN|)|peptide|HT|concentration (r_nmod) content_30\NN|NONE (r_pobj) in_10\IN|during (r_prep) changes_9\NNS|to|attack|and (l_prep) during_31\IN|in (l_pobj) headache_34\NN|NONE
D012701_D006261 NONE 5-hydroxytriptamine_26\NN|NONE (r_punct) ,_27\,|NONE (r_punct) 5-HT_28\CD|)|peptide|serotonin|concentration (r_nmod) content_30\NN|NONE (r_pobj) in_10\IN|during (r_prep) changes_9\NNS|to|attack|and (l_prep) during_31\IN|in (l_pobj) headache_34\NN|NONE
D012701_D006261 NONE 5-HT_28\CD|)|peptide|serotonin|concentration (r_nmod) content_30\NN|NONE (r_pobj) in_10\IN|during (r_prep) changes_9\NNS|to|attack|and (l_prep) during_31\IN|in (l_pobj) headache_34\NN|NONE
D012701_D006261 NONE serotonin_3\NN|from (r_compound) release_4\NN|does|migraine|In|,|not (r_nsubj) provoke_9\VB|even|may|,|headache|it|. (r_ccomp) counteract_15\VB|NONE (l_dobj) headache_17\NN|provoke|even|may|,|it|.
D015740_D006261 NONE peptide_17\NN|)|HT|serotonin|concentration (r_nmod) content_30\NN|NONE (r_pobj) in_10\IN|during (r_prep) changes_9\NNS|to|attack|and (l_prep) during_31\IN|in (l_pobj) headache_34\NN|NONE
D015740_D006261 NONE CGRP_19\NN|and|(|) (r_nmod) concentration_21\NN|)|peptide|HT|serotonin (r_nmod) content_30\NN|NONE (r_pobj) in_10\IN|during (r_prep) changes_9\NNS|to|attack|and (l_prep) during_31\IN|in (l_pobj) headache_34\NN|NONE
D015740_D006261 NONE CGRP_3\NNP|plasma (r_compound) concentrations_4\NNS|.|However|change|, (r_nsubj) failed_5\VBD|NONE (l_xcomp) change_7\VB|concentrations|.|However|, (l_prep) during_8\IN|to (l_pobj) headache_10\NN|and|in
D015740_D006261 NONE CGRP_7\NN|plasma (r_compound) concentration_8\NN|with|that (r_nsubj) correlates_9\VBZ|the (l_prep) with_10\IN|concentration|that (l_pobj) timing_12\NN|NONE (l_prep) of_15\IN|and|the|severity (l_pobj) headache_18\NN|NONE
D015740_D006261 NONE CGRP_24\NN|NONE (r_pobj) between_23\IN|a|direct (r_prep) relationship_22\NN|fact|,|.|In (r_dobj) suggests_19\VBZ|NONE (l_nsubj) fact_4\NN|,|.|relationship|In (l_acl) correlates_9\VBZ|the (l_prep) with_10\IN|concentration|that (l_pobj) timing_12\NN|NONE (l_prep) of_15\IN|and|the|severity (l_pobj) headache_18\NN|NONE
D015740_D006261 NONE CGRP_21\NN|the|in|concomitant (r_compound) release_22\NN|the|and (r_conj) headache_17\NN|provoke|even|may|,|it|.
D012701_D008881 NONE serotonin_24\NN|NONE (r_compound) release_25\NN|NONE (r_pobj) with_22\IN|negative (r_prep) correlation_21\NN|and|)|CGRP|( (r_conj) concentration_18\NN|related|plasma|calcitonin (r_appos) peptide_14\NN|NONE (r_pobj) in_8\IN|strong (r_prep) increase_7\NN|.|migraine|induced|: (r_appos) attack_4\NN|NONE (l_compound) migraine_3\JJ|.|increase|induced|:
D012701_D008881 NONE serotonin_24\NN|)|peptide|HT|concentration (r_nmod) content_30\NN|NONE (r_pobj) in_10\IN|during (r_prep) changes_9\NNS|to|attack|and (r_dobj) investigate_8\VB|aim|. (l_conj) attack_40\NN|changes|to|and (l_compound) migraine_39\JJ|the|delayed|genuine|provoked
D012701_D008881 NONE 5-hydroxytriptamine_26\NN|NONE (r_punct) ,_27\,|NONE (r_punct) 5-HT_28\CD|)|peptide|serotonin|concentration (r_nmod) content_30\NN|NONE (r_pobj) in_10\IN|during (r_prep) changes_9\NNS|to|attack|and (r_dobj) investigate_8\VB|aim|. (l_conj) attack_40\NN|changes|to|and (l_compound) migraine_39\JJ|the|delayed|genuine|provoked
D012701_D008881 NONE 5-HT_28\CD|)|peptide|serotonin|concentration (r_nmod) content_30\NN|NONE (r_pobj) in_10\IN|during (r_prep) changes_9\NNS|to|attack|and (r_dobj) investigate_8\VB|aim|. (l_conj) attack_40\NN|changes|to|and (l_compound) migraine_39\JJ|the|delayed|genuine|provoked
D012701_D008881 NONE 5-HT_8\CD|NONE (r_nummod) content_9\NN|be (r_nsubj) tended_10\VBD|NONE (l_xcomp) be_12\VB|content (l_prep) in_14\IN|to|lower (l_pobj) subjects_15\NNS|NONE (l_relcl) experienced_17\VBD|NONE (l_dobj) attack_20\NN|who (l_compound) migraine_19\JJ|a
D012701_D008881 NONE serotonin_1\NN|NONE (r_compound) content_2\NN|P<.|but|observed|after|significantly (r_nsubj) decreased_3\VBD|NONE (l_prep) after_8\IN|P<.|but|observed|content|significantly (l_pobj) nitroglycerin_9\NN|NONE (l_prep) in_10\IN|NONE (l_pobj) subjects_11\NNS|NONE (l_prep) with_12\IN|NONE (l_pobj) attack_15\NN|NONE (l_compound) migraine_14\JJ|no
D012701_D008881 NONE serotonin_1\NN|NONE (r_compound) content_2\NN|P<.|but|observed|after|significantly (r_nsubj) decreased_3\VBD|NONE (l_conj) observed_21\VBN|P<.|but|content|after|significantly (l_prep) in_22\IN|was|.|change (l_pobj) patients_23\NNS|NONE (l_prep) with_24\IN|NONE (l_pobj) attack_26\NN|NONE (l_compound) migraine_25\JJ|NONE
D012701_D008881 NONE serotonin_3\NN|from (r_compound) release_4\NN|does|migraine|In|,|not (r_nsubj) provoke_9\VB|even|may|,|headache|it|. (l_dobj) migraine_10\NN|does|In|release|,|not
D005996_D008881 NONE nitroglycerin_43\NN|NONE (r_pobj) by_42\IN|NONE (r_agent) provoked_41\VBN|migraine|the|delayed|genuine (r_acl) attack_40\NN|changes|to|and (l_compound) migraine_39\JJ|the|delayed|genuine|provoked
D005996_D008881 NONE nitroglycerin_16\NN|the (r_compound) application_17\NN|NONE (r_pobj) after_14\IN|min|and (r_conj) before_12\RB|min|from|times|,|Blood|was|and (r_advmod) collected_2\VBN|NONE (l_conj) min_23\NN|before|from|times|,|Blood|was|and (l_prep) after_24\IN||.|;|subjects (l_pobj) beginning_26\NN|NONE (l_prep) of_27\IN|the (l_pobj) attack_30\NN|NONE (l_compound) migraine_29\JJ|the|mean
D005996_D008881 NONE nitroglycerin_9\NN|NONE (l_prep) in_10\IN|NONE (l_pobj) subjects_11\NNS|NONE (l_prep) with_12\IN|NONE (l_pobj) attack_15\NN|NONE (l_compound) migraine_14\JJ|no
D005996_D008881 NONE nitroglycerin_9\NN|NONE (r_pobj) after_8\IN|P<.|but|observed|content|significantly (r_prep) decreased_3\VBD|NONE (l_conj) observed_21\VBN|P<.|but|content|after|significantly (l_prep) in_22\IN|was|.|change (l_pobj) patients_23\NNS|NONE (l_prep) with_24\IN|NONE (l_pobj) attack_26\NN|NONE (l_compound) migraine_25\JJ|NONE
D009569_D008881 NONE NO_0\RB| (r_intj) induced_2\VBN|.|increase|migraine|: (r_amod) attack_4\NN|NONE (l_compound) migraine_3\JJ|.|increase|induced|:
D015740_D008881 NONE peptide_14\NN|NONE (r_pobj) in_8\IN|strong (r_prep) increase_7\NN|.|migraine|induced|: (r_appos) attack_4\NN|NONE (l_compound) migraine_3\JJ|.|increase|induced|:
D015740_D008881 NONE CGRP_16\NN|and|correlation|)|( (r_nmod) concentration_18\NN|related|plasma|calcitonin (r_appos) peptide_14\NN|NONE (r_pobj) in_8\IN|strong (r_prep) increase_7\NN|.|migraine|induced|: (r_appos) attack_4\NN|NONE (l_compound) migraine_3\JJ|.|increase|induced|:
D015740_D008881 NONE peptide_17\NN|)|HT|serotonin|concentration (r_nmod) content_30\NN|NONE (r_pobj) in_10\IN|during (r_prep) changes_9\NNS|to|attack|and (r_dobj) investigate_8\VB|aim|. (l_conj) attack_40\NN|changes|to|and (l_compound) migraine_39\JJ|the|delayed|genuine|provoked
D015740_D008881 NONE CGRP_19\NN|and|(|) (r_nmod) concentration_21\NN|)|peptide|HT|serotonin (r_nmod) content_30\NN|NONE (r_pobj) in_10\IN|during (r_prep) changes_9\NNS|to|attack|and (r_dobj) investigate_8\VB|aim|. (l_conj) attack_40\NN|changes|to|and (l_compound) migraine_39\JJ|the|delayed|genuine|provoked
D015740_D008881 NONE CGRP_1\NN|Plasma (r_compound) concentration_2\NN|significantly|during|.|returned|P<.|and (r_nsubj) increased_3\VBD|NONE (l_prep) during_8\IN|significantly|.|concentration|returned|P<.|and (l_pobj) attack_11\NN|NONE (l_compound) migraine_10\JJ|the
D015740_D008881 NONE CGRP_1\NN|Plasma (r_compound) concentration_2\NN|significantly|during|.|returned|P<.|and (r_nsubj) increased_3\VBD|NONE (l_conj) returned_13\VBD|significantly|during|.|concentration|P<.|and (l_prep) after_16\IN|to (l_pobj) cessation_18\NN|NONE (l_prep) of_19\IN|the (l_pobj) migraine_21\NN|NONE
D015740_D008881 NONE CGRP_3\NNP|plasma (r_compound) concentrations_4\NNS|.|However|change|, (r_nsubj) failed_5\VBD|NONE (l_xcomp) change_7\VB|concentrations|.|However|, (l_prep) during_8\IN|to (l_conj) in_12\IN|and|headache (l_pobj) subjects_14\NNS|NONE (l_prep) with_15\IN|the (l_pobj) attack_18\NN|NONE (l_compound) migraine_17\JJ|no
D015740_D008881 NONE CGRP_1\NNP|Basal (r_compound) concentration_2\NN|.|and|platelet|higher (r_nsubj) was_3\VBD|NONE (l_conj) platelet_7\NN|concentration|.|and|higher (l_ccomp) tended_10\VBD|NONE (l_xcomp) be_12\VB|content (l_prep) in_14\IN|to|lower (l_pobj) subjects_15\NNS|NONE (l_relcl) experienced_17\VBD|NONE (l_dobj) attack_20\NN|who (l_compound) migraine_19\JJ|a
D015740_D008881 NONE CGRP_7\NN|plasma (r_compound) concentration_8\NN|with|that (r_nsubj) correlates_9\VBZ|the (l_prep) with_10\IN|concentration|that (l_pobj) timing_12\NN|NONE (l_prep) of_15\IN|and|the|severity (l_pobj) headache_18\NN|NONE (l_compound) migraine_17\JJ|a
D015740_D008881 NONE CGRP_7\NN|plasma (r_compound) concentration_8\NN|with|that (r_nsubj) correlates_9\VBZ|the (r_acl) fact_4\NN|,|.|relationship|In (r_nsubj) suggests_19\VBZ|NONE (l_dobj) relationship_22\NN|fact|,|.|In (l_prep) between_23\IN|a|direct (l_pobj) CGRP_24\NN|NONE (l_conj) migraine_26\NN|and
D015740_D008881 NONE CGRP_24\NN|NONE (r_pobj) between_23\IN|a|direct (r_prep) relationship_22\NN|fact|,|.|In (r_dobj) suggests_19\VBZ|NONE (l_nsubj) fact_4\NN|,|.|relationship|In (l_acl) correlates_9\VBZ|the (l_prep) with_10\IN|concentration|that (l_pobj) timing_12\NN|NONE (l_prep) of_15\IN|and|the|severity (l_pobj) headache_18\NN|NONE (l_compound) migraine_17\JJ|a
D015740_D008881 NONE CGRP_24\NN|NONE (l_conj) migraine_26\NN|and
D015740_D008881 NONE CGRP_21\NN|the|in|concomitant (r_compound) release_22\NN|the|and (r_conj) headache_17\NN|provoke|even|may|,|it|. (r_dobj) counteract_15\VB|NONE (l_ccomp) provoke_9\VB|even|may|,|headache|it|. (l_dobj) migraine_10\NN|does|In|release|,|not
18513945
D010121_D007022 CID Oxytocin_0\NN|.|uterotonic (r_nsubj) is_1\VBZ|NONE (l_attr) uterotonic_5\NN|Oxytocin|. (l_relcl) cause_8\VB|used|a (l_dobj) hypotension_13\NN|that|,|given|can
D010121_D007022 CID Oxytocin_0\NN| (r_npadvmod) induced_2\VBN|at (r_amod) hypotension_3\NN|may|to|be|incorrectly|.
D010121_D007022 CID oxytocin_4\NN|NONE (r_pobj) to_3\IN|NONE (r_prep) response_2\NN|NONE (r_pobj) in_1\IN|NONE (r_prep) Hypotension_0\NN|with|was|.
D010121_D006473 NONE Oxytocin_0\NN| (r_npadvmod) induced_2\VBN|at (r_amod) hypotension_3\NN|may|to|be|incorrectly|. (r_nsubjpass) attributed_10\VBN|NONE (l_prep) to_11\IN|hypotension|may|be|incorrectly|. (l_pobj) loss_13\NN|NONE
D010121_D020521 NONE oxytocin_4\NN|NONE (r_pobj) to_3\IN|NONE (r_prep) response_2\NN|NONE (r_pobj) in_1\IN|NONE (r_prep) Hypotension_0\NN|with|was|. (r_nsubjpass) associated_6\VBN|NONE (l_prep) with_7\IN|was|.|Hypotension (l_pobj) decrease_9\NN|NONE (l_conj) increase_17\NN|and|in|a (l_prep) in_18\IN|compensatory|a (l_pobj) volume_20\NN|NONE (l_compound) stroke_19\NN|,|rate
6892185
D002217_D015878 CID carbachol_53\NN|NONE (r_pobj) by_52\IN|NONE (r_agent) produced_51\VBN|tonic (r_acl) convulsions_50\NNS|and (r_conj) tremor_45\NN|, (r_conj) mydriasis_43\NN|,|attack
D002217_D015878 CID carbachol_15\NN|NONE (r_pobj) by_14\IN|NONE (r_agent) evoked_13\VBN|,|tremor (r_acl) mydriasis_5\NN|were|not|On|by|,|.|significantly
D002217_D015878 CID carbachol_30\NN|NONE (r_pobj) by_29\IN|NONE (r_agent) caused_28\VBN|can|"|vocalization|from|"|that|chloride (r_acl) dissociate_8\VB|It|.|apparent (l_prep) from_13\IN|can|"|caused|vocalization|"|that|chloride (l_pobj) phenomena_17\NNS|NONE (l_prep) as_19\IN|autonomic (l_pobj) mydriasis_20\NN|such
D002122_D014202 NONE chloride_4\NN|NONE (r_pobj) of_2\IN|The (r_prep) effect_1\NN|,|)|injected|fighting|into|upon (r_nsubj) injected_5\VBD|was|.|similarly (l_advcl) fighting_26\VBG|effect|,|)|injected|into|upon (l_conj) mydriasis_43\NN|,|attack (l_conj) tremor_45\NN|,
D002122_D014202 NONE chloride_24\NN|NONE (r_pobj) by_22\IN|were|not|On|,|.|significantly|mydriasis (r_agent) changed_21\VBN|NONE (l_nsubjpass) mydriasis_5\NN|were|not|On|by|,|.|significantly (l_conj) tremor_7\NN|,|evoked
D002122_D014202 NONE chloride_5\NN|can|"|caused|vocalization|from|"|that (r_nsubj) dissociate_8\VB|It|.|apparent (l_prep) from_13\IN|can|"|caused|vocalization|"|that|chloride (l_pobj) phenomena_17\NNS|NONE (l_prep) as_19\IN|autonomic (l_pobj) mydriasis_20\NN|such (l_conj) tremor_22\NN|,
D002122_D004830 NONE chloride_4\NN|NONE (r_pobj) of_2\IN|The (r_prep) effect_1\NN|,|)|injected|fighting|into|upon (r_nsubj) injected_5\VBD|was|.|similarly (l_advcl) fighting_26\VBG|effect|,|)|injected|into|upon (l_conj) mydriasis_43\NN|,|attack (l_conj) tremor_45\NN|, (l_conj) convulsions_50\NNS|and
D002122_D004830 NONE chloride_24\NN|NONE (r_pobj) by_22\IN|were|not|On|,|.|significantly|mydriasis (r_agent) changed_21\VBN|NONE (l_nsubjpass) mydriasis_5\NN|were|not|On|by|,|.|significantly (l_conj) tremor_7\NN|,|evoked (l_conj) convulsions_12\NNS|and
D002122_D004830 NONE chloride_5\NN|can|"|caused|vocalization|from|"|that (r_nsubj) dissociate_8\VB|It|.|apparent (l_prep) from_13\IN|can|"|caused|vocalization|"|that|chloride (l_pobj) phenomena_17\NNS|NONE (l_prep) as_19\IN|autonomic (l_pobj) mydriasis_20\NN|such (l_conj) tremor_22\NN|, (l_conj) convulsions_27\NNS|and
D002122_D015878 NONE chloride_4\NN|NONE (r_pobj) of_2\IN|The (r_prep) effect_1\NN|,|)|injected|fighting|into|upon (r_nsubj) injected_5\VBD|was|.|similarly (l_advcl) fighting_26\VBG|effect|,|)|injected|into|upon (l_conj) mydriasis_43\NN|,|attack
D002122_D015878 NONE chloride_24\NN|NONE (r_pobj) by_22\IN|were|not|On|,|.|significantly|mydriasis (r_agent) changed_21\VBN|NONE (l_nsubjpass) mydriasis_5\NN|were|not|On|by|,|.|significantly
D002122_D015878 NONE chloride_5\NN|can|"|caused|vocalization|from|"|that (r_nsubj) dissociate_8\VB|It|.|apparent (l_prep) from_13\IN|can|"|caused|vocalization|"|that|chloride (l_pobj) phenomena_17\NNS|NONE (l_prep) as_19\IN|autonomic (l_pobj) mydriasis_20\NN|such
D010830_D015878 CID eserine_55\NN|and (r_conj) carbachol_53\NN|NONE (r_pobj) by_52\IN|NONE (r_agent) produced_51\VBN|tonic (r_acl) convulsions_50\NNS|and (r_conj) tremor_45\NN|, (r_conj) mydriasis_43\NN|,|attack
D010830_D015878 CID eserine_17\NN|and (r_conj) carbachol_15\NN|NONE (r_pobj) by_14\IN|NONE (r_agent) evoked_13\VBN|,|tremor (r_acl) mydriasis_5\NN|were|not|On|by|,|.|significantly
D010830_D015878 CID eserine_32\NN|and (r_conj) carbachol_30\NN|NONE (r_pobj) by_29\IN|NONE (r_agent) caused_28\VBN|can|"|vocalization|from|"|that|chloride (r_acl) dissociate_8\VB|It|.|apparent (l_prep) from_13\IN|can|"|caused|vocalization|"|that|chloride (l_pobj) phenomena_17\NNS|NONE (l_prep) as_19\IN|autonomic (l_pobj) mydriasis_20\NN|such
D010830_D004830 CID eserine_55\NN|and (r_conj) carbachol_53\NN|NONE (r_pobj) by_52\IN|NONE (r_agent) produced_51\VBN|tonic (r_acl) convulsions_50\NNS|and
D010830_D004830 CID eserine_17\NN|and (r_conj) carbachol_15\NN|NONE (r_pobj) by_14\IN|NONE (r_agent) evoked_13\VBN|,|tremor (r_acl) mydriasis_5\NN|were|not|On|by|,|.|significantly (l_conj) tremor_7\NN|,|evoked (l_conj) convulsions_12\NNS|and
D010830_D004830 CID eserine_32\NN|and (r_conj) carbachol_30\NN|NONE (r_pobj) by_29\IN|NONE (r_agent) caused_28\VBN|can|"|vocalization|from|"|that|chloride (r_acl) dissociate_8\VB|It|.|apparent (l_prep) from_13\IN|can|"|caused|vocalization|"|that|chloride (l_pobj) phenomena_17\NNS|NONE (l_prep) as_19\IN|autonomic (l_pobj) mydriasis_20\NN|such (l_conj) tremor_22\NN|, (l_conj) convulsions_27\NNS|and
D002217_D004830 CID carbachol_53\NN|NONE (r_pobj) by_52\IN|NONE (r_agent) produced_51\VBN|tonic (r_acl) convulsions_50\NNS|and
D002217_D004830 CID carbachol_15\NN|NONE (r_pobj) by_14\IN|NONE (r_agent) evoked_13\VBN|,|tremor (r_acl) mydriasis_5\NN|were|not|On|by|,|.|significantly (l_conj) tremor_7\NN|,|evoked (l_conj) convulsions_12\NNS|and
D002217_D004830 CID carbachol_30\NN|NONE (r_pobj) by_29\IN|NONE (r_agent) caused_28\VBN|can|"|vocalization|from|"|that|chloride (r_acl) dissociate_8\VB|It|.|apparent (l_prep) from_13\IN|can|"|caused|vocalization|"|that|chloride (l_pobj) phenomena_17\NNS|NONE (l_prep) as_19\IN|autonomic (l_pobj) mydriasis_20\NN|such (l_conj) tremor_22\NN|, (l_conj) convulsions_27\NNS|and
D002217_D014202 CID carbachol_53\NN|NONE (r_pobj) by_52\IN|NONE (r_agent) produced_51\VBN|tonic (r_acl) convulsions_50\NNS|and (r_conj) tremor_45\NN|,
D002217_D014202 CID carbachol_15\NN|NONE (r_pobj) by_14\IN|NONE (r_agent) evoked_13\VBN|,|tremor (r_acl) mydriasis_5\NN|were|not|On|by|,|.|significantly (l_conj) tremor_7\NN|,|evoked
D002217_D014202 CID carbachol_30\NN|NONE (r_pobj) by_29\IN|NONE (r_agent) caused_28\VBN|can|"|vocalization|from|"|that|chloride (r_acl) dissociate_8\VB|It|.|apparent (l_prep) from_13\IN|can|"|caused|vocalization|"|that|chloride (l_pobj) phenomena_17\NNS|NONE (l_prep) as_19\IN|autonomic (l_pobj) mydriasis_20\NN|such (l_conj) tremor_22\NN|,
D010830_D014202 CID eserine_55\NN|and (r_conj) carbachol_53\NN|NONE (r_pobj) by_52\IN|NONE (r_agent) produced_51\VBN|tonic (r_acl) convulsions_50\NNS|and (r_conj) tremor_45\NN|,
D010830_D014202 CID eserine_17\NN|and (r_conj) carbachol_15\NN|NONE (r_pobj) by_14\IN|NONE (r_agent) evoked_13\VBN|,|tremor (r_acl) mydriasis_5\NN|were|not|On|by|,|.|significantly (l_conj) tremor_7\NN|,|evoked
D010830_D014202 CID eserine_32\NN|and (r_conj) carbachol_30\NN|NONE (r_pobj) by_29\IN|NONE (r_agent) caused_28\VBN|can|"|vocalization|from|"|that|chloride (r_acl) dissociate_8\VB|It|.|apparent (l_prep) from_13\IN|can|"|caused|vocalization|"|that|chloride (l_pobj) phenomena_17\NNS|NONE (l_prep) as_19\IN|autonomic (l_pobj) mydriasis_20\NN|such (l_conj) tremor_22\NN|,
12198388
D000431_D012640 NONE alcohol_6\NN| (r_compound) na_8\TO|mice (r_aux) ve_9\VB|was|in|.|sensitivity (l_dobj) mice_23\NNS|na (l_nmod) Prone_13\NNP|(|)|WSR (l_compound) Seizure_11\NN|WSP||(|Resistant|Withdrawal|and
D000431_D012640 NONE ethanol_18\NN|NONE (r_compound) withdrawal_19\NN|NONE (r_compound) severity_20\NN|NONE (r_pobj) with_17\IN|be|and|that|implicate|may|differences (r_prep) associated_16\VBN|.|results (l_nsubjpass) differences_4\NNS|be|and|that|implicate|may|with (l_prep) in_5\IN|NONE (l_pobj) activity_7\NN|NONE (l_conj) sensitivity_10\NN|and|cholinergic (l_prep) to_11\IN|postsynaptic (l_pobj) convulsants_13\NNS|NONE
D000431_D012640 NONE alcohol_26\NN|NONE (r_compound) withdrawal_27\NN|NONE (r_pobj) in_25\IN|cholinergic (r_prep) mechanisms_24\NNS|NONE (r_dobj) implicate_22\VB|be|and|that|may|differences|with (r_conj) associated_16\VBN|.|results (l_nsubjpass) differences_4\NNS|be|and|that|implicate|may|with (l_prep) in_5\IN|NONE (l_pobj) activity_7\NN|NONE (l_conj) sensitivity_10\NN|and|cholinergic (l_prep) to_11\IN|postsynaptic (l_pobj) convulsants_13\NNS|NONE
D009538_D014202 NONE nicotine_3\NN|were|,|Animals|and|recorded (r_dobj) administered_2\VBN|NONE (l_conj) recorded_25\VBN|nicotine|were|,|Animals|and (l_nsubjpass) latencies_17\NNS|and|were|.|converted (l_relcl) onset_19\VB|the (l_prep) of_20\IN|to (l_pobj) tremor_21\NN|NONE
D009388_D014202 NONE neostigmine_8\JJ|,|or (r_conj) carbachol_5\NN|, (r_conj) nicotine_3\NN|were|,|Animals|and|recorded (r_dobj) administered_2\VBN|NONE (l_conj) recorded_25\VBN|nicotine|were|,|Animals|and (l_nsubjpass) latencies_17\NNS|and|were|.|converted (l_relcl) onset_19\VB|the (l_prep) of_20\IN|to (l_pobj) tremor_21\NN|NONE
D000109_D012640 NONE acetylcholine_4\NN|hippocampal|sensitivity|and (r_compound) release_5\NN|NONE (l_conj) sensitivity_9\NN|acetylcholine|hippocampal|and (l_prep) in_10\IN|convulsant|cholinergic (l_pobj) lines_22\NNS|NONE (l_amod) prone_14\JJ|resistant|selected|mouse|withdrawal (l_npadvmod) seizure_12\NN||withdrawal|and
D000109_D012640 NONE acetylcholine_4\NN|hippocampal|sensitivity|and (r_compound) release_5\NN|NONE (l_conj) sensitivity_9\NN|acetylcholine|hippocampal|and (l_prep) in_10\IN|convulsant|cholinergic (l_pobj) lines_22\NNS|NONE (l_amod) resistant_19\JJ|prone|selected|mouse|withdrawal (l_npadvmod) seizure_17\NN|
D000109_D012640 NONE ACh_1\NNS|during|.|was|also (r_nsubjpass) measured_4\VBN|NONE (l_prep) during_5\IN|ACh|.|was|also (l_pobj) testing_6\VBG|NONE (l_prep) for_7\IN|NONE (l_pobj) convulsions_11\NNS|NONE
D000109_D012640 NONE ACh_2\NNS|during|was|When (r_nsubjpass) measured_4\VBN|elevated|,|%|ACh|but|in|significantly|,|was|. (l_prep) during_5\IN|ACh|was|When (l_pobj) testing_6\VBG|NONE (l_prep) for_7\IN|NONE (l_pobj) convulsions_11\NNS|NONE
D000109_D012640 NONE ACh_14\NNS|elevated|measured|,|%|but|in|significantly|,|was|. (r_nsubjpass) elevated_17\JJ|NONE (l_advcl) measured_4\VBN|elevated|,|%|ACh|but|in|significantly|,|was|. (l_prep) during_5\IN|ACh|was|When (l_pobj) testing_6\VBG|NONE (l_prep) for_7\IN|NONE (l_pobj) convulsions_11\NNS|NONE
D002217_D012640 CID carbachol_9\NN|, (r_conj) nicotine_7\NN|NONE (r_pobj) by_6\IN|NONE (r_agent) induced_5\VBN|convulsion|several (r_acl) endpoints_4\NNS|NONE (l_compound) convulsion_3\NN|induced|several
D009538_D012640 CID nicotine_7\NN|NONE (r_pobj) by_6\IN|NONE (r_agent) induced_5\VBN|convulsion|several (r_acl) endpoints_4\NNS|NONE (l_compound) convulsion_3\NN|induced|several
D002217_D014202 NONE carbachol_5\NN|, (r_conj) nicotine_3\NN|were|,|Animals|and|recorded (r_dobj) administered_2\VBN|NONE (l_conj) recorded_25\VBN|nicotine|were|,|Animals|and (l_nsubjpass) latencies_17\NNS|and|were|.|converted (l_relcl) onset_19\VB|the (l_prep) of_20\IN|to (l_pobj) tremor_21\NN|NONE
D009388_D012640 CID neostigmine_12\NN|and|,|to (r_conj) Sensitivity_0\NN|.|greater (l_prep) to_1\IN|and|neostigmine|, (l_pobj) endpoints_4\NNS|NONE (l_compound) convulsion_3\NN|induced|several
7053705
D013866_D054198 NONE 6-thioguanine_27\CD|NONE (r_punct) ._28\.|of|occlusive|reversible (r_punct) disease_5\NN|NONE (l_prep) of_6\IN|.|occlusive|reversible (l_pobj) liver_8\NN|NONE (l_acl) developed_9\VBN|the (l_prep) in_10\IN|with|after (l_pobj) man_15\NN|NONE (l_prep) with_16\IN|old|a (l_pobj) leukemia_19\NN|NONE
D013866_D006504 CID 6-thioguanine_7\CD|NONE (r_pobj) by_6\IN|NONE (r_agent) caused_5\VBN|Hepatic|.|occlusive (r_acl) disease_4\NN|NONE
D013866_D006504 CID 6-thioguanine_27\CD|NONE (r_punct) ._28\.|of|occlusive|reversible (r_punct) disease_5\NN|NONE (l_prep) of_6\IN|.|occlusive|reversible (l_pobj) liver_8\NN|NONE
D013866_D006504 CID 6-thioguanine_35\CD|solely (r_pobj) to_34\IN|occlusive (r_prep) related_32\VBN|NONE (r_pobj) of_28\IN|first|the (r_prep) case_27\NN|may (r_attr) be_24\VB|,|.|and|opportunity|case (r_conj) presented_2\VBD|NONE (l_dobj) opportunity_5\NN|,|.|and|be|case (l_acl) observe_7\VB|a|unique (l_dobj) features_10\NNS|to|over (l_prep) of_11\IN|the|histologic (l_pobj) disease_18\NN|NONE
11532387
D018967_D001480 CID risperidone_9\NN|NONE (r_pobj) of_8\IN|dose (r_prep) reduction_7\NN|NONE (r_pobj) during_5\IN|emergent|rabbit|. (r_prep) syndrome_4\NN|NONE
D018967_D001480 CID risperidone_8\NN|NONE (r_pobj) of_7\IN|dose (r_prep) reduction_6\NN|NONE (r_pobj) during_4\IN|RS|.|patient (r_prep) developed_2\VBN|NONE (l_dobj) RS_3\NN|.|during|patient
D018967_D001480 CID risperidone_21\NN|NONE (r_pobj) of_20\IN|the|pharmacological (r_prep) profile_19\NN|NONE (r_pobj) to_16\IN|been|mechanism|may|.|have|,|suggesting (r_prep) related_15\VBN|NONE (l_nsubjpass) mechanism_2\NN|been|may|.|have|,|suggesting|to (l_prep) of_3\IN|underlying|in|The (l_pobj) RS_7\NN|NONE
D018967_D001480 CID risperidone_21\NN|NONE (r_pobj) of_20\IN|the|pharmacological (r_prep) profile_19\NN|NONE (r_pobj) to_16\IN|been|mechanism|may|.|have|,|suggesting (r_prep) related_15\VBN|NONE (l_advcl) suggesting_29\VBG|been|mechanism|may|.|have|,|to (l_dobj) influence_32\NN|NONE (l_prep) in_37\IN|pathophysiologic|of|the (l_pobj) development_39\NN|NONE (l_prep) of_40\IN|the (l_pobj) RS_41\NN|NONE
D018967_D013375 CID risperidone_9\NN|NONE (r_pobj) of_8\IN|dose (r_prep) reduction_7\NN|NONE (r_pobj) during_5\IN|emergent|rabbit|. (r_prep) syndrome_4\NN|NONE
D018967_D013375 CID risperidone_21\NN|NONE (r_pobj) of_20\IN|the|pharmacological (r_prep) profile_19\NN|NONE (r_pobj) to_16\IN|been|mechanism|may|.|have|,|suggesting (r_prep) related_15\VBN|NONE (l_nsubjpass) mechanism_2\NN|been|may|.|have|,|suggesting|to (l_prep) of_3\IN|underlying|in|The (l_pobj) RS_7\NN|NONE
D012701_D001480 NONE serotonin_24\NN| (r_compound) dopamine_26\NN|a (r_compound) antagonist_27\NN|, (r_appos) risperidone_21\NN|NONE (r_pobj) of_20\IN|the|pharmacological (r_prep) profile_19\NN|NONE (r_pobj) to_16\IN|been|mechanism|may|.|have|,|suggesting (r_prep) related_15\VBN|NONE (l_nsubjpass) mechanism_2\NN|been|may|.|have|,|suggesting|to (l_prep) of_3\IN|underlying|in|The (l_pobj) RS_7\NN|NONE
D012701_D001480 NONE serotonin_24\NN| (r_compound) dopamine_26\NN|a (r_compound) antagonist_27\NN|, (r_appos) risperidone_21\NN|NONE (r_pobj) of_20\IN|the|pharmacological (r_prep) profile_19\NN|NONE (r_pobj) to_16\IN|been|mechanism|may|.|have|,|suggesting (r_prep) related_15\VBN|NONE (l_advcl) suggesting_29\VBG|been|mechanism|may|.|have|,|to (l_dobj) influence_32\NN|NONE (l_prep) in_37\IN|pathophysiologic|of|the (l_pobj) development_39\NN|NONE (l_prep) of_40\IN|the (l_pobj) RS_41\NN|NONE
D012701_D001480 NONE serotonin_35\NN|the (r_compound) system_36\NN|NONE (r_pobj) of_33\IN|pathophysiologic|in|the (r_prep) influence_32\NN|NONE (r_dobj) suggesting_29\VBG|been|mechanism|may|.|have|,|to (r_advcl) related_15\VBN|NONE (l_nsubjpass) mechanism_2\NN|been|may|.|have|,|suggesting|to (l_prep) of_3\IN|underlying|in|The (l_pobj) RS_7\NN|NONE
D012701_D001480 NONE serotonin_35\NN|the (r_compound) system_36\NN|NONE (r_pobj) of_33\IN|pathophysiologic|in|the (r_prep) influence_32\NN|NONE (l_prep) in_37\IN|pathophysiologic|of|the (l_pobj) development_39\NN|NONE (l_prep) of_40\IN|the (l_pobj) RS_41\NN|NONE
D012701_D013375 NONE serotonin_24\NN| (r_compound) dopamine_26\NN|a (r_compound) antagonist_27\NN|, (r_appos) risperidone_21\NN|NONE (r_pobj) of_20\IN|the|pharmacological (r_prep) profile_19\NN|NONE (r_pobj) to_16\IN|been|mechanism|may|.|have|,|suggesting (r_prep) related_15\VBN|NONE (l_nsubjpass) mechanism_2\NN|been|may|.|have|,|suggesting|to (l_prep) of_3\IN|underlying|in|The (l_pobj) RS_7\NN|NONE
D012701_D013375 NONE serotonin_35\NN|the (r_compound) system_36\NN|NONE (r_pobj) of_33\IN|pathophysiologic|in|the (r_prep) influence_32\NN|NONE (r_dobj) suggesting_29\VBG|been|mechanism|may|.|have|,|to (r_advcl) related_15\VBN|NONE (l_nsubjpass) mechanism_2\NN|been|may|.|have|,|suggesting|to (l_prep) of_3\IN|underlying|in|The (l_pobj) RS_7\NN|NONE
D004298_D013375 NONE dopamine_26\NN|a (r_compound) antagonist_27\NN|, (r_appos) risperidone_21\NN|NONE (r_pobj) of_20\IN|the|pharmacological (r_prep) profile_19\NN|NONE (r_pobj) to_16\IN|been|mechanism|may|.|have|,|suggesting (r_prep) related_15\VBN|NONE (l_nsubjpass) mechanism_2\NN|been|may|.|have|,|suggesting|to (l_prep) of_3\IN|underlying|in|The (l_pobj) RS_7\NN|NONE
D004298_D001480 NONE dopamine_26\NN|a (r_compound) antagonist_27\NN|, (r_appos) risperidone_21\NN|NONE (r_pobj) of_20\IN|the|pharmacological (r_prep) profile_19\NN|NONE (r_pobj) to_16\IN|been|mechanism|may|.|have|,|suggesting (r_prep) related_15\VBN|NONE (l_nsubjpass) mechanism_2\NN|been|may|.|have|,|suggesting|to (l_prep) of_3\IN|underlying|in|The (l_pobj) RS_7\NN|NONE
D004298_D001480 NONE dopamine_26\NN|a (r_compound) antagonist_27\NN|, (r_appos) risperidone_21\NN|NONE (r_pobj) of_20\IN|the|pharmacological (r_prep) profile_19\NN|NONE (r_pobj) to_16\IN|been|mechanism|may|.|have|,|suggesting (r_prep) related_15\VBN|NONE (l_advcl) suggesting_29\VBG|been|mechanism|may|.|have|,|to (l_dobj) influence_32\NN|NONE (l_prep) in_37\IN|pathophysiologic|of|the (l_pobj) development_39\NN|NONE (l_prep) of_40\IN|the (l_pobj) RS_41\NN|NONE
12734532
D010665_D062787 NONE PPA_7\NNP|NONE (r_pobj) of_6\IN|with|the (r_prep) abuse_5\NN|.|involved|reports|,|have (r_dobj) linked_3\VBN|NONE (l_advcl) involved_16\VBN|abuse|.|reports|,|have (l_nsubjpass) overdose_14\NN|is|when|especially
D010665_D009203 CID Dexatrim_3\NNP|.|Case|: (l_prep) as_7\IN|Phenylpropanolamine|(|) (l_pobj) cause_9\NN|NONE (l_prep) of_10\IN|a (l_pobj) infarction_12\NN|NONE
D010665_D009203 CID Phenylpropanolamine_5\NNP|as|(|) (r_appos) Dexatrim_3\NNP|.|Case|: (l_prep) as_7\IN|Phenylpropanolamine|(|) (l_pobj) cause_9\NN|NONE (l_prep) of_10\IN|a (l_pobj) infarction_12\NN|NONE
D010665_D009202 NONE PPA_7\NNP|NONE (r_pobj) of_6\IN|with|the (r_prep) abuse_5\NN|.|involved|reports|,|have (l_prep) with_8\IN|of|the (l_pobj) injury_10\NN|NONE
D010665_D009202 NONE Dexatrim_7\NNP|myocardial|PPA)induced|in (r_nmod) injury_11\NN|NONE
D010665_D009202 NONE PPA)-induced_9\VBN|myocardial|Dexatrim|in (r_amod) injury_11\NN|NONE
D010665_D009202 NONE PPA_10\NN|NONE (r_pobj) of_9\IN|the||other|related (r_prep) cases_8\NNS|In|we|.|, (l_acl) related_11\VBN|the||other|of (l_dobj) injury_13\NN|NONE
1867351
D015767_D008288 NONE mefloquine_10\NN|NONE (r_pobj) with_9\IN|NONE (r_prep) treatment_8\NN|malaria|and (r_conj) prophylaxis_6\NN|NONE (l_compound) malaria_5\NN|treatment|and
1786266
D000928_D001480 NONE antidepressant_3\NN|,|and|findings (r_compound) use_4\NN|.|,|Rabbit (r_conj) syndrome_1\NN|NONE
19944333
C471405_D003329 CID Sorafenib_0\NNP|due|infarction||. (r_npadvmod) induced_2\VBN|NONE (l_prep) due_6\IN|infarction|Sorafenib||. (l_pobj) spasm_10\NN|to
C471405_D003329 CID sorafenib_6\NN| (r_npadvmod) induced_8\VBN|artery|coronary (r_amod) spasm_11\NN|NONE
D020108_D060050 NONE nicorandil_3\NN|NONE (r_pobj) of_1\IN|NONE (r_prep) Addition_0\NN|maintained|.|symptoms|and (r_nsubj) reduced_4\VBD|NONE (l_conj) maintained_8\VBD|.|Addition|symptoms|and (l_dobj) status_11\NN|NONE (l_compound) angina_10\NN|NONE
C471405_D009203 NONE Sorafenib_0\NNP|due|infarction||. (r_npadvmod) induced_2\VBN|NONE (l_dobj) infarction_5\NN|due|Sorafenib||.
15737522
D002443_D001660 CID Ceftriaxone_0\NN| (r_npadvmod) associated_2\VBN|biliary|in|. (r_amod) pseudolithiasis_4\NN|NONE
D002443_D001660 CID ceftriaxone_5\NN|pseudolithiasis|that (r_nsubj) leads_6\VBZ|.|It|is|well (l_xcomp) pseudolithiasis_8\NN|ceftriaxone|that
D002443_D001660 CID ceftriaxone_19\CD|,|had (r_compound) treatment_20\NN|NONE (r_dobj) receiving_18\VBG|surgical|paediatric (r_acl) patients_17\NNS|NONE (r_pobj) in_14\IN|NONE (r_prep) pseudolithiasis_13\NN|NONE
12536034
D002220_D004832 CID carbamazepine_13\NN|NONE (r_pobj) of_12\IN|NONE (r_prep) administration_11\NN|NONE (r_pobj) after_10\IN|patients|.|authors (r_prep) present_2\VBP|NONE (l_dobj) patients_4\NNS|.|authors|after (l_prep) with_5\IN|three (l_pobj) epilepsy_9\NN|NONE
D020888_D004832 CID vigabatrin_15\NN|and (r_conj) carbamazepine_13\NN|NONE (r_pobj) of_12\IN|NONE (r_prep) administration_11\NN|NONE (r_pobj) after_10\IN|patients|.|authors (r_prep) present_2\VBP|NONE (l_dobj) patients_4\NNS|.|authors|after (l_prep) with_5\IN|three (l_pobj) epilepsy_9\NN|NONE
D005680_D004832 NONE acid_4\NN| (r_npadvmod) transmitted_6\VBN|thalamocortical (r_amod) circuitry_8\NN|aminobutyric|for|.|The (r_compound) accounts_9\VBZ|NONE (l_prep) for_10\IN|aminobutyric|.|circuitry|The (l_pobj) part_13\NN|NONE (l_prep) of_14\IN|major|a (l_pobj) neurophysiology_17\NN|NONE (l_prep) of_18\IN|underlying|the (l_pobj) epilepsy_21\NN|NONE
9270571
D015632_D020734 CID MPTP_9\NNP| (r_npadvmod) induced_11\VBN|NONE (r_amod) parkinsonism_12\NN|as
C416545_D004409 NONE LY-171555_16\NNP|and (r_conj) levodopa_14\NN|NONE (r_pobj) as_13\IN|parkinsonism (r_prep) alleviating_8\VBG|NONE (r_pcomp) in_7\IN|as (r_prep) efficacious_6\JJ|A|,|administration|was|.|but (r_acomp) was_4\VBD|NONE (l_conj) was_19\VBD|A|efficacious|,|administration|.|but (l_acomp) likely_21\JJ|NONE (l_xcomp) reproduce_23\VB|less (l_dobj) dyskinesias_28\NNS|to|than
C416545_D004409 NONE LY-171555_35\NNP|of (r_amod) challenge_38\NN|NONE (r_pobj) with_33\IN|NONE (r_prep) than_32\IN|to|dyskinesias (r_prep) reproduce_23\VB|less (l_dobj) dyskinesias_28\NNS|to|than
D007980_D020734 NONE levodopa_7\NN| (r_npadvmod) primed_9\VBN|parkinsonian (r_amod) monkeys_10\NNS|NONE (l_amod) parkinsonian_6\JJ|primed
D007980_D020734 NONE levodopa_14\NN|NONE (r_pobj) as_13\IN|parkinsonism (r_prep) alleviating_8\VBG|NONE (l_dobj) parkinsonism_12\NN|as
D007980_D020734 NONE levodopa_25\RB| (r_npadvmod) induced_27\VBN|the|in (r_amod) dyskinesias_28\NNS|to|than (r_dobj) reproduce_23\VB|less (r_xcomp) likely_21\JJ|NONE (r_acomp) was_19\VBD|A|efficacious|,|administration|.|but (r_conj) was_4\VBD|NONE (l_acomp) efficacious_6\JJ|A|,|administration|was|.|but (l_prep) in_7\IN|as (l_pcomp) alleviating_8\VBG|NONE (l_dobj) parkinsonism_12\NN|as
D007980_D020734 NONE levodopa_40\NN|NONE (r_pobj) of_39\IN|LY (r_prep) challenge_38\NN|NONE (r_pobj) with_33\IN|NONE (r_prep) than_32\IN|to|dyskinesias (r_prep) reproduce_23\VB|less (r_xcomp) likely_21\JJ|NONE (r_acomp) was_19\VBD|A|efficacious|,|administration|.|but (r_conj) was_4\VBD|NONE (l_acomp) efficacious_6\JJ|A|,|administration|was|.|but (l_prep) in_7\IN|as (l_pcomp) alleviating_8\VBG|NONE (l_dobj) parkinsonism_12\NN|as
D015632_D004409 NONE 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine_12\CD|NONE (r_pobj) in_10\IN|response|acute|present|the (r_prep) study_9\NN|dyskinesias|therefore|We|evaluate|. (r_dobj) conducted_2\VBD|NONE (l_dobj) dyskinesias_23\NNS|therefore|We|evaluate|study|.
D015632_D004409 NONE 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine_12\CD|NONE (r_pobj) in_10\IN|response|acute|present|the (r_prep) study_9\NN|dyskinesias|therefore|We|evaluate|. (r_dobj) conducted_2\VBD|NONE (l_advcl) evaluate_25\VB|dyskinesias|therefore|We|study|. (l_dobj) effects_30\NNS|to (l_amod) locomotor_27\NN|the|on (l_conj) dyskinetic_29\JJ|and
D015632_D004409 NONE MPTP)-exposed_14\VBN|(|cynomolgus|primed (r_amod) monkeys_16\NNS|four (r_appos) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine_12\CD|NONE (r_pobj) in_10\IN|response|acute|present|the (r_prep) study_9\NN|dyskinesias|therefore|We|evaluate|. (r_dobj) conducted_2\VBD|NONE (l_dobj) dyskinesias_23\NNS|therefore|We|evaluate|study|.
D015632_D004409 NONE MPTP)-exposed_14\VBN|(|cynomolgus|primed (r_amod) monkeys_16\NNS|four (r_appos) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine_12\CD|NONE (r_pobj) in_10\IN|response|acute|present|the (r_prep) study_9\NN|dyskinesias|therefore|We|evaluate|. (r_dobj) conducted_2\VBD|NONE (l_advcl) evaluate_25\VB|dyskinesias|therefore|We|study|. (l_dobj) effects_30\NNS|to (l_amod) locomotor_27\NN|the|on (l_conj) dyskinetic_29\JJ|and
D015632_D004409 NONE MPTP_9\NNP| (r_npadvmod) induced_11\VBN|NONE (r_amod) parkinsonism_12\NN|as (r_dobj) alleviating_8\VBG|NONE (r_pcomp) in_7\IN|as (r_prep) efficacious_6\JJ|A|,|administration|was|.|but (r_acomp) was_4\VBD|NONE (l_conj) was_19\VBD|A|efficacious|,|administration|.|but (l_acomp) likely_21\JJ|NONE (l_xcomp) reproduce_23\VB|less (l_dobj) dyskinesias_28\NNS|to|than
C416545_D020734 NONE LY-171555_16\NNP|and (r_conj) levodopa_14\NN|NONE (r_pobj) as_13\IN|parkinsonism (r_prep) alleviating_8\VBG|NONE (l_dobj) parkinsonism_12\NN|as
C416545_D020734 NONE LY-171555_35\NNP|of (r_amod) challenge_38\NN|NONE (r_pobj) with_33\IN|NONE (r_prep) than_32\IN|to|dyskinesias (r_prep) reproduce_23\VB|less (r_xcomp) likely_21\JJ|NONE (r_acomp) was_19\VBD|A|efficacious|,|administration|.|but (r_conj) was_4\VBD|NONE (l_acomp) efficacious_6\JJ|A|,|administration|was|.|but (l_prep) in_7\IN|as (l_pcomp) alleviating_8\VBG|NONE (l_dobj) parkinsonism_12\NN|as
C095427_D020734 NONE A-86929_0\NNS|NONE (l_dep) study_4\NN|.|: (l_prep) in_5\IN|acute|an (l_pobj) monkeys_10\NNS|NONE (l_amod) parkinsonian_6\JJ|primed
C095427_D020734 NONE A-86929_3\NNS|efficacious|,|administration|was|.|but (r_punct) was_4\VBD|NONE (l_acomp) efficacious_6\JJ|A|,|administration|was|.|but (l_prep) in_7\IN|as (l_pcomp) alleviating_8\VBG|NONE (l_dobj) parkinsonism_12\NN|as
D007980_D004409 CID levodopa_20\RB| (r_npadvmod) induced_22\VBN|NONE (r_amod) dyskinesias_23\NNS|therefore|We|evaluate|study|.
D007980_D004409 CID levodopa_20\RB| (r_npadvmod) induced_22\VBN|NONE (r_amod) dyskinesias_23\NNS|therefore|We|evaluate|study|. (r_dobj) conducted_2\VBD|NONE (l_advcl) evaluate_25\VB|dyskinesias|therefore|We|study|. (l_dobj) effects_30\NNS|to (l_amod) locomotor_27\NN|the|on (l_conj) dyskinetic_29\JJ|and
D007980_D004409 CID levodopa_14\NN|NONE (r_pobj) as_13\IN|parkinsonism (r_prep) alleviating_8\VBG|NONE (r_pcomp) in_7\IN|as (r_prep) efficacious_6\JJ|A|,|administration|was|.|but (r_acomp) was_4\VBD|NONE (l_conj) was_19\VBD|A|efficacious|,|administration|.|but (l_acomp) likely_21\JJ|NONE (l_xcomp) reproduce_23\VB|less (l_dobj) dyskinesias_28\NNS|to|than
D007980_D004409 CID levodopa_25\RB| (r_npadvmod) induced_27\VBN|the|in (r_amod) dyskinesias_28\NNS|to|than
D007980_D004409 CID levodopa_40\NN|NONE (r_pobj) of_39\IN|LY (r_prep) challenge_38\NN|NONE (r_pobj) with_33\IN|NONE (r_prep) than_32\IN|to|dyskinesias (r_prep) reproduce_23\VB|less (l_dobj) dyskinesias_28\NNS|to|than
D004298_D004409 NONE DA_62\NNP|Dlike|a|with|receptor|selective (r_compound) agonist_65\NN|four|from|)|,|of|( (r_appos) doses_35\NNS|NONE (r_pobj) with_33\IN|NONE (r_prep) challenge_32\NN|NONE (r_pobj) on_31\IN|the|locomotor (r_prep) effects_30\NNS|to (r_dobj) evaluate_25\VB|dyskinesias|therefore|We|study|. (r_advcl) conducted_2\VBD|NONE (l_dobj) dyskinesias_23\NNS|therefore|We|evaluate|study|.
D004298_D004409 NONE DA_62\NNP|Dlike|a|with|receptor|selective (r_compound) agonist_65\NN|four|from|)|,|of|( (r_appos) doses_35\NNS|NONE (r_pobj) with_33\IN|NONE (r_prep) challenge_32\NN|NONE (r_pobj) on_31\IN|the|locomotor (r_prep) effects_30\NNS|to (l_amod) locomotor_27\NN|the|on (l_conj) dyskinetic_29\JJ|and
C095427_D004409 NONE A-86929_44\NNS|) (r_punct) ,_57\,|four|from|)|agonist|of|( (r_punct) doses_35\NNS|NONE (r_pobj) with_33\IN|NONE (r_prep) challenge_32\NN|NONE (r_pobj) on_31\IN|the|locomotor (r_prep) effects_30\NNS|to (r_dobj) evaluate_25\VB|dyskinesias|therefore|We|study|. (r_advcl) conducted_2\VBD|NONE (l_dobj) dyskinesias_23\NNS|therefore|We|evaluate|study|.
C095427_D004409 NONE A-86929_44\NNS|) (r_punct) ,_57\,|four|from|)|agonist|of|( (r_punct) doses_35\NNS|NONE (r_pobj) with_33\IN|NONE (r_prep) challenge_32\NN|NONE (r_pobj) on_31\IN|the|locomotor (r_prep) effects_30\NNS|to (l_amod) locomotor_27\NN|the|on (l_conj) dyskinetic_29\JJ|and
C095427_D004409 NONE 10-diol_55\JJ|NONE (r_punct) )_56\-RRB-|A (r_punct) ,_57\,|four|from|)|agonist|of|( (r_punct) doses_35\NNS|NONE (r_pobj) with_33\IN|NONE (r_prep) challenge_32\NN|NONE (r_pobj) on_31\IN|the|locomotor (r_prep) effects_30\NNS|to (r_dobj) evaluate_25\VB|dyskinesias|therefore|We|study|. (r_advcl) conducted_2\VBD|NONE (l_dobj) dyskinesias_23\NNS|therefore|We|evaluate|study|.
C095427_D004409 NONE 10-diol_55\JJ|NONE (r_punct) )_56\-RRB-|A (r_punct) ,_57\,|four|from|)|agonist|of|( (r_punct) doses_35\NNS|NONE (r_pobj) with_33\IN|NONE (r_prep) challenge_32\NN|NONE (r_pobj) on_31\IN|the|locomotor (r_prep) effects_30\NNS|to (l_amod) locomotor_27\NN|the|on (l_conj) dyskinetic_29\JJ|and
C095427_D004409 NONE A-86929_3\NNS|efficacious|,|administration|was|.|but (r_punct) was_4\VBD|NONE (l_conj) was_19\VBD|A|efficacious|,|administration|.|but (l_acomp) likely_21\JJ|NONE (l_xcomp) reproduce_23\VB|less (l_dobj) dyskinesias_28\NNS|to|than
C095427_D010300 NONE A-86929_13\NNS|D|with|receptor (r_punct) agents_4\NNS|.|tools (r_nsubj) are_23\VBP|NONE (l_attr) tools_26\NNS|.|agents (l_prep) in_27\IN|potential|and|merit|therapeutic (l_pobj) PD_28\NNP|NONE
D004298_D010300 NONE dopamine_4\NN|NONE (r_pobj) of_3\IN|agonists|The|clinical (r_prep) utility_2\NN|unclear|.|still (l_appos) agonists_10\NNS|The|clinical|of (l_prep) in_11\IN|receptor|D|DA|(|) (l_pobj) treatment_13\NN|NONE (l_prep) of_14\IN|the (l_pobj) disease_17\NN|NONE
D004298_D010300 NONE dopamine_4\NN|NONE (r_pobj) of_3\IN|agonists|The|clinical (r_prep) utility_2\NN|unclear|.|still (l_appos) agonists_10\NNS|The|clinical|of (l_prep) in_11\IN|receptor|D|DA|(|) (l_pobj) treatment_13\NN|NONE (l_prep) of_14\IN|the (l_pobj) disease_17\NN|NONE (l_appos) PD_19\NNP|(|Parkinson|)
D004298_D010300 NONE DA_6\NNP|in|receptor|D|(|) (r_nmod) agonists_10\NNS|The|clinical|of (l_prep) in_11\IN|receptor|D|DA|(|) (l_pobj) treatment_13\NN|NONE (l_prep) of_14\IN|the (l_pobj) disease_17\NN|NONE
D004298_D010300 NONE DA_6\NNP|in|receptor|D|(|) (r_nmod) agonists_10\NNS|The|clinical|of (l_prep) in_11\IN|receptor|D|DA|(|) (l_pobj) treatment_13\NN|NONE (l_prep) of_14\IN|the (l_pobj) disease_17\NN|NONE (l_appos) PD_19\NNP|(|Parkinson|)
D004298_D010300 NONE DA_1\NNP|Potent (r_compound) D1_2\NN|with|A|receptor (r_compound) agents_4\NNS|.|tools (r_nsubj) are_23\VBP|NONE (l_attr) tools_26\NNS|.|agents (l_prep) in_27\IN|potential|and|merit|therapeutic (l_pobj) PD_28\NNP|NONE
20882060
D006220_D002375 CID haloperidol_5\NN| (r_npadvmod) induced_7\VBN|:|studies|parkinsonian (r_amod) catalepsy_9\NN|NONE
D006220_D002375 CID haloperidol_9\NN| (r_npadvmod) induced_11\VBN|parkinsonian (r_amod) catalepsy_13\NN|in|.|infusions
D009496_D002375 NONE neurotensin_3\NN|NONE (l_prep) on_4\IN|pallidal (l_pobj) catalepsy_9\NN|NONE
D009496_D002375 NONE neurotensin_3\NN|NONE (r_pobj) of_2\IN|Bilateral (r_prep) infusions_1\NNS|in|.|catalepsy (r_nsubj) reversed_8\VBD|NONE (l_dobj) catalepsy_13\NN|in|.|infusions
D006220_D010302 NONE haloperidol_12\NN| (r_npadvmod) induced_14\VBN|parkinsonian (r_amod) symptoms_16\NNS|NONE
D009496_D010302 NONE neurotensin_10\NN|NONE (l_prep) on_11\IN|pallidal (l_pobj) symptoms_16\NNS|NONE
15858223
C075750_D009336 NONE 15-F(2t)-IsoP_18\CD|NONE (r_pobj) of_17\IN|,|precedes (r_prep) levels_16\NNS|NONE (l_relcl) precedes_21\VBZ|,|of (l_dobj) onset_23\NN|which (l_prep) of_24\IN|the (l_pobj) necrosis_25\NN|NONE
D005978_D056486 NONE glutathione_11\NN|)||GST|S|( (r_compound) transferase_14\NNP|NONE (r_pobj) of_8\IN|serum (r_prep) levels_7\NNS|by|and (r_pobj) on_5\IN|NONE (r_prep) based_4\VBN|toxicity|.|was (r_prep) evaluated_3\VBN|NONE (l_nsubjpass) toxicity_1\NN|based|.|was
D014635_D005234 CID VPA_6\NNP|measured|that|,|treatment|in (r_compound) results_8\NNS|findings|Overall|,|. (l_advcl) measured_14\VBN|VPA|that|,|treatment|in (l_agent) by_15\IN|as (l_pobj) levels_16\NNS|NONE (l_relcl) precedes_21\VBZ|,|of (l_dobj) onset_23\NN|which (l_prep) of_24\IN|the (l_pobj) necrosis_25\NN|NONE (l_conj) steatosis_27\NN|,
D014635_D056486 CID acid_14\NN|NONE (r_compound) metabolite_15\NN|valproic|in (r_amod) levels_16\NNS|liver|and|, (r_conj) toxicity_10\NN|,|peroxidation
D014635_D056486 CID VPA_9\NNP| (r_npadvmod) associated_11\VBN|hepatotoxicity|and|oxidative|, (r_amod) stress_13\NN|NONE (l_conj) hepatotoxicity_15\NN|and|associated|oxidative|,
D014635_D056486 CID VPA_27\NNP|NONE (r_pobj) with_26\IN|were|for|.|daily|ip|rats|determine (r_prep) treated_24\VBN|NONE (l_advcl) determine_1\VB|were|for|.|with|daily|ip|rats (l_ccomp) was_4\VBD|To (l_attr) relationship_7\NN|there|whether (l_prep) between_8\IN|temporal|a (l_pobj) stress_13\NN|NONE (l_conj) hepatotoxicity_15\NN|and|associated|oxidative|,
D014635_D009336 CID VPA_6\NNP|measured|that|,|treatment|in (r_compound) results_8\NNS|findings|Overall|,|. (l_advcl) measured_14\VBN|VPA|that|,|treatment|in (l_agent) by_15\IN|as (l_pobj) levels_16\NNS|NONE (l_relcl) precedes_21\VBZ|,|of (l_dobj) onset_23\NN|which (l_prep) of_24\IN|the (l_pobj) necrosis_25\NN|NONE
C075750_D005234 NONE 15-F(2t)-IsoP_18\CD|NONE (r_pobj) of_17\IN|,|precedes (r_prep) levels_16\NNS|NONE (l_relcl) precedes_21\VBZ|,|of (l_dobj) onset_23\NN|which (l_prep) of_24\IN|the (l_pobj) necrosis_25\NN|NONE (l_conj) steatosis_27\NN|,
10743694
8494478
D002939_D007674 NONE Ciprofloxacin_0\NNP|nephrotoxicity|.| (r_npadvmod) induced_2\VBN|NONE (l_dobj) nephrotoxicity_3\NN|.|Ciprofloxacin|
D002939_D007674 NONE ciprofloxacin_3\NNS|NONE (r_pobj) with_2\IN|NONE (r_prep) associated_1\VBN|NONE (r_acl) Nephrotoxicity_0\NN|uncommon|.
D002939_D009369 NONE Ciprofloxacin_0\NNP|nephrotoxicity|.| (r_npadvmod) induced_2\VBN|NONE (l_dobj) nephrotoxicity_3\NN|.|Ciprofloxacin| (l_prep) in_4\IN|NONE (l_pobj) patients_5\NNS|NONE (l_prep) with_6\IN|NONE (l_pobj) cancer_7\NN|NONE
D002939_D009369 NONE ciprofloxacin_13\NNS|NONE (r_pobj) with_12\IN|NONE (r_prep) treatment_11\NN|that (r_dobj) followed_10\VBD|acute|renal (r_relcl) failure_8\NN|who (r_dobj) developed_5\VBD|with|Five (r_relcl) patients_1\NNS|are|reviewed|and (l_prep) with_2\IN|Five|developed (l_pobj) cancer_3\NN|NONE
D002939_D058186 CID ciprofloxacin_13\NNS|NONE (r_pobj) with_12\IN|NONE (r_prep) treatment_11\NN|that (r_dobj) followed_10\VBD|acute|renal (r_relcl) failure_8\NN|who
D002939_D058186 CID ciprofloxacin_18\NNS| (r_npadvmod) induced_20\VBN|renal|acute (r_amod) failure_23\NN|NONE
15266362
D004280_D004342 CID dobutamine_13\NN|that|hypersensitivity|was (r_xcomp) related_11\VBN|NONE (l_nsubjpass) hypersensitivity_5\NN|that|dobutamine|was
D004280_D009205 CID dobutamine_13\NN|that|hypersensitivity|was (r_xcomp) related_11\VBN|NONE (l_nsubjpass) hypersensitivity_5\NN|that|dobutamine|was (l_amod) myocarditis_9\NN|eosinophilic|(|)|the
D004280_D002312 NONE dobutamine_22\NN|drugs|and (r_compound) infusion_23\NN|NONE (r_pobj) with_21\IN|aggressively|assessed (r_prep) managed_19\VBD|with|patient|and|.|was (r_conj) admitted_14\VBN|NONE (l_nsubjpass) patient_5\NN|with|managed|and|.|was (l_acl) known_7\VBN|,|female|,|The|old (l_xcomp) have_9\VB|NONE (l_dobj) cardiomyopathy_11\NN|to
D004280_D004802 CID dobutamine_13\NN|that|hypersensitivity|was (r_xcomp) related_11\VBN|NONE (l_nsubjpass) hypersensitivity_5\NN|that|dobutamine|was (l_amod) eosinophilic_7\JJ|(|)|the|myocarditis
D004280_D018754 NONE dobutamine_22\NN|drugs|and (r_compound) infusion_23\NN|NONE (r_pobj) with_21\IN|aggressively|assessed (r_prep) managed_19\VBD|with|patient|and|.|was (r_conj) admitted_14\VBN|NONE (l_prep) with_15\IN|patient|managed|and|.|was (l_pobj) failure_17\NN|NONE
10406016
C007789_D007249 NONE Fucoidan_0\NNP| (r_npadvmod) treated_2\VBN|NONE (r_amod) rats_3\NNS|had|,|.|evidence (r_nsubj) exhibited_4\VBD|NONE (l_conj) had_13\VBD|rats|,|.|evidence (l_conj) tended_18\VBD|hematomas|and|, (l_xcomp) have_20\VB|NONE (l_dobj) inflammation_22\NN|to|after
C007789_D002543 NONE fucoidan_2\JJ|on (r_compound) treatment_3\NN|NONE (l_prep) on_4\IN|fucoidan (l_pobj) hemorrhage_9\NN|NONE
C007789_D002543 NONE fucoidan_5\RB|in|We|. (r_dobj) tested_1\VBD|NONE (l_prep) in_17\IN|fucoidan|We|. (l_pobj) model_20\NN|NONE (l_prep) of_21\IN|rat|induced|a (l_pobj) hemorrhage_23\NN|NONE
C007789_D020141 CID Fucoidan_0\NNP| (r_npadvmod) treated_2\VBN|NONE (r_amod) rats_3\NNS|had|,|.|evidence (r_nsubj) exhibited_4\VBD|NONE (l_dobj) evidence_5\NN|had|rats|,|. (l_prep) of_6\IN|NONE (l_pobj) clotting_9\NN|NONE
C007789_D020141 CID Fucoidan_0\NNP| (r_npadvmod) treated_2\VBN|NONE (r_amod) rats_3\NNS|had|,|.|evidence (r_nsubj) exhibited_4\VBD|NONE (l_dobj) evidence_5\NN|had|rats|,|. (l_prep) of_6\IN|NONE (l_pobj) clotting_9\NN|NONE (l_conj) hemodilution_11\NN|blood|impaired|and
C007789_D006406 NONE Fucoidan_0\NNP| (r_npadvmod) treated_2\VBN|NONE (r_amod) rats_3\NNS|had|,|.|evidence (r_nsubj) exhibited_4\VBD|NONE (l_conj) had_13\VBD|rats|,|.|evidence (l_dobj) hematomas_15\NNS|and|,|tended
C007789_D006406 NONE Fucoidan_0\NNP| (r_npadvmod) treated_2\VBN|NONE (r_amod) rats_3\NNS|had|,|.|evidence (r_nsubj) exhibited_4\VBD|NONE (l_conj) had_13\VBD|rats|,|.|evidence (l_conj) tended_18\VBD|hematomas|and|, (l_xcomp) have_20\VB|NONE (l_dobj) inflammation_22\NN|to|after (l_prep) in_23\IN|less (l_pobj) vicinity_25\NN|NONE (l_prep) of_26\IN|the (l_pobj) hematoma_28\NN|NONE
C007789_D001925 NONE fucoidan_5\RB|in|We|. (l_relcl) reported_10\VBN|sulfated|the|,|,|polysaccharide (l_xcomp) reduce_12\VB|has|been|which (l_dobj) damage_15\NN|to
10328196
D020123_D019559 CID sirolimus_5\NN|NONE (r_pobj) of_4\IN|NONE (r_prep) administration_3\NN|NONE (r_dobj) following_2\VBG|Systemic|for|rapamycin|association|)|:|.|( (r_prep) toxicity_1\NN|NONE (l_appos) association_13\NN|Systemic|for|rapamycin|following|)|:|.|( (l_prep) of_14\IN|with (l_pobj) syndrome_17\NN|NONE
D020123_D019559 CID rapamycin_8\VBZ|Systemic|for|association|following|)|:|.|( (r_appos) toxicity_1\NN|NONE (l_appos) association_13\NN|Systemic|for|rapamycin|following|)|:|.|( (l_prep) of_14\IN|with (l_pobj) syndrome_17\NN|NONE
D020123_D019559 CID sirolimus_14\NN|lesional|skin (r_nmod) cells_17\NNS|NONE (r_pobj) with_12\IN|NONE (r_prep) treatment_11\NN|NONE (r_pobj) following_10\VBG|leak|a (r_acl) syndrome_9\NN|and|individuals|After|.|analyzed
D020123_D019559 CID sirolimus_8\NN| (r_npadvmod) induced_10\VBN|leak (r_amod) syndrome_13\NN|NONE
D020123_D019559 CID sirolimus_32\NN| (r_npadvmod) treated_34\VBN|)|an|%|unaffected|(|with (r_amod) patient_35\NN|NONE (r_pobj) with_29\IN|NONE (r_prep) compared_28\VBN|increase|.|specimen (r_prep) had_14\VBD|NONE (l_nsubj) specimen_3\NN|increase|compared|. (l_prep) from_4\IN|skin|keratome|A (l_pobj) patient_6\NN|NONE (l_prep) with_7\IN| (l_pobj) syndrome_13\NN|NONE
D020123_D019559 CID sirolimus_4\NN|NONE (r_pobj) of_3\IN|adverse|Severe (r_prep) effects_2\NNS|fever|. (r_nsubj) include_5\VBP|NONE (l_dobj) fever_6\NN|effects|. (l_conj) anemia_8\NN|, (l_conj) syndrome_13\NN|and|,
D020123_D000740 NONE sirolimus_4\NN|NONE (r_pobj) of_3\IN|adverse|Severe (r_prep) effects_2\NNS|fever|. (r_nsubj) include_5\VBP|NONE (l_dobj) fever_6\NN|effects|. (l_conj) anemia_8\NN|,
D003907_D011565 NONE dexamethasone_15\NN| (r_npadvmod) induced_17\VBN|greater|or (r_conj) spontaneous_13\JJ|did (r_amod) apoptosis_18\NN|to (r_oprd) exhibit_11\VB|NONE (r_xcomp) tended_9\VBD|cells|. (r_ccomp) Activated_0\VBN|NONE (l_dobj) cells_4\NNS|tended|. (l_prep) from_5\IN|peripheral|T (l_pobj) patients_6\NNS|NONE (l_prep) with_7\IN|NONE (l_pobj) psoriasis_8\NN|NONE
D020123_D005334 NONE sirolimus_4\NN|NONE (r_pobj) of_3\IN|adverse|Severe (r_prep) effects_2\NNS|fever|. (r_nsubj) include_5\VBP|NONE (l_dobj) fever_6\NN|effects|.
D020123_D011565 NONE sirolimus_5\NN|NONE (r_pobj) of_4\IN|NONE (r_prep) administration_3\NN|NONE (r_dobj) following_2\VBG|Systemic|for|rapamycin|association|)|:|.|( (r_prep) toxicity_1\NN|NONE (l_prep) for_10\IN|Systemic|rapamycin|association|following|)|:|.|( (l_pobj) psoriasis_11\NN|NONE
D020123_D011565 NONE rapamycin_8\VBZ|Systemic|for|association|following|)|:|.|( (r_appos) toxicity_1\NN|NONE (l_prep) for_10\IN|Systemic|rapamycin|association|following|)|:|.|( (l_pobj) psoriasis_11\NN|NONE
D020123_D011565 NONE sirolimus_14\NN|lesional|skin (r_nmod) cells_17\NNS|NONE (r_pobj) with_12\IN|NONE (r_prep) treatment_11\NN|NONE (r_pobj) following_10\VBG|leak|a (r_acl) syndrome_9\NN|and|individuals|After|.|analyzed (r_dobj) developed_5\VBD|NONE (l_nsubj) individuals_2\NNS|and|After|syndrome|.|analyzed (l_prep) with_3\IN| (l_pobj) psoriasis_4\NN|NONE
D020123_D011565 NONE sirolimus_8\NN| (r_npadvmod) induced_10\VBN|leak (r_amod) syndrome_13\NN|NONE (r_pobj) with_7\IN| (r_prep) patient_6\NN|NONE (r_pobj) from_4\IN|skin|keratome|A (r_prep) specimen_3\NN|increase|compared|. (r_nsubj) had_14\VBD|NONE (l_prep) compared_28\VBN|increase|.|specimen (l_prep) with_29\IN|NONE (l_pobj) patient_35\NN|NONE (l_prep) with_36\IN|)|treated|an|%|unaffected|( (l_pobj) psoriasis_37\NN|NONE
D020123_D011565 NONE sirolimus_32\NN| (r_npadvmod) treated_34\VBN|)|an|%|unaffected|(|with (r_amod) patient_35\NN|NONE (l_prep) with_36\IN|)|treated|an|%|unaffected|( (l_pobj) psoriasis_37\NN|NONE
D020123_D011565 NONE sirolimus_30\NN|NONE (r_pobj) of_29\IN|the (r_prep) presence_28\NN|particularly (r_pobj) in_26\IN|,|than|cells (r_prep) did_20\VBD|spontaneous (r_advcl) apoptosis_18\NN|to (r_oprd) exhibit_11\VB|NONE (r_xcomp) tended_9\VBD|cells|. (r_ccomp) Activated_0\VBN|NONE (l_dobj) cells_4\NNS|tended|. (l_prep) from_5\IN|peripheral|T (l_pobj) patients_6\NNS|NONE (l_prep) with_7\IN|NONE (l_pobj) psoriasis_8\NN|NONE
D020123_D064420 NONE sirolimus_5\NN|NONE (r_pobj) of_4\IN|NONE (r_prep) administration_3\NN|NONE (r_dobj) following_2\VBG|Systemic|for|rapamycin|association|)|:|.|( (r_prep) toxicity_1\NN|NONE
D020123_D064420 NONE rapamycin_8\VBZ|Systemic|for|association|following|)|:|.|( (r_appos) toxicity_1\NN|NONE
2484011
D000588_D011596 NONE amines_6\NNS|NONE (r_pobj) of_3\IN|biochemical|The (r_prep) results_2\NNS|.|decrease (r_nsubj) suggest_13\VBP|NONE (l_dobj) decrease_16\NN|.|results (l_conj) increase_29\NN|by|a|probable|and|of (l_relcl) account_38\VB|in|a|resulting (l_prep) for_39\IN|which|may (l_pobj) depression_42\NN|NONE
D000547_D011596 CID amantadine_2\NN|NONE (r_pobj) of_1\IN|NONE (r_prep) Readministration_0\NN|in|,|.|motility|from|,|after|with (r_nsubj) increased_12\VBN|NONE (l_prep) with_21\IN|in|,|.|motility|from|,|after|Readministration (l_pobj) exception_22\NN|NONE (l_prep) of_23\IN|NONE (l_pobj) mice_28\NNS|NONE (l_relcl) occurred_33\VBD|the|C (l_nsubj) suppression_30\NN|where (l_prep) of_31\IN|NONE (l_pobj) motility_32\NN|NONE
D000547_D011596 CID amantadine_45\NN|NONE (r_pobj) by_44\IN|in (r_agent) caused_43\VBN|behavioral|a (r_acl) depression_42\NN|NONE
D009638_D011596 NONE norepinephrine_35\NN|NONE (r_pobj) of_34\IN|O| (r_prep) methylation_33\NN|NONE (r_pobj) in_30\IN|a|resulting|account (r_prep) increase_29\NN|by|a|probable|and|of (l_relcl) account_38\VB|in|a|resulting (l_prep) for_39\IN|which|may (l_pobj) depression_42\NN|NONE
D000547_D003866 NONE amantadine_4\JJ|locomotor|depressed (r_nmod) activity_7\NN|NONE (l_amod) depressed_5\JJ|locomotor|amantadine
D002395_D011596 NONE catecholamine_18\NN|turnover|metabolism|and/or (r_compound) rate_20\NN|NONE (r_pobj) of_17\IN|by|increase|a|probable|and (r_prep) decrease_16\NN|.|results (l_conj) increase_29\NN|by|a|probable|and|of (l_relcl) account_38\VB|in|a|resulting (l_prep) for_39\IN|which|may (l_pobj) depression_42\NN|NONE
18239197
D014282_D003221 NONE trihexyphenidyl_19\NN|NONE (l_prep) on_20\IN|NONE (l_pobj) measures_21\NNS|NONE (l_acl) reflecting_22\VBG|NONE (l_dobj) sedation_23\NN|NONE (l_conj) confusion_25\NN|and
D014282_D003221 NONE trihexyphenidyl_32\NN| (r_npadvmod) induced_34\VBN|and|subjective|performance (r_amod) effects_36\NNS|NONE (r_pobj) between_31\IN|the (r_prep) relationship_30\NN|to (r_dobj) investigate_28\VB|to|and|relationship (r_conj) examine_9\VB|.|objectives (l_dobj) relationship_11\NN|to|investigate|and (l_conj) effects_17\NNS|the|between (l_prep) of_18\IN|subjective (l_pobj) trihexyphenidyl_19\NN|NONE (l_prep) on_20\IN|NONE (l_pobj) measures_21\NNS|NONE (l_acl) reflecting_22\VBG|NONE (l_dobj) sedation_23\NN|NONE (l_conj) confusion_25\NN|and
D014282_D003072 CID trihexyphenidyl_10\JJ|NONE (r_pcomp) after_9\IN|with (r_prep) associated_3\VBN|.|mental|Increased (r_acl) slowing_2\NN|NONE
D014282_D003072 CID trihexyphenidyl_5\JJ|NONE (r_pobj) of_4\IN|oral|.mg|A (r_prep) dose_3\NN|in|. (r_nsubj) resulted_6\VBD|NONE (l_prep) in_7\IN|dose|. (l_pobj) ratings_10\NNS|NONE (l_prep) of_11\IN|subjective|increased (l_pobj) slowness_13\NN|NONE
D014282_D003072 CID trihexyphenidyl_10\JJ|NONE (r_pobj) between_7\IN|difference|on (r_prep) scores_6\NNS|NONE (l_prep) on_13\IN|difference|between (l_pobj) ratings_14\NNS|NONE (l_prep) of_15\IN|NONE (l_pobj) slowness_17\NN|NONE
D014282_D003072 CID trihexyphenidyl_14\JJ|anticholinergic (r_amod) challenge_16\NN|NONE (r_pobj) after_13\IN|subjective|mental|increased (r_prep) slowing_12\NN|NONE
11250767
D011441_D010493 CID Propylthiouracil_0\NNP| (r_npadvmod) induced_2\VBN|cytoplasmic|staining|in|positive|.|antineutrophil (r_amod) vasculitis_11\NN|NONE (l_prep) in_12\IN|induced|cytoplasmic|staining|positive|.|antineutrophil (l_pobj) conjunction_13\NN|NONE (l_prep) with_14\IN|NONE (l_pobj) pericarditis_15\NN|NONE
D011441_D010493 CID propylthiouracil_5\NN| (r_npadvmod) induced_7\VBN|manifesting (r_amod) vasculitis_8\NN|NONE (l_acl) manifesting_9\VBG|induced (l_prep) with_10\IN|NONE (l_pobj) pericarditis_11\NN|NONE
D011441_D010493 CID propylthiouracil_13\NN|NONE (l_relcl) developed_25\VBD|NONE (l_nsubj) syndrome_17\NN|in (l_prep) of_18\IN|a (l_pobj) pericarditis_19\NN|NONE
D011441_D010493 CID uracil_20\NN|propylthio (r_compound) therapy_21\NN|NONE (r_pobj) with_18\IN|NONE (r_prep) associated_17\VBN|MPO|positive (r_acl) vasculitis_16\NN|NONE (r_pobj) in_9\IN|no|prior|of (r_prep) reports_6\NNS|review|. (l_prep) of_7\IN|no|prior|in (l_pobj) pericarditis_8\NN|NONE
D011441_D010493 CID uracil_14\NN|NONE (r_compound) therapy_15\NN|NONE (r_appos) propylthio-_13\VB|NONE (r_pobj) to_12\IN|NONE (r_prep) attributable_11\JJ|of|initial|the (r_amod) manifestation_5\NN|may|.|Pericarditis (r_attr) be_2\VB|NONE (l_nsubj) Pericarditis_0\NNP|may|.|manifestation
D011441_D014657 NONE Propylthiouracil_0\NNP| (r_npadvmod) induced_2\VBN|cytoplasmic|staining|in|positive|.|antineutrophil (r_amod) vasculitis_11\NN|NONE
D011441_D014657 NONE propylthiouracil_5\NN| (r_npadvmod) induced_7\VBN|manifesting (r_amod) vasculitis_8\NN|NONE
D011441_D014657 NONE uracil_20\NN|propylthio (r_compound) therapy_21\NN|NONE (r_pobj) with_18\IN|NONE (r_prep) associated_17\VBN|MPO|positive (r_acl) vasculitis_16\NN|NONE
D011441_D014657 NONE uracil_14\NN|NONE (r_compound) therapy_15\NN|NONE (r_appos) propylthio-_13\VB|NONE (r_pobj) to_12\IN|NONE (r_prep) attributable_11\JJ|of|initial|the (r_amod) manifestation_5\NN|may|.|Pericarditis (l_prep) of_6\IN|attributable|initial|the (l_pobj) vasculitis_10\NN|NONE
D011441_D005921 CID propylthiouracil_13\NN|NONE (l_relcl) developed_25\VBD|NONE (l_nsubj) syndrome_17\NN|in (l_prep) of_18\IN|a (l_pobj) pericarditis_19\NN|NONE (l_conj) fever_21\NN|, (l_conj) glomerulonephritis_24\NN|and|,
D011441_D006980 NONE propylthiouracil_13\NN|NONE (r_pobj) with_12\IN|NONE (r_prep) treated_11\VBN|first|case|of|the (r_acl) report_5\NN|We|. (l_prep) of_6\IN|first|treated|case|the (l_pobj) woman_8\NN|NONE (l_prep) with_9\IN|a (l_pobj) hyperthyroidism_10\NN|NONE
D011441_D005334 CID propylthiouracil_13\NN|NONE (l_relcl) developed_25\VBD|NONE (l_nsubj) syndrome_17\NN|in (l_prep) of_18\IN|a (l_pobj) pericarditis_19\NN|NONE (l_conj) fever_21\NN|,
7053303
D002927_D007674 NONE cimetidine_10\NN|to|possibly (l_prep) in_27\IN|with|hr|(|) (l_pobj) group_29\NN|NONE (l_prep) of_30\IN|a (l_pobj) patients_32\NNS|NONE (l_prep) without_33\IN| (l_pobj) disease_37\NN|NONE
D002927_D007674 NONE cimetidine_40\JJ|NONE (r_compound) levels_41\NNS|above|who (r_dobj) had_39\VBD|liver (r_relcl) disease_37\NN|NONE
D002927_D003704 CID cimetidine_10\NN|to|possibly (r_pobj) due_8\IN|one|of (r_amod) case_4\NN|There|. (l_prep) of_5\IN|one|due (l_pobj) dementia_6\NN|NONE
D002927_D003704 CID cimetidine_40\JJ|NONE (r_compound) levels_41\NNS|above|who (r_dobj) had_39\VBD|liver (r_relcl) disease_37\NN|NONE (r_pobj) without_33\IN| (r_prep) patients_32\NNS|NONE (r_pobj) of_30\IN|a (r_prep) group_29\NN|NONE (r_pobj) in_27\IN|with|hr|(|) (r_prep) cimetidine_10\NN|to|possibly (r_pobj) due_8\IN|one|of (r_amod) case_4\NN|There|. (l_prep) of_5\IN|one|due (l_pobj) dementia_6\NN|NONE
D002927_D003704 CID cimetidine_3\NN|high|alone (r_compound) levels_4\NNS|always|do|Thus|.|,|dementia|not (r_nsubj) induce_9\VB|NONE (l_dobj) dementia_10\NN|always|levels|do|Thus|.|,|not
D002927_D008107 NONE cimetidine_10\NN|to|possibly (l_prep) in_27\IN|with|hr|(|) (l_pobj) group_29\NN|NONE (l_prep) of_30\IN|a (l_pobj) patients_32\NNS|NONE (l_prep) without_33\IN| (l_pobj) disease_37\NN|NONE
D002927_D008107 NONE cimetidine_40\JJ|NONE (r_compound) levels_41\NNS|above|who (r_dobj) had_39\VBD|liver (r_relcl) disease_37\NN|NONE
84204
D002927_D051437 NONE cimetidine_19\FW|,|P|renal|)|(|as|both (r_conj) dysfunction_8\NN|patients|.
D002927_D008107 NONE cimetidine_19\FW|,|P|renal|)|(|as|both (r_conj) dysfunction_8\NN|patients|.
D002927_D003221 CID cimetidine_7\NN| (r_npadvmod) associated_9\VBN|mental (r_amod) confusion_11\NN|NONE
D002927_D003221 CID cimetidine_3\NN| (r_npadvmod) associated_5\VBN|mental (r_amod) confusion_7\NN|NONE
6666578
D010396_D001018 CID penicillamine_2\NN|in||.|angiopathy (r_compound) induced_4\VBN|NONE (l_advmod) angiopathy_5\NN|in||.|penicillamine
8677458
D007069_D064420 NONE ifosfamide_8\NN|NONE (r_pobj) of_7\IN|potential|prevented|major|a (r_prep) toxicity_6\NN|.|cystitis
D015080_D064420 NONE mesna_15\NN|along (r_dobj) administering_14\VBG|NONE (r_pcomp) by_13\IN|that|can|be (r_agent) prevented_12\VBN|of|potential|major|a (r_relcl) toxicity_6\NN|.|cystitis
D007069_D006470 CID ifosfamide_7\RB| (r_advmod) induced_9\VBN|hemorrhagic (r_amod) cystitis_11\NN|to
D007069_D006470 CID ifosfamide_8\NN|NONE (r_pobj) of_7\IN|potential|prevented|major|a (r_prep) toxicity_6\NN|.|cystitis (r_attr) is_2\VBZ|NONE (l_nsubj) cystitis_1\NN|.|toxicity
D015080_D006470 CID mesna_4\NN|NONE (r_pobj) of_3\IN|.|prevent|Continuous|subcutaneous (r_prep) administration_2\NN|NONE (l_relcl) prevent_6\VB|.|Continuous|of|subcutaneous (l_dobj) cystitis_11\NN|to
D015080_D006470 CID mesna_15\NN|along (r_dobj) administering_14\VBG|NONE (r_pcomp) by_13\IN|that|can|be (r_agent) prevented_12\VBN|of|potential|major|a (r_relcl) toxicity_6\NN|.|cystitis (r_attr) is_2\VBZ|NONE (l_nsubj) cystitis_1\NN|.|toxicity
D007069_D003556 CID ifosfamide_7\RB| (r_advmod) induced_9\VBN|hemorrhagic (r_amod) cystitis_11\NN|to
D007069_D003556 CID ifosfamide_8\NN|NONE (r_pobj) of_7\IN|potential|prevented|major|a (r_prep) toxicity_6\NN|.|cystitis (r_attr) is_2\VBZ|NONE (l_nsubj) cystitis_1\NN|.|toxicity
D015080_D014839 NONE mesna_19\NN|as|,|inadequate (r_compound) concentrations_20\NNS|NONE (l_prep) as_23\IN|,|inadequate|mesna (l_prep) in_24\IN|such (l_pobj) patient_26\NN|NONE (l_relcl) experiences_31\VBZ|taking|a (l_dobj) emesis_36\NN|is|who|and
D015080_D014839 NONE mesna_29\NN|NONE (r_dobj) taking_27\VBG|experiences|a (r_acl) patient_26\NN|NONE (l_relcl) experiences_31\VBZ|taking|a (l_dobj) emesis_36\NN|is|who|and
D007069_D014839 NONE ifosfamide_33\RB| (r_advmod) induced_35\VBN|severe (r_amod) emesis_36\NN|is|who|and
D015080_D003556 CID mesna_4\NN|NONE (r_pobj) of_3\IN|.|prevent|Continuous|subcutaneous (r_prep) administration_2\NN|NONE (l_relcl) prevent_6\VB|.|Continuous|of|subcutaneous (l_dobj) cystitis_11\NN|to
D015080_D003556 CID mesna_15\NN|along (r_dobj) administering_14\VBG|NONE (r_pcomp) by_13\IN|that|can|be (r_agent) prevented_12\VBN|of|potential|major|a (r_relcl) toxicity_6\NN|.|cystitis (r_attr) is_2\VBZ|NONE (l_nsubj) cystitis_1\NN|.|toxicity
3120485
1601297
D003042_D012559 NONE cocaine_7\NN| (r_npadvmod) abusing_9\VBG| (r_amod) patients_10\NNS|NONE (r_pobj) of_5\IN|(|) (r_prep) ECG_3\NNP|The (r_appos) electrocardiograms_1\NNS|.|were|with (r_nsubjpass) compared_12\VBN|NONE (l_prep) with_13\IN|.|were|electrocardiograms (l_pobj) ECGs_15\NNS|NONE (l_prep) of_16\IN|the (l_pobj) controls_19\NNS|NONE (l_amod) schizophrenic_18\JJ|
D003042_D009202 NONE cocaine_8\NN|hospitalized (r_compound) abusers_9\NNS|NONE (r_pobj) in_5\IN|myocardial (r_prep) injury_4\NN|NONE
D003042_D009202 NONE cocaine_3\NN|the (r_compound) abusers_4\NNS|NONE (r_pobj) of_1\IN|and|none (r_prep) Eleven_0\CD|evidence|. (r_nsubj) had_10\VBD|NONE (l_dobj) evidence_12\NN|Eleven|. (l_prep) of_13\IN|ECG (l_pobj) injury_16\NN|NONE
D003042_D007511 NONE cocaine_3\NN|the (r_compound) abusers_4\NNS|NONE (r_pobj) of_1\IN|and|none (r_prep) Eleven_0\CD|evidence|. (r_nsubj) had_10\VBD|NONE (l_dobj) evidence_12\NN|Eleven|. (l_prep) of_13\IN|ECG (l_pobj) injury_16\NN|NONE (l_acl) defined_17\VBN|significant|myocardial (l_prep) as_18\IN|NONE (l_pobj) infarction_20\NN|NONE (l_conj) ischemia_22\NN|,|myocardial
D003042_D009203 CID cocaine_3\NN|the (r_compound) abusers_4\NNS|NONE (r_pobj) of_1\IN|and|none (r_prep) Eleven_0\CD|evidence|. (r_nsubj) had_10\VBD|NONE (l_dobj) evidence_12\NN|Eleven|. (l_prep) of_13\IN|ECG (l_pobj) injury_16\NN|NONE (l_acl) defined_17\VBN|significant|myocardial (l_prep) as_18\IN|NONE (l_pobj) infarction_20\NN|NONE
D003042_D002037 CID cocaine_3\NN|the (r_compound) abusers_4\NNS|NONE (r_pobj) of_1\IN|and|none (r_prep) Eleven_0\CD|evidence|. (r_nsubj) had_10\VBD|NONE (l_dobj) evidence_12\NN|Eleven|. (l_prep) of_13\IN|ECG (l_pobj) injury_16\NN|NONE (l_acl) defined_17\VBN|significant|myocardial (l_prep) as_18\IN|NONE (l_pobj) infarction_20\NN|NONE (l_conj) ischemia_22\NN|,|myocardial (l_conj) block_27\NN|and|,
8742498
D011064_D056486 NONE )_19\-RRB-|PARP|;|)|EC|ribose|( (r_punct) polymerase_20\NN|NONE (r_pobj) of_15\IN|selective|on|a (r_prep) inhibitor_14\NN|acid|nicotinic|, (r_appos) amide_10\NN|NONE (r_pobj) of_7\IN|the|hepatoprotective (r_prep) effects_6\NNS|,|AAP)hepatitis|we|.|suggesting|Recently|, (r_dobj) demonstrated_3\VBD|NONE (l_npadvmod) AAP)-hepatitis_33\NNP|,|we|.|suggesting|Recently|effects|,
D011064_D056486 NONE )_19\-RRB-|PARP|;|)|EC|ribose|( (r_punct) polymerase_20\NN|NONE (r_pobj) of_15\IN|selective|on|a (r_prep) inhibitor_14\NN|acid|nicotinic|, (r_appos) amide_10\NN|NONE (r_pobj) of_7\IN|the|hepatoprotective (r_prep) effects_6\NNS|,|AAP)hepatitis|we|.|suggesting|Recently|, (r_dobj) demonstrated_3\VBD|NONE (l_advcl) suggesting_35\VBG|,|AAP)hepatitis|we|.|Recently|effects|, (l_ccomp) involves_43\VBZ|NONE (l_nsubj) injury_42\NN|that|step
D019289_D056486 NONE pyruvate_18\NN|(|GPT|) (r_compound) transaminase_19\NN|)|GOT|(|and|oxaloacetate (r_conj) transaminase_11\NN|NONE (r_pobj) of_7\IN|serum (r_prep) activities_6\NNS|NONE (r_pobj) as_4\IN|injuries|.|were (r_prep) quantified_3\VBN|NONE (l_nsubjpass) injuries_1\NNS|as|.|were
D009243_D056486 NONE NAD_5\NNP| (r_compound) precursors_7\NNS|NONE (r_pobj) of_4\IN|on (r_prep) free_3\JJ|.|of (l_prep) on_8\IN|of (l_pobj) hepatotoxicity_10\NN|acetaminophen
D009243_D056486 NONE NAD_13\NNP|NONE (l_appos) substrate_16\NN|, (l_relcl) acts_20\VBZ|the (l_prep) in_22\IN|and|evaluates|,|on|PARP (l_pobj) mice_25\NNS|NONE (l_prep) with_26\IN|NMRI|female (l_pobj) hepatitis_28\NN|NONE
D009243_D056486 NONE NAD_37\NNP|enzyme (r_appos) substrate_36\NN|NONE (r_pobj) of_32\IN|dietary (r_prep) depletion_31\NN|NONE (r_pobj) by_29\IN|NAA|or (r_conj) by_26\IN|product|of (r_prep) inhibition_23\NN|NONE (r_pobj) by_19\IN|hepatitis|that|either|be|can (r_agent) reduced_18\VBN|NONE (l_nsubjpass) hepatitis_9\NN|by|that|either|be|can
D009536_D056486 NONE amide_10\NN|NONE (r_pobj) of_7\IN|the|hepatoprotective (r_prep) effects_6\NNS|,|AAP)hepatitis|we|.|suggesting|Recently|, (r_dobj) demonstrated_3\VBD|NONE (l_npadvmod) AAP)-hepatitis_33\NNP|,|we|.|suggesting|Recently|effects|,
D009536_D056486 NONE amide_10\NN|NONE (r_pobj) of_7\IN|the|hepatoprotective (r_prep) effects_6\NNS|,|AAP)hepatitis|we|.|suggesting|Recently|, (r_dobj) demonstrated_3\VBD|NONE (l_advcl) suggesting_35\VBG|,|AAP)hepatitis|we|.|Recently|effects|, (l_ccomp) involves_43\VBZ|NONE (l_nsubj) injury_42\NN|that|step
D009536_D056486 NONE NAA_11\NNP|when|was|to (r_nsubjpass) given_13\VBN|,|reduction|was|. (r_advcl) observed_8\VBN|NONE (l_nsubjpass) reduction_4\NN|,|given|was|. (l_prep) of_5\IN|further|%|A (l_pobj) hepatitis_6\NN|NONE
D009536_D056486 NONE NAA_27\NNP|by|or (r_pobj) by_26\IN|product|of (r_prep) inhibition_23\NN|NONE (r_pobj) by_19\IN|hepatitis|that|either|be|can (r_agent) reduced_18\VBN|NONE (l_nsubjpass) hepatitis_9\NN|by|that|either|be|can
D009536_D056486 NONE NAA_6\NNP|NONE (r_pobj) of_5\IN|the|main (r_prep) application_4\NN|in|as|We|. (r_dobj) see_1\VBP|NONE (l_prep) in_17\IN|as|We|.|application (l_pobj) order_18\NN|NONE (l_acl) avoid_20\VB|NONE (l_dobj) damage_22\NN|to
D062907_D056486 NONE oxaloacetate_10\NN|)|transaminase|GOT|(|and (r_compound) transaminase_11\NN|NONE (r_pobj) of_7\IN|serum (r_prep) activities_6\NNS|NONE (r_pobj) as_4\IN|injuries|.|were (r_prep) quantified_3\VBN|NONE (l_nsubjpass) injuries_1\NNS|as|.|were
D000431_D056486 CID ethanol_35\NN|simultaneous|in (r_compound) consumption_36\NN|NONE (r_pobj) of_33\IN|the (r_prep) influence_32\NN|NONE (r_dobj) evaluates_30\VBZ|and|in|,|on|PARP (r_conj) acts_20\VBZ|the (l_prep) in_22\IN|and|evaluates|,|on|PARP (l_pobj) mice_25\NNS|NONE (l_prep) with_26\IN|NMRI|female (l_pobj) hepatitis_28\NN|NONE
D000431_D056486 CID ethanol_25\NN|NONE (r_pobj) by_24\IN|in|on (r_agent) caused_23\VBN|the (r_acl) exacerbation_22\NN|NONE (r_pobj) unlike_20\IN|.|damage|,|was|by (r_prep) inhibited_37\VBN|In|,|were|increases|,|and|in (l_nsubjpass) damage_35\NN|unlike|.|,|was|by
D000431_D056486 CID ethanol_42\NN|NONE (r_pobj) by_41\IN| (r_prep) %_40\NN|NONE (r_pobj) by_38\IN|unlike|.|damage|,|was (r_agent) inhibited_37\VBN|In|,|were|increases|,|and|in (l_nsubjpass) damage_35\NN|unlike|.|,|was|by
D000431_D056486 CID ethanol_15\NN|AAP||/ (r_nmod) mice_19\NNS|NONE (r_pobj) to_14\IN|when|NAA|was (r_dative) given_13\VBN|,|reduction|was|. (r_advcl) observed_8\VBN|NONE (l_nsubjpass) reduction_4\NN|,|given|was|. (l_prep) of_5\IN|further|%|A (l_pobj) hepatitis_6\NN|NONE
D000431_D056486 CID ethanol_14\NN|NONE (r_pobj) by_13\IN|its (r_prep) exacerbation_12\NN|induced|and|the (r_conj) hepatitis_9\NN|by|that|either|be|can
D018698_D056486 NONE glutamate_8\NN| (r_compound) oxaloacetate_10\NN|)|transaminase|GOT|(|and (r_compound) transaminase_11\NN|NONE (r_pobj) of_7\IN|serum (r_prep) activities_6\NNS|NONE (r_pobj) as_4\IN|injuries|.|were (r_prep) quantified_3\VBN|NONE (l_nsubjpass) injuries_1\NNS|as|.|were
D018698_D056486 NONE glutamate_16\NN| (r_npadvmod) pyruvate_18\NN|(|GPT|) (r_compound) transaminase_19\NN|)|GOT|(|and|oxaloacetate (r_conj) transaminase_11\NN|NONE (r_pobj) of_7\IN|serum (r_prep) activities_6\NNS|NONE (r_pobj) as_4\IN|injuries|.|were (r_prep) quantified_3\VBN|NONE (l_nsubjpass) injuries_1\NNS|as|.|were
D000082_D056486 CID acetaminophen_9\NN|hepatotoxicity (r_pobj) on_8\IN|of (l_pobj) hepatotoxicity_10\NN|acetaminophen
D000082_D056486 CID acetaminophen_31\NN|NONE (r_pobj) from_30\IN|mice (r_prep) suffering_29\VBG|NONE (r_pcomp) on_27\IN|selective|a|of (r_prep) inhibitor_14\NN|acid|nicotinic|, (r_appos) amide_10\NN|NONE (r_pobj) of_7\IN|the|hepatoprotective (r_prep) effects_6\NNS|,|AAP)hepatitis|we|.|suggesting|Recently|, (r_dobj) demonstrated_3\VBD|NONE (l_npadvmod) AAP)-hepatitis_33\NNP|,|we|.|suggesting|Recently|effects|,
D000082_D056486 CID acetaminophen_31\NN|NONE (r_pobj) from_30\IN|mice (r_prep) suffering_29\VBG|NONE (r_pcomp) on_27\IN|selective|a|of (r_prep) inhibitor_14\NN|acid|nicotinic|, (r_appos) amide_10\NN|NONE (r_pobj) of_7\IN|the|hepatoprotective (r_prep) effects_6\NNS|,|AAP)hepatitis|we|.|suggesting|Recently|, (r_dobj) demonstrated_3\VBD|NONE (l_advcl) suggesting_35\VBG|,|AAP)hepatitis|we|.|Recently|effects|, (l_ccomp) involves_43\VBZ|NONE (l_nsubj) injury_42\NN|that|step
D000082_D056486 CID AAP)-hepatitis_33\NNP|,|we|.|suggesting|Recently|effects|,
D000082_D056486 CID AAP)-hepatitis_33\NNP|,|we|.|suggesting|Recently|effects|, (r_npadvmod) demonstrated_3\VBD|NONE (l_advcl) suggesting_35\VBG|,|AAP)hepatitis|we|.|Recently|effects|, (l_ccomp) involves_43\VBZ|NONE (l_nsubj) injury_42\NN|that|step
D000082_D056486 CID AAP_38\NNP| (r_npadvmod) induced_40\VBN|liver|the (r_amod) injury_42\NN|that|step (r_nsubj) involves_43\VBZ|NONE (r_ccomp) suggesting_35\VBG|,|AAP)hepatitis|we|.|Recently|effects|, (r_advcl) demonstrated_3\VBD|NONE (l_npadvmod) AAP)-hepatitis_33\NNP|,|we|.|suggesting|Recently|effects|,
D000082_D056486 CID AAP_38\NNP| (r_npadvmod) induced_40\VBN|liver|the (r_amod) injury_42\NN|that|step
D000082_D056486 CID AAP_27\NNP|NONE (r_compound) hepatitis_28\NN|NONE
D000082_D056486 CID AAP_17\NNP|NONE (r_pobj) of_16\IN|the (r_prep) presence_15\NN|NONE (r_pobj) in_13\IN|In|,|were|increases|inhibited|,|and (r_prep) measured_12\VBN|NONE (l_conj) inhibited_37\VBN|In|,|were|increases|,|and|in (l_nsubjpass) damage_35\NN|unlike|.|,|was|by
D000082_D056486 CID AAP_17\NNP|ethanol||/ (r_compound) mice_19\NNS|NONE (r_pobj) to_14\IN|when|NAA|was (r_dative) given_13\VBN|,|reduction|was|. (r_advcl) observed_8\VBN|NONE (l_nsubjpass) reduction_4\NN|,|given|was|. (l_prep) of_5\IN|further|%|A (l_pobj) hepatitis_6\NN|NONE
D000082_D056486 CID AAP_6\NNP| (r_npadvmod) induced_8\VBN|exacerbation|and|the (r_amod) hepatitis_9\NN|by|that|either|be|can
D000082_D056486 CID acetaminophen_16\NN|NONE (r_pobj) of_15\IN|pharmaceutical (r_prep) preparations_14\NNS|NONE (r_pobj) in_12\IN|combinational|the (r_prep) use_11\NN|NONE (r_pobj) for_8\IN|NONE (r_prep) as_7\IN|in|We|.|application (r_prep) see_1\VBP|NONE (l_prep) in_17\IN|as|We|.|application (l_pobj) order_18\NN|NONE (l_acl) avoid_20\VB|NONE (l_dobj) damage_22\NN|to
10739826
D003276_D054556 CID contraceptives_5\NNS|NONE (l_conj) risk_8\NN|newer|oral|and (l_prep) of_9\IN|the (l_pobj) thromboembolism_11\NN|NONE
D003276_D054556 CID contraceptives_17\NNS|NONE (r_pobj) with_14\IN|NONE (r_prep) associated_13\VBN|venous|(|VTE|) (r_acl) thromboembolism_9\NN|NONE
D003276_D054556 CID contraceptives_17\NNS|NONE (r_pobj) with_14\IN|NONE (r_prep) associated_13\VBN|venous|(|VTE|) (r_acl) thromboembolism_9\NN|NONE (l_appos) VTE_11\NNP|venous|associated|(|)
D003276_D054556 CID OC_19\NNP|oral|newer (r_appos) contraceptives_17\NNS|NONE (r_pobj) with_14\IN|NONE (r_prep) associated_13\VBN|venous|(|VTE|) (r_acl) thromboembolism_9\NN|NONE
D003276_D054556 CID OC_19\NNP|oral|newer (r_appos) contraceptives_17\NNS|NONE (r_pobj) with_14\IN|NONE (r_prep) associated_13\VBN|venous|(|VTE|) (r_acl) thromboembolism_9\NN|NONE (l_appos) VTE_11\NNP|venous|associated|(|)
D003276_D054556 CID OC_27\NNP|,|users (r_compound) use_28\NN|NONE (r_pobj) of_26\IN|NONE (r_prep) patterns_25\NNS|NONE (r_pobj) between_24\IN|studies|.|did|not (r_prep) distinguish_23\VB|NONE (l_nsubj) studies_2\NNS|.|did|not|between (l_relcl) assessed_4\VBD|epidemiological|The (l_dobj) risk_6\NN|that (l_prep) of_7\IN|the (l_pobj) thromboembolism_9\NN|NONE
D003276_D054556 CID OC_27\NNP|,|users (r_compound) use_28\NN|NONE (r_pobj) of_26\IN|NONE (r_prep) patterns_25\NNS|NONE (r_pobj) between_24\IN|studies|.|did|not (r_prep) distinguish_23\VB|NONE (l_nsubj) studies_2\NNS|.|did|not|between (l_relcl) assessed_4\VBD|epidemiological|The (l_dobj) risk_6\NN|that (l_prep) of_7\IN|the (l_pobj) thromboembolism_9\NN|NONE (l_appos) VTE_11\NNP|venous|associated|(|)
D003276_D054556 CID OC_12\NNP|NONE (r_pobj) of_9\IN|repeat (r_prep) users_8\NNS|NONE (r_pobj) for_6\IN|The|adjusted|of|rate (r_prep) ratio_3\NN|%|was|repeat|.|, (l_prep) of_4\IN|for|The|adjusted|rate (l_pobj) VTE_5\NN|NONE
15974569
D007608_D010146 NONE kainate_7\NN|GluR|receptor|potent (r_compound) antagonists_9\NNS|in (r_compound) actives_10\NNS|NONE (l_prep) in_11\IN|antagonists (l_pobj) models_14\NNS|NONE (l_prep) of_15\IN|animal|three (l_pobj) pain_16\NN|NONE
D005557_D010146 NONE formalin_17\NN| (r_npadvmod) induced_19\VBN|paw (r_amod) licking_21\NN|NONE (r_pobj) of_16\IN|hyperalgesia|, (r_prep) reversal_15\NN|:|three|of (r_appos) models_11\NNS|NONE (l_prep) of_12\IN|:|reversal|three (l_pobj) pain_13\NN|NONE
D005557_D006930 NONE formalin_17\NN| (r_npadvmod) induced_19\VBN|paw (r_amod) licking_21\NN|NONE (r_pobj) of_16\IN|hyperalgesia|, (r_prep) reversal_15\NN|:|three|of (l_conj) hyperalgesia_27\NN|,|of
D005557_D006930 NONE formalin_17\NN| (r_npadvmod) induced_19\VBN|paw (r_amod) licking_21\NN|NONE (r_pobj) of_16\IN|hyperalgesia|, (r_prep) reversal_15\NN|:|three|of (l_conj) hyperalgesia_27\NN|,|of (l_conj) hyperalgesia_34\NN|induced|thermal|,|and
D002211_D010146 NONE capsaicin_30\NN| (r_npadvmod) induced_32\VBN|mechanical (r_amod) hyperalgesia_34\NN|induced|thermal|,|and (r_conj) hyperalgesia_27\NN|,|of (r_conj) reversal_15\NN|:|three|of (r_appos) models_11\NNS|NONE (l_prep) of_12\IN|:|reversal|three (l_pobj) pain_13\NN|NONE
D002351_D010146 NONE carrageenan_23\NN| (r_npadvmod) induced_25\VBN|thermal|,|and|hyperalgesia (r_amod) hyperalgesia_27\NN|,|of (r_conj) reversal_15\NN|:|three|of (r_appos) models_11\NNS|NONE (l_prep) of_12\IN|:|reversal|three (l_pobj) pain_13\NN|NONE
D002211_D006930 CID capsaicin_30\NN| (r_npadvmod) induced_32\VBN|mechanical (r_amod) hyperalgesia_34\NN|induced|thermal|,|and (r_conj) hyperalgesia_27\NN|,|of
D002211_D006930 CID capsaicin_30\NN| (r_npadvmod) induced_32\VBN|mechanical (r_amod) hyperalgesia_34\NN|induced|thermal|,|and
D002351_D006930 CID carrageenan_23\NN| (r_npadvmod) induced_25\VBN|thermal|,|and|hyperalgesia (r_amod) hyperalgesia_27\NN|,|of
D002351_D006930 CID carrageenan_23\NN| (r_npadvmod) induced_25\VBN|thermal|,|and|hyperalgesia (r_amod) hyperalgesia_27\NN|,|of (l_conj) hyperalgesia_34\NN|induced|thermal|,|and
2004015
D015215_D007239 NONE AZT_28\NNP| (r_npadvmod) induced_30\VBN|NONE (r_amod) anaemia_31\NN|due|,|in|if (r_nsubj) is_32\VBZ|to (r_ccomp) determine_26\VB|.|We|model|decreased|,|have (r_xcomp) used_2\VBN|NONE (l_dobj) model_5\NN|determine|.|We|decreased|,|have (l_prep) of_6\IN|a|murine (l_pobj) AIDS_7\NNP|NONE (l_appos) infection_9\NN|,
D015215_C565469 NONE azidothymidine_8\NN|mice|.|Sensitivity (r_advmod) treated_9\VBN|NONE (l_dobj) mice_11\NNS|azidothymidine|.|Sensitivity (l_amod) immunodeficient_10\JJ|NONE
C030299_D000740 NONE phenylhydrazine_22\NN|)|mice|(|PHZ (r_npadvmod) treated_26\VBD|.|levels|in|were|treated (r_conj) observed_6\VBD|NONE (l_conj) were_11\VBD|.|levels|in|treated|treated (l_acomp) appropriate_12\JJ|NONE (l_prep) for_13\IN|NONE (l_pobj) degree_15\NN|NONE (l_prep) of_16\IN|observed|the (l_pobj) anaemia_17\NN|NONE
C030299_D000740 NONE PHZ_24\NNP|)|mice|(|phenylhydrazine (r_nsubj) treated_26\VBD|.|levels|in|were|treated (r_conj) observed_6\VBD|NONE (l_conj) were_11\VBD|.|levels|in|treated|treated (l_acomp) appropriate_12\JJ|NONE (l_prep) for_13\IN|NONE (l_pobj) degree_15\NN|NONE (l_prep) of_16\IN|observed|the (l_pobj) anaemia_17\NN|NONE
C030299_D000740 NONE PHZ_19\NNP|and (r_conj) AZT_17\NNP|mice|with (r_nsubj) treated_20\VBD|were|numbers|. (l_prep) with_22\IN|mice|AZT (l_pobj) degrees_24\NNS|NONE (l_prep) of_25\IN|similar (l_pobj) anaemia_26\NN|NONE
D015215_D007938 NONE AZT_28\NNP| (r_npadvmod) induced_30\VBN|NONE (r_amod) anaemia_31\NN|due|,|in|if (r_nsubj) is_32\VBZ|to (r_ccomp) determine_26\VB|.|We|model|decreased|,|have (r_xcomp) used_2\VBN|NONE (l_dobj) model_5\NN|determine|.|We|decreased|,|have (l_prep) of_6\IN|a|murine (l_pobj) AIDS_7\NNP|NONE (l_appos) infection_9\NN|, (l_prep) of_10\IN|NONE (l_pobj) mice_13\NNS|NONE (l_prep) with_14\IN|CBL/|female (l_pobj) leukaemia_19\NN|NONE
D015215_D045262 NONE AZT_12\NNP|NONE (r_pobj) in_11\IN|NONE (r_prep) observed_10\VBN|of|the (r_acl) degree_7\NN|NONE (r_pobj) for_5\IN|NONE (r_prep) inappropriate_4\JJ|.|However|treated|,|reticulocytosis (r_acomp) was_3\VBD|NONE (l_nsubj) reticulocytosis_2\NN|inappropriate|.|However|treated|,
D015215_D000740 CID 3'-azido-3'dideoxythymidine_4\NN|NONE (r_pobj) by_3\IN|NONE (r_agent) induced_2\VBN|The (r_acl) anaemia_1\NN|is|poorly|.
D015215_D000740 CID AZT_6\NNP|NONE (r_appos) 3'-azido-3'dideoxythymidine_4\NN|NONE (r_pobj) by_3\IN|NONE (r_agent) induced_2\VBN|The (r_acl) anaemia_1\NN|is|poorly|.
D015215_D000740 CID AZT_28\NNP| (r_npadvmod) induced_30\VBN|NONE (r_amod) anaemia_31\NN|due|,|in|if
D015215_D000740 CID AZT_0\NNP|,|in|anaemia|.|in (r_nsubj) produced_1\VBD|NONE (l_dobj) anaemia_2\NN|,|in|AZT|.|in
D015215_D000740 CID AZT_15\NNP|NONE (r_pobj) in_14\IN|marrow||BFU (r_prep) e_13\NNP|NONE (r_pobj) of_6\IN|the (r_prep) number_5\NN|,|Despite|mice (r_nsubj) treated_16\VBD|over|observed|to|.|up (l_prep) Despite_0\IN|,|number|mice (l_pobj) anaemia_2\NN|NONE
D015215_D000740 CID AZT_8\NNP|NONE (r_pobj) in_7\IN|.|levels|were|treated|treated (r_prep) observed_6\VBD|NONE (l_conj) were_11\VBD|.|levels|in|treated|treated (l_acomp) appropriate_12\JJ|NONE (l_prep) for_13\IN|NONE (l_pobj) degree_15\NN|NONE (l_prep) of_16\IN|observed|the (l_pobj) anaemia_17\NN|NONE
D015215_D000740 CID AZT_17\NNP|mice|with (r_nsubj) treated_20\VBD|were|numbers|. (l_prep) with_22\IN|mice|AZT (l_pobj) degrees_24\NNS|NONE (l_prep) of_25\IN|similar (l_pobj) anaemia_26\NN|NONE
D015215_D000740 CID AZT_12\NNP|NONE (r_pobj) in_11\IN|NONE (r_prep) observed_10\VBN|of|the (r_acl) degree_7\NN|NONE (l_prep) of_8\IN|observed|the (l_pobj) anaemia_9\NN|NONE
D015215_D000740 CID AZT_0\NNP||in|levels|anaemia|and (r_npadvmod) induced_2\VBN|NONE (l_dobj) anaemia_4\NN||in|AZT|levels|and
D015215_D000163 NONE AZT_28\NNP| (r_npadvmod) induced_30\VBN|NONE (r_amod) anaemia_31\NN|due|,|in|if (r_nsubj) is_32\VBZ|to (r_ccomp) determine_26\VB|.|We|model|decreased|,|have (r_xcomp) used_2\VBN|NONE (l_dobj) model_5\NN|determine|.|We|decreased|,|have (l_prep) of_6\IN|a|murine (l_pobj) AIDS_7\NNP|NONE
10365197
D003042_D019964 CID Cocaine_0\NN| (r_npadvmod) induced_2\VBN|.|:|mood|rates (r_amod) disorder_4\NN|NONE
D003042_D019964 CID cocaine_14\NN| (r_npadvmod) dependent_16\JJ|an|outpatient (r_amod) sample_17\NN|NONE (r_pobj) in_11\IN|symptoms|and|prevalence (r_prep) rates_7\NNS|.|:|induced|mood (r_appos) disorder_4\NN|NONE
D003042_D019964 CID cocaine_1\NN| (r_npadvmod) dependent_3\JJ|disorders|with|,| (r_amod) outpatients_4\NNS|were|on|. (l_prep) with_5\IN|disorders|,|dependent| (l_pobj) disorder_10\NN|NONE
D003042_D019964 CID cocaine_1\NN| (r_npadvmod) dependent_3\JJ|disorders|with|,| (r_amod) outpatients_4\NNS|were|on|. (l_conj) disorders_17\NNS|with|,|dependent|
D003042_D019964 CID cocaine_1\NN| (r_npadvmod) dependent_3\JJ|disorders|with|,| (r_amod) outpatients_4\NNS|were|on|. (l_conj) disorders_17\NNS|with|,|dependent| (l_conj) disorder_22\NN|,|or|mood|other
D003042_D019964 CID cocaine_6\NN| (r_npadvmod) induced_8\VBN|CIMD|)|mood|( (r_amod) disorder_10\NN|NONE
D003042_D019964 CID cocaine_6\NN| (r_npadvmod) induced_8\VBN|CIMD|)|mood|( (r_amod) disorder_10\NN|NONE (r_pobj) with_5\IN|disorders|,|dependent| (r_prep) outpatients_4\NNS|were|on|. (l_conj) disorders_17\NNS|with|,|dependent|
D003042_D019964 CID cocaine_6\NN| (r_npadvmod) induced_8\VBN|CIMD|)|mood|( (r_amod) disorder_10\NN|NONE (r_pobj) with_5\IN|disorders|,|dependent| (r_prep) outpatients_4\NNS|were|on|. (l_conj) disorders_17\NNS|with|,|dependent| (l_conj) disorder_22\NN|,|or|mood|other
D003042_D001523 NONE Cocaine_0\NN| (r_npadvmod) induced_2\VBN|.|:|mood|rates (r_amod) disorder_4\NN|NONE (l_appos) rates_7\NNS|.|:|induced|mood (l_conj) symptoms_10\NNS|and|in|prevalence (l_amod) psychiatric_9\JJ|NONE
D003042_D001523 NONE cocaine_14\NN| (r_npadvmod) dependent_16\JJ|an|outpatient (r_amod) sample_17\NN|NONE (r_pobj) in_11\IN|symptoms|and|prevalence (r_prep) rates_7\NNS|.|:|induced|mood (l_conj) symptoms_10\NNS|and|in|prevalence (l_amod) psychiatric_9\JJ|NONE
D003042_D001523 NONE cocaine_1\NN| (r_npadvmod) dependent_3\JJ|disorders|with|,| (r_amod) outpatients_4\NNS|were|on|. (r_nsubjpass) compared_24\VBN|NONE (l_prep) on_25\IN|were|.|outpatients (l_pobj) measures_26\NNS|NONE (l_prep) of_27\IN|NONE (l_pobj) symptoms_29\NNS|NONE (l_amod) psychiatric_28\JJ|NONE
D003042_D001523 NONE cocaine_6\NN| (r_npadvmod) induced_8\VBN|CIMD|)|mood|( (r_amod) disorder_10\NN|NONE (r_pobj) with_5\IN|disorders|,|dependent| (r_prep) outpatients_4\NNS|were|on|. (r_nsubjpass) compared_24\VBN|NONE (l_prep) on_25\IN|were|.|outpatients (l_pobj) measures_26\NNS|NONE (l_prep) of_27\IN|NONE (l_pobj) symptoms_29\NNS|NONE (l_amod) psychiatric_28\JJ|NONE
D003042_D019970 NONE cocaine_1\NN| (r_npadvmod) dependent_3\JJ|disorders|with|,| (r_amod) outpatients_4\NNS|were|on|. (l_prep) with_5\IN|disorders|,|dependent| (l_pobj) disorder_10\NN|NONE (l_appos) CIMD_12\NNP|)|mood|induced|(
D003042_D019970 NONE cocaine_6\NN| (r_npadvmod) induced_8\VBN|CIMD|)|mood|( (r_amod) disorder_10\NN|NONE (l_appos) CIMD_12\NNP|)|mood|induced|(
2790457
D008012_D012640 CID lidocaine_13\NN|and (r_conj) cocaine_11\NN|NONE (r_pobj) by_10\IN|NONE (r_agent) kindled_9\VBN|anesthetic|local (r_acl) seizures_8\NNS|NONE
D008012_D012640 CID lidocaine-_8\NN|NONE (r_nmod) seizures_13\NNS|NONE
D008012_D012640 CID lidocaine-_8\NN|NONE (r_nmod) seizures_13\NNS|NONE (r_pobj) of_6\IN|the (r_prep) development_5\NN|.|had|CBZ|but|, (r_dobj) inhibited_3\VBD|NONE (l_conj) had_16\VBD|.|CBZ|but|development|, (l_dobj) effect_18\NN|NONE (l_prep) on_19\IN|little (l_pobj) seizures_25\NNS|NONE
D008012_D012640 CID lidocaine_18\NN|acute||or (r_npadvmod) kindled_20\VBN|induced|completed (r_amod) seizures_26\NNS|NONE
D008012_D012640 CID lidocaine-_17\NN|kindled (r_nmod) seizures_22\NNS|NONE
D002220_D012640 NONE carbamazepine_1\NN|development|. (r_nsubj) inhibits_2\VBZ|NONE (l_dobj) development_4\NN|.|carbamazepine (l_prep) of_5\IN|the (l_pobj) seizures_8\NNS|NONE
D002220_D012640 NONE carbamazepine_3\NN|NONE (l_appos) treatment_7\NN|NONE (l_prep) on_8\IN|)|CBZ|( (l_pobj) seizures_13\NNS|NONE
D002220_D012640 NONE CBZ_5\NNP|on|)|( (r_nmod) treatment_7\NN|NONE (l_prep) on_8\IN|)|CBZ|( (l_pobj) seizures_13\NNS|NONE
D002220_D012640 NONE CBZ_30\NNP|NONE (r_compound) administration_31\NN|NONE (r_pobj) of_29\IN|different (r_prep) methods_28\NNS|NONE (r_pobj) under_26\IN|and|stages (r_conj) in_18\IN|were|effects|. (r_prep) evaluated_17\VBN|NONE (l_nsubjpass) effects_1\NNS|were|.|in (l_prep) of_2\IN|The (l_pobj) carbamazepine_3\NN|NONE (l_appos) treatment_7\NN|NONE (l_prep) on_8\IN|)|CBZ|( (l_pobj) seizures_13\NNS|NONE
D002220_D012640 NONE CBZ_2\NN|.|had|but|development|, (r_nsubj) inhibited_3\VBD|NONE (l_dobj) development_5\NN|.|had|CBZ|but|, (l_prep) of_6\IN|the (l_pobj) seizures_13\NNS|NONE
D002220_D012640 NONE CBZ_2\NN|.|had|but|development|, (r_nsubj) inhibited_3\VBD|NONE (l_conj) had_16\VBD|.|CBZ|but|development|, (l_dobj) effect_18\NN|NONE (l_prep) on_19\IN|little (l_pobj) seizures_25\NNS|NONE
D002220_D012640 NONE CBZ_1\NN|.|also|incidence (r_nsubj) decreased_3\VBD|NONE (l_dobj) incidence_5\NN|.|also|CBZ (l_prep) of_6\IN|the (l_pobj) mortality_10\NN|NONE (l_amod) related_9\VBN|in (l_npadvmod) seizure_7\NN|
D002220_D012640 NONE CBZ_1\NN|.|effect (r_nsubj) had_13\VBD|NONE (l_dobj) effect_15\NN|CBZ|. (l_prep) on_16\IN|no (l_pobj) seizures_26\NNS|NONE
D002220_D012640 NONE CBZ_4\NNP|NONE (r_pobj) of_3\IN|Repeated|i.p.|) (r_prep) injection_2\NN|.|also|without (r_nsubj) was_10\VBD|NONE (l_prep) without_11\IN|.|injection|also (l_pobj) effect_12\NN|NONE (l_prep) on_13\IN|NONE (l_pobj) development_15\NN|NONE (l_prep) of_16\IN|the (l_pobj) seizures_22\NNS|NONE
D002220_D012640 NONE CBZ_4\NN|NONE (r_pobj) of_3\IN|differential|depending|The (r_prep) effects_2\NNS|underlie|. (l_prep) depending_5\VBG|differential|of|The (l_prep) upon_6\IN|NONE (l_pobj) stage_7\NN|NONE (l_prep) of_8\IN|NONE (l_pobj) development_10\NN|NONE (l_compound) seizure_9\NN|NONE
D002220_D012640 NONE CBZ_4\NN|NONE (r_pobj) of_3\IN|differential|depending|The (r_prep) effects_2\NNS|underlie|. (r_nsubj) suggest_11\VBP|NONE (l_ccomp) underlie_15\VBP|effects|. (l_dobj) development_17\NN|mechanisms|that (l_prep) versus_18\IN|the (l_pobj) maintenance_19\NN|NONE (l_prep) of_20\IN|NONE (l_pobj) seizures_25\NNS|NONE
D003042_D012640 CID cocaine_11\NN|NONE (r_pobj) by_10\IN|NONE (r_agent) kindled_9\VBN|anesthetic|local (r_acl) seizures_8\NNS|NONE
D003042_D012640 CID cocaine_10\NN| (r_npadvmod) induced_12\VBN|and|both (r_conj) lidocaine-_8\NN|NONE (r_nmod) seizures_13\NNS|NONE
D003042_D012640 CID cocaine_10\NN| (r_npadvmod) induced_12\VBN|and|both (r_conj) lidocaine-_8\NN|NONE (r_nmod) seizures_13\NNS|NONE (r_pobj) of_6\IN|the (r_prep) development_5\NN|.|had|CBZ|but|, (r_dobj) inhibited_3\VBD|NONE (l_conj) had_16\VBD|.|CBZ|but|development|, (l_dobj) effect_18\NN|NONE (l_prep) on_19\IN|little (l_pobj) seizures_25\NNS|NONE
D003042_D012640 CID cocaine_13\NN| (r_npadvmod) injected_15\VBN|the (r_amod) rats_16\NNS|NONE (r_pobj) in_11\IN|related (r_prep) mortality_10\NN|NONE (l_amod) related_9\VBN|in (l_npadvmod) seizure_7\NN|
D003042_D012640 CID cocaine_23\NN| (r_npadvmod) induced_25\VBN|completed|kindled (r_amod) seizures_26\NNS|NONE
D003042_D012640 CID cocaine_19\NN| (r_npadvmod) kindled_21\VBN|lidocaine (r_amod) seizures_22\NNS|NONE
16904497
D002045_D011128 CID bupivacaine_18\NN|and (r_conj) triamcinolone_16\NN|NONE (r_pobj) of_15\IN|epidural (r_prep) injection_14\NN|NONE (r_pobj) by_12\IN|possibly (r_agent) caused_11\VBN|of|a (r_acl) report_5\NN|.|case (l_prep) of_6\IN|a|caused (l_pobj) syndrome_9\NN|NONE
D014221_D011128 NONE triamcinolone_16\NN|NONE (r_pobj) of_15\IN|epidural (r_prep) injection_14\NN|NONE (r_pobj) by_12\IN|possibly (r_agent) caused_11\VBN|of|a (r_acl) report_5\NN|.|case (l_prep) of_6\IN|a|caused (l_pobj) syndrome_9\NN|NONE
D013256_D010146 NONE steroid_16\NN|epidural (r_compound) injection_17\NN|NONE (r_pobj) for_14\IN|.|woman|was (r_prep) scheduled_13\VBN|NONE (l_nsubjpass) woman_4\NN|.|for|was (l_prep) with_5\IN|A|old (l_pobj) pain_11\NN|NONE
D013256_D011128 NONE steroid_5\NN|epidural (r_compound) injection_6\NN|NONE (r_pobj) after_3\IN|:|.|equina|report (r_prep) syndrome_2\NN|NONE
D013256_D009422 NONE steroid_10\NN|epidural (r_compound) injections_11\NNS|NONE (r_pobj) after_8\IN|continued|for (r_prep) vigilance_4\NN|Clinical|and (l_prep) for_5\IN|continued|after (l_pobj) deterioration_7\NN|NONE
D013256_D011843 NONE steroid_11\NN|medications|,|epidural (r_compound) injections_12\NNS|,|physical (r_conj) therapy_8\NN|methods|. (r_attr) are_6\VBP|NONE (l_nsubj) methods_2\NNS|therapy|. (l_prep) of_3\IN|treatment|Conventional (l_pobj) radiculopathy_5\NN|NONE
D013256_D017116 NONE steroid_16\NN|epidural (r_compound) injection_17\NN|NONE (r_pobj) for_14\IN|.|woman|was (r_prep) scheduled_13\VBN|NONE (l_nsubjpass) woman_4\NN|.|for|was (l_prep) with_5\IN|A|old (l_pobj) pain_11\NN|NONE
8643973
D017239_D010051 NONE Paclitaxel_0\NNP|NONE (l_acl) combined_1\VBD|. (l_prep) in_4\IN|with (l_pobj) treatment_9\NN|NONE (l_prep) of_10\IN|line|the (l_pobj) cancer_13\NN|NONE
D017239_D010051 NONE paclitaxel_12\NN|NONE (r_pobj) of_11\IN|maximum|Taxol|tolerated|the (r_prep) dose_10\NN|given|to (r_dobj) determine_6\VB|escalated|I|In (l_prep) given_26\VBN|to|dose (l_prep) as_27\IN|NONE (l_pobj) infusion_30\NN|NONE (l_acl) administered_35\VBN|hour|a|in (l_prep) to_39\IN|days (l_pobj) women_40\NNS|NONE (l_prep) with_41\IN|NONE (l_pobj) cancer_44\NN|NONE
D017239_D010051 NONE Taxol_14\NNP|maximum|of|tolerated|the (r_appos) dose_10\NN|given|to (r_dobj) determine_6\VB|escalated|I|In (l_prep) given_26\VBN|to|dose (l_prep) as_27\IN|NONE (l_pobj) infusion_30\NN|NONE (l_acl) administered_35\VBN|hour|a|in (l_prep) to_39\IN|days (l_pobj) women_40\NNS|NONE (l_prep) with_41\IN|NONE (l_pobj) cancer_44\NN|NONE
D017239_D010051 NONE paclitaxel_46\NN|NONE (r_compound) doses_47\NNS|.|follows|level|were (r_nsubjpass) escalated_49\VBN|determine|I|In (r_conj) study_4\VBP|NONE (l_xcomp) determine_6\VB|escalated|I|In (l_prep) given_26\VBN|to|dose (l_prep) as_27\IN|NONE (l_pobj) infusion_30\NN|NONE (l_acl) administered_35\VBN|hour|a|in (l_prep) to_39\IN|days (l_pobj) women_40\NNS|NONE (l_prep) with_41\IN|NONE (l_pobj) cancer_44\NN|NONE
D016190_D010051 NONE carboplatin_3\NN|NONE (r_pobj) with_2\IN|in (r_prep) combined_1\VBD|. (l_prep) in_4\IN|with (l_pobj) treatment_9\NN|NONE (l_prep) of_10\IN|line|the (l_pobj) cancer_13\NN|NONE
D016190_D010051 NONE carboplatin_34\NN|NONE (r_pobj) with_33\IN|NONE (r_prep) combination_32\NN|NONE (r_pobj) in_31\IN|hour|a|administered (r_prep) infusion_30\NN|NONE (l_acl) administered_35\VBN|hour|a|in (l_prep) to_39\IN|days (l_pobj) women_40\NNS|NONE (l_prep) with_41\IN|NONE (l_pobj) cancer_44\NN|NONE
18186898
D016559_D028361 NONE tacrolimus_20\NN|NONE (r_pobj) by_19\IN|augmented|is|and|which (r_agent) triggered_18\VBN|mitochondrial (r_relcl) dysfunction_15\NN|NONE
D016559_D000138 NONE tacrolimus_1\NN|and|replaced|Although|was|be (r_nsubjpass) suspected_3\VBN|NONE (l_xcomp) be_5\VB|and|tacrolimus|replaced|Although|was (l_attr) cause_7\NN|to (l_prep) of_8\IN|the (l_pobj) acidosis_14\NN|NONE
D016559_D000138 NONE tacrolimus_1\NN|and|replaced|Although|was|be (r_nsubjpass) suspected_3\VBN|NONE (l_conj) replaced_17\VBN|and|tacrolimus|Although|was|be (l_agent) by_18\IN|was (l_pobj) sirolimus_19\NN|NONE (l_conj) acidosis_21\NN|,
D016559_D009135 CID tacrolimus_20\NN|NONE (r_pobj) by_19\IN|augmented|is|and|which (r_agent) triggered_18\VBN|mitochondrial (r_relcl) dysfunction_15\NN|NONE (r_pobj) from_13\IN|dysfunction|that|may|have (r_prep) resulted_12\VBN|We|. (l_nsubj) dysfunction_7\NN|that|from|may|have (l_conj) myopathy_9\NNS|tubular|patient|and
D019259_D005198 CID lamivudine_24\NN|NONE (r_pobj) by_23\IN|NONE (r_agent) augmented_22\VBN|is|and|by|which (r_conj) triggered_18\VBN|mitochondrial (r_relcl) dysfunction_15\NN|NONE (r_pobj) from_13\IN|dysfunction|that|may|have (r_prep) resulted_12\VBN|We|. (l_nsubj) dysfunction_7\NN|that|from|may|have
D019259_D006509 NONE Lamivudine_0\NNP|.|was|because (r_nsubjpass) added_2\VBN|NONE (l_prep) because_3\IN|Lamivudine|.|was (l_pobj) infection_9\NN|of
D019259_D028361 NONE lamivudine_24\NN|NONE (r_pobj) by_23\IN|NONE (r_agent) augmented_22\VBN|is|and|by|which (r_conj) triggered_18\VBN|mitochondrial (r_relcl) dysfunction_15\NN|NONE
D016559_D005198 CID tacrolimus_20\NN|NONE (r_pobj) by_19\IN|augmented|is|and|which (r_agent) triggered_18\VBN|mitochondrial (r_relcl) dysfunction_15\NN|NONE (r_pobj) from_13\IN|dysfunction|that|may|have (r_prep) resulted_12\VBN|We|. (l_nsubj) dysfunction_7\NN|that|from|may|have
D020123_D000138 NONE sirolimus_19\NN|NONE (r_pobj) by_18\IN|was (r_agent) replaced_17\VBN|and|tacrolimus|Although|was|be (r_conj) suspected_3\VBN|NONE (l_xcomp) be_5\VB|and|tacrolimus|replaced|Although|was (l_attr) cause_7\NN|to (l_prep) of_8\IN|the (l_pobj) acidosis_14\NN|NONE
D020123_D000138 NONE sirolimus_19\NN|NONE (l_conj) acidosis_21\NN|,
D019259_D009135 CID lamivudine_24\NN|NONE (r_pobj) by_23\IN|NONE (r_agent) augmented_22\VBN|is|and|by|which (r_conj) triggered_18\VBN|mitochondrial (r_relcl) dysfunction_15\NN|NONE (r_pobj) from_13\IN|dysfunction|that|may|have (r_prep) resulted_12\VBN|We|. (l_nsubj) dysfunction_7\NN|that|from|may|have (l_conj) myopathy_9\NNS|tubular|patient|and
14975762
D004317_D006333 CID doxorubicin_11\RB| (r_compound) induced_13\VBN|NONE (r_pobj) from_10\IN|cardiac|p|protects (r_prep) myocytes_9\NNS|NONE (r_pobj) of_5\IN|that (r_prep) overexpression_4\NN|and|reduces (r_nsubj) apoptosis_14\NN|.|findings (l_conj) reduces_16\VBZ|and|overexpression (l_dobj) extent_18\NN|NONE (l_prep) of_19\IN|the (l_pobj) failure_22\NN|NONE
D004317_D009369 NONE Doxorubicin_0\NNP|agent (r_nsubj) is_1\VBZ|. (l_attr) agent_6\NN|Doxorubicin (l_compound) tumor_5\NN|an|represses
6381653
D007980_D013786 NONE levodopa_2\NN| (r_npadvmod) induced_4\VBN|by (r_amod) dyskinesias_5\NNS|NONE (l_prep) by_6\IN|induced (l_pobj) lesions_8\NNS|NONE
D007980_D004409 CID Levodopa_0\NNP| (r_npadvmod) induced_2\VBN|thalamotomy|.|and (r_amod) dyskinesia_3\JJ|NONE
D007980_D004409 CID Levodopa_0\NNP||alleviated|.|dyskinesia (r_npadvmod) induced_2\VBN|NONE (l_dobj) dyskinesia_3\NN||alleviated|.|Levodopa
D007980_D004409 CID levodopa_2\NN| (r_npadvmod) induced_4\VBN|by (r_amod) dyskinesias_5\NNS|NONE
D007980_D020821 NONE Levodopa_0\NNP||alleviated|.|dyskinesia (r_npadvmod) induced_2\VBN|NONE (l_dobj) dyskinesia_3\NN||alleviated|.|Levodopa (l_prep) in_7\IN|of (l_pobj) cases_9\NNS|NONE (l_prep) of_10\IN|thirteen (l_pobj) Parkinsonism_11\NNP|NONE (l_relcl) was_14\VBD|,|, (l_attr) choreic_15\JJ|which (l_conj) ballistic_17\JJ|in|, (l_conj) dystonic_19\JJ|or
D007980_D010302 NONE Levodopa_0\NNP||alleviated|.|dyskinesia (r_npadvmod) induced_2\VBN|NONE (l_dobj) dyskinesia_3\NN||alleviated|.|Levodopa (l_prep) in_7\IN|of (l_pobj) cases_9\NNS|NONE (l_prep) of_10\IN|thirteen (l_pobj) Parkinsonism_11\NNP|NONE
D007980_D010302 NONE levodopa_2\NN| (r_npadvmod) induced_4\VBN|by (r_amod) dyskinesias_5\NNS|NONE (r_pobj) of_1\IN|in (r_prep) Control_0\NN|is|. (l_prep) in_9\IN|of (l_pobj) course_11\NN|NONE (l_prep) of_12\IN|the (l_pobj) treatment_14\NN|NONE (l_prep) of_15\IN|routine (l_pobj) Parkinsonism_16\NNP|NONE
12042105
C020243_D053040 NONE phosphate_29\NN|NONE (r_compound) nephrolithiasis_30\NN|NONE
C052342_D004827 NONE Topiramate_0\NNP|medication|. (r_nsubj) is_1\VBZ|NONE (l_attr) medication_6\NN|Topiramate|. (l_relcl) becoming_9\VBG|antiepileptic|developed|a (l_prep) because_13\IN|that|prescribed|is (l_pobj) efficacy_16\NN|of (l_prep) in_17\IN|its (l_pcomp) treating_18\VBG|NONE (l_dobj) seizures_20\NNS|NONE
C052342_D053040 CID Topiramate_0\NNP| (r_npadvmod) induced_2\VBN|. (r_amod) nephrolithiasis_3\NN|NONE
C052342_D053040 CID topiramate_7\RB| (r_npadvmod) induced_9\VBN|in (r_amod) nephrolithiasis_10\NN|NONE
9034419
C047426_D012640 CID venlafaxine_4\NNP|a (r_amod) overdose_5\NN|NONE (r_pobj) from_2\IN|NONE (r_prep) resulting_1\VBG|. (r_acl) Seizure_0\NN|NONE
C047426_D012640 CID venlafaxine_5\NNP|NONE (r_pobj) of_3\IN|the|tablets (r_prep) ingestion_2\NN|NONE (r_pobj) After_0\IN|seizure|,|.|patient (r_prep) experienced_11\VBD|NONE (l_dobj) seizure_15\NN|After|,|.|patient
C047426_D012640 CID venlafaxine_11\NNP|NONE (r_amod) overdose_12\NN|NONE (r_pobj) of_10\IN|first|reported|resulted|the (r_prep) case_9\NN|.|,|To|this (l_relcl) resulted_14\VBD|first|of|reported|the (l_prep) in_15\IN|that (l_pobj) seizure_18\NN|NONE
C047426_D012640 CID venlafaxine_1\NNP|in|The (r_amod) overdose_2\NN|.|in|but|elicited (r_nsubj) resulted_6\VBD|NONE (l_prep) in_7\IN|.|but|elicited|overdose (l_pobj) episode_10\NN|NONE (l_prep) of_11\IN|a|single (l_pobj) seizure_13\NN|NONE
C047426_D003865 NONE venlafaxine_12\NN|NONE (r_pobj) of_11\IN|an (r_prep) overdose_10\NN|woman|.|in (r_dobj) took_8\VBD|NONE (l_nsubj) woman_4\NN|overdose|.|in (l_prep) with_5\IN|A|old (l_pobj) depression_7\NN|NONE
C047426_D062787 CID venlafaxine_4\NNP|a (r_amod) overdose_5\NN|NONE
C047426_D062787 CID venlafaxine_5\NNP|NONE (r_amod) overdose_6\NN|NONE
C047426_D062787 CID venlafaxine_12\NN|NONE (r_pobj) of_11\IN|an (r_prep) overdose_10\NN|woman|.|in
C047426_D062787 CID venlafaxine_11\NNP|NONE (r_amod) overdose_12\NN|NONE
C047426_D062787 CID venlafaxine_1\NNP|in|The (r_amod) overdose_2\NN|.|in|but|elicited
1928887
D002216_D007022 NONE captopril_6\NN|NONE (r_compound) overdose_7\NN|to (r_pobj) due_4\IN|of|Naloxone|. (r_prep) reversal_1\NN|NONE (l_prep) of_2\IN|Naloxone|.|due (l_pobj) hypotension_3\NN|NONE
D002216_D007022 NONE captopril_15\NN|NONE (r_pobj) of_14\IN|the|hypotensive (r_prep) actions_13\NNS|NONE (l_amod) hypotensive_12\JJ|the|of
D002216_D007022 NONE captopril_7\NN|intentional|an (r_compound) overdose_8\NN|NONE (r_pobj) of_4\IN|a (r_prep) case_3\NN|.|,|resolved|manifested|We (r_dobj) report_1\VBP|NONE (l_advcl) manifested_10\VBN|.|,|resolved|We|case (l_agent) by_11\IN|NONE (l_pobj) hypotension_13\NN|NONE
D002216_D007022 NONE captopril_11\NN| (r_npadvmod) induced_13\VBN|treated (r_amod) hypotension_14\NN|NONE
D002216_D007022 NONE captopril_15\NN|NONE (r_pobj) from_14\IN|NONE (r_prep) resulting_13\VBG|NONE (r_acl) hypotension_12\NN|NONE
D002216_D062787 NONE captopril_6\NN|NONE (r_compound) overdose_7\NN|to
D002216_D062787 NONE captopril_7\NN|intentional|an (r_compound) overdose_8\NN|NONE
D009270_D007022 NONE Naloxone_0\NN|of|.|due (r_compound) reversal_1\NN|NONE (l_prep) of_2\IN|Naloxone|.|due (l_pobj) hypotension_3\NN|NONE
D009270_D007022 NONE naloxone_3\NN|The|opioid (r_appos) antagonist_2\NN|block|.|been|has (r_nsubjpass) shown_6\VBN|NONE (l_xcomp) block_8\VB|.|antagonist|been|has (l_conj) reverse_10\VB|or|to (l_dobj) actions_13\NNS|NONE (l_amod) hypotensive_12\JJ|the|of
D009270_D007022 NONE naloxone_22\NN|NONE (r_pobj) of_21\IN|the (r_prep) administration_20\NN|NONE (r_pobj) with_18\IN|,|that|promptly (r_prep) resolved_16\VBD|.|,|manifested|We|case (r_ccomp) report_1\VBP|NONE (l_advcl) manifested_10\VBN|.|,|resolved|We|case (l_agent) by_11\IN|NONE (l_pobj) hypotension_13\NN|NONE
D009270_D007022 NONE naloxone_17\NN|NONE (r_pobj) with_16\IN|NONE (r_prep) treated_15\VBN|induced (r_acl) hypotension_14\NN|NONE
D009270_D007022 NONE naloxone_7\NN|NONE (l_prep) in_8\IN|NONE (l_pobj) reversal_10\NN|NONE (l_prep) of_11\IN|the (l_pobj) hypotension_12\NN|NONE
D009270_D062787 NONE Naloxone_0\NN|of|.|due (r_compound) reversal_1\NN|NONE (l_prep) due_4\IN|of|Naloxone|. (l_pobj) overdose_7\NN|to
D009270_D062787 NONE naloxone_22\NN|NONE (r_pobj) of_21\IN|the (r_prep) administration_20\NN|NONE (r_pobj) with_18\IN|,|that|promptly (r_prep) resolved_16\VBD|.|,|manifested|We|case (r_ccomp) report_1\VBP|NONE (l_dobj) case_3\NN|.|,|resolved|manifested|We (l_prep) of_4\IN|a (l_pobj) overdose_8\NN|NONE
15042318
D004317_D001281 CID doxorubicin_34\NN| (r_npadvmod) based_36\VBN|NONE (r_amod) chemotherapy_37\NN|NONE (r_pobj) of_33\IN|one (r_prep) cycle_32\NN|in (r_pobj) following_30\VBG|sudden|atrial (r_prep) fibrillation_29\NN|,|the|common|and|of
D004317_C535648 NONE doxorubicin_34\NN| (r_npadvmod) based_36\VBN|NONE (r_amod) chemotherapy_37\NN|NONE (r_pobj) of_33\IN|one (r_prep) cycle_32\NN|in (r_pobj) following_30\VBG|sudden|atrial (r_prep) fibrillation_29\NN|,|the|common|and|of (r_conj) form_20\NN|lymphoma|diffuse|, (r_appos) dystrophy_15\NN|NONE (l_nmod) lymphoma_12\NN|diffuse|form|,
D004317_D009136 NONE doxorubicin_34\NN| (r_npadvmod) based_36\VBN|NONE (r_amod) chemotherapy_37\NN|NONE (r_pobj) of_33\IN|one (r_prep) cycle_32\NN|in (r_pobj) following_30\VBG|sudden|atrial (r_prep) fibrillation_29\NN|,|the|common|and|of (r_conj) form_20\NN|lymphoma|diffuse|, (l_prep) of_21\IN|,|the|common|and|fibrillation (l_pobj) dystrophy_24\NN|NONE
D004317_D009223 NONE doxorubicin_34\NN| (r_npadvmod) based_36\VBN|NONE (r_amod) chemotherapy_37\NN|NONE (r_pobj) of_33\IN|one (r_prep) cycle_32\NN|in (r_pobj) following_30\VBG|sudden|atrial (r_prep) fibrillation_29\NN|,|the|common|and|of (r_conj) form_20\NN|lymphoma|diffuse|, (r_appos) dystrophy_15\NN|NONE
1085609
D011736_D012640 NONE pyridoxine_1\NN|Neonatal|responsive|due|. (r_nmod) convulsions_3\NNS|NONE
D011736_D012640 NONE pyridoxine_9\NN|NONE (r_dobj) administering_7\VBG|NONE (r_pcomp) of_6\IN| (r_prep) hours_5\NNS|NONE (r_pobj) within_3\IN|.|fits|,|suggesting (r_prep) ceased_2\VBD|NONE (l_nsubj) fits_1\NNS|.|,|within|suggesting
D011736_D012640 NONE pyridoxine_15\JJ|secondary (r_compound) deficiency_16\NN|NONE (r_pobj) of_14\IN|an|isoniazid (r_prep) aetiology_13\NN|NONE (r_dobj) suggesting_11\VBG|.|fits|,|within (r_advcl) ceased_2\VBD|NONE (l_nsubj) fits_1\NNS|.|,|within|suggesting
D007538_D014376 NONE isoniazid_6\NN|therapy (r_pobj) on_5\IN|daily|old|because|A (r_prep) infant_4\NN|after|was|. (l_prep) because_13\IN|daily|on|old|A (l_pobj) tuberculosis_16\NN|of
D007538_D012640 CID isoniazid_6\NN|NONE (r_amod) therapy_7\NN|to (r_pobj) due_4\IN|pyridoxine|Neonatal|responsive|. (r_amod) convulsions_3\NNS|NONE
D007538_D012640 CID isoniazid_6\NN|therapy (r_pobj) on_5\IN|daily|old|because|A (r_prep) infant_4\NN|after|was|. (r_nsubjpass) admitted_18\VBN|NONE (l_prep) after_19\IN|was|.|infant (l_pobj) days_21\NNS|NONE (l_prep) of_22\IN| (l_pobj) fits_24\NNS|NONE
D007538_D012640 CID isoniazid_19\NN|an|of (r_relcl) aetiology_13\NN|NONE (r_dobj) suggesting_11\VBG|.|fits|,|within (r_advcl) ceased_2\VBD|NONE (l_nsubj) fits_1\NNS|.|,|within|suggesting
11284996
D005996_D006261 CID trinitrate_20\NN|NONE (r_pobj) by_15\IN|in (r_agent) induced_14\VBN|NONE (r_acl) headache_13\NN|NONE
D005996_D006261 CID GTN_22\NNP|)|NO|glyceryl|(|the (r_appos) trinitrate_20\NN|NONE (r_pobj) by_15\IN|in (r_agent) induced_14\VBN|NONE (r_acl) headache_13\NN|NONE
D005996_D006261 CID GTN_13\NNP|to (l_conj) placebo_15\NN|or|min (l_prep) over_16\IN|NONE (l_pobj) min_18\NN|NONE (l_prep) on_19\IN| (l_pobj) days_24\NNS|NONE (l_amod) free_23\JJ|two (l_npadvmod) headache_21\NN|
D005996_D006261 CID GTN_11\NNP|the (r_compound) day_12\NN|NONE (r_pobj) on_9\IN|than|immediate|stronger (r_prep) headache_8\NN|was|and|patients
D005996_D006261 CID GTN_11\NNP|the (r_compound) day_12\NN|NONE (r_pobj) on_9\IN|than|immediate|stronger (r_prep) headache_8\NN|was|and|patients (r_dobj) developed_4\VBD|NONE (l_conj) was_21\VBD|and|patients|headache (l_nsubj) headache_20\NN|.|pronounced
D009569_D051270 NONE oxide_6\NN|associated|that (r_nsubj) induced_10\VBN|.|has|It|been (l_ccomp) associated_17\VBN|oxide|that (l_nsubjpass) headache_11\NN|be|may|with (l_prep) in_12\IN|NONE (l_pobj) headaches_14\NNS|NONE
D009569_D051270 NONE NO_8\NNP|nitric|(|) (r_intj) oxide_6\NN|associated|that (r_nsubj) induced_10\VBN|.|has|It|been (l_ccomp) associated_17\VBN|oxide|that (l_nsubjpass) headache_11\NN|be|may|with (l_prep) in_12\IN|NONE (l_pobj) headaches_14\NNS|NONE
D009569_D018781 NONE oxide_8\NN| (r_npadvmod) induced_10\VBN|nitric|in (r_amod) headache_11\NN|NONE (l_prep) in_12\IN|nitric|induced (l_pobj) patients_13\NNS|NONE (l_prep) with_14\IN|NONE (l_pobj) headache_19\NN|NONE
D009569_D018781 NONE NO_17\JJ|)|glyceryl|(|GTN|the (r_det) trinitrate_20\NN|NONE (r_pobj) by_15\IN|in (r_agent) induced_14\VBN|NONE (l_prep) in_24\IN|by (l_pobj) patients_26\NNS|NONE (l_prep) with_27\IN| (l_pobj) headache_32\NN|NONE
D009569_D006261 CID oxide_8\NN| (r_npadvmod) induced_10\VBN|nitric|in (r_amod) headache_11\NN|NONE
D009569_D006261 CID oxide_6\NN|associated|that (r_nsubj) induced_10\VBN|.|has|It|been (l_ccomp) associated_17\VBN|oxide|that (l_nsubjpass) headache_11\NN|be|may|with
D009569_D006261 CID NO_8\NNP|nitric|(|) (r_intj) oxide_6\NN|associated|that (r_nsubj) induced_10\VBN|.|has|It|been (l_ccomp) associated_17\VBN|oxide|that (l_nsubjpass) headache_11\NN|be|may|with
D009569_D006261 CID NO_17\JJ|)|glyceryl|(|GTN|the (r_det) trinitrate_20\NN|NONE (r_pobj) by_15\IN|in (r_agent) induced_14\VBN|NONE (r_acl) headache_13\NN|NONE
D009569_D006261 CID NO_5\RB| (r_intj) induced_7\VBN|immediate (r_amod) headache_9\NN|with|not|is|that
D005996_D018781 NONE trinitrate_20\NN|NONE (r_pobj) by_15\IN|in (r_agent) induced_14\VBN|NONE (l_prep) in_24\IN|by (l_pobj) patients_26\NNS|NONE (l_prep) with_27\IN| (l_pobj) headache_32\NN|NONE
D005996_D018781 NONE GTN_22\NNP|)|NO|glyceryl|(|the (r_appos) trinitrate_20\NN|NONE (r_pobj) by_15\IN|in (r_agent) induced_14\VBN|NONE (l_prep) in_24\IN|by (l_pobj) patients_26\NNS|NONE (l_prep) with_27\IN| (l_pobj) headache_32\NN|NONE
2476560
D001556_D000741 CID lindane_4\NN|is|Evidence (r_dobj) accumulating_2\VBG|and|can|.|toxic|associated (r_csubj) be_6\VB|NONE (l_conj) associated_16\VBN|and|accumulating|can|.|toxic (l_prep) with_17\IN|may|be (l_pobj) anaemia_19\NN|NONE
D001556_D012532 NONE lindane_12\NN|;|.|most|initiated (r_dobj) consider_11\VBP|NONE (l_ccomp) initiated_5\VBN|;|lindane|.|most (l_nsubjpass) Treatment_0\NN|by|is|usually (l_prep) for_1\IN|NONE (l_pobj) scabies_2\NNS|NONE
D001556_D012532 NONE hexachloride_16\NN|(|)|treatment (r_appos) lindane_12\NN|;|.|most|initiated (r_dobj) consider_11\VBP|NONE (l_ccomp) initiated_5\VBN|;|lindane|.|most (l_nsubjpass) Treatment_0\NN|by|is|usually (l_prep) for_1\IN|NONE (l_pobj) scabies_2\NNS|NONE
D001556_D002493 CID lindane_4\NN|is|Evidence (r_dobj) accumulating_2\VBG|and|can|.|toxic|associated (r_csubj) be_6\VB|NONE (l_acomp) toxic_7\JJ|and|accumulating|can|.|associated (l_prep) to_8\IN|NONE (l_pobj) system_12\NN|NONE
8586822
D017673_D006973 CID chloride_31\NN|dietary (r_compound) supplementation_32\NN|NONE (r_pobj) of_28\IN|hypertensive|the (r_prep) effect_27\NN|NONE (r_pobj) to_24\IN|test|.|system|,|importantly (r_prep) contributes_22\VBZ|NONE (l_advcl) test_1\VB|to|.|system|,|importantly (l_dobj) hypothesis_3\NN|To (l_relcl) treated_10\VBN|the (l_dobj) rats_13\NNS|captopril||spontaneously|in|that|, (l_amod) hypertensive_12\JJ|SHR|)|(
D017673_D006973 CID chloride_31\NN|dietary (r_compound) supplementation_32\NN|NONE (r_pobj) of_28\IN|hypertensive|the (r_prep) effect_27\NN|NONE (l_amod) hypertensive_26\JJ|of|the
D017673_D006973 CID chloride_19\NN| (r_npadvmod) induced_21\VBN|sodium|in|in|the (r_amod) increase_22\NN|that (l_prep) in_23\IN|sodium|induced|in|the (l_pobj) MAP_24\NNP|NONE
D018738_D006973 NONE hexamethonium_6\NN|NONE (r_pobj) of_2\IN|Intravenous (r_prep) infusion_1\NN|.|in (r_nsubj) resulted_7\VBD|NONE (l_prep) in_8\IN|.|infusion (l_pobj) decline_11\NN|NONE (l_relcl) eliminated_15\VBD|in|a|rapid (l_dobj) increase_22\NN|that (l_prep) in_23\IN|sodium|induced|in|the (l_pobj) MAP_24\NNP|NONE
D002216_D006973 NONE captopril_12\FW|rats|Contribution||. (r_npadvmod) treated_14\VBN|NONE (l_dobj) rats_17\NNS|captopril|Contribution||. (l_amod) hypertensive_16\JJ|NONE
D002216_D006973 NONE captopril_8\FW||spontaneously|in|rats|that|, (r_npadvmod) treated_10\VBN|the (l_dobj) rats_13\NNS|captopril||spontaneously|in|that|, (l_amod) hypertensive_12\JJ|SHR|)|(
D002216_D006973 NONE captopril_8\FW||spontaneously|in|rats|that|, (r_npadvmod) treated_10\VBN|the (r_relcl) hypothesis_3\NN|To (r_dobj) test_1\VB|to|.|system|,|importantly (r_advcl) contributes_22\VBZ|NONE (l_prep) to_24\IN|test|.|system|,|importantly (l_pobj) effect_27\NN|NONE (l_amod) hypertensive_26\JJ|of|the
6727060
D008787_D004409 CID metoclopramide_7\NN|NONE (r_pobj) by_6\IN|NONE (r_agent) caused_5\VBN|tardive (r_acl) dyskinesia_4\JJ|NONE
D008787_D004409 CID metoclopramide_23\RB|for|he|after|in (r_dobj) took_22\VBD|movements|.|in (r_advcl) appeared_3\VBD|NONE (l_nsubj) movements_2\NNS|took|.|in
D008787_D004409 CID metoclopramide_2\JJ|the (r_compound) administration_3\NN|When|was (r_nsubjpass) discontinued_5\VBN|.|movements|gradually|,|to (r_advcl) improved_11\VBD|NONE (l_nsubj) movements_9\NNS|.|discontinued|gradually|,|to
D008787_D005767 NONE metoclopramide_23\RB|for|he|after|in (r_dobj) took_22\VBD|movements|.|in (l_prep) for_24\IN|he|metoclopramide|after|in (l_pobj) disorder_26\NN|NONE
12464714
D004878_D004244 NONE ergotamine_19\NNP|/ (r_nmod) caffeine_21\NN|and (r_conj) rizatriptan_17\NN|NONE (r_pobj) after_16\IN|%|or|incidence (r_prep) >_7\XX|adverse|The|nausea|common|,|( (r_appos) events_4\NNS|,|.|dizziness|respectively|, (r_nsubj) were_25\VBD|NONE (l_attr) dizziness_26\NN|,|.|respectively|events|,
C093622_D006261 NONE rizatriptan_19\JJ|NONE (r_dobj) preferring_18\VBG|NONE (r_acl) patients_17\NNS|NONE (r_pobj) of_16\IN|. (r_prep) %_15\NN|NONE (r_pobj) by_13\IN|NONE (r_agent) cited_12\VBN|the|,|important|for (r_acl) reason_8\NN|.|relief (r_attr) was_4\VBD|NONE (l_nsubj) relief_1\NN|.|reason (l_prep) of_2\IN|Faster (l_pobj) headache_3\NN|NONE
D002110_D008881 NONE caffeine_13\NN|.|of|Crossover (l_prep) in_14\IN|/|ergotamine|mg (l_pobj) migraine_15\NN|NONE
D002110_D008881 NONE caffeine_22\NN| (r_appos) ergotamine_18\NN|NONE (r_pobj) to_16\IN|mg (r_prep) tablet_15\NN| (r_amod) rizatriptan_12\JJ|NONE (r_pobj) for_10\IN|the (r_prep) preference_9\NN|tablets|in|.|study (r_dobj) assessed_7\VBD|NONE (l_prep) in_26\IN|preference|tablets|.|study (l_pobj) patients_28\NNS|NONE (l_acl) treating_29\VBG| (l_dobj) attack_33\NN|NONE (l_compound) migraine_32\JJ|with|a|single
D002110_D006970 NONE caffeine_21\NN|and (r_conj) rizatriptan_17\NN|NONE (r_pobj) after_16\IN|%|or|incidence (r_prep) >_7\XX|adverse|The|nausea|common|,|( (r_appos) events_4\NNS|,|.|dizziness|respectively|, (l_appos) nausea_34\NN|>|adverse|The|common|,|( (l_conj) somnolence_42\NN|.|and|)|(
D002110_D014839 NONE caffeine_7\NN|NONE (l_prep) in_8\IN|/|ergotamine (l_pobj) proportions_10\NNS|NONE (l_prep) of_11\IN|the (l_pobj) patients_12\NNS|NONE (l_prep) with_13\IN|NONE (l_pobj) nausea_15\NN|NONE (l_conj) vomiting_17\VBG|no|,
D004878_D012001 NONE ergotamine_5\NN|/|in (r_nmod) caffeine_7\NN|NONE (l_prep) in_8\IN|/|ergotamine (l_pobj) proportions_10\NNS|NONE (l_prep) of_11\IN|the (l_pobj) patients_12\NNS|NONE (l_prep) with_13\IN|NONE (l_pobj) nausea_15\NN|NONE (l_conj) vomiting_17\VBG|no|, (l_conj) phonophobia_19\NNS|for|,|and
C093622_D012001 NONE Rizatriptan_0\NNP|h|also|superior|. (r_nsubj) was_1\VBD|NONE (l_acomp) superior_3\JJ|h|Rizatriptan|also|. (l_prep) to_4\IN|NONE (l_pobj) caffeine_7\NN|NONE (l_prep) in_8\IN|/|ergotamine (l_pobj) proportions_10\NNS|NONE (l_prep) of_11\IN|the (l_pobj) patients_12\NNS|NONE (l_prep) with_13\IN|NONE (l_pobj) nausea_15\NN|NONE (l_conj) vomiting_17\VBG|no|, (l_conj) phonophobia_19\NNS|for|,|and
D002110_D009325 NONE caffeine_7\NN|NONE (l_prep) in_8\IN|/|ergotamine (l_pobj) proportions_10\NNS|NONE (l_prep) of_11\IN|the (l_pobj) patients_12\NNS|NONE (l_prep) with_13\IN|NONE (l_pobj) nausea_15\NN|NONE
D002110_D009325 NONE caffeine_21\NN|and (r_conj) rizatriptan_17\NN|NONE (r_pobj) after_16\IN|%|or|incidence (r_prep) >_7\XX|adverse|The|nausea|common|,|( (r_appos) events_4\NNS|,|.|dizziness|respectively|, (l_appos) nausea_34\NN|>|adverse|The|common|,|(
D004878_D014839 NONE ergotamine_5\NN|/|in (r_nmod) caffeine_7\NN|NONE (l_prep) in_8\IN|/|ergotamine (l_pobj) proportions_10\NNS|NONE (l_prep) of_11\IN|the (l_pobj) patients_12\NNS|NONE (l_prep) with_13\IN|NONE (l_pobj) nausea_15\NN|NONE (l_conj) vomiting_17\VBG|no|,
D002110_D012001 NONE caffeine_7\NN|NONE (l_prep) in_8\IN|/|ergotamine (l_pobj) proportions_10\NNS|NONE (l_prep) of_11\IN|the (l_pobj) patients_12\NNS|NONE (l_prep) with_13\IN|NONE (l_pobj) nausea_15\NN|NONE (l_conj) vomiting_17\VBG|no|, (l_conj) phonophobia_19\NNS|for|,|and
D004878_D009325 NONE ergotamine_5\NN|/|in (r_nmod) caffeine_7\NN|NONE (l_prep) in_8\IN|/|ergotamine (l_pobj) proportions_10\NNS|NONE (l_prep) of_11\IN|the (l_pobj) patients_12\NNS|NONE (l_prep) with_13\IN|NONE (l_pobj) nausea_15\NN|NONE
D004878_D009325 NONE ergotamine_19\NNP|/ (r_nmod) caffeine_21\NN|and (r_conj) rizatriptan_17\NN|NONE (r_pobj) after_16\IN|%|or|incidence (r_prep) >_7\XX|adverse|The|nausea|common|,|( (r_appos) events_4\NNS|,|.|dizziness|respectively|, (l_appos) nausea_34\NN|>|adverse|The|common|,|(
C093622_D006970 NONE rizatriptan_17\NN|NONE (r_pobj) after_16\IN|%|or|incidence (r_prep) >_7\XX|adverse|The|nausea|common|,|( (r_appos) events_4\NNS|,|.|dizziness|respectively|, (l_appos) nausea_34\NN|>|adverse|The|common|,|( (l_conj) somnolence_42\NN|.|and|)|(
C093622_D020795 NONE Rizatriptan_0\NNP|h|also|superior|. (r_nsubj) was_1\VBD|NONE (l_acomp) superior_3\JJ|h|Rizatriptan|also|. (l_prep) to_4\IN|NONE (l_pobj) caffeine_7\NN|NONE (l_prep) in_8\IN|/|ergotamine (l_pobj) proportions_10\NNS|NONE (l_prep) of_11\IN|the (l_pobj) patients_12\NNS|NONE (l_prep) with_13\IN|NONE (l_pobj) nausea_15\NN|NONE (l_conj) vomiting_17\VBG|no|, (l_conj) phonophobia_19\NNS|for|,|and (l_conj) photophobia_21\NNS|or
D002110_D010146 NONE caffeine_22\NN|NONE (r_pobj) with_19\IN|NONE (r_prep) treated_18\VBN|. (r_acl) %_17\NN|NONE (r_pobj) with_15\IN|NONE (r_prep) compared_14\VBN|h|,|percent|.|,|free|being (r_prep) were_6\VBD|NONE (l_acomp) free_8\JJ|h|compared|,|percent|.|,|being (l_npadvmod) pain_7\NN|NONE
D002110_D010146 NONE caffeine_35\NN|NONE (r_pobj) on_32\IN|NONE (r_prep) patients_31\NNS|NONE (r_pobj) of_30\IN| (r_prep) %_29\NN|NONE (r_pobj) to_27\IN|NONE (r_prep) compared_26\VBN|and|%|,|had|.|free|at (r_prep) were_7\VBD|NONE (l_acomp) free_9\JJ|and|%|,|compared|had|.|at (l_npadvmod) pain_8\NN|NONE
C093622_D009325 CID Rizatriptan_0\NNP|h|also|superior|. (r_nsubj) was_1\VBD|NONE (l_acomp) superior_3\JJ|h|Rizatriptan|also|. (l_prep) to_4\IN|NONE (l_pobj) caffeine_7\NN|NONE (l_prep) in_8\IN|/|ergotamine (l_pobj) proportions_10\NNS|NONE (l_prep) of_11\IN|the (l_pobj) patients_12\NNS|NONE (l_prep) with_13\IN|NONE (l_pobj) nausea_15\NN|NONE
C093622_D009325 CID rizatriptan_17\NN|NONE (r_pobj) after_16\IN|%|or|incidence (r_prep) >_7\XX|adverse|The|nausea|common|,|( (r_appos) events_4\NNS|,|.|dizziness|respectively|, (l_appos) nausea_34\NN|>|adverse|The|common|,|(
C093622_D014839 NONE Rizatriptan_0\NNP|h|also|superior|. (r_nsubj) was_1\VBD|NONE (l_acomp) superior_3\JJ|h|Rizatriptan|also|. (l_prep) to_4\IN|NONE (l_pobj) caffeine_7\NN|NONE (l_prep) in_8\IN|/|ergotamine (l_pobj) proportions_10\NNS|NONE (l_prep) of_11\IN|the (l_pobj) patients_12\NNS|NONE (l_prep) with_13\IN|NONE (l_pobj) nausea_15\NN|NONE (l_conj) vomiting_17\VBG|no|,
D004878_D006261 NONE ergotamine_27\NN|/ (r_nmod) caffeine_29\NN|who (r_dobj) preferred_26\VBD|NONE (r_relcl) patients_24\NNS|NONE (r_pobj) of_23\IN|. (r_prep) %_22\NN|and (r_conj) rizatriptan_19\JJ|NONE (r_dobj) preferring_18\VBG|NONE (r_acl) patients_17\NNS|NONE (r_pobj) of_16\IN|. (r_prep) %_15\NN|NONE (r_pobj) by_13\IN|NONE (r_agent) cited_12\VBN|the|,|important|for (r_acl) reason_8\NN|.|relief (r_attr) was_4\VBD|NONE (l_nsubj) relief_1\NN|.|reason (l_prep) of_2\IN|Faster (l_pobj) headache_3\NN|NONE
C093622_D004244 CID rizatriptan_17\NN|NONE (r_pobj) after_16\IN|%|or|incidence (r_prep) >_7\XX|adverse|The|nausea|common|,|( (r_appos) events_4\NNS|,|.|dizziness|respectively|, (r_nsubj) were_25\VBD|NONE (l_attr) dizziness_26\NN|,|.|respectively|events|,
D004878_D010146 NONE ergotamine_20\NN|.|/ (r_nmod) caffeine_22\NN|NONE (r_pobj) with_19\IN|NONE (r_prep) treated_18\VBN|. (r_acl) %_17\NN|NONE (r_pobj) with_15\IN|NONE (r_prep) compared_14\VBN|h|,|percent|.|,|free|being (r_prep) were_6\VBD|NONE (l_acomp) free_8\JJ|h|compared|,|percent|.|,|being (l_npadvmod) pain_7\NN|NONE
D004878_D010146 NONE ergotamine_33\NNP|/|. (r_nmod) caffeine_35\NN|NONE (r_pobj) on_32\IN|NONE (r_prep) patients_31\NNS|NONE (r_pobj) of_30\IN| (r_prep) %_29\NN|NONE (r_pobj) to_27\IN|NONE (r_prep) compared_26\VBN|and|%|,|had|.|free|at (r_prep) were_7\VBD|NONE (l_acomp) free_9\JJ|and|%|,|compared|had|.|at (l_npadvmod) pain_8\NN|NONE
D004878_D006970 NONE ergotamine_19\NNP|/ (r_nmod) caffeine_21\NN|and (r_conj) rizatriptan_17\NN|NONE (r_pobj) after_16\IN|%|or|incidence (r_prep) >_7\XX|adverse|The|nausea|common|,|( (r_appos) events_4\NNS|,|.|dizziness|respectively|, (l_appos) nausea_34\NN|>|adverse|The|common|,|( (l_conj) somnolence_42\NN|.|and|)|(
D002110_D004244 NONE caffeine_21\NN|and (r_conj) rizatriptan_17\NN|NONE (r_pobj) after_16\IN|%|or|incidence (r_prep) >_7\XX|adverse|The|nausea|common|,|( (r_appos) events_4\NNS|,|.|dizziness|respectively|, (r_nsubj) were_25\VBD|NONE (l_attr) dizziness_26\NN|,|.|respectively|events|,
D002110_D020795 NONE caffeine_7\NN|NONE (l_prep) in_8\IN|/|ergotamine (l_pobj) proportions_10\NNS|NONE (l_prep) of_11\IN|the (l_pobj) patients_12\NNS|NONE (l_prep) with_13\IN|NONE (l_pobj) nausea_15\NN|NONE (l_conj) vomiting_17\VBG|no|, (l_conj) phonophobia_19\NNS|for|,|and (l_conj) photophobia_21\NNS|or
C093622_D008881 NONE rizatriptan_7\JJ|NONE (r_pobj) for_6\IN|NONE (r_prep) preference_5\NN|and (r_conj) efficacy_3\NN|NONE (r_pobj) of_2\IN|.|caffeine|Crossover (r_prep) comparison_1\NN|NONE (l_conj) caffeine_13\NN|.|of|Crossover (l_prep) in_14\IN|/|ergotamine|mg (l_pobj) migraine_15\NN|NONE
C093622_D008881 NONE Rizatriptan_0\NNP|agonist|. (r_nsubj) is_1\VBZ|NONE (l_attr) agonist_7\NN|Rizatriptan|. (l_prep) with_8\IN|selective|receptor|a (l_pobj) absorption_11\NN|NONE (l_conj) onset_14\NN|and|oral|rapid (l_prep) in_17\IN|of|early (l_pobj) treatment_20\NN|NONE (l_prep) of_21\IN|acute|the (l_pobj) migraine_22\NN|NONE
C093622_D008881 NONE rizatriptan_12\JJ|NONE (r_pobj) for_10\IN|the (r_prep) preference_9\NN|tablets|in|.|study (r_dobj) assessed_7\VBD|NONE (l_prep) in_26\IN|preference|tablets|.|study (l_pobj) patients_28\NNS|NONE (l_acl) treating_29\VBG| (l_dobj) attack_33\NN|NONE (l_compound) migraine_32\JJ|with|a|single
D004878_D020795 NONE ergotamine_5\NN|/|in (r_nmod) caffeine_7\NN|NONE (l_prep) in_8\IN|/|ergotamine (l_pobj) proportions_10\NNS|NONE (l_prep) of_11\IN|the (l_pobj) patients_12\NNS|NONE (l_prep) with_13\IN|NONE (l_pobj) nausea_15\NN|NONE (l_conj) vomiting_17\VBG|no|, (l_conj) phonophobia_19\NNS|for|,|and (l_conj) photophobia_21\NNS|or
D012701_D008881 NONE 5-HT(1B/1D_4\CD|) (r_nummod) receptor_6\NN|selective|with|a (r_compound) agonist_7\NN|Rizatriptan|. (l_prep) with_8\IN|selective|receptor|a (l_pobj) absorption_11\NN|NONE (l_conj) onset_14\NN|and|oral|rapid (l_prep) in_17\IN|of|early (l_pobj) treatment_20\NN|NONE (l_prep) of_21\IN|acute|the (l_pobj) migraine_22\NN|NONE
D002110_D006261 NONE caffeine_29\NN|who (r_dobj) preferred_26\VBD|NONE (r_relcl) patients_24\NNS|NONE (r_pobj) of_23\IN|. (r_prep) %_22\NN|and (r_conj) rizatriptan_19\JJ|NONE (r_dobj) preferring_18\VBG|NONE (r_acl) patients_17\NNS|NONE (r_pobj) of_16\IN|. (r_prep) %_15\NN|NONE (r_pobj) by_13\IN|NONE (r_agent) cited_12\VBN|the|,|important|for (r_acl) reason_8\NN|.|relief (r_attr) was_4\VBD|NONE (l_nsubj) relief_1\NN|.|reason (l_prep) of_2\IN|Faster (l_pobj) headache_3\NN|NONE
D004878_D008881 NONE ergotamine_11\NN|/|in|mg (r_nmod) caffeine_13\NN|.|of|Crossover (l_prep) in_14\IN|/|ergotamine|mg (l_pobj) migraine_15\NN|NONE
D004878_D008881 NONE ergotamine_18\NN|NONE (r_pobj) to_16\IN|mg (r_prep) tablet_15\NN| (r_amod) rizatriptan_12\JJ|NONE (r_pobj) for_10\IN|the (r_prep) preference_9\NN|tablets|in|.|study (r_dobj) assessed_7\VBD|NONE (l_prep) in_26\IN|preference|tablets|.|study (l_pobj) patients_28\NNS|NONE (l_acl) treating_29\VBG| (l_dobj) attack_33\NN|NONE (l_compound) migraine_32\JJ|with|a|single
C093622_D010146 NONE rizatriptan_12\NN|NONE (r_pobj) after_11\IN| (r_prep) h_10\NN|compared|,|percent|.|,|free|being (r_npadvmod) were_6\VBD|NONE (l_acomp) free_8\JJ|h|compared|,|percent|.|,|being (l_npadvmod) pain_7\NN|NONE
C093622_D010146 NONE rizatriptan_31\JJ|superior|within (r_nsubj) being_32\VBG|h|compared|,|percent|.|,|free (r_advcl) were_6\VBD|NONE (l_acomp) free_8\JJ|h|compared|,|percent|.|,|being (l_npadvmod) pain_7\NN|NONE
C093622_D010146 NONE rizatriptan_6\NN|NONE (r_dobj) taking_5\VBG|NONE (r_acl) patients_4\NNS|NONE (r_pobj) of_3\IN| (r_prep) %_2\NN|and|,|compared|had|.|free|at (r_nsubj) were_7\VBD|NONE (l_acomp) free_9\JJ|and|%|,|compared|had|.|at (l_npadvmod) pain_8\NN|NONE
18997632
D002110_D017180 CID caffeine_7\NN|NONE (r_compound) pretreatment_8\NN|NONE (r_pobj) to_6\IN|NONE (r_prep) related_5\VBN|ventricular (r_acl) tachycardia_4\NN|NONE
D002110_D017180 CID caffeine_25\NN|NONE (r_compound) administration_26\NN|NONE (r_pobj) after_24\IN|who|bigeminy (r_prep) developed_14\VBD|arrhythmia|cardiac|or (l_dobj) bigeminy_16\JJ|who|after (l_conj) runs_20\NNS|sustained|and (l_prep) of_21\IN|brief| (l_pobj) tachycardia_23\NN|NONE
D002110_D006331 NONE caffeine_25\NN|NONE (r_compound) administration_26\NN|NONE (r_pobj) after_24\IN|who|bigeminy (r_prep) developed_14\VBD|arrhythmia|cardiac|or (r_relcl) disease_10\NN|NONE
D002110_D001145 NONE caffeine_25\NN|NONE (r_compound) administration_26\NN|NONE (r_pobj) after_24\IN|who|bigeminy (r_prep) developed_14\VBD|arrhythmia|cardiac|or (r_relcl) disease_10\NN|NONE (l_conj) arrhythmia_12\NN|cardiac|developed|or
D002110_D001145 NONE caffeine_2\NN|generally|well|Although|is (r_nsubjpass) tolerated_6\VBN|clinician|should|,|aware|. (r_advcl) be_11\VB|NONE (l_acomp) aware_12\JJ|tolerated|clinician|should|,|. (l_prep) of_13\IN|NONE (l_pobj) potential_15\NN|NONE (l_prep) for_16\IN|the (l_pobj) arrhythmias_21\NNS|NONE
D002110_D012640 CID caffeine_1\NN|is|and|improve|commonly|.|tolerated (r_nsubjpass) used_4\VBN|NONE (l_xcomp) improve_6\VB|caffeine|is|and|commonly|.|tolerated (l_dobj) duration_8\NN|to (l_compound) seizure_7\NN|and|quality|in
D002110_D018879 CID caffeine_1\NN|is|and|improve|commonly|.|tolerated (r_nsubjpass) used_4\VBN|NONE (l_conj) tolerated_18\VBN|caffeine|is|and|improve|commonly|. (l_prep) from_20\IN|is|generally|aside|well (l_pobj) reports_22\NNS|NONE (l_prep) of_23\IN|occasional (l_pobj) ectopy_27\NN|NONE
6402369
D015080_D064420 NONE MESNA_7\NNP|and|the|series (r_compound) series_8\NN|NONE (l_conj) series_13\NN|and|the|MESNA (l_prep) with_14\IN|conventional|the|prophylaxis (l_pobj) respect_15\NN|NONE (l_prep) to_16\IN|NONE (l_pobj) toxicity_21\NN|NONE
D015080_D001745 NONE sulphonate_13\JJ|NONE (r_pobj) of_10\IN|oral (r_prep) administration_9\NN|NONE (r_pobj) by_7\IN|urothelial|induced (r_prep) toxicity_6\NN|NONE
D015080_D001745 NONE MESNA_15\NNP|mercaptoethane|sodium (r_appos) sulphonate_13\JJ|NONE (r_pobj) of_10\IN|oral (r_prep) administration_9\NN|NONE (r_pobj) by_7\IN|urothelial|induced (r_prep) toxicity_6\NN|NONE
D015080_D001745 NONE sulphonate_12\JJ|NONE (r_pobj) of_6\IN|oral (r_prep) administration_5\NN|NONE (r_pobj) of_3\IN|protective|The|against (r_prep) effect_2\NN|in|(|)|.|IF|was|as (l_prep) against_16\IN|protective|The|of (l_pobj) toxicity_18\NN|NONE
D015080_D001745 NONE MESNA_14\NNP|compound|mercaptoethane|thiol|sodium|the (r_appos) sulphonate_12\JJ|NONE (r_pobj) of_6\IN|oral (r_prep) administration_5\NN|NONE (r_pobj) of_3\IN|protective|The|against (r_prep) effect_2\NN|in|(|)|.|IF|was|as (l_prep) against_16\IN|protective|The|of (l_pobj) toxicity_18\NN|NONE
D007069_D008175 NONE ifosfamide_2\RB| (r_advmod) induced_4\VBN|urothelial|by (r_amod) toxicity_6\NN|NONE (r_pobj) of_1\IN|.|to (r_prep) Treatment_0\NN|NONE (l_prep) to_17\IN|of|. (l_pobj) patients_18\NNS|NONE (l_prep) with_19\IN|NONE (l_pobj) cancer_22\NN|NONE
D007069_D008175 NONE ifosfamide_21\NN|NONE (r_pobj) by_20\IN|NONE (r_agent) induced_19\VBN|urothelial (r_acl) toxicity_18\NN|NONE (r_pobj) against_16\IN|protective|The|of (r_prep) effect_2\NN|in|(|)|.|IF|was|as (r_nsubjpass) tested_26\VBN|NONE (l_prep) in_27\IN|(|)|effect|.|IF|was|as (l_pobj) group_29\NN|NONE (l_prep) of_30\IN|a (l_pobj) patients_32\NNS|NONE (l_prep) with_33\IN| (l_pobj) cancer_36\NN|NONE
D007069_D008175 NONE IF_23\IN|in|(|)|effect|.|was|as (r_mark) tested_26\VBN|NONE (l_prep) in_27\IN|(|)|effect|.|IF|was|as (l_pobj) group_29\NN|NONE (l_prep) of_30\IN|a (l_pobj) patients_32\NNS|NONE (l_prep) with_33\IN| (l_pobj) cancer_36\NN|NONE
D007069_D008175 NONE IF_40\IN|)||(|mg|/|on (r_mark) m2_45\NN|NONE (r_pobj) with_39\IN|NONE (r_prep) treatment_38\NN|NONE (r_pobj) under_37\IN|inoperable|lung (r_prep) cancer_36\NN|NONE
D007069_D001745 CID ifosfamide_2\RB| (r_advmod) induced_4\VBN|urothelial|by (r_amod) toxicity_6\NN|NONE
D007069_D001745 CID ifosfamide_21\NN|NONE (r_pobj) by_20\IN|NONE (r_agent) induced_19\VBN|urothelial (r_acl) toxicity_18\NN|NONE
D007069_D001745 CID IF_23\IN|in|(|)|effect|.|was|as (r_mark) tested_26\VBN|NONE (l_nsubjpass) effect_2\NN|in|(|)|.|IF|was|as (l_prep) against_16\IN|protective|The|of (l_pobj) toxicity_18\NN|NONE
D007069_D001745 CID IF_40\IN|)||(|mg|/|on (r_mark) m2_45\NN|NONE (r_pobj) with_39\IN|NONE (r_prep) treatment_38\NN|NONE (r_pobj) under_37\IN|inoperable|lung (r_prep) cancer_36\NN|NONE (r_pobj) with_33\IN| (r_prep) patients_32\NNS|NONE (r_pobj) of_30\IN|a (r_prep) group_29\NN|NONE (r_pobj) in_27\IN|(|)|effect|.|IF|was|as (r_prep) tested_26\VBN|NONE (l_nsubjpass) effect_2\NN|in|(|)|.|IF|was|as (l_prep) against_16\IN|protective|The|of (l_pobj) toxicity_18\NN|NONE
D013438_D001745 NONE thiol_8\JJ|compound|MESNA|mercaptoethane|sodium|the (r_compound) sulphonate_12\JJ|NONE (r_pobj) of_6\IN|oral (r_prep) administration_5\NN|NONE (r_pobj) of_3\IN|protective|The|against (r_prep) effect_2\NN|in|(|)|.|IF|was|as (l_prep) against_16\IN|protective|The|of (l_pobj) toxicity_18\NN|NONE
D015080_D008175 NONE sulphonate_13\JJ|NONE (r_pobj) of_10\IN|oral (r_prep) administration_9\NN|NONE (r_pobj) by_7\IN|urothelial|induced (r_prep) toxicity_6\NN|NONE (r_pobj) of_1\IN|.|to (r_prep) Treatment_0\NN|NONE (l_prep) to_17\IN|of|. (l_pobj) patients_18\NNS|NONE (l_prep) with_19\IN|NONE (l_pobj) cancer_22\NN|NONE
D015080_D008175 NONE MESNA_15\NNP|mercaptoethane|sodium (r_appos) sulphonate_13\JJ|NONE (r_pobj) of_10\IN|oral (r_prep) administration_9\NN|NONE (r_pobj) by_7\IN|urothelial|induced (r_prep) toxicity_6\NN|NONE (r_pobj) of_1\IN|.|to (r_prep) Treatment_0\NN|NONE (l_prep) to_17\IN|of|. (l_pobj) patients_18\NNS|NONE (l_prep) with_19\IN|NONE (l_pobj) cancer_22\NN|NONE
D015080_D008175 NONE sulphonate_12\JJ|NONE (r_pobj) of_6\IN|oral (r_prep) administration_5\NN|NONE (r_pobj) of_3\IN|protective|The|against (r_prep) effect_2\NN|in|(|)|.|IF|was|as (r_nsubjpass) tested_26\VBN|NONE (l_prep) in_27\IN|(|)|effect|.|IF|was|as (l_pobj) group_29\NN|NONE (l_prep) of_30\IN|a (l_pobj) patients_32\NNS|NONE (l_prep) with_33\IN| (l_pobj) cancer_36\NN|NONE
D015080_D008175 NONE MESNA_14\NNP|compound|mercaptoethane|thiol|sodium|the (r_appos) sulphonate_12\JJ|NONE (r_pobj) of_6\IN|oral (r_prep) administration_5\NN|NONE (r_pobj) of_3\IN|protective|The|against (r_prep) effect_2\NN|in|(|)|.|IF|was|as (r_nsubjpass) tested_26\VBN|NONE (l_prep) in_27\IN|(|)|effect|.|IF|was|as (l_pobj) group_29\NN|NONE (l_prep) of_30\IN|a (l_pobj) patients_32\NNS|NONE (l_prep) with_33\IN| (l_pobj) cancer_36\NN|NONE
D013438_D008175 NONE thiol_8\JJ|compound|MESNA|mercaptoethane|sodium|the (r_compound) sulphonate_12\JJ|NONE (r_pobj) of_6\IN|oral (r_prep) administration_5\NN|NONE (r_pobj) of_3\IN|protective|The|against (r_prep) effect_2\NN|in|(|)|.|IF|was|as (r_nsubjpass) tested_26\VBN|NONE (l_prep) in_27\IN|(|)|effect|.|IF|was|as (l_pobj) group_29\NN|NONE (l_prep) of_30\IN|a (l_pobj) patients_32\NNS|NONE (l_prep) with_33\IN| (l_pobj) cancer_36\NN|NONE
18329269
D006220_D002375 CID haloperidol_36\NN| (r_npadvmod) induced_38\VBN|rat|catalepsy|for (r_amod) model_40\NN|NONE (l_compound) catalepsy_39\NN|rat|for|induced
D006220_D010300 NONE haloperidol_36\NN| (r_npadvmod) induced_38\VBN|rat|catalepsy|for (r_amod) model_40\NN|NONE (l_prep) for_41\IN|rat|catalepsy|induced (l_pobj) disease_44\NN|NONE
6503301
D003606_D008545 NONE dacarbazine_6\NN|for|(|)|DTIC (r_compound) therapy_7\NN|NONE (l_prep) for_11\IN|(|dacarbazine|)|DTIC (l_pobj) melanoma_12\NN|NONE
D003606_D008545 NONE DTIC_9\NNP|for|(|dacarbazine|) (r_appos) therapy_7\NN|NONE (l_prep) for_11\IN|(|dacarbazine|)|DTIC (l_pobj) melanoma_12\NN|NONE
D003606_D008545 NONE dacarbazine_14\NN|for|(|DTIC|) (r_nmod) therapy_18\NN|is|case|.|after (l_prep) for_19\IN|(|dacarbazine|DTIC|) (l_pobj) melanoma_20\NN|NONE
D003606_D008545 NONE DTIC_16\NNP|for|(|dacarbazine|) (r_nmod) therapy_18\NN|is|case|.|after (l_prep) for_19\IN|(|dacarbazine|DTIC|) (l_pobj) melanoma_20\NN|NONE
D003606_D006504 CID dacarbazine_6\NN|for|(|)|DTIC (r_compound) therapy_7\NN|NONE (r_pobj) after_5\IN|.|occlusive|liver (r_prep) disease_4\NN|NONE
D003606_D006504 CID DTIC_9\NNP|for|(|dacarbazine|) (r_appos) therapy_7\NN|NONE (r_pobj) after_5\IN|.|occlusive|liver (r_prep) disease_4\NN|NONE
D003606_D006504 CID dacarbazine_14\NN|for|(|DTIC|) (r_nmod) therapy_18\NN|is|case|.|after (r_nsubjpass) reported_22\VBN|NONE (l_nsubjpass) case_1\NN|is|.|therapy|after (l_prep) of_2\IN|A (l_pobj) disease_6\NN|NONE (l_prep) of_7\IN|occlusive|with (l_pobj) liver_9\NN|NONE
D003606_D006504 CID DTIC_16\NNP|for|(|dacarbazine|) (r_nmod) therapy_18\NN|is|case|.|after (r_nsubjpass) reported_22\VBN|NONE (l_nsubjpass) case_1\NN|is|.|therapy|after (l_prep) of_2\IN|A (l_pobj) disease_6\NN|NONE (l_prep) of_7\IN|occlusive|with (l_pobj) liver_9\NN|NONE
15930398
D015742_D000647 CID propofol_12\NN|NONE (r_pobj) with_11\IN|procedural (r_prep) sedation_10\NN|NONE (r_pobj) during_8\IN|of|the|persistence|and (r_prep) onset_3\NN|NONE (l_prep) of_6\IN|during|the|persistence|and (l_pobj) amnesia_7\NN|NONE
9523850
D007505_D018771 CID dextran_19\NN|NONE (r_pobj) of_17\IN|total|dose|the (r_prep) infusion_16\NN|NONE (r_pobj) with_12\IN|NONE (r_prep) associated_11\VBN|the|myalgia (r_acl) syndrome_10\NN|NONE (l_compound) myalgia_9\NN|the|associated (l_compound) arthralgia_7\JJ|
D008775_D063806 NONE methylprednisolone_2\NN|NONE (r_pobj) of_1\IN|:|.|in|trial (r_prep) Value_0\NN|NONE (l_prep) in_3\IN|:|of|.|trial (l_pobj) prevention_4\NN|NONE (l_prep) of_5\IN|NONE (l_pobj) syndrome_10\NN|NONE (l_compound) myalgia_9\NN|the|associated
D008775_D063806 NONE MP_6\NNP|NONE (r_pobj) of_5\IN|before (r_prep) administration_4\NN|after|TDI|frequency|that (r_nsubj) reduces_11\VBZ|.|data (l_dobj) frequency_13\NN|administration|after|TDI|that (l_prep) of_16\IN|severity|the|and (l_pobj) syndrome_21\NN|NONE (l_compound) myalgia_20\NN|the
D008775_D018771 NONE methylprednisolone_2\NN|NONE (r_pobj) of_1\IN|:|.|in|trial (r_prep) Value_0\NN|NONE (l_prep) in_3\IN|:|of|.|trial (l_pobj) prevention_4\NN|NONE (l_prep) of_5\IN|NONE (l_pobj) syndrome_10\NN|NONE (l_compound) myalgia_9\NN|the|associated (l_compound) arthralgia_7\JJ|
D008775_D018771 NONE MP_6\NNP|NONE (r_pobj) of_5\IN|before (r_prep) administration_4\NN|after|TDI|frequency|that (r_nsubj) reduces_11\VBZ|.|data (l_dobj) frequency_13\NN|administration|after|TDI|that (l_prep) of_16\IN|severity|the|and (l_pobj) syndrome_21\NN|NONE (l_compound) myalgia_20\NN|the (l_compound) arthralgia_18\JJ|
D007505_D063806 NONE dextran_19\NN|NONE (r_pobj) of_17\IN|total|dose|the (r_prep) infusion_16\NN|NONE (r_pobj) with_12\IN|NONE (r_prep) associated_11\VBN|the|myalgia (r_acl) syndrome_10\NN|NONE (l_compound) myalgia_9\NN|the|associated
17194457
-1_D001523 NONE PCPA_3\NNP|NONE (r_pobj) to_2\IN|Chronic|alone (r_prep) exposure_1\NN|activity|but|significantly|increased|and|.|had (r_nsubj) decreased_6\VBD|NONE (l_conj) increased_10\VBN|activity|but|significantly|exposure|and|.|had (l_dobj) irritability_11\NN|NONE
-1_D001523 NONE PCPA_3\NNP|NONE (r_pobj) to_2\IN|Chronic|alone (r_prep) exposure_1\NN|activity|but|significantly|increased|and|.|had (r_nsubj) decreased_6\VBD|NONE (l_conj) had_13\VBD|activity|but|significantly|exposure|increased|and|. (l_dobj) effect_15\NN|NONE (l_prep) on_16\IN|no (l_pobj) behavior_18\NN|NONE (l_conj) preference_21\NN|,|sexual (l_conj) aggression_24\NN|partner|,|or
D012701_D001523 NONE 5-HT_16\CD|NONE (r_pobj) with_13\IN|AAS|pubertal (r_prep) users_12\NNS|prone|may|that (r_nsubj) be_18\VB|,|can|Based|be|it|. (l_acomp) prone_20\JJ|users|may|that (l_xcomp) exhibit_22\VB|especially (l_dobj) behavior_24\NN|to
D013739_D001523 CID T_0\NNP|.|effect|preference|but (r_nsubj) had_2\VBD|NONE (l_dobj) effect_4\NN|T|.|preference|but (l_prep) on_5\IN|no (l_pobj) locomotion_6\NN|NONE (l_conj) irritability_8\NN|,
D013739_D001523 CID T_0\NNP|.|effect|preference|but (r_nsubj) had_2\VBD|NONE (l_conj) preference_16\NN|T|.|effect|but (l_conj) aggression_18\NN|and|increased|partner
19346865
D008795_D007239 NONE metronidazole_4\NN|had|They|)|been|dosage|treat|.|( (r_dobj) taking_3\VBG|NONE (l_advcl) treat_23\VB|had|They|metronidazole|)|been|dosage|.|( (l_dobj) infection_25\NN|to
D008795_D001927 CID metronidazole_5\NN| (r_npadvmod) induced_7\VBN|NONE (r_amod) encephalopathy_8\NN|NONE (r_pobj) in_4\IN|findings|colliculus|inferior|.|:|Reversible (r_prep) lesion_3\NN|NONE
D008795_D001927 CID metronidazole_5\NN| (r_npadvmod) induced_7\VBN|NONE (r_amod) encephalopathy_8\NN|NONE
D008795_D001927 CID metronidazole_9\NN| (r_npadvmod) induced_11\VBN|NONE (r_amod) encephalopathy_12\NN|NONE (r_pobj) in_8\IN|inferior|colliculus|reversible (r_prep) lesions_7\NNS|,|to|focus
D008795_D001927 CID metronidazole_9\NN| (r_npadvmod) induced_11\VBN|NONE (r_amod) encephalopathy_12\NN|NONE
D008795_D001927 CID metronidazole_20\NN| (r_npadvmod) induced_22\VBN|(|;|range|years (r_amod) encephalopathy_23\NN|NONE
D008795_D001927 CID metronidazole_11\NN| (r_npadvmod) induced_13\VBN|NONE (r_amod) encephalopathy_14\NN|NONE (r_pobj) for_10\IN|the (r_prep) characteristic_9\NN|NONE (r_pobj) as_7\IN|.|next|lesions|could|be|, (r_prep) considered_6\VBN|NONE (l_nsubjpass) lesions_3\NNS|.|next|could|be|as|,
D008795_D001927 CID metronidazole_11\NN| (r_npadvmod) induced_13\VBN|NONE (r_amod) encephalopathy_14\NN|NONE
3409645
D008727_D007172 CID methotrexate_23\NNP|NONE (r_pobj) of_22\IN|the (r_prep) taking_21\NN|.|found|common|Impotence|and|and (r_conj) was_1\VBD|NONE (l_nsubj) Impotence_0\NN|.|found|common|taking|and|and
603022
D005702_D062787 NONE hydrobromide_1\RB|was|.|in (r_nsubjpass) used_16\VBN|NONE (l_prep) in_17\IN|hydrobromide|was|. (l_pobj) patient_19\JJ|NONE (l_acl) demonstrating_20\NN|a (l_dobj) effects_22\NNS|NONE (l_prep) of_23\IN|central (l_pobj) overdosage_28\NN|NONE
D012601_D062787 CID scopolamine_24\NN|hyoscine|)|( (r_nmod) overdosage_28\NN|NONE
D012601_D062787 CID hyoscine_26\NN|)|scopolamine|( (r_nmod) overdosage_28\NN|NONE
2334618
D009020_D013610 NONE morphine_26\NN|NONE (r_compound) infusion_27\NN|the (r_compound) group_28\NN|NONE (r_pobj) in_24\IN|P|ventricular|(|ectopic|) (r_prep) beats_17\NNS|P|)|(|and (r_conj) tachyarrhythmias_7\NNS|NONE
D009020_D018879 CID morphine_26\NN|NONE (r_compound) infusion_27\NN|the (r_compound) group_28\NN|NONE (r_pobj) in_24\IN|P|ventricular|(|ectopic|) (r_prep) beats_17\NNS|P|)|(|and
D009020_D020182 CID morphine_25\NN|a (r_compound) infusion_26\NN|who (r_dobj) had_23\VBD|NONE (r_relcl) patients_21\NNS|NONE (r_pobj) in_20\IN|frequently|obstructive|. (r_prep) occurred_17\VBD|NONE (l_nsubj) obstructive_1\JJ|frequently|in|. (l_appos) P_3\NN|Both|( (l_conj) apnoea_10\NN|.|)|and
D009020_D001049 NONE morphine_17\NN|NONE (r_pobj) of_16\IN|continuous|i.v.|a (r_prep) infusion_15\NN|NONE (r_dobj) receiving_11\VBG|and|mean|patients|five (r_acl) patients_10\NNS|NONE (r_pobj) between_8\IN|incidence|was|. (r_prep) compared_7\VBN|NONE (l_nsubjpass) incidence_1\NN|between|was|. (l_prep) of_2\IN|The (l_pobj) apnoea_5\NN|NONE
D009020_D020181 CID morphine_25\NN|a (r_compound) infusion_26\NN|who (r_dobj) had_23\VBD|NONE (r_relcl) patients_21\NNS|NONE (r_pobj) in_20\IN|frequently|obstructive|. (r_prep) occurred_17\VBD|NONE (l_nsubj) obstructive_1\JJ|frequently|in|. (l_appos) P_3\NN|Both|( (l_conj) apnoea_10\NN|.|)|and
D002045_D001049 NONE bupivacaine_34\NN|NONE (r_pobj) of_31\IN|continuous|extradural|a (r_prep) infusion_30\NN|NONE (r_dobj) receiving_26\VBG|in|five|mean (r_acl) patients_25\NNS|and|mean|receiving|five (r_conj) patients_10\NNS|NONE (r_pobj) between_8\IN|incidence|was|. (r_prep) compared_7\VBN|NONE (l_nsubjpass) incidence_1\NN|between|was|. (l_prep) of_2\IN|The (l_pobj) apnoea_5\NN|NONE
2071257
D005997_D008569 NONE glycerylphosphorylcholine_15\NN|NONE (r_pobj) of_10\IN|on|the (r_prep) effects_9\NNS|to (l_prep) on_23\IN|of|the (l_pobj) impairment_25\NN|NONE
D005997_D008569 NONE GFC_21\NNP|L|||alpha (r_appos) glycerylphosphorylcholine_15\NN|NONE (r_pobj) of_10\IN|on|the (r_prep) effects_9\NNS|to (l_prep) on_23\IN|of|the (l_pobj) impairment_25\NN|NONE
D005997_D000647 NONE phosphorylcholine_8\NN|NONE (r_pobj) of_1\IN|.|on (r_prep) Effect_0\NN|NONE (l_prep) on_9\IN|.|of (l_pobj) amnesia_10\NN|NONE
D012601_D008569 CID scopolamine_28\NN|NONE (r_pobj) by_27\IN|NONE (r_agent) induced_26\VBN|memory (r_acl) impairment_25\NN|NONE
D012601_D008569 CID scopolamine_20\NN|NONE (r_pobj) by_19\IN|NONE (r_agent) induced_18\VBN|of (r_acl) impairment_13\NN|to (l_prep) of_14\IN|induced (l_pobj) attention_15\NN|NONE (l_conj) memory_17\NN|and
D012601_D000647 NONE scopolamine_13\NN|NONE (r_pobj) by_12\IN|NONE (r_agent) caused_11\VBN|NONE (r_acl) amnesia_10\NN|NONE
19707748
D064704_D012640 CID levofloxacin_3\NNS|NONE (r_pobj) with_2\IN|NONE (r_prep) associated_1\VBN|.|presentation|: (r_acl) Seizures_0\NNS|NONE
D064704_D012640 CID levofloxacin_15\NNS|NONE (r_pobj) with_14\IN|NONE (r_prep) treatment_13\NN|and|discuss (r_dobj) initiating_12\VBG|shortly|as (r_pcomp) after_11\IN|who|seizures (r_prep) developed_8\VBD|of|,|a (l_dobj) seizures_9\NNS|after|who
D064704_D012640 CID levofloxacin_15\NNS|NONE (r_pobj) with_14\IN|NONE (r_prep) treatment_13\NN|and|discuss (r_dobj) initiating_12\VBG|shortly|as (r_pcomp) after_11\IN|who|seizures (r_prep) developed_8\VBD|of|,|a (r_relcl) patient_6\NN|NONE (l_prep) of_47\IN|developed|,|a (l_pobj) seizures_51\NNS|NONE
D064704_D012640 CID levofloxacin_48\NN| (r_npadvmod) induced_50\VBN|NONE (r_amod) seizures_51\NNS|NONE (r_pobj) of_47\IN|developed|,|a (r_prep) patient_6\NN|NONE (l_relcl) developed_8\VBD|of|,|a (l_dobj) seizures_9\NNS|after|who
D064704_D012640 CID levofloxacin_48\NN| (r_npadvmod) induced_50\VBN|NONE (r_amod) seizures_51\NNS|NONE
D064704_D012640 CID levofloxacin_3\NN| (r_npadvmod) induced_5\VBN|NONE (r_amod) seizures_6\NNS|NONE
11077455
D020888_D014786 CID vigabatrin_16\NN| (r_npadvmod) attributed_18\VBN|field (r_amod) constriction_21\NN|NONE
D020888_D014786 CID vigabatrin_9\NN|NONE (r_pobj) with_8\IN|be|to (r_prep) associated_7\VBN|constriction (r_xcomp) thought_4\NN|has|been|. (l_nsubj) constriction_3\NN|associated
D020888_D014786 CID vigabatrin_15\NN| (r_npadvmod) attributed_17\VBN|known|field (r_amod) loss_20\NN|NONE
D020888_D014786 CID vigabatrin_9\NN|NONE (r_compound) therapy_10\NN|NONE (r_pobj) with_8\IN|to|be (r_prep) associated_7\VBN|constriction|. (r_xcomp) appears_4\VBZ|NONE (l_nsubj) constriction_3\NN|associated|.
17285209
D000809_D007410 NONE angiotensin_3\NN| (r_npadvmod) converting_5\VBG|(|)|blocker|and|ACE (r_amod) enzyme_6\NN|NONE (r_pobj) of_2\IN|The (r_prep) recognition_1\NN|angioedema|(|.|challenge (r_nsubj) constitutes_19\VBZ|NONE (l_nsubj) angioedema_18\NN|recognition|(|.|challenge
D000809_D007410 NONE angiotensin_11\NN|receptor (r_compound) blocker_13\NN|(|converting|)|and|ACE (r_conj) enzyme_6\NN|NONE (r_pobj) of_2\IN|The (r_prep) recognition_1\NN|angioedema|(|.|challenge (r_nsubj) constitutes_19\VBZ|NONE (l_nsubj) angioedema_18\NN|recognition|(|.|challenge
C044946_D006973 NONE benazapril_28\NN|/ (r_compound) mg._30\CD|/|of|combination|a (r_appos) pill_24\NN|NONE (r_pobj) on_21\IN|was|who (r_prep) started_20\VBN|a|with|American|old|,|year (r_relcl) female_12\NN|NONE (l_prep) with_13\IN|started|a|American|old|,|year (l_pobj) hypertension_16\NN|NONE
D000809_D000799 NONE angiotensin_3\NN| (r_npadvmod) converting_5\VBG|(|)|blocker|and|ACE (r_amod) enzyme_6\NN|NONE (r_pobj) of_2\IN|The (r_prep) recognition_1\NN|angioedema|(|.|challenge (r_nsubj) constitutes_19\VBZ|NONE (l_nsubj) angioedema_18\NN|recognition|(|.|challenge
D000809_D000799 NONE angiotensin_11\NN|receptor (r_compound) blocker_13\NN|(|converting|)|and|ACE (r_conj) enzyme_6\NN|NONE (r_pobj) of_2\IN|The (r_prep) recognition_1\NN|angioedema|(|.|challenge (r_nsubj) constitutes_19\VBZ|NONE (l_nsubj) angioedema_18\NN|recognition|(|.|challenge
D017311_D006973 NONE amlodipine_26\NN|NONE (r_pobj) of_25\IN|/|combination|mg.|a (r_prep) pill_24\NN|NONE (r_pobj) on_21\IN|was|who (r_prep) started_20\VBN|a|with|American|old|,|year (r_relcl) female_12\NN|NONE (l_prep) with_13\IN|started|a|American|old|,|year (l_pobj) hypertension_16\NN|NONE
20003049
C031942_D013927 NONE argatroban_4\NN|NONE (l_prep) in_5\IN|.|elevation (l_pobj) patient_9\NN|NONE (l_prep) with_10\IN|transplant|a (l_pobj) history_13\NN|NONE (l_prep) of_14\IN|a|suspected (l_pobj) thrombocytopenia_18\NN|NONE (l_prep) with_19\IN|induced (l_pobj) thrombosis_20\NN|NONE
C031942_D013927 NONE argatroban_20\NN|In|,|.|during|patient|was (r_oprd) administered_19\VBN|NONE (l_nsubjpass) patient_11\JJ|In|,|.|argatroban|during|was (l_prep) with_12\IN|a|old|ill (l_pobj) history_15\NN|NONE (l_prep) of_16\IN|a|suspected (l_pobj) HITT_17\NNP|NONE
C031942_D008107 NONE argatroban_4\NN|NONE (r_pobj) of_3\IN|high (r_prep) concentrations_2\NNS|in|is|.|observed|and|were|, (r_nsubjpass) measured_6\VBN|NONE (l_conj) is_42\VBZ|in|concentrations|.|observed|and|were|, (l_attr) minutes_46\NNS|) (l_appos) minutes_52\NNS|[|]|| (l_prep) with_53\IN||<|= (l_pobj) impairment_55\NN|NONE
C031942_D008107 NONE argatroban_25\JJ|t(/|half (r_amod) life_27\NN|)|a|of|prolonged (r_npadvmod) plasma_24\NN|was|published (r_nsubjpass) observed_36\VBN|in|is|concentrations|.|and|were|, (r_conj) measured_6\VBN|NONE (l_conj) is_42\VBZ|in|concentrations|.|observed|and|were|, (l_attr) minutes_46\NNS|) (l_appos) minutes_52\NNS|[|]|| (l_prep) with_53\IN||<|= (l_pobj) impairment_55\NN|NONE
C031942_D016638 NONE argatroban_20\NN|In|,|.|during|patient|was (r_oprd) administered_19\VBN|NONE (l_nsubjpass) patient_11\JJ|In|,|.|argatroban|during|was (l_amod) ill_10\JJ|with|a|old
C031942_D013921 NONE argatroban_4\NN|NONE (l_prep) in_5\IN|.|elevation (l_pobj) patient_9\NN|NONE (l_prep) with_10\IN|transplant|a (l_pobj) history_13\NN|NONE (l_prep) of_14\IN|a|suspected (l_pobj) thrombocytopenia_18\NN|NONE
C031942_D013921 NONE argatroban_20\NN|In|,|.|during|patient|was (r_oprd) administered_19\VBN|NONE (l_nsubjpass) patient_11\JJ|In|,|.|argatroban|during|was (l_prep) with_12\IN|a|old|ill (l_pobj) history_15\NN|NONE (l_prep) of_16\IN|a|suspected (l_pobj) HITT_17\NNP|NONE
D006493_D013921 NONE heparin_15\NN| (r_npadvmod) induced_17\VBN|with (r_amod) thrombocytopenia_18\NN|NONE
D006493_D013921 NONE heparin_18\NN| (r_npadvmod) induced_20\VBN|HIT|( (r_amod) thrombocytopenia_21\NN|NONE
D006493_D013921 NONE heparin_18\NN| (r_npadvmod) induced_20\VBN|HIT|( (r_amod) thrombocytopenia_21\NN|NONE (l_appos) HIT_23\NNP|induced|(
D006493_D013921 NONE heparin_18\NN| (r_npadvmod) induced_20\VBN|HIT|( (r_amod) thrombocytopenia_21\NN|NONE (r_pobj) of_17\IN|a (r_prep) history_16\NN|NONE (r_pobj) with_14\IN|NONE (r_prep) patients_13\NNS|NONE (r_pobj) for_12\IN|NONE (r_prep) anticoagulation_11\NN|NONE (r_pobj) of_10\IN|an|alternative (r_prep) method_9\NN|HIT|inhibitors|or|. (r_dobj) provide_6\VBP|NONE (l_conj) HIT_26\VB|method|inhibitors|or|.
D006493_D013921 NONE heparin_18\NN| (r_npadvmod) induced_20\VBN|HIT|( (r_amod) thrombocytopenia_21\NN|NONE (r_pobj) of_17\IN|a (r_prep) history_16\NN|NONE (r_pobj) with_14\IN|NONE (r_prep) patients_13\NNS|NONE (r_pobj) for_12\IN|NONE (r_prep) anticoagulation_11\NN|NONE (r_pobj) of_10\IN|an|alternative (r_prep) method_9\NN|HIT|inhibitors|or|. (r_dobj) provide_6\VBP|NONE (l_conj) HIT_26\VB|method|inhibitors|or|. (l_prep) with_27\IN|undergoing (l_pobj) thrombosis_28\NN|NONE (l_appos) HITT_30\NNP|NONE
C031942_D001778 NONE argatroban_3\JJ|versus|Correlation (r_amod) concentration_4\NN|.|contributed (r_nsubj) suggest_14\VBP|NONE (l_ccomp) contributed_24\VBN|.|concentration (l_prep) to_25\IN|may|have|levels|that (l_pobj) coagulopathy_30\NN|NONE
C031942_D001778 NONE argatroban_21\NN|elevated|prolonged|of (r_amod) levels_18\NNS|may|have|that|to (r_nsubj) contributed_24\VBN|.|concentration (l_prep) to_25\IN|may|have|levels|that (l_pobj) coagulopathy_30\NN|NONE
C031942_D001778 NONE argatroban_8\JJ|in (r_amod) concentration_9\NN|and|to|plasma|extended (r_dobj) measure_6\VB|the|first (l_conj) extended_16\VBN|and|to|plasma|concentration (l_dobj) coagulopathy_17\NN|NONE
D006493_D013927 NONE heparin_15\NN| (r_npadvmod) induced_17\VBN|with (r_amod) thrombocytopenia_18\NN|NONE (l_prep) with_19\IN|induced (l_pobj) thrombosis_20\NN|NONE
D006493_D013927 NONE heparin_18\NN| (r_npadvmod) induced_20\VBN|HIT|( (r_amod) thrombocytopenia_21\NN|NONE (r_pobj) of_17\IN|a (r_prep) history_16\NN|NONE (r_pobj) with_14\IN|NONE (r_prep) patients_13\NNS|NONE (r_pobj) for_12\IN|NONE (r_prep) anticoagulation_11\NN|NONE (r_pobj) of_10\IN|an|alternative (r_prep) method_9\NN|HIT|inhibitors|or|. (r_dobj) provide_6\VBP|NONE (l_conj) HIT_26\VB|method|inhibitors|or|. (l_prep) with_27\IN|undergoing (l_pobj) thrombosis_28\NN|NONE
D006493_D013927 NONE heparin_18\NN| (r_npadvmod) induced_20\VBN|HIT|( (r_amod) thrombocytopenia_21\NN|NONE (r_pobj) of_17\IN|a (r_prep) history_16\NN|NONE (r_pobj) with_14\IN|NONE (r_prep) patients_13\NNS|NONE (r_pobj) for_12\IN|NONE (r_prep) anticoagulation_11\NN|NONE (r_pobj) of_10\IN|an|alternative (r_prep) method_9\NN|HIT|inhibitors|or|. (r_dobj) provide_6\VBP|NONE (l_conj) HIT_26\VB|method|inhibitors|or|. (l_prep) with_27\IN|undergoing (l_pobj) thrombosis_28\NN|NONE (l_appos) HITT_30\NNP|NONE
2375138
D008874_D003643 NONE midazolam_2\RB| (r_npadvmod) associated_4\VBN|intramuscular|Possible|cardiorespiratory|death|.|and (r_amod) arrest_6\NN|NONE (l_conj) death_8\NN|intramuscular|Possible|cardiorespiratory|.|associated|and
D008874_D003643 NONE midazolam_17\NN|NONE (r_pobj) of_16\IN|intramuscular (r_prep) administration_15\NN|NONE (r_pobj) with_13\IN|NONE (r_prep) associated_12\VBN|of|published|the|first (r_acl) case_6\NN|report|. (l_prep) of_7\IN|published|associated|the|first (l_pobj) arrest_9\NN|NONE (l_conj) death_11\NN|and|cardiorespiratory
D008874_D006323 CID midazolam_2\RB| (r_npadvmod) associated_4\VBN|intramuscular|Possible|cardiorespiratory|death|.|and (r_amod) arrest_6\NN|NONE
D008874_D006323 CID midazolam_17\NN|NONE (r_pobj) of_16\IN|intramuscular (r_prep) administration_15\NN|NONE (r_pobj) with_13\IN|NONE (r_prep) associated_12\VBN|of|published|the|first (r_acl) case_6\NN|report|. (l_prep) of_7\IN|published|associated|the|first (l_pobj) arrest_9\NN|NONE
15859940
D016572_D064420 NONE cyclosporine_7\NN|,|status|(|related (r_nmod) toxicity_11\NN|.|causes
D016559_D064420 NONE tacrolimus_9\NN|, (r_conj) cyclosporine_7\NN|,|status|(|related (r_nmod) toxicity_11\NN|.|causes
D016572_D057049 CID cyclosporine_18\NN|mainly (r_pobj) to_17\IN|NONE (r_prep) secondary_15\JJ|drug|, (r_amod) related_13\VBN|that|cause (r_acomp) was_11\VBD|We|. (l_nsubj) cause_7\NN|that|related (l_prep) of_8\IN|the|frequent (l_pobj) microangiopathy_10\NN|NONE
15565293
D004977_D009901 CID ethambutol_10\NN| (r_advmod) induced_12\VBN|optic (r_amod) neuropathy_14\NN|NONE
D004977_D009901 CID ethambutol_14\NN| (r_advmod) induced_16\VBN|optic (r_amod) neuropathy_18\NN|NONE
D004977_D009901 CID ethambutol_4\NN|NONE (r_pobj) of_3\IN|serious|A (r_prep) complication_2\NN|.|neuropathy (r_nsubj) is_5\VBZ|NONE (l_attr) neuropathy_8\NN|.|complication
D004977_D009901 CID ethambutol_6\NN|,|optic|of|(|and (r_amod) neuropathy_10\NN|NONE
D004977_D009901 CID EMB)-induced_8\VBN|NONE (r_amod) optic_9\JJ|,|of|ethambutol|(|and (r_compound) neuropathy_10\NN|NONE
D004977_D009901 CID EMB_6\NNP| (r_npadvmod) induced_8\VBN|optic (r_amod) neuropathy_10\NN|NONE
D004977_D009901 CID EMB_7\NNP| (r_npadvmod) induced_9\VBN|optic (r_amod) neuropathy_11\NN|NONE
D004977_D009901 CID EMB_7\NNP| (r_npadvmod) induced_9\VBN|optic (r_amod) neuropathy_11\NN|NONE
D004977_D009901 CID ethambutol_19\NN|in (r_amod) dosing_20\VBG|to|achieve|and|properly (r_dobj) manage_18\VB|NONE (r_xcomp) important_15\JJ|,|reached|in|.|,|Additionally|it (r_acomp) is_14\VBZ|NONE (l_prep) in_2\IN|,|reached|.|important|,|Additionally|it (l_pobj) terms_3\NNS|NONE (l_prep) of_4\IN|NONE (l_pobj) management_5\NN|NONE (l_prep) of_6\IN|NONE (l_pobj) neuropathy_11\NN|NONE
D004977_D014376 NONE Ethambutol_0\NNP|.|agent (r_nsubj) is_1\VBZ|NONE (l_attr) agent_4\NN|.|Ethambutol (l_acl) used_6\VBD|an|antimycobacterial (l_xcomp) treat_8\VB|often (l_dobj) tuberculosis_9\NN|to
D004977_D051437 NONE EMB_7\NNP| (r_npadvmod) induced_9\VBN|optic (r_amod) neuropathy_11\NN|NONE (r_pobj) of_6\IN|NONE (r_prep) management_5\NN|NONE (r_pobj) of_4\IN|NONE (r_prep) terms_3\NNS|NONE (r_pobj) in_2\IN|,|reached|.|important|,|Additionally|it (r_prep) is_14\VBZ|NONE (l_acomp) important_15\JJ|,|reached|in|.|,|Additionally|it (l_xcomp) manage_18\VB|NONE (l_dobj) dosing_20\VBG|to|achieve|and|properly (l_prep) in_21\IN|ethambutol (l_pobj) patients_22\NNS|NONE (l_prep) with_23\IN|NONE (l_pobj) impairment_25\NN|NONE
D004977_D051437 NONE ethambutol_19\NN|in (r_amod) dosing_20\VBG|to|achieve|and|properly (l_prep) in_21\IN|ethambutol (l_pobj) patients_22\NNS|NONE (l_prep) with_23\IN|NONE (l_pobj) impairment_25\NN|NONE
D004977_D009410 NONE ethambutol_14\NN| (r_advmod) induced_16\VBN|optic (r_amod) neuropathy_18\NN|NONE (r_pobj) in_13\IN|using|axonal (r_prep) degeneration_12\NN|NONE
D004977_D014786 CID ethambutol_6\NN|,|optic|of|(|and (r_amod) neuropathy_10\NN|NONE (r_pobj) of_5\IN|a (r_prep) history_4\NN|NONE (r_pobj) with_2\IN|Three (r_prep) subjects_1\NNS|examination|were|deficits|. (r_nsubjpass) administered_23\VBN|NONE (l_nsubjpass) deficits_21\NNS|subjects|examination|were|.
D004977_D014786 CID EMB)-induced_8\VBN|NONE (r_amod) optic_9\JJ|,|of|ethambutol|(|and (r_compound) neuropathy_10\NN|NONE (r_pobj) of_5\IN|a (r_prep) history_4\NN|NONE (r_pobj) with_2\IN|Three (r_prep) subjects_1\NNS|examination|were|deficits|. (r_nsubjpass) administered_23\VBN|NONE (l_nsubjpass) deficits_21\NNS|subjects|examination|were|.
D004977_D014786 CID EMB_6\NNP| (r_npadvmod) induced_8\VBN|optic (r_amod) neuropathy_10\NN|NONE (r_pobj) of_5\IN|NONE (r_prep) history_4\NN|NONE (r_pobj) with_3\IN|all (r_prep) subjects_2\NNS|NONE (r_pobj) In_0\IN|loss|there|.|with|,|, (r_prep) was_13\VBD|NONE (l_attr) loss_16\NN|there|.|with|In|,|, (l_prep) with_32\IN|loss|mean|,|)|a|of|in (l_pobj) recovery_34\NN|NONE (l_prep) with_48\IN|eventual|of (l_pobj) deficits_51\NNS|NONE
D004977_D014786 CID EMB_6\NNP| (r_npadvmod) induced_8\VBN|optic (r_amod) neuropathy_10\NN|NONE (r_pobj) of_5\IN|NONE (r_prep) history_4\NN|NONE (r_pobj) with_3\IN|all (r_prep) subjects_2\NNS|NONE (r_pobj) In_0\IN|loss|there|.|with|,|, (r_prep) was_13\VBD|NONE (l_attr) loss_16\NN|there|.|with|In|,|, (l_conj) loss_55\NN|mean|,|)|with|a|of|in (l_conj) C_58\NN|;|% (l_prep) with_60\IN|loss|,|patient|, (l_pobj) deficits_63\NNS|NONE
16740173
18343374
D002996_D013923 NONE CC_10\NN|NONE (r_pobj) of_9\IN|thromboembolic|the (r_prep) complications_8\NNS|NONE (l_compound) thromboembolic_7\JJ|the|of
D002996_D013923 NONE CC_24\NN|NONE (r_compound) intake_25\NN|NONE (r_pobj) after_23\IN|mild|visual (r_prep) disturbance_22\NN|not|although|uncommon (r_nsubj) is_26\VBZ|does|not|.|search|,|complication (r_advcl) include_13\VB|NONE (l_nsubj) search_1\NN|is|does|not|.|,|complication (l_prep) on_5\IN|of|A (l_pobj) complications_8\NNS|NONE (l_compound) thromboembolic_7\JJ|the|of
D002996_D014786 CID CC_10\NN|NONE (r_pobj) of_9\IN|thromboembolic|the (r_prep) complications_8\NNS|NONE (r_pobj) on_5\IN|of|A (r_prep) search_1\NN|is|does|not|.|,|complication (r_nsubj) include_13\VB|NONE (l_advcl) is_26\VBZ|does|not|.|search|,|complication (l_nsubj) disturbance_22\NN|not|although|uncommon
D002996_D014786 CID CC_24\NN|NONE (r_compound) intake_25\NN|NONE (r_pobj) after_23\IN|mild|visual (r_prep) disturbance_22\NN|not|although|uncommon
D002996_D012170 CID clomiphene_6\NN| (r_npadvmod) induced_8\VBN|NONE (r_amod) ovulation_9\NN|NONE (r_pobj) with_5\IN|NONE (r_prep) associated_4\VBN|vein|Central|. (r_acl) occlusion_3\NN|NONE
D002996_D012170 CID citrate_12\NN|NONE (r_pobj) with_10\IN|NONE (r_prep) associated_9\VBN|central|vein (r_acl) occlusion_8\NN|NONE
D002996_D012170 CID CC_14\NN|clomiphene|)|( (r_appos) citrate_12\NN|NONE (r_pobj) with_10\IN|NONE (r_prep) associated_9\VBN|central|vein (r_acl) occlusion_8\NN|NONE
D002996_D012170 CID CC_13\NN|NONE (r_pobj) with_12\IN|ovulation (r_prep) induction_11\NN|NONE (r_pobj) after_9\IN|vein|Central (r_prep) occlusion_8\NN|)|:|OUTCOME|.
D002996_D012170 CID CC_18\NN|NONE (r_pobj) of_17\IN|eight (r_prep) courses_16\NNS|NONE (r_pobj) after_14\IN|.|occlusion|:|woman|RESULT(S (r_prep) developed_9\VBD|NONE (l_dobj) occlusion_13\NN|after|.|:|woman|RESULT(S
D002996_D012170 CID CC_15\NN|NONE (r_pobj) with_14\IN|NONE (r_prep) treatment_13\NN|NONE (r_pobj) after_12\IN|vein (r_prep) occlusion_11\NN|NONE
D002996_D007247 NONE CC_9\NN|NONE (r_pobj) with_8\IN|patients (r_prep) treating_5\VBG|NONE (l_dobj) patients_7\NNS|with (l_compound) infertility_6\NN|NONE
9653867
D013974_D013971 CID Thyroxine_0\NNP|.|:|case (r_compound) abuse_1\NN|NONE (l_appos) case_5\NN|.|:|Thyroxine (l_prep) of_6\IN|unusual|an (l_pobj) thyrotoxicosis_7\NN|NONE
D013974_D013971 CID thyroxine_28\NN|NONE (r_compound) abuse_29\NN|explored|,|that|be|should|and|remains (r_nsubjpass) considered_32\VBN|us (l_advcl) remains_25\VBZ|explored|,|abuse|that|be|should|and (l_nsubj) cause_22\NN|obscure|when (l_prep) for_23\IN|a (l_pobj) thyrotoxicosis_24\NN|NONE
D013974_D001068 NONE thyroxine_28\NN|NONE (r_compound) abuse_29\NN|explored|,|that|be|should|and|remains (r_nsubjpass) considered_32\VBN|us (r_ccomp) reminds_17\VBZ|derangements|In|.|and|it (r_conj) illustrates_3\VBZ|NONE (l_dobj) derangements_5\NNS|reminds|In|.|and|it (l_prep) of_6\IN|the (l_pobj) function_8\NN|NONE (l_acl) seen_9\VBN|thyroid (l_prep) with_13\IN|in (l_pcomp) eating_14\VBG|NONE (l_dobj) disorders_15\NNS|NONE
18208574
D006493_D013921 CID heparin_12\NN| (r_npadvmod) induced_14\VBN|NONE (r_amod) thrombocytopenia_15\NN|NONE
D006493_D013921 CID heparin_12\NN| (r_npadvmod) induced_14\VBN|step|a|assay (r_amod) thrombocytopenia_15\NN|NONE
D006493_D013921 CID heparin_12\NN| (r_npadvmod) induced_14\VBN|step|a|assay (r_amod) thrombocytopenia_15\NN|NONE (l_appos) assay_20\NN|induced|step|a (l_nmod) HIT_17\NN|(|antigen|)|with
D006493_D013921 CID heparin_33\JJ|high|a (r_compound) concentration_34\NN|NONE (r_pobj) of_30\IN|inhibition (r_prep) characteristics_29\NNS|correlate|;|assay|. (r_dobj) utilizes_26\VBZ|NONE (l_advcl) correlate_1\VB|;|assay|characteristics|. (l_dobj) density_3\NN|To (l_prep) of_7\IN|and|inhibition|optical (l_pobj) thrombocytopenia_15\NN|NONE
D006493_D013921 CID heparin_33\JJ|high|a (r_compound) concentration_34\NN|NONE (r_pobj) of_30\IN|inhibition (r_prep) characteristics_29\NNS|correlate|;|assay|. (r_dobj) utilizes_26\VBZ|NONE (l_advcl) correlate_1\VB|;|assay|characteristics|. (l_dobj) density_3\NN|To (l_prep) of_7\IN|and|inhibition|optical (l_pobj) thrombocytopenia_15\NN|NONE (l_appos) assay_20\NN|induced|step|a (l_nmod) HIT_17\NN|(|antigen|)|with
D006493_D013921 CID heparin_21\NN|NONE (r_pobj) to_20\IN|NONE (r_prep) exposure_19\NN|NONE (r_pobj) after_18\IN|with (r_prep) Patients_0\NNS|were|in|. (l_prep) with_1\IN|after (l_pobj) decrease_6\NN|NONE (l_conj) thrombocytopenia_11\NNP|)|or|in|%
D006493_D013921 CID heparin_48\NN|NONE (r_pobj) of_47\IN|high (r_prep) concentration_46\NN|NONE (r_pobj) with_44\IN| (r_prep) inhibition_43\NN|assay|who (r_dobj) had_24\VBD|]|, (r_relcl) heparin_21\NN|NONE (r_pobj) to_20\IN|NONE (r_prep) exposure_19\NN|NONE (r_pobj) after_18\IN|with (r_prep) Patients_0\NNS|were|in|. (l_prep) with_1\IN|after (l_pobj) decrease_6\NN|NONE (l_conj) thrombocytopenia_11\NNP|)|or|in|%
D006493_D013927 CID heparin_12\NN| (r_npadvmod) induced_14\VBN|NONE (r_amod) thrombocytopenia_15\NN|NONE (r_pobj) with_11\IN|NONE (r_prep) patients_10\NNS|NONE (r_pobj) in_9\IN|NONE (r_prep) thrombosis_8\NN|.|density
D006493_D013927 CID heparin_12\NN| (r_npadvmod) induced_14\VBN|step|a|assay (r_amod) thrombocytopenia_15\NN|NONE (l_appos) assay_20\NN|induced|step|a (l_prep) with_21\IN|(|HIT|antigen|) (l_pobj) thrombosis_22\NN|NONE
D006493_D013927 CID heparin_33\JJ|high|a (r_compound) concentration_34\NN|NONE (r_pobj) of_30\IN|inhibition (r_prep) characteristics_29\NNS|correlate|;|assay|. (r_dobj) utilizes_26\VBZ|NONE (l_advcl) correlate_1\VB|;|assay|characteristics|. (l_dobj) density_3\NN|To (l_prep) of_7\IN|and|inhibition|optical (l_pobj) thrombocytopenia_15\NN|NONE (l_appos) assay_20\NN|induced|step|a (l_prep) with_21\IN|(|HIT|antigen|) (l_pobj) thrombosis_22\NN|NONE
8690168
D013311_D003920 NONE streptozotocin_22\NNS|and|in (r_pobj) by_21\IN|of (r_prep) induction_18\NN|months (l_prep) of_19\IN|by (l_pobj) diabetes_20\NNS|NONE
D013311_D003920 NONE streptozotocin_4\JJ| (r_amod) diabetic_6\JJ|with
D006497_D003920 NONE sulphate_1\NN| (r_npadvmod) associated_3\VBN|in|anionic|Heparan (r_amod) sites_5\NNS|,|employing|were|after|.|in (r_nsubjpass) studied_12\VBN|NONE (l_prep) after_17\IN|sites|,|employing|were|.|in (l_pobj) induction_18\NN|months (l_prep) of_19\IN|by (l_pobj) diabetes_20\NNS|NONE
D006497_D003920 NONE sulphate_18\NN|NONE (r_compound) charge_19\NN|heparan|reduced|a|/|barrier (r_compound) density_22\NN|in|that|at|is (r_nsubjpass) found_24\VBN|.|We (l_prep) in_3\IN|density|that|at|is (l_pobj) rats_7\NNS|NONE (l_amod) diabetic_6\JJ|with
D013311_D003928 CID streptozotocin_16\NNS| (r_npadvmod) induced_18\VBN|diabetic (r_amod) nephropathy_20\NN|NONE
D006497_D003928 NONE sulphate_3\NN| (r_npadvmod) associated_5\VBN|heparan|anionic|in (r_amod) sites_7\NNS|NONE (l_prep) in_8\IN|associated|heparan|anionic (l_pobj) membrane_12\NN|NONE (l_prep) of_13\IN|glomerular|basement|the (l_pobj) rats_14\NNS|NONE (l_prep) with_15\IN|NONE (l_pobj) nephropathy_20\NN|NONE
C015445_D003920 NONE blue_38\JJ|NONE (r_dobj) employing_33\VBG|sites|,|were|after|.|in (r_advcl) studied_12\VBN|NONE (l_prep) after_17\IN|sites|,|employing|were|.|in (l_pobj) induction_18\NN|months (l_prep) of_19\IN|by (l_pobj) diabetes_20\NNS|NONE
1728522
D019980_D056486 CID acid_9\NN|NONE (r_pobj) of_5\IN|NONE (r_prep) combination_4\NN|to (r_pobj) due_2\JJ|Granulomatous|. (r_prep) hepatitis_1\NN|NONE
D019980_D056486 CID acid_11\NN| (r_npadvmod) induced_13\VBN|clavulanic (r_amod) hepatitis_14\NN|NONE
D019980_D006099 CID acid_9\NN|NONE (r_pobj) of_5\IN|NONE (r_prep) combination_4\NN|to (r_pobj) due_2\JJ|Granulomatous|. (r_prep) hepatitis_1\NN|NONE
D019980_D006099 CID acid_11\NN| (r_npadvmod) induced_13\VBN|clavulanic (r_amod) hepatitis_14\NN|NONE (r_pobj) with_7\IN|a (r_prep) patient_6\NN|NONE (r_pobj) of_4\IN|with|the (r_prep) case_3\NN|We|. (l_prep) with_15\IN|of|the (l_pobj) granulomas_18\NNS|NONE
15579441
D011692_D009404 CID aminonucleoside_15\NN| (r_advmod) induced_17\VBN|hypoxia|nephrotic|and (r_amod) syndrome_19\NN|the
D011692_D000860 CID aminonucleoside_15\NN| (r_advmod) induced_17\VBN|hypoxia|nephrotic|and (r_amod) syndrome_19\NN|the (r_appos) puromycin_14\NNS|NONE (r_pobj) in_12\IN|hypoxia|to (r_prep) identify_8\VB|NONE (l_dobj) hypoxia_11\NN|to|in
D011692_D000860 CID aminonucleoside_15\NN| (r_advmod) induced_17\VBN|hypoxia|nephrotic|and (r_amod) syndrome_19\NN|the (l_conj) hypoxia_24\NN|nephrotic|and|induced
D011692_D000860 CID aminonucleoside_21\NN|puromycin (r_compound) model_22\NN|.fold|and (r_pobj) in_18\IN|.fold|,|showed|at (r_prep) reaching_13\VBG|Expression|throughout|.|, (r_advcl) increased_7\VBD|NONE (l_nsubj) Expression_0\NN|throughout|.|,|reaching (l_prep) of_1\IN|NONE (l_pobj) transgene_6\NN|NONE (l_amod) responsive_5\JJ|the (l_npadvmod) hypoxia_3\NN|
2055425
D018723_D003920 NONE bethanechol_23\NN|,|and (r_conj) ATP_20\NNP|,|nerve (r_conj) stimulation_18\NN|NONE (r_pobj) to_16\TO|contractile|of|from (r_prep) responses_8\NNS|NONE (l_prep) from_13\IN|contractile|of|to (l_pobj) rats_15\NNS|NONE (l_amod) diabetic_14\JJ|NONE
D018723_D003920 NONE bethanechol_22\NN|and|, (r_conj) ATP_19\NNP|,|nerve (r_conj) stimulation_17\NN|NONE (r_pobj) to_15\TO|of|from|contractile (r_prep) responses_7\NNS|NONE (l_prep) from_12\IN|of|to|contractile (l_pobj) rats_14\NNS|NONE (l_amod) diabetic_13\JJ|NONE
D013311_D003920 CID streptozotocin_17\NNS| (r_npadvmod) induced_19\VBN|NONE (r_amod) diabetes_20\NN|NONE (r_compound) mellitus_21\NN|NONE
D013311_D003920 CID streptozotocin_15\JJ| (r_npadvmod) diabetic_17\JJ|NONE
D013311_D003920 CID streptozotocin_7\NNS| (r_npadvmod) induced_9\VBN|on (r_amod) diabetes_10\NNS|NONE
D000255_D003920 NONE ATP_20\NNP|,|nerve (r_conj) stimulation_18\NN|NONE (r_pobj) to_16\TO|contractile|of|from (r_prep) responses_8\NNS|NONE (l_prep) from_13\IN|contractile|of|to (l_pobj) rats_15\NNS|NONE (l_amod) diabetic_14\JJ|NONE
D000255_D003920 NONE ATP_19\NNP|,|nerve (r_conj) stimulation_17\NN|NONE (r_pobj) to_15\TO|of|from|contractile (r_prep) responses_7\NNS|NONE (l_prep) from_12\IN|of|to|contractile (l_pobj) rats_14\NNS|NONE (l_amod) diabetic_13\JJ|NONE
17639754
D014859_D006470 CID warfarin_18\NN|NONE (r_pobj) between_17\IN|the (r_prep) interaction_16\NN|NONE (r_pobj) of_14\IN|the (r_prep) result_13\NN|to (r_attr) be_11\VB|that (r_xcomp) appear_9\VBP|serious|bleeding (r_relcl) complications_7\NNS|NONE (l_compound) bleeding_6\NN|appear|serious
D064704_D006470 CID levofloxacin_20\JJ|and (r_conj) warfarin_18\NN|NONE (r_pobj) between_17\IN|the (r_prep) interaction_16\NN|NONE (r_pobj) of_14\IN|the (r_prep) result_13\NN|to (r_attr) be_11\VB|that (r_xcomp) appear_9\VBP|serious|bleeding (r_relcl) complications_7\NNS|NONE (l_compound) bleeding_6\NN|appear|serious
3719553
D002945_D004342 NONE cisplatin_27\NN| (r_advmod) induced_29\VBN|impaired|renal (r_amod) function_32\NN|and|, (r_conj) cirrhosis_24\NN|,|oral|the (r_conj) cavity_22\NN|NONE (r_pobj) of_19\IN|recurrent (r_prep) carcinoma_18\NN|NONE (r_pobj) with_16\IN|a (r_prep) patient_15\NN|NONE (r_pobj) in_13\IN|.|reaction (r_prep) occurred_12\VBD|NONE (l_nsubj) reaction_2\NN|.|in
D002945_D005355 NONE cisplatin_27\NN| (r_advmod) induced_29\VBN|impaired|renal (r_amod) function_32\NN|and|, (r_conj) cirrhosis_24\NN|,|oral|the
D011241_D004342 NONE prednisone_3\NNP|and|Oral (r_conj) diphenhydramine_1\NN|in|ineffective|. (r_nsubj) were_4\VBD|NONE (l_prep) in_6\IN|ineffective|.|diphenhydramine (l_pcomp) preventing_7\VBG|NONE (l_dobj) recurrence_9\NN|NONE (l_prep) of_10\IN|the (l_pobj) reaction_13\NN|NONE
D004155_D004342 NONE diphenhydramine_1\NN|in|ineffective|. (r_nsubj) were_4\VBD|NONE (l_prep) in_6\IN|ineffective|.|diphenhydramine (l_pcomp) preventing_7\VBG|NONE (l_dobj) recurrence_9\NN|NONE (l_prep) of_10\IN|the (l_pobj) reaction_13\NN|NONE
D005472_D000799 CID 5-fluorouracil_11\CD|consisting|allergic|An (r_punct) reaction_2\NN|.|in (l_acl) consisting_3\VBG|allergic|fluorouracil|An (l_prep) of_4\IN|NONE (l_pobj) edema_6\NN|angioneurotic
D005472_D005355 NONE 5-fluorouracil_11\CD|consisting|allergic|An (r_punct) reaction_2\NN|.|in (r_nsubj) occurred_12\VBD|NONE (l_prep) in_13\IN|.|reaction (l_pobj) patient_15\NN|NONE (l_prep) with_16\IN|a (l_pobj) carcinoma_18\NN|NONE (l_prep) of_19\IN|recurrent (l_pobj) cavity_22\NN|NONE (l_conj) cirrhosis_24\NN|,|oral|the
D005472_D004342 NONE 5-fluorouracil_3\CD|NONE (r_punct) infusion_4\NN|NONE (r_pobj) to_2\IN|Allergic|. (r_prep) reaction_1\NN|NONE
D005472_D004342 NONE 5-fluorouracil_11\CD|consisting|allergic|An (r_punct) reaction_2\NN|.|in
D002945_D009062 NONE cisplatin_27\NN| (r_advmod) induced_29\VBN|impaired|renal (r_amod) function_32\NN|and|, (r_conj) cirrhosis_24\NN|,|oral|the (r_conj) cavity_22\NN|NONE
D002945_D000799 NONE cisplatin_27\NN| (r_advmod) induced_29\VBN|impaired|renal (r_amod) function_32\NN|and|, (r_conj) cirrhosis_24\NN|,|oral|the (r_conj) cavity_22\NN|NONE (r_pobj) of_19\IN|recurrent (r_prep) carcinoma_18\NN|NONE (r_pobj) with_16\IN|a (r_prep) patient_15\NN|NONE (r_pobj) in_13\IN|.|reaction (r_prep) occurred_12\VBD|NONE (l_nsubj) reaction_2\NN|.|in (l_acl) consisting_3\VBG|allergic|fluorouracil|An (l_prep) of_4\IN|NONE (l_pobj) edema_6\NN|angioneurotic
D005472_D007674 NONE 5-fluorouracil_11\CD|consisting|allergic|An (r_punct) reaction_2\NN|.|in (r_nsubj) occurred_12\VBD|NONE (l_prep) in_13\IN|.|reaction (l_pobj) patient_15\NN|NONE (l_prep) with_16\IN|a (l_pobj) carcinoma_18\NN|NONE (l_prep) of_19\IN|recurrent (l_pobj) cavity_22\NN|NONE (l_conj) cirrhosis_24\NN|,|oral|the (l_conj) function_32\NN|and|,
D005472_D009062 NONE 5-fluorouracil_11\CD|consisting|allergic|An (r_punct) reaction_2\NN|.|in (r_nsubj) occurred_12\VBD|NONE (l_prep) in_13\IN|.|reaction (l_pobj) patient_15\NN|NONE (l_prep) with_16\IN|a (l_pobj) carcinoma_18\NN|NONE (l_prep) of_19\IN|recurrent (l_pobj) cavity_22\NN|NONE
D002945_D007674 NONE cisplatin_27\NN| (r_advmod) induced_29\VBN|impaired|renal (r_amod) function_32\NN|and|,
2870085
D007545_D013610 CID isoproterenol_8\NN| (r_npadvmod) induced_10\VBN|NONE (r_amod) tachycardia_11\NN|NONE
C047847_D000789 NONE flestolol_6\NN|NONE (r_compound) infusion_7\NN|In|be|.|was|, (r_nsubjpass) found_9\VBN|NONE (l_prep) In_0\IN|infusion|be|.|was|, (l_pobj) patients_1\NNS|NONE (l_prep) with_2\IN|NONE (l_pobj) angina_4\NN|NONE
C047847_D013610 NONE Flestolol_0\NNP|.|attenuation (r_nsubj) produced_1\VBD|NONE (l_dobj) attenuation_6\NN|.|Flestolol (l_prep) of_7\IN|a|dependent (l_pobj) tachycardia_11\NN|NONE
C047847_D013617 NONE Flestolol_0\NNP|.|effectively|in|rate (r_nsubj) reduced_2\VBD|NONE (l_prep) in_5\IN|.|effectively|Flestolol|rate (l_pobj) patients_6\NNS|NONE (l_prep) with_7\IN|NONE (l_pobj) tachyarrhythmia_9\NN|NONE
C047847_D002637 NONE flestolol_6\NN|NONE (r_compound) infusion_7\NN|In|be|.|was|, (r_nsubjpass) found_9\VBN|NONE (l_xcomp) be_11\VB|infusion|In|.|was|, (l_acomp) safe_12\JJ|to (l_conj) effective_14\JJ|and (l_prep) in_15\IN|NONE (l_pcomp) controlling_16\VBG|NONE (l_dobj) pain_18\NN|NONE
12202650
D002211_D010146 CID Capsaicin_0\NNS|into|was|induce|. (r_nsubjpass) injected_7\VBN|NONE (l_advcl) induce_13\VB|into|was|Capsaicin|. (l_dobj) pain_14\NN|in|to
D002211_D063806 NONE Capsaicin_0\NN| (r_npadvmod) induced_2\VBN|muscle (r_amod) pain_4\NN|excitability|.
6118280
C014896_D009207 NONE MK-212_8\NNP|NONE (r_punct) and_9\CC|( (r_punct) -)-baclofen_11\:|management (r_punct) in_12\IN|of|the|possible (l_pobj) management_14\NN|)baclofen (l_prep) of_15\IN|the (l_pobj) myoclonus_17\NN|NONE
D002998_D009207 NONE clonazepam_4\NN|Of|,|was|be|. (r_nsubjpass) found_12\VBN|NONE (l_xcomp) be_14\VB|Of|,|was|.|clonazepam (l_prep) in_27\IN|to|mg/kg|potent (l_pcomp) blocking_28\VBG|NONE (l_dobj) jerks_31\NNS|NONE
D003975_D009207 NONE diazepam_20\NN|NONE (r_pobj) than_19\IN|more|fold (r_prep) potent_18\JJ|in|to|mg/kg (r_acomp) be_14\VB|Of|,|was|.|clonazepam (l_prep) in_27\IN|to|mg/kg|potent (l_pcomp) blocking_28\VBG|NONE (l_dobj) jerks_31\NNS|NONE
D009118_D009207 CID muscimol_7\NNS|in||jerks|.|drugs (r_npadvmod) induced_9\VBN|NONE (l_dobj) jerks_11\NNS|in||muscimol|.|drugs
D009118_D009207 CID muscimol_5\NNS|,|jerks|In|. (r_nsubj) produced_6\VBD|NONE (l_dobj) jerks_8\NNS|,|muscimol|In|.
D009118_D009207 CID muscimol_22\NN| (r_npadvmod) induced_24\VBN|the (r_amod) myoclonus_25\NN|,|clinical (r_appos) myoclonus_19\NN|NONE
D009118_D009207 CID muscimol_22\NN| (r_npadvmod) induced_24\VBN|the (r_amod) myoclonus_25\NN|,|clinical
D006916_D009207 NONE 5-HTP_4\NN|have|be|that|been (r_nsubjpass) found_10\VBN|the (l_xcomp) be_12\VB|have|HTP|that|been (l_acomp) beneficial_13\JJ|to (l_prep) in_14\IN|NONE (l_pobj) management_16\NN|NONE (l_prep) of_17\IN|the (l_pobj) myoclonus_19\NN|NONE
D006916_D009207 NONE 5-HTP_4\NN|have|be|that|been (r_nsubjpass) found_10\VBN|the (l_xcomp) be_12\VB|have|HTP|that|been (l_acomp) beneficial_13\JJ|to (l_prep) in_14\IN|NONE (l_pobj) management_16\NN|NONE (l_prep) of_17\IN|the (l_pobj) myoclonus_19\NN|NONE (l_appos) myoclonus_25\NN|,|clinical
D001569_D009207 NONE benzodiazepines_3\NNS|,|Serotonergic (r_conj) drugs_1\NNS|in||jerks|muscimol|. (r_nsubj) induced_9\VBN|NONE (l_dobj) jerks_11\NNS|in||muscimol|.|drugs
D001569_D009207 NONE benzodiazepines_2\NNS|NONE (r_pobj) Of_0\IN|,|was|be|.|clonazepam (r_prep) found_12\VBN|NONE (l_xcomp) be_14\VB|Of|,|was|.|clonazepam (l_prep) in_27\IN|to|mg/kg|potent (l_pcomp) blocking_28\VBG|NONE (l_dobj) jerks_31\NNS|NONE
D001569_D009207 NONE benzodiazepines_7\NNS|and (r_conj) 5-HTP_4\NN|have|be|that|been (r_nsubjpass) found_10\VBN|the (l_xcomp) be_12\VB|have|HTP|that|been (l_acomp) beneficial_13\JJ|to (l_prep) in_14\IN|NONE (l_pobj) management_16\NN|NONE (l_prep) of_17\IN|the (l_pobj) myoclonus_19\NN|NONE
D001569_D009207 NONE benzodiazepines_7\NNS|and (r_conj) 5-HTP_4\NN|have|be|that|been (r_nsubjpass) found_10\VBN|the (l_xcomp) be_12\VB|have|HTP|that|been (l_acomp) beneficial_13\JJ|to (l_prep) in_14\IN|NONE (l_pobj) management_16\NN|NONE (l_prep) of_17\IN|the (l_pobj) myoclonus_19\NN|NONE (l_appos) myoclonus_25\NN|,|clinical
D001418_D009207 NONE baclofen_5\JJ|NONE (r_compound) block_6\NN|and (r_conj) benzodiazepines_3\NNS|,|Serotonergic (r_conj) drugs_1\NNS|in||jerks|muscimol|. (r_nsubj) induced_9\VBN|NONE (l_dobj) jerks_11\NNS|in||muscimol|.|drugs
D001418_D009207 NONE -)-baclofen_11\:|management (r_punct) in_12\IN|of|the|possible (l_pobj) management_14\NN|)baclofen (l_prep) of_15\IN|the (l_pobj) myoclonus_17\NN|NONE
15649445
D018698_D004409 NONE glutamate_9\NN|synaptosomal (r_compound) uptake_10\NN|elicit|haloperidol|reserpine|.|and|treatments (r_dobj) change_6\VBP|NONE (l_conj) elicit_12\VBP|haloperidol|reserpine|uptake|.|and|treatments (l_dobj) dyskinesia_14\NN|NONE
D018698_D004409 NONE glutamate_5\NN|NONE (r_compound) uptake_6\NN|NONE (r_pobj) in_4\IN|a (r_prep) decrease_3\NN|with|.|negatively|Importantly|, (r_nsubj) correlates_7\VBZ|NONE (l_prep) with_9\IN|.|decrease|negatively|Importantly|, (l_pobj) increase_11\NN|NONE (l_prep) in_12\IN|an (l_pobj) incidence_14\NN|NONE (l_prep) of_15\IN|the (l_pobj) diskinesia_17\NN|NONE
D012110_D004409 CID reserpine_1\NN|elicit|haloperidol|uptake|.|and|treatments (r_nsubj) change_6\VBP|NONE (l_conj) elicit_12\VBP|haloperidol|reserpine|uptake|.|and|treatments (l_dobj) dyskinesia_14\NN|NONE
D012110_D004409 CID Reserpine-_0\NNP|models|. (l_conj) dyskinesia_6\NN|and
D012110_D004409 CID Reserpine-_0\NNP|models|. (r_nsubj) are_7\VBP|NONE (l_attr) models_10\NNS|Reserpine|. (l_prep) of_11\IN|animal|putative|related (l_pobj) dyskinesia_13\JJ|NONE
D012110_D004409 CID Reserpine-_0\NNP|models|. (r_nsubj) are_7\VBP|NONE (l_attr) models_10\NNS|Reserpine|. (l_prep) of_11\IN|animal|putative|related (l_pobj) dyskinesia_13\JJ|NONE (l_appos) TD_15\NN|tardive
D012110_D004409 CID reserpine_12\NN|NONE (r_pobj) by_10\IN|In|.|authors|,|dyskinesia (r_prep) induced_7\VBD|NONE (l_dobj) dyskinesia_9\NN|by|In|.|authors|,
D006220_D004409 CID haloperidol_4\NN|elicit|reserpine|uptake|.|and|treatments (r_compound) change_6\VBP|NONE (l_conj) elicit_12\VBP|haloperidol|reserpine|uptake|.|and|treatments (l_dobj) dyskinesia_14\NN|NONE
D006220_D004409 CID haloperidol_2\NN| (r_npadvmod) induced_4\VBN|orofacial (r_amod) dyskinesia_6\NN|and
D006220_D004409 CID haloperidol_2\NN| (r_npadvmod) induced_4\VBN|orofacial (r_amod) dyskinesia_6\NN|and (r_conj) Reserpine-_0\NNP|models|. (r_nsubj) are_7\VBP|NONE (l_attr) models_10\NNS|Reserpine|. (l_prep) of_11\IN|animal|putative|related (l_pobj) dyskinesia_13\JJ|NONE
D006220_D004409 CID haloperidol_2\NN| (r_npadvmod) induced_4\VBN|orofacial (r_amod) dyskinesia_6\NN|and (r_conj) Reserpine-_0\NNP|models|. (r_nsubj) are_7\VBP|NONE (l_attr) models_10\NNS|Reserpine|. (l_prep) of_11\IN|animal|putative|related (l_pobj) dyskinesia_13\JJ|NONE (l_appos) TD_15\NN|tardive
D006220_D004409 CID haloperidol_15\NN|subchronic (r_compound) administration_16\NN|acute|to|and (r_conj) reserpine_12\NN|NONE (r_pobj) by_10\IN|In|.|authors|,|dyskinesia (r_prep) induced_7\VBD|NONE (l_dobj) dyskinesia_9\NN|by|In|.|authors|,
9061311
D009240_D017114 NONE phenylalanine_15\NN|)|( (r_nmod) fMLP_17\NN|NONE (r_pobj) with_8\IN|from (r_prep) stimulated_7\VBN|NONE (l_prep) from_19\IN|with (l_pobj) patients_24\NNS|NONE (l_compound) ALF_23\NNP||further|a
D009240_D017114 NONE fMLP_17\NN|NONE (r_pobj) with_8\IN|from (r_prep) stimulated_7\VBN|NONE (l_prep) from_19\IN|with (l_pobj) patients_24\NNS|NONE (l_compound) ALF_23\NNP||further|a
D010100_D062787 NONE oxygen_5\NN|in|radical|due (r_nmod) production_7\NN|with|In|was|.|, (l_amod) due_12\IN|in|radical|oxygen (l_pobj) overdose_15\NN|to
D013481_D017114 NONE superoxide_1\NN|.|Neutrophil|in (r_nmod) production_5\NN|NONE (l_prep) in_6\IN|.|superoxide|Neutrophil (l_pobj) patients_7\NNS|NONE (l_prep) with_8\IN|NONE (l_pobj) failure_11\NN|NONE
D013481_D017114 NONE superoxide_2\NN|peroxide (r_amod) production_6\NN|NONE (r_pobj) in_1\IN|NONE (r_prep) Defects_0\NNS|be|may|in|. (r_nsubjpass) implicated_9\VBN|NONE (l_prep) in_10\IN|be|may|Defects|. (l_pobj) incidence_13\NN|NONE (l_prep) of_14\IN|high|the (l_pobj) infections_16\NNS|NONE (l_prep) in_17\IN|bacterial (l_pobj) patients_18\NNS|NONE (l_prep) with_19\IN|NONE (l_pobj) failure_22\NN|NONE
D013481_D017114 NONE superoxide_2\NN|peroxide (r_amod) production_6\NN|NONE (r_pobj) in_1\IN|NONE (r_prep) Defects_0\NNS|be|may|in|. (r_nsubjpass) implicated_9\VBN|NONE (l_prep) in_10\IN|be|may|Defects|. (l_pobj) incidence_13\NN|NONE (l_prep) of_14\IN|high|the (l_pobj) infections_16\NNS|NONE (l_prep) in_17\IN|bacterial (l_pobj) patients_18\NNS|NONE (l_prep) with_19\IN|NONE (l_pobj) failure_22\NN|NONE (l_appos) ALF_24\NNP|acute|(|liver|)
D013481_D017114 NONE Superoxide_0\NN|opsonized|.|reduced|with (l_prep) by_5\IN|production|and (l_pobj) neutrophils_7\NNS|NONE (l_compound) ALF_6\NNP|NONE
D013481_D017114 NONE Superoxide_0\NN|opsonized|.|reduced|with (r_nsubj) stimulated_8\VBN|NONE (l_dobj) opsonized_11\VBN|Superoxide|.|reduced|with (l_prep) with_12\IN|NONE (l_pobj) serum_14\NN|NONE (l_compound) ALF_13\NNP|NONE
D013481_D017114 NONE Superoxide_0\NN|unaffected|compared|. (l_prep) in_5\IN|production|and (l_pobj) neutrophils_6\NNS|NONE (l_acl) stimulated_7\VBN|NONE (l_prep) from_19\IN|with (l_pobj) patients_24\NNS|NONE (l_compound) ALF_23\NNP||further|a
D010100_D017114 NONE oxygen_5\NN|in|radical|due (r_nmod) production_7\NN|with|In|was|.|, (l_prep) in_8\IN|radical|oxygen|due (l_pobj) patients_9\NNS|NONE (l_prep) with_10\IN|NONE (l_pobj) ALF_11\NNP|NONE
D013481_D001424 NONE superoxide_2\NN|peroxide (r_amod) production_6\NN|NONE (r_pobj) in_1\IN|NONE (r_prep) Defects_0\NNS|be|may|in|. (r_nsubjpass) implicated_9\VBN|NONE (l_prep) in_10\IN|be|may|Defects|. (l_pobj) incidence_13\NN|NONE (l_prep) of_14\IN|high|the (l_pobj) infections_16\NNS|NONE
D000082_D017114 CID paracetamol_14\JJ|NONE (r_compound) overdose_15\NN|to (r_pobj) due_12\IN|in|radical|oxygen (r_amod) production_7\NN|with|In|was|.|, (l_prep) in_8\IN|radical|oxygen|due (l_pobj) patients_9\NNS|NONE (l_prep) with_10\IN|NONE (l_pobj) ALF_11\NNP|NONE
D000082_D017114 CID paracetamol_10\JJ|NONE (r_compound) overdose_11\NN|to (r_pobj) due_8\IN|defect|,|.|complement|results (r_prep) demonstrate_2\VBP|NONE (l_dobj) defect_5\NN|,|.|due|complement|results (l_prep) in_6\IN|a|neutrophil (l_pobj) ALF_7\NNP|NONE
D000082_D062787 NONE paracetamol_14\JJ|NONE (r_compound) overdose_15\NN|to
D000082_D062787 NONE paracetamol_10\JJ|NONE (r_compound) overdose_11\NN|to
D006861_D001424 NONE peroxide_5\NN|superoxide (r_compound) production_6\NN|NONE (r_pobj) in_1\IN|NONE (r_prep) Defects_0\NNS|be|may|in|. (r_nsubjpass) implicated_9\VBN|NONE (l_prep) in_10\IN|be|may|Defects|. (l_pobj) incidence_13\NN|NONE (l_prep) of_14\IN|high|the (l_pobj) infections_16\NNS|NONE
D006861_D017114 NONE peroxide_4\NN|and (r_conj) superoxide_1\NN|.|Neutrophil|in (r_nmod) production_5\NN|NONE (l_prep) in_6\IN|.|superoxide|Neutrophil (l_pobj) patients_7\NNS|NONE (l_prep) with_8\IN|NONE (l_pobj) failure_11\NN|NONE
D006861_D017114 NONE peroxide_5\NN|superoxide (r_compound) production_6\NN|NONE (r_pobj) in_1\IN|NONE (r_prep) Defects_0\NNS|be|may|in|. (r_nsubjpass) implicated_9\VBN|NONE (l_prep) in_10\IN|be|may|Defects|. (l_pobj) incidence_13\NN|NONE (l_prep) of_14\IN|high|the (l_pobj) infections_16\NNS|NONE (l_prep) in_17\IN|bacterial (l_pobj) patients_18\NNS|NONE (l_prep) with_19\IN|NONE (l_pobj) failure_22\NN|NONE
D006861_D017114 NONE peroxide_5\NN|superoxide (r_compound) production_6\NN|NONE (r_pobj) in_1\IN|NONE (r_prep) Defects_0\NNS|be|may|in|. (r_nsubjpass) implicated_9\VBN|NONE (l_prep) in_10\IN|be|may|Defects|. (l_pobj) incidence_13\NN|NONE (l_prep) of_14\IN|high|the (l_pobj) infections_16\NNS|NONE (l_prep) in_17\IN|bacterial (l_pobj) patients_18\NNS|NONE (l_prep) with_19\IN|NONE (l_pobj) failure_22\NN|NONE (l_appos) ALF_24\NNP|acute|(|liver|)
D006861_D017114 NONE peroxide_3\NN|NONE (r_compound) production_4\NN|and|by (r_conj) Superoxide_0\NN|opsonized|.|reduced|with (l_prep) by_5\IN|production|and (l_pobj) neutrophils_7\NNS|NONE (l_compound) ALF_6\NNP|NONE
D006861_D017114 NONE peroxide_3\NN|NONE (r_compound) production_4\NN|and|by (r_conj) Superoxide_0\NN|opsonized|.|reduced|with (r_nsubj) stimulated_8\VBN|NONE (l_dobj) opsonized_11\VBN|Superoxide|.|reduced|with (l_prep) with_12\IN|NONE (l_pobj) serum_14\NN|NONE (l_compound) ALF_13\NNP|NONE
D006861_D017114 NONE peroxide_3\NN|NONE (r_compound) production_4\NN|and|in (r_conj) Superoxide_0\NN|unaffected|compared|. (l_prep) in_5\IN|production|and (l_pobj) neutrophils_6\NNS|NONE (l_acl) stimulated_7\VBN|NONE (l_prep) from_19\IN|with (l_pobj) patients_24\NNS|NONE (l_compound) ALF_23\NNP||further|a
6817363
D012601_D003072 NONE scopolamine_77\NN| (r_npadvmod) induced_79\VBN|the|term (r_amod) amnesia_83\NN|NONE (r_pobj) of_75\IN|(|;|complete|)|protection|for|mice (r_prep) prevention_74\NN|or|(||(|) (r_conj) rats_67\NNS|of|complete||; (r_conj) prevention_40\NN|following|the|: (r_appos) effects_33\NNS|NONE (r_dobj) produced_30\VBD|effect|on|was|.|and (r_conj) studied_13\VBN|NONE (l_prep) on_14\IN|effect|produced|was|.|and (l_pobj) forms_16\NNS|NONE (l_prep) of_17\IN|various|in (l_pobj) functions_21\NNS|NONE
D012601_D000647 CID scopolamine_77\NN| (r_npadvmod) induced_79\VBN|the|term (r_amod) amnesia_83\NN|NONE
D012601_D000647 CID scopolamine_77\NN| (r_npadvmod) induced_79\VBN|the|term (r_amod) amnesia_83\NN|NONE (r_pobj) of_75\IN|(|;|complete|)|protection|for|mice (r_prep) prevention_74\NN|or|(||(|) (l_conj) protection_94\NN|(|;|complete|)|of|for|mice (l_prep) against_95\IN|;|for||prevention|complete (l_pobj) amnesia_96\NN|NONE
C036466_D006935 NONE aniracetam_3\NN|NONE (r_pobj) of_2\IN|The (r_prep) effect_1\NN|produced|on|was|.|and (r_nsubjpass) studied_13\VBN|NONE (l_conj) produced_30\VBD|effect|on|was|.|and (l_dobj) effects_33\NNS|NONE (l_appos) prevention_40\NN|following|the|: (l_prep) of_41\IN|complete|rats||; (l_pobj) incapacity_43\NN|NONE (l_acl) learn_45\VB|the (l_dobj) response_49\NN|to (l_prep) in_50\IN|escape|discrete|a (l_pobj) rats_51\NNS|NONE (l_acl) exposed_52\VBN|NONE (l_prep) to_53\IN|before (l_pobj) hypercapnia_55\NN|NONE
C036466_D006935 NONE aniracetam_3\NN|NONE (r_pobj) of_2\IN|The (r_prep) effect_1\NN|produced|on|was|.|and (r_nsubjpass) studied_13\VBN|NONE (l_conj) produced_30\VBD|effect|on|was|.|and (l_dobj) effects_33\NNS|NONE (l_appos) prevention_40\NN|following|the|: (l_conj) rats_67\NNS|of|complete||; (l_conj) prevention_74\NN|or|(||(|) (l_conj) protection_94\NN|(|;|complete|)|of|for|mice (l_conj) prevention_116\NN|;|for||complete|against (l_conj) reversal_149\NN||(|for|)|of|; (l_conj) prevention_186\NN|;|(|h|injected||,|administered|of|)|, (l_prep) in_190\IN|of||)|( (l_pobj) retrieval_192\NN|NONE (l_prep) of_193\IN|the (l_pobj) task_197\NN|NONE (l_acl) induced_198\VBN|an|active|applied|avoidance (l_agent) by_201\IN|in (l_pobj) electroshock_203\NN|NONE (l_conj) hypercapnia_205\NN|subconvulsant|or
C036466_D006935 NONE 5057_8\CD|NONE (r_prep) 13_6\CD|anisoylpyrrolidinone|, (r_nummod) Ro_5\NNP|)|( (r_appos) aniracetam_3\NN|NONE (r_pobj) of_2\IN|The (r_prep) effect_1\NN|produced|on|was|.|and (r_nsubjpass) studied_13\VBN|NONE (l_conj) produced_30\VBD|effect|on|was|.|and (l_dobj) effects_33\NNS|NONE (l_appos) prevention_40\NN|following|the|: (l_prep) of_41\IN|complete|rats||; (l_pobj) incapacity_43\NN|NONE (l_acl) learn_45\VB|the (l_dobj) response_49\NN|to (l_prep) in_50\IN|escape|discrete|a (l_pobj) rats_51\NNS|NONE (l_acl) exposed_52\VBN|NONE (l_prep) to_53\IN|before (l_pobj) hypercapnia_55\NN|NONE
C036466_D006935 NONE 5057_8\CD|NONE (r_prep) 13_6\CD|anisoylpyrrolidinone|, (r_nummod) Ro_5\NNP|)|( (r_appos) aniracetam_3\NN|NONE (r_pobj) of_2\IN|The (r_prep) effect_1\NN|produced|on|was|.|and (r_nsubjpass) studied_13\VBN|NONE (l_conj) produced_30\VBD|effect|on|was|.|and (l_dobj) effects_33\NNS|NONE (l_appos) prevention_40\NN|following|the|: (l_conj) rats_67\NNS|of|complete||; (l_conj) prevention_74\NN|or|(||(|) (l_conj) protection_94\NN|(|;|complete|)|of|for|mice (l_conj) prevention_116\NN|;|for||complete|against (l_conj) reversal_149\NN||(|for|)|of|; (l_conj) prevention_186\NN|;|(|h|injected||,|administered|of|)|, (l_prep) in_190\IN|of||)|( (l_pobj) retrieval_192\NN|NONE (l_prep) of_193\IN|the (l_pobj) task_197\NN|NONE (l_acl) induced_198\VBN|an|active|applied|avoidance (l_agent) by_201\IN|in (l_pobj) electroshock_203\NN|NONE (l_conj) hypercapnia_205\NN|subconvulsant|or
C036466_D006935 NONE 1-anisoyl-2-pyrrolidinone_10\CD||, (r_appos) Ro_5\NNP|)|( (r_appos) aniracetam_3\NN|NONE (r_pobj) of_2\IN|The (r_prep) effect_1\NN|produced|on|was|.|and (r_nsubjpass) studied_13\VBN|NONE (l_conj) produced_30\VBD|effect|on|was|.|and (l_dobj) effects_33\NNS|NONE (l_appos) prevention_40\NN|following|the|: (l_prep) of_41\IN|complete|rats||; (l_pobj) incapacity_43\NN|NONE (l_acl) learn_45\VB|the (l_dobj) response_49\NN|to (l_prep) in_50\IN|escape|discrete|a (l_pobj) rats_51\NNS|NONE (l_acl) exposed_52\VBN|NONE (l_prep) to_53\IN|before (l_pobj) hypercapnia_55\NN|NONE
C036466_D006935 NONE 1-anisoyl-2-pyrrolidinone_10\CD||, (r_appos) Ro_5\NNP|)|( (r_appos) aniracetam_3\NN|NONE (r_pobj) of_2\IN|The (r_prep) effect_1\NN|produced|on|was|.|and (r_nsubjpass) studied_13\VBN|NONE (l_conj) produced_30\VBD|effect|on|was|.|and (l_dobj) effects_33\NNS|NONE (l_appos) prevention_40\NN|following|the|: (l_conj) rats_67\NNS|of|complete||; (l_conj) prevention_74\NN|or|(||(|) (l_conj) protection_94\NN|(|;|complete|)|of|for|mice (l_conj) prevention_116\NN|;|for||complete|against (l_conj) reversal_149\NN||(|for|)|of|; (l_conj) prevention_186\NN|;|(|h|injected||,|administered|of|)|, (l_prep) in_190\IN|of||)|( (l_pobj) retrieval_192\NN|NONE (l_prep) of_193\IN|the (l_pobj) task_197\NN|NONE (l_acl) induced_198\VBN|an|active|applied|avoidance (l_agent) by_201\IN|in (l_pobj) electroshock_203\NN|NONE (l_conj) hypercapnia_205\NN|subconvulsant|or
D003513_D003072 NONE cycloheximide_140\NN|or (r_conj) chloramphenicol_138\NN|NONE (r_pobj) by_137\IN|in (r_agent) induced_132\VBN|administered|passive|avoidance|a (r_acl) task_131\NN|NONE (r_pobj) for_127\IN||(|reversal|)|of|; (r_prep) prevention_116\NN|;|for||complete|against (r_conj) protection_94\NN|(|;|complete|)|of|for|mice (r_conj) prevention_74\NN|or|(||(|) (r_conj) rats_67\NNS|of|complete||; (r_conj) prevention_40\NN|following|the|: (r_appos) effects_33\NNS|NONE (r_dobj) produced_30\VBD|effect|on|was|.|and (r_conj) studied_13\VBN|NONE (l_prep) on_14\IN|effect|produced|was|.|and (l_pobj) forms_16\NNS|NONE (l_prep) of_17\IN|various|in (l_pobj) functions_21\NNS|NONE
D003513_D003072 NONE cycloheximide_177\NN|NONE (r_pobj) by_176\IN|NONE (r_agent) induced_175\VBN|avoidance|passive|a (r_acl) task_174\NN|NONE (r_pobj) of_170\IN|retrieval|or (r_prep) retention_167\NN|NONE (r_pobj) in_166\IN|the (r_prep) deficit_165\NN|NONE (r_pobj) of_163\IN|;|(|prevention|h|injected||,|administered|)|, (r_prep) reversal_149\NN||(|for|)|of|; (r_conj) prevention_116\NN|;|for||complete|against (r_conj) protection_94\NN|(|;|complete|)|of|for|mice (r_conj) prevention_74\NN|or|(||(|) (r_conj) rats_67\NNS|of|complete||; (r_conj) prevention_40\NN|following|the|: (r_appos) effects_33\NNS|NONE (r_dobj) produced_30\VBD|effect|on|was|.|and (r_conj) studied_13\VBN|NONE (l_prep) on_14\IN|effect|produced|was|.|and (l_pobj) forms_16\NNS|NONE (l_prep) of_17\IN|various|in (l_pobj) functions_21\NNS|NONE
D002701_D000647 NONE chloramphenicol_138\NN|NONE (r_pobj) by_137\IN|in (r_agent) induced_132\VBN|administered|passive|avoidance|a (r_acl) task_131\NN|NONE (r_pobj) for_127\IN||(|reversal|)|of|; (r_prep) prevention_116\NN|;|for||complete|against (r_conj) protection_94\NN|(|;|complete|)|of|for|mice (r_conj) prevention_74\NN|or|(||(|) (l_prep) of_75\IN|(|;|complete|)|protection|for|mice (l_pobj) amnesia_83\NN|NONE
D002701_D000647 NONE chloramphenicol_138\NN|NONE (r_pobj) by_137\IN|in (r_agent) induced_132\VBN|administered|passive|avoidance|a (r_acl) task_131\NN|NONE (r_pobj) for_127\IN||(|reversal|)|of|; (r_prep) prevention_116\NN|;|for||complete|against (r_conj) protection_94\NN|(|;|complete|)|of|for|mice (l_prep) against_95\IN|;|for||prevention|complete (l_pobj) amnesia_96\NN|NONE
D003513_D006935 NONE cycloheximide_140\NN|or (r_conj) chloramphenicol_138\NN|NONE (r_pobj) by_137\IN|in (r_agent) induced_132\VBN|administered|passive|avoidance|a (r_acl) task_131\NN|NONE (r_pobj) for_127\IN||(|reversal|)|of|; (r_prep) prevention_116\NN|;|for||complete|against (r_conj) protection_94\NN|(|;|complete|)|of|for|mice (r_conj) prevention_74\NN|or|(||(|) (r_conj) rats_67\NNS|of|complete||; (r_conj) prevention_40\NN|following|the|: (l_prep) of_41\IN|complete|rats||; (l_pobj) incapacity_43\NN|NONE (l_acl) learn_45\VB|the (l_dobj) response_49\NN|to (l_prep) in_50\IN|escape|discrete|a (l_pobj) rats_51\NNS|NONE (l_acl) exposed_52\VBN|NONE (l_prep) to_53\IN|before (l_pobj) hypercapnia_55\NN|NONE
D003513_D006935 NONE cycloheximide_140\NN|or (r_conj) chloramphenicol_138\NN|NONE (r_pobj) by_137\IN|in (r_agent) induced_132\VBN|administered|passive|avoidance|a (r_acl) task_131\NN|NONE (r_pobj) for_127\IN||(|reversal|)|of|; (r_prep) prevention_116\NN|;|for||complete|against (l_conj) reversal_149\NN||(|for|)|of|; (l_conj) prevention_186\NN|;|(|h|injected||,|administered|of|)|, (l_prep) in_190\IN|of||)|( (l_pobj) retrieval_192\NN|NONE (l_prep) of_193\IN|the (l_pobj) task_197\NN|NONE (l_acl) induced_198\VBN|an|active|applied|avoidance (l_agent) by_201\IN|in (l_pobj) electroshock_203\NN|NONE (l_conj) hypercapnia_205\NN|subconvulsant|or
D003513_D006935 NONE cycloheximide_177\NN|NONE (r_pobj) by_176\IN|NONE (r_agent) induced_175\VBN|avoidance|passive|a (r_acl) task_174\NN|NONE (r_pobj) of_170\IN|retrieval|or (r_prep) retention_167\NN|NONE (r_pobj) in_166\IN|the (r_prep) deficit_165\NN|NONE (r_pobj) of_163\IN|;|(|prevention|h|injected||,|administered|)|, (r_prep) reversal_149\NN||(|for|)|of|; (r_conj) prevention_116\NN|;|for||complete|against (r_conj) protection_94\NN|(|;|complete|)|of|for|mice (r_conj) prevention_74\NN|or|(||(|) (r_conj) rats_67\NNS|of|complete||; (r_conj) prevention_40\NN|following|the|: (l_prep) of_41\IN|complete|rats||; (l_pobj) incapacity_43\NN|NONE (l_acl) learn_45\VB|the (l_dobj) response_49\NN|to (l_prep) in_50\IN|escape|discrete|a (l_pobj) rats_51\NNS|NONE (l_acl) exposed_52\VBN|NONE (l_prep) to_53\IN|before (l_pobj) hypercapnia_55\NN|NONE
D003513_D006935 NONE cycloheximide_177\NN|NONE (r_pobj) by_176\IN|NONE (r_agent) induced_175\VBN|avoidance|passive|a (r_acl) task_174\NN|NONE (r_pobj) of_170\IN|retrieval|or (r_prep) retention_167\NN|NONE (r_pobj) in_166\IN|the (r_prep) deficit_165\NN|NONE (r_pobj) of_163\IN|;|(|prevention|h|injected||,|administered|)|, (r_prep) reversal_149\NN||(|for|)|of|; (l_conj) prevention_186\NN|;|(|h|injected||,|administered|of|)|, (l_prep) in_190\IN|of||)|( (l_pobj) retrieval_192\NN|NONE (l_prep) of_193\IN|the (l_pobj) task_197\NN|NONE (l_acl) induced_198\VBN|an|active|applied|avoidance (l_agent) by_201\IN|in (l_pobj) electroshock_203\NN|NONE (l_conj) hypercapnia_205\NN|subconvulsant|or
D003513_D000647 NONE cycloheximide_140\NN|or (r_conj) chloramphenicol_138\NN|NONE (r_pobj) by_137\IN|in (r_agent) induced_132\VBN|administered|passive|avoidance|a (r_acl) task_131\NN|NONE (r_pobj) for_127\IN||(|reversal|)|of|; (r_prep) prevention_116\NN|;|for||complete|against (r_conj) protection_94\NN|(|;|complete|)|of|for|mice (r_conj) prevention_74\NN|or|(||(|) (l_prep) of_75\IN|(|;|complete|)|protection|for|mice (l_pobj) amnesia_83\NN|NONE
D003513_D000647 NONE cycloheximide_140\NN|or (r_conj) chloramphenicol_138\NN|NONE (r_pobj) by_137\IN|in (r_agent) induced_132\VBN|administered|passive|avoidance|a (r_acl) task_131\NN|NONE (r_pobj) for_127\IN||(|reversal|)|of|; (r_prep) prevention_116\NN|;|for||complete|against (r_conj) protection_94\NN|(|;|complete|)|of|for|mice (l_prep) against_95\IN|;|for||prevention|complete (l_pobj) amnesia_96\NN|NONE
D003513_D000647 NONE cycloheximide_177\NN|NONE (r_pobj) by_176\IN|NONE (r_agent) induced_175\VBN|avoidance|passive|a (r_acl) task_174\NN|NONE (r_pobj) of_170\IN|retrieval|or (r_prep) retention_167\NN|NONE (r_pobj) in_166\IN|the (r_prep) deficit_165\NN|NONE (r_pobj) of_163\IN|;|(|prevention|h|injected||,|administered|)|, (r_prep) reversal_149\NN||(|for|)|of|; (r_conj) prevention_116\NN|;|for||complete|against (r_conj) protection_94\NN|(|;|complete|)|of|for|mice (r_conj) prevention_74\NN|or|(||(|) (l_prep) of_75\IN|(|;|complete|)|protection|for|mice (l_pobj) amnesia_83\NN|NONE
D003513_D000647 NONE cycloheximide_177\NN|NONE (r_pobj) by_176\IN|NONE (r_agent) induced_175\VBN|avoidance|passive|a (r_acl) task_174\NN|NONE (r_pobj) of_170\IN|retrieval|or (r_prep) retention_167\NN|NONE (r_pobj) in_166\IN|the (r_prep) deficit_165\NN|NONE (r_pobj) of_163\IN|;|(|prevention|h|injected||,|administered|)|, (r_prep) reversal_149\NN||(|for|)|of|; (r_conj) prevention_116\NN|;|for||complete|against (r_conj) protection_94\NN|(|;|complete|)|of|for|mice (l_prep) against_95\IN|;|for||prevention|complete (l_pobj) amnesia_96\NN|NONE
D012601_D006935 NONE scopolamine_77\NN| (r_npadvmod) induced_79\VBN|the|term (r_amod) amnesia_83\NN|NONE (r_pobj) of_75\IN|(|;|complete|)|protection|for|mice (r_prep) prevention_74\NN|or|(||(|) (r_conj) rats_67\NNS|of|complete||; (r_conj) prevention_40\NN|following|the|: (l_prep) of_41\IN|complete|rats||; (l_pobj) incapacity_43\NN|NONE (l_acl) learn_45\VB|the (l_dobj) response_49\NN|to (l_prep) in_50\IN|escape|discrete|a (l_pobj) rats_51\NNS|NONE (l_acl) exposed_52\VBN|NONE (l_prep) to_53\IN|before (l_pobj) hypercapnia_55\NN|NONE
D012601_D006935 NONE scopolamine_77\NN| (r_npadvmod) induced_79\VBN|the|term (r_amod) amnesia_83\NN|NONE (r_pobj) of_75\IN|(|;|complete|)|protection|for|mice (r_prep) prevention_74\NN|or|(||(|) (l_conj) protection_94\NN|(|;|complete|)|of|for|mice (l_conj) prevention_116\NN|;|for||complete|against (l_conj) reversal_149\NN||(|for|)|of|; (l_conj) prevention_186\NN|;|(|h|injected||,|administered|of|)|, (l_prep) in_190\IN|of||)|( (l_pobj) retrieval_192\NN|NONE (l_prep) of_193\IN|the (l_pobj) task_197\NN|NONE (l_acl) induced_198\VBN|an|active|applied|avoidance (l_agent) by_201\IN|in (l_pobj) electroshock_203\NN|NONE (l_conj) hypercapnia_205\NN|subconvulsant|or
C036466_D003072 NONE aniracetam_3\NN|NONE (r_pobj) of_2\IN|The (r_prep) effect_1\NN|produced|on|was|.|and (r_nsubjpass) studied_13\VBN|NONE (l_prep) on_14\IN|effect|produced|was|.|and (l_pobj) forms_16\NNS|NONE (l_prep) of_17\IN|various|in (l_pobj) functions_21\NNS|NONE
C036466_D003072 NONE 5057_8\CD|NONE (r_prep) 13_6\CD|anisoylpyrrolidinone|, (r_nummod) Ro_5\NNP|)|( (r_appos) aniracetam_3\NN|NONE (r_pobj) of_2\IN|The (r_prep) effect_1\NN|produced|on|was|.|and (r_nsubjpass) studied_13\VBN|NONE (l_prep) on_14\IN|effect|produced|was|.|and (l_pobj) forms_16\NNS|NONE (l_prep) of_17\IN|various|in (l_pobj) functions_21\NNS|NONE
C036466_D003072 NONE 1-anisoyl-2-pyrrolidinone_10\CD||, (r_appos) Ro_5\NNP|)|( (r_appos) aniracetam_3\NN|NONE (r_pobj) of_2\IN|The (r_prep) effect_1\NN|produced|on|was|.|and (r_nsubjpass) studied_13\VBN|NONE (l_prep) on_14\IN|effect|produced|was|.|and (l_pobj) forms_16\NNS|NONE (l_prep) of_17\IN|various|in (l_pobj) functions_21\NNS|NONE
C036466_D003072 NONE aniracetam_12\JJ|oral|of (r_amod) doses_13\NNS|NONE (r_pobj) at_10\IN|improvements|.|were (r_prep) seen_9\VBN|NONE (l_nsubjpass) improvements_1\NNS|.|at|were (l_conj) normalizations_3\NNS|These|or (l_prep) of_4\IN|NONE (l_pobj) functions_7\NNS|NONE
D002701_D003072 NONE chloramphenicol_138\NN|NONE (r_pobj) by_137\IN|in (r_agent) induced_132\VBN|administered|passive|avoidance|a (r_acl) task_131\NN|NONE (r_pobj) for_127\IN||(|reversal|)|of|; (r_prep) prevention_116\NN|;|for||complete|against (r_conj) protection_94\NN|(|;|complete|)|of|for|mice (r_conj) prevention_74\NN|or|(||(|) (r_conj) rats_67\NNS|of|complete||; (r_conj) prevention_40\NN|following|the|: (r_appos) effects_33\NNS|NONE (r_dobj) produced_30\VBD|effect|on|was|.|and (r_conj) studied_13\VBN|NONE (l_prep) on_14\IN|effect|produced|was|.|and (l_pobj) forms_16\NNS|NONE (l_prep) of_17\IN|various|in (l_pobj) functions_21\NNS|NONE
C036466_D008569 NONE aniracetam_5\RB|NONE (l_appos) Ro_7\NNP|the|novel|compound|( (l_prep) upon_12\IN||) (l_pobj) learning_14\NN|NONE (l_conj) memory_16\NN|and|in|impaired
C036466_D008569 NONE 5057_10\CD|NONE (r_prep) 13_8\CD|upon|) (r_nummod) Ro_7\NNP|the|novel|compound|( (l_prep) upon_12\IN||) (l_pobj) learning_14\NN|NONE (l_conj) memory_16\NN|and|in|impaired
C036466_D000647 NONE aniracetam_3\NN|NONE (r_pobj) of_2\IN|The (r_prep) effect_1\NN|produced|on|was|.|and (r_nsubjpass) studied_13\VBN|NONE (l_conj) produced_30\VBD|effect|on|was|.|and (l_dobj) effects_33\NNS|NONE (l_appos) prevention_40\NN|following|the|: (l_conj) rats_67\NNS|of|complete||; (l_conj) prevention_74\NN|or|(||(|) (l_prep) of_75\IN|(|;|complete|)|protection|for|mice (l_pobj) amnesia_83\NN|NONE
C036466_D000647 NONE aniracetam_3\NN|NONE (r_pobj) of_2\IN|The (r_prep) effect_1\NN|produced|on|was|.|and (r_nsubjpass) studied_13\VBN|NONE (l_conj) produced_30\VBD|effect|on|was|.|and (l_dobj) effects_33\NNS|NONE (l_appos) prevention_40\NN|following|the|: (l_conj) rats_67\NNS|of|complete||; (l_conj) prevention_74\NN|or|(||(|) (l_conj) protection_94\NN|(|;|complete|)|of|for|mice (l_prep) against_95\IN|;|for||prevention|complete (l_pobj) amnesia_96\NN|NONE
C036466_D000647 NONE 5057_8\CD|NONE (r_prep) 13_6\CD|anisoylpyrrolidinone|, (r_nummod) Ro_5\NNP|)|( (r_appos) aniracetam_3\NN|NONE (r_pobj) of_2\IN|The (r_prep) effect_1\NN|produced|on|was|.|and (r_nsubjpass) studied_13\VBN|NONE (l_conj) produced_30\VBD|effect|on|was|.|and (l_dobj) effects_33\NNS|NONE (l_appos) prevention_40\NN|following|the|: (l_conj) rats_67\NNS|of|complete||; (l_conj) prevention_74\NN|or|(||(|) (l_prep) of_75\IN|(|;|complete|)|protection|for|mice (l_pobj) amnesia_83\NN|NONE
C036466_D000647 NONE 5057_8\CD|NONE (r_prep) 13_6\CD|anisoylpyrrolidinone|, (r_nummod) Ro_5\NNP|)|( (r_appos) aniracetam_3\NN|NONE (r_pobj) of_2\IN|The (r_prep) effect_1\NN|produced|on|was|.|and (r_nsubjpass) studied_13\VBN|NONE (l_conj) produced_30\VBD|effect|on|was|.|and (l_dobj) effects_33\NNS|NONE (l_appos) prevention_40\NN|following|the|: (l_conj) rats_67\NNS|of|complete||; (l_conj) prevention_74\NN|or|(||(|) (l_conj) protection_94\NN|(|;|complete|)|of|for|mice (l_prep) against_95\IN|;|for||prevention|complete (l_pobj) amnesia_96\NN|NONE
C036466_D000647 NONE 1-anisoyl-2-pyrrolidinone_10\CD||, (r_appos) Ro_5\NNP|)|( (r_appos) aniracetam_3\NN|NONE (r_pobj) of_2\IN|The (r_prep) effect_1\NN|produced|on|was|.|and (r_nsubjpass) studied_13\VBN|NONE (l_conj) produced_30\VBD|effect|on|was|.|and (l_dobj) effects_33\NNS|NONE (l_appos) prevention_40\NN|following|the|: (l_conj) rats_67\NNS|of|complete||; (l_conj) prevention_74\NN|or|(||(|) (l_prep) of_75\IN|(|;|complete|)|protection|for|mice (l_pobj) amnesia_83\NN|NONE
C036466_D000647 NONE 1-anisoyl-2-pyrrolidinone_10\CD||, (r_appos) Ro_5\NNP|)|( (r_appos) aniracetam_3\NN|NONE (r_pobj) of_2\IN|The (r_prep) effect_1\NN|produced|on|was|.|and (r_nsubjpass) studied_13\VBN|NONE (l_conj) produced_30\VBD|effect|on|was|.|and (l_dobj) effects_33\NNS|NONE (l_appos) prevention_40\NN|following|the|: (l_conj) rats_67\NNS|of|complete||; (l_conj) prevention_74\NN|or|(||(|) (l_conj) protection_94\NN|(|;|complete|)|of|for|mice (l_prep) against_95\IN|;|for||prevention|complete (l_pobj) amnesia_96\NN|NONE
C036466_D007859 NONE aniracetam_5\RB|NONE (l_appos) Ro_7\NNP|the|novel|compound|( (l_prep) upon_12\IN||) (l_pobj) learning_14\NN|NONE (l_conj) memory_16\NN|and|in|impaired
C036466_D007859 NONE 5057_10\CD|NONE (r_prep) 13_8\CD|upon|) (r_nummod) Ro_7\NNP|the|novel|compound|( (l_prep) upon_12\IN||) (l_pobj) learning_14\NN|NONE (l_conj) memory_16\NN|and|in|impaired
D002701_D006935 NONE chloramphenicol_138\NN|NONE (r_pobj) by_137\IN|in (r_agent) induced_132\VBN|administered|passive|avoidance|a (r_acl) task_131\NN|NONE (r_pobj) for_127\IN||(|reversal|)|of|; (r_prep) prevention_116\NN|;|for||complete|against (r_conj) protection_94\NN|(|;|complete|)|of|for|mice (r_conj) prevention_74\NN|or|(||(|) (r_conj) rats_67\NNS|of|complete||; (r_conj) prevention_40\NN|following|the|: (l_prep) of_41\IN|complete|rats||; (l_pobj) incapacity_43\NN|NONE (l_acl) learn_45\VB|the (l_dobj) response_49\NN|to (l_prep) in_50\IN|escape|discrete|a (l_pobj) rats_51\NNS|NONE (l_acl) exposed_52\VBN|NONE (l_prep) to_53\IN|before (l_pobj) hypercapnia_55\NN|NONE
D002701_D006935 NONE chloramphenicol_138\NN|NONE (r_pobj) by_137\IN|in (r_agent) induced_132\VBN|administered|passive|avoidance|a (r_acl) task_131\NN|NONE (r_pobj) for_127\IN||(|reversal|)|of|; (r_prep) prevention_116\NN|;|for||complete|against (l_conj) reversal_149\NN||(|for|)|of|; (l_conj) prevention_186\NN|;|(|h|injected||,|administered|of|)|, (l_prep) in_190\IN|of||)|( (l_pobj) retrieval_192\NN|NONE (l_prep) of_193\IN|the (l_pobj) task_197\NN|NONE (l_acl) induced_198\VBN|an|active|applied|avoidance (l_agent) by_201\IN|in (l_pobj) electroshock_203\NN|NONE (l_conj) hypercapnia_205\NN|subconvulsant|or
7234705
D011342_D018879 NONE procainamide_6\NN|orally|.|In|for|was|, (r_nsubjpass) administered_8\VBN|NONE (l_prep) for_10\IN|orally|.|In|was|,|procainamide (l_pobj) treatment_11\NN|NONE (l_prep) of_12\IN|NONE (l_pobj) contractions_16\NNS|NONE
D011342_D001282 NONE procainamide_6\NN|orally|.|In|for|was|, (r_nsubjpass) administered_8\VBN|NONE (l_prep) for_10\IN|orally|.|In|was|,|procainamide (l_pobj) treatment_11\NN|NONE (l_prep) of_12\IN|NONE (l_pobj) contractions_16\NNS|NONE (l_conj) flutter_19\NN|chronic|premature|ventricular|or
D011342_D008133 NONE procainamide_5\NN|can|with|syndrome|that (r_nsubj) produce_7\VB|.|cases (l_dobj) syndrome_14\NN|can|with|procainamide|that
D011342_D017180 CID Procainamide_0\NNP|tachycardia|.| (r_npadvmod) induced_2\VBN|NONE (l_dobj) tachycardia_5\NN|.|Procainamide|
D011342_D017180 CID procainamide_3\RB| (r_advmod) induced_5\VBN|ventricular|polymorphous (r_amod) tachycardia_8\NNS|NONE
D011342_D017180 CID procainamide_17\NN|NONE (r_pobj) of_16\IN| (r_prep) mg_15\IN|NONE (r_pobj) of_11\IN|for|intravenous (r_prep) administration_10\NN|NONE (r_pobj) after_8\IN|.|,|tachycardia|In (r_prep) appeared_7\VBD|NONE (l_nsubj) tachycardia_6\NN|.|,|after|In
D011342_D017180 CID procainamide_17\NN|NONE (r_pobj) of_16\IN| (r_prep) mg_15\IN|NONE (r_pobj) of_11\IN|for|intravenous (r_prep) administration_10\NN|NONE (l_prep) for_18\IN|of|intravenous (l_pobj) treatment_20\NN|NONE (l_prep) of_21\IN|the (l_pobj) tachycardia_24\NN|NONE
D011342_D017180 CID procainamide_16\NN|NONE (r_amod) therapy_17\NN|NONE (r_pobj) of_15\IN|NONE (r_prep) continuation_14\NN|NONE (r_pobj) despite_13\IN|,|tachycardia|.|not|did (r_prep) reoccur_24\VB|In|was|,|and|pacemaker|, (l_nsubj) tachycardia_21\NN|,|.|not|despite|did
D011342_D017180 CID procainamide_5\NN|can|with|syndrome|that (r_nsubj) produce_7\VB|.|cases (l_prep) with_15\IN|can|syndrome|procainamide|that (l_pobj) tachycardia_18\NN|NONE
1720453
D010710_D064420 NONE phosphate_51\NN|NONE (r_compound) reabsorption_52\NN||and|elevated|beta (r_conj) microglobulinuria_48\NN|NONE (r_pobj) with_44\IN|five (r_prep) patients_43\NNS|group|. (r_dobj) included_41\VBD|patients|;|:|first|and|identified (r_conj) included_13\VBD|NONE (l_dobj) patients_15\NNS|;|included|:|first|and|identified (l_relcl) developed_25\VBD|)|%|four|( (l_dobj) toxicity_27\NN|who
D003404_D000608 NONE creatinine_22\NN|,|reabsorption (r_compound) clearance_23\NN|, (r_conj) osmolarity_20\NN|,|urinary (r_conj) pH_18\NN|, (r_conj) aminoaciduria_15\JJ|,
D003404_D011507 NONE creatinine_22\NN|,|reabsorption (r_compound) clearance_23\NN|, (r_conj) osmolarity_20\NN|,|urinary (r_conj) pH_18\NN|, (r_conj) aminoaciduria_15\JJ|, (r_conj) proteinuria_13\NN|,
D010710_D011507 NONE phosphate_25\NN|tubular (r_nmod) reabsorption_27\NN|,|creatinine (r_conj) clearance_23\NN|, (r_conj) osmolarity_20\NN|,|urinary (r_conj) pH_18\NN|, (r_conj) aminoaciduria_15\JJ|, (r_conj) proteinuria_13\NN|,
D010710_D000608 NONE phosphate_25\NN|tubular (r_nmod) reabsorption_27\NN|,|creatinine (r_conj) clearance_23\NN|, (r_conj) osmolarity_20\NN|,|urinary (r_conj) pH_18\NN|, (r_conj) aminoaciduria_15\JJ|,
D007069_D064420 NONE ifosfamide_15\NN|NONE (r_pobj) of_14\IN|/||g (r_prep) m2_13\NN|NONE (r_pobj) of_9\IN|and|,|cumulative|the|,|predominance|age|higher (r_prep) dose_8\NN|NONE (r_pobj) with_4\IN|was|.|toxicity (r_prep) correlated_3\VBN|NONE (l_nsubjpass) toxicity_1\NN|with|was|.
D010710_D005198 NONE phosphate_51\NN|NONE (r_compound) reabsorption_52\NN||and|elevated|beta (r_conj) microglobulinuria_48\NN|NONE (r_pobj) with_44\IN|five (r_prep) patients_43\NNS|group|. (r_dobj) included_41\VBD|patients|;|:|first|and|identified (r_conj) included_13\VBD|NONE (l_dobj) patients_15\NNS|;|included|:|first|and|identified (l_relcl) developed_25\VBD|)|%|four|( (l_dobj) toxicity_27\NN|who (l_acl) resulting_28\VBG|major (l_prep) in_29\IN|NONE (l_pobj) syndrome_32\NN|NONE
D010710_D005198 NONE phosphate_51\NN|NONE (r_compound) reabsorption_52\NN||and|elevated|beta (r_conj) microglobulinuria_48\NN|NONE (r_pobj) with_44\IN|five (r_prep) patients_43\NNS|group|. (r_dobj) included_41\VBD|patients|;|:|first|and|identified (r_conj) included_13\VBD|NONE (l_dobj) patients_15\NNS|;|included|:|first|and|identified (l_relcl) developed_25\VBD|)|%|four|( (l_dobj) toxicity_27\NN|who (l_acl) resulting_28\VBG|major (l_prep) in_29\IN|NONE (l_pobj) syndrome_32\NN|NONE (l_appos) TDFS_34\NNP|Fanconi|)|(
D003404_D006030 NONE creatinine_22\NN|,|reabsorption (r_compound) clearance_23\NN|, (r_conj) osmolarity_20\NN|,|urinary (r_conj) pH_18\NN|, (r_conj) aminoaciduria_15\JJ|, (r_conj) proteinuria_13\NN|, (r_conj) glucosuria_11\NN|,|and|electrolytes
D007069_D007674 CID ifosfamide_7\JJ|in|renal (r_amod) toxicity_9\NN|NONE
D010710_D006030 NONE phosphate_25\NN|tubular (r_nmod) reabsorption_27\NN|,|creatinine (r_conj) clearance_23\NN|, (r_conj) osmolarity_20\NN|,|urinary (r_conj) pH_18\NN|, (r_conj) aminoaciduria_15\JJ|, (r_conj) proteinuria_13\NN|, (r_conj) glucosuria_11\NN|,|and|electrolytes
D007069_C535700 NONE ifosfamide_7\JJ|in|renal (r_amod) toxicity_9\NN|NONE (r_pobj) of_6\IN||term|follow (r_prep) up_5\NN|for|:|.|Society (r_nsubj) treated_12\VBN|NONE (l_prep) for_13\IN|:|.|up|Society (l_pobj) tumors_16\NNS|NONE
D007069_C535700 NONE ifosfamide_19\JJ|(|)|Society|MMT|same|chemotherapy|the (r_compound) protocol_21\NN|have|who (r_dobj) received_16\VBN|and|of|The|in|with|renal (r_relcl) function_2\NN|were|year|after|. (l_prep) with_6\IN|and|received|of|The|in|renal (l_pobj) tumors_9\NNS|NONE
D007069_C535700 NONE ifosfamide_19\JJ|(|)|Society|MMT|same|chemotherapy|the (r_compound) protocol_21\NN|have|who (l_appos) Society_24\NNP|(|)|MMT|same|ifosfamide|chemotherapy|the (l_prep) of_25\IN|International (l_pobj) Study_31\NNP|NONE (l_compound) Tumor_30\NNP|Oncology|Mesenchymal|Malignant
D007069_C535700 NONE ifosfamide_18\NN|NONE (r_pobj) of_17\IN|the|in (r_prep) efficacy_16\NN|NONE (l_prep) in_19\IN|of|the (l_pobj) treatment_21\NN|NONE (l_prep) of_22\IN|the|in (l_pobj) tumors_24\NNS|NONE
D007069_D009369 NONE ifosfamide_15\NN|NONE (r_pobj) of_14\IN|/||g (r_prep) m2_13\NN|NONE (r_pobj) of_9\IN|and|,|cumulative|the|,|predominance|age|higher (r_prep) dose_8\NN|NONE (l_conj) predominance_31\NN|and|,|cumulative|the|,|of|age|higher (l_prep) of_32\IN|a (l_pobj) involvement_35\NN|NONE (l_compound) tumor_34\NN|vesicoprostatic
1009330
C004658_D003556 NONE choloroaniline_10\NN|degradation|the (r_appos) product_7\NN|not|factor|that (r_nsubj) is_11\VBZ|results|.|have (l_attr) factor_15\NN|product|not|that (l_prep) in_16\IN|significant|a (l_pobj) cystitis_22\NN|NONE
C010882_D003556 CID digluconate_19\NN|NONE (r_npadvmod) associated_20\VBN|erosive (r_amod) cystitis_22\NN|NONE
D003091_D003556 CID colistin_6\NN|NONE (r_nmod) irrigations_11\NNS|NONE (r_pobj) of_3\IN|high|A (r_prep) percentage_2\NN|with|and|were|.|suggested (r_nsubjpass) associated_13\VBN|NONE (l_prep) with_14\IN|and|were|.|percentage|suggested (l_pobj) cystitis_16\NN|NONE
C005253_D003556 NONE Picloxydine_0\NNP|NONE (r_compound) irrigations_1\NNS|have|but|have (r_nsubj) appeared_2\VBD|NONE (l_xcomp) have_4\VB|have|irrigations|but (l_dobj) incidence_7\NN|to (l_prep) of_8\IN|lower|a (l_pobj) cystitis_10\NN|NONE
D011206_D003556 CID iodine_10\NN|kanamycin|and| (r_conj) colistin_6\NN|NONE (r_nmod) irrigations_11\NNS|NONE (r_pobj) of_3\IN|high|A (r_prep) percentage_2\NN|with|and|were|.|suggested (r_nsubjpass) associated_13\VBN|NONE (l_prep) with_14\IN|and|were|.|percentage|suggested (l_pobj) cystitis_16\NN|NONE
D007612_D003556 CID kanamycin_4\NN|and||iodine (r_compound) colistin_6\NN|NONE (r_nmod) irrigations_11\NNS|NONE (r_pobj) of_3\IN|high|A (r_prep) percentage_2\NN|with|and|were|.|suggested (r_nsubjpass) associated_13\VBN|NONE (l_prep) with_14\IN|and|were|.|percentage|suggested (l_pobj) cystitis_16\NN|NONE
17241657
C107044_D012640 NONE 21_15\CD|NONE (r_nummod) /-)-SM_14\SYM|+|(|or (r_conj) UMB24_10\NNP|NONE (r_pobj) with_9\IN|of (r_prep) pretreatment_4\NN|,|In|significantly|.|lethality|but|convulsions|, (r_nsubj) attenuated_17\VBN|NONE (l_dobj) convulsions_21\NNS|,|In|significantly|.|lethality|but|pretreatment|,
C519696_D012640 NONE UMB24_10\NNP|NONE (r_pobj) with_9\IN|of (r_prep) pretreatment_4\NN|,|In|significantly|.|lethality|but|convulsions|, (r_nsubj) attenuated_17\VBN|NONE (l_dobj) convulsions_21\NNS|,|In|significantly|.|lethality|but|pretreatment|,
D003042_D012640 CID cocaine_21\NN|NONE (r_pobj) of_20\IN|,|the|lethal|,|locomotor|stimulatory|convulsive (r_prep) actions_19\NNS|that|antagonism (l_amod) convulsive_11\JJ|,|the|lethal|,|locomotor|of|stimulatory
D003042_D012640 CID cocaine_18\NN| (r_npadvmod) induced_20\VBN|and|activity (r_amod) convulsions_21\NNS|,|In|significantly|.|lethality|but|pretreatment|,
14657095
C101425_D006333 NONE posaconazole_8\NN|after|for|was (r_nsubjpass) substituted_10\VBN|NONE (r_advcl) resolved_6\VBD|His|and|failure|echocardiographic (r_acl) abnormalities_2\NNS|NONE (l_conj) failure_5\NN|His|and|echocardiographic|resolved
D000666_D006333 CID B_20\NNP|NONE (r_pobj) with_18\IN|after|failure|who|for (r_prep) developed_5\VBD|a (l_dobj) failure_12\NN|after|who|with|for
D000666_D006333 CID AmB_22\NNP|amphotericin (r_appos) B_20\NNP|NONE (r_pobj) with_18\IN|after|failure|who|for (r_prep) developed_5\VBD|a (l_dobj) failure_12\NN|after|who|with|for
D000666_D006333 CID AmB._12\NN|NONE (r_pobj) for_11\IN|after|was|posaconazole (r_prep) substituted_10\VBN|NONE (r_advcl) resolved_6\VBD|His|and|failure|echocardiographic (r_acl) abnormalities_2\NNS|NONE (l_conj) failure_5\NN|His|and|echocardiographic|resolved
D000666_D003047 NONE B_20\NNP|NONE (r_pobj) with_18\IN|after|failure|who|for (r_prep) developed_5\VBD|a (l_prep) for_24\IN|after|failure|who|with (l_pobj) coccidioidomycosis_26\NN|NONE
D000666_D003047 NONE AmB_22\NNP|amphotericin (r_appos) B_20\NNP|NONE (r_pobj) with_18\IN|after|failure|who|for (r_prep) developed_5\VBD|a (l_prep) for_24\IN|after|failure|who|with (l_pobj) coccidioidomycosis_26\NN|NONE
D000666_D002311 CID B_6\NNP|amphotericin (r_compound) therapy_7\NN|NONE (r_pobj) to_4\IN|NONE (r_prep) related_3\VBN|Reversible|.|dilated (r_acl) cardiomyopathy_2\NN|NONE
D000666_D002311 CID B_20\NNP|NONE (r_pobj) with_18\IN|after|failure|who|for (r_prep) developed_5\VBD|a (l_dobj) failure_12\NN|after|who|with|for (l_amod) cardiomyopathy_7\NN|heart|dilated
D000666_D002311 CID AmB_22\NNP|amphotericin (r_appos) B_20\NNP|NONE (r_pobj) with_18\IN|after|failure|who|for (r_prep) developed_5\VBD|a (l_dobj) failure_12\NN|after|who|with|for (l_amod) cardiomyopathy_7\NN|heart|dilated
D000666_D064420 NONE AmB._12\NN|NONE (r_pobj) of_11\IN|the|rare (r_prep) toxicity_10\NN|to
3686155
D001971_D001523 NONE bromocriptine_16\NN|for|having (r_dobj) received_15\VBN|.|with|,|patients|were (r_advcl) seen_9\VBN|NONE (l_nsubjpass) patients_2\NNS|.|received|with|,|were (l_prep) with_3\IN|Two|multigravida (l_pobj) history_7\NN|NONE (l_amod) psychiatric_6\JJ|no|prior
D001971_D010300 NONE Bromocriptine_0\NNP|has|.|with|been (r_nsubjpass) associated_7\VBN|NONE (l_prep) with_8\IN|has|.|been|Bromocriptine (l_pobj) psychosis_9\NN|NONE (l_prep) in_10\IN|NONE (l_pobj) patients_11\NNS|NONE (l_acl) receiving_12\VBG|NONE (l_dobj) drug_14\NN|NONE (l_prep) for_15\IN|the (l_pobj) disease_18\NN|NONE
D001971_D011605 CID bromocriptine_4\NN|NONE (r_pobj) by_3\IN|.|psychosis (r_prep) induced_2\VBN|NONE (l_nsubj) psychosis_1\NN|.|by
D001971_D011605 CID bromocriptine_16\NN|for|having (r_dobj) received_15\VBN|.|with|,|patients|were (r_advcl) seen_9\VBN|NONE (l_prep) with_10\IN|.|received|,|patients|were (l_pobj) psychosis_12\NN|NONE
D001971_D011605 CID Bromocriptine_0\NNP|has|.|with|been (r_nsubjpass) associated_7\VBN|NONE (l_prep) with_8\IN|has|.|been|Bromocriptine (l_pobj) psychosis_9\NN|NONE
D001971_D011605 CID bromocriptine_4\NN|psychosis|may|given (r_nsubj) cause_6\VB|cases|. (l_dobj) psychosis_7\NN|may|bromocriptine|given
D001971_D007775 NONE bromocriptine_16\NN|for|having (r_dobj) received_15\VBN|.|with|,|patients|were (l_prep) for_17\IN|bromocriptine|having (l_pobj) inhibition_18\NN|NONE (l_prep) of_19\IN|NONE (l_pobj) lactation_20\NN|NONE
625456
D017693_D006934 CID bicarbonate_27\NN|calcium|sodium (r_compound) powders_28\NNS|NONE (r_pobj) of_20\IN|large (r_prep) amounts_19\NNS|who|regularly|for|had (r_dobj) consumed_17\VBN|NONE (r_relcl) patients_13\NNS|NONE (r_pobj) in_12\IN|are|two|case|. (r_prep) reported_11\VBN|NONE (l_nsubjpass) case_1\NN|are|two|in|. (l_prep) of_2\IN|One|and (l_pobj) hypercalcaemia_4\NN|NONE
D002119_D053040 CID ate_24\VBN||carbon| (r_amod) sodium_26\NN|calcium|bicarbonate (r_compound) powders_28\NNS|NONE (r_pobj) of_20\IN|large (r_prep) amounts_19\NNS|who|regularly|for|had (r_dobj) consumed_17\VBN|NONE (r_relcl) patients_13\NNS|NONE (r_pobj) in_12\IN|are|two|case|. (r_prep) reported_11\VBN|NONE (l_nsubjpass) two_6\CD|are|case|in|. (l_prep) of_7\IN|NONE (l_pobj) nephrolithiasis_9\NN|NONE
D002119_D006934 CID ate_24\VBN||carbon| (r_amod) sodium_26\NN|calcium|bicarbonate (r_compound) powders_28\NNS|NONE (r_pobj) of_20\IN|large (r_prep) amounts_19\NNS|who|regularly|for|had (r_dobj) consumed_17\VBN|NONE (r_relcl) patients_13\NNS|NONE (r_pobj) in_12\IN|are|two|case|. (r_prep) reported_11\VBN|NONE (l_nsubjpass) case_1\NN|are|two|in|. (l_prep) of_2\IN|One|and (l_pobj) hypercalcaemia_4\NN|NONE
D017693_D053040 CID bicarbonate_27\NN|calcium|sodium (r_compound) powders_28\NNS|NONE (r_pobj) of_20\IN|large (r_prep) amounts_19\NNS|who|regularly|for|had (r_dobj) consumed_17\VBN|NONE (r_relcl) patients_13\NNS|NONE (r_pobj) in_12\IN|are|two|case|. (r_prep) reported_11\VBN|NONE (l_nsubjpass) two_6\CD|are|case|in|. (l_prep) of_7\IN|NONE (l_pobj) nephrolithiasis_9\NN|NONE
7919560
D005839_D018805 NONE gentamicin_10\NN|.|boy|and|with|was (l_prep) because_11\IN|NONE (l_pobj) septicemia_14\NN|of
D000667_D009205 CID ampicillin_7\NN|NONE (r_pobj) by_6\IN|.|multiforme (r_agent) caused_5\VBN|NONE (l_nsubj) multiforme_1\NN|.|by (l_conj) myocarditis_4\NN|Erythema|and
D000667_D009205 CID ampicillin_12\NN|NONE (r_pobj) by_11\IN|NONE (r_agent) caused_10\VBN|of|a (r_acl) case_3\NN|To|. (l_prep) of_4\IN|a|caused (l_pobj) multiforme_6\NNS|NONE (l_conj) myocarditis_9\NN|erythema|and
D000667_D004892 CID ampicillin_7\NN|NONE (r_pobj) by_6\IN|.|multiforme (r_agent) caused_5\VBN|NONE (l_nsubj) multiforme_1\NN|.|by
D000667_D004892 CID ampicillin_12\NN|NONE (r_pobj) by_11\IN|NONE (r_agent) caused_10\VBN|of|a (r_acl) case_3\NN|To|. (l_prep) of_4\IN|a|caused (l_pobj) multiforme_6\NNS|NONE
D010406_D009205 NONE penicillins_11\NNS|NONE (r_pobj) to_10\IN|.|myocarditis|manifestation (r_prep) is_2\VBZ|NONE (l_nsubj) myocarditis_1\NN|.|manifestation|to
D010406_D004342 NONE penicillins_11\NNS|NONE (r_pobj) to_10\IN|.|myocarditis|manifestation (r_prep) is_2\VBZ|NONE (l_attr) manifestation_7\NN|.|myocarditis|to (l_prep) of_8\IN|a|rare (l_pobj) allergy_9\NN|NONE
D000667_D018805 NONE ampicillin_8\NN|NONE (r_pobj) with_7\IN|gentamicin|.|boy|and|was (r_prep) treated_6\VBN|NONE (l_conj) gentamicin_10\NN|.|boy|and|with|was (l_prep) because_11\IN|NONE (l_pobj) septicemia_14\NN|of
3341566
D009599_D007022 CID nitroprusside_10\RB| (r_advmod) induced_12\VBN|in|sodium (r_amod) hypotension_13\NN|NONE
D009599_D007022 CID SNP_21\NNP|the (r_compound) group_22\NN|NONE (r_pobj) in_19\IN|NONE (r_prep) that_18\DT|NONE (r_pobj) with_17\IN|NONE (r_prep) compared_16\VBN|NONE (r_prep) higher_15\RBR|output|During|.|lower (r_acomp) was_8\VBD|NONE (l_prep) During_0\IN|output|higher|.|lower (l_pobj) hypotension_4\NN|NONE
D009599_D007022 CID SNP_7\NNP|HEM (r_compound) groups_8\NNS|NONE (r_pobj) in_3\IN|mm|,|,|respectively|P|during|. (r_prep) Hg_2\NNP|NONE (l_prep) during_12\IN|mm|,|,|respectively|P|in|. (l_pobj) hypotension_13\NN|NONE
D009599_D006470 NONE nitroprusside_10\RB| (r_advmod) induced_12\VBN|in|sodium (r_amod) hypotension_13\NN|NONE (r_pobj) during_8\IN|NONE (r_prep) than_7\IN|greater|variation|.|during (r_prep) is_3\VBZ|NONE (l_prep) during_5\IN|greater|than|variation|. (l_pobj) hemorrhage_6\NN|NONE
D009599_D006470 NONE nitroprusside_28\NN|for|.|to|was|pressure (r_advcl) decreased_4\VBN|NONE (l_prep) for_9\IN|nitroprusside|.|to|was|pressure (l_pobj) minutes_11\NNS|NONE (l_prep) by_13\IN| (l_pobj) hemorrhage_14\NN|either|or|by
D009599_D006470 NONE nitroprusside_28\NN|for|.|to|was|pressure (r_advcl) decreased_4\VBN|NONE (l_prep) for_9\IN|nitroprusside|.|to|was|pressure (l_pobj) minutes_11\NNS|NONE (l_prep) by_13\IN| (l_pobj) hemorrhage_14\NN|either|or|by (l_appos) HEM_16\NNP|NONE
D009599_D006470 NONE SNP_30\NNP|)|,|(| (r_dep) n_32\CC|NONE (r_npadvmod) nitroprusside_28\NN|for|.|to|was|pressure (r_advcl) decreased_4\VBN|NONE (l_prep) for_9\IN|nitroprusside|.|to|was|pressure (l_pobj) minutes_11\NNS|NONE (l_prep) by_13\IN| (l_pobj) hemorrhage_14\NN|either|or|by
D009599_D006470 NONE SNP_30\NNP|)|,|(| (r_dep) n_32\CC|NONE (r_npadvmod) nitroprusside_28\NN|for|.|to|was|pressure (r_advcl) decreased_4\VBN|NONE (l_prep) for_9\IN|nitroprusside|.|to|was|pressure (l_pobj) minutes_11\NNS|NONE (l_prep) by_13\IN| (l_pobj) hemorrhage_14\NN|either|or|by (l_appos) HEM_16\NNP|NONE
D009599_D006470 NONE SNP_21\NNP|the (r_compound) group_22\NN|NONE (r_pobj) in_19\IN|NONE (r_prep) that_18\DT|NONE (r_pobj) with_17\IN|NONE (r_prep) compared_16\VBN|NONE (r_prep) higher_15\RBR|output|During|.|lower (r_acomp) was_8\VBD|NONE (l_prep) During_0\IN|output|higher|.|lower (l_pobj) hypotension_4\NN|NONE (l_amod) induced_3\VBN|NONE (l_npadvmod) HEM_1\NNP|
D009599_D006470 NONE SNP_17\NNP|the (r_compound) group_18\NN|NONE (r_pobj) in_15\IN|NONE (r_prep) Hg_14\NNP|.|P|+/ (r_appos) mm_13\NN|NONE (r_pobj) with_9\IN|NONE (r_prep) compared_8\VBN|mm|.|,|in (r_prep) Hg_2\NNP|NONE (l_prep) in_3\IN|mm|.|,|compared (l_pobj) group_6\NN|NONE (l_compound) HEM_5\NNP|the
D009599_D006470 NONE SNP_7\NNP|HEM (r_compound) groups_8\NNS|NONE (l_nmod) HEM_5\NNP|SNP
11745184
D004999_D009422 NONE amifostine_5\NN|and (r_conj) cisplatin_3\NN|NONE (r_pobj) of_2\IN|Early (r_prep) trials_1\NNS|also|.|reduced (r_nsubj) suggested_7\VBD|NONE (l_ccomp) reduced_24\VBN|trials|also|. (l_nsubjpass) incidence_10\NN|that|were (l_prep) of_13\IN|the|severity|and (l_pobj) nephrotoxicity_17\NN|NONE (l_conj) ototoxicity_19\NN|,|induced (l_conj) neuropathy_22\NN|and|,
D002945_D009369 NONE cisplatin_20\VB|NONE (r_acl) amifostine_18\NN|NONE (r_pobj) of_17\IN|the (r_prep) addition_16\NN|NONE (r_pobj) with_14\IN|was|effect|. (r_prep) observed_13\VBN|NONE (l_nsubjpass) effect_5\NN|with|was|. (l_amod) protective_4\JJ|reduced|Neither|nor|a (l_npadvmod) tumor_2\NN|
D004999_D007674 NONE amifostine_5\NN|and (r_conj) cisplatin_3\NN|NONE (r_pobj) of_2\IN|Early (r_prep) trials_1\NNS|also|.|reduced (r_nsubj) suggested_7\VBD|NONE (l_ccomp) reduced_24\VBN|trials|also|. (l_nsubjpass) incidence_10\NN|that|were (l_prep) of_13\IN|the|severity|and (l_pobj) nephrotoxicity_17\NN|NONE
D004999_D006311 NONE amifostine_5\NN|and (r_conj) cisplatin_3\NN|NONE (r_pobj) of_2\IN|Early (r_prep) trials_1\NNS|also|.|reduced (r_nsubj) suggested_7\VBD|NONE (l_ccomp) reduced_24\VBN|trials|also|. (l_nsubjpass) incidence_10\NN|that|were (l_prep) of_13\IN|the|severity|and (l_pobj) nephrotoxicity_17\NN|NONE (l_conj) ototoxicity_19\NN|,|induced
D002945_D001943 NONE cisplatin_5\NN|)|WR|( (r_nmod) amifostine_9\NN|NONE (r_pobj) of_4\IN|E|.|II|for|:|A (r_prep) trial_3\NN|NONE (l_prep) for_11\IN|E|of|.|II|:|A (l_pobj) carcinoma_14\NN|NONE
D002945_D001943 NONE Cisplatin_0\NNP|used|.|activity (r_nsubj) has_1\VBZ|NONE (l_advcl) used_6\VBN|.|Cisplatin|activity (l_prep) as_7\IN|when (l_pobj) treatment_13\NN|NONE (l_prep) of_14\IN|line|second (l_pobj) carcinoma_17\NN|NONE
D002945_D001943 NONE cisplatin_10\NN|NONE (r_pobj) with_9\IN|has|effect|been|Although (r_prep) observed_8\VBN|have|use|.|,|toxicities (r_advcl) limited_31\VBN|NONE (l_dobj) use_33\NN|have|.|,|observed|toxicities (l_prep) as_34\IN|its (l_pobj) treatment_36\NN|NONE (l_prep) for_37\IN|a (l_pobj) carcinoma_39\NN|NONE
D002945_D001943 NONE cisplatin_19\NN|NONE (r_pcomp) with_18\IN|NONE (r_prep) associated_17\VBN|the|limiting (r_acl) toxicities_16\NNS|have|use|.|,|observed (r_nsubj) limited_31\VBN|NONE (l_dobj) use_33\NN|have|.|,|observed|toxicities (l_prep) as_34\IN|its (l_pobj) treatment_36\NN|NONE (l_prep) for_37\IN|a (l_pobj) carcinoma_39\NN|NONE
D002945_D001943 NONE cisplatin_8\NN|NONE (r_pobj) of_7\IN|the (r_prep) combination_6\NN|NONE (r_pobj) of_4\IN|II|A (r_prep) study_3\NN|was|regimen|,|in|but (r_nsubjpass) conducted_12\VBN|NONE (l_prep) in_13\IN|study|was|regimen|,|but (l_pobj) patients_14\NNS|NONE (l_prep) with_15\IN|NONE (l_pobj) carcinoma_19\NN|NONE
D004999_D009369 NONE amifostine_18\NN|NONE (r_pobj) of_17\IN|the (r_prep) addition_16\NN|NONE (r_pobj) with_14\IN|was|effect|. (r_prep) observed_13\VBN|NONE (l_nsubjpass) effect_5\NN|with|was|. (l_amod) protective_4\JJ|reduced|Neither|nor|a (l_npadvmod) tumor_2\NN|
D004999_D001943 NONE WR-2721_7\NNP|)|cisplatin|( (r_nmod) amifostine_9\NN|NONE (r_pobj) of_4\IN|E|.|II|for|:|A (r_prep) trial_3\NN|NONE (l_prep) for_11\IN|E|of|.|II|:|A (l_pobj) carcinoma_14\NN|NONE
D004999_D001943 NONE amifostine_9\NN|NONE (r_pobj) of_4\IN|E|.|II|for|:|A (r_prep) trial_3\NN|NONE (l_prep) for_11\IN|E|of|.|II|:|A (l_pobj) carcinoma_14\NN|NONE
D004999_D001943 NONE amifostine_10\NN|plus (r_conj) cisplatin_8\NN|NONE (r_pobj) of_7\IN|the (r_prep) combination_6\NN|NONE (r_pobj) of_4\IN|II|A (r_prep) study_3\NN|was|regimen|,|in|but (r_nsubjpass) conducted_12\VBN|NONE (l_prep) in_13\IN|study|was|regimen|,|but (l_pobj) patients_14\NNS|NONE (l_prep) with_15\IN|NONE (l_pobj) carcinoma_19\NN|NONE
D004999_D064420 NONE amifostine_18\NN|NONE (r_pobj) of_17\IN|the (r_prep) addition_16\NN|NONE (r_pobj) with_14\IN|was|effect|. (r_prep) observed_13\VBN|NONE (l_nsubjpass) effect_5\NN|with|was|. (l_conj) reduced_7\VBN|Neither|nor|a|protective (l_dobj) toxicity_8\NN|to
D002945_D006311 CID cisplatin_10\NN|NONE (r_pobj) with_9\IN|has|effect|been|Although (r_prep) observed_8\VBN|have|use|.|,|toxicities (r_advcl) limited_31\VBN|NONE (l_nsubj) toxicities_16\NNS|have|use|.|,|observed (l_acl) associated_17\VBN|the|limiting (l_prep) with_18\IN|NONE (l_pcomp) cisplatin_19\NN|NONE (l_preconj) nephrotoxicity_23\NN|NONE (l_conj) ototoxicity_25\NN|,|,|e.g.|(|)
D002945_D006311 CID cisplatin_19\NN|NONE (l_preconj) nephrotoxicity_23\NN|NONE (l_conj) ototoxicity_25\NN|,|,|e.g.|(|)
D002945_D006311 CID cisplatin_3\NN|NONE (r_pobj) of_2\IN|Early (r_prep) trials_1\NNS|also|.|reduced (r_nsubj) suggested_7\VBD|NONE (l_ccomp) reduced_24\VBN|trials|also|. (l_nsubjpass) incidence_10\NN|that|were (l_prep) of_13\IN|the|severity|and (l_pobj) nephrotoxicity_17\NN|NONE (l_conj) ototoxicity_19\NN|,|induced
D002945_D006311 CID cisplatin_14\NN| (r_advmod) induced_16\VBN|,|ototoxicity (r_amod) nephrotoxicity_17\NN|NONE (l_conj) ototoxicity_19\NN|,|induced
D002945_D064420 NONE cisplatin_10\NN|NONE (r_pobj) with_9\IN|has|effect|been|Although (r_prep) observed_8\VBN|have|use|.|,|toxicities (r_advcl) limited_31\VBN|NONE (l_nsubj) toxicities_16\NNS|have|use|.|,|observed
D002945_D064420 NONE cisplatin_19\NN|NONE (r_pcomp) with_18\IN|NONE (r_prep) associated_17\VBN|the|limiting (r_acl) toxicities_16\NNS|have|use|.|,|observed
D002945_D064420 NONE cisplatin_20\VB|NONE (r_acl) amifostine_18\NN|NONE (r_pobj) of_17\IN|the (r_prep) addition_16\NN|NONE (r_pobj) with_14\IN|was|effect|. (r_prep) observed_13\VBN|NONE (l_nsubjpass) effect_5\NN|with|was|. (l_conj) reduced_7\VBN|Neither|nor|a|protective (l_dobj) toxicity_8\NN|to
D002945_D007674 CID cisplatin_10\NN|NONE (r_pobj) with_9\IN|has|effect|been|Although (r_prep) observed_8\VBN|have|use|.|,|toxicities (r_advcl) limited_31\VBN|NONE (l_nsubj) toxicities_16\NNS|have|use|.|,|observed (l_acl) associated_17\VBN|the|limiting (l_prep) with_18\IN|NONE (l_pcomp) cisplatin_19\NN|NONE (l_preconj) nephrotoxicity_23\NN|NONE
D002945_D007674 CID cisplatin_19\NN|NONE (l_preconj) nephrotoxicity_23\NN|NONE
D002945_D007674 CID cisplatin_3\NN|NONE (r_pobj) of_2\IN|Early (r_prep) trials_1\NNS|also|.|reduced (r_nsubj) suggested_7\VBD|NONE (l_ccomp) reduced_24\VBN|trials|also|. (l_nsubjpass) incidence_10\NN|that|were (l_prep) of_13\IN|the|severity|and (l_pobj) nephrotoxicity_17\NN|NONE
D002945_D007674 CID cisplatin_14\NN| (r_advmod) induced_16\VBN|,|ototoxicity (r_amod) nephrotoxicity_17\NN|NONE
D002945_D020258 NONE cisplatin_10\NN|NONE (r_pobj) with_9\IN|has|effect|been|Although (r_prep) observed_8\VBN|have|use|.|,|toxicities (r_advcl) limited_31\VBN|NONE (l_nsubj) toxicities_16\NNS|have|use|.|,|observed (l_acl) associated_17\VBN|the|limiting (l_prep) with_18\IN|NONE (l_pcomp) cisplatin_19\NN|NONE (l_preconj) nephrotoxicity_23\NN|NONE (l_conj) ototoxicity_25\NN|,|,|e.g.|(|) (l_conj) neurotoxicity_28\NN|,|and
D002945_D020258 NONE cisplatin_19\NN|NONE (l_preconj) nephrotoxicity_23\NN|NONE (l_conj) ototoxicity_25\NN|,|,|e.g.|(|) (l_conj) neurotoxicity_28\NN|,|and
D002945_D009422 CID cisplatin_3\NN|NONE (r_pobj) of_2\IN|Early (r_prep) trials_1\NNS|also|.|reduced (r_nsubj) suggested_7\VBD|NONE (l_ccomp) reduced_24\VBN|trials|also|. (l_nsubjpass) incidence_10\NN|that|were (l_prep) of_13\IN|the|severity|and (l_pobj) nephrotoxicity_17\NN|NONE (l_conj) ototoxicity_19\NN|,|induced (l_conj) neuropathy_22\NN|and|,
D002945_D009422 CID cisplatin_14\NN| (r_advmod) induced_16\VBN|,|ototoxicity (r_amod) nephrotoxicity_17\NN|NONE (l_conj) ototoxicity_19\NN|,|induced (l_conj) neuropathy_22\NN|and|,
7803371
D003915_D003072 CID dextromethorphan_8\NN|NONE (r_pobj) of_7\IN|term (r_prep) abuse_6\NN|NONE (r_pobj) from_2\IN|Cognitive|.|:|report (r_prep) deterioration_1\NN|NONE
D003915_D003072 CID DM_13\NN|NONE (r_pobj) of_12\IN|prolonged (r_prep) use_11\NN|NONE (r_pobj) from_9\IN|NONE (r_prep) resulting_8\VBG|cognitive (r_acl) deterioration_7\NN|NONE
8492347
D008274_D013746 NONE magnesium_10\NN|NONE (r_compound) supplementation_11\NN|NONE (r_pobj) of_9\IN|NONE (r_prep) importance_8\NN|rhabdomyolysis|.|due||and (r_appos) Tetany_0\NNP|NONE
D008274_D012206 NONE magnesium_10\NN|NONE (r_compound) supplementation_11\NN|NONE (r_pobj) of_9\IN|NONE (r_prep) importance_8\NN|rhabdomyolysis|.|due||and (r_appos) Tetany_0\NNP|NONE (l_conj) rhabdomyolysis_2\NN|.|due|importance||and
D002118_D013035 NONE calcium_25\NN|and (r_conj) potassium_23\NN|alone (r_nmod) supplementation_26\NN|NONE (r_pobj) by_22\IN|not|be|which|can (r_agent) corrected_21\VBN|with|hypomagnesemia|is|,|.|cause (r_ccomp) associated_11\VBN|NONE (l_prep) with_12\IN|hypomagnesemia|is|,|corrected|.|cause (l_pobj) spasms_14\NNS|NONE
D008274_D006996 NONE magnesium_27\NN|NONE (r_compound) depletion_28\NN|NONE (r_pobj) of_26\IN|the (r_prep) effects_25\NNS|.|in|not|were (r_nsubjpass) noted_31\VBN|(|)|but|,|was|in (r_conj) observed_19\VBN|)||(|and|has|in|been|hypokalemia (l_prep) in_14\IN|(|)|but|,|was|noted (l_pobj) hypocalcemia_17\NN|NONE
D005665_D012206 CID furosemide_6\NN|to (r_pobj) due_3\JJ|rhabdomyolysis|.|importance||and (r_prep) Tetany_0\NNP|NONE (l_conj) rhabdomyolysis_2\NN|.|due|importance||and
D002118_C537153 NONE calcium_25\NN|and (r_conj) potassium_23\NN|alone (r_nmod) supplementation_26\NN|NONE (r_pobj) by_22\IN|not|be|which|can (r_agent) corrected_21\VBN|with|hypomagnesemia|is|,|.|cause (r_ccomp) associated_11\VBN|NONE (l_nsubjpass) hypomagnesemia_9\NN|with|is|,|corrected|.|cause
D011188_D013035 NONE potassium_23\NN|alone (r_nmod) supplementation_26\NN|NONE (r_pobj) by_22\IN|not|be|which|can (r_agent) corrected_21\VBN|with|hypomagnesemia|is|,|.|cause (r_ccomp) associated_11\VBN|NONE (l_prep) with_12\IN|hypomagnesemia|is|,|corrected|.|cause (l_pobj) spasms_14\NNS|NONE
D008274_D007008 NONE magnesium_27\NN|NONE (r_compound) depletion_28\NN|NONE (r_pobj) of_26\IN|the (r_prep) effects_25\NNS|.|in|not|were (r_nsubjpass) noted_31\VBN|(|)|but|,|was|in (r_conj) observed_19\VBN|)||(|and|has|in|been|hypokalemia (r_conj) reported_4\VBN|NONE (l_nsubjpass) hypokalemia_1\NN|)||(|observed|and|has|in|been
D002118_D018908 NONE calcium_25\NN|and (r_conj) potassium_23\NN|alone (r_nmod) supplementation_26\NN|NONE (r_pobj) by_22\IN|not|be|which|can (r_agent) corrected_21\VBN|with|hypomagnesemia|is|,|.|cause (r_ccomp) associated_11\VBN|NONE (l_advcl) cause_4\VB|with|hypomagnesemia|is|,|corrected|. (l_dobj) weakness_6\NN|hypokalemia|may|While
D011188_D018908 NONE potassium_23\NN|alone (r_nmod) supplementation_26\NN|NONE (r_pobj) by_22\IN|not|be|which|can (r_agent) corrected_21\VBN|with|hypomagnesemia|is|,|.|cause (r_ccomp) associated_11\VBN|NONE (l_advcl) cause_4\VB|with|hypomagnesemia|is|,|corrected|. (l_dobj) weakness_6\NN|hypokalemia|may|While
D002118_D013746 NONE calcium_25\NN|and (r_conj) potassium_23\NN|alone (r_nmod) supplementation_26\NN|NONE (r_pobj) by_22\IN|not|be|which|can (r_agent) corrected_21\VBN|with|hypomagnesemia|is|,|.|cause (r_ccomp) associated_11\VBN|NONE (l_prep) with_12\IN|hypomagnesemia|is|,|corrected|.|cause (l_pobj) spasms_14\NNS|NONE (l_conj) tetany_16\NN|and|muscle
D011188_C537153 NONE potassium_23\NN|alone (r_nmod) supplementation_26\NN|NONE (r_pobj) by_22\IN|not|be|which|can (r_agent) corrected_21\VBN|with|hypomagnesemia|is|,|.|cause (r_ccomp) associated_11\VBN|NONE (l_nsubjpass) hypomagnesemia_9\NN|with|is|,|corrected|.|cause
D002118_D007008 NONE calcium_25\NN|and (r_conj) potassium_23\NN|alone (r_nmod) supplementation_26\NN|NONE (r_pobj) by_22\IN|not|be|which|can (r_agent) corrected_21\VBN|with|hypomagnesemia|is|,|.|cause (r_ccomp) associated_11\VBN|NONE (l_advcl) cause_4\VB|with|hypomagnesemia|is|,|corrected|. (l_nsubj) hypokalemia_2\NN|may|While|weakness
D005665_D013746 CID furosemide_6\NN|to (r_pobj) due_3\JJ|rhabdomyolysis|.|importance||and (r_prep) Tetany_0\NNP|NONE
D011188_D007008 NONE potassium_23\NN|alone (r_nmod) supplementation_26\NN|NONE (r_pobj) by_22\IN|not|be|which|can (r_agent) corrected_21\VBN|with|hypomagnesemia|is|,|.|cause (r_ccomp) associated_11\VBN|NONE (l_advcl) cause_4\VB|with|hypomagnesemia|is|,|corrected|. (l_nsubj) hypokalemia_2\NN|may|While|weakness
D011188_D013746 NONE potassium_23\NN|alone (r_nmod) supplementation_26\NN|NONE (r_pobj) by_22\IN|not|be|which|can (r_agent) corrected_21\VBN|with|hypomagnesemia|is|,|.|cause (r_ccomp) associated_11\VBN|NONE (l_prep) with_12\IN|hypomagnesemia|is|,|corrected|.|cause (l_pobj) spasms_14\NNS|NONE (l_conj) tetany_16\NN|and|muscle
8170551
D000086_D007669 CID acetazolamide_3\NN|NONE (r_pobj) on_2\IN|Three (r_prep) patients_1\NNS|calculi|. (r_nsubj) developed_8\VBN|NONE (l_dobj) calculi_10\NNS|patients|.
D000086_D009468 NONE Acetazolamide_0\RB| (r_npadvmod) induced_2\VBN|implications|.|: (r_amod) nephrolithiasis_3\NN|NONE (l_appos) implications_5\NNS|.|:|induced (l_prep) for_6\IN|NONE (l_pobj) treatment_7\NN|NONE (l_prep) of_8\IN|NONE (l_pobj) disorders_10\NNS|NONE
D000086_D053040 NONE Acetazolamide_0\RB| (r_npadvmod) induced_2\VBN|implications|.|: (r_amod) nephrolithiasis_3\NN|NONE
D000086_D053040 NONE acetazolamide_5\NN|NONE (r_pobj) of_4\IN|a (r_prep) complication_3\NN|preclude|but|.|Nephrolithiasis (r_attr) is_1\VBZ|NONE (l_nsubj) Nephrolithiasis_0\NNP|preclude|but|complication|.
15517007
D008942_D006331 CID mitoxantrone_11\NN|such (r_pobj) as_10\IN|NONE (r_prep) anthracyclines_8\NNS|or (r_conj) cyclophosphamide_6\NN|,|in|when|patients|,|are|for (r_nsubjpass) used_13\VBN|However|caution|,|is|. (l_prep) in_14\IN|,|when|patients|,|are|cyclophosphamide|for (l_pobj) patients_15\NNS|NONE (l_prep) with_16\IN|NONE (l_pobj) damage_21\NN|NONE
D018943_D012595 NONE anthracyclines_8\NNS|or (r_conj) cyclophosphamide_6\NN|,|in|when|patients|,|are|for (r_nsubjpass) used_13\VBN|However|caution|,|is|. (l_dobj) patients_28\NNS|,|in|when|,|are|cyclophosphamide|for (l_compound) sclerosis_27\NN|systemic
D003520_D012595 NONE cyclophosphamide_6\NN|,|in|when|patients|,|are|for (r_nsubjpass) used_13\VBN|However|caution|,|is|. (l_dobj) patients_28\NNS|,|in|when|,|are|cyclophosphamide|for (l_compound) sclerosis_27\NN|systemic
D008942_D012595 NONE mitoxantrone_11\NN|such (r_pobj) as_10\IN|NONE (r_prep) anthracyclines_8\NNS|or (r_conj) cyclophosphamide_6\NN|,|in|when|patients|,|are|for (r_nsubjpass) used_13\VBN|However|caution|,|is|. (l_dobj) patients_28\NNS|,|in|when|,|are|cyclophosphamide|for (l_compound) sclerosis_27\NN|systemic
D003520_D006331 CID cyclophosphamide_6\NN|,|in|when|patients|,|are|for (r_nsubjpass) used_13\VBN|However|caution|,|is|. (l_prep) in_14\IN|,|when|patients|,|are|cyclophosphamide|for (l_pobj) patients_15\NNS|NONE (l_prep) with_16\IN|NONE (l_pobj) damage_21\NN|NONE
D018943_D006331 NONE anthracyclines_8\NNS|or (r_conj) cyclophosphamide_6\NN|,|in|when|patients|,|are|for (r_nsubjpass) used_13\VBN|However|caution|,|is|. (l_prep) in_14\IN|,|when|patients|,|are|cyclophosphamide|for (l_pobj) patients_15\NNS|NONE (l_prep) with_16\IN|NONE (l_pobj) damage_21\NN|NONE
7858459
D005472_D013274 NONE 5-fluorouracil_18\CD|(|mg|dose|,|/ (r_punct) m2/24_23\NN|and|)|acid (r_compound) hours_24\NNS|etoposide|, (l_conj) acid_28\NN|m/|and|) (l_prep) for_29\IN|folinic (l_pobj) adenocarcinoma_33\NN|NONE
D005472_D001523 NONE 5-fluorouracil_35\CD|NONE (r_punct) of_34\IN|first|and|the|day (r_prep) dose_29\NN|acid|folinic (r_nmod) infusion_39\NN|NONE (r_pobj) during_26\IN|for (r_prep) lasting_21\VBG|,|into|then (r_advcl) lapsed_15\VBD|He|and|,|symptoms|. (r_conj) developed_1\VBD|NONE (l_dobj) symptoms_4\NNS|lapsed|He|and|,|. (l_prep) of_5\IN|acute|neurologic (l_pobj) confusion_7\NN|NONE (l_conj) disorientation_9\NN|mental|, (l_conj) irritability_11\NN|and
C007744_D020258 NONE fluorocitrate_16\NN|and (r_conj) fluoroacetate_14\NN|NONE (r_pobj) by_13\IN|,|a|cycle|Krebs|deficiency (r_prep) blockade_12\NN|NONE (r_pobj) to_8\IN|NONE (r_prep) due_7\JJ|may|.|pathogenesis (r_acomp) be_6\VB|NONE (l_nsubj) pathogenesis_1\NN|may|due|. (l_prep) of_2\IN|The (l_pobj) neurotoxicity_4\NN|NONE
D002955_D003221 CID acid_13\NN|a|and|dose|of (r_conj) infusion_8\NN|NONE (r_pobj) by_3\IN|confusion|. (r_agent) induced_2\VBN|NONE (l_nsubj) confusion_1\NN|by|.
D002955_D003221 CID acid_38\NN|dose|folinic (r_compound) infusion_39\NN|NONE (r_pobj) during_26\IN|for (r_prep) lasting_21\VBG|,|into|then (r_advcl) lapsed_15\VBD|He|and|,|symptoms|. (r_conj) developed_1\VBD|NONE (l_dobj) symptoms_4\NNS|lapsed|He|and|,|. (l_prep) of_5\IN|acute|neurologic (l_pobj) confusion_7\NN|NONE
D002955_D003221 CID acid_38\NN|dose|folinic (r_compound) infusion_39\NN|NONE (r_pobj) during_26\IN|for (r_prep) lasting_21\VBG|,|into|then (r_advcl) lapsed_15\VBD|He|and|,|symptoms|. (r_conj) developed_1\VBD|NONE (l_dobj) symptoms_4\NNS|lapsed|He|and|,|. (l_prep) of_5\IN|acute|neurologic (l_pobj) confusion_7\NN|NONE (l_conj) disorientation_9\NN|mental|,
D002955_D013274 NONE acid_28\NN|m/|and|) (l_prep) for_29\IN|folinic (l_pobj) adenocarcinoma_33\NN|NONE
C007419_D020258 NONE dihydrouracil_22\VBN|NONE (r_compound) dehydrogenase_23\NN|NONE (r_compound) deficiency_24\NN|or|,|thiamine (r_conj) deficiency_19\NN|,|by|a|cycle|Krebs (r_conj) blockade_12\NN|NONE (r_pobj) to_8\IN|NONE (r_prep) due_7\JJ|may|.|pathogenesis (r_acomp) be_6\VB|NONE (l_nsubj) pathogenesis_1\NN|may|due|. (l_prep) of_2\IN|The (l_pobj) neurotoxicity_4\NN|NONE
D002955_D020258 NONE acid_2\NN|Because|unlikely (r_nsubj) was_3\VBD|was|neurotoxicity|.|highly|,|fluorouracil (r_advcl) suspected_21\VBN|NONE (l_nsubjpass) neurotoxicity_12\NN|was|.|highly|,|was|fluorouracil
D002945_D013274 NONE cisplatinum_11\NN|chemotherapy (l_appos) hours_24\NNS|etoposide|, (l_conj) acid_28\NN|m/|and|) (l_prep) for_29\IN|folinic (l_pobj) adenocarcinoma_33\NN|NONE
D002955_D009369 NONE acid_6\NN|NONE (r_compound) infusion_7\NN|folinic|dose (r_compound) therapy_8\NN|.|has|recently|regimen (r_nsubj) become_11\VBN|NONE (l_attr) regimen_14\NN|.|has|therapy|recently (l_prep) for_15\IN|a|popular (l_pobj) cancers_17\NNS|NONE
D005472_D020258 NONE 5-fluorouracil_18\CD|was|neurotoxicity|.|highly|,|was (r_punct) suspected_21\VBN|NONE (l_nsubjpass) neurotoxicity_12\NN|was|.|highly|,|was|fluorouracil
D005472_D020258 NONE 5-fluorouracil_3\CD|NONE (r_punct) neurotoxicity_4\NN|NONE
D013831_D020258 NONE thiamine_18\NN|or|,|deficiency (r_compound) deficiency_19\NN|,|by|a|cycle|Krebs (r_conj) blockade_12\NN|NONE (r_pobj) to_8\IN|NONE (r_prep) due_7\JJ|may|.|pathogenesis (r_acomp) be_6\VB|NONE (l_nsubj) pathogenesis_1\NN|may|due|. (l_prep) of_2\IN|The (l_pobj) neurotoxicity_4\NN|NONE
D005472_D003221 CID 5-fluorouracil_10\CD|NONE (r_punct) of_9\IN|acid|a|and|dose (r_prep) infusion_8\NN|NONE (r_pobj) by_3\IN|confusion|. (r_agent) induced_2\VBN|NONE (l_nsubj) confusion_1\NN|by|.
D005472_D003221 CID 5-fluorouracil_35\CD|NONE (r_punct) of_34\IN|first|and|the|day (r_prep) dose_29\NN|acid|folinic (r_nmod) infusion_39\NN|NONE (r_pobj) during_26\IN|for (r_prep) lasting_21\VBG|,|into|then (r_advcl) lapsed_15\VBD|He|and|,|symptoms|. (r_conj) developed_1\VBD|NONE (l_dobj) symptoms_4\NNS|lapsed|He|and|,|. (l_prep) of_5\IN|acute|neurologic (l_pobj) confusion_7\NN|NONE
D005472_D003221 CID 5-fluorouracil_35\CD|NONE (r_punct) of_34\IN|first|and|the|day (r_prep) dose_29\NN|acid|folinic (r_nmod) infusion_39\NN|NONE (r_pobj) during_26\IN|for (r_prep) lasting_21\VBG|,|into|then (r_advcl) lapsed_15\VBD|He|and|,|symptoms|. (r_conj) developed_1\VBD|NONE (l_dobj) symptoms_4\NNS|lapsed|He|and|,|. (l_prep) of_5\IN|acute|neurologic (l_pobj) confusion_7\NN|NONE (l_conj) disorientation_9\NN|mental|,
D005472_D003128 CID 5-fluorouracil_35\CD|NONE (r_punct) of_34\IN|first|and|the|day (r_prep) dose_29\NN|acid|folinic (r_nmod) infusion_39\NN|NONE (r_pobj) during_26\IN|for (r_prep) lasting_21\VBG|,|into|then (r_advcl) lapsed_15\VBD|He|and|,|symptoms|. (l_prep) into_16\IN|,|lasting|then (l_pobj) coma_19\NN|NONE
D005047_D013274 NONE etoposide_13\NN|,|hours (r_conj) cisplatinum_11\NN|chemotherapy (l_appos) hours_24\NNS|etoposide|, (l_conj) acid_28\NN|m/|and|) (l_prep) for_29\IN|folinic (l_pobj) adenocarcinoma_33\NN|NONE
D002955_D003128 CID acid_38\NN|dose|folinic (r_compound) infusion_39\NN|NONE (r_pobj) during_26\IN|for (r_prep) lasting_21\VBG|,|into|then (r_advcl) lapsed_15\VBD|He|and|,|symptoms|. (l_prep) into_16\IN|,|lasting|then (l_pobj) coma_19\NN|NONE
D005472_D009369 NONE 5-fluorouracil_3\CD|/ (r_punct) folinic_5\JJ|infusion|dose (r_amod) therapy_8\NN|.|has|recently|regimen (r_nsubj) become_11\VBN|NONE (l_attr) regimen_14\NN|.|has|therapy|recently (l_prep) for_15\IN|a|popular (l_pobj) cancers_17\NNS|NONE
D002955_D001523 NONE acid_38\NN|dose|folinic (r_compound) infusion_39\NN|NONE (r_pobj) during_26\IN|for (r_prep) lasting_21\VBG|,|into|then (r_advcl) lapsed_15\VBD|He|and|,|symptoms|. (r_conj) developed_1\VBD|NONE (l_dobj) symptoms_4\NNS|lapsed|He|and|,|. (l_prep) of_5\IN|acute|neurologic (l_pobj) confusion_7\NN|NONE (l_conj) disorientation_9\NN|mental|, (l_conj) irritability_11\NN|and
D005463_D020258 NONE fluoroacetate_14\NN|NONE (r_pobj) by_13\IN|,|a|cycle|Krebs|deficiency (r_prep) blockade_12\NN|NONE (r_pobj) to_8\IN|NONE (r_prep) due_7\JJ|may|.|pathogenesis (r_acomp) be_6\VB|NONE (l_nsubj) pathogenesis_1\NN|may|due|. (l_prep) of_2\IN|The (l_pobj) neurotoxicity_4\NN|NONE
10342929
D000806_D000799 CID inhibitors_4\NNS|NONE (r_pobj) to_2\IN|NONE (r_pcomp) due_1\IN|. (r_prep) Angioedema_0\NNP|NONE
D000806_D000799 CID inhibitor_13\NN|)|ACE (r_compound) treatment_14\NN|(|incidence|.|patients (r_nsubj) is_15\VBZ|NONE (l_nsubj) incidence_2\NN|(|treatment|.|patients (l_prep) of_3\IN|during|estimated|The (l_pobj) angioedema_4\NN|NONE
20705401
D012701_D012559 NONE 5-HT6_20\CD|altered (r_nummod) receptors_21\NNS|in|that|are (r_nsubjpass) involved_23\VBN|evidence|. (r_ccomp) suggests_17\VBZ|were|models|reflect|,|and (r_conj) considered_4\VBN|NONE (l_xcomp) reflect_6\VB|were|suggests|models|,|and (l_dobj) symptoms_9\NNS|to (l_prep) of_10\IN|positive|the (l_pobj) schizophrenia_11\NN|NONE
D012701_D006948 NONE serotonin_1\NN|is|.|by|therapeutically|corrected (r_nsubjpass) targeted_9\VBN|NONE (l_agent) by_10\IN|is|.|therapeutically|corrected|serotonin (l_pobj) antipsychotics_14\NNS|NONE (l_prep) as_17\IN|several|generation|, (l_pobj) clozapine_18\NN|such (l_conj) hyperactivity_28\NN|induced|olanzapine|and|and|,
D012701_D006948 NONE 5-HT6_4\CD|(|)| (r_nummod) receptor_6\NN|The (r_appos) serotonin_1\NN|is|.|by|therapeutically|corrected (r_nsubjpass) targeted_9\VBN|NONE (l_agent) by_10\IN|is|.|therapeutically|corrected|serotonin (l_pobj) antipsychotics_14\NNS|NONE (l_prep) as_17\IN|several|generation|, (l_pobj) clozapine_18\NN|such (l_conj) hyperactivity_28\NN|induced|olanzapine|and|and|,
D012701_D006948 NONE 5-HT6_39\CD|receptor|a|selective (r_nummod) antagonist_41\NN|NONE (r_pobj) of_36\IN|the (r_prep) use_35\NN|NONE (r_pobj) with_33\IN|is (r_prep) corrected_32\VBN|is|.|by|therapeutically|serotonin (r_conj) targeted_9\VBN|NONE (l_agent) by_10\IN|is|.|therapeutically|corrected|serotonin (l_pobj) antipsychotics_14\NNS|NONE (l_prep) as_17\IN|several|generation|, (l_pobj) clozapine_18\NN|such (l_conj) hyperactivity_28\NN|induced|olanzapine|and|and|,
D008694_D012563 NONE methamphetamine_3\NN|NONE (r_pobj) of_2\IN|The|psychosis (r_prep) symptoms_1\NNS|similar|. (r_nsubj) are_7\VBP|NONE (l_acomp) similar_8\JJ|.|symptoms (l_prep) to_9\IN|NONE (l_pobj) those_10\DT|NONE (l_prep) of_11\IN|NONE (l_pobj) schizophrenia_14\NN|NONE
D008694_D012563 NONE METH)-induced_5\JJ|( (r_amod) psychosis_6\NN|The|of (r_appos) symptoms_1\NNS|similar|. (r_nsubj) are_7\VBP|NONE (l_acomp) similar_8\JJ|.|symptoms (l_prep) to_9\IN|NONE (l_pobj) those_10\DT|NONE (l_prep) of_11\IN|NONE (l_pobj) schizophrenia_14\NN|NONE
C076029_D006948 NONE olanzapine_20\NN|induced|and|and|hyperactivity|, (r_conj) clozapine_18\NN|such (l_conj) hyperactivity_28\NN|induced|olanzapine|and|and|,
D003913_D006948 NONE amphetamine_25\NN|d|| (r_npadvmod) induced_27\VBN|olanzapine|and|and|hyperactivity|, (r_conj) clozapine_18\NN|such (l_conj) hyperactivity_28\NN|induced|olanzapine|and|and|,
D003024_D006948 NONE clozapine_18\NN|such (l_conj) hyperactivity_28\NN|induced|olanzapine|and|and|,
D008694_D011605 CID methamphetamine_7\NN| (r_npadvmod) induced_9\VBN|in (r_amod) psychosis_10\NN|NONE
D008694_D011605 CID methamphetamine_3\NN|NONE (r_pobj) of_2\IN|The|psychosis (r_prep) symptoms_1\NNS|similar|. (l_appos) psychosis_6\NN|The|of
D008694_D011605 CID METH)-induced_5\JJ|( (r_amod) psychosis_6\NN|The|of
D008694_D011605 CID METH_17\NNP| (r_npadvmod) induced_19\VBN|NONE (r_amod) psychosis_20\NN|NONE
D008694_D011605 CID METH_29\NN| (r_npadvmod) induced_31\VBN|(|controls|)|psychosis|and|in| (r_amod) patients_33\NNS|control (l_compound) psychosis_32\NN|induced|(|controls|)|and|in|
D008694_D011605 CID METH_4\NNP| (r_npadvmod) induced_6\VBN|in|psychosis (r_amod) patients_8\NNS|NONE (l_compound) psychosis_7\NN|in|induced
D008694_D011605 CID METH_32\NNP| (r_npadvmod) induced_34\VBN|psychosis (r_amod) patients_36\NNS|an|between|, (l_compound) psychosis_35\NN|induced
D008694_D011605 CID METH_10\NNP| (r_npadvmod) induced_12\VBN|in (r_amod) psychosis_13\NN|NONE
D012701_D011605 NONE Serotonin_0\NN||receptor (r_nmod) gene_3\NN|.|is|with (r_nsubjpass) associated_5\VBN|NONE (l_prep) with_6\IN|.|is|gene (l_pobj) psychosis_10\NN|NONE
D012701_D011605 NONE 5-HT6_20\CD|altered (r_nummod) receptors_21\NNS|in|that|are (r_nsubjpass) involved_23\VBN|evidence|. (l_prep) in_24\IN|receptors|that|are (l_pobj) pathophysiology_26\NN|NONE (l_prep) of_27\IN|the (l_pobj) disorders_29\NNS|NONE
D012701_D011605 NONE 5-HT6_11\CD|(|HTR|)|with|the (r_nummod) gene_12\NN|NONE (l_prep) with_16\IN|(|HTR|HT|)|the (l_pobj) psychosis_20\NN|NONE
9915601
D007741_D001919 NONE labetalol_9\JJ|, (r_conj) pindolol_7\NN|after|, (r_conj) propranolol_5\NN|,|as|but|significantly|bradycardia|Isoniazid|,|after|. (r_advcl) increased_2\VBD|NONE (l_acomp) bradycardia_3\NNP|,|propranolol|as|but|significantly|Isoniazid|,|after|.
D007538_D001919 CID isoniazid_12\NN|NONE (r_pobj) with_11\IN|NONE (r_prep) pretreated_10\VBD|NONE (r_acl) rats_9\NNS|NONE (r_pobj) in_8\IN|adrenoceptor (r_prep) antagonists_7\NNS|NONE (r_pobj) by_3\IN|NONE (r_agent) induced_2\VBN|.|Enhanced (r_acl) bradycardia_1\NNS|NONE
D007538_D001919 CID isoniazid_3\NN|NONE (r_pobj) of_2\IN|.|hypotension|,|interaction|High (r_prep) doses_1\NNS|NONE (l_appos) hypotension_5\NN|of|.|,|interaction|High (l_conj) change_10\VB|increase|induced|and (l_prep) to_15\IN|tachycardia (l_pobj) bradycardia_16\NNP|NONE
D007538_D001919 CID isoniazid_9\NN|NONE (l_prep) of_10\IN|NONE (l_pobj) bradycardia_11\NN|NONE
D007538_D001919 CID Isoniazid_0\NNP|,|propranolol|as|but|significantly|bradycardia|,|after|. (r_nsubj) increased_2\VBD|NONE (l_acomp) bradycardia_3\NNP|,|propranolol|as|but|significantly|Isoniazid|,|after|.
D005680_D007022 NONE acid_29\NN|NONE (r_pobj) of_24\IN|decreased (r_prep) synthesis_23\NN|NONE (r_pobj) to_21\IN|NONE (r_prep) attributed_20\VBN|an (r_acl) interaction_19\NN|of|.|hypotension|,|High (r_appos) doses_1\NNS|NONE (l_appos) hypotension_5\NN|of|.|,|interaction|High
D005680_D007022 NONE GABA_31\NNP|aminobutyric|brain (r_appos) acid_29\NN|NONE (r_pobj) of_24\IN|decreased (r_prep) synthesis_23\NN|NONE (r_pobj) to_21\IN|NONE (r_prep) attributed_20\VBN|an (r_acl) interaction_19\NN|of|.|hypotension|,|High (r_appos) doses_1\NNS|NONE (l_appos) hypotension_5\NN|of|.|,|interaction|High
D001262_D001919 NONE atenolol_11\NN|and (r_conj) labetalol_9\JJ|, (r_conj) pindolol_7\NN|after|, (r_conj) propranolol_5\NN|,|as|but|significantly|bradycardia|Isoniazid|,|after|. (r_advcl) increased_2\VBD|NONE (l_acomp) bradycardia_3\NNP|,|propranolol|as|but|significantly|Isoniazid|,|after|.
D007538_D013610 NONE isoniazid_3\NN|NONE (r_pobj) of_2\IN|.|hypotension|,|interaction|High (r_prep) doses_1\NNS|NONE (l_appos) hypotension_5\NN|of|.|,|interaction|High (l_conj) change_10\VB|increase|induced|and (l_dobj) tachycardia_14\NN|to
D014520_D001919 NONE urethane_26\NN|NONE (r_pobj) with_23\IN|NONE (r_prep) anaesthetised_22\VBN|NONE (r_acl) rats_21\NNS|NONE (r_pobj) in_20\IN|.|In|enhancement|was|, (r_prep) determined_19\VBN|NONE (l_nsubjpass) enhancement_7\NN|.|in|In|was|, (l_prep) by_8\IN|the|possible|induced (l_pobj) isoniazid_9\NN|NONE (l_prep) of_10\IN|NONE (l_pobj) bradycardia_11\NN|NONE
D018738_D001919 NONE hexamethonium_22\NN|not (r_pobj) after_21\IN|,|propranolol|as|but|significantly|bradycardia|Isoniazid|,|. (r_conj) increased_2\VBD|NONE (l_acomp) bradycardia_3\NNP|,|propranolol|as|but|significantly|Isoniazid|,|after|.
D005680_D001919 NONE acid_29\NN|NONE (r_pobj) of_24\IN|decreased (r_prep) synthesis_23\NN|NONE (r_pobj) to_21\IN|NONE (r_prep) attributed_20\VBN|an (r_acl) interaction_19\NN|of|.|hypotension|,|High (r_appos) doses_1\NNS|NONE (l_appos) hypotension_5\NN|of|.|,|interaction|High (l_conj) change_10\VB|increase|induced|and (l_prep) to_15\IN|tachycardia (l_pobj) bradycardia_16\NNP|NONE
D005680_D001919 NONE GABA_31\NNP|aminobutyric|brain (r_appos) acid_29\NN|NONE (r_pobj) of_24\IN|decreased (r_prep) synthesis_23\NN|NONE (r_pobj) to_21\IN|NONE (r_prep) attributed_20\VBN|an (r_acl) interaction_19\NN|of|.|hypotension|,|High (r_appos) doses_1\NNS|NONE (l_appos) hypotension_5\NN|of|.|,|interaction|High (l_conj) change_10\VB|increase|induced|and (l_prep) to_15\IN|tachycardia (l_pobj) bradycardia_16\NNP|NONE
D003000_D001919 NONE clonidine_17\NN|NONE (r_pobj) after_16\IN|as|well (r_prep) as_15\IN|,|propranolol|but|significantly|bradycardia|Isoniazid|,|after|. (r_cc) increased_2\VBD|NONE (l_acomp) bradycardia_3\NNP|,|propranolol|as|but|significantly|Isoniazid|,|after|.
D005680_D013610 NONE acid_29\NN|NONE (r_pobj) of_24\IN|decreased (r_prep) synthesis_23\NN|NONE (r_pobj) to_21\IN|NONE (r_prep) attributed_20\VBN|an (r_acl) interaction_19\NN|of|.|hypotension|,|High (r_appos) doses_1\NNS|NONE (l_appos) hypotension_5\NN|of|.|,|interaction|High (l_conj) change_10\VB|increase|induced|and (l_dobj) tachycardia_14\NN|to
D005680_D013610 NONE GABA_31\NNP|aminobutyric|brain (r_appos) acid_29\NN|NONE (r_pobj) of_24\IN|decreased (r_prep) synthesis_23\NN|NONE (r_pobj) to_21\IN|NONE (r_prep) attributed_20\VBN|an (r_acl) interaction_19\NN|of|.|hypotension|,|High (r_appos) doses_1\NNS|NONE (l_appos) hypotension_5\NN|of|.|,|interaction|High (l_conj) change_10\VB|increase|induced|and (l_dobj) tachycardia_14\NN|to
D007538_D007022 CID isoniazid_3\NN|NONE (r_pobj) of_2\IN|.|hypotension|,|interaction|High (r_prep) doses_1\NNS|NONE (l_appos) hypotension_5\NN|of|.|,|interaction|High
D010869_D001919 NONE pindolol_7\NN|after|, (r_conj) propranolol_5\NN|,|as|but|significantly|bradycardia|Isoniazid|,|after|. (r_advcl) increased_2\VBD|NONE (l_acomp) bradycardia_3\NNP|,|propranolol|as|but|significantly|Isoniazid|,|after|.
D002217_D001919 NONE carbachol_24\NN|or (r_conj) hexamethonium_22\NN|not (r_pobj) after_21\IN|,|propranolol|as|but|significantly|bradycardia|Isoniazid|,|. (r_conj) increased_2\VBD|NONE (l_acomp) bradycardia_3\NNP|,|propranolol|as|but|significantly|Isoniazid|,|after|.
D011433_D001919 NONE propranolol_5\NN|,|as|but|significantly|bradycardia|Isoniazid|,|after|. (r_advcl) increased_2\VBD|NONE (l_acomp) bradycardia_3\NNP|,|propranolol|as|but|significantly|Isoniazid|,|after|.
D002698_D001919 NONE chloralose_24\NN| (r_compound) urethane_26\NN|NONE (r_pobj) with_23\IN|NONE (r_prep) anaesthetised_22\VBN|NONE (r_acl) rats_21\NNS|NONE (r_pobj) in_20\IN|.|In|enhancement|was|, (r_prep) determined_19\VBN|NONE (l_nsubjpass) enhancement_7\NN|.|in|In|was|, (l_prep) by_8\IN|the|possible|induced (l_pobj) isoniazid_9\NN|NONE (l_prep) of_10\IN|NONE (l_pobj) bradycardia_11\NN|NONE
2334179
D010396_D009404 CID Penicillamine_2\NN|in|syndrome (r_nsubj) caused_3\VBD|insufficiency|;|none|. (l_dobj) syndrome_5\NN|in|Penicillamine
D010396_D012594 NONE penicillamine_2\NN|NONE (l_prep) in_3\IN|D||. (l_pobj) treatment_5\NN|NONE (l_prep) of_6\IN|the (l_pobj) scleroderma_8\NN|NONE
D010396_D012594 NONE penicillamine_17\NN|NONE (r_pobj) with_14\IN|were|who (r_prep) treated_13\VBN||with (r_relcl) patients_4\NNS|NONE (l_prep) with_5\IN||treated (l_pobj) scleroderma_10\NN|NONE
D010396_D012594 NONE penicillamine_6\NN|that|effective|may (r_nsubj) be_8\VB|.|data (l_acomp) effective_9\JJ|penicillamine|that|may (l_prep) in_10\IN|NONE (l_pobj) cases_12\NNS|NONE (l_prep) of_13\IN|severe (l_pobj) scleroderma_15\NN|NONE
D010396_D051437 NONE Penicillamine_2\NN|in|syndrome (r_nsubj) caused_3\VBD|insufficiency|;|none|. (r_ccomp) developed_19\VBD|NONE (l_dobj) insufficiency_21\NN|;|none|.|caused
D010396_D011507 CID Penicillamine_2\NN|in|syndrome (r_nsubj) caused_3\VBD|insufficiency|;|none|. (l_prep) in_6\IN|Penicillamine|syndrome (l_pobj) patient_8\NN|NONE (l_conj) proteinuria_12\NN||and
20633755
D009943_D001049 CID poisons_17\NNS|NONE (r_pobj) by_12\IN|enzyme|in|gets (r_agent) deactivated_11\VBN|NONE (r_relcl) patients_5\NNS|NONE (r_pobj) in_4\IN|prolonged (r_prep) apnea_3\NN|Suxamethonium|.
D009943_D001049 CID compound_14\NN|NONE (r_pobj) by_12\IN|suicidal (r_prep) attempt_11\NN|NONE (r_pobj) about_9\IN|the (r_prep) information_8\NN|from|because|was (r_nsubjpass) concealed_16\VBN|apnea|. (r_advcl) ensued_5\VBD|NONE (l_nsubj) apnea_1\NN|concealed|.
D013390_D001049 CID Suxamethonium_0\NNS|.|apnea (r_nsubj) induced_1\VBD|NONE (l_dobj) apnea_3\NN|.|Suxamethonium
D013390_D001049 CID Suxamethonium_0\JJ|apnea|. (r_nsubj) causes_1\VBZ|NONE (l_dobj) apnea_3\NN|Suxamethonium|.
12739036
D001379_D007674 NONE azathioprine_23\NN|NONE (r_pobj) with_22\IN|NONE (r_prep) treatment_21\NN|NONE (r_pobj) of_20\IN|NONE (r_prep) periods_19\NNS|NONE (r_dobj) undergone_18\JJ|she|,|.|and|been|from|with|Since|had (r_conj) suffering_6\VBG|NONE (l_prep) with_14\IN|she|,|undergone|.|and|been|from|Since|had (l_pobj) involvement_16\NN|NONE
D002738_D009135 NONE chloroquine_15\NN| (r_advmod) induced_17\VBN|severe (r_amod) myopathy_18\NN|NONE
D002738_D009135 NONE chloroquine_3\NN| (r_npadvmod) induced_5\VBN|NONE (r_compound) myopathy_6\NN|it|As
D003520_D008180 NONE cyclophosphamide_25\NN|and (r_conj) azathioprine_23\NN|NONE (r_pobj) with_22\IN|NONE (r_prep) treatment_21\NN|NONE (r_pobj) of_20\IN|NONE (r_prep) periods_19\NNS|NONE (r_dobj) undergone_18\JJ|she|,|.|and|been|from|with|Since|had (r_conj) suffering_6\VBG|NONE (l_prep) from_7\IN|she|,|undergone|.|and|been|with|Since|had (l_pobj) erythematosus_10\NN|NONE
D003520_D008180 NONE cyclophosphamide_25\NN|and (r_conj) azathioprine_23\NN|NONE (r_pobj) with_22\IN|NONE (r_prep) treatment_21\NN|NONE (r_pobj) of_20\IN|NONE (r_prep) periods_19\NNS|NONE (r_dobj) undergone_18\JJ|she|,|.|and|been|from|with|Since|had (r_conj) suffering_6\VBG|NONE (l_prep) from_7\IN|she|,|undergone|.|and|been|with|Since|had (l_pobj) erythematosus_10\NN|NONE (l_appos) SLE_12\NNP|lupus|systemic|)|(
D002738_D018771 NONE chloroquine_3\NN|( (r_amod) CQ_5\NNP|NONE (r_pobj) with_2\IN|)|Additional (r_prep) therapy_1\NN|was|.|because (r_nsubjpass) started_8\VBN|NONE (l_prep) because_9\IN|therapy|was|. (l_pobj) arthralgia_11\NN|of
D002738_D018771 NONE CQ_5\NNP|NONE (r_pobj) with_2\IN|)|Additional (r_prep) therapy_1\NN|was|.|because (r_nsubjpass) started_8\VBN|NONE (l_prep) because_9\IN|therapy|was|. (l_pobj) arthralgia_11\NN|of
D013256_D009220 NONE steroids_10\NNS|NONE (r_pobj) with_9\IN|patient|.|was (r_prep) treated_8\VBN|Myositis|was|,|and (r_conj) suspected_2\VBN|NONE (l_nsubjpass) Myositis_0\NNP|was|treated|,|and
D003401_D008180 NONE creatine_5\NN|kinase|in (r_compound) levels_7\NNS|NONE (l_prep) in_8\IN|creatine|kinase (l_pobj) erythematosus_11\NN|NONE
D003520_D007674 NONE cyclophosphamide_25\NN|and (r_conj) azathioprine_23\NN|NONE (r_pobj) with_22\IN|NONE (r_prep) treatment_21\NN|NONE (r_pobj) of_20\IN|NONE (r_prep) periods_19\NNS|NONE (r_dobj) undergone_18\JJ|she|,|.|and|been|from|with|Since|had (r_conj) suffering_6\VBG|NONE (l_prep) with_14\IN|she|,|undergone|.|and|been|from|Since|had (l_pobj) involvement_16\NN|NONE
D001379_D008180 NONE azathioprine_23\NN|NONE (r_pobj) with_22\IN|NONE (r_prep) treatment_21\NN|NONE (r_pobj) of_20\IN|NONE (r_prep) periods_19\NNS|NONE (r_dobj) undergone_18\JJ|she|,|.|and|been|from|with|Since|had (r_conj) suffering_6\VBG|NONE (l_prep) from_7\IN|she|,|undergone|.|and|been|with|Since|had (l_pobj) erythematosus_10\NN|NONE
D001379_D008180 NONE azathioprine_23\NN|NONE (r_pobj) with_22\IN|NONE (r_prep) treatment_21\NN|NONE (r_pobj) of_20\IN|NONE (r_prep) periods_19\NNS|NONE (r_dobj) undergone_18\JJ|she|,|.|and|been|from|with|Since|had (r_conj) suffering_6\VBG|NONE (l_prep) from_7\IN|she|,|undergone|.|and|been|with|Since|had (l_pobj) erythematosus_10\NN|NONE (l_appos) SLE_12\NNP|lupus|systemic|)|(
11999899
D012110_D002375 CID Reserpine_0\NN|MK|also|.|tremor (r_nsubj) produced_2\VBD|NONE (l_dobj) tremor_3\NN|MK|also|.|Reserpine (l_conj) catalepsy_5\NN|,|and|are
D012110_D002375 CID reserpine_25\NN|NONE (r_pobj) by_24\IN|NONE (r_agent) induced_23\VBN|chewing|,|the|vacuous|protrusions (r_acl) movements_17\NNS|mg/kg|. (l_conj) protrusions_20\NNS|chewing|induced|,|the|vacuous (l_conj) catalepsy_22\NN|tongue|and
D012110_D002375 CID reserpine_5\NN|,|MK|increases|compared|On|. (r_nsubj) induced_6\VBN|NONE (l_dobj) increases_7\NNS|reserpine|,|MK|compared|On|. (l_prep) in_8\IN|NONE (l_pobj) tremor_9\NN|NONE (l_conj) catalepsy_11\NN|and
D012110_D002375 CID reserpine_12\NN|NONE (r_pobj) by_11\IN|NONE (r_agent) induced_10\VBN|the|tremor|and (r_acl) catalepsy_7\NN|administration|.|(
D012110_D002375 CID reserpine_2\NN|NONE (r_pobj) with_1\IN|produced (r_prep) Pretreatment_0\NN|NONE (l_acl) produced_13\VBD|with (l_conj) increases_26\NNS|,|mg/kg|reversed|before|,|test|(|as|increases|h|. (l_prep) in_27\IN|NONE (l_pobj) tremor_28\NN|NONE (l_conj) catalepsy_30\NN|and
D012110_D002375 CID reserpine_48\NN|NONE (r_pobj) of_47\IN|the (r_prep) effects_46\NNS|min|test|whereas|before (r_dobj) reversed_44\VBD|,|increases|mg/kg|before|,|test|(|as|increases|h|. (r_advcl) produced_13\VBD|with (l_conj) increases_26\NNS|,|mg/kg|reversed|before|,|test|(|as|increases|h|. (l_prep) in_27\IN|NONE (l_pobj) tremor_28\NN|NONE (l_conj) catalepsy_30\NN|and
D016291_D002375 NONE MK-801_16\NNP|also|.|tremor|Reserpine (r_punct) produced_2\VBD|NONE (l_dobj) tremor_3\NN|MK|also|.|Reserpine (l_conj) catalepsy_5\NN|,|and|are
D016291_D002375 NONE MK-801_17\NNP|reserpine|,|increases|compared|On|. (r_punct) induced_6\VBN|NONE (l_dobj) increases_7\NNS|reserpine|,|MK|compared|On|. (l_prep) in_8\IN|NONE (l_pobj) tremor_9\NN|NONE (l_conj) catalepsy_11\NN|and
D016291_D002375 NONE MK-801_33\NNP|mg/kg|) (r_punct) injection_38\NN| (r_nsubj) min_40\NN|effects|test|whereas|before (r_nsubj) reversed_44\VBD|,|increases|mg/kg|before|,|test|(|as|increases|h|. (r_advcl) produced_13\VBD|with (l_conj) increases_26\NNS|,|mg/kg|reversed|before|,|test|(|as|increases|h|. (l_prep) in_27\IN|NONE (l_pobj) tremor_28\NN|NONE (l_conj) catalepsy_30\NN|and
D012110_D014202 CID Reserpine_0\NN|MK|also|.|tremor (r_nsubj) produced_2\VBD|NONE (l_dobj) tremor_3\NN|MK|also|.|Reserpine
D012110_D014202 CID reserpine_11\NN| (r_npadvmod) treated_13\VBN|NONE (r_amod) mice_14\NNS|NONE (r_pobj) in_10\IN|of|a|significant (r_prep) increase_7\NN|MK|injection|However|,|. (l_prep) of_8\IN|in|a|significant (l_pobj) tremor_9\NN|NONE
D012110_D014202 CID reserpine_5\NN|,|MK|increases|compared|On|. (r_nsubj) induced_6\VBN|NONE (l_dobj) increases_7\NNS|reserpine|,|MK|compared|On|. (l_prep) in_8\IN|NONE (l_pobj) tremor_9\NN|NONE
D012110_D014202 CID reserpine_12\NN|NONE (r_pobj) by_11\IN|NONE (r_agent) induced_10\VBN|the|tremor|and (r_acl) catalepsy_7\NN|administration|.|( (l_conj) tremor_9\NN|the|induced|and
D012110_D014202 CID reserpine_2\NN|NONE (r_pobj) with_1\IN|produced (r_prep) Pretreatment_0\NN|NONE (l_acl) produced_13\VBD|with (l_conj) increases_26\NNS|,|mg/kg|reversed|before|,|test|(|as|increases|h|. (l_prep) in_27\IN|NONE (l_pobj) tremor_28\NN|NONE
D012110_D014202 CID reserpine_48\NN|NONE (r_pobj) of_47\IN|the (r_prep) effects_46\NNS|min|test|whereas|before (r_dobj) reversed_44\VBD|,|increases|mg/kg|before|,|test|(|as|increases|h|. (r_advcl) produced_13\VBD|with (l_conj) increases_26\NNS|,|mg/kg|reversed|before|,|test|(|as|increases|h|. (l_prep) in_27\IN|NONE (l_pobj) tremor_28\NN|NONE
D012110_D004409 CID Reserpine_0\NN|.|increases (r_nsubj) produced_15\VBD|NONE (l_dobj) increases_16\NNS|Reserpine|. (l_prep) in_17\IN|NONE (l_pobj) dyskinesia_19\NN|NONE (l_relcl) are_30\VBP|orofacial|,|,|protrusion (l_attr) signs_31\NNS|which (l_amod) indicative_32\JJ|NONE (l_prep) of_33\IN|NONE (l_pobj) dyskinesia_35\NN|NONE
D012110_D004409 CID reserpine_4\NN|movements|that (r_nsubj) produces_5\VBZ|.|results (l_dobj) movements_9\NNS|reserpine|that
D012110_D004409 CID reserpine_4\NN|movements|that (r_nsubj) produces_5\VBZ|.|results (l_dobj) movements_9\NNS|reserpine|that (l_relcl) related_13\VBN|different|, (l_conj) considered_22\VBN|and|are|to|which (l_prep) as_23\IN|be|can (l_pobj) signs_30\NNS|NONE (l_compound) dsykinesia_29\NN|parkinsonian
D016291_D010300 NONE MK-801_16\NNP|also|.|tremor|Reserpine (r_punct) produced_2\VBD|NONE (l_dobj) tremor_3\NN|MK|also|.|Reserpine (l_relcl) are_8\VBP|,|catalepsy|and (l_attr) signs_9\NNS|which (l_amod) suggestive_10\JJ|NONE (l_prep) of_11\IN|NONE (l_pobj) disease_14\NN|NONE
D016202_D014202 NONE NMDA_5\NNP|NONE (r_pobj) by_4\IN|NONE (r_agent) produced_3\VBN|The|glutamatergic (r_acl) blockage_2\NN|according|can|signs|. (r_nsubj) restore_7\VB|NONE (l_dobj) signs_9\NNS|according|can|.|blockage (l_prep) as_12\IN|,|these (l_pobj) movements_15\NNS|such (l_conj) protrusions_18\NNS|chewing|,|vacuous (l_conj) catalepsy_20\NN|,|tongue (l_conj) tremor_22\NN|and
D016291_D014202 NONE MK-801_16\NNP|also|.|tremor|Reserpine (r_punct) produced_2\VBD|NONE (l_dobj) tremor_3\NN|MK|also|.|Reserpine
D016291_D014202 NONE MK-801_2\NNP|increase|injection|However|,|. (r_punct) produced_4\VBD|NONE (l_dobj) increase_7\NN|MK|injection|However|,|. (l_prep) of_8\IN|in|a|significant (l_pobj) tremor_9\NN|NONE
D016291_D014202 NONE MK-801_17\NNP|reserpine|,|increases|compared|On|. (r_punct) induced_6\VBN|NONE (l_dobj) increases_7\NNS|reserpine|,|MK|compared|On|. (l_prep) in_8\IN|NONE (l_pobj) tremor_9\NN|NONE
D016291_D014202 NONE MK-801_33\NNP|mg/kg|) (r_punct) injection_38\NN| (r_nsubj) min_40\NN|effects|test|whereas|before (r_nsubj) reversed_44\VBD|,|increases|mg/kg|before|,|test|(|as|increases|h|. (r_advcl) produced_13\VBD|with (l_conj) increases_26\NNS|,|mg/kg|reversed|before|,|test|(|as|increases|h|. (l_prep) in_27\IN|NONE (l_pobj) tremor_28\NN|NONE
D016202_D002375 NONE NMDA_5\NNP|NONE (r_pobj) by_4\IN|NONE (r_agent) produced_3\VBN|The|glutamatergic (r_acl) blockage_2\NN|according|can|signs|. (r_nsubj) restore_7\VB|NONE (l_dobj) signs_9\NNS|according|can|.|blockage (l_prep) as_12\IN|,|these (l_pobj) movements_15\NNS|such (l_conj) protrusions_18\NNS|chewing|,|vacuous (l_conj) catalepsy_20\NN|,|tongue
D001058_D009069 NONE apomophine_15\JJ|min (r_amod) injection_16\NN|NONE (r_pobj) by_14\IN|NONE (r_agent) followed_13\VBN|before|Reserpine|and (r_conj) administered_6\VBN|in|,|did|.|dyskinesia|not (r_ccomp) produce_29\VB|NONE (l_dobj) dyskinesia_31\NN|administered|in|,|did|.|not
D012110_D009069 NONE Reserpine_0\NN|.|increases (r_nsubj) produced_15\VBD|NONE (l_dobj) increases_16\NNS|Reserpine|. (l_prep) in_17\IN|NONE (l_pobj) dyskinesia_19\NN|NONE
D012110_D009069 NONE Reserpine_0\NN|before|followed|and (r_nsubj) administered_6\VBN|in|,|did|.|dyskinesia|not (r_ccomp) produce_29\VB|NONE (l_dobj) dyskinesia_31\NN|administered|in|,|did|.|not
D012110_D010300 NONE Reserpine_0\NN|MK|also|.|tremor (r_nsubj) produced_2\VBD|NONE (l_dobj) tremor_3\NN|MK|also|.|Reserpine (l_relcl) are_8\VBP|,|catalepsy|and (l_attr) signs_9\NNS|which (l_amod) suggestive_10\JJ|NONE (l_prep) of_11\IN|NONE (l_pobj) disease_14\NN|NONE
D012110_D010300 NONE reserpine_4\NN|movements|that (r_nsubj) produces_5\VBZ|.|results (l_dobj) movements_9\NNS|reserpine|that (l_relcl) related_13\VBN|different|, (l_conj) considered_22\VBN|and|are|to|which (l_prep) as_23\IN|be|can (l_pobj) signs_30\NNS|NONE (l_amod) parkinsonian_24\JJ|dsykinesia
20520283
C522667_D011618 NONE Asenapine_0\NNP|.|by|in|is (r_nsubjpass) approved_2\VBN|NONE (l_prep) in_9\IN|.|Asenapine|by|is (l_pobj) adults_10\NNS|NONE (l_prep) for_11\IN|NONE (l_conj) of_17\IN|or|treatment (l_pobj) episodes_21\NNS|NONE (l_acl) associated_22\VBN|manic (l_prep) with_23\IN|NONE (l_pobj) disorder_26\NN|NONE (l_prep) with_27\IN|bipolar|I (l_conj) without_29\IN|or (l_pobj) features_31\NNS|NONE (l_amod) psychotic_30\JJ|NONE
C522667_D001480 CID asenapine_21\NN|NONE (r_pobj) of_19\IN|at| (r_prep) %_18\NN|,||and (r_conj) %_14\NN|%|respectively||and|, (r_appos) %_8\NN|NONE (r_pobj) in_6\IN|AEs|as (r_prep) occurred_5\VBD|.|symptoms (r_advcl) reported_2\VBD|NONE (l_nsubj) symptoms_1\NNS|.|occurred
C522667_D001480 CID asenapine_9\NN|NONE (r_pobj) with_8\IN|NONE (r_prep) similar_7\JJ|that|efficacy (r_acomp) was_6\VBD|analyses (r_ccomp) indicated_3\VBD|were|in|;|.|contrasts (r_ccomp) seen_16\VBN|NONE (l_prep) in_17\IN|were|;|indicated|.|contrasts (l_pobj) AEs_18\NNS|NONE (l_appos) symptoms_22\NNS|,
C522667_D012559 NONE asenapine_4\NN|NONE (r_pobj) of_3\IN|in|.|safety|and (r_prep) Efficacy_0\NN|NONE (l_prep) in_5\IN|.|of|safety|and (l_pobj) trial_12\NN|NONE (l_prep) in_13\IN|placebo|controlled (l_pobj) patients_14\NNS|NONE (l_prep) with_15\IN|NONE (l_pobj) exacerbation_17\NN|NONE (l_prep) of_18\IN|acute (l_pobj) schizophrenia_19\NN|NONE
C522667_D012559 NONE Asenapine_0\NNP|.|by|in|is (r_nsubjpass) approved_2\VBN|NONE (l_prep) in_9\IN|.|Asenapine|by|is (l_pobj) adults_10\NNS|NONE (l_prep) for_11\IN|NONE (l_pobj) treatment_13\NN|of|or (l_prep) of_14\IN|acute (l_pobj) schizophrenia_15\NN|NONE
C522667_D012559 NONE asenapine_22\NN|NONE (r_pobj) with_21\IN|dose (r_prep) treatment_20\NN|NONE (r_pobj) to_16\IN|,|.|were|asenapine|)|randomly|at|In|,|patients (r_prep) assigned_15\VBN|NONE (l_nsubjpass) patients_9\NNS|,|.|were|asenapine|)|randomly|at|In|,|to (l_prep) with_10\IN| (l_pobj) schizophrenia_12\NN|NONE
C522667_D012559 NONE asenapine_32\NN|,|.|were|)|randomly|at|In|,|to|patients (r_dep) assigned_15\VBN|NONE (l_nsubjpass) patients_9\NNS|,|.|were|asenapine|)|randomly|at|In|,|to (l_prep) with_10\IN| (l_pobj) schizophrenia_12\NN|NONE
D006220_D001480 CID haloperidol_29\NN|,|mg (r_conj) BID_27\NN|NONE (r_pobj) at_22\IN|of| (r_prep) %_18\NN|,||and (r_conj) %_14\NN|%|respectively||and|, (r_appos) %_8\NN|NONE (r_pobj) in_6\IN|AEs|as (r_prep) occurred_5\VBD|.|symptoms (r_advcl) reported_2\VBD|NONE (l_nsubj) symptoms_1\NNS|.|occurred
D006220_D001480 CID haloperidol_11\NN|and (r_conj) asenapine_9\NN|NONE (r_pobj) with_8\IN|NONE (r_prep) similar_7\JJ|that|efficacy (r_acomp) was_6\VBD|analyses (r_ccomp) indicated_3\VBD|were|in|;|.|contrasts (r_ccomp) seen_16\VBN|NONE (l_prep) in_17\IN|were|;|indicated|.|contrasts (l_pobj) AEs_18\NNS|NONE (l_appos) symptoms_22\NNS|,
D006220_D012559 NONE haloperidol_9\NN| (r_npadvmod) controlled_11\VBN|placebo|in (r_amod) trial_12\NN|NONE (l_prep) in_13\IN|placebo|controlled (l_pobj) patients_14\NNS|NONE (l_prep) with_15\IN|NONE (l_pobj) exacerbation_17\NN|NONE (l_prep) of_18\IN|acute (l_pobj) schizophrenia_19\NN|NONE
D006220_D012559 NONE haloperidol_41\NN|or|, (r_conj) placebo_38\NN|mg|, (r_conj) BID_36\NN|NONE (r_pobj) at_33\IN|verify (r_prep) asenapine_32\NN|,|.|were|)|randomly|at|In|,|to|patients (r_dep) assigned_15\VBN|NONE (l_nsubjpass) patients_9\NNS|,|.|were|asenapine|)|randomly|at|In|,|to (l_prep) with_10\IN| (l_pobj) schizophrenia_12\NN|NONE
C522667_D001714 NONE Asenapine_0\NNP|.|by|in|is (r_nsubjpass) approved_2\VBN|NONE (l_prep) in_9\IN|.|Asenapine|by|is (l_pobj) adults_10\NNS|NONE (l_prep) for_11\IN|NONE (l_conj) of_17\IN|or|treatment (l_pobj) episodes_21\NNS|NONE (l_amod) manic_18\JJ|associated
C522667_D001714 NONE Asenapine_0\NNP|.|by|in|is (r_nsubjpass) approved_2\VBN|NONE (l_prep) in_9\IN|.|Asenapine|by|is (l_pobj) adults_10\NNS|NONE (l_prep) for_11\IN|NONE (l_conj) of_17\IN|or|treatment (l_pobj) episodes_21\NNS|NONE (l_acl) associated_22\VBN|manic (l_prep) with_23\IN|NONE (l_pobj) disorder_26\NN|NONE
11302406
D015725_D008133 NONE fluconazole_5\NN|, (r_ccomp) aware_3\JJ|should|.|at|cause|Clinicians|, (r_acomp) be_2\VB|NONE (l_conj) cause_13\VB|aware|should|.|at|Clinicians|, (l_dobj) prolongation_14\NN|may|,|leading (l_prep) of_15\IN|NONE (l_pobj) interval_18\NN|NONE
D015725_D017180 NONE fluconazole_4\NN|when|was (r_nsubjpass) discontinued_6\VBN|TDP (r_advcl) resolved_2\VBD|;|tachycardia|have|:|however|until|and|patient|, (r_ccomp) continued_12\VBD|NONE (l_conj) tachycardia_21\NN|;|have|:|resolved|however|until|and|patient|,
D015725_D017180 NONE fluconazole_4\NN|when|was (r_nsubjpass) discontinued_6\VBN|TDP (r_advcl) resolved_2\VBD|;|tachycardia|have|:|however|until|and|patient|, (r_ccomp) continued_12\VBD|NONE (l_conj) tachycardia_21\NN|;|have|:|resolved|however|until|and|patient|, (l_appos) NSVT_23\NNP|(|)|ventricular|nonsustained
D015725_D017180 NONE fluconazole_22\NN|.|followed|as|strongly (r_dobj) suggests_21\VBZ|NONE (l_csubj) followed_9\VBN|.|as|strongly|fluconazole (l_nsubj) disappearance_2\NN|stopped|by (l_prep) of_3\IN|contractions|complete|and|The (l_pobj) NSVT_4\NNP|NONE
D015725_D009202 NONE fluconazole_33\NN|NONE (r_pobj) of_32\IN|the (r_prep) initiation_31\NN|NONE (r_pobj) between_29\IN|a|temporal (r_prep) association_28\NN|There (r_attr) was_25\VBD|for|,|no|risk|other|including (r_relcl) factors_6\NNS|.|patient (l_prep) including_10\VBG|for|,|no|risk|other|was (l_pobj) disease_13\NN|NONE (l_amod) cardiomyopathy_15\NN|artery|coronary|,
D015725_D006333 NONE fluconazole_33\NN|NONE (r_pobj) of_32\IN|the (r_prep) initiation_31\NN|NONE (r_pobj) between_29\IN|a|temporal (r_prep) association_28\NN|There (r_attr) was_25\VBD|for|,|no|risk|other|including (r_relcl) factors_6\NNS|.|patient (l_prep) including_10\VBG|for|,|no|risk|other|was (l_pobj) disease_13\NN|NONE (l_amod) cardiomyopathy_15\NN|artery|coronary|, (l_conj) failure_19\NN|,
D015725_D018879 NONE fluconazole_4\NN|when|was (r_nsubjpass) discontinued_6\VBN|TDP (r_advcl) resolved_2\VBD|;|tachycardia|have|:|however|until|and|patient|, (r_ccomp) continued_12\VBD|NONE (l_xcomp) have_14\VB|;|tachycardia|:|resolved|however|until|and|patient|, (l_dobj) contractions_17\NNS|to
D015725_D018879 NONE fluconazole_22\NN|.|followed|as|strongly (r_dobj) suggests_21\VBZ|NONE (l_csubj) followed_9\VBN|.|as|strongly|fluconazole (l_nsubj) disappearance_2\NN|stopped|by (l_conj) contractions_8\NNS|complete|and|of|The
D011188_D003866 NONE potassium_10\NN|rectifier (r_compound) currents_11\NNS|rapidly (r_dobj) activating_7\VBG|NONE (r_pcomp) of_5\IN|NONE (r_prep) depression_4\NN|mechanism|.
D015725_D016171 CID Fluconazole_0\NNP| (r_npadvmod) induced_2\VBN|NONE (r_amod) torsade_3\NN|.|de (r_nmod) pointes_5\FW|NONE
D015725_D016171 CID fluconazole_5\NN| (r_advmod) associated_7\VBN|)|TDP|torsade|(|de (r_amod) pointes_10\FW|NONE
D015725_D016171 CID fluconazole_5\NN| (r_advmod) associated_7\VBN|)|TDP|torsade|(|de (r_amod) pointes_10\FW|NONE (l_appos) TDP_12\NNP|)|associated|torsade|(|de
D015725_D016171 CID fluconazole_5\NN| (r_advmod) associated_7\VBN|)|TDP|torsade|(|de (r_amod) pointes_10\FW|NONE (r_pobj) of_4\IN|a (r_prep) case_3\NN|discuss|and|.|To (r_dobj) present_1\VB|NONE (l_conj) discuss_15\VB|and|.|case|To (l_dobj) role_18\NN|NONE (l_prep) in_19\IN|fluconazole (l_pcomp) causing_20\VBG|NONE (l_dobj) TDP_21\NNP|NONE
D015725_D016171 CID fluconazole_16\NN|in (r_poss) role_18\NN|NONE (r_dobj) discuss_15\VB|and|.|case|To (r_conj) present_1\VB|NONE (l_dobj) case_3\NN|discuss|and|.|To (l_prep) of_4\IN|a (l_pobj) pointes_10\FW|NONE
D015725_D016171 CID fluconazole_16\NN|in (r_poss) role_18\NN|NONE (r_dobj) discuss_15\VB|and|.|case|To (r_conj) present_1\VB|NONE (l_dobj) case_3\NN|discuss|and|.|To (l_prep) of_4\IN|a (l_pobj) pointes_10\FW|NONE (l_appos) TDP_12\NNP|)|associated|torsade|(|de
D015725_D016171 CID fluconazole_16\NN|in (r_poss) role_18\NN|NONE (l_prep) in_19\IN|fluconazole (l_pcomp) causing_20\VBG|NONE (l_dobj) TDP_21\NNP|NONE
D015725_D016171 CID fluconazole_21\NN|NONE (r_dobj) commencing_19\VBG|days (r_pcomp) after_18\IN|isolated|woman (r_prep) glabrata_8\NNS|NONE (l_xcomp) isolated_9\VBN|after|woman (l_prep) from_10\IN|NONE (l_pobj) abscess_13\NN|NONE (l_acl) developed_14\VBD|a|presacral (l_dobj) TDP_15\NNP|NONE
D015725_D016171 CID fluconazole_33\NN|NONE (r_pobj) of_32\IN|the (r_prep) initiation_31\NN|NONE (r_pobj) between_29\IN|a|temporal (r_prep) association_28\NN|There (r_attr) was_25\VBD|for|,|no|risk|other|including (r_relcl) factors_6\NNS|.|patient (l_prep) for_7\IN|,|no|risk|other|was|including (l_pobj) TDP_8\NNP|NONE
D015725_D016171 CID fluconazole_33\NN|NONE (l_conj) TDP_35\NNP|and
D015725_D016171 CID fluconazole_4\NN|when|was (r_nsubjpass) discontinued_6\VBN|TDP (r_advcl) resolved_2\VBD|;|tachycardia|have|:|however|until|and|patient|, (l_nsubj) TDP_1\NNP|discontinued
D015725_D016171 CID fluconazole_14\NN|NONE (r_pobj) of_13\IN|and|the|development (r_prep) use_12\NN|NONE (l_conj) development_17\NN|and|of|the (l_prep) of_18\IN|the (l_pobj) TDP_19\NNP|NONE
D015725_D016171 CID fluconazole_5\NN|, (r_ccomp) aware_3\JJ|should|.|at|cause|Clinicians|, (r_acomp) be_2\VB|NONE (l_conj) cause_13\VB|aware|should|.|at|Clinicians|, (l_advcl) leading_20\VBG|may|,|prolongation (l_prep) to_21\IN|NONE (l_pobj) TDP_22\NNP|NONE
D015725_D001145 NONE fluconazole_7\NN|in|is|when (r_nsubjpass) administered_9\VBN|be|.|may|monitoring (l_prep) in_10\IN|fluconazole|is|when (l_pobj) patients_11\NNS|NONE (l_relcl) are_13\VBP|NONE (l_prep) at_14\IN|who (l_pobj) risk_15\NN|NONE (l_prep) for_16\IN|NONE (l_pobj) arrhythmias_18\NNS|NONE
D015725_D003324 NONE fluconazole_33\NN|NONE (r_pobj) of_32\IN|the (r_prep) initiation_31\NN|NONE (r_pobj) between_29\IN|a|temporal (r_prep) association_28\NN|There (r_attr) was_25\VBD|for|,|no|risk|other|including (r_relcl) factors_6\NNS|.|patient (l_prep) including_10\VBG|for|,|no|risk|other|was (l_pobj) disease_13\NN|NONE
10520387
D015742_D017202 NONE propofol_26\NN|the|ephedrine|/|/ (r_nmod) mixtures_28\NNS|NONE (r_pobj) of_22\IN|NONE (r_prep) any_21\DT|NONE (r_pobj) of_20\IN|elderly (r_prep) patients_19\NNS|NONE (r_pobj) in_17\IN|the|studied (r_prep) use_16\NN|,|.|would|we|not|Due (r_dobj) recommend_14\VB|NONE (l_prep) Due_0\IN|use|,|.|would|we|not (l_pobj) risk_3\NN|to (l_prep) of_4\IN|the (l_pobj) tachycardia_6\NN|NONE (l_acl) inducing_7\VBG|this (l_dobj) ischemia_9\NN|NONE
D004809_D017202 NONE ephedrine_24\NN|the|propofol|/|/ (r_nmod) mixtures_28\NNS|NONE (r_pobj) of_22\IN|NONE (r_prep) any_21\DT|NONE (r_pobj) of_20\IN|elderly (r_prep) patients_19\NNS|NONE (r_pobj) in_17\IN|the|studied (r_prep) use_16\NN|,|.|would|we|not|Due (r_dobj) recommend_14\VB|NONE (l_prep) Due_0\IN|use|,|.|would|we|not (l_pobj) risk_3\NN|to (l_prep) of_4\IN|the (l_pobj) tachycardia_6\NN|NONE (l_acl) inducing_7\VBG|this (l_dobj) ischemia_9\NN|NONE
D004809_D007022 NONE ephedrine_11\NN|NONE (r_pobj) of_10\IN|different (r_prep) doses_9\NNS|propofol (r_dobj) adding_7\VBG|NONE (l_xcomp) propofol_13\NN|doses (l_prep) in_14\IN|to (l_pobj) order_15\NN|NONE (l_acl) obtund_17\VB|NONE (l_dobj) response_20\NN|to (l_amod) hypotensive_19\JJ|the
D004809_D007022 NONE ephedrine_3\NN|NONE (r_pobj) of_2\IN|propofol|The (r_prep) addition_1\NN|be|. (r_nsubj) appears_6\VBZ|NONE (l_xcomp) be_8\VB|addition|. (l_attr) method_11\NN|to (l_prep) of_12\IN|an|effective (l_pcomp) obtunding_13\VBG|NONE (l_dobj) response_16\NN|propofol (l_amod) hypotensive_15\JJ|the
D015742_D013610 CID propofol_13\NN|NONE (r_pobj) with_12\IN|NONE (r_prep) combination_11\NN|NONE (r_pobj) in_10\IN|the|of (r_prep) use_7\NN|NONE (r_pobj) with_5\IN|NONE (r_prep) associated_4\VBN|marked (r_acl) tachycardia_3\NNS|However|,|,|reaching|in|.
D015742_D013610 CID propofol_26\NN|the|ephedrine|/|/ (r_nmod) mixtures_28\NNS|NONE (r_pobj) of_22\IN|NONE (r_prep) any_21\DT|NONE (r_pobj) of_20\IN|elderly (r_prep) patients_19\NNS|NONE (r_pobj) in_17\IN|the|studied (r_prep) use_16\NN|,|.|would|we|not|Due (r_dobj) recommend_14\VB|NONE (l_prep) Due_0\IN|use|,|.|would|we|not (l_pobj) risk_3\NN|to (l_prep) of_4\IN|the (l_pobj) tachycardia_6\NN|NONE
D015742_D007022 CID propofol_13\NN|doses (l_prep) in_14\IN|to (l_pobj) order_15\NN|NONE (l_acl) obtund_17\VB|NONE (l_dobj) response_20\NN|to (l_amod) hypotensive_19\JJ|the
D015742_D007022 CID propofol_5\NN|The|of (r_acl) addition_1\NN|be|. (r_nsubj) appears_6\VBZ|NONE (l_xcomp) be_8\VB|addition|. (l_attr) method_11\NN|to (l_prep) of_12\IN|an|effective (l_pcomp) obtunding_13\VBG|NONE (l_dobj) response_16\NN|propofol (l_amod) hypotensive_15\JJ|the
D015742_D007022 CID propofol_18\NN|response (r_advcl) obtunding_13\VBG|NONE (l_dobj) response_16\NN|propofol (l_amod) hypotensive_15\JJ|the
D004809_D013610 CID ephedrine_9\NN|NONE (r_pobj) of_8\IN|the|in (r_prep) use_7\NN|NONE (r_pobj) with_5\IN|NONE (r_prep) associated_4\VBN|marked (r_acl) tachycardia_3\NNS|However|,|,|reaching|in|.
D004809_D013610 CID ephedrine_24\NN|the|propofol|/|/ (r_nmod) mixtures_28\NNS|NONE (r_pobj) of_22\IN|NONE (r_prep) any_21\DT|NONE (r_pobj) of_20\IN|elderly (r_prep) patients_19\NNS|NONE (r_pobj) in_17\IN|the|studied (r_prep) use_16\NN|,|.|would|we|not|Due (r_dobj) recommend_14\VB|NONE (l_prep) Due_0\IN|use|,|.|would|we|not (l_pobj) risk_3\NN|to (l_prep) of_4\IN|the (l_pobj) tachycardia_6\NN|NONE
20042557
D015742_D003704 NONE propofol_39\NN|NONE (r_amod) sedation_40\NN|NONE (r_pobj) with_38\IN|spinal (r_prep) anesthesia_37\NN|NONE (r_pobj) under_35\IN|fracture (r_prep) repair_34\NN|who (r_dobj) underwent_31\VBD|or|preoperative|dementia (r_relcl) delirium_26\NN|NONE (l_conj) dementia_29\NN|underwent|or|preoperative
D015742_D003693 CID propofol_39\NN|NONE (r_amod) sedation_40\NN|NONE (r_pobj) with_38\IN|spinal (r_prep) anesthesia_37\NN|NONE (r_pobj) under_35\IN|fracture (r_prep) repair_34\NN|who (r_dobj) underwent_31\VBD|or|preoperative|dementia (r_relcl) delirium_26\NN|NONE
D015742_D003693 CID propofol_4\NN|light (r_amod) sedation_5\NN|NONE (r_pobj) of_2\IN|The (r_prep) use_1\NN|.|prevalence (r_nsubj) decreased_6\VBD|NONE (l_dobj) prevalence_8\NN|.|use (l_prep) of_9\IN|by|the|compared (l_pobj) delirium_11\NN|NONE
D015742_D006620 NONE propofol_39\NN|NONE (r_amod) sedation_40\NN|NONE (r_pobj) with_38\IN|spinal (r_prep) anesthesia_37\NN|NONE (r_pobj) under_35\IN|fracture (r_prep) repair_34\NN|who (l_compound) fracture_33\NN|under
D015742_D011183 CID propofol_4\NN|light (r_amod) sedation_5\NN|NONE (r_pobj) of_2\IN|The (r_prep) use_1\NN|.|prevalence (r_nsubj) decreased_6\VBD|NONE (l_dobj) prevalence_8\NN|.|use (l_prep) of_9\IN|by|the|compared (l_pobj) delirium_11\NN|NONE
8410199
D018698_D012640 NONE glutamate_2\NN|NONE (r_compound) decarboxylase_3\NN|containing|in (r_nmod) neurons_7\NNS|NONE (r_pobj) of_1\IN|following|. (r_prep) Loss_0\NN|NONE (l_prep) following_13\VBG|of|. (l_pobj) seizures_17\NNS|NONE
D018698_D012640 NONE acid_10\NN|glutamic|neurons|( (r_compound) decarboxylase_11\NN|vulnerable|if (r_nsubj) are_26\VBP|to (l_acomp) vulnerable_27\JJ|decarboxylase|if (l_prep) to_28\IN|NONE (l_pobj) damage_32\NN|NONE (l_amod) induced_31\VBN|in (l_npadvmod) seizure_29\NN|
D018698_D012640 NONE acid_10\NN|glutamic|neurons|( (r_compound) decarboxylase_11\NN|vulnerable|if (r_nsubj) are_26\VBP|to (l_acomp) vulnerable_27\JJ|decarboxylase|if (l_prep) to_28\IN|NONE (l_pobj) damage_32\NN|NONE (l_prep) in_33\IN|induced (l_pobj) model_35\NN|NONE (l_prep) of_36\IN|a (l_pobj) seizures_38\NNS|NONE
D010862_D012640 CID pilocarpine_14\NN| (r_npadvmod) induced_16\VBN|NONE (r_amod) seizures_17\NNS|NONE
D010862_D012640 CID pilocarpine_8\NN|NONE (r_pobj) with_7\IN|rats|,|were|studied|intraperitoneally|and (r_prep) injected_5\VBN|NONE (l_conj) studied_15\VBN|rats|,|were|with|intraperitoneally|and (l_conj) intervals_27\NNS|formation|at|,|.|and|was|histologically (l_prep) after_28\IN|week (l_pobj) seizures_32\NNS|NONE
D010862_D012640 CID pilocarpine_29\NN| (r_npadvmod) induced_31\VBN|NONE (r_amod) seizures_32\NNS|NONE
C028911_D009410 NONE violet_6\NN|,|cresyl|methods (r_compound) staining_7\NN|NONE (l_conj) methods_11\NNS|,|cresyl|violet (l_compound) degeneration_10\NN|localization|and|,|neuronal
C028911_D009410 NONE violet_6\NN|,|cresyl|methods (r_compound) staining_7\NN|NONE (r_pobj) including_4\VBG|,|,|neuronanatomical|Additional (r_prep) studies_2\NNS|related|. (r_nsubj) suggested_22\VBD|NONE (l_ccomp) related_36\VBN|.|studies (l_prep) to_37\IN|was|that|decrease (l_pobj) loss_39\NN|to|than
2611118
D004008_D006521 NONE sodium_6\NN|diclofenac (r_compound) therapy_7\NN|NONE (r_pobj) with_4\IN|NONE (r_prep) associated_3\VBN|.|active|Chronic (r_acl) hepatitis_2\NN|NONE
D004008_D006521 NONE sodium_13\NN|NONE (r_pobj) with_11\IN|progressed|months (r_prep) therapy_10\NN|NONE (r_pobj) after_7\IN|hepatitis|finding|,|patient|. (r_prep) developed_3\VBD|NONE (l_dobj) hepatitis_6\NN|after|finding|,|patient|.
D004008_D056486 CID diclofenac_23\NNP|NONE (r_pobj) by_22\IN|,|commonly|,|hepatitis|. (r_agent) induced_21\VBN|been|and|have|abnormalities|tolerated|, (r_conj) recorded_13\VBN|NONE (l_nsubjpass) abnormalities_7\NNS|been|induced|and|have|tolerated|, (l_prep) of_8\IN|asymptomatic (l_pobj) function_10\NN|NONE
D004008_D056486 CID diclofenac_23\NNP|NONE (r_pobj) by_22\IN|,|commonly|,|hepatitis|. (r_agent) induced_21\VBN|been|and|have|abnormalities|tolerated|, (l_nsubj) hepatitis_20\NN|by|,|commonly|,|.
18201582
C084178_D006973 NONE telmisartan_32\NN|monotherapy (r_pobj) of_31\IN|a|with|dose (r_prep) combination_30\NN|NONE (l_prep) with_41\IN|a|dose|of (l_pobj) hypertension_44\NN|NONE
C084178_D006973 NONE telmisartan_23\NNP|NONE (r_pobj) of_22\IN|new|(|)|FDC|a|dose (r_prep) combination_18\NN|NONE (r_pobj) of_12\IN|the|tolerability|and (r_prep) efficacy_9\NN|+|to|mg|amlodipine (r_dobj) evaluate_7\VB|.|aim (l_conj) amlodipine_27\NN|+|to|efficacy|mg (l_prep) compared_33\VBN|)|mg (l_prep) with_34\IN|NONE (l_pobj) amlodipine_35\NN|NONE (l_appos) monotherapy_37\NN|NONE (l_prep) in_41\IN|A|mg (l_pobj) patients_44\NNS|NONE (l_prep) with_45\IN|adult|Indian (l_pobj) hypertension_48\NN|NONE
D017311_D006973 NONE amlodipine_34\NN|and|versus (r_conj) telmisartan_32\NN|monotherapy (r_pobj) of_31\IN|a|with|dose (r_prep) combination_30\NN|NONE (l_prep) with_41\IN|a|dose|of (l_pobj) hypertension_44\NN|NONE
D017311_D006973 NONE amlodipine_36\NN|NONE (r_pobj) versus_35\IN|amlodipine|and (r_prep) telmisartan_32\NN|monotherapy (r_pobj) of_31\IN|a|with|dose (r_prep) combination_30\NN|NONE (l_prep) with_41\IN|a|dose|of (l_pobj) hypertension_44\NN|NONE
D017311_D006973 NONE amlodipine_27\NN|+|to|efficacy|mg (l_prep) compared_33\VBN|)|mg (l_prep) with_34\IN|NONE (l_pobj) amlodipine_35\NN|NONE (l_appos) monotherapy_37\NN|NONE (l_prep) in_41\IN|A|mg (l_pobj) patients_44\NNS|NONE (l_prep) with_45\IN|adult|Indian (l_pobj) hypertension_48\NN|NONE
D017311_D006973 NONE amlodipine_35\NN|NONE (l_appos) monotherapy_37\NN|NONE (l_prep) in_41\IN|A|mg (l_pobj) patients_44\NNS|NONE (l_prep) with_45\IN|adult|Indian (l_pobj) hypertension_48\NN|NONE
12093990
D012254_D007239 NONE ribavirin_2\NN|Although|effective|not (r_nsubj) was_3\VBD|,|.|therapy|begun|unlikely (r_advcl) is_22\VBZ|NONE (l_advcl) begun_29\VBN|,|.|therapy|unlikely|was (l_prep) in_31\IN|if (l_pobj) course_33\NN|late (l_prep) of_34\IN|the (l_pobj) infection_36\NN|NONE
D012254_D006482 NONE Ribavirin_0\NNP|treat|.|,|is|is|and|in (r_nsubjpass) licensed_2\VBN|NONE (l_conj) is_27\VBZ|treat|.|Ribavirin|,|is|and|in (l_attr) treatment_29\NN|NONE (l_prep) for_32\IN|of|the (l_pobj) infection_33\NN|NONE (l_prep) with_34\IN|NONE (l_pobj) viruses_37\NNS|NONE
D012254_D006482 NONE ribavirin_26\RB|in|to (r_dobj) treat_22\VB|.|Ribavirin|,|is|is|and|in (r_conj) licensed_2\VBN|NONE (l_conj) is_27\VBZ|treat|.|Ribavirin|,|is|and|in (l_attr) treatment_29\NN|NONE (l_prep) for_32\IN|of|the (l_pobj) infection_33\NN|NONE (l_prep) with_34\IN|NONE (l_pobj) viruses_37\NNS|NONE
D012254_D000740 NONE ribavirin_7\RB|NONE (r_pobj) of_5\IN|common|The|adverse (r_prep) effect_4\NN|anemia|. (r_nsubj) is_8\VBZ|NONE (l_attr) anemia_11\NN|effect|.
D012254_D018357 NONE Ribavirin_0\NNP|treat|.|,|is|is|and|in (r_nsubjpass) licensed_2\VBN|NONE (l_prep) in_3\IN|treat|.|Ribavirin|,|is|is|and (l_pobj) form_5\NN|NONE (l_prep) for_6\IN|aerosol (l_pobj) treatment_8\NN|NONE (l_prep) of_9\IN|the (l_pobj) infection_13\NN|NONE
D012254_D018357 NONE ribavirin_26\RB|in|to (r_dobj) treat_22\VB|.|Ribavirin|,|is|is|and|in (r_conj) licensed_2\VBN|NONE (l_prep) in_3\IN|treat|.|Ribavirin|,|is|is|and (l_pobj) form_5\NN|NONE (l_prep) for_6\IN|aerosol (l_pobj) treatment_8\NN|NONE (l_prep) of_9\IN|the (l_pobj) infection_13\NN|NONE
C059262_D009503 CID cidofovir_2\NN|NONE (r_pobj) of_1\IN|in (r_prep) Use_0\NN|was|with|. (r_nsubjpass) associated_7\VBN|NONE (l_prep) with_8\IN|Use|was|. (l_pobj) failure_11\NN|NONE (l_conj) neutropenia_13\NN|and|progressive|renal
C059262_D000257 NONE cidofovir_3\NN|NONE (r_pobj) of_2\IN|The|in (r_prep) use_1\NN|by|been|has (l_prep) in_4\IN|of|The (l_pobj) infection_7\NN|NONE
C059262_D058186 CID cidofovir_2\NN|NONE (r_pobj) of_1\IN|in (r_prep) Use_0\NN|was|with|. (r_nsubjpass) associated_7\VBN|NONE (l_prep) with_8\IN|Use|was|. (l_pobj) failure_11\NN|NONE
D012254_D006526 NONE Ribavirin_0\NNP|treat|.|,|is|is|and|in (r_nsubjpass) licensed_2\VBN|NONE (l_conj) treat_22\VB|.|Ribavirin|,|is|is|and|in (l_dobj) ribavirin_26\RB|in|to (l_compound) Intravenous_25\NNP|NONE (l_compound) C._24\NNP|hepatitis
D012254_D006526 NONE ribavirin_26\RB|in|to (l_compound) Intravenous_25\NNP|NONE (l_compound) C._24\NNP|hepatitis
D012254_D000257 NONE ribavirin_1\JJ|for|in|Intravenous|. (r_compound) treatment_2\NN|NONE (l_prep) for_3\IN|in|Intravenous|ribavirin|. (l_pobj) disease_6\NN|NONE
D012254_D000257 NONE ribavirin_7\NN|intravenous (r_compound) therapy_8\NN|NONE (r_pobj) with_5\IN|in|our|for (r_prep) experience_4\NN|:|.|We|and|review (l_prep) for_9\IN|in|our|with (l_pobj) disease_12\NN|NONE
D012254_D000257 NONE ribavirin_12\RB|NONE (r_pobj) with_10\IN|for (r_prep) treated_9\VBN| (l_prep) for_13\IN|with (l_pobj) disease_17\NN|NONE
D012254_D000257 NONE ribavirin_2\NN|Although|effective|not (r_nsubj) was_3\VBD|,|.|therapy|begun|unlikely (l_acomp) effective_5\JJ|Although|not|ribavirin (l_prep) for_6\IN|NONE (l_pobj) children_8\NNS|NONE (l_prep) with_9\IN|all (l_pobj) disease_12\NN|NONE
D012254_D000257 NONE ribavirin_11\RB|NONE (r_pobj) with_9\IN|recovered|children|. (r_prep) treated_8\VBN|NONE (l_nsubj) children_3\NNS|recovered|with|. (l_prep) with_4\IN| (l_pobj) disease_7\NN|NONE
D012254_D000257 NONE ribavirin_33\NN|such (r_pobj) as_31\IN|useful|adenoviral|,|, (r_prep) therapies_28\NNS|NONE (r_pobj) of_22\IN|large|clinical|,|a|multicenter (r_prep) trial_21\NN|especially|, (r_conj) children_14\NNS|certain|, (r_appos) hosts_11\NNS|NONE (r_pobj) in_9\IN|of (r_prep) prevalence_5\NN|and|the|increasing (l_prep) of_6\IN|in (l_pobj) disease_8\NN|NONE
C059262_D007674 NONE cidofovir_3\NN|NONE (r_pobj) of_2\IN|The|in (r_prep) use_1\NN|by|been|has (r_nsubjpass) limited_10\VBN|,|.|significant|nephrotoxicity (r_ccomp) is_20\VBZ|NONE (l_attr) nephrotoxicity_21\NN|,|.|significant|limited
2950248
D004176_D003324 NONE dipyridamole_16\NN|preoperative (r_compound) therapy_17\NN|NONE (r_pobj) of_14\IN|side|a (r_prep) effect_13\NN|NONE (r_pobj) as_10\IN|has|,|,|this|previously|not|.|To|been|demonstrated (r_prep) reported_9\VBN|NONE (l_advcl) demonstrated_27\VBN|has|,|,|this|previously|not|.|as|To|been (l_xcomp) occur_29\VB|although|has|been|ischemia (l_prep) with_34\IN|in|to (l_pobj) disease_37\NN|NONE
D004176_D003324 NONE dipyridamole_20\NN| (r_dep) induced_22\VBN|myocardial (r_amod) ischemia_24\NN|although|has|been|occur (r_nsubjpass) demonstrated_27\VBN|has|,|,|this|previously|not|.|as|To|been (l_xcomp) occur_29\VB|although|has|been|ischemia (l_prep) with_34\IN|in|to (l_pobj) disease_37\NN|NONE
D004176_D007511 NONE dipyridamole_23\NN| (r_npadvmod) induced_25\VBN|the (r_amod) ischemia_26\NN|NONE
D004176_D000787 CID dipyridamole_10\NN|NONE (r_pobj) of_8\IN|NONE (r_prep) administration_7\NN|NONE (r_pobj) after_6\IN|in|Angina|. (r_prep) occurred_5\VBD|NONE (l_nsubj) Angina_0\NNP|in|after|.
D004176_D017202 NONE Dipyridamole_0\NNP| (r_npadvmod) induced_2\VBN|myocardial|. (r_amod) ischemia_4\NN|NONE
D004176_D017202 NONE dipyridamole_16\NN|preoperative (r_compound) therapy_17\NN|NONE (r_pobj) of_14\IN|side|a (r_prep) effect_13\NN|NONE (r_pobj) as_10\IN|has|,|,|this|previously|not|.|To|been|demonstrated (r_prep) reported_9\VBN|NONE (l_advcl) demonstrated_27\VBN|has|,|,|this|previously|not|.|as|To|been (l_nsubjpass) ischemia_24\NN|although|has|been|occur
D004176_D017202 NONE dipyridamole_20\NN| (r_dep) induced_22\VBN|myocardial (r_amod) ischemia_24\NN|although|has|been|occur
343678
D006514_D006509 NONE antigen_43\NN|(|HBsAG)positive (r_nmod) donors_46\NNS|NONE (r_pobj) to_39\IN|stick (r_prep) exposure_38\NN|NONE (r_pobj) after_34\IN|hepatitis (r_prep) preventing_30\VBG|NONE (r_pcomp) in_29\IN|their|relative (r_prep) efficacies_28\NNS|to (r_dobj) assess_25\VB|globulin|were|.|in (r_advcl) examined_15\VBN|NONE (l_nsubjpass) globulin_3\NN|were|.|assess|in (l_compound) B_1\NN|globulin|immune|and|HBIG
D006514_D006509 NONE antigen_43\NN|(|HBsAG)positive (r_nmod) donors_46\NNS|NONE (r_pobj) to_39\IN|stick (r_prep) exposure_38\NN|NONE (r_pobj) after_34\IN|hepatitis (r_prep) preventing_30\VBG|NONE (l_dobj) hepatitis_33\NN|after
D006514_D006509 NONE HBsAG)-positive_45\JJ|antigen|( (r_compound) donors_46\NNS|NONE (r_pobj) to_39\IN|stick (r_prep) exposure_38\NN|NONE (r_pobj) after_34\IN|hepatitis (r_prep) preventing_30\VBG|NONE (r_pcomp) in_29\IN|their|relative (r_prep) efficacies_28\NNS|to (r_dobj) assess_25\VB|globulin|were|.|in (r_advcl) examined_15\VBN|NONE (l_nsubjpass) globulin_3\NN|were|.|assess|in (l_compound) B_1\NN|globulin|immune|and|HBIG
D006514_D006509 NONE HBsAG)-positive_45\JJ|antigen|( (r_compound) donors_46\NNS|NONE (r_pobj) to_39\IN|stick (r_prep) exposure_38\NN|NONE (r_pobj) after_34\IN|hepatitis (r_prep) preventing_30\VBG|NONE (l_dobj) hepatitis_33\NN|after
20588063
D011692_D009401 CID aminonucleoside_17\JJ|puromycin (r_amod) nephrosis_18\NN|NONE
D011692_D009401 CID aminonucleoside_2\JJ|NONE (r_amod) nephrosis_3\NN|PAN|)|(
15096016
D007980_D018476 NONE levodopa_20\RB| (r_npadvmod) induced_22\VBN|NONE (r_amod) dyskinesias_23\NNS|NONE (r_dobj) improving_19\VBG|NONE (r_pcomp) in_18\IN|to (r_prep) be_17\VB|,|.|;|however|improves|strength (r_xcomp) seems_15\VBZ|NONE (l_ccomp) improves_2\VBZ|,|.|;|however|strength|be (l_dobj) bradykinesia_3\JJ|to|stimulation
D007980_D004409 CID levodopa_20\RB| (r_npadvmod) induced_22\VBN|NONE (r_amod) dyskinesias_23\NNS|NONE
D007980_D009127 NONE levodopa_20\RB| (r_npadvmod) induced_22\VBN|NONE (r_amod) dyskinesias_23\NNS|NONE (r_dobj) improving_19\VBG|NONE (r_pcomp) in_18\IN|to (r_prep) be_17\VB|,|.|;|however|improves|strength (r_xcomp) seems_15\VBZ|NONE (l_ccomp) improves_2\VBZ|,|.|;|however|strength|be (l_dobj) bradykinesia_3\JJ|to|stimulation (l_conj) rigidity_5\NN|and
1616457
D010424_D000647 CID pentobarbital_7\NN|NONE (r_pobj) by_6\IN|NONE (r_agent) caused_5\VBN|NONE (r_acl) amnesia_4\NN|NONE
D010424_D000647 CID pentobarbital_15\NN|,|(|mg/kg (r_nmod) ip_20\NNP|NONE (r_pobj) by_14\IN|NONE (r_agent) produced_13\VBN|NONE (r_acl) amnesia_12\NN|NONE
8546130
D017291_D007676 NONE Clarithromycin_0\NN| (r_npadvmod) associated_2\VBN|.|visual|in (r_amod) hallucinations_4\NNS|NONE (l_prep) in_5\IN|.|associated|visual (l_pobj) patient_7\NN|NONE (l_prep) with_8\IN|a (l_pobj) failure_11\NN|NONE
D017291_D007676 NONE clarithromycin_8\NN|NONE (r_pobj) of_7\IN|high|a|in|in (r_prep) dose_6\NN|NONE (l_prep) in_9\IN|of|high|a|in (l_pobj) face_10\NN|NONE (l_prep) of_11\IN|NONE (l_pobj) failure_14\NN|NONE
D000535_D007676 NONE aluminum_23\NN|underlying (r_compound) intoxication_24\NN|NONE (r_pobj) with_21\IN|of|,|,|The (r_prep) combination_1\NN|have|.|appearance|may (l_prep) of_2\IN|,|,|with|The (l_pobj) dose_6\NN|NONE (l_prep) in_9\IN|of|high|a|in (l_pobj) face_10\NN|NONE (l_prep) of_11\IN|NONE (l_pobj) failure_14\NN|NONE
D000535_D020258 NONE aluminum_23\NN|underlying (r_compound) intoxication_24\NN|NONE (r_pobj) with_21\IN|of|,|,|The (r_prep) combination_1\NN|have|.|appearance|may (r_nsubj) facilitated_28\VBN|NONE (l_dobj) appearance_30\NN|have|.|combination|may (l_prep) of_31\IN|the (l_pobj) effect_35\NN|NONE (l_amod) neurotoxic_33\JJ|side|this
D017291_D020258 NONE clarithromycin_8\NN|NONE (r_pobj) of_7\IN|high|a|in|in (r_prep) dose_6\NN|NONE (r_pobj) of_2\IN|,|,|with|The (r_prep) combination_1\NN|have|.|appearance|may (r_nsubj) facilitated_28\VBN|NONE (l_dobj) appearance_30\NN|have|.|combination|may (l_prep) of_31\IN|the (l_pobj) effect_35\NN|NONE (l_amod) neurotoxic_33\JJ|side|this
D017291_D006212 CID Clarithromycin_0\NN| (r_npadvmod) associated_2\VBN|.|visual|in (r_amod) hallucinations_4\NNS|NONE
D017291_D006212 CID clarithromycin_16\NN|the|macrolide|new|, (r_appos) antibiotic_14\NN|NONE (r_pobj) with_10\IN|NONE (r_prep) association_9\NN|NONE (r_pobj) in_8\IN|NONE (r_prep) occurring_7\VBG|visual (r_acl) hallucinations_6\NNS|is|.|in
D018942_D006212 NONE macrolide_13\NN|the|new|clarithromycin|, (r_amod) antibiotic_14\NN|NONE (r_pobj) with_10\IN|NONE (r_prep) association_9\NN|NONE (r_pobj) in_8\IN|NONE (r_prep) occurring_7\VBG|visual (r_acl) hallucinations_6\NNS|is|.|in
4027862
D003891_D003693 CID Desipramine_0\NN| (r_npadvmod) induced_2\VBN|at|. (r_amod) delirium_3\NN|NONE
D003891_D003693 CID Desipramine_7\NNP|.|was|patient|delirium (r_nsubj) developed_8\VBD|NONE (l_dobj) delirium_10\NN|.|was|Desipramine|patient
19957053
D010656_D002534 CID Phenylephrine_0\NNP|.|oxygenation (r_nsubj) reduces_4\VBZ|NONE (l_dobj) oxygenation_7\NN|Phenylephrine|.
D004809_D007022 NONE ephedrine_3\JJ|but (r_conj) Phenylephrine_0\NNP|.|oxygenation (r_nsubj) reduces_4\VBZ|NONE (l_dobj) oxygenation_7\NN|Phenylephrine|. (l_prep) following_8\VBG|frontal|lobe (l_dobj) hypotension_12\NN|NONE
D004809_D007022 NONE ephedrine_7\JJ|and (r_conj) phenylephrine_5\NN|NONE (r_pobj) of_4\IN|on|the (r_prep) effect_3\NN|following|We|. (r_dobj) describe_1\VBP|NONE (l_prep) following_16\VBG|We|effect|. (l_dobj) hypotension_20\NN|NONE
D004809_D007022 NONE ephedrine_18\JJ|while|oxygenation (r_nsubj) maintains_19\VBZ|)|impact|utilization|. (r_advcl) has_10\VBZ|NONE (l_nsubj) utilization_1\NN|)|impact|maintains|. (l_acl) correct_5\VB|of|The (l_dobj) hypotension_6\NN|to
D004809_D002534 NONE ephedrine_3\JJ|but (r_conj) Phenylephrine_0\NNP|.|oxygenation (r_nsubj) reduces_4\VBZ|NONE (l_dobj) oxygenation_7\NN|Phenylephrine|.
D010656_D007022 NONE Phenylephrine_0\NNP|.|oxygenation (r_nsubj) reduces_4\VBZ|NONE (l_dobj) oxygenation_7\NN|Phenylephrine|. (l_prep) following_8\VBG|frontal|lobe (l_dobj) hypotension_12\NN|NONE
D010656_D007022 NONE phenylephrine_5\NN|NONE (r_pobj) of_4\IN|on|the (r_prep) effect_3\NN|following|We|. (r_dobj) describe_1\VBP|NONE (l_prep) following_16\VBG|We|effect|. (l_dobj) hypotension_20\NN|NONE
D010656_D007022 NONE phenylephrine_3\NN|NONE (r_pobj) of_2\IN|correct|The (r_prep) utilization_1\NN|)|impact|maintains|. (l_acl) correct_5\VB|of|The (l_dobj) hypotension_6\NN|to
6496797
D014196_D006327 CID trazodone_8\NN|NONE (r_pobj) of_7\IN|a|single (r_prep) dose_6\NN|NONE (r_pobj) following_3\VBG|heart|Complete|. (r_prep) block_2\NN|NONE
D014196_D006327 CID trazodone_9\NN|NONE (r_pobj) of_8\IN|a|starting|single (r_prep) dose_7\NN|NONE (r_dobj) receiving_3\VBG|minutes (r_pcomp) after_2\IN|,|block|patient|. (r_prep) developed_13\VBD|NONE (l_dobj) block_16\NN|,|after|patient|.
1445986
D002511_D000743 NONE cephalosporins_22\NNS|and (r_conj) penicillins_17\NNS|NONE (r_dobj) receiving_16\VBG|NONE (r_acl) patients_15\NNS|NONE (r_pobj) in_14\IN|has|primarily|anemia|.|been (r_prep) described_12\VBN|NONE (l_nsubjpass) anemia_2\NN|has|in|primarily|.|been
D010406_D000743 NONE penicillins_17\NNS|NONE (r_dobj) receiving_16\VBG|NONE (r_acl) patients_15\NNS|NONE (r_pobj) in_14\IN|has|primarily|anemia|.|been (r_prep) described_12\VBN|NONE (l_nsubjpass) anemia_2\NN|has|in|primarily|.|been
D015313_D000740 NONE cefotetan_10\NN|while (r_dobj) receiving_8\VBG|anemia|who (r_advcl) developed_5\VBD|a (l_dobj) anemia_6\NN|receiving|who
D015313_D000743 CID Cefotetan_0\NNP| (r_npadvmod) induced_2\VBN|hemolytic|.|immune (r_amod) anemia_5\NN|NONE
17366349
C092292_D012559 NONE ziprasidone_34\NNP|NONE (r_pobj) of_31\IN|an|day (r_prep) dose_30\NN|NONE (r_pobj) with_25\IN|NONE (r_prep) treatment_24\NN|NONE (r_pobj) of_23\IN| (r_prep) days_22\NNS|NONE (r_pobj) after_20\IN|signs|who (r_prep) developed_14\VBD|NONE (r_relcl) schizophrenia_12\NN|NONE
C092292_D009459 CID ziprasidone_5\NN|NONE (r_pobj) by_4\IN|.|syndrome (r_prep) induced_3\VBN|NONE (l_nsubj) syndrome_2\NN|by|.
C092292_D009459 CID ziprasidone_16\NN|NONE (r_pobj) of_15\IN|the (r_prep) use_14\NN|NONE (r_pobj) with_12\IN|NONE (r_prep) associated_11\VBN|NMS|malignant|neuroleptic (r_acl) syndrome_7\NN|NONE
C092292_D009459 CID ziprasidone_16\NN|NONE (r_pobj) of_15\IN|the (r_prep) use_14\NN|NONE (r_pobj) with_12\IN|NONE (r_prep) associated_11\VBN|NMS|malignant|neuroleptic (r_acl) syndrome_7\NN|NONE (l_appos) NMS_9\NNP|malignant|associated|neuroleptic
C092292_D009459 CID ziprasidone_14\NN|NONE (r_pobj) like_13\IN|NMS|atypical|,|antipsychotic (r_prep) drugs_12\NNS|NONE (l_nmod) NMS_8\NNP|atypical|,|like|antipsychotic
C092292_D009459 CID ziprasidone_34\NNP|NONE (r_pobj) of_31\IN|an|day (r_prep) dose_30\NN|NONE (r_pobj) with_25\IN|NONE (r_prep) treatment_24\NN|NONE (r_pobj) of_23\IN| (r_prep) days_22\NNS|NONE (r_pobj) after_20\IN|signs|who (r_prep) developed_14\VBD|NONE (l_dobj) signs_15\NNS|after|who (l_prep) of_18\IN|and|symptoms (l_pobj) NMS_19\NNP|NONE
C092292_D009459 CID ziprasidone_3\NNP|NONE (r_xcomp) due_1\IN|NONE (r_amod) NMS_0\NNP|in|.
8988571
D003042_D003693 CID cocaine_4\NN|NONE (r_compound) use_5\NN|NONE (r_dobj) following_3\VBG|Fatal|excited (r_acl) delirium_2\NN|evidence|:|.|findings
D003042_D003693 CID cocaine_15\NN|NONE (r_compound) toxicity_16\NN|NONE (r_pobj) of_14\IN|NONE (r_prep) mechanisms_13\NNS|NONE (r_pobj) for_12\IN|new (r_prep) evidence_11\NN|delirium|:|.|findings (r_dobj) provide_9\VBP|NONE (l_dep) delirium_2\NN|evidence|:|.|findings
D003042_D003693 CID cocaine_7\NN| (r_npadvmod) induced_9\VBN|EDDs|between|(|excited (r_amod) delirium_11\NN|NONE
D003042_D003693 CID cocaine_7\NN| (r_npadvmod) induced_9\VBN|EDDs|between|(|excited (r_amod) delirium_11\NN|NONE (l_appos) EDDs_13\NNP|between|induced|(|excited
D003042_D003693 CID cocaine_5\NN| (r_npadvmod) related_7\VBN|in|all (r_amod) deaths_8\NNS|NONE (r_pobj) of_3\IN|a (r_prep) registry_2\NN|NONE (r_pobj) From_0\IN|with|,|EDDs|,|.|were|from (r_prep) compared_23\VBN|NONE (l_nsubjpass) EDDs_21\NNS|with|,|,|.|were|from|From
D003042_D003693 CID cocaine_5\NN| (r_npadvmod) related_7\VBN|in|all (r_amod) deaths_8\NNS|NONE (r_pobj) of_3\IN|a (r_prep) registry_2\NN|NONE (r_pobj) From_0\IN|with|,|EDDs|,|.|were|from (r_prep) compared_23\VBN|NONE (l_prep) with_24\IN|,|EDDs|,|.|were|from|From (l_pobj) victims_26\NNS|NONE (l_prep) without_31\IN||of (l_pobj) delirium_33\NN|NONE
D003042_D003693 CID cocaine_29\NN|accidental (r_compound) overdose_30\NN|NONE (r_pobj) of_27\IN|without| (r_prep) victims_26\NNS|NONE (r_pobj) with_24\IN|,|EDDs|,|.|were|from|From (r_prep) compared_23\VBN|NONE (l_nsubjpass) EDDs_21\NNS|with|,|,|.|were|from|From
D003042_D003693 CID cocaine_29\NN|accidental (r_compound) overdose_30\NN|NONE (r_pobj) of_27\IN|without| (r_prep) victims_26\NNS|NONE (l_prep) without_31\IN||of (l_pobj) delirium_33\NN|NONE
D003042_D003693 CID cocaine_4\NN|NONE (r_pobj) of_3\IN|were|in (r_prep) concentrations_2\NNS|.|EDDs (r_dobj) had_1\VBD|NONE (l_nsubj) EDDs_0\NNS|.|concentrations
D003042_D003693 CID cocaine_11\NN|chronic (r_compound) use_12\NN|that|and|function (r_nsubj) disrupts_13\VBZ|the (r_acl) hypothesis_8\NN|NONE (r_pobj) with_6\IN|most (r_prep) consistent_5\JJ|findings|.|precipitate|, (r_acomp) are_3\VBP|NONE (l_advcl) precipitate_26\VB|findings|.|,|consistent (l_dobj) agitation_27\NN|may|,|coupled (l_conj) delirium_29\NN|,
D003042_D003693 CID cocaine_22\NN|recent (r_compound) use_23\NN|NONE (r_pobj) with_20\IN|when (r_prep) coupled_19\VBN|may|agitation|, (r_advcl) precipitate_26\VB|findings|.|,|consistent (l_dobj) agitation_27\NN|may|,|coupled (l_conj) delirium_29\NN|,
D003042_D064420 NONE cocaine_4\NN|NONE (r_compound) use_5\NN|NONE (r_dobj) following_3\VBG|Fatal|excited (r_acl) delirium_2\NN|evidence|:|.|findings (r_dep) provide_9\VBP|NONE (l_dobj) evidence_11\NN|delirium|:|.|findings (l_prep) for_12\IN|new (l_pobj) mechanisms_13\NNS|NONE (l_prep) of_14\IN|NONE (l_pobj) toxicity_16\NN|NONE
D003042_D064420 NONE cocaine_15\NN|NONE (r_compound) toxicity_16\NN|NONE
D003042_D012206 CID cocaine_11\NN|chronic (r_compound) use_12\NN|that|and|function (r_nsubj) disrupts_13\VBZ|the (r_acl) hypothesis_8\NN|NONE (r_pobj) with_6\IN|most (r_prep) consistent_5\JJ|findings|.|precipitate|, (r_acomp) are_3\VBP|NONE (l_advcl) precipitate_26\VB|findings|.|,|consistent (l_dobj) agitation_27\NN|may|,|coupled (l_conj) delirium_29\NN|, (l_conj) thermoregulation_32\NN|, (l_conj) rhabdomyolysis_34\NN|,|aberrant
D003042_D012206 CID cocaine_22\NN|recent (r_compound) use_23\NN|NONE (r_pobj) with_20\IN|when (r_prep) coupled_19\VBN|may|agitation|, (r_advcl) precipitate_26\VB|findings|.|,|consistent (l_dobj) agitation_27\NN|may|,|coupled (l_conj) delirium_29\NN|, (l_conj) thermoregulation_32\NN|, (l_conj) rhabdomyolysis_34\NN|,|aberrant
D003042_D062787 NONE cocaine_5\NN| (r_npadvmod) related_7\VBN|in|all (r_amod) deaths_8\NNS|NONE (r_pobj) of_3\IN|a (r_prep) registry_2\NN|NONE (r_pobj) From_0\IN|with|,|EDDs|,|.|were|from (r_prep) compared_23\VBN|NONE (l_prep) with_24\IN|,|EDDs|,|.|were|from|From (l_pobj) victims_26\NNS|NONE (l_prep) of_27\IN|without| (l_pobj) overdose_30\NN|NONE
D003042_D062787 NONE cocaine_29\NN|accidental (r_compound) overdose_30\NN|NONE
C005618_D003693 NONE benzoylecgonine_6\NN|and (r_conj) cocaine_4\NN|NONE (r_pobj) of_3\IN|were|in (r_prep) concentrations_2\NNS|.|EDDs (r_dobj) had_1\VBD|NONE (l_nsubj) EDDs_0\NNS|.|concentrations
D003042_D003645 CID cocaine_11\NN|chronic (r_compound) use_12\NN|that|and|function (r_nsubj) disrupts_13\VBZ|the (r_acl) hypothesis_8\NN|NONE (r_pobj) with_6\IN|most (r_prep) consistent_5\JJ|findings|.|precipitate|, (r_acomp) are_3\VBP|NONE (l_advcl) precipitate_26\VB|findings|.|,|consistent (l_dobj) agitation_27\NN|may|,|coupled (l_conj) delirium_29\NN|, (l_conj) thermoregulation_32\NN|, (l_conj) rhabdomyolysis_34\NN|,|aberrant (l_conj) death_38\NN|,|and
D003042_D003645 CID cocaine_22\NN|recent (r_compound) use_23\NN|NONE (r_pobj) with_20\IN|when (r_prep) coupled_19\VBN|may|agitation|, (r_advcl) precipitate_26\VB|findings|.|,|consistent (l_dobj) agitation_27\NN|may|,|coupled (l_conj) delirium_29\NN|, (l_conj) thermoregulation_32\NN|, (l_conj) rhabdomyolysis_34\NN|,|aberrant (l_conj) death_38\NN|,|and
D003042_D011595 NONE cocaine_11\NN|chronic (r_compound) use_12\NN|that|and|function (r_nsubj) disrupts_13\VBZ|the (r_acl) hypothesis_8\NN|NONE (r_pobj) with_6\IN|most (r_prep) consistent_5\JJ|findings|.|precipitate|, (r_acomp) are_3\VBP|NONE (l_advcl) precipitate_26\VB|findings|.|,|consistent (l_dobj) agitation_27\NN|may|,|coupled
D003042_D011595 NONE cocaine_22\NN|recent (r_compound) use_23\NN|NONE (r_pobj) with_20\IN|when (r_prep) coupled_19\VBN|may|agitation|, (r_advcl) precipitate_26\VB|findings|.|,|consistent (l_dobj) agitation_27\NN|may|,|coupled
14513889
D007654_D009422 NONE Ketoconazole_0\NNP|.|sequelae| (r_npadvmod) induced_2\VBN|NONE (l_dobj) sequelae_4\NNS|.|Ketoconazole|
8599504
D004329_D004342 NONE droperidol_39\NN|NONE (r_pobj) of_38\IN|single|IV|a (r_prep) dose_37\NN|NONE (r_pobj) of_33\IN|the (r_prep) administration_32\NN|NONE (r_pobj) of_30\IN| (r_prep) minutes_29\NNS|NONE (r_pobj) within_27\IN|in|angioedema (r_prep) developed_26\VBN|drug|known|no (r_relcl) allergies_16\NNS|NONE
D004329_D000799 CID droperidol_3\NN|NONE (r_compound) administration_4\NN|NONE (r_pobj) with_2\IN|NONE (r_prep) associated_1\VBD|. (r_acl) Angioedema_0\NNP|NONE
D004329_D000799 CID droperidol_39\NN|NONE (r_pobj) of_38\IN|single|IV|a (r_prep) dose_37\NN|NONE (r_pobj) of_33\IN|the (r_prep) administration_32\NN|NONE (r_pobj) of_30\IN| (r_prep) minutes_29\NNS|NONE (r_pobj) within_27\IN|in|angioedema (r_prep) developed_26\VBN|drug|known|no (l_nsubj) angioedema_19\NN|within|in
D004329_D004487 NONE droperidol_39\NN|NONE (r_pobj) of_38\IN|single|IV|a (r_prep) dose_37\NN|NONE (r_pobj) of_33\IN|the (r_prep) administration_32\NN|NONE (r_pobj) of_30\IN| (r_prep) minutes_29\NNS|NONE (r_pobj) within_27\IN|in|angioedema (r_prep) developed_26\VBN|drug|known|no (l_nsubj) angioedema_19\NN|within|in (l_prep) with_20\IN|NONE (l_pobj) swelling_23\NN|NONE
D004329_D014060 NONE droperidol_39\NN|NONE (r_pobj) of_38\IN|single|IV|a (r_prep) dose_37\NN|NONE (r_pobj) of_33\IN|the (r_prep) administration_32\NN|NONE (r_pobj) of_30\IN| (r_prep) minutes_29\NNS|NONE (r_pobj) within_27\IN|in|angioedema (r_prep) developed_26\VBN|drug|known|no (l_nsubj) angioedema_19\NN|within|in (l_prep) with_20\IN|NONE (l_pobj) swelling_23\NN|NONE
10565806
C076029_D001714 CID olanzapine_6\NN|NONE (r_pobj) by_5\IN|.|Hypomania (r_prep) induced_4\VBN|NONE (l_nsubj) Hypomania_0\NNP|.|by
C076029_D001714 CID olanzapine_28\JJ|NONE (r_compound) treatment_29\NN|NONE (r_pobj) of_27\IN|the (r_prep) introduction_26\NN|shortly (r_pobj) after_24\IN|who|hypomania (r_prep) developed_21\VBD|psychotic|IV|a|specified (l_dobj) hypomania_22\NN|who|after
C076029_D011618 NONE olanzapine_28\JJ|NONE (r_compound) treatment_29\NN|NONE (r_pobj) of_27\IN|the (r_prep) introduction_26\NN|shortly (r_pobj) after_24\IN|who|hypomania (r_prep) developed_21\VBD|psychotic|IV|a|specified (r_relcl) disorder_14\NN|NONE
11860278
D000109_D012640 NONE acetylcholine_16\NN|and|both (r_conj) glutamate_14\NN|NONE (r_pobj) by_12\IN|NONE (r_agent) induced_11\VBN|NONE (r_acl) seizures_10\NNS|NONE
D018698_D012640 NONE glutamate_14\NN|NONE (r_pobj) by_12\IN|NONE (r_agent) induced_11\VBN|NONE (r_acl) seizures_10\NNS|NONE
D010862_D012640 CID pilocarpine_18\NN|NONE (r_pobj) with_14\IN|NONE (r_prep) treated_13\VBN|/|DR (r_acl) mice_12\NNS|NONE (r_pobj) in_9\IN|neurotoxicity|and (r_prep) seizures_6\NNS|NONE
D010862_D012640 CID pilocarpine_2\NN| (r_npadvmod) induced_4\VBN|NONE (r_amod) seizures_5\NNS|However|in|.|,
D010862_D020258 NONE pilocarpine_18\NN|NONE (r_pobj) with_14\IN|NONE (r_prep) treated_13\VBN|/|DR (r_acl) mice_12\NNS|NONE (r_pobj) in_9\IN|neurotoxicity|and (r_prep) seizures_6\NNS|NONE (l_conj) neurotoxicity_8\NN|in|and
D004298_D004827 NONE Dopamine_0\NNP|,|role|.|in (r_nsubj) plays_12\VBZ|NONE (l_prep) in_16\IN|,|Dopamine|role|. (l_pobj) control_18\NN|NONE (l_prep) of_19\IN|the (l_pobj) seizures_21\NNS|NONE
D004298_D004827 NONE DA_2\NNP|through|, (r_appos) Dopamine_0\NNP|,|role|.|in (r_nsubj) plays_12\VBZ|NONE (l_prep) in_16\IN|,|Dopamine|role|. (l_pobj) control_18\NN|NONE (l_prep) of_19\IN|the (l_pobj) seizures_21\NNS|NONE
D004298_D004827 NONE DA_11\NNP|NONE (r_compound) receptors_12\NNS|NONE (r_pobj) of_10\IN|the|in (r_prep) role_9\NN|NONE (l_prep) in_13\IN|of|the (l_pobj) occurrence_15\NN|NONE (l_prep) of_16\IN|the (l_pobj) death_22\NN|NONE (l_amod) induced_19\VBN|cell|neuronal (l_npadvmod) epilepsy_17\NN|
D007608_D012640 CID KA_23\NNP|NONE (r_pobj) to_22\IN|NONE (r_prep) comparison_21\NN|NONE (r_pobj) in_20\IN|a|neuronal|widespread|in (r_prep) death_12\NN|NONE (r_pobj) in_7\IN|However|seizures|.|, (r_prep) result_6\VBP|NONE (l_nsubj) seizures_5\NNS|However|in|.|,
6454943
D011692_D006973 NONE aminonucleoside_8\RB|existing (r_punct) -_9\HYPH|Effect|proteinuria|in|. (r_punct) induced_10\VBN|NONE (l_prep) in_12\IN|Effect|proteinuria||. (l_pobj) rats_15\NNS|NONE (l_amod) hypertensive_14\JJ|NONE
D002216_D007674 NONE captopril_9\NN|NONE (r_pobj) with_8\IN|the|same|renal (r_prep) abnormality_7\NN|NONE
D002216_D011507 NONE captopril_2\NN|NONE (r_pobj) of_1\IN|on (r_prep) Effect_0\NN|proteinuria||in|. (r_nsubj) induced_10\VBN|NONE (l_dobj) proteinuria_11\NN|Effect||in|.
D002216_D011507 NONE captopril_6\NN|in (r_compound) treatment_7\NN|NONE (r_pobj) of_5\IN|a|side (r_prep) effect_4\NN|.|Proteinuria (r_attr) is_1\VBZ|NONE (l_nsubj) Proteinuria_0\NNP|effect|.
D002216_D011507 NONE captopril_3\NN|NONE (r_pobj) of_2\IN|Oral|for|at (r_prep) administration_1\NN|aggravate|. (r_nsubj) failed_10\VBD|NONE (l_xcomp) aggravate_12\VB|.|administration (l_dobj) proteinuria_13\JJ|to
D002216_D011507 NONE captopril_2\NN|NONE (r_compound) treatment_3\NN|.|Also|,|potentiate (r_nsubj) failed_4\VBD|NONE (l_xcomp) potentiate_6\VB|.|Also|treatment|, (l_conj) facilitate_8\VB|or|to (l_dobj) development_9\NN|NONE (l_prep) of_10\IN|NONE (l_pobj) proteinuria_12\NN|NONE
D002216_D006973 NONE captopril_2\NN|NONE (r_pobj) of_1\IN|on (r_prep) Effect_0\NN|proteinuria||in|. (r_nsubj) induced_10\VBN|NONE (l_prep) in_12\IN|Effect|proteinuria||. (l_pobj) rats_15\NNS|NONE (l_amod) hypertensive_14\JJ|NONE
D002216_D006973 NONE captopril_6\NN|in (r_compound) treatment_7\NN|NONE (l_prep) in_8\IN|captopril (l_pobj) patients_10\NNS|NONE (l_amod) hypertensive_9\JJ|NONE
D011692_D011507 CID aminonucleoside_8\RB|existing (r_punct) -_9\HYPH|Effect|proteinuria|in|. (r_punct) induced_10\VBN|NONE (l_dobj) proteinuria_11\NN|Effect||in|.
D011692_D011507 CID aminonucleoside_16\NN|NONE (r_amod) puromycin_15\NNS|NONE (r_pobj) by_14\IN|NONE (r_agent) invoked_13\VBN|massive (r_acl) proteinuria_12\NN|NONE
14976857
D011405_D004437 NONE propafenone_9\NN|in (r_compound) overdose_10\NN|NONE (l_prep) in_11\IN|propafenone (l_pobj) woman_14\NN|NONE (l_prep) with_15\IN|young|a (l_pobj) anomaly_18\NN|NONE
D011405_-1 NONE propafenone_9\NN|in (r_compound) overdose_10\NN|NONE (r_pobj) by_8\IN|NONE (r_agent) induced_7\VBN|like|.|Transient (r_acl) syndrome_6\NN|NONE
D011405_D062787 NONE propafenone_9\NN|in (r_compound) overdose_10\NN|NONE
D011405_D062787 NONE propafenone_26\NN|a (r_compound) overdose_27\NN|NONE
D011405_D054092 NONE propafenone_26\NN|a (r_compound) overdose_27\NN|NONE (r_pobj) by_24\IN|probably|was (r_agent) precipitated_23\VBN|shunt|in|,|.|and (r_conj) occurred_9\VBD|NONE (l_nsubj) shunt_1\NN|in|,|precipitated|.|and (l_prep) via_4\IN|of|This (l_pobj) ovale_8\NN|NONE
16629641
D012254_D007674 NONE ribavirin_8\RB| (r_npadvmod) induced_10\VBN|NONE (r_amod) hemolysis_11\NN|NONE (r_pobj) of_7\IN|a (r_prep) result_6\NN|mainly (r_pobj) as_4\IN|,|concentrations|and|be (r_prep) decrease_2\VBP|NONE (l_conj) be_17\VB|,|concentrations|as|and (l_conj) comorbid_29\VBN|anemia|problematic|in|can|. (l_dobj) disorders_33\NNS|have|those
C026956_D000743 NONE Viramidine_0\NNP|potential (r_nsubj) has_10\VBZ|NONE (l_dobj) potential_12\NN|Viramidine (l_acl) maintain_14\VB|the (l_advcl) decreasing_21\VBG|efficacy|to (l_dobj) risk_23\NN|while (l_prep) of_24\IN|the (l_pobj) anemia_26\NN|NONE
D012254_D006461 NONE ribavirin_8\RB| (r_npadvmod) induced_10\VBN|NONE (r_amod) hemolysis_11\NN|NONE
D012254_D000740 NONE ribavirin_8\RB| (r_npadvmod) induced_10\VBN|NONE (r_amod) hemolysis_11\NN|NONE (r_pobj) of_7\IN|a (r_prep) result_6\NN|mainly (r_pobj) as_4\IN|,|concentrations|and|be (r_prep) decrease_2\VBP|NONE (l_conj) be_17\VB|,|concentrations|as|and (l_nsubj) anemia_15\NN|comorbid|problematic|in|can|.
D012254_D000740 NONE ribavirin_1\RB| (r_npadvmod) associated_3\VBN|NONE (r_amod) anemia_4\NN|can|be|by|Although
D012254_D000740 NONE ribavirin_8\RB| (r_npadvmod) associated_10\VBN|NONE (r_amod) anemia_11\NN|to
C026956_D019698 NONE Viramidine_0\NNP|potential (r_nsubj) has_10\VBZ|NONE (l_dobj) potential_12\NN|Viramidine (l_acl) maintain_14\VB|the (l_advcl) decreasing_21\VBG|efficacy|to (l_dobj) risk_23\NN|while (l_prep) of_24\IN|the (l_pobj) anemia_26\NN|NONE (l_prep) in_27\IN|hemolytic (l_pobj) patients_28\NNS|NONE (l_prep) with_29\IN|NONE (l_pobj) C._32\NNP|NONE
D012254_D002318 NONE ribavirin_8\RB| (r_npadvmod) induced_10\VBN|NONE (r_amod) hemolysis_11\NN|NONE (r_pobj) of_7\IN|a (r_prep) result_6\NN|mainly (r_pobj) as_4\IN|,|concentrations|and|be (r_prep) decrease_2\VBP|NONE (l_conj) be_17\VB|,|concentrations|as|and (l_conj) comorbid_29\VBN|anemia|problematic|in|can|. (l_dobj) disorders_33\NNS|have|those
D007372_D006526 NONE interferon_12\NN|NONE (r_pobj) with_10\IN|combination (r_prep) therapy_9\NN|.|treatment (r_attr) is_7\VBZ|NONE (l_nsubj) treatment_3\NN|.|therapy (l_prep) for_4\IN|current|The|best (l_pobj) infection_6\NN|NONE
D012254_D006526 NONE ribavirin_14\NN|and|pegylated (r_conj) interferon_12\NN|NONE (r_pobj) with_10\IN|combination (r_prep) therapy_9\NN|.|treatment (r_attr) is_7\VBZ|NONE (l_nsubj) treatment_3\NN|.|therapy (l_prep) for_4\IN|current|The|best (l_pobj) infection_6\NN|NONE
D012254_D006526 NONE ribavirin_8\RB| (r_npadvmod) induced_10\VBN|NONE (r_amod) hemolysis_11\NN|NONE (r_pobj) of_7\IN|a (r_prep) result_6\NN|mainly (r_pobj) as_4\IN|,|concentrations|and|be (r_prep) decrease_2\VBP|NONE (l_conj) be_17\VB|,|concentrations|as|and (l_prep) in_19\IN|comorbid|anemia|problematic|can|. (l_pobj) patients_20\NNS|NONE (l_prep) with_21\IN|NONE (l_pobj) infection_23\NN|NONE
D012254_D019698 NONE ribavirin_8\NN|NONE (r_pobj) of_7\IN|targeting|a (r_prep) prodrug_6\NN|,|, (r_appos) Viramidine_0\NNP|potential (r_nsubj) has_10\VBZ|NONE (l_dobj) potential_12\NN|Viramidine (l_acl) maintain_14\VB|the (l_advcl) decreasing_21\VBG|efficacy|to (l_dobj) risk_23\NN|while (l_prep) of_24\IN|the (l_pobj) anemia_26\NN|NONE (l_prep) in_27\IN|hemolytic (l_pobj) patients_28\NNS|NONE (l_prep) with_29\IN|NONE (l_pobj) C._32\NNP|NONE
D012254_D019698 NONE ribavirin_19\RB|NONE (r_pobj) of_18\IN|virologic|the (r_prep) efficacy_17\NN|decreasing|to (r_dobj) maintain_14\VB|the (l_advcl) decreasing_21\VBG|efficacy|to (l_dobj) risk_23\NN|while (l_prep) of_24\IN|the (l_pobj) anemia_26\NN|NONE (l_prep) in_27\IN|hemolytic (l_pobj) patients_28\NNS|NONE (l_prep) with_29\IN|NONE (l_pobj) C._32\NNP|NONE
D012254_D000743 CID ribavirin_8\NN|NONE (r_pobj) of_7\IN|targeting|a (r_prep) prodrug_6\NN|,|, (r_appos) Viramidine_0\NNP|potential (r_nsubj) has_10\VBZ|NONE (l_dobj) potential_12\NN|Viramidine (l_acl) maintain_14\VB|the (l_advcl) decreasing_21\VBG|efficacy|to (l_dobj) risk_23\NN|while (l_prep) of_24\IN|the (l_pobj) anemia_26\NN|NONE
D012254_D000743 CID ribavirin_19\RB|NONE (r_pobj) of_18\IN|virologic|the (r_prep) efficacy_17\NN|decreasing|to (r_dobj) maintain_14\VB|the (l_advcl) decreasing_21\VBG|efficacy|to (l_dobj) risk_23\NN|while (l_prep) of_24\IN|the (l_pobj) anemia_26\NN|NONE
17532790
D001971_D010300 NONE bromocriptine_36\NN|or||L (r_conj) DOPA_34\NNP|the|using|,|occurring (r_appos) changes_8\NNS|we|,|In|. (l_acl) occurring_9\VBG|the|using|DOPA|, (l_prep) at_10\IN|NONE (l_pobj) level_13\NN|NONE (l_acl) obtained_17\VBN|the|protein|in (l_prep) from_18\IN|NONE (l_pobj) model_25\NN|NONE (l_prep) of_26\IN|unilaterally|rat|the|treated (l_pobj) PD_27\NNP|NONE
D007980_D004409 CID DOPA_12\NNP||L| (r_npadvmod) induced_14\VBN|NONE (r_amod) dyskinesia_15\NN|NONE
D007980_D004409 CID DOPA_2\NNP|L|| (r_npadvmod) induced_4\VBN|LID (r_amod) dyskinesia_5\NN|.|among
D007980_D004409 CID DOPA_2\NNP|L|| (r_npadvmod) induced_4\VBN|LID (r_amod) dyskinesia_5\NN|.|among (l_appos) LID_7\NNP|induced
D007980_D004409 CID DOPA_31\NNP|NONE (r_pobj) with_28\IN|prolonged|a (r_prep) treatment_27\NN|NONE (r_pobj) after_24\IN|that|in (r_prep) arise_15\VBP|the|motor (r_relcl) complications_13\NNS|NONE (r_pobj) among_10\IN|.|dyskinesia (r_prep) is_9\VBZ|NONE (l_nsubj) dyskinesia_5\NN|.|among
D007980_D004409 CID DOPA_31\NNP|NONE (r_pobj) with_28\IN|prolonged|a (r_prep) treatment_27\NN|NONE (r_pobj) after_24\IN|that|in (r_prep) arise_15\VBP|the|motor (r_relcl) complications_13\NNS|NONE (r_pobj) among_10\IN|.|dyskinesia (r_prep) is_9\VBZ|NONE (l_nsubj) dyskinesia_5\NN|.|among (l_appos) LID_7\NNP|induced
D007980_D004409 CID DOPA_5\NNP|NONE (r_pobj) with_2\IN|Rats|allocated|. (r_prep) treated_1\VBD|NONE (l_conj) allocated_7\VBN|Rats|with|. (l_prep) to_8\IN|were (l_pobj) groups_10\NNS|NONE (l_acl) based_11\VBN|two (l_prep) on_12\IN|NONE (l_pobj) presence_14\NN|NONE (l_conj) absence_16\NN|the|or (l_prep) of_17\IN|NONE (l_pobj) LID_18\NNP|NONE
D007980_D010300 NONE DOPA_2\NNP|L|| (r_npadvmod) induced_4\VBN|LID (r_amod) dyskinesia_5\NN|.|among (r_nsubj) is_9\VBZ|NONE (l_prep) among_10\IN|.|dyskinesia (l_pobj) complications_13\NNS|NONE (l_relcl) arise_15\VBP|the|motor (l_prep) in_16\IN|that|after (l_pobj) patients_23\NNS|NONE (l_nmod) disease_19\NN|(|)|PD
D007980_D010300 NONE DOPA_2\NNP|L|| (r_npadvmod) induced_4\VBN|LID (r_amod) dyskinesia_5\NN|.|among (r_nsubj) is_9\VBZ|NONE (l_prep) among_10\IN|.|dyskinesia (l_pobj) complications_13\NNS|NONE (l_relcl) arise_15\VBP|the|motor (l_prep) in_16\IN|that|after (l_pobj) patients_23\NNS|NONE (l_nmod) PD_21\NNP|(|)|disease
D007980_D010300 NONE DOPA_31\NNP|NONE (r_pobj) with_28\IN|prolonged|a (r_prep) treatment_27\NN|NONE (r_pobj) after_24\IN|that|in (r_prep) arise_15\VBP|the|motor (l_prep) in_16\IN|that|after (l_pobj) patients_23\NNS|NONE (l_nmod) disease_19\NN|(|)|PD
D007980_D010300 NONE DOPA_31\NNP|NONE (r_pobj) with_28\IN|prolonged|a (r_prep) treatment_27\NN|NONE (r_pobj) after_24\IN|that|in (r_prep) arise_15\VBP|the|motor (l_prep) in_16\IN|that|after (l_pobj) patients_23\NNS|NONE (l_nmod) PD_21\NNP|(|)|disease
D007980_D010300 NONE DOPA_34\NNP|the|using|,|occurring (r_appos) changes_8\NNS|we|,|In|. (l_acl) occurring_9\VBG|the|using|DOPA|, (l_prep) at_10\IN|NONE (l_pobj) level_13\NN|NONE (l_acl) obtained_17\VBN|the|protein|in (l_prep) from_18\IN|NONE (l_pobj) model_25\NN|NONE (l_prep) of_26\IN|unilaterally|rat|the|treated (l_pobj) PD_27\NNP|NONE
D016627_D010300 NONE 6-hydroxydopamine_21\CD| (r_compound) lesion_23\NN|NONE (r_compound) rat_24\NN|unilaterally|of|the|treated (r_compound) model_25\NN|NONE (l_prep) of_26\IN|unilaterally|rat|the|treated (l_pobj) PD_27\NNP|NONE
188339
D013256_D008113 NONE steroids_19\NNS|NONE (r_dobj) using_16\VBG|.|,|been|in|tumors|Within|previously|have (r_advcl) seen_12\VBN|NONE (l_nsubjpass) tumors_9\NNS|.|,|been|in|Within|previously|have|using
D003276_D008113 CID contraceptives_11\NNS|NONE (r_pobj) with_9\IN|NONE (r_prep) associated_8\VBN|liver (r_acl) tumors_7\NNS|NONE
D003276_D008113 CID contraceptive_18\JJ|oral (r_amod) steroids_19\NNS|NONE (r_dobj) using_16\VBG|.|,|been|in|tumors|Within|previously|have (r_advcl) seen_12\VBN|NONE (l_nsubjpass) tumors_9\NNS|.|,|been|in|Within|previously|have|using
16403073
D007654_D016171 CID Ketoconazole_0\NNP|without|.|pointes (r_nsubj) induced_1\VBD|NONE (l_dobj) pointes_4\FW|Ketoconazole|without|.
D007654_D016171 CID ketoconazole_24\RB|for (r_dobj) taking_23\VBG|NONE (r_pcomp) after_22\IN|pointes (r_prep) torsades_16\NNS|interval|who|and (l_dobj) pointes_18\FW|after
D007654_D016171 CID ketoconazole_24\RB|for (r_dobj) taking_23\VBG|NONE (r_pcomp) after_22\IN|pointes (r_prep) torsades_16\NNS|interval|who|and (l_dobj) pointes_18\FW|after (l_appos) TdP_20\NN|)|de|(
D007654_D016171 CID ketoconazole_13\RB|and|that|by|induce|,|may|interval (r_nsubj) prolong_16\VB|We (l_conj) induce_20\VB|and|that|by|,|may|ketoconazole|interval (l_dobj) TdP._21\NN|NONE
D007654_D003324 NONE ketoconazole_24\RB|for (r_dobj) taking_23\VBG|NONE (r_pcomp) after_22\IN|pointes (r_prep) torsades_16\NNS|interval|who|and (r_conj) developed_9\VBD|a|with (r_relcl) woman_3\NN|.|We (l_prep) with_4\IN|a|developed (l_pobj) disease_7\NN|NONE
D007654_D008133 CID ketoconazole_24\RB|for (r_dobj) taking_23\VBG|NONE (r_pcomp) after_22\IN|pointes (r_prep) torsades_16\NNS|interval|who|and (r_conj) developed_9\VBD|a|with (l_dobj) interval_14\NN|who|and|torsades
D007654_D008133 CID ketoconazole_5\JJ|is|to|when (r_nsubjpass) administered_7\VBN|for|This|. (l_prep) to_8\IN|is|when|ketoconazole (l_pobj) patients_9\NNS|NONE (l_prep) with_10\IN|NONE (l_pobj) factors_12\NNS|NONE (l_prep) for_13\IN|risk (l_pobj) syndrome_17\NN|NONE
D007654_D009181 NONE ketoconazole_24\RB|for (r_dobj) taking_23\VBG|NONE (l_prep) for_25\IN|ketoconazole (l_pobj) treatment_26\NN|NONE (l_prep) of_27\IN|NONE (l_pobj) infection_29\NN|NONE
12109865
16820346
D003907_D006973 CID dexamethasone_4\NN| (r_npadvmod) induced_6\VBN|in (r_amod) hypertension_7\NN|NONE
D003907_D006973 CID dexamethasone_11\NN|NONE (l_appos) hypertension_14\NN|(
D003907_D006973 CID dex)-induced_13\VBN|, (r_amod) hypertension_14\NN|(
D003907_D006973 CID dex_2\NN| (r_npadvmod) induced_4\VBN|+/ (r_amod) hypertension_5\NN|Atorva|mmHg|and|,|vs.|)|decreased|mmHg
D003907_D006973 CID dexamethasone_6\NN| (r_npadvmod) induced_8\VBN|in (r_amod) hypertension_9\NN|NONE
D013481_D006973 NONE superoxide_25\RB|plasma (r_advmod) decreased_23\VBD|Atorva|hypertension|mmHg|and|,|vs.|)|mmHg (r_conj) reversed_1\VBN|NONE (l_dobj) hypertension_5\NN|Atorva|mmHg|and|,|vs.|)|decreased|mmHg
C065179_D006973 NONE Atorvastatin_0\NNS|.|and|reversed (r_nsubj) prevented_1\VBD|NONE (l_conj) reversed_3\VBD|.|Atorvastatin|and (l_dobj) hypertension_7\NN|NONE
C065179_D006973 NONE atorvastatin_6\NN|)|( (r_nmod) atorva_8\NN|NONE (r_pobj) of_5\IN|on|antioxidant|the (r_prep) effects_4\NNS|To (l_prep) on_10\IN|antioxidant|of|the (l_pobj) dexamethasone_11\NN|NONE (l_appos) hypertension_14\NN|(
C065179_D006973 NONE atorva_8\NN|NONE (r_pobj) of_5\IN|on|antioxidant|the (r_prep) effects_4\NNS|To (l_prep) on_10\IN|antioxidant|of|the (l_pobj) dexamethasone_11\NN|NONE (l_appos) hypertension_14\NN|(
C065179_D006973 NONE atorva_25\NN|tap|kg (r_nmod) water_34\NN|NONE (r_pobj) with_24\IN|for|rats|.|were|assess (r_prep) treated_23\VBN|NONE (l_advcl) assess_1\VB|for|with|rats|.|were (l_dobj) effects_4\NNS|To (l_prep) on_10\IN|antioxidant|of|the (l_pobj) dexamethasone_11\NN|NONE (l_appos) hypertension_14\NN|(
C065179_D006973 NONE Atorva_0\NN|hypertension|mmHg|and|,|vs.|)|decreased|mmHg (r_nsubj) reversed_1\VBN|NONE (l_dobj) hypertension_5\NN|Atorva|mmHg|and|,|vs.|)|decreased|mmHg
C065179_D006973 NONE atorvastatin_2\NN|reversed|Thus|and|.|, (r_nsubj) prevented_3\VBN|NONE (l_conj) reversed_5\VBN|Thus|atorvastatin|and|.|, (l_dobj) hypertension_9\NN|NONE
15188772
D004837_D018487 NONE epinephrine_12\NN|accidental|iatrogenic (r_amod) overdose_13\NN|to (r_pobj) due_8\IN|Severe|.|left|systolic|ventricular (r_prep) dysfunction_7\NN|NONE
D004837_D018487 NONE epinephrine_15\NN|NONE (r_pobj) of_14\IN| (r_prep) mg_13\NN|markers|.|woman (r_nsubj) developed_16\VBN|NONE (l_dobj) markers_44\NNS|.|mg|woman (l_amod) stunning_18\JJ|of|biochemical|elevated (l_relcl) characterized_21\VBN|myocardial (l_conj) left_32\VBD|,|was|by|and|that (l_dobj) dysfunction_37\NN|NONE
D004837_D017682 CID epinephrine_15\NN|NONE (r_pobj) of_14\IN| (r_prep) mg_13\NN|markers|.|woman (r_nsubj) developed_16\VBN|NONE (l_dobj) markers_44\NNS|.|mg|woman (l_amod) stunning_18\JJ|of|biochemical|elevated
D004837_D009202 NONE epinephrine_15\NN|NONE (r_pobj) of_14\IN| (r_prep) mg_13\NN|markers|.|woman (r_nsubj) developed_16\VBN|NONE (l_dobj) markers_44\NNS|.|mg|woman (l_prep) of_45\IN|stunning|biochemical|elevated (l_pobj) necrosis_47\NN|NONE
D002395_D009202 NONE Catecholamine_0\NN| (r_npadvmod) induced_2\VBN|due (r_amod) cardiomyopathy_3\NN|.|for|has|been
D002395_D009202 NONE catecholamines_10\NNS|NONE (r_pobj) of_8\IN|chronic (r_prep) excess_7\NN|to (r_pobj) due_4\IN|induced (r_prep) cardiomyopathy_3\NN|.|for|has|been
D004837_D062787 NONE epinephrine_12\NN|accidental|iatrogenic (r_amod) overdose_13\NN|to
3676049
D008628_D007022 NONE Hg_11\NNP|NONE (r_pobj) of_6\IN|average|an (r_prep) MAP_5\NNP|NONE (r_pobj) to_2\IN|Controlled (r_prep) hypotension_1\NN|and|by|maintained|.|was|,
D010100_D002532 NONE oxygen_8\NN|NONE (r_pobj) for_7\IN|cerebral|metabolic (r_prep) rate_6\NN|blood|Cerebral|and (r_conj) flow_2\NN|were|during|. (r_nsubjpass) measured_10\VBN|NONE (l_prep) during_11\IN|flow|were|. (l_pobj) hypotension_15\NN|NONE (l_prep) in_16\IN|induced (l_pobj) patients_18\NNS|NONE (l_acl) subjected_19\VBN| (l_prep) to_20\IN|NONE (l_pobj) craniotomy_21\NN|NONE (l_prep) for_22\IN|NONE (l_pobj) clipping_23\NN|NONE (l_prep) of_24\IN|NONE (l_pobj) aneurysm_27\NN|NONE
D007530_D002532 NONE isoflurane_6\RB| (r_npadvmod) induced_8\VBN|in (r_amod) hypotension_9\NN|NONE (l_prep) in_10\IN|induced (l_pobj) patients_11\NNS|NONE (l_acl) subjected_12\VBN|NONE (l_prep) for_15\IN|to (l_pobj) aneurysms_17\NNS|NONE
D007530_D002532 NONE isoflurane_12\RB| (r_npadvmod) induced_14\VBN|in (r_amod) hypotension_15\NN|NONE (l_prep) in_16\IN|induced (l_pobj) patients_18\NNS|NONE (l_acl) subjected_19\VBN| (l_prep) to_20\IN|NONE (l_pobj) craniotomy_21\NN|NONE (l_prep) for_22\IN|NONE (l_pobj) clipping_23\NN|NONE (l_prep) of_24\IN|NONE (l_pobj) aneurysm_27\NN|NONE
D007530_D000783 NONE isoflurane_7\JJ|the (r_amod) concentration_8\NN|was|After|.|to (r_nsubjpass) reduced_10\VBN|NONE (l_prep) After_0\IN|was|.|concentration|to (l_pobj) clipping_2\NN|NONE (l_prep) of_3\IN|the (l_pobj) aneurysm_5\NN|NONE
D014978_D013345 NONE xenon-133_24\.|were|Flow|after|by (r_punct) measured_4\VBN|NONE (l_prep) after_9\IN|xenon|were|Flow|by (l_pobj) haemorrhage_12\NN|days
D007530_D007022 CID isoflurane_6\RB| (r_npadvmod) induced_8\VBN|in (r_amod) hypotension_9\NN|NONE
D007530_D007022 CID isoflurane_12\RB| (r_npadvmod) induced_14\VBN|in (r_amod) hypotension_15\NN|NONE
D007530_D007022 CID isoflurane_19\NN|NONE (r_pobj) of_18\IN|the (r_prep) dose_17\NN|NONE (r_dobj) increasing_15\VBG|NONE (r_pcomp) by_14\IN|and|maintained|.|was|hypotension|, (r_prep) induced_13\VBN|NONE (l_nsubjpass) hypotension_1\NN|and|by|maintained|.|was|,
D010100_D007022 NONE oxygen_8\NN|NONE (r_pobj) for_7\IN|cerebral|metabolic (r_prep) rate_6\NN|blood|Cerebral|and (r_conj) flow_2\NN|were|during|. (r_nsubjpass) measured_10\VBN|NONE (l_prep) during_11\IN|flow|were|. (l_pobj) hypotension_15\NN|NONE
19445921
D007545_D006331 NONE isoproterenol_13\NN| (r_npadvmod) induced_15\VBN|attenuated|cardiac|and|injury (r_amod) dysfunction_17\NN|and|improved|of|for|A
D000244_D012131 NONE ADP_13\NNP|/ (r_nmod) O_15\NNP|control|decreased|and (r_conj) ratio_11\NN|NONE (r_pobj) by_7\IN|NONE (r_agent) characterized_6\VBN|respiratory|mitochondrial (r_acl) dysfunction_5\NN|In|.|was|in|,
D007545_D009203 CID isoproterenol_7\NN| (r_npadvmod) induced_9\VBN|in|myocardial (r_amod) infarction_11\NN|NONE
D007545_D009203 CID isoproterenol_15\NN| (r_npadvmod) induced_17\VBN|in|myocardial (r_amod) infarction_19\NN|NONE
D007545_D009203 CID isoproterenol_19\NN| (r_npadvmod) induced_21\VBN|myocardial (r_amod) infarction_23\NN|NONE
C066201_D006331 NONE A_4\NN|and|improved|of|for|dysfunction (r_appos) Administration_0\NN|NONE (l_conj) dysfunction_17\NN|and|improved|of|for|A
C066201_D009203 NONE A_5\NN|salvianolic (l_prep) on_6\IN|acid (l_pobj) infarction_11\NN|NONE
C066201_D009203 NONE A_13\NN|salvianolic (r_pobj) of_10\IN|cardioprotective|on|the (r_prep) potential_9\NN|to (l_prep) on_14\IN|cardioprotective|the|of (l_pobj) infarction_19\NN|NONE
C066201_D009203 NONE A_9\DT|that (r_appos) salvianolic_7\JJ|effect (r_nsubj) has_13\VBZ|.|results (l_dobj) effect_17\NN|salvianolic (l_prep) against_18\IN|a|significant|protective (l_pobj) infarction_23\NN|NONE
C066201_D009202 NONE A_4\NN|and|improved|of|for|dysfunction (r_appos) Administration_0\NN|NONE (l_conj) dysfunction_17\NN|and|improved|of|for|A (l_conj) injury_20\NN|attenuated|cardiac|and|induced
C066201_D009202 NONE A_6\NN|salvianolic (r_pobj) of_3\IN|protective|against|The (r_prep) role_2\NN|by|was|.|further (l_prep) against_7\IN|protective|of|The (l_pobj) damage_12\NN|NONE
D007545_D009202 NONE isoproterenol_13\NN| (r_npadvmod) induced_15\VBN|attenuated|cardiac|and|injury (r_amod) dysfunction_17\NN|and|improved|of|for|A (l_conj) injury_20\NN|attenuated|cardiac|and|induced
D007545_D009202 NONE isoproterenol_8\NN| (r_npadvmod) induced_10\VBN|myocardial (r_amod) damage_12\NN|NONE
D007545_D012131 NONE isoproterenol_19\NN| (r_npadvmod) treated_21\VBN|NONE (r_amod) rats_22\NNS|NONE (r_pobj) in_18\IN|In|.|was|,|dysfunction (r_prep) observed_17\VBN|NONE (l_nsubjpass) dysfunction_5\NN|In|.|was|in|,
6769133
D004317_D006333 CID adriamycin_13\NNS|m|cumulative|considered|an|average|below (r_compound) dose_14\NN|NONE (r_pobj) at_9\IN|.||failure (r_prep) developed_5\VBD|NONE (l_dobj) failure_8\NN|at|.|
D018943_D001768 NONE anthracycline_10\NN| (r_amod) induced_12\VBN|human (r_amod) cardiomyopathy_13\NN|NONE (r_pobj) in_8\IN|NONE (r_prep) found_7\VBN|NONE (r_acl) those_6\DT|lesions|,|.|Histologically (r_dobj) resembled_5\VBD|NONE (l_nsubj) lesions_4\NNS|,|.|those|Histologically
D004317_D066126 NONE adriamycin_6\NNS|NONE (r_pobj) of_5\IN|possible|in|leukemogenic (r_prep) effects_4\NNS|.|and (r_conj) Cardiotoxic_0\NNP|NONE
D018943_D009202 NONE anthracycline_10\NN| (r_amod) induced_12\VBN|human (r_amod) cardiomyopathy_13\NN|NONE
D004317_D007938 NONE adriamycin_4\NN|,|cardiotoxin|than|that|be|and (r_nsubj) is_5\VBZ|results|. (l_conj) be_20\VB|,|cardiotoxin|than|that|and|adriamycin (l_nsubj) leukemia_18\NN|that|may|consequence
D004317_D015470 CID adriamycin_16\NNS|NONE (r_pobj) of_15\IN|mg|/| (r_prep) m2_14\CD|NONE (r_dobj) receiving_10\VBG|NONE (r_pcomp) after_9\IN|leukemia| (r_prep) developed_5\VBD|alive|.|after|;|monkey (l_dobj) leukemia_8\NN|after|
6692345
D005200_D013274 CID N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide_7\NNP|NONE (r_pobj) with_6\IN|NONE (r_prep) aspirin_5\NN|NONE (r_pobj) of_4\IN|to|The| (r_prep) administration_3\NN|in|. (r_nsubj) resulted_13\VBD|NONE (l_prep) in_14\IN|administration|. (l_pobj) incidence_17\NN|NONE (l_conj) induction_27\NN|reduced|but|of|a (l_prep) of_28\IN|a|concomitant (l_pobj) tumors_30\NNS|NONE
D005200_D013274 CID FANFT_9\NNP|NONE (r_appos) N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide_7\NNP|NONE (r_pobj) with_6\IN|NONE (r_prep) aspirin_5\NN|NONE (r_pobj) of_4\IN|to|The| (r_prep) administration_3\NN|in|. (r_nsubj) resulted_13\VBD|NONE (l_prep) in_14\IN|administration|. (l_pobj) incidence_17\NN|NONE (l_conj) induction_27\NN|reduced|but|of|a (l_prep) of_28\IN|a|concomitant (l_pobj) tumors_30\NNS|NONE
D005200_D013274 CID FANFT_19\NNP| (r_npadvmod) induced_21\VBN|bladder (r_amod) carcinomas_23\NNS|NONE (r_pobj) of_18\IN|reduced|but|induction|a (r_prep) incidence_17\NN|NONE (l_conj) induction_27\NN|reduced|but|of|a (l_prep) of_28\IN|a|concomitant (l_pobj) tumors_30\NNS|NONE
D005200_D001749 CID N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide_7\NNP|NONE (r_pobj) with_6\IN|NONE (r_prep) aspirin_5\NN|NONE (r_pobj) of_4\IN|to|The| (r_prep) administration_3\NN|in|. (r_nsubj) resulted_13\VBD|NONE (l_prep) in_14\IN|administration|. (l_pobj) incidence_17\NN|NONE (l_prep) of_18\IN|reduced|but|induction|a (l_pobj) carcinomas_23\NNS|NONE
D005200_D001749 CID FANFT_9\NNP|NONE (r_appos) N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide_7\NNP|NONE (r_pobj) with_6\IN|NONE (r_prep) aspirin_5\NN|NONE (r_pobj) of_4\IN|to|The| (r_prep) administration_3\NN|in|. (r_nsubj) resulted_13\VBD|NONE (l_prep) in_14\IN|administration|. (l_pobj) incidence_17\NN|NONE (l_prep) of_18\IN|reduced|but|induction|a (l_pobj) carcinomas_23\NNS|NONE
D005200_D001749 CID FANFT_19\NNP| (r_npadvmod) induced_21\VBN|bladder (r_amod) carcinomas_23\NNS|NONE
D001241_D001749 NONE aspirin_5\NN|NONE (r_pobj) of_4\IN|to|The| (r_prep) administration_3\NN|in|. (r_nsubj) resulted_13\VBD|NONE (l_prep) in_14\IN|administration|. (l_pobj) incidence_17\NN|NONE (l_prep) of_18\IN|reduced|but|induction|a (l_pobj) carcinomas_23\NNS|NONE
D005200_D063646 NONE FANFT_16\NNP|in (r_compound) carcinogenesis_17\NN|NONE
D005200_D063646 NONE FANFT_30\NNP|NONE (r_pobj) on_29\IN|aspirin|in (r_prep) effect_28\NN|due|that|not (r_nsubj) is_34\VBZ|,|that|are|and|in|mechanisms (r_conj) involved_14\VBN|NONE (l_prep) in_15\IN|,|is|that|are|and|mechanisms (l_pobj) carcinogenesis_17\NN|NONE
D001241_D063646 NONE aspirin_26\NN|on|in (r_poss) effect_28\NN|due|that|not (r_nsubj) is_34\VBZ|,|that|are|and|in|mechanisms (r_conj) involved_14\VBN|NONE (l_prep) in_15\IN|,|is|that|are|and|mechanisms (l_pobj) carcinogenesis_17\NN|NONE
D001241_D013274 NONE aspirin_5\NN|NONE (r_pobj) of_4\IN|to|The| (r_prep) administration_3\NN|in|. (r_nsubj) resulted_13\VBD|NONE (l_prep) in_14\IN|administration|. (l_pobj) incidence_17\NN|NONE (l_conj) induction_27\NN|reduced|but|of|a (l_prep) of_28\IN|a|concomitant (l_pobj) tumors_30\NNS|NONE
6540303
D002395_D002389 NONE catecholamines_10\NNS|NONE (r_pobj) of_9\IN|the|on (r_prep) role_8\NN|in|to (l_prep) on_14\IN|of|the (l_pobj) catatonia_18\NN|NONE
D000588_D002389 NONE amine_2\NN|on (r_compound) pretreatment_3\NN|NONE (l_prep) on_4\IN|amine (l_pobj) catatonia_6\NN|NONE
D009638_D002389 NONE norepinephrine_22\NN|NONE (r_pobj) with_21\IN|NONE (r_prep) pretreatment_20\NN|not|. (r_nsubj) did_23\VBD|,|,|In|after|duration|pretreatment|but (r_conj) increased_8\VBD|NONE (l_dobj) duration_10\NN|,|did|,|In|after|pretreatment|but (l_prep) of_11\IN|the (l_pobj) catatonia_12\NNP|NONE
D007649_D002389 CID ketamine_5\NN|NONE (r_compound) catatonia_6\NN|NONE
D007649_D002389 CID ketamine_15\NN| (r_npadvmod) induced_17\VBN|NONE (r_amod) catatonia_18\NN|NONE
D007649_D002389 CID ketamine_17\NN|NONE (r_pobj) after_16\IN|,|did|,|In|duration|pretreatment|but (r_prep) increased_8\VBD|NONE (l_dobj) duration_10\NN|,|did|,|In|after|pretreatment|but (l_prep) of_11\IN|the (l_pobj) catatonia_12\NNP|NONE
D007649_D002389 CID ketamine_15\NN|than (r_compound) catatonia_16\NNP|NONE
D004298_D002389 CID dopamine_7\NN|NONE (r_pobj) with_6\IN|NONE (r_prep) pretreatment_5\NN|,|did|,|In|after|duration|but (r_nsubj) increased_8\VBD|NONE (l_dobj) duration_10\NN|,|did|,|In|after|pretreatment|but (l_prep) of_11\IN|the (l_pobj) catatonia_12\NNP|NONE
D004298_D002389 CID dopamine_2\NN|Furthermore|.|act|, (r_nsubj) appeared_3\VBD|NONE (l_xcomp) act_5\VB|dopamine|Furthermore|.|, (l_prep) on_6\IN|to (l_pobj) systems_7\NNS|NONE (l_acl) involved_10\JJ|NONE (l_prep) with_11\IN|closely (l_pobj) induction_13\NN|NONE (l_prep) of_14\IN|the|on (l_pobj) catatonia_16\NNP|NONE
1286498
D005442_D010146 NONE flumazenil_11\JJ|pain|and|the (r_compound) group_12\NN|NONE (l_conj) pain_19\NN|and|the|flumazenil
D005442_D009325 CID flumazenil_11\JJ|pain|and|the (r_compound) group_12\NN|NONE (r_pobj) in_9\IN|NONE (r_prep) vomiting_8\VBG|and (r_conj) nausea_6\NN|effects|.
D005442_D009325 CID flumazenil_11\JJ|pain|and|the (r_compound) group_12\NN|NONE (l_conj) pain_19\NN|and|the|flumazenil (l_nmod) nausea_14\NN|in
D005442_D014839 CID flumazenil_11\JJ|pain|and|the (r_compound) group_12\NN|NONE (r_pobj) in_9\IN|NONE (r_prep) vomiting_8\VBG|and
3412544
D010615_D007680 CID phenacetin_13\NN|NONE (r_pobj) of_12\IN|increased|, (r_prep) consumption_11\NN|NONE (l_relcl) increased_17\VBD|,|of (l_dobj) risk_19\NN|which|but|for|also (l_prep) for_20\IN|the (l_pobj) cancer_21\NN|NONE (l_prep) of_22\IN|NONE (l_pobj) pelvis_25\NN|NONE (l_conj) bladder_27\NN|the|and|renal
D010615_D007680 NONE phenacetin_22\JJ|NONE (r_pobj) of_20\IN|NONE (r_prep) consumption_19\NN|NONE (r_pobj) with_18\IN|NONE (r_prep) associated_17\VBN|the|ureter|,|renal (r_acl) pelvis_12\NN|NONE (l_conj) ureter_14\NN|associated|the|,|renal (l_conj) bladder_16\NN|or
D000082_D014516 NONE paracetamol_24\NNP|either|or (r_conj) phenacetin_22\JJ|NONE (r_pobj) of_20\IN|NONE (r_prep) consumption_19\NN|NONE (r_pobj) with_18\IN|NONE (r_prep) associated_17\VBN|the|ureter|,|renal (r_acl) pelvis_12\NN|NONE (l_conj) ureter_14\NN|associated|the|,|renal (l_conj) bladder_16\NN|or
D000082_D014516 NONE paracetamol_12\JJ|NONE (r_compound) consumption_13\NN|NONE (r_pobj) from_11\IN|an|or|any|for|increased (r_prep) risk_10\NN|to (r_dobj) substantiate_7\VB|NONE (r_xcomp) unable_5\JJ|By|we|.|was|, (r_acomp) were_4\VBD|NONE (l_advcl) was_25\VBD|By|unable|we|.|, (l_attr) suggestion_27\NN|although|there (l_prep) of_28\IN|a (l_pobj) association_30\NN|NONE (l_prep) with_31\IN|an (l_pobj) cancer_32\NN|NONE (l_prep) of_33\IN|NONE (l_pobj) ureter_35\NN|NONE
D000082_D014523 NONE paracetamol_1\JJ|Does|cancer|? (r_nsubj) cause_2\VB|NONE (l_dobj) cancer_4\NN|Does|paracetamol|?
D000082_D007681 NONE paracetamol_1\JJ|Does|cancer|? (r_nsubj) cause_2\VB|NONE (l_dobj) cancer_4\NN|Does|paracetamol|? (l_conj) necrosis_8\NN|urothelial|or
D000082_D007681 NONE paracetamol_24\NNP|either|or (r_conj) phenacetin_22\JJ|NONE (r_pobj) of_20\IN|NONE (r_prep) consumption_19\NN|NONE (r_pobj) with_18\IN|NONE (r_prep) associated_17\VBN|the|ureter|,|renal (r_acl) pelvis_12\NN|NONE (r_pobj) of_9\IN|renal|cancer|or|papillary (r_prep) necrosis_6\NN|NONE
D000082_D007681 NONE paracetamol_12\JJ|NONE (r_compound) consumption_13\NN|NONE (r_pobj) from_11\IN|an|or|any|for|increased (r_prep) risk_10\NN|to (l_prep) for_14\IN|an|from|or|any|increased (l_pobj) necrosis_17\NN|NONE
D000082_D009369 NONE paracetamol_12\JJ|NONE (r_compound) consumption_13\NN|NONE (r_pobj) from_11\IN|an|or|any|for|increased (r_prep) risk_10\NN|to (l_conj) any_19\DT|an|from|or|for|increased (l_prep) of_20\IN|NONE (l_pobj) cancers_22\NNS|NONE
D010615_D001749 CID phenacetin_13\NN|NONE (r_pobj) of_12\IN|increased|, (r_prep) consumption_11\NN|NONE (l_relcl) increased_17\VBD|,|of (l_dobj) risk_19\NN|which|but|for|also (l_prep) for_20\IN|the (l_pobj) cancer_21\NN|NONE (l_prep) of_22\IN|NONE (l_pobj) pelvis_25\NN|NONE (l_conj) bladder_27\NN|the|and|renal
D010615_D001749 NONE phenacetin_22\JJ|NONE (r_pobj) of_20\IN|NONE (r_prep) consumption_19\NN|NONE (r_pobj) with_18\IN|NONE (r_prep) associated_17\VBN|the|ureter|,|renal (r_acl) pelvis_12\NN|NONE (l_conj) ureter_14\NN|associated|the|,|renal (l_conj) bladder_16\NN|or
D000082_D007680 NONE paracetamol_24\NNP|either|or (r_conj) phenacetin_22\JJ|NONE (r_pobj) of_20\IN|NONE (r_prep) consumption_19\NN|NONE (r_pobj) with_18\IN|NONE (r_prep) associated_17\VBN|the|ureter|,|renal (r_acl) pelvis_12\NN|NONE (l_conj) ureter_14\NN|associated|the|,|renal (l_conj) bladder_16\NN|or
D000082_D001749 NONE paracetamol_24\NNP|either|or (r_conj) phenacetin_22\JJ|NONE (r_pobj) of_20\IN|NONE (r_prep) consumption_19\NN|NONE (r_pobj) with_18\IN|NONE (r_prep) associated_17\VBN|the|ureter|,|renal (r_acl) pelvis_12\NN|NONE (l_conj) ureter_14\NN|associated|the|,|renal (l_conj) bladder_16\NN|or
D010615_D014516 NONE phenacetin_22\JJ|NONE (r_pobj) of_20\IN|NONE (r_prep) consumption_19\NN|NONE (r_pobj) with_18\IN|NONE (r_prep) associated_17\VBN|the|ureter|,|renal (r_acl) pelvis_12\NN|NONE (l_conj) ureter_14\NN|associated|the|,|renal (l_conj) bladder_16\NN|or
D010615_D014516 NONE phenacetin_13\NN|NONE (r_pobj) of_12\IN|increased|, (r_prep) consumption_11\NN|NONE (l_relcl) increased_17\VBD|,|of (l_conj) for_30\IN|which|risk|but|also (l_pobj) cancer_32\NN|not
D010615_D007681 CID phenacetin_22\JJ|NONE (r_pobj) of_20\IN|NONE (r_prep) consumption_19\NN|NONE (r_pobj) with_18\IN|NONE (r_prep) associated_17\VBN|the|ureter|,|renal (r_acl) pelvis_12\NN|NONE (r_pobj) of_9\IN|renal|cancer|or|papillary (r_prep) necrosis_6\NN|NONE
D010615_D007681 CID phenacetin_13\NN|NONE (r_pobj) of_12\IN|increased|, (r_prep) consumption_11\NN|NONE (r_pobj) by_10\IN|risk|fold|was|. (r_agent) increased_7\VBN|NONE (l_nsubjpass) risk_1\NN|by|fold|was|. (l_prep) of_2\IN|The (l_pobj) necrosis_5\NN|NONE
12691807
D007980_D004421 CID Levodopa_0\NNP|dystonia||. (r_npadvmod) induced_2\VBN|NONE (l_dobj) dystonia_4\NN||.|Levodopa
D007980_D013494 NONE Levodopa_0\NNP|dystonia||. (r_npadvmod) induced_2\VBN|NONE (l_dobj) dystonia_4\NN||.|Levodopa (l_prep) in_5\IN|oromandibular (l_pobj) palsy_8\JJ|NONE
D007980_D013494 NONE levodopa_10\NN| (r_npadvmod) induced_12\VBN|(|)|OMD|Oromandibular|reversible (r_amod) dystonia_14\NN|NONE (r_pobj) of_8\IN|in|an|unusual (r_prep) case_7\NN|we|In|highlight|. (l_prep) in_18\IN|of|an|unusual (l_pobj) patient_21\NN|NONE (l_compound) PSP_20\NNP|a
D007980_D013494 NONE levodopa_10\NN| (r_npadvmod) induced_12\VBN|(|)|OMD|Oromandibular|reversible (r_amod) dystonia_14\NN|NONE (r_pobj) of_8\IN|in|an|unusual (r_prep) case_7\NN|we|In|highlight|. (r_dobj) describe_4\VBP|NONE (l_advcl) highlight_23\VB|case|we|In|. (l_dobj) importance_25\NN|to (l_prep) of_26\IN|the (l_pcomp) recognizing_27\VBG|NONE (l_dobj) complication_31\NN|,|discuss|and (l_prep) in_32\IN|related|this (l_pobj) management_34\NN|NONE (l_prep) of_35\IN|the (l_pobj) PSP_36\NNP|NONE
D007980_D010300 NONE Levodopa_0\NNP| (r_npadvmod) induced_2\VBN|NONE (r_amod) dyskinesias_3\NNS|.|have|in|been (r_nsubjpass) reported_6\VBN|NONE (l_prep) in_7\IN|.|have|dyskinesias|been (l_pobj) disease_10\NN|NONE
D007980_D004409 NONE Levodopa_0\NNP| (r_npadvmod) induced_2\VBN|NONE (r_amod) dyskinesias_3\NNS|.|have|in|been
D007980_D019578 NONE Levodopa_0\NNP| (r_npadvmod) induced_2\VBN|NONE (r_amod) dyskinesias_3\NNS|.|have|in|been (r_nsubjpass) reported_6\VBN|NONE (l_prep) in_7\IN|.|have|dyskinesias|been (l_pobj) disease_10\NN|NONE (l_conj) atrophy_14\NN|and|Parkinson
D007980_D008538 NONE levodopa_10\NN| (r_npadvmod) induced_12\VBN|(|)|OMD|Oromandibular|reversible (r_amod) dystonia_14\NN|NONE
D007980_D008538 NONE levodopa_10\NN| (r_npadvmod) induced_12\VBN|(|)|OMD|Oromandibular|reversible (r_amod) dystonia_14\NN|NONE (l_appos) OMD_16\NNP|(|)|induced|Oromandibular|reversible
230316
D006912_D020258 NONE hydroxyquinolines_3\NNS|NONE (r_pobj) of_1\IN|analysis|: (r_prep) Neurotoxicity_0\NN|outside|.
D006912_D020258 NONE hydroxyquinolines_13\NNS|NONE (r_pobj) to_11\IN|possible|neurotoxic (r_prep) reactions_10\NNS|NONE (l_amod) neurotoxic_9\JJ|possible|to
D007464_C538178 NONE clioquinol_13\NN|many|had (l_prep) as_14\IN|NONE (l_pobj) treatment_15\NN|NONE (l_prep) for_16\IN|NONE (l_pobj) enteropathica_18\NN|NONE
D007464_D009422 NONE clioquinol_25\NN|NONE (r_pobj) of_24\IN|high|a|over (r_prep) dose_23\NN|NONE (r_pobj) of_20\IN|the (r_prep) ingestion_19\NN|NONE (r_pobj) to_17\IN|usually (r_prep) related_16\VBN|acute|an|reversible (r_acl) encephalopathy_14\NN|NONE (r_pobj) of_10\IN|disturbance (r_prep) consisted_9\VBD|probable|the (l_nsubj) disturbance_8\NN|of
D007464_D001927 CID clioquinol_25\NN|NONE (r_pobj) of_24\IN|high|a|over (r_prep) dose_23\NN|NONE (r_pobj) of_20\IN|the (r_prep) ingestion_19\NN|NONE (r_pobj) to_17\IN|usually (r_prep) related_16\VBN|acute|an|reversible (r_acl) encephalopathy_14\NN|NONE
2008831
D008755_D000788 NONE methylergonovine_6\NN|NONE (r_pobj) of_5\IN|intracoronary|in|direct (r_prep) administration_4\NN|NONE (l_prep) in_7\IN|of|intracoronary|direct (l_pobj) patients_8\NNS|NONE (l_prep) with_9\IN|NONE (l_conj) without_11\IN|and (l_pobj) angina_13\NN|NONE
D008755_D000788 NONE methylergonovine_6\NN|NONE (r_pobj) of_5\IN|intracoronary (r_prep) administration_4\NN|NONE (r_pobj) of_2\IN|The (r_prep) effects_1\NNS|without|.|were|in (r_nsubjpass) studied_8\VBN|NONE (l_prep) in_9\IN|without|.|effects|were (l_pobj) patients_11\NNS|NONE (l_prep) with_12\IN| (l_pobj) angina_14\NN|NONE
D008755_D000788 NONE methylergonovine_19\NN|NONE (r_pobj) of_18\IN|low|a (r_prep) dose_17\NN|NONE (r_pobj) of_13\IN|intracoronary|an (r_prep) injection_12\NN|which (r_dobj) use_9\VBP|,|,|provocation|spasm (r_relcl) tests_6\NNS|be|and|that|sensitivity (r_nsubj) have_21\VBP|results|. (l_dobj) sensitivity_24\NN|be|tests|and|that (l_prep) in_25\IN|a|high (l_pobj) angina_27\NN|NONE
D008755_D002637 NONE methylergonovine_6\NN|NONE (r_pobj) of_5\IN|intracoronary (r_prep) administration_4\NN|NONE (r_pobj) of_2\IN|The (r_prep) effects_1\NNS|without|.|were|in (r_nsubjpass) studied_8\VBN|NONE (l_prep) in_9\IN|without|.|effects|were (l_pobj) patients_11\NNS|NONE (l_prep) with_12\IN| (l_pobj) angina_14\NN|NONE (l_conj) patients_17\NNS|variant|and (l_prep) with_18\IN| (l_pobj) pain_21\NN|and|in
D008755_D013035 NONE methylergonovine_19\NN|NONE (r_pobj) of_18\IN|low|a (r_prep) dose_17\NN|NONE (r_pobj) of_13\IN|intracoronary|an (r_prep) injection_12\NN|which (r_dobj) use_9\VBP|,|,|provocation|spasm (r_relcl) tests_6\NNS|be|and|that|sensitivity (l_compound) spasm_4\NN|,|use|,|provocation
D008755_D000787 NONE methylergonovine_6\NN|NONE (r_pobj) of_5\IN|intracoronary (r_prep) administration_4\NN|NONE (r_pobj) of_2\IN|The (r_prep) effects_1\NNS|without|.|were|in (r_nsubjpass) studied_8\VBN|NONE (l_prep) without_25\IN|.|effects|were|in (l_pobj) angina_26\NN|NONE (l_appos) pectoris_27\NN|NONE
1636026
D014527_D007674 NONE acid_39\NN|NONE (r_pobj) of_37\IN||/|mg (r_prep) dL_36\NN|NONE (r_pobj) of_32\IN|the (r_prep) addition_31\NN|NONE (r_pobj) without_29\IN|or (r_conj) with_27\IN|free (r_prep) buffer_26\NN|NONE (r_pobj) with_22\IN|NONE (r_prep) perfused_21\VBN|the|rat|isolated|recirculating (r_acl) kidney_20\NN|NONE (r_pobj) in_15\IN|mg|effects|.|were (r_prep) compared_14\VBN|NONE (l_nsubjpass) effects_3\NNS|mg|in|.|were (l_amod) nephrotoxic_2\JJ|of|The|direct
D013496_D007674 NONE suprofen_12\NN|NONE (r_pobj) of_11\IN|NONE (r_prep) mg_10\NN|effects|in|.|were (r_nsubjpass) compared_14\VBN|NONE (l_nsubjpass) effects_3\NNS|mg|in|.|were (l_amod) nephrotoxic_2\JJ|of|The|direct
D013496_D058186 CID suprofen_1\NN|with|been|Although|has (r_nsubjpass) associated_4\VBN|mechanism|,|.|unclear (l_prep) with_5\IN|been|Although|has|suprofen (l_pobj) development_7\NN|NONE (l_prep) of_8\IN|in|the (l_pobj) failure_11\NN|NONE
D013496_D058186 CID suprofen_3\VB|,|.|likely|,|declines|In (r_nsubj) causes_4\VBZ|NONE (l_dobj) declines_6\NNS|suprofen|,|.|likely|,|In (l_prep) in_7\IN|acute (l_pobj) function_9\NN|NONE
D014527_D058186 NONE acid_21\NN|NONE (r_pobj) of_19\IN|the|intrarenal (r_prep) distribution_18\NN|directly (r_dobj) altering_15\VBG|NONE (r_pcomp) by_13\IN|most (r_prep) likely_12\JJ|suprofen|,|.|,|declines|In (r_advcl) causes_4\VBZ|NONE (l_dobj) declines_6\NNS|suprofen|,|.|likely|,|In (l_prep) in_7\IN|acute (l_pobj) function_9\NN|NONE
15266215
D004008_D001172 NONE diclofenac_35\NN|mg|, (r_nmod) bid_38\NN|(|nonselective|ibuprofen (r_appos) NSAID_33\NNP|by|was|.|incidence|, (l_npadvmod) ibuprofen_40\VBD|(|nonselective|bid (l_conj) data_53\NNS|tid|naproxen|and|,|or (l_prep) from_54\IN|placebo (l_pobj) trials_61\NNS|NONE (l_compound) arthritis_60\NN|were|osteoarthritis
D009288_D013927 NONE naproxen_46\NN|tid|data|and|,|or (r_conj) ibuprofen_40\VBD|(|nonselective|bid (r_npadvmod) NSAID_33\NNP|by|was|.|incidence|, (r_appos) determined_19\VBN|NONE (l_nsubjpass) incidence_1\NN|by|was|.|NSAID|, (l_prep) of_2\IN|The (l_pobj) events_5\NNS|NONE (l_amod) thrombotic_4\JJ|(|thrombotic|)|cardiovascular
D009288_D013927 NONE naproxen_46\NN|tid|data|and|,|or (r_conj) ibuprofen_40\VBD|(|nonselective|bid (r_npadvmod) NSAID_33\NNP|by|was|.|incidence|, (r_appos) determined_19\VBN|NONE (l_nsubjpass) incidence_1\NN|by|was|.|NSAID|, (l_prep) of_2\IN|The (l_pobj) events_5\NNS|NONE (l_appos) thrombotic_16\JJ|(|)|cardiovascular|thrombotic
D009288_D001172 NONE naproxen_46\NN|tid|data|and|,|or (r_conj) ibuprofen_40\VBD|(|nonselective|bid (l_conj) data_53\NNS|tid|naproxen|and|,|or (l_prep) from_54\IN|placebo (l_pobj) trials_61\NNS|NONE (l_compound) arthritis_60\NN|were|osteoarthritis
D007052_D001172 NONE ibuprofen_40\VBD|(|nonselective|bid (l_conj) data_53\NNS|tid|naproxen|and|,|or (l_prep) from_54\IN|placebo (l_pobj) trials_61\NNS|NONE (l_compound) arthritis_60\NN|were|osteoarthritis
D007052_D010003 NONE ibuprofen_40\VBD|(|nonselective|bid (l_conj) data_53\NNS|tid|naproxen|and|,|or (l_prep) from_54\IN|placebo (l_pobj) trials_61\NNS|NONE (l_nmod) osteoarthritis_57\NN|arthritis|were
C406224_D001168 NONE valdecoxib_6\NNS|NONE (l_prep) versus_7\IN|specific|the|cyclooxygenase|inhibitor (l_pobj) agents_10\NNS|NONE (l_conj) placebo_12\NN|and|antiinflammatory|nonsteroidal (l_prep) on_13\IN|NONE (l_pobj) events_16\NNS|NONE (l_prep) in_17\IN|cardiovascular|thrombotic (l_pobj) patients_18\NNS|NONE (l_prep) with_19\IN|NONE (l_pobj) arthritis_20\NN|NONE
C406224_D013927 NONE valdecoxib_6\NNS|NONE (l_prep) versus_7\IN|specific|the|cyclooxygenase|inhibitor (l_pobj) agents_10\NNS|NONE (l_conj) placebo_12\NN|and|antiinflammatory|nonsteroidal (l_prep) on_13\IN|NONE (l_pobj) events_16\NNS|NONE (l_amod) thrombotic_15\JJ|cardiovascular|in
C406224_D013927 NONE valdecoxib_23\NNS|NONE (r_dobj) analyzing_21\VBG|NONE (r_pcomp) by_20\IN|was|.|NSAID|incidence|, (r_prep) determined_19\VBN|NONE (l_nsubjpass) incidence_1\NN|by|was|.|NSAID|, (l_prep) of_2\IN|The (l_pobj) events_5\NNS|NONE (l_amod) thrombotic_4\JJ|(|thrombotic|)|cardiovascular
C406224_D013927 NONE valdecoxib_23\NNS|NONE (r_dobj) analyzing_21\VBG|NONE (r_pcomp) by_20\IN|was|.|NSAID|incidence|, (r_prep) determined_19\VBN|NONE (l_nsubjpass) incidence_1\NN|by|was|.|NSAID|, (l_prep) of_2\IN|The (l_pobj) events_5\NNS|NONE (l_appos) thrombotic_16\JJ|(|)|cardiovascular|thrombotic
C406224_D013927 NONE valdecoxib_12\NNS|NONE (r_pobj) for_11\IN|NONE (r_prep) similar_10\JJ|.|incidences (r_acomp) were_9\VBD|NONE (l_nsubj) incidences_5\NNS|similar|. (l_prep) of_6\IN|adjusted|Crude (l_pobj) events_8\NNS|NONE (l_amod) thrombotic_7\JJ|NONE
C406224_D013927 NONE valdecoxib_11\NN|each (r_compound) dose_12\NN|NONE (r_pobj) for_9\IN|NONE (r_prep) similar_8\JJ|.|risk|also (r_acomp) was_6\VBD|NONE (l_nsubj) risk_1\NN|.|similar|also (l_prep) of_2\IN|The (l_pobj) events_5\NNS|NONE (l_amod) thrombotic_4\JJ|serious
C406224_D013927 NONE valdecoxib_23\NN|;|%|, (r_conj) placebo_15\NN|(|)|of (r_appos) nonusers_11\NNS|NONE (r_pobj) than_10\IN|aspirin (r_prep) users_9\NNS|NONE (r_pobj) of_7\IN|NONE (r_prep) users_6\NNS|NONE (r_pobj) for_5\IN|higher|.|risk (r_prep) was_2\VBD|NONE (l_nsubj) risk_1\NN|higher|.|for (l_amod) Thrombotic_0\JJ|NONE
C406224_D013927 NONE valdecoxib_24\NN|NONE (r_compound) doses_25\NNS|Short|term|with (r_conj) treatment_5\NN|not|with|was|. (r_nsubjpass) associated_28\VBN|NONE (l_prep) with_29\IN|not|treatment|was|. (l_pobj) incidence_32\NN|NONE (l_prep) of_33\IN|increased|an (l_pobj) events_35\NNS|NONE (l_amod) thrombotic_34\JJ|relative
D001241_D013927 CID aspirin_8\NN|than (r_compound) users_9\NNS|NONE (r_pobj) of_7\IN|NONE (r_prep) users_6\NNS|NONE (r_pobj) for_5\IN|higher|.|risk (r_prep) was_2\VBD|NONE (l_nsubj) risk_1\NN|higher|.|for (l_amod) Thrombotic_0\JJ|NONE
D001241_D013927 CID aspirin_13\NN|NONE (r_pobj) of_12\IN|(|placebo|) (r_prep) nonusers_11\NNS|NONE (r_pobj) than_10\IN|aspirin (r_prep) users_9\NNS|NONE (r_pobj) of_7\IN|NONE (r_prep) users_6\NNS|NONE (r_pobj) for_5\IN|higher|.|risk (r_prep) was_2\VBD|NONE (l_nsubj) risk_1\NN|higher|.|for (l_amod) Thrombotic_0\JJ|NONE
C406224_D010003 NONE valdecoxib_6\NNS|NONE (r_pobj) for_5\IN|,|event|cardiovascular|inhibitor (r_prep) data_4\NNS|.|We (l_appos) inhibitor_11\NN|for|,|event|cardiovascular (l_prep) in_12\IN|a|treated|COXspecific|new (l_pobj) patients_15\NNS|NONE (l_prep) with_16\IN| (l_pobj) osteoarthritis_17\NN|NONE
C406224_D010003 NONE valdecoxib_23\NNS|NONE (r_dobj) analyzing_21\VBG|NONE (r_pcomp) by_20\IN|was|.|NSAID|incidence|, (r_prep) determined_19\VBN|NONE (l_appos) NSAID_33\NNP|by|was|.|incidence|, (l_npadvmod) ibuprofen_40\VBD|(|nonselective|bid (l_conj) data_53\NNS|tid|naproxen|and|,|or (l_prep) from_54\IN|placebo (l_pobj) trials_61\NNS|NONE (l_nmod) osteoarthritis_57\NN|arthritis|were
C406224_D010003 NONE valdecoxib_24\NN|NONE (r_compound) doses_25\NNS|Short|term|with (r_conj) treatment_5\NN|not|with|was|. (r_nsubjpass) associated_28\VBN|NONE (l_prep) with_29\IN|not|treatment|was|. (l_pobj) incidence_32\NN|NONE (l_prep) of_33\IN|increased|an (l_pobj) events_35\NNS|NONE (l_amod) relative_36\JJ|thrombotic (l_prep) to_37\IN|NONE (l_pobj) NSAIDs_39\NNPS|NONE (l_prep) in_42\IN|or|nonselective|placebo|in (l_pobj) patients_47\NNS|NONE (l_nmod) osteoarthritis_43\NN|arthritis
D004008_D013927 NONE diclofenac_35\NN|mg|, (r_nmod) bid_38\NN|(|nonselective|ibuprofen (r_appos) NSAID_33\NNP|by|was|.|incidence|, (r_appos) determined_19\VBN|NONE (l_nsubjpass) incidence_1\NN|by|was|.|NSAID|, (l_prep) of_2\IN|The (l_pobj) events_5\NNS|NONE (l_amod) thrombotic_4\JJ|(|thrombotic|)|cardiovascular
D004008_D013927 NONE diclofenac_35\NN|mg|, (r_nmod) bid_38\NN|(|nonselective|ibuprofen (r_appos) NSAID_33\NNP|by|was|.|incidence|, (r_appos) determined_19\VBN|NONE (l_nsubjpass) incidence_1\NN|by|was|.|NSAID|, (l_prep) of_2\IN|The (l_pobj) events_5\NNS|NONE (l_appos) thrombotic_16\JJ|(|)|cardiovascular|thrombotic
C406224_D001172 NONE valdecoxib_6\NNS|NONE (r_pobj) for_5\IN|,|event|cardiovascular|inhibitor (r_prep) data_4\NNS|.|We (l_appos) inhibitor_11\NN|for|,|event|cardiovascular (l_prep) in_12\IN|a|treated|COXspecific|new (l_pobj) patients_15\NNS|NONE (l_prep) with_16\IN| (l_pobj) osteoarthritis_17\NN|NONE (l_conj) arthritis_20\NN|and
C406224_D001172 NONE valdecoxib_23\NNS|NONE (r_dobj) analyzing_21\VBG|NONE (r_pcomp) by_20\IN|was|.|NSAID|incidence|, (r_prep) determined_19\VBN|NONE (l_appos) NSAID_33\NNP|by|was|.|incidence|, (l_npadvmod) ibuprofen_40\VBD|(|nonselective|bid (l_conj) data_53\NNS|tid|naproxen|and|,|or (l_prep) from_54\IN|placebo (l_pobj) trials_61\NNS|NONE (l_compound) arthritis_60\NN|were|osteoarthritis
C406224_D001172 NONE valdecoxib_24\NN|NONE (r_compound) doses_25\NNS|Short|term|with (r_conj) treatment_5\NN|not|with|was|. (r_nsubjpass) associated_28\VBN|NONE (l_prep) with_29\IN|not|treatment|was|. (l_pobj) incidence_32\NN|NONE (l_prep) of_33\IN|increased|an (l_pobj) events_35\NNS|NONE (l_amod) relative_36\JJ|thrombotic (l_prep) to_37\IN|NONE (l_pobj) NSAIDs_39\NNPS|NONE (l_prep) in_42\IN|or|nonselective|placebo|in (l_pobj) patients_47\NNS|NONE (l_compound) arthritis_46\NN|osteoarthritis
D007052_D013927 NONE ibuprofen_40\VBD|(|nonselective|bid (r_npadvmod) NSAID_33\NNP|by|was|.|incidence|, (r_appos) determined_19\VBN|NONE (l_nsubjpass) incidence_1\NN|by|was|.|NSAID|, (l_prep) of_2\IN|The (l_pobj) events_5\NNS|NONE (l_amod) thrombotic_4\JJ|(|thrombotic|)|cardiovascular
D007052_D013927 NONE ibuprofen_40\VBD|(|nonselective|bid (r_npadvmod) NSAID_33\NNP|by|was|.|incidence|, (r_appos) determined_19\VBN|NONE (l_nsubjpass) incidence_1\NN|by|was|.|NSAID|, (l_prep) of_2\IN|The (l_pobj) events_5\NNS|NONE (l_appos) thrombotic_16\JJ|(|)|cardiovascular|thrombotic
D009288_D010003 NONE naproxen_46\NN|tid|data|and|,|or (r_conj) ibuprofen_40\VBD|(|nonselective|bid (l_conj) data_53\NNS|tid|naproxen|and|,|or (l_prep) from_54\IN|placebo (l_pobj) trials_61\NNS|NONE (l_nmod) osteoarthritis_57\NN|arthritis|were
D004008_D010003 NONE diclofenac_35\NN|mg|, (r_nmod) bid_38\NN|(|nonselective|ibuprofen (r_appos) NSAID_33\NNP|by|was|.|incidence|, (l_npadvmod) ibuprofen_40\VBD|(|nonselective|bid (l_conj) data_53\NNS|tid|naproxen|and|,|or (l_prep) from_54\IN|placebo (l_pobj) trials_61\NNS|NONE (l_nmod) osteoarthritis_57\NN|arthritis|were
4090988
D000082_D008113 CID paracetamol_2\NN|NONE (l_prep) of_3\IN|in (l_pobj) tumours_7\NNS|NONE
D000082_D008113 CID paracetamol_8\NN| (r_npadvmod) treated_10\VBN|NONE (r_amod) rats_11\NNS|NONE (r_pobj) of_7\IN|the (r_prep) livers_6\NNS|NONE (r_pobj) of_4\IN|An|microscope (r_prep) study_3\NN|.|changes (r_nsubj) revealed_12\VBD|NONE (l_dobj) changes_14\NNS|.|study (l_relcl) resemble_19\VBP|ultrastructural|in (l_dobj) those_20\DT|that (l_relcl) result_22\NN|NONE (l_prep) from_23\IN|that (l_pobj) exposure_24\NN|NONE (l_prep) to_25\IN|NONE (l_pobj) variety_27\NN|NONE (l_prep) of_28\IN|a (l_pobj) hepatocarcinogens_30\NNS|NONE
D000082_D006965 CID paracetamol_7\NN| (r_npadvmod) treated_9\VBN|NONE (r_amod) rats_10\NNS|NONE (r_pobj) of_6\IN| (r_prep) %_5\NN|hyperplasia|Additionally|.|, (r_nsubj) developed_11\VBD|NONE (l_dobj) hyperplasia_12\NN|%|Additionally|.|,
D000082_D009369 NONE paracetamol_12\JJ|NONE (r_compound) feeding_13\NN|NONE (r_dobj) following_11\VBG|also|.|yield (r_prep) arose_10\VBD|NONE (l_nsubj) yield_2\NN|following|also|. (l_prep) of_3\IN|low|at|A (l_pobj) tumours_4\NNS|NONE
D000082_D010212 NONE paracetamol_11\RB| (r_npadvmod) treated_13\VBN|all (r_amod) groups_14\NNS|NONE (r_pobj) in_9\IN|bore|and|,|Papillomas (r_prep) developed_8\VBN|NONE (l_nsubj) Papillomas_0\NNP|bore|and|,|in
D000082_D001744 NONE paracetamol_7\NN| (r_npadvmod) treated_9\VBN|NONE (r_amod) rats_10\NNS|NONE (r_pobj) of_6\IN| (r_prep) %_5\NN|hyperplasia|Additionally|.|, (r_nsubj) developed_11\VBD|NONE (l_dobj) hyperplasia_12\NN|%|Additionally|.|, (l_prep) of_13\IN|NONE (l_pobj) epithelium_16\NN|NONE (l_relcl) was_19\VBD|bladder|,|the (l_acomp) coincident_21\JJ|which|not (l_prep) with_22\IN|NONE (l_pobj) presence_24\NN|NONE (l_prep) of_25\IN|the (l_pobj) calculi_27\NNS|NONE
D000082_D001749 CID paracetamol_2\NN|NONE (l_prep) of_3\IN|in (l_pobj) tumours_7\NNS|NONE
D000082_D001749 CID paracetamol_11\RB| (r_npadvmod) treated_13\VBN|all (r_amod) groups_14\NNS|NONE (r_pobj) in_9\IN|bore|and|,|Papillomas (r_prep) developed_8\VBN|NONE (l_conj) bore_19\VBD|and|,|in|Papillomas (l_dobj) carcinomas_21\NNS|rats|.
20533999
D004298_D020258 NONE Dopamine_0\NN|not|essential|. (r_nsubj) is_1\VBZ|NONE (l_acomp) essential_3\JJ|Dopamine|not|. (l_prep) for_4\IN|NONE (l_pobj) development_6\NN|NONE (l_prep) of_7\IN|the (l_pobj) neurotoxicity_11\NN|NONE
D004298_D020258 NONE DA_29\NNP|induced (r_compound) neurotoxicity_30\NN|NONE
D004298_D020258 NONE DA_13\NN|NONE (r_pobj) in_11\IN|NONE (r_prep) deficient_10\JJ|to (r_acomp) be_9\VB|mice|develop|that|genetically (r_xcomp) engineered_7\VBN|we|Further|.|, (l_conj) develop_14\VBP|be|mice|that|genetically (l_dobj) neurotoxicity_16\NN|,|long
D004298_D020258 NONE DA_7\NNP|and|that|essential|not|suggest (r_nsubj) is_8\VBZ|,|Taken|findings|. (l_acomp) essential_10\JJ|and|that|not|DA|suggest (l_prep) for_11\IN|NONE (l_pobj) development_13\NN|NONE (l_prep) of_14\IN|the (l_pobj) neurotoxicity_19\NN|NONE
D004298_D020258 NONE DA_26\JJ|NONE (r_pobj) of_25\IN|NONE (r_prep) independent_24\JJ|NONE (r_amod) mechanisms_23\NNS|investigation|that (r_nsubj) warrant_27\NN|NONE (r_ccomp) suggest_21\VBP|and|that|essential|not|DA (r_conj) is_8\VBZ|,|Taken|findings|. (l_acomp) essential_10\JJ|and|that|not|DA|suggest (l_prep) for_11\IN|NONE (l_pobj) development_13\NN|NONE (l_prep) of_14\IN|the (l_pobj) neurotoxicity_19\NN|NONE
D019805_D020258 NONE tyrosine_24\NN|NONE (l_prep) on_25\IN||para (l_pobj) neurotoxicity_30\NN|NONE
D007980_D020258 NONE dihydroxyphenylalanine_11\NN|NONE (r_pobj) of_8\IN|reverse|reported|the (r_prep) ability_7\NN|by|also|is|that (l_acl) reverse_13\VB|reported|of|the (l_dobj) effect_16\NN|to (l_prep) of_17\IN|protective|the (l_pobj) tyrosine_24\NN|NONE (l_prep) on_25\IN||para (l_pobj) neurotoxicity_30\NN|NONE
D008694_D020258 CID methamphetamine_8\NN| (r_npadvmod) induced_10\VBN|NONE (r_amod) neurotoxicity_11\NN|NONE
D008694_D020258 CID METH_26\NNP| (r_npadvmod) induced_28\VBN|DA (r_amod) neurotoxicity_30\NN|NONE
D008694_D020258 CID METH_15\NNP|NONE (r_compound) neurotoxicity_16\NN|,|long
D008694_D020258 CID METH_25\NNP|NONE (r_pobj) of_24\IN|thermic|the (r_prep) effects_23\NNS|are|as (r_nsubjpass) preserved_27\VBN|as (r_advcl) long_19\RB|neurotoxicity|, (r_advmod) develop_14\VBP|be|mice|that|genetically (l_dobj) neurotoxicity_16\NN|,|long
D008694_D020258 CID METH_15\NNP| (r_npadvmod) induced_17\VBN|dopaminergic (r_amod) neurotoxicity_19\NN|NONE
D004298_D009461 NONE DA_13\NNP|unilateral (r_compound) deficits_14\NNS|to (r_dobj) have_10\VB|mice|develop|that|genetically (r_xcomp) engineered_8\VBN|In|we|.|, (l_conj) develop_15\VBP|mice|that|genetically|have (l_dobj) deficits_20\NNS|NONE
D008694_D009461 NONE METH_16\NN| (r_npadvmod) induced_18\VBN|dopaminergic|are (r_amod) deficits_20\NNS|NONE
D008694_D064420 NONE methamphetamine_10\NN|that|dopamine|decrease (l_acl) METH)-induced_12\JJ|(|, (l_dobj) toxicity_13\NN|brain
D008694_D064420 NONE methamphetamine_10\NN|that|dopamine|decrease (r_dobj) mediates_9\VBZ|is|.|It|widely (l_advcl) decrease_26\NN|methamphetamine|that|dopamine (l_dobj) toxicity_27\NN|because|enhance|drugs|,
D008694_D064420 NONE methamphetamine_10\NN|that|dopamine|decrease (r_dobj) mediates_9\VBZ|is|.|It|widely (l_advcl) decrease_26\NN|methamphetamine|that|dopamine (l_advcl) enhance_35\VB|because|toxicity|drugs|, (l_dobj) toxicity_36\NN|drugs|whereas
D008694_D064420 NONE METH)-induced_12\JJ|(|, (l_dobj) toxicity_13\NN|brain
D008694_D064420 NONE METH)-induced_12\JJ|(|, (r_acl) methamphetamine_10\NN|that|dopamine|decrease (r_dobj) mediates_9\VBZ|is|.|It|widely (l_advcl) decrease_26\NN|methamphetamine|that|dopamine (l_dobj) toxicity_27\NN|because|enhance|drugs|,
D008694_D064420 NONE METH)-induced_12\JJ|(|, (r_acl) methamphetamine_10\NN|that|dopamine|decrease (r_dobj) mediates_9\VBZ|is|.|It|widely (l_advcl) decrease_26\NN|methamphetamine|that|dopamine (l_advcl) enhance_35\VB|because|toxicity|drugs|, (l_dobj) toxicity_36\NN|drugs|whereas
D004298_D064420 NONE dopamine_5\NN|methamphetamine|that|decrease (r_nsubj) mediates_9\VBZ|is|.|It|widely (l_dobj) methamphetamine_10\NN|that|dopamine|decrease (l_acl) METH)-induced_12\JJ|(|, (l_dobj) toxicity_13\NN|brain
D004298_D064420 NONE dopamine_5\NN|methamphetamine|that|decrease (r_nsubj) mediates_9\VBZ|is|.|It|widely (l_advcl) decrease_26\NN|methamphetamine|that|dopamine (l_dobj) toxicity_27\NN|because|enhance|drugs|,
D004298_D064420 NONE dopamine_5\NN|methamphetamine|that|decrease (r_nsubj) mediates_9\VBZ|is|.|It|widely (l_advcl) decrease_26\NN|methamphetamine|that|dopamine (l_advcl) enhance_35\VB|because|toxicity|drugs|, (l_dobj) toxicity_36\NN|drugs|whereas
D004298_D064420 NONE DA_7\NNP|NONE (r_appos) dopamine_5\NN|methamphetamine|that|decrease (r_nsubj) mediates_9\VBZ|is|.|It|widely (l_dobj) methamphetamine_10\NN|that|dopamine|decrease (l_acl) METH)-induced_12\JJ|(|, (l_dobj) toxicity_13\NN|brain
D004298_D064420 NONE DA_7\NNP|NONE (r_appos) dopamine_5\NN|methamphetamine|that|decrease (r_nsubj) mediates_9\VBZ|is|.|It|widely (l_advcl) decrease_26\NN|methamphetamine|that|dopamine (l_dobj) toxicity_27\NN|because|enhance|drugs|,
D004298_D064420 NONE DA_7\NNP|NONE (r_appos) dopamine_5\NN|methamphetamine|that|decrease (r_nsubj) mediates_9\VBZ|is|.|It|widely (l_advcl) decrease_26\NN|methamphetamine|that|dopamine (l_advcl) enhance_35\VB|because|toxicity|drugs|, (l_dobj) toxicity_36\NN|drugs|whereas
D004298_D064420 NONE DA_24\NNP|NONE (r_compound) neurotransmission_25\NN|NONE (r_pobj) with_23\IN|that (r_prep) interfere_22\VBP|NONE (r_relcl) drugs_20\NNS|because|enhance|toxicity|, (r_nsubj) decrease_26\NN|methamphetamine|that|dopamine (r_advcl) mediates_9\VBZ|is|.|It|widely (l_dobj) methamphetamine_10\NN|that|dopamine|decrease (l_acl) METH)-induced_12\JJ|(|, (l_dobj) toxicity_13\NN|brain
D004298_D064420 NONE DA_24\NNP|NONE (r_compound) neurotransmission_25\NN|NONE (r_pobj) with_23\IN|that (r_prep) interfere_22\VBP|NONE (r_relcl) drugs_20\NNS|because|enhance|toxicity|, (r_nsubj) decrease_26\NN|methamphetamine|that|dopamine (l_dobj) toxicity_27\NN|because|enhance|drugs|,
D004298_D064420 NONE DA_24\NNP|NONE (r_compound) neurotransmission_25\NN|NONE (r_pobj) with_23\IN|that (r_prep) interfere_22\VBP|NONE (r_relcl) drugs_20\NNS|because|enhance|toxicity|, (r_nsubj) decrease_26\NN|methamphetamine|that|dopamine (l_advcl) enhance_35\VB|because|toxicity|drugs|, (l_dobj) toxicity_36\NN|drugs|whereas
D004298_D064420 NONE DA_33\NNP|NONE (r_compound) neurotransmission_34\NN|that (r_dobj) increase_32\VBP|NONE (r_relcl) drugs_30\NNS|toxicity|whereas (r_nsubj) enhance_35\VB|because|toxicity|drugs|, (r_advcl) decrease_26\NN|methamphetamine|that|dopamine (r_advcl) mediates_9\VBZ|is|.|It|widely (l_dobj) methamphetamine_10\NN|that|dopamine|decrease (l_acl) METH)-induced_12\JJ|(|, (l_dobj) toxicity_13\NN|brain
D004298_D064420 NONE DA_33\NNP|NONE (r_compound) neurotransmission_34\NN|that (r_dobj) increase_32\VBP|NONE (r_relcl) drugs_30\NNS|toxicity|whereas (r_nsubj) enhance_35\VB|because|toxicity|drugs|, (r_advcl) decrease_26\NN|methamphetamine|that|dopamine (l_dobj) toxicity_27\NN|because|enhance|drugs|,
D004298_D064420 NONE DA_33\NNP|NONE (r_compound) neurotransmission_34\NN|that (r_dobj) increase_32\VBP|NONE (r_relcl) drugs_30\NNS|toxicity|whereas (r_nsubj) enhance_35\VB|because|toxicity|drugs|, (l_dobj) toxicity_36\NN|drugs|whereas
14704468
C066440_D012640 NONE Loreclezole_0\NNP|reducing|,|action|. (r_nsubj) exerted_5\VBD|NONE (l_advcl) reducing_16\VBG|,|Loreclezole|action|. (l_dobj) seizure_18\NN|NONE
11672959
D012460_D005334 CID sulphasalazine_27\NN|NONE (r_pobj) of_25\IN|a (r_prep) course_24\NN|NONE (r_pobj) of_22\IN|the|th (r_prep) day_21\NN|NONE (r_pobj) on_18\IN|NONE (r_prep) beginning_17\VBG|constellation|.|,|lady (r_advcl) developed_5\VBD|NONE (l_dobj) constellation_7\NN|.|,|beginning|lady (l_prep) of_8\IN|a (l_pobj) dermatitis_9\NN|NONE (l_conj) fever_11\NN|,
D012460_D056486 CID sulphasalazine_27\NN|NONE (r_pobj) of_25\IN|a (r_prep) course_24\NN|NONE (r_pobj) of_22\IN|the|th (r_prep) day_21\NN|NONE (r_pobj) on_18\IN|NONE (r_prep) beginning_17\VBG|constellation|.|,|lady (r_advcl) developed_5\VBD|NONE (l_dobj) constellation_7\NN|.|,|beginning|lady (l_prep) of_8\IN|a (l_pobj) dermatitis_9\NN|NONE (l_conj) fever_11\NN|, (l_conj) lymphadenopathy_13\NN|, (l_conj) hepatitis_15\NN|and
D012460_D001172 NONE sulphasalazine_27\NN|NONE (l_prep) for_28\IN|oral (l_pobj) arthritis_33\NN|NONE
D012460_D003872 CID sulphasalazine_27\NN|NONE (r_pobj) of_25\IN|a (r_prep) course_24\NN|NONE (r_pobj) of_22\IN|the|th (r_prep) day_21\NN|NONE (r_pobj) on_18\IN|NONE (r_prep) beginning_17\VBG|constellation|.|,|lady (r_advcl) developed_5\VBD|NONE (l_dobj) constellation_7\NN|.|,|beginning|lady (l_prep) of_8\IN|a (l_pobj) dermatitis_9\NN|NONE
D012460_D008206 CID sulphasalazine_27\NN|NONE (r_pobj) of_25\IN|a (r_prep) course_24\NN|NONE (r_pobj) of_22\IN|the|th (r_prep) day_21\NN|NONE (r_pobj) on_18\IN|NONE (r_prep) beginning_17\VBG|constellation|.|,|lady (r_advcl) developed_5\VBD|NONE (l_dobj) constellation_7\NN|.|,|beginning|lady (l_prep) of_8\IN|a (l_pobj) dermatitis_9\NN|NONE (l_conj) fever_11\NN|, (l_conj) lymphadenopathy_13\NN|,
16755009
D010936_D003072 NONE DCE_2\NNP|.|Therefore|,|be|may (r_nsubj) prove_4\VB|NONE (l_xcomp) be_6\VB|.|Therefore|,|may|DCE (l_attr) remedy_9\NN|to (l_prep) for_10\IN|a|improving|useful (l_pobj) management_12\NN|NONE (l_prep) of_13\IN|the (l_pobj) dysfunctions_15\NNS|NONE
D010936_D000647 NONE DCE_2\NNP|Furthermore|.|amnesia|, (r_nsubj) reversed_3\VBD|NONE (l_dobj) amnesia_5\NN|Furthermore|.|DCE|,
D002784_D003072 NONE cholesterol_30\NN|activity (r_nsubj) lowering_31\VBG|, (r_conj) property_28\NN|memory (r_dobj) improving_27\VBG|for|a|useful (r_acl) remedy_9\NN|to (l_prep) for_10\IN|a|improving|useful (l_pobj) management_12\NN|NONE (l_prep) of_13\IN|the (l_pobj) dysfunctions_15\NNS|NONE
D012601_D000647 CID scopolamine-_2\NN|served (r_nmod) amnesia_7\NN|,|.
D012601_D000647 CID scopolamine_8\NN|NONE (r_pobj) by_7\IN|NONE (r_agent) induced_6\VBN|the (r_acl) amnesia_5\NN|Furthermore|.|DCE|,
D003975_D000647 CID Diazepam-_0\NN|NONE (l_appos) amnesia_7\NN|,|.
D003975_D000647 CID diazepam_16\NN|and|(|)|mg/kg (r_conj) scopolamine_8\NN|NONE (r_pobj) by_7\IN|NONE (r_agent) induced_6\VBN|the (r_acl) amnesia_5\NN|Furthermore|.|DCE|,
17042884
D014635_D001480 NONE DVP_12\NNP|+ (r_conj) QTP_8\NNP|NONE (r_pobj) with_7\IN|related|adverse (r_prep) events_6\NNS|,|.|Similarly|different (l_amod) related_4\VBN|with|adverse (l_npadvmod) EPS_2\NNP|
D014635_D001480 NONE DVP_26\NNP|+ (r_conj) PBO_22\NNP|NONE (r_pobj) with_21\IN|NONE (r_prep) than_20\IN|no (r_prep) different_19\JJ|events|,|.|Similarly (r_acomp) were_17\VBD|NONE (l_nsubj) events_6\NNS|,|.|Similarly|different (l_amod) related_4\VBN|with|adverse (l_npadvmod) EPS_2\NNP|
C069541_D001480 NONE quetiapine_11\NN|NONE (r_pobj) with_10\IN|.|level|of (r_prep) incidence_3\NN|NONE (l_prep) of_4\IN|.|level|with (l_pobj) symptoms_6\NNS|NONE
C069541_D001480 NONE quetiapine_11\NN|NONE (r_pobj) with_10\IN|.|level|of (r_prep) incidence_3\NN|NONE (l_prep) of_4\IN|.|level|with (l_pobj) symptoms_6\NNS|NONE (l_appos) EPS_8\NNP|extrapyramidal
C069541_D001480 NONE quetiapine_14\NN|NONE (r_pobj) with_13\IN|akathisia|, (r_prep) including_10\VBG|symptoms|To|, (r_prep) evaluate_3\VB|.|: (l_dobj) symptoms_5\NNS|To|including|,
C069541_D001480 NONE quetiapine_14\NN|NONE (r_pobj) with_13\IN|akathisia|, (r_prep) including_10\VBG|symptoms|To|, (r_prep) evaluate_3\VB|.|: (l_dobj) symptoms_5\NNS|To|including|, (l_appos) EPS_7\NNP|extrapyramidal
C069541_D001480 NONE quetiapine_16\NN|(|)|% (r_amod) monotherapy_17\NN|NONE (r_pobj) with_15\IN|no|than (r_prep) different_14\JJ|incidence|. (r_acomp) was_12\VBD|NONE (l_nsubj) incidence_1\NN|.|different (l_prep) of_2\IN|,|,|The|including (l_pobj) events_7\NNS|NONE (l_amod) related_5\VBN|adverse (l_npadvmod) EPS_3\NNP|
C069541_D001480 NONE QTP_8\NNP|NONE (r_pobj) with_7\IN|related|adverse (r_prep) events_6\NNS|,|.|Similarly|different (l_amod) related_4\VBN|with|adverse (l_npadvmod) EPS_2\NNP|
C069541_D001480 NONE quetiapine_41\NN|NONE (r_pcomp) than_40\IN|,|)|syndrome|(|,|and|% (r_prep) tremor_21\NN|incidence|.|Haloperidol (l_conj) syndrome_32\NN|,|)|than|(|,|and|%
C069541_D001480 NONE quetiapine_13\NN|NONE (r_amod) therapy_14\NN|similar|.|In|,|with|incidence (r_nsubj) is_15\VBZ|NONE (l_nsubj) incidence_5\NN|similar|.|In|,|with|therapy (l_prep) of_6\IN|,|including|the|, (l_pobj) EPS_7\NNP|NONE
D006220_D014202 CID Haloperidol_0\NNP|tremor|incidence|. (r_nsubj) induced_1\VBD|NONE (l_npadvmod) tremor_21\NN|incidence|.|Haloperidol
C069541_D017109 NONE quetiapine_14\NN|NONE (r_pobj) with_13\IN|akathisia|, (r_prep) including_10\VBG|symptoms|To|, (l_pobj) akathisia_11\NN|with|,
C069541_D017109 NONE quetiapine_16\NN|(|)|% (r_amod) monotherapy_17\NN|NONE (r_pobj) with_15\IN|no|than (r_prep) different_14\JJ|incidence|. (r_acomp) was_12\VBD|NONE (l_nsubj) incidence_1\NN|.|different (l_prep) including_9\VBG|of|,|,|The (l_pobj) akathisia_10\NN|NONE
C069541_D017109 NONE quetiapine_9\NN|)|(|%|placebo|and (r_amod) monotherapy_10\NN|NONE (r_pobj) with_8\IN|NONE (r_prep) similar_7\JJ|and (r_conj) low_5\JJ|incidence|.|and|,|with (r_acomp) was_4\VBD|NONE (l_nsubj) incidence_1\NN|.|low|and|,|with (l_prep) of_2\IN|The (l_pobj) akathisia_3\NN|NONE
C069541_D017109 NONE QTP_24\NNP|NONE (r_pobj) with_23\IN|incidence|.|low|and|, (r_conj) was_4\VBD|NONE (l_nsubj) incidence_1\NN|.|low|and|,|with (l_prep) of_2\IN|The (l_pobj) akathisia_3\NN|NONE
C069541_D017109 NONE quetiapine_41\NN|NONE (r_pcomp) than_40\IN|,|)|syndrome|(|,|and|% (r_prep) tremor_21\NN|incidence|.|Haloperidol (r_npadvmod) induced_1\VBD|NONE (l_dobj) incidence_5\NN|tremor|.|Haloperidol (l_appos) 0.001_9\CD|higher|a (l_prep) of_11\IN|(|<|)|p (l_pobj) akathisia_12\NN|NONE
C069541_D017109 NONE quetiapine_13\NN|NONE (r_amod) therapy_14\NN|similar|.|In|,|with|incidence (r_nsubj) is_15\VBZ|NONE (l_nsubj) incidence_5\NN|similar|.|In|,|with|therapy (l_prep) including_9\VBG|,|the|,|of (l_pobj) akathisia_10\NN|NONE
C069541_D014202 NONE quetiapine_20\NN|NONE (r_pobj) than_19\IN|a|.|(|)|)|(|%|%|higher (r_prep) incidence_7\NN|NONE (l_appos) 0.05_11\CD|a|(|)|)|than|(|%|%|higher (l_prep) of_13\IN|<|p|)|( (l_pobj) tremor_14\NN|NONE
C069541_D014202 NONE quetiapine_20\NN|NONE (r_pobj) than_19\IN|a|.|(|)|)|(|%|%|higher (r_prep) incidence_7\NN|NONE (r_pobj) with_3\IN|Lithium|was (r_prep) associated_2\VBN|have|to|;|tremor|may|. (r_ccomp) contributed_40\VBN|NONE (l_nsubj) tremor_27\NN|have|to|associated|;|may|.
C069541_D014202 NONE quetiapine_20\NN|NONE (r_pobj) than_19\IN|a|.|(|)|)|(|%|%|higher (r_prep) incidence_7\NN|NONE (r_pobj) with_3\IN|Lithium|was (r_prep) associated_2\VBN|have|to|;|tremor|may|. (r_ccomp) contributed_40\VBN|NONE (l_prep) to_41\IN|have|associated|;|tremor|may|. (l_pobj) rate_44\NN|NONE (l_prep) of_45\IN|elevated|in|the (l_pobj) tremor_46\NN|NONE
C069541_D014202 NONE quetiapine_41\NN|NONE (r_pcomp) than_40\IN|,|)|syndrome|(|,|and|% (r_prep) tremor_21\NN|incidence|.|Haloperidol
D006220_D017109 CID Haloperidol_0\NNP|tremor|incidence|. (r_nsubj) induced_1\VBD|NONE (l_dobj) incidence_5\NN|tremor|.|Haloperidol (l_appos) 0.001_9\CD|higher|a (l_prep) of_11\IN|(|<|)|p (l_pobj) akathisia_12\NN|NONE
D014635_D017109 NONE DVP_28\NNP|+ (r_conj) QTP_24\NNP|NONE (r_pobj) with_23\IN|incidence|.|low|and|, (r_conj) was_4\VBD|NONE (l_nsubj) incidence_1\NN|.|low|and|,|with (l_prep) of_2\IN|The (l_pobj) akathisia_3\NN|NONE
D014635_D017109 NONE DVP_38\NNP|+|)|%|( (r_conj) PBO_34\NNP|and|Li|)|(|/|% (r_conj) DVP_28\NNP|+ (r_conj) QTP_24\NNP|NONE (r_pobj) with_23\IN|incidence|.|low|and|, (r_conj) was_4\VBD|NONE (l_nsubj) incidence_1\NN|.|low|and|,|with (l_prep) of_2\IN|The (l_pobj) akathisia_3\NN|NONE
D008094_D014202 CID Lithium_0\NN|with|was (r_nsubjpass) associated_2\VBN|have|to|;|tremor|may|. (l_prep) with_3\IN|Lithium|was (l_pobj) incidence_7\NN|NONE (l_appos) 0.05_11\CD|a|(|)|)|than|(|%|%|higher (l_prep) of_13\IN|<|p|)|( (l_pobj) tremor_14\NN|NONE
D008094_D014202 CID Lithium_0\NN|with|was (r_nsubjpass) associated_2\VBN|have|to|;|tremor|may|. (r_ccomp) contributed_40\VBN|NONE (l_nsubj) tremor_27\NN|have|to|associated|;|may|.
D008094_D014202 CID Lithium_0\NN|with|was (r_nsubjpass) associated_2\VBN|have|to|;|tremor|may|. (r_ccomp) contributed_40\VBN|NONE (l_prep) to_41\IN|have|associated|;|tremor|may|. (l_pobj) rate_44\NN|NONE (l_prep) of_45\IN|elevated|in|the (l_pobj) tremor_46\NN|NONE
D008094_D014202 CID lithium_36\NN|NONE (r_pobj) of_35\IN|adverse|a|known (r_prep) effect_34\NN|which (r_attr) is_30\VBZ|cerebellar|,|, (r_relcl) tremor_27\NN|have|to|associated|;|may|. (r_nsubj) contributed_40\VBN|NONE (l_ccomp) associated_2\VBN|have|to|;|tremor|may|. (l_prep) with_3\IN|Lithium|was (l_pobj) incidence_7\NN|NONE (l_appos) 0.05_11\CD|a|(|)|)|than|(|%|%|higher (l_prep) of_13\IN|<|p|)|( (l_pobj) tremor_14\NN|NONE
D008094_D014202 CID lithium_36\NN|NONE (r_pobj) of_35\IN|adverse|a|known (r_prep) effect_34\NN|which (r_attr) is_30\VBZ|cerebellar|,|, (r_relcl) tremor_27\NN|have|to|associated|;|may|.
D008094_D014202 CID lithium_36\NN|NONE (r_pobj) of_35\IN|adverse|a|known (r_prep) effect_34\NN|which (r_attr) is_30\VBZ|cerebellar|,|, (r_relcl) tremor_27\NN|have|to|associated|;|may|. (r_nsubj) contributed_40\VBN|NONE (l_prep) to_41\IN|have|associated|;|tremor|may|. (l_pobj) rate_44\NN|NONE (l_prep) of_45\IN|elevated|in|the (l_pobj) tremor_46\NN|NONE
D008094_D014202 CID lithium_50\NN|NONE (r_compound) therapy_51\NN|NONE (r_dobj) receiving_49\VBG|NONE (r_acl) patients_48\NNS|NONE (r_pobj) in_47\IN|elevated|of|the (r_prep) rate_44\NN|NONE (r_pobj) to_41\IN|have|associated|;|tremor|may|. (r_prep) contributed_40\VBN|NONE (l_ccomp) associated_2\VBN|have|to|;|tremor|may|. (l_prep) with_3\IN|Lithium|was (l_pobj) incidence_7\NN|NONE (l_appos) 0.05_11\CD|a|(|)|)|than|(|%|%|higher (l_prep) of_13\IN|<|p|)|( (l_pobj) tremor_14\NN|NONE
D008094_D014202 CID lithium_50\NN|NONE (r_compound) therapy_51\NN|NONE (r_dobj) receiving_49\VBG|NONE (r_acl) patients_48\NNS|NONE (r_pobj) in_47\IN|elevated|of|the (r_prep) rate_44\NN|NONE (r_pobj) to_41\IN|have|associated|;|tremor|may|. (r_prep) contributed_40\VBN|NONE (l_nsubj) tremor_27\NN|have|to|associated|;|may|.
D008094_D014202 CID lithium_50\NN|NONE (r_compound) therapy_51\NN|NONE (r_dobj) receiving_49\VBG|NONE (r_acl) patients_48\NNS|NONE (r_pobj) in_47\IN|elevated|of|the (r_prep) rate_44\NN|NONE (l_prep) of_45\IN|elevated|in|the (l_pobj) tremor_46\NN|NONE
D008094_D001480 CID Li_10\NNP|)|/|%|( (r_nmod) DVP_12\NNP|+ (r_conj) QTP_8\NNP|NONE (r_pobj) with_7\IN|related|adverse (r_prep) events_6\NNS|,|.|Similarly|different (l_amod) related_4\VBN|with|adverse (l_npadvmod) EPS_2\NNP|
D008094_D001480 CID Li_24\NNP|/|%|(|) (r_nmod) DVP_26\NNP|+ (r_conj) PBO_22\NNP|NONE (r_pobj) with_21\IN|NONE (r_prep) than_20\IN|no (r_prep) different_19\JJ|events|,|.|Similarly (r_acomp) were_17\VBD|NONE (l_nsubj) events_6\NNS|,|.|Similarly|different (l_amod) related_4\VBN|with|adverse (l_npadvmod) EPS_2\NNP|
D008094_D001480 CID lithium_28\NN|NONE (r_pobj) with_27\IN|NONE (r_prep) treated_26\VBN|NONE (r_acl) patients_25\NNS|NONE (r_pobj) of_24\IN|. (r_prep) %_23\NN|NONE (r_pobj) whereas_21\IN|with (r_prep) treated_11\VBN|NONE (r_acl) patients_10\NNS|NONE (r_pobj) of_9\IN|. (r_prep) %_8\NN|NONE (r_pobj) in_6\IN|events|) (r_prep) occurred_5\VBD|NONE (l_nsubj) events_1\NNS|in|) (l_acl) related_2\VBN|Adverse (l_prep) to_3\IN|NONE (l_pobj) EPS_4\NNP|NONE
D006220_D001480 CID haloperidol_13\NN|NONE (r_pobj) with_12\IN|whereas (r_prep) treated_11\VBN|NONE (r_acl) patients_10\NNS|NONE (r_pobj) of_9\IN|. (r_prep) %_8\NN|NONE (r_pobj) in_6\IN|events|) (r_prep) occurred_5\VBD|NONE (l_nsubj) events_1\NNS|in|) (l_acl) related_2\VBN|Adverse (l_prep) to_3\IN|NONE (l_pobj) EPS_4\NNP|NONE
D006220_D001480 CID Haloperidol_0\NNP|tremor|incidence|. (r_nsubj) induced_1\VBD|NONE (l_npadvmod) tremor_21\NN|incidence|.|Haloperidol (l_conj) syndrome_32\NN|,|)|than|(|,|and|%
D008094_D017109 NONE Li_26\NNP|and|)|(|/|%|PBO (r_nmod) DVP_28\NNP|+ (r_conj) QTP_24\NNP|NONE (r_pobj) with_23\IN|incidence|.|low|and|, (r_conj) was_4\VBD|NONE (l_nsubj) incidence_1\NN|.|low|and|,|with (l_prep) of_2\IN|The (l_pobj) akathisia_3\NN|NONE
D008094_D017109 NONE Li_36\NNP|/ (r_compound) DVP_38\NNP|+|)|%|( (r_conj) PBO_34\NNP|and|Li|)|(|/|% (r_conj) DVP_28\NNP|+ (r_conj) QTP_24\NNP|NONE (r_pobj) with_23\IN|incidence|.|low|and|, (r_conj) was_4\VBD|NONE (l_nsubj) incidence_1\NN|.|low|and|,|with (l_prep) of_2\IN|The (l_pobj) akathisia_3\NN|NONE
C069541_D001714 NONE quetiapine_11\NN|NONE (l_prep) in_12\IN|NONE (l_pobj) studies_14\NNS|NONE (l_prep) of_15\IN|controlled (l_pobj) patients_16\NNS|NONE (l_prep) with_17\IN|NONE (l_pobj) mania_19\NN|NONE
C069541_D001714 NONE quetiapine_14\NN|NONE (l_prep) in_15\IN|NONE (l_pobj) patients_16\NNS|NONE (l_prep) with_17\IN|NONE (l_pobj) mania_19\NN|NONE
C069541_D001714 NONE quetiapine_13\NN|NONE (r_amod) therapy_14\NN|similar|.|In|,|with|incidence (r_nsubj) is_15\VBZ|NONE (l_prep) In_0\IN|similar|.|,|with|therapy|incidence (l_pobj) mania_2\NN|NONE
326460
D013999_D007008 NONE timolol_7\NN|NONE (r_pobj) by_6\IN|of|. (r_prep) Amelioration_0\NN|NONE (l_prep) of_1\IN|by|. (l_pobj) hypokalemia_5\NN|NONE
D013999_D007008 NONE timolol_6\NN|,|The|,|beta|blocking (r_appos) drug_4\NN|and|correct|was (r_nsubj) tended_8\VBD|NONE (l_xcomp) correct_10\VB|and|drug|was (l_dobj) hypokalemia_12\NN|to
D001539_D007008 CID bendrofluazide_2\NN| (r_advmod) induced_4\VBN|NONE (r_amod) hypokalemia_5\NN|NONE
D001539_D007008 CID bendrofluazide_17\NN|term|in (r_amod) treatment_18\NN|NONE (r_pobj) of_13\IN|the (r_prep) hypokalemia_12\NN|to
7710775
D008315_D002545 CID malondialdehyde_4\NN|NONE (r_pobj) of_2\IN|Time (r_prep) dependence_1\NN|nucleosides|and|,|. (r_nsubj) oxypurines_6\NNS|NONE (l_conj) nucleosides_9\NNS|dependence|and|,|. (l_prep) during_10\IN|NONE (l_pobj) ischemia_13\NN|NONE
-1_D002545 NONE oxypurines_6\NNS|NONE (l_conj) nucleosides_9\NNS|dependence|and|,|. (l_prep) during_10\IN|NONE (l_pobj) ischemia_13\NN|NONE
D009599_D007511 NONE nitroprusside_4\NN|hypotensive|the (r_acl) drug_3\NN|NONE (r_pobj) of_0\IN|.|,|intravenously|was|during|/ (r_prep) min_13\NN|NONE (l_prep) during_15\IN|.|,|intravenously|was|/|of (l_pobj) ischemia_16\NN|NONE
D008315_D007511 NONE malondialdehyde_1\NN|,|.|resulting|after (r_nsubj) increased_23\VBD|NONE (l_prep) after_24\IN|,|malondialdehyde|.|resulting (l_pobj) min_26\NN|NONE (l_prep) of_27\IN| (l_pobj) ischemia_28\NN|NONE
D008315_D007511 NONE malondialdehyde_23\NN|NONE (r_pobj) in_19\IN|although|higher (r_prep) was_24\VBD|.|,|intravenously|during|/|of (r_advcl) min_13\NN|NONE (l_prep) during_15\IN|.|,|intravenously|was|/|of (l_pobj) ischemia_16\NN|NONE
D008315_D007511 NONE malondialdehyde_8\NN|NONE (r_pobj) of_7\IN|the (r_prep) determination_6\NN|,|that|be|monitor|may (r_nsubjpass) used_20\VBN|data|. (l_xcomp) monitor_22\VB|,|that|determination|be|may (l_dobj) alterations_25\NNS|to (l_acl) occurring_28\VBG|metabolic|the|of (l_prep) during_29\IN|NONE (l_pobj) phenomena_31\NNS|NONE (l_amod) ischemic_30\JJ|NONE
D009705_D002545 NONE nucleosides_9\NNS|dependence|and|,|. (l_prep) during_10\IN|NONE (l_pobj) ischemia_13\NN|NONE
D001241_D007511 NONE acetylsalicylate_4\VBP|NONE (l_prep) before_7\IN|of|,|other|. (l_pobj) ischemia_8\NN|immediately|intravenously
D008315_D007022 NONE malondialdehyde_23\NN|NONE (r_pobj) in_19\IN|although|higher (r_prep) was_24\VBD|.|,|intravenously|during|/|of (r_advcl) min_13\NN|NONE (l_prep) of_0\IN|.|,|intravenously|was|during|/ (l_pobj) drug_3\NN|NONE (l_amod) hypotensive_2\JJ|nitroprusside|the
D009705_D007511 NONE nucleosides_12\NNS|and|plasma (r_conj) oxypurines_10\NNS|NONE (r_pobj) of_8\IN|a|dependent (r_prep) increase_7\NN|During|,|was|. (r_nsubjpass) observed_14\VBN|NONE (l_prep) During_0\IN|,|was|.|increase (l_pobj) ischemia_1\NN|NONE
D009705_D007511 NONE nucleosides_13\NNS|,|and (r_conj) oxypurines_10\NNS|, (r_conj) malondialdehyde_8\NN|NONE (r_pobj) of_7\IN|the (r_prep) determination_6\NN|,|that|be|monitor|may (r_nsubjpass) used_20\VBN|data|. (l_xcomp) monitor_22\VB|,|that|determination|be|may (l_dobj) alterations_25\NNS|to (l_acl) occurring_28\VBG|metabolic|the|of (l_prep) during_29\IN|NONE (l_pobj) phenomena_31\NNS|NONE (l_amod) ischemic_30\JJ|NONE
-1_D007511 NONE oxypurines_10\NNS|NONE (r_pobj) of_8\IN|a|dependent (r_prep) increase_7\NN|During|,|was|. (r_nsubjpass) observed_14\VBN|NONE (l_prep) During_0\IN|,|was|.|increase (l_pobj) ischemia_1\NN|NONE
-1_D007511 NONE oxypurines_10\NNS|, (r_conj) malondialdehyde_8\NN|NONE (r_pobj) of_7\IN|the (r_prep) determination_6\NN|,|that|be|monitor|may (r_nsubjpass) used_20\VBN|data|. (l_xcomp) monitor_22\VB|,|that|determination|be|may (l_dobj) alterations_25\NNS|to (l_acl) occurring_28\VBG|metabolic|the|of (l_prep) during_29\IN|NONE (l_pobj) phenomena_31\NNS|NONE (l_amod) ischemic_30\JJ|NONE
D009599_D007022 NONE nitroprusside_4\NN|hypotensive|the (r_acl) drug_3\NN|NONE (l_amod) hypotensive_2\JJ|nitroprusside|the
17344330
D008691_D016171 NONE methadone_21\NN|NONE (r_compound) users_22\NNS|NONE (r_pobj) in_20\IN|Prolongation|has|been|. (r_prep) reported_19\VBN|NONE (l_nsubjpass) Prolongation_0\NN|has|been|.|in (l_prep) of_1\IN|NONE (l_pobj) interval_4\NN|NONE (l_prep) in_5\IN|the|QT (l_pobj) ECG_7\NNP|NONE (l_prep) of_8\IN|the (l_pobj) patients_9\NNS|NONE (l_prep) with_10\IN|NONE (l_pobj) pointes_13\FW|NONE
D008691_D016171 NONE methadone_21\NN|NONE (r_compound) users_22\NNS|NONE (r_pobj) in_20\IN|Prolongation|has|been|. (r_prep) reported_19\VBN|NONE (l_nsubjpass) Prolongation_0\NN|has|been|.|in (l_prep) of_1\IN|NONE (l_pobj) interval_4\NN|NONE (l_prep) in_5\IN|the|QT (l_pobj) ECG_7\NNP|NONE (l_prep) of_8\IN|the (l_pobj) patients_9\NNS|NONE (l_prep) with_10\IN|NONE (l_pobj) pointes_13\FW|NONE (l_appos) TdP_15\NN|(|)|de|torsade
D008691_D016171 NONE methadone_53\NN|NONE (r_pobj) of_52\IN|the|proarrhythmic (r_prep) effect_51\NN|NONE (r_pobj) by_48\IN|,|may|mortality|be|.|,|in (r_agent) caused_47\VBN|might|underestimate|episodes|and|and|,|faint|,|doctors (r_conj) attribute_12\VB|NONE (l_conj) underestimate_24\VBP|might|caused|episodes|and|and|,|faint|,|doctors (l_dobj) incidence_26\NN|thereby (l_prep) of_27\IN|in|the (l_pobj) TdP_28\NNP|NONE
D003932_D016171 NONE heroin_1\NN|NONE (r_compound) addicts_2\NNS|using|sometimes|As (r_nsubj) faint_4\JJ|might|underestimate|caused|episodes|and|and|,|,|doctors (r_advcl) attribute_12\VB|NONE (l_conj) underestimate_24\VBP|might|caused|episodes|and|and|,|faint|,|doctors (l_dobj) incidence_26\NN|thereby (l_prep) of_27\IN|in|the (l_pobj) TdP_28\NNP|NONE
D003932_D008133 NONE heroin_10\NN|in (r_compound) dependence_11\NN|NONE (r_pobj) for_9\IN|with (r_prep) treated_6\VBN|NONE (r_acl) patients_5\NNS|NONE (r_pobj) among_4\IN|and|.|prolongation (r_prep) Syncope_0\NNP|NONE (l_conj) prolongation_3\NN|among|and|.
D003932_D008133 NONE heroin_15\NN|NONE (r_compound) addicts_16\NNS|NONE (r_pobj) of_14\IN|a (r_prep) population_13\NN|NONE (r_pobj) in_11\IN|NONE (r_prep) syncope_10\NN|NONE (r_pobj) of_9\IN|higher (r_prep) reporting_8\NN|and|QT (r_conj) prolongation_5\NN|NONE
D008691_D008133 CID methadone_8\NN|NONE (r_pobj) with_7\IN|for (r_prep) treated_6\VBN|NONE (r_acl) patients_5\NNS|NONE (r_pobj) among_4\IN|and|.|prolongation (r_prep) Syncope_0\NNP|NONE (l_conj) prolongation_3\NN|among|and|.
D008691_D008133 CID methadone_5\NN|NONE (r_pobj) with_4\IN|NONE (r_prep) treated_3\VBN|the (r_acl) subjects_2\NNS|NONE (r_pobj) Among_0\IN|.|interval (r_prep) had_14\VBD|NONE (l_dobj) interval_17\NN|Among|.
D008691_D008133 CID Methadone_0\NNP|is|with|. (r_nsubjpass) associated_2\VBN|NONE (l_prep) with_3\IN|is|Methadone|. (l_pobj) prolongation_5\NN|NONE
D008691_D013575 CID methadone_8\NN|NONE (r_pobj) with_7\IN|for (r_prep) treated_6\VBN|NONE (r_acl) patients_5\NNS|NONE (r_pobj) among_4\IN|and|.|prolongation (r_prep) Syncope_0\NNP|NONE
D008691_D013575 CID methadone_53\NN|NONE (r_pobj) of_52\IN|the|proarrhythmic (r_prep) effect_51\NN|NONE (r_pobj) by_48\IN|,|may|mortality|be|.|,|in (r_agent) caused_47\VBN|might|underestimate|episodes|and|and|,|faint|,|doctors (r_conj) attribute_12\VB|NONE (l_dobj) episodes_15\NNS|might|underestimate|caused|and|and|,|faint|,|doctors (l_prep) of_16\IN|many (l_pobj) syncope_17\NN|NONE
D008691_D013575 CID methadone_9\NN|reporting|and (r_compound) dose_10\NN|and|opioid|,|and|QT (l_conj) reporting_12\NN|methadone|and (l_prep) of_13\IN|NONE (l_pobj) syncope_14\NN|NONE
D008691_D013575 CID methadone_4\NN|NONE (r_compound) dose_5\NN|with|.|was (r_nsubjpass) associated_7\VBN|NONE (l_prep) with_8\IN|.|dose|was (l_pobj) CI_14\NNP|NONE (l_appos) odds_21\NNS|)|%|a|.|to (l_prep) for_22\IN|higher (l_pobj) syncope_23\NN|NONE
D008691_D013575 CID Methadone_0\NNP|is|with|. (r_nsubjpass) associated_2\VBN|NONE (l_prep) with_3\IN|is|Methadone|. (l_pobj) prolongation_5\NN|NONE (l_conj) reporting_8\NN|and|QT (l_prep) of_9\IN|higher (l_pobj) syncope_10\NN|NONE
D003932_D013575 NONE heroin_10\NN|in (r_compound) dependence_11\NN|NONE (r_pobj) for_9\IN|with (r_prep) treated_6\VBN|NONE (r_acl) patients_5\NNS|NONE (r_pobj) among_4\IN|and|.|prolongation (r_prep) Syncope_0\NNP|NONE
D003932_D013575 NONE heroin_1\NN|NONE (r_compound) addicts_2\NNS|using|sometimes|As (r_nsubj) faint_4\JJ|might|underestimate|caused|episodes|and|and|,|,|doctors (r_advcl) attribute_12\VB|NONE (l_dobj) episodes_15\NNS|might|underestimate|caused|and|and|,|faint|,|doctors (l_prep) of_16\IN|many (l_pobj) syncope_17\NN|NONE
D003932_D013575 NONE heroin_15\NN|NONE (r_compound) addicts_16\NNS|NONE (r_pobj) of_14\IN|a (r_prep) population_13\NN|NONE (r_pobj) in_11\IN|NONE (r_prep) syncope_10\NN|NONE
430165
D010672_D062787 CID diphenylhydantoin_6\NN|)|(|DPH (r_nmod) overdose_10\NN|NONE
D010672_D062787 CID DPH_8\NNP|)|diphenylhydantoin|( (r_nmod) overdose_10\NN|NONE
D010672_D062787 CID DPH_10\NNP|NONE (r_compound) overdose_11\NN|to
D010672_D002526 CID diphenylhydantoin_6\NN|)|(|DPH (r_nmod) overdose_10\NN|NONE (r_pobj) of_5\IN|common|side|the (r_prep) effects_4\NNS|NONE (r_pobj) Among_0\IN|,|those|signs|. (r_prep) are_18\VBP|NONE (l_nsubj) those_19\DT|,|Among|signs|. (l_prep) of_20\IN|NONE (l_pobj) dysfunction_22\NN|NONE
D010672_D002526 CID DPH_8\NNP|)|diphenylhydantoin|( (r_nmod) overdose_10\NN|NONE (r_pobj) of_5\IN|common|side|the (r_prep) effects_4\NNS|NONE (r_pobj) Among_0\IN|,|those|signs|. (r_prep) are_18\VBP|NONE (l_nsubj) those_19\DT|,|Among|signs|. (l_prep) of_20\IN|NONE (l_pobj) dysfunction_22\NN|NONE
D010672_D064420 NONE diphenylhydantoin_7\JJ|NONE (r_compound) toxicity_8\NN|NONE
D010672_D064420 NONE DPH_13\NNP|NONE (r_compound) toxicity_14\NN|as|to
D010672_D010291 CID diphenylhydantoin_7\JJ|NONE (r_compound) toxicity_8\NN|NONE (r_pobj) of_6\IN|a|rare (r_prep) manifestation_5\NN|:|.|Transient (r_appos) hemiparesis_1\NN|NONE
D010672_D010291 CID DPH_10\NNP|NONE (r_compound) overdose_11\NN|to (r_pobj) due_8\IN|hemiparesis|who (r_prep) suffered_5\VBD|patients|are|. (l_dobj) hemiparesis_7\NN|due|who
D010672_D001927 NONE DPH_13\NNP|NONE (r_compound) toxicity_14\NN|as|to (r_dobj) manifest_12\VB|NONE (r_xcomp) liable_10\JJ|that|patients (r_acomp) are_9\VBP|It|is|. (l_nsubj) patients_4\NNS|liable|that (l_prep) with_5\IN|NONE (l_pobj) damage_8\NN|NONE
7516729
D014700_D001919 CID verapamil_6\NN|NONE (r_pobj) by_5\IN|NONE (r_agent) induced_4\VBN|dependent (r_acl) bradycardia_3\NNS|.|was|by
6323692
D010433_D000699 NONE metrazol_37\NN|NONE (r_pobj) of_36\IN|convulsant|the (r_prep) action_35\NN|.|verapamil (r_dobj) affected_32\VBD|verapamil|and|and|antagonized|incoordination|and|, (r_conj) analgesia-_12\JJ|NONE
C018824_D000699 NONE NH4Ac_8\NNP|morphine (r_nmod) pretreatment_9\NN|i.p.|)|and|Both|mg/kg|( (r_conj) verapamil_1\NN|and|and|affected|antagonized|incoordination|and|, (r_nsubj) analgesia-_12\JJ|NONE
C018824_D000699 NONE NH4Ac_31\NNP|nor|neither (r_conj) verapamil_29\NN|.|action (r_nsubj) affected_32\VBD|verapamil|and|and|antagonized|incoordination|and|, (r_conj) analgesia-_12\JJ|NONE
D002118_D003866 NONE calcium_3\NN|NONE (r_pobj) of_1\IN|NONE (r_prep) Addition_0\NN|,|blocked|but|depression (r_nsubj) reversed_4\VBD|NONE (l_dobj) depression_6\NN|,|Addition|blocked|but
D002118_D003866 NONE calcium_12\NN| (r_npadvmod) independent_14\JJ|by|catecholamine (r_amod) release_16\NN|.|was|not|by (r_nsubjpass) blocked_21\VBN|,|Addition|but|depression (r_conj) reversed_4\VBD|NONE (l_dobj) depression_6\NN|,|Addition|blocked|but
D000079_D003866 NONE acetaldehyde_18\NN|NONE (r_pobj) by_17\IN|independent|catecholamine (r_prep) release_16\NN|.|was|not|by (r_nsubjpass) blocked_21\VBN|,|Addition|but|depression (r_conj) reversed_4\VBD|NONE (l_dobj) depression_6\NN|,|Addition|blocked|but
D003975_D001259 CID diazepam_33\NN|NONE (r_pobj) by_32\IN|increased|muscular|,|but (r_prep) incoordination_31\NN|on|mice|and|had
D003975_D001259 CID diazepam_14\NN| (r_npadvmod) induced_16\VBN|muscular (r_amod) incoordination_18\NN|verapamil|and|and|affected|antagonized|and|,
D010433_D001259 NONE metrazol_37\NN|NONE (r_pobj) of_36\IN|convulsant|the (r_prep) action_35\NN|.|verapamil (r_dobj) affected_32\VBD|verapamil|and|and|antagonized|incoordination|and|, (r_conj) analgesia-_12\JJ|NONE (l_conj) incoordination_18\NN|verapamil|and|and|affected|antagonized|and|,
C018824_D001259 CID acetate_3\NN|NONE (r_pobj) with_1\IN|NONE (r_prep) Pretreatment_0\NN|approximately|time|. (r_nsubj) doubled_15\VBD|NONE (l_npadvmod) time_17\NN|approximately|Pretreatment|. (l_relcl) remained_22\VBD|the (l_conj) incoordination_31\NN|on|mice|and|had
C018824_D001259 CID NH4Ac_5\NNP|)|(|ammonium|s.c. (r_appos) acetate_3\NN|NONE (r_pobj) with_1\IN|NONE (r_prep) Pretreatment_0\NN|approximately|time|. (r_nsubj) doubled_15\VBD|NONE (l_npadvmod) time_17\NN|approximately|Pretreatment|. (l_relcl) remained_22\VBD|the (l_conj) incoordination_31\NN|on|mice|and|had
C018824_D001259 CID NH4Ac_36\NNP|alone (r_compound) treatment_37\NN|effect (r_nsubj) had_39\VBD|on|mice|and|incoordination (r_conj) remained_22\VBD|the (l_conj) incoordination_31\NN|on|mice|and|had
C018824_D001259 CID NH4Ac_8\NNP|morphine (r_nmod) pretreatment_9\NN|i.p.|)|and|Both|mg/kg|( (r_conj) verapamil_1\NN|and|and|affected|antagonized|incoordination|and|, (r_nsubj) analgesia-_12\JJ|NONE (l_conj) incoordination_18\NN|verapamil|and|and|affected|antagonized|and|,
C018824_D001259 CID NH4Ac_31\NNP|nor|neither (r_conj) verapamil_29\NN|.|action (r_nsubj) affected_32\VBD|verapamil|and|and|antagonized|incoordination|and|, (r_conj) analgesia-_12\JJ|NONE (l_conj) incoordination_18\NN|verapamil|and|and|affected|antagonized|and|,
D002395_D003866 NONE catecholamine_15\NN|by|independent (r_compound) release_16\NN|.|was|not|by (r_nsubjpass) blocked_21\VBN|,|Addition|but|depression (r_conj) reversed_4\VBD|NONE (l_dobj) depression_6\NN|,|Addition|blocked|but
C018824_D003866 NONE NH4Ac_23\NNPS|NONE (r_pobj) by_22\IN|.|release|was|not (r_agent) blocked_21\VBN|,|Addition|but|depression (r_conj) reversed_4\VBD|NONE (l_dobj) depression_6\NN|,|Addition|blocked|but
D009020_D001259 NONE morphine_18\NN| (r_npadvmod) treated_20\VBN|NONE (r_amod) mice_21\NNS|on|and|had|incoordination (r_nsubj) remained_22\VBD|the (l_conj) incoordination_31\NN|on|mice|and|had
D009020_D001259 NONE morphine_11\NN|NHAc (r_appos) pretreatment_9\NN|i.p.|)|and|Both|mg/kg|( (r_conj) verapamil_1\NN|and|and|affected|antagonized|incoordination|and|, (r_nsubj) analgesia-_12\JJ|NONE (l_conj) incoordination_18\NN|verapamil|and|and|affected|antagonized|and|,
D000661_D001259 NONE amphetamine_21\NN| (r_npadvmod) induced_23\VBN|motor (r_amod) activity_25\NN|NONE (r_dobj) antagonized_20\VBN|verapamil|and|and|affected|incoordination|and|, (r_conj) analgesia-_12\JJ|NONE (l_conj) incoordination_18\NN|verapamil|and|and|affected|antagonized|and|,
D014700_D001259 NONE verapamil_1\NN|and|and|affected|antagonized|incoordination|and|, (r_nsubj) analgesia-_12\JJ|NONE (l_conj) incoordination_18\NN|verapamil|and|and|affected|antagonized|and|,
D014700_D001259 NONE verapamil_29\NN|.|action (r_nsubj) affected_32\VBD|verapamil|and|and|antagonized|incoordination|and|, (r_conj) analgesia-_12\JJ|NONE (l_conj) incoordination_18\NN|verapamil|and|and|affected|antagonized|and|,
D000661_D000699 NONE amphetamine_21\NN| (r_npadvmod) induced_23\VBN|motor (r_amod) activity_25\NN|NONE (r_dobj) antagonized_20\VBN|verapamil|and|and|affected|incoordination|and|, (r_conj) analgesia-_12\JJ|NONE
D003975_D000699 NONE diazepam_14\NN| (r_npadvmod) induced_16\VBN|muscular (r_amod) incoordination_18\NN|verapamil|and|and|affected|antagonized|and|, (r_conj) analgesia-_12\JJ|NONE
D014700_D000699 NONE verapamil_1\NN|and|and|affected|antagonized|incoordination|and|, (r_nsubj) analgesia-_12\JJ|NONE
D014700_D000699 NONE verapamil_29\NN|.|action (r_nsubj) affected_32\VBD|verapamil|and|and|antagonized|incoordination|and|, (r_conj) analgesia-_12\JJ|NONE
D009020_D000699 NONE morphine_11\NN|NHAc (r_appos) pretreatment_9\NN|i.p.|)|and|Both|mg/kg|( (r_conj) verapamil_1\NN|and|and|affected|antagonized|incoordination|and|, (r_nsubj) analgesia-_12\JJ|NONE
D002118_D022124 NONE calcium_7\NN|blocking|a|enhances (r_compound) channel_8\NN|hyperammonemia (r_dobj) exerts_5\VBZ|data|. (l_nsubj) hyperammonemia_4\NN|channel
16586083
D016861_D009203 CID inhibitors_25\NNS|NONE (r_pobj) with_23\IN|NONE (r_prep) treatment_22\NN|NONE (r_pobj) during_21\IN|,|hypertension (r_prep) stroke_15\NN|myocardial|, (r_conj) infarction_13\NN|NONE
D016861_D006333 CID inhibitors_25\NNS|NONE (r_pobj) with_23\IN|NONE (r_prep) treatment_22\NN|NONE (r_pobj) during_21\IN|,|hypertension (r_prep) stroke_15\NN|myocardial|, (l_conj) hypertension_17\NN|,|during (l_conj) failure_20\NN|and
D016861_D020521 CID inhibitors_25\NNS|NONE (r_pobj) with_23\IN|NONE (r_prep) treatment_22\NN|NONE (r_pobj) during_21\IN|,|hypertension (r_prep) stroke_15\NN|myocardial|,
C109794_D002318 NONE peptide_10\NN|such (r_pobj) as_3\IN|Diagnostic (r_prep) markers_1\NNS|avoiding|in|,|.|might (r_nsubj) help_25\VB|NONE (l_advcl) avoiding_36\VBG|markers|in|,|.|might (l_dobj) occurrence_38\NN|thus (l_prep) of_39\IN|the (l_pobj) toxicity_42\NN|NONE
C109794_D002318 NONE proBNP_14\NNP|natriuretic|brain|)|or|(|terminal|protein (r_appos) peptide_10\NN|such (r_pobj) as_3\IN|Diagnostic (r_prep) markers_1\NNS|avoiding|in|,|.|might (r_nsubj) help_25\VB|NONE (l_advcl) avoiding_36\VBG|markers|in|,|.|might (l_dobj) occurrence_38\NN|thus (l_prep) of_39\IN|the (l_pobj) toxicity_42\NN|NONE
D016861_D006973 CID inhibitors_25\NNS|NONE (r_pobj) with_23\IN|NONE (r_prep) treatment_22\NN|NONE (r_pobj) during_21\IN|,|hypertension (r_prep) stroke_15\NN|myocardial|, (l_conj) hypertension_17\NN|,|during
16938416
D000431_D003920 NONE alcohol_17\NN|NONE (r_compound) use_18\NN|blood|or|systolic|, (r_conj) pressure_14\NN|cholesterol|, (r_conj) level_10\NN|, (r_conj) diabetes_7\NNS|NONE
D002784_D003920 NONE cholesterol_9\NN|pressure|, (r_compound) level_10\NN|, (r_conj) diabetes_7\NNS|NONE
D013739_D050197 CID testosterone_3\NN|.|is|with (r_nsubjpass) associated_5\VBN|NONE (l_prep) with_6\IN|.|is|testosterone (l_pobj) atherosclerosis_7\NN|NONE
D013739_D050197 CID testosterone_32\NN|atherosclerosis|and|)|dose|reported|administered|esters (r_compound) therapy_33\NN|NONE (l_conj) atherosclerosis_42\NN|and|)|dose|reported|administered|esters|testosterone
D013739_D050197 CID testosterone_7\NN|dose (r_compound) therapy_8\NN|may|that|indicate|atherosclerosis|and|adversely (r_nsubj) affect_11\VB|results|. (l_dobj) atherosclerosis_12\NN|therapy|may|that|indicate|and|adversely
C032109_D050197 NONE esters_38\NNS|atherosclerosis|and|)|dose|reported|administered|testosterone (r_appos) therapy_33\NN|NONE (l_conj) atherosclerosis_42\NN|and|)|dose|reported|administered|esters|testosterone
D004967_D050197 NONE estrogen_30\NN| (r_compound) testosterone_32\NN|atherosclerosis|and|)|dose|reported|administered|esters (r_compound) therapy_33\NN|NONE (l_conj) atherosclerosis_42\NN|and|)|dose|reported|administered|esters|testosterone
950631
D010396_D001172 NONE penicillamine_18\NN|NONE (r_pobj) with_15\IN|NONE (r_prep) treatment_14\NN|NONE (r_pobj) of_13\IN| (r_prep) months_12\NNS|NONE (r_pobj) after_8\IN|.|proteinuria|patients (r_prep) developed_5\VBD|NONE (l_nsubj) patients_1\NNS|.|proteinuria|after (l_prep) with_2\IN|Four (l_pobj) arthritis_4\NN|NONE
D010396_D011507 CID penicillamine_18\NN|NONE (r_pobj) with_15\IN|NONE (r_prep) treatment_14\NN|NONE (r_pobj) of_13\IN| (r_prep) months_12\NNS|NONE (r_pobj) after_8\IN|.|proteinuria|patients (r_prep) developed_5\VBD|NONE (l_dobj) proteinuria_7\NN|.|after|patients
D010396_D007674 CID penicillamine_2\NN| (r_npadvmod) induced_4\VBN|glomerular (r_amod) disease_6\NN|NONE
3015567
D003345_D007022 NONE corticosterone_18\NN|between|a (r_compound) level_19\NN|NONE (r_pobj) at_15\IN|NONE (r_prep) occurs_14\VBZ|is|.|Suppression|and (r_conj) observed_12\VBN|NONE (l_nsubjpass) Suppression_0\NN|is|.|and|occurs (l_appos) secretion_3\NN|of (l_prep) in_4\IN|NONE (l_pobj) response_5\NN|NONE (l_prep) to_6\IN|NONE (l_pobj) hypotension_10\NN|NONE
D009599_D007022 CID Nitroprusside_0\NNP| (r_npadvmod) induced_2\VBN|NONE (r_amod) hypotension_3\NN|secretion|.
D009599_D007022 CID nitroprusside_7\RB| (r_advmod) induced_9\VBN|NONE (r_amod) hypotension_10\NN|NONE
7930386
D002997_D012893 CID Clomipramine_0\NNP| (r_npadvmod) induced_2\VBN|sleep (r_amod) disturbance_4\NN|action|not|does|.
D002997_D012893 CID clomipramine_15\NN|NONE (r_compound) administration_16\NN|NONE (r_pobj) by_14\IN|NONE (r_agent) induced_13\VBN|on|,|,|role|to (r_conj) examine_6\VB|study|.|was (l_dobj) role_8\NN|on|,|,|to|induced (l_prep) of_9\IN|the (l_pobj) disturbance_11\NN|NONE
19759529
-1_D002375 NONE SSR103800_6\NNP|,|not|However|did|Together|catalepsy|unlike|,|up|retention (r_nsubj) produce_9\VB|NONE (l_dobj) catalepsy_10\NN|,|not|However|did|SSR|Together|unlike|,|up|retention
-1_D006948 NONE SSR103800_12\NNP|NONE (r_pobj) of_11\IN|involving|like|potential|the (r_prep) properties_10\NNS|with|, (r_dobj) investigating_4\VBG|NONE (l_prep) with_14\IN|properties|, (l_pobj) focus_17\NN|NONE (l_prep) on_18\IN|,|particular|a (l_pobj) models_19\NNS|NONE (l_prep) of_20\IN|NONE (l_pobj) hyperactivity_21\NN|NONE
-1_D006948 NONE SSR103800_3\NNP|)|mg/kg|induced|p.o.|(|blocked (r_nmod) hyperactivity_12\NN|NONE
-1_D006948 NONE SSR103800_3\NNP|)|mg/kg|induced|p.o.|(|blocked (r_nmod) hyperactivity_12\NN|NONE (r_punct) that_2\IN|Results|.|reversed|and (r_dobj) showed_1\VBD|NONE (l_conj) reversed_26\VBD|Results|.|that|and (l_dobj) hyperactivity_28\NN|partially
-1_D006948 NONE SSR103800_3\NNP|,|In|affect|or|observed|) (r_nsubj) failed_4\VBD|NONE (l_xcomp) affect_6\VB|,|In|or|observed|)|SSR (l_dobj) hyperactivity_7\NN|to
C076029_D006948 NONE olanzapine_10\NN|)|,|(|aripiprazole|and (r_nmod) clozapine_12\NN|haloperidol (r_nmod) antipsychotics_16\NNS|.|effective (r_nsubj) were_17\VBD|NONE (l_acomp) effective_18\JJ|.|antipsychotics (l_prep) in_19\IN|NONE (l_pobj) models_22\NNS|NONE (l_prep) of_23\IN|all|these (l_pobj) hyperactivity_24\NN|NONE
D016291_D006948 CID MK-801_32\NNP|NONE (r_punct) )_33\-RRB-|(|ie|and|, (r_punct) amphetamine_30\NN|or|either|drug|mice (r_appos) challenge_26\NN|NONE (r_dobj) involving_23\VBG|of|like|potential|the (r_prep) properties_10\NNS|with|, (r_dobj) investigating_4\VBG|NONE (l_prep) with_14\IN|properties|, (l_pobj) focus_17\NN|NONE (l_prep) on_18\IN|,|particular|a (l_pobj) models_19\NNS|NONE (l_prep) of_20\IN|NONE (l_pobj) hyperactivity_21\NN|NONE
D016291_D006948 CID MK-801_23\NNP|NONE (r_punct) and_24\CC|Results|.|reversed|that (r_cc) showed_1\VBD|NONE (l_dobj) that_2\IN|Results|.|reversed|and (l_punct) hyperactivity_12\NN|NONE
D016291_D006948 CID MK-801_23\NNP|NONE (r_punct) and_24\CC|Results|.|reversed|that (r_cc) showed_1\VBD|NONE (l_conj) reversed_26\VBD|Results|.|that|and (l_dobj) hyperactivity_28\NN|partially
D016202_D012559 NONE aspartate_15\NNP||N (r_appos) methyl_11\NN|glutamate|the|NMDA|(|) (r_nmod) receptor_19\NN|NONE (r_pobj) of_6\IN|NONE (r_prep) antagonists_5\NNS|symptoms|that (r_nsubj) produce_20\VBP|the (l_dobj) symptoms_24\NNS|antagonists|that (l_amod) like_23\JJ|in (l_npadvmod) schizophrenic_21\JJ|
D016202_D012559 NONE NMDA_17\NNP|glutamate|the|methyl|(|) (r_nmod) receptor_19\NN|NONE (r_pobj) of_6\IN|NONE (r_prep) antagonists_5\NNS|symptoms|that (r_nsubj) produce_20\VBP|the (l_dobj) symptoms_24\NNS|antagonists|that (l_amod) like_23\JJ|in (l_npadvmod) schizophrenic_21\JJ|
D016202_D012559 NONE NMDA_41\NNP|its (r_compound) receptor_42\NN|NONE (r_pobj) via_39\IN|a|of (r_prep) dysfunctioning_34\NN|NONE (r_pobj) of_32\IN|the (r_prep) idea_31\NN|NONE (r_pobj) to_29\IN|has|observation|However|.|, (r_prep) led_28\VBN|NONE (l_nsubj) observation_3\NN|has|However|.|to|, (l_relcl) produce_20\VBP|the (l_dobj) symptoms_24\NNS|antagonists|that (l_amod) like_23\JJ|in (l_npadvmod) schizophrenic_21\JJ|
D006220_D006948 NONE haloperidol_5\NN|clozapine (r_nmod) antipsychotics_16\NNS|.|effective (r_nsubj) were_17\VBD|NONE (l_acomp) effective_18\JJ|.|antipsychotics (l_prep) in_19\IN|NONE (l_pobj) models_22\NNS|NONE (l_prep) of_23\IN|all|these (l_pobj) hyperactivity_24\NN|NONE
D016202_D006948 NONE NMDA_40\NNP|)|and|ie|,|(|DAT(/ (r_compound) Nr1(neo-/-_41\NNP|)|transgenic (r_appos) mice_36\NNS|amphetamine|or|either|drug (r_conj) challenge_26\NN|NONE (r_dobj) involving_23\VBG|of|like|potential|the (r_prep) properties_10\NNS|with|, (r_dobj) investigating_4\VBG|NONE (l_prep) with_14\IN|properties|, (l_pobj) focus_17\NN|NONE (l_prep) on_18\IN|,|particular|a (l_pobj) models_19\NNS|NONE (l_prep) of_20\IN|NONE (l_pobj) hyperactivity_21\NN|NONE
D016202_D006948 NONE NMDA_19\NNP|competitive|,|receptor|the (r_compound) antagonist_21\NN|NONE (r_pobj) by_14\IN|NONE (r_agent) induced_13\VBN|)|mg/kg|p.o.|(|blocked|SSR (r_acl) hyperactivity_12\NN|NONE
D016202_D006948 NONE NMDA_19\NNP|competitive|,|receptor|the (r_compound) antagonist_21\NN|NONE (r_pobj) by_14\IN|NONE (r_agent) induced_13\VBN|)|mg/kg|p.o.|(|blocked|SSR (r_acl) hyperactivity_12\NN|NONE (r_punct) that_2\IN|Results|.|reversed|and (r_dobj) showed_1\VBD|NONE (l_conj) reversed_26\VBD|Results|.|that|and (l_dobj) hyperactivity_28\NN|partially
D016202_D006948 NONE NMDA_30\NNP|Nr(neo/|) (r_nmod) mice_33\NNS|NONE (r_pobj) of_29\IN|spontaneous (r_prep) hyperactivity_28\NN|partially (r_dobj) reversed_26\VBD|Results|.|that|and (r_conj) showed_1\VBD|NONE (l_dobj) that_2\IN|Results|.|reversed|and (l_punct) hyperactivity_12\NN|NONE
D016202_D006948 NONE NMDA_30\NNP|Nr(neo/|) (r_nmod) mice_33\NNS|NONE (r_pobj) of_29\IN|spontaneous (r_prep) hyperactivity_28\NN|partially
D000661_D006948 CID amphetamine_30\NN|or|either|drug|mice (r_appos) challenge_26\NN|NONE (r_dobj) involving_23\VBG|of|like|potential|the (r_prep) properties_10\NNS|with|, (r_dobj) investigating_4\VBG|NONE (l_prep) with_14\IN|properties|, (l_pobj) focus_17\NN|NONE (l_prep) on_18\IN|,|particular|a (l_pobj) models_19\NNS|NONE (l_prep) of_20\IN|NONE (l_pobj) hyperactivity_21\NN|NONE
D000661_D006948 CID amphetamine_10\NN|NONE (r_pobj) by_9\IN|NONE (r_agent) induced_8\VBN|NONE (r_acl) hyperactivity_7\NN|to
C094645_D006948 NONE aripiprazole_14\NN|)|,|olanzapine|(|and (r_conj) clozapine_12\NN|haloperidol (r_nmod) antipsychotics_16\NNS|.|effective (r_nsubj) were_17\VBD|NONE (l_acomp) effective_18\JJ|.|antipsychotics (l_prep) in_19\IN|NONE (l_pobj) models_22\NNS|NONE (l_prep) of_23\IN|all|these (l_pobj) hyperactivity_24\NN|NONE
D004298_D012559 NONE dopamine_8\NN|NONE (r_compound) neurotransmission_9\NN|NONE (r_pobj) in_7\IN|NONE (r_prep) dysfunction_6\NN|NONE (r_pobj) with_5\IN|.|been|Schizophrenia|initially|has (r_prep) associated_4\VBN|NONE (l_nsubjpass) Schizophrenia_0\NNP|.|been|initially|with|has
D018698_D012559 NONE glutamate_8\NN|the|methyl|NMDA|(|) (r_nmod) receptor_19\NN|NONE (r_pobj) of_6\IN|NONE (r_prep) antagonists_5\NNS|symptoms|that (r_nsubj) produce_20\VBP|the (l_dobj) symptoms_24\NNS|antagonists|that (l_amod) like_23\JJ|in (l_npadvmod) schizophrenic_21\JJ|
D004298_D006948 NONE dopamine_15\NN|)|DAT(/|( (r_compound) transporter_16\NN|NONE (r_pobj) in_14\IN|naturally (r_prep) observed_13\VBN|,|In|affect|or|)|SSR (r_conj) failed_4\VBD|NONE (l_xcomp) affect_6\VB|,|In|or|observed|)|SSR (l_dobj) hyperactivity_7\NN|to
D003024_D006948 NONE clozapine_12\NN|haloperidol (r_nmod) antipsychotics_16\NNS|.|effective (r_nsubj) were_17\VBD|NONE (l_acomp) effective_18\JJ|.|antipsychotics (l_prep) in_19\IN|NONE (l_pobj) models_22\NNS|NONE (l_prep) of_23\IN|all|these (l_pobj) hyperactivity_24\NN|NONE
18161408
D002996_D013923 CID CC_17\NN|NONE (r_pobj) with_16\IN|ovulation (r_prep) induction_15\NN|NONE (r_pobj) after_13\IN|has|been|that (r_prep) reported_12\VBN|a|rare (r_relcl) complication_8\NN|.|Thromboembolism (r_attr) is_1\VBZ|NONE (l_nsubj) Thromboembolism_0\NN|.|complication
D002996_D009203 CID citrate_7\NN|NONE (r_pobj) with_5\IN|for (r_prep) associated_4\VBN|.|in|:|report|Myocardial (r_acl) infarction_1\NN|NONE
D002996_D009203 CID CC_13\NN|NONE (l_conj) infarction_16\NN|and
D002996_D013927 NONE CC_9\NN|NONE (r_pobj) of_8\IN|rare|a (r_prep) complication_7\NN|.|might|Thrombosis (r_attr) be_2\VB|NONE (l_nsubj) Thrombosis_0\NN|.|complication|might
D002996_D002637 NONE CC_12\NN|had|.|woman|for|presented|recently|and (r_dobj) received_11\VBN|NONE (l_conj) presented_17\VBD|had|.|CC|woman|for|recently|and (l_prep) with_18\IN|NONE (l_pobj) pain_20\NN|NONE
9431903
D005996_D013035 NONE trinitrate_3\NN|NONE (l_prep) on_4\IN|glyceryl (l_pobj) sphincter_6\NN|NONE (l_prep) of_7\IN|the (l_pobj) spasm_9\NN|NONE
D005996_D013035 NONE trinitrate_9\NN|NONE (l_prep) on_10\IN|glyceryl (l_pobj) sphincter_17\NN|NONE (l_prep) of_18\IN|the|induced (l_pobj) spasm_20\NN|NONE
D005996_D013035 NONE trinitrate_11\NN|NONE (l_prep) on_12\IN|glyceryl (l_pobj) sphincter_17\NN|NONE (l_prep) of_18\IN|the|induced (l_pobj) spasm_20\NN|NONE
D009020_D046628 CID morphine_14\NN|NONE (r_compound) administration_15\NN|NONE (r_pobj) by_11\IN|NONE (r_agent) evoked_10\VBN|Oddi (r_acl) spasm_9\NN|NONE
D009020_D046628 CID morphine_14\NN| (r_npadvmod) induced_16\VBN|the|of (r_amod) sphincter_17\NN|NONE (l_prep) of_18\IN|the|induced (l_pobj) spasm_20\NN|NONE
D009020_D046628 CID morphine_14\NN| (r_npadvmod) induced_16\VBN|the|of (r_amod) sphincter_17\NN|NONE (r_pobj) on_10\IN|glyceryl (r_prep) trinitrate_9\NN|NONE (r_pobj) of_7\IN|the (r_prep) effect_6\NN|OBJECTIVE|was|with|.|in|In|: (r_nsubjpass) evaluated_22\VBN|NONE (l_prep) with_27\IN|OBJECTIVE|was|effect|.|in|In|: (l_pobj) sphincter_28\NN|NONE (l_prep) of_29\IN|NONE (l_pobj) dyskinesia_31\NN|NONE
D009020_D046628 CID morphine_9\NN|prostigmine (r_compound) administration_10\NN|NONE (r_pobj) by_6\IN|visualized|spasm|and|was|. (r_agent) induced_5\VBN|NONE (l_nsubjpass) spasm_3\NN|visualized|by|and|was|.
D009020_D046628 CID morphine_19\NN|(|and|mg|intramuscularly|)|subcutaneously (r_conj) prostigmine_14\NN|morphine (r_parataxis) administration_10\NN|NONE (r_pobj) by_6\IN|visualized|spasm|and|was|. (r_agent) induced_5\VBN|NONE (l_nsubjpass) spasm_3\NN|visualized|by|and|was|.
D009020_D046628 CID morphine_14\NN| (r_npadvmod) induced_16\VBN|of|the (r_amod) sphincter_17\NN|NONE (l_prep) of_18\IN|the|induced (l_pobj) spasm_20\NN|NONE
D009020_D046628 CID morphine_12\NN|NONE (r_pobj) of_11\IN|even|drastic|the (r_prep) effect_10\NN|to (r_dobj) overcome_6\VB|NONE (r_xcomp) able_4\JJ|trinitrate|Since (r_acomp) is_3\VBZ|might|.|in|it|,|of (r_advcl) be_16\VB|NONE (l_prep) in_19\IN|might|.|is|it|,|of (l_pobj) treatment_21\NN|NONE (l_prep) of_22\IN|the (l_pobj) sphincter_23\NN|NONE (l_prep) of_24\IN|NONE (l_pobj) dyskinesia_26\NN|NONE
D009020_D013035 CID morphine_14\NN|NONE (r_compound) administration_15\NN|NONE (r_pobj) by_11\IN|NONE (r_agent) evoked_10\VBN|Oddi (r_acl) spasm_9\NN|NONE
D009020_D013035 CID morphine_14\NN| (r_npadvmod) induced_16\VBN|the|of (r_amod) sphincter_17\NN|NONE (l_prep) of_18\IN|the|induced (l_pobj) spasm_20\NN|NONE
D009020_D013035 CID morphine_9\NN|prostigmine (r_compound) administration_10\NN|NONE (r_pobj) by_6\IN|visualized|spasm|and|was|. (r_agent) induced_5\VBN|NONE (l_nsubjpass) spasm_3\NN|visualized|by|and|was|.
D009020_D013035 CID morphine_19\NN|(|and|mg|intramuscularly|)|subcutaneously (r_conj) prostigmine_14\NN|morphine (r_parataxis) administration_10\NN|NONE (r_pobj) by_6\IN|visualized|spasm|and|was|. (r_agent) induced_5\VBN|NONE (l_nsubjpass) spasm_3\NN|visualized|by|and|was|.
D009020_D013035 CID morphine_3\NN|NONE (r_compound) provocation_4\NN|+/|)|:|and|increases|.|indicating|. (r_nsubj) caused_5\VBD|NONE (l_advcl) indicating_97\VBG|+/|)|:|and|increases|.|provocation|. (l_dobj) spasm_100\NN|NONE
D009020_D013035 CID morphine_14\NN| (r_npadvmod) induced_16\VBN|of|the (r_amod) sphincter_17\NN|NONE (l_prep) of_18\IN|the|induced (l_pobj) spasm_20\NN|NONE
D009388_D046628 CID prostigmine_12\JJ| (r_compound) morphine_14\NN|NONE (r_compound) administration_15\NN|NONE (r_pobj) by_11\IN|NONE (r_agent) evoked_10\VBN|Oddi (r_acl) spasm_9\NN|NONE
D009388_D046628 CID prostigmine_12\JJ| (r_compound) morphine_14\NN| (r_npadvmod) induced_16\VBN|the|of (r_amod) sphincter_17\NN|NONE (l_prep) of_18\IN|the|induced (l_pobj) spasm_20\NN|NONE
D009388_D046628 CID prostigmine_12\JJ| (r_compound) morphine_14\NN| (r_npadvmod) induced_16\VBN|the|of (r_amod) sphincter_17\NN|NONE (r_pobj) on_10\IN|glyceryl (r_prep) trinitrate_9\NN|NONE (r_pobj) of_7\IN|the (r_prep) effect_6\NN|OBJECTIVE|was|with|.|in|In|: (r_nsubjpass) evaluated_22\VBN|NONE (l_prep) with_27\IN|OBJECTIVE|was|effect|.|in|In|: (l_pobj) sphincter_28\NN|NONE (l_prep) of_29\IN|NONE (l_pobj) dyskinesia_31\NN|NONE
D009388_D046628 CID prostigmine_7\JJ| (r_compound) morphine_9\NN|prostigmine (r_compound) administration_10\NN|NONE (r_pobj) by_6\IN|visualized|spasm|and|was|. (r_agent) induced_5\VBN|NONE (l_nsubjpass) spasm_3\NN|visualized|by|and|was|.
D009388_D046628 CID prostigmine_14\NN|morphine (r_parataxis) administration_10\NN|NONE (r_pobj) by_6\IN|visualized|spasm|and|was|. (r_agent) induced_5\VBN|NONE (l_nsubjpass) spasm_3\NN|visualized|by|and|was|.
D009388_D013035 CID prostigmine_12\JJ| (r_compound) morphine_14\NN|NONE (r_compound) administration_15\NN|NONE (r_pobj) by_11\IN|NONE (r_agent) evoked_10\VBN|Oddi (r_acl) spasm_9\NN|NONE
D009388_D013035 CID prostigmine_12\JJ| (r_compound) morphine_14\NN| (r_npadvmod) induced_16\VBN|the|of (r_amod) sphincter_17\NN|NONE (l_prep) of_18\IN|the|induced (l_pobj) spasm_20\NN|NONE
D009388_D013035 CID prostigmine_7\JJ| (r_compound) morphine_9\NN|prostigmine (r_compound) administration_10\NN|NONE (r_pobj) by_6\IN|visualized|spasm|and|was|. (r_agent) induced_5\VBN|NONE (l_nsubjpass) spasm_3\NN|visualized|by|and|was|.
D009388_D013035 CID prostigmine_14\NN|morphine (r_parataxis) administration_10\NN|NONE (r_pobj) by_6\IN|visualized|spasm|and|was|. (r_agent) induced_5\VBN|NONE (l_nsubjpass) spasm_3\NN|visualized|by|and|was|.
D009388_D013035 CID Prostigmine_1\JJ| (r_compound) morphine_3\NN|NONE (r_compound) provocation_4\NN|+/|)|:|and|increases|.|indicating|. (r_nsubj) caused_5\VBD|NONE (l_advcl) indicating_97\VBG|+/|)|:|and|increases|.|provocation|. (l_dobj) spasm_100\NN|NONE
D005996_D046628 NONE trinitrate_3\NN|NONE (l_prep) on_4\IN|glyceryl (l_pobj) sphincter_6\NN|NONE (l_prep) of_7\IN|the (l_pobj) spasm_9\NN|NONE
D005996_D046628 NONE trinitrate_9\NN|NONE (l_prep) on_10\IN|glyceryl (l_pobj) sphincter_17\NN|NONE (l_prep) of_18\IN|the|induced (l_pobj) spasm_20\NN|NONE
D005996_D046628 NONE trinitrate_9\NN|NONE (r_pobj) of_7\IN|the (r_prep) effect_6\NN|OBJECTIVE|was|with|.|in|In|: (r_nsubjpass) evaluated_22\VBN|NONE (l_prep) with_27\IN|OBJECTIVE|was|effect|.|in|In|: (l_pobj) sphincter_28\NN|NONE (l_prep) of_29\IN|NONE (l_pobj) dyskinesia_31\NN|NONE
D005996_D046628 NONE trinitrate_11\NN|NONE (l_prep) on_12\IN|glyceryl (l_pobj) sphincter_17\NN|NONE (l_prep) of_18\IN|the|induced (l_pobj) spasm_20\NN|NONE
D005996_D046628 NONE trinitrate_2\NN|able|Since (r_nsubj) is_3\VBZ|might|.|in|it|,|of (r_advcl) be_16\VB|NONE (l_prep) in_19\IN|might|.|is|it|,|of (l_pobj) treatment_21\NN|NONE (l_prep) of_22\IN|the (l_pobj) sphincter_23\NN|NONE (l_prep) of_24\IN|NONE (l_pobj) dyskinesia_26\NN|NONE
982002
D012293_D051437 NONE rifampicin_12\NNS|NONE (r_pobj) of_11\IN|the|intermittent (r_prep) administration_10\NN|NONE (r_pobj) after_7\IN|patients|.|failure|had (r_prep) developed_3\VBN|NONE (l_dobj) failure_6\NN|patients|.|after|had
D012293_D058186 CID rifampicin_8\NNS|NONE (r_pobj) of_7\IN|the (r_prep) administration_6\NN|NONE (r_pobj) to_4\IN|NONE (r_prep) subsequent_3\JJ|Acute|.|renal (r_amod) failure_2\NN|NONE
891050
D003276_D006463 CID contraceptives_17\NNS|NONE (r_dobj) taking_15\VBG|a (r_acl) woman_14\NN|NONE (r_pobj) in_12\IN|hemolytic|(|HUS|the|uremic|) (r_prep) syndrome_8\NN|NONE
D003276_D006463 CID contraceptives_17\NNS|NONE (r_dobj) taking_15\VBG|a (r_acl) woman_14\NN|NONE (r_pobj) in_12\IN|hemolytic|(|HUS|the|uremic|) (r_prep) syndrome_8\NN|NONE (l_appos) HUS_10\NNP|hemolytic|(|the|uremic|)|in
D006493_D001002 NONE heparin_4\JJ|NONE (r_pobj) with_3\IN|and|was|rose|She|; (r_prep) treated_2\VBN|NONE (l_conj) rose_20\VBD|with|and|was|She|; (l_conj) stopped_37\VBN|.|and|,|above|after|;|output (l_prep) after_28\IN|treatment|was|, (l_pobj) onset_30\NN|months (l_prep) of_31\IN|the (l_pobj) anuria_32\NN|NONE
D004176_D001002 NONE dipyridamole_6\NN|, (r_conj) heparin_4\JJ|NONE (r_pobj) with_3\IN|and|was|rose|She|; (r_prep) treated_2\VBN|NONE (l_conj) rose_20\VBD|with|and|was|She|; (l_conj) stopped_37\VBN|.|and|,|above|after|;|output (l_prep) after_28\IN|treatment|was|, (l_pobj) onset_30\NN|months (l_prep) of_31\IN|the (l_pobj) anuria_32\NN|NONE
3001299
D008094_D007037 CID lithium_22\NN|NONE (r_compound) treatment_23\NN|NONE (r_pobj) during_21\IN|of|the (r_prep) development_13\NN|NONE (l_prep) of_14\IN|during|the (l_pobj) insipidus_18\NN|NONE (l_conj) hypothyroidism_20\NN|and|nephrogenic|both|diabetes
D008094_D007037 CID lithium_9\NN|they|while|were (r_dobj) taking_8\VBG|.|in|Hypothyroidism (r_advcl) developed_1\VBD|NONE (l_nsubj) Hypothyroidism_0\NN|taking|.|in
D008094_D018500 NONE lithium_22\NN|NONE (r_compound) treatment_23\NN|NONE (r_pobj) during_21\IN|of|the (r_prep) development_13\NN|NONE (l_prep) of_14\IN|during|the (l_pobj) insipidus_18\NN|NONE
7265370
D014223_D053040 CID Triamterene_0\JJ|NONE (r_compound) nephrolithiasis_1\JJ|therapy|.
D014223_D053040 CID triamterene_3\JJ|NONE (r_compound) nephrolithiasis_4\NN|NONE
D014223_D053040 CID triamterene_2\JJ|NONE (r_compound) nephrolithiasis_3\NN|NONE
C020743_D053040 NONE dyazide_3\RB|NONE (r_compound) therapy_4\NN|nephrolithiasis|. (r_dobj) complicating_2\VBG|NONE (l_nsubj) nephrolithiasis_1\JJ|therapy|.
C020743_D053040 NONE triamterene_16\JJ|NONE (r_compound) therapy_17\NN|NONE (r_pobj) of_13\IN|for| (r_prep) years_12\NNS|NONE (r_pobj) after_10\IN|in|case|.|is (r_prep) reported_6\VBN|NONE (l_nsubjpass) case_1\NN|in|.|is|after (l_prep) of_2\IN|A (l_pobj) nephrolithiasis_4\NN|NONE
C020743_D006973 NONE triamterene_16\JJ|NONE (r_compound) therapy_17\NN|NONE (r_pobj) of_13\IN|for| (r_prep) years_12\NNS|NONE (l_prep) for_18\IN|of| (l_pobj) hypertension_19\NN|NONE
D014223_D006973 NONE triamterene_3\JJ|NONE (r_compound) nephrolithiasis_4\NN|NONE (r_pobj) of_2\IN|A (r_prep) case_1\NN|in|.|is|after (r_nsubjpass) reported_6\VBN|NONE (l_prep) after_10\IN|in|case|.|is (l_pobj) years_12\NNS|NONE (l_prep) for_18\IN|of| (l_pobj) hypertension_19\NN|NONE
2893236
D009270_D012133 NONE naloxone_3\NN|NONE (r_pobj) in_2\IN|GABA (r_prep) involvement_1\NN|reversal|. (r_nsubj) induced_4\VBN|NONE (l_dobj) reversal_5\NN|involvement|. (l_prep) of_6\IN|NONE (l_pobj) paralysis_8\NN|NONE
D009270_D012133 NONE naloxone_3\NN|In|.|paralysis (r_nsubj) reversed_4\VBD|NONE (l_dobj) paralysis_6\NN|naloxone|In|.
D009270_D012133 NONE Naloxone_0\NN|paralysis|.|control (r_nsubj) reversed_7\VBD|NONE (l_dobj) paralysis_9\NN|Naloxone|.|control
D009270_D012133 NONE naloxone_3\NN|and|paralysis|involves (r_nsubj) reverses_4\VBZ|.|data (l_dobj) paralysis_6\NN|and|naloxone|involves
D013874_D012133 CID thiopental_11\NN|NONE (r_pobj) by_10\IN|NONE (r_agent) produced_9\VBN|respiratory (r_acl) paralysis_8\NN|NONE
D013874_D012133 CID thiopental_9\NN|NONE (r_pobj) by_8\IN|NONE (r_agent) induced_7\VBN|respiratory (r_acl) paralysis_6\NN|naloxone|In|.
D013874_D012133 CID thiopental_9\NN|NONE (r_pobj) by_8\IN|NONE (r_agent) produced_7\VBN|respiratory (r_acl) paralysis_6\NN|and|naloxone|involves
D000596_D012131 NONE acids_29\NNS|NONE (r_pobj) of_26\IN|NONE (r_prep) any_25\DT|NONE (r_dobj) affecting_24\VBG|NONE (r_pcomp) without_23\IN|arrest|. (r_prep) stem_22\NN|NONE (l_nsubj) arrest_7\NN|without|.
D018698_D012133 NONE glutamate_11\NN|,|respiratory (r_conj) paralysis_9\NN|Naloxone|.|control
D005680_D012133 NONE GABA_0\NNP|in (r_compound) involvement_1\NN|reversal|. (r_nsubj) induced_4\VBN|NONE (l_dobj) reversal_5\NN|involvement|. (l_prep) of_6\IN|NONE (l_pobj) paralysis_8\NN|NONE
D005680_D012133 NONE GABA_13\NNP|levels|and (r_conj) glutamate_11\NN|,|respiratory (r_conj) paralysis_9\NN|Naloxone|.|control
D005680_D012133 NONE GABA_12\NNP|in (r_dobj) involves_11\VBZ|and|paralysis|naloxone (r_conj) reverses_4\VBZ|.|data (l_dobj) paralysis_6\NN|and|naloxone|involves
D005680_D012131 NONE GABA_12\NNP|NONE (r_pobj) in_11\IN|decrease|further|and (r_prep) increase_10\NN|NONE (r_pobj) with_8\IN|,|mg/kg|respiratory|produced|i.v. (r_prep) arrest_7\NN|without|.
D018698_D012131 NONE glutamate_16\NN|NONE (r_pobj) in_15\IN|again|in (r_prep) decrease_14\NN|further|and|in (r_conj) increase_10\NN|NONE (r_pobj) with_8\IN|,|mg/kg|respiratory|produced|i.v. (r_prep) arrest_7\NN|without|.
D013874_D012131 NONE thiopental_4\NN|NONE (r_npadvmod) produced_5\VBD|,|with|mg/kg|respiratory|i.v. (r_amod) arrest_7\NN|without|.
17490790
D007501_D010300 NONE Iron_0\NN|NONE (r_compound) accumulation_1\NN|is|involved|. (r_nsubjpass) considered_3\VBN|NONE (l_xcomp) involved_6\VBN|accumulation|is|. (l_prep) in_7\IN|to|be (l_pobj) pathogenesis_9\NN|NONE (l_prep) of_10\IN|the (l_pobj) disease_13\NN|NONE
D007505_D009410 CID dextran_2\NN|degeneration|. (r_nsubj) induced_3\VBD|NONE (l_dobj) degeneration_4\NN|.|dextran (l_prep) of_5\IN|NONE (l_pobj) neurons_7\NNS|NONE
D007505_D009410 CID dextran_66\NN|overloaded|iron (r_amod) animals_68\NNS|NONE (r_pobj) of_64\IN|the (r_prep) SN_63\NN|NONE (r_pobj) in_61\IN|iron|increased (r_prep) content_60\NN|detection|and|,|Perls|iron (r_conj) staining_40\NN|(|tyrosine|,|hydroxylase|)|TH (l_conj) detection_49\NN|and|,|Perls|iron|content (l_acl) study_51\VB|liquid|performance|and|electrochemical (l_dobj) degeneration_53\NN|to (l_prep) of_54\IN|the (l_pobj) neurons_56\NNS|NONE
D007505_D009410 CID dextran_6\NN|that|can|level (r_nsubj) increase_8\VB|.|results (l_dobj) level_11\NN|that|can|dextran (l_relcl) causes_19\VBZ|,|in|the|iron (l_dobj) degeneration_21\NN|iron|where (l_prep) of_22\IN|the (l_pobj) neurons_24\NNS|NONE
D014443_D009410 NONE tyrosine_30\NN|(|,|hydroxylase|staining|)|TH (r_det) immunohistochemistry_35\NN|fast|cyclic|, (l_conj) staining_40\NN|(|tyrosine|,|hydroxylase|)|TH (l_conj) detection_49\NN|and|,|Perls|iron|content (l_acl) study_51\VB|liquid|performance|and|electrochemical (l_dobj) degeneration_53\NN|to (l_prep) of_54\IN|the (l_pobj) neurons_56\NNS|NONE
D007501_D009410 NONE iron_6\NN|loss|and|peripheral (r_compound) overload_7\NN|NONE (r_pobj) between_4\IN|the (r_prep) relationship_3\NN|To (r_dobj) demonstrate_1\VB|we|,|voltammetry|.|in (r_advcl) used_25\VBD|NONE (l_dobj) voltammetry_28\NN|we|,|.|demonstrate|in (l_conj) immunohistochemistry_35\NN|fast|cyclic|, (l_conj) staining_40\NN|(|tyrosine|,|hydroxylase|)|TH (l_conj) detection_49\NN|and|,|Perls|iron|content (l_acl) study_51\VB|liquid|performance|and|electrochemical (l_dobj) degeneration_53\NN|to (l_prep) of_54\IN|the (l_pobj) neurons_56\NNS|NONE
D007501_D009410 NONE iron_39\NN|detection|and|,|Perls|content (r_compound) staining_40\NN|(|tyrosine|,|hydroxylase|)|TH (l_conj) detection_49\NN|and|,|Perls|iron|content (l_acl) study_51\VB|liquid|performance|and|electrochemical (l_dobj) degeneration_53\NN|to (l_prep) of_54\IN|the (l_pobj) neurons_56\NNS|NONE
D007501_D009410 NONE iron_59\NN|in|increased (r_compound) content_60\NN|detection|and|,|Perls|iron (r_conj) staining_40\NN|(|tyrosine|,|hydroxylase|)|TH (l_conj) detection_49\NN|and|,|Perls|iron|content (l_acl) study_51\VB|liquid|performance|and|electrochemical (l_dobj) degeneration_53\NN|to (l_prep) of_54\IN|the (l_pobj) neurons_56\NNS|NONE
D007501_D009410 NONE iron_10\NN|,|causes|in|the (r_compound) level_11\NN|that|can|dextran (l_relcl) causes_19\VBZ|,|in|the|iron (l_dobj) degeneration_21\NN|iron|where (l_prep) of_22\IN|the (l_pobj) neurons_24\NNS|NONE
D007501_D009410 NONE iron_18\NN|degeneration|where (r_nsubj) causes_19\VBZ|,|in|the|iron (l_dobj) degeneration_21\NN|iron|where (l_prep) of_22\IN|the (l_pobj) neurons_24\NNS|NONE
12617329
D005839_D058186 CID gentamicin_21\NN|(|GM|) (r_nmod) nephrotoxicity_25\NN|NONE (r_pobj) by_20\IN|NONE (r_agent) induced_19\VBN|renal|acute (r_acl) failure_18\NN|NONE
D005839_D058186 CID GM_23\NNP|(|gentamicin|) (r_nmod) nephrotoxicity_25\NN|NONE (r_pobj) by_20\IN|NONE (r_agent) induced_19\VBN|renal|acute (r_acl) failure_18\NN|NONE
D006170_D007683 NONE Arabic_20\JJ|together (r_pobj) with_18\IN|than|GM (r_prep) given_15\VBN|NONE (r_acl) rats_14\NNS|NONE (r_pobj) in_13\IN|less (r_prep) severe_12\JJ|to (r_acomp) be_9\VB|necrosis|. (r_xcomp) appeared_7\VBD|NONE (l_nsubj) necrosis_6\NN|be|.
D005839_D007674 NONE gentamicin_8\NN|in (r_amod) nephrotoxicity_9\NN|NONE
D005839_D007674 NONE gentamicin_21\NN|(|GM|) (r_nmod) nephrotoxicity_25\NN|NONE
D005839_D007674 NONE GM_23\NNP|(|gentamicin|) (r_nmod) nephrotoxicity_25\NN|NONE
D005839_D007674 NONE GM_22\NNP|NONE (r_compound) nephrotoxicity_23\NN|NONE
D005978_D007674 NONE glutathione_16\NN|concentrations|and (r_conj) measuring_4\VBG|and|by (r_pcomp) by_3\IN|was|.|Nephrotoxicity (r_prep) assessed_2\VBN|NONE (l_nsubjpass) Nephrotoxicity_0\NN|was|by|.
D005978_D007674 NONE GSH_18\NNP|in|reduced|, (r_appos) glutathione_16\NN|concentrations|and (r_conj) measuring_4\VBG|and|by (r_pcomp) by_3\IN|was|.|Nephrotoxicity (r_prep) assessed_2\VBN|NONE (l_nsubjpass) Nephrotoxicity_0\NN|was|by|.
D014508_D007674 NONE urea_10\NN|and (r_conj) creatinine_8\NN|NONE (r_pobj) of_7\IN|the|in (r_prep) concentrations_6\NNS|glutathione|and (r_dobj) measuring_4\VBG|and|by (r_pcomp) by_3\IN|was|.|Nephrotoxicity (r_prep) assessed_2\VBN|NONE (l_nsubjpass) Nephrotoxicity_0\NN|was|by|.
D006170_D058186 CID Arabic_14\JJ|NONE (r_pobj) with_12\IN|NONE (r_prep) rats_11\NNS|NONE (r_pobj) of_10\IN|on (r_prep) treatment_9\NN|NONE (l_prep) on_15\IN|of (l_pobj) failure_18\NN|NONE
D006170_D007674 NONE Arabic_6\JJ|NONE (r_pobj) with_4\IN|on (r_prep) treatment_3\NN|NONE (l_prep) on_7\IN|with (l_pobj) nephrotoxicity_9\NN|NONE
D006170_D007674 NONE Arabic_14\JJ|NONE (r_pobj) with_12\IN|NONE (r_prep) rats_11\NNS|NONE (r_pobj) of_10\IN|on (r_prep) treatment_9\NN|NONE (l_prep) on_15\IN|of (l_pobj) failure_18\NN|NONE (l_acl) induced_19\VBN|renal|acute (l_agent) by_20\IN|NONE (l_pobj) nephrotoxicity_25\NN|NONE
D006170_D007674 NONE Arabic_6\JJ|gum (r_amod) treatment_7\NN|has|amelioration|that (r_nsubj) induced_9\VBN|could|be|It|. (l_dobj) amelioration_12\NN|has|treatment|that (l_prep) of_13\IN|modest|a (l_pobj) some_14\DT|NONE (l_prep) of_15\IN|NONE (l_pobj) indices_20\NNS|NONE (l_prep) of_21\IN|histological|the (l_pobj) nephrotoxicity_23\NN|NONE
D003404_D007674 NONE creatinine_8\NN|NONE (r_pobj) of_7\IN|the|in (r_prep) concentrations_6\NNS|glutathione|and (r_dobj) measuring_4\VBG|and|by (r_pcomp) by_3\IN|was|.|Nephrotoxicity (r_prep) assessed_2\VBN|NONE (l_nsubjpass) Nephrotoxicity_0\NN|was|by|.
D005839_D007683 NONE GM_1\NNP| (r_npadvmod) induced_3\VBN|tubular|The|proximal (r_amod) necrosis_6\NN|be|.
D005839_D007683 NONE GM_16\NNP|than|with (r_dobj) given_15\VBN|NONE (r_acl) rats_14\NNS|NONE (r_pobj) in_13\IN|less (r_prep) severe_12\JJ|to (r_acomp) be_9\VB|necrosis|. (r_xcomp) appeared_7\VBD|NONE (l_nsubj) necrosis_6\NN|be|.
D005839_D007683 NONE GM_25\NNP|NONE (r_pobj) given_24\VBN|NONE (r_acl) those_23\DT|NONE (r_pobj) in_22\IN|NONE (r_prep) than_21\IN|with|GM (r_prep) given_15\VBN|NONE (r_acl) rats_14\NNS|NONE (r_pobj) in_13\IN|less (r_prep) severe_12\JJ|to (r_acomp) be_9\VB|necrosis|. (r_xcomp) appeared_7\VBD|NONE (l_nsubj) necrosis_6\NN|be|.
9249847
D014700_D002311 NONE verapamil_7\NN|in|and|cardiomyopathy|catheter (r_nmod) ablation_10\NN|NONE (l_conj) cardiomyopathy_24\NN|in|and|verapamil|catheter
D014700_D013611 CID verapamil_7\NN|in|and|cardiomyopathy|catheter (r_nmod) ablation_10\NN|NONE (r_pobj) after_6\IN|.|tachycardia|Iatrogenically (r_prep) induced_1\VBD|NONE (l_dobj) tachycardia_5\NN|.|Iatrogenically|after
D014700_D013611 CID verapamil_10\NN|of|antegrade|unidirectional (r_nmod) block_14\NN|NONE (r_pobj) after_9\IN|junctional|after|escape (r_prep) beats_8\NNS|NONE (r_pobj) by_5\IN|NONE (r_agent) caused_4\VBN|,|,|without (r_acl) QRS_0\UH|attack|. (r_nsubj) established_22\VBD|NONE (l_dobj) attack_25\NN|QRS|. (l_compound) AVRT_24\NN|frequent
D014700_D014927 NONE verapamil_7\NN|in|and|cardiomyopathy|catheter (r_nmod) ablation_10\NN|NONE (l_prep) in_11\IN|and|cardiomyopathy|verapamil|catheter (l_pobj) patient_13\NN|NONE (l_prep) with_14\IN|a (l_pobj) syndrome_20\NN|NONE
869641
D004298_D001919 NONE dopamine_12\NN|in|central (r_compound) formation_13\NN|NONE (r_pobj) via_10\IN|by|.|of (r_prep) Mediation_0\NN|NONE (l_prep) of_1\IN|by|.|via (l_pobj) bradycardia_5\NNP|NONE
D004298_D001919 NONE dopamine_3\NN|beta|| (r_compound) oxidase_7\NN|a (r_compound) inhibitor_8\NN|,|.|effect|did|not|,|FLA (r_nsubj) have_12\VB|NONE (l_dobj) effect_14\NN|inhibitor|,|.|did|not|,|FLA (l_prep) on_15\IN|any (l_pobj) hypotension_17\NN|NONE (l_appos) effect_24\NN|the|, (l_amod) bradycardia_19\NN|of
D015103_D001919 NONE dihydroxyphenylserine_21\NN||,|L (r_conj) dopa_15\NNP|NONE (r_pobj) by_12\IN|In|bradycardia|had|.|was|significantly|, (r_agent) enhanced_11\VBN|NONE (l_nsubjpass) bradycardia_4\NN|by|In|had|.|was|significantly|,
D005406_D001919 NONE FLA-63_0\NN|inhibitor|,|.|effect|did|not|, (r_mark) have_12\VB|NONE (l_dobj) effect_14\NN|inhibitor|,|.|did|not|,|FLA (l_prep) on_15\IN|any (l_pobj) hypotension_17\NN|NONE (l_appos) effect_24\NN|the|, (l_amod) bradycardia_19\NN|of
D007980_D007022 NONE dopa_28\NNP|NONE (r_pobj) of_25\IN|bradycardia (r_prep) effect_24\NN|the|, (r_appos) hypotension_17\NN|NONE
D007980_D001919 NONE dopa_9\NN|NONE (r_pobj) by_6\IN|.|via|of (r_prep) Mediation_0\NN|NONE (l_prep) of_1\IN|by|.|via (l_pobj) bradycardia_5\NNP|NONE
D007980_D001919 NONE dopa_15\NNP|NONE (r_pobj) by_12\IN|In|bradycardia|had|.|was|significantly|, (r_agent) enhanced_11\VBN|NONE (l_nsubjpass) bradycardia_4\NN|by|In|had|.|was|significantly|,
D007980_D001919 NONE dopa_28\NNP|NONE (r_pobj) of_25\IN|bradycardia (r_prep) effect_24\NN|the|, (l_amod) bradycardia_19\NN|of
D007980_D001919 NONE dopa_4\NNP|.|bradycardia|However|, (r_nsubj) restored_5\VBD|NONE (l_dobj) bradycardia_7\NN|dopa|.|However|,
D007980_D001919 NONE dopa_6\NNP|bradycardia|through|that (r_nsubj) enhances_7\VBZ|.|It|is (l_dobj) bradycardia_9\NN|through|that|dopa
D009638_D001919 CID norepinephrine_8\NN|NONE (r_pobj) by_6\IN|NONE (r_agent) caused_5\VBN|reflex (r_acl) bradycardia_4\NN|by|In|had|.|was|significantly|,
D009638_D001919 CID norepinephrine_35\NN|NONE (r_pobj) to_34\IN|reflex (r_prep) responses_33\NNS|or|heart (r_conj) rate_30\NN|,|blood (r_conj) pressure_27\NN|NONE (r_pobj) on_25\IN|no (r_prep) effect_24\NN|NONE (r_dobj) had_22\VBD|by|In|bradycardia|.|was|significantly|, (r_conj) enhanced_11\VBN|NONE (l_nsubjpass) bradycardia_4\NN|by|In|had|.|was|significantly|,
D009638_D001919 CID norepinephrine_10\NN|NONE (r_pobj) by_9\IN|in (r_agent) caused_8\VBN|the (r_acl) bradycardia_7\NN|dopa|.|However|,
D009638_D001919 CID norepinephrine_18\NN|NONE (r_pobj) to_17\IN|reflex|the (r_prep) bradycardia_16\NN|NONE
D004298_D007022 NONE dopamine_3\NN|beta|| (r_compound) oxidase_7\NN|a (r_compound) inhibitor_8\NN|,|.|effect|did|not|,|FLA (r_nsubj) have_12\VB|NONE (l_dobj) effect_14\NN|inhibitor|,|.|did|not|,|FLA (l_prep) on_15\IN|any (l_pobj) hypotension_17\NN|NONE
D006916_D001919 NONE 5-HTP_0\NNP|.|and|pressure|decreased (r_nsubj) decreased_6\VBD|NONE (l_conj) decreased_13\VBD|.|HTP|and|pressure (l_dobj) bradycardia_16\NN|NONE
D005406_D007022 NONE FLA-63_0\NN|inhibitor|,|.|effect|did|not|, (r_mark) have_12\VB|NONE (l_dobj) effect_14\NN|inhibitor|,|.|did|not|,|FLA (l_prep) on_15\IN|any (l_pobj) hypotension_17\NN|NONE
12716030
D006493_D006470 NONE heparin_7\VBN|In|,|.|volume (r_nsubj) enhanced_8\VBD|NONE (l_dobj) volume_11\NN|In|heparin|,|. (l_prep) over_13\IN|.fold|hematoma|the (l_pobj) that_14\DT|NONE (l_acl) seen_15\VBN|NONE (l_prep) in_16\IN|NONE (l_pobj) control_17\NN|NONE (l_dobj) animals_19\NNS|NONE (l_conj) bleeding_22\NN|and|ICH
D006493_D006406 CID heparin_7\VBN|In|,|.|volume (r_nsubj) enhanced_8\VBD|NONE (l_dobj) volume_11\NN|In|heparin|,|. (l_compound) hematoma_10\NN|.fold|over|the
D006493_D002543 NONE heparin_7\VBN|In|,|.|volume (r_nsubj) enhanced_8\VBD|NONE (l_prep) In_0\IN|heparin|,|.|volume (l_pobj) induction_2\NN|NONE (l_compound) ICH_1\NNP|using
D006493_D002543 NONE heparin_7\VBN|In|,|.|volume (r_nsubj) enhanced_8\VBD|NONE (l_dobj) volume_11\NN|In|heparin|,|. (l_prep) over_13\IN|.fold|hematoma|the (l_pobj) that_14\DT|NONE (l_acl) seen_15\VBN|NONE (l_prep) in_16\IN|NONE (l_pobj) control_17\NN|NONE (l_dobj) animals_19\NNS|NONE (l_compound) ICH_18\NNP|and|bleeding
20698227
D012254_D006461 NONE ribavirin_1\RB|been|has|inhibit|found (r_nsubjpass) found_4\VBN|NONE (l_conj) found_21\VBN|been|has|inhibit|ribavirin (l_advcl) cause_23\VB|have|been|.|number (l_dobj) hemolysis_25\NN|to
D012254_D000740 NONE ribavirin_16\RB|and|soluble (r_conj) markers_14\NNS|NONE (r_dobj) angiogenesis_12\NN|NONE (r_pobj) between_11\IN|a (r_prep) link_10\NN|NONE (r_dobj) investigating_8\VBG|the|in|first (r_acl) study_4\NN|induced|This (r_attr) is_1\VBZ|NONE (l_advcl) induced_17\VBD|This|study (l_dobj) anemia_18\NN|find|and
C473478_D006461 CID sunitinib_16\JJ|such (r_pobj) as_15\IN|angiogenesis (r_prep) inhibitors_13\NNS|NONE (r_pobj) of_11\IN|a (r_prep) number_10\NN|have|cause|been|. (r_nsubjpass) found_21\VBN|been|has|inhibit|ribavirin (l_advcl) cause_23\VB|have|been|.|number (l_dobj) hemolysis_25\NN|to
D012254_D019698 NONE ribavirin_16\RB|alpha|pegylated|and|interferon (r_conj) 2a_14\CD|NONE (r_pobj) by_10\IN|infected|.|were (r_agent) treated_9\VBN|NONE (l_csubjpass) infected_3\VBN|by|.|were (l_prep) with_4\IN|chronically|patients (l_pobj) virus_7\NN|NONE
D012254_D019698 NONE ribavirin_16\RB|and|soluble (r_conj) markers_14\NNS|NONE (r_dobj) angiogenesis_12\NN|NONE (r_pobj) between_11\IN|a (r_prep) link_10\NN|NONE (r_dobj) investigating_8\VBG|the|in|first (r_acl) study_4\NN|induced|This (r_attr) is_1\VBZ|NONE (l_advcl) induced_17\VBD|This|study (l_dobj) anemia_18\NN|find|and (l_prep) in_19\IN|NONE (l_pobj) patients_20\NNS|NONE (l_prep) with_21\IN|NONE (l_pobj) C_23\NNP|NONE
C100416_D019698 NONE 2a_14\CD|NONE (r_pobj) by_10\IN|infected|.|were (r_agent) treated_9\VBN|NONE (l_csubjpass) infected_3\VBN|by|.|were (l_prep) with_4\IN|chronically|patients (l_pobj) virus_7\NN|NONE
D012254_D000743 NONE ribavirin_8\RB|NONE (r_pobj) for_7\IN|NONE (r_prep) treatment_6\NN|NONE (r_pobj) of_5\IN|associated|a (r_prep) target_4\NN|angiogenesis|Can|? (l_acl) associated_9\VBN|a|of (l_dobj) anemia_11\NN|NONE
C471405_D006461 CID sorafenib_18\NNS|and (r_conj) sunitinib_16\JJ|such (r_pobj) as_15\IN|angiogenesis (r_prep) inhibitors_13\NNS|NONE (r_pobj) of_11\IN|a (r_prep) number_10\NN|have|cause|been|. (r_nsubjpass) found_21\VBN|been|has|inhibit|ribavirin (l_advcl) cause_23\VB|have|been|.|number (l_dobj) hemolysis_25\NN|to
3015327
D007538_D009422 CID isoniazid_6\NN|in (r_compound) neuropathy_7\NN|NONE
D007538_D009422 CID isoniazid_8\NN|NONE (r_pobj) of_7\IN|single|in|a (r_prep) dose_6\NN|NONE (r_pobj) by_3\IN|NONE (r_agent) caused_2\VBN|The (r_acl) neuropathy_1\NN|.|was|with
15145918
D008750_D007022 CID methyldopa_10\NN|or (r_conj) rilmenidine_6\NN|operated|, (r_amod) rats_4\NNS|NONE (r_pobj) In_0\IN|hypotension|. (r_prep) elicited_11\VBD|NONE (l_dobj) hypotension_13\NN|In|.
D008750_D007022 CID methyldopa_9\NN|NONE (r_pobj) to_6\IN|hypotensive|the (r_prep) response_5\NN|.|significantly|in|,|Ovx (l_amod) hypotensive_4\JJ|to|the
D008750_D007022 CID methyldopa_9\NN|NONE (r_pobj) to_6\IN|hypotensive|the (r_prep) response_5\NN|.|significantly|in|,|Ovx (r_dobj) enhanced_2\VBD|NONE (l_prep) in_11\IN|.|response|significantly|,|Ovx (l_pobj) contrast_12\NN|NONE (l_prep) to_13\IN|NONE (l_pobj) effect_15\NN|NONE (l_prep) on_16\IN|no (l_pobj) hypotension_18\NN|NONE
D008750_D007022 CID methyldopa_4\NN|in|The|enhanced (r_compound) hypotension_5\NN|.|with|was
D008750_D007022 CID methyldopa_25\NN| (r_compound) estrogen_27\NN|NONE (r_compound) interaction_28\NN|NONE (r_pobj) in_22\IN|cardiac|the|autonomic (r_prep) control_21\NN|NONE (r_pobj) for_17\IN|a (r_prep) role_16\NN|NONE (r_dobj) highlight_14\VB|and|alpha|estrogen|hypotension|but|that (r_conj) downregulates_5\VBZ|findings|. (l_conj) hypotension_12\NN|and|alpha|estrogen|highlight|but|that
D004967_D007022 NONE estrogen_3\NN|NONE (l_prep) of_4\IN|NONE (l_pobj) hypotension_11\NN|NONE
D004967_D007022 NONE estrogen_5\NN|effect|and|negatively|implicates|that (r_nsubj) modulates_7\VBZ|recently|have|We|. (l_dobj) effect_10\NN|and|estrogen|negatively|implicates|that (l_amod) hypotensive_9\JJ|the|of
D004967_D007022 NONE estrogen_4\NN|and|alpha|hypotension|highlight|but|that (r_nsubj) downregulates_5\VBZ|findings|. (l_conj) hypotension_12\NN|and|alpha|estrogen|highlight|but|that
D004967_D007022 NONE estrogen_27\NN|NONE (r_compound) interaction_28\NN|NONE (r_pobj) in_22\IN|cardiac|the|autonomic (r_prep) control_21\NN|NONE (r_pobj) for_17\IN|a (r_prep) role_16\NN|NONE (r_dobj) highlight_14\VB|and|alpha|estrogen|hypotension|but|that (r_conj) downregulates_5\VBZ|findings|. (l_conj) hypotension_12\NN|and|alpha|estrogen|highlight|but|that
D048288_D007022 NONE I1-imidazoline_7\NNP||receptor (r_punct) mediated_10\VBN|and (r_conj) alpha2-adrenergic_5\JJ|in (r_amod) hypotension_11\NN|NONE
D003000_D007022 NONE clonidine_12\NN|NONE (r_pobj) of_11\IN|hypotensive|the (r_prep) effect_10\NN|and|estrogen|negatively|implicates|that (l_amod) hypotensive_9\JJ|the|of
C032302_D007022 CID rilmenidine_6\NN|operated|, (r_amod) rats_4\NNS|NONE (r_pobj) In_0\IN|hypotension|. (r_prep) elicited_11\VBD|NONE (l_dobj) hypotension_13\NN|In|.
C032302_D007022 CID rilmenidine_17\JJ|NONE (r_amod) hypotension_18\NN|NONE (r_pobj) on_16\IN|no (r_prep) effect_15\NN|NONE (r_pobj) to_13\IN|NONE (r_prep) contrast_12\NN|NONE (r_pobj) in_11\IN|.|response|significantly|,|Ovx (r_prep) enhanced_2\VBD|NONE (l_dobj) response_5\NN|.|significantly|in|,|Ovx (l_amod) hypotensive_4\JJ|to|the
C032302_D007022 CID rilmenidine_17\JJ|NONE (r_amod) hypotension_18\NN|NONE
D008750_D001523 NONE methyldopa_4\NN|in|The|enhanced (r_compound) hypotension_5\NN|.|with|was (r_nsubjpass) paralleled_10\VBN|NONE (l_prep) with_11\IN|.|hypotension|was (l_pobj) reduction_13\NN|NONE (l_conj) activity_20\NN|in|further|and
16826348
D003561_D064420 NONE arabinoside_10\NN|NONE (r_pobj) of_5\IN|system|central|The (r_prep) toxicity_4\NN|reported|,|is|but|well
D003561_D064420 NONE arabinoside_10\NN|NONE (r_pobj) of_5\IN|system|central|The (r_prep) toxicity_4\NN|reported|,|is|but|well (r_nsubjpass) recognized_13\VBN|NONE (l_conj) reported_29\VBN|,|toxicity|is|but|well (l_nsubjpass) toxicity_17\NN|been|has|infrequently|.
D003561_D064420 NONE arabinoside_20\NN|NONE (r_pobj) of_18\IN|the (r_prep) toxicity_17\NN|been|has|infrequently|. (r_nsubjpass) reported_29\VBN|,|toxicity|is|but|well (r_conj) recognized_13\VBN|NONE (l_nsubjpass) toxicity_4\NN|reported|,|is|but|well
D003561_D064420 NONE arabinoside_20\NN|NONE (r_pobj) of_18\IN|the (r_prep) toxicity_17\NN|been|has|infrequently|.
D003561_D015470 NONE arabinoside_8\NN|dose|cytosine|in (r_amod) treatment_9\NN|NONE (l_prep) in_10\IN|dose|arabinoside|cytosine (l_pobj) patient_12\NN|NONE (l_prep) with_13\IN|a (l_pobj) leukemia_16\NN|NONE
D003561_D010523 CID arabinoside_8\NN|dose|cytosine|in (r_amod) treatment_9\NN|NONE (r_pobj) by_3\IN|NONE (r_agent) caused_2\VBN|Peripheral|. (r_acl) neuropathy_1\NNS|NONE
D003561_D010523 CID arabinoside_14\NN|,|play|therapy|and|,|are (r_nsubj) is_15\VBZ|NONE (l_advcl) are_6\VBP|,|arabinoside|play|therapy|and|, (l_nsubj) mechanisms_2\NNS|still|Although|unclear (l_prep) of_3\IN|the (l_pobj) neuropathy_5\NN|NONE
D003561_D006987 NONE arabinoside_8\NN|NONE (r_pobj) of_3\IN|first|The (r_prep) course_2\NN|,|complained|in|but (r_nsubj) resulted_9\VBD|NONE (l_conj) complained_28\VBD|,|course|in|but (l_prep) of_29\IN|on|patient|,|in|. (l_pobj) numbness_30\NN|NONE
D008775_D006086 NONE methylprednisolone_38\NN|NONE (r_pobj) to_37\IN|symptoms|.|subsequently (r_prep) responded_36\VBD|,|,|symptoms|,|received|with|and (r_conj) worsened_19\VBD|NONE (l_prep) with_21\IN|,|responded|,|symptoms|,|received|and (l_pobj) development_23\NN|NONE (l_prep) of_24\IN|the (l_pobj) disease_30\NN|NONE
D008775_D009422 NONE methylprednisolone_38\NN|NONE (r_pobj) to_37\IN|symptoms|.|subsequently (r_prep) responded_36\VBD|,|,|symptoms|,|received|with|and (r_conj) worsened_19\VBD|NONE (l_ccomp) received_11\VBD|,|responded|,|symptoms|,|with|and (l_ccomp) resolving_4\VBG|transplantation|however|after|;|,|patient (l_nsubj) neuropathy_1\NN|was|gradually
11334364
D000638_D007674 NONE amiodarone_18\NN| (r_npadvmod) induced_20\VBN|cardiotoxicity|and|lung (r_amod) toxicity_22\NN|,|induced (r_conj) nephrotoxicity_16\NN|NONE
D000638_D007674 NONE amiodarone_21\NN|,|(|AAP)induced (r_appos) nephrotoxicity_19\NN|AMI)induced|,|lung|doxorubicin|and|(
D000638_D007674 NONE AMI)-induced_23\JJ|,|lung|doxorubicin|and|nephrotoxicity|( (r_amod) toxicity_25\NN|to|acetaminophen (l_nmod) nephrotoxicity_19\NN|AMI)induced|,|lung|doxorubicin|and|(
D000082_D009336 CID acetaminophen_13\RB| (r_advmod) induced_15\VBN|,|toxicity (r_amod) nephrotoxicity_16\NN|NONE (r_pobj) during_12\IN|associated|cell|apoptotic (r_prep) deaths_11\NNS|of|vivo (l_amod) apoptotic_7\JJ|associated|cell|during (l_conj) necrotic_9\JJ|and
D000082_D009336 CID AAP_9\NNP|,|as|the|all (r_appos) drugs_4\NNS|,|in|.|Interestingly|death (r_nsubj) induced_14\VBD|NONE (l_prep) in_17\IN|,|.|drugs|Interestingly|death (l_pobj) addition_18\NN|NONE (l_prep) to_19\IN|NONE (l_pobj) necrosis_20\NN|NONE
D004317_D009336 CID doxorubicin_24\NN| (r_npadvmod) induced_26\VBN|by (r_amod) cardiotoxicity_27\NN|and|induced|lung (r_conj) toxicity_22\NN|,|induced (r_conj) nephrotoxicity_16\NN|NONE (r_pobj) during_12\IN|associated|cell|apoptotic (r_prep) deaths_11\NNS|of|vivo (l_amod) apoptotic_7\JJ|associated|cell|during (l_conj) necrotic_9\JJ|and
D004317_D009336 CID DOX_13\NNP|and (r_conj) AMI_11\NNP|, (r_conj) AAP_9\NNP|,|as|the|all (r_appos) drugs_4\NNS|,|in|.|Interestingly|death (r_nsubj) induced_14\VBD|NONE (l_prep) in_17\IN|,|.|drugs|Interestingly|death (l_pobj) addition_18\NN|NONE (l_prep) to_19\IN|NONE (l_pobj) necrosis_20\NN|NONE
D004317_D008171 NONE doxorubicin_24\NN| (r_npadvmod) induced_26\VBN|by (r_amod) cardiotoxicity_27\NN|and|induced|lung (r_conj) toxicity_22\NN|,|induced
D004317_D008171 NONE doxorubicin_28\NN|AMI)induced|,|lung|and|nephrotoxicity|( (r_conj) toxicity_25\NN|to|acetaminophen
D004317_D008171 NONE DOX)-induced_30\JJ|(|in (r_amod) cardiotoxicity_31\NN|NONE (r_dobj) doxorubicin_28\NN|AMI)induced|,|lung|and|nephrotoxicity|( (r_conj) toxicity_25\NN|to|acetaminophen
C511402_D017695 NONE GSPE_30\NNP|than (r_compound) preexposure_31\NN|NONE (r_pobj) of_29\IN|the (r_prep) absence_28\NN|NONE (r_pobj) in_26\IN|a|of|by (r_prep) variety_17\NN|NONE (r_pobj) with_15\IN|tissue|massive (r_prep) damage_14\NN|NONE
C511402_D009336 NONE extract_35\NN|NONE (r_pobj) by_28\IN|induced (r_prep) cardiotoxicity_27\NN|and|induced|lung (r_conj) toxicity_22\NN|,|induced (r_conj) nephrotoxicity_16\NN|NONE (r_pobj) during_12\IN|associated|cell|apoptotic (r_prep) deaths_11\NNS|of|vivo (l_amod) apoptotic_7\JJ|associated|cell|during (l_conj) necrotic_9\JJ|and
C511402_D009336 NONE GSPE_31\NNP|NONE (r_pobj) by_30\IN|effectively|was|which (r_agent) blocked_29\VBN|in (r_relcl) necrosis_20\NN|NONE
D004317_D007674 NONE doxorubicin_24\NN| (r_npadvmod) induced_26\VBN|by (r_amod) cardiotoxicity_27\NN|and|induced|lung (r_conj) toxicity_22\NN|,|induced (r_conj) nephrotoxicity_16\NN|NONE
D004317_D007674 NONE doxorubicin_28\NN|AMI)induced|,|lung|and|nephrotoxicity|( (r_conj) toxicity_25\NN|to|acetaminophen (l_nmod) nephrotoxicity_19\NN|AMI)induced|,|lung|doxorubicin|and|(
D004317_D007674 NONE DOX)-induced_30\JJ|(|in (r_amod) cardiotoxicity_31\NN|NONE (r_dobj) doxorubicin_28\NN|AMI)induced|,|lung|and|nephrotoxicity|( (r_conj) toxicity_25\NN|to|acetaminophen (l_nmod) nephrotoxicity_19\NN|AMI)induced|,|lung|doxorubicin|and|(
D000638_D008171 CID amiodarone_18\NN| (r_npadvmod) induced_20\VBN|cardiotoxicity|and|lung (r_amod) toxicity_22\NN|,|induced
D000638_D008171 CID amiodarone_21\NN|,|(|AAP)induced (r_appos) nephrotoxicity_19\NN|AMI)induced|,|lung|doxorubicin|and|( (r_nmod) toxicity_25\NN|to|acetaminophen
D000638_D008171 CID AMI)-induced_23\JJ|,|lung|doxorubicin|and|nephrotoxicity|( (r_amod) toxicity_25\NN|to|acetaminophen
D000638_D066126 NONE amiodarone_18\NN| (r_npadvmod) induced_20\VBN|cardiotoxicity|and|lung (r_amod) toxicity_22\NN|,|induced (l_conj) cardiotoxicity_27\NN|and|induced|lung
D000638_D066126 NONE amiodarone_21\NN|,|(|AAP)induced (r_appos) nephrotoxicity_19\NN|AMI)induced|,|lung|doxorubicin|and|( (r_nmod) toxicity_25\NN|to|acetaminophen (l_conj) doxorubicin_28\NN|AMI)induced|,|lung|and|nephrotoxicity|( (l_dobj) cardiotoxicity_31\NN|NONE
D000638_D066126 NONE AMI)-induced_23\JJ|,|lung|doxorubicin|and|nephrotoxicity|( (r_amod) toxicity_25\NN|to|acetaminophen (l_conj) doxorubicin_28\NN|AMI)induced|,|lung|and|nephrotoxicity|( (l_dobj) cardiotoxicity_31\NN|NONE
C511402_D066126 NONE extract_35\NN|NONE (r_pobj) by_28\IN|induced (r_prep) cardiotoxicity_27\NN|and|induced|lung
C511402_D066126 NONE extract_10\NN|NONE (r_pobj) of_5\IN|prevent|the (r_prep) ability_4\NN|.|study (l_acl) prevent_15\VB|of|the (l_dobj) toxicity_25\NN|to|acetaminophen (l_conj) doxorubicin_28\NN|AMI)induced|,|lung|and|nephrotoxicity|( (l_dobj) cardiotoxicity_31\NN|NONE
C511402_D066126 NONE GSPE_12\NNP|IH|proanthocyanidin|)|( (r_appos) extract_10\NN|NONE (r_pobj) of_5\IN|prevent|the (r_prep) ability_4\NN|.|study (l_acl) prevent_15\VB|of|the (l_dobj) toxicity_25\NN|to|acetaminophen (l_conj) doxorubicin_28\NN|AMI)induced|,|lung|and|nephrotoxicity|( (l_dobj) cardiotoxicity_31\NN|NONE
D004317_D066126 CID doxorubicin_24\NN| (r_npadvmod) induced_26\VBN|by (r_amod) cardiotoxicity_27\NN|and|induced|lung
D004317_D066126 CID doxorubicin_28\NN|AMI)induced|,|lung|and|nephrotoxicity|( (l_dobj) cardiotoxicity_31\NN|NONE
D004317_D066126 CID DOX)-induced_30\JJ|(|in (r_amod) cardiotoxicity_31\NN|NONE
C511402_D008171 NONE extract_35\NN|NONE (r_pobj) by_28\IN|induced (r_prep) cardiotoxicity_27\NN|and|induced|lung (r_conj) toxicity_22\NN|,|induced
C511402_D008171 NONE extract_10\NN|NONE (r_pobj) of_5\IN|prevent|the (r_prep) ability_4\NN|.|study (l_acl) prevent_15\VB|of|the (l_dobj) toxicity_25\NN|to|acetaminophen
C511402_D008171 NONE GSPE_12\NNP|IH|proanthocyanidin|)|( (r_appos) extract_10\NN|NONE (r_pobj) of_5\IN|prevent|the (r_prep) ability_4\NN|.|study (l_acl) prevent_15\VB|of|the (l_dobj) toxicity_25\NN|to|acetaminophen
D000082_D008171 NONE acetaminophen_13\RB| (r_advmod) induced_15\VBN|,|toxicity (r_amod) nephrotoxicity_16\NN|NONE (l_conj) toxicity_22\NN|,|induced
D000082_D008171 NONE acetaminophen_16\RB|to|toxicity (r_advmod) prevent_15\VB|of|the (l_dobj) toxicity_25\NN|to|acetaminophen
D000082_D008171 NONE AAP)-induced_18\VBN|,|(|amiodarone (r_compound) nephrotoxicity_19\NN|AMI)induced|,|lung|doxorubicin|and|( (r_nmod) toxicity_25\NN|to|acetaminophen
D000082_D007674 CID acetaminophen_13\RB| (r_advmod) induced_15\VBN|,|toxicity (r_amod) nephrotoxicity_16\NN|NONE
D000082_D007674 CID acetaminophen_16\RB|to|toxicity (r_advmod) prevent_15\VB|of|the (l_dobj) toxicity_25\NN|to|acetaminophen (l_nmod) nephrotoxicity_19\NN|AMI)induced|,|lung|doxorubicin|and|(
D000082_D007674 CID AAP)-induced_18\VBN|,|(|amiodarone (r_compound) nephrotoxicity_19\NN|AMI)induced|,|lung|doxorubicin|and|(
C511402_D007674 NONE extract_35\NN|NONE (r_pobj) by_28\IN|induced (r_prep) cardiotoxicity_27\NN|and|induced|lung (r_conj) toxicity_22\NN|,|induced (r_conj) nephrotoxicity_16\NN|NONE
C511402_D007674 NONE extract_10\NN|NONE (r_pobj) of_5\IN|prevent|the (r_prep) ability_4\NN|.|study (l_acl) prevent_15\VB|of|the (l_dobj) toxicity_25\NN|to|acetaminophen (l_nmod) nephrotoxicity_19\NN|AMI)induced|,|lung|doxorubicin|and|(
C511402_D007674 NONE GSPE_12\NNP|IH|proanthocyanidin|)|( (r_appos) extract_10\NN|NONE (r_pobj) of_5\IN|prevent|the (r_prep) ability_4\NN|.|study (l_acl) prevent_15\VB|of|the (l_dobj) toxicity_25\NN|to|acetaminophen (l_nmod) nephrotoxicity_19\NN|AMI)induced|,|lung|doxorubicin|and|(
D000082_D066126 NONE acetaminophen_13\RB| (r_advmod) induced_15\VBN|,|toxicity (r_amod) nephrotoxicity_16\NN|NONE (l_conj) toxicity_22\NN|,|induced (l_conj) cardiotoxicity_27\NN|and|induced|lung
D000082_D066126 NONE acetaminophen_16\RB|to|toxicity (r_advmod) prevent_15\VB|of|the (l_dobj) toxicity_25\NN|to|acetaminophen (l_conj) doxorubicin_28\NN|AMI)induced|,|lung|and|nephrotoxicity|( (l_dobj) cardiotoxicity_31\NN|NONE
D000082_D066126 NONE AAP)-induced_18\VBN|,|(|amiodarone (r_compound) nephrotoxicity_19\NN|AMI)induced|,|lung|doxorubicin|and|( (r_nmod) toxicity_25\NN|to|acetaminophen (l_conj) doxorubicin_28\NN|AMI)induced|,|lung|and|nephrotoxicity|( (l_dobj) cardiotoxicity_31\NN|NONE
D000638_D009336 CID amiodarone_18\NN| (r_npadvmod) induced_20\VBN|cardiotoxicity|and|lung (r_amod) toxicity_22\NN|,|induced (r_conj) nephrotoxicity_16\NN|NONE (r_pobj) during_12\IN|associated|cell|apoptotic (r_prep) deaths_11\NNS|of|vivo (l_amod) apoptotic_7\JJ|associated|cell|during (l_conj) necrotic_9\JJ|and
D000638_D009336 CID AMI_11\NNP|, (r_conj) AAP_9\NNP|,|as|the|all (r_appos) drugs_4\NNS|,|in|.|Interestingly|death (r_nsubj) induced_14\VBD|NONE (l_prep) in_17\IN|,|.|drugs|Interestingly|death (l_pobj) addition_18\NN|NONE (l_prep) to_19\IN|NONE (l_pobj) necrosis_20\NN|NONE
15458908
D020849_D005705 NONE Raloxifene_0\NNP|not|disease|did|risk|,|. (r_nsubj) increase_3\VB|NONE (l_dep) disease_20\NN|not|did|Raloxifene|risk|,|.
D020849_D005705 NONE Raloxifene_0\NNP|but|was|,|with|was (r_nsubjpass) associated_2\VBN|NONE (l_conj) was_13\VBD|but|Raloxifene|,|with|was (l_attr) risk_16\NN|there|. (l_prep) for_17\IN|increased|no (l_pobj) cataracts_18\NNS|NONE (l_conj) disease_21\NN|,
D020849_D002386 NONE Raloxifene_0\NNP|not|disease|did|risk|,|. (r_nsubj) increase_3\VB|NONE (l_dobj) risk_4\NN|not|disease|did|Raloxifene|,|. (l_prep) for_5\IN|NONE (l_pobj) cataracts_6\NNS|NONE
D020849_D002386 NONE Raloxifene_0\NNP|but|was|,|with|was (r_nsubjpass) associated_2\VBN|NONE (l_conj) was_13\VBD|but|Raloxifene|,|with|was (l_attr) risk_16\NN|there|. (l_prep) for_17\IN|increased|no (l_pobj) cataracts_18\NNS|NONE
D020849_D010024 NONE Raloxifene_4\NNP|,|trial|, (r_compound) Evaluation_5\NNP|NONE (r_pobj) of_3\IN|Multiple|The (r_prep) Outcomes_2\NNPS|women|with|. (r_nsubj) enrolled_17\VBD|NONE (l_prep) with_21\IN|women|Outcomes|. (l_pobj) osteoporosis_22\NN|NONE
D020849_D016889 NONE Raloxifene_0\NNP|not|disease|did|risk|,|. (r_nsubj) increase_3\VB|NONE (l_dep) disease_20\NN|not|did|Raloxifene|risk|,|. (l_appos) CI_27\NNP|;|(|RR|gallbladder (l_appos) hyperplasia_34\NN|%|)|.|, (l_appos) %_40\NN|(|endometrial (l_conj) cancer_49\NN|;|or|.|%|;||,|RR
D020849_D016889 NONE Raloxifene_0\NNP|but|was|,|with|was (r_nsubjpass) associated_2\VBN|NONE (l_conj) was_13\VBD|but|Raloxifene|,|with|was (l_attr) risk_16\NN|there|. (l_prep) for_17\IN|increased|no (l_pobj) cataracts_18\NNS|NONE (l_conj) disease_21\NN|, (l_conj) hyperplasia_24\NN|gallbladder|, (l_conj) cancer_28\NN|,|endometrial|or
D020849_D054556 CID raloxifene_11\NN|with|:|During|was|,|. (r_nsubjpass) associated_13\VBN|NONE (l_prep) with_14\IN|:|During|was|,|.|raloxifene (l_pobj) risk_17\NN|NONE (l_prep) for_18\IN|an|increased (l_pobj) thromboembolism_20\NN|NONE
D020849_D054556 CID Raloxifene_0\NNP|but|was|,|with|was (r_nsubjpass) associated_2\VBN|NONE (l_prep) with_3\IN|but|Raloxifene|was|,|was (l_pobj) risk_6\NN|NONE (l_prep) for_7\IN|an|increased (l_pobj) thromboembolism_9\NN|NONE
D020849_D004714 NONE Raloxifene_0\NNP|not|disease|did|risk|,|. (r_nsubj) increase_3\VB|NONE (l_dep) disease_20\NN|not|did|Raloxifene|risk|,|. (l_appos) CI_27\NNP|;|(|RR|gallbladder (l_appos) hyperplasia_34\NN|%|)|.|,
D020849_D004714 NONE Raloxifene_0\NNP|but|was|,|with|was (r_nsubjpass) associated_2\VBN|NONE (l_conj) was_13\VBD|but|Raloxifene|,|with|was (l_attr) risk_16\NN|there|. (l_prep) for_17\IN|increased|no (l_pobj) cataracts_18\NNS|NONE (l_conj) disease_21\NN|, (l_conj) hyperplasia_24\NN|gallbladder|,
12369736
C103477_D009069 NONE 55562_1\CD|,|side (r_nummod) GR_0\NNP|.|shell|prior|attenuated (r_nsubj) administered_11\VBN|NONE (l_conj) attenuated_23\VBD|.|GR|shell|prior (l_dobj) hyperactivity_29\NN|dependently
C103477_D009069 NONE 55562_38\CD|NONE (r_nummod) GR_37\NNP|)|HTB|the|(|receptor (r_appos) antagonist_35\NN|NONE (r_pobj) of_31\IN|inhibitory (r_prep) effects_30\NNS|NONE (r_pobj) in_26\IN|NONE (r_prep) consisting_25\VBG|respectively|,|this|agonist|and|core (r_acl) modification_24\NN|but|,|the|accumbens (r_conj) shell_17\NN|NONE (r_pobj) into_14\IN|NONE (r_prep) microinjected_13\VBN|receptor|HTB (r_acl) ligands_12\NNS|NONE (r_pobj) by_9\IN|hyperlocomotion|.|is (r_agent) modified_8\VBN|findings|induced (l_nsubjpass) hyperlocomotion_6\NN|.|by|is
D003042_D009069 CID cocaine_14\NN| (r_npadvmod) induced_16\VBN|the|in|locomotor (r_amod) hyperactivity_18\NN|NONE
D003042_D009069 CID cocaine_34\NN|NONE (r_pobj) by_33\IN|NONE (r_agent) induced_32\VBN|the|locomotor (r_acl) hyperactivity_31\NN|NONE
D003042_D009069 CID cocaine_18\NN|NONE (r_pobj) to_17\IN|NONE (r_prep) prior_16\RB|.|GR|shell|attenuated (r_advmod) administered_11\VBN|NONE (l_conj) attenuated_23\VBD|.|GR|shell|prior (l_dobj) hyperactivity_29\NN|dependently
D003042_D009069 CID cocaine_4\NN|that (r_nsubj) induced_5\VBN|findings|modified (r_ccomp) indicate_2\VBP|NONE (l_ccomp) modified_8\VBN|findings|induced (l_nsubjpass) hyperlocomotion_6\NN|.|by|is
C065046_D009069 CID 93129_44\CD|(|) (r_nummod) CP_43\NNP|, (r_appos) agonist_41\NN|respectively|consisting|,|this|and|core (r_conj) modification_24\NN|but|,|the|accumbens (r_conj) shell_17\NN|NONE (r_pobj) into_14\IN|NONE (r_prep) microinjected_13\VBN|receptor|HTB (r_acl) ligands_12\NNS|NONE (r_pobj) by_9\IN|hyperlocomotion|.|is (r_agent) modified_8\VBN|findings|induced (l_nsubjpass) hyperlocomotion_6\NN|.|by|is
18221780
D003915_D059787 NONE dextromethorphan_5\NNP|NONE (r_pobj) by_4\IN|of (r_prep) Enhancement_0\NN|.|with|,|in|was (r_nsubjpass) seen_7\VBN|NONE (l_prep) in_8\IN|.|with|,|was|Enhancement (l_pobj) males_10\NNS|NONE (l_prep) in_13\IN|and|females|both (l_pobj) models_17\NNS|NONE (l_compound) pain_16\NN|acute|the
D009020_D010146 NONE morphine_7\NN|NONE (r_compound) antihyperalgesia_8\NN|NONE (r_pobj) of_6\IN|NMDA|antagonist (r_prep) enhancement_5\NN|NONE (r_pobj) in_2\IN|Sex|:|.|comparisons|in (r_prep) differences_1\NNS|NONE (l_prep) in_9\IN|Sex|:|.|comparisons|in (l_pobj) model_12\NN|NONE (l_prep) of_13\IN|a|capsaicin (l_pobj) pain_15\NN|NONE
D009020_D010146 NONE morphine_12\NN|NMDA|and (r_conj) antagonists_10\NNS|NONE (r_pobj) between_8\IN|in|dimorphic|a (r_prep) interaction_7\NN|findings|. (l_prep) in_13\IN|dimorphic|between|a (l_pobj) model_17\NN|NONE (l_compound) pain_16\NN|a|persistent|distinguished
D016202_D059787 NONE NMDA_3\NNP|of|antagonist (r_compound) enhancement_5\NN|NONE (r_pobj) in_2\IN|Sex|:|.|comparisons|in (r_prep) differences_1\NNS|NONE (l_appos) comparisons_17\NNS|Sex|:|.|in|in (l_prep) to_18\IN|NONE (l_pobj) models_20\NNS|NONE (l_prep) of_21\IN|two (l_pobj) pain_23\NN|NONE
D016202_D059787 NONE aspartate_11\NNP|)|NMDA|(|methyl (r_nmod) antagonists_15\NNS|to|In|effects|. (r_nsubj) enhance_16\VBP|NONE (l_prep) In_0\IN|to|antagonists|effects|. (l_pobj) models_3\NNS|, (l_compound) pain_2\NN|acute
D016202_D059787 NONE NMDA_13\NNP|)|aspartate|(|methyl (r_nmod) antagonists_15\NNS|to|In|effects|. (r_nsubj) enhance_16\VBP|NONE (l_prep) In_0\IN|to|antagonists|effects|. (l_pobj) models_3\NNS|, (l_compound) pain_2\NN|acute
D016202_D059787 NONE NMDA_9\NNP|morphine|and (r_compound) antagonists_10\NNS|NONE (r_pobj) between_8\IN|in|dimorphic|a (r_prep) interaction_7\NN|findings|. (l_prep) in_13\IN|dimorphic|between|a (l_pobj) model_17\NN|NONE (l_relcl) distinguished_21\VBN|a|pain|persistent (l_prep) from_22\IN|can|be|that (l_pobj) those_23\DT|NONE (l_acl) observed_24\VBN|NONE (l_prep) in_25\IN|NONE (l_pobj) models_28\NNS|NONE (l_compound) pain_27\NN|acute
D002211_D010146 NONE capsaicin_11\NN|a|of (r_compound) model_12\NN|NONE (l_prep) of_13\IN|a|capsaicin (l_pobj) pain_15\NN|NONE
D016202_D010146 NONE NMDA_3\NNP|of|antagonist (r_compound) enhancement_5\NN|NONE (r_pobj) in_2\IN|Sex|:|.|comparisons|in (r_prep) differences_1\NNS|NONE (l_prep) in_9\IN|Sex|:|.|comparisons|in (l_pobj) model_12\NN|NONE (l_prep) of_13\IN|a|capsaicin (l_pobj) pain_15\NN|NONE
D016202_D010146 NONE NMDA_9\NNP|morphine|and (r_compound) antagonists_10\NNS|NONE (r_pobj) between_8\IN|in|dimorphic|a (r_prep) interaction_7\NN|findings|. (l_prep) in_13\IN|dimorphic|between|a (l_pobj) model_17\NN|NONE (l_compound) pain_16\NN|a|persistent|distinguished
D009020_D059787 NONE morphine_7\NN|NONE (r_compound) antihyperalgesia_8\NN|NONE (r_pobj) of_6\IN|NMDA|antagonist (r_prep) enhancement_5\NN|NONE (r_pobj) in_2\IN|Sex|:|.|comparisons|in (r_prep) differences_1\NNS|NONE (l_appos) comparisons_17\NNS|Sex|:|.|in|in (l_prep) to_18\IN|NONE (l_pobj) models_20\NNS|NONE (l_prep) of_21\IN|two (l_pobj) pain_23\NN|NONE
D009020_D059787 NONE morphine_21\NN|NONE (r_pobj) of_20\IN|the|antinociceptive (r_prep) effects_19\NNS|to|antagonists|In|. (r_dobj) enhance_16\VBP|NONE (l_prep) In_0\IN|to|antagonists|effects|. (l_pobj) models_3\NNS|, (l_compound) pain_2\NN|acute
D009020_D059787 NONE morphine_2\NN|NONE (r_compound) antinociception_3\NN|NONE (r_pobj) of_1\IN|by (r_prep) Enhancement_0\NN|.|with|,|in|was (r_nsubjpass) seen_7\VBN|NONE (l_prep) in_8\IN|.|with|,|was|Enhancement (l_pobj) males_10\NNS|NONE (l_prep) in_13\IN|and|females|both (l_pobj) models_17\NNS|NONE (l_compound) pain_16\NN|acute|the
D009020_D059787 NONE morphine_12\NN|NMDA|and (r_conj) antagonists_10\NNS|NONE (r_pobj) between_8\IN|in|dimorphic|a (r_prep) interaction_7\NN|findings|. (l_prep) in_13\IN|dimorphic|between|a (l_pobj) model_17\NN|NONE (l_relcl) distinguished_21\VBN|a|pain|persistent (l_prep) from_22\IN|can|be|that (l_pobj) those_23\DT|NONE (l_acl) observed_24\VBN|NONE (l_prep) in_25\IN|NONE (l_pobj) models_28\NNS|NONE (l_compound) pain_27\NN|acute
D002211_D006930 CID capsaicin_11\NN|NONE (r_pobj) of_10\IN|in (r_prep) administration_9\NN|NONE (r_pobj) by_8\IN|immersed|was|.|To|,|,|hyperalgesia (r_agent) induced_7\VBN|NONE (l_nsubjpass) hyperalgesia_5\NN|immersed|was|.|To|by|,|,
D002211_D059787 NONE capsaicin_11\NN|a|of (r_compound) model_12\NN|NONE (r_pobj) in_9\IN|Sex|:|.|comparisons|in (r_prep) differences_1\NNS|NONE (l_appos) comparisons_17\NNS|Sex|:|.|in|in (l_prep) to_18\IN|NONE (l_pobj) models_20\NNS|NONE (l_prep) of_21\IN|two (l_pobj) pain_23\NN|NONE
15764424
D008694_D006948 CID Methamphetamine_0\NN|were|to|. (r_nsubjpass) related_5\VBN|NONE (l_prep) to_6\IN|were|.|Methamphetamine (l_pobj) scores_9\NNS|NONE (l_conj) rating_14\NN|psychopathology|and|several (l_compound) hyperkinesia_13\NN|global|the
D002395_D001523 NONE catecholamines_10\NNS|,|quantitative|drug|stimulant (r_conj) levels_8\NNS|NONE (r_pobj) between_4\IN|the (r_prep) relationship_3\NN|To (r_dobj) examine_1\VB|,|patients|collected|were|and|, (r_advcl) interviewed_34\VBN|NONE (l_nsubjpass) patients_17\NNS|examine|,|collected|were|and|, (l_prep) in_18\IN|nineteen (l_pobj) service_22\NN|NONE (l_amod) psychiatric_20\JJ|emergency|a|with
D002395_D001523 NONE catecholamine_49\NN|and|stimulant (r_conj) drug_47\NN|metabolite (r_nmod) levels_51\NNS|NONE (r_pobj) of_45\IN|quantitative (r_prep) assays_44\NNS|NONE (r_pobj) for_42\IN|.|plasma|were (r_prep) collected_41\VBN|examine|,|patients|were|and|, (r_conj) interviewed_34\VBN|NONE (l_nsubjpass) patients_17\NNS|examine|,|collected|were|and|, (l_prep) in_18\IN|nineteen (l_pobj) service_22\NN|NONE (l_amod) psychiatric_20\JJ|emergency|a|with
D000661_D001523 NONE amphetamine-_27\JJ| (r_npadvmod) induced_31\VBN|NONE (r_amod) psychosis_32\NN|NONE (r_pobj) of_26\IN|a (r_prep) diagnosis_25\NN|NONE (r_pobj) with_23\IN|emergency|a|psychiatric (r_prep) service_22\NN|NONE (l_amod) psychiatric_20\JJ|emergency|a|with
D000661_D011605 CID amphetamine-_27\JJ| (r_npadvmod) induced_31\VBN|NONE (r_amod) psychosis_32\NN|NONE (r_pobj) of_26\IN|a (r_prep) diagnosis_25\NN|NONE (r_pobj) with_23\IN|emergency|a|psychiatric (r_prep) service_22\NN|NONE (r_pobj) in_18\IN|nineteen (r_prep) patients_17\NNS|examine|,|collected|were|and|, (r_nsubjpass) interviewed_34\VBN|NONE (l_advcl) examine_1\VB|,|patients|collected|were|and|, (l_dobj) relationship_3\NN|To (l_prep) between_4\IN|the (l_pobj) levels_8\NNS|NONE (l_conj) catecholamines_10\NNS|,|quantitative|drug|stimulant (l_conj) symptoms_14\NNS|,|and
D000661_D011605 CID amphetamine-_27\JJ| (r_npadvmod) induced_31\VBN|NONE (r_amod) psychosis_32\NN|NONE
D002395_D011605 NONE catecholamines_12\NNS|symptom|, (r_conj) severity_10\NN|NONE (r_pobj) to_8\IN|NONE (r_prep) relationship_7\NN|.|in|drug|Quantitative|: (r_appos) levels_2\NNS|NONE (l_prep) in_3\IN|.|drug|relationship|Quantitative|: (l_pobj) psychosis_5\NN|NONE
D002395_D011605 NONE catecholamines_10\NNS|,|quantitative|drug|stimulant (l_conj) symptoms_14\NNS|,|and
D002395_D011605 NONE catecholamines_10\NNS|,|quantitative|drug|stimulant (r_conj) levels_8\NNS|NONE (r_pobj) between_4\IN|the (r_prep) relationship_3\NN|To (r_dobj) examine_1\VB|,|patients|collected|were|and|, (r_advcl) interviewed_34\VBN|NONE (l_nsubjpass) patients_17\NNS|examine|,|collected|were|and|, (l_prep) in_18\IN|nineteen (l_pobj) service_22\NN|NONE (l_prep) with_23\IN|emergency|a|psychiatric (l_pobj) diagnosis_25\NN|NONE (l_prep) of_26\IN|a (l_pobj) psychosis_32\NN|NONE
D002395_D011605 NONE catecholamine_49\NN|and|stimulant (r_conj) drug_47\NN|metabolite (r_nmod) levels_51\NNS|NONE (r_pobj) of_45\IN|quantitative (r_prep) assays_44\NNS|NONE (r_pobj) for_42\IN|.|plasma|were (r_prep) collected_41\VBN|examine|,|patients|were|and|, (r_conj) interviewed_34\VBN|NONE (l_advcl) examine_1\VB|,|patients|collected|were|and|, (l_dobj) relationship_3\NN|To (l_prep) between_4\IN|the (l_pobj) levels_8\NNS|NONE (l_conj) catecholamines_10\NNS|,|quantitative|drug|stimulant (l_conj) symptoms_14\NNS|,|and
D002395_D011605 NONE catecholamine_49\NN|and|stimulant (r_conj) drug_47\NN|metabolite (r_nmod) levels_51\NNS|NONE (r_pobj) of_45\IN|quantitative (r_prep) assays_44\NNS|NONE (r_pobj) for_42\IN|.|plasma|were (r_prep) collected_41\VBN|examine|,|patients|were|and|, (r_conj) interviewed_34\VBN|NONE (l_nsubjpass) patients_17\NNS|examine|,|collected|were|and|, (l_prep) in_18\IN|nineteen (l_pobj) service_22\NN|NONE (l_prep) with_23\IN|emergency|a|psychiatric (l_pobj) diagnosis_25\NN|NONE (l_prep) of_26\IN|a (l_pobj) psychosis_32\NN|NONE
D002395_D006948 NONE catecholamines_12\NNS|symptom|, (l_conj) hyperkinesia_14\NN|and
D003042_D011605 CID cocaine_29\NN|or (r_conj) amphetamine-_27\JJ| (r_npadvmod) induced_31\VBN|NONE (r_amod) psychosis_32\NN|NONE (r_pobj) of_26\IN|a (r_prep) diagnosis_25\NN|NONE (r_pobj) with_23\IN|emergency|a|psychiatric (r_prep) service_22\NN|NONE (r_pobj) in_18\IN|nineteen (r_prep) patients_17\NNS|examine|,|collected|were|and|, (r_nsubjpass) interviewed_34\VBN|NONE (l_advcl) examine_1\VB|,|patients|collected|were|and|, (l_dobj) relationship_3\NN|To (l_prep) between_4\IN|the (l_pobj) levels_8\NNS|NONE (l_conj) catecholamines_10\NNS|,|quantitative|drug|stimulant (l_conj) symptoms_14\NNS|,|and
D003042_D011605 CID cocaine_29\NN|or (r_conj) amphetamine-_27\JJ| (r_npadvmod) induced_31\VBN|NONE (r_amod) psychosis_32\NN|NONE
D003042_D001523 NONE cocaine_29\NN|or (r_conj) amphetamine-_27\JJ| (r_npadvmod) induced_31\VBN|NONE (r_amod) psychosis_32\NN|NONE (r_pobj) of_26\IN|a (r_prep) diagnosis_25\NN|NONE (r_pobj) with_23\IN|emergency|a|psychiatric (r_prep) service_22\NN|NONE (l_amod) psychiatric_20\JJ|emergency|a|with
D000661_D006948 CID amphetamine_2\NN|NONE (r_compound) levels_3\NNS|or (r_conj) Methamphetamine_0\NN|were|to|. (r_nsubjpass) related_5\VBN|NONE (l_prep) to_6\IN|were|.|Methamphetamine (l_pobj) scores_9\NNS|NONE (l_conj) rating_14\NN|psychopathology|and|several (l_compound) hyperkinesia_13\NN|global|the
6773726
D005996_D007022 CID nitroglycerin_5\NN|NONE (r_pobj) by_4\IN|postural (r_prep) hypotension_3\NN|NONE
D005996_D003929 NONE nitroglycerin_5\NN|NONE (l_prep) in_6\IN|NONE (l_pobj) neuropathy_9\NN|NONE
D005996_D009422 NONE nitroglycerin_3\NN|NONE (r_pobj) of_2\IN|The (r_prep) effect_1\NN|.|in|was (r_nsubjpass) compared_12\VBN|NONE (l_prep) in_13\IN|effect|.|was (l_pobj) subjects_16\NNS|NONE (l_appos) subjects_20\NNS||,|normal (l_prep) without_21\IN||and|diabetic|,|subjects (l_pobj) neuropathy_23\NN|NONE
D005996_D009422 NONE nitroglycerin_3\NN|NONE (r_pobj) of_2\IN|The (r_prep) effect_1\NN|.|in|was (r_nsubjpass) compared_12\VBN|NONE (l_prep) in_13\IN|effect|.|was (l_pobj) subjects_16\NNS|NONE (l_appos) subjects_20\NNS||,|normal (l_conj) subjects_28\NNS|without||and|diabetic|, (l_prep) with_29\IN|diabetic| (l_pobj) neuropathy_31\NN|NONE
D005996_D009422 NONE nitroglycerin_19\NN|NONE (r_pobj) after_18\IN|the|in (r_prep) decrease_13\NN|the|in|and (r_conj) increase_7\NN|NONE (r_pobj) of_5\IN|magnitude (r_prep) course_4\NN|similar|occurred|,|. (r_nsubj) were_20\VBD|NONE (l_acomp) similar_21\JJ|course|occurred|,|. (l_prep) in_22\IN|NONE (l_pobj) subjects_27\NNS|NONE (l_prep) without_28\IN|the|normal (l_pobj) neuropathy_30\NN|NONE
D005996_D009422 NONE nitroglycerin_19\NN|NONE (r_pobj) after_18\IN|the|in (r_prep) decrease_13\NN|the|in|and (r_conj) increase_7\NN|NONE (r_pobj) of_5\IN|magnitude (r_prep) course_4\NN|similar|occurred|,|. (r_nsubj) were_20\VBD|NONE (l_advcl) occurred_47\VBD|similar|course|,|. (l_prep) in_48\IN|increase|whereas (l_pobj) subjects_51\NNS|NONE (l_prep) with_52\IN|diabetic|the (l_pobj) neuropathy_54\NN|NONE
D005996_D003920 NONE nitroglycerin_3\NN|NONE (r_pobj) of_2\IN|The (r_prep) effect_1\NN|.|in|was (r_nsubjpass) compared_12\VBN|NONE (l_prep) in_13\IN|effect|.|was (l_pobj) subjects_16\NNS|NONE (l_appos) subjects_20\NNS||,|normal (l_amod) diabetic_19\JJ|without||and|,|subjects
D005996_D003920 NONE nitroglycerin_3\NN|NONE (r_pobj) of_2\IN|The (r_prep) effect_1\NN|.|in|was (r_nsubjpass) compared_12\VBN|NONE (l_prep) in_13\IN|effect|.|was (l_pobj) subjects_16\NNS|NONE (l_appos) subjects_20\NNS||,|normal (l_conj) subjects_28\NNS|without||and|diabetic|, (l_amod) diabetic_27\JJ|with|
D005996_D003920 NONE nitroglycerin_19\NN|NONE (r_pobj) after_18\IN|the|in (r_prep) decrease_13\NN|the|in|and (r_conj) increase_7\NN|NONE (r_pobj) of_5\IN|magnitude (r_prep) course_4\NN|similar|occurred|,|. (r_nsubj) were_20\VBD|NONE (l_acomp) similar_21\JJ|course|occurred|,|. (l_prep) in_22\IN|NONE (l_pobj) subjects_27\NNS|NONE (l_amod) normal_24\JJ|without|the (l_conj) diabetic_26\JJ|and
D005996_D003920 NONE nitroglycerin_19\NN|NONE (r_pobj) after_18\IN|the|in (r_prep) decrease_13\NN|the|in|and (r_conj) increase_7\NN|NONE (r_pobj) of_5\IN|magnitude (r_prep) course_4\NN|similar|occurred|,|. (r_nsubj) were_20\VBD|NONE (l_advcl) occurred_47\VBD|similar|course|,|. (l_prep) in_48\IN|increase|whereas (l_pobj) subjects_51\NNS|NONE (l_amod) diabetic_50\JJ|with|the
8739323
D008466_D007674 NONE nitrogranulogen_8\NN|such (r_pobj) as_7\IN|anticancer (r_prep) drugs_5\NNS|NONE (r_pobj) of_3\IN|The|nephrotoxic|MTX|FU|administered (r_prep) action_2\NN|in|.|was (l_amod) nephrotoxic_1\JJ|The|of|MTX|FU|administered
D008466_D007674 NONE NG_10\NNP|methotrexate|, (r_appos) nitrogranulogen_8\NN|such (r_pobj) as_7\IN|anticancer (r_prep) drugs_5\NNS|NONE (r_pobj) of_3\IN|The|nephrotoxic|MTX|FU|administered (r_prep) action_2\NN|in|.|was (l_amod) nephrotoxic_1\JJ|The|of|MTX|FU|administered
D003520_D006470 CID CY_0\NNP|in|,|cause|but|cystitis (r_nsubj) caused_1\VBD|NONE (l_dobj) cystitis_3\NN|in|,|cause|CY|but
D008727_D007674 NONE methotrexate_13\NNP|NG|, (r_conj) nitrogranulogen_8\NN|such (r_pobj) as_7\IN|anticancer (r_prep) drugs_5\NNS|NONE (r_pobj) of_3\IN|The|nephrotoxic|MTX|FU|administered (r_prep) action_2\NN|in|.|was (l_amod) nephrotoxic_1\JJ|The|of|MTX|FU|administered
D008727_D007674 NONE MTX_15\NNP|, (r_appos) methotrexate_13\NNP|NG|, (r_conj) nitrogranulogen_8\NN|such (r_pobj) as_7\IN|anticancer (r_prep) drugs_5\NNS|NONE (r_pobj) of_3\IN|The|nephrotoxic|MTX|FU|administered (r_prep) action_2\NN|in|.|was (l_amod) nephrotoxic_1\JJ|The|of|MTX|FU|administered
D008727_D007674 NONE MTX_33\NNP|The|nephrotoxic|of|FU|administered (r_appos) action_2\NN|in|.|was (l_amod) nephrotoxic_1\JJ|The|of|MTX|FU|administered
D008727_D007674 NONE MTX_6\NNP|NONE (r_pobj) of_5\IN|that|+ (r_prep) nephrotoxicity_4\NN|.|studies|is
D008727_D006470 NONE MTX_22\NNP|and (r_conj) 5-FU_20\CD|NONE (r_pobj) with_19\IN|when (r_prep) combined_18\VBN|did|it|complication|not|. (r_advcl) cause_14\VB|in|,|CY|but|cystitis (r_conj) caused_1\VBD|NONE (l_dobj) cystitis_3\NN|in|,|cause|CY|but
D005472_D006470 NONE 5-FU_20\CD|NONE (r_pobj) with_19\IN|when (r_prep) combined_18\VBN|did|it|complication|not|. (r_advcl) cause_14\VB|in|,|CY|but|cystitis (r_conj) caused_1\VBD|NONE (l_dobj) cystitis_3\NN|in|,|cause|CY|but
D005472_D007674 NONE 5-fluorouracil_18\CD|cyclophosphamide|)|and|( (r_punct) 5-FU_20\CD|The|nephrotoxic|of|MTX|administered (r_appos) action_2\NN|in|.|was (l_amod) nephrotoxic_1\JJ|The|of|MTX|FU|administered
D005472_D007674 NONE 5-FU_20\CD|The|nephrotoxic|of|MTX|administered (r_appos) action_2\NN|in|.|was (l_amod) nephrotoxic_1\JJ|The|of|MTX|FU|administered
D005472_D007674 NONE 5-FU_35\CD|+|[ (r_conj) MTX_33\NNP|The|nephrotoxic|of|FU|administered (r_appos) action_2\NN|in|.|was (l_amod) nephrotoxic_1\JJ|The|of|MTX|FU|administered
D005472_D007674 NONE 5-FU_8\CD|lower (r_nsubj) is_13\VBZ|nephrotoxicity|.|studies (r_ccomp) indicate_2\VBP|NONE (l_dobj) nephrotoxicity_4\NN|.|studies|is
D005472_D003556 NONE 5-FU_20\CD|NONE (r_pobj) with_19\IN|when (r_prep) combined_18\VBN|did|it|complication|not|. (r_advcl) cause_14\VB|in|,|CY|but|cystitis (r_conj) caused_1\VBD|NONE (l_dobj) cystitis_3\NN|in|,|cause|CY|but
D003520_D003556 CID CY_0\NNP|in|,|cause|but|cystitis (r_nsubj) caused_1\VBD|NONE (l_dobj) cystitis_3\NN|in|,|cause|CY|but
D008727_D003556 NONE MTX_22\NNP|and (r_conj) 5-FU_20\CD|NONE (r_pobj) with_19\IN|when (r_prep) combined_18\VBN|did|it|complication|not|. (r_advcl) cause_14\VB|in|,|CY|but|cystitis (r_conj) caused_1\VBD|NONE (l_dobj) cystitis_3\NN|in|,|cause|CY|but
D003520_D007674 NONE cyclophosphamide_23\NN|)|fluorouracil|and|( (r_conj) 5-FU_20\CD|The|nephrotoxic|of|MTX|administered (r_appos) action_2\NN|in|.|was (l_amod) nephrotoxic_1\JJ|The|of|MTX|FU|administered
D003520_D007674 NONE CY_25\NNP|NONE (r_appos) cyclophosphamide_23\NN|)|fluorouracil|and|( (r_conj) 5-FU_20\CD|The|nephrotoxic|of|MTX|administered (r_appos) action_2\NN|in|.|was (l_amod) nephrotoxic_1\JJ|The|of|MTX|FU|administered
D003520_D007674 NONE CY_37\NNP|+ (r_conj) 5-FU_35\CD|+|[ (r_conj) MTX_33\NNP|The|nephrotoxic|of|FU|administered (r_appos) action_2\NN|in|.|was (l_amod) nephrotoxic_1\JJ|The|of|MTX|FU|administered
D003520_D007674 NONE CY_10\NNP|administered|+ (r_conj) 5-FU_8\CD|lower (r_nsubj) is_13\VBZ|nephrotoxicity|.|studies (r_ccomp) indicate_2\VBP|NONE (l_dobj) nephrotoxicity_4\NN|.|studies|is
761833
D004298_D003128 NONE dopamine_3\NN|NONE (r_pobj) of_2\IN|Intraventricular (r_prep) infusion_1\NN|.|prevent|raise (r_nsubj) sufficient_4\JJ|NONE (l_conj) prevent_16\VB|.|infusion|raise (l_dobj) coma_19\NN|not|affect|nor|did
D004298_D003128 NONE dopamine_9\NN|to|to (r_dobj) raise_6\VB|.|infusion|prevent (r_xcomp) sufficient_4\JJ|NONE (l_conj) prevent_16\VB|.|infusion|raise (l_dobj) coma_19\NN|not|affect|nor|did
D004298_D003128 NONE dopamine_29\NN|NONE (r_pobj) of_28\IN|the|on|peripheral (r_prep) effect_27\NN|NONE (r_pobj) by_24\IN|can|.|,|be|for|reduction|Thus|, (r_agent) accounted_22\VBN|NONE (l_nsubjpass) reduction_3\NN|can|.|,|by|be|for|Thus|, (l_conj) prevention_11\NN|and|the|in (l_prep) of_12\IN|after|the (l_pobj) coma_14\NN|NONE
D007980_D003128 NONE dopa_9\NNP|NONE (r_pobj) by_6\IN|NONE (r_prep) rats_5\NNS|NONE (r_pobj) in_4\IN|ammonia (r_prep) coma_3\NN|NONE
D007980_D003128 NONE dopa_9\NN|NONE (r_pobj) with_4\IN|was|coma|.|before (r_prep) prevented_3\VBN|NONE (l_nsubjpass) coma_1\NN|was|.|with|before
D007980_D003128 NONE dopa_9\NN|NONE (l_conj) coma_18\NN||and|L|on
D007980_D003128 NONE dopa_18\NNP|NONE (r_pobj) after_15\IN|of|the (r_prep) prevention_11\NN|and|the|in (l_prep) of_12\IN|after|the (l_pobj) coma_14\NN|NONE
D064751_D003128 NONE salt_19\NN|the (r_compound) injection_20\NN|minutes (r_pobj) before_16\IN|was|coma|.|with (r_prep) prevented_3\VBN|NONE (l_nsubjpass) coma_1\NN|was|.|with|before
D000641_D003128 NONE ammonia_2\NN|in (r_compound) coma_3\NN|NONE
D000641_D003128 NONE Ammonia_0\NN|NONE (r_compound) coma_1\NN|in|was|.
D000641_D003128 NONE ammonia_18\NN|the (r_compound) coma_19\NN|not|affect|nor|did
D000641_D003128 NONE ammonia_26\NN|the|blood (r_compound) concentrations_27\NNS|NONE (r_dobj) affect_21\VB|not|coma|nor|did (r_conj) prevent_16\VB|.|infusion|raise (l_dobj) coma_19\NN|not|affect|nor|did
D000641_D003128 NONE ammonia_14\NN|NONE (r_pobj) on_10\IN|coma||and|L (r_prep) dopa_9\NN|NONE (l_conj) coma_18\NN||and|L|on
D000641_D003128 NONE ammonia_17\NN|the (r_compound) coma_18\NN||and|L|on
D000641_D003128 NONE ammonia_8\NN|NONE (r_pobj) in_4\IN|and|the|prevention (r_prep) reduction_3\NN|can|.|,|by|be|for|Thus|, (l_conj) prevention_11\NN|and|the|in (l_prep) of_12\IN|after|the (l_pobj) coma_14\NN|NONE
D000641_D003128 NONE ammonia_13\NN|NONE (r_compound) coma_14\NN|NONE
D007980_D001927 NONE dopa_18\NNP|NONE (r_dobj) receiving_15\VBG|some|encephalopathic (r_acl) patients_14\NNS|NONE (l_amod) encephalopathic_13\JJ|receiving|some
D000643_D003128 CID NH4CL_17\NN|NONE (r_pobj) of_14\IN|an (r_prep) intraperitonealinjection_13\NN|NONE (r_pobj) of_11\IN| (r_prep) minutes_10\NNS|NONE (r_pobj) within_6\IN|NONE (r_prep) rats_5\NNS|NONE (r_pobj) in_4\IN|was|.|coma (r_prep) produced_3\VBN|NONE (l_nsubjpass) coma_1\NN|in|was|.
6153967
D004737_D004827 NONE enflurane_6\NN|NONE (r_pobj) by_5\IN|NONE (r_agent) activated_4\VBN|and|ablated|foci|and|are (r_conj) delineated_2\VBN|NONE (l_nsubj) foci_1\NN|and|ablated|activated|and|are (l_amod) Epileptic_0\JJ|NONE
D004737_D004827 NONE enflurane_5\NN|On|be|,|may|. (r_nsubj) prove_7\VB|NONE (l_xcomp) be_9\VB|On|enflurane|,|may|. (l_attr) activator_14\NN|to (l_prep) of_15\IN|acting|during|fast|a|safe (l_pobj) foci_17\VBD|NONE (l_amod) epileptic_16\JJ|NONE
D004737_D012640 CID enflurane_4\NN|In|in|.|, (r_nsubj) resulted_10\VBD|NONE (l_prep) in_11\IN|enflurane|In|.|, (l_pobj) seizures_15\NNS|NONE
D004737_D012640 CID enflurane_6\NN|NONE (r_pobj) by_5\IN|NONE (r_agent) activated_4\VBN|and|ablated|foci|and|are (r_conj) delineated_2\VBN|NONE (l_conj) are_13\VBP|and|ablated|foci|activated|and (l_acomp) free_17\JJ|patients|.|now (l_npadvmod) seizure_15\NN|
9334596
D013739_D007172 NONE testosterone_6\NN|NONE (r_pobj) of_4\IN|in|the (r_prep) results_3\NNS|.|We|,|compared|results|and (l_prep) in_10\IN|of|the (l_pobj) patients_12\NNS|NONE (l_acl) referred_13\VBD|, (l_prep) because_14\IN|NONE (l_pobj) dysfunction_17\NN|of
D013739_D007172 NONE testosterone_5\NN|the|low|other (r_compound) levels_6\NNS|NONE (r_pobj) of_1\IN|NONE (r_prep) Most_0\JJS|result|. (r_nsubj) seemed_7\VBD|NONE (l_xcomp) result_9\VB|.|Most (l_prep) because_14\IN|from|to (l_conj) have_24\VB|hormone|of|and (l_dobj) role_28\NN|to (l_prep) in_29\IN|a|small|only (l_pobj) dysfunction_31\NN|NONE
D013739_D007172 NONE testosterone_6\NN|NONE (r_pobj) of_4\IN|in (r_prep) effects_3\NNS|and|Low (l_prep) in_10\IN|of (l_pobj) dysfunction_12\NN|NONE
D013739_D010911 NONE testosterone_6\NN|NONE (r_compound) determination_7\NN|NONE (r_pobj) after_5\IN|were|tumors|. (r_prep) discovered_4\VBN|NONE (l_nsubjpass) tumors_2\NNS|were|after|.
D001971_D006966 NONE bromocriptine_13\NN|and (l_prep) for_14\IN|NONE (l_pobj) hyperprolactinemia_15\NN|NONE
D001971_D007006 NONE bromocriptine_13\NN|and (r_conj) hypogonadism_11\NN|NONE
C004648_D006966 NONE heptylate_5\NN|NONE (l_conj) gonadotropin_9\NN|or|testosterone (l_prep) for_10\IN|chorionic|human (l_pobj) hypogonadism_11\NN|NONE (l_conj) bromocriptine_13\NN|and (l_prep) for_14\IN|NONE (l_pobj) hyperprolactinemia_15\NN|NONE
D013739_D006177 NONE testosterone_5\NN|NONE (r_pobj) for_4\IN|.|patient|screened|was (r_prep) screened_3\VBN|NONE (l_conj) screened_9\VBN|.|patient|was|for (l_prep) on_12\IN|were|for (l_pobj) basis_14\NN|NONE (l_prep) of_15\IN|the (l_pobj) desire_18\NN|NONE (l_conj) gynecomastia_20\NN|,|sexual|low
D013739_D006177 NONE testosterone_22\NN|or (r_conj) gynecomastia_20\NN|,|sexual|low
D013739_D006177 NONE testosterone_14\NN|and/or (r_conj) gynecomastia_12\NN|sexual|,|low
D013739_D020018 CID testosterone_5\NN|NONE (r_pobj) for_4\IN|.|patient|screened|was (r_prep) screened_3\VBN|NONE (l_conj) screened_9\VBN|.|patient|was|for (l_prep) on_12\IN|were|for (l_pobj) basis_14\NN|NONE (l_prep) of_15\IN|the (l_pobj) desire_18\NN|NONE
D013739_D020018 CID testosterone_22\NN|or (r_conj) gynecomastia_20\NN|,|sexual|low (r_conj) desire_18\NN|NONE
D013739_D020018 CID testosterone_1\NN|in (r_dobj) Determining_0\VBG|%|.|have|would (l_prep) in_3\IN|testosterone (l_pobj) cases_4\NNS|only (l_prep) of_5\IN|NONE (l_pobj) desire_8\NN|NONE
D013739_D020018 CID testosterone_23\NN|NONE (r_pobj) with_21\IN|the (r_prep) cases_20\NNS|NONE (r_pobj) of_18\IN| (r_prep) %_17\NN|.|Determining|have|would (r_dobj) missed_15\VBN|NONE (l_csubj) Determining_0\VBG|%|.|have|would (l_prep) in_3\IN|testosterone (l_pobj) cases_4\NNS|only (l_prep) of_5\IN|NONE (l_pobj) desire_8\NN|NONE
D013739_D020018 CID testosterone_8\NN|before|that|be|in|but|measured (r_nsubjpass) determined_10\VBN|now|We|. (l_prep) in_12\IN|before|that|be|but|measured|testosterone (l_pobj) cases_13\NNS|only (l_prep) of_14\IN|NONE (l_pobj) desire_17\NN|NONE
D013739_D020018 CID testosterone_14\NN|and/or (r_conj) gynecomastia_12\NN|sexual|,|low (r_conj) desire_10\NN|NONE
D013739_D007027 NONE testosterone_5\NN|the|low|other (r_compound) levels_6\NNS|NONE (r_pobj) of_1\IN|NONE (r_prep) Most_0\JJS|result|. (r_nsubj) seemed_7\VBD|NONE (l_xcomp) result_9\VB|.|Most (l_prep) from_10\IN|because|to (l_pobj) dysfunction_13\NN|NONE
C004648_D007006 NONE heptylate_5\NN|NONE (l_conj) gonadotropin_9\NN|or|testosterone (l_prep) for_10\IN|chorionic|human (l_pobj) hypogonadism_11\NN|NONE
14648024
D014212_D010146 NONE ATRA_23\NNP|NONE (r_compound) therapy_24\NN|NONE (r_pobj) after_22\IN|over|subsequent|multiple|erythematous|,|painful (r_prep) nodules_6\NNS|.|and (l_amod) painful_4\JJ|over|subsequent|multiple|erythematous|after|,
D014212_D004893 CID acid_4\NN| (r_npadvmod) induced_6\VBN|NONE (r_amod) erythema_7\NN|in|retinoic (r_compound) nodosum_8\NN|.
D014212_D004893 CID acid_8\NN|NONE (r_pobj) with_3\IN|for (r_prep) associated_2\VBD|Erythema (r_acl) nodosum_1\NN|.|rare
D014212_D004893 CID ATRA_10\NNP|(|)|all|retinoic (r_appos) acid_8\NN|NONE (r_pobj) with_3\IN|for (r_prep) associated_2\VBD|Erythema (r_acl) nodosum_1\NN|.|rare
D014212_D004893 CID ATRA_12\NNP|NONE (r_compound) therapy_13\NN|NONE (r_pobj) during_11\IN|who|nodosum (r_prep) developed_8\VBD|classic (l_dobj) nodosum_10\NN|during|who
D014212_D004893 CID ATRA_23\NNP|NONE (r_compound) therapy_24\NN|NONE (r_pobj) after_22\IN|over|subsequent|multiple|erythematous|,|painful (r_prep) nodules_6\NNS|.|and
D014212_D004893 CID ATRA_0\NNP|be|. (r_nsubj) seemed_1\VBD|NONE (l_xcomp) be_3\VB|ATRA|. (l_attr) etiology_7\NN|to (l_prep) of_8\IN|possible|the (l_pobj) nodosum_10\NN|NONE
D014212_D004893 CID ATRA_10\NNP| (r_npadvmod) induced_12\VBN|erythema (r_amod) nodosum_14\NN|NONE
D014212_D005334 CID ATRA_23\NNP|NONE (r_compound) therapy_24\NN|NONE (r_pobj) after_22\IN|over|subsequent|multiple|erythematous|,|painful (r_prep) nodules_6\NNS|.|and (r_conj) Fever_0\NN|NONE
D013256_D004893 NONE steroid_5\NN|NONE (r_pobj) of_4\IN|term (r_prep) use_3\NN|effective|in|. (r_nsubj) is_6\VBZ|NONE (l_prep) in_9\IN|effective|.|use (l_pobj) nodosum_14\NN|NONE
D014212_D015473 NONE acid_4\NN| (r_npadvmod) induced_6\VBN|NONE (r_amod) erythema_7\NN|in|retinoic (r_compound) nodosum_8\NN|. (l_prep) in_9\IN|erythema|retinoic (l_pobj) patients_10\NNS|NONE (l_prep) with_11\IN|NONE (l_pobj) leukemia_14\NN|NONE
D014212_D015473 NONE acid_8\NN|NONE (r_pobj) with_3\IN|for (r_prep) associated_2\VBD|Erythema (l_prep) for_12\IN|with (l_pobj) leukemia_15\NN|NONE
D014212_D015473 NONE acid_8\NN|NONE (r_pobj) with_3\IN|for (r_prep) associated_2\VBD|Erythema (l_prep) for_12\IN|with (l_pobj) leukemia_15\NN|NONE (l_appos) APL_17\NNP|)|promyelocytic|acute|(
D014212_D015473 NONE ATRA_10\NNP|(|)|all|retinoic (r_appos) acid_8\NN|NONE (r_pobj) with_3\IN|for (r_prep) associated_2\VBD|Erythema (l_prep) for_12\IN|with (l_pobj) leukemia_15\NN|NONE
D014212_D015473 NONE ATRA_10\NNP|(|)|all|retinoic (r_appos) acid_8\NN|NONE (r_pobj) with_3\IN|for (r_prep) associated_2\VBD|Erythema (l_prep) for_12\IN|with (l_pobj) leukemia_15\NN|NONE (l_appos) APL_17\NNP|)|promyelocytic|acute|(
D014212_D015473 NONE ATRA_12\NNP|NONE (r_compound) therapy_13\NN|NONE (r_pobj) during_11\IN|who|nodosum (r_prep) developed_8\VBD|classic (r_relcl) APL_6\NNP|NONE
1378968
D008094_D051437 NONE lithium_2\NN| (r_npadvmod) induced_4\VBN|NONE (r_amod) nephropathy_5\NN|NONE (r_pobj) with_1\IN|NONE (r_prep) Rats_0\NNS|were|to|,|in|. (r_nsubjpass) subjected_7\VBN|NONE (l_prep) in_26\IN|Rats|were|to|,|. (l_pobj) attempt_28\NN|NONE (l_acl) induce_30\VB|an (l_dobj) hyperfiltration_32\NN|to (l_conj) progression_35\NN|glomerular|and (l_prep) of_36\IN|further (l_pobj) failure_38\NN|NONE
D008094_D051437 NONE lithium_21\NN|pretreated (r_nmod) rats_23\NNS|NONE (r_pobj) in_20\IN|plasma|creatinine (r_prep) levels_19\NNS|NONE (r_dobj) decrease_16\NN|GFR|to (r_conj) increase_13\VB|.|in (r_xcomp) tended_11\VBD|HP|accentuante|and (r_conj) failed_1\VBD|NONE (l_xcomp) accentuante_3\NN|HP|and|tended (l_dobj) progression_4\NN|to (l_prep) of_5\IN|NONE (l_pobj) failure_7\NN|NONE
D008094_D011507 CID Lithium_0\NN|.|also|proteinuria|in (r_nsubj) caused_2\VBD|NONE (l_dobj) proteinuria_3\NN|.|Lithium|also|in
D008094_D011507 CID Li_4\NNP| (r_npadvmod) induced_6\VBN|,|,|reduced (r_amod) nephropathy_7\NN|with|is|that (r_nsubjpass) associated_19\VBN|results|. (l_prep) with_20\IN|nephropathy|is|that (l_pobj) proteinuria_21\NN|NONE
D008094_D007676 CID lithium_8\NN| (r_npadvmod) induced_10\VBN|renal|in|chronic (r_amod) failure_13\NN|NONE
D003404_D051437 NONE creatinine_18\NN|in|plasma (r_compound) levels_19\NNS|NONE (r_dobj) decrease_16\NN|GFR|to (r_conj) increase_13\VB|.|in (r_xcomp) tended_11\VBD|HP|accentuante|and (r_conj) failed_1\VBD|NONE (l_xcomp) accentuante_3\NN|HP|and|tended (l_dobj) progression_4\NN|to (l_prep) of_5\IN|NONE (l_pobj) failure_7\NN|NONE
D008094_D006973 CID Lithium_0\NN|.|also|proteinuria|in (r_nsubj) caused_2\VBD|NONE (l_dobj) proteinuria_3\NN|.|Lithium|also|in (l_conj) hypertension_6\NN|and
D008094_D006973 CID Li_4\NNP| (r_npadvmod) induced_6\VBN|,|,|reduced (r_amod) nephropathy_7\NN|with|is|that (r_nsubjpass) associated_19\VBN|results|. (l_prep) with_20\IN|nephropathy|is|that (l_pobj) proteinuria_21\NN|NONE (l_conj) hypertension_25\NN|and
D008094_D007674 NONE lithium_2\NN| (r_npadvmod) induced_4\VBN|NONE (r_amod) nephropathy_5\NN|NONE
D008094_D007674 NONE Li_4\NNP| (r_npadvmod) induced_6\VBN|,|,|reduced (r_amod) nephropathy_7\NN|with|is|that
D008094_D005921 NONE Lithium_0\NN|.|also|proteinuria|in (r_nsubj) caused_2\VBD|NONE (l_prep) in_7\IN|.|Lithium|also|proteinuria (l_pobj) absence_8\NN|NONE (l_prep) of_9\IN|NONE (l_pobj) glomerulosclerosis_10\NN|NONE
11752998
D002211_D004342 NONE capsaicin_27\NN| (r_npadvmod) evoked_29\VBN|mechanical (r_amod) hypersensitivity_31\NN|and|both|noxious|acute
D002211_D004342 NONE capsaicin_20\NN|peripheral (r_compound) injection_21\NN|NONE (r_pobj) after_18\IN|sensitization|to (r_prep) reflect_13\VB|NONE (r_xcomp) presumed_11\VBN|inhibition|.|,|results (r_advcl) show_2\VBP|NONE (l_dobj) inhibition_4\NN|.|presumed|,|results (l_prep) by_5\IN|selective (l_pobj) adenosine_7\NN|NONE (l_prep) of_8\IN|intrathecal (l_pobj) hypersensitivity_9\NN|NONE
D000241_D004342 NONE adenosine_4\NN|NONE (r_pobj) of_2\IN|Preclinical (r_prep) studies_1\NNS|and|be|suggests (r_nsubj) suggest_5\VBP|NONE (l_conj) suggests_34\VBZ|and|be|studies (l_ccomp) be_37\VB|studies|. (l_acomp) effective_38\JJ|it|may|but|with (l_prep) in_39\IN|NONE (l_pobj) states_41\NNS|NONE (l_compound) hypersensitivity_40\NN|NONE
D000241_D004342 NONE adenosine_33\NN|NONE (r_pobj) of_32\IN|a|Swedish (r_prep) formulation_31\NN|NONE (r_pobj) with_28\IN|patients|and (r_prep) volunteers_25\NNS|NONE (r_pobj) in_24\IN|preliminary (r_prep) studies_23\NNS|be|. (r_nsubj) suggests_34\VBZ|and|be|studies (l_ccomp) be_37\VB|studies|. (l_acomp) effective_38\JJ|it|may|but|with (l_prep) in_39\IN|NONE (l_pobj) states_41\NNS|NONE (l_compound) hypersensitivity_40\NN|NONE
D000241_D004342 NONE adenosine_15\NN|NONE (r_pobj) of_14\IN|a|different (r_prep) formulation_13\NN|NONE (r_pobj) of_10\IN|NONE (r_prep) efficacy_9\NN|NONE (r_pobj) for_8\IN|,|to|using (r_prep) screen_7\VB|purpose|. (l_advcl) using_21\VBG|,|to|for (l_dobj) stimulation_25\NN|NONE (l_conj) hypersensitivity_31\NN|and|both|noxious|acute
D000241_D004342 NONE adenosine_7\NN|NONE (l_prep) of_8\IN|intrathecal (l_pobj) hypersensitivity_9\NN|NONE
D000241_D009437 NONE adenosine_27\NN|NONE (r_pobj) of_26\IN|in|prolonged (r_prep) residence_25\NN|to (r_pobj) due_22\JJ|not (r_acomp) is_20\VBZ|effect|consistent|.|and (r_conj) is_5\VBZ|NONE (l_acomp) consistent_6\JJ|effect|.|is|and (l_prep) with_7\IN|NONE (l_pcomp) observed_9\VBN|NONE (l_prep) in_10\IN|that (l_pobj) reports_12\NNS|NONE (l_prep) of_13\IN|preliminary (l_pobj) patients_14\NNS|NONE (l_prep) with_15\IN|NONE (l_pobj) pain_18\NN|NONE
D000241_D059787 NONE adenosine_4\NN|NONE (r_pobj) of_2\IN|Preclinical (r_prep) studies_1\NNS|and|be|suggests (r_nsubj) suggest_5\VBP|NONE (l_ccomp) be_8\VB|and|suggests|studies (l_acomp) effective_9\JJ|it|,|may (l_prep) in_10\IN|NONE (l_pobj) treatment_12\NN|NONE (l_prep) of_13\IN|the (l_pobj) pain_17\NN|NONE
D000241_D059787 NONE adenosine_33\NN|NONE (r_pobj) of_32\IN|a|Swedish (r_prep) formulation_31\NN|NONE (r_pobj) with_28\IN|patients|and (r_prep) volunteers_25\NNS|NONE (r_pobj) in_24\IN|preliminary (r_prep) studies_23\NNS|be|. (r_nsubj) suggests_34\VBZ|and|be|studies (r_conj) suggest_5\VBP|NONE (l_ccomp) be_8\VB|and|suggests|studies (l_acomp) effective_9\JJ|it|,|may (l_prep) in_10\IN|NONE (l_pobj) treatment_12\NN|NONE (l_prep) of_13\IN|the (l_pobj) pain_17\NN|NONE
D000241_D010146 NONE adenosine_34\NN|of|and|trial|intrathecal (r_amod) doses_35\NNS|NONE (r_pobj) with_32\IN|escalating|label|,|,|an (r_prep) trial_31\NN|two|: (r_appos) trials_21\NNS|NONE (r_pobj) in_19\IN|Following|volunteers|were|obtained|, (r_prep) studied_18\VBN|NONE (l_conj) obtained_59\VBN|Following|volunteers|were|in|, (l_conj) determined_85\VBN|was|,|fluid|for|and (l_nsubjpass) ratings_66\NNS|.|were (l_compound) pain_65\NN|in
D000241_D010146 NONE adenosine_52\NN|NONE (r_pobj) of_51\IN|controlled|blind|a|, (r_prep) trial_50\NN|of|and|adenosine|intrathecal (r_conj) doses_35\NNS|NONE (r_pobj) with_32\IN|escalating|label|,|,|an (r_prep) trial_31\NN|two|: (r_appos) trials_21\NNS|NONE (r_pobj) in_19\IN|Following|volunteers|were|obtained|, (r_prep) studied_18\VBN|NONE (l_conj) obtained_59\VBN|Following|volunteers|were|in|, (l_conj) determined_85\VBN|was|,|fluid|for|and (l_nsubjpass) ratings_66\NNS|.|were (l_compound) pain_65\NN|in
D000241_D010146 NONE Adenosine_0\NNP|effect|to (r_nsubj) produced_1\VBD|NONE (l_dobj) effect_3\NN|Adenosine|to (l_prep) on_4\IN|no (l_pobj) report_6\NN|NONE (l_compound) pain_5\NN|NONE
D000241_D059350 NONE adenosine_4\NN|NONE (r_pobj) of_2\IN|Preclinical (r_prep) studies_1\NNS|and|be|suggests (r_nsubj) suggest_5\VBP|NONE (l_ccomp) be_8\VB|and|suggests|studies (l_acomp) effective_9\JJ|it|,|may (l_prep) in_10\IN|NONE (l_pobj) treatment_12\NN|NONE (l_prep) of_13\IN|the (l_pobj) pain_17\NN|NONE
D000241_D059350 NONE adenosine_33\NN|NONE (r_pobj) of_32\IN|a|Swedish (r_prep) formulation_31\NN|NONE (r_pobj) with_28\IN|patients|and (r_prep) volunteers_25\NNS|NONE (r_pobj) in_24\IN|preliminary (r_prep) studies_23\NNS|be|. (r_nsubj) suggests_34\VBZ|and|be|studies (r_conj) suggest_5\VBP|NONE (l_ccomp) be_8\VB|and|suggests|studies (l_acomp) effective_9\JJ|it|,|may (l_prep) in_10\IN|NONE (l_pobj) treatment_12\NN|NONE (l_prep) of_13\IN|the (l_pobj) pain_17\NN|NONE
D002211_D010146 NONE capsaicin_82\NN|intradermal (r_compound) injection_83\NN|NONE (r_pobj) after_80\IN|heat|acute|areas|and (r_prep) stimuli_72\NNS|NONE (r_pobj) to_69\IN|NONE (r_prep) response_68\NN|NONE (r_pobj) in_67\IN|pain (r_prep) ratings_66\NNS|.|were (l_compound) pain_65\NN|in
D002211_D010146 NONE capsaicin_22\NN|intradermal (r_compound) injection_23\NN|NONE (r_pobj) from_20\IN|NONE (r_prep) allodynia_19\NN|mechanical|for|and|reduced (r_conj) hyperalgesia_17\NN|acute|but|thermal|noxious (r_conj) stimulation_13\NN|NONE (r_pobj) to_7\IN|effect|Adenosine (r_prep) produced_1\VBD|NONE (l_dobj) effect_3\NN|Adenosine|to (l_prep) on_4\IN|no (l_pobj) report_6\NN|NONE (l_compound) pain_5\NN|NONE
D000241_D006930 NONE adenosine_34\NN|of|and|trial|intrathecal (r_amod) doses_35\NNS|NONE (r_pobj) with_32\IN|escalating|label|,|,|an (r_prep) trial_31\NN|two|: (r_appos) trials_21\NNS|NONE (r_pobj) in_19\IN|Following|volunteers|were|obtained|, (r_prep) studied_18\VBN|NONE (l_conj) obtained_59\VBN|Following|volunteers|were|in|, (l_conj) determined_85\VBN|was|,|fluid|for|and (l_nsubjpass) ratings_66\NNS|.|were (l_prep) in_67\IN|pain (l_pobj) response_68\NN|NONE (l_prep) to_69\IN|NONE (l_pobj) stimuli_72\NNS|NONE (l_conj) areas_74\NNS|heat|acute|and|after (l_prep) of_75\IN|NONE (l_pobj) hyperalgesia_77\NN|NONE
D000241_D006930 NONE adenosine_34\NN|of|and|trial|intrathecal (r_amod) doses_35\NNS|NONE (r_pobj) with_32\IN|escalating|label|,|,|an (r_prep) trial_31\NN|two|: (r_appos) trials_21\NNS|NONE (r_pobj) in_19\IN|Following|volunteers|were|obtained|, (r_prep) studied_18\VBN|NONE (l_conj) obtained_59\VBN|Following|volunteers|were|in|, (l_conj) determined_85\VBN|was|,|fluid|for|and (l_nsubjpass) ratings_66\NNS|.|were (l_prep) in_67\IN|pain (l_pobj) response_68\NN|NONE (l_prep) to_69\IN|NONE (l_pobj) stimuli_72\NNS|NONE (l_conj) areas_74\NNS|heat|acute|and|after (l_prep) of_75\IN|NONE (l_pobj) hyperalgesia_77\NN|NONE (l_conj) allodynia_79\NN|mechanical|and
D000241_D006930 NONE adenosine_52\NN|NONE (r_pobj) of_51\IN|controlled|blind|a|, (r_prep) trial_50\NN|of|and|adenosine|intrathecal (r_conj) doses_35\NNS|NONE (r_pobj) with_32\IN|escalating|label|,|,|an (r_prep) trial_31\NN|two|: (r_appos) trials_21\NNS|NONE (r_pobj) in_19\IN|Following|volunteers|were|obtained|, (r_prep) studied_18\VBN|NONE (l_conj) obtained_59\VBN|Following|volunteers|were|in|, (l_conj) determined_85\VBN|was|,|fluid|for|and (l_nsubjpass) ratings_66\NNS|.|were (l_prep) in_67\IN|pain (l_pobj) response_68\NN|NONE (l_prep) to_69\IN|NONE (l_pobj) stimuli_72\NNS|NONE (l_conj) areas_74\NNS|heat|acute|and|after (l_prep) of_75\IN|NONE (l_pobj) hyperalgesia_77\NN|NONE
D000241_D006930 NONE adenosine_52\NN|NONE (r_pobj) of_51\IN|controlled|blind|a|, (r_prep) trial_50\NN|of|and|adenosine|intrathecal (r_conj) doses_35\NNS|NONE (r_pobj) with_32\IN|escalating|label|,|,|an (r_prep) trial_31\NN|two|: (r_appos) trials_21\NNS|NONE (r_pobj) in_19\IN|Following|volunteers|were|obtained|, (r_prep) studied_18\VBN|NONE (l_conj) obtained_59\VBN|Following|volunteers|were|in|, (l_conj) determined_85\VBN|was|,|fluid|for|and (l_nsubjpass) ratings_66\NNS|.|were (l_prep) in_67\IN|pain (l_pobj) response_68\NN|NONE (l_prep) to_69\IN|NONE (l_pobj) stimuli_72\NNS|NONE (l_conj) areas_74\NNS|heat|acute|and|after (l_prep) of_75\IN|NONE (l_pobj) hyperalgesia_77\NN|NONE (l_conj) allodynia_79\NN|mechanical|and
D000241_D006930 NONE Adenosine_0\NNP|effect|to (r_nsubj) produced_1\VBD|NONE (l_prep) to_7\IN|effect|Adenosine (l_pobj) stimulation_13\NN|NONE (l_conj) hyperalgesia_17\NN|acute|but|thermal|noxious
D000241_D006930 NONE Adenosine_0\NNP|effect|to (r_nsubj) produced_1\VBD|NONE (l_prep) to_7\IN|effect|Adenosine (l_pobj) stimulation_13\NN|NONE (l_conj) hyperalgesia_17\NN|acute|but|thermal|noxious (l_conj) allodynia_19\NN|mechanical|for|and|reduced
D002211_D006930 CID capsaicin_82\NN|intradermal (r_compound) injection_83\NN|NONE (r_pobj) after_80\IN|heat|acute|areas|and (r_prep) stimuli_72\NNS|NONE (l_conj) areas_74\NNS|heat|acute|and|after (l_prep) of_75\IN|NONE (l_pobj) hyperalgesia_77\NN|NONE
D002211_D006930 CID capsaicin_82\NN|intradermal (r_compound) injection_83\NN|NONE (r_pobj) after_80\IN|heat|acute|areas|and (r_prep) stimuli_72\NNS|NONE (l_conj) areas_74\NNS|heat|acute|and|after (l_prep) of_75\IN|NONE (l_pobj) hyperalgesia_77\NN|NONE (l_conj) allodynia_79\NN|mechanical|and
D002211_D006930 CID capsaicin_22\NN|intradermal (r_compound) injection_23\NN|NONE (r_pobj) from_20\IN|NONE (r_prep) allodynia_19\NN|mechanical|for|and|reduced (r_conj) hyperalgesia_17\NN|acute|but|thermal|noxious
D002211_D006930 CID capsaicin_22\NN|intradermal (r_compound) injection_23\NN|NONE (r_pobj) from_20\IN|NONE (r_prep) allodynia_19\NN|mechanical|for|and|reduced
12745515
D016642_D012892 NONE bupropion_9\NN|sleep|and (r_conj) deprivation_4\NN|NONE
D016642_D012892 NONE bupropion_12\NN|release|deprivation|and (r_compound) use_13\NN|NONE (l_conj) deprivation_16\NN|release|bupropion|and
D016642_D012892 NONE bupropion_11\NN| (r_npadvmod) associated_13\VBN|NONE (r_amod) seizures_14\NNS|NONE (r_pobj) of_10\IN|the (r_prep) risk_9\NN|NONE (r_pobj) to_7\IN|may|that|deprivation (r_prep) add_6\VB|We|. (l_nsubj) deprivation_4\NN|to|may|that
D016642_D012640 CID bupropion_9\NN|sleep|and (r_conj) deprivation_4\NN|NONE (r_pobj) with_2\IN|NONE (r_prep) associated_1\VBN|. (r_acl) Seizure_0\NN|NONE
D016642_D012640 CID bupropion_12\NN|release|deprivation|and (r_compound) use_13\NN|NONE (r_pobj) with_8\IN|NONE (r_prep) associated_7\VBN|a|generalized (r_acl) seizure_6\NN|report|.
D016642_D012640 CID bupropion_4\NN|NONE (r_compound) use_5\NN|NONE (r_pobj) of_3\IN| (r_prep) weeks_2\NNS|NONE (r_pobj) After_0\IN|seizure|.|subject|after|, (r_prep) experienced_9\VBD|NONE (l_dobj) seizure_14\NN|.|After|subject|after|,
D016642_D012640 CID bupropion_11\NN| (r_npadvmod) associated_13\VBN|NONE (r_amod) seizures_14\NNS|NONE
9812111
D006220_D011595 NONE haloperidol_12\NN|,|phase (r_appos) A_7\NNP|who (r_dobj) completed_5\VBD|the| (r_relcl) patients_3\NNS|NONE (r_pobj) For_0\IN|efficacious|. (r_prep) was_13\VBD|NONE (l_acomp) efficacious_14\JJ|For|. (l_prep) to_17\IN|and|superior (l_pobj) haloperidol_22\NN|NONE (l_prep) for_25\IN|dose|placebo|and|both (l_pobj) scores_26\NNS|NONE (l_prep) on_27\IN|NONE (l_conj) on_36\IN|factor|and (l_pobj) agitation_38\NN|NONE
D006220_D011595 NONE haloperidol_22\NN|NONE (l_prep) for_25\IN|dose|placebo|and|both (l_pobj) scores_26\NNS|NONE (l_prep) on_27\IN|NONE (l_conj) on_36\IN|factor|and (l_pobj) agitation_38\NN|NONE
D006220_D001480 CID haloperidol_8\NN|NONE (r_pobj) for_7\IN|therapeutic|favorable|in|a (r_prep) profile_6\NN|.|results|developed|, (r_dobj) indicated_2\VBD|NONE (l_advcl) developed_22\VBD|.|results|,|profile (l_acomp) moderate_23\JJ|subgroup|although (l_prep) to_24\TO|NONE (l_pobj) signs_27\NNS|NONE
D006220_D011618 NONE haloperidol_11\NN|NONE (l_prep) for_12\IN|NONE (l_pobj) psychosis_13\NN|NONE
D006220_D011618 NONE haloperidol_17\NN|NONE (r_pobj) of_16\IN|two (r_prep) doses_15\NNS|NONE (r_pobj) of_13\IN|the|effects|and (r_prep) efficacy_9\NN|to|in (r_dobj) compare_7\VB|goal|. (l_prep) in_20\IN|to|efficacy (l_pobj) treatment_22\NN|NONE (l_prep) of_23\IN|in|the (l_pobj) psychosis_24\NN|NONE
D006220_D011618 NONE haloperidol_12\NN|,|phase (r_appos) A_7\NNP|who (r_dobj) completed_5\VBD|the| (r_relcl) patients_3\NNS|NONE (r_pobj) For_0\IN|efficacious|. (r_prep) was_13\VBD|NONE (l_acomp) efficacious_14\JJ|For|. (l_prep) to_17\IN|and|superior (l_pobj) haloperidol_22\NN|NONE (l_prep) for_25\IN|dose|placebo|and|both (l_pobj) scores_26\NNS|NONE (l_prep) on_27\IN|NONE (l_pobj) factor_34\NN|and|on (l_compound) psychosis_33\NN|the|Brief|Scale
D006220_D011618 NONE haloperidol_22\NN|NONE (l_prep) for_25\IN|dose|placebo|and|both (l_pobj) scores_26\NNS|NONE (l_prep) on_27\IN|NONE (l_pobj) factor_34\NN|and|on (l_compound) psychosis_33\NN|the|Brief|Scale
D006220_D011618 NONE haloperidol_6\NN|NONE (r_pobj) with_5\IN|window (r_prep) observed_4\VBN|may|.|also|to (r_nsubj) apply_9\VB|NONE (l_prep) to_10\IN|may|.|observed|also (l_pobj) neuroleptics_12\NNS|NONE (l_acl) used_13\VBN|other (l_prep) in_14\IN|NONE (l_pobj) patients_18\NNS|NONE (l_prep) with_19\IN|disease|Alzheimer (l_pobj) psychosis_20\NN|NONE
D006220_D019958 NONE haloperidol_11\NN|NONE (l_prep) for_12\IN|NONE (l_pobj) psychosis_13\NN|NONE (l_conj) behaviors_16\NNS|and|in
D006220_D019958 NONE haloperidol_17\NN|NONE (r_pobj) of_16\IN|two (r_prep) doses_15\NNS|NONE (r_pobj) of_13\IN|the|effects|and (r_prep) efficacy_9\NN|to|in (r_dobj) compare_7\VB|goal|. (l_prep) in_20\IN|to|efficacy (l_pobj) treatment_22\NN|NONE (l_prep) of_23\IN|in|the (l_pobj) psychosis_24\NN|NONE (l_conj) behaviors_27\NNS|and
D006220_D019958 NONE haloperidol_6\NN|NONE (r_pobj) with_5\IN|window (r_prep) observed_4\VBN|may|.|also|to (r_nsubj) apply_9\VB|NONE (l_prep) to_10\IN|may|.|observed|also (l_pobj) neuroleptics_12\NNS|NONE (l_acl) used_13\VBN|other (l_prep) in_14\IN|NONE (l_pobj) patients_18\NNS|NONE (l_prep) with_19\IN|disease|Alzheimer (l_pobj) psychosis_20\NN|NONE (l_conj) behaviors_23\NNS|and
D006220_D000544 NONE haloperidol_11\NN|NONE (l_prep) for_12\IN|NONE (l_pobj) psychosis_13\NN|NONE (l_prep) in_17\IN|and|behaviors (l_pobj) disease_20\NN|NONE
D006220_D000544 NONE haloperidol_17\NN|NONE (r_pobj) of_16\IN|two (r_prep) doses_15\NNS|NONE (r_pobj) of_13\IN|the|effects|and (r_prep) efficacy_9\NN|to|in (r_dobj) compare_7\VB|goal|. (l_prep) in_20\IN|to|efficacy (l_pobj) treatment_22\NN|NONE (l_prep) in_28\IN|of|the (l_pobj) patients_29\NNS|NONE (l_prep) with_30\IN|NONE (l_pobj) disease_33\NN|NONE
D006220_D000544 NONE haloperidol_20\NN|(|)|A|haloperidol|and|,|, (r_appos) phase_16\NN|trial (r_preconj) In_0\IN|in|.|were|, (r_prep) compared_48\VBN|NONE (l_prep) in_49\IN|In|.|were|, (l_pobj) outpatients_51\NNS|NONE (l_prep) with_52\IN| (l_pobj) disease_55\NN|NONE
D006220_D000544 NONE haloperidol_34\NN|(|)|A|and|haloperidol|,|, (r_conj) phase_16\NN|trial (r_preconj) In_0\IN|in|.|were|, (r_prep) compared_48\VBN|NONE (l_prep) in_49\IN|In|.|were|, (l_pobj) outpatients_51\NNS|NONE (l_prep) with_52\IN| (l_pobj) disease_55\NN|NONE
D006220_D000544 NONE haloperidol_6\NN|NONE (r_pobj) with_5\IN|window (r_prep) observed_4\VBN|may|.|also|to (r_nsubj) apply_9\VB|NONE (l_prep) to_10\IN|may|.|observed|also (l_pobj) neuroleptics_12\NNS|NONE (l_acl) used_13\VBN|other (l_prep) in_14\IN|NONE (l_pobj) patients_18\NNS|NONE (l_compound) disease_17\NN|Alzheimer|with
2894433
D004837_D001919 CID adrenaline_12\NN|NONE (r_pobj) of_11\IN|)|intravenous|micrograms|( (r_prep) infusion_10\NN|NONE (r_pobj) by_8\IN|was|in|,|.|bradycardia|Also (r_agent) produced_5\VBN|NONE (l_nsubjpass) bradycardia_3\NN|by|was|in|,|.|Also
D004837_D001919 CID adrenaline_14\NN| (r_npadvmod) induced_16\VBN|the|pressor (r_amod) effect_18\NN|NONE (r_pobj) in_12\IN|no (r_prep) change_11\NN|although (r_dobj) causing_9\VBG|of|,|Intravenous|with (r_advcl) pretreatment_1\NN|did|,|.|bradycardia (r_nsubj) enhance_21\VB|NONE (l_dobj) bradycardia_27\NN|did|,|.|pretreatment
D004837_D001919 CID adrenaline_23\NN| (r_npadvmod) induced_25\VBN|the|reflex (r_amod) bradycardia_27\NN|did|,|.|pretreatment
D004837_D001919 CID adrenaline_6\NN| (r_npadvmod) induced_8\VBN|reflex (r_amod) bradycardia_10\NN|NONE
D001569_D001919 NONE benzodiazepine_36\JJ|the|chloride|macromolecular|channel (r_amod) complex_43\NN|NONE (r_pobj) with_34\IN|NONE (r_prep) associated_33\VBN|NONE (r_acl) sites_32\NNS|NONE (r_pobj) to_31\IN|NONE (r_prep) binding_30\VBG|NONE (r_pcomp) by_29\IN|agent|channels (r_prep) blocks_26\NNS|(|) (r_appos) picrotoxin_22\NN|NONE (r_pobj) of_21\IN|an|intravenous (r_prep) dose_20\NN|NONE (r_pobj) with_17\IN|of (r_prep) pretreatment_14\NN|NONE (r_pobj) by_13\IN|However|,|was|.|enhancement (r_agent) antagonized_12\VBN|NONE (l_nsubjpass) enhancement_4\NN|However|by|,|was|. (l_prep) of_5\IN|the|diazepam (l_pobj) bradycardia_10\NN|NONE
D001569_D001919 NONE benzodiazepine_8\JJ|macromolecular|channel|the|within|chloride (r_amod) complex_15\NN|NONE (r_pobj) through_6\IN|diazepam|facilitate|that (r_prep) acts_5\VBZ|data|. (l_advcl) facilitate_22\VB|diazepam|that|through (l_dobj) bradycardia_24\NN|to
D002712_D001919 NONE chloride_27\NN|NONE (r_compound) channels_28\NNS|agent|by (r_dobj) blocks_26\NNS|(|) (r_appos) picrotoxin_22\NN|NONE (r_pobj) of_21\IN|an|intravenous (r_prep) dose_20\NN|NONE (r_pobj) with_17\IN|of (r_prep) pretreatment_14\NN|NONE (r_pobj) by_13\IN|However|,|was|.|enhancement (r_agent) antagonized_12\VBN|NONE (l_nsubjpass) enhancement_4\NN|However|by|,|was|. (l_prep) of_5\IN|the|diazepam (l_pobj) bradycardia_10\NN|NONE
D002712_D001919 NONE chloride_40\NN|the|macromolecular|channel|benzodiazepine (r_compound) complex_43\NN|NONE (r_pobj) with_34\IN|NONE (r_prep) associated_33\VBN|NONE (r_acl) sites_32\NNS|NONE (r_pobj) to_31\IN|NONE (r_prep) binding_30\VBG|NONE (r_pcomp) by_29\IN|agent|channels (r_prep) blocks_26\NNS|(|) (r_appos) picrotoxin_22\NN|NONE (r_pobj) of_21\IN|an|intravenous (r_prep) dose_20\NN|NONE (r_pobj) with_17\IN|of (r_prep) pretreatment_14\NN|NONE (r_pobj) by_13\IN|However|,|was|.|enhancement (r_agent) antagonized_12\VBN|NONE (l_nsubjpass) enhancement_4\NN|However|by|,|was|. (l_prep) of_5\IN|the|diazepam (l_pobj) bradycardia_10\NN|NONE
D002712_D001919 NONE chloride_12\NN|macromolecular|benzodiazepine|channel|the|within (r_compound) complex_15\NN|NONE (r_pobj) through_6\IN|diazepam|facilitate|that (r_prep) acts_5\VBZ|data|. (l_advcl) facilitate_22\VB|diazepam|that|through (l_dobj) bradycardia_24\NN|to
D005680_D001919 NONE GABA_38\NNP|| (r_compound) chloride_40\NN|the|macromolecular|channel|benzodiazepine (r_compound) complex_43\NN|NONE (r_pobj) with_34\IN|NONE (r_prep) associated_33\VBN|NONE (r_acl) sites_32\NNS|NONE (r_pobj) to_31\IN|NONE (r_prep) binding_30\VBG|NONE (r_pcomp) by_29\IN|agent|channels (r_prep) blocks_26\NNS|(|) (r_appos) picrotoxin_22\NN|NONE (r_pobj) of_21\IN|an|intravenous (r_prep) dose_20\NN|NONE (r_pobj) with_17\IN|of (r_prep) pretreatment_14\NN|NONE (r_pobj) by_13\IN|However|,|was|.|enhancement (r_agent) antagonized_12\VBN|NONE (l_nsubjpass) enhancement_4\NN|However|by|,|was|. (l_prep) of_5\IN|the|diazepam (l_pobj) bradycardia_10\NN|NONE
D005680_D001919 NONE GABA_10\NNP|| (r_compound) chloride_12\NN|macromolecular|benzodiazepine|channel|the|within (r_compound) complex_15\NN|NONE (r_pobj) through_6\IN|diazepam|facilitate|that (r_prep) acts_5\VBZ|data|. (l_advcl) facilitate_22\VB|diazepam|that|through (l_dobj) bradycardia_24\NN|to
D003975_D001919 CID Diazepam_0\NNP|.|bradycardia (r_nsubj) facilitates_1\VBZ|NONE (l_dobj) bradycardia_3\NN|Diazepam|.
D003975_D001919 CID diazepam_6\NN|NONE (r_pobj) with_5\IN|of|,|causing|Intravenous (r_prep) pretreatment_1\NN|did|,|.|bradycardia (r_nsubj) enhance_21\VB|NONE (l_dobj) bradycardia_27\NN|did|,|.|pretreatment
D003975_D001919 CID diazepam_3\NN|the|of (r_compound) enhancement_4\NN|However|by|,|was|. (l_prep) of_5\IN|the|diazepam (l_pobj) bradycardia_10\NN|NONE
D003975_D001919 CID diazepam_4\NN|facilitate|that|through (r_nsubj) acts_5\VBZ|data|. (l_advcl) facilitate_22\VB|diazepam|that|through (l_dobj) bradycardia_24\NN|to
D010852_D001919 NONE picrotoxin_22\NN|NONE (r_pobj) of_21\IN|an|intravenous (r_prep) dose_20\NN|NONE (r_pobj) with_17\IN|of (r_prep) pretreatment_14\NN|NONE (r_pobj) by_13\IN|However|,|was|.|enhancement (r_agent) antagonized_12\VBN|NONE (l_nsubjpass) enhancement_4\NN|However|by|,|was|. (l_prep) of_5\IN|the|diazepam (l_pobj) bradycardia_10\NN|NONE
8073369
C007112_D009140 NONE coniine_5\NN|NONE (r_pobj) by_3\IN|NONE (r_agent) caused_2\VBN|The (r_acl) deformations_1\NNS|.|flexion
C007112_D009140 NONE coniine_5\NN|NONE (r_pobj) by_3\IN|NONE (r_agent) caused_2\VBN|The (r_acl) deformations_1\NNS|.|flexion (r_nsubj) were_9\VBD|NONE (l_attr) flexion_11\NN|.|deformations (l_prep) of_14\IN|extension|excessive|or (l_pobj) toes_18\NNS|NONE
C007112_D001176 CID coniine_2\NN|has|However|.|is|,|produce|and (r_nsubj) failed_4\VBN|NONE (l_xcomp) produce_6\VB|has|coniine|However|.|is|,|and (l_dobj) arthrogryposis_7\NN|to
C007112_D001176 CID coniine_15\RB| (r_npadvmod) induced_17\VBN|NONE (r_amod) arthrogryposis_18\NN|NONE
D009538_D009140 NONE nicotine_7\NN|NONE (r_compound) sulfate_8\NN|and|both (r_conj) coniine_5\NN|NONE (r_pobj) by_3\IN|NONE (r_agent) caused_2\VBN|The (r_acl) deformations_1\NNS|.|flexion
D009538_D009140 NONE nicotine_7\NN|NONE (r_compound) sulfate_8\NN|and|both (r_conj) coniine_5\NN|NONE (r_pobj) by_3\IN|NONE (r_agent) caused_2\VBN|The (r_acl) deformations_1\NNS|.|flexion (r_nsubj) were_9\VBD|NONE (l_attr) flexion_11\NN|.|deformations (l_prep) of_14\IN|extension|excessive|or (l_pobj) toes_18\NNS|NONE
D009538_D002543 CID nicotine_30\NN|all|treated (r_nmod) chicks_34\NNS|NONE (r_pobj) in_28\IN|however|hemorrhage|;|seen|,|. (r_prep) occurred_27\VBD|NONE (l_nsubj) hemorrhage_26\NN|however|;|seen|,|.|in
18177388
D000661_D054549 CID amphetamine_21\NN|NONE (r_compound) use_22\NN|NONE (r_pobj) of_20\IN|the (r_prep) setting_19\NN|NONE (r_pobj) in_17\IN|young|a (r_prep) woman_16\NN|NONE (r_pobj) in_13\IN|.|Reverse|)|cardiomyopathy|syndrome (r_prep) left_3\VBN|NONE (l_dobj) syndrome_7\NN|.|Reverse|)|cardiomyopathy|in
D000661_D054549 CID amphetamine_21\NN|NONE (r_compound) use_22\NN|NONE (r_pobj) of_20\IN|the (r_prep) setting_19\NN|NONE (r_pobj) in_17\IN|young|a (r_prep) woman_16\NN|NONE (r_pobj) in_13\IN|.|Reverse|)|cardiomyopathy|syndrome (r_prep) left_3\VBN|NONE (l_oprd) cardiomyopathy_11\NN|.|Reverse|)|syndrome|in
D000661_D054549 CID amphetamine_26\NN|NONE (r_compound) use_27\NN|NONE (r_pobj) after_25\IN|NONE (r_prep) occurring_24\VBG|this|rare|of (r_acl) type_18\NN|NONE (l_prep) of_19\IN|occurring|this|rare (l_pobj) syndrome_23\NN|NONE
17241784
D019821_-1 NONE Statins_0\NNS|can|.|myopathy|necrotizing (r_nsubj) cause_2\VB|NONE (l_ccomp) myopathy_5\NN|can|.|Statins|necrotizing (l_conj) hyperCKaemia_7\NN|and
D019821_D009135 CID statin_12\NN|NONE (r_compound) therapy_13\NN|NONE (r_pobj) with_11\IN|NONE (r_prep) associated_10\VBD|Progressive|.|with (r_acl) myopathy_1\NNS|NONE
D019821_D009135 CID Statins_0\NNS|can|.|myopathy|necrotizing (r_nsubj) cause_2\VB|NONE (l_ccomp) myopathy_5\NN|can|.|Statins|necrotizing
D019821_D009135 CID statins_9\NNS|whereby|myopathy|may (r_nsubj) induce_11\VB|,|persists|a (l_dobj) myopathy_13\NN|statins|whereby|may
D019821_D009135 CID statins_4\NNS|myopathy|may|that (r_nsubj) initiate_6\VB|observations|. (l_dobj) myopathy_11\NN|statins|may|that
D019821_D009135 CID statins_13\NNS|NONE (r_pobj) by_12\IN|the (r_prep) induction_11\NN|may (r_dobj) involve_9\VB|but|uncertain|.|mechanism (r_conj) is_5\VBZ|NONE (l_nsubj) mechanism_1\NN|but|uncertain|.|involve (l_prep) of_2\IN|The (l_pobj) myopathy_4\NN|NONE
3183120
C033706_D001927 CID tiazofurin_5\NN|NONE (r_compound) usage_6\NN|NONE (r_pobj) with_4\IN|NONE (r_prep) associated_3\VBN|.|cerebral|demonstration|:|Reversible (r_acl) lesions_2\NNS|NONE
16298782
D005839_D034381 CID gentamicin_4\NN| (r_npadvmod) induced_6\VBN|hearing (r_amod) loss_8\NN|NAME|gave|but|.|,|in
D019331_D034381 NONE NAME_2\NN|gave|but|.|loss|,|in (r_nsubj) reduced_3\VBN|NONE (l_dobj) loss_8\NN|NAME|gave|but|.|,|in
D000617_D006311 NONE aminoglycoside_32\NN| (r_npadvmod) induced_34\VBN|hearing (r_amod) loss_37\NN|NONE (r_pobj) of_31\IN|the (r_prep) prevention_30\NN|NONE (r_pobj) for_28\IN|the|of (r_prep) use_24\NN|to (r_dobj) assess_22\VB|we|is|,|. (r_xcomp) need_20\VBP|NONE (l_ccomp) is_2\VBZ|we|,|assess|. (l_nsubj) ototoxicity_1\NN|problem|and|,|involves
D000617_D006311 NONE aminoglycoside_32\NN| (r_npadvmod) induced_34\VBN|hearing (r_amod) loss_37\NN|NONE (r_pobj) of_31\IN|the (r_prep) prevention_30\NN|NONE (r_pobj) for_28\IN|the|of (r_prep) use_24\NN|to (r_dobj) assess_22\VB|we|is|,|. (r_xcomp) need_20\VBP|NONE (l_ccomp) is_2\VBZ|we|,|assess|. (l_conj) involves_13\VBZ|problem|and|,|ototoxicity (l_nsubj) mechanism_12\NN|production|as (l_compound) ototoxic_11\JJ|their
D000617_D006319 NONE aminoglycoside_32\NN| (r_npadvmod) induced_34\VBN|hearing (r_amod) loss_37\NN|NONE
D005839_D006316 NONE gentamicin_32\NN|NONE (r_pobj) by_31\IN|NONE (r_agent) caused_30\VBN|frequency|hearing (r_acl) loss_29\NN|NONE
D019331_D006311 NONE ester_6\NN|NONE (l_appos) protector_10\NN|arginine|:|methyl|. (l_prep) against_11\IN|potential|a (l_pobj) ototoxicity_13\NN|NONE
D009569_D006316 NONE oxide_2\NN|needed|as|,|but|may (r_nsubj) act_20\VB|NONE (l_prep) as_21\IN|needed|,|but|oxide|may (l_pobj) otoprotectant_23\NN|NONE (l_prep) against_24\IN|an (l_pobj) loss_29\NN|NONE
D009569_D006316 NONE NO_4\NNP|NAME|arginine|methyl|)|inhibitor|( (r_intj) ester_13\NN|nitric|The|( (r_appos) oxide_2\NN|needed|as|,|but|may (r_nsubj) act_20\VB|NONE (l_prep) as_21\IN|needed|,|but|oxide|may (l_pobj) otoprotectant_23\NN|NONE (l_prep) against_24\IN|an (l_pobj) loss_29\NN|NONE
D005839_D006311 NONE gentamicin_12\NN|NONE (r_compound) ototoxicity_13\NN|NONE
D009569_D006319 NONE NO_17\DT|NONE (r_pobj) of_16\IN|the (r_prep) production_15\NN|mechanism|as (r_dobj) involves_13\VBZ|problem|and|,|ototoxicity (r_conj) is_2\VBZ|we|,|assess|. (r_ccomp) need_20\VBP|NONE (l_xcomp) assess_22\VB|we|is|,|. (l_dobj) use_24\NN|to (l_prep) for_28\IN|the|of (l_pobj) prevention_30\NN|NONE (l_prep) of_31\IN|the (l_pobj) loss_37\NN|NONE
D009569_D006319 NONE NO_26\DT|NONE (r_det) inhibitors_27\NNS|NONE (r_pobj) of_25\IN|the|for (r_prep) use_24\NN|to (l_prep) for_28\IN|the|of (l_pobj) prevention_30\NN|NONE (l_prep) of_31\IN|the (l_pobj) loss_37\NN|NONE
D019331_D006316 NONE ester_13\NN|nitric|The|( (r_appos) oxide_2\NN|needed|as|,|but|may (r_nsubj) act_20\VB|NONE (l_prep) as_21\IN|needed|,|but|oxide|may (l_pobj) otoprotectant_23\NN|NONE (l_prep) against_24\IN|an (l_pobj) loss_29\NN|NONE
D019331_D006316 NONE NAME_17\NN|NO|arginine|methyl|)|inhibitor|( (r_appos) ester_13\NN|nitric|The|( (r_appos) oxide_2\NN|needed|as|,|but|may (r_nsubj) act_20\VB|NONE (l_prep) as_21\IN|needed|,|but|oxide|may (l_pobj) otoprotectant_23\NN|NONE (l_prep) against_24\IN|an (l_pobj) loss_29\NN|NONE
D009569_D006311 NONE NO_17\DT|NONE (r_pobj) of_16\IN|the (r_prep) production_15\NN|mechanism|as (r_dobj) involves_13\VBZ|problem|and|,|ototoxicity (r_conj) is_2\VBZ|we|,|assess|. (l_nsubj) ototoxicity_1\NN|problem|and|,|involves
D009569_D006311 NONE NO_17\DT|NONE (r_pobj) of_16\IN|the (r_prep) production_15\NN|mechanism|as (r_dobj) involves_13\VBZ|problem|and|,|ototoxicity (l_nsubj) mechanism_12\NN|production|as (l_compound) ototoxic_11\JJ|their
D009569_D006311 NONE NO_26\DT|NONE (r_det) inhibitors_27\NNS|NONE (r_pobj) of_25\IN|the|for (r_prep) use_24\NN|to (r_dobj) assess_22\VB|we|is|,|. (r_xcomp) need_20\VBP|NONE (l_ccomp) is_2\VBZ|we|,|assess|. (l_nsubj) ototoxicity_1\NN|problem|and|,|involves
D009569_D006311 NONE NO_26\DT|NONE (r_det) inhibitors_27\NNS|NONE (r_pobj) of_25\IN|the|for (r_prep) use_24\NN|to (r_dobj) assess_22\VB|we|is|,|. (r_xcomp) need_20\VBP|NONE (l_ccomp) is_2\VBZ|we|,|assess|. (l_conj) involves_13\VBZ|problem|and|,|ototoxicity (l_nsubj) mechanism_12\NN|production|as (l_compound) ototoxic_11\JJ|their
18217897
C467567_D008223 NONE lenalidomide_31\NN|,|generation|immunomodulatory|the (r_appos) agent_29\NN|NONE (r_pobj) with_24\IN|NONE (r_prep) reported_23\VBN|higher|the|activity (r_acl) level_22\NN|NONE (r_pobj) with_18\IN|NONE (r_prep) contrast_17\NN|and|rate|to (r_conj) demonstrate_4\VB|results|. (l_dobj) rate_8\NN|and|to|contrast (l_prep) in_13\IN|important|an|response|to (l_pobj) lymphomas_15\NNS|NONE
D013792_D008228 NONE Thalidomide_0\NNP|has|in|activity (r_nsubj) limited_2\VBN|NONE (l_prep) in_7\IN|has|activity|Thalidomide (l_pobj) lymphomas_15\NNS|NONE
D013792_D009101 NONE Thalidomide_0\NNP|agent|. (r_nsubj) is_1\VBZ|NONE (l_attr) agent_4\NN|.|Thalidomide (l_prep) with_5\IN|immunomodulatory|an (l_pobj) activity_7\NN|NONE (l_prep) in_8\IN|demonstrated (l_pobj) myeloma_10\NN|NONE
D013792_D008223 NONE Thalidomide_0\NNP|agent|. (r_nsubj) is_1\VBZ|NONE (l_attr) agent_4\NN|.|Thalidomide (l_prep) with_5\IN|immunomodulatory|an (l_pobj) activity_7\NN|NONE (l_prep) in_8\IN|demonstrated (l_pobj) myeloma_10\NN|NONE (l_conj) lymphoma_14\NN|,|multiple (l_conj) lymphoma_17\NN|cell|mantle|and
D013792_D008223 NONE thalidomide_16\NN|daily|patients|with|tolerated|Between|.|, (r_dobj) received_15\VBD|NONE (l_nsubj) patients_8\NNS|daily|thalidomide|with|tolerated|Between|.|, (l_prep) with_9\IN| (l_pobj) lymphomas_14\NNS|NONE
D013792_D008223 NONE thalidomide_12\NN|NONE (r_pobj) to_9\IN|important|in|an|response (r_prep) rate_8\NN|and|to|contrast (l_prep) in_13\IN|important|an|response|to (l_pobj) lymphomas_15\NNS|NONE
D013792_D009369 NONE Thalidomide_0\NNP|has|in|activity (r_nsubj) limited_2\VBN|NONE (l_prep) in_7\IN|has|activity|Thalidomide (l_pobj) lymphomas_15\NNS|NONE (l_appos) trial_20\NN|indolent|Hodgkin|relapsed|: (l_prep) of_21\IN|II|phase|a (l_pobj) Cancer_23\NNP|NONE
D013792_D007938 NONE Thalidomide_0\NNP|has|in|activity (r_nsubj) limited_2\VBN|NONE (l_prep) in_7\IN|has|activity|Thalidomide (l_pobj) lymphomas_15\NNS|NONE (l_appos) trial_20\NN|indolent|Hodgkin|relapsed|: (l_prep) of_21\IN|II|phase|a (l_pobj) Cancer_23\NNP|NONE (l_conj) B._27\NNP|and|the (l_compound) Leukemia_25\NNP|Group
D013792_D020522 NONE Thalidomide_0\NNP|agent|. (r_nsubj) is_1\VBZ|NONE (l_attr) agent_4\NN|.|Thalidomide (l_prep) with_5\IN|immunomodulatory|an (l_pobj) activity_7\NN|NONE (l_prep) in_8\IN|demonstrated (l_pobj) myeloma_10\NN|NONE (l_conj) lymphoma_14\NN|,|multiple
10091617
D012642_D007024 CID Selegiline_0\NNP|:|.|study||hypotension (r_advmod) induced_2\VBN|NONE (l_dobj) hypotension_4\NN|:|.|study||Selegiline
D012642_D007024 CID selegiline_7\NN|NONE (r_pobj) with_6\IN|and|dopa (r_prep) therapy_5\NN|that|was|with (r_nsubjpass) associated_13\VBN|we|,|Recently|. (l_prep) with_14\IN|therapy|that|was (l_pobj) hypotension_18\NN|NONE
D012642_D007024 CID selegiline_25\NN|NONE (r_pobj) of_24\IN|NONE (r_prep) withdrawal_23\NN|NONE (r_pobj) by_22\IN|which|was (r_agent) abolished_21\VBN|selective|systolic|orthostatic (r_relcl) hypotension_18\NN|NONE
D012642_D007024 CID selegiline_29\NN|in (r_dobj) stopping_28\VBG|NONE (l_prep) in_30\IN|selegiline (l_pobj) expectation_32\NN|NONE (l_acl) shed_36\VB|the (l_prep) on_38\IN|light|might|this|that (l_pobj) mechanisms_40\NNS|NONE (l_relcl) causes_45\VBZ|the (l_dobj) hypotension_47\NN|drug|by
D012642_D007024 CID selegiline_18\NN|NONE (r_pobj) on_17\IN|which|was|in (r_prep) marked_10\VBN|orthostatic|lost|,|systolic (r_relcl) hypotension_7\NN|.|tilt
D012642_D007024 CID selegiline_9\NN|NONE (r_pobj) of_8\IN|NONE (r_prep) withdrawal_7\NN|days (r_pobj) after_6\IN|hypotension|.|abolished|was|and (r_prep) ameliorated_3\VBN|NONE (l_nsubjpass) hypotension_1\NN|.|after|abolished|was|and
D012642_D007024 CID selegiline_1\NN|NONE (r_dobj) Stopping_0\VBG|pressures|significantly|.|also (r_csubj) reduced_4\VBD|NONE (l_dobj) pressures_11\NNS|significantly|.|Stopping|also
D012642_D007024 CID selegiline_7\NN|is|with (r_nsubjpass) associated_15\VBN|our|previous (l_prep) with_16\IN|is|selegiline (l_pobj) hypotension_19\NN|NONE
D007980_D007024 NONE dopa_11\NNP|and|with (r_conj) therapy_5\NN|that|was|with (r_nsubjpass) associated_13\VBN|we|,|Recently|. (l_prep) with_14\IN|therapy|that|was (l_pobj) hypotension_18\NN|NONE
D007980_D007024 NONE dopa_13\NNP|NONE (r_pobj) with_10\IN|NONE (r_prep) combination_9\NN|NONE (r_pobj) in_8\IN|that (r_prep) selegiline_7\NN|is|with (r_nsubjpass) associated_15\VBN|our|previous (l_prep) with_16\IN|is|selegiline (l_pobj) hypotension_19\NN|NONE
D007980_D010300 NONE dopa_36\NN|with|. (r_nsubj) compared_37\VBN|mortality|trial|and (r_conj) found_12\VBD|NONE (l_nsubj) trial_11\NN|mortality|and|compared (l_nmod) Group_7\NNP|)|UKPDRG|( (l_compound) Disease_5\NNP|Parkinson|Research
D007980_D010300 NONE dopa_36\NN|with|. (r_nsubj) compared_37\VBN|mortality|trial|and (r_conj) found_12\VBD|NONE (l_dobj) mortality_15\NN|trial|and|compared (l_prep) in_16\IN|randomized|increased|an (l_pobj) patients_17\NNS|NONE (l_prep) with_18\IN|NONE (l_pobj) disease_21\NN|NONE
D007980_D010300 NONE dopa_36\NN|with|. (r_nsubj) compared_37\VBN|mortality|trial|and (r_conj) found_12\VBD|NONE (l_dobj) mortality_15\NN|trial|and|compared (l_prep) in_16\IN|randomized|increased|an (l_pobj) patients_17\NNS|NONE (l_prep) with_18\IN|NONE (l_pobj) disease_21\NN|NONE (l_appos) PD_23\NNP|(|Parkinson|)
D007980_D010300 NONE dopa_43\NN|alone (r_dobj) taking_40\VBG|NONE (r_acl) those_39\DT|NONE (r_pobj) with_38\IN|.|dopa (r_prep) compared_37\VBN|mortality|trial|and (r_conj) found_12\VBD|NONE (l_nsubj) trial_11\NN|mortality|and|compared (l_nmod) Group_7\NNP|)|UKPDRG|( (l_compound) Disease_5\NNP|Parkinson|Research
D007980_D010300 NONE dopa_43\NN|alone (r_dobj) taking_40\VBG|NONE (r_acl) those_39\DT|NONE (r_pobj) with_38\IN|.|dopa (r_prep) compared_37\VBN|mortality|trial|and (r_conj) found_12\VBD|NONE (l_dobj) mortality_15\NN|trial|and|compared (l_prep) in_16\IN|randomized|increased|an (l_pobj) patients_17\NNS|NONE (l_prep) with_18\IN|NONE (l_pobj) disease_21\NN|NONE
D007980_D010300 NONE dopa_43\NN|alone (r_dobj) taking_40\VBG|NONE (r_acl) those_39\DT|NONE (r_pobj) with_38\IN|.|dopa (r_prep) compared_37\VBN|mortality|trial|and (r_conj) found_12\VBD|NONE (l_dobj) mortality_15\NN|trial|and|compared (l_prep) in_16\IN|randomized|increased|an (l_pobj) patients_17\NNS|NONE (l_prep) with_18\IN|NONE (l_pobj) disease_21\NN|NONE (l_appos) PD_23\NNP|(|Parkinson|)
D012642_D010300 NONE Selegiline_0\NNP|:|.|study||hypotension (r_advmod) induced_2\VBN|NONE (l_dobj) hypotension_4\NN|:|.|study||Selegiline (l_prep) in_5\IN|postural (l_pobj) disease_8\NN|NONE
D012642_D010300 NONE selegiline_30\NN|to (r_dobj) receive_27\VB|NONE (r_xcomp) randomized_25\VBN|increased|an|in (r_acl) mortality_15\NN|trial|and|compared (r_dobj) found_12\VBD|NONE (l_nsubj) trial_11\NN|mortality|and|compared (l_nmod) Group_7\NNP|)|UKPDRG|( (l_compound) Disease_5\NNP|Parkinson|Research
D012642_D010300 NONE selegiline_30\NN|to (r_dobj) receive_27\VB|NONE (r_xcomp) randomized_25\VBN|increased|an|in (r_acl) mortality_15\NN|trial|and|compared (l_prep) in_16\IN|randomized|increased|an (l_pobj) patients_17\NNS|NONE (l_prep) with_18\IN|NONE (l_pobj) disease_21\NN|NONE
D012642_D010300 NONE selegiline_30\NN|to (r_dobj) receive_27\VB|NONE (r_xcomp) randomized_25\VBN|increased|an|in (r_acl) mortality_15\NN|trial|and|compared (l_prep) in_16\IN|randomized|increased|an (l_pobj) patients_17\NNS|NONE (l_prep) with_18\IN|NONE (l_pobj) disease_21\NN|NONE (l_appos) PD_23\NNP|(|Parkinson|)
D012642_D010300 NONE selegiline_17\RB|NONE (r_dobj) receiving_16\VBG|PD (r_acl) patients_15\NNS|NONE (l_compound) PD_14\NNP|receiving
D012642_D010300 NONE selegiline_18\NN|NONE (r_pobj) on_17\IN|which|was|in (r_prep) marked_10\VBN|orthostatic|lost|,|systolic (l_prep) in_11\IN|on|which|was (l_pobj) patients_16\NNS|NONE (l_compound) PD_15\NNP|
11868798
D013148_D009369 NONE Spironolactone_0\NNP|:|drug|it|? (r_npadvmod) is_2\VBZ|NONE (l_attr) drug_6\NN|:|it|?|Spironolactone (l_prep) for_7\IN|novel|a (l_pobj) prevention_9\NN|NONE (l_prep) of_10\IN|the (l_pobj) hypokalemia_15\NN|NONE (l_prep) in_16\IN|related (l_pobj) patients_18\NNS|NONE (l_compound) cancer_17\NN|NONE
D000666_D007008 CID B_12\NN| (r_npadvmod) related_14\VBN|in (r_amod) hypokalemia_15\NN|NONE
D000666_D007008 CID AmB_22\JJ|NONE (r_compound) treatment_23\NN|NONE (r_pobj) on_21\IN|neutropenic (r_prep) patients_20\NNS|NONE (r_pobj) in_18\IN|NONE (r_prep) hypokalemia_17\NN|to
D000666_D007008 CID AmB_21\JJ|NONE (r_compound) treatment_22\NN|NONE (r_pobj) on_20\IN|neutropenic (r_prep) patients_19\NNS|NONE (r_pobj) in_17\IN|potassium|urinary (r_prep) loss_16\NN|NONE (r_dobj) reducing_13\VBG|NONE (r_pcomp) by_12\IN|hypokalemia (r_prep) prevent_10\VBP|that|requirements|can|and|spironolactone (l_dobj) hypokalemia_11\NN|by
D000666_D009503 NONE AmB_22\JJ|NONE (r_compound) treatment_23\NN|NONE (r_pobj) on_21\IN|neutropenic (r_prep) patients_20\NNS|NONE (l_amod) neutropenic_19\JJ|on
D000666_D009503 NONE AmB_21\JJ|NONE (r_compound) treatment_22\NN|NONE (r_pobj) on_20\IN|neutropenic (r_prep) patients_19\NNS|NONE (l_amod) neutropenic_18\JJ|on
D011188_D064420 NONE potassium_12\NN|the|is|profound (r_compound) wasting_13\VBG|NONE (r_pobj) for_9\IN|NONE (r_prep) responsible_8\JJ|to (r_acomp) be_7\VB|potentiates|toxicity (r_xcomp) seems_5\VBZ|NONE (l_nsubj) toxicity_4\NN|potentiates|be
D011188_D064420 NONE potassium_12\NN|the|is|profound (r_compound) wasting_13\VBG|NONE (r_pobj) for_9\IN|NONE (r_prep) responsible_8\JJ|to (r_acomp) be_7\VB|potentiates|toxicity (r_xcomp) seems_5\VBZ|NONE (l_conj) potentiates_28\VBZ|toxicity|be (l_dobj) toxicity_31\NN|also
D011188_D064420 NONE Potassium_25\NN|NONE (r_compound) depletion_26\NN|NONE (r_pobj) with_23\IN|NONE (r_prep) treatment_22\NN|NONE (r_pobj) of_21\IN|major|side|a (r_prep) effect_20\NN|that (r_attr) is_15\VBZ|the|potassium|profound (r_relcl) wasting_13\VBG|NONE (r_pobj) for_9\IN|NONE (r_prep) responsible_8\JJ|to (r_acomp) be_7\VB|potentiates|toxicity (r_xcomp) seems_5\VBZ|NONE (l_nsubj) toxicity_4\NN|potentiates|be
D011188_D064420 NONE Potassium_25\NN|NONE (r_compound) depletion_26\NN|NONE (r_pobj) with_23\IN|NONE (r_prep) treatment_22\NN|NONE (r_pobj) of_21\IN|major|side|a (r_prep) effect_20\NN|that (r_attr) is_15\VBZ|the|potassium|profound (r_relcl) wasting_13\VBG|NONE (r_pobj) for_9\IN|NONE (r_prep) responsible_8\JJ|to (r_acomp) be_7\VB|potentiates|toxicity (r_xcomp) seems_5\VBZ|NONE (l_conj) potentiates_28\VBZ|toxicity|be (l_dobj) toxicity_31\NN|also
D000666_D007674 NONE B_9\NNP|NONE (r_pobj) of_7\IN|adverse|major|the (r_prep) effect_6\NN|:|.|limiting|,|Nephrotoxicity (r_attr) is_2\VBZ|NONE (l_nsubj) Nephrotoxicity_1\NN|:|.|limiting|,|effect
D000666_D007674 NONE AmB_11\NNP|amphotericin (r_appos) B_9\NNP|NONE (r_pobj) of_7\IN|adverse|major|the (r_prep) effect_6\NN|:|.|limiting|,|Nephrotoxicity (r_attr) is_2\VBZ|NONE (l_nsubj) Nephrotoxicity_1\NN|:|.|limiting|,|effect
D000666_D064420 NONE AmB._24\NNP|NONE (r_compound) Potassium_25\NN|NONE (r_compound) depletion_26\NN|NONE (r_pobj) with_23\IN|NONE (r_prep) treatment_22\NN|NONE (r_pobj) of_21\IN|major|side|a (r_prep) effect_20\NN|that (r_attr) is_15\VBZ|the|potassium|profound (r_relcl) wasting_13\VBG|NONE (r_pobj) for_9\IN|NONE (r_prep) responsible_8\JJ|to (r_acomp) be_7\VB|potentiates|toxicity (r_xcomp) seems_5\VBZ|NONE (l_nsubj) toxicity_4\NN|potentiates|be
D000666_D064420 NONE AmB._24\NNP|NONE (r_compound) Potassium_25\NN|NONE (r_compound) depletion_26\NN|NONE (r_pobj) with_23\IN|NONE (r_prep) treatment_22\NN|NONE (r_pobj) of_21\IN|major|side|a (r_prep) effect_20\NN|that (r_attr) is_15\VBZ|the|potassium|profound (r_relcl) wasting_13\VBG|NONE (r_pobj) for_9\IN|NONE (r_prep) responsible_8\JJ|to (r_acomp) be_7\VB|potentiates|toxicity (r_xcomp) seems_5\VBZ|NONE (l_conj) potentiates_28\VBZ|toxicity|be (l_dobj) toxicity_31\NN|also
D000666_D064420 NONE AmB._33\NN|NONE (r_pobj) of_32\IN|tubular|the (r_prep) toxicity_31\NN|also (r_dobj) potentiates_28\VBZ|toxicity|be (r_conj) seems_5\VBZ|NONE (l_nsubj) toxicity_4\NN|potentiates|be
D000666_D064420 NONE AmB._33\NN|NONE (r_pobj) of_32\IN|tubular|the (r_prep) toxicity_31\NN|also
D011188_D009503 NONE potassium_12\NN|NONE (r_compound) requirements_13\NNS|to|and|prevent (r_dobj) reduce_11\VB|of|the (l_conj) prevent_16\VB|requirements|to|and (l_dobj) hypokalemia_17\NN|to (l_prep) in_18\IN|NONE (l_pobj) patients_20\NNS|NONE (l_amod) neutropenic_19\JJ|on
D011188_D009503 NONE potassium_7\NN|NONE (r_compound) requirements_8\NNS|that|can|and|prevent|spironolactone (r_dobj) reduce_6\VB|.|study (l_conj) prevent_10\VBP|that|requirements|can|and|spironolactone (l_prep) by_12\IN|hypokalemia (l_pcomp) reducing_13\VBG|NONE (l_dobj) loss_16\NN|NONE (l_prep) in_17\IN|potassium|urinary (l_pobj) patients_19\NNS|NONE (l_amod) neutropenic_18\JJ|on
D011188_D009503 NONE potassium_15\NN|in|urinary (r_compound) loss_16\NN|NONE (l_prep) in_17\IN|potassium|urinary (l_pobj) patients_19\NNS|NONE (l_amod) neutropenic_18\JJ|on
D000666_D009181 NONE AmB_15\VB|developing|daily|twice|to (r_dobj) receive_12\VB|In|patients|were|. (l_advcl) developing_27\VBG|daily|twice|to|AmB (l_dobj) infection_33\NN|when
D000666_D009181 NONE AmB_18\JJ|spironolactone|alone|either|or|intravenous (r_conj) AmB_15\VB|developing|daily|twice|to (r_dobj) receive_12\VB|In|patients|were|. (l_advcl) developing_27\VBG|daily|twice|to|AmB (l_dobj) infection_33\NN|when
D013148_D009503 NONE spironolactone_9\NN|NONE (r_pobj) of_8\IN|reduce|the (r_prep) ability_7\NN|to (l_acl) reduce_11\VB|of|the (l_conj) prevent_16\VB|requirements|to|and (l_dobj) hypokalemia_17\NN|to (l_prep) in_18\IN|NONE (l_pobj) patients_20\NNS|NONE (l_amod) neutropenic_19\JJ|on
D013148_D009503 NONE spironolactone_4\NN|that|requirements|can|and|prevent (r_nsubj) reduce_6\VB|.|study (l_conj) prevent_10\VBP|that|requirements|can|and|spironolactone (l_prep) by_12\IN|hypokalemia (l_pcomp) reducing_13\VBG|NONE (l_dobj) loss_16\NN|NONE (l_prep) in_17\IN|potassium|urinary (l_pobj) patients_19\NNS|NONE (l_amod) neutropenic_18\JJ|on
D013148_D007008 NONE Spironolactone_0\NNP|:|drug|it|? (r_npadvmod) is_2\VBZ|NONE (l_attr) drug_6\NN|:|it|?|Spironolactone (l_prep) for_7\IN|novel|a (l_pobj) prevention_9\NN|NONE (l_prep) of_10\IN|the (l_pobj) hypokalemia_15\NN|NONE
D013148_D007008 NONE spironolactone_9\NN|NONE (r_pobj) of_8\IN|reduce|the (r_prep) ability_7\NN|to (l_acl) reduce_11\VB|of|the (l_conj) prevent_16\VB|requirements|to|and (l_dobj) hypokalemia_17\NN|to
D013148_D007008 NONE spironolactone_4\NN|that|requirements|can|and|prevent (r_nsubj) reduce_6\VB|.|study (l_conj) prevent_10\VBP|that|requirements|can|and|spironolactone (l_dobj) hypokalemia_11\NN|by
D000666_D006402 NONE AmB_15\VB|developing|daily|twice|to (r_dobj) receive_12\VB|In|patients|were|. (r_xcomp) randomized_10\VBN|NONE (l_nsubjpass) patients_4\NNS|In|receive|were|. (l_prep) with_5\IN| (l_pobj) disorders_8\NNS|NONE
D000666_D006402 NONE AmB_18\JJ|spironolactone|alone|either|or|intravenous (r_conj) AmB_15\VB|developing|daily|twice|to (r_dobj) receive_12\VB|In|patients|were|. (r_xcomp) randomized_10\VBN|NONE (l_nsubjpass) patients_4\NNS|In|receive|were|. (l_prep) with_5\IN| (l_pobj) disorders_8\NNS|NONE
D013148_D006402 NONE spironolactone_21\NN|AmB|alone|either|or|intravenous (r_conj) AmB_15\VB|developing|daily|twice|to (r_dobj) receive_12\VB|In|patients|were|. (r_xcomp) randomized_10\VBN|NONE (l_nsubjpass) patients_4\NNS|In|receive|were|. (l_prep) with_5\IN| (l_pobj) disorders_8\NNS|NONE
D000666_D009369 NONE B_12\NN| (r_npadvmod) related_14\VBN|in (r_amod) hypokalemia_15\NN|NONE (l_prep) in_16\IN|related (l_pobj) patients_18\NNS|NONE (l_compound) cancer_17\NN|NONE
D011188_D007008 NONE potassium_12\NN|NONE (r_compound) requirements_13\NNS|to|and|prevent (r_dobj) reduce_11\VB|of|the (l_conj) prevent_16\VB|requirements|to|and (l_dobj) hypokalemia_17\NN|to
D011188_D007008 NONE potassium_7\NN|NONE (r_compound) requirements_8\NNS|that|can|and|prevent|spironolactone (r_dobj) reduce_6\VB|.|study (l_conj) prevent_10\VBP|that|requirements|can|and|spironolactone (l_dobj) hypokalemia_11\NN|by
D011188_D007008 NONE potassium_15\NN|in|urinary (r_compound) loss_16\NN|NONE (r_dobj) reducing_13\VBG|NONE (r_pcomp) by_12\IN|hypokalemia (r_prep) prevent_10\VBP|that|requirements|can|and|spironolactone (l_dobj) hypokalemia_11\NN|by
D013148_D009181 NONE spironolactone_21\NN|AmB|alone|either|or|intravenous (r_conj) AmB_15\VB|developing|daily|twice|to (r_dobj) receive_12\VB|In|patients|were|. (l_advcl) developing_27\VBG|daily|twice|to|AmB (l_dobj) infection_33\NN|when
3131282
D002083_D063646 NONE hydroxyanisole_17\NN|NONE (r_pobj) with_15\IN|effect|. (r_prep) induced_14\VBN|NONE (l_nsubj) effect_3\NN|with|. (l_amod) carcinogenic_2\JJ|on|of
D002083_D017573 NONE BHA_5\NNP|at (r_dobj) given_2\VBN|NONE (r_acl) rats_1\NNS|NONE (r_pobj) In_0\IN|%|effect|. (r_prep) showed_23\VBD|NONE (l_dobj) effect_29\NN|%|In|. (l_prep) on_30\IN|dependent|a|enhancing (l_pobj) development_32\NN|NONE (l_prep) of_33\IN|the (l_pobj) hyperplasia_39\NN|NONE
D002083_D017573 NONE BHA_35\NNP| (r_npadvmod) induced_37\VBN|the|epithelial (r_amod) hyperplasia_39\NN|NONE
D002083_D013274 CID hydroxyanisole_17\NN|NONE (r_pobj) with_15\IN|effect|. (r_prep) induced_14\VBN|NONE (l_nsubj) effect_3\NN|with|. (l_prep) on_7\IN|of|carcinogenic (l_pobj) carcinogenesis_9\NN|NONE
D002083_D013274 CID hydroxyanisole_12\NN|NONE (r_pobj) on_10\IN|of|modifying|The|potential (r_prep) effect_3\NN|.|was|tumorigenesis|( (r_nsubjpass) examined_19\VBN|NONE (l_nsubjpass) tumorigenesis_17\NN|effect|.|was|(
D002083_D013274 CID BHA)-induced_14\JJ|NONE (r_amod) rat_15\NN|forestomach (r_compound) tumorigenesis_17\NN|effect|.|was|(
D002083_D013274 CID BHA_5\NNP|NONE (r_dobj) given_2\VBN|NONE (r_acl) groups_1\NNS|NONE (r_pobj) In_0\IN|.|in|,|increased|were|changes|marked (r_prep) observed_16\VBN|NONE (l_conj) increased_35\VBD|.|in|In|,|were|changes|marked (l_dobj) incidence_37\NN|from|to|RA (l_prep) of_38\IN|(|)|the|papilloma (l_pobj) tumors_40\NNS|NONE
D002083_D013274 CID BHA_13\NNP|forestomach|the|of (r_compound) carcinogenesis_15\NN|that|as|RA
C009166_D017573 NONE RA_7\NNP|NONE (r_punct) co_8\NNP|NONE (r_punct) -_9\HYPH|NONE (r_punct) administered_10\VBN|dose (r_punct) at_11\IN|BHA (r_prep) given_2\VBN|NONE (r_acl) rats_1\NNS|NONE (r_pobj) In_0\IN|%|effect|. (r_prep) showed_23\VBD|NONE (l_dobj) effect_29\NN|%|In|. (l_prep) on_30\IN|dependent|a|enhancing (l_pobj) development_32\NN|NONE (l_prep) of_33\IN|the (l_pobj) hyperplasia_39\NN|NONE
C009166_D002277 NONE RA_27\NNP|from|to|incidence (r_nsubj) increased_35\VBD|.|in|In|,|were|changes|marked (l_dobj) incidence_37\NN|from|to|RA (l_appos) papilloma_44\NN|(|)|the|of (l_conj) carcinoma_46\NN|and|cell|squamous
C009166_D002277 NONE RA_27\NNP|from|to|incidence (r_nsubj) increased_35\VBD|.|in|In|,|were|changes|marked (l_prep) to_48\IN|from|RA|incidence (l_pobj) %_50\NN|NONE (l_appos) rats_55\NNS| (l_prep) with_56\IN||,|(|/|) (l_pobj) carcinoma_57\NN|NONE
C009166_D002277 NONE RA_27\NNP|from|to|incidence (r_nsubj) increased_35\VBD|.|in|In|,|were|changes|marked (l_prep) from_59\IN|to|RA|incidence (l_pobj) %_61\NN|in (l_appos) rat_66\NN|/|,|)|(| (l_prep) with_67\IN|one (l_pobj) carcinoma_68\NN|NONE
C009166_D002277 NONE RA_74\NNP| (r_npadvmod) free_76\JJ|NONE (r_amod) water_77\NN|NONE (r_dobj) given_73\VBN|the (r_acl) group_72\NN|NONE (r_pobj) in_70\IN|% (r_prep) from_59\IN|to|RA|incidence (r_prep) increased_35\VBD|.|in|In|,|were|changes|marked (l_dobj) incidence_37\NN|from|to|RA (l_appos) papilloma_44\NN|(|)|the|of (l_conj) carcinoma_46\NN|and|cell|squamous
C009166_D002277 NONE RA_74\NNP| (r_npadvmod) free_76\JJ|NONE (r_amod) water_77\NN|NONE (r_dobj) given_73\VBN|the (r_acl) group_72\NN|NONE (r_pobj) in_70\IN|% (r_prep) from_59\IN|to|RA|incidence (r_prep) increased_35\VBD|.|in|In|,|were|changes|marked (l_prep) to_48\IN|from|RA|incidence (l_pobj) %_50\NN|NONE (l_appos) rats_55\NNS| (l_prep) with_56\IN||,|(|/|) (l_pobj) carcinoma_57\NN|NONE
C009166_D002277 NONE RA_74\NNP| (r_npadvmod) free_76\JJ|NONE (r_amod) water_77\NN|NONE (r_dobj) given_73\VBN|the (r_acl) group_72\NN|NONE (r_pobj) in_70\IN|% (r_prep) from_59\IN|to|RA|incidence (l_pobj) %_61\NN|in (l_appos) rat_66\NN|/|,|)|(| (l_prep) with_67\IN|one (l_pobj) carcinoma_68\NN|NONE
D002083_D010212 NONE BHA_5\NNP|NONE (r_dobj) given_2\VBN|NONE (r_acl) groups_1\NNS|NONE (r_pobj) In_0\IN|.|in|,|increased|were|changes|marked (r_prep) observed_16\VBN|NONE (l_conj) increased_35\VBD|.|in|In|,|were|changes|marked (l_dobj) incidence_37\NN|from|to|RA (l_appos) papilloma_44\NN|(|)|the|of
C009166_D013274 NONE acetate_6\NN|NONE (r_pobj) of_4\IN|on|carcinogenic (r_prep) effect_3\NN|with|. (l_prep) on_7\IN|of|carcinogenic (l_pobj) carcinogenesis_9\NN|NONE
C009166_D013274 NONE acetate_6\NN|NONE (r_pobj) of_4\IN|modifying|The|on|potential (r_prep) effect_3\NN|.|was|tumorigenesis|( (r_nsubjpass) examined_19\VBN|NONE (l_nsubjpass) tumorigenesis_17\NN|effect|.|was|(
C009166_D013274 NONE RA_8\NNP|retinyl (r_appos) acetate_6\NN|NONE (r_pobj) of_4\IN|modifying|The|on|potential (r_prep) effect_3\NN|.|was|tumorigenesis|( (r_nsubjpass) examined_19\VBN|NONE (l_nsubjpass) tumorigenesis_17\NN|effect|.|was|(
C009166_D013274 NONE RA_27\NNP|from|to|incidence (r_nsubj) increased_35\VBD|.|in|In|,|were|changes|marked (l_dobj) incidence_37\NN|from|to|RA (l_prep) of_38\IN|(|)|the|papilloma (l_pobj) tumors_40\NNS|NONE
C009166_D013274 NONE RA_74\NNP| (r_npadvmod) free_76\JJ|NONE (r_amod) water_77\NN|NONE (r_dobj) given_73\VBN|the (r_acl) group_72\NN|NONE (r_pobj) in_70\IN|% (r_prep) from_59\IN|to|RA|incidence (r_prep) increased_35\VBD|.|in|In|,|were|changes|marked (l_dobj) incidence_37\NN|from|to|RA (l_prep) of_38\IN|(|)|the|papilloma (l_pobj) tumors_40\NNS|NONE
C009166_D013274 NONE RA_4\NNP|carcinogenesis|that|as (r_nsubj) acted_5\VBD|findings|. (l_dobj) carcinogenesis_15\NN|that|as|RA
C009166_D063646 NONE acetate_6\NN|NONE (r_pobj) of_4\IN|on|carcinogenic (r_prep) effect_3\NN|with|. (l_amod) carcinogenic_2\JJ|on|of
C009166_D010212 NONE RA_27\NNP|from|to|incidence (r_nsubj) increased_35\VBD|.|in|In|,|were|changes|marked (l_dobj) incidence_37\NN|from|to|RA (l_appos) papilloma_44\NN|(|)|the|of
C009166_D010212 NONE RA_74\NNP| (r_npadvmod) free_76\JJ|NONE (r_amod) water_77\NN|NONE (r_dobj) given_73\VBN|the (r_acl) group_72\NN|NONE (r_pobj) in_70\IN|% (r_prep) from_59\IN|to|RA|incidence (r_prep) increased_35\VBD|.|in|In|,|were|changes|marked (l_dobj) incidence_37\NN|from|to|RA (l_appos) papilloma_44\NN|(|)|the|of
C009166_D010212 NONE RA_17\NN|and|in (r_pobj) with_14\IN||)|(|% (r_prep) rats_9\NNS|NONE (r_pobj) in_7\IN|.|Tumors|were (r_prep) induced_6\VBN|NONE (l_nsubjpass) Tumors_0\NNS|.|in|were (l_appos) papillomas_3\NNS|,|,
C009166_D010212 NONE RA_29\NNP||% (r_compound) administration_32\NN|NONE (r_punct) ._33\.|in|Tumors|were (r_punct) induced_6\VBN|NONE (l_nsubjpass) Tumors_0\NNS|.|in|were (l_appos) papillomas_3\NNS|,|,
C009166_D009369 NONE RA_17\NN|and|in (r_pobj) with_14\IN||)|(|% (r_prep) rats_9\NNS|NONE (r_pobj) in_7\IN|.|Tumors|were (r_prep) induced_6\VBN|NONE (l_nsubjpass) Tumors_0\NNS|.|in|were
C009166_D009369 NONE RA_29\NNP||% (r_compound) administration_32\NN|NONE (r_punct) ._33\.|in|Tumors|were (r_punct) induced_6\VBN|NONE (l_nsubjpass) Tumors_0\NNS|.|in|were
D002083_D002277 NONE BHA_5\NNP|NONE (r_dobj) given_2\VBN|NONE (r_acl) groups_1\NNS|NONE (r_pobj) In_0\IN|.|in|,|increased|were|changes|marked (r_prep) observed_16\VBN|NONE (l_conj) increased_35\VBD|.|in|In|,|were|changes|marked (l_dobj) incidence_37\NN|from|to|RA (l_appos) papilloma_44\NN|(|)|the|of (l_conj) carcinoma_46\NN|and|cell|squamous
D002083_D002277 NONE BHA_5\NNP|NONE (r_dobj) given_2\VBN|NONE (r_acl) groups_1\NNS|NONE (r_pobj) In_0\IN|.|in|,|increased|were|changes|marked (r_prep) observed_16\VBN|NONE (l_conj) increased_35\VBD|.|in|In|,|were|changes|marked (l_prep) to_48\IN|from|RA|incidence (l_pobj) %_50\NN|NONE (l_appos) rats_55\NNS| (l_prep) with_56\IN||,|(|/|) (l_pobj) carcinoma_57\NN|NONE
D002083_D002277 NONE BHA_5\NNP|NONE (r_dobj) given_2\VBN|NONE (r_acl) groups_1\NNS|NONE (r_pobj) In_0\IN|.|in|,|increased|were|changes|marked (r_prep) observed_16\VBN|NONE (l_conj) increased_35\VBD|.|in|In|,|were|changes|marked (l_prep) from_59\IN|to|RA|incidence (l_pobj) %_61\NN|in (l_appos) rat_66\NN|/|,|)|(| (l_prep) with_67\IN|one (l_pobj) carcinoma_68\NN|NONE
11573852
D000431_D012640 NONE alcohol_9\NN|withdrawal|as (r_compound) intake_10\NN|;|of|a (r_conj) history_4\NN|.|patient|cause (r_dobj) had_2\VBD|NONE (l_conj) cause_17\VB|.|history|patient (l_dobj) seizures_18\NNS|also|can
D000666_D004830 NONE B_18\NNP|NONE (r_pobj) of_16\IN|intravenous (r_prep) infusion_15\NN|NONE (r_pobj) during_13\IN|man|then|stopped|,|seizures|. (r_prep) experienced_8\VBD|NONE (l_dobj) seizures_12\NNS|man|then|during|stopped|,|.
D000666_D012640 CID B_1\NN| (r_npadvmod) induced_3\VBN|in|. (r_amod) seizures_4\NNS|NONE
D000666_D012640 CID B_16\NNP|NONE (r_compound) infusion_17\NN|NONE (r_pobj) following_14\VBG|of|a (r_prep) case_3\NN|To|. (l_prep) of_4\IN|a|following (l_pobj) episodes_6\NNS|NONE (l_prep) of_7\IN|multiple|in (l_pobj) activity_9\NN|NONE (l_compound) seizure_8\NN|NONE
D000666_D012640 CID B_18\NNP|NONE (r_pobj) of_16\IN|intravenous (r_prep) infusion_15\NN|NONE (r_pobj) during_13\IN|man|then|stopped|,|seizures|. (r_prep) experienced_8\VBD|NONE (l_conj) stopped_28\VBN|man|then|during|,|seizures|. (l_nsubjpass) seizures_23\NNS|and|was|decreased
D000666_D012640 CID B_15\NNP|amphotercin (r_compound) administration_16\NN|only (r_pobj) during_13\IN|NONE (r_prep) occurred_11\VBD|,|and|.|Despite|seizures (r_conj) persisted_9\VBD|NONE (l_nsubj) seizures_8\NNS|,|and|.|Despite|occurred
D000666_D012640 CID B_8\NNP|cause|that (r_nsubj) was_9\VBD|.|course (l_attr) cause_11\NN|that|B (l_prep) of_12\IN|the (l_pobj) seizures_14\NNS|NONE
D000666_D012640 CID B_1\NNP|be|. (r_nsubj) seems_2\VBZ|NONE (l_xcomp) be_4\VB|.|B (l_attr) cause_7\NN|to (l_prep) of_8\IN|probable|the (l_pobj) seizures_10\NNS|NONE
D000666_D012640 CID B_11\NNP|NONE (r_pobj) with_9\IN|NONE (r_prep) associated_8\VBN|NONE (r_acl) seizures_7\NNS|NONE
D000666_D000163 NONE B_1\NN| (r_npadvmod) induced_3\VBN|in|. (r_amod) seizures_4\NNS|NONE (l_prep) in_5\IN|.|induced (l_pobj) patient_7\NN|NONE (l_prep) with_8\IN|a (l_pobj) AIDS_9\NNP|NONE
D000666_D000163 NONE B_16\NNP|NONE (r_compound) infusion_17\NN|NONE (r_pobj) following_14\VBG|of|a (r_prep) case_3\NN|To|. (l_prep) of_4\IN|a|following (l_pobj) episodes_6\NNS|NONE (l_prep) in_10\IN|multiple|of (l_pobj) patent_13\NN|NONE (l_compound) AIDS_12\NNP|an
D000666_D000163 NONE B_8\NNP|cause|that (r_nsubj) was_9\VBD|.|course (l_attr) cause_11\NN|that|B (l_prep) of_12\IN|the (l_pobj) seizures_14\NNS|NONE (l_prep) in_15\IN|the (l_pobj) patient_18\NN|NONE (l_compound) AIDS_17\NNP|this
D008140_D012640 NONE lorazepam_5\NN|and (r_conj) phenytoin_3\NN|NONE (r_pobj) of_2\IN|NONE (r_prep) administration_1\NN|NONE (r_pobj) Despite_0\IN|,|and|.|occurred|seizures (r_prep) persisted_9\VBD|NONE (l_nsubj) seizures_8\NNS|,|and|.|Despite|occurred
D010672_D012640 NONE phenytoin_3\NN|NONE (r_pobj) of_2\IN|NONE (r_prep) administration_1\NN|NONE (r_pobj) Despite_0\IN|,|and|.|occurred|seizures (r_prep) persisted_9\VBD|NONE (l_nsubj) seizures_8\NNS|,|and|.|Despite|occurred
D016049_D012640 NONE Didanosine_0\NNP|potential|also|. (r_nsubj) has_2\VBZ|NONE (l_dobj) potential_4\NN|Didanosine|also|. (l_prep) for_5\IN|a (l_pcomp) inducing_6\VBG|NONE (l_dobj) seizures_7\NNS|NONE
D000431_D000437 NONE alcohol_9\NN|withdrawal|as (r_compound) intake_10\NN|;|of|a (r_conj) history_4\NN|.|patient|cause (l_prep) of_5\IN|;|a|intake (l_pobj) abuse_7\NN|NONE
9284778
D017402_D008107 NONE chlorofluorocarbons_14\NNS|NONE (r_pobj) of_13\IN|sparing (r_prep) substitutes_12\NNS|NONE (r_pobj) as_8\IN|NONE (r_prep) used_7\VBN|NONE (r_acl) hydrochlorofluorocarbons_6\NNS|NONE (r_pobj) by_5\IN|NONE (r_agent) caused_4\VBN|of|. (r_acl) Epidemic_0\NN|NONE (l_prep) of_1\IN|caused|. (l_pobj) disease_3\NN|NONE
C067411_D056486 NONE 124_9\CD|and| (r_conj) HCFCs_6\NNS|NONE (r_pobj) to_5\IN|Repeated|of (r_prep) exposure_1\NN|.|in|can (r_nsubj) result_11\VB|NONE (l_prep) in_12\IN|.|exposure|can (l_pobj) injury_15\NN|NONE
D014269_D056486 NONE trifluoroacetyl_16\NNS|NONE (r_compound) halide_17\NN|reactive|,|implicated (r_compound) intermediates_18\NNS|to (l_relcl) implicated_23\VBN|halide|reactive|, (l_prep) in_24\IN|been|which|have (l_pobj) hepatotoxicity_26\NN|NONE
D014269_D056486 NONE trifluoroacetyl_17\NN| (r_npadvmod) altered_19\VBN|liver (r_amod) proteins_21\NNS|are|that (r_nsubjpass) involved_23\VBN|,|known|results|. (r_ccomp) suggest_15\VBP|NONE (l_advcl) known_11\VBN|,|results|.|involved (l_nsubjpass) mechanism_3\NN|not|is|Although (l_prep) of_4\IN|the|exact (l_pobj) hepatotoxicity_5\NN|NONE
D006221_D056486 NONE 1-bromo-1-chloro-2,2,2-trifluoroethane_9\CD|NONE (r_pobj) as_8\IN|same|the (r_prep) way_7\NN|NONE (r_pobj) in_4\IN|form|are|.|compounds (r_prep) metabolised_3\VBN|NONE (l_advcl) form_14\VB|are|in|.|compounds (l_dobj) intermediates_18\NNS|to (l_relcl) implicated_23\VBN|halide|reactive|, (l_prep) in_24\IN|been|which|have (l_pobj) hepatotoxicity_26\NN|NONE
D006221_D056486 NONE halothane_11\NN|NONE (r_appos) 1-bromo-1-chloro-2,2,2-trifluoroethane_9\CD|NONE (r_pobj) as_8\IN|same|the (r_prep) way_7\NN|NONE (r_pobj) in_4\IN|form|are|.|compounds (r_prep) metabolised_3\VBN|NONE (l_advcl) form_14\VB|are|in|.|compounds (l_dobj) intermediates_18\NNS|to (l_relcl) implicated_23\VBN|halide|reactive|, (l_prep) in_24\IN|been|which|have (l_pobj) hepatotoxicity_26\NN|NONE
D006221_D056486 NONE halothane_28\NN|NONE (r_pobj) of_27\IN|the (r_prep) hepatotoxicity_26\NN|NONE
D010126_D008107 NONE ozone_9\NN| (r_npadvmod) sparing_11\VBG|of (r_amod) substitutes_12\NNS|NONE (r_pobj) as_8\IN|NONE (r_prep) used_7\VBN|NONE (r_acl) hydrochlorofluorocarbons_6\NNS|NONE (r_pobj) by_5\IN|NONE (r_agent) caused_4\VBN|of|. (r_acl) Epidemic_0\NN|NONE (l_prep) of_1\IN|caused|. (l_pobj) disease_3\NN|NONE
C072959_D056486 NONE 124_9\CD|and| (r_conj) HCFCs_6\NNS|NONE (r_pobj) to_5\IN|Repeated|of (r_prep) exposure_1\NN|.|in|can (r_nsubj) result_11\VB|NONE (l_prep) in_12\IN|.|exposure|can (l_pobj) injury_15\NN|NONE
-1_D008107 NONE hydrochlorofluorocarbons_6\NNS|NONE (r_pobj) by_5\IN|NONE (r_agent) caused_4\VBN|of|. (r_acl) Epidemic_0\NN|NONE (l_prep) of_1\IN|caused|. (l_pobj) disease_3\NN|NONE
C072959_D008107 CID 1-chloro-1,2,2,2-tetrafluoroethane_27\NN|)|HCFC|(|and|)| (r_conj) HCFC_23\NNP|( (r_appos) 1,1-dichloro-2,2,2-trifluoroethane_21\CD|NONE (r_pobj) of_20\IN|a (r_prep) mixture_19\NN|NONE (r_pobj) to_17\IN|accidental (r_prep) exposure_16\NN|had|had|who (r_dobj) repeated_14\VBN|industrial|nine (r_relcl) workers_10\NNS|NONE (r_pobj) in_7\IN|an|of (r_prep) epidemic_3\NN|We|. (l_prep) of_4\IN|an|in (l_pobj) disease_6\NN|NONE
C072959_D008107 CID 124_30\CD|NONE (r_nummod) HCFC_29\NNP|)|(|chloro,,,tetrafluoroethane|and|)| (r_appos) HCFC_23\NNP|( (r_appos) 1,1-dichloro-2,2,2-trifluoroethane_21\CD|NONE (r_pobj) of_20\IN|a (r_prep) mixture_19\NN|NONE (r_pobj) to_17\IN|accidental (r_prep) exposure_16\NN|had|had|who (r_dobj) repeated_14\VBN|industrial|nine (r_relcl) workers_10\NNS|NONE (r_pobj) in_7\IN|an|of (r_prep) epidemic_3\NN|We|. (l_prep) of_4\IN|an|in (l_pobj) disease_6\NN|NONE
C072959_D008107 CID 124_8\CD|and| (r_conj) HCFCs_5\NNS|whether|can|in (r_nsubj) result_10\VB|to (l_prep) in_11\IN|whether|can|HCFCs (l_pobj) disease_14\NN|NONE
C067411_D008107 CID 1,1-dichloro-2,2,2-trifluoroethane_21\CD|NONE (r_pobj) of_20\IN|a (r_prep) mixture_19\NN|NONE (r_pobj) to_17\IN|accidental (r_prep) exposure_16\NN|had|had|who (r_dobj) repeated_14\VBN|industrial|nine (r_relcl) workers_10\NNS|NONE (r_pobj) in_7\IN|an|of (r_prep) epidemic_3\NN|We|. (l_prep) of_4\IN|an|in (l_pobj) disease_6\NN|NONE
C067411_D008107 CID 123_24\CD|)|HCFC|(|chloro,,,tetrafluoroethane|and|) (r_nummod) HCFC_23\NNP|( (r_appos) 1,1-dichloro-2,2,2-trifluoroethane_21\CD|NONE (r_pobj) of_20\IN|a (r_prep) mixture_19\NN|NONE (r_pobj) to_17\IN|accidental (r_prep) exposure_16\NN|had|had|who (r_dobj) repeated_14\VBN|industrial|nine (r_relcl) workers_10\NNS|NONE (r_pobj) in_7\IN|an|of (r_prep) epidemic_3\NN|We|. (l_prep) of_4\IN|an|in (l_pobj) disease_6\NN|NONE
C067411_D008107 CID 124_8\CD|and| (r_conj) HCFCs_5\NNS|whether|can|in (r_nsubj) result_10\VB|to (l_prep) in_11\IN|whether|can|HCFCs (l_pobj) disease_14\NN|NONE
3076126
D016572_D051437 NONE cyclosporin_31\NN|NONE (r_pobj) with_30\IN|concomitantly (r_prep) treated_29\VBN|NONE (r_acl) patients_27\NNS|especially (r_pobj) in_26\IN|in|.|,|been|with|,|rarely|has (r_prep) reported_21\VBN|,|and|in (l_prep) in_10\IN|.|,|in|been|with|,|rarely|has (l_pobj) cases_12\NNS|NONE (l_prep) with_13\IN| (l_pobj) failure_16\NN|NONE
D015248_D009135 CID gemfibrozil_33\NN|, (r_conj) cyclosporin_31\NN|NONE (r_pobj) with_30\IN|concomitantly (r_prep) treated_29\VBN|NONE (r_acl) patients_27\NNS|especially (r_pobj) in_26\IN|in|.|,|been|with|,|rarely|has (r_prep) reported_21\VBN|,|and|in (r_conj) associated_2\VBN|, (r_acl) Myopathy_0\NNP|NONE
D008148_D009135 NONE lovastatin_23\NN|NONE (r_pobj) with_22\IN|in|.|,|in|been|,|rarely|has (r_prep) reported_21\VBN|,|and|in (r_conj) associated_2\VBN|, (r_acl) Myopathy_0\NNP|NONE
D015248_D051437 NONE gemfibrozil_33\NN|, (r_conj) cyclosporin_31\NN|NONE (r_pobj) with_30\IN|concomitantly (r_prep) treated_29\VBN|NONE (r_acl) patients_27\NNS|especially (r_pobj) in_26\IN|in|.|,|been|with|,|rarely|has (r_prep) reported_21\VBN|,|and|in (l_prep) in_10\IN|.|,|in|been|with|,|rarely|has (l_pobj) cases_12\NNS|NONE (l_prep) with_13\IN| (l_pobj) failure_16\NN|NONE
D009525_D051437 NONE niacin_35\NN|or (r_conj) gemfibrozil_33\NN|, (r_conj) cyclosporin_31\NN|NONE (r_pobj) with_30\IN|concomitantly (r_prep) treated_29\VBN|NONE (r_acl) patients_27\NNS|especially (r_pobj) in_26\IN|in|.|,|been|with|,|rarely|has (r_prep) reported_21\VBN|,|and|in (l_prep) in_10\IN|.|,|in|been|with|,|rarely|has (l_pobj) cases_12\NNS|NONE (l_prep) with_13\IN| (l_pobj) failure_16\NN|NONE
D015248_D009212 NONE gemfibrozil_33\NN|, (r_conj) cyclosporin_31\NN|NONE (r_pobj) with_30\IN|concomitantly (r_prep) treated_29\VBN|NONE (r_acl) patients_27\NNS|especially (r_pobj) in_26\IN|in|.|,|been|with|,|rarely|has (r_prep) reported_21\VBN|,|and|in (r_conj) associated_2\VBN|, (l_prep) in_3\IN|,|reported|and (l_pobj) cases_5\NNS|NONE (l_prep) with_6\IN|some (l_pobj) myoglobinuria_7\NNS|NONE
D009525_D009135 CID niacin_35\NN|or (r_conj) gemfibrozil_33\NN|, (r_conj) cyclosporin_31\NN|NONE (r_pobj) with_30\IN|concomitantly (r_prep) treated_29\VBN|NONE (r_acl) patients_27\NNS|especially (r_pobj) in_26\IN|in|.|,|been|with|,|rarely|has (r_prep) reported_21\VBN|,|and|in (r_conj) associated_2\VBN|, (r_acl) Myopathy_0\NNP|NONE
D009525_D009212 NONE niacin_35\NN|or (r_conj) gemfibrozil_33\NN|, (r_conj) cyclosporin_31\NN|NONE (r_pobj) with_30\IN|concomitantly (r_prep) treated_29\VBN|NONE (r_acl) patients_27\NNS|especially (r_pobj) in_26\IN|in|.|,|been|with|,|rarely|has (r_prep) reported_21\VBN|,|and|in (r_conj) associated_2\VBN|, (l_prep) in_3\IN|,|reported|and (l_pobj) cases_5\NNS|NONE (l_prep) with_6\IN|some (l_pobj) myoglobinuria_7\NNS|NONE
D016572_D009212 NONE cyclosporin_31\NN|NONE (r_pobj) with_30\IN|concomitantly (r_prep) treated_29\VBN|NONE (r_acl) patients_27\NNS|especially (r_pobj) in_26\IN|in|.|,|been|with|,|rarely|has (r_prep) reported_21\VBN|,|and|in (r_conj) associated_2\VBN|, (l_prep) in_3\IN|,|reported|and (l_pobj) cases_5\NNS|NONE (l_prep) with_6\IN|some (l_pobj) myoglobinuria_7\NNS|NONE
D008148_D051437 CID lovastatin_23\NN|NONE (r_pobj) with_22\IN|in|.|,|in|been|,|rarely|has (r_prep) reported_21\VBN|,|and|in (l_prep) in_10\IN|.|,|in|been|with|,|rarely|has (l_pobj) cases_12\NNS|NONE (l_prep) with_13\IN| (l_pobj) failure_16\NN|NONE
D008148_D009212 CID lovastatin_23\NN|NONE (r_pobj) with_22\IN|in|.|,|in|been|,|rarely|has (r_prep) reported_21\VBN|,|and|in (r_conj) associated_2\VBN|, (l_prep) in_3\IN|,|reported|and (l_pobj) cases_5\NNS|NONE (l_prep) with_6\IN|some (l_pobj) myoglobinuria_7\NNS|NONE
D016572_D009135 CID cyclosporin_31\NN|NONE (r_pobj) with_30\IN|concomitantly (r_prep) treated_29\VBN|NONE (r_acl) patients_27\NNS|especially (r_pobj) in_26\IN|in|.|,|been|with|,|rarely|has (r_prep) reported_21\VBN|,|and|in (r_conj) associated_2\VBN|, (r_acl) Myopathy_0\NNP|NONE
19761039
D012110_D004409 CID reserpine_17\NN| (r_npadvmod) induced_19\VBN|orofacial|and|alterations (r_amod) dyskinesia_21\JJ|NONE
D012110_D004409 CID reserpine_16\NN| (r_npadvmod) induced_18\VBN|stress|orofacial|and (r_amod) dyskinesia_20\JJ|NONE
D010936_D004409 NONE sinensis_7\NN|NONE (r_pobj) of_4\IN|methanolic (r_prep) extract_3\NN|NONE (r_pobj) of_1\IN|)|mg/kg|( (r_prep) Effect_0\NN|was|.|on (r_nsubjpass) studied_15\VBN|NONE (l_prep) on_16\IN|was|.|Effect (l_pobj) dyskinesia_21\JJ|NONE
D010936_D004409 NONE sinensis_10\NN|that|role (r_nsubj) had_11\VBD|results|. (l_dobj) role_14\NN|that|sinensis (l_prep) against_15\IN|a|protective (l_pobj) dyskinesia_20\JJ|NONE
20552622
D001262_D013610 NONE atenolol_51\NN|such (r_pobj) as_50\IN|a||beta (r_prep) blocker_48\NN|that|it|may (r_nsubj) relieve_60\VB|and|while (r_conj) swallowing_42\VBG|trigger|that|may|agonist (r_advcl) be_31\VB|to (l_nsubj) agonist_21\NN|trigger|swallowing|that|may (l_acl) known_25\VBN||a|beta|like (l_xcomp) induce_27\VB|)|( (l_dobj) tachycardia_28\NN|to
D000420_D013610 NONE salbutamol_23\NN|NONE (r_pobj) like_22\IN||known|a|beta (r_prep) agonist_21\NN|trigger|swallowing|that|may (l_acl) known_25\VBN||a|beta|like (l_xcomp) induce_27\VB|)|( (l_dobj) tachycardia_28\NN|to
D000420_D013617 CID salbutamol_7\NN|NONE (r_pobj) by_6\IN|NONE (r_agent) triggered_5\VBN|atrial|induced|report (r_acl) tachyarrhythmia_4\NN|NONE
D000420_D013617 CID Salbutamol_0\NNP|here|.|as|is (r_nsubjpass) presented_2\VBN|NONE (l_prep) as_4\IN|here|.|Salbutamol|is (l_pobj) trigger_7\NN|NONE (l_prep) for_8\IN|a|possible (l_pobj) SIAT_9\NNP|NONE
D001262_D001145 NONE atenolol_6\NN|NONE (r_pobj) with_5\IN|but|after|recurred|.|,|arrhythmia (r_prep) resolved_2\VBD|NONE (l_nsubj) arrhythmia_1\NN|but|after|recurred|.|with|,
D001262_D001145 NONE atenolol_13\NN|NONE (r_pobj) with_11\IN|a (r_prep) week_10\NN|NONE (r_pobj) after_8\IN|.|arrhythmia|,|After (r_prep) disappeared_17\VBD|NONE (l_nsubj) arrhythmia_16\NN|after|.|,|After
384871
D004977_D009901 CID ethambutol_6\NN|NONE (r_nmod) treatment_9\NN|to (r_pobj) due_3\IN|.|optic (r_prep) neuropathy_2\NN|NONE
D004977_D064420 NONE ethambutol_8\NN|to (r_pobj) due_6\IN|of|The (r_amod) hazards_1\NNS|are|. (l_prep) of_2\IN|The|due (l_pobj) toxicity_5\NN|NONE
D007538_D009901 CID isoniazid_8\NN|combined|and (r_conj) ethambutol_6\NN|NONE (r_nmod) treatment_9\NN|to (r_pobj) due_3\IN|.|optic (r_prep) neuropathy_2\NN|NONE
3084782
D006046_D003872 CID gold_32\NN|B|and (r_compound) thiosulphate_33\NN|to (r_pobj) due_30\IN|dermatitis (r_prep) between_28\IN|has|.|and|,|due|been|association|between (r_prep) found_5\VBN|NONE (l_prep) between_6\IN|has|.|and|between|,|due|been|association (l_pobj) nephritis_7\NN|NONE (l_conj) dermatitis_9\NN|and
D006046_D003872 CID gold_32\NN|B|and (r_compound) thiosulphate_33\NN|to (r_pobj) due_30\IN|dermatitis (r_prep) between_28\IN|has|.|and|,|due|been|association|between (l_pobj) dermatitis_29\NN|due
D008625_D001172 NONE Tiopronin_17\NNP|NONE (r_npadvmod) related_18\VBN|nephritis|the (r_amod) group_20\NN|NONE (r_pobj) for_15\IN|NONE (r_prep) except_14\IN|with (r_prep) patients_11\NNS|NONE (l_prep) with_12\IN|except (l_pobj) RA_13\NNP|NONE
D010396_D009393 NONE Penicillamine_17\NN|class|)|and|BCw|( (r_appos) Tiopronin_12\NNP|NONE (r_pobj) to_11\IN|NONE (r_pcomp) due_10\IN|has|.|and|between|,|been|association|between (r_prep) found_5\VBN|NONE (l_prep) between_6\IN|has|.|and|between|,|due|been|association (l_pobj) nephritis_7\NN|NONE
-1_D009393 NONE thiosulphate_33\NN|to (r_pobj) due_30\IN|dermatitis (r_prep) between_28\IN|has|.|and|,|due|been|association|between (r_prep) found_5\VBN|NONE (l_prep) between_6\IN|has|.|and|between|,|due|been|association (l_pobj) nephritis_7\NN|NONE
D006046_D009393 NONE gold_32\NN|B|and (r_compound) thiosulphate_33\NN|to (r_pobj) due_30\IN|dermatitis (r_prep) between_28\IN|has|.|and|,|due|been|association|between (r_prep) found_5\VBN|NONE (l_prep) between_6\IN|has|.|and|between|,|due|been|association (l_pobj) nephritis_7\NN|NONE
D008625_D003872 CID Tiopronin_12\NNP|NONE (r_pobj) to_11\IN|NONE (r_pcomp) due_10\IN|has|.|and|between|,|been|association|between (r_prep) found_5\VBN|NONE (l_prep) between_6\IN|has|.|and|between|,|due|been|association (l_pobj) nephritis_7\NN|NONE (l_conj) dermatitis_9\NN|and
D008625_D003872 CID Tiopronin_12\NNP|NONE (r_pobj) to_11\IN|NONE (r_pcomp) due_10\IN|has|.|and|between|,|been|association|between (r_prep) found_5\VBN|NONE (l_prep) between_28\IN|has|.|and|,|due|been|association|between (l_pobj) dermatitis_29\NN|due
D010396_D003872 NONE Penicillamine_17\NN|class|)|and|BCw|( (r_appos) Tiopronin_12\NNP|NONE (r_pobj) to_11\IN|NONE (r_pcomp) due_10\IN|has|.|and|between|,|been|association|between (r_prep) found_5\VBN|NONE (l_prep) between_6\IN|has|.|and|between|,|due|been|association (l_pobj) nephritis_7\NN|NONE (l_conj) dermatitis_9\NN|and
D010396_D003872 NONE Penicillamine_17\NN|class|)|and|BCw|( (r_appos) Tiopronin_12\NNP|NONE (r_pobj) to_11\IN|NONE (r_pcomp) due_10\IN|has|.|and|between|,|been|association|between (r_prep) found_5\VBN|NONE (l_prep) between_28\IN|has|.|and|,|due|been|association|between (l_pobj) dermatitis_29\NN|due
D008625_D009393 CID Tiopronin_12\NNP|NONE (r_pobj) to_11\IN|NONE (r_pcomp) due_10\IN|has|.|and|between|,|been|association|between (r_prep) found_5\VBN|NONE (l_prep) between_6\IN|has|.|and|between|,|due|been|association (l_pobj) nephritis_7\NN|NONE
D008625_D009393 CID Tiopronin_17\NNP|NONE (r_npadvmod) related_18\VBN|nephritis|the (r_amod) group_20\NN|NONE (l_compound) nephritis_19\NN|related|the
-1_D003872 NONE thiosulphate_33\NN|to (r_pobj) due_30\IN|dermatitis (r_prep) between_28\IN|has|.|and|,|due|been|association|between (r_prep) found_5\VBN|NONE (l_prep) between_6\IN|has|.|and|between|,|due|been|association (l_pobj) nephritis_7\NN|NONE (l_conj) dermatitis_9\NN|and
-1_D003872 NONE thiosulphate_33\NN|to (r_pobj) due_30\IN|dermatitis (r_prep) between_28\IN|has|.|and|,|due|been|association|between (l_pobj) dermatitis_29\NN|due
9321531
D007980_D004409 CID levodopa_11\RB| (r_npadvmod) induced_13\VBN|and|disability (r_amod) dyskinesias_14\NNS|,|In|pallidotomy|.|significantly
D007980_D010300 NONE levodopa_11\RB| (r_npadvmod) induced_13\VBN|and|disability (r_amod) dyskinesias_14\NNS|,|In|pallidotomy|.|significantly (r_dobj) reduces_10\VBZ|NONE (l_prep) In_0\IN|dyskinesias|,|pallidotomy|.|significantly (l_pobj) disease_6\NN|NONE
20080983
C048833_D012893 NONE modafinil_15\NN|NONE (l_conj) sleepiness_20\NN|on|dosed
C048833_D012893 NONE Modafinil_0\NNP|.|was|measured|,|with (r_nsubjpass) associated_2\VBN|NONE (l_advcl) measured_10\VBN|.|was|,|Modafinil|with (l_conj) decrease_22\NN|as|,|and|by (l_prep) in_23\IN|a|significant (l_pobj) sleepiness_26\NN|NONE
C048833_D012893 NONE modafinil_3\NN|,|.|normalizes|sleep (r_nsubj) promotes_4\VBZ|NONE (l_conj) normalizes_8\VBZ|,|.|modafinil|sleep (l_conj) decreases_13\VBZ|architecture|,|and (l_dobj) sleepiness_15\NN|NONE
D003042_D012893 CID cocaine_23\NN|chronic (r_compound) users_24\NNS|NONE (r_pobj) in_21\IN|daytime (r_prep) sleepiness_20\NN|on|dosed
D003042_D012893 CID cocaine_18\NN|abstinent (r_compound) users_19\NNS|NONE (r_pobj) in_16\IN|daytime (r_prep) sleepiness_15\NN|NONE
7650771
D004456_D018908 CID iodide_12\NN|echothiophate|ophthalmic (r_nmod) drops_14\NNS|NONE (r_pobj) of_10\IN|the (r_prep) use_9\NN|NONE (r_pobj) from_7\IN|a|severe|cholinergic (r_prep) syndrome_6\NN|presented|,|.|patient (r_dobj) developed_2\VBD|NONE (l_conj) presented_16\VBN|syndrome|,|.|patient (l_prep) with_17\IN|given|and (l_pobj) weakness_20\NN|NONE
D004456_D009157 NONE iodide_12\NN|echothiophate|ophthalmic (r_nmod) drops_14\NNS|NONE (r_pobj) of_10\IN|the (r_prep) use_9\NN|NONE (r_pobj) from_7\IN|a|severe|cholinergic (r_prep) syndrome_6\NN|presented|,|.|patient (r_dobj) developed_2\VBD|NONE (l_conj) presented_16\VBN|syndrome|,|.|patient (l_conj) given_24\VBN|and|with (l_dobj) diagnosis_26\NN|initially|was (l_prep) of_27\IN|the (l_pobj) gravis_29\NN|NONE
D004456_D064420 NONE iodide_8\NN|eye|echothiophate (r_compound) drops_10\VBZ|NONE (r_pobj) of_6\IN|ocular (r_prep) instillation_5\NN|NONE (r_pobj) from_3\IN|NONE (r_prep) resulting_2\VBG|.|Cholinergic (r_acl) toxicity_1\NN|NONE
3629586
C021341_D064420 NONE cefazedone_12\NN|or (r_conj) cefonicid_10\NN|NONE (r_pobj) of_9\IN|intravenous|the|to (r_prep) administration_8\NN|thrombocytopenia|incidence|In|.|, (r_nsubj) caused_16\VBD|NONE (l_prep) In_0\IN|thrombocytopenia|incidence|.|,|administration (l_pobj) studies_4\NNS|NONE (l_compound) toxicity_3\NN|subacute|four
C021341_D013921 CID cefazedone_12\NN|or (r_conj) cefonicid_10\NN|NONE (r_pobj) of_9\IN|intravenous|the|to (r_prep) administration_8\NN|thrombocytopenia|incidence|In|.|, (r_nsubj) caused_16\VBD|NONE (l_ccomp) thrombocytopenia_28\NN|incidence|In|.|,|administration
C021341_D006402 NONE cefazedone_6\NN|and (r_conj) cefonicid_4\NN|NONE (r_pobj) of_3\IN|.|The|:|hematologic|model (r_prep) effects_2\NNS|NONE (l_appos) model_13\NN|.|The|:|of|hematologic (l_prep) of_14\IN|potential|a (l_pobj) hematotoxicity_16\NN|NONE
C021341_D006402 NONE cefazedone_29\NN|or||mg/kg (r_conj) cefonicid_23\NN|NONE (r_dobj) receiving_18\VBG|NONE (r_acl) dogs_17\NNS|NONE (r_pobj) of_16\IN| (r_prep) %_15\NN|NONE (r_pobj) in_12\IN|NONE (r_prep) occurred_11\VBD|anemia|and|compromising|. (r_conj) was_3\VBD|NONE (l_attr) compromising_6\NN|anemia|and|occurred|. (l_prep) of_7\IN|the|most (l_pobj) cytopenias_9\NNS|NONE
C021341_D006402 NONE cefazedone)-treated_20\VBN|cefonicid|( (r_amod) dogs_21\NNS|compared|.|reproduced|period|; (r_nsubj) showed_22\VBD|NONE (l_ccomp) reproduced_10\VBN|dogs|compared|.|period|; (l_nsubjpass) syndrome_8\NN|,|was|Upon|in
C021341_D006402 NONE cefazedone_11\NN|or (r_conj) cefonicid_9\NN|NONE (r_pobj) of_8\IN|high (r_prep) doses_7\NNS|NONE (r_pobj) of_5\IN|to|the (r_prep) administration_4\NN|hematotoxicity|that|can|provides|and (r_nsubj) induce_15\VB|.|We (l_dobj) hematotoxicity_16\NN|administration|that|can|provides|and
C021341_D006402 NONE cefazedone_11\NN|or (r_conj) cefonicid_9\NN|NONE (r_pobj) of_8\IN|high (r_prep) doses_7\NNS|NONE (r_pobj) of_5\IN|to|the (r_prep) administration_4\NN|hematotoxicity|that|can|provides|and (r_nsubj) induce_15\VB|.|We (l_dobj) hematotoxicity_16\NN|administration|that|can|provides|and (l_amod) similar_17\JJ|NONE (l_prep) to_18\IN|NONE (l_pobj) dyscrasias_24\NNS|NONE
D002511_D006402 NONE cephalosporin_15\JJ|in (r_amod) hematotoxicity_16\NN|NONE
D002511_D006402 NONE Cephalosporin_0\JJ|NONE (r_amod) antibiotics_1\NNS|characterized|.|variety (r_nsubj) cause_2\VBP|NONE (l_dobj) variety_4\NN|characterized|.|antibiotics (l_prep) of_5\IN|,|a (l_pobj) disturbances_7\NNS|NONE
D002511_D006402 NONE cephalosporin_4\NN|NONE (r_pobj) with_2\IN|NONE (r_prep) rechallenge_1\VB|NONE (r_pobj) Upon_0\IN|,|syndrome|was|in (r_prep) reproduced_10\VBN|dogs|compared|.|period|; (l_nsubjpass) syndrome_8\NN|,|was|Upon|in
D002511_D006402 NONE cephalosporin_20\NN| (r_advmod) induced_22\VBN|described|blood|the (r_amod) dyscrasias_24\NNS|NONE (r_pobj) to_18\IN|NONE (r_prep) similar_17\JJ|NONE (r_amod) hematotoxicity_16\NN|administration|that|can|provides|and
D002511_D006402 NONE cephalosporin_20\NN| (r_advmod) induced_22\VBN|described|blood|the (r_amod) dyscrasias_24\NNS|NONE
D015790_D064420 NONE cefonicid_10\NN|NONE (r_pobj) of_9\IN|intravenous|the|to (r_prep) administration_8\NN|thrombocytopenia|incidence|In|.|, (r_nsubj) caused_16\VBD|NONE (l_prep) In_0\IN|thrombocytopenia|incidence|.|,|administration (l_pobj) studies_4\NNS|NONE (l_compound) toxicity_3\NN|subacute|four
C021341_D009503 CID cefazedone_12\NN|or (r_conj) cefonicid_10\NN|NONE (r_pobj) of_9\IN|intravenous|the|to (r_prep) administration_8\NN|thrombocytopenia|incidence|In|.|, (r_nsubj) caused_16\VBD|NONE (l_dobj) incidence_21\NN|thrombocytopenia|In|.|,|administration (l_prep) of_22\IN|dependent|a (l_pobj) anemia_23\NN|NONE (l_conj) neutropenia_25\NN|,
C021341_D000740 CID cefazedone_12\NN|or (r_conj) cefonicid_10\NN|NONE (r_pobj) of_9\IN|intravenous|the|to (r_prep) administration_8\NN|thrombocytopenia|incidence|In|.|, (r_nsubj) caused_16\VBD|NONE (l_dobj) incidence_21\NN|thrombocytopenia|In|.|,|administration (l_prep) of_22\IN|dependent|a (l_pobj) anemia_23\NN|NONE
C021341_D000740 CID cefazedone_29\NN|or||mg/kg (r_conj) cefonicid_23\NN|NONE (r_dobj) receiving_18\VBG|NONE (r_acl) dogs_17\NNS|NONE (r_pobj) of_16\IN| (r_prep) %_15\NN|NONE (r_pobj) in_12\IN|NONE (r_prep) occurred_11\VBD|anemia|and|compromising|. (r_conj) was_3\VBD|NONE (l_nsubj) anemia_2\NN|and|occurred|compromising|.
D015790_D006402 NONE cefonicid_4\NN|NONE (r_pobj) of_3\IN|.|The|:|hematologic|model (r_prep) effects_2\NNS|NONE (l_appos) model_13\NN|.|The|:|of|hematologic (l_prep) of_14\IN|potential|a (l_pobj) hematotoxicity_16\NN|NONE
D015790_D006402 NONE cefonicid_23\NN|NONE (r_dobj) receiving_18\VBG|NONE (r_acl) dogs_17\NNS|NONE (r_pobj) of_16\IN| (r_prep) %_15\NN|NONE (r_pobj) in_12\IN|NONE (r_prep) occurred_11\VBD|anemia|and|compromising|. (r_conj) was_3\VBD|NONE (l_attr) compromising_6\NN|anemia|and|occurred|. (l_prep) of_7\IN|the|most (l_pobj) cytopenias_9\NNS|NONE
D015790_D006402 NONE cefonicid_16\NN|cefazedone)treated|( (r_amod) dogs_21\NNS|compared|.|reproduced|period|; (r_nsubj) showed_22\VBD|NONE (l_ccomp) reproduced_10\VBN|dogs|compared|.|period|; (l_nsubjpass) syndrome_8\NN|,|was|Upon|in
D015790_D006402 NONE cefonicid_9\NN|NONE (r_pobj) of_8\IN|high (r_prep) doses_7\NNS|NONE (r_pobj) of_5\IN|to|the (r_prep) administration_4\NN|hematotoxicity|that|can|provides|and (r_nsubj) induce_15\VB|.|We (l_dobj) hematotoxicity_16\NN|administration|that|can|provides|and
D015790_D006402 NONE cefonicid_9\NN|NONE (r_pobj) of_8\IN|high (r_prep) doses_7\NNS|NONE (r_pobj) of_5\IN|to|the (r_prep) administration_4\NN|hematotoxicity|that|can|provides|and (r_nsubj) induce_15\VB|.|We (l_dobj) hematotoxicity_16\NN|administration|that|can|provides|and (l_amod) similar_17\JJ|NONE (l_prep) to_18\IN|NONE (l_pobj) dyscrasias_24\NNS|NONE
D015790_D013921 CID cefonicid_10\NN|NONE (r_pobj) of_9\IN|intravenous|the|to (r_prep) administration_8\NN|thrombocytopenia|incidence|In|.|, (r_nsubj) caused_16\VBD|NONE (l_ccomp) thrombocytopenia_28\NN|incidence|In|.|,|administration
D015790_D009503 CID cefonicid_10\NN|NONE (r_pobj) of_9\IN|intravenous|the|to (r_prep) administration_8\NN|thrombocytopenia|incidence|In|.|, (r_nsubj) caused_16\VBD|NONE (l_dobj) incidence_21\NN|thrombocytopenia|In|.|,|administration (l_prep) of_22\IN|dependent|a (l_pobj) anemia_23\NN|NONE (l_conj) neutropenia_25\NN|,
D015790_D000740 CID cefonicid_10\NN|NONE (r_pobj) of_9\IN|intravenous|the|to (r_prep) administration_8\NN|thrombocytopenia|incidence|In|.|, (r_nsubj) caused_16\VBD|NONE (l_dobj) incidence_21\NN|thrombocytopenia|In|.|,|administration (l_prep) of_22\IN|dependent|a (l_pobj) anemia_23\NN|NONE
D015790_D000740 CID cefonicid_23\NN|NONE (r_dobj) receiving_18\VBG|NONE (r_acl) dogs_17\NNS|NONE (r_pobj) of_16\IN| (r_prep) %_15\NN|NONE (r_pobj) in_12\IN|NONE (r_prep) occurred_11\VBD|anemia|and|compromising|. (r_conj) was_3\VBD|NONE (l_nsubj) anemia_2\NN|and|occurred|compromising|.
19299179
D015662_D015658 NONE trimoxazole_11\NN|for|report||dose (r_amod) treatment_12\NN|NONE (l_prep) for_13\IN|trimoxazole|report||dose (l_pobj) pneumonia_15\NN|NONE (l_prep) in_16\IN|Pneumocystis (l_pobj) patients_20\NNS|NONE (l_amod) infected_19\VBN|NONE
D015662_D015658 NONE trimoxazole_25\NN|NONE (r_punct) ._26\.|is|pneumonia|generally|with (r_punct) treated_18\VBN|NONE (l_nsubjpass) pneumonia_1\NN|is|.|generally|with (l_appos) infection_9\NN|,|PCP|,|(|)|Pneumocystis (l_prep) in_10\IN|common|a|opportunistic (l_pobj) individuals_14\NNS|NONE (l_amod) infected_13\VBN|NONE
D015662_D015658 NONE trimoxazole_35\NN|for (r_amod) treatment_36\NN|cases|we|Here|.|, (r_dobj) report_3\VBP|NONE (l_dobj) cases_5\NNS|we|Here|.|,|treatment (l_prep) of_6\IN|in|and|two (l_pobj) patients_12\NNS|NONE (l_amod) infected_11\VBN|immunocompromised|developed
D015662_D011020 NONE trimoxazole_11\NN|for|report||dose (r_amod) treatment_12\NN|NONE (l_prep) for_13\IN|trimoxazole|report||dose (l_pobj) pneumonia_15\NN|NONE
D015662_D011020 NONE trimoxazole_25\NN|NONE (r_punct) ._26\.|is|pneumonia|generally|with (r_punct) treated_18\VBN|NONE (l_nsubjpass) pneumonia_1\NN|is|.|generally|with
D015662_D011020 NONE trimoxazole_25\NN|NONE (r_punct) ._26\.|is|pneumonia|generally|with (r_punct) treated_18\VBN|NONE (l_nsubjpass) pneumonia_1\NN|is|.|generally|with (l_appos) PCP_3\NNP|,|,|(|)|Pneumocystis|infection
D015662_D011020 NONE trimoxazole_35\NN|for (r_amod) treatment_36\NN|cases|we|Here|.|, (l_prep) for_37\IN|trimoxazole (l_pobj) PCP_38\NNP|NONE
D015662_D008100 NONE trimoxazole_35\NN|for (r_amod) treatment_36\NN|cases|we|Here|.|, (r_dobj) report_3\VBP|NONE (l_dobj) cases_5\NNS|we|Here|.|,|treatment (l_conj) in_20\IN|and|two|of (l_pobj) lesions_23\NNS|, (l_acl) mimicking_24\VBG|one|patient (l_dobj) formation_27\NN|NONE (l_compound) abscess_26\NN|on|liver
D015662_D009894 NONE trimoxazole_25\NN|NONE (r_punct) ._26\.|is|pneumonia|generally|with (r_punct) treated_18\VBN|NONE (l_nsubjpass) pneumonia_1\NN|is|.|generally|with (l_appos) infection_9\NN|,|PCP|,|(|)|Pneumocystis
D015662_D002780 CID trimoxazole_35\NN|for (r_amod) treatment_36\NN|cases|we|Here|.|, (r_dobj) report_3\VBP|NONE (l_dobj) cases_5\NNS|we|Here|.|,|treatment (l_prep) of_6\IN|in|and|two (l_pobj) patients_12\NNS|NONE (l_relcl) developed_14\VBD|immunocompromised|infected (l_dobj) cholestasis_17\NN|,|who
D015662_D002779 NONE trimoxazole_11\NN|for|report||dose (r_amod) treatment_12\NN|NONE (r_pobj) after_5\IN|Severe|. (r_prep) cholestasis_4\NN|NONE
19581773
D012254_D004172 NONE ribavirin_21\RB|and (r_conj) alpha-2b_19\CD|(|) (r_conj) IFN_17\NNP|pegylated (r_appos) interferon_15\NN|NONE (r_pobj) of_13\IN|NONE (r_prep) administration_12\NN|NONE (r_pobj) of_11\IN| (r_prep) weeks_10\NNS|NONE (r_pobj) after_8\IN|experienced|.|for|sudden|old|A (r_prep) diplopia_7\NN|NONE
C417083_D009157 CID interferon_6\NN|for|pegylated (r_nmod) treatment_9\NN|NONE (r_pobj) during_4\IN|of (r_prep) Development_0\NN|NONE (l_prep) of_1\IN|during (l_pobj) myasthenia_3\NN|NONE
C417083_D009157 CID alpha-2b_10\CD|NONE (r_pobj) of_7\IN|combination (r_prep) therapy_6\NN|NONE (r_pobj) with_4\IN|NONE (r_prep) associated_3\VBN|ocular|The (r_acl) myasthenia_2\NN|is|rarely
C417083_D009157 CID IFN_35\NNP|NONE (r_compound) therapy_36\NN|NONE (r_pobj) of_34\IN|the|eye|various (r_prep) complications_33\NNS|NONE (r_pobj) of_29\IN|a (r_prep) review_28\NN|NONE (r_pobj) with_26\IN|we|case|therefore|;|.|reported|, (r_prep) present_23\VBP|NONE (l_ccomp) reported_18\VBN|with|we|case|therefore|;|.|, (l_nsubjpass) myasthenia_2\NN|is|rarely
D012254_D009157 CID ribavirin_8\JJ|and (r_conj) interferon_6\NN|for|pegylated (r_nmod) treatment_9\NN|NONE (r_pobj) during_4\IN|of (r_prep) Development_0\NN|NONE (l_prep) of_1\IN|during (l_pobj) myasthenia_3\NN|NONE
D012254_D009157 CID ribavirin_12\RB|pegylated|IFN|for|and (r_conj) alpha-2b_10\CD|NONE (r_pobj) of_7\IN|combination (r_prep) therapy_6\NN|NONE (r_pobj) with_4\IN|NONE (r_prep) associated_3\VBN|ocular|The (r_acl) myasthenia_2\NN|is|rarely
D012254_D019698 NONE ribavirin_8\JJ|and (r_conj) interferon_6\NN|for|pegylated (r_nmod) treatment_9\NN|NONE (l_prep) for_10\IN|interferon|pegylated (l_pobj) C._13\NNP|NONE
D012254_D019698 NONE ribavirin_21\RB|and (r_conj) alpha-2b_19\CD|(|) (r_conj) IFN_17\NNP|pegylated (r_appos) interferon_15\NN|NONE (r_pobj) of_13\IN|NONE (r_prep) administration_12\NN|NONE (r_pobj) of_11\IN| (r_prep) weeks_10\NNS|NONE (r_pobj) after_8\IN|experienced|.|for|sudden|old|A (r_prep) diplopia_7\NN|NONE (l_prep) for_22\IN|experienced|.|sudden|after|old|A (l_pobj) C_25\NNP|NONE
D012254_D019698 NONE ribavirin_21\RB|and (r_conj) alpha-2b_19\CD|(|) (r_conj) IFN_17\NNP|pegylated (r_appos) interferon_15\NN|NONE (r_pobj) of_13\IN|NONE (r_prep) administration_12\NN|NONE (r_pobj) of_11\IN| (r_prep) weeks_10\NNS|NONE (r_pobj) after_8\IN|experienced|.|for|sudden|old|A (r_prep) diplopia_7\NN|NONE (l_prep) for_22\IN|experienced|.|sudden|after|old|A (l_pobj) C_25\NNP|NONE (l_appos) CHC_27\NNP|hepatitis|(|chronic|)
D012254_D019698 NONE ribavirin_12\RB|pegylated|IFN|for|and (r_conj) alpha-2b_10\CD|NONE (l_prep) for_13\IN|pegylated|ribavirin|IFN|and (l_pobj) CHC_14\NNP|NONE
C417083_D004172 NONE alpha-2b_19\CD|(|) (r_conj) IFN_17\NNP|pegylated (r_appos) interferon_15\NN|NONE (r_pobj) of_13\IN|NONE (r_prep) administration_12\NN|NONE (r_pobj) of_11\IN| (r_prep) weeks_10\NNS|NONE (r_pobj) after_8\IN|experienced|.|for|sudden|old|A (r_prep) diplopia_7\NN|NONE
C417083_D019698 NONE interferon_6\NN|for|pegylated (r_nmod) treatment_9\NN|NONE (l_prep) for_10\IN|interferon|pegylated (l_pobj) C._13\NNP|NONE
C417083_D019698 NONE alpha-2b_19\CD|(|) (r_conj) IFN_17\NNP|pegylated (r_appos) interferon_15\NN|NONE (r_pobj) of_13\IN|NONE (r_prep) administration_12\NN|NONE (r_pobj) of_11\IN| (r_prep) weeks_10\NNS|NONE (r_pobj) after_8\IN|experienced|.|for|sudden|old|A (r_prep) diplopia_7\NN|NONE (l_prep) for_22\IN|experienced|.|sudden|after|old|A (l_pobj) C_25\NNP|NONE
C417083_D019698 NONE alpha-2b_19\CD|(|) (r_conj) IFN_17\NNP|pegylated (r_appos) interferon_15\NN|NONE (r_pobj) of_13\IN|NONE (r_prep) administration_12\NN|NONE (r_pobj) of_11\IN| (r_prep) weeks_10\NNS|NONE (r_pobj) after_8\IN|experienced|.|for|sudden|old|A (r_prep) diplopia_7\NN|NONE (l_prep) for_22\IN|experienced|.|sudden|after|old|A (l_pobj) C_25\NNP|NONE (l_appos) CHC_27\NNP|hepatitis|(|chronic|)
C417083_D019698 NONE alpha-2b_10\CD|NONE (l_prep) for_13\IN|pegylated|ribavirin|IFN|and (l_pobj) CHC_14\NNP|NONE
C417083_D019698 NONE IFN_35\NNP|NONE (r_compound) therapy_36\NN|NONE (r_pobj) of_34\IN|the|eye|various (r_prep) complications_33\NNS|NONE (r_pobj) of_29\IN|a (r_prep) review_28\NN|NONE (r_pobj) with_26\IN|we|case|therefore|;|.|reported|, (r_prep) present_23\VBP|NONE (l_ccomp) reported_18\VBN|with|we|case|therefore|;|.|, (l_nsubjpass) myasthenia_2\NN|is|rarely (l_acl) associated_3\VBN|ocular|The (l_prep) with_4\IN|NONE (l_pobj) therapy_6\NN|NONE (l_prep) of_7\IN|combination (l_pobj) alpha-2b_10\CD|NONE (l_prep) for_13\IN|pegylated|ribavirin|IFN|and (l_pobj) CHC_14\NNP|NONE
8251368
D009543_D013684 CID nifedipine_1\RB| (r_advmod) induced_3\VBN|facial (r_amod) telangiectasia_5\NN|.
D009543_D013684 CID nifedipine_4\NN|Adalat (r_dobj) starting_3\VBG|months (r_pcomp) after_2\IN|,|telangiectasia|patients|. (r_prep) developed_11\VBD|NONE (l_dobj) telangiectasia_14\NN|,|patients|.|after
D009543_D013684 CID Adalat_6\NNP|nifedipine (r_oprd) starting_3\VBG|months (r_pcomp) after_2\IN|,|telangiectasia|patients|. (r_prep) developed_11\VBD|NONE (l_dobj) telangiectasia_14\NN|,|patients|.|after
D017311_D013684 CID amlodipine_6\NN|One|.|later|with|, (r_dobj) commenced_1\VBD|NONE (l_prep) with_11\IN|One|.|later|amlodipine|, (l_pobj) recurrence_12\NN|NONE (l_prep) of_13\IN|NONE (l_pobj) telangiectasia_14\NN|NONE
12571256
D003404_D003920 NONE creatinine_9\JJ|of|underwent|serum (r_compound) concentrations_10\NNS|NONE (r_pobj) with_7\IN|NONE (r_prep) diabetes_6\NNS|NONE
C044834_D007674 NONE iodixanol_29\NN|,|dimeric|an|,|,|contrast|osmolar|nonionic|, (r_appos) medium_27\NN|NONE (r_pobj) of_17\IN|with|nephrotoxic|the (r_prep) effects_16\NNS|NONE (l_amod) nephrotoxic_15\JJ|of|with|the
C044834_D007674 NONE iodixanol_17\NN|than|is|when (r_nsubjpass) used_19\VBN|to|in (r_advcl) develop_10\VB|less (r_xcomp) likely_8\JJ|may|induced|. (r_acomp) be_6\VB|NONE (l_csubj) induced_1\VBN|may|.|likely (l_nsubj) Nephropathy_0\NNP|by
D007472_D007674 CID iohexol_45\NN|nonionic (r_pobj) of_33\IN|NONE (r_prep) those_32\DT|NONE (r_pobj) with_31\IN|of|nephrotoxic|the (r_prep) effects_16\NNS|NONE (l_amod) nephrotoxic_15\JJ|of|with|the
8888541
D014191_D003866 NONE tranylcypromine_22\NN|who|was (l_prep) for_23\IN|NONE (l_pobj) depression_24\NN|NONE
D012701_D003221 NONE serotonin_3\NN|HTA (r_nmod) receptors_5\NNS|NONE (r_pobj) of_2\IN|Excessive (r_prep) stimulation_1\NN|syndrome|. (r_nsubj) causes_6\VBZ|NONE (l_dobj) syndrome_8\NN|stimulation|. (l_prep) of_9\IN|a (l_pobj) excess_11\NN|NONE (l_relcl) consists_13\VBZ|serotonin (l_prep) of_14\IN|that (l_pcomp) shivering_15\VBG|NONE (l_conj) rigidity_18\NN|, (l_conj) salivation_20\NN|,|muscle (l_conj) confusion_22\NN|,
D012701_D003221 NONE serotonin_10\NN|consists (r_compound) excess_11\NN|NONE (l_relcl) consists_13\VBZ|serotonin (l_prep) of_14\IN|that (l_pcomp) shivering_15\VBG|NONE (l_conj) rigidity_18\NN|, (l_conj) salivation_20\NN|,|muscle (l_conj) confusion_22\NN|,
D003975_D009127 NONE diazepam_4\NN|NONE (r_pobj) of_3\IN|i.v.| (r_prep) mg_2\NN|NONE (r_pobj) After_0\IN|.|he|tremulous (r_prep) remained_7\VBD|NONE (l_acomp) tremulous_8\JJ|.|he|After (l_prep) with_9\IN|NONE (l_pobj) rigidity_11\NN|NONE
D012701_D011595 NONE serotonin_3\NN|HTA (r_nmod) receptors_5\NNS|NONE (r_pobj) of_2\IN|Excessive (r_prep) stimulation_1\NN|syndrome|. (r_nsubj) causes_6\VBZ|NONE (l_dobj) syndrome_8\NN|stimulation|. (l_prep) of_9\IN|a (l_pobj) excess_11\NN|NONE (l_relcl) consists_13\VBZ|serotonin (l_prep) of_14\IN|that (l_pcomp) shivering_15\VBG|NONE (l_conj) rigidity_18\NN|, (l_conj) salivation_20\NN|,|muscle (l_conj) confusion_22\NN|, (l_conj) agitation_24\NN|,
D012701_D011595 NONE serotonin_10\NN|consists (r_compound) excess_11\NN|NONE (l_relcl) consists_13\VBZ|serotonin (l_prep) of_14\IN|that (l_pcomp) shivering_15\VBG|NONE (l_conj) rigidity_18\NN|, (l_conj) salivation_20\NN|,|muscle (l_conj) confusion_22\NN|, (l_conj) agitation_24\NN|,
D012701_D005334 NONE serotonin_3\NN|HTA (r_nmod) receptors_5\NNS|NONE (r_pobj) of_2\IN|Excessive (r_prep) stimulation_1\NN|syndrome|. (r_nsubj) causes_6\VBZ|NONE (l_dobj) syndrome_8\NN|stimulation|. (l_prep) of_9\IN|a (l_pobj) excess_11\NN|NONE (l_relcl) consists_13\VBZ|serotonin (l_prep) of_14\IN|that (l_pcomp) shivering_15\VBG|NONE (l_conj) rigidity_18\NN|, (l_conj) salivation_20\NN|,|muscle (l_conj) confusion_22\NN|, (l_conj) agitation_24\NN|, (l_conj) hyperthermia_26\NN|and
D012701_D005334 NONE serotonin_10\NN|consists (r_compound) excess_11\NN|NONE (l_relcl) consists_13\VBZ|serotonin (l_prep) of_14\IN|that (l_pcomp) shivering_15\VBG|NONE (l_conj) rigidity_18\NN|, (l_conj) salivation_20\NN|,|muscle (l_conj) confusion_22\NN|, (l_conj) agitation_24\NN|, (l_conj) hyperthermia_26\NN|and
D012701_D009127 NONE serotonin_3\NN|HTA (r_nmod) receptors_5\NNS|NONE (r_pobj) of_2\IN|Excessive (r_prep) stimulation_1\NN|syndrome|. (r_nsubj) causes_6\VBZ|NONE (l_dobj) syndrome_8\NN|stimulation|. (l_prep) of_9\IN|a (l_pobj) excess_11\NN|NONE (l_relcl) consists_13\VBZ|serotonin (l_prep) of_14\IN|that (l_pcomp) shivering_15\VBG|NONE (l_conj) rigidity_18\NN|,
D012701_D009127 NONE serotonin_10\NN|consists (r_compound) excess_11\NN|NONE (l_relcl) consists_13\VBZ|serotonin (l_prep) of_14\IN|that (l_pcomp) shivering_15\VBG|NONE (l_conj) rigidity_18\NN|,
C047426_D003866 NONE venlafaxine_3\NNP| (r_compound) MAOI_5\NNP|a|resulted (r_compound) interaction_6\NN|We|. (l_relcl) resulted_8\VBD|MAOI|a (l_prep) in_13\IN|that|in (l_pobj) male_18\NN|NONE (l_relcl) taking_21\VBG|old|a (l_dobj) tranylcypromine_22\NN|who|was (l_prep) for_23\IN|NONE (l_pobj) depression_24\NN|NONE
D012701_D012798 NONE serotonin_3\NN|HTA (r_nmod) receptors_5\NNS|NONE (r_pobj) of_2\IN|Excessive (r_prep) stimulation_1\NN|syndrome|. (r_nsubj) causes_6\VBZ|NONE (l_dobj) syndrome_8\NN|stimulation|. (l_prep) of_9\IN|a (l_pobj) excess_11\NN|NONE (l_relcl) consists_13\VBZ|serotonin (l_prep) of_14\IN|that (l_pcomp) shivering_15\VBG|NONE (l_conj) rigidity_18\NN|, (l_conj) salivation_20\NN|,|muscle
D012701_D012798 NONE serotonin_10\NN|consists (r_compound) excess_11\NN|NONE (l_relcl) consists_13\VBZ|serotonin (l_prep) of_14\IN|that (l_pcomp) shivering_15\VBG|NONE (l_conj) rigidity_18\NN|, (l_conj) salivation_20\NN|,|muscle
C047426_D020230 CID venlafaxine_3\NNP| (r_compound) tranylcypromine_5\NN|NONE (r_compound) interaction_6\NN|NONE (r_pobj) from_2\IN|.|Serotonin (r_prep) syndrome_1\NN|NONE
C047426_D020230 CID venlafaxine_3\NNP| (r_compound) MAOI_5\NNP|a|resulted (r_compound) interaction_6\NN|We|. (l_relcl) resulted_8\VBD|MAOI|a (l_prep) in_9\IN|that|in (l_pobj) syndrome_12\NN|NONE
D014191_D020230 CID tranylcypromine_5\NN|NONE (r_compound) interaction_6\NN|NONE (r_pobj) from_2\IN|.|Serotonin (r_prep) syndrome_1\NN|NONE
D014191_D020230 CID tranylcypromine_22\NN|who|was (r_dobj) taking_21\VBG|old|a (r_relcl) male_18\NN|NONE (r_pobj) in_13\IN|that|in (r_prep) resulted_8\VBD|MAOI|a (l_prep) in_9\IN|that|in (l_pobj) syndrome_12\NN|NONE
1610717
D003042_D012640 CID Cocaine_0\NN| (r_npadvmod) induced_2\VBN|brainstem|.|behavior|and (r_amod) seizures_4\NNS|NONE
15811908
C037689_D010673 NONE benzamide_14\JJ|substituted (r_amod) drugs_15\NNS|NONE (r_pobj) of_12\IN|the (r_prep) use_11\NN|NONE (r_pobj) with_9\IN|but|,|is|are|often|symptoms (r_prep) associated_8\VBN|NONE (l_nsubjpass) symptoms_3\NNS|but|,|is|are|with|often (l_prep) of_4\IN|induced (l_pobj) pheochromocytoma_5\NN|NONE
C012052_D010673 NONE amisulpride_3\NN|NONE (r_pobj) by_2\IN|Pheochromocytoma|. (r_prep) unmasked_1\VBD|NONE (l_nsubj) Pheochromocytoma_0\NNP|.|by
C012052_D010673 NONE amisulpride_11\NN|NONE (r_pobj) with_10\IN|NONE (r_prep) treated_9\VBN|a (r_acl) patient_8\NN|NONE (r_pobj) in_6\IN|of|the (r_prep) unmasking_3\NN|.|To (l_prep) of_4\IN|in|the (l_pobj) pheochromocytoma_5\NN|NONE
C012052_D010673 NONE amisulpride-_14\JJ|NONE (r_pobj) of_13\IN|the|reported|first|in (r_prep) case_12\NN|.|this|,|As (l_prep) in_21\IN|the|reported|first|of (l_pobj) patient_23\NN|NONE (l_prep) with_24\IN|a (l_pobj) pheochromocytoma_25\NN|NONE
C012052_D006973 CID amisulpride_21\NN|NONE (r_pobj) of_20\IN|the|first (r_prep) doses_19\NNS|hours (r_pobj) after_16\IN|NONE (r_prep) vomiting_13\NN|and|man|hypertension (r_conj) developed_6\VBD|NONE (l_dobj) hypertension_8\NN|and|man|vomiting
C012052_D006973 CID amisulpride_19\NN|and|the|hypertensive (r_conj) crisis_17\NN|NONE (l_amod) hypertensive_16\JJ|amisulpride|and|the
C012052_D006973 CID amisulpride-_14\JJ|NONE (l_conj) crisis_20\NN|and (l_amod) hypertensive_19\JJ|induced
D063325_D010673 NONE tiapride_5\NN|and (r_conj) amisulpride_3\NN|NONE (r_pobj) by_2\IN|Pheochromocytoma|. (r_prep) unmasked_1\VBD|NONE (l_nsubj) Pheochromocytoma_0\NNP|.|by
D063325_D010673 NONE tiapride_13\NN|and (r_conj) amisulpride_11\NN|NONE (r_pobj) with_10\IN|NONE (r_prep) treated_9\VBN|a (r_acl) patient_8\NN|NONE (r_pobj) in_6\IN|of|the (r_prep) unmasking_3\NN|.|To (l_prep) of_4\IN|in|the (l_pobj) pheochromocytoma_5\NN|NONE
D063325_D010673 NONE tiapride_16\NN| (r_npadvmod) induced_18\VBN|hypertensive (r_amod) crisis_20\NN|and (r_conj) amisulpride-_14\JJ|NONE (r_pobj) of_13\IN|the|reported|first|in (r_prep) case_12\NN|.|this|,|As (l_prep) in_21\IN|the|reported|first|of (l_pobj) patient_23\NN|NONE (l_prep) with_24\IN|a (l_pobj) pheochromocytoma_25\NN|NONE
C012052_D006261 CID amisulpride_21\NN|NONE (r_pobj) of_20\IN|the|first (r_prep) doses_19\NNS|hours (r_pobj) after_16\IN|NONE (r_prep) vomiting_13\NN|and|man|hypertension (r_conj) developed_6\VBD|NONE (l_dobj) hypertension_8\NN|and|man|vomiting (l_prep) with_9\IN|acute (l_pobj) headache_11\NN|NONE
C012052_D014839 CID amisulpride_21\NN|NONE (r_pobj) of_20\IN|the|first (r_prep) doses_19\NNS|hours (r_pobj) after_16\IN|NONE (r_prep) vomiting_13\NN|and|man|hypertension
D063325_D006973 CID tiapride_21\NN|NONE (r_compound) therapy_22\NN|and (r_conj) amisulpride_19\NN|and|the|hypertensive (r_conj) crisis_17\NN|NONE (l_amod) hypertensive_16\JJ|amisulpride|and|the
D063325_D006973 CID tiapride_16\NN| (r_npadvmod) induced_18\VBN|hypertensive (r_amod) crisis_20\NN|and (l_amod) hypertensive_19\JJ|induced
3088349
D000661_-1 NONE amphetamine_17\NN|NONE (r_pobj) by_16\IN|NONE (r_prep) exhaustion_15\NN|NONE (r_pobj) to_14\TO|rotation|susceptibility|. (r_prep) reflects_8\VBZ|NONE (l_nsubj) rotation_2\NN|to|susceptibility|. (l_prep) following_3\VBG|contralateral|Transient (l_pobj) lesion_7\NN|NONE
D016627_-1 NONE 6-OHDA_2\CD|NONE (r_pobj) Following_0\VBG|lesion (r_prep) induced_3\VBN|been|.|has|period|precede (l_dobj) lesion_5\NN|Following
D000661_D009069 CID amphetamine_17\NN|NONE (r_pobj) by_16\IN|NONE (r_prep) exhaustion_15\NN|NONE (r_pobj) to_14\TO|rotation|susceptibility|. (r_prep) reflects_8\VBZ|NONE (l_nsubj) rotation_2\NN|to|susceptibility|.
D000661_D009069 CID amphetamine_26\NN| (r_npadvmod) induced_28\VBN|rotational (r_amod) behavior_30\NN|NONE (r_pobj) on_25\IN|effect|In|we|,|. (r_prep) examined_12\VBD|NONE (l_prep) In_0\IN|effect|we|,|.|on (l_pobj) order_1\NN|NONE (l_acl) clarify_3\VB|NONE (l_dobj) nature_5\NN|to (l_prep) of_6\IN|the (l_pobj) rotation_10\NN|NONE
D000661_D009069 CID amphetamine_26\NN| (r_npadvmod) induced_28\VBN|rotational (r_amod) behavior_30\NN|NONE
D000661_D009069 CID amphetamine_10\NN|when|was|for (r_nsubjpass) administered_12\VBN|evident|indicating|,|still|degree|. (r_advcl) was_6\VBD|NONE (l_advcl) indicating_22\VBG|evident|administered|,|still|degree|. (l_dobj) involvement_23\NN|NONE (l_prep) of_24\IN|NONE (l_pobj) cells_26\NNS|NONE (l_prep) in_27\IN|spared (l_pobj) rotation_30\NN|NONE
D000661_D009069 CID amphetamine_16\NN|or|exercise|, (r_compound) dose_17\NN|lesion|,|either (r_conj) volume_14\NN|NONE (r_pobj) of_11\IN|NONE (r_prep) irrespective_10\RB|of|and|the|( (r_conj) duration_5\NN|NONE (r_pobj) of_3\IN|NONE (r_prep) regardless_2\RB|However|circled|become|,|,|rotation|,|and (r_advmod) tended_31\VBD|NONE (l_nsubj) rotation_30\NN|regardless|However|circled|become|,|,|,|and
D000661_D009069 CID amphetamine_27\NN| (r_npadvmod) induced_29\VBN|NONE (r_amod) rotation_30\NN|regardless|However|circled|become|,|,|,|and
D000661_D009069 CID amphetamine_55\NN|further (r_compound) injections_56\NNS|NONE (r_pobj) to_53\IN|NONE (r_prep) response_52\NN|NONE (r_pobj) in_51\IN|rats|ipsilaterally|.|to (r_prep) circled_46\VBD|regardless|However|become|,|,|rotation|,|and (r_conj) tended_31\VBD|NONE (l_nsubj) rotation_30\NN|regardless|However|circled|become|,|,|,|and
D000661_D009069 CID amphetamine_4\NN|effect|that (r_nsubj) has_5\VBZ|.|findings (l_dobj) effect_8\NN|amphetamine|that (l_prep) on_9\IN|an|irreversible (l_pobj) pool_15\NN|NONE (l_acl) contributing_16\VBG|lesion|DA|the (l_prep) to_17\IN|NONE (l_pobj) rotation_19\NN|NONE
D016627_D009069 NONE 6-OHDA_2\CD|NONE (r_pobj) Following_0\VBG|lesion (r_prep) induced_3\VBN|been|.|has|period|precede (r_ccomp) reported_15\VBN|NONE (l_nsubjpass) period_9\NN|been|induced|.|has|precede (l_prep) of_10\IN|transient|a (l_pobj) rotation_12\NN|NONE
D016627_D009069 NONE 6-OHDA_2\CD|NONE (r_pobj) Following_0\VBG|lesion (r_prep) induced_3\VBN|been|.|has|period|precede (r_ccomp) reported_15\VBN|NONE (l_xcomp) precede_17\VB|been|induced|.|has|period (l_dobj) circling_21\NN|to
10524660
D009569_D010146 NONE oxide_13\NN|in|is|that (r_nsubjpass) involved_18\VBN|In|.|has|evidence|, (l_prep) in_19\IN|is|that|oxide (l_pobj) mechanisms_21\NNS|NONE (l_compound) pain_20\NN|without|of
D009569_D010146 NONE NO_15\NNP|(|nitric|the|molecule|) (r_appos) oxide_13\NN|in|is|that (r_nsubjpass) involved_18\VBN|In|.|has|evidence|, (l_prep) in_19\IN|is|that|oxide (l_pobj) mechanisms_21\NNS|NONE (l_compound) pain_20\NN|without|of
D009569_D010146 NONE NO_5\DT|in|is|that (r_nsubjpass) involved_7\VBN|.|results|therefore (l_prep) in_8\IN|NO|is|that (l_pobj) mechanisms_11\NNS|NONE (l_compound) pain_10\NN|with|of|the
D005996_D006261 NONE trinitrate_28\NN|NONE (r_pobj) of_26\IN|intravenous (r_prep) infusion_25\NN|NONE (r_pobj) to_23\IN|the|headache (r_prep) response_22\NN|.|in|we|In|,|min (l_compound) headache_21\NN|the|to
D005996_D006261 NONE GTN_30\NNP|)|(|glyceryl (r_appos) trinitrate_28\NN|NONE (r_pobj) of_26\IN|intravenous (r_prep) infusion_25\NN|NONE (r_pobj) to_23\IN|the|headache (r_prep) response_22\NN|.|in|we|In|,|min (l_compound) headache_21\NN|the|to
D005996_D006261 NONE GTN_14\NNP|after|during|as|p=. (r_compound) infusion_15\NN|.|severe|Headache (r_advcl) was_1\VBD|NONE (l_nsubj) Headache_0\NNP|.|severe|infusion
D005996_D006261 NONE GTN_5\NNP| (r_npadvmod) induced_7\VBN|the (r_amod) headache_8\NN|In|.|peak|,|gradually|,
D005996_D006261 NONE GTN_5\NNP| (r_npadvmod) induced_7\VBN|the (r_amod) headache_8\NN|In|.|peak|,|gradually|, (r_nsubj) disappeared_10\VBD|NONE (l_advcl) peak_15\JJ|In|.|headache|,|gradually|, (l_ccomp) occurred_18\VBD|in|whereas (l_nsubj) intensity_17\NN|at (l_compound) headache_16\NN|NONE
D009569_D006261 NONE NO_9\DT|in|to (r_intj) liberate_8\VB|depression|been|has|Since (r_xcomp) shown_6\VBN|.|understanding|may|,|finding (r_advcl) help_16\VB|NONE (l_dobj) understanding_18\NN|.|may|shown|,|finding (l_prep) of_19\IN|our (l_pobj) coupling_21\NN|NONE (l_prep) between_22\IN|the (l_pobj) depression_25\NN|NONE (l_conj) headache_27\NN|cortical|and|spreading
D009569_D020326 CID oxide_13\NN|in|is|that (r_nsubjpass) involved_18\VBN|In|.|has|evidence|, (l_prep) in_19\IN|is|that|oxide (l_pobj) mechanisms_21\NNS|NONE (l_prep) without_24\IN|pain|of (l_pobj) aura_25\NN|NONE
D009569_D020326 CID NO_15\NNP|(|nitric|the|molecule|) (r_appos) oxide_13\NN|in|is|that (r_nsubjpass) involved_18\VBN|In|.|has|evidence|, (l_prep) in_19\IN|is|that|oxide (l_pobj) mechanisms_21\NNS|NONE (l_prep) without_24\IN|pain|of (l_pobj) aura_25\NN|NONE
D005996_D020325 NONE trinitrate_1\NN|.|attacks (r_nsubj) induces_2\VBZ|NONE (l_dobj) attacks_3\NNS|trinitrate|. (l_prep) without_6\IN|of (l_pobj) aura_7\NN|NONE (l_prep) in_8\IN|NONE (l_pobj) sufferers_9\NNS|NONE (l_prep) with_12\IN|of (l_pobj) aura_13\NN|NONE
D005996_D020325 NONE trinitrate_28\NN|NONE (r_pobj) of_26\IN|intravenous (r_prep) infusion_25\NN|NONE (r_pobj) to_23\IN|the|headache (r_prep) response_22\NN|.|in|we|In|,|min (r_dobj) examined_19\VBD|NONE (l_prep) In_0\IN|.|in|we|,|min|response (l_pobj) order_1\NN|NONE (l_acl) clarify_3\VB|NONE (l_ccomp) is_7\VBZ|to (l_acomp) true_8\JJ|whether|same (l_prep) for_9\IN|NONE (l_pobj) migraine_10\NN|NONE (l_prep) with_11\IN|NONE (l_pobj) aura_12\NN|NONE
D005996_D020325 NONE trinitrate_28\NN|NONE (r_pobj) of_26\IN|intravenous (r_prep) infusion_25\NN|NONE (r_pobj) to_23\IN|the|headache (r_prep) response_22\NN|.|in|we|In|,|min (r_dobj) examined_19\VBD|NONE (l_parataxis) min_38\NN|.|in|we|In|,|response (l_prep) in_43\IN|)|/|(|microg|for|. (l_pobj) sufferers_45\NNS|NONE (l_prep) with_48\IN|of| (l_pobj) aura_49\NN|NONE
D005996_D020325 NONE GTN_30\NNP|)|(|glyceryl (r_appos) trinitrate_28\NN|NONE (r_pobj) of_26\IN|intravenous (r_prep) infusion_25\NN|NONE (r_pobj) to_23\IN|the|headache (r_prep) response_22\NN|.|in|we|In|,|min (r_dobj) examined_19\VBD|NONE (l_prep) In_0\IN|.|in|we|,|min|response (l_pobj) order_1\NN|NONE (l_acl) clarify_3\VB|NONE (l_ccomp) is_7\VBZ|to (l_acomp) true_8\JJ|whether|same (l_prep) for_9\IN|NONE (l_pobj) migraine_10\NN|NONE (l_prep) with_11\IN|NONE (l_pobj) aura_12\NN|NONE
D005996_D020325 NONE GTN_30\NNP|)|(|glyceryl (r_appos) trinitrate_28\NN|NONE (r_pobj) of_26\IN|intravenous (r_prep) infusion_25\NN|NONE (r_pobj) to_23\IN|the|headache (r_prep) response_22\NN|.|in|we|In|,|min (r_dobj) examined_19\VBD|NONE (l_parataxis) min_38\NN|.|in|we|In|,|response (l_prep) in_43\IN|)|/|(|microg|for|. (l_pobj) sufferers_45\NNS|NONE (l_prep) with_48\IN|of| (l_pobj) aura_49\NN|NONE
D009569_D003866 NONE NO_9\DT|in|to (r_intj) liberate_8\VB|depression|been|has|Since (r_xcomp) shown_6\VBN|.|understanding|may|,|finding (l_nsubjpass) depression_3\NN|been|has|liberate|Since
D009569_D003866 NONE NO_9\DT|in|to (r_intj) liberate_8\VB|depression|been|has|Since (r_xcomp) shown_6\VBN|.|understanding|may|,|finding (r_advcl) help_16\VB|NONE (l_dobj) understanding_18\NN|.|may|shown|,|finding (l_prep) of_19\IN|our (l_pobj) coupling_21\NN|NONE (l_prep) between_22\IN|the (l_pobj) depression_25\NN|NONE
D005996_D008881 NONE GTN_14\NNP|after|during|as|p=. (r_compound) infusion_15\NN|.|severe|Headache (r_advcl) was_1\VBD|NONE (l_acomp) severe_3\JJ|.|Headache|infusion (l_prep) in_4\IN|than|more (l_pobj) migraineurs_5\NNS|NONE
D005996_D008881 NONE GTN_5\NNP| (r_npadvmod) induced_7\VBN|the (r_amod) headache_8\NN|In|.|peak|,|gradually|, (r_nsubj) disappeared_10\VBD|NONE (l_advcl) peak_15\JJ|In|.|headache|,|gradually|, (l_prep) in_13\IN|whereas|occurred (l_pobj) migraineurs_14\NNS|NONE
D009569_D020325 NONE NO_5\DT|in|is|that (r_nsubjpass) involved_7\VBN|.|results|therefore (l_prep) in_8\IN|NO|is|that (l_pobj) mechanisms_11\NNS|NONE (l_prep) with_14\IN|pain|of|the (l_pobj) aura_15\NN|NONE
D009569_D020325 NONE NO_9\DT|in|to (r_intj) liberate_8\VB|depression|been|has|Since (r_xcomp) shown_6\VBN|.|understanding|may|,|finding (r_advcl) help_16\VB|NONE (l_dobj) understanding_18\NN|.|may|shown|,|finding (l_prep) of_19\IN|our (l_pobj) coupling_21\NN|NONE (l_prep) between_22\IN|the (l_pobj) depression_25\NN|NONE (l_conj) headache_27\NN|cortical|and|spreading (l_prep) with_30\IN|in (l_pobj) aura_31\NN|NONE
D005996_D020326 CID trinitrate_1\NN|.|attacks (r_nsubj) induces_2\VBZ|NONE (l_dobj) attacks_3\NNS|trinitrate|. (l_prep) without_6\IN|of (l_pobj) aura_7\NN|NONE
11063349
D016572_D064420 NONE cyclosporine_16\NN|NONE (l_appos) CsA_18\NNP|NONE (l_conj) toxicity_25\NN|or|(|)
D016572_D064420 NONE CsA_18\NNP|NONE (l_conj) toxicity_25\NN|or|(|)
D016572_D064420 NONE CsA_6\NNP|.|indications (l_conj) nephrotoxicity_9\NN|hepatotoxicity|or|,|in|and|chronic (l_conj) CsA_15\NNP|,|,||disorder|Tac (l_conj) toxicity_18\NN|or||acute|dysmorphism|,
D016572_D064420 NONE CsA_15\NNP|,|,||disorder|Tac (l_conj) toxicity_18\NN|or||acute|dysmorphism|,
D016559_D064420 NONE tacrolimus_21\NN|Tac|(|) (r_nmod) toxicity_25\NN|or|(|)
D016559_D064420 NONE Tac_23\NN|tacrolimus|(|) (r_nmod) toxicity_25\NN|or|(|)
D016559_D064420 NONE Tac_8\NNP|CsA|,|,||disorder (r_compound) nephrotoxicity_9\NN|hepatotoxicity|or|,|in|and|chronic (l_conj) CsA_15\NNP|,|,||disorder|Tac (l_conj) toxicity_18\NN|or||acute|dysmorphism|,
D016559_D064420 NONE Tac_17\NNP|NONE (r_compound) toxicity_18\NN|or||acute|dysmorphism|,
D020123_D011014 NONE RAPA_0\NNP|PTLD|was|,|because|in|. (r_nsubjpass) discontinued_2\VBN|NONE (l_prep) because_7\IN|RAPA|PTLD|was|,|in|. (l_pobj) pneumonia_9\NN|of
D016559_D008232 NONE Tac_8\NNP|CsA|,|,||disorder (r_compound) nephrotoxicity_9\NN|hepatotoxicity|or|,|in|and|chronic (l_conj) disorder_32\NN|CsA|,|,||Tac
D016559_D008232 NONE Tac_8\NNP|CsA|,|,||disorder (r_compound) nephrotoxicity_9\NN|hepatotoxicity|or|,|in|and|chronic (l_conj) disorder_32\NN|CsA|,|,||Tac (l_appos) PTLD_34\NN|posttransplant|lymphoproliferative|(|)
D016559_D008232 NONE Tac_17\NNP|NONE (r_compound) toxicity_18\NN|or||acute|dysmorphism|, (r_conj) CsA_15\NNP|,|,||disorder|Tac (r_conj) nephrotoxicity_9\NN|hepatotoxicity|or|,|in|and|chronic (l_conj) disorder_32\NN|CsA|,|,||Tac
D016559_D008232 NONE Tac_17\NNP|NONE (r_compound) toxicity_18\NN|or||acute|dysmorphism|, (r_conj) CsA_15\NNP|,|,||disorder|Tac (r_conj) nephrotoxicity_9\NN|hepatotoxicity|or|,|in|and|chronic (l_conj) disorder_32\NN|CsA|,|,||Tac (l_appos) PTLD_34\NN|posttransplant|lymphoproliferative|(|)
D003404_D007674 NONE creatinine_17\NN|NONE (r_pobj) in_15\IN|to|at|+/|a|significant (r_prep) decrease_14\NN|:|there|]|.|In (r_attr) was_11\VBD|NONE (l_prep) In_1\IN|:|there|]|decrease|. (l_pobj) patients_4\NNS|NONE (l_acl) switched_5\VBD||the (l_prep) because_6\IN|NONE (l_pobj) nephrotoxicity_9\NN|of
D016572_D056486 NONE CsA_6\NNP|.|indications (l_conj) hepatotoxicity_43\NN|or|,|nephrotoxicity|in|and|chronic
D016572_D056486 NONE CsA_15\NNP|,|,||disorder|Tac (r_conj) nephrotoxicity_9\NN|hepatotoxicity|or|,|in|and|chronic (r_conj) CsA_6\NNP|.|indications (l_conj) hepatotoxicity_43\NN|or|,|nephrotoxicity|in|and|chronic
D016559_-1 NONE Tac_8\NNP|CsA|,|,||disorder (r_compound) nephrotoxicity_9\NN|hepatotoxicity|or|,|in|and|chronic (l_conj) CsA_15\NNP|,|,||disorder|Tac (l_conj) dysmorphism_25\NN|or||toxicity|acute|,
D016559_-1 NONE Tac_17\NNP|NONE (r_compound) toxicity_18\NN|or||acute|dysmorphism|, (r_conj) CsA_15\NNP|,|,||disorder|Tac (l_conj) dysmorphism_25\NN|or||toxicity|acute|,
D016572_D007674 CID CsA_6\NNP|.|indications (l_conj) nephrotoxicity_9\NN|hepatotoxicity|or|,|in|and|chronic
D016572_D007674 CID CsA_15\NNP|,|,||disorder|Tac (r_conj) nephrotoxicity_9\NN|hepatotoxicity|or|,|in|and|chronic
D016572_D008232 NONE CsA_6\NNP|.|indications (l_conj) nephrotoxicity_9\NN|hepatotoxicity|or|,|in|and|chronic (l_conj) disorder_32\NN|CsA|,|,||Tac
D016572_D008232 NONE CsA_6\NNP|.|indications (l_conj) nephrotoxicity_9\NN|hepatotoxicity|or|,|in|and|chronic (l_conj) disorder_32\NN|CsA|,|,||Tac (l_appos) PTLD_34\NN|posttransplant|lymphoproliferative|(|)
D016572_D008232 NONE CsA_15\NNP|,|,||disorder|Tac (r_conj) nephrotoxicity_9\NN|hepatotoxicity|or|,|in|and|chronic (l_conj) disorder_32\NN|CsA|,|,||Tac
D016572_D008232 NONE CsA_15\NNP|,|,||disorder|Tac (r_conj) nephrotoxicity_9\NN|hepatotoxicity|or|,|in|and|chronic (l_conj) disorder_32\NN|CsA|,|,||Tac (l_appos) PTLD_34\NN|posttransplant|lymphoproliferative|(|)
D020123_D013281 NONE RAPA_0\NNP|PTLD|was|,|because|in|. (r_nsubjpass) discontinued_2\VBN|NONE (l_appos) PTLD_13\NN|RAPA|was|,|because|in|. (l_conj) ulcers_20\NNS|and|,|,|in
D020123_D008232 NONE RAPA_0\NNP|PTLD|was|,|because|in|. (r_nsubjpass) discontinued_2\VBN|NONE (l_appos) PTLD_13\NN|RAPA|was|,|because|in|.
D016559_D007674 CID Tac_8\NNP|CsA|,|,||disorder (r_compound) nephrotoxicity_9\NN|hepatotoxicity|or|,|in|and|chronic
D016559_D007674 CID Tac_17\NNP|NONE (r_compound) toxicity_18\NN|or||acute|dysmorphism|, (r_conj) CsA_15\NNP|,|,||disorder|Tac (r_conj) nephrotoxicity_9\NN|hepatotoxicity|or|,|in|and|chronic
D020123_D011020 NONE RAPA_6\NNP|drug (r_compound) levels_8\NNS|NONE (r_pobj) to_5\IN|when|patients (r_prep) converting_3\VBG|over|should|However|be|avoid|, (r_csubjpass) monitored_11\VBN|be|prophylaxis|should|. (r_advcl) given_27\VBN|NONE (l_nsubjpass) prophylaxis_24\NN|be|monitored|should|. (l_compound) pneumonia_23\NN|NONE
D016572_-1 NONE CsA_6\NNP|.|indications (l_conj) nephrotoxicity_9\NN|hepatotoxicity|or|,|in|and|chronic (l_conj) CsA_15\NNP|,|,||disorder|Tac (l_conj) dysmorphism_25\NN|or||toxicity|acute|,
D016572_-1 NONE CsA_15\NNP|,|,||disorder|Tac (l_conj) dysmorphism_25\NN|or||toxicity|acute|,
D020123_D064420 NONE RAPA_11\NNP|in (r_compound) conversion_12\NN|NONE (l_prep) in_13\IN|RAPA (l_pobj) patients_14\NNS|NONE (l_acl) undergoing_15\VBG|NONE (l_dobj) cyclosporine_16\NN|NONE (l_appos) CsA_18\NNP|NONE (l_conj) toxicity_25\NN|or|(|)
D016559_D056486 NONE Tac_8\NNP|CsA|,|,||disorder (r_compound) nephrotoxicity_9\NN|hepatotoxicity|or|,|in|and|chronic (r_conj) CsA_6\NNP|.|indications (l_conj) hepatotoxicity_43\NN|or|,|nephrotoxicity|in|and|chronic
D016559_D056486 NONE Tac_17\NNP|NONE (r_compound) toxicity_18\NN|or||acute|dysmorphism|, (r_conj) CsA_15\NNP|,|,||disorder|Tac (r_conj) nephrotoxicity_9\NN|hepatotoxicity|or|,|in|and|chronic (r_conj) CsA_6\NNP|.|indications (l_conj) hepatotoxicity_43\NN|or|,|nephrotoxicity|in|and|chronic
3107448
D013453_D056486 NONE sulfonylureas_14\NNS|NONE (r_pobj) with_13\IN|hepatotoxicity|,|common|been|infrequently|.|has|, (r_prep) reported_10\VBN|NONE (l_nsubjpass) hepatotoxicity_3\NN|,|with|common|been|infrequently|.|has|,
D013453_D056486 NONE sulfonylurea_7\NN|reports|,|For|.|, (r_nsubj) exist_15\VBP|NONE (l_nsubj) reports_12\NNS|sulfonylurea|,|For|.|, (l_prep) of_13\IN|two|brief (l_pobj) hepatotoxicity_14\NN|NONE
D005905_D003924 NONE glyburide_18\NN|NONE (r_amod) therapy_19\NN|NONE (r_pobj) of_17\IN|NONE (r_prep) initiation_16\NN|soon (r_pobj) after_15\IN|patients|syndrome|. (r_prep) developed_7\VBD|NONE (l_nsubj) patients_1\NNS|after|syndrome|. (l_prep) with_2\IN|Two (l_pobj) mellitus_6\NN|NONE
D005905_D056486 CID Glyburide_0\NN| (r_npadvmod) induced_2\VBN|. (r_amod) hepatitis_3\NN|NONE
D005905_D056486 CID glyburide_1\NN|NONE (r_pobj) For_0\IN|reports|sulfonylurea|,|.|, (r_prep) exist_15\VBP|NONE (l_nsubj) reports_12\NNS|sulfonylurea|,|For|.|, (l_prep) of_13\IN|two|brief (l_pobj) hepatotoxicity_14\NN|NONE
D005905_D056486 CID glyburide_18\NN|NONE (r_amod) therapy_19\NN|NONE (r_pobj) of_17\IN|NONE (r_prep) initiation_16\NN|soon (r_pobj) after_15\IN|patients|syndrome|. (r_prep) developed_7\VBD|NONE (l_dobj) syndrome_13\NN|patients|after|.
D005905_D056486 CID Glyburide_0\NNP|can|illness|. (r_nsubj) produce_2\VB|NONE (l_dobj) illness_8\NN|can|Glyburide|.
2322844
D015232_D006930 CID E2_1\NNP|effect|,|but|lasted (r_nsubj) showed_2\VBD|NONE (l_dobj) effect_5\NN|,|but|E|lasted (l_amod) hyperalgesic_4\JJ|at|a
D015232_D006930 CID E2-induced_3\NNP|prostaglandin (r_amod) hyperalgesia_4\NN|Conversely|,|was|but|by|.|by
D015232_D006930 CID E2_9\NNP|prostaglandin|and|both (r_conj) D2_6\NN|that|in|,|hyperalgesia|but (r_nsubj) exert_10\VBP|results|. (l_dobj) hyperalgesia_11\NN|that|in|,|D|but
D015237_D010146 NONE alpha_2\NN|.|effect (r_nsubj) had_3\VBD|NONE (l_dobj) effect_5\NN|alpha|. (l_prep) on_6\IN|little (l_pobj) responses_8\NNS|NONE (l_compound) pain_7\NN|NONE
D019342_D010146 NONE acid_21\NN|and|hot (r_conj) plate_18\NN|writhing (r_dobj) using_16\VBG|NONE (r_pcomp) by_15\IN|.|were|effects (r_prep) evaluated_14\VBN|NONE (l_nsubjpass) effects_1\NNS|.|were|by (l_prep) on_7\IN|of|The (l_pobj) responses_9\NNS|NONE (l_compound) pain_8\NN|in
C053876_D006930 NONE AH6809_28\NN|not (r_pobj) by_27\IN|by|was|effect|but|. (r_agent) blocked_7\VBN|NONE (l_nsubjpass) effect_2\NN|by|was|but|.|by (l_amod) hyperalgesic_1\JJ|of|The
C053876_D006930 NONE AH6809_8\NN|NONE (r_pobj) by_7\IN|Conversely|,|was|hyperalgesia|but|by|. (r_agent) blocked_6\VBN|NONE (l_nsubjpass) hyperalgesia_4\NN|Conversely|,|was|but|by|.|by
D011453_D006930 NONE pg_10\NN|NONE (r_pobj) of_8\IN|to (r_prep) doses_7\NNS|NONE (r_pobj) at_6\IN|hyperalgesic|a (r_prep) effect_5\NN|,|but|E|lasted (l_amod) hyperalgesic_4\JJ|at|a
D015230_D006930 CID D2_1\NN|during|.|action (r_nsubj) had_10\VBD|NONE (l_dobj) action_13\NN|D|during|. (l_amod) hyperalgesic_12\JJ|a|on
D015230_D006930 CID D2_32\NN|NONE (r_pobj) of_30\IN|NONE (r_prep) that_29\DT|NONE (r_pobj) than_28\IN||shorter|(|) (r_prep) min_26\NN|effect|. (r_dobj) lasted_20\VBD|effect|,|but|E (r_conj) showed_2\VBD|NONE (l_dobj) effect_5\NN|,|but|E|lasted (l_amod) hyperalgesic_4\JJ|at|a
D015230_D006930 CID D2_5\NN|NONE (r_pobj) of_3\IN|hyperalgesic|The (r_prep) effect_2\NN|by|was|but|.|by (l_amod) hyperalgesic_1\JJ|of|The
D015230_D006930 CID D2_6\NN|that|in|,|hyperalgesia|but (r_nsubj) exert_10\VBP|results|. (l_dobj) hyperalgesia_11\NN|that|in|,|D|but
D011453_D010146 NONE prostaglandins_6\NNS|NONE (r_pobj) of_5\IN|intrathecal (r_prep) administration_4\NN|NONE (r_pobj) of_2\IN|on|The (r_prep) effects_1\NNS|.|were|by (l_prep) on_7\IN|of|The (l_pobj) responses_9\NNS|NONE (l_compound) pain_8\NN|in
11704023
D013999_D009798 NONE timolol_56\NN|(|gellan|morning|or|)|, (r_compound) solution_57\NN|over|,|in|)|to (r_conj) crossed_32\VBN|were|patients|.|and (r_conj) randomized_30\VBN|NONE (l_nsubjpass) patients_4\NNS|were|.|and|crossed (l_prep) with_5\IN|Caucasian|three (l_pobj) glaucoma_10\NN|NONE (l_conj) hypertension_13\NN|primary|or|angle
D013999_D009798 NONE timolol_68\NN|)|morning|( (r_compound) gellan_69\NN|(|timolol|morning|or|)|, (r_conj) solution_57\NN|over|,|in|)|to (r_conj) crossed_32\VBN|were|patients|.|and (r_conj) randomized_30\VBN|NONE (l_nsubjpass) patients_4\NNS|were|.|and|crossed (l_prep) with_5\IN|Caucasian|three (l_pobj) glaucoma_10\NN|NONE (l_conj) hypertension_13\NN|primary|or|angle
D013999_D005902 NONE timolol_56\NN|(|gellan|morning|or|)|, (r_compound) solution_57\NN|over|,|in|)|to (r_conj) crossed_32\VBN|were|patients|.|and (r_conj) randomized_30\VBN|NONE (l_nsubjpass) patients_4\NNS|were|.|and|crossed (l_prep) with_5\IN|Caucasian|three (l_pobj) glaucoma_10\NN|NONE
D013999_D005902 NONE timolol_68\NN|)|morning|( (r_compound) gellan_69\NN|(|timolol|morning|or|)|, (r_conj) solution_57\NN|over|,|in|)|to (r_conj) crossed_32\VBN|were|patients|.|and (r_conj) randomized_30\VBN|NONE (l_nsubjpass) patients_4\NNS|were|.|and|crossed (l_prep) with_5\IN|Caucasian|three (l_pobj) glaucoma_10\NN|NONE
D013999_D005901 NONE timolol_6\NN|NONE (l_prep) on_9\IN|ophthalmic|aqueous|with (l_pobj) response_14\NN|NONE (l_prep) in_15\IN|hour|rate|the (l_pobj) patients_16\NNS|NONE (l_prep) on_17\IN|NONE (l_pobj) treatment_18\NN|NONE (l_prep) for_19\IN|NONE (l_pobj) glaucoma_20\NN|NONE
D013999_D005901 NONE timolol_11\NN|,|of|the (l_conj) suspension_21\NN|)|solution|%|aqueous|and|( (l_relcl) forms_23\VBZ|a|%|timolol (l_prep) on_26\IN|gel|that (l_pobj) application_27\NN|NONE (l_prep) on_35\IN|to (l_pobj) rate_39\NN|NONE (l_prep) in_40\IN|heart|hour|the (l_pobj) patients_41\NNS|NONE (l_acl) treated_44\VBN|NONE (l_prep) for_45\IN|quantify|being|currently (l_pobj) glaucoma_46\NN|NONE
D013999_D005901 NONE timolol_13\NN|NONE (r_compound) solution_14\NN|)|suspension|%|aqueous|and|( (r_appos) timolol_11\NN|,|of|the (l_conj) suspension_21\NN|)|solution|%|aqueous|and|( (l_relcl) forms_23\VBZ|a|%|timolol (l_prep) on_26\IN|gel|that (l_pobj) application_27\NN|NONE (l_prep) on_35\IN|to (l_pobj) rate_39\NN|NONE (l_prep) in_40\IN|heart|hour|the (l_pobj) patients_41\NNS|NONE (l_acl) treated_44\VBN|NONE (l_prep) for_45\IN|quantify|being|currently (l_pobj) glaucoma_46\NN|NONE
D013999_D005901 NONE timolol_20\NN|a|forms|% (r_compound) suspension_21\NN|)|solution|%|aqueous|and|( (l_relcl) forms_23\VBZ|a|%|timolol (l_prep) on_26\IN|gel|that (l_pobj) application_27\NN|NONE (l_prep) on_35\IN|to (l_pobj) rate_39\NN|NONE (l_prep) in_40\IN|heart|hour|the (l_pobj) patients_41\NNS|NONE (l_acl) treated_44\VBN|NONE (l_prep) for_45\IN|quantify|being|currently (l_pobj) glaucoma_46\NN|NONE
D013999_D005901 NONE timolol_32\NN|)|( (r_compound) gellan_33\NN|the (r_appos) conjunctiva_30\NN|NONE (r_pobj) to_28\IN|on (r_prep) application_27\NN|NONE (l_prep) on_35\IN|to (l_pobj) rate_39\NN|NONE (l_prep) in_40\IN|heart|hour|the (l_pobj) patients_41\NNS|NONE (l_acl) treated_44\VBN|NONE (l_prep) for_45\IN|quantify|being|currently (l_pobj) glaucoma_46\NN|NONE
17263743
D003000_D002547 NONE clonidine_15\NN|NONE (r_pobj) after_13\IN|NONE (r_prep) anesthesia_12\NN|NONE (r_pobj) of_11\IN|sevoflurane (r_prep) induction_10\NN|NONE (r_dobj) undergoing_8\VBG|.|Cardiac|in (r_acl) arrest_1\NN|NONE (l_prep) in_2\IN|.|Cardiac|undergoing (l_pobj) child_4\NN|NONE (l_prep) with_5\IN|a (l_pobj) palsy_7\JJ|NONE
D003000_D002547 NONE clonidine_18\NN|for (r_dobj) receiving_17\VBG|,|case|We|. (r_advcl) present_1\VBP|NONE (l_dobj) case_3\NN|,|receiving|We|. (l_prep) of_4\IN|a (l_pobj) child_9\NN|NONE (l_prep) with_10\IN|a|old (l_pobj) disorder_15\NN|NONE (l_nmod) palsy_12\JJ|seizure
D001418_D002547 NONE baclofen_28\JJ|a (r_compound) pump_29\NN|NONE (r_pobj) of_26\IN|NONE (r_prep) placement_25\NN|NONE (r_pobj) for_24\IN|who (r_prep) presented_23\VBD|, (r_relcl) restlessness_20\NN|NONE (r_pobj) for_19\IN|clonidine (r_prep) receiving_17\VBG|,|case|We|. (r_advcl) present_1\VBP|NONE (l_dobj) case_3\NN|,|receiving|We|. (l_prep) of_4\IN|a (l_pobj) child_9\NN|NONE (l_prep) with_10\IN|a|old (l_pobj) disorder_15\NN|NONE (l_nmod) palsy_12\JJ|seizure
C009250_D006323 NONE sevoflurane_9\NN|of (r_amod) induction_10\NN|NONE (r_dobj) undergoing_8\VBG|.|Cardiac|in (r_acl) arrest_1\NN|NONE
D003000_D004827 NONE clonidine_18\NN|for (r_dobj) receiving_17\VBG|,|case|We|. (r_advcl) present_1\VBP|NONE (l_dobj) case_3\NN|,|receiving|We|. (l_prep) of_4\IN|a (l_pobj) child_9\NN|NONE (l_prep) with_10\IN|a|old (l_pobj) disorder_15\NN|NONE
D001418_D011595 NONE baclofen_28\JJ|a (r_compound) pump_29\NN|NONE (r_pobj) of_26\IN|NONE (r_prep) placement_25\NN|NONE (r_pobj) for_24\IN|who (r_prep) presented_23\VBD|, (r_relcl) restlessness_20\NN|NONE
D003000_D011595 NONE clonidine_18\NN|for (r_dobj) receiving_17\VBG|,|case|We|. (l_prep) for_19\IN|clonidine (l_pobj) restlessness_20\NN|NONE
D003000_D001008 NONE clonidine_16\NN|NONE (r_pobj) of_15\IN|three (r_prep) doses_14\NNS|Without|reduce|,|during|.|before|mother (r_dobj) administered_12\VBD|NONE (l_advcl) reduce_26\VB|Without|,|during|.|before|mother|doses (l_dobj) anxiety_27\NN|to
D001418_D004827 NONE baclofen_28\JJ|a (r_compound) pump_29\NN|NONE (r_pobj) of_26\IN|NONE (r_prep) placement_25\NN|NONE (r_pobj) for_24\IN|who (r_prep) presented_23\VBD|, (r_relcl) restlessness_20\NN|NONE (r_pobj) for_19\IN|clonidine (r_prep) receiving_17\VBG|,|case|We|. (r_advcl) present_1\VBP|NONE (l_dobj) case_3\NN|,|receiving|We|. (l_prep) of_4\IN|a (l_pobj) child_9\NN|NONE (l_prep) with_10\IN|a|old (l_pobj) disorder_15\NN|NONE
D003000_D006323 CID clonidine_15\NN|NONE (r_pobj) after_13\IN|NONE (r_prep) anesthesia_12\NN|NONE (r_pobj) of_11\IN|sevoflurane (r_prep) induction_10\NN|NONE (r_dobj) undergoing_8\VBG|.|Cardiac|in (r_acl) arrest_1\NN|NONE
D003000_D006323 CID clonidine_6\NN| (r_npadvmod) associated_8\VBN|cardiac|in (r_amod) arrest_10\NN|NONE
C009250_D002547 NONE sevoflurane_9\NN|of (r_amod) induction_10\NN|NONE (r_dobj) undergoing_8\VBG|.|Cardiac|in (r_acl) arrest_1\NN|NONE (l_prep) in_2\IN|.|Cardiac|undergoing (l_pobj) child_4\NN|NONE (l_prep) with_5\IN|a (l_pobj) palsy_7\JJ|NONE
12757899
D004958_D001930 NONE Estradiol_0\NN|.|injury|in|but (r_nsubj) reduces_1\VBZ|NONE (l_dobj) injury_6\NN|.|in|but|Estradiol
D007608_D001930 NONE acid_10\NN| (r_npadvmod) induced_12\VBN|SE|kainic (r_amod) status_13\NN|NONE (r_pobj) by_8\IN|NONE (r_agent) induced_7\VBN|)|.|Estrogens|rats (r_advcl) protect_1\VBP|NONE (l_dobj) rats_3\NNS|)|induced|.|Estrogens (l_prep) from_4\IN|ovariectomized (l_pobj) injury_6\NN|NONE
D008094_D013226 CID lithium_17\NN| (r_compound) pilocarpine_19\NN| (r_npadvmod) induced_21\VBN|NONE (r_amod) SE_22\NNP|NONE
D007608_D013226 NONE acid_10\NN| (r_npadvmod) induced_12\VBN|SE|kainic (r_amod) status_13\NN|NONE (l_appos) SE_16\NNP|kainic|induced (l_amod) epilepticus_14\NN|(
D007608_D013226 NONE acid_10\NN| (r_npadvmod) induced_12\VBN|SE|kainic (r_amod) status_13\NN|NONE (l_appos) SE_16\NNP|kainic|induced
D004958_D012640 NONE Estradiol_0\NN|.|injury|in|but (r_nsubj) reduces_1\VBZ|NONE (l_dobj) injury_6\NN|.|in|but|Estradiol (l_amod) induced_4\VBN|hippocampal|in (l_npadvmod) seizure_2\NN|
D004958_D012640 NONE estradiol_7\NN|NONE (r_pobj) of_6\IN|on|the (r_prep) effects_5\NNS|be|by|that|may (l_prep) on_8\IN|of|the (l_pobj) threshold_10\NN|NONE (l_compound) seizure_9\NN|and|damage
D012834_D013226 NONE silver_3\NN| (r_npadvmod) stained_5\VBN|and|neurons (r_amod) CA3_6\NN|NONE (r_pobj) of_2\IN|The (r_prep) extent_1\NN|.|was|after (r_nsubjpass) evaluated_12\VBN|NONE (l_prep) after_15\IN|.|extent|was (l_pobj) SE_16\NNP|days
D004958_D013226 NONE estradiol_7\NN|NONE (r_pobj) of_4\IN|and|in|the|rats (r_prep) effects_3\NNS|.|We (l_conj) rats_14\NNS|and|of|in|the (l_acl) subjected_15\VBN|ovariectomized|female (l_prep) to_16\IN|NONE (l_pobj) SE_22\NNP|NONE
D010862_D013226 CID pilocarpine_19\NN| (r_npadvmod) induced_21\VBN|NONE (r_amod) SE_22\NNP|NONE
19203554
D012460_D005921 NONE sulphasalazine_10\JJ|NONE (r_compound) treatment_11\NN|NONE (r_dobj) restarting_9\VBG|NONE (r_pcomp) after_8\IN|Proteinase|.|glomerulonephritis|antineutrophil|cytoplasmic (r_prep) antibody-(PR3-ANCA_3\NNS|NONE (l_appos) glomerulonephritis_7\NN|Proteinase|after|.|antineutrophil|cytoplasmic
D012460_D005921 NONE sulphasalazine_4\NN|glomerulonephritis|can|that (r_nsubj) induce_6\VB|.|case (l_dobj) glomerulonephritis_11\NN|can|sulphasalazine|that
D012460_D004802 NONE sulphasalazine_22\JJ|NONE (r_compound) treatment_23\NN|NONE (r_pobj) of_21\IN|NONE (r_prep) restarting_20\VBG|NONE (r_pcomp) after_19\IN|eyes|woman|. (r_prep) developed_8\VBD|NONE (l_dobj) eyes_10\NNS|woman|.|after (l_conj) effusion_13\NN|red|, (l_conj) eosinophilia_15\NN|,|pleural
D013256_D005128 NONE steroid_32\NN|NONE (r_compound) therapy_33\NN|resulted|we|,|increased|rose|, (r_dobj) initiated_31\VBD|NONE (l_advcl) resulted_5\VBD|we|,|increased|therapy|rose|, (l_prep) in_6\IN|cessation|Although (l_pobj) improvements_7\NNS|NONE (l_prep) in_8\IN|NONE (l_pobj) fever_9\NN|NONE (l_appos) eyes_12\NNS|,
D013256_D002637 NONE steroid_32\NN|NONE (r_compound) therapy_33\NN|resulted|we|,|increased|rose|, (r_dobj) initiated_31\VBD|NONE (l_advcl) resulted_5\VBD|we|,|increased|therapy|rose|, (l_prep) in_6\IN|cessation|Although (l_pobj) improvements_7\NNS|NONE (l_prep) in_8\IN|NONE (l_pobj) fever_9\NN|NONE (l_appos) eyes_12\NNS|, (l_conj) pain_15\NN|red|,
D012460_D010996 CID sulphasalazine_22\JJ|NONE (r_compound) treatment_23\NN|NONE (r_pobj) of_21\IN|NONE (r_prep) restarting_20\VBG|NONE (r_pcomp) after_19\IN|eyes|woman|. (r_prep) developed_8\VBD|NONE (l_dobj) eyes_10\NNS|woman|.|after (l_conj) effusion_13\NN|red|,
D012460_D010996 CID sulphasalazine_3\NN|NONE (r_compound) treatment_4\NN|NONE (r_pobj) of_2\IN|NONE (r_prep) cessation_1\NN|in|Although (r_nsubj) resulted_5\VBD|we|,|increased|therapy|rose|, (l_prep) in_6\IN|cessation|Although (l_pobj) improvements_7\NNS|NONE (l_prep) in_8\IN|NONE (l_pobj) fever_9\NN|NONE (l_appos) eyes_12\NNS|, (l_conj) pain_15\NN|red|, (l_conj) titer_17\NN|chest|, (l_prep) of_18\IN|NONE (l_pobj) protein_22\NN|NONE (l_prep) of_25\IN|and|volume|reactive (l_pobj) effusions_28\NNS|NONE
D012460_D010996 CID sulphasalazine_3\NN|NONE (r_compound) treatment_4\NN|NONE (r_pobj) of_2\IN|NONE (r_prep) cessation_1\NN|in|Although (r_nsubj) resulted_5\VBD|we|,|increased|therapy|rose|, (r_advcl) initiated_31\VBD|NONE (l_conj) increased_45\VBD|resulted|we|,|therapy|rose|, (l_conj) remained_56\VBD|,|to|count|,|and (l_nsubj) effusion_55\NN|.
D012460_D005128 NONE sulphasalazine_22\JJ|NONE (r_compound) treatment_23\NN|NONE (r_pobj) of_21\IN|NONE (r_prep) restarting_20\VBG|NONE (r_pcomp) after_19\IN|eyes|woman|. (r_prep) developed_8\VBD|NONE (l_dobj) eyes_10\NNS|woman|.|after
D012460_D005128 NONE sulphasalazine_3\NN|NONE (r_compound) treatment_4\NN|NONE (r_pobj) of_2\IN|NONE (r_prep) cessation_1\NN|in|Although (r_nsubj) resulted_5\VBD|we|,|increased|therapy|rose|, (l_prep) in_6\IN|cessation|Although (l_pobj) improvements_7\NNS|NONE (l_prep) in_8\IN|NONE (l_pobj) fever_9\NN|NONE (l_appos) eyes_12\NNS|,
D012460_D003093 NONE sulphasalazine_22\JJ|NONE (r_compound) treatment_23\NN|NONE (r_pobj) of_21\IN|NONE (r_prep) restarting_20\VBG|NONE (r_pcomp) after_19\IN|eyes|woman|. (r_prep) developed_8\VBD|NONE (l_nsubj) woman_4\NN|eyes|.|after (l_prep) with_5\IN|old|A (l_pobj) colitis_7\NN|NONE
D012460_D005334 CID sulphasalazine_3\NN|NONE (r_compound) treatment_4\NN|NONE (r_pobj) of_2\IN|NONE (r_prep) cessation_1\NN|in|Although (r_nsubj) resulted_5\VBD|we|,|increased|therapy|rose|, (l_prep) in_6\IN|cessation|Although (l_pobj) improvements_7\NNS|NONE (l_prep) in_8\IN|NONE (l_pobj) fever_9\NN|NONE
D013256_D005334 NONE steroid_32\NN|NONE (r_compound) therapy_33\NN|resulted|we|,|increased|rose|, (r_dobj) initiated_31\VBD|NONE (l_advcl) resulted_5\VBD|we|,|increased|therapy|rose|, (l_prep) in_6\IN|cessation|Although (l_pobj) improvements_7\NNS|NONE (l_prep) in_8\IN|NONE (l_pobj) fever_9\NN|NONE
D012460_D001745 NONE sulphasalazine_22\JJ|NONE (r_compound) treatment_23\NN|NONE (r_pobj) of_21\IN|NONE (r_prep) restarting_20\VBG|NONE (r_pcomp) after_19\IN|eyes|woman|. (r_prep) developed_8\VBD|NONE (l_dobj) eyes_10\NNS|woman|.|after (l_conj) effusion_13\NN|red|, (l_conj) eosinophilia_15\NN|,|pleural (l_conj) abnormalities_18\NNS|and
D012460_D002637 NONE sulphasalazine_3\NN|NONE (r_compound) treatment_4\NN|NONE (r_pobj) of_2\IN|NONE (r_prep) cessation_1\NN|in|Although (r_nsubj) resulted_5\VBD|we|,|increased|therapy|rose|, (l_prep) in_6\IN|cessation|Although (l_pobj) improvements_7\NNS|NONE (l_prep) in_8\IN|NONE (l_pobj) fever_9\NN|NONE (l_appos) eyes_12\NNS|, (l_conj) pain_15\NN|red|,
D013256_D010996 NONE steroid_32\NN|NONE (r_compound) therapy_33\NN|resulted|we|,|increased|rose|, (r_dobj) initiated_31\VBD|NONE (l_advcl) resulted_5\VBD|we|,|increased|therapy|rose|, (l_prep) in_6\IN|cessation|Although (l_pobj) improvements_7\NNS|NONE (l_prep) in_8\IN|NONE (l_pobj) fever_9\NN|NONE (l_appos) eyes_12\NNS|, (l_conj) pain_15\NN|red|, (l_conj) titer_17\NN|chest|, (l_prep) of_18\IN|NONE (l_pobj) protein_22\NN|NONE (l_prep) of_25\IN|and|volume|reactive (l_pobj) effusions_28\NNS|NONE
D013256_D010996 NONE steroid_32\NN|NONE (r_compound) therapy_33\NN|resulted|we|,|increased|rose|, (r_dobj) initiated_31\VBD|NONE (l_conj) increased_45\VBD|resulted|we|,|therapy|rose|, (l_conj) remained_56\VBD|,|to|count|,|and (l_nsubj) effusion_55\NN|.
D013256_D010996 NONE steroid_3\NN|NONE (r_compound) therapy_4\NN|month (r_pobj) after_2\IN|and|,|,|normalized|effusion (r_prep) disappeared_9\VBD|NONE (l_nsubj) effusion_8\NN|and|,|after|,|normalized
1300436
D003404_D058186 NONE creatinine_46\NN|NONE (r_pobj) in_44\IN|from|a (r_prep) rise_43\NN|NONE (r_pobj) with_41\IN|)|occurred|.|were|,|,|significantly|in (r_prep) deteriorated_26\VBD|NONE
D005665_D015431 NONE furosemide_9\NN| (r_npadvmod) treated_11\VBN|the (r_amod) group_12\NN|NONE (r_pobj) in_7\IN|weight (r_prep) loss_6\NN|NONE
D005665_D051437 NONE furosemide_9\NN| (r_npadvmod) treated_11\VBN|the (r_amod) group_12\NN|NONE (r_pobj) in_7\IN|weight (r_prep) loss_6\NN|NONE (r_pobj) with_4\IN|failure|.|was (r_prep) associated_3\VBN|NONE (l_nsubjpass) failure_1\NN|.|was|with
D005665_D058186 CID furosemide_32\NN|NONE (r_pobj) with_31\IN|NONE (r_prep) pretreated_30\VBN|the (r_acl) group_29\NN|NONE (r_pobj) in_27\IN|)|occurred|with|.|were|,|,|significantly (r_prep) deteriorated_26\VBD|NONE
D005665_D007674 NONE furosemide_4\NN|NONE (r_pobj) of_3\IN|in|Potential|.|deleterious (r_prep) effect_2\NN|NONE (l_prep) in_5\IN|of|Potential|.|deleterious (l_pobj) nephropathy_7\NN|NONE
D005665_D007674 NONE furosemide_11\NN|NONE (r_pobj) of_10\IN|the (r_prep) efficacy_9\NN|to|in (r_dobj) determine_7\VB|purpose|. (l_prep) in_12\IN|to|efficacy (l_pobj) addition_13\NN|NONE (l_prep) in_17\IN|to (l_pobj) prevention_19\NN|NONE (l_prep) of_20\IN|the (l_pobj) nephropathy_22\NN|NONE
D005665_D007674 NONE Furosemide_0\NNP|in|.|may|deleterious (r_nsubj) be_2\VB|NONE (l_prep) in_4\IN|.|may|Furosemide|deleterious (l_pobj) prevention_6\NN|NONE (l_prep) of_7\IN|the (l_pobj) nephropathy_9\NN|NONE
12789195
D008914_D004194 NONE minoxidil_9\NN|NONE (r_pobj) of_8\IN|term|the (r_prep) use_7\NN|NONE (r_pobj) by_2\IN|.|Pseudoacromegaly (r_agent) induced_1\VBN|NONE (l_nsubj) Pseudoacromegaly_0\NNS|by|.
D008914_D004194 NONE minoxidil_15\NN|NONE (r_pobj) of_14\IN|term|the|at (r_prep) use_13\NN|NONE (r_pobj) from_8\IN|that (r_prep) resulted_7\VBD|a|with (r_relcl) patient_3\NN|We|. (l_prep) with_4\IN|a|resulted (l_pobj) pseudoacromegaly_5\NNS|NONE
D008914_D004194 NONE minoxidil_13\JJ|NONE (r_amod) use_14\NN|NONE (r_pobj) of_12\IN|a|side (r_prep) effect_11\NN|NONE (r_pobj) as_8\IN|the|first|of|case (r_prep) report_5\NN|.|This (l_prep) of_6\IN|the|first|as|case (l_pobj) pseudoacromegaly_7\NNS|NONE
1664218
C042315_D002289 NONE CI-921_7\NNP|NONE (r_punct) (_8\-LRB-|)| (r_punct) NSC_9\NNP|.|in|II|of (r_appos) study_2\NN|NONE (l_prep) in_12\IN|NSC|.|II|of (l_pobj) cancer_18\NN|NONE
C042315_D002289 NONE 343499_10\CD|)|( (r_nummod) NSC_9\NNP|.|in|II|of (r_appos) study_2\NN|NONE (l_prep) in_12\IN|NSC|.|II|of (l_pobj) cancer_18\NN|NONE
D000677_D002289 NONE amsacrine_5\NN|the (r_compound) analogue_6\NN|NONE (r_pobj) of_3\IN|NSC|.|in|II (r_prep) study_2\NN|NONE (l_prep) in_12\IN|NSC|.|II|of (l_pobj) cancer_18\NN|NONE
2709684
D013311_D006029 NONE streptozotocin_3\NNS| (r_npadvmod) induced_5\VBN|NONE (r_amod) diabetes_6\NN|DM (r_compound) mellitus_7\NN|NONE (r_pobj) with_2\IN|NONE (r_prep) rats_1\NNS|Because|diuresis (r_nsubj) have_11\VBP|,|we|have|.|be (l_dobj) diuresis_15\NN|Because|rats (l_appos) glycosuria_17\NN|(|a|)|solute
D013311_D003920 CID streptozotocin_3\NNS| (r_npadvmod) induced_5\VBN|NONE (r_amod) diabetes_6\NN|DM (r_compound) mellitus_7\NN|NONE
D013311_D003920 CID streptozotocin_3\NNS| (r_npadvmod) induced_5\VBN|NONE (r_amod) diabetes_6\NN|DM (r_compound) mellitus_7\NN|NONE (l_appos) DM_9\NNP|diabetes
D010695_D003920 NONE phlorizin_24\NN|NONE (r_pobj) with_23\IN|glucose|tubular (r_prep) reabsorption_22\NN|NONE (r_pobj) of_19\IN|NONE (r_prep) blockage_18\NN|NONE (r_pobj) by_17\IN|NONE (r_agent) induced_16\VBN|diabetic|with (r_acl) rats_11\NNS|NONE (l_amod) diabetic_10\JJ|induced|with
D010695_D003920 NONE P_26\NN|)|( (r_appos) phlorizin_24\NN|NONE (r_pobj) with_23\IN|glucose|tubular (r_prep) reabsorption_22\NN|NONE (r_pobj) of_19\IN|NONE (r_prep) blockage_18\NN|NONE (r_pobj) by_17\IN|NONE (r_agent) induced_16\VBN|diabetic|with (r_acl) rats_11\NNS|NONE (l_amod) diabetic_10\JJ|induced|with
D010695_D003920 NONE P_13\NN|the|treated (r_nmod) animals_15\NNS|NONE (r_pobj) of_11\IN|NONE (r_prep) that_10\DT|NONE (r_pobj) to_9\IN|NONE (r_prep) degree_8\NN|NONE (r_pobj) in_7\IN|NONE (r_prep) similar_6\JJ|)|mild|( (r_amod) glycosuria_4\NN|NONE (r_pobj) with_2\IN|DM (r_prep) rats_1\NNS|also|.|were (l_compound) DM_0\NNP|with
D010695_D003920 NONE P_3\NN|II|;|Group|for|P (r_nsubj) received_6\VBD|NONE (l_conj) II_19\NNP|;|Group|for|P|P (l_conj) III_27\NNP|;|Group|(|P (l_acl) gentamicin_29\NN|(|.|Group (l_conj) IV_34\NNP|)|alone|and (l_appos) DM_37\NNP|Group
D010695_D003920 NONE P_7\NN|II|;|Group|for|P (r_dobj) received_6\VBD|NONE (l_conj) II_19\NNP|;|Group|for|P|P (l_conj) III_27\NNP|;|Group|(|P (l_acl) gentamicin_29\NN|(|.|Group (l_conj) IV_34\NNP|)|alone|and (l_appos) DM_37\NNP|Group
D010695_D003920 NONE P_21\NN|III|;|Group|( (r_appos) II_19\NNP|;|Group|for|P|P (l_conj) III_27\NNP|;|Group|(|P (l_acl) gentamicin_29\NN|(|.|Group (l_conj) IV_34\NNP|)|alone|and (l_appos) DM_37\NNP|Group
D005839_D006029 NONE gentamicin_7\NN|in (r_compound) nephrotoxicity_8\NN|not|does|glycosuria|. (r_dobj) prevent_6\VB|NONE (l_nsubj) glycosuria_3\NN|not|does|.|nephrotoxicity
D005839_D006029 NONE gentamicin_41\NN| (r_npadvmod) induced_43\VBN|ARF|acute|renal (r_amod) failure_46\NN|NONE (r_pobj) to_40\IN|their (r_prep) resistance_39\NN|NONE (r_pobj) for_37\IN|NONE (r_prep) responsible_36\JJ|this|in|that|may (r_acomp) be_35\VB|,|we|have|have|. (r_ccomp) suggested_29\VBN|NONE (l_advcl) have_11\VBP|,|we|have|.|be (l_dobj) diuresis_15\NN|Because|rats (l_appos) glycosuria_17\NN|(|a|)|solute
D010695_D058186 NONE P_4\NN|did|;|ARF|not|,|.|In|less|day (r_nsubj) prevent_7\VB|NONE (l_dobj) ARF_10\NNP|did|;|not|P|,|.|In|less|day
D010695_D058186 NONE P_21\NN||decrease|(|,|gentamicin (r_appos) ARF_10\NNP|did|;|not|P|,|.|In|less|day
D005947_D003920 NONE glucose_21\NN|with|tubular (r_compound) reabsorption_22\NN|NONE (r_pobj) of_19\IN|NONE (r_prep) blockage_18\NN|NONE (r_pobj) by_17\IN|NONE (r_agent) induced_16\VBN|diabetic|with (r_acl) rats_11\NNS|NONE (l_amod) diabetic_10\JJ|induced|with
D013311_D058186 NONE streptozotocin_3\NNS| (r_npadvmod) induced_5\VBN|NONE (r_amod) diabetes_6\NN|DM (r_compound) mellitus_7\NN|NONE (r_pobj) with_2\IN|NONE (r_prep) rats_1\NNS|Because|diuresis (r_nsubj) have_11\VBP|,|we|have|.|be (r_advcl) suggested_29\VBN|NONE (l_ccomp) be_35\VB|,|we|have|have|. (l_acomp) responsible_36\JJ|this|in|that|may (l_prep) for_37\IN|NONE (l_pobj) resistance_39\NN|NONE (l_prep) to_40\IN|their (l_pobj) failure_46\NN|NONE
D013311_D058186 NONE streptozotocin_3\NNS| (r_npadvmod) induced_5\VBN|NONE (r_amod) diabetes_6\NN|DM (r_compound) mellitus_7\NN|NONE (r_pobj) with_2\IN|NONE (r_prep) rats_1\NNS|Because|diuresis (r_nsubj) have_11\VBP|,|we|have|.|be (r_advcl) suggested_29\VBN|NONE (l_ccomp) be_35\VB|,|we|have|have|. (l_acomp) responsible_36\JJ|this|in|that|may (l_prep) for_37\IN|NONE (l_pobj) resistance_39\NN|NONE (l_prep) to_40\IN|their (l_pobj) failure_46\NN|NONE (l_appos) ARF_48\NNP|acute|renal|induced
D005839_D003920 NONE gentamicin_41\NN| (r_npadvmod) induced_43\VBN|ARF|acute|renal (r_amod) failure_46\NN|NONE (r_pobj) to_40\IN|their (r_prep) resistance_39\NN|NONE (r_pobj) for_37\IN|NONE (r_prep) responsible_36\JJ|this|in|that|may (r_acomp) be_35\VB|,|we|have|have|. (r_ccomp) suggested_29\VBN|NONE (l_advcl) have_11\VBP|,|we|have|.|be (l_nsubj) rats_1\NNS|Because|diuresis (l_prep) with_2\IN|NONE (l_pobj) mellitus_7\NN|NONE
D005839_D003920 NONE gentamicin_41\NN| (r_npadvmod) induced_43\VBN|ARF|acute|renal (r_amod) failure_46\NN|NONE (r_pobj) to_40\IN|their (r_prep) resistance_39\NN|NONE (r_pobj) for_37\IN|NONE (r_prep) responsible_36\JJ|this|in|that|may (r_acomp) be_35\VB|,|we|have|have|. (r_ccomp) suggested_29\VBN|NONE (l_advcl) have_11\VBP|,|we|have|.|be (l_nsubj) rats_1\NNS|Because|diuresis (l_prep) with_2\IN|NONE (l_pobj) mellitus_7\NN|NONE (l_appos) DM_9\NNP|diabetes
D005839_D003920 NONE gentamicin_3\NN|NONE (r_amod) nephrotoxicity_4\NN|NONE (r_pobj) from_2\IN|The (r_prep) protection_1\NN|was|.|in (r_nsubjpass) studied_6\VBN|NONE (l_prep) in_7\IN|protection|was|. (l_pobj) rats_11\NNS|NONE (l_amod) diabetic_10\JJ|induced|with
D005839_D003920 NONE gentamicin_23\NN|)|+ (r_conj) P_21\NN|III|;|Group|( (r_appos) II_19\NNP|;|Group|for|P|P (l_conj) III_27\NNP|;|Group|(|P (l_acl) gentamicin_29\NN|(|.|Group (l_conj) IV_34\NNP|)|alone|and (l_appos) DM_37\NNP|Group
D005839_D003920 NONE gentamicin_29\NN|(|.|Group (l_conj) IV_34\NNP|)|alone|and (l_appos) DM_37\NNP|Group
D005839_D003920 NONE gentamicin_39\NN|mild|(|)|+ (r_conj) DM_37\NNP|Group
D005839_D058186 CID gentamicin_41\NN| (r_npadvmod) induced_43\VBN|ARF|acute|renal (r_amod) failure_46\NN|NONE
D005839_D058186 CID gentamicin_41\NN| (r_npadvmod) induced_43\VBN|ARF|acute|renal (r_amod) failure_46\NN|NONE (l_appos) ARF_48\NNP|acute|renal|induced
D005839_D058186 CID gentamicin_8\NN||decrease|P|(|, (r_compound) ARF_10\NNP|did|;|not|P|,|.|In|less|day
D010695_D007674 NONE Phlorizin_0\NNP| (r_npadvmod) induced_2\VBN|NONE (r_amod) glycosuria_3\NN|not|does|.|nephrotoxicity (r_nsubj) prevent_6\VB|NONE (l_dobj) nephrotoxicity_8\NN|not|does|glycosuria|.
D010695_D007674 NONE phlorizin_24\NN|NONE (r_pobj) with_23\IN|glucose|tubular (r_prep) reabsorption_22\NN|NONE (r_pobj) of_19\IN|NONE (r_prep) blockage_18\NN|NONE (r_pobj) by_17\IN|NONE (r_agent) induced_16\VBN|diabetic|with (r_acl) rats_11\NNS|NONE (r_pobj) in_7\IN|protection|was|. (r_prep) studied_6\VBN|NONE (l_nsubjpass) protection_1\NN|was|.|in (l_prep) from_2\IN|The (l_pobj) nephrotoxicity_4\NN|NONE
D010695_D007674 NONE P_26\NN|)|( (r_appos) phlorizin_24\NN|NONE (r_pobj) with_23\IN|glucose|tubular (r_prep) reabsorption_22\NN|NONE (r_pobj) of_19\IN|NONE (r_prep) blockage_18\NN|NONE (r_pobj) by_17\IN|NONE (r_agent) induced_16\VBN|diabetic|with (r_acl) rats_11\NNS|NONE (r_pobj) in_7\IN|protection|was|. (r_prep) studied_6\VBN|NONE (l_nsubjpass) protection_1\NN|was|.|in (l_prep) from_2\IN|The (l_pobj) nephrotoxicity_4\NN|NONE
D010695_D007674 NONE P_4\NN|and|glycosuria|,|In|CCr|I (r_nsubj) induced_5\VBD|NONE (l_conj) CCr_33\IN|and|glycosuria|,|In|P|I (l_nsubj) evidence_27\NN|min|baseline|.|score (l_prep) of_28\IN|functional|no (l_pobj) dysfunction_30\NN|NONE
D005839_D007674 NONE gentamicin_7\NN|in (r_compound) nephrotoxicity_8\NN|not|does|glycosuria|.
D005839_D007674 NONE gentamicin_3\NN|NONE (r_amod) nephrotoxicity_4\NN|NONE
D005839_D007674 NONE gentamicin_11\NN|NONE (r_pobj) of_10\IN|Nephrotoxic|body|)|( (r_prep) doses_1\NNS|were|to|during|to|. (l_amod) Nephrotoxic_0\JJ|body|of|)|(
D010695_D006029 NONE Phlorizin_0\NNP| (r_npadvmod) induced_2\VBN|NONE (r_amod) glycosuria_3\NN|not|does|.|nephrotoxicity
D010695_D006029 NONE P_13\NN|the|treated (r_nmod) animals_15\NNS|NONE (r_pobj) of_11\IN|NONE (r_prep) that_10\DT|NONE (r_pobj) to_9\IN|NONE (r_prep) degree_8\NN|NONE (r_pobj) in_7\IN|NONE (r_prep) similar_6\JJ|)|mild|( (r_amod) glycosuria_4\NN|NONE
D010695_D006029 NONE P_4\NN|and|glycosuria|,|In|CCr|I (r_nsubj) induced_5\VBD|NONE (l_dobj) glycosuria_10\NN|and|,|In|P|CCr|I
D005947_D007674 NONE glucose_21\NN|with|tubular (r_compound) reabsorption_22\NN|NONE (r_pobj) of_19\IN|NONE (r_prep) blockage_18\NN|NONE (r_pobj) by_17\IN|NONE (r_agent) induced_16\VBN|diabetic|with (r_acl) rats_11\NNS|NONE (r_pobj) in_7\IN|protection|was|. (r_prep) studied_6\VBN|NONE (l_nsubjpass) protection_1\NN|was|.|in (l_prep) from_2\IN|The (l_pobj) nephrotoxicity_4\NN|NONE
D005839_D009956 NONE gentamicin_8\NN||decrease|P|(|, (r_compound) ARF_10\NNP|did|;|not|P|,|.|In|less|day (r_dobj) prevent_7\VB|NONE (l_conj) day_34\NN|did|;|ARF|not|P|,|.|In|less (l_conj) score_39\NN|;|and|/|micrograms (l_compound) necrosis_38\NN|.|)|tubular|,
D010695_D009956 NONE P_4\NN|and|glycosuria|,|In|CCr|I (r_nsubj) induced_5\VBD|NONE (l_conj) CCr_33\IN|and|glycosuria|,|In|P|I (l_dobj) score_49\NN|min|baseline|evidence|. (l_compound) necrosis_48\NN|]|maximum|)|[|(|tubular|zero|,|
D010695_D009956 NONE P_4\NN|did|;|ARF|not|,|.|In|less|day (r_nsubj) prevent_7\VB|NONE (l_conj) day_34\NN|did|;|ARF|not|P|,|.|In|less (l_conj) score_39\NN|;|and|/|micrograms (l_compound) necrosis_38\NN|.|)|tubular|,
D010695_D009956 NONE P_21\NN||decrease|(|,|gentamicin (r_appos) ARF_10\NNP|did|;|not|P|,|.|In|less|day (r_dobj) prevent_7\VB|NONE (l_conj) day_34\NN|did|;|ARF|not|P|,|.|In|less (l_conj) score_39\NN|;|and|/|micrograms (l_compound) necrosis_38\NN|.|)|tubular|,
12820454
D005485_D000740 CID flutamide_23\NN|,|per|,|mg (r_nmod) tid_25\NN|every||plus (r_conj) days_19\NNS|)|intramuscularly|A|mg|(|leuprolide|,|[|CAB|, (r_appos) acetate_6\NN|evaluated|and|.|patients (r_dobj) received_2\VBD|NONE (l_conj) evaluated_32\VBN|and|acetate|.|patients (l_prep) for_33\IN|by|were (l_pobj) anemia_34\NN|NONE
D016729_D000740 CID acetate_6\NN|evaluated|and|.|patients (r_dobj) received_2\VBD|NONE (l_conj) evaluated_32\VBN|and|acetate|.|patients (l_prep) for_33\IN|by|were (l_pobj) anemia_34\NN|NONE
D016729_D000740 CID A_10\NNP|)|intramuscularly|days|mg|(|leuprolide|,|[|CAB|, (r_appos) acetate_6\NN|evaluated|and|.|patients (r_dobj) received_2\VBD|NONE (l_conj) evaluated_32\VBN|and|acetate|.|patients (l_prep) for_33\IN|by|were (l_pobj) anemia_34\NN|NONE
3780697
D005283_D009127 CID fentanyl_5\NN|NONE (r_compound) administration_6\NN|NONE (r_pobj) after_4\IN|operative|. (r_prep) rigidity_3\NN|NONE
D005283_D009127 CID fentanyl_29\NN|NONE (r_pobj) of_28\IN|a|moderate (r_prep) dose_27\NN|who (r_dobj) received_24\VBD|an|elderly (r_relcl) patient_22\NN|NONE (r_pobj) in_19\IN|the|operative (r_prep) period_18\NN|NONE (r_pobj) in_13\IN|case|.|is (r_prep) described_12\VBN|NONE (l_nsubjpass) case_1\NN|.|in|is (l_prep) of_2\IN|A (l_pobj) rigidity_6\NN|NONE
D005283_D012131 NONE fentanyl_29\NN|NONE (r_pobj) of_28\IN|a|moderate (r_prep) dose_27\NN|who (r_dobj) received_24\VBD|an|elderly (r_relcl) patient_22\NN|NONE (r_pobj) in_19\IN|the|operative (r_prep) period_18\NN|NONE (r_pobj) in_13\IN|case|.|is (r_prep) described_12\VBN|NONE (l_nsubjpass) case_1\NN|.|in|is (l_prep) of_2\IN|A (l_pobj) rigidity_6\NN|NONE (l_acl) leading_7\VBG|abdominal (l_prep) to_8\IN|NONE (l_pobj) failure_10\NN|NONE
6518066
D008094_D006331 NONE lithium_9\NN|NONE (r_pobj) to_8\IN|during|screening (r_prep) exposed_7\VBN|assessment|.|can (r_csubj) provide_13\VB|NONE (l_dobj) assessment_18\NN|exposed|.|can (l_prep) of_19\IN|accurate|,|noninvasive (l_pobj) presence_21\NN|NONE (l_prep) of_24\IN|the|absence|or (l_pobj) malformations_29\NNS|NONE
D008094_D006331 NONE lithium_25\NN| (r_npadvmod) induced_27\VBN|cardiac (r_amod) malformations_29\NNS|NONE
D008094_D004437 CID lithium_1\NN|NONE (l_conj) anomaly_6\NN|.|and|Maternal
8638206
D001279_D010243 CID atracurium_6\NN|NONE (r_pobj) of_5\IN|in|prolonged (r_prep) use_4\NN|NONE (r_pobj) after_2\IN|Persistent|. (r_prep) paralysis_1\NN|NONE
D001279_D010243 CID besylate_1\NN|used|has|,|been|also|with|but (r_nsubjpass) associated_22\VBN|NONE (l_prep) with_23\IN|used|has|,|been|also|besylate|but (l_pobj) paralysis_25\NN|NONE
D001279_D010243 CID atracurium_5\NN| (r_npadvmod) related_7\VBN|persisting (r_amod) paralysis_8\NN|NONE
D014673_D010243 CID bromide_21\NN|such (r_pobj) as_19\IN|based (r_prep) NMBAs_17\NNS|Reports|often|have|,|used|. (r_dobj) involved_13\VBN|NONE (l_nsubj) Reports_0\NNS|often|have|NMBAs|,|used|. (l_prep) of_1\IN|after (l_pobj) paralysis_3\NN|NONE
-1_D010243 NONE benzylisoquinolinium_7\NN|acting|eliminated|a (r_amod) NMBA_8\NNP|,|,|Atracurium (r_appos) besylate_1\NN|used|has|,|been|also|with|but (r_nsubjpass) associated_22\VBN|NONE (l_prep) with_23\IN|used|has|,|been|also|besylate|but (l_pobj) paralysis_25\NN|NONE
9209318
D015215_D009190 CID azidothymidine_5\NN|NONE (r_pcomp) with_4\IN|of|AZT|Lifetime (r_prep) treatment_1\NN|myelodysplasia|. (r_nsubj) produces_9\VBZ|NONE (l_dobj) myelodysplasia_10\NN|.|treatment
D015215_D009190 CID AZT_7\NNP|of|with|Lifetime (r_appos) treatment_1\NN|myelodysplasia|. (r_nsubj) produces_9\VBZ|NONE (l_dobj) myelodysplasia_10\NN|.|treatment
D015215_D009190 CID AZT_2\NNP|NONE (r_compound) incorporation_3\NN|have|hemopoiesis|may (r_nsubj) induced_6\VBN|Above|. (l_dobj) hemopoiesis_9\NN|have|incorporation|may (l_prep) in_10\IN|an|ineffective (l_pobj) cells_15\NNS|NONE (l_relcl) known_19\VBN|progenitor|,|primitive|the (l_xcomp) seen_22\VBN|is|which (l_prep) in_24\IN|be|to|commonly (l_pobj) syndrome_27\NN|NONE
D015215_D000748 CID AZT_0\NNP|.|anemia|has (r_nsubj) induced_2\VBN|NONE (l_dobj) anemia_5\NN|.|AZT|has
D015215_D000748 CID AZT_12\NNP|NONE (r_compound) therapy_13\NN|long (r_appos) term_11\NN|NONE (r_pobj) on_9\IN|macrocytic|in|a (r_prep) anemia_5\NN|.|AZT|has
D015215_D000163 NONE AZT_0\NNP|.|anemia|has (r_nsubj) induced_2\VBN|NONE (l_dobj) anemia_5\NN|.|AZT|has (l_prep) in_6\IN|macrocytic|on|a (l_pobj) patients_8\NNS|NONE (l_compound) AIDS_7\NNP|NONE
D015215_D000163 NONE AZT_12\NNP|NONE (r_compound) therapy_13\NN|long (r_appos) term_11\NN|NONE (r_pobj) on_9\IN|macrocytic|in|a (r_prep) anemia_5\NN|.|AZT|has (l_prep) in_6\IN|macrocytic|on|a (l_pobj) patients_8\NNS|NONE (l_compound) AIDS_7\NNP|NONE
567256
D004054_D008113 CID diethylstilbestrol_6\NN|NONE (r_pobj) with_5\IN|NONE (r_prep) associated_4\VBN|the (r_acl) liver_3\NN|NONE
D004054_D008113 CID diethylstilbestrol_25\NN|NONE (r_pobj) with_24\IN|the (r_prep) liver_23\NN|NONE (r_pobj) of_21\IN|a|differentiated (r_prep) adenocarcinoma_20\NN|NONE (r_pobj) for_15\IN|who|for|had|been (r_prep) treated_14\VBN|a|old (r_relcl) man_10\NN|NONE (r_pobj) in_5\IN|Angiosarcoma|. (r_prep) occurred_4\VBD|NONE (l_nsubj) Angiosarcoma_0\NNP|in|. (l_prep) of_1\IN|NONE (l_pobj) liver_3\NN|NONE
D004054_D008113 NONE diethylstilbestrol_25\NN|NONE (r_pobj) with_24\IN|the (r_prep) liver_23\NN|NONE
D004054_D000230 NONE diethylstilbestrol_25\NN|NONE (r_pobj) with_24\IN|the (r_prep) liver_23\NN|NONE
D004054_D006394 CID diethylstilbestrol_6\NN|NONE (r_pobj) with_5\IN|NONE (r_prep) associated_4\VBN|the (r_acl) liver_3\NN|NONE
D004054_D006394 CID diethylstilbestrol_25\NN|NONE (r_pobj) with_24\IN|the (r_prep) liver_23\NN|NONE (r_pobj) of_21\IN|a|differentiated (r_prep) adenocarcinoma_20\NN|NONE (r_pobj) for_15\IN|who|for|had|been (r_prep) treated_14\VBN|a|old (r_relcl) man_10\NN|NONE (r_pobj) in_5\IN|Angiosarcoma|. (r_prep) occurred_4\VBD|NONE (l_nsubj) Angiosarcoma_0\NNP|in|. (l_prep) of_1\IN|NONE (l_pobj) liver_3\NN|NONE
12452237
D008012_D063806 NONE lidocaine_9\JJ|on (r_compound) pretreatment_10\NN|NONE (l_prep) on_11\IN|lidocaine (l_pobj) reduction_12\NN|NONE (l_prep) of_13\IN|NONE (l_pobj) myalgia_17\NN|NONE
D013390_D063806 NONE succinylcholine_14\NN| (r_npadvmod) induced_16\VBN|in (r_amod) myalgia_17\NN|NONE
D013390_D010149 CID succinylcholine_3\NN|induced|lidocaine|?|Can (r_dobj) reduce_2\VB|NONE (l_conj) induced_4\VBD|succinylcholine|lidocaine|?|Can (l_dobj) myalgia_6\NN|NONE
D013390_D010149 CID succinylcholine_4\NN|is|where (r_nsubjpass) used_6\VBN|is|In|lidocaine|,|,|be|. (r_advcl) proven_10\VBN|NONE (l_xcomp) be_12\VB|is|used|In|lidocaine|,|,|. (l_attr) agent_16\NN|to (l_prep) for_17\IN|useful|the|pretreatment (l_pobj) reduction_19\NN|NONE (l_prep) of_20\IN|the (l_pobj) myalgia_22\NN|NONE
D008012_D010149 NONE lidocaine_1\RB|succinylcholine|induced|?|Can (r_nsubj) reduce_2\VB|NONE (l_conj) induced_4\VBD|succinylcholine|lidocaine|?|Can (l_dobj) myalgia_6\NN|NONE
D008012_D010149 NONE lidocaine_8\NN|is|used|In|,|,|be|. (r_nsubjpass) proven_10\VBN|NONE (l_xcomp) be_12\VB|is|used|In|lidocaine|,|,|. (l_attr) agent_16\NN|to (l_prep) for_17\IN|useful|the|pretreatment (l_pobj) reduction_19\NN|NONE (l_prep) of_20\IN|the (l_pobj) myalgia_22\NN|NONE
6387529
D011433_D008569 CID propranolol_14\NN|NONE (r_advcl) diazepam_12\NN|NONE (r_pobj) for_11\IN|NONE (r_prep) greater_10\JJR|decrease|. (r_acomp) was_9\VBD|drugs|recall|but (r_conj) impaired_2\VBD|NONE (l_dobj) recall_5\NN|drugs|but|was
D003975_D000379 NONE diazepam_3\NN|NONE (r_pobj) of_2\IN|propranolol|Behavioral|.|and (r_prep) effects_1\NNS|NONE (l_conj) propranolol_5\NN|of|Behavioral|.|and (l_prep) in_6\IN|NONE (l_pobj) patients_7\NNS|NONE (l_prep) with_8\IN|NONE (l_pobj) disorder_10\NN|NONE (l_conj) agoraphobia_12\NNP|panic|and
D003975_D000379 NONE diazepam_6\NN|NONE (r_pobj) of_5\IN|oral|and|(|dose (r_prep) doses_4\NNS|NONE (r_pobj) of_2\IN|The (r_prep) effects_1\NNS|dose (r_nsubj) propranolol_27\NN|.|dose|were|in (r_advcl) investigated_58\VBN|NONE (l_nsubjpass) dose_37\NN|.|were|propranolol|in (l_prep) on_47\IN|of|)|for|a|median (l_pobj) performance_49\NN|NONE (l_prep) of_50\IN|psychological (l_pobj) patients_51\NNS|NONE (l_prep) with_52\IN|NONE (l_pobj) disorders_54\NNS|NONE (l_conj) agoraphobia_56\NNP|panic|and
D003975_D016584 NONE diazepam_3\NN|NONE (r_pobj) of_2\IN|propranolol|Behavioral|.|and (r_prep) effects_1\NNS|NONE (l_conj) propranolol_5\NN|of|Behavioral|.|and (l_prep) in_6\IN|NONE (l_pobj) patients_7\NNS|NONE (l_prep) with_8\IN|NONE (l_pobj) disorder_10\NN|NONE
D003975_D016584 NONE diazepam_6\NN|NONE (r_pobj) of_5\IN|oral|and|(|dose (r_prep) doses_4\NNS|NONE (r_pobj) of_2\IN|The (r_prep) effects_1\NNS|dose (r_nsubj) propranolol_27\NN|.|dose|were|in (r_advcl) investigated_58\VBN|NONE (l_nsubjpass) dose_37\NN|.|were|propranolol|in (l_prep) on_47\IN|of|)|for|a|median (l_pobj) performance_49\NN|NONE (l_prep) of_50\IN|psychological (l_pobj) patients_51\NNS|NONE (l_prep) with_52\IN|NONE (l_pobj) disorders_54\NNS|NONE
D003975_D008569 CID diazepam_12\NN|NONE (r_pobj) for_11\IN|NONE (r_prep) greater_10\JJR|decrease|. (r_acomp) was_9\VBD|drugs|recall|but (r_conj) impaired_2\VBD|NONE (l_dobj) recall_5\NN|drugs|but|was
D011433_D016584 NONE propranolol_5\NN|of|Behavioral|.|and (l_prep) in_6\IN|NONE (l_pobj) patients_7\NNS|NONE (l_prep) with_8\IN|NONE (l_pobj) disorder_10\NN|NONE
D011433_D016584 NONE propranolol_27\NN|.|dose|were|in (r_advcl) investigated_58\VBN|NONE (l_nsubjpass) dose_37\NN|.|were|propranolol|in (l_prep) on_47\IN|of|)|for|a|median (l_pobj) performance_49\NN|NONE (l_prep) of_50\IN|psychological (l_pobj) patients_51\NNS|NONE (l_prep) with_52\IN|NONE (l_pobj) disorders_54\NNS|NONE
D011433_D000379 NONE propranolol_5\NN|of|Behavioral|.|and (l_prep) in_6\IN|NONE (l_pobj) patients_7\NNS|NONE (l_prep) with_8\IN|NONE (l_pobj) disorder_10\NN|NONE (l_conj) agoraphobia_12\NNP|panic|and
D011433_D000379 NONE propranolol_27\NN|.|dose|were|in (r_advcl) investigated_58\VBN|NONE (l_nsubjpass) dose_37\NN|.|were|propranolol|in (l_prep) on_47\IN|of|)|for|a|median (l_pobj) performance_49\NN|NONE (l_prep) of_50\IN|psychological (l_pobj) patients_51\NNS|NONE (l_prep) with_52\IN|NONE (l_pobj) disorders_54\NNS|NONE (l_conj) agoraphobia_56\NNP|panic|and
9245658
D009538_D050197 CID nicotine_7\NN|,|that|role|could (r_nsubj) play_9\VB|is|studies|but (l_dobj) role_11\NN|nicotine|,|that|could (l_prep) in_12\IN|a (l_pcomp) accelerating_13\VBG|NONE (l_dobj) atherosclerosis_14\NN|NONE
D009538_D002318 CID nicotine_3\NN|NONE (r_pobj) of_2\IN|.|The|in (r_prep) role_1\NN|NONE (l_prep) in_4\IN|of|.|The (l_pobj) disease_9\NN|NONE
D009538_D002318 CID Nicotine_0\NNP|and|system|contribute (r_nsubj) activates_1\VBZ|NONE (l_conj) contribute_11\VB|and|system|Nicotine (l_prep) to_12\IN|in|.|could (l_pobj) disease_14\NN|NONE
D009538_D013927 NONE Nicotine_0\NN|.|does|not|enhance (r_nsubj) appear_3\VB|NONE (l_xcomp) enhance_5\VB|.|does|Nicotine|not (l_dobj) thrombosis_6\NN|to
1628552
D002738_D013575 CID chloroquine_9\NN|regular (r_amod) ingestion_10\NN|NONE (r_pobj) of_7\IN|NONE (r_prep) history_6\NN|NONE (r_pobj) with_5\IN|year|African|old|A (r_prep) woman_4\NN|with|. (r_nsubj) presented_11\VBN|NONE (l_prep) with_12\IN|.|woman (l_pobj) deterioration_14\NN|NONE (l_conj) fatiguability_19\NN|,|of|progressive (l_conj) dyspnoea_21\NN|easy|, (l_conj) dizziness_23\NN|, (l_acl) progressing_24\VBG|NONE (l_prep) to_25\IN|NONE (l_pobj) attacks_27\NNS|NONE
D002738_D004417 CID chloroquine_9\NN|regular (r_amod) ingestion_10\NN|NONE (r_pobj) of_7\IN|NONE (r_prep) history_6\NN|NONE (r_pobj) with_5\IN|year|African|old|A (r_prep) woman_4\NN|with|. (r_nsubj) presented_11\VBN|NONE (l_prep) with_12\IN|.|woman (l_pobj) deterioration_14\NN|NONE (l_conj) fatiguability_19\NN|,|of|progressive (l_conj) dyspnoea_21\NN|easy|,
D002738_D006333 CID chloroquine_5\NN|NONE (r_amod) retinopathy_6\NN|NONE (r_pobj) of_4\IN|NONE (r_prep) features_3\NNS|assessment (r_dobj) revealed_2\VBD|,|.|assessment|features (r_ccomp) revealed_10\VBD|NONE (l_dobj) features_11\NNS|,|.|assessment|revealed (l_prep) of_12\IN|and|block (l_pobj) failure_14\NN|NONE
D002738_D006333 CID chloroquine_15\NN|NONE (r_amod) discontinuation_16\NN|NONE (r_dobj) following_14\VBG|failure|spontaneously|. (r_prep) resolved_12\VBD|by|block|and|was (l_nsubj) failure_11\NN|spontaneously|following|.
D002738_D006327 NONE Chloroquine_0\NNP|:|block (r_nsubj) related_1\VBD|case|. (l_dobj) block_4\NN|Chloroquine|:
D002738_D006327 NONE chloroquine_5\NN|NONE (r_amod) retinopathy_6\NN|NONE (r_pobj) of_4\IN|NONE (r_prep) features_3\NNS|assessment (r_dobj) revealed_2\VBD|,|.|assessment|features (r_ccomp) revealed_10\VBD|NONE (l_dobj) features_11\NNS|,|.|assessment|revealed (l_conj) block_19\NN|of|and
D002738_D006327 NONE chloroquine_15\NN|NONE (r_amod) discontinuation_16\NN|NONE (r_dobj) following_14\VBG|failure|spontaneously|. (r_prep) resolved_12\VBD|by|block|and|was (r_conj) treated_4\VBN|NONE (l_nsubjpass) block_2\NN|resolved|by|and|was
D002738_D015354 NONE chloroquine_9\NN|regular (r_amod) ingestion_10\NN|NONE (r_pobj) of_7\IN|NONE (r_prep) history_6\NN|NONE (r_pobj) with_5\IN|year|African|old|A (r_prep) woman_4\NN|with|. (r_nsubj) presented_11\VBN|NONE (l_prep) with_12\IN|.|woman (l_pobj) deterioration_14\NN|NONE (l_prep) of_15\IN|,|fatiguability|progressive (l_pobj) vision_16\NN|NONE
D002738_D005221 CID chloroquine_9\NN|regular (r_amod) ingestion_10\NN|NONE (r_pobj) of_7\IN|NONE (r_prep) history_6\NN|NONE (r_pobj) with_5\IN|year|African|old|A (r_prep) woman_4\NN|with|. (r_nsubj) presented_11\VBN|NONE (l_prep) with_12\IN|.|woman (l_pobj) deterioration_14\NN|NONE (l_conj) fatiguability_19\NN|,|of|progressive
D002738_D004244 CID chloroquine_9\NN|regular (r_amod) ingestion_10\NN|NONE (r_pobj) of_7\IN|NONE (r_prep) history_6\NN|NONE (r_pobj) with_5\IN|year|African|old|A (r_prep) woman_4\NN|with|. (r_nsubj) presented_11\VBN|NONE (l_prep) with_12\IN|.|woman (l_pobj) deterioration_14\NN|NONE (l_conj) fatiguability_19\NN|,|of|progressive (l_conj) dyspnoea_21\NN|easy|, (l_conj) dizziness_23\NN|,
D002738_D002037 CID chloroquine_5\NN|NONE (r_amod) retinopathy_6\NN|NONE (r_pobj) of_4\IN|NONE (r_prep) features_3\NNS|assessment (r_dobj) revealed_2\VBD|,|.|assessment|features (r_ccomp) revealed_10\VBD|NONE (l_dobj) features_11\NNS|,|.|assessment|revealed (l_conj) block_19\NN|of|and (l_prep) with_20\IN|complete|a|heart (l_pobj) pattern_25\NN|NONE (l_compound) block_24\NN|right|bundle
D002738_D001766 CID Chloroquine_0\NNP|:|block (r_nsubj) related_1\VBD|case|. (l_dobj) block_4\NN|Chloroquine|: (l_prep) with_5\IN|complete|heart (l_pobj) blindness_6\NN|NONE
D002738_D012164 CID chloroquine_5\NN|NONE (r_amod) retinopathy_6\NN|NONE
16844102
D010100_D020258 NONE oxygen_19\NN|reactive (r_compound) species_20\NNS|NONE (r_pobj) of_17\IN|DFO|and|a|, (r_prep) scavenger_16\NN|,||chelator|TC|(|alpha|,|)|, (r_appos) tocopherol_8\NN|NONE (r_pobj) of_5\IN|on|the (r_prep) effect_4\NN|.|study (l_prep) on_32\IN|the|of (l_pobj) neurotoxicity_37\NN|NONE
D008694_D020258 NONE methamphetamine_8\NN| (r_npadvmod) induced_10\VBN|NONE (r_amod) neurotoxicity_11\NN|NONE
D008694_D020258 NONE Methamphetamine_0\NN|is|.|associated (l_appos) neurotoxicity_4\NN|NONE
D008694_D020258 NONE MA)-induced_2\VBN|dopaminergic (r_amod) neurotoxicity_4\NN|NONE
D008694_D020258 NONE MA_34\NNP| (r_npadvmod) induced_36\VBN|the (r_amod) neurotoxicity_37\NN|NONE
D024502_D009422 NONE TC_5\NNP|that|damage|by (r_nsubj) ameliorate_8\VB|This|. (l_dobj) damage_14\NN|that|TC|by
D008694_D005334 CID MA_7\NNP| (r_npadvmod) induced_9\VBN|the (r_amod) hyperthermia_10\NN|.|alterations|as|TC
D007501_D020258 NONE iron_29\NN|an (r_compound) chelator_30\NN|scavenger|,||TC|(|alpha|,|)|, (r_appos) tocopherol_8\NN|NONE (r_pobj) of_5\IN|on|the (r_prep) effect_4\NN|.|study (l_prep) on_32\IN|the|of (l_pobj) neurotoxicity_37\NN|NONE
D008694_D009422 CID MA_10\NNP| (r_npadvmod) induced_12\VBN|neuronal|the (r_amod) damage_14\NN|that|TC|by
D003676_D005334 NONE DFO_4\NNP||alpha|and (r_conj) TC_2\NNP|hyperthermia|.|alterations|as (r_nsubj) attenuated_5\VBD|NONE (l_dobj) hyperthermia_10\NN|.|alterations|as|TC
D003676_D020258 NONE deferoxamine_6\NN|alpha||and (l_prep) on_7\IN|NONE (l_pobj) neurotoxicity_11\NN|NONE
D003676_D020258 NONE deferoxamine_23\NN|(|) (r_nmod) DFO_25\NNP|of|and|a|, (r_conj) scavenger_16\NN|,||chelator|TC|(|alpha|,|)|, (r_appos) tocopherol_8\NN|NONE (r_pobj) of_5\IN|on|the (r_prep) effect_4\NN|.|study (l_prep) on_32\IN|the|of (l_pobj) neurotoxicity_37\NN|NONE
D003676_D020258 NONE DFO_25\NNP|of|and|a|, (r_conj) scavenger_16\NN|,||chelator|TC|(|alpha|,|)|, (r_appos) tocopherol_8\NN|NONE (r_pobj) of_5\IN|on|the (r_prep) effect_4\NN|.|study (l_prep) on_32\IN|the|of (l_pobj) neurotoxicity_37\NN|NONE
D024502_D005334 NONE TC_2\NNP|hyperthermia|.|alterations|as (r_nsubj) attenuated_5\VBD|NONE (l_dobj) hyperthermia_10\NN|.|alterations|as|TC
D024502_D020258 NONE tocopherol_4\NN|NONE (l_conj) deferoxamine_6\NN|alpha||and (l_prep) on_7\IN|NONE (l_pobj) neurotoxicity_11\NN|NONE
D024502_D020258 NONE tocopherol_8\NN|NONE (r_pobj) of_5\IN|on|the (r_prep) effect_4\NN|.|study (l_prep) on_32\IN|the|of (l_pobj) neurotoxicity_37\NN|NONE
D024502_D020258 NONE TC_12\NNP|scavenger|,||chelator|(|alpha|,|)|, (r_appos) tocopherol_8\NN|NONE (r_pobj) of_5\IN|on|the (r_prep) effect_4\NN|.|study (l_prep) on_32\IN|the|of (l_pobj) neurotoxicity_37\NN|NONE
D003676_D009422 NONE DFO_7\NNP||and|alpha (r_conj) TC_5\NNP|that|damage|by (r_nsubj) ameliorate_8\VB|This|. (l_dobj) damage_14\NN|that|TC|by
12584269
D020123_D005355 NONE SRL_3\NNP|FK (r_compound) combination_4\NN|.|compared|degree (r_nsubj) showed_5\VBD|NONE (l_dobj) degree_10\NN|.|combination|compared (l_prep) of_11\IN|a|only|higher (l_pobj) fibrosis_12\NN|NONE
D016559_D007674 CID FK506_14\NNP|better|was|whereas (r_nsubjpass) tolerated_19\VBN|effect|.|,|study (r_advcl) demonstrated_3\VBD|NONE (l_dobj) effect_7\NN|.|,|study|tolerated (l_amod) nephrotoxic_6\JJ|a|synergistic|of
D020123_D007674 CID SRL_5\NN|,|is|.|act (r_nsubj) seems_6\VBZ|but|These|nephrotoxic|, (r_conj) are_1\VBP|NONE (l_acomp) nephrotoxic_2\JJ|but|These|seems|,
D020123_D007674 CID SRL_5\NN|,|is|.|act (r_nsubj) seems_6\VBZ|but|These|nephrotoxic|, (l_xcomp) act_8\VB|,|is|.|SRL (l_advcl) displaying_10\VBG|differently|to (l_dobj) effects_14\NNS|NONE (l_amod) nephrotoxic_13\JJ|only|minor
D020123_D007674 CID SRL_7\NN|with|was|where (r_nsubjpass) combined_9\VBN|treatment (l_prep) with_10\IN|was|where|SRL (l_pobj) indications_14\NNS|NONE (l_prep) of_15\IN|inhibitor|calcineurin|a (l_pobj) effect_19\NN|NONE (l_amod) nephrotoxic_18\JJ|synergistic|a
D020123_D007674 CID SRL_11\NNP|plus (r_conj) CsA_9\NNP|NONE (r_pobj) of_8\IN|a|nephrotoxic|synergistic (r_prep) effect_7\NN|.|,|study|tolerated (l_amod) nephrotoxic_6\JJ|a|synergistic|of
D020123_D007674 CID SRL_16\NNP|plus (r_conj) FK506_14\NNP|better|was|whereas (r_nsubjpass) tolerated_19\VBN|effect|.|,|study (r_advcl) demonstrated_3\VBD|NONE (l_dobj) effect_7\NN|.|,|study|tolerated (l_amod) nephrotoxic_6\JJ|a|synergistic|of
D016572_D007674 CID CsA_9\NNP|NONE (r_pobj) of_8\IN|a|nephrotoxic|synergistic (r_prep) effect_7\NN|.|,|study|tolerated (l_amod) nephrotoxic_6\JJ|a|synergistic|of
D016559_D005355 NONE FK506_1\NNP|SRL (r_nmod) combination_4\NN|.|compared|degree (r_nsubj) showed_5\VBD|NONE (l_dobj) degree_10\NN|.|combination|compared (l_prep) of_11\IN|a|only|higher (l_pobj) fibrosis_12\NN|NONE
21029050
D013390_D001049 CID succinylcholine_9\NN|NONE (r_pobj) after_8\IN|.|gene|in (r_prep) mutations_2\NNS|NONE (l_prep) in_3\IN|.|gene|after (l_pobj) patients_4\NNS|NONE (l_prep) with_5\IN|NONE (l_pobj) apnea_7\NN|NONE
D013390_D001049 CID succinylcholine_11\NN|NONE (r_pobj) of_10\IN|NONE (r_prep) action_9\NN|NONE (r_pobj) of_8\IN|prolonged|a (r_prep) duration_7\NN|NONE (r_pobj) with_4\IN| (r_prep) patients_3\NNS|NONE (r_pobj) of_1\IN|NONE (r_prep) eleven_0\CD|.|mutations|,|indicating (r_nsubj) had_12\VBD|NONE (l_advcl) indicating_17\VBG|.|eleven|mutations|, (l_ccomp) is_20\VBZ|NONE (l_attr) reason_23\NN|that|this (l_prep) for_24\IN|possible|the (l_pobj) period_27\NN|NONE (l_prep) of_28\IN|prolonged|a (l_pobj) apnea_29\NN|NONE
2425813
D011239_D006529 CID prednisolone_14\NN|NONE (r_pobj) of_13\IN|the|subcutaneous (r_prep) administration_12\NN|NONE (r_pobj) following_9\VBG|enlargement|in|. (r_prep) occurred_5\VBD|NONE (l_nsubj) enlargement_1\NN|in|.|following
D011239_D009133 CID prednisolone_14\NN|NONE (r_pobj) of_13\IN|the|subcutaneous (r_prep) administration_12\NN|NONE (r_pobj) following_9\VBG|enlargement|in|. (r_prep) occurred_5\VBD|NONE (l_nsubj) enlargement_1\NN|in|.|following (l_conj) wastage_4\NN|Liver|and
3031535
D006220_D002375 CID haloperidol_28\NN|NONE (r_pobj) by_27\IN|NONE (r_agent) induced_26\VBN|important|in|neurons|whereas (r_advcl) are_22\VBP|,|role|neurons|that (r_advcl) have_6\VBP|.|results (l_dobj) role_9\NN|,|neurons|are|that (l_prep) in_10\IN|an|important (l_pobj) manifestation_12\NN|NONE (l_prep) of_13\IN|induced|the (l_pobj) catalepsy_14\NN|NONE
D006220_D002375 CID haloperidol_28\NN|NONE (r_pobj) by_27\IN|NONE (r_agent) induced_26\VBN|important|in|neurons|whereas (r_advcl) are_22\VBP|,|role|neurons|that (l_prep) in_24\IN|important|neurons|whereas|induced (l_pobj) catalepsy_25\NN|NONE
D013759_D002375 CID 9-tetrahydrocannabinol_7\NN|NONE (r_pobj) by_5\IN|.|involvement (r_agent) induced_4\VBN|NONE (l_nsubj) involvement_1\NN|.|by (l_prep) in_2\IN|Noradrenergic (l_pobj) catalepsy_3\NN|NONE
D013759_D002375 CID THC_17\NNP|NONE (r_pobj) by_16\IN|NONE (r_agent) induced_15\VBN|of|the (r_acl) manifestation_12\NN|NONE (l_prep) of_13\IN|induced|the (l_pobj) catalepsy_14\NN|NONE
D013759_D002375 CID THC_17\NNP|NONE (r_pobj) by_16\IN|NONE (r_agent) induced_15\VBN|of|the (r_acl) manifestation_12\NN|NONE (r_pobj) in_10\IN|an|important (r_prep) role_9\NN|,|neurons|are|that (r_dobj) have_6\VBP|.|results (l_advcl) are_22\VBP|,|role|neurons|that (l_prep) in_24\IN|important|neurons|whereas|induced (l_pobj) catalepsy_25\NN|NONE
10840460
D003520_D059265 NONE Cyclophosphamide_0\NNP| (r_npadvmod) induced_2\VBN|in|.|approach|: (r_amod) cystitis_3\NN|NONE (l_appos) approach_12\NN|in|induced|.|: (l_prep) to_13\IN|behavioral (l_pobj) model_16\NN|NONE (l_prep) of_17\IN|a|new (l_pobj) pain_19\NN|NONE
D003520_D059265 NONE CP_10\NNP| (r_npadvmod) induced_12\VBN|NONE (r_amod) cystitis_13\NN|NONE (r_pobj) of_9\IN|experimental|this (r_prep) model_8\NN|model|may|,|that|allowing (r_nsubj) be_15\VB|Overall|results|.|, (l_attr) model_20\NN|model|may|,|that|allowing (l_prep) of_21\IN|interesting|an|new|behavioral (l_pobj) pain_24\NN|NONE
D000171_D003556 NONE acrolein_22\NN|NONE (r_pobj) through_17\IN|effects|to (r_prep) produce_10\VB|NONE (r_xcomp) known_8\VBN|an|antitumoral (r_acl) agent_7\NN|,|CP|, (r_appos) Cyclophosphamide_0\NNP|induce|.|was (r_nsubjpass) used_25\VBN|NONE (l_xcomp) induce_27\VB|Cyclophosphamide|.|was (l_dobj) cystitis_28\NN|to
D009020_D004487 NONE morphine_6\NN|NONE (r_pobj) of_5\IN|modifications|, (r_prep) administration_4\NN|NONE (l_appos) modifications_9\NNS|of|, (l_prep) as_16\IN|,|of|histological (l_pobj) edema_21\NN|such
D003520_D010146 CID CP_10\NNP| (r_npadvmod) induced_12\VBN|NONE (r_amod) cystitis_13\NN|NONE (r_pobj) of_9\IN|experimental|this (r_prep) model_8\NN|model|may|,|that|allowing (r_nsubj) be_15\VB|Overall|results|.|, (l_advcl) allowing_26\VBG|model|model|may|,|that (l_dobj) understanding_29\NN|NONE (l_prep) of_30\IN|better|and|a|approach (l_pobj) syndromes_33\NNS|NONE
D009020_D001523 NONE Morphine_0\NNP|.|disorders|dependently (r_nsubj) reversed_4\VBD|NONE (l_dobj) disorders_7\NNS|.|Morphine|dependently
D003520_D003556 CID Cyclophosphamide_0\NNP| (r_npadvmod) induced_2\VBN|in|.|approach|: (r_amod) cystitis_3\NN|NONE
D003520_D003556 CID Cyclophosphamide_0\NNP|induce|.|was (r_nsubjpass) used_25\VBN|NONE (l_xcomp) induce_27\VB|Cyclophosphamide|.|was (l_dobj) cystitis_28\NN|to
D003520_D003556 CID CP_2\NNP|,|,|agent (r_appos) Cyclophosphamide_0\NNP|induce|.|was (r_nsubjpass) used_25\VBN|NONE (l_xcomp) induce_27\VB|Cyclophosphamide|.|was (l_dobj) cystitis_28\NN|to
D003520_D003556 CID CP_10\NNP| (r_npadvmod) induced_12\VBN|NONE (r_amod) cystitis_13\NN|NONE
20667451
D010634_D003072 CID phenobarbitone_8\NN|NONE (r_pobj) in_7\IN|oxidative (r_prep) damage_6\NN|and|cognitive|administered (r_conj) dysfunction_3\NN|Curcumin|.
D010634_D003072 CID phenobarbitone_4\NN|The|,|antiepileptic (r_conj) drugs_2\NNS|known|. (r_nsubj) are_7\VBP|NONE (l_acomp) known_9\JJ|drugs|. (l_xcomp) cause_11\VB|well (l_dobj) impairment_13\NN|to
D010634_D003072 CID phenobarbitone-_17\JJ|and|cognitive|stress (r_nmod) impairment_23\NN|NONE
D010634_D003072 CID phenobarbitone_3\NN|NONE (r_pobj) of_2\IN|for|The (r_prep) administration_1\NN|.|impairment (r_nsubj) caused_8\VBD|NONE (l_dobj) impairment_11\NN|.|administration (l_prep) of_12\IN|significant|a (l_pobj) learning_13\NN|stress (l_conj) memory_15\NN|as|and
D010634_D003072 CID phenobarbitone_22\NN|NONE (r_pobj) with_21\IN|without (r_prep) treated_20\VBN|NONE (r_acl) rats_19\NNS|NONE (r_pobj) in_18\IN|oxidative (r_prep) damage_17\NN|cognitive|and (r_conj) functions_14\NNS|NONE
D010634_D003072 CID phenobarbitone_16\NN|can|be|as|curcumin|that (l_prep) in_20\IN|therapy|to|and (l_pcomp) preventing_21\VBG|NONE (l_dobj) impairment_23\NN|NONE
D003474_D003072 NONE Curcumin_0\NN|dysfunction|. (r_nsubj) ameliorates_1\VBZ|NONE (l_dobj) dysfunction_3\NN|Curcumin|.
D003474_D003072 NONE curcumin_14\NN|chronic (r_compound) administration_15\NN|NONE (r_pobj) of_12\IN|the|on (r_prep) effect_11\NN|to (l_prep) on_16\IN|the|of (l_pobj) impairment_23\NN|NONE
D003474_D003072 NONE curcumin_1\NN|Concomitant (r_compound) administration_2\NN|and|impairment|.|decreased (r_nsubj) prevented_3\VBD|NONE (l_dobj) impairment_6\NN|administration|and|.|decreased
D003474_D003072 NONE curcumin_4\NN|effect|that (r_nsubj) has_5\VBZ|.|results (l_dobj) effect_7\NN|curcumin|that (l_prep) in_8\IN|beneficial (l_pcomp) mitigating_9\VBG|NONE (l_dobj) deterioration_11\NN|NONE (l_prep) of_12\IN|the (l_pobj) functions_14\NNS|NONE
D003474_D003072 NONE curcumin_4\NN|can|phenobarbitone|be|as|that (r_nsubjpass) considered_7\VBN|.|findings (l_advcl) phenobarbitone_16\NN|can|be|as|curcumin|that (l_prep) in_20\IN|therapy|to|and (l_pcomp) preventing_21\VBG|NONE (l_dobj) impairment_23\NN|NONE
D002220_D003072 CID carbamazepine_10\NN|and (r_conj) phenobarbitone_8\NN|NONE (r_pobj) in_7\IN|oxidative (r_prep) damage_6\NN|and|cognitive|administered (r_conj) dysfunction_3\NN|Curcumin|.
D002220_D003072 CID carbamazepine_6\NN|and (r_conj) phenobarbitone_4\NN|The|,|antiepileptic (r_conj) drugs_2\NNS|known|. (r_nsubj) are_7\VBP|NONE (l_acomp) known_9\JJ|drugs|. (l_xcomp) cause_11\VB|well (l_dobj) impairment_13\NN|to
D002220_D003072 CID carbamazepine_19\NN| (r_npadvmod) induced_21\VBN|and (r_conj) phenobarbitone-_17\JJ|and|cognitive|stress (r_nmod) impairment_23\NN|NONE
D002220_D003072 CID carbamazepine_5\NN|and (r_conj) phenobarbitone_3\NN|NONE (r_pobj) of_2\IN|for|The (r_prep) administration_1\NN|.|impairment (r_nsubj) caused_8\VBD|NONE (l_dobj) impairment_11\NN|.|administration (l_prep) of_12\IN|significant|a (l_pobj) learning_13\NN|stress (l_conj) memory_15\NN|as|and
D002220_D003072 CID carbamazepine_24\NN|and (r_conj) phenobarbitone_22\NN|NONE (r_pobj) with_21\IN|without (r_prep) treated_20\VBN|NONE (r_acl) rats_19\NNS|NONE (r_pobj) in_18\IN|oxidative (r_prep) damage_17\NN|cognitive|and (r_conj) functions_14\NNS|NONE
D002220_D003072 CID carbamazepine_18\NN|NONE (r_compound) therapy_19\NN|in|to|and (r_conj) phenobarbitone_16\NN|can|be|as|curcumin|that (l_prep) in_20\IN|therapy|to|and (l_pcomp) preventing_21\VBG|NONE (l_dobj) impairment_23\NN|NONE
17574447
D010634_D002761 CID phenobarbital_8\JJ|term|:|report (r_amod) therapy_9\NN|NONE (r_pobj) to_4\IN|NONE (r_prep) related_3\VBN|cholangitis|and|. (r_acl) Hepatonecrosis_0\NNP|NONE (l_conj) cholangitis_2\NN|and|.|related
D010634_D056487 NONE PB_15\NNP| (r_npadvmod) related_17\VBN|asymptomatic|chronic|enzyme (r_amod) dysfunction_22\NN|NONE
D010634_D004827 NONE PB_15\NNP|NONE (r_pobj) with_14\IN|NONE (r_prep) treated_13\VBN|of|a|long (r_acl) history_10\NN|NONE (l_prep) of_11\IN|a|treated|long (l_pobj) epilepsy_12\NN|NONE
D010634_D001996 NONE PB_15\NNP|NONE (r_pobj) with_14\IN|NONE (r_prep) treated_13\VBN|of|a|long (r_acl) history_10\NN|NONE (r_pobj) with_7\IN|.|of|Here|we|one|: (r_prep) report_2\VBP|NONE (l_appos) one_20\CD|.|with|of|Here|we|: (l_appos) other_28\JJ|as|, (l_prep) of_29\IN|the (l_pobj) bronchopneumonia_31\NN|NONE
D010634_D006323 NONE PB_15\NNP|NONE (r_pobj) with_14\IN|NONE (r_prep) treated_13\VBN|of|a|long (r_acl) history_10\NN|NONE (r_pobj) with_7\IN|.|of|Here|we|one|: (r_prep) report_2\VBP|NONE (l_appos) one_20\CD|.|with|of|Here|we|: (l_prep) as_21\IN|other|, (l_pobj) consequence_22\NN|NONE (l_prep) of_23\IN|NONE (l_pobj) arrest_25\NN|NONE
D010634_-1 NONE phenobarbital_8\JJ|term|:|report (r_amod) therapy_9\NN|NONE (r_pobj) to_4\IN|NONE (r_prep) related_3\VBN|cholangitis|and|. (r_acl) Hepatonecrosis_0\NNP|NONE
D010634_D008107 CID Phenobarbital_0\NNP|,|and|reputation|believed (r_nsubj) has_4\VBZ|NONE (l_conj) believed_14\VBN|,|Phenobarbital|and|reputation (l_ccomp) indicate_26\VB|it|commonly|is|. (l_conj) predict_28\VB|not|or|do|increases|that (l_dobj) development_30\NN|NONE (l_prep) of_31\IN|the (l_pobj) disease_35\NN|NONE
D010634_D008107 CID PB_2\NNP|(|) (r_appos) Phenobarbital_0\NNP|,|and|reputation|believed (r_nsubj) has_4\VBZ|NONE (l_conj) believed_14\VBN|,|Phenobarbital|and|reputation (l_ccomp) indicate_26\VB|it|commonly|is|. (l_conj) predict_28\VB|not|or|do|increases|that (l_dobj) development_30\NN|NONE (l_prep) of_31\IN|the (l_pobj) disease_35\NN|NONE
D010634_D008107 CID PB_16\NNP| (r_npadvmod) related_18\VBN|in (r_amod) increases_19\NNS|not|predict|or|do|that (r_nsubj) indicate_26\VB|it|commonly|is|. (l_conj) predict_28\VB|not|or|do|increases|that (l_dobj) development_30\NN|NONE (l_prep) of_31\IN|the (l_pobj) disease_35\NN|NONE
D010634_D008107 CID PB_4\NNP|that|may|with|be (r_nsubjpass) associated_7\VBN|.|findings (l_prep) with_8\IN|that|PB|may|be (l_pobj) damage_11\NN|NONE
16274958
D017255_D055154 CID acitretin_3\NN|Recurrent|and|. (r_conj) dysphonia_1\NN|NONE
D017255_D055154 CID acitretin_15\NN|NONE (r_pobj) by_14\IN|she|was|while (r_agent) treated_13\VBN|We|case|. (r_advcl) report_1\VBP|NONE (l_dobj) case_3\NN|We|treated|. (l_prep) of_4\IN|the (l_pobj) woman_6\NN|NONE (l_acl) complaining_7\VBG|a (l_prep) of_8\IN|NONE (l_pobj) dysphonia_9\NN|NONE
D017255_D055154 CID acitretin_10\NN| (r_advmod) induced_12\VBN|NONE (r_amod) dysphonia_13\NN|NONE
18503483
D016559_D020968 CID tacrolimus_2\NN| (r_npadvmod) associated_4\VBN|brachial (r_amod) neuritis_6\NN|NONE
C107135_D020968 NONE everolimus_10\NN|NONE (r_pobj) to_9\TO|in (r_prep) conversion_8\NN|NONE (r_pobj) after_7\IN|.|of|report| (r_prep) Recovery_0\NN|NONE (l_prep) of_1\IN|.|report|after| (l_pobj) neuritis_6\NN|NONE
10523326
D010100_D006973 NONE oxygen_5\NN|reactive|(|elevated|)|,|ROS (r_compound) species_6\NNS|.|We|,|recently|increased|and|excretion (r_dobj) showed_2\VBD|NONE (l_conj) increased_22\VBD|.|We|,|recently|species|and|excretion (l_dobj) sequestration_24\NN|NONE (l_prep) as_25\IN|NO (l_pobj) nitrotyrosine_26\JJ|NONE (l_prep) in_27\IN|NONE (l_pobj) tissues_29\NNS|NONE (l_prep) in_30\IN|various (l_pobj) rats_31\NNS|NONE (l_prep) with_32\IN|NONE (l_pobj) hypertension_36\NN|NONE
C002744_D006973 NONE nitrotyrosine_26\JJ|NONE (l_prep) in_27\IN|NONE (l_pobj) tissues_29\NNS|NONE (l_prep) in_30\IN|various (l_pobj) rats_31\NNS|NONE (l_prep) with_32\IN|NONE (l_pobj) hypertension_36\NN|NONE
D009569_D006973 NONE oxide_1\NN|NONE (r_compound) synthase_2\NN|.|Nitric|in (r_compound) expression_3\NN|NONE (l_prep) in_4\IN|.|Nitric|synthase (l_pobj) course_6\NN|NONE (l_prep) of_7\IN|the (l_pobj) hypertension_11\NN|NONE
D009569_D006973 NONE NO_15\DT|NOx|(|) (r_det) metabolites_16\NNS|NONE (r_pobj) of_14\IN|urinary|reduced (r_prep) excretion_13\NN|.|We|,|recently|species|increased|and (r_dobj) showed_2\VBD|NONE (l_conj) increased_22\VBD|.|We|,|recently|species|and|excretion (l_dobj) sequestration_24\NN|NONE (l_prep) as_25\IN|NO (l_pobj) nitrotyrosine_26\JJ|NONE (l_prep) in_27\IN|NONE (l_pobj) tissues_29\NNS|NONE (l_prep) in_30\IN|various (l_pobj) rats_31\NNS|NONE (l_prep) with_32\IN|NONE (l_pobj) hypertension_36\NN|NONE
D009569_D006973 NONE NO_23\DT|as (r_det) sequestration_24\NN|NONE (l_prep) as_25\IN|NO (l_pobj) nitrotyrosine_26\JJ|NONE (l_prep) in_27\IN|NONE (l_pobj) tissues_29\NNS|NONE (l_prep) in_30\IN|various (l_pobj) rats_31\NNS|NONE (l_prep) with_32\IN|NONE (l_pobj) hypertension_36\NN|NONE
D009569_D006973 NONE NO_25\DT|depressed (r_det) synthase_26\NN|(|NOS|) (r_nmod) expression_30\NN|to (r_pobj) due_22\IN|,|,|in|reduction|whether (r_prep) is_17\VBZ|to (l_nsubj) reduction_8\NN|,|,|due|in|whether (l_prep) in_12\IN|the|in (l_pobj) hypertension_16\NN|NONE
D009569_D006973 NONE NO_11\DT|,|inhibition|mediated (r_compound) inactivation_12\NN|to (l_appos) inhibition_17\NN|,|mediated|NO (l_conj) actions_25\NNS|and|,|of|associated (l_prep) of_26\IN|stimulatory|perhaps (l_pobj) stress_29\NN|NONE (l_acl) associated_30\VBN|shear|increased (l_prep) with_31\IN|NONE (l_pobj) hypertension_32\NN|NONE
D007854_D006973 CID lead_8\NN| (r_npadvmod) induced_10\VBN|NONE (r_amod) hypertension_11\NN|NONE
D007854_D006973 CID lead_33\NN| (r_npadvmod) induced_35\VBN|NONE (r_amod) hypertension_36\NN|NONE
D007854_D006973 CID lead_13\NN| (r_npadvmod) induced_15\VBN|NONE (r_amod) hypertension_16\NN|NONE
D007854_D006973 CID lead_3\NN| (r_npadvmod) induced_5\VBN|in (r_amod) hypertension_6\NN|with|,|.|was|In
D007854_D006973 CID lead_14\NN| (r_npadvmod) associated_16\VBN|and|,|actions|of (r_amod) inhibition_17\NN|,|mediated|NO (l_conj) actions_25\NNS|and|,|of|associated (l_prep) of_26\IN|stimulatory|perhaps (l_pobj) stress_29\NN|NONE (l_acl) associated_30\VBN|shear|increased (l_prep) with_31\IN|NONE (l_pobj) hypertension_32\NN|NONE
D008315_D006973 NONE MDA_8\NNP|plasma (r_compound) concentration_9\NN|,|eNOS|raised|and (r_dobj) lowered_6\VBD|,|hypertension|supplementation|. (r_conj) ameliorated_3\VBD|NONE (l_dobj) hypertension_4\NN|lowered|,|supplementation|.
D014810_D006973 NONE E_1\NN|NONE (r_compound) supplementation_2\NN|lowered|,|hypertension|. (r_nsubj) ameliorated_3\VBD|NONE (l_dobj) hypertension_4\NN|lowered|,|supplementation|.
663266
D003973_D014693 NONE diatrizoate_3\JJ|with (r_pobj) from_2\IN|.|Ventricular (r_prep) fibrillation_1\NN|NONE
D003974_D014693 NONE Renografin_7\NNP|NONE (r_pobj) with_6\IN|.|often|,|fibrillation|suggesting (r_prep) occurred_2\VBD|NONE (l_nsubj) fibrillation_1\NN|.|often|,|with|suggesting
D003974_D064420 NONE Renografin_7\NNP|NONE (r_pobj) with_6\IN|.|often|,|fibrillation|suggesting (r_prep) occurred_2\VBD|NONE (l_advcl) suggesting_9\VBG|.|often|,|fibrillation|with (l_ccomp) contribute_13\VBP|NONE (l_prep) to_14\IN|that|in|agents (l_pobj) toxicity_15\NN|NONE
C027278_D064420 NONE %_5\NN|of|The (r_appos) toxicity_1\NN|into|%|with|was|.
C027278_D064420 NONE %_13\NN|into|with|toxicity|was|. (r_npadvmod) compared_7\VBN|NONE (l_nsubjpass) toxicity_1\NN|into|%|with|was|.
12180796
D009569_D009369 NONE oxide_7\NN|NONE (l_appos) factor_15\NN|,|(|iNOS|nitric|) (l_conj) growth_21\NN|and|(|growth|)|basic|bFGF (l_compound) tumor_20\NN|NONE
D009569_D009369 NONE oxide_21\NN|iNOS|nitric|,|(|factor|) (r_compound) synthase_22\NN|NONE (l_appos) factor_30\NN|iNOS|nitric|,|oxide|(|) (l_conj) beta1_39\NNP|bFGF|growth|and|basic|)|( (l_compound) factor_37\NN|(|)|beta (l_compound) tumor_35\NN|growth|
D018818_D009369 NONE fenoldopam_7\NN|examined|Arteritis|in|, (r_npadvmod) induced_1\VBN|NONE (l_conj) examined_12\VBN|fenoldopam|Arteritis|in|, (l_prep) for_14\IN|,|immunohistochemically|was|. (l_pobj) expressions_15\NNS|NONE (l_prep) of_16\IN|NONE (l_pobj) type_18\NN|NONE (l_prep) of_19\IN|inducible (l_pobj) synthase_22\NN|NONE (l_appos) factor_30\NN|iNOS|nitric|,|oxide|(|) (l_conj) beta1_39\NNP|bFGF|growth|and|basic|)|( (l_compound) factor_37\NN|(|)|beta (l_compound) tumor_35\NN|growth|
D018818_D001167 CID fenoldopam_12\NN|NONE (r_pobj) by_11\IN|NONE (r_prep) rats_10\NNS|NONE (r_pobj) in_9\IN|.|,|beta|vasodilators (r_prep) induced_8\VBN|NONE (l_nsubj) beta1_0\NNP|in|.|,|vasodilators (l_prep) in_6\IN|(|)|beta (l_pobj) arteritis_7\NN|NONE
D018818_D001167 CID fenoldopam_7\NN|examined|Arteritis|in|, (r_npadvmod) induced_1\VBN|NONE (l_nsubj) Arteritis_0\NNP|examined|fenoldopam|in|,
D013806_D001167 CID theophylline_14\NN|and (r_conj) fenoldopam_12\NN|NONE (r_pobj) by_11\IN|NONE (r_prep) rats_10\NNS|NONE (r_pobj) in_9\IN|.|,|beta|vasodilators (r_prep) induced_8\VBN|NONE (l_nsubj) beta1_0\NNP|in|.|,|vasodilators (l_prep) in_6\IN|(|)|beta (l_pobj) arteritis_7\NN|NONE
D013806_D001167 CID theophylline_9\NN|and (r_conj) fenoldopam_7\NN|examined|Arteritis|in|, (r_npadvmod) induced_1\VBN|NONE (l_nsubj) Arteritis_0\NNP|examined|fenoldopam|in|,
D009569_D001167 NONE oxide_21\NN|iNOS|nitric|,|(|factor|) (r_compound) synthase_22\NN|NONE (r_pobj) of_19\IN|inducible (r_prep) type_18\NN|NONE (r_pobj) of_16\IN|NONE (r_prep) expressions_15\NNS|NONE (r_pobj) for_14\IN|,|immunohistochemically|was|. (r_prep) examined_12\VBN|fenoldopam|Arteritis|in|, (r_conj) induced_1\VBN|NONE (l_nsubj) Arteritis_0\NNP|examined|fenoldopam|in|,
D013806_D009369 NONE theophylline_9\NN|and (r_conj) fenoldopam_7\NN|examined|Arteritis|in|, (r_npadvmod) induced_1\VBN|NONE (l_conj) examined_12\VBN|fenoldopam|Arteritis|in|, (l_prep) for_14\IN|,|immunohistochemically|was|. (l_pobj) expressions_15\NNS|NONE (l_prep) of_16\IN|NONE (l_pobj) type_18\NN|NONE (l_prep) of_19\IN|inducible (l_pobj) synthase_22\NN|NONE (l_appos) factor_30\NN|iNOS|nitric|,|oxide|(|) (l_conj) beta1_39\NNP|bFGF|growth|and|basic|)|( (l_compound) factor_37\NN|(|)|beta (l_compound) tumor_35\NN|growth|
19944736
D013619_D001930 CID Tacrine_0\NNP|seizures|.|and|delayed (r_nsubj) induces_10\VBZ|NONE (l_conj) delayed_14\VBD|seizures|Tacrine|.|and (l_dobj) damage_16\NN|NONE
D013619_D001930 CID tacrine_3\NN| (r_npadvmod) loaded_5\VBN|nanoparticles (r_amod) administration_7\NN|In|.|,|solution|damage|, (r_nsubj) induced_8\VBD|NONE (l_dobj) damage_9\NN|In|.|,|solution|administration|, (l_prep) of_10\IN|in (l_pobj) cells_12\NNS|NONE
D013619_D001930 CID tacrine_29\NN|NONE (r_pobj) of_28\IN|%|the|while|saline (r_prep) solution_27\NN|In|.|,|administration|damage|, (r_advcl) induced_8\VBD|NONE (l_dobj) damage_9\NN|In|.|,|solution|administration|, (l_prep) of_10\IN|in (l_pobj) cells_12\NNS|NONE
D013619_D004827 NONE tacrine_5\NN| (r_npadvmod) loaded_7\VBN|NONE (r_amod) nanoparticles_8\NNS|NONE (r_pobj) with_4\IN|animals (r_prep) treated_3\VBN|outcome|. (r_csubj) showed_9\VBD|NONE (l_dobj) outcome_12\NN|.|treated (l_prep) of_13\IN|an|earlier|with (l_pobj) symptoms_16\NNS|NONE (l_appos) onset_20\NN|CNS|adverse|,|, (l_amod) epileptic_19\JJ|i.e.
D013619_D004827 NONE tacrine_22\NN| (r_compound) lithium_24\NN|in|the|of (r_compound) model_25\NN|NONE (l_prep) of_26\IN|in|lithium|the (l_pobj) epilepsy_27\NN|NONE
D018021_D012640 CID LiCl_4\NNP|NONE (r_pobj) in_3\IN|NONE (r_prep) administered_2\VBN|rats|,|, (r_acl) Tacrine_0\NNP|seizures|.|and|delayed (r_nsubj) induces_10\VBZ|NONE (l_dobj) seizures_12\NNS|Tacrine|.|and|delayed
D008094_D004827 NONE lithium_24\NN|in|the|of (r_compound) model_25\NN|NONE (l_prep) of_26\IN|in|lithium|the (l_pobj) epilepsy_27\NN|NONE
D013619_D012640 CID Tacrine_0\NNP|seizures|.|and|delayed (r_nsubj) induces_10\VBZ|NONE (l_dobj) seizures_12\NNS|Tacrine|.|and|delayed
D018021_D001930 CID LiCl_4\NNP|NONE (r_pobj) in_3\IN|NONE (r_prep) administered_2\VBN|rats|,|, (r_acl) Tacrine_0\NNP|seizures|.|and|delayed (r_nsubj) induces_10\VBZ|NONE (l_conj) delayed_14\VBD|seizures|Tacrine|.|and (l_dobj) damage_16\NN|NONE
4069770
D005839_D058186 CID gentamicin_18\NN|NONE (r_pobj) with_17\IN|penicillin|day|and (r_prep) therapy_16\NN|NONE (r_pobj) after_15\IN|who|of (r_prep) died_10\VBD|a|premature (l_prep) of_11\IN|who|after (l_pobj) failure_14\NN|NONE
D010406_D058186 NONE penicillin_28\NN|day|with|and (r_conj) therapy_16\NN|NONE (r_pobj) after_15\IN|who|of (r_prep) died_10\VBD|a|premature (l_prep) of_11\IN|who|after (l_pobj) failure_14\NN|NONE
D005839_D001002 NONE gentamicin_2\NN|serum|The (r_compound) concentration_3\NN|.|had|levels|developed (r_nsubj) reached_5\VBN|NONE (l_advcl) developed_10\VBD|.|had|levels|concentration (l_nsubj) anuria_9\NN|when
D005839_D007674 NONE Gentamicin_0\NNP|.|in (r_amod) nephropathy_1\NN|NONE
12852481
D001241_D005767 NONE ASA_20\NNP|is|when|on (r_nsubjpass) administered_22\VBN|to|results (r_advcl) compare_7\VB|Objectives|;|. (r_xcomp) were_5\VBD|NONE (l_nsubj) Objectives_0\NNS|compare|;|. (l_acl) compare_33\VB|of (l_conj) test_50\VB|to|;|and|patterns (l_dobj) hypothesis_52\NN|to (l_acl) confounds_57\VBZ|the (l_nsubj) toxicity_56\NN|that|detection|used
D001241_D005767 NONE ASA_65\NNP|NONE (r_pobj) with_64\IN|incidence|low (r_prep) malformations_63\NNS|NONE (r_pobj) of_60\IN|the (r_prep) detection_59\NN|that|toxicity|used (r_dobj) confounds_57\VBZ|the (l_nsubj) toxicity_56\NN|that|detection|used
D001241_D000014 CID Aspirin_0\NNP|,|acid|)|induces|cyclooxygenase|(|,|.| (r_nsubj) acetylsalicylic_2\JJ|NONE (l_conj) induces_17\VBZ|,|Aspirin|acid|)|cyclooxygenase|(|,|.| (l_dobj) anomalies_19\NNS|administered
D001241_D000014 CID acid_3\NN|,|Aspirin|)|induces|cyclooxygenase|(|,|.| (r_npadvmod) acetylsalicylic_2\JJ|NONE (l_conj) induces_17\VBZ|,|Aspirin|acid|)|cyclooxygenase|(|,|.| (l_dobj) anomalies_19\NNS|administered
D001241_D000014 CID ASA_5\NNP|NONE (r_appos) acid_3\NN|,|Aspirin|)|induces|cyclooxygenase|(|,|.| (r_npadvmod) acetylsalicylic_2\JJ|NONE (l_conj) induces_17\VBZ|,|Aspirin|acid|)|cyclooxygenase|(|,|.| (l_dobj) anomalies_19\NNS|administered
D001241_D000014 CID ASA_20\NNP|is|when|on (r_nsubjpass) administered_22\VBN|to|results (r_advcl) compare_7\VB|Objectives|;|. (r_xcomp) were_5\VBD|NONE (l_nsubj) Objectives_0\NNS|compare|;|. (l_acl) compare_33\VB|of (l_conj) test_50\VB|to|;|and|patterns (l_dobj) hypothesis_52\NN|to (l_acl) confounds_57\VBZ|the (l_dobj) detection_59\NN|that|toxicity|used (l_prep) of_60\IN|the (l_pobj) malformations_63\NNS|NONE
D001241_D000014 CID ASA_65\NNP|NONE (r_pobj) with_64\IN|incidence|low (r_prep) malformations_63\NNS|NONE
D001241_D000014 CID ASA_16\NNP|malformations|though|even (r_nsubj) induces_17\VBZ|,|study|)|,|;|.|on|,|hence (r_advcl) focused_9\VBD|NONE (l_prep) on_10\IN|,|induces|study|)|,|;|.|,|hence (l_pobj) malformations_12\NNS|NONE
D001241_D000014 CID ASA_16\NNP|malformations|though|even (r_nsubj) induces_17\VBZ|,|study|)|,|;|.|on|,|hence (l_dobj) malformations_23\NNS|ASA|though|even
D001241_D000014 CID ASA_6\NNP|was|when|as (r_nsubjpass) administered_8\VBN|Variations|.|GDs|similar (r_advcl) were_3\VBD|NONE (l_nsubj) Variations_0\NNS|administered|.|GDs|similar (l_conj) malformations_2\NNS|and
D001241_D000014 CID ASA_38\NNP|NONE (r_pobj) with_37\IN|,|that|,|also|be|malformations|could (r_prep) induced_36\VBN|evident|also|It|. (l_nsubjpass) malformations_17\NNS|,|that|,|also|be|could|with
3950060
D000583_D007674 CID amikacin_10\JJ|NONE (r_dobj) receiving_9\VBG|NONE (r_acl) patients_8\NNS|NONE (r_pobj) in_7\IN|outcome|and (r_prep) nephrotoxicity_3\NN|NONE
D000583_D007674 CID amikacin_6\JJ|NONE (r_pobj) with_5\IN|NONE (r_prep) treated_4\VBN| (r_acl) patients_3\NNS|NONE (r_pobj) from_1\IN|NONE (r_prep) Data_0\NNS|for|.|were (r_nsubjpass) analyzed_8\VBN|NONE (l_prep) for_9\IN|Data|.|were (l_pobj) factors_10\NNS|NONE (l_acl) associated_11\VBN|NONE (l_prep) with_12\IN|NONE (l_pobj) nephrotoxicity_13\NN|NONE
8841157
D000804_D006973 NONE II_5\CD|a|angiotensin|for (r_compound) antagonist_6\NN|,|.|:|study (l_prep) for_7\IN|a|II|angiotensin (l_pobj) treatment_9\NN|NONE (l_prep) of_10\IN|the (l_pobj) hypertension_12\NN|NONE
D017311_D004487 CID amlodipine_13\NN|the (r_compound) group_14\NN|NONE (r_pobj) in_11\IN|higher|,|incidence|%|at|. (r_prep) was_8\VBD|NONE (l_nsubj) incidence_1\NN|in|higher|,|%|at|. (l_prep) of_2\IN|The (l_pobj) edema_7\NN|NONE
D017311_D004487 CID amlodipine_38\NN|NONE (r_pobj) for_35\IN|;|)|%|;|.|% (r_prep) %_34\NN|in|higher|,|incidence|at|. (r_npadvmod) was_8\VBD|NONE (l_nsubj) incidence_1\NN|in|higher|,|%|at|. (l_prep) of_2\IN|The (l_pobj) edema_7\NN|NONE
D017311_D004487 CID amlodipine_47\NN|for||plus (r_conj) %_41\NN|;|)|%|;|.|for (r_conj) %_34\NN|in|higher|,|incidence|at|. (r_npadvmod) was_8\VBD|NONE (l_nsubj) incidence_1\NN|in|higher|,|%|at|. (l_prep) of_2\IN|The (l_pobj) edema_7\NN|NONE
D017311_D004487 CID amlodipine_54\NN|NONE (r_pobj) for_51\IN|. (r_prep) %_50\NN|;|)|;|.|%|for (r_appos) %_34\NN|in|higher|,|incidence|at|. (r_npadvmod) was_8\VBD|NONE (l_nsubj) incidence_1\NN|in|higher|,|%|at|. (l_prep) of_2\IN|The (l_pobj) edema_7\NN|NONE
C081489_D006973 NONE Valsartan_0\NNP|NONE (l_appos) antagonist_6\NN|,|.|:|study (l_prep) for_7\IN|a|II|angiotensin (l_pobj) treatment_9\NN|NONE (l_prep) of_10\IN|the (l_pobj) hypertension_12\NN|NONE
C081489_D006973 NONE valsartan_27\NN|to (r_dobj) receive_24\VB|were|randomly|outpatients|.|in (r_advcl) allocated_14\VBN|NONE (l_nsubjpass) outpatients_6\NNS|receive|were|randomly|.|in (l_prep) with_7\IN|eight|hundred|adult (l_pobj) hypertension_11\NN|NONE
C081489_D006973 NONE valsartan_4\NN|effective|that (r_nsubj) is_5\VBZ|data|. (l_acomp) effective_9\JJ|valsartan|that (l_prep) as_10\IN|as|least (l_pobj) amlodipine_11\NN|NONE (l_prep) in_12\IN|NONE (l_pobj) treatment_14\NN|NONE (l_prep) of_15\IN|the (l_pobj) hypertension_19\NN|NONE
D017311_D006973 NONE amlodipine_23\NN|NONE (r_pobj) against_22\IN|NONE (r_prep) safety_21\NN|and|the (r_conj) efficacy_19\NN|NONE (r_pobj) of_17\IN|a|comparative (r_prep) study_16\NN|antagonist|,|.|: (r_appos) Valsartan_0\NNP|NONE (l_appos) antagonist_6\NN|,|.|:|study (l_prep) for_7\IN|a|II|angiotensin (l_pobj) treatment_9\NN|NONE (l_prep) of_10\IN|the (l_pobj) hypertension_12\NN|NONE
D017311_D006973 NONE amlodipine_31\NN|or||mg (r_conj) valsartan_27\NN|to (r_dobj) receive_24\VB|were|randomly|outpatients|.|in (r_advcl) allocated_14\VBN|NONE (l_nsubjpass) outpatients_6\NNS|receive|were|randomly|.|in (l_prep) with_7\IN|eight|hundred|adult (l_pobj) hypertension_11\NN|NONE
D017311_D006973 NONE amlodipine_11\NN|NONE (l_prep) in_12\IN|NONE (l_pobj) treatment_14\NN|NONE (l_prep) of_15\IN|the (l_pobj) hypertension_19\NN|NONE
C081489_D004487 CID valsartan_31\NN|NONE (r_pobj) for_28\IN|. (r_prep) %_27\NN|;|a|of|( (r_appos) dose_19\NN|particularly (r_pobj) at_17\IN|in|higher|,|incidence|%|. (r_prep) was_8\VBD|NONE (l_nsubj) incidence_1\NN|in|higher|,|%|at|. (l_prep) of_2\IN|The (l_pobj) edema_7\NN|NONE
C081489_D004487 CID valsartan_43\NN|NONE (r_pobj) for_42\IN||amlodipine|plus (r_prep) %_41\NN|;|)|%|;|.|for (r_conj) %_34\NN|in|higher|,|incidence|at|. (r_npadvmod) was_8\VBD|NONE (l_nsubj) incidence_1\NN|in|higher|,|%|at|. (l_prep) of_2\IN|The (l_pobj) edema_7\NN|NONE
11027905
D016202_D009437 NONE aspartate_13\NNP|,|as|)|NMDA|( (r_nmod) antagonists_17\NNS|that|effective|may|, (r_nsubj) be_24\VB|studies|have|. (l_acomp) effective_25\JJ|that|may|antagonists|, (l_prep) in_26\IN|NONE (l_pcomp) improving_27\VBG|NONE (l_dobj) analgesia_29\NN|NONE (l_prep) in_30\IN|opioid (l_pobj) syndromes_33\NNS|NONE (l_prep) as_36\IN|,|difficult|pain (l_pobj) pain_38\NN|such
D016202_D009437 NONE NMDA_15\NNP|aspartate|,|as|)|( (r_nmod) antagonists_17\NNS|that|effective|may|, (r_nsubj) be_24\VB|studies|have|. (l_acomp) effective_25\JJ|that|may|antagonists|, (l_prep) in_26\IN|NONE (l_pcomp) improving_27\VBG|NONE (l_dobj) analgesia_29\NN|NONE (l_prep) in_30\IN|opioid (l_pobj) syndromes_33\NNS|NONE (l_prep) as_36\IN|,|difficult|pain (l_pobj) pain_38\NN|such
D007649_D010146 NONE ketamine_21\NN|such (r_pobj) as_20\IN|aspartate|,|)|NMDA|( (r_prep) antagonists_17\NNS|that|effective|may|, (r_nsubj) be_24\VB|studies|have|. (l_acomp) effective_25\JJ|that|may|antagonists|, (l_prep) in_26\IN|NONE (l_pcomp) improving_27\VBG|NONE (l_dobj) analgesia_29\NN|NONE (l_prep) in_30\IN|opioid (l_pobj) syndromes_33\NNS|NONE (l_compound) pain_32\NN|as|,|difficult
D007649_D010146 NONE ketamine_7\NN|NONE (r_pobj) of_6\IN|(|.|subhypnotic|) (r_prep) doses_5\NNS|NONE (r_pobj) of_3\IN|slow|A (r_prep) bolus_2\NN|.|was|to (r_nsubjpass) given_16\VBN|NONE (l_dative) to_17\IN|.|was|bolus (l_pobj) patients_20\NNS|NONE (l_relcl) was_23\VBD|cancer| (l_nsubj) pain_22\NN|unrelieved|in
D007649_D010146 NONE Ketamine_0\NN|.|intensity|in|significantly (r_nsubj) reduced_8\VBD|NONE (l_dobj) intensity_11\NN|.|Ketamine|in|significantly (l_compound) pain_10\NN|the
D007649_D010146 NONE Ketamine_0\NNP|analgesia|.|can (r_nsubj) improve_2\VB|NONE (l_dobj) analgesia_4\NN|Ketamine|.|can (l_prep) in_5\IN|morphine (l_pobj) syndromes_8\NNS|NONE (l_compound) pain_7\NN|,|difficult|as
D009020_D010146 NONE morphine_4\NN|NONE (r_pobj) to_3\IN|not (r_prep) responsive_2\JJ|NONE (r_amod) Pain_0\NN|problematic|often|.
D009020_D010146 NONE morphine_26\NN|NONE (r_pobj) by_25\IN|NONE (r_prep) unrelieved_24\JJ|in|pain (r_acomp) was_23\VBD|cancer| (l_nsubj) pain_22\NN|unrelieved|in
D009020_D010146 NONE morphine_3\NN|in (r_compound) analgesia_4\NN|Ketamine|.|can (l_prep) in_5\IN|morphine (l_pobj) syndromes_8\NNS|NONE (l_compound) pain_7\NN|,|difficult|as
D009020_D009437 NONE morphine_3\NN|in (r_compound) analgesia_4\NN|Ketamine|.|can (l_prep) in_5\IN|morphine (l_pobj) syndromes_8\NNS|NONE (l_prep) as_11\IN|,|difficult|pain (l_pobj) pain_13\NN|such
D007649_D009437 NONE ketamine_21\NN|such (r_pobj) as_20\IN|aspartate|,|)|NMDA|( (r_prep) antagonists_17\NNS|that|effective|may|, (r_nsubj) be_24\VB|studies|have|. (l_acomp) effective_25\JJ|that|may|antagonists|, (l_prep) in_26\IN|NONE (l_pcomp) improving_27\VBG|NONE (l_dobj) analgesia_29\NN|NONE (l_prep) in_30\IN|opioid (l_pobj) syndromes_33\NNS|NONE (l_prep) as_36\IN|,|difficult|pain (l_pobj) pain_38\NN|such
D007649_D009437 NONE Ketamine_0\NNP|analgesia|.|can (r_nsubj) improve_2\VB|NONE (l_dobj) analgesia_4\NN|Ketamine|.|can (l_prep) in_5\IN|morphine (l_pobj) syndromes_8\NNS|NONE (l_prep) as_11\IN|,|difficult|pain (l_pobj) pain_13\NN|such
D007649_D009369 NONE ketamine_4\NN|NONE (l_prep) in_5\IN|intravenous (l_pobj) patients_7\NNS|NONE (l_compound) cancer_6\NN|on
D007649_D009369 NONE ketamine_7\NN|NONE (r_pobj) of_6\IN|(|.|subhypnotic|) (r_prep) doses_5\NNS|NONE (r_pobj) of_3\IN|slow|A (r_prep) bolus_2\NN|.|was|to (r_nsubjpass) given_16\VBN|NONE (l_dative) to_17\IN|.|was|bolus (l_pobj) patients_20\NNS|NONE (l_compound) cancer_19\NN|was|
D016202_D010146 NONE aspartate_13\NNP|,|as|)|NMDA|( (r_nmod) antagonists_17\NNS|that|effective|may|, (r_nsubj) be_24\VB|studies|have|. (l_acomp) effective_25\JJ|that|may|antagonists|, (l_prep) in_26\IN|NONE (l_pcomp) improving_27\VBG|NONE (l_dobj) analgesia_29\NN|NONE (l_prep) in_30\IN|opioid (l_pobj) syndromes_33\NNS|NONE (l_compound) pain_32\NN|as|,|difficult
D016202_D010146 NONE NMDA_15\NNP|aspartate|,|as|)|( (r_nmod) antagonists_17\NNS|that|effective|may|, (r_nsubj) be_24\VB|studies|have|. (l_acomp) effective_25\JJ|that|may|antagonists|, (l_prep) in_26\IN|NONE (l_pcomp) improving_27\VBG|NONE (l_dobj) analgesia_29\NN|NONE (l_prep) in_30\IN|opioid (l_pobj) syndromes_33\NNS|NONE (l_compound) pain_32\NN|as|,|difficult
D009020_D009369 NONE morphine_9\NN|NONE (r_compound) therapy_10\NN|NONE (r_pobj) on_8\IN|cancer (r_prep) patients_7\NNS|NONE (l_compound) cancer_6\NN|on
D009020_D009369 NONE morphine_26\NN|NONE (r_pobj) by_25\IN|NONE (r_prep) unrelieved_24\JJ|in|pain (r_acomp) was_23\VBD|cancer| (r_relcl) patients_20\NNS|NONE (l_compound) cancer_19\NN|was|
3057041
D002744_D006255 NONE chlorpheniramine_20\NN|, (r_conj) azelastine_18\NN|NONE (r_pobj) of_17\IN|safety (r_prep) trial_16\NN|in|and|,|groups|,|dose (r_conj) efficacy_13\NN|blind|.|, (l_prep) in_24\IN|and|,|groups|,|trial|dose (l_pobj) treatment_26\NN|NONE (l_prep) of_27\IN|the (l_pobj) rhinitis_30\NN|NONE
D002744_D006255 NONE maleate_11\NN|NONE (l_prep) for_14\IN|chlorpheniramine|and|placebo (l_pobj) efficacy_15\NN|NONE (l_prep) in_18\IN|safety|and (l_pobj) treatment_20\NN|NONE (l_prep) of_21\IN|in|the (l_pobj) rhinitis_24\NN|NONE
C020976_D006255 NONE azelastine_18\NN|NONE (r_pobj) of_17\IN|safety (r_prep) trial_16\NN|in|and|,|groups|,|dose (r_conj) efficacy_13\NN|blind|.|, (l_prep) in_24\IN|and|,|groups|,|trial|dose (l_pobj) treatment_26\NN|NONE (l_prep) of_27\IN|the (l_pobj) rhinitis_30\NN|NONE
C020976_D006255 NONE Azelastine_0\NNP|was|with|. (r_nsubjpass) compared_8\VBN|NONE (l_prep) with_9\IN|was|Azelastine|. (l_pobj) maleate_11\NN|NONE (l_prep) for_14\IN|chlorpheniramine|and|placebo (l_pobj) efficacy_15\NN|NONE (l_prep) in_18\IN|safety|and (l_pobj) treatment_20\NN|NONE (l_prep) of_21\IN|in|the (l_pobj) rhinitis_24\NN|NONE
C020976_D006255 NONE Azelastine_0\NNP|be|. (r_nsubj) appears_1\VBZ|NONE (l_xcomp) be_3\VB|Azelastine|. (l_attr) medication_8\NN|to (l_prep) for_9\IN|safe|a|efficacious|, (l_pobj) rhinitis_12\NN|NONE
C020976_D006970 CID azelastine_16\NN|dose|the (r_compound) group_17\NN|only (r_pobj) in_11\IN|over|were|.|Drowsiness|significantly (r_prep) increased_6\VBN|NONE (l_nsubjpass) Drowsiness_0\VB|over|were|.|in|significantly
C020976_D013651 CID azelastine_16\NN|dose|the (r_compound) group_17\NN|only (r_pobj) in_11\IN|over|were|.|Drowsiness|significantly (r_prep) increased_6\VBN|NONE (l_nsubjpass) Drowsiness_0\VB|over|were|.|in|significantly (l_conj) perception_4\NN|and
19300240
D002395_D054549 NONE catecholamines_9\NNS|NONE (r_pobj) of_7\IN|caused|supraphysiologic|both (r_prep) levels_6\NNS|development|,|have|may|.|In (r_nsubj) contributed_24\VBN|NONE (l_dobj) development_26\NN|,|have|may|.|levels|In (l_prep) of_27\IN|the (l_pobj) ABS_28\NN|NONE
D005472_D054549 CID flourouracil_1\NN| (r_npadvmod) induced_3\VBN|report||.|ballooning|: (r_amod) syndrome_6\NN|NONE
D002395_D009369 NONE catecholamines_9\NNS|NONE (r_pobj) of_7\IN|caused|supraphysiologic|both (r_prep) levels_6\NNS|development|,|have|may|.|In (l_acl) caused_14\VBN|supraphysiologic|both|of (l_agent) by_15\IN|NONE (l_pobj) diagnosis_17\NN|NONE (l_compound) cancer_16\NN|as|chemotherapy
D005472_D015179 NONE fluorouracil_5\NN|NONE (r_pobj) with_4\IN|She|for|.|chemotherapy (r_prep) underwent_1\VBD|NONE (l_prep) for_6\IN|She|.|with|chemotherapy (l_pobj) cancer_9\NN|NONE
10743446
D008012_D010146 NONE lidocaine_11\NN|and (r_conj) ketamine_9\NN|NONE (r_pobj) of_8\IN|on|systemic (r_prep) administration_7\NN|NONE (l_prep) on_12\IN|of|systemic (l_pobj) hyperalgesia_27\NN|NONE (l_nmod) pain_19\NN|static|(|evoked|)
D002211_D010146 CID capsaicin_30\NN|NONE (r_pobj) by_29\IN|NONE (r_agent) induced_28\VBN|the|of (r_acl) effect_4\NN|have|.|We (l_prep) of_5\IN|the|induced (l_pobj) administration_7\NN|NONE (l_prep) on_12\IN|of|systemic (l_pobj) hyperalgesia_27\NN|NONE (l_nmod) pain_19\NN|static|(|evoked|)
D007649_D010146 NONE ketamine_9\NN|NONE (r_pobj) of_8\IN|on|systemic (r_prep) administration_7\NN|NONE (l_prep) on_12\IN|of|systemic (l_pobj) hyperalgesia_27\NN|NONE (l_nmod) pain_19\NN|static|(|evoked|)
D007649_D010146 NONE Ketamine_0\NN|significantly|tended|area|and (r_nsubj) reduced_1\VBD|NONE (l_conj) tended_17\VBD|Ketamine|significantly|area|and (l_xcomp) reduce_19\VB|it|. (l_dobj) pain_23\NN|to
D008012_D006930 NONE lidocaine_7\NN|administered|and|on (r_conj) ketamine_5\NN|NONE (l_prep) on_8\IN|lidocaine|administered|and (l_pobj) hyperalgesia_12\NN|NONE
D008012_D006930 NONE lidocaine_11\NN|and (r_conj) ketamine_9\NN|NONE (r_pobj) of_8\IN|on|systemic (r_prep) administration_7\NN|NONE (l_prep) on_12\IN|of|systemic (l_pobj) hyperalgesia_27\NN|NONE
D008012_D006930 NONE Lidocaine_0\NN|significantly|.|area (r_nsubj) reduced_1\VBD|NONE (l_dobj) area_3\NN|significantly|.|Lidocaine (l_prep) of_4\IN|the (l_pobj) hyperalgesia_8\NN|NONE
D008012_D006930 NONE lidocaine_6\NN|and (r_conj) ketamine_4\NN|NONE (r_pobj) of_3\IN|on|differential|The (r_prep) effects_2\NNS|mediated|. (l_prep) on_7\IN|differential|of|The (l_pobj) hyperalgesia_11\NN|NONE
D008012_D006930 NONE lidocaine_6\NN|and (r_conj) ketamine_4\NN|NONE (r_pobj) of_3\IN|on|differential|The (r_prep) effects_2\NNS|mediated|. (r_nsubj) suggest_12\VBP|NONE (l_ccomp) mediated_20\VBN|.|effects (l_nsubjpass) types_16\NNS|by|that|and|are|have (l_prep) of_17\IN|two|the (l_pobj) hyperalgesia_18\NN|NONE
D002211_D006930 CID capsaicin_16\NN|NONE (r_pobj) by_14\IN|NONE (r_agent) induced_13\VBN|Differential|.|of (r_acl) effects_1\NNS|NONE (l_prep) of_2\IN|Differential|.|induced (l_pobj) ketamine_5\NN|NONE (l_prep) on_8\IN|lidocaine|administered|and (l_pobj) hyperalgesia_12\NN|NONE
D002211_D006930 CID capsaicin_30\NN|NONE (r_pobj) by_29\IN|NONE (r_agent) induced_28\VBN|the|of (r_acl) effect_4\NN|have|.|We (l_prep) of_5\IN|the|induced (l_pobj) administration_7\NN|NONE (l_prep) on_12\IN|of|systemic (l_pobj) hyperalgesia_27\NN|NONE
D007649_D006930 NONE ketamine_5\NN|NONE (l_prep) on_8\IN|lidocaine|administered|and (l_pobj) hyperalgesia_12\NN|NONE
D007649_D006930 NONE ketamine_9\NN|NONE (r_pobj) of_8\IN|on|systemic (r_prep) administration_7\NN|NONE (l_prep) on_12\IN|of|systemic (l_pobj) hyperalgesia_27\NN|NONE
D007649_D006930 NONE Ketamine_0\NN|significantly|tended|area|and (r_nsubj) reduced_1\VBD|NONE (l_dobj) area_4\NN|Ketamine|significantly|tended|and (l_prep) of_5\IN|both|the (l_pobj) hyperalgesia_13\NN|NONE
D007649_D006930 NONE ketamine_4\NN|NONE (r_pobj) of_3\IN|on|differential|The (r_prep) effects_2\NNS|mediated|. (l_prep) on_7\IN|differential|of|The (l_pobj) hyperalgesia_11\NN|NONE
D007649_D006930 NONE ketamine_4\NN|NONE (r_pobj) of_3\IN|on|differential|The (r_prep) effects_2\NNS|mediated|. (r_nsubj) suggest_12\VBP|NONE (l_ccomp) mediated_20\VBN|.|effects (l_nsubjpass) types_16\NNS|by|that|and|are|have (l_prep) of_17\IN|two|the (l_pobj) hyperalgesia_18\NN|NONE
20880751
D007980_D004409 CID Levodopa_0\NNP||.|dyskinesias|filling|: (r_npadvmod) induced_2\VBN|NONE (l_dobj) dyskinesias_3\NNS||.|Levodopa|filling|:
D007980_D004409 CID levodopa_17\NN| (r_npadvmod) induced_19\VBN|underlying (r_amod) dyskinesias_20\NNS|a|key
D007980_D004409 CID levodopa_41\NN| (r_npadvmod) induced_43\VBN|NONE (r_amod) dyskinesias_44\NNS|NONE
D018698_D004409 NONE glutamate_28\NN|systems|and|ionotropic|, (r_compound) receptors_29\NNS|,|receptor|dopamine (l_conj) systems_36\NNS|and|ionotropic|glutamate|, (l_prep) in_37\IN|neurotransmitter|dopaminergic (l_pobj) pathophysiology_39\NN|NONE (l_prep) of_40\IN|the (l_pobj) dyskinesias_44\NNS|NONE
D007980_D010300 NONE Levodopa_0\NNP||.|dyskinesias|filling|: (r_npadvmod) induced_2\VBN|NONE (l_dobj) dyskinesias_3\NNS||.|Levodopa|filling|: (l_prep) in_4\IN|NONE (l_pobj) patients_5\NNS|NONE (l_prep) with_6\IN|NONE (l_pobj) disease_9\NN|NONE
D007980_D010300 NONE Levodopa_0\NNP|drug|. (r_nsubj) is_1\VBZ|NONE (l_attr) drug_5\NN|Levodopa|. (l_prep) for_6\IN|effective|the (l_pobj) treatment_8\NN|NONE (l_prep) of_9\IN|the (l_pobj) disease_12\NN|NONE
D004298_D004409 NONE dopamine_9\NN|this (r_compound) precursor_10\NN|NONE (r_pobj) of_7\IN|the|term (r_prep) use_6\NN|is|by|However|.|, (r_nsubjpass) complicated_12\VBN|NONE (l_agent) by_13\IN|is|use|However|.|, (l_pobj) fluctuations_16\NNS|NONE (l_conj) dyskinesias_18\NNS|and|disabling
D004298_D004409 NONE dopamine_21\NN|receptors|,|receptor (r_compound) subtypes_23\NNS|promising|of|, (l_conj) receptors_29\NNS|,|receptor|dopamine (l_conj) systems_36\NNS|and|ionotropic|glutamate|, (l_prep) in_37\IN|neurotransmitter|dopaminergic (l_pobj) pathophysiology_39\NN|NONE (l_prep) of_40\IN|the (l_pobj) dyskinesias_44\NNS|NONE
3101906
D007654_D003643 NONE ketoconazole_9\JJ|NONE (r_compound) treatment_10\NN|NONE (r_pobj) with_8\IN|probably (r_prep) associated_7\VBN|three|the (r_acl) deaths_5\NNS|NONE
D007654_D007565 CID ketoconazole_9\JJ|NONE (r_compound) treatment_10\NN|NONE (r_pobj) with_8\IN|probably (r_prep) associated_7\VBN|three|the (r_acl) deaths_5\NNS|NONE (r_pobj) of_2\IN|NONE (r_prep) two_1\CD|NONE (r_pobj) In_0\IN|.|drug|been|had|after (r_prep) continued_15\VBN|NONE (l_prep) after_16\IN|.|drug|been|had|In (l_pobj) onset_18\NN|NONE (l_prep) of_19\IN|the (l_pobj) jaundice_20\NN|NONE
D007654_D056486 CID ketoconazole_9\JJ|NONE (r_compound) treatment_10\NN|NONE (r_pobj) with_8\IN|probably (r_prep) associated_7\VBN|three|the (r_acl) deaths_5\NNS|NONE (r_pobj) of_2\IN|NONE (r_prep) two_1\CD|NONE (r_pobj) In_0\IN|.|drug|been|had|after (r_prep) continued_15\VBN|NONE (l_prep) after_16\IN|.|drug|been|had|In (l_pobj) onset_18\NN|NONE (l_prep) of_19\IN|the (l_pobj) jaundice_20\NN|NONE (l_conj) symptoms_23\NNS|and (l_prep) of_24\IN|other (l_pobj) hepatitis_25\NN|NONE
D007654_D056486 CID ketoconazole_18\NN|NONE (r_pobj) with_17\IN|term (r_prep) treatment_16\NN|NONE (r_pobj) during_13\IN|prevent|is|.|monitoring (r_prep) advised_12\VBN|NONE (l_nsubjpass) monitoring_3\NN|prevent|during|is|. (l_prep) for_7\IN|Clinical|at (l_pobj) evidence_8\NN|NONE (l_prep) of_9\IN|NONE (l_pobj) hepatitis_10\NN|NONE
D007654_D056486 CID ketoconazole_18\NN|NONE (r_pobj) with_17\IN|term (r_prep) treatment_16\NN|NONE (r_pobj) during_13\IN|prevent|is|.|monitoring (r_prep) advised_12\VBN|NONE (l_advcl) prevent_20\VB|during|is|.|monitoring (l_dobj) injury_24\NN|to
18004067
D000082_D017093 CID paracetamol_32\JJ|NONE (r_advmod) 4_30\CD|/ (r_nummod) day_34\NN|NONE (r_pobj) with_29\IN|while|being (r_prep) treated_28\VBN|consumption (r_advcl) stopping_23\VBG|and|who|within|failure (r_conj) developed_12\VBD|and|consumers|who (l_dobj) failure_14\NN|and|who|within|stopping
D000431_D017114 NONE alcohol_8\NN|regular|ingesting (r_compound) consumption_9\NN|NONE (r_pobj) with_6\IN|two (r_prep) patients_5\NNS|NONE (r_pobj) in_3\IN|Acute|.|liver (r_prep) failure_2\NN|NONE
D000431_D056486 NONE alcohol_4\NN|NONE (r_pobj) of_3\IN|possible|in|The (r_prep) role_2\NN|is|currently|. (l_prep) in_5\IN|possible|of|The (l_pobj) development_7\NN|NONE (l_prep) of_8\IN|the (l_pobj) hepatotoxicity_9\NN|NONE
D000082_D056486 CID paracetamol_15\JJ|NONE (r_pobj) of_14\IN|therapeutic (r_prep) doses_13\NNS|NONE (r_pobj) with_11\IN|NONE (r_prep) associated_10\VBN|NONE (r_acl) hepatotoxicity_9\NN|NONE
D000082_D056486 CID acetaminophen_17\NN|(|) (r_appos) paracetamol_15\JJ|NONE (r_pobj) of_14\IN|therapeutic (r_prep) doses_13\NNS|NONE (r_pobj) with_11\IN|NONE (r_prep) associated_10\VBN|NONE (r_acl) hepatotoxicity_9\NN|NONE
D000082_D056486 CID paracetamol_15\NN|NONE (r_pobj) of_14\IN|therapeutic (r_prep) doses_13\NNS|NONE (r_pobj) with_11\IN|NONE (r_prep) treated_10\VBN|NONE (r_acl) patients_9\NNS|NONE (r_pobj) in_8\IN|of|the (r_prep) development_5\NN|NONE (l_prep) of_6\IN|in|the (l_pobj) hepatotoxicity_7\NN|NONE
D000082_D017114 NONE paracetamol_11\NN|at (r_dobj) ingesting_10\VBG|regular|alcohol (r_acl) consumption_9\NN|NONE (r_pobj) with_6\IN|two (r_prep) patients_5\NNS|NONE (r_pobj) in_3\IN|Acute|.|liver (r_prep) failure_2\NN|NONE
D000431_D017093 NONE alcohol_9\NN|NONE (r_pobj) of_8\IN|regular (r_prep) consumers_7\NNS|developed|and|who (r_attr) were_5\VBD| (l_conj) developed_12\VBD|and|consumers|who (l_dobj) failure_14\NN|and|who|within|stopping
D000431_D017093 NONE alcohol_24\NN|NONE (r_compound) consumption_25\NN|treated (r_dobj) stopping_23\VBG|and|who|within|failure (r_conj) developed_12\VBD|and|consumers|who (l_dobj) failure_14\NN|and|who|within|stopping
D000431_D017093 NONE alcohol_10\NN|NONE (r_pobj) of_9\IN|e.g.|regular (r_prep) consumption_8\NN|,|risk (r_appos) factors_4\NNS|NONE (r_pobj) with_2\IN|NONE (r_prep) patients_1\NNS|NONE (r_pobj) In_0\IN|ingested|possible|,|failure|. (r_prep) is_14\VBZ|NONE (l_nsubj) failure_13\NN|In|ingested|possible|,|.
20683499
C029036_D000544 NONE crocin_9\NNS|,|sativus (l_prep) on_10\IN|NONE (l_pobj) model_14\NN|NONE (l_prep) of_15\IN|induced (l_pobj) disease_19\NN|NONE
C029036_D000544 NONE crocins_8\NNS|NONE (l_prep) on_9\IN|NONE (l_pobj) disease_13\NN|NONE
C029036_D000544 NONE crocin_8\NNS|NONE (r_pobj) of_7\IN|)|mg/kg|the|(|in (r_prep) effectiveness_6\NN|Therefore|results|.|, (l_prep) in_13\IN|of|)|mg/kg|the|( (l_pcomp) antagonizing_14\VBG|NONE (l_dobj) deficits_17\NNS|NONE (l_acl) caused_18\VBN|the|cognitive (l_prep) in_23\IN|by (l_pobj) rats_24\NNS|NONE (l_conj) potential_27\NN|and (l_prep) in_28\IN|its (l_pobj) treatment_30\NN|NONE (l_prep) of_31\IN|the (l_pobj) diseases_33\NNS|NONE (l_prep) as_35\IN|neurodegenerative (l_pobj) disease_38\NN|such
C029036_D003072 NONE crocin_8\NNS|NONE (r_pobj) of_7\IN|)|mg/kg|the|(|in (r_prep) effectiveness_6\NN|Therefore|results|.|, (l_prep) in_13\IN|of|)|mg/kg|the|( (l_pcomp) antagonizing_14\VBG|NONE (l_dobj) deficits_17\NNS|NONE
C029036_D008569 NONE crocin_3\NNS|NONE (l_prep) in_4\IN|.|,|In (l_pobj) impairment_14\NN|NONE
C029036_D019636 NONE crocin_8\NNS|NONE (r_pobj) of_7\IN|)|mg/kg|the|(|in (r_prep) effectiveness_6\NN|Therefore|results|.|, (l_prep) in_13\IN|of|)|mg/kg|the|( (l_pcomp) antagonizing_14\VBG|NONE (l_dobj) deficits_17\NNS|NONE (l_acl) caused_18\VBN|the|cognitive (l_prep) in_23\IN|by (l_pobj) rats_24\NNS|NONE (l_conj) potential_27\NN|and (l_prep) in_28\IN|its (l_pobj) treatment_30\NN|NONE (l_prep) of_31\IN|the (l_pobj) diseases_33\NNS|NONE
D013311_D003072 CID STZ_20\NNP| (r_compound) icv_22\NN|NONE (r_pobj) by_19\IN|in (r_agent) caused_18\VBN|the|cognitive (r_acl) deficits_17\NNS|NONE
C029036_D007859 NONE crocin_3\NNS|NONE (l_prep) in_4\IN|.|,|In (l_pobj) impairment_14\NN|NONE
D013311_D019636 NONE STZ_20\NNP| (r_compound) icv_22\NN|NONE (r_pobj) by_19\IN|in (r_agent) caused_18\VBN|the|cognitive (l_prep) in_23\IN|by (l_pobj) rats_24\NNS|NONE (l_conj) potential_27\NN|and (l_prep) in_28\IN|its (l_pobj) treatment_30\NN|NONE (l_prep) of_31\IN|the (l_pobj) diseases_33\NNS|NONE
D013311_D007859 NONE STZ_17\NNP| (r_npadvmod) injected_19\VBN|in|treated (r_amod) group_20\NN|NONE (r_pobj) in_15\IN|attenuated|learning|dose (r_prep) impairment_14\NN|NONE
D013311_D000544 CID streptozocin_11\NNS| (r_npadvmod) induced_13\VBN|of (r_amod) model_14\NN|NONE (l_prep) of_15\IN|induced (l_pobj) disease_19\NN|NONE
D013311_D000544 CID streptozocin_20\NNP|of|the (r_appos) effect_6\NN|In|.|,|was (l_prep) of_7\IN|the|streptozocin (l_pobj) crocins_8\NNS|NONE (l_prep) on_9\IN|NONE (l_pobj) disease_13\NN|NONE
D013311_D000544 CID STZ_22\NNP|(|)|icv (r_appos) streptozocin_20\NNP|of|the (r_appos) effect_6\NN|In|.|,|was (l_prep) of_7\IN|the|streptozocin (l_pobj) crocins_8\NNS|NONE (l_prep) on_9\IN|NONE (l_pobj) disease_13\NN|NONE
D013311_D000544 CID STZ_10\NNP| (r_compound) icv_12\NN|NONE (r_pobj) with_9\IN|,|In|in|rats|)|bilaterally|were (r_prep) injected_8\VBN|,|was|.|application (l_prep) In_0\IN|,|in|rats|)|with|bilaterally|were (l_pobj) groups_4\NNS|NONE (l_compound) disease_3\NN|Alzheimer
D013311_D000544 CID STZ_28\NNP| (r_compound) icv_30\NN|similar|a (r_compound) application_31\NN|,|was|.|injected (r_nsubjpass) repeated_33\VBN|NONE (l_ccomp) injected_8\VBN|,|was|.|application (l_prep) In_0\IN|,|in|rats|)|with|bilaterally|were (l_pobj) groups_4\NNS|NONE (l_compound) disease_3\NN|Alzheimer
D013311_D000544 CID STZ_20\NNP| (r_compound) icv_22\NN|NONE (r_pobj) by_19\IN|in (r_agent) caused_18\VBN|the|cognitive (l_prep) in_23\IN|by (l_pobj) rats_24\NNS|NONE (l_conj) potential_27\NN|and (l_prep) in_28\IN|its (l_pobj) treatment_30\NN|NONE (l_prep) of_31\IN|the (l_pobj) diseases_33\NNS|NONE (l_prep) as_35\IN|neurodegenerative (l_pobj) disease_38\NN|such
D013311_D008569 NONE STZ_17\NNP| (r_npadvmod) injected_19\VBN|in|treated (r_amod) group_20\NN|NONE (r_pobj) in_15\IN|attenuated|learning|dose (r_prep) impairment_14\NN|NONE
8958188
D005492_D064420 NONE acid_16\NN|,|low|folic|dose (r_compound) administration_17\NN|NONE (r_pobj) by_12\IN|following|that|toxicity|can|be|for (r_agent) prevented_11\VBN|studies|. (l_nsubjpass) toxicity_6\NN|following|that|by|can|be|for
D005492_D064420 NONE acid_13\NN|confirmed|folic (r_compound) supplementation_14\NN|NONE (l_relcl) confirmed_17\VBN|acid|folic (l_ccomp) reduced_26\VBN|which|has (l_nsubjpass) toxicity_20\NN|markedly|be|that|by|can
D005492_D064420 NONE acid_29\NN|folic (r_compound) supplementation_30\NN|NONE (r_pobj) by_27\IN|markedly|be|that|can|toxicity (r_agent) reduced_26\VBN|which|has (l_nsubjpass) toxicity_20\NN|markedly|be|that|by|can
D005492_D064420 NONE folate_13\JJ|plasma (r_compound) elevation_14\NN|NONE (r_pobj) of_11\IN|the (r_prep) extent_10\NN|clinical|and (r_conj) toxicity_7\NN|NONE
D005492_D064420 NONE acid_12\NN|folic (r_compound) administration_13\NN|NONE (r_pobj) by_10\IN|indicating|were|not|pharmacokinetics|that (r_agent) altered_9\VBN|studies|. (l_advcl) indicating_14\VBG|were|by|not|pharmacokinetics|that (l_ccomp) is_17\VBZ|NONE (l_acomp) unlikely_18\JJ|that|supplementation (l_xcomp) reduce_20\VB|NONE (l_dobj) toxicity_21\NN|by|to
C045894_D064420 NONE lometrexol_7\NN|NONE (r_pobj) of_6\IN|the|clinical|initial (r_prep) development_5\NN|.|However|,|was|because (r_nsubjpass) curtailed_9\VBN|NONE (l_prep) because_10\IN|.|However|,|development|was (l_pobj) toxicities_16\NNS|of
C045894_D064420 NONE lometrexol_8\NN|NONE (r_pobj) of_7\IN|the (r_prep) toxicity_6\NN|following|that|by|can|be|for
C045894_D064420 NONE lometrexol_9\NN|NONE (r_pobj) of_8\IN|given|clinical|I (r_prep) study_7\NN|observation|.|Phase (l_acl) given_10\VBN|of|clinical|I (l_prep) with_11\IN|NONE (l_pobj) supplementation_14\NN|NONE (l_relcl) confirmed_17\VBN|acid|folic (l_ccomp) reduced_26\VBN|which|has (l_nsubjpass) toxicity_20\NN|markedly|be|that|by|can
C045894_D064420 NONE lometrexol_22\NN|NONE (r_pobj) of_21\IN|the (r_prep) toxicity_20\NN|markedly|be|that|by|can
C045894_D064420 NONE lometrexol_4\NN|NONE (r_compound) plasma_5\NN|NONE (r_compound) pharmacokinetics_6\NNS|indicating|were|by|not|that (r_nsubjpass) altered_9\VBN|studies|. (l_advcl) indicating_14\VBG|were|by|not|pharmacokinetics|that (l_ccomp) is_17\VBZ|NONE (l_acomp) unlikely_18\JJ|that|supplementation (l_xcomp) reduce_20\VB|NONE (l_dobj) toxicity_21\NN|by|to
C045894_D064420 NONE lometrexol_24\NN|NONE (r_compound) plasma_25\NN|NONE (r_compound) clearance_26\NN|NONE (r_dobj) enhancing_23\VBG|NONE (r_pcomp) by_22\IN|toxicity|to (r_prep) reduce_20\VB|NONE (l_dobj) toxicity_21\NN|by|to
C045894_D009369 NONE lometrexol_9\NN|activity|that (r_nsubj) has_10\VBZ|data|.|have (l_dobj) activity_11\NN|that|lometrexol (l_prep) against_12\IN|NONE (l_pobj) tumours_13\NNS|NONE
D008727_D009369 NONE methotrexate_22\NNP|other|, (r_appos) drugs_19\NNS|NONE (r_pobj) to_17\IN|NONE (r_prep) refractory_16\JJ|which (r_acomp) are_15\VBP|NONE (r_relcl) tumours_13\NNS|NONE
12615818
D004997_D011085 NONE estradiol_5\NN|acetate|is|for|and|in|is|. (r_nsubjpass) licensed_12\VBN|NONE (l_conj) is_26\VBZ|acetate|is|estradiol|for|and|in|. (l_attr) option_30\NN|also (l_prep) for_31\IN|a|treatment (l_pobj) syndrome_34\NN|NONE
D004997_D011085 NONE estradiol_5\NN|acetate|is|for|and|in|is|. (r_nsubjpass) licensed_12\VBN|NONE (l_conj) is_26\VBZ|acetate|is|estradiol|for|and|in|. (l_attr) option_30\NN|also (l_prep) for_31\IN|a|treatment (l_pobj) syndrome_34\NN|NONE (l_appos) PCOS_36\NNP|(|)|polycystic|ovary
D004997_D011085 NONE EE_9\NNP|(|) (r_appos) estradiol_5\NN|acetate|is|for|and|in|is|. (r_nsubjpass) licensed_12\VBN|NONE (l_conj) is_26\VBZ|acetate|is|estradiol|for|and|in|. (l_attr) option_30\NN|also (l_prep) for_31\IN|a|treatment (l_pobj) syndrome_34\NN|NONE
D004997_D011085 NONE EE_9\NNP|(|) (r_appos) estradiol_5\NN|acetate|is|for|and|in|is|. (r_nsubjpass) licensed_12\VBN|NONE (l_conj) is_26\VBZ|acetate|is|estradiol|for|and|in|. (l_attr) option_30\NN|also (l_prep) for_31\IN|a|treatment (l_pobj) syndrome_34\NN|NONE (l_appos) PCOS_36\NNP|(|)|polycystic|ovary
D004997_D011085 NONE EE_44\NNP|NONE (r_pobj) with_41\IN|NONE (r_prep) associated_40\VBN|NONE (r_acl) VTE_39\NNP|NONE (r_pobj) of_38\IN|the (r_prep) risk_37\NN|to (r_dobj) estimate_35\VB|.|Using|analysis|we|years (r_advcl) conducted_7\VBD|NONE (l_npadvmod) years_27\NNS|.|Using|analysis|we|estimate (l_prep) with_28\IN| (l_pobj) acne_29\NN|NONE (l_conj) hirsutism_31\NN|, (l_conj) PCOS_33\NNP|or
D004997_D011085 NONE EE_15\NNP|NONE (r_pobj) of_12\IN|the|in (r_prep) use_11\NN|NONE (l_prep) in_16\IN|the|of (l_pobj) women_17\NNS|NONE (l_prep) with_18\IN|NONE (l_pobj) acne_19\NN|NONE (l_conj) hirsutism_21\NN|, (l_conj) PCOS_23\NNP|or
D004997_D054556 CID estradiol_14\NN|.|of|The (r_appos) risk_1\NN|NONE (l_prep) of_2\IN|estradiol|.|The (l_pobj) thromboembolism_4\NN|NONE
D004997_D054556 CID EE_17\NNP|NONE (r_pobj) with_14\IN|NONE (r_prep) associated_13\VBN|(|)|VTE|venous (r_acl) thromboembolism_9\NN|NONE
D004997_D054556 CID EE_17\NNP|NONE (r_pobj) with_14\IN|NONE (r_prep) associated_13\VBN|(|)|VTE|venous (r_acl) thromboembolism_9\NN|NONE (l_appos) VTE_11\NNP|(|)|venous|associated
D004997_D054556 CID EE_44\NNP|NONE (r_pobj) with_41\IN|NONE (r_prep) associated_40\VBN|NONE (r_acl) VTE_39\NNP|NONE
D004997_D054556 CID EE_15\NNP|NONE (r_pobj) of_12\IN|the|in (r_prep) use_11\NN|NONE (r_pobj) with_9\IN|confounding (r_prep) associated_8\VBN|increased|an|of (r_acl) risk_5\NN|.|have|We|excluded (l_prep) of_6\IN|increased|an|associated (l_pobj) VTE_7\NNP|NONE
D017373_D000152 NONE acetate_1\NN|is|estradiol|for|and|in|is|. (r_nsubjpass) licensed_12\VBN|NONE (l_prep) for_16\IN|acetate|is|estradiol|and|in|is|. (l_pobj) treatment_18\NN|NONE (l_prep) of_19\IN|the (l_pobj) women_20\NNS|NONE (l_prep) with_21\IN|NONE (l_pobj) acne_22\NN|NONE
D017373_D000152 NONE CPA_7\NNP|/ (r_nmod) EE_9\NNP|(|) (r_appos) estradiol_5\NN|acetate|is|for|and|in|is|. (r_nsubjpass) licensed_12\VBN|NONE (l_prep) for_16\IN|acetate|is|estradiol|and|in|is|. (l_pobj) treatment_18\NN|NONE (l_prep) of_19\IN|the (l_pobj) women_20\NNS|NONE (l_prep) with_21\IN|NONE (l_pobj) acne_22\NN|NONE
D017373_D000152 NONE CPA_42\NNP|/ (r_nmod) EE_44\NNP|NONE (r_pobj) with_41\IN|NONE (r_prep) associated_40\VBN|NONE (r_acl) VTE_39\NNP|NONE (r_pobj) of_38\IN|the (r_prep) risk_37\NN|to (r_dobj) estimate_35\VB|.|Using|analysis|we|years (r_advcl) conducted_7\VBD|NONE (l_npadvmod) years_27\NNS|.|Using|analysis|we|estimate (l_prep) with_28\IN| (l_pobj) acne_29\NN|NONE
D017373_D000152 NONE CPA_13\NNP|/ (r_nmod) EE_15\NNP|NONE (r_pobj) of_12\IN|the|in (r_prep) use_11\NN|NONE (l_prep) in_16\IN|the|of (l_pobj) women_17\NNS|NONE (l_prep) with_18\IN|NONE (l_pobj) acne_19\NN|NONE
D003276_D054556 NONE contraceptives_23\NNS|NONE (r_pobj) with_19\IN|NONE (r_prep) compared_18\VBN|studies|have|.|risk (r_prep) demonstrated_3\VBN|NONE (l_dobj) risk_6\NN|studies|have|.|compared (l_prep) of_7\IN|increased|an (l_pobj) thromboembolism_9\NN|NONE
D003276_D054556 NONE contraceptives_23\NNS|NONE (r_pobj) with_19\IN|NONE (r_prep) compared_18\VBN|studies|have|.|risk (r_prep) demonstrated_3\VBN|NONE (l_dobj) risk_6\NN|studies|have|.|compared (l_prep) of_7\IN|increased|an (l_pobj) thromboembolism_9\NN|NONE (l_appos) VTE_11\NNP|(|)|venous|associated
D017373_D006628 NONE acetate_1\NN|is|estradiol|for|and|in|is|. (r_nsubjpass) licensed_12\VBN|NONE (l_prep) for_16\IN|acetate|is|estradiol|and|in|is|. (l_pobj) treatment_18\NN|NONE (l_prep) of_19\IN|the (l_pobj) women_20\NNS|NONE (l_prep) with_21\IN|NONE (l_pobj) acne_22\NN|NONE (l_conj) hirsutism_24\NN|and
D017373_D006628 NONE CPA_7\NNP|/ (r_nmod) EE_9\NNP|(|) (r_appos) estradiol_5\NN|acetate|is|for|and|in|is|. (r_nsubjpass) licensed_12\VBN|NONE (l_prep) for_16\IN|acetate|is|estradiol|and|in|is|. (l_pobj) treatment_18\NN|NONE (l_prep) of_19\IN|the (l_pobj) women_20\NNS|NONE (l_prep) with_21\IN|NONE (l_pobj) acne_22\NN|NONE (l_conj) hirsutism_24\NN|and
D017373_D006628 NONE CPA_42\NNP|/ (r_nmod) EE_44\NNP|NONE (r_pobj) with_41\IN|NONE (r_prep) associated_40\VBN|NONE (r_acl) VTE_39\NNP|NONE (r_pobj) of_38\IN|the (r_prep) risk_37\NN|to (r_dobj) estimate_35\VB|.|Using|analysis|we|years (r_advcl) conducted_7\VBD|NONE (l_npadvmod) years_27\NNS|.|Using|analysis|we|estimate (l_prep) with_28\IN| (l_pobj) acne_29\NN|NONE (l_conj) hirsutism_31\NN|,
D017373_D006628 NONE CPA_13\NNP|/ (r_nmod) EE_15\NNP|NONE (r_pobj) of_12\IN|the|in (r_prep) use_11\NN|NONE (l_prep) in_16\IN|the|of (l_pobj) women_17\NNS|NONE (l_prep) with_18\IN|NONE (l_pobj) acne_19\NN|NONE (l_conj) hirsutism_21\NN|,
D004997_D006628 NONE estradiol_5\NN|acetate|is|for|and|in|is|. (r_nsubjpass) licensed_12\VBN|NONE (l_prep) for_16\IN|acetate|is|estradiol|and|in|is|. (l_pobj) treatment_18\NN|NONE (l_prep) of_19\IN|the (l_pobj) women_20\NNS|NONE (l_prep) with_21\IN|NONE (l_pobj) acne_22\NN|NONE (l_conj) hirsutism_24\NN|and
D004997_D006628 NONE EE_9\NNP|(|) (r_appos) estradiol_5\NN|acetate|is|for|and|in|is|. (r_nsubjpass) licensed_12\VBN|NONE (l_prep) for_16\IN|acetate|is|estradiol|and|in|is|. (l_pobj) treatment_18\NN|NONE (l_prep) of_19\IN|the (l_pobj) women_20\NNS|NONE (l_prep) with_21\IN|NONE (l_pobj) acne_22\NN|NONE (l_conj) hirsutism_24\NN|and
D004997_D006628 NONE EE_44\NNP|NONE (r_pobj) with_41\IN|NONE (r_prep) associated_40\VBN|NONE (r_acl) VTE_39\NNP|NONE (r_pobj) of_38\IN|the (r_prep) risk_37\NN|to (r_dobj) estimate_35\VB|.|Using|analysis|we|years (r_advcl) conducted_7\VBD|NONE (l_npadvmod) years_27\NNS|.|Using|analysis|we|estimate (l_prep) with_28\IN| (l_pobj) acne_29\NN|NONE (l_conj) hirsutism_31\NN|,
D004997_D006628 NONE EE_15\NNP|NONE (r_pobj) of_12\IN|the|in (r_prep) use_11\NN|NONE (l_prep) in_16\IN|the|of (l_pobj) women_17\NNS|NONE (l_prep) with_18\IN|NONE (l_pobj) acne_19\NN|NONE (l_conj) hirsutism_21\NN|,
D004997_D000152 NONE estradiol_5\NN|acetate|is|for|and|in|is|. (r_nsubjpass) licensed_12\VBN|NONE (l_prep) for_16\IN|acetate|is|estradiol|and|in|is|. (l_pobj) treatment_18\NN|NONE (l_prep) of_19\IN|the (l_pobj) women_20\NNS|NONE (l_prep) with_21\IN|NONE (l_pobj) acne_22\NN|NONE
D004997_D000152 NONE EE_9\NNP|(|) (r_appos) estradiol_5\NN|acetate|is|for|and|in|is|. (r_nsubjpass) licensed_12\VBN|NONE (l_prep) for_16\IN|acetate|is|estradiol|and|in|is|. (l_pobj) treatment_18\NN|NONE (l_prep) of_19\IN|the (l_pobj) women_20\NNS|NONE (l_prep) with_21\IN|NONE (l_pobj) acne_22\NN|NONE
D004997_D000152 NONE EE_44\NNP|NONE (r_pobj) with_41\IN|NONE (r_prep) associated_40\VBN|NONE (r_acl) VTE_39\NNP|NONE (r_pobj) of_38\IN|the (r_prep) risk_37\NN|to (r_dobj) estimate_35\VB|.|Using|analysis|we|years (r_advcl) conducted_7\VBD|NONE (l_npadvmod) years_27\NNS|.|Using|analysis|we|estimate (l_prep) with_28\IN| (l_pobj) acne_29\NN|NONE
D004997_D000152 NONE EE_15\NNP|NONE (r_pobj) of_12\IN|the|in (r_prep) use_11\NN|NONE (l_prep) in_16\IN|the|of (l_pobj) women_17\NNS|NONE (l_prep) with_18\IN|NONE (l_pobj) acne_19\NN|NONE
D017373_D011085 NONE acetate_1\NN|is|estradiol|for|and|in|is|. (r_nsubjpass) licensed_12\VBN|NONE (l_conj) is_26\VBZ|acetate|is|estradiol|for|and|in|. (l_attr) option_30\NN|also (l_prep) for_31\IN|a|treatment (l_pobj) syndrome_34\NN|NONE
D017373_D011085 NONE acetate_1\NN|is|estradiol|for|and|in|is|. (r_nsubjpass) licensed_12\VBN|NONE (l_conj) is_26\VBZ|acetate|is|estradiol|for|and|in|. (l_attr) option_30\NN|also (l_prep) for_31\IN|a|treatment (l_pobj) syndrome_34\NN|NONE (l_appos) PCOS_36\NNP|(|)|polycystic|ovary
D017373_D011085 NONE CPA_7\NNP|/ (r_nmod) EE_9\NNP|(|) (r_appos) estradiol_5\NN|acetate|is|for|and|in|is|. (r_nsubjpass) licensed_12\VBN|NONE (l_conj) is_26\VBZ|acetate|is|estradiol|for|and|in|. (l_attr) option_30\NN|also (l_prep) for_31\IN|a|treatment (l_pobj) syndrome_34\NN|NONE
D017373_D011085 NONE CPA_7\NNP|/ (r_nmod) EE_9\NNP|(|) (r_appos) estradiol_5\NN|acetate|is|for|and|in|is|. (r_nsubjpass) licensed_12\VBN|NONE (l_conj) is_26\VBZ|acetate|is|estradiol|for|and|in|. (l_attr) option_30\NN|also (l_prep) for_31\IN|a|treatment (l_pobj) syndrome_34\NN|NONE (l_appos) PCOS_36\NNP|(|)|polycystic|ovary
D017373_D011085 NONE CPA_42\NNP|/ (r_nmod) EE_44\NNP|NONE (r_pobj) with_41\IN|NONE (r_prep) associated_40\VBN|NONE (r_acl) VTE_39\NNP|NONE (r_pobj) of_38\IN|the (r_prep) risk_37\NN|to (r_dobj) estimate_35\VB|.|Using|analysis|we|years (r_advcl) conducted_7\VBD|NONE (l_npadvmod) years_27\NNS|.|Using|analysis|we|estimate (l_prep) with_28\IN| (l_pobj) acne_29\NN|NONE (l_conj) hirsutism_31\NN|, (l_conj) PCOS_33\NNP|or
D017373_D011085 NONE CPA_13\NNP|/ (r_nmod) EE_15\NNP|NONE (r_pobj) of_12\IN|the|in (r_prep) use_11\NN|NONE (l_prep) in_16\IN|the|of (l_pobj) women_17\NNS|NONE (l_prep) with_18\IN|NONE (l_pobj) acne_19\NN|NONE (l_conj) hirsutism_21\NN|, (l_conj) PCOS_23\NNP|or
D017373_D054556 CID acetate_9\NN|cyproterone (r_oprd) prescribed_7\VBD|NONE (r_acl) women_6\NNS|NONE (r_pobj) in_5\IN|venous (r_prep) thromboembolism_4\NN|NONE
D017373_D054556 CID CPA_15\NNP|/ (r_nmod) EE_17\NNP|NONE (r_pobj) with_14\IN|NONE (r_prep) associated_13\VBN|(|)|VTE|venous (r_acl) thromboembolism_9\NN|NONE
D017373_D054556 CID CPA_15\NNP|/ (r_nmod) EE_17\NNP|NONE (r_pobj) with_14\IN|NONE (r_prep) associated_13\VBN|(|)|VTE|venous (r_acl) thromboembolism_9\NN|NONE (l_appos) VTE_11\NNP|(|)|venous|associated
D017373_D054556 CID CPA_42\NNP|/ (r_nmod) EE_44\NNP|NONE (r_pobj) with_41\IN|NONE (r_prep) associated_40\VBN|NONE (r_acl) VTE_39\NNP|NONE
D017373_D054556 CID CPA_13\NNP|/ (r_nmod) EE_15\NNP|NONE (r_pobj) of_12\IN|the|in (r_prep) use_11\NN|NONE (r_pobj) with_9\IN|confounding (r_prep) associated_8\VBN|increased|an|of (r_acl) risk_5\NN|.|have|We|excluded (l_prep) of_6\IN|increased|an|associated (l_pobj) VTE_7\NNP|NONE
9098464
D005473_D006966 CID hydrochloride_13\NN|NONE (r_pobj) by_11\IN|on (r_agent) induced_10\VBN|of|the (r_acl) effects_7\NNS|murine|:|of|.|A (l_prep) of_8\IN|induced|the (l_pobj) hyperprolactinemia_9\NN|NONE
D005473_D006966 CID fluoxetine_9\NN|hyperprolactinemia|whether (r_nsubj) caused_16\VBD|to (l_dobj) hyperprolactinemia_17\NN|whether|fluoxetine
D005473_D006966 CID Fluoxetine_0\NNP|produce|for|was|to|. (r_nsubjpass) given_8\VBN|NONE (l_advcl) produce_17\VB|Fluoxetine|for|was|to|. (l_dobj) hyperprolactinemia_18\NN|to
D012701_D062788 NONE serotonin_17\NN|reuptake|selective|a (r_compound) inhibitor_19\NN|,|fluoxetine|, (r_appos) hydrochloride_13\NN|NONE (r_pobj) by_11\IN|on (r_agent) induced_10\VBN|of|the (r_acl) effects_7\NNS|murine|:|of|.|A (r_appos) model_2\NN|NONE (l_prep) of_3\IN|murine|:|effects|.|A (l_pobj) adenomyosis_4\NN|NONE
D012701_D062788 NONE serotonin_17\NN|reuptake|selective|a (r_compound) inhibitor_19\NN|,|fluoxetine|, (r_appos) hydrochloride_13\NN|NONE (r_pobj) by_11\IN|on (r_agent) induced_10\VBN|of|the (l_prep) on_21\IN|by (l_pobj) induction_23\NN|NONE (l_compound) adenomyosis_22\NN|in
D012701_D006966 NONE serotonin_17\NN|reuptake|selective|a (r_compound) inhibitor_19\NN|,|fluoxetine|, (r_appos) hydrochloride_13\NN|NONE (r_pobj) by_11\IN|on (r_agent) induced_10\VBN|of|the (r_acl) effects_7\NNS|murine|:|of|.|A (l_prep) of_8\IN|induced|the (l_pobj) hyperprolactinemia_9\NN|NONE
D012701_D006966 NONE serotonin_3\NN|reuptake|a (r_compound) inhibitor_5\NN|,|, (r_appos) Fluoxetine_0\NNP|produce|for|was|to|. (r_nsubjpass) given_8\VBN|NONE (l_advcl) produce_17\VB|Fluoxetine|for|was|to|. (l_dobj) hyperprolactinemia_18\NN|to
D005473_D062788 CID hydrochloride_13\NN|NONE (r_pobj) by_11\IN|on (r_agent) induced_10\VBN|of|the (r_acl) effects_7\NNS|murine|:|of|.|A (r_appos) model_2\NN|NONE (l_prep) of_3\IN|murine|:|effects|.|A (l_pobj) adenomyosis_4\NN|NONE
D005473_D062788 CID hydrochloride_13\NN|NONE (r_pobj) by_11\IN|on (r_agent) induced_10\VBN|of|the (l_prep) on_21\IN|by (l_pobj) induction_23\NN|NONE (l_compound) adenomyosis_22\NN|in
D005473_D062788 CID fluoxetine_9\NN|hyperprolactinemia|whether (r_nsubj) caused_16\VBD|to (l_dobj) hyperprolactinemia_17\NN|whether|fluoxetine (l_conj) effects_20\NNS|and (l_prep) with_21\IN|its (l_pobj) respect_22\NN|NONE (l_prep) to_23\IN|NONE (l_pobj) adenomyosis_24\NN|NONE
D005473_D062788 CID fluoxetine_14\NN|NONE (r_dobj) receiving_13\VBG|noncastrated|the (r_acl) group_12\NN|all (r_pobj) within_9\IN|.|cases|studies (r_prep) revealed_2\VBD|NONE (l_dobj) cases_4\NNS|.|within|studies (l_prep) of_5\IN|,| (l_pobj) adenomyosis_6\NN|NONE
3437726
D013034_D064420 NONE sparteine_11\NN|/ (r_nmod) debrisoquine_13\JJ|,|in|,|constitutes (r_compound) polymorphism_14\NN|NONE (r_pobj) of_10\IN|the|metabolizer (r_prep) phenotype_9\NN|NONE (r_pobj) to_4\IN|NONE (r_prep) belonging_3\VBG|NONE (r_acl) patients_2\NNS|Therefore|.|may|reactions|treated|, (r_nsubj) experience_29\VB|NONE (l_dobj) reactions_32\NNS|Therefore|.|may|treated|,|patients
D003647_D064420 NONE debrisoquine_13\JJ|,|in|,|constitutes (r_compound) polymorphism_14\NN|NONE (r_pobj) of_10\IN|the|metabolizer (r_prep) phenotype_9\NN|NONE (r_pobj) to_4\IN|NONE (r_prep) belonging_3\VBG|NONE (r_acl) patients_2\NNS|Therefore|.|may|reactions|treated|, (r_nsubj) experience_29\VB|NONE (l_dobj) reactions_32\NNS|Therefore|.|may|treated|,|patients
11807648
D014148_D012640 CID tAMCA_5\NN|action|whether|incorporated (r_nsubj) retains_6\VBZ|to (l_dobj) action_9\NN|tAMCA|whether|incorporated (l_amod) convulsive_8\JJ|its
D014148_D012640 CID tAMCA_4\NN|:|FS (r_appos) FINDINGS_0\NNS|.|activity (r_nsubj) caused_5\VBD|NONE (l_dobj) activity_8\NN|.|FINDINGS (l_relcl) associated_11\VBN|brain|paroxysmal (l_prep) with_12\IN|was|which (l_pobj) behaviours_15\NNS|NONE (l_amod) convulsive_14\JJ|distinct
D014148_D012640 CID tAMCA_10\CD|NONE (r_pobj) of_9\IN|increasing (r_prep) concentration_8\NN|NONE (r_pobj) with_6\IN|.|degree (r_prep) increased_5\VBD|NONE (l_nsubj) degree_1\NN|.|with (l_prep) of_2\IN|The (l_pobj) seizures_4\NNS|NONE
D014148_D012640 CID tAMCA_0\NN|evoked|seizures|. (r_advmod) evoked_1\VBD|NONE (l_dobj) seizures_3\NNS|tAMCA|evoked|.
D014148_D012640 CID tAMCA_0\NN|evoked|seizures|. (r_advmod) evoked_1\VBD|NONE (l_advcl) evoked_24\VBD|tAMCA|seizures|. (l_dobj) episodes_26\NNS|)|concentration|while|only (l_prep) of_27\IN|brief (l_pobj) potentials_32\NNS|NONE (l_amod) convulsive_31\JJ|in|correlated
D014148_D012640 CID tAMCA_16\NN|/|(|.|mg (r_nmod) ml_21\NNS|NONE (r_pobj) of_15\IN|lowest|the (r_prep) concentration_14\NN|)|while|episodes|only (r_nsubj) evoked_24\VBD|tAMCA|seizures|. (r_advcl) evoked_1\VBD|NONE (l_dobj) seizures_3\NNS|tAMCA|evoked|.
D014148_D012640 CID tAMCA_16\NN|/|(|.|mg (r_nmod) ml_21\NNS|NONE (r_pobj) of_15\IN|lowest|the (r_prep) concentration_14\NN|)|while|episodes|only (r_nsubj) evoked_24\VBD|tAMCA|seizures|. (l_dobj) episodes_26\NNS|)|concentration|while|only (l_prep) of_27\IN|brief (l_pobj) potentials_32\NNS|NONE (l_amod) convulsive_31\JJ|in|correlated
D014148_D012640 CID acid_1\NN|action|. (r_nsubj) retains_2\VBZ|NONE (l_dobj) action_5\NN|acid|. (l_amod) convulsive_4\JJ|its|within
D014148_D004827 NONE acid_10\NN|in (r_dobj) containing_8\VBG|fibrin (r_acl) sealants_7\NNS|NONE (r_pobj) of_5\IN|cortical (r_prep) application_4\NN|NONE (r_dobj) following_2\VBG|.|Epileptic (r_prep) seizures_1\NNS|NONE
D014148_D004827 NONE tAMCA_2\NN|However|cause|has|been|,|. (r_nsubjpass) shown_5\VBN|NONE (l_xcomp) cause_7\VB|However|has|been|,|tAMCA|. (l_dobj) seizures_9\NNS|to
1545575
D015080_D003556 NONE mesna_19\NN|NONE (r_pobj) with_18\IN|feasibility|a|of|,|neutralizes (r_prep) trial_15\NN|,|we|In|. (l_relcl) neutralizes_22\VBZ|with|feasibility|a|of|, (l_dobj) metabolite_25\NN|which (l_relcl) causes_29\VBZ|of|the|hepatic (l_dobj) cystitis_31\NN|that
D015080_D003556 NONE mesna_10\JJ|NONE (r_amod) uroprophylaxis_11\NNS|before|who (r_dobj) received_9\VBD|consecutive|four (r_relcl) patients_7\NNS|cystitis|for|In|.|, (r_nsubj) had_17\VBD|NONE (l_dobj) cystitis_20\NN|for|In|patients|.|,
D003520_D006470 CID cyclophosphamide_11\NN|administered|dose (r_compound) therapy_12\NN|NONE (r_pobj) of_7\IN|serious|a (r_prep) complication_6\NN|.|cystitis (r_attr) is_2\VBZ|NONE (l_nsubj) cystitis_1\NN|.|complication
D003520_D006470 CID cyclophosphamide_27\NN|NONE (r_pobj) of_26\IN|causes|the|hepatic (r_prep) metabolite_25\NN|which (l_relcl) causes_29\VBZ|of|the|hepatic (l_dobj) cystitis_31\NN|that
D003520_D003556 CID cyclophosphamide_11\NN|administered|dose (r_compound) therapy_12\NN|NONE (r_pobj) of_7\IN|serious|a (r_prep) complication_6\NN|.|cystitis (r_attr) is_2\VBZ|NONE (l_nsubj) cystitis_1\NN|.|complication
D003520_D003556 CID cyclophosphamide_27\NN|NONE (r_pobj) of_26\IN|causes|the|hepatic (r_prep) metabolite_25\NN|which (l_relcl) causes_29\VBZ|of|the|hepatic (l_dobj) cystitis_31\NN|that
D015080_D006470 NONE mesna_19\NN|NONE (r_pobj) with_18\IN|feasibility|a|of|,|neutralizes (r_prep) trial_15\NN|,|we|In|. (l_relcl) neutralizes_22\VBZ|with|feasibility|a|of|, (l_dobj) metabolite_25\NN|which (l_relcl) causes_29\VBZ|of|the|hepatic (l_dobj) cystitis_31\NN|that
D015080_D006470 NONE mesna_10\JJ|NONE (r_amod) uroprophylaxis_11\NNS|before|who (r_dobj) received_9\VBD|consecutive|four (r_relcl) patients_7\NNS|cystitis|for|In|.|, (r_nsubj) had_17\VBD|NONE (l_dobj) cystitis_20\NN|for|In|patients|.|,
3187073
D005472_D013610 NONE 5-FU_6\CD|NONE (r_compound) treatment_7\NN|NONE (r_pobj) on_5\IN|NONE (r_prep) patients_4\NNS|and|should|that|under|discontinued (r_nsubj) be_9\VB|is|It|. (l_conj) discontinued_19\VBN|patients|and|should|that|under (l_advcl) observed_26\VBN|be|that|should|treatment (l_nsubjpass) pain_22\NN|if|is (l_conj) tachyarrhythmia_24\NN|or|chest
D005472_D002637 CID 5-FU_6\CD|NONE (r_compound) treatment_7\NN|NONE (r_pobj) on_5\IN|NONE (r_prep) patients_4\NNS|and|should|that|under|discontinued (r_nsubj) be_9\VB|is|It|. (l_conj) discontinued_19\VBN|patients|and|should|that|under (l_advcl) observed_26\VBN|be|that|should|treatment (l_nsubjpass) pain_22\NN|if|is
8854309
D016578_D010259 NONE cocaine_14\NN|endorsing|crack (r_compound) abusers_15\NNS|NONE (l_acl) endorsing_16\VBG|cocaine|crack (l_prep) past_17\IN|from (l_pobj) CIP_18\NNP|NONE
D016578_D010259 NONE cocaine_14\NN|endorsing|crack (r_compound) abusers_15\NNS|NONE (l_acl) endorsing_16\VBG|cocaine|crack (l_prep) from_24\IN|past (l_pobj) group_26\NN|NONE (l_relcl) denied_31\VBD|of|another (l_prep) past_32\IN|who (l_pobj) CIP_33\NNP|NONE
D016578_D010259 NONE crack_28\NN|NONE (r_compound) addicts_29\NNS|NONE (r_pobj) of_27\IN|another|denied (r_prep) group_26\NN|NONE (r_pobj) from_24\IN|past (r_prep) endorsing_16\VBG|cocaine|crack (l_prep) past_17\IN|from (l_pobj) CIP_18\NNP|NONE
D016578_D010259 NONE crack_28\NN|NONE (r_compound) addicts_29\NNS|NONE (r_pobj) of_27\IN|another|denied (r_prep) group_26\NN|NONE (l_relcl) denied_31\VBD|of|another (l_prep) past_32\IN|who (l_pobj) CIP_33\NNP|NONE
D003042_D011681 CID cocaine_9\NN| (r_npadvmod) induced_11\VBN|NONE (r_amod) paranoia_12\NN|NONE (r_pobj) of_8\IN|a (r_prep) marker_7\NN|NONE (r_pobj) as_5\IN|of|.|A (r_prep) measure_1\NN|NONE (l_prep) of_2\IN|.|as|A (l_pobj) oscillation_4\NN|NONE
D003042_D010259 CID cocaine_9\NN| (r_npadvmod) induced_11\VBN|NONE (r_amod) paranoia_12\NN|NONE
D003042_D010259 CID Cocaine_0\NN| (r_npadvmod) induced_2\VBN|(|)|CIP (r_amod) paranoia_3\NN|model|.
D003042_D010259 CID Cocaine_0\NN| (r_npadvmod) induced_2\VBN|(|)|CIP (r_amod) paranoia_3\NN|model|. (l_appos) CIP_5\NNP|(|)|induced
D003042_D010259 CID Cocaine_0\NN| (r_npadvmod) induced_2\VBN|(|)|CIP (r_amod) paranoia_3\NN|model|. (r_nsubj) remains_7\VBZ|NONE (l_attr) model_13\NN|.|paranoia (l_prep) of_14\IN|induced|important|an (l_pobj) paranoia_16\NN|NONE
D016578_D011681 NONE cocaine_14\NN|endorsing|crack (r_compound) abusers_15\NNS|NONE (r_pobj) of_11\IN|a (r_prep) group_10\NN|to|significantly (r_dobj) distinguish_8\VB|NONE (r_xcomp) able_5\JJ|.|Measures (r_acomp) were_4\VBD|NONE (l_nsubj) Measures_0\NNS|.|able (l_prep) of_1\IN|NONE (l_pobj) oscillation_3\NN|NONE
D016578_D011681 NONE crack_28\NN|NONE (r_compound) addicts_29\NNS|NONE (r_pobj) of_27\IN|another|denied (r_prep) group_26\NN|NONE (r_pobj) from_24\IN|past (r_prep) endorsing_16\VBG|cocaine|crack (r_acl) abusers_15\NNS|NONE (r_pobj) of_11\IN|a (r_prep) group_10\NN|to|significantly (r_dobj) distinguish_8\VB|NONE (r_xcomp) able_5\JJ|.|Measures (r_acomp) were_4\VBD|NONE (l_nsubj) Measures_0\NNS|.|able (l_prep) of_1\IN|NONE (l_pobj) oscillation_3\NN|NONE
7083920
D000638_D006327 CID amiodarone_13\NN|for (r_compound) treatment_14\NN|NONE (r_pobj) under_12\IN|in|without (r_prep) occurring_11\VBG|a|reversible|Hisian (r_acl) block_10\NN|NONE
D000638_D013617 NONE amiodarone_13\NN|for (r_compound) treatment_14\NN|NONE (l_prep) for_15\IN|amiodarone (l_pobj) tachycardia_17\NNS|NONE
D000638_D006345 NONE amiodarone_13\NN|for (r_compound) treatment_14\NN|NONE (r_pobj) under_12\IN|in|without (r_prep) occurring_11\VBG|a|reversible|Hisian (l_prep) without_21\IN|under|in (l_pobj) abnormalities_25\NNS|NONE
D000638_D001282 NONE amiodarone_3\NN|NONE (r_compound) discontinuation_4\NN|days (r_pobj) after_2\IN|electrograms|,|flutter|. (r_prep) showed_9\VBD|NONE (l_dobj) flutter_11\NN|electrograms|,|after|.
11705128
D016898_D019698 NONE alpha_24\NN|in (r_compound) monotherapy_25\NN|NONE (l_prep) in_26\IN|alpha (l_pobj) treatment_28\NN|NONE (l_prep) of_29\IN|the (l_pobj) C_32\NNP|NONE
D016898_D019698 NONE alpha_24\NN|in (r_compound) monotherapy_25\NN|NONE (l_prep) in_26\IN|alpha (l_pobj) treatment_28\NN|NONE (l_prep) of_29\IN|the (l_pobj) C_32\NNP|NONE (l_appos) CHC_34\NNP|chronic|)|(|hepatitis
D012254_D006526 NONE ribavirin_3\RB| (r_npadvmod) induced_5\VBN|in|hemolytic (r_amod) anemia_7\NN|NONE (l_prep) in_8\IN|hemolytic|induced (l_pobj) treatment_10\NN|NONE (l_prep) of_11\IN|the (l_pobj) C_13\NNP|NONE
D012254_D019698 NONE ribavirin_19\RB|and (r_conj) interferon_15\NN|NONE (r_pobj) with_14\IN|combination (r_prep) therapy_13\NN|NONE (r_pobj) of_11\IN|and|increased|effectiveness (r_prep) efficacy_6\NN|have|studies|.|compared (r_dobj) demonstrated_4\VBN|NONE (l_prep) compared_20\VBN|have|studies|efficacy|. (l_prep) with_21\IN|NONE (l_pobj) monotherapy_25\NN|NONE (l_prep) in_26\IN|alpha (l_pobj) treatment_28\NN|NONE (l_prep) of_29\IN|the (l_pobj) C_32\NNP|NONE
D012254_D019698 NONE ribavirin_19\RB|and (r_conj) interferon_15\NN|NONE (r_pobj) with_14\IN|combination (r_prep) therapy_13\NN|NONE (r_pobj) of_11\IN|and|increased|effectiveness (r_prep) efficacy_6\NN|have|studies|.|compared (r_dobj) demonstrated_4\VBN|NONE (l_prep) compared_20\VBN|have|studies|efficacy|. (l_prep) with_21\IN|NONE (l_pobj) monotherapy_25\NN|NONE (l_prep) in_26\IN|alpha (l_pobj) treatment_28\NN|NONE (l_prep) of_29\IN|the (l_pobj) C_32\NNP|NONE (l_appos) CHC_34\NNP|chronic|)|(|hepatitis
D012254_D000743 CID ribavirin_3\RB| (r_npadvmod) induced_5\VBN|in|hemolytic (r_amod) anemia_7\NN|NONE
D012254_D000743 CID ribavirin_11\RB|.|associated||anemia|: (r_npadvmod) induced_13\VBN|NONE (l_dobj) anemia_15\NN|.|associated||ribavirin|:
D012254_D000743 CID ribavirin_11\RB|.|associated||anemia|: (r_npadvmod) induced_13\VBN|NONE (l_dobj) anemia_15\NN|.|associated||ribavirin|: (l_appos) RIHA_17\NNP|(|)|hemolytic
D012254_D000743 CID ribavirin_14\JJ|the (r_compound) dosage_15\NN|NONE (r_pobj) of_12\IN|or|discontinuation (r_prep) reduction_9\NN|standard|. (r_attr) is_8\VBZ|NONE (l_nsubj) standard_1\NN|.|reduction (l_prep) for_4\IN|The|of (l_pobj) management_5\NN|NONE (l_prep) of_6\IN|NONE (l_pobj) RIHA_7\NNP|NONE
D012254_D000743 CID ribavirin_7\NN|NONE (r_pobj) of_6\IN|incidence|the|optimal|and (r_prep) dose_5\NN|NONE (l_conj) incidence_10\NN|of|the|optimal|and (l_prep) of_11\IN|the|in (l_pobj) RIHA_12\NNP|NONE
16600756
D011453_D053201 NONE prostaglandins_4\NNS|in|Nerve|growth|.|and (r_conj) factor_2\NN|NONE (l_prep) in_5\IN|Nerve|growth|.|and|prostaglandins (l_pobj) urine_7\NN|NONE (l_prep) of_8\IN|the (l_pobj) patients_10\NNS|NONE (l_prep) with_11\IN|female (l_pobj) bladder_13\NN|NONE
D011453_D053201 NONE PGs_7\NNS|urinary|and (l_prep) in_8\IN|NONE (l_pobj) women_9\NNS|NONE (l_prep) with_10\IN|NONE (l_pobj) OAB_11\NNP|NONE
D011453_D053201 NONE PG_8\NNP|urinary|and (r_conj) NGF_6\NNP|NONE (r_pobj) between_4\IN|and|,|parameters (r_prep) correlations_3\NNS|In|were|,|. (l_conj) parameters_12\NNS|and|,|between (l_prep) in_13\IN|urodynamic (l_pobj) patients_14\NNS|NONE (l_prep) with_15\IN|NONE (l_pobj) OAB_16\NNP|NONE
D011453_D053201 NONE PGs_2\NNS|and (r_conj) NGF_0\NNP|roles|. (r_nsubj) have_3\VBP|NONE (l_dobj) roles_5\NNS|NGF|. (l_prep) in_6\IN|important (l_pobj) development_8\NN|NONE (l_prep) of_9\IN|the (l_pobj) symptoms_11\NNS|NONE (l_compound) OAB_10\NNP|in
D015232_D053201 CID PGE2_3\NNP|,|Urinary (r_conj) NGF_1\NNP|in|.|)|compared|were|significantly (r_nsubjpass) increased_8\VBN|NONE (l_prep) in_9\IN|NGF|.|)|compared|were|significantly (l_pobj) patients_10\NNS|NONE (l_prep) with_11\IN|NONE (l_pobj) OAB_12\NNP|NONE
D015232_D053201 CID PGE2_5\NNP|NONE (l_compound) OAB_3\NNP|urinary
D015237_D053201 CID PGF2alpha_5\NNP|and (r_conj) PGE2_3\NNP|,|Urinary (r_conj) NGF_1\NNP|in|.|)|compared|were|significantly (r_nsubjpass) increased_8\VBN|NONE (l_prep) in_9\IN|NGF|.|)|compared|were|significantly (l_pobj) patients_10\NNS|NONE (l_prep) with_11\IN|NONE (l_pobj) OAB_12\NNP|NONE
D015237_D053201 CID PGF2alpha_3\NNP|,|Urinary (r_appos) NGF_1\NNP|.|with|did|not (r_nsubj) correlate_8\VB|NONE (l_prep) with_9\IN|NGF|.|did|not (l_pobj) parameters_11\NNS|NONE (l_prep) in_12\IN|urodynamic (l_pobj) patients_13\NNS|NONE (l_prep) with_14\IN|NONE (l_pobj) OAB_15\NNP|NONE
D011464_D053201 NONE PGI2_3\NNP|different|However|.|not|, (r_nsubj) was_4\VBD|NONE (l_acomp) different_6\JJ|PGI|However|.|not|, (l_prep) between_7\IN|NONE (l_pobj) controls_8\NNS|NONE (l_prep) with_11\IN|and|patients (l_pobj) OAB_12\NNP|NONE
D011464_D053201 NONE PGI2_5\NNP|and (r_conj) PGF2alpha_3\NNP|,|Urinary (r_appos) NGF_1\NNP|.|with|did|not (r_nsubj) correlate_8\VB|NONE (l_prep) with_9\IN|NGF|.|did|not (l_pobj) parameters_11\NNS|NONE (l_prep) in_12\IN|urodynamic (l_pobj) patients_13\NNS|NONE (l_prep) with_14\IN|NONE (l_pobj) OAB_15\NNP|NONE
3615541
D002116_D006948 NONE calcitonin_12\NN|intracerebral (r_compound) injections_13\NNS|NONE (r_pobj) by_10\IN|of|the (r_prep) antagonism_4\NN|NONE (l_prep) of_5\IN|by|the (l_pobj) hyperactivity_9\NN|NONE
D000661_D006948 CID amphetamine_6\NN| (r_npadvmod) induced_8\VBN|NONE (r_amod) hyperactivity_9\NN|NONE
18951540
D007980_D004409 CID levodopa_5\NN| (r_npadvmod) induced_7\VBN|in (r_amod) dyskinesias_8\NNS|NONE
D007980_D010300 NONE levodopa_5\NN| (r_npadvmod) induced_7\VBN|in (r_amod) dyskinesias_8\NNS|NONE (l_prep) in_9\IN|induced (l_pobj) disease_12\NN|NONE
10683478
D004298_D007035 NONE dopamine_28\NN|distinct (r_relcl) changes_26\NNS|to (r_dobj) produce_24\VB|,|hypothermia|to|and (r_conj) induce_19\VB|its (l_dobj) hypothermia_20\NN|,|produce|to|and
D001058_D006948 CID apomorphine_5\NN| (r_npadvmod) induced_7\VBN|NONE (r_amod) hyperactivity_8\NN|NONE
D018491_D007035 NONE agonist_5\NN|,|, (r_appos) Apomorphine_0\NNP|,|was|ability|due|. (r_nsubjpass) selected_8\VBN|NONE (l_dobj) ability_17\NN|,|was|due|Apomorphine|. (l_acl) induce_19\VB|its (l_dobj) hypothermia_20\NN|,|produce|to|and
D001058_D007035 CID Apomorphine_0\NNP|,|was|ability|due|. (r_nsubjpass) selected_8\VBN|NONE (l_dobj) ability_17\NN|,|was|due|Apomorphine|. (l_acl) induce_19\VB|its (l_dobj) hypothermia_20\NN|,|produce|to|and
D001058_D007035 CID apomorphine_11\NN|,|.|conditions|upon|can|Moreover (l_prep) as_13\IN|to (l_pobj) hypothermia_17\NN|such
1687392
D013469_D002375 CID sulpiride_11\NN|.|catalepsy|fluphenazine (r_npadvmod) induced_12\VBD|NONE (l_dobj) catalepsy_13\NN|.|sulpiride|fluphenazine
D013469_D002375 CID sulpiride_5\NN|NONE (r_pobj) with_4\IN|of (r_prep) Combination_0\NN|.|potentiation|did|not (r_nsubj) induce_8\VB|NONE (l_dobj) potentiation_10\NN|.|Combination|did|not (l_compound) catalepsy_9\NN|NONE
D013469_D002375 CID sulpiride_20\NN|or| (r_conj) SCH_17\NNP|, (r_appos) fluphenazine_15\NN|NONE (r_pobj) by_14\IN|NONE (r_agent) induced_13\VBN|the (r_acl) catalepsy_12\NN|quinpirole|.
D015647_D002375 NONE 38393_5\CD||agonist|or|D|agonist (r_nummod) SKF_4\NNP|NONE (r_nmod) quinpirole_9\NN|catalepsy|. (r_nsubj) decreased_10\VBD|NONE (l_dobj) catalepsy_12\NN|quinpirole|.
D015647_D002375 NONE 38393_3\CD|NONE (r_nummod) SKF_2\NNP|NONE (r_pobj) of_1\IN|with (r_prep) Combination_0\NN|did|not|potentiated|. (r_nsubj) cause_8\VB|NONE (l_ccomp) potentiated_9\VBN|did|not|Combination|. (l_dobj) effect_11\NN|NONE (l_prep) on_12\IN|inhibitory|induced (l_pobj) catalepsy_13\NN|NONE
D004298_D002375 NONE dopamine_6\NN|both (r_compound) receptors_7\NNS|NONE (r_pobj) of_1\IN|NONE (r_prep) Blockade_0\NN|may|.|in|catalepsy (r_nsubj) induce_9\VB|NONE (l_dobj) catalepsy_10\NN|may|.|in|Blockade
D004298_D002375 NONE dopamine_4\NN|NONE (r_compound) antagonists_5\NNS|NONE (r_pobj) by_3\IN|NONE (r_agent) induced_2\VBN|The (r_acl) catalepsy_1\NN|been|and|has|determined
D004298_D002375 NONE dopamine_4\NN|NONE (r_compound) antagonists_5\NNS|NONE (r_pobj) by_3\IN|NONE (r_agent) induced_2\VBN|The (r_acl) catalepsy_1\NN|been|and|has|determined (r_nsubjpass) tested_8\VBN|NONE (l_conj) determined_18\VBN|been|and|catalepsy|has (l_nsubjpass) subtypes_13\NNS|was|. (l_acl) involved_14\VBN|possible|dopamine|the (l_prep) in_15\IN|NONE (l_pobj) catalepsy_16\NN|NONE
D004298_D002375 NONE dopamine_12\NN|possible|the|involved (r_compound) subtypes_13\NNS|was|. (r_nsubjpass) determined_18\VBN|been|and|catalepsy|has (r_conj) tested_8\VBN|NONE (l_nsubjpass) catalepsy_1\NN|been|and|has|determined
D004298_D002375 NONE dopamine_12\NN|possible|the|involved (r_compound) subtypes_13\NNS|was|. (l_acl) involved_14\VBN|possible|dopamine|the (l_prep) in_15\IN|NONE (l_pobj) catalepsy_16\NN|NONE
D004298_D002375 NONE Dopamine_0\NN|antagonist|SCH|, (r_compound) fluphenazine_2\NN|.|catalepsy|sulpiride (r_nsubj) induced_12\VBD|NONE (l_dobj) catalepsy_13\NN|.|sulpiride|fluphenazine
D004298_D002375 NONE dopamine_16\NN|NONE (r_compound) antagonists_17\NNS|NONE (r_pobj) by_15\IN|NONE (r_agent) induced_14\VBN|on|inhibitory (r_acl) effect_11\NN|NONE (l_prep) on_12\IN|inhibitory|induced (l_pobj) catalepsy_13\NN|NONE
D019257_D002375 NONE quinpirole_9\NN|catalepsy|. (r_nsubj) decreased_10\VBD|NONE (l_dobj) catalepsy_12\NN|quinpirole|.
D019257_D002375 NONE quinpirole_5\NN|NONE (r_pobj) with_4\IN|of (r_prep) Combination_0\NN|did|not|potentiated|. (r_nsubj) cause_8\VB|NONE (l_ccomp) potentiated_9\VBN|did|not|Combination|. (l_dobj) effect_11\NN|NONE (l_prep) on_12\IN|inhibitory|induced (l_pobj) catalepsy_13\NN|NONE
D005476_D002375 CID fluphenazine_2\NN|.|catalepsy|sulpiride (r_nsubj) induced_12\VBD|NONE (l_dobj) catalepsy_13\NN|.|sulpiride|fluphenazine
D005476_D002375 CID fluphenazine_15\NN|NONE (r_pobj) by_14\IN|NONE (r_agent) induced_13\VBN|the (r_acl) catalepsy_12\NN|quinpirole|.
C534628_D002375 CID 23390_7\CD|or|antagonist|D (r_nummod) SCH_6\NNP|Dopamine|antagonist|, (r_appos) fluphenazine_2\NN|.|catalepsy|sulpiride (r_nsubj) induced_12\VBD|NONE (l_dobj) catalepsy_13\NN|.|sulpiride|fluphenazine
C534628_D002375 CID 23390_3\CD|NONE (r_nummod) SCH_2\NNP|NONE (r_pobj) of_1\IN|with (r_prep) Combination_0\NN|.|potentiation|did|not (r_nsubj) induce_8\VB|NONE (l_dobj) potentiation_10\NN|.|Combination|did|not (l_compound) catalepsy_9\NN|NONE
C534628_D002375 CID 23390_18\CD|or|sulpiride (r_nummod) SCH_17\NNP|, (r_appos) fluphenazine_15\NN|NONE (r_pobj) by_14\IN|NONE (r_agent) induced_13\VBN|the (r_acl) catalepsy_12\NN|quinpirole|.
12760988
D013390_D063806 CID succinylcholine_5\NN| (r_npadvmod) associated_7\VBN|NONE (r_amod) myalgia_8\NN|NONE
D013390_D063806 CID succinylcholine_20\NN|NONE (r_pobj) before_19\IN|with (r_prep) pretreated_14\VBN| (r_acl) patients_13\NNS|NONE (r_pobj) in_11\IN|incidence|.|was (r_prep) determined_10\VBN|NONE (l_nsubjpass) incidence_1\NN|in|.|was (l_prep) of_4\IN|and|The|severity (l_pobj) myalgia_8\NN|NONE
D013390_D063806 CID succinylcholine_12\NN| (r_npadvmod) associated_14\VBN|NONE (r_amod) myalgia_15\NN|NONE
D003907_D010149 NONE dexamethasone_4\NN|NONE (r_pobj) of_3\IN|NONE (r_prep) Administration_2\NN|:|before (r_appos) IMPLICATIONS_0\NNS|not|effective|. (r_nsubj) was_7\VBD|NONE (l_acomp) effective_9\JJ|not|.|IMPLICATIONS (l_prep) in_10\IN|NONE (l_pcomp) decreasing_11\VBG|NONE (l_dobj) incidence_13\NN|NONE (l_conj) severity_16\NN|the|or (l_prep) of_17\IN|the (l_pobj) myalgia_22\NN|NONE
D003907_D010149 NONE dexamethasone_2\NN|NONE (r_pobj) with_1\IN|NONE (r_prep) Pretreatment_0\NN|.|not|justified (r_nsubj) is_3\VBZ|NONE (l_acomp) justified_5\VBN|.|not|Pretreatment (l_xcomp) prevent_7\VB|NONE (l_dobj) myalgia_9\NN|after|to
D013390_D010149 CID succinylcholine_3\NN|NONE (r_pobj) after_2\IN|.|Postoperative|:|evidence (r_prep) myalgia_1\NN|NONE
D013390_D010149 CID succinylcholine_6\NN|NONE (r_pobj) with_5\IN|NONE (r_prep) associated_4\VBN|common|A|side (r_acl) effect_3\NN|.|myalgia (r_nsubj) is_7\VBZ|NONE (l_attr) myalgia_9\NN|.|effect
D013390_D010149 CID succinylcholine_6\NN|NONE (r_pobj) before_5\IN|:|Administration (r_punct) IMPLICATIONS_0\NNS|not|effective|. (r_nsubj) was_7\VBD|NONE (l_acomp) effective_9\JJ|not|.|IMPLICATIONS (l_prep) in_10\IN|NONE (l_pcomp) decreasing_11\VBG|NONE (l_dobj) incidence_13\NN|NONE (l_conj) severity_16\NN|the|or (l_prep) of_17\IN|the (l_pobj) myalgia_22\NN|NONE
D013390_D010149 CID succinylcholine_18\NN| (r_npadvmod) induced_20\VBN|postoperative (r_amod) myalgia_22\NN|NONE
D013390_D010149 CID succinylcholine_11\NN|NONE (r_pobj) after_10\IN|myalgia|to (r_prep) prevent_7\VB|NONE (l_dobj) myalgia_9\NN|after|to
D003907_D063806 NONE dexamethasone_18\NN|or (r_conj) saline_16\NN|NONE (r_pobj) with_15\IN|before (r_prep) pretreated_14\VBN| (r_acl) patients_13\NNS|NONE (r_pobj) in_11\IN|incidence|.|was (r_prep) determined_10\VBN|NONE (l_nsubjpass) incidence_1\NN|in|.|was (l_prep) of_4\IN|and|The|severity (l_pobj) myalgia_8\NN|NONE
D003907_D063806 NONE dexamethasone_18\NN|the (r_compound) group_19\NN|NONE (r_pobj) in_16\IN| (r_prep) patients_15\NNS|,|compared|and|of|reported (r_nsubj) complained_20\VBD|two|the|: (r_acl) groups_12\NNS|NONE (r_pobj) between_9\IN|not|significantly|Incidence|did (r_prep) differ_7\VB|NONE (l_nsubj) Incidence_0\NN|not|significantly|did|between (l_conj) severity_2\NN|and (l_prep) of_3\IN|NONE (l_pobj) myalgia_4\NN|NONE
D003907_D063806 NONE dexamethasone_18\NN|the (r_compound) group_19\NN|NONE (r_pobj) in_16\IN| (r_prep) patients_15\NNS|,|compared|and|of|reported (r_nsubj) complained_20\VBD|two|the|: (l_prep) of_21\IN|,|compared|patients|and|reported (l_pobj) myalgia_22\NN|NONE
D003907_D063806 NONE dexamethasone_18\NN|the (r_compound) group_19\NN|NONE (r_pobj) in_16\IN| (r_prep) patients_15\NNS|,|compared|and|of|reported (r_nsubj) complained_20\VBD|two|the|: (l_conj) reported_36\VBN|,|compared|patients|and|of (l_nsubjpass) myalgia_34\NN|was|by|.
11524350
D002045_D001145 NONE bupivacaine_26\NN|NONE (r_pobj) of_25\IN|NONE (r_prep) those_24\DT|NONE (r_pobj) than_23\IN|NONE (r_prep) larger_22\JJR|.|they (r_acomp) were_21\VBD|,|doses|but|smaller (r_conj) were_10\VBD|NONE (l_nsubj) doses_2\NNS|were|,|but|smaller (l_relcl) produced_6\VBD|cumulative|The|of (l_dobj) dysrhythmias_7\NNS|that
C476513_D001145 CID levobupivacaine_4\NN|NONE (r_pobj) of_3\IN|cumulative|produced|The (r_prep) doses_2\NNS|were|,|but|smaller (l_relcl) produced_6\VBD|cumulative|The|of (l_dobj) dysrhythmias_7\NNS|that
C037663_D012640 CID ropivacaine_6\VBP|and (r_conj) levobupivacaine_4\NN|NONE (r_pobj) of_3\IN|The|cumulative (r_prep) doses_2\NNS|and|seizures|similar|were|. (r_nsubj) were_10\VBD|NONE (l_nsubj) seizures_9\NNS|and|similar|were|doses|.
D002045_D012640 NONE bupivacaine_18\NN|NONE (r_pobj) of_17\IN|NONE (r_prep) those_16\DT|NONE (r_pobj) than_15\IN|NONE (r_prep) larger_14\JJR|NONE (r_acomp) were_13\VBD|and|seizures|similar|doses|. (r_conj) were_10\VBD|NONE (l_nsubj) seizures_9\NNS|and|similar|were|doses|.
C476513_D064420 NONE levobupivacaine-_7\JJ|, (r_conj) bupivacaine-_5\DT|NONE (r_nmod) rats_13\NNS|NONE (r_pobj) in_4\IN|.|Systemic|resuscitation|and (r_prep) toxicity_1\NN|NONE
C476513_D064420 NONE levobupivacaine_8\NN|,|systemic|of|the (r_conj) toxicity_4\NN|.|We
C476513_D064420 NONE levobupivacaine_7\NN|NONE (r_pobj) of_6\IN|systemic|the (r_prep) toxicity_5\NN|intermediate|that|administered
C476513_D064420 NONE levobupivacaine_42\NN|or (r_conj) bupivacaine_40\NN|NONE (r_pobj) by_39\IN|NONE (r_agent) induced_38\VBN|NONE (r_acl) that_37\DT|NONE (r_pobj) than_36\IN|more|to (r_prep) susceptible_33\JJ|to (r_acomp) be_31\VB|.|arrest (r_xcomp) appears_29\VBZ|and|when|at (r_conj) administered_17\VBN|toxicity|intermediate|that (r_advcl) is_8\VBZ|We (l_nsubj) toxicity_5\NN|intermediate|that|administered
C476513_D012640 CID levobupivacaine_4\NN|NONE (r_pobj) of_3\IN|The|cumulative (r_prep) doses_2\NNS|and|seizures|similar|were|. (r_nsubj) were_10\VBD|NONE (l_nsubj) seizures_9\NNS|and|similar|were|doses|.
C037663_D064420 NONE ropivacaine_10\NN| (r_npadvmod) infused_12\VBN|,|or (r_conj) levobupivacaine-_7\JJ|, (r_conj) bupivacaine-_5\DT|NONE (r_nmod) rats_13\NNS|NONE (r_pobj) in_4\IN|.|Systemic|resuscitation|and (r_prep) toxicity_1\NN|NONE
C037663_D064420 NONE ropivacaine_11\NN|,|and (r_conj) levobupivacaine_8\NN|,|systemic|of|the (r_conj) toxicity_4\NN|.|We
C037663_D064420 NONE ropivacaine_13\NN|NONE (r_pobj) of_12\IN|NONE (r_prep) that_11\DT|NONE (r_pobj) between_10\IN|NONE (r_prep) intermediate_9\JJ|toxicity|that|administered (r_acomp) is_8\VBZ|We (l_nsubj) toxicity_5\NN|intermediate|that|administered
C037663_D064420 NONE ropivacaine_24\NN| (r_npadvmod) induced_26\VBN|cardiac|that (r_amod) arrest_28\NN|.|be (r_nsubj) appears_29\VBZ|and|when|at (r_conj) administered_17\VBN|toxicity|intermediate|that (r_advcl) is_8\VBZ|We (l_nsubj) toxicity_5\NN|intermediate|that|administered
D002045_D064420 NONE bupivacaine-_5\DT|NONE (r_nmod) rats_13\NNS|NONE (r_pobj) in_4\IN|.|Systemic|resuscitation|and (r_prep) toxicity_1\NN|NONE
D002045_D064420 NONE bupivacaine_6\NN|NONE (r_pobj) of_5\IN|,|systemic|the|levobupivacaine (r_prep) toxicity_4\NN|.|We
D002045_D064420 NONE bupivacaine_15\NN|and (r_conj) ropivacaine_13\NN|NONE (r_pobj) of_12\IN|NONE (r_prep) that_11\DT|NONE (r_pobj) between_10\IN|NONE (r_prep) intermediate_9\JJ|toxicity|that|administered (r_acomp) is_8\VBZ|We (l_nsubj) toxicity_5\NN|intermediate|that|administered
D002045_D064420 NONE bupivacaine_40\NN|NONE (r_pobj) by_39\IN|NONE (r_agent) induced_38\VBN|NONE (r_acl) that_37\DT|NONE (r_pobj) than_36\IN|more|to (r_prep) susceptible_33\JJ|to (r_acomp) be_31\VB|.|arrest (r_xcomp) appears_29\VBZ|and|when|at (r_conj) administered_17\VBN|toxicity|intermediate|that (r_advcl) is_8\VBZ|We (l_nsubj) toxicity_5\NN|intermediate|that|administered
C037663_D001145 CID ropivacaine_17\NN|NONE (r_pobj) of_16\IN|corresponding|the (r_prep) doses_15\NNS|NONE (r_pobj) than_12\IN|NONE (r_prep) smaller_11\JJR|were|,|doses|but (r_acomp) were_10\VBD|NONE (l_nsubj) doses_2\NNS|were|,|but|smaller (l_relcl) produced_6\VBD|cumulative|The|of (l_dobj) dysrhythmias_7\NNS|that
C476513_D006323 CID levobupivacaine_4\NN|NONE (r_pobj) of_3\IN|cumulative|produced|The (r_prep) doses_2\NNS|were|,|but|smaller (l_relcl) produced_6\VBD|cumulative|The|of (l_dobj) dysrhythmias_7\NNS|that (l_conj) asystole_9\NN|and
C476513_D006323 CID levobupivacaine_7\NN|NONE (r_pobj) of_6\IN|systemic|the (r_prep) toxicity_5\NN|intermediate|that|administered (r_nsubj) is_8\VBZ|We (l_advcl) administered_17\VBN|toxicity|intermediate|that (l_conj) appears_29\VBZ|and|when|at (l_nsubj) arrest_28\NN|.|be
C476513_D006323 CID levobupivacaine_42\NN|or (r_conj) bupivacaine_40\NN|NONE (r_pobj) by_39\IN|NONE (r_agent) induced_38\VBN|NONE (r_acl) that_37\DT|NONE (r_pobj) than_36\IN|more|to (r_prep) susceptible_33\JJ|to (r_acomp) be_31\VB|.|arrest (r_xcomp) appears_29\VBZ|and|when|at (l_nsubj) arrest_28\NN|.|be
C037663_D006323 CID ropivacaine_17\NN|NONE (r_pobj) of_16\IN|corresponding|the (r_prep) doses_15\NNS|NONE (r_pobj) than_12\IN|NONE (r_prep) smaller_11\JJR|were|,|doses|but (r_acomp) were_10\VBD|NONE (l_nsubj) doses_2\NNS|were|,|but|smaller (l_relcl) produced_6\VBD|cumulative|The|of (l_dobj) dysrhythmias_7\NNS|that (l_conj) asystole_9\NN|and
C037663_D006323 CID ropivacaine_13\NN|NONE (r_pobj) of_12\IN|NONE (r_prep) that_11\DT|NONE (r_pobj) between_10\IN|NONE (r_prep) intermediate_9\JJ|toxicity|that|administered (r_acomp) is_8\VBZ|We (l_advcl) administered_17\VBN|toxicity|intermediate|that (l_conj) appears_29\VBZ|and|when|at (l_nsubj) arrest_28\NN|.|be
C037663_D006323 CID ropivacaine_24\NN| (r_npadvmod) induced_26\VBN|cardiac|that (r_amod) arrest_28\NN|.|be
D002045_D006323 NONE bupivacaine_26\NN|NONE (r_pobj) of_25\IN|NONE (r_prep) those_24\DT|NONE (r_pobj) than_23\IN|NONE (r_prep) larger_22\JJR|.|they (r_acomp) were_21\VBD|,|doses|but|smaller (r_conj) were_10\VBD|NONE (l_nsubj) doses_2\NNS|were|,|but|smaller (l_relcl) produced_6\VBD|cumulative|The|of (l_dobj) dysrhythmias_7\NNS|that (l_conj) asystole_9\NN|and
D002045_D006323 NONE bupivacaine_15\NN|and (r_conj) ropivacaine_13\NN|NONE (r_pobj) of_12\IN|NONE (r_prep) that_11\DT|NONE (r_pobj) between_10\IN|NONE (r_prep) intermediate_9\JJ|toxicity|that|administered (r_acomp) is_8\VBZ|We (l_advcl) administered_17\VBN|toxicity|intermediate|that (l_conj) appears_29\VBZ|and|when|at (l_nsubj) arrest_28\NN|.|be
D002045_D006323 NONE bupivacaine_40\NN|NONE (r_pobj) by_39\IN|NONE (r_agent) induced_38\VBN|NONE (r_acl) that_37\DT|NONE (r_pobj) than_36\IN|more|to (r_prep) susceptible_33\JJ|to (r_acomp) be_31\VB|.|arrest (r_xcomp) appears_29\VBZ|and|when|at (l_nsubj) arrest_28\NN|.|be
10533019
D004110_D013746 CID diltiazem_6\NN| (r_npadvmod) induced_8\VBN|threatening|with (r_amod) tetany_9\NN|NONE
D004110_D013746 CID diltiazem_16\NN|NONE (r_pobj) of_14\IN|the (r_prep) infusion_13\NN|NONE (r_pobj) after_11\IN|who|tetany|with (r_prep) developed_5\VBD|a (l_dobj) tetany_6\NN|who|after|with
D004110_D013746 CID diltiazem_17\NN|NONE (r_pobj) of_15\IN|the (r_prep) administration_14\NN|that|tetany|may|and|be (r_dobj) accompany_12\VB|NONE (l_nsubj) tetany_10\NN|that|may|and|be|administration
D004110_D012131 NONE diltiazem_16\NN|NONE (r_pobj) of_14\IN|the (r_prep) infusion_13\NN|NONE (r_pobj) after_11\IN|who|tetany|with (r_prep) developed_5\VBD|a (l_prep) with_7\IN|who|tetany|after (l_pobj) arrest_10\NN|NONE
D002122_D013746 NONE chloride_12\NN|NONE (r_pobj) with_10\IN|induced|threatening (r_prep) tetany_9\NN|NONE
D002122_D013746 NONE chloride_4\NN|NONE (r_pobj) of_2\IN|The (r_prep) administration_1\NN|.|rapidly|,|averting|tetany (r_nsubj) resolved_6\VBD|NONE (l_dobj) tetany_10\NN|.|rapidly|administration|,|averting
D002122_D013746 NONE chloride_21\NN|may|remedy|that (r_nsubj) be_23\VB|that|tetany|may|and|administration (r_conj) accompany_12\VB|NONE (l_nsubj) tetany_10\NN|that|may|and|be|administration
6308526
D009020_D000699 NONE morphine_5\NN|significantly|analgesia|.|Pretreatment|at (r_dobj) blocked_4\VBD|NONE (l_npadvmod) analgesia_6\NN|significantly|morphine|.|Pretreatment|at
D009020_D007022 CID morphine_6\NN| (r_npadvmod) induced_8\VBN|hypotension|the (r_amod) depression_12\NN|,|was|significantly|.|Moreover|,|naloxazone (l_nmod) hypotension_9\NN|the|induced
D009020_D007022 CID morphine_15\NN| (r_npadvmod) induced_17\VBN|NONE (r_amod) bradycardia_18\NN|affected|whereas (r_nsubj) was_19\VBD|,|significantly|.|Moreover|,|depression|naloxazone (r_advcl) attenuated_4\VBD|NONE (l_dobj) depression_12\NN|,|was|significantly|.|Moreover|,|naloxazone (l_nmod) hypotension_9\NN|the|induced
D009020_D012131 NONE morphine_6\NN| (r_npadvmod) induced_8\VBN|hypotension|the (r_amod) depression_12\NN|,|was|significantly|.|Moreover|,|naloxazone
D009020_D012131 NONE morphine_15\NN| (r_npadvmod) induced_17\VBN|NONE (r_amod) bradycardia_18\NN|affected|whereas (r_nsubj) was_19\VBD|,|significantly|.|Moreover|,|depression|naloxazone (r_advcl) attenuated_4\VBD|NONE (l_dobj) depression_12\NN|,|was|significantly|.|Moreover|,|naloxazone
C024224_D007022 NONE naloxazone_2\NN|,|was|significantly|.|Moreover|,|depression (r_nsubj) attenuated_4\VBD|NONE (l_dobj) depression_12\NN|,|was|significantly|.|Moreover|,|naloxazone (l_nmod) hypotension_9\NN|the|induced
C024224_D000699 NONE naloxazone_2\NN|NONE (r_pobj) with_1\IN|NONE (r_prep) Pretreatment_0\NN|significantly|analgesia|morphine|.|at (r_nsubj) blocked_4\VBD|NONE (l_npadvmod) analgesia_6\NN|significantly|morphine|.|Pretreatment|at
D009020_D002375 CID morphine_5\NN|significantly|analgesia|.|Pretreatment|at (r_dobj) blocked_4\VBD|NONE (l_npadvmod) analgesia_6\NN|significantly|morphine|.|Pretreatment|at (l_conj) catalepsy_8\NN|,
C024224_D007035 NONE naloxazone_2\NN|NONE (r_pobj) with_1\IN|NONE (r_prep) Pretreatment_0\NN|significantly|analgesia|morphine|.|at (r_nsubj) blocked_4\VBD|NONE (l_npadvmod) analgesia_6\NN|significantly|morphine|.|Pretreatment|at (l_conj) catalepsy_8\NN|, (l_conj) hypothermia_10\VBN|and
D009020_D001919 CID morphine_6\NN| (r_npadvmod) induced_8\VBN|hypotension|the (r_amod) depression_12\NN|,|was|significantly|.|Moreover|,|naloxazone (r_dobj) attenuated_4\VBD|NONE (l_advcl) was_19\VBD|,|significantly|.|Moreover|,|depression|naloxazone (l_nsubj) bradycardia_18\NN|affected|whereas
D009020_D001919 CID morphine_15\NN| (r_npadvmod) induced_17\VBN|NONE (r_amod) bradycardia_18\NN|affected|whereas
D009020_D007035 CID morphine_5\NN|significantly|analgesia|.|Pretreatment|at (r_dobj) blocked_4\VBD|NONE (l_npadvmod) analgesia_6\NN|significantly|morphine|.|Pretreatment|at (l_conj) catalepsy_8\NN|, (l_conj) hypothermia_10\VBN|and
C024224_D001919 NONE naloxazone_2\NN|,|was|significantly|.|Moreover|,|depression (r_nsubj) attenuated_4\VBD|NONE (l_advcl) was_19\VBD|,|significantly|.|Moreover|,|depression|naloxazone (l_nsubj) bradycardia_18\NN|affected|whereas
C024224_D002375 NONE naloxazone_2\NN|NONE (r_pobj) with_1\IN|NONE (r_prep) Pretreatment_0\NN|significantly|analgesia|morphine|.|at (r_nsubj) blocked_4\VBD|NONE (l_npadvmod) analgesia_6\NN|significantly|morphine|.|Pretreatment|at (l_conj) catalepsy_8\NN|,
C024224_D012131 NONE naloxazone_2\NN|,|was|significantly|.|Moreover|,|depression (r_nsubj) attenuated_4\VBD|NONE (l_dobj) depression_12\NN|,|was|significantly|.|Moreover|,|naloxazone
10791295
D001058_D010554 CID apomorphine_2\NN|NONE (r_pobj) of_1\IN|NONE (r_prep) Development_0\NN|comparison|:||.|behavior (r_nsubj) induced_4\VBN|NONE (l_dobj) behavior_6\NN|comparison|Development|:||.
D001058_D010554 CID apomorphine_3\NN|NONE (r_pobj) of_2\IN|The (r_prep) development_1\NN||daily|behavior|.|s.c.|studied|) (r_nsubj) induced_5\VBN|NONE (l_dobj) behavior_14\NN|development||daily|.|s.c.|studied|)
D001058_D010554 CID apomorphine_5\NN|repeated (r_compound) treatment_6\NN|In|development|.|,|evidenced (r_nsubj) induced_7\VBD|NONE (l_dobj) development_10\NN|treatment|In|.|,|evidenced (l_prep) of_11\IN|a|gradual (l_pobj) behavior_13\NN|NONE
D001058_D010554 CID apomorphine_5\NN|repeated (r_compound) treatment_6\NN|In|development|.|,|evidenced (r_nsubj) induced_7\VBD|NONE (l_advcl) evidenced_15\VBN|treatment|In|development|.|, (l_agent) by_16\IN|and|shortened|as (l_pobj) intensity_19\NN|NONE (l_prep) of_20\IN|increased|the (l_pobj) aggressiveness_21\NN|NONE
D001058_D010554 CID apomorphine_14\NN|NONE (r_preconj) the_13\DT|aggressive|induced (r_det) behavior_18\NN|NONE
14982270
D008713_D002779 NONE Methimazole_0\NN| (r_npadvmod) induced_2\VBN|NONE (r_amod) cholestasis_3\NN|propranolol|was|and|,
D008713_D007565 NONE methimazole_14\NN|and|(|tid|)|propranolol (r_dobj) receiving_13\VBG|NONE (r_pcomp) after_12\IN|month (r_prep) itching_9\NN|.|and|jaundice|woman (r_conj) had_5\VBD|NONE (l_dobj) jaundice_7\NN|itching|.|and|woman
D011433_D002779 NONE propranolol_8\NN|was|and|cholestasis|, (r_conj) diagnosed_5\VBN|was|. (l_nsubjpass) cholestasis_3\NN|propranolol|was|and|,
D008713_D041781 CID Methimazole_0\NN| (r_npadvmod) induced_2\VBN|.|cholestatic (r_amod) jaundice_4\NN|NONE
D011433_D011537 NONE propranolol_21\NN|and|(|tid|)|methimazole (r_conj) receiving_13\VBG|NONE (r_pcomp) after_12\IN|month (r_prep) itching_9\NN|.|and|jaundice|woman
D008713_D011537 CID methimazole_14\NN|and|(|tid|)|propranolol (r_dobj) receiving_13\VBG|NONE (r_pcomp) after_12\IN|month (r_prep) itching_9\NN|.|and|jaundice|woman
D008713_D006980 NONE methimazole_14\NN|and|(|tid|)|propranolol (r_dobj) receiving_13\VBG|NONE (l_conj) propranolol_21\NN|and|(|tid|)|methimazole (l_prep) for_27\IN|tid (l_pobj) treatment_28\NN|NONE (l_prep) of_29\IN|NONE (l_pobj) hyperthyroidism_30\NN|NONE
D011433_D006980 NONE propranolol_21\NN|and|(|tid|)|methimazole (l_prep) for_27\IN|tid (l_pobj) treatment_28\NN|NONE (l_prep) of_29\IN|NONE (l_pobj) hyperthyroidism_30\NN|NONE
D011433_D007565 NONE propranolol_21\NN|and|(|tid|)|methimazole (r_conj) receiving_13\VBG|NONE (r_pcomp) after_12\IN|month (r_prep) itching_9\NN|.|and|jaundice|woman (r_conj) had_5\VBD|NONE (l_dobj) jaundice_7\NN|itching|.|and|woman
9514561
D002211_D010146 CID capsaicin_5\NN|NONE (r_pobj) by_4\IN|NONE (r_agent) elicited_3\VBN|cranial|Experimental|.|:|study (r_acl) pain_2\NN|NONE
D002211_D010146 CID capsaicin_4\NN|NONE (r_pobj) of_3\IN|small|A (r_prep) amount_2\NN|in|subcutaneously|was|evoke|. (r_nsubjpass) administered_6\VBN|NONE (l_advcl) evoke_13\VB|amount|in|subcutaneously|was|. (l_dobj) sensation_17\NN|to (l_amod) painful_16\JJ|burning|a|in
2024540
D004656_D006333 NONE enalapril_11\NN|NONE (r_pobj) of_10\IN|in (r_prep) safety_9\NN|of|analysis|.|:|and (l_prep) in_14\IN|of (l_pobj) phase_18\NN|NONE (l_prep) of_19\IN|the|initial|treatment (l_pobj) patients_20\NNS|NONE (l_prep) with_21\IN|NONE (l_pobj) failure_24\NN|NONE
D004656_D007022 NONE enalapril_8\NN|ACE|the (r_appos) inhibitor_7\NN|NONE (r_pobj) of_4\IN|the (r_prep) safety_3\NN|To (r_dobj) assess_1\VB|.|was|trial|compared|that (r_advcl) designed_19\VBN|NONE (l_prep) compared_21\VBD|.|was|trial|that|assess (l_pobj) incidence_23\NN|NONE (l_prep) of_26\IN|and|severity|the (l_pobj) hypotension_28\NN|NONE
D004656_D007022 NONE enalapril_3\RB|who (r_dobj) received_2\VBD|NONE (r_relcl) Patients_0\NNS|hypotension|. (r_nsubj) experienced_4\VBD|NONE (l_dobj) hypotension_11\NN|Patients|.
D000806_D007022 CID inhibitors_10\NNS|NONE (r_appos) enzyme_6\NN|into (r_dobj) converting_5\VBG|NONE (l_prep) into_11\IN|enzyme (l_pobj) treatment_14\NN|NONE (l_prep) of_15\IN|the|adjunctive (l_pobj) patients_16\NNS|NONE (l_prep) with_17\IN|NONE (l_pobj) failure_20\NN|NONE (l_conj) cases_22\NNS|heart|,|congestive (l_prep) of_23\IN|NONE (l_pobj) hypotension_25\NN|NONE
D000806_D007022 CID inhibitor_7\NN|NONE (r_pobj) of_4\IN|the (r_prep) safety_3\NN|To (r_dobj) assess_1\VB|.|was|trial|compared|that (r_advcl) designed_19\VBN|NONE (l_prep) compared_21\VBD|.|was|trial|that|assess (l_pobj) incidence_23\NN|NONE (l_prep) of_26\IN|and|severity|the (l_pobj) hypotension_28\NN|NONE
D011224_D007022 CID prazosin_14\NN| (r_npadvmod) controlled_16\VBN|,|multicenter|,|a|randomized (r_amod) trial_17\NN|.|was|compared|that|assess (r_nsubjpass) designed_19\VBN|NONE (l_prep) compared_21\VBD|.|was|trial|that|assess (l_pobj) incidence_23\NN|NONE (l_prep) of_26\IN|and|severity|the (l_pobj) hypotension_28\NN|NONE
D011224_D007022 CID prazosin_21\NN|who (r_dobj) received_20\VBD|the (r_relcl) patients_18\NNS|NONE (r_pobj) than_16\IN|)|(|clinically|% (r_prep) hypotension_11\NN|Patients|.
D000806_D006333 NONE inhibitors_10\NNS|NONE (r_appos) enzyme_6\NN|into (r_dobj) converting_5\VBG|NONE (l_prep) into_11\IN|enzyme (l_pobj) treatment_14\NN|NONE (l_prep) of_15\IN|the|adjunctive (l_pobj) patients_16\NNS|NONE (l_prep) with_17\IN|NONE (l_pobj) failure_20\NN|NONE
D011224_D006333 NONE prazosin_13\NN|and (r_conj) enalapril_11\NN|NONE (r_pobj) of_10\IN|in (r_prep) safety_9\NN|of|analysis|.|:|and (l_prep) in_14\IN|of (l_pobj) phase_18\NN|NONE (l_prep) of_19\IN|the|initial|treatment (l_pobj) patients_20\NNS|NONE (l_prep) with_21\IN|NONE (l_pobj) failure_24\NN|NONE
18631865
D020123_D011507 CID sirolimus_5\NN|NONE (r_pobj) to_4\IN|NONE (r_prep) due_3\JJ|Whether|proteinuria (r_acomp) was_2\VBD|unsolved|.|observed (l_nsubj) proteinuria_1\NN|due|Whether
D020123_D011507 CID sirolimus_5\NN|NONE (r_pobj) to_4\IN|NONE (r_prep) due_3\JJ|Whether|proteinuria (r_acomp) was_2\VBD|unsolved|.|observed (r_csubj) remained_14\VBD|NONE (l_advcl) observed_22\VBN|unsolved|.|was (l_nsubjpass) proteinuria_19\NN|been|has|until|in|during
D020123_D011507 CID sirolimus_24\NN|NONE (r_compound) therapy_25\NN|NONE (r_pobj) during_23\IN|been|has|until|in|proteinuria (r_prep) observed_22\VBN|unsolved|.|was (r_advcl) remained_14\VBD|NONE (l_csubj) was_2\VBD|unsolved|.|observed (l_nsubj) proteinuria_1\NN|due|Whether
D020123_D011507 CID sirolimus_24\NN|NONE (r_compound) therapy_25\NN|NONE (r_pobj) during_23\IN|been|has|until|in|proteinuria (r_prep) observed_22\VBN|unsolved|.|was (l_nsubjpass) proteinuria_19\NN|been|has|until|in|during
D020123_D011507 CID sirolimus_34\NN|de (r_nmod) novo_36\NNP|who (r_dobj) received_33\VBD|NONE (r_relcl) patients_31\NNS|NONE (r_pobj) in_30\IN|transplantation|and (r_conj) in_26\IN|been|has|until|during|proteinuria (r_prep) observed_22\VBN|unsolved|.|was (r_advcl) remained_14\VBD|NONE (l_csubj) was_2\VBD|unsolved|.|observed (l_nsubj) proteinuria_1\NN|due|Whether
D020123_D011507 CID sirolimus_34\NN|de (r_nmod) novo_36\NNP|who (r_dobj) received_33\VBD|NONE (r_relcl) patients_31\NNS|NONE (r_pobj) in_30\IN|transplantation|and (r_conj) in_26\IN|been|has|until|during|proteinuria (r_prep) observed_22\VBN|unsolved|.|was (l_nsubjpass) proteinuria_19\NN|been|has|until|in|during
D020123_D051436 NONE rapamycin_16\NNS|mToR|,|sirolimus|, (r_nmod) inhibitors_20\NNS|NONE (r_pobj) of_15\IN|mammalian (r_prep) target_14\NN|NONE (r_pobj) to_12\IN|in|from (r_prep) conversion_8\NN|NONE (l_prep) in_25\IN|to|from (l_pobj) recipients_28\NNS|NONE (l_prep) with_29\IN|transplant|renal (l_pobj) nephropathy_32\NN|NONE
D020123_D051436 NONE sirolimus_23\NN|mToR|,|rapamycin|, (r_appos) inhibitors_20\NNS|NONE (r_pobj) of_15\IN|mammalian (r_prep) target_14\NN|NONE (r_pobj) to_12\IN|in|from (r_prep) conversion_8\NN|NONE (l_prep) in_25\IN|to|from (l_pobj) recipients_28\NNS|NONE (l_prep) with_29\IN|transplant|renal (l_pobj) nephropathy_32\NN|NONE
7437994
2522601
D002220_D051437 CID carbamazepine_2\NN|NONE (r_pobj) to_1\IN|presenting|. (r_prep) Hypersensitivity_0\NN|NONE (l_acl) presenting_3\VBG|to|. (l_prep) with_4\IN|NONE (l_pobj) reaction_7\NN|NONE (l_conj) failure_15\NN|a|eosinophilia|,|leukemoid
D002220_D051437 CID carbamazepine_8\NN|NONE (r_pobj) to_7\IN|NONE (r_prep) hypersensitivity_6\NN|in|with (r_nsubj) presented_9\VBN|reaction|a|, (r_relcl) patient_3\NN|.|We (l_conj) reaction_17\NN|a|,|presented (l_conj) eosinophilia_19\NN|leukemoid|,|a|severe (l_conj) hyponatremia_21\NN|, (l_conj) failure_25\NN|,|and
D002220_D007010 CID carbamazepine_8\NN|NONE (r_pobj) to_7\IN|NONE (r_prep) hypersensitivity_6\NN|in|with (r_nsubj) presented_9\VBN|reaction|a|, (r_relcl) patient_3\NN|.|We (l_conj) reaction_17\NN|a|,|presented (l_conj) eosinophilia_19\NN|leukemoid|,|a|severe (l_conj) hyponatremia_21\NN|,
D002220_D003873 CID carbamazepine_2\NN|NONE (r_pobj) to_1\IN|presenting|. (r_prep) Hypersensitivity_0\NN|NONE (l_acl) presenting_3\VBG|to|. (l_prep) with_4\IN|NONE (l_pobj) reaction_7\NN|NONE (l_conj) eosinophilia_9\NN|a|failure|,|leukemoid (l_conj) erythroderma_11\NN|,
D002220_D003873 CID carbamazepine_8\NN|NONE (r_pobj) to_7\IN|NONE (r_prep) hypersensitivity_6\NN|in|with (r_nsubj) presented_9\VBN|reaction|a|, (l_prep) with_10\IN|in|hypersensitivity (l_pobj) erythroderma_12\NN|NONE
D002220_D004342 CID carbamazepine_2\NN|NONE (r_pobj) to_1\IN|presenting|. (r_prep) Hypersensitivity_0\NN|NONE
D002220_D004342 CID carbamazepine_8\NN|NONE (r_pobj) to_7\IN|NONE (r_prep) hypersensitivity_6\NN|in|with
D002220_D004802 NONE carbamazepine_2\NN|NONE (r_pobj) to_1\IN|presenting|. (r_prep) Hypersensitivity_0\NN|NONE (l_acl) presenting_3\VBG|to|. (l_prep) with_4\IN|NONE (l_pobj) reaction_7\NN|NONE (l_conj) eosinophilia_9\NN|a|failure|,|leukemoid
D002220_D004802 NONE carbamazepine_8\NN|NONE (r_pobj) to_7\IN|NONE (r_prep) hypersensitivity_6\NN|in|with (r_nsubj) presented_9\VBN|reaction|a|, (r_relcl) patient_3\NN|.|We (l_conj) reaction_17\NN|a|,|presented (l_conj) eosinophilia_19\NN|leukemoid|,|a|severe
D002220_D007955 CID carbamazepine_2\NN|NONE (r_pobj) to_1\IN|presenting|. (r_prep) Hypersensitivity_0\NN|NONE (l_acl) presenting_3\VBG|to|. (l_prep) with_4\IN|NONE (l_pobj) reaction_7\NN|NONE
D002220_D007955 CID carbamazepine_8\NN|NONE (r_pobj) to_7\IN|NONE (r_prep) hypersensitivity_6\NN|in|with (r_nsubj) presented_9\VBN|reaction|a|, (r_relcl) patient_3\NN|.|We (l_conj) reaction_17\NN|a|,|presented
16174948
D003042_D013345 CID cocaine_6\NN| (r_npadvmod) associated_8\VBN|subarachnoid (r_amod) hemorrhage_10\NN|NONE
D003042_D013345 CID cocaine_12\NN| (r_npadvmod) associated_14\VBN|SAH|subarachnoid|underwent (r_amod) hemorrhage_16\NN|NONE
D003042_D013345 CID cocaine_12\NN| (r_npadvmod) associated_14\VBN|SAH|subarachnoid|underwent (r_amod) hemorrhage_16\NN|NONE (l_appos) SAH_18\NNP|associated|subarachnoid|underwent
D003042_D013345 CID cocaine_25\NN|NONE (r_compound) use_26\NN|shortly (r_pobj) after_24\IN|who|angiography (r_prep) underwent_21\VBD|associated|SAH|subarachnoid (r_relcl) hemorrhage_16\NN|NONE
D003042_D013345 CID cocaine_25\NN|NONE (r_compound) use_26\NN|shortly (r_pobj) after_24\IN|who|angiography (r_prep) underwent_21\VBD|associated|SAH|subarachnoid (r_relcl) hemorrhage_16\NN|NONE (l_appos) SAH_18\NNP|associated|subarachnoid|underwent
D003042_D013345 CID cocaine_14\NN|NONE (r_pobj) for_13\IN|positive|urine (r_prep) toxicology_12\NN|NONE (r_pobj) with_9\IN|NONE (r_prep) those_8\DT|NONE (r_dobj) identified_7\VBD|patients|We|retrospectively|and|. (r_conj) screened_1\VBD|NONE (l_dobj) patients_2\NNS|We|retrospectively|and|.|identified (l_prep) with_3\IN|NONE (l_pobj) SAH_4\NNP|NONE
D003042_D013345 CID cocaine_31\NN|NONE (r_compound) use_32\NN|NONE (r_pobj) with_30\IN|NONE (r_prep) associated_29\VBN|aneurysmal (r_acl) SAH_28\NNP|NONE
D003042_D017542 CID cocaine_31\NN|NONE (r_compound) use_32\NN|NONE (r_pobj) with_30\IN|NONE (r_prep) associated_29\VBN|aneurysmal (r_acl) SAH_28\NNP|NONE (l_amod) aneurysmal_27\NN|associated
D003042_D014657 NONE Cocaine_0\NN|NONE (r_compound) use_1\NN|has|.|been|with (r_nsubjpass) associated_4\VBN|NONE (l_prep) with_5\IN|has|.|use|been (l_pobj) complications_7\NNS|NONE (l_prep) including_9\VBG|neurovascular|, (l_pobj) vasoconstriction_11\NN|NONE (l_conj) vasculitis_13\NN|arterial|and
D003042_D014657 NONE cocaine_31\NN|NONE (r_compound) use_32\NN|NONE (r_pobj) with_30\IN|NONE (r_prep) associated_29\VBN|aneurysmal (r_acl) SAH_28\NNP|NONE (r_pobj) after_26\IN|angiography|who (r_prep) underwent_24\VBD|NONE (r_relcl) patients_22\NNS|NONE (r_pobj) in_21\IN|be|could|evidence|. (r_prep) found_20\VBN|NONE (l_nsubjpass) evidence_2\NN|be|could|in|. (l_prep) for_3\IN|quantitative|No (l_pobj) narrowing_4\VBG|NONE (l_prep) of_5\IN|NONE (l_pobj) arteries_8\NNS|NONE (l_conj) evidence_12\NN|or|large|cerebral (l_prep) for_13\IN|angiographic|qualitative (l_pobj) narrowing_15\NN|NONE (l_conj) vasculitis_17\NN|distal|or
D003042_D013901 NONE Cocaine_0\NN|NONE (r_compound) use_1\NN|has|.|been|with (r_nsubjpass) associated_4\VBN|NONE (l_prep) with_5\IN|has|.|use|been (l_pobj) complications_7\NNS|NONE
15275829
D000109_D006948 NONE acetylcholine_5\NN|nicotinic|receptor|alpha (r_compound) subunits_7\NNS|necessary|for|. (r_nsubj) are_8\VBP|NONE (l_prep) for_10\IN|necessary|subunits|. (l_pobj) seizures_14\NNS|NONE (l_conj) hypolocomotion_16\NN|induced|and
D009538_D006948 NONE nicotine_11\NN| (r_npadvmod) induced_13\VBN|hypolocomotion|and (r_amod) seizures_14\NNS|NONE (l_conj) hypolocomotion_16\NN|induced|and
D009538_D006948 NONE nicotine_9\NN| (r_npadvmod) induced_11\VBN|NONE (r_amod) seizures_12\NNS|NONE (r_pobj) in_8\IN|hypolocomotion|beta|and|the (r_prep) subunits_7\NNS|NONE (l_conj) hypolocomotion_14\NN|beta|and|the|in
D009538_D006948 NONE nicotine_15\NN| (r_npadvmod) induced_17\VBN|hypolocomotion|and (r_amod) seizures_18\NNS|NONE (l_conj) hypolocomotion_20\NN|induced|and
D000109_D014202 NONE acetylcholine_5\NN|nAChRs|nicotinic|)|( (r_compound) receptors_6\NNS|NONE (r_pobj) to_3\IN|of (r_prep) Binding_0\NN|.|series (r_nsubj) elicits_10\VBZ|NONE (l_dobj) series_12\NN|.|Binding (l_prep) of_13\IN|a (l_pobj) behaviors_17\NNS|NONE (l_relcl) go_19\VBP|dependent (l_prep) from_20\IN|to|that|, (l_pobj) exploration_22\NN|NONE (l_conj) sedation_24\NN|altered|, (l_conj) tremors_27\NNS|and|,
D009538_D003643 NONE nicotine_2\NN|NONE (r_pobj) of_1\IN|to (r_prep) Binding_0\NN|.|series (r_nsubj) elicits_10\VBZ|NONE (l_dobj) series_12\NN|.|Binding (l_prep) of_13\IN|a (l_pobj) behaviors_17\NNS|NONE (l_relcl) go_19\VBP|dependent (l_prep) to_29\IN|that|,|from (l_pobj) seizures_30\NNS|NONE (l_conj) death_32\NN|and
D000109_D012640 NONE acetylcholine_5\NN|nicotinic|receptor|alpha (r_compound) subunits_7\NNS|necessary|for|. (r_nsubj) are_8\VBP|NONE (l_prep) for_10\IN|necessary|subunits|. (l_pobj) seizures_14\NNS|NONE
D000109_D012640 NONE acetylcholine_5\NN|nAChRs|nicotinic|)|( (r_compound) receptors_6\NNS|NONE (r_pobj) to_3\IN|of (r_prep) Binding_0\NN|.|series (r_nsubj) elicits_10\VBZ|NONE (l_dobj) series_12\NN|.|Binding (l_prep) of_13\IN|a (l_pobj) behaviors_17\NNS|NONE (l_relcl) go_19\VBP|dependent (l_prep) to_29\IN|that|,|from (l_pobj) seizures_30\NNS|NONE
D009538_D012640 CID nicotine_11\NN| (r_npadvmod) induced_13\VBN|hypolocomotion|and (r_amod) seizures_14\NNS|NONE
D009538_D012640 CID nicotine_2\NN|NONE (r_pobj) of_1\IN|to (r_prep) Binding_0\NN|.|series (r_nsubj) elicits_10\VBZ|NONE (l_dobj) series_12\NN|.|Binding (l_prep) of_13\IN|a (l_pobj) behaviors_17\NNS|NONE (l_relcl) go_19\VBP|dependent (l_prep) to_29\IN|that|,|from (l_pobj) seizures_30\NNS|NONE
D009538_D012640 CID nicotine_9\NN| (r_npadvmod) induced_11\VBN|NONE (r_amod) seizures_12\NNS|NONE
D009538_D012640 CID nicotine_10\NN|NONE (r_pobj) of_9\IN|the|at (r_prep) effects_8\NNS|NONE (r_pobj) to_6\IN|less (r_prep) sensitive_5\JJ|,|.|measured|mice (r_acomp) were_3\VBD|NONE (l_advcl) measured_16\VBN|,|.|mice|sensitive (l_conj) measured_30\VBN|,|and|as|at (l_prep) as_31\IN|NONE (l_pobj) sensitivity_32\NN|NONE (l_prep) to_33\IN|NONE (l_pobj) seizures_37\NNS|NONE
D009538_D012640 CID nicotine_34\NN| (r_npadvmod) induced_36\VBN|NONE (r_amod) seizures_37\NNS|NONE
D009538_D012640 CID nicotine_7\NN| (r_npadvmod) induced_9\VBN|NONE (r_amod) seizures_10\NNS|NONE
D009538_D012640 CID nicotine_15\NN| (r_npadvmod) induced_17\VBN|hypolocomotion|and (r_amod) seizures_18\NNS|NONE
D009538_D014202 NONE nicotine_2\NN|NONE (r_pobj) of_1\IN|to (r_prep) Binding_0\NN|.|series (r_nsubj) elicits_10\VBZ|NONE (l_dobj) series_12\NN|.|Binding (l_prep) of_13\IN|a (l_pobj) behaviors_17\NNS|NONE (l_relcl) go_19\VBP|dependent (l_prep) from_20\IN|to|that|, (l_pobj) exploration_22\NN|NONE (l_conj) sedation_24\NN|altered|, (l_conj) tremors_27\NNS|and|,
D000109_D003643 NONE acetylcholine_5\NN|nAChRs|nicotinic|)|( (r_compound) receptors_6\NNS|NONE (r_pobj) to_3\IN|of (r_prep) Binding_0\NN|.|series (r_nsubj) elicits_10\VBZ|NONE (l_dobj) series_12\NN|.|Binding (l_prep) of_13\IN|a (l_pobj) behaviors_17\NNS|NONE (l_relcl) go_19\VBP|dependent (l_prep) to_29\IN|that|,|from (l_pobj) seizures_30\NNS|NONE (l_conj) death_32\NN|and
6615052
D006493_D013927 NONE Heparin_0\NNP| (r_npadvmod) induced_2\VBN|.|thrombosis|, (r_amod) thrombocytopenia_3\NN|NONE (l_conj) thrombosis_5\NN|.|induced|,
D006493_D001791 NONE heparin_12\NN|NONE (r_pobj) to_11\IN|NONE (r_prep) resistance_10\NN|added|,|and (r_dobj) increased_9\VBN|,|has|testing|.|count (r_conj) revealed_3\VBN|NONE (l_dobj) count_7\NN|increased|,|has|testing|.
D006493_D001791 NONE heparin_24\NN|aggregation|when|is (r_nsubjpass) added_26\VBN|,|resistance|and (r_conj) increased_9\VBN|,|has|testing|.|count (r_conj) revealed_3\VBN|NONE (l_dobj) count_7\NN|increased|,|has|testing|.
D006493_D001791 NONE heparin_15\JJ|,|using|is|patient|while (l_appos) testing_19\NN|, (l_compound) aggregation_18\NN|NONE
D006493_D013921 CID Heparin_0\NNP| (r_npadvmod) induced_2\VBN|.|thrombosis|, (r_amod) thrombocytopenia_3\NN|NONE
D006493_D013921 CID heparin_6\NN| (r_npadvmod) induced_8\VBN|a (r_amod) thrombocytopenia_9\NN|NONE
D006493_D013923 CID heparin_17\VBN|NONE (r_dobj) receiving_16\VBG|NONE (r_acl) patients_15\NNS|NONE (r_pobj) in_14\IN|thromboembolic (r_prep) events_13\NNS|,|or|frequently|, (l_compound) thromboembolic_12\JJ|in
D006493_D006470 CID Heparin_0\NNP| (r_npadvmod) induced_2\VBN|.|thrombosis|, (r_amod) thrombocytopenia_3\NN|NONE (l_conj) thrombosis_5\NN|.|induced|, (l_conj) hemorrhage_8\NN|and|,
D006493_D006470 CID heparin_17\VBN|NONE (r_dobj) receiving_16\VBG|NONE (r_acl) patients_15\NNS|NONE (r_pobj) in_14\IN|thromboembolic (r_prep) events_13\NNS|,|or|frequently|, (r_appos) hemorrhage_6\NN|.|manifestations
7565311
D016190_D018233 NONE carboplatin_15\NN|NONE (r_pobj) with_11\IN|who|for|was (r_prep) treated_10\VBN||a|old (l_prep) for_16\IN|with|who|was (l_pobj) rhabdomyosarcoma_20\NN|NONE
D016190_D058186 CID carboplatin_6\NN|dose|high (r_compound) chemotherapy_7\NN|NONE (r_pobj) in_3\IN|Acute|.|renal (r_prep) failure_2\NN|NONE
D016190_D058186 CID Carboplatin_0\NNP|cause|has|.|been (r_nsubjpass) reported_3\VBN|NONE (l_xcomp) cause_5\VB|has|.|Carboplatin|been (l_dobj) failure_8\NN|administered|to
16157917
C047781_C562694 NONE Lamotrigine_0\NNP|NONE (l_acl) associated_1\VBD|. (l_prep) with_2\IN|NONE (l_pobj) exacerbation_3\NN|NONE (l_prep) in_8\IN|myoclonus|or (l_pobj) epilepsies_11\NNS|NONE
C047781_C562694 NONE lamotrigine_11\NNP|NONE (r_pobj) with_10\IN|experienced|.|patients (r_prep) treated_9\VBN|NONE (l_nsubj) patients_1\NNS|experienced|.|with (l_prep) with_2\IN|Five (l_pobj) epilepsies_5\NNS|NONE
C047781_C562694 NONE lamotrigine_11\NNP|NONE (r_pobj) with_10\IN|experienced|.|patients (r_prep) treated_9\VBN|NONE (l_nsubj) patients_1\NNS|experienced|.|with (l_prep) with_2\IN|Five (l_pobj) epilepsies_5\NNS|NONE (l_appos) IGE_7\NNP|(|)|idiopathic|generalized
C047781_C562694 NONE LTG_13\NNP|(|) (r_appos) lamotrigine_11\NNP|NONE (r_pobj) with_10\IN|experienced|.|patients (r_prep) treated_9\VBN|NONE (l_nsubj) patients_1\NNS|experienced|.|with (l_prep) with_2\IN|Five (l_pobj) epilepsies_5\NNS|NONE
C047781_C562694 NONE LTG_13\NNP|(|) (r_appos) lamotrigine_11\NNP|NONE (r_pobj) with_10\IN|experienced|.|patients (r_prep) treated_9\VBN|NONE (l_nsubj) patients_1\NNS|experienced|.|with (l_prep) with_2\IN|Five (l_pobj) epilepsies_5\NNS|NONE (l_appos) IGE_7\NNP|(|)|idiopathic|generalized
C047781_D009207 CID Lamotrigine_0\NNP|NONE (l_acl) associated_1\VBD|. (l_prep) with_2\IN|NONE (l_pobj) exacerbation_3\NN|NONE (l_conj) myoclonus_7\NN|in|or
C047781_D009207 CID lamotrigine_11\NNP|NONE (r_pobj) with_10\IN|experienced|.|patients (r_prep) treated_9\VBN|NONE (l_advcl) experienced_15\VBD|.|patients|with (l_dobj) exacerbation_16\NN|NONE (l_conj) appearance_20\NN|or (l_prep) of_21\IN|novo|de (l_pobj) jerks_23\NNS|NONE
C047781_D009207 CID lamotrigine_11\NNP|NONE (r_pobj) with_10\IN|experienced|.|patients (r_prep) treated_9\VBN|NONE (l_advcl) experienced_15\VBD|.|patients|with (l_dobj) exacerbation_16\NN|NONE (l_conj) appearance_20\NN|or (l_prep) of_21\IN|novo|de (l_pobj) jerks_23\NNS|NONE (l_appos) MJ_25\NNP|myoclonic|)|(
C047781_D009207 CID LTG_13\NNP|(|) (r_appos) lamotrigine_11\NNP|NONE (r_pobj) with_10\IN|experienced|.|patients (r_prep) treated_9\VBN|NONE (l_advcl) experienced_15\VBD|.|patients|with (l_dobj) exacerbation_16\NN|NONE (l_conj) appearance_20\NN|or (l_prep) of_21\IN|novo|de (l_pobj) jerks_23\NNS|NONE
C047781_D009207 CID LTG_13\NNP|(|) (r_appos) lamotrigine_11\NNP|NONE (r_pobj) with_10\IN|experienced|.|patients (r_prep) treated_9\VBN|NONE (l_advcl) experienced_15\VBD|.|patients|with (l_dobj) exacerbation_16\NN|NONE (l_conj) appearance_20\NN|or (l_prep) of_21\IN|novo|de (l_pobj) jerks_23\NNS|NONE (l_appos) MJ_25\NNP|myoclonic|)|(
C047781_D009207 CID LTG_4\NNP|,|MJ|in|.|In (r_nsubj) exacerbated_5\VBD|NONE (l_dobj) MJ_6\NNP|LTG|,|in|.|In
C047781_D009207 CID LTG_3\NNP|NONE (r_compound) dose_4\NN|by|when|was (r_nsubjpass) decreased_6\VBN|MJ|. (r_advcl) disappeared_1\VBD|NONE (l_nsubj) MJ_0\NNP|decreased|.
C047781_D009207 CID LTG_4\NNP|.|In|,|with|in|,|MJ (r_nsubj) exacerbated_5\VBD|NONE (l_dobj) MJ_6\NNP|.|In|,|with|in|,|LTG
C047781_D009207 CID LTG_4\NNP|.|In|,|with|in|,|MJ (r_nsubj) exacerbated_5\VBD|NONE (l_prep) with_15\IN|.|In|,|in|,|MJ|LTG (l_pobj) status_17\NN|NONE
C047781_D009207 CID LTG_22\NNP|NONE (r_compound) withdrawal_23\NN|NONE (r_pobj) after_21\IN|only|that (r_prep) ceased_20\VBD|myoclonic (r_relcl) status_17\NN|NONE (r_pobj) with_15\IN|.|In|,|in|,|MJ|LTG (r_prep) exacerbated_5\VBD|NONE (l_dobj) MJ_6\NNP|.|In|,|with|in|,|LTG
C047781_D009207 CID LTG_22\NNP|NONE (r_compound) withdrawal_23\NN|NONE (r_pobj) after_21\IN|only|that (r_prep) ceased_20\VBD|myoclonic (r_relcl) status_17\NN|NONE
11135224
D002945_D002289 NONE cisplatin_2\NN|.|, (l_conj) chemotherapy_7\NN|,|and (l_prep) within_8\IN|combination (l_pobj) approach_12\NN|NONE (l_prep) in_13\IN|therapeutic|multidisciplinary|a (l_pobj) carcinoma_18\NN|NONE
D002945_D002289 NONE Cisplatin_0\NN| (r_npadvmod) based_2\VBN|chemotherapy (r_amod) combinations_4\NNS|.|quality (r_nsubj) improve_5\VBP|NONE (l_dobj) quality_6\NN|.|combinations (l_prep) in_11\IN|of (l_pobj) carcinoma_16\NN|NONE
D002945_D002289 NONE Cisplatin_0\NN| (r_npadvmod) based_2\VBN|chemotherapy (r_amod) combinations_4\NNS|.|quality (r_nsubj) improve_5\VBP|NONE (l_dobj) quality_6\NN|.|combinations (l_prep) in_11\IN|of (l_pobj) carcinoma_16\NN|NONE (l_appos) NSCLC_18\NNP|)|(|lung|advanced|nonsmall
D002945_D002289 NONE cisplatin_20\NN|a|,|combination (r_conj) paclitaxel_18\NN|NONE (r_pobj) of_16\IN|NONE (r_prep) toxicity_15\NN|and|response|, (r_conj) rate_12\NN|the|, (r_conj) feasibility_9\NN|to|treat (r_dobj) determine_7\VB|objective|. (l_xcomp) treat_26\VB|to|feasibility (l_dobj) NSCLC_28\NN|to
D002945_D002289 NONE cisplatin_47\NN|on|.|)|with|)|gemcitabine|,|and|patients|on|)|given|given|given|,|were (r_conj) treated_25\VBN|NONE (l_nsubjpass) patients_7\NNS|on|.|)|with|)|gemcitabine|cisplatin|,|and|on|)|given|given|given|,|were (l_prep) with_8\IN|naive|consecutive|five (l_pobj) NSCLC_11\NNP|NONE
D002945_D002289 NONE cisplatin_5\NN|, (r_conj) paclitaxel_3\NN|NONE (r_pobj) of_2\IN|gemcitabine|,|The|and (r_prep) combination_1\NN|well|.|and|is|shows (r_nsubjpass) tolerated_11\VBN|NONE (l_conj) shows_13\VBZ|well|.|and|is|combination (l_prep) in_16\IN|activity (l_pobj) NSCLC_18\NNP|NONE
D002945_D064420 NONE cisplatin_20\NN|a|,|combination (r_conj) paclitaxel_18\NN|NONE (r_pobj) of_16\IN|NONE (r_prep) toxicity_15\NN|and|response|,
D017239_D064420 NONE paclitaxel_18\NN|NONE (r_pobj) of_16\IN|NONE (r_prep) toxicity_15\NN|and|response|,
C056507_D064420 NONE gemcitabine_23\NN|NONE (r_compound) combination_24\NN|cisplatin|a|, (r_conj) paclitaxel_18\NN|NONE (r_pobj) of_16\IN|NONE (r_prep) toxicity_15\NN|and|response|,
D017239_D002289 NONE Paclitaxel_0\NNP|NONE (l_conj) cisplatin_2\NN|.|, (l_conj) chemotherapy_7\NN|,|and (l_prep) within_8\IN|combination (l_pobj) approach_12\NN|NONE (l_prep) in_13\IN|therapeutic|multidisciplinary|a (l_pobj) carcinoma_18\NN|NONE
D017239_D002289 NONE paclitaxel_18\NN|NONE (r_pobj) of_16\IN|NONE (r_prep) toxicity_15\NN|and|response|, (r_conj) rate_12\NN|the|, (r_conj) feasibility_9\NN|to|treat (r_dobj) determine_7\VB|objective|. (l_xcomp) treat_26\VB|to|feasibility (l_dobj) NSCLC_28\NN|to
D017239_D002289 NONE paclitaxel_30\NN|NONE (r_pobj) of_29\IN|(|m(|)|a (r_prep) combination_28\NN|NONE (r_pobj) with_26\IN|on|.|)|)|gemcitabine|cisplatin|,|and|patients|on|)|given|given|given|,|were (r_prep) treated_25\VBN|NONE (l_nsubjpass) patients_7\NNS|on|.|)|with|)|gemcitabine|cisplatin|,|and|on|)|given|given|given|,|were (l_prep) with_8\IN|naive|consecutive|five (l_pobj) NSCLC_11\NNP|NONE
D017239_D002289 NONE paclitaxel_3\NN|NONE (r_pobj) of_2\IN|gemcitabine|,|The|and (r_prep) combination_1\NN|well|.|and|is|shows (r_nsubjpass) tolerated_11\VBN|NONE (l_conj) shows_13\VBZ|well|.|and|is|combination (l_prep) in_16\IN|activity (l_pobj) NSCLC_18\NNP|NONE
C056507_D002289 NONE gemcitabine_5\NN|NONE (r_compound) combination_6\NN|within (r_compound) chemotherapy_7\NN|,|and (l_prep) within_8\IN|combination (l_pobj) approach_12\NN|NONE (l_prep) in_13\IN|therapeutic|multidisciplinary|a (l_pobj) carcinoma_18\NN|NONE
C056507_D002289 NONE gemcitabine_23\NN|NONE (r_compound) combination_24\NN|cisplatin|a|, (r_conj) paclitaxel_18\NN|NONE (r_pobj) of_16\IN|NONE (r_prep) toxicity_15\NN|and|response|, (r_conj) rate_12\NN|the|, (r_conj) feasibility_9\NN|to|treat (r_dobj) determine_7\VB|objective|. (l_xcomp) treat_26\VB|to|feasibility (l_dobj) NSCLC_28\NN|to
C056507_D002289 NONE gemcitabine_65\NN|on|.|)|with|)|cisplatin|,|and|patients|on|)|given|given|given|,|were (r_conj) treated_25\VBN|NONE (l_nsubjpass) patients_7\NNS|on|.|)|with|)|gemcitabine|cisplatin|,|and|on|)|given|given|given|,|were (l_prep) with_8\IN|naive|consecutive|five (l_pobj) NSCLC_11\NNP|NONE
C056507_D002289 NONE gemcitabine_8\NN|of|,|The|and (r_conj) combination_1\NN|well|.|and|is|shows (r_nsubjpass) tolerated_11\VBN|NONE (l_conj) shows_13\VBZ|well|.|and|is|combination (l_prep) in_16\IN|activity (l_pobj) NSCLC_18\NNP|NONE
9867728
D020372_D006349 NONE dexfenfluramine_10\NN|and (r_conj) fenfluramine_8\NN|NONE (r_pobj) of_7\IN|underwent (r_prep) users_6\NNS|NONE (r_pobj) among_5\IN|heart|valvular (r_prep) disease_4\NN|NONE
D020372_D006349 NONE dexfenfluramine_18\NN|and (r_conj) fenfluramine_16\NN|NONE (r_pobj) of_15\IN|NONE (r_prep) users_14\NNS|NONE (r_pobj) of_13\IN| (r_prep) %_12\NN|disease (r_nsubj) had_19\VBD|Because|surveys (l_dobj) disease_21\NN|%
D020372_D006349 NONE dexfenfluramine_15\NN|or (r_conj) fenfluramine_13\NN|NONE (r_pobj) of_12\IN|underwent (r_prep) users_11\NNS|NONE (r_pobj) among_10\IN|new|valvular (r_prep) abnormalities_9\NNS|NONE
D010645_D006349 NONE phentermine_20\NN|NONE (r_dobj) receiving_17\VBG|Two|]|(|%|) (r_acl) patients_1\NNS|.|disease (r_nsubj) developed_21\VBD|NONE (l_dobj) disease_24\NN|.|patients
D005277_D006349 NONE fenfluramine_8\NN|NONE (r_pobj) of_7\IN|underwent (r_prep) users_6\NNS|NONE (r_pobj) among_5\IN|heart|valvular (r_prep) disease_4\NN|NONE
D005277_D006349 NONE fenfluramine_16\NN|NONE (r_pobj) of_15\IN|NONE (r_prep) users_14\NNS|NONE (r_pobj) of_13\IN| (r_prep) %_12\NN|disease (r_nsubj) had_19\VBD|Because|surveys (l_dobj) disease_21\NN|%
D005277_D006349 NONE fenfluramine_13\NN|NONE (r_pobj) of_12\IN|underwent (r_prep) users_11\NNS|NONE (r_pobj) among_10\IN|new|valvular (r_prep) abnormalities_9\NNS|NONE
D005277_D006349 NONE fenfluramine_18\JJ| (r_compound) phentermine_20\NN|NONE (r_dobj) receiving_17\VBG|Two|]|(|%|) (r_acl) patients_1\NNS|.|disease (r_nsubj) developed_21\VBD|NONE (l_dobj) disease_24\NN|.|patients
17879945
D019438_D050197 CID ritonavir_5\VBZ|NONE (r_compound) treatment_6\NN|to|formation|that (r_nsubj) increases_7\VBZ|have|.|We|previously (l_dobj) formation_10\NN|to|treatment|that (l_compound) lesion_9\NN|in|atherosclerotic
20621845
D002122_D017545 CID CaCl2-induced_14\VBN|aortic|thoracic|in (r_amod) aneurysm_17\NN|degeneration
D002122_D017545 CID chloride_18\NN|NONE (r_pobj) by_16\IN|and|model|to|explore (r_prep) establish_5\VB|metalloproteinases|.|study|was|, (l_dobj) model_8\NN|and|by|to|explore (l_prep) of_9\IN|rat|a (l_pobj) aneurysm_12\NN|NONE
D002122_D017545 CID chloride_18\NN|NONE (r_pobj) by_16\IN|and|model|to|explore (r_prep) establish_5\VB|metalloproteinases|.|study|was|, (l_dobj) model_8\NN|and|by|to|explore (l_prep) of_9\IN|rat|a (l_pobj) aneurysm_12\NN|NONE (l_appos) TAA_14\NNP|(|thoracic|)|aortic
D002122_D017545 CID chloride_18\NN|NONE (r_pobj) by_16\IN|and|model|to|explore (r_prep) establish_5\VB|metalloproteinases|.|study|was|, (r_xcomp) designed_3\VBN|NONE (l_conj) metalloproteinases_39\NNS|establish|.|study|was|, (l_conj) inhibitors_46\NNS|(|)|matrix|MMPs|and (l_prep) in_50\IN|)|TIMPs|endogenous|(|their (l_pobj) formation_52\NN|NONE (l_compound) TAA_51\NNP|NONE
D002122_D017545 CID CaCl(2))-induced_20\VBN|arterial|( (r_amod) injury_22\NN|calcium (r_appos) chloride_18\NN|NONE (r_pobj) by_16\IN|and|model|to|explore (r_prep) establish_5\VB|metalloproteinases|.|study|was|, (l_dobj) model_8\NN|and|by|to|explore (l_prep) of_9\IN|rat|a (l_pobj) aneurysm_12\NN|NONE
D002122_D017545 CID CaCl(2))-induced_20\VBN|arterial|( (r_amod) injury_22\NN|calcium (r_appos) chloride_18\NN|NONE (r_pobj) by_16\IN|and|model|to|explore (r_prep) establish_5\VB|metalloproteinases|.|study|was|, (l_dobj) model_8\NN|and|by|to|explore (l_prep) of_9\IN|rat|a (l_pobj) aneurysm_12\NN|NONE (l_appos) TAA_14\NNP|(|thoracic|)|aortic
D002122_D017545 CID CaCl(2))-induced_20\VBN|arterial|( (r_amod) injury_22\NN|calcium (r_appos) chloride_18\NN|NONE (r_pobj) by_16\IN|and|model|to|explore (r_prep) establish_5\VB|metalloproteinases|.|study|was|, (r_xcomp) designed_3\VBN|NONE (l_conj) metalloproteinases_39\NNS|establish|.|study|was|, (l_conj) inhibitors_46\NNS|(|)|matrix|MMPs|and (l_prep) in_50\IN|)|TIMPs|endogenous|(|their (l_pobj) formation_52\NN|NONE (l_compound) TAA_51\NNP|NONE
D002122_D017545 CID )_9\-RRB-|by|study|model (r_punct) establishes_2\VBZ|NONE (l_dobj) model_5\NN|)|by|study (l_compound) TAA_4\NNP|a
D002122_D014652 NONE chloride_18\NN|NONE (l_appos) injury_22\NN|calcium
D002122_D014652 NONE CaCl(2))-induced_20\VBN|arterial|( (r_amod) injury_22\NN|calcium
1130930
D005839_D051437 NONE sulfate_26\NN|NONE (r_compound) therapy_27\NN|NONE (r_dobj) gentamicin_25\NN|they|and|combination|were|while (r_conj) receiving_18\VBG|.|,|patients|necrosis (r_advcl) developed_2\VBD|NONE (l_dobj) necrosis_5\NN|receiving|.|,|patients (l_acl) characterized_7\VBN|acute|,|tubular (l_agent) by_9\IN|NONE (l_pobj) failure_13\NN|clinically
D002512_D007674 NONE cephalothin_3\NN| (r_compound) gentamicin_5\NN|combined (r_compound) regimen_6\NN|NONE (r_pobj) of_1\IN|. (r_prep) Nephrotoxicity_0\NN|NONE
D002512_D007683 CID sodium_23\NN|NONE (r_pobj) of_21\IN|a (r_prep) combination_20\NN|they|and|gentamicin|were|while (r_dobj) receiving_18\VBG|.|,|patients|necrosis (r_advcl) developed_2\VBD|NONE (l_dobj) necrosis_5\NN|receiving|.|,|patients
D005839_D007683 CID sulfate_26\NN|NONE (r_compound) therapy_27\NN|NONE (r_dobj) gentamicin_25\NN|they|and|combination|were|while (r_conj) receiving_18\VBG|.|,|patients|necrosis (r_advcl) developed_2\VBD|NONE (l_dobj) necrosis_5\NN|receiving|.|,|patients
D005839_D007674 NONE gentamicin_5\NN|combined (r_compound) regimen_6\NN|NONE (r_pobj) of_1\IN|. (r_prep) Nephrotoxicity_0\NN|NONE
D005839_D009846 NONE sulfate_26\NN|NONE (r_compound) therapy_27\NN|NONE (r_dobj) gentamicin_25\NN|they|and|combination|were|while (r_conj) receiving_18\VBG|.|,|patients|necrosis (r_advcl) developed_2\VBD|NONE (l_dobj) necrosis_5\NN|receiving|.|,|patients (l_acl) characterized_7\VBN|acute|,|tubular (l_agent) by_9\IN|NONE (l_pobj) failure_13\NN|clinically
D002512_D009846 NONE sodium_23\NN|NONE (r_pobj) of_21\IN|a (r_prep) combination_20\NN|they|and|gentamicin|were|while (r_dobj) receiving_18\VBG|.|,|patients|necrosis (r_advcl) developed_2\VBD|NONE (l_dobj) necrosis_5\NN|receiving|.|,|patients (l_acl) characterized_7\VBN|acute|,|tubular (l_agent) by_9\IN|NONE (l_pobj) failure_13\NN|clinically
D002512_D051437 NONE sodium_23\NN|NONE (r_pobj) of_21\IN|a (r_prep) combination_20\NN|they|and|gentamicin|were|while (r_dobj) receiving_18\VBG|.|,|patients|necrosis (r_advcl) developed_2\VBD|NONE (l_dobj) necrosis_5\NN|receiving|.|,|patients (l_acl) characterized_7\VBN|acute|,|tubular (l_agent) by_9\IN|NONE (l_pobj) failure_13\NN|clinically
15985056
D008874_D006606 NONE midazolam_9\NN|anaesthesia|( (r_appos) benzodiazepines_7\NNS|(|,|)|dexamethasone (r_appos) Corticosteroids_0\NNS|.|agents|have (r_nsubj) been_15\VBN|NONE (l_attr) agents_18\NNS|.|have|Corticosteroids (l_acl) mentioned_19\VBD|the|specific (l_prep) as_25\IN|in|frequently (l_pcomp) associated_27\VBN|NONE (l_prep) with_28\IN|being (l_pobj) development_30\NN|NONE (l_prep) of_31\IN|the (l_pobj) hiccups_32\NNS|NONE
D008775_D006606 NONE methylprednisolone_4\NN|and (r_conj) dexamethasone_2\NN|(|,|)|benzodiazepines (r_appos) Corticosteroids_0\NNS|.|agents|have (r_nsubj) been_15\VBN|NONE (l_attr) agents_18\NNS|.|have|Corticosteroids (l_acl) mentioned_19\VBD|the|specific (l_prep) as_25\IN|in|frequently (l_pcomp) associated_27\VBN|NONE (l_prep) with_28\IN|being (l_pobj) development_30\NN|NONE (l_prep) of_31\IN|the (l_pobj) hiccups_32\NNS|NONE
D017963_D010612 NONE azithromycin_11\RB|for (r_advmod) beginning_10\VBG|NONE (l_prep) for_12\IN|azithromycin (l_pobj) treatment_14\NN|NONE (l_prep) of_15\IN|the (l_pobj) pharyngitis_16\NN|NONE
D017963_D006606 CID azithromycin_1\RB| (r_advmod) associated_3\VBN|Possible|. (r_amod) hiccups_4\NNS|NONE
D017963_D006606 CID azithromycin_9\CD|NONE (r_amod) therapy_10\NN|NONE (r_pobj) by_8\IN|NONE (r_agent) associated_7\VBN|persistent (r_acl) hiccups_6\NNS|NONE
D017963_D006606 CID azithromycin_11\RB|for (r_advmod) beginning_10\VBG|NONE (r_pcomp) after_9\IN|with|.|man (r_prep) presented_5\VBN|NONE (l_prep) with_6\IN|after|.|man (l_pobj) hiccups_8\NNS|NONE
D017963_D006606 CID azithromycin_2\NNP|NONE (r_pobj) of_1\IN|therapy|and (r_prep) Discontinuation_0\NN|.|finally|hiccups (r_nsubj) resolved_8\VBD|NONE (l_dobj) hiccups_9\NNS|.|finally|Discontinuation
D017963_D006606 CID azithromycin_9\WP|NONE (r_pobj) by_8\IN|NONE (r_agent) mediated_7\VBN|vagal|a (r_acl) mechanism_6\NN|pathogenesis|could|that (r_nsubj) be_11\VB|hypothesis|. (l_attr) pathogenesis_13\NN|mechanism|could|that (l_prep) of_14\IN|the (l_pobj) hiccups_15\NNS|NONE
D001418_D006606 CID baclofen_6\NN|NONE (r_pobj) with_5\IN|NONE (r_prep) therapy_4\NN|of|and (r_conj) Discontinuation_0\NN|.|finally|hiccups (r_nsubj) resolved_8\VBD|NONE (l_dobj) hiccups_9\NNS|.|finally|Discontinuation
D001569_D006606 NONE benzodiazepines_7\NNS|(|,|)|dexamethasone (r_appos) Corticosteroids_0\NNS|.|agents|have (r_nsubj) been_15\VBN|NONE (l_attr) agents_18\NNS|.|have|Corticosteroids (l_acl) mentioned_19\VBD|the|specific (l_prep) as_25\IN|in|frequently (l_pcomp) associated_27\VBN|NONE (l_prep) with_28\IN|being (l_pobj) development_30\NN|NONE (l_prep) of_31\IN|the (l_pobj) hiccups_32\NNS|NONE
D018942_D006606 NONE macrolide_12\NN|NONE (r_amod) antimicrobials_13\NNS|NONE (r_pobj) to_11\IN|NONE (r_prep) related_10\VBN|been|cases|have|. (r_oprd) reported_9\VBN|NONE (l_nsubjpass) cases_1\NNS|been|related|have|. (l_prep) of_2\IN|Few (l_pobj) hiccups_6\NNS|NONE
D018942_D006606 NONE macrolides_36\NNS|NONE (r_pobj) with_34\IN|absence|this|and (r_prep) reaction_33\NN|NONE (l_conj) absence_39\NN|this|and|with (l_prep) of_40\IN|the (l_pobj) explanation_43\NN|NONE (l_prep) for_44\IN|any|alternative (l_pobj) hiccups_45\NNS|NONE
D018942_D006606 NONE macrolide_2\NN|NONE (r_amod) antimicrobials_3\NNS|been|explain|However|associated|.|have|, (r_nsubjpass) reported_6\VBN|NONE (l_xcomp) associated_9\VBN|antimicrobials|been|explain|However|.|have|, (l_prep) with_10\IN|to|be (l_pobj) mechanism_14\NN|NONE (l_nmod) hiccups_11\NNS|vagal
D003907_D006606 NONE dexamethasone_2\NN|(|,|)|benzodiazepines (r_appos) Corticosteroids_0\NNS|.|agents|have (r_nsubj) been_15\VBN|NONE (l_attr) agents_18\NNS|.|have|Corticosteroids (l_acl) mentioned_19\VBD|the|specific (l_prep) as_25\IN|in|frequently (l_pcomp) associated_27\VBN|NONE (l_prep) with_28\IN|being (l_pobj) development_30\NN|NONE (l_prep) of_31\IN|the (l_pobj) hiccups_32\NNS|NONE
18308784
D009020_D007859 CID morphine_10\NN|chronic|in (r_compound) administration_11\NN|NONE (r_pobj) by_8\IN|NONE (r_agent) induced_7\VBN|of|the (r_acl) impairment_4\NN|.|Rg (l_prep) of_5\IN|induced|the (l_pobj) learning_6\VBG|NONE
D009020_D007859 CID morphine_17\NN|mechanism|chronic|and (r_compound) administration_18\NN|NONE (r_pobj) by_15\IN|learning (r_prep) impairment_14\NN|NONE
C035054_D007859 NONE Rg1_1\NNP|.|impairment (r_nsubj) restores_2\VBZ|NONE (l_dobj) impairment_4\NN|.|Rg (l_prep) of_5\IN|induced|the (l_pobj) learning_6\VBG|NONE
C035054_D007859 NONE Rg1_0\NNP|NONE (l_advcl) ameliorate_11\VB|.|, (l_dobj) impairment_14\NN|as|could|,
C035054_D007859 NONE Rg1_11\NN|NONE (r_pobj) of_10\IN|on|the (r_prep) effect_9\NN|to (l_prep) on_12\IN|the|of (l_pobj) impairment_14\NN|NONE
D036145_D007859 NONE ginsenoside_4\NN|NONE (r_pobj) as_2\IN|could|,|impairment (r_prep) ameliorate_11\VB|.|, (l_dobj) impairment_14\NN|as|could|,
6538499
D011092_D064420 NONE 400_4\CD|.|adriamycin|Effect (r_nummod) glycol_3\NN|NONE (l_advcl) adriamycin_6\JJ|.|Effect| (l_dobj) toxicity_7\NN|NONE
D004317_D002286 NONE ADR_6\NNP|in|antitumor|the|tumor (r_compound) activity_8\NN|.|treatment|did|not (l_relcl) tumor_16\NN|ADR|in|antitumor|the
D004317_D009202 CID ADR_8\NNP| (r_npadvmod) induced_10\VBN|cardiac|morphological (r_amod) alterations_13\NNS|NONE
D004317_D007939 NONE ADR_6\NNP|in|antitumor|the|tumor (r_compound) activity_8\NN|.|treatment|did|not (l_prep) in_9\IN|ADR|antitumor|the|tumor (l_pobj) leukemia_11\NN|and
D004317_D064420 NONE adriamycin_6\JJ|.|Effect| (l_dobj) toxicity_7\NN|NONE
1899352
D015080_D006417 NONE Mesna_22\NNP|to (r_dobj) adding_21\VBG|essential|,|monitoring|. (r_advcl) is_18\VBZ|precise|and|not|frequency|, (r_conj) are_6\VBP|NONE (l_nsubj) frequency_1\NN|is|precise|and|not|, (l_conj) predictability_3\NN|and|The (l_prep) of_4\IN|NONE (l_pobj) hematuria_5\NN|NONE
D015080_D006417 NONE Mesna_22\NNP|to (r_dobj) adding_21\VBG|essential|,|monitoring|. (l_prep) to_23\IN|Mesna (l_pobj) infusate_25\NN|NONE (l_prep) in_26\IN|the (l_pobj) patients_27\NNS|NONE (l_prep) with_28\IN|NONE (l_pobj) hematuria_30\NN|NONE
11337188
D010068_D016470 NONE oxacillin_9\NN|NONE (r_pobj) with_8\IN|for|who|was|because (r_prep) treated_7\VBN|old|A (l_prep) because_13\IN|for|with|who|was (l_pobj) bacteremia_17\NN|of
D010068_D018366 CID oxacillin_5\NN|NONE (r_pobj) with_4\IN|NONE (r_prep) associated_3\VBN|.|leucocytoclastic|Cutaneous (r_acl) vasculitis_2\NN|NONE
D010068_D018366 CID Oxacillin_0\NNP|be|among|.|should (r_nsubjpass) included_3\VBN|NONE (l_prep) among_4\IN|be|.|Oxacillin|should (l_pobj) drugs_6\NNS|NONE (l_relcl) cause_9\VB|the (l_dobj) vasculitis_11\NN|can|that
D010068_D051437 CID oxacillin_9\NN|NONE (r_pobj) with_8\IN|for|who|was|because (r_prep) treated_7\VBN|old|A (r_relcl) man_4\NN|failure|. (r_nsubj) developed_19\VBD|NONE (l_dobj) failure_21\NN|man|.
D010068_D013203 NONE oxacillin_9\NN|NONE (r_pobj) with_8\IN|for|who|was|because (r_prep) treated_7\VBN|old|A (l_prep) because_13\IN|for|with|who|was (l_pobj) bacteremia_17\NN|of
D010068_D011693 NONE oxacillin_9\NN|NONE (r_pobj) with_8\IN|for|who|was|because (r_prep) treated_7\VBN|old|A (r_relcl) man_4\NN|failure|. (r_nsubj) developed_19\VBD|NONE (l_dobj) failure_21\NN|man|. (l_appos) lesions_29\NNS|and|,|diffuse|renal
6747681
D000431_D014786 NONE ethanol_11\NN|the (r_compound) diluent_12\NN|NONE (r_pobj) of_9\IN|the (r_prep) concentration_8\NN|was|after (r_nsubjpass) lowered_14\VBN|.|frequency (r_advcl) decreased_5\VBD|NONE (l_nsubj) frequency_1\NN|.|lowered (l_prep) of_2\IN|The (l_pobj) loss_4\NN|NONE
D002330_D001254 NONE BCNU_29\NNP|arterial (r_compound) therapy_30\NN|NONE (r_pobj) of_25\IN|eight (r_prep) courses_24\NNS|patients|. (r_dobj) received_20\VBD|NONE (l_nsubj) patients_3\NNS|.|courses (l_prep) to_8\IN|with|four (l_pobj) astrocytomas_10\NN|NONE
D002330_D005910 NONE BCNU_3\NNP|.|arterial|for (r_compound) chemotherapy_4\NN|NONE (l_prep) for_5\IN|.|arterial|BCNU (l_pobj) treatment_6\NN|NONE (l_prep) of_7\IN|NONE (l_pobj) gliomas_9\NNS|NONE
D002330_D005910 NONE BCNU_7\NNP|)|( (r_nmod) 1,3-bis-(2-chloroethyl)-1-nitrosourea_9\NN|NONE (r_pobj) of_6\IN|systemic|rapid|the (r_prep) clearance_5\NN|of (r_pobj) Because_0\IN|administration|advantage|,|should|. (r_prep) provide_17\VB|NONE (l_dobj) advantage_20\NN|administration|Because|,|should|. (l_prep) over_21\IN|a|substantial (l_pobj) administration_23\NN|NONE (l_prep) for_24\IN|intravenous (l_pobj) treatment_26\NN|NONE (l_prep) of_27\IN|the (l_pobj) gliomas_29\NNS|NONE
D002330_D005910 NONE 1,3-bis-(2-chloroethyl)-1-nitrosourea_9\NN|NONE (r_pobj) of_6\IN|systemic|rapid|the (r_prep) clearance_5\NN|of (r_pobj) Because_0\IN|administration|advantage|,|should|. (r_prep) provide_17\VB|NONE (l_dobj) advantage_20\NN|administration|Because|,|should|. (l_prep) over_21\IN|a|substantial (l_pobj) administration_23\NN|NONE (l_prep) for_24\IN|intravenous (l_pobj) treatment_26\NN|NONE (l_prep) of_27\IN|the (l_pobj) gliomas_29\NNS|NONE
12231232
D006220_D009127 CID Haloperidol_0\NN|rigidity|. (r_nsubj) induced_6\VBD|NONE (l_dobj) rigidity_11\NN|Haloperidol|.
D006220_D009127 CID haloperidol_11\NN| (r_npadvmod) induced_13\VBN|muscle|the (r_amod) rigidity_15\NN|.|AIDA
D006220_D010300 NONE Haloperidol_0\NN|rigidity|. (r_nsubj) induced_6\VBD|NONE (l_dobj) rigidity_11\NN|Haloperidol|. (l_amod) parkinsonian_7\JJ|,|muscle|measured
C095756_D009127 NONE AIDA_0\NNP|.|rigidity (r_nsubj) diminished_9\VBD|NONE (l_dobj) rigidity_15\NN|.|AIDA
6293644
D006220_D002375 CID haloperidol_7\NN| (r_npadvmod) induced_9\VBN|NONE (r_amod) catalepsy_10\NN|NONE
D001058_D002375 NONE apomorphine_16\NN| (r_npadvmod) induced_18\VBN|NONE (r_amod) hyperactivity_19\NN|NONE (r_pobj) of_15\IN|partial|a (r_prep) prevention_14\NN|a|of|and (r_conj) potentiation_5\NN|NONE (l_prep) of_6\IN|prevention|a|and (l_pobj) catalepsy_10\NN|NONE
D001058_D006948 CID apomorphine_16\NN| (r_npadvmod) induced_18\VBN|NONE (r_amod) hyperactivity_19\NN|NONE
D006220_D006948 NONE haloperidol_7\NN| (r_npadvmod) induced_9\VBN|NONE (r_amod) catalepsy_10\NN|NONE (r_pobj) of_6\IN|prevention|a|and (r_prep) potentiation_5\NN|NONE (l_conj) prevention_14\NN|a|of|and (l_prep) of_15\IN|partial|a (l_pobj) hyperactivity_19\NN|NONE
8111719
D006220_D011595 NONE haloperidol_12\NN|)|(|potency|marked|, (r_appos) neuroleptics_8\NNS|may|effective|. (l_amod) marked_3\JJ|)|(|potency|haloperidol|, (l_auxpass) becomes_2\VBZ|NONE (l_nsubj) agitation_1\NN|If
D007069_D020258 NONE ifosfamide_2\RB| (r_advmod) induced_4\VBN|NONE (r_amod) neurotoxicity_5\NN|.|and
D007069_D020258 NONE ifosfamide_16\NN|NONE (r_pobj) of_15\IN|known|a|side (r_prep) effect_14\NN|.|Hallucinations (r_attr) are_7\VBP|NONE (l_nsubj) Hallucinations_0\NNS|effect|. (l_prep) as_1\IN|NONE (l_pobj) symptom_3\NN|NONE (l_prep) of_4\IN|a (l_pobj) neurotoxicity_6\NN|NONE
D007069_D020258 NONE ifosfamide_7\RB| (r_npadvmod) induced_9\VBN|occur|,|possible (r_amod) hallucinations_10\NNS|NONE (l_relcl) occur_14\VB|induced|,|possible (l_prep) without_15\IN|may|which (l_pobj) signs_17\NNS|NONE (l_prep) of_18\IN|other (l_pobj) neurotoxicity_19\NN|NONE
D007069_D006212 CID ifosfamide_2\RB| (r_advmod) induced_4\VBN|NONE (r_amod) neurotoxicity_5\NN|.|and (r_conj) Hallucinations_0\NNS|NONE
D007069_D006212 CID ifosfamide_16\NN|NONE (r_pobj) of_15\IN|known|a|side (r_prep) effect_14\NN|.|Hallucinations (r_attr) are_7\VBP|NONE (l_nsubj) Hallucinations_0\NNS|effect|.
D007069_D006212 CID ifosfamide_3\RB| (r_npadvmod) induced_5\VBN|NONE (r_amod) hallucinations_6\NNS|NONE
D007069_D006212 CID ifosfamide_6\RB| (r_npadvmod) induced_8\VBN|NONE (r_amod) hallucinations_9\NNS|NONE
D007069_D006212 CID ifosfamide_7\RB| (r_npadvmod) induced_9\VBN|occur|,|possible (r_amod) hallucinations_10\NNS|NONE
20084309
D008874_D008944 NONE MZ_38\NNP|the (r_compound) dose_39\NN|and|) (r_conj) MR_34\NNP|(|mitral (r_appos) regurgitation_32\NN|,|of
D008874_D008944 NONE MZ_38\NNP|the (r_compound) dose_39\NN|and|) (r_conj) MR_34\NNP|(|mitral
D008874_D008944 NONE MZ_17\NNP|NONE (r_pobj) of_16\IN|high (r_prep) doses_15\NNS|severe|MR|%|,|associated|( (r_appos) MP_8\NNP|NONE (l_nmod) MR_6\NNP|severe|%|,|doses|associated|(
D008874_D000860 CID MZ_42\NNP|NONE (r_compound) use_43\NN|NONE (r_pobj) by_41\IN|NONE (r_agent) caused_40\VBN|NONE (r_acl) hypoxia_39\NN|to (r_pobj) due_37\JJ|;|.|due|was|patients|hypoxia (r_prep) presented_20\VBD|NONE (l_dobj) hypoxia_22\NN|;|.|due|was|patients|due
D008874_D000860 CID MZ_42\NNP|NONE (r_compound) use_43\NN|NONE (r_pobj) by_41\IN|NONE (r_agent) caused_40\VBN|NONE (r_acl) hypoxia_39\NN|to
D008874_D000402 NONE MZ_42\NNP|NONE (r_compound) use_43\NN|NONE (r_pobj) by_41\IN|NONE (r_agent) caused_40\VBN|NONE (r_acl) hypoxia_39\NN|to (r_pobj) due_37\JJ|;|.|due|was|patients|hypoxia (r_prep) presented_20\VBD|NONE (l_prep) due_23\IN|;|.|was|patients|due|hypoxia (l_pobj) obstruction_27\NN|to
D008874_D009202 NONE MZ_38\NNP|the (r_compound) dose_39\NN|and|) (r_conj) MR_34\NNP|(|mitral (r_appos) regurgitation_32\NN|,|of (r_conj) duration_26\NN|to|influence (r_dobj) test_7\VB|analyses|.|were (l_dobj) influence_9\NN|to|duration (l_prep) of_10\IN|the (l_pobj) variables_13\NNS|NONE (l_appos) age_15\NN|the|:|,|clinical (l_conj) sex_17\NN|, (l_conj) stroke_19\UH|, (l_conj) MP_23\NNP|, (l_amod) myocardiopathy_21\NN|(|)
D008874_D009202 NONE MZ_38\NNP|the (r_compound) dose_39\NN|and|) (r_conj) MR_34\NNP|(|mitral (r_appos) regurgitation_32\NN|,|of (r_conj) duration_26\NN|to|influence (r_dobj) test_7\VB|analyses|.|were (l_dobj) influence_9\NN|to|duration (l_prep) of_10\IN|the (l_pobj) variables_13\NNS|NONE (l_appos) age_15\NN|the|:|,|clinical (l_conj) sex_17\NN|, (l_conj) stroke_19\UH|, (l_conj) MP_23\NNP|,
D008874_D009202 NONE MZ_17\NNP|NONE (r_pobj) of_16\IN|high (r_prep) doses_15\NNS|severe|MR|%|,|associated|( (r_appos) MP_8\NNP|NONE
D008874_D020521 NONE MZ_38\NNP|the (r_compound) dose_39\NN|and|) (r_conj) MR_34\NNP|(|mitral (r_appos) regurgitation_32\NN|,|of (r_conj) duration_26\NN|to|influence (r_dobj) test_7\VB|analyses|.|were (l_dobj) influence_9\NN|to|duration (l_prep) of_10\IN|the (l_pobj) variables_13\NNS|NONE (l_appos) age_15\NN|the|:|,|clinical (l_conj) sex_17\NN|, (l_conj) stroke_19\UH|,
1967484
D013469_D004421 CID Sulpiride_0\NNP|.||dystonia (r_npadvmod) induced_2\VBN|NONE (l_dobj) dystonia_4\NN|.||Sulpiride
D013469_D004421 CID sulpiride_17\NN|NONE (r_compound) therapy_18\NN|NONE (r_dobj) starting_16\VBG|NONE (r_pcomp) after_15\IN|dystonia|within|who (r_prep) developed_8\VBD|a|old (l_dobj) dystonia_11\NN|after|within|who
D013469_D004421 CID sulpiride_8\NN| (r_npadvmod) induced_10\VBN|tardive (r_amod) dystonia_12\NN|NONE
D013469_D010302 NONE sulpiride_11\NN||,|thought|dyskinesia (r_npadvmod) induced_13\VBN|been|have|occasionally|. (l_dobj) dyskinesia_15\JJ||,|sulpiride|thought (l_conj) parkinsonism_17\NN|tardive|and
D013469_D004409 NONE sulpiride_11\NN||,|thought|dyskinesia (r_npadvmod) induced_13\VBN|been|have|occasionally|. (l_dobj) dyskinesia_15\JJ||,|sulpiride|thought
2304736
D011224_D014550 CID Prazosin_0\NN| (r_npadvmod) induced_2\VBN|.|stress (r_amod) incontinence_4\NN|NONE
D011224_D014550 CID prazosin_8\NN|to (r_pobj) due_6\IN|of|A (r_amod) case_1\NN|is|. (l_prep) of_2\IN|due|A (l_pobj) incontinence_5\NN|NONE
D011224_D014550 CID prazosin_8\NN|while (r_dobj) taking_7\VBG|who|with (r_advcl) present_2\VBP|NONE (l_prep) with_3\IN|taking|who (l_pobj) incontinence_5\NN|NONE
D011224_D014549 NONE prazosin_8\NN|while (r_dobj) taking_7\VBG|who|with (r_advcl) present_2\VBP|NONE (r_relcl) Patients_0\NNS|,|.|resolve|before|medication|should (r_nsubj) change_10\VB|NONE (l_advcl) resolve_22\VB|,|.|before|Patients|medication|should (l_nsubj) incontinence_20\NN|may|spontaneously|with|because
2339463
D015119_D008595 NONE acid_22\NN|for|aminocaproic|prolonged (r_compound) therapy_23\NN|NONE (l_prep) for_24\IN|aminocaproic|prolonged|acid (l_pobj) menorrhagia_25\NN|NONE
D015119_D020225 NONE acid_22\NN|for|aminocaproic|prolonged (r_compound) therapy_23\NN|NONE (r_pobj) with_17\IN|NONE (r_prep) associated_16\VBN|transverse|sinus (r_acl) thrombosis_15\NN|NONE
D015119_D020227 NONE acid_22\NN|for|aminocaproic|prolonged (r_compound) therapy_23\NN|NONE (r_pobj) with_17\IN|NONE (r_prep) associated_16\VBN|transverse|sinus (r_acl) thrombosis_15\NN|NONE
D015119_D013923 NONE acid_15\NN|NONE (r_pobj) with_11\IN|NONE (r_prep) treatment_10\NN|NONE (r_pobj) during_9\IN|risk|increased|been|has (r_prep) reported_8\VBN|.|not|been|has|previously (l_nsubjpass) risk_2\NN|increased|been|during|has (l_prep) of_3\IN|NONE (l_pobj) disease_5\NN|NONE
D015119_D012851 NONE acid_15\NN|NONE (l_appos) thrombosis_19\NN|aminocaproic|,
19037603
D006514_D012216 NONE antigen_24\NN|NONE (r_pobj) in_19\IN|the|of|prophylactic (r_prep) administration_16\NN|NONE (r_pobj) of_13\IN|the (r_prep) effectiveness_12\NN|NONE (r_pobj) concerning_10\VBG|to|experience (r_prep) report_7\VB|patients|objective|. (r_xcomp) was_5\VBD|NONE (l_attr) patients_30\NNS|report|objective|. (l_prep) with_31\IN|)|positive (l_pobj) disease_33\NN|NONE
D006514_D012216 NONE Ag_27\NNP|virus|surface (r_appos) antigen_24\NN|NONE (r_pobj) in_19\IN|the|of|prophylactic (r_prep) administration_16\NN|NONE (r_pobj) of_13\IN|the (r_prep) effectiveness_12\NN|NONE (r_pobj) concerning_10\VBG|to|experience (r_prep) report_7\VB|patients|objective|. (r_xcomp) was_5\VBD|NONE (l_attr) patients_30\NNS|report|objective|. (l_prep) with_31\IN|)|positive (l_pobj) disease_33\NN|NONE
D006514_D012216 NONE Ag_9\NNP|positive|with (r_nmod) patients_11\NNS|,|,|were|retrospectively|From|. (l_prep) with_12\IN|Ag|positive (l_pobj) diseases_14\NNS|NONE
D019259_D012216 NONE lamivudine_3\NN|NONE (r_pobj) of_2\IN|with|.|Prophylactic (r_prep) use_1\NN|NONE (l_prep) with_4\IN|of|.|Prophylactic (l_pobj) therapy_7\NN|NONE (l_prep) for_8\IN|chronic|immunosuppressive (l_pobj) disorders_10\NNS|NONE
D019259_D012216 NONE lamivudine_18\NN|NONE (r_pobj) of_17\IN|the|prophylactic|in (r_prep) administration_16\NN|NONE (r_pobj) of_13\IN|the (r_prep) effectiveness_12\NN|NONE (r_pobj) concerning_10\VBG|to|experience (r_prep) report_7\VB|patients|objective|. (r_xcomp) was_5\VBD|NONE (l_attr) patients_30\NNS|report|objective|. (l_prep) with_31\IN|)|positive (l_pobj) disease_33\NN|NONE
D019259_D012216 NONE lamivudine_23\JJ|immunosuppressive (r_compound) therapies_24\NNS|NONE (r_pobj) on_18\IN|who (r_prep) were_17\VBD|,|rheumatologic (r_relcl) diseases_14\NNS|NONE
1428568
D015784_D003866 NONE betaxolol_4\NN|could|that|less (r_nsubj) be_6\VB|.|results (l_attr) less_7\JJR|could|that|betaxolol (l_prep) of_8\IN|than (l_pobj) inducer_12\NN|NONE (l_compound) depression_10\NN||a
D013999_D003866 CID timolol_6\NN|NONE (r_compound) 0.5%/12h_7\CD|NONE (r_pobj) with_5\IN|suffering|patients|,|chronically (r_prep) treated_4\VBN|were|.|in|, (l_advcl) suffering_9\VBG|with|patients|,|chronically (l_prep) from_10\IN|diagnosed (l_pobj) depression_11\NN|NONE
D013999_D003866 CID timolol_15\NN|NONE (r_compound) treatment_16\NN|NONE (r_pobj) under_14\IN|the (r_prep) patients_13\NNS|In|,|values|. (r_nsubj) presented_17\VBD|NONE (l_dobj) values_20\NNS|patients|In|,|. (l_compound) depression_19\NN|measured|.|higher
D013999_D003866 CID timolol_14\NN|NONE (r_pobj) than_13\IN|of (r_prep) less_7\JJR|could|that|betaxolol (l_prep) of_8\IN|than (l_pobj) inducer_12\NN|NONE (l_compound) depression_10\NN||a
D013999_D005901 NONE timolol_6\NN|NONE (r_compound) 0.5%/12h_7\CD|NONE (r_pobj) with_5\IN|suffering|patients|,|chronically (r_prep) treated_4\VBN|were|.|in|, (l_nsubj) patients_2\NNS|suffering|with|,|chronically (l_amod) glaucomatous_1\JJ|Eight
17854040
D012964_D015658 NONE na_9\TO|.|Mutations|virus (r_aux) ve_10\VB|NONE (l_dobj) virus_13\NN|.|Mutations|na (l_appos) patients_18\NNS|B|HBV|(|) (l_prep) with_19\IN|infected (l_conj) without_21\IN|and (l_pobj) implications_27\NNS|NONE (l_punct) :_26\:|patients|for (l_punct) infection_25\NN|NONE
D012964_D015658 NONE na_9\TO|.|Mutations|virus (r_aux) ve_10\VB|NONE (l_dobj) virus_13\NN|.|Mutations|na (l_appos) patients_18\NNS|B|HBV|(|) (l_prep) with_19\IN|infected (l_conj) without_21\IN|and (l_pobj) implications_27\NNS|NONE (l_conj) patients_40\NNS|:|for (l_amod) infected_37\VBN|African
D012964_D015658 NONE na_21\NN|carriers|with (r_aux) ve_22\VB|exploratory|investigate|strains|an (r_acl) study_4\NN|.|This (r_attr) was_1\VBD|NONE (l_punct) ._41\.|This|study (l_punct) in_37\IN|NONE (l_punct) infection_36\NN|patients
D012964_D015658 NONE na_21\TO|patients (r_aux) ve_22\VB|NONE (l_dobj) patients_29\NNS|na (l_amod) infected_28\VBN|NONE
D019259_D006509 NONE lamivudine_3\NN||in (r_compound) resistance_5\NN|NONE (r_pobj) with_2\IN|NONE (r_prep) associated_1\VBN|NONE (r_acl) Mutations_0\NNS|.|na|virus (r_nsubj) ve_10\VB|NONE (l_dobj) virus_13\NN|.|Mutations|na (l_appos) patients_18\NNS|B|HBV|(|) (l_amod) infected_17\JJ|with
D019259_D006509 NONE lamivudine_3\NN||in (r_compound) resistance_5\NN|NONE (r_pobj) with_2\IN|NONE (r_prep) associated_1\VBN|NONE (r_acl) Mutations_0\NNS|.|na|virus (r_nsubj) ve_10\VB|NONE (l_dobj) virus_13\NN|.|Mutations|na (l_appos) patients_18\NNS|B|HBV|(|) (l_prep) with_19\IN|infected (l_conj) without_21\IN|and (l_pobj) implications_27\NNS|NONE (l_conj) patients_40\NNS|:|for (l_amod) infected_37\VBN|African
D019259_D006509 NONE lamivudine_7\JJ| (r_npadvmod) resistant_9\JJ|B (r_amod) virus_12\NN|to (l_compound) B_11\NN|resistant
D019259_D006509 NONE lamivudine_19\NN|selected| (r_compound) na_21\NN|carriers|with (r_aux) ve_22\VB|exploratory|investigate|strains|an (r_acl) study_4\NN|.|This (l_acl) investigate_6\VB|exploratory|ve|strains|an (l_dobj) virus_12\NN|to (l_compound) B_11\NN|resistant
D019259_D006509 NONE lamivudine_1\NN| (r_npadvmod) resistant_3\JJ|HBV (r_amod) strains_4\NNS|patients|were|and|in|. (r_nsubjpass) detected_6\VBN|NONE (l_prep) in_7\IN|patients|strains|were|and|. (l_pobj) patients_17\NNS|NONE (l_compound) B_16\NNP|infected|chronic|
D019259_D006509 NONE lamivudine_1\NN| (r_npadvmod) resistant_3\JJ|HBV (r_amod) strains_4\NNS|patients|were|and|in|. (r_nsubjpass) detected_6\VBN|NONE (l_conj) patients_28\NNS|strains|were|and|in|. (l_amod) infected_27\VBN|
D019259_D006509 NONE lamivudine_14\NN| (r_npadvmod) resistant_16\JJ|in|HBV (r_amod) strains_17\NNS|NONE (l_prep) in_18\IN|resistant|HBV (l_pcomp) ve_22\VB|NONE (l_dobj) patients_29\NNS|na (l_amod) infected_28\VBN|NONE
D019259_D006509 NONE lamivudine_22\NN|when|treatment| (r_npadvmod) containing_24\VBG|of|widespread (r_advcl) emergence_16\NN|NONE (r_pobj) in_14\IN|whether|applied|could|mutations (r_prep) result_13\VB|to|be (l_conj) applied_38\VBN|whether|could|mutations|in (l_advcl) is_45\VBZ|in|become|regimens|widely|, (l_acomp) likely_46\JJ|as|this (l_xcomp) have_48\VB|NONE (l_dobj) implications_50\NNS|to (l_prep) in_51\IN|potential (l_pobj) management_53\NN|NONE (l_prep) of_54\IN|the (l_pobj) patients_61\NNS|NONE (l_amod) infected_60\VBN|NONE
D012964_D006509 NONE na_9\TO|.|Mutations|virus (r_aux) ve_10\VB|NONE (l_dobj) virus_13\NN|.|Mutations|na (l_appos) patients_18\NNS|B|HBV|(|) (l_amod) infected_17\JJ|with
D012964_D006509 NONE na_9\TO|.|Mutations|virus (r_aux) ve_10\VB|NONE (l_dobj) virus_13\NN|.|Mutations|na (l_appos) patients_18\NNS|B|HBV|(|) (l_prep) with_19\IN|infected (l_conj) without_21\IN|and (l_pobj) implications_27\NNS|NONE (l_conj) patients_40\NNS|:|for (l_amod) infected_37\VBN|African
D012964_D006509 NONE na_21\NN|carriers|with (r_aux) ve_22\VB|exploratory|investigate|strains|an (r_acl) study_4\NN|.|This (l_acl) investigate_6\VB|exploratory|ve|strains|an (l_dobj) virus_12\NN|to (l_compound) B_11\NN|resistant
D012964_D006509 NONE na_21\TO|patients (r_aux) ve_22\VB|NONE (l_dobj) patients_29\NNS|na (l_amod) infected_28\VBN|NONE
D019259_D015658 NONE lamivudine_3\NN||in (r_compound) resistance_5\NN|NONE (r_pobj) with_2\IN|NONE (r_prep) associated_1\VBN|NONE (r_acl) Mutations_0\NNS|.|na|virus (r_nsubj) ve_10\VB|NONE (l_dobj) virus_13\NN|.|Mutations|na (l_appos) patients_18\NNS|B|HBV|(|) (l_prep) with_19\IN|infected (l_conj) without_21\IN|and (l_pobj) implications_27\NNS|NONE (l_punct) :_26\:|patients|for (l_punct) infection_25\NN|NONE
D019259_D015658 NONE lamivudine_3\NN||in (r_compound) resistance_5\NN|NONE (r_pobj) with_2\IN|NONE (r_prep) associated_1\VBN|NONE (r_acl) Mutations_0\NNS|.|na|virus (r_nsubj) ve_10\VB|NONE (l_dobj) virus_13\NN|.|Mutations|na (l_appos) patients_18\NNS|B|HBV|(|) (l_prep) with_19\IN|infected (l_conj) without_21\IN|and (l_pobj) implications_27\NNS|NONE (l_conj) patients_40\NNS|:|for (l_amod) infected_37\VBN|African
D019259_D015658 NONE lamivudine_7\JJ| (r_npadvmod) resistant_9\JJ|B (r_amod) virus_12\NN|to (r_dobj) investigate_6\VB|exploratory|ve|strains|an (r_acl) study_4\NN|.|This (r_attr) was_1\VBD|NONE (l_punct) ._41\.|This|study (l_punct) in_37\IN|NONE (l_punct) infection_36\NN|patients
D019259_D015658 NONE lamivudine_19\NN|selected| (r_compound) na_21\NN|carriers|with (r_aux) ve_22\VB|exploratory|investigate|strains|an (r_acl) study_4\NN|.|This (r_attr) was_1\VBD|NONE (l_punct) ._41\.|This|study (l_punct) in_37\IN|NONE (l_punct) infection_36\NN|patients
D019259_D015658 NONE lamivudine_1\NN| (r_npadvmod) resistant_3\JJ|HBV (r_amod) strains_4\NNS|patients|were|and|in|. (r_nsubjpass) detected_6\VBN|NONE (l_conj) patients_28\NNS|strains|were|and|in|. (l_amod) infected_27\VBN|
D019259_D015658 NONE lamivudine_14\NN| (r_npadvmod) resistant_16\JJ|in|HBV (r_amod) strains_17\NNS|NONE (l_prep) in_18\IN|resistant|HBV (l_pcomp) ve_22\VB|NONE (l_dobj) patients_29\NNS|na (l_amod) infected_28\VBN|NONE
D019259_D015658 NONE lamivudine_22\NN|when|treatment| (r_npadvmod) containing_24\VBG|of|widespread (r_advcl) emergence_16\NN|NONE (r_pobj) in_14\IN|whether|applied|could|mutations (r_prep) result_13\VB|to|be (l_conj) applied_38\VBN|whether|could|mutations|in (l_advcl) is_45\VBZ|in|become|regimens|widely|, (l_acomp) likely_46\JJ|as|this (l_xcomp) have_48\VB|NONE (l_dobj) implications_50\NNS|to (l_prep) in_51\IN|potential (l_pobj) management_53\NN|NONE (l_prep) of_54\IN|the (l_pobj) patients_61\NNS|NONE (l_amod) infected_60\VBN|NONE
7282516
D004317_D009202 CID doxorubicin_9\NN|NONE (r_compound) cardiomyopathy_10\NN|NONE
D004317_D009202 CID doxorubicin_10\NN|NONE (l_nsubj) CM_3\NNP|DXR|) (l_amod) cardiomyopathy_1\NN|)|produced|The|(
D004317_D009202 CID doxorubicin_10\NN|NONE (l_nsubj) CM_3\NNP|DXR|)
D004317_D009202 CID DXR_12\NN|CM|) (r_appos) doxorubicin_10\NN|NONE (l_nsubj) CM_3\NNP|DXR|) (l_amod) cardiomyopathy_1\NN|)|produced|The|(
D004317_D009202 CID DXR_12\NN|CM|) (r_appos) doxorubicin_10\NN|NONE (l_nsubj) CM_3\NNP|DXR|)
D004317_D009202 CID Adriamycin_1\NNP|opportunity|)|(|. (r_nsubj) provides_3\VBZ|NONE (l_dobj) opportunity_6\NN|Adriamycin|)|(|. (l_acl) analyze_8\VB|unique|a (l_dobj) relationships_16\NNS|to (l_prep) during_17\IN|effect (l_pobj) development_18\NN|NONE (l_prep) of_19\IN|NONE (l_pobj) disease_21\NN|NONE
D004317_D009202 CID DXR_1\NNP| (r_compound) CM_3\NNP|myocardial
D004317_D009202 CID DXR_1\NNP| (r_compound) CM_3\NNP|myocardial (r_nmod) damage_5\NN|NONE
D004317_D009202 CID DXR_15\NNP|NONE (r_compound) dose_16\NN|cytotoxic|(|) (r_appos) insult_13\NN|NONE (r_pobj) of_11\IN|the (r_prep) degree_10\NN|NONE (r_pobj) to_8\IN|NONE (r_prep) proportional_7\JJ|preserved|In|. (r_acomp) is_6\VBZ|NONE (l_prep) In_0\IN|preserved|.|proportional (l_pobj) damage_5\NN|NONE (l_nmod) CM_3\NNP|myocardial
D004317_D009202 CID DXR_15\NNP|NONE (r_compound) dose_16\NN|cytotoxic|(|) (r_appos) insult_13\NN|NONE (r_pobj) of_11\IN|the (r_prep) degree_10\NN|NONE (r_pobj) to_8\IN|NONE (r_prep) proportional_7\JJ|preserved|In|. (r_acomp) is_6\VBZ|NONE (l_prep) In_0\IN|preserved|.|proportional (l_pobj) damage_5\NN|NONE
12911170
D002939_D009395 CID Ciprofloxacin_0\NNP|.|nephritis| (r_npadvmod) induced_2\VBN|NONE (l_dobj) nephritis_5\NN|.|Ciprofloxacin|
D002939_D009395 CID Ciprofloxacin_0\NNP|been|with|has|. (r_nsubjpass) associated_3\VBN|NONE (l_prep) with_4\IN|been|has|.|Ciprofloxacin (l_pobj) effects_7\NNS|NONE (l_prep) including_8\VBG|side|several (l_pobj) nephritis_10\NN|NONE
D002939_D009395 CID ciprofloxacin_9\NNS| (r_npadvmod) induced_11\VBN|interstitial|anemia|and (r_amod) nephritis_13\NN|NONE
D013256_D000743 NONE steroid_10\NN|NONE (r_compound) therapy_11\NN|NONE (r_pobj) of_9\IN|NONE (r_prep) initiation_8\NN|and|the (r_conj) drug_6\NN|NONE (r_dobj) stopping_4\VBG|NONE (r_pcomp) after_3\IN|anemia|. (r_prep) improved_2\VBD|NONE (l_nsubj) anemia_1\NN|.|after
D002939_D000743 CID Ciprofloxacin_0\NNP|been|with|has|. (r_nsubjpass) associated_3\VBN|NONE (l_prep) with_4\IN|been|has|.|Ciprofloxacin (l_pobj) effects_7\NNS|NONE (l_prep) including_8\VBG|side|several (l_pobj) nephritis_10\NN|NONE (l_conj) anemia_13\NN|and|interstitial
D002939_D000744 NONE Ciprofloxacin_0\NNP|.|nephritis| (r_npadvmod) induced_2\VBN|NONE (l_dobj) nephritis_5\NN|.|Ciprofloxacin| (l_conj) anemia_9\NN|and|interstitial|acute
D002939_D000744 NONE ciprofloxacin_9\NNS| (r_npadvmod) induced_11\VBN|interstitial|anemia|and (r_amod) nephritis_13\NN|NONE (l_conj) anemia_17\NN|interstitial|induced|and
18356633
D000583_D007674 CID amikacin_3\JJ|in (r_amod) nephrotoxicity_4\NN|NONE
D000583_D007674 CID amikacin_2\RB| (r_npadvmod) associated_4\VBN|NONE (r_amod) nephrotoxicity_5\NN|in|To
D000583_D007674 CID amikacin_17\JJ|NONE (r_prep) via_16\IN|of (r_prep) evaluation_13\NN|and|serum (r_conj) creatinine_11\NN|NONE (r_pobj) in_9\IN|an (r_prep) increase_8\NN|NONE (r_pobj) of_6\IN|NONE (r_prep) means_5\NNS|NONE (r_pobj) by_4\IN|of|The (r_prep) occurrence_1\NN|.|were (l_prep) of_2\IN|by|The (l_pobj) nephrotoxicity_3\NN|NONE
D000617_D009369 NONE aminoglycoside_17\NN|NONE (r_pobj) with_15\IN|NONE (r_prep) treatment_14\NN|that (r_dobj) required_13\VBD|a|oncologic (r_relcl) disorder_11\NN|NONE
D000583_D007239 NONE Amikacin_0\NNP|.|aminoglycoside (r_nsubj) is_1\VBZ|NONE (l_attr) aminoglycoside_3\NN|Amikacin|. (l_acl) used_5\VBN|an (l_xcomp) provide_7\VB|commonly (l_dobj) treatment_13\NN|to (l_prep) for_14\IN|negative|double|empirical (l_pobj) neutropenia_16\NN|NONE (l_conj) infections_20\NNS|febrile|and
D000617_D007239 NONE aminoglycoside_3\NN|Amikacin|. (l_acl) used_5\VBN|an (l_xcomp) provide_7\VB|commonly (l_dobj) treatment_13\NN|to (l_prep) for_14\IN|negative|double|empirical (l_pobj) neutropenia_16\NN|NONE (l_conj) infections_20\NNS|febrile|and
D003404_D007674 NONE creatinine_11\NN|NONE (r_pobj) in_9\IN|an (r_prep) increase_8\NN|NONE (r_pobj) of_6\IN|NONE (r_prep) means_5\NNS|NONE (r_pobj) by_4\IN|of|The (r_prep) occurrence_1\NN|.|were (l_prep) of_2\IN|by|The (l_pobj) nephrotoxicity_3\NN|NONE
D000583_D006402 NONE amikacin_27\JJ|NONE (r_pobj) to_20\IN|.|patients|were (r_prep) randomized_19\VBN|NONE (l_nsubjpass) patients_1\NNS|to|.|were (l_prep) with_2\IN|Forty (l_pobj) diagnosis_4\NN|NONE (l_amod) consistent_5\JJ|a (l_prep) with_6\IN|NONE (l_pobj) disorder_11\NN|NONE
D000583_D009369 NONE amikacin_27\JJ|NONE (r_pobj) to_20\IN|.|patients|were (r_prep) randomized_19\VBN|NONE (l_nsubjpass) patients_1\NNS|to|.|were (l_prep) with_2\IN|Forty (l_pobj) diagnosis_4\NN|NONE (l_amod) consistent_5\JJ|a (l_prep) with_6\IN|NONE (l_pobj) disorder_11\NN|NONE
D000617_D006402 NONE aminoglycoside_17\NN|NONE (r_pobj) with_15\IN|NONE (r_prep) treatment_14\NN|that (r_dobj) required_13\VBD|a|oncologic (r_relcl) disorder_11\NN|NONE
D000583_D009503 NONE Amikacin_0\NNP|.|aminoglycoside (r_nsubj) is_1\VBZ|NONE (l_attr) aminoglycoside_3\NN|Amikacin|. (l_acl) used_5\VBN|an (l_xcomp) provide_7\VB|commonly (l_dobj) treatment_13\NN|to (l_prep) for_14\IN|negative|double|empirical (l_pobj) neutropenia_16\NN|NONE
D000617_D009503 NONE aminoglycoside_3\NN|Amikacin|. (l_acl) used_5\VBN|an (l_xcomp) provide_7\VB|commonly (l_dobj) treatment_13\NN|to (l_prep) for_14\IN|negative|double|empirical (l_pobj) neutropenia_16\NN|NONE
8302922
D014294_D007022 CID trimethaphan_7\RB|prostaglandin|or (r_conj) E1_5\NNP|NONE (r_pobj) during_3\IN|blood|Epidural (r_prep) flow_2\NN|hypotension|. (r_nsubj) induced_8\VBD|NONE (l_dobj) hypotension_9\NN|flow|.
D014294_D007022 CID trimethaphan_11\NN|or|E|(|prostaglandin|) (r_conj) PGE1_8\NNP|NONE (r_pobj) of_4\IN|the (r_prep) effect_3\NN|To (r_dobj) evaluate_1\VB|during|hypotension (r_csubj) induced_15\VBN|,|.|using|was|EBF (l_dobj) hypotension_16\NN|during|evaluate
D014294_D007022 CID TMP_13\NNP|NONE (r_appos) trimethaphan_11\NN|or|E|(|prostaglandin|) (r_conj) PGE1_8\NNP|NONE (r_pobj) of_4\IN|the (r_prep) effect_3\NN|To (r_dobj) evaluate_1\VB|during|hypotension (r_csubj) induced_15\VBN|,|.|using|was|EBF (l_dobj) hypotension_16\NN|during|evaluate
D014294_D007022 CID TMP_4\NNP|product|or (r_conj) PGE1_2\NNP|NONE (r_dobj) starting_1\VBG|NONE (r_pcomp) After_0\IN|compared|significantly|,|remained|and (r_prep) decreased_14\VBD|NONE (l_conj) remained_34\VBD|After|compared|significantly|,|and (l_nsubj) degree_28\NN|constant|.|until (l_prep) of_29\IN|due|the (l_pobj) hypotension_30\NN|NONE
D014294_D007022 CID TMP_9\VB|NONE (l_prep) for_10\IN|to (l_pobj) anaesthesia_12\NN|NONE (l_amod) hypotensive_11\JJ|in
D014294_D007022 CID TMP_17\NNP|EBF|because (r_nsubj) decreased_18\VBD|PGE|may|preferable|that (r_advcl) be_6\VB|.|results (l_acomp) preferable_7\JJ|PGE|may|that|decreased (l_xcomp) TMP_9\VB|NONE (l_prep) for_10\IN|to (l_pobj) anaesthesia_12\NN|NONE (l_amod) hypotensive_11\JJ|in
D000527_D007022 CID E1_5\NNP|NONE (r_pobj) during_3\IN|blood|Epidural (r_prep) flow_2\NN|hypotension|. (r_nsubj) induced_8\VBD|NONE (l_dobj) hypotension_9\NN|flow|.
D000527_D007022 CID E1_6\NNP|or|trimethaphan|(|prostaglandin|) (r_nmod) PGE1_8\NNP|NONE (r_pobj) of_4\IN|the (r_prep) effect_3\NN|To (r_dobj) evaluate_1\VB|during|hypotension (r_csubj) induced_15\VBN|,|.|using|was|EBF (l_dobj) hypotension_16\NN|during|evaluate
D000527_D007022 CID PGE1_8\NNP|NONE (r_pobj) of_4\IN|the (r_prep) effect_3\NN|To (r_dobj) evaluate_1\VB|during|hypotension (r_csubj) induced_15\VBN|,|.|using|was|EBF (l_dobj) hypotension_16\NN|during|evaluate
D000527_D007022 CID PGE1_2\NNP|NONE (r_dobj) starting_1\VBG|NONE (r_pcomp) After_0\IN|compared|significantly|,|remained|and (r_prep) decreased_14\VBD|NONE (l_conj) remained_34\VBD|After|compared|significantly|,|and (l_nsubj) degree_28\NN|constant|.|until (l_prep) of_29\IN|due|the (l_pobj) hypotension_30\NN|NONE
D000527_D007022 CID PGE1_33\NNP|NONE (r_pobj) to_32\IN|NONE (r_pcomp) due_31\IN|of|the (r_prep) degree_28\NN|constant|.|until (l_prep) of_29\IN|due|the (l_pobj) hypotension_30\NN|NONE
D000527_D007022 CID PGE1_4\NNP|may|preferable|that|decreased (r_nsubj) be_6\VB|.|results (l_acomp) preferable_7\JJ|PGE|may|that|decreased (l_xcomp) TMP_9\VB|NONE (l_prep) for_10\IN|to (l_pobj) anaesthesia_12\NN|NONE (l_amod) hypotensive_11\JJ|in
D007530_D007022 NONE isoflurane_47\JJ|NONE (r_amod) anaesthesia_48\NN|NONE (r_pobj) under_46\IN|interbody|lateral (r_prep) fusion_45\NN|who (r_dobj) underwent_40\VBD| (r_relcl) patients_38\NNS|NONE (r_pobj) in_36\IN|method (r_prep) using_31\VBG|,|.|induced|was|EBF (r_advcl) measured_30\VBN|NONE (l_advcl) induced_15\VBN|,|.|using|was|EBF (l_dobj) hypotension_16\NN|during|evaluate
19917396
D016559_D006332 CID tacrolimus_5\NNS|NONE (r_pobj) by_4\IN|NONE (r_agent) induced_3\VBN|myocardial|Reversible (r_acl) hypertrophy_2\NN|case|.|:
D016559_D006332 CID tacrolimus_8\NNS|NONE (r_pobj) by_7\IN|NONE (r_agent) induced_6\VBN|transient|myocardial (r_acl) hypertrophy_5\NN|Herein|.|we
D016559_D006332 CID tacrolimus_10\NN|NONE (r_pobj) of_9\IN|the|target (r_prep) concentration_8\NN|NONE (r_dobj) reducing_5\VBG|NONE (r_pcomp) upon_4\IN|recur|and|hypertrophy|.|completely (r_prep) resolved_3\VBN|NONE (l_nsubj) hypertrophy_1\NN|recur|and|upon|.|completely
D016559_D006332 CID tacrolimus_5\NN|hypertrophy|that (r_nsubj) induces_6\VBZ|.|Thus|we|, (l_dobj) hypertrophy_9\NN|tacrolimus|that
9875685
D003404_D007674 NONE creatinine_2\NN|.|versus|was|without|,|in (r_nsubjpass) observed_4\VBN|NONE (l_prep) without_20\IN|.|versus|was|creatinine|,|in (l_pobj) evidence_21\NN|NONE (l_prep) of_22\IN|NONE (l_pobj) nephrotoxicity_23\NN|NONE
D014031_D064420 NONE tobramicyn_17\NN|NONE (l_prep) on_18\IN|NONE (l_pobj) concentrations_23\NNS|NONE (l_conj) toxicity_25\NN|and|state|serum
19356307
C032208_D003704 NONE alcohol_13\NN|NONE (r_pobj) of_5\IN|The|dementia (r_prep) effects_4\NNS|.|were|using (l_compound) dementia_3\NN|of|The
C032208_D008569 NONE alcohol_19\NN|,|;|however|and|deficit|improve|only|,|.|showed (r_nsubj) relieved_20\VBD|NONE (l_ccomp) showed_4\VBD|,|;|however|and|alcohol|deficit|improve|only|,|. (l_dobj) ability_6\NN|oils (l_acl) improve_8\VB|strong (l_dobj) memory_9\NN|to (l_amod) impaired_10\VBN|NONE
C032208_D008569 NONE alcohol_19\NN|,|;|however|and|deficit|improve|only|,|.|showed (r_nsubj) relieved_20\VBD|NONE (l_dobj) deficit_22\NN|,|;|however|and|alcohol|improve|only|,|.|showed (l_prep) of_23\IN|the|in (l_pobj) memory_25\NN|NONE
C008281_D003704 NONE limonene_8\NN|NONE (r_nmod) alcohol_13\NN|NONE (r_pobj) of_5\IN|The|dementia (r_prep) effects_4\NNS|.|were|using (l_compound) dementia_3\NN|of|The
D012601_D003704 NONE scopolamine_9\NN|NONE (r_pobj) by_8\IN|.|Components (r_agent) induced_7\VBN|NONE (l_nsubj) Components_0\NNS|.|by (l_prep) of_1\IN|NONE (l_pobj) dementia_6\NN|NONE
D012601_D008569 CID scopolamine_12\NN|NONE (r_pobj) by_11\IN|NONE (r_agent) impaired_10\VBN|NONE
D012601_D008569 CID scopolamine_12\NN|NONE (r_pobj) by_11\IN|NONE (r_agent) impaired_10\VBN|NONE (r_amod) memory_9\NN|to (r_dobj) improve_8\VB|strong (r_acl) ability_6\NN|oils (r_dobj) showed_4\VBD|,|;|however|and|alcohol|deficit|improve|only|,|. (r_ccomp) relieved_20\VBD|NONE (l_dobj) deficit_22\NN|,|;|however|and|alcohol|improve|only|,|.|showed (l_prep) of_23\IN|the|in (l_pobj) memory_25\NN|NONE
15338796
D000420_D008173 NONE salbutamol_19\NN|NONE (r_pobj) of_18\IN|cumulative (r_prep) doses_17\NNS|NONE (r_pobj) of_15\IN|NONE (r_prep) administration_14\NN|NONE (r_pobj) after_13\IN|lung|obstructive (r_prep) disease_12\NN|NONE
D000420_D014202 CID salbutamol_4\NN|NONE (r_pobj) of_3\IN|side|.|,|quantified|Tremor (r_prep) effects_2\NNS|NONE (l_compound) Tremor_0\NNP|side|of|.|,|quantified
D000420_D014202 CID salbutamol_6\NN|NONE (r_pobj) of_5\IN|side|tremor (r_prep) effects_4\NNS|To (l_compound) tremor_2\JJ|side|of
D000420_D014202 CID salbutamol_19\NN|NONE (r_pobj) of_18\IN|cumulative (r_prep) doses_17\NNS|NONE (r_pobj) of_15\IN|NONE (r_prep) administration_14\NN|NONE (r_pobj) after_13\IN|lung|obstructive (r_prep) disease_12\NN|NONE (r_pobj) with_9\IN| (r_prep) patients_8\NNS|NONE (r_pobj) in_6\IN|.|we|determine|tremor (r_prep) assessed_4\VBD|NONE (l_dobj) tremor_5\NN|.|we|in|determine
D000420_D014202 CID Salbutamol_0\NNP|severity|in|.|significantly (r_nsubj) increased_2\VBD|NONE (l_dobj) severity_4\NN|in|Salbutamol|.|significantly (l_compound) tremor_3\NN|NONE
28952
D012964_D007008 NONE sodium_18\NN|dietary (r_compound) restriction_19\NN|NONE (r_pobj) of_16\IN|the (r_prep) influence_15\NN|hypokalaemia|potassium|:|.|Initial|and (r_appos) loss_2\NN|NONE (l_conj) hypokalaemia_4\NN|potassium|influence|:|.|Initial|and
D011188_D007008 NONE potassium_1\NN|hypokalaemia|influence|:|.|Initial|and (r_compound) loss_2\NN|NONE (l_conj) hypokalaemia_4\NN|potassium|influence|:|.|Initial|and
D011188_D007008 NONE potassium_4\NN|initial|the|during|development|and (r_compound) loss_5\NN|To (l_conj) development_7\NN|initial|the|during|potassium|and (l_prep) of_8\IN|NONE (l_pobj) hypokalaemia_9\NN|NONE
D011188_D007008 NONE potassium_4\NN|initial|the|during|development|and (r_compound) loss_5\NN|To (r_dobj) investigate_1\VB|were|in|. (r_csubjpass) performed_22\VBN|NONE (l_prep) in_23\IN|were|investigate|. (l_pobj) patients_25\NNS|NONE (l_prep) with_26\IN|ten (l_pobj) hypertension_28\NN|NONE (l_relcl) shown_31\VBN|essential (l_dobj) hypokalaemia_32\NN|had|under|who
D011188_D006973 NONE potassium_1\NN|hypokalaemia|influence|:|.|Initial|and (r_compound) loss_2\NN|NONE (l_conj) hypokalaemia_4\NN|potassium|influence|:|.|Initial|and (l_prep) during_5\IN|NONE (l_pobj) administration_7\NN|NONE (l_prep) in_8\IN|chlorthalidone (l_pobj) patients_9\NNS|NONE (l_prep) with_10\IN|NONE (l_pobj) hypertension_12\NN|NONE
D011188_D006973 NONE potassium_4\NN|initial|the|during|development|and (r_compound) loss_5\NN|To (r_dobj) investigate_1\VB|were|in|. (r_csubjpass) performed_22\VBN|NONE (l_prep) in_23\IN|were|investigate|. (l_pobj) patients_25\NNS|NONE (l_prep) with_26\IN|ten (l_pobj) hypertension_28\NN|NONE
D002752_D006973 NONE chlorthalidone_6\NN|in (r_compound) administration_7\NN|NONE (l_prep) in_8\IN|chlorthalidone (l_pobj) patients_9\NNS|NONE (l_prep) with_10\IN|NONE (l_pobj) hypertension_12\NN|NONE
D012964_D006973 NONE sodium_18\NN|dietary (r_compound) restriction_19\NN|NONE (r_pobj) of_16\IN|the (r_prep) influence_15\NN|hypokalaemia|potassium|:|.|Initial|and (r_appos) loss_2\NN|NONE (l_conj) hypokalaemia_4\NN|potassium|influence|:|.|Initial|and (l_prep) during_5\IN|NONE (l_pobj) administration_7\NN|NONE (l_prep) in_8\IN|chlorthalidone (l_pobj) patients_9\NNS|NONE (l_prep) with_10\IN|NONE (l_pobj) hypertension_12\NN|NONE
D002752_D007008 CID chlorthalidone_6\NN|in (r_compound) administration_7\NN|NONE (r_pobj) during_5\IN|NONE (r_prep) hypokalaemia_4\NN|potassium|influence|:|.|Initial|and
19631624
D018817_D007859 CID ecstasy_5\NN|NONE (r_compound) users_6\NNS|NONE (r_pobj) in_4\IN|correlates|and|Learning (r_prep) deficits_3\NNS|NONE
D018817_D007859 CID ecstasy_6\NN|NONE (r_compound) users_7\NNS|that|impairments (r_nsubj) display_8\VBP|has|It|consistently|.|been (l_dobj) impairments_9\NNS|that|users (l_prep) in_10\IN|NONE (l_pobj) performance_14\NN|NONE (l_nmod) learning_11\NN|NONE (l_conj) memory_13\NN|and
D002188_D006948 NONE cannabis_12\NN|NONE (r_compound) users_13\NNS|NONE (r_pobj) in_11\IN|frontocortical (r_prep) hypoactivity_10\NN|and|parahippocampal (r_conj) hyperactivity_7\NN|.|in|:
D002188_D007859 NONE cannabis_12\NN|NONE (r_compound) users_13\NNS|NONE (r_pobj) in_11\IN|frontocortical (r_prep) hypoactivity_10\NN|and|parahippocampal (r_conj) hyperactivity_7\NN|.|in|: (r_appos) Deficits_0\NNS|NONE (l_prep) in_1\IN|.|hyperactivity|: (l_pobj) learning_2\NN|NONE (l_conj) memory_4\NN|and
D018817_D020258 NONE ecstasy_1\NN| (r_npadvmod) specific_3\JJ|These (r_amod) effects_4\NNS|to|.|be|may (r_nsubjpass) related_7\VBN|NONE (l_prep) to_8\IN|.|effects|be|may (l_pobj) vulnerability_10\NN|NONE (l_prep) to_16\IN|of|the (l_pobj) effects_19\NNS|NONE (l_amod) neurotoxic_18\JJ|the|of
D018817_D020258 NONE ecstasy_21\NN|NONE (r_pobj) of_20\IN|the|neurotoxic (r_prep) effects_19\NNS|NONE (l_amod) neurotoxic_18\JJ|the|of
D018817_D008569 CID ecstasy_5\NN|NONE (r_compound) users_6\NNS|NONE (r_pobj) in_4\IN|correlates|and|Learning (r_prep) deficits_3\NNS|NONE
D018817_D008569 CID ecstasy_6\NN|NONE (r_compound) users_7\NNS|that|impairments (r_nsubj) display_8\VBP|has|It|consistently|.|been (l_dobj) impairments_9\NNS|that|users (l_prep) in_10\IN|NONE (l_pobj) performance_14\NN|NONE (l_nmod) learning_11\NN|NONE (l_conj) memory_13\NN|and
D002188_D008569 NONE cannabis_12\NN|NONE (r_compound) users_13\NNS|NONE (r_pobj) in_11\IN|frontocortical (r_prep) hypoactivity_10\NN|and|parahippocampal (r_conj) hyperactivity_7\NN|.|in|: (r_appos) Deficits_0\NNS|NONE (l_prep) in_1\IN|.|hyperactivity|: (l_pobj) learning_2\NN|NONE (l_conj) memory_4\NN|and
D018817_D006948 NONE ecstasy_13\NN| (r_npadvmod) specific_15\JJ|in (r_amod) hyperactivity_16\NN|,|left|.|analysis
19820426
C558899_D001919 CID ritonavir_15\NNS|,|agent (r_compound) therapy_16\NN|/ (r_appos) lopinavir_13\NNS|NONE (r_pobj) to_12\IN|NONE (r_prep) related_11\VBN|dilated (r_acl) cardiomyopathy_10\NN|complete|heart|and (r_conj) block_7\NN|One|,|.|developed (r_dobj) developed_4\VBD|NONE (l_advcl) developed_29\VBD|One|,|block|. (l_dobj) bradycardia_31\NNS|twin|while
C558899_D002311 CID ritonavir_15\NNS|,|agent (r_compound) therapy_16\NN|/ (r_appos) lopinavir_13\NNS|NONE (r_pobj) to_12\IN|NONE (r_prep) related_11\VBN|dilated (r_acl) cardiomyopathy_10\NN|complete|heart|and
C558899_D066126 NONE ritonavir_10\NNS|NONE (r_compound) therapy_11\NN|/ (r_appos) lopinavir_8\NNS|NONE (r_pobj) to_7\IN|NONE (r_prep) related_6\VBN|cardiac (r_acl) toxicity_5\NN|NONE
C558899_D006327 CID ritonavir_15\NNS|,|agent (r_compound) therapy_16\NN|/ (r_appos) lopinavir_13\NNS|NONE (r_pobj) to_12\IN|NONE (r_prep) related_11\VBN|dilated (r_acl) cardiomyopathy_10\NN|complete|heart|and (r_conj) block_7\NN|One|,|.|developed
3503576
D003676_D064420 NONE deferoxamine_9\NN|NONE (r_compound) doses_10\NNS|in|were|initially|Since| (r_dobj) receiving_8\VBG|was|with|,|and|therapy|demonstrated|, (r_advcl) restarted_24\VBN|NONE (l_conj) demonstrated_55\VBN|was|with|,|receiving|and|therapy|, (l_nsubjpass) toxicity_53\NN|was|.|with
D003676_D000740 NONE deferoxamine_26\NN|NONE (r_pobj) with_23\IN|were|who|therapy (r_prep) receiving_19\VBG|dependent (r_relcl) anemia_16\NN|NONE
D003676_D014786 NONE deferoxamine_26\NN|NONE (r_pobj) with_23\IN|were|who|therapy (r_prep) receiving_19\VBG|dependent (r_relcl) anemia_16\NN|NONE (r_pobj) with_12\IN| (r_prep) patients_11\NNS|NONE (r_pobj) in_7\IN|previously|neurotoxicity|.|was (r_prep) documented_6\VBN|NONE (l_nsubjpass) neurotoxicity_3\NN|previously|.|was|in
D007501_D000740 NONE iron_20\NN|chelation (r_compound) therapy_22\NN|with|were|who (r_dobj) receiving_19\VBG|dependent (r_relcl) anemia_16\NN|NONE
D007501_D006311 NONE iron_20\NN|chelation (r_compound) therapy_22\NN|with|were|who (r_dobj) receiving_19\VBG|dependent (r_relcl) anemia_16\NN|NONE (r_pobj) with_12\IN| (r_prep) patients_11\NNS|NONE (r_pobj) in_7\IN|previously|neurotoxicity|.|was (r_prep) documented_6\VBN|NONE (l_nsubjpass) neurotoxicity_3\NN|previously|.|was|in
D003676_D006311 NONE deferoxamine_8\NN|NONE (r_compound) therapy_9\NN|NONE (r_dobj) receiving_7\VBG|NONE (r_acl) patients_6\NNS|NONE (r_pobj) in_5\IN|.|of|Serial (r_prep) studies_1\NNS|NONE (l_prep) of_2\IN|in|.|Serial (l_pobj) neurotoxicity_4\NN|NONE
D003676_D006311 NONE deferoxamine_26\NN|NONE (r_pobj) with_23\IN|were|who|therapy (r_prep) receiving_19\VBG|dependent (r_relcl) anemia_16\NN|NONE (r_pobj) with_12\IN| (r_prep) patients_11\NNS|NONE (r_pobj) in_7\IN|previously|neurotoxicity|.|was (r_prep) documented_6\VBN|NONE (l_nsubjpass) neurotoxicity_3\NN|previously|.|was|in
D003676_D006311 NONE deferoxamine_9\NN|NONE (r_compound) doses_10\NNS|in|were|initially|Since| (r_dobj) receiving_8\VBG|was|with|,|and|therapy|demonstrated|, (r_advcl) restarted_24\VBN|NONE (l_prep) with_25\IN|was|,|receiving|and|therapy|demonstrated|, (l_pobj) doses_27\NNS|NONE (l_prep) depending_36\VBG|mg/kg|,|lower (l_prep) on_37\IN|NONE (l_pobj) degree_39\NN|NONE (l_prep) of_40\IN|the (l_pobj) abnormality_42\NN|NONE
D003676_D006311 NONE deferoxamine_14\NN|not (r_dobj) receiving_13\VBG|and (r_conj) receiving_10\VBG|individual (r_acl) patients_9\NNS|NONE (r_pobj) in_7\IN|serially|respectively|.|deterioration|,|,|provided|, (r_prep) demonstrated_5\VBD|NONE (l_prep) provided_18\VBD|serially|respectively|.|deterioration|,|in|,|, (l_pcomp) convincing_19\JJ|NONE (l_dobj) evidence_20\NN|NONE (l_prep) for_21\IN|NONE (l_pobj) relation_28\NN|NONE (l_prep) between_29\IN|cause|a (l_pobj) administration_31\NN|NONE (l_conj) ototoxicity_33\NN|and|deferoxamine
D003676_D006311 NONE deferoxamine_30\NN|and|ototoxicity (r_compound) administration_31\NN|NONE (l_conj) ototoxicity_33\NN|and|deferoxamine
D007501_D014786 NONE iron_20\NN|chelation (r_compound) therapy_22\NN|with|were|who (r_dobj) receiving_19\VBG|dependent (r_relcl) anemia_16\NN|NONE (r_pobj) with_12\IN| (r_prep) patients_11\NNS|NONE (r_pobj) in_7\IN|previously|neurotoxicity|.|was (r_prep) documented_6\VBN|NONE (l_nsubjpass) neurotoxicity_3\NN|previously|.|was|in
20635749
D000638_D006333 NONE amiodarone_6\NN|presenting (r_pobj) on_5\IN|Severe|failure|:|report|. (r_prep) patient_4\NN|NONE (l_compound) failure_3\NN|Severe|on|:|report|.
D000638_D006333 NONE amiodarone_10\NN| (r_npadvmod) induced_12\VBN|NONE (r_amod) hypothyroidism_13\NN|NONE (r_pobj) to_9\IN|secondary|in (r_prep) coma_7\NN|report|This|. (l_prep) in_14\IN|secondary|to (l_pobj) patient_16\NN|NONE (l_prep) with_17\IN|a (l_pobj) failure_21\NN|NONE
D000638_D006333 NONE amiodarone_10\NN| (r_npadvmod) induced_12\VBN|NONE (r_amod) hypothyroidism_13\NN|NONE (r_pobj) to_9\IN|secondary|in (r_prep) coma_7\NN|report|This|. (l_prep) in_14\IN|secondary|to (l_pobj) patient_16\NN|NONE (l_prep) with_17\IN|a (l_pobj) failure_21\NN|NONE (l_appos) CHF_23\NNP|severe|heart
D000638_D006333 NONE amiodarone_4\NN|NONE (r_pobj) on_3\IN|with (r_prep) Patients_0\NNS|,|deserve|and|may|.|morbidity (l_prep) with_1\IN|on (l_pobj) CHF_2\NNP|NONE
D000638_D006333 NONE amiodarone_13\NN|NONE (l_prep) among_14\IN|NONE (l_pobj) patients_16\NNS|NONE (l_compound) CHF_15\NNP|NONE
D000638_D003128 CID amiodarone_6\NN|presenting (r_pobj) on_5\IN|Severe|failure|:|report|. (l_pcomp) presenting_7\VBG|amiodarone (l_prep) with_8\IN|NONE (l_pobj) coma_10\NN|NONE
D000638_D003128 CID amiodarone_10\NN| (r_npadvmod) induced_12\VBN|NONE (r_amod) hypothyroidism_13\NN|NONE (r_pobj) to_9\IN|secondary|in (r_prep) coma_7\NN|report|This|.
D000638_D003128 CID amiodarone_19\NN|term (r_compound) therapy_20\NN|NONE (r_pobj) during_16\IN|of|one|case (r_prep) report_12\NN|there|To|. (l_prep) of_13\IN|one|case|during (l_pobj) coma_15\NN|NONE
D000638_D007037 CID amiodarone_10\NN| (r_npadvmod) induced_12\VBN|NONE (r_amod) hypothyroidism_13\NN|NONE
D000638_D007037 CID amiodarone_4\NN|NONE (r_pobj) on_3\IN|with (r_prep) Patients_0\NNS|,|deserve|and|may|.|morbidity (r_nsubj) suffer_6\VB|NONE (l_dobj) morbidity_8\NN|,|deserve|Patients|and|may|. (l_prep) from_11\IN|mortality|serious|and (l_pobj) hypothyroidism_12\NN|NONE
D000638_D009230 CID amiodarone_6\NN|presenting (r_pobj) on_5\IN|Severe|failure|:|report|. (l_pcomp) presenting_7\VBG|amiodarone (l_prep) with_8\IN|NONE (l_pobj) coma_10\NN|NONE
D000638_D009230 CID amiodarone_10\NN| (r_npadvmod) induced_12\VBN|NONE (r_amod) hypothyroidism_13\NN|NONE (r_pobj) to_9\IN|secondary|in (r_prep) coma_7\NN|report|This|.
D000638_D009230 CID amiodarone_19\NN|term (r_compound) therapy_20\NN|NONE (r_pobj) during_16\IN|of|one|case (r_prep) report_12\NN|there|To|. (l_prep) of_13\IN|one|case|during (l_pobj) coma_15\NN|NONE
6942642
D049971_D007008 NONE Thiazide_0\NNP|,|hypokalemia|. (r_compound) diuretics_1\NNS|NONE (l_conj) hypokalemia_3\JJ|,|Thiazide|.
D049971_D007008 NONE thiazide_9\NN|chronic (r_compound) therapy_10\NN|NONE (r_pobj) of_7\IN|encountered|metabolic|a (r_prep) consequence_6\NN|.|Hypokalemia (r_attr) is_1\VBZ|NONE (l_nsubj) Hypokalemia_0\NNP|.|consequence
D049971_D007008 NONE thiazide_5\JJ|hypokalemia|that (r_csubj) cause_7\VBP|In|we|. (l_dobj) hypokalemia_8\NN|thiazide|that
D011188_D007008 NONE potassium_13\NN|NONE (r_pobj) of_11\IN|NONE (r_prep) depletion_10\NN|and (r_conj) hypokalemia_8\NN|thiazide|that
D006852_C563897 NONE hydrochlorothiazide_18\NN|NONE (r_pobj) with_17\IN|diastolic|moderate (r_prep) hypertension_16\NN|NONE
D006852_C563897 NONE HCTC_20\NNP|administered (r_appos) hydrochlorothiazide_18\NN|NONE (r_pobj) with_17\IN|diastolic|moderate (r_prep) hypertension_16\NN|NONE
D049971_D001145 NONE Thiazide_0\NNP|,|hypokalemia|. (r_compound) diuretics_1\NNS|NONE (l_conj) hypokalemia_3\JJ|,|Thiazide|. (l_conj) arrhythmias_6\NNS|and
19139001
D000518_D015179 NONE difluoromethylornithine_13\NN|NONE (l_conj) sulindac_15\NN|and (l_prep) for_16\IN|NONE (l_pobj) prevention_17\NN|NONE (l_prep) of_18\IN|NONE (l_pobj) adenomas_21\NNS|NONE
D013467_D015179 NONE sulindac_15\NN|and (l_prep) for_16\IN|NONE (l_pobj) prevention_17\NN|NONE (l_prep) of_18\IN|NONE (l_pobj) adenomas_21\NNS|NONE
D000518_D034381 NONE DFMO_10\NN|NONE (r_pobj) with_9\IN|NONE (r_prep) treatment_8\NN|NONE (r_pobj) of_7\IN|a|,|known (r_prep) toxicity_6\NN|.|developed|loss (r_attr) is_3\VBZ|NONE (l_nsubj) loss_2\NN|.|developed|toxicity
D000518_D034381 NONE DFMO_12\NN|sulindac|experienced|the (r_nmod) group_15\NN|NONE (l_relcl) experienced_17\VBD|sulindac|DFMO|the (l_dobj) loss_21\NN|compared|who
D000518_D064420 NONE DFMO_10\NN|NONE (r_pobj) with_9\IN|NONE (r_prep) treatment_8\NN|NONE (r_pobj) of_7\IN|a|,|known (r_prep) toxicity_6\NN|.|developed|loss
D013467_D018256 NONE sulindac_22\NN|(|DFMO|plus|) (r_conj) difluoromethylornithine_17\NN|NONE (r_pobj) with_16\IN| (r_prep) months_15\NNS|NONE (r_pobj) for_13\IN|NONE (r_prep) treatment_12\NN|NONE (r_pobj) after_11\IN|adenomatous (r_prep) polyps_10\NNS|NONE
D013467_D034381 CID sulindac_14\NN|DFMO|experienced|the (r_compound) group_15\NN|NONE (l_relcl) experienced_17\VBD|sulindac|DFMO|the (l_dobj) loss_21\NN|compared|who
D000518_D018256 NONE difluoromethylornithine_17\NN|NONE (r_pobj) with_16\IN| (r_prep) months_15\NNS|NONE (r_pobj) for_13\IN|NONE (r_prep) treatment_12\NN|NONE (r_pobj) after_11\IN|adenomatous (r_prep) polyps_10\NNS|NONE
D000518_D018256 NONE DFMO_19\NN|(|sulindac|plus|) (r_appos) difluoromethylornithine_17\NN|NONE (r_pobj) with_16\IN| (r_prep) months_15\NNS|NONE (r_pobj) for_13\IN|NONE (r_prep) treatment_12\NN|NONE (r_pobj) after_11\IN|adenomatous (r_prep) polyps_10\NNS|NONE
6229975
D013999_D009203 NONE timolol_8\NN|after|term (r_compound) treatment_9\NN|NONE (l_prep) after_10\IN|timolol|term (l_pobj) infarction_12\NN|NONE
D013999_D009203 NONE timolol_6\NN|term|on (r_compound) treatment_7\NN|NONE (r_pobj) of_2\IN|The|after (r_prep) effect_1\NN|in|by|was|.|timolol (l_prep) after_11\IN|of|The (l_pobj) infarction_13\NN|NONE
D013999_D009203 NONE timolol_33\NN|in|effect|by|was|. (r_conj) evaluated_15\VBN|NONE (l_nsubjpass) effect_1\NN|in|by|was|.|timolol (l_prep) after_11\IN|of|The (l_pobj) infarction_13\NN|NONE
D013999_D001919 NONE timolol_6\NN| (r_npadvmod) induced_8\VBN|and|increase (r_amod) bradycardia_9\NN|NONE
D013999_D007238 NONE timolol_17\NN|the (r_compound) group_18\NN|NONE (r_pobj) in_15\IN|unchanged (r_prep) remained_13\VBD|,|After|in|size|.|and (r_conj) increased_7\VBD|NONE (l_punct) ,_4\,|After|in|size|.|remained|and (l_punct) infarction_3\NN|NONE
17147461
D020123_D011507 CID Sirolimus_0\NNP| (r_npadvmod) associated_2\VBN|dysfunction|and|. (r_amod) proteinuria_3\NN|NONE
D020123_D011507 CID sirolimus_11\NN|under|is|with|that|,|, (r_nsubjpass) associated_13\VBN|reports|However|.|, (l_prep) with_14\IN|under|sirolimus|is|that|,|, (l_pobj) proteinuria_15\NN|NONE
D020123_D011507 CID sirolimus_3\NN| (r_npadvmod) associated_5\VBN|NONE (r_amod) proteinuria_6\NN|NONE
D020123_D011507 CID sirolimus_21\NN|NONE (r_pobj) of_20\IN|on|the|molecular (r_prep) effects_19\NNS|NONE (r_pobj) of_16\IN|NONE (r_prep) knowledge_15\NN|NONE (r_pobj) by_14\IN|,|use|could|,|occurrence|be|occur|. (r_agent) minimised_13\VBN|NONE (l_dep) use_27\NN|,|by|could|,|occurrence|be|occur|. (l_appos) monitoring_36\NN|,|of|the|in (l_prep) of_37\IN|use|,|close|occurs (l_pobj) proteinuria_38\NN|NONE
D020123_D011507 CID sirolimus_21\NN|NONE (r_pobj) of_20\IN|on|the|molecular (r_prep) effects_19\NNS|NONE (r_pobj) of_16\IN|NONE (r_prep) knowledge_15\NN|NONE (r_pobj) by_14\IN|,|use|could|,|occurrence|be|occur|. (r_agent) minimised_13\VBN|NONE (l_dep) use_27\NN|,|by|could|,|occurrence|be|occur|. (l_appos) monitoring_36\NN|,|of|the|in (l_advcl) occurs_57\VBZ|use|,|of|close (l_nsubj) proteinuria_56\NN|and|if|withdrawal|needed
D020123_D011507 CID sirolimus_29\NN|NONE (r_pobj) of_28\IN|monitoring|,|the|in (r_prep) use_27\NN|,|by|could|,|occurrence|be|occur|. (l_appos) monitoring_36\NN|,|of|the|in (l_prep) of_37\IN|use|,|close|occurs (l_pobj) proteinuria_38\NN|NONE
D020123_D011507 CID sirolimus_29\NN|NONE (r_pobj) of_28\IN|monitoring|,|the|in (r_prep) use_27\NN|,|by|could|,|occurrence|be|occur|. (l_appos) monitoring_36\NN|,|of|the|in (l_advcl) occurs_57\VBZ|use|,|of|close (l_nsubj) proteinuria_56\NN|and|if|withdrawal|needed
D020123_D007674 CID Sirolimus_0\NNP| (r_npadvmod) associated_2\VBN|dysfunction|and|. (r_amod) proteinuria_3\NN|NONE (l_conj) dysfunction_6\NN|and|.|associated
D020123_D007674 CID Sirolimus_0\NNP|.|advance (r_nsubj) represents_1\VBZ|NONE (l_dobj) advance_5\NN|Sirolimus|. (l_prep) in_6\IN|a|major|therapeutic (l_pobj) prevention_8\NN|NONE (l_prep) of_9\IN|the (l_pobj) rejection_13\NN|NONE (l_conj) nephropathy_17\NN|allograft|acute|and
D020123_D007674 CID sirolimus_1\NN|does|Because|not|effects|vasomotor (r_nsubj) share_4\VB|been|it|has|drug|.|, (r_advcl) designated_18\VBN|NONE (l_oprd) drug_24\NN|been|it|share|has|.|, (l_amod) nephrotoxic_23\JJ|'|'|a
D020123_D058186 NONE sirolimus_11\NN|under|is|with|that|,|, (r_nsubjpass) associated_13\VBN|reports|However|.|, (l_prep) with_14\IN|under|sirolimus|is|that|,|, (l_pobj) proteinuria_15\NN|NONE (l_conj) dysfunction_19\NN|and
D020123_D058186 NONE sirolimus_6\NN|NONE (r_pobj) with_5\IN|NONE (r_prep) associated_4\VBN|acute|renal|)|The|as|( (r_acl) dysfunction_3\NN|may|due|.
D000809_D011507 NONE angiotensin_45\NN| (r_npadvmod) converting_47\VBG|blockers|enzyme|or (r_amod) inhibitors_49\NNS|NONE (r_pobj) of_44\IN|NONE (r_prep) use_43\NN|,|of|close|occurs (r_conj) monitoring_36\NN|,|of|the|in (l_prep) of_37\IN|use|,|close|occurs (l_pobj) proteinuria_38\NN|NONE
D000809_D011507 NONE angiotensin_45\NN| (r_npadvmod) converting_47\VBG|blockers|enzyme|or (r_amod) inhibitors_49\NNS|NONE (r_pobj) of_44\IN|NONE (r_prep) use_43\NN|,|of|close|occurs (r_conj) monitoring_36\NN|,|of|the|in (l_advcl) occurs_57\VBZ|use|,|of|close (l_nsubj) proteinuria_56\NN|and|if|withdrawal|needed
D000804_D011507 NONE II_52\CD|angiotensin|receptor (r_compound) blockers_54\NNS|converting|enzyme|or (r_conj) inhibitors_49\NNS|NONE (r_pobj) of_44\IN|NONE (r_prep) use_43\NN|,|of|close|occurs (r_conj) monitoring_36\NN|,|of|the|in (l_prep) of_37\IN|use|,|close|occurs (l_pobj) proteinuria_38\NN|NONE
D000804_D011507 NONE II_52\CD|angiotensin|receptor (r_compound) blockers_54\NNS|converting|enzyme|or (r_conj) inhibitors_49\NNS|NONE (r_pobj) of_44\IN|NONE (r_prep) use_43\NN|,|of|close|occurs (r_conj) monitoring_36\NN|,|of|the|in (l_advcl) occurs_57\VBZ|use|,|of|close (l_nsubj) proteinuria_56\NN|and|if|withdrawal|needed
8701950
D016572_D000743 NONE A_19\NNP|In|FK|not|.|,|does (l_appos) drug_28\NN|with|react|,|CyA|cyclosporin (l_acl) known_30\VBN|an|suppressive (l_xcomp) induce_32\VB|already (l_dobj) MAHA_33\NNP|to
D016572_D000743 NONE CyA_21\NN|drug|with|react|,|cyclosporin (r_appos) A_19\NNP|In|FK|not|.|,|does (l_appos) drug_28\NN|with|react|,|CyA|cyclosporin (l_acl) known_30\VBN|an|suppressive (l_xcomp) induce_32\VB|already (l_dobj) MAHA_33\NNP|to
D001241_D000743 NONE aspirin_20\NN|, (r_conj) corticosteroids_18\NNS|,|plasma|fresh (r_conj) replacement_16\NN|of|, (r_appos) discontinuation_4\NN|.|to|In|, (r_nsubj) led_24\VBD|NONE (l_prep) to_25\IN|.|In|discontinuation|, (l_pobj) resolution_26\NN|NONE (l_prep) of_27\IN|NONE (l_pobj) MAHA_28\NNP|NONE
D016559_D000743 CID FK506_4\NNP|anemia|. (r_dobj) complicating_3\VBG|NONE (l_nsubj) anemia_2\NN|FK|.
D016559_D000743 CID tacrolimus_6\NNP|NONE (r_nmod) therapy_8\NN|( (r_appos) FK506_4\NNP|anemia|. (r_dobj) complicating_3\VBG|NONE (l_nsubj) anemia_2\NN|FK|.
D016559_D000743 CID FK506_17\NNP|tacrolimus (r_nmod) therapy_21\NN|NONE (r_pobj) under_16\IN|organ|solid| (r_prep) recipients_15\NNS|NONE (r_pobj) in_11\IN|of| (r_prep) episodes_3\NNS|We|. (l_prep) of_4\IN||in (l_pobj) anemia_7\NN|NONE
D016559_D000743 CID FK506_17\NNP|tacrolimus (r_nmod) therapy_21\NN|NONE (r_pobj) under_16\IN|organ|solid| (r_prep) recipients_15\NNS|NONE (r_pobj) in_11\IN|of| (r_prep) episodes_3\NNS|We|. (l_prep) of_4\IN||in (l_pobj) anemia_7\NN|NONE (l_appos) MAHA_9\NNP|microangiopathic|(|hemolytic|)
D016559_D000743 CID tacrolimus_19\NNP|FK (r_nmod) therapy_21\NN|NONE (r_pobj) under_16\IN|organ|solid| (r_prep) recipients_15\NNS|NONE (r_pobj) in_11\IN|of| (r_prep) episodes_3\NNS|We|. (l_prep) of_4\IN||in (l_pobj) anemia_7\NN|NONE
D016559_D000743 CID tacrolimus_19\NNP|FK (r_nmod) therapy_21\NN|NONE (r_pobj) under_16\IN|organ|solid| (r_prep) recipients_15\NNS|NONE (r_pobj) in_11\IN|of| (r_prep) episodes_3\NNS|We|. (l_prep) of_4\IN||in (l_pobj) anemia_7\NN|NONE (l_appos) MAHA_9\NNP|microangiopathic|(|hemolytic|)
D016559_D000743 CID FK506_6\NNP|NONE (r_pobj) of_5\IN|replacement|, (r_prep) discontinuation_4\NN|.|to|In|, (r_nsubj) led_24\VBD|NONE (l_prep) to_25\IN|.|In|discontinuation|, (l_pobj) resolution_26\NN|NONE (l_prep) of_27\IN|NONE (l_pobj) MAHA_28\NNP|NONE
D016559_D000743 CID FK506_6\NNP|NONE (r_pobj) of_5\IN|NONE (r_prep) reintroduction_4\NN|In|.|,|to (r_nsubj) led_7\VBD|NONE (l_prep) to_8\IN|In|.|reintroduction|, (l_pobj) recurrence_10\NN|NONE (l_prep) of_11\IN|rapid (l_pobj) MAHA_12\NNP|NONE
D016559_D000743 CID FK506-associated_0\VBN|NONE (r_amod) MAHA_1\NNP|probably|be|rare|but
D016559_D000743 CID FK506_9\NNP|In|not|A|.|,|does (r_nsubj) seem_12\VB|NONE (l_oprd) A_19\NNP|In|FK|not|.|,|does (l_appos) drug_28\NN|with|react|,|CyA|cyclosporin (l_acl) known_30\VBN|an|suppressive (l_xcomp) induce_32\VB|already (l_dobj) MAHA_33\NNP|to
D000305_D000743 NONE corticosteroids_18\NNS|,|plasma|fresh (r_conj) replacement_16\NN|of|, (r_appos) discontinuation_4\NN|.|to|In|, (r_nsubj) led_24\VBD|NONE (l_prep) to_25\IN|.|In|discontinuation|, (l_pobj) resolution_26\NN|NONE (l_prep) of_27\IN|NONE (l_pobj) MAHA_28\NNP|NONE
D004176_D000743 NONE dipyridamole_23\NN|,|and (r_conj) aspirin_20\NN|, (r_conj) corticosteroids_18\NNS|,|plasma|fresh (r_conj) replacement_16\NN|of|, (r_appos) discontinuation_4\NN|.|to|In|, (r_nsubj) led_24\VBD|NONE (l_prep) to_25\IN|.|In|discontinuation|, (l_pobj) resolution_26\NN|NONE (l_prep) of_27\IN|NONE (l_pobj) MAHA_28\NNP|NONE
16330766
C040029_D009437 NONE gabapentin_11\NN|NONE (l_appos) drug_14\NN|, (l_amod) effective_15\JJ|a (l_prep) in_16\IN|NONE (l_pobj) patients_19\NNS|NONE (l_compound) pain_18\NN|neuropathic
C040029_D006930 NONE gabapentin_15\NN| (r_npadvmod) induced_17\VBN|the|of|in (r_amod) modulation_18\NN|.|Using|we|, (l_prep) in_22\IN|the|of|induced (l_pobj) response_23\NN|NONE (l_prep) to_24\IN|NONE (l_pobj) stimulation_27\NN|NONE (l_prep) of_28\IN|nociceptive|mechanical (l_pobj) skin_30\NN|NONE (l_conj) hyperalgesia_36\NN|and|normal
D002211_D006930 CID capsaicin_32\NN| (r_npadvmod) induced_34\VBN|secondary (r_amod) hyperalgesia_36\NN|and|normal
16364460
D012601_D000647 CID scopolamine_10\NN| (r_npadvmod) induced_12\VBN|in (r_amod) amnesia_13\NN|Microinjection|.
D012601_D000647 CID scopolamine_9\NN|(|antagonist)induced|muscarinic|cholinergic|in (r_nmod) amnesia_14\NN|NONE
D012601_D000647 CID scopolamine_16\NN| (r_npadvmod) induced_18\VBN|the (r_amod) amnesia_19\NN|microinjection|that
D016713_D000647 NONE ritanserin_2\NN|NONE (r_pobj) of_1\IN|into (r_prep) Microinjection_0\NN|.|amnesia (r_nsubj) improves_9\VBZ|NONE (l_dobj) amnesia_13\NN|Microinjection|.
D016713_D000647 NONE ritanserin_3\NN|NONE (r_pobj) of_2\IN|The|antagonist|on (r_prep) effect_1\NN|MWM|.|was (l_prep) on_8\IN|The|of|antagonist (l_pobj) amnesia_14\NN|NONE
D016713_D000647 NONE ritanserin_6\NN|NONE (r_pobj) of_5\IN|into (r_prep) microinjection_4\NN|that|amnesia (r_nsubj) improves_14\VBZ|.|findings (l_dobj) amnesia_19\NN|microinjection|that
18405372
D012460_D001168 NONE sulfasalazine_3\NN|NONE (l_prep) in_4\IN|NONE (l_pobj) arthritis_6\NN|NONE
D012460_D056486 CID sulfasalazine_3\NN|NONE (r_pobj) with_2\IN|NONE (r_prep) associated_1\VBN|: (r_acl) Hepatotoxicity_0\NN|NONE
D012460_D056486 CID sulfasalazine_7\NN|NONE (r_pobj) on_6\IN|who|hepatotoxicity|and|met (r_prep) had_4\VBD|,|'|, (l_dobj) hepatotoxicity_5\NN|who|on|and|met
D012460_D056486 CID sulfasalazine_6\NN|NONE (r_pobj) with_5\IN|NONE (r_prep) hepatotoxicity_4\NN|NONE
D012460_D056486 CID sulfasalazine_7\NN|NONE (r_pobj) with_6\IN|serious (r_prep) hepatotoxicity_5\NN|NONE
D012460_D056486 CID sulfasalazine_4\NN|NONE (r_pobj) with_3\IN|NONE (r_prep) associated_2\VBN|Serious (r_acl) hepatotoxicity_1\NN|is|.|be
6534871
D007545_D009203 CID isoproterenol_8\NN| (r_npadvmod) induced_10\VBN|myocardial (r_amod) infarction_12\NN|NONE
8955532
D010656_D006973 CID phenylephrine_19\NN| (r_npadvmod) induced_21\VBN|acute|in (r_amod) hypertension_23\NN|NONE
D003911_D006973 NONE dextran_15\NN|NONE (r_pobj) of_11\IN|before (r_prep) clearance_10\NN|NONE (l_prep) before_16\IN|of (l_conj) during_18\IN|and (l_pobj) hypertension_23\NN|NONE
D001920_D006973 NONE bradykinin_4\NN|NONE (l_prep) in_7\IN|receptors (l_pobj) disruption_8\NN|NONE (l_prep) during_15\IN|of (l_pobj) hypertension_17\NN|NONE
D001920_D006973 NONE bradykinin_15\NN|NONE (r_pobj) of_14\IN|synthesis|/ (r_prep) release_13\NN|NONE (r_pobj) of_10\IN|the (r_prep) role_9\NN|to|activate (r_dobj) determine_7\VB|.|goal (l_xcomp) activate_17\VB|to|role (l_prep) in_20\IN|to|receptors (l_pobj) disruption_21\NN|NONE (l_prep) during_28\IN|of (l_pobj) hypertension_30\NN|NONE
D001920_D006973 NONE bradykinin_23\NN|NONE (r_pobj) of_22\IN|the|/|synthesis (r_prep) release_21\NN|NONE (r_pobj) to_17\IN|not|activate|is (r_prep) related_16\VBN|findings|. (l_auxpass) is_14\VBZ|not|activate|to (l_nsubj) disruption_4\NN|that (l_prep) during_11\IN|of (l_pobj) hypertension_13\NN|NONE
C065679_D006973 NONE Hoe-140_30\NNP|and|microM (r_conj) vehicle_28\NN|NONE (r_pobj) with_27\IN|NONE (r_prep) treated_26\VBN|NONE (r_acl) rats_25\NNS|NONE (r_pobj) in_24\IN|induced|acute (r_prep) hypertension_23\NN|NONE
11694026
C012655_D014581 NONE nimesulide_2\NN|NONE (r_pobj) of_1\IN|.|in (r_prep) Tolerability_0\DT|NONE (l_prep) in_5\IN|of|. (l_pobj) patients_6\NNS|NONE (l_prep) with_7\IN|NONE (l_pobj) angioedema_13\NN|NONE (l_nmod) urticaria_11\NN|NONE
C012655_D014581 NONE nimesulide_9\NN|NONE (r_pobj) of_8\IN|reliability|and (r_prep) tolerability_5\NN|In|in|.|we (r_dobj) investigated_4\VBD|NONE (l_prep) in_12\IN|In|.|we|tolerability (l_pobj) number_16\NN|NONE (l_prep) of_17\IN|large|a (l_pobj) patients_18\NNS|NONE (l_prep) with_19\IN|NONE (l_pobj) history_25\NN|NONE (l_prep) of_26\IN|an|exclusive|documented (l_pobj) angioedema_32\NN|NONE (l_nmod) urticaria_30\NN|/
C012655_D014581 NONE nimesulide_10\NN|NONE (r_pobj) with_9\IN|controlled|oral|A|challenge (r_prep) procedure_8\NN|.|to|with|was (r_nsubjpass) applied_14\VBN|NONE (l_prep) with_18\IN|procedure|.|to|was (l_pobj) history_20\NN|NONE (l_prep) of_21\IN|a (l_pobj) angioedema_27\NN|NONE (l_nmod) urticaria_25\NN|/
C012655_D014581 NONE nimesulide_10\NN|NONE (r_pobj) of_9\IN|good|in|the (r_prep) tolerability_8\NN|.|,|Taken|results (l_prep) in_13\IN|good|of|the (l_pobj) patients_14\NNS|NONE (l_relcl) experienced_16\VBD|NONE (l_dobj) angioedema_19\NNP|who (l_nmod) urticaria_17\NN|caused
D000082_D014581 NONE paracetamol_4\NN|and (r_conj) nimesulide_2\NN|NONE (r_pobj) of_1\IN|.|in (r_prep) Tolerability_0\DT|NONE (l_prep) in_5\IN|of|. (l_pobj) patients_6\NNS|NONE (l_prep) with_7\IN|NONE (l_pobj) angioedema_13\NN|NONE (l_nmod) urticaria_11\NN|NONE
D000082_D014581 NONE paracetamol_11\NN|and (r_conj) nimesulide_9\NN|NONE (r_pobj) of_8\IN|reliability|and (r_prep) tolerability_5\NN|In|in|.|we (r_dobj) investigated_4\VBD|NONE (l_prep) in_12\IN|In|.|we|tolerability (l_pobj) number_16\NN|NONE (l_prep) of_17\IN|large|a (l_pobj) patients_18\NNS|NONE (l_prep) with_19\IN|NONE (l_pobj) history_25\NN|NONE (l_prep) of_26\IN|an|exclusive|documented (l_pobj) angioedema_32\NN|NONE (l_nmod) urticaria_30\NN|/
D000082_D014581 NONE paracetamol_12\NNP|or (r_conj) nimesulide_10\NN|NONE (r_pobj) with_9\IN|controlled|oral|A|challenge (r_prep) procedure_8\NN|.|to|with|was (r_nsubjpass) applied_14\VBN|NONE (l_prep) with_18\IN|procedure|.|to|was (l_pobj) history_20\NN|NONE (l_prep) of_21\IN|a (l_pobj) angioedema_27\NN|NONE (l_nmod) urticaria_25\NN|/
D000082_D014581 NONE paracetamol_12\NN|and (r_conj) nimesulide_10\NN|NONE (r_pobj) of_9\IN|good|in|the (r_prep) tolerability_8\NN|.|,|Taken|results (l_prep) in_13\IN|good|of|the (l_pobj) patients_14\NNS|NONE (l_relcl) experienced_16\VBD|NONE (l_dobj) angioedema_19\NNP|who (l_nmod) urticaria_17\NN|caused
C012655_D000799 CID nimesulide_2\NN|NONE (r_pobj) of_1\IN|.|in (r_prep) Tolerability_0\DT|NONE (l_prep) in_5\IN|of|. (l_pobj) patients_6\NNS|NONE (l_prep) with_7\IN|NONE (l_pobj) angioedema_13\NN|NONE
C012655_D000799 CID nimesulide_9\NN|NONE (r_pobj) of_8\IN|reliability|and (r_prep) tolerability_5\NN|In|in|.|we (r_dobj) investigated_4\VBD|NONE (l_prep) in_12\IN|In|.|we|tolerability (l_pobj) number_16\NN|NONE (l_prep) of_17\IN|large|a (l_pobj) patients_18\NNS|NONE (l_prep) with_19\IN|NONE (l_pobj) history_25\NN|NONE (l_prep) of_26\IN|an|exclusive|documented (l_pobj) angioedema_32\NN|NONE
C012655_D000799 CID nimesulide_10\NN|NONE (r_pobj) with_9\IN|controlled|oral|A|challenge (r_prep) procedure_8\NN|.|to|with|was (r_nsubjpass) applied_14\VBN|NONE (l_prep) with_18\IN|procedure|.|to|was (l_pobj) history_20\NN|NONE (l_prep) of_21\IN|a (l_pobj) angioedema_27\NN|NONE
C012655_D000799 CID nimesulide_10\NN|NONE (r_pobj) of_9\IN|good|in|the (r_prep) tolerability_8\NN|.|,|Taken|results (l_prep) in_13\IN|good|of|the (l_pobj) patients_14\NNS|NONE (l_relcl) experienced_16\VBD|NONE (l_dobj) angioedema_19\NNP|who
D000894_D000799 CID NSAID_8\NNP| (r_npadvmod) induced_10\VBN|/ (r_amod) urticaria_11\NN|NONE (r_nmod) angioedema_13\NN|NONE
D000894_D000799 CID NSAID_27\NNP| (r_npadvmod) induced_29\VBN|NONE (r_amod) urticaria_30\NN|/ (r_nmod) angioedema_32\NN|NONE
D000894_D000799 CID NSAID_22\NNP| (r_npadvmod) induced_24\VBN|NONE (r_amod) urticaria_25\NN|/ (r_nmod) angioedema_27\NN|NONE
D000894_D000799 CID NSAID_21\NNP| (r_npadvmod) induced_23\VBN|/ (r_amod) urticaria_24\NN|angioedema|alone|or|( (r_nmod) angioedema_26\NN|NONE
D000894_D000799 CID NSAID_21\NNP| (r_npadvmod) induced_23\VBN|/ (r_amod) urticaria_24\NN|angioedema|alone|or|( (r_nmod) angioedema_26\NN|NONE (l_conj) angioedema_28\NN|alone|or|(|urticaria
D000894_D000799 CID NSAIDs_22\NNS|NONE (r_pobj) by_21\IN|NONE (r_agent) caused_20\VBN|urticaria (r_acl) angioedema_19\NNP|who
D000894_D000799 CID NSAID_29\NNP| (r_npadvmod) induced_31\VBN|NONE (r_amod) angioedema_32\NN|NONE
D000894_D014581 NONE NSAID_8\NNP| (r_npadvmod) induced_10\VBN|/ (r_amod) urticaria_11\NN|NONE
D000894_D014581 NONE NSAID_27\NNP| (r_npadvmod) induced_29\VBN|NONE (r_amod) urticaria_30\NN|/
D000894_D014581 NONE NSAID_22\NNP| (r_npadvmod) induced_24\VBN|NONE (r_amod) urticaria_25\NN|/
D000894_D014581 NONE NSAID_21\NNP| (r_npadvmod) induced_23\VBN|/ (r_amod) urticaria_24\NN|angioedema|alone|or|( (r_nmod) angioedema_26\NN|NONE (r_pobj) of_20\IN|an|with (r_prep) history_19\NN|NONE (r_pobj) with_17\IN|NONE (r_prep) subjects_16\NNS|NONE (r_pobj) of_15\IN|. (r_prep) %_14\NN|and|of|a (r_conj) history_8\NN|NONE (l_prep) of_9\IN|%|and|a (l_pobj) urticaria_11\NN|NONE
D000894_D014581 NONE NSAID_21\NNP| (r_npadvmod) induced_23\VBN|/ (r_amod) urticaria_24\NN|angioedema|alone|or|(
D000894_D014581 NONE NSAID_21\NNP| (r_npadvmod) induced_23\VBN|/ (r_amod) urticaria_24\NN|angioedema|alone|or|( (r_nmod) angioedema_26\NN|NONE (r_pobj) of_20\IN|an|with (r_prep) history_19\NN|NONE (l_prep) with_31\IN|of|an (l_conj) without_33\IN|or (l_pobj) urticaria_35\NN|NONE
D000894_D014581 NONE NSAIDs_22\NNS|NONE (r_pobj) by_21\IN|NONE (r_agent) caused_20\VBN|urticaria (r_acl) angioedema_19\NNP|who (l_nmod) urticaria_17\NN|caused
D000894_D014581 NONE NSAID_29\NNP| (r_npadvmod) induced_31\VBN|NONE (r_amod) angioedema_32\NN|NONE (r_pobj) of_28\IN|a (r_prep) history_27\NN|NONE (r_pobj) by_25\IN|risk|and|statistically|However|is|.|,|all|by|,|, (r_prep) increased_13\VBN|NONE (l_agent) by_14\IN|by|risk|and|statistically|However|is|.|,|all|,|, (l_pobj) history_16\NN|NONE (l_prep) of_17\IN|a (l_pobj) urticaria_19\NN|NONE
D000082_D000799 CID paracetamol_4\NN|and (r_conj) nimesulide_2\NN|NONE (r_pobj) of_1\IN|.|in (r_prep) Tolerability_0\DT|NONE (l_prep) in_5\IN|of|. (l_pobj) patients_6\NNS|NONE (l_prep) with_7\IN|NONE (l_pobj) angioedema_13\NN|NONE
D000082_D000799 CID paracetamol_11\NN|and (r_conj) nimesulide_9\NN|NONE (r_pobj) of_8\IN|reliability|and (r_prep) tolerability_5\NN|In|in|.|we (r_dobj) investigated_4\VBD|NONE (l_prep) in_12\IN|In|.|we|tolerability (l_pobj) number_16\NN|NONE (l_prep) of_17\IN|large|a (l_pobj) patients_18\NNS|NONE (l_prep) with_19\IN|NONE (l_pobj) history_25\NN|NONE (l_prep) of_26\IN|an|exclusive|documented (l_pobj) angioedema_32\NN|NONE
D000082_D000799 CID paracetamol_12\NNP|or (r_conj) nimesulide_10\NN|NONE (r_pobj) with_9\IN|controlled|oral|A|challenge (r_prep) procedure_8\NN|.|to|with|was (r_nsubjpass) applied_14\VBN|NONE (l_prep) with_18\IN|procedure|.|to|was (l_pobj) history_20\NN|NONE (l_prep) of_21\IN|a (l_pobj) angioedema_27\NN|NONE
D000082_D000799 CID paracetamol_12\NN|and (r_conj) nimesulide_10\NN|NONE (r_pobj) of_9\IN|good|in|the (r_prep) tolerability_8\NN|.|,|Taken|results (l_prep) in_13\IN|good|of|the (l_pobj) patients_14\NNS|NONE (l_relcl) experienced_16\VBD|NONE (l_dobj) angioedema_19\NNP|who
9226773
D008094_D011141 CID lithium_8\NN|NONE (r_pobj) of_7\IN|NONE (r_prep) cessation_6\NN|NONE (r_pobj) despite_5\IN|NONE (r_prep) polyuric_4\JJ|and
D008094_D011141 CID Lithium_0\NN|insipidus (r_nsubj) induced_1\VBD|is|be|. (r_csubjpass) considered_6\VBN|NONE (l_xcomp) be_8\VB|is|induced|. (l_acomp) reversible_9\JJ|stopped|to (l_prep) on_10\IN|NONE (l_pobj) cessation_11\NN|NONE (l_prep) of_12\IN|persisted (l_pobj) therapy_13\NN|NONE (l_conj) polyuria_15\NN|but
D008094_D011141 CID lithium_24\NN|after|was (r_nsubjpass) stopped_26\VBN|reversible|to (r_advcl) be_8\VB|is|induced|. (l_acomp) reversible_9\JJ|stopped|to (l_prep) on_10\IN|NONE (l_pobj) cessation_11\NN|NONE (l_prep) of_12\IN|persisted (l_pobj) therapy_13\NN|NONE (l_conj) polyuria_15\NN|but
D014667_D018500 NONE vasopressin_21\NN|NONE (r_compound) secretion_22\NN|osmoregulated|normal|and (r_conj) thirst_19\NN|,|to|him|with (r_dobj) have_16\VB|NONE (l_prep) with_24\IN|,|to|him|thirst (l_pobj) evidence_26\NN|NONE (l_prep) of_27\IN|clear (l_pobj) insipidus_30\NN|NONE
D014667_D011141 NONE vasopressin_21\NN|NONE (r_compound) secretion_22\NN|osmoregulated|normal|and (r_conj) thirst_19\NN|,|to|him|with (r_dobj) have_16\VB|NONE (r_ccomp) showed_13\VBD|thirsty|He|. (r_conj) remained_1\VBD|NONE (l_acomp) thirsty_2\JJ|showed|He|. (l_conj) polyuric_4\JJ|and
D008094_D018500 CID lithium_5\NN|NONE (r_compound) therapy_6\NN|NONE (r_dobj) following_4\VBG|diabetes|. (r_prep) insipidus_3\NN|NONE
D008094_D018500 CID lithium_9\NN| (r_npadvmod) induced_11\VBN|diabetes (r_amod) insipidus_14\NN|to
D008094_D018500 CID lithium_17\NN|NONE (r_compound) therapy_18\NN|been|had|. (r_nsubjpass) discontinued_21\VBN|,|years|he|previously|and|been|had|have (r_conj) diagnosed_6\VBN|NONE (l_xcomp) have_8\VB|,|years|he|previously|and|been|had|discontinued (l_dobj) insipidus_14\NN|to
D008094_D018500 CID lithium_8\NN|NONE (r_pobj) of_7\IN|NONE (r_prep) cessation_6\NN|NONE (r_pobj) despite_5\IN|NONE (r_prep) polyuric_4\JJ|and (r_conj) thirsty_2\JJ|showed|He|. (r_acomp) remained_1\VBD|NONE (l_conj) showed_13\VBD|thirsty|He|. (l_ccomp) have_16\VB|NONE (l_prep) with_24\IN|,|to|him|thirst (l_pobj) evidence_26\NN|NONE (l_prep) of_27\IN|clear (l_pobj) insipidus_30\NN|NONE
D008094_D018500 CID Lithium_0\NN|insipidus (r_nsubj) induced_1\VBD|is|be|. (l_dobj) insipidus_4\NN|Lithium
D008094_D018500 CID lithium_24\NN|after|was (r_nsubjpass) stopped_26\VBN|reversible|to (r_advcl) be_8\VB|is|induced|. (r_xcomp) considered_6\VBN|NONE (l_csubjpass) induced_1\VBD|is|be|. (l_dobj) insipidus_4\NN|Lithium
D008094_D018500 CID lithium_14\NN| (r_npadvmod) induced_16\VBN|diabetes (r_amod) insipidus_19\NN|NONE
8682684
D000082_D000707 NONE acetaminophen_2\RB|been|has|produce|However|,|. (r_nsubjpass) demonstrated_5\VBN|NONE (l_xcomp) produce_7\VB|been|acetaminophen|has|However|,|. (l_dobj) symptoms_8\NNS|to (l_prep) of_9\IN|,|in|,|including (l_pobj) anaphylaxis_10\NN|NONE
D000082_D016638 NONE acetaminophen_18\NN|NONE (r_pobj) of_17\IN|NONE (r_prep) administration_16\NN|NONE (r_pobj) after_15\IN|episodes|reproducibly|in (r_prep) developed_14\VBN|ill|two (r_relcl) patients_6\NNS|article|. (l_amod) ill_5\JJ|developed|two
D000082_D007022 CID Acetaminophen_0\NNP| (r_npadvmod) induced_2\VBN|. (r_amod) hypotension_3\NN|NONE
D000082_D007022 CID acetaminophen_2\RB|been|has|produce|However|,|. (r_nsubjpass) demonstrated_5\VBN|NONE (l_xcomp) produce_7\VB|been|acetaminophen|has|However|,|. (l_dobj) symptoms_8\NNS|to (l_prep) including_12\VBG|,|in|of|, (l_pobj) hypotension_13\NN|NONE
D000082_D007022 CID acetaminophen_18\NN|NONE (r_pobj) of_17\IN|NONE (r_prep) administration_16\NN|NONE (r_pobj) after_15\IN|episodes|reproducibly|in (r_prep) developed_14\VBN|ill|two (l_nsubj) episodes_10\NNS|after|reproducibly|in (l_prep) of_11\IN|transient (l_pobj) hypotension_12\NN|NONE
D000082_D007022 CID acetaminophen_9\NN|for|to|in|clinicians (r_dobj) consider_8\VB|the (l_prep) in_10\IN|for|acetaminophen|to|clinicians (l_pobj) patients_11\NNS|NONE (l_prep) with_12\IN|NONE (l_pobj) hypotension_13\NN|NONE
D000082_D002318 NONE acetaminophen_3\NN|NONE (r_pobj) for_2\IN|produce|The (r_prep) potential_1\NN|low|. (l_acl) produce_5\VB|for|The (l_dobj) toxicities_7\NNS|to
10692744
D000086_D003221 NONE acetazolamide_4\NN|NONE (r_pobj) by_3\IN|NONE (r_agent) induced_2\VBN|Acute (r_acl) confusion_1\NN|reaction|.
D000086_D005862 CID Acetazolamide_0\RB| (r_npadvmod) induced_2\VBN|.|Gerstmann (r_amod) syndrome_4\NN|NONE
D000086_D005862 CID acetazolamide_5\NN| (r_npadvmod) induced_7\VBN|Gerstmann (r_amod) syndrome_9\NN|NONE
D000086_D007674 NONE acetazolamide_4\NN|NONE (r_pobj) by_3\IN|NONE (r_agent) induced_2\VBN|Acute (r_acl) confusion_1\NN|reaction|. (r_nsubj) is_5\VBZ|NONE (l_attr) reaction_11\NN|confusion|. (l_prep) in_12\IN|known|a|adverse|drug (l_pobj) patients_13\NNS|NONE (l_prep) with_14\IN|NONE (l_pobj) impairment_16\NN|NONE
3828020
D010665_D002544 CID phenylpropanolamine_8\NN|NONE (r_pobj) of_7\IN|a|single|oral (r_prep) dose_6\NN|NONE (r_pobj) with_2\IN|Cerebral|. (r_prep) infarction_1\NN|NONE
D010665_D002544 CID PPA_20\NNP|NONE (r_pobj) of_19\IN|single|a|oral (r_prep) dose_18\NN|NONE (r_dobj) taking_14\VBG|NONE (r_pcomp) after_13\IN|infarction|who (r_prep) suffered_9\VBD|young|a (l_dobj) infarction_12\NN|after|who
16337777
D010862_D004833 CID pilocarpine_49\NN|of|the (r_amod) model_50\NN|NONE (l_prep) of_51\IN|the|pilocarpine (l_pobj) epilepsy_54\NN|NONE
D010862_D004827 NONE pilocarpine_12\NN|NONE (r_pobj) by_11\IN|NONE (r_agent) induced_10\VBN|of|experimental|the (r_acl) model_7\NN|NONE (l_prep) of_8\IN|induced|experimental|the (l_pobj) epilepsy_9\NN|NONE
D010862_D013226 NONE pilocarpine_49\NN|of|the (r_amod) model_50\NN|NONE (r_pobj) of_47\IN|the|chronic (r_prep) phase_46\NN|NONE (r_pobj) in_43\IN|to|abnormalities (r_prep) provoke_18\VB|NONE (r_xcomp) sufficient_16\JJ|generation|whether|would (r_acomp) be_15\VB|,|.|we|In (l_nsubj) generation_8\NN|whether|sufficient|would (l_prep) during_11\IN|of|increased (l_pobj) epilepticus_13\NN|NONE
7881871
D011692_D007674 CID aminonucleoside_7\NN| (r_advmod) induced_9\VBN|puromycin (r_amod) nephropathy_10\NN|NONE
D011692_D007674 CID aminonucleoside_12\NN|(|puromycin|PAN)induced (r_nmod) nephropathy_15\NN|NONE
D011692_D007674 CID PAN)-induced_14\JJ|aminonucleoside|(|puromycin (r_amod) nephropathy_15\NN|NONE
D011692_D007674 CID PAN_14\NNP|NONE (r_compound) nephropathy_15\NN|NONE
D010100_D007674 NONE oxygen_1\NN|Reactive (r_compound) species_2\NNS|with|been|.|have|,|in (r_nsubjpass) implicated_5\VBN|NONE (l_prep) in_6\IN|with|been|species|.|have|, (l_pobj) pathogenesis_8\NN|NONE (l_prep) of_9\IN|the (l_pobj) nephropathy_15\NN|NONE
D011692_D011507 CID aminonucleoside_12\NN|(|puromycin|PAN)induced (r_nmod) nephropathy_15\NN|NONE (r_pobj) of_9\IN|the (r_prep) pathogenesis_8\NN|NONE (r_pobj) in_6\IN|with|been|species|.|have|, (r_prep) implicated_5\VBN|NONE (l_prep) with_17\IN|been|species|.|have|,|in (l_pcomp) reducing_20\VBG|NONE (l_dobj) proteinuria_22\NN|significantly|antioxidants
D011692_D011507 CID PAN)-induced_14\JJ|aminonucleoside|(|puromycin (r_amod) nephropathy_15\NN|NONE (r_pobj) of_9\IN|the (r_prep) pathogenesis_8\NN|NONE (r_pobj) in_6\IN|with|been|species|.|have|, (r_prep) implicated_5\VBN|NONE (l_prep) with_17\IN|been|species|.|have|,|in (l_pcomp) reducing_20\VBG|NONE (l_dobj) proteinuria_22\NN|significantly|antioxidants
D011692_D011507 CID PAN_14\NNP|NONE (r_compound) nephropathy_15\NN|NONE (r_pobj) in_13\IN|the|proteinuric (r_prep) injury_12\NN|NONE
D010100_D011507 NONE oxygen_1\NN|Reactive (r_compound) species_2\NNS|with|been|.|have|,|in (r_nsubjpass) implicated_5\VBN|NONE (l_prep) with_17\IN|been|species|.|have|,|in (l_pcomp) reducing_20\VBG|NONE (l_dobj) proteinuria_22\NN|significantly|antioxidants
19274460
D003907_D009101 NONE dexamethasone_14\NN|NONE (r_pobj) with_11\IN|NONE (r_prep) combination_10\NN|NONE (r_pobj) in_9\IN|for|dose|for (r_prep) definition_5\NN|XI|.|: (l_prep) for_15\IN|for|dose|in (l_pobj) induction_17\NN|NONE (l_prep) in_18\IN|remission (l_pobj) patients_19\NNS|NONE (l_prep) with_20\IN|NONE (l_pobj) myeloma_23\NN|NONE
D003907_D009101 NONE dexamethasone_17\NN|and (r_conj) bortezomib_15\NNS|NONE (r_pobj) with_14\IN|NONE (r_prep) combination_13\NN|NONE (r_pobj) in_12\IN|to|as|dose (r_prep) evaluate_6\VB|trial|was|. (l_prep) as_18\IN|to|in|dose (l_pobj) treatment_20\NN|NONE (l_prep) before_21\IN|induction (l_pobj) transplantation_24\NN|NONE (l_prep) for_25\IN|cell (l_pobj) patients_27\NNS|NONE (l_prep) with_28\IN|younger (l_pobj) myeloma_32\NN|NONE
D003907_D009101 NONE dexamethasone_17\NN|and (r_conj) bortezomib_15\NNS|NONE (r_pobj) with_14\IN|NONE (r_prep) combination_13\NN|NONE (r_pobj) in_12\IN|to|as|dose (r_prep) evaluate_6\VB|trial|was|. (l_prep) as_18\IN|to|in|dose (l_pobj) treatment_20\NN|NONE (l_prep) before_21\IN|induction (l_pobj) transplantation_24\NN|NONE (l_prep) for_25\IN|cell (l_pobj) patients_27\NNS|NONE (l_prep) with_28\IN|younger (l_pobj) myeloma_32\NN|NONE (l_appos) MM_34\NNP|multiple|diagnosed
D003907_D009101 NONE dexamethasone_16\NN|bortezomib|treatment|that (r_nsubj) is_17\VBZ|results|. (l_attr) treatment_21\NN|bortezomib|dexamethasone|that (l_prep) for_22\IN|warrants|an|effective|induction (l_pobj) patients_23\NNS|NONE (l_prep) with_24\IN|NONE (l_pobj) MM_27\NNP|NONE
D003520_D009101 NONE cyclophosphamide_8\NN|NONE (r_pobj) for_6\IN|dose|for|in (r_prep) definition_5\NN|XI|.|: (l_prep) for_15\IN|for|dose|in (l_pobj) induction_17\NN|NONE (l_prep) in_18\IN|remission (l_pobj) patients_19\NNS|NONE (l_prep) with_20\IN|NONE (l_pobj) myeloma_23\NN|NONE
D003520_D009101 NONE cyclophosphamide_11\NN|NONE (r_pobj) of_10\IN|recommended|the (r_prep) dose_9\NN|to|in|as (r_dobj) evaluate_6\VB|trial|was|. (l_prep) as_18\IN|to|in|dose (l_pobj) treatment_20\NN|NONE (l_prep) before_21\IN|induction (l_pobj) transplantation_24\NN|NONE (l_prep) for_25\IN|cell (l_pobj) patients_27\NNS|NONE (l_prep) with_28\IN|younger (l_pobj) myeloma_32\NN|NONE
D003520_D009101 NONE cyclophosphamide_11\NN|NONE (r_pobj) of_10\IN|recommended|the (r_prep) dose_9\NN|to|in|as (r_dobj) evaluate_6\VB|trial|was|. (l_prep) as_18\IN|to|in|dose (l_pobj) treatment_20\NN|NONE (l_prep) before_21\IN|induction (l_pobj) transplantation_24\NN|NONE (l_prep) for_25\IN|cell (l_pobj) patients_27\NNS|NONE (l_prep) with_28\IN|younger (l_pobj) myeloma_32\NN|NONE (l_appos) MM_34\NNP|multiple|diagnosed
D003520_D009101 NONE cyclophosphamide_8\NN|NONE (r_pobj) with_7\IN|NONE (r_prep) combination_6\NN|NONE (r_pobj) in_5\IN|and|at (r_prep) bortezomib_4\NNS|treatment|dexamethasone|that (r_nsubj) is_17\VBZ|results|. (l_attr) treatment_21\NN|bortezomib|dexamethasone|that (l_prep) for_22\IN|warrants|an|effective|induction (l_pobj) patients_23\NNS|NONE (l_prep) with_24\IN|NONE (l_pobj) MM_27\NNP|NONE
C400082_D009101 NONE bortezomib_12\NNS|/ (r_amod) dexamethasone_14\NN|NONE (r_pobj) with_11\IN|NONE (r_prep) combination_10\NN|NONE (r_pobj) in_9\IN|for|dose|for (r_prep) definition_5\NN|XI|.|: (l_prep) for_15\IN|for|dose|in (l_pobj) induction_17\NN|NONE (l_prep) in_18\IN|remission (l_pobj) patients_19\NNS|NONE (l_prep) with_20\IN|NONE (l_pobj) myeloma_23\NN|NONE
C400082_D009101 NONE bortezomib_15\NNS|NONE (r_pobj) with_14\IN|NONE (r_prep) combination_13\NN|NONE (r_pobj) in_12\IN|to|as|dose (r_prep) evaluate_6\VB|trial|was|. (l_prep) as_18\IN|to|in|dose (l_pobj) treatment_20\NN|NONE (l_prep) before_21\IN|induction (l_pobj) transplantation_24\NN|NONE (l_prep) for_25\IN|cell (l_pobj) patients_27\NNS|NONE (l_prep) with_28\IN|younger (l_pobj) myeloma_32\NN|NONE
C400082_D009101 NONE bortezomib_15\NNS|NONE (r_pobj) with_14\IN|NONE (r_prep) combination_13\NN|NONE (r_pobj) in_12\IN|to|as|dose (r_prep) evaluate_6\VB|trial|was|. (l_prep) as_18\IN|to|in|dose (l_pobj) treatment_20\NN|NONE (l_prep) before_21\IN|induction (l_pobj) transplantation_24\NN|NONE (l_prep) for_25\IN|cell (l_pobj) patients_27\NNS|NONE (l_prep) with_28\IN|younger (l_pobj) myeloma_32\NN|NONE (l_appos) MM_34\NNP|multiple|diagnosed
C400082_D009101 NONE bortezomib_4\NNS|treatment|dexamethasone|that (r_nsubj) is_17\VBZ|results|. (l_attr) treatment_21\NN|bortezomib|dexamethasone|that (l_prep) for_22\IN|warrants|an|effective|induction (l_pobj) patients_23\NNS|NONE (l_prep) with_24\IN|NONE (l_pobj) MM_27\NNP|NONE
16563323
C071741_D009325 NONE remifentanil_2\NN|NONE (r_pobj) with_1\IN|myoclonus (r_prep) Pretreatment_0\NN|induction|.|after|without (r_nsubj) etomidate_10\NN|NONE (l_prep) without_12\IN|induction|.|Pretreatment|after (l_pobj) effects_14\NNS|NONE (l_prep) as_16\IN|side (l_pobj) sedation_17\NN|such (l_conj) apnea_19\NN|, (l_conj) nausea_21\NN|,
C071741_D011537 NONE remifentanil_2\NN|NONE (r_pobj) with_1\IN|myoclonus (r_prep) Pretreatment_0\NN|induction|.|after|without (r_nsubj) etomidate_10\NN|NONE (l_prep) without_12\IN|induction|.|Pretreatment|after (l_pobj) effects_14\NNS|NONE (l_prep) as_16\IN|side (l_pobj) sedation_17\NN|such (l_conj) apnea_19\NN|, (l_conj) nausea_21\NN|, (l_conj) pruritus_24\NN|or|,
C071741_D009207 NONE Remifentanil_0\NNP|NONE (r_compound) pretreatment_1\NN|.|myoclonus|etomidate (r_nsubj) reduces_2\VBZ|NONE (l_dobj) myoclonus_3\NN|pretreatment|.|etomidate
C071741_D009207 NONE remifentanil_13\NN|/||microg (r_nmod) kg_17\NNS|NONE (r_pobj) with_12\IN|and|effect (r_prep) pretreatment_11\NN|NONE (l_conj) effect_20\NN|and|with (l_prep) on_23\IN|after|the|of (l_pobj) incidence_25\NN|NONE (l_prep) of_26\IN|the (l_pobj) myoclonus_27\NN|NONE
C071741_D009207 NONE remifentanil_9\NN|(|the|)|% (r_compound) group_10\NN|NONE (r_pobj) in_7\IN|significantly|than (r_prep) lower_6\JJR|incidence|(|P|. (r_acomp) was_4\VBD|NONE (l_nsubj) incidence_1\NN|(|P|.|lower (l_prep) of_2\IN|The (l_pobj) myoclonus_3\NN|NONE
C071741_D009207 NONE remifentanil_2\NN|NONE (r_pobj) with_1\IN|myoclonus (r_prep) Pretreatment_0\NN|induction|.|after|without (l_appos) myoclonus_8\NN|with
D005045_D001049 NONE etomidate_10\NN|NONE (l_prep) without_12\IN|induction|.|Pretreatment|after (l_pobj) effects_14\NNS|NONE (l_prep) as_16\IN|side (l_pobj) sedation_17\NN|such (l_conj) apnea_19\NN|,
C071741_D001049 NONE remifentanil_2\NN|NONE (r_pobj) with_1\IN|myoclonus (r_prep) Pretreatment_0\NN|induction|.|after|without (r_nsubj) etomidate_10\NN|NONE (l_prep) without_12\IN|induction|.|Pretreatment|after (l_pobj) effects_14\NNS|NONE (l_prep) as_16\IN|side (l_pobj) sedation_17\NN|such (l_conj) apnea_19\NN|,
D005045_D011537 NONE etomidate_10\NN|NONE (l_prep) without_12\IN|induction|.|Pretreatment|after (l_pobj) effects_14\NNS|NONE (l_prep) as_16\IN|side (l_pobj) sedation_17\NN|such (l_conj) apnea_19\NN|, (l_conj) nausea_21\NN|, (l_conj) pruritus_24\NN|or|,
D005045_D009207 CID etomidate_5\NN|pretreatment|.|myoclonus (r_advcl) reduces_2\VBZ|NONE (l_dobj) myoclonus_3\NN|pretreatment|.|etomidate
D005045_D009207 CID etomidate_32\NN|NONE (r_pobj) with_31\IN|NONE (r_prep) induction_30\NN|NONE (r_amod) anesthesia_29\NN|NONE (r_pobj) after_28\IN|the|on|of (r_prep) effect_20\NN|and|with (l_prep) on_23\IN|after|the|of (l_pobj) incidence_25\NN|NONE (l_prep) of_26\IN|the (l_pobj) myoclonus_27\NN|NONE
D005045_D009207 CID etomidate_16\NN|were|In|.|with|patients|, (r_advcl) associated_8\VBN|NONE (l_prep) with_9\IN|were|In|etomidate|.|patients|, (l_pobj) incidence_12\NN|NONE (l_prep) of_13\IN|increased (l_pobj) myoclonus_14\NN|NONE
D005045_D009207 CID etomidate_10\NN|NONE (l_nsubj) Pretreatment_0\NN|induction|.|after|without (l_appos) myoclonus_8\NN|with
D005045_D009207 CID etomidate_9\NN|.|experience|incidence (r_advcl) increased_2\VBD|NONE (l_dobj) incidence_3\NN|etomidate|.|experience (l_prep) of_4\IN|NONE (l_pobj) myoclonus_5\NN|NONE
D005045_D009325 NONE etomidate_10\NN|NONE (l_prep) without_12\IN|induction|.|Pretreatment|after (l_pobj) effects_14\NNS|NONE (l_prep) as_16\IN|side (l_pobj) sedation_17\NN|such (l_conj) apnea_19\NN|, (l_conj) nausea_21\NN|,
1079693
D000305_D002386 NONE corticosteroids_2\NNS|Systemically (r_dobj) administered_1\VBN|were|in (r_csubjpass) used_4\VBN|.|;|number|was (r_ccomp) found_19\VBN|NONE (l_nsubjpass) number_13\NN|used|.|;|was (l_prep) of_14\IN|significant|a (l_pobj) cataracts_17\NNS|NONE
D006886_D012164 CID hydroxychloroquine_4\NN|or (r_conj) chloroquine_2\NN|We|.|and|found (r_xcomp) used_1\VBD|NONE (l_conj) found_11\VBD|We|.|chloroquine|and (l_dobj) case_14\NN|NONE (l_prep) of_15\IN|one (l_pobj) chorioretinopathy_16\JJ|NONE
D000305_D014605 NONE corticosteroids_27\NNS|NONE (r_pobj) with_26\IN|intensive|topical (r_prep) treatment_25\NN|NONE (r_pobj) of_22\IN|six (r_prep) months_21\NNS|NONE (r_pobj) to_17\IN|%|did|not|,|after|. (r_prep) respond_16\VB|NONE (l_nsubj) %_9\NN|did|not|,|after|.|to (l_prep) of_10\IN| (l_pobj) cases_11\NNS|NONE (l_prep) of_12\IN|NONE (l_pobj) uveitis_13\NN|NONE
D002738_D012164 NONE chloroquine_2\NN|We|.|and|found (r_xcomp) used_1\VBD|NONE (l_conj) found_11\VBD|We|.|chloroquine|and (l_dobj) case_14\NN|NONE (l_prep) of_15\IN|one (l_pobj) chorioretinopathy_16\JJ|NONE
15233872
D007545_D009203 CID isoproterenol_7\NN| (r_npadvmod) induced_9\VBN|myocardial|in (r_amod) infarction_11\NN|NONE
C007145_D009203 NONE Crataegus_5\NNP|NONE (r_pobj) of_4\IN|NONE (r_prep) tincture_3\NN|NONE (r_pobj) of_2\IN|.|on|Cardioprotective (r_prep) effect_1\NN|NONE (l_prep) on_6\IN|.|of|Cardioprotective (l_pobj) infarction_11\NN|NONE
C007145_D009203 NONE TCR_11\NNP|NONE (r_pobj) of_10\IN|protective|the|on (r_prep) effect_9\NN|to (l_prep) on_12\IN|protective|the|of (l_pobj) infarction_16\NN|NONE
6216862
D010396_D012871 NONE penicillamine_32\NN|NONE (r_pobj) with_31\IN|NONE (r_prep) treated_30\VBN|with (r_acl) patients_26\NNS|not (r_pobj) in_25\IN|has|been|which|as|but (r_conj) reported_11\VBN|perforans|elastosis|, (r_relcl) serpiginosa_6\NN|.|lesion (r_dobj) resembled_3\VBD|NONE (l_nsubj) lesion_2\NN|serpiginosa|.
D010396_D008180 CID penicillamine_20\NN|NONE (r_compound) therapy_21\NN|NONE (r_pobj) of_19\IN|in (r_prep) complications_18\NNS|NONE (r_pobj) as_17\IN|have|all|rashes|.|been (r_prep) recorded_16\VBN|NONE (l_nsubjpass) rashes_1\NNS|have|all|as|.|been (l_conj) proteinuria_3\NN|Skin|, (l_conj) erythematosus_7\NN|,
D010396_C536202 NONE penicillamine_32\NN|NONE (r_pobj) with_31\IN|NONE (r_prep) treated_30\VBN|with (r_acl) patients_26\NNS|not (r_pobj) in_25\IN|has|been|which|as|but (r_conj) reported_11\VBN|perforans|elastosis|, (r_relcl) serpiginosa_6\NN|.|lesion
D010396_D006527 NONE penicillamine_32\NN|NONE (r_pobj) with_31\IN|NONE (r_prep) treated_30\VBN|with (r_acl) patients_26\NNS|not (r_pobj) in_25\IN|has|been|which|as|but (r_conj) reported_11\VBN|perforans|elastosis|, (l_prep) as_12\IN|has|been|in|which|but (l_pobj) effect_16\NN|NONE (l_prep) in_17\IN|side|rare|a (l_pobj) patients_18\NNS|NONE (l_prep) with_19\IN|NONE (l_pobj) disease_22\NN|NONE
D010396_D011507 CID penicillamine_20\NN|NONE (r_compound) therapy_21\NN|NONE (r_pobj) of_19\IN|in (r_prep) complications_18\NNS|NONE (r_pobj) as_17\IN|have|all|rashes|.|been (r_prep) recorded_16\VBN|NONE (l_nsubjpass) rashes_1\NNS|have|all|as|.|been (l_conj) proteinuria_3\NN|Skin|,
D010396_D001172 NONE penicillamine_4\NN|NONE (r_compound) therapy_5\NN|NONE (r_pobj) of_3\IN|Multiple|.|in|side (r_prep) effects_2\NNS|NONE (l_prep) in_6\IN|of|Multiple|.|side (l_pobj) patient_8\NN|NONE (l_prep) with_9\IN|one (l_pobj) arthritis_11\NN|NONE
D010396_D001172 NONE penicillamine_20\NN|NONE (r_compound) therapy_21\NN|NONE (r_pobj) of_19\IN|in (r_prep) complications_18\NNS|NONE (l_prep) in_22\IN|of (l_pobj) patients_23\NNS|NONE (l_prep) with_24\IN|NONE (l_pobj) arthritis_26\NN|NONE
D010396_D001172 NONE penicillamine_32\NN|NONE (r_pobj) with_31\IN|NONE (r_prep) treated_30\VBN|with (r_acl) patients_26\NNS|not (l_prep) with_27\IN|treated (l_pobj) arthritis_29\NN|NONE
D010396_D005076 CID penicillamine_20\NN|NONE (r_compound) therapy_21\NN|NONE (r_pobj) of_19\IN|in (r_prep) complications_18\NNS|NONE (r_pobj) as_17\IN|have|all|rashes|.|been (r_prep) recorded_16\VBN|NONE (l_nsubjpass) rashes_1\NNS|have|all|as|.|been
D010396_D009157 CID penicillamine_20\NN|NONE (r_compound) therapy_21\NN|NONE (r_pobj) of_19\IN|in (r_prep) complications_18\NNS|NONE (r_pobj) as_17\IN|have|all|rashes|.|been (r_prep) recorded_16\VBN|NONE (l_nsubjpass) rashes_1\NNS|have|all|as|.|been (l_conj) proteinuria_3\NN|Skin|, (l_conj) erythematosus_7\NN|, (l_conj) polymyositis_9\NN|systemic|lupus|, (l_conj) gravis_12\NN|myasthenia|and
D010396_D017285 CID penicillamine_20\NN|NONE (r_compound) therapy_21\NN|NONE (r_pobj) of_19\IN|in (r_prep) complications_18\NNS|NONE (r_pobj) as_17\IN|have|all|rashes|.|been (r_prep) recorded_16\VBN|NONE (l_nsubjpass) rashes_1\NNS|have|all|as|.|been (l_conj) proteinuria_3\NN|Skin|, (l_conj) erythematosus_7\NN|, (l_conj) polymyositis_9\NN|systemic|lupus|,
3173179
D014700_D006973 NONE Verapamil_0\NNP|.|as (r_compound) withdrawal_1\NN|NONE (l_prep) as_2\IN|.|Verapamil (l_pobj) cause_5\NN|NONE (l_prep) of_6\IN|possible|a (l_pobj) infarction_8\NN|NONE (l_prep) in_9\IN|with|myocardial (l_pobj) woman_12\NN|NONE (l_amod) hypertensive_11\JJ|a
D014700_D006973 NONE verapamil_18\NN|NONE (r_pobj) of_17\IN|the|in (r_prep) withdrawal_16\NN|of|and|the (l_prep) in_19\IN|the|of (l_pobj) woman_23\NN|NONE (l_prep) with_24\IN|asymptomatic|a (l_pobj) hypertension_26\NN|NONE
D002216_D009203 NONE captopril_13\NN|NONE (r_pobj) of_12\IN|and|the|withdrawal (r_prep) introduction_11\NN|NONE (r_pobj) with_9\IN|infarction|in (r_prep) coincided_8\VBD|a (l_nsubj) infarction_7\NN|in|with
D002216_D006973 NONE captopril_13\NN|NONE (r_pobj) of_12\IN|and|the|withdrawal (r_prep) introduction_11\NN|NONE (l_conj) withdrawal_16\NN|of|and|the (l_prep) in_19\IN|the|of (l_pobj) woman_23\NN|NONE (l_prep) with_24\IN|asymptomatic|a (l_pobj) hypertension_26\NN|NONE
D014700_D009203 CID Verapamil_0\NNP|.|as (r_compound) withdrawal_1\NN|NONE (l_prep) as_2\IN|.|Verapamil (l_pobj) cause_5\NN|NONE (l_prep) of_6\IN|possible|a (l_pobj) infarction_8\NN|NONE
D014700_D009203 CID verapamil_18\NN|NONE (r_pobj) of_17\IN|the|in (r_prep) withdrawal_16\NN|of|and|the (r_conj) introduction_11\NN|NONE (r_pobj) with_9\IN|infarction|in (r_prep) coincided_8\VBD|a (l_nsubj) infarction_7\NN|in|with
48362
D011802_D056486 CID Quinidine_0\NN|. (r_compound) hepatitis_1\NN|NONE
D011802_D056486 CID quinidine_6\VBN|NONE (r_poss) hepatotoxicity_7\NN|and|that|believe|patient
12090760
D015215_D000740 CID azidothymidine_9\RB| (r_advmod) induced_11\VBN|NONE (r_amod) anemia_12\NN|and|in
D015215_D000740 CID Azidothymidine_0\NNP|anemia|and|by|can|be|.|interleukin (r_nsubjpass) reversed_8\VBN|NONE (l_nsubjpass) anemia_3\NN|and|by|can|be|.|Azidothymidine|interleukin
D015215_D000740 CID AZT)-induced_2\VBN|in|( (r_compound) anemia_3\NN|and|by|can|be|.|Azidothymidine|interleukin
3780814
D004052_D063646 NONE diethylnitrosamine_9\NN|NONE (r_pobj) with_8\IN|simultaneously (r_prep) given_6\VBN|carcinogenic|.|of (r_prep) action_3\NN|NONE (l_amod) carcinogenic_2\JJ|.|of|given
D004052_D063646 NONE diethylnitrosamine_33\JJ|NONE (r_pobj) with_32\IN|simultaneously|is|when|it (r_prep) administered_30\VBN|to|effect (r_advcl) elucidate_9\VB|NONE (l_dobj) effect_11\NN|administered|to (l_prep) on_25\IN|the|of (l_pobj) carcinogenesis_26\NN|NONE
D004052_D063646 NONE DEN_35\NNP|in|has|been|work|. (r_parataxis) planned_5\VBN|NONE (l_prep) in_6\IN|has|been|work|DEN|. (l_pobj) order_7\NN|NONE (l_acl) elucidate_9\VB|NONE (l_dobj) effect_11\NN|administered|to (l_prep) on_25\IN|the|of (l_pobj) carcinogenesis_26\NN|NONE
D004052_D063646 NONE DEN_9\NNP|by|or (r_pobj) by_8\IN|during|were|rats|according|. (r_agent) treated_7\VBN|NONE (l_prep) according_23\VBG|by|during|were|rats|. (l_prep) to_24\IN|NONE (l_pobj) schedule_26\NN|NONE (l_prep) for_27\IN|our (l_pobj) hepatocarcinogenesis_28\NN|NONE
D004052_D063646 NONE DEN_13\NNP|NONE (r_pobj) by_12\IN|DEN|or (r_conj) by_8\IN|during|were|rats|according|. (r_agent) treated_7\VBN|NONE (l_prep) according_23\VBG|by|during|were|rats|. (l_prep) to_24\IN|NONE (l_pobj) schedule_26\NN|NONE (l_prep) for_27\IN|our (l_pobj) hepatocarcinogenesis_28\NN|NONE
D004052_D063646 NONE DEN_13\NNP|the (r_compound) treatment_14\NN|NONE (r_pobj) after_11\IN|when (r_prep) administered_10\VBN|which|carcinogenesis (r_advcl) promotes_7\VBZ|,|, (l_dobj) carcinogenesis_8\NN|administered|which
D004052_D063646 NONE DEN_24\NNP|NONE (r_pobj) with_23\IN|simultaneously|when (r_prep) given_21\VBN|that|PB|effect (r_advcl) reduces_16\VBZ|.|is|It (l_nsubj) PB_4\NNP|that|effect|given (l_relcl) promotes_7\VBZ|,|, (l_dobj) carcinogenesis_8\NN|administered|which
D004052_D009369 NONE DEN_1\NNP|rats (r_nsubj) treated_4\VBN|prolonged|survival|In|decreased|and|, (r_ccomp) was_9\VBD|NONE (l_conj) decreased_15\VBD|prolonged|survival|In|and|,|treated (l_nsubj) incidence_14\NN|.|as (l_compound) tumor_13\NN|the
D004052_D009369 NONE DEN_23\NNP|NONE (r_pobj) by_22\IN|alone (r_agent) obtained_21\VBN|the (r_acl) results_20\NNS|NONE (r_pobj) with_18\IN|NONE (r_prep) compared_17\VBN|NONE (r_prep) as_16\IN|incidence|. (r_prep) decreased_15\VBD|prolonged|survival|In|and|,|treated (l_nsubj) incidence_14\NN|.|as (l_compound) tumor_13\NN|the
D010634_D063646 NONE phenobarbital_5\JJ|NONE (r_pobj) of_4\IN|carcinogenic|.|given (r_prep) action_3\NN|NONE (l_amod) carcinogenic_2\JJ|.|of|given
D010634_D063646 NONE phenobarbital_13\JJ|NONE (r_pobj) of_12\IN|the|on (r_prep) effect_11\NN|administered|to (l_prep) on_25\IN|the|of (l_pobj) carcinogenesis_26\NN|NONE
D010634_D063646 NONE PB_15\NNP|)|( (r_appos) phenobarbital_13\JJ|NONE (r_pobj) of_12\IN|the|on (r_prep) effect_11\NN|administered|to (l_prep) on_25\IN|the|of (l_pobj) carcinogenesis_26\NN|NONE
D010634_D063646 NONE PB_15\NNP|+ (r_conj) DEN_13\NNP|NONE (r_pobj) by_12\IN|DEN|or (r_conj) by_8\IN|during|were|rats|according|. (r_agent) treated_7\VBN|NONE (l_prep) according_23\VBG|by|during|were|rats|. (l_prep) to_24\IN|NONE (l_pobj) schedule_26\NN|NONE (l_prep) for_27\IN|our (l_pobj) hepatocarcinogenesis_28\NN|NONE
D010634_D063646 NONE PB_4\NNP|that|effect|given (l_relcl) promotes_7\VBZ|,|, (l_dobj) carcinogenesis_8\NN|administered|which
D010634_D009369 NONE PB_3\NNP|+ (r_conj) DEN_1\NNP|rats (r_nsubj) treated_4\VBN|prolonged|survival|In|decreased|and|, (r_ccomp) was_9\VBD|NONE (l_conj) decreased_15\VBD|prolonged|survival|In|and|,|treated (l_nsubj) incidence_14\NN|.|as (l_compound) tumor_13\NN|the
D010634_D011230 NONE PB_22\NNP|for|simultaneously|with|was|when (r_nsubjpass) given_24\VBN|After|significantly|,|was|.|number (r_advcl) reduced_20\VBN|NONE (l_nsubjpass) number_8\NN|After|significantly|,|was|given|. (l_conj) size_11\NN|and|the (l_prep) of_12\IN|the (l_pcomp) induced_13\VBN|NONE (l_dobj) foci_17\NN|NONE
D004052_D011230 CID DEN_27\NNP|NONE (r_pobj) with_26\IN|for|simultaneously|was|PB|when (r_prep) given_24\VBN|After|significantly|,|was|.|number (r_advcl) reduced_20\VBN|NONE (l_nsubjpass) number_8\NN|After|significantly|,|was|given|. (l_conj) size_11\NN|and|the (l_prep) of_12\IN|the (l_pcomp) induced_13\VBN|NONE (l_dobj) foci_17\NN|NONE
2750819
D008274_D064420 NONE magnesium_11\NN|NONE (r_pobj) of_10\IN|the (r_prep) toxicity_9\NN|that|nifedipine|can|seriously
D009543_D064420 NONE nifedipine_4\NN|that|can|seriously|toxicity (r_nsubj) potentiate_7\VB|reaction|. (l_dobj) toxicity_9\NN|that|nifedipine|can|seriously
D009543_D020879 CID nifedipine_6\NN|and|magnesium (r_conj) sulfate_4\NN|NONE (r_pobj) with_2\IN|Neuromuscular|. (r_prep) blockade_1\NN|NONE
D009543_D020879 CID nifedipine_6\NN|developed|neuromuscular (r_nmod) blockade_9\NN|NONE
D008278_D020879 CID sulfate_4\NN|NONE (r_pobj) with_2\IN|Neuromuscular|. (r_prep) blockade_1\NN|NONE
D008278_D020879 CID sulfate_15\NN|NONE (r_pobj) of_13\IN| (r_prep) mg_12\NN|.|was|after|patient (r_nsubjpass) administered_17\VBN|NONE (l_nsubjpass) patient_1\NN|.|was|after|mg (l_relcl) received_3\VBD|A (l_dobj) tocolysis_4\NN|who (l_prep) with_5\IN|NONE (l_pobj) blockade_9\NN|NONE
7785794
D014700_D006327 CID verapamil_8\NN|NONE (r_compound) SR_9\NNP|NONE (r_pobj) after_7\IN|Refractory|.|metoprolol|and|block|cardiogenic|and (r_prep) shock_2\NN|NONE (l_conj) block_6\NN|after|Refractory|.|metoprolol|and|cardiogenic|and
D014700_D006327 CID verapamil_27\NN|NONE (r_pobj) of_23\IN|therapeutic|with|a (r_prep) dose_22\NN|days (r_pobj) after_19\IN|woman|.|with (r_prep) presented_9\VBN|NONE (l_prep) with_10\IN|after|woman|. (l_pobj) block_13\NN|NONE
D004280_D006327 NONE dobutamine_30\NN|and (r_conj) dopamine_28\NN|such (r_pobj) as_27\IN|pressor (r_prep) agents_25\NNS|NONE (r_pobj) of_23\IN|high (r_prep) doses_22\NNS|multiple|of (r_conj) uses_14\NNS|even (r_pobj) with_12\IN|hypotensive|to|, (r_prep) remain_4\VB|.|patient (l_acomp) hypotensive_5\JJ|to|with|, (l_prep) with_6\IN|NONE (l_pobj) block_9\NN|NONE
D001285_D006327 NONE atropine_17\NN|NONE (r_pobj) of_15\IN|multiple|doses (r_prep) uses_14\NNS|even (r_pobj) with_12\IN|hypotensive|to|, (r_prep) remain_4\VB|.|patient (l_acomp) hypotensive_5\JJ|to|with|, (l_prep) with_6\IN|NONE (l_pobj) block_9\NN|NONE
D002122_D007022 NONE chloride_9\NN|NONE (l_conj) hypotension_13\NN|intravenous|calcium|,
D004298_D007022 NONE dopamine_28\NN|such (r_pobj) as_27\IN|pressor (r_prep) agents_25\NNS|NONE (r_pobj) of_23\IN|high (r_prep) doses_22\NNS|multiple|of (r_conj) uses_14\NNS|even (r_pobj) with_12\IN|hypotensive|to|, (r_prep) remain_4\VB|.|patient (l_acomp) hypotensive_5\JJ|to|with|,
D008790_D012770 NONE metoprolol_11\NN|after|Refractory|.|and|block|cardiogenic|and (r_conj) shock_2\NN|NONE
D008790_D006327 CID metoprolol_11\NN|after|Refractory|.|and|block|cardiogenic|and (r_conj) shock_2\NN|NONE (l_conj) block_6\NN|after|Refractory|.|metoprolol|and|cardiogenic|and
D008790_D006327 CID metoprolol_32\NN|NONE (r_pobj) of_31\IN|concomitant (r_prep) use_30\NN|NONE (r_pobj) with_28\IN|therapeutic|of|a (r_prep) dose_22\NN|days (r_pobj) after_19\IN|woman|.|with (r_prep) presented_9\VBN|NONE (l_prep) with_10\IN|after|woman|. (l_pobj) block_13\NN|NONE
D002122_D006327 NONE chloride_9\NN|NONE (l_conj) hypotension_13\NN|intravenous|calcium|, (l_conj) block_17\NN|the|refractory|and
D014700_D007022 CID verapamil_27\NN|NONE (r_pobj) of_23\IN|therapeutic|with|a (r_prep) dose_22\NN|days (r_pobj) after_19\IN|woman|.|with (r_prep) presented_9\VBN|NONE (l_prep) with_10\IN|after|woman|. (l_pobj) block_13\NN|NONE (l_conj) hypotension_16\NN|and|heart|complete
D004280_D007022 NONE dobutamine_30\NN|and (r_conj) dopamine_28\NN|such (r_pobj) as_27\IN|pressor (r_prep) agents_25\NNS|NONE (r_pobj) of_23\IN|high (r_prep) doses_22\NNS|multiple|of (r_conj) uses_14\NNS|even (r_pobj) with_12\IN|hypotensive|to|, (r_prep) remain_4\VB|.|patient (l_acomp) hypotensive_5\JJ|to|with|,
D014700_D012770 NONE verapamil_8\NN|NONE (r_compound) SR_9\NNP|NONE (r_pobj) after_7\IN|Refractory|.|metoprolol|and|block|cardiogenic|and (r_prep) shock_2\NN|NONE
D001285_D007022 NONE atropine_17\NN|NONE (r_pobj) of_15\IN|multiple|doses (r_prep) uses_14\NNS|even (r_pobj) with_12\IN|hypotensive|to|, (r_prep) remain_4\VB|.|patient (l_acomp) hypotensive_5\JJ|to|with|,
D008790_D007022 CID metoprolol_32\NN|NONE (r_pobj) of_31\IN|concomitant (r_prep) use_30\NN|NONE (r_pobj) with_28\IN|therapeutic|of|a (r_prep) dose_22\NN|days (r_pobj) after_19\IN|woman|.|with (r_prep) presented_9\VBN|NONE (l_prep) with_10\IN|after|woman|. (l_pobj) block_13\NN|NONE (l_conj) hypotension_16\NN|and|heart|complete
D004298_D006327 NONE dopamine_28\NN|such (r_pobj) as_27\IN|pressor (r_prep) agents_25\NNS|NONE (r_pobj) of_23\IN|high (r_prep) doses_22\NNS|multiple|of (r_conj) uses_14\NNS|even (r_pobj) with_12\IN|hypotensive|to|, (r_prep) remain_4\VB|.|patient (l_acomp) hypotensive_5\JJ|to|with|, (l_prep) with_6\IN|NONE (l_pobj) block_9\NN|NONE
11226639
C032232_D053608 NONE barbiturate_5\NN| (r_npadvmod) induced_7\VBN|in (r_amod) narcosis_8\NN|NONE
C032232_D053608 NONE barbiturate_9\NN|manner|a (r_compound) narcosis_10\NN|NONE
C032232_D053608 NONE barbiturate_14\NN|NONE (r_compound) narcosis_15\NN|NONE
C032232_D053608 NONE barbiturate_16\JJ|of|the (r_compound) mechanism_17\NN|NONE (r_pobj) for_14\IN|NONE (r_prep) specific_13\JJ|to (r_acomp) be_12\VB|.|Thus|action|, (r_xcomp) seems_10\VBZ|NONE (l_nsubj) action_4\NN|.|Thus|be|, (l_prep) of_5\IN|dual|the (l_pobj) melatonin_6\NN|NONE (l_prep) on_7\IN|NONE (l_pobj) narcosis_9\NN|NONE
D007649_D053608 CID ketamine-_13\NNS|NONE (r_nmod) narcosis_18\NN|NONE
D008550_D053608 CID melatonin_3\NN|NONE (l_prep) on_4\IN|NONE (l_pobj) narcosis_8\NN|NONE
D008550_D053608 CID Melatonin_0\NNP|is|cycle|but|, (r_nsubj) affects_1\VBZ|NONE (l_conj) is_11\VBZ|Melatonin|cycle|but|, (l_ccomp) influence_17\VB|.|not|it|clear (l_dobj) narcosis_21\NN|it|whether|may
D008550_D053608 CID Melatonin_0\NNP|however|was|,|correlation|,|. (r_nsubjpass) found_20\VBN|NONE (l_punct) ,_11\,|however|Melatonin|was|,|correlation|. (l_punct) affected_4\VBN|NONE (l_prep) in_5\IN|treatment (l_pobj) narcosis_10\NN|NONE
D008550_D053608 CID melatonin_7\NN|NONE (r_pobj) of_6\IN|the|highest (r_prep) dose_5\NN|In|and|produced|reduction|.|increase|and|, (r_nsubj) caused_12\VBD|NONE (l_conj) produced_20\VBD|In|and|reduction|.|increase|dose|and|, (l_dobj) reduction_23\NN|, (l_prep) of_24\IN|a|sustained (l_pobj) duration_26\NN|NONE (l_prep) of_27\IN|the (l_pobj) narcosis_28\NN|NONE
D008550_D053608 CID Melatonin_0\NNP|duration|. (r_nsubj) influenced_5\VBD|NONE (l_dobj) duration_7\NN|Melatonin|. (l_conj) latency_11\NN|but|the (l_prep) of_12\IN|not|the (l_pobj) narcosis_18\NN|NONE
D008550_D053608 CID melatonin_6\NN|NONE (l_prep) on_7\IN|NONE (l_pobj) narcosis_9\NN|NONE
D003975_D053608 CID diazepam_15\NN| (r_npadvmod) induced_17\VBN|or (r_conj) ketamine-_13\NNS|NONE (r_nmod) narcosis_18\NN|NONE
16680561
C476217_D009325 CID cinacalcet_15\NN|NONE (r_pobj) with_14\IN|desipramine|%|when (r_prep) receiving_12\VBG|NONE (r_pcomp) than_10\IN|NONE (r_prep) alone_9\RB|adverse|following (r_amod) events_4\NNS|subjects (r_dobj) reported_2\VBD|been|.|,|have|nausea|frequent|for (r_ccomp) reported_35\VBN|NONE (l_nsubjpass) nausea_29\NN|been|.|,|have|reported|frequent|for
C476217_D009325 CID cinacalcet_43\NN|or|either (r_conj) desipramine_41\NN|NONE (r_pobj) with_39\IN|NONE (r_prep) treated_38\VBN|NONE (r_acl) patients_37\NNS|NONE (r_pobj) for_36\IN|been|.|,|have|reported|nausea|frequent (r_prep) reported_35\VBN|NONE (l_nsubjpass) nausea_29\NN|been|.|,|have|reported|frequent|for
C476217_D006261 CID cinacalcet_15\NN|NONE (r_pobj) with_14\IN|desipramine|%|when (r_prep) receiving_12\VBG|NONE (r_pcomp) than_10\IN|NONE (r_prep) alone_9\RB|adverse|following (r_amod) events_4\NNS|subjects (r_dobj) reported_2\VBD|been|.|,|have|nausea|frequent|for (r_ccomp) reported_35\VBN|NONE (l_nsubjpass) nausea_29\NN|been|.|,|have|reported|frequent|for (l_conj) headache_31\NN|and|(|)
C476217_D006261 CID cinacalcet_43\NN|or|either (r_conj) desipramine_41\NN|NONE (r_pobj) with_39\IN|NONE (r_prep) treated_38\VBN|NONE (r_acl) patients_37\NNS|NONE (r_pobj) for_36\IN|been|.|,|have|reported|nausea|frequent (r_prep) reported_35\VBN|NONE (l_nsubjpass) nausea_29\NN|been|.|,|have|reported|frequent|for (l_conj) headache_31\NN|and|(|)
D003891_D006261 CID desipramine_8\NN|NONE (r_pobj) with_7\IN|NONE (r_prep) treatment_6\NN|NONE (r_dobj) following_5\VBG|adverse|alone (r_acl) events_4\NNS|subjects (r_dobj) reported_2\VBD|been|.|,|have|nausea|frequent|for (r_ccomp) reported_35\VBN|NONE (l_nsubjpass) nausea_29\NN|been|.|,|have|reported|frequent|for (l_conj) headache_31\NN|and|(|)
D003891_D006261 CID desipramine_13\NN|with|%|when (r_dobj) receiving_12\VBG|NONE (r_pcomp) than_10\IN|NONE (r_prep) alone_9\RB|adverse|following (r_amod) events_4\NNS|subjects (r_dobj) reported_2\VBD|been|.|,|have|nausea|frequent|for (r_ccomp) reported_35\VBN|NONE (l_nsubjpass) nausea_29\NN|been|.|,|have|reported|frequent|for (l_conj) headache_31\NN|and|(|)
D003891_D006261 CID desipramine_41\NN|NONE (r_pobj) with_39\IN|NONE (r_prep) treated_38\VBN|NONE (r_acl) patients_37\NNS|NONE (r_pobj) for_36\IN|been|.|,|have|reported|nausea|frequent (r_prep) reported_35\VBN|NONE (l_nsubjpass) nausea_29\NN|been|.|,|have|reported|frequent|for (l_conj) headache_31\NN|and|(|)
D003891_D009325 CID desipramine_8\NN|NONE (r_pobj) with_7\IN|NONE (r_prep) treatment_6\NN|NONE (r_dobj) following_5\VBG|adverse|alone (r_acl) events_4\NNS|subjects (r_dobj) reported_2\VBD|been|.|,|have|nausea|frequent|for (r_ccomp) reported_35\VBN|NONE (l_nsubjpass) nausea_29\NN|been|.|,|have|reported|frequent|for
D003891_D009325 CID desipramine_13\NN|with|%|when (r_dobj) receiving_12\VBG|NONE (r_pcomp) than_10\IN|NONE (r_prep) alone_9\RB|adverse|following (r_amod) events_4\NNS|subjects (r_dobj) reported_2\VBD|been|.|,|have|nausea|frequent|for (r_ccomp) reported_35\VBN|NONE (l_nsubjpass) nausea_29\NN|been|.|,|have|reported|frequent|for
D003891_D009325 CID desipramine_41\NN|NONE (r_pobj) with_39\IN|NONE (r_prep) treated_38\VBN|NONE (r_acl) patients_37\NNS|NONE (r_pobj) for_36\IN|been|.|,|have|reported|nausea|frequent (r_prep) reported_35\VBN|NONE (l_nsubjpass) nausea_29\NN|been|.|,|have|reported|frequent|for
8231633
D002118_D012640 NONE calcium_10\NN|NONE (r_compound) channel_11\NN|NONE (r_compound) blockers_12\NNS|time (r_nsubj) decreased_13\VBD|was|significantly|not|but (l_dobj) time_15\NN|blockers (l_relcl) obtain_19\VB|the|of (l_dobj) convulsions_23\NNS|to
D002045_D012640 CID bupivacaine_4\NN|NONE (r_pobj) of_3\IN|The|convulsant (r_prep) activity_2\NN|NONE (r_nsubj) was_5\VBD|significantly|decreased|not|but (r_auxpass) modified_8\VBN|pronounced|effect|;|. (l_conj) decreased_13\VBD|was|significantly|not|but (l_dobj) time_15\NN|blockers (l_relcl) obtain_19\VB|the|of (l_dobj) convulsions_23\NNS|to
D002045_D012640 CID bupivacaine_20\NN| (r_npadvmod) induced_22\VBN|NONE (r_amod) convulsions_23\NNS|to
D015764_D012640 NONE bepridil_31\NN|NONE (r_pcomp) with_30\IN|less (r_prep) pronounced_29\VBN|effect|modified|;|. (r_acomp) was_27\VBD|NONE (l_ccomp) modified_8\VBN|pronounced|effect|;|. (l_conj) decreased_13\VBD|was|significantly|not|but (l_dobj) time_15\NN|blockers (l_relcl) obtain_19\VB|the|of (l_dobj) convulsions_23\NNS|to
D002045_D064420 NONE bupivacaine_6\NN| (r_npadvmod) induced_8\VBN|NONE (r_amod) toxicity_9\NN|NONE
D002045_D064420 NONE bupivacaine_15\NN| (r_npadvmod) induced_17\VBN|acute (r_amod) toxicity_19\NN|NONE
D002118_D064420 NONE calcium_2\NN|NONE (r_compound) channel_3\NN|on (r_compound) blockers_4\NNS|NONE (l_prep) on_5\IN|channel (l_pobj) toxicity_9\NN|NONE
D002118_D064420 NONE calcium_11\NN|NONE (r_compound) channel_12\NN|on (r_compound) blockers_13\NNS|NONE (l_prep) on_14\IN|channel (l_pobj) toxicity_19\NN|NONE
6466532
D006024_D001919 NONE glycopyrrolate_3\NN|NONE (l_prep) in_6\IN|atropine|i.v.|and (l_pobj) prevention_8\NN|NONE (l_prep) of_9\IN|the (l_pobj) bradycardia_10\NN|NONE
D006024_D001919 NONE glycopyrrolate_5\NN|NONE (r_pobj) of_4\IN|NONE (r_prep) administration_3\NN|NONE (r_pobj) of_2\IN|The|,|before|prevent (r_prep) effectiveness_1\NN|,|was|. (l_acl) prevent_27\VB|of|The|,|before (l_dobj) arrhythmia_28\NN|to|following (l_conj) bradycardia_30\NNP|and
D001285_D001145 NONE atropine_5\NN|i.v.|and|in (r_conj) glycopyrrolate_3\NN|NONE (l_prep) in_6\IN|atropine|i.v.|and (l_pobj) prevention_8\NN|NONE (l_prep) of_9\IN|the (l_pobj) bradycardia_10\NN|NONE (l_conj) arrhythmias_12\NNS|and|following
D001285_D001145 NONE atropine_12\NN|micrograms|and (r_conj) kg-1_10\NNS|NONE (r_dobj) glycopyrrolate_5\NN|NONE (r_pobj) of_4\IN|NONE (r_prep) administration_3\NN|NONE (r_pobj) of_2\IN|The|,|before|prevent (r_prep) effectiveness_1\NN|,|was|. (l_acl) prevent_27\VB|of|The|,|before (l_dobj) arrhythmia_28\NN|to|following
D006024_D001145 NONE glycopyrrolate_3\NN|NONE (l_prep) in_6\IN|atropine|i.v.|and (l_pobj) prevention_8\NN|NONE (l_prep) of_9\IN|the (l_pobj) bradycardia_10\NN|NONE (l_conj) arrhythmias_12\NNS|and|following
D006024_D001145 NONE glycopyrrolate_5\NN|NONE (r_pobj) of_4\IN|NONE (r_prep) administration_3\NN|NONE (r_pobj) of_2\IN|The|,|before|prevent (r_prep) effectiveness_1\NN|,|was|. (l_acl) prevent_27\VB|of|The|,|before (l_dobj) arrhythmia_28\NN|to|following
D013390_D001145 NONE suxamethonium_17\NN|NONE (r_pobj) of_16\IN|repeated (r_prep) doses_15\NNS|NONE (r_pobj) following_13\VBG|and|arrhythmias (r_prep) bradycardia_10\NN|NONE (l_conj) arrhythmias_12\NNS|and|following
D013390_D001145 NONE suxamethonium_35\NN|NONE (r_pobj) of_34\IN|repeated (r_prep) doses_33\NNS|NONE (r_pobj) following_31\VBG|to|arrhythmia (r_prep) prevent_27\VB|of|The|,|before (l_dobj) arrhythmia_28\NN|to|following
D001285_D001919 NONE atropine_5\NN|i.v.|and|in (r_conj) glycopyrrolate_3\NN|NONE (l_prep) in_6\IN|atropine|i.v.|and (l_pobj) prevention_8\NN|NONE (l_prep) of_9\IN|the (l_pobj) bradycardia_10\NN|NONE
D001285_D001919 NONE atropine_12\NN|micrograms|and (r_conj) kg-1_10\NNS|NONE (r_dobj) glycopyrrolate_5\NN|NONE (r_pobj) of_4\IN|NONE (r_prep) administration_3\NN|NONE (r_pobj) of_2\IN|The|,|before|prevent (r_prep) effectiveness_1\NN|,|was|. (l_acl) prevent_27\VB|of|The|,|before (l_dobj) arrhythmia_28\NN|to|following (l_conj) bradycardia_30\NNP|and
D013390_D001919 CID suxamethonium_17\NN|NONE (r_pobj) of_16\IN|repeated (r_prep) doses_15\NNS|NONE (r_pobj) following_13\VBG|and|arrhythmias (r_prep) bradycardia_10\NN|NONE
D013390_D001919 CID suxamethonium_35\NN|NONE (r_pobj) of_34\IN|repeated (r_prep) doses_33\NNS|NONE (r_pobj) following_31\VBG|to|arrhythmia (r_prep) prevent_27\VB|of|The|,|before (l_dobj) arrhythmia_28\NN|to|following (l_conj) bradycardia_30\NNP|and
9523805
D011318_D009422 CID prilocaine_11\NN|NONE (r_pobj) with_10\IN|than|lower|a (r_prep) incidence_9\NN|after|neurologic|.|:|Transient (r_appos) symptoms_2\NNS|NONE
D011318_D009422 CID prilocaine_11\JJ|,|,|.|present|Accordingly|study (l_prep) with_12\IN|NONE (l_pobj) lidocaine_13\NN|NONE (l_conj) bupivacaine_15\NN|and (l_prep) with_16\IN|NONE (l_pobj) respect_17\NN|NONE (l_prep) to_18\IN|NONE (l_pobj) duration_19\NN|NONE (l_prep) of_20\IN|NONE (l_pobj) action_21\NN|NONE (l_conj) risk_24\NN|and (l_prep) of_25\IN|relative (l_pobj) TNSs_26\NNS|NONE
D011318_D009422 CID prilocaine_15\NN|NONE (r_dobj) receiving_14\VBG| (r_acl) patients_13\NNS|:|patients|them|,|had|and|, (r_nsubj) had_21\VBD|NONE (l_nsubj) patients_4\NNS|:|them|,|had|and|,|patients (l_acl) receiving_5\VBG| (l_dobj) TNSs_8\NNS|lidocaine
D011318_D009422 CID prilocaine_15\NN|NONE (r_dobj) receiving_14\VBG| (r_acl) patients_13\NNS|:|patients|them|,|had|and|, (r_nsubj) had_21\VBD|NONE (l_conj) had_31\VBD|:|patients|them|,|and|,|patients (l_dobj) TNSs_32\NNS|none|.
D011318_D009422 CID Prilocaine_0\NNP|.|preferable|has|may (r_nsubj) be_2\VB|NONE (l_advcl) has_12\VBZ|.|preferable|Prilocaine|may (l_dobj) duration_15\NN|because|it (l_conj) incidence_21\NN|but|of|a|similar (l_prep) of_22\IN|lower|a (l_pobj) TNSs_23\NNS|NONE
D002045_D009422 NONE bupivacaine_13\NN|and (r_conj) prilocaine_11\NN|NONE (r_pobj) with_10\IN|than|lower|a (r_prep) incidence_9\NN|after|neurologic|.|:|Transient (r_appos) symptoms_2\NNS|NONE
D002045_D009422 NONE bupivacaine_19\NN|NONE (r_pobj) with_18\IN|NONE (r_prep) infrequent_17\JJ|NONE (r_acomp) are_16\VBP|but|frequently|symptoms|anesthesia|that (r_conj) follow_11\VBP|.|evidence (l_nsubj) symptoms_6\NNS|but|frequently|are|anesthesia|that
D002045_D009422 NONE bupivacaine_19\NN|NONE (r_pobj) with_18\IN|NONE (r_prep) infrequent_17\JJ|NONE (r_acomp) are_16\VBP|but|frequently|symptoms|anesthesia|that (r_conj) follow_11\VBP|.|evidence (l_nsubj) symptoms_6\NNS|but|frequently|are|anesthesia|that (l_appos) TNSs_8\NNS|neurologic|transient|)|(
D002045_D009422 NONE bupivacaine_15\NN|and (l_prep) with_16\IN|NONE (l_pobj) respect_17\NN|NONE (l_prep) to_18\IN|NONE (l_pobj) duration_19\NN|NONE (l_prep) of_20\IN|NONE (l_pobj) action_21\NN|NONE (l_conj) risk_24\NN|and (l_prep) of_25\IN|relative (l_pobj) TNSs_26\NNS|NONE
D002045_D009422 NONE bupivacaine_30\NN|NONE (r_dobj) receiving_29\VBG| (r_acl) patients_28\NNS|NONE (r_pobj) of_26\IN|NONE (r_prep) none_25\NN|TNSs|. (r_nsubj) had_31\VBD|:|patients|them|,|and|,|patients (r_conj) had_21\VBD|NONE (l_nsubj) patients_4\NNS|:|them|,|had|and|,|patients (l_acl) receiving_5\VBG| (l_dobj) TNSs_8\NNS|lidocaine
D002045_D009422 NONE bupivacaine_30\NN|NONE (r_dobj) receiving_29\VBG| (r_acl) patients_28\NNS|NONE (r_pobj) of_26\IN|NONE (r_prep) none_25\NN|TNSs|. (r_nsubj) had_31\VBD|:|patients|them|,|and|,|patients (l_dobj) TNSs_32\NNS|none|.
D008012_D009422 CID lidocaine_16\NN|NONE (r_pobj) with_15\IN|NONE (r_prep) than_14\IN|lower|a|with (r_prep) incidence_9\NN|after|neurologic|.|:|Transient (r_appos) symptoms_2\NNS|NONE
D008012_D009422 CID lidocaine_12\NN|spinal (r_amod) anesthesia_14\NN|but|frequently|symptoms|are|that (r_dobj) follow_11\VBP|.|evidence (l_nsubj) symptoms_6\NNS|but|frequently|are|anesthesia|that
D008012_D009422 CID lidocaine_12\NN|spinal (r_amod) anesthesia_14\NN|but|frequently|symptoms|are|that (r_dobj) follow_11\VBP|.|evidence (l_nsubj) symptoms_6\NNS|but|frequently|are|anesthesia|that (l_appos) TNSs_8\NNS|neurologic|transient|)|(
D008012_D009422 CID lidocaine_13\NN|NONE (l_conj) bupivacaine_15\NN|and (l_prep) with_16\IN|NONE (l_pobj) respect_17\NN|NONE (l_prep) to_18\IN|NONE (l_pobj) duration_19\NN|NONE (l_prep) of_20\IN|NONE (l_pobj) action_21\NN|NONE (l_conj) risk_24\NN|and (l_prep) of_25\IN|relative (l_pobj) TNSs_26\NNS|NONE
D008012_D009422 CID lidocaine_6\NN|TNSs (r_dobj) receiving_5\VBG| (l_dobj) TNSs_8\NNS|lidocaine
D008012_D009422 CID lidocaine_6\NN|TNSs (r_dobj) receiving_5\VBG| (r_acl) patients_4\NNS|:|them|,|had|and|,|patients (r_nsubj) had_21\VBD|NONE (l_conj) had_31\VBD|:|patients|them|,|and|,|patients (l_dobj) TNSs_32\NNS|none|.
D008012_D009422 CID lidocaine_5\NN|NONE (r_xcomp) preferable_3\JJ|.|has|Prilocaine|may (r_acomp) be_2\VB|NONE (l_advcl) has_12\VBZ|.|preferable|Prilocaine|may (l_dobj) duration_15\NN|because|it (l_conj) incidence_21\NN|but|of|a|similar (l_prep) of_22\IN|lower|a (l_pobj) TNSs_23\NNS|NONE
8607407
D002110_D006973 CID caffeine_5\NN|NONE (r_pobj) with_4\IN|.|Acute|in|pressure (r_prep) elevations_3\NNS|NONE (l_prep) in_6\IN|.|Acute|pressure|with (l_pobj) men_7\NNS|NONE (l_prep) with_8\IN|NONE (l_pobj) hypertension_11\NN|NONE
D002110_D006973 CID caffeine_5\NN|NONE (r_pobj) of_4\IN|the|vasoconstrictive (r_prep) actions_3\NNS|in|are|Whether (r_nsubjpass) enhanced_7\VBN|has|been|not|. (l_prep) in_8\IN|are|Whether|actions (l_pobj) persons_10\NNS|NONE (l_amod) hypertensive_9\JJ|NONE
D002110_D006973 CID caffeine_24\NN|NONE (r_compound) ingestion_25\NN|NONE (r_pobj) after_23\IN|%|exhibited|Consequently|.|,|levels|, (r_prep) achieved_19\VBD|NONE (l_dobj) levels_22\NNS|%|exhibited|Consequently|after|.|,|, (l_amod) hypertensive_20\JJ|BP
D002110_D006973 CID caffeine_10\NN|NONE (r_pobj) to_9\IN|exaggerated (r_prep) responses_8\NNS|,|Thus|,|,|.|selective|replicated|consistent|in|: (r_nsubj) were_11\VBD|NONE (l_prep) in_2\IN|,|Thus|,|,|.|selective|replicated|consistent|responses|: (l_pobj) men_5\NNS|NONE (l_amod) hypertensive_4\JJ|borderline
D002110_D006973 CID caffeine_10\NN|NONE (r_pobj) to_9\IN|exaggerated (r_prep) responses_8\NNS|,|Thus|,|,|.|selective|replicated|consistent|in|: (r_nsubj) were_11\VBD|NONE (l_advcl) replicated_23\VBN|,|Thus|,|,|.|selective|consistent|in|responses|: (l_conj) representative_29\NN|and|,|in (l_prep) of_30\IN|NONE (l_pobj) hypertensives_34\NNS|NONE
2257294
D015215_-1 NONE AZT_10\NNP|NONE (r_pobj) of_9\IN|the (r_prep) administration_8\NN|NONE (r_pobj) by_6\IN|)|mL|for|( (r_prep) leukopenic_5\JJ|and|anemic (r_conj) rendered_2\VBD|NONE (r_acl) mice_1\NNS|NONE (r_pobj) In_0\IN|anemia|P|,|partially|.|)|,|administration|increased (r_prep) reversed_39\VBD|NONE (l_conj) increased_67\VBN|anemia|P|,|partially|.|In|)|,|administration (l_conj) improved_74\VBN|and|,|cellularity|in (l_dobj) megaloblastosis_75\NN|NONE
D015215_-1 NONE AZT_28\NNP|NONE (r_pobj) of_27\IN|continued|orally|the (r_prep) administration_26\NN|anemia|P|,|partially|.|In|)|,|increased (r_nsubj) reversed_39\VBD|NONE (l_conj) increased_67\VBN|anemia|P|,|partially|.|In|)|,|administration (l_conj) improved_74\VBN|and|,|cellularity|in (l_dobj) megaloblastosis_75\NN|NONE
D015215_-1 NONE AZT_40\NNP| (r_npadvmod) induced_42\VBN|reticulocytes|(|and|leukopenia|P (r_amod) anemia_43\NN|P|,|partially|.|In|)|,|administration|increased (r_dobj) reversed_39\VBD|NONE (l_conj) increased_67\VBN|anemia|P|,|partially|.|In|)|,|administration (l_conj) improved_74\VBN|and|,|cellularity|in (l_dobj) megaloblastosis_75\NN|NONE
D015215_D007153 NONE azidothymidine_2\RB| (r_advmod) induced_4\VBN|marrow (r_amod) suppression_6\NN|.|Benzylacyclouridine|without (r_dobj) reverses_1\VBZ|NONE (l_prep) without_7\IN|.|Benzylacyclouridine|suppression (l_pobj) impairment_8\NN|NONE (l_prep) of_9\IN|NONE (l_pobj) activity_15\NN|NONE (l_compound) virus_14\NN|human (l_compound) immunodeficiency_13\NN|NONE
D015215_D007153 NONE azidothymidine_17\NN|, (r_advmod) vitro_15\FW|NONE (r_amod) in_14\IN|to|,|inhibition (r_prep) reduce_12\VB|have|.|concentrations|been (l_dobj) inhibition_20\NN|to|,|in (l_prep) without_28\IN|(|AZT)induced|of (l_pobj) impairment_29\NN|NONE (l_prep) of_30\IN|NONE (l_pobj) virus_34\NN|NONE (l_compound) immunodeficiency_33\NN|antihuman|its|activity
D015215_D007153 NONE AZT)-induced_19\JJ|(|without|of (r_compound) inhibition_20\NN|to|,|in (l_prep) without_28\IN|(|AZT)induced|of (l_pobj) impairment_29\NN|NONE (l_prep) of_30\IN|NONE (l_pobj) virus_34\NN|NONE (l_compound) immunodeficiency_33\NN|antihuman|its|activity
C034753_D000740 NONE benzylacyclouridine_14\NN|NONE (r_pobj) of_13\IN|effect|the (r_prep) ability_12\NN|in|Because|,|,|anemia|,|was|. (r_nsubjpass) assessed_31\VBN|NONE (l_nsubjpass) anemia_27\NN|in|Because|,|,|ability|,|was|.
C034753_D000740 NONE BAU_16\NNP|(|) (r_appos) benzylacyclouridine_14\NN|NONE (r_pobj) of_13\IN|effect|the (r_prep) ability_12\NN|in|Because|,|,|anemia|,|was|. (r_nsubjpass) assessed_31\VBN|NONE (l_nsubjpass) anemia_27\NN|in|Because|,|,|ability|,|was|.
C034753_D000740 NONE BAU_31\NNP|(|plus|,|mg/kg (r_conj) AZT_28\NNP|NONE (r_pobj) of_27\IN|continued|orally|the (r_prep) administration_26\NN|anemia|P|,|partially|.|In|)|,|increased (r_nsubj) reversed_39\VBD|NONE (l_prep) In_0\IN|anemia|P|,|partially|.|)|,|administration|increased (l_pobj) mice_1\NNS|NONE (l_acl) rendered_2\VBD|NONE (l_oprd) anemic_3\JJ|and|leukopenic
C034753_D000740 NONE BAU_31\NNP|(|plus|,|mg/kg (r_conj) AZT_28\NNP|NONE (r_pobj) of_27\IN|continued|orally|the (r_prep) administration_26\NN|anemia|P|,|partially|.|In|)|,|increased (r_nsubj) reversed_39\VBD|NONE (l_dobj) anemia_43\NN|P|,|partially|.|In|)|,|administration|increased
C034753_D007970 NONE benzylacyclouridine_14\NN|NONE (r_pobj) of_13\IN|effect|the (r_prep) ability_12\NN|in|Because|,|,|anemia|,|was|. (r_nsubjpass) assessed_31\VBN|NONE (l_nsubjpass) anemia_27\NN|in|Because|,|,|ability|,|was|. (l_conj) leukopenia_29\NN|induced|and
C034753_D007970 NONE BAU_16\NNP|(|) (r_appos) benzylacyclouridine_14\NN|NONE (r_pobj) of_13\IN|effect|the (r_prep) ability_12\NN|in|Because|,|,|anemia|,|was|. (r_nsubjpass) assessed_31\VBN|NONE (l_nsubjpass) anemia_27\NN|in|Because|,|,|ability|,|was|. (l_conj) leukopenia_29\NN|induced|and
C034753_D007970 NONE BAU_31\NNP|(|plus|,|mg/kg (r_conj) AZT_28\NNP|NONE (r_pobj) of_27\IN|continued|orally|the (r_prep) administration_26\NN|anemia|P|,|partially|.|In|)|,|increased (r_nsubj) reversed_39\VBD|NONE (l_prep) In_0\IN|anemia|P|,|partially|.|)|,|administration|increased (l_pobj) mice_1\NNS|NONE (l_acl) rendered_2\VBD|NONE (l_conj) leukopenic_5\JJ|and|anemic
C034753_D007970 NONE BAU_31\NNP|(|plus|,|mg/kg (r_conj) AZT_28\NNP|NONE (r_pobj) of_27\IN|continued|orally|the (r_prep) administration_26\NN|anemia|P|,|partially|.|In|)|,|increased (r_nsubj) reversed_39\VBD|NONE (l_dobj) anemia_43\NN|P|,|partially|.|In|)|,|administration|increased (l_conj) leukopenia_45\NN|induced|reticulocytes|(|and|P
C034753_D007153 NONE Benzylacyclouridine_0\NN|.|without|suppression (r_nsubj) reverses_1\VBZ|NONE (l_prep) without_7\IN|.|Benzylacyclouridine|suppression (l_pobj) impairment_8\NN|NONE (l_prep) of_9\IN|NONE (l_pobj) activity_15\NN|NONE (l_compound) virus_14\NN|human (l_compound) immunodeficiency_13\NN|NONE
C034753_D064420 NONE benzylacyclouridine_14\NN|NONE (r_pobj) of_13\IN|effect|the (r_prep) ability_12\NN|in|Because|,|,|anemia|,|was|. (r_nsubjpass) assessed_31\VBN|NONE (l_prep) Because_0\IN|in|,|,|ability|anemia|,|was|. (l_pobj) toxicities_4\NNS|of
C034753_D064420 NONE BAU_16\NNP|(|) (r_appos) benzylacyclouridine_14\NN|NONE (r_pobj) of_13\IN|effect|the (r_prep) ability_12\NN|in|Because|,|,|anemia|,|was|. (r_nsubjpass) assessed_31\VBN|NONE (l_prep) Because_0\IN|in|,|,|ability|anemia|,|was|. (l_pobj) toxicities_4\NNS|of
D014529_D007970 NONE Urd_8\NNP|chronic (r_compound) administration_9\NN|NONE (r_pobj) with_6\IN|NONE (r_prep) associated_5\VBN|clinical|the (r_acl) toxicities_4\NNS|of (r_pobj) Because_0\IN|in|,|,|ability|anemia|,|was|. (r_prep) assessed_31\VBN|NONE (l_nsubjpass) anemia_27\NN|in|Because|,|,|ability|,|was|. (l_conj) leukopenia_29\NN|induced|and
C034753_D001855 NONE Benzylacyclouridine_0\NN|.|without|suppression (r_nsubj) reverses_1\VBZ|NONE (l_dobj) suppression_6\NN|.|Benzylacyclouridine|without
C034753_D001855 NONE BAU_11\NNP|,|.|coadministered|toxicity (r_nsubj) reduced_12\VBD|NONE (l_dobj) toxicity_17\NN|,|.|BAU|coadministered
D015215_D000740 CID AZT_24\NNP| (r_npadvmod) induced_26\VBN|leukopenia|and (r_amod) anemia_27\NN|in|Because|,|,|ability|,|was|.
D015215_D000740 CID AZT_10\NNP|NONE (r_pobj) of_9\IN|the (r_prep) administration_8\NN|NONE (r_pobj) by_6\IN|)|mL|for|( (r_prep) leukopenic_5\JJ|and|anemic (r_conj) rendered_2\VBD|NONE (l_oprd) anemic_3\JJ|and|leukopenic
D015215_D000740 CID AZT_10\NNP|NONE (r_pobj) of_9\IN|the (r_prep) administration_8\NN|NONE (r_pobj) by_6\IN|)|mL|for|( (r_prep) leukopenic_5\JJ|and|anemic (r_conj) rendered_2\VBD|NONE (r_acl) mice_1\NNS|NONE (r_pobj) In_0\IN|anemia|P|,|partially|.|)|,|administration|increased (r_prep) reversed_39\VBD|NONE (l_dobj) anemia_43\NN|P|,|partially|.|In|)|,|administration|increased
D015215_D000740 CID AZT_28\NNP|NONE (r_pobj) of_27\IN|continued|orally|the (r_prep) administration_26\NN|anemia|P|,|partially|.|In|)|,|increased (r_nsubj) reversed_39\VBD|NONE (l_prep) In_0\IN|anemia|P|,|partially|.|)|,|administration|increased (l_pobj) mice_1\NNS|NONE (l_acl) rendered_2\VBD|NONE (l_oprd) anemic_3\JJ|and|leukopenic
D015215_D000740 CID AZT_28\NNP|NONE (r_pobj) of_27\IN|continued|orally|the (r_prep) administration_26\NN|anemia|P|,|partially|.|In|)|,|increased (r_nsubj) reversed_39\VBD|NONE (l_dobj) anemia_43\NN|P|,|partially|.|In|)|,|administration|increased
D015215_D000740 CID AZT_40\NNP| (r_npadvmod) induced_42\VBN|reticulocytes|(|and|leukopenia|P (r_amod) anemia_43\NN|P|,|partially|.|In|)|,|administration|increased (r_dobj) reversed_39\VBD|NONE (l_prep) In_0\IN|anemia|P|,|partially|.|)|,|administration|increased (l_pobj) mice_1\NNS|NONE (l_acl) rendered_2\VBD|NONE (l_oprd) anemic_3\JJ|and|leukopenic
D015215_D000740 CID AZT_40\NNP| (r_npadvmod) induced_42\VBN|reticulocytes|(|and|leukopenia|P (r_amod) anemia_43\NN|P|,|partially|.|In|)|,|administration|increased
D014529_D007153 NONE uridine_4\NN|NONE (r_pobj) of_3\IN|extracellular|Increased (r_prep) concentrations_2\NNS|have|reduce|.|been (r_nsubjpass) reported_10\VBN|NONE (l_xcomp) reduce_12\VB|have|.|concentrations|been (l_dobj) inhibition_20\NN|to|,|in (l_prep) without_28\IN|(|AZT)induced|of (l_pobj) impairment_29\NN|NONE (l_prep) of_30\IN|NONE (l_pobj) virus_34\NN|NONE (l_compound) immunodeficiency_33\NN|antihuman|its|activity
D014529_D007153 NONE Urd_6\NNP|NONE (r_appos) uridine_4\NN|NONE (r_pobj) of_3\IN|extracellular|Increased (r_prep) concentrations_2\NNS|have|reduce|.|been (r_nsubjpass) reported_10\VBN|NONE (l_xcomp) reduce_12\VB|have|.|concentrations|been (l_dobj) inhibition_20\NN|to|,|in (l_prep) without_28\IN|(|AZT)induced|of (l_pobj) impairment_29\NN|NONE (l_prep) of_30\IN|NONE (l_pobj) virus_34\NN|NONE (l_compound) immunodeficiency_33\NN|antihuman|its|activity
D015215_D001855 CID azidothymidine_2\RB| (r_advmod) induced_4\VBN|marrow (r_amod) suppression_6\NN|.|Benzylacyclouridine|without
D015215_D001855 CID AZT_3\NNP|NONE (r_pobj) with_2\IN|When|from (r_prep) coadministered_1\VBN|,|.|BAU|toxicity (r_advcl) reduced_12\VBD|NONE (l_dobj) toxicity_17\NN|,|.|BAU|coadministered
D015215_D001855 CID AZT_13\NNP| (r_npadvmod) induced_15\VBN|marrow (r_amod) toxicity_17\NN|,|.|BAU|coadministered
D015215_D007970 CID AZT_24\NNP| (r_npadvmod) induced_26\VBN|leukopenia|and (r_amod) anemia_27\NN|in|Because|,|,|ability|,|was|. (l_conj) leukopenia_29\NN|induced|and
D015215_D007970 CID AZT_10\NNP|NONE (r_pobj) of_9\IN|the (r_prep) administration_8\NN|NONE (r_pobj) by_6\IN|)|mL|for|( (r_prep) leukopenic_5\JJ|and|anemic
D015215_D007970 CID AZT_10\NNP|NONE (r_pobj) of_9\IN|the (r_prep) administration_8\NN|NONE (r_pobj) by_6\IN|)|mL|for|( (r_prep) leukopenic_5\JJ|and|anemic (r_conj) rendered_2\VBD|NONE (r_acl) mice_1\NNS|NONE (r_pobj) In_0\IN|anemia|P|,|partially|.|)|,|administration|increased (r_prep) reversed_39\VBD|NONE (l_dobj) anemia_43\NN|P|,|partially|.|In|)|,|administration|increased (l_conj) leukopenia_45\NN|induced|reticulocytes|(|and|P
D015215_D007970 CID AZT_28\NNP|NONE (r_pobj) of_27\IN|continued|orally|the (r_prep) administration_26\NN|anemia|P|,|partially|.|In|)|,|increased (r_nsubj) reversed_39\VBD|NONE (l_prep) In_0\IN|anemia|P|,|partially|.|)|,|administration|increased (l_pobj) mice_1\NNS|NONE (l_acl) rendered_2\VBD|NONE (l_conj) leukopenic_5\JJ|and|anemic
D015215_D007970 CID AZT_28\NNP|NONE (r_pobj) of_27\IN|continued|orally|the (r_prep) administration_26\NN|anemia|P|,|partially|.|In|)|,|increased (r_nsubj) reversed_39\VBD|NONE (l_dobj) anemia_43\NN|P|,|partially|.|In|)|,|administration|increased (l_conj) leukopenia_45\NN|induced|reticulocytes|(|and|P
D015215_D007970 CID AZT_40\NNP| (r_npadvmod) induced_42\VBN|reticulocytes|(|and|leukopenia|P (r_amod) anemia_43\NN|P|,|partially|.|In|)|,|administration|increased (r_dobj) reversed_39\VBD|NONE (l_prep) In_0\IN|anemia|P|,|partially|.|)|,|administration|increased (l_pobj) mice_1\NNS|NONE (l_acl) rendered_2\VBD|NONE (l_conj) leukopenic_5\JJ|and|anemic
D015215_D007970 CID AZT_40\NNP| (r_npadvmod) induced_42\VBN|reticulocytes|(|and|leukopenia|P (r_amod) anemia_43\NN|P|,|partially|.|In|)|,|administration|increased (l_conj) leukopenia_45\NN|induced|reticulocytes|(|and|P
D014529_D064420 NONE Urd_8\NNP|chronic (r_compound) administration_9\NN|NONE (r_pobj) with_6\IN|NONE (r_prep) associated_5\VBN|clinical|the (r_acl) toxicities_4\NNS|of
D014529_D064420 NONE Urd_3\NNP|NONE (r_compound) catabolism_4\NN|.|agent|and|increases|, (r_dobj) inhibits_2\VBZ|NONE (l_conj) increases_10\VBZ|.|agent|and|catabolism|, (l_prep) without_23\IN|,|in|,|concentration|in (l_pobj) toxicity_27\NN|NONE
D014529_D064420 NONE Urd_15\NNP|NONE (r_pobj) of_14\IN|plasma|the (r_prep) concentration_13\NN|,|in|without|,|in (r_dobj) increases_10\VBZ|.|agent|and|catabolism|, (l_prep) without_23\IN|,|in|,|concentration|in (l_pobj) toxicity_27\NN|NONE
D014529_D064420 NONE Urd_24\NNP| (r_npadvmod) related_26\VBN|NONE (r_amod) toxicity_27\NN|NONE
D015215_D064420 NONE AZT_24\NNP| (r_npadvmod) induced_26\VBN|leukopenia|and (r_amod) anemia_27\NN|in|Because|,|,|ability|,|was|. (r_nsubjpass) assessed_31\VBN|NONE (l_prep) Because_0\IN|in|,|,|ability|anemia|,|was|. (l_pobj) toxicities_4\NNS|of
C034753_-1 NONE BAU_31\NNP|(|plus|,|mg/kg (r_conj) AZT_28\NNP|NONE (r_pobj) of_27\IN|continued|orally|the (r_prep) administration_26\NN|anemia|P|,|partially|.|In|)|,|increased (r_nsubj) reversed_39\VBD|NONE (l_conj) increased_67\VBN|anemia|P|,|partially|.|In|)|,|administration (l_conj) improved_74\VBN|and|,|cellularity|in (l_dobj) megaloblastosis_75\NN|NONE
D014529_D000740 NONE Urd_8\NNP|chronic (r_compound) administration_9\NN|NONE (r_pobj) with_6\IN|NONE (r_prep) associated_5\VBN|clinical|the (r_acl) toxicities_4\NNS|of (r_pobj) Because_0\IN|in|,|,|ability|anemia|,|was|. (r_prep) assessed_31\VBN|NONE (l_nsubjpass) anemia_27\NN|in|Because|,|,|ability|,|was|.
14568327
D015632_D004409 NONE MPTP_7\NNP| (r_npadvmod) induced_9\VBN|NONE (r_amod) parkinsonism_10\NN|NONE (r_pobj) of_6\IN|different (r_prep) types_5\NNS|NONE (r_pobj) with_3\IN|monkeys (r_prep) Using_0\VBG|study|.|degree|, (r_advcl) evaluated_15\VBD|NONE (l_dobj) degree_17\NN|Using|study|.|, (l_relcl) involved_38\VBN|the (l_prep) in_39\IN|may|to|severity|be (l_pobj) development_41\NN|NONE (l_prep) of_42\IN|the (l_pobj) LIDs_43\NNS|NONE
D015632_D004409 NONE MPTP_8\NNP|acute|,|onset (r_compound) exposure_9\NN|NONE (r_pobj) with_1\IN|NONE (r_prep) Monkeys_0\NNS|dyskinesia|.|prior|days (r_nsubj) developed_24\VBD|NONE (l_dobj) dyskinesia_25\RB|.|prior|Monkeys|days
D015632_D004409 NONE MPTP_8\NNP|term (r_compound) exposure_9\NN|NONE (r_pobj) with_4\IN|NONE (r_prep) monkeys_3\NNS|symptom|,|and/or|In|slow|,|duration|prior (r_nsubj) progression_13\NN|developed|resistant|. (r_nsubj) were_24\VBD|NONE (l_acomp) resistant_26\JJ|developed|progression|. (l_prep) to_27\IN|more (l_pcomp) developing_28\VBG|NONE (l_dobj) LIDs_29\NNS|NONE
D015632_D004409 NONE MPTP_8\NNP|term (r_compound) exposure_9\NN|NONE (r_pobj) with_4\IN|NONE (r_prep) monkeys_3\NNS|symptom|,|and/or|In|slow|,|duration|prior (r_nsubj) progression_13\NN|developed|resistant|. (r_nsubj) were_24\VBD|NONE (l_parataxis) developed_34\VBD|progression|resistant|. (l_nsubj) dyskinesia_33\NN|(|)|,|sooner|e.g.
D007980_D004409 CID levodopa_2\NN| (r_npadvmod) induced_4\VBN|in (r_amod) dyskinesias_5\NNS|NONE
D007980_D004409 CID Levodopa_0\NNP| (r_npadvmod) induced_2\VBN|LIDs|)|( (r_amod) dyskinesias_3\NNS|problem|.
D007980_D004409 CID Levodopa_0\NNP| (r_npadvmod) induced_2\VBN|LIDs|)|( (r_amod) dyskinesias_3\NNS|problem|. (l_appos) LIDs_5\NNPS|induced|)|(
D007980_D004409 CID levodopa_34\NN|NONE (r_compound) therapy_35\NN|NONE (r_pobj) of_33\IN|NONE (r_prep) duration_32\NN|and|to (r_conj) response_29\NN|rate|and|,|symptom|, (r_conj) severity_26\NN|may|in|to|be (r_nsubjpass) involved_38\VBN|the (l_prep) in_39\IN|may|to|severity|be (l_pobj) development_41\NN|NONE (l_prep) of_42\IN|the (l_pobj) LIDs_43\NNS|NONE
D007980_D004409 CID levodopa_22\NN|NONE (r_compound) therapy_23\NN|NONE (r_pobj) of_21\IN|NONE (r_prep) initiation_20\NN|NONE (r_pobj) to_19\IN|NONE (r_prep) prior_18\RB|dyskinesia|.|Monkeys|days (r_advmod) developed_24\VBD|NONE (l_dobj) dyskinesia_25\RB|.|prior|Monkeys|days
D007980_D004409 CID levodopa_33\JJ|daily (r_compound) administration_34\NN|NONE (r_pobj) of_31\IN| (r_prep) days_30\NNS|dyskinesia|.|prior|Monkeys (r_npadvmod) developed_24\VBD|NONE (l_dobj) dyskinesia_25\RB|.|prior|Monkeys|days
D007980_D004409 CID levodopa_22\NN|NONE (r_compound) therapy_23\NN|NONE (r_pobj) of_21\IN|NONE (r_prep) initiation_20\NN|NONE (r_pobj) to_19\IN|NONE (r_prep) prior_18\RB|symptom|monkeys|,|and/or|In|slow|,|duration (r_advmod) progression_13\NN|developed|resistant|. (r_nsubj) were_24\VBD|NONE (l_acomp) resistant_26\JJ|developed|progression|. (l_prep) to_27\IN|more (l_pcomp) developing_28\VBG|NONE (l_dobj) LIDs_29\NNS|NONE
D007980_D004409 CID levodopa_22\NN|NONE (r_compound) therapy_23\NN|NONE (r_pobj) of_21\IN|NONE (r_prep) initiation_20\NN|NONE (r_pobj) to_19\IN|NONE (r_prep) prior_18\RB|symptom|monkeys|,|and/or|In|slow|,|duration (r_advmod) progression_13\NN|developed|resistant|. (r_nsubj) were_24\VBD|NONE (l_parataxis) developed_34\VBD|progression|resistant|. (l_nsubj) dyskinesia_33\NN|(|)|,|sooner|e.g.
D007980_D004409 CID levodopa_42\JJ|chronic (r_compound) administration_43\NN|NONE (r_pobj) of_40\IN| (r_prep) days_39\NNS|NONE (r_pobj) than_37\IN|no (r_prep) sooner_36\RBR|(|)|,|dyskinesia|e.g. (r_advmod) developed_34\VBD|progression|resistant|. (r_parataxis) were_24\VBD|NONE (l_acomp) resistant_26\JJ|developed|progression|. (l_prep) to_27\IN|more (l_pcomp) developing_28\VBG|NONE (l_dobj) LIDs_29\NNS|NONE
D007980_D004409 CID levodopa_42\JJ|chronic (r_compound) administration_43\NN|NONE (r_pobj) of_40\IN| (r_prep) days_39\NNS|NONE (r_pobj) than_37\IN|no (r_prep) sooner_36\RBR|(|)|,|dyskinesia|e.g. (r_advmod) developed_34\VBD|progression|resistant|. (l_nsubj) dyskinesia_33\NN|(|)|,|sooner|e.g.
D007980_D004409 CID levodopa_24\VB|NONE (r_pobj) to_23\IN|NONE (r_prep) prior_22\RB|LIDs|with|to (r_advmod) develop_9\VB|the (l_dobj) LIDs_10\NNS|prior|with|to
D007980_D004409 CID levodopa_24\VB|NONE (r_pobj) to_23\IN|NONE (r_prep) prior_22\RB|LIDs|with|to (r_advmod) develop_9\VB|the (r_acl) propensity_7\NN|NONE (r_pobj) in_5\IN|distinct (r_prep) differences_4\NNS|demonstrate|data|.|and (r_dobj) suggest_2\VBP|NONE (l_conj) demonstrate_26\VB|data|.|differences|and (l_dobj) value_28\NN|NONE (l_prep) for_32\IN|of|the (l_pcomp) studying_34\VBG|NONE (l_dobj) pathophysiology_36\NN|further (l_prep) of_37\IN|the (l_pobj) LIDs_38\NNS|NONE
D007980_D010300 NONE levodopa_2\NN| (r_npadvmod) induced_4\VBN|in (r_amod) dyskinesias_5\NNS|NONE (l_prep) in_6\IN|induced (l_pobj) monkeys_8\NNS|NONE (l_amod) parkinsonian_7\JJ|NONE
D007980_D010300 NONE Levodopa_0\NNP| (r_npadvmod) induced_2\VBN|LIDs|)|( (r_amod) dyskinesias_3\NNS|problem|. (r_nsubj) present_7\VBP|NONE (l_dobj) problem_10\NN|.|dyskinesias (l_prep) for_11\IN|major|a (l_pobj) management_16\NN|NONE (l_prep) of_17\IN|the|term (l_pobj) patients_24\NNS|NONE (l_nmod) disease_20\NN|)|PD|(
D007980_D010300 NONE Levodopa_0\NNP| (r_npadvmod) induced_2\VBN|LIDs|)|( (r_amod) dyskinesias_3\NNS|problem|. (r_nsubj) present_7\VBP|NONE (l_dobj) problem_10\NN|.|dyskinesias (l_prep) for_11\IN|major|a (l_pobj) management_16\NN|NONE (l_prep) of_17\IN|the|term (l_pobj) patients_24\NNS|NONE (l_nmod) PD_22\NNP|)|(|disease
D007980_D010302 NONE levodopa_34\NN|NONE (r_compound) therapy_35\NN|NONE (r_pobj) of_33\IN|NONE (r_prep) duration_32\NN|and|to (r_conj) response_29\NN|rate|and|,|symptom|, (r_conj) severity_26\NN|may|in|to|be (r_nsubjpass) involved_38\VBN|the (r_relcl) degree_17\NN|Using|study|.|, (r_dobj) evaluated_15\VBD|NONE (l_advcl) Using_0\VBG|study|.|degree|, (l_prep) with_3\IN|monkeys (l_pobj) types_5\NNS|NONE (l_prep) of_6\IN|different (l_pobj) parkinsonism_10\NN|NONE
D015632_D010302 CID MPTP_7\NNP| (r_npadvmod) induced_9\VBN|NONE (r_amod) parkinsonism_10\NN|NONE
9067481
D005688_D064420 NONE galactosamine_52\NN| (r_npadvmod) induced_54\VBN|and (r_conj) chloroform-_50\JJ|NONE (r_nmod) toxicity_55\NN|carbon|acetaminophen|,
-1_D066126 NONE CS_13\NNP|mg|(|)|i.p.|,|/ (r_nmod) kg_17\NNS|NONE (r_pobj) of_12\IN|a|single (r_prep) dose_11\NN|NONE (r_pobj) with_8\IN|of|h|A (r_prep) pretreatment_2\NN|,|.|in (r_nsubj) resulted_22\VBD|NONE (l_prep) in_23\IN|,|pretreatment|. (l_pobj) protection_25\NN|NONE (l_prep) against_26\IN|significant (l_pobj) effects_29\NNS|NONE (l_prep) of_30\IN|the|hepatotoxic (l_pobj) CHCl3_33\NNP|NONE (l_conj) acetaminophen_35\RB|,|CCl|, (l_conj) against_39\IN|and|galactosamine|and (l_pobj) lethal_41\JJ|NONE (l_conj) effect_47\NN|(|and|the (l_amod) cardiotoxic_45\JJ|)|of
D002251_D056486 CID tetrachloride_35\NN|hepatotoxic|CCl|the|of (r_advmod) effects_32\NNS|NONE (l_amod) hepatotoxic_31\JJ|tetrachloride|CCl|the|of
D002251_D056486 CID CCl4_37\NNP|hepatotoxic|tetrachloride|the|of (r_appos) effects_32\NNS|NONE (l_amod) hepatotoxic_31\JJ|tetrachloride|CCl|the|of
D002251_D056486 CID CCl4_31\NNP|,|,|acetaminophen (r_nmod) CHCl3_33\NNP|NONE (r_pobj) of_30\IN|the|hepatotoxic (r_prep) effects_29\NNS|NONE (l_amod) hepatotoxic_28\JJ|the|of
D002251_D066126 NONE CCl4_31\NNP|,|,|acetaminophen (r_nmod) CHCl3_33\NNP|NONE (l_conj) acetaminophen_35\RB|,|CCl|, (l_conj) against_39\IN|and|galactosamine|and (l_pobj) lethal_41\JJ|NONE (l_conj) effect_47\NN|(|and|the (l_amod) cardiotoxic_45\JJ|)|of
D002725_D066126 NONE CHCl3_33\NNP|NONE (l_conj) acetaminophen_35\RB|,|CCl|, (l_conj) against_39\IN|and|galactosamine|and (l_pobj) lethal_41\JJ|NONE (l_conj) effect_47\NN|(|and|the (l_amod) cardiotoxic_45\JJ|)|of
D005688_D056486 CID galactosamine_37\NN|and|and|against (r_conj) acetaminophen_35\RB|,|CCl|, (r_conj) CHCl3_33\NNP|NONE (r_pobj) of_30\IN|the|hepatotoxic (r_prep) effects_29\NNS|NONE (l_amod) hepatotoxic_28\JJ|the|of
D005688_D056486 CID galactosamine_30\NN|NONE (r_amod) hepatotoxicity_31\NN|NONE
D002251_D064420 NONE tetrachloride-_48\NN|NONE (l_appos) toxicity_55\NN|carbon|acetaminophen|,
C013440_D056486 NONE hemisuccinate_14\NN|stabilizer|of|, (r_conj) rigidifier_9\NN|NONE (r_pobj) as_5\IN|its (r_prep) use_4\NN|NONE (r_pobj) to_2\IN|NONE (r_prep) addition_1\NN|NONE (r_pobj) In_0\IN|been|.|also|protect|has (r_prep) shown_25\VBN|NONE (l_xcomp) protect_27\VB|In|been|.|also|has (l_prep) from_29\IN|rats|to (l_pobj) effects_32\NNS|NONE (l_amod) hepatotoxic_31\JJ|tetrachloride|CCl|the|of
D004317_D064420 NONE adriamycin-_45\JJ|,|, (r_conj) acetaminophen-_43\NN|carbon|,|toxicity (r_nmod) tetrachloride-_48\NN|NONE (l_appos) toxicity_55\NN|carbon|acetaminophen|,
-1_D056486 NONE salt_17\NN|(|tris|CS|) (r_nmod) administration_21\NN|cholesteryl|, (r_conj) hemisuccinate_14\NN|stabilizer|of|, (r_conj) rigidifier_9\NN|NONE (r_pobj) as_5\IN|its (r_prep) use_4\NN|NONE (r_pobj) to_2\IN|NONE (r_prep) addition_1\NN|NONE (r_pobj) In_0\IN|been|.|also|protect|has (r_prep) shown_25\VBN|NONE (l_xcomp) protect_27\VB|In|been|.|also|has (l_prep) from_29\IN|rats|to (l_pobj) effects_32\NNS|NONE (l_amod) hepatotoxic_31\JJ|tetrachloride|CCl|the|of
-1_D056486 NONE CS_19\NNP|(|tris|)|salt (r_nmod) administration_21\NN|cholesteryl|, (r_conj) hemisuccinate_14\NN|stabilizer|of|, (r_conj) rigidifier_9\NN|NONE (r_pobj) as_5\IN|its (r_prep) use_4\NN|NONE (r_pobj) to_2\IN|NONE (r_prep) addition_1\NN|NONE (r_pobj) In_0\IN|been|.|also|protect|has (r_prep) shown_25\VBN|NONE (l_xcomp) protect_27\VB|In|been|.|also|has (l_prep) from_29\IN|rats|to (l_pobj) effects_32\NNS|NONE (l_amod) hepatotoxic_31\JJ|tetrachloride|CCl|the|of
-1_D056486 NONE CS_13\NNP|mg|(|)|i.p.|,|/ (r_nmod) kg_17\NNS|NONE (r_pobj) of_12\IN|a|single (r_prep) dose_11\NN|NONE (r_pobj) with_8\IN|of|h|A (r_prep) pretreatment_2\NN|,|.|in (r_nsubj) resulted_22\VBD|NONE (l_prep) in_23\IN|,|pretreatment|. (l_pobj) protection_25\NN|NONE (l_prep) against_26\IN|significant (l_pobj) effects_29\NNS|NONE (l_amod) hepatotoxic_28\JJ|the|of
-1_D056486 NONE CS_3\NNP|NONE (r_compound) protection_4\NN|NONE (r_pobj) of_2\IN|The (r_prep) mechanism_1\NN|not|does|)|.|be (r_nsubj) appear_7\VB|NONE (l_xcomp) be_9\VB|not|does|)|mechanism|. (l_acomp) dependent_10\JJ|to (l_prep) on_11\IN|NONE (l_pobj) inhibition_13\NN|NONE (l_prep) to_17\IN|the|of (l_pobj) in_23\IN|NONE (l_pobj) light_24\NN|(|intermediate (l_prep) of_25\IN|NONE (l_pobj) protection_27\NN|NONE (l_acl) observed_28\VBN|the (l_prep) against_29\IN|NONE (l_pobj) hepatotoxicity_31\NN|NONE
D004317_D056486 NONE adriamycin_49\NNS|NONE (r_amod) administration_50\NN|NONE (r_pobj) of_48\IN|cardiotoxic|) (r_prep) effect_47\NN|(|and|the (r_conj) lethal_41\JJ|NONE (r_pobj) against_39\IN|and|galactosamine|and (r_conj) acetaminophen_35\RB|,|CCl|, (r_conj) CHCl3_33\NNP|NONE (r_pobj) of_30\IN|the|hepatotoxic (r_prep) effects_29\NNS|NONE (l_amod) hepatotoxic_28\JJ|the|of
D000082_D064420 NONE acetaminophen-_43\NN|carbon|,|toxicity (r_nmod) tetrachloride-_48\NN|NONE (l_appos) toxicity_55\NN|carbon|acetaminophen|,
D002725_D064420 NONE chloroform-_50\JJ|NONE (r_nmod) toxicity_55\NN|carbon|acetaminophen|,
D002725_D056486 CID CHCl3_33\NNP|NONE (r_pobj) of_30\IN|the|hepatotoxic (r_prep) effects_29\NNS|NONE (l_amod) hepatotoxic_28\JJ|the|of
C103872_D064420 NONE acid_35\NN|, (l_conj) salt_38\NN|cholesteryloxybutyric|, (l_prep) against_42\IN|tris|CSE (l_pobj) tetrachloride-_48\NN|NONE (l_appos) toxicity_55\NN|carbon|acetaminophen|,
D000082_D066126 NONE acetaminophen_35\RB|,|CCl|, (l_conj) against_39\IN|and|galactosamine|and (l_pobj) lethal_41\JJ|NONE (l_conj) effect_47\NN|(|and|the (l_amod) cardiotoxic_45\JJ|)|of
-1_D064420 NONE CS_8\NNP|NONE (r_compound) cytoprotection_9\NN|NONE (r_pobj) of_7\IN|the (r_prep) mechanism_6\NN|NONE (r_pobj) of_4\IN|our (r_prep) understanding_3\NN|To (r_dobj) further_1\VB|,|and|we|mice|in|. (r_advmod) examined_12\VBD|NONE (l_conj) mice_16\NNS|,|and|we|further|in|. (l_dobj) abilities_19\NNS|NONE (l_prep) of_20\IN|protective|the (l_pobj) CS_21\NNP|NONE (l_conj) form_28\NN|and (l_prep) of_29\IN|hydrolyzable|ether|the (l_pobj) CS_30\NNP|NONE (l_conj) acid_35\NN|, (l_conj) salt_38\NN|cholesteryloxybutyric|, (l_prep) against_42\IN|tris|CSE (l_pobj) tetrachloride-_48\NN|NONE (l_appos) toxicity_55\NN|carbon|acetaminophen|,
-1_D064420 NONE CS_21\NNP|NONE (l_conj) form_28\NN|and (l_prep) of_29\IN|hydrolyzable|ether|the (l_pobj) CS_30\NNP|NONE (l_conj) acid_35\NN|, (l_conj) salt_38\NN|cholesteryloxybutyric|, (l_prep) against_42\IN|tris|CSE (l_pobj) tetrachloride-_48\NN|NONE (l_appos) toxicity_55\NN|carbon|acetaminophen|,
-1_D064420 NONE CS_30\NNP|NONE (l_conj) acid_35\NN|, (l_conj) salt_38\NN|cholesteryloxybutyric|, (l_prep) against_42\IN|tris|CSE (l_pobj) tetrachloride-_48\NN|NONE (l_appos) toxicity_55\NN|carbon|acetaminophen|,
-1_D064420 NONE salt_38\NN|cholesteryloxybutyric|, (l_prep) against_42\IN|tris|CSE (l_pobj) tetrachloride-_48\NN|NONE (l_appos) toxicity_55\NN|carbon|acetaminophen|,
-1_D064420 NONE CSE_40\NNP|tris|against (r_appos) salt_38\NN|cholesteryloxybutyric|, (l_prep) against_42\IN|tris|CSE (l_pobj) tetrachloride-_48\NN|NONE (l_appos) toxicity_55\NN|carbon|acetaminophen|,
D004317_D066126 CID adriamycin_49\NNS|NONE (r_amod) administration_50\NN|NONE (r_pobj) of_48\IN|cardiotoxic|) (r_prep) effect_47\NN|(|and|the (l_amod) cardiotoxic_45\JJ|)|of
D005688_D066126 NONE galactosamine_37\NN|and|and|against (r_conj) acetaminophen_35\RB|,|CCl|, (l_conj) against_39\IN|and|galactosamine|and (l_pobj) lethal_41\JJ|NONE (l_conj) effect_47\NN|(|and|the (l_amod) cardiotoxic_45\JJ|)|of
D000082_D056486 CID acetaminophen_35\RB|,|CCl|, (r_conj) CHCl3_33\NNP|NONE (r_pobj) of_30\IN|the|hepatotoxic (r_prep) effects_29\NNS|NONE (l_amod) hepatotoxic_28\JJ|the|of
19058010
D010936_D009203 NONE tea_3\NN|in (r_nmod) combination_7\NN|NONE (r_pobj) of_1\IN|NONE (r_prep) Effect_0\NN|.|infarction (r_nsubj) induced_10\VBN|NONE (l_dobj) infarction_12\NN|Effect|.
D010936_D009203 NONE tea_12\NN|NONE (r_pobj) of_10\IN|,|bound|on|the|weight|combined (r_prep) effects_9\NNS|to (r_dobj) investigate_6\VB|study|ISO)induced|.|was (r_xcomp) aimed_4\VBN|NONE (l_parataxis) ISO)-induced_39\VBN|study|.|investigate|was (l_dobj) infarction_41\NN|(
D010936_D009203 NONE tea_9\NN|NONE (r_pobj) of_7\IN|protective|the|synergistic|during (r_prep) effect_6\NN|findings|induced|. (r_dobj) indicate_2\VBP|NONE (l_ccomp) induced_15\VBN|findings|effect|. (l_dobj) infarction_17\NN|NONE
D007545_D009203 CID isoproterenol_9\JJ|NONE (r_pobj) in_8\IN|tea (r_prep) combination_7\NN|NONE (r_pobj) of_1\IN|NONE (r_prep) Effect_0\NN|.|infarction (r_nsubj) induced_10\VBN|NONE (l_dobj) infarction_12\NN|Effect|.
D007545_D009203 CID isoproterenol_37\NN|NONE (r_pobj) in_36\IN|ATPases (r_prep) bound_34\VBN|,|on|the|weight|combined|of (r_acl) effects_9\NNS|to (r_dobj) investigate_6\VB|study|ISO)induced|.|was (r_xcomp) aimed_4\VBN|NONE (l_parataxis) ISO)-induced_39\VBN|study|.|investigate|was (l_dobj) infarction_41\NN|(
D007545_D009203 CID ISO)-induced_39\VBN|study|.|investigate|was (l_dobj) infarction_41\NN|(
D007545_D009203 CID ISO_14\NN|NONE (r_pobj) during_13\IN|protective|the|of|synergistic (r_prep) effect_6\NN|findings|induced|. (r_dobj) indicate_2\VBP|NONE (l_ccomp) induced_15\VBN|findings|effect|. (l_dobj) infarction_17\NN|NONE
D014810_D009203 NONE E_6\NN|green|and (r_conj) tea_3\NN|in (r_nmod) combination_7\NN|NONE (r_pobj) of_1\IN|NONE (r_prep) Effect_0\NN|.|infarction (r_nsubj) induced_10\VBN|NONE (l_dobj) infarction_12\NN|Effect|.
D014810_D009203 NONE E_15\NN|and|green (r_conj) tea_12\NN|NONE (r_pobj) of_10\IN|,|bound|on|the|weight|combined (r_prep) effects_9\NNS|to (r_dobj) investigate_6\VB|study|ISO)induced|.|was (r_xcomp) aimed_4\VBN|NONE (l_parataxis) ISO)-induced_39\VBN|study|.|investigate|was (l_dobj) infarction_41\NN|(
D014810_D009203 NONE E_12\NN|and|green (r_conj) tea_9\NN|NONE (r_pobj) of_7\IN|protective|the|synergistic|during (r_prep) effect_6\NN|findings|induced|. (r_dobj) indicate_2\VBP|NONE (l_ccomp) induced_15\VBN|findings|effect|. (l_dobj) infarction_17\NN|NONE
6674249
D015119_D009336 CID acid_12\NN|)|( (r_nmod) EACA_14\NNP|a|short|in|aminocaproic (r_nmod) treatment_16\NN|to (r_pobj) due_5\IN|myopathy (r_prep) necrotizing_3\VBG|NONE (l_advmod) myopathy_4\NNS|due
D015119_D009336 CID EACA_14\NNP|a|short|in|aminocaproic (r_nmod) treatment_16\NN|to (r_pobj) due_5\IN|myopathy (r_prep) necrotizing_3\VBG|NONE (l_advmod) myopathy_4\NNS|due
D015119_D013345 NONE acid_12\NN|)|( (r_nmod) EACA_14\NNP|a|short|in|aminocaproic (r_nmod) treatment_16\NN|to (l_prep) in_17\IN|a|short|EACA|aminocaproic (l_pobj) patient_23\NN|NONE (l_prep) with_24\IN|a|old (l_pobj) haemorrhage_26\NN|NONE
D015119_D013345 NONE acid_12\NN|)|( (r_nmod) EACA_14\NNP|a|short|in|aminocaproic (r_nmod) treatment_16\NN|to (r_pobj) due_5\IN|myopathy (r_prep) necrotizing_3\VBG|NONE (r_pcomp) of_2\IN|A (r_prep) case_1\NN|.|is|)|( (r_nsubjpass) described_31\VBN|NONE (l_punct) (_27\-LRB-|.|case|is|) (l_preconj) SAH_28\NNP|NONE
D015119_D013345 NONE EACA_14\NNP|a|short|in|aminocaproic (r_nmod) treatment_16\NN|to (l_prep) in_17\IN|a|short|EACA|aminocaproic (l_pobj) patient_23\NN|NONE (l_prep) with_24\IN|a|old (l_pobj) haemorrhage_26\NN|NONE
D015119_D013345 NONE EACA_14\NNP|a|short|in|aminocaproic (r_nmod) treatment_16\NN|to (r_pobj) due_5\IN|myopathy (r_prep) necrotizing_3\VBG|NONE (r_pcomp) of_2\IN|A (r_prep) case_1\NN|.|is|)|( (r_nsubjpass) described_31\VBN|NONE (l_punct) (_27\-LRB-|.|case|is|) (l_preconj) SAH_28\NNP|NONE
D015119_D009135 CID acid_5\NN|Why|myopathy|may|in|? (r_nsubj) induce_9\VBP|NONE (l_dobj) myopathy_10\NNS|Why|acid|may|in|?
D015119_D009135 CID EACA_7\NNP|aminocaproic (r_appos) acid_5\NN|Why|myopathy|may|in|? (r_nsubj) induce_9\VBP|NONE (l_dobj) myopathy_10\NNS|Why|acid|may|in|?
D015119_D009135 CID acid_12\NN|)|( (r_nmod) EACA_14\NNP|a|short|in|aminocaproic (r_nmod) treatment_16\NN|to (r_pobj) due_5\IN|myopathy (r_prep) necrotizing_3\VBG|NONE (l_advmod) myopathy_4\NNS|due
D015119_D009135 CID EACA_14\NNP|a|short|in|aminocaproic (r_nmod) treatment_16\NN|to (r_pobj) due_5\IN|myopathy (r_prep) necrotizing_3\VBG|NONE (l_advmod) myopathy_4\NNS|due
15325671
D018943_D003920 NONE anthracyclines_70\NNS|NONE (r_pobj) of_69\IN|prior|and|irradiation|, (r_prep) use_68\NN|diabetes|, (r_conj) mellitus_65\NN|,
D018943_D001943 NONE anthracyclines_70\NNS|NONE (r_pobj) of_69\IN|prior|and|irradiation|, (r_prep) use_68\NN|diabetes|, (r_conj) mellitus_65\NN|, (r_conj) smoking_62\NN|prior|,|cardiac (r_conj) history_60\NN|of|, (r_appos) presence_46\NN|following|the|:|pretreatment (r_appos) characteristics_44\NNS|and|responsive|metastatic|breast|receiving (r_conj) cancer_12\NN|NONE
D018943_D006333 NONE anthracyclines_70\NNS|NONE (r_pobj) of_69\IN|prior|and|irradiation|, (r_prep) use_68\NN|diabetes|, (r_conj) mellitus_65\NN|, (r_conj) smoking_62\NN|prior|,|cardiac (r_conj) history_60\NN|of|, (r_appos) presence_46\NN|following|the|:|pretreatment (r_appos) characteristics_44\NNS|and|responsive|metastatic|breast|receiving (r_conj) cancer_12\NN|NONE (l_acl) receiving_13\VBG|and|responsive|metastatic|characteristics|breast (l_prep) as_17\IN|cyclophosphamide (l_pobj) part_18\NN|NONE (l_prep) of_19\IN|NONE (l_pobj) regimen_26\NN|NONE (l_acl) assess_28\VB|triple|dose|a|sequential (l_dobj) association_29\NN|to (l_prep) between_30\IN|NONE (l_pobj) presence_31\NN|NONE (l_prep) of_32\IN|NONE (l_pobj) failure_36\NN|NONE
D018943_D006333 NONE anthracyclines_70\NNS|NONE (r_pobj) of_69\IN|prior|and|irradiation|, (r_prep) use_68\NN|diabetes|, (r_conj) mellitus_65\NN|, (r_conj) smoking_62\NN|prior|,|cardiac (r_conj) history_60\NN|of|, (r_appos) presence_46\NN|following|the|:|pretreatment (r_appos) characteristics_44\NNS|and|responsive|metastatic|breast|receiving (r_conj) cancer_12\NN|NONE (l_acl) receiving_13\VBG|and|responsive|metastatic|characteristics|breast (l_prep) as_17\IN|cyclophosphamide (l_pobj) part_18\NN|NONE (l_prep) of_19\IN|NONE (l_pobj) regimen_26\NN|NONE (l_acl) assess_28\VB|triple|dose|a|sequential (l_dobj) association_29\NN|to (l_prep) between_30\IN|NONE (l_pobj) presence_31\NN|NONE (l_prep) of_32\IN|NONE (l_pobj) failure_36\NN|NONE (l_appos) CHF_38\NNP|heart|peritransplant
D003520_D066126 NONE cyclophosphamide_9\NN| (r_npadvmod) based_11\VBN|dose|for (r_amod) chemotherapy_12\NN|NONE (r_pobj) with_5\IN|NONE (r_prep) association_4\NN|NONE (r_pobj) in_3\IN|.|toxicity (r_prep) observed_2\VBD|NONE (l_nsubj) toxicity_1\NN|in|.
D003520_D066126 NONE cyclophosphamide_3\NN| (r_npadvmod) related_5\VBN|%|cardiac|transient|(|) (r_amod) toxicity_7\NN|NONE
D017239_D001943 NONE paclitaxel_2\NN|. (l_conj) melphalan_4\NN|combined|, (l_conj) cyclophosphamide_9\NN|and (l_conj) thiotepa_11\NNS|dose|, (l_conj) carboplatin_14\VB|and|, (l_dobj) regimen_22\NN|in (l_prep) for_23\IN|triple|dose|a|sequential (l_pobj) patients_24\NNS|NONE (l_prep) with_25\IN|NONE (l_pobj) cancer_28\NN|NONE
D003520_D003920 NONE cyclophosphamide_16\NN|as (r_dobj) receiving_13\VBG|and|responsive|metastatic|characteristics|breast (r_acl) cancer_12\NN|NONE (l_conj) characteristics_44\NNS|and|responsive|metastatic|breast|receiving (l_appos) presence_46\NN|following|the|:|pretreatment (l_appos) history_60\NN|of|, (l_conj) smoking_62\NN|prior|,|cardiac (l_conj) mellitus_65\NN|,
D018943_D006973 NONE anthracyclines_70\NNS|NONE (r_pobj) of_69\IN|prior|and|irradiation|, (r_prep) use_68\NN|diabetes|, (r_conj) mellitus_65\NN|, (r_conj) smoking_62\NN|prior|,|cardiac (r_conj) history_60\NN|of|, (r_appos) presence_46\NN|following|the|:|pretreatment (l_prep) of_47\IN|,|history (l_pobj) electrocardiogram_48\NN|NONE (l_appos) abnormalities_52\NNS|(|EKG (l_appos) hypertension_56\NN|age|,
D003520_D001943 NONE cyclophosphamide_9\NN| (r_npadvmod) based_11\VBN|dose|for (r_amod) chemotherapy_12\NN|NONE (l_prep) for_13\IN|based|dose (l_pobj) cancer_16\NN|NONE
D003520_D001943 NONE cyclophosphamide_9\NN|and (l_conj) thiotepa_11\NNS|dose|, (l_conj) carboplatin_14\VB|and|, (l_dobj) regimen_22\NN|in (l_prep) for_23\IN|triple|dose|a|sequential (l_pobj) patients_24\NNS|NONE (l_prep) with_25\IN|NONE (l_pobj) cancer_28\NN|NONE
D003520_D001943 NONE cyclophosphamide_16\NN|as (r_dobj) receiving_13\VBG|and|responsive|metastatic|characteristics|breast (r_acl) cancer_12\NN|NONE
D003520_D006973 NONE cyclophosphamide_16\NN|as (r_dobj) receiving_13\VBG|and|responsive|metastatic|characteristics|breast (r_acl) cancer_12\NN|NONE (l_conj) characteristics_44\NNS|and|responsive|metastatic|breast|receiving (l_appos) presence_46\NN|following|the|:|pretreatment (l_prep) of_47\IN|,|history (l_pobj) electrocardiogram_48\NN|NONE (l_appos) abnormalities_52\NNS|(|EKG (l_appos) hypertension_56\NN|age|,
D008558_D001943 NONE melphalan_4\NN|combined|, (l_conj) cyclophosphamide_9\NN|and (l_conj) thiotepa_11\NNS|dose|, (l_conj) carboplatin_14\VB|and|, (l_dobj) regimen_22\NN|in (l_prep) for_23\IN|triple|dose|a|sequential (l_pobj) patients_24\NNS|NONE (l_prep) with_25\IN|NONE (l_pobj) cancer_28\NN|NONE
D003520_D006333 CID cyclophosphamide_16\NN|as (r_dobj) receiving_13\VBG|and|responsive|metastatic|characteristics|breast (l_prep) as_17\IN|cyclophosphamide (l_pobj) part_18\NN|NONE (l_prep) of_19\IN|NONE (l_pobj) regimen_26\NN|NONE (l_acl) assess_28\VB|triple|dose|a|sequential (l_dobj) association_29\NN|to (l_prep) between_30\IN|NONE (l_pobj) presence_31\NN|NONE (l_prep) of_32\IN|NONE (l_pobj) failure_36\NN|NONE
D003520_D006333 CID cyclophosphamide_16\NN|as (r_dobj) receiving_13\VBG|and|responsive|metastatic|characteristics|breast (l_prep) as_17\IN|cyclophosphamide (l_pobj) part_18\NN|NONE (l_prep) of_19\IN|NONE (l_pobj) regimen_26\NN|NONE (l_acl) assess_28\VB|triple|dose|a|sequential (l_dobj) association_29\NN|to (l_prep) between_30\IN|NONE (l_pobj) presence_31\NN|NONE (l_prep) of_32\IN|NONE (l_pobj) failure_36\NN|NONE (l_appos) CHF_38\NNP|heart|peritransplant
D003520_D006333 CID cyclophosphamide_16\NN|with (r_dobj) following_14\VBG|Six|.|grade (r_prep) developed_8\VBD|NONE (l_dobj) grade_11\NN|Six|following|. (l_appos) CHF_13\NNP|reversible
D003520_D006333 CID cyclophosphamide_5\NN|NONE (r_pobj) during_3\IN|EKG (r_prep) monitoring_2\NN|development|did|.|not (r_nsubj) predict_8\VB|NONE (l_dobj) development_10\NN|monitoring|did|.|not (l_compound) CHF_9\NNP|NONE
D013852_D001943 NONE thiotepa_11\NNS|dose|, (l_conj) carboplatin_14\VB|and|, (l_dobj) regimen_22\NN|in (l_prep) for_23\IN|triple|dose|a|sequential (l_pobj) patients_24\NNS|NONE (l_prep) with_25\IN|NONE (l_pobj) cancer_28\NN|NONE
D016190_D001943 NONE carboplatin_14\VB|and|, (l_dobj) regimen_22\NN|in (l_prep) for_23\IN|triple|dose|a|sequential (l_pobj) patients_24\NNS|NONE (l_prep) with_25\IN|NONE (l_pobj) cancer_28\NN|NONE
2894766
D012460_D015212 NONE sulfasalazine_3\NN|treat|who (r_dobj) use_2\VBP|NONE (l_xcomp) treat_5\VB|who|sulfasalazine (l_dobj) patients_6\NNS|to (l_prep) with_7\IN|NONE (l_pobj) disease_10\NN|NONE
D012460_D015212 NONE sulfasalazine_18\NN| (r_npadvmod) induced_20\VBN|lupus (r_amod) syndrome_22\NN|NONE (r_pobj) of_17\IN|the (r_prep) signs_16\NNS|NONE (r_pobj) of_14\IN|NONE (r_prep) aware_13\JJ|Physicians|should|. (r_acomp) be_12\VB|NONE (l_nsubj) Physicians_0\NNS|aware|should|. (l_relcl) use_2\VBP|NONE (l_xcomp) treat_5\VB|who|sulfasalazine (l_dobj) patients_6\NNS|to (l_prep) with_7\IN|NONE (l_pobj) disease_10\NN|NONE
D012460_D011014 CID sulfasalazine_29\NN|term (r_compound) therapy_30\NN|who|was|for (r_dobj) receiving_25\VBG|,|old|a (r_relcl) man_21\NN|NONE (r_pobj) in_16\IN|NONE (r_prep) developed_15\VBN|positive (r_acl) autoantibodies_14\NNS|of|,|echocardiographic|and (r_conj) evidence_7\NN|,|pleural|.|bilateral|Pneumonitis|, (r_appos) effusions_4\NNS|NONE (l_dep) Pneumonitis_0\NNP|,|pleural|.|evidence|bilateral|,
D012460_D002305 CID sulfasalazine_29\NN|term (r_compound) therapy_30\NN|who|was|for (r_dobj) receiving_25\VBG|,|old|a (r_relcl) man_21\NN|NONE (r_pobj) in_16\IN|NONE (r_prep) developed_15\VBN|positive (r_acl) autoantibodies_14\NNS|of|,|echocardiographic|and (r_conj) evidence_7\NN|,|pleural|.|bilateral|Pneumonitis|, (l_prep) of_8\IN|autoantibodies|,|echocardiographic|and (l_pobj) tamponade_10\NN|NONE
D012460_D010996 CID sulfasalazine_29\NN|term (r_compound) therapy_30\NN|who|was|for (r_dobj) receiving_25\VBG|,|old|a (r_relcl) man_21\NN|NONE (r_pobj) in_16\IN|NONE (r_prep) developed_15\VBN|positive (r_acl) autoantibodies_14\NNS|of|,|echocardiographic|and (r_conj) evidence_7\NN|,|pleural|.|bilateral|Pneumonitis|, (r_appos) effusions_4\NNS|NONE
D012460_D012700 NONE sulfasalazine_7\RB| (r_npadvmod) induced_9\VBN|,|manifested (r_amod) lupus_10\NN|that|patient (l_relcl) manifested_13\VBD|induced|, (l_prep) with_14\IN|which|in (l_pobj) serositis_15\NN|NONE
D012460_D003093 NONE sulfasalazine_29\NN|term (r_compound) therapy_30\NN|who|was|for (r_dobj) receiving_25\VBG|,|old|a (l_prep) for_31\IN|who|therapy|was (l_pobj) colitis_34\NN|NONE
D012460_D008180 CID Sulfasalazine_0\NNP| (r_npadvmod) induced_2\VBN|.|lupus (r_amod) erythematosus_4\NN|NONE
D012460_D008180 CID sulfasalazine_7\RB| (r_npadvmod) induced_9\VBN|,|manifested (r_amod) lupus_10\NN|that|patient
D012460_D008180 CID sulfasalazine_3\NN|treat|who (r_dobj) use_2\VBP|NONE (r_relcl) Physicians_0\NNS|aware|should|. (r_nsubj) be_12\VB|NONE (l_acomp) aware_13\JJ|Physicians|should|. (l_prep) of_14\IN|NONE (l_pobj) signs_16\NNS|NONE (l_prep) of_17\IN|the (l_pobj) syndrome_22\NN|NONE
D012460_D008180 CID sulfasalazine_18\NN| (r_npadvmod) induced_20\VBN|lupus (r_amod) syndrome_22\NN|NONE
18081909
C026098_D012640 NONE LEV_15\NNP|NONE (r_pobj) with_14\IN|added|.|was|)|man (r_prep) treated_13\VBN|NONE (l_nsubjpass) man_4\NN|with|added|.|was|) (l_acl) suffering_5\VBG|old|A (l_prep) with_9\IN|from (l_pobj) seizures_11\NNS|NONE
C026098_D012640 NONE LEV_3\NNP|NONE (r_pobj) of_2\IN|NONE (r_prep) discontinuation_1\NN|improved (r_pobj) Following_0\VBG|NONE (l_preconj) improved_9\VBN|discontinuation (l_conj) decreased_13\VBD|and (l_nsubj) frequency_12\NN|. (l_compound) seizure_11\NN|NONE
C026098_C562694 NONE LEV_15\NNP|NONE (r_pobj) with_14\IN|added|.|was|)|man (r_prep) treated_13\VBN|NONE (l_nsubjpass) man_4\NN|with|added|.|was|) (l_acl) suffering_5\VBG|old|A (l_prep) from_6\IN|with (l_pobj) epilepsy_8\NN|NONE
D014635_C562694 NONE valproate_22\VB|NONE (r_xcomp) added_20\VBN|with|.|was|)|man (r_conj) treated_13\VBN|NONE (l_nsubjpass) man_4\NN|with|added|.|was|) (l_acl) suffering_5\VBG|old|A (l_prep) from_6\IN|with (l_pobj) epilepsy_8\NN|NONE
D014635_C562694 NONE VPA_24\NNP|)|to|mg|(|)|( (r_dobj) valproate_22\VB|NONE (r_xcomp) added_20\VBN|with|.|was|)|man (r_conj) treated_13\VBN|NONE (l_nsubjpass) man_4\NN|with|added|.|was|) (l_acl) suffering_5\VBG|old|A (l_prep) from_6\IN|with (l_pobj) epilepsy_8\NN|NONE
C026098_D001927 CID levetiracetam_3\NN|NONE (r_pcomp) by_2\IN|Encephalopathy|.|added (r_prep) induced_1\VBN|NONE (l_nsubj) Encephalopathy_0\JJ|by|.|added
C026098_D001927 CID levetiracetam_7\FW|(|LEV)induced|a (r_amod) encephalopathy_10\JJ|NONE
C026098_D001927 CID LEV)-induced_9\VBN|levetiracetam|(|a (r_amod) encephalopathy_10\JJ|NONE
D014635_D012640 NONE valproate_22\VB|NONE (r_xcomp) added_20\VBN|with|.|was|)|man (r_conj) treated_13\VBN|NONE (l_nsubjpass) man_4\NN|with|added|.|was|) (l_acl) suffering_5\VBG|old|A (l_prep) with_9\IN|from (l_pobj) seizures_11\NNS|NONE
D014635_D012640 NONE VPA_24\NNP|)|to|mg|(|)|( (r_dobj) valproate_22\VB|NONE (r_xcomp) added_20\VBN|with|.|was|)|man (r_conj) treated_13\VBN|NONE (l_nsubjpass) man_4\NN|with|added|.|was|) (l_acl) suffering_5\VBG|old|A (l_prep) with_9\IN|from (l_pobj) seizures_11\NNS|NONE
D014635_D001927 CID valproate_6\VB|NONE (r_xcomp) added_4\VBN|by|Encephalopathy|. (r_conj) induced_1\VBN|NONE (l_nsubj) Encephalopathy_0\JJ|by|.|added
11583940
C063008_D007674 NONE mofetil_7\NNS|.|,|have|agents (r_dobj) mycophenolate_6\VB|NONE (l_dep) have_14\VBP|mofetil|.|,|agents (l_dobj) nephrotoxicity_16\NN|NONE
D020123_D007674 NONE sirolimus_9\NN|rapamycin|and (r_conj) mofetil_7\NNS|.|,|have|agents (r_dobj) mycophenolate_6\VB|NONE (l_dep) have_14\VBP|mofetil|.|,|agents (l_dobj) nephrotoxicity_16\NN|NONE
D020123_D007674 NONE rapamycin_11\NNS|sirolimus|and (r_appos) mofetil_7\NNS|.|,|have|agents (r_dobj) mycophenolate_6\VB|NONE (l_dep) have_14\VBP|mofetil|.|,|agents (l_dobj) nephrotoxicity_16\NN|NONE
2343592
C044650_D007674 NONE cilastatin_32\NN|NONE (r_pobj) of_29\IN|maximum (r_prep) doses_28\NNS|while (r_dobj) receiving_26\VBG|seizures|evidence|. (r_advcl) developed_23\VBN|patients|trauma|and (l_nsubj) evidence_19\NN|seizures|receiving|. (l_prep) of_20\IN|no (l_pobj) disease_22\NN|NONE
C044650_D012640 CID cilastatin_32\NN|NONE (r_pobj) of_29\IN|maximum (r_prep) doses_28\NNS|while (r_dobj) receiving_26\VBG|seizures|evidence|. (r_advcl) developed_23\VBN|patients|trauma|and (l_dobj) seizures_24\NNS|evidence|receiving|.
D010672_D012640 NONE phenytoin_8\NN|NONE (r_pobj) of_7\IN|therapeutic (r_prep) doses_6\NNS|NONE (r_pobj) with_4\IN|seizures|.|were (r_prep) controlled_3\VBN|NONE (l_nsubjpass) seizures_1\NNS|.|were|with
C044650_D020521 NONE cilastatin_32\NN|NONE (r_pobj) of_29\IN|maximum (r_prep) doses_28\NNS|while (r_dobj) receiving_26\VBG|seizures|evidence|. (r_advcl) developed_23\VBN|patients|trauma|and (r_conj) head_15\NN|NONE (l_nsubj) patients_2\NNS|developed|trauma|and (l_prep) with_3\IN|Two|elderly (l_pobj) history_5\NN|NONE (l_prep) of_6\IN|a (l_pobj) accident_10\NN|NONE
C044650_D020521 NONE cilastatin_32\NN|NONE (r_pobj) of_29\IN|maximum (r_prep) doses_28\NNS|while (r_dobj) receiving_26\VBG|seizures|evidence|. (r_advcl) developed_23\VBN|patients|trauma|and (r_conj) head_15\NN|NONE (l_nsubj) patients_2\NNS|developed|trauma|and (l_prep) with_3\IN|Two|elderly (l_pobj) history_5\NN|NONE (l_prep) of_6\IN|a (l_pobj) accident_10\NN|NONE (l_appos) CVA_12\NNP|(|vascular|either|cerebral|or
D015378_D012640 NONE imipenem_3\NN|factors|: (r_compound) therapy_4\NN|NONE (r_pobj) with_2\IN|.|Seizure (r_prep) activity_1\NN|NONE (l_compound) Seizure_0\NN|with|.
C044650_D006259 NONE cilastatin_32\NN|NONE (r_pobj) of_29\IN|maximum (r_prep) doses_28\NNS|while (r_dobj) receiving_26\VBG|seizures|evidence|. (r_advcl) developed_23\VBN|patients|trauma|and (r_conj) head_15\NN|NONE (l_dobj) trauma_16\NN|patients|developed|and
D047090_D012640 NONE lactam_10\NN|other (r_compound) antibiotics_11\NNS|NONE (r_pobj) of_6\IN|maximum (r_prep) doses_5\NNS|without|patients|had|. (r_dobj) received_3\VBN|NONE (l_prep) without_12\IN|doses|patients|had|. (l_pobj) evidence_13\NN|NONE (l_prep) of_14\IN|NONE (l_pobj) activity_16\NN|NONE (l_compound) seizure_15\NN|NONE
15075188
D011692_D009404 CID aminonucleoside_11\RB| (r_advmod) induced_13\VBN|in|puromycin|nephrotic (r_amod) syndrome_15\NN|NONE
D011692_D009404 CID PAN_38\NNP| (r_npadvmod) induced_40\VBN|nephrotic (r_amod) syndrome_42\NN|NONE
D012964_D011507 NONE sodium_14\NN|,|ascites|and (r_compound) excretion_15\NN|,|induced|. (r_dobj) decreased_12\VBD|NONE (l_advcl) induced_6\VBD|,|excretion|. (l_dobj) proteinuria_8\NN|After|treatment|,
D011692_D001201 CID PAN_4\NNP|NONE (r_compound) treatment_5\NN|After|proteinuria|, (r_nsubj) induced_6\VBD|,|excretion|. (r_advcl) decreased_12\VBD|NONE (l_dobj) excretion_15\NN|,|induced|. (l_conj) ascites_19\NNS|sodium|,|and
D012964_D009404 NONE sodium_6\NN|and|edema (r_compound) retention_7\NN|NONE (r_pobj) by_5\IN|.|is|syndrome|often (r_agent) accompanied_4\VBN|NONE (l_nsubjpass) syndrome_1\NN|.|is|by|often
D012964_D009404 NONE sodium_34\NN|associated|the (r_compound) retention_35\NN|NONE (l_acl) associated_36\VBN|the|sodium (l_prep) with_37\IN|NONE (l_pobj) syndrome_42\NN|NONE
D012964_D004487 NONE sodium_6\NN|and|edema (r_compound) retention_7\NN|NONE (l_conj) edema_10\NN|and|sodium
D011692_D034141 CID PAN_4\NNP|NONE (r_compound) treatment_5\NN|After|proteinuria|, (r_nsubj) induced_6\VBD|,|excretion|. (l_dobj) proteinuria_8\NN|After|treatment|, (l_appos) hypoalbuminemia_10\NN|significant|,
D012964_D001201 NONE sodium_14\NN|,|ascites|and (r_compound) excretion_15\NN|,|induced|. (l_conj) ascites_19\NNS|sodium|,|and
D011692_D011507 CID PAN_4\NNP|NONE (r_compound) treatment_5\NN|After|proteinuria|, (r_nsubj) induced_6\VBD|,|excretion|. (l_dobj) proteinuria_8\NN|After|treatment|,
D012964_D034141 NONE sodium_14\NN|,|ascites|and (r_compound) excretion_15\NN|,|induced|. (r_dobj) decreased_12\VBD|NONE (l_advcl) induced_6\VBD|,|excretion|. (l_dobj) proteinuria_8\NN|After|treatment|, (l_appos) hypoalbuminemia_10\NN|significant|,
7651879
D005442_D012131 NONE Flumazenil_0\NNP|antagonist|. (r_nsubj) is_1\VBZ|NONE (l_attr) antagonist_5\NN|Flumazenil|. (l_acl) used_6\VBD|a|benzodiazepine|receptor (l_xcomp) reverse_8\VB|NONE (l_dobj) sedation_9\NN|to (l_conj) depression_12\NN|induced|and
D005442_D012640 CID flumazenil_2\JJ|in (r_compound) administration_3\NN|NONE (r_pobj) after_1\IN|. (r_prep) Seizure_0\NN|NONE
D005442_D012640 CID flumazenil_19\JJ|NONE (r_pobj) of_18\IN|the (r_prep) administration_17\NN|NONE (r_pobj) following_15\VBG|a|pediatric (r_acl) patient_14\NN|NONE (r_pobj) in_11\IN|a|generalized|clonic (r_prep) seizure_10\NN|NONE
D001569_D012131 NONE benzodiazepine_3\JJ|a|receptor|used (r_amod) antagonist_5\NN|Flumazenil|. (l_acl) used_6\VBD|a|benzodiazepine|receptor (l_xcomp) reverse_8\VB|NONE (l_dobj) sedation_9\NN|to (l_conj) depression_12\NN|induced|and
D001569_D012131 NONE benzodiazepines_15\NNS|NONE (r_pobj) by_14\IN|NONE (r_agent) induced_13\VBN|and|depression (r_acl) sedation_9\NN|to (l_conj) depression_12\NN|induced|and
2819587
2273650
D009020_D000647 NONE morphine_9\NN|NONE (r_pobj) by_8\IN|facilitated|given|were|,|and|Amnesia (r_agent) reversed_7\VBN|NONE (l_nsubjpass) Amnesia_0\NNP|facilitated|given|were|,|and|by
D009020_D000647 NONE morphine_27\NN|retrieval|.|also (r_nsubj) facilitated_29\VBD|given|were|,|and|by|Amnesia (r_conj) reversed_7\VBN|NONE (l_nsubjpass) Amnesia_0\NNP|facilitated|given|were|,|and|by
D009270_D000647 NONE naloxone_37\NN|during (r_dobj) administered_36\VBN|memory|in|the (r_acl) retrieval_32\NN|.|morphine|also (r_dobj) facilitated_29\VBD|given|were|,|and|by|Amnesia (r_conj) reversed_7\VBN|NONE (l_nsubjpass) Amnesia_0\NNP|facilitated|given|were|,|and|by
D012601_D000647 CID scopolamine_3\NN|NONE (r_pobj) by_2\IN|NONE (r_agent) produced_1\VBN|NONE (r_acl) Amnesia_0\NNP|facilitated|given|were|,|and|by
D012601_D000647 CID scopolamine_5\NN|,|partially|amnesia|Similarly|but|failed (r_nsubj) reversed_7\VBD|NONE (l_dobj) amnesia_12\NN|,|scopolamine|partially|Similarly|but|failed
D012601_D000647 CID scopolamine_5\NN|,|partially|amnesia|Similarly|but|failed (r_nsubj) reversed_7\VBD|NONE (l_conj) failed_23\VBD|,|scopolamine|partially|amnesia|Similarly|but (l_xcomp) reverse_25\VB|significantly|cycloheximide|. (l_dobj) amnesia_30\NN|to
D012601_D000647 CID scopolamine_9\NN| (r_npadvmod) induced_11\VBN|the (r_amod) amnesia_12\NN|,|scopolamine|partially|Similarly|but|failed
D012601_D000647 CID scopolamine_9\NN| (r_npadvmod) induced_11\VBN|the (r_amod) amnesia_12\NN|,|scopolamine|partially|Similarly|but|failed (r_dobj) reversed_7\VBD|NONE (l_conj) failed_23\VBD|,|scopolamine|partially|amnesia|Similarly|but (l_xcomp) reverse_25\VB|significantly|cycloheximide|. (l_dobj) amnesia_30\NN|to
D003513_D000647 CID cycloheximide_5\NN|and (r_conj) scopolamine_3\NN|NONE (r_pobj) by_2\IN|NONE (r_agent) produced_1\VBN|NONE (r_acl) Amnesia_0\NNP|facilitated|given|were|,|and|by
D003513_D000647 CID cycloheximide_22\NN|significantly|reverse|. (r_nsubj) failed_23\VBD|,|scopolamine|partially|amnesia|Similarly|but (r_conj) reversed_7\VBD|NONE (l_dobj) amnesia_12\NN|,|scopolamine|partially|Similarly|but|failed
D003513_D000647 CID cycloheximide_22\NN|significantly|reverse|. (r_nsubj) failed_23\VBD|,|scopolamine|partially|amnesia|Similarly|but (l_xcomp) reverse_25\VB|significantly|cycloheximide|. (l_dobj) amnesia_30\NN|to
D003513_D000647 CID cycloheximide_27\RB| (r_advmod) induced_29\VBN|the (r_amod) amnesia_30\NN|to (r_dobj) reverse_25\VB|significantly|cycloheximide|. (r_xcomp) failed_23\VBD|,|scopolamine|partially|amnesia|Similarly|but (r_conj) reversed_7\VBD|NONE (l_dobj) amnesia_12\NN|,|scopolamine|partially|Similarly|but|failed
D003513_D000647 CID cycloheximide_27\RB| (r_advmod) induced_29\VBN|the (r_amod) amnesia_30\NN|to
6308277
D000082_D012640 NONE acetaminophen_11\NN|NONE (r_pobj) with_10\IN|)|:| (r_prep) pretreatment_9\NN|reduced|interval|that (r_nsubj) increased_16\VBD|Studies|. (l_dobj) interval_18\NN|reduced|pretreatment|that (l_prep) between_19\IN|the (l_pobj) administration_21\NN|NONE (l_conj) onset_33\NN|of|and|IP|the (l_prep) of_34\IN|and|;|pretreatment|the|by (l_pobj) convulsions_36\NNS|NONE
D000082_D012640 NONE acetaminophen_11\NN|NONE (r_pobj) with_10\IN|)|:| (r_prep) pretreatment_9\NN|reduced|interval|that (r_nsubj) increased_16\VBD|Studies|. (l_conj) reduced_54\VBD|pretreatment|interval|that (l_dobj) incidence_56\NN|IP|(|) (l_prep) of_57\IN|the (l_pobj) seizures_59\NNS|NONE
D000082_D012640 NONE acetaminophen_49\NN|NONE (r_pobj) with_48\IN|)| (r_prep) pretreatment_47\NN|and|of|;|the|by (r_conj) onset_33\NN|of|and|IP|the (l_prep) of_34\IN|and|;|pretreatment|the|by (l_pobj) convulsions_36\NNS|NONE
D000082_D012640 NONE acetaminophen_49\NN|NONE (r_pobj) with_48\IN|)| (r_prep) pretreatment_47\NN|and|of|;|the|by (r_conj) onset_33\NN|of|and|IP|the (r_conj) administration_21\NN|NONE (r_pobj) between_19\IN|the (r_prep) interval_18\NN|reduced|pretreatment|that (r_dobj) increased_16\VBD|Studies|. (l_conj) reduced_54\VBD|pretreatment|interval|that (l_dobj) incidence_56\NN|IP|(|) (l_prep) of_57\IN|the (l_pobj) seizures_59\NNS|NONE
D000082_D012640 NONE acetaminophen_21\NN|NONE (r_pobj) by_20\IN|.|was|from|frequency (r_agent) reduced_14\VBN|NONE (l_nsubjpass) frequency_1\NN|by|.|was|from (l_prep) of_2\IN|The|after (l_pobj) seizures_6\NNS|NONE
D000082_D012640 NONE acetaminophen_6\FW|alter|did|.|not|,|and|In|seizures (r_nsubj) modify_15\VB|NONE (l_dobj) seizures_17\NNS|alter|did|.|not|,|and|In|acetaminophen
D002110_D064420 NONE caffeine_2\NN|NONE (r_compound) toxicity_3\NN|NONE
D002110_D064420 NONE caffeine_11\NN|NONE (r_pobj) of_10\IN|on|the|stimulatory (r_prep) effects_9\NNS|to (r_dobj) augment_6\VB|Because|been|salicylates|have (r_xcomp) reported_4\VBN|was|.|attention|,|on (r_advcl) focused_18\VBN|NONE (l_prep) on_19\IN|was|.|attention|,|reported (l_pobj) possibility_21\NN|NONE (l_acl) reduced_33\VBD|the (l_dobj) toxicity_36\NN|presence|micrograms|(|that
D002110_D064420 NONE caffeine_38\NN|NONE (r_pobj) of_37\IN|the|CNS (r_prep) toxicity_36\NN|presence|micrograms|(|that
D000082_D064420 NONE acetaminophen_5\NN|NONE (r_pobj) by_4\IN|.|in (r_prep) Reduction_0\NN|NONE (l_prep) in_1\IN|.|by (l_pobj) toxicity_3\NN|NONE
D000082_D064420 NONE acetaminophen_26\NN|NONE (r_pobj) of_25\IN|the (r_prep) presence_24\NN|toxicity|micrograms|(|that (r_nsubj) reduced_33\VBD|the (l_dobj) toxicity_36\NN|presence|micrograms|(|that
D002110_D012640 CID caffeine_23\NN|NONE (r_pobj) of_22\IN|and|IP|the|onset (r_prep) administration_21\NN|NONE (l_conj) onset_33\NN|of|and|IP|the (l_prep) of_34\IN|and|;|pretreatment|the|by (l_pobj) convulsions_36\NNS|NONE
D002110_D012640 CID caffeine_23\NN|NONE (r_pobj) of_22\IN|and|IP|the|onset (r_prep) administration_21\NN|NONE (r_pobj) between_19\IN|the (r_prep) interval_18\NN|reduced|pretreatment|that (r_dobj) increased_16\VBD|Studies|. (l_conj) reduced_54\VBD|pretreatment|interval|that (l_dobj) incidence_56\NN|IP|(|) (l_prep) of_57\IN|the (l_pobj) seizures_59\NNS|NONE
D002110_D012640 CID caffeine_65\NN|NONE (r_pobj) of_64\IN|the (r_prep) presence_63\NN|NONE (r_pobj) in_61\IN|NONE (r_prep) produced_60\VBN|audiogenic (r_acl) seizures_59\NNS|NONE (r_pobj) of_57\IN|the (r_prep) incidence_56\NN|IP|(|) (r_dobj) reduced_54\VBD|pretreatment|interval|that (r_conj) increased_16\VBD|Studies|. (l_dobj) interval_18\NN|reduced|pretreatment|that (l_prep) between_19\IN|the (l_pobj) administration_21\NN|NONE (l_conj) onset_33\NN|of|and|IP|the (l_prep) of_34\IN|and|;|pretreatment|the|by (l_pobj) convulsions_36\NNS|NONE
D002110_D012640 CID caffeine_65\NN|NONE (r_pobj) of_64\IN|the (r_prep) presence_63\NN|NONE (r_pobj) in_61\IN|NONE (r_prep) produced_60\VBN|audiogenic (r_acl) seizures_59\NNS|NONE
D002110_D012640 CID caffeine_12\NN|NONE (r_pobj) after_7\IN|of|The (r_prep) frequency_1\NN|by|.|was|from (l_prep) of_2\IN|The|after (l_pobj) seizures_6\NNS|NONE
D002110_D012640 CID caffeine_4\NN|NONE (r_pobj) of_3\IN|the (r_prep) absence_2\NN|NONE (r_pobj) In_0\IN|alter|did|.|not|,|and|seizures|acetaminophen (r_prep) modify_15\VB|NONE (l_dobj) seizures_17\NNS|alter|did|.|not|,|and|In|acetaminophen
D010433_D012640 CID pentylenetetrezol_30\NN|NONE (r_pobj) of_29\IN|tests|convulsant|in|the (r_prep) dose_28\NN|not|did (r_dobj) alter_25\VB|did|.|not|,|and|In|seizures|acetaminophen (r_conj) modify_15\VB|NONE (l_dobj) seizures_17\NNS|alter|did|.|not|,|and|In|acetaminophen
17965424
C422649_D006973 CID etoricoxib_17\NN|NONE (r_pobj) with_16\IN|significantly (r_prep) higher_15\JJR|.|compared|p<.|incidence|; (r_acomp) were_13\VBD|NONE (l_nsubj) incidence_1\NN|.|compared|p<.|;|higher (l_prep) of_2\IN|The (l_pobj) discontinuations_3\NNS|NONE (l_prep) for_4\IN|NONE (l_pobj) AEs_12\NNS|NONE (l_amod) related_7\VBN|NONE (l_npadvmod) hypertension_5\NN||related|and
C422649_D006973 CID etoricoxib_17\NN|NONE (r_pobj) with_16\IN|significantly (r_prep) higher_15\JJR|.|compared|p<.|incidence|; (r_acomp) were_13\VBD|NONE (l_dep) p<0.001_37\VB|.|compared|incidence|;|higher (l_prep) for_38\IN|) (l_pobj) hypertension_39\NN|NONE
D004008_D001172 NONE sodium_15\NN|II|trial|gastrointestinal|and|diclofenac (r_compound) tolerability_17\NN|NONE (r_pobj) vs_13\IN|the (r_prep) etoricoxib_12\NN|NONE (r_pobj) of_10\IN|) (r_prep) results_9\NNS|of|Gastrointestinal|.|: (r_appos) tolerability_1\NN|NONE (l_prep) of_2\IN|results|Gastrointestinal|.|: (l_pobj) etoricoxib_3\NN|NONE (l_prep) in_4\IN|NONE (l_pobj) patients_7\NNS|NONE (l_compound) arthritis_6\NN|rheumatoid
D004008_D001172 NONE diclofenac_22\NN|and (r_conj) etoricoxib_20\NN|NONE (r_pobj) of_19\IN|,|the|safety|gastrointestinal|)|GI|( (r_prep) tolerability_14\NN|in|to (r_dobj) compare_8\VB|.|blind|randomised|,|A (l_prep) in_23\IN|tolerability|to (l_pobj) patients_24\NNS|NONE (l_prep) with_25\IN|NONE (l_pobj) arthritis_27\NN|NONE
D004008_D001172 NONE diclofenac_22\NN|and (r_conj) etoricoxib_20\NN|NONE (r_pobj) of_19\IN|,|the|safety|gastrointestinal|)|GI|( (r_prep) tolerability_14\NN|in|to (r_dobj) compare_8\VB|.|blind|randomised|,|A (l_prep) in_23\IN|tolerability|to (l_pobj) patients_24\NNS|NONE (l_prep) with_25\IN|NONE (l_pobj) arthritis_27\NN|NONE (l_appos) RA_29\NNP|)|rheumatoid|(
D004008_D001172 NONE diclofenac_28\NN| (r_nmod) mg_30\NN|)||daily (r_compound) twice_31\RB|and|were|or|years|.|received (r_conj) enrolled_15\VBN|NONE (l_nsubjpass) years_9\NNS|and|were|or|.|received|twice (l_acl) diagnosed_11\VBD|.|)|A|age (l_prep) with_12\IN|NONE (l_pobj) RA_13\NNP|NONE
C422649_D001172 NONE etoricoxib_3\NN|NONE (l_prep) in_4\IN|NONE (l_pobj) patients_7\NNS|NONE (l_compound) arthritis_6\NN|rheumatoid
C422649_D001172 NONE etoricoxib_12\NN|NONE (r_pobj) of_10\IN|) (r_prep) results_9\NNS|of|Gastrointestinal|.|: (r_appos) tolerability_1\NN|NONE (l_prep) of_2\IN|results|Gastrointestinal|.|: (l_pobj) etoricoxib_3\NN|NONE (l_prep) in_4\IN|NONE (l_pobj) patients_7\NNS|NONE (l_compound) arthritis_6\NN|rheumatoid
C422649_D001172 NONE etoricoxib_20\NN|NONE (r_pobj) of_19\IN|,|the|safety|gastrointestinal|)|GI|( (r_prep) tolerability_14\NN|in|to (r_dobj) compare_8\VB|.|blind|randomised|,|A (l_prep) in_23\IN|tolerability|to (l_pobj) patients_24\NNS|NONE (l_prep) with_25\IN|NONE (l_pobj) arthritis_27\NN|NONE
C422649_D001172 NONE etoricoxib_20\NN|NONE (r_pobj) of_19\IN|,|the|safety|gastrointestinal|)|GI|( (r_prep) tolerability_14\NN|in|to (r_dobj) compare_8\VB|.|blind|randomised|,|A (l_prep) in_23\IN|tolerability|to (l_pobj) patients_24\NNS|NONE (l_prep) with_25\IN|NONE (l_pobj) arthritis_27\NN|NONE (l_appos) RA_29\NNP|)|rheumatoid|(
C422649_D001172 NONE etoricoxib_18\RB|daily (r_dobj) received_17\VBN|and|were|or|years|.|twice (r_conj) enrolled_15\VBN|NONE (l_nsubjpass) years_9\NNS|and|were|or|.|received|twice (l_acl) diagnosed_11\VBD|.|)|A|age (l_prep) with_12\IN|NONE (l_pobj) RA_13\NNP|NONE
D004008_D006973 NONE diclofenac_28\NNP|NONE (r_pobj) with_27\IN|respectively (r_prep) compared_26\VBN|.|p<.|incidence|;|higher (r_prep) were_13\VBD|NONE (l_nsubj) incidence_1\NN|.|compared|p<.|;|higher (l_prep) of_2\IN|The (l_pobj) discontinuations_3\NNS|NONE (l_prep) for_4\IN|NONE (l_pobj) AEs_12\NNS|NONE (l_amod) related_7\VBN|NONE (l_npadvmod) hypertension_5\NN||related|and
D004008_D006973 NONE diclofenac_28\NNP|NONE (r_pobj) with_27\IN|respectively (r_prep) compared_26\VBN|.|p<.|incidence|;|higher (r_prep) were_13\VBD|NONE (l_dep) p<0.001_37\VB|.|compared|incidence|;|higher (l_prep) for_38\IN|) (l_pobj) hypertension_39\NN|NONE
C422649_D004487 CID etoricoxib_17\NN|NONE (r_pobj) with_16\IN|significantly (r_prep) higher_15\JJR|.|compared|p<.|incidence|; (r_acomp) were_13\VBD|NONE (l_nsubj) incidence_1\NN|.|compared|p<.|;|higher (l_prep) of_2\IN|The (l_pobj) discontinuations_3\NNS|NONE (l_prep) for_4\IN|NONE (l_pobj) AEs_12\NNS|NONE (l_amod) related_7\VBN|NONE (l_conj) related_11\VBN|hypertension||and (l_npadvmod) oedema_9\NN|
C422649_D004487 CID etoricoxib_17\NN|NONE (r_pobj) with_16\IN|significantly (r_prep) higher_15\JJR|.|compared|p<.|incidence|; (r_acomp) were_13\VBD|NONE (l_dep) p<0.001_37\VB|.|compared|incidence|;|higher (l_prep) for_38\IN|) (l_pobj) hypertension_39\NN|NONE (l_conj) p<0.01_41\NN|and (l_prep) for_42\IN|NONE (l_pobj) oedema_43\NN|NONE
C422649_D005767 NONE etoricoxib_12\NN|NONE (r_pobj) with_11\IN|significantly (r_prep) lower_10\JJR|;|rate|ratio|. (r_acomp) was_8\VBD|NONE (l_nsubj) rate_3\NN|;|lower|ratio|. (l_amod) due_4\IN|The|cumulative|discontinuation (l_pcomp) to_5\IN|NONE (l_pobj) AEs_7\NNS|NONE
C422649_D005767 NONE Etoricoxib_0\NNP|common|risk|mg|, (r_nsubj) demonstrated_3\VBD|.|higher|, (l_dobj) risk_7\NN|common|mg|Etoricoxib|, (l_prep) for_8\IN|lower|a (l_pcomp) discontinuing_9\VBG|NONE (l_prep) due_11\IN|compared|treatment (l_pcomp) to_12\IN|NONE (l_pobj) AEs_14\NNS|NONE
C422649_D005767 NONE Etoricoxib_0\NNP|common|risk|mg|, (r_nsubj) demonstrated_3\VBD|.|higher|, (l_advcl) common_27\JJ|risk|mg|Etoricoxib|, (l_prep) than_28\IN|although|less (l_pobj) discontinuations_29\NNS|NONE (l_prep) from_30\IN|NONE (l_pobj) AEs_32\NNS|NONE
C422649_D005767 NONE etoricoxib_38\NN|NONE (r_pobj) with_37\IN|significantly (r_prep) higher_36\JJR|demonstrated|.|, (r_acomp) were_34\VBD|NONE (l_ccomp) demonstrated_3\VBD|.|higher|, (l_dobj) risk_7\NN|common|mg|Etoricoxib|, (l_prep) for_8\IN|lower|a (l_pcomp) discontinuing_9\VBG|NONE (l_prep) due_11\IN|compared|treatment (l_pcomp) to_12\IN|NONE (l_pobj) AEs_14\NNS|NONE
C422649_D005767 NONE etoricoxib_38\NN|NONE (r_pobj) with_37\IN|significantly (r_prep) higher_36\JJR|demonstrated|.|, (r_acomp) were_34\VBD|NONE (l_ccomp) demonstrated_3\VBD|.|higher|, (l_advcl) common_27\JJ|risk|mg|Etoricoxib|, (l_prep) than_28\IN|although|less (l_pobj) discontinuations_29\NNS|NONE (l_prep) from_30\IN|NONE (l_pobj) AEs_32\NNS|NONE
D004008_D004487 NONE diclofenac_28\NNP|NONE (r_pobj) with_27\IN|respectively (r_prep) compared_26\VBN|.|p<.|incidence|;|higher (r_prep) were_13\VBD|NONE (l_nsubj) incidence_1\NN|.|compared|p<.|;|higher (l_prep) of_2\IN|The (l_pobj) discontinuations_3\NNS|NONE (l_prep) for_4\IN|NONE (l_pobj) AEs_12\NNS|NONE (l_amod) related_7\VBN|NONE (l_conj) related_11\VBN|hypertension||and (l_npadvmod) oedema_9\NN|
D004008_D004487 NONE diclofenac_28\NNP|NONE (r_pobj) with_27\IN|respectively (r_prep) compared_26\VBN|.|p<.|incidence|;|higher (r_prep) were_13\VBD|NONE (l_dep) p<0.001_37\VB|.|compared|incidence|;|higher (l_prep) for_38\IN|) (l_pobj) hypertension_39\NN|NONE (l_conj) p<0.01_41\NN|and (l_prep) for_42\IN|NONE (l_pobj) oedema_43\NN|NONE
D004008_D005767 CID diclofenac_14\NNP|NONE (r_pobj) than_13\IN|NONE (r_prep) etoricoxib_12\NN|NONE (r_pobj) with_11\IN|significantly (r_prep) lower_10\JJR|;|rate|ratio|. (r_acomp) was_8\VBD|NONE (l_nsubj) rate_3\NN|;|lower|ratio|. (l_amod) due_4\IN|The|cumulative|discontinuation (l_pcomp) to_5\IN|NONE (l_pobj) AEs_7\NNS|NONE
D004008_D005767 CID diclofenac_17\NNP|mg.|from| (r_nmod) Discontinuations_20\NNS|NONE (r_pobj) with_16\IN|NONE (r_prep) compared_15\VBN|due|treatment (r_prep) discontinuing_9\VBG|NONE (l_prep) due_11\IN|compared|treatment (l_pcomp) to_12\IN|NONE (l_pobj) AEs_14\NNS|NONE
D004008_D005767 CID diclofenac_17\NNP|mg.|from| (r_nmod) Discontinuations_20\NNS|NONE (r_pobj) with_16\IN|NONE (r_prep) compared_15\VBN|due|treatment (r_prep) discontinuing_9\VBG|NONE (r_pcomp) for_8\IN|lower|a (r_prep) risk_7\NN|common|mg|Etoricoxib|, (r_dobj) demonstrated_3\VBD|.|higher|, (l_advcl) common_27\JJ|risk|mg|Etoricoxib|, (l_prep) than_28\IN|although|less (l_pobj) discontinuations_29\NNS|NONE (l_prep) from_30\IN|NONE (l_pobj) AEs_32\NNS|NONE
234669
D000628_D012131 NONE aminophylline_2\NN|NONE (r_pobj) of_1\IN|for|. (r_prep) Effects_0\NNS|NONE (l_prep) for_6\IN|of|. (l_pcomp) initiating_7\VBG|NONE (l_prep) during_10\IN|fibrillation (l_pobj) failure_12\NN|NONE
D000628_D012131 NONE aminophylline_3\NN|NONE (r_pobj) of_2\IN|and|during|The (r_prep) effects_1\NNS|were|.|in (l_conj) during_16\IN|and|of|The (l_pobj) failure_18\NN|NONE
D000628_D012131 NONE aminophylline_30\NN|NONE (r_pobj) of_29\IN|NONE (r_prep) infusion_28\NN|in|PC|.|,|produced (r_nsubj) resulted_31\VBD|NONE (l_advcl) produced_4\VBN|in|PC|.|,|infusion (l_nsubjpass) failure_2\NN|was|by|When
D000628_D012131 NONE aminophylline_24\NN|,|pharmacologic|, (r_appos) agents_21\NNS|contribute|that|may|,|role (r_nsubj) play_27\VB|experiments|. (l_advcl) contribute_8\VB|that|agents|may|,|role (l_prep) to_9\IN|although|factors|may (l_pobj) incidence_12\NN|NONE (l_prep) of_13\IN|the|increased (l_pobj) arrhythmias_15\NNS|NONE (l_prep) in_16\IN|ventricular (l_pobj) failure_18\NN|NONE
D010100_D014693 NONE oxygen_26\NN|NONE (r_pobj) of_25\IN|pH (r_prep) pressures_24\NNS|when|were|within (r_nsubjpass) kept_37\VBN|,|by|During|.|was|threshold (r_advcl) reduced_11\VBN|NONE (l_nsubjpass) threshold_9\NN|kept|,|by|During|.|was (l_compound) fibrillation_8\NN|ventricular|the
D002245_D014693 NONE dioxide_32\NN|)|and (r_conj) PO2_28\NNP|( (r_appos) oxygen_26\NN|NONE (r_pobj) of_25\IN|pH (r_prep) pressures_24\NNS|when|were|within (r_nsubjpass) kept_37\VBN|,|by|During|.|was|threshold (r_advcl) reduced_11\VBN|NONE (l_nsubjpass) threshold_9\NN|kept|,|by|During|.|was (l_compound) fibrillation_8\NN|ventricular|the
D002245_D014693 NONE CO2_34\NNP|carbon (r_appos) dioxide_32\NN|)|and (r_conj) PO2_28\NNP|( (r_appos) oxygen_26\NN|NONE (r_pobj) of_25\IN|pH (r_prep) pressures_24\NNS|when|were|within (r_nsubjpass) kept_37\VBN|,|by|During|.|was|threshold (r_advcl) reduced_11\VBN|NONE (l_nsubjpass) threshold_9\NN|kept|,|by|During|.|was (l_compound) fibrillation_8\NN|ventricular|the
D000628_D001145 NONE aminophylline_24\NN|,|pharmacologic|, (r_appos) agents_21\NNS|contribute|that|may|,|role (r_nsubj) play_27\VB|experiments|. (l_advcl) contribute_8\VB|that|agents|may|,|role (l_prep) to_9\IN|although|factors|may (l_pobj) incidence_12\NN|NONE (l_prep) of_13\IN|the|increased (l_pobj) arrhythmias_15\NNS|NONE
D000628_D014693 CID aminophylline_2\NN|NONE (r_pobj) of_1\IN|for|. (r_prep) Effects_0\NNS|NONE (l_prep) for_6\IN|of|. (l_pcomp) initiating_7\VBG|NONE (l_dobj) fibrillation_9\NN|during
D000628_D014693 CID aminophylline_3\NN|NONE (l_prep) on_4\IN|NONE (l_pobj) threshold_8\NN|NONE (l_compound) fibrillation_7\NN|the|during
D000628_D014693 CID aminophylline_4\NN|NONE (r_pobj) of_3\IN|the (r_prep) infusion_2\NN|NONE (r_pobj) During_0\IN|kept|,|by|.|was|threshold (r_prep) reduced_11\VBN|NONE (l_nsubjpass) threshold_9\NN|kept|,|by|During|.|was (l_compound) fibrillation_8\NN|ventricular|the
D000628_D014693 CID aminophylline_30\NN|NONE (r_pobj) of_29\IN|NONE (r_prep) infusion_28\NN|in|PC|.|,|produced (r_nsubj) resulted_31\VBD|NONE (l_prep) in_32\IN|PC|.|,|infusion|produced (l_pobj) decrease_36\NN|NONE (l_prep) in_37\IN|an|greater (l_pobj) threshold_40\NN|NONE (l_compound) fibrillation_39\NN|to
C093415_D014693 NONE PO2_28\NNP|( (r_appos) oxygen_26\NN|NONE (r_pobj) of_25\IN|pH (r_prep) pressures_24\NNS|when|were|within (r_nsubjpass) kept_37\VBN|,|by|During|.|was|threshold (r_advcl) reduced_11\VBN|NONE (l_nsubjpass) threshold_9\NN|kept|,|by|During|.|was (l_compound) fibrillation_8\NN|ventricular|the
D000628_D007040 NONE aminophylline_30\NN|NONE (r_pobj) of_29\IN|NONE (r_prep) infusion_28\NN|in|PC|.|,|produced (r_nsubj) resulted_31\VBD|NONE (l_advcl) produced_4\VBN|in|PC|.|,|infusion (l_agent) by_5\IN|was|failure|When (l_pobj) hypoventilation_6\NN|NONE
8638876
D011374_D012851 CID progesterone_13\NN|and (r_conj) estradiol_11\NN|NONE (r_pobj) of_10\IN|and|the|DM (r_prep) use_9\NN|that|thrombogenicity (r_nsubj) increased_18\VBD|authors|.|,|In (l_dobj) thrombogenicity_20\NN|that|use (l_relcl) provided_23\VBD|vascular|, (l_dobj) denominator_26\NN|which (l_prep) for_27\IN|a|common (l_pobj) thrombosis_28\NN|NONE (l_prep) of_29\IN|NONE (l_pobj) ICA_32\NNP|NONE (l_conj) sinus_36\NN|and|the|both
D004958_D014839 NONE estradiol_28\NN|and (r_conj) progesterone_26\NN|NONE (r_pobj) of_25\IN|parenteral (r_prep) use_24\NN|days (r_pobj) after_22\IN|hemiparesis (r_prep) left_16\VBD|headache|woman|.|, (r_conj) developed_9\VBD|NONE (l_dobj) headache_10\NN|left|woman|.|, (l_conj) nausea_12\NN|, (l_conj) vomiting_14\NN|and
D011374_D009325 NONE progesterone_26\NN|NONE (r_pobj) of_25\IN|parenteral (r_prep) use_24\NN|days (r_pobj) after_22\IN|hemiparesis (r_prep) left_16\VBD|headache|woman|.|, (r_conj) developed_9\VBD|NONE (l_dobj) headache_10\NN|left|woman|.|, (l_conj) nausea_12\NN|,
D011374_D002341 CID progesterone_13\NN|and (r_conj) estradiol_11\NN|NONE (r_pobj) of_10\IN|and|the|DM (r_prep) use_9\NN|that|thrombogenicity (r_nsubj) increased_18\VBD|authors|.|,|In (l_dobj) thrombogenicity_20\NN|that|use (l_relcl) provided_23\VBD|vascular|, (l_dobj) denominator_26\NN|which (l_prep) for_27\IN|a|common (l_pobj) thrombosis_28\NN|NONE (l_prep) of_29\IN|NONE (l_pobj) ICA_32\NNP|NONE (l_conj) sinus_36\NN|and|the|both
D011374_D003920 NONE progesterone_13\NN|and (r_conj) estradiol_11\NN|NONE (r_pobj) of_10\IN|and|the|DM (r_prep) use_9\NN|that|thrombogenicity (l_conj) DM_17\NNP|and|the|of
D011374_D014839 NONE progesterone_26\NN|NONE (r_pobj) of_25\IN|parenteral (r_prep) use_24\NN|days (r_pobj) after_22\IN|hemiparesis (r_prep) left_16\VBD|headache|woman|.|, (r_conj) developed_9\VBD|NONE (l_dobj) headache_10\NN|left|woman|.|, (l_conj) nausea_12\NN|, (l_conj) vomiting_14\NN|and
D011374_D006261 NONE progesterone_26\NN|NONE (r_pobj) of_25\IN|parenteral (r_prep) use_24\NN|days (r_pobj) after_22\IN|hemiparesis (r_prep) left_16\VBD|headache|woman|.|, (r_conj) developed_9\VBD|NONE (l_dobj) headache_10\NN|left|woman|.|,
D004958_D002341 CID estradiol_11\NN|NONE (r_pobj) of_10\IN|and|the|DM (r_prep) use_9\NN|that|thrombogenicity (r_nsubj) increased_18\VBD|authors|.|,|In (l_dobj) thrombogenicity_20\NN|that|use (l_relcl) provided_23\VBD|vascular|, (l_dobj) denominator_26\NN|which (l_prep) for_27\IN|a|common (l_pobj) thrombosis_28\NN|NONE (l_prep) of_29\IN|NONE (l_pobj) ICA_32\NNP|NONE (l_conj) sinus_36\NN|and|the|both
D011374_D012640 NONE progesterone_26\NN|NONE (r_pobj) of_25\IN|parenteral (r_prep) use_24\NN|days (r_pobj) after_22\IN|hemiparesis (r_prep) left_16\VBD|headache|woman|.|, (l_dobj) hemiparesis_17\NN|after (l_conj) seizure_19\NN|and
D004958_D012851 CID estradiol_11\NN|NONE (r_pobj) of_10\IN|and|the|DM (r_prep) use_9\NN|that|thrombogenicity (r_nsubj) increased_18\VBD|authors|.|,|In (l_dobj) thrombogenicity_20\NN|that|use (l_relcl) provided_23\VBD|vascular|, (l_dobj) denominator_26\NN|which (l_prep) for_27\IN|a|common (l_pobj) thrombosis_28\NN|NONE (l_prep) of_29\IN|NONE (l_pobj) ICA_32\NNP|NONE (l_conj) sinus_36\NN|and|the|both
D004958_D006261 NONE estradiol_28\NN|and (r_conj) progesterone_26\NN|NONE (r_pobj) of_25\IN|parenteral (r_prep) use_24\NN|days (r_pobj) after_22\IN|hemiparesis (r_prep) left_16\VBD|headache|woman|.|, (r_conj) developed_9\VBD|NONE (l_dobj) headache_10\NN|left|woman|.|,
D004958_D003920 NONE estradiol_11\NN|NONE (r_pobj) of_10\IN|and|the|DM (r_prep) use_9\NN|that|thrombogenicity (l_conj) DM_17\NNP|and|the|of
D004958_D009325 NONE estradiol_28\NN|and (r_conj) progesterone_26\NN|NONE (r_pobj) of_25\IN|parenteral (r_prep) use_24\NN|days (r_pobj) after_22\IN|hemiparesis (r_prep) left_16\VBD|headache|woman|.|, (r_conj) developed_9\VBD|NONE (l_dobj) headache_10\NN|left|woman|.|, (l_conj) nausea_12\NN|,
D004958_D012640 NONE estradiol_28\NN|and (r_conj) progesterone_26\NN|NONE (r_pobj) of_25\IN|parenteral (r_prep) use_24\NN|days (r_pobj) after_22\IN|hemiparesis (r_prep) left_16\VBD|headache|woman|.|, (l_dobj) hemiparesis_17\NN|after (l_conj) seizure_19\NN|and
D004958_D010291 NONE estradiol_28\NN|and (r_conj) progesterone_26\NN|NONE (r_pobj) of_25\IN|parenteral (r_prep) use_24\NN|days (r_pobj) after_22\IN|hemiparesis (r_prep) left_16\VBD|headache|woman|.|, (l_dobj) hemiparesis_17\NN|after
D011374_D010291 NONE progesterone_26\NN|NONE (r_pobj) of_25\IN|parenteral (r_prep) use_24\NN|days (r_pobj) after_22\IN|hemiparesis (r_prep) left_16\VBD|headache|woman|.|, (l_dobj) hemiparesis_17\NN|after
8752018
D008094_D003072 CID Lithium_0\NN| (r_npadvmod) associated_2\VBN|reduced|.|cognitive (r_amod) deficits_6\NNS|NONE
D008094_D003072 CID lithium_15\NN|NONE (r_pobj) of_14\IN|,|adverse|the|common|as (r_prep) effects_13\NNS|NONE (r_pobj) of_8\IN|the (r_prep) management_7\NN|NONE (r_pobj) about_5\IN|been|much|has|Although (r_prep) written_4\VBN|effects|.|,|understudied (r_advcl) remain_40\VBP|NONE (l_nsubj) effects_27\NNS|.|,|understudied|written (l_prep) as_29\IN|subtle|lithium|side (l_pobj) deficits_31\NNS|such
D008094_D003072 CID lithium_15\NN|NONE (r_pobj) of_14\IN|,|adverse|the|common|as (r_prep) effects_13\NNS|NONE (r_pobj) of_8\IN|the (r_prep) management_7\NN|NONE (r_pobj) about_5\IN|been|much|has|Although (r_prep) written_4\VBN|effects|.|,|understudied (r_advcl) remain_40\VBP|NONE (l_nsubj) effects_27\NNS|.|,|understudied|written (l_prep) as_29\IN|subtle|lithium|side (l_pobj) deficits_31\NNS|such (l_conj) loss_33\NN|cognitive|, (l_prep) of_34\IN|impairments|and|, (l_pobj) creativity_35\NN|NONE
D008094_D003072 CID lithium_15\NN|NONE (r_pobj) of_14\IN|,|adverse|the|common|as (r_prep) effects_13\NNS|NONE (r_pobj) of_8\IN|the (r_prep) management_7\NN|NONE (r_pobj) about_5\IN|been|much|has|Although (r_prep) written_4\VBN|effects|.|,|understudied (r_advcl) remain_40\VBP|NONE (l_nsubj) effects_27\NNS|.|,|understudied|written (l_prep) as_29\IN|subtle|lithium|side (l_pobj) deficits_31\NNS|such (l_conj) loss_33\NN|cognitive|, (l_conj) impairments_39\NNS|of|and|,
D008094_D003072 CID lithium_25\NN|subtle|as|side (r_compound) effects_27\NNS|.|,|understudied|written (l_prep) as_29\IN|subtle|lithium|side (l_pobj) deficits_31\NNS|such
D008094_D003072 CID lithium_25\NN|subtle|as|side (r_compound) effects_27\NNS|.|,|understudied|written (l_prep) as_29\IN|subtle|lithium|side (l_pobj) deficits_31\NNS|such (l_conj) loss_33\NN|cognitive|, (l_prep) of_34\IN|impairments|and|, (l_pobj) creativity_35\NN|NONE
D008094_D003072 CID lithium_25\NN|subtle|as|side (r_compound) effects_27\NNS|.|,|understudied|written (l_prep) as_29\IN|subtle|lithium|side (l_pobj) deficits_31\NNS|such (l_conj) loss_33\NN|cognitive|, (l_conj) impairments_39\NNS|of|and|,
D008094_D003072 CID lithium_10\NN|NONE (r_pobj) from_9\IN|patients|divalproex (r_prep) switching_6\VBG|NONE (l_advcl) divalproex_12\NN|patients|from (l_xcomp) alleviate_15\VB|sodium|to (l_dobj) impairments_20\NNS|to
D008094_D003072 CID lithium_8\NN|NONE (r_pobj) of_7\IN|,|,|with|fully (r_prep) substitution_6\NN|where|helpful (r_nsubj) was_18\VBD|seven (l_acomp) helpful_20\JJ|where|substitution (l_prep) in_21\IN|extremely (l_pcomp) reducing_22\VBG|NONE (l_dobj) cognitive_24\JJ|NONE (l_conj) motivational_26\JJ|,|the|attributed (l_conj) deficits_30\NNS|,|or
D008094_D003072 CID lithium_33\NN|NONE (r_pobj) to_32\IN|NONE (r_prep) attributed_31\VBN|,|the|motivational (r_acl) cognitive_24\JJ|NONE (l_conj) motivational_26\JJ|,|the|attributed (l_conj) deficits_30\NNS|,|or
D008094_D003072 CID lithium_12\NN|NONE (l_prep) in_13\IN|NONE (l_pobj) patients_15\NNS|NONE (l_acl) experiencing_16\VBG|bipolar (l_dobj) deficits_18\NNS|NONE
D008094_D003072 CID lithium_12\NN|NONE (l_prep) in_13\IN|NONE (l_pobj) patients_15\NNS|NONE (l_acl) experiencing_16\VBG|bipolar (l_dobj) deficits_18\NNS|NONE (l_conj) loss_20\NN|,|cognitive (l_prep) of_21\IN|NONE (l_pobj) creativity_22\NN|NONE
D008094_D003072 CID lithium_12\NN|NONE (l_prep) in_13\IN|NONE (l_pobj) patients_15\NNS|NONE (l_acl) experiencing_16\VBG|bipolar (l_dobj) deficits_18\NNS|NONE (l_conj) loss_20\NN|,|cognitive (l_prep) of_21\IN|NONE (l_pobj) creativity_22\NN|NONE (l_conj) impairments_26\NNS|,|and
D014635_D003072 NONE sodium_13\NN|to (r_dobj) divalproex_12\NN|by (r_advcl) reduced_7\VBN|.|associated|cognitive (r_acl) deficits_6\NNS|NONE
D014635_D003072 NONE sodium_13\NN|to|alleviate (r_dobj) divalproex_12\NN|patients|from (l_xcomp) alleviate_15\VB|sodium|to (l_dobj) impairments_20\NNS|to
D014635_D003072 NONE sodium_17\NN|NONE (r_pobj) with_15\IN|of|,|,|fully (r_prep) substitution_6\NN|where|helpful (r_nsubj) was_18\VBD|seven (l_acomp) helpful_20\JJ|where|substitution (l_prep) in_21\IN|extremely (l_pcomp) reducing_22\VBG|NONE (l_dobj) cognitive_24\JJ|NONE (l_conj) motivational_26\JJ|,|the|attributed (l_conj) deficits_30\NNS|,|or
D014635_D003072 NONE sodium_6\NN|alternative|In|.|, (r_nsubj) was_7\VBD|NONE (l_attr) alternative_10\NN|In|.|,|sodium (l_prep) to_11\IN|superior|a (l_pobj) lithium_12\NN|NONE (l_prep) in_13\IN|NONE (l_pobj) patients_15\NNS|NONE (l_acl) experiencing_16\VBG|bipolar (l_dobj) deficits_18\NNS|NONE
D014635_D003072 NONE sodium_6\NN|alternative|In|.|, (r_nsubj) was_7\VBD|NONE (l_attr) alternative_10\NN|In|.|,|sodium (l_prep) to_11\IN|superior|a (l_pobj) lithium_12\NN|NONE (l_prep) in_13\IN|NONE (l_pobj) patients_15\NNS|NONE (l_acl) experiencing_16\VBG|bipolar (l_dobj) deficits_18\NNS|NONE (l_conj) loss_20\NN|,|cognitive (l_prep) of_21\IN|NONE (l_pobj) creativity_22\NN|NONE
D014635_D003072 NONE sodium_6\NN|alternative|In|.|, (r_nsubj) was_7\VBD|NONE (l_attr) alternative_10\NN|In|.|,|sodium (l_prep) to_11\IN|superior|a (l_pobj) lithium_12\NN|NONE (l_prep) in_13\IN|NONE (l_pobj) patients_15\NNS|NONE (l_acl) experiencing_16\VBG|bipolar (l_dobj) deficits_18\NNS|NONE (l_conj) loss_20\NN|,|cognitive (l_prep) of_21\IN|NONE (l_pobj) creativity_22\NN|NONE (l_conj) impairments_26\NNS|,|and
D008094_D001714 NONE Lithium_0\NN|.|treatment (r_nsubj) remains_1\VBZ|NONE (l_attr) treatment_6\NN|Lithium|. (l_prep) for_7\IN|line|a (l_pobj) treatment_12\NN|NONE (l_prep) of_13\IN|acute|the (l_pobj) disorder_15\NN|NONE
D008094_D001714 NONE lithium_10\NN|NONE (r_pobj) from_9\IN|patients|divalproex (r_prep) switching_6\VBG|NONE (l_dobj) patients_8\NNS|from|divalproex (l_amod) bipolar_7\JJ|NONE
D008094_D001714 NONE lithium_8\NN|NONE (r_pobj) of_7\IN|,|,|with|fully (r_prep) substitution_6\NN|where|helpful (r_nsubj) was_18\VBD|seven (l_acomp) helpful_20\JJ|where|substitution (l_prep) in_21\IN|extremely (l_pcomp) reducing_22\VBG|NONE (l_dobj) cognitive_24\JJ|NONE (l_acl) attributed_31\VBN|,|the|motivational (l_prep) to_32\IN|NONE (l_pobj) lithium_33\NN|NONE (l_prep) in_34\IN|NONE (l_pobj) patients_37\NNS|NONE (l_amod) bipolar_36\JJ|our
D008094_D001714 NONE lithium_33\NN|NONE (l_prep) in_34\IN|NONE (l_pobj) patients_37\NNS|NONE (l_amod) bipolar_36\JJ|our
D008094_D001714 NONE lithium_12\NN|NONE (l_prep) in_13\IN|NONE (l_pobj) patients_15\NNS|NONE (l_amod) bipolar_14\JJ|experiencing
D008094_D014202 NONE lithium_15\NN|NONE (r_pobj) of_14\IN|,|adverse|the|common|as (r_prep) effects_13\NNS|NONE (l_prep) as_18\IN|,|of|adverse|the|common (l_pobj) polyuria_19\NN|such (l_conj) tremor_21\NN|and
D008094_D014202 NONE lithium_25\NN|subtle|as|side (r_compound) effects_27\NNS|.|,|understudied|written (r_nsubj) remain_40\VBP|NONE (l_advcl) written_4\VBN|effects|.|,|understudied (l_prep) about_5\IN|been|much|has|Although (l_pobj) management_7\NN|NONE (l_prep) of_8\IN|the (l_pobj) effects_13\NNS|NONE (l_prep) as_18\IN|,|of|adverse|the|common (l_pobj) polyuria_19\NN|such (l_conj) tremor_21\NN|and
D008094_D011141 NONE lithium_15\NN|NONE (r_pobj) of_14\IN|,|adverse|the|common|as (r_prep) effects_13\NNS|NONE (l_prep) as_18\IN|,|of|adverse|the|common (l_pobj) polyuria_19\NN|such
D008094_D011141 NONE lithium_25\NN|subtle|as|side (r_compound) effects_27\NNS|.|,|understudied|written (r_nsubj) remain_40\VBP|NONE (l_advcl) written_4\VBN|effects|.|,|understudied (l_prep) about_5\IN|been|much|has|Although (l_pobj) management_7\NN|NONE (l_prep) of_8\IN|the (l_pobj) effects_13\NNS|NONE (l_prep) as_18\IN|,|of|adverse|the|common (l_pobj) polyuria_19\NN|such
D014635_D001714 NONE sodium_13\NN|to|alleviate (r_dobj) divalproex_12\NN|patients|from (r_advcl) switching_6\VBG|NONE (l_dobj) patients_8\NNS|from|divalproex (l_amod) bipolar_7\JJ|NONE
D014635_D001714 NONE sodium_17\NN|NONE (r_pobj) with_15\IN|of|,|,|fully (r_prep) substitution_6\NN|where|helpful (r_nsubj) was_18\VBD|seven (l_acomp) helpful_20\JJ|where|substitution (l_prep) in_21\IN|extremely (l_pcomp) reducing_22\VBG|NONE (l_dobj) cognitive_24\JJ|NONE (l_acl) attributed_31\VBN|,|the|motivational (l_prep) to_32\IN|NONE (l_pobj) lithium_33\NN|NONE (l_prep) in_34\IN|NONE (l_pobj) patients_37\NNS|NONE (l_amod) bipolar_36\JJ|our
D014635_D001714 NONE sodium_6\NN|alternative|In|.|, (r_nsubj) was_7\VBD|NONE (l_attr) alternative_10\NN|In|.|,|sodium (l_prep) to_11\IN|superior|a (l_pobj) lithium_12\NN|NONE (l_prep) in_13\IN|NONE (l_pobj) patients_15\NNS|NONE (l_amod) bipolar_14\JJ|experiencing
18023325
D004221_D010243 NONE disulfiram_24\NN|dose (r_compound) intoxication_25\NN|NONE (r_pobj) by_20\IN|NONE (r_agent) caused_19\VBN|acute|severe|sensorimotor|axonal (r_acl) polyneuropathy_18\NN|NONE (r_dobj) superimposed_13\VBN|and|This|case|. (r_conj) was_1\VBD|NONE (l_attr) case_3\NN|and|superimposed|This|. (l_prep) of_4\IN|a (l_pobj) palsy_6\JJ|NONE
D004221_D014826 CID disulfiram_6\NN|acute (r_compound) intoxication_7\NN|NONE (r_pobj) after_4\IN|Acute|.|fold (r_prep) palsy_3\JJ|NONE
D004221_D014826 CID disulfiram_6\NN|a (r_compound) overdose_7\NN|NONE (r_pobj) by_4\IN|NONE (r_agent) caused_3\VBN|peripheral|Acute (r_acl) neuropathy_2\NN|is|rare|and (r_nsubj) is_8\VBZ|NONE (l_conj) is_13\VBZ|neuropathy|rare|and (l_attr) report_15\NN|.|there (l_acl) leading_18\VBG|of|no (l_prep) to_19\IN|NONE (l_pobj) palsy_22\JJ|NONE
D004221_D011115 NONE disulfiram_24\NN|dose (r_compound) intoxication_25\NN|NONE (r_pobj) by_20\IN|NONE (r_agent) caused_19\VBN|acute|severe|sensorimotor|axonal (r_acl) polyneuropathy_18\NN|NONE
D004221_D062787 NONE disulfiram_6\NN|a (r_compound) overdose_7\NN|NONE
D004221_D010523 CID disulfiram_6\NN|a (r_compound) overdose_7\NN|NONE (r_pobj) by_4\IN|NONE (r_agent) caused_3\VBN|peripheral|Acute (r_acl) neuropathy_2\NN|is|rare|and
17261653
D003000_D001919 CID Clonidine_0\NNP|bradycardia||in (r_npadvmod) induced_2\VBN|%|. (l_dobj) bradycardia_3\NN|Clonidine||in
804391
D012293_D014376 NONE rifampin_8\NN|NONE (r_advmod) treated_9\VBN|with (r_amod) patients_10\NNS|NONE (l_prep) with_11\IN|treated (l_pobj) tuberculosis_12\NN|NONE
D012293_D014376 NONE rifampin_13\NN|NONE (r_pobj) with_12\IN|patients (r_prep) treated_11\VBN|in|proteinuria|was|. (l_nsubj) patients_10\NNS|with (l_compound) tuberculosis_9\NN|
D012293_D011507 CID rifampin_8\NN|NONE (r_advmod) treated_9\VBN|with (r_amod) patients_10\NNS|NONE (r_pobj) in_7\IN|immunity|chain|Light|.|and (r_prep) proteinuria_2\NN|NONE
D012293_D011507 CID rifampin_13\NN|NONE (r_pobj) with_12\IN|patients (r_prep) treated_11\VBN|in|proteinuria|was|. (r_advcl) found_4\VBN|NONE (l_nsubjpass) proteinuria_2\NN|in|was|.|treated
9522152
D002045_D009461 NONE bupivacaine_11\NN|NONE (r_pobj) of_7\IN|intrathecal (r_prep) injection_6\NN|NONE (r_dobj) following_4\VBG|.|transient|neurological|A (r_acl) deficit_3\NN|NONE
D002045_D009461 NONE bupivacaine_21\NN|NONE (r_pobj) with_14\IN|spinal|unilateral (r_prep) anaesthesia_13\NN|NONE (r_pobj) after_10\IN|that (r_prep) occurred_9\VBD|transient|neurological (r_relcl) deficit_7\NN|NONE
11642480
D015283_D003865 NONE citalopram_8\NN|NONE (r_pobj) with_7\IN|by (r_prep) treatment_6\NN|NONE (l_prep) by_9\IN|with (l_pobj) boy_14\NN|NONE (l_prep) with_15\IN|old|a (l_pobj) depression_17\NN|NONE
D015283_D004409 CID citalopram_7\NN|NONE (r_pobj) on_6\IN|depressed|a (r_prep) adolescent_5\NN|NONE (r_pobj) in_2\IN|.|Palpebral (r_prep) twitching_1\VBG|NONE
D015283_D004409 CID citalopram_8\NN|NONE (r_pobj) with_7\IN|by (r_prep) treatment_6\NN|NONE (l_prep) by_9\IN|with (l_pobj) boy_14\NN|NONE (l_prep) with_15\IN|old|a (l_pobj) depression_17\NN|NONE (l_relcl) exhibited_19\VBD|major (l_dobj) twitching_21\NN|during|who
D015283_D003866 NONE citalopram_7\NN|NONE (r_pobj) on_6\IN|depressed|a (r_prep) adolescent_5\NN|NONE (l_amod) depressed_4\JJ|a|on
3952818
D005472_D003329 NONE 5-FU_14\CD|NONE (r_pobj) to_13\IN|NONE (r_pcomp) due_12\JJ|and|cause|may|,|used|that|spasm (r_prep) be_7\VB|data|. (l_nsubj) spasm_5\NN|and|cause|may|,|due|used|that
D005472_D003329 NONE 5-FU_30\CD|NONE (r_compound) cardiotoxicity_31\NN|NONE (r_pobj) of_29\IN|the|or|treatment (r_prep) prevention_26\NN|NONE (r_pobj) in_24\IN|probably|that|be|may|antagonists (r_prep) used_23\VBN|and|cause|may|,|due|that|spasm (r_conj) be_7\VB|data|. (l_nsubj) spasm_5\NN|and|cause|may|,|due|used|that
D002118_D003329 NONE calcium_18\NN|NONE (r_compound) antagonists_19\NNS|probably|that|be|may|in (r_nsubjpass) used_23\VBN|and|cause|may|,|due|that|spasm (r_conj) be_7\VB|data|. (l_nsubj) spasm_5\NN|and|cause|may|,|due|used|that
D005472_D002637 CID 5-fluorouracil_18\CD|(|)|FU (r_punct) administration_22\NN|NONE (r_pobj) after_17\IN|pain|who (r_prep) presented_14\VBD|a|with (l_dobj) pain_16\NN|who|after
D005472_D002637 CID 5-FU_20\CD|(|fluorouracil|) (r_nmod) administration_22\NN|NONE (r_pobj) after_17\IN|pain|who (r_prep) presented_14\VBD|a|with (l_dobj) pain_16\NN|who|after
D009543_D000788 NONE nifedipine_19\NN|NONE (r_pobj) with_18\IN|.|pain|promptly (r_prep) resolved_17\VBD|evolution|and|similar|, (r_conj) was_3\VBD|NONE (l_acomp) similar_4\JJ|resolved|evolution|and|, (l_prep) to_5\IN|NONE (l_pobj) that_6\DT|NONE (l_acl) observed_7\VBN|NONE (l_prep) in_8\IN|NONE (l_pobj) angina_11\NN|NONE
D009543_D002637 NONE nifedipine_19\NN|NONE (r_pobj) with_18\IN|.|pain|promptly (r_prep) resolved_17\VBD|evolution|and|similar|, (l_nsubj) pain_15\NN|.|promptly|with
D002118_D066126 NONE calcium_18\NN|NONE (r_compound) antagonists_19\NNS|probably|that|be|may|in (r_nsubjpass) used_23\VBN|and|cause|may|,|due|that|spasm (r_conj) be_7\VB|data|. (l_attr) cause_9\NN|and|may|,|due|used|that|spasm (l_prep) of_10\IN|the (l_pobj) cardiotoxicity_11\NN|NONE
D002118_D066126 NONE calcium_18\NN|NONE (r_compound) antagonists_19\NNS|probably|that|be|may|in (r_nsubjpass) used_23\VBN|and|cause|may|,|due|that|spasm (l_prep) in_24\IN|probably|that|be|may|antagonists (l_pobj) prevention_26\NN|NONE (l_prep) of_29\IN|the|or|treatment (l_pobj) cardiotoxicity_31\NN|NONE
D005472_D003110 NONE 5-fluorouracil_18\CD|(|)|FU (r_punct) administration_22\NN|NONE (r_pobj) after_17\IN|pain|who (r_prep) presented_14\VBD|a|with (r_relcl) patient_6\NN|NONE (l_prep) with_7\IN|a|presented (l_pobj) carcinoma_9\NN|NONE
D005472_D003110 NONE 5-FU_20\CD|(|fluorouracil|) (r_nmod) administration_22\NN|NONE (r_pobj) after_17\IN|pain|who (r_prep) presented_14\VBD|a|with (r_relcl) patient_6\NN|NONE (l_prep) with_7\IN|a|presented (l_pobj) carcinoma_9\NN|NONE
D005472_D066126 NONE 5-fluorouracil_3\CD|NONE (r_punct) ._4\.|of|Cardiac (r_punct) toxicity_1\NN|NONE
D005472_D066126 NONE 5-FU_14\CD|NONE (r_pobj) to_13\IN|NONE (r_pcomp) due_12\JJ|and|cause|may|,|used|that|spasm (r_prep) be_7\VB|data|. (l_attr) cause_9\NN|and|may|,|due|used|that|spasm (l_prep) of_10\IN|the (l_pobj) cardiotoxicity_11\NN|NONE
D005472_D066126 NONE 5-FU_14\CD|NONE (r_pobj) to_13\IN|NONE (r_pcomp) due_12\JJ|and|cause|may|,|used|that|spasm (r_prep) be_7\VB|data|. (l_conj) used_23\VBN|and|cause|may|,|due|that|spasm (l_prep) in_24\IN|probably|that|be|may|antagonists (l_pobj) prevention_26\NN|NONE (l_prep) of_29\IN|the|or|treatment (l_pobj) cardiotoxicity_31\NN|NONE
D005472_D066126 NONE 5-FU_30\CD|NONE (r_compound) cardiotoxicity_31\NN|NONE (r_pobj) of_29\IN|the|or|treatment (r_prep) prevention_26\NN|NONE (r_pobj) in_24\IN|probably|that|be|may|antagonists (r_prep) used_23\VBN|and|cause|may|,|due|that|spasm (r_conj) be_7\VB|data|. (l_attr) cause_9\NN|and|may|,|due|used|that|spasm (l_prep) of_10\IN|the (l_pobj) cardiotoxicity_11\NN|NONE
D005472_D066126 NONE 5-FU_30\CD|NONE (r_compound) cardiotoxicity_31\NN|NONE
D005472_D009362 NONE 5-fluorouracil_18\CD|(|)|FU (r_punct) administration_22\NN|NONE (r_pobj) after_17\IN|pain|who (r_prep) presented_14\VBD|a|with (r_relcl) patient_6\NN|NONE (l_prep) with_7\IN|a|presented (l_pobj) carcinoma_9\NN|NONE (l_conj) metastasis_12\NN|and|colon
D005472_D009362 NONE 5-FU_20\CD|(|fluorouracil|) (r_nmod) administration_22\NN|NONE (r_pobj) after_17\IN|pain|who (r_prep) presented_14\VBD|a|with (r_relcl) patient_6\NN|NONE (l_prep) with_7\IN|a|presented (l_pobj) carcinoma_9\NN|NONE (l_conj) metastasis_12\NN|and|colon
15686794
D000638_D017116 CID amiodarone_8\NN|NONE (r_pobj) of_7\IN|intravenous (r_prep) administration_6\NN|NONE (r_pobj) during_4\IN|.|Acute|report|:|back (r_prep) pain_3\NN|NONE
D000638_D017116 CID amiodarone_28\NN|intravenous (r_compound) loading_29\NN|NONE (r_pobj) of_26\IN|NONE (r_prep) initiation_25\NN|minutes (r_pobj) after_24\IN|who|pain (r_prep) experienced_14\VBD|onset|atrial|, (l_dobj) pain_20\NN|after|who
D000638_D001281 NONE Amiodarone_0\NNP|drug|. (r_nsubj) represents_1\VBZ|NONE (l_dobj) drug_5\NN|Amiodarone|. (l_prep) for_6\IN|antiarrhythmic|an|effective (l_pobj) cardioversion_7\NN|NONE (l_prep) of_8\IN|NONE (l_pobj) fibrillation_13\NN|NONE
D000638_D001281 NONE Amiodarone_0\NNP|drug|. (r_nsubj) represents_1\VBZ|NONE (l_dobj) drug_5\NN|Amiodarone|. (l_prep) for_6\IN|antiarrhythmic|an|effective (l_pobj) cardioversion_7\NN|NONE (l_prep) of_8\IN|NONE (l_pobj) fibrillation_13\NN|NONE (l_appos) AF_15\NNP|(|atrial|onset
D000638_D001281 NONE amiodarone_28\NN|intravenous (r_compound) loading_29\NN|NONE (r_pobj) of_26\IN|NONE (r_prep) initiation_25\NN|minutes (r_pobj) after_24\IN|who|pain (r_prep) experienced_14\VBD|onset|atrial|, (r_relcl) fibrillation_11\NN|NONE
17242861
D010862_D004833 CID pilocarpine_4\NN| (r_npadvmod) induced_6\VBN|model|,|, (r_amod) seizures_7\NNS|NONE (l_appos) model_10\NN|,|induced|, (l_prep) of_11\IN|a (l_pobj) epilepsy_14\NN|NONE
D010862_D012640 NONE pilocarpine_4\NN| (r_npadvmod) induced_6\VBN|model|,|, (r_amod) seizures_7\NNS|NONE
D010862_D012640 NONE pilocarpine_4\NN| (r_npadvmod) induced_6\VBN|model|,|, (r_amod) seizures_7\NNS|NONE (r_pobj) to_3\IN|NONE (r_prep) susceptibility_2\NN|NONE (r_pobj) for_1\IN|NONE (r_prep) QTLs_0\NNS|,|been|used|and|have|not (r_nsubjpass) reported_19\VBN|NONE (l_conj) used_27\VBN|,|been|and|have|QTLs|not (l_xcomp) localize_29\VB|not|been|.|have|CSS|previously (l_dobj) genes_32\NNS|to (l_compound) susceptibility_31\NN|NONE (l_compound) seizure_30\NN|NONE
D010862_D012640 NONE pilocarpine_9\NN| (r_npadvmod) induced_11\VBN|NONE (r_amod) seizures_12\NNS|NONE
D010862_D012640 NONE pilocarpine_23\NN| (r_npadvmod) induced_25\VBN|NONE (r_amod) seizures_26\NNS|NONE
9205462
D004967_D001943 NONE estrogen_13\NN|breast|II|stage|positive (r_compound) carcinoma_18\NN|NONE
D013629_D009369 NONE tamoxifen_8\NN|tumors|and (r_compound) use_9\NN|NONE (l_conj) tumors_12\NNS|tamoxifen|and
D013629_D006106 NONE tamoxifen_2\NN| (r_npadvmod) induced_4\VBN|liver (r_amod) dysfunction_6\NN|NONE (r_pobj) with_1\IN|NONE (r_prep) Patients_0\NNS|because|may|.|at (r_nsubj) be_8\VB|NONE (l_prep) at_9\IN|because|may|.|Patients (l_pobj) risk_11\NN|NONE (l_prep) for_12\IN|increased (l_pobj) tumors_15\NNS|NONE
D013629_D006106 NONE tamoxifen_20\NN|NONE (r_compound) metabolism_21\NN|NONE (r_pobj) in_19\IN|NONE (r_prep) alterations_18\NNS|of (r_pobj) because_16\IN|may|.|Patients|at (r_prep) be_8\VB|NONE (l_prep) at_9\IN|because|may|.|Patients (l_pobj) risk_11\NN|NONE (l_prep) for_12\IN|increased (l_pobj) tumors_15\NNS|NONE
D013629_D001943 NONE tamoxifen_9\NN|NONE (r_pobj) with_8\IN|woman|for|.|was (r_prep) treated_7\VBN|NONE (l_prep) for_10\IN|with|woman|.|was (l_pobj) carcinoma_18\NN|NONE
D013629_D017093 CID tamoxifen_2\NN| (r_npadvmod) induced_4\VBN|liver (r_amod) dysfunction_6\NN|NONE
D013629_D017093 CID tamoxifen_20\NN|NONE (r_compound) metabolism_21\NN|NONE (r_pobj) in_19\IN|NONE (r_prep) alterations_18\NNS|of (r_pobj) because_16\IN|may|.|Patients|at (r_prep) be_8\VB|NONE (l_nsubj) Patients_0\NNS|because|may|.|at (l_prep) with_1\IN|NONE (l_pobj) dysfunction_6\NN|NONE
D013629_C537296 CID tamoxifen_9\NN|antecedent (r_compound) use_10\NN|NONE (r_pobj) with_7\IN|NONE (r_prep) associated_6\VBN|the (r_acl) ovary_5\NN|NONE
11058428
D000305_D009135 NONE corticosteroid_13\NN|NONE (r_pobj) of_11\IN|cause|the|myopathy (r_prep) possibility_10\NN|NONE (l_prep) myopathy_14\NNS|cause|of|the
D000305_D009135 NONE corticosteroid_21\NN|NONE (r_nsubj) myopathy_22\NNS|methylprednisolone|may|that
D013256_D013119 NONE steroid_2\NN|NONE (r_compound) myopathy_3\NN|Further|be|and|naturally|, (r_nsubj) recovers_4\VBZ|NONE (l_conj) be_15\VB|Further|and|myopathy|naturally|, (l_attr) recording_18\NN|improvement|.|may (l_cc) of_30\IN|a|just|of|, (l_pobj) protection_32\NN|instead (l_relcl) methylprednisolone_34\NN|any (l_dobj) offers_35\VBZ|that (l_prep) to_36\IN|NONE (l_pobj) injury_40\NN|NONE
D013256_D013119 NONE steroid_26\NN|NONE (r_compound) myopathy_27\NNS|NONE (r_pobj) from_24\IN|motor|this|natural (r_prep) recovery_23\NN|NONE (r_pobj) of_19\IN|a|of|just|, (r_prep) recording_18\NN|improvement|.|may (l_cc) of_30\IN|a|just|of|, (l_pobj) protection_32\NN|instead (l_relcl) methylprednisolone_34\NN|any (l_dobj) offers_35\VBZ|that (l_prep) to_36\IN|NONE (l_pobj) injury_40\NN|NONE
D013256_D009135 NONE steroid_2\NN|NONE (r_compound) myopathy_3\NN|Further|be|and|naturally|,
D013256_D009135 NONE steroid_2\NN|NONE (r_compound) myopathy_3\NN|Further|be|and|naturally|, (r_nsubj) recovers_4\VBZ|NONE (l_conj) be_15\VB|Further|and|myopathy|naturally|, (l_attr) recording_18\NN|improvement|.|may (l_prep) of_19\IN|a|of|just|, (l_pobj) recovery_23\NN|NONE (l_prep) from_24\IN|motor|this|natural (l_pobj) myopathy_27\NNS|NONE
D013256_D009135 NONE steroid_26\NN|NONE (r_compound) myopathy_27\NNS|NONE (r_pobj) from_24\IN|motor|this|natural (r_prep) recovery_23\NN|NONE (r_pobj) of_19\IN|a|of|just|, (r_prep) recording_18\NN|improvement|.|may (r_attr) be_15\VB|Further|and|myopathy|naturally|, (r_conj) recovers_4\VBZ|NONE (l_nsubj) myopathy_3\NN|Further|be|and|naturally|,
D013256_D009135 NONE steroid_26\NN|NONE (r_compound) myopathy_27\NNS|NONE
D008775_D013119 NONE methylprednisolone_3\NN|.|may|harm (r_nsubj) do_5\VB|NONE (l_dobj) harm_7\NN|.|methylprednisolone|may (l_prep) for_8\IN|more (l_pobj) injury_11\NN|NONE
D008775_D013119 NONE methylprednisolone_16\NN|Because|.|standard (r_nsubj) became_17\VBD|NONE (l_prep) Because_0\IN|.|standard|methylprednisolone (l_pobj) Studies_8\NNP|of (l_compound) Injury_7\NNP|National|NASCIS|the|,|(
D008775_D013119 NONE methylprednisolone_16\NN|Because|.|standard (r_nsubj) became_17\VBD|NONE (l_attr) standard_19\NN|Because|.|methylprednisolone (l_prep) for_22\IN|the|of (l_pobj) injury_27\NN|NONE
D008775_D013119 NONE methylprednisolone_34\NN|any (l_dobj) offers_35\VBZ|that (l_prep) to_36\IN|NONE (l_pobj) injury_40\NN|NONE
D008775_D009135 CID methylprednisolone_19\NN|that|may (r_nsubj) cause_21\VB|of|the|myopathy (r_acl) possibility_10\NN|NONE (l_prep) myopathy_14\NNS|cause|of|the
D008775_D009135 CID methylprednisolone_34\NN|any (r_relcl) protection_32\NN|instead (r_pobj) of_30\IN|a|just|of|, (r_cc) recording_18\NN|improvement|.|may (r_attr) be_15\VB|Further|and|myopathy|naturally|, (r_conj) recovers_4\VBZ|NONE (l_nsubj) myopathy_3\NN|Further|be|and|naturally|,
D008775_D009135 CID methylprednisolone_34\NN|any (r_relcl) protection_32\NN|instead (r_pobj) of_30\IN|a|just|of|, (r_cc) recording_18\NN|improvement|.|may (l_prep) of_19\IN|a|of|just|, (l_pobj) recovery_23\NN|NONE (l_prep) from_24\IN|motor|this|natural (l_pobj) myopathy_27\NNS|NONE
D008775_D009135 CID methylprednisolone_14\NN|may|that|myopathy (r_nsubj) cause_19\VB|the (l_ccomp) myopathy_22\NNS|methylprednisolone|may|that
7161250
D006220_D010302 CID haloperidol_10\NN|NONE (r_pobj) of_9\IN|higher (r_prep) doses_8\NNS|and|in (r_pobj) at_6\IN|incidence|.|higher (r_prep) was_4\VBD|NONE (l_nsubj) incidence_1\NN|.|at|higher (l_prep) of_2\IN|The (l_pobj) parkinsonism_3\NN|NONE
D008140_D017109 NONE lorazepam_6\NN|NONE (r_pobj) by_3\IN|was|were|.|,|Akathisia (r_agent) controlled_2\VBN|NONE (l_nsubjpass) Akathisia_0\NNP|was|by|were|.|,
D001569_D017109 NONE benzodiazepine_5\JJ|out|in|the (r_amod) lorazepam_6\NN|NONE (r_pobj) by_3\IN|was|were|.|,|Akathisia (r_agent) controlled_2\VBN|NONE (l_nsubjpass) Akathisia_0\NNP|was|by|were|.|,
19884587
D013449_D000014 CID Sulfonamides_0\NNS|indicating|.|with|were|, (r_nsubjpass) associated_4\VBN|NONE (l_prep) with_5\IN|indicating|Sulfonamides|.|were|, (l_pobj) defects_8\NNS|NONE
D009582_D000014 CID nitrofurantoins_2\NNS|and (r_conj) Sulfonamides_0\NNS|indicating|.|with|were|, (r_nsubjpass) associated_4\VBN|NONE (l_prep) with_5\IN|indicating|Sulfonamides|.|were|, (l_pobj) defects_8\NNS|NONE
D009582_D002971 CID Nitrofurantoins_0\NNS|.|with|AOR|were (r_nsubjpass) associated_2\VBN|NONE (l_appos) AOR_8\NNP|.|with|Nitrofurantoins|were (l_appos) AOR_26\NNP|(|AOR|CI|,|;|=|syndrome|. (l_conj) lip_58\NN|,|(|)|;|CI|,|CI|;|AOR|=|and|(|)|.|defects
D009582_D006344 CID Nitrofurantoins_0\NNS|.|with|AOR|were (r_nsubjpass) associated_2\VBN|NONE (l_appos) AOR_8\NNP|.|with|Nitrofurantoins|were (l_appos) AOR_26\NNP|(|AOR|CI|,|;|=|syndrome|. (l_appos) defects_41\NNS|,|(|)|;|CI|lip|,|CI|;|AOR|=|and|(|)|.
D002511_D000014 NONE cephalosporins_7\NNS|,|and (r_conj) erythromycins_4\NNS|,|,|,|used (r_conj) penicillins_2\NNS|.|with|were|not|,|Reassuringly (r_nsubjpass) associated_18\VBN|NONE (l_prep) with_19\IN|penicillins|.|were|not|,|Reassuringly (l_pobj) defects_22\NNS|NONE
D013449_D018636 CID Sulfonamides_0\NNS|with|were (r_nsubjpass) associated_2\VBN|)|;|,|%|,|confidence|syndrome|.|CI (r_ccomp) interval_17\NN|NONE (l_appos) syndrome_30\NN|)|;|,|%|,|confidence|associated|.|CI
D009582_D002972 CID Nitrofurantoins_0\NNS|.|with|AOR|were (r_nsubjpass) associated_2\VBN|NONE (l_appos) AOR_8\NNP|.|with|Nitrofurantoins|were (l_appos) AOR_26\NNP|(|AOR|CI|,|;|=|syndrome|. (l_conj) lip_58\NN|,|(|)|;|CI|,|CI|;|AOR|=|and|(|)|.|defects (l_prep) with_59\IN|cleft (l_pobj) palate_61\NN|NONE
D010406_D000014 NONE penicillins_2\NNS|.|with|were|not|,|Reassuringly (r_nsubjpass) associated_18\VBN|NONE (l_prep) with_19\IN|penicillins|.|were|not|,|Reassuringly (l_pobj) defects_22\NNS|NONE
D009582_D018636 CID Nitrofurantoins_0\NNS|.|with|AOR|were (r_nsubjpass) associated_2\VBN|NONE (l_appos) AOR_8\NNP|.|with|Nitrofurantoins|were (l_appos) syndrome_24\NN|(|AOR|CI|,|;|=|AOR|.
D009582_D008850 CID Nitrofurantoins_0\NNS|.|with|AOR|were (r_nsubjpass) associated_2\VBN|NONE (l_prep) with_3\IN|.|Nitrofurantoins|AOR|were (l_pobj) anophthalmia_4\NN|NONE (l_conj) microphthalmos_6\NNS|or
D004917_D000014 NONE erythromycins_4\NNS|,|,|,|used (r_conj) penicillins_2\NNS|.|with|were|not|,|Reassuringly (r_nsubjpass) associated_18\VBN|NONE (l_prep) with_19\IN|penicillins|.|were|not|,|Reassuringly (l_pobj) defects_22\NNS|NONE
D013449_D000757 CID Sulfonamides_0\NNS|with|were (r_nsubjpass) associated_2\VBN|)|;|,|%|,|confidence|syndrome|.|CI (l_prep) with_3\IN|Sulfonamides|were (l_pobj) AOR_9\NNP|NONE (l_amod) anencephaly_4\NNS|(|adjusted|]|OR|.|[
D009582_D000853 CID Nitrofurantoins_0\NNS|.|with|AOR|were (r_nsubjpass) associated_2\VBN|NONE (l_prep) with_3\IN|.|Nitrofurantoins|AOR|were (l_pobj) anophthalmia_4\NN|NONE
7292072
D003891_D017180 CID desipramine_4\JJ|NONE (r_amod) toxicity_5\NN|NONE (r_pobj) in_3\IN|ventricular|Variant|. (r_prep) tachycardia_2\NN|NONE
D003891_D017180 CID desipramine_10\NN|NONE (r_amod) toxicity_11\NN|NONE (r_pobj) by_9\IN|NONE (r_agent) induced_8\VBN|ventricular|variant (r_acl) tachycardia_7\NN|NONE
D003891_D064420 NONE desipramine_4\JJ|NONE (r_amod) toxicity_5\NN|NONE
D003891_D064420 NONE desipramine_10\NN|NONE (r_amod) toxicity_11\NN|NONE
3750012
D002738_D001172 NONE chloroquine_6\NN|for (r_amod) therapy_7\NN|and (l_prep) for_8\IN|chloroquine (l_pobj) arthritis_10\NN|NONE
D002738_D001172 NONE chloroquine_18\NN|for (r_compound) therapy_19\NN|and (l_prep) for_20\IN|chloroquine (l_pobj) arthritis_22\NN|NONE
D010396_D001172 NONE penicillamine_4\NN|NONE (l_conj) therapy_7\NN|and (l_prep) for_8\IN|chloroquine (l_pobj) arthritis_10\NN|NONE
D010396_D001172 NONE penicillamine_16\NN|NONE (l_conj) therapy_19\NN|and (l_prep) for_20\IN|chloroquine (l_pobj) arthritis_22\NN|NONE
D010396_D009157 CID penicillamine_4\NN|NONE (r_pobj) by_3\IN|NONE (r_agent) caused_2\VBN|.|Myasthenia (r_acl) gravis_1\NN|NONE
D010396_D009157 CID penicillamine_16\NN|NONE (r_pobj) after_15\IN|gravis|who (r_prep) had_7\VBD|a|unique (l_dobj) gravis_14\NN|after|who
D002738_D009157 CID chloroquine_6\NN|for (r_amod) therapy_7\NN|and (r_conj) penicillamine_4\NN|NONE (r_pobj) by_3\IN|NONE (r_agent) caused_2\VBN|.|Myasthenia (r_acl) gravis_1\NN|NONE
D002738_D009157 CID chloroquine_18\NN|for (r_compound) therapy_19\NN|and (r_conj) penicillamine_16\NN|NONE (r_pobj) after_15\IN|gravis|who (r_prep) had_7\VBD|a|unique (l_dobj) gravis_14\NN|after|who
7791169
D016595_D010146 NONE misoprostol_2\NNP|NONE (r_pobj) of_1\IN|NONE (r_prep) Addition_0\NN|impairment|without|can|. (r_nsubj) minimize_4\VB|NONE (l_prep) without_8\IN|impairment|Addition|can|. (l_pcomp) affecting_9\VBG|NONE (l_dobj) control_11\NN|NONE (l_compound) pain_10\NN|NONE
D007213_D007674 CID indomethacin_5\NN|NONE (r_pobj) on_4\IN|NONE (r_prep) misoprostol_3\NNP|NONE (r_pobj) of_2\IN|Protective (r_prep) effect_1\NN|dysfunction|. (r_nsubj) induced_6\VBD|NONE (l_dobj) dysfunction_8\NN|effect|.
D007213_D007674 CID indomethacin_8\NN|renal|related (r_nmod) dysfunction_11\NN|NONE
D016595_D007674 NONE misoprostol_3\NNP|NONE (r_pobj) of_2\IN|Protective (r_prep) effect_1\NN|dysfunction|. (r_nsubj) induced_6\VBD|NONE (l_dobj) dysfunction_8\NN|effect|.
D016595_D007674 NONE misoprostol_2\NNP|NONE (r_pobj) of_1\IN|NONE (r_prep) Addition_0\NN|impairment|without|can|. (r_nsubj) minimize_4\VB|NONE (l_dobj) impairment_7\NN|Addition|without|can|.
9201797
D006220_D002375 CID haloperidol_14\NN| (r_npadvmod) induced_16\VBN|in (r_amod) catalepsy_17\NN|NONE
D006220_D002375 CID haloperidol_11\NN| (r_npadvmod) induced_13\VBN|the (r_amod) catalepsy_14\NN|NONE
D006220_D002375 CID haloperidol_7\NN| (r_npadvmod) induced_9\VBN|NONE (r_amod) catalepsy_10\NN|that|expected|carteolol|and|via
D002354_D009069 NONE Carteolol_0\NNP|did|not|.|signs (r_nsubj) evoke_3\VB|NONE (l_dobj) signs_10\NNS|did|Carteolol|not|. (l_prep) as_12\IN|dopamine|behavioral|stimulating|postsynaptic (l_pobj) stereotypy_13\NN|such (l_conj) hyperlocomotion_15\NN|in|and
D006220_D017109 NONE haloperidol_7\NN| (r_npadvmod) induced_9\VBN|NONE (r_amod) catalepsy_10\NN|that|expected|carteolol|and|via (r_dobj) improves_6\VBZ|strongly|results|. (l_conj) expected_20\VBN|catalepsy|that|carteolol|and|via (l_xcomp) be_22\VB|is (l_acomp) effective_23\JJ|to (l_prep) in_24\IN|NONE (l_pobj) treatment_26\NN|NONE (l_prep) of_27\IN|the|without (l_pobj) akathisia_28\NN|NONE
D002354_D002375 NONE hydrochloride_5\NN|NONE (r_pobj) of_3\IN|.|The|attenuating|on (r_prep) effect_2\NN|NONE (l_prep) on_13\IN|.|The|attenuating|of (l_pobj) catalepsy_17\NN|NONE
D002354_D002375 NONE carteolol_5\NN|NONE (r_pobj) of_4\IN|,|antagonist|the (r_prep) effects_3\NNS|behaviorally|and|,|Therefore|were|compared|. (l_appos) antagonist_11\NN|,|of|the (l_prep) on_13\IN|,|a|adrenoceptor (l_pobj) catalepsy_17\NN|NONE
D002354_D002375 NONE Carteolol_0\NNP|NONE (l_conj) propranolol_5\NN|.|as|, (l_conj) inhibited_9\VBD|and|biperiden|, (l_dobj) catalepsy_14\NN|NONE
D002354_D002375 NONE carteolol_5\NN|catalepsy|that|expected|and|via (r_nsubj) improves_6\VBZ|strongly|results|. (l_dobj) catalepsy_10\NN|that|expected|carteolol|and|via
D004298_D009069 NONE dopamine_5\NN|behavioral|stimulating|postsynaptic|as (r_nmod) signs_10\NNS|did|Carteolol|not|. (l_prep) as_12\IN|dopamine|behavioral|stimulating|postsynaptic (l_pobj) stereotypy_13\NN|such (l_conj) hyperlocomotion_15\NN|in|and
D004298_D017109 NONE dopamine_40\NN|NONE (r_nmod) receptor_41\NN|antagonistic|its|postsynaptic (r_nmod) activity_43\NN|NONE (r_pobj) to_37\IN|NONE (r_pcomp) due_36\IN|effects (r_prep) attenuating_30\VBG|NONE (r_pcomp) without_29\IN|the|of (r_prep) treatment_26\NN|NONE (l_prep) of_27\IN|the|without (l_pobj) akathisia_28\NN|NONE
D011433_D002375 NONE propranolol_28\NN|NONE (r_pobj) of_27\IN|antagonist|, (r_prep) those_26\DT|NONE (r_pobj) with_25\IN|NONE (r_prep) compared_24\VBN|behaviorally|effects|and|,|Therefore|were|. (r_conj) studied_22\VBN|NONE (l_nsubjpass) effects_3\NNS|behaviorally|and|,|Therefore|were|compared|. (l_appos) antagonist_11\NN|,|of|the (l_prep) on_13\IN|,|a|adrenoceptor (l_pobj) catalepsy_17\NN|NONE
D011433_D002375 NONE propranolol_5\NN|.|as|, (l_conj) inhibited_9\VBD|and|biperiden|, (l_dobj) catalepsy_14\NN|NONE
D002354_D017109 NONE carteolol_5\NN|catalepsy|that|expected|and|via (r_nsubj) improves_6\VBZ|strongly|results|. (l_conj) expected_20\VBN|catalepsy|that|carteolol|and|via (l_xcomp) be_22\VB|is (l_acomp) effective_23\JJ|to (l_prep) in_24\IN|NONE (l_pobj) treatment_26\NN|NONE (l_prep) of_27\IN|the|without (l_pobj) akathisia_28\NN|NONE
D004298_D002375 NONE dopamine_40\NN|NONE (r_nmod) receptor_41\NN|antagonistic|its|postsynaptic (r_nmod) activity_43\NN|NONE (r_pobj) to_37\IN|NONE (r_pcomp) due_36\IN|effects (r_prep) attenuating_30\VBG|NONE (r_pcomp) without_29\IN|the|of (r_prep) treatment_26\NN|NONE (r_pobj) in_24\IN|NONE (r_prep) effective_23\JJ|to (r_acomp) be_22\VB|is (r_xcomp) expected_20\VBN|catalepsy|that|carteolol|and|via (r_conj) improves_6\VBZ|strongly|results|. (l_dobj) catalepsy_10\NN|that|expected|carteolol|and|via
D001712_D002375 NONE biperiden_30\VBN|and (r_conj) propranolol_28\NN|NONE (r_pobj) of_27\IN|antagonist|, (r_prep) those_26\DT|NONE (r_pobj) with_25\IN|NONE (r_prep) compared_24\VBN|behaviorally|effects|and|,|Therefore|were|. (r_conj) studied_22\VBN|NONE (l_nsubjpass) effects_3\NNS|behaviorally|and|,|Therefore|were|compared|. (l_appos) antagonist_11\NN|,|of|the (l_prep) on_13\IN|,|a|adrenoceptor (l_pobj) catalepsy_17\NN|NONE
D001712_D002375 NONE biperiden_7\RB|and|inhibited|, (r_conj) propranolol_5\NN|.|as|, (l_conj) inhibited_9\VBD|and|biperiden|, (l_dobj) catalepsy_14\NN|NONE
3108839
D016685_D006463 CID C_1\NNP|.|syndrome (r_nsubj) associated_2\VBD|NONE (l_dobj) syndrome_5\NN|.|C
D016685_D006463 CID C_1\NNP|Syndrome (r_nsubj) associated_2\VBD|condition|. (l_dobj) Syndrome_5\NNP|C
D016685_D006463 CID C_1\NNP|Syndrome (r_nsubj) associated_2\VBD|condition|. (l_dobj) Syndrome_5\NNP|C (l_appos) HUS_7\NNP|Hemolytic|Uremic|)
D016685_D051437 CID C_15\NN|mitomycin (r_compound) treatment_16\NN|NONE (r_pobj) with_13\IN|and (r_prep) associated_12\VBN|progressive|renal (r_acl) failure_11\NN|and
D016685_D051437 CID C_14\NN|mitomycin (r_compound) treatment_15\NN|NONE (r_pobj) of_12\IN|NONE (r_prep) start_11\NN|NONE (r_pobj) after_10\IN|is|failure|usually|and|mth (r_prep) develops_4\VBZ|NONE (l_nsubj) failure_2\NN|is|after|usually|and|mth
D016685_D051437 CID C_14\NN|mitomycin (r_compound) treatment_15\NN|NONE (r_pobj) of_12\IN|NONE (r_prep) start_11\NN|NONE (r_pobj) after_10\IN|is|failure|usually|and|mth (r_prep) develops_4\VBZ|NONE (l_conj) is_19\VBZ|failure|after|usually|and|mth (l_attr) %_22\NN|.|mortality (l_prep) from_23\IN| (l_pobj) failure_25\NN|NONE
D016685_D051437 CID C_29\NN|NONE (r_pobj) with_27\IN|NONE (r_prep) treatment_26\NN|while (r_pobj) on_25\IN|died|course|We|.|and|in (r_advcl) describe_1\VBP|NONE (l_prep) in_8\IN|on|died|course|We|.|and (l_pobj) man_14\NN|NONE (l_relcl) developed_19\VBD|a|with|old| (l_dobj) failure_21\NN|thrombocytopenia|who|and
D016685_D013921 NONE C_15\NN|mitomycin (r_compound) treatment_16\NN|NONE (r_pobj) with_13\IN|and (r_prep) associated_12\VBN|progressive|renal (r_acl) failure_11\NN|and (r_conj) thrombocytopenia_7\JJ|microangiopathic|,|hemolytic
D016685_D013921 NONE C_29\NN|NONE (r_pobj) with_27\IN|NONE (r_prep) treatment_26\NN|while (r_pobj) on_25\IN|died|course|We|.|and|in (r_advcl) describe_1\VBP|NONE (l_prep) in_8\IN|on|died|course|We|.|and (l_pobj) man_14\NN|NONE (l_relcl) developed_19\VBD|a|with|old| (l_conj) thrombocytopenia_23\NN|who|failure|and
D016685_D000743 NONE C_15\NN|mitomycin (r_compound) treatment_16\NN|NONE (r_pobj) with_13\IN|and (r_prep) associated_12\VBN|progressive|renal (r_acl) failure_11\NN|and (r_conj) thrombocytopenia_7\JJ|microangiopathic|,|hemolytic (r_conj) anemia_5\NN|NONE
D016685_D013274 NONE C_29\NN|NONE (r_pobj) with_27\IN|NONE (r_prep) treatment_26\NN|while (r_pobj) on_25\IN|died|course|We|.|and|in (r_advcl) describe_1\VBP|NONE (l_prep) in_8\IN|on|died|course|We|.|and (l_pobj) man_14\NN|NONE (l_prep) with_15\IN|a|developed|old| (l_pobj) adenocarcinoma_17\NN|NONE
D016685_D011654 NONE C_14\NN|mitomycin (r_compound) treatment_15\NN|NONE (r_pobj) of_12\IN|NONE (r_prep) start_11\NN|NONE (r_pobj) after_10\IN|is|failure|usually|and|mth (r_prep) develops_4\VBZ|NONE (l_conj) is_19\VBZ|failure|after|usually|and|mth (l_attr) %_22\NN|.|mortality (l_prep) from_23\IN| (l_pobj) failure_25\NN|NONE (l_conj) edema_28\NN|renal|or
D016685_D011654 NONE C_29\NN|NONE (r_pobj) with_27\IN|NONE (r_prep) treatment_26\NN|while (r_pobj) on_25\IN|died|course|We|.|and|in (r_advcl) describe_1\VBP|NONE (l_conj) died_31\VBD|on|course|We|.|and|in (l_prep) in_32\IN|NONE (l_pobj) edema_34\NN|NONE
14596845
D013395_D006948 CID sucrose_6\NN|had|that (r_dobj) experienced_4\VBN|The (r_relcl) animals_1\NNS|.|hyperactive|in|compared (r_nsubj) were_9\VBD|NONE (l_acomp) hyperactive_10\JJ|.|in|animals|compared
D013395_D006948 CID sucrose_25\NN|chow|,|(|)|chow|,|four|control (r_appos) groups_19\NNS|NONE (r_pobj) with_16\IN|NONE (r_prep) compared_15\VBN|.|hyperactive|in|animals (r_prep) were_9\VBD|NONE (l_acomp) hyperactive_10\JJ|.|in|animals|compared
D013395_D006948 CID sucrose_50\NN|,|or (r_conj) amphetamine_44\NN|NONE (r_pobj) with_43\IN|ad|libitum (r_prep) chow_42\NN|,|(|sucrose|)|chow|,|four|control (r_appos) groups_19\NNS|NONE (r_pobj) with_16\IN|NONE (r_prep) compared_15\VBN|.|hyperactive|in|animals (r_prep) were_9\VBD|NONE (l_acomp) hyperactive_10\JJ|.|in|animals|compared
D000661_D019966 NONE amphetamine_15\NN|NONE (r_pobj) of_14\IN|a|low (r_prep) dose_13\NN|NONE (r_pobj) to_10\IN|behavioral||cross (r_prep) sensitization_9\NN|diet|. (r_dobj) causes_5\VBZ|NONE (l_nsubj) diet_1\NN|sensitization|. (l_acl) promoting_2\VBG|A (l_dobj) dependency_4\NN|NONE
D000661_D006948 CID amphetamine_15\NN|NONE (r_pobj) of_14\IN|a|low (r_prep) dose_13\NN|NONE (r_pobj) to_10\IN|behavioral||cross (r_prep) sensitization_9\NN|diet|.
D000661_D006948 CID amphetamine_24\NN|NONE (r_pobj) of_23\IN|low|a (r_prep) dose_22\NN|NONE (r_pobj) to_19\IN|whether|sensitization|rats|would (r_prep) show_14\VB|study|. (l_dobj) sensitization_18\NN|whether|to|rats|would
D000661_D006948 CID amphetamine_14\NN|NONE (r_pobj) to_13\IN|NONE (r_prep) response_12\NN|NONE (r_pobj) in_11\IN|.|hyperactive|animals|compared (r_prep) were_9\VBD|NONE (l_acomp) hyperactive_10\JJ|.|in|animals|compared
D000661_D006948 CID amphetamine_30\NN|NONE (r_compound) injection_31\NN|NONE (r_pobj) by_29\IN|NONE (r_agent) followed_28\VBN|%|chow|and|libitum (r_acl) sucrose_25\NN|chow|,|(|)|chow|,|four|control (r_appos) groups_19\NNS|NONE (r_pobj) with_16\IN|NONE (r_prep) compared_15\VBN|.|hyperactive|in|animals (r_prep) were_9\VBD|NONE (l_acomp) hyperactive_10\JJ|.|in|animals|compared
D000661_D006948 CID amphetamine_37\NN|NONE (r_compound) injection_38\NN|NONE (r_pobj) by_36\IN|NONE (r_agent) followed_35\VBN|cyclic (r_acl) chow_34\NN|chow|,|(|sucrose|)|,|four|control (r_appos) groups_19\NNS|NONE (r_pobj) with_16\IN|NONE (r_prep) compared_15\VBN|.|hyperactive|in|animals (r_prep) were_9\VBD|NONE (l_acomp) hyperactive_10\JJ|.|in|animals|compared
D000661_D006948 CID amphetamine_44\NN|NONE (r_pobj) with_43\IN|ad|libitum (r_prep) chow_42\NN|,|(|sucrose|)|chow|,|four|control (r_appos) groups_19\NNS|NONE (r_pobj) with_16\IN|NONE (r_prep) compared_15\VBN|.|hyperactive|in|animals (r_prep) were_9\VBD|NONE (l_acomp) hyperactive_10\JJ|.|in|animals|compared
9758264
D005492_D001327 NONE acid_35\NN|NONE (r_pobj) of_33\IN|>|(|the|)|therapeutic (r_prep) dose_25\NN|therefore|,|damage|.|cluster (r_nsubj) triggered_36\VBD|NONE (l_ccomp) damage_15\VB|therefore|,|.|dose|cluster (l_nsubj) disease_6\NN|barrier|could
D005492_D001327 NONE acid_9\NN|NONE (r_pobj) of_7\IN|(|)|<| (r_prep) mg_5\NN|Physiological|in|without|,|, (r_appos) dose_1\NN|did|risk|not|. (l_prep) without_19\IN|Physiological|in|,|,|mg (l_pobj) disease_22\NN|all
D005492_D000014 NONE acid_6\NN| (r_npadvmod) containing_8\VBG|multivitamin|folic|in (r_amod) supplementation_10\NN|NONE (r_pobj) of_4\IN|the (r_prep) effect_3\NN|in|To|.|before (r_dobj) study_1\VB|NONE (l_prep) in_18\IN|effect|To|.|before (l_pobj) order_19\NN|NONE (l_acl) determine_21\VB|NONE (l_dobj) rate_23\NN|to (l_prep) of_24\IN|the (l_pobj) defects_27\NNS|NONE
D005492_D008180 CID acid_4\NN|NONE (r_pobj) of_2\IN|Epileptogenic (r_prep) activity_1\NN|after|)|SLE (r_nsubj) induces_7\VBZ|NONE (l_dobj) SLE_8\NNP|activity|after|)
D005492_D008180 CID acid_11\NN|( (r_appos) SLE_8\NNP|activity|after|)
D005492_D008180 CID acid_35\NN|NONE (r_pobj) of_33\IN|>|(|the|)|therapeutic (r_prep) dose_25\NN|therefore|,|damage|.|cluster (r_nsubj) triggered_36\VBD|NONE (l_ccomp) damage_15\VB|therefore|,|.|dose|cluster (l_nsubj) disease_6\NN|barrier|could (l_appos) lupus_12\NN|(|autoimmune|patient|)
D005492_D004827 NONE acid_4\NN|NONE (r_pobj) of_2\IN|Epileptogenic (r_prep) activity_1\NN|after|)|SLE (r_nsubj) induces_7\VBZ|NONE (l_dobj) SLE_8\NNP|activity|after|) (l_appos) acid_11\NN|( (l_conj) epilepsy_13\NN|and|folic
D005492_D004827 NONE acid_11\NN|( (l_conj) epilepsy_13\NN|and|folic
D005492_D004827 NONE acid_6\NN| (r_npadvmod) containing_8\VBG|multivitamin|folic|in (r_amod) supplementation_10\NN|NONE (l_prep) in_11\IN|containing|multivitamin|folic (l_pobj) women_13\NNS|NONE (l_amod) epileptic_12\JJ|NONE
D005492_D004827 NONE acid_6\NN| (r_npadvmod) containing_8\VBG|multivitamin|folic|in (r_amod) supplementation_10\NN|NONE (r_pobj) of_4\IN|the (r_prep) effect_3\NN|in|To|.|before (r_dobj) study_1\VB|NONE (l_prep) in_18\IN|effect|To|.|before (l_pobj) order_19\NN|NONE (l_acl) determine_21\VB|NONE (l_dobj) rate_23\NN|to (l_prep) of_24\IN|the (l_pobj) defects_27\NNS|NONE (l_conj) effects_33\NNS|birth|structural|and (l_amod) related_31\VBN|side (l_npadvmod) epilepsy_29\NN|
D005492_D004827 NONE acid_7\NN|NONE (r_pobj) with_4\IN|epileptic||. (r_prep) women_3\NNS|NONE (l_amod) epileptic_2\JJ|with||.
D005492_D004827 NONE acid_7\NN|NONE (l_appos) effects_21\NNS|periconceptional|supplementation|,|(|folic (l_amod) related_19\VBN|side|during|developed (l_npadvmod) epilepsy_17\NN|
D005492_D004827 NONE acid_14\NN|and (r_conj) carbamazepine_10\NN|NONE (r_pobj) by_9\IN|.|woman|was|continuously (r_agent) treated_7\VBN|NONE (l_nsubjpass) woman_5\NN|.|by|was|continuously (l_amod) epileptic_4\JJ|This|old
D005492_D004827 NONE acid_35\NN|NONE (r_pobj) of_33\IN|>|(|the|)|therapeutic (r_prep) dose_25\NN|therefore|,|damage|.|cluster (r_nsubj) triggered_36\VBD|NONE (l_ccomp) damage_15\VB|therefore|,|.|dose|cluster (l_nsubj) disease_6\NN|barrier|could (l_poss) patient_3\NN|(|autoimmune|)|lupus (l_amod) epileptic_1\JJ|'s|The|pregnant
D005492_D004827 NONE acid_9\NN|NONE (r_pobj) of_7\IN|(|)|<| (r_prep) mg_5\NN|Physiological|in|without|,|, (r_appos) dose_1\NN|did|risk|not|. (l_prep) in_11\IN|Physiological|without|,|,|mg (l_pobj) women_16\NNS|both (l_amod) epileptic_15\JJ||healthy
D005492_D004827 NONE acid_9\NN|NONE (r_pobj) of_7\IN|(|)|<| (r_prep) mg_5\NN|Physiological|in|without|,|, (r_appos) dose_1\NN|did|risk|not|. (r_nsubj) increase_26\VB|NONE (l_dobj) risk_28\NN|dose|did|not|. (l_prep) for_29\IN|the (l_pobj) seizures_31\NNS|NONE
D005492_D012640 CID acid_35\NN|NONE (r_pobj) of_33\IN|>|(|the|)|therapeutic (r_prep) dose_25\NN|therefore|,|damage|.|cluster (r_nsubj) triggered_36\VBD|NONE (l_dobj) cluster_38\NN|therefore|,|damage|.|dose (l_prep) of_39\IN|a (l_pobj) seizures_40\NNS|NONE
D002220_D004827 NONE carbamazepine_10\NN|NONE (r_pobj) by_9\IN|.|woman|was|continuously (r_agent) treated_7\VBN|NONE (l_nsubjpass) woman_5\NN|.|by|was|continuously (l_amod) epileptic_4\JJ|This|old
1527456
D008012_D014012 NONE lignocaine_7\NN|NONE (r_pobj) of_6\IN|intratympanic (r_prep) instillation_5\NN|NONE (r_pobj) by_3\IN|.||of|through (r_prep) Treatment_0\NN|NONE (l_prep) of_1\IN|.||through|by (l_pobj) tinnitus_2\NN|NONE
D008012_D014012 NONE lidocaine_9\NN|NONE (r_appos) lignocaine_7\NN|NONE (r_pobj) of_6\IN|intratympanic (r_prep) instillation_5\NN|NONE (r_pobj) by_3\IN|.||of|through (r_prep) Treatment_0\NN|NONE (l_prep) of_1\IN|.||through|by (l_pobj) tinnitus_2\NN|NONE
D008012_D014012 NONE lignocaine_12\NN|NONE (r_pobj) of_11\IN|intratympanic (r_prep) instillation_10\NN|NONE (r_pobj) by_8\IN|IST (r_prep) treating_6\VBG|NONE (l_dobj) IST_7\NNP|by
D008012_D014012 NONE lidocaine_14\NN|NONE (r_appos) lignocaine_12\NN|NONE (r_pobj) of_11\IN|intratympanic (r_prep) instillation_10\NN|NONE (r_pobj) by_8\IN|IST (r_prep) treating_6\VBG|NONE (l_dobj) IST_7\NNP|by
7421734
D004967_D006689 NONE estrogens_16\NNS|treatment (r_dobj) received_14\VBD|and|failure|,|She|. (r_conj) had_1\VBD|NONE (l_dobj) failure_3\NN|and|,|received|She|. (l_prep) after_4\IN|ovarian (l_pobj) irradiation_6\NN|NONE (l_prep) for_9\IN|chemotherapy|and|abdominal (l_pobj) disease_11\NN|NONE
D004967_D016889 CID estrogens_16\NNS|treatment (r_dobj) received_14\VBD|and|failure|,|She|. (l_npadvmod) treatment_19\NN|estrogens (l_acl) implicated_20\VBN|a|, (l_prep) in_21\IN|NONE (l_pobj) development_23\NN|NONE (l_prep) of_24\IN|the (l_pobj) cancer_26\NN|NONE
D004967_D016889 CID estrogens_4\NNS|NONE (r_pobj) on_2\IN|Young (r_prep) women_1\NNS|and|examined|risk|may|also|have|therapy|after|. (r_nsubj) increased_14\VBN|NONE (l_dobj) risk_15\NN|and|examined|may|also|have|therapy|women|after|. (l_prep) of_16\IN|NONE (l_pobj) carcinoma_18\NN|NONE
D004967_D010049 NONE estrogens_16\NNS|treatment (r_dobj) received_14\VBD|and|failure|,|She|. (r_conj) had_1\VBD|NONE (l_dobj) failure_3\NN|and|,|received|She|.
D004967_D010049 NONE estrogens_4\NNS|NONE (l_prep) for_5\IN|replacement (l_pobj) failure_7\NN|NONE
D004967_D009369 NONE estrogens_4\NNS|NONE (r_pobj) on_2\IN|Young (r_prep) women_1\NNS|and|examined|risk|may|also|have|therapy|after|. (r_nsubj) increased_14\VBN|NONE (l_nsubj) therapy_10\NN|and|examined|risk|may|also|have|women|after|. (l_compound) cancer_9\NN|NONE
2887062
D001971_D015175 NONE bromocriptine_14\NN|NONE (r_amod) treatment_15\NN|NONE (r_pobj) after_13\IN|induced|rat (r_prep) prolactinomas_12\NNS|NONE
D001971_D015175 NONE bromocriptine_5\NN|NONE (r_pobj) of_4\IN|on|the (r_prep) effects_3\NNS|To (l_prep) on_6\IN|the|of (l_pobj) cells_8\NNS|NONE (l_compound) prolactinoma_7\NN|in
D001971_D015175 NONE bromocriptine_5\NN|NONE (r_pobj) of_4\IN|on|the (r_prep) effects_3\NNS|To (r_dobj) clarify_1\VB|.|to|were|analyses|h (r_advcl) applied_19\VBN|NONE (l_prep) to_20\IN|.|clarify|were|analyses|h (l_pobj) cells_26\NNS|NONE (l_compound) prolactinoma_25\NN|rat|and|h|induced
D001971_D015175 NONE bromocriptine_35\NN|NONE (r_pobj) of_34\IN|NONE (r_prep) injection_33\NN|NONE (r_pobj) after_32\IN||mg/kg (r_prep) h_31\NN|.|to|clarify|were|analyses (r_conj) applied_19\VBN|NONE (l_advcl) clarify_1\VB|.|to|were|analyses|h (l_dobj) effects_3\NNS|To (l_prep) on_6\IN|the|of (l_pobj) cells_8\NNS|NONE (l_compound) prolactinoma_7\NN|in
D001971_D015175 NONE bromocriptine_35\NN|NONE (r_pobj) of_34\IN|NONE (r_prep) injection_33\NN|NONE (r_pobj) after_32\IN||mg/kg (r_prep) h_31\NN|.|to|clarify|were|analyses (r_conj) applied_19\VBN|NONE (l_prep) to_20\IN|.|clarify|were|analyses|h (l_pobj) cells_26\NNS|NONE (l_compound) prolactinoma_25\NN|rat|and|h|induced
D001971_D000236 NONE bromocriptine_15\JJ|of (r_amod) treatment_16\NN|NONE (l_prep) of_17\IN|bromocriptine (l_pobj) cells_20\NNS|NONE (l_compound) adenoma_19\NN|the
D004967_D015175 CID estrogen_8\NN| (r_npadvmod) induced_10\VBN|rat|after (r_amod) prolactinomas_12\NNS|NONE
D004967_D015175 CID estrogen_21\NN| (r_npadvmod) induced_23\VBN|rat|and|h|prolactinoma (r_amod) cells_26\NNS|NONE (r_pobj) to_20\IN|.|clarify|were|analyses|h (r_prep) applied_19\VBN|NONE (l_advcl) clarify_1\VB|.|to|were|analyses|h (l_dobj) effects_3\NNS|To (l_prep) on_6\IN|the|of (l_pobj) cells_8\NNS|NONE (l_compound) prolactinoma_7\NN|in
D004967_D015175 CID estrogen_21\NN| (r_npadvmod) induced_23\VBN|rat|and|h|prolactinoma (r_amod) cells_26\NNS|NONE (l_compound) prolactinoma_25\NN|rat|and|h|induced
6127992
D000319_D017202 NONE drugs_24\NNS|NONE (r_pobj) with_17\IN|combined (r_prep) therapy_16\NN|NONE (r_pobj) during_14\IN|NONE (r_prep) bradycardia_13\NN|and (r_conj) hypotension_11\NN|,|profound|cardiac (r_conj) failure_9\NN|.|patients (r_dobj) developed_6\VBD|NONE (l_nsubj) patients_1\NNS|.|failure (l_prep) with_2\IN|Three (l_pobj) disease_5\NN|NONE
D000319_D007022 CID drugs_24\NNS|NONE (r_pobj) with_17\IN|combined (r_prep) therapy_16\NN|NONE (r_pobj) during_14\IN|NONE (r_prep) bradycardia_13\NN|and (r_conj) hypotension_11\NN|,|profound|cardiac
D000319_D001919 CID drugs_24\NNS|NONE (r_pobj) with_17\IN|combined (r_prep) therapy_16\NN|NONE (r_pobj) during_14\IN|NONE (r_prep) bradycardia_13\NN|and
D014700_D017202 NONE verapamil_18\NN|blocking (r_nmod) drugs_24\NNS|NONE (r_pobj) with_17\IN|combined (r_prep) therapy_16\NN|NONE (r_pobj) during_14\IN|NONE (r_prep) bradycardia_13\NN|and (r_conj) hypotension_11\NN|,|profound|cardiac (r_conj) failure_9\NN|.|patients (r_dobj) developed_6\VBD|NONE (l_nsubj) patients_1\NNS|.|failure (l_prep) with_2\IN|Three (l_pobj) disease_5\NN|NONE
D014700_D001919 CID verapamil_18\NN|blocking (r_nmod) drugs_24\NNS|NONE (r_pobj) with_17\IN|combined (r_prep) therapy_16\NN|NONE (r_pobj) during_14\IN|NONE (r_prep) bradycardia_13\NN|and
D014700_D007022 CID verapamil_18\NN|blocking (r_nmod) drugs_24\NNS|NONE (r_pobj) with_17\IN|combined (r_prep) therapy_16\NN|NONE (r_pobj) during_14\IN|NONE (r_prep) bradycardia_13\NN|and (r_conj) hypotension_11\NN|,|profound|cardiac
D000319_D006333 CID drugs_24\NNS|NONE (r_pobj) with_17\IN|combined (r_prep) therapy_16\NN|NONE (r_pobj) during_14\IN|NONE (r_prep) bradycardia_13\NN|and (r_conj) hypotension_11\NN|,|profound|cardiac (r_conj) failure_9\NN|.|patients
D014700_D006333 CID verapamil_18\NN|blocking (r_nmod) drugs_24\NNS|NONE (r_pobj) with_17\IN|combined (r_prep) therapy_16\NN|NONE (r_pobj) during_14\IN|NONE (r_prep) bradycardia_13\NN|and (r_conj) hypotension_11\NN|,|profound|cardiac (r_conj) failure_9\NN|.|patients
9862868
D004997_D002780 CID estradiol_9\NNP|and|(|extrahepatic|)|EE (r_nmod) treatment_13\NN|by (r_nmod) cholestasis_16\NN|models|determine|We|. (r_dobj) used_1\VBD|NONE (l_dobj) models_3\NNS|determine|We|.|cholestasis (l_prep) of_4\IN|rat (l_pobj) cholestasis_6\NN|NONE
D004997_D002780 CID EE_11\NNP|and|estradiol|(|extrahepatic|) (r_nmod) treatment_13\NN|by (r_nmod) cholestasis_16\NN|models|determine|We|. (r_dobj) used_1\VBD|NONE (l_dobj) models_3\NNS|determine|We|.|cholestasis (l_prep) of_4\IN|rat (l_pobj) cholestasis_6\NN|NONE
D004997_D001651 NONE estradiol_9\NNP|and|(|extrahepatic|)|EE (r_nmod) treatment_13\NN|by (r_nmod) cholestasis_16\NN|models|determine|We|.
D004997_D001651 NONE EE_11\NNP|and|estradiol|(|extrahepatic|) (r_nmod) treatment_13\NN|by (r_nmod) cholestasis_16\NN|models|determine|We|.
7905523
C059896_D015658 NONE deoxynojirimycin_10\NNP|cells|.|safety|/ (l_conj) zidovudine_15\NN||SC||N|and|butyl (l_prep) in_16\IN|NONE (l_pobj) patients_17\NNS|NONE (l_prep) with_18\IN|and (l_pobj) infection_20\NN|NONE
C059896_D015658 NONE SC-48334_12\NNP|||N|zidovudine|and|butyl (r_appos) deoxynojirimycin_10\NNP|cells|.|safety|/ (l_conj) zidovudine_15\NN||SC||N|and|butyl (l_prep) in_16\IN|NONE (l_pobj) patients_17\NNS|NONE (l_prep) with_18\IN|and (l_pobj) infection_20\NN|NONE
D015215_D015658 NONE zidovudine_15\NN||SC||N|and|butyl (l_prep) in_16\IN|NONE (l_pobj) patients_17\NNS|NONE (l_prep) with_18\IN|and (l_pobj) infection_20\NN|NONE
C059896_D007153 NONE SC-48334_2\VBP|mean|The|ml|state|trough (r_nmod) level_7\NN|.|below (r_nsubj) was_16\VBD|NONE (l_prep) below_17\IN|.|level (l_pobj) concentration_22\NN|NONE (l_prep) for_23\IN|the|vitro|inhibitory (l_pobj) virus_26\NN|NONE (l_compound) immunodeficiency_25\NN|)|human|(|HIV
3431591
C031662_D001943 NONE 3717_6\CD|NONE (r_nummod) CB_5\NNP|NONE (r_pobj) with_4\IN|early|clinical (r_prep) studies_3\NNS|NONE (r_pobj) In_0\IN|has|.|activity|in|,|been (r_prep) seen_11\VBN|NONE (l_prep) in_12\IN|has|.|In|activity|,|been (l_pobj) cancer_14\NN|NONE
C031662_D064420 NONE 3717_1\CD|,|acid|, (r_nummod) CB_0\NN|inhibitor|. (r_nsubj) is_6\VBZ|NONE (l_attr) inhibitor_11\NN|CB|. (l_relcl) mediated_21\VBN|a|of|binding (l_nsubjpass) cytotoxicity_19\NN|is|through
C031662_D064420 NONE acid_4\NN||,|, (r_appos) CB_0\NN|inhibitor|. (r_nsubj) is_6\VBZ|NONE (l_attr) inhibitor_11\NN|CB|. (l_relcl) mediated_21\VBN|a|of|binding (l_nsubjpass) cytotoxicity_19\NN|is|through
C031662_D064420 NONE 3717_28\CD|, (r_nummod) CB_27\NNP|NONE (r_pobj) than_26\IN|more (r_prep) potent_25\JJ||,||, (r_amod) 26-_17\NNPS|and|be|respectively|,|As (r_attr) are_16\VBP|NONE (l_conj) be_39\VB|and|respectively||,|As (l_attr) determinant_42\NN|.|may|,|formation|therefore|, (l_prep) of_43\IN|important|an (l_pobj) cytotoxicity_46\NN|NONE
C031662_D064420 NONE 3717_45\CD|CB (r_nummod) cytotoxicity_46\NN|NONE
C031662_D006528 NONE 3717_6\CD|NONE (r_nummod) CB_5\NNP|NONE (r_pobj) with_4\IN|early|clinical (r_prep) studies_3\NNS|NONE (r_pobj) In_0\IN|has|.|activity|in|,|been (r_prep) seen_11\VBN|NONE (l_prep) in_12\IN|has|.|In|activity|,|been (l_pobj) cancer_14\NN|NONE (l_conj) cancer_17\NN|breast|, (l_conj) hepatoma_19\NN|ovarian|,
C031662_D008654 NONE 3717_6\CD|NONE (r_nummod) CB_5\NNP|NONE (r_pobj) with_4\IN|early|clinical (r_prep) studies_3\NNS|NONE (r_pobj) In_0\IN|has|.|activity|in|,|been (r_prep) seen_11\VBN|NONE (l_prep) in_12\IN|has|.|In|activity|,|been (l_pobj) cancer_14\NN|NONE (l_conj) cancer_17\NN|breast|, (l_conj) hepatoma_19\NN|ovarian|, (l_conj) mesothelioma_22\NN|and|,
C031662_D010051 NONE 3717_6\CD|NONE (r_nummod) CB_5\NNP|NONE (r_pobj) with_4\IN|early|clinical (r_prep) studies_3\NNS|NONE (r_pobj) In_0\IN|has|.|activity|in|,|been (r_prep) seen_11\VBN|NONE (l_prep) in_12\IN|has|.|In|activity|,|been (l_pobj) cancer_14\NN|NONE (l_conj) cancer_17\NN|breast|,
2266990
D008454_D020388 NONE mazindol_7\NN|NONE (l_prep) in_8\IN|NONE (l_pobj) dystrophy_10\NN|NONE
D008454_D020388 NONE mazindol_7\NN|NONE (r_pobj) of_6\IN|,|,|a|controlled|inhibitor|month (r_prep) trial_5\NN|.|We|in (r_dobj) conducted_1\VBD|NONE (l_prep) in_16\IN|trial|.|We (l_pobj) boys_18\NNS|NONE (l_prep) with_19\IN| (l_pobj) dystrophy_21\NN|NONE
D008454_D020388 NONE Mazindol_0\JJ|NONE (r_compound) doses_1\NNS|.|progression|not (r_nsubj) slow_3\VBP|NONE (l_dobj) progression_5\NN|.|doses|not (l_prep) of_6\IN|the (l_pobj) weakness_7\NN|NONE (l_prep) in_8\IN|NONE (l_pobj) dystrophy_10\NN|NONE
D008454_D018908 NONE Mazindol_0\JJ|NONE (r_compound) doses_1\NNS|.|progression|not (r_nsubj) slow_3\VBP|NONE (l_dobj) progression_5\NN|.|doses|not (l_prep) of_6\IN|the (l_pobj) weakness_7\NN|NONE
D008454_D012817 CID mazindol_4\NN|NONE (r_pobj) to_3\IN|NONE (r_prep) attributable_2\JJ|Side (r_amod) effects_1\NNS|appetite (r_nsubj) included_5\VBN|dosage|was|.|;|in (l_dobj) appetite_7\NN|effects (l_appos) change_21\NN|%|decreased|(|,|,|mouth|) (l_conj) symptoms_29\NNS|%|,|behavioral|)|and|(
D008454_D012817 CID mazindol_35\NN|NONE (r_amod) dosage_36\NN|included|was|.|;|in (r_nsubjpass) reduced_38\VBN|NONE (l_ccomp) included_5\VBN|dosage|was|.|;|in (l_dobj) appetite_7\NN|effects (l_appos) change_21\NN|%|decreased|(|,|,|mouth|) (l_conj) symptoms_29\NNS|%|,|behavioral|)|and|(
D008454_D014987 CID mazindol_4\NN|NONE (r_pobj) to_3\IN|NONE (r_prep) attributable_2\JJ|Side (r_amod) effects_1\NNS|appetite (r_nsubj) included_5\VBN|dosage|was|.|;|in (l_dobj) appetite_7\NN|effects (l_appos) mouth_14\NN|%|decreased|change|(|,|,|)
D008454_D014987 CID mazindol_35\NN|NONE (r_amod) dosage_36\NN|included|was|.|;|in (r_nsubjpass) reduced_38\VBN|NONE (l_ccomp) included_5\VBN|dosage|was|.|;|in (l_dobj) appetite_7\NN|effects (l_appos) mouth_14\NN|%|decreased|change|(|,|,|)
D008454_D001068 CID mazindol_4\NN|NONE (r_pobj) to_3\IN|NONE (r_prep) attributable_2\JJ|Side (r_amod) effects_1\NNS|appetite (r_nsubj) included_5\VBN|dosage|was|.|;|in (l_dobj) appetite_7\NN|effects
D008454_D001068 CID mazindol_35\NN|NONE (r_amod) dosage_36\NN|included|was|.|;|in (r_nsubjpass) reduced_38\VBN|NONE (l_ccomp) included_5\VBN|dosage|was|.|;|in (l_dobj) appetite_7\NN|effects
17923537
D005446_D014605 NONE acetonide_9\NN|fluocinolone (r_compound) implants_10\NNS|NONE (r_pobj) with_7\IN|NONE (r_prep) treated_6\VBN|.|in|Intraocular (r_acl) pressure_1\NN|NONE (l_prep) in_2\IN|.|treated|Intraocular (l_pobj) patients_3\NNS|NONE (l_prep) with_4\IN|NONE (l_pobj) uveitis_5\NN|NONE
D005446_D014605 NONE acetonide_21\NN|NONE (r_pobj) with_18\IN|NONE (r_prep) treated_17\VBN|with (r_acl) patients_14\NNS|NONE (l_prep) with_15\IN|treated (l_pobj) uveitis_16\NN|NONE
D005446_D014605 NONE FA_23\NNP|intravitreal|)|( (r_nmod) implant_26\NN|the|fluocinolone (r_appos) acetonide_21\NN|NONE (r_pobj) with_18\IN|NONE (r_prep) treated_17\VBN|with (r_acl) patients_14\NNS|NONE (l_prep) with_15\IN|treated (l_pobj) uveitis_16\NN|NONE
D005446_D009798 CID acetonide_21\NN|NONE (r_pobj) with_18\IN|NONE (r_prep) treated_17\VBN|with (r_acl) patients_14\NNS|NONE (r_pobj) in_13\IN|and|management|of|the (r_prep) incidence_3\NN|.|To (l_prep) of_6\IN|and|management|the|in (l_pobj) pressure_9\NN|NONE
D005446_D009798 CID FA_23\NNP|intravitreal|)|( (r_nmod) implant_26\NN|the|fluocinolone (r_appos) acetonide_21\NN|NONE (r_pobj) with_18\IN|NONE (r_prep) treated_17\VBN|with (r_acl) patients_14\NNS|NONE (r_pobj) in_13\IN|and|management|of|the (r_prep) incidence_3\NN|.|To (l_prep) of_6\IN|and|management|the|in (l_pobj) pressure_9\NN|NONE
10737864
D003000_D001919 CID clonidine_14\NN|NONE (r_pobj) given_12\VBN|withdrawal (r_prep) induces_15\VBZ|and|Given|,|pattern (l_dobj) withdrawal_17\NN|given (l_conj) bradycardia_19\NNP|sympathetic|and
D003000_D001919 CID clonidine_24\NN|developmental|on (r_poss) effects_27\NNS|other|that|would (r_nsubj) mirror_35\VB|.|we|,|exhibits (r_ccomp) hypothesized_22\VBD|NONE (l_ccomp) exhibits_5\VBZ|mirror|.|we|, (l_conj) induces_15\VBZ|and|Given|,|pattern (l_dobj) withdrawal_17\NN|given (l_conj) bradycardia_19\NNP|sympathetic|and
D003000_D001919 CID clonidine_19\NN| (r_npadvmod) induced_21\VBN|NONE (r_amod) bradycardia_22\NN|and|cardiac|baseline
10910842
D011239_D018908 CID Prednisolone_0\NNP| (r_npadvmod) induced_2\VBN|muscle (r_amod) dysfunction_4\NN|is|by|.|more
D000109_D001284 NONE acetylcholine_13\NN|altered|receptor (r_compound) expression_15\NN|NONE (r_pobj) by_11\IN|NONE (r_prep) than_10\IN|NONE (r_prep) atrophy_9\NN|NONE
D000109_D009133 NONE acetylcholine_22\NN|receptor (r_compound) expression_24\NN|NONE (r_pobj) in_21\IN|NONE (r_prep) changes_20\NNS|NONE (r_pobj) from_19\IN|NONE (r_prep) less_18\JJR|NONE (r_advmod) derive_17\VB|primarily|and|from (r_conj) derive_11\VBP|dependent|effects|that|and (l_prep) from_13\IN|derive|primarily|and (l_pobj) atrophy_15\NN|NONE
D011239_D009133 CID prednisolone_8\NN|NONE (r_pobj) after_7\IN|neuromuscular|the (r_prep) dysfunction_6\NN|dependent|that|and|derives|, (r_nsubj) is_9\VBZ|results|. (l_conj) derives_15\VBZ|dependent|that|and|dysfunction|, (l_prep) from_17\IN|primarily|derives|and (l_pobj) atrophy_19\NN|NONE
D014403_D013746 NONE tubocurarine_27\NN|NONE (r_pobj) of_24\IN|response|in|the (r_prep) curves_23\NNS|and|, (r_conj) fatigability_16\NN|and|,|tetanic (r_conj) tensions_13\NNS|,|peak|evoked|twitch|the (l_compound) tetanic_12\JJ|and|,|fatigability
D011239_D001284 NONE Prednisolone_0\NNP| (r_npadvmod) induced_2\VBN|muscle (r_amod) dysfunction_4\NN|is|by|.|more (r_nsubjpass) caused_6\VBN|NONE (l_agent) by_8\IN|is|.|more|dysfunction (l_pobj) atrophy_9\NN|NONE
D000109_D018908 NONE acetylcholine_13\NN|altered|receptor (r_compound) expression_15\NN|NONE (r_pobj) by_11\IN|NONE (r_prep) than_10\IN|NONE (r_prep) atrophy_9\NN|NONE (r_pobj) by_8\IN|is|.|more|dysfunction (r_agent) caused_6\VBN|NONE (l_nsubjpass) dysfunction_4\NN|is|by|.|more
D011239_D009468 NONE prednisolone_8\NN|NONE (r_pobj) after_7\IN|neuromuscular|the (r_prep) dysfunction_6\NN|dependent|that|and|derives|,
3997294
D013256_D011014 NONE steroid_26\NN|continued (r_compound) therapy_27\NN|ensure|but (r_conj) prompt_23\JJ|,|of|immediate|and (r_conj) withdrawal_18\NN|Review|.|need|, (r_dobj) indicates_7\VBZ|NONE (l_dobj) need_9\NN|Review|.|withdrawal|, (l_prep) for_10\IN|the (l_pobj) diagnosis_12\NN|NONE (l_prep) of_13\IN|early (l_pobj) pneumonitis_15\NN|NONE
D000638_D009422 NONE amiodarone_9\NN|NONE (r_compound) therapy_10\NN|NONE (r_pobj) during_8\IN|neuropathy|and|pleural (r_prep) effusion_5\NN|NONE (l_conj) neuropathy_7\NN|and|during|pleural
D000638_D010996 CID amiodarone_9\NN|NONE (r_compound) therapy_10\NN|NONE (r_pobj) during_8\IN|neuropathy|and|pleural (r_prep) effusion_5\NN|NONE
D000638_D013617 NONE amiodarone_11\NN|NONE (l_prep) for_28\IN|dose|(|, (l_pobj) control_29\NN|NONE (l_prep) of_30\IN|NONE (l_pobj) tachyarrhythmias_32\NNS|NONE
D000638_D010490 CID amiodarone_9\NN|NONE (r_compound) therapy_10\NN|NONE (r_pobj) during_8\IN|neuropathy|and|pleural (r_prep) effusion_5\NN|NONE
D000638_D002318 NONE amiodarone_11\NN|NONE (r_pobj) with_10\IN|was|.|patient (r_prep) treated_9\VBN|NONE (l_nsubjpass) patient_1\NN|with|was|. (l_prep) with_2\IN|pacemaker|A|and (l_pobj) disease_4\NN|NONE
D000638_D011014 CID amiodarone_14\NN|NONE (r_compound) pneumonitis_15\NN|NONE
D000638_D011014 CID amiodarone_20\NN|NONE (r_pobj) of_19\IN|,|prompt|immediate|and (r_prep) withdrawal_18\NN|Review|.|need|, (r_dobj) indicates_7\VBZ|NONE (l_dobj) need_9\NN|Review|.|withdrawal|, (l_prep) for_10\IN|the (l_pobj) diagnosis_12\NN|NONE (l_prep) of_13\IN|early (l_pobj) pneumonitis_15\NN|NONE
220563
C023470_D000787 NONE maleate_12\NN|in|and (r_pobj) with_10\IN|of|for|a (r_prep) complication_7\NN|NONE (l_prep) for_30\IN|with|of|a (l_pobj) treatment_33\NN|NONE (l_prep) of_34\IN|prophylactic|the (l_pobj) pectoris_36\NN|NONE
C023470_D010523 CID maleate_1\NN|NONE (l_conj) neuropathy_4\NN|and|Perhexiline|.
C023470_D010523 CID maleate_12\NN|in|and (r_pobj) with_10\IN|of|for|a (r_prep) complication_7\NN|NONE (r_pobj) as_5\IN|neuropathy|been|.|has (r_prep) noted_4\VBN|NONE (l_nsubjpass) neuropathy_1\NN|been|.|has|as
1549199
D007980_D012893 NONE levodopa_13\RB| (r_npadvmod) induced_15\VBN|,|disturbances (r_amod) psychosis_16\NN|orthostatic|, (l_conj) disturbances_19\NNS|,|induced
D007980_D020447 CID levodopa_13\RB| (r_npadvmod) induced_15\VBN|,|disturbances (r_amod) psychosis_16\NN|orthostatic|, (l_conj) disturbances_19\NNS|,|induced (l_conj) parasomnias_21\NNS|or|sleep
D007980_D007024 CID levodopa_13\RB| (r_npadvmod) induced_15\VBN|,|disturbances (r_amod) psychosis_16\NN|orthostatic|, (r_conj) hypotension_11\NN|,|gastrointestinal
D007980_D005767 CID levodopa_13\RB| (r_npadvmod) induced_15\VBN|,|disturbances (r_amod) psychosis_16\NN|orthostatic|, (r_conj) hypotension_11\NN|,|gastrointestinal (r_conj) disorders_8\NNS|such
D002230_D064420 NONE carbidopa_36\NN|"||,|to|lead (r_compound) levodopa_38\NN|to (l_relcl) lead_49\VB|"||carbidopa|,|to (l_prep) to_50\IN|can|which (l_pobj) toxicity_51\NN|NONE
D007980_D011618 NONE levodopa_13\RB| (r_npadvmod) induced_15\VBN|,|disturbances (r_amod) psychosis_16\NN|orthostatic|,
D007980_D064420 NONE levodopa_9\NN|NONE (r_compound) therapy_10\NN|NONE (r_pobj) for_8\IN|NONE (r_prep) dose_7\NN|NONE (r_dobj) starting_6\NN|no|single (r_acl) correct_5\JJ|there|While (r_attr) is_2\VBZ|following|be|can|on|.|individuals|,|, (r_advcl) started_16\VBN|NONE (l_prep) following_27\VBG|is|be|can|on|.|individuals|,|, (l_pobj) rule_30\NN|NONE (l_relcl) attempt_33\VB|general|the (l_xcomp) titrate_35\VB|to|not (l_dobj) levodopa_38\NN|to (l_relcl) lead_49\VB|"||carbidopa|,|to (l_prep) to_50\IN|can|which (l_pobj) toxicity_51\NN|NONE
D007980_D064420 NONE levodopa_38\NN|to (l_relcl) lead_49\VB|"||carbidopa|,|to (l_prep) to_50\IN|can|which (l_pobj) toxicity_51\NN|NONE
18768591
D004317_D005355 NONE Doxorubicin_0\NNP| (r_npadvmod) induced_2\VBN|NONE (r_amod) nephropathy_3\NN|.|to (r_nsubj) leads_4\VBZ|NONE (l_prep) to_5\IN|.|nephropathy (l_pobj) channel_8\NN|NONE (l_appos) retention_12\NN|epithelial|sodium (l_conj) fibrosis_15\NN|volume|(|ENaC)dependent|and
D014508_D009404 NONE urea_8\NN|serum (r_compound) concentrations_9\NNS|than|in|During|,|)|faster (r_nsubj) increased_10\VBD|NONE (l_prep) During_0\IN|than|in|concentrations|,|)|faster (l_pobj) course_2\NN|NONE (l_prep) of_3\IN|the (l_pobj) syndrome_5\NN|NONE
D000450_D009404 NONE aldosterone_1\NN|Plasma (r_compound) levels_2\NNS|followed|.|and|in (r_nsubj) increased_3\VBD|NONE (l_prep) in_4\IN|levels|followed|.|and (l_pobj) mice_6\NNS|NONE (l_amod) nephrotic_5\JJ|of
D000450_D005355 NONE aldosterone_1\NN| (r_npadvmod) sensitive_3\JJ|kinase|The (r_amod) SGK1_10\NNP|has|participate|been|. (r_nsubjpass) shown_13\VBN|NONE (l_xcomp) participate_15\VB|has|been|.|SGK (l_conj) mediate_23\VB|and|in|to (l_dobj) fibrosis_25\NN|to
D012964_D016055 NONE sodium_7\NN|epithelial|retention (r_compound) channel_8\NN|NONE (l_appos) retention_12\NN|epithelial|sodium
D004317_D011507 CID Doxorubicin_0\NNP|NONE (r_compound) treatment_1\NN|and|in|/|)|. (r_nsubj) resulted_2\VBD|NONE (l_prep) in_3\IN|and|/|treatment|)|. (l_pobj) proteinuria_5\NN|NONE
D004317_D009404 CID doxorubicin_8\NN| (r_npadvmod) induced_10\VBN|nephrotic (r_amod) syndrome_12\NN|NONE
D004317_D009404 CID Doxorubicin_0\NNP|NONE (r_compound) treatment_1\NN|and|in|/|)|. (r_nsubj) resulted_2\VBD|NONE (l_conj) 15/44_21\CD|and|in|treatment|)|. (l_prep) of_22\IN|NONE (l_pobj) mice_25\NNS|NONE (l_acl) leading_26\VBG|)|sgk(/ (l_prep) to_27\IN|NONE (l_pobj) syndrome_30\NN|NONE
D012964_D005355 NONE sodium_7\NN|epithelial|retention (r_compound) channel_8\NN|NONE (l_appos) retention_12\NN|epithelial|sodium (l_conj) fibrosis_15\NN|volume|(|ENaC)dependent|and
D004317_D034141 CID Doxorubicin_0\NNP|NONE (r_compound) treatment_1\NN|and|in|/|)|. (r_nsubj) resulted_2\VBD|NONE (l_conj) 15/44_21\CD|and|in|treatment|)|. (l_prep) of_22\IN|NONE (l_pobj) mice_25\NNS|NONE (l_acl) leading_26\VBG|)|sgk(/ (l_prep) to_27\IN|NONE (l_pobj) syndrome_30\NN|NONE (l_prep) with_31\IN|nephrotic|severe (l_pobj) ascites_32\NNS|NONE (l_conj) lipidemia_34\NN|, (l_conj) hypoalbuminemia_37\VB|,|and
D004317_D001201 CID Doxorubicin_0\NNP|NONE (r_compound) treatment_1\NN|and|in|/|)|. (r_nsubj) resulted_2\VBD|NONE (l_conj) 15/44_21\CD|and|in|treatment|)|. (l_prep) of_22\IN|NONE (l_pobj) mice_25\NNS|NONE (l_acl) leading_26\VBG|)|sgk(/ (l_prep) to_27\IN|NONE (l_pobj) syndrome_30\NN|NONE (l_prep) with_31\IN|nephrotic|severe (l_pobj) ascites_32\NNS|NONE
D004317_D007674 NONE Doxorubicin_0\NNP| (r_npadvmod) induced_2\VBN|NONE (r_amod) nephropathy_3\NN|.|to
D004317_D016055 NONE Doxorubicin_0\NNP| (r_npadvmod) induced_2\VBN|NONE (r_amod) nephropathy_3\NN|.|to (r_nsubj) leads_4\VBZ|NONE (l_prep) to_5\IN|.|nephropathy (l_pobj) channel_8\NN|NONE (l_appos) retention_12\NN|epithelial|sodium
D012964_D007674 NONE sodium_7\NN|epithelial|retention (r_compound) channel_8\NN|NONE (r_pobj) to_5\IN|.|nephropathy (r_prep) leads_4\VBZ|NONE (l_nsubj) nephropathy_3\NN|.|to
D004317_D006949 CID Doxorubicin_0\NNP|NONE (r_compound) treatment_1\NN|and|in|/|)|. (r_nsubj) resulted_2\VBD|NONE (l_conj) 15/44_21\CD|and|in|treatment|)|. (l_prep) of_22\IN|NONE (l_pobj) mice_25\NNS|NONE (l_acl) leading_26\VBG|)|sgk(/ (l_prep) to_27\IN|NONE (l_pobj) syndrome_30\NN|NONE (l_prep) with_31\IN|nephrotic|severe (l_pobj) ascites_32\NNS|NONE (l_conj) lipidemia_34\NN|,
16160878
D003345_D010409 NONE corticosterone_35\NN|induced (r_compound) level_36\NN|,|was|.|effect|erection|,|and|administration (r_conj) had_12\VBD|NONE (l_dobj) erection_25\NN|,|level|was|.|effect|,|and|administration
D014579_D001919 NONE II_8\NNP|NONE (r_pobj) of_5\IN|NONE (r_prep) injection_4\NN|.|stimulates|hypertension|Intracerebroventricular|and (r_nsubj) causes_9\NNS|NONE (l_dobj) hypertension_10\NN|.|injection|stimulates|Intracerebroventricular|and (l_conj) bradycardia_12\NN|and
D014579_D006973 NONE II_8\NNP|NONE (r_pobj) of_5\IN|NONE (r_prep) injection_4\NN|.|stimulates|hypertension|Intracerebroventricular|and (r_nsubj) causes_9\NNS|NONE (l_dobj) hypertension_10\NN|.|injection|stimulates|Intracerebroventricular|and
D014579_D001523 NONE II_6\NNP|may|that|in|be (r_nsubjpass) involved_9\VBN|data|. (l_prep) in_10\IN|may|that|II|be (l_pobj) aspects_12\NNS|NONE (l_prep) of_13\IN|some (l_pobj) disorders_15\NNS|NONE
D014579_D010409 NONE II_11\NNP|NONE (r_pobj) of_8\IN|the|central (r_prep) administration_7\NN|,|level|was|.|effect|erection|,|and (r_nsubj) had_12\VBD|NONE (l_dobj) erection_25\NN|,|level|was|.|effect|,|and|administration
D001058_D010409 CID apomorphine_21\NN| (r_npadvmod) induced_23\VBN|penile|and|behavior (r_amod) erection_25\NN|,|level|was|.|effect|,|and|administration
8045270
D006220_D002375 CID haloperidol_7\NN|by|and (r_pobj) by_6\IN|NONE (r_agent) induced_5\VBN|the (r_acl) catalepsy_4\NN|also|.|KF
D000241_D002375 NONE adenosine_23\NN|,|AA|receptor|an|CGS (r_amod) agonist_26\NN|NONE (r_pobj) of_21\IN|intracerebroventricular (r_prep) administration_20\NN|NONE (r_pobj) by_18\IN|NONE (r_agent) induced_17\VBN|cataleptic|the (r_acl) responses_16\NNS|,|significantly|in|.|administration (l_amod) cataleptic_15\JJ|the|induced
C081198_D002375 NONE KF17837_3\NNP|NONE (r_pobj) of_2\IN|.|Oral (r_prep) administration_1\NN|,|responses|significantly|in|. (r_nsubj) ameliorated_13\VBD|NONE (l_dobj) responses_16\NNS|,|significantly|in|.|administration (l_amod) cataleptic_15\JJ|the|induced
C081198_D002375 NONE KF17837_0\NN|catalepsy|also|. (r_nsubj) reduced_2\VBD|NONE (l_dobj) catalepsy_4\NN|also|.|KF
D012110_D002375 CID reserpine_15\NN|NONE (r_pobj) by_14\IN|haloperidol|and (r_conj) by_6\IN|NONE (r_agent) induced_5\VBN|the (r_acl) catalepsy_4\NN|also|.|KF
C081198_D010302 NONE KF17837_2\NN|Furthermore|drug|.|may|, (r_nsubj) be_4\VB|NONE (l_attr) drug_7\NN|KF|Furthermore|.|may|, (l_prep) in_8\IN|a|useful (l_pobj) treatment_10\NN|NONE (l_prep) of_11\IN|the (l_pobj) parkinsonism_12\NN|NONE
C061282_D002375 CID 21680_29\CD|micrograms|(|) (r_nummod) CGS_28\NNP|adenosine|,|AA|receptor|an (r_appos) agonist_26\NN|NONE (r_pobj) of_21\IN|intracerebroventricular (r_prep) administration_20\NN|NONE (r_pobj) by_18\IN|NONE (r_agent) induced_17\VBN|cataleptic|the (r_acl) responses_16\NNS|,|significantly|in|.|administration (l_amod) cataleptic_15\JJ|the|induced
8384253
D014750_D009422 NONE vincristine_8\NN|NONE (r_pobj) with_4\IN|signs|that|reversible (r_prep) are_17\VBP|good (l_nsubj) signs_11\NNS|that|with|reversible (l_conj) symptoms_13\NNS|schedule|dose|and (l_prep) of_14\IN|NONE (l_pobj) neuropathy_16\NN|NONE
D014750_D009422 NONE vincristine_15\NN|NONE (r_compound) neuropathy_16\NN|NONE
D014750_D008228 NONE vincristine_10\NN|NONE (r_pobj) with_9\IN|patients|.|investigated|between (r_prep) treated_8\VBN|NONE (l_nsubj) patients_1\NNS|with|.|investigated|between (l_prep) with_2\IN|Forty (l_pobj) Lymphoma_7\NNP|NONE
D014750_D008228 NONE vincristine_37\NN|NONE (r_pobj) of_36\IN|term|the|on (r_prep) effects_35\NNS|to (r_dobj) evaluate_31\VB|NONE (r_acl) order_29\NN|NONE (r_pobj) in_28\IN|(|were|dose (r_prep) investigated_27\VBN|with|patients|.|between (r_parataxis) treated_8\VBN|NONE (l_nsubj) patients_1\NNS|with|.|investigated|between (l_prep) with_2\IN|Forty (l_pobj) Lymphoma_7\NNP|NONE
2576810
D009627_D006948 CID nomifensine_4\NN|NONE (r_pobj) by_3\IN|NONE (r_agent) induced_2\VBN|The (r_acl) hyperactivity_1\NN|.|unaffected
D016666_D006948 CID fluvoxamine_4\NNP|NONE (r_pobj) with_3\IN|)|daily|repeated|(|A (r_prep) treatment_2\NN|weaker|hyperactivity|.|in (r_nsubj) potentiated_12\VBN|NONE (l_dobj) hyperactivity_25\NN|weaker|treatment|.|in
D016666_D006948 CID fluvoxamine_10\NN|NONE (r_pobj) by_9\IN|NONE (r_prep) unaffected_8\JJ|hyperactivity|. (r_acomp) remained_7\VBD|NONE (l_nsubj) hyperactivity_1\NN|.|unaffected
D000661_D006948 CID amphetamine_22\NN| (r_npadvmod) induced_24\VBN|the (r_amod) hyperactivity_25\NN|weaker|treatment|.|in
11206082
D010433_D012640 CID pentylenetetrazol_27\NN| (r_npadvmod) induced_29\VBN|and (r_conj) picrotoxin-_25\NN|after (r_amod) seizures_30\NNS|the|vigilance|,|and
C036150_D012640 CID carboline_10\NN| (r_npadvmod) induced_12\VBN|NONE (r_amod) seizures_13\NNS|NONE
C036150_D012640 CID carboline-3-carboxylate_32\NN|NONE (r_pobj) of_28\IN|a|i.p.|single (r_prep) injection_27\NN|NONE (r_pobj) by_23\IN|NONE (r_agent) induced_22\VBN|NONE (r_acl) seizures_21\NNS|NONE
C036150_D012640 CID CCM_36\NNP|agonist|beta||)|,|methyl (r_appos) carboline-3-carboxylate_32\NN|NONE (r_pobj) of_28\IN|a|i.p.|single (r_prep) injection_27\NN|NONE (r_pobj) by_23\IN|NONE (r_agent) induced_22\VBN|NONE (r_acl) seizures_21\NNS|NONE
D003975_D012640 NONE diazepam_2\NN| (r_npadvmod) induced_4\VBN|NONE (r_amod) anxiolysis_5\NN|,|.|with|sedation|We (r_dobj) measured_1\VBD|NONE (l_dobj) sedation_17\NN|,|anxiolysis|.|with|We (l_prep) by_18\IN|induced (l_pcomp) recording_19\VBG|NONE (l_dobj) states_22\NNS|NONE (l_conj) seizures_30\NNS|the|vigilance|,|and
D003975_D012640 NONE diazepam_14\NN| (r_npadvmod) induced_16\VBN|by (r_amod) sedation_17\NN|,|anxiolysis|.|with|We (l_prep) by_18\IN|induced (l_pcomp) recording_19\VBG|NONE (l_dobj) states_22\NNS|NONE (l_conj) seizures_30\NNS|the|vigilance|,|and
D001569_D012640 NONE benzodiazepine_47\NN|GABA(A|the|receptor (r_amod) site_48\NN|NONE (r_pobj) of_42\IN|inverse|an (r_prep) agonist_41\NN|beta||)|CCM|,|methyl (r_appos) carboline-3-carboxylate_32\NN|NONE (r_pobj) of_28\IN|a|i.p.|single (r_prep) injection_27\NN|NONE (r_pobj) by_23\IN|NONE (r_agent) induced_22\VBN|NONE (r_acl) seizures_21\NNS|NONE
D005680_D012640 NONE GABA(A_24\NNP|)|other|receptor (r_nmod) ligands_27\NNS|NONE (r_pobj) of_22\IN|pharmacological|various (r_prep) effects_21\NNS|NONE (r_pobj) to_18\IN|differentially (r_prep) sensitive_17\JJ|lines|also|. (r_acomp) are_14\VBP|NONE (l_nsubj) lines_2\NNS|also|sensitive|. (l_acl) selected_3\VBN|Two|mouse (l_prep) for_4\IN|NONE (l_pobj) sensitivities_6\NNS|NONE (l_prep) to_7\IN|differential (l_pobj) seizures_13\NNS|NONE
D005680_D012640 NONE GABA(A_44\NNP|benzodiazepine|the|receptor (r_nmod) site_48\NN|NONE (r_pobj) of_42\IN|inverse|an (r_prep) agonist_41\NN|beta||)|CCM|,|methyl (r_appos) carboline-3-carboxylate_32\NN|NONE (r_pobj) of_28\IN|a|i.p.|single (r_prep) injection_27\NN|NONE (r_pobj) by_23\IN|NONE (r_agent) induced_22\VBN|NONE (r_acl) seizures_21\NNS|NONE
D010852_D012640 CID picrotoxin-_25\NN|after (r_amod) seizures_30\NNS|the|vigilance|,|and
7843916
D013256_D005901 NONE Steroid_0\NN|NONE (r_compound) treatment_1\NN|.|in (r_nsubj) resulted_2\VBD|NONE (l_prep) in_3\IN|.|treatment (l_pobj) changes_5\NNS|NONE (l_prep) in_6\IN|morphologic (l_pobj) meshwork_9\NN|NONE (l_amod) similar_10\JJ|trabecular|the (l_prep) to_11\IN|NONE (l_pobj) those_12\DT|NONE (l_acl) reported_13\VBN|NONE (l_prep) for_14\IN|NONE (l_pobj) glaucoma_16\NN|NONE
D013256_D005902 NONE Steroid_0\NN|NONE (r_compound) treatment_1\NN|.|in (r_nsubj) resulted_2\VBD|NONE (l_prep) in_3\IN|.|treatment (l_pobj) changes_5\NNS|NONE (l_prep) in_6\IN|morphologic (l_pobj) meshwork_9\NN|NONE (l_amod) similar_10\JJ|trabecular|the (l_prep) to_11\IN|NONE (l_pobj) those_12\DT|NONE (l_acl) reported_13\VBN|NONE (l_prep) for_14\IN|NONE (l_pobj) glaucoma_16\NN|NONE (l_conj) glaucoma_20\NN|and|corticosteroid
D003907_D009798 CID Dexamethasone_0\NN|hypertension||. (r_npadvmod) induced_2\VBN|NONE (l_dobj) hypertension_4\NN|Dexamethasone||.
D003907_D009798 CID dexamethasone_4\NN| (r_npadvmod) treated_6\VBN|hypertensive|the (r_amod) eyes_8\NNS|,|beams|In|.|,|had|decreased
D003907_D009798 CID Dexamethasone_0\NN|of (r_compound) treatment_1\NN|.|to (r_nsubj) led_10\VBD|NONE (l_prep) to_11\IN|.|treatment (l_pobj) generation_13\NN|NONE (l_prep) of_14\IN|the|in (l_pobj) hypertension_16\NN|NONE
D003907_D009798 CID dexamethasone_23\NN| (r_npadvmod) treated_25\VBN|the (r_amod) eyes_26\NNS|NONE (r_pobj) of_21\IN| (r_prep) %_20\NN|NONE (r_pobj) in_17\IN|of|the (r_prep) generation_13\NN|NONE (l_prep) of_14\IN|the|in (l_pobj) hypertension_16\NN|NONE
18417364
D010100_D009759 NONE oxygen_4\NN|)|activity|BOLD|in|dependent|( (r_nmod) levels_12\NNS|NONE (r_pobj) with_2\IN|NIN|. (r_prep) correlated_1\VBD|NONE (l_nsubj) NIN_0\NNP|with|.
D009538_D009759 CID Nicotine_0\NN| (r_npadvmod) induced_2\VBN|NONE (r_amod) nystagmus_3\NN|with|.
D009538_D009759 CID nicotine_3\NN| (r_npadvmod) induced_5\VBN|NIN|(|) (r_amod) nystagmus_6\NN|NONE
D009538_D009759 CID nicotine_3\NN| (r_npadvmod) induced_5\VBN|NIN|(|) (r_amod) nystagmus_6\NN|NONE (l_appos) NIN_8\NNP|induced|(|)
9305828
D010862_D012640 NONE pilocarpine_1\NN|by|model|.|is (r_nsubjpass) characterized_9\VBN|NONE (l_agent) by_10\IN|pilocarpine|model|.|is (l_pobj) period_13\NN|NONE (l_acl) followed_17\VBN|an|of|acute (l_agent) by_18\IN|NONE (l_pobj) seizures_21\NNS|NONE
D010862_D012640 NONE PILO_3\NNP|(|)|of (r_nmod) model_5\NN|pilocarpine|by|.|is (r_nsubjpass) characterized_9\VBN|NONE (l_agent) by_10\IN|pilocarpine|model|.|is (l_pobj) period_13\NN|NONE (l_acl) followed_17\VBN|an|of|acute (l_agent) by_18\IN|NONE (l_pobj) seizures_21\NNS|NONE
D010862_D004833 CID pilocarpine_6\NN|of|the (r_amod) model_7\NN|NONE (l_prep) of_8\IN|pilocarpine|the (l_pobj) epilepsy_11\NN|NONE
D010862_D004833 CID PILO_30\NNP|the|of (r_amod) model_31\NN|NONE (l_prep) of_32\IN|PILO|the (l_pobj) TLE_33\NNP|NONE
D010862_D004827 NONE pilocarpine_1\NN|by|model|.|is (r_nsubjpass) characterized_9\VBN|NONE (l_nsubjpass) model_5\NN|pilocarpine|by|.|is (l_prep) of_6\IN|(|)|PILO (l_pobj) epilepsy_7\NN|NONE
D010862_D004827 NONE PILO_3\NNP|(|)|of (r_nmod) model_5\NN|pilocarpine|by|.|is (l_prep) of_6\IN|(|)|PILO (l_pobj) epilepsy_7\NN|NONE
D010862_D001930 NONE pilocarpine_1\NN|by|model|.|is (r_nsubjpass) characterized_9\VBN|NONE (l_agent) by_10\IN|pilocarpine|model|.|is (l_pobj) period_13\NN|NONE (l_acl) followed_17\VBN|an|of|acute (l_agent) by_18\IN|NONE (l_pobj) seizures_21\NNS|NONE (l_conj) damage_25\NN|spontaneous|and|recurrent
D010862_D001930 NONE PILO_3\NNP|(|)|of (r_nmod) model_5\NN|pilocarpine|by|.|is (r_nsubjpass) characterized_9\VBN|NONE (l_agent) by_10\IN|pilocarpine|model|.|is (l_pobj) period_13\NN|NONE (l_acl) followed_17\VBN|an|of|acute (l_agent) by_18\IN|NONE (l_pobj) seizures_21\NNS|NONE (l_conj) damage_25\NN|spontaneous|and|recurrent
D010862_D013226 NONE pilocarpine_1\NN|by|model|.|is (r_nsubjpass) characterized_9\VBN|NONE (l_agent) by_10\IN|pilocarpine|model|.|is (l_pobj) period_13\NN|NONE (l_prep) of_14\IN|an|followed|acute (l_pobj) epilepticus_16\NN|NONE
D010862_D013226 NONE PILO_3\NNP|(|)|of (r_nmod) model_5\NN|pilocarpine|by|.|is (r_nsubjpass) characterized_9\VBN|NONE (l_agent) by_10\IN|pilocarpine|model|.|is (l_pobj) period_13\NN|NONE (l_prep) of_14\IN|an|followed|acute (l_pobj) epilepticus_16\NN|NONE
2632720
D006854_D006973 NONE cortisol_8\NN|plasma|urinary (r_compound) levels_9\NNS|In|following|.|been|had|demonstrated (r_nsubjpass) achieved_12\VBN|NONE (l_conj) demonstrated_22\VBD|In|following|.|been|had|levels (l_dobj) hypertension_23\NN|NONE
D007654_D006973 CID ketoconazole_7\JJ|prolonged (r_compound) treatment_8\NN|NONE (r_pobj) of_5\IN|a (r_prep) complication_4\NN|NONE (r_pobj) as_2\IN|.|Arterial (r_prep) hypertension_1\NN|NONE
D007654_D006973 CID ketoconazole_16\JJ|NONE (r_pobj) with_15\IN|a|term (r_prep) basis_14\NN|NONE (r_pobj) on_9\IN|.|patients|developed (r_prep) treated_8\VBN|NONE (l_advcl) developed_17\VBN|on|.|patients (l_dobj) hypertension_19\NN|NONE
D007654_D006973 CID ketoconazole_14\JJ|,|yet|monitoring (r_compound) therapy_15\NN|NONE (r_dobj) following_13\VBG|In|.|been|had|demonstrated|levels (r_prep) achieved_12\VBN|NONE (l_conj) demonstrated_22\VBD|In|following|.|been|had|levels (l_dobj) hypertension_23\NN|NONE
D007654_D006973 CID ketoconazole_12\NN|NONE (r_pobj) of_11\IN|high (r_prep) doses_10\NNS|NONE (r_pobj) with_8\IN|term (r_prep) treatment_7\NN|blockade|that|may (r_nsubj) induce_14\VB|findings|. (l_dobj) blockade_16\NN|that|treatment|may (l_acl) leading_17\VBG|enzyme (l_prep) to_18\IN|NONE (l_pobj) hypertension_22\NN|NONE
D007654_D003480 NONE ketoconazole_16\JJ|NONE (r_pobj) with_15\IN|a|term (r_prep) basis_14\NN|NONE (r_pobj) on_9\IN|.|patients|developed (r_prep) treated_8\VBN|NONE (l_nsubj) patients_3\NNS|on|.|developed (l_prep) with_4\IN| (l_pobj) syndrome_7\NN|NONE
11847945
D004177_D000699 NONE dipyrone_7\NN|NONE (l_prep) for_8\IN|NONE (l_pobj) analgesia_9\NN|NONE
D007530_D002779 CID isoflurane_6\RB|NONE (r_pobj) to_5\IN|NONE (r_prep) exposure_4\NN|NONE (r_pobj) after_3\IN|Acute|cholestatic|. (r_prep) hepatitis_2\NN|NONE
D007530_D002779 CID isoflurane_14\RB|NONE (r_pobj) to_10\IN|NONE (r_prep) exposure_9\NN|NONE (r_pobj) following_8\VBG|of|a (r_prep) case_3\NN|To|. (l_prep) of_4\IN|a|following (l_pobj) hepatitis_7\NN|NONE
D007530_D002779 CID Isoflurane_0\NNP|.|can|,|hepatitis (r_nsubj) cause_8\VB|NONE (l_dobj) hepatitis_11\NN|Isoflurane|.|can|,
D007530_D056486 CID isoflurane_6\RB|NONE (r_pobj) to_5\IN|NONE (r_prep) exposure_4\NN|NONE (r_pobj) after_3\IN|Acute|cholestatic|. (r_prep) hepatitis_2\NN|NONE
D007530_D056486 CID isoflurane_14\RB|NONE (r_pobj) to_10\IN|NONE (r_prep) exposure_9\NN|NONE (r_pobj) following_8\VBG|of|a (r_prep) case_3\NN|To|. (l_prep) of_4\IN|a|following (l_pobj) hepatitis_7\NN|NONE
D007530_D056486 CID Isoflurane_0\NNP|.|can|,|hepatitis (r_nsubj) cause_8\VB|NONE (l_dobj) hepatitis_11\NN|Isoflurane|.|can|,
17931375
D006493_D003288 CID heparin_10\JJ|subcutaneous|on (r_compound) injection_11\NN|NONE (l_prep) on_12\IN|heparin|subcutaneous (l_pobj) bruising_13\VBG|NONE
D006493_D003288 CID heparin_24\NN|NONE (r_pobj) of_23\IN|the|subcutaneous (r_prep) injection_22\NN|NONE (r_pobj) of_19\IN|the (r_prep) administration_18\NN|NONE (r_pobj) following_16\VBG|of|the (r_prep) effect_8\NN|to (l_prep) of_9\IN|the|following (l_pobj) duration_11\NN|NONE (l_prep) on_12\IN|injection (l_pobj) bruising_13\VBG|NONE
D006493_D003288 CID heparin_13\NN|NONE (r_pobj) of_12\IN|subcutaneous|the (r_prep) injection_11\NN|NONE (r_pobj) following_8\VBG|to|bruising (r_prep) prevent_4\VB|different (l_dobj) bruising_5\NN|to|following
D006493_D003288 CID heparin_13\NN|NONE (r_pobj) of_12\IN|subcutaneous|the (r_prep) injection_11\NN|NONE (r_pobj) following_8\VBG|to|bruising (r_prep) prevent_4\VB|different (r_acl) methods_2\NNS|widely|Although|have|described|been|and (r_nsubjpass) studied_17\VBN|little|is|.|,|effect (r_advcl) documented_35\JJ|NONE (l_nsubjpass) effect_22\NN|little|is|.|,|studied (l_prep) of_23\IN|the (l_pobj) duration_25\NN|NONE (l_prep) on_26\IN|injection (l_pobj) occurrence_28\NN|NONE (l_prep) of_29\IN|the (l_pobj) bruising_30\VBG|NONE
D006493_D003288 CID heparin_6\NN|areas (r_pobj) on_4\IN|the (r_prep) bruising_3\NN|NONE
D006493_D003288 CID heparin_18\NN|NONE (r_pobj) of_17\IN|subcutaneous|the (r_prep) administration_16\NN|NONE (r_pobj) following_13\VBG|duration|effect|that (r_prep) had_6\VBD|was|It|. (l_dobj) effect_8\NN|duration|following|that (l_prep) on_9\IN|an (l_pobj) bruising_10\VBG|NONE
D006493_D010146 CID heparin_10\JJ|subcutaneous|on (r_compound) injection_11\NN|NONE (l_prep) on_12\IN|heparin|subcutaneous (l_pobj) bruising_13\VBG|NONE (l_conj) pain_15\NN|and
D006493_D010146 CID heparin_24\NN|NONE (r_pobj) of_23\IN|the|subcutaneous (r_prep) injection_22\NN|NONE (r_pobj) of_19\IN|the (r_prep) administration_18\NN|NONE (r_pobj) following_16\VBG|of|the (r_prep) effect_8\NN|to (l_prep) of_9\IN|the|following (l_pobj) duration_11\NN|NONE (l_prep) on_12\IN|injection (l_pobj) bruising_13\VBG|NONE (l_conj) pain_15\NN|and
D006493_D010146 CID heparin_13\NN|NONE (r_pobj) of_12\IN|subcutaneous|the (r_prep) injection_11\NN|NONE (r_pobj) following_8\VBG|to|bruising (r_prep) prevent_4\VB|different (l_dobj) bruising_5\NN|to|following (l_conj) pain_7\NN|and
D006493_D010146 CID heparin_13\NN|NONE (r_pobj) of_12\IN|subcutaneous|the (r_prep) injection_11\NN|NONE (r_pobj) following_8\VBG|to|bruising (r_prep) prevent_4\VB|different (r_acl) methods_2\NNS|widely|Although|have|described|been|and (r_nsubjpass) studied_17\VBN|little|is|.|,|effect (r_advcl) documented_35\JJ|NONE (l_nsubjpass) effect_22\NN|little|is|.|,|studied (l_prep) of_23\IN|the (l_pobj) duration_25\NN|NONE (l_prep) on_26\IN|injection (l_pobj) occurrence_28\NN|NONE (l_prep) of_29\IN|the (l_pobj) bruising_30\VBG|NONE (l_conj) pain_32\NN|and
D006493_D010146 CID heparin_18\NN|NONE (r_pobj) of_17\IN|subcutaneous|the (r_prep) administration_16\NN|NONE (r_pobj) following_13\VBG|duration|effect|that (r_prep) had_6\VBD|was|It|. (l_dobj) effect_8\NN|duration|following|that (l_prep) on_9\IN|an (l_pobj) bruising_10\VBG|NONE (l_conj) pain_12\NN|and
16418614
D011441_D014424 NONE PTU_0\NNP| (r_npadvmod) associated_2\VBN|in|. (r_amod) vasculitis_3\NN|NONE (l_prep) in_4\IN|associated|. (l_pobj) girl_6\NN|NONE (l_prep) with_7\IN|a (l_pobj) Syndrome_9\NNP|NONE
D011441_D014657 CID PTU_0\NNP| (r_npadvmod) associated_2\VBN|in|. (r_amod) vasculitis_3\NN|NONE
D011441_D014657 CID propylthiouracil_3\NN|NONE (r_pobj) of_2\IN|The (r_prep) diagnosis_1\NN|detection|was|.|by|(|,|vasculitis (r_nsubjpass) made_8\VBN|NONE (l_nsubjpass) vasculitis_6\NN|detection|was|.|by|(|,|diagnosis
D011441_D014657 CID PTU)-associated_5\VBN|NONE (r_amod) vasculitis_6\NN|detection|was|.|by|(|,|diagnosis
D011441_D014657 CID PTU_37\NNP|NONE (r_pobj) of_36\IN|NONE (r_prep) withdrawal_35\NN|NONE (r_dobj) following_34\VBG|clinical|observed|the|of (r_acl) resolution_31\NN|and|the|of|, (r_conj) detection_17\NN|was|.|by|(|,|vasculitis|diagnosis (r_appos) made_8\VBN|NONE (l_nsubjpass) vasculitis_6\NN|detection|was|.|by|(|,|diagnosis
D011441_D006111 NONE PTU_0\NNP| (r_npadvmod) associated_2\VBN|in|. (r_amod) vasculitis_3\NN|NONE (l_prep) in_4\IN|associated|. (l_pobj) girl_6\NN|NONE (l_prep) with_7\IN|a (l_pobj) Syndrome_9\NNP|NONE (l_conj) disease_13\NN|Turner|and
12523465
C022189_D012640 NONE Zonisamide_0\NNP|drug|. (r_nsubj) is_1\VBZ|NONE (l_attr) drug_7\NN|Zonisamide|. (l_acl) used_8\VBN|a|spectrum|antiepileptic (l_xcomp) treat_10\VB|NONE (l_dobj) types_12\NNS|to (l_prep) of_13\IN|various (l_pobj) seizures_14\NNS|NONE
C022189_D006212 CID zonisamide_4\NN|NONE (r_pobj) with_3\IN|NONE (r_prep) associated_2\VBN|Visual|. (r_acl) hallucinations_1\NNS|NONE
C022189_D006212 CID zonisamide_29\NN|NONE (r_amod) treatment_30\NN|NONE (r_pobj) after_28\IN|status (r_prep) altered_25\VBD|hallucinations|and|who (r_conj) experienced_20\VBD|three (r_relcl) patients_18\NNS|,|begun|we|.|reported (r_dobj) describe_16\VBP|NONE (l_advcl) reported_6\VBN|,|begun|we|patients|. (l_nsubjpass) hallucinations_2\NNS|as|been|not|have|Although
C022189_D006212 CID zonisamide_29\NN|NONE (r_amod) treatment_30\NN|NONE (r_pobj) after_28\IN|status (r_prep) altered_25\VBD|hallucinations|and|who (r_conj) experienced_20\VBD|three (l_dobj) hallucinations_23\NNS|altered|and|who
16710500
D004977_D009901 CID Ethambutol_0\NN| (r_npadvmod) associated_2\VBN|.|optic (r_amod) neuropathy_4\NN|NONE
D004977_D009901 CID ethambutol_3\NN| (r_npadvmod) associated_5\VBN|optic (r_amod) neuropathy_8\NNS|NONE
D004977_D014376 NONE Ethambutol_2\NNP|INTRODUCTION|,|is|and|:|associated|.|in (r_nsubjpass) used_4\VBN|NONE (l_prep) in_5\IN|INTRODUCTION|,|Ethambutol|is|and|:|associated|. (l_pobj) treatment_7\NN|NONE (l_prep) of_8\IN|,|is|the (l_pobj) tuberculosis_9\NN|NONE
D004977_D014786 CID Ethambutol_2\NNP|INTRODUCTION|,|is|and|:|associated|.|in (r_nsubjpass) used_4\VBN|NONE (l_conj) associated_22\VBN|INTRODUCTION|,|Ethambutol|is|and|:|.|in (l_prep) with_23\IN|be|can (l_pobj) loss_26\NN|NONE
D004977_D014786 CID Ethambutol_0\NNP|NONE (r_compound) usage_1\NN|with|and|.|is|avoided (r_nsubjpass) associated_3\VBN|NONE (l_prep) with_4\IN|usage|and|.|is|avoided (l_pobj) loss_7\NN|NONE
10669626
D014807_D061205 NONE D._11\NNP|vitamin|and (r_conj) growth_8\NN|NONE (r_pobj) by_7\IN|calcification|is (r_agent) accelerated_6\VBN|NONE (l_nsubjpass) calcification_4\NN|is|by
D014807_D061205 NONE D_8\JJ|and (r_conj) growth_5\NN|NONE (r_nmod) treatment_9\NN|that|extent|given (r_nsubj) enhance_10\VB|.|studies (l_dobj) extent_12\NN|that|given|treatment (l_prep) of_13\IN|the (l_pobj) calcification_15\NN|NONE
D014807_D061205 NONE D_11\NN|NONE (r_pobj) between_9\IN|possible|the|in (r_prep) synergy_8\NN|.|set (l_prep) in_14\IN|possible|the|between (l_pobj) calcification_16\NN|NONE
D014807_D061205 NONE D_4\NNP|NONE (r_pobj) of_2\IN|High (r_prep) doses_1\NNS|cause|.|are (r_nsubjpass) known_6\VBN|NONE (l_xcomp) cause_8\VB|doses|.|are (l_dobj) calcification_9\NN|to|in (l_prep) of_10\IN|NONE (l_pobj) media_13\NNS|NONE (l_compound) artery_12\NN|the
D014807_D061205 NONE D_10\NN|on (r_compound) dose_11\NN|NONE (l_prep) on_12\IN|D (l_pobj) calcification_14\NN|NONE
D014807_D061205 NONE D_10\NN|on (r_compound) dose_11\NN|NONE (r_pobj) of_8\IN|the|effect|and (r_prep) effect_7\NN|NONE (l_conj) effect_17\NN|the|of|and (l_prep) of_18\IN|the (l_pobj) dose_21\NN|NONE (l_prep) on_22\IN|D (l_pobj) elevation_24\NN|NONE (l_relcl) suggests_30\VBZ|,|of|the (l_ccomp) induce_35\VB|which (l_dobj) calcification_37\NN|through|that|may|D
D014807_D061205 NONE D_20\NNP|on (r_compound) dose_21\NN|NONE (r_pobj) of_18\IN|the (r_prep) effect_17\NN|the|of|and (r_conj) effect_7\NN|NONE (l_prep) of_8\IN|the|effect|and (l_pobj) dose_11\NN|NONE (l_prep) on_12\IN|D (l_pobj) calcification_14\NN|NONE
D014807_D061205 NONE D_20\NNP|on (r_compound) dose_21\NN|NONE (l_prep) on_22\IN|D (l_pobj) elevation_24\NN|NONE (l_relcl) suggests_30\VBZ|,|of|the (l_ccomp) induce_35\VB|which (l_dobj) calcification_37\NN|through|that|may|D
D014807_D061205 NONE D_33\NN|through|that|may|calcification (r_nsubj) induce_35\VB|which (r_ccomp) suggests_30\VBZ|,|of|the (r_relcl) elevation_24\NN|NONE (r_pobj) on_22\IN|D (r_prep) dose_21\NN|NONE (r_pobj) of_18\IN|the (r_prep) effect_17\NN|the|of|and (r_conj) effect_7\NN|NONE (l_prep) of_8\IN|the|effect|and (l_pobj) dose_11\NN|NONE (l_prep) on_12\IN|D (l_pobj) calcification_14\NN|NONE
D014807_D061205 NONE D_33\NN|through|that|may|calcification (r_nsubj) induce_35\VB|which (l_dobj) calcification_37\NN|through|that|may|D
D014807_D061205 NONE D_18\NNP|NONE (r_pobj) with_16\IN|NONE (r_prep) treated_15\VBN|NONE (r_acl) rats_14\NNS|NONE (r_pobj) in_13\IN|artery (r_prep) calcification_12\NN|NONE
D014859_D061205 CID Warfarin_0\NNP| (r_npadvmod) induced_2\VBN|artery (r_amod) calcification_4\NN|is|by
D014859_D061205 CID Warfarin_22\NNP|NONE (r_pobj) of_21\IN|sufficient (r_prep) doses_20\NNS|inhibit (r_dobj) given_18\VBN|that|extent|treatment (r_prep) enhance_10\VB|.|studies (l_dobj) extent_12\NN|that|given|treatment (l_prep) of_13\IN|the (l_pobj) calcification_15\NN|NONE
D014859_D061205 CID Warfarin_17\NNP| (r_npadvmod) treated_19\VBN|NONE (r_amod) rats_20\NNS|NONE (r_pobj) in_16\IN|artery (r_prep) calcification_15\NN|NONE
D014859_D061205 CID Warfarin_5\NNP|NONE (r_pobj) with_4\IN|for (r_prep) Treatment_0\NN|calcification|. (r_nsubj) caused_6\VBD|NONE (l_dobj) calcification_9\NN|Treatment|. (l_prep) of_10\IN|focal|calcification|massive|and|in (l_pobj) media_13\NNS|NONE (l_compound) artery_12\NN|the
D014859_D061205 CID Warfarin_20\NNP|NONE (r_compound) treatment_21\NN|NONE (r_pobj) of_19\IN| (r_prep) weeks_18\NNS|even (r_pobj) after_16\IN|.|In|in|calcification|could|be|, (r_prep) detected_8\VBN|NONE (l_nsubjpass) calcification_5\NN|.|In|in|could|after|be|,
D014859_D061205 CID Warfarin_8\NNP| (r_npadvmod) induced_10\VBN|in|artery (r_amod) calcification_12\NN|NONE
D014859_D061205 CID Warfarin_7\NNP|NONE (r_pobj) with_6\IN|dietary|both (r_prep) groups_5\NNS|NONE (r_pobj) of_2\IN|Concurrent (r_prep) treatment_1\NN|calcification|. (r_nsubj) produced_8\VBD|NONE (l_dobj) calcification_11\NN|treatment|. (l_prep) of_12\IN|calcification|massive|but|in|focal (l_pobj) media_15\NNS|NONE (l_compound) artery_14\NN|the
D014859_D061205 CID Warfarin_7\NNP|NONE (r_pobj) with_6\IN|dietary|both (r_prep) groups_5\NNS|NONE (r_pobj) of_2\IN|Concurrent (r_prep) treatment_1\NN|calcification|. (r_nsubj) produced_8\VBD|NONE (l_dobj) calcification_11\NN|treatment|. (l_conj) calcification_27\NN|massive|but|in|of|focal
D014859_D061205 CID Warfarin_61\NNP| (r_npadvmod) induced_63\VBN|artery (r_amod) calcification_65\NN|NONE (r_pobj) to_60\IN|NONE (r_prep) resistant_59\JJ|that (r_acomp) was_58\VBD|the (r_relcl) groups_56\NNS|NONE (r_pobj) of_54\IN|NONE (r_prep) either_53\DT|NONE (r_pobj) with_52\IN|rats (r_prep) compared_51\VBN|fed|ad (r_prep) rats_50\NNS|between|,|,|with|a (r_appos) relationship_24\NN|,|determined|.|there (r_attr) was_22\VBD|NONE (l_advcl) determined_15\VBN|,|relationship|.|there (l_nsubjpass) explanation_2\NN|not|can|from|be|Although (l_prep) for_3\IN|the (l_pobj) association_5\NN|NONE (l_prep) between_6\IN|the (l_pobj) calcification_8\NN|NONE
D014859_D061205 CID Warfarin_61\NNP| (r_npadvmod) induced_63\VBN|artery (r_amod) calcification_65\NN|NONE (r_pobj) to_60\IN|NONE (r_prep) resistant_59\JJ|that (r_acomp) was_58\VBD|the (r_relcl) groups_56\NNS|NONE (r_pobj) of_54\IN|NONE (r_prep) either_53\DT|NONE (r_pobj) with_52\IN|rats (r_prep) compared_51\VBN|fed|ad (r_prep) rats_50\NNS|between|,|,|with|a (r_appos) relationship_24\NN|,|determined|.|there (l_prep) between_25\IN|,|rats|,|with|a (l_pobj) phosphate_28\NN|NONE (l_conj) susceptibility_30\NN|serum|higher|and (l_prep) to_31\IN|NONE (l_pobj) calcification_33\NN|NONE
D014859_D061205 CID Warfarin_61\NNP| (r_npadvmod) induced_63\VBN|artery (r_amod) calcification_65\NN|NONE
D014859_D061205 CID Warfarin_7\NNP| (r_npadvmod) induced_9\VBN|artery (r_amod) calcification_11\NN|NONE
D014859_D061205 CID Warfarin_13\NNP|and|vitamin (r_conj) D_11\NN|NONE (r_pobj) between_9\IN|possible|the|in (r_prep) synergy_8\NN|.|set (l_prep) in_14\IN|possible|the|between (l_pobj) calcification_16\NN|NONE
D014859_D061205 CID Warfarin_0\NNP|,|at|also|.|but|cause|are (r_nsubjpass) known_3\VBN|NONE (l_xcomp) cause_5\VB|,|at|also|.|Warfarin|but|are (l_dobj) calcification_6\NN|to (l_prep) of_7\IN|NONE (l_pobj) media_10\NNS|NONE (l_compound) artery_9\NN|the
D014859_D061205 CID Warfarin_20\NNP|plus|vitamin (r_conj) D_18\NNP|NONE (r_pobj) with_16\IN|NONE (r_prep) treated_15\VBN|NONE (r_acl) rats_14\NNS|NONE (r_pobj) in_13\IN|artery (r_prep) calcification_12\NN|NONE
D014859_D002114 NONE Warfarin_22\NNP|NONE (r_pobj) of_21\IN|sufficient (r_prep) doses_20\NNS|inhibit (r_dobj) given_18\VBN|that|extent|treatment (l_advcl) inhibit_24\VB|doses (l_dobj) carboxylation_27\NN|to (l_prep) of_28\IN|gamma| (l_pobj) protein_31\NN|NONE (l_appos) inhibitor_35\NN|,|matrix|Gla (l_compound) calcification_34\NN|known
D014859_D002114 NONE Warfarin_5\NNP|NONE (r_pobj) with_4\IN|for (r_prep) Treatment_0\NN|calcification|. (r_nsubj) caused_6\VBD|NONE (l_dobj) calcification_9\NN|Treatment|. (l_conj) calcification_23\NN|focal|of|massive|and|in
D014859_D002114 NONE Warfarin_17\NNP|concurrent (r_compound) administration_18\NN|that|dramatically|extent (r_nsubj) increased_20\VBD|NONE (l_dobj) extent_22\NN|that|administration|dramatically (l_prep) of_23\IN|the (l_pobj) calcification_24\NN|NONE
D014859_D002114 NONE Warfarin_1\NNP|NONE (r_compound) treatment_2\NN|Because|effect (r_nsubj) had_3\VBD|is|by|.|probably|best (r_advcl) explained_27\VBN|NONE (l_agent) by_28\IN|is|.|probably|had|best (l_pobj) hypothesis_30\NN|NONE (l_acl) inhibits_33\VBZ|the (l_prep) as_40\IN|activity|that|Warfarin (l_pobj) inhibitor_43\NN|NONE (l_compound) calcification_42\NN|a
D014859_D002114 NONE Warfarin_20\NNP|NONE (r_nmod) D_23\NN|NONE (r_pobj) between_19\IN|the (r_prep) synergy_18\NN|,|vitamin (r_appos) D_15\NN|NONE (r_pobj) by_13\IN|NONE (r_agent) produced_12\VBN|serum (r_acl) calcium_11\NN|NONE (r_pobj) in_9\IN|the (r_prep) elevation_8\NN|NONE (r_pobj) on_6\IN|no (r_prep) effect_5\NN|Because|treatment (r_dobj) had_3\VBD|is|by|.|probably|best (r_advcl) explained_27\VBN|NONE (l_agent) by_28\IN|is|.|probably|had|best (l_pobj) hypothesis_30\NN|NONE (l_acl) inhibits_33\VBZ|the (l_prep) as_40\IN|activity|that|Warfarin (l_pobj) inhibitor_43\NN|NONE (l_compound) calcification_42\NN|a
D014859_D002114 NONE Warfarin_32\NNP|activity|as|that (r_nsubj) inhibits_33\VBZ|the (l_prep) as_40\IN|activity|that|Warfarin (l_pobj) inhibitor_43\NN|NONE (l_compound) calcification_42\NN|a
D015055_D061205 NONE carboxylated_36\JJ|that|indeed|protein (r_acomp) was_31\VBD|analysis|. (r_ccomp) showed_25\VBD|levels|at|are|,|and (r_conj) found_7\VBN|NONE (l_prep) at_8\IN|levels|are|,|and|showed (l_pobj) sites_9\NNS|NONE (l_prep) of_10\IN|NONE (l_pobj) calcification_12\NN|NONE
D010710_D061205 NONE phosphate_28\NN|NONE (r_pobj) between_25\IN|,|rats|,|with|a (r_prep) relationship_24\NN|,|determined|.|there (r_attr) was_22\VBD|NONE (l_advcl) determined_15\VBN|,|relationship|.|there (l_nsubjpass) explanation_2\NN|not|can|from|be|Although (l_prep) for_3\IN|the (l_pobj) association_5\NN|NONE (l_prep) between_6\IN|the (l_pobj) calcification_8\NN|NONE
D010710_D061205 NONE phosphate_28\NN|NONE (l_conj) susceptibility_30\NN|serum|higher|and (l_prep) to_31\IN|NONE (l_pobj) calcification_33\NN|NONE
D010710_D061205 NONE phosphate_28\NN|NONE (r_pobj) between_25\IN|,|rats|,|with|a (r_prep) relationship_24\NN|,|determined|.|there (l_appos) rats_50\NNS|between|,|,|with|a (l_prep) compared_51\VBN|fed|ad (l_prep) with_52\IN|rats (l_pobj) either_53\DT|NONE (l_prep) of_54\IN|NONE (l_pobj) groups_56\NNS|NONE (l_relcl) was_58\VBD|the (l_acomp) resistant_59\JJ|that (l_prep) to_60\IN|NONE (l_pobj) calcification_65\NN|NONE
D010710_D061205 NONE phosphate_42\NN|NONE (r_pobj) of_40\IN|higher|in (r_prep) levels_39\NNS|NONE (r_pobj) with_35\IN|between|,|rats|,|a (r_prep) relationship_24\NN|,|determined|.|there (r_attr) was_22\VBD|NONE (l_advcl) determined_15\VBN|,|relationship|.|there (l_nsubjpass) explanation_2\NN|not|can|from|be|Although (l_prep) for_3\IN|the (l_pobj) association_5\NN|NONE (l_prep) between_6\IN|the (l_pobj) calcification_8\NN|NONE
D010710_D061205 NONE phosphate_42\NN|NONE (r_pobj) of_40\IN|higher|in (r_prep) levels_39\NNS|NONE (r_pobj) with_35\IN|between|,|rats|,|a (r_prep) relationship_24\NN|,|determined|.|there (l_prep) between_25\IN|,|rats|,|with|a (l_pobj) phosphate_28\NN|NONE (l_conj) susceptibility_30\NN|serum|higher|and (l_prep) to_31\IN|NONE (l_pobj) calcification_33\NN|NONE
D010710_D061205 NONE phosphate_42\NN|NONE (r_pobj) of_40\IN|higher|in (r_prep) levels_39\NNS|NONE (r_pobj) with_35\IN|between|,|rats|,|a (r_prep) relationship_24\NN|,|determined|.|there (l_appos) rats_50\NNS|between|,|,|with|a (l_prep) compared_51\VBN|fed|ad (l_prep) with_52\IN|rats (l_pobj) either_53\DT|NONE (l_prep) of_54\IN|NONE (l_pobj) groups_56\NNS|NONE (l_relcl) was_58\VBD|the (l_acomp) resistant_59\JJ|that (l_prep) to_60\IN|NONE (l_pobj) calcification_65\NN|NONE
D010710_D061205 NONE phosphate_18\NN|higher (r_compound) levels_19\NNS|NONE (r_pobj) to_15\IN|that|could|susceptibility|be (r_prep) related_14\VBN|.|observation (l_nsubjpass) susceptibility_5\NN|that|to|could|be (l_prep) to_6\IN|increased (l_pobj) calcification_11\NN|NONE
D015055_D002114 NONE carboxyglutamate_8\NN|of|the (r_compound) residues_9\NNS|are|apparently|although|as|for (r_nsubjpass) required_16\VBN|for|are|that|not|,|they (l_prep) as_20\IN|are|apparently|although|residues|for (l_pobj) inhibitor_23\NN|NONE (l_compound) calcification_22\NN|a
D015055_D002114 NONE carboxyglutamate_8\NN|of|the (r_compound) residues_9\NNS|are|apparently|although|as|for (r_nsubjpass) required_16\VBN|for|are|that|not|,|they (r_advcl) required_28\VBN|observations|. (l_prep) for_29\IN|are|that|not|,|they|required (l_pobj) accumulation_31\NN|NONE (l_prep) at_32\IN|its (l_pobj) sites_34\NNS|NONE (l_compound) calcification_33\NN|NONE
D014807_D002114 NONE D_8\JJ|and (r_conj) growth_5\NN|NONE (r_nmod) treatment_9\NN|that|extent|given (r_nsubj) enhance_10\VB|.|studies (l_prep) given_18\VBN|that|extent|treatment (l_advcl) inhibit_24\VB|doses (l_dobj) carboxylation_27\NN|to (l_prep) of_28\IN|gamma| (l_pobj) protein_31\NN|NONE (l_appos) inhibitor_35\NN|,|matrix|Gla (l_compound) calcification_34\NN|known
D014807_D002114 NONE D_30\NN| (r_npadvmod) treated_32\VBN|vitamin (r_amod) rats_33\NNS|NONE (r_pobj) of_28\IN|the (r_prep) media_27\NNS|NONE (r_pobj) in_25\IN|at (r_prep) calcification_24\NN|NONE
D014807_D002114 NONE D_15\NN|NONE (r_pobj) by_13\IN|NONE (r_agent) produced_12\VBN|serum (r_acl) calcium_11\NN|NONE (r_pobj) in_9\IN|the (r_prep) elevation_8\NN|NONE (r_pobj) on_6\IN|no (r_prep) effect_5\NN|Because|treatment (r_dobj) had_3\VBD|is|by|.|probably|best (r_advcl) explained_27\VBN|NONE (l_agent) by_28\IN|is|.|probably|had|best (l_pobj) hypothesis_30\NN|NONE (l_acl) inhibits_33\VBZ|the (l_prep) as_40\IN|activity|that|Warfarin (l_pobj) inhibitor_43\NN|NONE (l_compound) calcification_42\NN|a
D014807_D002114 NONE D_23\NN|NONE (r_pobj) between_19\IN|the (r_prep) synergy_18\NN|,|vitamin (r_appos) D_15\NN|NONE (r_pobj) by_13\IN|NONE (r_agent) produced_12\VBN|serum (r_acl) calcium_11\NN|NONE (r_pobj) in_9\IN|the (r_prep) elevation_8\NN|NONE (r_pobj) on_6\IN|no (r_prep) effect_5\NN|Because|treatment (r_dobj) had_3\VBD|is|by|.|probably|best (r_advcl) explained_27\VBN|NONE (l_agent) by_28\IN|is|.|probably|had|best (l_pobj) hypothesis_30\NN|NONE (l_acl) inhibits_33\VBZ|the (l_prep) as_40\IN|activity|that|Warfarin (l_pobj) inhibitor_43\NN|NONE (l_compound) calcification_42\NN|a
D002118_D002114 NONE calcium_11\NN|NONE (r_pobj) in_9\IN|the (r_prep) elevation_8\NN|NONE (r_pobj) on_6\IN|no (r_prep) effect_5\NN|Because|treatment (r_dobj) had_3\VBD|is|by|.|probably|best (r_advcl) explained_27\VBN|NONE (l_agent) by_28\IN|is|.|probably|had|best (l_pobj) hypothesis_30\NN|NONE (l_acl) inhibits_33\VBZ|the (l_prep) as_40\IN|activity|that|Warfarin (l_pobj) inhibitor_43\NN|NONE (l_compound) calcification_42\NN|a
D002118_D061205 NONE calcium_27\NN|NONE (r_pobj) of_25\IN|,|suggests|the (r_prep) elevation_24\NN|NONE (r_pobj) on_22\IN|D (r_prep) dose_21\NN|NONE (r_pobj) of_18\IN|the (r_prep) effect_17\NN|the|of|and (r_conj) effect_7\NN|NONE (l_prep) of_8\IN|the|effect|and (l_pobj) dose_11\NN|NONE (l_prep) on_12\IN|D (l_pobj) calcification_14\NN|NONE
D002118_D061205 NONE calcium_27\NN|NONE (r_pobj) of_25\IN|,|suggests|the (r_prep) elevation_24\NN|NONE (l_relcl) suggests_30\VBZ|,|of|the (l_ccomp) induce_35\VB|which (l_dobj) calcification_37\NN|through|that|may|D
D002118_D061205 NONE calcium_43\NN|NONE (r_pobj) on_41\IN|its (r_prep) effect_40\NN|NONE (r_pobj) through_38\IN|that|may|D|calcification (r_prep) induce_35\VB|which (r_ccomp) suggests_30\VBZ|,|of|the (r_relcl) elevation_24\NN|NONE (r_pobj) on_22\IN|D (r_prep) dose_21\NN|NONE (r_pobj) of_18\IN|the (r_prep) effect_17\NN|the|of|and (r_conj) effect_7\NN|NONE (l_prep) of_8\IN|the|effect|and (l_pobj) dose_11\NN|NONE (l_prep) on_12\IN|D (l_pobj) calcification_14\NN|NONE
D002118_D061205 NONE calcium_43\NN|NONE (r_pobj) on_41\IN|its (r_prep) effect_40\NN|NONE (r_pobj) through_38\IN|that|may|D|calcification (r_prep) induce_35\VB|which (l_dobj) calcification_37\NN|through|that|may|D
12041669
D010396_D000741 CID penicillamine_8\NN| (r_npadvmod) induced_10\VBN|aplastic (r_amod) anemia_12\NN|NONE
D010396_D000741 CID penicillamine_14\NN|NONE (r_compound) therapy_15\NN|.|patient|is (r_nsubjpass) described_17\VBN|NONE (l_nsubjpass) patient_1\NN|.|therapy|is (l_relcl) received_3\VBD|A (l_prep) for_7\IN|antithymocyte|due|who|therapy (l_pobj) anemia_9\NN|NONE
D010396_D000741 CID penicillamine_12\NN| (r_npadvmod) induced_14\VBN|aplastic (r_amod) anemia_16\NN|NONE
D000961_D000741 NONE globulin_1\NN|NONE (l_prep) in_2\IN|.|Antithymocyte (l_pobj) treatment_4\NN|NONE (l_prep) of_5\IN|the (l_pobj) anemia_12\NN|NONE
D000961_D000741 NONE globulin_5\NN|NONE (r_compound) therapy_6\NN|antithymocyte|due|for|who (r_dobj) received_3\VBD|A (l_prep) for_7\IN|antithymocyte|due|who|therapy (l_pobj) anemia_9\NN|NONE
D000961_D000741 NONE globulin_3\NN|of (r_dobj) Use_0\NN|treatment|may|. (r_nsubj) be_5\VB|NONE (l_attr) treatment_8\NN|Use|may|. (l_prep) of_9\IN|the|optimal (l_pobj) anemia_16\NN|NONE
7582165
D000305_D004342 NONE corticosteroids_5\NNS|NONE (r_pobj) to_4\IN|:|allergic|.|diagnosis (r_prep) reactions_3\NNS|NONE
D010248_D004342 NONE paramethasone_3\NN|NONE (r_pobj) from_2\IN|NONE (r_prep) different_1\JJ|NONE (r_amod) Corticosteroids_0\NNS|also|reactions (r_nsubj) produced_5\VBD|however|.|,|were|;|few (l_dobj) reactions_7\NNS|also|Corticosteroids (l_compound) hypersensitivity_6\NN|in
D010248_D004342 NONE paramethasone_16\NN|NONE (r_pobj) by_15\IN|NONE (r_agent) caused_14\VBN|pseudo||a (r_acl) allergy_13\NN|NONE
3693336
D014229_D001714 CID Triazolam_0\NNP||.|episodes (r_npadvmod) induced_2\VBN|NONE (l_dobj) episodes_4\NNS||.|Triazolam (l_prep) of_5\IN|brief|in (l_pobj) mania_7\NN|NONE
D014229_D001714 CID triazolam_3\NN|NONE (r_pobj) of_2\IN|Large (r_prep) doses_1\NNS|repeatedly|episodes|. (r_nsubj) induced_5\VBD|NONE (l_dobj) episodes_7\NNS|repeatedly|.|doses (l_prep) of_8\IN|brief|in (l_pobj) mania_9\NN|NONE
D014229_D001714 CID triazolam_10\NN|NONE (r_pobj) of_9\IN|NONE (r_prep) action_8\NN|NONE (r_pobj) of_7\IN|the (r_prep) duration_6\NN|NONE (r_pobj) with_4\IN|NONE (r_prep) coincident_3\JJ|.|excitement (r_acomp) was_2\VBD|NONE (l_nsubj) excitement_1\NN|.|coincident (l_amod) Manic_0\JJ|NONE
D014229_D003866 NONE Triazolam_0\NNP||.|episodes (r_npadvmod) induced_2\VBN|NONE (l_dobj) episodes_4\NNS||.|Triazolam (l_prep) in_8\IN|brief|of (l_pobj) patient_11\NN|NONE (l_amod) depressed_10\JJ|a
D014229_D003866 NONE triazolam_3\NN|NONE (r_pobj) of_2\IN|Large (r_prep) doses_1\NNS|repeatedly|episodes|. (r_nsubj) induced_5\VBD|NONE (l_dobj) episodes_7\NNS|repeatedly|.|doses (l_prep) in_10\IN|brief|of (l_pobj) woman_14\NN|NONE (l_amod) depressed_12\JJ|elderly|a
3969369
D013739_D063646 NONE testosterone_3\NN|NONE (r_pobj) of_2\IN|Promotional|on|. (r_prep) effects_1\NNS|NONE (l_prep) on_7\IN|Promotional|of|. (l_pobj) carcinogenesis_9\NN|NONE
D013739_D011472 CID testosterone_9\NN|NONE (r_pobj) with_8\IN|developed (r_prep) treated_7\VBN|and|.|L|diet|rats (l_advcl) developed_10\VBD|with (l_dobj) prostatitis_12\NN|NONE
D013739_D009369 NONE testosterone_6\NN|NONE (r_pobj) with_5\IN|at|months (r_prep) implanted_4\VBN|,|LW|, (r_acl) rats_2\NNS|incidence|after (r_nsubj) developed_12\VBD|:|%|and|%|,|tumors|had|. (r_ccomp) developed_30\VBN|NONE (l_dobj) tumors_32\NNS|:|%|and|%|,|developed|had|.
D013739_D009369 NONE testosterone_6\NN|NONE (r_pobj) with_5\IN|at|months (r_prep) implanted_4\VBN|,|LW|, (r_acl) rats_2\NNS|incidence|after (r_nsubj) developed_12\VBD|:|%|and|%|,|tumors|had|. (r_ccomp) developed_30\VBN|NONE (l_conj) %_36\NN|:|%|and|,|tumors|developed|had|. (l_advcl) included_39\VBD| (l_dobj) tumors_41\NNS|it|when
D013739_D011471 CID testosterone_6\NN|NONE (r_pobj) with_5\IN|at|months (r_prep) implanted_4\VBN|,|LW|, (r_acl) rats_2\NNS|incidence|after (r_nsubj) developed_12\VBD|:|%|and|%|,|tumors|had|. (l_dobj) incidence_15\NN|rats|after (l_prep) of_16\IN|higher|a (l_pobj) cancer_18\NN|NONE
D013739_D011471 CID testosterone_4\NN| (r_npadvmod) treated_6\VBN|LW|fed|that (r_amod) rats_8\NNS|results|. (l_relcl) fed_11\VBN|LW|that|treated (l_dobj) diet_14\NN|were|that (l_relcl) supplemented_18\VBN|,|the|same (l_dobj) fat_26\NN|was|which|with (l_conj) cancer_30\NN|,|%
2802551
D012964_D007674 NONE Sodium_0\NN|NONE (r_compound) status_1\NN|.|nephrotoxicity (r_nsubj) influences_2\VBZ|NONE (l_dobj) nephrotoxicity_6\NN|.|status
D000666_D007674 CID B_5\NN|in|chronic (r_compound) nephrotoxicity_6\NN|.|status
D000666_D007674 CID B_5\NNP|NONE (r_pobj) of_3\IN|The|nephrotoxic (r_prep) potential_2\NN|for|) (l_amod) nephrotoxic_1\JJ|of|The
2886572
D004837_D006973 CID epinephrine_7\NN| (r_npadvmod) induced_9\VBN|hypertensive (r_amod) rats_11\NNS|NONE (l_amod) hypertensive_10\JJ|induced
3411101
D011802_D056486 NONE Quinidine_0\NN|responsible|may|. (r_nsubj) be_5\VB|NONE (l_acomp) responsible_6\JJ|may|.|Quinidine (l_prep) for_7\IN|NONE (l_pobj) hepatitis_9\NN|NONE
C033457_D056486 CID phenylethylbarbiturate_1\NN||in|.|Quinidine|hepatitis (r_npadvmod) induced_3\VBN|NONE (l_dobj) hepatitis_5\NN||in|.|Quinidine|phenylethylbarbiturate
C033457_D056486 CID phenylethylbarbiturate_28\NN|NONE (r_pobj) of_26\IN|a|month (r_prep) administration_25\NN|NONE (r_pobj) after_22\IN|during|by (r_prep) affected_11\VBN|old|a|Laotian (l_agent) by_12\IN|during|after (l_pobj) hepatitis_14\NN|NONE
C033457_D056486 CID phenylethylbarbiturate_3\NN|itself|or (r_conj) Quinidine_0\NN|responsible|may|. (r_nsubj) be_5\VB|NONE (l_acomp) responsible_6\JJ|may|.|Quinidine (l_prep) for_7\IN|NONE (l_pobj) hepatitis_9\NN|NONE
9855119
D016559_D005923 CID FK506_1\NNP|NONE (r_compound) nephropathy_2\NN|,|of (r_nsubj) consisted_3\VBD|arteriolopathy|.|(|of|;|biopsies (r_ccomp) angiodegeneration_17\NN|NONE (l_appos) biopsies_24\NNS|arteriolopathy|.|(|of|consisted|; (l_conj) glomerulosclerosis_29\NN||,|)
D016559_D005355 NONE FK506_1\NNP|NONE (r_compound) nephropathy_2\NN|,|of (r_nsubj) consisted_3\VBD|arteriolopathy|.|(|of|;|biopsies (r_ccomp) angiodegeneration_17\NN|NONE (l_appos) biopsies_24\NNS|arteriolopathy|.|(|of|consisted|; (l_conj) glomerulosclerosis_29\NN||,|) (l_conj) form_37\NN|segmental|focal|and|(|biopsies|) (l_prep) of_38\IN|the|striped (l_pobj) fibrosis_40\NN|NONE
D016559_D007674 NONE FK506_28\NN|nephropathy|)|n|(|chronic|and|type|, (r_compound) nephropathy_29\NN|,|,|n|normal
D016559_D007674 NONE FK506_28\NN|nephropathy|)|n|(|chronic|and|type|, (r_compound) nephropathy_29\NN|,|,|n|normal (l_conj) nephropathy_41\NN|FK|)|n|(|chronic|and|type|,
D016559_D007674 NONE FK506_40\NN|)|n|( (r_compound) nephropathy_41\NN|FK|)|n|(|chronic|and|type|, (r_conj) nephropathy_29\NN|,|,|n|normal
D016559_D007674 NONE FK506_40\NN|)|n|( (r_compound) nephropathy_41\NN|FK|)|n|(|chronic|and|type|,
D016559_D007674 NONE FK506_18\NN|chronic|type (r_compound) nephropathy_19\NN|Of|biopsies|respectively|.|,|,
D016559_D007674 NONE FK506_1\NNP|NONE (r_compound) nephropathy_2\NN|,|of
D016559_D007674 NONE FK506_12\NN|NONE (r_compound) nephropathy_13\NN|,|type|,|included|the|chronic
D016559_D007674 NONE FK506_12\NN|NONE (r_compound) nephropathy_13\NN|,|type|,|included|the|chronic (r_compound) group_14\NN|NONE (r_pobj) in_6\IN|NONE (r_prep) patients_5\NNS|NONE (r_pobj) of_4\IN|serum|creatinine|The (r_prep) levels_3\NNS|.|higher (r_nsubj) were_22\VBD|NONE (l_acomp) higher_24\JJR|.|levels (l_prep) than_25\IN|statistically (l_pobj) those_26\DT|NONE (l_prep) in_27\IN|NONE (l_pobj) group_34\NN|NONE (l_compound) FK506-nephropathy_33\NNP|(|P|the|)|type
D016559_D007674 NONE FK506-nephropathy_33\NNP|(|P|the|)|type (r_compound) group_34\NN|NONE (r_pobj) in_27\IN|NONE (r_prep) those_26\DT|NONE (r_pobj) than_25\IN|statistically (r_prep) higher_24\JJR|.|levels (r_acomp) were_22\VBD|NONE (l_nsubj) levels_3\NNS|.|higher (l_prep) of_4\IN|serum|creatinine|The (l_pobj) patients_5\NNS|NONE (l_prep) in_6\IN|NONE (l_pobj) group_14\NN|NONE (l_compound) nephropathy_13\NN|,|type|,|included|the|chronic
D016559_D007674 NONE FK506-nephropathy_33\NNP|(|P|the|)|type
D016559_D007674 NONE FK506_5\NNP|chronic (r_compound) nephropathy_6\NN|that|primarily|,|of
D016559_D007674 NONE FK506_5\NNP|chronic (r_compound) nephropathy_6\NN|that|primarily|,|of (r_nsubj) consists_7\VBZ|and|.|study|suggests (r_ccomp) demonstrates_2\VBZ|NONE (l_conj) suggests_21\VBZ|and|consists|.|study (l_ccomp) is_29\VBZ|NONE (l_nsubj) nephropathy_28\NN|condition|that
D016559_D007674 NONE FK506_27\NN|chronic|type (r_compound) nephropathy_28\NN|condition|that (r_nsubj) is_29\VBZ|NONE (r_ccomp) suggests_21\VBZ|and|consists|.|study (r_conj) demonstrates_2\VBZ|NONE (l_ccomp) consists_7\VBZ|and|.|study|suggests (l_nsubj) nephropathy_6\NN|that|primarily|,|of
D016559_D007674 NONE FK506_27\NN|chronic|type (r_compound) nephropathy_28\NN|condition|that
D016559_D005922 NONE FK506_28\NN|nephropathy|)|n|(|chronic|and|type|, (r_compound) nephropathy_29\NN|,|,|n|normal (r_conj) findings_17\NNS|.|recurrent|,|IgA|n (r_conj) nephropathy_9\NN|n
D016559_D005922 NONE FK506_40\NN|)|n|( (r_compound) nephropathy_41\NN|FK|)|n|(|chronic|and|type|, (r_conj) nephropathy_29\NN|,|,|n|normal (r_conj) findings_17\NNS|.|recurrent|,|IgA|n (r_conj) nephropathy_9\NN|n
D003404_D007674 NONE creatinine_2\NN|serum|The|of (r_compound) levels_3\NNS|.|higher (l_prep) of_4\IN|serum|creatinine|The (l_pobj) patients_5\NNS|NONE (l_prep) in_6\IN|NONE (l_pobj) group_14\NN|NONE (l_compound) nephropathy_13\NN|,|type|,|included|the|chronic
D003404_D007674 NONE creatinine_2\NN|serum|The|of (r_compound) levels_3\NNS|.|higher (r_nsubj) were_22\VBD|NONE (l_acomp) higher_24\JJR|.|levels (l_prep) than_25\IN|statistically (l_pobj) those_26\DT|NONE (l_prep) in_27\IN|NONE (l_pobj) group_34\NN|NONE (l_compound) FK506-nephropathy_33\NNP|(|P|the|)|type
14698717
D010672_D014277 NONE phenytoin_10\JJ|for (r_compound) treatment_11\NN|NONE (l_prep) for_12\IN|phenytoin (l_pobj) neuralgia_14\NN|NONE
D010672_D004827 NONE phenytoin_10\JJ|in (r_compound) treatment_11\NN|NONE (l_prep) in_12\IN|phenytoin (l_pobj) patients_15\NNS|NONE (l_amod) epileptic_14\JJ|some
D010672_D011605 NONE phenytoin_6\NN|NONE (r_pobj) with_5\IN|in (r_prep) treatment_4\NN|to (r_pobj) due_2\IN|Acute|. (r_amod) psychosis_1\NN|NONE
D010672_D011605 NONE phenytoin_10\JJ|for (r_compound) treatment_11\NN|NONE (r_dobj) following_9\VBG|NONE (r_acl) psychosis_8\NN|who
D010672_D011605 NONE phenytoin_10\JJ|in (r_compound) treatment_11\NN|NONE (r_pobj) following_9\VBG|that (r_prep) occur_8\VBP|psychotic|the (r_relcl) symptoms_6\NNS|may|result|that
D010672_D012640 NONE phenytoin_10\JJ|in (r_compound) treatment_11\NN|NONE (r_pobj) following_9\VBG|that (r_prep) occur_8\VBP|psychotic|the (r_relcl) symptoms_6\NNS|may|result|that (r_nsubj) be_17\VB|.|case (l_attr) result_20\NN|may|symptoms|that (l_amod) unrelated_24\JJ|the|of|,|direct (l_prep) to_25\IN|NONE (l_pobj) seizures_26\NNS|NONE
1504402
D007741_D056486 CID dilevalol_7\NN| (r_npadvmod) associated_9\VBN|NONE (r_amod) hepatitis_10\NN|NONE
D007741_D056486 CID dilevalol_7\VB|To|reactivity (l_conj) serum_10\VB|to|and (l_prep) in_19\IN|containing|to (l_pobj) case_21\NN|NONE (l_prep) of_22\IN|a (l_pobj) injury_27\NN|NONE
D007741_D056486 CID dilevalol_15\JJ|putative|ex|vivo|metabolites|or (r_compound) antigens_16\NNS|NONE (r_dobj) containing_11\VBG|in|to (r_xcomp) serum_10\VB|to|and (l_prep) in_19\IN|containing|to (l_pobj) case_21\NN|NONE (l_prep) of_22\IN|a (l_pobj) injury_27\NN|NONE
D007741_D056486 CID dilevalol_23\NN| (r_npadvmod) induced_25\VBN|liver (r_amod) injury_27\NN|NONE
D007741_D056486 CID dilevalol_10\NN| (r_npadvmod) induced_12\VBN|liver (r_amod) injury_14\NN|NONE
D007741_D056486 CID dilevalol_16\JJ|prepared|ex (r_compound) antigens_17\NNS|NONE (r_dobj) containing_11\VBG|NONE (r_acl) sera_10\NN|NONE (r_pobj) to_9\IN|lymphocyte (r_prep) sensitization_8\NN|NONE (r_pobj) of_6\IN|the (r_prep) detection_5\NN|methodology|.|,|suggesting (r_dobj) allowed_3\VBD|NONE (l_advcl) suggesting_19\VBG|methodology|.|detection|, (l_dobj) involvement_21\NN|NONE (l_prep) of_22\IN|the (l_pobj) mechanism_25\NN|NONE (l_prep) in_26\IN|immunologic|an (l_pobj) injury_31\NN|NONE
D007741_D056486 CID dilevalol_27\NN| (r_npadvmod) induced_29\VBN|liver (r_amod) injury_31\NN|NONE
D007741_D004342 CID dilevalol_7\NN| (r_npadvmod) associated_9\VBN|NONE (r_amod) hepatitis_10\NN|NONE (r_pobj) for_6\IN|a (r_prep) mechanism_5\NN|NONE (r_pobj) as_3\IN|.|immune|Hypersensitivity (r_prep) reaction_2\NN|NONE (l_nmod) Hypersensitivity_0\NN|.|as|immune
1992636
D009853_D053609 CID omeprazole_17\NN|NONE (r_pobj) with_16\IN|therapy (r_prep) starting_14\VBG|days (r_pcomp) after_13\IN|lethargy|developed|.|, (r_prep) weakness_3\NN|NONE (l_conj) lethargy_5\NN|developed|.|after|,
D009853_D000743 CID omeprazole_7\NN|NONE (r_pobj) of_6\IN|the (r_prep) use_5\NN|NONE (r_pobj) with_3\IN|NONE (r_prep) associated_2\VBN|Hemolytic|. (r_acl) anemia_1\NN|NONE
D009853_D000743 CID omeprazole_17\NN|NONE (r_pobj) of_16\IN|the (r_prep) use_15\NN|NONE (r_pobj) with_13\IN|a|term|adverse|serious (r_prep) reaction_12\NN|NONE (r_pobj) of_5\IN|the|first|:|anemia (r_prep) case_4\NN|We|. (l_appos) anemia_20\NN|the|of|first|:
D009853_D000743 CID omeprazole_4\NN|by|is (r_nsubj) caused_5\VBD|but|The|,|alerted (l_ccomp) is_11\VBZ|by|omeprazole (l_nsubj) anemia_10\NN|uncertain
D009853_D004417 CID omeprazole_17\NN|NONE (r_pobj) with_16\IN|therapy (r_prep) starting_14\VBG|days (r_pcomp) after_13\IN|lethargy|developed|.|, (r_prep) weakness_3\NN|NONE (l_conj) lethargy_5\NN|developed|.|after|, (l_conj) shortness_8\NN|,|and (l_prep) of_9\IN|NONE (l_pobj) breath_10\NN|NONE
15814210
D003907_D009422 CID dexamethasone_19\NN|in (r_compound) treatment_20\NN|NONE (r_pobj) after_18\IN|at|,|Minor|neurological|.|development (r_prep) dysfunction_2\NN|NONE
D003907_D009422 CID dexamethasone_19\NN|in (r_compound) therapy_20\NN|NONE (r_pobj) after_18\IN|to|dysfunction (r_prep) assess_7\VB|objective|. (l_dobj) dysfunction_10\NN|to|after
D003907_D009422 CID dexamethasone_1\NN|NONE (r_compound) treatment_2\NN|NONE (r_pobj) After_0\IN|rate|,|.|children (r_prep) showed_5\VBD|NONE (l_dobj) rate_8\NN|,|After|.|children (l_prep) of_9\IN|higher|a (l_pobj) dysfunctions_12\NNS|NONE
18627295
D004317_D007249 NONE Doxorubicin_0\NNP|are|.|by (l_dobj) inflammation_4\NN|and|apoptosis
D004317_D007249 NONE DOX_17\NNP|NONE (r_compound) cardiomyopathy_18\NN|NONE (r_pobj) of_16\IN|the (r_prep) development_15\NN|NONE (r_pobj) during_13\IN|role|)|To (r_prep) elucidate_1\VB|by|mice|.|,|we (r_advcl) studied_21\VBD|NONE (l_prep) by_29\IN|mice|elucidate|.|,|we (l_pcomp) investigating_30\VBG|NONE (l_dobj) inflammation_32\NN|and|apoptosis
D004317_D007249 NONE DOX_38\NNP| (r_npadvmod) induced_40\VBN|NONE (r_amod) cardiomyopathy_41\NN|NONE (r_pobj) of_37\IN|NONE (r_prep) induction_36\NN|NONE (r_pobj) after_35\IN|NONE (r_prep) apoptosis_34\NN|and|inflammation (r_conj) investigating_30\VBG|NONE (l_dobj) inflammation_32\NN|and|apoptosis
D004317_D009202 CID Doxorubicin_0\NNP|are|.|by (l_dobj) inflammation_4\NN|and|apoptosis (l_amod) induced_3\VBN|NONE (l_npadvmod) cardiomyopathy_1\NN|
D004317_D009202 CID DOX_17\NNP|NONE (r_compound) cardiomyopathy_18\NN|NONE
D004317_D009202 CID DOX_17\NNP|NONE (r_compound) cardiomyopathy_18\NN|NONE (r_pobj) of_16\IN|the (r_prep) development_15\NN|NONE (r_pobj) during_13\IN|role|)|To (r_prep) elucidate_1\VB|by|mice|.|,|we (r_advcl) studied_21\VBD|NONE (l_prep) by_29\IN|mice|elucidate|.|,|we (l_pcomp) investigating_30\VBG|NONE (l_conj) apoptosis_34\NN|and|inflammation (l_prep) after_35\IN|NONE (l_pobj) induction_36\NN|NONE (l_prep) of_37\IN|NONE (l_pobj) cardiomyopathy_41\NN|NONE
D004317_D009202 CID DOX_38\NNP| (r_npadvmod) induced_40\VBN|NONE (r_amod) cardiomyopathy_41\NN|NONE (r_pobj) of_37\IN|NONE (r_prep) induction_36\NN|NONE (r_pobj) after_35\IN|NONE (r_prep) apoptosis_34\NN|and|inflammation (r_conj) investigating_30\VBG|NONE (r_pcomp) by_29\IN|mice|elucidate|.|,|we (r_prep) studied_21\VBD|NONE (l_advcl) elucidate_1\VB|by|mice|.|,|we (l_prep) during_13\IN|role|)|To (l_pobj) development_15\NN|NONE (l_prep) of_16\IN|the (l_pobj) cardiomyopathy_18\NN|NONE
D004317_D009202 CID DOX_38\NNP| (r_npadvmod) induced_40\VBN|NONE (r_amod) cardiomyopathy_41\NN|NONE
D004317_D009202 CID DOX_8\NNP|NONE (r_pobj) in_7\IN|detrimental|mediates|cardiomyopathy|that|BR (r_prep) is_5\VBZ|findings|. (l_acl) cardiomyopathy_9\NN|detrimental|mediates|in|that|BR
D004317_D009202 CID DOX_16\NNP|NONE (r_compound) cardiomyopathy_17\NN|NONE
D004317_D066126 NONE doxorubicin_5\NN|NONE (r_pobj) of_2\IN|Clinical (r_prep) use_1\NN|is|.|by (r_nsubjpass) limited_10\VBN|NONE (l_agent) by_11\IN|is|.|use (l_pobj) effects_14\NNS|NONE (l_amod) cardiotoxic_13\JJ|attributed|,|its
D004317_D066126 NONE DOX_7\NNP|)|the|anthracycline (r_appos) doxorubicin_5\NN|NONE (r_pobj) of_2\IN|Clinical (r_prep) use_1\NN|is|.|by (r_nsubjpass) limited_10\VBN|NONE (l_agent) by_11\IN|is|.|use (l_pobj) effects_14\NNS|NONE (l_amod) cardiotoxic_13\JJ|attributed|,|its
D004317_D006331 NONE DOX_0\NN|NONE (r_compound) control_1\NN|NONE (r_compound) mice_2\NNS|dysfunction|. (r_nsubj) showed_3\VBD|NONE (l_dobj) dysfunction_5\NN|.|mice
D004317_D006331 NONE DOX_1\NNP|BR(/|) (r_nmod) mice_4\NNS|NONE (r_pobj) In_0\IN|compared|dysfunction|.|,|was (r_prep) improved_9\VBN|NONE (l_nsubjpass) dysfunction_7\NN|In|compared|.|,|was
D004317_D006331 NONE DOX_12\NNP|associated|control|, (r_compound) mice_14\NNS|NONE (r_pobj) to_11\IN|NONE (r_prep) compared_10\VBN|In|dysfunction|.|,|was (r_prep) improved_9\VBN|NONE (l_nsubjpass) dysfunction_7\NN|In|compared|.|,|was
D018943_D066126 NONE anthracycline_4\NN|)|the|DOX (r_amod) doxorubicin_5\NN|NONE (r_pobj) of_2\IN|Clinical (r_prep) use_1\NN|is|.|by (r_nsubjpass) limited_10\VBN|NONE (l_agent) by_11\IN|is|.|use (l_pobj) effects_14\NNS|NONE (l_amod) cardiotoxic_13\JJ|attributed|,|its
2557556
D009020_D006930 NONE Morphine_0\NNP|not|however|.|,|hyperalgesia|did|, (r_nsubj) alter_6\VB|NONE (l_dobj) hyperalgesia_8\NN|not|however|.|,|Morphine|did|,
D015232_D006930 CID E2-induced_23\VBN|prostaglandin (r_amod) hyperalgesia_24\NN|NONE
D015124_D006930 CID monophosphate_14\NN|NONE (r_pobj) by_10\IN|NONE (r_agent) induced_9\VBN|the (r_acl) hyperalgesia_8\NN|not|however|.|,|Morphine|did|,
7449470
D004317_D066126 NONE doxorubicin_3\NN|,|Late|late|. (r_compound) cardiotoxicity_4\NN|NONE
D004317_D066126 NONE adriamycin_11\NNS|NONE (r_pobj) of_10\IN|the|as (r_prep) use_9\NN|which (r_dobj) limits_7\VBZ|major|a (r_relcl) complication_5\NN|.|toxicity (r_attr) is_2\VBZ|NONE (l_nsubj) toxicity_1\NN|.|complication
3732088
D011188_D003324 NONE potassium_25\NN| (r_npadvmod) conserving_27\VBG|NONE (r_amod) diuretic_28\JJ|(|a (r_amod) amiloride_30\NN|NONE (r_pobj) with_23\IN|NONE (r_prep) treatment_22\NN|NONE (r_pobj) of_21\IN| (r_prep) weeks_20\NNS|NONE (r_pobj) after_18\IN|)|disease (r_prep) known_14\VBN|excitability|Thus|and|.|period|in|was|,|and (l_dobj) disease_17\NN|)|after
D011188_D003324 NONE potassium_38\NN| (r_npadvmod) losing_40\VBG|a|)|diuretic|( (r_amod) chlorthalidone_43\NN|NONE (r_pobj) on_36\IN|a|in|similar (r_prep) period_35\NN|excitability|Thus|and|.|in|was|known|,|and (r_conj) measured_6\VBN|NONE (l_conj) known_14\VBN|excitability|Thus|and|.|period|in|was|,|and (l_dobj) disease_17\NN|)|after
D000584_D003324 NONE amiloride_30\NN|NONE (r_pobj) with_23\IN|NONE (r_prep) treatment_22\NN|NONE (r_pobj) of_21\IN| (r_prep) weeks_20\NNS|NONE (r_pobj) after_18\IN|)|disease (r_prep) known_14\VBN|excitability|Thus|and|.|period|in|was|,|and (l_dobj) disease_17\NN|)|after
D000584_D006973 NONE amiloride_30\NN|NONE (r_pobj) with_23\IN|NONE (r_prep) treatment_22\NN|NONE (r_pobj) of_21\IN| (r_prep) weeks_20\NNS|NONE (r_pobj) after_18\IN|)|disease (r_prep) known_14\VBN|excitability|Thus|and|.|period|in|was|,|and (r_conj) measured_6\VBN|NONE (l_prep) in_7\IN|excitability|Thus|and|.|period|was|known|,|and (l_pobj) patients_8\NNS|NONE (l_prep) with_9\IN|NONE (l_pobj) hypertension_12\NN|NONE
D011188_D003327 NONE potassium_2\NN|,|in|. (r_conj) Diuretics_0\NNS|NONE (l_prep) in_5\IN|potassium|,|. (l_pobj) disease_8\NN|NONE
D002752_D003324 NONE chlorthalidone_43\NN|NONE (r_pobj) on_36\IN|a|in|similar (r_prep) period_35\NN|excitability|Thus|and|.|in|was|known|,|and (r_conj) measured_6\VBN|NONE (l_conj) known_14\VBN|excitability|Thus|and|.|period|in|was|,|and (l_dobj) disease_17\NN|)|after
D002752_D018879 CID chlorthalidone_6\NN|the (r_compound) phase_7\NN|,|was|and|increased|period|.|with|Compared|, (r_nsubjpass) associated_9\VBN|NONE (l_prep) with_10\IN|,|was|and|phase|increased|period|.|Compared|, (l_pobj) frequency_13\NN|NONE (l_prep) of_14\IN|an|grading|increased|and (l_pobj) beats_17\NNS|NONE
D011188_D001145 NONE potassium_2\NN|,|in|. (l_conj) arrhythmias_4\NNS|and
D011188_D001145 NONE potassium_9\NN|NONE (r_pobj) in_7\IN|modest (r_prep) changes_6\NNS|tendency|that|can (r_nsubj) alter_11\VB|has|It|.|been (l_dobj) tendency_13\NN|changes|that|can (l_prep) towards_14\IN|the (l_pobj) arrhythmias_16\NNS|NONE
D011188_D017202 NONE potassium_6\NN| (r_npadvmod) losing_8\VBG|diuretic (r_amod) therapy_10\NN|excitability|because|can (r_nsubj) increase_12\VB|in|that|,|minor (l_dobj) excitability_15\NN|therapy|because|can (l_prep) in_16\IN|electrical|myocardial (l_pobj) patients_17\NNS|NONE (l_prep) with_18\IN|NONE (l_pobj) disease_21\NN|NONE
D011188_D017202 NONE potassium_28\NN|plasma (r_compound) concentrations_29\NNS|NONE (r_pobj) in_26\IN|that|,|increase|minor (r_prep) falls_25\VBZ|.|avoided|results (l_advcl) increase_12\VB|in|that|,|minor (l_dobj) excitability_15\NN|therapy|because|can (l_prep) in_16\IN|electrical|myocardial (l_pobj) patients_17\NNS|NONE (l_prep) with_18\IN|NONE (l_pobj) disease_21\NN|NONE
D002752_D006973 NONE chlorthalidone_43\NN|NONE (r_pobj) on_36\IN|a|in|similar (r_prep) period_35\NN|excitability|Thus|and|.|in|was|known|,|and (r_conj) measured_6\VBN|NONE (l_prep) in_7\IN|excitability|Thus|and|.|period|was|known|,|and (l_pobj) patients_8\NNS|NONE (l_prep) with_9\IN|NONE (l_pobj) hypertension_12\NN|NONE
D011188_D006973 NONE potassium_2\NN|,|in|. (r_conj) Diuretics_0\NNS|NONE (l_prep) in_5\IN|potassium|,|. (l_pobj) disease_8\NN|NONE (l_amod) hypertensive_6\JJ|coronary
D011188_D006973 NONE potassium_25\NN| (r_npadvmod) conserving_27\VBG|NONE (r_amod) diuretic_28\JJ|(|a (r_amod) amiloride_30\NN|NONE (r_pobj) with_23\IN|NONE (r_prep) treatment_22\NN|NONE (r_pobj) of_21\IN| (r_prep) weeks_20\NNS|NONE (r_pobj) after_18\IN|)|disease (r_prep) known_14\VBN|excitability|Thus|and|.|period|in|was|,|and (r_conj) measured_6\VBN|NONE (l_prep) in_7\IN|excitability|Thus|and|.|period|was|known|,|and (l_pobj) patients_8\NNS|NONE (l_prep) with_9\IN|NONE (l_pobj) hypertension_12\NN|NONE
D011188_D006973 NONE potassium_38\NN| (r_npadvmod) losing_40\VBG|a|)|diuretic|( (r_amod) chlorthalidone_43\NN|NONE (r_pobj) on_36\IN|a|in|similar (r_prep) period_35\NN|excitability|Thus|and|.|in|was|known|,|and (r_conj) measured_6\VBN|NONE (l_prep) in_7\IN|excitability|Thus|and|.|period|was|known|,|and (l_pobj) patients_8\NNS|NONE (l_prep) with_9\IN|NONE (l_pobj) hypertension_12\NN|NONE
D000584_D018879 NONE amiloride_2\NN|NONE (r_compound) treatment_3\NN|NONE (r_pobj) to_1\IN|NONE (r_prep) Compared_0\VBN|,|was|and|phase|increased|period|.|with|, (r_prep) associated_9\VBN|NONE (l_prep) with_10\IN|,|was|and|phase|increased|period|.|Compared|, (l_pobj) frequency_13\NN|NONE (l_prep) of_14\IN|an|grading|increased|and (l_pobj) beats_17\NNS|NONE
17049862
D001285_D001919 NONE atropine_13\NN|NONE (r_pobj) to_12\IN|NONE (r_prep) refractory_11\JJ|.|,|patient|Following|bradycardia|, (r_advcl) developed_6\VBD|NONE (l_dobj) bradycardia_9\NN|.|,|patient|Following|,|refractory
D010672_D012640 NONE phenytoin_1\NN|during|.|was (r_nsubjpass) administered_3\VBN|NONE (l_prep) during_4\IN|phenytoin|.|was (l_pobj) part_7\NN|NONE (l_prep) of_8\IN|later|the (l_pobj) surgery_10\NN|NONE (l_prep) for_11\IN|the (l_pobj) prophylaxis_13\NN|NONE (l_compound) seizure_12\NN|NONE
D010672_D007035 NONE phenytoin_1\JJ|NONE (r_compound) administration_2\NN|safe|? (r_nsubj) Is_0\VBZ|NONE (l_acomp) safe_3\JJ|administration|? (l_prep) in_4\IN|NONE (l_pobj) child_7\NN|NONE (l_amod) hypothermic_6\JJ|a
D010672_D007035 NONE phenytoin_5\NN|NONE (l_conj) hypothermia_7\NN|and
D010672_D007035 NONE phenytoin_2\NN|NONE (r_pobj) of_1\IN|in (r_prep) Administration_0\NN|may|.|to (l_prep) in_3\IN|of (l_pobj) presence_5\NN|NONE (l_prep) of_6\IN|the (l_pobj) hypothermia_7\NN|NONE
D010672_D001919 CID phenytoin_1\JJ|NONE (r_compound) administration_2\NN|NONE (r_pobj) Following_0\VBG|.|,|patient|bradycardia|,|refractory (r_prep) developed_6\VBD|NONE (l_dobj) bradycardia_9\NN|.|,|patient|Following|,|refractory
D004837_D001919 NONE adrenaline_15\NN|and (r_conj) atropine_13\NN|NONE (r_pobj) to_12\IN|NONE (r_prep) refractory_11\JJ|.|,|patient|Following|bradycardia|, (r_advcl) developed_6\VBD|NONE (l_dobj) bradycardia_9\NN|.|,|patient|Following|,|refractory
6415512
D002220_D004832 CID carbamazepine_10\NN|NONE (r_compound) therapy_11\NN|NONE (r_pobj) of_9\IN|in (r_prep) institution_8\NN|NONE (r_dobj) following_7\VBG|.|Myoclonic (r_prep) seizures_6\NNS|NONE
D002220_D004832 CID carbamazepine_11\NN|NONE (r_pobj) with_10\IN|had|,|.|children (r_prep) treated_9\VBN|NONE (l_conj) had_15\VBD|,|.|with|children (l_dobj) reaction_19\NN|NONE (l_acl) characterized_20\VBN|an|acute|aberrant (l_agent) by_21\IN|NONE (l_pobj) onset_23\NN|NONE (l_prep) of_24\IN|the (l_pobj) absence_28\NN|NONE (l_conj) seizures_35\NNS|,|atypical|and/or|myoclonic
D002220_D004831 CID carbamazepine_10\NN|NONE (r_compound) therapy_11\NN|NONE (r_pobj) of_9\IN|in (r_prep) institution_8\NN|NONE (r_dobj) following_7\VBG|.|Myoclonic (r_prep) seizures_6\NNS|NONE
D002220_D004831 CID carbamazepine_11\NN|NONE (r_pobj) with_10\IN|had|,|.|children (r_prep) treated_9\VBN|NONE (l_conj) had_15\VBD|,|.|with|children (l_dobj) reaction_19\NN|NONE (l_acl) characterized_20\VBN|an|acute|aberrant (l_agent) by_21\IN|NONE (l_pobj) onset_23\NN|NONE (l_prep) of_24\IN|the (l_pobj) absence_28\NN|NONE (l_conj) seizures_35\NNS|,|atypical|and/or|myoclonic
D002220_D012640 NONE carbamazepine_2\NN|When|was (r_nsubjpass) discontinued_4\VBN|quickly|to|two|, (r_advcl) returned_10\VBD|resolve|two|,|and|had|, (r_ccomp) had_19\VBD|NONE (l_ccomp) resolve_24\VBP|returned|two|,|and|had|, (l_nsubj) seizures_23\NNS|in
D002220_D012640 NONE carbamazepine_2\NN|When|was (r_nsubjpass) discontinued_4\VBN|quickly|to|two|, (r_advcl) returned_10\VBD|resolve|two|,|and|had|, (r_ccomp) had_19\VBD|NONE (l_conj) had_33\VBD|resolve|returned|two|,|and|, (l_ccomp) persist_36\VB|one|. (l_nsubj) seizures_35\NNS|NONE
D002220_D004827 NONE carbamazepine_11\NN|NONE (l_prep) for_12\IN|NONE (l_pobj) epilepsy_13\NN|NONE
15804801
D017239_D003323 CID paclitaxel_6\NN| (r_compound) eluting_8\VBG|a (r_amod) stent_9\NN|NONE (r_pobj) of_4\IN|NONE (r_prep) implantation_3\NN|NONE (r_pobj) after_2\IN|.|Coronary (r_prep) aneurysm_1\NN|NONE
D017239_D003323 CID paclitaxel_22\NN| (r_compound) eluting_24\VBG|a (r_amod) stent_25\NN|NONE (r_dobj) receiving_20\VBG|months (r_pcomp) after_19\IN|in|who|aneurysm (r_prep) developed_8\VBD|a|old (l_dobj) aneurysm_11\NN|after|in|who
12589964
D004317_D005355 NONE DOX_8\NNP|NONE (r_pobj) given_7\VBN|all (r_prep) rats_6\NNS|NONE (r_pobj) from_4\IN|NONE (r_prep) hearts_3\NNS|NONE (r_pobj) of_2\IN|Histological (r_prep) evaluation_1\NN|degrees|. (r_nsubj) revealed_9\VBD|NONE (l_dobj) degrees_12\NNS|evaluation|. (l_prep) of_13\IN|significant|slight (l_pobj) fibrosis_17\NN|NONE
D004317_D066126 NONE DOX_13\NNP|NONE (r_pobj) after_12\IN|of|,|the (r_prep) amount_7\NN|NONE (r_pobj) between_5\IN|a (r_prep) discrepancy_4\NN|there|due|Although (r_attr) was_2\VBD|,|likely|.|it (r_advcl) is_33\VBZ|NONE (l_acomp) likely_34\JJ|,|was|.|it (l_ccomp) indicates_41\VBZ|NONE (l_conj) be_55\VB|that|DOX|cTnT|damage|induced|after|and (l_attr) marker_58\NN|should|cTnT|that (l_prep) for_59\IN|a|useful (l_pobj) prediction_61\NN|NONE (l_prep) of_62\IN|the (l_pobj) cardiotoxicity_65\NN|NONE
D004317_D066126 NONE DOX_40\NNP|that|cTnT|damage|induced|after|and|be (r_nsubj) indicates_41\VBZ|NONE (l_conj) be_55\VB|that|DOX|cTnT|damage|induced|after|and (l_attr) marker_58\NN|should|cTnT|that (l_prep) for_59\IN|a|useful (l_pobj) prediction_61\NN|NONE (l_prep) of_62\IN|the (l_pobj) cardiotoxicity_65\NN|NONE
D004317_D006331 NONE doxorubicin_20\NN|NONE (r_pobj) of_19\IN|rat|cardiomyopathy|a (r_prep) model_18\NN|NONE (r_pobj) in_15\IN|myocardial (r_prep) damage_14\NN|NONE (r_pobj) of_12\IN|the (r_prep) diagnosis_11\NN|NONE (r_pobj) for_9\IN|and|We|examined|value|, (r_prep) investigated_1\VBD|NONE (l_conj) examined_27\VBD|and|We|for|value|, (l_dobj) relationship_29\NN|we|. (l_prep) with_35\IN|between|the (l_pobj) development_37\NN|NONE (l_prep) of_38\IN|the (l_pobj) disorders_40\NNS|NONE
D004317_D006331 NONE DOX)-induced_22\VBN|( (r_amod) cardiomyopathy_23\NN|rat|a|of (r_appos) model_18\NN|NONE (r_pobj) in_15\IN|myocardial (r_prep) damage_14\NN|NONE (r_pobj) of_12\IN|the (r_prep) diagnosis_11\NN|NONE (r_pobj) for_9\IN|and|We|examined|value|, (r_prep) investigated_1\VBD|NONE (l_conj) examined_27\VBD|and|We|for|value|, (l_dobj) relationship_29\NN|we|. (l_prep) with_35\IN|between|the (l_pobj) development_37\NN|NONE (l_prep) of_38\IN|the (l_pobj) disorders_40\NNS|NONE
D004317_D017202 NONE DOX_6\NNP|NONE (r_pobj) after_5\IN|of (r_prep) markers_1\NNS|NONE (l_prep) of_2\IN|after (l_pobj) injury_4\NN|NONE
D004317_D009202 CID doxorubicin_14\NN| (r_npadvmod) induced_16\VBN|cardiomyopathy (r_amod) rats_18\NNS|NONE (r_pobj) in_13\IN|myocardial (r_prep) damage_12\NN|NONE
D004317_D009202 CID doxorubicin_14\NN| (r_npadvmod) induced_16\VBN|cardiomyopathy (r_amod) rats_18\NNS|NONE (l_amod) cardiomyopathy_17\NN|induced
D004317_D009202 CID doxorubicin_20\NN|NONE (r_pobj) of_19\IN|rat|cardiomyopathy|a (r_prep) model_18\NN|NONE (r_pobj) in_15\IN|myocardial (r_prep) damage_14\NN|NONE
D004317_D009202 CID doxorubicin_20\NN|NONE (r_pobj) of_19\IN|rat|cardiomyopathy|a (r_prep) model_18\NN|NONE (l_appos) cardiomyopathy_23\NN|rat|a|of
D004317_D009202 CID DOX)-induced_22\VBN|( (r_amod) cardiomyopathy_23\NN|rat|a|of (r_appos) model_18\NN|NONE (r_pobj) in_15\IN|myocardial (r_prep) damage_14\NN|NONE
D004317_D009202 CID DOX)-induced_22\VBN|( (r_amod) cardiomyopathy_23\NN|rat|a|of
D004317_D009202 CID DOX_6\NNP|NONE (r_pobj) after_5\IN|of (r_prep) markers_1\NNS|NONE (r_pobj) Among_0\IN|.|cTnT|,|ability (r_prep) showed_11\VBD|NONE (l_dobj) ability_14\NN|.|Among|cTnT|, (l_acl) detect_16\VB|the|greatest (l_dobj) damage_18\NN|to
D004317_D064420 NONE DOX_3\NNP|the (r_compound) rats_4\NNS|NONE (r_pobj) of_1\IN|NONE (r_prep) Eighteen_0\CD|.|of|during|prematurely (r_nsubj) died_5\VBD|NONE (l_prep) of_7\IN|.|during|Eighteen|prematurely (l_pobj) toxicity_9\NN|NONE
11245434
D016190_D000740 CID carboplatin_8\NN|NONE (r_pobj) of_7\IN|resulting|a|)|i.v.|single (r_prep) dose_6\NN|NONE (r_dobj) using_3\VBG|.|was|Anemia (r_xcomp) induced_2\VBN|NONE (l_nsubjpass) Anemia_0\NN|.|was|using
D016190_D000740 CID carboplatin_29\NN|NONE (r_amod) application_30\NN|NONE (r_pobj) before_28\IN| (r_prep) days_27\NNS|NONE (r_dobj) starting_25\VBG|week|s.c. (r_advcl) administered_19\VBN|.|by|In|was|development|, (r_conj) prevented_10\VBN|NONE (l_nsubjpass) development_6\NN|.|by|In|administered|was|, (l_prep) of_7\IN|the (l_pobj) anemia_8\NN|NONE
D003520_D009369 NONE cyclophosphamide_8\NN|in (r_compound) cytotoxicity_9\NN|NONE (l_prep) in_10\IN|cyclophosphamide (l_pobj) tumors_12\NNS|NONE
D003520_D009369 NONE cyclophosphamide_25\NN|NONE (r_pobj) of_24\IN|in|the (r_prep) cytotoxicity_23\NN|NONE (l_prep) in_26\IN|of|the (l_pobj) tumors_29\NNS|NONE
D003520_D009369 NONE cyclophosphamide_9\NN|NONE (r_pobj) of_8\IN|mg/kg|)|a|single|( (r_prep) dose_7\NN|NONE (r_pobj) with_4\IN|tumors|after|When|were (r_prep) treated_3\VBN|,|was|.|delay (l_nsubjpass) tumors_1\NNS|after|When|were|with
D003520_D009369 NONE cyclophosphamide_9\NN|NONE (r_pobj) of_8\IN|mg/kg|)|a|single|( (r_prep) dose_7\NN|NONE (r_pobj) with_4\IN|tumors|after|When|were (r_prep) treated_3\VBN|,|was|.|delay (r_advcl) observed_31\VBN|NONE (l_nsubjpass) delay_22\NN|,|was|.|treated (l_prep) with_23\IN|growth|a (l_pobj) regrowth_26\NN|NONE (l_prep) of_27\IN|subsequent|a (l_pobj) tumors_29\NNS|NONE
D003520_D009369 NONE cyclophosphamide_11\NN|NONE (r_pobj) of_10\IN|in (r_prep) cytotoxicity_9\NN|that|increases|,|anemia (l_prep) in_12\IN|of (l_pobj) tumors_13\NNS|NONE
D003520_D009369 NONE cyclophosphamide_11\NN|NONE (r_pobj) of_10\IN|in (r_prep) cytotoxicity_9\NN|that|increases|,|anemia (r_dobj) reduces_8\VBZ|results|. (l_advcl) increases_26\VBZ|cytotoxicity|that|,|anemia (l_prep) as_31\IN|,|correction|sensitivity|whereas (l_pobj) result_33\NN|probably (l_prep) of_34\IN|a (l_pobj) supply_38\NN|NONE (l_prep) to_39\IN|improved|an|oxygen (l_pobj) tissue_41\NN|NONE (l_compound) tumor_40\NN|NONE
D016190_D012509 NONE carboplatin_3\NN|NONE (r_amod) treatment_4\NN|days (r_pobj) after_2\IN|s.c.|.|were|onto|tumors|, (r_prep) implanted_16\VBN|NONE (l_nsubjpass) tumors_6\NNS|s.c.|after|.|were|onto|, (l_appos) sarcoma_10\NN|(|)
D003520_D064420 NONE cyclophosphamide_8\NN|in (r_compound) cytotoxicity_9\NN|NONE
D003520_D064420 NONE cyclophosphamide_25\NN|NONE (r_pobj) of_24\IN|in|the (r_prep) cytotoxicity_23\NN|NONE
D003520_D064420 NONE cyclophosphamide_11\NN|NONE (r_pobj) of_10\IN|in (r_prep) cytotoxicity_9\NN|that|increases|,|anemia
D010100_D009369 NONE oxygen_37\NN|to|improved|an (r_compound) supply_38\NN|NONE (r_pobj) of_34\IN|a (r_prep) result_33\NN|probably (r_pobj) as_31\IN|,|correction|sensitivity|whereas (r_prep) increases_26\VBZ|cytotoxicity|that|,|anemia (r_advcl) reduces_8\VBZ|results|. (l_dobj) cytotoxicity_9\NN|that|increases|,|anemia (l_prep) in_12\IN|of (l_pobj) tumors_13\NNS|NONE
D010100_D009369 NONE oxygen_37\NN|to|improved|an (r_compound) supply_38\NN|NONE (l_prep) to_39\IN|improved|an|oxygen (l_pobj) tissue_41\NN|NONE (l_compound) tumor_40\NN|NONE
D016190_D009369 NONE carboplatin_3\NN|NONE (r_amod) treatment_4\NN|days (r_pobj) after_2\IN|s.c.|.|were|onto|tumors|, (r_prep) implanted_16\VBN|NONE (l_nsubjpass) tumors_6\NNS|s.c.|after|.|were|onto|,
D016190_D009369 NONE carboplatin_1\NN|NONE (l_conj) influenced_5\VBN|.|treatment|Neither|nor (l_dobj) rate_8\NN|se (l_compound) tumor_6\NN|growth
D010100_D000740 NONE oxygen_37\NN|to|improved|an (r_compound) supply_38\NN|NONE (r_pobj) of_34\IN|a (r_prep) result_33\NN|probably (r_pobj) as_31\IN|,|correction|sensitivity|whereas (r_prep) increases_26\VBZ|cytotoxicity|that|,|anemia (r_advcl) reduces_8\VBZ|results|. (l_nsubj) anemia_7\NN|cytotoxicity|that|increases|,
D010100_D000740 NONE oxygen_37\NN|to|improved|an (r_compound) supply_38\NN|NONE (r_pobj) of_34\IN|a (r_prep) result_33\NN|probably (r_pobj) as_31\IN|,|correction|sensitivity|whereas (r_prep) increases_26\VBZ|cytotoxicity|that|,|anemia (l_nsubj) correction_16\NN|,|as|sensitivity|whereas (l_prep) of_17\IN|by (l_pobj) anemia_18\NN|NONE
D003520_D000740 NONE cyclophosphamide_8\NN|in (r_compound) cytotoxicity_9\NN|NONE (r_pobj) in_7\IN|induced|the (r_prep) reduction_6\NN|.|Erythropoietin (l_amod) induced_5\VBN|in|the (l_npadvmod) anemia_3\NN|
D003520_D000740 NONE cyclophosphamide_25\NN|NONE (r_pobj) of_24\IN|in|the (r_prep) cytotoxicity_23\NN|NONE (r_pobj) on_21\IN|(|)|erythropoietin|rHuEPO (r_prep) treatment_20\NN|NONE (r_pobj) by_13\IN|of|the (r_prep) impact_9\NN|to (l_prep) of_10\IN|by|the (l_pobj) prevention_12\NN|NONE (l_compound) anemia_11\NN|NONE
D003520_D000740 NONE cyclophosphamide_11\NN|NONE (r_pobj) of_10\IN|in (r_prep) cytotoxicity_9\NN|that|increases|,|anemia (r_dobj) reduces_8\VBZ|results|. (l_nsubj) anemia_7\NN|cytotoxicity|that|increases|,
D003520_D000740 NONE cyclophosphamide_11\NN|NONE (r_pobj) of_10\IN|in (r_prep) cytotoxicity_9\NN|that|increases|,|anemia (r_dobj) reduces_8\VBZ|results|. (l_advcl) increases_26\VBZ|cytotoxicity|that|,|anemia (l_nsubj) correction_16\NN|,|as|sensitivity|whereas (l_prep) of_17\IN|by (l_pobj) anemia_18\NN|NONE
D010100_D064420 NONE oxygen_37\NN|to|improved|an (r_compound) supply_38\NN|NONE (r_pobj) of_34\IN|a (r_prep) result_33\NN|probably (r_pobj) as_31\IN|,|correction|sensitivity|whereas (r_prep) increases_26\VBZ|cytotoxicity|that|,|anemia (r_advcl) reduces_8\VBZ|results|. (l_dobj) cytotoxicity_9\NN|that|increases|,|anemia
2396046
D002794_D006528 CID choline_13\NN| (r_npadvmod) supplemented_15\VBN|the|plain (r_amod) diet_16\NN|fed|developed|,|.|nodules (r_dobj) fed_10\VBD|NONE (l_nsubj) nodules_3\NNS|fed|developed|,|diet|. (l_conj) carcinomas_6\NNS|hepatic|preneoplastic|No|developed|or
D002794_D006528 CID choline_13\NN| (r_npadvmod) supplemented_15\VBN|the|plain (r_amod) diet_16\NN|fed|developed|,|.|nodules (r_dobj) fed_10\VBD|NONE (l_advcl) developed_26\VBN|fed|,|diet|.|nodules (l_nsubj) nodule_21\NN|while|in (l_conj) carcinoma_25\NN|and|preneoplastic|one
D002794_D006528 CID choline_23\NN| (r_npadvmod) devoid_25\JJ|plain|the (r_amod) diet_26\NN|in|,|%|in|and|rats|, (r_dobj) fed_20\VBD|respectively|.|,|%|incidence|,|fed (r_conj) was_9\VBD|NONE (l_nsubj) incidence_1\NN|respectively|.|,|fed|%|,|fed (l_prep) of_2\IN|The (l_conj) of_6\IN|and|nodules (l_pobj) carcinomas_8\NNS|NONE
D002794_D006528 CID choline_42\NN| (r_npadvmod) devoid_44\JJ|the|containing (r_amod) diet_45\NN|NONE (r_dobj) fed_37\VBD|respectively|.|,|fed|%|incidence|, (r_conj) was_9\VBD|NONE (l_nsubj) incidence_1\NN|respectively|.|,|fed|%|,|fed (l_prep) of_2\IN|The (l_conj) of_6\IN|and|nodules (l_pobj) carcinomas_8\NNS|NONE
D010634_D006528 NONE phenobarbital_35\NN|NONE (r_dobj) containing_34\VBG|same|the (r_acl) diet_33\NN|NONE (r_dobj) fed_30\VBD|developed|,|diet|.|nodules (r_conj) fed_10\VBD|NONE (l_nsubj) nodules_3\NNS|fed|developed|,|diet|. (l_conj) carcinomas_6\NNS|hepatic|preneoplastic|No|developed|or
D010634_D006528 NONE phenobarbital_35\NN|NONE (r_dobj) containing_34\VBG|same|the (r_acl) diet_33\NN|NONE (r_dobj) fed_30\VBD|developed|,|diet|.|nodules (r_conj) fed_10\VBD|NONE (l_advcl) developed_26\VBN|fed|,|diet|.|nodules (l_nsubj) nodule_21\NN|while|in (l_conj) carcinoma_25\NN|and|preneoplastic|one
D010634_D006528 NONE phenobarbital_39\RB| (r_npadvmod) containing_41\VBG|the|devoid (r_amod) diet_45\NN|NONE (r_dobj) fed_37\VBD|respectively|.|,|fed|%|incidence|, (r_conj) was_9\VBD|NONE (l_nsubj) incidence_1\NN|respectively|.|,|fed|%|,|fed (l_prep) of_2\IN|The (l_conj) of_6\IN|and|nodules (l_pobj) carcinomas_8\NNS|NONE
2907585
D002065_D002375 NONE buspirone_5\NN|novel|anxiolytic|The|,|, (r_appos) drug_3\NN|.|catalepsy (r_nsubj) reverses_7\VBZ|NONE (l_dobj) catalepsy_8\NN|.|drug
D002065_D002375 NONE buspirone_8\NN|NONE (r_pobj) of_7\IN|piperazine (r_prep) analogues_6\NNS|NONE (r_pobj) of_2\IN|A (r_prep) series_1\NN|induced|for|were|. (r_nsubjpass) tested_14\VBN|NONE (l_conj) induced_21\VBN|for|series|were|. (l_dobj) catalepsy_22\NN|NONE
D006220_D002375 CID haloperidol_11\NN|NONE (r_pobj) by_10\IN|NONE (r_agent) induced_9\VBN|NONE (r_acl) catalepsy_8\NN|.|drug
D006220_D002375 CID haloperidol_20\NN|to (r_dobj) reverse_19\VB|their (r_acl) ability_17\NN|NONE (r_pobj) for_15\IN|induced|series|were|. (r_prep) tested_14\VBN|NONE (l_conj) induced_21\VBN|for|series|were|. (l_dobj) catalepsy_22\NN|NONE
-1_D002375 NONE piperazine_10\NN|novel|anxiolytic (r_nmod) drugs_12\NNS|NONE (r_pobj) by_6\IN|of|. (r_prep) Reversal_0\NN|NONE (l_prep) of_1\IN|by|. (l_pobj) catalepsy_5\NN|NONE
-1_D002375 NONE piperazine_5\NN|of (r_compound) analogues_6\NNS|NONE (r_pobj) of_2\IN|A (r_prep) series_1\NN|induced|for|were|. (r_nsubjpass) tested_14\VBN|NONE (l_conj) induced_21\VBN|for|series|were|. (l_dobj) catalepsy_22\NN|NONE
D058825_D002375 NONE agonists_12\NNS|and (r_conj) buspirone_8\NN|NONE (r_pobj) of_7\IN|piperazine (r_prep) analogues_6\NNS|NONE (r_pobj) of_2\IN|A (r_prep) series_1\NN|induced|for|were|. (r_nsubjpass) tested_14\VBN|NONE (l_conj) induced_21\VBN|for|series|were|. (l_dobj) catalepsy_22\NN|NONE
D012701_D002375 NONE 5-hydroxytryptamine1a_6\CD|NONE (r_compound) receptors_7\NNS|NONE (r_pobj) for_5\IN|strong (r_prep) affinity_4\NN|NONE (r_pobj) with_2\IN|Those (r_prep) drugs_1\NNS|able|. (r_nsubj) were_8\VBD|NONE (l_acomp) able_9\JJ|.|drugs (l_xcomp) reverse_11\VB|NONE (l_dobj) catalepsy_12\NN|to
D012701_D002375 NONE 5-HT_5\CD|postsynaptic (r_compound) receptors_6\NNS|NONE (r_pobj) of_3\IN|NONE (r_prep) inhibition_2\NN|However|nor|neither|,|.|potentiated (r_nsubj) inhibited_8\VBN|NONE (l_conj) potentiated_10\VBN|However|inhibition|nor|neither|,|. (l_dobj) reversal_11\NN|leaves|and (l_prep) of_12\IN|NONE (l_pobj) catalepsy_13\NN|NONE
424937
D008750_D017093 NONE methyldopa_17\NN|for|who|had|been (r_dobj) taking_16\VBG|,|, (r_relcl) another_11\DT|over|resolution (r_nsubj) showed_22\VBD|and|,|having|in (r_conj) presented_5\VBN|,|.|patient (l_prep) in_6\IN|and|showed|,|having (l_pobj) failure_8\NN|NONE
D008750_D017114 NONE methyldopa_22\NN| (r_npadvmod) induced_24\VBN|NONE (r_amod) hepatitis_25\NN|NONE (r_pobj) of_21\IN|a|prior (r_prep) episode_20\NN|NONE (r_pobj) after_17\IN|year|drug|when|was|accidentally (r_prep) recommenced_14\VBN|hepatitis|patient|. (r_advcl) developed_6\VBD|NONE (l_dobj) hepatitis_8\NN|recommenced|patient|.
D008750_D056486 CID methyldopa_6\NN|NONE (r_pobj) by_5\IN|Patterns|. (r_agent) induced_4\VBN|NONE (l_nsubj) Patterns_0\NNS|by|. (l_prep) of_1\IN|NONE (l_pobj) injury_3\NN|NONE
D008750_D056486 CID methyldopa_22\NN| (r_npadvmod) induced_24\VBN|NONE (r_amod) hepatitis_25\NN|NONE
D008750_D056486 CID methyldopa_14\NN|NONE (r_pobj) between_13\IN|the|causal (r_prep) relationship_12\NN|In|was|.|in|,|with (r_nsubjpass) proved_19\VBN|NONE (l_prep) with_20\IN|relationship|In|was|.|in|, (l_pobj) recurrence_22\NN|NONE (l_prep) of_23\IN|within|to|the (l_pobj) hepatitis_24\NN|NONE
D008750_D008107 NONE methyldopa_7\NN|NONE (r_pobj) to_6\IN|NONE (r_prep) related_5\VBN|liver (r_acl) disease_4\NN|NONE
D008750_D008107 NONE methyldopa_14\NN|NONE (l_conj) dysfunction_17\NN|and
12483326
D016190_D064420 NONE carboplatin_7\NN|NONE (r_amod) toxicity_8\NN|NONE
D016190_D009916 NONE carboplatin_9\NN|NONE (r_pobj) of_8\IN|for|intracarotid (r_prep) injection_7\NN|NONE (r_pobj) after_5\IN|Severe|ocular|. (r_prep) toxicity_4\NN|NONE
D016190_D009916 NONE carboplatin_2\NN|.|Generally|is|,|have|known (r_nsubjpass) said_4\VBN|NONE (l_ccomp) known_20\JJ|.|Generally|is|,|have|carboplatin (l_auxpass) are_18\VBP|well (l_nsubj) toxicity_17\NN|NONE
D016190_D009916 NONE carboplatin_16\NN|NONE (r_pobj) of_15\IN|,|reported|intracarotid (r_prep) injection_14\NN|NONE (r_pobj) after_12\IN|we|However|case|.|, (r_prep) experienced_3\VBD|NONE (l_dobj) case_5\NN|we|However|after|.|, (l_prep) of_6\IN|a (l_pobj) toxicity_11\NN|NONE
D002945_D005128 NONE cisplatin_11\NN|NONE (r_pcomp) than_10\IN|,|side|milder (r_prep) effects_9\NNS|to (r_dobj) have_6\VB|.|Generally|is|,|carboplatin|known (r_xcomp) said_4\VBN|NONE (l_ccomp) known_20\JJ|.|Generally|is|,|have|carboplatin (l_auxpass) are_18\VBP|well (l_nsubj) toxicity_17\NN|NONE
D016190_D005128 NONE carboplatin_9\NN|NONE (r_pobj) of_8\IN|for|intracarotid (r_prep) injection_7\NN|NONE (r_pobj) after_5\IN|Severe|ocular|. (r_prep) toxicity_4\NN|NONE
D016190_D005128 NONE carboplatin_2\NN|.|Generally|is|,|have|known (r_nsubjpass) said_4\VBN|NONE (l_ccomp) known_20\JJ|.|Generally|is|,|have|carboplatin (l_auxpass) are_18\VBP|well (l_nsubj) toxicity_17\NN|NONE
D016190_D005128 NONE carboplatin_16\NN|NONE (r_pobj) of_15\IN|,|reported|intracarotid (r_prep) injection_14\NN|NONE (r_pobj) after_12\IN|we|However|case|.|, (r_prep) experienced_3\VBD|NONE (l_dobj) case_5\NN|we|However|after|.|, (l_prep) of_6\IN|a (l_pobj) toxicity_11\NN|NONE
D016190_D005128 NONE carboplatin_5\NN|NONE (r_pobj) of_4\IN|intracarotid (r_prep) injection_3\NN|When (r_dobj) performing_1\VBG|we|aware|,|must|. (r_advcl) be_9\VB|NONE (l_acomp) aware_10\JJ|performing|we|,|must|. (l_prep) of_11\IN|NONE (l_pobj) toxicity_16\NN|NONE
D002945_D009916 NONE cisplatin_11\NN|NONE (r_pcomp) than_10\IN|,|side|milder (r_prep) effects_9\NNS|to (r_dobj) have_6\VB|.|Generally|is|,|carboplatin|known (r_xcomp) said_4\VBN|NONE (l_ccomp) known_20\JJ|.|Generally|is|,|have|carboplatin (l_auxpass) are_18\VBP|well (l_nsubj) toxicity_17\NN|NONE
D016190_D005909 NONE carboplatin_9\NN|NONE (r_pobj) of_8\IN|for|intracarotid (r_prep) injection_7\NN|NONE (l_prep) for_10\IN|intracarotid|of (l_pobj) glioblastomas_12\NNS|NONE
D016190_D005909 NONE carboplatin_10\NN|NONE (r_pobj) of_9\IN|for|in|an|intracarotid (r_prep) injection_8\NN|.|man (l_prep) for_11\IN|of|in|an|intracarotid (l_pobj) glioblastomas_13\NNS|NONE
17491223
D004280_D007511 NONE dobutamine_37\NN| (r_npadvmod) induced_39\VBN|myocardial (r_amod) ischemia_41\NN|,|using (r_dobj) detecting_36\VBG|NONE (r_pcomp) for_35\IN|,|compared|,|To|computed|value (r_prep) assess_3\VB|.|: (l_conj) computed_51\VBD|,|compared|,|for|To|value (l_advcl) assess_60\VB|tomography (l_dobj) presence_62\NN|to (l_prep) of_65\IN|the|or|absence (l_pobj) ischemia_66\NN|NONE
D017256_D007511 NONE Sestamibi_46\NNP|photon (r_nmod) emission_50\NN|NONE (r_dobj) using_43\VBG|,|ischemia (r_conj) detecting_36\VBG|NONE (r_pcomp) for_35\IN|,|compared|,|To|computed|value (r_prep) assess_3\VB|.|: (l_conj) computed_51\VBD|,|compared|,|for|To|value (l_advcl) assess_60\VB|tomography (l_dobj) presence_62\NN|to (l_prep) of_65\IN|the|or|absence (l_pobj) ischemia_66\NN|NONE
D017256_D017202 NONE Sestamibi_46\NNP|photon (r_nmod) emission_50\NN|NONE (r_dobj) using_43\VBG|,|ischemia (r_conj) detecting_36\VBG|NONE (l_dobj) ischemia_41\NN|,|using
D004280_D017202 CID dobutamine_14\NN| (r_npadvmod) induced_16\VBN|myocardial (r_amod) ischemia_18\NN|NONE
D004280_D017202 CID dobutamine_8\NN| (r_npadvmod) induced_10\VBN|myocardial (r_amod) ischemia_12\NN|NONE
D004280_D017202 CID dobutamine_37\NN| (r_npadvmod) induced_39\VBN|myocardial (r_amod) ischemia_41\NN|,|using
